1	In	In	B-PP	IN	O	25	VMOD
2	unanesthetized	unanesthetized	B-NP	JJ	O	5	AMOD
3	,	,	I-NP	,	O	5	P
4	spontaneously	spontaneously	I-NP	RB	O	5	AMOD
5	hypertensive	hypertensive	I-NP	JJ	O	6	NMOD
6	rats	rat	I-NP	NNS	O	1	PMOD
7	the	the	B-NP	DT	O	8	NMOD
8	decrease	decrease	I-NP	NN	O	25	SUB
9	in	in	B-PP	IN	O	25	VMOD
10	blood	blood	B-NP	NN	O	11	NMOD
11	pressure	pressure	I-NP	NN	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	heart	heart	I-NP	NN	O	14	NMOD
14	rate	rate	I-NP	NN	O	9	PMOD
15	produced	produce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	intravenous	intravenous	B-NP	JJ	O	18	NMOD
18	clonidine	clonidine	I-NP	NN	O	16	PMOD
19	,	,	O	,	O	25	P
20	5	5	B-NP	CD	O	22	AMOD
21	to	to	I-NP	TO	O	22	AMOD
22	20	20	I-NP	CD	O	23	NMOD
23	micrograms/kg	micrograms/kg	I-NP	NN	O	25	SUB
24	,	,	O	,	O	23	P
25	was	be	B-VP	VBD	O	0	ROOT
26	inhibited	inhibit	I-VP	VBN	O	25	VC
27	or	or	I-VP	CC	O	26	VMOD
28	reversed	reverse	I-VP	VBN	O	26	VMOD
29	by	by	B-PP	IN	O	28	VMOD
30	nalozone	nalozone	B-NP	NN	O	35	NMOD
31	,	,	O	,	O	35	P
32	0.2	0.2	B-NP	CD	O	34	AMOD
33	to	to	I-NP	TO	O	34	AMOD
34	2	2	I-NP	CD	O	35	NMOD
35	mg/kg	mg/kg	I-NP	NN	O	29	PMOD
36	.	.	O	.	O	25	P

1	The	The	B-NP	DT	O	3	NMOD
2	hypotensive	hypotensive	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	100	100	B-NP	CD	O	7	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	7	NMOD
7	alpha-methyldopa	alpha-methyldopa	I-NP	NN	O	4	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	also	also	I-VP	RB	O	8	VMOD
10	partially	partially	I-VP	RB	O	8	VMOD
11	reversed	reverse	I-VP	VBN	O	8	VC
12	by	by	B-PP	IN	O	11	VMOD
13	naloxone	naloxone	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	21	VMOD
2	brain	brain	B-NP	NN	O	3	NMOD
3	membranes	membrane	I-NP	NNS	O	1	PMOD
4	from	from	B-PP	IN	O	3	NMOD
5	spontaneously	spontaneously	B-NP	RB	O	6	AMOD
6	hypertensive	hypertensive	I-NP	JJ	O	7	NMOD
7	rats	rat	I-NP	NNS	O	8	NMOD
8	clonidine	clonidine	I-NP	NN	O	15	NMOD
9	,	,	O	,	O	15	P
10	10	10	B-NP	CD	O	15	AMOD
11	(	(	O	(	O	13	DEP
12	-8	-8	B-NP	CD	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	to	to	B-PP	TO	O	15	AMOD
15	10	10	B-NP	CD	O	4	PMOD
16	(	(	O	(	O	18	DEP
17	-5	-5	B-NP	CD	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	M	M	B-NP	NN	O	1	PMOD
20	,	,	O	,	O	21	P
21	did	do	B-VP	VBD	O	50	VMOD
22	not	not	I-VP	RB	O	21	VMOD
23	influence	influence	I-VP	VB	O	21	VC
24	stereoselective	stereoselective	B-NP	JJ	O	25	NMOD
25	binding	binding	I-NP	NN	O	23	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	[	[	O	(	O	29	DEP
28	3H	3H	B-NP	NN	O	29	DEP
29	]	]	O	)	O	30	NMOD
30	-naloxone	-naloxone	B-NP	NN	O	26	PMOD
31	(	(	O	(	O	34	DEP
32	8	8	B-NP	CD	O	33	NMOD
33	nM	nM	I-NP	NN	O	34	DEP
34	)	)	O	)	O	30	NMOD
35	,	,	O	,	O	44	P
36	and	and	O	CC	O	44	NMOD
37	naloxone	naloxone	B-NP	NN	O	44	NMOD
38	,	,	O	,	O	44	P
39	10	10	B-NP	CD	O	44	NMOD
40	(	(	O	(	O	42	DEP
41	-8	-8	B-NP	CD	O	42	DEP
42	)	)	O	)	O	39	NMOD
43	to	to	B-PP	TO	O	44	AMOD
44	10	10	B-NP	CD	O	48	NMOD
45	(	(	O	(	O	47	DEP
46	-4	-4	B-NP	CD	O	47	DEP
47	)	)	O	)	O	44	NMOD
48	M	M	B-NP	NN	O	50	SUB
49	,	,	O	,	O	48	P
50	did	do	B-VP	VBD	O	0	ROOT
51	not	not	I-VP	RB	O	50	VMOD
52	influence	influence	I-VP	VB	O	50	VC
53	clonidine-suppressible	clonidine-suppressible	B-NP	JJ	O	54	NMOD
54	binding	binding	I-NP	NN	O	52	OBJ
55	of	of	B-PP	IN	O	54	NMOD
56	[	[	B-NP	(	O	58	DEP
57	3H	3H	I-NP	NN	O	58	DEP
58	]	]	I-NP	)	O	55	PMOD
59	-dihydroergocryptine	-dihydroergocryptine	I-NP	JJ	O	58	NMOD
60	(	(	O	(	O	63	DEP
61	1	1	B-NP	CD	O	62	NMOD
62	nM	nM	I-NP	NN	O	63	DEP
63	)	)	O	)	O	59	NMOD
64	.	.	O	.	O	50	P

1	Lidocaine	Lidocaine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cardiac	cardiac	B-NP	JJ	O	4	NMOD
4	asystole	asystole	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	7	NMOD
5	single	single	I-NP	JJ	O	7	NMOD
6	50-mg	50-mg	I-NP	JJ	O	7	NMOD
7	bolus	bolus	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	lidocaine	lidocaine	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	2	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	67-year-old	67-year-old	I-NP	JJ	O	13	NMOD
13	man	man	I-NP	NN	O	10	PMOD
14	resulted	result	B-VP	VBD	O	0	ROOT
15	in	in	B-PP	IN	O	14	VMOD
16	profound	profound	B-NP	JJ	O	17	NMOD
17	depression	depression	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	activity	activity	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	27	NMOD
23	sinoatrial	sinoatrial	I-NP	JJ	O	27	NMOD
24	and	and	I-NP	CC	O	27	NMOD
25	atrioventricular	atrioventricular	I-NP	JJ	O	27	NMOD
26	nodal	nodal	I-NP	JJ	O	27	NMOD
27	pacemakers	pacemaker	I-NP	NNS	O	21	PMOD
28	.	.	O	.	O	14	P

1	Suxamethonium	Suxamethonium	B-NP	NN	O	3	NMOD
2	infusion	infusion	I-NP	NN	O	3	NMOD
3	rate	rate	I-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	observed	observe	B-NP	VBN	O	6	NMOD
6	fasciculations	fasciculation	I-NP	NNS	O	0	ROOT
7	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	infusion	infusion	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	discontinued	discontinue	I-VP	VBN	O	3	VC
5	either	either	O	CC	O	6	DEP
6	when	when	B-ADVP	WRB	O	3	VMOD
7	there	there	B-NP	EX	O	8	SUB
8	was	be	B-VP	VBD	O	6	SBAR
9	no	no	B-NP	DT	O	11	NMOD
10	muscular	muscular	I-NP	JJ	O	11	NMOD
11	response	response	I-NP	NN	O	8	PRD
12	to	to	B-PP	TO	O	11	NMOD
13	tetanic	tetanic	B-NP	JJ	O	14	NMOD
14	stimulation	stimulation	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	ulnar	ulnar	I-NP	JJ	O	18	NMOD
18	nerve	nerve	I-NP	NN	O	15	PMOD
19	or	or	O	CC	O	8	VMOD
20	when	when	B-ADVP	WRB	O	19	PRD
21	Sch	Sch	B-NP	NNP	O	23	NMOD
22	120	120	I-NP	CD	O	23	NMOD
23	mg	mg	I-NP	NN	O	24	SUB
24	was	be	B-VP	VBD	O	20	SBAR
25	exceeded	exceed	I-VP	VBN	O	24	VC
26	.	.	O	.	O	3	P

1	Galanthamine	Galanthamine	B-NP	NN	O	2	NMOD
2	hydrobromide	hydrobromide	I-NP	NN	O	6	NMOD
3	,	,	O	,	O	6	P
4	an	an	B-NP	DT	O	6	NMOD
5	anticholinesterase	anticholinesterase	I-NP	NN	B-protein	6	NMOD
6	drug	drug	I-NP	NN	O	14	SUB
7	capable	capable	B-ADJP	JJ	O	6	NMOD
8	of	of	B-PP	IN	O	7	AMOD
9	penetrating	penetrate	B-VP	VBG	O	8	PMOD
10	the	the	B-NP	DT	O	12	NMOD
11	blood-brain	blood-brain	I-NP	NN	O	12	NMOD
12	barrier	barrier	I-NP	NN	O	9	OBJ
13	,	,	O	,	O	6	P
14	was	be	B-VP	VBD	O	0	ROOT
15	used	use	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	18	NMOD
18	patient	patient	I-NP	NN	O	16	PMOD
19	demonstrating	demonstrate	B-VP	VBG	O	18	NMOD
20	central	central	B-NP	JJ	O	21	NMOD
21	effects	effect	I-NP	NNS	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	scopolamine	scopolamine	B-NP	NN	O	27	NMOD
24	(	(	O	(	O	26	DEP
25	hyoscine	hyoscine	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	overdosage	overdosage	B-NP	NN	O	22	PMOD
28	.	.	O	.	O	14	P

1	Effects	Effect	B-NP	NNS	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	uninephrectomy	uninephrectomy	B-NP	JJ	O	7	NMOD
4	and	and	I-NP	CC	O	7	NMOD
5	high	high	I-NP	JJ	O	7	NMOD
6	protein	protein	I-NP	NN	O	7	NMOD
7	feeding	feeding	I-NP	NN	O	2	PMOD
8	on	on	B-PP	IN	O	1	NMOD
9	lithium	lithium	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	chronic	chronic	B-NP	JJ	O	13	NMOD
12	renal	renal	I-NP	JJ	O	13	NMOD
13	failure	failure	I-NP	NN	O	10	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	10	P

1	Rats	Rat	B-NP	NNS	O	6	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	lithium	lithium	B-NP	NN	O	5	NMOD
4	induced	induce	I-NP	VBN	O	5	NMOD
5	nephropathy	nephropathy	I-NP	NN	O	2	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	subjected	subject	I-VP	VBN	O	6	VC
8	to	to	B-PP	TO	O	7	VMOD
9	high	high	B-NP	JJ	O	10	NMOD
10	protein	protein	I-NP	NN	O	22	NMOD
11	(	(	O	(	O	13	DEP
12	HP	HP	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	feeding	feeding	B-NP	NN	O	10	NMOD
15	,	,	O	,	O	22	P
16	uninephrectomy	uninephrectomy	B-NP	NN	O	22	NMOD
17	(	(	O	(	O	19	DEP
18	NX	NX	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	or	or	O	CC	O	22	NMOD
21	a	a	B-NP	DT	O	22	NMOD
22	combination	combination	I-NP	NN	O	8	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	these	these	B-NP	DT	O	23	PMOD
25	,	,	O	,	O	7	P
26	in	in	B-PP	IN	O	7	VMOD
27	an	an	B-NP	DT	O	28	NMOD
28	attempt	attempt	I-NP	NN	O	26	PMOD
29	to	to	B-VP	TO	O	30	VMOD
30	induce	induce	I-VP	VB	O	28	NMOD
31	glomerular	glomerular	B-NP	JJ	O	32	NMOD
32	hyperfiltration	hyperfiltration	I-NP	NN	O	35	NMOD
33	and	and	O	CC	O	35	NMOD
34	further	further	B-NP	JJ	O	35	NMOD
35	progression	progression	I-NP	NN	O	30	OBJ
36	of	of	B-PP	IN	O	35	NMOD
37	renal	renal	B-NP	JJ	O	38	NMOD
38	failure	failure	I-NP	NN	O	36	PMOD
39	.	.	O	.	O	6	P

1	Lithium	Lithium	B-NP	NN	O	3	SUB
2	also	also	B-ADVP	RB	O	3	VMOD
3	caused	cause	B-VP	VBD	O	0	ROOT
4	proteinuria	proteinuria	B-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	systolic	systolic	B-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	3	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	absence	absence	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	3	P

1	HP	HP	B-NP	NN	O	2	SUB
2	failed	fail	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	accentuante	accentuante	I-VP	VB	O	2	VMOD
5	progression	progression	B-NP	NN	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	renal	renal	B-NP	JJ	O	8	NMOD
8	failure	failure	I-NP	NN	O	6	PMOD
9	and	and	B-PP	CC	O	4	VMOD
10	in	in	B-PP	IN	O	4	VMOD
11	fact	fact	B-NP	NN	O	12	SUB
12	tended	tend	B-VP	VBD	O	10	SBAR
13	to	to	I-VP	TO	O	14	VMOD
14	increase	increase	I-VP	VB	O	12	VMOD
15	GFR	GFR	B-NP	NN	B-protein	14	OBJ
16	and	and	O	CC	O	14	VMOD
17	decrease	decrease	B-VP	VB	O	14	VMOD
18	plasma	plasma	B-NP	NN	O	20	NMOD
19	creatinine	creatinine	I-NP	NN	O	20	NMOD
20	levels	level	I-NP	NNS	O	17	OBJ
21	in	in	B-PP	IN	O	17	VMOD
22	lithium	lithium	B-NP	NN	O	24	NMOD
23	pretreated	pretreate	B-NP	VBN	O	24	NMOD
24	rats	rat	I-NP	NNS	O	21	PMOD
25	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	Li	Li	B-NP	NN	B-protein	6	SUB
6	induced	induce	B-VP	VBD	O	4	SBAR
7	nephropathy	nephropathy	B-NP	NN	O	6	OBJ
8	,	,	O	,	O	6	P
9	even	even	B-ADVP	RB	O	10	AMOD
10	when	when	I-ADVP	WRB	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	GFR	GFR	I-NP	NN	B-protein	13	SUB
13	is	be	B-VP	VBZ	O	10	SBAR
14	only	only	I-VP	RB	O	13	VMOD
15	modestly	modestly	I-VP	RB	O	14	AMOD
16	reduced	reduce	I-VP	VBN	O	13	VC
17	,	,	O	,	O	6	P
18	is	be	B-VP	VBZ	O	6	VMOD
19	associated	associate	I-VP	VBN	O	18	VC
20	with	with	B-PP	IN	O	19	VMOD
21	proteinuria	proteinuria	B-NP	NN	O	25	NMOD
22	and	and	O	CC	O	25	NMOD
23	arterial	arterial	B-NP	JJ	O	25	NMOD
24	systolic	systolic	I-NP	JJ	O	25	NMOD
25	hypertension	hypertension	I-NP	NN	O	20	PMOD
26	.	.	O	.	O	3	P

1	Treatment	Treatment	B-NP	NN	O	11	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	Crohn	Crohn	B-NP	NN	O	5	NMOD
4	's	's	B-NP	POS	O	5	NMOD
5	disease	disease	I-NP	NN	O	2	PMOD
6	with	with	B-PP	IN	O	1	NMOD
7	fusidic	fusidic	B-NP	JJ	O	8	NMOD
8	acid	acid	I-NP	NN	O	6	PMOD
9	:	:	O	:	O	1	P
10	an	an	B-NP	DT	O	11	NMOD
11	antibiotic	antibiotic	I-NP	NN	O	0	ROOT
12	with	with	B-PP	IN	O	11	NMOD
13	immunosuppressive	immunosuppressive	B-NP	JJ	O	14	NMOD
14	properties	property	I-NP	NNS	O	12	PMOD
15	similar	similar	B-ADJP	JJ	O	14	NMOD
16	to	to	B-PP	TO	O	15	AMOD
17	cyclosporin	cyclosporin	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	11	P

1	Because	Because	B-PP	IN	O	19	VMOD
2	of	of	I-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	4	NMOD
4	need	need	I-NP	NN	O	18	NMOD
5	for	for	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	development	development	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	new	new	B-NP	JJ	O	10	NMOD
10	treatments	treatment	I-NP	NNS	O	8	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	Crohn	Crohn	B-NP	NNP	O	14	NMOD
13	's	's	B-NP	POS	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	18	P
16	a	a	B-NP	DT	O	18	NMOD
17	pilot	pilot	I-NP	NN	O	18	NMOD
18	study	study	I-NP	NN	O	19	SUB
19	was	be	B-VP	VBD	O	0	ROOT
20	undertaken	undertake	I-VP	VBN	O	19	VC
21	to	to	I-VP	TO	O	22	VMOD
22	estimate	estimate	I-VP	VB	O	20	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	pharmacodynamics	pharmacodynamic	I-NP	NNS	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	tolerability	tolerability	I-NP	NN	O	22	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	fusidic	fusidic	B-NP	JJ	O	30	NMOD
29	acid	acid	I-NP	NN	O	30	NMOD
30	treatment	treatment	I-NP	NN	O	27	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	chronic	chronic	B-NP	JJ	O	36	NMOD
33	active	active	I-NP	JJ	O	35	AMOD
34	,	,	I-NP	,	O	35	P
35	therapy-resistant	therapy-resistant	I-NP	JJ	O	36	NMOD
36	patients	patient	I-NP	NNS	O	31	PMOD
37	.	.	O	.	O	19	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	6	NMOD
5	pilot	pilot	I-NP	NN	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	suggest	suggest	B-VP	VBP	O	0	ROOT
8	that	that	B-SBAR	IN	O	7	VMOD
9	fusidic	fusidic	B-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	11	SUB
11	may	may	B-VP	MD	O	8	SBAR
12	be	be	I-VP	VB	O	11	VC
13	of	of	B-PP	IN	O	12	PRD
14	benefit	benefit	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	12	VMOD
16	selected	select	B-NP	VBN	O	22	NMOD
17	chronic	chronic	I-NP	JJ	O	22	NMOD
18	active	active	I-NP	JJ	O	22	NMOD
19	Crohn	Crohn	I-NP	NN	O	22	NMOD
20	's	's	B-NP	POS	O	22	NMOD
21	disease	disease	I-NP	NN	O	22	NMOD
22	patients	patient	I-NP	NNS	O	15	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	whom	whom	B-NP	WP	O	26	NMOD
25	conventional	conventional	B-NP	JJ	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	23	PMOD
27	is	be	B-VP	VBZ	O	11	VMOD
28	ineffective	ineffective	B-ADJP	JJ	O	27	PRD
29	.	.	O	.	O	7	P

1	Electrocardiographic	Electrocardiographic	B-NP	JJ	O	2	NMOD
2	evidence	evidence	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	myocardial	myocardial	B-NP	JJ	O	5	NMOD
5	injury	injury	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	psychiatrically	psychiatrically	B-NP	RB	O	8	AMOD
8	hospitalized	hospitalize	I-NP	VBN	O	10	NMOD
9	cocaine	cocaine	I-NP	NN	O	10	NMOD
10	abusers	abuser	I-NP	NNS	O	6	PMOD
11	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	electrocardiograms	electrocardiogram	I-NP	NNS	O	10	SUB
3	(	(	O	(	O	5	DEP
4	ECG	ECG	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	of	of	B-PP	IN	O	2	NMOD
7	99	99	B-NP	CD	O	9	NMOD
8	cocaine-abusing	cocaine-abusing	I-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	6	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	compared	compare	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	ECGs	ECG	I-NP	NNS	B-protein	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	50	50	B-NP	CD	O	18	NMOD
17	schizophrenic	schizophrenic	I-NP	JJ	O	18	NMOD
18	controls	control	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	10	P

1	Sulpiride	Sulpiride	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	tardive	tardive	B-NP	JJ	O	4	NMOD
4	dystonia	dystonia	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	13	VMOD
2	initially	initially	B-VP	RB	O	3	VMOD
3	thought	think	I-VP	VBN	O	1	SBAR
4	to	to	I-VP	TO	O	5	VMOD
5	be	be	I-VP	VB	O	3	VMOD
6	free	free	B-ADJP	JJ	O	5	PRD
7	of	of	B-PP	IN	O	6	AMOD
8	extrapyramidal	extrapyramidal	B-NP	JJ	O	10	NMOD
9	side	side	I-NP	NN	O	10	NMOD
10	effects	effect	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	13	P
12	sulpiride	sulpiride	B-NP	NN	O	13	SUB
13	induced	induce	B-VP	VBD	O	0	ROOT
14	tardive	tardive	B-NP	JJ	O	17	NMOD
15	dyskinesia	dyskinesia	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	parkinsonism	parkinsonism	I-NP	NN	O	13	OBJ
18	have	have	B-VP	VBP	O	13	VMOD
19	been	be	I-VP	VBN	O	18	VC
20	reported	report	I-VP	VBN	O	19	VC
21	occasionally	occasionally	B-ADVP	RB	O	20	VMOD
22	.	.	O	.	O	13	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	37-year-old	37-year-old	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	persistent	persistent	B-NP	JJ	O	10	NMOD
9	segmental	segmental	I-NP	JJ	O	10	NMOD
10	dystonia	dystonia	I-NP	NN	O	7	OBJ
11	within	within	B-PP	IN	O	7	VMOD
12	2	2	B-NP	CD	O	13	NMOD
13	months	month	I-NP	NNS	O	11	PMOD
14	after	after	B-PP	IN	O	7	VMOD
15	starting	start	B-VP	VBG	O	14	PMOD
16	sulpiride	sulpiride	B-NP	NN	O	17	NMOD
17	therapy	therapy	I-NP	NN	O	15	OBJ
18	.	.	O	.	O	2	P

1	Ocular	Ocular	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	auditory	auditory	I-NP	JJ	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	hemodialyzed	hemodialyze	B-NP	VBN	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	PMOD
8	receiving	receive	B-VP	VBG	O	7	NMOD
9	desferrioxamine	desferrioxamine	B-NP	NN	O	8	OBJ
10	.	.	O	.	O	4	P

1	During	During	B-PP	IN	O	23	VMOD
2	an	an	B-NP	DT	O	4	NMOD
3	18-month	18-month	I-NP	JJ	O	4	NMOD
4	period	period	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	study	study	B-NP	NN	O	9	NMOD
7	41	41	I-NP	CD	O	6	NMOD
8	hemodialyzed	hemodialyze	B-VP	VBN	O	9	NMOD
9	patients	patient	B-NP	NNS	O	5	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	desferrioxamine	desferrioxamine	B-NP	NN	O	10	OBJ
12	(	(	O	(	O	18	DEP
13	10-40	10-40	B-NP	CD	O	16	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	16	NMOD
15	BW/3	BW/3	I-NP	NN	O	16	NMOD
16	times	time	I-NP	NNS	O	18	DEP
17	weekly	weekly	B-ADVP	RB	O	16	NMOD
18	)	)	O	)	O	11	NMOD
19	for	for	B-PP	IN	O	11	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	first	first	I-NP	JJ	O	22	NMOD
22	time	time	I-NP	NN	O	19	PMOD
23	were	be	B-VP	VBD	O	0	ROOT
24	monitored	monitor	I-VP	VBN	O	23	VC
25	for	for	B-PP	IN	O	24	VMOD
26	detection	detection	B-NP	NN	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	audiovisual	audiovisual	B-NP	JJ	O	29	NMOD
29	toxicity.	toxicity.	I-NP	NN	O	31	NMOD
30	6	6	B-NP	CD	O	31	NMOD
31	patients	patient	I-NP	NNS	O	27	PMOD
32	presented	present	B-VP	VBD	O	23	VMOD
33	clinical	clinical	B-NP	JJ	O	34	NMOD
34	symptoms	symptom	I-NP	NNS	O	32	OBJ
35	of	of	B-PP	IN	O	34	NMOD
36	visual	visual	B-NP	JJ	O	39	NMOD
37	or	or	I-NP	CC	O	39	NMOD
38	auditory	auditory	I-NP	JJ	O	39	NMOD
39	toxicity	toxicity	I-NP	NN	O	35	PMOD
40	.	.	O	.	O	23	P

1	Desferrioxamine	Desferrioxamine	B-NP	NN	O	2	NMOD
2	withdrawal	withdrawal	I-NP	NN	O	3	SUB
3	resulted	result	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	complete	complete	I-NP	JJ	O	7	NMOD
7	recovery	recovery	I-NP	NN	O	16	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	visual	visual	B-NP	JJ	O	10	NMOD
10	function	function	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	NMOD
12	1	1	B-NP	CD	O	13	NMOD
13	patient	patient	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	16	NMOD
15	partial	partial	B-NP	JJ	O	16	NMOD
16	recovery	recovery	I-NP	NN	O	4	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	3	3	B-NP	CD	O	17	PMOD
19	,	,	O	,	O	3	VMOD
20	and	and	O	CC	O	23	NMOD
21	a	a	B-NP	DT	O	23	NMOD
22	complete	complete	I-NP	JJ	O	23	NMOD
23	reversal	reversal	I-NP	NN	O	19	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	hearing	hearing	B-NP	NN	O	26	NMOD
26	loss	loss	I-NP	NN	O	24	PMOD
27	in	in	B-PP	IN	O	23	NMOD
28	3	3	B-NP	CD	O	29	NMOD
29	patients	patient	I-NP	NNS	O	32	NMOD
30	and	and	O	CC	O	32	NMOD
31	partial	partial	B-NP	JJ	O	32	NMOD
32	recovery	recovery	I-NP	NN	O	27	PMOD
33	in	in	B-PP	IN	O	23	NMOD
34	3	3	B-NP	CD	O	33	PMOD
35	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	3	SUB
3	appeared	appear	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	receiving	receive	B-VP	VBG	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	higher	high	I-NP	JJR	O	9	NMOD
9	doses	dose	I-NP	NNS	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	desferrioxamine	desferrioxamine	B-NP	NN	O	10	PMOD
12	or	or	O	CC	O	3	VMOD
13	coincided	coincide	B-VP	VBD	O	3	VMOD
14	with	with	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	normalization	normalization	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	ferritin	ferritin	B-NP	NN	B-protein	22	NMOD
19	or	or	I-NP	CC	O	22	NMOD
20	aluminium	aluminium	I-NP	NN	O	22	NMOD
21	serum	serum	I-NP	NN	O	22	NMOD
22	levels	level	I-NP	NNS	O	17	PMOD
23	.	.	O	.	O	3	P

1	Myasthenia	Myasthenia	B-NP	NNP	O	0	ROOT
2	gravis	gravi	B-VP	VBZ	O	1	NMOD
3	presenting	present	I-VP	VBG	O	2	VC
4	as	as	B-PP	IN	O	3	VMOD
5	weakness	weakness	B-NP	NN	O	4	PMOD
6	after	after	B-PP	IN	O	3	VMOD
7	magnesium	magnesium	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	with	with	B-PP	IN	O	4	NMOD
6	no	no	B-NP	DT	O	8	NMOD
7	prior	prior	I-NP	JJ	O	8	NMOD
8	history	history	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	neuromuscular	neuromuscular	B-NP	JJ	B-cell_type	11	NMOD
11	disease	disease	I-NP	NN	I-cell_type	9	PMOD
12	who	who	B-NP	WP	I-cell_type	11	NMOD
13	became	become	B-VP	VBD	O	12	SBAR
14	virtually	virtually	B-ADJP	RB	O	15	AMOD
15	quadriplegic	quadriplegic	I-ADJP	JJ	O	13	PRD
16	after	after	B-PP	IN	O	15	AMOD
17	parenteral	parenteral	B-NP	JJ	O	19	NMOD
18	magnesium	magnesium	I-NP	NN	O	19	NMOD
19	administration	administration	I-NP	NN	O	16	PMOD
20	for	for	B-PP	IN	O	19	NMOD
21	preeclampsia	preeclampsia	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	17	VMOD
2	paralysis	paralysis	B-NP	NN	O	6	SUB
3	after	after	B-PP	IN	O	2	NMOD
4	magnesium	magnesium	B-NP	NN	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	has	have	B-VP	VBZ	O	1	SBAR
7	been	be	I-VP	VBN	O	6	VC
8	described	describe	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	known	know	B-NP	VBN	O	14	NMOD
13	myasthenia	myasthenia	I-NP	NN	O	14	NMOD
14	gravis	gravis	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	17	P
16	it	it	B-NP	PRP	O	17	SUB
17	has	have	B-VP	VBZ	O	0	ROOT
18	not	not	I-VP	RB	O	17	VMOD
19	previously	previously	I-VP	RB	O	17	VMOD
20	been	be	I-VP	VBN	O	17	VC
21	reported	report	I-VP	VBN	O	20	VC
22	to	to	I-VP	TO	O	23	VMOD
23	be	be	I-VP	VB	O	21	VMOD
24	the	the	B-NP	DT	O	28	NMOD
25	initial	initial	I-NP	JJ	O	28	NMOD
26	or	or	I-NP	CC	O	28	NMOD
27	only	only	I-NP	JJ	O	28	NMOD
28	manifestation	manifestation	I-NP	NN	O	23	PRD
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	disease	disease	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	17	P

1	Based	Base	B-PP	VBN	O	0	ROOT
2	on	on	B-PP	IN	O	1	PMOD
3	clinical	clinical	B-NP	JJ	O	4	NMOD
4	data	datum	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	1	P
6	indicating	indicate	B-VP	VBG	O	1	VMOD
7	that	that	B-SBAR	IN	O	6	VMOD
8	chloroacetaldehyde	chloroacetaldehyde	B-NP	NN	O	12	SUB
9	(	(	O	(	O	11	DEP
10	CAA	CAA	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	is	be	B-VP	VBZ	O	7	SBAR
13	an	an	B-NP	DT	O	15	NMOD
14	important	important	I-NP	JJ	O	15	NMOD
15	metabolite	metabolite	I-NP	NN	O	22	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	oxazaphosphorine	oxazaphosphorine	B-NP	NN	O	18	NMOD
18	cytostatics	cytostatic	I-NP	NNS	O	16	PMOD
19	,	,	O	,	O	22	P
20	an	an	B-NP	DT	O	22	NMOD
21	experimental	experimental	I-NP	JJ	O	22	NMOD
22	study	study	I-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	12	VMOD
24	carried	carry	I-VP	VBN	O	23	VC
25	out	out	B-PRT	RP	O	24	VMOD
26	in	in	B-SBAR	IN	O	24	VMOD
27	order	order	O	NN	O	26	DEP
28	to	to	B-VP	TO	O	29	VMOD
29	elucidate	elucidate	I-VP	VB	O	26	SBAR
30	the	the	B-NP	DT	O	31	NMOD
31	role	role	I-NP	NN	O	29	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	CAA	CAA	B-NP	NN	B-protein	32	PMOD
34	in	in	B-PP	IN	O	31	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	development	development	I-NP	NN	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	hemorrhagic	hemorrhagic	B-NP	JJ	O	39	NMOD
39	cystitis	cystitis	I-NP	NN	O	37	PMOD
40	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	CAA	CAA	B-NP	NN	B-protein	9	SUB
6	after	after	B-PP	IN	O	5	NMOD
7	i.v.	i.v.	B-NP	JJ	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	does	do	B-VP	VBZ	O	4	SBAR
10	not	not	I-VP	RB	O	9	VMOD
11	contribute	contribute	I-VP	VB	O	9	VC
12	to	to	B-PP	TO	O	11	VMOD
13	bladder	bladder	B-NP	NN	O	14	NMOD
14	damage	damage	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	3	P

1	Twenty	Twenty	B-NP	CD	O	4	NMOD
2	common	common	I-NP	JJ	O	4	NMOD
3	migraine	migraine	I-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	5	SUB
5	received	receive	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	10	NMOD
7	one	one	I-NP	CD	O	10	NMOD
8	sided	sided	I-NP	JJ	O	10	NMOD
9	frontotemporal	frontotemporal	I-NP	JJ	O	10	NMOD
10	application	application	I-NP	NN	O	19	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	nitroglycerin	nitroglycerin	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	16	DEP
14	10	10	B-NP	CD	O	15	NMOD
15	patients	patient	I-NP	NNS	O	16	DEP
16	)	)	O	)	O	10	NMOD
17	or	or	O	CC	O	19	NMOD
18	placebo	placebo	B-NP	NN	O	19	NMOD
19	ointment	ointment	I-NP	NN	O	5	OBJ
20	(	(	O	(	O	23	DEP
21	10	10	B-NP	CD	O	22	NMOD
22	patients	patient	I-NP	NNS	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	in	in	B-PP	IN	O	5	VMOD
25	a	a	B-NP	DT	O	28	NMOD
26	double	double	I-NP	JJ	O	28	NMOD
27	blind	blind	I-NP	JJ	O	28	NMOD
28	study	study	I-NP	NN	O	24	PMOD
29	.	.	O	.	O	5	P

1	Early	Early	B-NP	JJ	O	4	NMOD
2	onset	onset	I-NP	NN	O	4	NMOD
3	migraine	migraine	I-NP	NN	O	4	NMOD
4	attacks	attack	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	induced	induce	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	nitroglycerin	nitroglycerin	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	VMOD
10	seven	seven	B-NP	CD	O	12	AMOD
11	out	out	I-NP	IN	O	12	AMOD
12	of	of	I-NP	IN	O	14	NMOD
13	10	10	I-NP	CD	O	12	AMOD
14	patients	patient	I-NP	NNS	O	9	PMOD
15	versus	versus	B-PP	IN	O	14	NMOD
16	no	no	B-NP	DT	O	17	NMOD
17	patient	patient	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	placebo	placebo	I-NP	NN	O	21	NMOD
21	group	group	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	5	P

1	Subsequently	Subsequently	B-NP	RB	O	4	NMOD
2	20	20	I-NP	CD	O	4	NMOD
3	migraine	migraine	I-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	16	SUB
5	,	,	O	,	O	4	P
6	who	who	B-NP	WP	O	4	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	an	an	B-NP	DT	O	11	NMOD
9	early	early	I-NP	JJ	O	11	NMOD
10	onset	onset	I-NP	NN	O	11	NMOD
11	attack	attack	I-NP	NN	O	7	OBJ
12	with	with	B-PP	IN	O	7	VMOD
13	frontotemporal	frontotemporal	B-NP	JJ	O	14	NMOD
14	nitroglycerin	nitroglycerin	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	4	P
16	received	receive	B-VP	VBD	O	0	ROOT
17	the	the	B-NP	DT	O	18	NMOD
18	drug	drug	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	a	a	B-NP	DT	O	23	NMOD
21	second	second	I-NP	JJ	O	23	NMOD
22	induction	induction	I-NP	NN	O	23	NMOD
23	test	test	I-NP	NN	O	19	PMOD
24	at	at	B-PP	IN	O	23	NMOD
25	other	other	B-NP	JJ	O	27	NMOD
26	body	body	I-NP	NN	O	27	NMOD
27	areas	area	I-NP	NNS	O	24	PMOD
28	.	.	O	.	O	16	P

1	Thus	Thus	B-ADVP	RB	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	migraine-inducing	migraine-inducing	I-NP	JJ	O	4	NMOD
4	effect	effect	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	nitroglycerin	nitroglycerin	B-NP	NN	O	5	PMOD
7	seems	seem	B-VP	VBZ	O	0	ROOT
8	to	to	I-VP	TO	O	9	VMOD
9	depend	depend	I-VP	VB	O	7	VMOD
10	on	on	B-PP	IN	O	9	VMOD
11	direct	direct	B-NP	JJ	O	12	NMOD
12	stimulation	stimulation	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	habitual	habitual	I-NP	JJ	O	16	NMOD
16	site	site	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	pain	pain	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	7	P
20	suggesting	suggest	B-VP	VBG	O	7	VMOD
21	that	that	B-SBAR	IN	O	20	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	frontotemporal	frontotemporal	I-NP	JJ	B-DNA	24	NMOD
24	region	region	I-NP	NN	I-DNA	25	SUB
25	is	be	B-VP	VBZ	O	21	SBAR
26	of	of	B-PP	IN	O	25	PRD
27	crucial	crucial	B-NP	JJ	O	28	NMOD
28	importance	importance	I-NP	NN	O	26	PMOD
29	in	in	B-PP	IN	O	25	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	development	development	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	a	a	B-NP	DT	O	35	NMOD
34	migraine	migraine	I-NP	NN	O	35	NMOD
35	crisis	crisis	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	7	P

1	Clotiazepam	Clotiazepam	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	acute	acute	B-NP	JJ	O	4	NMOD
4	hepatitis	hepatitis	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	18	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	who	who	B-NP	WP	O	7	NMOD
9	developed	develop	B-VP	VBD	O	8	SBAR
10	acute	acute	B-NP	JJ	O	11	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	9	OBJ
12	with	with	B-PP	IN	O	9	VMOD
13	extensive	extensive	B-NP	JJ	O	15	NMOD
14	hepatocellular	hepatocellular	I-NP	JJ	O	15	NMOD
15	necrosis	necrosis	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	18	P
17	7	7	B-NP	CD	O	18	NMOD
18	months	month	I-NP	NNS	O	2	OBJ
19	after	after	B-SBAR	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	onset	onset	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	administration	administration	B-NP	NN	O	29	NMOD
24	of	of	B-PP	IN	O	23	NMOD
25	clotiazepam	clotiazepam	B-NP	NN	O	24	PMOD
26	,	,	O	,	O	29	P
27	a	a	B-NP	DT	O	29	NMOD
28	thienodiazepine	thienodiazepine	I-NP	NN	O	29	NMOD
29	derivative	derivative	I-NP	NN	O	22	PMOD
30	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	several	several	B-NP	JJ	O	5	NMOD
5	benzodiazepines	benzodiazepine	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	2	P
7	chemically	chemically	B-VP	RB	O	8	VMOD
8	related	relate	I-VP	VBN	O	2	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	clotiazepam	clotiazepam	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	2	P
12	did	do	B-VP	VBD	O	0	ROOT
13	not	not	I-VP	RB	O	12	VMOD
14	interfere	interfere	I-VP	VB	O	12	VC
15	with	with	B-PP	IN	O	14	VMOD
16	recovery	recovery	B-NP	NN	O	15	PMOD
17	and	and	O	CC	O	12	VMOD
18	did	do	B-VP	VBD	O	12	VMOD
19	not	not	I-VP	RB	O	18	VMOD
20	induce	induce	I-VP	VB	O	18	VC
21	any	any	B-NP	DT	O	22	NMOD
22	relapse	relapse	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	hepatitis	hepatitis	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	12	P

1	Arterial	Arterial	B-NP	JJ	O	2	NMOD
2	hypertension	hypertension	I-NP	NN	O	0	ROOT
3	as	as	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	complication	complication	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	prolonged	prolonged	B-NP	JJ	O	9	NMOD
8	ketoconazole	ketoconazole	I-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	16	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	14	14	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	Cushing	Cushing	B-NP	NN	O	7	NMOD
7	's	's	B-NP	POS	O	8	NMOD
8	syndrome	syndrome	I-NP	NN	O	5	PMOD
9	treated	treat	B-VP	VBN	O	8	NMOD
10	on	on	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	long-term	long-term	I-NP	JJ	O	13	NMOD
13	basis	basis	I-NP	NN	O	10	PMOD
14	with	with	B-PP	IN	O	8	NMOD
15	ketoconazole	ketoconazole	B-NP	NN	O	14	PMOD
16	developed	develop	B-VP	VBD	O	0	ROOT
17	sustained	sustained	B-NP	JJ	O	18	NMOD
18	hypertension	hypertension	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	16	P

1	In	In	B-PP	IN	O	11	VMOD
2	both	both	B-NP	DT	O	3	NMOD
3	cases	case	I-NP	NNS	O	1	PMOD
4	normal	normal	B-NP	JJ	O	5	NMOD
5	plasma	plasma	I-NP	NN	O	10	NMOD
6	and	and	O	CC	O	10	NMOD
7	urinary	urinary	B-NP	JJ	O	10	NMOD
8	free	free	I-NP	JJ	O	10	NMOD
9	cortisol	cortisol	I-NP	NN	O	10	NMOD
10	levels	level	I-NP	NNS	O	11	SUB
11	had	have	B-VP	VBD	O	0	ROOT
12	been	be	I-VP	VBN	O	11	VC
13	achieved	achieve	I-VP	VBN	O	12	VC
14	following	follow	B-PP	VBG	O	13	VMOD
15	ketoconazole	ketoconazole	B-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	14	PMOD
17	,	,	O	,	O	11	P
18	yet	yet	B-NP	RB	O	19	AMOD
19	continuous	continuous	I-NP	JJ	O	32	NMOD
20	blood	blood	I-NP	NN	O	22	NMOD
21	pressure	pressure	I-NP	NN	O	22	NMOD
22	monitoring	monitoring	I-NP	NN	O	32	NMOD
23	demonstrated	demonstrate	B-VP	VBD	O	32	NMOD
24	hypertension	hypertension	B-NP	NN	O	32	NMOD
25	31	31	I-NP	CD	O	24	NMOD
26	(	(	O	(	O	29	DEP
27	patient	patient	B-NP	NN	O	29	DEP
28	1	1	I-NP	CD	O	27	NMOD
29	)	)	O	)	O	24	NMOD
30	and	and	O	CC	O	32	NMOD
31	52	52	B-NP	CD	O	32	NMOD
32	weeks	week	I-NP	NNS	O	11	OBJ
33	(	(	O	(	O	36	DEP
34	patient	patient	B-NP	NN	O	36	DEP
35	2	2	I-NP	CD	O	34	NMOD
36	)	)	O	)	O	32	NMOD
37	after	after	B-PP	IN	O	11	VMOD
38	treatment	treatment	B-NP	NN	O	37	PMOD
39	.	.	O	.	O	11	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	an	an	B-NP	DT	O	4	NMOD
4	inhibitor	inhibitor	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	angiotensin	angiotensin	B-NP	NN	B-protein	8	NMOD
7	converting	convert	B-VP	VBG	I-protein	8	NMOD
8	enzyme	enzyme	B-NP	NN	I-protein	5	PMOD
9	(	(	O	(	O	11	DEP
10	Captopril	Captopril	B-NP	NNP	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	on	on	B-PP	IN	O	1	NMOD
13	pulmonary	pulmonary	B-NP	JJ	O	15	AMOD
14	and	and	I-NP	CC	O	15	AMOD
15	renal	renal	I-NP	JJ	O	16	NMOD
16	insufficiency	insufficiency	I-NP	NN	O	12	PMOD
17	due	due	B-PP	JJ	O	1	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	intravascular	intravascular	B-NP	JJ	O	20	NMOD
20	coagulation	coagulation	I-NP	NN	O	18	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	rat	rat	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	1	P

1	Induction	Induction	B-NP	NN	O	6	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	intravascular	intravascular	B-NP	JJ	O	4	NMOD
4	coagulation	coagulation	I-NP	NN	O	2	PMOD
5	and	and	I-NP	CC	O	6	NMOD
6	inhibition	inhibition	I-NP	NN	O	22	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	fibrinolysis	fibrinolysis	B-NP	NN	O	7	PMOD
9	by	by	B-PP	IN	O	6	NMOD
10	injection	injection	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	thrombin	thrombin	B-NP	NN	B-protein	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	tranexamic	tranexamic	B-NP	JJ	O	15	NMOD
15	acid	acid	I-NP	NN	O	11	PMOD
16	(	(	O	(	O	18	DEP
17	AMCA	AMCA	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	in	in	B-PP	IN	O	6	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	rat	rat	I-NP	NN	O	19	PMOD
22	gives	give	B-VP	VBZ	O	0	ROOT
23	rise	rise	B-NP	NN	O	22	OBJ
24	to	to	B-PP	TO	O	22	VMOD
25	pulmonary	pulmonary	B-NP	JJ	O	28	NMOD
26	and	and	I-NP	CC	O	28	NMOD
27	renal	renal	I-NP	JJ	O	28	NMOD
28	insufficiency	insufficiency	I-NP	NN	O	24	PMOD
29	resembling	resemble	B-VP	VBG	O	28	NMOD
30	that	that	B-SBAR	IN	O	29	VMOD
31	occurring	occur	B-VP	VBG	O	30	SBAR
32	after	after	B-PP	IN	O	31	VMOD
33	trauma	trauma	B-NP	NN	O	35	NMOD
34	or	or	I-NP	CC	O	35	NMOD
35	sepsis	sepsis	I-NP	NN	O	32	PMOD
36	in	in	B-PP	IN	O	35	NMOD
37	man	man	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	22	P

1	Injection	Injection	B-NP	NN	O	19	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	Captopril	Captopril	B-NP	NNP	O	10	NMOD
4	(	(	O	(	O	7	DEP
5	1	1	B-NP	CD	O	6	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	7	DEP
7	)	)	O	)	O	3	NMOD
8	,	,	O	,	O	10	P
9	an	an	B-NP	DT	O	10	NMOD
10	inhibitor	inhibitor	I-NP	NN	O	2	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	angiotensin	angiotensin	B-NP	NN	B-protein	14	NMOD
13	converting	convert	B-VP	VBG	I-protein	14	NMOD
14	enzyme	enzyme	B-NP	NN	I-protein	11	PMOD
15	(	(	O	(	O	17	DEP
16	ACE	ACE	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	,	,	O	,	O	14	P
19	reduced	reduce	B-VP	VBD	O	0	ROOT
20	both	both	O	CC	O	23	AMOD
21	pulmonary	pulmonary	B-NP	JJ	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	renal	renal	I-NP	JJ	O	24	NMOD
24	insufficiency	insufficiency	I-NP	NN	O	19	OBJ
25	in	in	B-PP	IN	O	24	NMOD
26	this	this	B-NP	DT	O	28	NMOD
27	rat	rat	I-NP	NN	O	28	NMOD
28	model	model	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	19	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	damage	damage	I-NP	NN	O	15	SUB
3	as	as	B-SBAR	IN	O	2	NMOD
4	reflected	reflect	B-VP	VBN	O	3	SBAR
5	by	by	B-PP	IN	O	4	VMOD
6	an	an	B-NP	DT	O	7	NMOD
7	increase	increase	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	serum	serum	B-NP	NN	O	10	NMOD
10	urea	urea	I-NP	NN	O	8	PMOD
11	and	and	B-PP	CC	O	5	PMOD
12	in	in	B-PP	IN	O	5	PMOD
13	kidney	kidney	B-NP	NN	O	14	NMOD
14	weight	weight	I-NP	NN	O	12	PMOD
15	was	be	B-VP	VBD	O	0	ROOT
16	prevented	prevent	I-VP	VBN	O	15	VC
17	by	by	B-PP	IN	O	16	VMOD
18	Captopril	Captopril	B-NP	NNP	O	17	PMOD
19	.	.	O	.	O	15	P

1	A	A	B-NP	DT	O	3	NMOD
2	randomized	randomize	I-NP	VBN	O	3	NMOD
3	comparison	comparison	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	labetalol	labetalol	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	nitroprusside	nitroprusside	I-NP	NN	O	4	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	induced	induce	B-NP	VBN	O	10	NMOD
10	hypotension	hypotension	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	7	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	randomized	randomize	I-NP	VBN	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	labetalol	labetalol	B-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	hypotension	hypotension	B-NP	NN	O	12	NMOD
9	and	and	I-NP	CC	O	12	NMOD
10	nitroprusside	nitroprusside	I-NP	NN	O	12	NMOD
11	induced	induce	I-NP	VBN	O	12	NMOD
12	hypotension	hypotension	I-NP	NN	O	7	OBJ
13	were	be	B-VP	VBD	O	7	VMOD
14	compared	compare	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	20	20	B-NP	CD	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	(	(	O	(	O	23	DEP
19	10	10	B-NP	CD	O	23	DEP
20	in	in	B-PP	IN	O	19	NMOD
21	each	each	B-NP	DT	O	22	NMOD
22	group	group	I-NP	NN	O	20	PMOD
23	)	)	O	)	O	17	NMOD
24	scheduled	schedule	B-VP	VBN	O	17	NMOD
25	for	for	B-PP	IN	O	24	VMOD
26	major	major	B-NP	JJ	O	28	NMOD
27	orthopedic	orthopedic	I-NP	JJ	O	28	NMOD
28	procedures	procedure	I-NP	NNS	O	25	PMOD
29	.	.	O	.	O	7	P

1	Nitroprusside	Nitroprusside	B-NP	NN	O	2	NMOD
2	infusion	infusion	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	24	VMOD
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	significant	significant	I-NP	JJ	O	14	NMOD
8	(	(	O	(	O	13	DEP
9	p	p	B-NP	NN	O	11	SUB
10	less	less	B-ADJP	JJR	O	11	AMOD
11	than	than	B-PP	IN	O	13	DEP
12	0.05	0.05	B-NP	CD	O	11	AMOD
13	)	)	O	)	O	7	NMOD
14	increase	increase	B-NP	NN	O	20	NMOD
15	in	in	B-PP	IN	O	14	NMOD
16	heart	heart	B-NP	NN	O	17	NMOD
17	rate	rate	I-NP	NN	O	15	PMOD
18	and	and	O	CC	O	20	NMOD
19	cardiac	cardiac	B-NP	JJ	O	20	NMOD
20	output	output	I-NP	NN	O	5	PMOD
21	;	;	O	:	O	24	P
22	rebound	rebound	B-NP	NN	O	23	NMOD
23	hypertension	hypertension	I-NP	NN	O	24	SUB
24	was	be	B-VP	VBD	O	0	ROOT
25	observed	observe	I-VP	VBN	O	24	VC
26	in	in	B-PP	IN	O	25	VMOD
27	three	three	B-NP	CD	O	28	NMOD
28	patients	patient	I-NP	NNS	O	26	PMOD
29	after	after	B-PP	IN	O	28	NMOD
30	discontinuation	discontinuation	B-NP	NN	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	nitroprusside	nitroprusside	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	24	P

1	Chronic	Chronic	B-NP	JJ	O	3	NMOD
2	carbamazepine	carbamazepine	I-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	13	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	rat	rat	I-NP	NN	O	4	PMOD
7	:	:	O	:	O	3	P
8	efficacy	efficacy	B-NP	NN	O	13	NMOD
9	,	,	O	,	O	13	P
10	toxicity	toxicity	B-NP	NN	O	13	NMOD
11	,	,	O	,	O	13	P
12	and	and	O	CC	O	13	NMOD
13	effect	effect	B-NP	NN	O	0	ROOT
14	on	on	B-PP	IN	O	13	NMOD
15	plasma	plasma	B-NP	NN	O	19	NMOD
16	and	and	I-NP	CC	O	19	NMOD
17	tissue	tissue	I-NP	NN	O	19	NMOD
18	folate	folate	I-NP	NN	O	19	NMOD
19	concentrations	concentration	I-NP	NNS	O	14	PMOD
20	.	.	O	.	O	13	P

1	In	In	B-PP	IN	O	22	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	course	course	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	developing	develop	B-VP	VBG	O	4	PMOD
6	this	this	B-NP	DT	O	7	NMOD
7	model	model	I-NP	NN	O	5	OBJ
8	,	,	O	,	O	22	P
9	a	a	B-NP	DT	O	11	NMOD
10	common	common	I-NP	JJ	O	11	NMOD
11	vehicle	vehicle	I-NP	NN	O	14	NMOD
12	,	,	O	,	O	14	P
13	propylene	propylene	B-NP	NN	O	14	NMOD
14	glycol	glycol	I-NP	NN	O	22	SUB
15	,	,	O	,	O	14	P
16	by	by	B-PP	IN	O	14	NMOD
17	itself	itself	B-NP	PRP	O	16	PMOD
18	in	in	B-PP	IN	O	14	NMOD
19	high	high	B-NP	JJ	O	20	NMOD
20	doses	dose	I-NP	NNS	O	18	PMOD
21	,	,	O	,	O	14	P
22	was	be	B-VP	VBD	O	0	ROOT
23	found	find	I-VP	VBN	O	22	VC
24	to	to	I-VP	TO	O	25	VMOD
25	exhibit	exhibit	I-VP	VB	O	23	VMOD
26	protective	protective	B-NP	JJ	O	27	NMOD
27	properties	property	I-NP	NNS	O	25	OBJ
28	against	against	B-PP	IN	O	27	NMOD
29	induced	induce	B-NP	VBN	O	30	NMOD
30	seizures	seizure	I-NP	NNS	O	28	PMOD
31	and	and	O	CC	O	22	VMOD
32	inhibited	inhibit	B-VP	VBD	O	22	VMOD
33	weight	weight	B-NP	NN	O	34	NMOD
34	gain	gain	I-NP	NN	O	32	OBJ
35	.	.	O	.	O	22	P

1	Seizures	Seizure	B-NP	NNS	O	9	SUB
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	hexafluorodiethyl	hexafluorodiethyl	B-NP	NN	O	5	NMOD
5	ether	ether	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	8	DEP
7	HFDE	HFDE	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	also	also	I-VP	RB	O	9	VMOD
11	found	find	I-VP	VBN	O	9	VC
12	to	to	I-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	11	VMOD
14	a	a	B-NP	DT	O	17	NMOD
15	more	more	I-NP	RBR	O	16	AMOD
16	sensitive	sensitive	I-NP	JJ	O	17	NMOD
17	measure	measure	I-NP	NN	O	13	PRD
18	of	of	B-PP	IN	O	17	NMOD
19	protection	protection	B-NP	NN	O	18	PMOD
20	by	by	B-PP	IN	O	17	NMOD
21	CBZ	CBZ	B-NP	NN	B-protein	20	PMOD
22	than	than	B-PP	IN	O	17	NMOD
23	seizures	seizure	B-NP	NNS	O	22	PMOD
24	induced	induce	B-VP	VBN	O	23	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	maximal	maximal	B-NP	JJ	O	27	NMOD
27	electroshock	electroshock	I-NP	NN	O	25	PMOD
28	(	(	O	(	O	30	DEP
29	MES	MES	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	.	.	O	.	O	9	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	11	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	CBZ	CBZ	B-NP	NN	B-protein	3	PMOD
5	as	as	B-PP	IN	O	2	NMOD
6	an	an	B-NP	DT	O	8	NMOD
7	aqueous	aqueous	I-NP	JJ	O	8	NMOD
8	suspension	suspension	I-NP	NN	O	5	PMOD
9	every	every	B-NP	DT	O	11	NMOD
10	8	8	I-NP	CD	O	11	NMOD
11	h	h	I-NP	NN	O	18	SUB
12	at	at	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	dose	dose	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	250	250	B-NP	CD	O	17	NMOD
17	mg/kg	mg/kg	I-NP	NN	O	15	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	continuously	continuously	B-ADJP	RB	O	20	AMOD
20	protective	protective	I-ADJP	JJ	O	18	PRD
21	against	against	B-PP	IN	O	20	AMOD
22	HFDE	HFDE	B-NP	NN	B-protein	24	NMOD
23	induced	induce	I-NP	VBN	O	24	NMOD
24	seizures	seizure	I-NP	NNS	O	21	PMOD
25	and	and	O	CC	O	18	VMOD
26	was	be	B-VP	VBD	O	18	VMOD
27	minimally	minimally	B-ADJP	RB	O	28	AMOD
28	toxic	toxic	I-ADJP	JJ	O	26	PRD
29	as	as	B-SBAR	IN	O	28	AMOD
30	measured	measure	B-VP	VBN	O	29	SBAR
31	by	by	B-PP	IN	O	30	VMOD
32	weight	weight	B-NP	NN	O	33	NMOD
33	gain	gain	I-NP	NN	O	31	PMOD
34	over	over	B-PP	IN	O	30	VMOD
35	8	8	B-NP	CD	O	36	NMOD
36	weeks	week	I-NP	NNS	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	treatment	treatment	B-NP	NN	O	37	PMOD
39	.	.	O	.	O	18	P

1	Mean	Mean	B-NP	JJ	O	3	NMOD
2	arterial	arterial	I-NP	JJ	O	3	NMOD
3	pressure	pressure	I-NP	NN	O	0	ROOT
4	(	(	O	(	O	3	NMOD
5	as	as	B-PP	IN	O	82	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	percentage	percentage	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	control	control	B-NP	NN	O	11	NMOD
10	+/-	+/-	I-NP	SYM	O	11	NMOD
11	SEM	SEM	I-NP	NN	O	8	PMOD
12	)	)	O	)	O	11	NMOD
13	during	during	B-PP	IN	O	82	VMOD
14	randomized	randomize	B-NP	VBN	O	15	NMOD
15	infusions	infusion	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	0.03	0.03	B-NP	CD	O	26	VMOD
18	,	,	I-NP	,	O	26	P
19	0.1	0.1	I-NP	CD	O	26	VMOD
20	,	,	I-NP	,	O	26	P
21	0.3	0.3	I-NP	CD	O	26	VMOD
22	,	,	O	,	O	26	P
23	or	or	O	CC	O	26	VMOD
24	1.0	1.0	B-NP	CD	O	25	NMOD
25	microgram/kg/min	microgram/kg/min	I-NP	NN	O	26	SUB
26	was	be	B-VP	VBD	O	16	SBAR
27	99	99	B-NP	CD	O	29	AMOD
28	+/-	+/-	I-NP	SYM	O	29	AMOD
29	1	1	I-NP	CD	O	33	NMOD
30	,	,	I-NP	,	O	33	P
31	95	95	I-NP	CD	O	33	AMOD
32	+/-	+/-	I-NP	SYM	O	33	AMOD
33	1	1	I-NP	CD	O	26	PRD
34	(	(	O	(	O	39	DEP
35	p	p	B-NP	NN	O	37	SUB
36	less	less	B-ADJP	JJR	O	37	AMOD
37	than	than	B-PP	IN	O	39	DEP
38	0.05	0.05	B-NP	CD	O	37	AMOD
39	)	)	O	)	O	15	NMOD
40	,	,	O	,	O	82	P
41	93	93	B-NP	CD	O	43	AMOD
42	+/-	+/-	I-NP	SYM	O	43	AMOD
43	1	1	I-NP	CD	O	55	NMOD
44	(	(	O	(	O	49	DEP
45	p	p	B-NP	NN	O	47	SUB
46	less	less	B-ADJP	JJR	O	47	AMOD
47	than	than	B-PP	IN	O	49	DEP
48	0.01	0.01	B-NP	CD	O	47	AMOD
49	)	)	O	)	O	43	NMOD
50	,	,	O	,	O	55	P
51	or	or	O	CC	O	54	AMOD
52	79	79	B-NP	CD	O	54	AMOD
53	+/-	+/-	I-NP	SYM	O	54	AMOD
54	6	6	I-NP	CD	O	55	NMOD
55	%	%	I-NP	NN	O	82	SUB
56	(	(	O	(	O	61	DEP
57	p	p	B-NP	NN	O	61	DEP
58	less	less	B-ADJP	JJR	O	57	NMOD
59	than	than	B-PP	IN	O	58	AMOD
60	0.001	0.001	B-NP	CD	O	59	PMOD
61	)	)	O	)	O	55	NMOD
62	,	,	O	,	O	55	P
63	respectively	respectively	B-ADVP	RB	O	82	VMOD
64	,	,	O	,	O	82	P
65	but	but	O	CC	O	82	VMOD
66	no	no	B-NP	DT	O	67	NMOD
67	tachycardia	tachycardia	I-NP	NN	O	70	NMOD
68	and	and	O	CC	O	70	NMOD
69	no	no	B-NP	DT	O	70	NMOD
70	augmentation	augmentation	I-NP	NN	O	82	SUB
71	of	of	B-PP	IN	O	70	NMOD
72	the	the	B-NP	DT	O	75	NMOD
73	norepinephrine	norepinephrine	I-NP	NN	O	75	NMOD
74	release	release	I-NP	NN	O	75	NMOD
75	rate	rate	I-NP	NN	O	71	PMOD
76	(	(	O	(	O	81	DEP
77	up	up	B-NP	RB	O	80	NMOD
78	to	to	I-NP	TO	O	77	AMOD
79	0.3	0.3	I-NP	CD	O	77	AMOD
80	microgram/kg/min	microgram/kg/min	I-NP	NN	O	81	DEP
81	)	)	O	)	O	75	NMOD
82	were	be	B-VP	VBD	O	4	SBAR
83	observed	observe	I-VP	VBN	O	82	VC
84	,	,	O	,	O	82	P
85	which	which	B-NP	WDT	O	82	VMOD
86	is	be	B-VP	VBZ	O	85	SBAR
87	in	in	B-PP	IN	O	86	PRD
88	contrast	contrast	B-NP	NN	O	87	PMOD
89	to	to	B-PP	TO	O	88	NMOD
90	comparable	comparable	B-NP	JJ	O	91	NMOD
91	hypotension	hypotension	I-NP	NN	O	89	PMOD
92	induced	induce	B-VP	VBN	O	91	NMOD
93	by	by	B-PP	IN	O	92	VMOD
94	hydralazine	hydralazine	B-NP	NN	O	96	NMOD
95	or	or	I-NP	CC	O	96	NMOD
96	nitroglycerin	nitroglycerin	I-NP	NN	O	93	PMOD
97	.	.	O	.	O	3	P

1	Impotence	Impotence	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	more	more	B-ADJP	RBR	O	4	AMOD
4	common	common	I-ADJP	JJ	O	2	PRD
5	among	among	B-PP	IN	O	4	AMOD
6	male	male	B-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	PMOD
8	than	than	B-PP	IN	O	7	NMOD
9	controls	control	B-NP	NNS	O	8	PMOD
10	and	and	O	CC	O	2	VMOD
11	was	be	B-VP	VBD	O	2	VMOD
12	found	find	I-VP	VBN	O	11	VC
13	to	to	I-VP	TO	O	14	VMOD
14	be	be	I-VP	VB	O	12	VMOD
15	associated	associate	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	co-morbidity	co-morbidity	B-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	taking	taking	I-NP	NN	O	16	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	methotrexate	methotrexate	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	2	P

1	Does	Does	B-NP	NNP	O	2	NMOD
2	paracetamol	paracetamol	I-NP	NN	O	3	SUB
3	cause	cause	B-VP	VBP	O	0	ROOT
4	urothelial	urothelial	B-NP	JJ	O	5	NMOD
5	cancer	cancer	I-NP	NN	O	9	NMOD
6	or	or	O	CC	O	9	NMOD
7	renal	renal	B-NP	JJ	O	9	NMOD
8	papillary	papillary	I-NP	JJ	O	9	NMOD
9	necrosis	necrosis	I-NP	NN	O	3	OBJ
10	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	26	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	developing	develop	B-VP	VBG	O	3	PMOD
5	renal	renal	B-NP	JJ	O	7	NMOD
6	papillary	papillary	I-NP	JJ	O	7	NMOD
7	necrosis	necrosis	I-NP	NN	O	9	NMOD
8	or	or	I-NP	CC	O	9	NMOD
9	cancer	cancer	I-NP	NN	O	4	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	renal	renal	I-NP	JJ	O	13	NMOD
13	pelvis	pelvis	I-NP	NN	O	17	NMOD
14	,	,	I-NP	,	O	17	P
15	ureter	ureter	I-NP	NN	O	17	NMOD
16	or	or	I-NP	CC	O	17	NMOD
17	bladder	bladder	I-NP	NN	O	10	PMOD
18	associated	associate	B-VP	VBN	O	17	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	consumption	consumption	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	either	either	O	CC	O	25	NMOD
23	phenacetin	phenacetin	B-NP	NN	O	25	NMOD
24	or	or	I-NP	CC	O	25	NMOD
25	paracetamol	paracetamol	I-NP	NN	O	21	PMOD
26	was	be	B-VP	VBD	O	0	ROOT
27	calculated	calculate	I-VP	VBN	O	26	VC
28	from	from	B-PP	IN	O	27	VMOD
29	data	datum	B-NP	NNS	O	28	PMOD
30	acquired	acquire	B-VP	VBN	O	29	NMOD
31	by	by	B-PP	IN	O	30	VMOD
32	questionnaire	questionnaire	B-NP	NN	O	31	PMOD
33	from	from	B-PP	IN	O	32	NMOD
34	381	381	B-NP	CD	O	35	NMOD
35	cases	case	I-NP	NNS	O	38	NMOD
36	and	and	O	CC	O	38	NMOD
37	808	808	B-NP	CD	O	38	NMOD
38	controls	control	I-NP	NNS	O	33	PMOD
39	.	.	O	.	O	26	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	renal	renal	B-NP	JJ	O	6	NMOD
5	papillary	papillary	I-NP	JJ	O	6	NMOD
6	necrosis	necrosis	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	increased	increase	I-VP	VBN	O	7	VC
9	nearly	nearly	B-ADVP	RB	O	8	VMOD
10	20-fold	20-fold	I-ADVP	RB	O	9	AMOD
11	by	by	B-PP	IN	O	8	VMOD
12	consumption	consumption	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	phenacetin	phenacetin	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	14	P
16	which	which	B-NP	WDT	O	14	NMOD
17	also	also	B-ADVP	RB	O	18	VMOD
18	increased	increase	B-VP	VBD	O	16	SBAR
19	the	the	B-NP	DT	O	20	NMOD
20	risk	risk	I-NP	NN	O	18	OBJ
21	for	for	B-PP	IN	O	20	NMOD
22	cancer	cancer	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	renal	renal	I-NP	JJ	O	26	NMOD
26	pelvis	pelvis	I-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	bladder	bladder	I-NP	NN	O	23	PMOD
29	but	but	B-PP	CC	O	21	PMOD
30	not	not	B-PP	RB	O	31	PMOD
31	for	for	I-PP	IN	O	21	PMOD
32	ureteric	ureteric	B-NP	JJ	O	33	NMOD
33	cancer	cancer	I-NP	NN	O	31	PMOD
34	.	.	O	.	O	7	P

1	Dapsone-associated	Dapsone-associated	B-NP	JJ	O	5	NMOD
2	Heinz	Heinz	I-NP	NN	O	5	NMOD
3	body	body	I-NP	NN	O	5	NMOD
4	hemolytic	hemolytic	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	Cambodian	Cambodian	I-NP	JJ	O	9	NMOD
9	woman	woman	I-NP	NN	O	6	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	hemoglobin	hemoglobin	B-NP	NN	B-protein	13	NMOD
12	E	E	I-NP	NN	O	13	NMOD
13	trait	trait	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	3	NMOD
2	Cambodian	Cambodian	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	13	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	hemoglobin	hemoglobin	B-NP	NN	B-protein	7	NMOD
6	E	E	I-NP	NN	O	7	NMOD
7	trait	trait	I-NP	NN	O	12	NMOD
8	(	(	O	(	O	10	DEP
9	AE	AE	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	and	and	O	CC	O	12	NMOD
12	leprosy	leprosy	B-NP	NN	O	4	PMOD
13	developed	develop	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	18	NMOD
15	Heinz	Heinz	I-NP	NNP	O	18	NMOD
16	body	body	I-NP	NN	O	18	NMOD
17	hemolytic	hemolytic	I-NP	JJ	O	18	NMOD
18	anemia	anemia	I-NP	NN	O	13	OBJ
19	while	while	B-SBAR	IN	O	13	VMOD
20	taking	take	B-VP	VBG	O	19	SBAR
21	a	a	B-NP	DT	O	22	NMOD
22	dose	dose	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	dapsone	dapsone	B-NP	NN	O	23	PMOD
25	(	(	O	(	O	28	DEP
26	50	50	B-NP	CD	O	27	NMOD
27	mg/day	mg/day	I-NP	NN	O	28	DEP
28	)	)	O	)	O	24	NMOD
29	not	not	B-VP	RB	O	31	VMOD
30	usually	usually	I-VP	RB	O	29	NMOD
31	associated	associate	I-VP	VBN	O	20	VMOD
32	with	with	B-PP	IN	O	31	VMOD
33	clinical	clinical	B-NP	JJ	O	34	NMOD
34	hemolysis	hemolysis	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	13	P

1	Thus	Thus	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	AE	AE	B-NP	NN	B-cell_type	4	NMOD
4	RBCs	RBC	I-NP	NNS	I-cell_type	5	SUB
5	appear	appear	B-VP	VBP	O	0	ROOT
6	to	to	I-VP	TO	O	7	VMOD
7	have	have	I-VP	VB	O	5	VMOD
8	an	an	B-NP	DT	O	10	NMOD
9	increased	increase	I-NP	VBN	O	10	NMOD
10	sensitivity	sensitivity	I-NP	NN	O	7	OBJ
11	to	to	B-PP	TO	O	10	NMOD
12	oxidant	oxidant	B-NP	JJ	O	13	NMOD
13	stress	stress	I-NP	NN	O	11	PMOD
14	both	both	O	CC	O	15	AMOD
15	in	in	B-ADVP	FW	O	7	VMOD
16	vitro	vitro	I-ADVP	FW	O	15	AMOD
17	and	and	O	CC	O	15	AMOD
18	in	in	B-ADVP	FW	O	15	AMOD
19	vivo	vivo	I-ADVP	FW	O	18	AMOD
20	,	,	O	,	O	5	P
21	since	since	B-SBAR	IN	O	5	VMOD
22	dapsone	dapsone	B-NP	NN	O	23	SUB
23	does	do	B-VP	VBZ	O	21	SBAR
24	not	not	I-VP	RB	O	23	VMOD
25	cause	cause	I-VP	VB	O	23	VC
26	hemolytic	hemolytic	B-NP	JJ	O	27	NMOD
27	anemia	anemia	I-NP	NN	O	25	OBJ
28	at	at	B-PP	IN	O	25	VMOD
29	this	this	B-NP	DT	O	30	NMOD
30	dose	dose	I-NP	NN	O	28	PMOD
31	in	in	B-PP	IN	O	25	VMOD
32	hematologically	hematologically	B-NP	RB	O	33	AMOD
33	normal	normal	I-NP	JJ	O	34	NMOD
34	individuals	individual	I-NP	NNS	O	31	PMOD
35	.	.	O	.	O	5	P

1	Triazolam	Triazolam	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	brief	brief	B-NP	JJ	O	4	NMOD
4	episodes	episode	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	secondary	secondary	B-NP	JJ	O	7	NMOD
7	mania	mania	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	2	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	depressed	depressed	I-NP	JJ	O	11	NMOD
11	patient	patient	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	Large	Large	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	triazolam	triazolam	B-NP	NN	O	3	PMOD
5	repeatedly	repeatedly	B-ADVP	RB	O	6	VMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	brief	brief	B-NP	JJ	O	8	NMOD
8	episodes	episode	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	mania	mania	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	6	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	depressed	depressed	I-NP	JJ	O	15	NMOD
14	elderly	elderly	I-NP	JJ	O	15	NMOD
15	woman	woman	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	6	P

1	Manic	Manic	B-NP	JJ	O	2	NMOD
2	excitement	excitement	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	coincident	coincident	B-ADJP	JJ	O	3	PRD
5	with	with	B-PP	IN	O	4	AMOD
6	the	the	B-NP	DT	O	7	NMOD
7	duration	duration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	action	action	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	triazolam	triazolam	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	3	P

1	On	On	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	3	NMOD
3	mechanisms	mechanism	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	development	development	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	tolerance	tolerance	B-NP	NN	O	7	PMOD
9	to	to	B-PP	TO	O	6	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	muscular	muscular	I-NP	JJ	O	12	NMOD
12	rigidity	rigidity	I-NP	NN	O	9	PMOD
13	produced	produce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	morphine	morphine	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	development	development	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	tolerance	tolerance	B-NP	NN	O	3	PMOD
5	to	to	B-PP	TO	O	2	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	muscular	muscular	I-NP	JJ	O	8	NMOD
8	rigidity	rigidity	I-NP	NN	O	5	PMOD
9	produced	produce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	morphine	morphine	B-NP	NN	O	10	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	studied	study	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	12	P

1	Saline-pretreated	Saline-pretreated	B-NP	JJ	O	2	NMOD
2	controls	control	I-NP	NNS	O	14	SUB
3	given	give	B-VP	VBN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	test	test	I-NP	NN	O	6	NMOD
6	dose	dose	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	morphine	morphine	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	13	DEP
10	20	20	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	13	DEP
12	i.p.	i.p.	B-ADVP	RB	O	11	NMOD
13	)	)	O	)	O	6	NMOD
14	showed	show	B-VP	VBD	O	0	ROOT
15	a	a	B-NP	DT	O	17	NMOD
16	pronounced	pronounced	I-NP	JJ	O	17	NMOD
17	rigidity	rigidity	I-NP	NN	O	14	OBJ
18	recorded	record	B-VP	VBN	O	17	NMOD
19	as	as	B-PP	IN	O	18	VMOD
20	tonic	tonic	B-NP	JJ	O	21	NMOD
21	activity	activity	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	electromyogram	electromyogram	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	14	P

1	Rats	Rat	B-NP	NNS	O	13	SUB
2	treated	treat	B-VP	VBN	O	1	NMOD
3	for	for	B-PP	IN	O	2	VMOD
4	11	11	B-NP	CD	O	5	NMOD
5	days	day	I-NP	NNS	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	morphine	morphine	B-NP	NN	O	6	PMOD
8	and	and	O	CC	O	2	VMOD
9	withdrawn	withdraw	B-VP	VBN	O	2	VMOD
10	for	for	B-PP	IN	O	9	VMOD
11	36-40	36-40	B-NP	CD	O	12	NMOD
12	h	h	I-NP	NN	O	10	PMOD
13	showed	show	B-VP	VBD	O	0	ROOT
14	differences	difference	B-NP	NNS	O	13	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	development	development	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	tolerance	tolerance	B-NP	NN	O	18	PMOD
20	:	:	O	:	O	13	P
21	about	about	B-NP	IN	O	13	VMOD
22	half	half	I-NP	NN	O	26	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	animals	animal	I-NP	NNS	O	23	PMOD
26	showed	show	B-VP	VBD	O	21	SBAR
27	a	a	B-NP	DT	O	28	NMOD
28	rigidity	rigidity	I-NP	NN	O	26	OBJ
29	after	after	B-PP	IN	O	26	VMOD
30	the	the	B-NP	DT	O	32	NMOD
31	test	test	I-NP	NN	O	32	NMOD
32	dose	dose	I-NP	NN	O	29	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	morphine	morphine	B-NP	NN	O	33	PMOD
35	that	that	B-NP	WDT	O	32	NMOD
36	was	be	B-VP	VBD	O	35	SBAR
37	not	not	O	RB	O	36	VMOD
38	significantly	significantly	B-ADJP	RB	O	39	AMOD
39	less	less	I-ADJP	JJR	O	36	VMOD
40	than	than	B-PP	IN	O	39	AMOD
41	in	in	B-PP	IN	O	40	PMOD
42	the	the	B-NP	DT	O	43	NMOD
43	controls	control	I-NP	NNS	O	41	PMOD
44	and	and	O	CC	O	36	VMOD
45	were	be	B-VP	VBD	O	36	VMOD
46	akinetic	akinetic	B-ADJP	JJ	O	45	PRD
47	(	(	O	(	O	50	DEP
48	A	A	B-NP	NN	O	49	NMOD
49	group	group	I-NP	NN	O	50	DEP
50	)	)	O	)	O	46	AMOD
51	.	.	O	.	O	13	P

1	In	In	B-PP	IN	O	14	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	further	further	I-NP	JJ	O	4	NMOD
4	series	series	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	experiments	experiment	B-NP	NNS	O	5	PMOD
7	,	,	O	,	O	14	P
8	haloperidol	haloperidol	B-NP	NN	O	14	SUB
9	(	(	O	(	O	13	DEP
10	0.2	0.2	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	13	DEP
12	i.p.	i.p.	B-ADVP	RB	O	11	NMOD
13	)	)	O	)	O	8	NMOD
14	was	be	B-VP	VBD	O	0	ROOT
15	used	use	I-VP	VBN	O	14	VC
16	in	in	B-SBAR	IN	O	15	VMOD
17	order	order	O	NN	O	16	DEP
18	to	to	B-VP	TO	O	19	VMOD
19	block	block	I-VP	VB	O	16	SBAR
20	the	the	B-NP	DT	O	22	NMOD
21	dopaminergic	dopaminergic	I-NP	JJ	O	22	NMOD
22	activation	activation	I-NP	NN	O	19	OBJ
23	and	and	O	CC	O	19	VMOD
24	to	to	B-VP	TO	O	25	VMOD
25	estimate	estimate	I-VP	VB	O	19	VMOD
26	the	the	B-NP	DT	O	28	NMOD
27	real	real	I-NP	JJ	O	28	NMOD
28	degree	degree	I-NP	NN	O	25	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	tolerance	tolerance	I-NP	NN	O	29	PMOD
32	to	to	B-PP	TO	O	31	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	rigidity	rigidity	I-NP	NN	O	32	PMOD
35	without	without	B-PP	IN	O	25	VMOD
36	any	any	B-NP	DT	O	38	NMOD
37	dopaminergic	dopaminergic	I-NP	JJ	O	38	NMOD
38	interference	interference	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	14	P

1	Haloperidol	Haloperidol	B-NP	NN	O	2	SUB
2	enhanced	enhance	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	rigidity	rigidity	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	A	A	I-NP	NN	O	8	NMOD
8	group	group	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	rigidity	rigidity	B-NP	NN	O	22	SUB
6	,	,	O	,	O	5	P
7	which	which	B-NP	WDT	O	5	NMOD
8	is	be	B-VP	VBZ	O	7	SBAR
9	assumed	assume	I-VP	VBN	O	8	VC
10	to	to	I-VP	TO	O	11	VMOD
11	be	be	I-VP	VB	O	9	VMOD
12	due	due	B-PP	IN	O	13	PMOD
13	to	to	B-PP	TO	O	11	PRD
14	an	an	B-NP	DT	O	15	NMOD
15	action	action	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	morphine	morphine	B-NP	NN	O	16	PMOD
18	in	in	B-PP	IN	O	15	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	striatum	striatum	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	5	P
22	can	can	B-VP	MD	O	4	SBAR
23	be	be	I-VP	VB	O	22	VC
24	antagonized	antagonize	I-VP	VBN	O	23	VC
25	by	by	B-PP	IN	O	24	VMOD
26	another	another	B-NP	DT	O	27	NMOD
27	process	process	I-NP	NN	O	25	PMOD
28	leading	lead	B-VP	VBG	O	27	NMOD
29	to	to	B-PP	TO	O	28	VMOD
30	dopaminergic	dopaminergic	B-NP	JJ	O	31	NMOD
31	activation	activation	I-NP	NN	O	29	PMOD
32	in	in	B-PP	IN	O	31	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	striatum	striatum	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	3	P

1	Compression	Compression	B-NP	NN	O	2	NMOD
2	neuropathy	neuropathy	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	radial	radial	I-NP	JJ	O	6	NMOD
6	nerve	nerve	I-NP	NN	O	3	PMOD
7	due	due	B-ADJP	JJ	O	2	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	pentazocine	pentazocine	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	fibrous	fibrous	B-NP	JJ	O	12	NMOD
12	myopathy	myopathy	I-NP	NN	O	10	OBJ
13	.	.	O	.	O	10	P

1	Fibrous	Fibrous	B-NP	JJ	O	2	NMOD
2	myopathy	myopathy	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	9	NMOD
5	common	common	I-NP	JJ	O	7	AMOD
6	,	,	I-NP	,	O	7	P
7	well-known	well-known	I-NP	JJ	O	9	NMOD
8	side	side	I-NP	NN	O	9	NMOD
9	effect	effect	I-NP	NN	O	3	PRD
10	of	of	B-PP	IN	O	9	NMOD
11	repeated	repeat	B-NP	VBN	O	13	NMOD
12	pentazocine	pentazocine	I-NP	NN	O	13	NMOD
13	injection	injection	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	3	P

1	However	However	B-ADVP	RB	O	14	VMOD
2	,	,	O	,	O	14	P
3	compression	compression	B-NP	NN	O	4	NMOD
4	neuropathy	neuropathy	I-NP	NN	O	14	SUB
5	due	due	B-ADJP	JJ	O	4	NMOD
6	to	to	B-PP	TO	O	5	AMOD
7	fibrotic	fibrotic	B-NP	JJ	O	8	NMOD
8	muscle	muscle	I-NP	NN	O	6	PMOD
9	affected	affect	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	pentazocine	pentazocine	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	myopathy	myopathy	I-NP	NN	O	10	PMOD
14	has	have	B-VP	VBZ	O	0	ROOT
15	not	not	I-VP	RB	O	14	VMOD
16	previously	previously	I-VP	RB	O	14	VMOD
17	been	be	I-VP	VBN	O	14	VC
18	reported	report	I-VP	VBN	O	17	VC
19	.	.	O	.	O	14	P

1	Recurrent	Recurrent	B-NP	JJ	O	5	NMOD
2	reversible	reversible	I-NP	JJ	O	5	NMOD
3	acute	acute	I-NP	JJ	O	5	NMOD
4	renal	renal	I-NP	JJ	O	5	NMOD
5	failure	failure	I-NP	NN	O	0	ROOT
6	from	from	B-PP	IN	O	5	NMOD
7	amphotericin	amphotericin	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	cryptogenic	cryptogenic	B-NP	JJ	O	5	NMOD
5	cirrhosis	cirrhosis	I-NP	NN	O	3	PMOD
6	and	and	O	CC	O	8	NMOD
7	disseminated	disseminate	B-NP	VBN	O	8	NMOD
8	sporotrichosis	sporotrichosis	I-NP	NN	O	2	NMOD
9	developed	develop	B-VP	VBD	O	8	SBAR
10	acute	acute	B-NP	JJ	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	failure	failure	I-NP	NN	O	9	OBJ
13	immediately	immediately	B-VP	RB	O	14	VMOD
14	following	follow	I-VP	VBG	O	12	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	administration	administration	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	amphotericin	amphotericin	B-NP	NN	O	19	NMOD
19	B	B	I-NP	NN	O	17	PMOD
20	on	on	B-PP	IN	O	16	NMOD
21	four	four	B-NP	CD	O	23	NMOD
22	separate	separate	I-NP	JJ	O	23	NMOD
23	occasions	occasion	I-NP	NNS	O	20	PMOD
24	.	.	O	.	O	2	P

1	Pneumonitis	Pneumonitis	B-NP	NN	O	0	ROOT
2	with	with	B-PP	IN	O	1	NMOD
3	pleural	pleural	B-NP	JJ	O	8	NMOD
4	and	and	I-NP	CC	O	8	NMOD
5	pericardial	pericardial	I-NP	JJ	O	6	NMOD
6	effusion	effusion	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	neuropathy	neuropathy	I-NP	NN	O	2	PMOD
9	during	during	B-PP	IN	O	1	NMOD
10	amiodarone	amiodarone	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	sinuatrial	sinuatrial	B-NP	JJ	O	5	NMOD
5	disease	disease	I-NP	NN	O	3	PMOD
6	and	and	O	CC	O	8	NMOD
7	implanted	implant	B-NP	VBN	O	8	NMOD
8	pacemaker	pacemaker	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	2	NMOD
10	treated	treat	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	amiodarone	amiodarone	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	24	DEP
14	maximum	maximum	B-NP	JJ	O	17	NMOD
15	dose	dose	I-NP	NN	O	17	NMOD
16	1000	1000	I-NP	CD	O	17	NMOD
17	mg	mg	I-NP	NN	O	22	NMOD
18	,	,	O	,	O	22	P
19	maintenance	maintenance	B-NP	NN	O	22	NMOD
20	dose	dose	I-NP	NN	O	22	NMOD
21	800	800	I-NP	CD	O	22	NMOD
22	mg	mg	I-NP	NN	O	24	DEP
23	daily	daily	B-ADVP	RB	O	22	NMOD
24	)	)	O	)	O	12	NMOD
25	for	for	B-PP	IN	O	10	VMOD
26	10	10	B-NP	CD	O	27	NMOD
27	months	month	I-NP	NNS	O	25	PMOD
28	,	,	O	,	O	10	P
29	for	for	B-PP	IN	O	10	VMOD
30	control	control	B-NP	NN	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	supraventricular	supraventricular	B-NP	JJ	O	33	NMOD
33	tachyarrhythmias	tachyarrhythmia	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	2	P

1	Indomethacin	Indomethacin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	renal	renal	B-NP	JJ	O	4	NMOD
4	insufficiency	insufficiency	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	P
6	recurrence	recurrence	B-NP	NN	O	2	VMOD
7	on	on	B-PP	IN	O	2	VMOD
8	rechallenge	rechallenge	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	reported	report	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	5	NMOD
5	case	case	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	acute	acute	B-NP	JJ	O	10	NMOD
8	oliguric	oliguric	I-NP	JJ	O	10	NMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	6	PMOD
11	with	with	B-PP	IN	O	5	NMOD
12	hyperkalemia	hyperkalemia	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	3	VMOD
14	a	a	B-NP	DT	O	15	NMOD
15	patient	patient	I-NP	NN	O	23	NMOD
16	with	with	B-PP	IN	O	15	NMOD
17	cirrhosis	cirrhosis	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	23	P
19	ascites	ascite	B-NP	NNS	O	23	NMOD
20	,	,	O	,	O	23	P
21	and	and	O	CC	O	23	NMOD
22	cor	cor	B-NP	NN	O	23	NMOD
23	pulmonale	pulmonale	I-NP	NN	O	13	PMOD
24	after	after	B-PP	IN	O	23	NMOD
25	indomethacin	indomethacin	B-NP	NN	O	26	NMOD
26	therapy	therapy	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	2	P

1	Prompt	Prompt	B-NP	JJ	O	2	NMOD
2	restoration	restoration	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	renal	renal	B-NP	JJ	O	5	NMOD
5	function	function	I-NP	NN	O	3	PMOD
6	followed	follow	B-VP	VBD	O	0	ROOT
7	drug	drug	B-NP	NN	O	8	NMOD
8	withdrawal	withdrawal	I-NP	NN	O	6	OBJ
9	,	,	O	,	O	6	P
10	while	while	B-SBAR	IN	O	6	VMOD
11	re-exposure	re-exposure	B-NP	NN	O	18	SUB
12	to	to	B-PP	TO	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	single	single	I-NP	JJ	O	15	NMOD
15	dose	dose	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	indomethacin	indomethacin	B-NP	NN	O	16	PMOD
18	caused	cause	B-VP	VBD	O	10	SBAR
19	recurrence	recurrence	B-NP	NN	O	18	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	acute	acute	B-NP	JJ	O	23	NMOD
22	reversible	reversible	I-NP	JJ	O	23	NMOD
23	oliguria	oliguria	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	6	P

1	Changes	Change	B-NP	NNS	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	heart	heart	B-NP	NN	O	4	NMOD
4	size	size	I-NP	NN	O	2	PMOD
5	during	during	B-PP	IN	O	1	NMOD
6	long-term	long-term	B-NP	JJ	O	8	NMOD
7	timolol	timolol	I-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	5	PMOD
9	after	after	B-PP	IN	O	8	NMOD
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	infarction	infarction	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	long-term	long-term	B-NP	JJ	O	6	NMOD
5	timolol	timolol	I-NP	NN	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	3	PMOD
7	on	on	B-PP	IN	O	2	NMOD
8	heart	heart	B-NP	NN	O	9	NMOD
9	size	size	I-NP	NN	O	7	PMOD
10	after	after	B-PP	IN	O	2	NMOD
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	infarction	infarction	I-NP	NN	O	10	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	evaluated	evaluate	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	X-ray	X-ray	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	double-blind	double-blind	I-NP	JJ	O	20	NMOD
20	study	study	I-NP	NN	O	17	PMOD
21	including	include	B-PP	VBG	O	20	NMOD
22	241	241	B-NP	CD	O	23	NMOD
23	patients	patient	I-NP	NNS	O	21	PMOD
24	(	(	O	(	O	30	DEP
25	placebo	placebo	B-NP	NN	O	28	NMOD
26	126	126	I-NP	CD	O	25	NMOD
27	,	,	O	,	O	28	P
28	timolol	timolol	B-NP	NN	B-protein	30	DEP
29	115	115	I-NP	CD	I-protein	28	NMOD
30	)	)	O	)	O	23	NMOD
31	.	.	O	.	O	13	P

1	These	These	B-NP	DT	O	2	NMOD
2	differences	difference	I-NP	NNS	O	3	SUB
3	may	may	B-VP	MD	O	0	ROOT
4	be	be	I-VP	VB	O	3	VC
5	caused	cause	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	timolol	timolol	B-NP	NN	O	9	NMOD
8	induced	induce	B-VP	VBD	O	9	NMOD
9	bradycardia	bradycardia	B-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	compensatory	compensatory	I-NP	JJ	O	13	NMOD
13	increase	increase	I-NP	NN	O	6	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	end-diastolic	end-diastolic	B-NP	JJ	O	16	NMOD
16	volume	volume	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	3	P

1	Vitamin	Vitamin	B-NP	NN	O	3	NMOD
2	D3	D3	I-NP	NN	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	dairy	dairy	B-NP	NN	O	6	NMOD
6	cows	cow	I-NP	NNS	O	4	PMOD
7	.	.	O	.	O	3	P

1	Large	Large	B-NP	JJ	O	3	NMOD
2	parenteral	parenteral	I-NP	JJ	O	3	NMOD
3	doses	dose	I-NP	NNS	O	20	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	vitamin	vitamin	B-NP	NN	O	6	NMOD
6	D3	D3	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	19	DEP
8	15	15	B-NP	CD	O	10	AMOD
9	to	to	I-NP	TO	O	10	AMOD
10	17.5	17.5	I-NP	CD	O	18	NMOD
11	x	x	I-NP	NN	O	10	NMOD
12	10	10	I-NP	CD	O	11	NMOD
13	(	(	O	(	O	15	DEP
14	6	6	B-NP	CD	O	15	DEP
15	)	)	O	)	O	11	NMOD
16	IU	IU	B-NP	NN	O	18	NMOD
17	vitamin	vitamin	I-NP	NN	O	18	NMOD
18	D3	D3	I-NP	NN	O	19	DEP
19	)	)	O	)	O	6	NMOD
20	were	be	B-VP	VBD	O	0	ROOT
21	associated	associate	I-VP	VBN	O	20	VC
22	with	with	B-PP	IN	O	21	VMOD
23	prolonged	prolonged	B-NP	JJ	O	24	NMOD
24	hypercalcemia	hypercalcemia	I-NP	NN	O	36	NMOD
25	,	,	O	,	O	36	P
26	hyperphosphatemia	hyperphosphatemia	B-NP	NN	O	36	NMOD
27	,	,	O	,	O	36	P
28	and	and	O	CC	O	36	NMOD
29	large	large	B-NP	JJ	O	30	NMOD
30	increases	increase	I-NP	NNS	O	36	NMOD
31	of	of	B-PP	IN	O	30	NMOD
32	vitamin	vitamin	B-NP	NN	O	33	NMOD
33	D3	D3	I-NP	NN	O	31	PMOD
34	and	and	O	CC	O	36	NMOD
35	its	its	B-NP	PRP$	O	36	NMOD
36	metabolites	metabolite	I-NP	NNS	O	22	PMOD
37	in	in	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	40	NMOD
39	blood	blood	I-NP	NN	O	40	NMOD
40	plasma	plasma	I-NP	NN	O	37	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	nonlactating	nonlactating	B-NP	JJ	O	47	NMOD
43	nonpregnant	nonpregnant	I-NP	JJ	O	47	NMOD
44	and	and	I-NP	CC	O	47	NMOD
45	pregnant	pregnant	I-NP	JJ	O	47	NMOD
46	Jersey	Jersey	I-NP	NNP	O	47	NMOD
47	cows	cow	I-NP	NNS	O	41	PMOD
48	.	.	O	.	O	20	P

1	None	None	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	cows	cow	I-NP	NNS	O	2	PMOD
5	treated	treat	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	vitamin	vitamin	B-NP	NN	O	8	NMOD
8	D3	D3	I-NP	NN	O	6	PMOD
9	showed	show	B-VP	VBD	O	27	VMOD
10	signs	sign	B-NP	NNS	O	9	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	milk	milk	B-NP	NN	O	13	NMOD
13	fever	fever	I-NP	NN	O	11	PMOD
14	during	during	B-PP	IN	O	9	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	peripartal	peripartal	I-NP	JJ	O	17	NMOD
17	period	period	I-NP	NN	O	14	PMOD
18	;	;	O	:	O	27	P
19	however	however	B-ADVP	RB	O	27	VMOD
20	,	,	O	,	O	27	P
21	22	22	B-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	27	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	control	control	I-NP	NN	O	26	NMOD
26	cows	cow	I-NP	NNS	O	23	PMOD
27	developed	develop	B-VP	VBD	O	0	ROOT
28	clinical	clinical	B-NP	JJ	O	29	NMOD
29	signs	sign	I-NP	NNS	O	27	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	milk	milk	B-NP	NN	O	32	NMOD
32	fever	fever	I-NP	NN	O	30	PMOD
33	during	during	B-PP	IN	O	29	NMOD
34	this	this	B-NP	DT	O	35	NMOD
35	period	period	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	27	P

1	Signs	Sign	B-NP	NNS	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	vitamin	vitamin	B-NP	NN	O	5	NMOD
4	D3	D3	I-NP	NN	O	5	NMOD
5	toxicity	toxicity	I-NP	NN	O	2	PMOD
6	were	be	B-VP	VBD	O	19	VMOD
7	not	not	I-VP	RB	O	6	VMOD
8	observed	observe	I-VP	VBN	O	6	VC
9	in	in	B-PP	IN	O	8	VMOD
10	nonlactating	nonlactating	B-NP	JJ	O	12	NMOD
11	nonpregnant	nonpregnant	I-NP	JJ	O	12	NMOD
12	cows	cow	I-NP	NNS	O	9	PMOD
13	;	;	O	:	O	19	P
14	however	however	B-ADVP	RB	O	19	VMOD
15	,	,	O	,	O	19	P
16	pregnant	pregnant	B-NP	JJ	O	17	NMOD
17	cows	cow	I-NP	NNS	O	19	SUB
18	commonly	commonly	B-ADVP	RB	O	19	VMOD
19	developed	develop	B-VP	VBD	O	0	ROOT
20	severe	severe	B-NP	JJ	O	21	NMOD
21	signs	sign	I-NP	NNS	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	vitamin	vitamin	B-NP	NN	O	25	NMOD
24	D3	D3	I-NP	NN	O	25	NMOD
25	toxicity	toxicity	I-NP	NN	O	22	PMOD
26	and	and	O	CC	O	30	NMOD
27	10	10	B-NP	CD	O	28	AMOD
28	of	of	B-PP	IN	O	30	NMOD
29	17	17	B-NP	CD	O	28	AMOD
30	cows	cow	I-NP	NNS	O	31	SUB
31	died	die	B-VP	VBD	O	21	NMOD
32	.	.	O	.	O	19	P

1	Peripheral	Peripheral	B-NP	JJ	O	2	NMOD
2	neuropathy	neuropathy	I-NP	NN	O	11	SUB
3	due	due	B-PP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	nutritional	nutritional	B-NP	JJ	O	6	NMOD
6	deficiency	deficiency	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	thiamine	thiamine	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	riboflavin	riboflavin	I-NP	NN	O	7	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	common	common	B-ADJP	JJ	O	11	VMOD
13	(	(	O	(	O	16	DEP
14	10.1	10.1	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	AMOD
17	and	and	O	CC	O	12	DEP
18	presented	present	B-VP	VBN	O	12	DEP
19	mainly	mainly	B-ADVP	RB	O	18	VMOD
20	as	as	B-PP	IN	O	18	VMOD
21	sensory	sensory	B-NP	JJ	O	24	NMOD
22	and	and	I-NP	CC	O	24	NMOD
23	sensori-motor	sensori-motor	I-NP	JJ	O	24	NMOD
24	neuropathy	neuropathy	I-NP	NN	O	20	PMOD
25	.	.	O	.	O	11	P

1	Isoniazid	Isoniazid	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	most	most	I-NP	RBS	O	5	AMOD
5	frequent	frequent	I-NP	JJ	O	6	NMOD
6	agent	agent	I-NP	NN	O	2	PRD
7	in	in	B-PP	IN	O	2	VMOD
8	drug	drug	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	double-blind	double-blind	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	efficacy	efficacy	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	safety	safety	I-NP	NN	O	4	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	dothiepin	dothiepin	B-NP	NN	O	11	NMOD
11	hydrochloride	hydrochloride	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	3	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	major	major	B-NP	JJ	O	18	NMOD
17	depressive	depressive	I-NP	JJ	O	18	NMOD
18	disorder	disorder	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	12	VMOD
2	a	a	B-NP	DT	O	7	NMOD
3	6-week	6-week	I-NP	JJ	O	5	AMOD
4	double-blind	double-blind	I-NP	JJ	O	5	AMOD
5	parallel	parallel	I-NP	JJ	O	7	NMOD
6	treatment	treatment	I-NP	NN	O	7	NMOD
7	study	study	I-NP	NN	O	1	PMOD
8	,	,	O	,	O	12	P
9	dothiepin	dothiepin	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	amitriptyline	amitriptyline	I-NP	NN	O	12	SUB
12	were	be	B-VP	VBD	O	0	ROOT
13	compared	compare	I-VP	VBN	O	12	VC
14	to	to	B-PP	TO	O	13	VMOD
15	placebo	placebo	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	33	33	B-NP	CD	O	22	NMOD
21	depressed	depressed	I-NP	JJ	O	22	NMOD
22	outpatients	outpatient	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	12	P

1	Dothiepin	Dothiepin	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	amitriptyline	amitriptyline	I-NP	NN	O	4	SUB
4	were	be	B-VP	VBD	O	17	VMOD
5	equally	equally	B-ADJP	RB	O	6	AMOD
6	effective	effective	I-ADJP	JJ	O	4	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	alleviating	alleviate	B-VP	VBG	O	7	PMOD
9	the	the	B-NP	DT	O	10	NMOD
10	symptoms	symptom	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	depressive	depressive	B-NP	JJ	O	13	NMOD
13	illness	illness	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	17	P
15	and	and	O	CC	O	17	VMOD
16	both	both	B-NP	DT	O	17	SUB
17	were	be	B-VP	VBD	O	0	ROOT
18	significantly	significantly	B-ADJP	RB	O	19	AMOD
19	superior	superior	I-ADJP	JJ	O	17	PRD
20	to	to	B-PP	TO	O	19	AMOD
21	placebo	placebo	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	17	P

1	The	The	B-NP	DT	O	3	NMOD
2	overall	overall	I-NP	JJ	O	3	NMOD
3	incidence	incidence	I-NP	NN	O	21	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	side	side	B-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	11	NMOD
7	and	and	O	CC	O	11	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	frequency	frequency	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	severity	severity	I-NP	NN	O	20	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	blurred	blurred	B-NP	JJ	O	14	NMOD
14	vision	vision	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	20	P
16	dry	dry	B-NP	JJ	O	17	NMOD
17	mouth	mouth	I-NP	NN	O	20	NMOD
18	,	,	O	,	O	20	P
19	and	and	O	CC	O	20	NMOD
20	drowsiness	drowsiness	B-NP	NN	O	4	PMOD
21	were	be	B-VP	VBD	O	0	ROOT
22	significantly	significantly	B-ADJP	RB	O	23	AMOD
23	less	less	I-ADJP	JJR	O	21	PRD
24	with	with	B-PP	IN	O	23	AMOD
25	dothiepin	dothiepin	B-NP	NN	O	24	PMOD
26	than	than	B-PP	IN	O	23	AMOD
27	with	with	B-PP	IN	O	26	PMOD
28	amitriptyline	amitriptyline	B-NP	NN	O	27	PMOD
29	.	.	O	.	O	21	P

1	Behavioral	Behavioral	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	diazepam	diazepam	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	propranolol	propranolol	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	panic	panic	B-NP	NN	O	11	NMOD
11	disorder	disorder	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	agoraphobia	agoraphobia	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	oral	oral	B-NP	JJ	O	5	NMOD
5	doses	dose	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	diazepam	diazepam	B-NP	NN	O	6	PMOD
8	(	(	O	(	O	24	DEP
9	single	single	B-NP	JJ	O	10	NMOD
10	dose	dose	I-NP	NN	O	17	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	10	10	B-NP	CD	O	13	NMOD
13	mg	mg	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	17	NMOD
15	a	a	B-NP	DT	O	17	NMOD
16	median	median	I-NP	JJ	O	17	NMOD
17	dose	dose	I-NP	NN	O	24	DEP
18	of	of	B-PP	IN	O	17	NMOD
19	30	30	B-NP	CD	O	20	NMOD
20	mg/day	mg/day	I-NP	NN	O	18	PMOD
21	for	for	B-PP	IN	O	17	NMOD
22	2	2	B-NP	CD	O	23	NMOD
23	weeks	week	I-NP	NNS	O	21	PMOD
24	)	)	O	)	O	5	NMOD
25	and	and	O	CC	O	26	NMOD
26	propranolol	propranolol	B-NP	NN	O	54	SUB
27	(	(	O	(	O	43	DEP
28	single	single	B-NP	JJ	O	29	NMOD
29	dose	dose	I-NP	NN	O	36	NMOD
30	of	of	B-PP	IN	O	29	NMOD
31	80	80	B-NP	CD	O	32	NMOD
32	mg	mg	I-NP	NN	O	30	PMOD
33	and	and	O	CC	O	36	NMOD
34	a	a	B-NP	DT	O	36	NMOD
35	median	median	I-NP	JJ	O	36	NMOD
36	dose	dose	I-NP	NN	O	43	DEP
37	of	of	B-PP	IN	O	36	NMOD
38	240	240	B-NP	CD	O	39	NMOD
39	mg/day	mg/day	I-NP	NN	O	37	PMOD
40	for	for	B-PP	IN	O	36	NMOD
41	2	2	B-NP	CD	O	42	NMOD
42	weeks	week	I-NP	NNS	O	40	PMOD
43	)	)	O	)	O	26	NMOD
44	on	on	B-PP	IN	O	26	NMOD
45	psychological	psychological	B-NP	JJ	O	46	NMOD
46	performance	performance	I-NP	NN	O	53	NMOD
47	of	of	B-PP	IN	O	46	NMOD
48	patients	patient	B-NP	NNS	O	47	PMOD
49	with	with	B-PP	IN	O	48	NMOD
50	panic	panic	B-NP	NN	O	51	NMOD
51	disorders	disorder	I-NP	NNS	O	49	PMOD
52	and	and	O	CC	O	53	NMOD
53	agoraphobia	agoraphobia	B-NP	NN	O	44	PMOD
54	were	be	B-VP	VBD	O	5	NMOD
55	investigated	investigate	I-VP	VBN	O	54	VC
56	in	in	B-PP	IN	O	55	VMOD
57	a	a	B-NP	DT	O	58	NMOD
58	double-blind	double-blind	I-NP	JJ	O	63	NMOD
59	,	,	O	,	O	58	P
60	randomized	randomize	B-VP	VBN	O	58	NMOD
61	and	and	O	CC	O	58	NMOD
62	crossover	crossover	B-NP	NN	O	63	NMOD
63	design	design	I-NP	NN	O	56	PMOD
64	.	.	O	.	O	2	P

1	Both	Both	B-NP	DT	O	2	NMOD
2	drugs	drug	I-NP	NNS	O	3	SUB
3	impaired	impair	B-VP	VBD	O	10	VMOD
4	immediate	immediate	B-NP	JJ	O	5	AMOD
5	free	free	I-NP	JJ	O	10	VMOD
6	recall	recall	I-NP	NN	O	5	NMOD
7	but	but	O	CC	O	10	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	decrease	decrease	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	greater	great	B-ADJP	JJR	O	10	PRD
12	for	for	B-PP	IN	O	11	AMOD
13	diazepam	diazepam	B-NP	NN	O	12	PMOD
14	than	than	B-PP	IN	O	11	AMOD
15	propranolol	propranolol	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	co-administration	co-administration	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	aspirin	aspirin	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	2	NMOD
6	N-	N-	B-NP	NN	O	5	PMOD
7	[	[	O	(	O	2	NMOD
8	4-	4-	B-NP	NN	O	14	NMOD
9	(	(	O	(	O	11	DEP
10	5-nitro-2-furyl	5-nitro-2-furyl	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	-2-thiazolyl	-2-thiazolyl	O	JJ	O	14	NMOD
13	]	]	O	)	O	14	NMOD
14	-formamide	-formamide	B-NP	NN	O	20	SUB
15	(	(	O	(	O	17	DEP
16	FANFT	FANFT	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	to	to	B-PP	TO	O	14	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	resulted	result	B-VP	VBD	O	7	SBAR
21	in	in	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	reduced	reduce	I-NP	VBN	O	24	NMOD
24	incidence	incidence	I-NP	NN	O	27	SUB
25	of	of	B-PP	IN	O	24	NMOD
26	FANFT	FANFT	B-NP	NN	B-protein	25	PMOD
27	induced	induce	B-VP	VBD	O	21	SBAR
28	bladder	bladder	B-NP	NN	O	29	NMOD
29	carcinomas	carcinoma	I-NP	NNS	O	33	NMOD
30	but	but	O	CC	O	33	NMOD
31	a	a	B-NP	DT	O	33	NMOD
32	concomitant	concomitant	I-NP	JJ	O	33	NMOD
33	induction	induction	I-NP	NN	O	27	OBJ
34	of	of	B-PP	IN	O	33	NMOD
35	forestomach	forestomach	B-NP	NN	O	36	NMOD
36	tumors	tumor	I-NP	NNS	O	34	PMOD
37	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	results	result	I-NP	NNS	O	4	SUB
4	are	be	B-VP	VBP	O	0	ROOT
5	consistent	consistent	B-ADJP	JJ	O	4	PRD
6	with	with	B-PP	IN	O	5	AMOD
7	the	the	B-NP	DT	O	9	NMOD
8	carcinogenicity	carcinogenicity	I-NP	NN	O	9	NMOD
9	experiment	experiment	I-NP	NN	O	6	PMOD
10	suggesting	suggest	B-VP	VBG	O	4	VMOD
11	that	that	B-SBAR	IN	O	26	DEP
12	different	different	B-NP	JJ	O	13	NMOD
13	mechanisms	mechanism	I-NP	NNS	O	14	SUB
14	are	be	B-VP	VBP	O	11	SBAR
15	involved	involve	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	FANFT	FANFT	B-NP	NN	O	18	NMOD
18	carcinogenesis	carcinogenesis	I-NP	NN	O	16	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	23	NMOD
21	bladder	bladder	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	forestomach	forestomach	I-NP	NN	O	19	PMOD
24	,	,	O	,	O	26	P
25	and	and	O	CC	O	26	DEP
26	that	that	B-SBAR	IN	O	10	VMOD
27	aspirin	aspirin	B-NP	NN	O	29	NMOD
28	's	's	B-NP	POS	O	29	NMOD
29	effect	effect	I-NP	NN	O	35	SUB
30	on	on	B-PP	IN	O	29	NMOD
31	FANFT	FANFT	B-NP	NN	B-protein	30	PMOD
32	in	in	B-PP	IN	O	29	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	forestomach	forestomach	I-NP	NN	O	32	PMOD
35	is	be	B-VP	VBZ	O	26	SBAR
36	not	not	O	RB	O	35	VMOD
37	due	due	B-ADJP	JJ	O	35	PRD
38	to	to	B-PP	TO	O	37	AMOD
39	an	an	B-NP	DT	O	41	NMOD
40	irritant	irritant	I-NP	JJ	O	41	NMOD
41	effect	effect	I-NP	NN	O	38	PMOD
42	associated	associate	B-VP	VBN	O	41	NMOD
43	with	with	B-PP	IN	O	42	VMOD
44	increased	increase	B-NP	VBN	O	46	NMOD
45	cell	cell	I-NP	NN	O	46	NMOD
46	proliferation	proliferation	I-NP	NN	O	43	PMOD
47	.	.	O	.	O	4	P

1	Provocation	Provocation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	postural	postural	B-NP	JJ	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	2	PMOD
5	by	by	B-PP	IN	O	1	NMOD
6	nitroglycerin	nitroglycerin	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	diabetic	diabetic	B-NP	JJ	O	10	NMOD
9	autonomic	autonomic	I-NP	JJ	O	10	NMOD
10	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	nitroglycerin	nitroglycerin	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	heart	heart	B-NP	NN	O	7	NMOD
7	rate	rate	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	systolic	systolic	B-NP	JJ	O	11	NMOD
10	blood	blood	I-NP	NN	O	11	NMOD
11	pressure	pressure	I-NP	NN	O	5	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	compared	compare	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	5	5	B-NP	CD	O	17	NMOD
16	normal	normal	I-NP	JJ	O	17	NMOD
17	subjects	subject	I-NP	NNS	O	14	PMOD
18	,	,	O	,	O	12	P
19	12	12	B-NP	CD	O	21	NMOD
20	diabetic	diabetic	I-NP	JJ	O	21	NMOD
21	subjects	subject	I-NP	NNS	O	29	NMOD
22	without	without	B-PP	IN	O	21	NMOD
23	autonomic	autonomic	B-NP	JJ	O	24	NMOD
24	neuropathy	neuropathy	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	29	P
26	and	and	O	CC	O	29	NMOD
27	5	5	B-NP	CD	O	29	NMOD
28	diabetic	diabetic	I-NP	JJ	O	29	NMOD
29	subjects	subject	I-NP	NNS	O	12	VMOD
30	with	with	B-PP	IN	O	29	NMOD
31	autonomic	autonomic	B-NP	JJ	O	32	NMOD
32	neuropathy	neuropathy	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	5	NMOD
2	magnitude	magnitude	I-NP	NN	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	time	time	I-NP	NN	O	5	NMOD
5	course	course	I-NP	NN	O	21	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	increase	increase	I-NP	NN	O	14	NMOD
9	in	in	B-PP	IN	O	8	NMOD
10	heart	heart	B-NP	NN	O	11	NMOD
11	rate	rate	I-NP	NN	O	9	PMOD
12	and	and	O	CC	O	14	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	decrease	decrease	I-NP	NN	O	6	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	systolic	systolic	B-NP	JJ	O	18	NMOD
17	blood	blood	I-NP	NN	O	18	NMOD
18	pressure	pressure	I-NP	NN	O	15	PMOD
19	after	after	B-PP	IN	O	14	NMOD
20	nitroglycerin	nitroglycerin	B-NP	NN	O	19	PMOD
21	were	be	B-VP	VBD	O	0	ROOT
22	similar	similar	B-ADJP	JJ	O	21	PRD
23	in	in	B-PP	IN	O	22	AMOD
24	the	the	B-NP	DT	O	28	NMOD
25	normal	normal	I-NP	JJ	O	28	NMOD
26	and	and	I-NP	CC	O	28	NMOD
27	diabetic	diabetic	I-NP	JJ	O	28	NMOD
28	subjects	subject	I-NP	NNS	O	23	PMOD
29	without	without	B-PP	IN	O	22	AMOD
30	autonomic	autonomic	B-NP	JJ	O	31	NMOD
31	neuropathy	neuropathy	I-NP	NN	O	29	PMOD
32	,	,	O	,	O	21	P
33	whereas	whereas	O	IN	O	21	VMOD
34	a	a	B-NP	DT	O	36	NMOD
35	lesser	less	I-NP	JJR	O	36	NMOD
36	increase	increase	I-NP	NN	O	43	NMOD
37	in	in	B-PP	IN	O	36	NMOD
38	heart	heart	B-NP	NN	O	39	NMOD
39	rate	rate	I-NP	NN	O	37	PMOD
40	and	and	O	CC	O	43	NMOD
41	a	a	B-NP	DT	O	43	NMOD
42	greater	great	I-NP	JJR	O	43	NMOD
43	decrease	decrease	I-NP	NN	O	48	SUB
44	in	in	B-PP	IN	O	43	NMOD
45	systolic	systolic	B-NP	JJ	O	47	NMOD
46	blood	blood	I-NP	NN	O	47	NMOD
47	pressure	pressure	I-NP	NN	O	44	PMOD
48	occurred	occur	B-VP	VBD	O	33	SBAR
49	in	in	B-PP	IN	O	48	VMOD
50	the	the	B-NP	DT	O	52	NMOD
51	diabetic	diabetic	I-NP	JJ	O	52	NMOD
52	subjects	subject	I-NP	NNS	O	49	PMOD
53	with	with	B-PP	IN	O	52	NMOD
54	autonomic	autonomic	B-NP	JJ	O	55	NMOD
55	neuropathy	neuropathy	I-NP	NN	O	53	PMOD
56	.	.	O	.	O	21	P

1	Characterization	Characterization	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	estrogen	estrogen	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	adenohypophyseal	adenohypophyseal	B-NP	JJ	O	6	NMOD
6	tumors	tumor	I-NP	NNS	O	4	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	Fischer	Fischer	I-NP	NNP	O	11	NMOD
10	344	344	I-NP	CD	O	11	NMOD
11	rat	rat	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	4	P

1	Pituitary	Pituitary	B-NP	JJ	O	2	NMOD
2	tumors	tumor	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	induced	induce	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	F344	F344	B-NP	NN	O	8	NMOD
7	female	female	I-NP	JJ	O	8	NMOD
8	rats	rat	I-NP	NNS	O	5	PMOD
9	by	by	B-PP	IN	O	4	VMOD
10	chronic	chronic	B-NP	JJ	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	diethylstilbestrol	diethylstilbestrol	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	19	DEP
15	DES	DES	B-NP	NNP	O	18	NMOD
16	,	,	O	,	O	18	P
17	8-10	8-10	B-NP	CD	O	18	NMOD
18	mg	mg	I-NP	NN	O	19	DEP
19	)	)	O	)	O	3	VMOD
20	implanted	implant	B-VP	VBN	O	3	VC
21	subcutaneously	subcutaneously	B-ADVP	RB	O	20	VMOD
22	in	in	B-PP	IN	O	20	VMOD
23	silastic	silastic	B-NP	JJ	O	24	NMOD
24	capsules	capsule	I-NP	NNS	O	22	PMOD
25	.	.	O	.	O	3	P

1	Triamterene	Triamterene	B-NP	NN	O	2	NMOD
2	nephrolithiasis	nephrolithiasis	I-NP	NN	O	0	ROOT
3	complicating	complicate	B-VP	VBG	O	2	NMOD
4	dyazide	dyazide	B-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	3	OBJ
6	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	triamterene	triamterene	B-NP	NN	O	5	NMOD
5	nephrolithiasis	nephrolithiasis	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	reported	report	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	10	NMOD
10	man	man	I-NP	NN	O	8	PMOD
11	after	after	B-PP	IN	O	7	VMOD
12	4	4	B-NP	CD	O	13	NMOD
13	years	year	I-NP	NNS	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	hydrochlorothiazide-triamterene	hydrochlorothiazide-triamterene	B-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	14	PMOD
17	for	for	B-PP	IN	O	16	NMOD
18	hypertension	hypertension	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	6	P

1	Metabolic	Metabolic	B-NP	JJ	O	2	NMOD
2	involvement	involvement	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	adriamycin	adriamycin	B-NP	NN	O	5	NMOD
5	cardiotoxicity	cardiotoxicity	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	cardiotoxic	cardiotoxic	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	adriamycin	adriamycin	B-NP	NN	O	4	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	studied	study	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	mammalian	mammalian	B-NP	JJ	B-cell_type	11	NMOD
10	myocardial	myocardial	I-NP	JJ	I-cell_type	11	NMOD
11	cells	cell	I-NP	NNS	I-cell_type	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	culture	culture	B-NP	NN	O	12	PMOD
14	as	as	B-PP	IN	O	7	VMOD
15	a	a	B-NP	DT	O	17	NMOD
16	model	model	I-NP	NN	O	17	NMOD
17	system	system	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	6	P

1	Age-dependent	Age-dependent	B-NP	JJ	O	2	NMOD
2	sensitivity	sensitivity	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	rat	rat	I-NP	NN	O	3	PMOD
6	to	to	B-PP	TO	O	2	NMOD
7	neurotoxic	neurotoxic	B-NP	JJ	O	8	NMOD
8	effects	effect	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	streptomycin	streptomycin	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	Crescentic	Crescentic	B-NP	JJ	O	3	NMOD
2	fibrillary	fibrillary	I-NP	JJ	O	3	NMOD
3	glomerulonephritis	glomerulonephritis	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	intermittent	intermittent	B-NP	JJ	O	8	NMOD
7	rifampin	rifampin	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	pulmonary	pulmonary	B-NP	JJ	O	11	NMOD
11	tuberculosis	tuberculosis	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	3	NMOD
2	case	case	I-NP	NN	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	reveals	reveal	B-VP	VBZ	O	0	ROOT
5	an	an	B-NP	DT	O	7	NMOD
6	unusual	unusual	I-NP	JJ	O	7	NMOD
7	finding	finding	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	rapidly	rapidly	B-NP	RB	O	12	NMOD
10	proliferative	proliferative	I-NP	JJ	O	9	AMOD
11	crescentic	crescentic	I-NP	JJ	O	9	AMOD
12	glomerulonephritis	glomerulonephritis	I-NP	NN	O	8	PMOD
13	in	in	B-PP	IN	O	7	NMOD
14	a	a	B-NP	DT	O	15	NMOD
15	patient	patient	I-NP	NN	O	13	PMOD
16	treated	treat	B-VP	VBN	O	15	NMOD
17	with	with	B-PP	IN	O	16	VMOD
18	rifampin	rifampin	B-NP	NN	O	17	PMOD
19	who	who	B-NP	WP	O	15	NMOD
20	had	have	B-VP	VBD	O	19	SBAR
21	no	no	B-NP	DT	O	24	NMOD
22	other	other	I-NP	JJ	O	24	NMOD
23	identifiable	identifiable	I-NP	JJ	O	24	NMOD
24	causes	cause	I-NP	NNS	O	20	OBJ
25	for	for	B-PP	IN	O	20	VMOD
26	developing	develop	B-VP	VBG	O	25	PMOD
27	this	this	B-NP	DT	O	28	NMOD
28	disease	disease	I-NP	NN	O	26	OBJ
29	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	underwent	undergo	B-VP	VBD	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	10-month	10-month	I-NP	JJ	O	6	NMOD
6	regimen	regimen	I-NP	NN	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	rifampin	rifampin	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	isoniazid	isoniazid	I-NP	NN	O	7	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	pulmonary	pulmonary	B-NP	JJ	O	13	NMOD
13	tuberculosis	tuberculosis	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	3	VMOD
15	was	be	B-VP	VBD	O	3	VMOD
16	discovered	discover	I-VP	VBN	O	15	VC
17	to	to	I-VP	TO	O	18	VMOD
18	have	have	I-VP	VB	O	16	VMOD
19	developed	develop	I-VP	VBN	O	18	VC
20	signs	sign	B-NP	NNS	O	19	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	severe	severe	B-NP	JJ	O	24	NMOD
23	renal	renal	I-NP	JJ	O	24	NMOD
24	failure	failure	I-NP	NN	O	26	NMOD
25	five	five	B-NP	CD	O	24	NMOD
26	weeks	week	I-NP	NNS	O	21	PMOD
27	after	after	B-PP	IN	O	20	NMOD
28	completion	completion	B-NP	NN	O	27	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	therapy	therapy	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	3	P

1	Time	Time	B-NP	NN	O	2	NMOD
2	course	course	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	lipid	lipid	B-NP	NN	O	5	NMOD
5	peroxidation	peroxidation	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	puromycin	puromycin	B-NP	NN	O	8	NMOD
8	aminonucleoside	aminonucleoside	I-NP	NN	O	6	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	nephropathy	nephropathy	B-NP	NN	O	9	OBJ
11	.	.	O	.	O	9	P

1	Reactive	Reactive	B-NP	JJ	O	3	NMOD
2	oxygen	oxygen	I-NP	NN	O	3	NMOD
3	species	specie	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	implicated	implicate	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	pathogenesis	pathogenesis	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	acute	acute	B-NP	JJ	O	13	NMOD
12	puromycin	puromycin	I-NP	NN	O	13	NMOD
13	aminonucleoside	aminonucleoside	I-NP	NN	O	18	NMOD
14	(	(	O	(	O	16	DEP
15	PAN	PAN	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	induced	induce	B-NP	VBN	O	18	NMOD
18	nephropathy	nephropathy	I-NP	NN	O	10	PMOD
19	,	,	O	,	O	6	P
20	with	with	B-PP	IN	O	6	VMOD
21	antioxidants	antioxidant	B-NP	NNS	O	20	PMOD
22	significantly	significantly	B-VP	RB	O	23	VMOD
23	reducing	reduce	I-VP	VBG	O	21	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	proteinuria	proteinuria	I-NP	NN	O	23	OBJ
26	.	.	O	.	O	4	P

1	Clomipramine	Clomipramine	B-NP	NN	O	4	NMOD
2	induced	induce	B-VP	VBD	O	4	NMOD
3	sleep	sleep	B-NP	NN	O	4	NMOD
4	disturbance	disturbance	I-NP	NN	O	5	SUB
5	does	do	B-VP	VBZ	O	0	ROOT
6	not	not	I-VP	RB	O	5	VMOD
7	impair	impair	I-VP	VB	O	5	VC
8	its	its	B-NP	PRP$	O	10	NMOD
9	prolactin-releasing	prolactin-releasing	I-NP	JJ	O	10	NMOD
10	action	action	I-NP	NN	O	7	OBJ
11	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	undertaken	undertake	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	examine	examine	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	role	role	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	sleep	sleep	B-NP	NN	O	12	NMOD
12	disturbance	disturbance	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	7	P
14	induced	induce	B-VP	VBN	O	7	VMOD
15	by	by	B-PP	IN	O	14	VMOD
16	clomipramine	clomipramine	B-NP	NN	O	17	NMOD
17	administration	administration	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	14	P
19	on	on	B-PP	IN	O	14	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	secretory	secretory	I-NP	JJ	O	22	NMOD
22	rate	rate	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	prolactin	prolactin	B-NP	NN	O	23	PMOD
25	(	(	O	(	O	27	DEP
26	PRL	PRL	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	in	in	B-PP	IN	O	14	VMOD
29	addition	addition	B-NP	NN	O	28	PMOD
30	to	to	B-PP	TO	O	28	PMOD
31	the	the	B-NP	DT	O	34	NMOD
32	direct	direct	I-NP	JJ	O	34	NMOD
33	drug	drug	I-NP	NN	O	34	NMOD
34	effect	effect	I-NP	NN	O	28	PMOD
35	.	.	O	.	O	4	P

1	Angioedema	Angioedema	B-NP	NN	O	0	ROOT
2	following	follow	B-PP	VBG	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	intravenous	intravenous	I-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	metoprolol	metoprolol	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	2	NMOD
2	history	history	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	angioedema	angioedema	B-NP	NN	O	3	PMOD
5	secondary	secondary	B-ADJP	JJ	O	4	NMOD
6	to	to	B-PP	TO	O	5	AMOD
7	lisinopril	lisinopril	B-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	elicited	elicit	I-VP	VBN	O	9	VC
11	.	.	O	.	O	9	P

1	During	During	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	4	NMOD
3	first	first	I-NP	JJ	O	4	NMOD
4	day	day	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	hospitalization	hospitalization	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	10	DEP
8	while	while	B-SBAR	IN	O	10	DEP
9	intubated	intubate	B-VP	VBN	O	10	DEP
10	)	)	O	)	O	1	PMOD
11	,	,	O	,	O	1	VMOD
12	intravenous	intravenous	B-NP	JJ	O	13	NMOD
13	metoprolol	metoprolol	I-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	11	SBAR
15	given	give	I-VP	VBN	O	14	VC
16	,	,	O	,	O	14	P
17	resulting	result	B-VP	VBG	O	14	VMOD
18	in	in	B-PP	IN	O	17	VMOD
19	severe	severe	B-NP	JJ	O	20	NMOD
20	angioedema	angioedema	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	1	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	coniine	coniine	B-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	failed	fail	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	produce	produce	I-VP	VB	O	5	VMOD
8	arthrogryposis	arthrogryposis	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	rats	rat	B-NP	NNS	O	12	NMOD
11	or	or	I-NP	CC	O	12	NMOD
12	mice	mouse	I-NP	NNS	O	9	PMOD
13	and	and	O	CC	O	4	VMOD
14	is	be	B-VP	VBZ	O	4	VMOD
15	only	only	B-ADJP	RB	O	17	AMOD
16	weakly	weakly	I-ADJP	RB	O	17	AMOD
17	teratogenic	teratogenic	I-ADJP	JJ	O	14	PRD
18	in	in	B-PP	IN	O	17	AMOD
19	rabbits	rabbit	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	deformations	deformation	I-NP	NNS	O	10	SUB
3	caused	cause	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	both	both	O	CC	O	9	NMOD
6	coniine	coniine	B-NP	NN	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	nicotine	nicotine	B-NP	NN	O	9	NMOD
9	sulfate	sulfate	I-NP	NN	O	4	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	excessive	excessive	B-NP	JJ	O	14	NMOD
12	flexion	flexion	I-NP	NN	O	14	NMOD
13	or	or	I-NP	CC	O	14	NMOD
14	extension	extension	I-NP	NN	O	10	PRD
15	of	of	B-PP	IN	O	14	NMOD
16	one	one	B-NP	CD	O	19	NMOD
17	or	or	I-NP	CC	O	19	NMOD
18	more	more	I-NP	JJR	O	19	NMOD
19	toes	toe	I-NP	NNS	O	15	PMOD
20	.	.	O	.	O	10	P

1	No	No	B-NP	DT	O	5	NMOD
2	histopathological	histopathological	I-NP	JJ	O	3	NMOD
3	alterations	alteration	I-NP	NNS	O	5	NMOD
4	or	or	I-NP	CC	O	5	NMOD
5	differences	difference	I-NP	NNS	O	9	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	bone	bone	B-NP	NN	O	8	NMOD
8	formation	formation	I-NP	NN	O	6	PMOD
9	were	be	B-VP	VBD	O	28	VMOD
10	seen	see	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	limbs	limb	I-NP	NNS	O	15	NMOD
14	or	or	I-NP	CC	O	15	NMOD
15	toes	toe	I-NP	NNS	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	any	any	B-NP	DT	O	18	NMOD
18	chicks	chick	I-NP	NNS	O	16	PMOD
19	from	from	B-PP	IN	O	18	NMOD
20	any	any	B-NP	DT	O	21	NMOD
21	group	group	I-NP	NN	O	19	PMOD
22	;	;	O	:	O	28	P
23	however	however	B-ADVP	RB	O	28	VMOD
24	,	,	O	,	O	28	P
25	extensive	extensive	B-NP	JJ	O	26	AMOD
26	cranial	cranial	I-NP	JJ	O	27	NMOD
27	hemorrhage	hemorrhage	I-NP	NN	O	28	SUB
28	occurred	occur	B-VP	VBD	O	0	ROOT
29	in	in	B-PP	IN	O	28	VMOD
30	all	all	B-NP	DT	O	33	NMOD
31	nicotine	nicotine	I-NP	NN	B-protein	33	NMOD
32	sulfate-treated	sulfate-treated	I-NP	JJ	I-protein	33	NMOD
33	chicks	chick	I-NP	NNS	I-protein	29	PMOD
34	.	.	O	.	O	28	P

1	Epidural	Epidural	B-NP	JJ	O	3	NMOD
2	blood	blood	I-NP	NN	O	3	NMOD
3	flow	flow	I-NP	NN	O	9	SUB
4	during	during	B-PP	IN	O	3	NMOD
5	prostaglandin	prostaglandin	B-NP	NN	O	6	NMOD
6	E1	E1	I-NP	NN	O	8	NMOD
7	or	or	I-NP	CC	O	8	NMOD
8	trimethaphan	trimethaphan	I-NP	NN	O	4	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	hypotension	hypotension	B-NP	NN	O	9	OBJ
11	.	.	O	.	O	9	P

1	To	To	B-VP	TO	O	2	VMOD
2	evaluate	evaluate	I-VP	VB	O	30	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	17	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	prostaglandin	prostaglandin	B-NP	NN	B-protein	7	NMOD
7	E1	E1	I-NP	NN	I-protein	12	NMOD
8	(	(	O	(	O	10	DEP
9	PGE1	PGE1	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	or	or	O	CC	O	12	NMOD
12	trimethaphan	trimethaphan	B-NP	NN	O	5	PMOD
13	(	(	O	(	O	15	DEP
14	TMP	TMP	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	induced	induce	B-VP	VBD	O	17	NMOD
17	hypotension	hypotension	B-NP	NN	O	2	OBJ
18	on	on	B-PP	IN	O	17	NMOD
19	epidural	epidural	B-NP	JJ	O	21	NMOD
20	blood	blood	I-NP	NN	O	21	NMOD
21	flow	flow	I-NP	NN	O	18	PMOD
22	(	(	O	(	O	24	DEP
23	EBF	EBF	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	during	during	B-PP	IN	O	21	NMOD
26	spinal	spinal	B-NP	JJ	O	27	NMOD
27	surgery	surgery	I-NP	NN	O	25	PMOD
28	,	,	O	,	O	30	P
29	EBF	EBF	B-NP	NN	B-protein	30	SUB
30	was	be	B-VP	VBD	O	0	ROOT
31	measured	measure	I-VP	VBN	O	30	VC
32	using	use	B-VP	VBG	O	31	VMOD
33	the	the	B-NP	DT	O	36	NMOD
34	heat	heat	I-NP	NN	O	36	NMOD
35	clearance	clearance	I-NP	NN	O	36	NMOD
36	method	method	I-NP	NN	O	32	OBJ
37	in	in	B-PP	IN	O	32	VMOD
38	30	30	B-NP	CD	O	39	NMOD
39	patients	patient	I-NP	NNS	O	37	PMOD
40	who	who	B-NP	WP	O	39	NMOD
41	underwent	undergo	B-VP	VBD	O	40	SBAR
42	postero-lateral	postero-lateral	B-NP	JJ	O	44	NMOD
43	interbody	interbody	I-NP	NN	O	44	NMOD
44	fusion	fusion	I-NP	NN	O	41	OBJ
45	under	under	B-PP	IN	O	41	VMOD
46	isoflurane	isoflurane	B-NP	NN	O	47	NMOD
47	anaesthesia	anaesthesia	I-NP	NN	O	45	PMOD
48	.	.	O	.	O	30	P

1	After	After	B-PP	IN	O	35	VMOD
2	starting	start	B-VP	VBG	O	1	NMOD
3	PGE1	PGE1	B-NP	NN	B-protein	11	NMOD
4	or	or	I-NP	CC	O	11	NMOD
5	TMP	TMP	I-NP	NN	B-protein	11	NMOD
6	,	,	I-NP	,	O	11	P
7	MAP	MAP	I-NP	NN	B-protein	11	NMOD
8	and	and	I-NP	CC	O	11	NMOD
9	rate	rate	I-NP	NN	B-protein	11	NMOD
10	pressure	pressure	I-NP	NN	I-protein	11	NMOD
11	product	product	I-NP	NN	I-protein	2	OBJ
12	(	(	O	(	O	14	DEP
13	RPP	RPP	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	decreased	decrease	B-VP	VBD	O	1	SBAR
16	significantly	significantly	B-ADVP	RB	O	15	VMOD
17	compared	compare	B-PP	VBN	O	15	VC
18	with	with	B-PP	IN	O	17	PMOD
19	preinfusion	preinfusion	B-NP	NN	O	20	NMOD
20	values	value	I-NP	NNS	O	18	PMOD
21	(	(	O	(	O	25	DEP
22	P	P	B-NP	NN	O	25	DEP
23	<	<	O	SYM	O	22	NMOD
24	0.01	0.01	B-NP	CD	O	23	AMOD
25	)	)	O	)	O	20	NMOD
26	,	,	O	,	O	35	P
27	and	and	O	CC	O	29	NMOD
28	the	the	B-NP	DT	O	29	NMOD
29	degree	degree	I-NP	NN	O	35	SUB
30	of	of	B-PP	IN	O	29	NMOD
31	hypotension	hypotension	B-NP	NN	O	30	PMOD
32	due	due	B-ADJP	JJ	O	29	NMOD
33	to	to	B-PP	TO	O	32	AMOD
34	PGE1	PGE1	B-NP	NN	B-protein	33	PMOD
35	remained	remain	B-VP	VBD	O	0	ROOT
36	constant	constant	B-ADJP	JJ	O	35	PRD
37	until	until	B-SBAR	IN	O	35	VMOD
38	60	60	B-NP	CD	O	39	NMOD
39	min	min	I-NP	NN	O	37	PMOD
40	after	after	B-PP	IN	O	39	NMOD
41	its	its	B-NP	PRP$	O	42	NMOD
42	discontinuation	discontinuation	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	35	P

1	Focal	Focal	B-NP	JJ	O	2	NMOD
2	injury	injury	I-NP	NN	O	6	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	cortex	cortex	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	produced	produce	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	infusion	infusion	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	lactate	lactate	B-NP	NN	O	10	PMOD
12	at	at	B-PP	IN	O	9	NMOD
13	acid	acid	B-NP	NN	O	14	NMOD
14	pH	pH	I-NP	NN	O	12	PMOD
15	or	or	B-PP	CC	O	8	PMOD
16	by	by	B-PP	IN	O	8	PMOD
17	stab	stab	B-NP	NN	O	16	PMOD
18	caused	cause	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	needle	needle	B-NP	NN	O	21	NMOD
21	insertion	insertion	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	6	P

1	Infarcts	Infarct	B-NP	NNS	O	7	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	substantia	substantia	B-NP	NN	O	6	NMOD
4	nigra	nigra	I-NP	NN	O	6	NMOD
5	pars	par	I-NP	NNS	O	6	NMOD
6	reticulata	reticulata	I-NP	NNS	O	2	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	evoked	evoke	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	prolonged	prolong	B-NP	VBN	O	11	NMOD
11	pilocarpine	pilocarpine	I-NP	NN	O	14	NMOD
12	induced	induce	B-VP	VBD	O	11	AMOD
13	status	status	B-NP	NN	O	14	NMOD
14	epilepticus	epilepticus	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	7	P

1	Increase	Increase	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	Parkinson	Parkinson	B-NP	NNP	O	4	NMOD
4	disability	disability	I-NP	NN	O	2	PMOD
5	after	after	B-PP	IN	O	1	NMOD
6	fluoxetine	fluoxetine	B-NP	NN	O	7	NMOD
7	medication	medication	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	increased	increase	I-NP	VBN	O	5	NMOD
5	amount	amount	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	motor	motor	B-NP	NN	O	8	NMOD
8	disability	disability	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	5	NMOD
10	four	four	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	idiopathic	idiopathic	B-NP	JJ	O	16	NMOD
14	Parkinson	Parkinson	I-NP	NNP	O	15	NMOD
15	's	's	B-NP	POS	O	16	NMOD
16	disease	disease	I-NP	NN	O	12	PMOD
17	after	after	B-PP	IN	O	5	NMOD
18	exposure	exposure	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	antidepressant	antidepressant	I-NP	NN	O	22	NMOD
22	fluoxetine	fluoxetine	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	2	P

1	Acetaminophen	Acetaminophen	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hypotension	hypotension	B-NP	NN	O	2	OBJ
4	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	potential	potential	I-NP	NN	O	9	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	acetaminophen	acetaminophen	B-NP	NN	O	3	PMOD
5	to	to	B-VP	TO	O	6	VMOD
6	produce	produce	I-VP	VB	O	3	PMOD
7	cardiovascular	cardiovascular	B-NP	JJ	O	8	NMOD
8	toxicities	toxicity	I-NP	NNS	O	6	OBJ
9	is	be	B-VP	VBZ	O	0	ROOT
10	very	very	B-ADJP	RB	O	11	AMOD
11	low	low	I-ADJP	JJ	O	9	PRD
12	.	.	O	.	O	9	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	acetaminophen	acetaminophen	B-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	demonstrated	demonstrate	I-VP	VBN	O	5	VC
7	to	to	I-VP	TO	O	8	VMOD
8	produce	produce	I-VP	VB	O	6	VMOD
9	symptoms	symptom	B-NP	NNS	O	8	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	anaphylaxis	anaphylaxis	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	11	P
13	including	include	B-PP	VBG	O	11	NMOD
14	hypotension	hypotension	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	14	P
16	in	in	B-PP	IN	O	14	NMOD
17	sensitive	sensitive	B-NP	JJ	O	18	NMOD
18	individuals	individual	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	2	NMOD
2	article	article	I-NP	NN	O	3	SUB
3	describes	describe	B-VP	VBZ	O	0	ROOT
4	two	two	B-NP	CD	O	7	NMOD
5	critically	critically	I-NP	RB	O	6	AMOD
6	ill	ill	I-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	3	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	whom	whom	B-NP	WP	O	8	PMOD
10	transient	transient	B-NP	JJ	O	11	NMOD
11	episodes	episode	I-NP	NNS	O	15	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	hypotension	hypotension	B-NP	NN	O	12	PMOD
14	reproducibly	reproducibly	B-ADVP	RB	O	15	VMOD
15	developed	develop	B-VP	VBD	O	9	SBAR
16	after	after	B-PP	IN	O	15	VMOD
17	administration	administration	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	acetaminophen	acetaminophen	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	3	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	9	NMOD
3	,	,	O	,	O	9	P
4	autoimmune	autoimmune	B-NP	JJ	O	6	NMOD
5	hemolytic	hemolytic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	and	and	O	CC	O	9	NMOD
9	erythroblastocytopenia	erythroblastocytopenia	B-NP	NN	O	0	ROOT
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	ceftriaxone	ceftriaxone	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	9	P

1	An	An	B-NP	DT	O	3	NMOD
2	80-yr-old	80-yr-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	acute	acute	B-NP	JJ	O	6	NMOD
6	hepatitis	hepatitis	I-NP	NN	O	4	OBJ
7	shortly	shortly	B-ADVP	RB	O	8	PMOD
8	after	after	B-PP	IN	O	4	VMOD
9	ingesting	ingest	B-VP	VBG	O	8	PMOD
10	oral	oral	B-NP	JJ	O	11	NMOD
11	ceftriaxone	ceftriaxone	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	4	P

1	Although	Although	B-SBAR	IN	O	16	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	transaminases	transaminase	I-NP	NNS	B-protein	5	SUB
4	gradually	gradually	B-ADVP	RB	O	5	VMOD
5	returned	return	B-VP	VBD	O	1	SBAR
6	to	to	B-PP	TO	O	5	VMOD
7	baseline	baseline	B-NP	NN	O	6	PMOD
8	after	after	B-PP	IN	O	5	VMOD
9	withholding	withhold	B-VP	VBG	O	8	PMOD
10	the	the	B-NP	DT	O	13	NMOD
11	beta	beta	I-NP	NN	O	13	NMOD
12	lactam	lactam	I-NP	NN	O	13	NMOD
13	antibiotic	antibiotic	I-NP	NN	O	9	OBJ
14	,	,	O	,	O	16	P
15	there	there	B-NP	EX	O	16	SUB
16	was	be	B-VP	VBD	O	0	ROOT
17	a	a	B-NP	DT	O	19	NMOD
18	gradual	gradual	I-NP	JJ	O	19	NMOD
19	increase	increase	I-NP	NN	O	25	NMOD
20	in	in	B-PP	IN	O	19	NMOD
21	serum	serum	B-NP	NN	B-protein	22	NMOD
22	bilirubin	bilirubin	I-NP	NN	I-protein	20	PMOD
23	and	and	O	CC	O	25	NMOD
24	a	a	B-NP	DT	O	25	NMOD
25	decrease	decrease	I-NP	NN	O	16	PRD
26	in	in	B-PP	IN	O	25	NMOD
27	hemoglobin	hemoglobin	B-NP	NN	B-protein	28	NMOD
28	concentration	concentration	I-NP	NN	O	26	PMOD
29	caused	cause	B-VP	VBN	O	28	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	an	an	B-NP	DT	O	34	NMOD
32	autoimmune	autoimmune	I-NP	JJ	O	34	NMOD
33	hemolytic	hemolytic	I-NP	JJ	O	34	NMOD
34	anemia	anemia	I-NP	NN	O	36	NMOD
35	and	and	I-NP	CC	O	36	NMOD
36	erythroblastocytopenia	erythroblastocytopenia	I-NP	NN	O	30	PMOD
37	.	.	O	.	O	16	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	tetrandrine	tetrandrine	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	fangchinoline	fangchinoline	I-NP	NN	O	2	PMOD
6	on	on	B-PP	IN	O	1	NMOD
7	experimental	experimental	B-NP	JJ	O	8	NMOD
8	thrombosis	thrombosis	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	mice	mouse	B-NP	NNS	O	14	NMOD
11	and	and	O	CC	O	14	NMOD
12	human	human	B-NP	JJ	O	14	NMOD
13	platelet	platelet	I-NP	NN	O	14	NMOD
14	aggregation	aggregation	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	undertaken	undertake	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	effects	effect	I-NP	NNS	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	TET	TET	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	FAN	FAN	I-NP	NN	B-protein	10	PMOD
14	on	on	B-PP	IN	O	9	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	experimental	experimental	I-NP	JJ	O	17	NMOD
17	thrombosis	thrombosis	I-NP	NN	O	14	PMOD
18	induced	induce	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	collagen	collagen	B-NP	NN	B-protein	22	NMOD
21	plus	plus	O	CC	O	22	NMOD
22	epinephrine	epinephrine	B-NP	NN	O	19	PMOD
23	(	(	O	(	O	25	DEP
24	EP	EP	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	in	in	B-PP	IN	O	22	NMOD
27	mice	mouse	B-NP	NNS	O	26	PMOD
28	,	,	O	,	O	34	P
29	and	and	O	CC	O	34	NMOD
30	platelet	platelet	B-NP	NN	B-cell_type	31	NMOD
31	aggregation	aggregation	I-NP	NN	O	34	NMOD
32	and	and	O	CC	O	34	NMOD
33	blood	blood	B-NP	NN	O	34	NMOD
34	coagulation	coagulation	I-NP	NN	O	7	VMOD
35	in	in	B-ADVP	FW	O	7	VMOD
36	vitro	vitro	I-ADVP	FW	O	35	AMOD
37	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	21	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	in	in	I-NP	FW	O	4	AMOD
4	vivo	vivo	I-NP	FW	O	5	NMOD
5	study	study	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	21	P
7	the	the	B-NP	DT	O	8	NMOD
8	administration	administration	I-NP	NN	O	18	NMOD
9	(	(	O	(	O	14	DEP
10	50	50	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	14	DEP
12	,	,	O	,	O	11	P
13	i.p.	i.p.	B-ADVP	RB	O	11	NMOD
14	)	)	O	)	O	8	NMOD
15	of	of	B-PP	IN	O	8	NMOD
16	TET	TET	B-NP	NN	B-protein	15	PMOD
17	and	and	I-NP	CC	O	18	NMOD
18	FAN	FAN	I-NP	NN	O	21	SUB
19	in	in	B-PP	IN	O	18	NMOD
20	mice	mouse	B-NP	NNS	O	19	PMOD
21	showed	show	B-VP	VBD	O	0	ROOT
22	the	the	B-NP	DT	O	23	NMOD
23	inhibition	inhibition	I-NP	NN	O	21	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	thrombosis	thrombosis	B-NP	NN	O	24	PMOD
26	by	by	B-PP	IN	O	21	VMOD
27	55	55	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	31	NMOD
29	and	and	O	CC	O	31	NMOD
30	35	35	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	26	PMOD
32	,	,	O	,	O	21	P
33	respectively	respectively	B-ADVP	RB	O	21	VMOD
34	,	,	O	,	O	21	P
35	while	while	B-SBAR	IN	O	21	VMOD
36	acetylsalicylic	acetylsalicylic	B-NP	JJ	O	37	NMOD
37	acid	acid	I-NP	NN	O	49	NMOD
38	(	(	O	(	O	45	DEP
39	ASA	ASA	B-NP	NN	O	42	NMOD
40	,	,	O	,	O	42	P
41	50	50	B-NP	CD	O	42	NMOD
42	mg/kg	mg/kg	I-NP	NN	O	45	DEP
43	,	,	O	,	O	42	P
44	i.p.	i.p.	B-ADVP	RB	O	42	NMOD
45	)	)	O	)	O	37	NMOD
46	,	,	O	,	O	49	P
47	a	a	B-NP	DT	O	49	NMOD
48	positive	positive	I-NP	JJ	O	49	NMOD
49	control	control	I-NP	NN	O	51	SUB
50	,	,	O	,	O	49	P
51	showed	show	B-VP	VBD	O	35	SBAR
52	only	only	B-NP	RB	O	55	NMOD
53	30	30	I-NP	CD	O	52	AMOD
54	%	%	I-NP	NN	O	52	AMOD
55	inhibition	inhibition	I-NP	NN	O	51	OBJ
56	.	.	O	.	O	21	P

1	In	In	B-PP	IN	O	18	VMOD
2	the	the	B-NP	DT	O	6	NMOD
3	vitro	vitro	I-NP	FW	O	6	NMOD
4	human	human	I-NP	JJ	O	6	NMOD
5	platelet	platelet	I-NP	NN	O	6	NMOD
6	aggregations	aggregation	I-NP	NNS	O	1	PMOD
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	agonists	agonist	I-NP	NNS	O	8	PMOD
11	used	use	B-VP	VBN	O	10	NMOD
12	in	in	B-PP	IN	O	11	VMOD
13	tests	test	B-NP	NNS	O	12	PMOD
14	,	,	I-NP	,	O	18	P
15	TET	TET	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	FAN	FAN	I-NP	NN	O	18	SUB
18	showed	show	B-VP	VBD	O	0	ROOT
19	the	the	B-NP	DT	O	20	NMOD
20	inhibitions	inhibition	I-NP	NNS	O	18	OBJ
21	dose	dose	I-NP	NN	O	22	AMOD
22	dependently	dependently	B-ADVP	RB	O	20	NMOD
23	.	.	O	.	O	18	P

1	Gemcitabine	Gemcitabine	B-NP	NN	O	3	NMOD
2	plus	plus	I-NP	CC	O	3	NMOD
3	vinorelbine	vinorelbine	I-NP	NN	O	16	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	nonsmall	nonsmall	B-NP	JJ	O	9	NMOD
6	cell	cell	I-NP	NN	O	9	NMOD
7	lung	lung	I-NP	NN	O	9	NMOD
8	carcinoma	carcinoma	I-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	12	NMOD
10	age	age	I-NP	NN	O	12	NMOD
11	70	70	B-NP	CD	O	12	NMOD
12	years	year	I-NP	NNS	O	4	PMOD
13	or	or	O	CC	O	16	NMOD
14	older	old	B-ADJP	JJR	O	16	NMOD
15	or	or	O	CC	O	16	NMOD
16	patients	patient	B-NP	NNS	O	0	ROOT
17	who	who	B-NP	WP	O	16	NMOD
18	can	can	B-VP	MD	O	17	SBAR
19	not	not	I-VP	RB	O	18	VMOD
20	receive	receive	I-VP	VB	O	18	VC
21	cisplatin	cisplatin	B-NP	NN	O	20	OBJ
22	.	.	O	.	O	16	P

1	Recent	Recent	B-NP	JJ	O	2	NMOD
2	reports	report	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	single	single	B-NP	JJ	O	7	NMOD
6	agent	agent	I-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	18	SUB
8	with	with	B-PP	IN	O	7	NMOD
9	vinorelbine	vinorelbine	B-NP	NN	O	14	NMOD
10	(	(	O	(	O	12	DEP
11	VNB	VNB	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	or	or	O	CC	O	14	NMOD
14	gemcitabine	gemcitabine	B-NP	NN	O	8	PMOD
15	(	(	O	(	O	17	DEP
16	GEM	GEM	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	may	may	B-VP	MD	O	4	SBAR
19	obtain	obtain	I-VP	VB	O	18	VC
20	a	a	B-NP	DT	O	22	NMOD
21	response	response	I-NP	NN	O	22	NMOD
22	rate	rate	I-NP	NN	O	19	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	20-30	20-30	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	22	NMOD
27	elderly	elderly	B-NP	JJ	O	28	NMOD
28	patients	patient	I-NP	NNS	O	26	PMOD
29	,	,	O	,	O	19	P
30	with	with	B-PP	IN	O	19	VMOD
31	acceptable	acceptable	B-NP	JJ	O	32	NMOD
32	toxicity	toxicity	I-NP	NN	O	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	improvement	improvement	I-NP	NN	O	38	NMOD
35	in	in	B-PP	IN	O	34	NMOD
36	symptoms	symptom	B-NP	NNS	O	35	PMOD
37	and	and	O	CC	O	38	NMOD
38	quality	quality	B-NP	NN	O	30	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	life	life	B-NP	NN	O	39	PMOD
41	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	30	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	current	current	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	the	the	B-NP	DT	O	8	NMOD
6	efficacy	efficacy	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	30	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	combination	combination	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	GEM	GEM	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	VNB	VNB	I-NP	NN	B-protein	12	PMOD
16	in	in	B-PP	IN	O	11	NMOD
17	elderly	elderly	B-NP	JJ	O	18	NMOD
18	patients	patient	I-NP	NNS	O	23	NMOD
19	with	with	B-PP	IN	O	18	NMOD
20	advanced	advance	B-NP	VBN	O	21	NMOD
21	NSCLC	NSCLC	I-NP	NN	B-protein	19	PMOD
22	or	or	O	CC	O	23	NMOD
23	those	those	B-NP	DT	O	16	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	some	some	B-NP	DT	O	26	NMOD
26	contraindication	contraindication	I-NP	NN	O	24	PMOD
27	to	to	B-PP	TO	O	26	NMOD
28	receiving	receive	B-VP	VBG	O	27	PMOD
29	cisplatin	cisplatin	B-NP	NN	O	28	OBJ
30	were	be	B-VP	VBD	O	0	ROOT
31	assessed	assess	I-VP	VBN	O	30	VC
32	.	.	O	.	O	30	P

1	METHODS	METHODS	B-NP	NNS	O	22	SUB
2	:	:	O	:	O	1	P
3	Forty-nine	Forty-nine	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	8	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	advanced	advance	B-NP	VBN	O	7	NMOD
7	NSCLC	NSCLC	I-NP	NN	B-protein	5	PMOD
8	were	be	B-VP	VBD	O	22	VMOD
9	included	include	I-VP	VBN	O	8	VC
10	,	,	O	,	O	9	P
11	38	38	B-NP	CD	O	9	VMOD
12	of	of	B-PP	IN	O	11	NMOD
13	whom	whom	B-NP	WP	O	12	PMOD
14	were	be	B-VP	VBD	O	22	VMOD
15	age	age	I-VP	NN	O	19	NMOD
16	>	>	B-NP	SYM	O	19	NMOD
17	/=	/=	B-VP	SYM	O	19	NMOD
18	70	70	B-NP	CD	O	19	NMOD
19	years	year	I-NP	NNS	O	14	PRD
20	and	and	O	CC	O	22	VMOD
21	11	11	B-NP	CD	O	22	SUB
22	were	be	B-VP	VBD	O	0	ROOT
23	age	age	B-NP	NN	O	26	NMOD
24	<	<	O	SYM	O	26	P
25	70	70	B-NP	CD	O	26	NMOD
26	years	year	I-NP	NNS	O	22	PRD
27	but	but	O	CC	O	26	NMOD
28	who	who	B-NP	WP	O	27	DEP
29	had	have	B-VP	VBD	O	28	SBAR
30	some	some	B-NP	DT	O	31	NMOD
31	contraindication	contraindication	I-NP	NN	O	29	OBJ
32	to	to	B-PP	TO	O	29	VMOD
33	receiving	receive	B-VP	VBG	O	32	PMOD
34	cisplatin	cisplatin	B-NP	NN	O	33	OBJ
35	.	.	O	.	O	22	P

1	Warfarin	Warfarin	B-NP	NN	O	4	NMOD
2	induced	induce	B-VP	VBD	O	4	NMOD
3	artery	artery	B-NP	NN	O	4	NMOD
4	calcification	calcification	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	accelerated	accelerate	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	growth	growth	B-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	vitamin	vitamin	I-NP	NN	O	11	NMOD
11	D	D	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	growth	growth	B-NP	NN	O	10	NMOD
7	and	and	I-NP	CC	O	10	NMOD
8	vitamin	vitamin	I-NP	NN	O	10	NMOD
9	D	D	I-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	11	SUB
11	enhance	enhance	B-VP	VBP	O	5	SBAR
12	the	the	B-NP	DT	O	13	NMOD
13	extent	extent	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	artery	artery	B-NP	NN	O	16	NMOD
16	calcification	calcification	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	rats	rat	B-NP	NNS	O	21	NMOD
19	given	give	B-VP	VBN	O	21	NMOD
20	sufficient	sufficient	B-NP	JJ	O	21	NMOD
21	doses	dose	I-NP	NNS	O	17	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	Warfarin	Warfarin	B-NP	NNP	O	22	PMOD
24	to	to	B-VP	TO	O	25	VMOD
25	inhibit	inhibit	I-VP	VB	O	13	NMOD
26	gamma-carboxylation	gamma-carboxylation	B-NP	NN	O	25	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	matrix	matrix	B-NP	NN	B-protein	30	NMOD
29	Gla	Gla	I-NP	NN	I-protein	30	NMOD
30	protein	protein	I-NP	NN	I-protein	34	NMOD
31	,	,	O	,	O	34	P
32	a	a	B-NP	DT	O	34	NMOD
33	calcification	calcification	I-NP	NN	O	34	NMOD
34	inhibitor	inhibitor	I-NP	NN	O	27	PMOD
35	known	know	B-VP	VBN	O	34	NMOD
36	to	to	I-VP	TO	O	37	VMOD
37	be	be	I-VP	VB	O	35	VMOD
38	expressed	express	I-VP	VBN	O	37	VC
39	by	by	B-PP	IN	O	38	VMOD
40	smooth	smooth	B-NP	JJ	B-cell_type	42	NMOD
41	muscle	muscle	I-NP	NN	I-cell_type	42	NMOD
42	cells	cell	I-NP	NNS	I-cell_type	44	NMOD
43	and	and	O	CC	O	44	NMOD
44	macrophages	macrophage	B-NP	NNS	B-cell_type	39	PMOD
45	in	in	B-PP	IN	O	38	VMOD
46	the	the	B-NP	DT	O	48	NMOD
47	artery	artery	I-NP	NN	O	48	NMOD
48	wall	wall	I-NP	NN	O	45	PMOD
49	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	first	first	I-NP	JJ	O	3	NMOD
3	series	series	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	experiments	experiment	B-NP	NNS	O	4	PMOD
6	examined	examine	B-VP	VBN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	influence	influence	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	age	age	B-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	growth	growth	I-NP	NN	O	13	NMOD
13	status	status	I-NP	NN	O	9	PMOD
14	on	on	B-PP	IN	O	8	NMOD
15	artery	artery	B-NP	NN	O	16	NMOD
16	calcification	calcification	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	Warfarin-treated	Warfarin-treated	B-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	3	P

1	Treatment	Treatment	B-NP	NN	O	7	SUB
2	for	for	B-PP	IN	O	1	NMOD
3	2	2	B-NP	CD	O	4	NMOD
4	weeks	week	I-NP	NNS	O	2	PMOD
5	with	with	B-PP	IN	O	1	NMOD
6	Warfarin	Warfarin	B-NP	NN	O	5	PMOD
7	caused	cause	B-VP	VBD	O	0	ROOT
8	massive	massive	B-NP	JJ	O	10	NMOD
9	focal	focal	I-NP	JJ	O	10	NMOD
10	calcification	calcification	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	artery	artery	I-NP	NN	O	14	NMOD
14	media	medium	I-NP	NNS	O	11	PMOD
15	in	in	B-PP	IN	O	7	VMOD
16	20-day-old	20-day-old	B-NP	JJ	O	17	NMOD
17	rats	rat	I-NP	NNS	O	22	NMOD
18	and	and	O	CC	O	22	NMOD
19	less	less	B-NP	RBR	O	20	AMOD
20	extensive	extensive	I-NP	JJ	O	22	NMOD
21	focal	focal	I-NP	JJ	O	22	NMOD
22	calcification	calcification	I-NP	NN	O	15	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	42-day-old	42-day-old	B-NP	JJ	O	25	NMOD
25	rats	rat	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	7	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	7	P
4	no	no	B-NP	DT	O	6	NMOD
5	artery	artery	I-NP	NN	O	6	NMOD
6	calcification	calcification	I-NP	NN	O	7	SUB
7	could	could	B-VP	MD	O	0	ROOT
8	be	be	I-VP	VB	O	7	VC
9	detected	detect	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	10-month-old	10-month-old	B-NP	JJ	O	13	NMOD
12	adult	adult	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	10	PMOD
14	even	even	B-ADVP	RB	O	15	PMOD
15	after	after	B-PP	IN	O	9	VMOD
16	4	4	B-NP	CD	O	17	NMOD
17	weeks	week	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	Warfarin	Warfarin	B-NP	NN	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	7	P

1	To	To	B-VP	TO	O	3	VMOD
2	directly	directly	I-VP	RB	O	3	VMOD
3	examine	examine	I-VP	VB	O	22	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	importance	importance	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	growth	growth	B-NP	NN	O	6	PMOD
8	to	to	B-PP	TO	O	5	NMOD
9	Warfarin	Warfarin	B-NP	NN	O	12	NMOD
10	induced	induced	I-NP	JJ	O	12	NMOD
11	artery	artery	I-NP	NN	O	12	NMOD
12	calcification	calcification	I-NP	NN	O	8	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	animals	animal	B-NP	NNS	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	same	same	I-NP	JJ	O	18	NMOD
18	age	age	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	22	P
20	20-day-old	20-day-old	B-NP	JJ	O	21	NMOD
21	rats	rat	I-NP	NNS	O	22	SUB
22	were	be	B-VP	VBD	O	0	ROOT
23	fed	feed	I-VP	VBN	O	22	VC
24	for	for	B-PP	IN	O	23	VMOD
25	2	2	B-NP	CD	O	26	NMOD
26	weeks	week	I-NP	NNS	O	36	NMOD
27	either	either	O	CC	O	36	NMOD
28	an	an	B-NP	DT	O	31	NMOD
29	ad	ad	I-NP	NN	O	31	NMOD
30	libitum	libitum	I-NP	NN	O	31	NMOD
31	diet	diet	I-NP	NN	O	36	NMOD
32	or	or	O	CC	O	36	NMOD
33	a	a	B-NP	DT	O	36	NMOD
34	6-g/d	6-g/d	I-NP	JJ	O	36	NMOD
35	restricted	restricted	I-NP	JJ	O	36	NMOD
36	diet	diet	I-NP	NN	O	24	PMOD
37	that	that	B-NP	WDT	O	36	NMOD
38	maintains	maintain	B-VP	VBZ	O	37	SBAR
39	weight	weight	B-NP	NN	O	38	OBJ
40	but	but	O	CC	O	38	VMOD
41	prevents	prevent	B-VP	VBZ	O	38	VMOD
42	growth	growth	B-NP	NN	O	41	OBJ
43	.	.	O	.	O	22	P

1	Concurrent	Concurrent	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	both	both	B-NP	DT	O	6	NMOD
5	dietary	dietary	I-NP	JJ	O	6	NMOD
6	groups	group	I-NP	NNS	O	3	PMOD
7	with	with	B-PP	IN	O	2	NMOD
8	Warfarin	Warfarin	B-NP	NN	O	7	PMOD
9	produced	produce	B-VP	VBD	O	0	ROOT
10	massive	massive	B-NP	JJ	O	12	NMOD
11	focal	focal	I-NP	JJ	O	12	NMOD
12	calcification	calcification	I-NP	NN	O	9	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	artery	artery	I-NP	NN	O	16	NMOD
16	media	medium	I-NP	NNS	O	13	PMOD
17	in	in	B-PP	IN	O	9	VMOD
18	the	the	B-NP	DT	O	21	NMOD
19	ad	ad	I-NP	NN	O	21	NMOD
20	libitum-fed	libitum-fed	I-NP	JJ	O	21	NMOD
21	rats	rat	I-NP	NNS	O	17	PMOD
22	but	but	O	CC	O	9	VMOD
23	no	no	B-NP	DT	O	26	NMOD
24	detectable	detectable	I-NP	JJ	O	26	NMOD
25	artery	artery	I-NP	NN	O	26	NMOD
26	calcification	calcification	I-NP	NN	O	22	PRD
27	in	in	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	32	NMOD
29	restricted-diet	restricted-diet	I-NP	JJ	O	31	AMOD
30	,	,	I-NP	,	O	31	P
31	growth-inhibited	growth-inhibited	I-NP	JJ	O	32	NMOD
32	group	group	I-NP	NN	O	27	PMOD
33	.	.	O	.	O	9	P

1	Although	Although	B-SBAR	IN	O	23	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	explanation	explanation	I-NP	NN	O	13	SUB
4	for	for	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	association	association	I-NP	NN	O	4	PMOD
7	between	between	B-PP	IN	O	6	NMOD
8	artery	artery	B-NP	NN	O	9	NMOD
9	calcification	calcification	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	growth	growth	B-NP	NN	O	12	NMOD
12	status	status	I-NP	NN	O	7	PMOD
13	can	can	B-VP	MD	O	1	SBAR
14	not	not	I-VP	RB	O	13	VMOD
15	be	be	I-VP	VB	O	13	VC
16	determined	determine	I-VP	VBN	O	15	VC
17	from	from	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	present	present	I-NP	JJ	O	20	NMOD
20	study	study	I-NP	NN	O	17	PMOD
21	,	,	O	,	O	23	P
22	there	there	B-NP	EX	O	23	SUB
23	was	be	B-VP	VBD	O	0	ROOT
24	a	a	B-NP	DT	O	25	NMOD
25	relationship	relationship	I-NP	NN	O	39	AMOD
26	between	between	B-PP	IN	O	25	NMOD
27	higher	high	B-NP	JJR	O	29	NMOD
28	serum	serum	I-NP	NN	O	29	NMOD
29	phosphate	phosphate	I-NP	NN	O	31	NMOD
30	and	and	O	CC	O	31	NMOD
31	susceptibility	susceptibility	B-NP	NN	O	26	PMOD
32	to	to	B-PP	TO	O	31	NMOD
33	artery	artery	B-NP	NN	O	34	NMOD
34	calcification	calcification	I-NP	NN	O	32	PMOD
35	,	,	O	,	O	25	P
36	with	with	B-PP	IN	O	25	NMOD
37	30	30	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	36	PMOD
39	higher	high	B-NP	JJR	O	40	NMOD
40	levels	level	I-NP	NNS	O	23	PRD
41	of	of	B-PP	IN	O	40	NMOD
42	serum	serum	B-NP	NN	O	43	NMOD
43	phosphate	phosphate	I-NP	NN	O	41	PMOD
44	in	in	B-PP	IN	O	40	NMOD
45	young	young	B-NP	JJ	O	49	NMOD
46	,	,	I-NP	,	O	49	P
47	ad	ad	I-NP	NN	O	49	NMOD
48	libitum-fed	libitum-fed	I-NP	JJ	O	49	NMOD
49	rats	rat	I-NP	NNS	O	44	PMOD
50	compared	compare	B-PP	VBN	O	40	NMOD
51	with	with	B-PP	IN	O	50	PMOD
52	either	either	B-NP	DT	O	51	PMOD
53	of	of	B-PP	IN	O	52	NMOD
54	the	the	B-NP	DT	O	55	NMOD
55	groups	group	I-NP	NNS	O	53	PMOD
56	that	that	B-NP	WDT	O	52	NMOD
57	was	be	B-VP	VBD	O	56	SBAR
58	resistant	resistant	B-ADJP	JJ	O	57	PRD
59	to	to	B-PP	TO	O	58	AMOD
60	Warfarin	Warfarin	B-NP	NN	O	63	NMOD
61	induced	induced	I-NP	JJ	O	63	NMOD
62	artery	artery	I-NP	NN	O	63	NMOD
63	calcification	calcification	I-NP	NN	O	69	NMOD
64	,	,	O	,	O	69	P
65	ie	ie	B-NP	FW	O	69	NMOD
66	,	,	O	,	O	69	P
67	the	the	B-NP	DT	O	69	NMOD
68	10-month-old	10-month-old	I-NP	JJ	O	69	NMOD
69	rats	rat	I-NP	NNS	O	76	NMOD
70	and	and	O	CC	O	76	NMOD
71	the	the	B-NP	DT	O	76	NMOD
72	restricted-diet	restricted-diet	I-NP	JJ	O	74	AMOD
73	,	,	I-NP	,	O	74	P
74	growth-inhibited	growth-inhibited	I-NP	JJ	O	76	NMOD
75	young	young	I-NP	JJ	O	76	NMOD
76	rats	rat	I-NP	NNS	O	59	PMOD
77	.	.	O	.	O	23	P

1	This	This	B-NP	DT	O	2	NMOD
2	observation	observation	I-NP	NN	O	3	SUB
3	suggests	suggest	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	increased	increase	B-NP	VBN	O	6	NMOD
6	susceptibility	susceptibility	I-NP	NN	O	12	SUB
7	to	to	B-PP	TO	O	6	NMOD
8	Warfarin	Warfarin	B-NP	NN	O	11	NMOD
9	induced	induced	I-NP	JJ	O	11	NMOD
10	artery	artery	I-NP	NN	O	11	NMOD
11	calcification	calcification	I-NP	NN	O	7	PMOD
12	could	could	B-VP	MD	O	4	SBAR
13	be	be	I-VP	VB	O	12	VC
14	related	relate	I-VP	VBN	O	13	PRD
15	to	to	B-PP	TO	O	14	AMOD
16	higher	high	B-NP	JJR	O	19	NMOD
17	serum	serum	I-NP	NN	O	19	NMOD
18	phosphate	phosphate	I-NP	NN	O	19	NMOD
19	levels	level	I-NP	NNS	O	15	PMOD
20	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	second	second	I-NP	JJ	O	3	NMOD
3	set	set	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	experiments	experiment	B-NP	NNS	O	4	PMOD
6	examined	examine	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	possible	possible	I-NP	JJ	O	9	NMOD
9	synergy	synergy	I-NP	NN	O	6	OBJ
10	between	between	B-PP	IN	O	9	NMOD
11	vitamin	vitamin	B-NP	NN	O	12	NMOD
12	D	D	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	Warfarin	Warfarin	I-NP	NN	O	10	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	artery	artery	B-NP	NN	O	17	NMOD
17	calcification	calcification	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	6	P

1	High	High	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	vitamin	vitamin	B-NP	NN	O	5	NMOD
5	D	D	I-NP	NN	O	3	PMOD
6	are	be	B-VP	VBP	O	0	ROOT
7	known	know	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	cause	cause	I-VP	VB	O	7	VMOD
10	calcification	calcification	B-NP	NN	O	9	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	artery	artery	I-NP	NN	O	14	NMOD
14	media	medium	I-NP	NNS	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	as	as	B-NP	RB	O	18	AMOD
17	little	little	I-NP	JJ	O	18	AMOD
18	as	as	I-NP	IN	O	22	NMOD
19	3	3	I-NP	CD	O	18	AMOD
20	to	to	I-NP	TO	O	18	AMOD
21	4	4	I-NP	CD	O	18	AMOD
22	days	day	I-NP	NNS	O	15	PMOD
23	.	.	O	.	O	6	P

1	High	High	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	8	NMOD
5	vitamin	vitamin	I-NP	NN	O	8	NMOD
6	K	K	I-NP	NN	O	8	NMOD
7	antagonist	antagonist	I-NP	NN	O	8	NMOD
8	Warfarin	Warfarin	I-NP	NN	O	3	PMOD
9	are	be	B-VP	VBP	O	0	ROOT
10	also	also	I-VP	RB	O	9	VMOD
11	known	know	I-VP	VBN	O	9	VC
12	to	to	I-VP	TO	O	13	VMOD
13	cause	cause	I-VP	VB	O	11	VMOD
14	calcification	calcification	B-NP	NN	O	13	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	artery	artery	I-NP	NN	O	18	NMOD
18	media	medium	I-NP	NNS	O	15	PMOD
19	,	,	O	,	O	9	P
20	but	but	O	CC	O	19	ROOT
21	at	at	B-PP	IN	O	20	PRD
22	treatment	treatment	B-NP	NN	O	23	NMOD
23	times	time	I-NP	NNS	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	2	2	B-NP	CD	O	26	NMOD
26	weeks	week	I-NP	NNS	O	24	PMOD
27	or	or	O	CC	O	21	PMOD
28	longer	long	B-ADJP	JJR	O	27	PRD
29	yet	yet	O	CC	O	28	AMOD
30	not	not	O	RB	O	29	DEP
31	at	at	B-PP	IN	O	30	PMOD
32	1	1	B-NP	CD	O	33	NMOD
33	week	week	I-NP	NN	O	31	PMOD
34	.	.	O	.	O	20	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	current	current	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	we	we	B-NP	PRP	O	7	SUB
7	investigated	investigate	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	synergy	synergy	I-NP	NN	O	7	OBJ
10	between	between	B-PP	IN	O	9	NMOD
11	these	these	B-NP	DT	O	13	NMOD
12	2	2	I-NP	CD	O	13	NMOD
13	treatments	treatment	I-NP	NNS	O	10	PMOD
14	and	and	O	CC	O	7	VMOD
15	found	find	B-VP	VBD	O	7	VMOD
16	that	that	B-SBAR	IN	O	15	VMOD
17	concurrent	concurrent	B-NP	JJ	O	19	NMOD
18	Warfarin	Warfarin	I-NP	NNP	O	19	NMOD
19	administration	administration	I-NP	NN	O	21	SUB
20	dramatically	dramatically	B-ADVP	RB	O	21	VMOD
21	increased	increase	B-VP	VBD	O	16	SBAR
22	the	the	B-NP	DT	O	23	NMOD
23	extent	extent	I-NP	NN	O	21	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	calcification	calcification	B-NP	NN	O	24	PMOD
26	in	in	B-PP	IN	O	23	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	media	medium	I-NP	NNS	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	vitamin	vitamin	B-NP	NN	O	32	NMOD
31	D-treated	D-treated	I-NP	JJ	O	32	NMOD
32	rats	rat	I-NP	NNS	O	29	PMOD
33	at	at	B-PP	IN	O	21	VMOD
34	3	3	B-NP	CD	O	36	AMOD
35	and	and	I-NP	CC	O	36	AMOD
36	4	4	I-NP	CD	O	37	NMOD
37	days	day	I-NP	NNS	O	33	PMOD
38	.	.	O	.	O	7	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	close	close	I-NP	JJ	O	5	NMOD
5	parallel	parallel	I-NP	NN	O	2	PRD
6	between	between	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	effect	effect	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	vitamin	vitamin	B-NP	NN	O	12	NMOD
11	D	D	I-NP	NN	O	12	NMOD
12	dose	dose	I-NP	NN	O	9	PMOD
13	on	on	B-PP	IN	O	8	NMOD
14	artery	artery	B-NP	NN	O	15	NMOD
15	calcification	calcification	I-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	effect	effect	I-NP	NN	O	13	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	vitamin	vitamin	B-NP	NN	O	22	NMOD
21	D	D	I-NP	NN	O	22	NMOD
22	dose	dose	I-NP	NN	O	19	PMOD
23	on	on	B-PP	IN	O	18	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	elevation	elevation	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	serum	serum	B-NP	NN	O	28	NMOD
28	calcium	calcium	I-NP	NN	O	26	PMOD
29	,	,	O	,	O	18	P
30	which	which	B-NP	WDT	O	18	NMOD
31	suggests	suggest	B-VP	VBZ	O	30	SBAR
32	that	that	B-SBAR	IN	O	31	VMOD
33	vitamin	vitamin	B-NP	NN	O	34	NMOD
34	D	D	I-NP	NN	O	35	SUB
35	may	may	B-VP	MD	O	32	SBAR
36	induce	induce	I-VP	VB	O	35	VC
37	artery	artery	B-NP	NN	O	38	NMOD
38	calcification	calcification	I-NP	NN	O	36	OBJ
39	through	through	B-PP	IN	O	36	VMOD
40	its	its	B-NP	PRP$	O	41	NMOD
41	effect	effect	I-NP	NN	O	39	PMOD
42	on	on	B-PP	IN	O	41	NMOD
43	serum	serum	B-NP	NN	O	44	NMOD
44	calcium	calcium	I-NP	NN	O	42	PMOD
45	.	.	O	.	O	2	P

1	Because	Because	B-SBAR	IN	O	25	VMOD
2	Warfarin	Warfarin	B-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	1	SBAR
5	no	no	B-NP	DT	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	OBJ
7	on	on	B-PP	IN	O	4	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	elevation	elevation	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	serum	serum	B-NP	NN	O	12	NMOD
12	calcium	calcium	I-NP	NN	O	10	PMOD
13	produced	produce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	vitamin	vitamin	B-NP	NN	O	16	NMOD
16	D	D	I-NP	NN	O	14	PMOD
17	,	,	O	,	O	25	P
18	the	the	B-NP	DT	O	19	NMOD
19	synergy	synergy	I-NP	NN	O	25	SUB
20	between	between	B-PP	IN	O	19	NMOD
21	Warfarin	Warfarin	B-NP	NN	O	24	NMOD
22	and	and	I-NP	CC	O	24	NMOD
23	vitamin	vitamin	I-NP	NN	O	24	NMOD
24	D	D	I-NP	NN	O	20	PMOD
25	is	be	B-VP	VBZ	O	0	ROOT
26	probably	probably	I-VP	RB	O	25	VMOD
27	best	well	I-VP	RBS	O	25	VMOD
28	explained	explain	I-VP	VBN	O	25	VC
29	by	by	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	hypothesis	hypothesis	I-NP	NN	O	29	PMOD
32	that	that	B-SBAR	IN	O	31	NMOD
33	Warfarin	Warfarin	B-NP	NN	B-protein	34	SUB
34	inhibits	inhibit	B-VP	VBZ	O	32	SBAR
35	the	the	B-NP	DT	O	36	NMOD
36	activity	activity	I-NP	NN	O	34	OBJ
37	of	of	B-PP	IN	O	36	NMOD
38	matrix	matrix	B-NP	NN	B-protein	40	NMOD
39	Gla	Gla	I-NP	NN	I-protein	40	NMOD
40	protein	protein	I-NP	NN	I-protein	37	PMOD
41	as	as	B-PP	IN	O	34	VMOD
42	a	a	B-NP	DT	O	44	NMOD
43	calcification	calcification	I-NP	NN	O	44	NMOD
44	inhibitor	inhibitor	I-NP	NN	O	41	PMOD
45	.	.	O	.	O	25	P

1	High	High	B-NP	JJ	O	2	NMOD
2	levels	level	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	matrix	matrix	B-NP	NN	B-protein	6	NMOD
5	Gla	Gla	I-NP	NN	I-protein	6	NMOD
6	protein	protein	I-NP	NN	I-protein	3	PMOD
7	are	be	B-VP	VBP	O	26	VMOD
8	found	find	I-VP	VBN	O	7	VC
9	at	at	B-PP	IN	O	8	VMOD
10	sites	site	B-NP	NNS	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	artery	artery	B-NP	NN	O	13	NMOD
13	calcification	calcification	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	10	NMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	treated	treat	B-VP	VBN	O	15	NMOD
17	with	with	B-PP	IN	O	16	VMOD
18	vitamin	vitamin	B-NP	NN	O	19	NMOD
19	D	D	I-NP	NN	O	21	NMOD
20	plus	plus	O	CC	O	21	NMOD
21	Warfarin	Warfarin	B-NP	NN	O	17	PMOD
22	,	,	O	,	O	26	P
23	and	and	O	CC	O	26	VMOD
24	chemical	chemical	B-NP	NN	O	25	NMOD
25	analysis	analysis	I-NP	NN	O	26	SUB
26	showed	show	B-VP	VBD	O	0	ROOT
27	that	that	B-SBAR	IN	O	26	VMOD
28	the	the	B-NP	DT	O	29	NMOD
29	protein	protein	I-NP	NN	O	32	SUB
30	that	that	B-NP	WDT	O	29	NMOD
31	accumulated	accumulate	B-VP	VBD	O	30	SBAR
32	was	be	B-VP	VBD	O	27	SBAR
33	indeed	indeed	I-VP	RB	O	32	VMOD
34	not	not	I-VP	RB	O	32	VMOD
35	gamma-carboxylated	gamma-carboxylate	I-VP	VBN	O	32	VC
36	.	.	O	.	O	26	P

1	Antidepressant	Antidepressant	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	mania	mania	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	bipolar	bipolar	B-NP	JJ	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	:	:	O	:	O	2	P
8	identification	identification	B-NP	NN	O	2	VMOD
9	of	of	B-PP	IN	O	8	NMOD
10	risk	risk	B-NP	NN	B-protein	11	NMOD
11	factors	factor	I-NP	NNS	I-protein	9	PMOD
12	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Concerns	Concern	B-NP	NNS	O	14	SUB
4	about	about	B-PP	IN	O	3	NMOD
5	possible	possible	B-NP	JJ	O	6	NMOD
6	risks	risk	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	switching	switch	B-VP	VBG	O	7	PMOD
9	to	to	B-PP	TO	O	8	VMOD
10	mania	mania	B-NP	NN	O	9	PMOD
11	associated	associate	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	antidepressants	antidepressant	B-NP	NNS	O	12	PMOD
14	continue	continue	B-VP	VBP	O	1	NMOD
15	to	to	I-VP	TO	O	16	VMOD
16	interfere	interfere	I-VP	VB	O	14	VMOD
17	with	with	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	establishment	establishment	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	an	an	B-NP	DT	O	24	NMOD
22	optimal	optimal	I-NP	JJ	O	24	NMOD
23	treatment	treatment	I-NP	NN	O	24	NMOD
24	paradigm	paradigm	I-NP	NN	O	20	PMOD
25	for	for	B-PP	IN	O	24	NMOD
26	bipolar	bipolar	B-NP	JJ	O	27	NMOD
27	depression	depression	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	1	P

1	Patients	Patient	B-NP	NNS	O	9	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	experienced	experience	B-VP	VBD	O	2	SBAR
4	a	a	B-NP	DT	O	8	NMOD
5	manic	manic	I-NP	JJ	O	7	AMOD
6	or	or	I-NP	CC	O	7	AMOD
7	hypomanic	hypomanic	I-NP	JJ	O	8	NMOD
8	switch	switch	I-NP	NN	O	3	OBJ
9	were	be	B-VP	VBD	O	0	ROOT
10	compared	compare	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	those	those	B-NP	DT	O	11	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	did	do	B-VP	VBD	O	13	SBAR
15	not	not	O	RB	O	14	VMOD
16	on	on	B-PP	IN	O	14	VMOD
17	several	several	B-NP	JJ	O	18	NMOD
18	variables	variable	I-NP	NNS	O	16	PMOD
19	including	include	B-PP	VBG	O	18	NMOD
20	age	age	B-NP	NN	O	34	NMOD
21	,	,	O	,	O	34	P
22	sex	sex	B-NP	NN	O	34	NMOD
23	,	,	O	,	O	34	P
24	diagnosis	diagnosis	B-NP	NN	O	34	NMOD
25	(	(	O	(	O	32	DEP
26	DSM-IV	DSM-IV	B-NP	NN	O	28	NMOD
27	bipolar	bipolar	B-ADJP	JJ	O	28	NMOD
28	I	I	B-NP	PRP	O	32	DEP
29	vs.	vs.	B-PP	IN	O	28	NMOD
30	bipolar	bipolar	B-NP	JJ	B-protein	31	NMOD
31	II	II	I-NP	CD	I-protein	29	PMOD
32	)	)	O	)	O	24	NMOD
33	,	,	O	,	O	34	P
34	number	number	B-NP	NN	O	40	NMOD
35	of	of	B-PP	IN	O	34	NMOD
36	previous	previous	B-NP	JJ	O	38	NMOD
37	manic	manic	I-NP	JJ	O	38	NMOD
38	episodes	episode	I-NP	NNS	O	35	PMOD
39	,	,	O	,	O	40	P
40	type	type	B-NP	NN	O	67	NMOD
41	of	of	B-PP	IN	O	40	NMOD
42	antidepressant	antidepressant	B-NP	NN	O	43	NMOD
43	therapy	therapy	I-NP	NN	O	41	PMOD
44	used	use	B-VP	VBN	O	43	NMOD
45	(	(	O	(	O	63	DEP
46	electroconvulsive	electroconvulsive	B-NP	JJ	O	47	NMOD
47	therapy	therapy	I-NP	NN	O	63	DEP
48	vs.	vs.	B-PP	IN	O	47	NMOD
49	antidepressant	antidepressant	B-NP	JJ	O	50	NMOD
50	drugs	drug	I-NP	NNS	O	59	NMOD
51	and	and	O	CC	O	59	NMOD
52	,	,	O	,	O	59	P
53	more	more	B-ADVP	RBR	O	54	AMOD
54	particularly	particularly	I-ADVP	RB	O	59	NMOD
55	,	,	O	,	O	59	P
56	selective	selective	B-NP	JJ	O	59	NMOD
57	serotonin	serotonin	I-NP	NN	O	59	NMOD
58	reuptake	reuptake	I-NP	NN	O	59	NMOD
59	inhibitors	inhibitor	I-NP	NNS	O	48	PMOD
60	[	[	O	(	O	62	DEP
61	SSRIs	SSRI	B-NP	NNS	O	62	DEP
62	]	]	O	)	O	59	NMOD
63	)	)	O	)	O	43	NMOD
64	,	,	O	,	O	67	P
65	use	use	B-NP	NN	O	67	NMOD
66	and	and	I-NP	CC	O	67	NMOD
67	type	type	I-NP	NN	O	19	PMOD
68	of	of	B-PP	IN	O	67	NMOD
69	mood	mood	B-NP	NN	O	70	NMOD
70	stabilizers	stabilizer	I-NP	NNS	O	68	PMOD
71	(	(	O	(	O	75	DEP
72	lithium	lithium	B-NP	NN	O	75	DEP
73	vs.	vs.	B-PP	IN	O	72	NMOD
74	anticonvulsants	anticonvulsant	B-NP	NNS	O	73	PMOD
75	)	)	O	)	O	70	NMOD
76	,	,	O	,	O	78	P
77	and	and	O	CC	O	78	NMOD
78	temperament	temperament	B-NP	NN	O	9	VMOD
79	of	of	B-PP	IN	O	78	NMOD
80	the	the	B-NP	DT	O	81	NMOD
81	patient	patient	I-NP	NN	O	79	PMOD
82	,	,	O	,	O	78	P
83	assessed	assess	B-VP	VBN	O	78	NMOD
84	during	during	B-PP	IN	O	83	VMOD
85	a	a	B-NP	DT	O	87	NMOD
86	normothymic	normothymic	I-NP	JJ	O	87	NMOD
87	period	period	I-NP	NN	O	84	PMOD
88	using	use	B-VP	VBG	O	78	NMOD
89	the	the	B-NP	DT	O	91	NMOD
90	hyperthymia	hyperthymia	I-NP	NN	O	91	NMOD
91	component	component	I-NP	NN	O	88	OBJ
92	of	of	B-PP	IN	O	91	NMOD
93	the	the	B-NP	DT	O	97	NMOD
94	Semi-structured	Semi-structured	I-NP	JJ	O	97	NMOD
95	Affective	Affective	I-NP	JJ	O	97	NMOD
96	Temperament	Temperament	I-NP	NNP	O	97	NMOD
97	Interview	Interview	I-NP	NNP	O	92	PMOD
98	.	.	O	.	O	9	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Switches	Switch	B-NP	NNS	O	8	SUB
4	to	to	B-PP	TO	O	3	NMOD
5	hypomania	hypomania	B-NP	NN	O	7	NMOD
6	or	or	I-NP	CC	O	7	NMOD
7	mania	mania	I-NP	NN	O	4	PMOD
8	occurred	occur	B-VP	VBD	O	1	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	27	27	B-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	all	all	B-NP	DT	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	(	(	O	(	O	19	DEP
16	N	N	B-NP	NN	O	18	SUB
17	=	=	B-VP	SYM	O	18	VMOD
18	12	12	B-NP	CD	O	19	DEP
19	)	)	O	)	O	14	NMOD
20	(	(	O	(	O	14	NMOD
21	and	and	O	CC	O	45	VMOD
22	in	in	B-PP	IN	O	45	VMOD
23	24	24	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	subgroup	subgroup	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	patients	patient	B-NP	NNS	O	28	PMOD
30	treated	treat	B-VP	VBN	O	29	NMOD
31	with	with	B-PP	IN	O	30	VMOD
32	SSRIs	SSRI	B-NP	NNS	B-protein	31	PMOD
33	[	[	O	(	O	35	DEP
34	8/33	8/33	B-NP	CD	O	35	DEP
35	]	]	O	)	O	29	NMOD
36	)	)	O	)	O	27	NMOD
37	;	;	O	:	O	45	P
38	16	16	B-NP	CD	O	39	NMOD
39	%	%	I-NP	NN	O	45	SUB
40	(	(	O	(	O	44	DEP
41	N	N	B-NP	NN	O	43	SUB
42	=	=	B-VP	SYM	O	43	VMOD
43	7	7	B-NP	CD	O	44	DEP
44	)	)	O	)	O	39	NMOD
45	experienced	experience	B-VP	VBD	O	57	VMOD
46	manic	manic	B-NP	JJ	O	47	NMOD
47	episodes	episode	I-NP	NNS	O	45	OBJ
48	,	,	O	,	O	57	P
49	and	and	O	CC	O	51	NMOD
50	11	11	B-NP	CD	O	51	NMOD
51	%	%	I-NP	NN	O	57	SUB
52	(	(	O	(	O	56	DEP
53	N	N	B-NP	NN	O	56	DEP
54	=	=	B-VP	SYM	O	53	NMOD
55	5	5	B-NP	CD	O	54	AMOD
56	)	)	O	)	O	51	NMOD
57	experienced	experience	B-VP	VBD	O	20	SBAR
58	hypomanic	hypomanic	B-NP	JJ	O	59	NMOD
59	episodes	episode	I-NP	NNS	O	57	OBJ
60	.	.	O	.	O	1	P

1	Caffeine	Caffeine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cardiac	cardiac	B-NP	JJ	O	4	NMOD
4	arrhythmia	arrhythmia	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	P
6	an	an	B-NP	DT	O	8	NMOD
7	unrecognised	unrecognised	I-NP	JJ	O	8	NMOD
8	danger	danger	I-NP	NN	O	2	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	healthfood	healthfood	B-NP	NN	B-protein	11	NMOD
11	products	product	I-NP	NNS	I-protein	9	PMOD
12	.	.	O	.	O	2	P

1	Bladder	Bladder	B-NP	NN	O	2	NMOD
2	retention	retention	I-NP	NN	O	17	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	urine	urine	B-NP	NN	O	3	PMOD
5	as	as	B-PP	IN	O	2	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	result	result	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	continuous	continuous	B-NP	JJ	O	11	NMOD
10	intravenous	intravenous	I-NP	JJ	O	11	NMOD
11	infusion	infusion	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	fentanyl	fentanyl	B-NP	NN	O	12	PMOD
14	:	:	O	:	O	2	P
15	2	2	B-NP	CD	O	17	NMOD
16	case	case	I-NP	NN	O	17	NMOD
17	reports	report	I-NP	NNS	O	0	ROOT
18	.	.	O	.	O	17	P

1	Various	Various	B-NP	NNP	O	2	SUB
2	reported	report	B-VP	VBD	O	0	ROOT
3	side	side	B-NP	NN	O	4	NMOD
4	effects	effect	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	fentanyl	fentanyl	B-NP	NN	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	include	include	B-VP	VBP	O	2	VMOD
9	chest	chest	B-NP	NN	O	11	NMOD
10	wall	wall	I-NP	NN	O	11	NMOD
11	rigidity	rigidity	I-NP	NN	O	19	NMOD
12	,	,	O	,	O	19	P
13	hypotension	hypotension	B-NP	NN	O	19	NMOD
14	,	,	O	,	O	19	P
15	respiratory	respiratory	B-NP	JJ	O	16	NMOD
16	depression	depression	I-NP	NN	O	19	NMOD
17	,	,	O	,	O	19	P
18	and	and	O	CC	O	19	NMOD
19	bradycardia	bradycardia	B-NP	NN	O	8	OBJ
20	.	.	O	.	O	2	P

1	Combined	Combine	B-NP	VBN	O	3	NMOD
2	antiretroviral	antiretroviral	I-NP	JJ	O	3	NMOD
3	therapy	therapy	I-NP	NN	O	4	SUB
4	causes	cause	B-VP	VBZ	O	0	ROOT
5	cardiomyopathy	cardiomyopathy	B-NP	NN	O	4	OBJ
6	and	and	O	CC	O	4	VMOD
7	elevates	elevate	B-VP	VBZ	O	4	VMOD
8	plasma	plasma	B-NP	NN	O	9	NMOD
9	lactate	lactate	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	transgenic	transgenic	B-NP	JJ	O	13	NMOD
12	AIDS	AIDS	I-NP	NN	O	13	NMOD
13	mice	mouse	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	4	P

1	Highly	Highly	B-NP	RB	O	2	AMOD
2	active	active	I-NP	JJ	O	4	NMOD
3	antiretroviral	antiretroviral	I-NP	JJ	O	4	NMOD
4	therapy	therapy	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	HAART	HAART	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	implicated	implicate	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	cardiomyopathy	cardiomyopathy	B-NP	NN	O	10	PMOD
12	(	(	O	(	O	14	DEP
13	CM	CM	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	and	and	O	CC	O	10	PMOD
16	in	in	B-PP	IN	O	10	PMOD
17	elevated	elevate	B-NP	VBN	O	19	NMOD
18	plasma	plasma	I-NP	NN	O	19	NMOD
19	lactate	lactate	I-NP	NN	O	16	PMOD
20	(	(	O	(	O	22	DEP
21	LA	LA	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	in	in	B-PP	IN	O	19	NMOD
24	AIDS	AIDS	B-NP	NN	O	23	PMOD
25	through	through	B-PP	IN	O	9	VMOD
26	mechanisms	mechanism	B-NP	NNS	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	mitochondrial	mitochondrial	B-NP	JJ	O	29	NMOD
29	dysfunction	dysfunction	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	8	P

1	To	To	B-VP	TO	O	2	VMOD
2	determine	determine	I-VP	VB	O	25	VMOD
3	mitochondrial	mitochondrial	B-NP	JJ	O	4	NMOD
4	events	event	I-NP	NNS	O	2	VMOD
5	from	from	B-PP	IN	O	4	NMOD
6	HAART	HAART	B-NP	NN	B-protein	5	PMOD
7	in	in	B-ADVP	FW	O	8	AMOD
8	vivo	vivo	I-ADVP	FW	O	4	NMOD
9	,	,	O	,	O	25	P
10	8-week-old	8-week-old	B-NP	JJ	O	14	NMOD
11	hemizygous	hemizygous	I-NP	JJ	O	14	NMOD
12	transgenic	transgenic	I-NP	JJ	O	14	NMOD
13	AIDS	AIDS	I-NP	NN	O	14	NMOD
14	mice	mouse	I-NP	NNS	O	25	SUB
15	(	(	O	(	O	20	DEP
16	NL4-3Delta	NL4-3Delta	B-NP	NN	O	17	NMOD
17	gag/pol	gag/pol	I-NP	NN	O	19	NMOD
18	;	;	O	:	O	19	P
19	TG	TG	B-NP	NN	O	20	DEP
20	)	)	O	)	O	14	NMOD
21	and	and	O	CC	O	24	NMOD
22	wild-type	wild-type	B-NP	JJ	O	24	NMOD
23	FVB/n	FVB/n	I-NP	NN	O	24	NMOD
24	littermates	littermate	I-NP	NNS	O	25	SUB
25	were	be	B-VP	VBD	O	0	ROOT
26	treated	treat	I-VP	VBN	O	25	VC
27	with	with	B-PP	IN	O	26	VMOD
28	the	the	B-NP	DT	O	30	NMOD
29	HAART	HAART	I-NP	NN	O	30	NMOD
30	combination	combination	I-NP	NN	O	27	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	zidovudine	zidovudine	B-NP	NN	O	40	NMOD
33	,	,	O	,	O	40	P
34	lamivudine	lamivudine	B-NP	NN	O	40	NMOD
35	,	,	O	,	O	40	P
36	and	and	O	CC	O	40	NMOD
37	indinavir	indinavir	B-NP	NN	O	40	NMOD
38	or	or	O	CC	O	40	NMOD
39	vehicle	vehicle	B-NP	NN	O	40	NMOD
40	control	control	I-NP	NN	O	31	PMOD
41	for	for	B-PP	IN	O	40	NMOD
42	10	10	B-NP	CD	O	43	NMOD
43	days	day	I-NP	NNS	O	46	NMOD
44	or	or	O	CC	O	46	NMOD
45	35	35	B-NP	CD	O	46	NMOD
46	days	day	I-NP	NNS	O	41	PMOD
47	.	.	O	.	O	25	P

1	At	At	B-PP	IN	O	8	VMOD
2	termination	termination	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	experiments	experiment	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	8	P
7	mice	mouse	B-NP	NNS	O	8	SUB
8	underwent	undergo	B-VP	VBD	O	0	ROOT
9	echocardiography	echocardiography	B-NP	NN	O	11	NMOD
10	,	,	O	,	O	11	P
11	quantitation	quantitation	B-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	abundance	abundance	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	molecular	molecular	B-NP	JJ	O	16	NMOD
16	markers	marker	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	CM	CM	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	36	DEP
20	ventricular	ventricular	B-NP	JJ	B-RNA	21	NMOD
21	mRNA	mRNA	I-NP	NN	I-RNA	32	NMOD
22	encoding	encode	B-VP	VBG	O	32	VMOD
23	atrial	atrial	B-NP	JJ	B-protein	25	NMOD
24	natriuretic	natriuretic	I-NP	JJ	I-protein	25	NMOD
25	factor	factor	I-NP	NN	I-protein	32	NMOD
26	[	[	O	(	O	28	DEP
27	ANF	ANF	B-NP	NN	O	28	DEP
28	]	]	O	)	O	25	NMOD
29	and	and	O	CC	O	32	NMOD
30	sarcoplasmic	sarcoplasmic	B-NP	JJ	B-protein	32	NMOD
31	calcium	calcium	I-NP	NN	I-protein	32	NMOD
32	ATPase	ATPase	I-NP	NN	I-protein	36	DEP
33	[	[	O	(	O	35	DEP
34	SERCA2	SERCA2	B-NP	NN	B-protein	35	DEP
35	]	]	O	)	O	32	NMOD
36	)	)	O	)	O	18	NMOD
37	,	,	O	,	O	8	VMOD
38	and	and	O	CC	O	39	NMOD
39	determination	determination	B-NP	NN	O	37	SUB
40	of	of	B-PP	IN	O	39	NMOD
41	plasma	plasma	B-NP	NN	O	42	NMOD
42	LA	LA	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	8	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	contraceptives	contraceptive	I-NP	NNS	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	risk	risk	I-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	infarction	infarction	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	5	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	An	An	B-NP	DT	O	4	NMOD
4	association	association	I-NP	NN	O	17	SUB
5	between	between	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	use	use	I-NP	NN	O	13	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	oral	oral	B-NP	JJ	O	10	NMOD
10	contraceptives	contraceptive	I-NP	NNS	O	8	PMOD
11	and	and	O	CC	O	13	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	risk	risk	I-NP	NN	O	5	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	myocardial	myocardial	B-NP	JJ	O	16	NMOD
16	infarction	infarction	I-NP	NN	O	14	PMOD
17	has	have	B-VP	VBZ	O	1	NMOD
18	been	be	I-VP	VBN	O	17	VC
19	found	find	I-VP	VBN	O	18	VC
20	in	in	B-PP	IN	O	19	VMOD
21	some	some	B-NP	DT	O	27	NMOD
22	,	,	O	,	O	27	P
23	but	but	O	CC	O	27	NMOD
24	not	not	B-NP	RB	O	27	NMOD
25	all	all	I-NP	DT	O	24	NMOD
26	,	,	O	,	O	27	P
27	studies	study	B-NP	NNS	O	20	PMOD
28	.	.	O	.	O	17	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	57	VMOD
3	this	this	B-NP	DT	O	4	NMOD
4	association	association	I-NP	NN	O	2	OBJ
5	,	,	O	,	O	4	P
6	according	accord	B-PP	VBG	O	4	NMOD
7	to	to	B-PP	TO	O	6	PMOD
8	the	the	B-NP	DT	O	9	NMOD
9	type	type	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	progestagen	progestagen	B-NP	NN	O	10	PMOD
12	included	include	B-VP	VBN	O	11	NMOD
13	in	in	B-PP	IN	O	12	VMOD
14	third-generation	third-generation	B-NP	NN	O	23	NMOD
15	(	(	O	(	O	23	NMOD
16	i.e.	i.e.	B-NP	FW	O	23	NMOD
17	,	,	O	,	O	23	P
18	desogestrel	desogestrel	B-NP	NN	O	20	NMOD
19	or	or	O	CC	O	20	NMOD
20	gestodene	gestodene	B-NP	NN	O	23	NMOD
21	)	)	O	)	O	20	NMOD
22	and	and	O	CC	O	23	NMOD
23	second-generation	second-generation	B-NP	NN	O	41	NMOD
24	(	(	O	(	O	41	NMOD
25	i.e.	i.e.	B-NP	FW	O	30	NMOD
26	,	,	O	,	O	30	P
27	levonorgestrel	levonorgestrel	B-NP	NN	O	30	NMOD
28	)	)	O	)	O	30	NMOD
29	oral	oral	B-NP	JJ	O	30	NMOD
30	contraceptives	contraceptive	I-NP	NNS	O	41	NMOD
31	,	,	O	,	O	41	P
32	the	the	B-NP	DT	O	33	NMOD
33	dose	dose	I-NP	NN	O	41	NMOD
34	of	of	B-PP	IN	O	33	NMOD
35	estrogen	estrogen	B-NP	NN	O	34	PMOD
36	,	,	O	,	O	41	P
37	and	and	O	CC	O	41	NMOD
38	the	the	B-NP	DT	O	41	NMOD
39	presence	presence	I-NP	NN	O	41	NMOD
40	or	or	I-NP	CC	O	41	NMOD
41	absence	absence	I-NP	NN	O	13	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	prothrombotic	prothrombotic	B-NP	JJ	O	45	NMOD
44	mutations	mutation	I-NP	NNS	O	45	NMOD
45	METHODS	METHODS	I-NP	NNS	O	42	PMOD
46	:	:	O	:	O	2	P
47	In	In	B-PP	IN	O	2	VMOD
48	a	a	B-NP	DT	O	54	NMOD
49	nationwide	nationwide	I-NP	JJ	O	53	AMOD
50	,	,	I-NP	,	O	53	P
51	population-based	population-based	I-NP	JJ	O	53	AMOD
52	,	,	I-NP	,	O	53	P
53	case-control	case-control	I-NP	JJ	O	54	NMOD
54	study	study	I-NP	NN	O	47	PMOD
55	,	,	O	,	O	2	P
56	we	we	B-NP	PRP	O	57	SUB
57	identified	identify	B-VP	VBD	O	0	ROOT
58	and	and	O	CC	O	57	VMOD
59	enrolled	enrol	B-VP	VBD	O	57	VMOD
60	248	248	B-NP	CD	O	61	NMOD
61	women	woman	I-NP	NNS	O	59	OBJ
62	18	18	B-NP	CD	O	61	NMOD
63	through	through	B-PP	IN	O	61	NMOD
64	49	49	B-NP	CD	O	65	NMOD
65	years	year	I-NP	NNS	O	63	PMOD
66	of	of	B-PP	IN	O	65	NMOD
67	age	age	B-NP	NN	O	66	PMOD
68	who	who	B-NP	WP	O	65	NMOD
69	had	have	B-VP	VBD	O	68	SBAR
70	had	have	I-VP	VBN	O	69	VC
71	a	a	B-NP	DT	O	74	NMOD
72	first	first	I-NP	JJ	O	74	NMOD
73	myocardial	myocardial	I-NP	JJ	O	74	NMOD
74	infarction	infarction	I-NP	NN	O	70	OBJ
75	between	between	B-PP	IN	O	70	VMOD
76	1990	1990	B-NP	CD	O	82	NMOD
77	and	and	I-NP	CC	O	82	NMOD
78	1995	1995	I-NP	CD	O	82	NMOD
79	and	and	I-NP	CC	O	82	NMOD
80	925	925	I-NP	CD	O	82	NMOD
81	control	control	I-NP	NN	O	82	NMOD
82	women	woman	I-NP	NNS	O	98	NMOD
83	who	who	B-NP	WP	O	82	NMOD
84	had	have	B-VP	VBD	O	83	SBAR
85	not	not	I-VP	RB	O	84	VMOD
86	had	have	I-VP	VBN	O	84	VC
87	a	a	B-NP	DT	O	89	NMOD
88	myocardial	myocardial	I-NP	JJ	O	89	NMOD
89	infarction	infarction	I-NP	NN	O	86	OBJ
90	and	and	O	CC	O	98	NMOD
91	who	who	B-NP	WP	O	98	NMOD
92	were	be	B-VP	VBD	O	91	SBAR
93	matched	match	I-VP	VBN	O	92	VC
94	for	for	B-PP	IN	O	93	VMOD
95	age	age	B-NP	NN	O	94	PMOD
96	,	,	O	,	O	98	P
97	calendar	calendar	B-NP	NN	O	98	NMOD
98	year	year	I-NP	NN	O	75	PMOD
99	of	of	B-PP	IN	O	98	NMOD
100	the	the	B-NP	DT	O	102	NMOD
101	index	index	I-NP	NN	O	102	NMOD
102	event	event	I-NP	NN	O	99	PMOD
103	,	,	O	,	O	75	P
104	and	and	O	CC	O	105	NMOD
105	area	area	B-NP	NN	O	75	PMOD
106	of	of	B-PP	IN	O	105	NMOD
107	residence	residence	B-NP	NN	O	106	PMOD
108	.	.	O	.	O	57	P

1	An	An	B-NP	DT	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	15	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	factor	factor	B-NP	NN	O	6	NMOD
5	V	V	I-NP	NNP	O	6	NMOD
6	Leiden	Leiden	I-NP	NNP	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	G20210A	G20210A	I-NP	NN	O	10	NMOD
10	mutation	mutation	I-NP	NN	O	3	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	prothrombin	prothrombin	I-NP	NN	B-DNA	14	NMOD
14	gene	gene	I-NP	NN	I-DNA	11	PMOD
15	was	be	B-VP	VBD	O	47	VMOD
16	conducted	conduct	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	217	217	B-NP	CD	O	19	NMOD
19	patients	patient	I-NP	NNS	O	23	NMOD
20	and	and	O	CC	O	23	NMOD
21	763	763	B-NP	CD	O	22	NMOD
22	controls	control	I-NP	NNS	O	23	NMOD
23	RESULTS	RESULTS	I-NP	NNS	O	17	PMOD
24	:	:	O	:	O	15	P
25	The	The	B-NP	DT	O	27	NMOD
26	odds	odd	I-NP	NNS	O	27	NMOD
27	ratio	ratio	I-NP	NN	O	15	PRD
28	for	for	B-PP	IN	O	27	NMOD
29	myocardial	myocardial	B-NP	JJ	O	30	NMOD
30	infarction	infarction	I-NP	NN	O	28	PMOD
31	among	among	B-PP	IN	O	30	NMOD
32	women	woman	B-NP	NNS	O	31	PMOD
33	who	who	B-NP	WP	O	32	NMOD
34	used	use	B-VP	VBD	O	33	SBAR
35	any	any	B-NP	DT	O	36	NMOD
36	type	type	I-NP	NN	O	34	OBJ
37	of	of	B-PP	IN	O	36	NMOD
38	combined	combined	B-NP	JJ	O	40	NMOD
39	oral	oral	I-NP	JJ	O	40	NMOD
40	contraceptive	contraceptive	I-NP	NN	O	37	PMOD
41	,	,	O	,	O	15	P
42	as	as	B-SBAR	IN	O	15	VMOD
43	compared	compare	B-PP	VBN	O	42	SBAR
44	with	with	B-PP	IN	O	43	VMOD
45	nonusers	nonuser	B-NP	NNS	O	44	PMOD
46	,	,	O	,	O	15	P
47	was	be	B-VP	VBD	O	0	ROOT
48	2.0	2.0	B-NP	CD	O	47	PRD
49	(	(	O	(	O	58	DEP
50	95	95	B-NP	CD	O	53	NMOD
51	percent	percent	I-NP	NN	O	53	NMOD
52	confidence	confidence	I-NP	NN	O	53	NMOD
53	interval	interval	I-NP	NN	O	57	VMOD
54	,	,	O	,	O	57	P
55	1.5	1.5	B-NP	CD	O	57	AMOD
56	to	to	B-PP	TO	O	57	AMOD
57	2.8	2.8	B-NP	CD	O	58	DEP
58	)	)	O	)	O	48	NMOD
59	.	.	O	.	O	47	P

1	Among	Among	B-PP	IN	O	11	VMOD
2	women	woman	B-NP	NNS	O	1	PMOD
3	who	who	B-NP	WP	O	2	NMOD
4	used	use	B-VP	VBD	O	3	SBAR
5	oral	oral	B-NP	JJ	O	6	NMOD
6	contraceptives	contraceptive	I-NP	NNS	O	4	OBJ
7	,	,	O	,	O	11	P
8	the	the	B-NP	DT	O	9	NMOD
9	odds	odd	I-NP	NNS	O	10	NMOD
10	ratio	ratio	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	53	VMOD
12	2.1	2.1	B-NP	CD	O	11	PRD
13	(	(	O	(	O	22	DEP
14	95	95	B-NP	CD	O	17	NMOD
15	percent	percent	I-NP	NN	O	17	NMOD
16	confidence	confidence	I-NP	NN	O	17	NMOD
17	interval	interval	I-NP	NN	O	21	NMOD
18	,	,	O	,	O	21	P
19	1.5	1.5	B-NP	CD	O	21	AMOD
20	to	to	B-PP	TO	O	21	AMOD
21	3.0	3.0	B-NP	CD	O	22	DEP
22	)	)	O	)	O	12	NMOD
23	for	for	B-PP	IN	O	11	VMOD
24	those	those	B-NP	DT	O	23	PMOD
25	without	without	B-PP	IN	O	24	NMOD
26	a	a	B-NP	DT	O	28	NMOD
27	prothrombotic	prothrombotic	I-NP	JJ	O	28	NMOD
28	mutation	mutation	I-NP	NN	O	30	NMOD
29	and	and	O	CC	O	30	NMOD
30	1.9	1.9	B-NP	CD	O	25	PMOD
31	(	(	O	(	O	40	DEP
32	95	95	B-NP	CD	O	35	NMOD
33	percent	percent	I-NP	NN	O	35	NMOD
34	confidence	confidence	I-NP	NN	O	35	NMOD
35	interval	interval	I-NP	NN	O	39	VMOD
36	,	,	O	,	O	39	P
37	0.6	0.6	B-NP	CD	O	39	AMOD
38	to	to	B-PP	TO	O	39	AMOD
39	5.5	5.5	B-NP	CD	O	40	DEP
40	)	)	O	)	O	30	NMOD
41	for	for	B-PP	IN	O	30	NMOD
42	those	those	B-NP	DT	O	41	PMOD
43	with	with	B-PP	IN	O	42	NMOD
44	a	a	B-NP	DT	O	46	NMOD
45	mutation	mutation	I-NP	NN	O	46	NMOD
46	CONCLUSIONS	CONCLUSIONS	I-NP	NNS	O	43	PMOD
47	:	:	O	:	O	11	P
48	The	The	B-NP	DT	O	49	NMOD
49	risk	risk	I-NP	NN	O	53	SUB
50	of	of	B-PP	IN	O	49	NMOD
51	myocardial	myocardial	B-NP	JJ	O	52	NMOD
52	infarction	infarction	I-NP	NN	O	50	PMOD
53	was	be	B-VP	VBD	O	0	ROOT
54	increased	increase	I-VP	VBN	O	53	VC
55	among	among	B-PP	IN	O	54	VMOD
56	women	woman	B-NP	NNS	O	55	PMOD
57	who	who	B-NP	WP	O	56	NMOD
58	used	use	B-VP	VBD	O	57	SBAR
59	second-generation	second-generation	B-NP	JJ	O	61	NMOD
60	oral	oral	I-NP	JJ	O	61	NMOD
61	contraceptives	contraceptive	I-NP	NNS	O	58	OBJ
62	.	.	O	.	O	53	P

1	Effects	Effect	B-NP	NNS	O	16	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	5-HT1B	5-HT1B	B-NP	NN	O	5	NMOD
4	receptor	receptor	I-NP	NN	O	5	NMOD
5	ligands	ligand	I-NP	NNS	O	2	PMOD
6	microinjected	microinjecte	B-VP	VBN	O	5	NMOD
7	into	into	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	accumbal	accumbal	I-NP	JJ	O	10	NMOD
10	shell	shell	I-NP	NN	O	12	NMOD
11	or	or	I-NP	CC	O	12	NMOD
12	core	core	I-NP	NN	O	7	PMOD
13	on	on	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	cocaine	cocaine	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	locomotor	locomotor	B-NP	NN	O	18	NMOD
18	hyperactivity	hyperactivity	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	examine	examine	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	effect	effect	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	5-HT1B	5-HT1B	B-NP	NN	O	13	NMOD
12	receptor	receptor	I-NP	NN	O	13	NMOD
13	ligands	ligand	I-NP	NNS	O	10	PMOD
14	microinjected	microinjecte	B-VP	VBN	O	13	NMOD
15	into	into	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	subregions	subregion	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	nucleus	nucleus	I-NP	NN	O	21	NMOD
21	accumbens	accumbens	I-NP	NN	O	18	PMOD
22	(	(	O	(	O	28	DEP
23	the	the	B-NP	DT	O	24	NMOD
24	shell	shell	I-NP	NN	O	27	NMOD
25	and	and	O	CC	O	27	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	core	core	I-NP	NN	O	28	DEP
28	)	)	O	)	O	21	NMOD
29	on	on	B-PP	IN	O	9	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	locomotor	locomotor	I-NP	JJ	O	32	NMOD
32	hyperactivity	hyperactivity	I-NP	NN	O	29	PMOD
33	induced	induce	B-VP	VBN	O	32	NMOD
34	by	by	B-PP	IN	O	33	VMOD
35	cocaine	cocaine	B-NP	NN	O	34	PMOD
36	in	in	B-PP	IN	O	35	NMOD
37	rats	rat	B-NP	NNS	O	36	PMOD
38	.	.	O	.	O	4	P

1	GR	GR	B-NP	NN	B-protein	10	NMOD
2	55562	55562	I-NP	CD	O	1	NMOD
3	(	(	O	(	O	6	DEP
4	0.1-10	0.1-10	B-NP	CD	O	5	NMOD
5	microg/side	microg/side	I-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	,	,	O	,	O	1	P
8	administered	administer	B-VP	VBN	O	10	NMOD
9	intra-accumbens	intra-accumbens	B-NP	JJ	O	10	NMOD
10	shell	shell	I-NP	NN	O	16	SUB
11	prior	prior	B-ADJP	JJ	O	10	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	cocaine	cocaine	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	10	P
15	dose-dependently	dose-dependently	B-ADVP	RB	O	16	VMOD
16	attenuated	attenuate	B-VP	VBD	O	0	ROOT
17	the	the	B-NP	DT	O	18	NMOD
18	psychostimulant	psychostimulant	I-NP	NN	O	21	NMOD
19	induced	induce	B-VP	VBD	O	21	NMOD
20	locomotor	locomotor	B-NP	NN	O	21	NMOD
21	hyperactivity	hyperactivity	I-NP	NN	O	16	OBJ
22	.	.	O	.	O	16	P

1	Ticlopidine	Ticlopidine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cholestatic	cholestatic	B-NP	JJ	O	4	NMOD
4	hepatitis	hepatitis	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	2	2	B-NP	CD	O	6	NMOD
6	cases	case	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	ticlopidine	ticlopidine	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	1	NMOD
10	cholestatic	cholestatic	B-NP	JJ	O	11	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	9	OBJ
12	,	,	O	,	O	13	P
13	investigate	investigate	B-VP	VB	O	9	VMOD
14	its	its	B-NP	PRP$	O	15	NMOD
15	mechanism	mechanism	I-NP	NN	O	13	OBJ
16	,	,	O	,	O	1	P
17	and	and	O	CC	O	18	VMOD
18	compare	compare	B-VP	VBP	O	1	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	observed	observe	I-NP	VBN	O	22	NMOD
21	main	main	I-NP	JJ	O	22	NMOD
22	characteristics	characteristic	I-NP	NNS	O	18	OBJ
23	with	with	B-PP	IN	O	22	NMOD
24	those	those	B-NP	DT	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	published	publish	I-NP	VBN	O	28	NMOD
28	cases	case	I-NP	NNS	O	25	PMOD
29	.	.	O	.	O	18	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARIES	SUMMARIES	I-NP	NNS	O	5	NMOD
3	:	:	O	:	O	2	P
4	Two	Two	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	6	SUB
6	developed	develop	B-VP	VBD	O	0	ROOT
7	prolonged	prolonged	B-NP	JJ	O	8	AMOD
8	cholestatic	cholestatic	I-NP	JJ	O	9	NMOD
9	hepatitis	hepatitis	I-NP	NN	O	6	OBJ
10	after	after	B-PP	IN	O	6	VMOD
11	receiving	receive	B-VP	VBG	O	10	PMOD
12	ticlopidine	ticlopidine	B-NP	NN	O	11	OBJ
13	following	follow	B-PP	VBG	O	12	NMOD
14	percutaneous	percutaneous	B-NP	JJ	O	16	NMOD
15	coronary	coronary	I-NP	JJ	O	16	NMOD
16	angioplasty	angioplasty	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	6	P
18	with	with	B-PP	IN	O	6	VMOD
19	complete	complete	B-NP	JJ	O	20	NMOD
20	remission	remission	I-NP	NN	O	18	PMOD
21	during	during	B-PP	IN	O	6	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	follow-up	follow-up	I-NP	JJ	O	24	NMOD
24	period	period	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	6	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Cholestatic	Cholestatic	B-NP	JJ	O	4	NMOD
4	hepatitis	hepatitis	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	17	VMOD
6	a	a	B-NP	DT	O	8	NMOD
7	rare	rare	I-NP	JJ	O	8	NMOD
8	complication	complication	I-NP	NN	O	5	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	antiplatelet	antiplatelet	I-NP	JJ	O	13	NMOD
12	agent	agent	I-NP	NN	O	13	NMOD
13	ticlopidine	ticlopidine	I-NP	NN	O	9	PMOD
14	;	;	O	:	O	17	P
15	several	several	B-NP	JJ	O	16	NMOD
16	cases	case	I-NP	NNS	O	17	SUB
17	have	have	B-VP	VBP	O	0	ROOT
18	been	be	I-VP	VBN	O	17	VC
19	reported	report	I-VP	VBN	O	18	VC
20	but	but	O	CC	O	19	DEP
21	few	few	B-ADJP	JJ	O	19	PRD
22	in	in	B-PP	IN	O	19	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	English	English	I-NP	JJ	O	25	NMOD
25	literature	literature	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	17	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	developed	develop	B-VP	VBD	O	0	ROOT
4	jaundice	jaundice	B-NP	NN	O	3	OBJ
5	following	follow	B-PP	VBG	O	4	NMOD
6	treatment	treatment	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	ticlopidine	ticlopidine	B-NP	NN	O	7	PMOD
9	and	and	O	CC	O	3	VMOD
10	showed	show	B-VP	VBD	O	3	VMOD
11	the	the	B-NP	DT	O	15	NMOD
12	clinical	clinical	I-NP	JJ	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	laboratory	laboratory	I-NP	JJ	O	15	NMOD
15	characteristics	characteristic	I-NP	NNS	O	10	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	cholestatic	cholestatic	B-NP	JJ	O	18	NMOD
18	hepatitis	hepatitis	I-NP	NN	O	16	PMOD
19	,	,	O	,	O	3	P
20	which	which	B-NP	WDT	O	3	VMOD
21	resolved	resolve	B-VP	VBD	O	20	SBAR
22	after	after	B-PP	IN	O	21	VMOD
23	discontinuation	discontinuation	B-NP	NN	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	drug	drug	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanisms	mechanism	I-NP	NNS	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	7	NMOD
5	ticlopidine	ticlopidine	I-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	cholestasis	cholestasis	I-NP	NN	O	3	PMOD
8	are	be	B-VP	VBP	O	0	ROOT
9	unclear	unclear	B-ADJP	JJ	O	8	PRD
10	.	.	O	.	O	8	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cholestatic	Cholestatic	B-NP	JJ	O	4	NMOD
4	hepatitis	hepatitis	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	rare	rare	I-NP	JJ	O	9	NMOD
8	adverse	adverse	I-NP	JJ	O	9	NMOD
9	effect	effect	I-NP	NN	O	5	PRD
10	of	of	B-PP	IN	O	9	NMOD
11	ticlopidine	ticlopidine	B-NP	NN	O	10	PMOD
12	that	that	B-NP	WDT	O	9	NMOD
13	may	may	B-VP	MD	O	12	SBAR
14	be	be	I-VP	VB	O	13	VC
15	immune	immune	B-ADJP	JJ	O	14	PRD
16	mediated	mediate	B-VP	VBN	O	15	AMOD
17	.	.	O	.	O	1	P

1	Epithelial	Epithelial	B-NP	JJ	B-protein	3	NMOD
2	sodium	sodium	I-NP	NN	I-protein	3	NMOD
3	channel	channel	I-NP	NN	I-protein	11	NMOD
4	(	(	O	(	O	6	DEP
5	ENaC	ENaC	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	subunit	subunit	B-NP	NN	O	8	NMOD
8	mRNA	mRNA	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	protein	protein	B-NP	NN	O	11	NMOD
11	expression	expression	I-NP	NN	O	17	SUB
12	in	in	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	11	NMOD
15	puromycin	puromycin	B-NP	NN	O	16	NMOD
16	aminonucleoside	aminonucleoside	I-NP	NN	O	14	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	nephrotic	nephrotic	B-NP	JJ	O	19	NMOD
19	syndrome	syndrome	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	17	P

1	In	In	B-PP	IN	O	9	VMOD
2	experimental	experimental	B-NP	JJ	O	4	NMOD
3	nephrotic	nephrotic	I-NP	JJ	O	4	NMOD
4	syndrome	syndrome	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	9	P
6	urinary	urinary	B-NP	JJ	O	8	NMOD
7	sodium	sodium	I-NP	NN	O	8	NMOD
8	excretion	excretion	I-NP	NN	O	9	SUB
9	is	be	B-VP	VBZ	O	0	ROOT
10	decreased	decrease	I-VP	VBN	O	9	VC
11	during	during	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	early	early	I-NP	JJ	O	14	NMOD
14	phase	phase	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	disease	disease	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	examined	examine	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	abundance	abundance	I-NP	NN	O	17	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	ENaC	ENaC	B-NP	NN	B-RNA	8	NMOD
7	subunit	subunit	I-NP	NN	I-RNA	8	NMOD
8	mRNAs	mRNA	I-NP	NNS	I-RNA	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	proteins	protein	I-NP	NNS	O	5	PMOD
11	in	in	B-PP	IN	O	4	NMOD
12	puromycin	puromycin	B-NP	NN	O	13	NMOD
13	aminonucleoside	aminonucleoside	I-NP	NN	O	11	PMOD
14	(	(	O	(	O	16	DEP
15	PAN	PAN	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	induced	induce	B-VP	VBD	O	2	VMOD
18	nephrotic	nephrotic	B-NP	JJ	O	19	NMOD
19	syndrome	syndrome	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	time	time	I-NP	NN	O	3	NMOD
3	courses	course	I-NP	NNS	O	13	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	urinary	urinary	B-NP	JJ	O	7	NMOD
6	sodium	sodium	I-NP	NN	O	7	NMOD
7	excretion	excretion	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	13	P
9	plasma	plasma	B-NP	NN	O	11	NMOD
10	aldosterone	aldosterone	I-NP	NN	O	11	NMOD
11	concentration	concentration	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	proteinuria	proteinuria	I-NP	NN	O	14	SUB
14	were	be	B-VP	VBD	O	0	ROOT
15	studied	study	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	male	male	B-NP	JJ	O	19	NMOD
18	Sprague-Dawley	Sprague-Dawley	I-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	16	PMOD
20	treated	treat	B-VP	VBN	O	19	NMOD
21	with	with	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	single	single	I-NP	JJ	O	24	NMOD
24	dose	dose	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	either	either	O	CC	O	29	NMOD
27	PAN	PAN	B-NP	NN	B-protein	29	NMOD
28	or	or	I-NP	CC	O	29	NMOD
29	vehicle	vehicle	I-NP	NN	O	25	PMOD
30	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	kinetics	kinetic	I-NP	NNS	O	9	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	urinary	urinary	B-NP	JJ	O	6	NMOD
5	sodium	sodium	I-NP	NN	O	6	NMOD
6	excretion	excretion	I-NP	NN	O	3	PMOD
7	and	and	O	CC	O	9	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	appearance	appearance	I-NP	NN	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	proteinuria	proteinuria	B-NP	NN	O	10	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	comparable	comparable	B-ADJP	JJ	O	12	PRD
14	with	with	B-PP	IN	O	13	AMOD
15	those	those	B-NP	DT	O	14	PMOD
16	reported	report	B-VP	VBN	O	15	NMOD
17	previously	previously	B-ADVP	RB	O	16	VMOD
18	.	.	O	.	O	12	P

1	NO	NO	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	migraine	migraine	B-NP	NN	O	4	NMOD
4	attack	attack	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	P
6	strong	strong	B-NP	JJ	O	7	NMOD
7	increase	increase	I-NP	NN	O	19	NMOD
8	in	in	B-PP	IN	O	7	NMOD
9	plasma	plasma	B-NP	NN	O	12	NMOD
10	calcitonin	calcitonin	I-NP	NN	O	12	NMOD
11	gene-related	gene-related	I-NP	JJ	O	12	NMOD
12	peptide	peptide	I-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	CGRP	CGRP	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	concentration	concentration	B-NP	NN	O	8	PMOD
17	and	and	O	CC	O	19	NMOD
18	negative	negative	B-NP	JJ	O	19	NMOD
19	correlation	correlation	I-NP	NN	O	2	VMOD
20	with	with	B-PP	IN	O	19	NMOD
21	platelet	platelet	B-NP	NN	B-protein	23	NMOD
22	serotonin	serotonin	I-NP	NN	I-protein	23	NMOD
23	release	release	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	investigate	investigate	I-VP	VB	O	7	PRD
10	changes	change	B-NP	NNS	O	9	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	16	NMOD
13	plasma	plasma	I-NP	NN	O	16	NMOD
14	calcitonin	calcitonin	I-NP	NN	O	16	NMOD
15	gene-related	gene-related	I-NP	JJ	O	16	NMOD
16	peptide	peptide	I-NP	NN	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	CGRP	CGRP	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	concentration	concentration	B-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	platelet	platelet	B-NP	NN	B-protein	23	NMOD
23	serotonin	serotonin	I-NP	NN	I-protein	29	NMOD
24	(	(	O	(	O	28	DEP
25	5-hydroxytriptamine	5-hydroxytriptamine	B-NP	NN	O	27	NMOD
26	,	,	O	,	O	27	P
27	5-HT	5-HT	B-NP	NN	O	28	DEP
28	)	)	O	)	O	23	NMOD
29	content	content	B-NP	NN	O	39	NMOD
30	during	during	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	33	NMOD
32	immediate	immediate	I-NP	JJ	O	33	NMOD
33	headache	headache	I-NP	NN	O	30	PMOD
34	and	and	O	CC	O	39	NMOD
35	the	the	B-NP	DT	O	39	NMOD
36	delayed	delay	I-NP	VBN	O	39	NMOD
37	genuine	genuine	I-NP	JJ	O	39	NMOD
38	migraine	migraine	I-NP	NN	O	39	NMOD
39	attack	attack	I-NP	NN	O	11	PMOD
40	provoked	provoke	B-VP	VBN	O	39	NMOD
41	by	by	B-PP	IN	O	40	VMOD
42	nitroglycerin	nitroglycerin	B-NP	NN	B-protein	41	PMOD
43	.	.	O	.	O	7	P

1	Blood	Blood	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	collected	collect	I-VP	VBN	O	2	VC
4	from	from	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	9	NMOD
6	antecubital	antecubital	I-NP	JJ	O	9	NMOD
7	vein	vein	I-NP	NN	O	9	NMOD
8	four	four	B-NP	CD	O	9	NMOD
9	times	time	I-NP	NNS	O	4	PMOD
10	:	:	O	:	O	2	P
11	60	60	B-NP	CD	O	12	NMOD
12	min	min	I-NP	NN	O	18	NMOD
13	before	before	B-PP	IN	O	12	NMOD
14	and	and	I-PP	CC	O	13	PMOD
15	after	after	I-PP	IN	O	13	PMOD
16	the	the	B-NP	DT	O	18	NMOD
17	nitroglycerin	nitroglycerin	I-NP	NN	O	18	NMOD
18	application	application	I-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	and	and	O	CC	O	24	NMOD
21	60	60	B-NP	CD	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	120	120	I-NP	CD	O	24	NMOD
24	min	min	I-NP	NN	O	2	PRD
25	after	after	B-PP	IN	O	2	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	beginning	beginning	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	migraine	migraine	I-NP	NN	O	31	NMOD
31	attack	attack	I-NP	NN	O	28	PMOD
32	(	(	O	(	O	41	DEP
33	mean	mean	B-NP	NN	O	37	NMOD
34	344	344	I-NP	CD	O	36	AMOD
35	and	and	I-NP	CC	O	36	AMOD
36	404	404	I-NP	CD	O	37	NMOD
37	min	min	I-NP	NN	O	40	NMOD
38	;	;	O	:	O	40	P
39	12	12	B-NP	CD	O	40	NMOD
40	subjects	subject	I-NP	NNS	O	41	DEP
41	)	)	O	)	O	2	VMOD
42	.	.	O	.	O	2	P

1	Plasma	Plasma	B-NP	NN	O	3	NMOD
2	CGRP	CGRP	I-NP	NN	O	3	NMOD
3	concentration	concentration	I-NP	NN	O	4	SUB
4	increased	increase	B-VP	VBD	O	0	ROOT
5	significantly	significantly	B-ADVP	RB	O	4	VMOD
6	(	(	O	(	O	10	DEP
7	P	P	B-NP	NN	O	10	DEP
8	<	<	O	SYM	O	7	NMOD
9	0.01	0.01	B-NP	CD	O	8	AMOD
10	)	)	O	)	O	4	VMOD
11	during	during	B-PP	IN	O	4	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	migraine	migraine	I-NP	NN	O	14	NMOD
14	attack	attack	I-NP	NN	O	11	PMOD
15	and	and	O	CC	O	4	VMOD
16	returned	return	B-VP	VBD	O	4	VMOD
17	to	to	B-PP	TO	O	16	VMOD
18	baseline	baseline	B-NP	NN	O	17	PMOD
19	after	after	B-PP	IN	O	16	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	cessation	cessation	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	migraine	migraine	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	4	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	plasma	plasma	B-NP	NN	O	5	NMOD
4	CGRP	CGRP	I-NP	NN	O	5	NMOD
5	concentrations	concentration	I-NP	NNS	O	6	SUB
6	failed	fail	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	change	change	I-VP	VB	O	6	VMOD
9	during	during	B-PP	IN	O	8	VMOD
10	immediate	immediate	B-NP	JJ	O	11	NMOD
11	headache	headache	I-NP	NN	O	9	PMOD
12	and	and	B-PP	CC	O	8	VMOD
13	in	in	B-PP	IN	O	8	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	subjects	subject	I-NP	NNS	O	13	PMOD
16	with	with	B-PP	IN	O	8	VMOD
17	no	no	B-NP	DT	O	19	NMOD
18	migraine	migraine	I-NP	NN	O	19	NMOD
19	attack	attack	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	6	P

1	Basal	Basal	B-NP	JJ	O	3	NMOD
2	CGRP	CGRP	I-NP	NN	O	3	NMOD
3	concentration	concentration	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	significantly	significantly	B-ADJP	RB	O	6	AMOD
6	higher	high	I-ADJP	JJR	O	4	PRD
7	and	and	O	CC	O	11	VMOD
8	platelet	platelet	B-NP	NN	O	10	NMOD
9	5-HT	5-HT	I-NP	NN	O	10	NMOD
10	content	content	I-NP	NN	O	11	SUB
11	tended	tend	B-VP	VBD	O	4	VMOD
12	to	to	I-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	11	VMOD
14	lower	low	B-ADJP	JJR	O	13	PRD
15	in	in	B-PP	IN	O	14	AMOD
16	subjects	subject	B-NP	NNS	O	15	PMOD
17	who	who	B-NP	WP	O	16	NMOD
18	experienced	experience	B-VP	VBD	O	17	SBAR
19	a	a	B-NP	DT	O	21	NMOD
20	migraine	migraine	I-NP	NN	O	21	NMOD
21	attack	attack	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	4	P

1	Platelet	Platelet	B-NP	NN	O	3	NMOD
2	serotonin	serotonin	I-NP	NN	O	3	NMOD
3	content	content	I-NP	NN	O	4	SUB
4	decreased	decrease	B-VP	VBD	O	23	VMOD
5	significantly	significantly	B-ADVP	RB	O	4	VMOD
6	(	(	O	(	O	10	DEP
7	P	P	B-NP	NN	O	10	DEP
8	<	<	B-NP	SYM	O	7	NMOD
9	0.01	0.01	I-NP	CD	O	8	AMOD
10	)	)	O	)	O	5	AMOD
11	after	after	B-PP	IN	O	4	VMOD
12	nitroglycerin	nitroglycerin	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	subjects	subject	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	no	no	B-NP	DT	O	18	NMOD
17	migraine	migraine	I-NP	NN	O	18	NMOD
18	attack	attack	I-NP	NN	O	15	PMOD
19	but	but	O	CC	O	23	VMOD
20	no	no	B-NP	DT	O	22	NMOD
21	consistent	consistent	I-NP	JJ	O	22	NMOD
22	change	change	I-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	0	ROOT
24	observed	observe	I-VP	VBN	O	23	VC
25	in	in	B-PP	IN	O	24	VMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	migraine	migraine	B-NP	NN	O	29	NMOD
29	attack	attack	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	23	P

1	In	In	B-PP	IN	O	20	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	20	P
4	the	the	B-NP	DT	O	5	NMOD
5	fact	fact	I-NP	NN	O	20	SUB
6	that	that	B-SBAR	IN	O	5	NMOD
7	plasma	plasma	B-NP	NN	O	9	NMOD
8	CGRP	CGRP	I-NP	NN	O	9	NMOD
9	concentration	concentration	I-NP	NN	O	10	SUB
10	correlates	correlate	B-VP	VBZ	O	6	SBAR
11	with	with	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	timing	timing	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	severity	severity	I-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	a	a	B-NP	DT	O	19	NMOD
18	migraine	migraine	I-NP	NN	O	19	NMOD
19	headache	headache	I-NP	NN	O	16	PMOD
20	suggests	suggest	B-VP	VBZ	O	0	ROOT
21	a	a	B-NP	DT	O	23	NMOD
22	direct	direct	I-NP	JJ	O	23	NMOD
23	relationship	relationship	I-NP	NN	O	20	OBJ
24	between	between	B-PP	IN	O	23	NMOD
25	CGRP	CGRP	B-NP	NN	B-protein	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	migraine	migraine	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	20	P

1	Coronary	Coronary	B-NP	JJ	O	2	NMOD
2	aneurysm	aneurysm	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	implantation	implantation	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	paclitaxel-eluting	paclitaxel-eluting	I-NP	JJ	O	8	NMOD
8	stent	stent	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	43-year-old	43-year-old	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	a	a	B-NP	DT	O	10	NMOD
9	coronary	coronary	I-NP	JJ	O	10	NMOD
10	aneurysm	aneurysm	I-NP	NN	O	7	OBJ
11	in	in	B-PP	IN	O	7	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	right	right	I-NP	JJ	O	15	NMOD
14	coronary	coronary	I-NP	JJ	O	15	NMOD
15	artery	artery	I-NP	NN	O	11	PMOD
16	6	6	B-NP	CD	O	15	NMOD
17	months	month	I-NP	NNS	O	15	NMOD
18	after	after	B-PP	IN	O	7	VMOD
19	receiving	receive	B-VP	VBG	O	18	PMOD
20	a	a	B-NP	DT	O	22	NMOD
21	paclitaxel-eluting	paclitaxel-eluting	I-NP	JJ	O	22	NMOD
22	stent	stent	I-NP	NN	O	19	OBJ
23	.	.	O	.	O	2	P

1	Intracerebroventricular	Intracerebroventricular	O	JJ	O	5	NMOD
2	(	(	O	(	O	4	DEP
3	i.c.v.	i.c.v.	B-ADJP	JJ	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	injection	injection	B-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	U-II	U-II	B-NP	NN	B-protein	6	PMOD
8	causes	cause	B-VP	VBZ	O	0	ROOT
9	hypertension	hypertension	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	bradycardia	bradycardia	I-NP	NN	O	8	OBJ
12	and	and	O	CC	O	8	VMOD
13	stimulates	stimulate	B-VP	VBZ	O	8	VMOD
14	prolactin	prolactin	B-NP	NN	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	thyrotropin	thyrotropin	I-NP	NN	O	17	NMOD
17	secretion	secretion	I-NP	NN	O	13	OBJ
18	.	.	O	.	O	8	P

1	Whatever	Whatever	B-NP	WDT	O	8	NMOD
2	was	be	B-VP	VBD	O	1	SBAR
3	the	the	B-NP	DT	O	4	NMOD
4	dose	dose	I-NP	NN	O	2	PRD
5	,	,	O	,	O	8	P
6	the	the	B-NP	DT	O	8	NMOD
7	central	central	I-NP	JJ	O	8	NMOD
8	administration	administration	I-NP	NN	O	11	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	U-II	U-II	B-NP	NN	B-protein	9	PMOD
11	had	have	B-VP	VBD	O	0	ROOT
12	no	no	B-NP	DT	O	13	NMOD
13	effect	effect	I-NP	NN	O	11	OBJ
14	on	on	B-PP	IN	O	11	VMOD
15	body	body	B-NP	NN	O	16	NMOD
16	temperature	temperature	I-NP	NN	O	21	SUB
17	,	,	O	,	O	21	P
18	nociception	nociception	B-NP	NN	O	21	SUB
19	,	,	O	,	O	21	P
20	apomorphine	apomorphine	B-NP	NN	O	21	SUB
21	induced	induce	B-VP	VBD	O	30	VMOD
22	penile	penile	B-NP	JJ	O	23	NMOD
23	erection	erection	I-NP	NN	O	21	OBJ
24	and	and	O	CC	O	21	VMOD
25	climbing	climb	B-VP	VBG	O	21	VMOD
26	behavior	behavior	B-NP	NN	O	25	OBJ
27	,	,	O	,	O	30	P
28	and	and	O	CC	O	30	VMOD
29	stress	stress	B-NP	NN	O	30	SUB
30	induced	induce	B-VP	VBD	O	14	SBAR
31	plasma	plasma	B-NP	NN	O	33	NMOD
32	corticosterone	corticosterone	I-NP	NN	O	33	NMOD
33	level	level	I-NP	NN	O	30	OBJ
34	.	.	O	.	O	11	P

1	Recurrent	Recurrent	B-NP	JJ	O	4	NMOD
2	dysphonia	dysphonia	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	acitretin	acitretin	I-NP	NN	O	0	ROOT
5	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	woman	woman	I-NP	NN	O	5	PMOD
8	complaining	complain	B-VP	VBG	O	7	NMOD
9	of	of	B-PP	IN	O	8	VMOD
10	dysphonia	dysphonia	B-NP	NN	O	9	PMOD
11	while	while	B-SBAR	IN	O	4	NMOD
12	she	she	B-NP	PRP	O	13	SUB
13	was	be	B-VP	VBD	O	11	SBAR
14	treated	treat	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	acitretin	acitretin	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	assess	assess	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	effects	effect	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	gabapentin	gabapentin	B-NP	NN	B-protein	15	NMOD
13	,	,	O	,	O	15	P
14	a	a	B-NP	DT	O	15	NMOD
15	drug	drug	I-NP	NN	O	11	PMOD
16	effective	effective	B-ADJP	JJ	O	15	NMOD
17	in	in	B-PP	IN	O	16	AMOD
18	neuropathic	neuropathic	B-NP	JJ	O	20	NMOD
19	pain	pain	I-NP	NN	O	20	NMOD
20	patients	patient	I-NP	NNS	O	17	PMOD
21	,	,	O	,	O	8	P
22	on	on	B-PP	IN	O	8	VMOD
23	brain	brain	B-NP	NN	O	24	NMOD
24	processing	processing	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	nociceptive	nociceptive	B-NP	JJ	O	27	NMOD
27	information	information	I-NP	NN	O	25	PMOD
28	in	in	B-PP	IN	O	24	NMOD
29	normal	normal	B-NP	JJ	O	31	AMOD
30	and	and	I-NP	CC	O	31	AMOD
31	central	central	I-NP	JJ	O	33	NMOD
32	sensitization	sensitization	I-NP	NN	O	33	NMOD
33	states	state	I-NP	NNS	O	28	PMOD
34	.	.	O	.	O	6	P

1	Using	Use	B-VP	VBG	O	14	VMOD
2	functional	functional	B-NP	JJ	O	5	NMOD
3	magnetic	magnetic	I-NP	JJ	O	5	NMOD
4	resonance	resonance	I-NP	NN	O	5	NMOD
5	imaging	imaging	I-NP	NN	O	1	OBJ
6	(	(	O	(	O	8	DEP
7	fMRI	fMRI	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	in	in	B-PP	IN	O	5	NMOD
10	normal	normal	B-NP	JJ	O	11	NMOD
11	volunteers	volunteer	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	14	P
13	we	we	B-NP	PRP	O	14	SUB
14	studied	study	B-VP	VBD	O	0	ROOT
15	the	the	B-NP	DT	O	16	NMOD
16	gabapentin	gabapentin	I-NP	NN	B-protein	18	NMOD
17	induced	induce	B-VP	VBD	O	18	NMOD
18	modulation	modulation	B-NP	NN	O	33	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	brain	brain	B-NP	NN	O	21	NMOD
21	activity	activity	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	18	NMOD
23	response	response	B-NP	NN	O	22	PMOD
24	to	to	B-PP	TO	O	23	NMOD
25	nociceptive	nociceptive	B-NP	JJ	O	26	AMOD
26	mechanical	mechanical	I-NP	JJ	O	27	NMOD
27	stimulation	stimulation	I-NP	NN	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	normal	normal	B-NP	JJ	O	30	NMOD
30	skin	skin	I-NP	NN	O	32	NMOD
31	and	and	I-NP	CC	O	32	NMOD
32	capsaicin	capsaicin	I-NP	NN	O	28	PMOD
33	induced	induce	B-VP	VBD	O	14	VMOD
34	secondary	secondary	B-NP	JJ	O	35	NMOD
35	hyperalgesia	hyperalgesia	I-NP	NN	O	33	OBJ
36	.	.	O	.	O	14	P

1	MDMA	MDMA	B-NP	NN	O	3	NMOD
2	polydrug	polydrug	I-NP	NN	O	3	NMOD
3	users	user	I-NP	NNS	O	4	SUB
4	show	show	B-VP	VBP	O	0	ROOT
5	process-specific	process-specific	B-NP	JJ	O	8	NMOD
6	central	central	I-NP	JJ	O	8	NMOD
7	executive	executive	I-NP	NN	O	8	NMOD
8	impairments	impairment	I-NP	NNS	O	4	OBJ
9	coupled	couple	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	impaired	impair	B-NP	VBN	O	14	AMOD
12	social	social	I-NP	JJ	O	14	AMOD
13	and	and	I-NP	CC	O	14	AMOD
14	emotional	emotional	I-NP	JJ	O	16	NMOD
15	judgement	judgement	I-NP	NN	O	16	NMOD
16	processes	process	I-NP	NNS	O	10	PMOD
17	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	7	VMOD
2	recent	recent	B-NP	JJ	O	3	NMOD
3	years	year	I-NP	NNS	O	1	PMOD
4	working	work	B-VP	VBG	O	3	NMOD
5	memory	memory	B-NP	NN	O	6	NMOD
6	deficits	deficit	I-NP	NNS	O	4	OBJ
7	have	have	B-VP	VBP	O	0	ROOT
8	been	be	I-VP	VBN	O	7	VC
9	reported	report	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	users	user	B-NP	NNS	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	MDMA	MDMA	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	20	DEP
15	3	3	B-NP	CD	O	17	NMOD
16	,	,	O	,	O	17	P
17	4-methylenedioxymethamphetamine	4-methylenedioxymethamphetamine	B-NP	NN	O	20	DEP
18	,	,	O	,	O	17	P
19	ecstasy	ecstasy	B-ADJP	JJ	O	17	NMOD
20	)	)	O	)	O	13	NMOD
21	.	.	O	.	O	7	P

1	Severe	Severe	B-NP	JJ	O	3	NMOD
2	citrate	citrate	I-NP	NN	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	0	ROOT
4	complicating	complicate	B-VP	VBG	O	3	NMOD
5	volunteer	volunteer	B-NP	NN	O	8	NMOD
6	apheresis	apheresis	I-NP	NN	O	8	NMOD
7	platelet	platelet	I-NP	NN	O	8	NMOD
8	donation	donation	I-NP	NN	O	4	OBJ
9	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	severe	severe	B-NP	JJ	O	8	NMOD
7	citrate	citrate	I-NP	NN	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	5	PMOD
9	during	during	B-PP	IN	O	4	NMOD
10	volunteer	volunteer	B-NP	NN	O	14	NMOD
11	donor	donor	I-NP	NN	O	14	NMOD
12	apheresis	apheresis	I-NP	NN	O	14	NMOD
13	platelet	platelet	I-NP	NN	O	14	NMOD
14	collection	collection	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	2	P

1	Empirical	Empirical	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	7	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	intravenous	intravenous	B-NP	JJ	O	6	NMOD
5	calcium	calcium	I-NP	NN	O	6	NMOD
6	gluconate	gluconate	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	14	VMOD
8	initiated	initiate	I-VP	VBN	O	7	VC
9	,	,	O	,	O	14	P
10	and	and	O	CC	O	14	VMOD
11	muscle	muscle	B-NP	NN	O	12	NMOD
12	contractions	contraction	I-NP	NNS	O	14	SUB
13	slowly	slowly	B-ADVP	RB	O	14	VMOD
14	subsided	subside	B-VP	VBD	O	0	ROOT
15	over	over	B-PP	IN	O	14	VMOD
16	approximately	approximately	B-NP	RB	O	20	NMOD
17	10	10	I-NP	CD	O	16	AMOD
18	to	to	I-NP	TO	O	16	AMOD
19	15	15	I-NP	CD	O	16	AMOD
20	minutes	minute	I-NP	NNS	O	15	PMOD
21	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	events	event	I-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	0	ROOT
4	consistent	consistent	B-ADJP	JJ	O	3	PRD
5	with	with	B-PP	IN	O	4	AMOD
6	a	a	B-NP	DT	O	8	NMOD
7	severe	severe	I-NP	JJ	O	8	NMOD
8	reaction	reaction	I-NP	NN	O	5	PMOD
9	to	to	B-PP	TO	O	8	NMOD
10	calcium	calcium	B-NP	NN	O	11	NMOD
11	chelation	chelation	I-NP	NN	O	9	PMOD
12	by	by	B-PP	IN	O	8	NMOD
13	sodium	sodium	B-NP	NN	O	15	NMOD
14	citrate	citrate	I-NP	NN	O	15	NMOD
15	anticoagulant	anticoagulant	I-NP	NN	O	12	PMOD
16	resulting	result	B-VP	VBG	O	15	NMOD
17	in	in	B-PP	IN	O	16	VMOD
18	symptomatic	symptomatic	B-NP	JJ	O	20	NMOD
19	systemic	systemic	I-NP	JJ	O	20	NMOD
20	hypocalcemia	hypocalcemia	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	3	P

1	Upon	Upon	B-PP	IN	O	7	VMOD
2	additional	additional	B-NP	JJ	O	4	NMOD
3	retrospective	retrospective	I-NP	JJ	O	4	NMOD
4	analysis	analysis	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	it	it	B-NP	PRP	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	noted	note	I-VP	VBN	O	7	VC
9	that	that	B-SBAR	IN	O	8	VMOD
10	bumetanide	bumetanide	B-NP	NN	O	11	SUB
11	is	be	B-VP	VBZ	O	9	SBAR
12	a	a	B-NP	DT	O	14	NMOD
13	loop	loop	I-NP	NN	O	14	NMOD
14	diuretic	diuretic	I-NP	JJ	O	11	PRD
15	that	that	B-NP	WDT	O	14	NMOD
16	may	may	B-VP	MD	O	15	SBAR
17	cause	cause	I-VP	VB	O	16	VC
18	significant	significant	B-NP	JJ	O	19	NMOD
19	hypocalcemia	hypocalcemia	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	careful	careful	B-NP	JJ	O	5	NMOD
5	screening	screening	I-NP	NN	O	14	SUB
6	for	for	B-PP	IN	O	5	NMOD
7	medications	medication	B-NP	NNS	O	6	PMOD
8	and	and	O	CC	O	5	DEP
9	underlying	underlie	B-VP	VBG	O	5	NMOD
10	conditions	condition	B-NP	NNS	O	9	OBJ
11	predisposing	predispose	B-VP	VBG	O	10	NMOD
12	to	to	B-PP	TO	O	11	VMOD
13	hypocalcemia	hypocalcemia	B-NP	NN	O	12	PMOD
14	is	be	B-VP	VBZ	O	3	SBAR
15	recommended	recommend	I-VP	VBN	O	14	VC
16	to	to	I-VP	TO	O	17	VMOD
17	help	help	I-VP	VB	O	15	VMOD
18	prevent	prevent	I-VP	VB	O	17	VMOD
19	severe	severe	B-NP	JJ	O	20	NMOD
20	reactions	reaction	I-NP	NNS	O	18	OBJ
21	due	due	B-ADJP	JJ	O	20	NMOD
22	to	to	B-VP	TO	O	23	VMOD
23	citrate	citrate	I-VP	VB	O	21	AMOD
24	toxicity	toxicity	B-NP	NN	O	23	OBJ
25	.	.	O	.	O	2	P

1	Proteinuria	Proteinuria	B-NP	NN	O	0	ROOT
2	after	after	B-PP	IN	O	1	NMOD
3	conversion	conversion	B-NP	NN	O	2	PMOD
4	to	to	B-PP	TO	O	3	NMOD
5	sirolimus	sirolimus	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	renal	renal	B-NP	JJ	O	9	NMOD
8	transplant	transplant	I-NP	NN	O	9	NMOD
9	recipients	recipient	I-NP	NNS	O	6	PMOD
10	.	.	O	.	O	1	P

1	More	More	B-ADVP	RBR	O	2	AMOD
2	recently	recently	I-ADVP	RB	O	5	VMOD
3	,	,	O	,	O	5	P
4	proteinuria	proteinuria	B-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	reported	report	I-VP	VBN	O	6	VC
8	as	as	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	10	NMOD
10	consequence	consequence	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	sirolimus	sirolimus	B-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	5	P
15	although	although	B-SBAR	IN	O	5	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	mechanism	mechanism	I-NP	NN	O	18	SUB
18	has	have	B-VP	VBZ	O	15	SBAR
19	remained	remain	I-VP	VBN	O	18	VC
20	unclear	unclear	B-ADJP	JJ	O	19	PRD
21	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	3	SUB
2	retrospectively	retrospectively	B-ADVP	RB	O	3	VMOD
3	examined	examine	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	records	record	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	25	25	B-NP	CD	O	10	NMOD
8	renal	renal	I-NP	JJ	O	10	NMOD
9	transplant	transplant	I-NP	NN	O	10	NMOD
10	patients	patient	I-NP	NNS	O	6	PMOD
11	,	,	O	,	O	5	P
12	who	who	B-NP	WP	O	5	NMOD
13	developed	develop	B-VP	VBD	O	12	SBAR
14	or	or	I-VP	CC	O	13	VMOD
15	displayed	display	I-VP	VBD	O	13	VMOD
16	increased	increase	B-NP	VBN	O	17	NMOD
17	proteinuria	proteinuria	I-NP	NN	O	15	OBJ
18	after	after	B-PP	IN	O	15	VMOD
19	SRL	SRL	B-NP	NN	O	20	NMOD
20	conversion	conversion	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	patient	patient	I-NP	NN	O	3	NMOD
3	cohort	cohort	I-NP	NN	O	11	SUB
4	(	(	O	(	O	10	DEP
5	14	14	B-NP	CD	O	6	NMOD
6	men	man	I-NP	NNS	O	9	NMOD
7	,	,	O	,	O	9	P
8	11	11	B-NP	CD	O	9	NMOD
9	women	woman	I-NP	NNS	O	10	DEP
10	)	)	O	)	O	3	NMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	treated	treat	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	SRL	SRL	B-NP	NN	B-protein	13	PMOD
15	as	as	B-PP	IN	O	12	VMOD
16	conversion	conversion	B-NP	NN	O	17	NMOD
17	therapy	therapy	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	12	P
19	due	due	B-PP	JJ	O	20	PMOD
20	to	to	B-PP	TO	O	12	VMOD
21	chronic	chronic	B-NP	JJ	O	23	NMOD
22	allograft	allograft	I-NP	NN	O	23	NMOD
23	nephropathy	nephropathy	I-NP	NN	O	32	NMOD
24	(	(	O	(	O	26	DEP
25	CAN	CAN	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	(	(	O	(	O	31	DEP
28	n	n	B-NP	NN	O	31	DEP
29	=	=	B-VP	SYM	O	28	NMOD
30	15	15	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	23	NMOD
32	neoplasia	neoplasia	B-NP	NN	O	20	PMOD
33	(	(	O	(	O	37	DEP
34	n	n	B-NP	NN	O	36	SUB
35	=	=	B-VP	SYM	O	36	VMOD
36	8	8	B-NP	CD	O	37	DEP
37	)	)	O	)	O	32	NMOD
38	;	;	O	:	O	11	P
39	Kaposi	Kaposi	B-NP	NN	O	41	NMOD
40	's	's	B-NP	POS	O	41	NMOD
41	sarcoma	sarcoma	I-NP	NN	O	54	NMOD
42	,	,	O	,	O	54	P
43	Four	Four	B-NP	CD	O	45	NMOD
44	skin	skin	I-NP	NN	O	45	NMOD
45	cancers	cancer	I-NP	NNS	O	54	NMOD
46	,	,	O	,	O	54	P
47	One	One	B-NP	CD	O	49	NMOD
48	intestinal	intestinal	I-NP	JJ	O	49	NMOD
49	tumors	tumor	I-NP	NNS	O	54	NMOD
50	,	,	O	,	O	54	P
51	One	One	B-NP	CD	O	54	NMOD
52	renal	renal	I-NP	JJ	O	54	NMOD
53	cell	cell	I-NP	NN	O	54	NMOD
54	carsinom	carsinom	I-NP	NN	O	59	NMOD
55	)	)	O	)	O	54	NMOD
56	or	or	O	CC	O	59	NMOD
57	BK	BK	B-NP	NN	O	59	NMOD
58	virus	virus	I-NP	NN	O	59	NMOD
59	nephropathy	nephropathy	I-NP	NN	O	11	PRD
60	(	(	O	(	O	64	DEP
61	n	n	B-NP	NN	O	63	SUB
62	=	=	B-VP	SYM	O	63	VMOD
63	2	2	B-NP	CD	O	64	DEP
64	)	)	O	)	O	59	NMOD
65	.	.	O	.	O	11	P

1	Heavy	Heavy	B-NP	JJ	O	2	NMOD
2	proteinuria	proteinuria	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	common	common	B-ADJP	JJ	O	3	PRD
5	after	after	B-SBAR	IN	O	3	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	use	use	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	SRL	SRL	B-NP	NN	B-protein	8	PMOD
10	as	as	B-PP	IN	O	7	NMOD
11	rescue	rescue	B-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	renal	renal	B-NP	JJ	O	15	NMOD
15	transplantation	transplantation	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	3	P

1	In	In	B-NP	FW	O	2	AMOD
2	vitro	vitro	I-NP	FW	O	3	NMOD
3	characterization	characterization	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	parasympathetic	parasympathetic	B-NP	JJ	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	sympathetic	sympathetic	I-NP	JJ	O	8	NMOD
8	responses	response	I-NP	NNS	O	4	PMOD
9	in	in	B-PP	IN	O	3	NMOD
10	cyclophosphamide	cyclophosphamide	B-NP	NN	O	12	NMOD
11	induced	induce	B-VP	VBD	O	12	NMOD
12	cystitis	cystitis	B-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	rat	rat	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	11	VMOD
2	cyclophosphamide	cyclophosphamide	B-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	1	SBAR
4	cystitis	cystitis	B-NP	NN	O	3	OBJ
5	in	in	B-PP	IN	O	3	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	rat	rat	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	11	P
9	detrusor	detrusor	B-NP	NN	O	10	NMOD
10	function	function	I-NP	NN	O	11	SUB
11	is	be	B-VP	VBZ	O	0	ROOT
12	impaired	impaired	B-ADJP	JJ	O	17	NMOD
13	and	and	O	CC	O	17	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	expression	expression	B-NP	NN	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	effects	effect	B-NP	NNS	O	11	PRD
18	of	of	B-PP	IN	O	17	NMOD
19	muscarinic	muscarinic	B-NP	JJ	B-protein	20	NMOD
20	receptors	receptor	I-NP	NNS	I-protein	18	PMOD
21	altered	alter	B-VP	VBN	O	20	NMOD
22	.	.	O	.	O	11	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	use	use	B-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	BZDs/RDs	BZDs/RD	B-NP	NNS	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	associated	associate	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	dizziness	dizziness	B-NP	NN	O	11	NMOD
10	,	,	O	,	O	11	P
11	inability	inability	B-NP	NN	O	8	PMOD
12	to	to	B-VP	TO	O	13	VMOD
13	sleep	sleep	I-VP	VB	O	11	NMOD
14	after	after	B-PP	IN	O	13	VMOD
15	awaking	awake	B-VP	VBG	O	14	PMOD
16	at	at	B-PP	IN	O	15	VMOD
17	night	night	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	tiredness	tiredness	I-NP	NN	O	16	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	mornings	morning	I-NP	NNS	O	20	PMOD
23	during	during	B-PP	IN	O	15	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	week	week	I-NP	NN	O	23	PMOD
26	prior	prior	B-ADVP	RB	O	27	PMOD
27	to	to	B-PP	TO	O	13	VMOD
28	admission	admission	B-NP	NN	O	27	PMOD
29	and	and	O	CC	O	27	PMOD
30	with	with	B-PP	IN	O	13	VMOD
31	stronger	strong	B-NP	JJR	O	33	NMOD
32	depressive	depressive	I-NP	JJ	O	33	NMOD
33	symptoms	symptom	I-NP	NNS	O	30	PMOD
34	measured	measure	B-VP	VBN	O	33	NMOD
35	at	at	B-PP	IN	O	34	VMOD
36	the	the	B-NP	DT	O	37	NMOD
37	beginning	beginning	I-NP	NN	O	35	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	the	the	B-NP	DT	O	41	NMOD
40	hospital	hospital	I-NP	NN	O	41	NMOD
41	stay	stay	I-NP	NN	O	38	PMOD
42	.	.	O	.	O	6	P

1	Acute	Acute	B-NP	JJ	O	3	AMOD
2	vocal	vocal	I-NP	JJ	O	3	AMOD
3	fold	fold	I-NP	JJ	O	4	NMOD
4	palsy	palsy	I-NP	NN	O	0	ROOT
5	after	after	B-PP	IN	O	4	NMOD
6	acute	acute	B-NP	JJ	O	8	NMOD
7	disulfiram	disulfiram	I-NP	NN	O	8	NMOD
8	intoxication	intoxication	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	4	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	peripheral	peripheral	I-NP	JJ	O	3	NMOD
3	neuropathy	neuropathy	I-NP	NN	O	9	SUB
4	caused	cause	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	8	NMOD
7	disulfiram	disulfiram	I-NP	NN	O	8	NMOD
8	overdose	overdose	I-NP	NN	O	5	PMOD
9	is	be	B-VP	VBZ	O	14	VMOD
10	very	very	B-ADJP	RB	O	11	AMOD
11	rare	rare	I-ADJP	JJ	O	9	PRD
12	and	and	O	CC	O	14	VMOD
13	there	there	B-NP	EX	O	14	SUB
14	is	be	B-VP	VBZ	O	0	ROOT
15	no	no	B-NP	DT	O	16	NMOD
16	report	report	I-NP	NN	O	14	PRD
17	of	of	B-PP	IN	O	16	NMOD
18	it	it	B-NP	PRP	O	17	PMOD
19	leading	lead	B-VP	VBG	O	18	NMOD
20	to	to	B-PP	TO	O	19	VMOD
21	vocal	vocal	B-NP	JJ	O	22	AMOD
22	fold	fold	I-NP	JJ	O	23	NMOD
23	palsy	palsy	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	14	P

1	Higher	High	B-NP	JJR	O	2	AMOD
2	optical	optical	I-NP	JJ	O	3	NMOD
3	density	density	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	an	an	B-NP	DT	O	7	NMOD
6	antigen	antigen	I-NP	NN	O	7	NMOD
7	assay	assay	I-NP	NN	O	4	PMOD
8	predicts	predict	B-VP	VBZ	O	0	ROOT
9	thrombosis	thrombosis	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	heparin	heparin	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	thrombocytopenia	thrombocytopenia	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	8	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	correlate	correlate	I-VP	VB	O	1	NMOD
5	optical	optical	B-NP	JJ	O	6	NMOD
6	density	density	I-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	percent	percent	I-NP	NN	O	9	NMOD
9	inhibition	inhibition	I-NP	NN	O	4	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	20	NMOD
12	two-step	two-step	I-NP	JJ	O	20	NMOD
13	heparin	heparin	I-NP	NN	O	20	NMOD
14	induced	induced	I-NP	JJ	O	20	NMOD
15	thrombocytopenia	thrombocytopenia	I-NP	NN	B-protein	19	NMOD
16	(	(	O	(	I-protein	19	NMOD
17	HIT	HIT	B-NP	NN	I-protein	19	NMOD
18	)	)	O	)	I-protein	19	NMOD
19	antigen	antigen	B-NP	NN	I-protein	20	NMOD
20	assay	assay	I-NP	NN	O	10	PMOD
21	with	with	B-PP	IN	O	4	VMOD
22	thrombosis	thrombosis	B-NP	NN	O	21	PMOD
23	;	;	O	:	O	1	P
24	the	the	B-NP	DT	O	25	NMOD
25	assay	assay	I-NP	NN	O	1	NMOD
26	utilizes	utilize	B-VP	VBZ	O	25	SBAR
27	reaction	reaction	B-NP	NN	O	29	NMOD
28	inhibition	inhibition	I-NP	NN	O	29	NMOD
29	characteristics	characteristic	I-NP	NNS	O	26	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	a	a	B-NP	DT	O	34	NMOD
32	high	high	I-NP	JJ	O	34	NMOD
33	heparin	heparin	I-NP	NN	O	34	NMOD
34	concentration	concentration	I-NP	NN	O	30	PMOD
35	.	.	O	.	O	1	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	57	SUB
4	:	:	O	:	O	3	P
5	Patients	Patient	B-NP	NNS	O	56	DEP
6	with	with	B-PP	IN	O	5	NMOD
7	more	more	B-NP	JJR	O	8	AMOD
8	than	than	I-NP	IN	O	11	NMOD
9	50	50	I-NP	CD	O	8	AMOD
10	%	%	I-NP	NN	O	11	NMOD
11	decrease	decrease	I-NP	NN	O	50	NMOD
12	in	in	B-PP	IN	O	11	NMOD
13	platelet	platelet	B-NP	NN	O	14	NMOD
14	count	count	I-NP	NN	O	16	NMOD
15	or	or	O	CC	O	16	NMOD
16	thrombocytopenia	thrombocytopenia	B-NP	NN	O	12	PMOD
17	(	(	O	(	O	26	DEP
18	<	<	B-NP	SYM	O	21	NMOD
19	150	150	I-NP	CD	O	21	NMOD
20	x	x	I-NP	SYM	O	21	NMOD
21	10	10	I-NP	CD	O	25	NMOD
22	(	(	O	(	O	24	DEP
23	9	9	B-NP	CD	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	/L	/L	B-NP	NN	O	26	DEP
26	)	)	O	)	O	16	NMOD
27	after	after	B-PP	IN	O	11	NMOD
28	exposure	exposure	B-NP	NN	O	27	PMOD
29	to	to	B-PP	TO	O	28	NMOD
30	heparin	heparin	B-NP	NN	O	29	PMOD
31	,	,	O	,	O	11	P
32	who	who	B-NP	WP	O	11	NMOD
33	had	have	B-VP	VBD	O	32	SBAR
34	a	a	B-NP	DT	O	38	NMOD
35	positive	positive	I-NP	JJ	B-protein	38	NMOD
36	two-step	two-step	I-NP	JJ	I-protein	38	NMOD
37	antigen	antigen	I-NP	NN	I-protein	38	NMOD
38	assay	assay	I-NP	NN	O	33	OBJ
39	[	[	O	(	O	50	NMOD
40	optical	optical	B-NP	JJ	O	41	NMOD
41	density	density	I-NP	NN	O	50	NMOD
42	(	(	O	(	O	44	DEP
43	OD	OD	B-NP	NN	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	>	>	B-NP	SYM	O	50	NMOD
46	0.4	0.4	I-NP	CD	O	50	NMOD
47	and	and	O	CC	O	50	NMOD
48	>	>	B-NP	SYM	O	50	NMOD
49	50	50	B-NP	CD	O	50	NMOD
50	inhibition	inhibition	I-NP	NN	O	6	PMOD
51	with	with	B-PP	IN	O	50	NMOD
52	high	high	B-NP	JJ	O	53	NMOD
53	concentration	concentration	I-NP	NN	O	51	PMOD
54	of	of	B-PP	IN	O	53	NMOD
55	heparin	heparin	B-NP	NN	O	54	PMOD
56	]	]	O	)	O	3	NMOD
57	were	be	B-VP	VBD	O	0	ROOT
58	included	include	I-VP	VBN	O	57	VC
59	in	in	B-PP	IN	O	58	VMOD
60	the	the	B-NP	DT	O	61	NMOD
61	study	study	I-NP	NN	O	59	PMOD
62	.	.	O	.	O	57	P

1	Central	Central	B-NP	JJ	O	4	NMOD
2	retinal	retinal	I-NP	JJ	O	4	NMOD
3	vein	vein	I-NP	NN	O	4	NMOD
4	occlusion	occlusion	I-NP	NN	O	0	ROOT
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	clomiphene	clomiphene	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	ovulation	ovulation	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	4	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	central	central	B-NP	JJ	O	11	NMOD
9	retinal	retinal	I-NP	JJ	O	11	NMOD
10	vein	vein	I-NP	NN	O	11	NMOD
11	occlusion	occlusion	I-NP	NN	O	7	PMOD
12	associated	associate	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	clomiphene	clomiphene	B-NP	NN	O	15	NMOD
15	citrate	citrate	I-NP	NN	O	13	PMOD
16	(	(	O	(	O	18	DEP
17	CC	CC	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	.	.	O	.	O	1	P

1	MAIN	MAIN	B-NP	NN	O	3	NMOD
2	OUTCOME	OUTCOME	I-NP	NN	O	3	NMOD
3	MEASURE	MEASURE	I-NP	NN	O	11	NMOD
4	(	(	O	(	O	6	DEP
5	S	S	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	:	:	O	:	O	3	P
8	Central	Central	B-NP	JJ	O	11	NMOD
9	retinal	retinal	I-NP	JJ	O	11	NMOD
10	vein	vein	I-NP	NN	O	11	NMOD
11	occlusion	occlusion	I-NP	NN	O	0	ROOT
12	after	after	B-PP	IN	O	11	NMOD
13	ovulation	ovulation	B-NP	NN	O	14	NMOD
14	induction	induction	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	CC	CC	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	11	P

1	RESULT	RESULT	B-NP	NN	O	9	NMOD
2	(	(	O	(	O	4	DEP
3	S	S	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	:	:	O	:	O	1	P
6	A	A	B-NP	DT	O	9	NMOD
7	36-year-old	36-year-old	I-NP	JJ	O	9	NMOD
8	Chinese	Chinese	I-NP	JJ	O	9	NMOD
9	woman	woman	I-NP	NN	O	10	SUB
10	developed	develop	B-VP	VBD	O	0	ROOT
11	central	central	B-NP	JJ	O	14	NMOD
12	retinal	retinal	I-NP	JJ	O	14	NMOD
13	vein	vein	I-NP	NN	O	14	NMOD
14	occlusion	occlusion	I-NP	NN	O	10	OBJ
15	after	after	B-PP	IN	O	10	VMOD
16	eight	eight	B-NP	CD	O	17	NMOD
17	courses	course	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	CC	CC	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	2	NMOD
2	search	search	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	literature	literature	I-NP	NN	O	3	PMOD
6	on	on	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	thromboembolic	thromboembolic	I-NP	JJ	O	9	NMOD
9	complications	complication	I-NP	NNS	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	CC	CC	B-NP	NN	O	10	PMOD
12	does	do	B-VP	VBZ	O	0	ROOT
13	not	not	I-VP	RB	O	12	VMOD
14	include	include	I-VP	VB	O	12	VC
15	this	this	B-NP	DT	O	18	NMOD
16	severe	severe	I-NP	JJ	O	18	NMOD
17	ophthalmic	ophthalmic	I-NP	JJ	O	18	NMOD
18	complication	complication	I-NP	NN	O	14	OBJ
19	,	,	O	,	O	14	P
20	although	although	B-SBAR	IN	O	14	VMOD
21	mild	mild	B-NP	JJ	O	23	NMOD
22	visual	visual	I-NP	JJ	O	23	NMOD
23	disturbance	disturbance	I-NP	NN	O	27	SUB
24	after	after	B-PP	IN	O	23	NMOD
25	CC	CC	B-NP	NN	O	26	NMOD
26	intake	intake	I-NP	NN	O	24	PMOD
27	is	be	B-VP	VBZ	O	20	SBAR
28	not	not	O	RB	O	27	VMOD
29	uncommon	uncommon	B-ADJP	JJ	O	27	PRD
30	.	.	O	.	O	12	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	7	SUB
2	(	(	O	(	O	4	DEP
3	S	S	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	:	:	O	:	O	1	P
6	This	This	B-NP	DT	O	1	NMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	the	the	B-NP	DT	O	11	NMOD
9	first	first	I-NP	JJ	O	11	NMOD
10	reported	report	I-NP	VBN	O	11	NMOD
11	case	case	I-NP	NN	O	7	PRD
12	of	of	B-PP	IN	O	11	NMOD
13	central	central	B-NP	JJ	O	16	NMOD
14	retinal	retinal	I-NP	JJ	O	16	NMOD
15	vein	vein	I-NP	NN	O	16	NMOD
16	occlusion	occlusion	I-NP	NN	O	12	PMOD
17	after	after	B-PP	IN	O	7	VMOD
18	treatment	treatment	B-NP	NN	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	CC	CC	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	7	P

1	Nicotine	Nicotine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	4	VMOD
3	nystagmus	nystagmus	B-NP	NN	O	4	SUB
4	correlates	correlate	B-VP	VBZ	O	0	ROOT
5	with	with	B-PP	IN	O	4	VMOD
6	midpontine	midpontine	B-NP	JJ	O	7	NMOD
7	activation	activation	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	pathomechanism	pathomechanism	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	nicotine	nicotine	B-NP	NN	O	6	NMOD
5	induced	induce	I-NP	VBN	O	6	NMOD
6	nystagmus	nystagmus	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	NIN	NIN	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	unknown	unknown	B-ADJP	JJ	O	10	PRD
12	.	.	O	.	O	10	P

1	NIN	NIN	B-NP	NN	B-protein	2	SUB
2	correlated	correlate	B-VP	VBD	O	0	ROOT
3	with	with	B-PP	IN	O	2	VMOD
4	blood	blood	B-NP	NN	O	5	NMOD
5	oxygen	oxygen	I-NP	NN	O	11	NMOD
6	level-dependent	level-dependent	B-ADJP	JJ	O	5	AMOD
7	(	(	O	(	O	9	DEP
8	BOLD	BOLD	B-NP	NN	O	9	DEP
9	)	)	O	)	O	5	NMOD
10	activity	activity	B-NP	NN	O	11	NMOD
11	levels	level	I-NP	NNS	O	3	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	midpontine	midpontine	I-NP	JJ	B-DNA	15	NMOD
15	site	site	I-NP	NN	I-DNA	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	posterior	posterior	I-NP	JJ	O	20	NMOD
19	basis	basis	I-NP	NN	O	20	NMOD
20	pontis	pontis	I-NP	NN	O	16	PMOD
21	.	.	O	.	O	2	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	verapamil	verapamil	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	gastric	gastric	B-NP	JJ	O	8	NMOD
7	hemorrhagic	hemorrhagic	I-NP	JJ	O	8	NMOD
8	ulcers	ulcer	I-NP	NNS	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	severe	severe	B-NP	JJ	O	12	NMOD
11	atherosclerotic	atherosclerotic	I-NP	JJ	O	12	NMOD
12	rats	rat	I-NP	NNS	O	9	PMOD
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	examine	examine	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	role	role	I-NP	NN	O	22	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	gastric	gastric	B-NP	JJ	O	14	NMOD
13	acid	acid	I-NP	NN	O	14	NMOD
14	back-diffusion	back-diffusion	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	22	P
16	mast	mast	B-NP	NN	O	19	NMOD
17	cell	cell	I-NP	NN	O	19	NMOD
18	histamine	histamine	I-NP	NN	O	19	NMOD
19	release	release	I-NP	NN	O	22	NMOD
20	,	,	O	,	O	22	P
21	lipid	lipid	B-NP	NN	O	22	NMOD
22	peroxide	peroxide	I-NP	NN	O	26	NMOD
23	(	(	O	(	O	25	DEP
24	LPO	LPO	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	generation	generation	B-NP	NN	O	30	NMOD
27	and	and	O	CC	O	30	NMOD
28	mucosal	mucosal	B-NP	JJ	O	30	NMOD
29	microvascular	microvascular	I-NP	JJ	O	30	NMOD
30	permeability	permeability	I-NP	NN	O	8	OBJ
31	in	in	B-PP	IN	O	30	NMOD
32	modulating	modulate	B-VP	VBG	O	31	PMOD
33	gastric	gastric	B-NP	JJ	O	34	NMOD
34	hemorrhage	hemorrhage	I-NP	NN	O	36	NMOD
35	and	and	I-NP	CC	O	36	NMOD
36	ulcer	ulcer	I-NP	NN	O	32	OBJ
37	in	in	B-PP	IN	O	32	VMOD
38	rats	rat	B-NP	NNS	O	37	PMOD
39	with	with	B-PP	IN	O	38	NMOD
40	atherosclerosis	atherosclerosis	B-NP	NN	O	39	PMOD
41	induced	induce	B-VP	VBN	O	40	NMOD
42	by	by	B-PP	IN	O	41	VMOD
43	coadministration	coadministration	B-NP	NN	O	42	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	vitamin	vitamin	B-NP	NN	O	46	NMOD
46	D2	D2	I-NP	NN	O	48	NMOD
47	and	and	I-NP	CC	O	48	NMOD
48	cholesterol	cholesterol	I-NP	NN	O	44	PMOD
49	.	.	O	.	O	6	P

1	Additionally	Additionally	B-ADVP	RB	O	12	VMOD
2	,	,	O	,	O	12	P
3	the	the	B-NP	DT	O	5	NMOD
4	protective	protective	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	verapamil	verapamil	B-NP	NN	O	6	PMOD
8	on	on	B-PP	IN	O	5	NMOD
9	this	this	B-NP	DT	O	11	NMOD
10	ulcer	ulcer	I-NP	NN	O	11	NMOD
11	model	model	I-NP	NN	O	8	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	evaluated	evaluate	I-VP	VBN	O	12	VC
14	.	.	O	.	O	12	P

1	Male	Male	B-NP	JJ	O	3	NMOD
2	Wistar	Wistar	I-NP	NNP	O	3	NMOD
3	rats	rat	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	challenged	challenge	I-VP	VBN	O	4	VC
6	intragastrically	intragastrically	B-ADJP	RB	O	5	VMOD
7	once	once	I-ADJP	RB	O	6	AMOD
8	daily	daily	I-ADJP	JJ	O	5	PRD
9	for	for	B-PP	IN	O	8	AMOD
10	9	9	B-NP	CD	O	11	NMOD
11	days	day	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	1.0	1.0	B-NP	CD	O	14	NMOD
14	ml/kg	ml/kg	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	corn	corn	B-NP	NN	O	17	NMOD
17	oil	oil	I-NP	NN	O	15	PMOD
18	containing	contain	B-VP	VBG	O	17	NMOD
19	vitamin	vitamin	B-NP	NN	O	20	NMOD
20	D2	D2	I-NP	NN	O	22	NMOD
21	and	and	O	CC	O	22	NMOD
22	cholesterol	cholesterol	B-NP	NN	O	18	OBJ
23	to	to	B-VP	TO	O	24	VMOD
24	induce	induce	I-VP	VB	O	22	NMOD
25	atherosclerosis	atherosclerosis	B-NP	NN	O	24	OBJ
26	.	.	O	.	O	4	P

1	Gastric	Gastric	B-NP	JJ	O	3	NMOD
2	acid	acid	I-NP	NN	O	3	NMOD
3	back-diffusion	back-diffusion	I-NP	NN	O	20	NMOD
4	,	,	O	,	O	20	P
5	mucosal	mucosal	B-NP	JJ	O	7	NMOD
6	LPO	LPO	I-NP	NN	O	7	NMOD
7	generation	generation	I-NP	NN	O	20	NMOD
8	,	,	O	,	O	20	P
9	histamine	histamine	B-NP	NN	O	10	NMOD
10	concentration	concentration	I-NP	NN	O	20	NMOD
11	,	,	O	,	O	20	P
12	microvascular	microvascular	B-NP	JJ	O	13	NMOD
13	permeability	permeability	I-NP	NN	O	20	NMOD
14	,	,	O	,	O	20	P
15	luminal	luminal	B-NP	JJ	B-protein	17	NMOD
16	hemoglobin	hemoglobin	I-NP	NN	I-protein	17	NMOD
17	content	content	I-NP	NN	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	ulcer	ulcer	I-NP	NN	O	20	NMOD
20	areas	area	I-NP	NNS	O	21	SUB
21	were	be	B-VP	VBD	O	0	ROOT
22	determined	determine	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	Elevated	Elevated	B-NP	JJ	O	3	NMOD
2	atherosclerotic	atherosclerotic	I-NP	JJ	O	3	NMOD
3	parameters	parameter	I-NP	NNS	O	15	NMOD
4	,	,	O	,	O	3	P
5	such	such	B-PP	JJ	O	6	PMOD
6	as	as	I-PP	IN	O	3	NMOD
7	serum	serum	B-NP	NN	O	8	NMOD
8	calcium	calcium	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	15	P
10	total	total	B-NP	JJ	O	11	NMOD
11	cholesterol	cholesterol	I-NP	NN	O	15	NMOD
12	and	and	O	CC	O	15	NMOD
13	low-density	low-density	B-NP	JJ	B-protein	15	NMOD
14	lipoprotein	lipoprotein	I-NP	NN	I-protein	15	NMOD
15	concentration	concentration	I-NP	NN	O	16	SUB
16	were	be	B-VP	VBD	O	0	ROOT
17	obtained	obtain	I-VP	VBN	O	16	VC
18	in	in	B-PP	IN	O	17	VMOD
19	atherosclerotic	atherosclerotic	B-NP	JJ	O	20	NMOD
20	rats	rat	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	16	P

1	Severe	Severe	B-NP	JJ	O	3	NMOD
2	gastric	gastric	I-NP	JJ	O	3	NMOD
3	ulcers	ulcer	I-NP	NNS	O	24	SUB
4	accompanied	accompany	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	increased	increase	B-NP	VBN	O	8	NMOD
7	ulcerogenic	ulcerogenic	I-NP	JJ	B-protein	8	NMOD
8	factors	factor	I-NP	NNS	I-protein	5	PMOD
9	,	,	O	,	O	8	P
10	including	include	B-PP	VBG	O	8	NMOD
11	gastric	gastric	B-NP	JJ	O	13	NMOD
12	acid	acid	I-NP	NN	O	13	NMOD
13	back-diffusion	back-diffusion	I-NP	NN	O	23	NMOD
14	,	,	O	,	O	23	P
15	histamine	histamine	B-NP	NN	O	16	NMOD
16	release	release	I-NP	NN	O	23	NMOD
17	,	,	O	,	O	23	P
18	LPO	LPO	B-NP	NN	O	19	NMOD
19	generation	generation	I-NP	NN	O	23	NMOD
20	and	and	O	CC	O	23	NMOD
21	luminal	luminal	B-NP	JJ	B-protein	23	NMOD
22	hemoglobin	hemoglobin	I-NP	NN	I-protein	23	NMOD
23	content	content	I-NP	NN	O	10	OBJ
24	were	be	B-VP	VBD	O	0	ROOT
25	also	also	I-VP	RB	O	24	VMOD
26	observed	observe	I-VP	VBN	O	24	VC
27	in	in	B-PP	IN	O	26	VMOD
28	these	these	B-NP	DT	O	29	NMOD
29	rats	rat	I-NP	NNS	O	27	PMOD
30	.	.	O	.	O	24	P

1	Moreover	Moreover	B-ADVP	RB	O	14	VMOD
2	,	,	O	,	O	14	P
3	a	a	B-NP	DT	O	5	NMOD
4	positive	positive	I-NP	JJ	O	5	NMOD
5	correlation	correlation	I-NP	NN	O	14	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	histamine	histamine	B-NP	NN	O	6	PMOD
8	to	to	B-PP	TO	O	5	NMOD
9	gastric	gastric	B-NP	JJ	O	10	NMOD
10	hemorrhage	hemorrhage	I-NP	NN	O	8	PMOD
11	and	and	B-PP	CC	O	8	PMOD
12	to	to	B-PP	TO	O	8	PMOD
13	ulcer	ulcer	B-NP	NN	O	12	PMOD
14	was	be	B-VP	VBD	O	0	ROOT
15	found	find	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	those	those	B-NP	DT	O	19	NMOD
18	atherosclerotic	atherosclerotic	I-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	14	P

1	This	This	B-NP	DT	O	3	NMOD
2	hemorrhagic	hemorrhagic	I-NP	JJ	O	3	NMOD
3	ulcer	ulcer	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	various	various	B-NP	JJ	O	7	NMOD
6	ulcerogenic	ulcerogenic	I-NP	JJ	O	7	NMOD
7	parameters	parameter	I-NP	NNS	O	8	SUB
8	were	be	B-VP	VBD	O	0	ROOT
9	dose-dependently	dose-dependently	I-VP	RB	O	8	VMOD
10	ameliorated	ameliorate	I-VP	VBN	O	8	VC
11	by	by	B-PP	IN	O	10	VMOD
12	daily	daily	B-NP	JJ	O	14	NMOD
13	intragastric	intragastric	I-NP	JJ	O	14	NMOD
14	verapamil	verapamil	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	8	P

1	Adriamycin	Adriamycin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	autophagic	autophagic	B-NP	JJ	O	5	NMOD
4	cardiomyocyte	cardiomyocyte	I-NP	NN	O	5	NMOD
5	death	death	I-NP	NN	O	6	SUB
6	plays	play	B-VP	VBZ	O	2	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	pathogenic	pathogenic	I-NP	JJ	O	9	NMOD
9	role	role	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	rat	rat	I-NP	NN	O	13	NMOD
13	model	model	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	heart	heart	B-NP	NN	O	16	NMOD
16	failure	failure	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	mechanisms	mechanism	I-NP	NNS	O	11	SUB
5	underlying	underlie	B-VP	VBG	O	4	NMOD
6	heart	heart	B-NP	NN	O	7	NMOD
7	failure	failure	I-NP	NN	O	5	OBJ
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	adriamycin	adriamycin	B-NP	NN	O	9	PMOD
11	are	be	B-VP	VBP	O	1	NMOD
12	very	very	B-ADJP	RB	O	13	AMOD
13	complicated	complicate	I-ADJP	VBN	O	11	PRD
14	and	and	O	CC	O	13	DEP
15	still	still	B-ADJP	RB	O	16	AMOD
16	unclear	unclear	I-ADJP	JJ	O	13	PRD
17	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	investigate	investigate	I-VP	VB	O	6	PRD
9	whether	whether	B-SBAR	IN	O	8	VMOD
10	autophagy	autophagy	B-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	9	SBAR
12	involved	involve	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	progression	progression	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	heart	heart	B-NP	NN	O	18	NMOD
18	failure	failure	I-NP	NN	O	16	PMOD
19	induced	induce	B-VP	VBN	O	15	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	adriamycin	adriamycin	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	8	P
23	so	so	B-SBAR	IN	O	24	DEP
24	that	that	I-SBAR	IN	O	8	VMOD
25	we	we	B-NP	PRP	O	26	SUB
26	can	can	B-VP	MD	O	24	SBAR
27	develop	develop	I-VP	VB	O	26	VC
28	a	a	B-NP	DT	O	31	NMOD
29	novel	novel	I-NP	JJ	O	31	NMOD
30	treatment	treatment	I-NP	NN	O	31	NMOD
31	strategy	strategy	I-NP	NN	O	27	OBJ
32	for	for	B-PP	IN	O	31	NMOD
33	heart	heart	B-NP	NN	O	34	NMOD
34	failure	failure	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	6	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	3-methyladenine	3-methyladenine	B-NP	NN	O	10	NMOD
4	(	(	O	(	O	6	DEP
5	3MA	3MA	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	,	,	O	,	O	10	P
8	a	a	B-NP	DT	O	10	NMOD
9	specific	specific	I-NP	JJ	O	10	NMOD
10	inhibitor	inhibitor	I-NP	NN	O	13	SUB
11	on	on	B-PP	IN	O	10	NMOD
12	autophagy	autophagy	B-NP	NN	O	11	PMOD
13	was	be	B-VP	VBD	O	1	NMOD
14	used	use	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	a	a	B-NP	DT	O	19	NMOD
17	heart	heart	I-NP	NN	O	19	NMOD
18	failure	failure	I-NP	NN	O	19	NMOD
19	model	model	I-NP	NN	O	15	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	rats	rat	B-NP	NNS	O	20	PMOD
22	induced	induce	B-VP	VBN	O	21	NMOD
23	by	by	B-PP	IN	O	22	VMOD
24	adriamycin	adriamycin	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Autophagic	Autophagic	B-NP	JJ	O	5	NMOD
4	cardiomyocyte	cardiomyocyte	I-NP	NN	O	5	NMOD
5	death	death	I-NP	NN	O	6	SUB
6	plays	play	B-VP	VBZ	O	1	NMOD
7	an	an	B-NP	DT	O	9	NMOD
8	important	important	I-NP	JJ	O	9	NMOD
9	role	role	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	pathogenesis	pathogenesis	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	heart	heart	B-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	12	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	induced	induce	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	adriamycin	adriamycin	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	1	P

1	Confusion	Confusion	B-NP	NN	O	8	NMOD
2	,	,	O	,	O	8	P
3	a	a	B-NP	DT	O	8	NMOD
4	rather	rather	I-NP	RB	O	5	AMOD
5	serious	serious	I-NP	JJ	O	8	NMOD
6	adverse	adverse	I-NP	JJ	O	8	NMOD
7	drug	drug	I-NP	NN	O	8	NMOD
8	reaction	reaction	I-NP	NN	O	14	NMOD
9	with	with	B-PP	IN	O	8	NMOD
10	valproic	valproic	B-NP	JJ	O	11	NMOD
11	acid	acid	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	8	P
13	a	a	B-NP	DT	O	14	NMOD
14	review	review	I-NP	NN	O	0	ROOT
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	French	French	I-NP	JJ	O	19	NMOD
18	Pharmacovigilance	Pharmacovigilance	I-NP	NN	O	19	NMOD
19	database	database	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	14	P

1	INTRODUCTION	INTRODUCTION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Confusion	Confusion	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	an	an	B-NP	DT	O	8	NMOD
6	adverse	adverse	I-NP	JJ	O	8	NMOD
7	drug	drug	I-NP	NN	O	8	NMOD
8	reaction	reaction	I-NP	NN	O	4	PRD
9	frequently	frequently	B-VP	RB	O	10	VMOD
10	observed	observe	I-VP	VBN	O	8	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	valproic	valproic	B-NP	JJ	O	13	NMOD
13	acid	acid	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	4	P

1	METHODS	METHODS	B-NP	NNS	O	10	VMOD
2	:	:	O	:	O	1	P
3	Using	Use	B-VP	VBG	O	1	NMOD
4	the	the	B-NP	DT	O	7	NMOD
5	French	French	I-NP	JJ	O	7	NMOD
6	Pharmacovigilance	Pharmacovigilance	I-NP	NN	O	7	NMOD
7	database	database	I-NP	NN	O	3	OBJ
8	,	,	O	,	O	10	P
9	we	we	B-NP	PRP	O	10	SUB
10	selected	select	B-VP	VBD	O	0	ROOT
11	the	the	B-NP	DT	O	12	NMOD
12	cases	case	I-NP	NNS	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	confusion	confusion	B-NP	NN	O	13	PMOD
15	reported	report	B-VP	VBD	O	10	VMOD
16	since	since	B-PP	IN	O	15	VMOD
17	1985	1985	B-NP	CD	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	valproic	valproic	B-NP	JJ	O	20	NMOD
20	acid	acid	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	10	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	272	272	B-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	confusion	confusion	B-NP	NN	O	5	PMOD
7	were	be	B-VP	VBD	O	1	NMOD
8	reported	report	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	valproic	valproic	B-NP	JJ	O	11	NMOD
11	acid	acid	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	8	P
13	153	153	B-NP	CD	O	14	NMOD
14	women	woman	I-NP	NNS	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	119	119	B-NP	CD	O	17	NMOD
17	men	man	I-NP	NNS	O	8	VMOD
18	.	.	O	.	O	1	P

1	Confusion	Confusion	B-NP	NN	O	3	SUB
2	mostly	mostly	B-ADVP	RB	O	3	VMOD
3	occurred	occur	B-VP	VBD	O	0	ROOT
4	during	during	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	two	two	I-NP	CD	O	8	NMOD
7	first	first	I-NP	JJ	O	8	NMOD
8	weeks	week	I-NP	NNS	O	4	PMOD
9	following	follow	B-PP	VBG	O	3	VMOD
10	valproic	valproic	B-NP	JJ	O	12	NMOD
11	acid	acid	I-NP	NN	O	12	NMOD
12	exposure	exposure	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	16	DEP
14	39.7	39.7	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	.	.	O	.	O	3	P

1	Learning	Learning	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	memory	memory	I-NP	NN	O	4	NMOD
4	deficits	deficit	I-NP	NNS	O	11	NMOD
5	in	in	B-PP	IN	O	4	NMOD
6	ecstasy	ecstasy	B-NP	JJ	O	7	NMOD
7	users	user	I-NP	NNS	O	5	PMOD
8	and	and	O	CC	O	11	NMOD
9	their	their	B-NP	PRP$	O	11	NMOD
10	neural	neural	I-NP	JJ	O	11	NMOD
11	correlates	correlate	I-NP	NNS	O	0	ROOT
12	during	during	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	face-learning	face-learning	I-NP	JJ	O	15	NMOD
15	task	task	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	11	P

1	It	It	B-NP	PRP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	consistently	consistently	I-VP	RB	O	3	VMOD
5	shown	show	I-VP	VBN	O	3	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	ecstasy	ecstasy	B-NP	JJ	O	8	NMOD
8	users	user	I-NP	NNS	O	9	SUB
9	display	display	B-VP	VBP	O	6	SBAR
10	impairments	impairment	B-NP	NNS	O	9	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	learning	learning	B-NP	NN	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	memory	memory	I-NP	NN	O	15	NMOD
15	performance	performance	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	2	P

1	Deficits	Deficit	B-NP	NNS	O	11	NMOD
2	in	in	B-PP	IN	O	1	NMOD
3	learning	learning	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	memory	memory	I-NP	NN	O	2	PMOD
6	:	:	O	:	O	1	P
7	parahippocampal	parahippocampal	B-NP	JJ	O	8	NMOD
8	hyperactivity	hyperactivity	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	frontocortical	frontocortical	B-NP	JJ	O	11	NMOD
11	hypoactivity	hypoactivity	I-NP	NN	O	0	ROOT
12	in	in	B-PP	IN	O	11	NMOD
13	cannabis	cannabis	B-NP	NN	O	14	NMOD
14	users	user	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	11	P

1	A	A	B-NP	DT	O	3	NMOD
2	conjunction	conjunction	I-NP	NN	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	13	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	9	NMOD
6	encode	encode	I-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	recall	recall	I-NP	NN	O	9	NMOD
9	phases	phase	I-NP	NNS	O	4	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	task	task	I-NP	NN	O	10	PMOD
13	revealed	reveal	B-VP	VBD	O	0	ROOT
14	ecstasy-specific	ecstasy-specific	B-NP	JJ	O	15	NMOD
15	hyperactivity	hyperactivity	I-NP	NN	O	13	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	bilateral	bilateral	B-NP	JJ	B-DNA	19	NMOD
18	frontal	frontal	I-NP	JJ	I-DNA	19	NMOD
19	regions	region	I-NP	NNS	I-DNA	16	PMOD
20	,	,	O	,	O	13	P
21	left	leave	B-VP	VBD	O	13	VMOD
22	temporal	temporal	B-NP	JJ	O	24	AMOD
23	,	,	I-NP	,	O	24	P
24	right	right	I-NP	JJ	O	28	NMOD
25	parietal	parietal	I-NP	JJ	O	28	NMOD
26	,	,	I-NP	,	O	28	P
27	bilateral	bilateral	I-NP	JJ	O	28	NMOD
28	temporal	temporal	I-NP	JJ	O	21	VMOD
29	,	,	O	,	O	34	P
30	and	and	O	CC	O	34	NMOD
31	bilateral	bilateral	B-NP	JJ	O	34	NMOD
32	occipital	occipital	I-NP	NN	O	34	NMOD
33	brain	brain	I-NP	NN	O	34	NMOD
34	regions	region	I-NP	NNS	O	13	VMOD
35	.	.	O	.	O	13	P

1	Prolonged	Prolonged	B-NP	JJ	O	2	NMOD
2	elevation	elevation	I-NP	NN	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	plasma	plasma	B-NP	NN	O	5	NMOD
5	argatroban	argatroban	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	a	a	B-NP	DT	O	10	NMOD
8	cardiac	cardiac	I-NP	JJ	O	10	NMOD
9	transplant	transplant	I-NP	NN	O	10	NMOD
10	patient	patient	I-NP	NN	O	6	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	suspected	suspect	I-NP	VBN	O	14	NMOD
14	history	history	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	heparin	heparin	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	thrombocytopenia	thrombocytopenia	B-NP	NN	O	17	OBJ
19	with	with	B-PP	IN	O	18	NMOD
20	thrombosis	thrombosis	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	17	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Direct	Direct	B-NP	JJ	O	5	NMOD
4	thrombin	thrombin	I-NP	NN	B-protein	5	NMOD
5	inhibitors	inhibitor	I-NP	NNS	O	9	SUB
6	(	(	O	(	O	8	DEP
7	DTIs	DTI	B-NP	NNS	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	provide	provide	B-VP	VBP	O	1	NMOD
10	an	an	B-NP	DT	O	12	NMOD
11	alternative	alternative	I-NP	JJ	O	12	NMOD
12	method	method	I-NP	NN	O	9	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	anticoagulation	anticoagulation	B-NP	NN	O	13	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	19	NMOD
19	history	history	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	heparin	heparin	B-NP	NN	O	23	NMOD
22	induced	induce	I-NP	VBN	O	23	NMOD
23	thrombocytopenia	thrombocytopenia	I-NP	NN	O	28	NMOD
24	(	(	O	(	O	26	DEP
25	HIT	HIT	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	or	or	O	CC	O	28	NMOD
28	HIT	HIT	B-NP	NN	B-protein	20	PMOD
29	with	with	B-PP	IN	O	16	NMOD
30	thrombosis	thrombosis	B-NP	NN	O	29	PMOD
31	(	(	O	(	O	33	DEP
32	HITT	HITT	B-NP	NN	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	undergoing	undergo	B-VP	VBG	O	30	NMOD
35	cardiopulmonary	cardiopulmonary	B-NP	JJ	O	36	NMOD
36	bypass	bypass	I-NP	NN	O	34	OBJ
37	(	(	O	(	O	39	DEP
38	CPB	CPB	B-NP	NN	B-protein	39	DEP
39	)	)	O	)	O	36	NMOD
40	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	following	follow	I-NP	VBG	O	4	NMOD
4	report	report	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	17	P
6	a	a	B-NP	DT	O	10	NMOD
7	65-year-old	65-year-old	I-NP	JJ	O	9	AMOD
8	critically	critically	I-NP	RB	O	9	AMOD
9	ill	ill	I-NP	JJ	O	10	NMOD
10	patient	patient	I-NP	NN	O	17	SUB
11	with	with	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	suspected	suspect	I-NP	VBN	O	14	NMOD
14	history	history	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	HITT	HITT	B-NP	NN	B-protein	15	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	administered	administer	I-VP	VBN	O	17	VC
19	argatroban	argatroban	B-NP	NN	O	18	OBJ
20	for	for	B-PP	IN	O	19	NMOD
21	anticoagulation	anticoagulation	B-NP	NN	O	20	PMOD
22	on	on	B-PP	IN	O	19	NMOD
23	bypass	bypass	B-NP	NN	O	22	PMOD
24	during	during	B-PP	IN	O	18	VMOD
25	heart	heart	B-NP	NN	O	26	NMOD
26	transplantation	transplantation	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	17	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Unexpectedly	Unexpectedly	B-NP	RB	O	5	NMOD
4	high	high	I-NP	JJ	O	5	NMOD
5	concentrations	concentration	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	argatroban	argatroban	B-NP	NN	O	6	PMOD
8	were	be	B-VP	VBD	O	36	VMOD
9	measured	measure	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	these	these	B-NP	DT	O	12	NMOD
12	samples	sample	I-NP	NNS	O	10	PMOD
13	(	(	O	(	O	18	DEP
14	range	range	B-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	0-32	0-32	B-NP	CD	O	17	NMOD
17	microg/mL	microg/mL	I-NP	NN	O	18	DEP
18	)	)	O	)	O	12	NMOD
19	,	,	O	,	O	36	P
20	and	and	O	CC	O	26	NMOD
21	a	a	B-NP	DT	O	26	NMOD
22	prolonged	prolong	I-NP	VBN	O	26	NMOD
23	plasma	plasma	I-NP	NN	O	26	NMOD
24	argatroban	argatroban	I-NP	NN	O	26	NMOD
25	half	half	I-NP	NN	O	26	NMOD
26	life	life	I-NP	NN	O	36	SUB
27	(	(	O	(	O	32	DEP
28	t	t	B-NP	NN	O	32	DEP
29	(	(	O	(	O	31	DEP
30	1/2	1/2	B-NP	CD	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	)	)	O	)	O	26	NMOD
33	of	of	B-PP	IN	O	26	NMOD
34	514	514	B-NP	CD	O	35	NMOD
35	minutes	minute	I-NP	NNS	O	33	PMOD
36	was	be	B-VP	VBD	O	1	NMOD
37	observed	observe	I-VP	VBN	O	36	VC
38	(	(	O	(	O	58	DEP
39	published	publish	B-NP	VBN	O	41	NMOD
40	elimination	elimination	I-NP	NN	O	41	NMOD
41	t	t	I-NP	NN	O	45	SUB
42	(	(	O	(	O	44	DEP
43	1/2	1/2	B-NP	CD	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	is	be	B-VP	VBZ	O	58	DEP
46	39-51	39-51	B-NP	CD	O	47	NMOD
47	minutes	minute	I-NP	NNS	O	45	PRD
48	[	[	O	(	O	57	DEP
49	<	<	B-NP	SYM	O	51	P
50	or	or	O	CC	O	51	AMOD
51	=	=	B-VP	SYM	O	57	DEP
52	181	181	B-NP	CD	O	51	AMOD
53	minutes	minute	I-NP	NNS	O	51	AMOD
54	with	with	B-PP	IN	O	53	NMOD
55	hepatic	hepatic	B-NP	JJ	O	56	NMOD
56	impairment	impairment	I-NP	NN	O	54	PMOD
57	]	]	O	)	O	47	NMOD
58	)	)	O	)	O	36	VMOD
59	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Correlation	Correlation	B-NP	NN	O	17	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	plasma	plasma	B-NP	NN	O	7	NMOD
6	argatroban	argatroban	I-NP	NN	O	7	NMOD
7	concentration	concentration	I-NP	NN	O	16	NMOD
8	versus	versus	B-PP	IN	O	16	NMOD
9	the	the	B-NP	DT	O	13	NMOD
10	patient	patient	I-NP	NN	O	13	NMOD
11	's	's	B-NP	POS	O	13	NMOD
12	coagulation	coagulation	I-NP	NN	O	13	NMOD
13	variables	variable	I-NP	NNS	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	clinical	clinical	B-NP	JJ	O	16	NMOD
16	course	course	I-NP	NN	O	4	PMOD
17	suggest	suggest	B-VP	VBP	O	1	NMOD
18	that	that	B-SBAR	IN	O	17	VMOD
19	prolonged	prolonged	B-NP	JJ	O	21	NMOD
20	elevated	elevated	I-NP	JJ	O	21	NMOD
21	levels	level	I-NP	NNS	O	25	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	plasma	plasma	B-NP	NN	O	24	NMOD
24	argatroban	argatroban	I-NP	NN	O	22	PMOD
25	may	may	B-VP	MD	O	18	SBAR
26	have	have	I-VP	VB	O	25	VC
27	contributed	contribute	I-VP	VBN	O	26	VC
28	to	to	B-PP	TO	O	27	VMOD
29	the	the	B-NP	DT	O	33	NMOD
30	patient	patient	I-NP	NN	O	33	NMOD
31	's	's	B-NP	POS	O	33	NMOD
32	extended	extended	I-NP	JJ	O	33	NMOD
33	coagulopathy	coagulopathy	I-NP	NN	O	28	PMOD
34	.	.	O	.	O	1	P

1	Antituberculosis	Antituberculosis	B-NP	NN	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	acute	acute	B-NP	JJ	O	6	NMOD
5	liver	liver	I-NP	NN	O	6	NMOD
6	failure	failure	I-NP	NN	O	3	OBJ
7	:	:	O	:	O	3	P
8	magnitude	magnitude	B-NP	NN	O	15	NMOD
9	,	,	O	,	O	15	P
10	profile	profile	B-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	prognosis	prognosis	B-NP	NN	O	15	NMOD
13	,	,	O	,	O	15	P
14	and	and	O	CC	O	15	NMOD
15	predictors	predictor	B-NP	NNS	O	3	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	outcome	outcome	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	3	P

1	Antituberculosis	Antituberculosis	B-NP	NN	O	9	NMOD
2	therapy	therapy	I-NP	NN	O	9	NMOD
3	(	(	I-NP	(	O	9	NMOD
4	ATT	ATT	I-NP	NN	O	9	NMOD
5	)	)	I-NP	)	O	9	NMOD
6	-associated	-associated	I-NP	JJ	O	9	NMOD
7	acute	acute	I-NP	JJ	O	9	NMOD
8	liver	liver	I-NP	NN	O	9	NMOD
9	failure	failure	I-NP	NN	O	13	SUB
10	(	(	O	(	O	12	DEP
11	ATT-ALF	ATT-ALF	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	is	be	B-VP	VBZ	O	0	ROOT
14	the	the	B-NP	DT	O	16	NMOD
15	commonest	common	I-NP	JJS	O	16	NMOD
16	drug	drug	I-NP	NN	O	13	PRD
17	induced	induce	B-VP	VBD	O	16	NMOD
18	ALF	ALF	B-NP	NN	B-protein	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	South	South	B-NP	NNP	O	21	NMOD
21	Asia	Asia	I-NP	NNP	O	19	PMOD
22	.	.	O	.	O	13	P

1	In	In	B-PP	IN	O	8	VMOD
2	multivariate	multivariate	B-NP	JJ	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	8	P
5	three	three	B-NP	CD	O	6	NMOD
6	factors	factor	I-NP	NNS	O	8	SUB
7	independently	independently	B-ADVP	RB	O	8	VMOD
8	predicted	predict	B-VP	VBD	O	0	ROOT
9	mortality	mortality	B-NP	NN	O	8	OBJ
10	:	:	O	:	O	8	P
11	serum	serum	B-NP	NN	O	12	NMOD
12	bilirubin	bilirubin	I-NP	NN	O	20	NMOD
13	(	(	O	(	O	17	DEP
14	>	>	B-NP	SYM	O	16	NMOD
15	or=10.8	or=10.8	I-NP	NN	O	16	NMOD
16	mg/dL	mg/dL	I-NP	NN	O	17	DEP
17	)	)	O	)	O	12	NMOD
18	,	,	O	,	O	20	P
19	prothrombin	prothrombin	B-NP	NN	O	20	NMOD
20	time	time	I-NP	NN	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	PT	PT	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	prolongation	prolongation	B-NP	NN	O	34	NMOD
25	(	(	O	(	O	29	DEP
26	>	>	B-NP	JJR	O	28	NMOD
27	or=26	or=26	I-NP	CD	O	28	NMOD
28	seconds	second	I-NP	NNS	O	29	DEP
29	)	)	O	)	O	24	NMOD
30	,	,	O	,	O	34	P
31	and	and	O	CC	O	34	NMOD
32	grade	grade	B-NP	NN	O	34	NMOD
33	III/IV	III/IV	I-NP	NN	O	34	NMOD
34	encephalopathy	encephalopathy	I-NP	NN	O	8	OBJ
35	at	at	B-PP	IN	O	34	NMOD
36	presentation	presentation	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	8	P

1	CNS	CNS	B-NP	NN	O	2	NMOD
2	complications	complication	I-NP	NNS	O	3	SUB
3	included	include	B-VP	VBD	O	0	ROOT
4	posterior	posterior	B-NP	JJ	O	7	NMOD
5	reversible	reversible	I-NP	JJ	O	7	NMOD
6	leukoencephalopathy	leukoencephalopathy	I-NP	NN	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	32	NMOD
8	(	(	O	(	O	12	DEP
9	n	n	B-NP	NN	O	12	DEP
10	=	=	B-VP	SYM	O	9	NMOD
11	10	10	B-NP	CD	O	10	AMOD
12	)	)	O	)	O	7	NMOD
13	,	,	O	,	O	32	P
14	stroke	stroke	B-NP	NN	O	32	NMOD
15	(	(	O	(	O	19	DEP
16	n	n	B-NP	NN	O	19	DEP
17	=	=	B-VP	SYM	O	16	NMOD
18	5	5	B-NP	CD	O	17	AMOD
19	)	)	O	)	O	14	NMOD
20	,	,	O	,	O	32	P
21	temporal	temporal	B-NP	JJ	O	23	NMOD
22	lobe	lobe	I-NP	NN	O	23	NMOD
23	epilepsy	epilepsy	I-NP	NN	O	32	NMOD
24	(	(	O	(	O	28	DEP
25	n	n	B-NP	NN	O	27	SUB
26	=	=	B-VP	SYM	O	27	VMOD
27	2	2	B-NP	CD	O	28	DEP
28	)	)	O	)	O	23	NMOD
29	,	,	O	,	O	32	P
30	high-dose	high-dose	B-NP	JJ	O	32	NMOD
31	methotrexate	methotrexate	I-NP	NN	O	32	NMOD
32	toxicity	toxicity	I-NP	NN	O	39	NMOD
33	(	(	O	(	O	37	DEP
34	n	n	B-NP	NN	O	37	DEP
35	=	=	B-VP	SYM	O	34	NMOD
36	2	2	B-NP	CD	O	35	AMOD
37	)	)	O	)	O	32	NMOD
38	,	,	O	,	O	39	P
39	syndrome	syndrome	B-NP	NN	O	54	NMOD
40	of	of	B-PP	IN	O	39	NMOD
41	inappropriate	inappropriate	B-NP	JJ	O	44	NMOD
42	antidiuretic	antidiuretic	I-NP	JJ	O	44	NMOD
43	hormone	hormone	I-NP	NN	O	44	NMOD
44	secretion	secretion	I-NP	NN	O	40	PMOD
45	(	(	O	(	O	49	DEP
46	n	n	B-NP	NN	O	48	SUB
47	=	=	B-VP	SYM	O	48	VMOD
48	1	1	B-NP	CD	O	49	DEP
49	)	)	O	)	O	44	NMOD
50	,	,	O	,	O	39	P
51	and	and	O	CC	O	54	NMOD
52	other	other	B-NP	JJ	O	54	NMOD
53	unclassified	unclassified	I-NP	JJ	O	54	NMOD
54	events	event	I-NP	NNS	O	3	OBJ
55	(	(	O	(	O	59	DEP
56	n	n	B-NP	NN	O	58	SUB
57	=	=	B-VP	SYM	O	58	VMOD
58	7	7	B-NP	CD	O	59	DEP
59	)	)	O	)	O	54	NMOD
60	.	.	O	.	O	3	P

1	IMPORTANCE	IMPORTANCE	B-NP	NN	O	6	NMOD
2	OF	OF	B-PP	IN	O	1	NMOD
3	THE	THE	B-NP	DT	O	4	NMOD
4	FIELD	FIELD	I-NP	NN	O	2	PMOD
5	:	:	O	:	O	1	P
6	Fluoropyrimidines	Fluoropyrimidine	B-NP	NNS	O	15	SUB
7	,	,	O	,	O	6	P
8	in	in	B-PP	IN	O	6	NMOD
9	particular	particular	B-NP	JJ	O	10	NMOD
10	5-fluorouracil	5-fluorouracil	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	5-FU	5-FU	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	,	,	O	,	O	6	P
15	have	have	B-VP	VBP	O	0	ROOT
16	been	be	I-VP	VBN	O	15	VC
17	the	the	B-NP	DT	O	18	NMOD
18	mainstay	mainstay	I-NP	NN	O	16	PRD
19	of	of	B-PP	IN	O	18	NMOD
20	treatment	treatment	B-NP	NN	O	19	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	several	several	B-NP	JJ	O	24	NMOD
23	solid	solid	I-NP	JJ	O	24	NMOD
24	tumors	tumor	I-NP	NNS	O	21	PMOD
25	,	,	O	,	O	24	P
26	including	include	B-PP	VBG	O	24	NMOD
27	colorectal	colorectal	B-NP	JJ	O	34	NMOD
28	,	,	I-NP	,	O	34	P
29	breast	breast	I-NP	NN	O	34	NMOD
30	and	and	I-NP	CC	O	34	NMOD
31	head	head	I-NP	NN	O	34	NMOD
32	and	and	I-NP	CC	O	34	NMOD
33	neck	neck	I-NP	NN	O	34	NMOD
34	cancers	cancer	I-NP	NNS	O	26	PMOD
35	,	,	O	,	O	16	P
36	for	for	B-PP	IN	O	16	VMOD
37	>	>	B-NP	JJR	O	39	NMOD
38	40	40	I-NP	CD	O	39	NMOD
39	years	year	I-NP	NNS	O	36	PMOD
40	.	.	O	.	O	15	P

1	WHAT	WHAT	B-NP	WDT	O	5	NMOD
2	THE	THE	B-NP	DT	O	5	NMOD
3	READER	READER	I-NP	NN	O	5	NMOD
4	WILL	WILL	I-NP	NN	O	5	NMOD
5	GAIN	GAIN	I-NP	NN	O	8	NMOD
6	:	:	O	:	O	5	P
7	The	The	B-NP	DT	O	8	NMOD
8	reader	reader	I-NP	NN	O	9	SUB
9	will	will	B-VP	MD	O	0	ROOT
10	gain	gain	I-VP	VB	O	9	VC
11	better	good	B-NP	JJR	O	12	NMOD
12	insight	insight	I-NP	NN	O	10	OBJ
13	into	into	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	safety	safety	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	capecitabine	capecitabine	B-NP	NN	O	16	PMOD
18	in	in	B-PP	IN	O	15	NMOD
19	special	special	B-NP	JJ	O	20	NMOD
20	populations	population	I-NP	NNS	O	18	PMOD
21	such	such	B-PP	JJ	O	22	PMOD
22	as	as	I-PP	IN	O	20	NMOD
23	patients	patient	B-NP	NNS	O	31	NMOD
24	with	with	B-PP	IN	O	23	NMOD
25	advanced	advanced	B-NP	JJ	O	26	NMOD
26	age	age	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	31	P
28	renal	renal	B-NP	JJ	O	31	NMOD
29	and	and	I-NP	CC	O	31	NMOD
30	kidney	kidney	I-NP	NN	O	31	NMOD
31	disease	disease	I-NP	NN	O	22	PMOD
32	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	6	NMOD
2	most	most	I-NP	RBS	O	3	AMOD
3	commonly	commonly	I-NP	RB	O	4	AMOD
4	reported	report	I-NP	VBN	O	6	NMOD
5	toxic	toxic	I-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	capecitabine	capecitabine	B-NP	NN	O	7	PMOD
9	are	be	B-VP	VBP	O	0	ROOT
10	diarrhea	diarrhea	B-NP	NN	O	19	NMOD
11	,	,	O	,	O	19	P
12	nausea	nausea	B-NP	NN	O	19	NMOD
13	,	,	O	,	O	19	P
14	vomiting	vomiting	B-NP	NN	O	19	NMOD
15	,	,	O	,	O	19	P
16	stomatitis	stomatitis	B-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	hand-foot	hand-foot	B-NP	JJ	O	19	NMOD
19	syndrome	syndrome	I-NP	NN	O	9	PRD
20	.	.	O	.	O	9	P

1	Effects	Effect	B-NP	NNS	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	pallidal	pallidal	B-NP	JJ	B-protein	4	NMOD
4	neurotensin	neurotensin	I-NP	NN	I-protein	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	haloperidol	haloperidol	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	parkinsonian	parkinsonian	B-NP	JJ	O	9	NMOD
9	catalepsy	catalepsy	I-NP	NN	O	7	OBJ
10	:	:	O	:	O	7	P
11	behavioral	behavioral	B-NP	JJ	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	electrophysiological	electrophysiological	I-NP	JJ	O	14	NMOD
14	studies	study	I-NP	NNS	O	7	OBJ
15	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	aimed	aim	B-VP	VBD	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	investigate	investigate	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	effects	effect	I-NP	NNS	O	14	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	pallidal	pallidal	B-NP	JJ	B-protein	11	NMOD
11	neurotensin	neurotensin	I-NP	NN	I-protein	9	PMOD
12	on	on	B-PP	IN	O	8	NMOD
13	haloperidol	haloperidol	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	6	VMOD
15	parkinsonian	parkinsonian	B-NP	JJ	O	16	NMOD
16	symptoms	symptom	I-NP	NNS	O	14	OBJ
17	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Bilateral	Bilateral	B-NP	JJ	O	4	NMOD
4	infusions	infusion	I-NP	NNS	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	neurotensin	neurotensin	B-NP	NN	B-protein	5	PMOD
7	into	into	B-PP	IN	O	4	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	globus	globus	I-NP	NN	O	10	NMOD
10	pallidus	pallidus	I-NP	NN	O	7	PMOD
11	reversed	reverse	B-VP	VBD	O	1	NMOD
12	haloperidol	haloperidol	B-NP	NN	O	15	NMOD
13	induced	induced	I-NP	JJ	O	15	NMOD
14	parkinsonian	parkinsonian	I-NP	JJ	O	15	NMOD
15	catalepsy	catalepsy	I-NP	NN	O	11	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	1	P

1	Pulmonary	Pulmonary	B-NP	JJ	O	2	NMOD
2	shunt	shunt	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	cardiovascular	cardiovascular	B-NP	JJ	O	5	NMOD
5	responses	response	I-NP	NNS	O	0	ROOT
6	to	to	B-PP	TO	O	5	NMOD
7	CPAP	CPAP	B-NP	NN	B-protein	6	PMOD
8	during	during	B-PP	IN	O	5	NMOD
9	nitroprusside	nitroprusside	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	hypotension	hypotension	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	5	P

1	Ten	Ten	B-NP	CD	O	4	NMOD
2	cm	cm	I-NP	NN	O	4	NMOD
3	H2O	H2O	I-NP	NN	O	4	NMOD
4	CPAP	CPAP	I-NP	NN	O	8	SUB
5	before	before	B-PP	IN	O	4	NMOD
6	nitroprusside	nitroprusside	B-NP	NN	O	7	NMOD
7	infusion	infusion	I-NP	NN	O	5	PMOD
8	produced	produce	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	further	further	I-NP	JJ	O	11	NMOD
11	decrease	decrease	I-NP	NN	O	8	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	arterial	arterial	B-NP	JJ	O	15	NMOD
14	blood	blood	I-NP	NN	O	15	NMOD
15	pressure	pressure	I-NP	NN	O	12	PMOD
16	and	and	O	CC	O	8	VMOD
17	significantly	significantly	B-VP	RB	O	18	VMOD
18	increased	increase	I-VP	VBD	O	8	VMOD
19	heart	heart	B-NP	NN	O	20	NMOD
20	rate	rate	I-NP	NN	O	18	OBJ
21	and	and	O	CC	O	18	VMOD
22	decreased	decrease	B-VP	VBD	O	18	VMOD
23	cardiac	cardiac	B-NP	JJ	O	22	OBJ
24	output	output	I-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	QS/QT	QS/QT	I-NP	NN	B-protein	23	NMOD
27	.	.	O	.	O	8	P

1	Nitroprusside	Nitroprusside	B-NP	NNP	O	2	SUB
2	caused	cause	B-VP	VBD	O	0	ROOT
3	significant	significant	B-NP	JJ	O	4	NMOD
4	decreases	decrease	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	arterial	arterial	B-NP	JJ	O	8	NMOD
7	blood	blood	I-NP	NN	O	8	NMOD
8	pressure	pressure	I-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	systemic	systemic	B-NP	JJ	O	12	NMOD
11	vascular	vascular	I-NP	JJ	O	12	NMOD
12	resistance	resistance	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	increases	increase	I-NP	NNS	O	5	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	heart	heart	B-NP	NN	O	17	NMOD
17	rate	rate	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	2	P
19	but	but	O	CC	O	2	VMOD
20	did	do	B-VP	VBD	O	2	VMOD
21	not	not	I-VP	RB	O	20	VMOD
22	change	change	I-VP	VB	O	20	VC
23	cardiac	cardiac	B-NP	JJ	O	26	NMOD
24	output	output	I-NP	NN	O	26	NMOD
25	or	or	I-NP	CC	O	26	NMOD
26	QS/QT	QS/QT	I-NP	NN	B-protein	22	OBJ
27	.	.	O	.	O	2	P

1	Mediation	Mediation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	enhanced	enhance	B-NP	VBN	O	6	NMOD
4	reflex	reflex	I-NP	NN	O	6	NMOD
5	vagal	vagal	I-NP	JJ	O	6	NMOD
6	bradycardia	bradycardia	I-NP	NN	O	2	PMOD
7	by	by	B-PP	IN	O	1	NMOD
8	L-dopa	L-dopa	B-NP	NN	B-protein	7	PMOD
9	via	via	B-PP	IN	O	1	NMOD
10	central	central	B-NP	JJ	O	12	NMOD
11	dopamine	dopamine	I-NP	NN	O	12	NMOD
12	formation	formation	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	dogs	dog	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	10	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	10	P
4	reflex	reflex	B-NP	NN	O	5	NMOD
5	bradycardia	bradycardia	I-NP	NN	O	10	SUB
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	injected	inject	B-NP	VBN	O	9	NMOD
9	norepinephrine	norepinephrine	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	17	VMOD
11	significantly	significantly	I-VP	RB	O	10	VMOD
12	enhanced	enhance	I-VP	VBN	O	10	VC
13	by	by	B-PP	IN	O	12	VMOD
14	L-dopa	L-dopa	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	17	P
16	DL-Threo-dihydroxyphenylserine	DL-Threo-dihydroxyphenylserine	B-NP	NN	O	17	SUB
17	had	have	B-VP	VBD	O	0	ROOT
18	no	no	B-NP	DT	O	19	NMOD
19	effect	effect	I-NP	NN	O	17	OBJ
20	on	on	B-PP	IN	O	17	VMOD
21	blood	blood	B-NP	NN	O	22	NMOD
22	pressure	pressure	I-NP	NN	O	20	PMOD
23	,	,	O	,	O	17	P
24	heart	heart	B-NP	NN	O	25	NMOD
25	rate	rate	I-NP	NN	O	28	NMOD
26	or	or	I-NP	CC	O	28	NMOD
27	reflex	reflex	I-NP	NN	O	28	NMOD
28	responses	response	I-NP	NNS	O	17	OBJ
29	to	to	B-PP	TO	O	28	NMOD
30	norepinephrine	norepinephrine	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	17	P

1	FLA-63	FLA-63	B-NP	NN	B-protein	5	NMOD
2	,	,	O	,	O	5	P
3	a	a	B-NP	DT	O	5	NMOD
4	dopamine-beta-oxidase	dopamine-beta-oxidase	I-NP	NN	O	5	NMOD
5	inhibitor	inhibitor	I-NP	NN	O	7	SUB
6	,	,	O	,	O	5	P
7	did	do	B-VP	VBD	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	have	have	I-VP	VB	O	7	VC
10	any	any	B-NP	DT	O	11	NMOD
11	effect	effect	I-NP	NN	O	9	OBJ
12	on	on	B-PP	IN	O	9	VMOD
13	the	the	B-NP	DT	O	19	NMOD
14	hypotension	hypotension	I-NP	NN	O	19	NMOD
15	,	,	I-NP	,	O	19	P
16	bradycardia	bradycardia	I-NP	NN	O	19	NMOD
17	or	or	I-NP	CC	O	19	NMOD
18	reflex-enhancing	reflex-enhancing	I-NP	JJ	O	19	NMOD
19	effect	effect	I-NP	NN	O	12	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	L-dopa	L-dopa	B-NP	NN	B-protein	20	PMOD
22	.	.	O	.	O	7	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	L-dopa	L-dopa	B-NP	NN	O	4	SUB
4	restored	restore	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	bradycardia	bradycardia	I-NP	NN	O	27	NMOD
7	caused	cause	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	norepinephrine	norepinephrine	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	VMOD
11	addition	addition	B-NP	NN	O	10	PMOD
12	to	to	B-PP	TO	O	11	NMOD
13	decreasing	decrease	B-VP	VBG	O	12	PMOD
14	blood	blood	B-NP	NN	O	15	NMOD
15	pressure	pressure	I-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	heart	heart	B-NP	NN	O	19	NMOD
18	rate.	rate.	I-NP	NN	O	19	NMOD
19	5-HTP	5-HTP	I-NP	NN	O	13	OBJ
20	(	(	O	(	O	24	DEP
21	5	5	B-NP	CD	O	22	AMOD
22	mg/kg	mg/kg	I-NP	NN	O	23	NMOD
23	i.v.	i.v.	I-NP	NN	O	24	DEP
24	)	)	O	)	O	19	NMOD
25	decreased	decrease	B-VP	VBD	O	27	NMOD
26	blood	blood	B-NP	NN	O	27	NMOD
27	pressure	pressure	I-NP	NN	O	30	NMOD
28	and	and	I-NP	CC	O	30	NMOD
29	heart	heart	I-NP	NN	O	30	NMOD
30	rate	rate	I-NP	NN	O	4	OBJ
31	and	and	O	CC	O	4	VMOD
32	decreased	decrease	B-VP	VBD	O	4	VMOD
33	the	the	B-NP	DT	O	35	NMOD
34	reflex	reflex	I-NP	NN	O	35	NMOD
35	bradycardia	bradycardia	I-NP	NN	O	32	OBJ
36	to	to	B-PP	TO	O	35	NMOD
37	norepinephrine	norepinephrine	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	4	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	concluded	conclude	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	L-dopa	L-dopa	B-NP	NN	B-protein	6	SUB
6	enhances	enhance	B-VP	VBZ	O	4	SBAR
7	reflex	reflex	B-NP	NN	O	8	NMOD
8	bradycardia	bradycardia	I-NP	NN	O	6	OBJ
9	through	through	B-PP	IN	O	8	NMOD
10	central	central	B-NP	JJ	B-protein	12	NMOD
11	alpha-receptor	alpha-receptor	I-NP	NN	I-protein	12	NMOD
12	stimulation	stimulation	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	2	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	myocardial	myocardial	B-NP	JJ	O	4	NMOD
4	infarction	infarction	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	P
6	clinical	clinical	B-NP	JJ	O	7	NMOD
7	observations	observation	I-NP	NNS	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	pathogenetic	pathogenetic	B-NP	JJ	O	10	NMOD
10	considerations	consideration	I-NP	NNS	O	2	VMOD
11	.	.	O	.	O	2	P

1	Clinical	Clinical	B-NP	JJ	O	3	AMOD
2	and	and	I-NP	CC	O	3	AMOD
3	experimental	experimental	I-NP	JJ	O	4	NMOD
4	data	datum	I-NP	NNS	O	8	SUB
5	published	publish	B-VP	VBN	O	4	NMOD
6	to	to	B-PP	TO	O	5	VMOD
7	date	date	B-NP	NN	O	6	PMOD
8	suggest	suggest	B-VP	VBP	O	0	ROOT
9	several	several	B-NP	JJ	O	11	NMOD
10	possible	possible	I-NP	JJ	O	11	NMOD
11	mechanisms	mechanism	I-NP	NNS	O	8	OBJ
12	by	by	B-PP	IN	O	11	NMOD
13	which	which	B-NP	WDT	O	12	PMOD
14	cocaine	cocaine	B-NP	NN	O	15	SUB
15	may	may	B-VP	MD	O	12	SBAR
16	result	result	I-VP	VB	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	myocardial	myocardial	I-NP	JJ	O	20	NMOD
20	infarction	infarction	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	14	VMOD
2	individuals	individual	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	preexisting	preexisting	B-NP	JJ	O	9	NMOD
5	,	,	I-NP	,	O	9	P
6	high-grade	high-grade	I-NP	JJ	O	9	NMOD
7	coronary	coronary	I-NP	JJ	O	9	NMOD
8	arterial	arterial	I-NP	JJ	O	9	NMOD
9	narrowing	narrowing	I-NP	NN	O	3	PMOD
10	,	,	O	,	O	14	P
11	acute	acute	B-NP	JJ	O	13	NMOD
12	myocardial	myocardial	I-NP	JJ	O	13	NMOD
13	infarction	infarction	I-NP	NN	O	14	SUB
14	may	may	B-VP	MD	O	0	ROOT
15	result	result	I-VP	VB	O	14	VC
16	from	from	B-PP	IN	O	15	VMOD
17	an	an	B-NP	DT	O	18	NMOD
18	increase	increase	I-NP	NN	O	26	SUB
19	in	in	B-PP	IN	O	18	NMOD
20	myocardial	myocardial	B-NP	JJ	O	22	NMOD
21	oxygen	oxygen	I-NP	NN	O	22	NMOD
22	demand	demand	I-NP	NN	O	19	PMOD
23	associated	associate	B-VP	VBN	O	22	NMOD
24	with	with	B-PP	IN	O	23	VMOD
25	cocaine	cocaine	B-NP	NN	O	24	PMOD
26	induced	induce	B-VP	VBD	O	16	SBAR
27	increase	increase	B-NP	NN	O	26	OBJ
28	in	in	B-PP	IN	O	27	NMOD
29	rate-pressure	rate-pressure	B-NP	JJ	B-protein	30	NMOD
30	product	product	I-NP	NN	I-protein	28	PMOD
31	.	.	O	.	O	14	P

1	With	With	B-PP	IN	O	9	VMOD
2	regard	regard	B-NP	NN	O	1	PMOD
3	to	to	B-PP	TO	O	2	NMOD
4	spasm	spasm	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	9	P
6	the	the	B-NP	DT	O	8	NMOD
7	clinical	clinical	I-NP	JJ	O	8	NMOD
8	findings	finding	I-NP	NNS	O	9	SUB
9	are	be	B-VP	VBP	O	20	VMOD
10	largely	largely	B-ADJP	RB	O	11	AMOD
11	circumstantial	circumstantial	I-ADJP	JJ	O	9	PRD
12	,	,	O	,	O	20	P
13	and	and	O	CC	O	15	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	locus	locus	I-NP	NN	O	20	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	cocaine	cocaine	B-NP	NN	O	19	NMOD
18	induced	induced	I-NP	JJ	O	19	NMOD
19	vasoconstriction	vasoconstriction	I-NP	NN	O	16	PMOD
20	remains	remain	B-VP	VBZ	O	0	ROOT
21	speculative	speculative	B-ADJP	JJ	O	20	PRD
22	.	.	O	.	O	20	P

1	Rabbit	Rabbit	B-NP	NN	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	12	NMOD
3	,	,	O	,	O	12	P
4	antidepressant	antidepressant	B-NP	NN	O	5	NMOD
5	use	use	I-NP	NN	O	12	NMOD
6	,	,	O	,	O	12	P
7	and	and	O	CC	O	12	NMOD
8	cerebral	cerebral	B-NP	JJ	O	12	NMOD
9	perfusion	perfusion	I-NP	NN	O	12	NMOD
10	SPECT	SPECT	I-NP	NN	O	12	NMOD
11	scan	scan	I-NP	NN	O	12	NMOD
12	findings	finding	I-NP	NNS	O	0	ROOT
13	.	.	O	.	O	12	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	bronchodilating	bronchodilating	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	ipratropium	ipratropium	B-NP	NN	O	6	NMOD
6	bromide	bromide	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	theophylline	theophylline	I-NP	NN	O	4	PMOD
9	in	in	B-PP	IN	O	3	NMOD
10	chronic	chronic	B-NP	JJ	O	13	NMOD
11	obstructive	obstructive	I-NP	JJ	O	13	NMOD
12	pulmonary	pulmonary	I-NP	JJ	O	13	NMOD
13	disease	disease	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	bronchodilator	bronchodilator	I-NP	NN	O	3	NMOD
3	effects	effect	I-NP	NNS	O	31	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	single	single	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	19	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	ipratropium	ipratropium	B-NP	NN	O	11	NMOD
10	bromide	bromide	I-NP	NN	O	11	NMOD
11	aerosol	aerosol	I-NP	NN	O	8	PMOD
12	(	(	O	(	O	15	DEP
13	36	36	B-NP	CD	O	14	NMOD
14	micrograms	microgram	I-NP	NNS	O	15	DEP
15	)	)	O	)	O	7	NMOD
16	and	and	O	CC	O	19	NMOD
17	short-acting	short-acting	B-NP	JJ	O	19	NMOD
18	theophylline	theophylline	I-NP	NN	O	19	NMOD
19	tablets	tablet	I-NP	NNS	O	4	PMOD
20	(	(	O	(	O	30	DEP
21	dose	dose	B-NP	NN	O	30	DEP
22	titrated	titrate	B-VP	VBN	O	21	NMOD
23	to	to	B-VP	TO	O	24	VMOD
24	produce	produce	I-VP	VB	O	22	VMOD
25	serum	serum	B-NP	NN	O	26	NMOD
26	levels	level	I-NP	NNS	O	24	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	10-20	10-20	B-NP	CD	O	29	NMOD
29	micrograms/mL	micrograms/mL	I-NP	NN	O	27	PMOD
30	)	)	O	)	O	19	NMOD
31	were	be	B-VP	VBD	O	0	ROOT
32	compared	compare	I-VP	VBN	O	31	VC
33	in	in	B-PP	IN	O	32	VMOD
34	a	a	B-NP	DT	O	39	NMOD
35	double-blind	double-blind	I-NP	JJ	O	37	AMOD
36	,	,	I-NP	,	O	37	P
37	placebo-controlled	placebo-controlled	I-NP	JJ	O	39	NMOD
38	crossover	crossover	I-NP	NN	O	39	NMOD
39	study	study	I-NP	NN	O	33	PMOD
40	in	in	B-PP	IN	O	39	NMOD
41	21	21	B-NP	CD	O	42	NMOD
42	patients	patient	I-NP	NNS	O	40	PMOD
43	with	with	B-PP	IN	O	42	NMOD
44	stable	stable	B-NP	JJ	O	49	NMOD
45	,	,	I-NP	,	O	49	P
46	chronic	chronic	I-NP	JJ	O	49	NMOD
47	obstructive	obstructive	I-NP	JJ	O	49	NMOD
48	pulmonary	pulmonary	I-NP	JJ	O	49	NMOD
49	disease	disease	I-NP	NN	O	43	PMOD
50	.	.	O	.	O	31	P

1	While	While	B-SBAR	IN	O	12	VMOD
2	side	side	B-NP	NN	O	3	NMOD
3	effects	effect	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	1	SBAR
5	rare	rare	B-ADJP	JJ	O	4	PRD
6	,	,	O	,	O	12	P
7	those	those	B-NP	DT	O	12	SUB
8	experienced	experience	B-VP	VBN	O	7	NMOD
9	after	after	B-PP	IN	O	8	VMOD
10	theophylline	theophylline	B-NP	NN	O	11	NMOD
11	use	use	I-NP	NN	O	9	PMOD
12	did	do	B-VP	VBD	O	0	ROOT
13	involve	involve	I-VP	VB	O	12	VC
14	the	the	B-NP	DT	O	18	NMOD
15	cardiovascular	cardiovascular	I-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	gastrointestinal	gastrointestinal	I-NP	JJ	O	18	NMOD
18	systems	system	I-NP	NNS	O	13	OBJ
19	.	.	O	.	O	12	P

1	Renal	Renal	B-NP	JJ	O	3	NMOD
2	papillary	papillary	I-NP	JJ	O	3	NMOD
3	necrosis	necrosis	I-NP	NN	O	12	NMOD
4	(	(	O	(	O	6	DEP
5	RPN	RPN	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	and	and	O	CC	O	12	NMOD
8	a	a	B-NP	DT	O	12	NMOD
9	decreased	decrease	I-NP	VBN	O	12	NMOD
10	urinary	urinary	I-NP	JJ	O	12	NMOD
11	concentrating	concentrate	I-NP	VBG	O	12	NMOD
12	ability	ability	I-NP	NN	O	0	ROOT
13	developed	develop	B-VP	VBN	O	12	NMOD
14	during	during	B-PP	IN	O	13	VMOD
15	continuous	continuous	B-NP	JJ	O	17	NMOD
16	long-term	long-term	I-NP	JJ	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	14	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	aspirin	aspirin	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	paracetamol	paracetamol	I-NP	NN	O	18	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	female	female	B-NP	JJ	O	26	NMOD
24	Fischer	Fischer	I-NP	NNP	O	26	NMOD
25	344	344	I-NP	CD	O	26	NMOD
26	rats	rat	I-NP	NNS	O	22	PMOD
27	.	.	O	.	O	12	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	adriamycin	adriamycin	B-NP	NN	O	2	PMOD
4	combined	combine	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	whole	whole	B-NP	JJ	O	8	NMOD
7	body	body	I-NP	NN	O	8	NMOD
8	hyperthermia	hyperthermia	I-NP	NN	O	5	PMOD
9	on	on	B-PP	IN	O	8	NMOD
10	tumor	tumor	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	normal	normal	B-NP	JJ	O	13	NMOD
13	tissues	tissue	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	1	P

1	Thermal	Thermal	B-NP	JJ	O	2	NMOD
2	enhancement	enhancement	I-NP	NN	O	10	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	Adriamycin-mediated	Adriamycin-mediated	B-NP	JJ	O	6	NMOD
5	antitumor	antitumor	I-NP	JJ	O	6	NMOD
6	activity	activity	I-NP	NN	O	3	PMOD
7	and	and	O	CC	O	9	NMOD
8	normal	normal	B-NP	JJ	O	9	NMOD
9	tissue	tissue	I-NP	NN	O	10	NMOD
10	toxicities	toxicity	I-NP	NNS	O	15	SUB
11	by	by	B-PP	IN	O	10	NMOD
12	whole	whole	B-NP	JJ	O	14	NMOD
13	body	body	I-NP	NN	O	14	NMOD
14	hyperthermia	hyperthermia	I-NP	NN	O	11	PMOD
15	were	be	B-VP	VBD	O	0	ROOT
16	compared	compare	I-VP	VBN	O	15	VC
17	using	use	B-VP	VBG	O	15	VMOD
18	a	a	B-NP	DT	O	21	NMOD
19	F344	F344	I-NP	NN	O	21	NMOD
20	rat	rat	I-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	17	OBJ
22	.	.	O	.	O	15	P

1	Whole	Whole	B-NP	JJ	O	3	NMOD
2	body	body	I-NP	NN	O	3	NMOD
3	hyperthermia	hyperthermia	I-NP	NN	O	12	SUB
4	(	(	O	(	O	11	DEP
5	120	120	B-NP	CD	O	6	NMOD
6	min	min	I-NP	NN	O	11	DEP
7	at	at	B-PP	IN	O	6	NMOD
8	41.5	41.5	B-NP	CD	O	10	NMOD
9	degrees	degree	I-NP	NNS	O	10	NMOD
10	C	C	I-NP	NN	O	7	PMOD
11	)	)	O	)	O	3	NMOD
12	enhanced	enhance	B-VP	VBD	O	0	ROOT
13	both	both	O	CC	O	20	NMOD
14	Adriamycin-mediated	Adriamycin-mediated	B-NP	JJ	O	15	AMOD
15	antitumor	antitumor	I-NP	JJ	O	16	NMOD
16	activity	activity	I-NP	NN	O	20	NMOD
17	and	and	O	CC	O	20	NMOD
18	toxic	toxic	B-NP	JJ	O	20	NMOD
19	side	side	I-NP	NN	O	20	NMOD
20	effects	effect	I-NP	NNS	O	12	OBJ
21	.	.	O	.	O	12	P

1	Prazosin	Prazosin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	stress	stress	B-NP	NN	O	4	NMOD
4	incontinence	incontinence	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	genuine	genuine	B-NP	JJ	O	6	NMOD
5	stress	stress	I-NP	NN	O	6	NMOD
6	incontinence	incontinence	I-NP	NN	O	3	PMOD
7	due	due	B-PP	IN	O	2	NMOD
8	to	to	B-PP	TO	O	7	PMOD
9	prazosin	prazosin	B-NP	NN	O	14	NMOD
10	,	,	O	,	O	14	P
11	a	a	B-NP	DT	O	14	NMOD
12	common	common	I-NP	JJ	O	14	NMOD
13	antihypertensive	antihypertensive	I-NP	JJ	O	14	NMOD
14	drug	drug	I-NP	NN	O	8	PMOD
15	,	,	O	,	O	2	P
16	is	be	B-VP	VBZ	O	0	ROOT
17	presented	present	I-VP	VBN	O	16	VC
18	.	.	O	.	O	16	P

1	Myocardial	Myocardial	B-NP	JJ	O	2	NMOD
2	infarction	infarction	I-NP	NN	O	0	ROOT
3	following	follow	B-PP	VBG	O	2	NMOD
4	sublingual	sublingual	B-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	isosorbide	isosorbide	B-NP	NN	O	8	NMOD
8	dinitrate	dinitrate	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	78-year-old	78-year-old	I-NP	JJ	O	7	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	healed	heal	B-NP	VBN	O	6	NMOD
5	septal	septal	I-NP	JJ	O	6	NMOD
6	necrosis	necrosis	I-NP	NN	O	3	PMOD
7	suffered	suffer	B-VP	VBD	O	0	ROOT
8	a	a	B-NP	DT	O	11	NMOD
9	recurrent	recurrent	I-NP	JJ	O	10	AMOD
10	myocardial	myocardial	I-NP	JJ	O	11	NMOD
11	infarction	infarction	I-NP	NN	O	7	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	anterior	anterior	I-NP	JJ	O	15	NMOD
15	wall	wall	I-NP	NN	O	12	PMOD
16	following	follow	B-PP	VBG	O	7	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	administration	administration	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	isosorbide	isosorbide	B-NP	NN	O	23	NMOD
21	dinitrate	dinitrate	I-NP	NN	O	23	NMOD
22	5	5	I-NP	CD	O	23	NMOD
23	mg	mg	I-NP	NN	O	19	PMOD
24	sublingually	sublingually	B-ADVP	RB	O	18	NMOD
25	.	.	O	.	O	7	P

1	Fluoxetine	Fluoxetine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	akathisia	akathisia	B-NP	NN	O	2	OBJ
4	:	:	O	:	O	8	P
5	clinical	clinical	B-NP	JJ	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	theoretical	theoretical	I-NP	JJ	O	8	NMOD
8	implications	implication	I-NP	NNS	O	2	VMOD
9	.	.	O	.	O	2	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	15	SUB
3	receiving	receive	B-VP	VBG	O	2	NMOD
4	fluoxetine	fluoxetine	B-NP	NN	O	3	OBJ
5	for	for	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	obsessive	obsessive	B-NP	JJ	O	11	NMOD
10	compulsive	compulsive	I-NP	JJ	O	11	NMOD
11	disorder	disorder	I-NP	NN	O	14	NMOD
12	or	or	O	CC	O	14	NMOD
13	major	major	B-NP	JJ	O	14	NMOD
14	depression	depression	I-NP	NN	O	8	PMOD
15	developed	develop	B-VP	VBD	O	0	ROOT
16	akathisia	akathisia	B-NP	NN	O	15	OBJ
17	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	3	NMOD
2	typical	typical	I-NP	JJ	O	3	NMOD
3	fluoxetine	fluoxetine	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	23	VMOD
5	symptoms	symptom	B-NP	NNS	O	22	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	restlessness	restlessness	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	22	P
9	constant	constant	B-NP	JJ	O	10	NMOD
10	pacing	pacing	I-NP	NN	O	22	NMOD
11	,	,	O	,	O	22	P
12	purposeless	purposeless	B-NP	JJ	O	13	NMOD
13	movements	movement	I-NP	NNS	O	22	NMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	18	NMOD
16	feet	foot	I-NP	NNS	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	legs	leg	I-NP	NNS	O	14	PMOD
19	,	,	O	,	O	22	P
20	and	and	O	CC	O	22	NMOD
21	marked	marked	B-NP	JJ	O	22	NMOD
22	anxiety	anxiety	I-NP	NN	O	23	SUB
23	were	be	B-VP	VBD	O	0	ROOT
24	indistinguishable	indistinguishable	B-ADJP	JJ	O	23	PRD
25	from	from	B-PP	IN	O	24	AMOD
26	those	those	B-NP	DT	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	neuroleptic	neuroleptic	B-NP	JJ	O	30	NMOD
29	induced	induce	I-NP	VBN	O	30	NMOD
30	akathisia	akathisia	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	23	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	12	SUB
3	who	who	B-NP	WP	O	2	NMOD
4	had	have	B-VP	VBD	O	3	SBAR
5	experienced	experience	I-VP	VBN	O	4	VC
6	neuroleptic	neuroleptic	B-NP	JJ	O	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	akathisia	akathisia	I-NP	NN	O	5	OBJ
9	in	in	B-PP	IN	O	5	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	past	past	I-NP	NN	O	9	PMOD
12	reported	report	B-VP	VBD	O	0	ROOT
13	that	that	B-SBAR	IN	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	symptoms	symptom	I-NP	NNS	O	20	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	fluoxetine	fluoxetine	B-NP	NN	O	19	NMOD
18	induced	induce	I-NP	VBN	O	19	NMOD
19	akathisia	akathisia	I-NP	NN	O	16	PMOD
20	were	be	B-VP	VBD	O	13	SBAR
21	identical	identical	B-ADJP	JJ	O	20	PRD
22	,	,	O	,	O	20	P
23	although	although	B-SBAR	IN	O	20	VMOD
24	somewhat	somewhat	B-ADJP	RB	O	25	AMOD
25	milder	mild	I-ADJP	JJR	O	23	SBAR
26	.	.	O	.	O	12	P

1	Akathisia	Akathisia	B-NP	NNP	O	2	SUB
2	appeared	appear	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	be	be	I-VP	VB	O	2	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	common	common	I-NP	JJ	O	8	NMOD
7	side	side	I-NP	NN	O	8	NMOD
8	effect	effect	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	fluoxetine	fluoxetine	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	4	VMOD
12	generally	generally	B-VP	RB	O	2	VMOD
13	responded	respond	I-VP	VBD	O	2	VMOD
14	well	well	I-VP	RB	O	13	VMOD
15	to	to	I-VP	TO	O	13	VMOD
16	treatment	treatment	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	21	NMOD
19	beta-adrenergic	beta-adrenergic	I-NP	JJ	O	21	NMOD
20	antagonist	antagonist	I-NP	NN	O	21	NMOD
21	propranolol	propranolol	I-NP	NN	O	27	NMOD
22	,	,	O	,	O	27	P
23	dose	dose	B-NP	NN	O	24	NMOD
24	reduction	reduction	I-NP	NN	O	27	NMOD
25	,	,	O	,	O	27	P
26	or	or	O	CC	O	27	NMOD
27	both	both	B-NP	DT	O	17	PMOD
28	.	.	O	.	O	2	P

1	Chronic	Chronic	B-NP	JJ	O	3	NMOD
2	active	active	I-NP	JJ	O	3	NMOD
3	hepatitis	hepatitis	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	diclofenac	diclofenac	B-NP	NN	O	8	NMOD
7	sodium	sodium	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	3	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	generally	generally	B-NP	RB	O	3	AMOD
3	well-tolerated	well-tolerated	I-NP	JJ	O	5	AMOD
4	,	,	I-NP	,	O	5	P
5	asymptomatic	asymptomatic	I-NP	JJ	O	6	NMOD
6	abnormalities	abnormality	I-NP	NNS	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	liver	liver	B-NP	NN	O	9	NMOD
9	function	function	I-NP	NN	O	7	PMOD
10	have	have	B-VP	VBP	O	1	SBAR
11	been	be	I-VP	VBN	O	10	VC
12	recorded	record	I-VP	VBN	O	11	VC
13	and	and	O	CC	O	10	VMOD
14	,	,	O	,	O	10	P
15	less	less	B-ADVP	RBR	O	16	AMOD
16	commonly	commonly	I-ADVP	RB	O	10	VMOD
17	,	,	O	,	O	1	DEP
18	severe	severe	B-NP	JJ	O	19	NMOD
19	hepatitis	hepatitis	I-NP	NN	O	17	SUB
20	induced	induce	B-VP	VBN	O	19	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	diclofenac	diclofenac	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	1	P

1	Stroke	Stroke	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	cocaine	cocaine	B-NP	NN	O	5	NMOD
5	use	use	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	eight	eight	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	whom	whom	B-NP	WP	O	8	NMOD
7	cocaine	cocaine	B-NP	NN	O	8	NMOD
8	use	use	I-NP	NN	O	5	PMOD
9	was	be	B-VP	VBD	O	2	VMOD
10	related	relate	I-VP	VBN	O	9	VC
11	to	to	I-VP	TO	O	12	VMOD
12	stroke	stroke	I-VP	VB	O	10	VMOD
13	and	and	I-VP	CC	O	12	VMOD
14	review	review	I-VP	VB	O	12	VMOD
15	39	39	B-NP	CD	O	16	NMOD
16	cases	case	I-NP	NNS	O	14	OBJ
17	from	from	B-PP	IN	O	14	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	literature	literature	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	2	P

1	Stroke	Stroke	B-NP	NNP	O	2	SUB
2	followed	follow	B-VP	VBD	O	0	ROOT
3	cocaine	cocaine	B-NP	NN	O	4	NMOD
4	use	use	I-NP	NN	O	2	OBJ
5	by	by	B-PP	IN	O	2	VMOD
6	inhalation	inhalation	B-NP	NN	O	14	NMOD
7	,	,	O	,	O	14	P
8	intranasal	intranasal	B-NP	JJ	O	14	NMOD
9	,	,	I-NP	,	O	14	P
10	intravenous	intravenous	I-NP	JJ	O	14	NMOD
11	,	,	O	,	O	14	P
12	and	and	O	CC	O	14	NMOD
13	intramuscular	intramuscular	B-NP	JJ	O	14	NMOD
14	routes	route	I-NP	NNS	O	5	PMOD
15	.	.	O	.	O	2	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	(	(	B-LST	(	O	6	DEP
6	1	1	I-LST	LS	O	17	VMOD
7	)	)	O	)	O	6	DEP
8	the	the	B-NP	DT	O	10	NMOD
9	apparent	apparent	I-NP	JJ	O	10	NMOD
10	incidence	incidence	I-NP	NN	O	17	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	stroke	stroke	B-NP	NN	O	11	PMOD
13	related	relate	B-VP	VBN	O	12	NMOD
14	to	to	B-PP	TO	O	13	AMOD
15	cocaine	cocaine	B-NP	NN	O	16	NMOD
16	use	use	I-NP	NN	O	14	PMOD
17	is	be	B-VP	VBZ	O	4	SBAR
18	increasing	increase	I-VP	VBG	O	17	PRD
19	.	.	O	.	O	3	P

1	(	(	B-LST	(	O	2	DEP
2	2	2	I-LST	LS	O	6	VMOD
3	)	)	O	)	O	2	DEP
4	cocaine-associated	cocaine-associated	B-NP	JJ	O	5	NMOD
5	stroke	stroke	I-NP	NN	O	6	SUB
6	occurs	occur	B-VP	VBZ	O	0	ROOT
7	primarily	primarily	B-ADVP	RB	O	6	VMOD
8	in	in	B-PP	IN	O	6	VMOD
9	young	young	B-NP	JJ	O	10	NMOD
10	adults	adult	I-NP	NNS	O	8	PMOD
11	.	.	O	.	O	6	P

1	(	(	B-LST	(	O	2	DEP
2	3	3	I-LST	LS	O	5	VMOD
3	)	)	O	)	O	2	DEP
4	stroke	stroke	B-NP	NN	O	5	SUB
5	may	may	B-VP	MD	O	0	ROOT
6	follow	follow	I-VP	VB	O	5	VC
7	any	any	B-NP	DT	O	8	NMOD
8	route	route	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	cocaine	cocaine	B-NP	NN	O	11	NMOD
11	administration	administration	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	5	P

1	Glyburide	Glyburide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hepatitis	hepatitis	B-NP	NN	O	2	OBJ
4	.	.	O	.	O	2	P

1	Drug	Drug	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hepatotoxicity	hepatotoxicity	B-NP	NN	O	2	OBJ
4	,	,	O	,	O	2	P
5	although	although	B-SBAR	IN	O	2	VMOD
6	common	common	B-ADJP	JJ	O	5	DEP
7	,	,	O	,	O	2	P
8	has	have	B-VP	VBZ	O	2	VMOD
9	been	be	I-VP	VBN	O	8	VC
10	reported	report	I-VP	VBN	O	9	VC
11	only	only	B-ADVP	RB	O	10	VMOD
12	infrequently	infrequently	I-ADVP	RB	O	11	AMOD
13	with	with	B-PP	IN	O	11	PMOD
14	sulfonylureas	sulfonylurea	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	2	P

1	For	For	B-PP	IN	O	0	ROOT
2	glyburide	glyburide	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	11	P
4	a	a	B-NP	DT	O	6	NMOD
5	second-generation	second-generation	I-NP	JJ	O	6	NMOD
6	sulfonylurea	sulfonylurea	I-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	only	only	B-NP	RB	O	11	NMOD
9	two	two	I-NP	CD	O	8	AMOD
10	brief	brief	I-NP	JJ	O	11	NMOD
11	reports	report	I-NP	NNS	O	1	VMOD
12	of	of	B-PP	IN	O	11	NMOD
13	hepatotoxicity	hepatotoxicity	B-NP	NN	O	14	NMOD
14	exist	exist	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	11	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	8	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	type	type	B-NP	NN	O	6	NMOD
5	II	II	I-NP	CD	O	6	NMOD
6	diabetes	diabete	I-NP	NNS	O	7	NMOD
7	mellitus	mellitus	I-NP	NN	O	3	PMOD
8	developed	develop	B-VP	VBD	O	0	ROOT
9	an	an	B-NP	DT	O	12	NMOD
10	acute	acute	I-NP	JJ	O	12	NMOD
11	hepatitis-like	hepatitis-like	I-NP	JJ	O	12	NMOD
12	syndrome	syndrome	I-NP	NN	O	8	OBJ
13	soon	soon	B-ADVP	RB	O	8	VMOD
14	after	after	B-PP	IN	O	8	VMOD
15	initiation	initiation	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	glyburide	glyburide	B-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	8	P

1	Systolic	Systolic	B-NP	JJ	O	3	NMOD
2	pressure	pressure	I-NP	NN	O	3	NMOD
3	variation	variation	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	greater	great	B-ADJP	JJR	O	4	PRD
6	during	during	B-PP	IN	O	5	AMOD
7	hemorrhage	hemorrhage	B-NP	NN	O	6	PMOD
8	than	than	B-PP	IN	O	5	AMOD
9	during	during	B-PP	IN	O	8	PMOD
10	sodium	sodium	B-NP	NN	O	11	NMOD
11	nitroprusside	nitroprusside	I-NP	NN	O	13	NMOD
12	induced	induce	B-VP	VBD	O	11	AMOD
13	hypotension	hypotension	B-NP	NN	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	ventilated	ventilate	B-NP	VBN	O	16	NMOD
16	dogs	dog	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	4	P

1	Mean	Mean	B-NP	JJ	O	3	NMOD
2	arterial	arterial	I-NP	JJ	O	3	NMOD
3	pressure	pressure	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	decreased	decrease	I-VP	VBN	O	4	VC
6	to	to	B-PP	TO	O	5	VMOD
7	50	50	B-NP	CD	O	8	AMOD
8	mm	mm	I-NP	NN	O	9	NMOD
9	Hg	Hg	I-NP	NN	O	6	PMOD
10	for	for	B-PP	IN	O	5	VMOD
11	30	30	B-NP	CD	O	12	NMOD
12	minutes	minute	I-NP	NNS	O	10	PMOD
13	either	either	B-PP	CC	O	10	PMOD
14	by	by	B-PP	IN	O	10	PMOD
15	hemorrhage	hemorrhage	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	22	DEP
17	HEM	HEM	B-NP	NN	O	21	NMOD
18	,	,	O	,	O	21	P
19	n	n	B-NP	NN	O	21	SUB
20	=	=	B-VP	SYM	O	21	VMOD
21	7	7	B-NP	CD	O	22	DEP
22	)	)	O	)	O	15	NMOD
23	or	or	O	CC	O	10	PMOD
24	by	by	B-PP	IN	O	10	PMOD
25	continuous	continuous	B-NP	JJ	O	26	NMOD
26	infusion	infusion	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	sodium	sodium	B-NP	NN	O	29	NMOD
29	nitroprusside	nitroprusside	I-NP	NN	O	27	PMOD
30	(	(	O	(	O	36	DEP
31	SNP	SNP	B-NP	NN	O	35	NMOD
32	,	,	O	,	O	35	P
33	n	n	B-NP	NN	O	35	SUB
34	=	=	B-VP	SYM	O	35	VMOD
35	7	7	B-NP	CD	O	36	DEP
36	)	)	O	)	O	29	NMOD
37	.	.	O	.	O	4	P

1	During	During	B-PP	IN	O	8	VMOD
2	HEM	HEM	B-NP	NN	B-protein	4	NMOD
3	induced	induce	B-VP	VBD	O	4	NMOD
4	hypotension	hypotension	B-NP	NN	O	1	PMOD
5	the	the	B-NP	DT	O	7	NMOD
6	cardiac	cardiac	I-NP	JJ	O	7	NMOD
7	output	output	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	significantly	significantly	B-ADJP	RB	O	10	AMOD
10	lower	low	B-NP	JJR	O	8	PRD
11	and	and	I-NP	CC	O	15	AMOD
12	systemic	systemic	I-NP	JJ	O	14	NMOD
13	vascular	vascular	I-NP	JJ	O	14	NMOD
14	resistance	resistance	I-NP	NN	O	15	AMOD
15	higher	high	B-ADJP	JJR	O	8	PRD
16	compared	compare	B-PP	VBN	O	15	AMOD
17	with	with	B-PP	IN	O	16	PMOD
18	that	that	B-NP	DT	O	17	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	SNP	SNP	I-NP	NN	O	22	NMOD
22	group	group	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	SPV	SPV	I-NP	NN	O	5	SUB
3	during	during	B-PP	IN	O	2	NMOD
4	hypotension	hypotension	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	15.7	15.7	B-NP	CD	O	8	AMOD
7	+/-	+/-	I-NP	SYM	O	8	AMOD
8	6.7	6.7	I-NP	CD	O	10	NMOD
9	mm	mm	I-NP	NN	O	10	NMOD
10	Hg	Hg	I-NP	NN	O	5	PRD
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	HEM	HEM	I-NP	NN	B-protein	14	NMOD
14	group	group	I-NP	NN	I-protein	11	PMOD
15	,	,	O	,	O	10	P
16	compared	compare	B-PP	VBN	O	10	NMOD
17	with	with	B-PP	IN	O	16	PMOD
18	9.1	9.1	B-NP	CD	O	20	AMOD
19	+/-	+/-	I-NP	SYM	O	20	AMOD
20	2.0	2.0	I-NP	CD	O	22	NMOD
21	mm	mm	I-NP	NN	O	22	NMOD
22	Hg	Hg	I-NP	NN	O	17	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	SNP	SNP	I-NP	NN	O	26	NMOD
26	group	group	I-NP	NN	O	23	PMOD
27	(	(	O	(	O	32	DEP
28	P	P	B-NP	NN	O	32	DEP
29	less	less	B-ADJP	JJR	O	28	NMOD
30	than	than	B-PP	IN	O	29	AMOD
31	0.02	0.02	B-NP	CD	O	30	PMOD
32	)	)	O	)	O	22	NMOD
33	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	18	SUB
2	delta	delta	I-NP	SYM	O	1	NMOD
3	down	down	B-PRT	RP	O	2	VMOD
4	,	,	O	,	O	1	P
5	which	which	B-NP	WDT	O	1	NMOD
6	is	be	B-VP	VBZ	O	5	SBAR
7	the	the	B-NP	DT	O	8	NMOD
8	measure	measure	I-NP	NN	O	6	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	decrease	decrease	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	SBP	SBP	B-NP	NN	B-protein	11	PMOD
13	after	after	B-PP	IN	O	10	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	mechanical	mechanical	I-NP	JJ	O	16	NMOD
16	breath	breath	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	1	P
18	was	be	B-VP	VBD	O	0	ROOT
19	20.3	20.3	B-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	8.4	8.4	I-NP	CD	O	25	AMOD
22	and	and	I-NP	CC	O	25	AMOD
23	10.1	10.1	I-NP	CD	O	25	AMOD
24	+/-	+/-	I-NP	SYM	O	25	AMOD
25	3.8	3.8	I-NP	CD	O	27	NMOD
26	mm	mm	I-NP	NN	O	27	NMOD
27	Hg	Hg	I-NP	NN	O	18	PRD
28	in	in	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	33	NMOD
30	HEM	HEM	I-NP	NN	O	33	NMOD
31	and	and	I-NP	CC	O	33	NMOD
32	SNP	SNP	I-NP	NN	O	33	NMOD
33	groups	group	I-NP	NNS	O	28	PMOD
34	,	,	O	,	O	27	P
35	respectively	respectively	B-ADVP	RB	O	27	NMOD
36	,	,	O	,	O	27	P
37	during	during	B-PP	IN	O	27	NMOD
38	hypotension	hypotension	B-NP	NN	O	37	PMOD
39	(	(	O	(	O	44	DEP
40	P	P	B-NP	NN	O	44	DEP
41	less	less	B-ADJP	JJR	O	40	NMOD
42	than	than	B-PP	IN	O	41	AMOD
43	0.02	0.02	B-NP	CD	O	42	PMOD
44	)	)	O	)	O	38	NMOD
45	.	.	O	.	O	18	P

1	Drug	Drug	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	arterial	arterial	B-NP	JJ	O	4	NMOD
4	spasm	spasm	I-NP	NN	O	2	OBJ
5	relieved	relieve	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	lidocaine	lidocaine	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	2	P

1	Following	Follow	B-PP	VBG	O	12	VMOD
2	major	major	B-NP	JJ	O	4	NMOD
3	intracranial	intracranial	I-NP	JJ	O	4	NMOD
4	surgery	surgery	I-NP	NN	O	1	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	35-year-old	35-year-old	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	12	P
10	sodium	sodium	B-NP	NN	O	11	NMOD
11	pentothal	pentothal	I-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	0	ROOT
13	intravenously	intravenously	I-VP	RB	O	12	VMOD
14	infused	infuse	I-VP	VBN	O	12	VC
15	to	to	I-VP	TO	O	16	VMOD
16	minimize	minimize	I-VP	VB	O	14	VMOD
17	cerebral	cerebral	B-NP	JJ	O	18	NMOD
18	ischaemia	ischaemia	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	12	P

1	Cerebral	Cerebral	B-NP	JJ	O	3	NMOD
2	blood	blood	I-NP	NN	O	3	NMOD
3	flow	flow	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	metabolism	metabolism	I-NP	NN	O	8	SUB
6	during	during	B-PP	IN	O	5	NMOD
7	isoflurane	isoflurane	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	hypotension	hypotension	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	subjected	subject	B-VP	VBN	O	11	NMOD
13	to	to	B-PP	TO	O	12	VMOD
14	surgery	surgery	B-NP	NN	O	13	PMOD
15	for	for	B-PP	IN	O	12	VMOD
16	cerebral	cerebral	B-NP	JJ	O	17	NMOD
17	aneurysms	aneurysm	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	8	P

1	Cerebral	Cerebral	B-NP	JJ	O	3	NMOD
2	blood	blood	I-NP	NN	O	3	NMOD
3	flow	flow	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	cerebral	cerebral	B-NP	JJ	O	7	NMOD
6	metabolic	metabolic	I-NP	JJ	O	7	NMOD
7	rate	rate	I-NP	NN	O	10	SUB
8	for	for	B-PP	IN	O	7	NMOD
9	oxygen	oxygen	B-NP	NN	O	8	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	measured	measure	I-VP	VBN	O	10	VC
12	during	during	B-PP	IN	O	11	VMOD
13	isoflurane	isoflurane	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	13	NMOD
15	hypotension	hypotension	B-NP	NN	O	14	OBJ
16	in	in	B-PP	IN	O	14	VMOD
17	10	10	B-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	subjected	subject	B-VP	VBN	O	18	NMOD
20	to	to	B-PP	TO	O	19	VMOD
21	craniotomy	craniotomy	B-NP	NN	O	20	PMOD
22	for	for	B-PP	IN	O	19	VMOD
23	clipping	clipping	B-NP	NN	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	a	a	B-NP	DT	O	27	NMOD
26	cerebral	cerebral	I-NP	JJ	O	27	NMOD
27	aneurysm	aneurysm	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	10	P

1	Flow	Flow	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	metabolism	metabolism	I-NP	NN	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	measured	measure	I-VP	VBN	O	4	VC
6	5-13	5-13	B-NP	JJ	O	7	NMOD
7	days	day	I-NP	NNS	O	8	PMOD
8	after	after	B-PP	IN	O	5	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	subarachnoid	subarachnoid	I-NP	JJ	O	11	NMOD
11	haemorrhage	haemorrhage	I-NP	NN	O	8	PMOD
12	by	by	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	modification	modification	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	classical	classical	I-NP	JJ	O	19	NMOD
18	Kety-Schmidt	Kety-Schmidt	I-NP	NNP	O	19	NMOD
19	technique	technique	I-NP	NN	O	15	PMOD
20	using	use	B-VP	VBG	O	5	VMOD
21	xenon-133	xenon-133	B-NP	NN	O	22	NMOD
22	i.v	i.v	I-NP	NN	O	20	OBJ
23	.	.	O	.	O	4	P

1	Controlled	Controlled	B-NP	JJ	O	2	NMOD
2	hypotension	hypotension	I-NP	NN	O	11	SUB
3	to	to	B-PP	TO	O	2	NMOD
4	an	an	B-NP	DT	O	6	NMOD
5	average	average	I-NP	JJ	O	6	NMOD
6	MAP	MAP	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	50-55	50-55	B-NP	CD	O	10	NMOD
9	mm	mm	I-NP	NN	O	10	NMOD
10	Hg	Hg	I-NP	NN	O	7	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	induced	induce	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	increasing	increase	B-VP	VBG	O	13	PMOD
15	the	the	B-NP	DT	O	16	NMOD
16	dose	dose	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	isoflurane	isoflurane	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	11	P
20	and	and	O	CC	O	11	VMOD
21	maintained	maintain	B-VP	VBD	O	11	VMOD
22	at	at	B-PP	IN	O	21	VMOD
23	an	an	B-NP	DT	O	25	NMOD
24	inspired	inspired	I-NP	JJ	O	25	NMOD
25	concentration	concentration	I-NP	NN	O	22	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	2.2	2.2	B-NP	CD	O	29	AMOD
28	+/-	+/-	I-NP	SYM	O	29	AMOD
29	0.2	0.2	I-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	26	PMOD
31	.	.	O	.	O	11	P

1	After	After	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	clipping	clipping	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	aneurysm	aneurysm	I-NP	NN	O	4	PMOD
7	the	the	B-NP	DT	O	9	NMOD
8	isoflurane	isoflurane	I-NP	NN	O	9	NMOD
9	concentration	concentration	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	reduced	reduce	I-VP	VBN	O	10	VC
12	to	to	B-PP	TO	O	11	VMOD
13	0.75	0.75	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	10	P

1	Allergic	Allergic	B-NP	JJ	O	2	NMOD
2	reaction	reaction	I-NP	NN	O	0	ROOT
3	to	to	B-PP	TO	O	2	NMOD
4	5-fluorouracil	5-fluorouracil	B-NP	NN	O	5	NMOD
5	infusion	infusion	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	3	NMOD
2	allergic	allergic	I-NP	JJ	O	3	NMOD
3	reaction	reaction	I-NP	NN	O	13	SUB
4	consisting	consist	B-VP	VBG	O	3	NMOD
5	of	of	B-PP	IN	O	4	VMOD
6	angioneurotic	angioneurotic	B-NP	JJ	O	7	NMOD
7	edema	edema	I-NP	NN	O	5	PMOD
8	secondary	secondary	B-ADJP	JJ	O	7	NMOD
9	to	to	B-PP	TO	O	8	AMOD
10	continuous	continuous	B-NP	JJ	O	12	NMOD
11	infusion	infusion	I-NP	NN	O	12	NMOD
12	5-fluorouracil	5-fluorouracil	I-NP	NN	O	9	PMOD
13	occurred	occur	B-VP	VBD	O	0	ROOT
14	in	in	B-PP	IN	O	13	VMOD
15	a	a	B-NP	DT	O	16	NMOD
16	patient	patient	I-NP	NN	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	recurrent	recurrent	B-NP	JJ	O	19	NMOD
19	carcinoma	carcinoma	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	oral	oral	I-NP	JJ	O	23	NMOD
23	cavity	cavity	I-NP	NN	O	29	SUB
24	,	,	O	,	O	29	P
25	cirrhosis	cirrhosis	B-NP	NN	O	29	SUB
26	,	,	O	,	O	29	P
27	and	and	O	CC	O	29	VMOD
28	cisplatin	cisplatin	B-NP	NN	B-protein	29	SUB
29	induced	induce	B-VP	VBD	O	20	SBAR
30	impaired	impaired	B-NP	JJ	O	32	NMOD
31	renal	renal	I-NP	JJ	O	32	NMOD
32	function	function	I-NP	NN	O	29	OBJ
33	.	.	O	.	O	13	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	sinoatrial	sinoatrial	B-NP	JJ	O	4	NMOD
4	block	block	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	observed	observe	B-VP	VBD	O	0	ROOT
3	sinoatrial	sinoatrial	B-NP	JJ	O	4	NMOD
4	block	block	I-NP	NN	O	2	OBJ
5	due	due	B-PP	JJ	O	4	NMOD
6	to	to	B-PP	TO	O	5	AMOD
7	chronic	chronic	B-NP	JJ	O	9	NMOD
8	amiodarone	amiodarone	I-NP	NN	O	9	NMOD
9	administration	administration	I-NP	NN	O	22	NMOD
10	in	in	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	5-year-old	5-year-old	I-NP	JJ	O	13	NMOD
13	boy	boy	I-NP	NN	O	10	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	primary	primary	B-NP	JJ	O	16	NMOD
16	cardiomyopathy	cardiomyopathy	I-NP	NN	O	14	PMOD
17	,	,	O	,	O	22	P
18	Wolff-Parkinson-White	Wolff-Parkinson-White	B-NP	JJ	O	19	NMOD
19	syndrome	syndrome	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	supraventricular	supraventricular	B-NP	JJ	O	22	NMOD
22	tachycardia	tachycardia	I-NP	NN	O	6	PMOD
23	.	.	O	.	O	2	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	infants	infant	I-NP	NNS	O	20	SUB
3	,	,	O	,	O	2	P
4	born	bear	B-VP	VBN	O	2	NMOD
5	of	of	B-PP	IN	O	4	VMOD
6	two	two	B-NP	CD	O	7	NMOD
7	mothers	mother	I-NP	NNS	O	5	PMOD
8	with	with	B-PP	IN	O	4	VMOD
9	inflammatory	inflammatory	B-NP	JJ	O	11	NMOD
10	bowel	bowel	I-NP	NN	O	11	NMOD
11	disease	disease	I-NP	NN	O	8	PMOD
12	who	who	B-NP	WP	O	4	VMOD
13	received	receive	B-VP	VBD	O	12	SBAR
14	treatment	treatment	B-NP	NN	O	13	OBJ
15	with	with	B-PP	IN	O	13	VMOD
16	sulphasalazine	sulphasalazine	B-NP	NN	O	15	PMOD
17	throughout	throughout	B-PP	IN	O	13	VMOD
18	pregnancy	pregnancy	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	2	P
20	were	be	B-VP	VBD	O	0	ROOT
21	found	find	I-VP	VBN	O	20	VC
22	to	to	I-VP	TO	O	23	VMOD
23	have	have	I-VP	VB	O	21	VMOD
24	major	major	B-NP	JJ	O	26	NMOD
25	congenital	congenital	I-NP	JJ	O	26	NMOD
26	anomalies	anomaly	I-NP	NNS	O	23	OBJ
27	.	.	O	.	O	20	P

1	Veno-occlusive	Veno-occlusive	B-NP	JJ	O	3	NMOD
2	liver	liver	I-NP	NN	O	3	NMOD
3	disease	disease	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	dacarbazine	dacarbazine	B-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	9	DEP
8	DTIC	DTIC	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	for	for	B-PP	IN	O	6	NMOD
11	melanoma	melanoma	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	20	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	veno-occlusive	veno-occlusive	B-NP	JJ	O	5	NMOD
5	disease	disease	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	liver	liver	I-NP	NN	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	fatal	fatal	B-NP	JJ	O	11	NMOD
11	outcome	outcome	I-NP	NN	O	9	PMOD
12	after	after	B-PP	IN	O	11	NMOD
13	dacarbazine	dacarbazine	B-NP	NN	O	17	NMOD
14	(	(	O	(	O	16	DEP
15	DTIC	DTIC	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	therapy	therapy	B-NP	NN	O	12	PMOD
18	for	for	B-PP	IN	O	17	NMOD
19	melanoma	melanoma	B-NP	NN	O	18	PMOD
20	is	be	B-VP	VBZ	O	0	ROOT
21	reported	report	I-VP	VBN	O	20	VC
22	.	.	O	.	O	20	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	tardive	tardive	B-NP	JJ	O	5	NMOD
5	dyskinesia	dyskinesia	I-NP	NN	O	3	PMOD
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	metoclopramide	metoclopramide	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	Abnormal	Abnormal	B-NP	JJ	O	3	NMOD
2	involuntary	involuntary	I-NP	JJ	O	3	NMOD
3	movements	movement	I-NP	NNS	O	4	SUB
4	appeared	appear	B-VP	VBD	O	0	ROOT
5	in	in	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	13	NMOD
7	mouth	mouth	I-NP	NN	O	13	NMOD
8	,	,	I-NP	,	O	13	P
9	tongue	tongue	I-NP	NN	O	13	NMOD
10	,	,	I-NP	,	O	13	P
11	neck	neck	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	abdomen	abdomen	I-NP	NN	O	5	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	18	NMOD
16	64-year-old	64-year-old	I-NP	JJ	O	18	NMOD
17	male	male	I-NP	JJ	O	18	NMOD
18	patient	patient	I-NP	NN	O	14	PMOD
19	after	after	B-SBAR	IN	O	4	VMOD
20	he	he	B-NP	PRP	O	21	SUB
21	took	take	B-VP	VBD	O	19	SBAR
22	metoclopramide	metoclopramide	B-NP	NN	O	21	OBJ
23	for	for	B-PP	IN	O	22	NMOD
24	gastrointestinal	gastrointestinal	B-NP	JJ	O	25	NMOD
25	disorder	disorder	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	a	a	B-NP	DT	O	28	NMOD
28	regimen	regimen	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	30	30	B-NP	CD	O	31	NMOD
31	mg	mg	I-NP	NN	O	29	PMOD
32	per	per	B-PP	IN	O	21	VMOD
33	day	day	B-NP	NN	O	32	PMOD
34	for	for	B-PP	IN	O	21	VMOD
35	a	a	B-NP	DT	O	36	NMOD
36	total	total	I-NP	NN	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	about	about	B-NP	IN	O	40	NMOD
39	260	260	I-NP	CD	O	38	AMOD
40	days	day	I-NP	NNS	O	37	PMOD
41	.	.	O	.	O	4	P

1	When	When	B-ADVP	WRB	O	12	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	metoclopramide	metoclopramide	I-NP	NN	O	4	NMOD
4	administration	administration	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	1	SBAR
6	discontinued	discontinue	I-VP	VBN	O	5	VC
7	,	,	O	,	O	12	P
8	the	the	B-NP	DT	O	10	NMOD
9	abnormal	abnormal	I-NP	JJ	O	10	NMOD
10	movements	movement	I-NP	NNS	O	12	SUB
11	gradually	gradually	B-ADVP	RB	O	12	VMOD
12	improved	improve	B-VP	VBD	O	0	ROOT
13	to	to	B-PP	TO	O	12	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	considerable	considerable	I-NP	JJ	O	16	NMOD
16	extent	extent	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	12	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	presented	present	I-VP	VBN	O	3	VC
5	of	of	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	9	NMOD
7	reversible	reversible	I-NP	JJ	O	9	NMOD
8	intra-Hisian	intra-Hisian	I-NP	JJ	O	9	NMOD
9	block	block	I-NP	NN	O	5	PMOD
10	occurring	occur	B-VP	VBG	O	9	NMOD
11	under	under	B-PP	IN	O	10	VMOD
12	amiodarone	amiodarone	B-NP	NN	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	11	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	atrial	atrial	B-NP	JJ	O	16	NMOD
16	tachycardia	tachycardia	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	13	NMOD
18	a	a	B-NP	DT	O	19	NMOD
19	patient	patient	I-NP	NN	O	17	PMOD
20	without	without	B-PP	IN	O	19	NMOD
21	clear	clear	B-NP	JJ	O	24	NMOD
22	intraventricular	intraventricular	I-NP	JJ	O	24	NMOD
23	conduction	conduction	I-NP	NN	O	24	NMOD
24	abnormalities	abnormality	I-NP	NNS	O	20	PMOD
25	.	.	O	.	O	3	P

1	Thirty	Thirty	B-NP	CD	O	2	NMOD
2	days	day	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	10	VMOD
4	amiodarone	amiodarone	B-NP	NN	O	5	NMOD
5	discontinuation	discontinuation	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	10	P
7	His	His	B-NP	PRP$	O	9	NMOD
8	bundle	bundle	I-NP	NN	O	9	NMOD
9	electrograms	electrogram	I-NP	NNS	O	10	SUB
10	showed	show	B-VP	VBD	O	0	ROOT
11	atrial	atrial	B-NP	JJ	O	12	NMOD
12	flutter	flutter	I-NP	NN	O	10	OBJ
13	without	without	B-PP	IN	O	10	VMOD
14	intra-Hisian	intra-Hisian	B-NP	JJ	O	17	NMOD
15	or	or	I-NP	CC	O	17	NMOD
16	infra-Hisian	infra-Hisian	I-NP	JJ	O	17	NMOD
17	delay	delay	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	10	P

1	Busulfan	Busulfan	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hemorrhagic	hemorrhagic	B-NP	JJ	O	4	NMOD
4	cystitis	cystitis	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	busulfan	busulfan	I-NP	NN	O	3	PMOD
6	induced	induce	B-VP	VBD	O	9	VMOD
7	hemorrhage	hemorrhage	B-NP	NN	O	8	NMOD
8	cystitis	cystitis	I-NP	NN	O	9	SUB
9	is	be	B-VP	VBZ	O	0	ROOT
10	reported	report	I-VP	VBN	O	9	VC
11	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	similarity	similarity	I-NP	NN	O	16	NMOD
3	between	between	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	histologic	histologic	I-NP	JJ	O	6	NMOD
6	appearances	appearance	I-NP	NNS	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	busulfan	busulfan	B-NP	NN	O	9	NMOD
9	cystitis	cystitis	I-NP	NN	O	7	PMOD
10	and	and	O	CC	O	16	NMOD
11	both	both	O	CC	O	16	NMOD
12	radiation	radiation	B-NP	NN	O	16	NMOD
13	and	and	I-NP	CC	O	16	NMOD
14	cyclophosphamide	cyclophosphamide	I-NP	NN	O	15	AMOD
15	induced	induce	I-NP	VBN	O	16	NMOD
16	cystitis	cystitis	I-NP	NN	O	17	SUB
17	is	be	B-VP	VBZ	O	23	VMOD
18	discussed	discuss	I-VP	VBN	O	17	VC
19	and	and	O	CC	O	23	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	world	world	I-NP	NN	O	22	NMOD
22	literature	literature	I-NP	NN	O	23	SUB
23	reviewed	review	B-VP	VBN	O	0	ROOT
24	.	.	O	.	O	23	P

1	Rebound	Rebound	B-VP	VB	O	0	ROOT
2	hypertensive	hypertensive	B-ADJP	JJ	O	1	OBJ
3	after	after	B-PP	IN	O	2	AMOD
4	sodium	sodium	B-NP	NN	O	5	NMOD
5	nitroprusside	nitroprusside	I-NP	NN	O	3	PMOD
6	prevented	prevent	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	saralasin	saralasin	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	26	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	8	NMOD
5	renin	renin	I-NP	NN	B-protein	8	NMOD
6	--	--	O	:	O	8	P
7	angiotensin	angiotensin	B-NP	NN	O	8	NMOD
8	system	system	I-NP	NN	O	3	PMOD
9	in	in	B-PP	IN	O	2	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	maintenance	maintenance	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	blood	blood	B-NP	NN	O	14	NMOD
14	pressure	pressure	I-NP	NN	O	12	PMOD
15	during	during	B-PP	IN	O	2	NMOD
16	halothane	halothane	B-NP	NN	O	17	NMOD
17	anesthesia	anesthesia	I-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	sodium	sodium	B-NP	NN	O	20	NMOD
20	nitroprusside	nitroprusside	I-NP	NN	O	25	NMOD
21	(	(	O	(	O	23	DEP
22	SNP	SNP	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	induced	induce	B-NP	VBN	O	25	NMOD
25	hypotension	hypotension	I-NP	NN	O	15	PMOD
26	was	be	B-VP	VBD	O	0	ROOT
27	evaluated	evaluate	I-VP	VBN	O	26	VC
28	.	.	O	.	O	26	P

1	During	During	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	SNP	SNP	I-NP	NN	O	4	NMOD
4	infusion	infusion	I-NP	NN	O	1	PMOD
5	the	the	B-NP	DT	O	7	NMOD
6	control	control	I-NP	NN	O	7	NMOD
7	animals	animal	I-NP	NNS	O	8	SUB
8	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	progressive	progressive	I-NP	JJ	O	11	NMOD
11	increase	increase	I-NP	NN	O	8	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	blood	blood	B-NP	NN	O	14	NMOD
14	pressure	pressure	I-NP	NN	O	12	PMOD
15	to	to	B-PP	TO	O	14	NMOD
16	61	61	B-NP	CD	O	17	NMOD
17	torr	torr	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	8	P
19	whereas	whereas	O	IN	O	8	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	saralasin-treated	saralasin-treated	I-NP	JJ	O	22	NMOD
22	animals	animal	I-NP	NNS	O	23	SUB
23	showed	show	B-VP	VBD	O	19	SBAR
24	no	no	B-NP	DT	O	25	NMOD
25	change	change	I-NP	NN	O	23	OBJ
26	.	.	O	.	O	8	P

1	Toxic	Toxic	B-NP	JJ	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	9	NMOD
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	antithyroid	antithyroid	B-NP	JJ	O	6	NMOD
6	drugs	drug	I-NP	NNS	O	4	PMOD
7	:	:	O	:	O	2	P
8	four	four	B-NP	CD	O	9	NMOD
9	cases	case	I-NP	NNS	O	0	ROOT
10	including	include	B-PP	VBG	O	9	NMOD
11	one	one	B-NP	CD	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	cross-reactivity	cross-reactivity	B-NP	NN	O	12	PMOD
14	between	between	B-PP	IN	O	13	NMOD
15	carbimazole	carbimazole	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	benzylthiouracil	benzylthiouracil	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	9	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	cholestatic	cholestatic	I-NP	JJ	O	6	NMOD
6	hepatitis	hepatitis	I-NP	NN	O	3	OBJ
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	carbimazole	carbimazole	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	13	DEP
11	N	N	B-NP	NN	O	12	NMOD
12	omercazole	omercazole	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	.	.	O	.	O	3	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	others	other	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	a	a	O	DT	O	3	OBJ
5	mixed	mixed	O	JJ	O	4	NMOD
6	(	(	O	(	O	5	AMOD
7	cholestatic	cholestatic	B-NP	JJ	O	11	NMOD
8	and	and	I-NP	CC	O	11	NMOD
9	cytolytic	cytolytic	I-NP	JJ	O	11	NMOD
10	)	)	I-NP	)	O	11	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	6	PMOD
12	following	follow	B-PP	VBG	O	11	NMOD
13	carbimazole	carbimazole	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	3	P

1	One	One	B-NP	CD	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	latter	latter	I-NP	JJ	O	6	NMOD
5	two	two	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	2	PMOD
7	further	further	B-ADVP	RBR	O	8	VMOD
8	experienced	experience	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	cytolytic	cytolytic	I-NP	JJ	O	11	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	8	OBJ
12	which	which	B-NP	WDT	O	11	NMOD
13	appeared	appear	B-VP	VBD	O	12	SBAR
14	after	after	B-PP	IN	O	13	VMOD
15	Benzylthiouracil	Benzylthiouracil	B-NP	NN	O	20	SUB
16	(	(	O	(	O	19	DEP
17	Basd	Basd	B-NP	NN	O	18	NMOD
18	ne	ne	I-NP	NN	O	19	DEP
19	)	)	O	)	O	15	NMOD
20	had	have	B-VP	VBD	O	14	SBAR
21	replaced	replace	I-VP	VBN	O	22	NMOD
22	carbimazole	carbimazole	B-NP	NN	O	20	OBJ
23	.	.	O	.	O	8	P

1	Study	Study	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	role	role	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	vitamin	vitamin	B-NP	NN	B-protein	7	NMOD
7	B12	B12	I-NP	NN	I-protein	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	folinic	folinic	B-NP	JJ	O	11	NMOD
10	acid	acid	I-NP	NN	O	11	NMOD
11	supplementation	supplementation	I-NP	NN	O	5	PMOD
12	in	in	B-PP	IN	O	1	NMOD
13	preventing	prevent	B-VP	VBG	O	12	PMOD
14	hematologic	hematologic	B-NP	JJ	O	15	NMOD
15	toxicity	toxicity	I-NP	NN	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	zidovudine	zidovudine	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	5	NMOD
2	prospective	prospective	I-NP	JJ	O	4	AMOD
3	,	,	I-NP	,	O	4	P
4	randomized	randomize	I-NP	VBN	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	conducted	conduct	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	evaluate	evaluate	I-VP	VB	O	7	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	role	role	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	vitamin	vitamin	B-NP	NN	B-protein	14	NMOD
14	B12	B12	I-NP	NN	I-protein	18	NMOD
15	and	and	O	CC	O	18	NMOD
16	folinic	folinic	B-NP	JJ	O	18	NMOD
17	acid	acid	I-NP	NN	O	18	NMOD
18	supplementation	supplementation	I-NP	NN	O	12	PMOD
19	in	in	B-PP	IN	O	9	VMOD
20	preventing	prevent	B-VP	VBG	O	19	PMOD
21	zidovudine	zidovudine	B-NP	NN	O	20	OBJ
22	(	(	O	(	O	24	DEP
23	ZDV	ZDV	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	induced	induce	B-VP	VBD	O	21	NMOD
26	bone	bone	B-NP	NN	O	28	NMOD
27	marrow	marrow	I-NP	NN	O	28	NMOD
28	suppression	suppression	I-NP	NN	O	25	OBJ
29	.	.	O	.	O	6	P

1	Seventy-five	Seventy-five	B-NP	CD	O	4	NMOD
2	human	human	I-NP	JJ	O	4	NMOD
3	immunodeficiency	immunodeficiency	I-NP	NN	O	4	NMOD
4	virus	virus	I-NP	NN	O	9	NMOD
5	(	(	O	(	O	7	DEP
6	HIV	HIV	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	-infected	-infected	B-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	16	SUB
10	with	with	B-PP	IN	O	9	NMOD
11	CD4+	CD4+	B-NP	JJ	B-protein	13	NMOD
12	cell	cell	I-NP	NN	O	13	NMOD
13	counts	count	I-NP	NNS	O	15	NMOD
14	<	<	B-NP	SYM	O	15	NMOD
15	500/mm3	500/mm3	B-NP	CD	O	10	PMOD
16	were	be	B-VP	VBD	O	0	ROOT
17	randomized	randomize	I-VP	VBN	O	16	VC
18	to	to	B-VP	TO	O	19	VMOD
19	receive	receive	I-VP	VB	O	17	VMOD
20	either	either	O	CC	O	19	VMOD
21	ZDV	ZDV	B-NP	NN	B-protein	20	PMOD
22	(	(	O	(	O	26	DEP
23	500	500	B-NP	CD	O	24	NMOD
24	mg	mg	I-NP	NN	O	25	NMOD
25	daily	daily	I-NP	JJ	O	26	DEP
26	)	)	O	)	O	21	NMOD
27	alone	alone	B-ADVP	RB	O	21	NMOD
28	(	(	O	(	O	35	DEP
29	group	group	B-NP	NN	O	30	NMOD
30	I	I	I-NP	NN	O	35	DEP
31	,	,	O	,	O	35	P
32	n	n	B-NP	NN	O	35	DEP
33	=	=	B-VP	SYM	O	32	NMOD
34	38	38	B-NP	CD	O	33	AMOD
35	)	)	O	)	O	21	NMOD
36	or	or	O	CC	O	21	NMOD
37	in	in	B-PP	IN	O	36	PMOD
38	combination	combination	B-NP	NN	O	37	PMOD
39	with	with	B-PP	IN	O	38	NMOD
40	folinic	folinic	B-NP	JJ	O	41	NMOD
41	acid	acid	I-NP	NN	O	50	NMOD
42	(	(	O	(	O	46	DEP
43	15	15	B-NP	CD	O	44	AMOD
44	mg	mg	I-NP	NN	O	46	DEP
45	daily	daily	I-NP	JJ	O	44	NMOD
46	)	)	O	)	O	41	NMOD
47	and	and	O	CC	O	50	NMOD
48	intramascular	intramascular	B-NP	JJ	O	50	NMOD
49	vitamin	vitamin	I-NP	NN	O	50	NMOD
50	B12	B12	I-NP	NN	O	39	PMOD
51	(	(	O	(	O	55	DEP
52	1000	1000	B-NP	CD	O	53	NMOD
53	micrograms	microgram	I-NP	NNS	O	55	DEP
54	monthly	monthly	B-ADJP	JJ	O	53	NMOD
55	)	)	O	)	O	50	NMOD
56	(	(	O	(	O	63	DEP
57	group	group	B-NP	NN	O	62	NMOD
58	II	II	I-NP	CD	O	57	NMOD
59	,	,	O	,	O	62	P
60	n	n	B-NP	NN	O	62	SUB
61	=	=	B-VP	SYM	O	62	VMOD
62	37	37	B-NP	CD	O	63	DEP
63	)	)	O	)	O	50	NMOD
64	.	.	O	.	O	16	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	correlation	correlation	I-NP	NN	O	2	PRD
5	between	between	B-PP	IN	O	4	NMOD
6	vitamin	vitamin	B-NP	NN	B-protein	7	NMOD
7	B12	B12	I-NP	NN	I-protein	10	NMOD
8	or	or	O	CC	O	10	NMOD
9	folate	folate	B-NP	JJ	O	10	NMOD
10	levels	level	I-NP	NNS	O	12	NMOD
11	and	and	O	CC	O	12	NMOD
12	development	development	B-NP	NN	O	5	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	myelosuppression	myelosuppression	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	confusion	confusion	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	high-dose	high-dose	I-NP	JJ	O	7	NMOD
7	infusion	infusion	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	5-fluorouracil	5-fluorouracil	B-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	folinic	folinic	B-NP	JJ	O	12	NMOD
12	acid	acid	I-NP	NN	O	8	PMOD
13	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	61-year-old	61-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	treated	treat	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	combination	combination	B-NP	NN	O	8	NMOD
8	chemotherapy	chemotherapy	I-NP	NN	O	6	PMOD
9	incorporating	incorporate	B-VP	VBG	O	8	NMOD
10	cisplatinum	cisplatinum	B-NP	NN	O	25	NMOD
11	,	,	O	,	O	25	P
12	etoposide	etoposide	B-NP	NN	O	25	NMOD
13	,	,	O	,	O	25	P
14	high-dose	high-dose	B-NP	JJ	O	15	NMOD
15	5-fluorouracil	5-fluorouracil	I-NP	NN	O	25	NMOD
16	(	(	O	(	O	22	DEP
17	2	2	B-NP	CD	O	21	NMOD
18	,	,	O	,	O	21	P
19	250	250	B-NP	CD	O	21	NMOD
20	mg/m2/24	mg/m2/24	I-NP	NN	O	21	NMOD
21	hours	hour	I-NP	NNS	O	22	DEP
22	)	)	O	)	O	15	NMOD
23	and	and	O	CC	O	25	NMOD
24	folinic	folinic	B-NP	JJ	O	25	NMOD
25	acid	acid	I-NP	NN	O	9	OBJ
26	for	for	B-PP	IN	O	8	NMOD
27	an	an	B-NP	DT	O	30	NMOD
28	inoperable	inoperable	I-NP	JJ	O	30	NMOD
29	gastric	gastric	I-NP	JJ	O	30	NMOD
30	adenocarcinoma	adenocarcinoma	I-NP	NN	O	26	PMOD
31	.	.	O	.	O	4	P

1	He	He	B-NP	PRP	O	2	SUB
2	developed	develop	B-VP	VBD	O	16	VMOD
3	acute	acute	B-NP	JJ	O	4	AMOD
4	neurologic	neurologic	I-NP	JJ	O	5	NMOD
5	symptoms	symptom	I-NP	NNS	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	mental	mental	B-NP	JJ	O	8	NMOD
8	confusion	confusion	I-NP	NN	O	12	NMOD
9	,	,	I-NP	,	O	12	P
10	disorientation	disorientation	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	irritability	irritability	I-NP	NN	O	6	PMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	VMOD
15	then	then	B-ADVP	RB	O	16	VMOD
16	lapsed	lapse	B-VP	VBD	O	0	ROOT
17	into	into	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	20	NMOD
19	deep	deep	I-NP	JJ	O	20	NMOD
20	coma	coma	I-NP	NN	O	17	PMOD
21	,	,	O	,	O	16	P
22	lasting	last	B-VP	VBG	O	16	VMOD
23	for	for	B-PP	IN	O	22	VMOD
24	approximately	approximately	B-NP	RB	O	26	NMOD
25	40	40	I-NP	CD	O	24	AMOD
26	hours	hour	I-NP	NNS	O	23	PMOD
27	during	during	B-PP	IN	O	22	VMOD
28	the	the	B-NP	DT	O	30	NMOD
29	first	first	I-NP	JJ	O	30	NMOD
30	dose	dose	I-NP	NN	O	40	NMOD
31	(	(	O	(	O	34	DEP
32	day	day	B-NP	NN	O	34	DEP
33	2	2	I-NP	CD	O	32	NMOD
34	)	)	O	)	O	30	NMOD
35	of	of	B-PP	IN	O	30	NMOD
36	5-fluorouracil	5-fluorouracil	B-NP	NN	O	35	PMOD
37	and	and	O	CC	O	40	NMOD
38	folinic	folinic	B-NP	JJ	O	40	NMOD
39	acid	acid	I-NP	NN	O	40	NMOD
40	infusion	infusion	I-NP	NN	O	27	PMOD
41	.	.	O	.	O	16	P

1	Because	Because	B-SBAR	IN	O	18	VMOD
2	folinic	folinic	B-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	SBAR
5	unlikely	unlikely	B-ADJP	JJ	O	4	PRD
6	to	to	B-VP	TO	O	7	VMOD
7	be	be	I-VP	VB	O	5	AMOD
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	this	this	B-NP	DT	O	11	NMOD
11	condition	condition	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	18	P
13	neurotoxicity	neurotoxicity	B-NP	NN	O	18	SUB
14	due	due	B-ADJP	JJ	O	13	NMOD
15	to	to	B-PP	TO	O	14	AMOD
16	high-dose	high-dose	B-NP	JJ	O	17	NMOD
17	5-fluorouracil	5-fluorouracil	I-NP	NN	O	15	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	highly	highly	I-VP	RB	O	18	VMOD
20	suspected	suspect	I-VP	VBN	O	18	VC
21	.	.	O	.	O	18	P

1	The	The	B-NP	DT	O	2	NMOD
2	pathogenesis	pathogenesis	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	5-fluorouracil	5-fluorouracil	B-NP	NN	O	5	NMOD
5	neurotoxicity	neurotoxicity	I-NP	NN	O	3	PMOD
6	may	may	B-VP	MD	O	0	ROOT
7	be	be	I-VP	VB	O	6	VC
8	due	due	B-ADVP	JJ	O	9	PMOD
9	to	to	B-PP	TO	O	7	PRD
10	a	a	B-NP	DT	O	13	NMOD
11	Krebs	Krebs	I-NP	NNP	O	13	NMOD
12	cycle	cycle	I-NP	NN	O	13	NMOD
13	blockade	blockade	I-NP	NN	O	25	NMOD
14	by	by	B-PP	IN	O	13	NMOD
15	fluoroacetate	fluoroacetate	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	fluorocitrate	fluorocitrate	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	25	P
19	thiamine	thiamine	B-NP	NN	O	20	NMOD
20	deficiency	deficiency	I-NP	NN	O	25	NMOD
21	,	,	O	,	O	25	P
22	or	or	O	CC	O	25	NMOD
23	dihydrouracil	dihydrouracil	B-NP	NN	O	25	NMOD
24	dehydrogenase	dehydrogenase	I-NP	NN	O	25	NMOD
25	deficiency	deficiency	I-NP	NN	O	9	PMOD
26	.	.	O	.	O	6	P

1	Carbamazepine	Carbamazepine	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	switched	switch	I-VP	VBN	O	2	VC
4	to	to	B-PP	TO	O	3	VMOD
5	its	its	B-NP	PRP$	O	8	NMOD
6	10-keto	10-keto	I-NP	JJ	O	8	NMOD
7	analogue	analogue	I-NP	NN	O	8	NMOD
8	oxcarbazepine	oxcarbazepine	I-NP	NN	O	4	PMOD
9	among	among	B-PP	IN	O	3	VMOD
10	six	six	B-NP	CD	O	16	NMOD
11	difficult-to-treat	difficult-to-treat	I-NP	JJ	O	12	AMOD
12	schizophrenic	schizophrenic	I-NP	JJ	O	16	NMOD
13	or	or	I-NP	CC	O	16	NMOD
14	organic	organic	I-NP	JJ	O	16	NMOD
15	psychotic	psychotic	I-NP	JJ	O	16	NMOD
16	patients	patient	I-NP	NNS	O	9	PMOD
17	using	use	B-VP	VBG	O	3	VMOD
18	concomitantly	concomitantly	B-NP	RB	O	23	NMOD
19	haloperidol	haloperidol	I-NP	NN	O	23	NMOD
20	,	,	I-NP	,	O	23	P
21	chlorpromazine	chlorpromazine	I-NP	NN	O	23	NMOD
22	or	or	I-NP	CC	O	23	NMOD
23	clozapine	clozapine	I-NP	NN	O	17	OBJ
24	.	.	O	.	O	2	P

1	Erythema	Erythema	B-NP	NN	O	5	NMOD
2	multiforme	multiforme	I-NP	JJ	O	1	AMOD
3	and	and	I-NP	CC	O	1	NMOD
4	hypersensitivity	hypersensitivity	I-NP	NN	O	5	NMOD
5	myocarditis	myocarditis	I-NP	NN	O	0	ROOT
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	ampicillin	ampicillin	B-NP	NN	B-protein	7	PMOD
9	.	.	O	.	O	5	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	erythema	erythema	B-NP	NN	O	9	NMOD
9	multiforme	multiforme	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	hypersensitivity	hypersensitivity	B-NP	NN	O	12	NMOD
12	myocarditis	myocarditis	I-NP	NN	O	7	PMOD
13	caused	cause	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	ampicillin	ampicillin	B-NP	NN	B-protein	14	PMOD
16	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	6	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	6	NMOD
5	13-year-old	13-year-old	I-NP	JJ	O	6	NMOD
6	boy	boy	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	treated	treat	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	ampicillin	ampicillin	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	gentamicin	gentamicin	I-NP	NN	O	9	PMOD
13	because	because	B-PP	IN	O	8	VMOD
14	of	of	I-PP	IN	O	13	PMOD
15	suspected	suspect	B-NP	VBN	O	16	NMOD
16	septicemia	septicemia	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	7	P

1	Immediate	Immediate	B-NP	JJ	O	3	NMOD
2	allergic	allergic	I-NP	JJ	O	3	NMOD
3	reactions	reaction	I-NP	NNS	O	0	ROOT
4	to	to	B-PP	TO	O	3	NMOD
5	amoxicillin	amoxicillin	B-NP	NN	B-protein	4	PMOD
6	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	large	large	I-NP	JJ	O	3	NMOD
3	group	group	I-NP	NN	O	13	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	suspected	suspect	B-NP	VBN	O	9	NMOD
8	allergic	allergic	I-NP	JJ	O	9	NMOD
9	reactions	reaction	I-NP	NNS	O	6	PMOD
10	to	to	B-PP	TO	O	3	NMOD
11	beta-lactam	beta-lactam	B-NP	NN	O	12	NMOD
12	antibiotics	antibiotic	I-NP	NNS	O	10	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	evaluated	evaluate	I-VP	VBN	O	13	VC
15	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	4	NMOD
2	detailed	detailed	I-NP	JJ	O	4	NMOD
3	clinical	clinical	I-NP	JJ	O	4	NMOD
4	history	history	I-NP	NN	O	22	SUB
5	,	,	O	,	O	4	P
6	together	together	B-ADVP	RB	O	7	PMOD
7	with	with	B-PP	IN	O	4	NMOD
8	skin	skin	B-NP	NN	O	9	NMOD
9	tests	test	I-NP	NNS	O	20	NMOD
10	,	,	O	,	O	20	P
11	RAST	RAST	B-NP	NN	B-protein	20	NMOD
12	(	(	O	(	O	15	DEP
13	radioallergosorbent	radioallergosorbent	B-NP	JJ	O	14	NMOD
14	test	test	I-NP	NN	O	15	DEP
15	)	)	O	)	O	11	NMOD
16	,	,	O	,	O	20	P
17	and	and	O	CC	O	20	NMOD
18	controlled	control	B-NP	VBN	O	20	NMOD
19	challenge	challenge	I-NP	NN	O	20	NMOD
20	tests	test	I-NP	NNS	O	7	PMOD
21	,	,	O	,	O	4	P
22	was	be	B-VP	VBD	O	0	ROOT
23	used	use	I-VP	VBN	O	22	VC
24	to	to	B-VP	TO	O	25	VMOD
25	establish	establish	I-VP	VB	O	23	VMOD
26	whether	whether	B-SBAR	IN	O	25	VMOD
27	patients	patient	B-NP	NNS	O	32	SUB
28	allergic	allergic	B-ADJP	JJ	O	27	NMOD
29	to	to	B-PP	TO	O	28	AMOD
30	beta-lactam	beta-lactam	B-NP	NN	O	31	NMOD
31	antibiotics	antibiotic	I-NP	NNS	O	29	PMOD
32	had	have	B-VP	VBD	O	26	SBAR
33	selective	selective	B-NP	JJ	O	36	NMOD
34	immediate	immediate	I-NP	JJ	O	36	NMOD
35	allergic	allergic	I-NP	JJ	O	36	NMOD
36	responses	response	I-NP	NNS	O	32	OBJ
37	to	to	B-PP	TO	O	32	VMOD
38	amoxicillin	amoxicillin	B-NP	NN	O	37	PMOD
39	(	(	O	(	O	41	DEP
40	AX	AX	B-NP	NN	O	41	DEP
41	)	)	O	)	O	38	NMOD
42	or	or	O	CC	O	32	VMOD
43	were	be	B-VP	VBD	O	32	VMOD
44	cross-reacting	cross-reacting	B-ADJP	JJ	O	43	PRD
45	with	with	B-PP	IN	O	44	AMOD
46	other	other	B-NP	JJ	O	48	NMOD
47	penicillin	penicillin	I-NP	NN	O	48	NMOD
48	derivatives	derivative	I-NP	NNS	O	45	PMOD
49	.	.	O	.	O	22	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	177	177	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	diagnosed	diagnose	I-VP	VBN	O	6	VC
8	as	as	B-PP	IN	O	7	VMOD
9	allergic	allergic	B-ADJP	JJ	O	8	PMOD
10	to	to	B-PP	TO	O	9	AMOD
11	beta-lactam	beta-lactam	B-NP	NN	O	12	NMOD
12	antibiotics	antibiotic	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	selected	select	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	54	54	I-NP	CD	O	2	OBJ
5	(	(	O	(	O	8	DEP
6	30.5	30.5	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	cases	case	B-NP	NNS	O	4	NMOD
10	of	of	B-PP	IN	O	4	NMOD
11	immediate	immediate	B-NP	JJ	O	13	NMOD
12	AX	AX	I-NP	NN	O	13	NMOD
13	allergy	allergy	I-NP	NN	O	10	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	good	good	B-NP	JJ	O	16	NMOD
16	tolerance	tolerance	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	PG	PG	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	2	P

1	All	All	B-NP	PDT	O	3	NMOD
2	the	the	I-NP	DT	O	3	NMOD
3	patients	patient	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	skin	skin	B-NP	NN	O	6	NMOD
6	test	test	I-NP	NN	O	18	SUB
7	negative	negative	B-ADJP	JJ	O	6	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	BPO	BPO	B-NP	NN	B-protein	8	PMOD
10	;	;	O	:	O	18	P
11	49	49	B-NP	CD	O	12	AMOD
12	of	of	B-PP	IN	O	18	SUB
13	51	51	B-NP	CD	O	12	AMOD
14	(	(	O	(	O	17	DEP
15	96	96	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	17	DEP
17	)	)	O	)	O	12	PMOD
18	were	be	B-VP	VBD	O	4	VMOD
19	also	also	B-ADVP	RB	O	18	VMOD
20	negative	negative	B-ADJP	JJ	O	18	PRD
21	to	to	B-PP	TO	O	20	AMOD
22	MDM	MDM	B-NP	NN	B-cell_type	21	PMOD
23	,	,	O	,	O	31	P
24	and	and	O	CC	O	31	DEP
25	44	44	B-NP	CD	O	26	AMOD
26	of	of	B-PP	IN	O	31	NMOD
27	46	46	B-NP	CD	O	26	AMOD
28	(	(	O	(	O	31	DEP
29	96	96	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	31	DEP
31	)	)	O	)	O	18	VMOD
32	to	to	B-PP	TO	O	18	VMOD
33	PG	PG	B-NP	NN	O	32	PMOD
34	.	.	O	.	O	4	P

1	Challenge	Challenge	B-NP	NN	O	2	NMOD
2	tests	test	I-NP	NNS	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	AX	AX	B-NP	NN	O	3	PMOD
5	were	be	B-VP	VBD	O	40	VMOD
6	performed	perform	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	23	23	B-NP	CD	O	9	NMOD
9	subjects	subject	I-NP	NNS	O	7	PMOD
10	(	(	O	(	O	13	DEP
11	43	43	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	to	to	B-VP	TO	O	15	VMOD
15	establish	establish	I-VP	VB	O	5	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	diagnosis	diagnosis	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	immediate	immediate	B-NP	JJ	O	20	AMOD
20	allergic	allergic	I-NP	JJ	O	21	NMOD
21	reaction	reaction	I-NP	NN	O	18	PMOD
22	to	to	B-PP	TO	O	21	NMOD
23	AX	AX	B-NP	NN	O	22	PMOD
24	,	,	O	,	O	32	P
25	and	and	O	CC	O	32	DEP
26	in	in	B-PP	IN	O	32	DEP
27	15	15	B-NP	CD	O	28	NMOD
28	cases	case	I-NP	NNS	O	26	PMOD
29	(	(	O	(	O	32	DEP
30	28	28	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	32	DEP
32	)	)	O	)	O	37	NMOD
33	both	both	O	CC	O	37	NMOD
34	skin	skin	B-NP	NN	O	35	NMOD
35	test	test	I-NP	NN	O	37	NMOD
36	and	and	O	CC	O	37	NMOD
37	RAST	RAST	B-NP	NN	B-protein	40	SUB
38	for	for	B-PP	IN	O	37	NMOD
39	AX	AX	B-NP	NN	O	38	PMOD
40	were	be	B-VP	VBD	O	0	ROOT
41	negative	negative	B-ADJP	JJ	O	40	PRD
42	.	.	O	.	O	40	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	largest	large	I-NP	JJS	O	5	NMOD
5	group	group	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	AX-allergic	AX-allergic	B-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	have	have	B-VP	VBP	O	9	SBAR
11	tolerated	tolerate	I-VP	VBN	O	10	VC
12	PG	PG	B-NP	NN	O	11	OBJ
13	reported	report	B-VP	VBN	O	12	NMOD
14	so	so	B-ADVP	RB	O	13	VMOD
15	far	far	I-ADVP	RB	O	14	AMOD
16	.	.	O	.	O	2	P

1	Persistent	Persistent	B-NP	JJ	O	2	NMOD
2	paralysis	paralysis	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	prolonged	prolonged	B-NP	JJ	O	5	NMOD
5	use	use	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	atracurium	atracurium	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	absence	absence	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	corticosteroids	corticosteroid	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	2	P

1	Reports	Report	B-NP	NNS	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	persistent	persistent	B-NP	JJ	O	4	NMOD
4	paralysis	paralysis	I-NP	NN	O	2	PMOD
5	after	after	B-PP	IN	O	1	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	discontinuance	discontinuance	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	these	these	B-NP	DT	O	10	NMOD
10	drugs	drug	I-NP	NNS	O	8	PMOD
11	have	have	B-VP	VBP	O	0	ROOT
12	most	most	I-VP	RBS	O	13	AMOD
13	often	often	I-VP	RB	O	11	VMOD
14	involved	involve	I-VP	VBN	O	11	VC
15	aminosteroid-based	aminosteroid-based	B-NP	JJ	O	16	NMOD
16	NMBAs	NMBA	I-NP	NNS	O	14	OBJ
17	such	such	B-PP	JJ	O	18	PMOD
18	as	as	I-PP	IN	O	16	NMOD
19	vecuronium	vecuronium	B-NP	NN	O	20	NMOD
20	bromide	bromide	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	16	P
22	especially	especially	B-ADVP	RB	O	23	AMOD
23	when	when	B-ADVP	WRB	O	16	NMOD
24	used	use	B-VP	VBN	O	23	SBAR
25	in	in	B-PP	IN	O	24	VMOD
26	conjunction	conjunction	B-NP	NN	O	25	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	corticosteroids	corticosteroid	B-NP	NNS	O	27	PMOD
29	.	.	O	.	O	11	P

1	Atracurium	Atracurium	B-NP	NNP	O	2	NMOD
2	besylate	besylate	I-NP	NN	O	7	NMOD
3	,	,	O	,	O	7	P
4	a	a	B-NP	DT	O	7	NMOD
5	short-acting	short-acting	I-NP	JJ	O	7	NMOD
6	benzylisoquinolinium	benzylisoquinolinium	I-NP	NN	O	7	NMOD
7	NMBA	NMBA	I-NP	NN	O	18	SUB
8	that	that	B-NP	WDT	O	7	NMOD
9	is	be	B-VP	VBZ	O	8	SBAR
10	eliminated	eliminate	I-VP	VBN	O	9	VC
11	independently	independently	B-ADVP	RB	O	10	VMOD
12	of	of	B-PP	IN	O	11	AMOD
13	renal	renal	B-NP	JJ	O	16	NMOD
14	or	or	I-NP	CC	O	16	NMOD
15	hepatic	hepatic	I-NP	JJ	O	16	NMOD
16	function	function	I-NP	NN	O	12	PMOD
17	,	,	O	,	O	7	P
18	has	have	B-VP	VBZ	O	0	ROOT
19	also	also	I-VP	RB	O	18	VMOD
20	been	be	I-VP	VBN	O	18	VC
21	associated	associate	I-VP	VBN	O	20	VC
22	with	with	B-PP	IN	O	21	VMOD
23	persistent	persistent	B-NP	JJ	O	24	NMOD
24	paralysis	paralysis	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	18	P
26	but	but	O	CC	O	18	VMOD
27	only	only	O	RB	O	26	DEP
28	when	when	B-ADVP	WRB	O	18	VMOD
29	used	use	B-VP	VBN	O	28	SBAR
30	with	with	B-PP	IN	O	29	VMOD
31	corticosteroids	corticosteroid	B-NP	NNS	O	30	PMOD
32	.	.	O	.	O	18	P

1	Habitual	Habitual	B-NP	JJ	O	2	NMOD
2	use	use	I-NP	NN	O	15	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	acetaminophen	acetaminophen	B-NP	NN	O	3	PMOD
5	as	as	B-PP	IN	O	2	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	risk	risk	I-NP	NN	O	8	NMOD
8	factor	factor	I-NP	NN	O	5	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	chronic	chronic	B-NP	JJ	O	11	AMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	failure	failure	I-NP	NN	O	9	PMOD
13	:	:	O	:	O	2	P
14	a	a	B-NP	DT	O	15	NMOD
15	comparison	comparison	I-NP	NN	O	0	ROOT
16	with	with	B-PP	IN	O	15	NMOD
17	phenacetin	phenacetin	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	15	P

1	Six	Six	B-NP	CD	O	3	NMOD
2	epidemiologic	epidemiologic	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	10	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	9	NMOD
6	United	United	I-NP	NNP	O	9	NMOD
7	States	State	I-NP	NNPS	O	9	NMOD
8	and	and	O	CC	O	9	NMOD
9	Europe	Europe	B-NP	NNP	O	4	SBAR
10	indicate	indicate	B-VP	VBP	O	0	ROOT
11	that	that	B-SBAR	IN	O	10	VMOD
12	habitual	habitual	B-NP	JJ	O	13	NMOD
13	use	use	I-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	phenacetin	phenacetin	B-NP	NN	O	14	PMOD
16	is	be	B-VP	VBZ	O	11	SBAR
17	associated	associate	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	development	development	I-NP	NN	O	28	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	chronic	chronic	B-NP	JJ	O	24	NMOD
23	renal	renal	I-NP	JJ	O	24	NMOD
24	failure	failure	I-NP	NN	O	21	PMOD
25	and	and	O	CC	O	28	NMOD
26	end-stage	end-stage	B-NP	JJ	O	28	NMOD
27	renal	renal	I-NP	JJ	O	28	NMOD
28	disease	disease	I-NP	NN	O	18	PMOD
29	(	(	O	(	O	31	DEP
30	ESRD	ESRD	B-NP	NN	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	,	,	O	,	O	17	P
33	with	with	B-PP	IN	O	17	VMOD
34	a	a	B-NP	DT	O	36	NMOD
35	relative	relative	I-NP	JJ	O	36	NMOD
36	risk	risk	I-NP	NN	O	33	PMOD
37	in	in	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	39	NMOD
39	range	range	I-NP	NN	O	37	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	4	4	B-NP	CD	O	43	NMOD
42	to	to	B-PP	TO	O	43	NMOD
43	19	19	B-NP	CD	O	40	PMOD
44	.	.	O	.	O	10	P

1	However	However	B-ADVP	RB	O	23	VMOD
2	,	,	O	,	O	23	P
3	three	three	B-NP	CD	O	6	NMOD
4	case	case	I-NP	NN	O	6	NMOD
5	control	control	I-NP	NN	O	6	NMOD
6	studies	study	I-NP	NNS	O	21	NMOD
7	,	,	O	,	O	21	P
8	one	one	B-NP	CD	O	21	NMOD
9	each	each	B-NP	DT	O	8	NMOD
10	in	in	B-PP	IN	O	8	NMOD
11	North	North	B-NP	NNP	O	12	NMOD
12	Carolina	Carolina	I-NP	NNP	O	10	PMOD
13	,	,	O	,	O	21	P
14	northern	northern	B-NP	JJ	O	15	NMOD
15	Maryland	Maryland	I-NP	NNP	O	21	NMOD
16	,	,	O	,	O	21	P
17	and	and	O	CC	O	21	NMOD
18	West	West	B-NP	NNP	O	19	NMOD
19	Berlin	Berlin	I-NP	NNP	O	21	NMOD
20	,	,	O	,	O	21	P
21	Germany	Germany	B-NP	NNP	O	23	VMOD
22	,	,	O	,	O	23	P
23	showed	show	B-VP	VBD	O	0	ROOT
24	that	that	B-SBAR	IN	O	23	VMOD
25	habitual	habitual	B-NP	JJ	O	26	NMOD
26	use	use	I-NP	NN	O	29	SUB
27	of	of	B-PP	IN	O	26	NMOD
28	acetaminophen	acetaminophen	B-NP	NN	O	27	PMOD
29	is	be	B-VP	VBZ	O	24	SBAR
30	also	also	I-VP	RB	O	29	VMOD
31	associated	associate	I-VP	VBN	O	29	VC
32	with	with	B-PP	IN	O	31	VMOD
33	chronic	chronic	B-NP	JJ	O	35	NMOD
34	renal	renal	I-NP	JJ	O	35	NMOD
35	failure	failure	I-NP	NN	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	ESRD	ESRD	I-NP	NN	O	32	PMOD
38	,	,	O	,	O	31	P
39	with	with	B-PP	IN	O	31	VMOD
40	a	a	B-NP	DT	O	42	NMOD
41	relative	relative	I-NP	JJ	O	42	NMOD
42	risk	risk	I-NP	NN	O	39	PMOD
43	in	in	B-PP	IN	O	42	NMOD
44	the	the	B-NP	DT	O	45	NMOD
45	range	range	I-NP	NN	O	43	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	2	2	B-NP	CD	O	49	NMOD
48	to	to	B-PP	TO	O	49	NMOD
49	4	4	B-NP	CD	O	46	PMOD
50	.	.	O	.	O	23	P

1	These	These	B-NP	DT	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	both	both	O	CC	O	8	NMOD
6	phenacetin	phenacetin	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	acetaminophen	acetaminophen	I-NP	NN	O	9	SUB
9	may	may	B-VP	MD	O	4	SBAR
10	contribute	contribute	I-VP	VB	O	9	VC
11	to	to	B-PP	TO	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	burden	burden	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	ESRD	ESRD	B-NP	NNP	O	14	PMOD
16	,	,	O	,	O	10	P
17	with	with	B-PP	IN	O	10	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	risk	risk	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	latter	latter	I-NP	JJ	O	23	SUB
23	being	be	B-VP	VBG	O	20	PMOD
24	somewhat	somewhat	B-ADJP	RB	O	25	AMOD
25	less	less	I-ADJP	JJR	O	23	PRD
26	than	than	B-PP	IN	O	25	AMOD
27	that	that	B-NP	DT	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	former	former	I-NP	JJ	O	28	PMOD
31	.	.	O	.	O	3	P

1	Reduction	Reduction	B-NP	NN	O	16	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	heparan	heparan	B-NP	NN	B-DNA	6	NMOD
4	sulphate-associated	sulphate-associated	I-NP	JJ	I-DNA	6	NMOD
5	anionic	anionic	I-NP	JJ	I-DNA	6	NMOD
6	sites	site	I-NP	NNS	I-DNA	2	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	glomerular	glomerular	I-NP	JJ	O	11	NMOD
10	basement	basement	I-NP	NN	O	11	NMOD
11	membrane	membrane	I-NP	NN	O	7	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	1	NMOD
15	streptozotocin	streptozotocin	B-NP	NN	B-protein	14	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	diabetic	diabetic	B-NP	JJ	O	18	NMOD
18	nephropathy	nephropathy	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	16	P

1	Heparan	Heparan	B-NP	NN	B-DNA	4	NMOD
2	sulphate-associated	sulphate-associated	I-NP	JJ	I-DNA	4	NMOD
3	anionic	anionic	I-NP	JJ	I-DNA	4	NMOD
4	sites	site	I-NP	NNS	I-DNA	10	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	glomerular	glomerular	I-NP	JJ	O	9	NMOD
8	basement	basement	I-NP	NN	O	9	NMOD
9	membrane	membrane	I-NP	NN	O	5	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	studied	study	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	rats	rat	B-NP	NNS	O	15	NMOD
14	8	8	B-NP	CD	O	15	NMOD
15	months	month	I-NP	NNS	O	16	PMOD
16	after	after	B-PP	IN	O	12	PMOD
17	induction	induction	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	diabetes	diabetes	B-NP	NN	O	18	PMOD
20	by	by	B-PP	IN	O	17	NMOD
21	streptozotocin	streptozotocin	B-NP	NN	O	20	PMOD
22	and	and	B-PP	CC	O	20	PMOD
23	in	in	B-PP	IN	O	20	PMOD
24	age-	age-	B-NP	NN	O	28	NMOD
25	adn	adn	I-NP	NN	O	28	NMOD
26	sex-matched	sex-matched	I-NP	JJ	O	28	NMOD
27	control	control	I-NP	NN	O	28	NMOD
28	rats	rat	I-NP	NNS	O	23	PMOD
29	,	,	O	,	O	11	P
30	employing	employ	B-VP	VBG	O	11	VMOD
31	the	the	B-NP	DT	O	35	NMOD
32	cationic	cationic	I-NP	JJ	O	35	NMOD
33	dye	dye	I-NP	NN	O	35	NMOD
34	cuprolinic	cuprolinic	I-NP	JJ	O	35	NMOD
35	blue	blue	I-NP	NN	O	30	OBJ
36	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	3	NMOD
2	nephrotoxic	nephrotoxic	I-NP	JJ	O	3	NMOD
3	action	action	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	anticancer	anticancer	B-NP	JJ	O	6	NMOD
6	drugs	drug	I-NP	NNS	O	4	PMOD
7	such	such	B-PP	JJ	O	8	PMOD
8	as	as	I-PP	IN	O	6	NMOD
9	nitrogranulogen	nitrogranulogen	B-NP	NN	O	24	NMOD
10	(	(	O	(	O	12	DEP
11	NG	NG	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	,	,	O	,	O	24	P
14	methotrexate	methotrexate	B-NP	NN	O	24	NMOD
15	(	(	O	(	O	17	DEP
16	MTX	MTX	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	,	,	O	,	O	24	P
19	5-fluorouracil	5-fluorouracil	B-NP	NN	O	24	NMOD
20	(	(	O	(	O	22	DEP
21	5-FU	5-FU	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	and	and	O	CC	O	24	NMOD
24	cyclophosphamide	cyclophosphamide	B-NP	NN	O	8	PMOD
25	(	(	O	(	O	27	DEP
26	CY	CY	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	administered	administer	B-VP	VBN	O	24	NMOD
29	alone	alone	B-ADVP	RB	O	28	VMOD
30	or	or	O	CC	O	29	DEP
31	in	in	B-PP	IN	O	29	PMOD
32	combination	combination	B-NP	NN	O	31	PMOD
33	[	[	O	(	O	24	NMOD
34	MTX	MTX	B-NP	NN	B-protein	43	SUB
35	+	+	I-NP	SYM	O	34	NMOD
36	5-FU	5-FU	I-NP	NN	O	35	AMOD
37	+	+	O	SYM	O	36	NMOD
38	CY	CY	B-NP	NN	O	42	DEP
39	(	(	O	(	O	41	DEP
40	CMF	CMF	B-NP	NN	O	41	DEP
41	)	)	O	)	O	38	NMOD
42	]	]	O	)	O	37	AMOD
43	was	be	B-VP	VBD	O	33	SBAR
44	evaluated	evaluate	I-VP	VBN	O	43	VC
45	in	in	B-PP	IN	O	44	VMOD
46	experiments	experiment	B-NP	NNS	O	45	PMOD
47	on	on	B-PP	IN	O	46	NMOD
48	Wistar	Wistar	B-NP	NNP	O	49	NMOD
49	rats	rat	I-NP	NNS	O	47	PMOD
50	.	.	O	.	O	3	P

1	CY	CY	B-NP	NN	O	2	SUB
2	caused	cause	B-VP	VBD	O	13	VMOD
3	hemorrhagic	hemorrhagic	B-NP	JJ	O	4	NMOD
4	cystitis	cystitis	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	40	40	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	rats	rat	B-NP	NNS	O	8	PMOD
10	,	,	O	,	O	13	P
11	but	but	O	CC	O	13	VMOD
12	it	it	B-NP	PRP	O	13	SUB
13	did	do	B-VP	VBD	O	0	ROOT
14	not	not	I-VP	RB	O	13	VMOD
15	cause	cause	I-VP	VB	O	13	VC
16	this	this	B-NP	DT	O	17	NMOD
17	complication	complication	I-NP	NN	O	15	OBJ
18	when	when	B-ADVP	WRB	O	15	VMOD
19	combined	combine	B-VP	VBN	O	18	SBAR
20	with	with	B-PP	IN	O	19	VMOD
21	5-FU	5-FU	B-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	MTX	MTX	I-NP	NN	B-protein	20	PMOD
24	.	.	O	.	O	13	P

1	Lithium-associated	Lithium-associated	B-NP	JJ	O	5	NMOD
2	cognitive	cognitive	I-NP	JJ	O	4	AMOD
3	and	and	I-NP	CC	O	4	AMOD
4	functional	functional	I-NP	JJ	O	5	NMOD
5	deficits	deficit	I-NP	NNS	O	16	NMOD
6	reduced	reduce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	switch	switch	I-NP	NN	O	7	PMOD
10	to	to	B-PP	TO	O	9	NMOD
11	divalproex	divalproex	B-NP	NN	O	12	NMOD
12	sodium	sodium	I-NP	NN	O	10	PMOD
13	:	:	O	:	O	5	P
14	a	a	B-NP	DT	O	16	NMOD
15	case	case	I-NP	NN	O	16	NMOD
16	series	series	I-NP	NN	O	0	ROOT
17	.	.	O	.	O	16	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Lithium	Lithium	B-NP	NN	O	4	SUB
4	remains	remain	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	first-line	first-line	I-NP	JJ	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	4	OBJ
8	for	for	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	13	NMOD
10	acute	acute	I-NP	JJ	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	maintenance	maintenance	I-NP	NN	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	8	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	bipolar	bipolar	B-NP	JJ	O	16	NMOD
16	disorder	disorder	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	1	P

1	Although	Although	B-SBAR	IN	O	41	VMOD
2	much	much	B-NP	JJ	O	3	SUB
3	has	have	B-VP	VBZ	O	1	SBAR
4	been	be	I-VP	VBN	O	3	VC
5	written	write	I-VP	VBN	O	4	VC
6	about	about	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	management	management	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	14	NMOD
11	more	more	I-NP	RBR	O	12	AMOD
12	common	common	I-NP	JJ	O	14	NMOD
13	adverse	adverse	I-NP	JJ	O	14	NMOD
14	effects	effect	I-NP	NNS	O	9	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	lithium	lithium	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	16	P
18	such	such	B-PP	JJ	O	19	PMOD
19	as	as	I-PP	IN	O	16	NMOD
20	polyuria	polyuria	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	tremor	tremor	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	41	P
24	more	more	B-NP	RBR	O	25	AMOD
25	subtle	subtle	I-NP	JJ	O	28	NMOD
26	lithium	lithium	I-NP	NN	O	28	NMOD
27	side	side	I-NP	NN	O	28	NMOD
28	effects	effect	I-NP	NNS	O	41	SUB
29	such	such	B-PP	JJ	O	30	PMOD
30	as	as	I-PP	IN	O	28	NMOD
31	cognitive	cognitive	B-NP	JJ	O	32	NMOD
32	deficits	deficit	I-NP	NNS	O	30	PMOD
33	,	,	O	,	O	41	P
34	loss	loss	B-NP	NN	O	41	SUB
35	of	of	B-PP	IN	O	34	NMOD
36	creativity	creativity	B-NP	NN	O	35	PMOD
37	,	,	O	,	O	41	P
38	and	and	O	CC	O	41	VMOD
39	functional	functional	B-NP	JJ	O	40	NMOD
40	impairments	impairment	I-NP	NNS	O	41	SUB
41	remain	remain	B-VP	VBP	O	0	ROOT
42	understudied	understudied	B-ADJP	JJ	O	41	PRD
43	.	.	O	.	O	41	P

1	This	This	B-NP	DT	O	2	NMOD
2	report	report	I-NP	NN	O	3	SUB
3	summarizes	summarize	B-VP	VBZ	O	0	ROOT
4	our	our	B-NP	PRP$	O	5	NMOD
5	experience	experience	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	switching	switch	B-VP	VBG	O	6	PMOD
8	bipolar	bipolar	B-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	OBJ
10	from	from	B-PP	IN	O	9	NMOD
11	lithium	lithium	B-NP	NN	O	10	PMOD
12	to	to	B-PP	TO	O	7	VMOD
13	divalproex	divalproex	B-NP	NN	O	14	NMOD
14	sodium	sodium	I-NP	NN	O	12	PMOD
15	to	to	B-VP	TO	O	16	VMOD
16	alleviate	alleviate	I-VP	VB	O	14	NMOD
17	such	such	B-NP	JJ	O	18	AMOD
18	cognitive	cognitive	I-NP	JJ	O	20	AMOD
19	and	and	I-NP	CC	O	20	AMOD
20	functional	functional	I-NP	JJ	O	21	NMOD
21	impairments	impairment	I-NP	NNS	O	16	OBJ
22	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	report	report	B-VP	VBP	O	0	ROOT
5	seven	seven	B-NP	CD	O	6	NMOD
6	cases	case	I-NP	NNS	O	4	OBJ
7	where	where	B-ADVP	WRB	O	6	NMOD
8	substitution	substitution	B-NP	NN	O	20	VMOD
9	of	of	B-PP	IN	O	8	NMOD
10	lithium	lithium	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	20	P
12	either	either	O	CC	O	20	VMOD
13	fully	fully	B-ADVP	RB	O	20	VMOD
14	or	or	I-ADVP	CC	O	13	AMOD
15	partially	partially	I-ADVP	RB	O	13	AMOD
16	,	,	O	,	O	20	P
17	with	with	B-PP	IN	O	20	VMOD
18	divalproex	divalproex	B-NP	NN	O	19	NMOD
19	sodium	sodium	I-NP	NN	O	17	PMOD
20	was	be	B-VP	VBD	O	7	SBAR
21	extremely	extremely	B-ADJP	RB	O	22	AMOD
22	helpful	helpful	I-ADJP	JJ	O	20	PRD
23	in	in	B-PP	IN	O	22	AMOD
24	reducing	reduce	B-VP	VBG	O	23	PMOD
25	the	the	B-NP	DT	O	32	NMOD
26	cognitive	cognitive	I-NP	JJ	O	32	NMOD
27	,	,	I-NP	,	O	32	P
28	motivational	motivational	I-NP	JJ	O	32	NMOD
29	,	,	I-NP	,	O	32	P
30	or	or	I-NP	CC	O	32	NMOD
31	creative	creative	I-NP	JJ	O	32	NMOD
32	deficits	deficit	I-NP	NNS	O	24	OBJ
33	attributed	attribute	B-VP	VBN	O	32	NMOD
34	to	to	B-PP	TO	O	33	VMOD
35	lithium	lithium	B-NP	NN	O	34	PMOD
36	in	in	B-PP	IN	O	33	VMOD
37	our	our	B-NP	PRP$	O	39	NMOD
38	bipolar	bipolar	I-NP	JJ	O	39	NMOD
39	patients	patient	I-NP	NNS	O	36	PMOD
40	.	.	O	.	O	4	P

1	Treatment	Treatment	B-NP	NN	O	25	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	previously	previously	B-NP	RB	O	4	AMOD
4	treated	treat	I-NP	VBN	O	7	NMOD
5	metastatic	metastatic	I-NP	JJ	O	7	NMOD
6	breast	breast	I-NP	NN	O	7	NMOD
7	cancer	cancer	I-NP	NN	O	2	PMOD
8	by	by	B-PP	IN	O	1	NMOD
9	mitoxantrone	mitoxantrone	B-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	48-hour	48-hour	B-NP	JJ	O	13	NMOD
12	continuous	continuous	I-NP	JJ	O	13	NMOD
13	infusion	infusion	I-NP	NN	O	8	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	high-dose	high-dose	B-NP	JJ	O	16	NMOD
16	5-FU	5-FU	I-NP	NN	O	18	NMOD
17	and	and	O	CC	O	18	NMOD
18	leucovorin	leucovorin	B-NP	NN	O	14	PMOD
19	(	(	O	(	O	21	DEP
20	MFL	MFL	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	:	:	O	:	O	1	P
23	low	low	B-NP	JJ	O	25	NMOD
24	palliative	palliative	I-NP	JJ	O	25	NMOD
25	benefit	benefit	I-NP	NN	O	29	NMOD
26	and	and	O	CC	O	29	NMOD
27	high	high	B-NP	JJ	O	29	NMOD
28	treatment-related	treatment-related	I-NP	JJ	O	29	NMOD
29	toxicity	toxicity	I-NP	NN	O	0	ROOT
30	.	.	O	.	O	29	P

1	From	From	B-PP	IN	O	9	VMOD
2	October	October	B-NP	NNP	O	1	PMOD
3	1993	1993	I-NP	CD	O	2	NMOD
4	to	to	B-PP	TO	O	2	NMOD
5	November	November	B-NP	NNP	O	4	PMOD
6	1995	1995	I-NP	CD	O	5	NMOD
7	,	,	O	,	O	9	P
8	we	we	B-NP	PRP	O	9	SUB
9	treated	treat	B-VP	VBD	O	0	ROOT
10	13	13	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	OBJ
12	with	with	B-PP	IN	O	11	NMOD
13	previously	previously	B-NP	RB	O	14	AMOD
14	chemotherapy-treated	chemotherapy-treated	I-NP	JJ	O	17	NMOD
15	metastatic	metastatic	I-NP	JJ	O	17	NMOD
16	breast	breast	I-NP	NN	O	17	NMOD
17	cancer	cancer	I-NP	NN	O	12	PMOD
18	by	by	B-PP	IN	O	9	VMOD
19	mitoxantrone	mitoxantrone	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	9	P
21	12	12	B-NP	CD	O	22	NMOD
22	mg/m2	mg/m2	I-NP	NN	O	9	OBJ
23	,	,	O	,	O	9	P
24	on	on	B-PP	IN	O	9	VMOD
25	day	day	B-NP	NN	O	29	NMOD
26	1	1	I-NP	CD	O	25	NMOD
27	and	and	O	CC	O	29	NMOD
28	continuous	continuous	B-NP	JJ	O	29	NMOD
29	infusion	infusion	I-NP	NN	O	24	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	5-FU	5-FU	B-NP	NN	O	30	PMOD
32	,	,	O	,	O	9	P
33	3000	3000	B-NP	CD	O	34	NMOD
34	mg/m2	mg/m2	I-NP	NN	O	9	VMOD
35	,	,	O	,	O	34	P
36	together	together	B-ADVP	RB	O	34	NMOD
37	with	with	B-PP	IN	O	34	NMOD
38	leucovorin	leucovorin	B-NP	NN	O	41	NMOD
39	,	,	O	,	O	41	P
40	300	300	B-NP	CD	O	41	NMOD
41	mg/m2	mg/m2	I-NP	NN	O	37	PMOD
42	,	,	O	,	O	34	P
43	for	for	B-PP	IN	O	34	NMOD
44	48	48	B-NP	CD	O	45	NMOD
45	h	h	I-NP	NN	O	43	PMOD
46	from	from	B-PP	IN	O	45	NMOD
47	day	day	B-NP	NN	O	46	PMOD
48	1	1	I-NP	CD	O	47	NMOD
49	to	to	B-PP	TO	O	45	NMOD
50	2	2	B-NP	CD	O	49	PMOD
51	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	MFL	MFL	I-NP	NNP	O	3	NMOD
3	regimen	regimen	I-NP	NN	O	4	SUB
4	achieves	achieve	B-VP	VBZ	O	0	ROOT
5	little	little	B-NP	JJ	O	7	NMOD
6	palliative	palliative	I-NP	JJ	O	7	NMOD
7	benefit	benefit	I-NP	NN	O	4	OBJ
8	and	and	O	CC	O	4	VMOD
9	induces	induce	B-VP	VBZ	O	4	VMOD
10	severe	severe	B-NP	JJ	O	11	NMOD
11	toxicity	toxicity	I-NP	NN	O	9	OBJ
12	at	at	B-PP	IN	O	9	VMOD
13	a	a	B-NP	DT	O	16	NMOD
14	fairly	fairly	I-NP	RB	O	15	AMOD
15	high	high	I-NP	JJ	O	16	NMOD
16	rate	rate	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	4	P

1	Upregulation	Upregulation	B-NP	NN	O	17	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	expression	expression	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	vasopressin	vasopressin	B-NP	NN	B-DNA	7	NMOD
7	gene	gene	I-NP	NN	I-DNA	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	the	the	B-NP	DT	O	13	NMOD
10	paraventricular	paraventricular	I-NP	JJ	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	supraoptic	supraoptic	I-NP	JJ	O	13	NMOD
13	nuclei	nucleus	I-NP	NNS	O	8	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	lithium	lithium	I-NP	NN	O	14	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	diabetes	diabetes	B-NP	NN	O	20	NMOD
19	insipidus	insipidus	I-NP	NN	O	20	NMOD
20	rat	rat	I-NP	NN	O	17	OBJ
21	.	.	O	.	O	17	P

1	The	The	B-NP	DT	O	2	NMOD
2	expression	expression	I-NP	NN	O	22	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	arginine	arginine	B-NP	NN	B-DNA	9	NMOD
5	vasopressin	vasopressin	I-NP	NN	I-DNA	9	NMOD
6	(	(	O	(	I-DNA	9	NMOD
7	AVP	AVP	B-NP	NN	I-DNA	9	NMOD
8	)	)	O	)	I-DNA	9	NMOD
9	gene	gene	B-NP	NN	I-DNA	3	PMOD
10	in	in	B-PP	IN	O	2	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	paraventricular	paraventricular	I-NP	JJ	O	18	NMOD
13	(	(	O	(	O	15	DEP
14	PVN	PVN	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	18	NMOD
17	supraoptic	supraoptic	B-NP	JJ	O	18	NMOD
18	nuclei	nucleus	I-NP	NNS	O	10	PMOD
19	(	(	O	(	O	21	DEP
20	SON	SON	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	was	be	B-VP	VBD	O	0	ROOT
23	investigated	investigate	I-VP	VBN	O	22	VC
24	in	in	B-PP	IN	O	23	VMOD
25	rats	rat	B-NP	NNS	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	lithium	lithium	B-NP	NN	O	32	NMOD
28	(	(	O	(	O	30	DEP
29	Li	Li	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	induced	induce	B-NP	VBN	O	32	NMOD
32	polyuria	polyuria	I-NP	NN	O	26	PMOD
33	,	,	O	,	O	22	P
34	using	use	B-VP	VBG	O	22	VMOD
35	in	in	B-NP	FW	O	36	AMOD
36	situ	situ	I-NP	FW	O	40	NMOD
37	hybridization	hybridization	I-NP	NN	O	38	NMOD
38	histochemistry	histochemistry	I-NP	NN	O	40	NMOD
39	and	and	I-NP	CC	O	40	NMOD
40	radioimmunoassay	radioimmunoassay	I-NP	NN	O	34	OBJ
41	.	.	O	.	O	22	P

1	The	The	B-NP	DT	O	4	NMOD
2	male	male	I-NP	JJ	O	4	NMOD
3	Wistar	Wistar	I-NP	NNP	O	4	NMOD
4	rats	rat	I-NP	NNS	O	18	SUB
5	consuming	consume	B-VP	VBG	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	diet	diet	I-NP	NN	O	5	OBJ
8	that	that	B-NP	WDT	O	7	NMOD
9	contained	contain	B-VP	VBD	O	8	SBAR
10	LiCl	LiCl	B-NP	NN	O	9	OBJ
11	(	(	O	(	O	14	DEP
12	60	60	B-NP	CD	O	13	NMOD
13	mmol/kg	mmol/kg	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	for	for	B-PP	IN	O	10	NMOD
16	4	4	B-NP	CD	O	17	NMOD
17	weeks	week	I-NP	NNS	O	15	PMOD
18	developed	develop	B-VP	VBD	O	0	ROOT
19	marked	marked	B-NP	JJ	O	20	NMOD
20	polyuria	polyuria	I-NP	NN	O	18	OBJ
21	.	.	O	.	O	18	P

1	Suxamethonium	Suxamethonium	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cardiac	cardiac	B-NP	JJ	O	4	NMOD
4	arrest	arrest	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	death	death	I-NP	NN	O	2	OBJ
7	following	follow	B-PP	VBG	O	6	NMOD
8	5	5	B-NP	CD	O	9	NMOD
9	days	day	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	immobilization	immobilization	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	report	report	I-NP	NN	O	4	SUB
4	describes	describe	B-VP	VBZ	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	12	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	cardiac	cardiac	B-NP	JJ	O	9	NMOD
9	arrest	arrest	I-NP	NN	O	7	PMOD
10	and	and	O	CC	O	12	NMOD
11	subsequent	subsequent	B-NP	JJ	O	12	NMOD
12	death	death	I-NP	NN	O	4	OBJ
13	as	as	B-PP	IN	O	4	VMOD
14	a	a	B-NP	DT	O	15	NMOD
15	result	result	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	hyperkalaemia	hyperkalaemia	B-NP	NN	O	16	PMOD
18	following	follow	B-PP	VBG	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	use	use	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	suxamethonium	suxamethonium	B-NP	NN	O	21	PMOD
23	in	in	B-PP	IN	O	20	NMOD
24	a	a	B-NP	DT	O	27	NMOD
25	23-year-old	23-year-old	I-NP	JJ	O	27	NMOD
26	Malawian	Malawian	I-NP	JJ	O	27	NMOD
27	woman	woman	I-NP	NN	O	23	PMOD
28	.	.	O	.	O	4	P

1	Forty	Forty	B-NP	CD	O	2	NMOD
2	seconds	second	I-NP	NNS	O	12	SUB
3	after	after	B-PP	IN	O	2	NMOD
4	injection	injection	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	suxamethonium	suxamethonium	B-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	bradycardia	bradycardia	B-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	arrest	arrest	I-NP	NN	O	5	PMOD
12	occurred	occur	B-VP	VBD	O	0	ROOT
13	.	.	O	.	O	12	P

1	Apart	Apart	B-ADVP	RB	O	14	VMOD
2	from	from	B-PP	IN	O	1	AMOD
3	the	the	B-NP	DT	O	4	NMOD
4	reduction	reduction	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	patient	patient	I-NP	NN	O	8	NMOD
8	's	's	B-NP	POS	O	9	NMOD
9	level	level	I-NP	NN	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	consciousness	consciousness	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	14	P
13	there	there	B-NP	EX	O	14	SUB
14	were	be	B-VP	VBD	O	0	ROOT
15	no	no	B-NP	DT	O	16	NMOD
16	signs	sign	I-NP	NNS	O	14	PRD
17	of	of	B-PP	IN	O	16	NMOD
18	motor	motor	B-NP	NN	O	20	NMOD
19	neurone	neurone	I-NP	NN	O	20	NMOD
20	damage	damage	I-NP	NN	O	17	PMOD
21	or	or	B-PP	CC	O	17	PMOD
22	of	of	B-PP	IN	O	17	PMOD
23	any	any	B-NP	DT	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	29	NMOD
26	other	other	I-NP	JJ	O	29	NMOD
27	known	know	I-NP	VBN	O	29	NMOD
28	predisposing	predispose	I-NP	VBG	O	29	NMOD
29	conditions	condition	I-NP	NNS	O	24	PMOD
30	for	for	B-PP	IN	O	23	NMOD
31	hyperkalaemia	hyperkalaemia	B-NP	NN	O	30	PMOD
32	following	follow	B-PP	VBG	O	23	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	administration	administration	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	suxamethonium	suxamethonium	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	14	P

1	An	An	B-NP	DT	O	2	NMOD
2	increase	increase	I-NP	NN	O	21	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	blood	blood	B-NP	NN	O	5	NMOD
5	pressure	pressure	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	2	P
7	accompanied	accompany	B-VP	VBN	O	2	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	atrial	atrial	B-NP	JJ	O	10	NMOD
10	fibrillation	fibrillation	I-NP	NN	O	17	NMOD
11	,	,	O	,	O	17	P
12	agitation	agitation	B-NP	NN	O	17	NMOD
13	,	,	O	,	O	17	P
14	incomprehensible	incomprehensible	B-NP	JJ	O	15	NMOD
15	shouts	shout	I-NP	NNS	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	loss	loss	B-NP	NN	O	8	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	consciousness	consciousness	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	2	P
21	was	be	B-VP	VBD	O	0	ROOT
22	observed	observe	I-VP	VBN	O	21	VC
23	in	in	B-PP	IN	O	22	VMOD
24	an	an	B-NP	DT	O	29	NMOD
25	elderly	elderly	I-NP	JJ	O	29	NMOD
26	,	,	I-NP	,	O	29	P
27	ASA	ASA	I-NP	NN	B-protein	29	NMOD
28	classification	classification	I-NP	NN	I-protein	29	NMOD
29	group	group	I-NP	NN	I-protein	23	PMOD
30	II	II	I-NP	CD	I-protein	29	NMOD
31	,	,	O	,	O	21	P
32	cardiovascularly	cardiovascularly	B-NP	RB	O	33	AMOD
33	medicated	medicate	I-NP	VBN	O	37	NMOD
34	male	male	I-NP	NN	O	37	NMOD
35	,	,	O	,	O	37	P
36	12	12	B-NP	CD	O	37	NMOD
37	min	min	I-NP	NN	O	38	PMOD
38	after	after	B-PP	IN	O	21	VMOD
39	performance	performance	B-NP	NN	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	axillary	axillary	B-NP	JJ	O	42	NMOD
42	block	block	I-NP	NN	O	40	PMOD
43	with	with	B-PP	IN	O	42	NMOD
44	mepivacaine	mepivacaine	B-NP	NN	O	46	NMOD
45	850	850	I-NP	CD	O	46	NMOD
46	mg	mg	I-NP	NN	O	43	PMOD
47	containing	contain	B-VP	VBG	O	46	NMOD
48	adrenaline	adrenaline	B-NP	NN	O	50	NMOD
49	0.225	0.225	I-NP	CD	O	50	NMOD
50	mg	mg	I-NP	NN	O	47	OBJ
51	,	,	O	,	O	38	P
52	for	for	B-PP	IN	O	38	PMOD
53	correction	correction	B-NP	NN	O	52	PMOD
54	of	of	B-PP	IN	O	53	NMOD
55	Dupuytren	Dupuytren	B-NP	NNP	O	56	NMOD
56	's	's	B-NP	POS	O	57	NMOD
57	contracture	contracture	I-NP	NN	O	54	PMOD
58	.	.	O	.	O	21	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	6	NMOD
4	main	main	I-NP	JJ	O	6	NMOD
5	pathologic	pathologic	I-NP	JJ	O	6	NMOD
6	diagnoses	diagnosis	I-NP	NNS	O	11	SUB
7	(	(	O	(	O	10	DEP
8	some	some	B-NP	DT	O	9	NMOD
9	overlap	overlap	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	were	be	B-VP	VBD	O	1	NMOD
12	acute	acute	B-NP	JJ	O	13	NMOD
13	rejection	rejection	I-NP	NN	O	38	NMOD
14	(	(	O	(	O	20	DEP
15	AR	AR	B-NP	NN	B-protein	17	NMOD
16	;	;	O	:	O	17	P
17	n	n	B-NP	NN	O	19	SUB
18	=	=	B-VP	SYM	O	19	VMOD
19	4	4	B-NP	CD	O	20	DEP
20	)	)	O	)	O	13	NMOD
21	,	,	O	,	O	38	P
22	chronic	chronic	B-NP	JJ	O	23	NMOD
23	rejection	rejection	I-NP	NN	O	38	NMOD
24	(	(	O	(	O	28	DEP
25	CR	CR	B-NP	NN	O	27	NMOD
26	;	;	O	:	O	27	P
27	n=5	n=5	B-NP	NN	O	28	DEP
28	)	)	O	)	O	23	NMOD
29	,	,	O	,	O	38	P
30	AR+CR	AR+CR	B-NP	NN	B-protein	38	NMOD
31	(	(	O	(	O	34	DEP
32	n	n	B-NP	NN	O	33	NMOD
33	=4	=4	I-NP	NN	O	34	DEP
34	)	)	O	)	O	30	NMOD
35	,	,	O	,	O	38	P
36	recurrent	recurrent	B-NP	JJ	O	38	NMOD
37	IgA	IgA	I-NP	NN	O	38	NMOD
38	nephropathy	nephropathy	I-NP	NN	O	54	NMOD
39	(	(	O	(	O	42	DEP
40	n	n	B-NP	NN	O	42	DEP
41	=5	=5	I-NP	CD	O	40	NMOD
42	)	)	O	)	O	38	NMOD
43	,	,	O	,	O	54	P
44	normal	normal	B-NP	JJ	O	45	NMOD
45	findings	finding	I-NP	NNS	O	54	NMOD
46	(	(	O	(	O	49	DEP
47	n	n	B-NP	NN	O	48	NMOD
48	=2	=2	I-NP	NN	O	49	DEP
49	)	)	O	)	O	45	NMOD
50	,	,	O	,	O	54	P
51	minimal-type	minimal-type	B-NP	JJ	O	54	NMOD
52	chronic	chronic	I-NP	JJ	O	54	NMOD
53	FK506	FK506	I-NP	NN	O	54	NMOD
54	nephropathy	nephropathy	I-NP	NN	O	11	PRD
55	(	(	O	(	O	59	DEP
56	n	n	B-NP	NN	O	59	DEP
57	=	=	B-VP	SYM	O	56	NMOD
58	9	9	B-NP	CD	O	57	AMOD
59	)	)	O	)	O	54	NMOD
60	,	,	O	,	O	11	P
61	and	and	O	CC	O	64	NMOD
62	mild-type	mild-type	B-NP	JJ	O	64	NMOD
63	FK506	FK506	I-NP	NN	O	64	NMOD
64	nephropathy	nephropathy	I-NP	NN	O	60	OBJ
65	(	(	O	(	O	69	DEP
66	n	n	B-NP	NN	O	68	SUB
67	=	=	B-VP	SYM	O	68	VMOD
68	11	11	B-NP	CD	O	69	DEP
69	)	)	O	)	O	64	NMOD
70	.	.	O	.	O	1	P

1	Of	Of	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	nonepisode	nonepisode	I-NP	JJ	O	4	NMOD
4	biopsies	biopsy	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	10	P
6	7	7	B-NP	CD	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	4	4	I-NP	CD	O	9	NMOD
9	biopsies	biopsy	I-NP	NNS	O	10	SUB
10	showed	show	B-VP	VBD	O	0	ROOT
11	minimal-type	minimal-type	B-NP	JJ	O	16	NMOD
12	and	and	I-NP	CC	O	16	NMOD
13	mild-type	mild-type	I-NP	JJ	O	16	NMOD
14	chronic	chronic	I-NP	JJ	O	16	NMOD
15	FK506	FK506	I-NP	NN	O	16	NMOD
16	nephropathy	nephropathy	I-NP	NN	O	10	OBJ
17	,	,	O	,	O	16	P
18	respectively	respectively	B-ADVP	RB	O	16	NMOD
19	.	.	O	.	O	10	P

1	Chronic	Chronic	B-NP	JJ	O	3	NMOD
2	FK506	FK506	I-NP	NN	O	3	NMOD
3	nephropathy	nephropathy	I-NP	NN	O	4	SUB
4	consisted	consist	B-VP	VBD	O	0	ROOT
5	of	of	B-PP	IN	O	4	VMOD
6	rough	rough	B-NP	JJ	O	8	AMOD
7	and	and	I-NP	CC	O	8	AMOD
8	foamy	foamy	I-NP	JJ	O	10	NMOD
9	tubular	tubular	I-NP	JJ	O	10	NMOD
10	vacuolization	vacuolization	I-NP	NN	O	16	NMOD
11	(	(	O	(	O	14	DEP
12	5	5	B-NP	CD	O	13	NMOD
13	biopsies	biopsy	I-NP	NNS	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	,	,	O	,	O	16	P
16	arteriolopathy	arteriolopathy	B-NP	NN	O	30	NMOD
17	(	(	O	(	O	26	DEP
18	angiodegeneration	angiodegeneration	B-NP	NN	O	25	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	arteriolar	arteriolar	I-NP	JJ	O	22	NMOD
22	wall	wall	I-NP	NN	O	19	PMOD
23	;	;	O	:	O	25	P
24	20	20	B-NP	CD	O	25	NMOD
25	biopsies	biopsy	I-NP	NNS	O	26	DEP
26	)	)	O	)	O	16	NMOD
27	,	,	O	,	O	30	P
28	focal	focal	B-NP	JJ	O	30	NMOD
29	segmental	segmental	I-NP	JJ	O	30	NMOD
30	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	38	NMOD
31	(	(	O	(	O	34	DEP
32	4	4	B-NP	CD	O	33	NMOD
33	biopsies	biopsy	I-NP	NNS	O	34	DEP
34	)	)	O	)	O	30	NMOD
35	and	and	O	CC	O	38	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	striped	strip	I-NP	VBN	O	38	NMOD
38	form	form	I-NP	NN	O	5	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	interstitial	interstitial	B-NP	JJ	O	41	NMOD
41	fibrosis	fibrosis	I-NP	NN	O	39	PMOD
42	(	(	O	(	O	45	DEP
43	11	11	B-NP	CD	O	44	NMOD
44	biopsies	biopsy	I-NP	NNS	O	45	DEP
45	)	)	O	)	O	38	NMOD
46	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	4	NMOD
2	serum	serum	I-NP	NN	O	4	NMOD
3	creatinine	creatinine	I-NP	NN	O	4	NMOD
4	levels	level	I-NP	NNS	O	21	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	13	NMOD
9	mild-type	mild-type	I-NP	JJ	O	13	NMOD
10	chronic	chronic	I-NP	JJ	O	13	NMOD
11	FK506	FK506	I-NP	NN	O	13	NMOD
12	nephropathy	nephropathy	I-NP	NN	O	13	NMOD
13	group	group	I-NP	NN	O	7	PMOD
14	,	,	O	,	O	4	P
15	which	which	B-NP	WDT	O	4	NMOD
16	included	include	B-VP	VBD	O	15	SBAR
17	7	7	B-NP	CD	O	19	NMOD
18	episode	episode	I-NP	NN	O	19	NMOD
19	biopsies	biopsy	I-NP	NNS	O	16	OBJ
20	,	,	O	,	O	4	P
21	were	be	B-VP	VBD	O	0	ROOT
22	statistically	statistically	B-ADJP	RB	O	23	AMOD
23	higher	high	I-ADJP	JJR	O	21	PRD
24	than	than	B-PP	IN	O	23	AMOD
25	those	those	B-NP	DT	O	24	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	31	NMOD
28	minimum-type	minimum-type	I-NP	JJ	O	31	NMOD
29	chronic	chronic	I-NP	JJ	O	31	NMOD
30	FK506-nephropathy	FK506-nephropathy	I-NP	NN	O	31	NMOD
31	group	group	I-NP	NN	O	26	PMOD
32	(	(	O	(	O	36	DEP
33	P	P	B-NP	NN	O	35	SUB
34	<	<	O	SYM	O	35	VMOD
35	0.001	0.001	B-NP	CD	O	36	DEP
36	)	)	O	)	O	23	AMOD
37	.	.	O	.	O	21	P

1	In	In	B-PP	IN	O	15	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	mouse	mouse	I-NP	NN	O	5	NMOD
4	passive-avoidance	passive-avoidance	I-NP	NN	O	5	NMOD
5	test	test	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	15	P
7	PG-9	PG-9	B-NP	NN	B-protein	15	SUB
8	(	(	O	(	O	13	DEP
9	10-30	10-30	B-NP	CD	O	10	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	13	DEP
11	,	,	O	,	O	10	P
12	i.p.	i.p.	B-ADVP	RB	O	10	NMOD
13	)	)	O	)	O	7	NMOD
14	,	,	O	,	O	7	P
15	administered	administer	B-VP	VBN	O	17	NMOD
16	20	20	B-NP	CD	O	17	NMOD
17	min	min	I-NP	NN	O	23	SUB
18	before	before	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	training	training	I-NP	NN	O	21	NMOD
21	session	session	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	17	P
23	prevented	prevent	B-VP	VBD	O	0	ROOT
24	amnesia	amnesia	B-NP	NN	O	23	OBJ
25	induced	induce	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	both	both	O	CC	O	38	NMOD
28	the	the	B-NP	DT	O	33	NMOD
29	non	non	I-NP	JJ	O	33	NMOD
30	selective	selective	I-NP	JJ	O	33	NMOD
31	antimuscarinic	antimuscarinic	I-NP	JJ	O	33	NMOD
32	drug	drug	I-NP	NN	O	33	NMOD
33	scopolamine	scopolamine	I-NP	NN	O	38	NMOD
34	and	and	O	CC	O	38	NMOD
35	the	the	B-NP	DT	O	38	NMOD
36	M1-selective	M1-selective	I-NP	JJ	O	38	NMOD
37	antagonist	antagonist	I-NP	NN	O	38	NMOD
38	S-	S-	I-NP	NN	O	42	NMOD
39	(	(	O	(	O	41	DEP
40	-	-	O	SYM	O	41	DEP
41	)	)	O	)	O	38	NMOD
42	-ET-126	-ET-126	B-NP	NN	O	26	PMOD
43	.	.	O	.	O	23	P

1	In	In	B-PP	IN	O	16	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	same	same	I-NP	JJ	O	5	NMOD
4	experimental	experimental	I-NP	JJ	O	5	NMOD
5	conditions	condition	I-NP	NNS	O	1	PMOD
6	,	,	O	,	O	16	P
7	PG-9	PG-9	B-NP	NN	B-protein	16	SUB
8	(	(	O	(	O	15	DEP
9	5-20	5-20	B-NP	CD	O	10	NMOD
10	microg	microg	I-NP	NN	O	15	DEP
11	per	per	B-PP	IN	O	10	NMOD
12	mouse	mouse	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	10	P
14	i.c.v.	i.c.v.	B-ADJP	JJ	O	10	NMOD
15	)	)	O	)	O	7	NMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	also	also	B-ADVP	RB	O	16	VMOD
18	able	able	B-ADJP	JJ	O	16	PRD
19	to	to	B-VP	TO	O	20	VMOD
20	prevent	prevent	I-VP	VB	O	18	AMOD
21	antimuscarine	antimuscarine	B-NP	JJ	O	23	NMOD
22	induced	induce	I-NP	VBN	O	23	NMOD
23	amnesia	amnesia	I-NP	NN	O	20	OBJ
24	,	,	O	,	O	16	P
25	demonstrating	demonstrate	B-VP	VBG	O	16	VMOD
26	a	a	B-NP	DT	O	28	NMOD
27	central	central	I-NP	JJ	O	28	NMOD
28	localization	localization	I-NP	NN	O	25	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	activity	activity	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	16	P

1	Angioedema	Angioedema	B-NP	NN	O	0	ROOT
2	due	due	B-ADJP	JJ	O	1	NMOD
3	to	to	B-PP	TO	O	2	AMOD
4	ACE	ACE	B-NP	NN	O	5	NMOD
5	inhibitors	inhibitor	I-NP	NNS	O	3	PMOD
6	:	:	O	:	O	1	P
7	common	common	B-ADJP	JJ	O	10	AMOD
8	and	and	O	CC	O	10	AMOD
9	inadequately	inadequately	B-ADJP	RB	O	10	AMOD
10	diagnosed	diagnose	I-ADJP	VBN	O	1	NMOD
11	.	.	O	.	O	1	P

1	Recurrent	Recurrent	B-NP	JJ	O	2	NMOD
2	use	use	I-NP	NN	O	9	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	newer	new	B-NP	JJR	O	6	NMOD
5	oral	oral	I-NP	JJ	O	6	NMOD
6	contraceptives	contraceptive	I-NP	NNS	O	3	PMOD
7	and	and	O	CC	O	9	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	risk	risk	I-NP	NN	O	0	ROOT
10	of	of	B-PP	IN	O	9	NMOD
11	venous	venous	B-NP	JJ	O	12	NMOD
12	thromboembolism	thromboembolism	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	epidemiological	epidemiological	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	22	SUB
4	that	that	B-NP	WDT	O	3	NMOD
5	assessed	assess	B-VP	VBD	O	4	SBAR
6	the	the	B-NP	DT	O	7	NMOD
7	risk	risk	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	venous	venous	B-NP	JJ	O	10	NMOD
10	thromboembolism	thromboembolism	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	VTE	VTE	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	associated	associate	B-VP	VBN	O	7	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	newer	new	B-NP	JJR	O	18	NMOD
17	oral	oral	I-NP	JJ	O	18	NMOD
18	contraceptives	contraceptive	I-NP	NNS	O	15	PMOD
19	(	(	O	(	O	21	DEP
20	OC	OC	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	did	do	B-VP	VBD	O	0	ROOT
23	not	not	I-VP	RB	O	22	VMOD
24	distinguish	distinguish	I-VP	VB	O	22	VC
25	between	between	B-PP	IN	O	24	VMOD
26	patterns	pattern	B-NP	NNS	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	OC	OC	B-NP	NN	O	29	NMOD
29	use	use	I-NP	NN	O	37	NMOD
30	,	,	O	,	O	37	P
31	namely	namely	B-NP	RB	O	32	AMOD
32	first-time	first-time	I-NP	JJ	O	33	NMOD
33	users	user	I-NP	NNS	O	37	NMOD
34	,	,	O	,	O	37	P
35	repeaters	repeater	B-NP	NNS	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	switchers	switcher	I-NP	NNS	O	27	PMOD
38	.	.	O	.	O	22	P

1	The	The	B-NP	DT	O	4	NMOD
2	adjusted	adjust	I-NP	VBN	O	4	NMOD
3	rate	rate	I-NP	NN	O	4	NMOD
4	ratio	ratio	I-NP	NN	O	14	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	VTE	VTE	B-NP	NN	O	5	PMOD
7	for	for	B-PP	IN	O	4	NMOD
8	repeat	repeat	B-NP	NN	O	9	NMOD
9	users	user	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	third	third	B-NP	JJ	O	13	NMOD
12	generation	generation	I-NP	NN	O	13	NMOD
13	OC	OC	I-NP	NN	O	10	PMOD
14	was	be	B-VP	VBD	O	32	VMOD
15	0.6	0.6	B-NP	CD	O	14	OBJ
16	(	(	O	(	O	22	DEP
17	95	95	B-NP	CD	O	19	NMOD
18	%	%	I-NP	NN	O	19	NMOD
19	CI	CI	I-NP	NN	O	21	NMOD
20	:	:	O	:	O	21	P
21	0.3-1.2	0.3-1.2	B-NP	CD	O	22	DEP
22	)	)	O	)	O	15	NMOD
23	relative	relative	B-ADJP	JJ	O	15	NMOD
24	to	to	B-VP	TO	O	25	VMOD
25	repeat	repeat	I-VP	VB	O	23	AMOD
26	users	user	B-NP	NNS	O	25	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	second	second	B-NP	JJ	O	30	NMOD
29	generation	generation	I-NP	NN	O	30	NMOD
30	pills	pill	I-NP	NNS	O	27	PMOD
31	,	,	O	,	O	32	P
32	whereas	whereas	O	IN	O	0	ROOT
33	it	it	B-NP	PRP	O	34	SUB
34	was	be	B-VP	VBD	O	32	VMOD
35	1.3	1.3	B-NP	CD	O	34	PRD
36	(	(	O	(	O	42	DEP
37	95	95	B-NP	CD	O	39	NMOD
38	%	%	I-NP	NN	O	39	NMOD
39	CI	CI	I-NP	NN	O	41	NMOD
40	:	:	O	:	O	41	P
41	0.7-2.4	0.7-2.4	B-NP	CD	O	42	DEP
42	)	)	O	)	O	35	NMOD
43	for	for	B-PP	IN	O	34	VMOD
44	switchers	switcher	B-NP	NNS	O	43	PMOD
45	from	from	B-PP	IN	O	44	NMOD
46	second	second	B-NP	JJ	O	45	PMOD
47	to	to	B-PP	TO	O	45	PMOD
48	third	third	B-NP	JJ	O	47	PMOD
49	generation	generation	I-NP	NN	O	47	PMOD
50	pills	pill	I-NP	NNS	O	47	PMOD
51	relative	relative	B-ADVP	JJ	O	34	VMOD
52	to	to	B-PP	TO	O	51	AMOD
53	switchers	switcher	B-NP	NNS	O	52	PMOD
54	from	from	B-PP	IN	O	53	NMOD
55	third	third	B-ADJP	JJ	O	54	PMOD
56	to	to	B-PP	TO	O	54	PMOD
57	second	second	B-NP	JJ	O	59	NMOD
58	generation	generation	I-NP	NN	O	59	NMOD
59	pills	pill	I-NP	NNS	O	56	PMOD
60	.	.	O	.	O	32	P

1	Development	Development	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	apomorphine	apomorphine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	aggressive	aggressive	B-NP	JJ	O	6	NMOD
6	behavior	behavior	I-NP	NN	O	4	OBJ
7	:	:	O	:	O	4	P
8	comparison	comparison	B-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	adult	adult	B-NP	JJ	O	15	NMOD
11	male	male	I-NP	JJ	O	15	NMOD
12	and	and	I-NP	CC	O	15	NMOD
13	female	female	I-NP	JJ	O	15	NMOD
14	Wistar	Wistar	I-NP	NNP	O	15	NMOD
15	rats	rat	I-NP	NNS	O	9	PMOD
16	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	development	development	I-NP	NN	O	27	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	apomorphine	apomorphine	B-NP	NN	O	14	NMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	(	(	O	(	O	12	DEP
7	1.0	1.0	B-NP	CD	O	9	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	9	NMOD
9	s.c.	s.c.	I-NP	NN	O	12	DEP
10	once	once	B-ADVP	RB	O	9	NMOD
11	daily	daily	I-ADVP	RB	O	10	AMOD
12	)	)	O	)	O	4	NMOD
13	aggressive	aggressive	B-NP	JJ	O	14	NMOD
14	behavior	behavior	I-NP	NN	O	3	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	adult	adult	B-NP	JJ	O	21	NMOD
17	male	male	I-NP	JJ	O	21	NMOD
18	and	and	I-NP	CC	O	21	NMOD
19	female	female	I-NP	JJ	O	21	NMOD
20	Wistar	Wistar	I-NP	NNP	O	21	NMOD
21	rats	rat	I-NP	NNS	O	15	PMOD
22	obtained	obtain	B-VP	VBN	O	21	NMOD
23	from	from	B-PP	IN	O	22	VMOD
24	the	the	B-NP	DT	O	26	NMOD
25	same	same	I-NP	JJ	O	26	NMOD
26	breeder	breeder	I-NP	NN	O	23	PMOD
27	was	be	B-VP	VBD	O	0	ROOT
28	studied	study	I-VP	VBN	O	27	VC
29	in	in	B-PP	IN	O	28	VMOD
30	two	two	B-NP	CD	O	32	NMOD
31	consecutive	consecutive	I-NP	JJ	O	32	NMOD
32	sets	set	I-NP	NNS	O	29	PMOD
33	.	.	O	.	O	27	P

1	In	In	B-PP	IN	O	8	VMOD
2	male	male	B-NP	JJ	O	3	NMOD
3	animals	animal	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	8	P
5	repeated	repeat	B-NP	VBN	O	7	NMOD
6	apomorphine	apomorphine	I-NP	NN	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	8	SUB
8	induced	induce	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	gradual	gradual	I-NP	JJ	O	11	NMOD
11	development	development	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	aggressive	aggressive	B-NP	JJ	O	14	NMOD
14	behavior	behavior	I-NP	NN	O	12	PMOD
15	as	as	B-SBAR	IN	O	8	VMOD
16	evidenced	evidence	B-VP	VBN	O	15	SBAR
17	by	by	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	increased	increase	I-NP	VBN	O	20	NMOD
20	intensity	intensity	I-NP	NN	O	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	aggressiveness	aggressiveness	B-NP	NN	O	21	PMOD
23	and	and	O	CC	O	8	VMOD
24	shortened	shorten	B-VP	VBD	O	8	VMOD
25	latency	latency	B-NP	NN	O	24	OBJ
26	before	before	B-PP	IN	O	24	VMOD
27	the	the	B-NP	DT	O	29	NMOD
28	first	first	I-NP	JJ	O	29	NMOD
29	attack	attack	I-NP	NN	O	26	PMOD
30	toward	toward	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	32	NMOD
32	opponent	opponent	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	8	P

1	Serotonergic	Serotonergic	B-NP	JJ	O	2	NMOD
2	antidepressants	antidepressant	I-NP	NNS	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	urinary	urinary	B-NP	JJ	O	5	NMOD
5	incontinence	incontinence	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	This	This	B-NP	DT	O	2	SUB
2	concerns	concern	B-VP	VBZ	O	0	ROOT
3	2	2	B-NP	CD	O	5	NMOD
4	male	male	I-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	experienced	experience	B-VP	VBD	O	6	SBAR
8	incontinence	incontinence	B-NP	NN	O	7	OBJ
9	while	while	B-SBAR	IN	O	7	VMOD
10	taking	take	B-VP	VBG	O	9	SBAR
11	venlafaxine	venlafaxine	B-NP	NN	O	10	OBJ
12	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	paper	paper	I-NP	NN	O	1	PMOD
5	the	the	B-NP	DT	O	6	NMOD
6	authors	author	I-NP	NNS	O	7	SUB
7	describe	describe	B-VP	VBP	O	0	ROOT
8	2	2	B-NP	CD	O	10	NMOD
9	female	female	I-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	7	OBJ
11	who	who	B-NP	WP	O	10	NMOD
12	developed	develop	B-VP	VBD	O	11	SBAR
13	incontinence	incontinence	B-NP	NN	O	12	OBJ
14	secondary	secondary	B-ADJP	JJ	O	13	NMOD
15	to	to	B-PP	TO	O	14	AMOD
16	the	the	B-NP	DT	O	20	NMOD
17	selective	selective	I-NP	JJ	O	20	NMOD
18	serotonin	serotonin	I-NP	NN	O	20	NMOD
19	reuptake	reuptake	I-NP	NN	O	20	NMOD
20	inhibitors	inhibitor	I-NP	NNS	O	23	NMOD
21	paroxetine	paroxetine	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	sertraline	sertraline	I-NP	NN	O	15	PMOD
24	,	,	O	,	O	7	P
25	as	as	B-CONJP	RB	O	29	NMOD
26	well	well	I-CONJP	RB	O	25	DEP
27	as	as	I-CONJP	IN	O	25	DEP
28	a	a	B-NP	DT	O	29	NMOD
29	third	third	I-NP	JJ	O	7	VMOD
30	who	who	B-NP	WP	O	29	NMOD
31	developed	develop	B-VP	VBD	O	30	SBAR
32	this	this	B-NP	DT	O	34	NMOD
33	side	side	I-NP	NN	O	34	NMOD
34	effect	effect	I-NP	NN	O	31	OBJ
35	on	on	B-PP	IN	O	34	NMOD
36	venlafaxine	venlafaxine	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	9	VMOD
2	2	2	B-NP	CD	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	3	3	I-NP	CD	O	6	NMOD
6	cases	case	I-NP	NNS	O	3	PMOD
7	the	the	B-NP	DT	O	8	NMOD
8	patients	patient	I-NP	NNS	O	9	SUB
9	were	be	B-VP	VBD	O	0	ROOT
10	also	also	I-VP	RB	O	9	VMOD
11	taking	take	I-VP	VBG	O	9	VMOD
12	lithium	lithium	B-NP	NN	O	13	NMOD
13	carbonate	carbonate	I-NP	NN	O	15	NMOD
14	and	and	O	CC	O	15	NMOD
15	beta-blockers	beta-blocker	B-NP	NNS	O	11	OBJ
16	,	,	O	,	O	9	P
17	both	both	B-NP	DT	O	18	NMOD
18	of	of	B-PP	IN	O	9	VMOD
19	which	which	B-NP	WDT	O	18	PMOD
20	could	could	B-VP	MD	O	18	SBAR
21	have	have	I-VP	VB	O	20	VC
22	contributed	contribute	I-VP	VBN	O	21	VC
23	to	to	B-PP	TO	O	22	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	incontinence	incontinence	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	9	P

1	Hypotension	Hypotension	B-NP	NN	O	0	ROOT
2	following	follow	B-PP	VBG	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	initiation	initiation	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	tizanidine	tizanidine	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	1	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	an	an	B-NP	DT	O	13	NMOD
13	angiotensin	angiotensin	I-NP	NN	O	11	PMOD
14	converting	convert	B-VP	VBG	O	13	NMOD
15	enzyme	enzyme	B-NP	NN	O	16	NMOD
16	inhibitor	inhibitor	I-NP	NN	O	14	OBJ
17	for	for	B-PP	IN	O	16	NMOD
18	chronic	chronic	B-NP	JJ	O	19	NMOD
19	hypertension	hypertension	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	1	P

1	Adults	Adult	B-NP	NNS	O	9	SUB
2	chronically	chronically	B-VP	RB	O	3	VMOD
3	treated	treat	I-VP	VBN	O	1	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	angiotensin	angiotensin	B-NP	NN	O	4	PMOD
6	converting	convert	B-VP	VBG	O	5	NMOD
7	enzyme	enzyme	B-NP	NN	O	8	NMOD
8	inhibitors	inhibitor	I-NP	NNS	O	6	OBJ
9	may	may	B-VP	MD	O	0	ROOT
10	have	have	I-VP	VB	O	9	VC
11	a	a	B-NP	DT	O	13	NMOD
12	limited	limit	I-NP	VBN	O	13	NMOD
13	ability	ability	I-NP	NN	O	10	OBJ
14	to	to	B-VP	TO	O	15	VMOD
15	respond	respond	I-VP	VB	O	13	NMOD
16	to	to	B-PP	TO	O	15	VMOD
17	hypotension	hypotension	B-NP	NN	O	16	PMOD
18	when	when	B-ADVP	WRB	O	10	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	sympathetic	sympathetic	I-NP	JJ	O	21	NMOD
21	response	response	I-NP	NN	O	22	SUB
22	is	be	B-VP	VBZ	O	18	SBAR
23	simultaneously	simultaneously	I-VP	RB	O	22	VMOD
24	blocked	block	I-VP	VBN	O	22	VC
25	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	present	present	B-VP	VBP	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	10-year-old	10-year-old	I-NP	JJ	O	6	NMOD
6	boy	boy	I-NP	NN	O	3	OBJ
7	chronically	chronically	B-VP	RB	O	8	VMOD
8	treated	treat	I-VP	VBN	O	6	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	lisinopril	lisinopril	B-NP	NN	O	13	NMOD
11	,	,	O	,	O	13	P
12	an	an	B-NP	DT	O	13	NMOD
13	angiotensin	angiotensin	I-NP	NN	O	9	PMOD
14	converting	convert	B-VP	VBG	O	13	NMOD
15	enzyme	enzyme	B-NP	NN	O	16	NMOD
16	inhibitor	inhibitor	I-NP	NN	O	14	OBJ
17	,	,	O	,	O	3	P
18	to	to	B-VP	TO	O	19	VMOD
19	control	control	I-VP	VB	O	3	VMOD
20	hypertension	hypertension	B-NP	NN	O	19	OBJ
21	who	who	B-NP	WP	O	20	NMOD
22	developed	develop	B-VP	VBD	O	21	SBAR
23	hypotension	hypotension	B-NP	NN	O	22	OBJ
24	following	follow	B-PP	VBG	O	22	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	addition	addition	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	tizanidine	tizanidine	B-NP	NN	O	32	NMOD
29	,	,	O	,	O	32	P
30	an	an	B-NP	DT	O	32	NMOD
31	alpha-2	alpha-2	I-NP	NN	O	32	NMOD
32	agonist	agonist	I-NP	NN	O	27	PMOD
33	,	,	O	,	O	3	P
34	for	for	B-PP	IN	O	3	VMOD
35	the	the	B-NP	DT	O	36	NMOD
36	treatment	treatment	I-NP	NN	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	spasticity	spasticity	B-NP	NN	O	37	PMOD
39	.	.	O	.	O	3	P

1	These	These	B-NP	DT	O	4	NMOD
2	13	13	I-NP	CD	O	4	NMOD
3	included	include	I-NP	VBN	O	4	NMOD
4	cases	case	I-NP	NNS	O	25	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	malignant	malignant	B-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	25	P
9	thrombotic	thrombotic	B-NP	JJ	O	10	NMOD
10	microangiopathy	microangiopathy	I-NP	NN	O	25	NMOD
11	,	,	O	,	O	25	P
12	lupus	lupus	B-NP	NN	O	13	NMOD
13	nephritis	nephritis	I-NP	NN	O	25	NMOD
14	,	,	O	,	O	25	P
15	Henoch-Schonlein	Henoch-Schonlein	B-NP	NN	O	16	NMOD
16	nephritis	nephritis	I-NP	NN	O	25	NMOD
17	,	,	O	,	O	25	P
18	crescentic	crescentic	B-NP	JJ	O	19	NMOD
19	glomerulonephritis	glomerulonephritis	I-NP	NN	O	25	NMOD
20	,	,	O	,	O	25	P
21	and	and	O	CC	O	25	NMOD
22	cocaine-related	cocaine-related	B-NP	JJ	O	25	NMOD
23	acute	acute	I-NP	JJ	O	25	NMOD
24	renal	renal	I-NP	JJ	O	25	NMOD
25	failure	failure	I-NP	NN	O	0	ROOT
26	.	.	O	.	O	25	P

1	In	In	B-PP	IN	O	16	VMOD
2	behavioral	behavioral	B-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	16	P
5	pre-treatment	pre-treatment	B-NP	NN	O	16	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	mice	mouse	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	5	NMOD
9	BD1018	BD1018	B-NP	NN	O	14	NMOD
10	,	,	O	,	O	14	P
11	BD1063	BD1063	B-NP	NN	O	14	NMOD
12	,	,	O	,	O	14	P
13	or	or	O	CC	O	14	NMOD
14	LR132	LR132	B-NP	NN	O	8	PMOD
15	significantly	significantly	B-ADVP	RB	O	16	VMOD
16	attenuated	attenuate	B-VP	VBD	O	0	ROOT
17	cocaine	cocaine	B-NP	NN	O	19	NMOD
18	induced	induced	I-NP	JJ	O	19	NMOD
19	convulsions	convulsion	I-NP	NNS	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	lethality	lethality	I-NP	NN	O	16	OBJ
22	.	.	O	.	O	16	P

1	In	In	B-PP	IN	O	0	ROOT
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	to	to	B-PP	TO	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	protection	protection	I-NP	NN	O	3	PMOD
6	provided	provide	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	putative	putative	I-NP	JJ	O	10	NMOD
10	antagonists	antagonist	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	1	VMOD
12	the	the	B-NP	DT	O	17	NMOD
13	well-characterized	well-characterized	I-NP	JJ	O	17	NMOD
14	sigma	sigma	I-NP	NN	O	17	NMOD
15	receptor	receptor	I-NP	NN	O	17	NMOD
16	agonist	agonist	I-NP	NN	O	17	NMOD
17	di-o-tolylguanidine	di-o-tolylguanidine	I-NP	NN	O	27	NMOD
18	(	(	O	(	O	20	DEP
19	DTG	DTG	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	and	and	O	CC	O	27	NMOD
22	the	the	B-NP	DT	O	27	NMOD
23	novel	novel	I-NP	JJ	O	27	NMOD
24	sigma	sigma	I-NP	NN	O	27	NMOD
25	receptor	receptor	I-NP	NN	O	27	NMOD
26	agonist	agonist	I-NP	NN	O	27	NMOD
27	BD1031	BD1031	I-NP	NN	O	11	NMOD
28	(	(	O	(	O	46	DEP
29	3R-1-	3R-1-	B-NP	NN	O	39	NMOD
30	[	[	O	(	O	38	DEP
31	2-	2-	B-NP	CD	O	38	DEP
32	(	(	O	(	O	38	DEP
33	3	3	B-NP	CD	O	37	NMOD
34	,	,	O	,	O	37	P
35	4-dichlorophenyl	4-dichlorophenyl	B-NP	NN	O	37	NMOD
36	)	)	O	)	O	37	NMOD
37	ethyl	ethyl	B-NP	NN	O	38	DEP
38	]	]	O	)	O	39	NMOD
39	-1	-1	B-NP	NN	O	45	NMOD
40	,	,	O	,	O	45	P
41	4-diazabicyclo	4-diazabicyclo	B-NP	NN	O	45	NMOD
42	[	[	O	(	O	44	DEP
43	4.3.0	4.3.0	B-NP	CD	O	44	DEP
44	]	]	O	)	O	45	NMOD
45	nonane	nonane	B-NP	NN	O	46	DEP
46	)	)	O	)	O	27	NMOD
47	each	each	B-NP	DT	O	27	NMOD
48	worsened	worsen	B-VP	VBD	O	47	SBAR
49	the	the	B-NP	DT	O	51	NMOD
50	behavioral	behavioral	I-NP	JJ	O	51	NMOD
51	toxicity	toxicity	I-NP	NN	O	48	OBJ
52	of	of	B-PP	IN	O	51	NMOD
53	cocaine	cocaine	B-NP	NN	O	52	PMOD
54	.	.	O	.	O	27	P

1	To	To	B-VP	TO	O	3	VMOD
2	further	further	I-VP	RB	O	3	VMOD
3	validate	validate	I-VP	VB	O	26	SUB
4	the	the	B-NP	DT	O	5	NMOD
5	hypothesis	hypothesis	I-NP	NN	O	3	OBJ
6	that	that	B-SBAR	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	anti-cocaine	anti-cocaine	I-NP	JJ	O	9	NMOD
9	effects	effect	I-NP	NNS	O	14	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	novel	novel	I-NP	JJ	O	13	NMOD
13	ligands	ligand	I-NP	NNS	O	10	PMOD
14	involved	involve	B-VP	VBD	O	6	SBAR
15	antagonism	antagonism	B-NP	NN	O	22	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	sigma	sigma	B-NP	NN	B-protein	18	NMOD
18	receptors	receptor	I-NP	NNS	I-protein	16	PMOD
19	,	,	O	,	O	22	P
20	an	an	B-NP	DT	O	22	NMOD
21	antisense	antisense	I-NP	JJ	O	22	NMOD
22	oligodeoxynucleotide	oligodeoxynucleotide	I-NP	NN	O	14	OBJ
23	against	against	B-PP	IN	O	22	NMOD
24	sigma1	sigma1	B-NP	NN	B-protein	25	NMOD
25	receptors	receptor	I-NP	NNS	I-protein	23	PMOD
26	was	be	B-VP	VBD	O	0	ROOT
27	also	also	I-VP	RB	O	26	VMOD
28	shown	show	I-VP	VBN	O	26	VC
29	to	to	I-VP	TO	O	31	VMOD
30	significantly	significantly	I-VP	RB	O	31	VMOD
31	attenuate	attenuate	I-VP	VB	O	28	VMOD
32	the	the	B-NP	DT	O	37	NMOD
33	convulsive	convulsive	I-NP	JJ	O	36	AMOD
34	and	and	I-NP	CC	O	36	AMOD
35	locomotor	locomotor	I-NP	JJ	O	36	AMOD
36	stimulatory	stimulatory	I-NP	JJ	O	37	NMOD
37	effects	effect	I-NP	NNS	O	31	OBJ
38	of	of	B-PP	IN	O	37	NMOD
39	cocaine	cocaine	B-NP	NN	O	38	PMOD
40	.	.	O	.	O	26	P

1	TDP	TDP	B-NP	NN	B-protein	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	side-effect	side-effect	I-NP	NN	O	2	PRD
5	that	that	B-NP	WDT	O	4	NMOD
6	has	have	B-VP	VBZ	O	5	SBAR
7	led	lead	I-VP	VBN	O	6	VC
8	to	to	B-PP	TO	O	7	VMOD
9	withdrawal	withdrawal	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	several	several	B-NP	JJ	O	12	NMOD
12	drugs	drug	I-NP	NNS	O	10	PMOD
13	from	from	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	market	market	I-NP	NN	O	13	PMOD
16	(	(	O	(	O	21	DEP
17	e.g.	e.g.	B-NP	FW	O	21	DEP
18	terfenadine	terfenadine	I-NP	NN	O	20	NMOD
19	and	and	O	CC	O	20	NMOD
20	terodiline	terodiline	B-NP	NN	O	21	DEP
21	)	)	O	)	O	15	NMOD
22	.	.	O	.	O	2	P
23	2	2	B-NP	CD	O	2	PRD
24	.	.	O	.	O	2	P

1	Four	Four	B-NP	CD	O	2	NMOD
2	compounds	compound	I-NP	NNS	O	11	SUB
3	known	know	B-VP	VBN	O	2	NMOD
4	to	to	B-VP	TO	O	5	VMOD
5	increase	increase	I-VP	VB	O	3	VMOD
6	QT	QT	B-NP	NN	O	7	NMOD
7	interval	interval	I-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	cause	cause	B-NP	NN	O	10	NMOD
10	TDP	TDP	I-NP	NN	O	5	OBJ
11	were	be	B-VP	VBD	O	0	ROOT
12	investigated	investigate	I-VP	VBN	O	11	VC
13	:	:	O	:	O	11	P
14	terfenadine	terfenadine	B-NP	NN	O	20	NMOD
15	,	,	I-NP	,	O	20	P
16	terodiline	terodiline	I-NP	NN	O	20	NMOD
17	,	,	I-NP	,	O	20	P
18	cisapride	cisapride	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	E4031	E4031	I-NP	NN	O	11	VMOD
21	.	.	O	.	O	11	P

1	For	For	B-PP	IN	O	0	ROOT
2	compounds	compound	B-NP	NNS	O	1	PMOD
3	that	that	B-NP	WDT	O	2	NMOD
4	have	have	B-VP	VBP	O	3	SBAR
5	shown	show	I-VP	VBN	O	4	VC
6	TDP	TDP	B-NP	NN	B-protein	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	clinic	clinic	I-NP	NN	O	7	PMOD
10	(	(	O	(	O	16	DEP
11	terfenadine	terfenadine	B-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	terodiline	terodiline	B-NP	NN	O	15	NMOD
14	,	,	O	,	O	15	P
15	cisapride	cisapride	B-NP	NN	O	16	DEP
16	)	)	O	)	O	9	NMOD
17	there	there	B-NP	EX	O	18	SUB
18	is	be	B-VP	VBZ	O	4	VMOD
19	little	little	B-NP	JJ	O	20	NMOD
20	differentiation	differentiation	I-NP	NN	O	18	PRD
21	between	between	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	dog	dog	I-NP	NN	O	24	NMOD
24	ED50	ED50	I-NP	NN	O	30	NMOD
25	and	and	O	CC	O	30	NMOD
26	the	the	B-NP	DT	O	30	NMOD
27	efficacious	efficacious	I-NP	JJ	O	28	AMOD
28	free	free	I-NP	JJ	O	30	NMOD
29	plasma	plasma	I-NP	NN	O	30	NMOD
30	concentrations	concentration	I-NP	NNS	O	21	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	man	man	B-NP	NN	O	31	PMOD
33	(	(	O	(	O	36	DEP
34	<	<	B-NP	SYM	O	36	DEP
35	10-fold	10-fold	B-ADVP	RB	O	34	NMOD
36	)	)	O	)	O	30	NMOD
37	reflecting	reflect	B-VP	VBG	O	30	NMOD
38	their	their	B-NP	PRP$	O	41	NMOD
39	limited	limit	I-NP	VBN	O	41	NMOD
40	safety	safety	I-NP	NN	O	41	NMOD
41	margins	margin	I-NP	NNS	O	37	OBJ
42	.	.	O	.	O	1	P

1	Fatal	Fatal	B-NP	JJ	O	2	NMOD
2	myeloencephalopathy	myeloencephalopathy	I-NP	NN	O	11	NMOD
3	due	due	B-PP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	accidental	accidental	B-NP	JJ	O	8	NMOD
6	intrathecal	intrathecal	I-NP	JJ	O	8	NMOD
7	vincristin	vincristin	I-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	4	PMOD
9	:	:	O	:	O	2	P
10	a	a	B-NP	DT	O	11	NMOD
11	report	report	I-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	two	two	B-NP	CD	O	14	NMOD
14	cases	case	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	11	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	on	on	B-PP	IN	O	2	VMOD
4	two	two	B-NP	CD	O	6	NMOD
5	fatal	fatal	I-NP	JJ	O	6	NMOD
6	cases	case	I-NP	NNS	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	accidental	accidental	B-NP	JJ	O	11	NMOD
9	intrathecal	intrathecal	I-NP	JJ	O	11	NMOD
10	vincristine	vincristine	I-NP	NN	O	11	NMOD
11	instillation	instillation	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	6	NMOD
13	a	a	B-NP	DT	O	16	NMOD
14	5-year	5-year	I-NP	JJ	O	16	NMOD
15	old	old	I-NP	JJ	O	16	NMOD
16	girl	girl	I-NP	NN	O	12	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	recurrent	recurrent	B-NP	JJ	O	21	NMOD
19	acute	acute	I-NP	JJ	O	21	NMOD
20	lymphoblastic	lymphoblastic	I-NP	JJ	O	21	NMOD
21	leucemia	leucemia	I-NP	NN	O	26	NMOD
22	and	and	O	CC	O	26	NMOD
23	a	a	B-NP	DT	O	26	NMOD
24	57-year	57-year	I-NP	JJ	O	26	NMOD
25	old	old	I-NP	JJ	O	26	NMOD
26	man	man	I-NP	NN	O	17	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	lymphoblastic	lymphoblastic	B-NP	JJ	O	29	NMOD
29	lymphoma	lymphoma	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	2	P

1	Histological	Histological	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	immunohistochemical	immunohistochemical	I-NP	JJ	O	4	NMOD
4	investigations	investigation	I-NP	NNS	O	12	SUB
5	(	(	O	(	O	11	DEP
6	HE-LFB	HE-LFB	B-NP	NN	B-protein	10	NMOD
7	,	,	O	,	O	10	P
8	CD-68	CD-68	B-NP	NN	B-protein	10	NMOD
9	,	,	O	,	O	10	P
10	Neurofilament	Neurofilament	B-NP	NN	O	11	DEP
11	)	)	O	)	O	4	NMOD
12	revealed	reveal	B-VP	VBD	O	0	ROOT
13	degeneration	degeneration	B-NP	NN	O	22	NMOD
14	of	of	B-PP	IN	O	13	NMOD
15	myelin	myelin	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	axons	axon	I-NP	NNS	O	14	PMOD
18	as	as	B-CONJP	RB	O	22	NMOD
19	well	well	I-CONJP	RB	O	18	DEP
20	as	as	I-CONJP	IN	O	18	DEP
21	pseudocystic	pseudocystic	B-NP	JJ	O	22	NMOD
22	transformation	transformation	I-NP	NN	O	12	OBJ
23	in	in	B-PP	IN	O	22	NMOD
24	areas	area	B-NP	NNS	O	23	PMOD
25	exposed	expose	B-VP	VBN	O	24	NMOD
26	to	to	B-PP	TO	O	25	VMOD
27	vincristine	vincristine	B-NP	NN	O	26	PMOD
28	,	,	O	,	O	22	P
29	accompanied	accompany	B-VP	VBN	O	22	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	secondary	secondary	B-NP	JJ	O	32	NMOD
32	changes	change	I-NP	NNS	O	30	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	numerous	numerous	B-NP	JJ	O	33	PMOD
35	prominent	prominent	I-NP	JJ	O	36	NMOD
36	macrophages	macrophage	I-NP	NNS	B-cell_type	34	NMOD
37	.	.	O	.	O	12	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	prochlorperazine	prochlorperazine	B-NP	NN	O	3	PMOD
5	by	by	B-PP	IN	O	2	NMOD
6	15-minute	15-minute	B-NP	JJ	O	7	NMOD
7	infusion	infusion	I-NP	NN	O	5	PMOD
8	versus	versus	B-PP	IN	O	7	NMOD
9	2-minute	2-minute	B-NP	JJ	O	10	NMOD
10	bolus	bolus	I-NP	NN	O	8	PMOD
11	does	do	B-VP	VBZ	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	affect	affect	I-VP	VB	O	11	VC
14	the	the	B-NP	DT	O	15	NMOD
15	incidence	incidence	I-NP	NN	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	akathisia	akathisia	B-NP	NN	O	16	PMOD
18	:	:	O	:	O	11	P
19	a	a	B-NP	DT	O	25	NMOD
20	prospective	prospective	I-NP	JJ	O	24	AMOD
21	,	,	I-NP	,	O	24	P
22	randomized	randomize	I-NP	VBN	O	24	AMOD
23	,	,	I-NP	,	O	24	P
24	controlled	control	I-NP	VBN	O	25	NMOD
25	trial	trial	I-NP	NN	O	11	VMOD
26	.	.	O	.	O	11	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	OBJECTIVE	OBJECTIVE	I-NP	NN	O	0	ROOT
3	:	:	O	:	O	2	P
4	We	We	B-NP	PRP	O	5	SUB
5	sought	seek	B-VP	VBD	O	2	NMOD
6	to	to	I-VP	TO	O	7	VMOD
7	compare	compare	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	rate	rate	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	akathisia	akathisia	B-NP	NN	O	10	PMOD
12	after	after	B-PP	IN	O	9	NMOD
13	administration	administration	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	intravenous	intravenous	B-NP	JJ	O	16	NMOD
16	prochlorperazine	prochlorperazine	I-NP	NN	O	14	PMOD
17	as	as	B-PP	IN	O	13	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	2-minute	2-minute	I-NP	JJ	O	20	NMOD
20	bolus	bolus	I-NP	NN	O	23	NMOD
21	or	or	O	CC	O	23	NMOD
22	15-minute	15-minute	B-NP	JJ	O	23	NMOD
23	infusion	infusion	I-NP	NN	O	17	PMOD
24	.	.	O	.	O	2	P

1	Patients	Patient	B-NP	NNS	O	17	SUB
2	aged	age	B-ADJP	VBN	O	17	VMOD
3	18	18	B-NP	CD	O	4	NMOD
4	years	year	I-NP	NNS	O	2	AMOD
5	or	or	O	CC	O	17	VMOD
6	older	old	B-NP	JJR	O	17	SUB
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	prochlorperazine	prochlorperazine	B-NP	NN	O	8	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	headache	headache	B-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	nausea	nausea	B-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	or	or	O	CC	O	16	NMOD
16	vomiting	vomiting	B-NP	NN	O	10	PMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	eligible	eligible	B-ADJP	JJ	O	17	PRD
19	for	for	B-PP	IN	O	18	AMOD
20	inclusion	inclusion	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	17	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	27	VMOD
2	:	:	O	:	O	27	P
3	A	A	B-NP	DT	O	6	NMOD
4	50	50	I-NP	CD	O	5	AMOD
5	%	%	I-NP	NN	O	6	NMOD
6	reduction	reduction	I-NP	NN	O	27	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	incidence	incidence	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	akathisia	akathisia	B-NP	NN	O	10	PMOD
12	when	when	B-ADVP	WRB	O	6	NMOD
13	prochlorperazine	prochlorperazine	B-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	12	SBAR
15	administered	administer	I-VP	VBN	O	14	VC
16	by	by	B-PP	IN	O	15	VMOD
17	means	mean	B-NP	NNS	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	15-minute	15-minute	B-NP	JJ	O	21	NMOD
20	intravenous	intravenous	I-NP	JJ	O	21	NMOD
21	infusion	infusion	I-NP	NN	O	18	PMOD
22	versus	versus	B-PP	IN	O	21	NMOD
23	a	a	B-NP	DT	O	26	NMOD
24	2-minute	2-minute	I-NP	JJ	O	26	NMOD
25	intravenous	intravenous	I-NP	JJ	O	26	NMOD
26	push	push	I-NP	NN	O	22	PMOD
27	was	be	B-VP	VBD	O	0	ROOT
28	not	not	I-VP	RB	O	27	VMOD
29	detected	detect	I-VP	VBN	O	27	VC
30	.	.	O	.	O	27	P

1	Antithymocyte	Antithymocyte	B-NP	NN	B-protein	2	NMOD
2	globulin	globulin	I-NP	NN	I-protein	8	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	D-penicillamine	D-penicillamine	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	aplastic	aplastic	B-NP	JJ	O	10	NMOD
10	anemia	anemia	I-NP	NN	O	8	OBJ
11	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	15	SUB
3	who	who	B-NP	WP	O	2	NMOD
4	received	receive	B-VP	VBD	O	3	SBAR
5	antithymocyte	antithymocyte	B-NP	JJ	B-protein	7	NMOD
6	globulin	globulin	I-NP	NN	I-protein	7	NMOD
7	therapy	therapy	I-NP	NN	O	4	OBJ
8	for	for	B-PP	IN	O	7	NMOD
9	aplastic	aplastic	B-NP	JJ	O	10	NMOD
10	anemia	anemia	I-NP	NN	O	8	PMOD
11	due	due	B-ADJP	JJ	O	2	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	D-penicillamine	D-penicillamine	B-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	is	be	B-VP	VBZ	O	0	ROOT
16	described	describe	I-VP	VBN	O	15	VC
17	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	2	NMOD
2	relationship	relationship	I-NP	NN	O	0	ROOT
3	between	between	B-PP	IN	O	2	NMOD
4	hippocampal	hippocampal	B-NP	JJ	O	6	NMOD
5	acetylcholine	acetylcholine	I-NP	NN	O	6	NMOD
6	release	release	I-NP	NN	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	cholinergic	cholinergic	B-NP	JJ	O	10	NMOD
9	convulsant	convulsant	I-NP	JJ	O	10	NMOD
10	sensitivity	sensitivity	I-NP	NN	O	3	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	withdrawal	withdrawal	B-NP	NN	B-cell_line	13	NMOD
13	seizure-prone	seizure-prone	I-NP	NN	I-cell_line	19	NMOD
14	and	and	O	CC	I-cell_line	19	NMOD
15	withdrawal	withdrawal	B-NP	NN	I-cell_line	19	NMOD
16	seizure-resistant	seizure-resistant	I-NP	JJ	I-cell_line	19	NMOD
17	selected	select	I-NP	VBN	I-cell_line	19	NMOD
18	mouse	mouse	I-NP	NN	I-cell_line	19	NMOD
19	lines	line	I-NP	NNS	I-cell_line	11	PMOD
20	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cholinergic	Cholinergic	B-NP	JJ	O	5	NMOD
4	convulsant	convulsant	I-NP	JJ	O	5	NMOD
5	sensitivity	sensitivity	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	1	NMOD
7	examined	examine	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	alcohol-na	alcohol-na	B-NP	JJ	O	12	NMOD
10	ve	ve	I-NP	NN	O	12	NMOD
11	Withdrawal	Withdrawal	I-NP	NN	O	12	NMOD
12	Seizure-Prone	Seizure-Prone	I-NP	NN	O	20	NMOD
13	(	(	O	(	O	20	NMOD
14	WSP	WSP	B-NP	NN	O	20	NMOD
15	)	)	O	)	O	20	NMOD
16	and-Resistant	and-Resistant	O	JJ	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	WSR	WSR	B-ADJP	JJ	O	19	DEP
19	)	)	O	)	O	16	AMOD
20	mice	mouse	B-NP	NNS	O	8	PMOD
21	.	.	O	.	O	1	P

1	Animals	Animal	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	25	VMOD
3	administered	administer	I-VP	VBN	O	2	VC
4	nicotine	nicotine	B-NP	NN	O	9	NMOD
5	,	,	O	,	O	9	P
6	carbachol	carbachol	B-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	or	or	O	CC	O	9	NMOD
9	neostigmine	neostigmine	B-NP	NN	O	3	OBJ
10	via	via	B-PP	IN	O	9	NMOD
11	timed	time	B-NP	VBN	O	14	NMOD
12	tail	tail	I-NP	NN	O	14	NMOD
13	vein	vein	I-NP	NN	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	10	PMOD
15	,	,	O	,	O	18	P
16	and	and	O	CC	O	18	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	latencies	latency	I-NP	NNS	O	25	SUB
19	to	to	B-PP	TO	O	18	NMOD
20	onset	onset	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	tremor	tremor	B-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	clonus	clonus	I-NP	NN	O	21	PMOD
25	were	be	B-VP	VBD	O	0	ROOT
26	recorded	record	I-VP	VBN	O	25	VC
27	and	and	O	CC	O	26	VMOD
28	converted	convert	B-VP	VBN	O	26	VMOD
29	to	to	B-VP	TO	O	30	VMOD
30	threshold	threshold	I-VP	VB	O	28	VMOD
31	dose	dose	B-NP	NN	O	30	OBJ
32	.	.	O	.	O	25	P

1	Hippocampal	Hippocampal	B-NP	JJ	O	2	NMOD
2	ACh	ACh	I-NP	NN	O	4	SUB
3	also	also	B-ADVP	RB	O	4	VMOD
4	was	be	B-VP	VBD	O	0	ROOT
5	measured	measure	I-VP	VBN	O	4	VC
6	during	during	B-PP	IN	O	5	VMOD
7	testing	testing	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	handling	handle	B-VP	VBG	O	8	PMOD
10	induced	induce	B-NP	VBN	O	11	NMOD
11	convulsions	convulsion	I-NP	NNS	O	9	OBJ
12	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Sensitivity	Sensitivity	B-NP	NN	O	16	SUB
4	to	to	B-PP	TO	O	3	NMOD
5	several	several	B-NP	JJ	O	7	NMOD
6	convulsion	convulsion	I-NP	NN	O	7	NMOD
7	endpoints	endpoint	I-NP	NNS	O	4	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	nicotine	nicotine	B-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	carbachol	carbachol	B-NP	NN	O	15	NMOD
13	,	,	O	,	O	15	P
14	and	and	O	CC	O	15	NMOD
15	neostigmine	neostigmine	B-NP	NN	O	9	PMOD
16	were	be	B-VP	VBD	O	1	NMOD
17	significantly	significantly	B-ADJP	RB	O	18	AMOD
18	greater	great	I-ADJP	JJR	O	16	PRD
19	in	in	B-PP	IN	O	18	AMOD
20	WSR	WSR	B-NP	NN	B-protein	19	PMOD
21	versus	versus	B-PP	IN	O	18	AMOD
22	WSP	WSP	B-NP	NN	O	23	NMOD
23	mice	mouse	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	1	P

1	When	When	B-ADVP	WRB	O	15	VMOD
2	hippocampal	hippocampal	B-NP	JJ	O	3	NMOD
3	ACh	ACh	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	SBAR
5	measured	measure	I-VP	VBN	O	4	VC
6	during	during	B-PP	IN	O	5	VMOD
7	testing	testing	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	handling	handle	B-VP	VBG	O	8	PMOD
10	induced	induce	B-NP	VBN	O	11	NMOD
11	convulsions	convulsion	I-NP	NNS	O	14	NMOD
12	,	,	O	,	O	14	P
13	extracellular	extracellular	B-NP	JJ	O	14	NMOD
14	ACh	ACh	I-NP	NN	O	9	OBJ
15	was	be	B-VP	VBD	O	0	ROOT
16	significantly	significantly	I-VP	RB	O	15	VMOD
17	elevated	elevate	I-VP	VBN	O	15	VC
18	(	(	O	(	O	21	DEP
19	192	192	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	VMOD
22	in	in	B-PP	IN	O	17	VMOD
23	WSP	WSP	B-NP	NN	O	24	NMOD
24	mice	mouse	I-NP	NNS	O	22	PMOD
25	,	,	O	,	O	15	P
26	but	but	O	CC	O	15	VMOD
27	was	be	B-VP	VBD	O	15	VMOD
28	nonsignificantly	nonsignificantly	I-VP	RB	O	27	VMOD
29	elevated	elevate	I-VP	VBN	O	27	VC
30	(	(	O	(	O	33	DEP
31	59	59	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	33	DEP
33	)	)	O	)	O	29	VMOD
34	in	in	B-PP	IN	O	29	VMOD
35	WSR	WSR	B-NP	JJ	O	36	NMOD
36	mice	mouse	I-NP	NNS	O	34	PMOD
37	.	.	O	.	O	15	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	These	These	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	differences	difference	B-NP	NNS	O	17	SUB
8	in	in	B-PP	IN	O	7	NMOD
9	cholinergic	cholinergic	B-NP	JJ	O	10	NMOD
10	activity	activity	I-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	postsynaptic	postsynaptic	B-NP	JJ	O	13	NMOD
13	sensitivity	sensitivity	I-NP	NN	O	8	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	cholinergic	cholinergic	B-NP	JJ	O	16	NMOD
16	convulsants	convulsant	I-NP	NNS	O	14	PMOD
17	may	may	B-VP	MD	O	6	SBAR
18	be	be	I-VP	VB	O	17	VC
19	associated	associate	I-VP	VBN	O	18	VC
20	with	with	B-PP	IN	O	19	VMOD
21	ethanol	ethanol	B-NP	NN	O	23	NMOD
22	withdrawal	withdrawal	I-NP	NN	O	23	NMOD
23	severity	severity	I-NP	NN	O	20	PMOD
24	and	and	O	CC	O	17	VMOD
25	implicate	implicate	B-VP	VBP	O	17	VMOD
26	cholinergic	cholinergic	B-NP	JJ	O	27	NMOD
27	mechanisms	mechanism	I-NP	NNS	O	25	OBJ
28	in	in	B-PP	IN	O	27	NMOD
29	alcohol	alcohol	B-NP	NN	O	30	NMOD
30	withdrawal	withdrawal	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	1	P

1	Prenatal	Prenatal	B-NP	JJ	O	3	NMOD
2	dexamethasone	dexamethasone	I-NP	NN	O	3	NMOD
3	programs	program	I-NP	NNS	O	7	NMOD
4	hypertension	hypertension	I-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	renal	renal	B-NP	JJ	O	7	NMOD
7	injury	injury	I-NP	NN	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	rat	rat	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	determine	determine	I-VP	VB	O	7	PRD
10	if	if	B-SBAR	IN	O	9	VMOD
11	prenatal	prenatal	B-NP	JJ	O	12	NMOD
12	dexamethasone	dexamethasone	I-NP	NN	O	13	SUB
13	programmed	program	B-VP	VBD	O	10	SBAR
14	a	a	B-NP	DT	O	16	NMOD
15	progressive	progressive	I-NP	JJ	O	16	NMOD
16	increase	increase	I-NP	NN	O	22	NMOD
17	in	in	B-PP	IN	O	16	NMOD
18	blood	blood	B-NP	NN	O	19	NMOD
19	pressure	pressure	I-NP	NN	O	17	PMOD
20	and	and	O	CC	O	22	NMOD
21	renal	renal	B-NP	JJ	O	22	NMOD
22	injury	injury	I-NP	NN	O	13	OBJ
23	in	in	B-PP	IN	O	22	NMOD
24	rats	rat	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	7	P

1	Offspring	Offspring	B-NP	NN	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	rats	rat	B-NP	NNS	O	5	NMOD
4	administered	administer	B-NP	VBN	O	5	NMOD
5	dexamethasone	dexamethasone	I-NP	NN	O	2	PMOD
6	on	on	B-PP	IN	O	1	NMOD
7	days	day	B-NP	NNS	O	11	NMOD
8	15	15	I-NP	CD	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	16	16	I-NP	CD	O	11	NMOD
11	gestation	gestation	I-NP	NN	O	6	PMOD
12	had	have	B-VP	VBD	O	0	ROOT
13	a	a	B-NP	DT	O	16	NMOD
14	20	20	I-NP	CD	O	15	AMOD
15	%	%	I-NP	NN	O	16	NMOD
16	reduction	reduction	I-NP	NN	O	12	OBJ
17	in	in	B-PP	IN	O	12	VMOD
18	glomerular	glomerular	B-NP	JJ	O	19	NMOD
19	number	number	I-NP	NN	O	17	PMOD
20	compared	compare	B-PP	VBN	O	17	PMOD
21	with	with	B-PP	IN	O	20	PMOD
22	control	control	B-NP	NN	O	21	PMOD
23	at	at	B-PP	IN	O	20	PMOD
24	6	6	B-NP	CD	O	26	AMOD
25	to	to	I-NP	TO	O	26	AMOD
26	9	9	I-NP	CD	O	27	NMOD
27	months	month	I-NP	NNS	O	23	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	age	age	B-NP	NN	O	28	PMOD
30	(	(	O	(	O	27	NMOD
31	22	22	B-NP	CD	O	32	NMOD
32	527+/-509	527+/-509	I-NP	CD	O	35	NMOD
33	versus	versus	B-PP	IN	O	35	NMOD
34	28	28	B-NP	CD	O	35	NMOD
35	050+/-561	050+/-561	I-NP	CD	O	37	NMOD
36	,	,	O	,	O	37	P
37	P	P	B-NP	NN	O	30	PMOD
38	<	<	B-NP	SYM	O	37	NMOD
39	0.05	0.05	I-NP	CD	O	38	AMOD
40	)	)	O	)	O	37	NMOD
41	,	,	O	,	O	37	P
42	which	which	B-NP	WDT	O	37	NMOD
43	was	be	B-VP	VBD	O	42	SBAR
44	comparable	comparable	B-ADJP	JJ	O	43	PRD
45	to	to	B-PP	TO	O	44	AMOD
46	the	the	B-NP	DT	O	48	NMOD
47	percent	percent	I-NP	NN	O	48	NMOD
48	reduction	reduction	I-NP	NN	O	45	PMOD
49	in	in	B-PP	IN	O	48	NMOD
50	glomeruli	glomerulus	B-NP	NNS	O	49	PMOD
51	measured	measure	B-VP	VBN	O	50	NMOD
52	at	at	B-PP	IN	O	51	VMOD
53	3	3	B-NP	CD	O	54	NMOD
54	weeks	week	I-NP	NNS	O	52	PMOD
55	of	of	B-PP	IN	O	54	NMOD
56	age	age	B-NP	NN	O	55	PMOD
57	.	.	O	.	O	12	P

1	Male	Male	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	23	SUB
3	that	that	B-NP	WDT	O	2	NMOD
4	received	receive	B-VP	VBD	O	3	SBAR
5	prenatal	prenatal	B-NP	JJ	O	6	NMOD
6	dexamethasone	dexamethasone	I-NP	NN	O	4	OBJ
7	on	on	B-PP	IN	O	4	VMOD
8	days	day	B-NP	NNS	O	20	NMOD
9	15	15	I-NP	CD	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	16	16	I-NP	CD	O	8	NMOD
12	,	,	I-NP	,	O	20	P
13	17	17	I-NP	CD	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	18	18	I-NP	CD	O	20	NMOD
16	,	,	O	,	O	20	P
17	and	and	O	CC	O	20	NMOD
18	13	13	B-NP	CD	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	14	14	I-NP	CD	O	7	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	gestation	gestation	B-NP	NN	O	21	PMOD
23	had	have	B-VP	VBD	O	36	VMOD
24	elevated	elevate	I-VP	VBN	O	23	VC
25	blood	blood	B-NP	NN	O	26	NMOD
26	pressures	pressure	I-NP	NNS	O	24	OBJ
27	at	at	B-PP	IN	O	24	VMOD
28	6	6	B-NP	CD	O	29	NMOD
29	months	month	I-NP	NNS	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	age	age	B-NP	NN	O	30	PMOD
32	;	;	O	:	O	36	P
33	the	the	B-NP	DT	O	35	NMOD
34	latter	latter	I-NP	JJ	O	35	NMOD
35	group	group	I-NP	NN	O	36	SUB
36	did	do	B-VP	VBD	O	0	ROOT
37	not	not	I-VP	RB	O	36	VMOD
38	have	have	I-VP	VB	O	36	VC
39	a	a	B-NP	DT	O	40	NMOD
40	reduction	reduction	I-NP	NN	O	38	OBJ
41	in	in	B-PP	IN	O	38	VMOD
42	glomerular	glomerular	B-NP	JJ	O	43	NMOD
43	number	number	I-NP	NN	O	41	PMOD
44	.	.	O	.	O	36	P

1	Adult	Adult	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	4	NMOD
3	given	give	B-NP	VBN	O	4	NMOD
4	dexamethasone	dexamethasone	I-NP	NN	O	12	SUB
5	on	on	B-PP	IN	O	4	NMOD
6	days	day	B-NP	NNS	O	5	PMOD
7	15	15	I-NP	CD	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	16	16	I-NP	CD	O	6	NMOD
10	of	of	B-PP	IN	O	6	NMOD
11	gestation	gestation	B-NP	NN	O	10	PMOD
12	had	have	B-VP	VBD	O	0	ROOT
13	more	more	B-ADJP	RBR	O	14	AMOD
14	glomeruli	glomeruli	I-ADJP	JJ	O	12	PRD
15	with	with	B-PP	IN	O	14	AMOD
16	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	15	PMOD
17	than	than	B-PP	IN	O	14	AMOD
18	control	control	B-NP	NN	O	19	NMOD
19	rats	rat	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	12	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	shows	show	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	prenatal	prenatal	B-NP	JJ	O	6	NMOD
6	dexamethasone	dexamethasone	I-NP	NN	O	9	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	results	result	B-VP	VBZ	O	4	SBAR
10	in	in	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	12	NMOD
12	reduction	reduction	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	glomerular	glomerular	B-NP	JJ	O	15	NMOD
15	number	number	I-NP	NN	O	20	NMOD
16	,	,	O	,	O	20	P
17	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	20	NMOD
18	,	,	O	,	O	20	P
19	and	and	O	CC	O	20	NMOD
20	hypertension	hypertension	B-NP	NN	O	13	PMOD
21	when	when	B-ADVP	WRB	O	9	VMOD
22	administered	administer	B-VP	VBN	O	21	SBAR
23	at	at	B-PP	IN	O	22	VMOD
24	specific	specific	B-NP	JJ	O	25	NMOD
25	points	point	I-NP	NNS	O	23	PMOD
26	during	during	B-PP	IN	O	22	VMOD
27	gestation	gestation	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	venous	venous	B-NP	JJ	O	5	NMOD
5	thromboembolism	thromboembolism	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	women	woman	B-NP	NNS	O	6	PMOD
8	prescribed	prescribe	B-VP	VBD	O	0	ROOT
9	cyproterone	cyproterone	B-NP	NN	O	10	NMOD
10	acetate	acetate	I-NP	NN	O	8	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	combination	combination	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	ethinyl	ethinyl	B-NP	NN	O	15	NMOD
15	estradiol	estradiol	I-NP	NN	O	13	PMOD
16	:	:	O	:	O	8	P
17	a	a	B-NP	DT	O	20	NMOD
18	nested	nested	I-NP	JJ	O	20	NMOD
19	cohort	cohort	I-NP	JJ	O	20	NMOD
20	analysis	analysis	I-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	case-control	case-control	B-NP	JJ	O	23	NMOD
23	study	study	I-NP	NN	O	8	VMOD
24	.	.	O	.	O	8	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cyproterone	Cyproterone	B-NP	NN	O	4	NMOD
4	acetate	acetate	I-NP	NN	O	12	SUB
5	combined	combine	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	ethinyl	ethinyl	B-NP	NN	O	8	NMOD
8	estradiol	estradiol	I-NP	NN	O	6	PMOD
9	(	(	O	(	O	11	DEP
10	CPA/EE	CPA/EE	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	is	be	B-VP	VBZ	O	1	NMOD
13	licensed	license	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	UK	UK	I-NP	NNP	O	14	PMOD
17	for	for	B-PP	IN	O	13	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	treatment	treatment	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	women	woman	B-NP	NNS	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	acne	acne	B-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	hirsutism	hirsutism	I-NP	NN	O	22	PMOD
26	and	and	O	CC	O	12	VMOD
27	is	be	B-VP	VBZ	O	12	VMOD
28	also	also	B-ADVP	RB	O	27	VMOD
29	a	a	B-NP	DT	O	31	NMOD
30	treatment	treatment	I-NP	NN	O	31	NMOD
31	option	option	I-NP	NN	O	27	PRD
32	for	for	B-PP	IN	O	31	NMOD
33	polycystic	polycystic	B-NP	JJ	O	35	NMOD
34	ovary	ovary	I-NP	NN	O	35	NMOD
35	syndrome	syndrome	I-NP	NN	O	32	PMOD
36	(	(	O	(	O	38	DEP
37	PCOS	PCOS	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	.	.	O	.	O	12	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	demonstrated	demonstrate	I-VP	VBN	O	3	VC
5	an	an	B-NP	DT	O	7	NMOD
6	increased	increase	I-NP	VBN	O	7	NMOD
7	risk	risk	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	venous	venous	B-NP	JJ	O	10	NMOD
10	thromboembolism	thromboembolism	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	VTE	VTE	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	associated	associate	B-VP	VBN	O	10	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	CPA/EE	CPA/EE	B-NP	NN	B-protein	15	PMOD
17	compared	compare	B-PP	VBN	O	4	VMOD
18	with	with	B-PP	IN	O	17	PMOD
19	conventional	conventional	B-NP	JJ	O	22	NMOD
20	combined	combined	I-NP	JJ	O	22	NMOD
21	oral	oral	I-NP	JJ	O	22	NMOD
22	contraceptives	contraceptive	I-NP	NNS	O	18	PMOD
23	(	(	O	(	O	25	DEP
24	COCs	COC	B-NP	NNS	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	10	SUB
2	:	:	O	:	O	1	P
3	Using	Use	B-VP	VBG	O	10	VMOD
4	the	the	B-NP	DT	O	8	NMOD
5	General	General	I-NP	NNP	O	8	NMOD
6	Practice	Practice	I-NP	NNP	O	8	NMOD
7	Research	Research	I-NP	NNP	O	8	NMOD
8	Database	Database	I-NP	NNP	O	3	OBJ
9	we	we	B-NP	PRP	O	10	SUB
10	conducted	conduct	B-VP	VBD	O	0	ROOT
11	a	a	B-NP	DT	O	13	NMOD
12	cohort	cohort	I-NP	JJ	O	13	NMOD
13	analysis	analysis	I-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	case-control	case-control	B-NP	JJ	O	16	NMOD
16	study	study	I-NP	NN	O	17	SUB
17	nested	nest	B-VP	VBD	O	10	VMOD
18	within	within	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	population	population	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	women	woman	B-NP	NNS	O	34	NMOD
23	aged	aged	B-ADJP	JJ	O	22	NMOD
24	between	between	B-PP	IN	O	23	AMOD
25	15	15	B-NP	CD	O	27	AMOD
26	and	and	I-NP	CC	O	27	AMOD
27	39	39	I-NP	CD	O	24	PMOD
28	years	year	I-NP	NNS	O	27	NMOD
29	with	with	B-PP	IN	O	27	NMOD
30	acne	acne	B-NP	NN	O	29	PMOD
31	,	,	O	,	O	34	P
32	hirsutism	hirsutism	B-NP	NN	O	34	NMOD
33	or	or	O	CC	O	34	NMOD
34	PCOS	PCOS	B-NP	NN	O	21	PMOD
35	to	to	B-VP	TO	O	36	VMOD
36	estimate	estimate	I-VP	VB	O	17	VMOD
37	the	the	B-NP	DT	O	38	NMOD
38	risk	risk	I-NP	NN	O	36	OBJ
39	of	of	B-PP	IN	O	38	NMOD
40	VTE	VTE	B-NP	NN	B-protein	39	PMOD
41	associated	associate	B-VP	VBN	O	38	NMOD
42	with	with	B-PP	IN	O	41	VMOD
43	CPA/EE	CPA/EE	B-NP	NN	B-protein	42	PMOD
44	.	.	O	.	O	10	P

1	Pseudoacromegaly	Pseudoacromegaly	B-ADVP	RB	O	2	VMOD
2	induced	induce	B-VP	VBN	O	0	ROOT
3	by	by	B-PP	IN	O	2	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	long-term	long-term	I-NP	JJ	O	6	NMOD
6	use	use	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	minoxidil	minoxidil	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	with	with	B-PP	IN	O	4	NMOD
6	pseudoacromegaly	pseudoacromegaly	B-NP	NN	O	5	PMOD
7	that	that	B-NP	WDT	O	4	NMOD
8	resulted	result	B-VP	VBD	O	7	SBAR
9	from	from	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	long-term	long-term	I-NP	JJ	O	12	NMOD
12	use	use	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	minoxidil	minoxidil	B-NP	NN	O	13	PMOD
15	at	at	B-PP	IN	O	12	NMOD
16	an	an	B-NP	DT	O	19	NMOD
17	unusually	unusually	I-NP	RB	O	18	AMOD
18	high	high	I-NP	JJ	O	19	NMOD
19	dose	dose	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	2	P

1	All	All	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	received	receive	B-VP	VBD	O	0	ROOT
4	CAB	CAB	B-NP	NN	B-protein	24	NMOD
5	[	[	O	(	O	24	NMOD
6	leuprolide	leuprolide	B-NP	NN	O	7	NMOD
7	acetate	acetate	I-NP	NN	O	12	NMOD
8	(	(	O	(	O	10	DEP
9	LHRH-A	LHRH-A	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	3.75	3.75	B-NP	CD	O	12	NMOD
12	mg	mg	I-NP	NN	O	18	NMOD
13	,	,	O	,	O	12	P
14	intramuscularly	intramuscularly	B-ADVP	RB	O	12	NMOD
15	,	,	O	,	O	12	P
16	every	every	B-NP	DT	O	18	NMOD
17	28	28	I-NP	CD	O	18	NMOD
18	days	day	I-NP	NNS	O	24	NMOD
19	plus	plus	O	CC	O	22	NMOD
20	250	250	B-NP	CD	O	21	AMOD
21	mg	mg	I-NP	NN	O	22	NMOD
22	flutamide	flutamide	I-NP	NN	O	24	NMOD
23	,	,	O	,	O	24	P
24	tid	tid	B-NP	NN	O	3	OBJ
25	,	,	O	,	O	3	P
26	per	per	B-PP	IN	O	3	VMOD
27	Os	O	B-NP	NNS	O	26	PMOD
28	]	]	O	)	O	3	VMOD
29	and	and	O	CC	O	3	VMOD
30	were	be	B-VP	VBD	O	3	VMOD
31	evaluated	evaluate	I-VP	VBN	O	30	VC
32	for	for	B-PP	IN	O	31	VMOD
33	anemia	anemia	B-NP	NN	O	45	NMOD
34	by	by	B-PP	IN	O	33	NMOD
35	physical	physical	B-NP	JJ	O	36	NMOD
36	examination	examination	I-NP	NN	O	39	NMOD
37	and	and	I-NP	CC	O	39	NMOD
38	laboratory	laboratory	I-NP	NN	O	39	NMOD
39	tests	test	I-NP	NNS	O	34	PMOD
40	at	at	B-PP	IN	O	33	NMOD
41	baseline	baseline	B-NP	NN	O	40	PMOD
42	and	and	O	CC	O	33	NMOD
43	4	4	B-NP	CD	O	45	NMOD
44	subsequent	subsequent	I-NP	JJ	O	45	NMOD
45	intervals	interval	I-NP	NNS	O	32	PMOD
46	(	(	O	(	O	56	DEP
47	1	1	B-NP	CD	O	55	NMOD
48	,	,	I-NP	,	O	55	P
49	2	2	I-NP	CD	O	55	NMOD
50	,	,	I-NP	,	O	55	P
51	3	3	I-NP	CD	O	55	NMOD
52	and	and	I-NP	CC	O	55	NMOD
53	6	6	I-NP	CD	O	55	NMOD
54	months	month	I-NP	NNS	O	55	NMOD
55	post-CAB	post-CAB	I-NP	NN	B-protein	56	DEP
56	)	)	O	)	O	45	NMOD
57	.	.	O	.	O	3	P

1	Reversible	Reversible	B-NP	JJ	O	3	NMOD
2	dilated	dilated	I-NP	JJ	O	3	NMOD
3	cardiomyopathy	cardiomyopathy	I-NP	NN	O	0	ROOT
4	related	relate	B-VP	VBN	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	amphotericin	amphotericin	B-NP	NN	O	8	NMOD
7	B	B	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	who	who	B-NP	WP	O	4	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	dilated	dilate	I-VP	VBN	O	6	VC
8	cardiomyopathy	cardiomyopathy	B-NP	NN	O	13	NMOD
9	and	and	O	CC	O	13	NMOD
10	clinical	clinical	B-NP	JJ	O	13	NMOD
11	congestive	congestive	I-NP	JJ	O	13	NMOD
12	heart	heart	I-NP	NN	O	13	NMOD
13	failure	failure	I-NP	NN	O	7	OBJ
14	after	after	B-PP	IN	O	13	NMOD
15	2	2	B-NP	CD	O	16	NMOD
16	months	month	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	therapy	therapy	B-NP	NN	O	17	PMOD
19	with	with	B-PP	IN	O	16	NMOD
20	amphotericin	amphotericin	B-NP	NN	O	21	NMOD
21	B	B	I-NP	NN	O	19	PMOD
22	(	(	O	(	O	24	DEP
23	AmB	AmB	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	for	for	B-PP	IN	O	16	NMOD
26	disseminated	disseminate	B-NP	VBN	O	27	NMOD
27	coccidioidomycosis	coccidioidomycosis	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	2	P

1	His	His	B-NP	PRP$	O	3	NMOD
2	echocardiographic	echocardiographic	I-NP	JJ	O	3	NMOD
3	abnormalities	abnormality	I-NP	NNS	O	10	SUB
4	and	and	O	CC	O	6	NMOD
5	heart	heart	B-NP	NN	O	6	NMOD
6	failure	failure	I-NP	NN	O	3	NMOD
7	resolved	resolve	B-VP	VBN	O	3	NMOD
8	after	after	B-PP	IN	O	7	VMOD
9	posaconazole	posaconazole	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	substituted	substitute	I-VP	VBN	O	10	VC
12	for	for	B-PP	IN	O	11	VMOD
13	AmB	AmB	B-NP	NN	B-protein	12	PMOD
14	.	.	O	.	O	10	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	the	the	B-NP	DT	O	8	NMOD
3	United	United	I-NP	NNP	O	8	NMOD
4	States	State	I-NP	NNPS	O	8	NMOD
5	Food	Food	I-NP	NNP	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	Drug	Drug	I-NP	NNP	O	8	NMOD
8	Administration	Administration	I-NP	NNP	O	9	SUB
9	banned	ban	B-VP	VBD	O	1	SBAR
10	its	its	B-NP	PRP$	O	11	NMOD
11	use	use	I-NP	NN	O	9	OBJ
12	for	for	B-PP	IN	O	11	NMOD
13	nocturnal	nocturnal	B-NP	JJ	O	15	NMOD
14	leg	leg	I-NP	NN	O	15	NMOD
15	cramps	cramp	I-NP	NNS	O	12	PMOD
16	due	due	B-ADJP	JJ	O	9	VMOD
17	to	to	B-PP	TO	O	16	AMOD
18	lack	lack	B-NP	NN	O	24	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	safety	safety	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	efficacy	efficacy	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	24	P
24	quinine	quinine	B-NP	NN	O	17	PMOD
25	is	be	B-VP	VBZ	O	1	DEP
26	widely	widely	B-ADJP	RB	O	27	AMOD
27	available	available	I-ADJP	JJ	O	25	PRD
28	in	in	B-PP	IN	O	27	AMOD
29	beverages	beverage	B-NP	NNS	O	28	PMOD
30	including	include	B-PP	VBG	O	29	NMOD
31	tonic	tonic	B-NP	JJ	O	32	NMOD
32	water	water	I-NP	NN	O	35	NMOD
33	and	and	O	CC	O	35	NMOD
34	bitter	bitter	B-NP	JJ	O	35	NMOD
35	lemon	lemon	I-NP	NN	O	30	PMOD
36	.	.	O	.	O	1	P

1	Numerous	Numerous	B-NP	JJ	O	3	NMOD
2	anecdotal	anecdotal	I-NP	JJ	O	3	NMOD
3	reports	report	I-NP	NNS	O	4	SUB
4	suggest	suggest	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	products	product	B-NP	NNS	O	9	SUB
7	containing	contain	B-VP	VBG	O	6	NMOD
8	quinine	quinine	B-NP	NN	O	7	OBJ
9	may	may	B-VP	MD	O	5	SBAR
10	produce	produce	I-VP	VB	O	9	VC
11	neurological	neurological	B-NP	JJ	O	12	NMOD
12	complications	complication	I-NP	NNS	O	10	OBJ
13	,	,	O	,	O	12	P
14	including	include	B-PP	VBG	O	12	NMOD
15	confusion	confusion	B-NP	NN	O	24	NMOD
16	,	,	O	,	O	24	P
17	altered	alter	B-NP	VBN	O	19	NMOD
18	mental	mental	I-NP	JJ	O	19	NMOD
19	status	status	I-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	seizures	seizure	B-NP	NNS	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	coma	coma	B-NP	NN	O	14	PMOD
25	,	,	O	,	O	24	P
26	particularly	particularly	B-ADVP	RB	O	27	PMOD
27	in	in	B-PP	IN	O	24	NMOD
28	older	old	B-NP	JJR	O	29	NMOD
29	women	woman	I-NP	NNS	O	27	PMOD
30	.	.	O	.	O	4	P

1	Organophosphate	Organophosphate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	convulsions	convulsion	B-NP	NNS	O	5	NMOD
4	and	and	O	CC	O	5	NMOD
5	prevention	prevention	B-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	neuropathological	neuropathological	B-NP	JJ	B-cell_type	8	NMOD
8	damages	damage	I-NP	NNS	I-cell_type	6	PMOD
9	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	acute	acute	I-NP	JJ	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	OPs	OP	B-NP	NNS	B-protein	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	result	result	I-NP	NN	O	6	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	their	their	B-NP	PRP$	O	12	NMOD
11	irreversible	irreversible	I-NP	JJ	O	12	NMOD
12	binding	binding	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	AChEs	AChE	B-NP	NNS	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	central	central	I-NP	JJ	O	19	NMOD
18	nervous	nervous	I-NP	JJ	O	19	NMOD
19	system	system	I-NP	NN	O	15	PMOD
20	(	(	O	(	O	22	DEP
21	CNS	CNS	B-NP	NN	B-protein	22	DEP
22	)	)	O	)	O	19	NMOD
23	,	,	O	,	O	19	P
24	which	which	B-NP	WDT	O	19	NMOD
25	elevates	elevate	B-VP	VBZ	O	24	SBAR
26	acetylcholine	acetylcholine	B-NP	NN	O	30	NMOD
27	(	(	O	(	O	29	DEP
28	ACh	ACh	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	levels	level	B-NP	NNS	O	25	OBJ
31	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	rats	rat	I-NP	NNS	O	6	SUB
3	treated	treat	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	DFP-atropine	DFP-atropine	B-NP	NN	O	4	PMOD
6	showed	show	B-VP	VBD	O	0	ROOT
7	severe	severe	B-NP	JJ	O	8	AMOD
8	typical	typical	I-NP	JJ	O	12	NMOD
9	OP	OP	I-NP	NN	O	12	NMOD
10	induced	induce	B-VP	VBD	O	12	NMOD
11	toxicity	toxicity	B-NP	NN	O	12	NMOD
12	signs	sign	I-NP	NNS	O	6	OBJ
13	.	.	O	.	O	6	P

1	When	When	B-ADVP	WRB	O	15	VMOD
2	CPA	CPA	B-NP	NN	B-protein	6	NMOD
3	,	,	I-NP	,	O	6	P
4	diazepam	diazepam	I-NP	NN	O	6	NMOD
5	or	or	I-NP	CC	O	6	NMOD
6	2PAM	2PAM	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	1	SBAR
8	given	give	I-VP	VBN	O	7	VC
9	immediately	immediately	B-ADVP	RB	O	8	VMOD
10	after	after	B-PP	IN	O	8	VMOD
11	DFP-atropine	DFP-atropine	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	15	P
13	these	these	B-NP	DT	O	14	NMOD
14	treatments	treatment	I-NP	NNS	O	15	SUB
15	prevented	prevent	B-VP	VBD	O	0	ROOT
16	,	,	O	,	O	15	P
17	delayed	delay	B-VP	VBD	O	15	VMOD
18	or	or	I-VP	CC	O	17	VMOD
19	shortened	shorten	I-VP	VBD	O	17	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	occurrence	occurrence	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	serious	serious	B-NP	JJ	O	24	NMOD
24	signs	sign	I-NP	NNS	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	poisoning	poisoning	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	15	P

1	Atropine-MK801	Atropine-MK801	B-NP	NN	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	offer	offer	I-VP	VB	O	2	VC
5	any	any	B-NP	DT	O	7	NMOD
6	additional	additional	I-NP	JJ	O	7	NMOD
7	protection	protection	I-NP	NN	O	4	OBJ
8	against	against	B-PP	IN	O	7	NMOD
9	DFP	DFP	B-NP	NN	O	10	NMOD
10	toxicity	toxicity	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	Differential	Differential	B-NP	JJ	O	2	NMOD
2	modulation	modulation	I-NP	NN	O	0	ROOT
3	by	by	B-PP	IN	O	2	NMOD
4	estrogen	estrogen	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	alpha2-adrenergic	alpha2-adrenergic	B-NP	JJ	O	10	NMOD
7	and	and	I-NP	CC	O	10	NMOD
8	I1-imidazoline	I1-imidazoline	I-NP	NN	O	10	NMOD
9	receptor-mediated	receptor-mediated	I-NP	JJ	O	10	NMOD
10	hypotension	hypotension	I-NP	NN	O	5	PMOD
11	in	in	B-PP	IN	O	4	NMOD
12	female	female	B-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	recently	recently	I-VP	RB	O	2	VMOD
4	shown	show	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	estrogen	estrogen	B-NP	NN	O	8	SUB
7	negatively	negatively	B-ADVP	RB	O	8	VMOD
8	modulates	modulate	B-VP	VBZ	O	5	SBAR
9	the	the	B-NP	DT	O	11	NMOD
10	hypotensive	hypotensive	I-NP	JJ	O	11	NMOD
11	effect	effect	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	clonidine	clonidine	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	18	DEP
15	mixed	mixed	B-NP	JJ	O	17	NMOD
16	alpha2-/I1-receptor	alpha2-/I1-receptor	I-NP	NN	O	17	NMOD
17	agonist	agonist	I-NP	NN	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	in	in	B-PP	IN	O	11	NMOD
20	female	female	B-NP	JJ	O	21	NMOD
21	rats	rat	I-NP	NNS	O	19	PMOD
22	and	and	O	CC	O	8	VMOD
23	implicates	implicate	B-VP	VBZ	O	8	VMOD
24	the	the	B-NP	DT	O	27	NMOD
25	cardiovascular	cardiovascular	I-NP	JJ	O	27	NMOD
26	autonomic	autonomic	I-NP	JJ	O	27	NMOD
27	control	control	I-NP	NN	O	23	OBJ
28	in	in	B-PP	IN	O	23	VMOD
29	this	this	B-NP	DT	O	30	NMOD
30	interaction	interaction	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	8	VMOD
2	sham-operated	sham-operated	B-NP	JJ	O	3	NMOD
3	rats	rat	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	8	P
5	rilmenidine	rilmenidine	B-NP	NN	O	7	NMOD
6	or	or	I-NP	CC	O	7	NMOD
7	alpha-methyldopa	alpha-methyldopa	I-NP	NN	O	8	SUB
8	elicited	elicit	B-VP	VBD	O	0	ROOT
9	similar	similar	B-NP	JJ	O	10	NMOD
10	hypotension	hypotension	I-NP	NN	O	8	OBJ
11	that	that	B-NP	WDT	O	10	NMOD
12	lasted	last	B-VP	VBD	O	11	SBAR
13	at	at	B-NP	IN	O	16	NMOD
14	least	least	I-NP	JJS	O	13	AMOD
15	5	5	I-NP	CD	O	13	AMOD
16	h	h	I-NP	NN	O	12	OBJ
17	and	and	O	CC	O	8	VMOD
18	was	be	B-VP	VBD	O	8	VMOD
19	associated	associate	I-VP	VBN	O	18	VC
20	with	with	B-PP	IN	O	19	VMOD
21	reductions	reduction	B-NP	NNS	O	20	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	standard	standard	B-NP	JJ	O	24	NMOD
24	deviation	deviation	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	mean	mean	B-NP	JJ	O	28	NMOD
27	arterial	arterial	I-NP	JJ	O	28	NMOD
28	pressure	pressure	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	8	P

1	Ovx	Ovx	B-NP	NN	B-protein	3	SUB
2	significantly	significantly	B-ADVP	RB	O	3	VMOD
3	enhanced	enhance	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	hypotensive	hypotensive	I-NP	JJ	O	6	NMOD
6	response	response	I-NP	NN	O	3	OBJ
7	to	to	B-PP	TO	O	6	NMOD
8	alpha-methyldopa	alpha-methyldopa	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	3	P
10	in	in	B-PP	IN	O	3	VMOD
11	contrast	contrast	B-NP	NN	O	10	PMOD
12	to	to	B-PP	TO	O	10	PMOD
13	no	no	B-NP	DT	O	14	NMOD
14	effect	effect	I-NP	NN	O	10	PMOD
15	on	on	B-PP	IN	O	14	NMOD
16	rilmenidine	rilmenidine	B-NP	NN	O	17	NMOD
17	hypotension	hypotension	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	4	NMOD
2	enhanced	enhance	I-NP	VBN	O	4	NMOD
3	alpha-methyldopa	alpha-methyldopa	I-NP	NN	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	8	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	Ovx	Ovx	B-NP	NN	O	7	NMOD
7	rats	rat	I-NP	NNS	O	5	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	paralleled	parallel	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	further	further	B-NP	JJ	O	12	NMOD
12	reduction	reduction	I-NP	NN	O	19	NMOD
13	in	in	B-PP	IN	O	12	NMOD
14	SDRR	SDRR	B-NP	NN	B-protein	13	PMOD
15	and	and	O	CC	O	19	NMOD
16	a	a	B-NP	DT	O	19	NMOD
17	reduced	reduce	I-NP	VBN	O	19	NMOD
18	locomotor	locomotor	I-NP	NN	O	19	NMOD
19	activity	activity	I-NP	NN	O	10	PMOD
20	.	.	O	.	O	8	P

1	Cardioprotective	Cardioprotective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	tincture	tincture	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	Crataegus	Crataegus	B-NP	NNP	O	5	PMOD
7	on	on	B-PP	IN	O	2	NMOD
8	isoproterenol	isoproterenol	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	infarction	infarction	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	done	do	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	protective	protective	I-NP	JJ	O	10	NMOD
10	effect	effect	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	TCR	TCR	B-NP	NN	B-protein	11	PMOD
13	on	on	B-PP	IN	O	10	NMOD
14	experimentally	experimentally	B-NP	RB	O	15	AMOD
15	induced	induce	I-NP	VBN	O	17	NMOD
16	myocardial	myocardial	I-NP	JJ	O	17	NMOD
17	infarction	infarction	I-NP	NN	O	13	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	4	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	Multiple	Multiple	I-NP	JJ	O	5	NMOD
5	Outcomes	Outcomes	I-NP	NNP	O	16	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	Raloxifene	Raloxifene	B-NP	NNP	O	8	NMOD
8	Evaluation	Evaluation	I-NP	NNP	O	6	PMOD
9	,	,	O	,	O	16	P
10	a	a	B-NP	DT	O	11	NMOD
11	multicenter	multicenter	I-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	randomized	randomize	B-NP	VBN	O	15	AMOD
14	,	,	I-NP	,	O	15	P
15	double-blind	double-blind	I-NP	JJ	O	16	NMOD
16	trial	trial	I-NP	NN	O	18	SUB
17	,	,	O	,	O	16	P
18	enrolled	enrol	B-VP	VBD	O	1	NMOD
19	7	7	B-NP	CD	O	23	NMOD
20	,	,	O	,	O	23	P
21	705	705	B-NP	CD	O	23	NMOD
22	postmenopausal	postmenopausal	I-NP	JJ	O	23	NMOD
23	women	woman	I-NP	NNS	O	18	OBJ
24	with	with	B-PP	IN	O	23	NMOD
25	osteoporosis	osteoporosis	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	During	During	B-PP	IN	O	12	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	mean	mean	I-NP	JJ	O	6	NMOD
6	follow-up	follow-up	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	3.3	3.3	B-NP	CD	O	9	NMOD
9	years	year	I-NP	NNS	O	7	PMOD
10	,	,	O	,	O	12	P
11	raloxifene	raloxifene	B-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	1	NMOD
13	associated	associate	I-VP	VBN	O	12	VC
14	with	with	B-PP	IN	O	13	VMOD
15	an	an	B-NP	DT	O	17	NMOD
16	increased	increase	I-NP	VBN	O	17	NMOD
17	risk	risk	I-NP	NN	O	14	PMOD
18	for	for	B-PP	IN	O	17	NMOD
19	venous	venous	B-NP	JJ	O	20	NMOD
20	thromboembolism	thromboembolism	I-NP	NN	O	18	PMOD
21	(	(	O	(	O	37	DEP
22	relative	relative	B-NP	JJ	O	23	NMOD
23	risk	risk	I-NP	NN	O	32	NMOD
24	[	[	O	(	O	26	DEP
25	RR	RR	B-NP	NN	B-protein	26	DEP
26	]	]	O	)	I-protein	23	NMOD
27	2.1	2.1	B-NP	CD	I-protein	23	NMOD
28	;	;	O	:	O	32	P
29	95	95	B-NP	CD	O	32	NMOD
30	%	%	I-NP	NN	O	32	NMOD
31	confidence	confidence	I-NP	NN	O	32	NMOD
32	interval	interval	I-NP	NN	O	37	DEP
33	[	[	O	(	O	35	DEP
34	CI	CI	B-NP	NN	O	35	DEP
35	]	]	O	)	O	32	NMOD
36	1.2-3.8	1.2-3.8	B-NP	CD	O	32	NMOD
37	)	)	O	)	O	20	NMOD
38	.	.	O	.	O	1	P

1	Raloxifene	Raloxifene	B-NP	NN	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	increase	increase	I-VP	VB	O	2	VC
5	risk	risk	B-NP	NN	O	4	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	cataracts	cataract	B-NP	NNS	O	31	NMOD
8	(	(	O	(	O	16	DEP
9	RR	RR	B-NP	NN	B-protein	16	DEP
10	0.9	0.9	I-NP	CD	I-protein	9	NMOD
11	;	;	O	:	O	16	P
12	95	95	B-NP	CD	O	14	NMOD
13	%	%	I-NP	NN	O	14	NMOD
14	CI	CI	I-NP	NN	O	16	DEP
15	0.8-1.1	0.8-1.1	I-NP	CD	O	14	NMOD
16	)	)	O	)	O	7	NMOD
17	,	,	O	,	O	31	P
18	gallbladder	gallbladder	B-NP	NN	O	19	NMOD
19	disease	disease	I-NP	NN	O	31	NMOD
20	(	(	O	(	O	28	DEP
21	RR	RR	B-NP	NN	O	28	DEP
22	1.0	1.0	I-NP	CD	O	21	NMOD
23	;	;	O	:	O	28	P
24	95	95	B-NP	CD	O	26	NMOD
25	%	%	I-NP	NN	O	26	NMOD
26	CI	CI	I-NP	NN	O	28	DEP
27	0.7-1.3	0.7-1.3	I-NP	CD	O	26	NMOD
28	)	)	O	)	O	19	NMOD
29	,	,	O	,	O	31	P
30	endometrial	endometrial	B-NP	JJ	O	31	NMOD
31	hyperplasia	hyperplasia	I-NP	NN	O	6	PMOD
32	(	(	O	(	O	40	DEP
33	RR	RR	B-NP	NN	O	40	DEP
34	1.3	1.3	I-NP	CD	O	33	NMOD
35	;	;	O	:	O	40	P
36	95	95	B-NP	CD	O	38	NMOD
37	%	%	I-NP	NN	O	38	NMOD
38	CI	CI	I-NP	NN	O	40	DEP
39	0.4-5.1	0.4-5.1	I-NP	CD	O	38	NMOD
40	)	)	O	)	O	31	NMOD
41	,	,	O	,	O	2	P
42	or	or	O	CC	O	44	NMOD
43	endometrial	endometrial	B-NP	JJ	O	44	NMOD
44	cancer	cancer	I-NP	NN	O	41	OBJ
45	(	(	O	(	O	44	NMOD
46	RR	RR	B-NP	NN	B-protein	45	DEP
47	0.9	0.9	I-NP	CD	I-protein	46	NMOD
48	;	;	O	:	O	49	P
49	95	95	B-NP	CD	O	46	NMOD
50	%	%	I-NP	NN	O	51	NMOD
51	CI	CI	I-NP	NN	O	53	DEP
52	0.3-2.7	0.3-2.7	I-NP	CD	O	51	NMOD
53	)	)	O	)	O	49	NMOD
54	.	.	O	.	O	2	P

1	Ceftriaxone-associated	Ceftriaxone-associated	B-NP	JJ	O	3	NMOD
2	biliary	biliary	I-NP	JJ	O	3	NMOD
3	pseudolithiasis	pseudolithiasis	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	paediatric	paediatric	B-NP	JJ	O	7	NMOD
6	surgical	surgical	I-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	4	PMOD
8	.	.	O	.	O	3	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	well	well	I-VP	RB	O	2	VMOD
4	known	know	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	ceftriaxone	ceftriaxone	B-NP	NN	O	7	SUB
7	leads	lead	B-VP	VBZ	O	5	SBAR
8	to	to	B-PP	TO	O	7	VMOD
9	pseudolithiasis	pseudolithiasis	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	some	some	B-NP	DT	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	7	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	we	we	B-NP	PRP	O	7	SUB
6	prospectively	prospectively	B-ADVP	RB	O	7	VMOD
7	evaluated	evaluate	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	12	NMOD
9	incidence	incidence	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	clinical	clinical	B-NP	JJ	O	12	NMOD
12	importance	importance	I-NP	NN	O	7	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	pseudolithiasis	pseudolithiasis	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	12	NMOD
16	paediatric	paediatric	B-NP	JJ	O	18	NMOD
17	surgical	surgical	I-NP	JJ	O	18	NMOD
18	patients	patient	I-NP	NNS	O	15	PMOD
19	receiving	receive	B-VP	VBG	O	18	NMOD
20	ceftriaxone	ceftriaxone	B-NP	NN	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	OBJ
22	,	,	O	,	O	18	P
23	who	who	B-NP	WP	O	18	NMOD
24	often	often	B-ADVP	RB	O	25	VMOD
25	had	have	B-VP	VBD	O	23	SBAR
26	to	to	I-VP	TO	O	27	VMOD
27	fast	fast	I-VP	VB	O	25	VMOD
28	in	in	B-PP	IN	O	27	VMOD
29	the	the	B-NP	DT	O	31	NMOD
30	post-operative	post-operative	I-NP	JJ	O	31	NMOD
31	period	period	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	7	P

1	Evaluation	Evaluation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	7	NMOD
4	anticocaine	anticocaine	I-NP	NN	B-protein	6	NMOD
5	monoclonal	monoclonal	I-NP	JJ	I-protein	6	NMOD
6	antibody	antibody	I-NP	NN	I-protein	7	NMOD
7	GNC92H2	GNC92H2	I-NP	NN	O	2	PMOD
8	as	as	B-PP	IN	O	1	NMOD
9	an	an	B-NP	DT	O	10	NMOD
10	immunotherapy	immunotherapy	I-NP	NN	O	8	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	cocaine	cocaine	B-NP	NN	O	13	NMOD
13	overdose	overdose	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	illicit	illicit	I-NP	JJ	O	3	NMOD
3	use	use	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	cocaine	cocaine	B-NP	NN	O	4	PMOD
6	continues	continue	B-VP	VBZ	O	15	VMOD
7	in	in	B-PP	IN	O	6	VMOD
8	epidemic	epidemic	B-NP	JJ	O	9	NMOD
9	proportions	proportion	I-NP	NNS	O	7	PMOD
10	and	and	O	CC	O	6	VMOD
11	treatment	treatment	B-NP	NN	O	15	SUB
12	for	for	B-PP	IN	O	11	NMOD
13	cocaine	cocaine	B-NP	NN	O	14	NMOD
14	overdose	overdose	I-NP	NN	O	12	PMOD
15	remains	remain	B-VP	VBZ	O	0	ROOT
16	elusive	elusive	B-ADJP	JJ	O	15	PRD
17	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	3	NMOD
2	therapeutic	therapeutic	I-NP	JJ	O	3	NMOD
3	potential	potential	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	anticocaine	anticocaine	I-NP	NN	B-protein	8	NMOD
7	antibody	antibody	I-NP	NN	I-protein	8	NMOD
8	GNC92H2	GNC92H2	I-NP	NN	I-protein	4	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	examined	examine	I-VP	VBN	O	9	VC
11	using	use	B-VP	VBG	O	10	VMOD
12	a	a	B-NP	DT	O	13	NMOD
13	model	model	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	cocaine	cocaine	B-NP	NN	O	16	NMOD
16	overdose	overdose	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	9	P

1	Significant	Significant	B-NP	JJ	O	2	NMOD
2	blockade	blockade	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cocaine	cocaine	B-NP	NN	O	5	NMOD
5	toxicity	toxicity	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	observed	observe	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	higher	high	I-NP	JJR	O	11	NMOD
11	dose	dose	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	GNC92H2	GNC92H2	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	17	DEP
15	190	190	B-NP	CD	O	16	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	11	NMOD
18	,	,	O	,	O	11	P
19	where	where	B-ADVP	WRB	O	11	NMOD
20	premorbid	premorbid	B-NP	JJ	O	21	NMOD
21	behaviors	behavior	I-NP	NNS	O	22	SUB
22	were	be	B-VP	VBD	O	19	SBAR
23	reduced	reduce	I-VP	VBN	O	22	VC
24	up	up	B-NP	RB	O	27	NMOD
25	to	to	I-NP	TO	O	24	AMOD
26	40	40	I-NP	CD	O	24	AMOD
27	%	%	I-NP	NN	O	23	OBJ
28	,	,	O	,	O	23	P
29	seizures	seizure	B-VP	VBZ	O	23	VMOD
30	up	up	B-NP	RB	O	33	NMOD
31	to	to	I-NP	TO	O	30	AMOD
32	77	77	I-NP	CD	O	30	AMOD
33	%	%	I-NP	NN	O	35	NMOD
34	and	and	O	CC	O	35	NMOD
35	death	death	B-NP	NN	O	29	OBJ
36	by	by	B-PP	IN	O	29	VMOD
37	72	72	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	36	PMOD
39	.	.	O	.	O	6	P

1	Importantly	Importantly	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	GNC92H2	GNC92H2	B-NP	NN	B-protein	4	SUB
4	prevented	prevent	B-VP	VBD	O	0	ROOT
5	death	death	B-NP	NN	O	8	NMOD
6	even	even	B-NP	RB	O	8	NMOD
7	post-cocaine	post-cocaine	I-NP	JJ	O	8	NMOD
8	injection	injection	I-NP	NN	O	4	OBJ
9	.	.	O	.	O	4	P

1	Ketoconazole	Ketoconazole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	torsades	torsade	B-NP	NNS	O	2	OBJ
4	de	de	B-PP	IN	O	2	VMOD
5	pointes	pointe	B-NP	NNS	O	4	PMOD
6	without	without	B-PP	IN	O	2	VMOD
7	concomitant	concomitant	B-NP	JJ	O	8	NMOD
8	use	use	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	QT	QT	B-NP	NN	O	12	NMOD
11	interval-prolonging	interval-prolonging	I-NP	JJ	O	12	NMOD
12	drug	drug	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	woman	woman	I-NP	NN	O	2	OBJ
5	with	with	B-PP	IN	O	4	NMOD
6	coronary	coronary	B-NP	JJ	O	8	NMOD
7	artery	artery	I-NP	NN	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	4	NMOD
10	developed	develop	B-VP	VBD	O	9	SBAR
11	a	a	B-NP	DT	O	15	NMOD
12	markedly	markedly	I-NP	RB	O	13	AMOD
13	prolonged	prolong	I-NP	VBN	O	15	NMOD
14	QT	QT	I-NP	NN	O	15	NMOD
15	interval	interval	I-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	torsades	torsade	B-NP	NNS	O	19	NMOD
18	de	de	I-NP	FW	O	19	NMOD
19	pointes	pointes	I-NP	FW	O	10	VMOD
20	(	(	O	(	O	22	DEP
21	TdP	TdP	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	after	after	B-PP	IN	O	10	VMOD
24	taking	take	B-VP	VBG	O	23	PMOD
25	ketoconazole	ketoconazole	B-NP	NN	O	24	OBJ
26	for	for	B-PP	IN	O	24	VMOD
27	treatment	treatment	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	fungal	fungal	B-NP	JJ	O	30	NMOD
30	infection	infection	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	postulate	postulate	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	by	by	B-PP	IN	O	16	VMOD
5	virtue	virtue	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	its	its	B-NP	PRP$	O	10	NMOD
8	direct	direct	I-NP	JJ	O	10	NMOD
9	blocking	block	I-NP	VBG	O	10	NMOD
10	action	action	I-NP	NN	O	6	PMOD
11	on	on	B-PP	IN	O	10	NMOD
12	IKr	IKr	B-NP	NN	B-protein	11	PMOD
13	,	,	O	,	O	16	P
14	ketoconazole	ketoconazole	B-NP	NN	O	16	SUB
15	alone	alone	B-ADVP	RB	O	14	NMOD
16	may	may	B-VP	MD	O	3	SBAR
17	prolong	prolong	I-VP	VB	O	16	VC
18	QT	QT	B-NP	NN	O	19	NMOD
19	interval	interval	I-NP	NN	O	17	OBJ
20	and	and	O	CC	O	17	VMOD
21	induce	induce	B-VP	VB	O	17	VMOD
22	TdP	TdP	B-NP	NN	B-protein	21	OBJ
23	.	.	O	.	O	2	P

1	Diazepam-	Diazepam-	B-NP	NN	O	8	VMOD
2	,	,	O	,	O	8	P
3	scopolamine-	scopolamine-	B-NP	NN	O	8	SUB
4	and	and	O	CC	O	3	DEP
5	ageing	age	B-VP	VBG	O	3	NMOD
6	induced	induce	B-NP	VBN	O	7	NMOD
7	amnesia	amnesia	I-NP	NN	O	5	OBJ
8	served	serve	B-VP	VBD	O	0	ROOT
9	as	as	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	interoceptive	interoceptive	I-NP	JJ	O	13	NMOD
12	behavioral	behavioral	I-NP	JJ	O	13	NMOD
13	models	model	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	8	P

1	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	DCE	DCE	B-NP	NN	O	4	SUB
4	reversed	reverse	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	amnesia	amnesia	I-NP	NN	O	4	OBJ
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	scopolamine	scopolamine	B-NP	NN	O	17	NMOD
10	(	(	O	(	O	15	DEP
11	0.4	0.4	B-NP	CD	O	12	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	15	DEP
13	,	,	O	,	O	12	P
14	i.p.	i.p.	B-ADVP	RB	O	12	NMOD
15	)	)	O	)	O	9	NMOD
16	and	and	O	CC	O	17	NMOD
17	diazepam	diazepam	B-NP	NN	O	8	PMOD
18	(	(	O	(	O	23	DEP
19	1	1	B-NP	CD	O	20	NMOD
20	mg/kg	mg/kg	I-NP	NN	O	23	DEP
21	,	,	O	,	O	20	P
22	i.p.	i.p.	B-ADVP	RB	O	20	NMOD
23	)	)	O	)	O	17	NMOD
24	.	.	O	.	O	4	P

1	Cauda	Cauda	B-NP	NNP	O	3	NMOD
2	equina	equina	I-NP	NNP	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	11	NMOD
4	after	after	B-PP	IN	O	3	NMOD
5	epidural	epidural	B-NP	JJ	O	7	NMOD
6	steroid	steroid	I-NP	NN	O	7	NMOD
7	injection	injection	I-NP	NN	O	4	PMOD
8	:	:	O	:	O	3	P
9	a	a	B-NP	DT	O	11	NMOD
10	case	case	I-NP	NN	O	11	NMOD
11	report	report	I-NP	NN	O	0	ROOT
12	.	.	O	.	O	11	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Conventional	Conventional	B-NP	JJ	O	5	NMOD
4	treatment	treatment	I-NP	NN	O	5	NMOD
5	methods	method	I-NP	NNS	O	9	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	lumbusacral	lumbusacral	B-NP	JJ	O	8	NMOD
8	radiculopathy	radiculopathy	I-NP	NN	O	6	PMOD
9	are	be	B-VP	VBP	O	1	NMOD
10	physical	physical	B-NP	JJ	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	epidural	epidural	B-NP	JJ	O	15	NMOD
14	steroid	steroid	I-NP	NN	O	15	NMOD
15	injections	injection	I-NP	NNS	O	23	NMOD
16	,	,	O	,	O	23	P
17	oral	oral	B-NP	JJ	O	18	NMOD
18	medications	medication	I-NP	NNS	O	23	NMOD
19	,	,	O	,	O	23	P
20	and	and	O	CC	O	23	NMOD
21	spinal	spinal	B-NP	JJ	O	23	NMOD
22	manipulative	manipulative	I-NP	JJ	O	23	NMOD
23	therapy	therapy	I-NP	NN	O	9	PRD
24	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	following	follow	I-NP	VBG	O	3	NMOD
3	case	case	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	report	report	I-NP	NN	O	4	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	cauda	cauda	B-NP	NN	O	10	NMOD
9	equina	equina	I-NP	NN	O	10	NMOD
10	syndrome	syndrome	I-NP	NN	O	7	PMOD
11	possibly	possibly	B-VP	RB	O	12	VMOD
12	caused	cause	I-VP	VBN	O	10	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	epidural	epidural	B-NP	JJ	O	15	NMOD
15	injection	injection	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	triamcinolone	triamcinolone	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	bupivacaine	bupivacaine	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	4	P

1	CLINICAL	CLINICAL	B-NP	JJ	O	2	NMOD
2	FEATURES	FEATURES	I-NP	NNS	O	0	ROOT
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	6	NMOD
5	50-year-old	50-year-old	I-NP	JJ	O	6	NMOD
6	woman	woman	I-NP	NN	O	14	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	low	low	B-NP	JJ	O	9	NMOD
9	back	back	I-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	right	right	B-NP	JJ	O	13	NMOD
12	leg	leg	I-NP	NN	O	13	NMOD
13	pain	pain	I-NP	NN	O	7	PMOD
14	was	be	B-VP	VBD	O	2	NMOD
15	scheduled	schedule	I-VP	VBN	O	14	VC
16	for	for	B-PP	IN	O	15	VMOD
17	epidural	epidural	B-NP	JJ	O	19	NMOD
18	steroid	steroid	I-NP	NN	O	19	NMOD
19	injection	injection	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	2	P

1	High-dose	High-dose	B-NP	JJ	O	2	NMOD
2	testosterone	testosterone	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	atherosclerosis	atherosclerosis	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	postmenopausal	postmenopausal	B-NP	JJ	O	9	NMOD
9	women	woman	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	17	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	17	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	population-based	population-based	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	3	PMOD
8	513	513	B-NP	CD	O	11	NMOD
9	naturally	naturally	I-NP	RB	O	10	AMOD
10	postmenopausal	postmenopausal	I-NP	JJ	O	11	NMOD
11	women	woman	I-NP	NNS	O	7	PMOD
12	aged	age	B-VP	VBN	O	11	NMOD
13	54-67	54-67	B-NP	CD	O	14	NMOD
14	years	year	I-NP	NNS	O	12	AMOD
15	,	,	O	,	O	17	P
16	we	we	B-NP	PRP	O	17	SUB
17	studied	study	B-VP	VBD	O	0	ROOT
18	the	the	B-NP	DT	O	19	NMOD
19	association	association	I-NP	NN	O	17	OBJ
20	between	between	B-PP	IN	O	19	NMOD
21	self-reported	self-reported	B-NP	JJ	O	23	AMOD
22	intramuscularly	intramuscularly	I-NP	RB	O	23	AMOD
23	administered	administer	I-NP	VBN	O	26	NMOD
24	high-dose	high-dose	I-NP	JJ	O	26	NMOD
25	estrogen-testosterone	estrogen-testosterone	I-NP	NN	O	26	NMOD
26	therapy	therapy	I-NP	NN	O	35	NMOD
27	(	(	O	(	O	32	DEP
28	estradiol-	estradiol-	B-NP	NN	O	31	NMOD
29	and	and	O	CC	O	31	NMOD
30	testosterone	testosterone	B-NP	NN	O	31	NMOD
31	esters	ester	I-NP	NNS	O	32	DEP
32	)	)	O	)	O	26	NMOD
33	and	and	O	CC	O	35	NMOD
34	aortic	aortic	B-NP	JJ	O	35	NMOD
35	atherosclerosis	atherosclerosis	I-NP	NN	O	20	PMOD
36	.	.	O	.	O	17	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	3	SUB
3	remained	remain	B-VP	VBD	O	0	ROOT
4	after	after	B-PP	IN	O	3	VMOD
5	additional	additional	B-NP	JJ	O	6	NMOD
6	adjustment	adjustment	I-NP	NN	O	4	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	diabetes	diabetes	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	3	P
10	cholesterol	cholesterol	B-NP	NN	O	11	NMOD
11	level	level	I-NP	NN	O	19	NMOD
12	,	,	O	,	O	19	P
13	systolic	systolic	B-NP	JJ	O	15	NMOD
14	blood	blood	I-NP	NN	O	15	NMOD
15	pressure	pressure	I-NP	NN	O	19	NMOD
16	,	,	O	,	O	19	P
17	or	or	O	CC	O	19	NMOD
18	alcohol	alcohol	B-NP	NN	O	19	NMOD
19	use	use	I-NP	NN	O	3	VMOD
20	.	.	O	.	O	3	P

1	Sirolimus-associated	Sirolimus-associated	B-NP	JJ	O	2	NMOD
2	proteinuria	proteinuria	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	renal	renal	B-NP	JJ	O	5	NMOD
5	dysfunction	dysfunction	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	Sirolimus	Sirolimus	B-NP	NNP	O	2	SUB
2	represents	represent	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	major	major	I-NP	JJ	O	6	NMOD
5	therapeutic	therapeutic	I-NP	JJ	O	6	NMOD
6	advance	advance	I-NP	NN	O	2	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	prevention	prevention	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	acute	acute	B-NP	JJ	O	14	NMOD
12	renal	renal	I-NP	JJ	O	14	NMOD
13	allograft	allograft	I-NP	NN	O	14	NMOD
14	rejection	rejection	I-NP	NN	O	18	NMOD
15	and	and	O	CC	O	18	NMOD
16	chronic	chronic	B-NP	JJ	O	18	NMOD
17	allograft	allograft	I-NP	NN	O	18	NMOD
18	nephropathy	nephropathy	I-NP	NN	O	10	PMOD
19	.	.	O	.	O	2	P

1	Because	Because	B-SBAR	IN	O	17	VMOD
2	sirolimus	sirolimus	B-NP	NN	O	3	SUB
3	does	do	B-VP	VBZ	O	1	SBAR
4	not	not	I-VP	RB	O	3	VMOD
5	share	share	I-VP	VB	O	3	VC
6	the	the	B-NP	DT	O	10	NMOD
7	vasomotor	vasomotor	I-NP	NN	O	10	NMOD
8	renal	renal	I-NP	JJ	O	10	NMOD
9	adverse	adverse	I-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	5	OBJ
11	exhibited	exhibit	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	calcineurin	calcineurin	B-NP	NN	B-protein	14	NMOD
14	inhibitors	inhibitor	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	17	P
16	it	it	B-NP	PRP	O	17	SUB
17	has	have	B-VP	VBZ	O	0	ROOT
18	been	be	I-VP	VBN	O	17	VC
19	designated	designate	I-VP	VBN	O	18	VC
20	a	a	B-NP	DT	O	22	NMOD
21	'non-nephrotoxic	'non-nephrotoxic	I-NP	JJ	O	22	NMOD
22	drug	drug	I-NP	NN	O	19	VMOD
23	'	'	O	"	O	22	NMOD
24	.	.	O	.	O	17	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	clinical	clinical	B-NP	JJ	O	4	NMOD
4	reports	report	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	,	,	O	,	O	6	P
8	under	under	B-PP	IN	O	13	VMOD
9	some	some	B-NP	DT	O	10	NMOD
10	circumstances	circumstance	I-NP	NNS	O	8	PMOD
11	,	,	O	,	O	13	P
12	sirolimus	sirolimus	B-NP	NN	O	13	SUB
13	is	be	B-VP	VBZ	O	6	SBAR
14	associated	associate	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	proteinuria	proteinuria	B-NP	NN	O	20	NMOD
17	and	and	O	CC	O	20	NMOD
18	acute	acute	B-NP	JJ	O	20	NMOD
19	renal	renal	I-NP	JJ	O	20	NMOD
20	dysfunction	dysfunction	I-NP	NN	O	15	PMOD
21	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanisms	mechanism	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	sirolimus-associated	sirolimus-associated	B-NP	JJ	O	5	NMOD
5	proteinuria	proteinuria	I-NP	NNS	O	3	PMOD
6	are	be	B-VP	VBP	O	0	ROOT
7	multifactorial	multifactorial	B-ADJP	JJ	O	6	PRD
8	and	and	O	CC	O	6	VMOD
9	may	may	B-VP	MD	O	6	VMOD
10	be	be	I-VP	VB	O	9	VC
11	due	due	B-ADVP	JJ	O	12	PMOD
12	to	to	B-PP	TO	O	10	PRD
13	an	an	B-NP	DT	O	14	NMOD
14	increase	increase	I-NP	NN	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	glomerular	glomerular	B-NP	JJ	O	18	NMOD
17	capillary	capillary	I-NP	JJ	O	18	NMOD
18	pressure	pressure	I-NP	NN	O	15	PMOD
19	following	follow	B-PP	VBG	O	18	NMOD
20	calcineurin	calcineurin	B-NP	NN	B-protein	22	NMOD
21	inhibitor	inhibitor	I-NP	NN	O	22	NMOD
22	withdrawal	withdrawal	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	4	NMOD
2	acute	acute	I-NP	JJ	O	4	NMOD
3	renal	renal	I-NP	JJ	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	16	SUB
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	sirolimus	sirolimus	B-NP	NN	O	6	PMOD
8	(	(	O	(	O	15	DEP
9	such	such	B-PP	JJ	O	10	PMOD
10	as	as	I-PP	IN	O	15	DEP
11	in	in	B-PP	IN	O	10	PMOD
12	delayed	delay	B-NP	VBN	O	14	NMOD
13	graft	graft	I-NP	NN	O	14	NMOD
14	function	function	I-NP	NN	O	11	PMOD
15	)	)	O	)	O	7	NMOD
16	may	may	B-VP	MD	O	0	ROOT
17	be	be	I-VP	VB	O	16	VC
18	due	due	B-ADJP	JJ	O	17	PRD
19	to	to	B-PP	TO	O	18	AMOD
20	suppression	suppression	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	compensatory	compensatory	B-NP	JJ	O	25	NMOD
23	renal	renal	I-NP	JJ	O	25	NMOD
24	cell	cell	I-NP	NN	O	25	NMOD
25	proliferation	proliferation	I-NP	NN	O	28	NMOD
26	and	and	I-NP	CC	O	28	NMOD
27	survival/repair	survival/repair	I-NP	NN	O	28	NMOD
28	processes	process	I-NP	NNS	O	21	PMOD
29	.	.	O	.	O	16	P

1	Although	Although	B-SBAR	IN	O	12	VMOD
2	these	these	B-NP	DT	O	4	NMOD
3	adverse	adverse	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	5	SUB
5	occur	occur	B-VP	VBP	O	1	SBAR
6	in	in	B-PP	IN	O	5	VMOD
7	some	some	B-NP	DT	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	,	,	O	,	O	12	P
10	their	their	B-NP	PRP$	O	11	NMOD
11	occurrence	occurrence	I-NP	NN	O	12	SUB
12	could	could	B-VP	MD	O	0	ROOT
13	be	be	I-VP	VB	O	12	VC
14	minimised	minimise	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	knowledge	knowledge	B-NP	NN	O	44	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	molecular	molecular	I-NP	JJ	O	20	NMOD
20	effects	effect	I-NP	NNS	O	28	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	sirolimus	sirolimus	B-NP	NN	O	21	PMOD
23	on	on	B-PP	IN	O	20	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	kidney	kidney	I-NP	NN	O	23	PMOD
26	,	,	O	,	O	28	P
27	the	the	B-NP	DT	O	28	NMOD
28	use	use	I-NP	NN	O	17	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	sirolimus	sirolimus	B-NP	NN	O	29	PMOD
31	in	in	B-PP	IN	O	28	NMOD
32	appropriate	appropriate	B-NP	JJ	O	34	NMOD
33	patient	patient	I-NP	NN	O	34	NMOD
34	populations	population	I-NP	NNS	O	31	PMOD
35	,	,	O	,	O	44	P
36	close	close	B-NP	JJ	O	37	NMOD
37	monitoring	monitoring	I-NP	NN	O	44	NMOD
38	of	of	B-PP	IN	O	37	NMOD
39	proteinuria	proteinuria	B-NP	NN	O	42	NMOD
40	and	and	O	CC	O	42	NMOD
41	renal	renal	B-NP	JJ	O	42	NMOD
42	function	function	I-NP	NN	O	38	PMOD
43	,	,	O	,	O	44	P
44	use	use	B-NP	NN	O	15	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	angiotensin-converting	angiotensin-converting	B-NP	JJ	O	48	NMOD
47	enzyme	enzyme	I-NP	NN	O	48	NMOD
48	inhibitors	inhibitor	I-NP	NNS	O	53	NMOD
49	or	or	O	CC	O	53	NMOD
50	angiotensin	angiotensin	B-NP	NN	O	53	NMOD
51	II	II	I-NP	CD	O	53	NMOD
52	receptor	receptor	I-NP	NN	O	53	NMOD
53	blockers	blocker	I-NP	NNS	O	45	PMOD
54	if	if	B-SBAR	IN	O	14	VMOD
55	proteinuria	proteinuria	B-NP	NN	O	56	SUB
56	occurs	occur	B-VP	VBZ	O	54	SBAR
57	and	and	O	CC	O	58	NMOD
58	withdrawal	withdrawal	B-NP	NN	O	54	SBAR
59	if	if	B-SBAR	IN	O	58	VMOD
60	needed	need	B-VP	VBN	O	59	SBAR
61	.	.	O	.	O	12	P

1	Progressive	Progressive	B-NP	JJ	O	2	NMOD
2	myopathy	myopathy	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	up-regulation	up-regulation	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	MHC-I	MHC-I	B-NP	NN	B-protein	5	PMOD
7	associated	associate	B-VP	VBN	O	4	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	statin	statin	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	Statins	Statin	B-NP	NNS	B-protein	2	SUB
2	can	can	B-VP	MD	O	0	ROOT
3	cause	cause	I-VP	VB	O	2	VC
4	a	a	B-NP	DT	O	6	NMOD
5	necrotizing	necrotize	I-NP	VBG	O	6	NMOD
6	myopathy	myopathy	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	hyperCKaemia	hyperCKaemia	I-NP	NN	O	3	OBJ
9	which	which	B-NP	WDT	O	8	NMOD
10	is	be	B-VP	VBZ	O	9	SBAR
11	reversible	reversible	B-ADJP	JJ	O	10	PRD
12	on	on	B-PP	IN	O	11	AMOD
13	cessation	cessation	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	drug	drug	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	What	What	B-NP	WP	O	6	SUB
2	is	be	B-VP	VBZ	O	1	NMOD
3	less	less	I-VP	RBR	O	4	AMOD
4	well	well	I-VP	RB	O	2	VMOD
5	known	know	I-VP	VBN	O	2	VC
6	is	be	B-VP	VBZ	O	0	ROOT
7	a	a	B-NP	DT	O	8	NMOD
8	phenomenon	phenomenon	I-NP	NN	O	6	PRD
9	whereby	whereby	B-ADVP	WRB	O	8	NMOD
10	statins	statin	B-NP	NNS	O	11	SUB
11	may	may	B-VP	MD	O	9	SBAR
12	induce	induce	I-VP	VB	O	11	VC
13	a	a	B-NP	DT	O	14	NMOD
14	myopathy	myopathy	I-NP	NN	O	12	OBJ
15	,	,	O	,	O	14	P
16	which	which	B-NP	WDT	O	14	NMOD
17	persists	persist	B-VP	VBZ	O	16	SBAR
18	or	or	O	CC	O	17	VMOD
19	may	may	B-VP	MD	O	17	VMOD
20	progress	progress	I-VP	VB	O	19	VC
21	after	after	B-PP	IN	O	20	VMOD
22	stopping	stop	B-VP	VBG	O	21	PMOD
23	the	the	B-NP	DT	O	24	NMOD
24	drug	drug	I-NP	NN	O	22	OBJ
25	.	.	O	.	O	6	P

1	These	These	B-NP	DT	O	2	NMOD
2	observations	observation	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	statins	statin	B-NP	NNS	B-protein	6	SUB
6	may	may	B-VP	MD	O	4	SBAR
7	initiate	initiate	I-VP	VB	O	6	VC
8	an	an	B-NP	DT	O	10	NMOD
9	immune-mediated	immune-mediated	I-NP	JJ	O	10	NMOD
10	myopathy	myopathy	I-NP	NN	O	7	OBJ
11	that	that	B-NP	WDT	O	10	NMOD
12	persists	persist	B-VP	VBZ	O	11	SBAR
13	after	after	B-PP	IN	O	12	VMOD
14	withdrawal	withdrawal	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	drug	drug	I-NP	NN	O	15	PMOD
18	and	and	O	CC	O	12	VMOD
19	responds	respond	B-VP	VBZ	O	12	VMOD
20	to	to	B-PP	TO	O	19	VMOD
21	immunosuppressive	immunosuppressive	B-NP	JJ	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	3	P

1	Clonidine	Clonidine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	bradycardia	bradycardia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	conscious	conscious	B-NP	JJ	O	7	NMOD
6	alpha2ABC-/-	alpha2ABC-/-	I-NP	JJ	O	7	NMOD
7	mice	mouse	I-NP	NNS	O	4	PMOD
8	was	be	B-VP	VBD	O	2	VMOD
9	32.3	32.3	B-NP	CD	O	10	NMOD
10	%	%	I-NP	NN	O	17	NMOD
11	(	(	O	(	O	14	DEP
12	10	10	B-NP	CD	O	13	NMOD
13	microg/kg	microg/kg	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	and	and	O	CC	O	17	NMOD
16	26.6	26.6	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	8	PRD
18	(	(	O	(	O	21	DEP
19	100	100	B-NP	CD	O	20	NMOD
20	microg/kg	microg/kg	I-NP	NN	O	21	DEP
21	)	)	O	)	O	8	VMOD
22	of	of	B-PP	IN	O	8	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	effect	effect	I-NP	NN	O	22	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	wild-type	wild-type	B-NP	JJ	O	27	NMOD
27	mice	mouse	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	influence	influence	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	smoking	smoking	B-NP	NN	O	3	PMOD
5	during	during	B-PP	IN	O	2	NMOD
6	pregnancy	pregnancy	B-NP	NN	O	5	PMOD
7	on	on	B-PP	IN	O	2	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	developing	develop	I-NP	VBG	O	10	NMOD
10	cochlea	cochlea	I-NP	NN	O	7	PMOD
11	has	have	B-VP	VBZ	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	been	be	I-VP	VBN	O	11	VC
14	estimated	estimate	I-VP	VBN	O	13	VC
15	,	,	O	,	O	11	P
16	although	although	B-SBAR	IN	O	11	VMOD
17	smoking	smoking	B-NP	NN	O	18	SUB
18	has	have	B-VP	VBZ	O	16	SBAR
19	been	be	I-VP	VBN	O	18	VC
20	positively	positively	I-VP	RB	O	19	VMOD
21	associated	associate	I-VP	VBN	O	19	VC
22	with	with	B-PP	IN	O	21	VMOD
23	hearing	hearing	B-NP	NN	O	24	NMOD
24	loss	loss	I-NP	NN	O	22	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	adults	adult	B-NP	NNS	O	25	PMOD
27	.	.	O	.	O	11	P

1	Neuroinflammation	Neuroinflammation	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	behavioral	behavioral	I-NP	JJ	O	4	NMOD
4	abnormalities	abnormality	I-NP	NNS	O	12	NMOD
5	after	after	B-PP	IN	O	4	NMOD
6	neonatal	neonatal	B-NP	JJ	O	8	NMOD
7	terbutaline	terbutaline	I-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	:	:	O	:	O	4	P
12	implications	implication	B-NP	NNS	O	0	ROOT
13	for	for	B-PP	IN	O	12	NMOD
14	autism	autism	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	12	P

1	Terbutaline	Terbutaline	B-NP	NN	O	5	NMOD
2	,	,	O	,	O	5	P
3	a	a	B-NP	DT	O	5	NMOD
4	beta2-adrenoceptor	beta2-adrenoceptor	I-NP	NN	O	5	NMOD
5	agonist	agonist	I-NP	NN	O	12	SUB
6	used	use	B-VP	VBN	O	5	NMOD
7	to	to	B-VP	TO	O	8	VMOD
8	arrest	arrest	I-VP	VB	O	6	VMOD
9	preterm	preterm	B-NP	JJ	O	10	NMOD
10	labor	labor	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	5	P
12	has	have	B-VP	VBZ	O	0	ROOT
13	been	be	I-VP	VBN	O	12	VC
14	associated	associate	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	increased	increase	B-NP	VBN	O	17	NMOD
17	concordance	concordance	I-NP	NN	O	15	PMOD
18	for	for	B-PP	IN	O	17	NMOD
19	autism	autism	B-NP	NN	O	18	PMOD
20	in	in	B-PP	IN	O	17	NMOD
21	dizygotic	dizygotic	B-NP	JJ	O	22	NMOD
22	twins	twin	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	12	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	myocarditis	myocarditis	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	clozapine	clozapine	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	4	P
3	A	A	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	14	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	acute	acute	B-NP	JJ	O	7	NMOD
7	myocarditis	myocarditis	I-NP	NN	O	5	PMOD
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	commencement	commencement	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	clozapine	clozapine	B-NP	NN	O	12	PMOD
14	is	be	B-VP	VBZ	O	0	ROOT
15	described	describe	I-VP	VBN	O	14	VC
16	,	,	O	,	O	14	P
17	highlighting	highlight	B-VP	VBG	O	14	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	onset	onset	I-NP	NN	O	25	NMOD
20	,	,	O	,	O	25	P
21	course	course	B-NP	NN	O	25	NMOD
22	and	and	O	CC	O	25	NMOD
23	possible	possible	B-NP	JJ	O	25	NMOD
24	contributing	contribute	I-NP	VBG	O	25	NMOD
25	factors	factor	I-NP	NNS	O	17	OBJ
26	.	.	O	.	O	14	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	20-year-old	20-year-old	I-NP	JJ	O	5	NMOD
5	male	male	I-NP	NN	O	8	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	schizophrenia	schizophrenia	B-NP	NN	O	6	PMOD
8	developed	develop	B-VP	VBD	O	1	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	sudden	sudden	I-NP	JJ	O	11	NMOD
11	onset	onset	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	myocarditis	myocarditis	B-NP	NN	O	12	PMOD
14	after	after	B-PP	IN	O	11	NMOD
15	commencement	commencement	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	clozapine	clozapine	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Myocarditis	Myocarditis	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	an	an	B-NP	DT	O	8	NMOD
6	increasingly	increasingly	I-NP	RB	O	7	AMOD
7	recognized	recognize	I-NP	VBN	O	8	NMOD
8	complication	complication	I-NP	NN	O	4	PRD
9	associated	associate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	use	use	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	clozapine	clozapine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	1	P

1	Considering	Consider	B-VP	VBG	O	4	VMOD
2	that	that	B-NP	DT	O	3	NMOD
3	clozapine	clozapine	I-NP	NN	O	4	SUB
4	remains	remain	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	gold	gold	I-NP	JJ	O	7	NMOD
7	standard	standard	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	treatment	treatment	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	resistant	resistant	B-NP	JJ	O	12	NMOD
12	psychosis	psychosis	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	4	P
14	there	there	B-NP	EX	O	15	SUB
15	is	be	B-VP	VBZ	O	4	VMOD
16	an	an	B-NP	DT	O	18	NMOD
17	urgent	urgent	I-NP	JJ	O	18	NMOD
18	need	need	I-NP	NN	O	15	PRD
19	to	to	B-VP	TO	O	20	VMOD
20	raise	raise	I-VP	VB	O	18	NMOD
21	awareness	awareness	B-NP	NN	O	20	OBJ
22	among	among	B-PP	IN	O	21	NMOD
23	medical	medical	B-NP	JJ	O	25	AMOD
24	and	and	I-NP	CC	O	25	AMOD
25	paramedical	paramedical	I-NP	JJ	O	26	NMOD
26	staff	staff	I-NP	NN	O	22	PMOD
27	involved	involve	B-VP	VBN	O	26	NMOD
28	in	in	B-PP	IN	O	27	VMOD
29	the	the	B-NP	DT	O	30	NMOD
30	care	care	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	these	these	B-NP	DT	O	33	NMOD
33	patients	patient	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	4	P

1	Encephalopathy	Encephalopathy	B-NP	NN	O	0	ROOT
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	levetiracetam	levetiracetam	B-NP	NN	O	3	PMOD
5	added	add	B-VP	VBN	O	4	NMOD
6	to	to	I-VP	TO	O	7	VMOD
7	valproate	valproate	I-VP	VB	O	5	VMOD
8	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	report	report	B-VP	VBP	O	0	ROOT
5	on	on	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	manifestation	manifestation	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	levetiracetam	levetiracetam	I-NP	NN	O	15	NMOD
11	(	(	O	(	O	13	DEP
12	LEV	LEV	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	induced	induce	B-NP	VBN	O	15	NMOD
15	encephalopathy	encephalopathy	I-NP	NN	O	8	PMOD
16	.	.	O	.	O	4	P

1	FINDINGS	FINDINGS	B-NP	NNS	O	5	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	28-year-old	28-year-old	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	13	SUB
6	suffering	suffer	B-VP	VBG	O	5	NMOD
7	from	from	B-PP	IN	O	6	VMOD
8	idiopathic	idiopathic	B-NP	JJ	O	9	NMOD
9	epilepsy	epilepsy	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	generalized	generalize	B-NP	VBN	O	12	NMOD
12	seizures	seizure	I-NP	NNS	O	10	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	treated	treat	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	LEV	LEV	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	20	DEP
18	3000	3000	B-NP	CD	O	19	NMOD
19	mg	mg	I-NP	NN	O	20	DEP
20	)	)	O	)	O	16	NMOD
21	added	add	B-VP	VBN	O	16	NMOD
22	to	to	B-PP	TO	O	21	VMOD
23	valproate	valproate	B-NP	NN	O	22	PMOD
24	(	(	O	(	O	26	DEP
25	VPA	VPA	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	(	(	O	(	O	30	DEP
28	2000	2000	B-NP	CD	O	29	NMOD
29	mg	mg	I-NP	NN	O	30	DEP
30	)	)	O	)	O	23	NMOD
31	.	.	O	.	O	13	P

1	Norepinephrine	Norepinephrine	B-NP	NN	O	2	NMOD
2	signaling	signaling	I-NP	NN	O	6	SUB
3	through	through	B-PP	IN	O	2	NMOD
4	beta-adrenergic	beta-adrenergic	B-NP	JJ	B-protein	5	NMOD
5	receptors	receptor	I-NP	NNS	I-protein	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	critical	critical	B-ADJP	JJ	O	6	PRD
8	for	for	B-PP	IN	O	7	AMOD
9	expression	expression	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	cocaine	cocaine	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	anxiety	anxiety	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	6	P

1	While	While	B-SBAR	IN	O	16	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	mechanisms	mechanism	I-NP	NNS	O	9	SUB
4	underlying	underlie	B-VP	VBG	O	3	NMOD
5	cocaine	cocaine	B-NP	NN	O	8	NMOD
6	's	's	B-NP	POS	O	8	NMOD
7	rewarding	rewarding	I-NP	JJ	O	8	NMOD
8	effects	effect	I-NP	NNS	O	4	OBJ
9	have	have	B-VP	VBP	O	1	SBAR
10	been	be	I-VP	VBN	O	9	VC
11	studied	study	I-VP	VBN	O	10	VC
12	extensively	extensively	B-ADVP	RB	O	11	VMOD
13	,	,	O	,	O	16	P
14	less	less	B-NP	JJR	O	15	NMOD
15	attention	attention	I-NP	NN	O	16	SUB
16	has	have	B-VP	VBZ	O	0	ROOT
17	been	be	I-VP	VBN	O	16	VC
18	paid	pay	I-VP	VBN	O	17	VC
19	to	to	B-PP	TO	O	18	VMOD
20	the	the	B-NP	DT	O	23	NMOD
21	unpleasant	unpleasant	I-NP	JJ	O	23	NMOD
22	behavioral	behavioral	I-NP	JJ	O	23	NMOD
23	states	state	I-NP	NNS	O	19	PMOD
24	induced	induce	B-VP	VBN	O	23	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	cocaine	cocaine	B-NP	NN	O	25	PMOD
27	,	,	O	,	O	23	P
28	such	such	B-PP	JJ	O	29	PMOD
29	as	as	I-PP	IN	O	23	NMOD
30	anxiety	anxiety	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	16	P

1	METHODS	METHODS	B-NP	NNS	O	8	VMOD
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	8	VMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	8	P
7	we	we	B-NP	PRP	O	8	SUB
8	evaluated	evaluate	B-VP	VBD	O	0	ROOT
9	the	the	B-NP	DT	O	10	NMOD
10	performance	performance	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	dopamine	dopamine	B-NP	NN	O	14	NMOD
13	beta-hydroxylase	beta-hydroxylase	I-NP	NN	O	14	NMOD
14	knockout	knockout	I-NP	NN	O	19	NMOD
15	(	(	O	(	O	18	DEP
16	Dbh	Dbh	B-NP	NN	O	18	DEP
17	-/-	-/-	B-ADJP	JJ	O	16	NMOD
18	)	)	O	)	O	14	NMOD
19	mice	mouse	B-NP	NNS	O	11	PMOD
20	,	,	O	,	O	19	P
21	which	which	B-NP	WDT	O	19	NMOD
22	lack	lack	B-VP	VBP	O	21	SBAR
23	norepinephrine	norepinephrine	B-NP	NN	O	22	OBJ
24	(	(	O	(	O	26	DEP
25	NE	NE	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	,	,	O	,	O	10	P
28	in	in	B-PP	IN	O	10	NMOD
29	the	the	B-NP	DT	O	32	NMOD
30	elevated	elevated	I-NP	JJ	O	32	NMOD
31	plus	plus	O	CC	O	32	NMOD
32	maze	maze	B-NP	NN	O	28	PMOD
33	(	(	O	(	O	35	DEP
34	EPM	EPM	B-NP	NN	B-protein	35	DEP
35	)	)	O	)	O	32	NMOD
36	to	to	B-VP	TO	O	37	VMOD
37	examine	examine	I-VP	VB	O	10	NMOD
38	the	the	B-NP	DT	O	39	NMOD
39	contribution	contribution	I-NP	NN	O	37	OBJ
40	of	of	B-PP	IN	O	39	NMOD
41	noradrenergic	noradrenergic	B-NP	JJ	O	42	NMOD
42	signaling	signaling	I-NP	NN	O	40	PMOD
43	to	to	B-PP	TO	O	39	NMOD
44	cocaine	cocaine	B-NP	NN	O	46	NMOD
45	induced	induced	I-NP	JJ	O	46	NMOD
46	anxiety	anxiety	I-NP	NN	O	43	PMOD
47	.	.	O	.	O	8	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	found	find	B-VP	VBD	O	1	NMOD
5	that	that	B-SBAR	IN	O	4	VMOD
6	cocaine	cocaine	B-NP	NN	O	8	SUB
7	dose-dependently	dose-dependently	B-ADVP	RB	O	8	VMOD
8	increased	increase	B-VP	VBD	O	5	SBAR
9	anxiety-like	anxiety-like	B-NP	JJ	O	10	NMOD
10	behavior	behavior	I-NP	NN	O	17	NMOD
11	in	in	B-PP	IN	O	10	NMOD
12	control	control	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	16	DEP
14	Dbh	Dbh	B-NP	NN	O	16	DEP
15	+/-	+/-	O	SYM	O	14	NMOD
16	)	)	O	)	O	10	NMOD
17	mice	mouse	B-NP	NNS	O	8	OBJ
18	,	,	O	,	O	8	P
19	as	as	B-SBAR	IN	O	8	VMOD
20	measured	measure	B-VP	VBN	O	19	SBAR
21	by	by	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	23	NMOD
23	decrease	decrease	I-NP	NN	O	21	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	open	open	B-NP	JJ	O	27	NMOD
26	arm	arm	I-NP	NN	O	27	NMOD
27	exploration	exploration	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	1	P

1	Cocaine	Cocaine	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	anxiety	anxiety	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	also	also	I-VP	RB	O	4	VMOD
6	attenuated	attenuate	I-VP	VBN	O	4	VC
7	in	in	B-PP	IN	O	6	VMOD
8	Dbh	Dbh	B-NP	NNP	O	10	NMOD
9	+/-	+/-	O	CC	O	10	NMOD
10	mice	mouse	B-NP	NNS	O	7	PMOD
11	following	follow	B-PP	VBG	O	6	VMOD
12	administration	administration	B-NP	NN	O	18	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	disulfiram	disulfiram	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	18	P
16	a	a	B-NP	DT	O	18	NMOD
17	dopamine	dopamine	I-NP	NN	B-protein	18	NMOD
18	beta-hydroxylase	beta-hydroxylase	I-NP	NN	I-protein	22	NMOD
19	(	(	O	(	O	21	DEP
20	DBH	DBH	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	inhibitor	inhibitor	B-NP	NN	O	11	PMOD
23	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	9	VMOD
2	experiments	experiment	B-NP	NNS	O	1	PMOD
3	using	use	B-VP	VBG	O	2	NMOD
4	specific	specific	B-NP	JJ	O	6	NMOD
5	adrenergic	adrenergic	I-NP	JJ	O	6	NMOD
6	antagonists	antagonist	I-NP	NNS	O	3	OBJ
7	,	,	O	,	O	9	P
8	we	we	B-NP	PRP	O	9	SUB
9	found	find	B-VP	VBD	O	0	ROOT
10	that	that	B-SBAR	IN	O	9	VMOD
11	pretreatment	pretreatment	B-NP	NN	O	18	SUB
12	with	with	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	17	NMOD
14	beta-adrenergic	beta-adrenergic	I-NP	JJ	O	17	NMOD
15	receptor	receptor	I-NP	NN	O	17	NMOD
16	antagonist	antagonist	I-NP	NN	O	17	NMOD
17	propranolol	propranolol	I-NP	NN	O	12	PMOD
18	blocked	block	B-VP	VBD	O	10	SBAR
19	cocaine	cocaine	B-NP	NN	O	22	NMOD
20	induced	induced	I-NP	JJ	O	22	NMOD
21	anxiety-like	anxiety-like	I-NP	JJ	O	22	NMOD
22	behavior	behavior	I-NP	NN	O	18	OBJ
23	in	in	B-PP	IN	O	18	VMOD
24	Dbh	Dbh	B-NP	NNP	O	29	NMOD
25	+/-	+/-	O	CC	O	29	NMOD
26	and	and	O	CC	O	29	NMOD
27	wild-type	wild-type	B-NP	JJ	O	29	NMOD
28	C57BL6/J	C57BL6/J	I-NP	NN	O	29	NMOD
29	mice	mouse	I-NP	NNS	O	23	PMOD
30	,	,	O	,	O	18	P
31	while	while	B-SBAR	IN	O	18	VMOD
32	the	the	B-NP	DT	O	38	NMOD
33	alpha	alpha	I-NP	NN	B-protein	38	NMOD
34	(	(	O	(	I-protein	38	NMOD
35	1	1	B-NP	CD	I-protein	38	NMOD
36	)	)	O	)	I-protein	38	NMOD
37	antagonist	antagonist	B-NP	NN	I-protein	38	NMOD
38	prazosin	prazosin	I-NP	NN	I-protein	41	NMOD
39	and	and	O	CC	O	41	NMOD
40	the	the	B-NP	DT	O	41	NMOD
41	alpha	alpha	I-NP	NN	O	46	NMOD
42	(	(	O	(	O	44	DEP
43	2	2	B-NP	CD	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	antagonist	antagonist	B-NP	NN	O	46	NMOD
46	yohimbine	yohimbine	I-NP	NN	O	47	SUB
47	had	have	B-VP	VBD	O	31	SBAR
48	no	no	B-NP	DT	O	49	NMOD
49	effect	effect	I-NP	NN	O	47	OBJ
50	.	.	O	.	O	9	P

1	Clonidine	Clonidine	B-NP	NN	O	0	ROOT
2	for	for	B-PP	IN	O	1	NMOD
3	attention-deficit/hyperactivity	attention-deficit/hyperactivity	B-NP	NN	O	4	NMOD
4	disorder	disorder	I-NP	NN	O	2	PMOD
5	:	:	O	:	O	1	P
6	II	II	B-NP	CD	O	1	NMOD
7	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	examine	examine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	safety	safety	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	tolerability	tolerability	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	clonidine	clonidine	B-NP	NN	O	9	PMOD
11	used	use	B-VP	VBN	O	10	NMOD
12	alone	alone	B-ADVP	RB	O	11	VMOD
13	or	or	O	CC	O	12	DEP
14	with	with	B-PP	IN	O	12	DEP
15	methylphenidate	methylphenidate	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	children	child	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	attention-deficit/hyperactivity	attention-deficit/hyperactivity	B-NP	NN	O	20	NMOD
20	disorder	disorder	I-NP	NN	O	18	PMOD
21	(	(	O	(	O	23	DEP
22	ADHD	ADHD	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	.	.	O	.	O	1	P

1	METHOD	METHOD	B-NP	NN	O	15	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	15	VMOD
4	a	a	B-NP	DT	O	9	NMOD
5	16-week	16-week	I-NP	JJ	O	8	AMOD
6	multicenter	multicenter	I-NP	JJ	O	8	AMOD
7	,	,	I-NP	,	O	8	P
8	double-blind	double-blind	I-NP	JJ	O	9	NMOD
9	trial	trial	I-NP	NN	O	3	PMOD
10	,	,	O	,	O	15	P
11	122	122	B-NP	CD	O	12	NMOD
12	children	child	I-NP	NNS	O	15	SUB
13	with	with	B-PP	IN	O	12	NMOD
14	ADHD	ADHD	B-NP	NN	O	13	PMOD
15	were	be	B-VP	VBD	O	0	ROOT
16	randomly	randomly	I-VP	RB	O	15	VMOD
17	assigned	assign	I-VP	VBN	O	15	VC
18	to	to	B-PP	TO	O	17	VMOD
19	clonidine	clonidine	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	24	DEP
21	n	n	B-NP	NN	O	24	DEP
22	=	=	B-VP	SYM	O	21	NMOD
23	31	31	B-NP	CD	O	22	AMOD
24	)	)	O	)	O	19	NMOD
25	,	,	O	,	O	35	P
26	methylphenidate	methylphenidate	B-NP	NN	O	35	NMOD
27	(	(	O	(	O	31	DEP
28	n	n	B-NP	NN	O	31	DEP
29	=	=	B-VP	SYM	O	28	NMOD
30	29	29	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	26	NMOD
32	,	,	O	,	O	35	P
33	clonidine	clonidine	B-NP	NN	O	35	NMOD
34	and	and	O	CC	O	35	NMOD
35	methylphenidate	methylphenidate	B-NP	NN	O	43	NMOD
36	(	(	O	(	O	40	DEP
37	n	n	B-NP	NN	O	40	DEP
38	=	=	B-VP	SYM	O	37	NMOD
39	32	32	B-NP	CD	O	38	AMOD
40	)	)	O	)	O	35	NMOD
41	,	,	O	,	O	43	P
42	or	or	O	CC	O	43	NMOD
43	placebo	placebo	B-NP	NN	O	15	VMOD
44	(	(	O	(	O	48	DEP
45	n	n	B-NP	NN	O	47	SUB
46	=	=	B-VP	SYM	O	47	VMOD
47	30	30	B-NP	CD	O	48	DEP
48	)	)	O	)	O	43	NMOD
49	.	.	O	.	O	15	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	There	There	B-NP	EX	O	4	SUB
4	were	be	B-VP	VBD	O	1	NMOD
5	more	more	B-NP	JJR	O	6	NMOD
6	incidents	incident	I-NP	NNS	O	4	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	bradycardia	bradycardia	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	subjects	subject	B-NP	NNS	O	9	PMOD
11	treated	treat	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	clonidine	clonidine	B-NP	NN	O	12	PMOD
14	compared	compare	B-PP	VBN	O	4	VMOD
15	with	with	B-PP	IN	O	14	PMOD
16	those	those	B-NP	DT	O	15	PMOD
17	not	not	B-VP	RB	O	18	VMOD
18	treated	treat	I-VP	VBN	O	16	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	clonidine	clonidine	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	30	DEP
22	17.5	17.5	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	26	NMOD
24	versus	versus	B-PP	IN	O	26	NMOD
25	3.4	3.4	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	29	NMOD
27	;	;	O	:	O	29	P
28	p	p	B-NP	NN	O	29	NMOD
29	=.02	=.02	I-NP	NN	O	30	DEP
30	)	)	O	)	O	20	NMOD
31	,	,	O	,	O	4	P
32	but	but	O	CC	O	31	AMOD
33	no	no	B-NP	DT	O	37	NMOD
34	other	other	I-NP	JJ	O	37	NMOD
35	significant	significant	I-NP	JJ	O	37	NMOD
36	group	group	I-NP	NN	O	37	NMOD
37	differences	difference	I-NP	NNS	O	32	PRD
38	regarding	regard	B-VP	VBG	O	37	NMOD
39	electrocardiogram	electrocardiogram	B-NP	NN	O	43	NMOD
40	and	and	O	CC	O	43	NMOD
41	other	other	B-NP	JJ	O	43	NMOD
42	cardiovascular	cardiovascular	I-NP	JJ	O	43	NMOD
43	outcomes	outcome	I-NP	NNS	O	38	OBJ
44	.	.	O	.	O	1	P

1	Drowsiness	Drowsiness	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	common	common	B-ADJP	JJ	O	2	PRD
4	on	on	B-PP	IN	O	3	AMOD
5	clonidine	clonidine	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	2	P
7	but	but	O	CC	O	2	VMOD
8	generally	generally	B-VP	RB	O	9	VMOD
9	resolved	resolve	I-VP	VBN	O	2	VC
10	by	by	B-PP	IN	O	9	VMOD
11	6	6	B-NP	CD	O	13	AMOD
12	to	to	I-NP	TO	O	13	AMOD
13	8	8	I-NP	CD	O	14	NMOD
14	weeks	week	I-NP	NNS	O	10	PMOD
15	.	.	O	.	O	2	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Clonidine	Clonidine	B-NP	NN	O	11	SUB
4	,	,	O	,	O	3	P
5	used	use	B-VP	VBN	O	3	NMOD
6	alone	alone	B-ADVP	RB	O	5	VMOD
7	or	or	O	CC	O	6	DEP
8	with	with	B-PP	IN	O	6	DEP
9	methylphenidate	methylphenidate	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	3	P
11	appears	appear	B-VP	VBZ	O	1	NMOD
12	safe	safe	B-ADJP	JJ	O	15	AMOD
13	and	and	O	CC	O	15	AMOD
14	well	well	B-ADJP	RB	O	15	AMOD
15	tolerated	tolerate	I-ADJP	VBN	O	11	VC
16	in	in	B-PP	IN	O	15	VMOD
17	childhood	childhood	B-NP	NN	O	18	NMOD
18	ADHD	ADHD	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	1	P

1	Thalidomide	Thalidomide	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	limited	limit	I-VP	VBN	O	2	VC
4	single-agent	single-agent	B-NP	JJ	O	5	NMOD
5	activity	activity	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	relapsed	relapsed	B-NP	JJ	O	12	NMOD
8	or	or	I-NP	CC	O	12	NMOD
9	refractory	refractory	I-NP	JJ	O	12	NMOD
10	indolent	indolent	I-NP	JJ	O	12	NMOD
11	non-Hodgkin	non-Hodgkin	I-NP	JJ	O	12	NMOD
12	lymphomas	lymphoma	I-NP	NNS	O	6	PMOD
13	:	:	O	:	O	2	P
14	a	a	B-NP	DT	O	17	NMOD
15	phase	phase	I-NP	NN	O	17	NMOD
16	II	II	I-NP	CD	O	17	NMOD
17	trial	trial	I-NP	NN	O	2	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	24	NMOD
20	Cancer	Cancer	I-NP	NNP	O	24	NMOD
21	and	and	I-NP	CC	O	24	NMOD
22	Leukemia	Leukemia	I-NP	NNP	O	24	NMOD
23	Group	Group	I-NP	NNP	O	24	NMOD
24	B	B	I-NP	NNP	O	18	PMOD
25	.	.	O	.	O	2	P

1	Thalidomide	Thalidomide	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	18	NMOD
3	an	an	B-NP	DT	O	5	NMOD
4	immunomodulatory	immunomodulatory	I-NP	JJ	O	5	NMOD
5	agent	agent	I-NP	NN	O	2	PRD
6	with	with	B-PP	IN	O	5	NMOD
7	demonstrated	demonstrate	B-NP	VBN	O	8	NMOD
8	activity	activity	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	multiple	multiple	B-NP	JJ	O	11	NMOD
11	myeloma	myeloma	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	18	P
13	mantle	mantle	B-NP	NN	O	15	NMOD
14	cell	cell	I-NP	NN	O	15	NMOD
15	lymphoma	lymphoma	I-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	lymphoplasmacytic	lymphoplasmacytic	B-NP	JJ	O	18	NMOD
18	lymphoma	lymphoma	I-NP	NN	O	0	ROOT
19	.	.	O	.	O	18	P

1	Between	Between	B-PP	IN	O	14	VMOD
2	July	July	B-NP	NNP	O	5	NMOD
3	2001	2001	I-NP	CD	O	2	NMOD
4	and	and	O	CC	O	5	NMOD
5	April	April	B-NP	NNP	O	1	SBAR
6	2004	2004	I-NP	CD	O	5	NMOD
7	,	,	O	,	O	14	P
8	24	24	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	14	SUB
10	with	with	B-PP	IN	O	9	NMOD
11	relapsed/refractory	relapsed/refractory	B-NP	NN	O	13	NMOD
12	indolent	indolent	I-NP	JJ	O	13	NMOD
13	lymphomas	lymphoma	I-NP	NNS	O	10	PMOD
14	received	receive	B-VP	VBD	O	0	ROOT
15	thalidomide	thalidomide	B-NP	IN	O	14	VMOD
16	200	200	I-NP	CD	O	17	NMOD
17	mg	mg	I-NP	NN	O	27	NMOD
18	daily	daily	B-ADVP	RB	O	17	NMOD
19	with	with	B-PP	IN	O	18	PMOD
20	escalation	escalation	B-NP	NN	O	19	PMOD
21	by	by	B-PP	IN	O	18	DEP
22	100	100	B-NP	CD	O	23	NMOD
23	mg	mg	I-NP	NN	O	21	PMOD
24	daily	daily	B-ADVP	RB	O	27	NMOD
25	every	every	B-NP	DT	O	27	NMOD
26	1-2	1-2	I-NP	CD	O	27	NMOD
27	weeks	week	I-NP	NNS	O	15	PMOD
28	as	as	B-SBAR	IN	O	14	VMOD
29	tolerated	tolerate	B-VP	VBN	O	28	SBAR
30	,	,	O	,	O	29	P
31	up	up	B-ADVP	IN	O	32	PMOD
32	to	to	B-PP	TO	O	29	VMOD
33	a	a	B-NP	DT	O	34	NMOD
34	maximum	maximum	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	800	800	B-NP	CD	O	37	NMOD
37	mg	mg	I-NP	NN	O	35	PMOD
38	daily	daily	B-ADVP	RB	O	29	VMOD
39	.	.	O	.	O	14	P

1	Intracavernous	Intracavernous	B-NP	JJ	O	2	NMOD
2	epinephrine	epinephrine	I-NP	NN	O	7	NMOD
3	:	:	O	:	O	2	P
4	a	a	B-NP	DT	O	7	NMOD
5	minimally	minimally	I-NP	RB	O	6	AMOD
6	invasive	invasive	I-NP	JJ	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	0	ROOT
8	for	for	B-PP	IN	O	7	NMOD
9	priapism	priapism	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	emergency	emergency	I-NP	NN	O	13	NMOD
13	department	department	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	3	NMOD
2	45-year-old	45-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	9	NMOD
4	,	,	O	,	O	9	P
5	an	an	B-NP	DT	O	9	NMOD
6	admitted	admit	I-NP	VBN	O	9	NMOD
7	frequent	frequent	I-NP	JJ	O	9	NMOD
8	cocaine	cocaine	I-NP	NN	O	9	NMOD
9	user	user	I-NP	NN	O	0	ROOT
10	,	,	O	,	O	9	P
11	presented	present	B-VP	VBN	O	9	NMOD
12	to	to	B-PP	TO	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	Emergency	Emergency	I-NP	NNP	O	15	NMOD
15	Department	Department	I-NP	NNP	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	ED	ED	B-VP	VBN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	on	on	B-PP	IN	O	11	VMOD
20	two	two	B-NP	CD	O	22	NMOD
21	separate	separate	I-NP	JJ	O	22	NMOD
22	occasions	occasion	I-NP	NNS	O	19	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	a	a	B-NP	DT	O	25	NMOD
25	history	history	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	priapism	priapism	B-NP	NN	O	26	PMOD
28	after	after	B-PP	IN	O	22	NMOD
29	cocaine	cocaine	B-NP	NN	O	30	NMOD
30	use	use	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	9	P

1	Effect	Effect	B-NP	NN	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	green	green	B-NP	JJ	O	4	NMOD
4	tea	tea	I-NP	NN	O	8	NMOD
5	and	and	I-NP	CC	O	8	NMOD
6	vitamin	vitamin	I-NP	NN	O	8	NMOD
7	E	E	I-NP	NN	O	8	NMOD
8	combination	combination	I-NP	NN	O	2	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	isoproterenol	isoproterenol	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	myocardial	myocardial	B-NP	JJ	O	13	NMOD
13	infarction	infarction	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	aimed	aim	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	combined	combine	I-NP	VBN	O	10	NMOD
10	effects	effect	I-NP	NNS	O	36	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	green	green	B-NP	JJ	O	13	NMOD
13	tea	tea	I-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	vitamin	vitamin	I-NP	NN	O	16	NMOD
16	E	E	I-NP	NN	O	11	PMOD
17	on	on	B-PP	IN	O	10	NMOD
18	heart	heart	B-NP	NN	O	19	NMOD
19	weight	weight	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	36	P
21	body	body	B-NP	NN	O	22	NMOD
22	weight	weight	I-NP	NN	O	36	NMOD
23	,	,	O	,	O	36	P
24	serum	serum	B-NP	NN	B-protein	26	NMOD
25	marker	marker	I-NP	NN	I-protein	26	NMOD
26	enzymes	enzyme	I-NP	NNS	I-protein	36	NMOD
27	,	,	O	,	O	36	P
28	lipid	lipid	B-NP	NN	O	29	NMOD
29	peroxidation	peroxidation	I-NP	NN	O	36	NMOD
30	,	,	O	,	O	36	P
31	endogenous	endogenous	B-NP	JJ	O	32	NMOD
32	antioxidants	antioxidant	I-NP	NNS	O	36	NMOD
33	and	and	O	CC	O	34	NMOD
34	membrane	membrane	B-NP	NN	B-protein	36	NMOD
35	bound	bind	B-VP	VBD	I-protein	36	NMOD
36	ATPases	ATPas	B-NP	NNS	I-protein	42	SUB
37	in	in	B-PP	IN	O	36	NMOD
38	isoproterenol	isoproterenol	B-NP	NN	O	37	PMOD
39	(	(	O	(	O	41	DEP
40	ISO	ISO	B-NP	NN	O	41	DEP
41	)	)	O	)	O	38	NMOD
42	induced	induce	B-VP	VBD	O	7	VMOD
43	myocardial	myocardial	B-NP	JJ	O	44	NMOD
44	infarction	infarction	I-NP	NN	O	42	OBJ
45	in	in	B-PP	IN	O	42	VMOD
46	rats	rat	B-NP	NNS	O	45	PMOD
47	.	.	O	.	O	4	P

1	Development	Development	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	ocular	ocular	B-NP	JJ	O	4	NMOD
4	myasthenia	myasthenia	I-NP	NN	O	2	PMOD
5	during	during	B-PP	IN	O	1	NMOD
6	pegylated	pegylate	B-NP	VBN	O	10	NMOD
7	interferon	interferon	I-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	ribavirin	ribavirin	I-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	5	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	chronic	chronic	B-NP	JJ	O	14	NMOD
13	hepatitis	hepatitis	I-NP	NN	O	14	NMOD
14	C	C	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	6	NMOD
2	63-year-old	63-year-old	I-NP	JJ	O	5	AMOD
3	male	male	I-NP	JJ	O	5	AMOD
4	experienced	experienced	I-NP	JJ	O	5	AMOD
5	sudden	sudden	I-NP	JJ	O	6	NMOD
6	diplopia	diplopia	I-NP	NN	O	0	ROOT
7	after	after	B-PP	IN	O	6	NMOD
8	9	9	B-NP	CD	O	9	NMOD
9	weeks	week	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	administration	administration	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	pegylated	pegylate	B-NP	VBN	O	14	NMOD
14	interferon	interferon	I-NP	NN	O	20	NMOD
15	(	(	O	(	O	17	DEP
16	IFN	IFN	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	alpha-2b	alpha-2b	B-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	ribavirin	ribavirin	I-NP	NN	O	12	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	chronic	chronic	B-NP	JJ	O	24	NMOD
23	hepatitis	hepatitis	I-NP	NN	O	24	NMOD
24	C	C	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	CHC	CHC	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	6	P

1	Schizophrenia	Schizophrenia	B-NP	NNP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	initially	initially	I-VP	RB	O	3	VMOD
5	associated	associate	I-VP	VBN	O	3	VC
6	with	with	B-PP	IN	O	5	VMOD
7	dysfunction	dysfunction	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	dopamine	dopamine	B-NP	NN	O	10	NMOD
10	neurotransmission	neurotransmission	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	However	However	B-ADVP	RB	O	20	VMOD
2	,	,	O	,	O	20	P
3	the	the	B-NP	DT	O	4	NMOD
4	observation	observation	I-NP	NN	O	20	SUB
5	that	that	B-SBAR	IN	O	4	NMOD
6	antagonists	antagonist	B-NP	NNS	O	15	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	14	NMOD
9	glutamate	glutamate	I-NP	NN	B-protein	14	NMOD
10	N-methyl-D-aspartate	N-methyl-D-aspartate	I-NP	NN	I-protein	14	NMOD
11	(	(	O	(	I-protein	14	NMOD
12	NMDA	NMDA	B-NP	NN	I-protein	14	NMOD
13	)	)	O	)	I-protein	14	NMOD
14	receptor	receptor	B-NP	NN	I-protein	7	PMOD
15	produce	produce	B-VP	VBP	O	5	SBAR
16	schizophrenic-like	schizophrenic-like	B-NP	JJ	O	17	NMOD
17	symptoms	symptom	I-NP	NNS	O	15	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	humans	human	B-NP	NNS	O	18	PMOD
20	has	have	B-VP	VBZ	O	0	ROOT
21	led	lead	I-VP	VBN	O	20	VC
22	to	to	B-PP	TO	O	21	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	idea	idea	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	a	a	B-NP	DT	O	27	NMOD
27	dysfunctioning	dysfunctioning	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	glutamatergic	glutamatergic	I-NP	JJ	O	31	NMOD
31	system	system	I-NP	NN	O	28	PMOD
32	via	via	B-PP	IN	O	24	NMOD
33	its	its	B-NP	PRP$	O	35	NMOD
34	NMDA	NMDA	I-NP	NN	B-protein	35	NMOD
35	receptor	receptor	I-NP	NN	I-protein	32	PMOD
36	.	.	O	.	O	20	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	0	ROOT
3	aimed	aim	B-VP	VBN	O	2	NMOD
4	at	at	B-PP	IN	O	3	VMOD
5	investigating	investigate	B-VP	VBG	O	4	PMOD
6	the	the	B-NP	DT	O	9	NMOD
7	potential	potential	I-NP	JJ	O	9	NMOD
8	antipsychotic-like	antipsychotic-like	I-NP	JJ	O	9	NMOD
9	properties	property	I-NP	NNS	O	5	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	SSR103800	SSR103800	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	2	P
13	with	with	B-PP	IN	O	2	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	particular	particular	I-NP	JJ	O	16	NMOD
16	focus	focus	I-NP	NN	O	13	PMOD
17	on	on	B-PP	IN	O	16	NMOD
18	models	model	B-NP	NNS	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	hyperactivity	hyperactivity	B-NP	NN	O	19	PMOD
21	,	,	O	,	O	16	P
22	involving	involve	B-VP	VBG	O	16	NMOD
23	either	either	O	CC	O	25	NMOD
24	drug	drug	B-NP	NN	O	25	NMOD
25	challenge	challenge	I-NP	NN	O	35	NMOD
26	(	(	O	(	O	32	DEP
27	ie	ie	B-NP	FW	O	31	NMOD
28	,	,	O	,	O	31	P
29	amphetamine	amphetamine	B-NP	NN	O	31	NMOD
30	and	and	O	CC	O	31	NMOD
31	MK-801	MK-801	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	25	NMOD
33	or	or	O	CC	O	35	NMOD
34	transgenic	transgenic	B-NP	JJ	O	35	NMOD
35	mice	mouse	I-NP	NNS	O	22	OBJ
36	(	(	O	(	O	49	DEP
37	ie	ie	B-NP	FW	O	45	NMOD
38	,	,	O	,	O	45	P
39	NMDA	NMDA	B-NP	NN	B-protein	40	NMOD
40	Nr1	Nr1	I-NP	NN	I-protein	45	NMOD
41	(	(	O	(	O	43	DEP
42	neo-/-	neo-/-	B-ADJP	JJ	O	43	DEP
43	)	)	O	)	O	40	NMOD
44	and	and	O	CC	O	45	NMOD
45	DAT	DAT	B-NP	NN	O	49	DEP
46	(	(	O	(	O	48	DEP
47	-/-	-/-	B-ADJP	JJ	O	48	DEP
48	)	)	O	)	O	45	NMOD
49	)	)	O	)	O	35	NMOD
50	.	.	O	.	O	2	P

1	Results	Result	B-NP	NNS	O	2	SUB
2	showed	show	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	SSR103800	SSR103800	B-NP	NN	O	10	SUB
5	(	(	O	(	O	9	DEP
6	10-30	10-30	B-NP	CD	O	8	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	8	NMOD
8	p.o.	p.o.	I-NP	NN	O	9	DEP
9	)	)	O	)	O	4	NMOD
10	blocked	block	B-VP	VBD	O	3	SBAR
11	hyperactivity	hyperactivity	B-NP	NN	O	10	OBJ
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	18	NMOD
15	non-competitive	non-competitive	I-NP	JJ	O	18	NMOD
16	NMDA	NMDA	I-NP	NN	O	18	NMOD
17	receptor	receptor	I-NP	NN	O	18	NMOD
18	antagonist	antagonist	I-NP	NN	O	20	NMOD
19	,	,	O	,	O	20	P
20	MK-801	MK-801	B-NP	NN	B-protein	13	PMOD
21	and	and	O	CC	O	10	VMOD
22	partially	partially	B-VP	RB	O	23	VMOD
23	reversed	reverse	I-VP	VBD	O	10	VMOD
24	spontaneous	spontaneous	B-NP	JJ	O	25	NMOD
25	hyperactivity	hyperactivity	I-NP	NN	O	23	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	NMDA	NMDA	B-NP	NN	B-protein	28	NMOD
28	Nr1	Nr1	I-NP	NN	I-protein	32	NMOD
29	(	(	O	(	O	31	DEP
30	neo-/-	neo-/-	O	JJ	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	mice	mouse	B-NP	NNS	O	26	PMOD
33	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	5	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	SSR103800	SSR103800	B-NP	NN	O	5	SUB
5	failed	fail	B-VP	VBD	O	0	ROOT
6	to	to	I-VP	TO	O	7	VMOD
7	affect	affect	I-VP	VB	O	5	VMOD
8	hyperactivity	hyperactivity	B-NP	NN	O	7	OBJ
9	induced	induce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	amphetamine	amphetamine	B-NP	NN	O	10	PMOD
12	or	or	O	CC	O	7	VMOD
13	naturally	naturally	B-VP	RB	O	7	VMOD
14	observed	observe	I-VP	VBN	O	7	VMOD
15	in	in	B-PP	IN	O	14	VMOD
16	dopamine	dopamine	B-NP	NN	O	17	NMOD
17	transporter	transporter	I-NP	NN	O	25	NMOD
18	(	(	O	(	O	23	DEP
19	DAT	DAT	B-NP	NN	O	23	DEP
20	(	(	O	(	O	22	DEP
21	-/-	-/-	B-ADJP	JJ	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	)	)	O	)	O	17	NMOD
24	knockout	knockout	B-NP	JJ	O	25	NMOD
25	mice	mouse	I-NP	NNS	O	15	PMOD
26	(	(	O	(	O	30	DEP
27	10-30	10-30	B-NP	CD	O	29	NMOD
28	mg/kg	mg/kg	I-NP	NN	O	29	NMOD
29	p.o.	p.o.	I-NP	NN	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	.	.	O	.	O	5	P

1	Importantly	Importantly	B-ADVP	RB	O	18	VMOD
2	,	,	O	,	O	18	P
3	both	both	O	DT	O	17	NMOD
4	classical	classical	O	JJ	O	17	NMOD
5	(	(	O	(	O	7	DEP
6	haloperidol	haloperidol	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	AMOD
8	and	and	O	CC	O	16	NMOD
9	atypical	atypical	B-NP	JJ	O	16	NMOD
10	(	(	O	(	O	16	DEP
11	olanzapine	olanzapine	B-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	clozapine	clozapine	B-NP	NN	O	15	NMOD
14	and	and	O	CC	O	15	NMOD
15	aripiprazole	aripiprazole	B-NP	NN	O	16	DEP
16	)	)	O	)	O	4	AMOD
17	antipsychotics	antipsychotic	B-NP	NNS	O	18	SUB
18	were	be	B-VP	VBD	O	0	ROOT
19	effective	effective	B-ADJP	JJ	O	18	PRD
20	in	in	B-PP	IN	O	19	AMOD
21	all	all	B-NP	PDT	O	23	NMOD
22	these	these	I-NP	DT	O	23	NMOD
23	models	model	I-NP	NNS	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	hyperactivity	hyperactivity	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	18	P

1	However	However	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	unlike	unlike	B-PP	IN	O	8	VMOD
4	these	these	B-NP	DT	O	5	NMOD
5	latter	latter	I-NP	JJ	O	3	PMOD
6	,	,	O	,	O	8	P
7	SSR103800	SSR103800	B-NP	NN	O	8	SUB
8	did	do	B-VP	VBD	O	0	ROOT
9	not	not	I-VP	RB	O	8	VMOD
10	produce	produce	I-VP	VB	O	8	VC
11	catalepsy	catalepsy	B-NP	NN	O	23	NMOD
12	(	(	O	(	O	18	DEP
13	retention	retention	B-NP	NN	O	18	DEP
14	on	on	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	bar	bar	I-NP	NN	O	17	NMOD
17	test	test	I-NP	NN	O	14	PMOD
18	)	)	O	)	O	11	NMOD
19	up	up	B-NP	IN	O	23	NMOD
20	to	to	I-NP	TO	O	19	AMOD
21	30	30	I-NP	CD	O	19	AMOD
22	mg/kg	mg/kg	I-NP	NN	O	23	NMOD
23	p.o	p.o	I-NP	NN	O	10	OBJ
24	.	.	O	.	O	8	P

1	Phenylephrine	Phenylephrine	B-NP	NN	O	4	NMOD
2	but	but	B-NP	CC	O	4	NMOD
3	not	not	I-NP	RB	O	2	DEP
4	ephedrine	ephedrine	B-NP	NN	O	5	SUB
5	reduces	reduce	B-VP	VBZ	O	0	ROOT
6	frontal	frontal	B-NP	JJ	O	8	NMOD
7	lobe	lobe	I-NP	NN	O	8	NMOD
8	oxygenation	oxygenation	I-NP	NN	O	5	OBJ
9	following	follow	B-PP	VBG	O	5	VMOD
10	anesthesia	anesthesia	B-NP	NN	O	12	NMOD
11	induced	induced	I-NP	JJ	O	12	NMOD
12	hypotension	hypotension	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	phenylephrine	phenylephrine	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	ephedrine	ephedrine	I-NP	NN	O	5	PMOD
9	on	on	B-PP	IN	O	4	NMOD
10	frontal	frontal	B-NP	JJ	O	12	NMOD
11	lobe	lobe	I-NP	NN	O	12	NMOD
12	oxygenation	oxygenation	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	12	NMOD
14	S	S	B-NP	NN	O	13	DEP
15	(	(	O	(	O	17	DEP
16	c	c	B-NP	NN	O	17	DEP
17	)	)	O	)	O	22	DEP
18	O	O	B-NP	NN	O	22	DEP
19	(	(	O	(	O	21	DEP
20	2	2	B-NP	CD	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	)	)	O	)	O	14	NMOD
23	following	follow	B-PP	VBG	O	14	NMOD
24	anesthesia	anesthesia	B-NP	NN	O	26	NMOD
25	induced	induced	I-NP	JJ	O	26	NMOD
26	hypotension	hypotension	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	14	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Clomipramine	Clomipramine	B-NP	NN	O	4	NMOD
4	exposure	exposure	I-NP	NN	O	8	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	immature	immature	B-NP	JJ	O	7	NMOD
7	rats	rat	I-NP	NNS	O	5	PMOD
8	produced	produce	B-VP	VBD	O	1	NMOD
9	significant	significant	B-NP	JJ	O	12	AMOD
10	behavioral	behavioral	I-NP	JJ	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	biochemical	biochemical	I-NP	JJ	O	13	NMOD
13	changes	change	I-NP	NNS	O	8	OBJ
14	that	that	B-NP	WDT	O	13	NMOD
15	include	include	B-VP	VBP	O	14	SBAR
16	enhanced	enhance	I-VP	VBN	O	17	NMOD
17	anxiety	anxiety	B-NP	NN	O	28	NMOD
18	(	(	O	(	O	25	DEP
19	elevated	elevate	B-VP	VBN	O	24	NMOD
20	plus	plus	O	CC	O	24	NMOD
21	maze	maze	B-NP	NN	O	24	NMOD
22	and	and	I-NP	CC	O	24	NMOD
23	marble	marble	I-NP	NN	O	24	NMOD
24	burying	burying	I-NP	NN	O	25	DEP
25	)	)	O	)	O	17	NMOD
26	,	,	O	,	O	28	P
27	behavioral	behavioral	B-NP	JJ	O	28	NMOD
28	inflexibility	inflexibility	I-NP	NN	O	15	OBJ
29	(	(	O	(	O	40	DEP
30	perseveration	perseveration	B-NP	NN	O	40	DEP
31	in	in	B-PP	IN	O	30	NMOD
32	the	the	B-NP	DT	O	39	NMOD
33	spontaneous	spontaneous	I-NP	JJ	O	35	NMOD
34	alternation	alternation	I-NP	NN	O	35	NMOD
35	task	task	I-NP	NN	O	39	NMOD
36	and	and	O	CC	O	39	NMOD
37	impaired	impaired	B-NP	JJ	O	39	NMOD
38	reversal	reversal	I-NP	NN	O	39	NMOD
39	learning	learning	I-NP	NN	O	31	PMOD
40	)	)	O	)	O	28	NMOD
41	,	,	O	,	O	28	P
42	working	work	B-VP	VBG	O	28	NMOD
43	memory	memory	B-NP	NN	O	44	NMOD
44	impairment	impairment	I-NP	NN	O	42	OBJ
45	(	(	O	(	O	50	DEP
46	e.g.	e.g.	B-NP	FW	O	49	NMOD
47	,	,	O	,	O	49	P
48	win-shift	win-shift	B-NP	JJ	O	49	NMOD
49	paradigm	paradigm	I-NP	NN	O	50	DEP
50	)	)	O	)	O	28	NMOD
51	,	,	O	,	O	28	P
52	hoarding	hoard	B-VP	VBG	O	28	NMOD
53	,	,	O	,	O	56	P
54	and	and	O	CC	O	56	NMOD
55	corticostriatal	corticostriatal	B-NP	JJ	O	56	NMOD
56	dysfunction	dysfunction	I-NP	NN	O	52	OBJ
57	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	reported	report	I-VP	VBN	O	3	VC
5	of	of	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	9	NMOD
7	hemolytic	hemolytic	I-NP	JJ	O	9	NMOD
8	uremic	uremic	I-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	5	PMOD
10	(	(	O	(	O	12	DEP
11	HUS	HUS	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	in	in	B-PP	IN	O	4	VMOD
14	a	a	B-NP	DT	O	15	NMOD
15	woman	woman	I-NP	NN	O	13	PMOD
16	taking	take	B-VP	VBG	O	15	NMOD
17	oral	oral	B-NP	JJ	O	18	NMOD
18	contraceptives	contraceptive	I-NP	NNS	O	16	OBJ
19	.	.	O	.	O	3	P

1	She	She	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	21	VMOD
3	treated	treat	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	heparin	heparin	B-NP	NN	O	9	NMOD
6	,	,	I-NP	,	O	9	P
7	dipyridamole	dipyridamole	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	hemodialysis	hemodialysis	I-NP	NN	O	4	PMOD
10	;	;	O	:	O	21	P
11	and	and	O	CC	O	21	VMOD
12	after	after	B-SBAR	IN	O	21	VMOD
13	more	more	B-NP	JJR	O	14	AMOD
14	than	than	I-NP	IN	O	16	NMOD
15	three	three	I-NP	CD	O	14	AMOD
16	months	month	I-NP	NNS	O	12	PMOD
17	,	,	O	,	O	21	P
18	her	her	B-NP	PRP$	O	20	NMOD
19	urinary	urinary	I-NP	JJ	O	20	NMOD
20	output	output	I-NP	NN	O	21	SUB
21	rose	rise	B-VP	VBD	O	28	VMOD
22	above	above	B-PP	IN	O	21	VMOD
23	500	500	B-NP	CD	O	24	NMOD
24	ml	ml	I-NP	NN	O	22	PMOD
25	;	;	O	:	O	28	P
26	and	and	O	CC	O	28	NMOD
27	six	six	B-NP	CD	O	28	NMOD
28	months	month	I-NP	NNS	O	0	ROOT
29	after	after	B-SBAR	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	onset	onset	I-NP	NN	O	36	NMOD
32	of	of	B-PP	IN	O	31	NMOD
33	anuria	anuria	B-NP	NN	O	32	PMOD
34	,	,	O	,	O	36	P
35	dialysis	dialysis	B-NP	NN	O	36	NMOD
36	treatment	treatment	I-NP	NN	O	37	SUB
37	was	be	B-VP	VBD	O	29	SBAR
38	stopped	stop	I-VP	VBN	O	37	VC
39	.	.	O	.	O	28	P

1	Effects	Effect	B-NP	NNS	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	acetylsalicylic	acetylsalicylic	B-NP	JJ	O	4	NMOD
4	acid	acid	I-NP	NN	O	9	NMOD
5	,	,	O	,	O	9	P
6	dipyridamole	dipyridamole	B-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	and	and	O	CC	O	9	NMOD
9	hydrocortisone	hydrocortisone	B-NP	NN	O	2	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	epinephrine	epinephrine	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	injury	injury	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	dogs	dog	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	12	P

1	A	A	B-NP	DT	O	3	NMOD
2	reproducible	reproducible	I-NP	JJ	O	3	NMOD
3	model	model	I-NP	NN	O	13	SUB
4	for	for	B-PP	IN	O	3	NMOD
5	producing	produce	B-VP	VBG	O	4	PMOD
6	diffuse	diffuse	B-NP	JJ	O	8	NMOD
7	myocardial	myocardial	I-NP	JJ	O	8	NMOD
8	injury	injury	I-NP	NN	O	5	OBJ
9	(	(	O	(	O	12	DEP
10	epinephrine	epinephrine	B-NP	NN	O	11	NMOD
11	infusion	infusion	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	has	have	B-VP	VBZ	O	0	ROOT
14	been	be	I-VP	VBN	O	13	VC
15	developed	develop	I-VP	VBN	O	14	VC
16	to	to	I-VP	TO	O	17	VMOD
17	study	study	I-VP	VB	O	13	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	cardioprotective	cardioprotective	I-NP	JJ	O	20	NMOD
20	effects	effect	I-NP	NNS	O	17	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	agents	agent	B-NP	NNS	O	24	NMOD
23	or	or	I-NP	CC	O	24	NMOD
24	maneuvers	maneuver	I-NP	NNS	O	21	PMOD
25	which	which	B-NP	WDT	O	20	NMOD
26	might	might	B-VP	MD	O	25	SBAR
27	alter	alter	I-VP	VB	O	26	VC
28	the	the	B-NP	DT	O	29	NMOD
29	evolution	evolution	I-NP	NN	O	27	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	acute	acute	B-NP	JJ	O	33	NMOD
32	myocardial	myocardial	I-NP	JJ	O	33	NMOD
33	infarction	infarction	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	13	P

1	Eight	Eight	B-NP	CD	O	3	NMOD
2	glaucomatous	glaucomatous	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	20	SUB
4	chronically	chronically	B-VP	RB	O	5	VMOD
5	treated	treat	I-VP	VBN	O	3	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	timolol	timolol	B-NP	NN	O	10	NMOD
8	0.5	0.5	I-NP	CD	O	10	NMOD
9	%	%	I-NP	NN	O	10	NMOD
10	/12h	/12h	I-NP	NN	O	6	PMOD
11	,	,	O	,	O	3	P
12	suffering	suffer	B-VP	VBG	O	3	NMOD
13	from	from	B-PP	IN	O	12	VMOD
14	depression	depression	B-NP	NN	O	13	PMOD
15	diagnosed	diagnose	B-VP	VBN	O	14	NMOD
16	through	through	B-PP	IN	O	15	VMOD
17	DMS-III-R	DMS-III-R	B-NP	NN	O	18	NMOD
18	criteria	criterion	I-NP	NNS	O	16	PMOD
19	,	,	O	,	O	3	P
20	were	be	B-VP	VBD	O	0	ROOT
21	included	include	I-VP	VBN	O	20	VC
22	in	in	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	study	study	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	20	P

1	In	In	B-PP	IN	O	16	VMOD
2	a	a	B-NP	DT	O	6	NMOD
3	double	double	I-NP	JJ	O	6	NMOD
4	blind	blind	I-NP	JJ	O	6	NMOD
5	cross-over	cross-over	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	1	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	control	control	B-NP	NN	O	9	NMOD
9	group	group	I-NP	NN	O	7	PMOD
10	,	,	O	,	O	16	P
11	the	the	B-NP	DT	O	12	NMOD
12	patients	patient	I-NP	NNS	O	16	SUB
13	under	under	B-PP	IN	O	12	NMOD
14	timolol	timolol	B-NP	NN	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	13	PMOD
16	presented	present	B-VP	VBD	O	0	ROOT
17	higher	high	B-NP	JJR	O	19	NMOD
18	depression	depression	I-NP	NN	O	19	NMOD
19	values	value	I-NP	NNS	O	16	OBJ
20	measured	measure	B-VP	VBN	O	19	NMOD
21	through	through	B-PP	IN	O	20	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	Beck	Beck	I-NP	NNP	O	27	NMOD
24	and	and	O	CC	O	27	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	Zung-Conde	Zung-Conde	I-NP	JJ	O	27	NMOD
27	scales	scale	I-NP	NNS	O	21	PMOD
28	(	(	O	(	O	34	DEP
29	p	p	B-NP	NN	O	33	NMOD
30	<	<	B-NP	JJR	O	33	NMOD
31	0.001	0.001	I-NP	CD	O	33	NMOD
32	vs	vs	O	CC	O	33	NMOD
33	control	control	B-NP	NN	O	34	DEP
34	)	)	O	)	O	27	NMOD
35	.	.	O	.	O	16	P

1	Long-term	Long-term	B-NP	JJ	O	2	NMOD
2	follow-up	follow-up	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	ifosfamide	ifosfamide	B-NP	NN	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	children	child	B-NP	NNS	O	7	PMOD
9	treated	treat	B-VP	VBN	O	8	NMOD
10	for	for	B-PP	IN	O	9	VMOD
11	malignant	malignant	B-NP	JJ	O	13	NMOD
12	mesenchymal	mesenchymal	I-NP	JJ	O	13	NMOD
13	tumors	tumor	I-NP	NNS	O	10	PMOD
14	:	:	O	:	O	2	P
15	an	an	B-NP	DT	O	17	NMOD
16	International	International	I-NP	NNP	O	17	NMOD
17	Society	Society	I-NP	NNP	O	2	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	Pediatric	Pediatric	B-NP	NNP	O	21	NMOD
20	Oncology	Oncology	I-NP	NNP	O	21	NMOD
21	report	report	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	function	function	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	74	74	B-NP	CD	O	6	NMOD
6	children	child	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	malignant	malignant	B-NP	JJ	O	10	NMOD
9	mesenchymal	mesenchymal	I-NP	JJ	O	10	NMOD
10	tumors	tumor	I-NP	NNS	O	7	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	complete	complete	B-NP	JJ	O	13	NMOD
13	remission	remission	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	10	NMOD
15	who	who	B-NP	WP	O	14	DEP
16	have	have	B-VP	VBP	O	15	SBAR
17	received	receive	I-VP	VBN	O	16	VC
18	the	the	B-NP	DT	O	22	NMOD
19	same	same	I-NP	JJ	O	22	NMOD
20	ifosfamide	ifosfamide	I-NP	NN	O	22	NMOD
21	chemotherapy	chemotherapy	I-NP	NN	O	22	NMOD
22	protocol	protocol	I-NP	NN	O	17	OBJ
23	(	(	O	(	O	15	VMOD
24	International	International	B-NP	NNP	O	25	NMOD
25	Society	Society	I-NP	NNP	O	40	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	Pediatric	Pediatric	B-NP	NNP	O	32	NMOD
28	Oncology	Oncology	I-NP	NNP	O	32	NMOD
29	Malignant	Malignant	I-NP	NNP	O	32	NMOD
30	Mesenchymal	Mesenchymal	I-NP	NNP	O	32	NMOD
31	Tumor	Tumor	I-NP	NNP	O	32	NMOD
32	Study	Study	I-NP	NNP	O	26	PMOD
33	84	84	I-NP	CD	O	32	NMOD
34	[	[	B-NP	(	O	38	DEP
35	SIOP	SIOP	I-NP	NN	O	36	NMOD
36	MMT	MMT	I-NP	NN	O	38	DEP
37	84	84	I-NP	CD	O	36	NMOD
38	]	]	O	)	O	32	NMOD
39	)	)	O	)	O	32	NMOD
40	were	be	B-VP	VBD	O	23	SBAR
41	studied	study	I-VP	VBN	O	40	VC
42	1	1	B-NP	CD	O	43	NMOD
43	year	year	I-NP	NN	O	41	OBJ
44	after	after	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	46	NMOD
46	completion	completion	I-NP	NN	O	44	PMOD
47	of	of	B-PP	IN	O	46	NMOD
48	treatment	treatment	B-NP	NN	O	47	PMOD
49	.	.	O	.	O	3	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	function	function	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	investigated	investigate	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	measuring	measure	B-VP	VBG	O	5	PMOD
7	plasma	plasma	B-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	urinary	urinary	B-NP	JJ	O	10	NMOD
10	electrolytes	electrolyte	I-NP	NNS	O	35	NMOD
11	,	,	O	,	O	35	P
12	glucosuria	glucosuria	B-NP	NN	O	35	NMOD
13	,	,	O	,	O	35	P
14	proteinuria	proteinuria	B-NP	NN	O	35	NMOD
15	,	,	O	,	O	35	P
16	aminoaciduria	aminoaciduria	B-NP	NN	O	35	NMOD
17	,	,	O	,	O	35	P
18	urinary	urinary	B-NP	JJ	O	19	NMOD
19	pH	pH	I-NP	NN	O	35	NMOD
20	,	,	O	,	O	35	P
21	osmolarity	osmolarity	B-NP	NN	O	35	NMOD
22	,	,	O	,	O	35	P
23	creatinine	creatinine	B-NP	NN	O	24	NMOD
24	clearance	clearance	I-NP	NN	O	35	NMOD
25	,	,	O	,	O	35	P
26	phosphate	phosphate	B-NP	NN	O	28	NMOD
27	tubular	tubular	I-NP	JJ	O	28	NMOD
28	reabsorption	reabsorption	I-NP	NN	O	35	NMOD
29	,	,	O	,	O	35	P
30	beta	beta	B-NP	NN	B-protein	32	NMOD
31	2	2	I-NP	CD	I-protein	32	NMOD
32	microglobulinuria	microglobulinuria	I-NP	NNS	I-protein	35	NMOD
33	,	,	O	,	O	35	P
34	and	and	O	CC	O	35	NMOD
35	lysozymuria	lysozymuria	B-NP	NN	O	6	OBJ
36	.	.	O	.	O	3	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	subsets	subset	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	were	be	B-VP	VBD	O	42	VMOD
6	identified	identify	I-VP	VBN	O	5	VC
7	from	from	B-PP	IN	O	6	VMOD
8	this	this	B-NP	DT	O	10	NMOD
9	latter	latter	I-NP	JJ	O	10	NMOD
10	group	group	I-NP	NN	O	7	PMOD
11	:	:	O	:	O	42	P
12	the	the	B-NP	DT	O	13	NMOD
13	first	first	I-NP	JJ	O	14	SUB
14	included	include	B-VP	VBD	O	42	VMOD
15	four	four	B-NP	CD	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	OBJ
17	(	(	O	(	O	24	DEP
18	5	5	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	24	DEP
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	total	total	I-NP	JJ	O	23	NMOD
23	population	population	I-NP	NN	O	20	PMOD
24	)	)	O	)	O	16	NMOD
25	who	who	B-NP	WP	O	16	NMOD
26	developed	develop	B-VP	VBD	O	25	SBAR
27	major	major	B-NP	JJ	O	28	NMOD
28	toxicity	toxicity	I-NP	NN	O	26	OBJ
29	resulting	result	B-VP	VBG	O	28	NMOD
30	in	in	B-PP	IN	O	29	VMOD
31	Fanconi	Fanconi	B-NP	NNP	O	33	NMOD
32	's	's	B-NP	POS	O	33	NMOD
33	syndrome	syndrome	I-NP	NN	O	30	PMOD
34	(	(	O	(	O	36	DEP
35	TDFS	TDFS	B-NP	NN	B-protein	36	DEP
36	)	)	O	)	O	33	NMOD
37	;	;	O	:	O	42	P
38	and	and	O	CC	O	42	VMOD
39	the	the	B-NP	DT	O	41	NMOD
40	second	second	I-NP	JJ	O	41	NMOD
41	group	group	I-NP	NN	O	42	SUB
42	included	include	B-VP	VBD	O	0	ROOT
43	five	five	B-NP	CD	O	44	NMOD
44	patients	patient	I-NP	NNS	O	42	OBJ
45	with	with	B-PP	IN	O	44	NMOD
46	elevated	elevate	B-NP	VBN	O	49	NMOD
47	beta	beta	I-NP	SYM	O	49	NMOD
48	2	2	I-NP	CD	O	49	NMOD
49	microglobulinuria	microglobulinuria	I-NP	NNS	O	53	NMOD
50	and	and	O	CC	O	53	NMOD
51	low	low	B-NP	JJ	O	53	NMOD
52	phosphate	phosphate	I-NP	NN	O	53	NMOD
53	reabsorption	reabsorption	I-NP	NN	O	45	PMOD
54	.	.	O	.	O	42	P

1	Severe	Severe	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	30	VMOD
4	correlated	correlate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	9	NMOD
7	higher	high	I-NP	JJR	O	8	AMOD
8	cumulative	cumulative	I-NP	JJ	O	9	NMOD
9	dose	dose	I-NP	NN	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	60	60	B-NP	CD	O	12	NMOD
12	g/m2	g/m2	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	ifosfamide	ifosfamide	B-NP	NN	O	18	NMOD
15	,	,	O	,	O	18	P
16	a	a	B-NP	DT	O	18	NMOD
17	younger	young	I-NP	JJR	O	18	NMOD
18	age	age	I-NP	NN	O	13	PMOD
19	(	(	O	(	O	26	DEP
20	less	less	B-NP	JJR	O	25	AMOD
21	than	than	I-NP	IN	O	25	AMOD
22	2	2	I-NP	CD	O	24	NMOD
23	1/2	1/2	I-NP	CD	O	24	NMOD
24	years	year	I-NP	NNS	O	25	NMOD
25	old	old	B-ADJP	JJ	O	26	DEP
26	)	)	O	)	O	4	VMOD
27	,	,	O	,	O	30	P
28	and	and	O	CC	O	30	NMOD
29	a	a	B-NP	DT	O	30	NMOD
30	predominance	predominance	I-NP	NN	O	0	ROOT
31	of	of	B-PP	IN	O	30	NMOD
32	vesicoprostatic	vesicoprostatic	B-NP	JJ	O	34	NMOD
33	tumor	tumor	I-NP	NN	O	34	NMOD
34	involvement	involvement	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	30	P

1	Evidence	Evidence	B-NP	NN	O	14	SUB
2	for	for	B-PP	IN	O	1	NMOD
3	an	an	B-NP	DT	O	4	NMOD
4	involvement	involvement	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	D1	D1	B-NP	NN	O	10	NMOD
7	and	and	I-NP	CC	O	10	NMOD
8	D2	D2	I-NP	NN	B-protein	10	NMOD
9	dopamine	dopamine	I-NP	NN	I-protein	10	NMOD
10	receptors	receptor	I-NP	NNS	I-protein	5	PMOD
11	in	in	B-PP	IN	O	1	NMOD
12	mediating	mediate	B-VP	VBG	O	11	PMOD
13	nicotine	nicotine	B-NP	NN	O	12	OBJ
14	induced	induce	B-VP	VBD	O	0	ROOT
15	hyperactivity	hyperactivity	B-NP	NN	O	14	OBJ
16	in	in	B-PP	IN	O	14	VMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	14	P

1	Nicotine	Nicotine	B-NP	NN	O	6	SUB
2	(	(	O	(	O	5	DEP
3	1.0	1.0	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	caused	cause	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	significant	significant	I-NP	JJ	O	9	NMOD
9	increase	increase	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	locomotor	locomotor	B-NP	NN	O	12	NMOD
12	activity	activity	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	rats	rat	B-NP	NNS	O	13	PMOD
15	that	that	B-NP	WDT	O	14	NMOD
16	were	be	B-VP	VBD	O	15	SBAR
17	habituated	habituate	I-VP	VBN	O	16	VC
18	to	to	B-PP	TO	O	17	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	test	test	I-NP	NN	O	21	NMOD
21	environment	environment	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	6	P
23	but	but	O	CC	O	6	VMOD
24	had	have	B-VP	VBD	O	6	VMOD
25	only	only	B-NP	RB	O	31	NMOD
26	a	a	I-NP	DT	O	31	NMOD
27	weak	weak	I-NP	JJ	O	29	AMOD
28	and	and	I-NP	CC	O	29	AMOD
29	delayed	delay	I-NP	VBN	O	31	NMOD
30	stimulant	stimulant	I-NP	NN	O	31	NMOD
31	action	action	I-NP	NN	O	24	OBJ
32	in	in	B-PP	IN	O	24	VMOD
33	rats	rat	B-NP	NNS	O	32	PMOD
34	that	that	B-NP	WDT	O	33	NMOD
35	were	be	B-VP	VBD	O	34	SBAR
36	unfamiliar	unfamiliar	B-ADJP	JJ	O	35	PRD
37	with	with	B-PP	IN	O	36	AMOD
38	the	the	B-NP	DT	O	40	NMOD
39	test	test	I-NP	NN	O	40	NMOD
40	environment	environment	I-NP	NN	O	37	PMOD
41	.	.	O	.	O	6	P

1	Nicotine	Nicotine	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	hyperactivity	hyperactivity	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	blocked	block	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	11	NMOD
8	selective	selective	I-NP	JJ	O	11	NMOD
9	D1	D1	I-NP	NN	O	11	NMOD
10	antagonist	antagonist	I-NP	NN	O	11	NMOD
11	SCH	SCH	I-NP	NN	O	6	PMOD
12	23390	23390	I-NP	CD	O	11	NMOD
13	,	,	O	,	O	4	P
14	the	the	B-NP	DT	O	18	NMOD
15	selective	selective	I-NP	JJ	O	18	NMOD
16	D2	D2	I-NP	NN	O	18	NMOD
17	antagonist	antagonist	I-NP	NN	O	18	NMOD
18	raclopride	raclopride	I-NP	NN	O	23	NMOD
19	and	and	O	CC	O	23	NMOD
20	the	the	B-NP	DT	O	23	NMOD
21	D1/D2	D1/D2	I-NP	NN	O	23	NMOD
22	antagonist	antagonist	I-NP	NN	O	23	NMOD
23	fluphenazine	fluphenazine	I-NP	NN	O	4	VMOD
24	.	.	O	.	O	4	P

1	Pretreatment	Pretreatment	B-NP	NN	O	7	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	D2	D2	I-NP	NN	O	6	NMOD
5	agonist	agonist	I-NP	NN	O	6	NMOD
6	PHNO	PHNO	I-NP	NN	O	2	PMOD
7	enhanced	enhance	B-VP	VBD	O	0	ROOT
8	nicotine	nicotine	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	hyperactivity	hyperactivity	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	7	P
12	whereas	whereas	O	IN	O	7	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	D1	D1	I-NP	NN	O	16	NMOD
15	agonist	agonist	I-NP	NN	O	16	NMOD
16	SKF	SKF	I-NP	NN	O	18	SUB
17	38393	38393	I-NP	CD	O	16	NMOD
18	had	have	B-VP	VBD	O	12	SBAR
19	no	no	B-NP	DT	O	20	NMOD
20	effect	effect	I-NP	NN	O	18	OBJ
21	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	acute	acute	B-NP	JJ	O	7	NMOD
6	nicotine	nicotine	I-NP	NN	O	7	NMOD
7	injection	injection	I-NP	NN	O	8	SUB
8	induces	induce	B-VP	VBZ	O	4	SBAR
9	a	a	B-NP	DT	O	11	NMOD
10	pronounced	pronounced	I-NP	JJ	O	11	NMOD
11	hyperactivity	hyperactivity	I-NP	NN	O	8	OBJ
12	in	in	B-PP	IN	O	8	VMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	habituated	habituate	B-VP	VBN	O	13	NMOD
15	to	to	B-PP	TO	O	14	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	test	test	I-NP	NN	O	18	NMOD
18	environment	environment	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	3	P

1	Reduction	Reduction	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	injection	injection	B-NP	NN	O	4	NMOD
4	pain	pain	I-NP	NN	O	2	PMOD
5	using	use	B-VP	VBG	O	1	NMOD
6	buffered	buffer	B-NP	VBN	O	7	NMOD
7	lidocaine	lidocaine	I-NP	NN	O	5	OBJ
8	as	as	B-PP	IN	O	5	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	local	local	I-NP	JJ	O	11	NMOD
11	anesthetic	anesthetic	I-NP	NN	O	8	PMOD
12	before	before	B-PP	IN	O	5	VMOD
13	cardiac	cardiac	B-NP	JJ	O	14	NMOD
14	catheterization	catheterization	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	reports	report	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	suggested	suggest	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	pain	pain	B-NP	NN	O	13	SUB
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	injection	injection	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	lidocaine	lidocaine	B-NP	NN	O	11	PMOD
13	is	be	B-VP	VBZ	O	5	SBAR
14	related	related	B-ADJP	JJ	O	13	PRD
15	to	to	B-PP	TO	O	14	AMOD
16	the	the	B-NP	DT	O	18	NMOD
17	acidic	acidic	I-NP	JJ	O	18	NMOD
18	pH	pH	I-NP	NN	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	solution	solution	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	To	To	B-VP	TO	O	2	VMOD
2	determine	determine	I-VP	VB	O	27	VMOD
3	if	if	B-SBAR	IN	O	2	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	addition	addition	I-NP	NN	O	20	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	buffering	buffering	I-NP	NN	O	9	NMOD
9	solution	solution	I-NP	NN	O	6	PMOD
10	to	to	B-VP	TO	O	11	VMOD
11	adjust	adjust	I-VP	VB	O	5	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	pH	pH	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	lidocaine	lidocaine	B-NP	NN	O	14	PMOD
16	into	into	B-PP	IN	O	11	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	physiologic	physiologic	I-NP	JJ	O	19	NMOD
19	range	range	I-NP	NN	O	16	PMOD
20	would	would	B-VP	MD	O	3	SBAR
21	reduce	reduce	I-VP	VB	O	20	VC
22	pain	pain	B-NP	NN	O	21	OBJ
23	during	during	B-PP	IN	O	21	VMOD
24	injection	injection	B-NP	NN	O	23	PMOD
25	,	,	O	,	O	27	P
26	we	we	B-NP	PRP	O	27	SUB
27	performed	perform	B-VP	VBD	O	0	ROOT
28	a	a	B-NP	DT	O	31	NMOD
29	blinded	blind	I-NP	VBN	O	31	NMOD
30	randomized	randomize	I-NP	VBN	O	31	NMOD
31	study	study	I-NP	NN	O	27	OBJ
32	in	in	B-PP	IN	O	27	VMOD
33	patients	patient	B-NP	NNS	O	32	PMOD
34	undergoing	undergo	B-VP	VBG	O	33	NMOD
35	cardiac	cardiac	B-NP	JJ	O	36	NMOD
36	catheterization	catheterization	I-NP	NN	O	34	OBJ
37	.	.	O	.	O	27	P

1	Twenty	Twenty	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	asked	ask	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	quantify	quantify	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	severity	severity	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	pain	pain	B-NP	NN	O	9	PMOD
11	after	after	B-PP	IN	O	6	VMOD
12	receiving	receive	B-VP	VBG	O	11	PMOD
13	standard	standard	B-NP	JJ	O	14	NMOD
14	lidocaine	lidocaine	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	one	one	B-NP	CD	O	18	NMOD
17	femoral	femoral	I-NP	JJ	O	18	NMOD
18	area	area	I-NP	NN	O	21	NMOD
19	and	and	O	CC	O	21	NMOD
20	buffered	buffer	B-NP	VBN	O	21	NMOD
21	lidocaine	lidocaine	I-NP	NN	O	15	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	26	NMOD
24	opposite	opposite	I-NP	JJ	O	26	NMOD
25	femoral	femoral	I-NP	JJ	O	26	NMOD
26	area	area	I-NP	NN	O	22	PMOD
27	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	4	NMOD
2	mean	mean	I-NP	JJ	O	4	NMOD
3	pain	pain	I-NP	NN	O	4	NMOD
4	score	score	I-NP	NN	O	8	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	buffered	buffer	B-NP	VBN	O	7	NMOD
7	lidocaine	lidocaine	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	significantly	significantly	B-ADJP	RB	O	10	AMOD
10	lower	low	I-ADJP	JJR	O	8	PRD
11	than	than	B-PP	IN	O	10	AMOD
12	the	the	B-NP	DT	O	14	NMOD
13	mean	mean	I-NP	JJ	O	14	NMOD
14	score	score	I-NP	NN	O	11	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	standard	standard	B-NP	JJ	O	17	NMOD
17	lidocaine	lidocaine	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	30	DEP
19	2.7	2.7	B-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	1.9	1.9	I-NP	CD	O	25	NMOD
22	vs.	vs.	B-PP	IN	O	25	NMOD
23	3.8	3.8	B-NP	CD	O	25	AMOD
24	+/-	+/-	I-NP	SYM	O	25	AMOD
25	2.2	2.2	I-NP	CD	O	30	DEP
26	,	,	O	,	O	30	P
27	P	P	B-NP	NN	O	30	DEP
28	=	=	B-VP	SYM	O	27	NMOD
29	0.03	0.03	B-NP	CD	O	28	AMOD
30	)	)	O	)	O	8	VMOD
31	.	.	O	.	O	8	P

1	Randomized	Randomize	B-NP	VBN	O	3	AMOD
2	,	,	I-NP	,	O	3	P
3	double-blind	double-blind	I-NP	JJ	O	4	NMOD
4	trial	trial	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	mazindol	mazindol	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	Duchenne	Duchenne	B-NP	NNP	O	9	NMOD
9	dystrophy	dystrophy	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	conducted	conduct	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	12-month	12-month	I-NP	JJ	O	6	NMOD
5	controlled	control	I-NP	VBN	O	6	NMOD
6	trial	trial	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	mazindol	mazindol	B-NP	NN	O	15	NMOD
9	,	,	O	,	O	15	P
10	a	a	B-NP	DT	O	15	NMOD
11	putative	putative	I-NP	JJ	O	15	NMOD
12	growth	growth	I-NP	NN	O	15	NMOD
13	hormone	hormone	I-NP	NN	O	15	NMOD
14	secretion	secretion	I-NP	NN	O	15	NMOD
15	inhibitor	inhibitor	I-NP	NN	O	7	PMOD
16	,	,	O	,	O	15	P
17	in	in	B-PP	IN	O	15	NMOD
18	83	83	B-NP	CD	O	19	NMOD
19	boys	boy	I-NP	NNS	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	Duchenne	Duchenne	B-NP	JJ	O	22	NMOD
22	dystrophy	dystrophy	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	2	P

1	Side	Side	B-NP	NN	O	2	NMOD
2	effects	effect	I-NP	NNS	O	6	SUB
3	attributable	attributable	B-ADJP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	mazindol	mazindol	B-NP	NN	O	4	PMOD
6	included	include	B-VP	VBD	O	38	VMOD
7	decreased	decrease	B-NP	VBN	O	8	NMOD
8	appetite	appetite	I-NP	NN	O	30	NMOD
9	(	(	O	(	O	12	DEP
10	36	36	B-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	,	,	O	,	O	30	P
14	dry	dry	B-NP	JJ	O	15	NMOD
15	mouth	mouth	I-NP	NN	O	30	NMOD
16	(	(	O	(	O	19	DEP
17	10	10	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	15	NMOD
20	,	,	O	,	O	30	P
21	behavioral	behavioral	B-NP	JJ	O	22	NMOD
22	change	change	I-NP	NN	O	30	NMOD
23	(	(	O	(	O	26	DEP
24	22	22	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	26	DEP
26	)	)	O	)	O	22	NMOD
27	,	,	O	,	O	30	P
28	and	and	O	CC	O	30	NMOD
29	gastrointestinal	gastrointestinal	B-NP	JJ	O	30	NMOD
30	symptoms	symptom	I-NP	NNS	O	6	OBJ
31	(	(	O	(	O	34	DEP
32	18	18	B-NP	CD	O	33	NMOD
33	%	%	I-NP	NN	O	34	DEP
34	)	)	O	)	O	30	NMOD
35	;	;	O	:	O	6	P
36	mazindol	mazindol	B-NP	NN	O	37	NMOD
37	dosage	dosage	I-NP	NN	O	38	SUB
38	was	be	B-VP	VBD	O	0	ROOT
39	reduced	reduce	I-VP	VBN	O	38	VC
40	in	in	B-PP	IN	O	39	VMOD
41	43	43	B-NP	CD	O	42	NMOD
42	%	%	I-NP	NN	O	40	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	patients	patient	B-NP	NNS	O	43	PMOD
45	.	.	O	.	O	38	P

1	Pentoxifylline	Pentoxifylline	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	Trental	Trental	B-ADJP	JJ	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	does	do	B-VP	VBZ	O	0	ROOT
6	not	not	I-VP	RB	O	5	VMOD
7	inhibit	inhibit	I-VP	VB	O	5	VC
8	dipyridamole	dipyridamole	B-NP	NN	O	11	NMOD
9	induced	induced	I-NP	JJ	O	11	NMOD
10	coronary	coronary	I-NP	JJ	O	11	NMOD
11	hyperemia	hyperemia	I-NP	NN	O	7	OBJ
12	:	:	O	:	O	5	P
13	implications	implication	B-NP	NNS	O	5	VMOD
14	for	for	B-PP	IN	O	13	NMOD
15	dipyridamole-thallium-201	dipyridamole-thallium-201	B-NP	NN	O	17	NMOD
16	myocardial	myocardial	I-NP	JJ	O	17	NMOD
17	imaging	imaging	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	13	P

1	Dipyridamole-thallium-201	Dipyridamole-thallium-201	B-NP	NN	O	2	NMOD
2	imaging	imaging	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	often	often	I-VP	RB	O	3	VMOD
5	performed	perform	I-VP	VBN	O	3	VC
6	in	in	B-PP	IN	O	5	VMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	unable	unable	B-ADJP	JJ	O	7	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	exercise	exercise	I-VP	VB	O	8	AMOD
11	because	because	B-PP	IN	O	10	VMOD
12	of	of	I-PP	IN	O	11	PMOD
13	peripheral	peripheral	B-NP	JJ	O	15	NMOD
14	vascular	vascular	I-NP	JJ	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	3	P

1	Many	Many	B-NP	JJ	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	these	these	B-NP	DT	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	PMOD
5	are	be	B-VP	VBP	O	0	ROOT
6	taking	take	I-VP	VBG	O	5	VC
7	pentoxifylline	pentoxifylline	B-NP	NN	O	14	NMOD
8	(	(	O	(	O	10	DEP
9	Trental	Trental	B-ADVP	JJ	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	,	,	O	,	O	14	P
12	a	a	B-NP	DT	O	14	NMOD
13	methylxanthine	methylxanthine	I-NP	NN	O	14	NMOD
14	derivative	derivative	I-NP	NN	O	6	OBJ
15	which	which	B-NP	WDT	O	14	NMOD
16	may	may	B-VP	MD	O	15	SBAR
17	improve	improve	I-VP	VB	O	16	VC
18	intermittent	intermittent	B-NP	JJ	O	19	NMOD
19	claudication	claudication	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	5	P

1	Whether	Whether	B-SBAR	IN	O	22	SUB
2	pentoxifylline	pentoxifylline	B-NP	NN	O	3	SUB
3	inhibits	inhibit	B-VP	VBZ	O	1	SBAR
4	dipyridamole	dipyridamole	B-NP	NN	O	7	NMOD
5	induced	induced	I-NP	JJ	O	7	NMOD
6	coronary	coronary	I-NP	JJ	O	7	NMOD
7	hyperemia	hyperemia	I-NP	NN	O	3	OBJ
8	like	like	B-PP	IN	O	7	NMOD
9	other	other	B-NP	JJ	O	10	NMOD
10	methylxanthines	methylxanthine	I-NP	NNS	O	8	PMOD
11	such	such	B-PP	JJ	O	12	PMOD
12	as	as	I-PP	IN	O	10	NMOD
13	theophylline	theophylline	B-NP	NN	O	12	PMOD
14	and	and	O	CC	O	3	VMOD
15	should	should	B-VP	MD	O	3	VMOD
16	be	be	I-VP	VB	O	15	VC
17	stopped	stop	I-VP	VBN	O	16	VC
18	prior	prior	B-ADVP	RB	O	19	PMOD
19	to	to	B-PP	TO	O	17	VMOD
20	dipyridamole-thallium-201	dipyridamole-thallium-201	B-NP	NN	O	21	NMOD
21	imaging	imaging	I-NP	NN	O	19	PMOD
22	is	be	B-VP	VBZ	O	0	ROOT
23	unknown	unknown	B-ADJP	JJ	O	22	PRD
24	.	.	O	.	O	22	P

1	Neither	Neither	O	CC	O	2	NMOD
2	dose	dose	B-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	pentoxifylline	pentoxifylline	B-NP	NN	O	3	PMOD
5	significantly	significantly	B-ADVP	RB	O	6	VMOD
6	decreased	decrease	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	dipyridamole	dipyridamole	I-NP	NN	O	6	OBJ
9	induced	induce	B-VP	VBD	O	8	NMOD
10	hyperemia	hyperemia	B-NP	NN	O	9	OBJ
11	,	,	O	,	O	6	P
12	while	while	B-SBAR	IN	O	6	VMOD
13	peak	peak	B-NP	NN	O	16	NMOD
14	coronary	coronary	I-NP	JJ	O	16	NMOD
15	blood	blood	I-NP	NN	O	16	NMOD
16	flow	flow	I-NP	NN	O	17	SUB
17	was	be	B-VP	VBD	O	12	SBAR
18	significantly	significantly	B-ADJP	RB	O	19	AMOD
19	lower	low	I-ADJP	JJR	O	17	PRD
20	after	after	B-PP	IN	O	17	VMOD
21	theophylline	theophylline	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	27	DEP
23	p	p	B-NP	NN	O	25	SUB
24	less	less	B-ADJP	JJR	O	25	AMOD
25	than	than	B-PP	IN	O	27	DEP
26	0.01	0.01	B-NP	CD	O	25	AMOD
27	)	)	O	)	O	17	VMOD
28	.	.	O	.	O	6	P

1	Tolerance	Tolerance	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	antiviral	antiviral	I-NP	JJ	O	4	NMOD
4	effect	effect	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	ribavirin	ribavirin	B-NP	NN	B-protein	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	Argentine	Argentine	B-NP	JJ	O	12	NMOD
11	hemorrhagic	hemorrhagic	I-NP	JJ	O	12	NMOD
12	fever	fever	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	Tolerance	Tolerance	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	antiviral	antiviral	I-NP	JJ	O	4	NMOD
4	effect	effect	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	ribavirin	ribavirin	B-NP	NN	O	5	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	studied	study	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	6	6	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	Argentine	Argentine	B-NP	JJ	O	15	NMOD
14	hemorrhagic	hemorrhagic	I-NP	JJ	O	15	NMOD
15	fever	fever	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	AHF	AHF	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	of	of	B-PP	IN	O	15	NMOD
20	more	more	B-NP	JJR	O	21	AMOD
21	than	than	I-NP	IN	O	23	NMOD
22	8	8	I-NP	CD	O	21	AMOD
23	days	day	I-NP	NNS	O	19	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	evolution	evolution	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	7	P

1	Administration	Administration	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ribavirin	ribavirin	B-NP	NN	O	2	PMOD
4	resulted	result	B-VP	VBD	O	0	ROOT
5	in	in	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	neutralization	neutralization	I-NP	NN	O	12	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	viremia	viremia	B-NP	NN	O	8	PMOD
10	and	and	O	CC	O	12	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	drop	drop	I-NP	NN	O	5	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	endogenous	endogenous	B-NP	JJ	O	16	NMOD
15	interferon	interferon	I-NP	NN	O	16	NMOD
16	titers	titer	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	4	P

1	From	From	B-PP	IN	O	6	VMOD
2	these	these	B-NP	DT	O	3	NMOD
3	results	result	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	conclude	conclude	B-VP	VBP	O	0	ROOT
7	that	that	B-SBAR	IN	O	20	DEP
8	ribavirin	ribavirin	B-NP	NN	B-protein	9	SUB
9	has	have	B-VP	VBZ	O	7	SBAR
10	an	an	B-NP	DT	O	12	NMOD
11	antiviral	antiviral	I-NP	JJ	O	12	NMOD
12	effect	effect	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	advanced	advance	B-NP	VBN	O	15	NMOD
15	cases	case	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	AHF	AHF	B-NP	NN	B-protein	16	PMOD
18	,	,	O	,	O	20	P
19	and	and	O	CC	O	20	DEP
20	that	that	B-SBAR	IN	O	6	VMOD
21	anemia	anemia	B-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	the	the	B-NP	DT	O	26	NMOD
24	only	only	I-NP	RB	O	25	AMOD
25	secondary	secondary	I-NP	JJ	O	26	NMOD
26	reaction	reaction	I-NP	NN	O	29	SUB
27	observed	observe	B-VP	VBN	O	26	NMOD
28	,	,	O	,	O	26	P
29	can	can	B-VP	MD	O	20	SBAR
30	be	be	I-VP	VB	O	29	VC
31	easily	easily	I-VP	RB	O	30	VMOD
32	managed	manage	I-VP	VBN	O	30	VC
33	.	.	O	.	O	6	P

1	Dipyridamole	Dipyridamole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	myocardial	myocardial	B-NP	JJ	O	4	NMOD
4	ischemia	ischemia	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Angina	Angina	B-NP	NNP	O	5	NMOD
2	and	and	O	CC	O	5	NMOD
3	ischemic	ischemic	B-NP	JJ	O	4	AMOD
4	electrocardiographic	electrocardiographic	I-NP	JJ	O	5	NMOD
5	changes	change	I-NP	NNS	O	6	SUB
6	occurred	occur	B-VP	VBD	O	0	ROOT
7	after	after	B-PP	IN	O	6	VMOD
8	administration	administration	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	oral	oral	B-NP	JJ	O	11	NMOD
11	dipyridamole	dipyridamole	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	8	NMOD
13	four	four	B-NP	CD	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	awaiting	await	B-VP	VBG	O	14	NMOD
16	urgent	urgent	B-NP	JJ	O	19	NMOD
17	myocardial	myocardial	I-NP	JJ	O	19	NMOD
18	revascularization	revascularization	I-NP	NN	O	19	NMOD
19	procedures	procedure	I-NP	NNS	O	15	OBJ
20	.	.	O	.	O	6	P

1	To	To	B-PP	TO	O	6	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	this	this	B-NP	DT	O	6	SUB
6	has	have	B-VP	VBZ	O	0	ROOT
7	not	not	I-VP	RB	O	6	VMOD
8	previously	previously	I-VP	RB	O	6	VMOD
9	been	be	I-VP	VBN	O	6	VC
10	reported	report	I-VP	VBN	O	9	VC
11	as	as	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	side	side	I-NP	NN	O	14	NMOD
14	effect	effect	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	preoperative	preoperative	B-NP	JJ	O	18	NMOD
17	dipyridamole	dipyridamole	I-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	6	P
20	although	although	B-SBAR	IN	O	6	VMOD
21	dipyridamole	dipyridamole	B-NP	NN	O	22	SUB
22	induced	induce	B-VP	VBD	O	20	SBAR
23	myocardial	myocardial	B-NP	JJ	O	24	NMOD
24	ischemia	ischemia	I-NP	NN	O	22	OBJ
25	has	have	B-VP	VBZ	O	6	VMOD
26	been	be	I-VP	VBN	O	25	VC
27	demonstrated	demonstrate	I-VP	VBN	O	26	VC
28	to	to	I-VP	TO	O	29	VMOD
29	occur	occur	I-VP	VB	O	27	VMOD
30	in	in	B-PP	IN	O	29	VMOD
31	animals	animal	B-NP	NNS	O	33	NMOD
32	and	and	I-NP	CC	O	33	NMOD
33	humans	human	I-NP	NNS	O	30	PMOD
34	with	with	B-PP	IN	O	33	NMOD
35	coronary	coronary	B-NP	JJ	O	37	NMOD
36	artery	artery	I-NP	NN	O	37	NMOD
37	disease	disease	I-NP	NN	O	34	PMOD
38	.	.	O	.	O	6	P

1	Nitroprusside	Nitroprusside	B-NP	RB	O	2	AMOD
2	induced	induce	I-NP	VBN	O	3	NMOD
3	hypotension	hypotension	I-NP	NN	O	4	SUB
4	evokes	evoke	B-VP	VBZ	O	0	ROOT
5	ACTH	ACTH	B-NP	NN	O	6	NMOD
6	secretion	secretion	I-NP	NN	O	4	OBJ
7	which	which	B-NP	WDT	O	6	NMOD
8	is	be	B-VP	VBZ	O	7	SBAR
9	primarily	primarily	I-VP	RB	O	8	VMOD
10	mediated	mediate	I-VP	VBN	O	8	VC
11	by	by	B-PP	IN	O	10	VMOD
12	enhanced	enhance	B-NP	VBN	O	13	NMOD
13	secretion	secretion	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	immunoreactive	immunoreactive	B-NP	JJ	B-protein	17	NMOD
16	corticotropin-releasing	corticotropin-releasing	I-NP	JJ	I-protein	17	NMOD
17	factor	factor	I-NP	NN	I-protein	14	PMOD
18	(	(	O	(	O	20	DEP
19	irCRF	irCRF	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	into	into	B-PP	IN	O	13	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	hypophysial-portal	hypophysial-portal	I-NP	JJ	O	24	NMOD
24	circulation	circulation	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	4	P

1	Noradrenergic	Noradrenergic	B-NP	JJ	O	2	NMOD
2	involvement	involvement	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	catalepsy	catalepsy	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	delta	delta	B-NP	SYM	O	8	NMOD
8	9-tetrahydrocannabinol	9-tetrahydrocannabinol	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	2	P

1	Intracranial	Intracranial	B-NP	JJ	O	2	NMOD
2	pressure	pressure	I-NP	NN	O	3	SUB
3	increases	increase	B-VP	VBZ	O	0	ROOT
4	during	during	B-PP	IN	O	3	VMOD
5	alfentanil	alfentanil	B-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	rigidity	rigidity	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	3	P

1	Intracranial	Intracranial	B-NP	JJ	O	2	NMOD
2	pressure	pressure	I-NP	NN	O	6	SUB
3	(	(	O	(	O	5	DEP
4	ICP	ICP	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	measured	measure	I-VP	VBN	O	6	VC
8	during	during	B-PP	IN	O	7	VMOD
9	alfentanil	alfentanil	B-NP	NN	O	11	NMOD
10	induced	induce	B-VP	VBD	O	11	NMOD
11	rigidity	rigidity	B-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	6	P

1	These	These	B-NP	DT	O	2	NMOD
2	variables	variable	I-NP	NNS	O	3	SUB
3	returned	return	B-VP	VBD	O	0	ROOT
4	to	to	B-PP	TO	O	3	VMOD
5	baseline	baseline	B-NP	NN	O	4	PMOD
6	when	when	B-ADVP	WRB	O	3	VMOD
7	rigidity	rigidity	B-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	6	SBAR
9	abolished	abolish	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	metocurine	metocurine	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	3	P

1	Verapamil	Verapamil	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	carbamazepine	carbamazepine	B-NP	NN	O	4	NMOD
4	neurotoxicity	neurotoxicity	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	13	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	signs	sign	B-NP	NNS	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	carbamazepine	carbamazepine	B-NP	NN	O	7	NMOD
7	neurotoxicity	neurotoxicity	I-NP	NN	O	5	PMOD
8	after	after	B-PP	IN	O	2	NMOD
9	combined	combined	B-NP	JJ	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	verapamil	verapamil	B-NP	NN	O	11	PMOD
13	showed	show	B-VP	VBD	O	0	ROOT
14	complete	complete	B-NP	JJ	O	15	NMOD
15	recovery	recovery	I-NP	NN	O	13	OBJ
16	after	after	B-PP	IN	O	15	NMOD
17	discontinuation	discontinuation	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	calcium	calcium	I-NP	NN	O	22	NMOD
21	entry	entry	I-NP	NN	O	22	NMOD
22	blocker	blocker	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	13	P

1	Serial	Serial	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	auditory	auditory	B-NP	JJ	O	5	NMOD
5	neurotoxicity	neurotoxicity	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	receiving	receive	B-VP	VBG	O	7	NMOD
9	deferoxamine	deferoxamine	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	OBJ
11	.	.	O	.	O	2	P

1	Visual	Visual	B-NP	JJ	O	3	AMOD
2	and	and	I-NP	CC	O	3	AMOD
3	auditory	auditory	I-NP	JJ	O	4	NMOD
4	neurotoxicity	neurotoxicity	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	previously	previously	I-VP	RB	O	5	VMOD
7	documented	document	I-VP	VBN	O	5	VC
8	in	in	B-PP	IN	O	7	VMOD
9	42	42	B-NP	CD	O	10	AMOD
10	of	of	B-PP	IN	O	8	PMOD
11	89	89	B-NP	CD	O	10	AMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	transfusion-dependent	transfusion-dependent	B-NP	JJ	O	15	NMOD
15	anemia	anemia	I-NP	NN	O	13	PMOD
16	who	who	B-NP	WP	O	12	NMOD
17	were	be	B-VP	VBD	O	16	SBAR
18	receiving	receive	I-VP	VBG	O	17	VC
19	iron	iron	B-NP	NN	O	21	NMOD
20	chelation	chelation	I-NP	NN	O	21	NMOD
21	therapy	therapy	I-NP	NN	O	18	OBJ
22	with	with	B-PP	IN	O	21	NMOD
23	daily	daily	B-NP	JJ	O	25	NMOD
24	subcutaneous	subcutaneous	I-NP	JJ	O	25	NMOD
25	deferoxamine	deferoxamine	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	5	P

1	Since	Since	B-PP	IN	O	24	VMOD
2	18	18	B-NP	CD	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	22	22	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	were	be	B-VP	VBD	O	1	SBAR
8	initially	initially	I-VP	RB	O	7	VMOD
9	receiving	receive	I-VP	VBG	O	7	VC
10	deferoxamine	deferoxamine	B-NP	NN	O	11	NMOD
11	doses	dose	I-NP	NNS	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	excess	excess	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	19	NMOD
16	commonly	commonly	I-NP	RB	O	17	AMOD
17	recommended	recommend	I-NP	VBN	O	19	NMOD
18	50	50	I-NP	CD	O	19	NMOD
19	mg/kg	mg/kg	I-NP	NN	O	14	PMOD
20	per	per	B-PP	IN	O	13	NMOD
21	dose	dose	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	24	P
23	therapy	therapy	B-NP	NN	O	24	SUB
24	was	be	B-VP	VBD	O	55	VMOD
25	restarted	restart	I-VP	VBN	O	55	VMOD
26	with	with	B-PP	IN	O	25	VMOD
27	lower	low	B-NP	JJR	O	28	NMOD
28	doses	dose	I-NP	NNS	O	26	PMOD
29	,	,	O	,	O	25	P
30	usually	usually	B-ADVP	RB	O	32	NMOD
31	50	50	B-NP	CD	O	30	AMOD
32	mg/kg	mg/kg	I-NP	NN	O	55	SUB
33	per	per	B-PP	IN	O	32	NMOD
34	dose	dose	B-NP	NN	O	33	PMOD
35	or	or	O	CC	O	37	VMOD
36	less	less	B-NP	JJR	O	37	AMOD
37	depending	depend	B-PP	VBG	O	32	NMOD
38	on	on	B-PP	IN	O	37	PMOD
39	the	the	B-NP	DT	O	40	NMOD
40	degree	degree	I-NP	NN	O	38	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	auditory	auditory	B-NP	JJ	O	43	NMOD
43	abnormality	abnormality	I-NP	NN	O	41	PMOD
44	,	,	O	,	O	32	P
45	and	and	O	CC	O	55	VMOD
46	with	with	B-PP	IN	O	55	VMOD
47	the	the	B-NP	DT	O	48	NMOD
48	exception	exception	I-NP	NN	O	46	PMOD
49	of	of	B-PP	IN	O	48	NMOD
50	two	two	B-NP	CD	O	51	NMOD
51	cases	case	I-NP	NNS	O	49	PMOD
52	no	no	B-NP	DT	O	54	NMOD
53	further	further	I-NP	JJ	O	54	NMOD
54	toxicity	toxicity	I-NP	NN	O	55	SUB
55	was	be	B-VP	VBD	O	0	ROOT
56	demonstrated	demonstrate	I-VP	VBN	O	55	VC
57	.	.	O	.	O	55	P

1	Auditory	Auditory	B-NP	JJ	O	2	NMOD
2	deterioration	deterioration	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	improvement	improvement	I-NP	NN	O	6	SUB
5	,	,	O	,	O	4	P
6	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
7	serially	serially	B-ADVP	RB	O	6	VMOD
8	in	in	B-PP	IN	O	6	VMOD
9	individual	individual	B-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	PMOD
11	receiving	receive	B-VP	VBG	O	10	NMOD
12	and	and	O	CC	O	11	VMOD
13	not	not	B-VP	RB	O	11	VMOD
14	receiving	receive	I-VP	VBG	O	11	VMOD
15	deferoxamine	deferoxamine	B-NP	NN	O	14	OBJ
16	,	,	O	,	O	6	P
17	respectively	respectively	B-ADVP	RB	O	6	VMOD
18	,	,	O	,	O	6	P
19	provided	provide	B-PP	VBN	O	6	VMOD
20	convincing	convince	B-VP	VBG	O	19	PMOD
21	evidence	evidence	B-NP	NN	O	20	OBJ
22	for	for	B-PP	IN	O	21	NMOD
23	a	a	B-NP	DT	O	25	NMOD
24	cause-and-effect	cause-and-effect	I-NP	JJ	O	25	NMOD
25	relation	relation	I-NP	NN	O	22	PMOD
26	between	between	B-PP	IN	O	25	NMOD
27	deferoxamine	deferoxamine	B-NP	NN	O	28	NMOD
28	administration	administration	I-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	ototoxicity	ototoxicity	I-NP	NN	O	26	PMOD
31	.	.	O	.	O	6	P

1	Flurbiprofen	Flurbiprofen	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	juvenile	juvenile	B-NP	JJ	O	8	NMOD
7	rheumatoid	rheumatoid	I-NP	JJ	O	8	NMOD
8	arthritis	arthritis	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	1	P

1	Thirty-four	Thirty-four	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	21	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	juvenile	juvenile	B-NP	JJ	O	6	NMOD
5	rheumatoid	rheumatoid	I-NP	JJ	O	6	NMOD
6	arthritis	arthritis	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	2	P
8	who	who	B-NP	WP	O	2	NMOD
9	were	be	B-VP	VBD	O	8	SBAR
10	treated	treat	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	flurbiprofen	flurbiprofen	B-NP	NN	O	11	PMOD
13	at	at	B-PP	IN	O	10	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	maximum	maximum	I-NP	NN	O	16	NMOD
16	dose	dose	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	4	4	B-NP	CD	O	19	NMOD
19	mg/kg/day	mg/kg/day	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	2	P
21	had	have	B-VP	VBD	O	0	ROOT
22	statistically	statistically	B-NP	RB	O	21	VMOD
23	significant	significant	I-NP	JJ	O	24	NMOD
24	decreases	decrease	I-NP	NNS	O	21	OBJ
25	from	from	B-PP	IN	O	24	NMOD
26	baseline	baseline	B-NP	NN	O	25	PMOD
27	in	in	B-PP	IN	O	24	NMOD
28	6	6	B-NP	CD	O	30	NMOD
29	arthritis	arthritis	I-NP	NN	O	30	NMOD
30	indices	index	I-NP	NNS	O	27	PMOD
31	after	after	B-PP	IN	O	30	NMOD
32	12	12	B-NP	CD	O	33	NMOD
33	weeks	week	I-NP	NNS	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	treatment	treatment	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	2	NMOD
2	correlation	correlation	I-NP	NN	O	9	SUB
3	between	between	B-PP	IN	O	2	NMOD
4	neurotoxic	neurotoxic	B-NP	JJ	B-protein	6	NMOD
5	esterase	esterase	I-NP	NN	I-protein	6	NMOD
6	inhibition	inhibition	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	mipafox	mipafox	I-NP	NN	O	3	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	neuropathic	neuropathic	B-NP	JJ	O	11	NMOD
11	damage	damage	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	correlation	correlation	I-NP	NN	O	18	SUB
3	between	between	B-PP	IN	O	2	NMOD
4	neuropathic	neuropathic	B-NP	JJ	O	5	NMOD
5	damage	damage	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	inhibition	inhibition	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	neurotoxic	neurotoxic	B-NP	JJ	B-protein	10	NMOD
10	esterase	esterase	I-NP	NN	I-protein	14	NMOD
11	or	or	I-NP	CC	O	14	NMOD
12	neuropathy	neuropathy	I-NP	NN	B-protein	14	NMOD
13	target	target	I-NP	NN	I-protein	14	NMOD
14	enzyme	enzyme	I-NP	NN	I-protein	8	PMOD
15	(	(	O	(	O	17	DEP
16	NTE	NTE	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	examined	examine	I-VP	VBN	O	18	VC
20	in	in	B-PP	IN	O	19	VMOD
21	rats	rat	B-NP	NNS	O	34	NMOD
22	acutely	acutely	B-VP	RB	O	23	VMOD
23	exposed	expose	I-VP	VBN	O	21	NMOD
24	to	to	B-PP	TO	O	23	VMOD
25	Mipafox	Mipafox	B-NP	NNP	O	24	PMOD
26	(	(	O	(	O	30	DEP
27	N	N	B-NP	NN	O	29	NMOD
28	,	,	O	,	O	29	P
29	N'-diisopropylphosphorodiamidofluoridate	N'-diisopropylphosphorodiamidofluoridate	B-NP	NN	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	,	,	O	,	O	34	P
32	a	a	B-NP	DT	O	34	NMOD
33	neurotoxic	neurotoxic	I-NP	JJ	O	34	NMOD
34	organophosphate	organophosphate	I-NP	NN	O	20	PMOD
35	.	.	O	.	O	18	P

1	In	In	B-PP	IN	O	0	ROOT
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	1	VMOD
4	dosages	dosage	B-NP	NNS	O	3	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	Mipafox	Mipafox	B-NP	NNP	O	5	PMOD
7	(	(	O	(	O	6	NMOD
8	less	less	B-ADJP	JJR	O	9	AMOD
9	than	than	B-PP	IN	O	7	AMOD
10	or	or	O	CC	O	9	AMOD
11	equal	equal	B-ADJP	JJ	O	9	PRD
12	to	to	B-PP	TO	O	11	AMOD
13	5	5	B-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	12	PMOD
15	)	)	O	)	O	14	NMOD
16	which	which	B-NP	WDT	O	14	NMOD
17	inhibited	inhibit	B-VP	VBD	O	40	VMOD
18	mean	mean	B-NP	JJ	O	20	NMOD
19	NTE	NTE	I-NP	NN	O	20	NMOD
20	activity	activity	I-NP	NN	O	17	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	spinal	spinal	B-NP	JJ	O	23	NMOD
23	cord	cord	I-NP	NN	O	21	PMOD
24	less	less	B-ADJP	JJR	O	40	VMOD
25	than	than	B-PP	IN	O	24	AMOD
26	or	or	O	CC	O	24	NMOD
27	equal	equal	B-ADJP	JJ	O	40	SUB
28	to	to	B-PP	TO	O	27	AMOD
29	61	61	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	32	NMOD
31	and	and	I-NP	CC	O	32	NMOD
32	brain	brain	I-NP	NN	O	28	PMOD
33	less	less	B-ADJP	JJR	O	36	AMOD
34	than	than	B-PP	IN	O	33	AMOD
35	or	or	O	CC	O	36	AMOD
36	equal	equal	B-ADJP	JJ	O	32	NMOD
37	to	to	B-PP	TO	O	36	AMOD
38	60	60	B-NP	CD	O	36	AMOD
39	%	%	I-NP	NN	O	36	AMOD
40	produced	produce	B-VP	VBD	O	16	SBAR
41	this	this	B-NP	DT	O	42	NMOD
42	degree	degree	I-NP	NN	O	40	OBJ
43	of	of	B-PP	IN	O	42	NMOD
44	cord	cord	B-NP	NN	O	45	NMOD
45	damage	damage	I-NP	NN	O	43	PMOD
46	in	in	B-PP	IN	O	40	VMOD
47	only	only	B-NP	RB	O	49	NMOD
48	9	9	I-NP	CD	O	47	AMOD
49	%	%	I-NP	NN	O	46	PMOD
50	of	of	B-PP	IN	O	49	NMOD
51	the	the	B-NP	DT	O	52	NMOD
52	animals	animal	I-NP	NNS	O	50	PMOD
53	.	.	O	.	O	4	P

1	Cerebral	Cerebral	B-NP	JJ	O	2	NMOD
2	infarction	infarction	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	7	NMOD
5	single	single	I-NP	JJ	O	7	NMOD
6	oral	oral	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	phenylpropanolamine	phenylpropanolamine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	2	P

1	Treatment	Treatment	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	psoriasis	psoriasis	B-NP	NN	O	2	PMOD
4	with	with	B-PP	IN	O	1	NMOD
5	azathioprine	azathioprine	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	1	P

1	Azathioprine	Azathioprine	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	benefited	benefit	B-VP	VBD	O	0	ROOT
4	19	19	B-NP	CD	O	3	OBJ
5	(	(	O	(	O	8	DEP
6	66	66	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	out	out	B-PP	IN	O	3	VMOD
10	of	of	B-PP	IN	O	9	PMOD
11	29	29	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	suffering	suffer	B-VP	VBG	O	12	NMOD
14	from	from	B-PP	IN	O	13	VMOD
15	severe	severe	B-NP	JJ	O	16	NMOD
16	psoriasis	psoriasis	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	3	P

1	Maternal	Maternal	B-NP	JJ	O	2	NMOD
2	lithium	lithium	I-NP	NN	O	9	NMOD
3	and	and	O	CC	O	9	NMOD
4	neonatal	neonatal	B-NP	JJ	O	6	NMOD
5	Ebstein	Ebstein	I-NP	NNP	O	6	NMOD
6	's	's	B-NP	POS	O	9	NMOD
7	anomaly	anomaly	B-ADVP	RB	O	6	NMOD
8	:	:	O	:	O	6	P
9	evaluation	evaluation	B-NP	NN	O	0	ROOT
10	with	with	B-PP	IN	O	9	NMOD
11	cross-sectional	cross-sectional	B-NP	JJ	O	12	NMOD
12	echocardiography	echocardiography	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	exercise	exercise	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	severity	severity	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	isoproterenol	isoproterenol	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	infarction	infarction	I-NP	NN	O	10	OBJ
13	were	be	B-VP	VBD	O	10	VMOD
14	studied	study	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	female	female	B-NP	JJ	O	18	NMOD
17	albino	albino	I-NP	JJ	O	18	NMOD
18	rats	rat	I-NP	NNS	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	20	20	B-NP	CD	O	27	NMOD
21	,	,	I-NP	,	O	27	P
22	40	40	I-NP	CD	O	27	NMOD
23	,	,	I-NP	,	O	27	P
24	60	60	I-NP	CD	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	80	80	I-NP	CD	O	27	NMOD
27	weeks	week	I-NP	NNS	O	19	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	age	age	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	10	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	polyethylene	polyethylene	B-NP	NN	O	4	NMOD
4	glycol	glycol	I-NP	NN	O	2	PMOD
5	400	400	I-NP	CD	O	4	NMOD
6	on	on	B-PP	IN	O	1	NMOD
7	adriamycin	adriamycin	B-NP	NN	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	mice	mouse	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	1	P

1	Light	Light	B-NP	NN	O	3	NMOD
2	microscopic	microscopic	I-NP	JJ	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	4	SUB
4	showed	show	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	significant	significant	I-NP	JJ	O	7	NMOD
7	protection	protection	I-NP	NN	O	10	SUB
8	against	against	B-PP	IN	O	7	NMOD
9	ADR	ADR	B-NP	NN	B-protein	8	PMOD
10	induced	induce	B-VP	VBD	O	4	VMOD
11	cardiac	cardiac	B-NP	JJ	O	13	NMOD
12	morphological	morphological	I-NP	JJ	O	13	NMOD
13	alterations	alteration	I-NP	NNS	O	10	OBJ
14	.	.	O	.	O	4	P

1	Intra-arterial	Intra-arterial	B-NP	JJ	O	3	NMOD
2	BCNU	BCNU	I-NP	NN	O	3	NMOD
3	chemotherapy	chemotherapy	I-NP	NN	O	0	ROOT
4	for	for	B-PP	IN	O	3	NMOD
5	treatment	treatment	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	malignant	malignant	B-NP	JJ	O	8	NMOD
8	gliomas	glioma	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	central	central	I-NP	JJ	O	13	NMOD
12	nervous	nervous	I-NP	JJ	O	13	NMOD
13	system	system	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	3	P

1	Because	Because	B-PP	IN	O	21	VMOD
2	of	of	I-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	6	NMOD
4	rapid	rapid	I-NP	JJ	O	5	AMOD
5	systemic	systemic	I-NP	JJ	O	6	NMOD
6	clearance	clearance	I-NP	NN	O	21	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	BCNU	BCNU	B-NP	NN	B-protein	20	NMOD
9	(	(	O	(	O	17	DEP
10	1	1	B-NP	CD	O	16	NMOD
11	,	,	I-NP	,	O	16	P
12	3-bis-	3-bis-	I-NP	CD	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	2-chloroethyl	2-chloroethyl	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	-1-nitrosourea	-1-nitrosourea	B-NP	NN	O	17	DEP
17	)	)	O	)	O	8	NMOD
18	,	,	O	,	O	20	P
19	intra-arterial	intra-arterial	B-NP	JJ	O	20	NMOD
20	administration	administration	I-NP	NN	O	7	PMOD
21	should	should	B-VP	MD	O	0	ROOT
22	provide	provide	I-VP	VB	O	21	VC
23	a	a	B-NP	DT	O	25	NMOD
24	substantial	substantial	I-NP	JJ	O	25	NMOD
25	advantage	advantage	I-NP	NN	O	22	OBJ
26	over	over	B-PP	IN	O	25	NMOD
27	intravenous	intravenous	B-NP	JJ	O	28	NMOD
28	administration	administration	I-NP	NN	O	26	PMOD
29	for	for	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	treatment	treatment	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	malignant	malignant	B-NP	JJ	O	34	NMOD
34	gliomas	glioma	I-NP	NNS	O	32	PMOD
35	.	.	O	.	O	21	P

1	Twenty-four	Twenty-four	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	15	NMOD
3	with	with	B-PP	IN	O	2	NMOD
4	recurrent	recurrent	B-NP	JJ	O	5	NMOD
5	Grade	Grade	I-NP	NN	O	9	NMOD
6	I	I	I-NP	CD	O	8	AMOD
7	to	to	I-NP	TO	O	8	AMOD
8	IV	IV	I-NP	CD	O	5	NMOD
9	astrocytomas	astrocytoma	I-NP	NNS	O	3	PMOD
10	,	,	O	,	O	2	P
11	whose	whose	B-NP	WP$	O	15	NMOD
12	resection	resection	I-NP	NN	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	irradiation	irradiation	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	16	SUB
16	had	have	B-VP	VBD	O	0	ROOT
17	failed	fail	I-VP	VBN	O	16	VC
18	,	,	O	,	O	16	P
19	received	receive	B-VP	VBD	O	16	VMOD
20	two	two	B-NP	CD	O	22	AMOD
21	to	to	I-NP	TO	O	22	AMOD
22	eight	eight	I-NP	CD	O	23	NMOD
23	courses	course	I-NP	NNS	O	19	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	intra-arterial	intra-arterial	B-NP	JJ	O	27	NMOD
26	BCNU	BCNU	I-NP	NN	O	27	NMOD
27	therapy	therapy	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	16	P

1	Intrarenal	Intrarenal	B-NP	JJ	O	2	NMOD
2	infusion	infusion	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	noradrenaline	noradrenaline	B-NP	NN	O	3	PMOD
5	caused	cause	B-VP	VBD	O	0	ROOT
6	hypertension	hypertension	B-NP	NN	O	5	OBJ
7	at	at	B-PP	IN	O	5	VMOD
8	doses	dose	B-NP	NNS	O	7	PMOD
9	which	which	B-NP	WDT	O	8	NMOD
10	did	do	B-VP	VBD	O	9	SBAR
11	not	not	I-VP	RB	O	10	VMOD
12	do	do	I-VP	VB	O	10	VC
13	so	so	B-ADVP	RB	O	12	VMOD
14	when	when	B-ADVP	WRB	O	12	VMOD
15	infused	infuse	B-VP	VBN	O	14	SBAR
16	intravenously	intravenously	B-ADVP	RB	O	15	VMOD
17	.	.	O	.	O	5	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	only	only	B-NP	RB	O	5	NMOD
4	one	one	I-NP	CD	O	3	AMOD
5	case	case	I-NP	NN	O	2	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	dementia	dementia	B-NP	NN	O	6	PMOD
8	possibly	possibly	B-ADVP	RB	O	9	PMOD
9	due	due	B-PP	IN	O	5	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	cimetidine	cimetidine	B-NP	NN	O	10	PMOD
12	(	(	O	(	O	25	DEP
13	with	with	B-PP	IN	O	25	DEP
14	a	a	B-NP	DT	O	16	NMOD
15	drug	drug	I-NP	NN	O	16	NMOD
16	level	level	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	1.9	1.9	B-NP	CD	O	21	NMOD
19	microgram/ml	microgram/ml	I-NP	NN	O	21	NMOD
20	6	6	B-NP	CD	O	21	NMOD
21	hr	hr	I-NP	NN	O	17	PMOD
22	after	after	B-PP	IN	O	13	PMOD
23	a	a	B-NP	DT	O	24	NMOD
24	dose	dose	I-NP	NN	O	22	PMOD
25	)	)	O	)	O	11	NMOD
26	in	in	B-PP	IN	O	11	NMOD
27	a	a	B-NP	DT	O	28	NMOD
28	group	group	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	13	13	B-NP	CD	O	31	NMOD
31	patients	patient	I-NP	NNS	O	29	PMOD
32	without	without	B-PP	IN	O	11	NMOD
33	liver	liver	B-NP	NN	O	36	NMOD
34	or	or	I-NP	CC	O	36	NMOD
35	kidney	kidney	I-NP	NN	O	36	NMOD
36	disease	disease	I-NP	NN	O	32	PMOD
37	who	who	B-NP	WP	O	36	NMOD
38	had	have	B-VP	VBD	O	37	SBAR
39	cimetidine	cimetidine	B-NP	NN	O	40	NMOD
40	levels	level	I-NP	NNS	O	38	OBJ
41	above	above	B-PP	IN	O	38	VMOD
42	1.25	1.25	B-NP	CD	O	43	NMOD
43	microgram/ml	microgram/ml	I-NP	NN	O	41	PMOD
44	.	.	O	.	O	2	P

1	Development	Development	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	clear	clear	B-NP	JJ	O	5	NMOD
4	cell	cell	I-NP	NN	O	5	NMOD
5	adenocarcinoma	adenocarcinoma	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	1	NMOD
7	DES-exposed	DES-exposed	B-NP	JJ	O	8	NMOD
8	offspring	offspring	I-NP	NN	O	6	PMOD
9	under	under	B-PP	IN	O	1	NMOD
10	observation	observation	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	1	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	21	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	clear	clear	B-NP	JJ	O	6	NMOD
5	cell	cell	I-NP	NN	O	6	NMOD
6	adenocarcinoma	adenocarcinoma	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	vagina	vagina	I-NP	NN	O	7	PMOD
10	detected	detect	B-VP	VBN	O	9	NMOD
11	at	at	B-PP	IN	O	10	VMOD
12	follow-up	follow-up	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	young	young	B-NP	JJ	O	15	NMOD
15	women	woman	I-NP	NNS	O	13	PMOD
16	exposed	expose	B-VP	VBN	O	15	NMOD
17	in	in	B-PP	IN	O	16	VMOD
18	utero	utero	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	17	PMOD
20	diethylstilbestrol	diethylstilbestrol	B-NP	NN	O	17	PMOD
21	are	be	B-VP	VBP	O	0	ROOT
22	reported	report	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	Phenobarbitone	Phenobarbitone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	16	VMOD
3	enlargement	enlargement	B-NP	NN	O	2	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	liver	liver	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	rat	rat	I-NP	NN	O	7	PMOD
10	:	:	O	:	O	2	P
11	its	its	B-NP	PRP$	O	12	NMOD
12	relationship	relationship	I-NP	NN	O	16	SUB
13	to	to	B-PP	TO	O	12	NMOD
14	carbon	carbon	B-NP	NN	O	15	NMOD
15	tetrachloride	tetrachloride	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	cirrhosis	cirrhosis	B-NP	NN	O	16	OBJ
18	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	2	NMOD
2	yield	yield	I-NP	NN	O	59	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	severe	severe	B-NP	JJ	O	5	NMOD
5	cirrhosis	cirrhosis	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	liver	liver	I-NP	NN	O	6	PMOD
9	(	(	O	(	O	46	DEP
10	defined	define	B-VP	VBN	O	45	NMOD
11	as	as	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	16	NMOD
13	shrunken	shrink	I-NP	VBN	O	15	AMOD
14	finely	finely	I-NP	RB	O	15	AMOD
15	nodular	nodular	I-NP	JJ	O	16	NMOD
16	liver	liver	I-NP	NN	O	11	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	micronodular	micronodular	B-NP	JJ	O	19	NMOD
19	histology	histology	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	10	P
21	ascites	ascite	B-VP	VBZ	O	10	VMOD
22	greater	great	B-NP	JJR	O	23	AMOD
23	than	than	I-NP	IN	O	25	NMOD
24	30	30	I-NP	CD	O	23	AMOD
25	ml	ml	I-NP	NN	O	28	NMOD
26	,	,	O	,	O	28	P
27	plasma	plasma	B-NP	NN	O	28	NMOD
28	albumin	albumin	I-NP	NN	O	32	NMOD
29	less	less	B-NP	JJR	O	30	AMOD
30	than	than	I-NP	IN	O	32	NMOD
31	2.2	2.2	I-NP	CD	O	30	AMOD
32	g/dl	g/dl	I-NP	NN	O	36	NMOD
33	,	,	O	,	O	36	P
34	splenomegaly	splenomegaly	B-NP	NN	O	36	NMOD
35	2-3	2-3	B-NP	CD	O	36	NMOD
36	times	time	I-NP	NNS	O	21	OBJ
37	normal	normal	B-ADJP	JJ	O	36	NMOD
38	,	,	O	,	O	45	P
39	and	and	O	CC	O	45	NMOD
40	testicular	testicular	B-NP	JJ	O	41	NMOD
41	atrophy	atrophy	I-NP	NN	O	45	NMOD
42	approximately	approximately	B-NP	RB	O	45	NMOD
43	half	half	I-NP	DT	O	45	NMOD
44	normal	normal	I-NP	JJ	O	45	NMOD
45	weight	weight	I-NP	NN	O	46	DEP
46	)	)	O	)	O	8	NMOD
47	after	after	B-PP	IN	O	2	NMOD
48	12	12	B-NP	CD	O	49	NMOD
49	doses	dose	I-NP	NNS	O	47	PMOD
50	of	of	B-PP	IN	O	49	NMOD
51	carbon	carbon	B-NP	NN	O	52	NMOD
52	tetrachloride	tetrachloride	I-NP	NN	O	50	PMOD
53	given	give	B-VP	VBN	O	49	NMOD
54	intragastrically	intragastrically	B-ADVP	RB	O	53	VMOD
55	in	in	B-PP	IN	O	53	VMOD
56	the	the	B-NP	DT	O	58	NMOD
57	phenobarbitone-primed	phenobarbitone-primed	I-NP	JJ	O	58	NMOD
58	rat	rat	I-NP	NN	O	55	PMOD
59	was	be	B-VP	VBD	O	0	ROOT
60	increased	increase	I-VP	VBN	O	59	VC
61	from	from	B-PP	IN	O	60	VMOD
62	25	25	B-NP	CD	O	63	NMOD
63	%	%	I-NP	NN	O	61	PMOD
64	to	to	B-PP	TO	O	60	VMOD
65	56	56	B-NP	CD	O	66	NMOD
66	%	%	I-NP	NN	O	64	PMOD
67	by	by	B-PP	IN	O	60	VMOD
68	giving	give	B-VP	VBG	O	67	PMOD
69	the	the	B-NP	DT	O	74	NMOD
70	initial	initial	I-NP	JJ	O	74	NMOD
71	"	"	I-NP	"	O	74	NMOD
72	calibrating	calibrate	I-NP	VBG	O	74	NMOD
73	"	"	I-NP	"	O	74	NMOD
74	dose	dose	I-NP	NN	O	68	OBJ
75	of	of	B-PP	IN	O	74	NMOD
76	carbon	carbon	B-NP	NN	O	77	NMOD
77	tetrachloride	tetrachloride	I-NP	NN	O	75	PMOD
78	at	at	B-PP	IN	O	68	VMOD
79	the	the	B-NP	DT	O	80	NMOD
80	peak	peak	I-NP	NN	O	78	PMOD
81	of	of	B-PP	IN	O	80	NMOD
82	the	the	B-NP	DT	O	83	NMOD
83	phenobarbitone	phenobarbitone	I-NP	NN	O	81	PMOD
84	induced	induce	B-VP	VBD	O	59	VMOD
85	enlargement	enlargement	B-NP	NN	O	84	OBJ
86	of	of	B-PP	IN	O	85	NMOD
87	the	the	B-NP	DT	O	88	NMOD
88	liver	liver	I-NP	NN	O	86	PMOD
89	.	.	O	.	O	59	P

1	Attenuation	Attenuation	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	lithium	lithium	I-NP	NN	O	2	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	diabetes-insipidus-like	diabetes-insipidus-like	B-NP	JJ	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	5	OBJ
8	by	by	B-PP	IN	O	5	VMOD
9	amiloride	amiloride	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	amiloride	amiloride	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	lithium	lithium	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	polydipsia	polydipsia	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	polyuria	polyuria	I-NP	NN	O	7	OBJ
11	and	and	B-PP	CC	O	7	VMOD
12	on	on	B-PP	IN	O	7	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	lithium	lithium	I-NP	NN	O	15	NMOD
15	concentration	concentration	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	28	NMOD
18	plasma	plasma	I-NP	NN	O	28	NMOD
19	,	,	I-NP	,	O	28	P
20	brain	brain	I-NP	NN	O	28	NMOD
21	,	,	I-NP	,	O	28	P
22	kidney	kidney	I-NP	NN	O	28	NMOD
23	,	,	I-NP	,	O	28	P
24	thyroid	thyroid	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	red	red	I-NP	JJ	B-cell_type	28	NMOD
27	blood	blood	I-NP	NN	I-cell_type	28	NMOD
28	cells	cell	I-NP	NNS	I-cell_type	16	PMOD
29	was	be	B-VP	VBD	O	7	VMOD
30	investigated	investigate	I-VP	VBN	O	29	VC
31	in	in	B-PP	IN	O	30	VMOD
32	rats	rat	B-NP	NNS	O	31	PMOD
33	,	,	O	,	O	7	P
34	chronically	chronically	B-VP	RB	O	7	VMOD
35	treated	treat	I-VP	VBN	O	7	VMOD
36	with	with	B-PP	IN	O	35	VMOD
37	LiCl	LiCl	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	11	VMOD
2	all	all	B-NP	PDT	O	4	NMOD
3	the	the	I-NP	DT	O	4	NMOD
4	experiments	experiment	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	11	P
6	the	the	B-NP	DT	O	7	NMOD
7	attenuation	attenuation	I-NP	NN	O	11	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	lithium	lithium	I-NP	NN	O	8	PMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	diabetes-insipidus-like	diabetes-insipidus-like	B-NP	JJ	O	13	NMOD
13	syndrome	syndrome	I-NP	NN	O	11	OBJ
14	by	by	B-PP	IN	O	11	VMOD
15	amiloride	amiloride	B-NP	NN	O	14	PMOD
16	was	be	B-VP	VBD	O	11	VMOD
17	accompanied	accompany	I-VP	VBN	O	16	VC
18	by	by	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	reduction	reduction	I-NP	NN	O	40	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	ratio	ratio	I-NP	NN	O	21	PMOD
24	between	between	B-PP	IN	O	20	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	lithium	lithium	I-NP	NN	O	27	NMOD
27	concentration	concentration	I-NP	NN	O	34	NMOD
28	in	in	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	renal	renal	I-NP	JJ	O	31	NMOD
31	medulla	medulla	I-NP	NN	O	28	PMOD
32	and	and	O	CC	O	34	NMOD
33	its	its	B-NP	PRP$	O	34	NMOD
34	levels	level	I-NP	NNS	O	24	PMOD
35	in	in	B-PP	IN	O	20	NMOD
36	the	the	B-NP	DT	O	37	NMOD
37	blood	blood	I-NP	NN	O	35	PMOD
38	and	and	O	CC	O	40	NMOD
39	an	an	B-NP	DT	O	40	NMOD
40	elevation	elevation	I-NP	NN	O	18	PMOD
41	in	in	B-PP	IN	O	40	NMOD
42	the	the	B-NP	DT	O	45	NMOD
43	plasma	plasma	I-NP	NN	O	45	NMOD
44	potassium	potassium	I-NP	NN	O	45	NMOD
45	level	level	I-NP	NN	O	41	PMOD
46	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	2	NMOD
2	efficacy	efficacy	I-NP	NN	O	19	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	alprazolam	alprazolam	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	placebo	placebo	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	panic	panic	B-NP	NN	O	9	NMOD
9	disorder	disorder	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	agoraphobia	agoraphobia	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	19	P
13	and	and	O	CC	O	19	NMOD
14	the	the	B-NP	DT	O	19	NMOD
15	side-effect	side-effect	I-NP	JJ	O	19	NMOD
16	and	and	I-NP	CC	O	19	NMOD
17	adverse	adverse	I-NP	JJ	O	19	NMOD
18	effect	effect	I-NP	NN	O	19	NMOD
19	profiles	profile	I-NP	NNS	O	24	SUB
20	of	of	B-PP	IN	O	19	NMOD
21	both	both	B-NP	DT	O	23	NMOD
22	drug	drug	I-NP	NN	O	23	NMOD
23	groups	group	I-NP	NNS	O	20	PMOD
24	were	be	B-VP	VBD	O	0	ROOT
25	measured	measure	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	METHOD	METHOD	B-NP	NN	O	18	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	1	NMOD
4	London	London	B-NP	NNP	O	6	NMOD
5	and	and	O	CC	O	6	NMOD
6	Toronto	Toronto	B-NP	NNP	O	8	NMOD
7	154	154	B-NP	CD	O	6	NMOD
8	patients	patient	I-NP	NNS	O	3	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	met	meet	B-VP	VBD	O	9	SBAR
11	DSM-III	DSM-III	B-NP	NN	O	12	NMOD
12	criteria	criterion	I-NP	NNS	O	10	OBJ
13	for	for	B-PP	IN	O	12	NMOD
14	panic	panic	B-NP	NN	O	15	NMOD
15	disorder	disorder	I-NP	NN	O	13	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	agoraphobia	agoraphobia	B-NP	NN	O	16	PMOD
18	were	be	B-VP	VBD	O	0	ROOT
19	randomised	randomise	I-VP	VBN	O	18	VC
20	to	to	B-PP	TO	O	19	VMOD
21	alprazolam	alprazolam	B-NP	NN	O	23	NMOD
22	or	or	I-NP	CC	O	23	NMOD
23	placebo	placebo	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	18	P

1	Compared	Compare	B-PP	VBN	O	8	VMOD
2	with	with	B-PP	IN	O	1	PMOD
3	placebo	placebo	B-NP	NN	O	4	NMOD
4	subjects	subject	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	8	P
6	alprazolam	alprazolam	B-NP	NN	O	7	NMOD
7	patients	patient	I-NP	NNS	O	8	SUB
8	developed	develop	B-VP	VBD	O	0	ROOT
9	more	more	B-NP	RBR	O	10	AMOD
10	adverse	adverse	I-NP	JJ	O	11	NMOD
11	reactions	reaction	I-NP	NNS	O	43	NMOD
12	(	(	O	(	O	43	NMOD
13	21	21	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	43	NMOD
15	v.	v.	B-PP	IN	O	14	NMOD
16	0	0	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	15	PMOD
18	)	)	O	)	O	26	NMOD
19	of	of	B-PP	IN	O	26	NMOD
20	depression	depression	B-NP	NN	O	19	PMOD
21	,	,	I-NP	,	O	26	P
22	enuresis	enuresis	I-NP	NN	O	26	NMOD
23	,	,	I-NP	,	O	26	P
24	disinhibition	disinhibition	I-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	aggression	aggression	I-NP	NN	O	15	PMOD
27	;	;	O	:	O	43	P
28	and	and	O	CC	O	43	NMOD
29	more	more	B-NP	JJR	O	30	NMOD
30	side-effects	side-effect	I-NP	NNS	O	43	NMOD
31	,	,	O	,	O	43	P
32	particularly	particularly	B-ADVP	RB	O	43	NMOD
33	sedation	sedation	B-NP	NN	O	43	NMOD
34	,	,	O	,	O	43	P
35	irritability	irritability	B-NP	NN	O	43	NMOD
36	,	,	O	,	O	43	P
37	impaired	impaired	B-NP	JJ	O	38	NMOD
38	memory	memory	I-NP	NN	O	43	NMOD
39	,	,	O	,	O	43	P
40	weight	weight	B-NP	NN	O	41	NMOD
41	loss	loss	I-NP	NN	O	43	NMOD
42	and	and	I-NP	CC	O	43	NMOD
43	ataxia	ataxia	I-NP	NN	O	8	OBJ
44	.	.	O	.	O	8	P

1	Dup	Dup	B-PP	IN	O	9	VMOD
2	753	753	B-NP	CD	O	3	NMOD
3	prevents	prevent	I-NP	NNS	O	1	PMOD
4	the	the	B-NP	DT	O	5	NMOD
5	development	development	I-NP	NN	O	9	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	puromycin	puromycin	B-NP	NN	O	8	NMOD
8	aminonucleoside	aminonucleoside	I-NP	NN	O	6	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	nephrosis	nephrosis	B-NP	NN	O	9	OBJ
11	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	appearance	appearance	I-NP	NN	O	28	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	nephrotic	nephrotic	B-NP	JJ	O	5	NMOD
5	syndromes	syndrome	I-NP	NNS	O	3	PMOD
6	such	such	B-PP	JJ	O	7	PMOD
7	as	as	I-PP	IN	O	5	NMOD
8	proteinuria	proteinuria	B-NP	NN	O	14	NMOD
9	,	,	O	,	O	14	P
10	hypoalbuminemia	hypoalbuminemia	B-NP	NN	O	14	NMOD
11	,	,	O	,	O	14	P
12	hypercholesterolemia	hypercholesterolemia	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	increase	increase	I-NP	NN	O	7	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	blood	blood	B-NP	NN	O	18	NMOD
17	nitrogen	nitrogen	I-NP	NN	O	18	NMOD
18	urea	urea	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	14	P
20	induced	induce	B-VP	VBN	O	14	NMOD
21	in	in	B-PP	IN	O	20	VMOD
22	rats	rat	B-NP	NNS	O	21	PMOD
23	by	by	B-PP	IN	O	20	VMOD
24	injection	injection	B-NP	NN	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	puromycin	puromycin	B-NP	NN	O	27	NMOD
27	aminonucleoside	aminonucleoside	I-NP	NN	O	25	PMOD
28	was	be	B-VP	VBD	O	0	ROOT
29	markedly	markedly	I-VP	RB	O	28	VMOD
30	inhibited	inhibit	I-VP	VBN	O	28	VC
31	by	by	B-PP	IN	O	30	VMOD
32	oral	oral	B-NP	JJ	O	33	NMOD
33	administration	administration	I-NP	NN	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	Dup	Dup	B-NP	NN	O	46	NMOD
36	753	753	I-NP	CD	O	35	NMOD
37	(	(	O	(	O	39	DEP
38	losartan	losartan	B-NP	NN	O	39	DEP
39	)	)	O	)	O	35	NMOD
40	,	,	O	,	O	46	P
41	a	a	B-NP	DT	O	46	NMOD
42	novel	novel	I-NP	JJ	O	46	NMOD
43	angiotensin	angiotensin	I-NP	NN	O	46	NMOD
44	II	II	I-NP	CD	O	46	NMOD
45	receptor	receptor	I-NP	NN	O	46	NMOD
46	antagonist	antagonist	I-NP	NN	O	34	PMOD
47	,	,	O	,	O	30	P
48	at	at	B-PP	IN	O	30	VMOD
49	a	a	B-NP	DT	O	50	NMOD
50	dose	dose	I-NP	NN	O	48	PMOD
51	of	of	B-PP	IN	O	50	NMOD
52	1	1	B-NP	CD	O	54	AMOD
53	or	or	I-NP	CC	O	54	AMOD
54	2	2	I-NP	CD	O	55	NMOD
55	mg/kg	mg/kg	I-NP	NN	O	51	PMOD
56	per	per	B-PP	IN	O	50	NMOD
57	day	day	B-NP	NN	O	56	PMOD
58	.	.	O	.	O	28	P

1	Sodium	Sodium	B-NP	NN	O	2	NMOD
2	bicarbonate	bicarbonate	I-NP	NN	O	3	SUB
3	alleviates	alleviate	B-VP	VBZ	O	0	ROOT
4	penile	penile	B-NP	JJ	B-protein	5	NMOD
5	pain	pain	I-NP	NN	I-protein	3	OBJ
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	intracavernous	intracavernous	B-NP	JJ	O	9	NMOD
9	injections	injection	I-NP	NNS	O	7	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	erectile	erectile	B-NP	JJ	O	12	NMOD
12	dysfunction	dysfunction	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	24	VMOD
2	an	an	B-NP	DT	O	3	NMOD
3	attempt	attempt	I-NP	NN	O	1	PMOD
4	to	to	B-VP	TO	O	5	VMOD
5	determine	determine	I-VP	VB	O	3	NMOD
6	whether	whether	B-SBAR	IN	O	5	VMOD
7	penile	penile	B-NP	JJ	O	8	NMOD
8	pain	pain	I-NP	NN	O	13	SUB
9	associated	associate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	intracorporeal	intracorporeal	B-NP	JJ	O	12	NMOD
12	injections	injection	I-NP	NNS	O	10	PMOD
13	could	could	B-VP	MD	O	6	SBAR
14	be	be	I-VP	VB	O	13	VC
15	due	due	B-ADVP	JJ	O	16	PMOD
16	to	to	B-PP	TO	O	14	PRD
17	the	the	B-NP	DT	O	18	NMOD
18	acidity	acidity	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	medication	medication	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	24	P
23	we	we	B-NP	PRP	O	24	SUB
24	performed	perform	B-VP	VBD	O	0	ROOT
25	a	a	B-NP	DT	O	27	NMOD
26	randomized	randomize	I-NP	VBN	O	27	NMOD
27	study	study	I-NP	NN	O	24	OBJ
28	comparing	compare	B-VP	VBG	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	incidence	incidence	I-NP	NN	O	28	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	penile	penile	B-NP	JJ	O	33	NMOD
33	pain	pain	I-NP	NN	O	31	PMOD
34	following	follow	B-PP	VBG	O	33	NMOD
35	intracorporeal	intracorporeal	B-NP	JJ	O	36	NMOD
36	injections	injection	I-NP	NNS	O	34	PMOD
37	with	with	B-PP	IN	O	36	NMOD
38	or	or	B-PP	CC	O	37	PMOD
39	without	without	B-PP	IN	O	37	PMOD
40	the	the	B-NP	DT	O	41	NMOD
41	addition	addition	I-NP	NN	O	37	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	sodium	sodium	B-NP	NN	O	44	NMOD
44	bicarbonate	bicarbonate	I-NP	NN	O	42	PMOD
45	to	to	B-PP	TO	O	41	NMOD
46	the	the	B-NP	DT	O	48	NMOD
47	intracorporeal	intracorporeal	I-NP	JJ	O	48	NMOD
48	medications	medication	I-NP	NNS	O	45	PMOD
49	.	.	O	.	O	24	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	38	38	B-NP	CD	O	6	NMOD
5	consecutive	consecutive	I-NP	JJ	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	presented	present	B-VP	VBD	O	7	SBAR
9	to	to	B-PP	TO	O	8	VMOD
10	our	our	B-NP	PRP$	O	11	NMOD
11	clinic	clinic	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	impotence	impotence	B-NP	NN	O	12	PMOD
14	received	receive	B-VP	VBD	O	0	ROOT
15	0.2	0.2	B-NP	CD	O	16	NMOD
16	ml.	ml.	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	19	NMOD
19	combination	combination	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	3	3	B-NP	CD	O	22	NMOD
22	drugs	drug	I-NP	NNS	O	20	PMOD
23	:	:	O	:	O	14	P
24	6	6	B-NP	CD	O	26	NMOD
25	mg.	mg.	I-NP	NN	O	26	NMOD
26	papaverine	papaverine	I-NP	NN	O	35	NMOD
27	,	,	O	,	O	35	P
28	100	100	B-NP	CD	O	30	NMOD
29	micrograms.	micrograms.	I-NP	NNS	O	30	NMOD
30	phentolamine	phentolamine	I-NP	NN	O	35	NMOD
31	and	and	O	CC	O	35	NMOD
32	10	10	B-NP	CD	O	33	NMOD
33	micrograms.	micrograms.	I-NP	NNS	O	35	NMOD
34	prostaglandin	prostaglandin	I-NP	NN	O	35	NMOD
35	E1	E1	I-NP	NN	O	14	OBJ
36	with	with	B-PP	IN	O	35	NMOD
37	(	(	O	(	O	40	DEP
38	pH	pH	B-NP	NN	O	40	DEP
39	7.05	7.05	I-NP	CD	O	38	NMOD
40	)	)	O	)	O	36	PMOD
41	or	or	O	CC	O	36	PMOD
42	without	without	B-PP	IN	O	36	PMOD
43	(	(	O	(	O	46	DEP
44	pH	pH	B-NP	NN	O	46	DEP
45	4.17	4.17	I-NP	CD	O	44	NMOD
46	)	)	O	)	O	42	AMOD
47	the	the	B-NP	DT	O	48	NMOD
48	addition	addition	I-NP	NN	O	42	PMOD
49	of	of	B-PP	IN	O	48	NMOD
50	sodium	sodium	B-NP	NN	O	51	NMOD
51	bicarbonate	bicarbonate	I-NP	NN	O	49	PMOD
52	(	(	O	(	O	55	DEP
53	0.03	0.03	B-NP	CD	O	54	NMOD
54	mEq.	mEq.	I-NP	NN	O	55	DEP
55	)	)	O	)	O	51	NMOD
56	.	.	O	.	O	14	P

1	Of	Of	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	4	NMOD
3	19	19	I-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	PMOD
5	without	without	B-PP	IN	O	4	NMOD
6	sodium	sodium	B-NP	NN	O	7	NMOD
7	bicarbonate	bicarbonate	I-NP	NN	O	5	PMOD
8	added	add	B-VP	VBN	O	4	NMOD
9	to	to	B-PP	TO	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	medication	medication	I-NP	NN	O	9	PMOD
12	11	11	I-NP	CD	O	11	NMOD
13	(	(	O	(	O	16	DEP
14	58	58	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	11	NMOD
17	complained	complain	B-VP	VBD	O	4	NMOD
18	of	of	B-PP	IN	O	17	VMOD
19	penile	penile	B-NP	JJ	O	20	NMOD
20	pain	pain	I-NP	NN	O	18	PMOD
21	due	due	B-PP	JJ	O	22	PMOD
22	to	to	B-PP	TO	O	1	PMOD
23	the	the	B-NP	DT	O	24	NMOD
24	medication	medication	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	26	P
26	while	while	B-SBAR	IN	O	1	VMOD
27	only	only	B-NP	RB	O	26	DEP
28	1	1	I-NP	CD	O	27	AMOD
29	of	of	B-PP	IN	O	27	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	19	19	I-NP	CD	O	32	NMOD
32	men	man	I-NP	NNS	O	29	PMOD
33	(	(	O	(	O	36	DEP
34	5	5	B-NP	CD	O	35	NMOD
35	%	%	I-NP	NN	O	36	DEP
36	)	)	O	)	O	27	NMOD
37	who	who	B-NP	WP	O	27	NMOD
38	received	receive	B-VP	VBD	O	37	SBAR
39	sodium	sodium	B-NP	NN	O	40	NMOD
40	bicarbonate	bicarbonate	I-NP	NN	O	38	OBJ
41	complained	complain	B-VP	VBN	O	40	NMOD
42	of	of	B-PP	IN	O	41	VMOD
43	penile	penile	B-NP	JJ	O	44	NMOD
44	pain	pain	I-NP	NN	O	42	PMOD
45	.	.	O	.	O	26	P

1	Prospective	Prospective	B-NP	JJ	O	2	NMOD
2	study	study	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	long-term	long-term	I-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	somatostatin	somatostatin	B-NP	NN	O	9	NMOD
9	analog	analog	I-NP	NN	O	7	PMOD
10	(	(	O	(	O	12	DEP
11	octreotide	octreotide	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	on	on	B-PP	IN	O	6	NMOD
14	gallbladder	gallbladder	B-NP	NN	O	15	NMOD
15	function	function	I-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	gallstone	gallstone	B-NP	NN	O	18	NMOD
18	formation	formation	I-NP	NN	O	13	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	Chinese	Chinese	B-NP	JJ	O	22	NMOD
21	acromegalic	acromegalic	I-NP	JJ	O	22	NMOD
22	patients	patient	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	article	article	I-NP	NN	O	3	SUB
3	reports	report	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	changes	change	I-NP	NNS	O	3	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	gallbladder	gallbladder	B-NP	NN	O	8	NMOD
8	function	function	I-NP	NN	O	6	PMOD
9	examined	examine	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	ultrasonography	ultrasonography	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	20	20	B-NP	CD	O	15	NMOD
14	Chinese	Chinese	I-NP	JJ	O	15	NMOD
15	patients	patient	I-NP	NNS	O	12	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	active	active	B-NP	JJ	O	16	PMOD
18	acromegaly	acromegaly	B-VP	RB	O	19	VMOD
19	treated	treat	I-VP	VBN	O	17	NMOD
20	with	with	B-PP	IN	O	19	VMOD
21	sc	sc	B-NP	NN	O	22	NMOD
22	injection	injection	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	27	NMOD
25	somatostatin	somatostatin	I-NP	NN	O	27	NMOD
26	analog	analog	I-NP	NN	O	27	NMOD
27	octreotide	octreotide	I-NP	NN	O	23	PMOD
28	in	in	B-PP	IN	O	19	VMOD
29	dosages	dosage	B-NP	NNS	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	300-1500	300-1500	B-NP	CD	O	32	NMOD
32	micrograms/day	micrograms/day	I-NP	NN	O	30	PMOD
33	for	for	B-PP	IN	O	19	VMOD
34	a	a	B-NP	DT	O	35	NMOD
35	mean	mean	I-NP	NN	O	33	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	24.2	24.2	B-NP	CD	O	39	AMOD
38	+/-	+/-	I-NP	SYM	O	39	AMOD
39	13.9	13.9	I-NP	CD	O	40	NMOD
40	months	month	I-NP	NNS	O	36	PMOD
41	.	.	O	.	O	3	P

1	During	During	B-PP	IN	O	12	VMOD
2	treatment	treatment	B-NP	NN	O	8	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	octreotide	octreotide	B-NP	NN	O	7	NMOD
5	,	,	O	,	O	7	P
6	17	17	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	3	PMOD
8	developed	develop	B-VP	VBD	O	1	SBAR
9	sludge	sludge	B-NP	NN	O	8	OBJ
10	,	,	O	,	O	12	P
11	10	10	B-NP	CD	O	12	SUB
12	had	have	B-VP	VBD	O	17	VMOD
13	gallstones	gallstone	B-NP	NNS	O	17	SUB
14	,	,	O	,	O	17	P
15	and	and	O	CC	O	17	VMOD
16	1	1	B-NP	CD	O	17	SUB
17	developed	develop	B-VP	VBD	O	0	ROOT
18	acute	acute	B-NP	JJ	O	19	NMOD
19	cholecystitis	cholecystitis	I-NP	NN	O	17	OBJ
20	requiring	require	B-VP	VBG	O	19	NMOD
21	surgery	surgery	B-NP	NN	O	20	OBJ
22	.	.	O	.	O	17	P

1	After	After	B-PP	IN	O	14	VMOD
2	withdrawal	withdrawal	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	octreotide	octreotide	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	10	10	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	PMOD
8	without	without	B-PP	IN	O	7	NMOD
9	gallstones	gallstone	B-NP	NNS	O	8	PMOD
10	,	,	O	,	O	14	P
11	8	8	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	14	SUB
13	assessed	assess	B-VP	VBN	O	12	NMOD
14	had	have	B-VP	VBD	O	0	ROOT
15	return	return	B-NP	NN	O	14	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	normal	normal	B-NP	JJ	O	19	NMOD
18	gallbladder	gallbladder	I-NP	NN	O	19	NMOD
19	contractility	contractility	I-NP	NN	O	16	PMOD
20	within	within	B-PP	IN	O	14	VMOD
21	1	1	B-NP	CD	O	22	NMOD
22	month	month	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	14	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	suppression	suppression	I-NP	NN	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	gallbladder	gallbladder	B-NP	NN	O	9	NMOD
9	contractility	contractility	I-NP	NN	O	7	PMOD
10	is	be	B-VP	VBZ	O	4	SBAR
11	the	the	B-NP	DT	O	12	NMOD
12	cause	cause	I-NP	NN	O	10	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	successive	successive	I-NP	JJ	O	16	NMOD
16	formation	formation	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	bile	bile	B-NP	NN	O	19	NMOD
19	sludge	sludge	I-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	gallstones	gallstone	B-NP	NNS	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	cholecystitis	cholecystitis	B-NP	NN	O	17	PMOD
25	during	during	B-PP	IN	O	10	VMOD
26	octreotide	octreotide	B-NP	NN	O	27	NMOD
27	therapy	therapy	I-NP	NN	O	25	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	Chinese	Chinese	B-NP	JJ	O	31	NMOD
30	acromegalic	acromegalic	I-NP	JJ	O	31	NMOD
31	patients	patient	I-NP	NNS	O	28	PMOD
32	.	.	O	.	O	3	P

1	Improvement	Improvement	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	levodopa	levodopa	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	dyskinesia	dyskinesia	B-NP	NN	O	4	OBJ
6	by	by	B-PP	IN	O	4	VMOD
7	propranolol	propranolol	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	Parkinson	Parkinson	B-NP	NNP	O	11	NMOD
10	's	's	B-NP	POS	O	11	NMOD
11	disease	disease	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	4	P

1	Seven	Seven	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	15	SUB
3	suffering	suffer	B-VP	VBG	O	2	NMOD
4	from	from	B-PP	IN	O	3	VMOD
5	Parkinson	Parkinson	B-NP	NNP	O	6	NMOD
6	's	's	B-NP	POS	O	7	NMOD
7	disease	disease	I-NP	NN	O	4	PMOD
8	(	(	O	(	O	10	DEP
9	PD	PD	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	with	with	B-PP	IN	O	7	NMOD
12	severely	severely	B-ADVP	RB	O	13	VMOD
13	disabling	disable	B-VP	VBG	O	11	PMOD
14	dyskinesia	dyskinesia	B-NP	NN	O	13	OBJ
15	received	receive	B-VP	VBD	O	0	ROOT
16	low-dose	low-dose	B-NP	JJ	O	17	NMOD
17	propranolol	propranolol	I-NP	NN	O	15	OBJ
18	as	as	B-PP	IN	O	15	VMOD
19	an	an	B-NP	DT	O	20	NMOD
20	adjunct	adjunct	I-NP	NN	O	18	PMOD
21	to	to	B-PP	TO	O	20	NMOD
22	the	the	B-NP	DT	O	26	NMOD
23	currently	currently	I-NP	RB	O	24	AMOD
24	used	use	I-NP	VBN	O	26	NMOD
25	medical	medical	I-NP	JJ	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	15	P

1	Morphological	Morphological	B-NP	JJ	O	2	NMOD
2	features	feature	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	encephalopathy	encephalopathy	B-NP	NN	O	3	PMOD
5	after	after	B-SBAR	IN	O	2	NMOD
6	chronic	chronic	B-NP	JJ	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	12	NMOD
10	antiepileptic	antiepileptic	I-NP	JJ	O	12	NMOD
11	drug	drug	I-NP	NN	O	12	NMOD
12	valproate	valproate	I-NP	NN	O	8	PMOD
13	to	to	B-PP	TO	O	7	NMOD
14	rats	rat	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	2	P

1	Long-term	Long-term	B-NP	JJ	O	3	NMOD
2	intragastric	intragastric	I-NP	JJ	O	3	NMOD
3	application	application	I-NP	NN	O	40	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	9	NMOD
6	antiepileptic	antiepileptic	I-NP	JJ	O	9	NMOD
7	drug	drug	I-NP	NN	O	9	NMOD
8	sodium	sodium	I-NP	NN	O	9	NMOD
9	valproate	valproate	I-NP	NN	O	4	PMOD
10	(	(	O	(	O	15	DEP
11	Vupral	Vupral	B-NP	JJ	O	13	NMOD
12	"	"	I-NP	"	O	13	NMOD
13	Polfa	Polfa	I-NP	NNP	O	15	DEP
14	"	"	O	"	O	13	NMOD
15	)	)	O	)	O	9	NMOD
16	at	at	B-PP	IN	O	3	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	effective	effective	I-NP	JJ	O	19	NMOD
19	dose	dose	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	200	200	B-NP	CD	O	22	AMOD
22	mg/kg	mg/kg	I-NP	NN	O	24	NMOD
23	b.	b.	I-NP	NN	O	24	NMOD
24	w.	w.	I-NP	NN	O	20	PMOD
25	once	once	B-ADVP	RB	O	40	VMOD
26	daily	daily	I-ADVP	RB	O	25	AMOD
27	to	to	B-PP	TO	O	25	AMOD
28	rats	rat	B-NP	NNS	O	27	PMOD
29	for	for	B-PP	IN	O	28	NMOD
30	1	1	B-NP	CD	O	39	NMOD
31	,	,	I-NP	,	O	39	P
32	3	3	I-NP	CD	O	39	NMOD
33	,	,	I-NP	,	O	39	P
34	6	6	I-NP	CD	O	39	NMOD
35	,	,	I-NP	,	O	39	P
36	9	9	I-NP	CD	O	38	NMOD
37	and	and	I-NP	CC	O	38	NMOD
38	12	12	I-NP	CD	O	39	NMOD
39	months	month	I-NP	NNS	O	29	PMOD
40	revealed	reveal	B-VP	VBD	O	0	ROOT
41	neurological	neurological	B-NP	JJ	O	42	NMOD
42	disorders	disorder	I-NP	NNS	O	40	OBJ
43	indicating	indicate	B-VP	VBG	O	42	NMOD
44	cerebellum	cerebellum	B-NP	NN	O	45	NMOD
45	damage	damage	I-NP	NN	O	43	OBJ
46	(	(	O	(	O	51	DEP
47	"	"	O	"	O	49	NMOD
48	valproate	valproate	B-NP	NN	O	49	NMOD
49	encephalopathy	encephalopathy	I-NP	NN	O	51	DEP
50	"	"	O	"	O	49	NMOD
51	)	)	O	)	O	45	NMOD
52	.	.	O	.	O	40	P

1	Macula	Macula	B-NP	NN	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	intravitreal	intravitreal	B-NP	JJ	O	5	NMOD
5	amikacin	amikacin	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Although	Although	B-SBAR	IN	O	1	VMOD
4	intravitreal	intravitreal	B-NP	JJ	O	5	NMOD
5	aminoglycosides	aminoglycoside	I-NP	NNS	O	6	SUB
6	have	have	B-VP	VBP	O	3	SBAR
7	substantially	substantially	I-VP	RB	O	8	VMOD
8	improved	improve	I-VP	VBN	O	6	VC
9	visual	visual	B-NP	JJ	O	10	NMOD
10	prognosis	prognosis	I-NP	NN	O	15	NMOD
11	in	in	B-PP	IN	O	10	NMOD
12	endophthalmitis	endophthalmitis	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	15	P
14	macular	macular	B-NP	JJ	O	15	NMOD
15	infarction	infarction	I-NP	NN	O	16	SUB
16	may	may	B-VP	MD	O	8	VMOD
17	impair	impair	I-VP	VB	O	16	VC
18	full	full	B-NP	JJ	O	19	AMOD
19	visual	visual	I-NP	JJ	O	20	NMOD
20	recovery	recovery	I-NP	NN	O	17	OBJ
21	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	present	present	B-VP	VBP	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	presumed	presume	B-NP	VBN	O	11	NMOD
9	amikacin	amikacin	I-NP	NN	O	11	NMOD
10	retinal	retinal	I-NP	NN	O	11	NMOD
11	toxicity	toxicity	I-NP	NN	O	7	PMOD
12	following	follow	B-PP	VBG	O	4	VMOD
13	treatment	treatment	B-NP	NN	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	amikacin	amikacin	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	vancomycin	vancomycin	I-NP	NN	O	14	PMOD
18	for	for	B-PP	IN	O	17	NMOD
19	alpha-haemolytic	alpha-haemolytic	B-NP	JJ	O	21	NMOD
20	streptococcal	streptococcal	I-NP	JJ	O	21	NMOD
21	endophthalmitis	endophthalmitis	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	1	P

1	Fundus	Fundus	B-NP	NN	O	3	NMOD
2	fluorescein	fluorescein	I-NP	NN	O	3	NMOD
3	angiography	angiography	I-NP	NN	O	4	SUB
4	confirmed	confirm	B-VP	VBD	O	0	ROOT
5	macular	macular	B-NP	JJ	O	7	NMOD
6	capillary	capillary	I-NP	JJ	O	7	NMOD
7	closure	closure	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	telangiectasis	telangiectasis	I-NP	NN	O	4	OBJ
10	.	.	O	.	O	4	P

1	Iatrogenically	Iatrogenically	B-NP	RB	O	2	AMOD
2	induced	induce	I-NP	VBN	O	0	ROOT
3	intractable	intractable	I-NP	JJ	O	6	NMOD
4	atrioventricular	atrioventricular	I-NP	JJ	O	6	NMOD
5	reentrant	reentrant	I-NP	JJ	O	6	NMOD
6	tachycardia	tachycardia	I-NP	NN	O	2	OBJ
7	after	after	B-PP	IN	O	2	VMOD
8	verapamil	verapamil	B-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	catheter	catheter	I-NP	NN	O	11	NMOD
11	ablation	ablation	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	patient	patient	I-NP	NN	O	21	NMOD
15	with	with	B-PP	IN	O	14	NMOD
16	Wolff-Parkinson-White	Wolff-Parkinson-White	B-NP	JJ	O	17	NMOD
17	syndrome	syndrome	I-NP	NN	O	15	PMOD
18	and	and	O	CC	O	21	NMOD
19	idiopathic	idiopathic	B-NP	JJ	O	21	NMOD
20	dilated	dilated	I-NP	JJ	O	21	NMOD
21	cardiomyopathy	cardiomyopathy	I-NP	NN	O	12	PMOD
22	.	.	O	.	O	2	P

1	Epidemic	Epidemic	B-NP	JJ	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	liver	liver	B-NP	NN	O	4	NMOD
4	disease	disease	I-NP	NN	O	2	PMOD
5	caused	cause	B-VP	VBN	O	1	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	hydrochlorofluorocarbons	hydrochlorofluorocarbon	B-NP	NNS	O	6	PMOD
8	used	use	B-VP	VBN	O	7	NMOD
9	as	as	B-PP	IN	O	8	VMOD
10	ozone-sparing	ozone-sparing	B-NP	JJ	O	11	NMOD
11	substitutes	substitute	I-NP	NNS	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	chlorofluorocarbons	chlorofluorocarbon	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	an	an	B-NP	DT	O	4	NMOD
4	epidemic	epidemic	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	liver	liver	B-NP	NN	O	7	NMOD
7	disease	disease	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	nine	nine	B-NP	CD	O	11	NMOD
10	industrial	industrial	I-NP	JJ	O	11	NMOD
11	workers	worker	I-NP	NNS	O	8	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	had	have	B-VP	VBD	O	12	SBAR
14	had	have	I-VP	VBN	O	13	VC
15	repeated	repeat	I-VP	VBN	O	14	VMOD
16	accidental	accidental	B-NP	JJ	O	17	NMOD
17	exposure	exposure	I-NP	NN	O	15	OBJ
18	to	to	B-PP	TO	O	17	NMOD
19	a	a	B-NP	DT	O	20	NMOD
20	mixture	mixture	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	1	1	B-NP	CD	O	21	PMOD
23	,	,	I-NP	,	O	28	P
24	1-dichloro-2	1-dichloro-2	I-NP	CD	O	28	NMOD
25	,	,	I-NP	,	O	28	P
26	2	2	I-NP	CD	O	28	NMOD
27	,	,	O	,	O	28	P
28	2-trifluoroethane	2-trifluoroethane	B-NP	NN	O	22	NMOD
29	(	(	O	(	O	32	DEP
30	HCFC	HCFC	B-NP	NN	B-protein	32	DEP
31	123	123	I-NP	CD	I-protein	30	NMOD
32	)	)	O	)	O	28	NMOD
33	and	and	O	CC	O	28	NMOD
34	1-chloro-1	1-chloro-1	B-NP	CD	O	38	NMOD
35	,	,	I-NP	,	O	38	P
36	2	2	I-NP	CD	O	38	NMOD
37	,	,	I-NP	,	O	38	P
38	2	2	I-NP	CD	O	33	PMOD
39	,	,	O	,	O	40	P
40	2-tetrafluoroethane	2-tetrafluoroethane	B-NP	NN	O	38	NMOD
41	(	(	O	(	O	44	DEP
42	HCFC	HCFC	B-NP	NN	B-DNA	44	DEP
43	124	124	I-NP	CD	I-DNA	42	NMOD
44	)	)	O	)	O	40	NMOD
45	.	.	O	.	O	2	P

1	Both	Both	B-NP	DT	O	2	NMOD
2	compounds	compound	I-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	0	ROOT
4	metabolised	metabolise	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	same	same	I-NP	JJ	O	8	NMOD
8	way	way	I-NP	NN	O	5	PMOD
9	as	as	B-PP	IN	O	19	VMOD
10	1-bromo-1-chloro-2	1-bromo-1-chloro-2	B-NP	CD	O	19	VMOD
11	,	,	I-NP	,	O	19	P
12	2	2	I-NP	CD	O	19	VMOD
13	,	,	O	,	O	19	P
14	2-trifluoroethane	2-trifluoroethane	B-NP	NN	O	19	SUB
15	(	(	O	(	O	17	DEP
16	halothane	halothane	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	to	to	B-VP	TO	O	19	VMOD
19	form	form	I-VP	VB	O	4	VMOD
20	reactive	reactive	B-NP	JJ	O	23	NMOD
21	trifluoroacetyl	trifluoroacetyl	I-NP	NN	O	23	NMOD
22	halide	halide	I-NP	NN	O	23	NMOD
23	intermediates	intermediate	I-NP	NNS	O	19	OBJ
24	,	,	O	,	O	23	P
25	which	which	B-NP	WDT	O	23	NMOD
26	have	have	B-VP	VBP	O	25	SBAR
27	been	be	I-VP	VBN	O	26	VC
28	implicated	implicate	I-VP	VBN	O	27	VC
29	in	in	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	hepatotoxicity	hepatotoxicity	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	halothane	halothane	B-NP	NN	O	32	PMOD
34	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	aimed	aim	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	test	test	I-VP	VB	O	2	VMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	HCFCs	HCFC	B-NP	NNS	O	9	NMOD
7	123	123	B-NP	CD	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	124	124	I-NP	CD	O	10	SUB
10	can	can	B-VP	MD	O	5	SBAR
11	result	result	I-VP	VB	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	serious	serious	B-NP	JJ	O	15	NMOD
14	liver	liver	I-NP	NN	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	INTERPRETATION	INTERPRETATION	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Repeated	Repeat	B-NP	VBN	O	4	NMOD
4	exposure	exposure	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	human	human	B-NP	JJ	O	7	NMOD
7	beings	being	I-NP	NNS	O	5	PMOD
8	to	to	B-PP	TO	O	4	NMOD
9	HCFCs	HCFC	B-NP	NNS	O	8	PMOD
10	123	123	B-NP	CD	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	124	124	I-NP	CD	O	9	NMOD
13	can	can	B-VP	MD	O	0	ROOT
14	result	result	I-VP	VB	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	serious	serious	B-NP	JJ	O	18	NMOD
17	liver	liver	I-NP	NN	O	18	NMOD
18	injury	injury	I-NP	NN	O	15	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	a	a	B-NP	DT	O	22	NMOD
21	large	large	I-NP	JJ	O	22	NMOD
22	proportion	proportion	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	exposed	expose	I-NP	VBN	O	26	NMOD
26	population	population	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	13	P

1	Patients	Patient	B-NP	NNS	O	3	NMOD
2	given	give	B-PP	VBN	O	3	NMOD
3	prilocaine	prilocaine	B-NP	NN	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	more	more	B-ADJP	RBR	O	6	AMOD
6	likely	likely	I-ADJP	JJ	O	4	PRD
7	to	to	B-VP	TO	O	8	VMOD
8	develop	develop	I-VP	VB	O	6	AMOD
9	hearing	hearing	B-NP	NN	O	10	NMOD
10	loss	loss	I-NP	NN	O	8	OBJ
11	(	(	O	(	O	16	DEP
12	10	10	B-NP	CD	O	14	AMOD
13	out	out	B-PP	IN	O	14	AMOD
14	of	of	B-PP	IN	O	16	DEP
15	22	22	B-NP	CD	O	14	AMOD
16	)	)	O	)	O	10	NMOD
17	than	than	B-PP	IN	O	10	NMOD
18	those	those	B-NP	DT	O	20	NMOD
19	given	give	I-NP	VBN	O	20	NMOD
20	bupivacaine	bupivacaine	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	26	DEP
22	4	4	B-NP	CD	O	24	AMOD
23	out	out	B-PP	IN	O	24	AMOD
24	of	of	B-PP	IN	O	26	DEP
25	22	22	B-NP	CD	O	24	AMOD
26	)	)	O	)	O	20	NMOD
27	(	(	O	(	O	31	DEP
28	P	P	B-NP	NN	O	31	DEP
29	<	<	O	SYM	O	28	NMOD
30	0.05	0.05	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	4	VMOD
32	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	4	NMOD
2	average	average	I-NP	JJ	O	4	NMOD
3	hearing	hearing	I-NP	NN	O	4	NMOD
4	loss	loss	I-NP	NN	O	8	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	speech	speech	B-NP	NN	O	7	NMOD
7	frequencies	frequency	I-NP	NNS	O	5	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	about	about	B-NP	IN	O	11	NMOD
10	10	10	I-NP	CD	O	9	AMOD
11	dB	dB	I-NP	NN	O	8	PRD
12	after	after	B-PP	IN	O	8	VMOD
13	prilocaine	prilocaine	B-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	15	15	B-NP	CD	O	16	NMOD
16	dB	dB	I-NP	NN	O	12	PMOD
17	after	after	B-PP	IN	O	16	NMOD
18	bupivacaine	bupivacaine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	4	NMOD
2	transient	transient	I-NP	JJ	O	3	AMOD
3	neurological	neurological	I-NP	JJ	O	4	NMOD
4	deficit	deficit	I-NP	NN	O	0	ROOT
5	following	follow	B-PP	VBG	O	4	NMOD
6	intrathecal	intrathecal	B-NP	JJ	O	7	NMOD
7	injection	injection	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	1	1	B-NP	CD	O	10	AMOD
10	%	%	I-NP	NN	O	12	NMOD
11	hyperbaric	hyperbaric	I-NP	JJ	O	12	NMOD
12	bupivacaine	bupivacaine	I-NP	NN	O	8	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	unilateral	unilateral	B-NP	JJ	O	16	NMOD
15	spinal	spinal	I-NP	JJ	O	16	NMOD
16	anaesthesia	anaesthesia	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	transient	transient	B-NP	JJ	O	7	AMOD
7	neurological	neurological	I-NP	JJ	O	8	NMOD
8	deficit	deficit	I-NP	NN	O	5	PMOD
9	that	that	B-NP	WDT	O	4	NMOD
10	occurred	occur	B-VP	VBD	O	9	SBAR
11	after	after	B-PP	IN	O	10	VMOD
12	unilateral	unilateral	B-NP	JJ	O	14	NMOD
13	spinal	spinal	I-NP	JJ	O	14	NMOD
14	anaesthesia	anaesthesia	I-NP	NN	O	11	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	8	8	B-NP	CD	O	17	NMOD
17	mg	mg	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	1	1	B-NP	CD	O	22	NMOD
20	%	%	I-NP	NN	O	22	NMOD
21	hyperbaric	hyperbaric	I-NP	JJ	O	22	NMOD
22	bupivacaine	bupivacaine	I-NP	NN	O	18	PMOD
23	slowly	slowly	B-VP	RB	O	24	VMOD
24	injected	inject	I-VP	VBN	O	22	NMOD
25	through	through	B-PP	IN	O	24	VMOD
26	a	a	B-NP	DT	O	30	NMOD
27	25-gauge	25-gauge	I-NP	JJ	O	30	NMOD
28	pencil-point	pencil-point	I-NP	JJ	O	30	NMOD
29	spinal	spinal	I-NP	JJ	O	30	NMOD
30	needle	needle	I-NP	NN	O	25	PMOD
31	.	.	O	.	O	2	P

1	Pethidine-associated	Pethidine-associated	B-NP	JJ	O	2	NMOD
2	seizure	seizure	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	8	NMOD
5	healthy	healthy	I-NP	JJ	O	8	NMOD
6	adolescent	adolescent	I-NP	JJ	O	8	NMOD
7	receiving	receive	I-NP	VBG	O	8	NMOD
8	pethidine	pethidine	I-NP	NN	O	3	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	postoperative	postoperative	B-NP	JJ	O	12	NMOD
11	pain	pain	I-NP	NN	O	12	NMOD
12	control	control	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	8	NMOD
2	healthy	healthy	I-NP	JJ	O	4	AMOD
3	17-year-old	17-year-old	I-NP	JJ	O	4	AMOD
4	male	male	I-NP	JJ	O	8	NMOD
5	received	receive	I-NP	VBN	O	7	AMOD
6	standard	standard	I-NP	JJ	O	7	AMOD
7	intermittent	intermittent	I-NP	JJ	O	8	NMOD
8	doses	dose	I-NP	NNS	O	0	ROOT
9	of	of	B-PP	IN	O	8	NMOD
10	pethidine	pethidine	B-NP	NN	O	9	PMOD
11	via	via	B-PP	IN	O	8	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	patient-controlled	patient-controlled	I-NP	JJ	O	14	NMOD
14	analgesia	analgesia	I-NP	NN	O	18	NMOD
15	(	(	O	(	O	17	DEP
16	PCA	PCA	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	pump	pump	B-NP	NN	O	11	PMOD
19	for	for	B-PP	IN	O	18	NMOD
20	management	management	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	postoperative	postoperative	B-NP	JJ	O	24	NMOD
23	pain	pain	I-NP	NN	O	24	NMOD
24	control	control	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	4	NMOD
2	previously	previously	I-NP	RB	O	3	AMOD
3	healthy	healthy	I-NP	JJ	O	4	NMOD
4	child	child	I-NP	NN	O	21	SUB
5	who	who	B-NP	WP	O	4	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	acute	acute	B-NP	JJ	O	16	NMOD
8	,	,	I-NP	,	O	16	P
9	severe	severe	I-NP	JJ	O	16	NMOD
10	,	,	I-NP	,	O	16	P
11	rapidly	rapidly	I-NP	RB	O	16	NMOD
12	progressive	progressive	I-NP	JJ	O	16	NMOD
13	vanishing	vanish	I-NP	VBG	O	16	NMOD
14	bile	bile	I-NP	NN	O	16	NMOD
15	duct	duct	I-NP	NN	O	16	NMOD
16	syndrome	syndrome	I-NP	NN	O	6	OBJ
17	shortly	shortly	B-ADVP	RB	O	6	VMOD
18	after	after	B-PP	IN	O	6	VMOD
19	Stevens-Johnson	Stevens-Johnson	B-NP	JJ	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	18	PMOD
21	is	be	B-VP	VBZ	O	25	VMOD
22	described	describe	I-VP	VBN	O	21	VC
23	;	;	O	:	O	25	P
24	this	this	B-NP	DT	O	25	SUB
25	was	be	B-VP	VBD	O	0	ROOT
26	temporally	temporally	I-VP	RB	O	25	VMOD
27	associated	associate	I-VP	VBN	O	25	VC
28	with	with	B-PP	IN	O	27	VMOD
29	ibuprofen	ibuprofen	B-NP	NN	O	30	NMOD
30	use	use	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	25	P

1	Despite	Despite	B-PP	IN	O	0	ROOT
2	therapy	therapy	B-NP	NN	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	ursodeoxycholic	ursodeoxycholic	B-NP	JJ	O	5	NMOD
5	acid	acid	I-NP	NN	O	16	SUB
6	,	,	O	,	O	16	P
7	prednisone	prednisone	B-NP	NN	O	16	SUB
8	,	,	O	,	O	16	P
9	and	and	O	CC	O	16	VMOD
10	then	then	B-ADVP	RB	O	16	VMOD
11	tacrolimus	tacrolimus	B-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	her	her	B-NP	PRP$	O	15	NMOD
14	cholestatic	cholestatic	I-NP	JJ	O	15	NMOD
15	disease	disease	I-NP	NN	O	16	SUB
16	was	be	B-VP	VBD	O	3	SBAR
17	unrelenting	unrelente	I-VP	VBG	O	16	PRD
18	,	,	O	,	O	1	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	cirrhosis	cirrhosis	B-NP	NN	O	19	PMOD
21	shown	show	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	biopsy	biopsy	B-NP	NN	O	25	NMOD
24	6	6	B-NP	CD	O	25	NMOD
25	months	month	I-NP	NNS	O	22	PMOD
26	after	after	B-PP	IN	O	25	NMOD
27	presentation	presentation	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	1	P

1	High	High	B-NP	JJ	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	primary	primary	B-NP	JJ	O	6	NMOD
5	pulmonary	pulmonary	I-NP	JJ	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	3	PMOD
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	appetite	appetite	B-NP	JJ	O	10	NMOD
10	suppressants	suppressant	I-NP	NNS	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	Belgium	Belgium	B-NP	NNP	O	11	PMOD
13	.	.	O	.	O	2	P

1	Primary	Primary	B-NP	JJ	O	3	NMOD
2	pulmonary	pulmonary	I-NP	JJ	O	3	NMOD
3	hypertension	hypertension	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	a	a	B-NP	DT	O	11	NMOD
6	rare	rare	I-NP	JJ	O	11	NMOD
7	,	,	I-NP	,	O	11	P
8	progressive	progressive	I-NP	JJ	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	incurable	incurable	I-NP	JJ	O	11	NMOD
11	disease	disease	I-NP	NN	O	4	PRD
12	,	,	O	,	O	11	P
13	which	which	B-NP	WDT	O	11	NMOD
14	has	have	B-VP	VBZ	O	13	SBAR
15	been	be	I-VP	VBN	O	14	VC
16	associated	associate	I-VP	VBN	O	15	VC
17	with	with	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	intake	intake	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	appetite	appetite	B-NP	JJ	O	23	NMOD
22	suppressant	suppressant	I-NP	NN	O	23	NMOD
23	drugs	drug	I-NP	NNS	O	20	PMOD
24	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	10	VMOD
2	8	8	B-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	the	the	B-NP	DT	O	5	NMOD
5	diagnosis	diagnosis	I-NP	NN	O	10	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	primary	primary	B-NP	JJ	O	9	NMOD
8	pulmonary	pulmonary	I-NP	JJ	O	9	NMOD
9	hypertension	hypertension	I-NP	NN	O	6	PMOD
10	was	be	B-VP	VBD	O	16	VMOD
11	uncertain	uncertain	B-ADJP	JJ	O	10	PRD
12	,	,	O	,	O	10	P
13	5	5	B-NP	CD	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	them	them	B-NP	PRP	O	14	PMOD
16	had	have	B-VP	VBD	O	0	ROOT
17	taken	take	I-VP	VBN	O	16	VC
18	appetite	appetite	B-NP	JJ	O	19	NMOD
19	suppressants	suppressant	I-NP	NNS	O	17	OBJ
20	.	.	O	.	O	16	P

1	A	A	B-NP	DT	O	2	NMOD
2	policy	policy	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	unrestricted	unrestricted	B-NP	JJ	O	5	NMOD
5	prescription	prescription	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	appetite	appetite	B-NP	JJ	O	8	NMOD
8	suppressants	suppressant	I-NP	NNS	O	6	PMOD
9	may	may	B-VP	MD	O	0	ROOT
10	lead	lead	I-VP	VB	O	9	VC
11	to	to	B-PP	TO	O	10	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	high	high	I-NP	JJ	O	14	NMOD
14	incidence	incidence	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	associated	associate	B-NP	VBN	O	19	NMOD
17	primary	primary	I-NP	JJ	O	19	NMOD
18	pulmonary	pulmonary	I-NP	JJ	O	19	NMOD
19	hypertension	hypertension	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	9	P

1	Choreoathetoid	Choreoathetoid	B-NP	JJ	O	2	NMOD
2	movements	movement	I-NP	NNS	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	rapid	rapid	B-NP	JJ	O	6	NMOD
6	adjustment	adjustment	I-NP	NN	O	4	PMOD
7	to	to	B-PP	TO	O	6	NMOD
8	methadone	methadone	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	Choreatiform	Choreatiform	B-NP	NN	O	2	NMOD
2	hyperkinesias	hyperkinesia	I-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	0	ROOT
4	known	know	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	be	be	I-VP	VB	O	4	VMOD
7	occasional	occasional	B-NP	JJ	O	9	NMOD
8	movement	movement	I-NP	NN	O	9	NMOD
9	abnormalities	abnormality	I-NP	NNS	O	6	PRD
10	during	during	B-PP	IN	O	9	NMOD
11	intoxications	intoxication	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	cocaine	cocaine	B-NP	NN	O	16	NMOD
14	but	but	B-NP	CC	O	16	NMOD
15	not	not	I-NP	RB	O	14	DEP
16	opiates	opiate	B-NP	NNS	O	12	PMOD
17	.	.	O	.	O	3	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	mood	mood	B-NP	NN	O	4	NMOD
4	disorder	disorder	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	P
6	prevalence	prevalence	B-NP	NN	O	7	NMOD
7	rates	rate	I-NP	NNS	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	psychiatric	psychiatric	B-NP	JJ	O	10	NMOD
10	symptoms	symptom	I-NP	NNS	O	2	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	an	an	B-NP	DT	O	15	NMOD
13	outpatient	outpatient	I-NP	NN	O	15	NMOD
14	cocaine-dependent	cocaine-dependent	I-NP	JJ	O	15	NMOD
15	sample	sample	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	paper	paper	I-NP	NN	O	3	SUB
3	attempts	attempt	B-VP	VBZ	O	0	ROOT
4	to	to	I-VP	TO	O	5	VMOD
5	examine	examine	I-VP	VB	O	3	VMOD
6	and	and	I-VP	CC	O	5	VMOD
7	compare	compare	I-VP	VB	O	5	VMOD
8	prevalence	prevalence	B-NP	NN	O	9	NMOD
9	rates	rate	I-NP	NNS	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	symptom	symptom	B-NP	NN	O	12	NMOD
12	patterns	pattern	I-NP	NNS	O	26	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	DSM	DSM	B-NP	NN	O	15	NMOD
15	substance	substance	I-NP	NN	O	20	NMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	and	and	O	CC	O	20	NMOD
18	other	other	B-NP	JJ	O	20	NMOD
19	mood	mood	I-NP	NN	O	20	NMOD
20	disorders.	disorders.	I-NP	NN	O	23	NMOD
21	243	243	I-NP	CD	O	23	NMOD
22	cocaine-dependent	cocaine-dependent	I-NP	JJ	O	23	NMOD
23	outpatients	outpatient	I-NP	NNS	O	13	PMOD
24	with	with	B-PP	IN	O	12	NMOD
25	cocaine	cocaine	B-NP	NN	O	24	PMOD
26	induced	induce	B-VP	VBD	O	5	VMOD
27	mood	mood	B-NP	NN	O	28	NMOD
28	disorder	disorder	I-NP	NN	O	40	NMOD
29	(	(	O	(	O	31	DEP
30	CIMD	CIMD	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	,	,	O	,	O	40	P
33	other	other	B-NP	JJ	O	35	NMOD
34	mood	mood	I-NP	NN	O	35	NMOD
35	disorders	disorder	I-NP	NNS	O	40	NMOD
36	,	,	O	,	O	40	P
37	or	or	O	CC	O	40	NMOD
38	no	no	B-NP	DT	O	40	NMOD
39	mood	mood	I-NP	NN	O	40	NMOD
40	disorder	disorder	I-NP	NN	O	26	OBJ
41	were	be	B-VP	VBD	O	26	VMOD
42	compared	compare	I-VP	VBN	O	41	VC
43	on	on	B-PP	IN	O	42	VMOD
44	measures	measure	B-NP	NNS	O	43	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	psychiatric	psychiatric	B-NP	JJ	O	47	NMOD
47	symptoms	symptom	I-NP	NNS	O	45	PMOD
48	.	.	O	.	O	3	P

1	Hemolysis	Hemolysis	B-NP	NN	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	human	human	B-NP	JJ	B-cell_type	4	NMOD
4	erythrocytes	erythrocyte	I-NP	NNS	I-cell_type	2	PMOD
5	induced	induce	B-VP	VBN	O	1	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	tamoxifen	tamoxifen	B-NP	NN	O	6	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	related	relate	I-VP	VBN	O	8	PRD
10	to	to	B-PP	TO	O	9	AMOD
11	disruption	disruption	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	membrane	membrane	B-NP	NN	O	14	NMOD
14	structure	structure	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	8	P

1	Tamoxifen	Tamoxifen	B-NP	NN	O	8	NMOD
2	(	(	O	(	O	4	DEP
3	TAM	TAM	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	,	,	O	,	O	8	P
6	the	the	B-NP	DT	O	8	NMOD
7	antiestrogenic	antiestrogenic	I-NP	JJ	O	8	NMOD
8	drug	drug	I-NP	NN	O	19	SUB
9	most	most	B-VP	RBS	O	10	AMOD
10	widely	widely	I-VP	RB	O	11	VMOD
11	prescribed	prescribe	I-VP	VBN	O	8	NMOD
12	in	in	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	chemotherapy	chemotherapy	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	breast	breast	B-NP	NN	O	17	NMOD
17	cancer	cancer	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	8	P
19	induces	induce	B-VP	VBZ	O	0	ROOT
20	changes	change	B-NP	NNS	O	19	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	normal	normal	B-NP	JJ	O	24	NMOD
23	discoid	discoid	I-NP	JJ	O	24	NMOD
24	shape	shape	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	erythrocytes	erythrocyte	B-NP	NNS	B-cell_type	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	hemolytic	hemolytic	B-NP	JJ	O	29	NMOD
29	anemia	anemia	I-NP	NN	O	25	PMOD
30	.	.	O	.	O	19	P

1	This	This	B-NP	DT	O	2	NMOD
2	work	work	I-NP	NN	O	3	SUB
3	evaluates	evaluate	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	TAM	TAM	B-NP	NN	O	6	PMOD
8	on	on	B-PP	IN	O	5	NMOD
9	isolated	isolate	B-NP	VBN	O	11	NMOD
10	human	human	I-NP	JJ	B-cell_type	11	NMOD
11	erythrocytes	erythrocyte	I-NP	NNS	I-cell_type	8	PMOD
12	,	,	O	,	O	3	P
13	attempting	attempt	B-VP	VBG	O	3	VMOD
14	to	to	I-VP	TO	O	15	VMOD
15	identify	identify	I-VP	VB	O	13	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	underlying	underlie	I-NP	VBG	O	18	NMOD
18	mechanisms	mechanism	I-NP	NNS	O	15	OBJ
19	on	on	B-PP	IN	O	18	NMOD
20	TAM	TAM	B-NP	NN	B-protein	19	PMOD
21	induced	induce	B-VP	VBD	O	13	VMOD
22	hemolytic	hemolytic	B-NP	JJ	O	23	NMOD
23	anemia	anemia	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	involvement	involvement	I-NP	NN	O	21	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	biomembranes	biomembrane	B-NP	NNS	O	27	PMOD
29	in	in	B-PP	IN	O	26	NMOD
30	its	its	B-NP	PRP$	O	33	NMOD
31	cytostatic	cytostatic	I-NP	JJ	O	33	NMOD
32	action	action	I-NP	NN	O	33	NMOD
33	mechanisms	mechanism	I-NP	NNS	O	29	PMOD
34	.	.	O	.	O	3	P

1	TAM	TAM	B-NP	NN	O	2	SUB
2	induces	induce	B-VP	VBZ	O	0	ROOT
3	hemolysis	hemolysis	B-NP	NN	O	2	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	erythrocytes	erythrocyte	B-NP	NNS	B-cell_type	4	PMOD
6	as	as	B-PP	IN	O	2	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	function	function	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	concentration	concentration	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	extension	extension	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	hemolysis	hemolysis	B-NP	NN	O	3	PMOD
5	is	be	B-VP	VBZ	O	15	VMOD
6	variable	variable	B-ADJP	JJ	O	5	PRD
7	with	with	B-PP	IN	O	6	AMOD
8	erythrocyte	erythrocyte	B-NP	NN	B-protein	9	NMOD
9	samples	sample	I-NP	NNS	I-protein	7	PMOD
10	,	,	O	,	O	15	P
11	but	but	O	CC	O	15	VMOD
12	12.5	12.5	B-NP	CD	O	14	NMOD
13	microM	microM	I-NP	NN	O	12	AMOD
14	TAM	TAM	I-NP	NN	O	15	SUB
15	induces	induce	B-VP	VBZ	O	0	ROOT
16	total	total	B-NP	JJ	O	17	NMOD
17	hemolysis	hemolysis	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	all	all	B-NP	DT	O	21	NMOD
20	tested	test	I-NP	VBN	O	21	NMOD
21	suspensions	suspension	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	3	NMOD
2	hemolytic	hemolytic	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	TAM	TAM	B-NP	NN	O	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	prevented	prevent	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	low	low	B-NP	JJ	O	10	NMOD
10	concentrations	concentration	I-NP	NNS	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	alpha-tocopherol	alpha-tocopherol	B-NP	NN	O	18	NMOD
13	(	(	O	(	O	15	DEP
14	alpha-T	alpha-T	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	18	NMOD
17	alpha-tocopherol	alpha-tocopherol	B-NP	NN	O	18	NMOD
18	acetate	acetate	I-NP	NN	O	11	PMOD
19	(	(	O	(	O	21	DEP
20	alpha-TAc	alpha-TAc	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	(	(	O	(	O	26	DEP
23	inactivated	inactivate	B-VP	VBN	O	25	NMOD
24	functional	functional	B-NP	JJ	O	25	NMOD
25	hydroxyl	hydroxyl	I-NP	NN	O	26	DEP
26	)	)	O	)	O	10	NMOD
27	indicating	indicate	B-VP	VBG	O	6	VMOD
28	that	that	B-SBAR	IN	O	27	VMOD
29	TAM	TAM	B-NP	NN	O	31	NMOD
30	induced	induced	I-NP	JJ	O	31	NMOD
31	hemolysis	hemolysis	I-NP	NN	O	32	SUB
32	is	be	B-VP	VBZ	O	28	SBAR
33	not	not	O	RB	O	32	VMOD
34	related	related	B-ADJP	JJ	O	32	PRD
35	to	to	B-PP	TO	O	34	AMOD
36	oxidative	oxidative	B-NP	JJ	O	38	NMOD
37	membrane	membrane	I-NP	NN	O	38	NMOD
38	damage	damage	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	6	P

1	This	This	B-NP	DT	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	further	further	I-VP	RB	O	2	VMOD
4	evidenced	evidence	I-VP	VBN	O	2	VC
5	by	by	B-PP	IN	O	4	VMOD
6	absence	absence	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	oxygen	oxygen	B-NP	NN	O	9	NMOD
9	consumption	consumption	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	hemoglobin	hemoglobin	B-NP	NN	B-protein	12	NMOD
12	oxidation	oxidation	I-NP	NN	O	7	PMOD
13	both	both	O	CC	O	4	VMOD
14	determined	determine	B-VP	VBN	O	4	VMOD
15	in	in	B-PP	IN	O	14	VMOD
16	parallel	parallel	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	TAM	TAM	B-NP	NN	O	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	hemolysis	hemolysis	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	2	P

1	Hemolysis	Hemolysis	B-NP	NN	O	5	SUB
2	caused	cause	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	TAM	TAM	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	not	not	I-VP	RB	O	5	VMOD
7	preceded	precede	I-VP	VBN	O	5	VC
8	by	by	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	leakage	leakage	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	K	K	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	15	DEP
14	+	+	B-NP	SYM	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	from	from	B-PP	IN	O	12	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	cells	cell	I-NP	NNS	O	16	PMOD
19	,	,	O	,	O	5	P
20	also	also	B-ADVP	RB	O	21	VMOD
21	excluding	exclude	B-VP	VBG	O	5	VMOD
22	a	a	B-NP	DT	O	25	NMOD
23	colloid-osmotic	colloid-osmotic	I-NP	JJ	O	25	NMOD
24	type	type	I-NP	NN	O	25	NMOD
25	mechanism	mechanism	I-NP	NN	O	21	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	hemolysis	hemolysis	B-NP	NN	O	26	PMOD
28	,	,	O	,	O	21	P
29	according	accord	B-PP	VBG	O	21	VMOD
30	to	to	B-PP	TO	O	29	PMOD
31	the	the	B-NP	DT	O	32	NMOD
32	effects	effect	I-NP	NNS	O	30	PMOD
33	on	on	B-PP	IN	O	32	NMOD
34	osmotic	osmotic	B-NP	JJ	O	36	NMOD
35	fragility	fragility	I-NP	NN	O	36	NMOD
36	curves	curve	I-NP	NNS	O	33	PMOD
37	.	.	O	.	O	5	P

1	These	These	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	protection	protection	I-NP	NN	O	11	SUB
7	from	from	B-PP	IN	O	6	NMOD
8	hemolysis	hemolysis	B-NP	NN	O	7	PMOD
9	by	by	B-PP	IN	O	6	NMOD
10	tocopherols	tocopherol	B-NP	NNS	O	9	PMOD
11	is	be	B-VP	VBZ	O	4	SBAR
12	related	related	B-ADJP	JJ	O	11	PRD
13	to	to	B-PP	TO	O	12	AMOD
14	a	a	B-NP	DT	O	17	NMOD
15	decreased	decrease	I-NP	VBN	O	17	NMOD
16	TAM	TAM	I-NP	NN	O	17	NMOD
17	incorporation	incorporation	I-NP	NN	O	24	NMOD
18	in	in	B-PP	IN	O	17	NMOD
19	condensed	condense	B-NP	VBN	O	20	NMOD
20	membranes	membrane	I-NP	NNS	O	18	PMOD
21	and	and	O	CC	O	24	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	structural	structural	I-NP	JJ	O	24	NMOD
24	damage	damage	I-NP	NN	O	13	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	erythrocyte	erythrocyte	I-NP	NN	O	28	NMOD
28	membrane	membrane	I-NP	NN	O	25	PMOD
29	is	be	B-VP	VBZ	O	11	VMOD
30	consequently	consequently	I-VP	RB	O	29	VMOD
31	avoided	avoid	I-VP	VBN	O	29	VC
32	.	.	O	.	O	3	P

1	Therefore	Therefore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	TAM	TAM	B-NP	NN	B-protein	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	hemolysis	hemolysis	B-NP	NN	O	6	NMOD
6	results	result	I-NP	NNS	O	4	OBJ
7	from	from	B-PP	IN	O	4	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	structural	structural	I-NP	JJ	O	10	NMOD
10	perturbation	perturbation	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	red	red	B-NP	JJ	B-cell_type	14	NMOD
13	cell	cell	I-NP	NN	I-cell_type	14	NMOD
14	membrane	membrane	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	4	P
16	leading	lead	B-VP	VBG	O	4	VMOD
17	to	to	B-PP	TO	O	16	VMOD
18	changes	change	B-NP	NNS	O	17	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	framework	framework	I-NP	NN	O	28	NMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	erythrocyte	erythrocyte	I-NP	NN	O	25	NMOD
25	membrane	membrane	I-NP	NN	O	22	PMOD
26	and	and	O	CC	O	28	NMOD
27	its	its	B-NP	PRP$	O	28	NMOD
28	cytoskeleton	cytoskeleton	I-NP	NN	O	19	PMOD
29	caused	cause	B-VP	VBN	O	28	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	its	its	B-NP	PRP$	O	33	NMOD
32	high	high	I-NP	JJ	O	33	NMOD
33	partition	partition	I-NP	NN	O	30	PMOD
34	in	in	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	membrane	membrane	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	4	P

1	These	These	B-NP	DT	O	2	NMOD
2	defects	defect	I-NP	NNS	O	3	SUB
3	explain	explain	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	7	NMOD
5	abnormal	abnormal	I-NP	JJ	O	7	NMOD
6	erythrocyte	erythrocyte	I-NP	NN	O	7	NMOD
7	shape	shape	I-NP	NN	O	3	OBJ
8	and	and	O	CC	O	3	VMOD
9	decreased	decrease	B-VP	VBD	O	3	VMOD
10	mechanical	mechanical	B-NP	JJ	O	11	NMOD
11	stability	stability	I-NP	NN	O	9	OBJ
12	promoted	promote	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	TAM	TAM	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	9	P
16	resulting	result	B-VP	VBG	O	9	VMOD
17	in	in	B-PP	IN	O	16	VMOD
18	hemolytic	hemolytic	B-NP	JJ	O	19	NMOD
19	anemia	anemia	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	3	P

1	Changes	Change	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	sodium	sodium	B-NP	NN	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	ATP	ATP	I-NP	NN	O	6	NMOD
6	affinities	affinity	I-NP	NNS	O	2	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	cardiac	cardiac	I-NP	JJ	O	7	PMOD
10	(	(	O	(	O	14	DEP
11	Na	Na	B-NP	NN	O	13	NMOD
12	,	,	O	,	O	13	P
13	K	K	B-NP	NN	O	14	DEP
14	)	)	O	)	O	9	NMOD
15	-ATPase	-ATPase	B-NP	NN	O	9	NMOD
16	during	during	B-PP	IN	O	1	NMOD
17	and	and	I-PP	CC	O	16	PMOD
18	after	after	I-PP	IN	O	16	PMOD
19	nitric	nitric	B-NP	JJ	O	22	NMOD
20	oxide	oxide	I-NP	NN	O	22	NMOD
21	deficient	deficient	I-NP	JJ	O	22	NMOD
22	hypertension	hypertension	I-NP	NN	O	16	PMOD
23	.	.	O	.	O	1	P

1	Inhibition	Inhibition	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	NO	NO	B-NP	NN	O	4	NMOD
4	synthesis	synthesis	I-NP	NN	O	2	PMOD
5	induces	induce	B-VP	VBZ	O	0	ROOT
6	sustained	sustained	B-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	5	OBJ
8	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	12	VMOD
2	several	several	B-NP	JJ	O	3	NMOD
3	models	model	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	hypertension	hypertension	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	12	P
7	elevation	elevation	B-NP	NN	O	12	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	intracellular	intracellular	B-NP	JJ	O	11	NMOD
10	sodium	sodium	I-NP	NN	O	11	NMOD
11	level	level	I-NP	NN	O	8	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	documented	document	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	cardiac	cardiac	B-NP	JJ	O	16	NMOD
16	tissue	tissue	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	12	P

1	To	To	B-VP	TO	O	2	VMOD
2	assess	assess	I-VP	VB	O	15	VMOD
3	the	the	B-NP	DT	O	5	NMOD
4	molecular	molecular	I-NP	JJ	O	5	NMOD
5	basis	basis	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	disturbances	disturbance	B-NP	NNS	O	6	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	transmembraneous	transmembraneous	B-NP	JJ	O	10	NMOD
10	transport	transport	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	Na+	Na+	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	15	P
14	we	we	B-NP	PRP	O	15	SUB
15	studied	study	B-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	17	NMOD
17	response	response	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	cardiac	cardiac	B-NP	JJ	O	25	NMOD
20	(	(	O	(	O	24	DEP
21	Na	Na	B-NP	NN	O	23	NMOD
22	,	,	O	,	O	23	P
23	K	K	B-NP	NN	O	24	DEP
24	)	)	O	)	O	19	NMOD
25	-ATPase	-ATPase	B-NP	NN	O	18	PMOD
26	to	to	B-PP	TO	O	25	NMOD
27	NO-deficient	NO-deficient	B-NP	JJ	O	28	NMOD
28	hypertension	hypertension	I-NP	NN	O	26	PMOD
29	induced	induce	B-VP	VBN	O	28	NMOD
30	in	in	B-PP	IN	O	29	VMOD
31	rats	rat	B-NP	NNS	O	30	PMOD
32	by	by	B-PP	IN	O	29	VMOD
33	NO-synthase	NO-synthase	B-NP	NN	B-protein	34	NMOD
34	inhibition	inhibition	I-NP	NN	O	32	PMOD
35	with	with	B-PP	IN	O	34	NMOD
36	40	40	B-NP	CD	O	37	AMOD
37	mg/kg/day	mg/kg/day	I-NP	NN	O	44	NMOD
38	N	N	I-NP	NN	O	44	NMOD
39	(	(	O	(	O	41	DEP
40	G	G	B-NP	NN	O	41	DEP
41	)	)	O	)	O	44	NMOD
42	-nitro-L-arginine	-nitro-L-arginine	B-NP	NN	O	44	NMOD
43	methyl	methyl	I-NP	NN	O	44	NMOD
44	ester	ester	I-NP	NN	O	35	PMOD
45	(	(	O	(	O	47	DEP
46	L-NAME	L-NAME	B-NP	NN	O	47	DEP
47	)	)	O	)	O	44	NMOD
48	for	for	B-PP	IN	O	34	NMOD
49	4	4	B-NP	CD	O	51	NMOD
50	four	four	I-NP	CD	O	51	NMOD
51	weeks	week	I-NP	NNS	O	48	PMOD
52	.	.	O	.	O	15	P

1	After	After	B-PP	IN	O	15	VMOD
2	recovery	recovery	B-NP	NN	O	1	PMOD
3	from	from	B-PP	IN	O	2	NMOD
4	hypertension	hypertension	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	15	P
6	the	the	B-NP	DT	O	7	NMOD
7	activity	activity	I-NP	NN	O	15	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	(	(	O	(	O	13	DEP
10	Na	Na	B-NP	NN	O	12	NMOD
11	,	,	O	,	O	12	P
12	K	K	B-NP	NN	O	13	DEP
13	)	)	O	)	O	14	NMOD
14	-ATPase	-ATPase	B-NP	NN	O	8	PMOD
15	increased	increase	B-VP	VBD	O	0	ROOT
16	,	,	O	,	O	15	P
17	due	due	B-ADJP	JJ	O	18	PMOD
18	to	to	B-PP	TO	O	15	VMOD
19	higher	high	B-NP	JJR	O	20	NMOD
20	affinity	affinity	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	ATP-binding	ATP-binding	I-NP	JJ	B-DNA	24	NMOD
24	site	site	I-NP	NN	I-DNA	21	PMOD
25	,	,	O	,	O	15	P
26	as	as	B-SBAR	IN	O	15	VMOD
27	revealed	reveal	B-VP	VBN	O	26	SBAR
28	from	from	B-PP	IN	O	27	VMOD
29	the	the	B-NP	DT	O	32	NMOD
30	lowered	lowered	I-NP	JJ	O	32	NMOD
31	Km	Km	I-NP	NN	O	32	NMOD
32	value	value	I-NP	NN	O	28	PMOD
33	for	for	B-PP	IN	O	32	NMOD
34	ATP	ATP	B-NP	NN	O	33	PMOD
35	.	.	O	.	O	15	P

1	Inhibition	Inhibition	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	NO-synthase	NO-synthase	B-NP	NN	B-protein	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	reversible	reversible	I-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	4	OBJ
8	accompanied	accompany	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	depressed	depressed	B-NP	JJ	O	11	NMOD
11	Na+-extrusion	Na+-extrusion	I-NP	NN	O	9	PMOD
12	from	from	B-PP	IN	O	11	NMOD
13	cardiac	cardiac	B-NP	JJ	B-cell_type	14	NMOD
14	cells	cell	I-NP	NNS	I-cell_type	12	PMOD
15	as	as	B-PP	IN	O	11	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	consequence	consequence	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	deteriorated	deteriorated	B-NP	JJ	O	21	NMOD
20	Na+-binding	Na+-binding	I-NP	JJ	O	21	NMOD
21	properties	property	I-NP	NNS	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	29	NMOD
24	(	(	O	(	O	28	DEP
25	Na	Na	B-NP	NN	O	27	NMOD
26	,	,	O	,	O	27	P
27	K	K	B-NP	NN	O	28	DEP
28	)	)	O	)	O	29	NMOD
29	-ATPase	-ATPase	B-NP	NN	O	22	PMOD
30	.	.	O	.	O	4	P

1	Effects	Effect	B-NP	NNS	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	long-term	long-term	B-NP	JJ	O	4	NMOD
4	pretreatment	pretreatment	I-NP	NN	O	2	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	isoproterenol	isoproterenol	B-NP	NN	O	5	PMOD
7	on	on	B-PP	IN	O	1	NMOD
8	bromocriptine	bromocriptine	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	tachycardia	tachycardia	B-NP	NN	O	9	OBJ
11	in	in	B-PP	IN	O	9	VMOD
12	conscious	conscious	B-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	9	P

1	It	It	B-NP	PRP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	shown	show	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	bromocriptine	bromocriptine	B-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	5	SBAR
8	tachycardia	tachycardia	B-NP	NN	O	7	OBJ
9	,	,	O	,	O	8	P
10	which	which	B-NP	WDT	O	8	NMOD
11	persisted	persist	B-VP	VBD	O	10	SBAR
12	after	after	B-PP	IN	O	11	VMOD
13	adrenalectomy	adrenalectomy	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	7	P
15	is	be	B-VP	VBZ	O	7	VMOD
16	(	(	O	(	O	18	DEP
17	i	i	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	VMOD
19	mediated	mediate	B-VP	VBN	O	15	VC
20	by	by	B-PP	IN	O	19	VMOD
21	central	central	B-NP	JJ	B-protein	25	NMOD
22	dopamine	dopamine	I-NP	NN	I-protein	25	NMOD
23	D2	D2	I-NP	NN	I-protein	25	NMOD
24	receptor	receptor	I-NP	NN	I-protein	25	NMOD
25	activation	activation	I-NP	NN	O	20	PMOD
26	and	and	O	CC	O	28	DEP
27	(	(	B-LST	(	O	28	DEP
28	ii	ii	I-LST	LS	O	7	VMOD
29	)	)	O	)	O	28	DEP
30	reduced	reduce	B-VP	VBN	O	28	DEP
31	by	by	B-PP	IN	O	30	VMOD
32	5-day	5-day	B-NP	JJ	O	34	NMOD
33	isoproterenol	isoproterenol	I-NP	NN	O	34	NMOD
34	pretreatment	pretreatment	I-NP	NN	O	31	PMOD
35	,	,	O	,	O	30	P
36	supporting	support	B-VP	VBG	O	30	VMOD
37	therefore	therefore	B-ADVP	RB	O	36	VMOD
38	the	the	B-NP	DT	O	39	NMOD
39	hypothesis	hypothesis	I-NP	NN	O	36	OBJ
40	that	that	B-SBAR	IN	O	39	NMOD
41	this	this	B-NP	DT	O	42	NMOD
42	effect	effect	I-NP	NN	O	43	SUB
43	is	be	B-VP	VBZ	O	40	SBAR
44	dependent	dependent	B-ADJP	JJ	O	43	PRD
45	on	on	B-PP	IN	O	44	AMOD
46	sympathetic	sympathetic	B-NP	JJ	O	47	NMOD
47	outflow	outflow	I-NP	NN	O	45	PMOD
48	to	to	B-PP	TO	O	47	NMOD
49	the	the	B-NP	DT	O	50	NMOD
50	heart	heart	I-NP	NN	O	48	PMOD
51	.	.	O	.	O	28	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	conducted	conduct	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	examine	examine	I-VP	VB	O	4	VMOD
7	whether	whether	B-SBAR	IN	O	6	VMOD
8	prolonged	prolong	B-NP	VBN	O	9	NMOD
9	pretreatment	pretreatment	I-NP	NN	O	12	SUB
10	with	with	B-PP	IN	O	9	NMOD
11	isoproterenol	isoproterenol	B-NP	NN	O	10	PMOD
12	could	could	B-VP	MD	O	7	SBAR
13	abolish	abolish	I-VP	VB	O	12	VC
14	bromocriptine	bromocriptine	B-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	tachycardia	tachycardia	I-NP	NN	O	13	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	conscious	conscious	B-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	3	P

1	Isoproterenol	Isoproterenol	B-NP	NN	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	6	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	15	15	B-NP	CD	O	5	NMOD
5	days	day	I-NP	NNS	O	3	PMOD
6	caused	cause	B-VP	VBD	O	0	ROOT
7	cardiac	cardiac	B-NP	JJ	O	8	NMOD
8	hypertrophy	hypertrophy	I-NP	NN	O	6	OBJ
9	without	without	B-PP	IN	O	6	VMOD
10	affecting	affect	B-VP	VBG	O	9	PMOD
11	baseline	baseline	B-NP	NN	O	13	NMOD
12	blood	blood	I-NP	NN	O	13	NMOD
13	pressure	pressure	I-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	heart	heart	I-NP	NN	O	16	NMOD
16	rate	rate	I-NP	NN	O	10	OBJ
17	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	11	VMOD
2	control	control	B-NP	NN	O	3	NMOD
3	rats	rat	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	11	P
5	intravenous	intravenous	B-NP	JJ	O	6	NMOD
6	bromocriptine	bromocriptine	I-NP	NN	O	11	SUB
7	(	(	O	(	O	10	DEP
8	150	150	B-NP	CD	O	9	NMOD
9	microg/kg	microg/kg	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	significant	significant	B-NP	JJ	O	15	NMOD
13	hypotension	hypotension	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	tachycardia	tachycardia	I-NP	NN	O	11	OBJ
16	.	.	O	.	O	11	P

1	Bromocriptine	Bromocriptine	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	hypotension	hypotension	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	unaffected	unaffected	B-ADJP	JJ	O	4	PRD
6	by	by	B-PP	IN	O	5	AMOD
7	isoproterenol	isoproterenol	B-NP	NN	O	8	NMOD
8	pretreatment	pretreatment	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	4	P
10	while	while	B-SBAR	IN	O	4	VMOD
11	tachycardia	tachycardia	B-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	10	SBAR
13	reversed	reverse	I-VP	VBN	O	12	VC
14	to	to	B-PP	TO	O	13	VMOD
15	significant	significant	B-NP	JJ	O	16	NMOD
16	bradycardia	bradycardia	I-NP	NN	O	19	NMOD
17	,	,	O	,	O	19	P
18	an	an	B-NP	DT	O	19	NMOD
19	effect	effect	I-NP	NN	O	14	PMOD
20	that	that	B-NP	WDT	O	19	NMOD
21	was	be	B-VP	VBD	O	20	SBAR
22	partly	partly	I-VP	RB	O	21	VMOD
23	reduced	reduce	I-VP	VBN	O	21	VC
24	by	by	B-PP	IN	O	23	VMOD
25	i.v.	i.v.	B-NP	JJ	O	26	NMOD
26	domperidone	domperidone	I-NP	NN	O	24	PMOD
27	(	(	O	(	O	30	DEP
28	0.5	0.5	B-NP	CD	O	29	NMOD
29	mg/kg	mg/kg	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	NMOD
31	.	.	O	.	O	4	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	show	show	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	15-day	15-day	B-NP	JJ	O	7	NMOD
6	isoproterenol	isoproterenol	I-NP	NN	O	7	NMOD
7	pretreatment	pretreatment	I-NP	NN	O	10	SUB
8	not	not	B-CONJP	RB	O	10	VMOD
9	only	only	I-CONJP	RB	O	8	DEP
10	abolished	abolish	B-VP	VBD	O	4	SBAR
11	but	but	I-VP	CC	O	10	VMOD
12	reversed	reverse	I-VP	VBD	O	10	VMOD
13	bromocriptine	bromocriptine	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	tachycardia	tachycardia	I-NP	NN	O	12	OBJ
16	to	to	B-PP	TO	O	12	VMOD
17	bradycardia	bradycardia	B-NP	NN	O	20	NMOD
18	,	,	O	,	O	20	P
19	an	an	B-NP	DT	O	20	NMOD
20	effect	effect	I-NP	NN	O	16	PMOD
21	that	that	B-NP	WDT	O	20	NMOD
22	is	be	B-VP	VBZ	O	21	SBAR
23	mainly	mainly	I-VP	RB	O	22	VMOD
24	related	relate	I-VP	VBN	O	22	PRD
25	to	to	B-PP	TO	O	24	AMOD
26	further	further	B-NP	JJ	O	29	NMOD
27	cardiac	cardiac	I-NP	JJ	O	29	NMOD
28	beta-adrenoceptor	beta-adrenoceptor	I-NP	NN	O	29	NMOD
29	desensitization	desensitization	I-NP	NN	O	25	PMOD
30	rather	rather	B-CONJP	RB	O	29	NMOD
31	than	than	I-CONJP	IN	O	30	DEP
32	to	to	B-PP	TO	O	30	AMOD
33	impairment	impairment	B-NP	NN	O	32	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	autonomic	autonomic	B-NP	JJ	O	36	NMOD
36	regulation	regulation	I-NP	NN	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	39	NMOD
39	heart	heart	I-NP	NN	O	37	PMOD
40	.	.	O	.	O	3	P

1	Given	Give	B-VP	VBN	O	13	VMOD
2	that	that	B-SBAR	IN	O	1	VMOD
3	sympathetic	sympathetic	B-NP	JJ	O	5	NMOD
4	neural	neural	I-NP	JJ	O	5	NMOD
5	dominance	dominance	I-NP	NN	O	6	SUB
6	exhibits	exhibit	B-VP	VBZ	O	2	SBAR
7	a	a	B-NP	DT	O	10	NMOD
8	similar	similar	I-NP	JJ	O	10	NMOD
9	developmental	developmental	I-NP	JJ	O	10	NMOD
10	pattern	pattern	I-NP	NN	O	6	OBJ
11	,	,	O	,	O	13	P
12	and	and	O	CC	O	13	VMOD
13	given	give	B-VP	VBN	O	23	VMOD
14	that	that	B-SBAR	IN	O	13	VMOD
15	clonidine	clonidine	B-NP	NN	O	16	SUB
16	induces	induce	B-VP	VBZ	O	14	SBAR
17	sympathetic	sympathetic	B-NP	JJ	O	18	NMOD
18	withdrawal	withdrawal	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	bradycardia	bradycardia	I-NP	NN	O	16	OBJ
21	,	,	O	,	O	23	P
22	we	we	B-NP	PRP	O	23	SUB
23	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT
24	that	that	B-SBAR	IN	O	23	VMOD
25	clonidine	clonidine	B-NP	NN	O	28	NMOD
26	's	's	B-NP	POS	O	28	NMOD
27	developmental	developmental	I-NP	JJ	O	28	NMOD
28	effects	effect	I-NP	NNS	O	35	SUB
29	on	on	B-PP	IN	O	28	NMOD
30	cardiac	cardiac	B-NP	JJ	O	31	NMOD
31	rate	rate	I-NP	NN	O	34	NMOD
32	and	and	I-NP	CC	O	34	NMOD
33	ultrasound	ultrasound	I-NP	NN	O	34	NMOD
34	production	production	I-NP	NN	O	29	PMOD
35	would	would	B-VP	MD	O	24	SBAR
36	mirror	mirror	I-VP	VB	O	35	VC
37	each	each	B-NP	DT	O	38	NMOD
38	other	other	I-NP	JJ	O	36	OBJ
39	.	.	O	.	O	23	P

1	Age-related	Age-related	B-NP	JJ	O	2	NMOD
2	changes	change	I-NP	NNS	O	6	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	ultrasound	ultrasound	B-NP	JJ	O	5	NMOD
5	production	production	I-NP	NN	O	3	PMOD
6	corresponded	correspond	B-VP	VBD	O	0	ROOT
7	with	with	B-PP	IN	O	6	VMOD
8	changes	change	B-NP	NNS	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	cardiovascular	cardiovascular	B-NP	JJ	O	11	NMOD
11	variables	variable	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	11	P
13	including	include	B-PP	VBG	O	11	NMOD
14	baseline	baseline	B-NP	NN	O	16	NMOD
15	cardiac	cardiac	I-NP	JJ	O	16	NMOD
16	rate	rate	I-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	clonidine	clonidine	I-NP	NN	O	13	PMOD
19	induced	induce	B-VP	VBD	O	6	VMOD
20	bradycardia	bradycardia	B-NP	NN	O	19	OBJ
21	.	.	O	.	O	6	P

1	Differential	Differential	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	systemically	systemically	B-NP	RB	O	5	AMOD
5	administered	administer	I-NP	VBN	O	8	NMOD
6	ketamine	ketamine	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	lidocaine	lidocaine	I-NP	NN	O	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	dynamic	dynamic	B-NP	JJ	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	static	static	I-NP	JJ	O	13	NMOD
13	hyperalgesia	hyperalgesia	I-NP	NN	O	9	PMOD
14	induced	induce	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	intradermal	intradermal	B-NP	JJ	O	17	NMOD
17	capsaicin	capsaicin	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	humans	human	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	examined	examine	I-VP	VBN	O	2	VC
4	the	the	B-NP	DT	O	5	NMOD
5	effect	effect	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	systemic	systemic	B-NP	JJ	O	8	NMOD
8	administration	administration	I-NP	NN	O	12	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	ketamine	ketamine	B-NP	NN	O	9	PMOD
11	and	and	I-NP	CC	O	12	NMOD
12	lidocaine	lidocaine	I-NP	NN	O	6	PMOD
13	on	on	B-PP	IN	O	5	NMOD
14	brush-evoked	brush-evoked	O	JJ	O	24	NMOD
15	(	(	O	(	O	17	DEP
16	dynamic	dynamic	B-ADJP	JJ	O	17	DEP
17	)	)	O	)	O	14	AMOD
18	pain	pain	B-NP	NN	O	24	NMOD
19	and	and	O	CC	O	24	NMOD
20	punctate-evoked	punctate-evoked	O	JJ	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	static	static	B-ADJP	JJ	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	hyperalgesia	hyperalgesia	B-NP	NN	O	13	PMOD
25	induced	induce	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	capsaicin	capsaicin	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	2	P

1	Ketamine	Ketamine	B-NP	NN	O	2	SUB
2	reduced	reduce	B-VP	VBD	O	0	ROOT
3	both	both	O	CC	O	14	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	area	area	I-NP	NN	O	14	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	brush-evoked	brush-evoked	B-NP	JJ	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	punctate-evoked	punctate-evoked	I-NP	JJ	O	10	NMOD
10	hyperalgesia	hyperalgesia	I-NP	NN	O	6	PMOD
11	significantly	significantly	B-ADVP	RB	O	14	VMOD
12	and	and	O	CC	O	11	AMOD
13	it	it	B-NP	PRP	O	14	SUB
14	tended	tend	B-VP	VBD	O	2	VMOD
15	to	to	I-VP	TO	O	16	VMOD
16	reduce	reduce	I-VP	VB	O	14	VMOD
17	brush-evoked	brush-evoked	B-NP	JJ	O	18	NMOD
18	pain	pain	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	2	P

1	Lidocaine	Lidocaine	B-NP	NN	O	2	SUB
2	reduced	reduce	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	area	area	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	punctate-evoked	punctate-evoked	B-NP	JJ	O	7	NMOD
7	hyperalgesia	hyperalgesia	I-NP	NN	O	5	PMOD
8	significantly	significantly	B-ADVP	RB	O	2	VMOD
9	.	.	O	.	O	2	P

1	Cyclosporine	Cyclosporine	B-NP	NN	O	5	NMOD
2	and	and	I-NP	CC	O	5	NMOD
3	tacrolimus-associated	tacrolimus-associated	I-NP	JJ	O	5	NMOD
4	thrombotic	thrombotic	I-NP	JJ	O	5	NMOD
5	microangiopathy	microangiopathy	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	development	development	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	thrombotic	thrombotic	B-NP	JJ	O	5	NMOD
5	microangiopathy	microangiopathy	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	8	DEP
7	TMA	TMA	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	associated	associate	B-VP	VBN	O	2	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	use	use	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	cyclosporine	cyclosporine	B-NP	NN	O	13	PMOD
15	has	have	B-VP	VBZ	O	0	ROOT
16	been	be	I-VP	VBN	O	15	VC
17	well	well	I-VP	RB	O	16	VMOD
18	documented	document	I-VP	VBN	O	16	VC
19	.	.	O	.	O	15	P

1	As	As	B-PP	IN	O	8	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	result	result	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	8	P
5	switching	switch	B-VP	VBG	O	8	SUB
6	to	to	B-PP	TO	O	5	VMOD
7	tacrolimus	tacrolimus	B-NP	NN	O	6	PMOD
8	has	have	B-VP	VBZ	O	0	ROOT
9	been	be	I-VP	VBN	O	8	VC
10	reported	report	I-VP	VBN	O	9	VC
11	to	to	I-VP	TO	O	12	VMOD
12	be	be	I-VP	VB	O	10	VMOD
13	a	a	B-NP	DT	O	16	NMOD
14	viable	viable	I-NP	JJ	O	16	NMOD
15	therapeutic	therapeutic	I-NP	JJ	O	16	NMOD
16	option	option	I-NP	NN	O	12	PRD
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	setting	setting	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	cyclosporine	cyclosporine	B-NP	NN	O	23	NMOD
22	induced	induced	I-NP	JJ	O	23	NMOD
23	TMA	TMA	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	8	P

1	With	With	B-PP	IN	O	14	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	more	more	I-NP	RBR	O	4	AMOD
4	widespread	widespread	I-NP	JJ	O	5	NMOD
5	application	application	I-NP	NN	O	1	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	tacrolimus	tacrolimus	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	organ	organ	B-NP	NN	O	10	NMOD
10	transplantation	transplantation	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	14	P
12	tacrolimus-associated	tacrolimus-associated	B-NP	JJ	O	13	NMOD
13	TMA	TMA	I-NP	NN	O	14	SUB
14	has	have	B-VP	VBZ	O	0	ROOT
15	also	also	I-VP	RB	O	14	VMOD
16	been	be	I-VP	VBN	O	14	VC
17	recognized	recognize	I-VP	VBN	O	16	VC
18	.	.	O	.	O	14	P

1	However	However	B-ADVP	RB	O	20	VMOD
2	,	,	O	,	O	20	P
3	literature	literature	B-NP	NN	O	20	SUB
4	regarding	regard	B-VP	VBG	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	recurrence	recurrence	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	TMA	TMA	B-NP	NN	B-protein	10	PMOD
12	in	in	B-PP	IN	O	9	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	exposed	expose	B-VP	VBN	O	13	NMOD
15	sequentially	sequentially	B-ADVP	RB	O	14	VMOD
16	to	to	B-PP	TO	O	15	PMOD
17	cyclosporine	cyclosporine	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	tacrolimus	tacrolimus	I-NP	NN	O	16	PMOD
20	is	be	B-VP	VBZ	O	0	ROOT
21	limited	limit	B-ADJP	VBN	O	20	VC
22	.	.	O	.	O	20	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	11	NMOD
7	living	live	I-NP	VBG	O	11	NMOD
8	donor	donor	I-NP	NN	O	11	NMOD
9	renal	renal	I-NP	JJ	O	11	NMOD
10	transplant	transplant	I-NP	NN	O	11	NMOD
11	recipient	recipient	I-NP	NN	O	5	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	developed	develop	B-VP	VBD	O	12	SBAR
14	cyclosporine	cyclosporine	B-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	TMA	TMA	I-NP	NN	O	13	OBJ
17	that	that	B-NP	WDT	O	16	NMOD
18	responded	respond	B-VP	VBD	O	17	SBAR
19	to	to	B-PP	TO	O	18	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	withdrawal	withdrawal	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	cyclosporine	cyclosporine	B-NP	NN	O	22	PMOD
24	in	in	B-PP	IN	O	21	NMOD
25	conjunction	conjunction	B-NP	NN	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	plasmapheresis	plasmapheresis	B-NP	NN	O	33	NMOD
28	and	and	O	CC	O	33	NMOD
29	fresh	fresh	B-NP	JJ	O	33	NMOD
30	frozen	frozen	I-NP	JJ	O	33	NMOD
31	plasma	plasma	I-NP	NN	O	33	NMOD
32	replacement	replacement	I-NP	NN	O	33	NMOD
33	therapy	therapy	I-NP	NN	O	26	PMOD
34	.	.	O	.	O	2	P

1	Introduction	Introduction	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	tacrolimus	tacrolimus	B-NP	NN	O	2	PMOD
4	as	as	B-PP	IN	O	1	NMOD
5	an	an	B-NP	DT	O	8	NMOD
6	alternative	alternative	I-NP	JJ	O	7	AMOD
7	immunosuppressive	immunosuppressive	I-NP	JJ	O	8	NMOD
8	agent	agent	I-NP	NN	O	4	PMOD
9	resulted	result	B-VP	VBD	O	0	ROOT
10	in	in	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	recurrence	recurrence	I-NP	NN	O	18	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	TMA	TMA	B-NP	NN	B-protein	13	PMOD
15	and	and	O	CC	O	18	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	subsequent	subsequent	I-NP	JJ	O	18	NMOD
18	loss	loss	I-NP	NN	O	10	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	renal	renal	I-NP	JJ	O	22	NMOD
22	allograft	allograft	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	9	P

1	Repeated	Repeat	B-NP	VBN	O	3	NMOD
2	transient	transient	I-NP	JJ	O	3	NMOD
3	anuria	anuria	I-NP	NN	O	0	ROOT
4	following	follow	B-PP	VBG	O	3	NMOD
5	losartan	losartan	B-NP	NN	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	solitary	solitary	I-NP	JJ	O	13	NMOD
13	kidney	kidney	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	70-year-old	70-year-old	I-NP	JJ	O	9	NMOD
8	hypertensive	hypertensive	I-NP	JJ	O	9	NMOD
9	man	man	I-NP	NN	O	5	PMOD
10	with	with	B-PP	IN	O	4	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	solitary	solitary	I-NP	JJ	O	13	NMOD
13	kidney	kidney	I-NP	NN	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	chronic	chronic	B-NP	JJ	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	insufficiency	insufficiency	I-NP	NN	O	10	PMOD
18	who	who	B-NP	WP	O	17	NMOD
19	developed	develop	B-VP	VBD	O	18	SBAR
20	two	two	B-NP	CD	O	21	NMOD
21	episodes	episode	I-NP	NNS	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	transient	transient	B-NP	JJ	O	24	NMOD
24	anuria	anuria	I-NP	NN	O	22	PMOD
25	after	after	B-PP	IN	O	21	NMOD
26	losartan	losartan	B-NP	NN	O	27	NMOD
27	administration	administration	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	2	P

1	Due	Due	B-PP	JJ	O	7	SUB
2	to	to	B-PP	TO	O	1	NMOD
3	severe	severe	B-NP	JJ	O	4	AMOD
4	systolic	systolic	I-NP	JJ	O	6	NMOD
5	dysfunction	dysfunction	I-NP	NN	O	6	NMOD
6	losartan	losartan	I-NP	NN	O	2	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	prescribed	prescribe	I-VP	VBN	O	7	VC
9	.	.	O	.	O	7	P

1	Surprisingly	Surprisingly	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	the	the	B-NP	DT	O	5	NMOD
4	first	first	I-NP	JJ	O	5	NMOD
5	dose	dose	I-NP	NN	O	11	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	50	50	B-NP	CD	O	8	NMOD
8	mg	mg	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	losartan	losartan	B-NP	NN	O	9	PMOD
11	resulted	result	B-VP	VBD	O	0	ROOT
12	in	in	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	sudden	sudden	I-NP	JJ	O	15	NMOD
15	anuria	anuria	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	15	P
17	which	which	B-NP	WDT	O	15	NMOD
18	lasted	last	B-VP	VBD	O	17	SBAR
19	eight	eight	B-NP	CD	O	20	NMOD
20	hours	hour	I-NP	NNS	O	18	OBJ
21	despite	despite	B-PP	IN	O	18	VMOD
22	high-dose	high-dose	B-NP	JJ	O	23	NMOD
23	furosemide	furosemide	I-NP	NN	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	amine	amine	I-NP	NN	O	26	NMOD
26	infusion	infusion	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	11	P

1	One	One	B-NP	CD	O	2	NMOD
2	week	week	I-NP	NN	O	9	SUB
3	later	later	B-ADVP	RB	O	9	VMOD
4	,	,	O	,	O	9	P
5	by	by	B-PP	IN	O	9	VMOD
6	mistake	mistake	B-NP	NN	O	5	PMOD
7	,	,	O	,	O	9	P
8	losartan	losartan	B-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	23	VMOD
10	prescribed	prescribe	I-VP	VBN	O	9	VC
11	again	again	B-ADVP	RB	O	10	VMOD
12	and	and	O	CC	O	11	DEP
13	after	after	B-PP	IN	O	11	AMOD
14	the	the	B-NP	DT	O	16	NMOD
15	second	second	I-NP	JJ	O	16	NMOD
16	dose	dose	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	50	50	B-NP	CD	O	19	NMOD
19	mg	mg	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	9	P
21	the	the	B-NP	DT	O	22	NMOD
22	patient	patient	I-NP	NN	O	23	SUB
23	developed	develop	B-VP	VBD	O	0	ROOT
24	a	a	B-NP	DT	O	26	NMOD
25	second	second	I-NP	JJ	O	26	NMOD
26	episode	episode	I-NP	NN	O	23	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	transient	transient	B-NP	JJ	O	29	NMOD
29	anuria	anuria	I-NP	NN	O	27	PMOD
30	lasting	last	B-VP	VBG	O	29	NMOD
31	10	10	B-NP	CD	O	32	NMOD
32	hours	hour	I-NP	NNS	O	30	OBJ
33	.	.	O	.	O	23	P

1	In	In	B-PP	IN	O	16	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	patient	patient	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	16	P
5	renal	renal	B-NP	JJ	O	7	NMOD
6	artery	artery	I-NP	NN	O	7	NMOD
7	stenosis	stenosis	I-NP	NN	O	16	SUB
8	combined	combine	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	heart	heart	B-NP	NN	O	11	NMOD
11	failure	failure	I-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	diuretic	diuretic	B-NP	JJ	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	9	PMOD
15	certainly	certainly	B-ADVP	RB	O	16	VMOD
16	resulted	result	B-VP	VBD	O	0	ROOT
17	in	in	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	20	NMOD
19	strong	strong	I-NP	JJ	O	20	NMOD
20	activation	activation	I-NP	NN	O	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	renin-angiotensin	renin-angiotensin	I-NP	NN	B-protein	24	NMOD
24	system	system	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	RAS	RAS	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	16	P

1	In	In	B-NP	FW	O	2	AMOD
2	vivo	vivo	I-NP	FW	O	3	NMOD
3	protection	protection	I-NP	NN	O	15	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	dna	dna	B-NP	NN	O	6	NMOD
6	damage	damage	I-NP	NN	O	12	NMOD
7	associated	associate	B-VP	VBN	O	12	NMOD
8	apoptotic	apoptotic	B-NP	JJ	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	necrotic	necrotic	I-NP	JJ	O	12	NMOD
11	cell	cell	I-NP	NN	O	12	NMOD
12	deaths	death	I-NP	NNS	O	4	PMOD
13	during	during	B-PP	IN	O	3	NMOD
14	acetaminophen	acetaminophen	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	0	ROOT
16	nephrotoxicity	nephrotoxicity	B-NP	NN	O	15	OBJ
17	,	,	O	,	O	15	P
18	amiodarone	amiodarone	B-NP	NN	O	15	VMOD
19	induced	induce	B-VP	VBD	O	18	NMOD
20	lung	lung	B-NP	NN	O	21	NMOD
21	toxicity	toxicity	I-NP	NN	O	19	OBJ
22	and	and	I-NP	CC	O	23	NMOD
23	doxorubicin	doxorubicin	I-NP	NN	O	21	NMOD
24	induced	induce	B-VP	VBD	O	23	SBAR
25	cardiotoxicity	cardiotoxicity	B-NP	NN	O	24	OBJ
26	by	by	B-PP	IN	O	24	VMOD
27	a	a	B-NP	DT	O	33	NMOD
28	novel	novel	I-NP	JJ	O	33	NMOD
29	IH636	IH636	I-NP	NN	O	33	NMOD
30	grape	grape	I-NP	NN	O	33	NMOD
31	seed	seed	I-NP	NN	O	33	NMOD
32	proanthocyanidin	proanthocyanidin	I-NP	NN	O	33	NMOD
33	extract	extract	I-NP	NN	O	26	PMOD
34	.	.	O	.	O	15	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	assessed	assess	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	ability	ability	I-NP	NN	O	33	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	IH636	IH636	B-NP	NN	O	11	NMOD
8	grape	grape	I-NP	NN	O	11	NMOD
9	seed	seed	I-NP	NN	O	11	NMOD
10	proanthocyanidin	proanthocyanidin	I-NP	NN	O	11	NMOD
11	extract	extract	I-NP	NN	O	6	PMOD
12	(	(	O	(	O	14	DEP
13	GSPE	GSPE	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	to	to	B-VP	TO	O	16	VMOD
16	prevent	prevent	I-VP	VB	O	5	NMOD
17	acetaminophen	acetaminophen	B-NP	NN	O	22	NMOD
18	(	(	O	(	O	20	DEP
19	AAP	AAP	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	induced	induce	B-NP	VBN	O	22	NMOD
22	nephrotoxicity	nephrotoxicity	I-NP	NN	O	16	OBJ
23	,	,	O	,	O	28	P
24	amiodarone	amiodarone	B-NP	NN	O	28	SUB
25	(	(	O	(	O	27	DEP
26	AMI	AMI	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	induced	induce	B-VP	VBD	O	33	NMOD
29	lung	lung	B-NP	NN	O	30	NMOD
30	toxicity	toxicity	I-NP	NN	O	28	OBJ
31	,	,	O	,	O	33	P
32	and	and	O	CC	O	33	NMOD
33	doxorubicin	doxorubicin	B-NP	NN	O	38	NMOD
34	(	(	O	(	O	36	DEP
35	DOX	DOX	B-NP	NN	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	induced	induce	B-VP	VBD	O	38	NMOD
38	cardiotoxicity	cardiotoxicity	B-NP	NN	O	3	OBJ
39	in	in	B-PP	IN	O	38	NMOD
40	mice	mouse	B-NP	NNS	O	39	PMOD
41	.	.	O	.	O	3	P

1	Histopathological	Histopathological	B-NP	JJ	O	2	NMOD
2	examination	examination	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	kidney	kidney	B-NP	NN	O	9	NMOD
5	,	,	I-NP	,	O	9	P
6	heart	heart	I-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	lung	lung	I-NP	NN	O	9	NMOD
9	sections	section	I-NP	NNS	O	3	PMOD
10	revealed	reveal	B-VP	VBD	O	0	ROOT
11	moderate	moderate	B-ADJP	JJ	O	10	PRD
12	to	to	B-PP	TO	O	11	AMOD
13	massive	massive	B-NP	JJ	O	15	NMOD
14	tissue	tissue	I-NP	NN	O	15	NMOD
15	damage	damage	I-NP	NN	O	12	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	a	a	B-NP	DT	O	18	NMOD
18	variety	variety	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	morphological	morphological	B-NP	JJ	O	21	NMOD
21	aberrations	aberration	I-NP	NNS	O	19	PMOD
22	by	by	B-PP	IN	O	15	NMOD
23	all	all	B-NP	PDT	O	26	NMOD
24	the	the	I-NP	DT	O	26	NMOD
25	three	three	I-NP	CD	O	26	NMOD
26	drugs	drug	I-NP	NNS	O	22	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	29	NMOD
29	absence	absence	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	GSPE	GSPE	B-NP	NN	O	32	NMOD
32	preexposure	preexposure	I-NP	NN	O	30	PMOD
33	than	than	B-PP	IN	O	11	AMOD
34	in	in	B-PP	IN	O	33	PMOD
35	its	its	B-NP	PRP$	O	36	NMOD
36	presence	presence	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	10	P

1	Interestingly	Interestingly	B-ADVP	RB	O	15	VMOD
2	,	,	O	,	O	15	P
3	all	all	B-NP	PDT	O	5	NMOD
4	the	the	I-NP	DT	O	5	NMOD
5	drugs	drug	I-NP	NNS	O	15	SUB
6	,	,	O	,	O	5	P
7	such	such	B-PP	JJ	O	8	PMOD
8	as	as	I-PP	IN	O	5	NMOD
9	,	,	O	,	O	15	P
10	AAP	AAP	B-NP	NN	B-protein	14	NMOD
11	,	,	O	,	O	14	P
12	AMI	AMI	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	DOX	DOX	I-NP	NN	O	15	SUB
15	induced	induce	B-VP	VBD	O	0	ROOT
16	apoptotic	apoptotic	B-NP	JJ	O	17	NMOD
17	death	death	I-NP	NN	O	15	OBJ
18	in	in	B-PP	IN	O	15	VMOD
19	addition	addition	B-NP	NN	O	18	PMOD
20	to	to	B-PP	TO	O	18	PMOD
21	necrosis	necrosis	B-NP	NN	O	18	PMOD
22	in	in	B-PP	IN	O	15	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	respective	respective	I-NP	JJ	O	25	NMOD
25	organs	organ	I-NP	NNS	O	22	PMOD
26	which	which	B-NP	WDT	O	25	NMOD
27	was	be	B-VP	VBD	O	26	SBAR
28	very	very	I-VP	RB	O	27	VMOD
29	effectively	effectively	I-VP	RB	O	28	AMOD
30	blocked	block	I-VP	VBN	O	27	VC
31	by	by	B-PP	IN	O	30	VMOD
32	GSPE	GSPE	B-NP	NN	B-protein	31	PMOD
33	.	.	O	.	O	15	P

1	Palpebral	Palpebral	B-NP	JJ	O	2	NMOD
2	twitching	twitching	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	depressed	depressed	I-NP	JJ	O	6	NMOD
6	adolescent	adolescent	I-NP	NN	O	3	PMOD
7	on	on	B-PP	IN	O	6	NMOD
8	citalopram	citalopram	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	favorable	favorable	I-NP	JJ	O	5	NMOD
5	response	response	I-NP	NN	O	2	OBJ
6	to	to	B-PP	TO	O	5	NMOD
7	treatment	treatment	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	citalopram	citalopram	B-NP	NN	O	8	PMOD
10	by	by	B-PP	IN	O	7	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	15-year-old	15-year-old	I-NP	JJ	O	13	NMOD
13	boy	boy	I-NP	NN	O	10	PMOD
14	with	with	B-PP	IN	O	7	NMOD
15	major	major	B-NP	JJ	O	16	NMOD
16	depression	depression	I-NP	NN	O	14	PMOD
17	who	who	B-NP	WP	O	16	NMOD
18	exhibited	exhibit	B-VP	VBD	O	17	SBAR
19	palpebral	palpebral	B-NP	JJ	O	20	NMOD
20	twitching	twitching	I-NP	NN	O	18	OBJ
21	during	during	B-PP	IN	O	18	VMOD
22	his	his	B-NP	PRP$	O	25	NMOD
23	first	first	I-NP	JJ	O	25	NMOD
24	2	2	I-NP	CD	O	25	NMOD
25	weeks	week	I-NP	NNS	O	21	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	treatment	treatment	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	2	P

1	Metamizol	Metamizol	B-NP	NN	O	2	SUB
2	potentiates	potentiate	B-VP	VBZ	O	0	ROOT
3	morphine	morphine	B-NP	NN	O	4	NMOD
4	antinociception	antinociception	I-NP	NN	O	7	NMOD
5	but	but	B-NP	CC	O	7	NMOD
6	not	not	I-NP	RB	O	5	DEP
7	constipation	constipation	B-NP	NN	O	2	OBJ
8	after	after	B-PP	IN	O	7	NMOD
9	chronic	chronic	B-NP	JJ	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	work	work	I-NP	NN	O	3	SUB
3	evaluates	evaluate	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	8	NMOD
5	antinociceptive	antinociceptive	I-NP	JJ	O	7	AMOD
6	and	and	I-NP	CC	O	7	AMOD
7	constipating	constipating	I-NP	JJ	O	8	NMOD
8	effects	effect	I-NP	NNS	O	3	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	combination	combination	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	3.2	3.2	B-NP	CD	O	16	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	16	NMOD
15	s.c.	s.c.	I-NP	JJ	O	16	NMOD
16	morphine	morphine	I-NP	NN	O	12	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	177.8	177.8	B-NP	CD	O	21	NMOD
19	mg/kg	mg/kg	I-NP	NN	O	21	NMOD
20	s.c.	s.c.	I-NP	JJ	O	21	NMOD
21	metamizol	metamizol	I-NP	NN	O	17	PMOD
22	in	in	B-PP	IN	O	8	NMOD
23	acutely	acutely	B-ADVP	RB	O	26	VMOD
24	and	and	I-ADVP	CC	O	23	AMOD
25	chronically	chronically	I-ADVP	RB	O	23	AMOD
26	treated	treat	B-VP	VBN	O	35	NMOD
27	(	(	O	(	O	34	DEP
28	once	once	O	RB	O	30	NMOD
29	a	a	B-NP	DT	O	30	NMOD
30	day	day	I-NP	NN	O	34	DEP
31	for	for	B-PP	IN	O	30	NMOD
32	12	12	B-NP	CD	O	33	NMOD
33	days	day	I-NP	NNS	O	31	PMOD
34	)	)	O	)	O	26	AMOD
35	rats	rat	B-NP	NNS	O	22	PMOD
36	.	.	O	.	O	3	P

1	On	On	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	13th	13th	I-NP	JJ	O	4	NMOD
4	day	day	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	8	P
6	antinociceptive	antinociceptive	B-NP	JJ	O	7	NMOD
7	effects	effect	I-NP	NNS	O	8	SUB
8	were	be	B-VP	VBD	O	18	VMOD
9	assessed	assess	I-VP	VBN	O	8	VC
10	using	use	B-VP	VBG	O	8	VMOD
11	a	a	B-NP	DT	O	12	NMOD
12	model	model	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	inflammatory	inflammatory	B-NP	JJ	O	15	NMOD
15	nociception	nociception	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	18	P
17	pain	pain	B-NP	NN	O	18	SUB
18	induced	induce	B-VP	VBD	O	28	VMOD
19	functional	functional	B-NP	JJ	O	21	NMOD
20	impairment	impairment	I-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	18	OBJ
22	,	,	O	,	O	28	P
23	and	and	O	CC	O	28	VMOD
24	the	the	B-NP	DT	O	27	NMOD
25	charcoal	charcoal	I-NP	NN	O	27	NMOD
26	meal	meal	I-NP	JJ	O	27	NMOD
27	test	test	I-NP	NN	O	28	SUB
28	was	be	B-VP	VBD	O	0	ROOT
29	used	use	I-VP	VBN	O	28	VC
30	to	to	B-VP	TO	O	31	VMOD
31	evaluate	evaluate	I-VP	VB	O	28	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	intestinal	intestinal	I-NP	JJ	O	34	NMOD
34	transit	transit	I-NP	NN	O	31	OBJ
35	.	.	O	.	O	28	P

1	In	In	B-PP	IN	O	6	VMOD
2	independent	independent	B-NP	JJ	O	3	NMOD
3	groups	group	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	morphine	morphine	B-NP	NN	O	6	SUB
6	inhibited	inhibit	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	intestinal	intestinal	I-NP	JJ	O	9	NMOD
9	transit	transit	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	48+/-4	48+/-4	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	38+/-4	38+/-4	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	10	PMOD
16	after	after	B-PP	IN	O	6	VMOD
17	acute	acute	B-NP	JJ	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	chronic	chronic	I-NP	JJ	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	16	PMOD
21	,	,	O	,	O	6	P
22	respectively	respectively	B-ADVP	RB	O	6	VMOD
23	,	,	O	,	O	6	P
24	suggesting	suggest	B-VP	VBG	O	6	VMOD
25	that	that	B-SBAR	IN	O	24	VMOD
26	tolerance	tolerance	B-NP	NN	O	27	SUB
27	did	do	B-VP	VBD	O	25	SBAR
28	not	not	I-VP	RB	O	27	VMOD
29	develop	develop	I-VP	VB	O	27	VC
30	to	to	B-PP	TO	O	29	VMOD
31	the	the	B-NP	DT	O	33	NMOD
32	constipating	constipate	I-NP	VBG	O	33	NMOD
33	effects	effect	I-NP	NNS	O	30	PMOD
34	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	combination	combination	I-NP	NN	O	3	SUB
3	inhibited	inhibit	B-VP	VBD	O	0	ROOT
4	intestinal	intestinal	B-NP	JJ	O	5	NMOD
5	transit	transit	I-NP	NN	O	3	OBJ
6	similar	similar	B-ADJP	JJ	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	that	that	B-NP	DT	O	7	PMOD
9	produced	produce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	morphine	morphine	B-NP	NN	O	10	PMOD
12	regardless	regardless	B-ADVP	RB	O	11	NMOD
13	of	of	B-PP	IN	O	12	AMOD
14	the	the	B-NP	DT	O	15	NMOD
15	time	time	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	treatment	treatment	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	3	P
19	suggesting	suggest	B-VP	VBG	O	3	VMOD
20	that	that	B-SBAR	IN	O	19	VMOD
21	metamizol	metamizol	B-NP	NN	O	22	SUB
22	did	do	B-VP	VBD	O	20	SBAR
23	not	not	I-VP	RB	O	22	VMOD
24	potentiate	potentiate	I-VP	VB	O	22	VC
25	morphine	morphine	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	constipation	constipation	I-NP	NN	O	24	OBJ
28	.	.	O	.	O	3	P

1	Ifosfamide	Ifosfamide	B-NP	NN	O	2	NMOD
2	encephalopathy	encephalopathy	I-NP	NN	O	0	ROOT
3	presenting	present	B-VP	VBG	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	asterixis	asterixis	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	51-year-old	51-year-old	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	4	NMOD
10	developed	develop	B-VP	VBD	O	9	SBAR
11	severe	severe	B-ADJP	JJ	O	10	VMOD
12	,	,	O	,	O	4	P
13	disabling	disable	B-VP	VBG	O	4	NMOD
14	negative	negative	B-NP	JJ	O	15	NMOD
15	myoclonus	myoclonus	I-NP	NN	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	21	NMOD
18	upper	upper	I-NP	JJ	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	lower	low	I-NP	JJR	O	21	NMOD
21	extremities	extremity	I-NP	NNS	O	16	PMOD
22	after	after	B-PP	IN	O	13	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	infusion	infusion	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	ifosfamide	ifosfamide	B-NP	NN	O	25	PMOD
27	for	for	B-PP	IN	O	24	NMOD
28	plasmacytoma	plasmacytoma	B-NP	NN	O	27	PMOD
29	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ifosfamide	ifosfamide	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	discontinued	discontinue	I-VP	VBN	O	5	VC
7	and	and	O	CC	O	6	VMOD
8	within	within	B-PP	IN	O	6	VMOD
9	12	12	B-NP	CD	O	10	NMOD
10	h	h	I-NP	NN	O	8	PMOD
11	the	the	B-NP	DT	O	12	NMOD
12	asterixis	asterixis	I-NP	NN	O	13	SUB
13	resolved	resolve	B-VP	VBD	O	6	VMOD
14	completely	completely	B-ADVP	RB	O	13	VMOD
15	.	.	O	.	O	5	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	29	SUB
2	:	:	O	:	O	1	P
3	Given	Give	B-VP	VBN	O	1	NMOD
4	its	its	B-NP	PRP$	O	6	NMOD
5	preclinical	preclinical	I-NP	JJ	O	6	NMOD
6	success	success	I-NP	NN	O	3	OBJ
7	for	for	B-PP	IN	O	6	NMOD
8	treating	treat	B-VP	VBG	O	7	PMOD
9	substance	substance	B-NP	NN	O	10	NMOD
10	abuse	abuse	I-NP	NN	O	14	NMOD
11	and	and	O	CC	O	14	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	increased	increase	I-NP	VBN	O	14	NMOD
14	risk	risk	I-NP	NN	O	8	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	visual	visual	B-NP	JJ	O	18	NMOD
17	field	field	I-NP	NN	O	18	NMOD
18	defects	defect	I-NP	NNS	O	15	PMOD
19	(	(	O	(	O	21	DEP
20	VFD	VFD	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	associated	associate	B-VP	VBN	O	18	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	cumulative	cumulative	B-NP	JJ	O	26	NMOD
25	lifetime	lifetime	I-NP	NN	O	26	NMOD
26	exposure	exposure	I-NP	NN	O	23	PMOD
27	,	,	O	,	O	29	P
28	we	we	B-NP	PRP	O	29	SUB
29	explored	explore	B-VP	VBD	O	0	ROOT
30	the	the	B-NP	DT	O	31	NMOD
31	effects	effect	I-NP	NNS	O	29	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	sub-chronic	sub-chronic	B-NP	JJ	O	36	NMOD
34	low	low	I-NP	JJ	O	36	NMOD
35	dose	dose	I-NP	NN	O	36	NMOD
36	GVG	GVG	I-NP	NN	O	32	PMOD
37	on	on	B-PP	IN	O	31	NMOD
38	cocaine	cocaine	B-NP	NN	O	40	NMOD
39	induced	induce	I-NP	VBN	O	40	NMOD
40	increases	increase	I-NP	NNS	O	37	PMOD
41	in	in	B-PP	IN	O	40	NMOD
42	nucleus	nucleus	B-NP	NN	O	43	NMOD
43	accumbens	accumbens	I-NP	NN	O	41	PMOD
44	(	(	O	(	O	46	DEP
45	NAcc	NAcc	B-NP	NN	O	46	DEP
46	)	)	O	)	O	43	NMOD
47	dopamine	dopamine	B-NP	NN	O	43	NMOD
48	(	(	O	(	O	50	DEP
49	DA	DA	B-NP	NN	O	50	DEP
50	)	)	O	)	O	47	NMOD
51	.	.	O	.	O	29	P

1	In	In	B-PP	IN	O	9	VMOD
2	ICH	ICH	B-NP	NN	O	3	NMOD
3	induction	induction	I-NP	NN	O	1	PMOD
4	using	use	B-VP	VBG	O	3	NMOD
5	0.014-unit	0.014-unit	B-NP	JJ	O	4	OBJ
6	collagenase	collagenase	I-NP	NN	B-protein	5	NMOD
7	,	,	O	,	O	9	P
8	heparin	heparin	B-NP	NN	O	9	SUB
9	enhanced	enhance	B-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	12	NMOD
11	hematoma	hematoma	I-NP	NN	O	12	NMOD
12	volume	volume	I-NP	NN	O	9	OBJ
13	3.4-fold	3.4-fold	B-ADVP	RB	O	9	VMOD
14	over	over	B-PP	IN	O	9	VMOD
15	that	that	B-NP	DT	O	14	PMOD
16	seen	see	B-VP	VBN	O	15	NMOD
17	in	in	B-PP	IN	O	16	VMOD
18	control	control	B-NP	NN	O	20	NMOD
19	ICH	ICH	I-NP	NN	O	20	NMOD
20	animals	animal	I-NP	NNS	O	17	PMOD
21	and	and	O	CC	O	24	AMOD
22	the	the	B-NP	DT	O	23	NMOD
23	bleeding	bleed	I-NP	VBG	O	24	NMOD
24	7.6-fold	7.6-fold	B-ADVP	RB	O	9	VMOD
25	.	.	O	.	O	9	P

1	Estradiol	Estradiol	B-NP	NN	O	2	SUB
2	reduces	reduce	B-VP	VBZ	O	0	ROOT
3	seizure	seizure	B-NP	NN	O	6	NMOD
4	induced	induced	I-NP	JJ	O	6	NMOD
5	hippocampal	hippocampal	I-NP	JJ	O	6	NMOD
6	injury	injury	I-NP	NN	O	2	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	ovariectomized	ovariectomize	B-NP	VBN	O	7	PMOD
9	female	female	I-NP	JJ	O	8	VMOD
10	but	but	B-PP	CC	O	9	PMOD
11	not	not	B-PP	RB	O	10	DEP
12	in	in	I-PP	IN	O	10	PMOD
13	male	male	B-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	2	P

1	Estrogens	Estrogen	B-NP	NNS	O	2	SUB
2	protect	protect	B-VP	VBP	O	0	ROOT
3	ovariectomized	ovariectomize	I-VP	VBN	O	4	NMOD
4	rats	rat	B-NP	NNS	O	2	OBJ
5	from	from	B-PP	IN	O	2	VMOD
6	hippocampal	hippocampal	B-NP	JJ	O	7	NMOD
7	injury	injury	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	kainic	kainic	B-NP	JJ	O	11	NMOD
11	acid	acid	I-NP	NN	O	9	PMOD
12	induced	induce	B-VP	VBD	O	2	VMOD
13	status	status	B-NP	NN	O	14	NMOD
14	epilepticus	epilepticus	I-NP	NN	O	12	OBJ
15	(	(	O	(	O	17	DEP
16	SE	SE	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	compared	compare	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	17beta-estradiol	17beta-estradiol	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	adult	adult	B-NP	JJ	O	13	NMOD
9	male	male	I-NP	JJ	O	11	AMOD
10	and	and	I-NP	CC	O	11	AMOD
11	ovariectomized	ovariectomize	I-NP	VBN	O	13	NMOD
12	female	female	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	7	PMOD
14	subjected	subject	B-VP	VBN	O	13	NMOD
15	to	to	B-PP	TO	O	14	VMOD
16	lithium-pilocarpine	lithium-pilocarpine	B-NP	NN	O	18	NMOD
17	induced	induced	I-NP	JJ	O	18	NMOD
18	SE	SE	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	extent	extent	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	silver-stained	silver-stained	B-NP	JJ	O	9	NMOD
5	CA3	CA3	I-NP	NN	B-protein	4	NMOD
6	and	and	I-NP	CC	O	4	NMOD
7	CA1	CA1	I-NP	NN	B-protein	4	NMOD
8	hippocampal	hippocampal	I-NP	JJ	O	9	NMOD
9	neurons	neuron	I-NP	NNS	O	3	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	evaluated	evaluate	I-VP	VBN	O	10	VC
12	2	2	B-NP	CD	O	13	NMOD
13	days	day	I-NP	NNS	O	17	SUB
14	after	after	B-PP	IN	O	13	NMOD
15	SE.	SE.	B-NP	NNP	O	16	NMOD
16	17beta-Estradiol	17beta-Estradiol	I-NP	NN	O	14	PMOD
17	did	do	B-VP	VBD	O	11	VMOD
18	not	not	I-VP	RB	O	17	VMOD
19	alter	alter	I-VP	VB	O	17	VC
20	the	the	B-NP	DT	O	21	NMOD
21	onset	onset	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	first	first	B-NP	JJ	O	24	NMOD
24	clonus	clonus	I-NP	NN	O	22	PMOD
25	in	in	B-PP	IN	O	21	NMOD
26	ovariectomized	ovariectomize	B-NP	VBN	O	27	NMOD
27	rats	rat	I-NP	NNS	O	25	PMOD
28	but	but	O	CC	O	10	VMOD
29	accelerated	accelerate	B-VP	VBD	O	10	VMOD
30	it	it	B-NP	PRP	O	29	OBJ
31	in	in	B-PP	IN	O	29	VMOD
32	males.	males.	B-NP	NN	O	33	NMOD
33	17beta-Estradiol	17beta-Estradiol	I-NP	NN	O	31	PMOD
34	reduced	reduce	B-VP	VBD	O	29	VMOD
35	the	the	B-NP	DT	O	37	NMOD
36	argyrophilic	argyrophilic	I-NP	JJ	O	37	NMOD
37	neurons	neuron	I-NP	NNS	O	34	OBJ
38	in	in	B-PP	IN	O	34	VMOD
39	the	the	B-NP	DT	O	43	NMOD
40	CA1	CA1	I-NP	NN	B-protein	43	NMOD
41	and	and	I-NP	CC	O	43	NMOD
42	CA3-C	CA3-C	I-NP	NN	O	43	NMOD
43	sectors	sector	I-NP	NNS	O	38	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	ovariectomized	ovariectomize	B-NP	VBN	O	46	NMOD
46	rats	rat	I-NP	NNS	O	44	PMOD
47	.	.	O	.	O	10	P

1	Delirium	Delirium	B-NP	NN	O	6	NMOD
2	during	during	B-PP	IN	O	1	NMOD
3	clozapine	clozapine	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	:	:	O	:	O	1	P
6	incidence	incidence	B-NP	NN	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	associated	associate	B-VP	VBN	O	10	NMOD
9	risk	risk	B-NP	NN	O	10	NMOD
10	factors	factor	I-NP	NNS	O	0	ROOT
11	.	.	O	.	O	10	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Incidence	Incidence	B-NP	NN	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	risk	risk	I-NP	NN	O	6	NMOD
6	factors	factor	I-NP	NNS	O	12	SUB
7	for	for	B-PP	IN	O	6	NMOD
8	delirium	delirium	B-NP	NN	O	7	PMOD
9	during	during	B-PP	IN	O	6	NMOD
10	clozapine	clozapine	B-NP	NN	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	require	require	B-VP	VBP	O	1	NMOD
13	further	far	B-NP	JJR	O	14	NMOD
14	clarification	clarification	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	12	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	used	use	B-VP	VBD	O	1	NMOD
5	computerized	computerized	B-NP	JJ	O	7	NMOD
6	pharmacy	pharmacy	I-NP	NN	O	7	NMOD
7	records	record	I-NP	NNS	O	4	OBJ
8	to	to	B-VP	TO	O	9	VMOD
9	identify	identify	I-VP	VB	O	4	VMOD
10	all	all	B-NP	DT	O	13	NMOD
11	adult	adult	I-NP	JJ	O	13	NMOD
12	psychiatric	psychiatric	I-NP	JJ	O	13	NMOD
13	inpatients	inpatient	I-NP	NNS	O	9	OBJ
14	treated	treat	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	clozapine	clozapine	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	19	DEP
18	1995-96	1995-96	B-NP	CD	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	4	P
21	reviewed	review	B-VP	VBD	O	4	VMOD
22	their	their	B-NP	PRP$	O	24	NMOD
23	medical	medical	I-NP	JJ	O	24	NMOD
24	records	record	I-NP	NNS	O	21	OBJ
25	to	to	B-VP	TO	O	26	VMOD
26	score	score	I-VP	VB	O	4	VMOD
27	incidence	incidence	B-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	severity	severity	I-NP	NN	O	26	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	delirium	delirium	B-NP	NN	O	30	PMOD
32	,	,	O	,	O	4	P
33	and	and	O	CC	O	4	VMOD
34	tested	test	B-VP	VBN	O	4	VMOD
35	associations	association	B-NP	NNS	O	34	OBJ
36	with	with	B-PP	IN	O	35	NMOD
37	potential	potential	B-NP	JJ	O	39	NMOD
38	risk	risk	I-NP	NN	O	39	NMOD
39	factors	factor	I-NP	NNS	O	36	PMOD
40	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Delirium	Delirium	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	found	find	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	10	10	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	clozapine-treated	clozapine-treated	B-NP	JJ	O	11	NMOD
11	inpatients	inpatient	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	6	P
13	particularly	particularly	B-ADVP	RB	O	14	PMOD
14	in	in	B-PP	IN	O	6	PMOD
15	older	old	B-NP	JJR	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	exposed	expose	B-VP	VBN	O	16	NMOD
18	to	to	B-PP	TO	O	17	VMOD
19	other	other	B-NP	JJ	O	21	NMOD
20	central	central	I-NP	JJ	O	21	NMOD
21	anticholinergics	anticholinergic	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	1	P

1	Ketoconazole	Ketoconazole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	neurologic	neurologic	B-NP	JJ	O	4	NMOD
4	sequelae	sequela	I-NP	NNS	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	77-y-old	77-y-old	I-NP	JJ	O	3	NMOD
3	patient	patient	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	weakness	weakness	B-NP	NN	O	16	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	extremities	extremity	B-NP	NNS	O	6	PMOD
8	,	,	O	,	O	16	P
9	legs	leg	B-NP	NNS	O	10	NMOD
10	paralysis	paralysis	I-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	dysarthria	dysarthria	B-NP	NN	O	16	NMOD
13	and	and	O	CC	O	16	NMOD
14	tremor	tremor	B-NP	NN	O	16	NMOD
15	1	1	I-NP	CD	O	16	NMOD
16	h	h	I-NP	NN	O	17	PMOD
17	after	after	B-PP	IN	O	4	VMOD
18	ingestion	ingestion	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	200	200	B-NP	CD	O	21	AMOD
21	mg	mg	I-NP	NN	O	22	NMOD
22	ketoconazole	ketoconazole	I-NP	NN	O	19	PMOD
23	for	for	B-PP	IN	O	18	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	first	first	I-NP	JJ	O	26	NMOD
26	time	time	I-NP	NN	O	23	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	his	his	B-NP	PRP$	O	29	NMOD
29	life	life	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	4	P

1	Capsaicin	Capsaicin	B-NP	NN	O	6	SUB
2	(	(	O	(	O	5	DEP
3	0.01-1	0.01-1	B-NP	CD	O	4	NMOD
4	mm	mm	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	applied	apply	B-VP	VBD	O	12	VMOD
7	to	to	B-PP	TO	O	12	VMOD
8	oral	oral	B-NP	JJ	O	11	NMOD
9	or	or	I-NP	CC	O	11	NMOD
10	nasal	nasal	I-NP	JJ	O	11	NMOD
11	mucosa	mucosa	I-NP	NN	O	12	SUB
12	induced	induce	B-VP	VBD	O	0	ROOT
13	increases	increase	B-NP	NNS	O	12	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	dural	dural	B-NP	JJ	O	19	NMOD
16	and	and	I-NP	CC	O	19	NMOD
17	cortical	cortical	I-NP	JJ	O	19	NMOD
18	blood	blood	I-NP	NN	O	19	NMOD
19	flow	flow	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	provoked	provoked	B-NP	JJ	O	22	NMOD
22	lacrimation	lacrimation	I-NP	NN	O	14	PMOD
23	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	3	NMOD
2	evoked	evoke	I-NP	VBN	O	3	NMOD
3	increases	increase	I-NP	NNS	O	8	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	dural	dural	B-NP	JJ	O	7	NMOD
6	blood	blood	I-NP	NN	O	7	NMOD
7	flow	flow	I-NP	NN	O	4	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	also	also	I-VP	RB	O	8	VMOD
10	abolished	abolish	I-VP	VBN	O	8	VC
11	by	by	B-PP	IN	O	10	VMOD
12	topical	topical	B-NP	JJ	O	13	NMOD
13	pre-administration	pre-administration	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	atropine	atropine	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	19	DEP
17	1	1	B-NP	CD	O	18	NMOD
18	mm	mm	I-NP	NN	O	19	DEP
19	)	)	O	)	O	15	NMOD
20	and	and	O	CC	O	11	PMOD
21	[	[	O	(	O	34	NMOD
22	Lys1	Lys1	B-NP	NN	B-protein	34	NMOD
23	,	,	O	,	O	34	P
24	Pro2	Pro2	B-NP	NN	O	34	NMOD
25	,	,	O	,	O	34	P
26	5	5	B-NP	CD	O	34	NMOD
27	,	,	O	,	O	34	P
28	Arg3	Arg3	B-NP	NN	O	34	NMOD
29	,	,	O	,	O	34	P
30	4	4	B-NP	CD	O	34	NMOD
31	,	,	O	,	O	34	P
32	Tyr6	Tyr6	B-NP	NN	O	34	NMOD
33	]	]	O	)	O	34	NMOD
34	-VIP	-VIP	B-NP	NN	O	43	NMOD
35	(	(	O	(	O	38	DEP
36	0.1	0.1	B-NP	CD	O	37	NMOD
37	mm	mm	I-NP	NN	O	38	DEP
38	)	)	O	)	O	34	NMOD
39	,	,	O	,	O	43	P
40	a	a	B-NP	DT	O	43	NMOD
41	vasoactive	vasoactive	I-NP	JJ	O	43	NMOD
42	intestinal	intestinal	I-NP	JJ	O	43	NMOD
43	polypeptide	polypeptide	I-NP	NN	O	47	NMOD
44	(	(	O	(	O	46	DEP
45	VIP	VIP	B-NP	NN	B-protein	46	DEP
46	)	)	O	)	O	43	NMOD
47	antagonist	antagonist	B-NP	NN	O	11	PMOD
48	,	,	O	,	O	47	P
49	onto	onto	B-PP	IN	O	47	NMOD
50	the	the	B-NP	DT	O	53	NMOD
51	exposed	expose	I-NP	VBN	O	53	NMOD
52	dura	dura	I-NP	NN	O	53	NMOD
53	mater	mater	I-NP	NN	O	49	PMOD
54	.	.	O	.	O	8	P

1	Similar	Similar	B-ADJP	JJ	O	8	VMOD
2	to	to	B-PP	TO	O	1	AMOD
3	rats	rat	B-NP	NNS	O	2	PMOD
4	,	,	O	,	O	8	P
5	systemic	systemic	B-NP	JJ	O	7	NMOD
6	pilocarpine	pilocarpine	I-NP	NN	O	7	NMOD
7	injection	injection	I-NP	NN	O	8	SUB
8	causes	cause	B-VP	VBZ	O	38	VMOD
9	status	status	B-NP	NN	O	10	NMOD
10	epilepticus	epilepticus	I-NP	NN	O	17	NMOD
11	(	(	O	(	O	13	DEP
12	SE	SE	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	and	and	O	CC	O	17	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	eventual	eventual	I-NP	JJ	O	17	NMOD
17	development	development	I-NP	NN	O	23	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	spontaneous	spontaneous	B-NP	JJ	O	20	NMOD
20	seizures	seizure	I-NP	NNS	O	18	PMOD
21	and	and	O	CC	O	23	NMOD
22	mossy	mossy	B-NP	NN	O	23	NMOD
23	fiber	fiber	I-NP	NN	O	8	OBJ
24	sprouting	sprout	B-VP	VBG	O	23	NMOD
25	in	in	B-PP	IN	O	24	VMOD
26	C57BL/6	C57BL/6	B-NP	NN	O	29	NMOD
27	and	and	I-NP	CC	O	29	NMOD
28	CD1	CD1	I-NP	NN	B-protein	29	NMOD
29	mice	mouse	I-NP	NNS	O	25	PMOD
30	,	,	O	,	O	38	P
31	but	but	O	CC	O	38	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	physiological	physiological	I-NP	JJ	O	34	NMOD
34	correlates	correlate	I-NP	NNS	O	38	SUB
35	of	of	B-PP	IN	O	34	NMOD
36	these	these	B-NP	DT	O	37	NMOD
37	events	event	I-NP	NNS	O	35	PMOD
38	have	have	B-VP	VBP	O	0	ROOT
39	not	not	I-VP	RB	O	38	VMOD
40	been	be	I-VP	VBN	O	38	VC
41	identified	identify	I-VP	VBN	O	40	VC
42	in	in	B-PP	IN	O	41	VMOD
43	mice	mouse	B-NP	NNS	O	42	PMOD
44	.	.	O	.	O	38	P

1	In	In	B-PP	IN	O	26	VMOD
2	Mg	Mg	B-NP	NN	B-cell_line	8	NMOD
3	(	(	O	(	I-cell_line	5	DEP
4	2+	2+	B-ADJP	JJ	I-cell_line	5	DEP
5	)	)	O	)	I-cell_line	2	NMOD
6	-free	-free	B-NP	JJ	I-cell_line	8	NMOD
7	bathing	bathing	I-NP	NN	I-cell_line	8	NMOD
8	medium	medium	I-NP	NN	I-cell_line	1	PMOD
9	containing	contain	B-VP	VBG	I-cell_line	8	NMOD
10	bicuculline	bicuculline	B-NP	NN	I-cell_line	12	NMOD
11	,	,	O	,	O	12	P
12	conditions	condition	B-NP	NNS	O	9	OBJ
13	designed	design	B-VP	VBN	O	12	NMOD
14	to	to	I-VP	TO	O	15	VMOD
15	increase	increase	I-VP	VB	O	13	VMOD
16	excitability	excitability	B-NP	NN	O	15	OBJ
17	in	in	B-PP	IN	O	15	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	slices	slice	I-NP	NNS	O	17	PMOD
20	,	,	O	,	O	26	P
21	electrical	electrical	B-NP	JJ	O	22	NMOD
22	stimulation	stimulation	I-NP	NN	O	26	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	hilus	hilus	I-NP	NN	O	23	PMOD
26	resulted	result	B-VP	VBD	O	0	ROOT
27	in	in	B-PP	IN	O	26	VMOD
28	a	a	B-NP	DT	O	31	NMOD
29	single	single	I-NP	JJ	O	31	NMOD
30	population	population	I-NP	NN	O	31	NMOD
31	spike	spike	I-NP	NN	O	27	PMOD
32	in	in	B-PP	IN	O	31	NMOD
33	granule	granule	B-NP	NN	B-cell_type	34	NMOD
34	cells	cell	I-NP	NNS	I-cell_type	32	PMOD
35	from	from	B-PP	IN	O	34	NMOD
36	control	control	B-NP	NN	O	37	NMOD
37	mice	mouse	I-NP	NNS	O	40	NMOD
38	and	and	O	CC	O	40	NMOD
39	pilocarpine-treated	pilocarpine-treated	B-NP	JJ	O	40	NMOD
40	mice	mouse	I-NP	NNS	O	35	PMOD
41	that	that	B-NP	WDT	O	31	NMOD
42	did	do	B-VP	VBD	O	41	SBAR
43	not	not	I-VP	RB	O	42	VMOD
44	experience	experience	I-VP	VB	O	42	VC
45	SE	SE	B-NP	NN	B-protein	44	OBJ
46	.	.	O	.	O	26	P

1	In	In	B-PP	IN	O	7	VMOD
2	SE	SE	B-NP	NN	O	3	NMOD
3	survivors	survivor	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	7	P
5	similar	similar	B-NP	JJ	O	6	NMOD
6	stimulation	stimulation	I-NP	NN	O	7	SUB
7	resulted	result	B-VP	VBD	O	0	ROOT
8	in	in	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	population	population	I-NP	NN	O	11	NMOD
11	spike	spike	I-NP	NN	O	12	SUB
12	followed	follow	B-VP	VBD	O	8	SBAR
13	,	,	O	,	O	12	P
14	at	at	B-PP	IN	O	12	VMOD
15	a	a	B-NP	DT	O	17	NMOD
16	variable	variable	I-NP	JJ	O	17	NMOD
17	latency	latency	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	12	P
19	by	by	B-PP	IN	O	12	VMOD
20	negative	negative	B-NP	JJ	O	22	NMOD
21	DC	DC	I-NP	NN	O	22	NMOD
22	shifts	shift	I-NP	NNS	O	25	NMOD
23	and	and	O	CC	O	25	NMOD
24	repetitive	repetitive	B-NP	JJ	O	25	NMOD
25	afterdischarges	afterdischarge	I-NP	NNS	O	19	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	3-60	3-60	B-NP	CD	O	29	NMOD
28	s	s	I-NP	NN	O	29	NMOD
29	duration	duration	I-NP	NN	O	26	PMOD
30	,	,	O	,	O	29	P
31	which	which	B-NP	WDT	O	29	NMOD
32	were	be	B-VP	VBD	O	31	SBAR
33	blocked	block	I-VP	VBN	O	32	VC
34	by	by	B-PP	IN	O	33	VMOD
35	ionotropic	ionotropic	B-NP	JJ	O	38	NMOD
36	glutamate	glutamate	I-NP	NN	O	38	NMOD
37	receptor	receptor	I-NP	NN	O	38	NMOD
38	antagonists	antagonist	I-NP	NNS	O	34	PMOD
39	.	.	O	.	O	7	P

1	Focal	Focal	B-NP	JJ	O	3	NMOD
2	glutamate	glutamate	I-NP	NN	O	3	NMOD
3	photostimulation	photostimulation	I-NP	NN	O	16	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	granule	granule	I-NP	NN	O	8	NMOD
7	cell	cell	I-NP	NN	O	8	NMOD
8	layer	layer	I-NP	NN	O	4	PMOD
9	at	at	B-PP	IN	O	3	NMOD
10	sites	site	B-NP	NNS	O	9	PMOD
11	distant	distant	B-ADJP	JJ	O	10	NMOD
12	from	from	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	15	NMOD
14	recording	record	I-NP	VBG	O	15	NMOD
15	pipette	pipette	I-NP	NN	O	12	PMOD
16	resulted	result	B-VP	VBD	O	0	ROOT
17	in	in	B-PP	IN	O	16	VMOD
18	population	population	B-NP	NN	O	19	NMOD
19	responses	response	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	1-30	1-30	B-NP	CD	O	23	NMOD
22	s	s	I-NP	NN	O	23	NMOD
23	duration	duration	I-NP	NN	O	20	PMOD
24	in	in	B-PP	IN	O	19	NMOD
25	slices	slice	B-NP	NNS	O	24	PMOD
26	from	from	B-PP	IN	O	25	NMOD
27	SE	SE	B-NP	NN	B-protein	28	NMOD
28	survivors	survivor	I-NP	NNS	I-protein	26	PMOD
29	but	but	O	CC	O	16	VMOD
30	not	not	O	RB	O	16	VMOD
31	other	other	B-NP	JJ	O	32	NMOD
32	groups	group	I-NP	NNS	O	16	OBJ
33	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	8	NMOD
2	alpha3	alpha3	I-NP	NN	B-protein	8	NMOD
3	and	and	I-NP	CC	I-protein	8	NMOD
4	beta4	beta4	I-NP	NN	I-protein	8	NMOD
5	nicotinic	nicotinic	I-NP	JJ	I-protein	8	NMOD
6	acetylcholine	acetylcholine	I-NP	NN	I-protein	8	NMOD
7	receptor	receptor	I-NP	NN	I-protein	8	NMOD
8	subunits	subunit	I-NP	NNS	I-protein	9	SUB
9	are	be	B-VP	VBP	O	0	ROOT
10	necessary	necessary	B-ADJP	JJ	O	9	PRD
11	for	for	B-PP	IN	O	10	AMOD
12	nicotine	nicotine	B-NP	NN	O	14	NMOD
13	induced	induce	I-NP	VBN	O	14	NMOD
14	seizures	seizure	I-NP	NNS	O	11	PMOD
15	and	and	O	CC	O	9	VMOD
16	hypolocomotion	hypolocomotion	B-NP	NN	O	9	VMOD
17	in	in	B-PP	IN	O	16	NMOD
18	mice	mouse	B-NP	NNS	O	17	PMOD
19	.	.	O	.	O	9	P

1	Binding	Binding	B-NP	NN	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	nicotine	nicotine	B-NP	NN	O	2	PMOD
4	to	to	B-PP	TO	O	1	NMOD
5	nicotinic	nicotinic	B-NP	JJ	B-protein	7	NMOD
6	acetylcholine	acetylcholine	I-NP	NN	I-protein	7	NMOD
7	receptors	receptor	I-NP	NNS	I-protein	4	PMOD
8	(	(	O	(	O	10	DEP
9	nAChRs	nAChR	B-NP	NNS	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	elicits	elicit	B-VP	VBZ	O	0	ROOT
12	a	a	B-NP	DT	O	13	NMOD
13	series	series	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	dose-dependent	dose-dependent	B-NP	JJ	O	16	NMOD
16	behaviors	behavior	I-NP	NNS	O	14	PMOD
17	that	that	B-NP	WDT	O	16	NMOD
18	go	go	B-VP	VBP	O	17	SBAR
19	from	from	B-PP	IN	O	18	VMOD
20	altered	alter	B-NP	VBN	O	21	NMOD
21	exploration	exploration	I-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	sedation	sedation	B-NP	NN	O	26	NMOD
24	,	,	O	,	O	26	P
25	and	and	O	CC	O	26	NMOD
26	tremors	tremor	B-NP	NNS	O	19	PMOD
27	,	,	O	,	O	13	P
28	to	to	B-PP	TO	O	11	VMOD
29	seizures	seizure	B-NP	NNS	O	32	NMOD
30	and	and	I-NP	CC	O	32	NMOD
31	death.	death.	I-NP	NN	O	32	NMOD
32	nAChRs	nAChR	I-NP	NNS	O	28	PMOD
33	are	be	B-VP	VBP	O	11	VMOD
34	pentameric	pentameric	B-NP	JJ	O	36	NMOD
35	ion	ion	I-NP	NN	O	36	NMOD
36	channels	channel	I-NP	NNS	O	33	PRD
37	usually	usually	B-VP	RB	O	38	VMOD
38	composed	compose	I-VP	VBN	O	36	NMOD
39	of	of	B-PP	IN	O	38	VMOD
40	alpha	alpha	B-NP	NN	B-protein	43	NMOD
41	and	and	O	CC	I-protein	43	NMOD
42	beta	beta	B-NP	NN	I-protein	43	NMOD
43	subunits	subunit	I-NP	NNS	I-protein	39	PMOD
44	.	.	O	.	O	11	P

1	We	We	B-NP	PRP	O	2	SUB
2	examined	examine	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	role	role	I-NP	NN	O	14	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	beta4	beta4	I-NP	NN	B-protein	8	NMOD
8	subunits	subunit	I-NP	NNS	I-protein	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	nicotine	nicotine	B-NP	NN	O	12	NMOD
11	induced	induce	I-NP	VBN	O	12	NMOD
12	seizures	seizure	I-NP	NNS	O	9	PMOD
13	and	and	O	CC	O	14	NMOD
14	hypolocomotion	hypolocomotion	B-NP	NN	O	2	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	beta4	beta4	B-NP	NN	O	18	NMOD
17	homozygous	homozygous	I-NP	JJ	O	18	NMOD
18	null	null	I-NP	NN	O	24	NMOD
19	(	(	O	(	O	22	DEP
20	beta4	beta4	B-NP	NN	O	22	DEP
21	-/-	-/-	B-ADJP	JJ	O	20	NMOD
22	)	)	O	)	O	18	NMOD
23	and	and	O	CC	O	24	NMOD
24	alpha3	alpha3	B-NP	NN	O	32	NMOD
25	heterozygous	heterozygous	B-ADJP	JJ	O	24	NMOD
26	(	(	O	(	O	28	DEP
27	+/-	+/-	B-ADJP	JJ	O	28	DEP
28	)	)	O	)	O	25	AMOD
29	mice.	mice.	B-NP	NN	O	32	NMOD
30	beta4	beta4	I-NP	NN	O	32	NMOD
31	-/-	-/-	I-NP	JJ	O	32	NMOD
32	mice	mouse	I-NP	NNS	O	15	PMOD
33	were	be	B-VP	VBD	O	2	VMOD
34	less	less	B-ADJP	RBR	O	35	AMOD
35	sensitive	sensitive	I-ADJP	JJ	O	33	PRD
36	to	to	B-PP	TO	O	35	AMOD
37	the	the	B-NP	DT	O	38	NMOD
38	effects	effect	I-NP	NNS	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	nicotine	nicotine	B-NP	NN	O	39	PMOD
41	both	both	B-PP	CC	O	36	PMOD
42	at	at	B-PP	IN	O	35	AMOD
43	low	low	B-NP	JJ	O	44	NMOD
44	doses	dose	I-NP	NNS	O	42	PMOD
45	,	,	O	,	O	42	P
46	measured	measure	B-VP	VBN	O	42	PMOD
47	as	as	B-PP	IN	O	35	AMOD
48	decreased	decrease	B-NP	VBN	O	49	NMOD
49	exploration	exploration	I-NP	NN	O	47	PMOD
50	in	in	B-PP	IN	O	49	NMOD
51	an	an	B-NP	DT	O	53	NMOD
52	open	open	I-NP	JJ	O	53	NMOD
53	field	field	I-NP	NN	O	50	PMOD
54	,	,	B-PP	,	O	47	P
55	and	and	I-PP	CC	O	47	PMOD
56	at	at	B-PP	IN	O	47	PMOD
57	high	high	B-NP	JJ	O	58	NMOD
58	doses	dose	I-NP	NNS	O	56	PMOD
59	,	,	O	,	O	33	P
60	measured	measure	B-VP	VBN	O	33	VMOD
61	as	as	B-PP	IN	O	60	VMOD
62	sensitivity	sensitivity	B-NP	NN	O	61	PMOD
63	to	to	B-PP	TO	O	62	NMOD
64	nicotine	nicotine	B-NP	NN	O	66	NMOD
65	induced	induced	I-NP	JJ	O	66	NMOD
66	seizures	seizure	I-NP	NNS	O	63	PMOD
67	.	.	O	.	O	2	P

1	Using	Use	B-VP	VBG	O	14	VMOD
2	in	in	B-NP	FW	O	3	AMOD
3	situ	situ	I-NP	FW	O	5	NMOD
4	hybridization	hybridization	I-NP	NN	O	5	NMOD
5	probes	probe	I-NP	NNS	O	1	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	11	NMOD
8	alpha3	alpha3	I-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	alpha5	alpha5	I-NP	NN	B-protein	11	NMOD
11	subunits	subunit	I-NP	NNS	I-protein	6	PMOD
12	,	,	O	,	O	14	P
13	we	we	B-NP	PRP	O	14	SUB
14	showed	show	B-VP	VBD	O	0	ROOT
15	that	that	B-SBAR	IN	O	14	VMOD
16	alpha5	alpha5	B-NP	NN	B-RNA	18	NMOD
17	mRNA	mRNA	I-NP	NN	I-RNA	18	NMOD
18	levels	level	I-NP	NNS	O	19	SUB
19	are	be	B-VP	VBP	O	22	VMOD
20	unchanged	unchanged	B-ADJP	JJ	O	19	PRD
21	,	,	O	,	O	22	P
22	whereas	whereas	O	IN	O	15	SBAR
23	alpha3	alpha3	B-NP	NN	B-RNA	25	NMOD
24	mRNA	mRNA	I-NP	NN	I-RNA	25	NMOD
25	levels	level	I-NP	NNS	O	26	SUB
26	are	be	B-VP	VBP	O	53	VMOD
27	selectively	selectively	I-VP	RB	O	28	VMOD
28	decreased	decrease	I-VP	VBN	O	26	VC
29	in	in	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	33	NMOD
31	mitral	mitral	I-NP	JJ	O	33	NMOD
32	cell	cell	I-NP	NN	O	33	NMOD
33	layer	layer	I-NP	NN	O	29	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	37	NMOD
36	olfactory	olfactory	I-NP	JJ	O	37	NMOD
37	bulb	bulb	I-NP	NN	O	34	PMOD
38	,	,	O	,	O	41	P
39	and	and	O	CC	O	41	NMOD
40	the	the	B-NP	DT	O	41	NMOD
41	inferior	inferior	I-NP	JJ	O	28	VMOD
42	and	and	O	CC	O	53	VMOD
43	the	the	B-NP	DT	O	45	NMOD
44	superior	superior	I-NP	JJ	O	45	NMOD
45	colliculus	colliculus	I-NP	NN	O	53	SUB
46	of	of	B-PP	IN	O	45	NMOD
47	beta4	beta4	B-NP	NN	B-protein	52	NMOD
48	-/-	-/-	I-NP	JJ	O	52	NMOD
49	brains.	brains.	I-NP	NN	O	52	NMOD
50	alpha3	alpha3	I-NP	NN	O	52	NMOD
51	+/-	+/-	B-NP	SYM	O	52	NMOD
52	mice	mouse	I-NP	NNS	O	46	PMOD
53	were	be	B-VP	VBD	O	22	VMOD
54	partially	partially	B-ADJP	RB	O	55	AMOD
55	resistant	resistant	I-ADJP	JJ	O	53	PRD
56	to	to	B-PP	TO	O	55	AMOD
57	nicotine	nicotine	B-NP	NN	O	59	NMOD
58	induced	induced	I-NP	JJ	O	59	NMOD
59	seizures	seizure	I-NP	NNS	O	56	PMOD
60	when	when	B-ADVP	WRB	O	53	VMOD
61	compared	compare	B-VP	VBN	O	60	SBAR
62	to	to	B-PP	TO	O	61	VMOD
63	wild-type	wild-type	B-NP	JJ	B-RNA	66	NMOD
64	littermates.	littermates.	I-NP	NN	I-RNA	66	NMOD
65	mRNA	mRNA	I-NP	NN	I-RNA	66	NMOD
66	levels	level	I-NP	NNS	O	62	PMOD
67	for	for	B-PP	IN	O	66	NMOD
68	the	the	B-NP	DT	O	69	NMOD
69	alpha5	alpha5	I-NP	NN	B-protein	73	NMOD
70	and	and	O	CC	O	73	NMOD
71	the	the	B-NP	DT	O	73	NMOD
72	beta4	beta4	I-NP	NN	B-protein	73	NMOD
73	subunits	subunit	I-NP	NNS	I-protein	67	PMOD
74	were	be	B-VP	VBD	O	53	VMOD
75	unchanged	unchanged	B-ADJP	JJ	O	74	PRD
76	in	in	B-PP	IN	O	75	AMOD
77	alpha3	alpha3	B-NP	NN	O	79	NMOD
78	+/-	+/-	I-NP	SYM	O	79	NMOD
79	brains	brain	I-NP	NNS	O	76	PMOD
80	.	.	O	.	O	14	P

1	Recurrent	Recurrent	B-NP	JJ	O	4	NMOD
2	acute	acute	I-NP	JJ	O	4	NMOD
3	interstitial	interstitial	I-NP	JJ	O	4	NMOD
4	nephritis	nephritis	I-NP	NN	O	0	ROOT
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	azithromycin	azithromycin	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	14-year-old	14-year-old	I-NP	JJ	O	3	NMOD
3	girl	girl	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	reported	report	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	recurrent	recurrent	B-NP	JJ	O	10	VMOD
8	,	,	I-NP	,	O	10	P
9	azithromycin	azithromycin	I-NP	NN	O	10	SUB
10	induced	induce	B-VP	VBD	O	6	SBAR
11	,	,	O	,	O	10	P
12	acute	acute	B-NP	JJ	O	14	NMOD
13	interstitial	interstitial	I-NP	JJ	O	14	NMOD
14	nephritis	nephritis	I-NP	NN	O	10	OBJ
15	.	.	O	.	O	4	P

1	Valproate	Valproate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	encephalopathy	encephalopathy	B-NP	NN	O	2	OBJ
4	.	.	O	.	O	2	P

1	Valproate	Valproate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	encephalopathy	encephalopathy	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	2	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	rare	rare	I-NP	JJ	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	4	PRD
8	that	that	B-NP	WDT	O	7	NMOD
9	may	may	B-VP	MD	O	8	SBAR
10	manifest	manifest	I-VP	VB	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	otherwise	otherwise	B-NP	RB	O	13	AMOD
13	normal	normal	I-NP	JJ	O	15	NMOD
14	epileptic	epileptic	I-NP	JJ	O	15	NMOD
15	individuals	individual	I-NP	NNS	O	11	PMOD
16	.	.	O	.	O	2	P

1	Nitro-L-arginine	Nitro-L-arginine	B-NP	JJ	O	3	NMOD
2	methyl	methyl	I-NP	NN	O	3	NMOD
3	ester	ester	I-NP	NN	O	7	NMOD
4	:	:	O	:	O	3	P
5	a	a	B-NP	DT	O	7	NMOD
6	potential	potential	I-NP	JJ	O	7	NMOD
7	protector	protector	I-NP	NN	O	0	ROOT
8	against	against	B-PP	IN	O	7	NMOD
9	gentamicin	gentamicin	B-NP	NN	O	10	NMOD
10	ototoxicity	ototoxicity	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	3	NMOD
2	nitric	nitric	I-NP	JJ	O	3	NMOD
3	oxide	oxide	I-NP	NN	O	10	NMOD
4	(	(	O	(	O	6	DEP
5	NO	NO	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	inhibitor	inhibitor	B-NP	NN	O	10	NMOD
8	nitro-L-arginine	nitro-L-arginine	I-NP	NN	O	10	NMOD
9	methyl	methyl	I-NP	NN	O	10	NMOD
10	ester	ester	I-NP	NN	O	14	SUB
11	(	(	O	(	O	13	DEP
12	L-NAME	L-NAME	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	may	may	B-VP	MD	O	30	VMOD
15	act	act	I-VP	VB	O	14	VC
16	as	as	B-PP	IN	O	15	VMOD
17	an	an	B-NP	DT	O	18	NMOD
18	otoprotectant	otoprotectant	I-NP	NN	O	16	PMOD
19	against	against	B-PP	IN	O	18	NMOD
20	high-frequency	high-frequency	B-NP	NN	O	22	NMOD
21	hearing	hearing	I-NP	NN	O	22	NMOD
22	loss	loss	I-NP	NN	O	19	PMOD
23	caused	cause	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	gentamicin	gentamicin	B-NP	NN	O	24	PMOD
26	,	,	O	,	O	30	P
27	but	but	O	CC	O	30	VMOD
28	further	further	B-NP	JJ	O	29	NMOD
29	studies	study	I-NP	NNS	O	30	SUB
30	are	be	B-VP	VBP	O	0	ROOT
31	needed	need	I-VP	VBN	O	30	VC
32	to	to	B-VP	TO	O	33	VMOD
33	confirm	confirm	I-VP	VB	O	31	VMOD
34	this	this	B-NP	DT	O	33	OBJ
35	.	.	O	.	O	30	P

1	Their	Their	B-NP	PRP$	O	2	NMOD
2	ototoxicity	ototoxicity	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	21	VMOD
4	a	a	B-NP	DT	O	7	NMOD
5	serious	serious	I-NP	JJ	O	7	NMOD
6	health	health	I-NP	NN	O	7	NMOD
7	problem	problem	I-NP	NN	O	3	PRD
8	and	and	O	CC	O	3	VMOD
9	,	,	O	,	O	3	P
10	as	as	B-SBAR	IN	O	3	VMOD
11	their	their	B-NP	PRP$	O	13	NMOD
12	ototoxic	ototoxic	I-NP	JJ	O	13	NMOD
13	mechanism	mechanism	I-NP	NN	O	14	SUB
14	involves	involve	B-VP	VBZ	O	10	SBAR
15	the	the	B-NP	DT	O	16	NMOD
16	production	production	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	NO	NO	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	21	P
20	we	we	B-NP	PRP	O	21	SUB
21	need	need	B-VP	VBP	O	0	ROOT
22	to	to	I-VP	TO	O	23	VMOD
23	assess	assess	I-VP	VB	O	21	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	use	use	I-NP	NN	O	23	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	NO	NO	B-NP	NN	O	28	NMOD
28	inhibitors	inhibitor	I-NP	NNS	O	26	PMOD
29	for	for	B-PP	IN	O	25	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	prevention	prevention	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	aminoglycoside	aminoglycoside	B-NP	NN	O	32	PMOD
34	induced	induce	B-VP	VBD	O	21	VMOD
35	sensorineural	sensorineural	B-NP	JJ	O	37	NMOD
36	hearing	hearing	I-NP	NN	O	37	NMOD
37	loss	loss	I-NP	NN	O	34	OBJ
38	.	.	O	.	O	21	P

1	Cerebral	Cerebral	B-NP	JJ	O	2	NMOD
2	vasculitis	vasculitis	I-NP	NN	O	13	NMOD
3	following	follow	B-PP	VBG	O	2	NMOD
4	oral	oral	B-NP	JJ	O	6	NMOD
5	methylphenidate	methylphenidate	I-NP	NN	O	6	NMOD
6	intake	intake	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	an	an	B-NP	DT	O	9	NMOD
9	adult	adult	I-NP	NN	O	7	PMOD
10	:	:	O	:	O	2	P
11	a	a	B-NP	DT	O	13	NMOD
12	case	case	I-NP	NN	O	13	NMOD
13	report	report	I-NP	NN	O	0	ROOT
14	.	.	O	.	O	13	P

1	Cerebral	Cerebral	B-NP	JJ	O	2	NMOD
2	vasculitis	vasculitis	I-NP	NN	O	7	SUB
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	amphetamine	amphetamine	B-NP	NN	O	6	NMOD
6	abuse	abuse	I-NP	NN	O	4	PMOD
7	is	be	B-VP	VBZ	O	17	VMOD
8	well	well	I-VP	RB	O	7	VMOD
9	documented	document	I-VP	VBN	O	7	VC
10	,	,	O	,	O	17	P
11	and	and	O	CC	O	17	VMOD
12	in	in	B-PP	IN	O	17	VMOD
13	rare	rare	B-NP	JJ	O	14	NMOD
14	cases	case	I-NP	NNS	O	12	PMOD
15	ischaemic	ischaemic	B-NP	JJ	O	16	NMOD
16	stroke	stroke	I-NP	NN	O	17	SUB
17	has	have	B-VP	VBZ	O	0	ROOT
18	been	be	I-VP	VBN	O	17	VC
19	reported	report	I-VP	VBN	O	18	VC
20	after	after	B-PP	IN	O	19	VMOD
21	methylphenidate	methylphenidate	B-NP	NN	O	22	NMOD
22	intake	intake	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	children	child	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	17	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	63-year-old	63-year-old	I-NP	JJ	O	8	NMOD
8	female	female	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	was	be	B-VP	VBD	O	9	SBAR
11	treated	treat	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	methylphenidate	methylphenidate	B-NP	NN	O	12	PMOD
14	due	due	B-ADJP	JJ	O	13	NMOD
15	to	to	B-PP	TO	O	14	AMOD
16	hyperactivity	hyperactivity	B-NP	NN	O	15	PMOD
17	and	and	O	CC	O	2	VMOD
18	suffered	suffer	B-VP	VBD	O	2	VMOD
19	from	from	B-PP	IN	O	18	VMOD
20	multiple	multiple	B-NP	JJ	O	22	NMOD
21	ischaemic	ischaemic	I-NP	JJ	O	22	NMOD
22	strokes	stroke	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	methylphenidate	methylphenidate	B-NP	NN	O	6	NMOD
5	mediated	mediate	I-NP	VBN	O	6	NMOD
6	vasculitis	vasculitis	I-NP	NN	O	7	SUB
7	should	should	B-VP	MD	O	3	SBAR
8	be	be	I-VP	VB	O	7	VC
9	considered	consider	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	neurological	neurological	B-NP	JJ	O	14	NMOD
14	symptoms	symptom	I-NP	NNS	O	12	PMOD
15	and	and	O	CC	O	7	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	history	history	I-NP	NN	O	15	PRD
18	of	of	B-PP	IN	O	17	NMOD
19	methylphenidate	methylphenidate	B-NP	NN	O	20	NMOD
20	therapy	therapy	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	Cerebral	Cerebral	B-NP	JJ	O	2	NMOD
2	haemorrhage	haemorrhage	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	warfarin	warfarin	B-NP	NN	O	8	NMOD
6	-	-	O	HYPH	O	8	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	influence	influence	I-NP	NN	O	4	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	drug-drug	drug-drug	B-NP	JJ	O	11	NMOD
11	interactions	interaction	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	2	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	10	NMOD
6	frequency	frequency	I-NP	NN	O	10	NMOD
7	,	,	I-NP	,	O	10	P
8	severity	severity	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	preventability	preventability	I-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	warfarin	warfarin	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	4	VMOD
14	cerebral	cerebral	B-NP	JJ	O	15	NMOD
15	haemorrhages	haemorrhage	I-NP	NNS	O	13	OBJ
16	due	due	B-ADJP	JJ	O	15	NMOD
17	to	to	B-PP	TO	O	16	AMOD
18	warfarin	warfarin	B-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	warfarin-drug	warfarin-drug	I-NP	NN	O	21	NMOD
21	interactions	interaction	I-NP	NNS	O	17	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	patients	patient	B-NP	NNS	O	22	PMOD
24	living	live	B-VP	VBG	O	23	NMOD
25	in	in	B-PP	IN	O	24	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	county	county	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	Osterg	Osterg	B-NP	NNP	O	30	NMOD
30	tland	tland	I-NP	NNP	O	32	NMOD
31	,	,	O	,	O	32	P
32	Sweden	Sweden	B-NP	NNP	O	28	PMOD
33	.	.	O	.	O	4	P

1	Medical	Medical	B-NP	JJ	O	2	NMOD
2	records	record	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	studied	study	I-VP	VBN	O	3	VC
5	retrospectively	retrospectively	B-ADVP	RB	O	4	VMOD
6	to	to	B-VP	TO	O	7	VMOD
7	evaluate	evaluate	I-VP	VB	O	4	VMOD
8	whether	whether	B-SBAR	IN	O	7	VMOD
9	warfarin	warfarin	B-NP	NN	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	warfarin-drug	warfarin-drug	I-NP	NN	O	12	NMOD
12	interactions	interaction	I-NP	NNS	O	13	SUB
13	could	could	B-VP	MD	O	8	SBAR
14	have	have	I-VP	VB	O	13	VC
15	caused	cause	I-VP	VBN	O	14	VC
16	the	the	B-NP	DT	O	18	NMOD
17	cerebral	cerebral	I-NP	JJ	O	18	NMOD
18	haemorrhage	haemorrhage	I-NP	NN	O	15	OBJ
19	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Among	Among	B-PP	IN	O	1	NMOD
4	593	593	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	15	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	cerebral	cerebral	B-NP	JJ	O	8	NMOD
8	haemorrhage	haemorrhage	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	15	P
10	59	59	B-NP	CD	O	15	SUB
11	(	(	O	(	O	14	DEP
12	10	10	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	were	be	B-VP	VBD	O	3	SBAR
16	assessed	assess	I-VP	VBN	O	15	VC
17	as	as	B-SBAR	IN	O	16	VMOD
18	related	relate	B-VP	VBN	O	17	SBAR
19	to	to	B-PP	TO	O	18	VMOD
20	warfarin	warfarin	B-NP	NN	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	3	NMOD
2	warfarin-drug	warfarin-drug	I-NP	JJ	O	3	NMOD
3	interaction	interaction	I-NP	NN	O	4	SUB
4	could	could	B-VP	MD	O	0	ROOT
5	have	have	I-VP	VB	O	4	VC
6	contributed	contribute	I-VP	VBN	O	5	VC
7	to	to	B-PP	TO	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	haemorrhage	haemorrhage	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	6	VMOD
11	24	24	B-NP	CD	O	10	PMOD
12	(	(	O	(	O	15	DEP
13	41	41	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	15	DEP
15	)	)	O	)	O	11	NMOD
16	of	of	B-PP	IN	O	11	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	warfarin	warfarin	I-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	16	PMOD
20	and	and	O	CC	O	10	PMOD
21	in	in	B-PP	IN	O	10	PMOD
22	7	7	B-NP	CD	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	these	these	B-NP	DT	O	31	NMOD
25	(	(	O	(	O	28	DEP
26	12	12	B-NP	CD	O	27	NMOD
27	%	%	I-NP	NN	O	28	DEP
28	)	)	O	)	O	31	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	bleeding	bleed	I-NP	VBG	O	31	NMOD
31	complication	complication	I-NP	NN	O	23	PMOD
32	was	be	B-VP	VBD	O	4	VMOD
33	considered	consider	I-VP	VBN	O	32	VC
34	being	be	B-VP	VBG	O	33	VMOD
35	possible	possible	B-ADJP	JJ	O	34	PRD
36	to	to	B-VP	TO	O	37	VMOD
37	avoid	avoid	I-VP	VB	O	34	VMOD
38	.	.	O	.	O	4	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Warfarin	Warfarin	B-NP	NN	O	6	NMOD
4	induced	induce	B-VP	VBD	O	6	NMOD
5	cerebral	cerebral	B-NP	JJ	O	6	NMOD
6	haemorrhages	haemorrhage	I-NP	NNS	O	7	SUB
7	are	be	B-VP	VBP	O	1	NMOD
8	a	a	B-NP	DT	O	11	NMOD
9	major	major	I-NP	JJ	O	11	NMOD
10	clinical	clinical	I-NP	JJ	O	11	NMOD
11	problem	problem	I-NP	NN	O	7	PRD
12	with	with	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	16	NMOD
14	high	high	I-NP	JJ	O	16	NMOD
15	fatality	fatality	I-NP	NN	O	16	NMOD
16	rate	rate	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	1	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	postoperative	postoperative	B-NP	JJ	O	11	NMOD
9	emetic	emetic	I-NP	JJ	O	11	NMOD
10	side	side	I-NP	NN	O	11	NMOD
11	effects	effect	I-NP	NNS	O	7	PMOD
12	after	after	B-SBAR	IN	O	4	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	administration	administration	I-NP	NN	O	18	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	methylprednisolone	methylprednisolone	B-NP	NN	O	15	PMOD
17	and	and	I-NP	CC	O	18	NMOD
18	gentamicin	gentamicin	I-NP	NN	O	12	PMOD
19	into	into	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	23	NMOD
21	posterior	posterior	I-NP	JJ	O	23	NMOD
22	sub-Tenon	sub-Tenon	I-NP	NN	O	23	NMOD
23	's	's	B-NP	POS	O	24	NMOD
24	space	space	I-NP	NN	O	19	PMOD
25	at	at	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	end	end	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	routine	routine	B-NP	JJ	O	31	NMOD
30	cataract	cataract	I-NP	NN	O	31	NMOD
31	surgery	surgery	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	4	P

1	METHODS	METHODS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	The	The	B-NP	DT	O	7	NMOD
6	present	present	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	8	SUB
8	is	be	B-VP	VBZ	O	3	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	multicenter	multicenter	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	10	P
12	randomized	randomize	B-NP	VBN	O	10	AMOD
13	,	,	I-NP	,	O	15	P
14	double-blind	double-blind	I-NP	JJ	O	15	NMOD
15	comparison	comparison	I-NP	NN	O	8	PRD
16	of	of	B-PP	IN	O	15	NMOD
17	iopamidol	iopamidol	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	iodixanol	iodixanol	I-NP	NN	O	16	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	patients	patient	B-NP	NNS	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	chronic	chronic	B-NP	JJ	O	25	NMOD
24	kidney	kidney	I-NP	NN	O	25	NMOD
25	disease	disease	I-NP	NN	O	22	PMOD
26	(	(	O	(	O	36	DEP
27	estimated	estimate	B-NP	VBN	O	30	NMOD
28	glomerular	glomerular	I-NP	JJ	O	30	NMOD
29	filtration	filtration	I-NP	NN	O	30	NMOD
30	rate	rate	I-NP	NN	O	35	NMOD
31	,	,	O	,	O	35	P
32	20	20	B-NP	CD	O	34	AMOD
33	to	to	I-NP	TO	O	34	AMOD
34	59	59	I-NP	CD	O	35	NMOD
35	mL/min	mL/min	I-NP	NN	O	36	DEP
36	)	)	O	)	O	25	NMOD
37	who	who	B-NP	WP	O	21	NMOD
38	underwent	undergo	B-VP	VBD	O	37	SBAR
39	cardiac	cardiac	B-NP	JJ	O	40	NMOD
40	angiography	angiography	I-NP	NN	O	44	NMOD
41	or	or	O	CC	O	44	NMOD
42	percutaneous	percutaneous	B-NP	JJ	O	44	NMOD
43	coronary	coronary	I-NP	JJ	O	44	NMOD
44	interventions	intervention	I-NP	NNS	O	38	OBJ
45	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	26	VMOD
2	414	414	B-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	26	P
5	contrast	contrast	B-NP	NN	O	6	NMOD
6	volume	volume	I-NP	NN	O	8	NMOD
7	,	,	O	,	O	8	P
8	presence	presence	B-NP	NN	O	25	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	diabetes	diabetes	B-NP	NN	O	11	NMOD
11	mellitus	mellitus	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	25	P
13	use	use	B-NP	NN	O	25	NMOD
14	of	of	B-PP	IN	O	13	NMOD
15	N-acetylcysteine	N-acetylcysteine	B-NP	NN	O	14	PMOD
16	,	,	O	,	O	25	P
17	mean	mean	B-NP	JJ	O	19	NMOD
18	baseline	baseline	I-NP	NN	O	19	NMOD
19	SCr	SCr	I-NP	NN	O	25	NMOD
20	,	,	O	,	O	25	P
21	and	and	O	CC	O	25	NMOD
22	estimated	estimate	B-NP	VBN	O	25	NMOD
23	glomerular	glomerular	I-NP	JJ	O	25	NMOD
24	filtration	filtration	I-NP	NN	O	25	NMOD
25	rate	rate	I-NP	NN	O	26	SUB
26	were	be	B-VP	VBD	O	0	ROOT
27	comparable	comparable	B-ADJP	JJ	O	26	PRD
28	in	in	B-PP	IN	O	27	AMOD
29	the	the	B-NP	DT	O	31	NMOD
30	2	2	I-NP	CD	O	31	NMOD
31	groups	group	I-NP	NNS	O	28	PMOD
32	.	.	O	.	O	26	P

1	In	In	B-PP	IN	O	13	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	diabetes	diabetes	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	13	P
6	SCr	SCr	B-NP	NN	B-protein	7	SUB
7	increases	increase	B-VP	VBZ	O	13	VMOD
8	>	>	B-NP	SYM	O	12	NMOD
9	or	or	O	CC	O	10	AMOD
10	=	=	B-VP	SYM	O	12	NMOD
11	0.5	0.5	B-NP	CD	O	12	NMOD
12	mg/dL	mg/dL	I-NP	NN	O	7	OBJ
13	were	be	B-VP	VBD	O	0	ROOT
14	5.1	5.1	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	13	PRD
16	(	(	O	(	O	21	DEP
17	4	4	B-NP	CD	O	21	DEP
18	of	of	B-PP	IN	O	17	NMOD
19	78	78	B-NP	CD	O	20	NMOD
20	patients	patient	I-NP	NNS	O	18	PMOD
21	)	)	O	)	O	15	NMOD
22	with	with	B-PP	IN	O	15	NMOD
23	iopamidol	iopamidol	B-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	13.0	13.0	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	22	PMOD
27	(	(	O	(	O	32	DEP
28	12	12	B-NP	CD	O	32	DEP
29	of	of	B-PP	IN	O	28	NMOD
30	92	92	B-NP	CD	O	31	NMOD
31	patients	patient	I-NP	NNS	O	29	PMOD
32	)	)	O	)	O	26	NMOD
33	with	with	B-PP	IN	O	26	NMOD
34	iodixanol	iodixanol	B-NP	NN	O	33	PMOD
35	(	(	O	(	O	37	DEP
36	P=0.11	P=0.11	B-NP	NN	O	37	DEP
37	)	)	O	)	O	34	NMOD
38	,	,	O	,	O	13	P
39	whereas	whereas	O	IN	O	13	VMOD
40	SCr	SCr	B-NP	NN	B-protein	41	SUB
41	increases	increase	B-VP	VBZ	O	39	SBAR
42	>	>	B-NP	SYM	O	44	AMOD
43	or	or	O	CC	O	44	AMOD
44	=	=	B-VP	SYM	O	41	OBJ
45	25	25	B-NP	CD	O	46	NMOD
46	%	%	I-NP	NN	O	44	AMOD
47	were	be	B-VP	VBD	O	41	VMOD
48	10.3	10.3	B-NP	CD	O	49	NMOD
49	%	%	I-NP	NN	O	47	PRD
50	and	and	O	CC	O	47	VMOD
51	15.2	15.2	B-NP	CD	O	52	NMOD
52	%	%	I-NP	NN	O	50	AMOD
53	,	,	O	,	O	52	P
54	respectively	respectively	B-ADVP	RB	O	52	NMOD
55	(	(	O	(	O	57	DEP
56	P=0.37	P=0.37	B-NP	NN	O	57	DEP
57	)	)	O	)	O	54	AMOD
58	.	.	O	.	O	13	P

1	Mean	Mean	B-NP	JJ	O	3	NMOD
2	post-SCr	post-SCr	I-NP	JJ	O	3	NMOD
3	increases	increase	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	significantly	significantly	B-ADJP	RB	O	6	AMOD
6	less	less	I-ADJP	JJR	O	4	PRD
7	with	with	B-PP	IN	O	6	AMOD
8	iopamidol	iopamidol	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	40	DEP
10	all	all	B-NP	DT	O	11	NMOD
11	patients	patient	I-NP	NNS	O	23	NMOD
12	:	:	O	:	O	23	P
13	0.07	0.07	B-NP	CD	O	16	NMOD
14	versus	versus	I-NP	IN	O	16	NMOD
15	0.12	0.12	I-NP	CD	O	16	NMOD
16	mg/dL	mg/dL	I-NP	NN	O	21	NMOD
17	,	,	O	,	O	21	P
18	6.2	6.2	B-NP	CD	O	21	NMOD
19	versus	versus	I-NP	IN	O	21	NMOD
20	10.6	10.6	I-NP	CD	O	21	NMOD
21	micromol/L	micromol/L	I-NP	NN	O	23	NMOD
22	,	,	O	,	O	23	P
23	P=0.03	P=0.03	B-NP	NN	O	39	NMOD
24	;	;	O	:	O	39	P
25	patients	patient	B-NP	NNS	O	39	NMOD
26	with	with	B-PP	IN	O	25	NMOD
27	diabetes	diabete	B-NP	NNS	O	26	PMOD
28	:	:	O	:	O	39	P
29	0.07	0.07	B-NP	CD	O	32	NMOD
30	versus	versus	I-NP	IN	O	32	NMOD
31	0.16	0.16	I-NP	CD	O	32	NMOD
32	mg/dL	mg/dL	I-NP	NN	O	39	NMOD
33	,	,	O	,	O	39	P
34	6.2	6.2	B-NP	CD	O	37	NMOD
35	versus	versus	I-NP	IN	O	37	NMOD
36	14.1	14.1	I-NP	CD	O	37	NMOD
37	micromol/L	micromol/L	I-NP	NN	O	39	NMOD
38	,	,	O	,	O	39	P
39	P=0.01	P=0.01	B-NP	NN	O	40	DEP
40	)	)	O	)	O	8	NMOD
41	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	novel	novel	I-NP	JJ	O	3	NMOD
3	compound	compound	I-NP	NN	O	6	NMOD
4	,	,	O	,	O	6	P
5	maltolyl	maltolyl	B-NP	NN	O	6	NMOD
6	p-coumarate	p-coumarate	I-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	attenuates	attenuate	B-VP	VBZ	O	0	ROOT
9	cognitive	cognitive	B-NP	JJ	O	10	NMOD
10	deficits	deficit	I-NP	NNS	O	8	OBJ
11	and	and	O	CC	O	8	VMOD
12	shows	show	B-VP	VBZ	O	8	VMOD
13	neuroprotective	neuroprotective	B-NP	JJ	O	14	NMOD
14	effects	effect	I-NP	NNS	O	12	OBJ
15	in	in	B-ADVP	FW	O	12	VMOD
16	vitro	vitro	I-ADVP	FW	O	15	AMOD
17	and	and	O	CC	O	15	AMOD
18	in	in	B-NP	FW	O	19	AMOD
19	vivo	vivo	I-NP	FW	O	21	NMOD
20	dementia	dementia	I-NP	NN	O	21	NMOD
21	models	model	I-NP	NNS	O	15	AMOD
22	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	we	we	B-NP	PRP	O	7	SUB
7	investigated	investigate	B-VP	VBD	O	0	ROOT
8	whether	whether	B-SBAR	IN	O	7	VMOD
9	maltolyl	maltolyl	B-NP	NN	O	11	SUB
10	p-coumarate	p-coumarate	B-NP	JJ	O	9	NMOD
11	could	could	B-VP	MD	O	8	SBAR
12	improve	improve	I-VP	VB	O	11	VC
13	cognitive	cognitive	B-NP	JJ	O	14	NMOD
14	decline	decline	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	scopolamine-injected	scopolamine-injected	B-NP	JJ	O	17	NMOD
17	rats	rat	I-NP	NNS	O	15	PMOD
18	and	and	B-PP	CC	O	15	PMOD
19	in	in	B-PP	IN	O	15	PMOD
20	amyloid	amyloid	B-NP	JJ	O	22	NMOD
21	beta	beta	I-NP	SYM	O	22	NMOD
22	peptide	peptide	I-NP	NN	O	27	NMOD
23	(	(	O	(	O	27	NMOD
24	1-42	1-42	B-NP	CD	O	27	NMOD
25	)	)	O	)	O	27	NMOD
26	-infused	-infused	B-NP	JJ	O	27	NMOD
27	rats	rat	I-NP	NNS	O	19	PMOD
28	.	.	O	.	O	7	P

1	Maltolyl	Maltolyl	B-NP	JJ	O	2	NMOD
2	p-coumarate	p-coumarate	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	found	find	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	attenuate	attenuate	I-VP	VB	O	4	VMOD
7	cognitive	cognitive	B-NP	JJ	O	8	NMOD
8	deficits	deficit	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	both	both	B-NP	DT	O	12	NMOD
11	rat	rat	I-NP	NN	O	12	NMOD
12	models	model	I-NP	NNS	O	9	PMOD
13	using	use	B-VP	VBG	O	6	VMOD
14	passive	passive	B-NP	JJ	O	16	NMOD
15	avoidance	avoidance	I-NP	NN	O	16	NMOD
16	test	test	I-NP	NN	O	13	OBJ
17	and	and	O	CC	O	6	VMOD
18	to	to	B-VP	TO	O	19	VMOD
19	reduce	reduce	I-VP	VB	O	6	VMOD
20	apoptotic	apoptotic	B-NP	JJ	O	22	NMOD
21	cell	cell	I-NP	NN	O	22	NMOD
22	death	death	I-NP	NN	O	19	OBJ
23	observed	observe	B-VP	VBN	O	22	NMOD
24	in	in	B-PP	IN	O	23	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	hippocampus	hippocampus	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	31	NMOD
29	amyloid	amyloid	I-NP	JJ	O	31	NMOD
30	beta	beta	I-NP	NN	O	31	NMOD
31	peptide	peptide	I-NP	NN	O	36	NMOD
32	(	(	O	(	O	36	NMOD
33	1-42	1-42	B-NP	CD	O	36	NMOD
34	)	)	O	)	O	36	NMOD
35	-infused	-infused	B-NP	JJ	O	36	NMOD
36	rats	rat	I-NP	NNS	O	27	PMOD
37	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	3	3	B-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	serious	serious	B-NP	JJ	O	8	NMOD
7	bleeding	bleed	I-NP	VBG	O	8	NMOD
8	complications	complication	I-NP	NNS	O	5	PMOD
9	that	that	B-NP	WDT	O	8	NMOD
10	appear	appear	B-VP	VBP	O	9	SBAR
11	to	to	I-VP	TO	O	12	VMOD
12	be	be	I-VP	VB	O	10	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	result	result	I-NP	NN	O	12	PRD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	interaction	interaction	I-NP	NN	O	15	PMOD
18	between	between	B-PP	IN	O	17	NMOD
19	warfarin	warfarin	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	levofloxacin	levofloxacin	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	2	P

1	Mutations	Mutation	B-NP	NNS	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	lamivudine-resistance	lamivudine-resistance	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	therapy-na	therapy-na	B-NP	JJ	O	10	NMOD
7	ve	ve	I-NP	NN	O	10	NMOD
8	hepatitis	hepatitis	I-NP	NN	O	10	NMOD
9	B	B	I-NP	NN	O	10	NMOD
10	virus	virus	I-NP	NN	O	5	PMOD
11	(	(	O	(	O	10	NMOD
12	HBV	HBV	B-NP	NN	O	15	NMOD
13	)	)	O	)	O	15	NMOD
14	infected	infected	B-NP	JJ	O	15	NMOD
15	patients	patient	I-NP	NNS	O	22	NMOD
16	with	with	B-PP	IN	O	15	NMOD
17	and	and	I-PP	CC	O	16	PMOD
18	without	without	I-PP	IN	O	16	PMOD
19	HIV	HIV	B-NP	NN	O	20	NMOD
20	co-infection	co-infection	I-NP	NN	O	16	PMOD
21	:	:	O	:	O	15	P
22	implications	implication	B-NP	NNS	O	11	PMOD
23	for	for	B-PP	IN	O	22	NMOD
24	antiretroviral	antiretroviral	B-NP	JJ	O	25	NMOD
25	therapy	therapy	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	HBV	HBV	B-NP	NN	O	33	NMOD
28	and	and	O	CC	O	33	NMOD
29	HIV	HIV	B-NP	NN	O	33	NMOD
30	co-infected	co-infected	I-NP	JJ	O	32	AMOD
31	South	South	I-NP	JJ	O	32	AMOD
32	African	African	I-NP	JJ	O	33	NMOD
33	patients	patient	I-NP	NNS	O	26	PMOD
34	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	exploratory	exploratory	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	2	PRD
6	to	to	B-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	5	NMOD
8	lamivudine-resistant	lamivudine-resistant	B-NP	JJ	O	11	NMOD
9	hepatitis	hepatitis	I-NP	NN	O	11	NMOD
10	B	B	I-NP	NN	O	11	NMOD
11	virus	virus	I-NP	NN	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	HBV	HBV	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	strains	strain	B-NP	NNS	O	7	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	selected	select	B-NP	VBN	O	21	NMOD
18	lamivudine-na	lamivudine-na	I-NP	JJ	O	21	NMOD
19	ve	ve	I-NP	NN	O	21	NMOD
20	HBV	HBV	I-NP	NN	O	21	NMOD
21	carriers	carrier	I-NP	NNS	O	16	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	and	and	O	CC	O	22	PMOD
24	without	without	B-PP	IN	O	22	PMOD
25	human	human	B-NP	JJ	O	27	NMOD
26	immunodeficiency	immunodeficiency	I-NP	NN	O	27	NMOD
27	virus	virus	I-NP	NN	O	31	NMOD
28	(	(	O	(	O	30	DEP
29	HIV	HIV	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	co-infection	co-infection	B-NP	NN	O	22	PMOD
32	in	in	B-PP	IN	O	31	NMOD
33	South	South	B-NP	JJ	O	35	NMOD
34	African	African	I-NP	JJ	O	35	NMOD
35	patients	patient	I-NP	NNS	O	32	PMOD
36	.	.	O	.	O	2	P

1	Thirty-five	Thirty-five	B-NP	CD	O	4	NMOD
2	lamivudine-na	lamivudine-na	I-NP	JJ	O	4	NMOD
3	ve	ve	I-NP	NN	O	4	NMOD
4	HBV	HBV	I-NP	NN	O	6	NMOD
5	infected	infected	B-NP	JJ	O	6	NMOD
6	patients	patient	I-NP	NNS	O	12	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	or	or	B-PP	CC	O	7	PMOD
9	without	without	B-PP	IN	O	7	PMOD
10	HIV	HIV	B-NP	NN	O	11	NMOD
11	co-infection	co-infection	I-NP	NN	O	7	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	studied	study	I-VP	VBN	O	24	NMOD
14	:	:	O	:	O	24	P
15	15	15	B-NP	CD	O	19	NMOD
16	chronic	chronic	I-NP	JJ	O	19	NMOD
17	HBV	HBV	I-NP	NN	O	19	NMOD
18	mono-infected	mono-infected	B-NP	JJ	O	19	NMOD
19	patients	patient	I-NP	NNS	O	24	NMOD
20	and	and	O	CC	O	24	NMOD
21	20	20	B-NP	CD	O	24	NMOD
22	HBV-HIV	HBV-HIV	I-NP	NN	O	24	NMOD
23	co-infected	co-infected	B-NP	JJ	O	24	NMOD
24	patients	patient	I-NP	NNS	O	12	PRD
25	.	.	O	.	O	12	P

1	HBV	HBV	B-NP	NN	O	3	NMOD
2	lamivudine-resistant	lamivudine-resistant	I-NP	JJ	O	3	NMOD
3	strains	strain	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	detected	detect	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	3	3	B-NP	CD	O	8	AMOD
8	of	of	B-PP	IN	O	6	PMOD
9	15	15	B-NP	CD	O	14	NMOD
10	mono-infected	mono-infected	I-NP	JJ	O	14	NMOD
11	chronic	chronic	I-NP	JJ	O	14	NMOD
12	hepatitis	hepatitis	I-NP	NN	O	14	NMOD
13	B	B	I-NP	NN	O	14	NMOD
14	patients	patient	I-NP	NNS	O	21	NMOD
15	and	and	O	CC	O	21	NMOD
16	10	10	B-NP	CD	O	17	AMOD
17	of	of	I-NP	IN	O	19	NMOD
18	20	20	I-NP	CD	O	17	AMOD
19	HBV-HIV	HBV-HIV	I-NP	NN	O	21	NMOD
20	co-infected	co-infected	I-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	8	PMOD
22	.	.	O	.	O	4	P

1	To	To	B-PP	TO	O	9	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	best	good	I-NP	JJS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	our	our	B-NP	PRP$	O	6	NMOD
6	knowledge	knowledge	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	9	P
8	this	this	B-NP	DT	O	9	SUB
9	constitutes	constitute	B-VP	VBZ	O	0	ROOT
10	the	the	B-NP	DT	O	12	NMOD
11	first	first	I-NP	JJ	O	12	NMOD
12	report	report	I-NP	NN	O	9	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	HBV	HBV	B-NP	NN	B-protein	16	NMOD
15	lamivudine-resistant	lamivudine-resistant	I-NP	JJ	I-protein	16	NMOD
16	strains	strain	I-NP	NNS	I-protein	13	PMOD
17	in	in	B-PP	IN	O	12	NMOD
18	therapy-na	therapy-na	B-NP	JJ	O	22	NMOD
19	ve	ve	I-NP	NN	O	22	NMOD
20	HBV-HIV	HBV-HIV	I-NP	NN	O	22	NMOD
21	co-infected	co-infected	B-NP	JJ	O	22	NMOD
22	patients	patient	I-NP	NNS	O	17	PMOD
23	.	.	O	.	O	9	P

1	Sex	Sex	B-NP	NN	O	2	NMOD
2	differences	difference	I-NP	NNS	O	18	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	NMDA	NMDA	B-NP	NN	O	6	NMOD
5	antagonist	antagonist	I-NP	NN	O	6	NMOD
6	enhancement	enhancement	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	morphine	morphine	B-NP	NN	O	9	NMOD
9	antihyperalgesia	antihyperalgesia	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	2	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	capsaicin	capsaicin	I-NP	NN	O	13	NMOD
13	model	model	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	persistent	persistent	B-NP	JJ	O	16	NMOD
16	pain	pain	I-NP	NN	O	14	PMOD
17	:	:	O	:	O	2	P
18	comparisons	comparison	B-NP	NNS	O	0	ROOT
19	to	to	B-PP	TO	O	18	NMOD
20	two	two	B-NP	CD	O	21	NMOD
21	models	model	I-NP	NNS	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	acute	acute	B-NP	JJ	O	24	NMOD
24	pain	pain	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	18	P

1	In	In	B-PP	IN	O	11	VMOD
2	acute	acute	B-NP	JJ	O	4	NMOD
3	pain	pain	I-NP	NN	O	4	NMOD
4	models	model	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	11	P
6	N-methyl-D-aspartate	N-methyl-D-aspartate	B-NP	NN	O	10	NMOD
7	(	(	O	(	O	9	DEP
8	NMDA	NMDA	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	antagonists	antagonist	B-NP	NNS	O	11	SUB
11	enhance	enhance	B-VP	VBP	O	0	ROOT
12	the	the	B-NP	DT	O	14	NMOD
13	antinociceptive	antinociceptive	I-NP	JJ	O	14	NMOD
14	effects	effect	I-NP	NNS	O	11	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	morphine	morphine	B-NP	NN	O	15	PMOD
17	to	to	B-PP	TO	O	11	VMOD
18	a	a	B-NP	DT	O	20	NMOD
19	greater	great	I-NP	JJR	O	20	NMOD
20	extent	extent	I-NP	NN	O	17	PMOD
21	in	in	B-PP	IN	O	11	VMOD
22	males	male	B-NP	NNS	O	21	PMOD
23	than	than	B-PP	IN	O	22	NMOD
24	females	female	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	11	P

1	To	To	B-PP	TO	O	7	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	end	end	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	persistent	persistent	B-NP	JJ	O	6	NMOD
6	hyperalgesia	hyperalgesia	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	induced	induce	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	administration	administration	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	capsaicin	capsaicin	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	8	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	tail	tail	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	gonadally	gonadally	B-NP	RB	O	18	AMOD
18	intact	intact	I-NP	JJ	O	20	NMOD
19	F344	F344	I-NP	NN	O	20	NMOD
20	rats	rat	I-NP	NNS	O	16	PMOD
21	,	,	O	,	O	8	P
22	following	follow	B-PP	VBG	O	8	VMOD
23	which	which	B-NP	WDT	O	22	PMOD
24	the	the	B-NP	DT	O	25	NMOD
25	tail	tail	I-NP	NN	O	26	SUB
26	was	be	B-VP	VBD	O	37	NMOD
27	immersed	immerse	I-VP	VBN	O	26	VC
28	in	in	B-PP	IN	O	27	VMOD
29	a	a	B-NP	DT	O	33	NMOD
30	mildly	mildly	I-NP	RB	O	31	AMOD
31	noxious	noxious	I-NP	JJ	O	33	NMOD
32	thermal	thermal	I-NP	JJ	O	33	NMOD
33	stimulus	stimulus	I-NP	NN	O	28	PMOD
34	,	,	O	,	O	37	P
35	and	and	O	CC	O	37	NMOD
36	tail-withdrawal	tail-withdrawal	B-NP	JJ	O	37	NMOD
37	latencies	latency	I-NP	NNS	O	22	PMOD
38	measured	measure	B-VP	VBN	O	37	NMOD
39	.	.	O	.	O	7	P

1	Enhancement	Enhancement	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	morphine	morphine	B-NP	NN	O	4	NMOD
4	antinociception	antinociception	I-NP	NN	O	2	PMOD
5	by	by	B-PP	IN	O	1	NMOD
6	dextromethorphan	dextromethorphan	B-NP	NN	O	5	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	seen	see	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	both	both	B-NP	CC	O	13	NMOD
11	males	male	I-NP	NNS	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	females	female	I-NP	NNS	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	18	NMOD
16	acute	acute	I-NP	JJ	B-cell_type	18	NMOD
17	pain	pain	I-NP	NN	I-cell_type	18	NMOD
18	models	model	I-NP	NNS	I-cell_type	14	PMOD
19	,	,	O	,	O	8	P
20	with	with	B-PP	IN	O	8	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	magnitude	magnitude	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	this	this	B-NP	DT	O	25	NMOD
25	effect	effect	I-NP	NN	O	23	PMOD
26	being	be	B-VP	VBG	O	25	NMOD
27	greater	great	B-ADJP	JJR	O	26	PRD
28	in	in	B-PP	IN	O	27	AMOD
29	males	male	B-NP	NNS	O	28	PMOD
30	.	.	O	.	O	7	P

1	Development	Development	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	proteinuria	proteinuria	B-NP	NN	O	2	PMOD
4	after	after	B-PP	IN	O	1	NMOD
5	switch	switch	B-NP	NN	O	4	PMOD
6	to	to	B-PP	TO	O	5	NMOD
7	sirolimus-based	sirolimus-based	B-NP	JJ	O	8	NMOD
8	immunosuppression	immunosuppression	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	5	NMOD
10	long-term	long-term	B-NP	JJ	O	13	NMOD
11	cardiac	cardiac	I-NP	JJ	O	13	NMOD
12	transplant	transplant	I-NP	NN	O	13	NMOD
13	patients	patient	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	8	NMOD
2	novel	novel	I-NP	JJ	O	3	AMOD
3	immunosuppressive	immunosuppressive	I-NP	JJ	O	8	NMOD
4	(	(	O	(	O	6	DEP
5	IS	IS	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	AMOD
7	drug	drug	B-NP	NN	O	8	NMOD
8	sirolmus	sirolmus	I-NP	NN	O	12	SUB
9	(	(	O	(	O	11	DEP
10	Srl	Srl	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	lacks	lack	B-VP	VBZ	O	22	VMOD
13	nephrotoxic	nephrotoxic	B-NP	JJ	O	14	NMOD
14	effects	effect	I-NP	NNS	O	12	OBJ
15	;	;	O	:	O	12	P
16	however	however	B-ADVP	RB	O	22	VMOD
17	,	,	O	,	O	22	P
18	proteinuria	proteinuria	B-NP	NN	O	22	SUB
19	associated	associate	B-VP	VBN	O	18	NMOD
20	with	with	B-PP	IN	O	19	VMOD
21	Srl	Srl	B-NP	NN	B-protein	20	PMOD
22	has	have	B-VP	VBZ	O	0	ROOT
23	been	be	I-VP	VBN	O	22	VC
24	reported	report	I-VP	VBN	O	23	VC
25	following	follow	B-PP	VBG	O	24	VMOD
26	renal	renal	B-NP	JJ	O	27	NMOD
27	transplantation	transplantation	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	22	P

1	In	In	B-PP	IN	O	12	VMOD
2	cardiac	cardiac	B-NP	JJ	O	3	NMOD
3	transplantation	transplantation	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	12	P
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	12	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	proteinuria	proteinuria	B-NP	NN	O	7	PMOD
9	associated	associate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	Srl	Srl	B-NP	NN	B-protein	10	PMOD
12	is	be	B-VP	VBZ	O	0	ROOT
13	unknown	unknown	B-ADJP	JJ	O	12	PRD
14	.	.	O	.	O	12	P

1	ACE	ACE	B-NP	NN	O	2	NMOD
2	inhibitor	inhibitor	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	angiotensin-releasing	angiotensin-releasing	B-NP	JJ	O	5	NMOD
5	blocker	blocker	I-NP	NN	O	0	ROOT
6	(	(	O	(	O	8	DEP
7	ARB	ARB	B-NP	NN	B-protein	8	DEP
8	)	)	O	)	O	5	NMOD
9	therapy	therapy	B-NP	NN	O	5	NMOD
10	reduced	reduce	B-VP	VBD	O	9	SBAR
11	proteinuria	proteinuria	B-NP	NN	O	12	NMOD
12	development	development	I-NP	NN	O	10	OBJ
13	.	.	O	.	O	5	P

1	Thus	Thus	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	proteinuria	proteinuria	B-NP	NN	O	4	SUB
4	may	may	B-VP	MD	O	0	ROOT
5	develop	develop	I-VP	VB	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	cardiac	cardiac	B-NP	JJ	O	9	NMOD
8	transplant	transplant	I-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	6	PMOD
10	after	after	B-PP	IN	O	9	NMOD
11	switch	switch	B-NP	NN	O	10	PMOD
12	to	to	B-PP	TO	O	11	NMOD
13	Srl	Srl	B-NP	NN	B-protein	12	PMOD
14	,	,	O	,	O	13	P
15	which	which	B-NP	WDT	O	13	NMOD
16	may	may	B-VP	MD	O	15	SBAR
17	have	have	I-VP	VB	O	16	VC
18	an	an	B-NP	DT	O	20	NMOD
19	adverse	adverse	I-NP	JJ	O	20	NMOD
20	effect	effect	I-NP	NN	O	17	OBJ
21	on	on	B-PP	IN	O	17	VMOD
22	renal	renal	B-NP	JJ	O	23	NMOD
23	function	function	I-NP	NN	O	21	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	these	these	B-NP	DT	O	26	NMOD
26	patients	patient	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	4	P

1	Methamphetamine	Methamphetamine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	neurotoxicity	neurotoxicity	B-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	microglial	microglial	B-NP	JJ	O	6	NMOD
6	activation	activation	I-NP	NN	O	2	OBJ
7	are	be	B-VP	VBP	O	2	VMOD
8	not	not	I-VP	RB	O	7	VMOD
9	mediated	mediate	I-VP	VBN	O	7	VC
10	by	by	B-PP	IN	O	9	VMOD
11	fractalkine	fractalkine	B-NP	NN	B-protein	13	NMOD
12	receptor	receptor	I-NP	NN	I-protein	13	NMOD
13	signaling	signaling	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	Neurosci.	Neurosci.	B-NP	NN	B-protein	7	NMOD
2	9	9	I-NP	CD	I-protein	1	NMOD
3	(	(	O	(	O	5	DEP
4	2006	2006	B-NP	CD	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	,	,	O	,	O	7	P
7	917	917	B-NP	CD	O	10	SUB
8	]	]	O	)	O	7	NMOD
9	recently	recently	B-ADVP	RB	O	10	VMOD
10	identified	identify	B-VP	VBD	O	0	ROOT
11	the	the	B-NP	DT	O	14	NMOD
12	microglial-specific	microglial-specific	I-NP	JJ	B-protein	14	NMOD
13	fractalkine	fractalkine	I-NP	NN	I-protein	14	NMOD
14	receptor	receptor	I-NP	NN	I-protein	10	OBJ
15	(	(	O	(	O	17	DEP
16	CX3CR1	CX3CR1	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	as	as	B-PP	IN	O	10	VMOD
19	an	an	B-NP	DT	O	21	NMOD
20	important	important	I-NP	JJ	O	21	NMOD
21	mediator	mediator	I-NP	NN	O	24	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	MPTP	MPTP	B-NP	NN	B-protein	22	PMOD
24	induced	induce	B-VP	VBD	O	18	SBAR
25	neurodegeneration	neurodegeneration	B-NP	NN	O	24	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	DA	DA	B-NP	NN	B-DNA	28	NMOD
28	neurons	neuron	I-NP	NNS	I-DNA	26	PMOD
29	.	.	O	.	O	10	P

1	Because	Because	B-SBAR	IN	O	25	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	CNS	CNS	I-NP	NN	O	4	NMOD
4	damage	damage	I-NP	NN	O	10	SUB
5	caused	cause	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	METH	METH	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	MPTP	MPTP	I-NP	NN	B-protein	6	PMOD
10	is	be	B-VP	VBZ	O	1	SBAR
11	highly	highly	B-ADJP	RB	O	12	AMOD
12	selective	selective	I-ADJP	JJ	O	10	PRD
13	for	for	B-PP	IN	O	12	AMOD
14	the	the	B-NP	DT	O	17	NMOD
15	DA	DA	I-NP	NN	O	17	NMOD
16	neuronal	neuronal	I-NP	JJ	O	17	NMOD
17	system	system	I-NP	NN	O	13	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	mouse	mouse	B-NP	NN	O	20	NMOD
20	models	model	I-NP	NNS	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	neurotoxicity	neurotoxicity	B-NP	NN	O	21	PMOD
23	,	,	O	,	O	25	P
24	we	we	B-NP	PRP	O	25	SUB
25	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT
26	that	that	B-SBAR	IN	O	25	VMOD
27	the	the	B-NP	DT	O	28	NMOD
28	CX3CR1	CX3CR1	I-NP	NN	B-protein	29	SUB
29	plays	play	B-VP	VBZ	O	26	SBAR
30	a	a	B-NP	DT	O	31	NMOD
31	role	role	I-NP	NN	O	29	OBJ
32	in	in	B-PP	IN	O	29	VMOD
33	METH	METH	B-NP	NN	O	34	SUB
34	induced	induce	B-VP	VBD	O	32	SBAR
35	neurotoxicity	neurotoxicity	B-NP	NN	O	38	NMOD
36	and	and	O	CC	O	38	NMOD
37	microglial	microglial	B-NP	JJ	O	38	NMOD
38	activation	activation	I-NP	NN	O	34	OBJ
39	.	.	O	.	O	25	P

1	Mice	Mouse	B-NP	NNS	O	7	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	which	which	B-NP	WDT	O	2	PMOD
4	the	the	B-NP	DT	O	6	NMOD
5	CX3CR1	CX3CR1	I-NP	NN	B-DNA	6	NMOD
6	gene	gene	I-NP	NN	I-DNA	2	PMOD
7	has	have	B-VP	VBZ	O	0	ROOT
8	been	be	I-VP	VBN	O	7	VC
9	deleted	delete	I-VP	VBN	O	8	VC
10	and	and	O	CC	O	9	VMOD
11	replaced	replace	B-VP	VBN	O	9	VMOD
12	with	with	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	cDNA	cDNA	I-NP	NN	O	15	NMOD
15	encoding	encoding	I-NP	NN	O	12	PMOD
16	enhanced	enhance	B-VP	VBD	O	7	VMOD
17	green	green	B-NP	JJ	B-protein	19	NMOD
18	fluorescent	fluorescent	I-NP	JJ	I-protein	19	NMOD
19	protein	protein	I-NP	NN	I-protein	16	OBJ
20	(	(	O	(	O	22	DEP
21	eGFP	eGFP	B-NP	NN	B-protein	22	DEP
22	)	)	O	)	O	19	NMOD
23	were	be	B-VP	VBD	O	16	VMOD
24	treated	treat	I-VP	VBN	O	23	VC
25	with	with	B-PP	IN	O	24	VMOD
26	METH	METH	B-NP	NN	O	25	PMOD
27	and	and	O	CC	O	24	VMOD
28	examined	examine	B-VP	VBN	O	24	VMOD
29	for	for	B-PP	IN	O	28	VMOD
30	striatal	striatal	B-NP	JJ	O	31	NMOD
31	neurotoxicity	neurotoxicity	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	from	from	B-PP	IN	O	2	VMOD
4	these	these	B-NP	DT	O	5	NMOD
5	studies	study	I-NP	NNS	O	3	PMOD
6	that	that	B-NP	IN	O	2	VMOD
7	CX3CR1	CX3CR1	B-NP	NN	B-protein	8	NMOD
8	signaling	signaling	I-NP	NN	O	9	SUB
9	does	do	B-VP	VBZ	O	6	SBAR
10	not	not	I-VP	RB	O	9	VMOD
11	modulate	modulate	I-VP	VB	O	9	VC
12	METH	METH	B-NP	NN	O	13	NMOD
13	neurotoxicity	neurotoxicity	I-NP	NN	O	16	NMOD
14	or	or	O	CC	O	16	NMOD
15	microglial	microglial	B-NP	JJ	O	16	NMOD
16	activation	activation	I-NP	NN	O	11	OBJ
17	.	.	O	.	O	2	P

1	Recovery	Recovery	B-NP	NN	O	18	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	tacrolimus-associated	tacrolimus-associated	B-NP	JJ	O	5	NMOD
4	brachial	brachial	I-NP	JJ	O	5	NMOD
5	neuritis	neuritis	I-NP	NN	O	2	PMOD
6	after	after	B-PP	IN	O	1	NMOD
7	conversion	conversion	B-NP	NN	O	6	PMOD
8	to	to	B-PP	TO	O	7	NMOD
9	everolimus	everolimus	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	7	NMOD
11	a	a	B-NP	DT	O	15	NMOD
12	pediatric	pediatric	I-NP	JJ	O	15	NMOD
13	renal	renal	I-NP	JJ	O	15	NMOD
14	transplant	transplant	I-NP	NN	O	15	NMOD
15	recipient	recipient	I-NP	NN	O	10	PMOD
16	--	--	O	:	O	1	P
17	case	case	B-NP	NN	O	18	NMOD
18	report	report	I-NP	NN	O	20	NMOD
19	and	and	O	CC	O	20	NMOD
20	review	review	B-NP	NN	O	0	ROOT
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	literature	literature	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	20	P

1	Valvular	Valvular	B-NP	JJ	O	3	NMOD
2	heart	heart	I-NP	NN	O	3	NMOD
3	disease	disease	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	Parkinson	Parkinson	B-NP	NNP	O	8	NMOD
8	's	's	B-NP	POS	O	9	NMOD
9	disease	disease	I-NP	NN	O	6	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	pergolide	pergolide	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	Valvular	Valvular	B-NP	JJ	O	3	NMOD
2	heart	heart	I-NP	NN	O	3	NMOD
3	abnormalities	abnormality	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	reported	report	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	Parkinson	Parkinson	B-NP	NNP	O	11	NMOD
11	's	's	B-NP	POS	O	12	NMOD
12	disease	disease	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	PD	PD	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	treated	treat	B-VP	VBN	O	12	NMOD
17	with	with	B-PP	IN	O	16	VMOD
18	pergolide	pergolide	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	4	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	All	All	B-NP	DT	O	5	NMOD
4	PD	PD	I-NP	NN	O	5	NMOD
5	patients	patient	I-NP	NNS	O	13	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	Amiens	Amiens	I-NP	NNP	O	9	NMOD
9	area	area	I-NP	NN	O	6	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	pergolide	pergolide	B-NP	NN	O	11	PMOD
13	were	be	B-VP	VBD	O	1	NMOD
14	invited	invite	I-VP	VBN	O	13	VC
15	to	to	B-VP	TO	O	16	VMOD
16	attend	attend	I-VP	VB	O	14	VMOD
17	a	a	B-NP	DT	O	19	NMOD
18	cardiologic	cardiologic	I-NP	JJ	O	19	NMOD
19	assessment	assessment	I-NP	NN	O	16	OBJ
20	including	include	B-PP	VBG	O	19	NMOD
21	transthoracic	transthoracic	B-NP	JJ	O	22	NMOD
22	echocardiography	echocardiography	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	3	NMOD
2	restrictive	restrictive	I-NP	JJ	O	3	NMOD
3	pattern	pattern	I-NP	NN	O	15	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	valvular	valvular	B-NP	JJ	O	6	NMOD
6	regurgitation	regurgitation	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	3	P
8	suggestive	suggestive	B-ADJP	JJ	O	3	NMOD
9	of	of	B-PP	IN	O	8	AMOD
10	the	the	B-NP	DT	O	11	NMOD
11	role	role	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	pergolide	pergolide	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	3	P
15	was	be	B-VP	VBD	O	0	ROOT
16	observed	observe	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	12/30	12/30	B-NP	CD	O	23	NMOD
19	(	(	O	(	O	22	DEP
20	40	40	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	22	DEP
22	)	)	O	)	O	23	NMOD
23	patients	patient	B-NP	NNS	O	17	PMOD
24	including	include	B-PP	VBG	O	23	NMOD
25	two	two	B-NP	CD	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	heart	heart	B-NP	NN	O	28	NMOD
28	failure	failure	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	15	P

1	Pergolide	Pergolide	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	discontinued	discontinue	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	10	10	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	valvular	valvular	B-NP	JJ	O	10	NMOD
9	heart	heart	I-NP	NN	O	10	NMOD
10	disease	disease	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	2	P
12	resulting	result	B-VP	VBG	O	2	VMOD
13	in	in	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	17	NMOD
15	lower	low	I-NP	JJR	O	17	NMOD
16	regurgitation	regurgitation	I-NP	NN	O	17	NMOD
17	grade	grade	I-NP	NN	O	29	NMOD
18	(	(	O	(	O	20	DEP
19	p=0.01	p=0.01	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	at	at	B-PP	IN	O	17	NMOD
22	the	the	B-NP	DT	O	25	NMOD
23	second	second	I-NP	JJ	O	25	NMOD
24	transthoracic	transthoracic	I-NP	JJ	O	25	NMOD
25	echocardiography	echocardiography	I-NP	NN	O	21	PMOD
26	and	and	O	CC	O	29	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	two	two	I-NP	CD	O	29	NMOD
29	patients	patient	I-NP	NNS	O	13	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	heart	heart	B-NP	NN	O	32	NMOD
32	failure	failure	I-NP	NN	O	30	PMOD
33	returned	return	B-VP	VBD	O	2	VMOD
34	to	to	B-PP	TO	O	33	VMOD
35	nearly	nearly	B-NP	RB	O	36	AMOD
36	normal	normal	I-NP	JJ	O	38	NMOD
37	clinical	clinical	I-NP	JJ	O	38	NMOD
38	examination	examination	I-NP	NN	O	34	PMOD
39	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Papaverine	Papaverine	B-NP	NN	O	4	NMOD
4	hydrochloride	hydrochloride	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	direct-acting	direct-acting	I-NP	JJ	O	8	NMOD
8	vasodilator	vasodilator	I-NP	NN	O	5	PRD
9	used	use	B-VP	VBN	O	8	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	manage	manage	I-VP	VB	O	9	VMOD
12	vasospasm	vasospasm	B-NP	NN	O	11	OBJ
13	during	during	B-PP	IN	O	11	VMOD
14	various	various	B-NP	JJ	O	16	NMOD
15	neurosurgical	neurosurgical	I-NP	JJ	O	16	NMOD
16	operations	operation	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	5	P

1	Transient	Transient	B-NP	JJ	O	4	NMOD
2	cranial	cranial	I-NP	JJ	O	4	NMOD
3	nerve	nerve	I-NP	NN	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	described	describe	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	few	few	I-NP	JJ	O	11	NMOD
11	cases	case	I-NP	NNS	O	8	PMOD
12	with	with	B-PP	IN	O	8	PMOD
13	topical	topical	B-NP	JJ	O	14	NMOD
14	papaverine	papaverine	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	5	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	conducted	conduct	B-VP	VBD	O	1	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	retrospective	retrospective	I-NP	JJ	O	7	NMOD
7	review	review	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	70	70	B-NP	CD	O	13	NMOD
10	consecutive	consecutive	I-NP	JJ	O	13	NMOD
11	microvascular	microvascular	I-NP	JJ	O	13	NMOD
12	decompression	decompression	I-NP	NN	O	13	NMOD
13	operations	operation	I-NP	NNS	O	8	PMOD
14	and	and	O	CC	O	4	VMOD
15	studied	study	B-VP	VBN	O	4	VMOD
16	those	those	B-NP	DT	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	OBJ
18	who	who	B-NP	WP	O	17	NMOD
19	received	receive	B-VP	VBD	O	18	SBAR
20	topical	topical	B-NP	JJ	O	21	NMOD
21	papaverine	papaverine	I-NP	NN	O	19	OBJ
22	for	for	B-PP	IN	O	21	NMOD
23	vasospasm	vasospasm	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	1	P

1	Topical	Topical	B-NP	JJ	O	2	NMOD
2	papaverine	papaverine	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	used	use	I-VP	VBN	O	3	VC
5	as	as	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	9	NMOD
7	direct	direct	I-NP	JJ	O	8	AMOD
8	therapeutic	therapeutic	I-NP	JJ	O	9	NMOD
9	action	action	I-NP	NN	O	5	PMOD
10	to	to	B-VP	TO	O	11	VMOD
11	manage	manage	I-VP	VB	O	4	VMOD
12	vasospasm	vasospasm	B-NP	NN	O	11	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	15	NMOD
15	total	total	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	11	11	B-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	3	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Topical	Topical	B-NP	JJ	O	4	NMOD
4	papaverine	papaverine	I-NP	NN	O	10	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	vasospasm	vasospasm	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	1	NMOD
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	onset	onset	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	18	NMOD
17	transient	transient	I-NP	JJ	O	18	NMOD
18	disturbance	disturbance	I-NP	NN	O	15	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	neurophysiological	neurophysiological	B-NP	JJ	O	21	NMOD
21	function	function	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	27	NMOD
24	ascending	ascend	I-NP	VBG	O	27	NMOD
25	auditory	auditory	I-NP	JJ	O	27	NMOD
26	brainstem	brainstem	I-NP	NN	O	27	NMOD
27	pathway	pathway	I-NP	NN	O	22	PMOD
28	.	.	O	.	O	1	P

1	Massive	Massive	B-NP	JJ	O	2	NMOD
2	proteinuria	proteinuria	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	failure	failure	I-NP	NN	O	0	ROOT
7	after	after	B-PP	IN	O	6	NMOD
8	oral	oral	B-NP	JJ	O	9	NMOD
9	bisphosphonate	bisphosphonate	I-NP	NN	O	13	NMOD
10	(	(	O	(	O	12	DEP
11	alendronate	alendronate	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	administration	administration	B-NP	NN	O	7	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	16	NMOD
16	patient	patient	I-NP	NN	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	focal	focal	B-NP	JJ	O	20	NMOD
19	segmental	segmental	I-NP	JJ	O	20	NMOD
20	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	4	NMOD
2	61-year-old	61-year-old	I-NP	JJ	O	4	NMOD
3	Japanese	Japanese	I-NP	JJ	O	4	NMOD
4	man	man	I-NP	NN	O	13	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	nephrotic	nephrotic	B-NP	JJ	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	5	PMOD
8	due	due	B-PP	JJ	O	4	NMOD
9	to	to	B-PP	TO	O	8	AMOD
10	focal	focal	B-NP	JJ	O	11	AMOD
11	segmental	segmental	I-NP	JJ	O	12	NMOD
12	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	9	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	initially	initially	I-VP	RB	O	15	VMOD
15	responding	respond	I-VP	VBG	O	13	VC
16	well	well	B-ADVP	RB	O	15	VMOD
17	to	to	B-PP	TO	O	15	VMOD
18	steroid	steroid	B-NP	NN	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	13	P

1	Within	Within	B-PP	IN	O	20	VMOD
2	14	14	B-NP	CD	O	3	NMOD
3	days	day	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	oral	oral	I-NP	JJ	O	7	NMOD
7	bisphosphonate	bisphosphonate	I-NP	NN	O	12	NMOD
8	(	(	O	(	O	12	NMOD
9	alendronate	alendronate	B-NP	NN	O	12	NMOD
10	sodium	sodium	I-NP	NN	O	12	NMOD
11	)	)	O	)	O	12	NMOD
12	administration	administration	B-NP	NN	O	4	PMOD
13	,	,	O	,	O	20	P
14	the	the	B-NP	DT	O	15	NMOD
15	amount	amount	I-NP	NN	O	20	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	daily	daily	B-NP	JJ	O	19	NMOD
18	urinary	urinary	I-NP	JJ	O	19	NMOD
19	protein	protein	I-NP	NN	O	16	PMOD
20	increased	increase	B-VP	VBD	O	0	ROOT
21	rapidly	rapidly	B-ADVP	RB	O	20	VMOD
22	up	up	B-NP	IN	O	25	NMOD
23	to	to	I-NP	TO	O	22	AMOD
24	12.8	12.8	I-NP	CD	O	22	AMOD
25	g	g	I-NP	NN	O	20	OBJ
26	with	with	B-PP	IN	O	25	NMOD
27	acute	acute	B-NP	JJ	O	29	NMOD
28	renal	renal	I-NP	JJ	O	29	NMOD
29	failure	failure	I-NP	NN	O	26	PMOD
30	.	.	O	.	O	20	P

1	Serum-	Serum-	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	glucocorticoid-inducible	glucocorticoid-inducible	I-NP	JJ	B-protein	4	NMOD
4	kinase	kinase	I-NP	NN	I-protein	8	SUB
5	1	1	I-NP	CD	I-protein	4	NMOD
6	in	in	B-PP	IN	O	4	NMOD
7	doxorubicin	doxorubicin	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	nephrotic	nephrotic	B-NP	JJ	O	10	NMOD
10	syndrome	syndrome	I-NP	NN	O	8	OBJ
11	.	.	O	.	O	8	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	nephropathy	nephropathy	B-NP	NN	O	4	SUB
4	leads	lead	B-VP	VBZ	O	2	VMOD
5	to	to	B-PP	TO	O	4	VMOD
6	epithelial	epithelial	B-NP	JJ	B-protein	8	NMOD
7	sodium	sodium	I-NP	NN	I-protein	8	NMOD
8	channel	channel	I-NP	NN	I-protein	14	NMOD
9	(	(	O	(	O	11	DEP
10	ENaC	ENaC	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	-dependent	-dependent	B-NP	JJ	O	14	NMOD
13	volume	volume	I-NP	NN	O	14	NMOD
14	retention	retention	I-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	fibrosis	fibrosis	I-NP	NN	O	5	PMOD
18	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	7	NMOD
2	aldosterone-sensitive	aldosterone-sensitive	I-NP	JJ	O	3	NMOD
3	serum-	serum-	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	glucocorticoid-inducible	glucocorticoid-inducible	B-NP	JJ	O	7	NMOD
6	kinase	kinase	I-NP	NN	O	7	NMOD
7	SGK1	SGK1	I-NP	NN	B-protein	8	SUB
8	has	have	B-VP	VBZ	O	0	ROOT
9	been	be	I-VP	VBN	O	8	VC
10	shown	show	I-VP	VBN	O	9	VC
11	to	to	I-VP	TO	O	12	VMOD
12	participate	participate	I-VP	VB	O	10	VMOD
13	in	in	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	stimulation	stimulation	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	ENaC	ENaC	B-NP	NN	O	16	PMOD
18	and	and	O	CC	O	12	VMOD
19	to	to	B-VP	TO	O	20	VMOD
20	mediate	mediate	I-VP	VB	O	12	VMOD
21	renal	renal	B-NP	JJ	O	22	NMOD
22	fibrosis	fibrosis	I-NP	NN	O	20	OBJ
23	following	follow	B-PP	VBG	O	20	VMOD
24	mineralocorticoid	mineralocorticoid	B-NP	NN	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	salt	salt	I-NP	NN	O	27	NMOD
27	excess	excess	I-NP	NN	O	23	PMOD
28	.	.	O	.	O	8	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	resulted	result	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	heavy	heavy	B-NP	JJ	O	6	NMOD
6	proteinuria	proteinuria	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	13	DEP
8	>	>	B-NP	SYM	O	10	AMOD
9	100	100	I-NP	CD	O	10	AMOD
10	mg	mg	I-NP	NN	O	12	NMOD
11	protein/mg	protein/mg	I-NP	NN	O	12	NMOD
12	crea	crea	I-NP	NN	O	13	DEP
13	)	)	O	)	O	6	NMOD
14	in	in	B-PP	IN	O	3	VMOD
15	15/44	15/44	B-NP	CD	O	22	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	sgk1	sgk1	B-NP	NN	O	16	PMOD
18	(	(	O	(	O	20	DEP
19	+/+	+/+	B-NP	SYM	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	and	and	O	CC	O	22	NMOD
22	15/44	15/44	B-NP	CD	O	14	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	sgk1	sgk1	B-NP	NN	O	28	NMOD
25	(	(	O	(	O	27	DEP
26	-/-	-/-	O	JJ	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	mice	mouse	B-NP	NNS	O	23	PMOD
29	leading	lead	B-VP	VBG	O	22	NMOD
30	to	to	B-PP	TO	O	29	VMOD
31	severe	severe	B-NP	JJ	O	33	NMOD
32	nephrotic	nephrotic	I-NP	JJ	O	33	NMOD
33	syndrome	syndrome	I-NP	NN	O	30	PMOD
34	with	with	B-PP	IN	O	33	NMOD
35	ascites	ascite	B-NP	NNS	O	40	NMOD
36	,	,	O	,	O	40	P
37	lipidemia	lipidemia	B-NP	NN	O	40	NMOD
38	,	,	O	,	O	40	P
39	and	and	O	CC	O	40	NMOD
40	hypoalbuminemia	hypoalbuminemia	B-NP	NN	O	34	PMOD
41	in	in	B-PP	IN	O	40	NMOD
42	both	both	B-NP	DT	O	43	NMOD
43	genotypes	genotype	I-NP	NNS	O	41	PMOD
44	.	.	O	.	O	3	P

1	Plasma	Plasma	B-NP	NN	O	3	NMOD
2	aldosterone	aldosterone	I-NP	NN	O	3	NMOD
3	levels	level	I-NP	NNS	O	4	SUB
4	increased	increase	B-VP	VBD	O	0	ROOT
5	in	in	B-PP	IN	O	4	VMOD
6	nephrotic	nephrotic	B-NP	JJ	O	7	NMOD
7	mice	mouse	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	both	both	O	CC	O	10	NMOD
10	genotypes	genotype	B-NP	NNS	O	8	PMOD
11	and	and	O	CC	O	4	VMOD
12	was	be	B-VP	VBD	O	4	VMOD
13	followed	follow	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	increased	increase	B-NP	VBN	O	18	NMOD
16	SGK1	SGK1	I-NP	NN	B-protein	18	NMOD
17	protein	protein	I-NP	NN	O	18	NMOD
18	expression	expression	I-NP	NN	O	14	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	sgk1	sgk1	B-NP	NN	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	+/+	+/+	O	SYM	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	mice	mouse	B-NP	NNS	O	19	PMOD
25	.	.	O	.	O	4	P

1	Urinary	Urinary	B-NP	JJ	O	3	NMOD
2	sodium	sodium	I-NP	NN	O	3	NMOD
3	excretion	excretion	I-NP	NN	O	4	SUB
4	reached	reach	B-VP	VBD	O	0	ROOT
5	signficantly	signficantly	B-NP	RB	O	6	AMOD
6	lower	low	I-NP	JJR	O	7	NMOD
7	values	value	I-NP	NNS	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	sgk1	sgk1	B-NP	NN	O	13	NMOD
10	(	(	O	(	O	12	DEP
11	+/+	+/+	O	SYM	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	mice	mouse	B-NP	NNS	O	8	PMOD
14	(	(	O	(	O	20	DEP
15	15	15	B-NP	CD	O	17	AMOD
16	+/-	+/-	I-NP	SYM	O	17	AMOD
17	5	5	I-NP	CD	O	18	AMOD
18	mumol/mg	mumol/mg	I-NP	NN	O	19	NMOD
19	crea	crea	I-NP	NN	O	20	DEP
20	)	)	O	)	O	13	NMOD
21	than	than	B-PP	IN	O	4	VMOD
22	in	in	B-PP	IN	O	21	PMOD
23	sgk1	sgk1	B-NP	NN	O	27	NMOD
24	(	(	O	(	O	26	DEP
25	-/-	-/-	O	JJ	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	mice	mouse	B-NP	NNS	O	22	PMOD
28	(	(	O	(	O	34	DEP
29	35	35	B-NP	CD	O	31	AMOD
30	+/-	+/-	I-NP	SYM	O	31	AMOD
31	5	5	I-NP	CD	O	33	NMOD
32	mumol/mg	mumol/mg	I-NP	NN	O	33	NMOD
33	crea	crea	I-NP	NN	O	34	DEP
34	)	)	O	)	O	4	VMOD
35	and	and	O	CC	O	4	VMOD
36	was	be	B-VP	VBD	O	4	VMOD
37	associated	associate	I-VP	VBN	O	36	VC
38	with	with	B-PP	IN	O	37	VMOD
39	a	a	B-NP	DT	O	44	NMOD
40	significantly	significantly	I-NP	RB	O	41	AMOD
41	higher	high	I-NP	JJR	O	44	NMOD
42	body	body	I-NP	NN	O	44	NMOD
43	weight	weight	I-NP	NN	O	44	NMOD
44	gain	gain	I-NP	NN	O	38	PMOD
45	in	in	B-PP	IN	O	44	NMOD
46	sgk1	sgk1	B-NP	NN	O	45	PMOD
47	(	(	O	(	O	49	DEP
48	+/+	+/+	O	SYM	O	49	DEP
49	)	)	O	)	O	46	NMOD
50	compared	compare	B-PP	VBN	O	37	VMOD
51	with	with	B-PP	IN	O	50	PMOD
52	sgk1	sgk1	B-NP	NN	B-protein	56	NMOD
53	(	(	O	(	O	55	DEP
54	-/-	-/-	O	JJ	O	55	DEP
55	)	)	O	)	O	52	NMOD
56	mice	mouse	B-NP	NNS	O	51	PMOD
57	(	(	O	(	O	66	DEP
58	+6.6	+6.6	B-NP	CD	O	60	AMOD
59	+/-	+/-	I-NP	SYM	O	60	AMOD
60	0.7	0.7	I-NP	CD	O	65	NMOD
61	vs.	vs.	B-PP	IN	O	65	NMOD
62	+4.1	+4.1	B-NP	CD	O	64	AMOD
63	+/-	+/-	I-NP	SYM	O	64	AMOD
64	0.8	0.8	I-NP	CD	O	65	NMOD
65	g	g	I-NP	NN	O	66	DEP
66	)	)	O	)	O	56	NMOD
67	.	.	O	.	O	4	P

1	During	During	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	course	course	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	nephrotic	nephrotic	B-NP	JJ	O	6	NMOD
6	syndrome	syndrome	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	11	P
8	serum	serum	B-NP	NN	O	10	NMOD
9	urea	urea	I-NP	NN	O	10	NMOD
10	concentrations	concentration	I-NP	NNS	O	11	SUB
11	increased	increase	B-VP	VBD	O	0	ROOT
12	significantly	significantly	B-ADJP	RB	O	13	AMOD
13	faster	fast	I-ADJP	JJR	O	11	PRD
14	in	in	B-PP	IN	O	13	AMOD
15	sgk1	sgk1	B-NP	NN	O	19	NMOD
16	(	(	O	(	O	18	DEP
17	-/-	-/-	O	JJ	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	mice	mouse	B-NP	NNS	O	14	PMOD
20	than	than	B-PP	IN	O	13	AMOD
21	in	in	B-PP	IN	O	20	PMOD
22	sgk1	sgk1	B-NP	NN	O	26	NMOD
23	(	(	O	(	O	25	DEP
24	+/+	+/+	O	SYM	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	mice	mouse	B-NP	NNS	O	21	PMOD
27	leading	lead	B-VP	VBG	O	26	NMOD
28	to	to	B-PP	TO	O	27	VMOD
29	uremia	uremia	B-NP	NN	O	34	NMOD
30	and	and	O	CC	O	34	NMOD
31	a	a	B-NP	DT	O	34	NMOD
32	reduced	reduce	I-NP	VBN	O	34	NMOD
33	median	median	I-NP	NN	O	34	NMOD
34	survival	survival	I-NP	NN	O	28	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	sgk1	sgk1	B-NP	NN	O	40	NMOD
37	(	(	O	(	O	39	DEP
38	-/-	-/-	O	JJ	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	mice	mouse	B-NP	NNS	O	35	PMOD
41	(	(	O	(	O	52	DEP
42	29	29	B-NP	CD	O	52	DEP
43	vs.	vs.	B-PP	IN	O	42	NMOD
44	40	40	B-NP	CD	O	45	NMOD
45	days	day	I-NP	NNS	O	43	PMOD
46	in	in	B-PP	IN	O	45	NMOD
47	sgk1	sgk1	B-NP	NN	O	51	NMOD
48	(	(	O	(	O	50	DEP
49	+/+	+/+	O	SYM	O	50	DEP
50	)	)	O	)	O	47	NMOD
51	mice	mouse	B-NP	NNS	O	46	PMOD
52	)	)	O	)	O	40	NMOD
53	.	.	O	.	O	11	P

1	Severe	Severe	B-NP	JJ	O	4	AMOD
2	and	and	I-NP	CC	O	4	AMOD
3	long	long	I-NP	JJ	O	4	AMOD
4	lasting	lasting	I-NP	JJ	O	5	NMOD
5	cholestasis	cholestasis	I-NP	NN	O	18	NMOD
6	after	after	B-PP	IN	O	5	NMOD
7	high-dose	high-dose	B-NP	JJ	O	9	NMOD
8	co-trimoxazole	co-trimoxazole	I-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	6	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	Pneumocystis	Pneumocystis	B-NP	NN	O	12	NMOD
12	pneumonia	pneumonia	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	9	NMOD
14	HIV-infected	HIV-infected	B-NP	JJ	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	--	--	O	:	O	5	P
17	a	a	B-NP	DT	O	18	NMOD
18	report	report	I-NP	NN	O	0	ROOT
19	of	of	B-PP	IN	O	18	NMOD
20	two	two	B-NP	CD	O	21	NMOD
21	cases	case	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	18	P

1	Pneumocystis	Pneumocystis	B-NP	NN	O	2	NMOD
2	pneumonia	pneumonia	I-NP	NN	O	10	NMOD
3	(	(	O	(	O	5	DEP
4	PCP	PCP	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	,	,	O	,	O	10	P
7	a	a	B-NP	DT	O	10	NMOD
8	common	common	I-NP	JJ	O	10	NMOD
9	opportunistic	opportunistic	I-NP	JJ	O	10	NMOD
10	infection	infection	I-NP	NN	O	15	SUB
11	in	in	B-PP	IN	O	10	NMOD
12	HIV-infected	HIV-infected	B-NP	JJ	O	13	NMOD
13	individuals	individual	I-NP	NNS	O	11	PMOD
14	,	,	O	,	O	10	P
15	is	be	B-VP	VBZ	O	0	ROOT
16	generally	generally	I-VP	RB	O	15	VMOD
17	treated	treat	I-VP	VBN	O	15	VC
18	with	with	B-PP	IN	O	17	VMOD
19	high	high	B-NP	JJ	O	20	NMOD
20	doses	dose	I-NP	NNS	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	co-trimoxazole	co-trimoxazole	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	15	P

1	Here	Here	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	report	report	B-VP	VBP	O	0	ROOT
5	two	two	B-NP	CD	O	6	NMOD
6	cases	case	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	severely	severely	B-NP	RB	O	9	AMOD
9	immunocompromised	immunocompromise	I-NP	VBN	O	11	NMOD
10	HIV-infected	HIV-infected	I-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	7	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	developed	develop	B-VP	VBD	O	12	SBAR
14	severe	severe	B-NP	JJ	O	15	AMOD
15	intrahepatic	intrahepatic	I-NP	JJ	O	16	NMOD
16	cholestasis	cholestasis	I-NP	NN	O	13	OBJ
17	,	,	O	,	O	36	P
18	and	and	O	CC	O	36	NMOD
19	in	in	B-PP	IN	O	18	PRD
20	one	one	B-NP	CD	O	22	NMOD
21	patient	patient	I-NP	NN	O	22	NMOD
22	lesions	lesion	I-NP	NNS	O	19	PMOD
23	mimicking	mimic	B-VP	VBG	O	22	NMOD
24	liver	liver	B-NP	NN	O	26	NMOD
25	abscess	abscess	I-NP	NN	O	26	NMOD
26	formation	formation	I-NP	NN	O	23	OBJ
27	on	on	B-PP	IN	O	23	VMOD
28	radiologic	radiologic	B-NP	JJ	O	29	NMOD
29	exams	exam	I-NP	NNS	O	27	PMOD
30	,	,	O	,	O	19	PMOD
31	during	during	B-PP	IN	O	30	NMOD
32	co-trimoxazole	co-trimoxazole	B-NP	NN	O	33	NMOD
33	treatment	treatment	I-NP	NN	O	31	PMOD
34	for	for	B-PP	IN	O	33	NMOD
35	PCP	PCP	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	4	P

1	Clinically	Clinically	B-NP	RB	O	2	AMOD
2	significant	significant	I-NP	JJ	O	3	NMOD
3	proteinuria	proteinuria	I-NP	NN	O	0	ROOT
4	following	follow	B-PP	VBG	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	sirolimus	sirolimus	B-NP	NN	O	7	PMOD
9	to	to	B-PP	TO	O	6	NMOD
10	renal	renal	B-NP	JJ	O	12	NMOD
11	transplant	transplant	I-NP	NN	O	12	NMOD
12	recipients	recipient	I-NP	NNS	O	9	PMOD
13	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Sirolimus	Sirolimus	B-NP	NNP	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	latest	late	I-NP	JJS	O	7	AMOD
7	immunosuppressive	immunosuppressive	I-NP	JJ	O	8	NMOD
8	agent	agent	I-NP	NN	O	4	PRD
9	used	use	B-VP	VBN	O	8	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	prevent	prevent	I-VP	VB	O	9	VMOD
12	rejection	rejection	B-NP	NN	O	11	OBJ
13	,	,	O	,	O	4	P
14	and	and	O	CC	O	4	VMOD
15	may	may	B-VP	MD	O	4	VMOD
16	have	have	I-VP	VB	O	15	VC
17	less	less	B-NP	JJR	O	18	NMOD
18	nephrotoxicity	nephrotoxicity	I-NP	NN	O	16	OBJ
19	than	than	B-PP	IN	O	18	NMOD
20	calcineurin	calcineurin	B-NP	NN	B-protein	21	NMOD
21	inhibitor	inhibitor	I-NP	NN	O	26	NMOD
22	(	(	O	(	O	24	DEP
23	CNI	CNI	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	-based	-based	B-NP	JJ	O	26	NMOD
26	regimens	regimen	I-NP	NNS	O	19	PMOD
27	.	.	O	.	O	1	P

1	To	To	B-PP	TO	O	4	VMOD
2	date	date	B-NP	NN	O	1	PMOD
3	there	there	B-NP	EX	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	little	little	B-NP	JJ	O	7	NMOD
7	documentation	documentation	I-NP	NN	O	5	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	clinically	clinically	B-NP	RB	O	10	AMOD
10	significant	significant	I-NP	JJ	O	11	NMOD
11	proteinuria	proteinuria	I-NP	NN	O	8	PMOD
12	linked	link	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	use	use	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	sirolimus	sirolimus	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	encountered	encounter	I-VP	VBN	O	2	VC
4	several	several	B-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	substantial	substantial	B-NP	JJ	O	9	NMOD
9	proteinuria	proteinuria	I-NP	NN	O	7	OBJ
10	associated	associate	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	sirolimus	sirolimus	B-NP	NN	O	13	NMOD
13	use	use	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	17	VMOD
2	each	each	B-NP	DT	O	3	NMOD
3	patient	patient	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	17	P
5	the	the	B-NP	DT	O	8	NMOD
6	close	close	I-NP	JJ	O	7	AMOD
7	temporal	temporal	I-NP	JJ	O	8	NMOD
8	association	association	I-NP	NN	O	17	SUB
9	between	between	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	commencement	commencement	I-NP	NN	O	16	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	sirolimus	sirolimus	B-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	and	and	I-NP	CC	O	16	NMOD
16	proteinuria	proteinuria	I-NP	NN	O	9	PMOD
17	implicated	implicate	B-VP	VBD	O	0	ROOT
18	sirolimus	sirolimus	B-NP	NN	O	17	OBJ
19	as	as	B-PP	IN	O	17	VMOD
20	the	the	B-NP	DT	O	23	NMOD
21	most	most	I-NP	RBS	O	22	AMOD
22	likely	likely	I-NP	JJ	O	23	NMOD
23	etiology	etiology	I-NP	NN	O	19	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	proteinuria	proteinuria	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	17	P

1	In	In	B-PP	IN	O	9	VMOD
2	these	these	B-NP	DT	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	9	P
5	the	the	B-NP	DT	O	6	NMOD
6	magnitude	magnitude	I-NP	NN	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	proteinuria	proteinuria	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	assessed	assess	I-VP	VBN	O	9	VC
11	on	on	B-PP	IN	O	10	VMOD
12	morning	morning	B-NP	NN	O	14	NMOD
13	urine	urine	I-NP	NN	O	14	NMOD
14	samples	sample	I-NP	NNS	O	11	PMOD
15	by	by	B-PP	IN	O	10	VMOD
16	turbidometric	turbidometric	B-NP	JJ	O	17	NMOD
17	measurement	measurement	I-NP	NN	O	21	NMOD
18	or	or	O	CC	O	21	NMOD
19	random	random	B-NP	JJ	B-protein	21	NMOD
20	urine	urine	I-NP	NN	I-protein	21	NMOD
21	protein	protein	I-NP	NN	I-protein	15	PMOD
22	:	:	O	:	O	9	P
23	creatinine	creatinine	B-NP	NN	O	24	NMOD
24	ratios	ratio	I-NP	NNS	O	27	NMOD
25	,	,	O	,	O	27	P
26	an	an	B-NP	DT	O	27	NMOD
27	estimate	estimate	I-NP	NN	O	9	VMOD
28	of	of	B-PP	IN	O	27	NMOD
29	grams	gram	B-NP	NNS	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	proteinuria/day	proteinuria/day	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	8	VMOD
2	7	7	B-NP	CD	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	28	28	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	there	there	B-NP	EX	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	12	NMOD
10	striking	striking	I-NP	JJ	O	12	NMOD
11	temporal	temporal	I-NP	JJ	O	12	NMOD
12	association	association	I-NP	NN	O	8	PRD
13	between	between	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	initiation	initiation	I-NP	NN	O	20	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	sirolimus	sirolimus	B-NP	NN	O	16	PMOD
18	and	and	O	CC	O	20	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	development	development	I-NP	NN	O	13	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	nephrotic-range	nephrotic-range	B-NP	JJ	O	23	NMOD
23	proteinuria	proteinuria	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	8	P

1	Proteinuria	Proteinuria	B-NP	NNP	O	2	SUB
2	correlated	correlate	B-VP	VBD	O	0	ROOT
3	most	most	B-ADVP	RBS	O	4	AMOD
4	strongly	strongly	I-ADVP	RB	O	2	VMOD
5	with	with	B-PP	IN	O	2	VMOD
6	sirolimus	sirolimus	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	when	when	B-ADVP	WRB	O	2	VMOD
9	compared	compare	B-VP	VBN	O	8	SBAR
10	to	to	B-PP	TO	O	9	VMOD
11	other	other	B-NP	JJ	O	10	PMOD
12	demographic	demographic	I-NP	JJ	O	11	NMOD
13	and	and	I-NP	CC	O	11	NMOD
14	clinical	clinical	I-NP	JJ	O	11	NMOD
15	variables	variable	I-NP	NNS	O	11	NMOD
16	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	8	VMOD
2	most	most	B-NP	JJS	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	8	P
5	discontinuation	discontinuation	B-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	sirolimus	sirolimus	B-NP	NN	O	6	PMOD
8	resulted	result	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	decrease	decrease	I-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	but	but	O	CC	O	15	NMOD
14	not	not	O	RB	O	13	DEP
15	resolution	resolution	B-NP	NN	O	9	PMOD
16	,	,	O	,	O	15	P
17	of	of	B-PP	IN	O	15	NMOD
18	proteinuria	proteinuria	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	8	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Sirolimus	Sirolimus	B-NP	NN	O	4	SUB
4	induces	induce	B-VP	VBZ	O	1	NMOD
5	or	or	I-VP	CC	O	4	VMOD
6	aggravates	aggravate	I-VP	VBZ	O	4	VMOD
7	pre-existing	pre-existing	B-NP	JJ	O	8	NMOD
8	proteinuria	proteinuria	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	4	VMOD
10	an	an	B-NP	DT	O	12	NMOD
11	unpredictable	unpredictable	I-NP	JJ	O	12	NMOD
12	subset	subset	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	renal	renal	B-NP	JJ	O	16	NMOD
15	allograft	allograft	I-NP	NN	O	16	NMOD
16	recipients	recipient	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	measured	measure	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	9	NMOD
5	objective	objective	I-NP	JJ	O	7	AMOD
6	and	and	I-NP	CC	O	7	AMOD
7	subjective	subjective	I-NP	JJ	O	8	AMOD
8	neurocognitive	neurocognitive	I-NP	JJ	O	9	NMOD
9	effects	effect	I-NP	NNS	O	3	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	14	NMOD
12	single	single	I-NP	JJ	O	14	NMOD
13	10-mg	10-mg	I-NP	JJ	O	14	NMOD
14	dose	dose	I-NP	NN	O	10	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	immediate-release	immediate-release	B-NP	JJ	O	17	NMOD
17	oxycodone	oxycodone	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	9	NMOD
19	healthy	healthy	B-NP	JJ	O	21	AMOD
20	,	,	O	,	O	21	P
21	older	old	B-ADJP	JJR	O	36	NMOD
22	(	(	O	(	O	26	DEP
23	>	>	B-NP	JJR	O	25	NMOD
24	65	65	I-NP	CD	O	25	NMOD
25	years	year	I-NP	NNS	O	26	DEP
26	)	)	O	)	O	21	AMOD
27	,	,	O	,	O	36	P
28	and	and	O	CC	O	36	NMOD
29	middle-aged	middle-aged	B-ADJP	JJ	O	36	NMOD
30	(	(	O	(	O	35	DEP
31	35	35	B-NP	CD	O	33	AMOD
32	to	to	O	TO	O	33	AMOD
33	55	55	B-NP	CD	O	34	NMOD
34	years	year	I-NP	NNS	O	35	DEP
35	)	)	O	)	O	29	AMOD
36	adults	adult	B-NP	NNS	O	18	PMOD
37	who	who	B-NP	WP	O	36	NMOD
38	were	be	B-VP	VBD	O	37	SBAR
39	not	not	I-VP	RB	O	38	VMOD
40	suffering	suffer	I-VP	VBG	O	38	VC
41	from	from	B-PP	IN	O	40	VMOD
42	chronic	chronic	B-NP	JJ	O	46	NMOD
43	or	or	I-NP	CC	O	46	NMOD
44	significant	significant	I-NP	JJ	O	45	AMOD
45	daily	daily	I-NP	JJ	O	46	NMOD
46	pain	pain	I-NP	NN	O	41	PMOD
47	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	suggests	suggest	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	for	for	B-PP	IN	O	30	VMOD
6	healthy	healthy	B-NP	JJ	O	7	AMOD
7	older	old	I-NP	JJR	O	8	NMOD
8	adults	adult	I-NP	NNS	O	5	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	are	be	B-VP	VBP	O	9	SBAR
11	not	not	I-VP	RB	O	12	VMOD
12	suffering	suffer	I-VP	VBG	O	10	VMOD
13	from	from	B-PP	IN	O	12	VMOD
14	chronic	chronic	B-NP	JJ	O	15	NMOD
15	pain	pain	I-NP	NN	O	20	NMOD
16	,	,	O	,	O	20	P
17	neurocognitive	neurocognitive	B-NP	JJ	O	19	AMOD
18	and	and	I-NP	CC	O	19	AMOD
19	pharmacodynamic	pharmacodynamic	I-NP	JJ	O	20	NMOD
20	changes	change	I-NP	NNS	O	13	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	response	response	B-NP	NN	O	21	PMOD
23	to	to	B-PP	TO	O	22	NMOD
24	a	a	B-NP	DT	O	26	NMOD
25	10-mg	10-mg	I-NP	JJ	O	26	NMOD
26	dose	dose	I-NP	NN	O	23	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	immediate-release	immediate-release	B-NP	JJ	O	29	NMOD
29	oxycodone	oxycodone	I-NP	NN	O	27	PMOD
30	are	be	B-VP	VBP	O	4	SBAR
31	similar	similar	B-ADJP	JJ	O	30	PRD
32	to	to	B-PP	TO	O	31	AMOD
33	those	those	B-NP	DT	O	32	PMOD
34	observed	observe	B-VP	VBN	O	33	NMOD
35	for	for	B-PP	IN	O	34	VMOD
36	middle-aged	middle-aged	B-NP	JJ	O	37	NMOD
37	adults	adult	I-NP	NNS	O	35	PMOD
38	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	purpose	purpose	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	present	present	I-NP	JJ	O	8	NMOD
8	study	study	I-NP	NN	O	5	PMOD
9	was	be	B-VP	VBD	O	1	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	determine	determine	I-VP	VB	O	9	PRD
12	the	the	B-NP	DT	O	13	NMOD
13	effect	effect	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	morning-dosed	morning-dosed	B-NP	JJ	O	16	NMOD
16	modafinil	modafinil	I-NP	NN	O	14	PMOD
17	on	on	B-PP	IN	O	13	NMOD
18	sleep	sleep	B-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	daytime	daytime	I-NP	NN	O	21	NMOD
21	sleepiness	sleepiness	I-NP	NN	O	17	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	chronic	chronic	B-NP	JJ	O	25	NMOD
24	cocaine	cocaine	I-NP	NN	O	25	NMOD
25	users	user	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	9	P

1	Modafinil	Modafinil	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	associated	associate	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	increased	increase	B-NP	VBN	O	8	NMOD
6	daytime	daytime	I-NP	NN	O	8	NMOD
7	sleep	sleep	I-NP	NN	O	8	NMOD
8	latency	latency	I-NP	NN	O	4	PMOD
9	,	,	O	,	O	2	P
10	as	as	B-SBAR	IN	O	2	VMOD
11	measured	measure	B-VP	VBN	O	10	SBAR
12	by	by	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	17	NMOD
14	Multiple	Multiple	I-NP	NNP	O	17	NMOD
15	Sleep	Sleep	I-NP	NNP	O	17	NMOD
16	Latency	Latency	I-NP	NNP	O	17	NMOD
17	Test	Test	I-NP	NNP	O	12	PMOD
18	,	,	O	,	O	10	P
19	and	and	O	CC	O	10	DEP
20	a	a	B-NP	DT	O	23	NMOD
21	nearly	nearly	I-NP	RB	O	22	AMOD
22	significant	significant	I-NP	JJ	O	23	NMOD
23	decrease	decrease	I-NP	NN	O	10	VMOD
24	in	in	B-PP	IN	O	23	VMOD
25	subjective	subjective	B-NP	JJ	O	27	NMOD
26	daytime	daytime	I-NP	NN	O	27	NMOD
27	sleepiness	sleepiness	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	2	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Morning-dosed	Morning-dosed	B-NP	JJ	O	4	NMOD
4	modafinil	modafinil	I-NP	NN	O	5	SUB
5	promotes	promote	B-VP	VBZ	O	1	NMOD
6	nocturnal	nocturnal	B-NP	JJ	O	7	NMOD
7	sleep	sleep	I-NP	NN	O	5	OBJ
8	,	,	O	,	O	5	P
9	normalizes	normalize	B-VP	VBZ	O	5	VMOD
10	sleep	sleep	B-NP	NN	O	11	NMOD
11	architecture	architecture	I-NP	NN	O	9	OBJ
12	,	,	O	,	O	5	P
13	and	and	O	CC	O	5	VMOD
14	decreases	decrease	B-VP	VBZ	O	5	VMOD
15	daytime	daytime	B-NP	NN	O	16	NMOD
16	sleepiness	sleepiness	I-NP	NN	O	14	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	abstinent	abstinent	B-NP	JJ	O	20	NMOD
19	cocaine	cocaine	I-NP	NN	O	20	NMOD
20	users	user	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	1	P

1	Efficacy	Efficacy	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	safety	safety	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	asenapine	asenapine	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	a	a	B-NP	DT	O	11	NMOD
8	placebo-	placebo-	I-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	haloperidol-controlled	haloperidol-controlled	I-NP	JJ	O	11	NMOD
11	trial	trial	I-NP	NN	O	6	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	acute	acute	B-NP	JJ	O	16	NMOD
16	exacerbation	exacerbation	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	schizophrenia	schizophrenia	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	3	P

1	Asenapine	Asenapine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	approved	approve	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	9	NMOD
6	Food	Food	I-NP	NNP	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	Drugs	Drugs	I-NP	NNP	O	9	NMOD
9	Administration	Administration	I-NP	NNP	O	4	PMOD
10	in	in	B-PP	IN	O	3	VMOD
11	adults	adult	B-NP	NNS	O	10	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	acute	acute	B-NP	JJ	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	schizophrenia	schizophrenia	B-NP	NN	O	15	PMOD
17	or	or	B-PP	CC	O	15	PMOD
18	of	of	B-PP	IN	O	15	PMOD
19	manic	manic	B-NP	JJ	O	22	NMOD
20	or	or	I-NP	CC	O	22	NMOD
21	mixed	mixed	I-NP	JJ	O	22	NMOD
22	episodes	episode	I-NP	NNS	O	18	PMOD
23	associated	associate	B-VP	VBN	O	22	NMOD
24	with	with	B-PP	IN	O	23	VMOD
25	bipolar	bipolar	B-NP	JJ	O	27	NMOD
26	I	I	I-NP	NN	O	27	NMOD
27	disorder	disorder	I-NP	NN	O	24	PMOD
28	with	with	B-PP	IN	O	27	NMOD
29	or	or	B-PP	CC	O	28	PMOD
30	without	without	B-PP	IN	O	28	PMOD
31	psychotic	psychotic	B-NP	JJ	O	32	NMOD
32	features	feature	I-NP	NNS	O	28	PMOD
33	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	12	VMOD
2	a	a	B-NP	DT	O	5	NMOD
3	double-blind	double-blind	I-NP	JJ	O	5	NMOD
4	6-week	6-week	I-NP	JJ	O	5	NMOD
5	trial	trial	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	12	P
7	458	458	B-NP	CD	O	8	NMOD
8	patients	patient	I-NP	NNS	O	12	SUB
9	with	with	B-PP	IN	O	8	NMOD
10	acute	acute	B-NP	JJ	O	11	NMOD
11	schizophrenia	schizophrenia	I-NP	NN	O	9	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	randomly	randomly	I-VP	RB	O	12	VMOD
14	assigned	assign	I-VP	VBN	O	12	VC
15	to	to	B-PP	TO	O	14	VMOD
16	fixed-dose	fixed-dose	B-NP	JJ	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	asenapine	asenapine	B-NP	NN	O	18	PMOD
20	at	at	B-PP	IN	O	14	VMOD
21	5	5	B-NP	CD	O	22	NMOD
22	mg	mg	I-NP	NN	O	20	PMOD
23	twice	twice	B-ADVP	RB	O	22	NMOD
24	daily	daily	O	RB	O	23	AMOD
25	(	(	O	(	O	27	DEP
26	BID	BID	B-NP	NN	O	27	DEP
27	)	)	O	)	O	23	AMOD
28	,	,	O	,	O	12	P
29	asenapine	asenapine	B-NP	NN	O	28	ROOT
30	at	at	B-PP	IN	O	29	NMOD
31	10	10	B-NP	CD	O	32	AMOD
32	mg	mg	I-NP	NN	O	33	NMOD
33	BID	BID	I-NP	NN	O	38	NMOD
34	,	,	O	,	O	38	P
35	placebo	placebo	B-NP	NN	O	38	NMOD
36	,	,	O	,	O	38	P
37	or	or	O	CC	O	38	NMOD
38	haloperidol	haloperidol	B-NP	NN	O	30	PMOD
39	at	at	B-PP	IN	O	38	NMOD
40	4	4	B-NP	CD	O	41	AMOD
41	mg	mg	I-NP	NN	O	42	NMOD
42	BID	BID	I-NP	NN	O	39	PMOD
43	(	(	O	(	O	48	DEP
44	to	to	B-VP	TO	O	45	VMOD
45	verify	verify	I-VP	VB	O	48	DEP
46	assay	assay	B-NP	NN	O	47	NMOD
47	sensitivity	sensitivity	I-NP	NN	O	45	OBJ
48	)	)	O	)	O	42	NMOD
49	.	.	O	.	O	29	P

1	Extrapyramidal	Extrapyramidal	B-NP	JJ	O	2	NMOD
2	symptoms	symptom	I-NP	NNS	O	0	ROOT
3	reported	report	B-VP	VBN	O	2	NMOD
4	as	as	B-SBAR	IN	O	3	VMOD
5	AEs	AE	B-NP	NNS	B-protein	6	SUB
6	occurred	occur	B-VP	VBD	O	4	SBAR
7	in	in	B-PP	IN	O	6	VMOD
8	15	15	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	18	18	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	19	NMOD
13	,	,	O	,	O	19	P
14	34	34	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	19	NMOD
16	,	,	O	,	O	19	P
17	and	and	O	CC	O	19	NMOD
18	10	10	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	7	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	asenapine	asenapine	I-NP	NN	O	20	PMOD
23	at	at	B-PP	IN	O	6	VMOD
24	5	5	B-NP	CD	O	26	AMOD
25	and	and	I-NP	CC	O	26	AMOD
26	10	10	I-NP	CD	O	34	NMOD
27	mg	mg	I-NP	NN	O	26	AMOD
28	BID	BID	I-NP	NN	O	26	NMOD
29	,	,	O	,	O	34	P
30	haloperidol	haloperidol	B-NP	NN	O	34	NMOD
31	,	,	O	,	O	34	P
32	and	and	O	CC	O	34	NMOD
33	placebo	placebo	B-NP	NN	O	34	NMOD
34	groups	group	I-NP	NNS	O	23	PMOD
35	,	,	O	,	O	6	P
36	respectively	respectively	B-ADVP	RB	O	6	VMOD
37	.	.	O	.	O	2	P

1	Permeability	Permeability	B-NP	NN	O	7	NMOD
2	,	,	O	,	O	7	P
3	ultrastructural	ultrastructural	B-NP	JJ	O	4	NMOD
4	changes	change	I-NP	NNS	O	7	NMOD
5	,	,	O	,	O	7	P
6	and	and	O	CC	O	7	NMOD
7	distribution	distribution	B-NP	NN	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	novel	novel	B-NP	JJ	B-protein	10	NMOD
10	proteins	protein	I-NP	NNS	I-protein	8	PMOD
11	in	in	B-PP	IN	O	7	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	glomerular	glomerular	I-NP	JJ	O	14	NMOD
14	barrier	barrier	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	early	early	B-NP	JJ	O	19	NMOD
17	puromycin	puromycin	I-NP	NN	O	19	NMOD
18	aminonucleoside	aminonucleoside	I-NP	NN	O	19	NMOD
19	nephrosis	nephrosis	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	7	P

1	Using	Use	B-VP	VBG	O	11	VMOD
2	puromycin	puromycin	B-NP	NN	O	4	NMOD
3	aminonucleoside	aminonucleoside	I-NP	NN	O	4	NMOD
4	nephrosis	nephrosis	I-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	PAN	PAN	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	rats	rat	B-NP	NNS	O	1	OBJ
9	,	,	O	,	O	11	P
10	we	we	B-NP	PRP	O	11	SUB
11	studied	study	B-VP	VBD	O	0	ROOT
12	early	early	B-NP	RB	O	13	AMOD
13	ultrastructural	ultrastructural	I-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	permeability	permeability	I-NP	NN	O	16	NMOD
16	changes	change	I-NP	NNS	O	11	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	relation	relation	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	expression	expression	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	podocyte-associated	podocyte-associated	I-NP	JJ	O	25	NMOD
25	molecules	molecule	I-NP	NNS	O	33	NMOD
26	nephrin	nephrin	I-NP	NN	O	33	NMOD
27	,	,	O	,	O	33	P
28	a-actinin	a-actinin	B-NP	NN	B-protein	33	NMOD
29	,	,	O	,	O	33	P
30	dendrin	dendrin	B-NP	NN	O	33	NMOD
31	,	,	O	,	O	33	P
32	and	and	O	CC	O	33	NMOD
33	plekhh2	plekhh2	B-NP	NN	B-protein	22	PMOD
34	,	,	O	,	O	38	P
35	the	the	B-NP	DT	O	38	NMOD
36	last	last	I-NP	JJ	O	38	NMOD
37	two	two	I-NP	CD	O	38	NMOD
38	of	of	B-PP	IN	O	33	NMOD
39	which	which	B-NP	WDT	O	38	PMOD
40	were	be	B-VP	VBD	O	22	SBAR
41	only	only	B-VP	RB	O	40	VMOD
42	recently	recently	I-VP	RB	O	41	AMOD
43	discovered	discover	I-VP	VBN	O	40	VC
44	in	in	B-PP	IN	O	43	VMOD
45	podocytes	podocyte	B-NP	NNS	B-cell_type	44	PMOD
46	.	.	O	.	O	11	P

1	Twin	Twin	B-NP	CD	O	3	NMOD
2	preterm	preterm	I-NP	JJ	O	3	NMOD
3	neonates	neonate	I-NP	NNS	O	0	ROOT
4	with	with	B-PP	IN	O	3	NMOD
5	cardiac	cardiac	B-NP	JJ	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	4	PMOD
7	related	relate	B-VP	VBN	O	6	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	lopinavir/ritonavir	lopinavir/ritonavir	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	3	P

1	One	One	B-NP	CD	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	twins	twin	I-NP	NNS	O	2	PMOD
5	developed	develop	B-VP	VBD	O	0	ROOT
6	complete	complete	B-NP	JJ	O	8	NMOD
7	heart	heart	I-NP	NN	O	8	NMOD
8	block	block	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	dilated	dilated	B-NP	JJ	O	11	NMOD
11	cardiomyopathy	cardiomyopathy	I-NP	NN	O	5	OBJ
12	related	relate	B-VP	VBN	O	11	NMOD
13	to	to	B-PP	TO	O	12	VMOD
14	lopinavir/ritonavir	lopinavir/ritonavir	B-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	5	P
17	a	a	B-NP	DT	O	20	NMOD
18	boosted	boost	I-NP	VBN	O	20	NMOD
19	protease-inhibitor	protease-inhibitor	I-NP	NN	O	20	NMOD
20	agent	agent	I-NP	NN	O	5	OBJ
21	,	,	O	,	O	5	P
22	while	while	B-SBAR	IN	O	5	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	other	other	I-NP	JJ	O	25	NMOD
25	twin	twin	I-NP	NN	O	26	SUB
26	developed	develop	B-VP	VBD	O	22	SBAR
27	mild	mild	B-NP	JJ	O	28	NMOD
28	bradycardia	bradycardia	I-NP	NN	O	26	OBJ
29	.	.	O	.	O	5	P

1	Learning	Learning	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	rats	rat	B-NP	NNS	O	2	PMOD
4	under	under	B-PP	IN	O	1	NMOD
5	amnesia	amnesia	B-NP	NN	O	4	PMOD
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	pentobarbital	pentobarbital	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	1	P

1	Dissociated	Dissociate	B-NP	VBN	O	2	NMOD
2	learning	learning	I-NP	NN	O	11	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	rats	rat	B-NP	NNS	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	normal	normal	I-NP	JJ	O	8	NMOD
8	state	state	I-NP	NN	O	5	PMOD
9	and	and	O	CC	O	11	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	state	state	I-NP	NN	O	23	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	amnesia	amnesia	B-NP	NN	O	12	PMOD
14	produced	produce	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	pentobarbital	pentobarbital	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	22	DEP
18	15	15	B-NP	CD	O	19	NMOD
19	mg/kg	mg/kg	I-NP	NN	O	22	DEP
20	,	,	O	,	O	19	P
21	ip	ip	B-ADJP	JJ	O	19	NMOD
22	)	)	O	)	O	16	NMOD
23	was	be	B-VP	VBD	O	0	ROOT
24	carried	carry	I-VP	VBN	O	23	VC
25	out	out	B-PRT	RP	O	24	VMOD
26	.	.	O	.	O	23	P

1	Angiosarcoma	Angiosarcoma	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	liver	liver	I-NP	NN	O	2	PMOD
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	diethylstilbestrol	diethylstilbestrol	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	1	P

1	Angiosarcoma	Angiosarcoma	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	liver	liver	I-NP	NN	O	2	PMOD
5	occurred	occur	B-VP	VBD	O	0	ROOT
6	in	in	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	76-year-old	76-year-old	I-NP	JJ	O	9	NMOD
9	man	man	I-NP	NN	O	6	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	had	have	B-VP	VBD	O	10	SBAR
12	been	be	I-VP	VBN	O	11	VC
13	treated	treat	I-VP	VBN	O	12	VC
14	for	for	B-PP	IN	O	13	VMOD
15	a	a	B-NP	DT	O	17	NMOD
16	well-differentiated	well-differentiated	I-NP	JJ	O	17	NMOD
17	adenocarcinoma	adenocarcinoma	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	liver	liver	I-NP	NN	O	18	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	diethylstilbestrol	diethylstilbestrol	B-NP	NN	O	21	PMOD
23	for	for	B-PP	IN	O	22	NMOD
24	13	13	B-NP	CD	O	25	NMOD
25	years	year	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	5	P

1	Role	Role	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	xanthine	xanthine	B-NP	NN	B-protein	4	NMOD
4	oxidase	oxidase	I-NP	NN	I-protein	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	dexamethasone	dexamethasone	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	hypertension	hypertension	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	rats.	rats.	B-NP	NN	B-protein	9	PMOD
11	1	1	I-NP	CD	I-protein	10	NMOD
12	.	.	O	.	O	7	P

1	Glucocorticoid	Glucocorticoid	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	10	VMOD
3	hypertension	hypertension	B-NP	NN	O	10	SUB
4	(	(	O	(	O	6	DEP
5	GC-HT	GC-HT	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	in	in	B-PP	IN	O	3	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	rat	rat	I-NP	NN	O	7	PMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	nitric	nitric	B-NP	JJ	B-protein	15	NMOD
14	oxide-redox	oxide-redox	I-NP	NN	I-protein	15	NMOD
15	imbalance.	imbalance.	I-NP	NN	I-protein	12	PMOD
16	2	2	I-NP	CD	I-protein	15	NMOD
17	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	role	role	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	xanthine	xanthine	B-NP	NN	B-protein	7	NMOD
7	oxidase	oxidase	I-NP	NN	I-protein	5	PMOD
8	(	(	O	(	O	10	DEP
9	XO	XO	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	,	,	O	,	O	7	P
12	which	which	B-NP	WDT	O	7	NMOD
13	is	be	B-VP	VBZ	O	12	SBAR
14	implicated	implicate	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	production	production	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	reactive	reactive	B-NP	JJ	O	21	NMOD
20	oxygen	oxygen	I-NP	NN	O	21	NMOD
21	species	specie	I-NP	NNS	O	18	PMOD
22	,	,	O	,	O	2	P
23	in	in	B-PP	IN	O	2	VMOD
24	dexamethasone	dexamethasone	B-NP	NN	O	25	SUB
25	induced	induce	B-VP	VBD	O	23	SBAR
26	hypertension	hypertension	B-NP	NN	O	25	OBJ
27	(	(	O	(	O	29	DEP
28	dex-HT	dex-HT	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	2	P
31	3	3	B-NP	CD	O	2	VMOD
32	.	.	O	.	O	2	P

1	Dex	Dex	B-NP	NN	O	2	SUB
2	increased	increase	B-VP	VBD	O	0	ROOT
3	SBP	SBP	B-NP	NN	B-protein	2	OBJ
4	(	(	O	(	O	15	DEP
5	110	110	B-NP	CD	O	9	AMOD
6	+/-	+/-	I-NP	SYM	O	9	AMOD
7	2-126	2-126	I-NP	CD	O	9	AMOD
8	+/-	+/-	I-NP	SYM	O	9	AMOD
9	3	3	I-NP	CD	O	10	NMOD
10	mmHg	mmHg	I-NP	NN	O	12	NMOD
11	;	;	O	:	O	12	P
12	P	P	B-NP	NN	O	14	SUB
13	<	<	B-NP	SYM	O	14	VMOD
14	0.001	0.001	I-NP	CD	O	15	DEP
15	)	)	O	)	O	3	NMOD
16	and	and	O	CC	O	2	VMOD
17	decreased	decrease	B-VP	VBD	O	2	VMOD
18	thymus	thymus	B-NP	NN	O	17	OBJ
19	(	(	O	(	O	23	DEP
20	P	P	B-NP	NN	O	22	SUB
21	<	<	O	SYM	O	22	VMOD
22	0.001	0.001	B-NP	CD	O	23	DEP
23	)	)	O	)	O	17	VMOD
24	and	and	O	CC	O	17	VMOD
25	bodyweights	bodyweight	B-NP	NNS	O	17	VMOD
26	(	(	O	(	O	31	DEP
27	P	P	B-NP	NN	O	30	SUB
28	"	"	O	"	O	30	AMOD
29	<	<	B-NP	SYM	O	30	AMOD
30	0.01	0.01	I-NP	CD	O	31	DEP
31	)	)	O	)	O	25	NMOD
32	.	.	O	.	O	2	P

1	Allopurinol	Allopurinol	B-NP	NN	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	prevent	prevent	I-VP	VB	O	2	VC
5	dex-HT	dex-HT	B-NP	NN	O	4	OBJ
6	.	.	O	.	O	2	P

1	Previous	Previous	B-NP	JJ	O	3	NMOD
2	clinical	clinical	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	proposed	propose	I-VP	VBN	O	4	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	risperidone	risperidone	B-NP	NN	O	10	NMOD
8	's	's	B-NP	POS	O	10	NMOD
9	pharmacologic	pharmacologic	I-NP	JJ	O	10	NMOD
10	profile	profile	I-NP	NN	O	11	SUB
11	may	may	B-VP	MD	O	6	SBAR
12	produce	produce	I-VP	VB	O	11	VC
13	improved	improved	B-NP	JJ	O	14	NMOD
14	efficacy	efficacy	I-NP	NN	O	12	OBJ
15	for	for	B-PP	IN	O	14	NMOD
16	negative	negative	B-NP	JJ	O	18	NMOD
17	psychotic	psychotic	I-NP	JJ	O	18	NMOD
18	symptoms	symptom	I-NP	NNS	O	15	PMOD
19	and	and	O	CC	O	4	VMOD
20	decreased	decrease	B-VP	VBD	O	4	VMOD
21	propensity	propensity	B-NP	NN	O	20	OBJ
22	for	for	B-PP	IN	O	21	NMOD
23	extrapyramidal	extrapyramidal	B-NP	JJ	O	25	NMOD
24	side	side	I-NP	NN	O	25	NMOD
25	effects	effect	I-NP	NNS	O	22	PMOD
26	;	;	O	:	O	4	VMOD
27	features	feature	B-NP	NNS	O	26	OBJ
28	shared	share	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	so-called	so-called	B-NP	JJ	O	33	NMOD
31	'atypical	'atypical	I-NP	JJ	O	33	NMOD
32	'	'	I-NP	"	O	33	NMOD
33	neuroleptics	neuroleptic	I-NP	NNS	O	29	PMOD
34	.	.	O	.	O	4	P

1	Drug	Drug	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	parkinsonism	parkinsonism	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	observed	observe	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	subjects	subject	B-NP	NNS	O	6	PMOD
8	treated	treat	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	risperidone	risperidone	B-NP	NN	O	16	NMOD
11	(	(	O	(	O	14	DEP
12	42	42	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	and	and	O	CC	O	16	NMOD
16	haloperidol	haloperidol	B-NP	NN	O	9	PMOD
17	(	(	O	(	O	20	DEP
18	29	29	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	20	DEP
20	)	)	O	)	O	16	NMOD
21	and	and	O	CC	O	4	VMOD
22	was	be	B-VP	VBD	O	4	VMOD
23	observed	observe	I-VP	VBN	O	22	VC
24	at	at	B-PP	IN	O	23	VMOD
25	occupancy	occupancy	B-NP	NN	O	26	NMOD
26	levels	level	I-NP	NNS	O	24	PMOD
27	above	above	B-PP	IN	O	23	VMOD
28	60	60	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	4	P

1	Simvastatin-ezetimibe	Simvastatin-ezetimibe	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hepatic	hepatic	B-NP	JJ	O	4	NMOD
4	failure	failure	I-NP	NN	O	2	OBJ
5	necessitating	necessitate	B-VP	VBG	O	4	NMOD
6	liver	liver	B-NP	NN	O	7	NMOD
7	transplantation	transplantation	I-NP	NN	O	5	OBJ
8	.	.	O	.	O	2	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	hepatotoxic	hepatotoxic	B-NP	JJ	O	4	NMOD
4	events	event	I-NP	NNS	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	not	not	I-VP	RB	O	5	VMOD
7	been	be	I-VP	VBN	O	5	VC
8	widely	widely	I-VP	RB	O	7	VMOD
9	published	publish	I-VP	VBN	O	7	VC
10	with	with	B-PP	IN	O	9	VMOD
11	ezetimibe	ezetimibe	B-NP	NN	O	16	NMOD
12	or	or	O	CC	O	16	NMOD
13	the	the	B-NP	DT	O	16	NMOD
14	combination	combination	I-NP	NN	O	16	NMOD
15	agent	agent	I-NP	NN	O	16	NMOD
16	simvastatin-ezetimibe	simvastatin-ezetimibe	I-NP	NN	O	10	PMOD
17	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	70-year-old	70-year-old	I-NP	JJ	O	6	NMOD
5	Hispanic	Hispanic	I-NP	JJ	O	6	NMOD
6	woman	woman	I-NP	NN	O	2	OBJ
7	who	who	B-NP	WP	O	6	NMOD
8	developed	develop	B-VP	VBD	O	7	SBAR
9	fulminant	fulminant	B-NP	JJ	O	11	NMOD
10	hepatic	hepatic	I-NP	JJ	O	11	NMOD
11	failure	failure	I-NP	NN	O	8	OBJ
12	necessitating	necessitate	B-VP	VBG	O	11	NMOD
13	liver	liver	B-NP	NN	B-protein	16	NMOD
14	transplantation	transplantation	I-NP	NN	I-protein	16	NMOD
15	10	10	B-NP	CD	I-protein	16	NMOD
16	weeks	week	I-NP	NNS	I-protein	12	OBJ
17	after	after	B-PP	IN	O	12	VMOD
18	conversion	conversion	B-NP	NN	O	17	PMOD
19	from	from	B-PP	IN	O	18	NMOD
20	simvastatin	simvastatin	B-NP	NN	O	22	NMOD
21	40	40	I-NP	CD	O	22	NMOD
22	mg/day	mg/day	I-NP	NN	O	19	PMOD
23	to	to	B-PP	TO	O	18	NMOD
24	simvastatin	simvastatin	B-NP	NN	O	28	NMOD
25	10	10	I-NP	CD	O	28	NMOD
26	mg-ezetimibe	mg-ezetimibe	I-NP	JJ	O	28	NMOD
27	40	40	I-NP	CD	O	28	NMOD
28	mg/day	mg/day	I-NP	NN	O	23	PMOD
29	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	5	NMOD
2	patient	patient	I-NP	NN	O	5	NMOD
3	's	's	B-NP	POS	O	5	NMOD
4	lipid	lipid	I-NP	NN	O	5	NMOD
5	panel	panel	I-NP	NN	O	6	SUB
6	had	have	B-VP	VBD	O	0	ROOT
7	been	be	I-VP	VBN	O	6	VC
8	maintained	maintain	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	simvastatin	simvastatin	B-NP	NN	O	9	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	18	18	B-NP	CD	O	13	NMOD
13	months	month	I-NP	NNS	O	11	PMOD
14	before	before	B-SBAR	IN	O	8	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	conversion	conversion	I-NP	NN	O	14	PMOD
17	without	without	B-PP	IN	O	16	NMOD
18	evidence	evidence	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	hepatotoxicity	hepatotoxicity	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	6	P

1	Simvastatinezetimibe	Simvastatinezetimibe	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	escitalopram	escitalopram	I-NP	NN	O	12	SUB
4	(	(	O	(	O	11	DEP
5	which	which	B-NP	WDT	O	11	DEP
6	she	she	B-NP	PRP	O	7	SUB
7	was	be	B-VP	VBD	O	5	SBAR
8	taking	take	I-VP	VBG	O	7	VMOD
9	for	for	B-PP	IN	O	8	VMOD
10	depression	depression	B-NP	NN	O	9	PMOD
11	)	)	O	)	O	3	NMOD
12	were	be	B-VP	VBD	O	18	VMOD
13	discontinued	discontinue	I-VP	VBN	O	12	VC
14	,	,	O	,	O	18	P
15	and	and	O	CC	O	18	NMOD
16	other	other	B-NP	JJ	O	18	NMOD
17	potential	potential	I-NP	JJ	O	18	NMOD
18	causes	cause	I-NP	NNS	O	21	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	hepatotoxicity	hepatotoxicity	B-NP	NN	O	19	PMOD
21	were	be	B-VP	VBD	O	0	ROOT
22	excluded	exclude	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	Ezetimibe	Ezetimibe	B-NP	NNP	O	2	SUB
2	undergoes	undergo	B-VP	VBZ	O	0	ROOT
3	extensive	extensive	B-NP	JJ	O	4	NMOD
4	glucuronidation	glucuronidation	I-NP	NN	O	2	OBJ
5	by	by	B-PP	IN	O	2	VMOD
6	uridine	uridine	B-NP	NN	B-protein	8	NMOD
7	diphosphate	diphosphate	I-NP	NN	I-protein	8	NMOD
8	glucoronosyltransferases	glucoronosyltransferas	I-NP	NNS	I-protein	5	PMOD
9	(	(	O	(	O	11	DEP
10	UGT	UGT	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	in	in	B-PP	IN	O	2	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	intestine	intestine	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	liver	liver	I-NP	NN	O	12	PMOD
17	and	and	O	CC	O	2	VMOD
18	may	may	B-VP	MD	O	2	VMOD
19	have	have	I-VP	VB	O	18	VC
20	inhibited	inhibit	I-VP	VBN	O	19	VC
21	the	the	B-NP	DT	O	22	NMOD
22	glucuronidation	glucuronidation	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	simvastatin	simvastatin	B-NP	NN	O	26	NMOD
25	hydroxy	hydroxy	I-NP	NN	O	26	NMOD
26	acid	acid	I-NP	NN	O	23	PMOD
27	,	,	O	,	O	20	P
28	resulting	result	B-VP	VBG	O	20	VMOD
29	in	in	B-PP	IN	O	28	VMOD
30	increased	increase	B-NP	VBN	O	32	NMOD
31	simvastatin	simvastatin	I-NP	NN	O	32	NMOD
32	exposure	exposure	I-NP	NN	O	35	NMOD
33	and	and	O	CC	O	35	NMOD
34	subsequent	subsequent	B-NP	JJ	O	35	NMOD
35	hepatotoxicity	hepatotoxicity	I-NP	NN	O	29	PMOD
36	.	.	O	.	O	2	P

1	To	To	B-PP	TO	O	6	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	this	this	B-NP	DT	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	the	the	B-NP	DT	O	10	NMOD
8	first	first	I-NP	JJ	O	10	NMOD
9	case	case	I-NP	NN	O	10	NMOD
10	report	report	I-NP	NN	O	6	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	simvastatin-ezetimibe	simvastatin-ezetimibe	B-NP	JJ	O	15	NMOD
13	induced	induce	I-NP	VBN	O	15	NMOD
14	liver	liver	I-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	11	PMOD
16	that	that	B-NP	WDT	O	15	NMOD
17	resulted	result	B-VP	VBD	O	16	SBAR
18	in	in	B-PP	IN	O	17	VMOD
19	liver	liver	B-NP	NN	O	20	NMOD
20	transplantation	transplantation	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	postulate	postulate	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	mechanism	mechanism	I-NP	NN	O	11	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	simvastatinezetimibe	simvastatinezetimibe	I-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	hepatotoxicity	hepatotoxicity	I-NP	NN	O	6	PMOD
11	is	be	B-VP	VBZ	O	3	SBAR
12	the	the	B-NP	DT	O	15	NMOD
13	increased	increase	I-NP	VBN	O	15	NMOD
14	simvastatin	simvastatin	I-NP	NN	O	15	NMOD
15	exposure	exposure	I-NP	NN	O	11	PRD
16	by	by	B-PP	IN	O	15	NMOD
17	ezetimibe	ezetimibe	B-NP	NN	O	18	NMOD
18	inhibition	inhibition	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	UGT	UGT	B-NP	NN	B-protein	21	NMOD
21	enzymes	enzyme	I-NP	NNS	I-protein	19	PMOD
22	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Methamphetamine	Methamphetamine	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	10	NMOD
6	very	very	I-NP	RB	O	7	AMOD
7	addictive	addictive	I-NP	JJ	O	9	AMOD
8	,	,	I-NP	,	O	9	P
9	powerful	powerful	I-NP	JJ	O	10	NMOD
10	stimulant	stimulant	I-NP	NN	O	4	PRD
11	that	that	B-NP	WDT	O	10	NMOD
12	increases	increase	B-VP	VBZ	O	11	SBAR
13	wakefulness	wakefulness	B-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	physical	physical	B-NP	JJ	O	16	NMOD
16	activity	activity	I-NP	NN	O	12	OBJ
17	and	and	O	CC	O	4	VMOD
18	can	can	B-VP	MD	O	4	VMOD
19	produce	produce	I-VP	VB	O	18	VC
20	other	other	B-NP	JJ	O	21	NMOD
21	effects	effect	I-NP	NNS	O	19	OBJ
22	such	such	B-PP	JJ	O	23	PMOD
23	as	as	I-PP	IN	O	21	NMOD
24	cardiac	cardiac	B-NP	JJ	O	25	NMOD
25	dysrhythmias	dysrhythmia	I-NP	NNS	O	33	NMOD
26	,	,	O	,	O	33	P
27	hypertension	hypertension	B-NP	NN	O	33	NMOD
28	,	,	O	,	O	33	P
29	hallucinations	hallucination	B-NP	NNS	O	33	NMOD
30	,	,	O	,	O	33	P
31	and	and	O	CC	O	33	NMOD
32	violent	violent	B-NP	JJ	O	33	NMOD
33	behavior	behavior	I-NP	NN	O	23	PMOD
34	.	.	O	.	O	4	P

1	Dental	Dental	B-NP	JJ	O	2	NMOD
2	patients	patient	I-NP	NNS	O	5	SUB
3	abusing	abuse	B-VP	VBG	O	2	NMOD
4	methamphetamine	methamphetamine	B-NP	NN	O	3	OBJ
5	can	can	B-VP	MD	O	0	ROOT
6	present	present	I-VP	VB	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	poor	poor	B-NP	JJ	O	10	NMOD
9	oral	oral	I-NP	JJ	O	10	NMOD
10	hygiene	hygiene	I-NP	NN	O	26	NMOD
11	,	,	O	,	O	26	P
12	xerostomia	xerostomia	B-NP	NN	O	26	NMOD
13	,	,	O	,	O	26	P
14	rampant	rampant	B-NP	JJ	O	15	NMOD
15	caries	cary	I-NP	NNS	O	26	NMOD
16	(	(	O	(	O	21	DEP
17	"	"	O	"	O	19	NMOD
18	meth	meth	B-NP	NN	O	19	NMOD
19	mouth	mouth	I-NP	NN	O	21	DEP
20	"	"	O	"	O	19	NMOD
21	)	)	O	)	O	15	NMOD
22	,	,	O	,	O	26	P
23	and	and	O	CC	O	26	NMOD
24	excessive	excessive	B-NP	JJ	O	26	NMOD
25	tooth	tooth	I-NP	NN	O	26	NMOD
26	wear	wear	I-NP	NN	O	7	PMOD
27	.	.	O	.	O	5	P

1	She	She	B-NP	PRP	O	2	SUB
2	reported	report	B-VP	VBD	O	0	ROOT
3	her	her	B-NP	PRP$	O	4	NMOD
4	use	use	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	methamphetamine	methamphetamine	B-NP	NN	O	5	PMOD
7	for	for	B-PP	IN	O	4	NMOD
8	five	five	B-NP	CD	O	9	NMOD
9	years	year	I-NP	NNS	O	7	PMOD
10	and	and	O	CC	O	2	VMOD
11	had	have	B-VP	VBD	O	2	VMOD
12	not	not	I-VP	RB	O	11	VMOD
13	experienced	experience	I-VP	VBN	O	11	VC
14	any	any	B-NP	DT	O	17	NMOD
15	major	major	I-NP	JJ	O	17	NMOD
16	carious	carious	I-NP	JJ	O	17	NMOD
17	episodes	episode	I-NP	NNS	O	13	OBJ
18	before	before	B-SBAR	IN	O	11	VMOD
19	she	she	B-NP	PRP	O	20	SUB
20	started	start	B-VP	VBD	O	18	SBAR
21	using	use	I-VP	VBG	O	20	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	drug	drug	I-NP	NN	O	21	OBJ
24	.	.	O	.	O	2	P

1	Thyroxine	Thyroxine	B-NP	NN	O	2	NMOD
2	abuse	abuse	I-NP	NN	O	6	NMOD
3	:	:	O	:	O	2	P
4	an	an	B-NP	DT	O	6	NMOD
5	unusual	unusual	I-NP	JJ	O	6	NMOD
6	case	case	I-NP	NN	O	0	ROOT
7	of	of	B-PP	IN	O	6	NMOD
8	thyrotoxicosis	thyrotoxicosis	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	pregnancy	pregnancy	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	6	P

1	Attenuation	Attenuation	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	methamphetamine	methamphetamine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	nigrostriatal	nigrostriatal	B-NP	JJ	O	7	NMOD
6	dopaminergic	dopaminergic	I-NP	JJ	O	7	NMOD
7	neurotoxicity	neurotoxicity	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	mice	mouse	B-NP	NNS	O	8	PMOD
10	by	by	B-PP	IN	O	4	VMOD
11	lipopolysaccharide	lipopolysaccharide	B-NP	NN	O	12	NMOD
12	pretreatment	pretreatment	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	4	P

1	Immunological	Immunological	B-NP	JJ	O	2	NMOD
2	activation	activation	I-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	proposed	propose	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	play	play	I-VP	VB	O	5	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	role	role	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	methamphetamine	methamphetamine	B-NP	NN	O	12	SUB
12	induced	induce	B-VP	VBD	O	10	SBAR
13	dopaminergic	dopaminergic	B-NP	JJ	O	15	NMOD
14	terminal	terminal	I-NP	JJ	O	15	NMOD
15	damage	damage	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	examined	examine	B-VP	VBD	O	23	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	roles	role	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	lipopolysaccharide	lipopolysaccharide	B-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	a	a	B-NP	DT	O	16	NMOD
13	pro-inflammatory	pro-inflammatory	I-NP	JJ	B-protein	15	AMOD
14	and	and	I-NP	CC	I-protein	15	AMOD
15	inflammatory	inflammatory	I-NP	JJ	I-protein	16	NMOD
16	factor	factor	I-NP	NN	I-protein	9	PMOD
17	,	,	O	,	O	6	P
18	treatment	treatment	B-NP	NN	O	23	SUB
19	in	in	B-PP	IN	O	18	NMOD
20	modulating	modulate	B-VP	VBG	O	19	PMOD
21	the	the	B-NP	DT	O	22	NMOD
22	methamphetamine	methamphetamine	I-NP	NN	O	20	OBJ
23	induced	induce	B-VP	VBD	O	0	ROOT
24	nigrostriatal	nigrostriatal	B-NP	JJ	O	26	NMOD
25	dopamine	dopamine	I-NP	NN	O	26	NMOD
26	neurotoxicity	neurotoxicity	I-NP	NN	O	23	OBJ
27	.	.	O	.	O	23	P

1	Lipopolysaccharide	Lipopolysaccharide	B-NP	NN	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	3	SUB
3	did	do	B-VP	VBD	O	0	ROOT
4	not	not	I-VP	RB	O	3	VMOD
5	affect	affect	I-VP	VB	O	3	VC
6	the	the	B-NP	DT	O	12	NMOD
7	basal	basal	I-NP	JJ	O	9	NMOD
8	body	body	I-NP	NN	O	9	NMOD
9	temperature	temperature	I-NP	NN	O	12	NMOD
10	or	or	O	CC	O	12	NMOD
11	methamphetamine-elicited	methamphetamine-elicited	B-NP	JJ	O	12	NMOD
12	hyperthermia	hyperthermia	I-NP	NN	O	14	NMOD
13	three	three	B-NP	CD	O	14	NMOD
14	days	day	I-NP	NNS	O	5	OBJ
15	later	later	B-ADVP	RB	O	14	NMOD
16	.	.	O	.	O	3	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	converting	convert	B-VP	VBG	O	2	PMOD
4	enzyme	enzyme	B-NP	NN	O	5	NMOD
5	inhibition	inhibition	I-NP	NN	O	3	OBJ
6	on	on	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	course	course	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	adriamycin	adriamycin	B-NP	NN	O	12	NMOD
11	induced	induced	I-NP	JJ	O	12	NMOD
12	nephropathy	nephropathy	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	7	NMOD
5	converting	convert	I-NP	VBG	O	7	NMOD
6	enzyme	enzyme	I-NP	NN	O	7	NMOD
7	inhibitor	inhibitor	I-NP	NN	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	CEI	CEI	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	enalapril	enalapril	B-NP	NN	O	3	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	assessed	assess	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	Munich-Wistar	Munich-Wistar	B-NP	JJ	O	16	NMOD
16	rats	rat	I-NP	NNS	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	established	establish	B-NP	VBN	O	20	NMOD
19	adriamycin	adriamycin	I-NP	NN	O	20	NMOD
20	nephrosis	nephrosis	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	12	P

1	Rats	Rat	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	given	give	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	6	NMOD
5	single	single	I-NP	JJ	O	6	NMOD
6	dose	dose	I-NP	NN	O	11	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	adriamycin	adriamycin	B-NP	NN	O	7	PMOD
9	and	and	O	CC	O	11	NMOD
10	one	one	B-NP	CD	O	11	NMOD
11	month	month	I-NP	NN	O	27	NMOD
12	later	later	B-VP	RB	O	13	VMOD
13	divided	divide	I-VP	VBN	O	11	NMOD
14	into	into	B-PP	IN	O	13	VMOD
15	four	four	B-NP	CD	O	16	NMOD
16	groups	group	I-NP	NNS	O	14	PMOD
17	matched	match	B-VP	VBN	O	16	NMOD
18	for	for	B-PP	IN	O	17	VMOD
19	albuminuria	albuminuria	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	27	P
21	blood	blood	B-NP	NN	O	22	NMOD
22	pressure	pressure	I-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	and	and	O	CC	O	27	NMOD
25	plasma	plasma	B-NP	NN	O	27	NMOD
26	albumin	albumin	I-NP	NN	O	27	NMOD
27	concentration	concentration	I-NP	NN	O	3	OBJ
28	.	.	O	.	O	2	P

1	These	These	B-NP	DT	O	3	NMOD
2	short-term	short-term	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	showed	show	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	enalapril	enalapril	B-NP	NN	O	7	SUB
7	reduced	reduce	B-VP	VBD	O	5	SBAR
8	arterial	arterial	B-NP	JJ	O	10	NMOD
9	blood	blood	I-NP	NN	O	10	NMOD
10	pressure	pressure	I-NP	NN	O	35	NMOD
11	(	(	O	(	O	35	NMOD
12	101	101	B-NP	CD	O	14	AMOD
13	+/-	+/-	I-NP	SYM	O	14	AMOD
14	2	2	I-NP	CD	O	20	NMOD
15	vs.	vs.	B-PP	IN	O	20	NMOD
16	124	124	B-NP	CD	O	18	AMOD
17	+/-	+/-	I-NP	SYM	O	18	AMOD
18	3	3	I-NP	CD	O	20	NMOD
19	mm	mm	I-NP	NN	O	20	NMOD
20	Hg	Hg	I-NP	NN	O	22	NMOD
21	,	,	O	,	O	22	P
22	group	group	B-NP	NN	O	35	NMOD
23	2	2	I-NP	CD	O	22	NMOD
24	vs.	vs.	B-PP	IN	O	31	DEP
25	1	1	B-NP	CD	O	27	NMOD
26	,	,	O	,	O	27	P
27	P	P	B-NP	NN	O	29	SUB
28	less	less	B-ADJP	JJR	O	29	AMOD
29	than	than	B-PP	IN	O	31	DEP
30	0.05	0.05	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	22	NMOD
32	and	and	O	CC	O	35	NMOD
33	glomerular	glomerular	B-NP	JJ	O	35	NMOD
34	capillary	capillary	I-NP	JJ	O	35	NMOD
35	pressure	pressure	I-NP	NN	O	7	OBJ
36	(	(	O	(	O	51	DEP
37	54	54	B-NP	CD	O	39	AMOD
38	+/-	+/-	B-NP	SYM	O	39	AMOD
39	1	1	I-NP	CD	O	45	NMOD
40	vs.	vs.	B-PP	IN	O	45	NMOD
41	61	61	B-NP	CD	O	43	AMOD
42	+/-	+/-	I-NP	SYM	O	43	AMOD
43	2	2	I-NP	CD	O	45	NMOD
44	mm	mm	I-NP	NN	O	45	NMOD
45	Hg	Hg	I-NP	NN	O	47	NMOD
46	,	,	O	,	O	47	P
47	P	P	B-NP	NN	O	49	SUB
48	less	less	B-ADJP	JJR	O	49	AMOD
49	than	than	B-PP	IN	O	51	DEP
50	0.05	0.05	B-NP	CD	O	49	AMOD
51	)	)	O	)	O	35	NMOD
52	without	without	B-PP	IN	O	7	VMOD
53	reducing	reduce	B-VP	VBG	O	52	PMOD
54	albuminuria	albuminuria	B-NP	NN	O	53	OBJ
55	(	(	O	(	O	54	NMOD
56	617	617	B-NP	CD	O	58	AMOD
57	+/-	+/-	I-NP	SYM	O	58	AMOD
58	50	50	I-NP	CD	O	55	PMOD
59	vs.	vs.	B-PP	IN	O	58	NMOD
60	570	570	B-NP	CD	O	62	AMOD
61	+/-	+/-	I-NP	SYM	O	62	AMOD
62	47	47	I-NP	CD	O	63	NMOD
63	mg/day	mg/day	I-NP	NN	O	66	NMOD
64	)	)	O	)	O	63	NMOD
65	or	or	O	CC	O	66	NMOD
66	GFR	GFR	B-NP	NN	B-protein	59	PMOD
67	(	(	O	(	O	76	DEP
68	1.03	1.03	B-NP	CD	O	70	AMOD
69	+/-	+/-	I-NP	SYM	O	70	AMOD
70	0.04	0.04	I-NP	CD	O	75	NMOD
71	vs.	vs.	B-PP	IN	O	75	NMOD
72	1.04	1.04	B-NP	CD	O	74	AMOD
73	+/-	+/-	I-NP	SYM	O	74	AMOD
74	0.11	0.11	I-NP	CD	O	75	NMOD
75	ml/min	ml/min	I-NP	NN	O	76	DEP
76	)	)	O	)	O	66	NMOD
77	.	.	O	.	O	4	P

1	Groups	Group	B-NP	NNS	O	5	SUB
2	3	3	I-NP	CD	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	4	4	I-NP	CD	O	1	NMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	studied	study	I-VP	VBN	O	5	VC
7	at	at	B-PP	IN	O	14	VMOD
8	four	four	B-NP	CD	O	7	PMOD
9	and	and	O	CC	O	7	PMOD
10	at	at	B-PP	IN	O	7	DEP
11	six	six	B-NP	CD	O	12	NMOD
12	months	month	I-NP	NNS	O	10	PMOD
13	to	to	B-VP	TO	O	14	VMOD
14	assess	assess	I-VP	VB	O	6	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	effect	effect	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	enalapril	enalapril	B-NP	NN	O	17	PMOD
19	on	on	B-PP	IN	O	16	NMOD
20	progression	progression	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	renal	renal	B-NP	JJ	O	23	NMOD
23	injury	injury	I-NP	NN	O	21	PMOD
24	in	in	B-PP	IN	O	20	NMOD
25	adriamycin	adriamycin	B-NP	NN	O	26	NMOD
26	nephrosis	nephrosis	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	5	P

1	Chronic	Chronic	B-NP	JJ	O	3	NMOD
2	enalapril	enalapril	I-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	4	SUB
4	reduced	reduce	B-VP	VBD	O	0	ROOT
5	blood	blood	B-NP	NN	O	6	NMOD
6	pressure	pressure	I-NP	NN	O	4	OBJ
7	without	without	B-PP	IN	O	4	VMOD
8	reducing	reduce	B-VP	VBG	O	7	PMOD
9	albuminuria	albuminuria	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	group	group	B-NP	NN	O	10	PMOD
12	4	4	I-NP	CD	O	11	NMOD
13	.	.	O	.	O	4	P

1	Butyrylcholinesterase	Butyrylcholinesterase	B-NP	NN	O	3	NMOD
2	gene	gene	I-NP	NN	O	3	NMOD
3	mutations	mutation	I-NP	NNS	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	prolonged	prolonged	B-NP	JJ	O	8	NMOD
8	apnea	apnea	I-NP	NN	O	6	PMOD
9	after	after	B-PP	IN	O	5	NMOD
10	succinylcholine	succinylcholine	B-NP	NN	O	9	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	electroconvulsive	electroconvulsive	B-NP	JJ	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	3	P

1	Ketamine	Ketamine	B-NP	NN	O	2	NMOD
2	sedation	sedation	I-NP	NN	O	0	ROOT
3	for	for	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	reduction	reduction	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	children	child	B-NP	NNS	O	9	NMOD
8	's	's	B-NP	POS	O	9	NMOD
9	fractures	fracture	I-NP	NNS	O	6	PMOD
10	in	in	B-PP	IN	O	5	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	emergency	emergency	I-NP	NN	O	13	NMOD
13	department	department	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	examine	examine	I-VP	VB	O	7	PRD
10	the	the	B-NP	DT	O	13	NMOD
11	safety	safety	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	efficacy	efficacy	I-NP	NN	O	9	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	ketamine	ketamine	B-NP	NN	O	14	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	sedation	sedation	B-NP	NN	O	16	PMOD
18	in	in	B-PP	IN	O	15	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	children	child	B-NP	NNS	O	24	NMOD
23	's	's	B-NP	POS	O	24	NMOD
24	fractures	fracture	I-NP	NNS	O	21	PMOD
25	in	in	B-PP	IN	O	20	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	emergency	emergency	I-NP	NN	O	28	NMOD
28	department	department	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	7	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	average	average	I-NP	JJ	O	5	NMOD
5	time	time	I-NP	NN	O	18	SUB
6	from	from	B-PP	IN	O	5	NMOD
7	intravenous	intravenous	B-NP	JJ	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	ketamine	ketamine	B-NP	NN	O	9	PMOD
11	to	to	B-PP	TO	O	5	NMOD
12	manipulation	manipulation	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	fracture	fracture	I-NP	NN	O	17	NMOD
16	or	or	I-NP	CC	O	17	NMOD
17	dislocation	dislocation	I-NP	NN	O	13	PMOD
18	was	be	B-VP	VBD	O	37	VMOD
19	one	one	B-NP	CD	O	20	NMOD
20	minute	minute	I-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	thirty-six	thirty-six	B-NP	CD	O	23	NMOD
23	seconds	second	I-NP	NNS	O	18	PRD
24	(	(	O	(	O	32	DEP
25	range	range	B-NP	NN	O	32	DEP
26	,	,	O	,	O	32	P
27	twenty	twenty	B-NP	CD	O	28	NMOD
28	seconds	second	I-NP	NNS	O	32	DEP
29	to	to	B-PP	TO	O	28	NMOD
30	five	five	B-NP	CD	O	31	NMOD
31	minutes	minute	I-NP	NNS	O	29	PMOD
32	)	)	O	)	O	23	NMOD
33	,	,	O	,	O	37	P
34	and	and	O	CC	O	37	NMOD
35	the	the	B-NP	DT	O	37	NMOD
36	average	average	I-NP	JJ	O	37	NMOD
37	time	time	I-NP	NN	O	43	SUB
38	from	from	B-PP	IN	O	37	NMOD
39	intramuscular	intramuscular	B-NP	JJ	O	40	NMOD
40	administration	administration	I-NP	NN	O	38	PMOD
41	to	to	B-PP	TO	O	37	NMOD
42	manipulation	manipulation	B-NP	NN	O	41	PMOD
43	was	be	B-VP	VBD	O	1	NMOD
44	four	four	B-NP	CD	O	45	NMOD
45	minutes	minute	I-NP	NNS	O	48	NMOD
46	and	and	O	CC	O	48	NMOD
47	forty-two	forty-two	B-NP	JJ	O	48	NMOD
48	seconds	second	I-NP	NNS	O	43	PRD
49	(	(	O	(	O	57	DEP
50	range	range	B-NP	NN	O	53	NMOD
51	,	,	O	,	O	53	P
52	sixty	sixty	B-NP	JJ	O	53	NMOD
53	seconds	second	I-NP	NNS	O	57	DEP
54	to	to	B-PP	TO	O	53	NMOD
55	fifteen	fifteen	B-NP	CD	O	56	NMOD
56	minutes	minute	I-NP	NNS	O	54	PMOD
57	)	)	O	)	O	48	NMOD
58	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Ketamine	Ketamine	B-NP	NN	O	1	NMOD
4	reliably	reliably	B-ADVP	RB	O	10	VMOD
5	,	,	O	,	O	10	P
6	safely	safely	B-ADVP	RB	O	10	VMOD
7	,	,	O	,	O	10	P
8	and	and	O	CC	O	10	VMOD
9	quickly	quickly	B-VP	RB	O	10	VMOD
10	provided	provide	I-VP	VBD	O	3	SBAR
11	adequate	adequate	B-NP	JJ	O	12	NMOD
12	sedation	sedation	I-NP	NN	O	10	OBJ
13	to	to	B-VP	TO	O	15	VMOD
14	effectively	effectively	I-VP	RB	O	15	VMOD
15	facilitate	facilitate	I-VP	VB	O	12	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	reduction	reduction	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	children	child	B-NP	NNS	O	21	NMOD
20	's	's	B-NP	POS	O	21	NMOD
21	fractures	fracture	I-NP	NNS	O	18	PMOD
22	in	in	B-PP	IN	O	17	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	emergency	emergency	I-NP	NN	O	25	NMOD
25	department	department	I-NP	NN	O	22	PMOD
26	at	at	B-PP	IN	O	12	NMOD
27	our	our	B-NP	PRP$	O	28	NMOD
28	institution	institution	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	1	P

1	Prophylactic	Prophylactic	B-NP	JJ	O	2	NMOD
2	use	use	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	lamivudine	lamivudine	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	chronic	chronic	B-NP	JJ	O	8	NMOD
7	immunosuppressive	immunosuppressive	I-NP	JJ	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	rheumatologic	rheumatologic	B-NP	JJ	O	11	NMOD
11	disorders	disorder	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	objective	objective	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	report	report	I-VP	VB	O	6	PRD
9	our	our	B-NP	PRP$	O	10	NMOD
10	experience	experience	I-NP	NN	O	8	OBJ
11	concerning	concern	B-VP	VBG	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	effectiveness	effectiveness	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	prophylactic	prophylactic	I-NP	JJ	O	17	NMOD
17	administration	administration	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	lamivudine	lamivudine	B-NP	NN	O	18	PMOD
20	in	in	B-PP	IN	O	13	NMOD
21	hepatitis	hepatitis	B-NP	NN	B-protein	25	NMOD
22	B	B	I-NP	NN	I-protein	25	NMOD
23	virus	virus	I-NP	NN	I-protein	25	NMOD
24	surface	surface	I-NP	NN	I-protein	25	NMOD
25	antigen	antigen	I-NP	NN	I-protein	31	NMOD
26	(	(	O	(	O	29	DEP
27	HBs	HB	B-NP	NNS	B-protein	28	NMOD
28	Ag	Ag	I-NP	NN	I-protein	29	DEP
29	)	)	O	)	O	25	NMOD
30	positive	positive	B-NP	JJ	O	31	NMOD
31	patients	patient	I-NP	NNS	O	20	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	rheumatologic	rheumatologic	B-NP	JJ	O	34	NMOD
34	disease	disease	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	6	P

1	From	From	B-PP	IN	O	27	VMOD
2	June	June	B-NP	NNP	O	1	PMOD
3	2004	2004	I-NP	CD	O	2	NMOD
4	to	to	B-PP	TO	O	2	NMOD
5	October	October	B-NP	NNP	O	12	NMOD
6	2006	2006	I-NP	CD	O	5	NMOD
7	,	,	I-NP	,	O	12	P
8	11	11	I-NP	CD	O	12	NMOD
9	HBs	HB	I-NP	NNS	O	12	NMOD
10	Ag	Ag	I-NP	NN	O	12	NMOD
11	positive	positive	B-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	4	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	rheumatologic	rheumatologic	B-NP	JJ	O	15	NMOD
15	diseases	disease	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	27	P
17	who	who	B-NP	WP	O	27	VMOD
18	were	be	B-VP	VBD	O	17	SBAR
19	on	on	B-PP	IN	O	18	PRD
20	both	both	B-NP	CC	O	23	AMOD
21	immunosuppressive	immunosuppressive	I-NP	JJ	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	prophylactic	prophylactic	I-NP	JJ	O	25	NMOD
24	lamivudine	lamivudine	I-NP	NN	O	25	NMOD
25	therapies	therapy	I-NP	NNS	O	19	PMOD
26	,	,	O	,	O	27	P
27	were	be	B-VP	VBD	O	0	ROOT
28	retrospectively	retrospectively	I-VP	RB	O	27	VMOD
29	assessed	assess	I-VP	VBN	O	27	VC
30	.	.	O	.	O	27	P

1	Uni-	Uni-	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	multivariate	multivariate	I-NP	JJ	O	4	NMOD
4	analyses	analysis	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	used	use	I-VP	VBN	O	5	VC
7	to	to	B-VP	TO	O	8	VMOD
8	test	test	I-VP	VB	O	6	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	influence	influence	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	clinical	clinical	I-NP	JJ	O	14	NMOD
14	variables	variable	I-NP	NNS	O	11	PMOD
15	:	:	O	:	O	5	P
16	age	age	B-NP	NN	O	40	NMOD
17	,	,	O	,	O	40	P
18	sex	sex	B-NP	NN	O	40	NMOD
19	,	,	O	,	O	40	P
20	stroke	stroke	B-NP	NN	O	40	NMOD
21	,	,	O	,	O	40	P
22	myocardiopathy	myocardiopathy	B-NP	NN	O	40	NMOD
23	(	(	O	(	O	25	DEP
24	MP	MP	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	,	,	O	,	O	40	P
27	duration	duration	B-NP	NN	O	40	NMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	test	test	I-NP	NN	O	28	PMOD
31	,	,	O	,	O	40	P
32	mitral	mitral	B-NP	JJ	O	33	NMOD
33	regurgitation	regurgitation	I-NP	NN	O	40	NMOD
34	(	(	O	(	O	36	DEP
35	MR	MR	B-NP	NN	B-protein	36	DEP
36	)	)	O	)	O	33	NMOD
37	and	and	O	CC	O	40	NMOD
38	the	the	B-NP	DT	O	40	NMOD
39	MZ	MZ	I-NP	NN	O	40	NMOD
40	dose	dose	I-NP	NN	O	5	VMOD
41	.	.	O	.	O	5	P

1	Mild	Mild	B-NP	JJ	O	2	NMOD
2	hypoxia	hypoxia	I-NP	NN	O	9	SUB
3	(	(	O	(	O	8	DEP
4	SO2	SO2	B-NP	NN	O	7	NMOD
5	<	<	O	SYM	O	7	NMOD
6	90	90	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	8	DEP
8	)	)	O	)	O	2	NMOD
9	was	be	B-VP	VBD	O	25	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	most	most	I-NP	RBS	O	12	AMOD
12	common	common	I-NP	JJ	O	13	NMOD
13	event	event	I-NP	NN	O	9	PRD
14	(	(	O	(	O	17	DEP
15	11	11	B-NP	CD	O	16	NMOD
16	patients	patient	I-NP	NNS	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	;	;	O	:	O	9	P
19	3	3	B-NP	CD	O	20	NMOD
20	patients	patient	I-NP	NNS	O	25	SUB
21	(	(	O	(	O	24	DEP
22	2	2	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	presented	present	B-VP	VBD	O	0	ROOT
26	transient	transient	B-NP	JJ	O	27	NMOD
27	hypoxia	hypoxia	I-NP	NN	O	25	OBJ
28	due	due	B-PP	JJ	O	27	NMOD
29	to	to	B-PP	TO	O	28	PMOD
30	upper	upper	B-NP	JJ	O	32	NMOD
31	airway	airway	I-NP	NN	O	32	NMOD
32	obstruction	obstruction	I-NP	NN	O	29	PMOD
33	by	by	B-PP	IN	O	32	NMOD
34	probe	probe	B-NP	NN	O	35	NMOD
35	introduction	introduction	I-NP	NN	O	37	NMOD
36	and	and	O	CC	O	37	NMOD
37	8	8	B-NP	CD	O	33	PMOD
38	(	(	O	(	O	41	DEP
39	5.8	5.8	B-NP	CD	O	40	NMOD
40	%	%	I-NP	NN	O	41	DEP
41	)	)	O	)	O	37	NMOD
42	due	due	B-PP	IN	O	25	VMOD
43	to	to	B-PP	TO	O	42	PMOD
44	hypoxia	hypoxia	B-NP	NN	O	42	PMOD
45	caused	cause	B-VP	VBN	O	44	NMOD
46	by	by	B-PP	IN	O	45	VMOD
47	MZ	MZ	B-NP	NN	O	48	NMOD
48	use	use	I-NP	NN	O	46	PMOD
49	.	.	O	.	O	25	P

1	The	The	B-NP	DT	O	3	NMOD
2	multivariate	multivariate	I-NP	JJ	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	4	SUB
4	showed	show	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	severe	severe	B-NP	JJ	O	7	NMOD
7	MR	MR	I-NP	NN	B-protein	18	NMOD
8	,	,	O	,	O	18	P
9	MP	MP	B-NP	NN	O	18	NMOD
10	(	(	O	(	O	15	DEP
11	EF	EF	B-NP	NN	O	14	NMOD
12	<	<	O	SYM	O	14	NMOD
13	45	45	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	15	DEP
15	)	)	O	)	O	9	NMOD
16	and	and	O	CC	O	18	NMOD
17	high	high	B-NP	JJ	O	18	NMOD
18	doses	dose	I-NP	NNS	O	25	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	MZ	MZ	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	24	DEP
22	>	>	B-NP	SYM	O	23	NMOD
23	5mg	5mg	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	were	be	B-VP	VBD	O	5	SBAR
26	associated	associate	I-VP	VBN	O	25	VC
27	with	with	B-PP	IN	O	26	VMOD
28	events	event	B-NP	NNS	O	27	PMOD
29	(	(	O	(	O	33	DEP
30	p	p	B-NP	NN	O	32	SUB
31	<	<	O	SYM	O	32	VMOD
32	0.001	0.001	B-NP	CD	O	33	DEP
33	)	)	O	)	O	26	VMOD
34	.	.	O	.	O	4	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	calcium	calcium	B-NP	NN	O	5	NMOD
4	channel	channel	I-NP	NN	O	5	NMOD
5	blockers	blocker	I-NP	NNS	O	2	PMOD
6	on	on	B-PP	IN	O	1	NMOD
7	bupivacaine	bupivacaine	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	toxicity	toxicity	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	investigate	investigate	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	influence	influence	I-NP	NN	O	17	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	calcium	calcium	B-NP	NN	O	14	NMOD
13	channel	channel	I-NP	NN	O	14	NMOD
14	blockers	blocker	I-NP	NNS	O	11	PMOD
15	on	on	B-PP	IN	O	10	NMOD
16	bupivacaine	bupivacaine	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	8	VMOD
18	acute	acute	B-NP	JJ	O	19	NMOD
19	toxicity	toxicity	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	6	P

1	Selegiline	Selegiline	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	postural	postural	B-NP	JJ	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	Parkinson	Parkinson	B-NP	NNP	O	8	NMOD
7	's	's	B-NP	POS	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	:	:	O	:	O	2	P
10	a	a	B-NP	DT	O	12	NMOD
11	longitudinal	longitudinal	I-NP	JJ	O	12	NMOD
12	study	study	I-NP	NN	O	2	OBJ
13	on	on	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	effects	effect	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	drug	drug	B-NP	NN	O	18	NMOD
18	withdrawal	withdrawal	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	2	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	10	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	10	NMOD
4	United	United	I-NP	NNP	O	10	NMOD
5	Kingdom	Kingdom	I-NP	NNP	O	10	NMOD
6	Parkinson	Parkinson	I-NP	NNP	O	10	NMOD
7	's	's	B-NP	POS	O	10	NMOD
8	Disease	Disease	I-NP	NNP	O	10	NMOD
9	Research	Research	I-NP	NNP	O	10	NMOD
10	Group	Group	I-NP	NNP	O	14	NMOD
11	(	(	O	(	O	14	NMOD
12	UKPDRG	UKPDRG	O	NNP	O	14	NMOD
13	)	)	O	)	O	14	NMOD
14	trial	trial	B-NP	NN	O	15	SUB
15	found	find	B-VP	VBD	O	0	ROOT
16	an	an	B-NP	DT	O	18	NMOD
17	increased	increase	I-NP	VBN	O	18	NMOD
18	mortality	mortality	I-NP	NN	O	15	OBJ
19	in	in	B-PP	IN	O	15	VMOD
20	patients	patient	B-NP	NNS	O	28	SUB
21	with	with	B-PP	IN	O	20	NMOD
22	Parkinson	Parkinson	B-NP	NNP	O	23	NMOD
23	's	's	B-NP	POS	O	24	NMOD
24	disease	disease	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	PD	PD	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	randomized	randomize	B-VP	VBD	O	19	SBAR
29	to	to	I-VP	TO	O	30	VMOD
30	receive	receive	I-VP	VB	O	28	VMOD
31	10	10	B-NP	CD	O	32	AMOD
32	mg	mg	I-NP	NN	O	33	NMOD
33	selegiline	selegiline	I-NP	NN	O	30	OBJ
34	per	per	B-PP	IN	O	30	VMOD
35	day	day	B-NP	NN	O	34	PMOD
36	and	and	O	CC	O	30	VMOD
37	L-dopa	L-dopa	B-NP	NN	O	30	VMOD
38	compared	compare	B-PP	VBN	O	37	NMOD
39	with	with	B-PP	IN	O	38	PMOD
40	those	those	B-NP	DT	O	42	NMOD
41	taking	take	I-NP	VBG	O	42	NMOD
42	L-dopa	L-dopa	I-NP	NN	O	39	PMOD
43	alone	alone	B-ADVP	RB	O	42	NMOD
44	.	.	O	.	O	15	P

1	Recently	Recently	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	found	find	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	therapy	therapy	B-NP	NN	O	11	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	selegiline	selegiline	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	L-dopa	L-dopa	I-NP	NN	O	7	PMOD
11	was	be	B-VP	VBD	O	5	SBAR
12	associated	associate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	selective	selective	B-NP	JJ	O	16	AMOD
15	systolic	systolic	I-NP	JJ	O	16	AMOD
16	orthostatic	orthostatic	I-NP	JJ	O	17	NMOD
17	hypotension	hypotension	I-NP	NN	O	13	PMOD
18	which	which	B-NP	WDT	O	17	NMOD
19	was	be	B-VP	VBD	O	18	SBAR
20	abolished	abolish	I-VP	VBN	O	19	VC
21	by	by	B-PP	IN	O	20	VMOD
22	withdrawal	withdrawal	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	selegiline	selegiline	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	aims	aim	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	confirm	confirm	I-VP	VB	O	6	PRD
9	our	our	B-NP	PRP$	O	11	NMOD
10	previous	previous	I-NP	JJ	O	11	NMOD
11	findings	finding	I-NP	NNS	O	8	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	separate	separate	I-NP	JJ	O	15	NMOD
15	cohort	cohort	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	and	and	O	CC	O	8	VMOD
19	to	to	B-VP	TO	O	20	VMOD
20	determine	determine	I-VP	VB	O	8	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	time	time	I-NP	NN	O	23	NMOD
23	course	course	I-NP	NN	O	20	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	cardiovascular	cardiovascular	I-NP	JJ	O	27	NMOD
27	consequences	consequence	I-NP	NNS	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	stopping	stop	B-VP	VBG	O	28	PMOD
30	selegiline	selegiline	B-NP	NN	O	29	OBJ
31	in	in	B-PP	IN	O	29	VMOD
32	the	the	B-NP	DT	O	33	NMOD
33	expectation	expectation	I-NP	NN	O	31	PMOD
34	that	that	B-SBAR	IN	O	29	VMOD
35	this	this	B-NP	DT	O	36	SUB
36	might	might	B-VP	MD	O	34	SBAR
37	shed	shed	I-VP	VB	O	36	VC
38	light	light	B-NP	NN	O	37	OBJ
39	on	on	B-PP	IN	O	37	VMOD
40	the	the	B-NP	DT	O	41	NMOD
41	mechanisms	mechanism	I-NP	NNS	O	39	PMOD
42	by	by	B-PP	IN	O	41	NMOD
43	which	which	B-NP	WDT	O	42	PMOD
44	the	the	B-NP	DT	O	45	NMOD
45	drug	drug	I-NP	NN	O	46	SUB
46	causes	cause	B-VP	VBZ	O	42	SBAR
47	orthostatic	orthostatic	B-NP	JJ	O	48	NMOD
48	hypotension	hypotension	I-NP	NN	O	46	OBJ
49	.	.	O	.	O	6	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	cardiovascular	cardiovascular	I-NP	JJ	O	5	NMOD
5	responses	response	I-NP	NNS	O	11	SUB
6	to	to	B-PP	TO	O	5	NMOD
7	standing	standing	B-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	head-up	head-up	B-NP	JJ	O	10	NMOD
10	tilt	tilt	I-NP	NN	O	6	PMOD
11	were	be	B-VP	VBD	O	1	NMOD
12	studied	study	I-VP	VBN	O	11	VC
13	repeatedly	repeatedly	B-ADVP	RB	O	12	VMOD
14	in	in	B-PP	IN	O	12	VMOD
15	PD	PD	B-NP	NN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	receiving	receive	B-VP	VBG	O	16	NMOD
18	selegiline	selegiline	B-NP	NN	O	17	OBJ
19	and	and	B-PP	CC	O	14	PMOD
20	as	as	B-PP	IN	O	14	PMOD
21	the	the	B-NP	DT	O	22	NMOD
22	drug	drug	I-NP	NN	O	20	PMOD
23	was	be	B-VP	VBD	O	11	VMOD
24	withdrawn	withdraw	I-VP	VBN	O	23	VC
25	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Head-up	Head-up	B-NP	JJ	O	4	NMOD
4	tilt	tilt	I-NP	NN	O	5	SUB
5	caused	cause	B-VP	VBD	O	1	NMOD
6	systolic	systolic	B-NP	JJ	O	7	AMOD
7	orthostatic	orthostatic	I-NP	JJ	O	8	NMOD
8	hypotension	hypotension	I-NP	NN	O	21	NMOD
9	which	which	B-NP	WDT	O	8	NMOD
10	was	be	B-VP	VBD	O	9	SBAR
11	marked	mark	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	six	six	B-NP	CD	O	14	AMOD
14	of	of	I-NP	IN	O	17	NMOD
15	20	20	I-NP	CD	O	14	AMOD
16	PD	PD	I-NP	NN	O	17	NMOD
17	patients	patient	I-NP	NNS	O	12	PMOD
18	on	on	B-PP	IN	O	17	NMOD
19	selegiline	selegiline	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	21	P
21	one	one	B-NP	CD	O	24	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	whom	whom	B-NP	WP	O	22	PMOD
24	lost	lose	B-VP	VBD	O	5	VMOD
25	consciousness	consciousness	B-NP	NN	O	24	OBJ
26	with	with	B-PP	IN	O	24	VMOD
27	unrecordable	unrecordable	B-NP	JJ	O	29	NMOD
28	blood	blood	I-NP	NN	O	29	NMOD
29	pressures	pressure	I-NP	NNS	O	26	PMOD
30	.	.	O	.	O	1	P

1	Orthostatic	Orthostatic	B-NP	JJ	O	2	NMOD
2	hypotension	hypotension	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	13	VMOD
4	ameliorated	ameliorate	I-VP	VBN	O	3	VC
5	4	4	B-NP	CD	O	6	NMOD
6	days	day	I-NP	NNS	O	7	PMOD
7	after	after	B-PP	IN	O	4	VMOD
8	withdrawal	withdrawal	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	selegiline	selegiline	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	3	VMOD
12	totally	totally	B-VP	RB	O	13	VMOD
13	abolished	abolish	I-VP	VBD	O	0	ROOT
14	7	7	B-NP	CD	O	15	NMOD
15	days	day	I-NP	NNS	O	16	PMOD
16	after	after	B-PP	IN	O	13	VMOD
17	discontinuation	discontinuation	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	drug	drug	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	13	P

1	Stopping	Stop	B-VP	VBG	O	5	SUB
2	selegiline	selegiline	B-NP	NN	O	1	OBJ
3	also	also	B-ADVP	RB	O	1	VMOD
4	significantly	significantly	B-VP	RB	O	5	VMOD
5	reduced	reduce	I-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	12	NMOD
7	supine	supine	I-NP	NN	O	12	NMOD
8	systolic	systolic	I-NP	JJ	O	12	NMOD
9	and	and	I-NP	CC	O	12	NMOD
10	diastolic	diastolic	I-NP	JJ	O	12	NMOD
11	blood	blood	I-NP	NN	O	12	NMOD
12	pressures	pressure	I-NP	NNS	O	5	OBJ
13	consistent	consistent	B-ADJP	JJ	O	12	NMOD
14	with	with	B-PP	IN	O	13	AMOD
15	a	a	B-NP	DT	O	20	NMOD
16	previously	previously	I-NP	RB	O	17	AMOD
17	undescribed	undescribed	I-NP	JJ	O	20	NMOD
18	supine	supine	I-NP	NN	O	20	NMOD
19	pressor	pressor	I-NP	NN	O	20	NMOD
20	action	action	I-NP	NN	O	14	PMOD
21	.	.	O	.	O	5	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	5	SUB
2	:	:	O	:	O	5	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	confirms	confirm	B-VP	VBZ	O	0	ROOT
6	our	our	B-NP	PRP$	O	8	NMOD
7	previous	previous	I-NP	JJ	O	8	NMOD
8	finding	finding	I-NP	NN	O	5	OBJ
9	that	that	B-SBAR	IN	O	8	NMOD
10	selegiline	selegiline	B-NP	NN	O	15	SUB
11	in	in	B-PP	IN	O	10	NMOD
12	combination	combination	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	L-dopa	L-dopa	B-NP	NN	O	13	PMOD
15	is	be	B-VP	VBZ	O	9	SBAR
16	associated	associate	I-VP	VBN	O	15	VC
17	with	with	B-PP	IN	O	16	VMOD
18	selective	selective	B-NP	JJ	O	20	NMOD
19	orthostatic	orthostatic	I-NP	JJ	O	20	NMOD
20	hypotension	hypotension	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	5	P

1	Explicit	Explicit	B-NP	JJ	O	3	NMOD
2	episodic	episodic	I-NP	JJ	O	3	NMOD
3	memory	memory	I-NP	NN	O	15	NMOD
4	for	for	B-PP	IN	O	3	NMOD
5	sensory-discriminative	sensory-discriminative	B-NP	JJ	O	6	NMOD
6	components	component	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	capsaicin	capsaicin	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	pain	pain	I-NP	NN	O	7	PMOD
11	:	:	O	:	O	3	P
12	immediate	immediate	B-NP	JJ	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	delayed	delay	I-NP	VBN	O	15	NMOD
15	ratings	rating	I-NP	NNS	O	0	ROOT
16	.	.	O	.	O	15	P

1	In	In	B-SBAR	IN	O	13	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	1	DEP
4	address	address	I-VP	VB	O	1	SBAR
5	long-term	long-term	B-NP	JJ	O	7	NMOD
6	pain	pain	I-NP	NN	O	7	NMOD
7	memory	memory	I-NP	NN	O	4	OBJ
8	,	,	O	,	O	13	P
9	nine	nine	B-NP	CD	O	12	NMOD
10	healthy	healthy	I-NP	JJ	O	11	AMOD
11	male	male	I-NP	JJ	O	12	NMOD
12	volunteers	volunteer	I-NP	NNS	O	13	SUB
13	received	receive	B-VP	VBD	O	0	ROOT
14	intradermal	intradermal	B-NP	JJ	O	15	NMOD
15	injections	injection	I-NP	NNS	O	36	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	three	three	B-NP	CD	O	18	NMOD
18	doses	dose	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	capsaicin	capsaicin	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	34	DEP
22	0.05	0.05	B-NP	CD	O	27	NMOD
23	,	,	I-NP	,	O	27	P
24	1	1	I-NP	CD	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	20	20	I-NP	CD	O	27	NMOD
27	microg	microg	I-NP	NN	O	34	DEP
28	,	,	O	,	O	27	P
29	separated	separate	B-VP	VBN	O	27	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	15	15	B-NP	CD	O	33	NMOD
32	min	min	I-NP	NN	O	33	NMOD
33	breaks	break	I-NP	NNS	O	30	PMOD
34	)	)	O	)	O	20	NMOD
35	,	,	O	,	O	36	P
36	each	each	B-NP	DT	O	13	OBJ
37	given	give	B-VP	VBN	O	36	NMOD
38	three	three	B-NP	CD	O	39	NMOD
39	times	time	I-NP	NNS	O	37	OBJ
40	in	in	B-PP	IN	O	37	VMOD
41	a	a	B-NP	DT	O	43	NMOD
42	balanced	balanced	I-NP	JJ	O	43	NMOD
43	design	design	I-NP	NN	O	40	PMOD
44	across	across	B-PP	IN	O	43	NMOD
45	three	three	B-NP	CD	O	46	NMOD
46	sessions	session	I-NP	NNS	O	44	PMOD
47	at	at	B-PP	IN	O	43	NMOD
48	one	one	B-NP	CD	O	50	NMOD
49	week	week	I-NP	NN	O	50	NMOD
50	intervals	interval	I-NP	NNS	O	47	PMOD
51	.	.	O	.	O	13	P

1	Subjects	Subject	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	able	able	B-ADJP	JJ	O	2	PRD
4	to	to	B-VP	TO	O	6	VMOD
5	reliably	reliably	I-VP	RB	O	6	VMOD
6	discriminate	discriminate	I-VP	VB	O	3	AMOD
7	pain	pain	B-NP	NN	O	8	NMOD
8	magnitude	magnitude	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	duration	duration	I-NP	NN	O	6	OBJ
11	across	across	B-PP	IN	O	6	VMOD
12	capsaicin	capsaicin	B-NP	NN	O	13	NMOD
13	doses	dose	I-NP	NNS	O	11	PMOD
14	(	(	O	(	O	19	DEP
15	both	both	O	CC	O	18	NMOD
16	p	p	B-NP	NN	O	18	NMOD
17	<	<	O	SYM	O	18	P
18	0.001	0.001	B-NP	CD	O	19	DEP
19	)	)	O	)	O	13	NMOD
20	,	,	O	,	O	6	P
21	regardless	regardless	B-ADVP	RB	O	6	VMOD
22	of	of	B-PP	IN	O	21	AMOD
23	whether	whether	B-SBAR	IN	O	22	PMOD
24	first-time	first-time	B-NP	JJ	O	25	NMOD
25	ratings	rating	I-NP	NNS	O	26	SUB
26	were	be	B-VP	VBD	O	23	SBAR
27	requested	request	I-VP	VBN	O	26	VC
28	immediately	immediately	B-ADVP	RB	O	27	VMOD
29	,	,	O	,	O	26	P
30	after	after	B-SBAR	IN	O	26	VMOD
31	one	one	B-NP	CD	O	32	NMOD
32	hour	hour	I-NP	NN	O	30	PMOD
33	or	or	O	CC	O	26	VMOD
34	after	after	B-PP	IN	O	26	VMOD
35	one	one	B-NP	CD	O	36	NMOD
36	day	day	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	2	P

1	Reversibility	Reversibility	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	captopril	captopril	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	renal	renal	B-NP	JJ	O	6	NMOD
6	insufficiency	insufficiency	I-NP	NN	O	4	OBJ
7	after	after	B-PP	IN	O	4	VMOD
8	prolonged	prolonged	B-NP	JJ	O	9	NMOD
9	use	use	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	an	an	B-NP	DT	O	13	NMOD
12	unusual	unusual	I-NP	JJ	O	13	NMOD
13	case	case	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	renovascular	renovascular	B-NP	JJ	O	16	NMOD
16	hypertension	hypertension	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	severe	severe	B-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	an	an	B-NP	DT	O	12	NMOD
10	occluded	occlude	I-NP	VBN	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	artery	artery	I-NP	NN	O	8	PMOD
13	to	to	B-PP	TO	O	12	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	solitary	solitary	I-NP	JJ	O	16	NMOD
16	kidney	kidney	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	2	P
18	who	who	B-NP	WP	O	2	VMOD
19	developed	develop	B-VP	VBD	O	18	SBAR
20	sudden	sudden	B-NP	JJ	O	21	NMOD
21	deterioration	deterioration	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	renal	renal	B-NP	JJ	O	24	NMOD
24	function	function	I-NP	NN	O	22	PMOD
25	following	follow	B-PP	VBG	O	19	VMOD
26	treatment	treatment	B-NP	NN	O	25	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	captopril	captopril	B-NP	NN	O	27	PMOD
29	.	.	O	.	O	2	P

1	Liver	Liver	B-NP	NN	O	2	NMOD
2	disease	disease	I-NP	NN	O	0	ROOT
3	caused	cause	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	propylthiouracil	propylthiouracil	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	report	report	I-NP	NN	O	3	SUB
3	presents	present	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	14	NMOD
5	clinical	clinical	I-NP	JJ	O	14	NMOD
6	,	,	I-NP	,	O	14	P
7	laboratory	laboratory	I-NP	NN	O	14	NMOD
8	,	,	O	,	O	14	P
9	and	and	O	CC	O	14	NMOD
10	light	light	B-NP	NN	O	14	NMOD
11	and	and	I-NP	CC	O	14	NMOD
12	electron	electron	I-NP	NN	O	14	NMOD
13	microscopic	microscopic	I-NP	JJ	O	14	NMOD
14	observations	observation	I-NP	NNS	O	3	OBJ
15	on	on	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	patient	patient	I-NP	NN	O	15	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	chronic	chronic	B-NP	JJ	O	24	NMOD
20	active	active	I-NP	JJ	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	aggressive	aggressive	B-ADJP	JJ	O	23	DEP
23	)	)	O	)	O	20	AMOD
24	hepatitis	hepatitis	B-NP	NN	O	18	PMOD
25	caused	cause	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	the	the	B-NP	DT	O	28	NMOD
28	administration	administration	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	propylthiouracil	propylthiouracil	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	3	P

1	Capsaicin	Capsaicin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	muscle	muscle	B-NP	NN	B-protein	4	NMOD
4	pain	pain	I-NP	NN	I-protein	5	SUB
5	alters	alter	B-VP	VBZ	O	2	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	excitability	excitability	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	12	NMOD
10	human	human	I-NP	JJ	B-protein	12	NMOD
11	jaw-stretch	jaw-stretch	I-NP	JJ	I-protein	12	NMOD
12	reflex	reflex	I-NP	NN	I-protein	8	PMOD
13	.	.	O	.	O	2	P

1	Capsaicin	Capsaicin	B-NP	NN	O	7	SUB
2	(	(	O	(	O	6	DEP
3	10	10	B-NP	CD	O	5	NMOD
4	micro	micro	I-NP	NN	O	5	NMOD
5	g	g	I-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	injected	inject	I-VP	VBN	O	7	VC
9	into	into	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	masseter	masseter	I-NP	NN	O	12	NMOD
12	muscle	muscle	I-NP	NN	O	9	PMOD
13	to	to	B-VP	TO	O	14	VMOD
14	induce	induce	I-VP	VB	O	8	VMOD
15	pain	pain	B-NP	NN	O	14	OBJ
16	in	in	B-PP	IN	O	14	VMOD
17	11	11	B-NP	CD	O	19	NMOD
18	healthy	healthy	I-NP	JJ	O	19	NMOD
19	volunteers	volunteer	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	7	P

1	Repetitive	Repetitive	B-NP	JJ	O	4	NMOD
2	transcranial	transcranial	I-NP	JJ	O	4	NMOD
3	magnetic	magnetic	I-NP	JJ	O	4	NMOD
4	stimulation	stimulation	I-NP	NN	O	0	ROOT
5	for	for	B-PP	IN	O	4	NMOD
6	levodopa	levodopa	B-NP	NN	O	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	dyskinesias	dyskinesia	I-NP	NNS	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	Parkinson	Parkinson	B-NP	NNP	O	12	NMOD
11	's	's	B-NP	POS	O	12	NMOD
12	disease	disease	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	13	VMOD
2	less	less	B-NP	JJR	O	3	AMOD
3	than	than	I-NP	IN	O	5	NMOD
4	1	1	I-NP	CD	O	3	AMOD
5	hour	hour	I-NP	NN	O	1	PMOD
6	after	after	B-PP	IN	O	1	PMOD
7	the	the	B-NP	DT	O	8	NMOD
8	ingestion	ingestion	I-NP	NN	O	1	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	alcohol	alcohol	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	13	P
12	he	he	B-NP	PRP	O	13	SUB
13	developed	develop	B-VP	VBD	O	0	ROOT
14	malaise	malaise	B-NP	NN	O	13	OBJ
15	with	with	B-PP	IN	O	14	NMOD
16	flushing	flushing	B-NP	NN	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	face	face	I-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	tachycardia	tachycardia	B-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	dyspnea	dyspnea	B-NP	NN	O	17	PMOD
25	.	.	O	.	O	13	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	hours	hour	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	7	VMOD
4	exposure	exposure	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	7	P
6	he	he	B-NP	PRP	O	7	SUB
7	developed	develop	B-VP	VBD	O	0	ROOT
8	disulfiram-like	disulfiram-like	B-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	7	OBJ
10	with	with	B-PP	IN	O	9	NMOD
11	flushing	flushing	B-NP	NN	O	17	NMOD
12	,	,	O	,	O	17	P
13	tachycardia	tachycardia	B-NP	NN	O	17	NMOD
14	,	,	O	,	O	17	P
15	and	and	O	CC	O	17	NMOD
16	arterial	arterial	B-NP	JJ	O	17	NMOD
17	hypotension	hypotension	I-NP	NN	O	10	PMOD
18	after	after	B-PP	IN	O	7	VMOD
19	consuming	consume	B-VP	VBG	O	18	PMOD
20	three	three	B-NP	CD	O	21	NMOD
21	glasses	glass	I-NP	NNS	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	wine	wine	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	acute	acute	I-NP	JJ	O	5	NMOD
4	experiment	experiment	I-NP	NN	O	5	NMOD
5	TRI	TRI	I-NP	NN	O	10	SUB
6	(	(	O	(	O	9	DEP
7	given	give	B-VP	VBN	O	9	DEP
8	i.p.	i.p.	B-ADVP	RB	O	7	VMOD
9	)	)	O	)	O	5	NMOD
10	does	do	B-VP	VBZ	O	0	ROOT
11	not	not	I-VP	RB	O	10	VMOD
12	antagonize	antagonize	I-VP	VB	O	10	VC
13	the	the	B-NP	DT	O	15	NMOD
14	reserpine	reserpine	I-NP	NN	O	15	NMOD
15	hypothermia	hypothermia	I-NP	NN	O	12	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	mice	mouse	B-NP	NNS	O	16	PMOD
18	and	and	O	CC	O	10	VMOD
19	does	do	B-VP	VBZ	O	10	VMOD
20	not	not	I-VP	RB	O	19	VMOD
21	potentiate	potentiate	I-VP	VB	O	19	VC
22	the	the	B-NP	DT	O	25	NMOD
23	5-hydroxytryptophan	5-hydroxytryptophan	I-NP	NN	O	25	NMOD
24	head	head	I-NP	NN	O	25	NMOD
25	twitches	twitch	I-NP	NNS	O	21	OBJ
26	in	in	B-PP	IN	O	25	NMOD
27	rats	rat	B-NP	NNS	O	26	PMOD
28	.	.	O	.	O	10	P

1	TRI	TRI	B-NP	NN	B-protein	6	SUB
2	given	give	B-VP	VBN	O	1	NMOD
3	repeatedly	repeatedly	B-ADVP	RB	O	2	VMOD
4	to	to	B-PP	TO	O	2	VMOD
5	rats	rat	B-NP	NNS	O	4	PMOD
6	increases	increase	B-VP	VBZ	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	locomotor	locomotor	I-NP	JJ	O	9	NMOD
9	hyperactivity	hyperactivity	I-NP	NN	O	6	OBJ
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	d-amphetamine	d-amphetamine	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	14	P
14	quinpirole	quinpirole	B-NP	NN	O	12	NMOD
15	and	and	O	CC	O	14	NMOD
16	(	(	O	(	O	18	DEP
17	+	+	O	SYM	O	18	DEP
18	)	)	O	)	O	19	NMOD
19	-7-hydroxy-dipropyloaminotetralin	-7-hydroxy-dipropyloaminotetralin	B-NP	NN	O	15	PMOD
20	(	(	O	(	O	26	DEP
21	dopamine	dopamine	B-NP	NN	O	22	NMOD
22	D2	D2	I-NP	NN	O	25	NMOD
23	and	and	O	CC	O	25	NMOD
24	D3	D3	B-NP	NN	O	25	NMOD
25	effects	effect	I-NP	NNS	O	26	DEP
26	)	)	O	)	O	19	NMOD
27	.	.	O	.	O	6	P

1	It	It	B-NP	PRP	O	2	SUB
2	increases	increase	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	behaviour	behaviour	I-NP	NN	O	5	NMOD
5	stimulation	stimulation	I-NP	NN	O	2	OBJ
6	evoked	evoke	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	phenylephrine	phenylephrine	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	12	DEP
10	given	give	B-VP	VBN	O	12	DEP
11	intraventricularly	intraventricularly	B-ADVP	RB	O	10	VMOD
12	)	)	O	)	O	8	NMOD
13	in	in	B-PP	IN	O	8	NMOD
14	rats	rat	B-NP	NNS	O	13	PMOD
15	,	,	O	,	O	2	P
16	evaluated	evaluate	B-VP	VBN	O	2	VMOD
17	in	in	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	21	NMOD
19	open	open	I-NP	JJ	O	21	NMOD
20	field	field	I-NP	NN	O	21	NMOD
21	test	test	I-NP	NN	O	26	NMOD
22	as	as	B-CONJP	RB	O	26	NMOD
23	well	well	I-CONJP	RB	O	22	DEP
24	as	as	I-CONJP	IN	O	22	DEP
25	the	the	B-NP	DT	O	26	NMOD
26	aggressiveness	aggressiveness	I-NP	NN	O	35	NMOD
27	evoked	evoke	B-VP	VBN	O	26	NMOD
28	by	by	B-PP	IN	O	27	VMOD
29	clonidine	clonidine	B-NP	NN	O	28	PMOD
30	in	in	B-PP	IN	O	29	NMOD
31	mice	mouse	B-NP	NNS	O	30	PMOD
32	,	,	O	,	O	35	P
33	both	both	B-NP	DT	O	35	NMOD
34	these	these	B-NP	DT	O	35	NMOD
35	effects	effect	I-NP	NNS	O	36	SUB
36	being	be	B-VP	VBG	O	17	PMOD
37	mediated	mediate	I-VP	VBN	O	36	VC
38	by	by	B-PP	IN	O	37	VMOD
39	an	an	B-NP	DT	O	41	NMOD
40	alpha1-adrenergic	alpha1-adrenergic	I-NP	JJ	B-protein	41	NMOD
41	receptor	receptor	I-NP	NN	I-protein	38	PMOD
42	.	.	O	.	O	2	P

1	Ranitidine	Ranitidine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	acute	acute	B-NP	JJ	O	5	NMOD
4	interstitial	interstitial	I-NP	JJ	O	5	NMOD
5	nephritis	nephritis	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	a	a	B-NP	DT	O	10	NMOD
8	cadaveric	cadaveric	I-NP	JJ	O	10	NMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	allograft	allograft	I-NP	NN	O	6	PMOD
11	.	.	O	.	O	2	P

1	Late	Late	B-ADVP	RB	O	5	NMOD
2	,	,	O	,	O	5	P
3	late	late	B-NP	JJ	O	5	NMOD
4	doxorubicin	doxorubicin	I-NP	NN	O	5	NMOD
5	cardiotoxicity	cardiotoxicity	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	major	major	I-NP	JJ	O	6	NMOD
6	complication	complication	I-NP	NN	O	3	PRD
7	which	which	B-NP	WDT	O	6	NMOD
8	limits	limit	B-VP	VBZ	O	7	SBAR
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	adriamycin	adriamycin	B-NP	NN	O	11	PMOD
13	as	as	B-PP	IN	O	8	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	16	NMOD
16	agent	agent	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	Acetazolamide	Acetazolamide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	nephrolithiasis	nephrolithiasis	B-NP	NN	O	2	OBJ
4	:	:	O	:	O	2	P
5	implications	implication	B-NP	NNS	O	4	ROOT
6	for	for	B-PP	IN	O	5	NMOD
7	treatment	treatment	B-NP	NN	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	neuromuscular	neuromuscular	B-NP	JJ	O	10	NMOD
10	disorders	disorder	I-NP	NNS	O	8	PMOD
11	.	.	O	.	O	5	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	9	SUB
3	on	on	B-PP	IN	O	2	NMOD
4	acetazolamide	acetazolamide	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	8	DEP
6	15	15	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	developed	develop	B-VP	VBD	O	0	ROOT
10	renal	renal	B-NP	JJ	O	11	NMOD
11	calculi	calculus	I-NP	NNS	O	9	OBJ
12	.	.	O	.	O	9	P

1	Treatment	Treatment	B-NP	NN	O	4	SUB
2	for	for	B-PP	IN	O	1	NMOD
3	scabies	scaby	B-NP	NNS	O	2	PMOD
4	is	be	B-VP	VBZ	O	0	ROOT
5	usually	usually	I-VP	RB	O	4	VMOD
6	initiated	initiate	I-VP	VBN	O	4	VC
7	by	by	B-PP	IN	O	6	VMOD
8	general	general	B-NP	JJ	O	9	NMOD
9	practitioners	practitioner	I-NP	NNS	O	7	PMOD
10	;	;	O	:	O	4	P
11	most	most	B-NP	RBS	O	12	AMOD
12	consider	consider	I-NP	JJ	O	20	NMOD
13	lindane	lindane	I-NP	NN	O	12	NMOD
14	(	(	O	(	O	18	DEP
15	gamma	gamma	B-NP	NN	O	17	NMOD
16	benzene	benzene	I-NP	NN	O	17	NMOD
17	hexachloride	hexachloride	I-NP	NN	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	4	PRD
21	of	of	B-PP	IN	O	20	NMOD
22	choice	choice	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	4	P

1	Evidence	Evidence	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	accumulating	accumulate	I-VP	VBG	O	2	VC
4	that	that	B-NP	DT	O	5	NMOD
5	lindane	lindane	I-NP	NN	O	3	OBJ
6	can	can	B-VP	MD	O	2	VMOD
7	be	be	I-VP	VB	O	6	VC
8	toxic	toxic	B-ADJP	JJ	O	7	PRD
9	to	to	B-PP	TO	O	8	AMOD
10	the	the	B-NP	DT	O	13	NMOD
11	central	central	I-NP	JJ	O	13	NMOD
12	nervous	nervous	I-NP	JJ	O	13	NMOD
13	system	system	I-NP	NN	O	9	PMOD
14	and	and	O	CC	O	2	VMOD
15	may	may	B-VP	MD	O	2	VMOD
16	be	be	I-VP	VB	O	15	VC
17	associated	associate	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	aplastic	aplastic	B-NP	JJ	O	20	NMOD
20	anaemia	anaemia	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	Toxicity	Toxicity	B-NP	NN	O	15	NMOD
2	in	in	B-PP	IN	O	1	NMOD
3	rhesus	rhesus	B-NP	NN	O	4	NMOD
4	monkeys	monkey	I-NP	NNS	O	2	PMOD
5	following	follow	B-PP	VBG	O	1	NMOD
6	administration	administration	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	8-aminoquinoline	8-aminoquinoline	I-NP	NN	O	7	PMOD
10	8-	8-	I-NP	CD	O	9	NMOD
11	[	[	O	(	O	14	DEP
12	(	(	O	(	O	14	DEP
13	4-amino-l-methylbutyl	4-amino-l-methylbutyl	B-NP	NN	O	14	DEP
14	)	)	O	)	O	1	NMOD
15	amino	amino	B-NP	NN	O	22	NMOD
16	]	]	O	)	O	15	NMOD
17	-	-	B-NP	HYPH	O	15	P
18	5-	5-	I-NP	CD	O	15	NMOD
19	(	(	O	(	O	21	DEP
20	l-hexyloxy	l-hexyloxy	O	JJ	O	21	DEP
21	)	)	O	)	O	15	NMOD
22	-6-methoxy-4-methylquinoline	-6-methoxy-4-methylquinoline	B-NP	NN	O	0	ROOT
23	(	(	O	(	O	25	DEP
24	WR242511	WR242511	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	.	.	O	.	O	22	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	selected	select	I-NP	VBN	O	5	NMOD
5	doses	dose	I-NP	NNS	O	22	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	WR242511	WR242511	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	5	P
9	which	which	B-NP	WDT	O	5	NMOD
10	produced	produce	B-VP	VBD	O	9	SBAR
11	significant	significant	B-NP	JJ	O	12	NMOD
12	methemoglobinemia	methemoglobinemia	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	beagle	beagle	B-NP	NN	O	15	NMOD
15	dogs	dog	I-NP	NNS	O	13	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	earlier	early	B-NP	JJR	O	18	NMOD
18	studies	study	I-NP	NNS	O	16	PMOD
19	conducted	conduct	B-VP	VBN	O	18	NMOD
20	elsewhere	elsewhere	B-ADVP	RB	O	19	VMOD
21	,	,	O	,	O	10	P
22	produced	produce	B-VP	VBD	O	1	NMOD
23	very	very	B-NP	RB	O	24	AMOD
24	little	little	I-NP	JJ	O	22	OBJ
25	MHb	MHb	I-NP	NN	O	24	NMOD
26	(	(	O	(	O	31	DEP
27	mean	mean	B-NP	NN	O	30	NMOD
28	<	<	O	SYM	O	30	NMOD
29	2.0	2.0	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	31	DEP
31	)	)	O	)	O	25	NMOD
32	in	in	B-PP	IN	O	24	NMOD
33	the	the	B-NP	DT	O	35	NMOD
34	rhesus	rhesus	I-NP	NN	O	35	NMOD
35	monkey	monkey	I-NP	NN	O	32	PMOD
36	.	.	O	.	O	1	P

1	Furthermore	Furthermore	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	transient	transient	B-NP	JJ	O	4	NMOD
4	hemoglobinuria	hemoglobinuria	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	23	VMOD
6	noted	note	I-VP	VBN	O	23	VMOD
7	approximately	approximately	B-NP	RB	O	10	NMOD
8	60	60	I-NP	CD	O	7	AMOD
9	minutes	minute	I-NP	NNS	O	10	NMOD
10	postinjection	postinjection	I-NP	NN	O	23	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	WR242511	WR242511	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	18	DEP
14	3.5	3.5	B-NP	CD	O	16	AMOD
15	or	or	I-NP	CC	O	16	AMOD
16	7.0	7.0	I-NP	CD	O	17	NMOD
17	mg/kg	mg/kg	I-NP	NN	O	18	DEP
18	)	)	O	)	O	12	NMOD
19	,	,	O	,	O	23	P
20	and	and	O	CC	O	23	VMOD
21	2	2	B-NP	CD	O	22	NMOD
22	lethalities	lethality	I-NP	NNS	O	23	SUB
23	occurred	occur	B-VP	VBD	O	0	ROOT
24	(	(	O	(	O	30	DEP
25	one	one	B-NP	CD	O	29	NMOD
26	IV	IV	I-NP	CD	O	25	NMOD
27	and	and	O	CC	O	29	NMOD
28	one	one	B-NP	CD	O	29	NMOD
29	PO	PO	I-NP	NN	O	30	DEP
30	)	)	O	)	O	23	VMOD
31	following	follow	B-PP	VBG	O	23	VMOD
32	the	the	B-NP	DT	O	35	NMOD
33	7.0	7.0	I-NP	CD	O	35	NMOD
34	mg/kg	mg/kg	I-NP	NN	O	35	NMOD
35	dose	dose	I-NP	NN	O	31	PMOD
36	.	.	O	.	O	23	P

1	Atypical	Atypical	B-NP	JJ	O	2	NMOD
2	sensations	sensation	I-NP	NNS	O	9	SUB
3	following	follow	B-PP	VBG	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	use	use	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	subcutaneous	subcutaneous	B-NP	JJ	O	8	NMOD
8	sumatriptan	sumatriptan	I-NP	NN	O	6	PMOD
9	are	be	B-VP	VBP	O	0	ROOT
10	common	common	B-ADJP	JJ	O	9	PRD
11	,	,	O	,	O	9	P
12	but	but	O	CC	O	9	VMOD
13	of	of	B-PP	IN	O	12	PRD
14	uncertain	uncertain	B-NP	JJ	O	15	NMOD
15	origin	origin	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	9	P

1	Tremor	Tremor	B-NP	NN	O	3	NMOD
2	side	side	I-NP	NN	O	3	NMOD
3	effects	effect	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	salbutamol	salbutamol	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	3	P
7	quantified	quantify	B-VP	VBN	O	3	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	12	NMOD
10	laser	laser	I-NP	NN	O	12	NMOD
11	pointer	pointer	I-NP	NN	O	12	NMOD
12	technique	technique	I-NP	NN	O	8	PMOD
13	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	study	study	I-VP	VB	O	18	VMOD
5	tremor	tremor	B-NP	NN	O	7	NMOD
6	side	side	I-NP	NN	O	7	NMOD
7	effects	effect	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	salbutamol	salbutamol	B-NP	NN	O	8	PMOD
10	an	an	B-NP	DT	O	17	NMOD
11	easily	easily	I-NP	RB	O	12	AMOD
12	applicable	applicable	I-NP	JJ	O	16	AMOD
13	,	,	I-NP	,	O	16	P
14	quick	quick	I-NP	JJ	O	16	AMOD
15	and	and	I-NP	CC	O	16	AMOD
16	low-priced	low-priced	I-NP	JJ	O	17	NMOD
17	method	method	I-NP	NN	O	18	SUB
18	is	be	B-VP	VBZ	O	1	NMOD
19	needed	need	I-VP	VBN	O	18	VC
20	.	.	O	.	O	18	P

1	To	To	B-VP	TO	O	2	VMOD
2	determine	determine	I-VP	VB	O	5	VMOD
3	sensitivity	sensitivity	B-NP	NN	O	2	OBJ
4	we	we	B-NP	PRP	O	5	SUB
5	assessed	assess	B-VP	VBD	O	0	ROOT
6	tremor	tremor	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	44	44	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	obstructive	obstructive	B-NP	JJ	O	13	NMOD
12	lung	lung	I-NP	NN	O	13	NMOD
13	disease	disease	I-NP	NN	O	10	PMOD
14	after	after	B-PP	IN	O	9	NMOD
15	administration	administration	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	cumulative	cumulative	B-NP	JJ	O	18	NMOD
18	doses	dose	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	salbutamol	salbutamol	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	5	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Salbutamol	Salbutamol	B-NP	NN	O	5	SUB
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	increased	increase	B-VP	VBD	O	1	NMOD
6	tremor	tremor	B-NP	NN	O	7	NMOD
7	severity	severity	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	dose-dependent	dose-dependent	I-NP	JJ	O	13	NMOD
13	way	way	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	1	P

1	Increased	Increase	B-NP	VBN	O	2	NMOD
2	frequency	frequency	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	venous	venous	B-NP	JJ	O	5	NMOD
5	thromboembolism	thromboembolism	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	combination	combination	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	docetaxel	docetaxel	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	thalidomide	thalidomide	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	metastatic	metastatic	B-NP	JJ	O	19	NMOD
17	androgen-independent	androgen-independent	I-NP	JJ	O	19	NMOD
18	prostate	prostate	I-NP	NN	O	19	NMOD
19	cancer	cancer	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	2	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	OBJECTIVE	OBJECTIVE	I-NP	NN	O	0	ROOT
3	:	:	O	:	O	2	P
4	To	To	B-VP	TO	O	5	VMOD
5	evaluate	evaluate	I-VP	VB	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	frequency	frequency	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	venous	venous	B-NP	JJ	O	10	NMOD
10	thromboembolism	thromboembolism	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	VTE	VTE	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	in	in	B-PP	IN	O	10	NMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	advanced	advance	B-NP	VBN	O	20	NMOD
18	androgen-independent	androgen-independent	I-NP	JJ	O	20	NMOD
19	prostate	prostate	I-NP	NN	O	20	NMOD
20	cancer	cancer	I-NP	NN	O	16	PMOD
21	who	who	B-NP	WP	O	15	NMOD
22	were	be	B-VP	VBD	O	21	SBAR
23	treated	treat	I-VP	VBN	O	22	VC
24	with	with	B-PP	IN	O	23	VMOD
25	docetaxel	docetaxel	B-NP	NN	O	24	PMOD
26	alone	alone	B-ADVP	RB	O	25	NMOD
27	or	or	O	CC	O	24	PMOD
28	in	in	B-PP	IN	O	24	PMOD
29	combination	combination	B-NP	NN	O	28	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	thalidomide	thalidomide	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	2	P

1	MEASUREMENTS	MEASUREMENTS	B-NP	NNS	O	4	NMOD
2	AND	AND	I-NP	CC	O	4	NMOD
3	MAIN	MAIN	I-NP	NN	O	4	NMOD
4	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT
5	:	:	O	:	O	4	P
6	None	None	B-NP	NN	O	14	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	23	23	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	received	receive	B-VP	VBD	O	10	SBAR
12	docetaxel	docetaxel	B-NP	NN	O	11	OBJ
13	alone	alone	B-ADVP	RB	O	11	VMOD
14	developed	develop	B-VP	VBD	O	17	VMOD
15	VTE	VTE	B-NP	NNP	O	14	OBJ
16	,	,	O	,	O	17	P
17	whereas	whereas	O	IN	O	4	NMOD
18	9	9	B-NP	CD	O	19	AMOD
19	of	of	B-PP	IN	O	21	NMOD
20	47	47	B-NP	CD	O	19	AMOD
21	patients	patient	I-NP	NNS	O	17	SBAR
22	(	(	O	(	O	25	DEP
23	19	19	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	25	DEP
25	)	)	O	)	O	21	NMOD
26	who	who	B-NP	WP	O	21	NMOD
27	received	receive	B-VP	VBD	O	31	VMOD
28	docetaxel	docetaxel	B-NP	NN	O	27	OBJ
29	plus	plus	I-NP	CC	O	31	VMOD
30	thalidomide	thalidomide	I-NP	NN	O	31	SUB
31	developed	develop	B-VP	VBD	O	26	SBAR
32	VTE	VTE	B-NP	NN	O	31	OBJ
33	(	(	O	(	O	35	DEP
34	p=0.025	p=0.025	B-NP	NN	O	35	DEP
35	)	)	O	)	O	32	NMOD
36	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	addition	addition	I-NP	NN	O	16	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	thalidomide	thalidomide	B-NP	NN	O	5	PMOD
7	to	to	B-PP	TO	O	4	NMOD
8	docetaxel	docetaxel	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	prostate	prostate	B-NP	NN	O	14	NMOD
14	cancer	cancer	I-NP	NN	O	12	PMOD
15	significantly	significantly	B-ADVP	RB	O	16	VMOD
16	increases	increase	B-VP	VBZ	O	1	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	frequency	frequency	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	VTE	VTE	B-NP	NN	B-protein	19	PMOD
21	.	.	O	.	O	16	P

1	UM-272	UM-272	B-NP	NN	O	11	NMOD
2	(	(	O	(	O	6	DEP
3	N	N	B-NP	NN	O	5	NMOD
4	,	,	O	,	O	5	P
5	N-dimethylpropranolol	N-dimethylpropranolol	B-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	,	,	O	,	O	11	P
8	a	a	B-NP	DT	O	11	NMOD
9	quaternary	quaternary	I-NP	JJ	O	11	NMOD
10	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	11	NMOD
11	agent	agent	I-NP	NN	O	13	SUB
12	,	,	O	,	O	11	P
13	was	be	B-VP	VBD	O	0	ROOT
14	administered	administer	I-VP	VBN	O	13	VC
15	sublingually	sublingually	B-ADVP	RB	O	14	VMOD
16	to	to	B-PP	TO	O	15	AMOD
17	dogs	dog	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	ouabain	ouabain	B-NP	NN	O	18	PMOD
20	induced	induce	B-VP	VBD	O	13	VMOD
21	ventricular	ventricular	B-NP	JJ	O	22	NMOD
22	tachycardias	tachycardia	I-NP	NNS	O	20	OBJ
23	.	.	O	.	O	13	P

1	Severe	Severe	B-NP	JJ	O	2	NMOD
2	thrombocytopenia	thrombocytopenia	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	haemolytic	haemolytic	B-NP	JJ	O	5	NMOD
5	anaemia	anaemia	I-NP	NN	O	12	NMOD
6	associated	associate	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	ciprofloxacin	ciprofloxacin	B-NP	NN	O	7	PMOD
9	:	:	O	:	O	5	P
10	a	a	B-NP	DT	O	12	NMOD
11	case	case	I-NP	NN	O	12	NMOD
12	report	report	I-NP	NN	O	0	ROOT
13	with	with	B-PP	IN	O	12	NMOD
14	fatal	fatal	B-NP	JJ	O	15	NMOD
15	outcome	outcome	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	12	P

1	A	A	B-NP	DT	O	5	NMOD
2	30-year	30-year	I-NP	JJ	O	5	NMOD
3	old	old	I-NP	JJ	O	5	NMOD
4	Caucasian	Caucasian	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	0	ROOT
6	reported	report	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	abdominal	abdominal	B-NP	JJ	O	9	NMOD
9	pain	pain	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	jaundice	jaundice	I-NP	NN	O	7	PMOD
12	after	after	B-SBAR	IN	O	5	NMOD
13	3-day	3-day	B-NP	JJ	O	14	NMOD
14	administration	administration	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	oral	oral	B-NP	JJ	O	17	NMOD
17	ciprofloxacin	ciprofloxacin	I-NP	NN	O	15	PMOD
18	for	for	B-PP	IN	O	14	NMOD
19	a	a	B-NP	DT	O	20	NMOD
20	suspect	suspect	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	urinary	urinary	B-NP	JJ	O	24	NMOD
23	tract	tract	I-NP	NN	O	24	NMOD
24	infection	infection	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	5	P

1	Simvastatin	Simvastatin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	bilateral	bilateral	B-NP	JJ	O	6	NMOD
4	leg	leg	I-NP	NN	O	6	NMOD
5	compartment	compartment	I-NP	NN	O	6	NMOD
6	syndrome	syndrome	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	myonecrosis	myonecrosis	I-NP	NN	O	2	OBJ
9	associated	associate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	hypothyroidism	hypothyroidism	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	6	NMOD
2	54-year-old	54-year-old	I-NP	JJ	O	6	NMOD
3	hypothyroid	hypothyroid	I-NP	NN	O	6	NMOD
4	male	male	I-NP	JJ	O	6	NMOD
5	taking	take	I-NP	VBG	O	6	NMOD
6	thyroxine	thyroxine	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	simvastatin	simvastatin	I-NP	NN	O	9	SUB
9	presented	present	B-VP	VBD	O	0	ROOT
10	with	with	B-PP	IN	O	9	VMOD
11	bilateral	bilateral	B-NP	JJ	O	14	NMOD
12	leg	leg	I-NP	NN	O	14	NMOD
13	compartment	compartment	I-NP	NN	O	14	NMOD
14	syndrome	syndrome	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	myonecrosis	myonecrosis	I-NP	NN	O	10	PMOD
17	.	.	O	.	O	9	P

1	Bile	Bile	B-NP	NN	O	3	NMOD
2	duct	duct	I-NP	NN	O	3	NMOD
3	hamartoma	hamartoma	I-NP	NN	O	0	ROOT
4	occurring	occur	B-VP	VBG	O	3	NMOD
5	in	in	B-PP	IN	O	4	VMOD
6	association	association	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	long-term	long-term	B-NP	JJ	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	danazol	danazol	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	bile	bile	B-NP	NN	O	8	NMOD
7	duct	duct	I-NP	NN	O	8	NMOD
8	hamartoma	hamartoma	I-NP	NN	O	5	PMOD
9	which	which	B-NP	WDT	O	4	NMOD
10	developed	develop	B-VP	VBD	O	9	SBAR
11	in	in	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	13	NMOD
13	patient	patient	I-NP	NN	O	11	PMOD
14	who	who	B-NP	WP	O	13	NMOD
15	had	have	B-VP	VBD	O	14	SBAR
16	been	be	I-VP	VBN	O	15	VC
17	on	on	B-PP	IN	O	16	PRD
18	long-term	long-term	B-NP	JJ	O	20	NMOD
19	danazol	danazol	I-NP	NN	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	2	P

1	Granulomatous	Granulomatous	B-NP	JJ	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	0	ROOT
3	due	due	B-ADJP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	combination	combination	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	amoxicillin	amoxicillin	B-NP	NN	B-protein	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	clavulanic	clavulanic	B-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	6	PMOD
11	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	amoxicillin-clavulanic	amoxicillin-clavulanic	B-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	8	PMOD
11	induced	induce	B-VP	VBD	O	2	VMOD
12	hepatitis	hepatitis	B-NP	NN	O	11	OBJ
13	with	with	B-PP	IN	O	12	NMOD
14	histologic	histologic	B-NP	JJ	O	16	NMOD
15	multiple	multiple	I-NP	JJ	O	16	NMOD
16	granulomas	granuloma	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	4	NMOD
4	review	review	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	admissions	admission	B-NP	NNS	O	5	PMOD
7	during	during	B-PP	IN	O	4	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	6-year	6-year	I-NP	JJ	O	10	NMOD
10	period	period	I-NP	NN	O	7	PMOD
11	revealed	reveal	B-VP	VBD	O	1	NMOD
12	14	14	B-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	11	OBJ
14	with	with	B-PP	IN	O	13	NMOD
15	cocaine-related	cocaine-related	B-NP	JJ	O	16	NMOD
16	aneurysms	aneurysm	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	1	P

1	Hunt	Hunt	B-NP	NNP	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	Hess	Hess	I-NP	NNP	O	4	NMOD
4	grade	grade	I-NP	NN	O	11	NMOD
5	(	(	O	(	O	9	DEP
6	P	P	B-NP	NN	O	8	SUB
7	<	<	O	SYM	O	8	VMOD
8	0.005	0.005	B-NP	CD	O	9	DEP
9	)	)	O	)	O	4	NMOD
10	and	and	O	CC	O	11	NMOD
11	age	age	B-NP	NN	O	17	SUB
12	(	(	O	(	O	16	DEP
13	P	P	B-NP	NN	O	16	DEP
14	<	<	B-NP	JJR	O	13	NMOD
15	0.007	0.007	I-NP	CD	O	14	AMOD
16	)	)	O	)	O	11	NMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	significant	significant	B-NP	JJ	O	19	NMOD
19	predictors	predictor	I-NP	NNS	O	17	PRD
20	of	of	B-PP	IN	O	19	NMOD
21	outcome	outcome	B-NP	NN	O	20	PMOD
22	for	for	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	patients	patient	I-NP	NNS	O	22	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	cocaine-related	cocaine-related	B-NP	JJ	O	27	NMOD
27	aneurysms	aneurysm	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	17	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	present	present	B-VP	VBP	O	0	ROOT
4	three	three	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	de	de	B-NP	FW	O	8	AMOD
8	novo	novo	I-NP	FW	O	10	NMOD
9	absence	absence	I-NP	NN	O	10	NMOD
10	epilepsy	epilepsy	I-NP	NN	O	6	PMOD
11	after	after	B-PP	IN	O	5	NMOD
12	administration	administration	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	carbamazepine	carbamazepine	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	vigabatrin	vigabatrin	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	5	NMOD
2	gamma-aminobutyric	gamma-aminobutyric	I-NP	JJ	O	5	NMOD
3	acid-transmitted	acid-transmitted	I-NP	JJ	O	5	NMOD
4	thalamocortical	thalamocortical	I-NP	JJ	O	5	NMOD
5	circuitry	circuitry	I-NP	NN	O	6	SUB
6	accounts	account	B-VP	VBZ	O	0	ROOT
7	for	for	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	major	major	I-NP	JJ	O	10	NMOD
10	part	part	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	underlying	underlie	I-NP	VBG	O	14	NMOD
14	neurophysiology	neurophysiology	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	absence	absence	I-NP	NN	O	18	NMOD
18	epilepsy	epilepsy	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	6	P

1	Procainamide	Procainamide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	polymorphous	polymorphous	B-NP	JJ	O	5	NMOD
4	ventricular	ventricular	I-NP	JJ	O	5	NMOD
5	tachycardia	tachycardia	I-NP	NN	O	2	OBJ
6	.	.	O	.	O	2	P

1	Seven	Seven	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	procainamide	procainamide	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	9	VMOD
6	polymorphous	polymorphous	B-NP	JJ	O	8	NMOD
7	ventricular	ventricular	I-NP	JJ	O	8	NMOD
8	tachycardia	tachycardia	I-NP	NN	O	9	SUB
9	are	be	B-VP	VBP	O	0	ROOT
10	presented	present	I-VP	VBN	O	9	VC
11	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	8	VMOD
2	four	four	B-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	8	P
5	polymorphous	polymorphous	B-NP	JJ	O	7	NMOD
6	ventricular	ventricular	I-NP	JJ	O	7	NMOD
7	tachycardia	tachycardia	I-NP	NN	O	8	SUB
8	appeared	appear	B-VP	VBD	O	0	ROOT
9	after	after	B-SBAR	IN	O	8	VMOD
10	intravenous	intravenous	B-NP	JJ	O	11	NMOD
11	administration	administration	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	200	200	B-NP	CD	O	15	AMOD
14	to	to	I-NP	TO	O	15	AMOD
15	400	400	I-NP	CD	O	16	NMOD
16	mg	mg	I-NP	NN	O	12	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	procainamide	procainamide	B-NP	NN	O	17	PMOD
19	for	for	B-PP	IN	O	11	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	sustained	sustained	B-NP	JJ	O	25	NMOD
24	ventricular	ventricular	I-NP	JJ	O	25	NMOD
25	tachycardia	tachycardia	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	remaining	remain	I-NP	VBG	O	5	NMOD
4	three	three	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	1	PMOD
6	,	,	O	,	O	8	P
7	procainamide	procainamide	B-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	administered	administer	I-VP	VBN	O	8	VC
10	orally	orally	B-ADVP	RB	O	9	VMOD
11	for	for	B-PP	IN	O	9	VMOD
12	treatment	treatment	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	chronic	chronic	B-NP	JJ	O	17	NMOD
15	premature	premature	I-NP	JJ	O	17	NMOD
16	ventricular	ventricular	I-NP	JJ	O	17	NMOD
17	contractions	contraction	I-NP	NNS	O	20	NMOD
18	or	or	O	CC	O	20	NMOD
19	atrial	atrial	B-NP	JJ	O	20	NMOD
20	flutter	flutter	I-NP	NN	O	13	PMOD
21	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	23	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	seventh	seventh	I-NP	JJ	O	4	NMOD
4	patient	patient	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	23	P
6	a	a	B-NP	DT	O	9	NMOD
7	permanent	permanent	I-NP	JJ	O	9	NMOD
8	ventricular	ventricular	I-NP	JJ	O	9	NMOD
9	pacemaker	pacemaker	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	23	VMOD
11	inserted	insert	I-VP	VBN	O	10	VC
12	and	and	O	CC	O	23	VMOD
13	,	,	O	,	O	23	P
14	despite	despite	B-PP	IN	O	23	VMOD
15	continuation	continuation	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	procainamide	procainamide	B-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	16	PMOD
19	,	,	O	,	O	23	P
20	polymorphous	polymorphous	B-NP	JJ	O	22	NMOD
21	ventricular	ventricular	I-NP	JJ	O	22	NMOD
22	tachycardia	tachycardia	I-NP	NN	O	23	SUB
23	did	do	B-VP	VBD	O	0	ROOT
24	not	not	I-VP	RB	O	23	VMOD
25	reoccur	reoccur	I-VP	VB	O	23	VC
26	.	.	O	.	O	23	P

1	Role	Role	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	activation	activation	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	bradykinin	bradykinin	B-NP	NN	B-protein	7	NMOD
6	B2	B2	I-NP	NN	I-protein	7	NMOD
7	receptors	receptor	I-NP	NNS	I-protein	4	PMOD
8	in	in	B-PP	IN	O	1	NMOD
9	disruption	disruption	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	blood-brain	blood-brain	I-NP	NN	O	13	NMOD
13	barrier	barrier	I-NP	NN	O	10	PMOD
14	during	during	B-PP	IN	O	1	NMOD
15	acute	acute	B-NP	JJ	O	16	NMOD
16	hypertension	hypertension	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	goal	goal	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	role	role	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	synthesis/release	synthesis/release	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	bradykinin	bradykinin	B-NP	NN	O	13	PMOD
15	to	to	B-VP	TO	O	16	VMOD
16	activate	activate	I-VP	VB	O	10	NMOD
17	B2	B2	B-NP	NN	B-protein	18	NMOD
18	receptors	receptor	I-NP	NNS	I-protein	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	disruption	disruption	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	blood-brain	blood-brain	I-NP	NN	O	24	NMOD
24	barrier	barrier	I-NP	NN	O	21	PMOD
25	during	during	B-PP	IN	O	16	VMOD
26	acute	acute	B-NP	JJ	O	27	NMOD
27	hypertension	hypertension	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	6	P

1	Permeability	Permeability	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	blood-brain	blood-brain	I-NP	NN	O	5	NMOD
5	barrier	barrier	I-NP	NN	O	2	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	quantitated	quantitate	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	clearance	clearance	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	fluorescent-labeled	fluorescent-labeled	B-NP	JJ	O	12	NMOD
12	dextran	dextran	I-NP	NN	O	10	PMOD
13	before	before	B-PP	IN	O	7	VMOD
14	and	and	I-PP	CC	O	13	PMOD
15	during	during	I-PP	IN	O	13	PMOD
16	phenylephrine	phenylephrine	B-NP	NN	O	13	PMOD
17	induced	induce	B-VP	VBD	O	16	NMOD
18	acute	acute	B-NP	JJ	O	19	NMOD
19	hypertension	hypertension	I-NP	NN	O	17	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	rats	rat	B-NP	NNS	O	20	PMOD
22	treated	treat	B-VP	VBN	O	21	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	vehicle	vehicle	B-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	Hoe-140	Hoe-140	I-NP	NN	O	23	PMOD
27	(	(	O	(	O	30	DEP
28	0.1	0.1	B-NP	CD	O	29	NMOD
29	microM	microM	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	NMOD
31	.	.	O	.	O	6	P

1	5-azacytidine	5-azacytidine	B-NP	NN	O	2	SUB
2	potentiates	potentiate	B-VP	VBZ	O	0	ROOT
3	initiation	initiation	B-NP	NN	O	2	OBJ
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	carcinogens	carcinogen	B-NP	NNS	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	rat	rat	B-NP	NN	O	9	NMOD
9	liver	liver	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	To	To	B-VP	TO	O	2	VMOD
2	test	test	I-VP	VB	O	38	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	validity	validity	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	hypothesis	hypothesis	I-NP	NN	O	5	PMOD
8	that	that	B-SBAR	IN	O	4	NMOD
9	hypomethylation	hypomethylation	B-NP	NN	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	DNA	DNA	B-NP	NN	O	10	PMOD
12	plays	play	B-VP	VBZ	O	8	SBAR
13	an	an	B-NP	DT	O	15	NMOD
14	important	important	I-NP	JJ	O	15	NMOD
15	role	role	I-NP	NN	O	12	OBJ
16	in	in	B-PP	IN	O	12	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	initiation	initiation	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	carcinogenic	carcinogenic	B-NP	JJ	O	21	NMOD
21	process	process	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	38	P
23	5-azacytidine	5-azacytidine	B-NP	NN	O	33	NMOD
24	(	(	O	(	O	26	DEP
25	5-AzC	5-AzC	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	(	(	O	(	O	30	DEP
28	10	10	B-NP	CD	O	29	NMOD
29	mg/kg	mg/kg	I-NP	NN	O	30	DEP
30	)	)	O	)	O	23	NMOD
31	,	,	O	,	O	33	P
32	an	an	B-NP	DT	O	33	NMOD
33	inhibitor	inhibitor	I-NP	NN	O	38	SUB
34	of	of	B-PP	IN	O	33	NMOD
35	DNA	DNA	B-NP	NN	O	36	NMOD
36	methylation	methylation	I-NP	NN	O	34	PMOD
37	,	,	O	,	O	33	P
38	was	be	B-VP	VBD	O	0	ROOT
39	given	give	I-VP	VBN	O	38	VC
40	to	to	B-PP	TO	O	39	VMOD
41	rats	rat	B-NP	NNS	O	40	PMOD
42	during	during	B-PP	IN	O	39	VMOD
43	the	the	B-NP	DT	O	44	NMOD
44	phase	phase	I-NP	NN	O	42	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	repair	repair	B-NP	NN	O	47	NMOD
47	synthesis	synthesis	I-NP	NN	O	45	PMOD
48	induced	induce	B-VP	VBN	O	47	NMOD
49	by	by	B-PP	IN	O	48	VMOD
50	the	the	B-NP	DT	O	52	NMOD
51	three	three	I-NP	CD	O	52	NMOD
52	carcinogens	carcinogen	I-NP	NNS	O	49	PMOD
53	,	,	O	,	O	72	P
54	benzo	benzo	B-NP	NN	O	58	NMOD
55	[	[	O	(	O	58	NMOD
56	a	a	O	DT	O	58	NMOD
57	]	]	O	)	B-DNA	58	NMOD
58	-pyrene	-pyrene	B-NP	NN	I-DNA	72	NMOD
59	(	(	O	(	O	62	DEP
60	200	200	B-NP	CD	O	61	NMOD
61	mg/kg	mg/kg	I-NP	NN	O	62	DEP
62	)	)	O	)	O	58	NMOD
63	,	,	O	,	O	72	P
64	N-methyl-N-nitrosourea	N-methyl-N-nitrosourea	B-NP	NN	B-protein	72	NMOD
65	(	(	O	(	I-protein	68	DEP
66	60	60	B-NP	CD	I-protein	67	NMOD
67	mg/kg	mg/kg	I-NP	NN	I-protein	68	DEP
68	)	)	O	)	I-protein	64	NMOD
69	and	and	O	CC	I-protein	64	NMOD
70	1	1	B-NP	CD	I-protein	64	NMOD
71	,	,	O	,	O	72	P
72	2-dimethylhydrazine	2-dimethylhydrazine	B-NP	NN	O	38	VMOD
73	(	(	O	(	O	77	DEP
74	1	1	B-NP	CD	O	76	NMOD
75	,	,	O	,	O	76	P
76	2-DMH	2-DMH	B-NP	NN	O	77	DEP
77	)	)	O	)	O	72	NMOD
78	(	(	O	(	O	81	DEP
79	100	100	B-NP	CD	O	80	NMOD
80	mg/kg	mg/kg	I-NP	NN	O	81	DEP
81	)	)	O	)	O	72	NMOD
82	.	.	O	.	O	38	P

1	Withdrawal-emergent	Withdrawal-emergent	B-NP	JJ	O	3	NMOD
2	rabbit	rabbit	I-NP	NN	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	0	ROOT
4	during	during	B-PP	IN	O	3	NMOD
5	dose	dose	B-NP	NN	O	6	NMOD
6	reduction	reduction	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	risperidone	risperidone	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	3	P

1	Verapamil	Verapamil	B-NP	NN	O	2	NMOD
2	withdrawal	withdrawal	I-NP	NN	O	0	ROOT
3	as	as	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	possible	possible	I-NP	JJ	O	6	NMOD
6	cause	cause	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	myocardial	myocardial	B-NP	JJ	O	9	NMOD
9	infarction	infarction	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	6	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	hypertensive	hypertensive	I-NP	JJ	O	13	NMOD
13	woman	woman	I-NP	NN	O	10	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	18	NMOD
16	normal	normal	I-NP	JJ	O	18	NMOD
17	coronary	coronary	I-NP	JJ	O	18	NMOD
18	angiogram	angiogram	I-NP	NN	O	14	PMOD
19	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	9	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	which	which	B-NP	WDT	O	5	PMOD
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	infarction	infarction	I-NP	NN	O	5	PMOD
9	coincided	coincide	B-VP	VBD	O	2	VMOD
10	with	with	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	introduction	introduction	I-NP	NN	O	17	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	captopril	captopril	B-NP	NN	O	13	PMOD
15	and	and	O	CC	O	17	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	withdrawal	withdrawal	I-NP	NN	O	10	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	verapamil	verapamil	B-NP	NN	O	18	PMOD
20	in	in	B-PP	IN	O	17	NMOD
21	a	a	B-NP	DT	O	24	NMOD
22	previously	previously	I-NP	RB	O	23	AMOD
23	asymptomatic	asymptomatic	I-NP	JJ	O	24	NMOD
24	woman	woman	I-NP	NN	O	20	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	severe	severe	B-NP	JJ	O	27	NMOD
27	hypertension	hypertension	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	2	P

1	Remission	Remission	B-NP	NN	O	2	NMOD
2	induction	induction	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	meningeal	meningeal	B-NP	JJ	O	5	NMOD
5	leukemia	leukemia	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	high-dose	high-dose	B-NP	JJ	O	9	NMOD
8	intravenous	intravenous	I-NP	JJ	O	9	NMOD
9	methotrexate	methotrexate	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	2	P

1	Twenty	Twenty	B-NP	CD	O	2	NMOD
2	children	child	I-NP	NNS	O	11	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	lymphoblastic	lymphoblastic	I-NP	JJ	O	6	NMOD
6	leukemia	leukemia	I-NP	NN	O	3	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	developed	develop	B-VP	VBD	O	7	SBAR
9	meningeal	meningeal	B-NP	JJ	O	10	NMOD
10	disease	disease	I-NP	NN	O	8	OBJ
11	were	be	B-VP	VBD	O	0	ROOT
12	treated	treat	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	18	NMOD
15	high-dose	high-dose	I-NP	JJ	O	18	NMOD
16	intravenous	intravenous	I-NP	JJ	O	18	NMOD
17	methotrexate	methotrexate	I-NP	NN	O	18	NMOD
18	regimen	regimen	I-NP	NN	O	13	PMOD
19	that	that	B-NP	WDT	O	11	VMOD
20	was	be	B-VP	VBD	O	19	SBAR
21	designed	design	I-VP	VBN	O	20	VC
22	to	to	B-VP	TO	O	23	VMOD
23	achieve	achieve	I-VP	VB	O	21	VMOD
24	and	and	I-VP	CC	O	23	VMOD
25	maintain	maintain	I-VP	VB	O	23	VMOD
26	CSF	CSF	B-NP	NN	B-protein	28	NMOD
27	methotrexate	methotrexate	I-NP	NN	O	28	NMOD
28	concentrations	concentration	I-NP	NNS	O	23	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	10	10	B-NP	CD	O	34	NMOD
31	(	(	O	(	O	33	DEP
32	-5	-5	B-NP	CD	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	mol/L	mol/L	B-NP	NN	O	29	PMOD
35	without	without	B-PP	IN	O	28	NMOD
36	the	the	B-NP	DT	O	37	NMOD
37	need	need	I-NP	NN	O	35	PMOD
38	for	for	B-PP	IN	O	37	NMOD
39	concomitant	concomitant	B-NP	JJ	O	41	NMOD
40	intrathecal	intrathecal	I-NP	JJ	O	41	NMOD
41	dosing	dosing	I-NP	NN	O	38	PMOD
42	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	4	NMOD
2	most	most	I-NP	RBS	O	3	AMOD
3	common	common	I-NP	JJ	O	4	NMOD
4	toxicities	toxicity	I-NP	NNS	O	6	SUB
5	encountered	encounter	B-VP	VBN	O	4	NMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	transient	transient	B-NP	JJ	O	12	NMOD
8	serum	serum	I-NP	NN	B-protein	9	NMOD
9	transaminase	transaminase	I-NP	NN	I-protein	7	NMOD
10	and	and	I-NP	CC	O	7	NMOD
11	bilirubin	bilirubin	I-NP	NN	O	12	NMOD
12	elevations	elevation	I-NP	NNS	O	17	NMOD
13	,	,	O	,	O	17	P
14	neutropenia	neutropenia	B-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	mucositis	mucositis	B-NP	NN	O	6	PRD
18	.	.	O	.	O	6	P

1	Hypersensitivity	Hypersensitivity	B-NP	NN	O	16	NMOD
2	to	to	B-PP	TO	O	1	NMOD
3	carbamazepine	carbamazepine	B-NP	NN	O	2	PMOD
4	presenting	present	B-VP	VBG	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	8	NMOD
7	leukemoid	leukemoid	I-NP	JJ	O	8	NMOD
8	reaction	reaction	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	16	P
10	eosinophilia	eosinophilia	B-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	erythroderma	erythroderma	B-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	NMOD
15	renal	renal	B-NP	JJ	O	16	NMOD
16	failure	failure	I-NP	NN	O	0	ROOT
17	.	.	O	.	O	16	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	10	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	whom	whom	B-NP	WP	O	5	PMOD
7	hypersensitivity	hypersensitivity	B-NP	NN	O	6	NMOD
8	to	to	B-PP	TO	O	7	NMOD
9	carbamazepine	carbamazepine	B-NP	NN	O	8	PMOD
10	presented	present	B-VP	VBD	O	2	VMOD
11	with	with	B-PP	IN	O	10	VMOD
12	generalized	generalize	B-NP	VBN	O	13	NMOD
13	erythroderma	erythroderma	I-NP	NN	O	26	NMOD
14	,	,	O	,	O	26	P
15	a	a	B-NP	DT	O	18	NMOD
16	severe	severe	I-NP	JJ	O	18	NMOD
17	leukemoid	leukemoid	I-NP	JJ	O	18	NMOD
18	reaction	reaction	I-NP	NN	O	26	NMOD
19	,	,	O	,	O	26	P
20	eosinophilia	eosinophilia	B-NP	NN	O	26	NMOD
21	,	,	O	,	O	26	P
22	hyponatremia	hyponatremia	B-NP	NN	O	26	NMOD
23	,	,	O	,	O	26	P
24	and	and	O	CC	O	26	NMOD
25	renal	renal	B-NP	JJ	O	26	NMOD
26	failure	failure	I-NP	NN	O	11	PMOD
27	.	.	O	.	O	2	P

1	Compared	Compare	B-PP	VBN	O	13	VMOD
2	with	with	B-PP	IN	O	1	PMOD
3	sham-operated	sham-operated	B-NP	JJ	O	4	NMOD
4	controls	control	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	13	P
6	lesions	lesion	B-NP	NNS	O	13	SUB
7	significantly	significantly	B-ADVP	RB	O	6	NMOD
8	(	(	O	(	O	12	DEP
9	p	p	B-NP	NN	O	11	NMOD
10	<	<	B-NP	JJR	O	11	NMOD
11	0.25	0.25	I-NP	CD	O	12	DEP
12	)	)	O	)	O	7	AMOD
13	blunted	blunt	B-VP	VBD	O	0	ROOT
14	the	the	B-NP	DT	O	15	NMOD
15	early	early	I-NP	JJ	O	13	OBJ
16	(	(	O	(	O	20	DEP
17	<	<	O	SYM	O	19	NMOD
18	60	60	B-NP	CD	O	19	NMOD
19	min	min	I-NP	NN	O	20	DEP
20	)	)	I-NP	)	O	15	NMOD
21	free-field	free-field	I-NP	JJ	O	23	NMOD
22	locomotor	locomotor	I-NP	NN	O	23	NMOD
23	hypoactivity	hypoactivity	I-NP	NN	O	15	NMOD
24	caused	cause	B-VP	VBN	O	15	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	nicotine	nicotine	B-NP	NN	O	25	PMOD
27	(	(	O	(	O	36	DEP
28	0.5	0.5	B-NP	CD	O	30	NMOD
29	mg	mg	I-NP	NN	O	30	NMOD
30	kg	kg	I-NP	NN	O	36	DEP
31	(	(	O	(	O	33	DEP
32	-1	-1	B-NP	CD	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	,	,	O	,	O	30	P
35	i.m.	i.m.	B-ADVP	JJ	O	30	NMOD
36	)	)	O	)	O	26	NMOD
37	,	,	O	,	O	13	P
38	enhanced	enhance	B-VP	VBD	O	13	VMOD
39	the	the	B-NP	DT	O	40	NMOD
40	later	later	I-NP	JJ	O	38	OBJ
41	(	(	O	(	O	44	DEP
42	60-120	60-120	B-NP	CD	O	43	NMOD
43	min	min	I-NP	NN	O	44	DEP
44	)	)	O	)	O	40	NMOD
45	nicotine	nicotine	B-NP	NN	O	40	NMOD
46	induced	induce	B-VP	VBD	O	45	SBAR
47	hyperactivity	hyperactivity	B-NP	NN	O	46	OBJ
48	,	,	O	,	O	13	P
49	and	and	O	CC	O	13	VMOD
50	raised	raise	B-VP	VBD	O	13	VMOD
51	spontaneous	spontaneous	B-NP	JJ	O	53	NMOD
52	nocturnal	nocturnal	I-NP	JJ	O	53	NMOD
53	activity	activity	I-NP	NN	O	50	OBJ
54	.	.	O	.	O	13	P

1	Assessment	Assessment	B-NP	NN	O	14	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	6	NMOD
4	new	new	I-NP	JJ	O	6	NMOD
5	non-invasive	non-invasive	I-NP	JJ	O	6	NMOD
6	index	index	I-NP	NN	O	2	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	cardiac	cardiac	B-NP	JJ	O	9	NMOD
9	performance	performance	I-NP	NN	O	7	PMOD
10	for	for	B-PP	IN	O	1	NMOD
11	detection	detection	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	dobutamine	dobutamine	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	0	ROOT
15	myocardial	myocardial	B-NP	JJ	O	16	NMOD
16	ischemia	ischemia	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	14	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Electrocardiography	Electrocardiography	B-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	8	NMOD
6	very	very	I-NP	RB	O	7	AMOD
7	low	low	I-NP	JJ	O	8	NMOD
8	sensitivity	sensitivity	I-NP	NN	O	4	OBJ
9	in	in	B-PP	IN	O	4	VMOD
10	detecting	detect	B-VP	VBG	O	9	PMOD
11	dobutamine	dobutamine	B-NP	NN	O	10	OBJ
12	induced	induce	B-VP	VBD	O	4	VMOD
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	ischemia	ischemia	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	4	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	added	add	I-NP	VBN	O	8	NMOD
7	diagnostic	diagnostic	I-NP	JJ	O	8	NMOD
8	value	value	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	14	NMOD
11	new	new	I-NP	JJ	O	14	NMOD
12	cardiac	cardiac	I-NP	JJ	O	14	NMOD
13	performance	performance	I-NP	NN	O	14	NMOD
14	index	index	I-NP	NN	O	18	NMOD
15	(	(	O	(	O	17	DEP
16	dP/dtejc	dP/dtejc	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	measurement	measurement	B-NP	NN	O	9	PMOD
19	,	,	O	,	O	4	P
20	based	base	B-PP	VBN	O	4	VMOD
21	on	on	B-PP	IN	O	20	PMOD
22	brachial	brachial	B-NP	JJ	O	25	NMOD
23	artery	artery	I-NP	NN	O	25	NMOD
24	flow	flow	I-NP	NN	O	25	NMOD
25	changes	change	I-NP	NNS	O	21	PMOD
26	,	,	O	,	O	4	P
27	as	as	B-SBAR	IN	O	4	VMOD
28	compared	compare	B-VP	VBN	O	27	SBAR
29	to	to	B-PP	TO	O	28	VMOD
30	standard	standard	B-NP	JJ	O	31	AMOD
31	12-lead	12-lead	I-NP	JJ	O	32	NMOD
32	ECG	ECG	I-NP	NN	O	29	PMOD
33	,	,	O	,	O	4	P
34	for	for	B-PP	IN	O	4	VMOD
35	detecting	detect	B-VP	VBG	O	34	PMOD
36	dobutamine	dobutamine	B-NP	NN	O	35	OBJ
37	induced	induce	B-VP	VBD	O	35	VMOD
38	myocardial	myocardial	B-NP	JJ	O	39	NMOD
39	ischemia	ischemia	I-NP	NN	O	37	OBJ
40	,	,	O	,	O	4	P
41	using	use	B-VP	VBG	O	4	VMOD
42	Tc99m-Sestamibi	Tc99m-Sestamibi	B-NP	NN	O	44	NMOD
43	single-photon	single-photon	I-NP	JJ	O	44	NMOD
44	emission	emission	I-NP	NN	O	41	OBJ
45	computed	compute	B-VP	VBD	O	4	VMOD
46	tomography	tomography	B-NP	NN	O	45	OBJ
47	as	as	B-PP	IN	O	45	VMOD
48	the	the	B-NP	DT	O	50	NMOD
49	gold	gold	I-NP	JJ	O	50	NMOD
50	standard	standard	I-NP	NN	O	47	PMOD
51	of	of	B-PP	IN	O	50	NMOD
52	comparison	comparison	B-NP	NN	O	51	PMOD
53	to	to	B-VP	TO	O	54	VMOD
54	assess	assess	I-VP	VB	O	45	VMOD
55	the	the	B-NP	DT	O	58	NMOD
56	presence	presence	I-NP	NN	O	58	NMOD
57	or	or	I-NP	CC	O	58	NMOD
58	absence	absence	I-NP	NN	O	54	OBJ
59	of	of	B-PP	IN	O	58	NMOD
60	ischemia	ischemia	B-NP	NN	O	59	PMOD
61	.	.	O	.	O	1	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	liver	liver	I-NP	NN	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	two	two	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	regular	regular	B-NP	JJ	O	10	NMOD
9	alcohol	alcohol	I-NP	NN	O	10	NMOD
10	consumption	consumption	I-NP	NN	O	7	PMOD
11	ingesting	ingest	B-VP	VBG	O	10	NMOD
12	paracetamol	paracetamol	B-NP	NN	O	11	OBJ
13	at	at	B-PP	IN	O	12	NMOD
14	therapeutic	therapeutic	B-NP	JJ	O	15	NMOD
15	dosage	dosage	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	possible	possible	I-NP	JJ	O	5	NMOD
5	role	role	I-NP	NN	O	22	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	alcohol	alcohol	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	development	development	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	hepatotoxicity	hepatotoxicity	B-NP	NN	O	11	PMOD
13	associated	associate	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	therapeutic	therapeutic	B-NP	JJ	O	16	NMOD
16	doses	dose	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	paracetamol	paracetamol	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	21	DEP
20	acetaminophen	acetaminophen	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	is	be	B-VP	VBZ	O	1	NMOD
23	currently	currently	I-VP	RB	O	22	VMOD
24	debated	debate	I-VP	VBN	O	22	VC
25	.	.	O	.	O	22	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	REPORT	REPORT	I-NP	NN	O	4	NMOD
3	:	:	O	:	O	2	P
4	We	We	B-NP	PRP	O	5	SUB
5	describe	describe	B-VP	VBP	O	0	ROOT
6	2	2	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	OBJ
8	who	who	B-NP	WP	O	7	NMOD
9	were	be	B-VP	VBD	O	11	NMOD
10	regular	regular	B-NP	JJ	O	11	NMOD
11	consumers	consumer	I-NP	NNS	O	8	SBAR
12	of	of	B-PP	IN	O	11	NMOD
13	alcohol	alcohol	B-NP	NN	O	12	PMOD
14	and	and	O	CC	O	13	NMOD
15	who	who	B-NP	WP	O	14	DEP
16	developed	develop	B-VP	VBD	O	15	SBAR
17	liver	liver	B-NP	NN	O	18	NMOD
18	failure	failure	I-NP	NN	O	16	OBJ
19	within	within	B-PP	IN	O	16	VMOD
20	3-5	3-5	B-NP	CD	O	21	NMOD
21	days	day	I-NP	NNS	O	19	PMOD
22	after	after	B-PP	IN	O	21	NMOD
23	hospitalization	hospitalization	B-NP	NN	O	22	PMOD
24	and	and	O	CC	O	16	VMOD
25	stopping	stop	B-VP	VBG	O	16	VMOD
26	alcohol	alcohol	B-NP	NN	O	27	NMOD
27	consumption	consumption	I-NP	NN	O	25	OBJ
28	while	while	B-SBAR	IN	O	25	VMOD
29	being	be	B-VP	VBG	O	28	SBAR
30	treated	treat	I-VP	VBN	O	29	VC
31	with	with	B-PP	IN	O	30	VMOD
32	4	4	B-NP	CD	O	34	NMOD
33	g	g	I-NP	NN	O	34	NMOD
34	paracetamol/day	paracetamol/day	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	5	P

1	Possible	Possible	B-NP	JJ	O	3	NMOD
2	risk	risk	I-NP	NN	O	3	NMOD
3	factors	factor	I-NP	NNS	O	17	SUB
4	for	for	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	development	development	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	hepatotoxicity	hepatotoxicity	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	treated	treat	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	therapeutic	therapeutic	B-NP	JJ	O	14	NMOD
14	doses	dose	I-NP	NNS	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	paracetamol	paracetamol	B-NP	NN	O	15	PMOD
17	are	be	B-VP	VBP	O	0	ROOT
18	discussed	discuss	I-VP	VBN	O	17	VC
19	.	.	O	.	O	17	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	17	VMOD
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	17	VMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	risk	risk	B-NP	NN	O	7	NMOD
7	factors	factor	I-NP	NNS	O	5	PMOD
8	,	,	O	,	O	17	P
9	e.g.	e.g.	B-NP	FW	O	11	NMOD
10	regular	regular	I-NP	JJ	O	11	NMOD
11	consumption	consumption	I-NP	NN	O	16	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	alcohol	alcohol	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	16	P
15	liver	liver	B-NP	NN	O	16	NMOD
16	failure	failure	I-NP	NN	O	17	SUB
17	is	be	B-VP	VBZ	O	0	ROOT
18	possible	possible	B-ADJP	JJ	O	17	PRD
19	when	when	B-ADVP	WRB	O	17	VMOD
20	therapeutic	therapeutic	B-NP	JJ	O	21	NMOD
21	doses	dose	I-NP	NNS	O	22	SUB
22	are	be	B-VP	VBP	O	19	SBAR
23	ingested	ingest	I-VP	VBN	O	22	VC
24	.	.	O	.	O	17	P

1	Cocaine	Cocaine	B-NP	NN	O	4	NMOD
2	related	related	I-NP	JJ	O	4	NMOD
3	chest	chest	I-NP	NN	O	4	NMOD
4	pain	pain	I-NP	NN	O	6	SUB
5	:	:	O	:	O	4	P
6	are	be	B-VP	VBP	O	0	ROOT
7	we	we	B-NP	PRP	O	6	PRD
8	seeing	see	B-VP	VBG	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	tip	tip	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	an	an	B-NP	DT	O	13	NMOD
13	iceberg	iceberg	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	12	VMOD
2	particular	particular	B-NP	JJ	O	1	PMOD
3	,	,	O	,	O	12	P
4	the	the	B-NP	DT	O	5	NMOD
5	tendency	tendency	I-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	cocaine	cocaine	B-NP	NN	O	6	PMOD
8	to	to	B-VP	TO	O	9	VMOD
9	produce	produce	I-VP	VB	O	5	NMOD
10	chest	chest	B-NP	NN	O	11	NMOD
11	pain	pain	I-NP	NN	O	9	OBJ
12	ought	ought	B-VP	MD	O	0	ROOT
13	to	to	I-VP	TO	O	14	VMOD
14	be	be	I-VP	VB	O	12	VC
15	in	in	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	mind	mind	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	emergency	emergency	I-NP	NN	O	21	NMOD
21	nurse	nurse	I-NP	NN	O	18	PMOD
22	when	when	B-ADVP	WRB	O	14	VMOD
23	faced	face	B-VP	VBN	O	22	SBAR
24	with	with	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	27	NMOD
26	young	young	I-NP	JJ	O	27	NMOD
27	victim	victim	I-NP	NN	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	chest	chest	B-NP	NN	O	30	NMOD
30	pain	pain	I-NP	NN	O	28	PMOD
31	who	who	B-NP	WP	O	30	NMOD
32	is	be	B-VP	VBZ	O	31	SBAR
33	otherwise	otherwise	B-ADVP	RB	O	32	VMOD
34	at	at	B-PP	IN	O	32	VMOD
35	low	low	B-NP	JJ	O	36	NMOD
36	risk	risk	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanism	mechanism	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	chest	chest	B-NP	NN	O	5	NMOD
5	pain	pain	I-NP	NN	O	3	PMOD
6	related	relate	B-VP	VBN	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	cocaine	cocaine	B-NP	NN	O	9	NMOD
9	use	use	I-NP	NN	O	7	PMOD
10	is	be	B-VP	VBZ	O	15	VMOD
11	discussed	discuss	I-VP	VBN	O	10	VC
12	and	and	O	CC	O	15	VMOD
13	treatment	treatment	B-NP	NN	O	14	NMOD
14	dilemmas	dilemma	I-NP	NNS	O	15	SUB
15	are	be	B-VP	VBP	O	0	ROOT
16	discussed	discuss	I-VP	VBN	O	15	VC
17	.	.	O	.	O	15	P

1	Severe	Severe	B-NP	JJ	O	2	NMOD
2	rhabdomyolysis	rhabdomyolysis	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	acute	acute	B-NP	JJ	O	6	NMOD
5	renal	renal	I-NP	JJ	O	6	NMOD
6	failure	failure	I-NP	NN	O	0	ROOT
7	secondary	secondary	B-ADJP	JJ	O	6	NMOD
8	to	to	B-PP	TO	O	7	AMOD
9	concomitant	concomitant	B-NP	JJ	O	10	NMOD
10	use	use	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	simvastatin	simvastatin	B-NP	NN	O	17	NMOD
13	,	,	O	,	O	17	P
14	amiodarone	amiodarone	B-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	atazanavir	atazanavir	B-NP	NN	O	11	PMOD
18	.	.	O	.	O	6	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	severe	severe	I-NP	JJ	O	10	NMOD
10	interaction	interaction	I-NP	NN	O	7	PMOD
11	between	between	B-PP	IN	O	10	NMOD
12	simvastatin	simvastatin	B-NP	NN	O	17	NMOD
13	,	,	O	,	O	17	P
14	amiodarone	amiodarone	B-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	atazanavir	atazanavir	B-NP	NN	O	11	PMOD
18	resulting	result	B-VP	VBG	O	17	NMOD
19	in	in	B-PP	IN	O	18	VMOD
20	rhabdomyolysis	rhabdomyolysis	B-NP	NN	O	24	NMOD
21	and	and	O	CC	O	24	NMOD
22	acute	acute	B-NP	JJ	O	24	NMOD
23	renal	renal	I-NP	JJ	O	24	NMOD
24	failure	failure	I-NP	NN	O	19	PMOD
25	.	.	O	.	O	1	P

1	Simvastatin	Simvastatin	B-NP	NN	O	12	NMOD
2	,	,	O	,	O	12	P
3	amiodarone	amiodarone	B-NP	NN	O	12	NMOD
4	,	,	O	,	O	12	P
5	and	and	O	CC	O	12	NMOD
6	the	the	B-NP	DT	O	12	NMOD
7	patient	patient	I-NP	NN	O	12	NMOD
8	's	's	B-NP	POS	O	12	NMOD
9	human	human	I-NP	JJ	O	12	NMOD
10	immunodeficiency	immunodeficiency	I-NP	NN	O	12	NMOD
11	virus	virus	I-NP	NN	O	12	NMOD
12	medications	medication	I-NP	NNS	O	13	SUB
13	were	be	B-VP	VBD	O	20	VMOD
14	all	all	B-NP	DT	O	16	AMOD
15	temporarily	temporarily	I-NP	RB	O	16	AMOD
16	discontinued	discontinue	I-NP	VBN	O	13	PRD
17	and	and	O	CC	O	20	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	patient	patient	I-NP	NN	O	20	SUB
20	was	be	B-VP	VBD	O	0	ROOT
21	given	give	I-VP	VBN	O	20	VC
22	forced	force	B-NP	VBN	O	24	NMOD
23	alkaline	alkaline	I-NP	NN	O	24	NMOD
24	diuresis	diuresis	I-NP	NN	O	21	OBJ
25	and	and	O	CC	O	21	VMOD
26	started	start	B-VP	VBN	O	21	VMOD
27	on	on	B-PP	IN	O	26	VMOD
28	dialysis	dialysis	B-NP	NN	O	27	PMOD
29	.	.	O	.	O	20	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	risk	risk	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	rhabdomyolysis	rhabdomyolysis	B-NP	NN	O	5	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	increased	increase	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	presence	presence	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	concomitant	concomitant	B-NP	JJ	O	14	NMOD
14	drugs	drug	I-NP	NNS	O	12	PMOD
15	that	that	B-NP	WDT	O	14	NMOD
16	inhibit	inhibit	B-VP	VBP	O	15	SBAR
17	simvastatin	simvastatin	B-NP	NN	O	18	NMOD
18	metabolism	metabolism	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	7	P

1	Phase	Phase	B-NP	NN	O	3	NMOD
2	II	II	I-NP	CD	O	3	NMOD
3	trial	trial	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	vinorelbine	vinorelbine	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	metastatic	metastatic	B-NP	JJ	O	11	NMOD
8	squamous	squamous	I-NP	JJ	O	11	NMOD
9	cell	cell	I-NP	NN	O	11	NMOD
10	esophageal	esophageal	I-NP	JJ	O	11	NMOD
11	carcinoma	carcinoma	I-NP	NN	O	6	PMOD
12	.	.	O	.	O	3	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	10	NMOD
6	response	response	I-NP	NN	O	7	NMOD
7	rate	rate	I-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	toxic	toxic	B-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	vinorelbine	vinorelbine	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	15	DEP
14	VNB	VNB	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	administered	administer	B-VP	VBN	O	12	NMOD
17	as	as	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	20	NMOD
19	single	single	I-NP	JJ	O	20	NMOD
20	agent	agent	I-NP	NN	O	17	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	metastatic	metastatic	B-NP	JJ	O	26	NMOD
23	squamous	squamous	I-NP	JJ	O	26	NMOD
24	cell	cell	I-NP	NN	O	26	NMOD
25	esophageal	esophageal	I-NP	JJ	O	26	NMOD
26	carcinoma	carcinoma	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	1	P

1	Thirty	Thirty	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	7	NMOD
3	without	without	B-PP	IN	O	2	NMOD
4	prior	prior	B-NP	JJ	O	5	NMOD
5	chemotherapy	chemotherapy	I-NP	NN	O	3	PMOD
6	and	and	O	CC	O	7	NMOD
7	16	16	B-NP	CD	O	12	SUB
8	pretreated	pretreate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	cisplatin-based	cisplatin-based	B-NP	JJ	O	11	NMOD
11	chemotherapy	chemotherapy	I-NP	NN	O	9	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	assessable	assessable	B-ADJP	JJ	O	12	PRD
14	for	for	B-PP	IN	O	13	AMOD
15	toxicity	toxicity	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	response	response	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	12	P

1	VNB	VNB	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	14	VMOD
3	well	well	I-VP	RB	O	2	VMOD
4	tolerated	tolerate	I-VP	VBN	O	2	VC
5	and	and	O	CC	O	14	VMOD
6	zero	zero	B-NP	CD	O	7	NMOD
7	instances	instance	I-NP	NNS	O	14	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	WHO	WHO	B-NP	NN	O	13	NMOD
10	grade	grade	I-NP	NN	O	13	NMOD
11	4	4	I-NP	CD	O	13	NMOD
12	nonhematologic	nonhematologic	I-NP	JJ	O	13	NMOD
13	toxicity	toxicity	I-NP	NN	O	8	PMOD
14	occurred	occur	B-VP	VBD	O	0	ROOT
15	.	.	O	.	O	14	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	5	VMOD
2	:	:	O	:	O	5	P
3	These	These	B-NP	DT	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	indicate	indicate	B-VP	VBP	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	VNB	VNB	B-NP	NN	B-protein	8	SUB
8	is	be	B-VP	VBZ	O	6	SBAR
9	an	an	B-NP	DT	O	11	NMOD
10	active	active	I-NP	JJ	O	11	NMOD
11	agent	agent	I-NP	NN	O	8	PRD
12	in	in	B-PP	IN	O	11	NMOD
13	metastatic	metastatic	B-NP	JJ	O	17	NMOD
14	esophageal	esophageal	I-NP	JJ	O	17	NMOD
15	squamous	squamous	I-NP	JJ	O	17	NMOD
16	cell	cell	I-NP	NN	O	17	NMOD
17	carcinoma	carcinoma	I-NP	NN	O	12	PMOD
18	.	.	O	.	O	5	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	8	NMOD
2	,	,	O	,	O	8	P
3	cisplatin	cisplatin	B-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	and	and	O	CC	O	8	NMOD
6	gemcitabine	gemcitabine	B-NP	NN	O	8	NMOD
7	combination	combination	I-NP	NN	O	8	NMOD
8	chemotherapy	chemotherapy	I-NP	NN	O	0	ROOT
9	within	within	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	13	NMOD
11	multidisciplinary	multidisciplinary	I-NP	JJ	O	13	NMOD
12	therapeutic	therapeutic	I-NP	JJ	O	13	NMOD
13	approach	approach	I-NP	NN	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	metastatic	metastatic	B-NP	JJ	O	19	NMOD
16	nonsmall	nonsmall	I-NP	JJ	O	19	NMOD
17	cell	cell	I-NP	NN	O	19	NMOD
18	lung	lung	I-NP	NN	O	19	NMOD
19	carcinoma	carcinoma	I-NP	NN	O	14	PMOD
20	.	.	O	.	O	8	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cisplatin-based	Cisplatin-based	B-NP	JJ	O	5	NMOD
4	chemotherapy	chemotherapy	I-NP	NN	O	5	NMOD
5	combinations	combination	I-NP	NNS	O	6	SUB
6	improve	improve	B-VP	VBP	O	1	NMOD
7	quality	quality	B-NP	NN	O	6	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	life	life	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	survival	survival	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	advanced	advance	B-NP	VBN	O	17	NMOD
14	nonsmall	nonsmall	I-NP	JJ	O	17	NMOD
15	cell	cell	I-NP	NN	O	17	NMOD
16	lung	lung	I-NP	NN	O	17	NMOD
17	carcinoma	carcinoma	I-NP	NN	O	12	PMOD
18	(	(	O	(	O	20	DEP
19	NSCLC	NSCLC	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	.	.	O	.	O	6	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	objective	objective	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	determine	determine	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	12	NMOD
12	feasibility	feasibility	I-NP	NN	O	18	NMOD
13	,	,	O	,	O	18	P
14	response	response	B-NP	NN	O	15	NMOD
15	rate	rate	I-NP	NN	O	18	NMOD
16	,	,	O	,	O	18	P
17	and	and	O	CC	O	18	NMOD
18	toxicity	toxicity	B-NP	NN	O	10	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	a	a	B-NP	DT	O	21	NMOD
21	paclitaxel	paclitaxel	I-NP	NN	O	27	NMOD
22	,	,	O	,	O	27	P
23	cisplatin	cisplatin	B-NP	NN	O	27	NMOD
24	,	,	O	,	O	27	P
25	and	and	O	CC	O	27	NMOD
26	gemcitabine	gemcitabine	B-NP	NN	O	27	NMOD
27	combination	combination	I-NP	NN	O	19	PMOD
28	to	to	B-VP	TO	O	29	VMOD
29	treat	treat	I-VP	VB	O	18	NMOD
30	metastatic	metastatic	B-NP	JJ	O	31	NMOD
31	NSCLC	NSCLC	I-NP	NN	O	29	OBJ
32	.	.	O	.	O	1	P

1	Thirty-five	Thirty-five	B-NP	CD	O	4	NMOD
2	consecutive	consecutive	I-NP	JJ	O	4	NMOD
3	chemotherapy-naive	chemotherapy-naive	I-NP	JJ	O	4	NMOD
4	patients	patient	I-NP	NNS	O	16	NMOD
5	with	with	B-PP	IN	O	4	NMOD
6	Stage	Stage	B-NP	NN	O	8	NMOD
7	IV	IV	I-NP	CD	O	8	NMOD
8	NSCLC	NSCLC	I-NP	NN	O	5	PMOD
9	and	and	O	CC	O	16	NMOD
10	an	an	B-NP	DT	O	16	NMOD
11	Eastern	Eastern	I-NP	NNP	O	16	NMOD
12	Cooperative	Cooperative	I-NP	NNP	O	16	NMOD
13	Oncology	Oncology	I-NP	NNP	O	16	NMOD
14	Group	Group	I-NP	NNP	O	16	NMOD
15	performance	performance	I-NP	NN	O	16	NMOD
16	status	status	I-NP	NN	O	19	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	0-2	0-2	B-NP	CD	O	17	PMOD
19	were	be	B-VP	VBD	O	0	ROOT
20	treated	treat	I-VP	VBN	O	19	VC
21	with	with	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	23	NMOD
23	combination	combination	I-NP	NN	O	60	NMOD
24	of	of	B-PP	IN	O	23	NMOD
25	paclitaxel	paclitaxel	B-NP	NN	O	24	PMOD
26	(	(	O	(	O	37	DEP
27	135	135	B-NP	CD	O	28	NMOD
28	mg/m	mg/m	I-NP	NN	O	37	DEP
29	(	(	O	(	O	31	DEP
30	2	2	B-NP	CD	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	given	give	B-VP	VBN	O	28	NMOD
33	intravenously	intravenously	B-ADVP	RB	O	32	VMOD
34	in	in	B-PP	IN	O	32	VMOD
35	3	3	B-NP	CD	O	36	NMOD
36	hours	hour	I-NP	NNS	O	34	PMOD
37	)	)	O	)	O	25	NMOD
38	on	on	B-PP	IN	O	23	NMOD
39	Day	Day	B-NP	NN	O	38	PMOD
40	1	1	I-NP	CD	O	39	NMOD
41	,	,	O	,	O	60	P
42	cisplatin	cisplatin	B-NP	NN	O	60	NMOD
43	(	(	O	(	O	54	DEP
44	120	120	B-NP	CD	O	45	NMOD
45	mg/m	mg/m	I-NP	NN	O	54	DEP
46	(	(	O	(	O	48	DEP
47	2	2	B-NP	CD	O	48	DEP
48	)	)	O	)	O	45	NMOD
49	given	give	B-VP	VBN	O	45	NMOD
50	intravenously	intravenously	B-ADVP	RB	O	49	VMOD
51	in	in	B-PP	IN	O	49	VMOD
52	6	6	B-NP	CD	O	53	NMOD
53	hours	hour	I-NP	NNS	O	51	PMOD
54	)	)	O	)	O	42	NMOD
55	on	on	B-PP	IN	O	42	NMOD
56	Day	Day	B-NP	NN	O	55	PMOD
57	1	1	I-NP	CD	O	56	NMOD
58	,	,	O	,	O	60	P
59	and	and	O	CC	O	60	NMOD
60	gemcitabine	gemcitabine	B-NP	NN	O	21	PMOD
61	(	(	O	(	O	72	DEP
62	800	800	B-NP	CD	O	63	NMOD
63	mg/m	mg/m	I-NP	NN	O	72	DEP
64	(	(	O	(	O	66	DEP
65	2	2	B-NP	CD	O	66	DEP
66	)	)	O	)	O	63	NMOD
67	given	give	B-VP	VBN	O	63	NMOD
68	intravenously	intravenously	B-ADVP	RB	O	67	VMOD
69	in	in	B-PP	IN	O	67	VMOD
70	30	30	B-NP	CD	O	71	NMOD
71	minutes	minute	I-NP	NNS	O	69	PMOD
72	)	)	O	)	O	60	NMOD
73	on	on	B-PP	IN	O	20	VMOD
74	Days	Day	B-NP	NNS	O	81	NMOD
75	1	1	I-NP	CD	O	77	NMOD
76	and	and	I-NP	CC	O	77	NMOD
77	8	8	I-NP	CD	O	74	NMOD
78	,	,	O	,	O	81	P
79	every	every	B-NP	DT	O	81	NMOD
80	4	4	I-NP	CD	O	81	NMOD
81	weeks	week	I-NP	NNS	O	73	PMOD
82	.	.	O	.	O	19	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	combination	combination	I-NP	NN	O	1	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	paclitaxel	paclitaxel	B-NP	NN	O	12	SUB
7	,	,	O	,	O	12	P
8	cisplatin	cisplatin	B-NP	NN	O	12	SUB
9	,	,	O	,	O	12	P
10	and	and	O	CC	O	12	VMOD
11	gemcitabine	gemcitabine	B-NP	NN	O	12	SUB
12	is	be	B-VP	VBZ	O	5	SBAR
13	well	well	I-VP	RB	O	12	VMOD
14	tolerated	tolerate	I-VP	VBN	O	12	VC
15	and	and	O	CC	O	12	VMOD
16	shows	show	B-VP	VBZ	O	12	VMOD
17	high	high	B-NP	JJ	O	18	NMOD
18	activity	activity	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	metastatic	metastatic	B-NP	JJ	O	21	NMOD
21	NSCLC	NSCLC	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	4	NMOD
2	ocular	ocular	I-NP	JJ	O	3	AMOD
3	hypotensive	hypotensive	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	statistically	statistically	B-ADJP	RB	O	7	AMOD
7	significant	significant	I-ADJP	JJ	O	17	AMOD
8	for	for	B-PP	IN	O	7	AMOD
9	apraclonidine-treated	apraclonidine-treated	B-NP	JJ	O	10	NMOD
10	eyes	eye	I-NP	NNS	O	8	PMOD
11	throughout	throughout	B-PP	IN	O	7	AMOD
12	the	the	B-NP	DT	O	13	NMOD
13	study	study	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	17	AMOD
15	also	also	B-ADVP	RB	O	17	AMOD
16	statistically	statistically	B-ADJP	RB	O	17	AMOD
17	significant	significant	I-ADJP	JJ	O	5	PRD
18	for	for	B-PP	IN	O	17	AMOD
19	contralateral	contralateral	B-NP	JJ	O	20	NMOD
20	eyes	eye	I-NP	NNS	O	18	PMOD
21	from	from	B-PP	IN	O	20	NMOD
22	three	three	B-NP	CD	O	23	NMOD
23	hours	hour	I-NP	NNS	O	21	PMOD
24	after	after	B-PP	IN	O	17	AMOD
25	topical	topical	B-NP	JJ	O	26	NMOD
26	administration	administration	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	1	1	B-NP	CD	O	29	AMOD
29	%	%	I-NP	NN	O	30	NMOD
30	apraclonidine	apraclonidine	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	5	P

1	Carmofur	Carmofur	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	organic	organic	B-NP	JJ	O	5	NMOD
4	mental	mental	I-NP	JJ	O	5	NMOD
5	disorders	disorder	I-NP	NNS	O	2	OBJ
6	.	.	O	.	O	2	P

1	Organic	Organic	B-NP	JJ	O	3	NMOD
2	mental	mental	I-NP	JJ	O	3	NMOD
3	disorder	disorder	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	observed	observe	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	29-year-old	29-year-old	I-NP	JJ	O	9	NMOD
9	female	female	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	prognostic	prognostic	I-NP	JJ	O	13	NMOD
13	period	period	I-NP	NN	O	10	PMOD
14	after	after	B-PP	IN	O	9	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	onset	onset	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	carmofur	carmofur	B-NP	NN	O	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	leukoencephalopathy	leukoencephalopathy	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	4	P

1	Consequently	Consequently	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	carmofur	carmofur	B-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	leukoencephalopathy	leukoencephalopathy	B-NP	NN	O	4	OBJ
6	may	may	B-VP	MD	O	4	VMOD
7	uncommonly	uncommonly	I-VP	RB	O	6	VMOD
8	result	result	I-VP	VB	O	6	VC
9	in	in	B-PP	IN	O	8	VMOD
10	organic	organic	B-NP	JJ	O	12	NMOD
11	personality	personality	I-NP	NN	O	12	NMOD
12	syndrome	syndrome	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	residual	residual	I-NP	JJ	O	16	NMOD
16	state	state	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	14	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	sustained	sustained	I-NP	JJ	O	8	NMOD
7	release	release	I-NP	NN	O	8	NMOD
8	form	form	I-NP	NN	O	4	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	mexiletine	mexiletine	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	13	DEP
12	Mexitil-Perlongets	Mexitil-Perlonget	B-NP	NNS	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	evaluated	evaluate	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	double-blind	double-blind	I-NP	JJ	O	20	NMOD
19	placebo	placebo	I-NP	NN	O	20	NMOD
20	trial	trial	I-NP	NN	O	16	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	630	630	B-NP	CD	O	23	NMOD
23	patients	patient	I-NP	NNS	O	21	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	recent	recent	B-NP	JJ	O	28	NMOD
26	documented	document	I-NP	VBN	O	28	NMOD
27	myocardial	myocardial	I-NP	JJ	O	28	NMOD
28	infarction	infarction	I-NP	NN	O	24	PMOD
29	.	.	O	.	O	14	P

1	There	There	B-NP	EX	O	2	SUB
2	were	be	B-VP	VBD	O	25	VMOD
3	more	more	B-NP	JJR	O	4	NMOD
4	deaths	death	I-NP	NNS	O	2	PRD
5	in	in	B-PP	IN	O	2	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	mexiletine	mexiletine	I-NP	NN	O	8	NMOD
8	group	group	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	12	DEP
10	7.6	7.6	B-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	than	than	B-PP	IN	O	2	VMOD
14	in	in	B-PP	IN	O	13	PMOD
15	the	the	B-NP	DT	O	17	NMOD
16	placebo	placebo	I-NP	NN	O	17	NMOD
17	group	group	I-NP	NN	O	14	PMOD
18	(	(	O	(	O	21	DEP
19	4.8	4.8	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	21	DEP
21	)	)	O	)	O	2	VMOD
22	;	;	O	:	O	25	P
23	the	the	B-NP	DT	O	24	NMOD
24	difference	difference	I-NP	NN	O	25	SUB
25	was	be	B-VP	VBD	O	0	ROOT
26	not	not	O	RB	O	25	VMOD
27	statistically	statistically	B-ADJP	RB	O	25	VMOD
28	significant	significant	I-ADJP	JJ	O	25	PRD
29	.	.	O	.	O	25	P

1	Regional	Regional	B-NP	JJ	O	2	NMOD
2	localization	localization	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	antagonism	antagonism	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	amphetamine	amphetamine	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	hyperactivity	hyperactivity	B-NP	NN	O	8	OBJ
10	by	by	B-PP	IN	O	8	VMOD
11	intracerebral	intracerebral	B-NP	JJ	O	13	NMOD
12	calcitonin	calcitonin	I-NP	NN	O	13	NMOD
13	injections	injection	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	8	P

1	Fatal	Fatal	B-NP	JJ	O	3	NMOD
2	intracranial	intracranial	I-NP	JJ	O	3	NMOD
3	bleeding	bleeding	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	prehospital	prehospital	B-NP	NN	O	7	NMOD
7	use	use	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	epinephrine	epinephrine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	sudden	sudden	I-NP	JJ	O	3	NMOD
3	onset	onset	I-NP	NN	O	17	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	respiratory	respiratory	B-NP	JJ	O	6	NMOD
6	distress	distress	I-NP	NN	O	12	NMOD
7	,	,	O	,	O	12	P
8	rash	rash	B-NP	NN	O	12	NMOD
9	,	,	O	,	O	12	P
10	and	and	O	CC	O	12	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	history	history	I-NP	NN	O	4	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	new	new	I-NP	JJ	O	16	NMOD
16	medicine	medicine	I-NP	NN	O	13	PMOD
17	led	lead	B-VP	VBD	O	0	ROOT
18	the	the	B-NP	DT	O	20	NMOD
19	two	two	I-NP	CD	O	20	NMOD
20	paramedics	paramedic	I-NP	NNS	O	17	OBJ
21	on	on	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	scene	scene	I-NP	NN	O	21	PMOD
24	to	to	B-VP	TO	O	25	VMOD
25	administer	administer	I-VP	VB	O	17	VMOD
26	subcutaneous	subcutaneous	B-NP	JJ	O	27	NMOD
27	epinephrine	epinephrine	I-NP	NN	O	25	OBJ
28	.	.	O	.	O	17	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	massive	massive	B-NP	JJ	O	5	NMOD
5	rhabdomyolysis	rhabdomyolysis	I-NP	NN	O	3	PMOD
6	following	follow	B-PP	VBG	O	2	NMOD
7	molindone	molindone	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	schizophrenic	schizophrenic	I-NP	JJ	O	6	NMOD
6	patient	patient	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	reported	report	I-VP	VBN	O	7	VC
9	to	to	I-VP	TO	O	10	VMOD
10	illustrate	illustrate	I-VP	VB	O	8	VMOD
11	massive	massive	B-NP	JJ	O	12	NMOD
12	rhabdomyolysis	rhabdomyolysis	I-NP	NN	O	17	NMOD
13	and	and	O	CC	O	17	NMOD
14	subsequent	subsequent	B-NP	JJ	O	17	NMOD
15	acute	acute	I-NP	JJ	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	failure	failure	I-NP	NN	O	10	OBJ
18	following	follow	B-PP	VBG	O	17	NMOD
19	molindone	molindone	B-NP	NN	O	20	NMOD
20	administration	administration	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	7	P

1	Cardiovascular	Cardiovascular	B-NP	JJ	O	2	NMOD
2	alterations	alteration	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	rat	rat	B-NP	NN	O	5	NMOD
5	fetuses	fetus	I-NP	NNS	O	3	PMOD
6	exposed	expose	B-VP	VBN	O	5	NMOD
7	to	to	B-PP	TO	O	6	VMOD
8	calcium	calcium	B-NP	NN	O	10	NMOD
9	channel	channel	I-NP	NN	O	10	NMOD
10	blockers	blocker	I-NP	NNS	O	7	PMOD
11	.	.	O	.	O	2	P

1	Preclinical	Preclinical	B-NP	JJ	O	3	NMOD
2	toxicologic	toxicologic	I-NP	JJ	O	3	NMOD
3	investigation	investigation	I-NP	NN	O	4	SUB
4	suggested	suggest	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	a	a	B-NP	DT	O	10	NMOD
7	new	new	I-NP	JJ	O	10	NMOD
8	calcium	calcium	I-NP	NN	O	10	NMOD
9	channel	channel	I-NP	NN	O	10	NMOD
10	blocker	blocker	I-NP	NN	O	15	SUB
11	,	,	O	,	O	15	P
12	Ro	Ro	B-NP	NN	O	15	SUB
13	40-5967	40-5967	I-NP	CD	O	12	NMOD
14	,	,	O	,	O	15	P
15	induced	induce	B-VP	VBD	O	5	SBAR
16	cardiovascular	cardiovascular	B-NP	JJ	O	17	NMOD
17	alterations	alteration	I-NP	NNS	O	15	OBJ
18	in	in	B-PP	IN	O	15	VMOD
19	rat	rat	B-NP	NN	O	20	NMOD
20	fetuses	fetus	I-NP	NNS	O	18	PMOD
21	exposed	expose	B-VP	VBN	O	20	NMOD
22	to	to	B-PP	TO	O	21	VMOD
23	this	this	B-NP	DT	O	24	NMOD
24	agent	agent	I-NP	NN	O	22	PMOD
25	during	during	B-PP	IN	O	21	VMOD
26	organogenesis	organogenesis	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	investigate	investigate	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	hypothesis	hypothesis	I-NP	NN	O	7	OBJ
10	that	that	B-SBAR	IN	O	9	NMOD
11	calcium	calcium	B-NP	NN	B-protein	13	NMOD
12	channel	channel	I-NP	NN	I-protein	13	NMOD
13	blockers	blocker	I-NP	NNS	I-protein	16	SUB
14	in	in	B-PP	IN	O	13	NMOD
15	general	general	B-NP	JJ	O	14	PMOD
16	induce	induce	B-VP	VBP	O	10	SBAR
17	cardiovascular	cardiovascular	B-NP	JJ	O	18	NMOD
18	malformations	malformation	I-NP	NNS	O	16	OBJ
19	indicating	indicate	B-VP	VBG	O	18	NMOD
20	a	a	B-NP	DT	O	23	NMOD
21	pharmacologic	pharmacologic	I-NP	JJ	O	23	NMOD
22	class	class	I-NP	NN	O	23	NMOD
23	effect	effect	I-NP	NN	O	19	OBJ
24	.	.	O	.	O	4	P

1	Pregnant	Pregnant	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	administered	administer	I-VP	VBN	O	3	VC
5	one	one	B-NP	CD	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	these	these	B-NP	DT	O	10	NMOD
8	calcium	calcium	I-NP	NN	O	10	NMOD
9	channel	channel	I-NP	NN	O	10	NMOD
10	blockers	blocker	I-NP	NNS	O	6	PMOD
11	during	during	B-PP	IN	O	4	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	period	period	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	cardiac	cardiac	B-NP	JJ	O	16	NMOD
16	morphogenesis	morphogenesis	I-NP	NN	O	14	PMOD
17	and	and	O	CC	O	3	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	offspring	offspring	I-NP	NN	O	17	OBJ
20	examined	examine	B-VP	VBN	O	19	NMOD
21	on	on	B-PP	IN	O	20	VMOD
22	day	day	B-NP	NN	O	21	PMOD
23	20	20	I-NP	CD	O	22	NMOD
24	of	of	B-PP	IN	O	22	NMOD
25	gestation	gestation	B-NP	NN	O	24	PMOD
26	for	for	B-PP	IN	O	22	NMOD
27	cardiovascular	cardiovascular	B-NP	JJ	O	28	NMOD
28	malformations	malformation	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	low	low	I-NP	JJ	O	3	NMOD
3	incidence	incidence	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	cardiovascular	cardiovascular	B-NP	JJ	O	6	NMOD
6	malformations	malformation	I-NP	NNS	O	4	PMOD
7	was	be	B-VP	VBD	O	23	VMOD
8	observed	observe	I-VP	VBN	O	7	VC
9	after	after	B-PP	IN	O	8	VMOD
10	exposure	exposure	B-NP	NN	O	9	PMOD
11	to	to	B-PP	TO	O	10	NMOD
12	each	each	B-NP	DT	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	18	NMOD
15	four	four	I-NP	CD	O	18	NMOD
16	calcium	calcium	I-NP	NN	O	18	NMOD
17	channel	channel	I-NP	NN	O	18	NMOD
18	blockers	blocker	I-NP	NNS	O	13	PMOD
19	,	,	O	,	O	23	P
20	but	but	O	CC	O	23	VMOD
21	this	this	B-NP	DT	O	22	NMOD
22	incidence	incidence	I-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	0	ROOT
24	statistically	statistically	B-ADJP	RB	O	23	VMOD
25	significant	significant	I-ADJP	JJ	O	23	PRD
26	only	only	B-ADVP	RB	O	27	PMOD
27	for	for	B-PP	IN	O	25	AMOD
28	verapamil	verapamil	B-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	nifedipine	nifedipine	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	sevoflurane	sevoflurane	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	lidocaine	lidocaine	B-NP	NN	O	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	convulsions	convulsion	I-NP	NNS	O	5	PMOD
9	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	influence	influence	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	sevoflurane	sevoflurane	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	lidocaine	lidocaine	B-NP	NN	O	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	convulsions	convulsion	I-NP	NNS	O	5	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	studied	study	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	cats	cat	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	convulsive	convulsive	I-NP	JJ	O	3	NMOD
3	threshold	threshold	I-NP	NN	O	9	SUB
4	(	(	O	(	O	8	DEP
5	mean	mean	B-NP	NN	O	7	NMOD
6	+/-	+/-	O	SYM	O	7	NMOD
7	SD	SD	B-NP	NN	O	8	DEP
8	)	)	O	)	O	3	NMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	41.4	41.4	B-NP	CD	O	12	AMOD
11	+/-	+/-	I-NP	SYM	O	12	AMOD
12	6.5	6.5	I-NP	CD	O	14	NMOD
13	mg.	mg.	I-NP	NN	O	14	NMOD
14	l	l	I-NP	NN	O	9	PRD
15	(	(	O	(	O	17	DEP
16	-1	-1	B-NP	CD	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	with	with	B-PP	IN	O	14	NMOD
19	lidocaine	lidocaine	B-NP	NN	O	20	NMOD
20	infusion	infusion	I-NP	NN	O	27	NMOD
21	(	(	O	(	O	27	NMOD
22	6	6	B-NP	CD	O	23	NMOD
23	mg.kg	mg.kg	I-NP	NN	O	27	NMOD
24	(	(	O	(	O	26	DEP
25	-1	-1	B-NP	CD	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	.min	.min	B-NP	NN	O	18	PMOD
28	(	(	O	(	O	30	DEP
29	-1	-1	B-NP	CD	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	)	)	O	)	O	14	NMOD
32	,	,	O	,	O	14	P
33	increasing	increase	B-VP	VBG	O	14	NMOD
34	significantly	significantly	B-ADVP	RB	O	33	VMOD
35	to	to	B-PP	TO	O	33	VMOD
36	66.6	66.6	B-NP	CD	O	38	AMOD
37	+/-	+/-	I-NP	SYM	O	38	AMOD
38	10.9	10.9	I-NP	CD	O	35	PMOD
39	mg.	mg.	I-NP	NN	O	40	NMOD
40	l	l	I-NP	NN	O	38	NMOD
41	(	(	O	(	O	43	DEP
42	-1	-1	B-NP	CD	O	43	DEP
43	)	)	O	)	O	40	NMOD
44	when	when	B-ADVP	WRB	O	33	VMOD
45	the	the	B-NP	DT	O	47	NMOD
46	end-tidal	end-tidal	I-NP	JJ	O	47	NMOD
47	concentration	concentration	I-NP	NN	O	50	SUB
48	of	of	B-PP	IN	O	47	NMOD
49	sevoflurane	sevoflurane	B-NP	NN	O	48	PMOD
50	was	be	B-VP	VBD	O	44	SBAR
51	0.8	0.8	B-NP	CD	O	52	NMOD
52	%	%	I-NP	NN	O	50	PRD
53	.	.	O	.	O	9	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	5	NMOD
4	significant	significant	I-NP	JJ	O	5	NMOD
5	difference	difference	I-NP	NN	O	2	PRD
6	in	in	B-PP	IN	O	2	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	convulsive	convulsive	I-NP	JJ	O	9	NMOD
9	threshold	threshold	I-NP	NN	O	6	PMOD
10	between	between	B-PP	IN	O	9	NMOD
11	sevoflurane	sevoflurane	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	enflurane	enflurane	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	rise	rise	I-NP	NN	O	6	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	blood	blood	B-NP	NN	O	5	NMOD
5	pressure	pressure	I-NP	NN	O	3	PMOD
6	became	become	B-VP	VBD	O	24	VMOD
7	less	less	B-ADJP	RBR	O	8	AMOD
8	marked	marked	I-ADJP	JJ	O	6	PRD
9	when	when	B-ADVP	WRB	O	6	VMOD
10	higher	high	B-NP	JJR	O	11	NMOD
11	concentrations	concentration	I-NP	NNS	O	16	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	sevoflurane	sevoflurane	B-NP	NN	O	15	NMOD
14	or	or	I-NP	CC	O	15	NMOD
15	enflurane	enflurane	I-NP	NN	O	12	PMOD
16	were	be	B-VP	VBD	O	9	SBAR
17	administered	administer	I-VP	VBN	O	16	VC
18	and	and	O	CC	O	24	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	blood	blood	I-NP	NN	O	21	NMOD
21	pressure	pressure	I-NP	NN	O	24	SUB
22	at	at	B-PP	IN	O	21	NMOD
23	convulsions	convulsion	B-NP	NNS	O	22	PMOD
24	decreased	decrease	B-VP	VBD	O	0	ROOT
25	significantly	significantly	B-ADVP	RB	O	24	VMOD
26	in	in	B-PP	IN	O	24	VMOD
27	1.6	1.6	B-NP	CD	O	29	NMOD
28	%	%	I-NP	NN	O	29	NMOD
29	sevoflurane	sevoflurane	I-NP	NN	O	26	PMOD
30	,	,	O	,	O	24	P
31	and	and	O	CC	O	24	VMOD
32	in	in	B-PP	IN	O	24	VMOD
33	0.8	0.8	B-NP	CD	O	34	NMOD
34	%	%	I-NP	NN	O	32	PMOD
35	and	and	O	CC	O	38	NMOD
36	1.6	1.6	B-NP	CD	O	38	NMOD
37	%	%	I-NP	NN	O	38	NMOD
38	enflurane	enflurane	I-NP	NN	O	24	VMOD
39	.	.	O	.	O	24	P

1	Apamin	Apamin	B-NP	NN	O	6	SUB
2	(	(	O	(	O	5	DEP
3	10	10	B-NP	CD	O	4	NMOD
4	ng	ng	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	had	have	B-VP	VBD	O	30	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	tendency	tendency	I-NP	NN	O	6	OBJ
9	to	to	B-VP	TO	O	10	VMOD
10	decrease	decrease	I-VP	VB	O	8	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	convulsive	convulsive	I-NP	JJ	O	13	NMOD
13	threshold	threshold	I-NP	NN	O	10	OBJ
14	(	(	O	(	O	27	DEP
15	21.6	21.6	B-NP	CD	O	17	AMOD
16	+/-	+/-	I-NP	SYM	O	17	AMOD
17	2.2	2.2	I-NP	CD	O	23	NMOD
18	to	to	I-NP	TO	O	23	NMOD
19	19.9	19.9	I-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	2.5	2.5	I-NP	CD	O	23	NMOD
22	mg.	mg.	I-NP	NN	O	23	NMOD
23	l	l	I-NP	NN	O	27	DEP
24	(	(	O	(	O	26	DEP
25	-1	-1	B-NP	CD	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	)	)	O	)	O	8	NMOD
28	but	but	O	CC	O	30	VMOD
29	this	this	B-NP	DT	O	30	SUB
30	was	be	B-VP	VBD	O	0	ROOT
31	not	not	O	RB	O	30	VMOD
32	statistically	statistically	B-ADJP	RB	O	30	VMOD
33	significant	significant	I-ADJP	JJ	O	30	PRD
34	.	.	O	.	O	30	P

1	Anti-oxidant	Anti-oxidant	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	atorvastatin	atorvastatin	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	dexamethasone	dexamethasone	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	hypertension	hypertension	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	rat.	rat.	I-NP	NN	B-protein	9	PMOD
12	1	1	I-NP	CD	I-protein	11	NMOD
13	.	.	O	.	O	7	P

1	Dexamethasone	Dexamethasone	B-NP	NN	O	6	NMOD
2	(	(	O	(	O	4	DEP
3	Dex	Dex	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	induced	induce	B-NP	VBN	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	0	ROOT
8	characterized	characterize	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	endothelial	endothelial	B-NP	JJ	O	11	NMOD
11	dysfunction	dysfunction	I-NP	NN	O	9	PMOD
12	associated	associate	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	nitric	nitric	B-NP	JJ	O	15	NMOD
15	oxide	oxide	I-NP	NN	O	19	NMOD
16	(	(	O	(	O	18	DEP
17	NO	NO	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	deficiency	deficiency	B-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	increased	increase	B-NP	VBN	O	22	NMOD
22	superoxide	superoxide	I-NP	NN	O	26	NMOD
23	(	(	O	(	O	25	DEP
24	O2-	O2-	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	production	production	B-NP	NN	O	13	PMOD
27	.	.	O	.	O	7	P

1	Atorvastatin	Atorvastatin	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	Ato	Ato	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	possesses	possess	B-VP	VBZ	O	0	ROOT
6	pleiotropic	pleiotropic	B-NP	JJ	O	7	NMOD
7	properties	property	I-NP	NNS	O	5	OBJ
8	that	that	B-NP	WDT	O	7	NMOD
9	have	have	B-VP	VBP	O	8	SBAR
10	been	be	I-VP	VBN	O	9	VC
11	reported	report	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	improve	improve	I-VP	VB	O	11	VMOD
14	endothelial	endothelial	B-NP	JJ	O	15	NMOD
15	function	function	I-NP	NN	O	13	OBJ
16	through	through	B-PP	IN	O	13	VMOD
17	increased	increase	B-NP	VBN	O	18	NMOD
18	availability	availability	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	NO	NO	B-NP	NN	O	19	PMOD
21	and	and	O	CC	O	5	VMOD
22	reduced	reduce	B-VP	VBD	O	5	VMOD
23	O2-	O2-	B-NP	NN	O	24	NMOD
24	production	production	I-NP	NN	O	22	OBJ
25	in	in	B-PP	IN	O	24	NMOD
26	various	various	B-NP	JJ	O	27	NMOD
27	forms	form	I-NP	NNS	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	hypertension	hypertension	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	5	P

1	99mTc-glucarate	99mTc-glucarate	B-ADJP	JJ	O	6	SUB
2	for	for	B-PP	IN	O	1	AMOD
3	detection	detection	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	isoproterenol	isoproterenol	B-NP	NN	O	4	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	infarction	infarction	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	3	NMOD
2	animal	animal	I-NP	NN	O	3	NMOD
3	model	model	I-NP	NN	O	8	SUB
4	used	use	B-VP	VBN	O	3	NMOD
5	to	to	B-VP	TO	O	6	VMOD
6	produce	produce	I-VP	VB	O	4	VMOD
7	infarction	infarction	B-NP	NN	O	6	OBJ
8	implies	imply	B-VP	VBZ	O	0	ROOT
9	artery	artery	B-NP	NN	O	10	NMOD
10	ligation	ligation	I-NP	NN	O	14	SUB
11	but	but	O	CC	O	14	VMOD
12	chemical	chemical	B-NP	JJ	O	13	NMOD
13	induction	induction	I-NP	NN	O	14	SUB
14	can	can	B-VP	MD	O	8	VMOD
15	be	be	I-VP	VB	O	14	VC
16	easily	easily	I-VP	RB	O	15	VMOD
17	obtained	obtain	I-VP	VBN	O	15	VC
18	with	with	B-PP	IN	O	17	VMOD
19	isoproterenol	isoproterenol	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	4	NMOD
2	new	new	I-NP	JJ	O	4	NMOD
3	infarct-avid	infarct-avid	I-NP	JJ	O	4	NMOD
4	radiopharmaceutical	radiopharmaceutical	I-NP	NN	O	9	SUB
5	based	base	B-PP	VBN	O	4	NMOD
6	on	on	B-PP	IN	O	5	PMOD
7	glucaric	glucaric	B-NP	JJ	O	8	NMOD
8	acid	acid	I-NP	NN	O	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	prepared	prepare	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	hospital	hospital	I-NP	NN	O	14	NMOD
14	radiopharmacy	radiopharmacy	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	INCMNSZ.	INCMNSZ.	I-NP	NNP	O	18	NMOD
18	99mTc-glucarate	99mTc-glucarate	I-NP	NNP	O	15	PMOD
19	was	be	B-VP	VBD	O	9	VMOD
20	easy	easy	B-ADJP	JJ	O	19	PRD
21	to	to	B-VP	TO	O	22	VMOD
22	prepare	prepare	I-VP	VB	O	20	AMOD
23	,	,	O	,	O	22	P
24	stable	stable	B-ADJP	JJ	O	22	VMOD
25	for	for	B-PP	IN	O	24	AMOD
26	96	96	B-NP	CD	O	27	NMOD
27	h	h	I-NP	NN	O	25	PMOD
28	and	and	O	CC	O	9	VMOD
29	was	be	B-VP	VBD	O	9	VMOD
30	used	use	I-VP	VBN	O	29	VC
31	to	to	B-VP	TO	O	32	VMOD
32	study	study	I-VP	VB	O	29	VMOD
33	its	its	B-NP	PRP$	O	34	NMOD
34	biodistribution	biodistribution	I-NP	NN	O	39	SUB
35	in	in	B-PP	IN	O	34	NMOD
36	rats	rat	B-NP	NNS	O	35	PMOD
37	with	with	B-PP	IN	O	36	NMOD
38	isoproterenol	isoproterenol	B-NP	NN	O	37	PMOD
39	induced	induce	B-VP	VBD	O	32	VMOD
40	acute	acute	B-NP	JJ	O	42	NMOD
41	myocardial	myocardial	I-NP	JJ	O	42	NMOD
42	infarction	infarction	I-NP	NN	O	39	OBJ
43	.	.	O	.	O	9	P

1	Histological	Histological	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	rats	rat	I-NP	NNS	O	7	SUB
7	developed	develop	B-VP	VBD	O	4	SBAR
8	an	an	B-NP	DT	O	11	NMOD
9	infarct	infarct	I-NP	NN	O	11	NMOD
10	18	18	I-NP	CD	O	11	NMOD
11	h	h	I-NP	NN	O	12	PMOD
12	after	after	B-PP	IN	O	7	VMOD
13	isoproterenol	isoproterenol	B-NP	NN	O	14	NMOD
14	administration	administration	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	6	NMOD
2	randomized	randomize	I-NP	VBN	O	4	AMOD
3	,	,	I-NP	,	O	4	P
4	placebo-controlled	placebo-controlled	I-NP	JJ	O	6	NMOD
5	dose-comparison	dose-comparison	I-NP	NN	O	6	NMOD
6	trial	trial	I-NP	NN	O	0	ROOT
7	of	of	B-PP	IN	O	6	NMOD
8	haloperidol	haloperidol	B-NP	NN	O	7	PMOD
9	for	for	B-PP	IN	O	6	NMOD
10	psychosis	psychosis	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	disruptive	disruptive	B-NP	JJ	O	13	NMOD
13	behaviors	behavior	I-NP	NNS	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	Alzheimer	Alzheimer	B-NP	NNP	O	17	NMOD
16	's	's	B-NP	POS	O	17	NMOD
17	disease	disease	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	6	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	goal	goal	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	compare	compare	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	15	NMOD
12	efficacy	efficacy	I-NP	NN	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	side	side	I-NP	NN	O	15	NMOD
15	effects	effect	I-NP	NNS	O	10	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	two	two	B-NP	CD	O	18	NMOD
18	doses	dose	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	haloperidol	haloperidol	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	placebo	placebo	I-NP	NN	O	19	PMOD
23	in	in	B-PP	IN	O	10	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	treatment	treatment	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	psychosis	psychosis	B-NP	NN	O	30	NMOD
28	and	and	O	CC	O	30	NMOD
29	disruptive	disruptive	B-NP	JJ	O	30	NMOD
30	behaviors	behavior	I-NP	NNS	O	26	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	patients	patient	B-NP	NNS	O	31	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	Alzheimer	Alzheimer	B-NP	NNP	O	36	NMOD
35	's	's	B-NP	POS	O	36	NMOD
36	disease	disease	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	8	P

1	METHOD	METHOD	B-NP	NN	O	36	VMOD
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	36	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	6-week	6-week	I-NP	JJ	O	6	NMOD
6	random-assignment	random-assignment	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	36	P
8	double-blind	double-blind	B-NP	JJ	O	10	AMOD
9	,	,	I-NP	,	O	10	P
10	placebo-controlled	placebo-controlled	I-NP	JJ	O	11	NMOD
11	trial	trial	I-NP	NN	O	36	SUB
12	(	(	O	(	O	15	DEP
13	phase	phase	B-NP	NN	B-protein	14	NMOD
14	A	A	I-NP	NN	I-protein	15	DEP
15	)	)	O	)	O	11	NMOD
16	,	,	O	,	O	36	P
17	haloperidol	haloperidol	B-NP	NN	O	36	SUB
18	,	,	O	,	O	36	P
19	2-3	2-3	B-NP	NN	O	20	NMOD
20	mg/day	mg/day	I-NP	NN	O	36	SUB
21	(	(	O	(	O	24	DEP
22	standard	standard	B-NP	JJ	O	23	NMOD
23	dose	dose	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	,	,	O	,	O	36	P
26	and	and	O	CC	O	36	VMOD
27	haloperidol	haloperidol	B-NP	NN	O	36	SUB
28	,	,	O	,	O	36	P
29	0.50-0.75	0.50-0.75	B-NP	CD	O	30	NMOD
30	mg/day	mg/day	I-NP	NN	O	36	SUB
31	(	(	O	(	O	34	DEP
32	low	low	B-NP	JJ	O	33	NMOD
33	dose	dose	I-NP	NN	O	34	DEP
34	)	)	O	)	O	30	NMOD
35	,	,	O	,	O	30	P
36	were	be	B-VP	VBD	O	0	ROOT
37	compared	compare	I-VP	VBN	O	36	VC
38	in	in	B-PP	IN	O	37	VMOD
39	71	71	B-NP	CD	O	40	NMOD
40	outpatients	outpatient	I-NP	NNS	O	38	PMOD
41	with	with	B-PP	IN	O	40	NMOD
42	Alzheimer	Alzheimer	B-NP	NNP	O	44	NMOD
43	's	's	B-NP	POS	O	44	NMOD
44	disease	disease	I-NP	NN	O	41	PMOD
45	.	.	O	.	O	36	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	For	For	B-PP	IN	O	14	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	60	60	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	completed	complete	B-VP	VBD	O	7	SBAR
9	phase	phase	B-NP	NN	O	10	NMOD
10	A	A	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	14	P
12	standard-dose	standard-dose	B-NP	JJ	O	13	NMOD
13	haloperidol	haloperidol	I-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	1	NMOD
15	efficacious	efficacious	B-ADJP	JJ	O	17	AMOD
16	and	and	I-ADJP	CC	O	17	AMOD
17	superior	superior	I-ADJP	JJ	O	14	PRD
18	to	to	B-PP	TO	O	17	AMOD
19	both	both	O	CC	O	23	NMOD
20	low-dose	low-dose	B-NP	JJ	O	21	NMOD
21	haloperidol	haloperidol	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	placebo	placebo	I-NP	NN	O	18	PMOD
24	for	for	B-PP	IN	O	17	AMOD
25	scores	score	B-NP	NNS	O	24	PMOD
26	on	on	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	33	NMOD
28	Brief	Brief	I-NP	NNP	O	33	NMOD
29	Psychiatric	Psychiatric	I-NP	NNP	O	33	NMOD
30	Rating	Rating	I-NP	NNP	O	33	NMOD
31	Scale	Scale	I-NP	NNP	O	33	NMOD
32	psychosis	psychosis	I-NP	NN	B-protein	33	NMOD
33	factor	factor	I-NP	NN	I-protein	26	PMOD
34	and	and	B-PP	CC	O	24	PMOD
35	on	on	B-PP	IN	O	24	PMOD
36	psychomotor	psychomotor	B-NP	NN	O	37	NMOD
37	agitation	agitation	I-NP	NN	O	35	PMOD
38	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	indicated	indicate	B-VP	VBD	O	1	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	favorable	favorable	I-NP	JJ	O	9	NMOD
8	therapeutic	therapeutic	I-NP	JJ	O	9	NMOD
9	profile	profile	I-NP	NN	O	5	OBJ
10	for	for	B-PP	IN	O	9	NMOD
11	haloperidol	haloperidol	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	9	NMOD
13	doses	dose	B-NP	NNS	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	2-3	2-3	B-NP	NN	O	16	NMOD
16	mg/day	mg/day	I-NP	NN	O	14	PMOD
17	,	,	O	,	O	5	P
18	although	although	B-SBAR	IN	O	5	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	subgroup	subgroup	I-NP	NN	O	21	SUB
21	developed	develop	B-VP	VBD	O	18	SBAR
22	moderate	moderate	B-ADJP	JJ	O	21	PRD
23	to	to	B-PP	TO	O	22	AMOD
24	severe	severe	B-NP	JJ	O	26	NMOD
25	extrapyramidal	extrapyramidal	I-NP	JJ	O	26	NMOD
26	signs	sign	I-NP	NNS	O	23	PMOD
27	.	.	O	.	O	1	P

1	Individual	Individual	B-NP	JJ	O	2	NMOD
2	differences	difference	I-NP	NNS	O	10	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	renal	renal	B-NP	JJ	O	6	NMOD
5	ACE	ACE	I-NP	NN	O	6	NMOD
6	activity	activity	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	healthy	healthy	B-NP	JJ	O	9	NMOD
9	rats	rat	I-NP	NNS	O	7	PMOD
10	predict	predict	B-VP	VBP	O	0	ROOT
11	susceptibility	susceptibility	B-NP	NN	O	14	SUB
12	to	to	B-PP	TO	O	11	NMOD
13	adriamycin	adriamycin	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	10	VMOD
15	renal	renal	B-NP	JJ	O	16	NMOD
16	damage	damage	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	10	P

1	Therefore	Therefore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	studied	study	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	predictive	predictive	I-NP	JJ	O	7	NMOD
7	effect	effect	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	renal	renal	B-NP	JJ	O	11	NMOD
10	ACE	ACE	I-NP	NN	O	11	NMOD
11	activity	activity	I-NP	NN	O	8	PMOD
12	for	for	B-PP	IN	O	7	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	severity	severity	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	damage	damage	I-NP	NN	O	15	PMOD
18	induced	induce	B-VP	VBN	O	14	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	single	single	I-NP	JJ	O	22	NMOD
22	injection	injection	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	adriamycin	adriamycin	B-NP	NN	O	23	PMOD
25	in	in	B-PP	IN	O	22	NMOD
26	rats	rat	B-NP	NNS	O	25	PMOD
27	.	.	O	.	O	4	P

1	After	After	B-PP	IN	O	8	VMOD
2	1	1	B-NP	CD	O	3	NMOD
3	week	week	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	recovery	recovery	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	8	P
7	proteinuria	proteinuria	B-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	induced	induce	I-VP	VBN	O	8	VC
10	by	by	B-PP	IN	O	9	VMOD
11	adriamycin	adriamycin	B-NP	NN	O	10	PMOD
12	[	[	O	(	O	30	DEP
13	1.5	1.5	B-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	23	NMOD
15	intravenously	intravenously	B-ADVP	RB	O	14	NMOD
16	(	(	O	(	O	18	DEP
17	i.v.	i.v.	O	RB	O	18	DEP
18	)	)	O	)	O	15	AMOD
19	n	n	B-NP	NN	O	15	AMOD
20	=	=	B-VP	SYM	O	19	NMOD
21	18	18	B-NP	CD	O	20	AMOD
22	;	;	O	:	O	14	P
23	controls	control	B-NP	NNS	O	27	NMOD
24	,	,	O	,	O	27	P
25	saline	saline	B-NP	NN	O	27	NMOD
26	i.v.	i.v.	I-NP	JJ	O	27	NMOD
27	n	n	I-NP	NN	O	30	DEP
28	=	=	B-VP	SYM	O	27	NMOD
29	9	9	B-NP	CD	O	28	AMOD
30	]	]	O	)	O	9	VMOD
31	.	.	O	.	O	8	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	As	As	B-SBAR	IN	O	7	VMOD
4	anticipated	anticipate	B-VP	VBN	O	3	SBAR
5	,	,	O	,	O	7	P
6	adriamycin	adriamycin	B-NP	NN	O	7	SUB
7	elicited	elicit	B-VP	VBD	O	1	NMOD
8	nephrotic	nephrotic	B-NP	JJ	O	10	NMOD
9	range	range	I-NP	NN	O	10	NMOD
10	proteinuria	proteinuria	I-NP	NN	O	18	NMOD
11	,	,	O	,	O	18	P
12	renal	renal	B-NP	JJ	O	14	NMOD
13	interstitial	interstitial	I-NP	JJ	O	14	NMOD
14	damage	damage	I-NP	NN	O	18	NMOD
15	and	and	O	CC	O	18	NMOD
16	mild	mild	B-NP	JJ	O	18	NMOD
17	focal	focal	I-NP	JJ	O	18	NMOD
18	glomerulosclerosis	glomerulosclerosis	I-NP	NN	O	7	OBJ
19	.	.	O	.	O	1	P

1	Baseline	Baseline	B-NP	NN	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	ACE	ACE	I-NP	NN	O	5	SUB
4	positively	positively	B-ADVP	RB	O	5	VMOD
5	correlated	correlate	B-VP	VBD	O	0	ROOT
6	with	with	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	relative	relative	I-NP	JJ	O	9	NMOD
9	rise	rise	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	proteinuria	proteinuria	B-NP	NN	O	10	PMOD
12	after	after	B-PP	IN	O	9	NMOD
13	adriamycin	adriamycin	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	9	NMOD
15	r	r	B-NP	NN	O	17	SUB
16	=	=	B-VP	SYM	O	17	VMOD
17	0.62	0.62	B-NP	CD	O	14	PMOD
18	,	,	O	,	O	28	P
19	P	P	B-NP	NN	O	28	NMOD
20	<	<	B-NP	SYM	O	19	NMOD
21	0.01	0.01	I-NP	CD	O	20	AMOD
22	)	)	O	)	O	19	NMOD
23	,	,	O	,	O	28	P
24	renal	renal	B-NP	JJ	B-protein	28	NMOD
25	interstitial	interstitial	I-NP	JJ	I-protein	28	NMOD
26	alpha-smooth	alpha-smooth	I-NP	JJ	I-protein	28	NMOD
27	muscle	muscle	I-NP	NN	I-protein	28	NMOD
28	actin	actin	I-NP	NN	I-protein	17	NMOD
29	(	(	O	(	O	28	NMOD
30	r	r	B-NP	NN	O	32	SUB
31	=	=	B-VP	SYM	O	32	VMOD
32	0.49	0.49	B-NP	CD	O	41	NMOD
33	,	,	O	,	O	41	P
34	P	P	B-NP	NN	O	41	NMOD
35	<	<	B-NP	SYM	O	34	NMOD
36	0.05	0.05	I-NP	CD	O	35	AMOD
37	)	)	O	)	O	34	NMOD
38	,	,	O	,	O	41	P
39	interstitial	interstitial	B-NP	JJ	O	41	NMOD
40	macrophage	macrophage	I-NP	NN	O	41	NMOD
41	influx	influx	I-NP	NN	O	29	PMOD
42	(	(	O	(	O	41	NMOD
43	r	r	B-NP	NN	O	45	SUB
44	=	=	B-VP	SYM	O	45	VMOD
45	0.56	0.56	B-NP	CD	O	53	NMOD
46	,	,	O	,	O	53	P
47	P	P	B-NP	NN	O	53	NMOD
48	<	<	B-NP	SYM	O	47	NMOD
49	0.05	0.05	I-NP	CD	O	48	AMOD
50	)	)	O	)	O	47	NMOD
51	,	,	O	,	O	53	P
52	interstitial	interstitial	B-NP	JJ	O	53	NMOD
53	collagen	collagen	I-NP	NN	O	42	PMOD
54	III	III	I-NP	CD	O	53	NMOD
55	(	(	O	(	O	89	DEP
56	r	r	B-NP	NN	O	58	SUB
57	=	=	B-VP	SYM	O	58	VMOD
58	0.53	0.53	B-NP	CD	O	68	NMOD
59	,	,	O	,	O	68	P
60	P	P	B-NP	NN	O	68	NMOD
61	<	<	B-NP	SYM	O	60	NMOD
62	0.05	0.05	I-NP	CD	O	61	AMOD
63	)	)	O	)	O	60	NMOD
64	,	,	O	,	O	68	P
65	glomerular	glomerular	B-NP	JJ	B-protein	68	NMOD
66	alpha-smooth	alpha-smooth	I-NP	JJ	I-protein	68	NMOD
67	muscle	muscle	I-NP	NN	I-protein	68	NMOD
68	actin	actin	I-NP	NN	I-protein	89	DEP
69	(	(	O	(	O	89	DEP
70	r	r	B-NP	NN	O	72	SUB
71	=	=	B-VP	SYM	O	72	VMOD
72	0.74	0.74	B-NP	CD	O	80	NMOD
73	,	,	O	,	O	80	P
74	P	P	B-NP	NN	O	80	NMOD
75	<	<	B-NP	SYM	O	74	NMOD
76	0.01	0.01	I-NP	CD	O	75	AMOD
77	)	)	O	)	O	74	NMOD
78	and	and	O	CC	O	80	NMOD
79	glomerular	glomerular	B-NP	JJ	O	80	NMOD
80	desmin	desmin	I-NP	NN	O	89	DEP
81	(	(	O	(	O	89	DEP
82	r	r	B-NP	NN	O	84	SUB
83	=	=	B-VP	SYM	O	84	VMOD
84	0.48	0.48	B-NP	CD	O	89	DEP
85	,	,	O	,	O	89	P
86	P	P	B-NP	NN	O	89	DEP
87	<	<	B-NP	SYM	O	86	NMOD
88	0.05	0.05	I-NP	CD	O	87	AMOD
89	)	)	O	)	O	53	NMOD
90	.	.	O	.	O	5	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Individual	Individual	B-NP	JJ	O	4	NMOD
4	differences	difference	I-NP	NNS	O	9	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	renal	renal	B-NP	JJ	O	8	NMOD
7	ACE	ACE	I-NP	NN	O	8	NMOD
8	activity	activity	I-NP	NN	O	5	PMOD
9	predict	predict	B-VP	VBP	O	1	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	severity	severity	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	adriamycin	adriamycin	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	9	VMOD
15	renal	renal	B-NP	JJ	O	16	NMOD
16	damage	damage	I-NP	NN	O	14	OBJ
17	in	in	B-PP	IN	O	14	VMOD
18	this	this	B-NP	DT	O	21	NMOD
19	outbred	outbred	I-NP	JJ	O	21	NMOD
20	rat	rat	I-NP	NN	O	21	NMOD
21	strain	strain	I-NP	NN	O	17	PMOD
22	.	.	O	.	O	1	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	nephrotoxicity	nephrotoxicity	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	tobramycin	tobramycin	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	gentamicin	gentamicin	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	2	P

1	Gentamicin	Gentamicin	B-NP	NN	O	2	NMOD
2	sulfate	sulfate	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	tobramycin	tobramycin	B-NP	NN	O	5	NMOD
5	sulfate	sulfate	I-NP	NN	O	6	SUB
6	continue	continue	B-VP	VBP	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	demonstrate	demonstrate	I-VP	VB	O	6	VMOD
9	ototoxicity	ototoxicity	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	nephrotoxicity	nephrotoxicity	I-NP	NN	O	8	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	both	both	B-NP	CC	O	17	NMOD
14	animal	animal	I-NP	JJ	O	17	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	clinical	clinical	I-NP	JJ	O	17	NMOD
17	studies	study	I-NP	NNS	O	12	PMOD
18	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	32	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	32	P
5	62	62	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	32	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	confirmed	confirm	B-NP	VBN	O	12	NMOD
9	initial	initial	I-NP	JJ	O	12	NMOD
10	normal	normal	I-NP	JJ	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	function	function	I-NP	NN	O	7	PMOD
13	and	and	O	CC	O	32	VMOD
14	treated	treat	B-VP	VBN	O	32	VMOD
15	with	with	B-PP	IN	O	14	VMOD
16	2	2	B-NP	CD	O	18	AMOD
17	to	to	I-NP	TO	O	18	AMOD
18	5	5	I-NP	CD	O	19	NMOD
19	mg/kg/day	mg/kg/day	I-NP	NN	O	15	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	gentamicin	gentamicin	B-NP	NN	O	22	NMOD
22	sulfate	sulfate	I-NP	NN	O	25	NMOD
23	or	or	O	CC	O	25	NMOD
24	tobramycin	tobramycin	B-NP	NN	O	25	NMOD
25	sulfate	sulfate	I-NP	NN	O	20	PMOD
26	for	for	B-PP	IN	O	14	VMOD
27	a	a	B-NP	DT	O	28	NMOD
28	minimum	minimum	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	seven	seven	B-NP	CD	O	31	NMOD
31	days	day	I-NP	NNS	O	29	PMOD
32	were	be	B-VP	VBD	O	0	ROOT
33	followed	follow	I-VP	VBN	O	32	VC
34	up	up	B-PRT	RP	O	33	VMOD
35	prospectively	prospectively	B-ADVP	RB	O	33	VMOD
36	for	for	B-PP	IN	O	33	VMOD
37	the	the	B-NP	DT	O	38	NMOD
38	development	development	I-NP	NN	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	aminoglycoside-related	aminoglycoside-related	B-NP	JJ	O	42	NMOD
41	renal	renal	I-NP	JJ	O	42	NMOD
42	failure	failure	I-NP	NN	O	39	PMOD
43	,	,	O	,	O	33	P
44	defined	define	B-VP	VBN	O	33	VMOD
45	as	as	B-PP	IN	O	44	VMOD
46	at	at	B-ADVP	IN	O	50	NMOD
47	least	least	I-ADVP	JJS	O	46	AMOD
48	a	a	B-NP	DT	O	50	NMOD
49	one-third	one-third	I-NP	JJ	O	50	NMOD
50	reduction	reduction	I-NP	NN	O	45	PMOD
51	in	in	B-PP	IN	O	50	NMOD
52	renal	renal	B-NP	JJ	O	53	NMOD
53	function	function	I-NP	NN	O	51	PMOD
54	.	.	O	.	O	32	P

1	Five	Five	B-NP	CD	O	2	AMOD
2	of	of	B-PP	IN	O	24	VMOD
3	33	33	B-NP	CD	O	2	AMOD
4	(	(	O	(	O	7	DEP
5	15	15	B-NP	CD	O	6	NMOD
6	%	%	I-NP	NN	O	7	DEP
7	)	)	O	)	O	2	VMOD
8	of	of	B-PP	IN	O	2	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	tobramycin-treated	tobramycin-treated	I-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	8	PMOD
12	and	and	O	CC	O	19	DEP
13	16	16	B-NP	CD	O	14	AMOD
14	of	of	B-PP	IN	O	19	DEP
15	29	29	B-NP	CD	O	14	AMOD
16	(	(	O	(	O	19	DEP
17	55.2	55.2	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	11	NMOD
20	of	of	B-PP	IN	O	11	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	gentamicin-treated	gentamicin-treated	I-NP	JJ	O	23	NMOD
23	patients	patient	I-NP	NNS	O	20	PMOD
24	had	have	B-VP	VBD	O	0	ROOT
25	renal	renal	B-NP	JJ	O	26	NMOD
26	failure	failure	I-NP	NN	O	24	OBJ
27	.	.	O	.	O	24	P

1	Neuroprotective	Neuroprotective	B-NP	JJ	O	2	NMOD
2	action	action	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	MPEP	MPEP	B-NP	NN	B-protein	9	NMOD
5	,	,	O	,	O	9	P
6	a	a	B-NP	DT	O	9	NMOD
7	selective	selective	I-NP	JJ	O	9	NMOD
8	mGluR5	mGluR5	I-NP	NN	O	9	NMOD
9	antagonist	antagonist	I-NP	NN	O	3	PMOD
10	,	,	O	,	O	2	P
11	in	in	B-PP	IN	O	2	NMOD
12	methamphetamine	methamphetamine	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	dopaminergic	dopaminergic	B-NP	JJ	O	15	NMOD
15	neurotoxicity	neurotoxicity	I-NP	NN	O	16	SUB
16	is	be	B-VP	VBZ	O	13	VMOD
17	associated	associate	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	decrease	decrease	I-NP	NN	O	25	NMOD
21	in	in	B-PP	IN	O	20	NMOD
22	dopamine	dopamine	B-NP	NN	O	23	NMOD
23	outflow	outflow	I-NP	NN	O	21	PMOD
24	and	and	I-NP	CC	O	25	NMOD
25	inhibition	inhibition	I-NP	NN	O	18	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	hyperthermia	hyperthermia	B-NP	NN	O	26	PMOD
28	in	in	B-PP	IN	O	25	NMOD
29	rats	rat	B-NP	NNS	O	28	PMOD
30	.	.	O	.	O	13	P

1	Moreover	Moreover	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	it	it	B-NP	PRP	O	5	SUB
4	transiently	transiently	B-ADVP	RB	O	5	VMOD
5	diminished	diminish	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	7	NMOD
7	methamphetamine	methamphetamine	I-NP	NN	O	13	SUB
8	(	(	O	(	O	12	DEP
9	10	10	B-NP	CD	O	11	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	11	NMOD
11	sc	sc	I-NP	NN	O	12	DEP
12	)	)	O	)	O	7	NMOD
13	induced	induce	B-VP	VBD	O	5	VMOD
14	hyperthermia	hyperthermia	B-NP	NN	O	19	NMOD
15	and	and	O	CC	O	19	NMOD
16	reduced	reduce	B-NP	VBN	O	19	NMOD
17	basal	basal	I-NP	JJ	O	19	NMOD
18	body	body	I-NP	NN	O	19	NMOD
19	temperature	temperature	I-NP	NN	O	13	OBJ
20	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	suggest	suggest	B-VP	VBP	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	blockade	blockade	I-NP	NN	O	14	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	mGluR5	mGluR5	B-NP	NN	B-protein	10	PMOD
12	by	by	B-PP	IN	O	9	NMOD
13	MPEP	MPEP	B-NP	NN	B-protein	12	PMOD
14	may	may	B-VP	MD	O	7	SBAR
15	protect	protect	I-VP	VB	O	14	VC
16	dopaminergic	dopaminergic	B-NP	JJ	O	17	NMOD
17	neurones	neurone	I-NP	NNS	O	15	OBJ
18	against	against	B-PP	IN	O	15	VMOD
19	methamphetamine	methamphetamine	B-NP	NN	O	21	NMOD
20	induced	induced	I-NP	JJ	O	21	NMOD
21	toxicity	toxicity	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	6	P

1	Fewer	Few	B-NP	JJR	O	2	NMOD
2	subjects	subject	I-NP	NNS	O	3	SUB
3	reported	report	B-VP	VBD	O	0	ROOT
4	adverse	adverse	B-NP	JJ	O	5	NMOD
5	events	event	I-NP	NNS	O	34	SUB
6	following	follow	B-PP	VBG	O	5	NMOD
7	treatment	treatment	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	desipramine	desipramine	B-NP	NN	O	8	PMOD
10	alone	alone	B-ADVP	RB	O	9	NMOD
11	than	than	B-PP	IN	O	5	NMOD
12	when	when	B-ADVP	WRB	O	11	SBAR
13	receiving	receive	B-VP	VBG	O	12	SBAR
14	desipramine	desipramine	B-NP	NN	O	13	OBJ
15	with	with	B-PP	IN	O	13	VMOD
16	cinacalcet	cinacalcet	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	22	DEP
18	33	33	B-NP	CD	O	21	NMOD
19	versus	versus	I-NP	IN	O	21	NMOD
20	86	86	I-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	22	DEP
22	)	)	O	)	O	13	VMOD
23	,	,	O	,	O	27	P
24	the	the	B-NP	DT	O	27	NMOD
25	most	most	I-NP	RBS	O	26	AMOD
26	frequent	frequent	I-NP	JJ	O	27	NMOD
27	of	of	B-PP	IN	O	5	NMOD
28	which	which	B-NP	WDT	O	27	PMOD
29	(	(	O	(	O	33	DEP
30	nausea	nausea	B-NP	NN	O	32	NMOD
31	and	and	O	CC	O	32	NMOD
32	headache	headache	B-NP	NN	O	33	DEP
33	)	)	O	)	O	5	NMOD
34	have	have	B-VP	VBP	O	3	VMOD
35	been	be	I-VP	VBN	O	34	VC
36	reported	report	I-VP	VBN	O	35	VC
37	for	for	B-PP	IN	O	36	VMOD
38	patients	patient	B-NP	NNS	O	37	PMOD
39	treated	treat	B-VP	VBN	O	38	NMOD
40	with	with	B-PP	IN	O	39	VMOD
41	either	either	O	CC	O	44	NMOD
42	desipramine	desipramine	B-NP	NN	O	44	NMOD
43	or	or	I-NP	CC	O	44	NMOD
44	cinacalcet	cinacalcet	I-NP	NN	O	40	PMOD
45	.	.	O	.	O	3	P

1	Proteomic	Proteomic	B-NP	JJ	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	striatal	striatal	B-NP	JJ	B-protein	5	NMOD
5	proteins	protein	I-NP	NNS	I-protein	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	rat	rat	I-NP	NN	O	9	NMOD
9	model	model	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	L-DOPA	L-DOPA	B-NP	NN	B-protein	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	dyskinesia	dyskinesia	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	L-DOPA	L-DOPA	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	dyskinesia	dyskinesia	B-NP	NN	O	2	OBJ
4	(	(	O	(	O	6	DEP
5	LID	LID	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	2	VMOD
8	among	among	B-PP	IN	O	7	PRD
9	the	the	B-NP	DT	O	11	NMOD
10	motor	motor	I-NP	NN	O	11	NMOD
11	complications	complication	I-NP	NNS	O	8	PMOD
12	that	that	B-NP	WDT	O	11	NMOD
13	arise	arise	B-VP	VBP	O	12	SBAR
14	in	in	B-PP	IN	O	13	VMOD
15	Parkinson	Parkinson	B-NP	NNP	O	16	NMOD
16	's	's	B-NP	POS	O	17	NMOD
17	disease	disease	I-NP	NN	O	21	NMOD
18	(	(	O	(	O	20	DEP
19	PD	PD	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	patients	patient	B-NP	NNS	O	14	PMOD
22	after	after	B-PP	IN	O	21	NMOD
23	a	a	B-NP	DT	O	25	NMOD
24	prolonged	prolong	I-NP	VBN	O	25	NMOD
25	treatment	treatment	I-NP	NN	O	22	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	L-DOPA	L-DOPA	B-NP	NN	B-protein	26	PMOD
28	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	we	we	B-NP	PRP	O	7	SUB
7	investigated	investigate	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	changes	change	I-NP	NNS	O	7	OBJ
10	occurring	occur	B-VP	VBG	O	9	NMOD
11	at	at	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	protein	protein	I-NP	NN	O	14	NMOD
14	level	level	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	10	VMOD
16	striatal	striatal	B-NP	JJ	O	17	NMOD
17	samples	sample	I-NP	NNS	O	15	PMOD
18	obtained	obtain	B-VP	VBN	O	17	NMOD
19	from	from	B-PP	IN	O	18	VMOD
20	the	the	B-NP	DT	O	24	NMOD
21	unilaterally	unilaterally	I-NP	RB	O	24	NMOD
22	6-hydroxydopamine-lesion	6-hydroxydopamine-lesion	I-NP	NN	O	24	NMOD
23	rat	rat	I-NP	NN	O	24	NMOD
24	model	model	I-NP	NN	O	19	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	PD	PD	B-NP	NN	O	25	PMOD
27	treated	treat	B-VP	VBN	O	26	NMOD
28	with	with	B-PP	IN	O	27	VMOD
29	saline	saline	B-NP	NN	O	33	NMOD
30	,	,	I-NP	,	O	33	P
31	L-DOPA	L-DOPA	I-NP	NN	B-protein	33	NMOD
32	or	or	I-NP	CC	O	33	NMOD
33	bromocriptine	bromocriptine	I-NP	NN	O	28	PMOD
34	using	use	B-VP	VBG	O	9	NMOD
35	two-dimensional	two-dimensional	B-NP	JJ	O	38	NMOD
36	difference	difference	I-NP	NN	O	38	NMOD
37	gel	gel	I-NP	NN	O	38	NMOD
38	electrophoresis	electrophoresis	I-NP	NN	O	41	NMOD
39	and	and	O	CC	O	41	NMOD
40	mass	mass	B-NP	NN	O	41	NMOD
41	spectrometry	spectrometry	I-NP	NN	O	34	OBJ
42	(	(	O	(	O	44	DEP
43	MS	MS	B-NP	NN	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	.	.	O	.	O	7	P

1	Rats	Rat	B-NP	NNS	O	5	SUB
2	treated	treat	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	L-DOPA	L-DOPA	B-NP	NN	B-protein	3	PMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	allocated	allocate	I-VP	VBN	O	5	VC
7	to	to	B-PP	TO	O	6	VMOD
8	two	two	B-NP	CD	O	9	NMOD
9	groups	group	I-NP	NNS	O	7	PMOD
10	based	base	B-PP	VBN	O	6	VMOD
11	on	on	B-PP	IN	O	6	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	presence	presence	I-NP	NN	O	15	NMOD
14	or	or	I-NP	CC	O	15	NMOD
15	absence	absence	I-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	LID	LID	B-NP	NN	B-protein	16	PMOD
18	.	.	O	.	O	5	P

1	Pseudo-allergic	Pseudo-allergic	B-NP	JJ	O	2	NMOD
2	reactions	reaction	I-NP	NNS	O	8	NMOD
3	to	to	B-PP	TO	O	2	NMOD
4	corticosteroids	corticosteroid	B-NP	NNS	O	3	PMOD
5	:	:	O	:	O	2	P
6	diagnosis	diagnosis	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	alternatives	alternative	I-NP	NNS	O	0	ROOT
9	.	.	O	.	O	8	P

1	Corticosteroids	Corticosteroid	B-NP	NNS	O	6	SUB
2	different	different	B-ADJP	JJ	O	1	NMOD
3	from	from	B-PP	IN	O	2	AMOD
4	paramethasone	paramethasone	B-NP	NN	O	3	PMOD
5	also	also	B-ADVP	RB	O	6	VMOD
6	produced	produce	B-VP	VBD	O	19	VMOD
7	hypersensitivity	hypersensitivity	B-NP	NN	O	8	NMOD
8	reactions	reaction	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	these	these	B-NP	DT	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	;	;	O	:	O	19	P
13	however	however	B-ADVP	RB	O	19	VMOD
14	,	,	O	,	O	19	P
15	a	a	B-NP	DT	O	16	NMOD
16	few	few	I-NP	JJ	O	19	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	them	them	B-NP	PRP	O	17	PMOD
19	were	be	B-VP	VBD	O	0	ROOT
20	tolerated	tolerate	I-VP	VBN	O	19	VC
21	.	.	O	.	O	19	P

1	Valproic	Valproic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	4	NMOD
3	induced	induce	I-NP	VBN	O	4	NMOD
4	encephalopathy	encephalopathy	I-NP	NN	O	8	NMOD
5	--	--	O	:	O	4	P
6	19	19	B-NP	CD	O	8	NMOD
7	new	new	I-NP	JJ	O	8	NMOD
8	cases	case	I-NP	NNS	O	0	ROOT
9	in	in	B-PP	IN	O	8	NMOD
10	Germany	Germany	B-NP	NNP	O	9	PMOD
11	from	from	B-PP	IN	O	10	NMOD
12	1994	1994	B-NP	CD	O	11	PMOD
13	to	to	B-PP	TO	O	10	NMOD
14	2003	2003	B-NP	CD	O	18	NMOD
15	--	--	O	:	O	18	P
16	a	a	B-NP	DT	O	18	NMOD
17	side	side	I-NP	JJ	O	18	NMOD
18	effect	effect	I-NP	NN	O	13	PMOD
19	associated	associate	B-VP	VBN	O	18	NMOD
20	to	to	B-PP	TO	O	19	VMOD
21	VPA-therapy	VPA-therapy	B-NP	NN	O	20	PMOD
22	not	not	B-CONJP	RB	O	19	VMOD
23	only	only	I-CONJP	RB	O	22	DEP
24	in	in	B-PP	IN	O	22	PMOD
25	young	young	B-NP	JJ	O	26	NMOD
26	children	child	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	8	P

1	Rare	Rare	B-NP	NN	O	3	NMOD
2	serious	serious	I-NP	JJ	O	3	NMOD
3	complications	complication	I-NP	NNS	O	4	SUB
4	may	may	B-VP	MD	O	0	ROOT
5	occur	occur	I-VP	VB	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	some	some	B-NP	DT	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	,	,	O	,	O	8	P
10	including	include	B-PP	VBG	O	8	NMOD
11	haemorrhagic	haemorrhagic	B-NP	JJ	O	12	NMOD
12	pancreatitis	pancreatitis	I-NP	NN	O	19	SUB
13	,	,	O	,	O	19	P
14	bone	bone	B-NP	NN	O	16	NMOD
15	marrow	marrow	I-NP	NN	O	16	NMOD
16	suppression	suppression	I-NP	NN	O	19	SUB
17	,	,	O	,	O	19	P
18	VPA	VPA	B-NP	NN	B-protein	19	SUB
19	induced	induce	B-VP	VBD	O	10	SBAR
20	hepatotoxicity	hepatotoxicity	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	VPA	VPA	I-NP	NN	B-protein	24	NMOD
23	induced	induce	B-VP	VBD	O	24	NMOD
24	encephalopathy	encephalopathy	B-NP	NN	O	19	OBJ
25	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	typical	typical	I-NP	JJ	O	3	NMOD
3	signs	sign	I-NP	NNS	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	VPA	VPA	B-NP	NN	B-protein	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	encephalopathy	encephalopathy	I-NP	NN	O	4	PMOD
8	are	be	B-VP	VBP	O	0	ROOT
9	impaired	impaired	B-NP	JJ	O	10	NMOD
10	consciousness	consciousness	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	sometimes	sometimes	B-NP	RB	O	15	NMOD
13	marked	marked	I-NP	JJ	O	15	NMOD
14	EEG	EEG	I-NP	NN	O	15	NMOD
15	background	background	I-NP	NN	O	20	NMOD
16	slowing	slow	B-VP	VBG	O	15	NMOD
17	,	,	O	,	O	20	P
18	increased	increase	B-NP	VBN	O	20	NMOD
19	seizure	seizure	I-NP	NN	O	20	NMOD
20	frequency	frequency	I-NP	NN	O	8	PRD
21	,	,	O	,	O	20	P
22	with	with	B-PP	IN	O	20	NMOD
23	or	or	B-PP	CC	O	22	PMOD
24	without	without	B-PP	IN	O	22	PMOD
25	hyperammonemia	hyperammonemia	B-NP	NN	O	22	PMOD
26	.	.	O	.	O	8	P

1	There	There	B-NP	EX	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	still	still	B-ADVP	RB	O	2	VMOD
4	no	no	B-NP	DT	O	5	NMOD
5	proof	proof	I-NP	NN	O	2	VMOD
6	of	of	B-PP	IN	O	5	NMOD
7	causative	causative	B-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	VPA	VPA	B-NP	NN	B-protein	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	encephalopathy	encephalopathy	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	5	P
16	but	but	O	CC	O	15	PMOD
17	only	only	B-ADVP	RB	O	16	DEP
18	of	of	B-PP	IN	O	17	AMOD
19	an	an	B-NP	DT	O	20	NMOD
20	association	association	I-NP	NN	O	18	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	an	an	B-NP	DT	O	25	NMOD
23	assumed	assume	I-NP	VBN	O	25	NMOD
24	causal	causal	I-NP	JJ	O	25	NMOD
25	relation	relation	I-NP	NN	O	21	PMOD
26	.	.	O	.	O	16	P

1	Haemolytic-uraemic	Haemolytic-uraemic	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	treatment	treatment	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	metronidazole	metronidazole	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	paper	paper	I-NP	NN	O	3	SUB
3	describes	describe	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	clinical	clinical	I-NP	JJ	O	6	NMOD
6	features	feature	I-NP	NNS	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	six	six	B-NP	CD	O	9	NMOD
9	children	child	I-NP	NNS	O	7	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	developed	develop	B-VP	VBD	O	10	SBAR
12	the	the	B-NP	DT	O	14	NMOD
13	haemolytic-uraemic	haemolytic-uraemic	I-NP	JJ	O	14	NMOD
14	syndrome	syndrome	I-NP	NN	O	11	OBJ
15	after	after	B-PP	IN	O	11	VMOD
16	treatment	treatment	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	metronidazole	metronidazole	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	3	P

1	Ototoxicity	Ototoxicity	B-NP	NN	O	2	SUB
2	appeared	appear	B-VP	VBD	O	0	ROOT
3	closely	closely	B-ADJP	RB	O	4	AMOD
4	related	related	I-ADJP	JJ	O	12	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	a	a	B-NP	DT	O	8	NMOD
7	prolonged	prolong	I-NP	VBN	O	8	NMOD
8	administration	administration	I-NP	NN	O	5	PMOD
9	and	and	O	CC	O	12	NMOD
10	higher	high	B-NP	JJR	O	12	NMOD
11	total	total	I-NP	JJ	O	12	NMOD
12	dose	dose	I-NP	NN	O	2	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	ototoxic	ototoxic	B-NP	JJ	O	15	NMOD
15	drugs	drug	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	2	P
17	particularly	particularly	B-ADVP	RB	O	18	PMOD
18	aminoglycosides	aminoglycosides	B-ADVP	IN	O	20	NMOD
19	and	and	O	CC	O	18	DEP
20	furosemide	furosemide	B-NP	NN	O	2	VMOD
21	.	.	O	.	O	2	P

1	Pharmacokinetic	Pharmacokinetic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	clinical	clinical	I-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	17	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	cimetidine-associated	cimetidine-associated	B-NP	JJ	O	10	NMOD
9	mental	mental	I-NP	JJ	O	10	NMOD
10	confusion.	confusion.	I-NP	NN	O	12	NMOD
11	15	15	B-NP	CD	O	12	NMOD
12	cases	case	I-NP	NNS	O	7	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	cimetidine-associated	cimetidine-associated	B-NP	JJ	O	16	NMOD
15	mental	mental	I-NP	JJ	O	16	NMOD
16	confusion	confusion	I-NP	NN	O	13	PMOD
17	have	have	B-VP	VBP	O	0	ROOT
18	been	be	I-VP	VBN	O	17	VC
19	reported	report	I-VP	VBN	O	18	VC
20	.	.	O	.	O	17	P

1	These	These	B-NP	DT	O	3	NMOD
2	6	6	I-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	both	both	B-NP	CC	O	9	NMOD
6	renal	renal	I-NP	JJ	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	liver	liver	B-NP	NN	O	9	NMOD
9	dysfunction	dysfunction	I-NP	NN	O	21	NMOD
10	(	(	O	(	O	15	DEP
11	P	P	B-NP	NN	O	13	SUB
12	less	less	B-ADJP	JJR	O	13	AMOD
13	than	than	B-PP	IN	O	15	DEP
14	0.05	0.05	B-NP	CD	O	13	AMOD
15	)	)	O	)	O	9	NMOD
16	,	,	O	,	O	21	P
17	as	as	B-CONJP	RB	O	21	NMOD
18	well	well	I-CONJP	RB	O	17	DEP
19	as	as	I-CONJP	IN	O	17	DEP
20	cimetidine	cimetidine	B-NP	NN	O	21	NMOD
21	trough-concentrations	trough-concentration	I-NP	NNS	O	4	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	more	more	B-NP	JJR	O	24	AMOD
24	than	than	I-NP	IN	O	26	NMOD
25	1.25	1.25	I-NP	CD	O	24	AMOD
26	microgram/ml	microgram/ml	I-NP	NN	O	22	PMOD
27	(	(	O	(	O	32	DEP
28	P	P	B-NP	NN	O	32	DEP
29	less	less	B-ADJP	JJR	O	28	NMOD
30	than	than	B-PP	IN	O	29	AMOD
31	0.05	0.05	B-NP	CD	O	30	PMOD
32	)	)	O	)	O	26	NMOD
33	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	rat	rat	B-NP	NN	O	4	NMOD
4	models	model	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	intrahepatic	intrahepatic	B-NP	JJ	O	7	NMOD
7	cholestasis	cholestasis	I-NP	NN	O	5	PMOD
8	by	by	B-PP	IN	O	2	VMOD
9	ethinyl	ethinyl	B-NP	NN	O	10	NMOD
10	estradiol	estradiol	I-NP	NN	O	14	NMOD
11	(	(	O	(	O	13	DEP
12	EE	EE	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	treatment	treatment	B-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	extrahepatic	extrahepatic	B-NP	JJ	O	17	NMOD
17	cholestasis	cholestasis	I-NP	NN	O	8	PMOD
18	by	by	B-PP	IN	O	2	VMOD
19	bile	bile	B-NP	NN	O	21	NMOD
20	duct	duct	I-NP	NN	O	21	NMOD
21	ligation	ligation	I-NP	NN	O	18	PMOD
22	(	(	O	(	O	24	DEP
23	BDL	BDL	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	to	to	B-VP	TO	O	27	VMOD
26	precisely	precisely	I-VP	RB	O	27	VMOD
27	determine	determine	I-VP	VB	O	2	VMOD
28	the	the	B-NP	DT	O	29	NMOD
29	site	site	I-NP	NN	O	27	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	TJ	TJ	B-NP	NN	O	32	NMOD
32	damage	damage	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	2	P

1	No	No	B-NP	DT	O	3	NMOD
2	ototoxic	ototoxic	I-NP	JJ	B-protein	3	NMOD
3	factor	factor	I-NP	NN	I-protein	9	SUB
4	,	,	O	,	O	3	P
5	other	other	B-ADJP	JJ	O	6	DEP
6	than	than	B-PP	IN	O	3	NMOD
7	DFO	DFO	B-NP	NNP	O	6	DEP
8	,	,	O	,	O	3	P
9	was	be	B-VP	VBD	O	0	ROOT
10	present	present	B-ADJP	JJ	O	9	PRD
11	in	in	B-PP	IN	O	10	AMOD
12	any	any	B-NP	DT	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	9	P

1	Subjects	Subject	B-NP	NNS	O	4	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	SNHL	SNHL	B-NP	NN	O	2	PMOD
4	were	be	B-VP	VBD	O	0	ROOT
5	submitted	submit	I-VP	VBN	O	4	VC
6	to	to	B-PP	TO	O	5	VMOD
7	DFO	DFO	B-NP	NN	O	8	NMOD
8	reduction	reduction	I-NP	NN	O	11	NMOD
9	or	or	O	CC	O	11	NMOD
10	temporary	temporary	B-NP	JJ	O	11	NMOD
11	withdrawal	withdrawal	I-NP	NN	O	6	PMOD
12	.	.	O	.	O	4	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	findings	finding	I-NP	NNS	O	5	SUB
5	are	be	B-VP	VBP	O	1	NMOD
6	indicative	indicative	B-ADJP	JJ	O	5	PRD
7	of	of	B-PP	IN	O	6	AMOD
8	DFO	DFO	B-NP	NNP	O	9	NMOD
9	's	's	B-NP	POS	O	11	NMOD
10	contributing	contribute	I-NP	VBG	O	11	NMOD
11	role	role	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	development	development	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	hearing	hear	B-VP	VBG	O	15	PMOD
17	impairment	impairment	B-NP	NN	O	16	OBJ
18	.	.	O	.	O	1	P

1	Design	Design	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	8	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	HYPREN-trial	HYPREN-trial	I-NP	JJ	O	4	PMOD
7	:	:	O	:	O	3	P
8	safety	safety	B-NP	NN	O	0	ROOT
9	of	of	B-PP	IN	O	8	NMOD
10	enalapril	enalapril	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	prazosin	prazosin	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	8	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	initial	initial	I-NP	JJ	O	17	NMOD
16	treatment	treatment	I-NP	NN	O	17	NMOD
17	phase	phase	I-NP	NN	O	13	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	congestive	congestive	B-NP	JJ	O	23	NMOD
22	heart	heart	I-NP	NN	O	23	NMOD
23	failure	failure	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	8	P

1	Since	Since	B-SBAR	IN	O	0	ROOT
2	the	the	B-NP	DT	O	3	NMOD
3	introduction	introduction	I-NP	NN	O	36	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	angiotensin	angiotensin	B-NP	NN	B-protein	7	NMOD
6	converting	convert	B-VP	VBG	I-protein	7	NMOD
7	enzyme	enzyme	B-NP	NN	I-protein	11	NMOD
8	(	(	O	(	O	10	DEP
9	ACE	ACE	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	inhibitors	inhibitor	B-NP	NNS	O	4	PMOD
12	into	into	B-PP	IN	O	3	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	adjunctive	adjunctive	I-NP	JJ	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	congestive	congestive	B-NP	JJ	O	21	NMOD
20	heart	heart	I-NP	NN	O	21	NMOD
21	failure	failure	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	36	P
23	cases	case	B-NP	NNS	O	36	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	severe	severe	B-NP	JJ	O	26	NMOD
26	hypotension	hypotension	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	23	P
28	especially	especially	B-ADVP	RB	O	29	PMOD
29	on	on	B-PP	IN	O	23	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	first	first	I-NP	JJ	O	32	NMOD
32	day	day	I-NP	NN	O	29	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	treatment	treatment	B-NP	NN	O	33	PMOD
35	,	,	O	,	O	23	P
36	have	have	B-VP	VBP	O	1	SBAR
37	occasionally	occasionally	I-VP	RB	O	36	VMOD
38	been	be	I-VP	VBN	O	36	VC
39	reported	report	I-VP	VBN	O	38	VC
40	.	.	O	.	O	1	P

1	To	To	B-VP	TO	O	2	VMOD
2	assess	assess	I-VP	VB	O	9	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	safety	safety	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	ACE	ACE	I-NP	NN	O	8	NMOD
8	inhibitor	inhibitor	I-NP	NN	O	5	PMOD
9	enalapril	enalapril	B-VP	VBP	O	0	ROOT
10	a	a	B-NP	DT	O	11	NMOD
11	multicenter	multicenter	I-NP	NN	O	16	NMOD
12	,	,	O	,	O	11	P
13	randomized	randomize	B-NP	VBN	O	15	AMOD
14	,	,	I-NP	,	O	15	P
15	prazosin-controlled	prazosin-controlled	I-NP	JJ	O	16	NMOD
16	trial	trial	I-NP	NN	O	17	SUB
17	was	be	B-VP	VBD	O	9	VMOD
18	designed	design	I-VP	VBN	O	17	VC
19	that	that	B-NP	WDT	O	17	VMOD
20	compared	compare	B-VP	VBD	O	19	SBAR
21	the	the	B-NP	DT	O	24	NMOD
22	incidence	incidence	I-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	severity	severity	I-NP	NN	O	20	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	symptomatic	symptomatic	B-NP	JJ	O	27	NMOD
27	hypotension	hypotension	I-NP	NN	O	25	PMOD
28	on	on	B-PP	IN	O	24	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	first	first	I-NP	JJ	O	31	NMOD
31	day	day	I-NP	NN	O	28	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	treatment	treatment	B-NP	NN	O	32	PMOD
34	.	.	O	.	O	9	P

1	Patients	Patient	B-NP	NNS	O	5	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	received	receive	B-VP	VBD	O	2	SBAR
4	enalapril	enalapril	B-NP	NN	O	3	OBJ
5	experienced	experience	B-VP	VBD	O	0	ROOT
6	clinically	clinically	B-ADVP	RB	O	5	VMOD
7	and	and	I-ADVP	CC	O	6	AMOD
8	statistically	statistically	B-NP	RB	O	6	AMOD
9	significantly	significantly	I-NP	RB	O	12	NMOD
10	less	less	I-NP	RBR	O	9	AMOD
11	symptomatic	symptomatic	I-NP	JJ	O	12	NMOD
12	hypotension	hypotension	I-NP	NN	O	5	OBJ
13	(	(	O	(	O	16	DEP
14	5.2	5.2	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	than	than	B-PP	IN	O	12	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	patients	patient	I-NP	NNS	O	17	PMOD
20	who	who	B-NP	WP	O	19	NMOD
21	received	receive	B-VP	VBD	O	20	SBAR
22	prazosin	prazosin	B-NP	NN	O	21	OBJ
23	(	(	O	(	O	26	DEP
24	12.9	12.9	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	26	DEP
26	)	)	O	)	O	19	NMOD
27	.	.	O	.	O	5	P

1	Antagonism	Antagonism	B-NP	NN	O	11	SUB
2	between	between	B-PP	IN	O	1	NMOD
3	interleukin	interleukin	B-NP	NN	B-protein	6	NMOD
4	3	3	I-NP	CD	I-protein	3	NMOD
5	and	and	O	CC	O	6	NMOD
6	erythropoietin	erythropoietin	B-NP	NN	B-protein	2	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	mice	mouse	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	azidothymidine	azidothymidine	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	anemia	anemia	B-NP	NN	O	11	OBJ
13	and	and	B-PP	CC	O	11	VMOD
14	in	in	B-PP	IN	O	11	VMOD
15	bone	bone	B-NP	NN	B-cell_type	18	NMOD
16	marrow	marrow	I-NP	NN	I-cell_type	18	NMOD
17	endothelial	endothelial	I-NP	JJ	I-cell_type	18	NMOD
18	cells	cell	I-NP	NNS	I-cell_type	14	PMOD
19	.	.	O	.	O	11	P

1	Azidothymidine	Azidothymidine	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	AZT	AZT	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	anemia	anemia	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	mice	mouse	B-NP	NNS	O	7	PMOD
9	can	can	B-VP	MD	O	5	VMOD
10	be	be	I-VP	VB	O	9	VC
11	reversed	reverse	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	administration	administration	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	IGF-IL-3	IGF-IL-3	B-NP	NN	B-protein	15	PMOD
17	(	(	O	(	O	16	NMOD
18	fusion	fusion	B-NP	NN	B-protein	19	NMOD
19	protein	protein	I-NP	NN	I-protein	17	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	insulin-like	insulin-like	B-NP	JJ	B-protein	23	NMOD
22	growth	growth	I-NP	NN	I-protein	23	NMOD
23	factor	factor	I-NP	NN	I-protein	20	PMOD
24	II	II	I-NP	CD	I-protein	23	NMOD
25	(	(	O	(	O	28	DEP
26	IGF	IGF	B-NP	NN	B-protein	28	DEP
27	II	II	I-NP	CD	I-protein	26	NMOD
28	)	)	O	)	O	23	NMOD
29	and	and	O	CC	O	30	NMOD
30	interleukin	interleukin	B-NP	NN	B-protein	32	DEP
31	3	3	I-NP	CD	I-protein	30	NMOD
32	)	)	O	)	O	23	NMOD
33	.	.	O	.	O	5	P

1	Dose-dependent	Dose-dependent	B-NP	JJ	O	2	NMOD
2	bradycardia	bradycardia	I-NP	NN	O	6	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	verapamil	verapamil	B-NP	NN	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	potentiated	potentiate	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	LNa	LNa	B-NP	NN	B-protein	14	NMOD
10	,	,	O	,	O	14	P
11	LCa	LCa	B-NP	NN	B-protein	14	NMOD
12	,	,	O	,	O	14	P
13	and	and	O	CC	O	14	NMOD
14	HCa	HCa	B-NP	NN	B-protein	8	PMOD
15	.	.	O	.	O	6	P

1	Sodium	Sodium	B-NP	NN	O	2	NMOD
2	status	status	I-NP	NN	O	3	SUB
3	influences	influence	B-VP	VBZ	O	0	ROOT
4	chronic	chronic	B-NP	JJ	O	7	NMOD
5	amphotericin	amphotericin	I-NP	NN	O	7	NMOD
6	B	B	I-NP	NN	O	7	NMOD
7	nephrotoxicity	nephrotoxicity	I-NP	NN	O	3	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	rats	rat	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	nephrotoxic	nephrotoxic	I-NP	JJ	O	3	NMOD
3	potential	potential	I-NP	NN	O	17	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	amphotericin	amphotericin	B-NP	NN	O	6	NMOD
6	B	B	I-NP	NN	O	4	PMOD
7	(	(	O	(	O	16	DEP
8	5	5	B-NP	CD	O	9	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	16	DEP
10	per	per	B-PP	IN	O	9	NMOD
11	day	day	B-NP	NN	O	10	PMOD
12	intraperitoneally	intraperitoneally	B-ADVP	RB	O	13	PMOD
13	for	for	B-PP	IN	O	9	NMOD
14	3	3	B-NP	CD	O	15	NMOD
15	weeks	week	I-NP	NNS	O	13	PMOD
16	)	)	O	)	O	6	NMOD
17	has	have	B-VP	VBZ	O	0	ROOT
18	been	be	I-VP	VBN	O	17	VC
19	investigated	investigate	I-VP	VBN	O	18	VC
20	in	in	B-PP	IN	O	19	VMOD
21	salt-depleted	salt-depleted	B-NP	JJ	O	27	NMOD
22	,	,	I-NP	,	O	27	P
23	normal-salt	normal-salt	I-NP	JJ	O	27	NMOD
24	,	,	O	,	O	27	P
25	and	and	O	CC	O	27	NMOD
26	salt-loaded	salt-loaded	B-NP	JJ	O	27	NMOD
27	rats	rat	I-NP	NNS	O	20	PMOD
28	.	.	O	.	O	17	P

1	Reversible	Reversible	B-NP	JJ	O	4	NMOD
2	inferior	inferior	I-NP	JJ	O	4	NMOD
3	colliculus	colliculus	I-NP	NN	O	4	NMOD
4	lesion	lesion	I-NP	NN	O	7	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	metronidazole	metronidazole	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	17	VMOD
8	encephalopathy	encephalopathy	B-NP	NN	O	7	OBJ
9	:	:	O	:	O	17	P
10	magnetic	magnetic	B-NP	JJ	O	12	NMOD
11	resonance	resonance	I-NP	NN	O	12	NMOD
12	findings	finding	I-NP	NNS	O	17	SUB
13	on	on	B-PP	IN	O	12	NMOD
14	diffusion-weighted	diffusion-weighted	B-NP	JJ	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	fluid	fluid	I-NP	NN	O	13	PMOD
17	attenuated	attenuate	B-VP	VBD	O	0	ROOT
18	inversion	inversion	B-NP	NN	O	20	NMOD
19	recovery	recovery	I-NP	NN	O	20	NMOD
20	imaging	imaging	I-NP	NN	O	17	OBJ
21	.	.	O	.	O	17	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	to	to	B-VP	TO	O	6	VMOD
6	present	present	I-VP	VB	O	4	PRD
7	reversible	reversible	B-NP	JJ	O	10	NMOD
8	inferior	inferior	I-NP	JJ	O	10	NMOD
9	colliculus	colliculus	I-NP	NN	O	10	NMOD
10	lesions	lesion	I-NP	NNS	O	6	OBJ
11	in	in	B-PP	IN	O	6	VMOD
12	metronidazole	metronidazole	B-NP	NN	O	13	SUB
13	induced	induce	B-VP	VBD	O	14	NMOD
14	encephalopathy	encephalopathy	B-NP	NN	O	11	PMOD
15	,	,	O	,	O	6	P
16	to	to	B-VP	TO	O	17	VMOD
17	focus	focus	I-VP	VB	O	6	VMOD
18	on	on	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	diffusion-weighted	diffusion-weighted	I-NP	JJ	O	21	NMOD
21	imaging	imaging	I-NP	NN	O	26	NMOD
22	(	(	O	(	O	24	DEP
23	DWI	DWI	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	and	and	O	CC	O	26	NMOD
26	fluid	fluid	B-NP	NN	O	18	PMOD
27	attenuated	attenuate	B-VP	VBD	O	26	NMOD
28	inversion	inversion	B-NP	NN	O	29	NMOD
29	recovery	recovery	I-NP	NN	O	33	NMOD
30	(	(	O	(	O	32	DEP
31	FLAIR	FLAIR	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	29	NMOD
33	imaging	imaging	B-NP	NN	O	27	OBJ
34	.	.	O	.	O	4	P

1	MATERIALS	MATERIALS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	From	From	B-PP	IN	O	3	NMOD
6	November	November	B-NP	NNP	O	5	PMOD
7	2005	2005	I-NP	CD	O	6	NMOD
8	to	to	B-PP	TO	O	6	NMOD
9	September	September	B-NP	NNP	O	21	VMOD
10	2007	2007	I-NP	CD	O	9	NMOD
11	,	,	O	,	O	21	P
12	8	8	B-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	21	SUB
14	(	(	O	(	O	20	DEP
15	5	5	B-NP	CD	O	16	NMOD
16	men	man	I-NP	NNS	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	3	3	B-NP	CD	O	19	NMOD
19	women	woman	I-NP	NNS	O	20	DEP
20	)	)	O	)	O	13	NMOD
21	were	be	B-VP	VBD	O	8	SBAR
22	diagnosed	diagnose	I-VP	VBN	O	21	VC
23	as	as	B-PP	IN	O	22	VMOD
24	having	have	B-VP	VBG	O	23	PMOD
25	metronidazole	metronidazole	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	encephalopathy	encephalopathy	I-NP	NN	O	24	OBJ
28	(	(	O	(	O	34	DEP
29	age	age	B-NP	NN	O	30	NMOD
30	range	range	I-NP	NN	O	33	SUB
31	;	;	O	:	O	33	P
32	43-78	43-78	B-NP	CD	O	33	NMOD
33	years	year	I-NP	NNS	O	34	DEP
34	)	)	O	)	O	27	NMOD
35	.	.	O	.	O	3	P

1	They	They	B-NP	PRP	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	been	be	I-VP	VBN	O	11	NMOD
4	taking	take	I-VP	VBG	O	5	NMOD
5	metronidazole	metronidazole	B-NP	NN	O	11	NMOD
6	(	(	O	(	O	11	NMOD
7	total	total	B-NP	JJ	O	8	NMOD
8	dosage	dosage	I-NP	NN	O	11	NMOD
9	,	,	O	,	O	11	P
10	45-120	45-120	B-NP	CD	O	11	NMOD
11	g	g	I-NP	NN	O	2	OBJ
12	;	;	O	:	O	2	P
13	duration	duration	B-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	30	30	B-NP	CD	O	16	NMOD
16	days	day	I-NP	NNS	O	2	OBJ
17	to	to	B-PP	TO	O	22	VMOD
18	2	2	B-NP	CD	O	19	NMOD
19	months	month	I-NP	NNS	O	17	PMOD
20	)	)	O	)	O	17	PMOD
21	to	to	B-VP	TO	O	22	VMOD
22	treat	treat	I-VP	VB	O	2	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	infection	infection	I-NP	NN	O	22	OBJ
25	in	in	B-PP	IN	O	22	VMOD
26	various	various	B-NP	JJ	O	27	NMOD
27	organs	organ	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	postoperative	postoperative	B-NP	JJ	O	6	NMOD
5	respiratory	respiratory	I-NP	JJ	O	6	NMOD
6	apnoea	apnoea	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	compared	compare	I-VP	VBN	O	7	VC
9	between	between	B-PP	IN	O	8	VMOD
10	five	five	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	receiving	receive	B-VP	VBG	O	11	NMOD
13	a	a	B-NP	DT	O	16	NMOD
14	continuous	continuous	I-NP	JJ	O	16	NMOD
15	i.v.	i.v.	I-NP	JJ	O	16	NMOD
16	infusion	infusion	I-NP	NN	O	26	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	morphine	morphine	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	23	DEP
20	mean	mean	B-NP	NN	O	22	NMOD
21	73.6	73.6	I-NP	CD	O	22	NMOD
22	mg	mg	I-NP	NN	O	23	DEP
23	)	)	O	)	O	16	NMOD
24	and	and	O	CC	O	26	NMOD
25	five	five	B-NP	CD	O	26	NMOD
26	patients	patient	I-NP	NNS	O	12	OBJ
27	receiving	receive	B-VP	VBG	O	26	NMOD
28	a	a	B-NP	DT	O	31	NMOD
29	continuous	continuous	I-NP	JJ	O	31	NMOD
30	extradural	extradural	I-NP	JJ	O	31	NMOD
31	infusion	infusion	I-NP	NN	O	27	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	0.25	0.25	B-NP	CD	O	35	NMOD
34	%	%	I-NP	NN	O	35	NMOD
35	bupivacaine	bupivacaine	I-NP	NN	O	32	PMOD
36	(	(	O	(	O	40	DEP
37	mean	mean	B-NP	NN	O	39	NMOD
38	192	192	I-NP	CD	O	39	NMOD
39	mg	mg	I-NP	NN	O	40	DEP
40	)	)	O	)	O	31	NMOD
41	in	in	B-PP	IN	O	27	VMOD
42	the	the	B-NP	DT	O	44	NMOD
43	24-h	24-h	I-NP	JJ	O	44	NMOD
44	period	period	I-NP	NN	O	41	PMOD
45	following	follow	B-PP	VBG	O	8	VMOD
46	upper	upper	B-NP	JJ	O	48	NMOD
47	abdominal	abdominal	I-NP	JJ	O	48	NMOD
48	surgery	surgery	I-NP	NN	O	45	PMOD
49	.	.	O	.	O	7	P

1	Both	Both	O	CC	O	11	NMOD
2	obstructive	obstructive	O	JJ	O	11	NMOD
3	(	(	O	(	O	8	DEP
4	P	P	B-NP	NN	O	6	SUB
5	less	less	B-ADJP	JJR	O	6	AMOD
6	than	than	B-PP	IN	O	8	DEP
7	0.05	0.05	B-NP	CD	O	6	AMOD
8	)	)	O	)	O	2	NMOD
9	and	and	O	CC	O	11	NMOD
10	central	central	B-NP	JJ	O	11	NMOD
11	apnoea	apnoea	I-NP	NN	O	18	SUB
12	(	(	O	(	O	17	DEP
13	P	P	B-NP	NN	O	15	SUB
14	less	less	B-ADJP	JJR	O	15	AMOD
15	than	than	B-PP	IN	O	17	DEP
16	0.05	0.05	B-NP	CD	O	15	AMOD
17	)	)	O	)	O	11	NMOD
18	occurred	occur	B-VP	VBD	O	0	ROOT
19	more	more	B-ADVP	RBR	O	20	AMOD
20	frequently	frequently	I-ADVP	RB	O	18	VMOD
21	in	in	B-PP	IN	O	18	VMOD
22	patients	patient	B-NP	NNS	O	21	PMOD
23	who	who	B-NP	WP	O	22	NMOD
24	had	have	B-VP	VBD	O	23	SBAR
25	a	a	B-NP	DT	O	27	NMOD
26	morphine	morphine	I-NP	NN	O	27	NMOD
27	infusion	infusion	I-NP	NN	O	24	OBJ
28	.	.	O	.	O	18	P

1	Magnetic	Magnetic	B-NP	JJ	O	3	NMOD
2	resonance	resonance	I-NP	NN	O	3	NMOD
3	volumetry	volumetry	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	cerebellum	cerebellum	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	epileptic	epileptic	B-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	after	after	B-PP	IN	O	9	NMOD
11	phenytoin	phenytoin	B-NP	NN	O	12	NMOD
12	overdosages	overdosage	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	evaluate	evaluate	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	relationship	relationship	I-NP	NN	O	8	OBJ
11	between	between	B-PP	IN	O	10	NMOD
12	phenytoin	phenytoin	B-NP	NN	O	13	NMOD
13	medication	medication	I-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	cerebellar	cerebellar	B-NP	JJ	O	16	NMOD
16	atrophy	atrophy	I-NP	NN	O	11	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	who	who	B-NP	WP	O	18	NMOD
20	had	have	B-VP	VBD	O	19	SBAR
21	experienced	experience	I-VP	VBN	O	20	VC
22	clinical	clinical	B-NP	JJ	O	23	NMOD
23	intoxication	intoxication	I-NP	NN	O	21	OBJ
24	.	.	O	.	O	6	P

1	Using	Use	B-VP	VBG	O	5	VMOD
2	linear	linear	B-NP	JJ	O	3	NMOD
3	regression	regression	I-NP	NN	O	1	OBJ
4	we	we	B-NP	PRP	O	5	SUB
5	found	find	B-VP	VBD	O	0	ROOT
6	that	that	B-SBAR	IN	O	21	NMOD
7	no	no	B-NP	DT	O	8	NMOD
8	correlation	correlation	I-NP	NN	O	9	SUB
9	exists	exist	B-VP	VBZ	O	6	SBAR
10	between	between	B-PP	IN	O	9	VMOD
11	seizure	seizure	B-NP	NN	O	12	NMOD
12	duration	duration	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	21	P
14	elevation	elevation	B-NP	NN	O	21	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	phenytoin	phenytoin	B-NP	NN	O	18	NMOD
17	serum	serum	I-NP	NN	O	18	NMOD
18	levels	level	I-NP	NNS	O	15	PMOD
19	and	and	O	CC	O	21	NMOD
20	cerebellar	cerebellar	B-NP	JJ	O	21	NMOD
21	volume	volume	I-NP	NN	O	5	OBJ
22	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	phenytoin	phenytoin	B-NP	NN	O	5	NMOD
5	overdosage	overdosage	I-NP	NN	O	6	SUB
6	does	do	B-VP	VBZ	O	3	SBAR
7	not	not	I-VP	RB	O	6	VMOD
8	necessarily	necessarily	I-VP	RB	O	6	VMOD
9	result	result	I-VP	VB	O	6	VC
10	in	in	B-PP	IN	O	9	VMOD
11	cerebellar	cerebellar	B-NP	JJ	O	12	NMOD
12	atrophy	atrophy	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	15	VMOD
14	it	it	B-NP	PRP	O	15	SUB
15	is	be	B-VP	VBZ	O	3	SBAR
16	unlikely	unlikely	B-ADJP	JJ	O	15	PRD
17	that	that	B-SBAR	IN	O	16	AMOD
18	phenytoin	phenytoin	B-NP	NN	O	19	NMOD
19	medication	medication	I-NP	NN	O	20	SUB
20	was	be	B-VP	VBD	O	17	SBAR
21	the	the	B-NP	DT	O	23	NMOD
22	only	only	I-NP	JJ	O	23	NMOD
23	cause	cause	I-NP	NN	O	20	PRD
24	of	of	B-PP	IN	O	23	NMOD
25	cerebellar	cerebellar	B-NP	JJ	O	26	NMOD
26	atrophy	atrophy	I-NP	NN	O	24	PMOD
27	in	in	B-PP	IN	O	20	VMOD
28	the	the	B-NP	DT	O	30	NMOD
29	remaining	remain	I-NP	VBG	O	30	NMOD
30	patients	patient	I-NP	NNS	O	27	PMOD
31	.	.	O	.	O	2	P

1	Evaluation	Evaluation	B-NP	NN	O	16	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	cardiac	cardiac	B-NP	JJ	O	8	NMOD
4	troponin	troponin	I-NP	NN	O	8	NMOD
5	I	I	I-NP	CD	O	4	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	T	T	I-NP	NN	O	8	NMOD
8	levels	level	I-NP	NNS	O	2	PMOD
9	as	as	B-PP	IN	O	1	NMOD
10	markers	marker	B-NP	NNS	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	myocardial	myocardial	B-NP	JJ	O	13	NMOD
13	damage	damage	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	1	NMOD
15	doxorubicin	doxorubicin	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	cardiomyopathy	cardiomyopathy	B-NP	NN	O	18	NMOD
18	rats	rat	I-NP	NNS	O	16	OBJ
19	,	,	O	,	O	16	VMOD
20	and	and	O	CC	O	22	NMOD
21	their	their	B-NP	PRP$	O	22	NMOD
22	relationship	relationship	I-NP	NN	O	19	OBJ
23	with	with	B-PP	IN	O	22	NMOD
24	echocardiographic	echocardiographic	B-NP	JJ	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	histological	histological	I-NP	JJ	O	27	NMOD
27	findings	finding	I-NP	NNS	O	23	PMOD
28	.	.	O	.	O	16	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	30	VMOD
3	the	the	B-NP	DT	O	5	NMOD
4	diagnostic	diagnostic	I-NP	JJ	O	5	NMOD
5	value	value	I-NP	NN	O	9	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	cTnI	cTnI	B-NP	NN	B-protein	6	PMOD
8	and	and	I-NP	CC	O	9	NMOD
9	cTnT	cTnT	I-NP	NN	O	2	OBJ
10	for	for	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	diagnosis	diagnosis	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	myocardial	myocardial	B-NP	JJ	O	15	NMOD
15	damage	damage	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	2	VMOD
17	a	a	B-NP	DT	O	19	NMOD
18	rat	rat	I-NP	NN	O	19	NMOD
19	model	model	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	doxorubicin	doxorubicin	B-NP	NN	O	26	NMOD
22	(	(	O	(	O	24	DEP
23	DOX	DOX	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	induced	induce	B-NP	VBN	O	26	NMOD
26	cardiomyopathy	cardiomyopathy	I-NP	NN	O	20	PMOD
27	,	,	O	,	O	30	P
28	and	and	O	CC	O	30	VMOD
29	we	we	B-NP	PRP	O	30	SUB
30	examined	examine	B-VP	VBD	O	0	ROOT
31	the	the	B-NP	DT	O	32	NMOD
32	relationship	relationship	I-NP	NN	O	30	OBJ
33	between	between	B-PP	IN	O	32	NMOD
34	serial	serial	B-NP	JJ	O	35	NMOD
35	cTnI	cTnI	I-NP	NN	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	cTnT	cTnT	I-NP	NN	O	33	PMOD
38	with	with	B-PP	IN	O	37	NMOD
39	the	the	B-NP	DT	O	40	NMOD
40	development	development	I-NP	NN	O	38	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	cardiac	cardiac	B-NP	JJ	O	43	NMOD
43	disorders	disorder	I-NP	NNS	O	41	PMOD
44	monitored	monitor	B-VP	VBN	O	43	NMOD
45	by	by	B-PP	IN	O	44	VMOD
46	echocardiography	echocardiography	B-NP	NN	O	49	NMOD
47	and	and	O	CC	O	49	NMOD
48	histological	histological	B-NP	JJ	O	49	NMOD
49	examinations	examination	I-NP	NNS	O	45	PMOD
50	in	in	B-PP	IN	O	49	NMOD
51	this	this	B-NP	DT	O	52	NMOD
52	model	model	I-NP	NN	O	50	PMOD
53	.	.	O	.	O	30	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Eighteen	Eighteen	B-NP	CD	O	1	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	DOX	DOX	I-NP	NN	O	7	NMOD
7	rats	rat	I-NP	NNS	O	4	PMOD
8	died	die	B-VP	VBD	O	1	NMOD
9	prematurely	prematurely	B-ADVP	RB	O	8	VMOD
10	of	of	B-PP	IN	O	9	AMOD
11	general	general	B-NP	JJ	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	10	PMOD
13	during	during	B-PP	IN	O	8	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	9-week	9-week	I-NP	JJ	O	16	NMOD
16	period	period	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	1	P

1	Histological	Histological	B-NP	JJ	O	2	NMOD
2	evaluation	evaluation	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	hearts	heart	B-NP	NNS	O	3	PMOD
5	from	from	B-PP	IN	O	4	NMOD
6	all	all	B-NP	DT	O	7	NMOD
7	rats	rat	I-NP	NNS	O	9	NMOD
8	given	give	B-VP	VBN	O	9	NMOD
9	DOX	DOX	B-NP	NN	O	5	PMOD
10	revealed	reveal	B-VP	VBD	O	0	ROOT
11	significant	significant	B-NP	JJ	O	12	AMOD
12	slight	slight	I-NP	JJ	O	13	NMOD
13	degrees	degree	I-NP	NNS	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	perivascular	perivascular	B-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	interstitial	interstitial	I-NP	JJ	O	18	NMOD
18	fibrosis	fibrosis	I-NP	NN	O	14	PMOD
19	.	.	O	.	O	10	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	14	SUB
2	:	:	O	:	O	1	P
3	Among	Among	B-PP	IN	O	14	VMOD
4	markers	marker	B-NP	NNS	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	ischemic	ischemic	B-NP	JJ	O	7	NMOD
7	injury	injury	I-NP	NN	O	5	PMOD
8	after	after	B-PP	IN	O	3	PMOD
9	DOX	DOX	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	,	,	O	,	O	14	P
13	cTnT	cTnT	B-NP	NN	O	14	SUB
14	showed	show	B-VP	VBD	O	0	ROOT
15	the	the	B-NP	DT	O	17	NMOD
16	greatest	great	I-NP	JJS	O	17	NMOD
17	ability	ability	I-NP	NN	O	14	OBJ
18	to	to	B-VP	TO	O	19	VMOD
19	detect	detect	I-VP	VB	O	17	NMOD
20	myocardial	myocardial	B-NP	JJ	O	21	NMOD
21	damage	damage	I-NP	NN	O	19	OBJ
22	assessed	assess	B-VP	VBN	O	21	NMOD
23	by	by	B-PP	IN	O	22	VMOD
24	echocardiographic	echocardiographic	B-NP	JJ	O	25	NMOD
25	detection	detection	I-NP	NN	O	28	NMOD
26	and	and	O	CC	O	28	NMOD
27	histological	histological	B-NP	JJ	O	28	NMOD
28	changes	change	I-NP	NNS	O	23	PMOD
29	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	reduction	reduction	I-NP	NN	O	11	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	cyclosporine-	cyclosporine-	B-NP	NN	O	8	NMOD
5	or	or	I-NP	CC	O	8	NMOD
6	tacrolimus	tacrolimus	I-NP	NN	O	8	NMOD
7	trough	trough	I-NP	NN	O	8	NMOD
8	levels	level	I-NP	NNS	O	3	PMOD
9	and	and	O	CC	O	11	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	administration	administration	I-NP	NN	O	16	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	calcium	calcium	B-NP	NN	O	15	NMOD
14	channel	channel	I-NP	NN	O	15	NMOD
15	blockers	blocker	I-NP	NNS	O	12	PMOD
16	led	lead	B-VP	VBD	O	0	ROOT
17	to	to	B-PP	TO	O	16	VMOD
18	relief	relief	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	pain	pain	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	2	NMOD
2	Calcineurin-inhibitor	Calcineurin-inhibitor	I-NP	NN	B-protein	3	SUB
3	Induced	Induce	B-VP	VBD	O	9	VMOD
4	Pain	Pain	B-NP	NN	O	5	NMOD
5	Syndrome	Syndrome	I-NP	NN	O	9	SUB
6	(	(	O	(	O	8	DEP
7	CIPS	CIPS	B-NP	NN	B-protein	8	DEP
8	)	)	O	)	O	5	NMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	a	a	B-NP	DT	O	15	NMOD
11	rare	rare	I-NP	JJ	O	13	AMOD
12	but	but	I-NP	CC	O	13	AMOD
13	severe	severe	I-NP	JJ	O	15	NMOD
14	side	side	I-NP	NN	O	15	NMOD
15	effect	effect	I-NP	NN	O	9	PRD
16	of	of	B-PP	IN	O	15	NMOD
17	cyclosporine	cyclosporine	B-NP	NN	O	19	NMOD
18	or	or	I-NP	CC	O	19	NMOD
19	tacrolimus	tacrolimus	I-NP	NN	O	16	PMOD
20	and	and	O	CC	O	9	VMOD
21	is	be	B-VP	VBZ	O	9	VMOD
22	accurately	accurately	I-VP	RB	O	21	VMOD
23	diagnosed	diagnose	I-VP	VBN	O	21	VC
24	by	by	B-PP	IN	O	23	VMOD
25	its	its	B-NP	PRP$	O	27	NMOD
26	typical	typical	I-NP	JJ	O	27	NMOD
27	presentation	presentation	I-NP	NN	O	34	NMOD
28	,	,	O	,	O	34	P
29	magnetic	magnetic	B-NP	JJ	O	31	NMOD
30	resonance	resonance	I-NP	NN	O	31	NMOD
31	imaging	imaging	I-NP	NN	O	34	NMOD
32	and	and	I-NP	CC	O	34	NMOD
33	bone	bone	I-NP	NN	O	34	NMOD
34	scans	scan	I-NP	NNS	O	24	PMOD
35	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	safety	safety	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	efficacy	efficacy	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	adding	add	B-VP	VBG	O	7	PMOD
9	different	different	B-NP	JJ	O	10	NMOD
10	doses	dose	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	ephedrine	ephedrine	B-NP	NN	O	11	PMOD
13	to	to	B-PP	TO	O	8	VMOD
14	propofol	propofol	B-NP	NN	O	13	PMOD
15	in	in	B-SBAR	IN	O	8	VMOD
16	order	order	O	NN	O	15	DEP
17	to	to	B-VP	TO	O	18	VMOD
18	obtund	obtund	I-VP	VB	O	15	SBAR
19	the	the	B-NP	DT	O	21	NMOD
20	hypotensive	hypotensive	I-NP	JJ	O	21	NMOD
21	response	response	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	addition	addition	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ephedrine	ephedrine	B-NP	NN	O	3	PMOD
5	to	to	B-PP	TO	O	2	NMOD
6	propofol	propofol	B-NP	NN	O	5	PMOD
7	appears	appear	B-VP	VBZ	O	0	ROOT
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	7	VMOD
10	an	an	B-NP	DT	O	12	NMOD
11	effective	effective	I-NP	JJ	O	12	NMOD
12	method	method	I-NP	NN	O	9	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	obtunding	obtund	B-VP	VBG	O	13	PMOD
15	the	the	B-NP	DT	O	17	NMOD
16	hypotensive	hypotensive	I-NP	JJ	O	17	NMOD
17	response	response	I-NP	NN	O	14	OBJ
18	to	to	B-PP	TO	O	17	NMOD
19	propofol	propofol	B-NP	NN	O	18	PMOD
20	at	at	B-PP	IN	O	19	NMOD
21	all	all	B-NP	DT	O	22	NMOD
22	doses	dose	I-NP	NNS	O	20	PMOD
23	used	use	B-VP	VBN	O	22	NMOD
24	in	in	B-PP	IN	O	23	VMOD
25	this	this	B-NP	DT	O	26	NMOD
26	study	study	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	7	P

1	However	However	B-ADVP	RB	O	15	VMOD
2	,	,	O	,	O	15	P
3	marked	marked	B-NP	JJ	O	4	NMOD
4	tachycardia	tachycardia	I-NP	NN	O	15	SUB
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	use	use	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	ephedrine	ephedrine	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	combination	combination	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	propofol	propofol	B-NP	NN	O	13	PMOD
15	occurred	occur	B-VP	VBD	O	0	ROOT
16	in	in	B-PP	IN	O	15	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	majority	majority	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	,	,	O	,	O	15	P
22	occasionally	occasionally	B-ADVP	RB	O	23	VMOD
23	reaching	reach	B-VP	VBG	O	15	VMOD
24	high	high	B-NP	JJ	O	25	NMOD
25	levels	level	I-NP	NNS	O	23	OBJ
26	in	in	B-PP	IN	O	25	NMOD
27	individual	individual	B-NP	JJ	O	28	NMOD
28	patients	patient	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	15	P

1	Neurotoxicity	Neurotoxicity	B-NP	NN	O	7	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	halogenated	halogenate	B-NP	VBN	O	4	NMOD
4	hydroxyquinolines	hydroxyquinoline	I-NP	NNS	O	2	PMOD
5	:	:	O	:	O	1	P
6	clinical	clinical	B-NP	JJ	O	7	NMOD
7	analysis	analysis	I-NP	NN	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	cases	case	B-NP	NNS	O	8	PMOD
10	reported	report	B-VP	VBN	O	9	NMOD
11	outside	outside	B-PP	IN	O	10	VMOD
12	Japan	Japan	B-NP	NNP	O	11	PMOD
13	.	.	O	.	O	7	P

1	An	An	B-NP	DT	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	presented	present	I-VP	VBN	O	3	VC
5	of	of	B-PP	IN	O	4	VMOD
6	220	220	B-NP	CD	O	7	NMOD
7	cases	case	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	possible	possible	B-NP	JJ	O	11	NMOD
10	neurotoxic	neurotoxic	I-NP	JJ	O	11	NMOD
11	reactions	reaction	I-NP	NNS	O	8	PMOD
12	to	to	B-PP	TO	O	4	VMOD
13	halogenated	halogenate	B-NP	VBN	O	14	NMOD
14	hydroxyquinolines	hydroxyquinoline	I-NP	NNS	O	12	PMOD
15	reported	report	B-VP	VBN	O	14	NMOD
16	from	from	B-PP	IN	O	15	VMOD
17	outside	outside	B-PP	IN	O	16	PMOD
18	Japan	Japan	B-NP	NNP	O	17	PMOD
19	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	10	VMOD
2	six	six	B-NP	CD	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	probable	probable	I-NP	JJ	O	6	NMOD
6	cases	case	I-NP	NNS	O	3	PMOD
7	the	the	B-NP	DT	O	9	NMOD
8	neurological	neurological	I-NP	JJ	O	9	NMOD
9	disturbance	disturbance	I-NP	NN	O	10	SUB
10	consisted	consist	B-VP	VBD	O	0	ROOT
11	of	of	B-PP	IN	O	10	VMOD
12	an	an	B-NP	DT	O	15	NMOD
13	acute	acute	I-NP	JJ	O	15	NMOD
14	reversible	reversible	I-NP	JJ	O	15	NMOD
15	encephalopathy	encephalopathy	I-NP	NN	O	11	PMOD
16	usually	usually	B-ADVP	RB	O	17	VMOD
17	related	relate	B-VP	VBN	O	15	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	the	the	B-NP	DT	O	20	NMOD
20	ingestion	ingestion	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	a	a	B-NP	DT	O	24	NMOD
23	high	high	I-NP	JJ	O	24	NMOD
24	dose	dose	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	clioquinol	clioquinol	B-NP	NN	O	25	PMOD
27	over	over	B-PP	IN	O	17	AMOD
28	a	a	B-NP	DT	O	30	NMOD
29	short	short	I-NP	JJ	O	30	NMOD
30	period	period	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	10	P

1	This	This	B-NP	DT	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	most	most	I-VP	RBS	O	4	AMOD
4	frequently	frequently	I-VP	RB	O	2	VMOD
5	found	find	I-VP	VBN	O	2	VC
6	in	in	B-PP	IN	O	5	VMOD
7	children	child	B-NP	NNS	O	6	PMOD
8	,	,	O	,	O	2	P
9	many	many	B-NP	DT	O	2	VMOD
10	of	of	B-PP	IN	O	9	NMOD
11	whom	whom	B-NP	WP	O	10	PMOD
12	had	have	B-VP	VBD	O	2	VMOD
13	received	receive	I-VP	VBN	O	12	VC
14	clioquinol	clioquinol	B-NP	NN	O	13	OBJ
15	as	as	B-PP	IN	O	13	VMOD
16	treatment	treatment	B-NP	NN	O	15	PMOD
17	for	for	B-PP	IN	O	16	NMOD
18	acrodermatitis	acrodermatitis	B-NP	NN	O	19	NMOD
19	enteropathica	enteropathica	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	2	P

1	Epileptic	Epileptic	B-NP	JJ	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	0	ROOT
3	following	follow	B-PP	VBG	O	2	NMOD
4	cortical	cortical	B-NP	JJ	O	5	NMOD
5	application	application	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	fibrin	fibrin	B-NP	NN	O	8	NMOD
8	sealants	sealant	I-NP	NNS	O	6	PMOD
9	containing	contain	B-VP	VBG	O	8	NMOD
10	tranexamic	tranexamic	B-NP	JJ	O	11	NMOD
11	acid	acid	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	2	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	tAMCA	tAMCA	B-NP	NN	B-protein	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	shown	show	I-VP	VBN	O	5	VC
7	to	to	I-VP	TO	O	8	VMOD
8	cause	cause	I-VP	VB	O	6	VMOD
9	epileptic	epileptic	B-NP	JJ	O	10	NMOD
10	seizures	seizure	I-NP	NNS	O	8	OBJ
11	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	wanted	want	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	study	study	I-VP	VB	O	2	VMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	tAMCA	tAMCA	B-NP	NN	B-protein	7	SUB
7	retains	retain	B-VP	VBZ	O	5	SBAR
8	its	its	B-NP	PRP$	O	10	NMOD
9	convulsive	convulsive	I-NP	JJ	O	10	NMOD
10	action	action	I-NP	NN	O	7	OBJ
11	if	if	B-SBAR	IN	O	7	VMOD
12	incorporated	incorporate	B-VP	VBN	O	11	SBAR
13	into	into	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	15	NMOD
15	FS	FS	I-NP	NN	B-protein	13	PMOD
16	.	.	O	.	O	2	P

1	FINDINGS	FINDINGS	B-NP	NNS	O	6	SUB
2	:	:	O	:	O	1	P
3	FS	FS	B-NP	NN	O	1	NMOD
4	containing	contain	B-VP	VBG	O	3	NMOD
5	tAMCA	tAMCA	B-NP	NN	O	4	OBJ
6	caused	cause	B-VP	VBD	O	0	ROOT
7	paroxysmal	paroxysmal	B-NP	JJ	O	9	NMOD
8	brain	brain	I-NP	NN	O	9	NMOD
9	activity	activity	I-NP	NN	O	6	OBJ
10	which	which	B-NP	WDT	O	9	NMOD
11	was	be	B-VP	VBD	O	10	SBAR
12	associated	associate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	distinct	distinct	B-NP	JJ	O	16	NMOD
15	convulsive	convulsive	I-NP	JJ	O	16	NMOD
16	behaviours	behaviour	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	degree	degree	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	these	these	B-NP	DT	O	5	NMOD
5	seizures	seizure	I-NP	NNS	O	3	PMOD
6	increased	increase	B-VP	VBD	O	0	ROOT
7	with	with	B-PP	IN	O	6	VMOD
8	increasing	increase	B-NP	VBG	O	9	NMOD
9	concentration	concentration	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	tAMCA	tAMCA	B-NP	NN	B-protein	10	PMOD
12	.	.	O	.	O	6	P

1	Thus	Thus	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	FS	FS	B-NP	NN	B-protein	8	SUB
4	containing	contain	B-VP	VBG	O	3	NMOD
5	47.5	47.5	B-NP	CD	O	7	NMOD
6	mg/ml	mg/ml	I-NP	NN	O	7	NMOD
7	tAMCA	tAMCA	I-NP	NN	O	4	OBJ
8	evoked	evoke	B-VP	VBD	O	0	ROOT
9	generalized	generalize	B-NP	VBN	O	10	NMOD
10	seizures	seizure	I-NP	NNS	O	8	OBJ
11	in	in	B-PP	IN	O	8	VMOD
12	all	all	B-NP	DT	O	14	NMOD
13	tested	test	I-NP	VBN	O	14	NMOD
14	rats	rat	I-NP	NNS	O	11	PMOD
15	(	(	O	(	O	17	DEP
16	n=6	n=6	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	while	while	B-SBAR	IN	O	8	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	lowest	low	I-NP	JJS	O	21	NMOD
21	concentration	concentration	I-NP	NN	O	29	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	tAMCA	tAMCA	B-NP	NN	O	22	PMOD
24	(	(	O	(	O	27	DEP
25	0.5	0.5	B-NP	CD	O	26	NMOD
26	mg/ml	mg/ml	I-NP	NN	O	27	DEP
27	)	)	O	)	O	23	NMOD
28	only	only	B-ADVP	RB	O	29	VMOD
29	evoked	evoke	B-VP	VBD	O	18	SBAR
30	brief	brief	B-NP	JJ	O	31	NMOD
31	episodes	episode	I-NP	NNS	O	29	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	jerk-correlated	jerk-correlated	B-NP	JJ	O	35	NMOD
34	convulsive	convulsive	I-NP	JJ	O	35	NMOD
35	potentials	potential	I-NP	NNS	O	32	PMOD
36	in	in	B-PP	IN	O	31	NMOD
37	1	1	B-NP	CD	O	36	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	6	6	B-NP	CD	O	40	NMOD
40	rats	rat	I-NP	NNS	O	38	PMOD
41	.	.	O	.	O	8	P

1	INTERPRETATION	INTERPRETATION	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Tranexamic	Tranexamic	B-NP	JJ	O	4	NMOD
4	acid	acid	I-NP	NN	O	5	SUB
5	retains	retain	B-VP	VBZ	O	0	ROOT
6	its	its	B-NP	PRP$	O	8	NMOD
7	convulsive	convulsive	I-NP	JJ	O	8	NMOD
8	action	action	I-NP	NN	O	5	OBJ
9	within	within	B-PP	IN	O	8	NMOD
10	FS	FS	B-NP	NN	B-protein	9	PMOD
11	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	2	NMOD
2	diet	diet	I-NP	NN	O	6	SUB
3	promoting	promote	B-VP	VBG	O	2	NMOD
4	sugar	sugar	B-NP	NN	O	5	NMOD
5	dependency	dependency	I-NP	NN	O	3	OBJ
6	causes	cause	B-VP	VBZ	O	0	ROOT
7	behavioral	behavioral	B-NP	JJ	O	8	NMOD
8	cross-sensitization	cross-sensitization	I-NP	NN	O	6	OBJ
9	to	to	B-PP	TO	O	8	NMOD
10	a	a	B-NP	DT	O	12	NMOD
11	low	low	I-NP	JJ	O	12	NMOD
12	dose	dose	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	amphetamine	amphetamine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	examined	examine	B-VP	VBD	O	0	ROOT
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	female	female	B-NP	JJ	O	7	NMOD
7	rats	rat	I-NP	NNS	O	14	SUB
8	on	on	B-PP	IN	O	7	NMOD
9	various	various	B-NP	JJ	O	10	NMOD
10	regimens	regimen	I-NP	NNS	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	sugar	sugar	B-NP	NN	O	13	NMOD
13	access	access	I-NP	NN	O	11	PMOD
14	would	would	B-VP	MD	O	5	SBAR
15	show	show	I-VP	VB	O	14	VC
16	behavioral	behavioral	B-NP	JJ	O	17	NMOD
17	cross-sensitization	cross-sensitization	I-NP	NN	O	15	OBJ
18	to	to	B-PP	TO	O	17	NMOD
19	a	a	B-NP	DT	O	21	NMOD
20	low	low	I-NP	JJ	O	21	NMOD
21	dose	dose	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	amphetamine	amphetamine	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	animals	animal	I-NP	NNS	O	10	SUB
3	that	that	B-NP	WDT	O	2	NMOD
4	had	have	B-VP	VBD	O	3	SBAR
5	experienced	experience	I-VP	VBN	O	4	VC
6	cyclic	cyclic	B-NP	JJ	O	7	NMOD
7	sucrose	sucrose	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	chow	chow	I-NP	NN	O	5	OBJ
10	were	be	B-VP	VBD	O	0	ROOT
11	hyperactive	hyperactive	B-ADJP	JJ	O	10	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	response	response	B-NP	NN	O	12	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	amphetamine	amphetamine	B-NP	NN	O	14	PMOD
16	compared	compare	B-PP	VBN	O	10	VMOD
17	with	with	B-PP	IN	O	16	PMOD
18	four	four	B-NP	CD	O	20	NMOD
19	control	control	I-NP	NN	O	20	NMOD
20	groups	group	I-NP	NNS	O	17	PMOD
21	(	(	O	(	O	58	DEP
22	ad	ad	B-NP	NN	O	26	NMOD
23	libitum	libitum	I-NP	NN	O	26	NMOD
24	10	10	B-NP	CD	O	26	NMOD
25	%	%	I-NP	NN	O	26	NMOD
26	sucrose	sucrose	I-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	chow	chow	I-NP	NN	O	53	NMOD
29	followed	follow	B-VP	VBN	O	28	NMOD
30	by	by	B-PP	IN	O	29	VMOD
31	amphetamine	amphetamine	B-NP	NN	O	32	NMOD
32	injection	injection	I-NP	NN	O	35	NMOD
33	,	,	O	,	O	35	P
34	cyclic	cyclic	B-NP	JJ	O	35	NMOD
35	chow	chow	I-NP	NN	O	43	NMOD
36	followed	follow	B-VP	VBN	O	35	NMOD
37	by	by	B-PP	IN	O	36	VMOD
38	amphetamine	amphetamine	B-NP	NN	O	39	NMOD
39	injection	injection	I-NP	NN	O	37	PMOD
40	,	,	O	,	O	43	P
41	ad	ad	B-NP	NN	O	43	NMOD
42	libitum	libitum	I-NP	NN	O	43	NMOD
43	chow	chow	I-NP	NN	O	30	PMOD
44	with	with	B-PP	IN	O	43	NMOD
45	amphetamine	amphetamine	B-NP	NN	O	44	PMOD
46	,	,	O	,	O	53	P
47	or	or	O	CC	O	53	NMOD
48	cyclic	cyclic	B-NP	JJ	O	50	AMOD
49	10	10	I-NP	CD	O	50	AMOD
50	%	%	I-NP	NN	O	51	NMOD
51	sucrose	sucrose	I-NP	NN	O	53	NMOD
52	and	and	I-NP	CC	O	53	NMOD
53	chow	chow	I-NP	NN	O	58	DEP
54	with	with	B-PP	IN	O	53	NMOD
55	a	a	B-NP	DT	O	57	NMOD
56	saline	saline	I-NP	NN	O	57	NMOD
57	injection	injection	I-NP	NN	O	54	PMOD
58	)	)	O	)	O	20	NMOD
59	.	.	O	.	O	10	P

1	D-penicillamine	D-penicillamine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	angiopathy	angiopathy	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	rats	rat	B-NP	NNS	O	4	PMOD
6	.	.	O	.	O	2	P

1	Brain	Brain	B-NP	NN	O	3	NMOD
2	natriuretic	natriuretic	I-NP	JJ	O	3	NMOD
3	peptide	peptide	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	predictor	predictor	I-NP	NN	O	4	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	anthracycline	anthracycline	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	cardiotoxicity	cardiotoxicity	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	4	P

1	Anthracyclines	Anthracycline	B-NP	NNS	O	2	SUB
2	are	be	B-VP	VBP	O	10	VMOD
3	effective	effective	B-NP	JJ	O	5	NMOD
4	antineoplastic	antineoplastic	I-NP	JJ	O	5	NMOD
5	drugs	drug	I-NP	NNS	O	2	PRD
6	,	,	O	,	O	10	P
7	but	but	O	CC	O	10	VMOD
8	they	they	B-NP	PRP	O	10	SUB
9	frequently	frequently	B-ADVP	RB	O	10	VMOD
10	cause	cause	B-VP	VBP	O	0	ROOT
11	dose-related	dose-related	B-NP	JJ	O	12	NMOD
12	cardiotoxicity	cardiotoxicity	I-NP	NN	O	10	OBJ
13	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	cardiotoxicity	cardiotoxicity	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	conventional	conventional	B-NP	JJ	O	6	NMOD
5	anthracycline	anthracycline	I-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	3	PMOD
7	highlights	highlight	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	9	NMOD
9	need	need	I-NP	NN	O	7	OBJ
10	to	to	B-VP	TO	O	11	VMOD
11	search	search	I-VP	VB	O	9	NMOD
12	for	for	B-PP	IN	O	11	VMOD
13	methods	method	B-NP	NNS	O	12	PMOD
14	that	that	B-NP	WDT	O	13	NMOD
15	are	be	B-VP	VBP	O	14	SBAR
16	highly	highly	B-ADJP	RB	O	17	AMOD
17	sensitive	sensitive	I-ADJP	JJ	O	19	AMOD
18	and	and	I-ADJP	CC	O	19	AMOD
19	capable	capable	I-ADJP	JJ	O	15	PRD
20	of	of	B-PP	IN	O	19	AMOD
21	predicting	predict	B-VP	VBG	O	20	PMOD
22	cardiac	cardiac	B-NP	JJ	O	23	NMOD
23	dysfunction	dysfunction	I-NP	NN	O	21	OBJ
24	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	measured	measure	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	plasma	plasma	I-NP	NN	O	5	NMOD
5	level	level	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	brain	brain	B-NP	NN	O	9	NMOD
8	natriuretic	natriuretic	I-NP	JJ	O	9	NMOD
9	peptide	peptide	I-NP	NN	O	6	PMOD
10	(	(	O	(	O	12	DEP
11	BNP	BNP	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	to	to	B-VP	TO	O	14	VMOD
14	determine	determine	I-VP	VB	O	2	VMOD
15	whether	whether	B-SBAR	IN	O	14	VMOD
16	BNP	BNP	B-NP	NN	B-protein	17	SUB
17	might	might	B-VP	MD	O	15	SBAR
18	serve	serve	I-VP	VB	O	17	VC
19	as	as	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	23	NMOD
21	simple	simple	I-NP	JJ	O	22	AMOD
22	diagnostic	diagnostic	I-NP	JJ	O	23	NMOD
23	indicator	indicator	I-NP	NN	O	26	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	anthracycline	anthracycline	B-NP	NN	O	24	PMOD
26	induced	induce	B-VP	VBD	O	19	SBAR
27	cardiotoxicity	cardiotoxicity	B-NP	NN	O	26	OBJ
28	in	in	B-PP	IN	O	26	VMOD
29	patients	patient	B-NP	NNS	O	28	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	acute	acute	B-NP	JJ	O	32	NMOD
32	leukemia	leukemia	I-NP	NN	O	30	PMOD
33	treated	treat	B-VP	VBN	O	32	NMOD
34	with	with	B-PP	IN	O	33	VMOD
35	a	a	B-NP	DT	O	36	NMOD
36	daunorubicin	daunorubicin	I-NP	NN	O	41	NMOD
37	(	(	O	(	O	39	DEP
38	DNR	DNR	B-NP	NN	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	-containing	-containing	B-NP	JJ	O	41	NMOD
41	regimen	regimen	I-NP	NN	O	34	PMOD
42	.	.	O	.	O	2	P

1	Thirteen	Thirteen	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	6	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	5	NMOD
5	leukemia	leukemia	I-NP	NN	O	3	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	treated	treat	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	DNR-containing	DNR-containing	I-NP	JJ	O	11	NMOD
11	regimen	regimen	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	6	P

1	On	On	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	BNP	BNP	B-NP	NN	B-protein	7	SUB
7	did	do	B-VP	VBD	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	increase	increase	I-VP	VB	O	7	VC
10	in	in	B-PP	IN	O	9	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	without	without	B-PP	IN	O	12	NMOD
14	heart	heart	B-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	13	PMOD
16	given	give	B-PP	VBN	O	12	NMOD
17	DNR	DNR	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	9	P
19	even	even	B-ADVP	RB	O	20	PMOD
20	at	at	B-PP	IN	O	9	VMOD
21	more	more	B-NP	JJR	O	22	AMOD
22	than	than	I-NP	IN	O	24	NMOD
23	700	700	I-NP	CD	O	22	AMOD
24	mg/m	mg/m	I-NP	NN	O	20	PMOD
25	(	(	O	(	O	27	DEP
26	2	2	B-NP	CD	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	7	P

1	Sulfonamides	Sulfonamide	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	associated	associate	I-VP	VBN	O	29	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	anencephaly	anencephaly	O	RB	O	4	PMOD
6	(	(	O	(	O	24	DEP
7	adjusted	adjust	B-NP	VBN	O	8	NMOD
8	OR	OR	I-NP	NN	O	24	DEP
9	[	[	O	(	O	11	DEP
10	AOR	AOR	B-NP	NN	O	11	DEP
11	]	]	O	)	O	8	NMOD
12	=	=	B-VP	SYM	O	8	NMOD
13	3.4	3.4	B-NP	CD	O	12	AMOD
14	;	;	O	:	O	24	P
15	95	95	B-NP	CD	O	18	NMOD
16	%	%	I-NP	NN	O	18	NMOD
17	confidence	confidence	I-NP	NN	O	18	NMOD
18	interval	interval	I-NP	NN	O	23	NMOD
19	[	[	O	(	O	21	DEP
20	CI	CI	B-NP	NN	O	21	DEP
21	]	]	O	)	O	18	NMOD
22	,	,	O	,	O	23	P
23	1.3-8.8	1.3-8.8	B-NP	CD	O	24	DEP
24	)	)	O	)	O	5	AMOD
25	,	,	O	,	O	3	P
26	hypoplastic	hypoplastic	B-NP	JJ	O	29	NMOD
27	left	left	I-NP	JJ	O	29	NMOD
28	heart	heart	I-NP	NN	O	29	NMOD
29	syndrome	syndrome	I-NP	NN	O	59	NMOD
30	(	(	O	(	O	40	DEP
31	AOR	AOR	B-NP	NN	O	39	NMOD
32	=	=	B-VP	SYM	O	31	NMOD
33	3.2	3.2	B-NP	CD	O	32	AMOD
34	;	;	O	:	O	39	P
35	95	95	B-NP	CD	O	37	NMOD
36	%	%	I-NP	NN	O	37	NMOD
37	CI	CI	I-NP	NN	O	39	SUB
38	,	,	O	,	O	39	P
39	1.3-7.6	1.3-7.6	B-NP	CD	O	40	DEP
40	)	)	O	)	O	29	NMOD
41	,	,	O	,	O	59	P
42	coarctation	coarctation	B-NP	NN	O	59	NMOD
43	of	of	B-PP	IN	O	42	NMOD
44	the	the	B-NP	DT	O	45	NMOD
45	aorta	aorta	I-NP	NN	O	43	PMOD
46	(	(	O	(	O	56	DEP
47	AOR	AOR	B-NP	NN	O	55	NMOD
48	=	=	B-VP	SYM	O	47	NMOD
49	2.7	2.7	B-NP	CD	O	48	AMOD
50	;	;	O	:	O	55	P
51	95	95	B-NP	CD	O	53	NMOD
52	%	%	I-NP	NN	O	53	NMOD
53	CI	CI	I-NP	NN	O	55	SUB
54	,	,	O	,	O	55	P
55	1.3-5.6	1.3-5.6	B-NP	CD	O	56	DEP
56	)	)	O	)	O	42	NMOD
57	,	,	O	,	O	59	P
58	choanal	choanal	B-NP	JJ	O	59	NMOD
59	atresia	atresia	I-NP	NN	O	74	NMOD
60	(	(	O	(	O	70	DEP
61	AOR	AOR	B-NP	NN	O	69	NMOD
62	=	=	B-VP	SYM	O	61	NMOD
63	8.0	8.0	B-NP	CD	O	62	AMOD
64	;	;	O	:	O	69	P
65	95	95	B-NP	CD	O	67	NMOD
66	%	%	I-NP	NN	O	67	NMOD
67	CI	CI	I-NP	NN	O	69	SUB
68	,	,	O	,	O	69	P
69	2.7-23.5	2.7-23.5	B-NP	CD	O	70	DEP
70	)	)	O	)	O	59	NMOD
71	,	,	O	,	O	74	P
72	transverse	transverse	B-NP	JJ	O	74	NMOD
73	limb	limb	I-NP	NN	O	74	NMOD
74	deficiency	deficiency	I-NP	NN	O	2	PRD
75	(	(	O	(	O	85	DEP
76	AOR	AOR	B-NP	NN	O	84	NMOD
77	=	=	B-VP	SYM	O	76	NMOD
78	2.5	2.5	B-NP	CD	O	77	AMOD
79	;	;	O	:	O	84	P
80	95	95	B-NP	CD	O	82	NMOD
81	%	%	I-NP	NN	O	82	NMOD
82	CI	CI	I-NP	NN	O	84	NMOD
83	,	,	O	,	O	84	P
84	1.0-5.9	1.0-5.9	B-NP	CD	O	85	DEP
85	)	)	O	)	O	74	NMOD
86	,	,	O	,	O	2	P
87	and	and	O	CC	O	89	NMOD
88	diaphragmatic	diaphragmatic	B-NP	JJ	O	89	NMOD
89	hernia	hernia	I-NP	NN	O	86	OBJ
90	(	(	O	(	O	100	DEP
91	AOR	AOR	B-NP	NN	O	99	NMOD
92	=	=	B-VP	SYM	O	91	NMOD
93	2.4	2.4	B-NP	CD	O	92	AMOD
94	;	;	O	:	O	99	P
95	95	95	B-NP	CD	O	97	NMOD
96	%	%	I-NP	NN	O	97	NMOD
97	CI	CI	I-NP	NN	O	99	SUB
98	,	,	O	,	O	99	P
99	1.1-5.4	1.1-5.4	B-NP	CD	O	100	DEP
100	)	)	O	)	O	89	NMOD
101	.	.	O	.	O	2	P

1	Nitrofurantoins	Nitrofurantoin	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	associated	associate	I-VP	VBN	O	23	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	anophthalmia	anophthalmia	B-NP	NN	O	7	NMOD
6	or	or	I-NP	CC	O	7	NMOD
7	microphthalmos	microphthalmo	I-NP	NNS	O	4	PMOD
8	(	(	O	(	O	18	DEP
9	AOR	AOR	B-NP	NN	O	17	NMOD
10	=	=	B-VP	SYM	O	9	NMOD
11	3.7	3.7	B-NP	CD	O	10	AMOD
12	;	;	O	:	O	17	P
13	95	95	B-NP	CD	O	15	NMOD
14	%	%	I-NP	NN	O	15	NMOD
15	CI	CI	I-NP	NN	O	17	NMOD
16	,	,	O	,	O	17	P
17	1.1-12.2	1.1-12.2	B-NP	CD	O	18	DEP
18	)	)	O	)	O	7	NMOD
19	,	,	O	,	O	3	P
20	hypoplastic	hypoplastic	B-NP	JJ	O	23	NMOD
21	left	left	I-NP	JJ	O	23	NMOD
22	heart	heart	I-NP	NN	O	23	NMOD
23	syndrome	syndrome	I-NP	NN	O	38	NMOD
24	(	(	O	(	O	34	DEP
25	AOR	AOR	B-NP	NN	O	33	NMOD
26	=	=	B-VP	SYM	O	25	NMOD
27	4.2	4.2	B-NP	CD	O	26	AMOD
28	;	;	O	:	O	33	P
29	95	95	B-NP	CD	O	31	NMOD
30	%	%	I-NP	NN	O	31	NMOD
31	CI	CI	I-NP	NN	O	33	SUB
32	,	,	O	,	O	33	P
33	1.9-9.1	1.9-9.1	B-NP	CD	O	34	DEP
34	)	)	O	)	O	23	NMOD
35	,	,	O	,	O	38	P
36	atrial	atrial	B-NP	JJ	O	38	NMOD
37	septal	septal	I-NP	JJ	O	38	NMOD
38	defects	defect	I-NP	NNS	O	53	NMOD
39	(	(	O	(	O	49	DEP
40	AOR	AOR	B-NP	NN	O	48	NMOD
41	=	=	B-VP	SYM	O	40	NMOD
42	1.9	1.9	B-NP	CD	O	41	AMOD
43	;	;	O	:	O	48	P
44	95	95	B-NP	CD	O	46	NMOD
45	%	%	I-NP	NN	O	46	NMOD
46	CI	CI	I-NP	NN	O	48	NMOD
47	,	,	O	,	O	48	P
48	1.1-3.4	1.1-3.4	B-NP	CD	O	49	DEP
49	)	)	O	)	O	38	NMOD
50	,	,	O	,	O	53	P
51	and	and	O	CC	O	53	NMOD
52	cleft	cleft	B-NP	NN	O	53	NMOD
53	lip	lip	I-NP	NN	O	2	PRD
54	with	with	B-PP	IN	O	53	NMOD
55	cleft	cleft	B-NP	NN	O	56	NMOD
56	palate	palate	I-NP	NN	O	54	PMOD
57	(	(	O	(	O	67	DEP
58	AOR	AOR	B-NP	NN	O	66	NMOD
59	=	=	B-VP	SYM	O	58	NMOD
60	2.1	2.1	B-NP	CD	O	59	AMOD
61	;	;	O	:	O	66	P
62	95	95	B-NP	CD	O	64	NMOD
63	%	%	I-NP	NN	O	64	NMOD
64	CI	CI	I-NP	NN	O	66	SUB
65	,	,	O	,	O	66	P
66	1.2-3.9	1.2-3.9	B-NP	CD	O	67	DEP
67	)	)	O	)	O	53	NMOD
68	.	.	O	.	O	2	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Reassuringly	Reassuringly	B-ADVP	RB	O	19	VMOD
4	,	,	O	,	O	19	P
5	penicillins	penicillin	B-NP	NNS	B-protein	10	NMOD
6	,	,	O	,	O	10	P
7	erythromycins	erythromycin	B-NP	NNS	O	10	NMOD
8	,	,	O	,	O	10	P
9	and	and	O	CC	O	10	NMOD
10	cephalosporins	cephalosporin	B-NP	NNS	O	19	SUB
11	,	,	O	,	O	10	P
12	although	although	B-SBAR	IN	O	19	VMOD
13	used	use	B-VP	VBN	O	12	SBAR
14	commonly	commonly	B-ADVP	RB	O	13	VMOD
15	by	by	B-PP	IN	O	13	VMOD
16	pregnant	pregnant	B-NP	JJ	O	17	NMOD
17	women	woman	I-NP	NNS	O	15	PMOD
18	,	,	O	,	O	19	P
19	were	be	B-VP	VBD	O	1	NMOD
20	not	not	I-VP	RB	O	19	VMOD
21	associated	associate	I-VP	VBN	O	19	VC
22	with	with	B-PP	IN	O	21	VMOD
23	many	many	B-NP	JJ	O	25	NMOD
24	birth	birth	I-NP	NN	O	25	NMOD
25	defects	defect	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	1	P

1	Patients	Patient	B-NP	NNS	O	6	SUB
2	treated	treat	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	alkylating	alkylate	B-NP	VBG	O	5	NMOD
5	agents	agent	I-NP	NNS	O	3	PMOD
6	have	have	B-VP	VBP	O	23	VMOD
7	an	an	B-NP	DT	O	9	NMOD
8	increased	increase	I-NP	VBN	O	9	NMOD
9	risk	risk	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	development	development	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	acute	acute	B-NP	JJ	O	15	NMOD
14	nonlymphocytic	nonlymphocytic	I-NP	JJ	O	15	NMOD
15	leukemia	leukemia	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	23	P
17	and	and	O	CC	O	22	NMOD
18	both	both	B-NP	DT	O	22	NMOD
19	alkylating	alkylate	I-NP	VBG	O	20	NMOD
20	agents	agent	I-NP	NNS	O	22	NMOD
21	and	and	O	CC	O	22	NMOD
22	azathioprine	azathioprine	B-NP	NN	O	23	SUB
23	are	be	B-VP	VBP	O	0	ROOT
24	associated	associate	I-VP	VBN	O	23	VC
25	with	with	B-PP	IN	O	24	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	development	development	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	31	NMOD
30	's	's	B-NP	POS	O	31	NMOD
31	lymphoma	lymphoma	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	23	P

1	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	3	SUB
3	increases	increase	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	risk	risk	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	carcinoma	carcinoma	B-NP	NN	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	bladder	bladder	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	3	P

1	There	There	B-NP	EX	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	several	several	B-NP	JJ	O	6	NMOD
5	long-term	long-term	I-NP	JJ	O	6	NMOD
6	studies	study	I-NP	NNS	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	rheumatoid	rheumatoid	B-NP	JJ	O	11	NMOD
11	arthritis	arthritis	I-NP	NN	O	9	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	azathioprine	azathioprine	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	cyclophosphamide	cyclophosphamide	I-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	incidence	incidence	I-NP	NN	O	13	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	most	most	B-NP	JJS	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	common	common	I-NP	JJ	O	25	NMOD
25	cancers	cancer	I-NP	NNS	O	22	PMOD
26	is	be	B-VP	VBZ	O	2	VMOD
27	not	not	I-VP	RB	O	26	VMOD
28	increased	increase	I-VP	VBN	O	26	VC
29	.	.	O	.	O	2	P

1	Patterns	Pattern	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	hepatic	hepatic	B-NP	JJ	O	4	NMOD
4	injury	injury	I-NP	NN	O	2	PMOD
5	induced	induce	B-VP	VBN	O	1	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	methyldopa	methyldopa	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	1	P

1	Twelve	Twelve	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	9	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	liver	liver	B-NP	NN	O	5	NMOD
5	disease	disease	I-NP	NN	O	3	PMOD
6	related	relate	B-VP	VBN	O	2	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	methyldopa	methyldopa	B-NP	NN	O	7	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	seen	see	I-VP	VBN	O	9	VC
11	between	between	B-PP	IN	O	10	VMOD
12	1967	1967	B-NP	CD	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	1977	1977	I-NP	CD	O	11	PMOD
15	.	.	O	.	O	9	P

1	One	One	B-NP	CD	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	died	die	B-VP	VBD	O	23	VMOD
4	,	,	O	,	O	3	P
5	having	have	B-VP	VBG	O	3	VMOD
6	presented	present	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	hepatic	hepatic	B-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	7	PMOD
10	,	,	O	,	O	23	P
11	and	and	O	CC	O	23	VMOD
12	another	another	B-NP	DT	O	23	VMOD
13	,	,	O	,	O	23	P
14	who	who	B-NP	WP	O	23	VMOD
15	had	have	B-VP	VBD	O	14	SBAR
16	been	be	I-VP	VBN	O	15	VC
17	taking	take	I-VP	VBG	O	18	NMOD
18	methyldopa	methyldopa	B-NP	NN	O	16	PRD
19	for	for	B-PP	IN	O	18	NMOD
20	7	7	B-NP	CD	O	21	NMOD
21	years	year	I-NP	NNS	O	19	PMOD
22	,	,	O	,	O	23	P
23	showed	show	B-VP	VBD	O	0	ROOT
24	slower	slow	B-NP	JJR	O	27	AMOD
25	clinical	clinical	I-NP	JJ	O	27	AMOD
26	and	and	I-NP	CC	O	27	AMOD
27	biochemical	biochemical	I-NP	JJ	O	28	NMOD
28	resolution	resolution	I-NP	NN	O	23	OBJ
29	over	over	B-PP	IN	O	23	VMOD
30	a	a	B-NP	DT	O	31	NMOD
31	period	period	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	several	several	B-NP	JJ	O	34	NMOD
34	months	month	I-NP	NNS	O	32	PMOD
35	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	3	NMOD
2	remaining	remain	I-NP	VBG	O	3	NMOD
3	patient	patient	I-NP	NN	O	7	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	series	series	I-NP	NN	O	4	PMOD
7	developed	develop	B-VP	VBD	O	0	ROOT
8	fulminant	fulminant	B-NP	JJ	O	9	NMOD
9	hepatitis	hepatitis	I-NP	NN	O	7	OBJ
10	when	when	B-ADVP	WRB	O	7	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	drug	drug	I-NP	NN	O	13	SUB
13	was	be	B-VP	VBD	O	10	SBAR
14	accidentally	accidentally	I-VP	RB	O	13	VMOD
15	recommenced	recommence	I-VP	VBN	O	13	VC
16	1	1	B-NP	CD	O	17	NMOD
17	year	year	I-NP	NN	O	15	OBJ
18	after	after	B-PP	IN	O	15	VMOD
19	a	a	B-NP	DT	O	21	NMOD
20	prior	prior	I-NP	JJ	O	21	NMOD
21	episode	episode	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	methyldopa	methyldopa	B-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	hepatitis	hepatitis	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	4	NMOD
2	phase	phase	I-NP	NN	O	4	NMOD
3	I/II	I/II	I-NP	NN	O	4	NMOD
4	study	study	I-NP	NN	O	19	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	paclitaxel	paclitaxel	B-NP	NN	O	8	NMOD
7	plus	plus	I-NP	CC	O	8	NMOD
8	cisplatin	cisplatin	I-NP	NN	O	5	PMOD
9	as	as	B-PP	IN	O	4	NMOD
10	first-line	first-line	B-NP	JJ	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	head	head	B-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	neck	neck	I-NP	NN	O	16	NMOD
16	cancers	cancer	I-NP	NNS	O	12	PMOD
17	:	:	O	:	O	4	P
18	preliminary	preliminary	B-NP	JJ	O	19	NMOD
19	results	result	I-NP	NNS	O	0	ROOT
20	.	.	O	.	O	19	P

1	Preliminary	Preliminary	B-NP	JJ	O	2	NMOD
2	results	result	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	an	an	B-NP	DT	O	9	NMOD
5	Eastern	Eastern	I-NP	NNP	O	9	NMOD
6	Cooperative	Cooperative	I-NP	NNP	O	9	NMOD
7	Oncology	Oncology	I-NP	NNP	O	9	NMOD
8	Group	Group	I-NP	NNP	O	9	NMOD
9	study	study	I-NP	NN	O	3	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	single-agent	single-agent	B-NP	JJ	O	12	NMOD
12	paclitaxel	paclitaxel	I-NP	NN	O	10	PMOD
13	(	(	O	(	O	12	NMOD
14	Taxol	Taxol	B-NP	NN	O	42	VMOD
15	;	;	O	:	O	42	P
16	Bristol-Myers	Bristol-Myers	B-NP	NNP	O	18	NMOD
17	Squibb	Squibb	I-NP	NNP	O	18	NMOD
18	Company	Company	I-NP	NNP	O	20	NMOD
19	,	,	O	,	O	20	P
20	Princeton	Princeton	B-NP	NNP	O	22	NMOD
21	,	,	O	,	O	22	P
22	NJ	NJ	B-NP	NNP	O	24	SUB
23	)	)	O	)	O	22	NMOD
24	reported	report	B-VP	VBD	O	42	VMOD
25	a	a	B-NP	DT	O	29	NMOD
26	37	37	I-NP	CD	O	27	AMOD
27	%	%	I-NP	NN	O	29	NMOD
28	response	response	I-NP	NN	O	29	NMOD
29	rate	rate	I-NP	NN	O	24	OBJ
30	in	in	B-PP	IN	O	29	NMOD
31	patients	patient	B-NP	NNS	O	30	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	head	head	B-NP	NN	O	36	NMOD
34	and	and	O	CC	O	36	NMOD
35	neck	neck	B-NP	NN	O	36	NMOD
36	cancer	cancer	I-NP	NN	O	32	PMOD
37	,	,	O	,	O	42	P
38	and	and	O	CC	O	42	VMOD
39	the	the	B-NP	DT	O	41	NMOD
40	paclitaxel/cisplatin	paclitaxel/cisplatin	I-NP	NN	O	41	NMOD
41	combination	combination	I-NP	NN	O	42	SUB
42	has	have	B-VP	VBZ	O	13	SBAR
43	been	be	I-VP	VBN	O	42	VC
44	used	use	I-VP	VBN	O	43	VC
45	successfully	successfully	B-ADVP	RB	O	44	VMOD
46	and	and	O	CC	O	42	VMOD
47	has	have	B-VP	VBZ	O	42	VMOD
48	significantly	significantly	I-VP	RB	O	49	AMOD
49	improved	improve	I-VP	VBN	O	47	VC
50	median	median	B-NP	JJ	O	52	NMOD
51	response	response	I-NP	NN	O	52	NMOD
52	duration	duration	I-NP	NN	O	49	OBJ
53	in	in	B-PP	IN	O	52	NMOD
54	ovarian	ovarian	B-NP	JJ	O	56	NMOD
55	cancer	cancer	I-NP	NN	O	56	NMOD
56	patients	patient	I-NP	NNS	O	53	PMOD
57	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	initiated	initiate	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	phase	phase	I-NP	NN	O	6	NMOD
5	I/II	I/II	I-NP	NN	O	6	NMOD
6	trial	trial	I-NP	NN	O	2	OBJ
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	2	VMOD
9	the	the	B-NP	DT	O	12	NMOD
10	response	response	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	8	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	escalating	escalate	B-VP	VBG	O	13	PMOD
15	paclitaxel	paclitaxel	B-NP	NN	O	16	NMOD
16	doses	dose	I-NP	NNS	O	14	OBJ
17	combined	combine	B-VP	VBN	O	16	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	fixed-dose	fixed-dose	B-NP	JJ	O	20	NMOD
20	cisplatin	cisplatin	I-NP	NN	O	18	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	granulocyte	granulocyte	B-NP	NN	B-protein	25	NMOD
23	colony-stimulating	colony-stimulating	I-NP	JJ	I-protein	25	NMOD
24	factor	factor	I-NP	NN	I-protein	25	NMOD
25	support	support	I-NP	NN	O	21	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	patients	patient	B-NP	NNS	O	26	PMOD
28	with	with	B-PP	IN	O	27	NMOD
29	untreated	untreated	B-NP	JJ	O	31	AMOD
30	locally	locally	I-NP	RB	O	31	AMOD
31	advanced	advanced	I-NP	JJ	O	36	NMOD
32	inoperable	inoperable	I-NP	JJ	O	33	NMOD
33	head	head	I-NP	NN	O	31	NMOD
34	and	and	I-NP	CC	O	31	NMOD
35	neck	neck	I-NP	NN	O	36	NMOD
36	carcinoma	carcinoma	I-NP	NN	O	28	PMOD
37	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	dose	dose	I-NP	NN	O	3	NMOD
3	levels	level	I-NP	NNS	O	11	NMOD
4	incorporate	incorporate	B-ADJP	JJ	O	3	NMOD
5	escalating	escalate	B-VP	VBG	O	4	AMOD
6	paclitaxel	paclitaxel	B-NP	NN	O	7	NMOD
7	doses	dose	I-NP	NNS	O	5	OBJ
8	,	,	O	,	O	11	P
9	and	and	O	CC	O	11	NMOD
10	intrapatient	intrapatient	B-NP	JJ	O	11	NMOD
11	escalations	escalation	I-NP	NNS	O	17	SUB
12	within	within	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	16	NMOD
14	given	give	I-NP	VBN	O	16	NMOD
15	dose	dose	I-NP	NN	O	16	NMOD
16	level	level	I-NP	NN	O	12	PMOD
17	are	be	B-VP	VBP	O	0	ROOT
18	permitted	permit	I-VP	VBN	O	17	VC
19	if	if	B-SBAR	IN	O	18	VMOD
20	toxicity	toxicity	B-NP	NN	O	21	NMOD
21	permits	permit	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	17	P

1	Paclitaxel/cisplatin	Paclitaxel/cisplatin	B-NP	NN	B-protein	2	SUB
2	is	be	B-VP	VBZ	O	17	VMOD
3	an	an	B-NP	DT	O	6	NMOD
4	effective	effective	I-NP	JJ	O	5	AMOD
5	first-line	first-line	I-NP	JJ	O	6	NMOD
6	regimen	regimen	I-NP	NN	O	2	PRD
7	for	for	B-PP	IN	O	6	NMOD
8	locoregionally	locoregionally	B-NP	RB	O	9	AMOD
9	advanced	advanced	I-NP	JJ	O	13	NMOD
10	head	head	I-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	neck	neck	I-NP	NN	O	13	NMOD
13	cancer	cancer	I-NP	NN	O	7	PMOD
14	and	and	O	CC	O	17	VMOD
15	continued	continued	B-NP	JJ	O	16	NMOD
16	study	study	I-NP	NN	O	17	SUB
17	is	be	B-VP	VBZ	O	0	ROOT
18	warranted	warrant	I-VP	VBN	O	17	VC
19	.	.	O	.	O	17	P

1	A	A	B-NP	DT	O	4	NMOD
2	Phase	Phase	I-NP	NN	O	4	NMOD
3	I	I	I-NP	CD	O	4	NMOD
4	study	study	I-NP	NN	O	15	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	intravenous	intravenous	B-NP	JJ	O	11	NMOD
7	(	(	O	(	O	9	DEP
8	IV	IV	O	CD	O	9	DEP
9	)	)	O	)	O	6	AMOD
10	bolus	bolus	B-NP	NN	O	11	NMOD
11	4'-0-tetrahydropyranyladriamycin	4'-0-tetrahydropyranyladriamycin	I-NP	NN	O	5	PMOD
12	(	(	O	(	O	14	DEP
13	Pirarubicin	Pirarubicin	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	was	be	B-VP	VBD	O	0	ROOT
16	done	do	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	55	55	B-NP	CD	O	19	NMOD
19	patients	patient	I-NP	NNS	O	17	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	good	good	B-NP	JJ	O	23	NMOD
22	performance	performance	I-NP	NN	O	23	NMOD
23	status	status	I-NP	NN	O	20	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	refractory	refractory	B-NP	JJ	O	26	NMOD
26	tumors	tumor	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	15	P

1	Differential	Differential	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	gamma-hexachlorocyclohexane	gamma-hexachlorocyclohexane	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	7	DEP
6	lindane	lindane	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	on	on	B-PP	IN	O	2	NMOD
9	pharmacologically	pharmacologically	B-NP	RB	O	10	AMOD
10	induced	induce	I-NP	VBN	O	11	NMOD
11	seizures	seizure	I-NP	NNS	O	8	PMOD
12	.	.	O	.	O	2	P

1	Gamma-hexachlorocyclohexane	Gamma-hexachlorocyclohexane	B-NP	NN	O	8	NMOD
2	(	(	O	(	O	4	DEP
3	gamma-HCH	gamma-HCH	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	,	,	O	,	O	8	P
6	the	the	B-NP	DT	O	8	NMOD
7	active	active	I-NP	JJ	O	8	NMOD
8	ingredient	ingredient	I-NP	NN	O	14	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	insecticide	insecticide	I-NP	NN	O	12	NMOD
12	lindane	lindane	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	8	P
14	has	have	B-VP	VBZ	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	shown	show	I-VP	VBN	O	15	VC
17	to	to	I-VP	TO	O	18	VMOD
18	decrease	decrease	I-VP	VB	O	16	VMOD
19	seizure	seizure	B-NP	NN	O	20	NMOD
20	threshold	threshold	I-NP	NN	O	18	OBJ
21	to	to	B-PP	TO	O	18	VMOD
22	pentylenetrazol	pentylenetrazol	B-NP	NN	O	27	NMOD
23	(	(	O	(	O	25	DEP
24	PTZ	PTZ	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	3	3	B-NP	CD	O	27	NMOD
27	h	h	I-NP	NN	O	21	PMOD
28	after	after	B-PP	IN	O	18	VMOD
29	exposure	exposure	B-NP	NN	O	28	PMOD
30	to	to	B-PP	TO	O	29	NMOD
31	gamma-HCH	gamma-HCH	B-NP	NN	O	30	PMOD
32	and	and	O	CC	O	18	VMOD
33	conversely	conversely	B-VP	RB	O	18	VMOD
34	increase	increase	I-VP	VBP	O	18	VMOD
35	threshold	threshold	B-NP	NN	O	34	OBJ
36	to	to	B-PP	TO	O	34	VMOD
37	PTZ	PTZ	B-NP	NN	B-protein	39	NMOD
38	induced	induce	B-VP	VBD	O	39	NMOD
39	seizures	seizure	B-NP	NNS	O	41	NMOD
40	24	24	B-NP	CD	O	39	NMOD
41	h	h	I-NP	NN	O	36	PMOD
42	after	after	B-PP	IN	O	34	VMOD
43	exposure	exposure	B-NP	NN	O	42	PMOD
44	to	to	B-PP	TO	O	43	NMOD
45	gamma-HCH	gamma-HCH	B-NP	NN	O	44	PMOD
46	(	(	O	(	O	51	DEP
47	Vohland	Vohland	B-NP	NNP	O	50	NMOD
48	et	et	I-NP	FW	O	47	NMOD
49	al.	al.	I-NP	FW	O	48	AMOD
50	1981	1981	I-NP	CD	O	51	DEP
51	)	)	O	)	O	14	VMOD
52	.	.	O	.	O	14	P

1	In	In	B-PP	IN	O	13	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	13	P
5	the	the	B-NP	DT	O	6	NMOD
6	severity	severity	I-NP	NN	O	13	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	response	response	B-NP	NN	O	7	PMOD
9	to	to	B-PP	TO	O	6	NMOD
10	other	other	B-NP	JJ	O	12	NMOD
11	seizure-inducing	seizure-inducing	I-NP	JJ	O	12	NMOD
12	agents	agent	I-NP	NNS	O	9	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	tested	test	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	mice	mouse	B-NP	NNS	O	20	NMOD
17	1	1	I-NP	CD	O	19	AMOD
18	and	and	I-NP	CC	O	19	AMOD
19	24	24	I-NP	CD	O	20	NMOD
20	h	h	I-NP	NN	O	15	PMOD
21	after	after	B-SBAR	IN	O	13	VMOD
22	intraperitoneal	intraperitoneal	B-NP	JJ	O	23	NMOD
23	administration	administration	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	80	80	B-NP	CD	O	27	NMOD
26	mg/kg	mg/kg	I-NP	NN	O	27	NMOD
27	gamma-HCH	gamma-HCH	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	13	P

1	One	One	B-NP	CD	O	2	NMOD
2	hour	hour	I-NP	NN	O	0	ROOT
3	after	after	B-SBAR	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	administration	administration	I-NP	NN	O	10	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	gamma-HCH	gamma-HCH	B-NP	NN	B-protein	6	PMOD
8	,	,	O	,	O	10	P
9	the	the	B-NP	DT	O	10	NMOD
10	activity	activity	I-NP	NN	O	14	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	seizure-inducing	seizure-inducing	B-NP	JJ	O	13	NMOD
13	agents	agent	I-NP	NNS	O	11	PMOD
14	was	be	B-VP	VBD	O	3	SBAR
15	increased	increase	I-VP	VBN	O	14	VC
16	,	,	O	,	O	15	P
17	regardless	regardless	B-ADVP	RB	O	15	VMOD
18	of	of	B-PP	IN	O	17	AMOD
19	their	their	B-NP	PRP$	O	20	NMOD
20	mechanism	mechanism	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	2	P
22	while	while	B-SBAR	IN	O	2	NMOD
23	24	24	B-NP	CD	O	24	NMOD
24	h	h	I-NP	NN	O	29	NMOD
25	after	after	B-PP	IN	O	24	NMOD
26	gamma-HCH	gamma-HCH	B-VP	NN	O	25	PMOD
27	a	a	B-NP	DT	O	29	NMOD
28	differential	differential	I-NP	JJ	O	29	NMOD
29	response	response	I-NP	NN	O	30	SUB
30	was	be	B-VP	VBD	O	22	SBAR
31	observed	observe	I-VP	VBN	O	30	VC
32	.	.	O	.	O	2	P

1	Seizure	Seizure	B-NP	NN	O	2	NMOD
2	activity	activity	I-NP	NN	O	11	SUB
3	due	due	B-PP	IN	O	2	NMOD
4	to	to	B-PP	TO	O	3	PMOD
5	PTZ	PTZ	B-NP	NN	B-protein	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	picrotoxin	picrotoxin	I-NP	NN	O	4	PMOD
8	(	(	O	(	O	10	DEP
9	PTX	PTX	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	was	be	B-VP	VBD	O	45	VMOD
12	significantly	significantly	I-VP	RB	O	11	VMOD
13	decreased	decrease	I-VP	VBN	O	11	VC
14	;	;	O	:	O	45	P
15	however	however	B-ADVP	RB	O	45	VMOD
16	,	,	O	,	O	45	P
17	seizure	seizure	B-NP	NN	O	18	NMOD
18	activity	activity	I-NP	NN	O	41	NMOD
19	due	due	B-PP	IN	O	18	NMOD
20	to	to	B-PP	TO	O	19	PMOD
21	3-mercaptopropionic	3-mercaptopropionic	B-NP	JJ	O	22	NMOD
22	acid	acid	I-NP	NN	O	20	PMOD
23	(	(	O	(	O	25	DEP
24	MPA	MPA	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	,	,	O	,	O	41	P
27	bicuculline	bicuculline	B-NP	NN	O	41	NMOD
28	(	(	O	(	O	30	DEP
29	BCC	BCC	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	,	,	O	,	O	41	P
32	methyl	methyl	B-NP	NN	O	41	NMOD
33	6	6	I-NP	CD	O	32	NMOD
34	,	,	O	,	O	41	P
35	7-dimethoxy-4-ethyl-B-carboline-3-carboxylate	7-dimethoxy-4-ethyl-B-carboline-3-carboxylate	B-NP	NN	O	41	NMOD
36	(	(	O	(	O	38	DEP
37	DMCM	DMCM	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	,	,	O	,	O	41	P
40	or	or	O	CC	O	41	NMOD
41	strychnine	strychnine	B-NP	NN	O	45	SUB
42	(	(	O	(	O	44	DEP
43	STR	STR	B-NP	NN	B-protein	44	DEP
44	)	)	O	)	O	41	NMOD
45	was	be	B-VP	VBD	O	0	ROOT
46	not	not	O	RB	O	45	VMOD
47	different	different	B-ADJP	JJ	O	45	PRD
48	from	from	B-PP	IN	O	47	AMOD
49	control	control	B-NP	NN	O	48	PMOD
50	.	.	O	.	O	45	P

1	The	The	B-NP	DT	O	4	NMOD
2	pharmacological	pharmacological	I-NP	JJ	O	4	NMOD
3	challenge	challenge	I-NP	NN	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	suggest	suggest	B-VP	VBP	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	tolerance	tolerance	B-NP	NN	O	8	SUB
8	may	may	B-VP	MD	O	6	SBAR
9	occur	occur	I-VP	VB	O	8	VC
10	to	to	B-PP	TO	O	9	VMOD
11	seizure	seizure	B-NP	NN	O	12	NMOD
12	activity	activity	I-NP	NN	O	10	PMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	PTZ	PTZ	B-NP	NN	B-protein	19	NMOD
16	and	and	I-NP	CC	O	19	NMOD
17	PTX	PTX	I-NP	NN	O	19	NMOD
18	24	24	I-NP	CD	O	19	NMOD
19	h	h	I-NP	NN	O	14	PMOD
20	after	after	B-PP	IN	O	13	VMOD
21	gamma-HCH	gamma-HCH	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	8	P
23	since	since	B-SBAR	IN	O	8	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	response	response	I-NP	NN	O	32	SUB
26	to	to	B-PP	TO	O	25	NMOD
27	only	only	B-NP	RB	O	31	NMOD
28	these	these	I-NP	DT	O	27	AMOD
29	two	two	I-NP	CD	O	27	AMOD
30	seizure-inducing	seizure-inducing	I-NP	JJ	O	27	NMOD
31	agents	agent	I-NP	NNS	O	26	PMOD
32	is	be	B-VP	VBZ	O	23	SBAR
33	decreased	decrease	I-VP	VBN	O	32	VC
34	.	.	O	.	O	5	P

1	Severe	Severe	B-NP	JJ	O	4	AMOD
2	ocular	ocular	I-NP	JJ	O	4	AMOD
3	and	and	I-NP	CC	O	4	AMOD
4	orbital	orbital	I-NP	JJ	O	5	NMOD
5	toxicity	toxicity	I-NP	NN	O	0	ROOT
6	after	after	B-PP	IN	O	5	NMOD
7	intracarotid	intracarotid	B-NP	JJ	O	8	NMOD
8	injection	injection	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	carboplatin	carboplatin	B-NP	NN	B-protein	9	PMOD
11	for	for	B-PP	IN	O	8	NMOD
12	recurrent	recurrent	B-NP	JJ	O	13	NMOD
13	glioblastomas	glioblastoma	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	5	P

1	Generally	Generally	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	carboplatin	carboplatin	B-NP	NN	B-protein	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	said	say	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	have	have	I-VP	VB	O	5	VMOD
8	milder	mild	B-NP	JJR	O	10	NMOD
9	side	side	I-NP	NN	O	10	NMOD
10	effects	effect	I-NP	NNS	O	7	OBJ
11	than	than	B-PP	IN	O	10	NMOD
12	cisplatin	cisplatin	B-NP	NN	O	18	NMOD
13	,	,	O	,	O	12	P
14	whose	whose	B-NP	WP$	O	18	NMOD
15	ocular	ocular	I-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	orbital	orbital	I-NP	JJ	O	18	NMOD
18	toxicity	toxicity	I-NP	NN	O	11	PMOD
19	are	be	B-VP	VBP	O	4	VMOD
20	well	well	B-ADJP	RB	O	19	VMOD
21	known	know	I-ADJP	VBN	O	19	VC
22	.	.	O	.	O	4	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	experienced	experience	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	severe	severe	B-NP	JJ	O	9	NMOD
9	ocular	ocular	I-NP	JJ	O	11	AMOD
10	and	and	I-NP	CC	O	11	AMOD
11	orbital	orbital	I-NP	JJ	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	7	PMOD
13	after	after	B-PP	IN	O	4	VMOD
14	intracarotid	intracarotid	B-NP	JJ	O	15	NMOD
15	injection	injection	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	carboplatin	carboplatin	B-NP	NN	B-protein	16	PMOD
18	,	,	O	,	O	17	P
19	which	which	B-NP	WDT	O	17	NMOD
20	is	be	B-VP	VBZ	O	19	SBAR
21	infrequently	infrequently	I-VP	RB	O	20	VMOD
22	reported	report	I-VP	VBN	O	20	VC
23	.	.	O	.	O	4	P

1	CASE	CASE	B-NP	NN	B-protein	5	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	58-year-old	58-year-old	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	6	SUB
6	received	receive	B-VP	VBD	O	0	ROOT
7	an	an	B-NP	DT	O	9	NMOD
8	intracarotid	intracarotid	I-NP	JJ	O	9	NMOD
9	injection	injection	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	carboplatin	carboplatin	B-NP	NN	B-protein	10	PMOD
12	for	for	B-PP	IN	O	9	NMOD
13	recurrent	recurrent	B-NP	JJ	O	14	NMOD
14	glioblastomas	glioblastoma	I-NP	NNS	O	12	PMOD
15	in	in	B-PP	IN	O	6	VMOD
16	his	his	B-NP	PRP$	O	19	NMOD
17	left	left	I-NP	JJ	O	19	NMOD
18	temporal	temporal	I-NP	JJ	O	19	NMOD
19	lobe	lobe	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	6	P

1	Various	Various	B-NP	JJ	O	3	NMOD
2	ocular	ocular	I-NP	JJ	O	3	NMOD
3	symptoms	symptom	I-NP	NNS	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	findings	finding	I-NP	NNS	O	10	SUB
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	carboplatin	carboplatin	B-NP	NN	O	9	NMOD
9	toxicity	toxicity	I-NP	NN	O	7	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	seen	see	I-VP	VBN	O	10	VC
12	.	.	O	.	O	10	P

1	Phase	Phase	B-NP	NN	O	3	NMOD
2	II	II	I-NP	CD	O	3	NMOD
3	study	study	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	amsacrine	amsacrine	I-NP	NN	O	8	NMOD
7	analogue	analogue	I-NP	NN	O	8	NMOD
8	CI-921	CI-921	I-NP	NN	O	4	PMOD
9	(	(	O	(	O	12	DEP
10	NSC	NSC	B-NP	NN	B-protein	12	DEP
11	343499	343499	I-NP	CD	I-protein	10	NMOD
12	)	)	O	)	O	8	NMOD
13	in	in	B-PP	IN	O	3	NMOD
14	non-small	non-small	B-NP	JJ	O	17	NMOD
15	cell	cell	I-NP	NN	O	17	NMOD
16	lung	lung	I-NP	NN	O	17	NMOD
17	cancer	cancer	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	3	P

1	Alpha-lipoic	Alpha-lipoic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	3	SUB
3	prevents	prevent	B-VP	VBZ	O	0	ROOT
4	mitochondrial	mitochondrial	B-NP	JJ	O	5	NMOD
5	damage	damage	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	neurotoxicity	neurotoxicity	I-NP	NN	O	3	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	experimental	experimental	B-NP	JJ	O	11	NMOD
10	chemotherapy	chemotherapy	I-NP	NN	O	11	NMOD
11	neuropathy	neuropathy	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	investigates	investigate	B-VP	VBZ	O	0	ROOT
4	if	if	B-SBAR	IN	O	3	VMOD
5	alpha-lipoic	alpha-lipoic	B-NP	JJ	O	6	NMOD
6	acid	acid	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	4	SBAR
8	neuroprotective	neuroprotective	B-ADJP	JJ	O	7	PRD
9	against	against	B-PP	IN	O	8	AMOD
10	chemotherapy	chemotherapy	B-NP	NN	O	12	NMOD
11	induced	induce	B-VP	VBD	O	12	NMOD
12	neurotoxicity	neurotoxicity	B-NP	NN	O	9	PMOD
13	,	,	O	,	O	3	P
14	if	if	B-SBAR	IN	O	3	VMOD
15	mitochondrial	mitochondrial	B-NP	JJ	O	16	NMOD
16	damage	damage	I-NP	NN	O	17	SUB
17	plays	play	B-VP	VBZ	O	14	SBAR
18	a	a	B-NP	DT	O	20	NMOD
19	critical	critical	I-NP	JJ	O	20	NMOD
20	role	role	I-NP	NN	O	17	OBJ
21	in	in	B-PP	IN	O	17	VMOD
22	toxic	toxic	B-NP	JJ	O	24	NMOD
23	neurodegenerative	neurodegenerative	I-NP	JJ	O	24	NMOD
24	cascade	cascade	I-NP	NN	O	21	PMOD
25	,	,	O	,	O	27	P
26	and	and	O	CC	O	27	DEP
27	if	if	B-SBAR	IN	O	3	VMOD
28	neuroprotective	neuroprotective	B-NP	JJ	O	29	NMOD
29	effects	effect	I-NP	NNS	O	33	SUB
30	of	of	B-PP	IN	O	29	NMOD
31	alpha-lipoic	alpha-lipoic	B-NP	JJ	O	32	NMOD
32	acid	acid	I-NP	NN	O	30	PMOD
33	depend	depend	B-VP	VBP	O	27	SBAR
34	on	on	B-PP	IN	O	33	VMOD
35	mitochondria	mitochondrion	B-NP	NNS	O	36	NMOD
36	protection	protection	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	an	an	B-NP	DT	O	6	NMOD
4	in	in	I-NP	FW	O	5	AMOD
5	vitro	vitro	I-NP	FW	O	6	NMOD
6	model	model	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	chemotherapy	chemotherapy	B-NP	NN	O	11	NMOD
9	induced	induced	I-NP	JJ	O	11	NMOD
10	peripheral	peripheral	I-NP	JJ	O	11	NMOD
11	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
12	that	that	B-NP	WDT	O	6	NMOD
13	closely	closely	B-ADVP	RB	O	14	VMOD
14	mimic	mimic	B-VP	VBP	O	12	SBAR
15	the	the	B-NP	DT	O	18	NMOD
16	in	in	I-NP	FW	O	17	AMOD
17	vivo	vivo	I-NP	FW	O	18	NMOD
18	condition	condition	I-NP	NN	O	14	OBJ
19	by	by	B-PP	IN	O	14	VMOD
20	exposing	expose	B-VP	VBG	O	19	PMOD
21	primary	primary	B-NP	JJ	B-cell_line	22	NMOD
22	cultures	culture	I-NP	NNS	I-cell_line	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	dorsal	dorsal	B-NP	JJ	B-protein	31	NMOD
25	root	root	I-NP	NN	I-protein	31	NMOD
26	ganglion	ganglion	I-NP	NN	I-protein	31	NMOD
27	(	(	O	(	I-protein	31	NMOD
28	DRG	DRG	B-NP	NN	I-protein	31	NMOD
29	)	)	O	)	I-protein	31	NMOD
30	sensory	sensory	B-NP	JJ	I-protein	31	NMOD
31	neurons	neuron	I-NP	NNS	I-protein	23	PMOD
32	to	to	B-PP	TO	O	20	VMOD
33	paclitaxel	paclitaxel	B-NP	NN	O	35	NMOD
34	and	and	I-NP	CC	O	35	NMOD
35	cisplatin	cisplatin	I-NP	NN	O	32	PMOD
36	,	,	O	,	O	20	P
37	two	two	B-NP	CD	O	44	NMOD
38	widely	widely	I-NP	RB	O	39	AMOD
39	used	use	I-NP	VBN	O	37	NMOD
40	and	and	O	CC	O	44	NMOD
41	highly	highly	B-NP	RB	O	42	AMOD
42	effective	effective	I-NP	JJ	O	44	NMOD
43	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	44	NMOD
44	drugs	drug	I-NP	NNS	O	20	OBJ
45	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	approach	approach	I-NP	NN	O	3	SUB
3	allowed	allow	B-VP	VBD	O	0	ROOT
4	investigating	investigate	I-VP	VBG	O	3	VC
5	the	the	B-NP	DT	O	6	NMOD
6	efficacy	efficacy	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	alpha-lipoic	alpha-lipoic	B-NP	JJ	O	9	NMOD
9	acid	acid	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	4	VMOD
11	preventing	prevent	B-VP	VBG	O	10	PMOD
12	axonal	axonal	B-NP	JJ	O	13	NMOD
13	damage	damage	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	apoptosis	apoptosis	I-NP	NN	O	21	NMOD
16	and	and	O	CC	O	21	NMOD
17	the	the	B-NP	DT	O	21	NMOD
18	function	function	I-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	ultrastructural	ultrastructural	I-NP	JJ	O	21	NMOD
21	morphology	morphology	I-NP	NN	O	11	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	mitochondria	mitochondrion	B-NP	NNS	O	22	PMOD
24	after	after	B-PP	IN	O	11	VMOD
25	exposure	exposure	B-NP	NN	O	31	NMOD
26	to	to	B-PP	TO	O	25	NMOD
27	toxic	toxic	B-NP	JJ	O	28	NMOD
28	agents	agent	I-NP	NNS	O	26	PMOD
29	and	and	O	CC	O	31	NMOD
30	alpha-lipoic	alpha-lipoic	B-NP	JJ	O	31	NMOD
31	acid	acid	I-NP	NN	O	24	PMOD
32	.	.	O	.	O	3	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	both	both	O	CC	O	8	NMOD
6	cisplatin	cisplatin	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	paclitaxel	paclitaxel	I-NP	NN	O	9	SUB
9	cause	cause	B-VP	VBP	O	4	SBAR
10	early	early	B-NP	JJ	O	12	NMOD
11	mitochondrial	mitochondrial	I-NP	JJ	O	12	NMOD
12	impairment	impairment	I-NP	NN	O	19	NMOD
13	with	with	B-PP	IN	O	12	NMOD
14	loss	loss	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	membrane	membrane	B-NP	NN	O	17	NMOD
17	potential	potential	I-NP	NN	O	15	PMOD
18	and	and	O	CC	O	19	NMOD
19	induction	induction	B-NP	NN	O	9	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	autophagic	autophagic	B-NP	JJ	O	22	NMOD
22	vacuoles	vacuole	I-NP	NNS	O	20	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	neurons	neuron	B-NP	NNS	B-cell_type	23	PMOD
25	.	.	O	.	O	3	P

1	Alpha-lipoic	Alpha-lipoic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	3	SUB
3	exerts	exert	B-VP	VBZ	O	15	VMOD
4	neuroprotective	neuroprotective	B-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	OBJ
6	against	against	B-PP	IN	O	3	VMOD
7	chemotherapy	chemotherapy	B-NP	NN	O	9	NMOD
8	induced	induce	B-VP	VBD	O	9	NMOD
9	neurotoxicity	neurotoxicity	B-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	sensory	sensory	B-NP	JJ	O	12	NMOD
12	neurons	neuron	I-NP	NNS	O	10	PMOD
13	:	:	O	:	O	15	P
14	it	it	B-NP	PRP	O	15	SUB
15	rescues	rescue	B-VP	VBZ	O	0	ROOT
16	the	the	B-NP	DT	O	18	NMOD
17	mitochondrial	mitochondrial	I-NP	JJ	O	18	NMOD
18	toxicity	toxicity	I-NP	NN	O	15	OBJ
19	and	and	O	CC	O	15	VMOD
20	induces	induce	B-VP	VBZ	O	15	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	expression	expression	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	frataxin	frataxin	B-NP	NN	O	27	NMOD
25	,	,	O	,	O	27	P
26	an	an	B-NP	DT	O	27	NMOD
27	essential	essential	I-NP	JJ	O	23	PMOD
28	mitochondrial	mitochondrial	I-NP	JJ	B-protein	29	NMOD
29	protein	protein	I-NP	NN	I-protein	27	NMOD
30	with	with	B-PP	IN	O	27	NMOD
31	anti-oxidant	anti-oxidant	B-NP	JJ	O	34	NMOD
32	and	and	I-NP	CC	O	34	NMOD
33	chaperone	chaperone	I-NP	NN	O	34	NMOD
34	properties	property	I-NP	NNS	O	30	PMOD
35	.	.	O	.	O	15	P

1	In	In	B-PP	IN	O	5	VMOD
2	conclusion	conclusion	B-NP	NN	O	4	NMOD
3	mitochondrial	mitochondrial	I-NP	JJ	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	an	an	B-NP	DT	O	9	NMOD
7	early	early	I-NP	JJ	O	8	AMOD
8	common	common	I-NP	JJ	O	9	NMOD
9	event	event	I-NP	NN	O	5	PRD
10	both	both	B-PP	CC	O	11	PMOD
11	in	in	B-PP	IN	O	5	VMOD
12	paclitaxel	paclitaxel	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	cisplatin	cisplatin	I-NP	NN	O	15	SUB
15	induced	induce	B-VP	VBD	O	11	SBAR
16	neurotoxicity	neurotoxicity	B-NP	NN	O	15	OBJ
17	.	.	O	.	O	5	P

1	Pooled	Pool	B-NP	VBN	O	2	NMOD
2	data	datum	I-NP	NNS	O	10	SUB
3	from	from	B-PP	IN	O	2	NMOD
4	trials	trial	B-NP	NNS	O	3	PMOD
5	comparing	compare	B-VP	VBG	O	4	NMOD
6	antithrombotic	antithrombotic	B-NP	JJ	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	OBJ
8	with	with	B-PP	IN	O	5	VMOD
9	placebo	placebo	B-NP	NN	O	8	PMOD
10	have	have	B-VP	VBP	O	0	ROOT
11	shown	show	I-VP	VBN	O	10	VC
12	that	that	B-SBAR	IN	O	24	DEP
13	warfarin	warfarin	B-NP	NN	O	14	SUB
14	reduces	reduce	B-VP	VBZ	O	12	SBAR
15	the	the	B-NP	DT	O	16	NMOD
16	risk	risk	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	stroke	stroke	B-NP	NN	O	17	PMOD
19	by	by	B-PP	IN	O	14	VMOD
20	62	62	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	DEP
24	that	that	B-SBAR	IN	O	11	VMOD
25	aspirin	aspirin	B-NP	NN	O	27	SUB
26	alone	alone	B-ADVP	RB	O	25	NMOD
27	reduces	reduce	B-VP	VBZ	O	24	SBAR
28	the	the	B-NP	DT	O	29	NMOD
29	risk	risk	I-NP	NN	O	27	OBJ
30	by	by	B-PP	IN	O	27	VMOD
31	22	22	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	10	P

1	Overall	Overall	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	in	in	B-PP	IN	O	8	VMOD
4	high-risk	high-risk	B-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	8	P
7	warfarin	warfarin	B-NP	NN	O	8	SUB
8	is	be	B-VP	VBZ	O	0	ROOT
9	superior	superior	B-ADJP	JJ	O	8	PRD
10	to	to	B-PP	TO	O	9	AMOD
11	aspirin	aspirin	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	9	AMOD
13	preventing	prevent	B-VP	VBG	O	12	PMOD
14	strokes	stroke	B-NP	NNS	O	13	OBJ
15	,	,	O	,	O	8	P
16	with	with	B-PP	IN	O	8	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	relative	relative	I-NP	JJ	O	20	NMOD
19	risk	risk	I-NP	NN	O	20	NMOD
20	reduction	reduction	I-NP	NN	O	16	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	36	36	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	8	P

1	Ximelagatran	Ximelagatran	B-NP	NN	O	7	NMOD
2	,	,	O	,	O	7	P
3	an	an	B-NP	DT	O	7	NMOD
4	oral	oral	I-NP	JJ	O	7	NMOD
5	direct	direct	I-NP	JJ	O	7	NMOD
6	thrombin	thrombin	I-NP	NN	B-protein	7	NMOD
7	inhibitor	inhibitor	I-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	was	be	B-VP	VBD	O	0	ROOT
10	found	find	I-VP	VBN	O	9	VC
11	to	to	I-VP	TO	O	12	VMOD
12	be	be	I-VP	VB	O	10	VMOD
13	as	as	B-ADJP	RB	O	14	AMOD
14	efficient	efficient	I-ADJP	JJ	O	12	PRD
15	as	as	B-PP	IN	O	14	AMOD
16	vitamin	vitamin	B-NP	NN	O	19	NMOD
17	K	K	I-NP	NN	O	19	NMOD
18	antagonist	antagonist	I-NP	NN	O	19	NMOD
19	drugs	drug	I-NP	NNS	O	15	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	prevention	prevention	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	embolic	embolic	B-NP	JJ	O	25	NMOD
25	events	event	I-NP	NNS	O	23	PMOD
26	,	,	O	,	O	9	P
27	but	but	O	CC	O	9	VMOD
28	has	have	B-VP	VBZ	O	9	VMOD
29	been	be	I-VP	VBN	O	28	VC
30	recently	recently	I-VP	RB	O	29	VMOD
31	withdrawn	withdraw	I-VP	VBN	O	29	VC
32	because	because	B-PP	IN	O	31	VMOD
33	of	of	I-PP	IN	O	32	PMOD
34	abnormal	abnormal	B-NP	JJ	O	37	NMOD
35	liver	liver	I-NP	NN	O	37	NMOD
36	function	function	I-NP	NN	O	37	NMOD
37	tests	test	I-NP	NNS	O	33	PMOD
38	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	ACTIVE-W	ACTIVE-W	I-NP	NN	O	16	NMOD
3	(	(	O	(	O	15	DEP
4	Atrial	Atrial	B-NP	JJ	O	7	NMOD
5	Fibrillation	Fibrillation	I-NP	NN	O	7	NMOD
6	Clopidogrel	Clopidogrel	I-NP	NN	O	7	NMOD
7	Trial	Trial	I-NP	NN	O	15	DEP
8	with	with	B-PP	IN	O	7	NMOD
9	Irbesartan	Irbesartan	B-NP	NN	O	8	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	Prevention	Prevention	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	Vascular	Vascular	B-NP	JJ	O	14	NMOD
14	Events	Event	I-NP	NNS	O	12	PMOD
15	)	)	O	)	O	2	NMOD
16	study	study	B-NP	NN	O	17	SUB
17	has	have	B-VP	VBZ	O	0	ROOT
18	demonstrated	demonstrate	I-VP	VBN	O	17	VC
19	that	that	B-SBAR	IN	O	18	VMOD
20	warfarin	warfarin	B-NP	NN	O	21	SUB
21	is	be	B-VP	VBZ	O	19	SBAR
22	superior	superior	B-ADJP	JJ	O	21	PRD
23	to	to	B-PP	TO	O	22	AMOD
24	platelet	platelet	B-NP	NN	O	25	NMOD
25	therapy	therapy	I-NP	NN	O	23	PMOD
26	(	(	O	(	O	30	DEP
27	clopidogrel	clopidogrel	B-NP	NN	O	29	NMOD
28	plus	plus	O	CC	O	29	NMOD
29	aspirin	aspirin	B-NP	NN	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	in	in	B-PP	IN	O	25	NMOD
32	the	the	B-NP	DT	O	33	NMOD
33	prevention	prevention	I-NP	NN	O	31	PMOD
34	af	af	B-PP	IN	O	25	NMOD
35	embolic	embolic	B-NP	JJ	O	36	NMOD
36	events	event	I-NP	NNS	O	34	PMOD
37	.	.	O	.	O	17	P

1	Idraparinux	Idraparinux	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	a	a	B-NP	DT	O	6	NMOD
4	Factor	Factor	I-NP	NN	O	6	NMOD
5	Xa	Xa	I-NP	NN	O	6	NMOD
6	inhibitor	inhibitor	I-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	is	be	B-VP	VBZ	O	0	ROOT
9	being	be	I-VP	VBG	O	8	VC
10	evaluated	evaluate	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	atrial	atrial	B-NP	JJ	O	15	NMOD
15	fibrillation	fibrillation	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	8	P

1	Angiotensin-converting	Angiotensin-converting	B-NP	JJ	O	3	NMOD
2	enzyme	enzyme	I-NP	NN	O	3	NMOD
3	inhibitors	inhibitor	I-NP	NNS	O	8	NMOD
4	and	and	O	CC	O	8	NMOD
5	angiotensin	angiotensin	B-NP	NN	O	8	NMOD
6	II	II	I-NP	CD	O	8	NMOD
7	receptor-blocking	receptor-blocking	I-NP	JJ	O	8	NMOD
8	drugs	drug	I-NP	NNS	O	9	SUB
9	hold	hold	B-VP	VBP	O	0	ROOT
10	promise	promise	B-NP	NN	O	9	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	atrial	atrial	B-NP	JJ	O	13	NMOD
13	fibrillation	fibrillation	I-NP	NN	O	11	PMOD
14	through	through	B-PP	IN	O	10	NMOD
15	cardiac	cardiac	B-NP	JJ	O	16	NMOD
16	remodelling	remodelling	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	3	NMOD
2	synergistic	synergistic	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	etoposide	etoposide	B-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	cyclosporin	cyclosporin	B-NP	NN	O	8	NMOD
8	A	A	I-NP	NN	O	4	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	observed	observe	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	13	NMOD
13	patient	patient	I-NP	NN	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	acute	acute	B-NP	JJ	O	17	NMOD
16	T-lymphocytic	T-lymphocytic	I-NP	JJ	O	17	NMOD
17	leukemia	leukemia	I-NP	NN	O	14	PMOD
18	in	in	B-PP	IN	O	13	NMOD
19	relapse	relapse	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	concomitant	concomitant	I-NP	JJ	O	3	NMOD
3	administration	administration	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	etoposide	etoposide	B-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	cyclosporin	cyclosporin	B-NP	NN	O	8	NMOD
8	A	A	I-NP	NN	O	4	PMOD
9	resulted	result	B-VP	VBD	O	0	ROOT
10	in	in	B-PP	IN	O	9	VMOD
11	eradication	eradication	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	hitherto	hitherto	B-NP	NN	O	16	NMOD
14	refractory	refractory	I-NP	JJ	O	16	NMOD
15	leukemic	leukemic	I-NP	JJ	O	16	NMOD
16	infiltration	infiltration	I-NP	NN	O	12	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	bone	bone	B-NP	NN	O	19	NMOD
19	marrow	marrow	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	hematologic	hematologic	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	14	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	cefonicid	cefonicid	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	cefazedone	cefazedone	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	3	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	dog	dog	I-NP	NN	O	8	PMOD
11	:	:	O	:	O	3	P
12	a	a	B-NP	DT	O	14	NMOD
13	potential	potential	I-NP	JJ	O	14	NMOD
14	model	model	I-NP	NN	O	0	ROOT
15	of	of	B-PP	IN	O	14	NMOD
16	cephalosporin	cephalosporin	B-NP	NN	O	17	NMOD
17	hematotoxicity	hematotoxicity	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	man	man	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	14	P

1	Cephalosporin	Cephalosporin	B-NP	NN	O	2	NMOD
2	antibiotics	antibiotic	I-NP	NNS	O	3	SUB
3	cause	cause	B-VP	VBP	O	0	ROOT
4	a	a	B-NP	DT	O	5	NMOD
5	variety	variety	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	hematologic	hematologic	B-NP	JJ	O	8	NMOD
8	disturbances	disturbance	I-NP	NNS	O	6	PMOD
9	in	in	B-PP	IN	O	3	VMOD
10	man	man	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	3	P
12	the	the	B-NP	DT	O	13	NMOD
13	pathogeneses	pathogenes	I-NP	NNS	O	3	OBJ
14	and	and	I-NP	CC	O	15	NMOD
15	hematopathology	hematopathology	I-NP	NN	O	16	NMOD
16	of	of	B-PP	IN	O	13	NMOD
17	which	which	B-NP	WDT	O	16	PMOD
18	remain	remain	B-VP	VBP	O	16	SBAR
19	poorly	poorly	B-ADJP	RB	O	20	VMOD
20	characterized	characterize	I-ADJP	VBN	O	18	VC
21	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	17	VMOD
2	four	four	B-NP	CD	O	5	NMOD
3	subacute	subacute	I-NP	JJ	O	5	NMOD
4	toxicity	toxicity	I-NP	NN	O	5	NMOD
5	studies	study	I-NP	NNS	O	1	PMOD
6	,	,	O	,	O	17	P
7	the	the	B-NP	DT	O	9	NMOD
8	intravenous	intravenous	I-NP	JJ	O	9	NMOD
9	administration	administration	I-NP	NN	O	17	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	cefonicid	cefonicid	B-NP	NN	O	13	NMOD
12	or	or	I-NP	CC	O	13	NMOD
13	cefazedone	cefazedone	I-NP	NN	O	10	PMOD
14	to	to	B-PP	TO	O	9	NMOD
15	beagle	beagle	B-NP	NN	O	16	NMOD
16	dogs	dog	I-NP	NNS	O	14	PMOD
17	caused	cause	B-VP	VBD	O	0	ROOT
18	a	a	B-NP	DT	O	20	NMOD
19	dose-dependent	dose-dependent	I-NP	JJ	O	20	NMOD
20	incidence	incidence	I-NP	NN	O	17	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	anemia	anemia	B-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	neutropenia	neutropenia	B-NP	NN	O	27	NMOD
25	,	,	O	,	O	27	P
26	and	and	O	CC	O	27	NMOD
27	thrombocytopenia	thrombocytopenia	B-NP	NN	O	21	PMOD
28	after	after	B-PP	IN	O	27	NMOD
29	1-3	1-3	B-NP	CD	O	30	NMOD
30	months	month	I-NP	NNS	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	treatment	treatment	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	17	P

1	A	A	B-NP	DT	O	3	NMOD
2	nonregenerative	nonregenerative	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	most	most	I-NP	RBS	O	7	AMOD
7	compromising	compromising	I-NP	JJ	O	4	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	cytopenias	cytopenia	I-NP	NNS	O	8	PMOD
11	and	and	O	CC	O	4	VMOD
12	occurred	occur	B-VP	VBD	O	4	VMOD
13	in	in	B-PP	IN	O	12	VMOD
14	approximately	approximately	B-NP	RB	O	16	NMOD
15	50	50	I-NP	CD	O	14	AMOD
16	%	%	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	dogs	dog	B-NP	NNS	O	17	PMOD
19	receiving	receive	B-VP	VBG	O	18	NMOD
20	400-500	400-500	B-NP	CD	O	22	NMOD
21	mg/kg	mg/kg	I-NP	NN	O	22	NMOD
22	cefonicid	cefonicid	I-NP	NN	O	26	NMOD
23	or	or	O	CC	O	26	NMOD
24	540-840	540-840	B-NP	CD	O	26	NMOD
25	mg/kg	mg/kg	I-NP	NN	O	26	NMOD
26	cefazedone	cefazedone	I-NP	NN	O	19	OBJ
27	.	.	O	.	O	4	P

1	Upon	Upon	B-PP	IN	O	10	VMOD
2	rechallenge	rechallenge	B-NP	NN	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	either	either	O	CC	O	5	NMOD
5	cephalosporin	cephalosporin	B-NP	NN	O	3	PMOD
6	,	,	O	,	O	10	P
7	the	the	B-NP	DT	O	9	NMOD
8	hematologic	hematologic	I-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	reproduced	reproduce	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	most	most	B-NP	JJS	O	14	NMOD
14	dogs	dog	I-NP	NNS	O	12	PMOD
15	tested	test	B-VP	VBN	O	14	NMOD
16	;	;	O	:	O	10	P
17	cefonicid	cefonicid	B-NP	NN	O	10	VMOD
18	(	(	O	(	O	17	NMOD
19	but	but	O	CC	O	25	VMOD
20	not	not	O	RB	O	19	DEP
21	cefazedone	cefazedone	B-NP	NN	O	24	NMOD
22	)	)	O	)	O	24	NMOD
23	-treated	-treated	B-NP	JJ	O	24	NMOD
24	dogs	dog	I-NP	NNS	O	25	SUB
25	showed	show	B-VP	VBD	O	18	SBAR
26	a	a	B-NP	DT	O	30	NMOD
27	substantially	substantially	I-NP	RB	O	28	AMOD
28	reduced	reduce	I-NP	VBN	O	30	NMOD
29	induction	induction	I-NP	NN	O	30	NMOD
30	period	period	I-NP	NN	O	25	OBJ
31	(	(	O	(	O	36	DEP
32	15	15	B-NP	CD	O	34	AMOD
33	+/-	+/-	I-NP	CC	O	34	AMOD
34	5	5	I-NP	CD	O	35	NMOD
35	days	day	I-NP	NNS	O	36	DEP
36	)	)	O	)	O	30	NMOD
37	compared	compare	B-VP	VBN	O	25	VMOD
38	to	to	B-PP	TO	O	37	PMOD
39	that	that	B-NP	DT	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	the	the	B-NP	DT	O	43	NMOD
42	first	first	I-NP	JJ	O	43	NMOD
43	exposure	exposure	I-NP	NN	O	40	PMOD
44	to	to	B-PP	TO	O	43	NMOD
45	the	the	B-NP	DT	O	46	NMOD
46	drug	drug	I-NP	NN	O	44	PMOD
47	(	(	O	(	O	52	DEP
48	61	61	B-NP	CD	O	50	AMOD
49	+/-	+/-	I-NP	CC	O	50	AMOD
50	24	24	I-NP	CD	O	51	NMOD
51	days	day	I-NP	NNS	O	52	DEP
52	)	)	O	)	O	43	NMOD
53	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	4	NMOD
2	pyridoxine-dependent	pyridoxine-dependent	I-NP	JJ	O	4	NMOD
3	behavioral	behavioral	I-NP	JJ	O	4	NMOD
4	disorder	disorder	I-NP	NN	O	0	ROOT
5	unmasked	unmasked	B-ADJP	JJ	O	4	NMOD
6	by	by	B-PP	IN	O	5	AMOD
7	isoniazid	isoniazid	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	3-year-old	3-year-old	I-NP	JJ	O	3	NMOD
3	girl	girl	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	behavioral	behavioral	B-NP	JJ	O	6	NMOD
6	deterioration	deterioration	I-NP	NN	O	4	OBJ
7	,	,	O	,	O	4	P
8	with	with	B-PP	IN	O	4	VMOD
9	hyperkinesis	hyperkinesis	B-NP	NN	O	15	NMOD
10	,	,	O	,	O	15	P
11	irritability	irritability	B-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	and	and	O	CC	O	15	NMOD
14	sleeping	sleep	B-VP	VBG	O	15	NMOD
15	difficulties	difficulty	B-NP	NNS	O	8	PMOD
16	after	after	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	therapeutic	therapeutic	I-NP	JJ	O	19	NMOD
19	administration	administration	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	isoniazid	isoniazid	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	4	P

1	Periodic	Periodic	B-NP	JJ	O	2	NMOD
2	withdrawal	withdrawal	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	pyridoxine	pyridoxine	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	associated	associate	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	return	return	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	hyperkinesis	hyperkinesis	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	5	P

1	NRA0160	NRA0160	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	clozapine	clozapine	I-NP	NN	O	4	SUB
4	antagonized	antagonize	B-VP	VBD	O	0	ROOT
5	locomotor	locomotor	B-NP	NN	O	6	NMOD
6	hyperactivity	hyperactivity	I-NP	NN	O	4	OBJ
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	methamphetamine	methamphetamine	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	12	DEP
11	MAP	MAP	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	in	in	B-PP	IN	O	9	NMOD
14	mice	mouse	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	4	P

1	NRA0160	NRA0160	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	clozapine	clozapine	I-NP	NN	O	5	SUB
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	catalepsy	catalepsy	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	,	,	O	,	O	5	P
10	although	although	B-SBAR	IN	O	5	VMOD
11	their	their	B-NP	PRP$	O	12	NMOD
12	effects	effect	I-NP	NNS	O	13	SUB
13	did	do	B-VP	VBD	O	10	SBAR
14	not	not	I-VP	RB	O	13	VMOD
15	exceed	exceed	I-VP	VB	O	13	VC
16	50	50	B-NP	CD	O	18	NMOD
17	%	%	I-NP	NN	O	18	NMOD
18	induction	induction	I-NP	NN	O	15	OBJ
19	even	even	B-ADVP	RB	O	20	PMOD
20	at	at	B-PP	IN	O	15	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	highest	high	I-NP	JJS	O	23	NMOD
23	dose	dose	I-NP	NN	O	20	PMOD
24	given	give	B-VP	VBN	O	23	NMOD
25	.	.	O	.	O	5	P

1	Prolonged	Prolonged	B-NP	JJ	O	2	NMOD
2	cholestasis	cholestasis	I-NP	NN	O	0	ROOT
3	after	after	B-SBAR	IN	O	2	NMOD
4	troleandomycin	troleandomycin	B-NP	NN	B-protein	5	SUB
5	induced	induce	B-VP	VBD	O	3	SBAR
6	acute	acute	B-NP	JJ	O	7	NMOD
7	hepatitis	hepatitis	I-NP	NN	O	5	OBJ
8	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	whom	whom	B-NP	WP	O	12	NMOD
10	troleandomycin	troleandomycin	B-NP	NN	B-protein	12	NMOD
11	induced	induce	I-NP	VBN	O	10	AMOD
12	hepatitis	hepatitis	I-NP	NN	O	8	PMOD
13	was	be	B-VP	VBD	O	2	VMOD
14	followed	follow	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	prolonged	prolonged	B-NP	JJ	O	18	NMOD
17	anicteric	anicteric	I-NP	JJ	O	18	NMOD
18	cholestasis	cholestasis	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	2	P

1	Jaundice	Jaundice	B-NP	NNP	O	2	SUB
2	occurred	occur	B-VP	VBD	O	0	ROOT
3	after	after	B-PP	IN	O	2	VMOD
4	administration	administration	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	troleandomycin	troleandomycin	B-NP	NN	O	5	PMOD
7	for	for	B-PP	IN	O	4	NMOD
8	7	7	B-NP	CD	O	9	NMOD
9	days	day	I-NP	NNS	O	7	PMOD
10	and	and	O	CC	O	2	VMOD
11	was	be	B-VP	VBD	O	2	VMOD
12	associated	associate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	hypereosinophilia	hypereosinophilia	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	2	P

1	Myopathy	Myopathy	B-NP	NN	O	19	SUB
2	,	,	O	,	O	1	P
3	associated	associate	B-VP	VBN	O	1	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	some	some	B-NP	DT	O	6	NMOD
6	cases	case	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	myoglobinuria	myoglobinuria	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	3	P
10	and	and	O	CC	O	3	VMOD
11	in	in	B-PP	IN	O	3	VMOD
12	2	2	B-NP	CD	O	13	NMOD
13	cases	case	I-NP	NNS	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	transient	transient	B-NP	JJ	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	failure	failure	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	1	P
19	has	have	B-VP	VBZ	O	0	ROOT
20	been	be	I-VP	VBN	O	19	VC
21	rarely	rarely	I-VP	RB	O	20	VMOD
22	reported	report	I-VP	VBN	O	20	VC
23	with	with	B-PP	IN	O	22	VMOD
24	lovastatin	lovastatin	B-NP	NN	O	23	PMOD
25	,	,	O	,	O	22	P
26	especially	especially	B-ADVP	RB	O	22	VMOD
27	in	in	B-PP	IN	O	26	PMOD
28	patients	patient	B-NP	NNS	O	27	PMOD
29	concomitantly	concomitantly	B-VP	RB	O	30	VMOD
30	treated	treat	I-VP	VBN	O	28	NMOD
31	with	with	B-PP	IN	O	30	VMOD
32	cyclosporin	cyclosporin	B-NP	NN	O	36	NMOD
33	,	,	I-NP	,	O	36	P
34	gemfibrozil	gemfibrozil	I-NP	NN	O	36	NMOD
35	or	or	I-NP	CC	O	36	NMOD
36	niacin	niacin	I-NP	NN	O	31	PMOD
37	.	.	O	.	O	19	P

1	Sulfasalazine	Sulfasalazine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	lupus	lupus	B-NP	NN	O	4	NMOD
4	erythematosus	erythematosus	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Pneumonitis	Pneumonitis	B-NP	NN	O	5	NMOD
2	,	,	O	,	O	5	P
3	bilateral	bilateral	B-NP	JJ	O	5	NMOD
4	pleural	pleural	I-NP	JJ	O	5	NMOD
5	effusions	effusion	I-NP	NNS	O	0	ROOT
6	,	,	O	,	O	8	P
7	echocardiographic	echocardiographic	B-NP	JJ	O	8	NMOD
8	evidence	evidence	I-NP	NN	O	5	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	tamponade	tamponade	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	8	P
13	and	and	O	CC	O	12	PMOD
14	positive	positive	B-NP	JJ	B-protein	15	NMOD
15	autoantibodies	autoantibody	I-NP	NNS	I-protein	13	NMOD
16	developed	develop	B-VP	VBN	O	15	NMOD
17	in	in	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	20	NMOD
19	43-year-old	43-year-old	I-NP	JJ	O	20	NMOD
20	man	man	I-NP	NN	O	17	PMOD
21	,	,	O	,	O	15	P
22	who	who	B-NP	WP	O	15	NMOD
23	was	be	B-VP	VBD	O	22	SBAR
24	receiving	receive	I-VP	VBG	O	23	VC
25	long-term	long-term	B-NP	JJ	O	27	NMOD
26	sulfasalazine	sulfasalazine	I-NP	NN	O	27	NMOD
27	therapy	therapy	I-NP	NN	O	24	OBJ
28	for	for	B-PP	IN	O	27	NMOD
29	chronic	chronic	B-NP	JJ	O	31	NMOD
30	ulcerative	ulcerative	I-NP	JJ	O	31	NMOD
31	colitis	colitis	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	15	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	suggested	suggest	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	7	SUB
7	had	have	B-VP	VBD	O	4	SBAR
8	sulfasalazine	sulfasalazine	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	lupus	lupus	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	2	P
12	which	which	B-NP	WDT	O	2	VMOD
13	manifested	manifest	B-VP	VBD	O	12	SBAR
14	with	with	B-PP	IN	O	13	VMOD
15	serositis	serositis	B-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	pulmonary	pulmonary	B-NP	JJ	O	19	NMOD
18	parenchymal	parenchymal	I-NP	JJ	O	19	NMOD
19	involvement	involvement	I-NP	NN	O	14	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	absence	absence	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	joint	joint	B-NP	JJ	O	25	NMOD
25	symptoms	symptom	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	2	P

1	While	While	B-SBAR	IN	O	15	VMOD
2	there	there	B-NP	EX	O	3	SUB
3	is	be	B-VP	VBZ	O	1	SBAR
4	no	no	B-NP	DT	O	8	NMOD
5	single	single	I-NP	JJ	O	8	NMOD
6	correct	correct	I-NP	JJ	O	8	NMOD
7	starting	starting	I-NP	NN	O	8	NMOD
8	dose	dose	I-NP	NN	O	3	PRD
9	for	for	B-PP	IN	O	8	NMOD
10	levodopa	levodopa	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	15	P
13	many	many	B-NP	JJ	O	14	NMOD
14	individuals	individual	I-NP	NNS	O	15	SUB
15	can	can	B-VP	MD	O	0	ROOT
16	be	be	I-VP	VB	O	15	VC
17	started	start	I-VP	VBN	O	16	VC
18	on	on	B-PP	IN	O	17	VMOD
19	either	either	O	CC	O	24	NMOD
20	the	the	B-NP	DT	O	24	NMOD
21	25/100	25/100	I-NP	CD	O	24	NMOD
22	or	or	O	CC	O	24	NMOD
23	controlled-release	controlled-release	B-NP	JJ	O	24	NMOD
24	formula	formula	I-NP	NN	O	18	PMOD
25	,	,	O	,	O	17	P
26	following	follow	B-PP	VBG	O	17	VMOD
27	the	the	B-NP	DT	O	29	NMOD
28	general	general	I-NP	JJ	O	29	NMOD
29	rule	rule	I-NP	NN	O	26	PMOD
30	not	not	O	RB	O	32	VMOD
31	to	to	B-VP	TO	O	32	VMOD
32	attempt	attempt	I-VP	VB	O	17	VMOD
33	to	to	I-VP	TO	O	34	VMOD
34	titrate	titrate	I-VP	VB	O	32	VMOD
35	carbidopa-levodopa	carbidopa-levodopa	B-NP	NN	O	34	OBJ
36	to	to	B-PP	TO	O	34	VMOD
37	the	the	B-NP	DT	O	38	NMOD
38	point	point	I-NP	NN	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	"	"	O	"	O	41	NMOD
41	normality	normality	B-NP	NN	O	39	PMOD
42	,	,	O	,	O	15	P
43	"	"	O	"	O	15	VMOD
44	which	which	B-NP	WDT	O	43	VMOD
45	can	can	B-VP	MD	O	44	SBAR
46	lead	lead	I-VP	VB	O	45	VC
47	to	to	B-PP	TO	O	46	VMOD
48	toxicity	toxicity	B-NP	NN	O	47	PMOD
49	.	.	O	.	O	15	P

1	Other	Other	B-NP	JJ	O	3	AMOD
2	possible	possible	I-NP	JJ	O	3	AMOD
3	adverse	adverse	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	28	SUB
5	--	--	O	:	O	4	P
6	such	such	B-PP	JJ	O	7	PMOD
7	as	as	I-PP	IN	O	4	NMOD
8	gastrointestinal	gastrointestinal	B-NP	JJ	O	9	NMOD
9	disorders	disorder	I-NP	NNS	O	15	SUB
10	,	,	O	,	O	15	P
11	orthostatic	orthostatic	B-NP	JJ	O	12	NMOD
12	hypotension	hypotension	I-NP	NN	O	15	SUB
13	,	,	O	,	O	15	P
14	levodopa	levodopa	B-NP	NN	O	15	SUB
15	induced	induce	B-VP	VBD	O	7	SBAR
16	psychosis	psychosis	B-NP	NN	O	25	NMOD
17	,	,	O	,	O	25	P
18	sleep	sleep	B-NP	NN	O	19	NMOD
19	disturbances	disturbance	I-NP	NNS	O	21	NMOD
20	or	or	I-NP	CC	O	21	NMOD
21	parasomnias	parasomnia	I-NP	NNS	O	25	NMOD
22	,	,	O	,	O	25	P
23	or	or	O	CC	O	25	NMOD
24	drug	drug	B-NP	NN	O	25	NMOD
25	interactions	interaction	I-NP	NNS	O	15	OBJ
26	--	--	O	:	O	4	P
27	also	also	B-ADVP	RB	O	28	VMOD
28	require	require	B-VP	VBP	O	0	ROOT
29	carefully	carefully	I-VP	RB	O	30	AMOD
30	monitored	monitor	I-VP	VBN	O	28	VC
31	individual	individual	B-NP	JJ	O	32	NMOD
32	treatment	treatment	I-NP	NN	O	30	OBJ
33	.	.	O	.	O	28	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	received	receive	B-VP	VBD	O	15	VMOD
4	high	high	B-NP	JJ	O	5	NMOD
5	doses	dose	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	chlormethiazole	chlormethiazole	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	3	VMOD
9	alcohol	alcohol	B-NP	NN	O	11	NMOD
10	withdrawal	withdrawal	I-NP	NN	O	11	NMOD
11	symptoms	symptom	I-NP	NNS	O	8	PMOD
12	,	,	O	,	O	15	P
13	and	and	O	CC	O	14	NMOD
14	one	one	B-NP	CD	O	15	SUB
15	took	take	B-VP	VBD	O	0	ROOT
16	a	a	B-NP	DT	O	18	NMOD
17	suicidal	suicidal	I-NP	JJ	O	18	NMOD
18	overdose	overdose	I-NP	NN	O	15	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	nitrazepam	nitrazepam	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	13	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	nitrazepam	nitrazepam	B-NP	NN	O	5	NMOD
5	overdose	overdose	I-NP	NN	O	3	PMOD
6	and	and	O	CC	O	7	NMOD
7	two	two	B-NP	CD	O	2	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	those	those	B-NP	DT	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	chlormethiazole	chlormethiazole	B-NP	NN	O	12	NMOD
12	intoxication	intoxication	I-NP	NN	O	10	PMOD
13	conformed	conform	B-VP	VBD	O	0	ROOT
14	to	to	B-PP	TO	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	criteria	criterion	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	'alpha	'alpha	B-NP	NN	O	19	NMOD
19	coma	coma	I-NP	NN	O	17	PMOD
20	'	'	O	"	O	19	NMOD
21	,	,	O	,	O	13	P
22	showing	show	B-VP	VBG	O	13	VMOD
23	non-reactive	non-reactive	B-ADJP	JJ	O	29	NMOD
24	generalized	generalize	B-VP	VBN	O	29	NMOD
25	or	or	O	CC	O	29	NMOD
26	frontally	frontally	B-NP	RB	O	27	AMOD
27	predominant	predominant	I-NP	JJ	O	29	NMOD
28	alpha	alpha	I-NP	NN	O	29	NMOD
29	activity	activity	I-NP	NN	O	22	OBJ
30	in	in	B-PP	IN	O	22	VMOD
31	the	the	B-NP	DT	O	32	NMOD
32	EEG	EEG	I-NP	NN	B-protein	30	PMOD
33	.	.	O	.	O	13	P

1	Omitting	Omit	B-VP	VBG	O	2	NMOD
2	fentanyl	fentanyl	B-NP	NN	O	3	SUB
3	reduces	reduce	B-VP	VBZ	O	0	ROOT
4	nausea	nausea	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	vomiting	vomiting	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	3	P
8	without	without	B-PP	IN	O	3	VMOD
9	increasing	increase	B-VP	VBG	O	8	PMOD
10	pain	pain	B-NP	NN	O	9	OBJ
11	,	,	O	,	O	3	P
12	after	after	B-PP	IN	O	3	VMOD
13	sevoflurane	sevoflurane	B-NP	NN	O	12	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	day	day	B-NP	NN	O	16	NMOD
16	surgery	surgery	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	OBJECTIVE	OBJECTIVE	I-NP	NN	O	20	SUB
4	:	:	O	:	O	3	P
5	Despite	Despite	B-PP	IN	O	20	VMOD
6	advantages	advantage	B-NP	NNS	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	induction	induction	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	maintenance	maintenance	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	anaesthesia	anaesthesia	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	sevoflurane	sevoflurane	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	20	P
16	postoperative	postoperative	B-NP	JJ	O	17	NMOD
17	nausea	nausea	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	vomiting	vomiting	I-NP	NN	O	20	SUB
20	occurs	occur	B-VP	VBZ	O	0	ROOT
21	frequently	frequently	B-ADVP	RB	O	20	VMOD
22	.	.	O	.	O	20	P

1	METHODS	METHODS	B-NP	NNS	O	6	VMOD
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	5	NMOD
4	double-blind	double-blind	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	examined	examine	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	10	NMOD
8	incidence	incidence	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	severity	severity	I-NP	NN	O	17	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	postoperative	postoperative	B-NP	JJ	O	13	NMOD
13	nausea	nausea	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	vomiting	vomiting	I-NP	NN	O	11	PMOD
16	and	and	I-NP	CC	O	17	NMOD
17	pain	pain	I-NP	NN	O	6	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	first	first	I-NP	JJ	O	22	NMOD
21	24	24	I-NP	CD	O	22	NMOD
22	h	h	I-NP	NN	O	18	PMOD
23	after	after	B-PP	IN	O	17	NMOD
24	sevoflurane	sevoflurane	B-NP	NN	O	25	NMOD
25	anaesthesia	anaesthesia	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	216	216	B-NP	CD	O	31	NMOD
28	adult	adult	I-NP	JJ	O	31	NMOD
29	day	day	I-NP	NN	O	31	NMOD
30	surgery	surgery	I-NP	NN	O	31	NMOD
31	patients	patient	I-NP	NNS	O	26	PMOD
32	.	.	O	.	O	6	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Omission	Omission	B-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	fentanyl	fentanyl	B-NP	NN	O	4	PMOD
6	did	do	B-VP	VBD	O	1	NMOD
7	not	not	I-VP	RB	O	6	VMOD
8	reduce	reduce	I-VP	VB	O	6	VC
9	the	the	B-NP	DT	O	11	NMOD
10	overall	overall	I-NP	JJ	O	11	NMOD
11	incidence	incidence	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	postoperative	postoperative	B-NP	JJ	O	14	NMOD
14	nausea	nausea	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	vomiting	vomiting	I-NP	NN	O	12	PMOD
17	,	,	O	,	O	6	P
18	but	but	O	CC	O	6	VMOD
19	did	do	B-VP	VBD	O	6	VMOD
20	reduce	reduce	I-VP	VB	O	19	VC
21	the	the	B-NP	DT	O	22	NMOD
22	incidence	incidence	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	vomiting	vomit	B-VP	VBG	O	23	PMOD
25	and/or	and/or	O	CC	O	26	AMOD
26	moderate	moderate	B-ADJP	JJ	O	24	VMOD
27	to	to	B-PP	TO	O	26	AMOD
28	severe	severe	B-NP	JJ	O	29	NMOD
29	nausea	nausea	I-NP	NN	O	27	PMOD
30	prior	prior	B-ADJP	JJ	O	29	NMOD
31	to	to	B-VP	TO	O	32	VMOD
32	discharge	discharge	I-VP	VB	O	30	AMOD
33	from	from	B-PP	IN	O	32	VMOD
34	20	20	B-NP	CD	O	35	NMOD
35	%	%	I-NP	NN	O	38	NMOD
36	and	and	O	CC	O	38	NMOD
37	17	17	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	33	PMOD
39	with	with	B-PP	IN	O	38	NMOD
40	fentanyl	fentanyl	B-NP	NN	O	42	NMOD
41	and	and	I-NP	CC	O	42	NMOD
42	fentanyl-dexamethasone	fentanyl-dexamethasone	I-NP	NN	O	39	PMOD
43	,	,	O	,	O	32	P
44	respectively	respectively	B-ADVP	RB	O	32	VMOD
45	,	,	O	,	O	32	P
46	to	to	B-PP	TO	O	32	VMOD
47	5	5	B-NP	CD	O	48	NMOD
48	%	%	I-NP	NN	O	46	PMOD
49	(	(	O	(	O	53	DEP
50	P	P	B-NP	NN	O	53	DEP
51	=	=	B-VP	SYM	O	50	NMOD
52	0.013	0.013	B-NP	CD	O	51	AMOD
53	)	)	O	)	O	24	VMOD
54	.	.	O	.	O	1	P

1	Dexamethasone	Dexamethasone	B-NP	NN	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	5	NMOD
4	significant	significant	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	2	OBJ
6	on	on	B-PP	IN	O	2	VMOD
7	the	the	B-NP	DT	O	10	NMOD
8	incidence	incidence	I-NP	NN	O	10	NMOD
9	or	or	I-NP	CC	O	10	NMOD
10	severity	severity	I-NP	NN	O	6	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	postoperative	postoperative	B-NP	JJ	O	13	NMOD
13	nausea	nausea	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	vomiting	vomiting	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	2	P

1	Combining	Combine	B-VP	VBG	O	5	NMOD
2	the	the	B-NP	DT	O	5	NMOD
3	two	two	I-NP	CD	O	5	NMOD
4	fentanyl	fentanyl	I-NP	NN	O	5	NMOD
5	groups	group	I-NP	NNS	O	6	SUB
6	revealed	reveal	B-VP	VBD	O	0	ROOT
7	further	further	B-NP	JJ	O	9	NMOD
8	significant	significant	I-NP	JJ	O	9	NMOD
9	benefits	benefit	I-NP	NNS	O	6	OBJ
10	from	from	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	avoidance	avoidance	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	opioids	opioid	B-NP	NNS	O	13	PMOD
15	,	,	O	,	O	6	P
16	reducing	reduce	B-VP	VBG	O	6	VMOD
17	postoperative	postoperative	B-NP	JJ	O	18	NMOD
18	nausea	nausea	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	vomiting	vomiting	I-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	nausea	nausea	I-NP	NN	O	16	OBJ
23	prior	prior	B-ADJP	JJ	O	22	NMOD
24	to	to	B-VP	TO	O	25	VMOD
25	discharge	discharge	I-VP	VB	O	23	AMOD
26	from	from	B-PP	IN	O	25	VMOD
27	35	35	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	26	PMOD
29	and	and	O	CC	O	37	NMOD
30	33	33	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	37	NMOD
32	to	to	B-PP	TO	O	31	NMOD
33	22	22	B-NP	CD	O	34	NMOD
34	%	%	I-NP	NN	O	32	PMOD
35	and	and	O	CC	O	37	NMOD
36	19	19	B-NP	CD	O	37	NMOD
37	%	%	I-NP	NN	O	16	OBJ
38	(	(	O	(	O	69	DEP
39	P	P	B-NP	NN	O	41	SUB
40	=	=	B-VP	SYM	O	41	VMOD
41	0.049	0.049	B-NP	CD	O	69	DEP
42	and	and	O	CC	O	69	DEP
43	P	P	B-NP	NN	O	69	DEP
44	=	=	B-VP	SYM	O	43	NMOD
45	0.035	0.035	B-NP	CD	O	44	AMOD
46	)	)	O	)	O	43	NMOD
47	,	,	O	,	O	43	P
48	respectively	respectively	B-ADVP	RB	O	43	NMOD
49	,	,	O	,	O	69	P
50	while	while	B-SBAR	IN	O	69	DEP
51	nausea	nausea	B-NP	NN	O	57	SUB
52	in	in	B-PP	IN	O	51	NMOD
53	the	the	B-NP	DT	O	56	NMOD
54	first	first	I-NP	JJ	O	56	NMOD
55	24	24	I-NP	CD	O	56	NMOD
56	h	h	I-NP	NN	O	52	PMOD
57	was	be	B-VP	VBD	O	50	SBAR
58	decreased	decrease	I-VP	VBN	O	57	VC
59	from	from	B-PP	IN	O	58	VMOD
60	42	42	B-NP	CD	O	61	NMOD
61	%	%	I-NP	NN	O	59	PMOD
62	to	to	B-PP	TO	O	58	VMOD
63	27	27	B-NP	CD	O	64	NMOD
64	%	%	I-NP	NN	O	62	PMOD
65	(	(	O	(	O	69	DEP
66	P	P	B-NP	NN	O	69	DEP
67	=	=	B-VP	SYM	O	66	NMOD
68	0.034	0.034	B-NP	CD	O	67	AMOD
69	)	)	O	)	O	37	NMOD
70	.	.	O	.	O	6	P

1	Pain	Pain	B-NP	NN	O	2	NMOD
2	severity	severity	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	analgesic	analgesic	B-NP	JJ	O	5	NMOD
5	requirements	requirement	I-NP	NNS	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	unaffected	unaffected	B-ADJP	JJ	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	omission	omission	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	fentanyl	fentanyl	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	6	P

1	Fentanyl	Fentanyl	B-NP	NN	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	reduce	reduce	I-VP	VB	O	2	VC
4	minor	minor	B-NP	JJ	O	5	AMOD
5	intraoperative	intraoperative	I-NP	JJ	O	6	NMOD
6	movement	movement	I-NP	NN	O	3	OBJ
7	but	but	O	CC	O	2	VMOD
8	had	have	B-VP	VBD	O	2	VMOD
9	no	no	B-NP	DT	O	11	NMOD
10	sevoflurane-sparing	sevoflurane-sparing	I-NP	JJ	O	11	NMOD
11	effect	effect	I-NP	NN	O	8	OBJ
12	and	and	O	CC	O	2	VMOD
13	increased	increase	B-VP	VBD	O	2	VMOD
14	respiratory	respiratory	B-NP	JJ	O	15	NMOD
15	depression	depression	I-NP	NN	O	19	NMOD
16	,	,	O	,	O	19	P
17	hypotension	hypotension	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	bradycardia	bradycardia	I-NP	NN	O	13	OBJ
20	.	.	O	.	O	2	P

1	Lamivudine	Lamivudine	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	added	add	I-VP	VBN	O	2	VC
4	because	because	B-PP	IN	O	3	VMOD
5	of	of	I-PP	IN	O	4	PMOD
6	de	de	B-NP	FW	O	7	AMOD
7	nova	nova	I-NP	FW	O	10	NMOD
8	hepatitis	hepatitis	I-NP	NN	O	10	NMOD
9	B	B	I-NP	NN	O	10	NMOD
10	infection	infection	I-NP	NN	O	4	PMOD
11	during	during	B-PP	IN	O	3	VMOD
12	her	her	B-NP	PRP$	O	13	NMOD
13	follow-up	follow-up	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	tacrolimus	tacrolimus	B-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	1	VMOD
4	suspected	suspect	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	be	be	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	cause	cause	I-NP	NN	O	6	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	late	late	B-NP	JJ	O	13	NMOD
11	post-transplant	post-transplant	I-NP	JJ	O	13	NMOD
12	renal	renal	I-NP	JJ	O	13	NMOD
13	acidosis	acidosis	I-NP	NN	O	9	PMOD
14	and	and	O	CC	O	3	VMOD
15	was	be	B-VP	VBD	O	3	VMOD
16	replaced	replace	I-VP	VBN	O	15	VC
17	by	by	B-PP	IN	O	16	VMOD
18	sirolimus	sirolimus	B-NP	NN	O	25	SUB
19	,	,	O	,	O	25	P
20	acidosis	acidosis	B-NP	NN	O	25	SUB
21	,	,	O	,	O	25	P
22	and	and	O	CC	O	25	VMOD
23	electrolyte	electrolyte	B-NP	NN	O	24	NMOD
24	imbalance	imbalance	I-NP	NN	O	25	SUB
25	got	get	B-VP	VBD	O	17	SBAR
26	worse	worse	B-ADJP	JJR	O	25	PRD
27	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	study	study	I-VP	VB	O	24	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	effect	effect	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	histamine	histamine	B-NP	NN	B-protein	17	NMOD
12	H	H	I-NP	NN	I-protein	17	NMOD
13	(	(	O	(	I-protein	17	NMOD
14	3	3	B-NP	CD	I-protein	17	NMOD
15	)	)	O	)	I-protein	17	NMOD
16	-receptor	-receptor	B-NP	JJ	I-protein	17	NMOD
17	ligands	ligand	I-NP	NNS	I-protein	10	PMOD
18	on	on	B-PP	IN	O	9	NMOD
19	neuroleptic	neuroleptic	B-NP	JJ	O	21	NMOD
20	induced	induce	I-NP	VBN	O	21	NMOD
21	catalepsy	catalepsy	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	24	P
23	apomorphine	apomorphine	B-NP	NN	O	24	SUB
24	induced	induce	B-VP	VBD	O	4	VMOD
25	climbing	climb	I-VP	VBG	O	24	VMOD
26	behavior	behavior	B-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	amphetamine	amphetamine	I-NP	NN	O	31	NMOD
29	induced	induce	B-VP	VBD	O	28	AMOD
30	locomotor	locomotor	B-NP	NN	O	31	NMOD
31	activities	activity	I-NP	NNS	O	25	OBJ
32	in	in	B-PP	IN	O	25	VMOD
33	mice	mouse	B-NP	NNS	O	32	PMOD
34	.	.	O	.	O	4	P

1	Catalepsy	Catalepsy	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	haloperidol	haloperidol	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	10	DEP
7	2	2	B-NP	CD	O	9	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	9	NMOD
9	p.o.	p.o.	I-NP	NN	O	10	DEP
10	)	)	O	)	O	5	NMOD
11	,	,	O	,	O	2	P
12	while	while	B-SBAR	IN	O	2	VMOD
13	apomorphine	apomorphine	B-NP	NN	O	20	NMOD
14	(	(	O	(	O	18	DEP
15	1.5	1.5	B-NP	CD	O	17	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	NMOD
17	s.c.	s.c.	I-NP	NN	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	and	and	O	CC	O	20	NMOD
20	amphetamine	amphetamine	B-NP	NN	O	26	SUB
21	(	(	O	(	O	25	DEP
22	2	2	B-NP	CD	O	24	NMOD
23	mg/kg	mg/kg	I-NP	NN	O	24	NMOD
24	s.c.	s.c.	I-NP	NN	O	25	DEP
25	)	)	O	)	O	20	NMOD
26	were	be	B-VP	VBD	O	12	SBAR
27	used	use	I-VP	VBN	O	26	VC
28	for	for	B-PP	IN	O	27	VMOD
29	studying	study	B-VP	VBG	O	28	PMOD
30	climbing	climb	I-VP	VBG	O	29	VC
31	behavior	behavior	B-NP	NN	O	34	NMOD
32	and	and	I-NP	CC	O	34	NMOD
33	locomotor	locomotor	I-NP	NN	O	34	NMOD
34	activities	activity	I-NP	NNS	O	30	OBJ
35	,	,	O	,	O	30	P
36	respectively	respectively	B-ADVP	RB	O	30	VMOD
37	.	.	O	.	O	2	P

1	(	(	O	(	O	3	DEP
2	R	R	B-NP	NN	O	3	DEP
3	)	)	O	)	O	26	VMOD
4	-alpha-methylhistamine	-alpha-methylhistamine	B-NP	NN	O	14	NMOD
5	(	(	O	(	O	7	DEP
6	RAMH	RAMH	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	(	(	O	(	O	12	DEP
9	5	5	B-NP	CD	O	10	AMOD
10	microg	microg	I-NP	NN	O	11	NMOD
11	i.c.v.	i.c.v.	I-NP	NN	O	12	DEP
12	)	)	O	)	O	4	NMOD
13	and	and	O	CC	O	14	NMOD
14	thioperamide	thioperamide	B-NP	NN	O	26	SUB
15	(	(	O	(	O	17	DEP
16	THP	THP	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	(	(	O	(	O	22	DEP
19	15	15	B-NP	CD	O	20	NMOD
20	mg/kg	mg/kg	I-NP	NN	O	22	DEP
21	i.p.	i.p.	B-ADVP	RB	O	20	NMOD
22	)	)	O	)	O	14	NMOD
23	,	,	O	,	O	14	P
24	per	per	B-ADVP	FW	O	14	NMOD
25	se	se	I-ADVP	FW	O	24	AMOD
26	did	do	B-VP	VBD	O	0	ROOT
27	not	not	I-VP	RB	O	26	VMOD
28	cause	cause	I-VP	VB	O	26	VC
29	catalepsy	catalepsy	B-NP	NN	O	28	OBJ
30	.	.	O	.	O	26	P

1	Administration	Administration	B-NP	NN	O	18	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	THP	THP	B-NP	NN	O	14	NMOD
4	(	(	O	(	O	12	DEP
5	3.75	3.75	B-NP	CD	O	10	NMOD
6	,	,	I-NP	,	O	10	P
7	7.5	7.5	I-NP	CD	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	15	15	I-NP	CD	O	10	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	12	DEP
11	i.p.	i.p.	B-ADVP	RB	O	10	NMOD
12	)	)	O	)	O	3	NMOD
13	1	1	B-NP	CD	O	14	NMOD
14	h	h	I-NP	NN	O	2	PMOD
15	prior	prior	B-ADJP	JJ	O	14	NMOD
16	to	to	B-PP	TO	O	15	AMOD
17	haloperidol	haloperidol	B-NP	NN	O	16	PMOD
18	resulted	result	B-VP	VBD	O	0	ROOT
19	in	in	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	dose-dependent	dose-dependent	I-NP	JJ	O	22	NMOD
22	increase	increase	I-NP	NN	O	19	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	catalepsy	catalepsy	I-NP	NN	O	26	NMOD
26	times	time	I-NP	NNS	O	23	PMOD
27	(	(	O	(	O	31	DEP
28	P	P	B-NP	NN	O	31	DEP
29	<	<	O	SYM	O	28	NMOD
30	0.05	0.05	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	22	NMOD
32	.	.	O	.	O	18	P

1	On	On	B-PP	IN	O	0	ROOT
2	amphetamine	amphetamine	B-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	1	VMOD
4	hyperactivity	hyperactivity	B-NP	NN	O	14	SUB
5	,	,	O	,	O	14	P
6	THP	THP	B-NP	NN	O	14	SUB
7	(	(	O	(	O	13	DEP
8	3.75	3.75	B-NP	CD	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	7.5	7.5	I-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	13	DEP
12	i.p.	i.p.	B-ADVP	RB	O	11	NMOD
13	)	)	O	)	O	6	NMOD
14	reduced	reduce	B-VP	VBD	O	3	VMOD
15	locomotor	locomotor	B-NP	NN	O	16	NMOD
16	time	time	I-NP	NN	O	22	NMOD
17	,	,	O	,	O	22	P
18	distance	distance	B-NP	NN	O	22	NMOD
19	traveled	travel	B-VP	VBN	O	18	NMOD
20	and	and	O	CC	O	22	NMOD
21	average	average	B-NP	JJ	O	22	NMOD
22	speed	speed	I-NP	NN	O	14	OBJ
23	(	(	O	(	O	27	DEP
24	P	P	B-NP	NN	O	27	DEP
25	<	<	O	SYM	O	24	NMOD
26	0.05	0.05	B-NP	CD	O	25	AMOD
27	)	)	O	)	O	22	NMOD
28	.	.	O	.	O	1	P

1	THP	THP	B-NP	NN	O	2	SUB
2	exhibited	exhibit	B-VP	VBD	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	antipsychotic-like	antipsychotic-like	I-NP	JJ	O	5	NMOD
5	profile	profile	I-NP	NN	O	2	OBJ
6	by	by	B-PP	IN	O	2	VMOD
7	potentiating	potentiate	B-VP	VBG	O	6	PMOD
8	haloperidol	haloperidol	B-NP	NN	O	10	NMOD
9	induced	induce	B-VP	VBD	O	10	NMOD
10	catalepsy	catalepsy	B-NP	NN	O	7	OBJ
11	,	,	O	,	O	2	P
12	reducing	reduce	B-VP	VBG	O	2	VMOD
13	amphetamine	amphetamine	B-NP	NN	O	12	OBJ
14	induced	induce	B-VP	VBD	O	13	NMOD
15	hyperactivity	hyperactivity	B-NP	NN	O	14	OBJ
16	and	and	O	CC	O	14	VMOD
17	reducing	reduce	B-VP	VBG	O	14	VMOD
18	apomorphine	apomorphine	B-NP	NN	O	17	OBJ
19	induced	induce	B-VP	VBD	O	2	VMOD
20	climbing	climb	I-VP	VBG	O	19	VMOD
21	in	in	B-PP	IN	O	20	VMOD
22	mice	mouse	B-NP	NNS	O	21	PMOD
23	.	.	O	.	O	2	P

1	Transient	Transient	B-NP	JJ	O	3	NMOD
2	platypnea-orthodeoxia-like	platypnea-orthodeoxia-like	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	0	ROOT
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	propafenone	propafenone	B-NP	NN	O	7	NMOD
7	overdose	overdose	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	young	young	I-NP	JJ	O	11	NMOD
11	woman	woman	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	Ebstein	Ebstein	B-NP	NNP	O	14	NMOD
14	's	's	B-NP	POS	O	15	NMOD
15	anomaly	anomaly	B-ADVP	RB	O	12	PMOD
16	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	shunt	shunt	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	blood	blood	B-NP	NN	O	3	PMOD
5	via	via	B-PP	IN	O	2	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	patent	patent	I-NP	NN	O	8	NMOD
8	foramen	foraman	I-NP	NNS	O	9	NMOD
9	ovale	ovale	I-NP	NN	O	5	PMOD
10	occurred	occur	B-VP	VBD	O	0	ROOT
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	presence	presence	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	19	NMOD
16	normal	normal	I-NP	JJ	O	19	NMOD
17	pulmonary	pulmonary	I-NP	JJ	O	19	NMOD
18	artery	artery	I-NP	NN	O	19	NMOD
19	pressure	pressure	I-NP	NN	O	14	PMOD
20	,	,	O	,	O	10	P
21	and	and	O	CC	O	10	VMOD
22	was	be	B-VP	VBD	O	10	VMOD
23	probably	probably	I-VP	RB	O	22	VMOD
24	precipitated	precipitate	I-VP	VBN	O	22	VC
25	by	by	B-PP	IN	O	24	VMOD
26	a	a	B-NP	DT	O	28	NMOD
27	propafenone	propafenone	I-NP	NN	O	28	NMOD
28	overdose	overdose	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	4	NMOD
2	Phase	Phase	I-NP	NN	O	4	NMOD
3	II	II	I-NP	CD	O	4	NMOD
4	trial	trial	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	cisplatin	cisplatin	B-NP	NN	O	8	NMOD
7	plus	plus	O	CC	O	8	NMOD
8	WR-2721	WR-2721	B-NP	NN	O	5	PMOD
9	(	(	O	(	O	11	DEP
10	amifostine	amifostine	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	for	for	B-PP	IN	O	8	NMOD
13	metastatic	metastatic	B-NP	JJ	O	15	NMOD
14	breast	breast	I-NP	NN	O	15	NMOD
15	carcinoma	carcinoma	I-NP	NN	O	12	PMOD
16	:	:	O	:	O	4	P
17	an	an	B-NP	DT	O	22	NMOD
18	Eastern	Eastern	I-NP	NNP	O	22	NMOD
19	Cooperative	Cooperative	I-NP	NNP	O	22	NMOD
20	Oncology	Oncology	I-NP	NNP	O	22	NMOD
21	Group	Group	I-NP	NNP	O	22	NMOD
22	Study	Study	I-NP	NNP	O	4	OBJ
23	(	(	O	(	O	25	DEP
24	E8188	E8188	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cisplatin	Cisplatin	B-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	1	NMOD
5	minimal	minimal	B-NP	JJ	O	7	NMOD
6	antitumor	antitumor	I-NP	JJ	O	7	NMOD
7	activity	activity	I-NP	NN	O	4	OBJ
8	when	when	B-ADVP	WRB	O	4	VMOD
9	used	use	B-VP	VBN	O	8	SBAR
10	as	as	B-PP	IN	O	9	VMOD
11	second-	second-	B-NP	JJ	O	14	NMOD
12	or	or	I-NP	CC	O	14	NMOD
13	third-line	third-line	I-NP	JJ	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	10	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	metastatic	metastatic	B-NP	JJ	O	18	NMOD
17	breast	breast	I-NP	NN	O	18	NMOD
18	carcinoma	carcinoma	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	4	P

1	Although	Although	B-SBAR	IN	O	27	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	dose-response	dose-response	I-NP	JJ	O	4	NMOD
4	effect	effect	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	1	SBAR
6	been	be	I-VP	VBN	O	5	VC
7	observed	observe	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	cisplatin	cisplatin	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	27	P
11	the	the	B-NP	DT	O	13	NMOD
12	dose-limiting	dose-limiting	I-NP	NN	O	13	NMOD
13	toxicities	toxicity	I-NP	NNS	O	27	SUB
14	associated	associate	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	cisplatin	cisplatin	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	26	DEP
18	e.g.	e.g.	B-NP	FW	O	25	NMOD
19	,	,	O	,	O	25	P
20	nephrotoxicity	nephrotoxicity	B-NP	NN	O	25	NMOD
21	,	,	O	,	O	25	P
22	ototoxicity	ototoxicity	B-NP	NN	O	25	NMOD
23	,	,	O	,	O	25	P
24	and	and	O	CC	O	25	NMOD
25	neurotoxicity	neurotoxicity	B-NP	NN	O	26	DEP
26	)	)	O	)	O	16	NMOD
27	have	have	B-VP	VBP	O	0	ROOT
28	limited	limit	I-VP	VBN	O	27	VC
29	its	its	B-NP	PRP$	O	30	NMOD
30	use	use	I-NP	NN	O	28	OBJ
31	as	as	B-PP	IN	O	28	VMOD
32	a	a	B-NP	DT	O	33	NMOD
33	treatment	treatment	I-NP	NN	O	31	PMOD
34	for	for	B-PP	IN	O	33	NMOD
35	breast	breast	B-NP	NN	O	36	NMOD
36	carcinoma	carcinoma	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	27	P

1	Early	Early	B-NP	JJ	O	2	NMOD
2	trials	trial	I-NP	NNS	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cisplatin	cisplatin	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	amifostine	amifostine	I-NP	NN	O	3	PMOD
7	also	also	B-ADVP	RB	O	8	VMOD
8	suggested	suggest	B-VP	VBD	O	0	ROOT
9	that	that	B-SBAR	IN	O	8	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	incidence	incidence	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	severity	severity	I-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	cisplatin	cisplatin	B-NP	NN	B-protein	14	PMOD
16	induced	induce	B-VP	VBD	O	9	SBAR
17	nephrotoxicity	nephrotoxicity	B-NP	NN	O	22	NMOD
18	,	,	O	,	O	22	P
19	ototoxicity	ototoxicity	B-NP	NN	O	22	NMOD
20	,	,	O	,	O	22	P
21	and	and	O	CC	O	22	NMOD
22	neuropathy	neuropathy	B-NP	NN	O	16	OBJ
23	were	be	B-VP	VBD	O	16	VMOD
24	reduced	reduce	I-VP	VBN	O	23	VC
25	.	.	O	.	O	8	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	6	NMOD
4	Phase	Phase	I-NP	NN	O	6	NMOD
5	II	II	I-NP	CD	O	6	NMOD
6	study	study	I-NP	NN	O	14	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	combination	combination	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	cisplatin	cisplatin	B-NP	NN	O	13	NMOD
12	plus	plus	I-NP	CC	O	13	NMOD
13	amifostine	amifostine	I-NP	NN	O	10	PMOD
14	was	be	B-VP	VBD	O	1	NMOD
15	conducted	conduct	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	progressive	progressive	B-NP	JJ	O	22	NMOD
20	metastatic	metastatic	I-NP	JJ	O	22	NMOD
21	breast	breast	I-NP	NN	O	22	NMOD
22	carcinoma	carcinoma	I-NP	NN	O	18	PMOD
23	who	who	B-NP	WP	O	17	NMOD
24	had	have	B-VP	VBD	O	23	SBAR
25	received	receive	I-VP	VBN	O	24	VC
26	one	one	B-NP	CD	O	35	NMOD
27	,	,	O	,	O	35	P
28	but	but	O	CC	O	35	NMOD
29	not	not	O	RB	O	28	DEP
30	more	more	B-NP	JJR	O	31	AMOD
31	than	than	I-NP	IN	O	35	NMOD
32	one	one	I-NP	CD	O	31	AMOD
33	,	,	I-NP	,	O	35	P
34	chemotherapy	chemotherapy	I-NP	NN	O	35	NMOD
35	regimen	regimen	I-NP	NN	O	25	OBJ
36	for	for	B-PP	IN	O	35	NMOD
37	metastatic	metastatic	B-NP	JJ	O	38	NMOD
38	disease	disease	I-NP	NN	O	36	PMOD
39	.	.	O	.	O	1	P

1	Warfarin	Warfarin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	iliopsoas	iliopsoas	B-NP	JJ	O	4	NMOD
4	hemorrhage	hemorrhage	I-NP	NN	O	2	OBJ
5	with	with	B-PP	IN	O	2	VMOD
6	subsequent	subsequent	B-NP	JJ	O	9	NMOD
7	femoral	femoral	I-NP	JJ	O	9	NMOD
8	nerve	nerve	I-NP	NN	O	9	NMOD
9	palsy	palsy	I-NP	NN	O	5	PMOD
10	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	28-year-old	28-year-old	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	on	on	B-PP	IN	O	4	NMOD
10	chronic	chronic	B-NP	JJ	O	12	NMOD
11	warfarin	warfarin	I-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	9	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	sustained	sustain	B-VP	VBD	O	13	SBAR
15	a	a	B-NP	DT	O	18	NMOD
16	minor	minor	I-NP	JJ	O	18	NMOD
17	muscle	muscle	I-NP	NN	O	18	NMOD
18	tear	tear	I-NP	NN	O	14	OBJ
19	and	and	O	CC	O	2	VMOD
20	developed	develop	B-VP	VBD	O	2	VMOD
21	increasing	increase	I-VP	VBG	O	20	VC
22	pain	pain	B-NP	NN	O	26	NMOD
23	and	and	O	CC	O	26	NMOD
24	a	a	B-NP	DT	O	26	NMOD
25	flexure	flexure	I-NP	NN	O	26	NMOD
26	contracture	contracture	I-NP	NN	O	21	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	30	NMOD
29	right	right	I-NP	JJ	O	30	NMOD
30	hip	hip	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	2	P

1	Myasthenia	Myasthenia	B-NP	NN	O	2	NMOD
2	gravis	gravis	I-NP	NN	O	0	ROOT
3	caused	cause	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	penicillamine	penicillamine	B-NP	NN	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	chloroquine	chloroquine	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	4	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	rheumatoid	rheumatoid	B-NP	JJ	O	11	NMOD
11	arthritis	arthritis	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	described	describe	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	6	NMOD
5	unique	unique	I-NP	JJ	O	6	NMOD
6	patient	patient	I-NP	NN	O	3	OBJ
7	who	who	B-NP	WP	O	6	NMOD
8	had	have	B-VP	VBD	O	7	SBAR
9	reversible	reversible	B-NP	JJ	O	13	NMOD
10	and	and	I-NP	CC	O	13	NMOD
11	dose-related	dose-related	I-NP	JJ	O	13	NMOD
12	myasthenia	myasthenia	I-NP	NN	O	13	NMOD
13	gravis	gravis	I-NP	NN	O	8	OBJ
14	after	after	B-PP	IN	O	8	VMOD
15	penicillamine	penicillamine	B-NP	NN	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	chloroquine	chloroquine	I-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	14	PMOD
19	for	for	B-PP	IN	O	18	NMOD
20	rheumatoid	rheumatoid	B-NP	JJ	O	21	NMOD
21	arthritis	arthritis	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	2	P

1	Nephrotoxicity	Nephrotoxicity	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	combined	combine	B-NP	VBN	O	5	NMOD
4	cephalothin-gentamicin	cephalothin-gentamicin	I-NP	NN	O	5	NMOD
5	regimen	regimen	I-NP	NN	O	2	PMOD
6	.	.	O	.	O	1	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	developed	develop	B-VP	VBD	O	0	ROOT
4	acute	acute	B-NP	JJ	O	6	NMOD
5	tubular	tubular	I-NP	JJ	O	6	NMOD
6	necrosis	necrosis	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	6	P
8	characterized	characterize	B-VP	VBN	O	6	NMOD
9	clinically	clinically	B-ADVP	RB	O	8	VMOD
10	by	by	B-PP	IN	O	8	VMOD
11	acute	acute	B-NP	JJ	O	14	NMOD
12	oliguric	oliguric	I-NP	JJ	O	14	NMOD
13	renal	renal	I-NP	JJ	O	14	NMOD
14	failure	failure	I-NP	NN	O	10	PMOD
15	,	,	O	,	O	3	P
16	while	while	B-SBAR	IN	O	3	VMOD
17	they	they	B-NP	PRP	O	18	SUB
18	were	be	B-VP	VBD	O	16	SBAR
19	receiving	receive	I-VP	VBG	O	18	VC
20	a	a	B-NP	DT	O	21	NMOD
21	combination	combination	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	cephalothin	cephalothin	B-NP	JJ	O	28	NMOD
24	sodium	sodium	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	gentamicin	gentamicin	I-NP	NN	O	28	NMOD
27	sulfate	sulfate	I-NP	NN	O	28	NMOD
28	therapy	therapy	I-NP	NN	O	22	PMOD
29	.	.	O	.	O	3	P

1	Components	Component	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	lemon	lemon	B-NP	NN	O	7	NMOD
4	essential	essential	I-NP	JJ	O	7	NMOD
5	oil	oil	I-NP	NN	O	7	NMOD
6	attenuate	attenuate	I-NP	NN	O	7	NMOD
7	dementia	dementia	I-NP	NN	O	2	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	scopolamine	scopolamine	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	anti-dementia	anti-dementia	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	s-limonene	s-limonene	B-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	s-perillyl	s-perillyl	B-NP	JJ	O	8	NMOD
8	alcohol	alcohol	I-NP	NN	O	4	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	observed	observe	I-VP	VBN	O	9	VC
11	using	use	B-VP	VBG	O	9	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	passive	passive	I-NP	JJ	O	15	NMOD
14	avoidance	avoidance	I-NP	NN	O	15	NMOD
15	test	test	I-NP	NN	O	24	NMOD
16	(	(	O	(	O	18	DEP
17	PA	PA	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	and	and	O	CC	O	24	NMOD
20	the	the	B-NP	DT	O	24	NMOD
21	open	open	I-NP	JJ	O	24	NMOD
22	field	field	I-NP	NN	O	24	NMOD
23	habituation	habituation	I-NP	NN	O	24	NMOD
24	test	test	I-NP	NN	O	11	OBJ
25	(	(	O	(	O	27	DEP
26	OFH	OFH	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	9	P

1	These	These	B-NP	DT	O	4	NMOD
2	lemon	lemon	I-NP	JJ	O	4	NMOD
3	essential	essential	I-NP	JJ	O	4	NMOD
4	oils	oil	I-NP	NNS	O	5	SUB
5	showed	show	B-VP	VBD	O	19	VMOD
6	strong	strong	B-NP	JJ	O	7	NMOD
7	ability	ability	I-NP	NN	O	5	OBJ
8	to	to	B-VP	TO	O	9	VMOD
9	improve	improve	I-VP	VB	O	7	NMOD
10	memory	memory	B-NP	NN	O	9	OBJ
11	impaired	impair	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	scopolamine	scopolamine	B-NP	NN	O	12	PMOD
14	;	;	O	:	O	19	P
15	however	however	B-ADVP	RB	O	19	VMOD
16	,	,	O	,	O	19	P
17	s-perillyl	s-perillyl	B-NP	JJ	O	18	NMOD
18	alcohol	alcohol	I-NP	NN	O	19	SUB
19	relieved	relieve	B-VP	VBD	O	0	ROOT
20	the	the	B-NP	DT	O	21	NMOD
21	deficit	deficit	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	associative	associative	B-NP	JJ	O	24	NMOD
24	memory	memory	I-NP	NN	O	22	PMOD
25	in	in	B-PP	IN	O	21	NMOD
26	PA	PA	B-NP	NN	O	25	PMOD
27	only	only	B-ADVP	RB	O	25	PMOD
28	,	,	O	,	O	19	P
29	and	and	O	CC	O	19	VMOD
30	did	do	B-VP	VBD	O	19	VMOD
31	not	not	I-VP	RB	O	30	VMOD
32	improve	improve	I-VP	VB	O	30	VC
33	non-associative	non-associative	B-NP	JJ	O	34	NMOD
34	memory	memory	I-NP	NN	O	32	OBJ
35	significantly	significantly	B-ADVP	RB	O	32	VMOD
36	in	in	B-PP	IN	O	32	VMOD
37	OFH	OFH	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	19	P

1	The	The	B-NP	DT	O	6	NMOD
2	selective	selective	I-NP	JJ	O	6	NMOD
3	5-HT6	5-HT6	I-NP	NN	O	6	NMOD
4	receptor	receptor	I-NP	NN	O	6	NMOD
5	antagonist	antagonist	I-NP	NN	O	6	NMOD
6	Ro4368554	Ro4368554	I-NP	NN	O	7	SUB
7	restores	restore	B-VP	VBZ	O	0	ROOT
8	memory	memory	B-NP	NN	O	9	NMOD
9	performance	performance	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	cholinergic	cholinergic	B-NP	JJ	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	serotonergic	serotonergic	I-NP	JJ	O	14	NMOD
14	models	model	I-NP	NNS	O	10	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	memory	memory	B-NP	NN	O	17	NMOD
17	deficiency	deficiency	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	9	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	rat	rat	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	7	P

1	Both	Both	O	CC	O	16	NMOD
2	,	,	O	,	O	16	P
3	Ro4368554	Ro4368554	B-NP	NN	O	16	NMOD
4	(	(	O	(	O	14	DEP
5	3	3	B-NP	CD	O	7	AMOD
6	and	and	I-NP	CC	O	7	AMOD
7	10	10	I-NP	CD	O	8	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	14	DEP
9	,	,	O	,	O	8	P
10	intraperitoneally	intraperitoneally	B-ADVP	RB	O	8	NMOD
11	(	(	O	(	O	13	DEP
12	i.p.	i.p.	B-ADVP	RB	O	13	DEP
13	)	)	O	)	O	10	AMOD
14	)	)	O	)	O	3	NMOD
15	and	and	O	CC	O	16	NMOD
16	metrifonate	metrifonate	B-NP	NN	O	25	SUB
17	(	(	O	(	O	24	DEP
18	10	10	B-NP	CD	O	19	NMOD
19	mg/kg	mg/kg	I-NP	NN	O	24	DEP
20	,	,	O	,	O	24	P
21	p.o.	p.o.	B-NP	FW	O	24	DEP
22	,	,	O	,	O	21	P
23	respectively	respectively	B-ADVP	RB	O	21	VMOD
24	)	)	O	)	O	16	NMOD
25	reversed	reverse	B-VP	VBD	O	0	ROOT
26	memory	memory	B-NP	NN	B-protein	27	NMOD
27	deficits	deficit	I-NP	NNS	I-protein	25	OBJ
28	induced	induce	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	scopolamine	scopolamine	B-NP	NN	O	33	NMOD
31	and	and	O	CC	O	33	NMOD
32	TRP	TRP	B-NP	NN	O	33	NMOD
33	depletion	depletion	I-NP	NN	O	29	PMOD
34	(	(	O	(	O	47	DEP
35	10	10	B-NP	CD	O	36	NMOD
36	mg/kg	mg/kg	I-NP	NN	O	47	DEP
37	,	,	O	,	O	36	P
38	i.p.	i.p.	B-ADVP	RB	O	36	NMOD
39	,	,	O	,	O	47	P
40	and	and	O	CC	O	47	DEP
41	3	3	B-NP	CD	O	42	NMOD
42	mg/kg	mg/kg	I-NP	NN	O	47	DEP
43	,	,	O	,	O	47	P
44	p.o.	p.o.	B-NP	FW	O	47	DEP
45	,	,	O	,	O	44	P
46	respectively	respectively	B-ADVP	RB	O	44	VMOD
47	)	)	O	)	O	33	NMOD
48	.	.	O	.	O	25	P

1	Lone	Lone	B-NP	NN	O	3	NMOD
2	atrial	atrial	I-NP	JJ	O	3	NMOD
3	fibrillation	fibrillation	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	creatine	creatine	B-NP	NN	O	8	NMOD
7	monohydrate	monohydrate	I-NP	NN	O	8	NMOD
8	supplementation	supplementation	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	3	P

1	Comparison	Comparison	B-NP	NN	O	19	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	developmental	developmental	B-NP	JJ	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	selective	selective	B-NP	JJ	O	8	AMOD
7	and	and	I-NP	CC	O	8	AMOD
8	non-selective	non-selective	I-NP	JJ	O	10	NMOD
9	cyclooxygenase-2	cyclooxygenase-2	I-NP	NN	O	10	NMOD
10	inhibitors	inhibitor	I-NP	NNS	O	5	PMOD
11	in	in	B-PP	IN	O	1	NMOD
12	CRL	CRL	B-NP	NN	O	11	PMOD
13	:	:	O	:	O	1	P
14	(	(	B-LST	(	O	15	DEP
15	WI	WI	I-LST	LS	O	19	NMOD
16	)	)	O	)	O	15	DEP
17	WUBR	WUBR	B-NP	NNP	O	19	NMOD
18	Wistar	Wistar	I-NP	NNP	O	19	NMOD
19	rats	rat	I-NP	NNS	O	24	NMOD
20	--	--	O	:	O	24	P
21	DFU	DFU	B-NP	NN	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	piroxicam	piroxicam	B-NP	NN	O	24	NMOD
24	study	study	I-NP	NN	O	0	ROOT
25	.	.	O	.	O	24	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	experiment	experiment	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	evaluate	evaluate	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	11	NMOD
10	developmental	developmental	I-NP	JJ	O	11	NMOD
11	toxicity	toxicity	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	33	NMOD
14	non-selective	non-selective	I-NP	JJ	O	19	AMOD
15	(	(	O	(	O	17	DEP
16	piroxicam	piroxicam	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	AMOD
18	and	and	O	CC	O	19	AMOD
19	selective	selective	B-NP	JJ	O	33	NMOD
20	(	(	O	(	O	33	NMOD
21	DFU	DFU	B-NP	NN	O	33	NMOD
22	;	;	O	:	O	33	P
23	5	5	B-NP	CD	O	33	NMOD
24	,	,	I-NP	,	O	33	P
25	5-dimethyl-3-	5-dimethyl-3-	I-NP	CD	O	33	NMOD
26	(	(	O	(	O	28	DEP
27	3-fluorophenyl	3-fluorophenyl	B-NP	NN	O	28	DEP
28	)	)	O	)	O	33	NMOD
29	-4-	-4-	B-NP	CD	O	33	NMOD
30	(	(	O	(	O	32	DEP
31	4-methylsulphonyl	4-methylsulphonyl	B-NP	NN	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	phenyl-2	phenyl-2	B-NP	NN	O	40	NMOD
34	(	(	O	(	O	36	DEP
35	5H	5H	B-NP	NN	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	-furanon	-furanon	B-NP	NN	O	33	NMOD
38	)	)	O	)	O	33	NMOD
39	COX-2	COX-2	B-NP	NN	O	40	NMOD
40	inhibitors	inhibitor	I-NP	NNS	O	12	PMOD
41	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	4	NMOD
2	pooled	pooled	I-NP	JJ	O	4	NMOD
3	statistical	statistical	I-NP	JJ	O	4	NMOD
4	analysis	analysis	I-NP	NN	O	17	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	ventricular	ventricular	B-NP	JJ	O	7	NMOD
7	septal	septal	I-NP	JJ	O	16	NMOD
8	(	(	O	(	O	10	DEP
9	VSD	VSD	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	and	and	O	CC	O	12	NMOD
12	midline	midline	B-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	MD	MD	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	defects	defect	B-NP	NNS	O	5	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	performed	perform	I-VP	VBN	O	17	VC
19	for	for	B-PP	IN	O	18	VMOD
20	rat	rat	B-NP	NN	O	21	NMOD
21	fetuses	fetus	I-NP	NNS	O	30	NMOD
22	exposed	expose	B-VP	VBN	O	21	NMOD
23	to	to	B-PP	TO	O	22	VMOD
24	piroxicam	piroxicam	B-NP	NN	O	23	PMOD
25	,	,	O	,	O	30	P
26	selective	selective	B-NP	JJ	O	30	NMOD
27	and	and	I-NP	CC	O	30	NMOD
28	non-selective	non-selective	I-NP	JJ	O	30	NMOD
29	COX-2	COX-2	I-NP	NN	O	30	NMOD
30	inhibitor	inhibitor	I-NP	NN	O	19	PMOD
31	based	base	B-VP	VBN	O	30	NMOD
32	on	on	B-PP	IN	O	31	PMOD
33	present	present	B-NP	JJ	O	36	NMOD
34	and	and	I-NP	CC	O	36	NMOD
35	historic	historic	I-NP	JJ	O	36	NMOD
36	data	datum	I-NP	NNS	O	32	PMOD
37	.	.	O	.	O	17	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Maternal	Maternal	B-NP	JJ	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	17	VMOD
5	,	,	O	,	O	17	P
6	intrauterine	intrauterine	B-NP	JJ	O	8	NMOD
7	growth	growth	I-NP	NN	O	8	NMOD
8	retardation	retardation	I-NP	NN	O	17	SUB
9	,	,	O	,	O	17	P
10	and	and	O	CC	O	11	NMOD
11	increase	increase	B-NP	NN	O	17	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	external	external	B-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	skeletal	skeletal	I-NP	JJ	O	16	NMOD
16	variations	variation	I-NP	NNS	O	12	PMOD
17	were	be	B-VP	VBD	O	1	NMOD
18	found	find	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	treated	treat	B-VP	VBN	O	20	NMOD
22	with	with	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	highest	high	I-NP	JJS	O	25	NMOD
25	dose	dose	I-NP	NN	O	22	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	piroxicam	piroxicam	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	1	P

1	Decrease	Decrease	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	fetal	fetal	B-NP	JJ	O	4	NMOD
4	length	length	I-NP	NN	O	2	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	only	only	I-NP	JJ	O	8	NMOD
8	signs	sign	I-NP	NNS	O	5	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	DFU	DFU	I-NP	NN	O	13	NMOD
12	developmental	developmental	I-NP	JJ	O	13	NMOD
13	toxicity	toxicity	I-NP	NN	O	9	PMOD
14	observed	observe	B-VP	VBN	O	13	NMOD
15	in	in	B-PP	IN	O	14	VMOD
16	pups	pup	B-NP	NNS	O	15	PMOD
17	exposed	expose	B-VP	VBN	O	16	NMOD
18	to	to	B-PP	TO	O	17	VMOD
19	the	the	B-NP	DT	O	22	NMOD
20	highest	high	I-NP	JJS	O	22	NMOD
21	compound	compound	I-NP	NN	O	22	NMOD
22	dose	dose	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	5	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	efficacy	efficacy	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	neuroactive	neuroactive	B-NP	JJ	O	5	NMOD
5	steroids	steroid	I-NP	NNS	O	3	PMOD
6	against	against	B-PP	IN	O	5	NMOD
7	cocaine	cocaine	B-NP	NN	O	8	NMOD
8	kindled-seizures	kindled-seizure	I-NP	NNS	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	mice	mouse	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	2	P

1	Neuroactive	Neuroactive	B-NP	JJ	O	2	NMOD
2	steroids	steroid	I-NP	NNS	O	3	SUB
3	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
4	pharmacological	pharmacological	B-NP	JJ	O	5	NMOD
5	actions	action	I-NP	NNS	O	3	OBJ
6	that	that	B-NP	WDT	O	5	NMOD
7	have	have	B-VP	VBP	O	6	SBAR
8	relevance	relevance	B-NP	NN	O	7	OBJ
9	for	for	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	11	NMOD
11	host	host	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	neurological	neurological	B-NP	JJ	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	psychiatric	psychiatric	I-NP	JJ	O	16	NMOD
16	disorders	disorder	I-NP	NNS	O	12	PMOD
17	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	evaluate	evaluate	I-VP	VB	O	4	VMOD
8	two	two	B-NP	CD	O	11	NMOD
9	endogenous	endogenous	I-NP	JJ	O	8	NMOD
10	and	and	O	CC	O	11	NMOD
11	one	one	B-NP	CD	O	14	NMOD
12	synthetic	synthetic	I-NP	JJ	O	13	AMOD
13	neuroactive	neuroactive	I-NP	JJ	O	14	NMOD
14	steroid	steroid	I-NP	NN	O	7	OBJ
15	that	that	B-NP	WDT	O	14	NMOD
16	positively	positively	B-ADVP	RB	O	17	VMOD
17	modulate	modulate	B-VP	VBP	O	15	SBAR
18	the	the	B-NP	DT	O	20	NMOD
19	gamma-aminobutyric	gamma-aminobutyric	I-NP	JJ	O	20	NMOD
20	acid	acid	I-NP	NN	O	27	NMOD
21	(	(	O	(	O	26	DEP
22	GABA	GABA	B-NP	NN	O	26	DEP
23	(	(	O	(	O	25	DEP
24	A	A	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	)	)	O	)	O	20	NMOD
27	receptor	receptor	B-NP	NN	O	17	OBJ
28	against	against	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	increase	increase	I-NP	NN	O	28	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	sensitivity	sensitivity	B-NP	NN	O	31	PMOD
33	to	to	B-PP	TO	O	32	NMOD
34	the	the	B-NP	DT	O	36	NMOD
35	convulsant	convulsant	I-NP	JJ	O	36	NMOD
36	effects	effect	I-NP	NNS	O	33	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	cocaine	cocaine	B-NP	NN	O	37	PMOD
39	engendered	engender	B-VP	VBN	O	38	NMOD
40	by	by	B-PP	IN	O	39	VMOD
41	repeated	repeat	B-NP	VBN	O	43	NMOD
42	cocaine	cocaine	I-NP	NN	O	43	NMOD
43	administration	administration	I-NP	NN	O	40	PMOD
44	(	(	O	(	O	47	DEP
45	seizure	seizure	B-NP	NN	O	46	NMOD
46	kindling	kindling	I-NP	NN	O	47	DEP
47	)	)	O	)	O	43	NMOD
48	.	.	O	.	O	4	P

1	Allopregnanolone	Allopregnanolone	B-NP	NN	O	11	NMOD
2	(	(	O	(	O	4	DEP
3	3alpha-hydroxy-5alpha-pregnan-20-one	3alpha-hydroxy-5alpha-pregnan-20-one	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	,	,	O	,	O	11	P
6	pregnanolone	pregnanolone	B-NP	NN	O	11	NMOD
7	(	(	O	(	O	9	DEP
8	3alpha-hydroxy-5beta-pregnan-20-one	3alpha-hydroxy-5beta-pregnan-20-one	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	and	and	O	CC	O	11	NMOD
11	ganaxolone	ganaxolone	B-NP	NN	O	20	SUB
12	(	(	O	(	O	19	DEP
13	a	a	B-NP	DT	O	15	NMOD
14	synthetic	synthetic	I-NP	JJ	O	15	NMOD
15	derivative	derivative	I-NP	NN	O	19	DEP
16	of	of	B-PP	IN	O	15	NMOD
17	allopregnanolone	allopregnanolone	B-NP	NN	O	18	NMOD
18	3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one	3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one	I-NP	NN	O	16	PMOD
19	)	)	O	)	O	11	NMOD
20	were	be	B-VP	VBD	O	0	ROOT
21	tested	test	I-VP	VBN	O	20	VC
22	for	for	B-PP	IN	O	21	VMOD
23	their	their	B-NP	PRP$	O	24	NMOD
24	ability	ability	I-NP	NN	O	34	NMOD
25	to	to	B-VP	TO	O	26	VMOD
26	suppress	suppress	I-VP	VB	O	24	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	expression	expression	I-NP	NN	O	26	OBJ
29	(	(	O	(	O	32	DEP
30	anticonvulsant	anticonvulsant	B-NP	JJ	O	31	NMOD
31	effect	effect	I-NP	NN	O	32	DEP
32	)	)	O	)	O	24	NMOD
33	and	and	O	CC	O	34	NMOD
34	development	development	B-NP	NN	O	22	PMOD
35	(	(	O	(	O	38	DEP
36	antiepileptogenic	antiepileptogenic	B-NP	JJ	O	37	NMOD
37	effect	effect	I-NP	NN	O	38	DEP
38	)	)	O	)	O	34	NMOD
39	of	of	B-PP	IN	O	34	NMOD
40	cocaine-kindled	cocaine-kindled	B-NP	JJ	O	41	NMOD
41	seizures	seizure	I-NP	NNS	O	39	PMOD
42	in	in	B-PP	IN	O	34	NMOD
43	male	male	B-NP	JJ	O	45	AMOD
44	,	,	I-NP	,	O	45	P
45	Swiss-Webster	Swiss-Webster	I-NP	JJ	O	46	NMOD
46	mice	mouse	I-NP	NNS	O	42	PMOD
47	.	.	O	.	O	20	P

1	Kindled	Kindle	B-NP	VBN	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	induced	induce	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	daily	daily	B-NP	JJ	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	60	60	B-NP	CD	O	11	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	11	NMOD
11	cocaine	cocaine	I-NP	NN	O	8	PMOD
12	for	for	B-PP	IN	O	7	NMOD
13	5	5	B-NP	CD	O	14	NMOD
14	days	day	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	3	P

1	All	All	B-NP	DT	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	these	these	B-NP	DT	O	5	NMOD
4	positive	positive	I-NP	JJ	O	5	NMOD
5	GABA	GABA	I-NP	NN	O	9	NMOD
6	(	(	O	(	O	8	DEP
7	A	A	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	modulators	modulator	B-NP	NNS	O	2	PMOD
10	suppressed	suppress	B-VP	VBD	O	0	ROOT
11	the	the	B-NP	DT	O	12	NMOD
12	expression	expression	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	kindled	kindled	B-NP	JJ	O	15	NMOD
15	seizures	seizure	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	10	P
17	whereas	whereas	O	IN	O	10	VMOD
18	only	only	B-NP	RB	O	21	NMOD
19	allopregnanolone	allopregnanolone	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	ganaxolone	ganaxolone	I-NP	NN	O	22	SUB
22	inhibited	inhibit	B-VP	VBD	O	17	SBAR
23	the	the	B-NP	DT	O	24	NMOD
24	development	development	I-NP	NN	O	22	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	kindling	kindling	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	10	P

1	These	These	B-NP	DT	O	2	SUB
2	are	be	B-VP	VBP	O	7	VMOD
3	nephrotoxic	nephrotoxic	B-ADJP	JJ	O	2	PRD
4	,	,	O	,	O	7	P
5	but	but	O	CC	O	7	VMOD
6	SRL	SRL	B-NP	NN	B-protein	7	SUB
7	seems	seem	B-VP	VBZ	O	0	ROOT
8	to	to	I-VP	TO	O	9	VMOD
9	act	act	I-VP	VB	O	7	VMOD
10	differently	differently	B-ADVP	RB	O	9	VMOD
11	displaying	display	B-VP	VBG	O	9	VMOD
12	only	only	B-NP	RB	O	13	AMOD
13	minor	minor	I-NP	JJ	O	15	NMOD
14	nephrotoxic	nephrotoxic	I-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	11	OBJ
16	,	,	O	,	O	7	P
17	although	although	B-SBAR	IN	O	7	VMOD
18	this	this	B-NP	DT	O	19	NMOD
19	question	question	I-NP	NN	O	20	SUB
20	is	be	B-VP	VBZ	O	17	SBAR
21	still	still	B-ADVP	RB	O	20	VMOD
22	open	open	B-ADJP	JJ	O	20	PRD
23	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	21	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	number	number	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	treatment	treatment	B-NP	NN	O	6	NMOD
6	protocols	protocol	I-NP	NNS	O	4	PMOD
7	where	where	B-ADVP	WRB	O	6	NMOD
8	SRL	SRL	B-NP	NN	B-protein	9	SUB
9	was	be	B-VP	VBD	O	7	SBAR
10	combined	combine	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	calcineurin	calcineurin	I-NP	NN	B-protein	15	NMOD
14	inhibitor	inhibitor	I-NP	NN	O	15	NMOD
15	indications	indication	I-NP	NNS	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	a	a	B-NP	DT	O	20	NMOD
18	synergistic	synergistic	I-NP	JJ	O	20	NMOD
19	nephrotoxic	nephrotoxic	I-NP	JJ	O	20	NMOD
20	effect	effect	I-NP	NN	O	16	PMOD
21	were	be	B-VP	VBD	O	0	ROOT
22	described	describe	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	3	NMOD
2	semi-quantitative	semi-quantitative	I-NP	JJ	O	3	NMOD
3	scoring	scoring	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	33	VMOD
5	significantly	significantly	B-ADJP	RB	O	4	PRD
6	worst	worst	I-ADJP	JJS	O	5	AMOD
7	in	in	B-PP	IN	O	5	AMOD
8	the	the	B-NP	DT	O	9	NMOD
9	group	group	I-NP	NN	O	7	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	CsA	CsA	B-NP	NN	O	14	NMOD
13	plus	plus	O	CC	O	14	NMOD
14	SRL	SRL	B-NP	NN	B-protein	11	PMOD
15	(	(	O	(	O	22	DEP
16	P	P	B-NP	NN	O	22	DEP
17	<	<	O	SYM	O	16	NMOD
18	0.001	0.001	B-NP	CD	O	17	AMOD
19	compared	compare	B-PP	VBN	O	16	NMOD
20	with	with	B-PP	IN	O	19	PMOD
21	controls	control	B-NP	NNS	O	20	PMOD
22	)	)	O	)	O	4	VMOD
23	and	and	O	CC	O	33	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	analysis	analysis	I-NP	NN	O	33	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	total	total	I-NP	JJ	O	29	NMOD
29	grade	grade	I-NP	NN	O	26	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	fibrosis	fibrosis	B-NP	NN	O	30	PMOD
32	also	also	B-ADVP	RB	O	33	VMOD
33	showed	show	B-VP	VBD	O	0	ROOT
34	the	the	B-NP	DT	O	36	NMOD
35	highest	high	I-NP	JJS	O	36	NMOD
36	proportion	proportion	I-NP	NN	O	33	OBJ
37	in	in	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	40	NMOD
39	same	same	I-NP	JJ	O	40	NMOD
40	group	group	I-NP	NN	O	37	PMOD
41	and	and	O	CC	O	33	VMOD
42	was	be	B-VP	VBD	O	33	VMOD
43	significantly	significantly	B-ADJP	RB	O	44	AMOD
44	different	different	I-ADJP	JJ	O	42	PRD
45	from	from	B-PP	IN	O	44	AMOD
46	controls	control	B-NP	NNS	O	45	PMOD
47	(	(	O	(	O	51	DEP
48	P	P	B-NP	NN	O	51	DEP
49	<	<	B-NP	JJR	O	48	NMOD
50	0.02	0.02	I-NP	CD	O	49	AMOD
51	)	)	O	)	O	46	NMOD
52	.	.	O	.	O	33	P

1	The	The	B-NP	DT	O	5	NMOD
2	FK506	FK506	I-NP	NN	O	5	NMOD
3	plus	plus	I-NP	CC	O	5	NMOD
4	SRL	SRL	I-NP	NN	O	5	NMOD
5	combination	combination	I-NP	NN	O	6	SUB
6	showed	show	B-VP	VBD	O	0	ROOT
7	only	only	B-NP	RB	O	11	NMOD
8	a	a	I-NP	DT	O	11	NMOD
9	marginally	marginally	I-NP	RB	O	10	AMOD
10	higher	high	I-NP	JJR	O	11	NMOD
11	degree	degree	I-NP	NN	O	6	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	fibrosis	fibrosis	B-NP	NN	O	12	PMOD
14	as	as	B-PP	IN	O	6	VMOD
15	compared	compare	B-PP	VBN	O	14	PMOD
16	with	with	B-PP	IN	O	15	VMOD
17	controls	control	B-NP	NNS	O	16	PMOD
18	(	(	O	(	O	20	DEP
19	P=0.05	P=0.05	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	.	.	O	.	O	6	P

1	Effect	Effect	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	fucoidan	fucoidan	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	collagenase	collagenase	B-NP	NN	B-protein	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	intracerebral	intracerebral	B-NP	JJ	O	9	NMOD
9	hemorrhage	hemorrhage	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	tested	test	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	sulfated	sulfated	I-NP	JJ	O	6	NMOD
5	polysaccharide	polysaccharide	I-NP	NN	O	6	NMOD
6	fucoidan	fucoidan	I-NP	NN	O	2	OBJ
7	,	,	O	,	O	6	P
8	which	which	B-NP	WDT	O	6	NMOD
9	has	have	B-VP	VBZ	O	8	SBAR
10	been	be	I-VP	VBN	O	9	VC
11	reported	report	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	reduce	reduce	I-VP	VB	O	11	VMOD
14	inflammatory	inflammatory	B-NP	JJ	O	16	NMOD
15	brain	brain	I-NP	NN	O	16	NMOD
16	damage	damage	I-NP	NN	O	13	OBJ
17	,	,	O	,	O	2	P
18	in	in	B-PP	IN	O	2	VMOD
19	a	a	B-NP	DT	O	21	NMOD
20	rat	rat	I-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	intracerebral	intracerebral	B-NP	JJ	O	24	NMOD
24	hemorrhage	hemorrhage	I-NP	NN	O	22	PMOD
25	induced	induce	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	injection	injection	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	bacterial	bacterial	B-NP	JJ	O	30	NMOD
30	collagenase	collagenase	I-NP	NN	B-protein	28	PMOD
31	into	into	B-PP	IN	O	27	NMOD
32	the	the	B-NP	DT	O	34	NMOD
33	caudate	caudate	I-NP	JJ	O	34	NMOD
34	nucleus	nucleus	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	2	P

1	Fucoidan-treated	Fucoidan-treated	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	3	SUB
3	exhibited	exhibit	B-VP	VBD	O	0	ROOT
4	evidence	evidence	B-NP	NN	O	3	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	impaired	impaired	B-NP	JJ	O	8	NMOD
7	blood	blood	I-NP	NN	O	8	NMOD
8	clotting	clotting	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	hemodilution	hemodilution	I-NP	NN	O	5	PMOD
11	,	,	O	,	O	3	P
12	had	have	B-VP	VBD	O	3	VMOD
13	larger	large	B-NP	JJR	O	14	NMOD
14	hematomas	hematoma	I-NP	NNS	O	12	OBJ
15	,	,	O	,	O	3	P
16	and	and	O	CC	O	3	VMOD
17	tended	tend	B-VP	VBD	O	3	VMOD
18	to	to	I-VP	TO	O	19	VMOD
19	have	have	I-VP	VB	O	17	VMOD
20	less	less	B-NP	JJR	O	21	NMOD
21	inflammation	inflammation	I-NP	NN	O	19	OBJ
22	in	in	B-PP	IN	O	19	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	vicinity	vicinity	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	hematoma	hematoma	I-NP	NN	O	25	PMOD
28	after	after	B-PP	IN	O	19	VMOD
29	three	three	B-NP	CD	O	30	NMOD
30	days	day	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	3	P

1	Paracetamol-associated	Paracetamol-associated	B-NP	JJ	O	2	NMOD
2	coma	coma	I-NP	NN	O	10	NMOD
3	,	,	O	,	O	10	P
4	metabolic	metabolic	B-NP	JJ	O	5	NMOD
5	acidosis	acidosis	I-NP	NN	O	10	NMOD
6	,	,	O	,	O	10	P
7	renal	renal	B-NP	JJ	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	hepatic	hepatic	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	In	In	B-PP	IN	O	14	VMOD
2	two	two	B-NP	CD	O	13	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	three	three	I-NP	CD	O	6	NMOD
6	deaths	death	I-NP	NNS	O	3	PMOD
7	probably	probably	B-ADVP	RB	O	8	VMOD
8	associated	associate	B-VP	VBN	O	13	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	ketoconazole	ketoconazole	B-NP	NN	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	the	the	B-NP	DT	O	13	NMOD
13	drug	drug	I-NP	NN	O	14	SUB
14	had	have	B-VP	VBD	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	continued	continue	I-VP	VBN	O	15	VC
17	after	after	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	onset	onset	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	jaundice	jaundice	B-NP	NN	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	other	other	B-NP	JJ	O	24	NMOD
24	symptoms	symptom	I-NP	NNS	O	20	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	hepatitis	hepatitis	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	14	P

1	Combined	Combine	B-NP	VBN	O	2	NMOD
2	effects	effect	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	prolonged	prolong	B-NP	VBN	B-protein	6	NMOD
5	prostaglandin	prostaglandin	I-NP	NN	I-protein	6	NMOD
6	E1	E1	I-NP	NN	I-protein	3	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	hypotension	hypotension	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	haemodilution	haemodilution	I-NP	NN	O	7	OBJ
11	on	on	B-PP	IN	O	10	NMOD
12	human	human	B-NP	JJ	O	14	NMOD
13	hepatic	hepatic	I-NP	JJ	O	14	NMOD
14	function	function	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	7	P

1	Combined	Combine	B-NP	VBN	O	2	NMOD
2	effects	effect	I-NP	NNS	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	prolonged	prolong	B-NP	VBN	O	6	NMOD
5	prostaglandin	prostaglandin	I-NP	NN	O	6	NMOD
6	E1	E1	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	PGE1	PGE1	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	hypotension	hypotension	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	haemodilution	haemodilution	I-NP	NN	O	10	OBJ
14	on	on	B-PP	IN	O	10	VMOD
15	hepatic	hepatic	B-NP	JJ	O	16	NMOD
16	function	function	I-NP	NN	O	14	PMOD
17	were	be	B-VP	VBD	O	10	VMOD
18	studied	study	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	30	30	B-NP	CD	O	21	NMOD
21	patients	patient	I-NP	NNS	O	19	PMOD
22	undergoing	undergo	B-VP	VBG	O	21	NMOD
23	hip	hip	B-NP	NN	O	24	NMOD
24	surgery	surgery	I-NP	NN	O	22	OBJ
25	.	.	O	.	O	10	P

1	Haemodilution	Haemodilution	B-NP	NN	O	7	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	groups	group	B-NP	NNS	O	6	NMOD
4	B	B	B-NP	NN	O	6	NMOD
5	and	and	O	CC	O	6	NMOD
6	C	C	B-NP	NN	O	2	PMOD
7	was	be	B-VP	VBD	O	31	VMOD
8	produced	produce	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	withdrawing	withdraw	B-VP	VBG	O	9	PMOD
11	approximately	approximately	B-NP	RB	O	13	NMOD
12	1000	1000	I-NP	CD	O	11	AMOD
13	mL	mL	I-NP	NN	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	blood	blood	B-NP	NN	O	14	PMOD
16	and	and	O	CC	O	10	VMOD
17	replacing	replace	B-VP	VBG	O	10	VMOD
18	it	it	B-NP	PRP	O	17	OBJ
19	with	with	B-PP	IN	O	17	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	same	same	I-NP	JJ	O	22	NMOD
22	amount	amount	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	dextran	dextran	B-NP	NN	O	25	NMOD
25	solution	solution	I-NP	NN	O	23	PMOD
26	,	,	O	,	O	31	P
27	and	and	O	CC	O	31	VMOD
28	final	final	B-NP	JJ	O	30	NMOD
29	haematocrit	haematocrit	I-NP	NN	O	30	NMOD
30	values	value	I-NP	NNS	O	31	SUB
31	were	be	B-VP	VBD	O	0	ROOT
32	21	21	B-NP	CD	O	34	AMOD
33	or	or	I-NP	CC	O	34	AMOD
34	22	22	I-NP	CD	O	35	NMOD
35	%	%	I-NP	NN	O	31	PRD
36	.	.	O	.	O	31	P

1	Controlled	Control	B-NP	VBN	O	2	NMOD
2	hypotension	hypotension	I-NP	NN	O	8	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	groups	group	B-NP	NNS	O	7	NMOD
5	A	A	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	C	C	I-NP	NN	O	3	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	induced	induce	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	PGE1	PGE1	B-NP	NN	O	10	PMOD
12	to	to	B-VP	TO	O	13	VMOD
13	maintain	maintain	I-VP	VB	O	8	VMOD
14	mean	mean	B-NP	JJ	O	17	NMOD
15	arterial	arterial	I-NP	JJ	O	17	NMOD
16	blood	blood	I-NP	NN	O	17	NMOD
17	pressure	pressure	I-NP	NN	O	13	OBJ
18	at	at	B-PP	IN	O	13	VMOD
19	55	55	B-NP	CD	O	20	NMOD
20	mmHg	mmHg	I-NP	NN	O	18	PMOD
21	for	for	B-PP	IN	O	13	VMOD
22	180	180	B-NP	CD	O	23	NMOD
23	min	min	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	6	VMOD
2	group	group	B-NP	NN	O	3	NMOD
3	C	C	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	AKBR	AKBR	B-NP	NN	B-protein	6	SUB
6	showed	show	B-VP	VBD	O	52	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	significant	significant	I-NP	JJ	O	9	NMOD
9	decrease	decrease	I-NP	NN	O	6	OBJ
10	at	at	B-PP	IN	O	9	NMOD
11	120	120	B-NP	CD	O	12	NMOD
12	min	min	I-NP	NN	O	10	PMOD
13	(	(	O	(	O	16	DEP
14	-40	-40	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	and	and	O	CC	O	10	PMOD
18	at	at	B-PP	IN	O	10	PMOD
19	180	180	B-NP	CD	O	20	NMOD
20	min	min	I-NP	NN	O	18	PMOD
21	(	(	O	(	O	24	DEP
22	-49	-49	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	after	after	B-PP	IN	O	20	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	start	start	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	hypotension	hypotension	B-NP	NN	O	28	PMOD
30	and	and	B-PP	CC	O	10	PMOD
31	at	at	B-PP	IN	O	10	PMOD
32	60	60	B-NP	CD	O	33	NMOD
33	min	min	I-NP	NN	O	31	PMOD
34	(	(	O	(	O	37	DEP
35	-32	-32	B-NP	CD	O	36	NMOD
36	%	%	I-NP	NN	O	37	DEP
37	)	)	O	)	O	33	NMOD
38	after	after	B-PP	IN	O	33	NMOD
39	recovery	recovery	B-NP	NN	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	normotension	normotension	B-NP	NN	O	40	PMOD
42	,	,	O	,	O	52	P
43	and	and	O	CC	O	52	VMOD
44	SGOT	SGOT	B-NP	NN	B-protein	51	NMOD
45	,	,	O	,	O	51	P
46	SGPT	SGPT	B-NP	NN	B-protein	51	NMOD
47	,	,	O	,	O	51	P
48	LDH	LDH	B-NP	NN	B-protein	51	NMOD
49	and	and	O	CC	O	51	NMOD
50	total	total	B-NP	JJ	O	51	NMOD
51	bilirubin	bilirubin	I-NP	NN	O	52	SUB
52	showed	show	B-VP	VBD	O	0	ROOT
53	significant	significant	B-NP	JJ	O	54	NMOD
54	increases	increase	I-NP	NNS	O	52	OBJ
55	after	after	B-PP	IN	O	54	NMOD
56	operation	operation	B-NP	NN	O	55	PMOD
57	.	.	O	.	O	52	P

1	Levodopa	Levodopa	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	dyskinesias	dyskinesia	B-NP	NNS	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	Parkinson	Parkinson	B-NP	NNP	O	9	NMOD
8	's	's	B-NP	POS	O	9	NMOD
9	disease	disease	I-NP	NN	O	6	PMOD
10	:	:	O	:	O	2	P
11	filling	fill	B-VP	VBG	O	2	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	bench-to-bedside	bench-to-bedside	I-NP	JJ	B-protein	14	NMOD
14	gap	gap	I-NP	NN	I-protein	11	OBJ
15	.	.	O	.	O	2	P

1	Levodopa	Levodopa	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	most	most	I-NP	RBS	O	5	AMOD
5	effective	effective	I-NP	JJ	O	6	NMOD
6	drug	drug	I-NP	NN	O	2	PRD
7	for	for	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	Parkinson	Parkinson	B-NP	NNP	O	13	NMOD
12	's	's	B-NP	POS	O	13	NMOD
13	disease	disease	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	However	However	B-ADVP	RB	O	10	VMOD
2	,	,	O	,	O	10	P
3	the	the	B-NP	DT	O	5	NMOD
4	long-term	long-term	I-NP	JJ	O	5	NMOD
5	use	use	I-NP	NN	O	10	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	this	this	B-NP	DT	O	9	NMOD
8	dopamine	dopamine	I-NP	NN	O	9	NMOD
9	precursor	precursor	I-NP	NN	O	6	PMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	complicated	complicate	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	highly	highly	B-VP	RB	O	14	AMOD
14	disabling	disable	I-VP	VBG	O	12	PMOD
15	fluctuations	fluctuation	B-NP	NNS	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	dyskinesias	dyskinesia	I-NP	NNS	O	14	OBJ
18	.	.	O	.	O	10	P

1	Although	Although	B-SBAR	IN	O	24	VMOD
2	preclinical	preclinical	B-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	clinical	clinical	I-NP	JJ	O	5	NMOD
5	findings	finding	I-NP	NNS	O	6	SUB
6	suggest	suggest	B-VP	VBP	O	1	SBAR
7	pulsatile	pulsatile	B-NP	JJ	O	8	NMOD
8	stimulation	stimulation	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	striatal	striatal	B-NP	JJ	B-protein	12	NMOD
11	postsynaptic	postsynaptic	I-NP	JJ	I-protein	12	NMOD
12	receptors	receptor	I-NP	NNS	I-protein	9	PMOD
13	as	as	B-PP	IN	O	8	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	key	key	I-NP	JJ	O	16	NMOD
16	mechanism	mechanism	I-NP	NN	O	13	PMOD
17	underlying	underlie	I-NP	VBG	O	16	NMOD
18	levodopa	levodopa	I-NP	NN	O	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	dyskinesias	dyskinesia	I-NP	NNS	O	17	OBJ
21	,	,	O	,	O	24	P
22	their	their	B-NP	PRP$	O	23	NMOD
23	pathogenesis	pathogenesis	I-NP	NN	O	24	SUB
24	is	be	B-VP	VBZ	O	0	ROOT
25	still	still	B-ADVP	RB	O	24	VMOD
26	unclear	unclear	B-ADJP	JJ	O	24	PRD
27	.	.	O	.	O	24	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	investigated	investigate	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	therapeutic	therapeutic	I-NP	JJ	O	9	NMOD
9	potential	potential	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	bone	bone	B-NP	NN	B-cell_type	14	NMOD
12	marrow	marrow	I-NP	NN	I-cell_type	14	NMOD
13	mononuclear	mononuclear	I-NP	JJ	I-cell_type	14	NMOD
14	cells	cell	I-NP	NNS	I-cell_type	10	PMOD
15	(	(	O	(	O	17	DEP
16	BMCs	BMC	B-NP	NNS	B-cell_type	17	DEP
17	)	)	O	)	O	14	NMOD
18	in	in	B-PP	IN	O	6	VMOD
19	a	a	B-NP	DT	O	20	NMOD
20	model	model	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	epilepsy	epilepsy	B-NP	NN	O	21	PMOD
23	induced	induce	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	pilocarpine	pilocarpine	B-NP	NN	O	24	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	rats	rat	B-NP	NNS	O	26	PMOD
28	.	.	O	.	O	6	P

1	Cardioprotective	Cardioprotective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	salvianolic	salvianolic	B-NP	JJ	B-protein	6	NMOD
5	acid	acid	I-NP	NN	I-protein	6	NMOD
6	A	A	I-NP	NN	I-protein	3	PMOD
7	on	on	B-PP	IN	O	2	NMOD
8	isoproterenol	isoproterenol	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	infarction	infarction	I-NP	NN	O	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	rats	rat	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	evaluate	evaluate	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	cardioprotective	cardioprotective	I-NP	JJ	O	10	NMOD
10	potential	potential	I-NP	NN	O	17	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	salvianolic	salvianolic	B-NP	JJ	B-protein	14	NMOD
13	acid	acid	I-NP	NN	I-protein	14	NMOD
14	A	A	I-NP	NN	I-protein	11	PMOD
15	on	on	B-PP	IN	O	10	NMOD
16	isoproterenol	isoproterenol	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	7	VMOD
18	myocardial	myocardial	B-NP	JJ	O	19	NMOD
19	infarction	infarction	I-NP	NN	O	17	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	rats	rat	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	15	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	15	P
4	mitochondrial	mitochondrial	B-NP	JJ	O	6	NMOD
5	respiratory	respiratory	I-NP	JJ	O	6	NMOD
6	dysfunction	dysfunction	I-NP	NN	O	15	SUB
7	characterized	characterize	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	decreased	decrease	B-NP	VBN	O	14	NMOD
10	respiratory	respiratory	I-NP	JJ	O	12	NMOD
11	control	control	I-NP	NN	O	12	NMOD
12	ratio	ratio	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	ADP/O	ADP/O	I-NP	NN	B-protein	8	PMOD
15	was	be	B-VP	VBD	O	0	ROOT
16	observed	observe	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	isoproterenol-treated	isoproterenol-treated	B-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	15	P

1	Administration	Administration	B-NP	NN	O	13	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	salvianolic	salvianolic	B-NP	JJ	B-protein	5	NMOD
4	acid	acid	I-NP	NN	I-protein	5	NMOD
5	A	A	I-NP	NN	I-protein	2	PMOD
6	for	for	B-PP	IN	O	1	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	period	period	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	8	8	B-NP	CD	O	11	NMOD
11	days	day	I-NP	NNS	O	9	PMOD
12	significantly	significantly	B-ADVP	RB	O	13	VMOD
13	attenuated	attenuate	B-VP	VBD	O	0	ROOT
14	isoproterenol	isoproterenol	B-NP	NN	O	17	NMOD
15	induced	induced	I-NP	JJ	O	17	NMOD
16	cardiac	cardiac	I-NP	JJ	O	17	NMOD
17	dysfunction	dysfunction	I-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	myocardial	myocardial	B-NP	JJ	O	20	NMOD
20	injury	injury	I-NP	NN	O	25	NMOD
21	and	and	O	CC	O	25	NMOD
22	improved	improve	B-NP	VBN	O	25	NMOD
23	mitochondrial	mitochondrial	I-NP	JJ	O	25	NMOD
24	respiratory	respiratory	I-NP	JJ	O	25	NMOD
25	function	function	I-NP	NN	O	13	OBJ
26	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	3	NMOD
2	protective	protective	I-NP	JJ	O	3	NMOD
3	role	role	I-NP	NN	O	10	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	salvianolic	salvianolic	B-NP	JJ	B-protein	7	NMOD
6	acid	acid	I-NP	NN	I-protein	7	NMOD
7	A	A	I-NP	NN	I-protein	4	PMOD
8	against	against	B-PP	IN	O	3	NMOD
9	isoproterenol	isoproterenol	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	damage	damage	I-NP	NN	O	10	OBJ
13	was	be	B-VP	VBD	O	10	VMOD
14	further	further	I-VP	RBR	O	15	VMOD
15	confirmed	confirm	I-VP	VBN	O	13	VC
16	by	by	B-PP	IN	O	15	VMOD
17	histopathological	histopathological	B-NP	JJ	O	18	NMOD
18	examination	examination	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	10	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	N-	N-	B-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	2-propylpentanoyl	2-propylpentanoyl	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	urea	urea	B-NP	NN	O	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	hippocampal	hippocampal	B-NP	JJ	O	13	NMOD
11	amino	amino	I-NP	JJ	O	13	NMOD
12	acid	acid	I-NP	NN	O	13	NMOD
13	neurotransmitters	neurotransmitter	I-NP	NNS	O	9	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	pilocarpine	pilocarpine	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	seizure	seizure	B-NP	NN	O	16	OBJ
18	in	in	B-PP	IN	O	16	VMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	16	P

1	VPU	VPU	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	more	more	B-ADJP	RBR	O	4	AMOD
4	potent	potent	I-ADJP	JJ	O	2	PRD
5	than	than	B-PP	IN	O	4	AMOD
6	VPA	VPA	B-NP	NN	B-protein	5	PMOD
7	,	,	O	,	O	4	P
8	exhibiting	exhibit	B-VP	VBG	O	4	DEP
9	the	the	B-NP	DT	O	12	NMOD
10	median	median	I-NP	JJ	O	12	NMOD
11	effective	effective	I-NP	JJ	O	12	NMOD
12	dose	dose	I-NP	NN	O	8	OBJ
13	(	(	O	(	O	17	DEP
14	ED	ED	B-VP	VBN	O	17	DEP
15	(	(	O	(	O	17	DEP
16	50	50	B-NP	CD	O	17	DEP
17	)	)	O	)	O	12	NMOD
18	)	)	O	)	O	4	AMOD
19	of	of	B-PP	IN	O	4	AMOD
20	49	49	B-NP	CD	O	21	NMOD
21	mg/kg	mg/kg	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	4	AMOD
23	protecting	protect	B-VP	VBG	O	22	PMOD
24	rats	rat	B-NP	NNS	O	23	OBJ
25	against	against	B-PP	IN	O	23	VMOD
26	pilocarpine	pilocarpine	B-NP	NN	O	25	PMOD
27	induced	induce	B-VP	VBD	O	22	SBAR
28	seizure	seizure	B-NP	NN	O	27	OBJ
29	whereas	whereas	B-PP	IN	O	27	VMOD
30	the	the	B-NP	DT	O	32	NMOD
31	corresponding	corresponding	I-NP	JJ	O	32	NMOD
32	value	value	I-NP	NN	O	35	SUB
33	for	for	B-PP	IN	O	32	NMOD
34	VPA	VPA	B-NP	NN	B-protein	33	PMOD
35	was	be	B-VP	VBD	O	29	SBAR
36	322	322	B-NP	CD	O	37	NMOD
37	mg/kg	mg/kg	I-NP	NN	O	35	PRD
38	.	.	O	.	O	2	P

1	Based	Base	B-PP	VBN	O	18	VMOD
2	on	on	B-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	4	NMOD
4	finding	finding	I-NP	NN	O	2	PMOD
5	that	that	B-SBAR	IN	O	4	NMOD
6	VPU	VPU	B-NP	NN	B-protein	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	VPA	VPA	I-NP	NN	B-protein	9	SUB
9	could	could	B-VP	MD	O	5	SBAR
10	protect	protect	I-VP	VB	O	9	VC
11	the	the	B-NP	DT	O	12	NMOD
12	animals	animal	I-NP	NNS	O	10	OBJ
13	against	against	B-PP	IN	O	10	VMOD
14	pilocarpine	pilocarpine	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	14	AMOD
16	seizure	seizure	B-NP	NN	O	15	OBJ
17	it	it	B-NP	PRP	O	18	SUB
18	is	be	B-VP	VBZ	O	0	ROOT
19	suggested	suggest	I-VP	VBN	O	18	VC
20	that	that	B-SBAR	IN	O	19	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	reduction	reduction	I-NP	NN	O	28	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	inhibitory	inhibitory	B-NP	JJ	O	27	NMOD
25	amino	amino	I-NP	JJ	O	27	NMOD
26	acid	acid	I-NP	NN	O	27	NMOD
27	neurotransmitters	neurotransmitter	I-NP	NNS	O	23	PMOD
28	was	be	B-VP	VBD	O	20	SBAR
29	comparatively	comparatively	B-ADJP	RB	O	30	AMOD
30	minor	minor	I-ADJP	JJ	O	28	PRD
31	and	and	O	CC	O	32	VMOD
32	offset	offset	B-VP	VBN	O	30	AMOD
33	by	by	B-PP	IN	O	32	VMOD
34	a	a	B-NP	DT	O	36	NMOD
35	pronounced	pronounced	I-NP	JJ	O	36	NMOD
36	reduction	reduction	I-NP	NN	O	33	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	glutamate	glutamate	B-NP	NN	O	40	NMOD
39	and	and	I-NP	CC	O	40	NMOD
40	aspartate	aspartate	I-NP	NN	O	37	PMOD
41	.	.	O	.	O	18	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	3	NMOD
3	attack	attack	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	exposure	exposure	B-NP	NN	O	4	PMOD
6	to	to	B-PP	TO	O	5	NMOD
7	telithromycin	telithromycin	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	3	P

1	He	He	B-NP	PRP	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	prescribed	prescribe	I-VP	VBN	O	3	VC
5	telithromycin	telithromycin	B-NP	NN	O	8	NMOD
6	400	400	I-NP	CD	O	8	NMOD
7	mg/d	mg/d	I-NP	NN	O	8	NMOD
8	PO	PO	I-NP	NN	O	4	OBJ
9	to	to	B-VP	TO	O	10	VMOD
10	treat	treat	I-VP	VB	O	8	NMOD
11	an	an	B-NP	DT	O	15	NMOD
12	upper	upper	I-NP	JJ	O	15	NMOD
13	respiratory	respiratory	I-NP	JJ	O	15	NMOD
14	tract	tract	I-NP	NN	O	15	NMOD
15	infection	infection	I-NP	NN	O	17	NMOD
16	7	7	B-NP	CD	O	15	NMOD
17	days	day	I-NP	NNS	O	10	OBJ
18	prior	prior	B-ADVP	RB	O	4	VMOD
19	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	suffered	suffer	I-VP	VBN	O	3	VC
5	a	a	B-NP	DT	O	7	NMOD
6	previous	previous	I-NP	JJ	O	7	NMOD
7	episode	episode	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	"	"	O	"	O	11	NMOD
10	acute	acute	B-NP	JJ	O	11	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	unknown	unknown	B-NP	JJ	O	14	NMOD
14	origin	origin	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	3	P
16	"	"	O	"	O	3	P
17	that	that	B-NP	WDT	O	3	VMOD
18	occurred	occur	B-VP	VBD	O	17	SBAR
19	after	after	B-PP	IN	O	18	VMOD
20	telithromycin	telithromycin	B-NP	NN	O	21	NMOD
21	usage	usage	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	Based	Base	B-PP	VBN	O	17	VMOD
2	on	on	B-PP	IN	O	1	PMOD
3	a	a	B-NP	DT	O	4	NMOD
4	score	score	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	8	8	B-NP	CD	O	5	PMOD
7	on	on	B-PP	IN	O	4	NMOD
8	the	the	B-NP	DT	O	14	NMOD
9	Naranjo	Naranjo	I-NP	NNP	O	14	NMOD
10	adverse	adverse	I-NP	JJ	O	14	NMOD
11	drug	drug	I-NP	NN	O	14	NMOD
12	reaction	reaction	I-NP	NN	O	14	NMOD
13	probability	probability	I-NP	NN	O	14	NMOD
14	scale	scale	I-NP	NN	O	7	PMOD
15	,	,	O	,	O	17	P
16	telithromycin	telithromycin	B-NP	NN	O	17	SUB
17	was	be	B-VP	VBD	O	31	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	probable	probable	I-NP	JJ	O	20	NMOD
20	cause	cause	I-NP	NN	O	17	PRD
21	of	of	B-PP	IN	O	20	NMOD
22	acute	acute	B-NP	JJ	O	23	NMOD
23	hepatitis	hepatitis	I-NP	NN	O	21	PMOD
24	in	in	B-PP	IN	O	17	VMOD
25	this	this	B-NP	DT	O	26	NMOD
26	patient	patient	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	31	P
28	and	and	O	CC	O	31	VMOD
29	pathological	pathological	B-NP	JJ	O	30	NMOD
30	findings	finding	I-NP	NNS	O	31	SUB
31	suggested	suggest	B-VP	VBD	O	0	ROOT
32	drug	drug	B-NP	NN	O	35	NMOD
33	induced	induced	I-NP	JJ	O	35	NMOD
34	toxic	toxic	I-NP	JJ	O	35	NMOD
35	hepatitis	hepatitis	I-NP	NN	O	31	OBJ
36	.	.	O	.	O	31	P

1	Recurrence	Recurrence	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	hepatitis	hepatitis	B-NP	NN	O	4	NMOD
4	attack	attack	I-NP	NN	O	2	PMOD
5	might	might	B-VP	MD	O	0	ROOT
6	have	have	I-VP	VB	O	5	VC
7	been	be	I-VP	VBN	O	6	VC
8	avoided	avoid	I-VP	VBN	O	7	VC
9	if	if	B-SBAR	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	initial	initial	I-NP	JJ	O	12	NMOD
12	incident	incident	I-NP	NN	O	13	SUB
13	had	have	B-VP	VBD	O	9	SBAR
14	been	be	I-VP	VBN	O	13	VC
15	communicated	communicate	I-VP	VBN	O	14	VC
16	to	to	B-PP	TO	O	15	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	attending	attend	I-NP	VBG	O	19	NMOD
19	physician	physician	I-NP	NN	O	16	PMOD
20	who	who	B-NP	WP	O	19	NMOD
21	prescribed	prescribe	B-VP	VBD	O	20	SBAR
22	telithromycin	telithromycin	B-NP	NN	O	21	OBJ
23	the	the	B-NP	DT	O	25	NMOD
24	second	second	I-NP	JJ	O	25	NMOD
25	time	time	I-NP	NN	O	13	OBJ
26	.	.	O	.	O	5	P

1	Spironolactone	Spironolactone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	renal	renal	B-NP	JJ	O	4	NMOD
4	insufficiency	insufficiency	I-NP	NN	O	6	NMOD
5	and	and	O	CC	O	6	NMOD
6	hyperkalemia	hyperkalemia	B-NP	NN	O	2	OBJ
7	in	in	B-PP	IN	O	2	VMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	heart	heart	B-NP	NN	O	11	NMOD
11	failure	failure	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	7	NMOD
4	previous	previous	I-NP	JJ	O	7	NMOD
5	randomized	randomize	I-NP	VBN	O	7	NMOD
6	controlled	control	I-NP	VBN	O	7	NMOD
7	trial	trial	I-NP	NN	O	17	SUB
8	evaluating	evaluate	B-VP	VBG	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	spironolactone	spironolactone	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	8	VMOD
14	heart	heart	B-NP	NN	O	16	NMOD
15	failure	failure	I-NP	NN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	13	PMOD
17	reported	report	B-VP	VBD	O	1	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	low	low	I-NP	JJ	O	20	NMOD
20	risk	risk	I-NP	NN	O	29	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	hyperkalemia	hyperkalemia	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	26	DEP
24	2	2	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	26	DEP
26	)	)	O	)	O	20	NMOD
27	and	and	O	CC	O	29	NMOD
28	renal	renal	B-NP	JJ	O	29	NMOD
29	insufficiency	insufficiency	I-NP	NN	O	17	OBJ
30	(	(	O	(	O	33	DEP
31	0	0	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	33	DEP
33	)	)	O	)	O	29	NMOD
34	.	.	O	.	O	17	P

1	Because	Because	B-SBAR	IN	O	21	VMOD
2	treatments	treatment	B-NP	NNS	O	6	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	heart	heart	B-NP	NN	O	5	NMOD
5	failure	failure	I-NP	NN	O	3	PMOD
6	have	have	B-VP	VBP	O	1	SBAR
7	changed	change	I-VP	VBN	O	6	VC
8	since	since	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	benefits	benefit	I-NP	NNS	O	13	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	spironolactone	spironolactone	B-NP	NN	O	11	PMOD
13	were	be	B-VP	VBD	O	8	SBAR
14	reported	report	I-VP	VBN	O	13	VC
15	,	,	O	,	O	21	P
16	the	the	B-NP	DT	O	17	NMOD
17	prevalence	prevalence	I-NP	NN	O	21	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	these	these	B-NP	DT	O	20	NMOD
20	complications	complication	I-NP	NNS	O	18	PMOD
21	may	may	B-VP	MD	O	0	ROOT
22	differ	differ	I-VP	VB	O	21	VC
23	in	in	B-PP	IN	O	22	VMOD
24	current	current	B-NP	JJ	O	25	AMOD
25	clinical	clinical	I-NP	JJ	O	26	NMOD
26	practice	practice	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	21	P

1	We	We	B-NP	PRP	O	3	SUB
2	therefore	therefore	B-ADVP	RB	O	3	VMOD
3	sought	seek	B-VP	VBD	O	0	ROOT
4	to	to	I-VP	TO	O	5	VMOD
5	determine	determine	I-VP	VB	O	3	VMOD
6	the	the	B-NP	DT	O	10	NMOD
7	prevalence	prevalence	I-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	clinical	clinical	B-NP	JJ	O	10	NMOD
10	associations	association	I-NP	NNS	O	5	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	hyperkalemia	hyperkalemia	B-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	renal	renal	B-NP	JJ	O	15	NMOD
15	insufficiency	insufficiency	I-NP	NN	O	11	PMOD
16	in	in	B-PP	IN	O	10	NMOD
17	heart	heart	B-NP	NN	O	19	NMOD
18	failure	failure	I-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	16	PMOD
20	treated	treat	B-VP	VBN	O	19	NMOD
21	with	with	B-PP	IN	O	20	VMOD
22	spironolactone	spironolactone	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	performed	perform	B-VP	VBD	O	1	NMOD
5	a	a	B-NP	DT	O	8	NMOD
6	case	case	I-NP	NN	O	8	NMOD
7	control	control	I-NP	NN	O	8	NMOD
8	study	study	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	heart	heart	B-NP	NN	O	12	NMOD
11	failure	failure	I-NP	NN	O	12	NMOD
12	patients	patient	I-NP	NNS	O	9	PMOD
13	treated	treat	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	spironolactone	spironolactone	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	13	VMOD
17	our	our	B-NP	PRP$	O	19	NMOD
18	clinical	clinical	I-NP	JJ	O	19	NMOD
19	practice	practice	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	1	P

1	Cases	Case	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	patients	patient	B-NP	NNS	O	2	PRD
4	who	who	B-NP	WP	O	3	NMOD
5	developed	develop	B-VP	VBD	O	4	SBAR
6	hyperkalemia	hyperkalemia	B-NP	NN	O	5	OBJ
7	(	(	O	(	O	15	DEP
8	K	K	B-NP	NN	O	14	NMOD
9	(	(	O	(	O	11	DEP
10	+	+	B-NP	SYM	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	>	>	O	SYM	O	14	NMOD
13	5.0	5.0	B-NP	CD	O	14	NMOD
14	mEq/L	mEq/L	I-NP	NN	O	15	DEP
15	)	)	O	)	O	3	NMOD
16	or	or	O	CC	O	18	NMOD
17	renal	renal	B-NP	JJ	O	18	NMOD
18	insufficiency	insufficiency	I-NP	NN	O	28	SUB
19	(	(	O	(	O	24	DEP
20	Cr	Cr	B-NP	NN	O	23	NMOD
21	>	>	O	SYM	O	23	NMOD
22	or=2.5	or=2.5	B-NP	NN	O	23	NMOD
23	mg/dL	mg/dL	I-NP	NN	O	24	DEP
24	)	)	O	)	O	18	NMOD
25	,	,	O	,	O	28	P
26	and	and	O	CC	O	28	VMOD
27	they	they	B-NP	PRP	O	28	SUB
28	were	be	B-VP	VBD	O	3	NMOD
29	compared	compare	I-VP	VBN	O	28	VC
30	to	to	B-PP	TO	O	29	VMOD
31	2	2	B-NP	CD	O	34	NMOD
32	randomly	randomly	I-NP	RB	O	33	AMOD
33	selected	select	I-NP	VBN	O	34	NMOD
34	controls	control	I-NP	NNS	O	30	PMOD
35	per	per	B-PP	IN	O	34	NMOD
36	case	case	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Sixty-seven	Sixty-seven	B-NP	CD	O	4	AMOD
4	of	of	B-PP	IN	O	1	NMOD
5	926	926	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	(	(	O	(	O	10	DEP
8	7.2	7.2	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	required	require	B-VP	VBD	O	4	SBAR
12	discontinuation	discontinuation	B-NP	NN	O	11	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	spironolactone	spironolactone	B-NP	NN	O	13	PMOD
15	due	due	B-ADJP	JJ	O	14	NMOD
16	to	to	B-PP	TO	O	15	AMOD
17	hyperkalemia	hyperkalemia	B-NP	NN	O	25	NMOD
18	(	(	O	(	O	22	DEP
19	n	n	B-NP	NN	O	21	SUB
20	=	=	B-VP	SYM	O	21	VMOD
21	33	33	B-NP	CD	O	22	DEP
22	)	)	O	)	O	17	NMOD
23	or	or	O	CC	O	25	NMOD
24	renal	renal	B-NP	JJ	O	25	NMOD
25	failure	failure	I-NP	NN	O	16	PMOD
26	(	(	O	(	O	30	DEP
27	n	n	B-NP	NN	O	29	SUB
28	=	=	B-VP	SYM	O	29	VMOD
29	34	34	B-NP	CD	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	.	.	O	.	O	1	P

1	Patients	Patient	B-NP	NNS	O	5	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	developed	develop	B-VP	VBD	O	2	SBAR
4	hyperkalemia	hyperkalemia	B-NP	NN	O	3	OBJ
5	were	be	B-VP	VBD	O	0	ROOT
6	older	old	B-ADJP	JJR	O	9	AMOD
7	and	and	O	CC	O	9	AMOD
8	more	more	B-ADJP	RBR	O	9	AMOD
9	likely	likely	I-ADJP	JJ	O	5	PRD
10	to	to	B-VP	TO	O	11	VMOD
11	have	have	I-VP	VB	O	9	AMOD
12	diabetes	diabete	B-NP	NNS	O	11	OBJ
13	,	,	O	,	O	5	P
14	had	have	B-VP	VBD	O	5	VMOD
15	higher	high	B-NP	JJR	O	19	NMOD
16	baseline	baseline	I-NP	NN	O	19	NMOD
17	serum	serum	I-NP	NN	O	19	NMOD
18	potassium	potassium	I-NP	NN	O	19	NMOD
19	levels	level	I-NP	NNS	O	14	OBJ
20	and	and	O	CC	O	25	NMOD
21	lower	low	B-NP	JJR	O	25	NMOD
22	baseline	baseline	I-NP	NN	O	25	NMOD
23	potassium	potassium	I-NP	NN	O	25	NMOD
24	supplement	supplement	I-NP	NN	O	25	NMOD
25	doses	dose	I-NP	NNS	O	14	OBJ
26	,	,	O	,	O	5	P
27	and	and	O	CC	O	5	VMOD
28	were	be	B-VP	VBD	O	5	VMOD
29	more	more	B-ADJP	RBR	O	30	AMOD
30	likely	likely	I-ADJP	JJ	O	28	PRD
31	to	to	B-VP	TO	O	32	VMOD
32	be	be	I-VP	VB	O	30	AMOD
33	treated	treat	I-VP	VBN	O	32	VC
34	with	with	B-PP	IN	O	33	VMOD
35	beta-blockers	beta-blocker	B-NP	NNS	O	34	PMOD
36	than	than	B-PP	IN	O	33	VMOD
37	controls	control	B-NP	NNS	O	36	PMOD
38	(	(	O	(	O	42	DEP
39	n	n	B-NP	NN	O	41	SUB
40	=	=	B-VP	SYM	O	41	VMOD
41	134	134	B-NP	CD	O	42	DEP
42	)	)	O	)	O	37	NMOD
43	.	.	O	.	O	5	P

1	Patients	Patient	B-NP	NNS	O	6	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	developed	develop	B-VP	VBD	O	2	SBAR
4	renal	renal	B-NP	JJ	O	5	NMOD
5	insufficiency	insufficiency	I-NP	NN	O	3	OBJ
6	had	have	B-VP	VBD	O	0	ROOT
7	lower	low	B-NP	JJR	O	10	NMOD
8	baseline	baseline	I-NP	NN	O	10	NMOD
9	body	body	I-NP	NN	O	10	NMOD
10	weight	weight	I-NP	NN	O	6	OBJ
11	and	and	O	CC	O	15	NMOD
12	higher	high	B-NP	JJR	O	15	NMOD
13	baseline	baseline	I-NP	NN	O	15	NMOD
14	serum	serum	I-NP	NN	O	15	NMOD
15	creatinine	creatinine	I-NP	NN	O	6	OBJ
16	,	,	O	,	O	6	P
17	required	require	B-VP	VBD	O	6	VMOD
18	higher	high	B-NP	JJR	O	19	NMOD
19	doses	dose	I-NP	NNS	O	17	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	loop	loop	B-NP	NN	O	22	NMOD
22	diuretics	diuretic	I-NP	NNS	O	20	PMOD
23	,	,	O	,	O	6	P
24	and	and	O	CC	O	6	VMOD
25	were	be	B-VP	VBD	O	6	VMOD
26	more	more	B-ADJP	RBR	O	27	AMOD
27	likely	likely	I-ADJP	JJ	O	25	PRD
28	to	to	B-VP	TO	O	29	VMOD
29	be	be	I-VP	VB	O	27	AMOD
30	treated	treat	I-VP	VBN	O	29	VC
31	with	with	B-PP	IN	O	30	VMOD
32	thiazide	thiazide	B-NP	NN	O	33	NMOD
33	diuretics	diuretic	I-NP	NNS	O	31	PMOD
34	than	than	B-PP	IN	O	30	VMOD
35	controls	control	B-NP	NNS	O	34	PMOD
36	.	.	O	.	O	6	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	calcineurin	calcineurin	I-NP	NN	B-protein	5	NMOD
5	inhibitors	inhibitor	I-NP	NNS	O	8	NMOD
6	cyclosporine	cyclosporine	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	tacrolimus	tacrolimus	I-NP	NN	O	9	SUB
9	are	be	B-VP	VBP	O	1	NMOD
10	both	both	O	DT	O	9	VMOD
11	known	know	B-VP	VBN	O	9	VC
12	to	to	I-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	11	VMOD
14	nephrotoxic	nephrotoxic	B-ADJP	JJ	O	13	PRD
15	.	.	O	.	O	9	P

1	Patients	Patient	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	divided	divide	I-VP	VBN	O	2	VC
4	into	into	B-PP	IN	O	3	VMOD
5	three	three	B-NP	CD	O	6	NMOD
6	groups	group	I-NP	NNS	O	4	PMOD
7	:	:	O	:	O	2	P
8	Controls	Control	B-NP	NNS	O	15	NMOD
9	,	,	O	,	O	15	P
10	no	no	B-NP	DT	O	13	NMOD
11	CRF	CRF	I-NP	NN	B-protein	13	NMOD
12	or	or	I-NP	CC	O	13	NMOD
13	ESRD	ESRD	I-NP	NN	B-protein	15	NMOD
14	,	,	O	,	O	15	P
15	n=748	n=748	B-NP	NN	O	19	SUB
16	;	;	O	:	O	19	P
17	CRF	CRF	B-NP	NN	O	19	SUB
18	,	,	O	,	O	19	P
19	sustained	sustain	B-VP	VBD	O	2	VMOD
20	serum	serum	B-NP	NN	O	24	NMOD
21	creatinine	creatinine	I-NP	NN	O	24	NMOD
22	>	>	O	SYM	O	24	NMOD
23	2.5	2.5	B-NP	CD	O	24	NMOD
24	mg/dl	mg/dl	I-NP	NN	O	26	NMOD
25	,	,	O	,	O	26	P
26	n=41	n=41	B-NP	NN	B-protein	19	OBJ
27	;	;	O	:	O	31	P
28	and	and	O	CC	O	31	NMOD
29	ESRD	ESRD	B-NP	NNP	O	31	NMOD
30	,	,	O	,	O	31	P
31	n=45	n=45	B-NP	NN	O	19	VMOD
32	.	.	O	.	O	2	P

1	Compared	Compare	B-PP	VBN	O	10	VMOD
2	with	with	B-PP	IN	O	1	PMOD
3	control	control	B-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	10	P
6	CRF	CRF	B-NP	NN	B-protein	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	ESRD	ESRD	B-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	10	SUB
10	had	have	B-VP	VBD	O	0	ROOT
11	higher	high	B-NP	JJR	O	15	NMOD
12	preoperative	preoperative	I-NP	JJ	O	15	NMOD
13	serum	serum	I-NP	NN	O	15	NMOD
14	creatinine	creatinine	I-NP	NN	O	15	NMOD
15	levels	level	I-NP	NNS	O	10	OBJ
16	,	,	O	,	O	10	P
17	a	a	B-NP	DT	O	19	NMOD
18	greater	great	I-NP	JJR	O	19	NMOD
19	percentage	percentage	I-NP	NN	O	28	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	patients	patient	B-NP	NNS	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	hepatorenal	hepatorenal	B-NP	JJ	O	24	NMOD
24	syndrome	syndrome	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	28	P
26	higher	high	B-NP	JJR	O	28	NMOD
27	percentage	percentage	I-NP	NN	O	28	NMOD
28	requirement	requirement	I-NP	NN	O	10	OBJ
29	for	for	B-PP	IN	O	28	NMOD
30	dialysis	dialysis	B-NP	NN	O	29	PMOD
31	in	in	B-PP	IN	O	28	NMOD
32	the	the	B-NP	DT	O	35	NMOD
33	first	first	I-NP	JJ	O	35	NMOD
34	3	3	I-NP	CD	O	35	NMOD
35	months	month	I-NP	NNS	O	31	PMOD
36	postoperatively	postoperatively	B-ADVP	RB	O	28	NMOD
37	,	,	O	,	O	43	P
38	and	and	O	CC	O	43	NMOD
39	a	a	B-NP	DT	O	43	NMOD
40	higher	high	I-NP	JJR	O	43	NMOD
41	1-year	1-year	I-NP	JJ	O	43	NMOD
42	serum	serum	I-NP	NN	O	43	NMOD
43	creatinine	creatinine	I-NP	NN	O	10	VMOD
44	.	.	O	.	O	10	P

1	Multivariate	Multivariate	B-NP	JJ	O	5	NMOD
2	stepwise	stepwise	I-NP	JJ	O	5	NMOD
3	logistic	logistic	I-NP	JJ	O	5	NMOD
4	regression	regression	I-NP	NN	O	5	NMOD
5	analysis	analysis	I-NP	NN	O	0	ROOT
6	using	use	B-VP	VBG	O	5	NMOD
7	preoperative	preoperative	B-NP	JJ	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	postoperative	postoperative	I-NP	JJ	O	10	NMOD
10	variables	variable	I-NP	NNS	O	6	OBJ
11	identified	identify	B-VP	VBN	O	10	NMOD
12	that	that	B-SBAR	IN	O	11	VMOD
13	an	an	B-NP	DT	O	14	NMOD
14	increase	increase	I-NP	NN	O	32	VMOD
15	of	of	B-PP	IN	O	14	NMOD
16	serum	serum	B-NP	NN	O	17	NMOD
17	creatinine	creatinine	I-NP	NN	O	15	PMOD
18	compared	compare	B-PP	VBN	O	14	NMOD
19	with	with	B-PP	IN	O	18	PMOD
20	average	average	B-NP	NN	O	19	PMOD
21	at	at	B-PP	IN	O	14	NMOD
22	1	1	B-NP	CD	O	23	NMOD
23	year	year	I-NP	NN	O	21	PMOD
24	,	,	O	,	O	32	P
25	3	3	B-NP	CD	O	26	NMOD
26	months	month	I-NP	NNS	O	32	SUB
27	,	,	O	,	O	32	P
28	and	and	O	CC	O	32	VMOD
29	4	4	B-NP	CD	O	30	NMOD
30	weeks	week	I-NP	NNS	O	32	SUB
31	postoperatively	postoperatively	B-ADVP	RB	O	32	VMOD
32	were	be	B-VP	VBD	O	12	SBAR
33	independent	independent	B-NP	JJ	O	35	NMOD
34	risk	risk	I-NP	NN	O	35	NMOD
35	factors	factor	I-NP	NNS	O	32	PRD
36	for	for	B-PP	IN	O	35	NMOD
37	the	the	B-NP	DT	O	38	NMOD
38	development	development	I-NP	NN	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	CRF	CRF	B-NP	NN	O	42	NMOD
41	or	or	I-NP	CC	O	42	NMOD
42	ESRD	ESRD	I-NP	NN	O	39	PMOD
43	with	with	B-PP	IN	O	42	NMOD
44	odds	odd	B-NP	NNS	O	45	NMOD
45	ratios	ratio	I-NP	NNS	O	43	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	2.6	2.6	B-NP	CD	O	52	NMOD
48	,	,	I-NP	,	O	52	P
49	2.2	2.2	I-NP	CD	O	52	NMOD
50	,	,	O	,	O	52	P
51	and	and	O	CC	O	52	NMOD
52	1.6	1.6	B-NP	CD	O	46	PMOD
53	,	,	O	,	O	52	P
54	respectively	respectively	B-ADVP	RB	O	52	NMOD
55	.	.	O	.	O	5	P

1	Patients	Patient	B-NP	NNS	O	5	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	develop	develop	B-VP	VBP	O	2	SBAR
4	ESRD	ESRD	B-NP	NNP	O	3	OBJ
5	have	have	B-VP	VBP	O	0	ROOT
6	a	a	B-NP	DT	O	12	NMOD
7	higher	high	I-NP	JJR	O	10	AMOD
8	preoperative	preoperative	I-NP	JJ	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	1-year	1-year	I-NP	JJ	O	12	NMOD
11	serum	serum	I-NP	NN	O	12	NMOD
12	creatinine	creatinine	I-NP	NN	O	5	OBJ
13	and	and	O	CC	O	5	VMOD
14	are	be	B-VP	VBP	O	5	VMOD
15	more	more	B-ADJP	RBR	O	16	AMOD
16	likely	likely	I-ADJP	JJ	O	14	PRD
17	to	to	B-VP	TO	O	18	VMOD
18	have	have	I-VP	VB	O	16	AMOD
19	hepatorenal	hepatorenal	B-NP	JJ	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	18	OBJ
21	.	.	O	.	O	5	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	intravenous	intravenous	B-NP	JJ	O	4	NMOD
4	nimodipine	nimodipine	I-NP	NN	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	blood	blood	B-NP	NN	O	7	NMOD
7	pressure	pressure	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	outcome	outcome	I-NP	NN	O	5	PMOD
10	after	after	B-PP	IN	O	9	NMOD
11	acute	acute	B-NP	JJ	O	12	NMOD
12	stroke	stroke	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	PURPOSE	PURPOSE	I-NP	NN	O	0	ROOT
4	:	:	O	:	O	3	P
5	The	The	B-NP	DT	O	11	NMOD
6	Intravenous	Intravenous	I-NP	JJ	O	11	NMOD
7	Nimodipine	Nimodipine	I-NP	NNP	O	11	NMOD
8	West	West	I-NP	NNP	O	11	NMOD
9	European	European	I-NP	NNP	O	11	NMOD
10	Stroke	Stroke	I-NP	NNP	O	11	NMOD
11	Trial	Trial	I-NP	NNP	O	15	SUB
12	(	(	O	(	O	14	DEP
13	INWEST	INWEST	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	found	find	B-VP	VBD	O	3	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	correlation	correlation	I-NP	NN	O	15	OBJ
18	between	between	B-PP	IN	O	17	NMOD
19	nimodipine	nimodipine	B-NP	NN	O	18	PMOD
20	induced	induce	B-VP	VBD	O	15	VMOD
21	reduction	reduction	B-NP	NN	O	31	NMOD
22	in	in	B-PP	IN	O	21	NMOD
23	blood	blood	B-NP	NN	O	24	NMOD
24	pressure	pressure	I-NP	NN	O	22	PMOD
25	(	(	O	(	O	27	DEP
26	BP	BP	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	and	and	O	CC	O	31	NMOD
29	an	an	B-NP	DT	O	31	NMOD
30	unfavorable	unfavorable	I-NP	JJ	O	31	NMOD
31	outcome	outcome	I-NP	NN	O	20	OBJ
32	in	in	B-PP	IN	O	20	VMOD
33	acute	acute	B-NP	JJ	O	34	NMOD
34	stroke	stroke	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	15	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Patients	Patient	B-NP	NNS	O	16	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	clinical	clinical	I-NP	JJ	O	7	NMOD
7	diagnosis	diagnosis	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	ischemic	ischemic	B-NP	JJ	O	10	NMOD
10	stroke	stroke	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	15	DEP
12	within	within	B-PP	IN	O	15	DEP
13	24	24	B-NP	CD	O	14	NMOD
14	hours	hour	I-NP	NNS	O	12	PMOD
15	)	)	O	)	O	7	NMOD
16	were	be	B-VP	VBD	O	1	NMOD
17	consecutively	consecutively	I-VP	RB	O	16	VMOD
18	allocated	allocate	I-VP	VBN	O	16	VC
19	to	to	I-VP	TO	O	20	VMOD
20	receive	receive	I-VP	VB	O	18	VMOD
21	placebo	placebo	B-NP	NN	O	20	OBJ
22	(	(	O	(	O	24	DEP
23	n=100	n=100	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	,	,	O	,	O	16	P
26	1	1	B-NP	CD	O	27	NMOD
27	mg/h	mg/h	I-NP	NN	O	38	NMOD
28	(	(	O	(	O	30	DEP
29	low-dose	low-dose	O	JJ	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	nimodipine	nimodipine	B-NP	NN	O	27	NMOD
32	(	(	O	(	O	34	DEP
33	n=101	n=101	B-NP	NN	B-protein	34	DEP
34	)	)	O	)	O	31	NMOD
35	,	,	O	,	O	38	P
36	or	or	O	CC	O	38	NMOD
37	2	2	B-NP	CD	O	38	NMOD
38	mg/h	mg/h	I-NP	NN	O	16	PRD
39	(	(	O	(	O	41	DEP
40	high-dose	high-dose	O	JJ	O	41	DEP
41	)	)	O	)	O	38	NMOD
42	nimodipine	nimodipine	B-NP	NN	O	38	NMOD
43	(	(	O	(	O	45	DEP
44	n=94	n=94	B-NP	NN	B-protein	45	DEP
45	)	)	O	)	O	42	NMOD
46	.	.	O	.	O	1	P

1	Nimodipine	Nimodipine	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	resulted	result	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	statistically	statistically	I-NP	RB	O	7	AMOD
7	significant	significant	I-NP	JJ	O	8	NMOD
8	reduction	reduction	I-NP	NN	O	4	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	systolic	systolic	B-NP	JJ	O	11	NMOD
11	BP	BP	I-NP	NN	O	17	NMOD
12	(	(	O	(	O	14	DEP
13	SBP	SBP	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	and	and	O	CC	O	17	NMOD
16	diastolic	diastolic	B-NP	JJ	O	17	NMOD
17	BP	BP	I-NP	NN	O	9	PMOD
18	(	(	O	(	O	20	DEP
19	DBP	DBP	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	from	from	B-PP	IN	O	17	NMOD
22	baseline	baseline	B-NP	NN	O	21	PMOD
23	compared	compare	B-PP	VBN	O	3	VMOD
24	with	with	B-PP	IN	O	23	PMOD
25	placebo	placebo	B-NP	NN	O	24	PMOD
26	during	during	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	30	NMOD
28	first	first	I-NP	JJ	O	30	NMOD
29	few	few	I-NP	JJ	O	30	NMOD
30	days	day	I-NP	NNS	O	26	PMOD
31	.	.	O	.	O	3	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	DBP	DBP	B-NP	NN	B-protein	10	VMOD
4	,	,	O	,	O	10	P
5	but	but	O	CC	O	10	VMOD
6	not	not	O	RB	O	5	DEP
7	SBP	SBP	B-NP	NN	B-protein	9	NMOD
8	,	,	O	,	O	9	P
9	reduction	reduction	B-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	1	NMOD
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	neurological	neurological	B-NP	JJ	O	14	SUB
14	worsening	worsen	I-NP	VBG	O	12	PMOD
15	after	after	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	intravenous	intravenous	I-NP	JJ	O	18	NMOD
18	administration	administration	I-NP	NN	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	high-dose	high-dose	B-NP	JJ	O	21	NMOD
21	nimodipine	nimodipine	I-NP	NN	O	19	PMOD
22	after	after	B-PP	IN	O	18	NMOD
23	acute	acute	B-NP	JJ	O	24	NMOD
24	stroke	stroke	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	1	P

1	Transient	Transient	B-NP	JJ	O	3	NMOD
2	neurologic	neurologic	I-NP	JJ	O	3	NMOD
3	symptoms	symptom	I-NP	NNS	O	4	PMOD
4	after	after	B-PP	IN	O	0	ROOT
5	spinal	spinal	B-NP	JJ	O	6	NMOD
6	anesthesia	anesthesia	I-NP	NN	O	4	PMOD
7	:	:	O	:	O	4	P
8	a	a	B-NP	DT	O	10	NMOD
9	lower	low	I-NP	JJR	O	10	NMOD
10	incidence	incidence	I-NP	NN	O	4	VMOD
11	with	with	B-PP	IN	O	10	NMOD
12	prilocaine	prilocaine	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	bupivacaine	bupivacaine	I-NP	NN	O	11	PMOD
15	than	than	B-PP	IN	O	10	NMOD
16	with	with	B-PP	IN	O	15	PMOD
17	lidocaine	lidocaine	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Recent	Recent	B-NP	JJ	O	4	NMOD
4	evidence	evidence	I-NP	NN	O	5	SUB
5	suggests	suggest	B-VP	VBZ	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	transient	transient	B-NP	JJ	O	9	NMOD
8	neurologic	neurologic	I-NP	JJ	O	9	NMOD
9	symptoms	symptom	I-NP	NNS	O	14	SUB
10	(	(	O	(	O	12	DEP
11	TNSs	TNS	B-NP	NNS	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	frequently	frequently	B-ADVP	RB	O	14	VMOD
14	follow	follow	B-VP	VBP	O	6	SBAR
15	lidocaine	lidocaine	B-NP	NN	O	17	NMOD
16	spinal	spinal	I-NP	JJ	O	17	NMOD
17	anesthesia	anesthesia	I-NP	NN	O	14	OBJ
18	but	but	O	CC	O	14	VMOD
19	are	be	B-VP	VBP	O	14	VMOD
20	infrequent	infrequent	B-ADJP	JJ	O	19	PRD
21	with	with	B-PP	IN	O	20	AMOD
22	bupivacaine	bupivacaine	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	1	P

1	Accordingly	Accordingly	B-ADVP	RB	O	9	VMOD
2	,	,	O	,	O	9	P
3	the	the	B-NP	DT	O	8	NMOD
4	present	present	I-NP	JJ	O	6	AMOD
5	,	,	I-NP	,	O	6	P
6	prospective	prospective	I-NP	JJ	O	8	NMOD
7	double-blind	double-blind	I-NP	JJ	O	8	NMOD
8	study	study	I-NP	NN	O	9	SUB
9	compares	compare	B-VP	VBZ	O	0	ROOT
10	prilocaine	prilocaine	B-NP	NN	O	9	OBJ
11	with	with	B-PP	IN	O	10	NMOD
12	lidocaine	lidocaine	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	bupivacaine	bupivacaine	I-NP	NN	O	11	PMOD
15	with	with	B-PP	IN	O	9	VMOD
16	respect	respect	B-NP	NN	O	15	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	duration	duration	B-NP	NN	O	23	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	action	action	B-NP	NN	O	19	PMOD
21	and	and	O	CC	O	23	NMOD
22	relative	relative	B-NP	JJ	O	23	NMOD
23	risk	risk	I-NP	NN	O	17	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	TNSs	TNS	B-NP	NNS	B-protein	24	PMOD
26	.	.	O	.	O	9	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Nine	Nine	B-NP	CD	O	4	AMOD
4	of	of	B-PP	IN	O	1	NMOD
5	30	30	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	receiving	receive	B-VP	VBG	O	6	NMOD
8	lidocaine	lidocaine	B-NP	NN	O	10	NMOD
9	experienced	experienced	I-NP	JJ	O	10	NMOD
10	TNSs	TNS	I-NP	NNS	O	7	OBJ
11	,	,	O	,	O	13	P
12	1	1	B-NP	CD	O	13	AMOD
13	of	of	B-PP	IN	O	4	PMOD
14	30	30	B-NP	CD	O	13	AMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	receiving	receive	B-VP	VBG	O	15	NMOD
17	prilocaine	prilocaine	B-NP	NN	O	16	OBJ
18	(	(	O	(	O	22	DEP
19	P	P	B-NP	NN	O	22	DEP
20	=	=	B-VP	SYM	O	19	NMOD
21	0.03	0.03	B-NP	CD	O	20	AMOD
22	)	)	O	)	O	15	NMOD
23	had	have	B-VP	VBD	O	4	SBAR
24	them	them	B-NP	PRP	O	23	OBJ
25	,	,	O	,	O	4	P
26	and	and	O	CC	O	4	PMOD
27	none	none	B-NP	NN	O	4	PMOD
28	of	of	B-PP	IN	O	4	PMOD
29	30	30	B-NP	CD	O	30	NMOD
30	patients	patient	I-NP	NNS	O	28	PMOD
31	receiving	receive	B-VP	VBG	O	30	NMOD
32	bupivacaine	bupivacaine	B-NP	NN	O	31	OBJ
33	had	have	B-VP	VBD	O	34	NMOD
34	TNSs	TNS	B-NP	NNS	B-protein	4	PMOD
35	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	nicotine	nicotine	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	smoking-related	smoking-related	B-NP	JJ	O	8	NMOD
7	cardiovascular	cardiovascular	I-NP	JJ	O	8	NMOD
8	disease	disease	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	Nicotine	Nicotine	B-NP	NN	O	2	SUB
2	activates	activate	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	sympathetic	sympathetic	I-NP	JJ	O	6	NMOD
5	nervous	nervous	I-NP	JJ	O	6	NMOD
6	system	system	I-NP	NN	O	2	OBJ
7	and	and	B-PP	CC	O	2	VMOD
8	in	in	B-PP	IN	O	2	VMOD
9	this	this	B-NP	DT	O	10	NMOD
10	way	way	I-NP	NN	O	8	PMOD
11	could	could	B-VP	MD	O	2	VMOD
12	contribute	contribute	I-VP	VB	O	11	VC
13	to	to	B-PP	TO	O	12	VMOD
14	cardiovascular	cardiovascular	B-NP	JJ	O	15	NMOD
15	disease	disease	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	2	P

1	Animal	Animal	B-NP	NN	O	2	NMOD
2	studies	study	I-NP	NNS	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	mechanistic	mechanistic	B-NP	JJ	O	5	NMOD
5	studies	study	I-NP	NNS	O	6	SUB
6	indicate	indicate	B-VP	VBP	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	nicotine	nicotine	B-NP	NN	O	9	SUB
9	could	could	B-VP	MD	O	18	NMOD
10	play	play	I-VP	VB	O	9	VC
11	a	a	B-NP	DT	O	12	NMOD
12	role	role	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	10	VMOD
14	accelerating	accelerate	B-NP	VBG	O	15	NMOD
15	atherosclerosis	atherosclerosis	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	18	P
17	but	but	O	CC	O	18	NMOD
18	evidence	evidence	B-NP	NN	O	21	SUB
19	among	among	B-PP	IN	O	18	NMOD
20	humans	human	B-NP	NNS	O	19	PMOD
21	is	be	B-VP	VBZ	O	7	SBAR
22	too	too	B-ADJP	RB	O	23	AMOD
23	inadequate	inadequate	I-ADJP	JJ	O	21	PRD
24	to	to	B-VP	TO	O	25	VMOD
25	be	be	I-VP	VB	O	23	AMOD
26	definitive	definitive	B-ADJP	JJ	O	25	PRD
27	about	about	B-PP	IN	O	25	VMOD
28	such	such	B-NP	JJ	O	30	NMOD
29	an	an	I-NP	DT	O	30	NMOD
30	effect	effect	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	6	P

1	Nicotine	Nicotine	B-NP	NN	O	2	SUB
2	does	do	B-VP	VBZ	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	appear	appear	I-VP	VB	O	2	VC
5	to	to	I-VP	TO	O	6	VMOD
6	enhance	enhance	I-VP	VB	O	4	VMOD
7	thrombosis	thrombosis	B-NP	NN	O	6	OBJ
8	among	among	B-PP	IN	O	7	NMOD
9	humans	human	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	2	P

1	Seizure	Seizure	B-NP	NN	O	0	ROOT
2	resulting	result	B-VP	VBG	O	1	NMOD
3	from	from	B-PP	IN	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	venlafaxine	venlafaxine	I-NP	NN	O	6	NMOD
6	overdose	overdose	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	venlafaxine	venlafaxine	B-NP	NN	O	9	NMOD
9	overdose	overdose	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	6	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	6	NMOD
5	40-year-old	40-year-old	I-NP	JJ	O	6	NMOD
6	woman	woman	I-NP	NN	O	10	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	major	major	B-NP	JJ	O	9	NMOD
9	depression	depression	I-NP	NN	O	7	PMOD
10	took	take	B-VP	VBD	O	0	ROOT
11	an	an	B-NP	DT	O	12	NMOD
12	overdose	overdose	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	venlafaxine	venlafaxine	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	10	VMOD
16	an	an	B-NP	DT	O	19	NMOD
17	apparent	apparent	I-NP	JJ	O	19	NMOD
18	suicide	suicide	I-NP	NN	O	19	NMOD
19	attempt	attempt	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	10	P

1	After	After	B-PP	IN	O	12	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	ingestion	ingestion	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	26	26	B-NP	CD	O	8	NMOD
6	venlafaxine	venlafaxine	I-NP	NN	O	8	NMOD
7	50-mg	50-mg	I-NP	JJ	O	8	NMOD
8	tablets	tablet	I-NP	NNS	O	4	PMOD
9	,	,	O	,	O	12	P
10	the	the	B-NP	DT	O	11	NMOD
11	patient	patient	I-NP	NN	O	12	SUB
12	experienced	experience	B-VP	VBD	O	0	ROOT
13	a	a	B-NP	DT	O	16	NMOD
14	witnessed	witness	I-NP	VBN	O	16	NMOD
15	generalized	generalize	I-NP	VBN	O	16	NMOD
16	seizure	seizure	I-NP	NN	O	12	OBJ
17	.	.	O	.	O	12	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	8	SUB
2	:	:	O	:	O	1	P
3	To	To	B-PP	TO	O	1	NMOD
4	our	our	B-NP	PRP$	O	5	NMOD
5	knowledge	knowledge	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	8	P
7	this	this	B-NP	DT	O	8	SUB
8	is	be	B-VP	VBZ	O	0	ROOT
9	the	the	B-NP	DT	O	12	NMOD
10	first	first	I-NP	JJ	O	12	NMOD
11	reported	report	I-NP	VBN	O	12	NMOD
12	case	case	I-NP	NN	O	8	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	venlafaxine	venlafaxine	B-NP	NN	O	15	NMOD
15	overdose	overdose	I-NP	NN	O	13	PMOD
16	that	that	B-NP	WDT	O	12	NMOD
17	resulted	result	B-VP	VBD	O	16	SBAR
18	in	in	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	21	NMOD
20	generalized	generalize	I-NP	VBN	O	21	NMOD
21	seizure	seizure	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	8	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	groups	group	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	receiving	receive	B-VP	VBG	O	4	NMOD
6	tacrolimus	tacrolimus	B-NP	NN	O	5	OBJ
7	were	be	B-VP	VBD	O	0	ROOT
8	compared	compare	I-VP	VBN	O	7	VC
9	over	over	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	period	period	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	1	1	B-NP	CD	O	14	NMOD
14	year	year	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	7	P
16	one	one	B-NP	CD	O	17	NMOD
17	group	group	I-NP	NN	O	31	NMOD
18	comprising	comprise	B-VP	VBG	O	17	NMOD
19	hypertensive	hypertensive	B-NP	JJ	O	20	NMOD
20	patients	patient	I-NP	NNS	O	18	OBJ
21	who	who	B-NP	WP	O	20	NMOD
22	were	be	B-VP	VBD	O	21	SBAR
23	receiving	receive	I-VP	VBG	O	22	VC
24	nifedipine	nifedipine	B-NP	NN	O	23	OBJ
25	,	,	O	,	O	31	P
26	and	and	O	CC	O	31	NMOD
27	the	the	B-NP	DT	O	31	NMOD
28	other	other	I-NP	JJ	O	31	NMOD
29	comprising	comprising	I-NP	JJ	O	31	NMOD
30	nonhypertensive	nonhypertensive	I-NP	JJ	O	31	NMOD
31	patients	patient	I-NP	NNS	O	7	VMOD
32	not	not	B-VP	RB	O	33	VMOD
33	receiving	receive	I-VP	VBG	O	31	NMOD
34	nifedipine	nifedipine	B-NP	NN	O	33	OBJ
35	.	.	O	.	O	7	P

1	Sinus	Sinus	B-NP	NN	O	2	NMOD
2	arrest	arrest	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	continuous-infusion	continuous-infusion	B-NP	JJ	O	6	NMOD
6	cimetidine	cimetidine	I-NP	NN	O	4	PMOD
7	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	intermittent	intermittent	B-NP	JJ	O	6	NMOD
5	intravenous	intravenous	I-NP	JJ	O	6	NMOD
6	infusions	infusion	I-NP	NNS	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	cimetidine	cimetidine	B-NP	NN	O	7	PMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	infrequently	infrequently	I-VP	RB	O	9	VMOD
11	associated	associate	I-VP	VBN	O	9	VC
12	with	with	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	development	development	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	bradyarrhythmias	bradyarrhythmia	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	3	NMOD
2	40-year-old	40-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	8	NMOD
4	with	with	B-PP	IN	O	3	NMOD
5	leukemia	leukemia	B-NP	NN	O	4	PMOD
6	and	and	O	CC	O	8	NMOD
7	no	no	B-NP	DT	O	8	NMOD
8	history	history	I-NP	NN	O	12	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	disease	disease	I-NP	NN	O	9	PMOD
12	developed	develop	B-VP	VBD	O	0	ROOT
13	recurrent	recurrent	B-NP	JJ	O	15	AMOD
14	,	,	I-NP	,	O	15	P
15	brief	brief	I-NP	JJ	O	16	NMOD
16	episodes	episode	I-NP	NNS	O	12	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	apparent	apparent	B-NP	JJ	O	20	NMOD
19	sinus	sinus	I-NP	NN	O	20	NMOD
20	arrest	arrest	I-NP	NN	O	17	PMOD
21	while	while	B-SBAR	IN	O	12	VMOD
22	receiving	receive	B-VP	VBG	O	21	SBAR
23	continuous-infusion	continuous-infusion	B-NP	JJ	O	26	NMOD
24	cimetidine	cimetidine	I-NP	NN	O	26	NMOD
25	50	50	I-NP	CD	O	26	NMOD
26	mg/hour	mg/hour	I-NP	NN	O	22	OBJ
27	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	arrhythmias	arrhythmia	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	temporally	temporally	B-ADJP	RB	O	5	AMOD
5	related	relate	I-ADJP	VBN	O	3	PRD
6	to	to	B-PP	TO	O	5	AMOD
7	cimetidine	cimetidine	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	3	P
10	disappeared	disappear	B-VP	VBD	O	3	VMOD
11	after	after	B-PP	IN	O	10	VMOD
12	dechallenge	dechallenge	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	3	P
14	and	and	O	CC	O	3	VMOD
15	did	do	B-VP	VBD	O	3	VMOD
16	not	not	I-VP	RB	O	15	VMOD
17	recur	recur	I-VP	VB	O	15	VC
18	during	during	B-PP	IN	O	17	VMOD
19	ranitidine	ranitidine	B-NP	NN	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	3	P

1	Composition	Composition	B-NP	NN	O	10	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	gall	gall	B-NP	NN	O	5	NMOD
4	bladder	bladder	I-NP	NN	O	5	NMOD
5	stones	stone	I-NP	NNS	O	2	PMOD
6	associated	associate	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	octreotide	octreotide	B-NP	NN	O	7	PMOD
9	:	:	O	:	O	1	P
10	response	response	B-NP	NN	O	0	ROOT
11	to	to	B-PP	TO	O	10	NMOD
12	oral	oral	B-NP	JJ	O	14	NMOD
13	ursodeoxycholic	ursodeoxycholic	I-NP	JJ	O	14	NMOD
14	acid	acid	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	10	P

1	Octreotide	Octreotide	B-NP	NN	O	5	NMOD
2	,	,	O	,	O	5	P
3	an	an	B-NP	DT	O	5	NMOD
4	effective	effective	I-NP	JJ	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	9	SUB
6	for	for	B-PP	IN	O	9	VMOD
7	acromegaly	acromegaly	B-NP	RB	O	6	PMOD
8	,	,	O	,	O	9	P
9	induces	induce	B-VP	VBZ	O	0	ROOT
10	gall	gall	B-NP	NN	O	12	NMOD
11	bladder	bladder	I-NP	NN	O	12	NMOD
12	stones	stone	I-NP	NNS	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	13-60	13-60	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	9	P

1	Because	Because	B-SBAR	IN	O	20	VMOD
2	knowledge	knowledge	B-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	stone	stone	B-NP	NN	O	5	NMOD
5	composition	composition	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	1	SBAR
7	essential	essential	B-ADJP	JJ	O	6	PRD
8	for	for	B-PP	IN	O	7	AMOD
9	studies	study	B-NP	NNS	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	their	their	B-NP	PRP$	O	12	NMOD
12	pathogenesis	pathogenesis	I-NP	NN	O	17	NMOD
13	,	,	O	,	O	17	P
14	treatment	treatment	B-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	prevention	prevention	B-NP	NN	O	10	PMOD
18	,	,	O	,	O	20	P
19	this	this	B-NP	DT	O	20	SUB
20	was	be	B-VP	VBD	O	0	ROOT
21	investigated	investigate	I-VP	VBN	O	20	VC
22	by	by	B-PP	IN	O	21	VMOD
23	direct	direct	B-NP	JJ	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	indirect	indirect	I-NP	JJ	O	26	NMOD
26	methods	method	I-NP	NNS	O	22	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	14	14	B-NP	CD	O	29	NMOD
29	octreotide	octreotide	I-NP	NN	O	27	PMOD
30	treated	treat	B-VP	VBN	O	29	NMOD
31	acromegalic	acromegalic	B-NP	JJ	O	32	NMOD
32	patients	patient	I-NP	NNS	O	30	OBJ
33	with	with	B-PP	IN	O	32	NMOD
34	gall	gall	B-NP	NN	O	35	NMOD
35	stones	stone	I-NP	NNS	O	33	PMOD
36	.	.	O	.	O	20	P

1	Chemical	Chemical	B-NP	JJ	O	2	NMOD
2	analysis	analysis	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	gall	gall	B-NP	NN	O	5	NMOD
5	stones	stone	I-NP	NNS	O	3	PMOD
6	retrieved	retrieve	B-VP	VBD	O	0	ROOT
7	at	at	B-PP	IN	O	6	VMOD
8	cholecystectomy	cholecystectomy	B-NP	NN	O	7	PMOD
9	from	from	B-PP	IN	O	8	NMOD
10	two	two	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	6	P
13	showed	show	B-VP	VBD	O	6	VMOD
14	that	that	B-SBAR	IN	O	13	VMOD
15	they	they	B-NP	PRP	O	16	SUB
16	contained	contain	B-VP	VBD	O	14	SBAR
17	71	71	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	22	NMOD
19	and	and	O	CC	O	22	NMOD
20	87	87	B-NP	CD	O	22	NMOD
21	%	%	I-NP	NN	O	20	AMOD
22	cholesterol	cholesterol	I-NP	NN	O	16	OBJ
23	by	by	B-PP	IN	O	22	NMOD
24	weight	weight	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	6	P

1	After	After	B-PP	IN	O	13	VMOD
2	one	one	B-NP	CD	O	3	NMOD
3	year	year	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	treatment	treatment	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	13	P
7	five	five	B-NP	CD	O	13	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	12	NMOD
10	remaining	remain	I-NP	VBG	O	12	NMOD
11	nine	nine	I-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	8	PMOD
13	showed	show	B-VP	VBD	O	0	ROOT
14	either	either	O	CC	O	30	NMOD
15	partial	partial	O	JJ	O	30	NMOD
16	(	(	O	(	O	20	DEP
17	n	n	B-NP	NN	O	19	SUB
18	=	=	B-VP	SYM	O	19	VMOD
19	3	3	B-NP	CD	O	20	DEP
20	)	)	O	)	O	15	NMOD
21	or	or	O	CC	O	30	NMOD
22	complete	complete	B-NP	JJ	O	30	NMOD
23	(	(	O	(	O	27	DEP
24	n	n	B-NP	NN	O	27	DEP
25	=	=	B-VP	SYM	O	24	NMOD
26	2	2	B-NP	CD	O	25	AMOD
27	)	)	O	)	O	22	NMOD
28	gall	gall	B-NP	NN	O	30	NMOD
29	stone	stone	I-NP	NN	O	30	NMOD
30	dissolution	dissolution	I-NP	NN	O	13	OBJ
31	,	,	O	,	O	13	P
32	suggesting	suggest	B-VP	VBG	O	13	VMOD
33	that	that	B-SBAR	IN	O	32	VMOD
34	their	their	B-NP	PRP$	O	35	NMOD
35	stones	stone	I-NP	NNS	O	36	SUB
36	were	be	B-VP	VBD	O	33	SBAR
37	cholesterol	cholesterol	B-ADJP	NN	O	36	PRD
38	rich	rich	I-ADJP	JJ	O	37	AMOD
39	.	.	O	.	O	13	P

1	Cardiovascular	Cardiovascular	B-NP	JJ	O	2	NMOD
2	complications	complication	I-NP	NNS	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	terbutaline	terbutaline	B-NP	NN	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	preterm	preterm	B-NP	JJ	O	9	NMOD
9	labor	labor	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	Of	Of	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	4	NMOD
3	20	20	I-NP	CD	O	4	NMOD
4	animals	animal	I-NP	NNS	O	1	PMOD
5	that	that	B-NP	WDT	O	4	NMOD
6	received	receive	B-VP	VBD	O	5	SBAR
7	subarachnoid	subarachnoid	B-NP	JJ	O	8	NMOD
8	injection	injection	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	2-chloroprocaine-CE	2-chloroprocaine-CE	B-NP	NN	O	9	PMOD
11	seven	seven	I-NP	CD	O	10	NMOD
12	(	(	O	(	O	15	DEP
13	35	35	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	15	DEP
15	)	)	O	)	O	10	NMOD
16	developed	develop	B-VP	VBD	O	1	VMOD
17	hind-limb	hind-limb	B-NP	NN	O	18	NMOD
18	paralysis	paralysis	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	1	P

1	None	None	B-NP	NN	O	20	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	animals	animal	I-NP	NNS	O	2	PMOD
5	that	that	B-NP	WDT	O	4	NMOD
6	received	receive	B-VP	VBD	O	5	SBAR
7	bupivacaine	bupivacaine	B-NP	NN	O	14	NMOD
8	,	,	O	,	O	14	P
9	normal	normal	B-NP	JJ	O	10	NMOD
10	saline	saline	I-NP	NN	O	14	NMOD
11	,	,	O	,	O	14	P
12	or	or	O	CC	O	14	NMOD
13	normal	normal	B-NP	JJ	O	14	NMOD
14	saline	saline	I-NP	NN	O	6	OBJ
15	titrated	titrate	B-VP	VBN	O	14	NMOD
16	to	to	B-PP	TO	O	15	VMOD
17	a	a	B-NP	DT	O	18	NMOD
18	pH	pH	I-NP	NN	O	16	PMOD
19	3.0	3.0	I-NP	CD	O	18	NMOD
20	developed	develop	B-VP	VBD	O	0	ROOT
21	hind-limb	hind-limb	B-NP	NN	O	22	NMOD
22	paralysis	paralysis	I-NP	NN	O	20	OBJ
23	.	.	O	.	O	20	P

1	Of	Of	B-PP	IN	O	14	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	15	15	I-NP	CD	O	5	NMOD
4	spinal	spinal	I-NP	JJ	O	5	NMOD
5	cords	cord	I-NP	NNS	O	1	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	animals	animal	I-NP	NNS	O	6	PMOD
9	that	that	B-NP	WDT	O	5	NMOD
10	received	receive	B-VP	VBD	O	9	SBAR
11	2-chloroprocaine-CE	2-chloroprocaine-CE	B-NP	NN	O	10	OBJ
12	,	,	O	,	O	14	P
13	13	13	B-NP	CD	O	14	SUB
14	showed	show	B-VP	VBD	O	24	VMOD
15	subpial	subpial	B-NP	JJ	O	16	NMOD
16	necrosis	necrosis	I-NP	NN	O	14	OBJ
17	;	;	O	:	O	24	P
18	the	the	B-NP	DT	O	20	NMOD
19	nerve	nerve	I-NP	NN	O	20	NMOD
20	roots	root	I-NP	NNS	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	subarachnoid	subarachnoid	B-NP	JJ	O	23	NMOD
23	vessels	vessel	I-NP	NNS	O	24	SUB
24	were	be	B-VP	VBD	O	0	ROOT
25	normal	normal	B-ADJP	JJ	O	24	PRD
26	.	.	O	.	O	24	P

1	Early	Early	B-NP	RB	O	2	AMOD
2	adjuvant	adjuvant	I-NP	JJ	O	3	NMOD
3	adriamycin	adriamycin	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	superficial	superficial	B-NP	JJ	O	7	NMOD
6	bladder	bladder	I-NP	NN	O	7	NMOD
7	carcinoma	carcinoma	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	3	P

1	Adriamycin	Adriamycin	B-NP	NN	O	7	SUB
2	(	(	O	(	O	6	DEP
3	50	50	B-NP	CD	O	5	NMOD
4	mg/50	mg/50	I-NP	NN	O	5	NMOD
5	ml	ml	I-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	administered	administer	I-VP	VBN	O	7	VC
9	intravesically	intravesically	B-ADVP	RB	O	8	VMOD
10	within	within	B-PP	IN	O	8	VMOD
11	24	24	B-NP	CD	O	12	NMOD
12	h	h	I-NP	NN	O	10	PMOD
13	after	after	B-PP	IN	O	8	VMOD
14	transurethral	transurethral	B-NP	JJ	O	15	NMOD
15	resection	resection	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	TA-T1	TA-T1	B-NP	NN	B-protein	22	NMOD
18	(	(	O	(	O	20	DEP
19	O-A	O-A	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	bladder	bladder	B-NP	NN	O	22	NMOD
22	tumors	tumor	I-NP	NNS	O	16	PMOD
23	.	.	O	.	O	7	P

1	Hyperkalemia	Hyperkalemia	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	sulindac	sulindac	B-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	1	P

1	Hyperkalemia	Hyperkalemia	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	recently	recently	I-VP	RB	O	2	VMOD
4	been	be	I-VP	VBN	O	2	VC
5	recognized	recognize	I-VP	VBN	O	4	VC
6	as	as	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	complication	complication	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	nonsteroidal	nonsteroidal	B-NP	JJ	O	12	NMOD
11	antiinflammatory	antiinflammatory	I-NP	JJ	O	12	NMOD
12	agents	agent	I-NP	NNS	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	NSAID	NSAID	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	such	such	B-PP	JJ	O	17	PMOD
17	as	as	I-PP	IN	O	12	NMOD
18	indomethacin	indomethacin	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	4	4	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	whom	whom	B-NP	WP	O	5	PMOD
7	hyperkalemia	hyperkalemia	B-NP	NN	O	6	NMOD
8	ranging	range	B-VP	VBG	O	4	NMOD
9	from	from	B-PP	IN	O	8	VMOD
10	6.1	6.1	B-NP	CD	O	9	AMOD
11	to	to	I-NP	TO	O	9	AMOD
12	6.9	6.9	I-NP	CD	O	9	AMOD
13	mEq/l	mEq/l	I-NP	NN	O	9	PMOD
14	developed	develop	B-VP	VBD	O	2	VMOD
15	within	within	B-PP	IN	O	14	VMOD
16	3	3	B-NP	CD	O	18	AMOD
17	to	to	I-NP	TO	O	18	AMOD
18	8	8	I-NP	CD	O	19	NMOD
19	days	day	I-NP	NNS	O	15	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	sulindac	sulindac	B-NP	NN	O	22	NMOD
22	administration	administration	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	2	P

1	As	As	B-SBAR	IN	O	19	VMOD
2	no	no	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	medications	medication	I-NP	NNS	O	10	SUB
5	known	know	B-VP	VBN	O	4	NMOD
6	to	to	B-VP	TO	O	7	VMOD
7	effect	effect	I-VP	VB	O	5	VMOD
8	serum	serum	B-NP	NN	O	9	NMOD
9	potassium	potassium	I-NP	NN	O	7	OBJ
10	had	have	B-VP	VBD	O	1	SBAR
11	been	be	I-VP	VBN	O	10	VC
12	given	give	I-VP	VBN	O	11	VC
13	concomitantly	concomitantly	B-ADVP	RB	O	12	VMOD
14	,	,	O	,	O	19	P
15	this	this	B-NP	DT	O	16	NMOD
16	course	course	I-NP	NN	O	19	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	events	event	B-NP	NNS	O	17	PMOD
19	is	be	B-VP	VBZ	O	0	ROOT
20	suggestive	suggestive	B-ADJP	JJ	O	19	PRD
21	of	of	B-PP	IN	O	20	AMOD
22	a	a	B-NP	DT	O	24	NMOD
23	cause-and-effect	cause-and-effect	I-NP	JJ	O	24	NMOD
24	relationship	relationship	I-NP	NN	O	21	PMOD
25	between	between	B-PP	IN	O	24	NMOD
26	sulindac	sulindac	B-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	hyperkalemia	hyperkalemia	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	19	P

1	Ventricular	Ventricular	B-NP	JJ	O	2	NMOD
2	tachyarrhythmias	tachyarrhythmia	I-NP	NNS	O	0	ROOT
3	during	during	B-PP	IN	O	2	NMOD
4	cesarean	cesarean	B-NP	JJ	O	5	NMOD
5	section	section	I-NP	NN	O	3	PMOD
6	after	after	B-PP	IN	O	5	NMOD
7	ritodrine	ritodrine	B-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	6	PMOD
9	:	:	O	:	O	2	P
10	interaction	interaction	B-NP	NN	O	2	NMOD
11	with	with	B-PP	IN	O	10	NMOD
12	anesthetics	anesthetic	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	3	SUB
3	illustrates	illustrate	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	patients	patient	B-NP	NNS	O	11	SUB
6	receiving	receive	B-VP	VBG	O	5	NMOD
7	ritodrine	ritodrine	B-NP	NN	O	6	OBJ
8	for	for	B-PP	IN	O	7	NMOD
9	preterm	preterm	B-NP	JJ	O	10	NMOD
10	labor	labor	I-NP	NN	O	8	PMOD
11	may	may	B-VP	MD	O	4	SBAR
12	risk	risk	I-VP	VB	O	11	VC
13	interactions	interaction	B-NP	NNS	O	12	OBJ
14	between	between	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	18	NMOD
16	residual	residual	I-NP	JJ	O	18	NMOD
17	betamimetic	betamimetic	I-NP	JJ	O	18	NMOD
18	effects	effect	I-NP	NNS	O	14	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	ritodrine	ritodrine	B-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	effects	effect	I-NP	NNS	O	19	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	anesthetics	anesthetic	B-NP	NNS	O	24	PMOD
26	during	during	B-PP	IN	O	12	VMOD
27	cesarean	cesarean	B-NP	JJ	O	28	NMOD
28	section	section	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	3	P

1	Such	Such	B-NP	JJ	O	2	NMOD
2	interactions	interaction	I-NP	NNS	O	3	SUB
3	may	may	B-VP	MD	O	0	ROOT
4	result	result	I-VP	VB	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	serious	serious	B-NP	JJ	O	8	NMOD
7	cardiovascular	cardiovascular	I-NP	JJ	O	8	NMOD
8	complications	complication	I-NP	NNS	O	5	PMOD
9	even	even	B-ADVP	RB	O	10	PMOD
10	after	after	B-PP	IN	O	8	NMOD
11	cessation	cessation	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	an	an	B-NP	DT	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	ritodrine	ritodrine	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	3	P

1	Immunohistochemical	Immunohistochemical	B-NP	JJ	O	7	NMOD
2	,	,	I-NP	,	O	7	P
3	electron	electron	I-NP	NN	O	7	NMOD
4	microscopic	microscopic	I-NP	JJ	O	3	NMOD
5	and	and	I-NP	CC	O	7	NMOD
6	morphometric	morphometric	I-NP	JJ	O	7	NMOD
7	studies	study	I-NP	NNS	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	estrogen	estrogen	B-NP	NN	O	12	NMOD
10	induced	induced	I-NP	JJ	O	12	NMOD
11	rat	rat	I-NP	NN	O	12	NMOD
12	prolactinomas	prolactinoma	I-NP	NNS	O	8	PMOD
13	after	after	B-PP	IN	O	7	NMOD
14	bromocriptine	bromocriptine	B-NP	NN	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	7	P

1	To	To	B-VP	TO	O	2	VMOD
2	clarify	clarify	I-VP	VB	O	19	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	18	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	bromocriptine	bromocriptine	B-NP	NN	O	5	PMOD
7	on	on	B-PP	IN	O	4	NMOD
8	prolactinoma	prolactinoma	B-NP	NN	B-cell_type	9	NMOD
9	cells	cell	I-NP	NNS	I-cell_type	7	PMOD
10	in	in	B-ADVP	FW	O	11	AMOD
11	vivo	vivo	I-ADVP	FW	O	9	NMOD
12	,	,	O	,	O	18	P
13	immunohistochemical	immunohistochemical	B-NP	JJ	O	18	NMOD
14	,	,	I-NP	,	O	18	P
15	ultrastructural	ultrastructural	I-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	morphometrical	morphometrical	I-NP	JJ	O	18	NMOD
18	analyses	analysis	I-NP	NNS	O	19	SUB
19	were	be	B-VP	VBD	O	0	ROOT
20	applied	apply	I-VP	VBN	O	19	VC
21	to	to	B-PP	TO	O	20	VMOD
22	estrogen	estrogen	B-NP	NN	O	26	NMOD
23	induced	induced	I-NP	JJ	O	22	AMOD
24	rat	rat	I-NP	NN	O	26	NMOD
25	prolactinoma	prolactinoma	I-NP	NN	O	26	NMOD
26	cells	cell	I-NP	NNS	O	28	NMOD
27	1	1	B-NP	CD	O	28	NMOD
28	h	h	I-NP	NN	O	21	PMOD
29	and	and	I-NP	CC	O	19	VMOD
30	6	6	I-NP	CD	O	31	NMOD
31	h	h	I-NP	NN	O	32	PMOD
32	after	after	B-PP	IN	O	19	VMOD
33	injection	injection	B-NP	NN	O	32	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	bromocriptine	bromocriptine	B-NP	NN	O	34	PMOD
36	(	(	O	(	O	42	DEP
37	3	3	B-NP	CD	O	38	NMOD
38	mg/kg	mg/kg	I-NP	NN	O	42	DEP
39	of	of	B-PP	IN	O	38	NMOD
40	body	body	B-NP	NN	O	41	NMOD
41	weight	weight	I-NP	NN	O	39	PMOD
42	)	)	O	)	O	35	NMOD
43	.	.	O	.	O	19	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	only	only	B-NP	RB	O	5	NMOD
4	secretory	secretory	I-NP	JJ	O	5	NMOD
5	granules	granule	I-NP	NNS	O	6	SUB
6	showed	show	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	10	NMOD
8	positive	positive	I-NP	JJ	B-protein	10	NMOD
9	reaction	reaction	I-NP	NN	I-protein	10	NMOD
10	products	product	I-NP	NNS	I-protein	6	OBJ
11	for	for	B-PP	IN	O	10	NMOD
12	prolactin	prolactin	B-NP	NN	O	14	NMOD
13	6	6	I-NP	CD	O	14	NMOD
14	h	h	I-NP	NN	O	11	PMOD
15	after	after	B-PP	IN	O	14	NMOD
16	bromocriptine	bromocriptine	B-NP	NN	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	adenoma	adenoma	I-NP	NN	B-cell_type	21	NMOD
21	cells	cell	I-NP	NNS	I-cell_type	18	PMOD
22	.	.	O	.	O	6	P

1	Liver	Liver	B-NP	NN	O	2	NMOD
2	enlargement	enlargement	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	muscle	muscle	B-NP	NN	O	5	NMOD
5	wastage	wastage	I-NP	NN	O	6	SUB
6	occurred	occur	B-VP	VBD	O	0	ROOT
7	in	in	B-PP	IN	O	6	VMOD
8	Wistar	Wistar	B-NP	NNP	O	9	NMOD
9	rats	rat	I-NP	NNS	O	7	PMOD
10	following	follow	B-PP	VBG	O	6	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	subcutaneous	subcutaneous	I-NP	JJ	O	13	NMOD
13	administration	administration	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	prednisolone	prednisolone	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	6	P

1	Possible	Possible	B-NP	JJ	O	5	NMOD
2	intramuscular	intramuscular	I-NP	JJ	O	5	NMOD
3	midazolam-associated	midazolam-associated	I-NP	JJ	O	5	NMOD
4	cardiorespiratory	cardiorespiratory	I-NP	JJ	O	5	NMOD
5	arrest	arrest	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	death	death	I-NP	NN	O	0	ROOT
8	.	.	O	.	O	7	P

1	This	This	B-NP	DT	O	2	NMOD
2	report	report	I-NP	NN	O	3	SUB
3	describes	describe	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	7	NMOD
5	first	first	I-NP	JJ	O	7	NMOD
6	published	publish	I-NP	VBN	O	7	NMOD
7	case	case	I-NP	NN	O	3	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	cardiorespiratory	cardiorespiratory	B-NP	JJ	O	10	NMOD
10	arrest	arrest	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	death	death	I-NP	NN	O	8	PMOD
13	associated	associate	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	intramuscular	intramuscular	B-NP	JJ	O	16	NMOD
16	administration	administration	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	midazolam	midazolam	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	3	P

1	Serial	Serial	B-NP	JJ	O	2	NMOD
2	epilepsy	epilepsy	I-NP	NN	O	0	ROOT
3	caused	cause	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	levodopa/carbidopa	levodopa/carbidopa	B-NP	NN	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	two	two	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	hemodialysis	hemodialysis	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	7	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	similar	similar	B-NP	JJ	O	6	NMOD
5	clinical	clinical	I-NP	JJ	O	6	NMOD
6	features	feature	I-NP	NNS	O	3	PMOD
7	are	be	B-VP	VBP	O	12	VMOD
8	presented	present	I-VP	VBN	O	7	VC
9	:	:	O	:	O	7	P
10	both	both	B-NP	DT	O	11	NMOD
11	patients	patient	I-NP	NNS	O	12	SUB
12	had	have	B-VP	VBD	O	31	VMOD
13	chronic	chronic	B-NP	JJ	O	15	NMOD
14	renal	renal	I-NP	JJ	O	15	NMOD
15	failure	failure	I-NP	NN	O	12	OBJ
16	,	,	O	,	O	12	P
17	on	on	B-PP	IN	O	12	VMOD
18	hemodialysis	hemodialysis	B-NP	NN	O	17	PMOD
19	for	for	B-PP	IN	O	18	NMOD
20	many	many	B-NP	JJ	O	21	NMOD
21	years	year	I-NP	NNS	O	19	PMOD
22	but	but	O	CC	O	12	VMOD
23	recently	recently	B-VP	RB	O	24	VMOD
24	begun	begin	I-VP	VBN	O	12	VC
25	on	on	B-PP	IN	O	24	VMOD
26	a	a	B-NP	DT	O	28	NMOD
27	high-flux	high-flux	I-NP	JJ	O	28	NMOD
28	dialyzer	dialyzer	I-NP	NN	O	25	PMOD
29	;	;	O	:	O	12	P
30	both	both	B-NP	DT	O	31	SUB
31	had	have	B-VP	VBD	O	40	VMOD
32	been	be	I-VP	VBN	O	31	VC
33	receiving	receive	I-VP	VBG	O	32	VMOD
34	a	a	B-NP	DT	O	36	NMOD
35	carbidopa/levodopa	carbidopa/levodopa	I-NP	NN	O	36	NMOD
36	preparation	preparation	I-NP	NN	O	33	OBJ
37	;	;	O	:	O	40	P
38	and	and	O	CC	O	40	VMOD
39	both	both	B-NP	DT	O	40	SUB
40	had	have	B-VP	VBD	O	0	ROOT
41	the	the	B-NP	DT	O	42	NMOD
42	onset	onset	I-NP	NN	O	40	OBJ
43	of	of	B-PP	IN	O	42	NMOD
44	hallucinosis	hallucinosis	B-NP	NN	O	47	NMOD
45	and	and	O	CC	O	47	NMOD
46	recurrent	recurrent	B-NP	JJ	O	47	NMOD
47	seizures	seizure	I-NP	NNS	O	43	PMOD
48	,	,	O	,	O	40	P
49	which	which	B-NP	WDT	O	40	VMOD
50	were	be	B-VP	VBD	O	49	SBAR
51	refractory	refractory	B-ADJP	JJ	O	50	PRD
52	to	to	B-PP	TO	O	51	AMOD
53	anticonvulsants	anticonvulsant	B-NP	NNS	O	52	PMOD
54	.	.	O	.	O	40	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	L-alpha-glyceryl-phosphorylcholine	L-alpha-glyceryl-phosphorylcholine	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	amnesia	amnesia	B-NP	NN	O	4	PMOD
6	caused	cause	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	scopolamine	scopolamine	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	carried	carry	I-VP	VBN	O	4	VC
6	out	out	B-PRT	RP	O	5	VMOD
7	to	to	B-VP	TO	O	8	VMOD
8	test	test	I-VP	VB	O	4	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	effects	effect	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	L-alpha-glycerylphosphorylcholine	L-alpha-glycerylphosphorylcholine	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	15	DEP
14	L-alpha-GFC	L-alpha-GFC	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	on	on	B-PP	IN	O	10	NMOD
17	memory	memory	B-NP	NN	O	18	NMOD
18	impairment	impairment	I-NP	NN	O	16	PMOD
19	induced	induce	B-VP	VBN	O	18	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	scopolamine	scopolamine	B-NP	NN	O	20	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	man	man	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	4	P

1	Seizures	Seizure	B-NP	NNS	O	0	ROOT
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	the	the	B-NP	DT	O	7	NMOD
5	cocaine	cocaine	I-NP	NN	O	7	NMOD
6	metabolite	metabolite	I-NP	NN	O	7	NMOD
7	benzoylecgonine	benzoylecgonine	I-NP	NN	O	3	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	rats	rat	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	half-life	half-life	I-NP	NN	O	8	SUB
3	(	(	O	(	O	5	DEP
4	t1/2	t1/2	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	of	of	B-PP	IN	O	2	NMOD
7	cocaine	cocaine	B-NP	NN	O	6	PMOD
8	is	be	B-VP	VBZ	O	27	VMOD
9	relatively	relatively	B-ADJP	RB	O	10	AMOD
10	short	short	I-ADJP	JJ	O	8	PRD
11	,	,	O	,	O	27	P
12	but	but	O	CC	O	27	VMOD
13	some	some	B-NP	DT	O	27	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	consequences	consequence	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	its	its	B-NP	PRP$	O	19	NMOD
19	use	use	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	16	P
21	such	such	B-PP	JJ	O	22	PMOD
22	as	as	I-PP	IN	O	16	NMOD
23	seizures	seizure	B-NP	NNS	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	strokes	stroke	I-NP	NNS	O	22	PMOD
26	,	,	O	,	O	13	P
27	can	can	B-VP	MD	O	0	ROOT
28	occur	occur	I-VP	VB	O	27	VC
29	hours	hour	B-NP	NNS	O	30	PMOD
30	after	after	B-PP	IN	O	28	VMOD
31	exposure	exposure	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	27	P

1	We	We	B-NP	PRP	O	2	SUB
2	evaluated	evaluate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	potential	potential	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	major	major	I-NP	JJ	O	8	NMOD
8	metabolite	metabolite	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cocaine	cocaine	B-NP	NN	O	12	NMOD
11	,	,	O	,	O	12	P
12	benzoylecgonine	benzoylecgonine	B-NP	NN	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	BE	BE	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	,	,	O	,	O	12	P
17	to	to	B-VP	TO	O	18	VMOD
18	cause	cause	I-VP	VB	O	12	NMOD
19	seizures	seizure	B-NP	NNS	O	18	OBJ
20	.	.	O	.	O	2	P

1	BE-Induced	BE-Induced	B-NP	JJ	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	occurred	occur	B-VP	VBD	O	0	ROOT
4	more	more	B-ADVP	RBR	O	5	AMOD
5	frequently	frequently	I-ADVP	RB	O	3	VMOD
6	and	and	O	CC	O	3	VMOD
7	had	have	B-VP	VBD	O	3	VMOD
8	significantly	significantly	B-NP	RB	O	9	AMOD
9	longer	long	I-NP	JJR	O	10	NMOD
10	latencies	latency	I-NP	NNS	O	7	OBJ
11	than	than	B-PP	IN	O	7	VMOD
12	those	those	B-NP	DT	O	11	PMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	equimolar	equimolar	B-NP	JJ	O	16	NMOD
16	amounts	amount	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	cocaine	cocaine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	3	P

1	Whereas	Whereas	B-SBAR	IN	O	16	VMOD
2	cocaine	cocaine	B-NP	NN	O	4	NMOD
3	induced	induce	I-NP	VBN	O	4	NMOD
4	seizures	seizure	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	1	SBAR
6	best	well	I-VP	RBS	O	7	AMOD
7	characterized	characterize	I-VP	VBN	O	5	VC
8	as	as	B-PP	IN	O	7	VMOD
9	brief	brief	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	9	P
11	generalized	generalize	B-VP	VBN	O	9	NMOD
12	,	,	O	,	O	16	P
13	and	and	O	CC	O	14	NMOD
14	tonic	tonic	B-ADJP	JJ	O	16	VMOD
15	and	and	O	CC	O	16	VMOD
16	resulted	result	B-VP	VBD	O	0	ROOT
17	in	in	B-PP	IN	O	16	VMOD
18	death	death	B-NP	NN	O	20	NMOD
19	,	,	O	,	O	20	P
20	those	those	B-NP	DT	O	24	SUB
21	induced	induce	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	BE	BE	B-NP	NN	O	22	PMOD
24	were	be	B-VP	VBD	O	36	VMOD
25	prolonged	prolonged	B-ADJP	JJ	O	24	PRD
26	,	,	O	,	O	24	P
27	often	often	B-ADVP	RB	O	24	VMOD
28	multiple	multiple	B-ADJP	JJ	O	30	AMOD
29	and	and	O	CC	O	30	AMOD
30	mixed	mixed	B-ADJP	JJ	O	36	VMOD
31	in	in	B-PP	IN	O	30	AMOD
32	type	type	B-NP	NN	O	31	PMOD
33	,	,	O	,	O	30	P
34	and	and	O	CC	O	30	VMOD
35	rarely	rarely	B-VP	RB	O	36	VMOD
36	resulted	result	I-VP	VBD	O	17	SBAR
37	in	in	B-PP	IN	O	36	VMOD
38	death	death	B-NP	NN	O	37	PMOD
39	.	.	O	.	O	16	P

1	BE-Injected	BE-Injected	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	0	ROOT
3	that	that	B-NP	WDT	O	2	NMOD
4	did	do	B-VP	VBD	O	3	SBAR
5	not	not	I-VP	RB	O	4	VMOD
6	have	have	I-VP	VB	O	4	VC
7	seizures	seizure	B-NP	NNS	O	8	SUB
8	had	have	B-VP	VBD	O	6	SBAR
9	significantly	significantly	B-NP	RB	O	12	NMOD
10	more	more	I-NP	RBR	O	9	AMOD
11	locomotor	locomotor	I-NP	JJ	O	9	AMOD
12	activity	activity	I-NP	NN	O	8	OBJ
13	than	than	B-PP	IN	O	12	NMOD
14	cocaine-injected	cocaine-injected	B-NP	JJ	O	15	NMOD
15	animals	animal	I-NP	NNS	O	13	PMOD
16	without	without	B-PP	IN	O	8	VMOD
17	seizures	seizure	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	2	P

1	Protection	Protection	B-NP	NN	O	4	SUB
2	against	against	B-PP	IN	O	1	NMOD
3	amphetamine	amphetamine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	neurotoxicity	neurotoxicity	B-NP	NN	B-protein	9	NMOD
6	toward	toward	B-PP	IN	I-protein	9	NMOD
7	striatal	striatal	B-NP	JJ	I-protein	9	NMOD
8	dopamine	dopamine	I-NP	NN	I-protein	9	NMOD
9	neurons	neuron	I-NP	NNS	I-protein	4	OBJ
10	in	in	B-PP	IN	O	4	VMOD
11	rodents	rodent	B-NP	NNS	O	10	PMOD
12	by	by	B-PP	IN	O	4	VMOD
13	LY274614	LY274614	B-NP	NN	O	19	NMOD
14	,	,	O	,	O	19	P
15	an	an	B-NP	DT	O	19	NMOD
16	excitatory	excitatory	I-NP	JJ	O	19	NMOD
17	amino	amino	I-NP	NN	O	19	NMOD
18	acid	acid	I-NP	NN	O	19	NMOD
19	antagonist	antagonist	I-NP	NN	O	12	PMOD
20	.	.	O	.	O	4	P

1	Neonatal	Neonatal	B-NP	JJ	O	4	NMOD
2	pyridoxine	pyridoxine	I-NP	NN	O	4	NMOD
3	responsive	responsive	I-NP	JJ	O	4	NMOD
4	convulsions	convulsion	I-NP	NNS	O	0	ROOT
5	due	due	B-ADJP	JJ	O	4	NMOD
6	to	to	B-PP	TO	O	5	AMOD
7	isoniazid	isoniazid	B-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	17-day-old	17-day-old	I-NP	JJ	O	3	NMOD
3	infant	infant	I-NP	NN	O	0	ROOT
4	on	on	B-PP	IN	O	3	NMOD
5	isoniazid	isoniazid	B-NP	NN	O	8	NMOD
6	therapy	therapy	I-NP	NN	O	8	NMOD
7	13	13	I-NP	CD	O	8	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	4	PMOD
9	daily	daily	B-ADVP	RB	O	10	PMOD
10	from	from	B-PP	IN	O	3	NMOD
11	birth	birth	B-NP	NN	O	10	PMOD
12	because	because	B-PP	IN	O	16	VMOD
13	of	of	I-PP	IN	O	12	PMOD
14	maternal	maternal	B-NP	JJ	O	15	NMOD
15	tuberculosis	tuberculosis	I-NP	NN	O	16	SUB
16	was	be	B-VP	VBD	O	10	SBAR
17	admitted	admit	I-VP	VBN	O	16	VC
18	after	after	B-PP	IN	O	17	VMOD
19	4	4	B-NP	CD	O	20	NMOD
20	days	day	I-NP	NNS	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	clonic	clonic	B-NP	JJ	O	23	NMOD
23	fits	fit	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	3	P

1	Reversal	Reversal	B-NP	NN	O	0	ROOT
2	by	by	B-PP	IN	O	1	NMOD
3	phenylephrine	phenylephrine	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	beneficial	beneficial	I-NP	JJ	O	7	NMOD
7	effects	effect	I-NP	NNS	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	intravenous	intravenous	B-NP	JJ	O	10	NMOD
10	nitroglycerin	nitroglycerin	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	acute	acute	B-NP	JJ	O	16	NMOD
15	myocardial	myocardial	I-NP	JJ	O	16	NMOD
16	infarction	infarction	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	1	P

1	Nitroglycerin	Nitroglycerin	B-NP	NN	B-protein	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	shown	show	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	reduce	reduce	I-VP	VB	O	4	VMOD
7	ST-segment	ST-segment	B-NP	NN	O	8	NMOD
8	elevation	elevation	I-NP	NN	O	6	OBJ
9	during	during	B-PP	IN	O	6	VMOD
10	acute	acute	B-NP	JJ	O	12	NMOD
11	myocardial	myocardial	I-NP	JJ	O	12	NMOD
12	infarction	infarction	I-NP	NN	O	15	NMOD
13	,	,	O	,	O	15	P
14	an	an	B-NP	DT	O	15	NMOD
15	effect	effect	I-NP	NN	O	16	SUB
16	potentiated	potentiate	B-VP	VBD	O	9	SBAR
17	in	in	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	dog	dog	I-NP	NN	O	17	PMOD
20	by	by	B-PP	IN	O	19	NMOD
21	agents	agent	B-NP	NNS	O	20	PMOD
22	that	that	B-NP	WDT	O	21	NMOD
23	reverse	reverse	B-VP	VBP	O	22	SBAR
24	nitroglycerin	nitroglycerin	B-NP	NN	B-protein	26	NMOD
25	induced	induce	I-NP	VBN	O	26	NMOD
26	hypotension	hypotension	I-NP	NN	O	23	OBJ
27	.	.	O	.	O	2	P

1	Ten	Ten	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	8	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	6	AMOD
5	transmural	transmural	I-NP	JJ	O	6	AMOD
6	myocardial	myocardial	I-NP	JJ	O	7	NMOD
7	infarctions	infarction	I-NP	NNS	O	3	PMOD
8	received	receive	B-VP	VBD	O	0	ROOT
9	intravenous	intravenous	B-NP	JJ	O	10	NMOD
10	nitroglycerin	nitroglycerin	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	10	P
12	sufficient	sufficient	B-ADJP	JJ	O	10	NMOD
13	to	to	B-VP	TO	O	14	VMOD
14	reduce	reduce	I-VP	VB	O	12	AMOD
15	mean	mean	B-NP	JJ	O	16	AMOD
16	arterial	arterial	I-NP	JJ	O	17	NMOD
17	pressure	pressure	I-NP	NN	O	14	OBJ
18	from	from	B-PP	IN	O	14	VMOD
19	107	107	B-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	6	6	I-NP	CD	O	18	PMOD
22	to	to	I-NP	TO	O	14	VMOD
23	85	85	I-NP	CD	O	25	AMOD
24	+/-	+/-	I-NP	SYM	O	25	AMOD
25	6	6	I-NP	CD	O	27	NMOD
26	mm	mm	I-NP	NN	O	27	NMOD
27	Hg	Hg	I-NP	NN	O	22	PMOD
28	(	(	O	(	O	33	DEP
29	P	P	B-NP	NN	O	33	DEP
30	less	less	B-ADJP	JJR	O	29	NMOD
31	than	than	B-PP	IN	O	30	AMOD
32	0.001	0.001	B-NP	CD	O	31	PMOD
33	)	)	O	)	O	27	NMOD
34	,	,	O	,	O	27	P
35	for	for	B-PP	IN	O	22	PMOD
36	60	60	B-NP	CD	O	37	NMOD
37	minutes	minute	I-NP	NNS	O	35	PMOD
38	.	.	O	.	O	8	P

1	Elevation	Elevation	B-NP	NN	O	16	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ADAM10	ADAM10	B-NP	NN	B-protein	10	NMOD
4	,	,	O	,	O	10	P
5	ADAM17	ADAM17	B-NP	NN	B-protein	10	NMOD
6	,	,	O	,	O	10	P
7	MMP-2	MMP-2	B-NP	NN	B-protein	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	MMP-9	MMP-9	B-NP	NN	B-protein	10	NMOD
10	expression	expression	I-NP	NN	O	2	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	media	medium	B-NP	NNS	O	15	NMOD
13	degeneration	degeneration	I-NP	NN	O	15	NMOD
14	features	feature	I-NP	NNS	O	15	NMOD
15	CaCl2	CaCl2	I-NP	NN	B-protein	11	PMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	thoracic	thoracic	B-NP	JJ	O	19	NMOD
18	aortic	aortic	I-NP	JJ	O	19	NMOD
19	aneurysm	aneurysm	I-NP	NN	O	16	OBJ
20	in	in	B-PP	IN	O	16	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	rat	rat	I-NP	NN	O	23	NMOD
23	model	model	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	16	P

1	PURPOSE	PURPOSE	B-NP	NN	O	5	SUB
2	:	:	O	:	O	5	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	designed	design	I-VP	VBN	O	5	VC
7	to	to	B-VP	TO	O	8	VMOD
8	establish	establish	I-VP	VB	O	6	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	rat	rat	I-NP	NN	O	11	NMOD
11	model	model	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	thoracic	thoracic	B-NP	JJ	O	15	NMOD
14	aortic	aortic	I-NP	JJ	O	15	NMOD
15	aneurysm	aneurysm	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	TAA	TAA	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	by	by	B-PP	IN	O	8	VMOD
20	calcium	calcium	B-NP	NN	O	21	NMOD
21	chloride	chloride	I-NP	NN	O	28	SUB
22	(	(	O	(	O	27	DEP
23	CaCl	CaCl	B-NP	NN	O	27	DEP
24	(	(	O	(	O	26	DEP
25	2	2	B-NP	CD	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	)	)	O	)	O	21	NMOD
28	induced	induce	B-VP	VBD	O	19	SBAR
29	arterial	arterial	B-NP	JJ	O	30	NMOD
30	injury	injury	I-NP	NN	O	28	OBJ
31	and	and	O	CC	O	28	VMOD
32	to	to	B-VP	TO	O	33	VMOD
33	explore	explore	I-VP	VB	O	28	VMOD
34	the	the	B-NP	DT	O	36	NMOD
35	potential	potential	I-NP	JJ	O	36	NMOD
36	role	role	I-NP	NN	O	33	OBJ
37	of	of	B-PP	IN	O	36	NMOD
38	a	a	B-NP	DT	O	39	NMOD
39	disintegrin	disintegrin	I-NP	NN	O	41	NMOD
40	and	and	I-NP	CC	O	41	NMOD
41	metalloproteinase	metalloproteinase	I-NP	NN	B-protein	54	NMOD
42	(	(	O	(	O	44	DEP
43	ADAM	ADAM	B-NP	NN	B-protein	44	DEP
44	)	)	O	)	O	41	NMOD
45	,	,	O	,	O	54	P
46	matrix	matrix	B-NP	NN	B-protein	47	NMOD
47	metalloproteinases	metalloproteinas	I-NP	NNS	I-protein	54	NMOD
48	(	(	O	(	O	50	DEP
49	MMPs	MMP	B-NP	NNS	B-protein	50	DEP
50	)	)	O	)	O	47	NMOD
51	and	and	O	CC	O	54	NMOD
52	their	their	B-NP	PRP$	O	54	NMOD
53	endogenous	endogenous	I-NP	JJ	O	54	NMOD
54	inhibitors	inhibitor	I-NP	NNS	O	37	PMOD
55	(	(	O	(	O	57	DEP
56	TIMPs	TIMP	B-NP	NNS	B-DNA	57	DEP
57	)	)	O	)	O	54	NMOD
58	in	in	B-PP	IN	O	36	NMOD
59	TAA	TAA	B-NP	NN	O	60	NMOD
60	formation	formation	I-NP	NN	O	58	PMOD
61	.	.	O	.	O	5	P

1	However	However	B-ADVP	RB	O	12	VMOD
2	,	,	O	,	O	12	P
3	a	a	B-NP	DT	O	4	NMOD
4	bolus	bolus	I-NP	NN	O	12	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	epinephrine	epinephrine	B-NP	NN	O	5	PMOD
7	injected	inject	B-VP	VBN	O	6	NMOD
8	through	through	B-PP	IN	O	7	VMOD
9	an	an	B-NP	DT	O	11	NMOD
10	alternative	alternative	I-NP	JJ	O	11	NMOD
11	catheter	catheter	I-NP	NN	O	8	PMOD
12	provoked	provoke	B-VP	VBD	O	0	ROOT
13	a	a	B-NP	DT	O	15	NMOD
14	hypertensive	hypertensive	I-NP	JJ	O	15	NMOD
15	crisis	crisis	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	12	P

1	Long-term	Long-term	B-NP	JJ	O	3	NMOD
2	glutamate	glutamate	I-NP	NN	O	3	NMOD
3	supplementation	supplementation	I-NP	NN	O	4	SUB
4	failed	fail	B-VP	VBD	O	0	ROOT
5	to	to	I-VP	TO	O	6	VMOD
6	protect	protect	I-VP	VB	O	4	VMOD
7	against	against	B-PP	IN	O	6	VMOD
8	peripheral	peripheral	B-NP	JJ	O	9	NMOD
9	neurotoxicity	neurotoxicity	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	paclitaxel	paclitaxel	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	4	P

1	Toxic	Toxic	B-NP	JJ	O	3	NMOD
2	peripheral	peripheral	I-NP	JJ	O	3	NMOD
3	neuropathy	neuropathy	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	still	still	B-ADVP	RB	O	4	VMOD
6	a	a	B-NP	DT	O	9	NMOD
7	significant	significant	I-NP	JJ	O	9	NMOD
8	limiting	limit	I-NP	VBG	O	9	NMOD
9	factor	factor	I-NP	NN	O	4	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	chemotherapy	chemotherapy	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	paclitaxel	paclitaxel	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	16	DEP
15	PAC	PAC	B-NP	NN	B-protein	16	DEP
16	)	)	O	)	O	13	NMOD
17	,	,	O	,	O	4	P
18	although	although	B-SBAR	IN	O	4	VMOD
19	glutamate	glutamate	B-NP	NN	O	26	NMOD
20	and	and	O	CC	O	26	NMOD
21	its	its	B-NP	PRP$	O	26	NMOD
22	closely	closely	I-NP	RB	O	23	AMOD
23	related	related	I-NP	JJ	O	26	NMOD
24	amino	amino	I-NP	JJ	O	26	NMOD
25	acid	acid	I-NP	NN	O	26	NMOD
26	glutamine	glutamine	I-NP	NN	O	27	SUB
27	were	be	B-VP	VBD	O	18	SBAR
28	claimed	claim	I-VP	VBN	O	27	VC
29	to	to	B-VP	TO	O	30	VMOD
30	ameliorate	ameliorate	I-VP	VB	O	28	VMOD
31	PAC	PAC	B-NP	NN	O	32	NMOD
32	neurotoxicity	neurotoxicity	I-NP	NN	O	30	OBJ
33	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	3	NMOD
2	pilot	pilot	I-NP	NN	O	3	NMOD
3	trial	trial	I-NP	NN	O	0	ROOT
4	aimed	aim	B-VP	VBN	O	3	NMOD
5	to	to	I-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	role	role	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	glutamate	glutamate	B-NP	NN	O	11	NMOD
11	supplementation	supplementation	I-NP	NN	O	9	PMOD
12	for	for	B-PP	IN	O	8	NMOD
13	preventing	prevent	B-VP	VBG	O	12	PMOD
14	PAC	PAC	B-NP	NN	B-protein	17	NMOD
15	induced	induced	I-NP	JJ	O	17	NMOD
16	peripheral	peripheral	I-NP	JJ	O	17	NMOD
17	neuropathy	neuropathy	I-NP	NN	O	13	OBJ
18	in	in	B-PP	IN	O	13	VMOD
19	a	a	B-NP	DT	O	28	NMOD
20	randomized	randomize	I-NP	VBN	O	28	NMOD
21	,	,	I-NP	,	O	28	P
22	placebo-controlled	placebo-controlled	I-NP	JJ	O	28	NMOD
23	,	,	I-NP	,	O	28	P
24	double-blinded	double-blinded	I-NP	JJ	O	25	AMOD
25	clinical	clinical	I-NP	JJ	O	28	NMOD
26	and	and	I-NP	CC	O	28	NMOD
27	electro-diagnostic	electro-diagnostic	I-NP	JJ	O	28	NMOD
28	study	study	I-NP	NN	O	18	PMOD
29	.	.	O	.	O	3	P

1	Forty-three	Forty-three	B-NP	CD	O	4	NMOD
2	ovarian	ovarian	I-NP	JJ	O	4	NMOD
3	cancer	cancer	I-NP	NN	O	4	NMOD
4	patients	patient	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	19	VMOD
6	available	available	B-ADJP	JJ	O	5	PRD
7	for	for	B-PP	IN	O	6	AMOD
8	analysis	analysis	B-NP	NN	O	7	PMOD
9	following	follow	B-PP	VBG	O	8	NMOD
10	six	six	B-NP	CD	O	11	NMOD
11	cycles	cycle	I-NP	NNS	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	16	NMOD
14	same	same	I-NP	JJ	O	16	NMOD
15	PAC-containing	PAC-containing	I-NP	JJ	O	16	NMOD
16	regimen	regimen	I-NP	NN	O	12	PMOD
17	:	:	O	:	O	5	P
18	23	23	B-NP	CD	O	19	SUB
19	had	have	B-VP	VBD	O	46	VMOD
20	been	be	I-VP	VBN	O	19	VC
21	supplemented	supplement	I-VP	VBN	O	20	VC
22	by	by	B-PP	IN	O	21	VMOD
23	glutamate	glutamate	B-NP	NN	O	22	PMOD
24	all	all	O	DT	O	21	VMOD
25	along	along	B-PP	IN	O	21	VMOD
26	the	the	B-NP	DT	O	28	NMOD
27	treatment	treatment	I-NP	NN	O	28	NMOD
28	period	period	I-NP	NN	O	25	PMOD
29	,	,	O	,	O	21	P
30	at	at	B-PP	IN	O	21	VMOD
31	a	a	B-NP	DT	O	33	NMOD
32	daily	daily	I-NP	JJ	O	33	NMOD
33	dose	dose	I-NP	NN	O	30	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	three	three	B-NP	CD	O	36	AMOD
36	times	time	I-NP	NNS	O	38	NMOD
37	500	500	I-NP	CD	O	38	NMOD
38	mg	mg	I-NP	NN	O	34	PMOD
39	(	(	O	(	O	42	DEP
40	group	group	B-NP	NN	O	41	NMOD
41	G	G	I-NP	NN	O	42	DEP
42	)	)	O	)	O	38	NMOD
43	,	,	O	,	O	46	P
44	and	and	O	CC	O	45	NMOD
45	20	20	B-NP	CD	O	46	SUB
46	had	have	B-VP	VBD	O	0	ROOT
47	received	receive	I-VP	VBN	O	46	VC
48	a	a	B-NP	DT	O	49	NMOD
49	placebo	placebo	I-NP	NN	O	47	OBJ
50	(	(	O	(	O	53	DEP
51	group	group	B-NP	NN	O	52	NMOD
52	P	P	I-NP	NN	O	53	DEP
53	)	)	O	)	O	49	NMOD
54	.	.	O	.	O	46	P

1	Attentional	Attentional	B-NP	JJ	O	2	NMOD
2	modulation	modulation	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	perceived	perceive	B-NP	VBN	O	6	NMOD
5	pain	pain	I-NP	NN	O	6	NMOD
6	intensity	intensity	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	capsaicin	capsaicin	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	secondary	secondary	B-NP	JJ	O	11	NMOD
11	hyperalgesia	hyperalgesia	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	it	it	B-NP	PRP	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	not	not	I-VP	RB	O	4	VMOD
6	known	know	I-VP	VBN	O	4	VC
7	that	that	B-SBAR	IN	O	6	VMOD
8	how	how	B-ADVP	WRB	O	12	DEP
9	pain	pain	B-NP	JJ	O	11	NMOD
10	intensity	intensity	I-NP	NN	O	11	NMOD
11	ratings	rating	I-NP	NNS	O	12	SUB
12	are	be	B-VP	VBP	O	7	SBAR
13	affected	affect	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	attention	attention	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	capsaicin	capsaicin	B-NP	NN	O	16	PMOD
18	induced	induce	B-VP	VBD	O	7	DEP
19	secondary	secondary	B-NP	JJ	O	20	NMOD
20	hyperalgesia	hyperalgesia	I-NP	NN	O	18	OBJ
21	.	.	O	.	O	4	P

1	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	it	it	B-NP	PRP	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	found	find	I-VP	VBN	O	4	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	magnitude	magnitude	I-NP	NN	O	15	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	attentional	attentional	B-NP	JJ	O	11	NMOD
11	modulation	modulation	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	secondary	secondary	B-NP	JJ	O	14	NMOD
14	hyperalgesia	hyperalgesia	I-NP	NN	O	12	PMOD
15	is	be	B-VP	VBZ	O	6	SBAR
16	very	very	B-ADJP	RB	O	17	AMOD
17	similar	similar	I-ADJP	JJ	O	15	PRD
18	to	to	B-PP	TO	O	17	AMOD
19	that	that	B-NP	DT	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	capsaicin-untreated	capsaicin-untreated	B-NP	JJ	O	23	AMOD
22	,	,	I-NP	,	O	23	P
23	control	control	I-NP	JJ	O	24	NMOD
24	condition	condition	I-NP	NN	O	20	PMOD
25	.	.	O	.	O	4	P

1	Testosterone-dependent	Testosterone-dependent	B-NP	JJ	O	2	NMOD
2	hypertension	hypertension	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	upregulation	upregulation	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	intrarenal	intrarenal	B-NP	JJ	B-protein	7	NMOD
7	angiotensinogen	angiotensinogen	I-NP	NN	I-protein	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	Dahl	Dahl	B-NP	NN	O	11	NMOD
10	salt-sensitive	salt-sensitive	I-NP	JJ	O	11	NMOD
11	rats	rat	I-NP	NNS	O	8	PMOD
12	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	7	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	the	the	B-NP	DT	O	6	NMOD
6	hypothesis	hypothesis	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	tested	test	I-VP	VBN	O	7	VC
9	that	that	B-SBAR	IN	O	8	VMOD
10	there	there	B-NP	EX	O	11	SUB
11	is	be	B-VP	VBZ	O	9	SBAR
12	a	a	B-NP	DT	O	14	NMOD
13	sexual	sexual	I-NP	JJ	O	14	NMOD
14	dimorphism	dimorphism	I-NP	NN	O	17	SUB
15	in	in	B-PP	IN	O	14	NMOD
16	HS	HS	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	11	VMOD
18	upregulation	upregulation	B-NP	NN	O	17	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	intrarenal	intrarenal	B-NP	JJ	B-protein	21	NMOD
21	angiotensinogen	angiotensinogen	I-NP	NN	I-protein	19	PMOD
22	mediated	mediate	B-VP	VBN	O	21	NMOD
23	by	by	B-PP	IN	O	22	VMOD
24	testosterone	testosterone	B-NP	NN	O	23	PMOD
25	that	that	B-NP	WDT	O	24	NMOD
26	also	also	B-ADVP	RB	O	27	VMOD
27	causes	cause	B-VP	VBZ	O	25	SBAR
28	increases	increase	B-NP	NNS	O	27	OBJ
29	in	in	B-PP	IN	O	28	NMOD
30	BP	BP	B-NP	NN	O	33	NMOD
31	and	and	O	CC	O	33	NMOD
32	renal	renal	B-NP	JJ	O	33	NMOD
33	injury	injury	I-NP	NN	O	29	PMOD
34	.	.	O	.	O	7	P

1	Testosterone	Testosterone	B-NP	NN	O	2	NMOD
2	replacement	replacement	I-NP	NN	O	7	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	castrated	castrate	B-NP	VBN	O	6	NMOD
5	DS	DS	I-NP	NN	O	6	NMOD
6	rats	rat	I-NP	NNS	O	3	PMOD
7	increased	increase	B-VP	VBD	O	0	ROOT
8	BP	BP	B-NP	NN	O	14	NMOD
9	,	,	O	,	O	14	P
10	renal	renal	B-NP	JJ	O	11	NMOD
11	injury	injury	I-NP	NN	O	14	NMOD
12	,	,	O	,	O	14	P
13	and	and	O	CC	O	14	NMOD
14	upregulation	upregulation	B-NP	NN	O	7	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	angiotensinogen	angiotensinogen	I-NP	NN	O	15	PMOD
18	associated	associate	B-VP	VBN	O	17	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	HS	HS	B-NP	NN	O	21	NMOD
21	diet	diet	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	7	P

1	No	No	B-NP	DT	O	2	NMOD
2	changes	change	I-NP	NNS	O	5	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	haloperidol	haloperidol	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	catalepsy	catalepsy	B-NP	NN	O	10	NMOD
7	or	or	I-NP	CC	O	10	NMOD
8	MK-801	MK-801	I-NP	NN	B-protein	9	AMOD
9	induced	induce	I-NP	VBN	O	10	NMOD
10	locomotion	locomotion	I-NP	NN	O	5	OBJ
11	were	be	B-VP	VBD	O	5	VMOD
12	seen	see	I-VP	VBN	O	11	VC
13	following	follow	B-PP	VBG	O	12	VMOD
14	PD	PD	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	5	P

1	Massive	Massive	B-NP	JJ	O	4	NMOD
2	urinary	urinary	I-NP	JJ	O	4	NMOD
3	protein	protein	I-NP	NN	O	4	NMOD
4	excretion	excretion	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	observed	observe	I-VP	VBN	O	6	VC
8	after	after	B-PP	IN	O	7	VMOD
9	conversion	conversion	B-NP	NN	O	8	PMOD
10	from	from	B-PP	IN	O	9	NMOD
11	calcineurin	calcineurin	B-NP	NN	B-protein	12	NMOD
12	inhibitors	inhibitor	I-NP	NNS	O	10	PMOD
13	to	to	B-PP	TO	O	9	NMOD
14	mammalian	mammalian	B-NP	JJ	O	15	NMOD
15	target	target	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	rapamycin	rapamycin	B-NP	NN	B-protein	21	NMOD
18	(	(	O	(	I-protein	21	NMOD
19	mToR	mToR	B-NP	NN	I-protein	21	NMOD
20	)	)	O	)	I-protein	21	NMOD
21	inhibitors	inhibitor	B-NP	NNS	I-protein	24	NMOD
22	,	,	O	,	O	24	P
23	especially	especially	B-NP	RB	O	24	NMOD
24	sirolimus	sirolimus	I-NP	NN	O	16	PMOD
25	,	,	O	,	O	7	P
26	in	in	B-PP	IN	O	7	VMOD
27	renal	renal	B-NP	JJ	O	29	NMOD
28	transplant	transplant	I-NP	NN	O	29	NMOD
29	recipients	recipient	I-NP	NNS	O	26	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	chronic	chronic	B-NP	JJ	O	33	NMOD
32	allograft	allograft	I-NP	NN	O	33	NMOD
33	nephropathy	nephropathy	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	5	P

1	Whether	Whether	B-SBAR	IN	O	15	SUB
2	proteinuria	proteinuria	B-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	1	SBAR
4	due	due	B-PP	IN	O	3	VMOD
5	to	to	B-PP	TO	O	4	PMOD
6	sirolimus	sirolimus	B-NP	NN	O	10	NMOD
7	or	or	O	CC	O	10	NMOD
8	only	only	B-NP	RB	O	10	NMOD
9	a	a	I-NP	DT	O	10	NMOD
10	consequence	consequence	I-NP	NN	O	5	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	calcineurin	calcineurin	B-NP	NN	B-protein	13	NMOD
13	inhibitors	inhibitor	I-NP	NNS	O	14	NMOD
14	withdrawal	withdrawal	I-NP	NN	O	11	PMOD
15	remained	remain	B-VP	VBD	O	0	ROOT
16	unsolved	unsolved	B-ADJP	JJ	O	15	PRD
17	until	until	B-SBAR	IN	O	15	VMOD
18	high	high	B-NP	JJ	O	20	NMOD
19	range	range	I-NP	NN	O	20	NMOD
20	proteinuria	proteinuria	I-NP	NN	O	21	SUB
21	has	have	B-VP	VBZ	O	17	SBAR
22	been	be	I-VP	VBN	O	21	VC
23	observed	observe	I-VP	VBN	O	22	VC
24	during	during	B-PP	IN	O	23	VMOD
25	sirolimus	sirolimus	B-NP	NN	O	26	NMOD
26	therapy	therapy	I-NP	NN	O	24	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	islet	islet	B-NP	NN	O	29	NMOD
29	transplantation	transplantation	I-NP	NN	O	27	PMOD
30	and	and	B-PP	CC	O	27	PMOD
31	in	in	B-PP	IN	O	27	PMOD
32	patients	patient	B-NP	NNS	O	31	PMOD
33	who	who	B-NP	WP	O	32	NMOD
34	received	receive	B-VP	VBD	O	33	SBAR
35	sirolimus	sirolimus	B-NP	FW	O	34	VMOD
36	de	de	I-NP	FW	O	37	NMOD
37	novo	novo	I-NP	FW	O	35	AMOD
38	.	.	O	.	O	15	P

1	Hypothalamic	Hypothalamic	B-NP	JJ	O	7	NMOD
2	prolactin	prolactin	I-NP	NN	O	7	NMOD
3	receptor	receptor	I-NP	NN	O	7	NMOD
4	messenger	messenger	I-NP	NN	O	7	NMOD
5	ribonucleic	ribonucleic	I-NP	JJ	O	7	NMOD
6	acid	acid	I-NP	NN	O	7	NMOD
7	levels	level	I-NP	NNS	O	14	NMOD
8	,	,	O	,	O	14	P
9	prolactin	prolactin	B-NP	NN	O	10	NMOD
10	signaling	signaling	I-NP	NN	O	14	NMOD
11	,	,	O	,	O	14	P
12	and	and	O	CC	O	14	NMOD
13	hyperprolactinemic	hyperprolactinemic	B-NP	JJ	O	14	NMOD
14	inhibition	inhibition	I-NP	NN	O	20	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	pulsatile	pulsatile	B-NP	JJ	O	19	NMOD
17	luteinizing	luteinizing	I-NP	NN	O	19	NMOD
18	hormone	hormone	I-NP	NN	O	19	NMOD
19	secretion	secretion	I-NP	NN	O	15	PMOD
20	are	be	B-VP	VBP	O	0	ROOT
21	dependent	dependent	B-ADJP	JJ	O	20	PRD
22	on	on	B-PP	IN	O	21	AMOD
23	estradiol	estradiol	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	20	P

1	We	We	B-NP	PRP	O	3	SUB
2	first	first	B-ADVP	RB	O	3	VMOD
3	tested	test	B-VP	VBD	O	0	ROOT
4	whether	whether	B-SBAR	IN	O	3	VMOD
5	chronic	chronic	B-NP	JJ	O	6	NMOD
6	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	7	SUB
7	inhibited	inhibit	B-VP	VBD	O	4	SBAR
8	two	two	B-NP	CD	O	10	NMOD
9	neuroendocrine	neuroendocrine	I-NP	JJ	O	10	NMOD
10	parameters	parameter	I-NP	NNS	O	7	OBJ
11	necessary	necessary	B-ADJP	JJ	O	10	NMOD
12	for	for	B-PP	IN	O	11	AMOD
13	female	female	B-NP	JJ	O	14	NMOD
14	fertility	fertility	I-NP	NN	O	12	PMOD
15	:	:	O	:	O	3	P
16	pulsatile	pulsatile	B-NP	JJ	O	18	NMOD
17	LH	LH	I-NP	NN	O	18	NMOD
18	secretion	secretion	I-NP	NN	O	24	NMOD
19	and	and	O	CC	O	24	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	estrogen	estrogen	I-NP	NN	O	24	NMOD
22	induced	induce	B-VP	VBD	O	21	AMOD
23	LH	LH	B-NP	NN	O	24	NMOD
24	surge	surge	I-NP	NN	O	3	VMOD
25	.	.	O	.	O	3	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	9	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	dopamine	dopamine	I-NP	NN	O	8	NMOD
7	antagonist	antagonist	I-NP	NN	O	8	NMOD
8	sulpiride	sulpiride	I-NP	NN	O	4	PMOD
9	caused	cause	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	16	NMOD
11	40	40	I-NP	CD	O	12	AMOD
12	%	%	I-NP	NN	O	16	NMOD
13	reduction	reduction	I-NP	NN	O	16	NMOD
14	LH	LH	I-NP	NN	O	16	NMOD
15	pulse	pulse	I-NP	NN	O	16	NMOD
16	frequency	frequency	I-NP	NN	O	9	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	ovariectomized	ovariectomize	B-NP	VBN	O	19	NMOD
19	rats	rat	I-NP	NNS	O	17	PMOD
20	,	,	O	,	O	16	P
21	but	but	O	CC	O	20	AMOD
22	only	only	B-ADVP	RB	O	23	PMOD
23	in	in	B-PP	IN	O	21	PRD
24	the	the	B-NP	DT	O	25	NMOD
25	presence	presence	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	chronic	chronic	B-NP	JJ	O	29	NMOD
28	low	low	I-NP	JJ	O	29	NMOD
29	levels	level	I-NP	NNS	O	26	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	estradiol	estradiol	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	21	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	show	show	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	GnRH	GnRH	B-NP	NN	O	7	NMOD
6	pulse	pulse	I-NP	NN	O	7	NMOD
7	frequency	frequency	I-NP	NN	O	8	SUB
8	is	be	B-VP	VBZ	O	4	SBAR
9	inhibited	inhibit	I-VP	VBN	O	8	VC
10	by	by	B-PP	IN	O	9	VMOD
11	chronic	chronic	B-NP	JJ	O	12	NMOD
12	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	steroid-dependent	steroid-dependent	I-NP	JJ	O	16	NMOD
16	manner	manner	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	previously	previously	I-VP	RB	O	2	VMOD
4	demonstrated	demonstrate	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	ritonavir	ritonavir	B-NP	NN	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	8	SUB
8	increases	increase	B-VP	VBZ	O	5	SBAR
9	atherosclerotic	atherosclerotic	B-NP	JJ	O	11	NMOD
10	lesion	lesion	I-NP	NN	O	11	NMOD
11	formation	formation	I-NP	NN	O	8	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	male	male	B-NP	JJ	O	14	NMOD
14	mice	mouse	I-NP	NNS	O	12	PMOD
15	to	to	B-PP	TO	O	14	NMOD
16	a	a	B-NP	DT	O	18	NMOD
17	greater	great	I-NP	JJR	O	18	NMOD
18	extent	extent	I-NP	NN	O	15	PMOD
19	than	than	B-PP	IN	O	11	NMOD
20	in	in	B-PP	IN	O	19	PMOD
21	female	female	B-NP	JJ	O	22	NMOD
22	mice	mouse	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	comparable	comparable	I-NP	JJ	O	3	NMOD
3	overexpression	overexpression	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	Pgp	Pgp	B-NP	NN	B-protein	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	BBB	BBB	I-NP	NN	B-protein	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	obtained	obtain	I-VP	VBN	O	9	VC
11	after	after	B-PP	IN	O	10	VMOD
12	pilocarpine	pilocarpine	B-NP	NN	O	14	NMOD
13	induced	induce	I-NP	VBN	O	14	NMOD
14	seizures	seizure	I-NP	NNS	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	wild-type	wild-type	B-NP	JJ	B-cell_line	18	NMOD
17	Wistar	Wistar	I-NP	NNP	I-cell_line	18	NMOD
18	rats	rat	I-NP	NNS	I-cell_line	15	PMOD
19	.	.	O	.	O	9	P

1	QTLs	QTL	B-NP	NNS	B-cell_type	22	NMOD
2	for	for	B-PP	IN	O	1	NMOD
3	susceptibility	susceptibility	B-NP	NN	O	16	SUB
4	to	to	B-PP	TO	O	3	NMOD
5	pilocarpine	pilocarpine	B-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	seizures	seizure	I-NP	NNS	O	4	PMOD
8	,	,	O	,	O	16	P
9	a	a	B-NP	DT	O	10	NMOD
10	model	model	I-NP	NN	O	16	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	temporal	temporal	B-NP	JJ	O	14	NMOD
13	lobe	lobe	I-NP	NN	O	14	NMOD
14	epilepsy	epilepsy	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	10	P
16	have	have	B-VP	VBP	O	2	SBAR
17	not	not	I-VP	RB	O	16	VMOD
18	been	be	I-VP	VBN	O	16	VC
19	reported	report	I-VP	VBN	O	18	VC
20	,	,	O	,	O	22	P
21	and	and	O	CC	O	22	NMOD
22	CSS	CSS	B-NP	NN	B-protein	23	SUB
23	have	have	B-VP	VBP	O	0	ROOT
24	not	not	I-VP	RB	O	23	VMOD
25	previously	previously	I-VP	RB	O	23	VMOD
26	been	be	I-VP	VBN	O	23	VC
27	used	use	I-VP	VBN	O	26	VC
28	to	to	B-VP	TO	O	29	VMOD
29	localize	localize	I-VP	VB	O	27	VMOD
30	seizure	seizure	B-NP	NN	B-DNA	32	NMOD
31	susceptibility	susceptibility	I-NP	NN	I-DNA	32	NMOD
32	genes	gene	I-NP	NNS	I-DNA	29	OBJ
33	.	.	O	.	O	23	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	QTLs	QTL	B-NP	NNS	B-cell_type	2	OBJ
4	identified	identify	B-VP	VBN	O	3	NMOD
5	using	use	B-VP	VBG	O	4	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	B6	B6	I-NP	NN	B-DNA	12	NMOD
8	(	(	O	(	O	10	DEP
9	host	host	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	x	x	B-NP	NN	O	12	NMOD
12	A/J	A/J	I-NP	NN	O	17	NMOD
13	(	(	O	(	O	15	DEP
14	donor	donor	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	CSS	CSS	B-NP	NN	O	17	NMOD
17	panel	panel	I-NP	NN	O	5	OBJ
18	to	to	B-VP	TO	O	19	VMOD
19	localize	localize	I-VP	VB	O	5	VMOD
20	genes	gene	B-NP	NNS	O	19	OBJ
21	involved	involve	B-VP	VBN	O	20	NMOD
22	in	in	B-PP	IN	O	21	VMOD
23	susceptibility	susceptibility	B-NP	NN	O	22	PMOD
24	to	to	B-PP	TO	O	23	NMOD
25	pilocarpine	pilocarpine	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	seizures	seizure	I-NP	NNS	O	24	PMOD
28	.	.	O	.	O	2	P

1	Three	Three	B-NP	CD	O	3	AMOD
2	hundred	hundred	I-NP	CD	O	3	AMOD
3	fifty-five	fifty-five	I-NP	CD	O	7	NMOD
4	adult	adult	I-NP	JJ	O	7	NMOD
5	male	male	I-NP	JJ	O	7	NMOD
6	CSS	CSS	I-NP	NN	O	7	NMOD
7	mice	mouse	I-NP	NNS	O	14	NMOD
8	,	,	O	,	O	14	P
9	58	58	B-NP	CD	B-protein	10	NMOD
10	B6	B6	I-NP	NN	I-protein	14	NMOD
11	,	,	O	,	O	14	P
12	and	and	O	CC	O	14	NMOD
13	39	39	B-NP	CD	O	14	NMOD
14	A/J	A/J	I-NP	NN	O	15	SUB
15	were	be	B-VP	VBD	O	0	ROOT
16	tested	test	I-VP	VBN	O	15	VC
17	for	for	B-PP	IN	O	16	VMOD
18	susceptibility	susceptibility	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	pilocarpine	pilocarpine	B-NP	NN	O	22	NMOD
21	induced	induced	I-NP	JJ	O	22	NMOD
22	seizures	seizure	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	15	P

1	Investigation	Investigation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	mitochondrial	mitochondrial	B-NP	JJ	O	4	NMOD
4	involvement	involvement	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	experimental	experimental	I-NP	JJ	O	8	NMOD
8	model	model	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	epilepsy	epilepsy	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	pilocarpine	pilocarpine	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	investigated	investigate	B-VP	VBD	O	0	ROOT
7	whether	whether	B-SBAR	IN	O	6	VMOD
8	increased	increase	B-NP	VBN	O	9	NMOD
9	generation	generation	I-NP	NN	O	15	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	FR	FR	B-NP	NN	O	10	PMOD
12	during	during	B-PP	IN	O	9	NMOD
13	status	status	B-NP	NN	O	14	NMOD
14	epilepticus	epilepticus	I-NP	NN	O	12	PMOD
15	would	would	B-VP	MD	O	7	SBAR
16	be	be	I-VP	VB	O	15	VC
17	sufficient	sufficient	B-ADJP	JJ	O	16	PRD
18	to	to	B-VP	TO	O	19	VMOD
19	provoke	provoke	I-VP	VB	O	15	VMOD
20	abnormalities	abnormality	B-NP	NNS	O	19	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	mtDNA	mtDNA	B-NP	NN	O	21	PMOD
23	and	and	B-PP	CC	O	21	PMOD
24	in	in	B-PP	IN	O	21	PMOD
25	the	the	B-NP	DT	O	28	NMOD
26	expression	expression	B-NP	NN	O	28	NMOD
27	and	and	O	CC	O	28	NMOD
28	activity	activity	B-NP	NN	O	24	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	cytochrome	cytochrome	B-NP	NN	B-protein	32	NMOD
31	c	c	I-NP	NN	I-protein	32	NMOD
32	oxidase	oxidase	I-NP	NN	I-protein	37	NMOD
33	(	(	O	(	O	35	DEP
34	CCO	CCO	B-NP	NN	B-protein	35	DEP
35	)	)	O	)	O	32	NMOD
36	,	,	O	,	O	37	P
37	complex	complex	B-NP	NN	O	29	PMOD
38	IV	IV	I-NP	CD	O	37	NMOD
39	of	of	B-PP	IN	O	37	NMOD
40	the	the	B-NP	DT	O	42	NMOD
41	respiratory	respiratory	I-NP	JJ	O	42	NMOD
42	chain	chain	I-NP	NN	O	39	PMOD
43	,	,	O	,	O	15	P
44	in	in	B-PP	IN	O	15	VMOD
45	the	the	B-NP	DT	O	47	NMOD
46	chronic	chronic	I-NP	JJ	O	47	NMOD
47	phase	phase	I-NP	NN	O	44	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	the	the	B-NP	DT	O	51	NMOD
50	pilocarpine	pilocarpine	I-NP	NN	O	51	NMOD
51	model	model	I-NP	NN	O	48	PMOD
52	of	of	B-PP	IN	O	51	NMOD
53	temporal	temporal	B-NP	JJ	O	55	NMOD
54	lobe	lobe	I-NP	NN	O	55	NMOD
55	epilepsy	epilepsy	I-NP	NN	O	52	PMOD
56	.	.	O	.	O	6	P

1	Other	Other	B-NP	JJ	O	2	NMOD
2	causes	cause	I-NP	NNS	O	3	SUB
3	include	include	B-VP	VBP	O	0	ROOT
4	drug-related	drug-related	B-ADJP	JJ	O	10	NMOD
5	(	(	O	(	O	10	NMOD
6	cyclosporine	cyclosporine	B-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	tacrolimus	tacrolimus	B-NP	NN	O	10	NMOD
9	)	)	O	)	O	10	NMOD
10	toxicity	toxicity	B-NP	NN	O	17	NMOD
11	,	,	O	,	O	17	P
12	procoagulant	procoagulant	B-NP	JJ	O	13	NMOD
13	status	status	I-NP	NN	O	17	NMOD
14	,	,	O	,	O	17	P
15	and	and	O	CC	O	17	NMOD
16	antibody-mediated	antibody-mediated	B-NP	JJ	O	17	NMOD
17	rejection	rejection	I-NP	NN	O	3	OBJ
18	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	found	find	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	most-frequent	most-frequent	I-NP	JJ	O	6	NMOD
6	cause	cause	I-NP	NN	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	thrombotic	thrombotic	B-NP	JJ	O	9	NMOD
9	microangiopathy	microangiopathy	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	3	SBAR
11	drug	drug	B-NP	NN	O	10	PRD
12	related	relate	B-ADJP	VBN	O	11	NMOD
13	,	,	O	,	O	11	P
14	secondary	secondary	B-ADJP	JJ	O	11	NMOD
15	mainly	mainly	I-ADJP	RB	O	16	PMOD
16	to	to	B-PP	TO	O	14	AMOD
17	cyclosporine	cyclosporine	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	2	P

1	Severe	Severe	B-NP	JJ	O	5	NMOD
2	reversible	reversible	I-NP	JJ	O	4	AMOD
3	left	left	I-NP	JJ	O	4	AMOD
4	ventricular	ventricular	I-NP	JJ	O	5	NMOD
5	systolic	systolic	I-NP	JJ	O	7	AMOD
6	and	and	I-NP	CC	O	7	AMOD
7	diastolic	diastolic	I-NP	JJ	O	8	NMOD
8	dysfunction	dysfunction	I-NP	NN	O	0	ROOT
9	due	due	B-PP	JJ	O	10	PMOD
10	to	to	B-PP	TO	O	8	NMOD
11	accidental	accidental	B-NP	JJ	O	14	NMOD
12	iatrogenic	iatrogenic	I-NP	JJ	O	14	NMOD
13	epinephrine	epinephrine	I-NP	NN	O	14	NMOD
14	overdose	overdose	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	8	P

1	Catecholamine	Catecholamine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cardiomyopathy	cardiomyopathy	B-NP	NN	O	11	SUB
4	due	due	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	chronic	chronic	B-NP	JJ	O	7	NMOD
7	excess	excess	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	endogenous	endogenous	B-NP	JJ	O	10	NMOD
10	catecholamines	catecholamine	I-NP	NNS	O	8	PMOD
11	has	have	B-VP	VBZ	O	2	VMOD
12	been	be	I-VP	VBN	O	11	VC
13	recognized	recognize	I-VP	VBN	O	12	VC
14	for	for	B-PP	IN	O	13	VMOD
15	decades	decade	B-NP	NNS	O	14	PMOD
16	as	as	B-PP	IN	O	13	VMOD
17	a	a	B-NP	DT	O	19	NMOD
18	clinical	clinical	I-NP	JJ	O	19	NMOD
19	phenomenon	phenomenon	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	2	P

1	Urinary	Urinary	B-NP	JJ	O	3	NMOD
2	bladder	bladder	I-NP	NN	O	3	NMOD
3	cancer	cancer	I-NP	NN	O	11	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	Wegener	Wegener	B-NP	NNP	O	6	NMOD
6	's	's	B-NP	POS	O	7	NMOD
7	granulomatosis	granulomatosis	I-NP	NN	O	4	PMOD
8	:	:	O	:	O	3	P
9	risks	risk	B-NP	NNS	O	11	NMOD
10	and	and	O	CC	O	11	NMOD
11	relation	relation	B-NP	NN	O	0	ROOT
12	to	to	B-PP	TO	O	11	NMOD
13	cyclophosphamide	cyclophosphamide	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	11	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	and	and	I-VP	CC	O	4	VMOD
6	characterise	characterise	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	risk	risk	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	bladder	bladder	B-NP	NN	O	11	NMOD
11	cancer	cancer	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	4	VMOD
13	and	and	O	CC	O	15	NMOD
14	its	its	B-NP	PRP$	O	15	NMOD
15	relation	relation	I-NP	NN	O	12	OBJ
16	to	to	B-PP	TO	O	15	NMOD
17	cyclophosphamide	cyclophosphamide	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	15	P
19	in	in	B-PP	IN	O	15	NMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	Wegener	Wegener	B-NP	NNP	O	24	NMOD
23	's	's	B-NP	POS	O	24	NMOD
24	granulomatosis	granulomatosis	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	1	P

1	Nested	Nest	B-VP	VBN	O	10	VMOD
2	within	within	B-PP	IN	O	1	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	cohort	cohort	I-NP	NN	O	2	PMOD
5	,	,	O	,	O	10	P
6	a	a	B-NP	DT	O	9	NMOD
7	matched	matched	I-NP	JJ	O	9	NMOD
8	case-control	case-control	I-NP	JJ	O	9	NMOD
9	study	study	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	performed	perform	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	estimate	estimate	I-VP	VB	O	11	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	association	association	I-NP	NN	O	13	OBJ
16	between	between	B-PP	IN	O	15	NMOD
17	cyclophosphamide	cyclophosphamide	B-NP	NN	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	bladder	bladder	I-NP	NN	O	20	NMOD
20	cancer	cancer	I-NP	NN	O	16	PMOD
21	using	use	B-VP	VBG	O	13	VMOD
22	odds	odd	B-NP	NNS	O	23	NMOD
23	ratios	ratio	I-NP	NNS	O	21	OBJ
24	(	(	O	(	O	26	DEP
25	ORs	OR	B-NP	NNS	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	as	as	B-PP	IN	O	21	VMOD
28	relative	relative	B-NP	JJ	O	29	NMOD
29	risk	risk	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	bladder	bladder	B-NP	NN	O	5	NMOD
5	cancer	cancer	I-NP	NN	O	3	PMOD
6	doubled	double	B-VP	VBD	O	0	ROOT
7	for	for	B-PP	IN	O	6	VMOD
8	every	every	B-NP	DT	O	11	NMOD
9	10	10	I-NP	CD	O	10	AMOD
10	g	g	I-NP	NN	O	11	NMOD
11	increment	increment	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	6	VMOD
13	cyclophosphamide	cyclophosphamide	B-NP	NN	O	28	SUB
14	(	(	O	(	O	25	DEP
15	OR	OR	B-NP	NN	O	22	NMOD
16	=	=	B-VP	SYM	O	15	NMOD
17	2.0	2.0	B-NP	CD	O	16	AMOD
18	,	,	O	,	O	22	P
19	95	95	B-NP	CD	O	22	NMOD
20	%	%	I-NP	NN	O	22	NMOD
21	confidence	confidence	I-NP	NN	O	22	NMOD
22	interval	interval	I-NP	NN	O	25	DEP
23	(	(	O	(	O	25	DEP
24	CI	CI	B-NP	NN	O	25	DEP
25	)	)	O	)	O	13	NMOD
26	0.8	0.8	B-NP	CD	O	28	AMOD
27	to	to	B-PP	TO	O	28	AMOD
28	4.9	4.9	B-NP	CD	O	12	PMOD
29	)	)	O	)	O	28	NMOD
30	.	.	O	.	O	6	P

1	L-arginine	L-arginine	B-NP	NN	O	2	NMOD
2	transport	transport	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	humans	human	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	cortisol	cortisol	B-NP	NN	O	8	NMOD
7	induced	induced	I-NP	JJ	O	8	NMOD
8	hypertension	hypertension	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	5	NMOD
2	deficient	deficient	I-NP	JJ	O	5	NMOD
3	L-arginine-nitric	L-arginine-nitric	I-NP	JJ	O	5	NMOD
4	oxide	oxide	I-NP	NN	O	5	NMOD
5	system	system	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	implicated	implicate	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	cortisol	cortisol	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	hypertension	hypertension	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	6	P

1	MR	MR	B-NP	NN	B-protein	2	NMOD
2	imaging	imaging	I-NP	NN	O	9	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	quantitative	quantitative	B-NP	JJ	O	6	NMOD
5	diffusion	diffusion	I-NP	NN	O	6	NMOD
6	mapping	mapping	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	tacrolimus	tacrolimus	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	neurotoxicity	neurotoxicity	B-NP	NN	O	9	OBJ
11	in	in	B-PP	IN	O	9	VMOD
12	organ	organ	B-NP	NN	O	14	NMOD
13	transplant	transplant	I-NP	NN	O	14	NMOD
14	patients	patient	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	9	P

1	Brain	Brain	B-NP	NN	O	3	NMOD
2	MR	MR	I-NP	NN	O	3	NMOD
3	studies	study	I-NP	NNS	O	9	SUB
4	,	,	O	,	O	3	P
5	including	include	B-PP	VBG	O	3	NMOD
6	DW	DW	B-NP	NN	O	7	NMOD
7	imaging	imaging	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	3	P
9	were	be	B-VP	VBD	O	0	ROOT
10	prospectively	prospectively	I-VP	RB	O	9	VMOD
11	performed	perform	I-VP	VBN	O	9	VC
12	in	in	B-PP	IN	O	11	VMOD
13	14	14	B-NP	CD	O	16	NMOD
14	organ	organ	I-NP	NN	O	16	NMOD
15	transplant	transplant	I-NP	NN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	12	PMOD
17	receiving	receive	B-VP	VBG	O	16	NMOD
18	tacrolimus	tacrolimus	B-NP	NN	O	17	OBJ
19	who	who	B-NP	WP	O	18	NMOD
20	developed	develop	B-VP	VBD	O	19	SBAR
21	neurologic	neurologic	B-NP	JJ	O	22	NMOD
22	complications	complication	I-NP	NNS	O	20	OBJ
23	.	.	O	.	O	9	P

1	Octreotide	Octreotide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hypoxemia	hypoxemia	B-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	pulmonary	pulmonary	B-NP	JJ	O	6	NMOD
6	hypertension	hypertension	I-NP	NN	O	2	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	premature	premature	B-NP	JJ	O	9	NMOD
9	neonates	neonate	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	observed	observe	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	2	VMOD
4	exencephaly	exencephaly	I-NP	RB	O	5	VMOD
5	induced	induce	I-VP	VBN	O	3	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	5-azacytidine	5-azacytidine	B-NP	NN	O	6	PMOD
8	at	at	B-PP	IN	O	5	VMOD
9	embryonic	embryonic	B-NP	JJ	B-DNA	10	NMOD
10	day	day	I-NP	NN	I-DNA	8	PMOD
11	13.5	13.5	I-NP	CD	I-DNA	10	NMOD
12	(	(	O	(	O	14	DEP
13	E13.5	E13.5	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	10	NMOD
15	,	,	O	,	O	2	P
16	let	let	B-VP	VBD	O	2	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	embryos	embryo	I-NP	NNS	O	16	OBJ
19	develop	develop	B-VP	VBP	O	2	VMOD
20	exo	exo	B-NP	NN	O	21	NMOD
21	utero	utero	I-NP	NN	O	19	OBJ
22	until	until	B-PP	IN	O	21	NMOD
23	E18.5	E18.5	B-NP	NN	B-protein	22	PMOD
24	,	,	O	,	O	2	P
25	and	and	O	CC	O	2	VMOD
26	re-observed	re-observe	B-VP	VBD	O	2	VMOD
27	the	the	B-NP	DT	O	29	NMOD
28	same	same	I-NP	JJ	O	29	NMOD
29	embryos	embryo	I-NP	NNS	O	26	OBJ
30	at	at	B-PP	IN	O	2	VMOD
31	E18.5	E18.5	B-NP	NN	B-protein	30	PMOD
32	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	4	NMOD
2	cocaine	cocaine	I-NP	NN	O	4	NMOD
3	induced	induced	I-NP	JJ	O	4	NMOD
4	seizures	seizure	I-NP	NNS	O	7	NMOD
5	:	:	O	:	O	4	P
6	differential	differential	B-NP	JJ	O	7	NMOD
7	sensitivity	sensitivity	I-NP	NN	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	six	six	B-NP	CD	O	12	NMOD
10	inbred	inbred	I-NP	JJ	O	12	NMOD
11	mouse	mouse	I-NP	NN	O	12	NMOD
12	strains	strain	I-NP	NNS	O	8	PMOD
13	.	.	O	.	O	7	P

1	Mature	Mature	B-NP	JJ	O	5	NMOD
2	male	male	I-NP	JJ	O	4	AMOD
3	and	and	I-NP	CC	O	4	AMOD
4	female	female	I-NP	JJ	O	5	NMOD
5	mice	mouse	I-NP	NNS	O	10	SUB
6	from	from	B-PP	IN	O	5	NMOD
7	six	six	B-NP	CD	O	9	NMOD
8	inbred	inbred	I-NP	JJ	O	9	NMOD
9	stains	stain	I-NP	NNS	O	6	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	tested	test	I-VP	VBN	O	10	VC
12	for	for	B-PP	IN	O	11	VMOD
13	susceptibility	susceptibility	B-NP	NN	O	12	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	behavioral	behavioral	B-NP	JJ	O	16	NMOD
16	seizures	seizure	I-NP	NNS	O	14	PMOD
17	induced	induce	B-VP	VBN	O	16	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	a	a	B-NP	DT	O	21	NMOD
20	single	single	I-NP	JJ	O	21	NMOD
21	injection	injection	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	cocaine	cocaine	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	10	P

1	Microangiopathic	Microangiopathic	B-NP	JJ	O	3	NMOD
2	hemolytic	hemolytic	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	0	ROOT
4	complicating	complicate	B-VP	VBG	O	3	NMOD
5	FK506	FK506	B-NP	NN	O	9	NMOD
6	(	(	O	(	O	8	DEP
7	tacrolimus	tacrolimus	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	therapy	therapy	B-NP	NN	O	4	OBJ
10	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	3	3	B-NP	CD	O	4	NMOD
4	episodes	episode	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	microangiopathic	microangiopathic	B-NP	JJ	O	8	NMOD
7	hemolytic	hemolytic	I-NP	JJ	O	8	NMOD
8	anemia	anemia	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	11	DEP
10	MAHA	MAHA	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	in	in	B-PP	IN	O	2	VMOD
13	2	2	B-NP	CD	O	16	NMOD
14	solid	solid	I-NP	JJ	O	16	NMOD
15	organ	organ	I-NP	NN	O	16	NMOD
16	recipients	recipient	I-NP	NNS	O	12	PMOD
17	under	under	B-PP	IN	O	2	VMOD
18	FK506	FK506	B-NP	NN	O	22	NMOD
19	(	(	O	(	O	21	DEP
20	tacrolimus	tacrolimus	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	therapy	therapy	B-NP	NN	O	17	PMOD
23	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	25	VMOD
2	both	both	B-NP	DT	O	3	NMOD
3	cases	case	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	25	P
5	discontinuation	discontinuation	B-NP	NN	O	9	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	FK506	FK506	B-NP	NN	O	6	PMOD
8	and	and	O	CC	O	9	NMOD
9	treatment	treatment	B-NP	NN	O	25	SUB
10	with	with	B-PP	IN	O	9	NMOD
11	plasma	plasma	B-NP	NN	O	12	NMOD
12	exchange	exchange	I-NP	NN	O	24	NMOD
13	,	,	O	,	O	24	P
14	fresh	fresh	B-NP	JJ	O	17	NMOD
15	frozen	freeze	I-NP	VBN	O	17	NMOD
16	plasma	plasma	I-NP	NN	O	17	NMOD
17	replacement	replacement	I-NP	NN	O	24	NMOD
18	,	,	O	,	O	24	P
19	corticosteroids	corticosteroid	B-NP	NNS	O	24	NMOD
20	,	,	O	,	O	24	P
21	aspirin	aspirin	B-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	dipyridamole	dipyridamole	B-NP	NN	O	10	PMOD
25	led	lead	B-VP	VBD	O	0	ROOT
26	to	to	B-PP	TO	O	25	VMOD
27	resolution	resolution	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	MAHA	MAHA	B-NP	NN	B-protein	28	PMOD
30	.	.	O	.	O	25	P

1	In	In	B-PP	IN	O	8	VMOD
2	one	one	B-NP	CD	O	3	NMOD
3	patient	patient	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	8	P
5	reintroduction	reintroduction	B-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	FK506	FK506	B-NP	NN	O	6	PMOD
8	led	lead	B-VP	VBD	O	0	ROOT
9	to	to	B-PP	TO	O	8	VMOD
10	rapid	rapid	B-NP	JJ	O	11	NMOD
11	recurrence	recurrence	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	MAHA	MAHA	B-NP	NN	B-protein	12	PMOD
14	.	.	O	.	O	8	P

1	FK506-associated	FK506-associated	B-NP	JJ	O	2	NMOD
2	MAHA	MAHA	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	probably	probably	B-ADVP	RB	O	3	VMOD
5	rare	rare	B-ADJP	JJ	O	3	PRD
6	but	but	O	CC	O	8	VMOD
7	physicians	physician	B-NP	NNS	O	8	SUB
8	must	must	B-VP	MD	O	3	VMOD
9	be	be	I-VP	VB	O	8	VC
10	aware	aware	B-ADJP	JJ	O	9	PRD
11	of	of	B-PP	IN	O	10	AMOD
12	this	this	B-NP	DT	O	14	NMOD
13	severe	severe	I-NP	JJ	O	14	NMOD
14	complication	complication	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	3	P

1	Variant	Variant	B-NP	JJ	O	3	NMOD
2	ventricular	ventricular	I-NP	JJ	O	3	NMOD
3	tachycardia	tachycardia	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	desipramine	desipramine	B-NP	NN	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	4	PMOD
7	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	variant	variant	B-NP	JJ	O	8	NMOD
7	ventricular	ventricular	I-NP	JJ	O	8	NMOD
8	tachycardia	tachycardia	I-NP	NN	O	5	PMOD
9	induced	induce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	desipramine	desipramine	B-NP	NN	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	2	P

1	Desipramine	Desipramine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	delirium	delirium	B-NP	NN	O	2	OBJ
4	at	at	B-PP	IN	O	2	VMOD
5	"	"	B-NP	"	O	8	NMOD
6	subtherapeutic	subtherapeutic	I-NP	JJ	O	8	NMOD
7	"	"	I-NP	"	O	8	NMOD
8	concentrations	concentration	I-NP	NNS	O	4	PMOD
9	:	:	O	:	O	2	P
10	a	a	B-NP	DT	O	12	NMOD
11	case	case	I-NP	NN	O	12	NMOD
12	report	report	I-NP	NN	O	2	VMOD
13	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	3	NMOD
2	elderly	elderly	I-NP	JJ	O	3	NMOD
3	patient	patient	I-NP	NN	O	9	SUB
4	treated	treat	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	low	low	B-NP	JJ	O	8	NMOD
7	dose	dose	I-NP	NN	O	8	NMOD
8	Desipramine	Desipramine	I-NP	NN	O	5	PMOD
9	developed	develop	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	11	NMOD
11	delirium	delirium	I-NP	NN	O	9	OBJ
12	while	while	B-SBAR	IN	O	9	VMOD
13	her	her	B-NP	PRP$	O	15	NMOD
14	plasma	plasma	I-NP	NN	O	15	NMOD
15	level	level	I-NP	NN	O	16	SUB
16	was	be	B-VP	VBD	O	12	SBAR
17	in	in	B-PP	IN	O	16	PRD
18	the	the	B-NP	DT	O	22	NMOD
19	"	"	I-NP	"	O	22	NMOD
20	subtherapeutic	subtherapeutic	I-NP	JJ	O	22	NMOD
21	"	"	I-NP	"	O	22	NMOD
22	range	range	I-NP	NN	O	17	PMOD
23	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	initial	initial	I-NP	JJ	O	3	NMOD
3	dose	dose	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	amantadine	amantadine	B-NP	NN	O	4	PMOD
6	depressed	depress	B-VP	VBD	O	0	ROOT
7	locomotor	locomotor	B-NP	NN	O	8	NMOD
8	activity	activity	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	6	VMOD
10	all	all	B-NP	DT	O	12	NMOD
11	mouse	mouse	I-NP	NN	O	12	NMOD
12	strains	strain	I-NP	NNS	O	9	PMOD
13	studied	study	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	BALB/C	BALB/C	I-NP	NN	O	17	NMOD
17	mice	mouse	I-NP	NNS	O	18	SUB
18	being	be	B-VP	VBG	O	14	PMOD
19	the	the	B-NP	DT	O	21	NMOD
20	most	most	I-NP	RBS	O	21	AMOD
21	sensitive	sensitive	I-NP	JJ	O	18	PRD
22	.	.	O	.	O	6	P

1	Readministration	Readministration	B-NP	NN	O	12	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	amantadine	amantadine	B-NP	NN	O	2	PMOD
4	,	,	O	,	O	1	P
5	after	after	B-PP	IN	O	1	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	drug-free	drug-free	I-NP	JJ	O	9	NMOD
8	overnight	overnight	I-NP	JJ	O	9	NMOD
9	period	period	I-NP	NN	O	5	PMOD
10	,	,	O	,	O	12	P
11	increased	increase	B-VP	VBD	O	12	NMOD
12	motility	motility	B-NP	NN	O	0	ROOT
13	from	from	B-PP	IN	O	12	NMOD
14	respective	respective	B-NP	JJ	O	16	NMOD
15	saline	saline	I-NP	NN	O	16	NMOD
16	control	control	I-NP	NN	O	13	PMOD
17	in	in	B-PP	IN	O	12	NMOD
18	all	all	B-NP	DT	O	19	NMOD
19	strains	strain	I-NP	NNS	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	exception	exception	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	BALB/C	BALB/C	I-NP	NN	O	25	NMOD
25	mice	mouse	I-NP	NNS	O	22	PMOD
26	where	where	B-ADVP	WRB	O	25	NMOD
27	suppression	suppression	B-NP	NN	O	30	SUB
28	of	of	B-PP	IN	O	27	NMOD
29	motility	motility	B-NP	NN	O	28	PMOD
30	occurred	occur	B-VP	VBD	O	26	SBAR
31	.	.	O	.	O	12	P

1	No	No	B-NP	DT	O	7	NMOD
2	hepatic	hepatic	I-NP	JJ	B-protein	4	NMOD
3	preneoplastic	preneoplastic	I-NP	JJ	I-protein	4	NMOD
4	nodules	nodule	I-NP	NNS	I-protein	7	NMOD
5	or	or	O	CC	O	7	NMOD
6	hepatocellular	hepatocellular	B-NP	JJ	O	7	NMOD
7	carcinomas	carcinoma	I-NP	NNS	O	0	ROOT
8	developed	develop	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	fed	feed	B-VP	VBN	O	10	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	plain	plain	I-NP	JJ	O	15	NMOD
14	choline-supplemented	choline-supplemented	I-NP	JJ	O	15	NMOD
15	diet	diet	I-NP	NN	O	11	VMOD
16	,	,	O	,	O	7	P
17	while	while	B-SBAR	IN	O	7	VMOD
18	one	one	B-NP	CD	O	20	NMOD
19	preneoplastic	preneoplastic	I-NP	JJ	O	20	NMOD
20	nodule	nodule	I-NP	NN	O	24	NMOD
21	and	and	O	CC	O	24	NMOD
22	one	one	B-NP	CD	O	24	NMOD
23	hepatocellular	hepatocellular	I-NP	JJ	O	24	NMOD
24	carcinoma	carcinoma	I-NP	NN	O	17	SBAR
25	developed	develop	B-VP	VBN	O	24	NMOD
26	in	in	B-PP	IN	O	25	VMOD
27	two	two	B-NP	CD	O	28	NMOD
28	rats	rat	I-NP	NNS	O	26	PMOD
29	fed	feed	B-VP	VBN	O	28	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	same	same	I-NP	JJ	O	32	NMOD
32	diet	diet	I-NP	NN	O	29	OBJ
33	containing	contain	B-VP	VBG	O	32	NMOD
34	phenobarbital	phenobarbital	B-NP	NN	O	33	OBJ
35	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	preneoplastic	preneoplastic	B-NP	JJ	O	5	NMOD
5	nodules	nodule	I-NP	NNS	O	3	PMOD
6	and	and	B-PP	CC	O	3	PMOD
7	of	of	B-PP	IN	O	3	PMOD
8	hepatocellular	hepatocellular	B-NP	JJ	O	9	NMOD
9	carcinomas	carcinoma	I-NP	NNS	O	7	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	10	10	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	37	37	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	32	NMOD
16	,	,	O	,	O	15	P
17	respectively	respectively	B-ADVP	RB	O	15	NMOD
18	,	,	O	,	O	15	P
19	in	in	B-PP	IN	O	15	NMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	fed	feed	B-VP	VBN	O	20	NMOD
22	the	the	B-NP	DT	O	25	NMOD
23	plain	plain	I-NP	JJ	O	25	NMOD
24	choline-devoid	choline-devoid	I-NP	JJ	O	25	NMOD
25	diet	diet	I-NP	NN	O	21	VMOD
26	,	,	O	,	O	32	P
27	and	and	O	CC	O	32	NMOD
28	17	17	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	32	NMOD
30	and	and	O	CC	O	32	NMOD
31	30	30	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	10	PRD
33	,	,	O	,	O	10	P
34	in	in	B-PP	IN	O	10	VMOD
35	rats	rat	B-NP	NNS	O	34	PMOD
36	fed	feed	B-VP	VBN	O	35	NMOD
37	the	the	B-NP	DT	O	40	NMOD
38	phenobarbital-containing	phenobarbital-containing	I-NP	JJ	O	40	NMOD
39	choline-devoid	choline-devoid	I-NP	JJ	O	40	NMOD
40	diet	diet	I-NP	NN	O	36	OBJ
41	.	.	O	.	O	10	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	direct	direct	B-NP	JJ	O	5	NMOD
4	intracoronary	intracoronary	I-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	methylergonovine	methylergonovine	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	and	and	O	CC	O	10	PMOD
12	without	without	B-PP	IN	O	10	PMOD
13	variant	variant	B-NP	JJ	O	14	NMOD
14	angina	angina	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	intracoronary	intracoronary	B-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	methylergonovine	methylergonovine	B-NP	NN	O	6	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	studied	study	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	21	21	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	variant	variant	B-NP	JJ	O	15	NMOD
15	angina	angina	I-NP	NN	O	13	PMOD
16	and	and	O	CC	O	18	NMOD
17	22	22	B-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	12	NMOD
19	with	with	B-PP	IN	O	18	NMOD
20	atypical	atypical	B-NP	JJ	O	22	NMOD
21	chest	chest	I-NP	NN	O	22	NMOD
22	pain	pain	I-NP	NN	O	19	PMOD
23	and	and	B-PP	CC	O	19	PMOD
24	in	in	B-PP	IN	O	19	PMOD
25	others	other	B-NP	NNS	O	24	PMOD
26	without	without	B-PP	IN	O	25	NMOD
27	angina	angina	B-NP	NN	O	28	NMOD
28	pectoris	pectoris	I-NP	NN	O	26	PMOD
29	(	(	O	(	O	32	DEP
30	control	control	B-NP	NN	O	31	NMOD
31	group	group	I-NP	NN	O	32	DEP
32	)	)	O	)	O	28	NMOD
33	.	.	O	.	O	8	P

1	Dobutamine	Dobutamine	B-NP	NN	O	3	NMOD
2	stress	stress	I-NP	NN	O	3	NMOD
3	echocardiography	echocardiography	I-NP	NN	O	7	NMOD
4	:	:	O	:	O	3	P
5	a	a	B-NP	DT	O	7	NMOD
6	sensitive	sensitive	I-NP	JJ	O	7	NMOD
7	indicator	indicator	I-NP	NN	O	0	ROOT
8	of	of	B-PP	IN	O	7	NMOD
9	diminished	diminish	B-NP	VBN	O	11	NMOD
10	myocardial	myocardial	I-NP	JJ	O	11	NMOD
11	function	function	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	asymptomatic	asymptomatic	B-NP	JJ	O	16	NMOD
14	doxorubicin-treated	doxorubicin-treated	I-NP	JJ	O	16	NMOD
15	long-term	long-term	I-NP	JJ	O	16	NMOD
16	survivors	survivor	I-NP	NNS	O	12	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	childhood	childhood	B-NP	NN	O	19	NMOD
19	cancer	cancer	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	7	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	7	NMOD
4	effective	effective	I-NP	JJ	O	5	AMOD
5	anticancer	anticancer	I-NP	JJ	O	6	AMOD
6	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	7	NMOD
7	agent	agent	I-NP	NN	O	2	PRD
8	known	know	B-VP	VBN	O	7	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	cause	cause	I-VP	VB	O	8	VMOD
11	acute	acute	B-NP	JJ	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	chronic	chronic	I-NP	JJ	O	14	NMOD
14	cardiomyopathy	cardiomyopathy	I-NP	NN	O	10	OBJ
15	.	.	O	.	O	2	P

1	To	To	B-VP	TO	O	2	VMOD
2	develop	develop	I-VP	VB	O	19	VMOD
3	a	a	B-NP	DT	O	8	NMOD
4	more	more	I-NP	RBR	O	5	AMOD
5	sensitive	sensitive	I-NP	JJ	O	8	NMOD
6	echocardiographic	echocardiographic	I-NP	JJ	O	8	NMOD
7	screening	screening	I-NP	NN	O	8	NMOD
8	test	test	I-NP	NN	O	2	OBJ
9	for	for	B-PP	IN	O	8	NMOD
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	damage	damage	I-NP	NN	O	9	PMOD
12	due	due	B-ADJP	JJ	O	2	VMOD
13	to	to	B-PP	TO	O	12	AMOD
14	doxorubicin	doxorubicin	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	19	P
16	a	a	B-NP	DT	O	18	NMOD
17	cohort	cohort	I-NP	JJ	O	18	NMOD
18	study	study	I-NP	NN	O	19	SUB
19	was	be	B-VP	VBD	O	0	ROOT
20	performed	perform	I-VP	VBN	O	19	VC
21	using	use	B-VP	VBG	O	20	VMOD
22	dobutamine	dobutamine	B-NP	NN	O	23	NMOD
23	infusion	infusion	I-NP	NN	O	21	OBJ
24	to	to	B-VP	TO	O	25	VMOD
25	differentiate	differentiate	I-VP	VB	O	23	NMOD
26	asymptomatic	asymptomatic	B-NP	JJ	O	28	NMOD
27	long-term	long-term	I-NP	JJ	O	28	NMOD
28	survivors	survivor	I-NP	NNS	O	25	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	childhood	childhood	B-NP	NN	O	31	NMOD
31	cancer	cancer	I-NP	NN	O	29	PMOD
32	treated	treat	B-VP	VBN	O	31	NMOD
33	with	with	B-PP	IN	O	32	VMOD
34	doxorubicin	doxorubicin	B-NP	NN	O	33	PMOD
35	from	from	B-PP	IN	O	32	VMOD
36	healthy	healthy	B-NP	JJ	O	38	NMOD
37	control	control	I-NP	NN	O	38	NMOD
38	subjects	subject	I-NP	NNS	O	35	PMOD
39	.	.	O	.	O	19	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	aminophylline	aminophylline	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	threshold	threshold	I-NP	NN	O	4	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	initiating	initiate	B-VP	VBG	O	7	PMOD
9	ventricular	ventricular	B-NP	JJ	O	10	NMOD
10	fibrillation	fibrillation	I-NP	NN	O	8	OBJ
11	during	during	B-PP	IN	O	8	VMOD
12	respiratory	respiratory	B-NP	JJ	O	13	NMOD
13	failure	failure	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	18	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	aminophylline	aminophylline	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	9	NMOD
7	ventricular	ventricular	I-NP	JJ	O	9	NMOD
8	fibrillation	fibrillation	I-NP	NN	O	9	NMOD
9	threshold	threshold	I-NP	NN	O	5	PMOD
10	during	during	B-PP	IN	O	2	NMOD
11	normal	normal	B-NP	JJ	O	13	NMOD
12	acid-base	acid-base	I-NP	NN	O	13	NMOD
13	conditions	condition	I-NP	NNS	O	10	PMOD
14	and	and	B-PP	CC	O	10	PMOD
15	during	during	B-PP	IN	O	10	PMOD
16	respiratory	respiratory	B-NP	JJ	O	17	NMOD
17	failure	failure	I-NP	NN	O	15	PMOD
18	were	be	B-VP	VBD	O	0	ROOT
19	studied	study	I-VP	VBN	O	18	VC
20	in	in	B-PP	IN	O	19	VMOD
21	anesthetized	anesthetize	B-NP	VBN	O	24	NMOD
22	open	open	I-NP	JJ	O	24	NMOD
23	chest	chest	I-NP	NN	O	24	NMOD
24	dogs	dog	I-NP	NNS	O	20	PMOD
25	.	.	O	.	O	18	P

1	During	During	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	infusion	infusion	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	aminophylline	aminophylline	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	11	P
7	the	the	B-NP	DT	O	10	NMOD
8	ventricular	ventricular	I-NP	JJ	O	10	NMOD
9	fibrillation	fibrillation	I-NP	NN	O	10	NMOD
10	threshold	threshold	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	reduced	reduce	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	30	30	B-NP	CD	O	16	AMOD
15	to	to	I-NP	TO	O	16	AMOD
16	40	40	I-NP	CD	O	17	NMOD
17	percent	percent	I-NP	NN	O	13	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	control	control	I-NP	NN	O	18	PMOD
21	when	when	B-ADVP	WRB	O	12	VMOD
22	pH	pH	B-NP	NN	O	25	NMOD
23	and	and	I-NP	CC	O	25	NMOD
24	partial	partial	I-NP	JJ	O	25	NMOD
25	pressures	pressure	I-NP	NNS	O	37	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	oxygen	oxygen	B-NP	NN	O	33	NMOD
28	(	(	O	(	O	30	DEP
29	PO2	PO2	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	and	and	O	CC	O	33	NMOD
32	carbon	carbon	B-NP	NN	O	33	NMOD
33	dioxide	dioxide	I-NP	NN	O	26	PMOD
34	(	(	O	(	O	36	DEP
35	CO2	CO2	B-NP	NN	B-protein	36	DEP
36	)	)	O	)	O	33	NMOD
37	were	be	B-VP	VBD	O	21	SBAR
38	kept	keep	I-VP	VBN	O	37	VC
39	within	within	B-PP	IN	O	38	VMOD
40	normal	normal	B-NP	JJ	O	41	NMOD
41	limits	limit	I-NP	NNS	O	39	PMOD
42	.	.	O	.	O	11	P

1	When	When	B-ADVP	WRB	O	0	ROOT
2	respiratory	respiratory	B-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	SBAR
5	produced	produce	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	hypoventilation	hypoventilation	B-NP	NN	O	29	NMOD
8	(	(	O	(	O	27	DEP
9	pH	pH	B-NP	NN	O	21	NMOD
10	7.05	7.05	I-NP	CD	O	12	AMOD
11	to	to	B-PP	TO	O	12	AMOD
12	7.25	7.25	B-NP	CD	O	9	NMOD
13	;	;	O	:	O	21	P
14	PC02	PC02	B-NP	NN	O	19	NMOD
15	70	70	B-NP	CD	O	17	AMOD
16	to	to	I-NP	TO	O	17	AMOD
17	100	100	I-NP	CD	O	19	NMOD
18	mm	mm	I-NP	NN	O	19	NMOD
19	Hg	Hg	I-NP	NN	O	21	NMOD
20	:	:	O	:	O	21	P
21	P02	P02	B-NP	NN	O	26	NMOD
22	20	20	B-NP	CD	O	24	AMOD
23	to	to	I-NP	TO	O	24	AMOD
24	40	40	I-NP	CD	O	26	NMOD
25	mm	mm	I-NP	NN	O	26	NMOD
26	Hg	Hg	I-NP	NN	O	27	DEP
27	)	)	O	)	O	7	NMOD
28	,	,	O	,	O	29	P
29	infusion	infusion	B-NP	NN	O	6	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	aminophylline	aminophylline	B-NP	NN	O	30	PMOD
32	resulted	result	B-VP	VBD	O	1	DEP
33	in	in	B-PP	IN	O	32	VMOD
34	an	an	B-NP	DT	O	37	NMOD
35	even	even	I-NP	RB	O	36	AMOD
36	greater	great	I-NP	JJR	O	37	NMOD
37	decrease	decrease	I-NP	NN	O	33	PMOD
38	in	in	B-PP	IN	O	37	NMOD
39	ventricular	ventricular	B-NP	JJ	O	41	NMOD
40	fibrillation	fibrillation	I-NP	NN	O	41	NMOD
41	threshold	threshold	I-NP	NN	O	38	PMOD
42	to	to	B-PP	TO	O	38	PMOD
43	60	60	B-NP	CD	O	44	NMOD
44	percent	percent	I-NP	NN	O	38	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	the	the	B-NP	DT	O	48	NMOD
47	control	control	I-NP	NN	O	48	NMOD
48	level	level	I-NP	NN	O	45	PMOD
49	.	.	O	.	O	1	P

1	Crossover	Crossover	B-NP	NN	O	2	NMOD
2	comparison	comparison	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	efficacy	efficacy	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	preference	preference	I-NP	NN	O	3	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	rizatriptan	rizatriptan	B-NP	NN	O	10	NMOD
9	10	10	I-NP	CD	O	10	NMOD
10	mg	mg	I-NP	NN	O	12	NMOD
11	versus	versus	I-NP	CC	O	12	NMOD
12	ergotamine/caffeine	ergotamine/caffeine	I-NP	NN	O	7	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	migraine	migraine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	2	P

1	Rizatriptan	Rizatriptan	B-NP	NNP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	selective	selective	I-NP	JJ	O	5	NMOD
5	5-HT	5-HT	I-NP	NN	O	10	NMOD
6	(	(	O	(	O	8	DEP
7	1B/1D	1B/1D	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	receptor	receptor	B-NP	NN	O	10	NMOD
10	agonist	agonist	I-NP	NN	O	17	NMOD
11	with	with	B-PP	IN	O	10	NMOD
12	rapid	rapid	B-NP	JJ	O	14	NMOD
13	oral	oral	I-NP	JJ	O	14	NMOD
14	absorption	absorption	I-NP	NN	O	11	PMOD
15	and	and	O	CC	O	17	NMOD
16	early	early	B-NP	JJ	O	17	NMOD
17	onset	onset	I-NP	NN	O	2	PRD
18	of	of	B-PP	IN	O	17	NMOD
19	action	action	B-NP	NN	O	18	PMOD
20	in	in	B-PP	IN	O	2	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	acute	acute	I-NP	JJ	O	23	NMOD
23	treatment	treatment	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	migraine	migraine	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	7	NMOD
2	randomized	randomize	I-NP	VBN	O	7	NMOD
3	double-	double-	I-NP	JJ	O	7	NMOD
4	blind	blind	I-NP	JJ	O	7	NMOD
5	crossover	crossover	I-NP	NN	O	7	NMOD
6	outpatient	outpatient	I-NP	NN	O	7	NMOD
7	study	study	I-NP	NN	O	8	SUB
8	assessed	assess	B-VP	VBD	O	0	ROOT
9	the	the	B-NP	DT	O	10	NMOD
10	preference	preference	I-NP	NN	O	8	OBJ
11	for	for	B-PP	IN	O	10	NMOD
12	1	1	B-NP	CD	O	15	AMOD
13	rizatriptan	rizatriptan	I-NP	NN	O	15	AMOD
14	10	10	B-NP	CD	O	15	AMOD
15	mg	mg	I-NP	NN	O	16	NMOD
16	tablet	tablet	I-NP	NN	O	11	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	2	2	B-NP	CD	O	24	NMOD
19	ergotamine	ergotamine	I-NP	NN	O	24	NMOD
20	1	1	B-NP	CD	O	24	NMOD
21	mg/caffeine	mg/caffeine	I-NP	NN	O	24	NMOD
22	100	100	B-NP	CD	O	24	NMOD
23	mg	mg	I-NP	NN	O	24	NMOD
24	tablets	tablet	I-NP	NNS	O	17	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	439	439	B-NP	CD	O	27	NMOD
27	patients	patient	I-NP	NNS	O	25	PMOD
28	treating	treat	B-VP	VBG	O	27	NMOD
29	a	a	B-NP	DT	O	32	NMOD
30	single	single	I-NP	JJ	O	32	NMOD
31	migraine	migraine	I-NP	NN	O	32	NMOD
32	attack	attack	I-NP	NN	O	28	OBJ
33	with	with	B-PP	IN	O	28	VMOD
34	each	each	B-NP	DT	O	35	NMOD
35	therapy	therapy	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	8	P

1	Faster	Faster	B-NP	NN	O	2	NMOD
2	relief	relief	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	headache	headache	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	9	NMOD
7	most	most	I-NP	RBS	O	8	AMOD
8	important	important	I-NP	JJ	O	9	NMOD
9	reason	reason	I-NP	NN	O	5	PRD
10	for	for	B-PP	IN	O	9	NMOD
11	preference	preference	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	9	P
13	cited	cite	B-VP	VBN	O	9	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	67.3	67.3	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	preferring	prefer	B-VP	VBG	O	18	NMOD
20	rizatriptan	rizatriptan	B-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	54.2	54.2	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	19	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	patients	patient	B-NP	NNS	O	24	PMOD
26	who	who	B-NP	WP	O	25	NMOD
27	preferred	prefer	B-VP	VBD	O	26	SBAR
28	ergotamine/caffeine	ergotamine/caffeine	B-NP	NN	O	27	OBJ
29	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	co-primary	co-primary	I-NP	JJ	O	3	NMOD
3	endpoint	endpoint	I-NP	NN	O	11	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	being	be	B-VP	VBG	O	4	PMOD
6	pain	pain	B-NP	NN	O	5	OBJ
7	free	free	B-ADJP	JJ	O	6	NMOD
8	at	at	B-PP	IN	O	7	AMOD
9	2	2	B-NP	CD	O	10	NMOD
10	h	h	I-NP	NN	O	8	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	also	also	B-ADVP	RB	O	11	VMOD
13	in	in	B-PP	IN	O	11	VMOD
14	favor	favor	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	rizatriptan	rizatriptan	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	11	P

1	Forty-nine	Forty-nine	B-NP	CD	O	2	NMOD
2	percent	percent	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	pain	pain	B-NP	NN	O	9	NMOD
7	free	free	I-NP	JJ	O	9	NMOD
8	2	2	I-NP	CD	O	9	NMOD
9	h	h	I-NP	NN	O	5	PRD
10	after	after	B-PP	IN	O	5	VMOD
11	rizatriptan	rizatriptan	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	5	P
13	compared	compare	B-PP	VBN	O	5	VMOD
14	with	with	B-PP	IN	O	13	PMOD
15	24.3	24.3	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	28	NMOD
17	treated	treat	B-VP	VBN	O	16	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	ergotamine/caffeine	ergotamine/caffeine	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	26	DEP
21	p	p	B-NP	NN	O	26	DEP
22	<	<	B-VP	SYM	O	21	NMOD
23	or	or	O	CC	O	22	AMOD
24	=	=	B-VP	SYM	O	23	NMOD
25	0.001	0.001	B-NP	CD	O	24	PRD
26	)	)	O	)	O	16	NMOD
27	,	,	O	,	O	28	P
28	rizatriptan	rizatriptan	B-NP	NN	O	29	SUB
29	being	be	B-VP	VBG	O	14	PMOD
30	superior	superior	B-ADJP	JJ	O	29	PRD
31	within	within	B-PP	IN	O	30	AMOD
32	1	1	B-NP	CD	O	33	NMOD
33	h	h	I-NP	NN	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	treatment	treatment	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	5	P

1	Headache	Headache	B-NP	NN	O	2	NMOD
2	relief	relief	I-NP	NN	O	6	SUB
3	at	at	B-PP	IN	O	2	NMOD
4	2	2	B-NP	CD	O	5	NMOD
5	h	h	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	75.9	75.9	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	6	PRD
9	for	for	B-PP	IN	O	8	NMOD
10	rizatriptan	rizatriptan	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	47.3	47.3	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	9	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	ergotamine/caffeine	ergotamine/caffeine	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	22	DEP
17	p	p	B-NP	NN	O	21	SUB
18	<	<	B-VP	SYM	O	21	VMOD
19	or	or	O	CC	O	21	VMOD
20	=	=	B-VP	SYM	O	21	VMOD
21	0.001	0.001	B-NP	CD	O	22	DEP
22	)	)	O	)	O	6	VMOD
23	,	,	O	,	O	6	P
24	with	with	B-PP	IN	O	6	VMOD
25	rizatriptan	rizatriptan	B-NP	NN	O	26	SUB
26	being	be	B-VP	VBG	O	24	PMOD
27	superior	superior	B-ADJP	JJ	O	26	PRD
28	to	to	B-VP	TO	O	29	VMOD
29	ergotamine/caffeine	ergotamine/caffeine	I-VP	VB	O	27	AMOD
30	within	within	B-PP	IN	O	29	VMOD
31	30	30	B-NP	CD	O	32	NMOD
32	min	min	I-NP	NN	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	dosing	dosing	B-NP	NN	O	33	PMOD
35	.	.	O	.	O	6	P

1	Almost	Almost	B-NP	RB	O	3	NMOD
2	36	36	I-NP	CD	O	1	AMOD
3	%	%	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	taking	take	B-VP	VBG	O	5	NMOD
7	rizatriptan	rizatriptan	B-NP	NN	O	6	OBJ
8	were	be	B-VP	VBD	O	0	ROOT
9	pain	pain	B-NP	NN	O	8	PRD
10	free	free	B-ADJP	JJ	O	9	NMOD
11	at	at	B-PP	IN	O	10	AMOD
12	2	2	B-NP	CD	O	13	NMOD
13	h	h	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	8	VMOD
15	had	have	B-VP	VBD	O	8	VMOD
16	no	no	B-NP	DT	O	19	NMOD
17	recurrence	recurrence	I-NP	NN	O	19	NMOD
18	or	or	I-NP	CC	O	19	NMOD
19	need	need	I-NP	NN	O	15	OBJ
20	for	for	B-PP	IN	O	19	NMOD
21	additional	additional	B-NP	JJ	O	22	NMOD
22	medication	medication	I-NP	NN	O	20	PMOD
23	within	within	B-PP	IN	O	22	NMOD
24	24	24	B-NP	CD	O	25	NMOD
25	h	h	I-NP	NN	O	23	PMOD
26	,	,	O	,	O	15	P
27	compared	compare	B-PP	VBN	O	15	VMOD
28	to	to	B-PP	TO	O	27	PMOD
29	20	20	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	patients	patient	B-NP	NNS	O	31	PMOD
33	on	on	B-PP	IN	O	32	NMOD
34	ergotamine/caffeine	ergotamine/caffeine	B-NP	NN	O	33	PMOD
35	(	(	O	(	O	41	DEP
36	p	p	B-NP	NN	O	40	SUB
37	<	<	B-VP	SYM	O	40	VMOD
38	or	or	O	CC	O	40	VMOD
39	=	=	B-VP	SYM	O	40	VMOD
40	0.001	0.001	B-NP	CD	O	41	DEP
41	)	)	O	)	O	8	VMOD
42	.	.	O	.	O	8	P

1	Rizatriptan	Rizatriptan	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	also	also	B-ADVP	RB	O	2	VMOD
4	superior	superior	B-ADJP	JJ	O	2	PRD
5	to	to	B-PP	TO	O	4	AMOD
6	ergotamine/caffeine	ergotamine/caffeine	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	proportions	proportion	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	no	no	B-NP	DT	O	20	NMOD
14	nausea	nausea	I-NP	NN	O	20	NMOD
15	,	,	I-NP	,	O	20	P
16	vomiting	vomiting	I-NP	NN	O	20	NMOD
17	,	,	I-NP	,	O	20	P
18	phonophobia	phonophobia	I-NP	NN	O	20	NMOD
19	or	or	I-NP	CC	O	20	NMOD
20	photophobia	photophobia	I-NP	NN	O	12	PMOD
21	and	and	B-PP	CC	O	7	PMOD
22	for	for	B-PP	IN	O	7	PMOD
23	patients	patient	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	normal	normal	B-NP	JJ	O	26	NMOD
26	function	function	I-NP	NN	O	28	NMOD
27	2	2	I-NP	CD	O	28	NMOD
28	h	h	I-NP	NN	O	24	PMOD
29	after	after	B-PP	IN	O	23	NMOD
30	drug	drug	B-NP	NN	O	31	NMOD
31	intake	intake	I-NP	NN	O	29	PMOD
32	(	(	O	(	O	38	DEP
33	p	p	B-NP	NN	O	37	SUB
34	<	<	B-VP	SYM	O	37	VMOD
35	or	or	O	CC	O	37	VMOD
36	=	=	B-VP	SYM	O	37	VMOD
37	0.001	0.001	B-NP	CD	O	38	DEP
38	)	)	O	)	O	23	NMOD
39	.	.	O	.	O	2	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	carcinoma	carcinoma	B-NP	NN	O	3	PMOD
5	developed	develop	B-VP	VBD	O	0	ROOT
6	thrombotic	thrombotic	B-NP	JJ	O	7	NMOD
7	microangiopathy	microangiopathy	I-NP	NN	O	5	OBJ
8	(	(	O	(	O	7	NMOD
9	characterized	characterize	B-VP	VBN	O	8	DEP
10	by	by	B-PP	IN	O	9	VMOD
11	renal	renal	B-NP	JJ	O	12	NMOD
12	insufficiency	insufficiency	I-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	microangiopathic	microangiopathic	B-NP	JJ	O	16	NMOD
15	hemolytic	hemolytic	I-NP	JJ	O	16	NMOD
16	anemia	anemia	I-NP	NN	O	20	NMOD
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	NMOD
19	usually	usually	B-ADVP	RB	O	20	NMOD
20	thrombocytopenia	thrombocytopenia	B-NP	NN	O	10	PMOD
21	)	)	O	)	O	20	NMOD
22	after	after	B-PP	IN	O	9	VMOD
23	treatment	treatment	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	cisplatin	cisplatin	B-NP	NN	O	32	NMOD
26	,	,	O	,	O	32	P
27	bleomycin	bleomycin	B-NP	NN	O	32	NMOD
28	,	,	O	,	O	32	P
29	and	and	O	CC	O	32	NMOD
30	a	a	B-NP	DT	O	32	NMOD
31	vinca	vinca	I-NP	NN	O	32	NMOD
32	alkaloid	alkaloid	I-NP	NN	O	24	PMOD
33	.	.	O	.	O	5	P

1	Salvage	Salvage	B-NP	NN	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	nelarabine	nelarabine	B-NP	NN	O	9	NMOD
5	,	,	O	,	O	9	P
6	etoposide	etoposide	B-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	and	and	O	CC	O	9	NMOD
9	cyclophosphamide	cyclophosphamide	B-NP	NN	O	3	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	relapsed/refractory	relapsed/refractory	B-NP	NN	O	15	NMOD
12	paediatric	paediatric	I-NP	JJ	O	15	NMOD
13	T-cell	T-cell	I-NP	NN	O	15	NMOD
14	lymphoblastic	lymphoblastic	I-NP	JJ	O	15	NMOD
15	leukaemia	leukaemia	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	lymphoma	lymphoma	I-NP	NN	O	10	PMOD
18	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	combination	combination	I-NP	NN	O	28	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	5	5	B-NP	CD	O	5	NMOD
5	d	d	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	nelarabine	nelarabine	B-NP	NN	O	6	PMOD
8	(	(	O	(	O	10	DEP
9	AraG	AraG	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	with	with	B-PP	IN	O	2	NMOD
12	5	5	B-NP	CD	O	13	NMOD
13	d	d	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	etoposide	etoposide	B-NP	NN	O	20	NMOD
16	(	(	O	(	O	18	DEP
17	VP	VP	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	and	and	O	CC	O	20	NMOD
20	cyclophosphamide	cyclophosphamide	B-NP	NN	O	27	NMOD
21	(	(	O	(	O	23	DEP
22	CPM	CPM	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	and	and	O	CC	O	27	NMOD
25	prophylactic	prophylactic	B-NP	JJ	O	27	NMOD
26	intrathecal	intrathecal	I-NP	JJ	O	27	NMOD
27	chemotherapy	chemotherapy	I-NP	NN	O	14	PMOD
28	was	be	B-VP	VBD	O	0	ROOT
29	used	use	I-VP	VBN	O	28	VC
30	as	as	B-PP	IN	O	29	VMOD
31	salvage	salvage	B-NP	NN	O	32	NMOD
32	therapy	therapy	I-NP	NN	O	30	PMOD
33	in	in	B-PP	IN	O	29	VMOD
34	seven	seven	B-NP	CD	O	35	NMOD
35	children	child	I-NP	NNS	O	33	PMOD
36	with	with	B-PP	IN	O	35	NMOD
37	refractory	refractory	B-NP	JJ	O	39	AMOD
38	or	or	I-NP	CC	O	39	AMOD
39	relapsed	relapse	I-NP	VBN	O	43	NMOD
40	T-cell	T-cell	I-NP	NN	O	41	NMOD
41	leukaemia	leukaemia	I-NP	NN	O	43	NMOD
42	or	or	I-NP	CC	O	43	NMOD
43	lymphoma	lymphoma	I-NP	NN	O	36	PMOD
44	.	.	O	.	O	28	P

1	The	The	B-NP	DT	O	5	NMOD
2	most	most	I-NP	RBS	O	3	AMOD
3	common	common	I-NP	JJ	O	5	NMOD
4	side	side	I-NP	NN	O	5	NMOD
5	effects	effect	I-NP	NNS	O	10	SUB
6	attributable	attributable	B-ADJP	JJ	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	the	the	B-NP	DT	O	9	NMOD
9	AraG	AraG	I-NP	NN	B-protein	7	PMOD
10	included	include	B-VP	VBD	O	0	ROOT
11	Grade	Grade	B-NP	NN	O	18	NMOD
12	2	2	I-NP	CD	O	11	NMOD
13	and	and	I-NP	CC	O	11	NMOD
14	3	3	I-NP	CD	O	11	NMOD
15	sensory	sensory	I-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	motor	motor	I-NP	NN	O	18	NMOD
18	neuropathy	neuropathy	I-NP	NN	O	21	NMOD
19	and	and	O	CC	O	21	NMOD
20	musculoskeletal	musculoskeletal	B-NP	JJ	O	21	NMOD
21	pain	pain	I-NP	NN	O	10	OBJ
22	.	.	O	.	O	10	P

1	Haematological	Haematological	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	greater	great	B-ADJP	JJR	O	3	PRD
5	for	for	B-PP	IN	O	4	AMOD
6	the	the	B-NP	DT	O	7	NMOD
7	combination	combination	I-NP	NN	O	5	PMOD
8	than	than	B-PP	IN	O	4	AMOD
9	AraG	AraG	B-NP	NN	B-protein	8	PMOD
10	alone	alone	B-ADVP	RB	O	9	NMOD
11	,	,	O	,	O	3	P
12	although	although	B-SBAR	IN	O	3	VMOD
13	median	median	B-NP	JJ	O	14	NMOD
14	time	time	I-NP	NN	O	20	SUB
15	to	to	B-PP	TO	O	14	NMOD
16	neutrophil	neutrophil	B-NP	NN	B-cell_type	19	NMOD
17	and	and	I-NP	CC	O	19	NMOD
18	platelet	platelet	I-NP	NN	O	19	NMOD
19	recovery	recovery	I-NP	NN	O	15	PMOD
20	was	be	B-VP	VBD	O	12	SBAR
21	consistent	consistent	B-ADJP	JJ	O	20	PRD
22	with	with	B-PP	IN	O	21	AMOD
23	other	other	B-NP	JJ	O	25	NMOD
24	salvage	salvage	I-NP	NN	O	25	NMOD
25	therapies	therapy	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	34-year-old	34-year-old	I-NP	JJ	O	3	NMOD
3	lady	lady	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	constellation	constellation	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	dermatitis	dermatitis	B-NP	NN	O	14	NMOD
9	,	,	I-NP	,	O	14	P
10	fever	fever	I-NP	NN	O	14	NMOD
11	,	,	I-NP	,	O	14	P
12	lymphadenopathy	lymphadenopathy	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	hepatitis	hepatitis	I-NP	NN	O	7	PMOD
15	,	,	O	,	O	4	P
16	beginning	begin	B-VP	VBG	O	4	VMOD
17	on	on	B-PP	IN	O	16	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	17th	17th	I-NP	JJ	O	20	NMOD
20	day	day	I-NP	NN	O	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	a	a	B-NP	DT	O	23	NMOD
23	course	course	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	oral	oral	B-NP	JJ	O	26	NMOD
26	sulphasalazine	sulphasalazine	I-NP	NN	O	24	PMOD
27	for	for	B-PP	IN	O	26	NMOD
28	sero-negative	sero-negative	B-NP	JJ	O	30	NMOD
29	rheumatoid	rheumatoid	I-NP	JJ	O	30	NMOD
30	arthritis	arthritis	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	4	P

1	Bupropion	Bupropion	B-NP	NN	O	5	NMOD
2	(	(	O	(	O	4	DEP
3	Zyban	Zyban	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	toxicity	toxicity	B-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	Recurrent	Recurrent	B-NP	JJ	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	treated	treat	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	diazepam	diazepam	B-NP	NN	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	broad	broad	B-NP	JJ	O	10	NMOD
9	complex	complex	I-NP	JJ	O	10	NMOD
10	tachycardia	tachycardia	I-NP	NN	O	5	PMOD
11	was	be	B-VP	VBD	O	3	VMOD
12	successfully	successfully	I-VP	RB	O	11	VMOD
13	treated	treat	I-VP	VBN	O	11	VC
14	with	with	B-PP	IN	O	13	VMOD
15	adenosine	adenosine	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	3	P

1	Bradykinin	Bradykinin	B-NP	NN	O	3	NMOD
2	receptors	receptor	I-NP	NNS	O	3	NMOD
3	antagonists	antagonist	I-NP	NNS	O	8	NMOD
4	and	and	O	CC	O	8	NMOD
5	nitric	nitric	B-NP	JJ	B-protein	8	NMOD
6	oxide	oxide	I-NP	NN	I-protein	8	NMOD
7	synthase	synthase	I-NP	NN	I-protein	8	NMOD
8	inhibitors	inhibitor	I-NP	NNS	O	13	SUB
9	in	in	B-PP	IN	O	8	NMOD
10	vincristine	vincristine	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	streptozotocin	streptozotocin	I-NP	NN	O	9	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	hyperalgesia	hyperalgesia	B-NP	NN	O	13	OBJ
15	in	in	B-PP	IN	O	13	VMOD
16	chemotherapy	chemotherapy	B-NP	NN	O	21	NMOD
17	and	and	O	CC	O	21	NMOD
18	diabetic	diabetic	B-NP	JJ	O	21	NMOD
19	neuropathy	neuropathy	I-NP	JJ	O	21	NMOD
20	rat	rat	I-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	15	PMOD
22	.	.	O	.	O	13	P

1	PURPOSE	PURPOSE	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	influence	influence	I-NP	NN	O	40	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	an	an	B-NP	DT	O	8	NMOD
7	irreversible	irreversible	I-NP	JJ	O	8	NMOD
8	inhibitor	inhibitor	I-NP	NN	O	24	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	constitutive	constitutive	B-NP	JJ	O	9	PMOD
11	NO	NO	I-NP	NN	B-protein	12	NMOD
12	synthase	synthase	I-NP	NN	I-protein	10	NMOD
13	(	(	O	(	O	19	DEP
14	L-NOArg	L-NOArg	B-NP	NN	O	18	NMOD
15	;	;	O	:	O	18	P
16	1.0	1.0	B-NP	CD	O	18	NMOD
17	mg/kg	mg/kg	I-NP	NN	O	18	NMOD
18	ip	ip	I-NP	NN	O	19	DEP
19	)	)	O	)	O	10	NMOD
20	,	,	O	,	O	24	P
21	a	a	B-NP	DT	O	24	NMOD
22	relatively	relatively	I-NP	RB	O	23	AMOD
23	selective	selective	I-NP	JJ	O	24	NMOD
24	inhibitor	inhibitor	I-NP	NN	O	5	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	inducible	inducible	B-NP	JJ	O	25	PMOD
27	NO	NO	I-NP	NN	B-protein	28	NMOD
28	synthase	synthase	I-NP	NN	I-protein	26	NMOD
29	(	(	O	(	O	35	DEP
30	L-NIL	L-NIL	B-NP	NN	O	35	DEP
31	;	;	O	:	O	35	P
32	1.0	1.0	B-NP	CD	O	34	NMOD
33	mg/kg	mg/kg	I-NP	NN	O	34	NMOD
34	ip	ip	I-NP	NN	O	35	DEP
35	)	)	O	)	O	26	NMOD
36	and	and	O	CC	O	40	NMOD
37	a	a	B-NP	DT	O	40	NMOD
38	relatively	relatively	I-NP	RB	O	39	AMOD
39	specific	specific	I-NP	JJ	O	40	NMOD
40	inhibitor	inhibitor	I-NP	NN	O	65	NMOD
41	of	of	B-PP	IN	O	40	NMOD
42	neuronal	neuronal	B-NP	JJ	B-protein	44	NMOD
43	NO	NO	I-NP	NN	I-protein	44	NMOD
44	synthase	synthase	I-NP	NN	I-protein	41	PMOD
45	(	(	O	(	O	51	DEP
46	7-NI	7-NI	B-NP	NN	O	50	NMOD
47	;	;	O	:	O	50	P
48	0.1	0.1	B-NP	CD	O	50	NMOD
49	mg/kg	mg/kg	I-NP	NN	O	50	NMOD
50	ip	ip	I-NP	NN	O	51	DEP
51	)	)	O	)	O	40	NMOD
52	,	,	O	,	O	40	P
53	on	on	B-PP	IN	O	40	NMOD
54	antihyperalgesic	antihyperalgesic	B-NP	JJ	O	55	NMOD
55	action	action	I-NP	NN	O	53	PMOD
56	of	of	B-PP	IN	O	55	NMOD
57	selective	selective	B-NP	JJ	O	58	NMOD
58	antagonists	antagonist	I-NP	NNS	O	56	PMOD
59	of	of	B-PP	IN	O	58	NMOD
60	B2	B2	B-NP	NN	B-protein	63	NMOD
61	and	and	I-NP	CC	O	63	NMOD
62	B1	B1	I-NP	NN	B-protein	63	NMOD
63	receptors	receptor	I-NP	NNS	I-protein	59	PMOD
64	:	:	O	:	O	40	P
65	D-Arg-	D-Arg-	B-NP	NN	O	75	NMOD
66	[	[	O	(	O	74	DEP
67	Hyp3	Hyp3	B-NP	NN	B-protein	73	NMOD
68	,	,	O	,	O	73	P
69	Thi5	Thi5	B-NP	NN	B-protein	73	NMOD
70	,	,	O	,	O	73	P
71	D-Tic7	D-Tic7	B-NP	NN	O	73	NMOD
72	,	,	O	,	O	73	P
73	Oic8	Oic8	B-NP	NN	B-protein	74	DEP
74	]	]	O	)	O	65	NMOD
75	bradykinin	bradykinin	B-NP	NN	O	111	SUB
76	(	(	O	(	O	83	DEP
77	HOE	HOE	B-NP	NN	O	82	NMOD
78	140	140	I-NP	CD	O	77	NMOD
79	;	;	O	:	O	82	P
80	70	70	B-NP	CD	O	82	NMOD
81	nmol/kg	nmol/kg	I-NP	NN	O	82	NMOD
82	ip	ip	I-NP	NN	O	83	DEP
83	)	)	O	)	O	75	NMOD
84	or	or	O	CC	O	85	VMOD
85	des	de	B-VP	VBZ	O	111	VMOD
86	Arg10	Arg10	B-NP	NNP	O	87	NMOD
87	HOE	HOE	I-NP	NNP	O	85	OBJ
88	140	140	I-NP	CD	O	87	NMOD
89	(	(	O	(	O	93	DEP
90	70	70	B-NP	CD	O	92	NMOD
91	nmol/kg	nmol/kg	I-NP	NN	O	92	NMOD
92	ip	ip	I-NP	NN	O	93	DEP
93	)	)	O	)	O	87	NMOD
94	respectively	respectively	B-ADVP	RB	O	85	VMOD
95	,	,	O	,	O	85	P
96	in	in	B-PP	IN	O	85	VMOD
97	model	model	B-NP	NN	O	96	PMOD
98	of	of	B-PP	IN	O	97	NMOD
99	diabetic	diabetic	B-NP	JJ	O	110	NMOD
100	(	(	O	(	O	103	DEP
101	streptozotocin	streptozotocin	B-NP	NN	O	103	DEP
102	induced	induce	B-VP	VBN	O	101	NMOD
103	)	)	O	)	O	99	NMOD
104	and	and	O	CC	O	110	NMOD
105	toxic	toxic	B-NP	JJ	O	110	NMOD
106	(	(	O	(	O	109	DEP
107	vincristine	vincristine	B-NP	NN	O	109	DEP
108	induced	induce	B-VP	VBN	O	107	AMOD
109	)	)	O	)	O	105	NMOD
110	neuropathy	neuropathy	B-NP	NN	O	98	PMOD
111	was	be	B-VP	VBD	O	0	ROOT
112	investigated	investigate	I-VP	VBN	O	111	VC
113	.	.	O	.	O	111	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	paper	paper	I-NP	NN	O	5	PMOD
8	confirm	confirm	B-VP	VBP	O	1	NMOD
9	that	that	B-SBAR	IN	O	8	VMOD
10	inhibition	inhibition	B-NP	NN	O	23	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	bradykinin	bradykinin	B-NP	NN	B-protein	13	NMOD
13	receptors	receptor	I-NP	NNS	I-protein	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	inducible	inducible	B-NP	JJ	O	17	NMOD
16	NO	NO	I-NP	NN	B-protein	17	NMOD
17	synthase	synthase	I-NP	NN	I-protein	11	PMOD
18	but	but	B-CONJP	CC	O	23	NMOD
19	not	not	I-CONJP	RB	O	18	DEP
20	neuronal	neuronal	B-NP	JJ	B-protein	23	NMOD
21	NO	NO	I-NP	NN	I-protein	23	NMOD
22	synthase	synthase	I-NP	NN	I-protein	23	NMOD
23	activity	activity	I-NP	NN	O	24	SUB
24	reduces	reduce	B-VP	VBZ	O	9	SBAR
25	diabetic	diabetic	B-NP	JJ	O	26	NMOD
26	hyperalgesia	hyperalgesia	I-NP	NN	O	24	OBJ
27	.	.	O	.	O	1	P

1	It	It	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	also	also	I-VP	RB	O	2	VMOD
4	shown	show	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	both	both	B-NP	DT	O	7	NMOD
7	products	product	I-NP	NNS	O	20	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	inducible	inducible	B-NP	JJ	O	11	NMOD
10	NO	NO	I-NP	NN	B-protein	11	NMOD
11	synthase	synthase	I-NP	NN	I-protein	16	NMOD
12	and	and	O	CC	O	16	NMOD
13	neuronal	neuronal	B-NP	JJ	B-protein	16	NMOD
14	NO	NO	I-NP	NN	I-protein	16	NMOD
15	synthase	synthase	I-NP	NN	I-protein	16	NMOD
16	activation	activation	I-NP	NN	O	8	PMOD
17	as	as	B-CONJP	RB	O	20	NMOD
18	well	well	I-CONJP	RB	O	17	DEP
19	as	as	I-CONJP	IN	O	17	DEP
20	bradykinin	bradykinin	B-NP	NN	O	21	SUB
21	are	be	B-VP	VBP	O	5	SBAR
22	involved	involve	I-VP	VBN	O	21	VC
23	in	in	B-PP	IN	O	22	VMOD
24	hyperalgesia	hyperalgesia	B-NP	NN	O	23	PMOD
25	produced	produce	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	vincristine	vincristine	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	2	P

1	Moreover	Moreover	B-ADVP	RB	O	9	VMOD
2	,	,	O	,	O	9	P
3	L-NOArg	L-NOArg	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	7-NI	7-NI	I-NP	NN	O	8	NMOD
6	but	but	B-NP	CC	O	8	NMOD
7	not	not	I-NP	RB	O	6	DEP
8	L-NIL	L-NIL	B-NP	NN	B-protein	9	SUB
9	intensify	intensify	B-VP	VBP	O	0	ROOT
10	antihyperalgesic	antihyperalgesic	B-NP	JJ	O	11	NMOD
11	activity	activity	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	HOE	HOE	B-NP	NN	O	16	NMOD
14	140	140	I-NP	CD	O	13	NMOD
15	or	or	O	CC	O	16	NMOD
16	des-Arg10HOE	des-Arg10HOE	B-NP	NN	O	12	PMOD
17	140	140	I-NP	CD	O	16	NMOD
18	in	in	B-PP	IN	O	9	VMOD
19	toxic	toxic	B-NP	JJ	O	20	NMOD
20	neuropathy	neuropathy	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	9	VMOD
2	streptozotocin	streptozotocin	B-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	1	SBAR
4	hyperalgesia	hyperalgesia	B-NP	NN	O	6	AMOD
5	,	,	O	,	O	6	P
6	inducible	inducible	B-NP	JJ	O	8	NMOD
7	NO	NO	I-NP	NN	B-protein	8	NMOD
8	synthase	synthase	I-NP	NN	I-protein	3	OBJ
9	participates	participate	B-VP	VBZ	O	0	ROOT
10	in	in	B-PP	IN	O	9	VMOD
11	pronociceptive	pronociceptive	B-NP	JJ	O	12	NMOD
12	activity	activity	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	bradykinin	bradykinin	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	9	P
16	whereas	whereas	O	IN	O	9	VMOD
17	in	in	B-PP	IN	O	22	VMOD
18	vincristine	vincristine	B-NP	NN	O	17	PMOD
19	induced	induce	B-VP	VBD	O	18	NMOD
20	hyperalgesia	hyperalgesia	B-NP	NN	B-protein	21	NMOD
21	bradykinin	bradykinin	I-NP	NN	I-protein	19	OBJ
22	seemed	seem	B-VP	VBD	O	16	SBAR
23	to	to	I-VP	TO	O	24	VMOD
24	activate	activate	I-VP	VB	O	22	VMOD
25	neuronal	neuronal	B-NP	JJ	B-protein	28	NMOD
26	NO	NO	I-NP	NN	I-protein	28	NMOD
27	synthase	synthase	I-NP	NN	I-protein	28	NMOD
28	pathway	pathway	I-NP	NN	O	24	OBJ
29	.	.	O	.	O	9	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	0	ROOT
3	observed	observe	B-VP	VBN	O	2	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	association	association	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	high-dose	high-dose	B-NP	JJ	O	9	NMOD
8	cyclophosphamide-based	cyclophosphamide-based	I-NP	JJ	O	9	NMOD
9	chemotherapy	chemotherapy	I-NP	NN	O	6	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	metastatic	metastatic	B-NP	JJ	O	13	NMOD
12	breast	breast	I-NP	NN	O	13	NMOD
13	cancer	cancer	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	2	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	DESIGN	DESIGN	I-NP	NN	O	5	SUB
3	:	:	O	:	O	2	P
4	We	We	B-NP	PRP	O	5	SUB
5	combined	combine	B-VP	VBD	O	0	ROOT
6	paclitaxel	paclitaxel	B-NP	NN	O	16	NMOD
7	,	,	O	,	O	16	P
8	melphalan	melphalan	B-NP	NN	O	16	NMOD
9	and	and	O	CC	O	16	NMOD
10	high-dose	high-dose	B-NP	JJ	O	11	NMOD
11	cyclophosphamide	cyclophosphamide	I-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	thiotepa	thiotepa	B-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	and	and	O	CC	O	16	NMOD
16	carboplatin	carboplatin	B-NP	NN	B-protein	5	OBJ
17	in	in	B-PP	IN	O	5	VMOD
18	a	a	B-NP	DT	O	22	NMOD
19	triple	triple	I-NP	JJ	O	22	NMOD
20	sequential	sequential	I-NP	JJ	O	22	NMOD
21	high-dose	high-dose	I-NP	JJ	O	22	NMOD
22	regimen	regimen	I-NP	NN	O	17	PMOD
23	for	for	B-PP	IN	O	22	NMOD
24	patients	patient	B-NP	NNS	O	23	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	metastatic	metastatic	B-NP	JJ	O	28	NMOD
27	breast	breast	I-NP	NN	O	28	NMOD
28	cancer	cancer	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	5	P

1	Analysis	Analysis	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	performed	perform	I-VP	VBN	O	2	VC
4	on	on	B-PP	IN	O	25	VMOD
5	61	61	B-NP	CD	O	6	NMOD
6	women	woman	I-NP	NNS	O	25	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	chemotherapy-responsive	chemotherapy-responsive	B-NP	JJ	O	11	NMOD
9	metastatic	metastatic	I-NP	JJ	O	11	NMOD
10	breast	breast	I-NP	NN	O	11	NMOD
11	cancer	cancer	I-NP	NN	O	7	PMOD
12	receiving	receive	B-VP	VBG	O	11	NMOD
13	96-h	96-h	B-NP	JJ	O	15	NMOD
14	infusional	infusional	I-NP	JJ	O	15	NMOD
15	cyclophosphamide	cyclophosphamide	I-NP	NN	O	12	OBJ
16	as	as	B-PP	IN	O	6	NMOD
17	part	part	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	a	a	B-NP	DT	O	23	NMOD
20	triple	triple	I-NP	JJ	O	23	NMOD
21	sequential	sequential	I-NP	JJ	O	23	NMOD
22	high-dose	high-dose	I-NP	JJ	O	23	NMOD
23	regimen	regimen	I-NP	NN	O	18	PMOD
24	to	to	B-VP	TO	O	25	VMOD
25	assess	assess	I-VP	VB	O	3	VMOD
26	association	association	B-NP	NN	O	25	OBJ
27	between	between	B-PP	IN	O	26	NMOD
28	presence	presence	B-NP	NN	O	41	NMOD
29	of	of	B-PP	IN	O	28	NMOD
30	peritransplant	peritransplant	B-NP	NN	O	33	NMOD
31	congestive	congestive	I-NP	JJ	O	33	NMOD
32	heart	heart	I-NP	NN	O	33	NMOD
33	failure	failure	I-NP	NN	O	29	PMOD
34	(	(	O	(	O	36	DEP
35	CHF	CHF	B-NP	NN	B-protein	36	DEP
36	)	)	O	)	O	33	NMOD
37	and	and	O	CC	O	41	NMOD
38	the	the	B-NP	DT	O	41	NMOD
39	following	follow	I-NP	VBG	O	41	NMOD
40	pretreatment	pretreatment	I-NP	NN	O	41	NMOD
41	characteristics	characteristic	I-NP	NNS	O	27	PMOD
42	:	:	O	:	O	2	P
43	presence	presence	B-NP	NN	O	72	NMOD
44	of	of	B-PP	IN	O	43	NMOD
45	electrocardiogram	electrocardiogram	B-NP	NN	O	49	NMOD
46	(	(	O	(	O	48	DEP
47	EKG	EKG	B-NP	NN	O	48	DEP
48	)	)	O	)	O	45	NMOD
49	abnormalities	abnormality	B-NP	NNS	O	65	NMOD
50	,	,	O	,	O	65	P
51	age	age	B-NP	NN	O	65	NMOD
52	,	,	O	,	O	65	P
53	hypertension	hypertension	B-NP	NN	O	65	NMOD
54	,	,	O	,	O	65	P
55	prior	prior	B-NP	JJ	O	57	NMOD
56	cardiac	cardiac	I-NP	JJ	O	57	NMOD
57	history	history	I-NP	NN	O	65	NMOD
58	,	,	O	,	O	65	P
59	smoking	smoking	B-NP	NN	O	65	NMOD
60	,	,	O	,	O	65	P
61	diabetes	diabetes	B-NP	NN	O	62	NMOD
62	mellitus	mellitus	I-NP	NN	O	65	NMOD
63	,	,	O	,	O	65	P
64	prior	prior	B-NP	JJ	O	65	NMOD
65	use	use	I-NP	NN	O	44	PMOD
66	of	of	B-PP	IN	O	65	NMOD
67	anthracyclines	anthracycline	B-NP	NNS	O	66	PMOD
68	,	,	O	,	O	72	P
69	and	and	O	CC	O	72	NMOD
70	left-sided	left-sided	B-NP	JJ	O	72	NMOD
71	chest	chest	I-NP	NN	O	72	NMOD
72	irradiation	irradiation	I-NP	NN	O	2	VMOD
73	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Six	Six	B-NP	CD	O	4	AMOD
4	of	of	B-PP	IN	O	1	NMOD
5	61	61	B-NP	CD	O	6	NMOD
6	women	woman	I-NP	NNS	O	4	PMOD
7	(	(	O	(	O	10	DEP
8	10	10	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	developed	develop	B-VP	VBD	O	4	SBAR
12	clinically	clinically	B-NP	RB	O	13	AMOD
13	reversible	reversible	I-NP	JJ	O	16	NMOD
14	grade	grade	I-NP	NN	O	16	NMOD
15	3	3	I-NP	CD	O	16	NMOD
16	CHF	CHF	I-NP	NN	O	11	OBJ
17	following	follow	B-PP	VBG	O	16	NMOD
18	infusional	infusional	B-NP	JJ	O	19	NMOD
19	cyclophosphamide	cyclophosphamide	I-NP	NN	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	a	a	B-NP	DT	O	24	NMOD
22	median	median	I-NP	JJ	O	24	NMOD
23	percent	percent	I-NP	NN	O	24	NMOD
24	decline	decline	I-NP	NN	O	20	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	ejection	ejection	B-NP	NN	O	27	NMOD
27	fraction	fraction	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	31	31	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	1	P

1	Incidence	Incidence	B-NP	NN	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	transient	transient	B-NP	JJ	O	6	NMOD
4	cyclophosphamide-related	cyclophosphamide-related	I-NP	JJ	O	6	NMOD
5	cardiac	cardiac	I-NP	JJ	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	2	PMOD
7	(	(	O	(	O	10	DEP
8	10	10	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	is	be	B-VP	VBZ	O	0	ROOT
12	comparable	comparable	B-ADJP	JJ	O	11	PRD
13	to	to	B-PP	TO	O	12	AMOD
14	previous	previous	B-NP	JJ	O	16	NMOD
15	recorded	record	I-NP	VBN	O	16	NMOD
16	literature	literature	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	11	P

1	Inappropriate	Inappropriate	B-NP	JJ	O	2	NMOD
2	use	use	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	carbamazepine	carbamazepine	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	vigabatrin	vigabatrin	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	typical	typical	B-NP	JJ	O	10	NMOD
9	absence	absence	I-NP	NN	O	10	NMOD
10	seizures	seizure	I-NP	NNS	O	7	PMOD
11	.	.	O	.	O	2	P

1	Carbamazepine	Carbamazepine	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	vigabatrin	vigabatrin	I-NP	NN	O	4	SUB
4	are	be	B-VP	VBP	O	0	ROOT
5	contraindicated	contraindicate	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	typical	typical	B-NP	JJ	O	9	NMOD
8	absence	absence	I-NP	NN	O	9	NMOD
9	seizures	seizure	I-NP	NNS	O	6	PMOD
10	.	.	O	.	O	4	P

1	Frequency	Frequency	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	absences	absence	B-NP	NNS	O	2	PMOD
4	increased	increase	B-VP	VBD	O	0	ROOT
5	in	in	B-PP	IN	O	4	VMOD
6	four	four	B-NP	CD	O	7	NMOD
7	children	child	I-NP	NNS	O	5	PMOD
8	treated	treat	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	carbamazepine	carbamazepine	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	12	NMOD
12	two	two	B-NP	CD	O	7	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	these	these	B-NP	DT	O	17	NMOD
15	developed	develop	I-NP	VBN	O	17	NMOD
16	myoclonic	myoclonic	I-NP	JJ	O	17	NMOD
17	jerks	jerk	I-NP	NNS	O	13	PMOD
18	,	,	O	,	O	4	P
19	which	which	B-NP	WDT	O	4	VMOD
20	resolved	resolve	B-VP	VBD	O	19	SBAR
21	on	on	B-PP	IN	O	20	VMOD
22	withdrawal	withdrawal	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	carbamazepine	carbamazepine	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	4	P

1	Hemolytic	Hemolytic	B-NP	JJ	O	2	NMOD
2	anemia	anemia	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	use	use	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	omeprazole	omeprazole	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	first	first	I-NP	JJ	O	5	NMOD
5	case	case	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	11	NMOD
8	serious	serious	I-NP	JJ	O	9	AMOD
9	short-term	short-term	I-NP	JJ	O	11	NMOD
10	adverse	adverse	I-NP	JJ	O	11	NMOD
11	reaction	reaction	I-NP	NN	O	6	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	use	use	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	omeprazole	omeprazole	B-NP	NN	O	15	PMOD
17	:	:	O	:	O	2	P
18	hemolytic	hemolytic	B-NP	JJ	O	19	NMOD
19	anemia	anemia	I-NP	NN	O	2	VMOD
20	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	developed	develop	B-VP	VBD	O	0	ROOT
4	weakness	weakness	B-NP	NN	O	3	OBJ
5	,	,	O	,	O	6	P
6	lethargy	lethargy	B-NP	NN	O	4	NMOD
7	,	,	O	,	O	6	NMOD
8	and	and	O	CC	O	7	PMOD
9	shortness	shortness	B-NP	NN	O	8	ROOT
10	of	of	B-PP	IN	O	9	NMOD
11	breath	breath	B-NP	NN	O	13	NMOD
12	2	2	B-NP	CD	O	13	NMOD
13	days	day	I-NP	NNS	O	10	PMOD
14	after	after	B-PP	IN	O	9	NMOD
15	starting	start	B-VP	VBG	O	14	PMOD
16	therapy	therapy	B-NP	NN	O	15	OBJ
17	with	with	B-PP	IN	O	16	NMOD
18	omeprazole	omeprazole	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	4	NMOD
2	use	use	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	31	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	didanosine	didanosine	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	9	DEP
8	ddI	ddI	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	in	in	B-PP	IN	O	4	NMOD
11	HIV	HIV	B-NP	NN	O	13	NMOD
12	antibody-positive	antibody-positive	I-NP	JJ	O	13	NMOD
13	individuals	individual	I-NP	NNS	O	10	PMOD
14	intolerant	intolerant	B-ADJP	JJ	O	13	NMOD
15	to	to	B-PP	TO	O	14	AMOD
16	zidovudine	zidovudine	B-NP	NN	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	AZT	AZT	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	One	One	B-NP	CD	O	24	NMOD
21	hundred	hundred	I-NP	CD	O	20	NMOD
22	and	and	O	CC	O	24	NMOD
23	fifty-one	fifty-one	B-NP	CD	O	24	NMOD
24	patients	patient	I-NP	NNS	O	15	PMOD
25	intolerant	intolerant	B-ADJP	JJ	O	24	NMOD
26	to	to	B-PP	TO	O	25	AMOD
27	zidovudine	zidovudine	B-NP	NN	O	26	PMOD
28	(	(	O	(	O	30	DEP
29	AZT	AZT	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	received	receive	B-VP	VBD	O	0	ROOT
32	didanosine	didanosine	B-NP	NN	O	31	OBJ
33	(	(	O	(	O	35	DEP
34	ddI	ddI	B-NP	NN	O	35	DEP
35	)	)	O	)	O	32	NMOD
36	to	to	B-PP	TO	O	31	VMOD
37	a	a	B-NP	DT	O	39	NMOD
38	maximum	maximum	I-NP	NN	O	39	NMOD
39	dose	dose	I-NP	NN	O	36	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	12.5	12.5	B-NP	CD	O	42	NMOD
42	mg/kg/day	mg/kg/day	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	31	P

1	Can	Can	O	MD	O	0	ROOT
2	angiogenesis	angiogenesis	B-NP	NN	O	1	SUB
3	be	be	B-VP	VB	O	1	VC
4	a	a	B-NP	DT	O	5	NMOD
5	target	target	I-NP	NN	O	3	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	treatment	treatment	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	ribavirin	ribavirin	B-NP	NN	O	12	NMOD
10	associated	associated	I-NP	JJ	O	9	AMOD
11	hemolytic	hemolytic	I-NP	JJ	O	12	NMOD
12	anemia	anemia	I-NP	NN	O	8	PMOD
13	.	.	O	.	O	1	P

1	BACKGROUND/AIMS	BACKGROUND/AIMS	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Recently	Recently	B-NP	RB	O	4	NMOD
4	ribavirin	ribavirin	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	22	VMOD
6	been	be	I-VP	VBN	O	5	VC
7	found	find	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	inhibit	inhibit	I-VP	VB	O	7	VMOD
10	angiogenesis	angiogenesis	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	a	a	B-NP	DT	O	13	NMOD
13	number	number	I-NP	NN	O	9	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	angiogenesis	angiogenesis	B-NP	NN	O	16	NMOD
16	inhibitors	inhibitor	I-NP	NNS	O	14	PMOD
17	such	such	B-PP	JJ	O	18	PMOD
18	as	as	I-PP	IN	O	16	NMOD
19	sunitinib	sunitinib	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	sorafenib	sorafenib	I-NP	NN	O	18	PMOD
22	have	have	B-VP	VBP	O	0	ROOT
23	been	be	I-VP	VBN	O	22	VC
24	found	find	I-VP	VBN	O	23	VC
25	to	to	I-VP	TO	O	26	VMOD
26	cause	cause	I-VP	VB	O	24	VMOD
27	acute	acute	B-NP	JJ	O	28	NMOD
28	hemolysis	hemolysis	I-NP	NN	O	26	OBJ
29	.	.	O	.	O	22	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Fourteen	Fourteen	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	11	SUB
5	chronically	chronically	B-VP	RB	O	6	VMOD
6	infected	infect	I-VP	VBN	O	4	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	hepatitis	hepatitis	B-NP	NN	O	10	NMOD
9	C	C	I-NP	NN	O	10	NMOD
10	virus	virus	I-NP	NN	O	7	PMOD
11	were	be	B-VP	VBD	O	1	NMOD
12	treated	treat	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	pegylated	pegylate	B-NP	VBN	O	19	NMOD
15	interferon	interferon	I-NP	NN	B-protein	16	NMOD
16	alpha	alpha	I-NP	NN	I-protein	17	NMOD
17	2a	2a	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	ribavirin	ribavirin	I-NP	NN	O	13	PMOD
20	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	29	SUB
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	SUB
4	is	be	B-VP	VBZ	O	29	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	first	first	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	20	SUB
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	literature	literature	I-NP	NN	O	8	PMOD
11	investigating	investigate	B-VP	VBG	O	10	NMOD
12	a	a	B-NP	DT	O	13	NMOD
13	link	link	I-NP	NN	O	11	OBJ
14	between	between	B-PP	IN	O	13	NMOD
15	angiogenesis	angiogenesis	B-NP	NN	B-protein	17	NMOD
16	soluble	soluble	I-NP	JJ	I-protein	17	NMOD
17	markers	marker	I-NP	NNS	I-protein	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	ribavirin	ribavirin	I-NP	NN	O	14	PMOD
20	induced	induce	B-VP	VBD	O	29	VMOD
21	anemia	anemia	B-NP	NN	O	20	OBJ
22	in	in	B-PP	IN	O	20	VMOD
23	patients	patient	B-NP	NNS	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	hepatitis	hepatitis	B-NP	NN	O	26	NMOD
26	C	C	I-NP	NN	O	24	PMOD
27	and	and	O	CC	O	29	VMOD
28	we	we	B-NP	PRP	O	29	SUB
29	could	could	B-VP	MD	O	0	ROOT
30	not	not	I-VP	RB	O	29	VMOD
31	find	find	I-VP	VB	O	29	VC
32	any	any	B-NP	DT	O	33	NMOD
33	relation	relation	I-NP	NN	O	31	OBJ
34	.	.	O	.	O	29	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	causes	cause	B-VP	VBZ	O	0	ROOT
3	memory	memory	B-NP	NN	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	learning	learning	I-NP	NN	O	6	NMOD
6	impairments	impairment	I-NP	NNS	O	2	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	:	:	O	:	O	2	P
10	involvement	involvement	B-NP	NN	O	21	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	nuclear	nuclear	B-NP	JJ	B-protein	15	NMOD
13	factor	factor	I-NP	NN	I-protein	15	NMOD
14	kappa	kappa	I-NP	NN	I-protein	15	NMOD
15	B	B	I-NP	NN	I-protein	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	oxidative	oxidative	B-NP	JJ	O	18	NMOD
18	stress	stress	I-NP	NN	O	11	PMOD
19	,	,	O	,	O	21	P
20	and	and	O	CC	O	21	NMOD
21	prevention	prevention	B-NP	NN	O	2	VMOD
22	by	by	B-PP	IN	O	21	NMOD
23	topiramate	topiramate	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	2	P

1	Different	Different	B-NP	JJ	O	2	NMOD
2	mechanisms	mechanism	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	suggested	suggest	I-VP	VBN	O	4	VC
6	for	for	B-PP	IN	O	5	VMOD
7	cocaine	cocaine	B-NP	NN	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	6	PMOD
9	including	include	B-PP	VBG	O	8	NMOD
10	an	an	B-NP	DT	O	11	NMOD
11	increase	increase	I-NP	NN	O	17	NMOD
12	in	in	B-PP	IN	O	11	NMOD
13	oxidative	oxidative	B-NP	JJ	O	14	NMOD
14	stress	stress	I-NP	NN	O	12	PMOD
15	but	but	O	CC	O	17	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	association	association	I-NP	NN	O	9	PMOD
18	between	between	B-PP	IN	O	17	NMOD
19	oxidative	oxidative	B-NP	JJ	O	20	NMOD
20	status	status	I-NP	NN	O	18	PMOD
21	in	in	B-PP	IN	O	17	NMOD
22	the	the	B-NP	DT	O	26	NMOD
23	brain	brain	I-NP	NN	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	cocaine	cocaine	I-NP	NN	O	26	NMOD
26	induced-behaviour	induced-behaviour	I-NP	NN	O	21	PMOD
27	is	be	B-VP	VBZ	O	3	VMOD
28	poorly	poorly	I-VP	RB	O	27	VMOD
29	understood	understand	I-VP	VBN	O	27	VC
30	.	.	O	.	O	3	P

1	Therefore	Therefore	B-NP	RB	O	37	SUB
2	NFkappaB	NFkappaB	I-NP	NN	B-protein	3	NMOD
3	activity	activity	I-NP	NN	O	15	NMOD
4	,	,	O	,	O	15	P
5	oxidative	oxidative	B-NP	JJ	O	6	NMOD
6	stress	stress	I-NP	NN	O	15	NMOD
7	,	,	O	,	O	15	P
8	neuronal	neuronal	B-NP	JJ	B-protein	11	NMOD
9	nitric	nitric	I-NP	JJ	I-protein	11	NMOD
10	oxide	oxide	I-NP	NN	I-protein	11	NMOD
11	synthase	synthase	I-NP	NN	I-protein	15	NMOD
12	(	(	O	(	O	14	DEP
13	nNOS	nNOS	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	activity	activity	B-NP	NN	O	25	NMOD
16	,	,	O	,	O	25	P
17	spatial	spatial	B-NP	JJ	O	18	NMOD
18	learning	learning	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	memory	memory	I-NP	NN	O	25	NMOD
21	as	as	B-CONJP	RB	O	25	NMOD
22	well	well	I-CONJP	RB	O	21	DEP
23	as	as	I-CONJP	IN	O	21	DEP
24	the	the	B-NP	DT	O	25	NMOD
25	effect	effect	I-NP	NN	O	1	NMOD
26	of	of	B-PP	IN	O	25	NMOD
27	topiramate	topiramate	B-NP	NN	O	32	NMOD
28	,	,	O	,	O	32	P
29	a	a	B-NP	DT	O	32	NMOD
30	previously	previously	I-NP	RB	O	31	AMOD
31	proposed	propose	I-NP	VBN	O	32	NMOD
32	therapy	therapy	I-NP	NN	O	26	PMOD
33	for	for	B-PP	IN	O	32	NMOD
34	cocaine	cocaine	B-NP	NN	O	35	NMOD
35	addiction	addiction	I-NP	NN	O	33	PMOD
36	,	,	O	,	O	25	P
37	were	be	B-VP	VBD	O	0	ROOT
38	evaluated	evaluate	I-VP	VBN	O	37	VC
39	in	in	B-PP	IN	O	38	VMOD
40	an	an	B-NP	DT	O	42	NMOD
41	experimental	experimental	I-NP	JJ	O	42	NMOD
42	model	model	I-NP	NN	O	39	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	cocaine	cocaine	B-NP	NN	O	45	NMOD
45	administration	administration	I-NP	NN	O	43	PMOD
46	in	in	B-PP	IN	O	45	NMOD
47	rats	rat	B-NP	NNS	O	46	PMOD
48	.	.	O	.	O	37	P

1	(	(	O	(	O	3	DEP
2	+/-	+/-	O	CC	O	3	DEP
3	)	)	O	)	O	11	SUB
4	-PG-9	-PG-9	B-NP	NN	O	3	NMOD
5	(	(	O	(	O	10	DEP
6	10-40	10-40	B-NP	CD	O	8	NMOD
7	mg	mg	I-NP	NN	O	8	NMOD
8	kg-1	kg-1	I-NP	NN	O	10	DEP
9	i.p.	i.p.	B-ADVP	RB	O	8	NMOD
10	)	)	O	)	O	4	NMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	able	able	B-ADJP	JJ	O	11	PRD
13	to	to	B-VP	TO	O	14	VMOD
14	prevent	prevent	I-VP	VB	O	12	AMOD
15	amnesia	amnesia	B-NP	NN	O	14	OBJ
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	scopolamine	scopolamine	B-NP	NN	O	26	NMOD
19	(	(	O	(	O	24	DEP
20	1	1	B-NP	CD	O	22	NMOD
21	mg	mg	I-NP	NN	O	22	NMOD
22	kg-1	kg-1	I-NP	NN	O	24	DEP
23	i.p.	i.p.	B-ADVP	RB	O	22	NMOD
24	)	)	O	)	O	18	NMOD
25	and	and	O	CC	O	26	NMOD
26	dicyclomine	dicyclomine	B-NP	NN	O	17	PMOD
27	(	(	O	(	O	32	DEP
28	2	2	B-NP	CD	O	30	NMOD
29	mg	mg	I-NP	NN	O	30	NMOD
30	kg-1	kg-1	I-NP	NN	O	32	DEP
31	i.p.	i.p.	B-ADVP	RB	O	30	NMOD
32	)	)	O	)	O	26	NMOD
33	in	in	B-PP	IN	O	16	VMOD
34	the	the	B-NP	DT	O	37	NMOD
35	mouse	mouse	I-NP	NN	O	37	NMOD
36	passive-avoidance	passive-avoidance	I-NP	NN	O	37	NMOD
37	test	test	I-NP	NN	O	33	PMOD
38	.	.	O	.	O	11	P

1	Affinity	Affinity	B-NP	NN	O	2	NMOD
2	profiles	profile	I-NP	NNS	O	45	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	(	(	O	(	O	6	DEP
5	+/-	+/-	O	CC	O	6	DEP
6	)	)	O	)	O	7	NMOD
7	-PG-9	-PG-9	B-NP	NN	O	3	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	muscarinic	muscarinic	B-NP	JJ	O	11	NMOD
10	receptor	receptor	I-NP	NN	O	11	NMOD
11	subtypes	subtype	I-NP	NNS	O	8	PMOD
12	,	,	O	,	O	2	P
13	determined	determine	B-VP	VBN	O	2	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	functional	functional	B-NP	JJ	O	16	NMOD
16	studies	study	I-NP	NNS	O	14	PMOD
17	(	(	O	(	O	43	DEP
18	rabbit	rabbit	B-NP	NN	O	20	NMOD
19	vas	vas	I-NP	NN	O	20	NMOD
20	deferens	deferen	I-NP	NNS	O	26	NMOD
21	for	for	B-PP	IN	O	20	NMOD
22	M1	M1	B-NP	NN	B-protein	21	PMOD
23	,	,	O	,	O	26	P
24	guinea	guinea	B-NP	NN	O	26	NMOD
25	pig	pig	I-NP	NN	O	26	NMOD
26	atrium	atrium	I-NP	NN	O	32	NMOD
27	for	for	B-PP	IN	O	26	NMOD
28	M2	M2	B-NP	NN	B-protein	27	PMOD
29	,	,	O	,	O	32	P
30	guinea	guinea	B-NP	NN	O	32	NMOD
31	pig	pig	I-NP	NN	O	32	NMOD
32	ileum	ileum	I-NP	NN	O	43	DEP
33	for	for	B-PP	IN	O	32	NMOD
34	M3	M3	B-NP	NN	O	39	NMOD
35	and	and	O	CC	O	39	NMOD
36	immature	immature	B-NP	JJ	O	39	NMOD
37	guinea	guinea	I-NP	NN	O	39	NMOD
38	pig	pig	I-NP	NN	O	39	NMOD
39	uterus	uterus	I-NP	NN	O	33	PMOD
40	for	for	B-PP	IN	O	39	NMOD
41	putative	putative	B-NP	JJ	O	42	NMOD
42	M4	M4	I-NP	NN	O	40	PMOD
43	)	)	O	)	O	16	NMOD
44	,	,	O	,	O	2	P
45	have	have	B-VP	VBP	O	0	ROOT
46	shown	show	I-VP	VBN	O	45	VC
47	an	an	B-NP	DT	O	50	NMOD
48	M4/M1	M4/M1	I-NP	NN	O	50	NMOD
49	selectivity	selectivity	I-NP	NN	O	50	NMOD
50	ratio	ratio	I-NP	NN	O	46	OBJ
51	of	of	B-PP	IN	O	50	NMOD
52	10.2	10.2	B-NP	CD	O	51	PMOD
53	that	that	B-NP	WDT	O	50	NMOD
54	might	might	B-VP	MD	O	53	SBAR
55	be	be	I-VP	VB	O	54	VC
56	responsible	responsible	B-ADJP	JJ	O	55	PRD
57	for	for	B-PP	IN	O	56	AMOD
58	the	the	B-NP	DT	O	59	NMOD
59	antinociception	antinociception	I-NP	NN	O	63	NMOD
60	and	and	O	CC	O	63	NMOD
61	the	the	B-NP	DT	O	63	NMOD
62	anti-amnesic	anti-amnesic	I-NP	JJ	O	63	NMOD
63	effect	effect	I-NP	NN	O	57	PMOD
64	induced	induce	B-VP	VBN	O	63	NMOD
65	by	by	B-PP	IN	O	64	VMOD
66	(	(	O	(	O	68	DEP
67	+/-	+/-	O	CC	O	68	DEP
68	)	)	O	)	O	69	NMOD
69	-PG-9	-PG-9	B-NP	NN	O	65	PMOD
70	through	through	B-PP	IN	O	64	VMOD
71	an	an	B-NP	DT	O	72	NMOD
72	increase	increase	I-NP	NN	O	70	PMOD
73	in	in	B-PP	IN	O	72	NMOD
74	acetylcholine	acetylcholine	B-NP	NN	O	76	NMOD
75	extracellular	extracellular	I-NP	JJ	O	76	NMOD
76	levels	level	I-NP	NNS	O	73	PMOD
77	.	.	O	.	O	45	P

1	Hyperbaric	Hyperbaric	B-NP	JJ	O	3	NMOD
2	oxygen	oxygen	I-NP	NN	O	3	NMOD
3	therapy	therapy	I-NP	NN	O	9	SUB
4	for	for	B-PP	IN	O	3	NMOD
5	control	control	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	intractable	intractable	B-NP	JJ	O	8	NMOD
8	cyclophosphamide	cyclophosphamide	I-NP	NN	O	6	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	hemorrhagic	hemorrhagic	B-NP	JJ	O	11	NMOD
11	cystitis	cystitis	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	intractable	intractable	B-NP	JJ	O	8	NMOD
7	hemorrhagic	hemorrhagic	I-NP	JJ	O	8	NMOD
8	cystitis	cystitis	I-NP	NN	O	5	PMOD
9	due	due	B-ADJP	JJ	O	8	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	cyclophosphamide	cyclophosphamide	B-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	Wegener	Wegener	B-NP	NNP	O	16	NMOD
15	's	's	B-NP	POS	O	16	NMOD
16	granulomatosis	granulomatosis	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	2	P

1	Conservative	Conservative	B-NP	JJ	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	17	SUB
3	,	,	O	,	O	2	P
4	including	include	B-PP	VBG	O	2	NMOD
5	bladder	bladder	B-NP	NN	O	6	NMOD
6	irrigation	irrigation	I-NP	NN	O	11	NMOD
7	with	with	B-PP	IN	O	6	NMOD
8	physiological	physiological	B-NP	JJ	O	9	NMOD
9	saline	saline	I-NP	NN	O	7	PMOD
10	and	and	I-NP	CC	O	11	NMOD
11	instillation	instillation	I-NP	NN	O	4	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	prostaglandin	prostaglandin	B-NP	NN	B-protein	15	NMOD
14	F2	F2	I-NP	NN	I-protein	15	NMOD
15	alpha	alpha	I-NP	NN	I-protein	12	PMOD
16	,	,	O	,	O	2	P
17	failed	fail	B-VP	VBD	O	0	ROOT
18	to	to	I-VP	TO	O	20	VMOD
19	totally	totally	I-VP	RB	O	20	VMOD
20	control	control	I-VP	VB	O	17	VMOD
21	hemorrhage	hemorrhage	B-NP	NN	O	20	OBJ
22	.	.	O	.	O	17	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	shown	show	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	the	the	B-NP	DT	O	9	NMOD
7	degradation	degradation	I-NP	NN	O	9	NMOD
8	product	product	I-NP	NN	O	9	NMOD
9	p-choloroaniline	p-choloroaniline	I-NP	NN	O	10	SUB
10	is	be	B-VP	VBZ	O	5	SBAR
11	not	not	O	RB	O	10	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	significant	significant	I-NP	JJ	O	14	NMOD
14	factor	factor	I-NP	NN	O	10	PRD
15	in	in	B-PP	IN	O	14	NMOD
16	chlorhexidine-digluconate	chlorhexidine-digluconate	B-NP	NN	O	19	NMOD
17	associated	associated	I-NP	JJ	O	19	NMOD
18	erosive	erosive	I-NP	JJ	O	19	NMOD
19	cystitis	cystitis	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	high	high	I-NP	JJ	O	3	NMOD
3	percentage	percentage	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	kanamycin-colistin	kanamycin-colistin	B-NP	NN	B-protein	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	povidone-iodine	povidone-iodine	I-NP	NN	O	8	NMOD
8	irrigations	irrigation	I-NP	NNS	O	4	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	associated	associate	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	erosive	erosive	B-NP	JJ	O	13	NMOD
13	cystitis	cystitis	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	9	VMOD
15	suggested	suggest	B-VP	VBD	O	9	VMOD
16	a	a	B-NP	DT	O	18	NMOD
17	possible	possible	I-NP	JJ	O	18	NMOD
18	complication	complication	I-NP	NN	O	15	OBJ
19	with	with	B-PP	IN	O	18	NMOD
20	human	human	B-NP	JJ	O	21	NMOD
21	usage	usage	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	double	double	I-NP	JJ	O	5	NMOD
4	blind	blind	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	1	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	haloperidol	haloperidol	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	11	P
9	both	both	B-NP	DT	O	10	NMOD
10	substances	substance	I-NP	NNS	O	11	SUB
11	were	be	B-VP	VBD	O	0	ROOT
12	found	find	I-VP	VBN	O	11	VC
13	to	to	I-VP	TO	O	14	VMOD
14	be	be	I-VP	VB	O	12	VMOD
15	highly	highly	B-ADJP	RB	O	16	AMOD
16	effective	effective	I-ADJP	JJ	O	14	PRD
17	in	in	B-PP	IN	O	16	AMOD
18	the	the	B-NP	DT	O	19	NMOD
19	treatment	treatment	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	psychotic	psychotic	B-NP	JJ	O	22	NMOD
22	syndromes	syndrome	I-NP	NNS	O	20	PMOD
23	belonging	belong	B-VP	VBG	O	22	NMOD
24	predominantly	predominantly	B-ADVP	RB	O	25	PMOD
25	to	to	B-PP	TO	O	23	VMOD
26	the	the	B-NP	DT	O	28	NMOD
27	schizophrenia	schizophrenia	I-NP	NN	O	28	NMOD
28	group	group	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	11	P

1	Curcumin	Curcumin	B-NP	NN	O	2	SUB
2	ameliorates	ameliorate	B-VP	VBZ	O	0	ROOT
3	cognitive	cognitive	B-NP	JJ	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	oxidative	oxidative	B-NP	JJ	O	7	NMOD
7	damage	damage	I-NP	NN	O	2	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	phenobarbitone	phenobarbitone	B-NP	NN	O	13	NMOD
10	and	and	I-NP	CC	O	13	NMOD
11	carbamazepine	carbamazepine	I-NP	NN	O	13	NMOD
12	administered	administer	I-NP	VBN	O	13	NMOD
13	rats	rat	I-NP	NNS	O	8	PMOD
14	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	antiepileptic	antiepileptic	I-NP	JJ	O	3	NMOD
3	drugs	drug	I-NP	NNS	O	7	NMOD
4	,	,	I-NP	,	O	7	P
5	phenobarbitone	phenobarbitone	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	carbamazepine	carbamazepine	I-NP	NN	O	8	SUB
8	are	be	B-VP	VBP	O	0	ROOT
9	well	well	I-VP	RB	O	8	VMOD
10	known	know	I-VP	VBN	O	8	VC
11	to	to	B-VP	TO	O	12	VMOD
12	cause	cause	I-VP	VB	O	10	VMOD
13	cognitive	cognitive	B-NP	JJ	O	14	NMOD
14	impairment	impairment	I-NP	NN	O	12	OBJ
15	on	on	B-PP	IN	O	12	VMOD
16	chronic	chronic	B-NP	JJ	O	17	NMOD
17	use	use	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	8	P

1	Therefore	Therefore	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	the	the	B-NP	DT	O	5	NMOD
4	present	present	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	carried	carry	I-VP	VBN	O	6	VC
8	out	out	B-PRT	RP	O	7	VMOD
9	to	to	B-VP	TO	O	10	VMOD
10	investigate	investigate	I-VP	VB	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	effect	effect	I-NP	NN	O	21	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	chronic	chronic	B-NP	JJ	O	16	NMOD
15	curcumin	curcumin	I-NP	NN	O	16	NMOD
16	administration	administration	I-NP	NN	O	13	PMOD
17	on	on	B-PP	IN	O	12	NMOD
18	phenobarbitone-	phenobarbitone-	B-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	carbamazepine	carbamazepine	I-NP	NN	O	17	PMOD
21	induced	induce	B-VP	VBD	O	10	VMOD
22	cognitive	cognitive	B-NP	JJ	O	23	NMOD
23	impairment	impairment	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	oxidative	oxidative	B-NP	JJ	O	26	NMOD
26	stress	stress	I-NP	NN	O	21	OBJ
27	in	in	B-PP	IN	O	21	VMOD
28	rats	rat	B-NP	NNS	O	27	PMOD
29	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	6	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	phenobarbitone	phenobarbitone	B-NP	NN	O	3	PMOD
5	and	and	I-NP	CC	O	6	NMOD
6	carbamazepine	carbamazepine	I-NP	NN	O	9	SUB
7	for	for	B-PP	IN	O	6	NMOD
8	21days	21day	B-NP	NNS	O	7	PMOD
9	caused	cause	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	12	NMOD
11	significant	significant	I-NP	JJ	O	12	NMOD
12	impairment	impairment	I-NP	NN	O	23	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	learning	learning	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	memory	memory	I-NP	NN	O	13	PMOD
17	as	as	B-CONJP	RB	O	23	NMOD
18	well	well	I-CONJP	RB	O	17	DEP
19	as	as	I-CONJP	IN	O	17	DEP
20	an	an	B-NP	DT	O	23	NMOD
21	increased	increase	I-NP	VBN	O	23	NMOD
22	oxidative	oxidative	I-NP	JJ	O	23	NMOD
23	stress	stress	I-NP	NN	O	9	OBJ
24	.	.	O	.	O	9	P

1	Concomitant	Concomitant	B-NP	JJ	O	3	NMOD
2	curcumin	curcumin	I-NP	NN	O	3	NMOD
3	administration	administration	I-NP	NN	O	4	SUB
4	prevented	prevent	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	cognitive	cognitive	I-NP	JJ	O	7	NMOD
7	impairment	impairment	I-NP	NN	O	4	OBJ
8	and	and	O	CC	O	4	VMOD
9	decreased	decrease	B-VP	VBD	O	4	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	increased	increase	I-NP	VBN	O	13	NMOD
12	oxidative	oxidative	I-NP	JJ	O	13	NMOD
13	stress	stress	I-NP	NN	O	9	OBJ
14	induced	induce	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	these	these	B-NP	DT	O	18	NMOD
17	antiepileptic	antiepileptic	I-NP	JJ	O	18	NMOD
18	drugs	drug	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	4	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	show	show	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	curcumin	curcumin	B-NP	NN	O	6	SUB
6	has	have	B-VP	VBZ	O	4	SBAR
7	beneficial	beneficial	B-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	6	VMOD
10	mitigating	mitigate	B-VP	VBG	O	9	PMOD
11	the	the	B-NP	DT	O	12	NMOD
12	deterioration	deterioration	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	cognitive	cognitive	B-NP	JJ	O	15	NMOD
15	functions	function	I-NP	NNS	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	oxidative	oxidative	B-NP	JJ	O	18	NMOD
18	damage	damage	I-NP	NN	O	13	PMOD
19	in	in	B-PP	IN	O	10	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	treated	treat	B-VP	VBN	O	20	NMOD
22	with	with	B-PP	IN	O	21	VMOD
23	phenobarbitone	phenobarbitone	B-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	carbamazepine	carbamazepine	I-NP	NN	O	22	PMOD
26	without	without	B-PP	IN	O	10	VMOD
27	significantly	significantly	B-VP	RB	O	28	VMOD
28	altering	alter	I-VP	VBG	O	26	PMOD
29	their	their	B-NP	PRP$	O	31	NMOD
30	serum	serum	I-NP	NN	O	31	NMOD
31	concentrations	concentration	I-NP	NNS	O	28	OBJ
32	.	.	O	.	O	3	P

1	Pyrrolidine	Pyrrolidine	B-NP	NN	O	2	NMOD
2	dithiocarbamate	dithiocarbamate	I-NP	NN	O	3	SUB
3	protects	protect	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	piriform	piriform	I-NP	JJ	O	6	NMOD
6	cortex	cortex	I-NP	NN	O	3	OBJ
7	in	in	B-PP	IN	O	3	VMOD
8	the	the	B-NP	DT	O	12	NMOD
9	pilocarpine	pilocarpine	I-NP	NN	O	12	NMOD
10	status	status	I-NP	NN	O	12	NMOD
11	epilepticus	epilepticus	I-NP	NN	O	12	NMOD
12	model	model	I-NP	NN	O	7	PMOD
13	.	.	O	.	O	3	P

1	Both	Both	O	CC	O	11	NMOD
2	,	,	O	,	O	11	P
3	production	production	B-NP	NN	O	11	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	reactive	reactive	B-NP	JJ	O	7	NMOD
6	oxygen	oxygen	I-NP	NN	O	7	NMOD
7	species	specie	I-NP	NNS	O	4	PMOD
8	as	as	B-CONJP	RB	O	11	NMOD
9	well	well	I-CONJP	RB	O	8	DEP
10	as	as	I-CONJP	IN	O	8	DEP
11	activation	activation	B-NP	NN	O	14	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	NF-kappaB	NF-kappaB	B-NP	NN	B-protein	12	PMOD
14	have	have	B-VP	VBP	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	implicated	implicate	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	severe	severe	B-NP	JJ	O	20	NMOD
19	neuronal	neuronal	I-NP	JJ	O	20	NMOD
20	damage	damage	I-NP	NN	O	17	PMOD
21	in	in	B-PP	IN	O	16	VMOD
22	different	different	B-NP	JJ	O	23	NMOD
23	sub-regions	sub-region	I-NP	NNS	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	hippocampus	hippocampus	I-NP	NN	O	24	PMOD
27	as	as	B-CONJP	RB	O	23	NMOD
28	well	well	I-CONJP	RB	O	27	DEP
29	as	as	I-CONJP	IN	O	27	DEP
30	in	in	B-PP	IN	O	27	PMOD
31	the	the	B-NP	DT	O	33	NMOD
32	surrounding	surround	I-NP	VBG	O	33	NMOD
33	cortices	cortex	I-NP	NNS	O	30	PMOD
34	.	.	O	.	O	14	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	PDTC	PDTC	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	status	status	B-NP	NN	O	9	NMOD
7	epilepticus-associated	epilepticus-associated	I-NP	JJ	O	9	NMOD
8	cell	cell	I-NP	NN	O	9	NMOD
9	loss	loss	I-NP	NN	O	5	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	15	NMOD
12	hippocampus	hippocampus	I-NP	NN	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	piriform	piriform	I-NP	NN	O	15	NMOD
15	cortex	cortex	I-NP	NN	O	10	PMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	evaluated	evaluate	I-VP	VBN	O	16	VC
18	in	in	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	rat	rat	I-NP	NN	O	21	SUB
21	fractionated	fractionate	B-VP	VBD	O	18	SBAR
22	pilocarpine	pilocarpine	B-NP	NN	O	23	NMOD
23	model	model	I-NP	NN	O	21	OBJ
24	.	.	O	.	O	16	P

1	Treatment	Treatment	B-NP	NN	O	12	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	150	150	B-NP	CD	O	5	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	NMOD
5	PDTC	PDTC	I-NP	NN	O	2	PMOD
6	before	before	B-PP	IN	O	1	NMOD
7	and	and	O	CC	O	6	PMOD
8	following	follow	B-PP	VBG	O	6	PMOD
9	status	status	B-NP	NN	O	10	NMOD
10	epilepticus	epilepticus	I-NP	NN	O	8	PMOD
11	significantly	significantly	B-ADVP	RB	O	12	VMOD
12	increased	increase	B-VP	VBD	O	0	ROOT
13	the	the	B-NP	DT	O	15	NMOD
14	mortality	mortality	I-NP	NN	O	15	NMOD
15	rate	rate	I-NP	NN	O	12	OBJ
16	to	to	B-PP	TO	O	15	NMOD
17	100	100	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	12	P

1	Administration	Administration	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	50	50	B-NP	CD	O	5	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	NMOD
5	PDTC	PDTC	I-NP	NN	O	2	PMOD
6	(	(	O	(	O	8	DEP
7	low-dose	low-dose	B-ADJP	JJ	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	did	do	B-VP	VBD	O	0	ROOT
10	not	not	I-VP	RB	O	9	VMOD
11	exert	exert	I-VP	VB	O	9	VC
12	major	major	B-NP	JJ	O	13	NMOD
13	effects	effect	I-NP	NNS	O	11	OBJ
14	on	on	B-PP	IN	O	11	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	development	development	I-NP	NN	O	24	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	status	status	I-NP	NN	O	20	NMOD
20	epilepticus	epilepticus	I-NP	NN	O	17	PMOD
21	or	or	O	CC	O	24	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	mortality	mortality	I-NP	NN	O	24	NMOD
24	rate	rate	I-NP	NN	O	14	PMOD
25	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	3	NMOD
2	significant	significant	I-NP	JJ	O	3	NMOD
3	decrease	decrease	I-NP	NN	O	12	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	neuronal	neuronal	B-NP	JJ	O	6	NMOD
6	density	density	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	hippocampal	hippocampal	I-NP	JJ	O	11	NMOD
10	hilar	hilar	I-NP	JJ	O	11	NMOD
11	formation	formation	I-NP	NN	O	7	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	identified	identify	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	vehicle-	vehicle-	B-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	PDTC-treated	PDTC-treated	B-NP	JJ	O	18	NMOD
18	rats	rat	I-NP	NNS	O	14	PMOD
19	following	follow	B-PP	VBG	O	13	VMOD
20	status	status	B-NP	NN	O	21	NMOD
21	epilepticus	epilepticus	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	12	P

1	In	In	B-PP	IN	O	10	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	10	P
4	the	the	B-NP	DT	O	6	NMOD
5	NF-kappaB	NF-kappaB	I-NP	NN	B-protein	6	NMOD
6	inhibitor	inhibitor	I-NP	NN	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	antioxidant	antioxidant	B-NP	JJ	O	9	NMOD
9	PDTC	PDTC	I-NP	NN	O	10	SUB
10	protected	protect	B-VP	VBD	O	0	ROOT
11	the	the	B-NP	DT	O	13	NMOD
12	piriform	piriform	I-NP	NN	O	13	NMOD
13	cortex	cortex	I-NP	NN	O	10	OBJ
14	,	,	O	,	O	10	P
15	whereas	whereas	O	IN	O	10	VMOD
16	it	it	B-NP	PRP	O	17	SUB
17	did	do	B-VP	VBD	O	15	SBAR
18	not	not	I-VP	RB	O	17	VMOD
19	affect	affect	I-VP	VB	O	17	VC
20	hilar	hilar	B-NP	JJ	O	22	NMOD
21	neuronal	neuronal	I-NP	JJ	O	22	NMOD
22	loss	loss	I-NP	NN	O	19	OBJ
23	.	.	O	.	O	10	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	might	might	B-VP	MD	O	0	ROOT
4	indicate	indicate	I-VP	VB	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	generation	generation	I-NP	NN	O	13	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	reactive	reactive	B-NP	JJ	O	11	NMOD
10	oxygen	oxygen	I-NP	NN	O	11	NMOD
11	species	specie	I-NP	NNS	O	8	PMOD
12	and	and	O	CC	O	13	NMOD
13	activation	activation	B-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	NF-kappaB	NF-kappaB	B-NP	NN	B-protein	14	PMOD
16	plays	play	B-VP	VBZ	O	5	SBAR
17	a	a	B-NP	DT	O	20	NMOD
18	more	more	I-NP	RBR	O	19	AMOD
19	central	central	I-NP	JJ	O	20	NMOD
20	role	role	I-NP	NN	O	16	OBJ
21	in	in	B-PP	IN	O	16	VMOD
22	seizure-associated	seizure-associated	B-NP	JJ	O	24	NMOD
23	neuronal	neuronal	I-NP	JJ	O	24	NMOD
24	damage	damage	I-NP	NN	O	21	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	temporal	temporal	I-NP	JJ	O	28	NMOD
28	cortex	cortex	I-NP	NN	O	25	PMOD
29	as	as	B-SBAR	IN	O	16	VMOD
30	compared	compare	B-PP	VBN	O	29	SBAR
31	to	to	B-PP	TO	O	30	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	hippocampal	hippocampal	I-NP	JJ	O	34	NMOD
34	hilus	hilus	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	3	P

1	Development	Development	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	levodopa	levodopa	B-NP	NN	O	5	NMOD
4	induced	induce	I-NP	VBN	O	5	NMOD
5	dyskinesias	dyskinesia	I-NP	NNS	O	2	PMOD
6	in	in	B-PP	IN	O	1	NMOD
7	parkinsonian	parkinsonian	B-NP	JJ	O	8	NMOD
8	monkeys	monkey	I-NP	NNS	O	6	PMOD
9	may	may	B-VP	MD	O	0	ROOT
10	depend	depend	I-VP	VB	O	9	VC
11	upon	upon	B-PP	IN	O	10	VMOD
12	rate	rate	B-NP	NN	O	17	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	symptom	symptom	B-NP	NN	O	15	NMOD
15	onset	onset	I-NP	NN	O	13	PMOD
16	and/or	and/or	O	CC	O	17	NMOD
17	duration	duration	B-NP	NN	O	11	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	symptoms	symptom	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	9	P

1	Levodopa	Levodopa	B-NP	NN	O	3	NMOD
2	induced	induce	I-NP	VBN	O	3	NMOD
3	dyskinesias	dyskinesia	I-NP	NNS	O	7	SUB
4	(	(	O	(	O	6	DEP
5	LIDs	LID	B-NP	NNS	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	present	present	B-VP	VBP	O	0	ROOT
8	a	a	B-NP	DT	O	10	NMOD
9	major	major	I-NP	JJ	O	10	NMOD
10	problem	problem	I-NP	NN	O	7	OBJ
11	for	for	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	long-term	long-term	I-NP	JJ	O	14	NMOD
14	management	management	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	Parkinson	Parkinson	B-NP	NNP	O	17	NMOD
17	's	's	B-NP	POS	O	18	NMOD
18	disease	disease	I-NP	NN	O	22	NMOD
19	(	(	O	(	O	21	DEP
20	PD	PD	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	patients	patient	B-NP	NNS	O	15	PMOD
23	.	.	O	.	O	7	P

1	Using	Use	B-VP	VBG	O	9	SUB
2	macaque	macaque	B-NP	JJ	O	3	NMOD
3	monkeys	monkey	I-NP	NNS	O	1	OBJ
4	with	with	B-PP	IN	O	3	NMOD
5	different	different	B-NP	JJ	O	6	NMOD
6	types	type	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	MPTP	MPTP	B-NP	NN	B-protein	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	parkinsonism	parkinsonism	B-NP	NN	O	14	NMOD
11	,	,	O	,	O	14	P
12	the	the	B-NP	DT	O	14	NMOD
13	current	current	I-NP	JJ	O	14	NMOD
14	study	study	I-NP	NN	O	15	SUB
15	evaluated	evaluate	B-VP	VBD	O	9	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	degree	degree	I-NP	NN	O	29	NMOD
18	to	to	B-PP	TO	O	17	NMOD
19	which	which	B-NP	WDT	O	18	PMOD
20	rate	rate	B-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	symptom	symptom	B-NP	NN	O	23	NMOD
23	progression	progression	I-NP	NN	O	21	PMOD
24	,	,	O	,	O	29	P
25	symptom	symptom	B-NP	NN	O	26	NMOD
26	severity	severity	I-NP	NN	O	29	NMOD
27	,	,	O	,	O	29	P
28	and	and	O	CC	O	29	NMOD
29	response	response	B-NP	NN	O	15	OBJ
30	to	to	B-PP	TO	O	29	NMOD
31	and	and	O	CC	O	30	PMOD
32	duration	duration	B-NP	NN	O	36	SUB
33	of	of	B-PP	IN	O	32	NMOD
34	levodopa	levodopa	B-NP	NN	O	35	NMOD
35	therapy	therapy	I-NP	NN	O	33	PMOD
36	may	may	B-VP	MD	O	30	SBAR
37	be	be	I-VP	VB	O	36	VC
38	involved	involve	I-VP	VBN	O	37	VC
39	in	in	B-PP	IN	O	38	VMOD
40	the	the	B-NP	DT	O	41	NMOD
41	development	development	I-NP	NN	O	39	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	LIDs	LID	B-NP	NNS	O	42	PMOD
44	.	.	O	.	O	9	P

1	Monkeys	Monkey	B-NP	NNS	O	23	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	acute	acute	O	JJ	O	8	NMOD
4	(	(	O	(	O	6	DEP
5	short-term	short-term	B-ADJP	JJ	O	6	DEP
6	)	)	O	)	O	3	AMOD
7	MPTP	MPTP	B-NP	NN	O	8	NMOD
8	exposure	exposure	I-NP	NN	O	16	NMOD
9	,	,	O	,	O	16	P
10	rapid	rapid	B-NP	JJ	O	12	NMOD
11	symptom	symptom	I-NP	NN	O	12	NMOD
12	onset	onset	I-NP	NN	O	16	NMOD
13	and	and	O	CC	O	16	NMOD
14	short	short	B-NP	JJ	O	16	NMOD
15	symptom	symptom	I-NP	NN	O	16	NMOD
16	duration	duration	I-NP	NN	O	2	PMOD
17	prior	prior	B-ADJP	JJ	O	16	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	initiation	initiation	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	levodopa	levodopa	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	developed	develop	B-VP	VBD	O	0	ROOT
24	dyskinesia	dyskinesia	B-NP	NN	O	23	OBJ
25	between	between	B-PP	IN	O	24	NMOD
26	11	11	B-NP	CD	O	29	NMOD
27	and	and	I-NP	CC	O	29	NMOD
28	24	24	I-NP	CD	O	29	NMOD
29	days	day	I-NP	NNS	O	25	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	daily	daily	B-NP	JJ	O	33	NMOD
32	levodopa	levodopa	I-NP	NN	O	33	NMOD
33	administration	administration	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	23	P

1	In	In	B-PP	IN	O	23	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	23	P
4	monkeys	monkey	B-NP	NNS	O	23	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	long-term	long-term	B-NP	JJ	O	8	NMOD
7	MPTP	MPTP	I-NP	NN	O	8	NMOD
8	exposure	exposure	I-NP	NN	O	16	NMOD
9	,	,	O	,	O	16	P
10	slow	slow	B-NP	JJ	O	12	NMOD
11	symptom	symptom	I-NP	NN	O	12	NMOD
12	progression	progression	I-NP	NN	O	16	NMOD
13	and/or	and/or	B-NP	CC	O	16	NMOD
14	long	long	I-NP	JJ	O	16	NMOD
15	symptom	symptom	I-NP	NN	O	16	NMOD
16	duration	duration	I-NP	NN	O	5	PMOD
17	prior	prior	B-ADJP	JJ	O	16	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	initiation	initiation	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	levodopa	levodopa	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	were	be	B-VP	VBD	O	0	ROOT
24	more	more	B-ADJP	RBR	O	25	AMOD
25	resistant	resistant	I-ADJP	JJ	O	23	PRD
26	to	to	B-PP	TO	O	25	AMOD
27	developing	develop	B-NP	VBG	O	28	NMOD
28	LIDs	LID	I-NP	NNS	O	26	PMOD
29	(	(	O	(	O	43	DEP
30	e.g.	e.g.	B-NP	FW	O	33	VMOD
31	,	,	O	,	O	33	P
32	dyskinesia	dyskinesia	B-NP	NN	O	33	SUB
33	developed	develop	B-VP	VBD	O	43	DEP
34	no	no	B-NP	DT	O	38	NMOD
35	sooner	sooner	I-NP	RBR	O	36	AMOD
36	than	than	I-NP	IN	O	38	NMOD
37	146	146	I-NP	CD	O	36	AMOD
38	days	day	I-NP	NNS	O	33	OBJ
39	of	of	B-PP	IN	O	38	NMOD
40	chronic	chronic	B-NP	JJ	O	42	NMOD
41	levodopa	levodopa	I-NP	NN	O	42	NMOD
42	administration	administration	I-NP	NN	O	39	PMOD
43	)	)	O	)	O	23	VMOD
44	.	.	O	.	O	23	P

1	Propylthiouracil	Propylthiouracil	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	perinuclear-staining	perinuclear-staining	B-NP	JJ	O	7	NMOD
4	antineutrophil	antineutrophil	I-NP	NN	O	7	NMOD
5	cytoplasmic	cytoplasmic	I-NP	JJ	O	7	NMOD
6	autoantibody-positive	autoantibody-positive	I-NP	JJ	O	7	NMOD
7	vasculitis	vasculitis	I-NP	NN	O	2	OBJ
8	in	in	B-PP	IN	O	2	VMOD
9	conjunction	conjunction	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	pericarditis	pericarditis	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	describe	describe	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	propylthiouracil	propylthiouracil	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	4	VMOD
10	vasculitis	vasculitis	B-NP	NN	O	9	OBJ
11	manifesting	manifest	B-VP	VBG	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	pericarditis	pericarditis	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	present	present	B-VP	VBP	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	first	first	I-NP	JJ	O	8	NMOD
7	case	case	I-NP	NN	O	8	NMOD
8	report	report	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	11	NMOD
11	woman	woman	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	hyperthyroidism	hyperthyroidism	B-NP	NN	O	12	PMOD
14	treated	treat	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	propylthiouracil	propylthiouracil	B-NP	NN	O	15	PMOD
17	in	in	B-PP	IN	O	11	NMOD
18	whom	whom	B-NP	WP	O	17	PMOD
19	a	a	B-NP	DT	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	28	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	pericarditis	pericarditis	B-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	fever	fever	B-NP	NN	O	27	NMOD
25	,	,	O	,	O	27	P
26	and	and	O	CC	O	27	NMOD
27	glomerulonephritis	glomerulonephritis	B-NP	NN	O	21	PMOD
28	developed	develop	B-VP	VBD	O	17	SBAR
29	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	3	NMOD
2	literature	literature	I-NP	NN	O	3	NMOD
3	review	review	I-NP	NN	O	4	SUB
4	revealed	reveal	B-VP	VBD	O	0	ROOT
5	no	no	B-NP	DT	O	7	NMOD
6	prior	prior	I-NP	JJ	O	7	NMOD
7	reports	report	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	pericarditis	pericarditis	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	anti-MPO	anti-MPO	B-NP	JJ	O	13	NMOD
12	pANCA-positive	pANCA-positive	I-NP	JJ	O	13	NMOD
13	vasculitis	vasculitis	I-NP	NN	O	10	PMOD
14	associated	associate	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	propylthio-	propylthio-	B-NP	JJ	O	18	NMOD
17	uracil	uracil	I-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	4	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	mouse	mouse	I-NP	NN	B-cell_line	3	NMOD
3	lines	line	I-NP	NNS	I-cell_line	12	SUB
4	selected	select	B-VP	VBN	O	3	NMOD
5	for	for	B-PP	IN	O	4	VMOD
6	differential	differential	B-NP	JJ	O	7	NMOD
7	sensitivities	sensitivity	I-NP	NNS	O	5	PMOD
8	to	to	B-PP	TO	O	7	NMOD
9	beta-carboline	beta-carboline	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	seizures	seizure	I-NP	NNS	O	8	PMOD
12	are	be	B-VP	VBP	O	0	ROOT
13	also	also	B-ADVP	RB	O	12	VMOD
14	differentially	differentially	B-ADJP	RB	O	15	AMOD
15	sensitive	sensitive	I-ADJP	JJ	O	12	PRD
16	to	to	B-PP	TO	O	15	AMOD
17	various	various	B-NP	JJ	O	19	NMOD
18	pharmacological	pharmacological	I-NP	JJ	O	19	NMOD
19	effects	effect	I-NP	NNS	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	other	other	B-NP	JJ	O	27	NMOD
22	GABA	GABA	I-NP	NN	B-protein	27	NMOD
23	(	(	I-NP	(	O	27	NMOD
24	A	A	I-NP	NN	O	27	NMOD
25	)	)	I-NP	)	O	27	NMOD
26	receptor	receptor	I-NP	NN	O	27	NMOD
27	ligands	ligand	I-NP	NNS	O	20	PMOD
28	.	.	O	.	O	12	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	mouse	mouse	I-NP	NN	B-cell_line	3	NMOD
3	lines	line	I-NP	NNS	I-cell_line	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	selectively	selectively	I-VP	RB	O	4	VMOD
6	bred	breed	I-VP	VBN	O	4	VC
7	according	accord	B-PP	VBG	O	6	VMOD
8	to	to	B-PP	TO	O	7	PMOD
9	their	their	B-NP	PRP$	O	10	NMOD
10	sensitivity	sensitivity	I-NP	NN	O	16	NMOD
11	(	(	O	(	O	14	DEP
12	BS	BS	B-NP	NN	B-cell_line	13	NMOD
13	line	line	I-NP	NN	I-cell_line	14	DEP
14	)	)	O	)	O	10	NMOD
15	or	or	O	CC	O	16	NMOD
16	resistance	resistance	B-NP	NN	O	8	PMOD
17	(	(	O	(	O	20	DEP
18	BR	BR	B-NP	NN	B-cell_line	19	NMOD
19	line	line	I-NP	NN	I-cell_line	20	DEP
20	)	)	O	)	O	16	NMOD
21	to	to	B-PP	TO	O	16	NMOD
22	seizures	seizure	B-NP	NNS	O	21	PMOD
23	induced	induce	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	28	NMOD
26	single	single	I-NP	JJ	O	28	NMOD
27	i.p.	i.p.	I-NP	JJ	O	28	NMOD
28	injection	injection	I-NP	NN	O	24	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	methyl	methyl	B-NP	NN	O	31	NMOD
31	beta-carboline-3-carboxylate	beta-carboline-3-carboxylate	I-NP	NN	O	38	NMOD
32	(	(	O	(	O	34	DEP
33	beta-CCM	beta-CCM	B-NP	NN	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	,	,	O	,	O	38	P
36	an	an	B-NP	DT	O	38	NMOD
37	inverse	inverse	I-NP	JJ	O	38	NMOD
38	agonist	agonist	I-NP	NN	O	29	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	the	the	B-NP	DT	O	47	NMOD
41	GABA	GABA	I-NP	NN	B-DNA	47	NMOD
42	(	(	O	(	I-DNA	47	NMOD
43	A	A	B-NP	NN	I-DNA	47	NMOD
44	)	)	O	)	I-DNA	47	NMOD
45	receptor	receptor	B-NP	NN	I-DNA	47	NMOD
46	benzodiazepine	benzodiazepine	I-NP	NN	I-DNA	47	NMOD
47	site	site	I-NP	NN	I-DNA	39	PMOD
48	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	measured	measure	B-VP	VBD	O	0	ROOT
3	diazepam	diazepam	B-NP	NN	O	5	NMOD
4	induced	induced	I-NP	JJ	O	5	NMOD
5	anxiolysis	anxiolysis	I-NP	NN	O	2	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	elevated	elevated	I-NP	JJ	O	10	NMOD
9	plus-maze	plus-maze	I-NP	JJ	O	10	NMOD
10	test	test	I-NP	NN	O	6	PMOD
11	,	,	O	,	O	2	P
12	diazepam	diazepam	B-NP	NN	O	26	NMOD
13	induced	induce	B-VP	VBD	O	26	NMOD
14	sedation	sedation	B-NP	NN	O	13	OBJ
15	by	by	B-PP	IN	O	13	VMOD
16	recording	record	B-VP	VBG	O	15	PMOD
17	the	the	B-NP	DT	O	19	NMOD
18	vigilance	vigilance	I-NP	NN	O	19	NMOD
19	states	state	I-NP	NNS	O	16	OBJ
20	,	,	O	,	O	26	P
21	and	and	O	CC	O	26	NMOD
22	picrotoxin-	picrotoxin-	B-NP	NN	O	26	NMOD
23	and	and	I-NP	CC	O	26	NMOD
24	pentylenetetrazol	pentylenetetrazol	I-NP	NN	O	26	NMOD
25	induced	induce	I-NP	VBN	O	26	NMOD
26	seizures	seizure	I-NP	NNS	O	2	OBJ
27	after	after	B-PP	IN	O	26	NMOD
28	i.p.	i.p.	B-NP	JJ	O	29	NMOD
29	injections	injection	I-NP	NNS	O	27	PMOD
30	.	.	O	.	O	2	P

1	Analgesic	Analgesic	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	23	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	intravenous	intravenous	B-NP	JJ	O	5	NMOD
5	ketamine	ketamine	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	cancer	cancer	B-NP	NN	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	on	on	B-PP	IN	O	8	NMOD
10	morphine	morphine	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	2	P
13	a	a	B-NP	DT	O	23	NMOD
14	randomized	randomize	I-NP	VBN	O	22	AMOD
15	,	,	I-NP	,	O	22	P
16	controlled	control	I-NP	VBN	O	22	AMOD
17	,	,	I-NP	,	O	22	P
18	double-blind	double-blind	I-NP	JJ	O	22	AMOD
19	,	,	I-NP	,	O	22	P
20	crossover	crossover	I-NP	JJ	O	22	AMOD
21	,	,	I-NP	,	O	22	P
22	double-dose	double-dose	I-NP	JJ	O	23	NMOD
23	study	study	I-NP	NN	O	0	ROOT
24	.	.	O	.	O	23	P

1	Pain	Pain	B-NP	NN	B-protein	3	AMOD
2	not	not	B-ADJP	RB	O	3	AMOD
3	responsive	responsive	I-ADJP	JJ	O	6	SUB
4	to	to	B-PP	TO	O	3	AMOD
5	morphine	morphine	B-NP	NN	O	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	often	often	B-ADVP	RB	O	6	VMOD
8	problematic	problematic	B-ADJP	JJ	O	6	PRD
9	.	.	O	.	O	6	P

1	Animal	Animal	B-NP	NN	O	4	NMOD
2	and	and	O	CC	O	4	NMOD
3	clinical	clinical	B-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	suggested	suggest	I-VP	VBN	O	5	VC
7	that	that	B-SBAR	IN	O	6	VMOD
8	N-methyl-D-aspartate	N-methyl-D-aspartate	B-NP	NN	O	12	NMOD
9	(	(	O	(	O	11	DEP
10	NMDA	NMDA	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	antagonists	antagonist	B-NP	NNS	O	18	SUB
13	,	,	O	,	O	12	P
14	such	such	B-PP	JJ	O	15	PMOD
15	as	as	I-PP	IN	O	12	NMOD
16	ketamine	ketamine	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	12	P
18	may	may	B-VP	MD	O	7	SBAR
19	be	be	I-VP	VB	O	18	VC
20	effective	effective	B-ADJP	JJ	O	19	PRD
21	in	in	B-PP	IN	O	20	AMOD
22	improving	improve	B-VP	VBG	O	21	PMOD
23	opioid	opioid	B-NP	JJ	O	24	NMOD
24	analgesia	analgesia	I-NP	NN	O	22	OBJ
25	in	in	B-PP	IN	O	22	VMOD
26	difficult	difficult	B-NP	JJ	O	28	NMOD
27	pain	pain	I-NP	NN	O	28	NMOD
28	syndromes	syndrome	I-NP	NNS	O	25	PMOD
29	,	,	O	,	O	28	P
30	such	such	B-PP	JJ	O	31	PMOD
31	as	as	I-PP	IN	O	28	NMOD
32	neuropathic	neuropathic	B-NP	JJ	B-protein	33	NMOD
33	pain	pain	I-NP	NN	I-protein	31	PMOD
34	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	3	NMOD
2	slow	slow	I-NP	JJ	O	3	NMOD
3	bolus	bolus	I-NP	NN	O	16	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	subhypnotic	subhypnotic	B-NP	JJ	O	6	NMOD
6	doses	dose	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	ketamine	ketamine	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	15	DEP
10	0.25	0.25	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	14	NMOD
12	or	or	O	CC	O	14	NMOD
13	0.50	0.50	B-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	15	DEP
15	)	)	O	)	O	8	NMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	given	give	I-VP	VBN	O	16	VC
18	to	to	B-PP	TO	O	17	VMOD
19	10	10	B-NP	CD	O	21	NMOD
20	cancer	cancer	I-NP	NN	O	21	NMOD
21	patients	patient	I-NP	NNS	O	18	PMOD
22	whose	whose	B-NP	WP$	O	23	NMOD
23	pain	pain	I-NP	NN	O	21	NMOD
24	was	be	B-VP	VBD	O	23	SBAR
25	unrelieved	unrelieved	B-ADJP	JJ	O	24	PRD
26	by	by	B-PP	IN	O	25	AMOD
27	morphine	morphine	B-NP	NN	O	26	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	a	a	B-NP	DT	O	37	NMOD
30	randomized	randomize	I-NP	VBN	O	36	AMOD
31	,	,	I-NP	,	O	36	P
32	double-blind	double-blind	I-NP	JJ	O	36	AMOD
33	,	,	I-NP	,	O	36	P
34	crossover	crossover	I-NP	JJ	O	36	AMOD
35	,	,	I-NP	,	O	36	P
36	double-dose	double-dose	I-NP	JJ	O	37	NMOD
37	study	study	I-NP	NN	O	28	PMOD
38	.	.	O	.	O	16	P

1	Ketamine	Ketamine	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	but	but	O	CC	O	6	NMOD
4	not	not	O	RB	O	3	DEP
5	saline	saline	B-NP	NN	O	6	NMOD
6	solution	solution	I-NP	NN	O	9	SUB
7	,	,	O	,	O	6	P
8	significantly	significantly	B-VP	RB	O	9	VMOD
9	reduced	reduce	I-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	12	NMOD
11	pain	pain	I-NP	NN	O	12	NMOD
12	intensity	intensity	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	almost	almost	B-NP	RB	O	17	NMOD
15	all	all	I-NP	PDT	O	14	AMOD
16	the	the	I-NP	DT	O	17	NMOD
17	patients	patient	I-NP	NNS	O	13	PMOD
18	at	at	B-PP	IN	O	17	NMOD
19	both	both	B-NP	DT	O	20	NMOD
20	doses	dose	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	9	P

1	Ketamine	Ketamine	B-NP	NN	O	2	SUB
2	can	can	B-VP	MD	O	0	ROOT
3	improve	improve	I-VP	VB	O	2	VC
4	morphine	morphine	B-NP	NN	O	5	NMOD
5	analgesia	analgesia	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	difficult	difficult	B-NP	JJ	O	9	NMOD
8	pain	pain	I-NP	NN	O	9	NMOD
9	syndromes	syndrome	I-NP	NNS	O	6	PMOD
10	,	,	O	,	O	9	P
11	such	such	B-PP	JJ	O	12	PMOD
12	as	as	I-PP	IN	O	9	NMOD
13	neuropathic	neuropathic	B-NP	JJ	B-protein	14	NMOD
14	pain	pain	I-NP	NN	I-protein	12	PMOD
15	.	.	O	.	O	2	P

1	PURPOSE	PURPOSE	B-NP	NN	O	4	VMOD
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	reviewed	review	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	results	result	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	serum	serum	B-NP	NN	O	9	NMOD
9	testosterone	testosterone	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	prolactin	prolactin	B-NP	NN	O	12	NMOD
12	determination	determination	I-NP	NN	O	7	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	1	1	B-NP	CD	O	17	NMOD
15	,	,	O	,	O	17	P
16	022	022	B-NP	CD	O	17	NMOD
17	patients	patient	I-NP	NNS	O	13	PMOD
18	referred	refer	B-VP	VBD	O	4	VMOD
19	because	because	B-PP	IN	O	18	VMOD
20	of	of	I-PP	IN	O	19	PMOD
21	erectile	erectile	B-NP	JJ	O	22	NMOD
22	dysfunction	dysfunction	I-NP	NN	O	20	PMOD
23	and	and	O	CC	O	4	VMOD
24	compared	compare	B-VP	VBD	O	4	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	data	datum	I-NP	NNS	O	24	OBJ
27	with	with	B-PP	IN	O	26	NMOD
28	history	history	B-NP	NN	O	27	PMOD
29	,	,	O	,	O	4	P
30	results	result	B-NP	NNS	O	44	SUB
31	of	of	B-PP	IN	O	30	NMOD
32	physical	physical	B-NP	JJ	O	33	NMOD
33	examination	examination	I-NP	NN	O	37	NMOD
34	,	,	O	,	O	37	P
35	other	other	B-NP	JJ	O	37	NMOD
36	etiological	etiological	I-NP	JJ	O	37	NMOD
37	investigations	investigation	I-NP	NNS	O	39	NMOD
38	and	and	I-NP	CC	O	39	NMOD
39	effects	effect	I-NP	NNS	O	31	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	endocrine	endocrine	B-NP	JJ	O	42	NMOD
42	therapy	therapy	I-NP	NN	O	40	PMOD
43	to	to	B-VP	TO	O	44	VMOD
44	refine	refine	I-VP	VB	O	4	VMOD
45	the	the	B-NP	DT	O	46	NMOD
46	rules	rule	I-NP	NNS	O	44	OBJ
47	of	of	B-PP	IN	O	46	NMOD
48	cost-effective	cost-effective	B-NP	JJ	O	50	NMOD
49	endocrine	endocrine	I-NP	JJ	O	50	NMOD
50	screening	screening	I-NP	NN	O	47	PMOD
51	and	and	O	CC	O	44	VMOD
52	to	to	B-VP	TO	O	53	VMOD
53	pinpoint	pinpoint	I-VP	VB	O	44	VMOD
54	actual	actual	B-NP	JJ	O	55	NMOD
55	responsibility	responsibility	I-NP	NN	O	53	OBJ
56	for	for	B-PP	IN	O	55	NMOD
57	hormonal	hormonal	B-NP	JJ	O	58	NMOD
58	abnormalities	abnormality	I-NP	NNS	O	56	PMOD
59	.	.	O	.	O	4	P

1	Every	Every	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	screened	screen	I-VP	VBN	O	3	VC
5	for	for	B-PP	IN	O	4	VMOD
6	testosterone	testosterone	B-NP	NN	O	8	NMOD
7	and	and	O	CC	O	8	NMOD
8	451	451	B-NP	CD	O	5	PMOD
9	were	be	B-VP	VBD	O	3	VMOD
10	screened	screen	I-VP	VBN	O	9	VC
11	for	for	B-PP	IN	O	10	VMOD
12	prolactin	prolactin	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	10	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	basis	basis	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	low	low	B-NP	JJ	O	19	NMOD
18	sexual	sexual	I-NP	JJ	O	19	NMOD
19	desire	desire	I-NP	NN	O	23	NMOD
20	,	,	O	,	O	23	P
21	gynecomastia	gynecomastia	B-NP	NN	O	23	NMOD
22	or	or	O	CC	O	23	NMOD
23	testosterone	testosterone	B-NP	NN	O	16	PMOD
24	less	less	B-NP	JJR	O	25	AMOD
25	than	than	I-NP	IN	O	27	NMOD
26	4	4	I-NP	CD	O	25	AMOD
27	ng./ml	ng./ml	I-NP	NN	O	13	PMOD
28	.	.	O	.	O	3	P

1	Endocrine	Endocrine	B-NP	JJ	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	3	SUB
3	consisted	consist	B-VP	VBD	O	0	ROOT
4	of	of	B-PP	IN	O	3	VMOD
5	testosterone	testosterone	B-NP	NN	O	6	NMOD
6	heptylate	heptylate	I-NP	NN	O	10	NMOD
7	or	or	O	CC	O	10	NMOD
8	human	human	B-NP	JJ	O	10	NMOD
9	chorionic	chorionic	I-NP	JJ	O	10	NMOD
10	gonadotropin	gonadotropin	I-NP	NN	O	4	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	hypogonadism	hypogonadism	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	bromocriptine	bromocriptine	I-NP	NN	O	11	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	3	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	pituitary	pituitary	I-NP	JJ	O	3	NMOD
3	tumors	tumor	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	discovered	discover	I-VP	VBN	O	4	VC
6	after	after	B-PP	IN	O	5	VMOD
7	testosterone	testosterone	B-NP	NN	O	8	NMOD
8	determination	determination	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	4	P

1	Most	Most	B-NP	JJS	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	7	NMOD
4	other	other	I-NP	JJ	O	7	NMOD
5	low	low	I-NP	JJ	O	7	NMOD
6	testosterone	testosterone	I-NP	NN	O	7	NMOD
7	levels	level	I-NP	NNS	O	2	PMOD
8	seemed	seem	B-VP	VBD	O	0	ROOT
9	to	to	I-VP	TO	O	10	VMOD
10	result	result	I-VP	VB	O	8	VMOD
11	from	from	B-PP	IN	O	10	VMOD
12	nonorganic	nonorganic	B-NP	JJ	O	14	NMOD
13	hypothalamic	hypothalamic	I-NP	JJ	O	14	NMOD
14	dysfunction	dysfunction	I-NP	NN	O	11	PMOD
15	because	because	B-PP	IN	O	10	VMOD
16	of	of	I-PP	IN	O	15	PMOD
17	normal	normal	B-NP	JJ	O	18	NMOD
18	serum	serum	I-NP	NN	O	16	PMOD
19	luteinizing	luteinize	B-VP	VBG	O	18	NMOD
20	hormone	hormone	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	prolactin	prolactin	I-NP	NN	O	19	OBJ
23	and	and	O	CC	O	10	VMOD
24	to	to	B-VP	TO	O	25	VMOD
25	have	have	I-VP	VB	O	10	VMOD
26	only	only	B-NP	RB	O	29	NMOD
27	a	a	I-NP	DT	O	29	NMOD
28	small	small	I-NP	JJ	O	29	NMOD
29	role	role	I-NP	NN	O	25	OBJ
30	in	in	B-PP	IN	O	25	VMOD
31	erectile	erectile	B-NP	JJ	O	32	NMOD
32	dysfunction	dysfunction	I-NP	NN	O	30	PMOD
33	(	(	O	(	O	44	DEP
34	definite	definite	B-NP	JJ	O	35	NMOD
35	improvement	improvement	I-NP	NN	O	44	DEP
36	in	in	B-PP	IN	O	35	NMOD
37	only	only	B-NP	RB	O	38	NMOD
38	16	16	I-NP	CD	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	44	44	B-NP	CD	O	39	PMOD
41	[	[	O	(	O	44	DEP
42	36	36	B-NP	CD	O	43	NMOD
43	%	%	I-NP	NN	O	44	DEP
44	]	]	O	)	O	32	NMOD
45	after	after	B-PP	IN	O	32	NMOD
46	androgen	androgen	B-NP	NN	O	47	NMOD
47	therapy	therapy	I-NP	NN	O	45	PMOD
48	,	,	O	,	O	10	P
49	normal	normal	B-NP	JJ	O	50	NMOD
50	morning	morning	I-NP	NN	O	53	NMOD
51	or	or	O	CC	O	53	NMOD
52	nocturnal	nocturnal	B-NP	JJ	O	53	NMOD
53	erections	erection	I-NP	NNS	O	10	VMOD
54	in	in	B-PP	IN	O	53	NMOD
55	30	30	B-NP	CD	O	60	NMOD
56	%	%	I-NP	NN	O	60	NMOD
57	and	and	I-NP	CC	O	60	NMOD
58	definite	definite	I-NP	JJ	O	60	NMOD
59	vasculogenic	vasculogenic	I-NP	JJ	O	60	NMOD
60	contributions	contribution	I-NP	NNS	O	54	PMOD
61	in	in	B-PP	IN	O	60	NMOD
62	42	42	B-NP	CD	O	63	NMOD
63	%	%	I-NP	NN	O	61	PMOD
64	)	)	O	)	O	53	NMOD
65	.	.	O	.	O	8	P

1	Determining	Determine	B-VP	VBG	O	2	NMOD
2	testosterone	testosterone	B-NP	NN	O	14	SUB
3	only	only	B-ADVP	RB	O	4	PMOD
4	in	in	B-PP	IN	O	2	NMOD
5	cases	case	B-NP	NNS	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	low	low	B-NP	JJ	O	9	NMOD
8	sexual	sexual	I-NP	JJ	O	9	NMOD
9	desire	desire	I-NP	NN	O	13	NMOD
10	or	or	O	CC	O	13	NMOD
11	abnormal	abnormal	B-NP	JJ	O	12	AMOD
12	physical	physical	I-NP	JJ	O	13	NMOD
13	examination	examination	I-NP	NN	O	6	PMOD
14	would	would	B-VP	MD	O	0	ROOT
15	have	have	I-VP	VB	O	14	VC
16	missed	miss	I-VP	VBN	O	15	VC
17	40	40	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	cases	case	I-NP	NNS	O	19	PMOD
22	with	with	B-PP	IN	O	18	NMOD
23	low	low	B-NP	JJ	O	24	NMOD
24	testosterone	testosterone	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	18	P
26	including	include	B-PP	VBG	O	18	NMOD
27	37	37	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	those	those	B-NP	DT	O	29	PMOD
31	subsequently	subsequently	B-VP	RB	O	32	VMOD
32	improved	improve	I-VP	VBN	O	30	NMOD
33	by	by	B-PP	IN	O	32	VMOD
34	androgen	androgen	B-NP	NN	O	35	NMOD
35	therapy	therapy	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	14	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	16	SUB
2	:	:	O	:	O	1	P
3	Low	Low	B-NP	JJ	O	4	NMOD
4	prevalences	prevalence	I-NP	NNS	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	effects	effect	I-NP	NNS	O	16	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	low	low	B-NP	JJ	O	9	NMOD
9	testosterone	testosterone	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	high	high	B-NP	JJ	O	12	NMOD
12	prolactin	prolactin	I-NP	NN	O	7	PMOD
13	in	in	B-PP	IN	O	6	NMOD
14	erectile	erectile	B-NP	JJ	O	15	NMOD
15	dysfunction	dysfunction	I-NP	NN	O	13	PMOD
16	can	can	B-VP	MD	O	0	ROOT
17	not	not	I-VP	RB	O	16	VMOD
18	justify	justify	I-VP	VB	O	16	VC
19	their	their	B-NP	PRP$	O	21	NMOD
20	routine	routine	I-NP	JJ	O	21	NMOD
21	determination	determination	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	16	P

1	We	We	B-NP	PRP	O	3	SUB
2	now	now	B-ADVP	RB	O	3	VMOD
3	advocate	advocate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	24	DEP
5	before	before	B-PP	IN	O	4	SBAR
6	age	age	B-NP	NN	O	9	NMOD
7	50	50	B-NP	CD	O	9	NMOD
8	years	year	I-NP	NNS	O	9	NMOD
9	testosterone	testosterone	I-NP	NN	O	5	PMOD
10	be	be	B-VP	VB	O	5	SBAR
11	determined	determine	I-VP	VBN	O	10	VC
12	only	only	B-ADVP	RB	O	13	PMOD
13	in	in	B-PP	IN	O	11	VMOD
14	cases	case	B-NP	NNS	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	low	low	B-NP	JJ	O	18	NMOD
17	sexual	sexual	I-NP	JJ	O	18	NMOD
18	desire	desire	I-NP	NN	O	22	NMOD
19	and	and	O	CC	O	22	NMOD
20	abnormal	abnormal	B-NP	JJ	O	22	NMOD
21	physical	physical	I-NP	JJ	O	22	NMOD
22	examination	examination	I-NP	NN	O	15	PMOD
23	but	but	O	CC	O	24	DEP
24	that	that	B-SBAR	IN	O	3	VMOD
25	it	it	B-NP	PRP	O	26	SUB
26	be	be	B-VP	VB	O	24	SBAR
27	measured	measure	I-VP	VBN	O	26	VC
28	in	in	B-PP	IN	O	27	VMOD
29	all	all	B-NP	DT	O	30	NMOD
30	men	man	I-NP	NNS	O	28	PMOD
31	older	old	B-ADJP	JJR	O	30	NMOD
32	than	than	B-PP	IN	O	31	AMOD
33	50	50	B-NP	CD	O	34	NMOD
34	years	year	I-NP	NNS	O	32	PMOD
35	.	.	O	.	O	3	P

1	Thiopentone	Thiopentone	B-NP	NN	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	0	ROOT
3	for	for	B-PP	IN	O	2	NMOD
4	propofol	propofol	B-NP	NN	B-protein	6	NMOD
5	injection	injection	I-NP	NN	I-protein	6	NMOD
6	pain	pain	I-NP	NN	I-protein	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	ambulatory	ambulatory	B-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	investigated	investigate	B-VP	VBD	O	0	ROOT
4	propofol	propofol	B-NP	NN	O	6	NMOD
5	injection	injection	I-NP	NN	O	6	NMOD
6	pain	pain	I-NP	NN	O	3	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	undergoing	undergo	B-VP	VBG	O	8	NMOD
10	ambulatory	ambulatory	B-NP	JJ	O	11	NMOD
11	anaesthesia	anaesthesia	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	3	P

1	Comparison	Comparison	B-NP	NN	O	6	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	i.v.	i.v.	B-NP	JJ	O	4	NMOD
4	glycopyrrolate	glycopyrrolate	I-NP	NN	O	2	PMOD
5	and	and	I-NP	CC	O	6	NMOD
6	atropine	atropine	I-NP	NN	O	0	ROOT
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	prevention	prevention	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	bradycardia	bradycardia	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	arrhythmias	arrhythmia	I-NP	NNS	O	10	PMOD
14	following	follow	B-PP	VBG	O	6	NMOD
15	repeated	repeat	B-NP	VBN	O	16	NMOD
16	doses	dose	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	suxamethonium	suxamethonium	B-NP	NN	O	17	PMOD
19	in	in	B-PP	IN	O	16	NMOD
20	children	child	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	effectiveness	effectiveness	I-NP	NN	O	40	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	administration	administration	B-NP	NN	O	10	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	glycopyrrolate	glycopyrrolate	B-NP	NN	B-protein	5	PMOD
7	5	5	I-NP	CD	I-protein	6	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	10	10	I-NP	CD	O	10	NMOD
10	micrograms	microgram	I-NP	NNS	O	17	NMOD
11	kg-1	kg-1	I-NP	NN	O	17	NMOD
12	and	and	I-NP	CC	O	17	NMOD
13	atropine	atropine	I-NP	NN	O	17	NMOD
14	10	10	I-NP	CD	O	13	NMOD
15	and	and	I-NP	CC	O	17	NMOD
16	20	20	I-NP	CD	O	17	NMOD
17	micrograms	microgram	I-NP	NNS	O	18	NMOD
18	kg-1	kg-1	I-NP	NN	O	3	PMOD
19	i.v.	i.v.	B-ADVP	RB	O	28	VMOD
20	immediately	immediately	I-ADVP	RB	O	19	AMOD
21	before	before	B-SBAR	IN	O	19	AMOD
22	the	the	B-NP	DT	O	23	NMOD
23	induction	induction	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	anaesthesia	anaesthesia	B-NP	NN	O	24	PMOD
26	,	,	O	,	O	19	P
27	to	to	B-VP	TO	O	28	VMOD
28	prevent	prevent	I-VP	VB	O	2	NMOD
29	arrhythmia	arrhythmia	B-NP	NN	O	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	bradycardia	bradycardia	I-NP	NN	O	28	OBJ
32	following	follow	B-PP	VBG	O	28	VMOD
33	repeated	repeated	B-NP	JJ	O	34	NMOD
34	doses	dose	I-NP	NNS	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	suxamethonium	suxamethonium	B-NP	NN	O	35	PMOD
37	in	in	B-PP	IN	O	34	NMOD
38	children	child	B-NP	NNS	O	37	PMOD
39	,	,	O	,	O	2	P
40	was	be	B-VP	VBD	O	0	ROOT
41	studied	study	I-VP	VBN	O	40	VC
42	.	.	O	.	O	40	P

1	Reduction	Reduction	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	caffeine	caffeine	B-NP	NN	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	2	PMOD
5	by	by	B-PP	IN	O	1	NMOD
6	acetaminophen	acetaminophen	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	1	P

1	Because	Because	B-SBAR	IN	O	18	VMOD
2	salicylates	salicylate	B-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	1	SBAR
4	been	be	I-VP	VBN	O	3	VC
5	reported	report	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	augment	augment	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	stimulatory	stimulatory	I-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	caffeine	caffeine	B-NP	NN	O	11	PMOD
13	on	on	B-PP	IN	O	7	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	CNS	CNS	I-NP	NN	B-protein	13	PMOD
16	,	,	O	,	O	18	P
17	attention	attention	B-NP	NN	O	18	SUB
18	was	be	B-VP	VBD	O	0	ROOT
19	focused	focus	I-VP	VBN	O	18	VC
20	on	on	B-PP	IN	O	19	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	possibility	possibility	I-NP	NN	O	20	PMOD
23	that	that	B-SBAR	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	presence	presence	I-NP	NN	O	32	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	acetaminophen	acetaminophen	B-NP	NN	O	26	PMOD
28	(	(	O	(	O	31	DEP
29	52	52	B-NP	CD	O	30	NMOD
30	micrograms/mL	micrograms/mL	I-NP	NN	O	31	DEP
31	)	)	O	)	O	27	NMOD
32	reduced	reduce	B-VP	VBD	O	23	SBAR
33	the	the	B-NP	DT	O	35	NMOD
34	CNS	CNS	I-NP	NN	O	35	NMOD
35	toxicity	toxicity	I-NP	NN	O	32	OBJ
36	of	of	B-PP	IN	O	35	NMOD
37	caffeine	caffeine	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	18	P

1	Studies	Study	B-NP	NNS	O	5	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	DBA/2J	DBA/2J	B-NP	NN	O	4	NMOD
4	mice	mouse	I-NP	NNS	O	2	PMOD
5	showed	show	B-VP	VBD	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	:	:	O	:	O	6	P
8	1	1	B-LST	LS	O	17	VMOD
9	)	)	O	)	O	8	DEP
10	pretreatment	pretreatment	B-NP	NN	O	17	SUB
11	with	with	B-PP	IN	O	10	NMOD
12	acetaminophen	acetaminophen	B-NP	NN	O	11	PMOD
13	(	(	O	(	O	16	DEP
14	100	100	B-NP	CD	O	15	NMOD
15	mg/kg	mg/kg	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	increased	increase	B-VP	VBD	O	6	SBAR
18	the	the	B-NP	DT	O	19	NMOD
19	interval	interval	I-NP	NN	O	17	OBJ
20	between	between	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	administration	administration	I-NP	NN	O	34	NMOD
23	of	of	B-PP	IN	O	22	NMOD
24	caffeine	caffeine	B-NP	NN	O	23	PMOD
25	(	(	O	(	O	31	DEP
26	300	300	B-NP	CD	O	28	AMOD
27	to	to	I-NP	TO	O	28	AMOD
28	450	450	I-NP	CD	O	30	NMOD
29	mg/kg	mg/kg	I-NP	NN	O	30	NMOD
30	IP	IP	I-NP	NN	O	31	DEP
31	)	)	O	)	O	22	NMOD
32	and	and	O	CC	O	34	NMOD
33	the	the	B-NP	DT	O	34	NMOD
34	onset	onset	I-NP	NN	O	20	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	fatal	fatal	B-NP	JJ	O	37	NMOD
37	convulsions	convulsion	I-NP	NNS	O	35	PMOD
38	by	by	B-PP	IN	O	17	VMOD
39	a	a	B-NP	DT	O	40	NMOD
40	factor	factor	I-NP	NN	O	38	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	about	about	B-NP	IN	O	46	NMOD
43	two	two	I-NP	CD	O	42	AMOD
44	;	;	O	:	O	42	P
45	and	and	O	CC	O	42	AMOD
46	2	2	B-LST	LS	O	48	NMOD
47	)	)	O	)	O	46	DEP
48	pretreatment	pretreatment	B-NP	NN	O	41	PMOD
49	with	with	B-PP	IN	O	48	NMOD
50	acetaminophen	acetaminophen	B-NP	NN	O	49	PMOD
51	(	(	O	(	O	54	DEP
52	75	75	B-NP	CD	O	53	NMOD
53	mg/kg	mg/kg	I-NP	NN	O	54	DEP
54	)	)	O	)	O	50	NMOD
55	reduced	reduce	B-VP	VBD	O	17	VMOD
56	the	the	B-NP	DT	O	57	NMOD
57	incidence	incidence	I-NP	NN	O	55	OBJ
58	of	of	B-PP	IN	O	57	NMOD
59	audiogenic	audiogenic	B-NP	JJ	O	60	NMOD
60	seizures	seizure	I-NP	NNS	O	58	PMOD
61	produced	produce	B-VP	VBN	O	60	NMOD
62	in	in	B-PP	IN	O	61	VMOD
63	the	the	B-NP	DT	O	64	NMOD
64	presence	presence	I-NP	NN	O	62	PMOD
65	of	of	B-PP	IN	O	64	NMOD
66	caffeine	caffeine	B-NP	NN	O	65	PMOD
67	(	(	O	(	O	73	DEP
68	12.5	12.5	B-NP	CD	O	70	AMOD
69	to	to	I-NP	TO	O	70	AMOD
70	75	75	I-NP	CD	O	72	NMOD
71	mg/kg	mg/kg	I-NP	NN	O	72	NMOD
72	IP	IP	I-NP	NN	O	73	DEP
73	)	)	O	)	O	66	NMOD
74	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	frequency	frequency	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	sound	sound	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	seizures	seizure	I-NP	NNS	O	3	PMOD
7	after	after	B-PP	IN	O	2	NMOD
8	12.5	12.5	B-NP	CD	O	10	AMOD
9	or	or	I-NP	CC	O	10	AMOD
10	25	25	I-NP	CD	O	12	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	12	NMOD
12	caffeine	caffeine	I-NP	NN	O	7	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	reduced	reduce	I-VP	VBN	O	13	VC
15	from	from	B-PP	IN	O	14	VMOD
16	50	50	B-NP	CD	O	18	AMOD
17	to	to	I-NP	TO	O	18	AMOD
18	5	5	I-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	15	PMOD
20	by	by	B-PP	IN	O	14	VMOD
21	acetaminophen	acetaminophen	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	13	P

1	In	In	B-PP	IN	O	24	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	absence	absence	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	caffeine	caffeine	B-NP	NN	O	14	SUB
6	,	,	O	,	O	14	P
7	acetaminophen	acetaminophen	B-NP	NN	O	14	SUB
8	(	(	O	(	O	13	DEP
9	up	up	B-NP	RB	O	12	NMOD
10	to	to	I-NP	TO	O	9	AMOD
11	300	300	I-NP	CD	O	9	AMOD
12	mg/kg	mg/kg	I-NP	NN	O	13	DEP
13	)	)	O	)	O	7	NMOD
14	did	do	B-VP	VBD	O	4	SBAR
15	not	not	I-VP	RB	O	14	VMOD
16	modify	modify	I-VP	VB	O	14	VC
17	the	the	B-NP	DT	O	18	NMOD
18	seizures	seizure	I-NP	NNS	O	16	OBJ
19	induced	induce	B-VP	VBN	O	18	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	maximal	maximal	B-NP	JJ	O	22	NMOD
22	electroshock	electroshock	I-NP	NN	O	20	PMOD
23	and	and	O	CC	O	1	VMOD
24	did	do	B-VP	VBD	O	0	ROOT
25	not	not	I-VP	RB	O	24	VMOD
26	alter	alter	I-VP	VB	O	24	VC
27	the	the	B-NP	DT	O	29	NMOD
28	convulsant	convulsant	I-NP	JJ	O	29	NMOD
29	dose	dose	I-NP	NN	O	26	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	pentylenetetrezol	pentylenetetrezol	B-NP	NN	O	30	PMOD
32	in	in	B-PP	IN	O	26	VMOD
33	mice	mouse	B-NP	NNS	O	32	PMOD
34	(	(	O	(	O	44	DEP
35	tests	test	B-NP	NNS	O	44	DEP
36	performed	perform	B-VP	VBN	O	35	NMOD
37	by	by	B-PP	IN	O	36	VMOD
38	the	the	B-NP	DT	O	41	NMOD
39	Anticonvulsant	Anticonvulsant	I-NP	NNP	O	41	NMOD
40	Screening	Screening	I-NP	NNP	O	41	NMOD
41	Project	Project	I-NP	NNP	O	37	PMOD
42	of	of	B-PP	IN	O	41	NMOD
43	NINCDS	NINCDS	B-NP	NN	O	42	PMOD
44	)	)	O	)	O	33	NMOD
45	.	.	O	.	O	24	P

1	Flestolol	Flestolol	B-NP	NN	O	2	SUB
2	produced	produce	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	dose-dependent	dose-dependent	I-NP	JJ	O	5	NMOD
5	attenuation	attenuation	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	isoproterenol	isoproterenol	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	tachycardia	tachycardia	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	2	P

1	Flestolol	Flestolol	B-NP	NN	O	3	SUB
2	effectively	effectively	B-ADVP	RB	O	3	VMOD
3	reduced	reduce	B-VP	VBD	O	0	ROOT
4	heart	heart	B-NP	NN	O	5	NMOD
5	rate	rate	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	supraventricular	supraventricular	B-NP	JJ	O	10	NMOD
10	tachyarrhythmia	tachyarrhythmia	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	9	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	unstable	unstable	B-NP	JJ	O	5	NMOD
5	angina	angina	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	9	P
7	flestolol	flestolol	B-NP	NN	O	8	NMOD
8	infusion	infusion	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	0	ROOT
10	found	find	I-VP	VBN	O	9	VC
11	to	to	I-VP	TO	O	12	VMOD
12	be	be	I-VP	VB	O	10	VMOD
13	safe	safe	B-ADJP	JJ	O	15	AMOD
14	and	and	I-ADJP	CC	O	15	AMOD
15	effective	effective	I-ADJP	JJ	O	12	PRD
16	in	in	B-PP	IN	O	15	AMOD
17	controlling	control	B-VP	VBG	O	16	PMOD
18	chest	chest	B-NP	NN	O	19	NMOD
19	pain	pain	I-NP	NN	O	17	OBJ
20	.	.	O	.	O	9	P

1	Adverse	Adverse	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	8	NMOD
5	calcium	calcium	I-NP	NN	O	8	NMOD
6	channel	channel	I-NP	NN	O	8	NMOD
7	blocker	blocker	I-NP	NN	O	8	NMOD
8	nitrendipine	nitrendipine	I-NP	NN	O	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	nephrosclerosis	nephrosclerosis	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	2	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	2	NMOD
14	renovascular	renovascular	B-NP	JJ	O	15	NMOD
15	hypertension	hypertension	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	35	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	6-week	6-week	I-NP	JJ	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	3	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	12	NMOD
9	calcium	calcium	I-NP	NN	O	12	NMOD
10	channel	channel	I-NP	NN	O	12	NMOD
11	blocker	blocker	I-NP	NN	O	12	NMOD
12	nitrendipine	nitrendipine	I-NP	NN	O	15	NMOD
13	or	or	O	CC	O	15	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	angiotensin	angiotensin	I-NP	NN	O	7	PMOD
16	converting	convert	B-VP	VBG	O	15	NMOD
17	enzyme	enzyme	B-NP	NN	O	19	NMOD
18	inhibitor	inhibitor	I-NP	NN	O	19	NMOD
19	enalapril	enalapril	I-NP	NN	O	16	OBJ
20	on	on	B-PP	IN	O	19	NMOD
21	blood	blood	B-NP	NN	O	22	NMOD
22	pressure	pressure	I-NP	NN	O	30	NMOD
23	,	,	O	,	O	30	P
24	albuminuria	albuminuria	B-NP	NN	O	30	NMOD
25	,	,	O	,	O	30	P
26	renal	renal	B-NP	JJ	O	27	NMOD
27	hemodynamics	hemodynamic	I-NP	NNS	O	30	NMOD
28	,	,	O	,	O	30	P
29	and	and	O	CC	O	30	NMOD
30	morphology	morphology	B-NP	NN	O	20	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	the	the	B-NP	DT	O	34	NMOD
33	nonclipped	nonclipped	I-NP	JJ	O	34	NMOD
34	kidney	kidney	I-NP	NN	O	31	PMOD
35	was	be	B-VP	VBD	O	0	ROOT
36	studied	study	I-VP	VBN	O	35	VC
37	in	in	B-PP	IN	O	36	VMOD
38	rats	rat	B-NP	NNS	O	37	PMOD
39	with	with	B-PP	IN	O	38	NMOD
40	two-kidney	two-kidney	B-NP	NN	O	45	NMOD
41	,	,	O	,	O	45	P
42	one	one	B-NP	CD	O	45	NMOD
43	clip	clip	I-NP	NN	O	45	NMOD
44	renovascular	renovascular	I-NP	JJ	O	45	NMOD
45	hypertension	hypertension	I-NP	NN	O	39	PMOD
46	.	.	O	.	O	35	P

1	Six	Six	B-NP	CD	O	2	NMOD
2	weeks	week	I-NP	NNS	O	19	SUB
3	after	after	B-PP	IN	O	2	NMOD
4	clipping	clip	B-VP	VBG	O	3	PMOD
5	of	of	B-PP	IN	O	4	VMOD
6	one	one	B-NP	CD	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	artery	artery	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	19	P
10	hypertensive	hypertensive	B-NP	JJ	O	11	NMOD
11	rats	rat	I-NP	NNS	O	19	SUB
12	(	(	O	(	O	18	DEP
13	178	178	B-NP	CD	O	15	AMOD
14	+/-	+/-	I-NP	SYM	O	15	AMOD
15	4	4	I-NP	CD	O	17	NMOD
16	mm	mm	I-NP	NN	O	17	NMOD
17	Hg	Hg	I-NP	NN	O	18	DEP
18	)	)	O	)	O	11	NMOD
19	were	be	B-VP	VBD	O	0	ROOT
20	randomly	randomly	I-VP	RB	O	19	VMOD
21	assigned	assign	I-VP	VBN	O	19	VC
22	to	to	B-PP	TO	O	21	VMOD
23	three	three	B-NP	CD	O	24	NMOD
24	groups	group	I-NP	NNS	O	22	PMOD
25	:	:	O	:	O	19	P
26	untreated	untreated	B-NP	JJ	O	28	NMOD
27	hypertensive	hypertensive	I-NP	JJ	O	28	NMOD
28	controls	control	I-NP	NNS	O	19	VMOD
29	(	(	O	(	O	33	DEP
30	n	n	B-NP	NN	O	32	SUB
31	=	=	B-VP	SYM	O	32	VMOD
32	8	8	B-NP	CD	O	33	DEP
33	)	)	O	)	O	28	NMOD
34	,	,	O	,	O	28	P
35	enalapril-treated	enalapril-treated	B-ADJP	JJ	O	28	NMOD
36	(	(	O	(	O	40	DEP
37	n	n	B-NP	NN	O	39	SUB
38	=	=	B-VP	SYM	O	39	VMOD
39	8	8	B-NP	CD	O	40	DEP
40	)	)	O	)	O	35	AMOD
41	,	,	O	,	O	48	P
42	or	or	O	CC	O	48	DEP
43	nitrendipine-treated	nitrendipine-treated	O	JJ	O	48	DEP
44	(	(	O	(	O	48	DEP
45	n	n	B-NP	NN	O	48	DEP
46	=	=	B-VP	SYM	O	45	NMOD
47	10	10	B-NP	CD	O	46	AMOD
48	)	)	O	)	O	28	NMOD
49	.	.	O	.	O	19	P

1	Renal	Renal	B-NP	JJ	O	3	NMOD
2	plasma	plasma	I-NP	NN	O	3	NMOD
3	flow	flow	I-NP	NN	O	4	SUB
4	increased	increase	B-VP	VBD	O	11	VMOD
5	,	,	O	,	O	11	P
6	but	but	O	CC	O	11	VMOD
7	albumin	albumin	B-NP	NN	O	8	NMOD
8	excretion	excretion	I-NP	NN	O	10	NMOD
9	and	and	O	CC	O	10	NMOD
10	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	11	SUB
11	did	do	B-VP	VBD	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	change	change	I-VP	VB	O	11	VC
14	after	after	B-PP	IN	O	13	VMOD
15	enalapril	enalapril	B-NP	NN	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	9	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	9	P
4	in	in	B-PP	IN	O	9	SUB
5	the	the	B-NP	DT	O	8	NMOD
6	nitrendipine-treated	nitrendipine-treated	I-NP	JJ	O	8	NMOD
7	group	group	I-NP	NN	O	8	NMOD
8	albuminuria	albuminuria	I-NP	NN	O	4	PMOD
9	increased	increase	B-VP	VBD	O	0	ROOT
10	from	from	B-PP	IN	O	9	VMOD
11	12.8	12.8	B-NP	CD	O	13	AMOD
12	+/-	+/-	I-NP	SYM	O	13	AMOD
13	2	2	I-NP	CD	O	10	PMOD
14	progressively	progressively	B-ADVP	RB	O	9	VMOD
15	to	to	B-PP	TO	O	14	PMOD
16	163	163	B-NP	CD	O	18	AMOD
17	+/-	+/-	I-NP	CC	O	18	AMOD
18	55	55	I-NP	CD	O	15	PMOD
19	compared	compare	B-PP	VBN	O	9	VMOD
20	with	with	B-PP	IN	O	19	PMOD
21	19.2	19.2	B-NP	CD	O	23	AMOD
22	+/-	+/-	I-NP	SYM	O	23	AMOD
23	9	9	I-NP	CD	O	25	NMOD
24	mg/24	mg/24	I-NP	NN	O	25	NMOD
25	hr	hr	I-NP	NN	O	20	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	hypertensive	hypertensive	I-NP	JJ	O	29	NMOD
29	controls	control	I-NP	NNS	O	26	PMOD
30	.	.	O	.	O	9	P

1	Furthermore	Furthermore	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	4	NMOD
4	index	index	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	significantly	significantly	I-VP	RB	O	5	VMOD
7	increased	increase	I-VP	VBN	O	5	VC
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	nitrendipine-treated	nitrendipine-treated	I-NP	JJ	O	11	NMOD
11	group	group	I-NP	NN	O	8	PMOD
12	compared	compare	B-PP	VBN	O	7	VMOD
13	with	with	B-PP	IN	O	12	PMOD
14	the	the	B-NP	DT	O	16	NMOD
15	hypertensive	hypertensive	I-NP	JJ	O	16	NMOD
16	controls	control	I-NP	NNS	O	13	PMOD
17	(	(	O	(	O	25	DEP
18	0.38	0.38	B-NP	CD	O	20	NMOD
19	+/-	+/-	I-NP	SYM	O	20	NMOD
20	0.1	0.1	I-NP	CD	O	24	NMOD
21	versus	versus	B-PP	IN	O	24	NMOD
22	0.13	0.13	B-NP	CD	O	24	AMOD
23	+/-	+/-	I-NP	SYM	O	24	AMOD
24	0.04	0.04	I-NP	CD	O	25	DEP
25	)	)	O	)	O	16	NMOD
26	.	.	O	.	O	5	P

1	Treatment	Treatment	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	tinnitus	tinnitus	B-NP	NN	O	2	PMOD
4	by	by	B-PP	IN	O	1	NMOD
5	intratympanic	intratympanic	B-NP	JJ	O	6	NMOD
6	instillation	instillation	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	lignocaine	lignocaine	B-NP	NN	B-protein	7	PMOD
9	(	(	O	(	I-protein	11	DEP
10	lidocaine	lidocaine	B-NP	NN	I-protein	11	DEP
11	)	)	O	)	I-protein	8	NMOD
12	2	2	B-NP	CD	I-protein	8	NMOD
13	per	per	B-PP	IN	O	1	NMOD
14	cent	cent	B-NP	NN	O	13	PMOD
15	through	through	B-PP	IN	O	1	NMOD
16	ventilation	ventilation	B-NP	NN	O	17	NMOD
17	tubes	tube	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	NMOD
2	paper	paper	I-NP	NN	O	3	SUB
3	presents	present	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	results	result	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	treating	treat	B-VP	VBG	O	6	PMOD
8	IST	IST	B-NP	NN	O	7	OBJ
9	by	by	B-PP	IN	O	7	VMOD
10	intratympanic	intratympanic	B-NP	JJ	O	11	NMOD
11	instillation	instillation	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	lignocaine	lignocaine	B-NP	NN	B-protein	12	PMOD
14	(	(	O	(	I-protein	16	DEP
15	lidocaine	lidocaine	B-NP	NN	I-protein	16	DEP
16	)	)	O	)	I-protein	13	NMOD
17	2	2	B-NP	CD	I-protein	13	NMOD
18	per	per	B-PP	IN	O	7	VMOD
19	cent	cent	B-NP	NN	O	18	PMOD
20	through	through	B-PP	IN	O	7	VMOD
21	a	a	B-NP	DT	O	22	NMOD
22	grommet	grommet	I-NP	NN	O	20	PMOD
23	,	,	O	,	O	3	P
24	for	for	B-PP	IN	O	3	VMOD
25	five	five	B-NP	CD	O	27	NMOD
26	weekly	weekly	I-NP	JJ	O	27	NMOD
27	courses	course	I-NP	NNS	O	24	PMOD
28	.	.	O	.	O	3	P

1	Perhexiline	Perhexiline	B-NP	NN	O	2	NMOD
2	maleate	maleate	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	peripheral	peripheral	B-NP	JJ	O	5	NMOD
5	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
6	.	.	O	.	O	5	P

1	Peripheral	Peripheral	B-NP	JJ	O	2	NMOD
2	neuropathy	neuropathy	I-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	noted	note	I-VP	VBN	O	4	VC
6	as	as	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	complication	complication	I-NP	NN	O	16	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	therapy	therapy	B-NP	NN	O	9	PMOD
11	with	with	B-PP	IN	O	8	NMOD
12	perhexiline	perhexiline	B-NP	NN	O	13	NMOD
13	maleate	maleate	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	16	P
15	a	a	B-NP	DT	O	16	NMOD
16	drug	drug	I-NP	NN	O	6	PMOD
17	widely	widely	B-VP	RB	O	18	VMOD
18	used	use	I-VP	VBN	O	16	NMOD
19	in	in	B-PP	IN	O	18	VMOD
20	France	France	B-NP	NNP	O	19	PMOD
21	(	(	O	(	O	30	DEP
22	and	and	O	CC	O	30	DEP
23	in	in	B-PP	IN	O	30	DEP
24	clinical	clinical	B-NP	JJ	O	25	NMOD
25	trials	trial	I-NP	NNS	O	23	PMOD
26	in	in	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	United	United	I-NP	NNP	O	29	NMOD
29	States	State	I-NP	NNPS	O	26	PMOD
30	)	)	O	)	O	20	NMOD
31	for	for	B-PP	IN	O	18	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	prophylactic	prophylactic	I-NP	JJ	O	34	NMOD
34	treatment	treatment	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	angina	angina	B-NP	NN	O	37	NMOD
37	pectoris	pectoris	I-NP	NN	O	35	PMOD
38	.	.	O	.	O	3	P

1	Effect	Effect	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	humoral	humoral	B-NP	JJ	O	4	NMOD
4	modulators	modulator	I-NP	NNS	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	morphine	morphine	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	increase	increase	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	locomotor	locomotor	B-NP	NN	O	11	NMOD
11	activity	activity	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	mice	mouse	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	humoral	humoral	B-NP	JJ	O	5	NMOD
5	modulators	modulator	I-NP	NNS	O	3	PMOD
6	on	on	B-PP	IN	O	2	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	morphine	morphine	I-NP	NN	O	6	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	increase	increase	B-NP	NN	O	9	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	locomotor	locomotor	B-NP	NN	O	13	NMOD
13	activity	activity	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	mice	mouse	B-NP	NNS	O	14	PMOD
16	was	be	B-VP	VBD	O	9	VMOD
17	studied	study	I-VP	VBN	O	16	VC
18	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	3	NMOD
2	subcutaneous	subcutaneous	I-NP	JJ	O	3	NMOD
3	administration	administration	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	10	10	B-NP	CD	O	6	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	morphine-HC1	morphine-HC1	B-NP	NN	O	7	PMOD
9	produced	produce	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	12	NMOD
11	marked	marked	I-NP	JJ	O	12	NMOD
12	increase	increase	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	locomotor	locomotor	B-NP	NN	O	15	NMOD
15	activity	activity	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	mice	mouse	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	4	NMOD
2	morphine	morphine	I-NP	NN	O	4	NMOD
3	induced	induce	I-NP	VBN	O	2	AMOD
4	hyperactivity	hyperactivity	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	potentiated	potentiate	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	scopolamine	scopolamine	B-NP	NN	O	7	PMOD
9	and	and	O	CC	O	6	VMOD
10	attenuated	attenuate	B-VP	VBN	O	6	VMOD
11	by	by	B-PP	IN	O	10	VMOD
12	physostigmine	physostigmine	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	17	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	17	P
4	both	both	O	CC	O	7	NMOD
5	methscopolamine	methscopolamine	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	neostigmine	neostigmine	I-NP	NN	O	17	SUB
8	,	,	O	,	O	7	P
9	which	which	B-NP	WDT	O	7	NMOD
10	do	do	B-VP	VBP	O	9	SBAR
11	not	not	I-VP	RB	O	10	VMOD
12	penetrate	penetrate	I-VP	VB	O	10	VC
13	the	the	B-NP	DT	O	15	NMOD
14	blood-brain	blood-brain	I-NP	NN	O	15	NMOD
15	barrier	barrier	I-NP	NN	O	12	OBJ
16	,	,	O	,	O	7	P
17	had	have	B-VP	VBD	O	0	ROOT
18	no	no	B-NP	DT	O	19	NMOD
19	effect	effect	I-NP	NN	O	17	OBJ
20	on	on	B-PP	IN	O	17	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	hyperactivity	hyperactivity	I-NP	NN	O	20	PMOD
23	produced	produce	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	morphine	morphine	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	17	P

1	On	On	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	1	VMOD
6	pretreatment	pretreatment	B-NP	NN	O	5	ROOT
7	with	with	B-PP	IN	O	6	NMOD
8	p-chlorophenylalamine	p-chlorophenylalamine	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	6	NMOD
10	3	3	B-NP	CD	O	12	AMOD
11	X	X	O	SYM	O	12	AMOD
12	320	320	B-NP	CD	O	13	NMOD
13	mg/kg	mg/kg	I-NP	NN	O	24	SUB
14	i.p.	i.p.	B-ADVP	RB	O	24	VMOD
15	,	,	O	,	O	24	P
16	24	24	B-NP	CD	O	17	NMOD
17	hr	hr	I-NP	NN	O	18	DEP
18	)	)	O	)	O	22	NMOD
19	,	,	O	,	O	22	P
20	a	a	B-NP	DT	O	22	NMOD
21	serotonin	serotonin	I-NP	NN	O	22	NMOD
22	depletor	depletor	I-NP	NN	O	24	SUB
23	,	,	O	,	O	22	P
24	caused	cause	B-VP	VBD	O	9	SBAR
25	no	no	B-NP	DT	O	27	NMOD
26	significant	significant	I-NP	JJ	O	27	NMOD
27	change	change	I-NP	NN	O	24	OBJ
28	in	in	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	hyperactivity	hyperactivity	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	6	P

1	Mechanisms	Mechanism	B-NP	NNS	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	FK	FK	B-NP	NN	O	2	PMOD
4	506	506	I-NP	CD	O	3	NMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	hypertension	hypertension	B-NP	NN	O	15	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	rat.	rat.	I-NP	NN	O	10	NMOD
10	-Tacrolimus	-Tacrolimus	I-NP	NN	O	7	PMOD
11	(	(	O	(	O	14	DEP
12	FK	FK	B-NP	NN	O	14	DEP
13	506	506	I-NP	CD	O	12	NMOD
14	)	)	O	)	O	10	NMOD
15	is	be	B-VP	VBZ	O	5	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	powerful	powerful	I-NP	JJ	O	15	PRD
18	,	,	O	,	O	15	P
19	widely	widely	B-VP	RB	O	20	VMOD
20	used	use	I-VP	VBN	O	15	VC
21	immunosuppressant	immunosuppressant	B-NP	NN	O	20	VMOD
22	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	clinical	clinical	I-NP	JJ	O	3	NMOD
3	utility	utility	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	FK	FK	B-NP	NN	O	4	PMOD
6	506	506	I-NP	CD	O	5	NMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	complicated	complicate	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	substantial	substantial	B-NP	JJ	O	13	NMOD
11	hypertension	hypertension	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	nephrotoxicity	nephrotoxicity	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	7	P

1	To	To	B-VP	TO	O	2	VMOD
2	clarify	clarify	I-VP	VB	O	12	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	mechanisms	mechanism	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	FK	FK	B-NP	NN	O	5	PMOD
7	506	506	I-NP	CD	O	6	NMOD
8	induced	induce	B-VP	VBD	O	2	VMOD
9	hypertension	hypertension	B-NP	NN	O	8	OBJ
10	,	,	O	,	O	12	P
11	we	we	B-NP	PRP	O	12	SUB
12	studied	study	B-VP	VBD	O	0	ROOT
13	the	the	B-NP	DT	O	15	NMOD
14	chronic	chronic	I-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	29	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	FK	FK	B-NP	NN	O	16	PMOD
18	506	506	I-NP	CD	O	17	NMOD
19	on	on	B-PP	IN	O	15	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	synthesis	synthesis	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	endothelin-1	endothelin-1	B-NP	NN	B-protein	22	PMOD
24	(	(	O	(	O	26	DEP
25	ET-1	ET-1	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	,	,	O	,	O	29	P
28	the	the	B-NP	DT	O	29	NMOD
29	expression	expression	I-NP	NN	O	12	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	mRNA	mRNA	B-NP	NN	B-RNA	30	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	ET-1	ET-1	B-NP	NN	B-protein	36	NMOD
34	and	and	O	CC	O	36	NMOD
35	endothelin-converting	endothelin-converting	B-NP	JJ	B-protein	36	NMOD
36	enzyme-1	enzyme-1	I-NP	NN	I-protein	45	NMOD
37	(	(	O	(	O	39	DEP
38	ECE-1	ECE-1	B-NP	NN	B-protein	39	DEP
39	)	)	O	)	O	36	NMOD
40	,	,	O	,	O	45	P
41	the	the	B-NP	DT	O	45	NMOD
42	endothelial	endothelial	I-NP	JJ	B-protein	45	NMOD
43	nitric	nitric	I-NP	JJ	I-protein	45	NMOD
44	oxide	oxide	I-NP	NN	I-protein	45	NMOD
45	synthase	synthase	I-NP	NN	I-protein	49	NMOD
46	(	(	O	(	O	48	DEP
47	eNOS	eNOS	B-NP	NN	O	48	DEP
48	)	)	O	)	O	45	NMOD
49	activity	activity	B-NP	NN	O	32	PMOD
50	,	,	O	,	O	69	P
51	and	and	O	CC	O	69	NMOD
52	the	the	B-NP	DT	O	53	NMOD
53	expression	expression	I-NP	NN	O	51	OBJ
54	of	of	B-PP	IN	O	53	NMOD
55	mRNA	mRNA	B-NP	NN	B-RNA	54	PMOD
56	of	of	B-PP	IN	O	55	NMOD
57	eNOS	eNOS	B-NP	NN	O	61	NMOD
58	and	and	O	CC	O	61	NMOD
59	C-type	C-type	B-NP	JJ	O	61	NMOD
60	natriuretic	natriuretic	I-NP	JJ	O	61	NMOD
61	peptide	peptide	I-NP	NN	O	56	PMOD
62	(	(	O	(	O	64	DEP
63	CNP	CNP	B-NP	NN	B-protein	64	DEP
64	)	)	O	)	O	61	NMOD
65	in	in	B-PP	IN	O	53	NMOD
66	rat	rat	B-NP	NN	O	68	NMOD
67	blood	blood	I-NP	NN	O	68	NMOD
68	vessels	vessel	I-NP	NNS	O	65	PMOD
69	.	.	O	.	O	12	P

1	In	In	B-PP	IN	O	19	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	19	P
4	the	the	B-NP	DT	O	5	NMOD
5	effect	effect	I-NP	NN	O	19	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	14	NMOD
8	specific	specific	I-NP	JJ	O	14	NMOD
9	endothelin	endothelin	I-NP	NN	O	14	NMOD
10	type	type	I-NP	NN	O	14	NMOD
11	A	A	I-NP	NN	O	14	NMOD
12	receptor	receptor	I-NP	NN	O	14	NMOD
13	antagonist	antagonist	I-NP	NN	O	14	NMOD
14	FR	FR	I-NP	NN	O	6	PMOD
15	139317	139317	I-NP	CD	O	14	NMOD
16	on	on	B-PP	IN	O	5	NMOD
17	FK	FK	B-NP	NN	O	16	PMOD
18	506	506	I-NP	CD	O	17	NMOD
19	induced	induce	B-VP	VBD	O	0	ROOT
20	hypertension	hypertension	B-NP	NN	O	19	OBJ
21	in	in	B-PP	IN	O	19	VMOD
22	rats	rat	B-NP	NNS	O	21	PMOD
23	was	be	B-VP	VBD	O	19	VMOD
24	studied	study	I-VP	VBN	O	23	VC
25	.	.	O	.	O	19	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	FR	FR	B-NP	NN	B-protein	3	PMOD
5	139317	139317	I-NP	CD	I-protein	4	NMOD
6	(	(	O	(	I-protein	11	DEP
7	10	10	B-NP	CD	I-protein	10	NMOD
8	mg.	mg.	I-NP	NN	I-protein	10	NMOD
9	kg-1.	kg-1.	I-NP	NN	I-protein	10	NMOD
10	d-1	d-1	I-NP	NN	I-protein	11	DEP
11	)	)	O	)	I-protein	4	NMOD
12	prevented	prevent	B-VP	VBD	I-protein	0	ROOT
13	FK	FK	B-NP	NN	I-protein	16	NMOD
14	506	506	I-NP	CD	I-protein	13	NMOD
15	induced	induce	B-VP	VBD	O	16	NMOD
16	hypertension	hypertension	B-NP	NN	O	12	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	rats	rat	B-NP	NNS	O	17	PMOD
19	.	.	O	.	O	12	P

1	Suxamethonium	Suxamethonium	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	prolonged	prolonged	B-NP	JJ	O	4	NMOD
4	apnea	apnea	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	receiving	receive	B-VP	VBG	O	7	NMOD
9	electroconvulsive	electroconvulsive	B-NP	JJ	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	OBJ
11	.	.	O	.	O	2	P

1	Suxamethonium	Suxamethonium	B-NP	NN	O	2	SUB
2	causes	cause	B-VP	VBZ	O	0	ROOT
3	prolonged	prolonged	B-NP	JJ	O	4	NMOD
4	apnea	apnea	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	whom	whom	B-NP	WP	O	7	PMOD
9	pseudocholinesterase	pseudocholinesterase	B-NP	NN	B-protein	10	NMOD
10	enzyme	enzyme	I-NP	NN	I-protein	8	NMOD
11	gets	get	B-VP	VBZ	O	2	VMOD
12	deactivated	deactivate	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	organophosphorus	organophosphorus	B-NP	NN	O	18	NMOD
15	(	(	O	(	O	17	DEP
16	OP	OP	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	poisons	poison	B-NP	NNS	O	13	PMOD
19	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	24	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	adjunctive	adjunctive	I-NP	JJ	O	6	NMOD
6	bupropion	bupropion	I-NP	NN	O	3	PMOD
7	on	on	B-PP	IN	O	2	NMOD
8	male	male	B-NP	JJ	O	10	NMOD
9	sexual	sexual	I-NP	JJ	O	10	NMOD
10	dysfunction	dysfunction	I-NP	NN	O	7	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	17	NMOD
14	selective	selective	I-NP	JJ	O	17	NMOD
15	serotonin	serotonin	I-NP	NN	O	17	NMOD
16	reuptake	reuptake	I-NP	NN	O	17	NMOD
17	inhibitor	inhibitor	I-NP	NN	O	12	PMOD
18	:	:	O	:	O	2	P
19	a	a	B-NP	DT	O	24	NMOD
20	double-blind	double-blind	I-NP	JJ	O	24	NMOD
21	placebo-controlled	placebo-controlled	I-NP	JJ	O	24	NMOD
22	and	and	I-NP	CC	O	24	NMOD
23	randomized	randomize	I-NP	VBN	O	24	NMOD
24	study	study	I-NP	NN	O	0	ROOT
25	.	.	O	.	O	24	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	safety	safety	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	efficacy	efficacy	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	adjunctive	adjunctive	B-NP	JJ	O	12	NMOD
11	bupropion	bupropion	I-NP	NN	O	12	NMOD
12	sustained-release	sustained-release	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	SR	SR	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	on	on	B-PP	IN	O	12	NMOD
17	male	male	B-NP	JJ	O	19	NMOD
18	sexual	sexual	I-NP	JJ	O	19	NMOD
19	dysfunction	dysfunction	I-NP	NN	O	16	PMOD
20	(	(	O	(	O	22	DEP
21	SD	SD	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	induced	induce	B-VP	VBN	O	19	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	29	NMOD
26	selective	selective	I-NP	JJ	O	29	NMOD
27	serotonin	serotonin	I-NP	NN	O	29	NMOD
28	reuptake	reuptake	I-NP	NN	O	29	NMOD
29	inhibitor	inhibitor	I-NP	NN	O	24	PMOD
30	(	(	O	(	O	32	DEP
31	SSRI	SSRI	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	29	NMOD
33	,	,	O	,	O	4	P
34	as	as	B-SBAR	IN	O	4	VMOD
35	SD	SD	B-NP	NN	O	36	SUB
36	is	be	B-VP	VBZ	O	34	SBAR
37	a	a	B-NP	DT	O	39	NMOD
38	common	common	I-NP	JJ	O	39	NMOD
39	side-effect	side-effect	I-NP	NN	O	36	PRD
40	of	of	B-PP	IN	O	39	NMOD
41	SSRIs	SSRI	B-NP	NNS	B-protein	40	PMOD
42	and	and	O	CC	O	46	NMOD
43	the	the	B-NP	DT	O	46	NMOD
44	most	most	I-NP	RBS	O	45	AMOD
45	effective	effective	I-NP	JJ	O	46	NMOD
46	treatments	treatment	I-NP	NNS	O	47	SUB
47	have	have	B-VP	VBP	O	39	SBAR
48	yet	yet	I-VP	RB	O	47	VMOD
49	to	to	I-VP	TO	O	50	VMOD
50	be	be	I-VP	VB	O	47	VMOD
51	determined	determine	I-VP	VBN	O	50	VC
52	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	8	VMOD
2	linear	linear	B-NP	JJ	O	4	NMOD
3	regression	regression	I-NP	NN	O	4	NMOD
4	analyses	analysis	I-NP	NNS	O	1	PMOD
5	the	the	B-NP	DT	O	7	NMOD
6	CGI-SF	CGI-SF	I-NP	NN	B-protein	7	NMOD
7	score	score	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	not	not	I-VP	RB	O	8	VMOD
10	affected	affect	I-VP	VBN	O	8	VC
11	significantly	significantly	B-ADVP	RB	O	10	VMOD
12	by	by	B-PP	IN	O	10	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	duration	duration	I-NP	NN	O	18	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	SD	SD	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	18	P
18	type	type	B-NP	NN	O	12	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	SSRI	SSRI	B-NP	NN	B-protein	23	NMOD
21	used	use	B-VP	VBN	O	20	NMOD
22	and	and	O	CC	O	23	NMOD
23	age	age	B-NP	NN	O	19	PMOD
24	.	.	O	.	O	8	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Bupropion	Bupropion	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	an	an	B-NP	DT	O	7	NMOD
6	effective	effective	I-NP	JJ	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	4	PRD
8	for	for	B-PP	IN	O	7	NMOD
9	male	male	B-NP	JJ	O	10	NMOD
10	SD	SD	I-NP	NN	O	8	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	SSRIs	SSRI	B-NP	NNS	B-protein	12	PMOD
14	.	.	O	.	O	1	P

1	Lamivudine	Lamivudine	B-NP	NN	O	0	ROOT
2	for	for	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	prevention	prevention	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	hepatitis	hepatitis	B-NP	NN	O	9	NMOD
7	B	B	I-NP	NN	O	9	NMOD
8	virus	virus	I-NP	NN	O	9	NMOD
9	reactivation	reactivation	I-NP	NN	O	5	PMOD
10	in	in	B-PP	IN	O	4	NMOD
11	hepatitis-B	hepatitis-B	B-NP	NN	B-protein	13	NMOD
12	surface	surface	I-NP	NN	I-protein	13	NMOD
13	antigen	antigen	I-NP	NN	I-protein	19	NMOD
14	(	(	O	(	O	16	DEP
15	HBSAG	HBSAG	B-NP	NN	B-protein	16	DEP
16	)	)	O	)	O	13	NMOD
17	seropositive	seropositive	B-NP	JJ	O	19	NMOD
18	cancer	cancer	I-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	10	PMOD
20	undergoing	undergo	B-VP	VBG	O	19	NMOD
21	cytotoxic	cytotoxic	B-NP	JJ	O	22	NMOD
22	chemotherapy	chemotherapy	I-NP	NN	O	20	OBJ
23	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	17	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	17	P
5	cancer	cancer	B-NP	NN	O	6	NMOD
6	patients	patient	I-NP	NNS	O	17	SUB
7	who	who	B-NP	WP	O	6	NMOD
8	have	have	B-VP	VBP	O	7	SBAR
9	solid	solid	B-NP	JJ	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	hematological	hematological	I-NP	JJ	O	12	NMOD
12	malignancies	malignancy	I-NP	NNS	O	8	OBJ
13	with	with	B-PP	IN	O	8	VMOD
14	chronic	chronic	B-NP	JJ	O	16	NMOD
15	HBV	HBV	I-NP	NN	O	16	NMOD
16	infection	infection	I-NP	NN	O	13	PMOD
17	received	receive	B-VP	VBD	O	0	ROOT
18	the	the	B-NP	DT	O	21	NMOD
19	antiviral	antiviral	I-NP	JJ	O	21	NMOD
20	agent	agent	I-NP	NN	O	21	NMOD
21	lamivudine	lamivudine	I-NP	NN	O	17	OBJ
22	prior	prior	B-ADVP	RB	O	17	VMOD
23	and	and	O	CC	O	22	DEP
24	during	during	B-PP	IN	O	22	AMOD
25	CT	CT	B-NP	NN	O	24	PMOD
26	compared	compare	B-PP	VBN	O	17	VMOD
27	with	with	B-PP	IN	O	26	PMOD
28	historical	historical	B-NP	JJ	O	30	NMOD
29	control	control	I-NP	NN	O	30	NMOD
30	group	group	I-NP	NN	O	27	PMOD
31	who	who	B-NP	WP	O	30	NMOD
32	did	do	B-VP	VBD	O	31	SBAR
33	not	not	I-VP	RB	O	32	VMOD
34	receive	receive	I-VP	VB	O	32	VC
35	lamivudine	lamivudine	B-NP	NN	O	34	OBJ
36	.	.	O	.	O	17	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	7	NMOD
3	prophylactic	prophylactic	I-NP	JJ	O	7	NMOD
4	lamivudine	lamivudine	I-NP	NN	O	7	NMOD
5	group	group	I-NP	NN	O	7	NMOD
6	severe	severe	I-NP	JJ	O	7	NMOD
7	hepatitis	hepatitis	I-NP	NN	O	8	SUB
8	were	be	B-VP	VBD	O	0	ROOT
9	observed	observe	I-VP	VBN	O	8	VC
10	only	only	B-ADVP	RB	O	11	PMOD
11	in	in	B-PP	IN	O	9	VMOD
12	1	1	B-NP	CD	O	13	NMOD
13	patient	patient	I-NP	NN	O	11	PMOD
14	(	(	O	(	O	17	DEP
15	2.7	2.7	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	of	of	B-PP	IN	O	13	NMOD
19	37	37	B-NP	CD	O	20	NMOD
20	patients	patient	I-NP	NNS	O	18	PMOD
21	(	(	O	(	O	25	DEP
22	p	p	B-NP	NN	O	25	DEP
23	<	<	B-NP	JJR	O	22	NMOD
24	0.006	0.006	I-NP	CD	O	23	AMOD
25	)	)	O	)	O	8	VMOD
26	.	.	O	.	O	8	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	suggests	suggest	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	prophylactic	prophylactic	B-NP	JJ	O	6	NMOD
6	lamivudine	lamivudine	I-NP	NN	O	8	SUB
7	significantly	significantly	B-ADVP	RB	O	8	VMOD
8	decreases	decrease	B-VP	VBZ	O	4	SBAR
9	the	the	B-NP	DT	O	10	NMOD
10	incidence	incidence	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	HBV	HBV	B-NP	NN	O	13	NMOD
13	reactivation	reactivation	I-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	overall	overall	B-NP	JJ	O	16	NMOD
16	morbidity	morbidity	I-NP	NN	O	11	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	cancer	cancer	B-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	17	PMOD
20	during	during	B-PP	IN	O	8	VMOD
21	and	and	I-PP	CC	O	20	PMOD
22	after	after	I-PP	IN	O	20	PMOD
23	immunosuppressive	immunosuppressive	B-NP	JJ	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	20	PMOD
25	.	.	O	.	O	3	P

1	Ginsenoside	Ginsenoside	B-NP	NN	O	2	NMOD
2	Rg1	Rg1	I-NP	NN	O	3	SUB
3	restores	restore	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	impairment	impairment	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	learning	learning	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	chronic	chronic	B-NP	JJ	O	12	NMOD
11	morphine	morphine	I-NP	NN	O	12	NMOD
12	administration	administration	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	rats	rat	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	3	P

1	Rg1	Rg1	B-NP	NN	B-protein	11	SUB
2	,	,	O	,	O	1	P
3	as	as	B-PP	IN	O	1	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	ginsenoside	ginsenoside	I-NP	NN	O	3	PMOD
6	extracted	extract	B-VP	VBN	O	5	NMOD
7	from	from	B-PP	IN	O	6	VMOD
8	Panax	Panax	B-NP	NN	O	9	NMOD
9	ginseng	ginseng	I-NP	NN	O	7	PMOD
10	,	,	O	,	O	1	P
11	could	could	B-VP	MD	O	0	ROOT
12	ameliorate	ameliorate	I-VP	VB	O	11	VC
13	spatial	spatial	B-NP	JJ	O	15	NMOD
14	learning	learning	I-NP	NN	O	15	NMOD
15	impairment	impairment	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	investigate	investigate	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	effect	effect	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	Rg1	Rg1	B-NP	NN	B-protein	11	PMOD
13	on	on	B-PP	IN	O	10	NMOD
14	learning	learn	B-VP	VBG	O	13	PMOD
15	impairment	impairment	B-NP	NN	O	14	OBJ
16	by	by	B-PP	IN	O	14	VMOD
17	chronic	chronic	B-NP	JJ	O	19	NMOD
18	morphine	morphine	I-NP	NN	O	19	NMOD
19	administration	administration	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	mechanism	mechanism	I-NP	NN	O	16	PMOD
23	responsible	responsible	B-ADJP	JJ	O	22	NMOD
24	for	for	B-PP	IN	O	23	AMOD
25	this	this	B-NP	DT	O	26	NMOD
26	effect	effect	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	0	ROOT
3	on	on	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	effect	effect	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	duration	duration	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	subcutaneous	subcutaneous	B-NP	JJ	O	12	NMOD
11	heparin	heparin	I-NP	NN	O	12	NMOD
12	injection	injection	I-NP	NN	O	9	PMOD
13	on	on	B-PP	IN	O	5	NMOD
14	bruising	bruising	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	pain	pain	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	2	P

1	AIM	AIM	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	study	study	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	carried	carry	I-VP	VBN	O	5	VC
7	out	out	B-PRT	RP	O	6	VMOD
8	to	to	B-VP	TO	O	9	VMOD
9	determine	determine	I-VP	VB	O	5	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	effect	effect	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	injection	injection	B-NP	NN	O	14	NMOD
14	duration	duration	I-NP	NN	O	12	PMOD
15	on	on	B-PP	IN	O	11	NMOD
16	bruising	bruise	B-NP	VBG	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	pain	pain	I-NP	NN	O	15	PMOD
19	following	follow	B-PP	VBG	O	9	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	administration	administration	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	subcutaneous	subcutaneous	I-NP	JJ	O	25	NMOD
25	injection	injection	I-NP	NN	O	22	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	heparin	heparin	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	5	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	36	VMOD
2	:	:	O	:	O	1	P
3	Although	Although	B-SBAR	IN	O	36	VMOD
4	different	different	B-NP	JJ	O	5	NMOD
5	methods	method	I-NP	NNS	O	7	SUB
6	to	to	B-VP	TO	O	7	VMOD
7	prevent	prevent	I-VP	VB	O	3	SBAR
8	bruising	bruising	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	pain	pain	I-NP	NN	O	7	OBJ
11	following	follow	B-PP	VBG	O	7	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	subcutaneous	subcutaneous	I-NP	JJ	O	14	NMOD
14	injection	injection	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	heparin	heparin	B-NP	NN	O	15	PMOD
17	have	have	B-VP	VBP	O	3	SBAR
18	been	be	I-VP	VBN	O	17	VC
19	widely	widely	I-VP	RB	O	18	VMOD
20	studied	study	I-VP	VBN	O	18	VC
21	and	and	I-VP	CC	O	20	VMOD
22	described	describe	I-VP	VBN	O	20	VMOD
23	,	,	O	,	O	36	P
24	the	the	B-NP	DT	O	25	NMOD
25	effect	effect	I-NP	NN	O	36	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	injection	injection	B-NP	NN	O	28	NMOD
28	duration	duration	I-NP	NN	O	26	PMOD
29	on	on	B-PP	IN	O	25	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	occurrence	occurrence	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	bruising	bruising	B-NP	NN	O	35	NMOD
34	and	and	I-NP	CC	O	35	NMOD
35	pain	pain	I-NP	NN	O	32	PMOD
36	is	be	B-VP	VBZ	O	0	ROOT
37	little	little	B-ADJP	JJ	O	36	PRD
38	documented	document	B-VP	VBN	O	37	AMOD
39	.	.	O	.	O	36	P

1	Dimensions	Dimension	B-NP	NNS	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	bruising	bruising	I-NP	NN	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	heparin	heparin	I-NP	NN	O	5	PMOD
8	applied	apply	B-VP	VBD	O	10	VMOD
9	areas	area	B-NP	NNS	O	10	SUB
10	were	be	B-VP	VBD	O	0	ROOT
11	measured	measure	I-VP	VBN	O	10	VC
12	using	use	B-VP	VBG	O	11	VMOD
13	transparent	transparent	B-NP	JJ	O	16	NMOD
14	millimetric	millimetric	I-NP	JJ	O	16	NMOD
15	measuring	measuring	I-NP	NN	O	16	NMOD
16	paper	paper	I-NP	NN	O	12	OBJ
17	.	.	O	.	O	10	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	It	It	B-NP	PRP	O	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	determined	determine	I-VP	VBN	O	4	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	injection	injection	B-NP	NN	O	8	NMOD
8	duration	duration	I-NP	NN	O	9	SUB
9	had	have	B-VP	VBD	O	6	SBAR
10	an	an	B-NP	DT	O	11	NMOD
11	effect	effect	I-NP	NN	O	9	OBJ
12	on	on	B-PP	IN	O	9	VMOD
13	bruising	bruise	B-NP	VBG	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	pain	pain	I-NP	NN	O	12	PMOD
16	following	follow	B-PP	VBG	O	9	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	subcutaneous	subcutaneous	I-NP	JJ	O	19	NMOD
19	administration	administration	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	heparin	heparin	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	1	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	reserpine	reserpine	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	subchronic	subchronic	B-NP	JJ	O	6	NMOD
5	haloperidol	haloperidol	I-NP	NN	O	6	NMOD
6	treatments	treatment	I-NP	NNS	O	7	SUB
7	change	change	B-VP	VBP	O	0	ROOT
8	synaptosomal	synaptosomal	B-NP	JJ	O	11	NMOD
9	brain	brain	I-NP	NN	O	11	NMOD
10	glutamate	glutamate	I-NP	NN	O	11	NMOD
11	uptake	uptake	I-NP	NN	O	7	OBJ
12	and	and	O	CC	O	7	VMOD
13	elicit	elicit	B-VP	VB	O	7	VMOD
14	orofacial	orofacial	B-NP	JJ	O	15	NMOD
15	dyskinesia	dyskinesia	I-NP	NN	O	13	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	7	P

1	Reserpine-	Reserpine-	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	haloperidol	haloperidol	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	7	VMOD
5	orofacial	orofacial	B-NP	JJ	O	6	NMOD
6	dyskinesia	dyskinesia	I-NP	NN	O	4	OBJ
7	are	be	B-VP	VBP	O	0	ROOT
8	putative	putative	B-NP	JJ	O	10	NMOD
9	animal	animal	I-NP	NN	O	10	NMOD
10	models	model	I-NP	NNS	O	7	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	tardive	tardive	B-NP	NN	O	13	NMOD
13	dyskinesia	dyskinesia	I-NP	NN	O	18	NMOD
14	(	(	O	(	O	16	DEP
15	TD	TD	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	whose	whose	B-NP	WP$	O	18	NMOD
18	pathophysiology	pathophysiology	I-NP	NN	O	11	PMOD
19	has	have	B-VP	VBZ	O	7	VMOD
20	been	be	I-VP	VBN	O	19	VC
21	related	relate	I-VP	VBN	O	20	VC
22	to	to	B-PP	TO	O	21	VMOD
23	free	free	B-NP	JJ	O	25	NMOD
24	radical	radical	I-NP	NN	O	25	NMOD
25	generation	generation	I-NP	NN	O	28	NMOD
26	and	and	O	CC	O	28	NMOD
27	oxidative	oxidative	B-NP	JJ	O	28	NMOD
28	stress	stress	I-NP	NN	O	22	PMOD
29	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	8	P
6	the	the	B-NP	DT	O	7	NMOD
7	authors	author	I-NP	NNS	O	8	SUB
8	induced	induce	B-VP	VBD	O	0	ROOT
9	orofacial	orofacial	B-NP	JJ	O	10	NMOD
10	dyskinesia	dyskinesia	I-NP	NN	O	8	OBJ
11	by	by	B-PP	IN	O	8	VMOD
12	acute	acute	B-NP	JJ	O	13	NMOD
13	reserpine	reserpine	I-NP	NN	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	subchronic	subchronic	B-NP	JJ	O	17	NMOD
16	haloperidol	haloperidol	I-NP	NN	O	17	NMOD
17	administration	administration	I-NP	NN	O	11	PMOD
18	to	to	B-PP	TO	O	17	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	8	P

1	Importantly	Importantly	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	a	a	B-NP	DT	O	4	NMOD
4	decrease	decrease	I-NP	NN	O	8	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	glutamate	glutamate	B-NP	NN	O	7	NMOD
7	uptake	uptake	I-NP	NN	O	5	PMOD
8	correlates	correlate	B-VP	VBZ	O	0	ROOT
9	negatively	negatively	B-ADVP	RB	O	8	VMOD
10	with	with	B-PP	IN	O	8	VMOD
11	an	an	B-NP	DT	O	12	NMOD
12	increase	increase	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	incidence	incidence	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	orofacial	orofacial	B-NP	JJ	O	18	NMOD
18	diskinesia	diskinesia	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	8	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	psychosis	psychosis	I-NP	NN	O	0	ROOT
3	due	due	B-ADJP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	treatment	treatment	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	phenytoin	phenytoin	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	nonepileptic	nonepileptic	I-NP	JJ	O	11	NMOD
11	patient	patient	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	6	NMOD
5	nonepileptic	nonepileptic	I-NP	JJ	O	6	NMOD
6	patient	patient	I-NP	NN	O	3	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	developed	develop	B-VP	VBD	O	7	SBAR
9	psychosis	psychosis	B-NP	NN	O	8	OBJ
10	following	follow	B-PP	VBG	O	8	VMOD
11	phenytoin	phenytoin	B-NP	NN	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	10	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	trigeminal	trigeminal	B-NP	JJ	O	15	NMOD
15	neuralgia	neuralgia	I-NP	NN	O	13	PMOD
16	is	be	B-VP	VBZ	O	0	ROOT
17	described	describe	I-VP	VBN	O	16	VC
18	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	16	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	treatment	treatment	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	gum	gum	B-NP	NN	O	5	PMOD
7	Arabic	Arabic	B-ADJP	JJ	O	6	NMOD
8	on	on	B-PP	IN	O	7	AMOD
9	gentamicin	gentamicin	B-NP	NN	O	10	NMOD
10	nephrotoxicity	nephrotoxicity	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	:	:	O	:	O	2	P
14	a	a	B-NP	DT	O	16	NMOD
15	preliminary	preliminary	I-NP	JJ	O	16	NMOD
16	study	study	I-NP	NN	O	0	ROOT
17	.	.	O	.	O	16	P

1	In	In	B-PP	IN	O	6	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	work	work	I-NP	NN	O	1	PMOD
5	we	we	B-NP	PRP	O	6	SUB
6	assessed	assess	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	effect	effect	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	treatment	treatment	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	10	NMOD
14	gum	gum	B-NP	NN	O	13	PMOD
15	Arabic	Arabic	B-ADJP	JJ	O	14	NMOD
16	on	on	B-PP	IN	O	15	AMOD
17	acute	acute	B-NP	JJ	O	19	NMOD
18	renal	renal	I-NP	JJ	O	19	NMOD
19	failure	failure	I-NP	NN	O	16	PMOD
20	induced	induce	B-VP	VBN	O	19	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	gentamicin	gentamicin	B-NP	NN	O	26	NMOD
23	(	(	O	(	O	25	DEP
24	GM	GM	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	nephrotoxicity	nephrotoxicity	B-NP	NN	O	21	PMOD
27	.	.	O	.	O	6	P

1	Nephrotoxicity	Nephrotoxicity	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	assessed	assess	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	measuring	measure	B-VP	VBG	O	4	PMOD
6	the	the	B-NP	DT	O	7	NMOD
7	concentrations	concentration	I-NP	NNS	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	creatinine	creatinine	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	urea	urea	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	7	NMOD
13	the	the	B-NP	DT	O	17	NMOD
14	plasma	plasma	I-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	reduced	reduce	B-NP	VBN	O	17	NMOD
17	glutathione	glutathione	I-NP	NN	O	12	PMOD
18	(	(	O	(	O	20	DEP
19	GSH	GSH	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	in	in	B-PP	IN	O	7	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	kidney	kidney	I-NP	NN	O	24	NMOD
24	cortex	cortex	I-NP	NN	O	21	PMOD
25	,	,	O	,	O	4	P
26	and	and	O	CC	O	4	PMOD
27	by	by	B-PP	IN	O	4	PMOD
28	light	light	B-NP	NN	O	30	NMOD
29	microscopic	microscopic	I-NP	JJ	O	30	NMOD
30	examination	examination	I-NP	NN	O	27	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	kidney	kidney	B-NP	NN	O	33	NMOD
33	sections	section	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicated	indicate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	concomitant	concomitant	B-NP	JJ	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	13	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	gum	gum	B-NP	NN	O	11	NMOD
9	Arabic	Arabic	I-NP	NNP	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	GM	GM	I-NP	NNP	O	7	PMOD
12	significantly	significantly	B-ADVP	RB	O	13	VMOD
13	increased	increase	B-VP	VBD	O	4	SBAR
14	creatinine	creatinine	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	urea	urea	I-NP	NN	O	13	OBJ
17	by	by	B-PP	IN	O	13	VMOD
18	about	about	B-NP	RB	O	17	PMOD
19	183	183	I-NP	CD	O	18	NMOD
20	and	and	I-NP	CC	O	18	AMOD
21	239	239	I-NP	CD	O	18	AMOD
22	%	%	I-NP	NN	O	18	NMOD
23	,	,	O	,	O	13	P
24	respectively	respectively	B-ADVP	RB	O	13	VMOD
25	(	(	O	(	O	13	VMOD
26	compared	compare	B-VP	VBN	O	13	VMOD
27	to	to	B-PP	TO	O	26	VMOD
28	432	432	B-NP	CD	O	30	AMOD
29	and	and	I-NP	CC	O	30	AMOD
30	346	346	I-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	27	PMOD
32	,	,	O	,	O	26	P
33	respectively	respectively	B-ADVP	RB	O	26	VMOD
34	,	,	O	,	O	13	P
35	in	in	B-PP	IN	O	13	VMOD
36	rats	rat	B-NP	NNS	O	35	PMOD
37	treated	treat	B-VP	VBN	O	36	NMOD
38	with	with	B-PP	IN	O	37	VMOD
39	cellulose	cellulose	B-NP	NN	O	41	NMOD
40	and	and	O	CC	O	41	NMOD
41	GM	GM	B-NP	NN	B-protein	38	PMOD
42	)	)	O	)	O	13	VMOD
43	,	,	O	,	O	13	P
44	and	and	O	CC	O	13	VMOD
45	decreased	decrease	B-VP	VBD	O	13	VMOD
46	that	that	B-SBAR	IN	O	45	VMOD
47	of	of	B-PP	IN	O	46	NMOD
48	cortical	cortical	B-NP	JJ	O	49	NMOD
49	GSH	GSH	I-NP	NN	O	47	PMOD
50	by	by	B-PP	IN	O	71	VMOD
51	21	21	B-NP	CD	O	52	NMOD
52	%	%	I-NP	NN	O	50	PMOD
53	(	(	O	(	O	64	DEP
54	compared	compare	B-VP	VBN	O	64	DEP
55	to	to	B-PP	TO	O	54	VMOD
56	27	27	B-NP	CD	O	57	NMOD
57	%	%	I-NP	NN	O	63	NMOD
58	in	in	B-PP	IN	O	57	NMOD
59	the	the	B-NP	DT	O	60	NMOD
60	cellulose	cellulose	I-NP	NN	O	58	PMOD
61	plus	plus	O	CC	O	63	NMOD
62	GM	GM	B-NP	NNP	O	63	NMOD
63	group	group	I-NP	NN	O	55	PMOD
64	)	)	O	)	O	52	NMOD
65	The	The	B-NP	DT	O	66	NMOD
66	GM	GM	I-NP	NNP	O	71	SUB
67	induced	induce	B-VP	VBD	O	66	NMOD
68	proximal	proximal	B-NP	JJ	O	70	NMOD
69	tubular	tubular	I-NP	JJ	O	70	NMOD
70	necrosis	necrosis	I-NP	NN	O	67	OBJ
71	appeared	appear	B-VP	VBD	O	46	SBAR
72	to	to	I-VP	TO	O	73	VMOD
73	be	be	I-VP	VB	O	71	VMOD
74	slightly	slightly	B-ADJP	RB	O	73	PRD
75	less	less	I-ADJP	RBR	O	74	AMOD
76	severe	severe	I-ADJP	JJ	O	74	AMOD
77	in	in	B-PP	IN	O	73	VMOD
78	rats	rat	B-NP	NNS	O	77	PMOD
79	given	give	B-VP	VBN	O	78	NMOD
80	GM	GM	B-NP	NNP	O	79	OBJ
81	together	together	B-ADVP	RB	O	82	PMOD
82	with	with	B-PP	IN	O	80	NMOD
83	gum	gum	B-NP	NN	O	82	PMOD
84	Arabic	Arabic	B-ADJP	JJ	O	83	NMOD
85	than	than	B-PP	IN	O	84	AMOD
86	in	in	B-PP	IN	O	85	PMOD
87	those	those	B-NP	DT	O	91	NMOD
88	given	give	B-PP	VBN	O	91	NMOD
89	GM	GM	B-NP	NNP	O	91	NMOD
90	and	and	O	CC	O	91	NMOD
91	cellulose	cellulose	B-NP	NN	O	86	PMOD
92	.	.	O	.	O	3	P

1	It	It	B-NP	PRP	O	2	SUB
2	could	could	B-VP	MD	O	0	ROOT
3	be	be	I-VP	VB	O	2	VC
4	inferred	infer	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	gum	gum	B-NP	NN	O	8	NMOD
7	Arabic	Arabic	I-NP	JJ	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	9	SUB
9	has	have	B-VP	VBZ	O	5	SBAR
10	induced	induce	I-VP	VBN	O	9	VC
11	a	a	B-NP	DT	O	13	NMOD
12	modest	modest	I-NP	JJ	O	13	NMOD
13	amelioration	amelioration	I-NP	NN	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	some	some	B-NP	DT	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	21	NMOD
18	histological	histological	I-NP	JJ	O	20	AMOD
19	and	and	I-NP	CC	O	20	AMOD
20	biochemical	biochemical	I-NP	JJ	O	21	NMOD
21	indices	index	I-NP	NNS	O	16	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	GM	GM	B-NP	NNP	O	24	NMOD
24	nephrotoxicity	nephrotoxicity	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	2	P

1	Visual	Visual	B-NP	JJ	O	2	NMOD
2	hallucinations	hallucination	I-NP	NNS	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	zonisamide	zonisamide	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	Zonisamide	Zonisamide	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	broad-spectrum	broad-spectrum	I-NP	JJ	O	6	NMOD
5	antiepileptic	antiepileptic	I-NP	JJ	O	6	NMOD
6	drug	drug	I-NP	NN	O	2	PRD
7	used	use	B-VP	VBN	O	6	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	treat	treat	I-VP	VB	O	7	VMOD
10	various	various	B-NP	JJ	O	11	NMOD
11	types	type	I-NP	NNS	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	seizures	seizure	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	17	VMOD
2	visual	visual	B-NP	JJ	O	3	NMOD
3	hallucinations	hallucination	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	1	SBAR
5	not	not	I-VP	RB	O	4	VMOD
6	been	be	I-VP	VBN	O	4	VC
7	reported	report	I-VP	VBN	O	6	VC
8	as	as	B-PP	IN	O	7	VMOD
9	an	an	B-NP	DT	O	11	NMOD
10	adverse	adverse	I-NP	JJ	O	11	NMOD
11	effect	effect	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	this	this	B-NP	DT	O	14	NMOD
14	agent	agent	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	17	P
16	we	we	B-NP	PRP	O	17	SUB
17	describe	describe	B-VP	VBP	O	37	VMOD
18	three	three	B-NP	CD	O	19	NMOD
19	patients	patient	I-NP	NNS	O	17	OBJ
20	who	who	B-NP	WP	O	19	NMOD
21	experienced	experience	B-VP	VBD	O	20	SBAR
22	complex	complex	B-NP	JJ	O	24	NMOD
23	visual	visual	I-NP	JJ	O	24	NMOD
24	hallucinations	hallucination	I-NP	NNS	O	28	NMOD
25	and	and	O	CC	O	28	NMOD
26	altered	alter	B-NP	VBN	O	28	NMOD
27	mental	mental	I-NP	JJ	O	28	NMOD
28	status	status	I-NP	NN	O	21	OBJ
29	after	after	B-PP	IN	O	21	VMOD
30	zonisamide	zonisamide	B-NP	NN	O	31	NMOD
31	treatment	treatment	I-NP	NN	O	29	PMOD
32	was	be	B-VP	VBD	O	37	VMOD
33	begun	begin	I-VP	VBN	O	32	VC
34	or	or	O	CC	O	37	VMOD
35	its	its	B-NP	PRP$	O	36	NMOD
36	dosage	dosage	I-NP	NN	O	37	SUB
37	increased	increase	B-VP	VBD	O	0	ROOT
38	.	.	O	.	O	37	P

1	GLEPP1	GLEPP1	B-NP	NN	B-protein	4	NMOD
2	receptor	receptor	I-NP	NN	I-protein	4	NMOD
3	tyrosine	tyrosine	I-NP	NN	I-protein	4	NMOD
4	phosphatase	phosphatase	I-NP	NN	I-protein	0	ROOT
5	(	(	O	(	O	7	DEP
6	Ptpro	Ptpro	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	in	in	B-PP	IN	O	4	NMOD
9	rat	rat	B-NP	NN	O	11	NMOD
10	PAN	PAN	I-NP	NN	O	11	NMOD
11	nephrosis	nephrosis	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	4	P

1	Puromycin	Puromycin	B-NP	NN	O	3	NMOD
2	aminonucleoside	aminonucleoside	I-NP	NN	O	3	NMOD
3	nephrosis	nephrosis	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	induced	induce	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	single	single	B-NP	JJ	O	8	AMOD
8	intraperitoneal	intraperitoneal	I-NP	JJ	O	9	NMOD
9	injection	injection	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	puromycin	puromycin	B-NP	NN	O	12	NMOD
12	aminonucleoside	aminonucleoside	I-NP	NN	O	10	PMOD
13	(	(	O	(	O	19	DEP
14	PAN	PAN	B-NP	NN	O	18	NMOD
15	,	,	O	,	O	18	P
16	20	20	B-NP	CD	O	18	NMOD
17	mg/100g	mg/100g	I-NP	NN	O	18	NMOD
18	BW	BW	I-NP	NN	O	19	DEP
19	)	)	O	)	O	12	NMOD
20	.	.	O	.	O	4	P

1	Tissues	Tissue	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	analyzed	analyze	I-VP	VBN	O	2	VC
4	at	at	B-PP	IN	O	3	VMOD
5	0	0	B-NP	CD	O	20	NMOD
6	,	,	I-NP	,	O	20	P
7	5	5	I-NP	CD	O	20	NMOD
8	,	,	I-NP	,	O	20	P
9	7	7	I-NP	CD	O	20	NMOD
10	,	,	I-NP	,	O	20	P
11	11	11	I-NP	CD	O	20	NMOD
12	,	,	I-NP	,	O	20	P
13	21	21	I-NP	CD	O	20	NMOD
14	,	,	I-NP	,	O	20	P
15	45	45	I-NP	CD	O	20	NMOD
16	,	,	I-NP	,	O	20	P
17	80	80	I-NP	CD	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	126	126	I-NP	CD	O	20	NMOD
20	days	day	I-NP	NNS	O	4	PMOD
21	after	after	B-PP	IN	O	3	VMOD
22	PAN	PAN	B-NP	NN	O	23	NMOD
23	injection	injection	I-NP	NN	O	21	PMOD
24	so	so	B-SBAR	RB	O	27	VMOD
25	as	as	I-SBAR	IN	O	24	DEP
26	to	to	B-VP	TO	O	27	VMOD
27	include	include	I-VP	VB	O	3	VMOD
28	both	both	O	CC	O	31	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	acute	acute	I-NP	JJ	O	31	NMOD
31	phase	phase	I-NP	NN	O	27	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	proteinuria	proteinuria	B-NP	NN	O	32	PMOD
34	associated	associate	B-VP	VBN	O	33	NMOD
35	with	with	B-PP	IN	O	34	VMOD
36	foot	foot	B-NP	NN	O	38	NMOD
37	process	process	I-NP	NN	O	38	NMOD
38	effacement	effacement	I-NP	NN	O	46	NMOD
39	(	(	O	(	O	42	DEP
40	days	day	B-NP	NNS	O	42	DEP
41	5-11	5-11	B-NP	CD	O	40	NMOD
42	)	)	O	)	O	38	NMOD
43	and	and	O	CC	O	46	NMOD
44	the	the	B-NP	DT	O	46	NMOD
45	chronic	chronic	I-NP	JJ	O	46	NMOD
46	phase	phase	I-NP	NN	O	35	PMOD
47	of	of	B-PP	IN	O	46	NMOD
48	proteinuria	proteinuria	B-NP	NN	O	47	PMOD
49	associated	associate	B-VP	VBN	O	48	NMOD
50	with	with	B-PP	IN	O	49	VMOD
51	glomerulosclerosis	glomerulosclerosis	B-NP	NN	O	50	PMOD
52	(	(	O	(	O	55	DEP
53	days	day	B-NP	NNS	O	55	DEP
54	45-126	45-126	B-NP	CD	O	53	NMOD
55	)	)	O	)	O	51	NMOD
56	.	.	O	.	O	2	P

1	Ticlopidine	Ticlopidine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	aplastic	aplastic	B-NP	JJ	O	4	NMOD
4	anemia	anemia	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	VMOD
6	report	report	B-NP	NN	O	5	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	three	three	B-NP	CD	O	10	NMOD
9	Chinese	Chinese	I-NP	JJ	O	10	NMOD
10	patients	patient	I-NP	NNS	O	12	NMOD
11	and	and	O	CC	O	12	NMOD
12	review	review	B-NP	NN	O	7	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	literature	literature	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	10	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	10	P
5	three	three	B-NP	CD	O	7	NMOD
6	Chinese	Chinese	I-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	10	SUB
8	with	with	B-PP	IN	O	7	NMOD
9	ticlopidine	ticlopidine	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	23	VMOD
11	aplastic	aplastic	B-NP	JJ	O	12	NMOD
12	anemia	anemia	I-NP	NN	O	10	OBJ
13	were	be	B-VP	VBD	O	10	VMOD
14	reported	report	I-VP	VBN	O	13	VC
15	and	and	O	CC	O	23	VMOD
16	another	another	B-NP	DT	O	18	NMOD
17	13	13	I-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	23	SUB
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	English	English	I-NP	JJ	O	22	NMOD
22	literature	literature	I-NP	NN	O	19	PMOD
23	were	be	B-VP	VBD	O	0	ROOT
24	reviewed	review	I-VP	VBN	O	23	VC
25	.	.	O	.	O	23	P

1	Agranulocytosis	Agranulocytosis	B-NP	NN	O	2	SUB
2	occurred	occur	B-VP	VBD	O	19	VMOD
3	3-20	3-20	B-NP	CD	O	4	NMOD
4	weeks	week	I-NP	NNS	O	5	PMOD
5	after	after	B-PP	IN	O	2	VMOD
6	initiation	initiation	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	ticlopidine	ticlopidine	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	2	P
10	so	so	B-NP	RB	O	11	AMOD
11	frequent	frequent	I-NP	JJ	O	12	NMOD
12	examination	examination	I-NP	NN	O	2	VMOD
13	of	of	B-PP	IN	O	12	NMOD
14	white	white	B-NP	JJ	O	16	NMOD
15	cell	cell	I-NP	NN	O	16	NMOD
16	count	count	I-NP	NN	O	13	PMOD
17	during	during	B-PP	IN	O	2	VMOD
18	treatment	treatment	B-NP	NN	O	17	PMOD
19	is	be	B-VP	VBZ	O	0	ROOT
20	recommended	recommend	I-VP	VBN	O	19	VC
21	.	.	O	.	O	19	P

1	Treatment	Treatment	B-NP	NN	O	4	SUB
2	for	for	B-PP	IN	O	1	NMOD
3	ticlopidine	ticlopidine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	aplastic	aplastic	B-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	4	OBJ
7	with	with	B-PP	IN	O	6	NMOD
8	colony-stimulating	colony-stimulating	B-NP	JJ	B-protein	9	NMOD
9	factors	factor	I-NP	NNS	I-protein	7	PMOD
10	seemed	seem	B-VP	VBD	O	4	VMOD
11	to	to	I-VP	TO	O	12	VMOD
12	have	have	I-VP	VB	O	10	VMOD
13	little	little	B-NP	JJ	O	14	NMOD
14	effect	effect	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	4	P

1	Amnesia	Amnesia	B-NP	NN	O	7	SUB
2	produced	produce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	scopolamine	scopolamine	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	cycloheximide	cycloheximide	I-NP	NN	O	3	PMOD
7	were	be	B-VP	VBD	O	26	VMOD
8	reversed	reverse	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	morphine	morphine	B-NP	NN	O	9	PMOD
11	given	give	B-VP	VBN	O	10	NMOD
12	30	30	B-NP	CD	O	13	NMOD
13	min	min	I-NP	NN	O	11	VMOD
14	before	before	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	test	test	I-NP	NN	O	17	NMOD
17	trial	trial	I-NP	NN	O	14	PMOD
18	(	(	O	(	O	20	DEP
19	pre-test	pre-test	B-ADVP	JJ	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	,	,	O	,	O	26	P
22	and	and	O	CC	O	24	NMOD
23	pre-test	pre-t	B-NP	JJS	O	24	NMOD
24	morphine	morphine	I-NP	NN	O	26	SUB
25	also	also	B-ADVP	RB	O	26	VMOD
26	facilitated	facilitate	B-VP	VBD	O	0	ROOT
27	the	the	B-NP	DT	O	29	NMOD
28	memory	memory	I-NP	NN	O	29	NMOD
29	retrieval	retrieval	I-NP	NN	O	26	OBJ
30	in	in	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	32	NMOD
32	animals	animal	I-NP	NNS	O	34	NMOD
33	administered	administer	B-VP	VBN	O	34	NMOD
34	naloxone	naloxone	B-NP	NN	O	30	PMOD
35	during	during	B-PP	IN	O	26	VMOD
36	the	the	B-NP	DT	O	38	NMOD
37	training	training	I-NP	NN	O	38	NMOD
38	trial	trial	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	26	P

1	Similarly	Similarly	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	pre-test	pre-test	B-NP	JJ	O	4	NMOD
4	scopolamine	scopolamine	I-NP	NN	O	6	SUB
5	partially	partially	B-ADVP	RB	O	6	VMOD
6	reversed	reverse	B-VP	VBD	O	19	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	scopolamine	scopolamine	I-NP	NN	O	10	NMOD
9	induced	induce	B-VP	VBD	O	10	NMOD
10	amnesia	amnesia	B-NP	NN	O	6	OBJ
11	,	,	O	,	O	19	P
12	but	but	O	CC	O	19	VMOD
13	not	not	O	RB	O	12	DEP
14	significantly	significantly	B-ADVP	RB	O	19	VMOD
15	;	;	O	:	O	19	P
16	and	and	O	CC	O	19	VMOD
17	pre-test	pre-test	B-NP	JJ	O	18	NMOD
18	cycloheximide	cycloheximide	I-NP	NN	O	19	SUB
19	failed	fail	B-VP	VBD	O	0	ROOT
20	to	to	I-VP	TO	O	21	VMOD
21	reverse	reverse	I-VP	VB	O	19	VMOD
22	the	the	B-NP	DT	O	25	NMOD
23	cycloheximide	cycloheximide	I-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	amnesia	amnesia	I-NP	NN	O	21	OBJ
26	.	.	O	.	O	19	P

1	Apomorphine	Apomorphine	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	a	a	B-NP	DT	O	6	NMOD
4	nonselective	nonselective	I-NP	JJ	O	6	NMOD
5	dopamine	dopamine	I-NP	NN	O	6	NMOD
6	agonist	agonist	I-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	was	be	B-VP	VBD	O	0	ROOT
9	selected	select	I-VP	VBN	O	8	VC
10	due	due	B-ADJP	JJ	O	11	PMOD
11	to	to	B-PP	TO	O	9	VMOD
12	its	its	B-NP	PRP$	O	15	NMOD
13	biphasic	biphasic	I-NP	JJ	O	14	AMOD
14	behavioral	behavioral	I-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	11	PMOD
16	,	,	O	,	O	8	VMOD
17	its	its	B-NP	PRP$	O	18	NMOD
18	ability	ability	I-NP	NN	O	16	OBJ
19	to	to	B-VP	TO	O	20	VMOD
20	induce	induce	I-VP	VB	O	18	NMOD
21	hypothermia	hypothermia	B-NP	NN	O	20	OBJ
22	,	,	O	,	O	20	P
23	and	and	O	CC	O	20	VMOD
24	to	to	B-VP	TO	O	25	VMOD
25	produce	produce	I-VP	VB	O	20	VMOD
26	distinct	distinct	B-NP	JJ	O	27	NMOD
27	changes	change	I-NP	NNS	O	25	OBJ
28	to	to	B-PP	TO	O	27	NMOD
29	dopamine	dopamine	B-NP	NN	O	30	NMOD
30	turnover	turnover	I-NP	NN	O	28	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	the	the	B-NP	DT	O	34	NMOD
33	rodent	rodent	I-NP	NN	O	34	NMOD
34	brain	brain	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	9	VMOD
2	rats	rat	B-NP	NNS	O	1	PMOD
3	,	,	O	,	O	9	P
4	detection	detection	B-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	apomorphine	apomorphine	B-NP	NN	O	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	hyperactivity	hyperactivity	I-NP	NN	O	5	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	facilitated	facilitate	I-VP	VBN	O	9	VC
11	by	by	B-PP	IN	O	10	VMOD
12	a	a	B-NP	DT	O	13	NMOD
13	period	period	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	acclimatization	acclimatization	B-NP	NN	O	14	PMOD
16	to	to	B-PP	TO	O	13	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	test	test	I-NP	NN	O	19	NMOD
19	conditions	condition	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	9	P

1	Moreover	Moreover	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	test	test	B-NP	NN	O	4	NMOD
4	conditions	condition	I-NP	NNS	O	5	SUB
5	can	can	B-VP	MD	O	0	ROOT
6	impact	impact	I-VP	VB	O	5	VC
7	upon	upon	B-PP	IN	O	6	VMOD
8	other	other	B-NP	JJ	O	10	NMOD
9	physiological	physiological	I-NP	JJ	O	10	NMOD
10	responses	response	I-NP	NNS	O	7	PMOD
11	to	to	B-PP	TO	O	10	NMOD
12	apomorphine	apomorphine	B-NP	NN	O	11	PMOD
13	such	such	B-PP	JJ	O	14	PMOD
14	as	as	I-PP	IN	O	12	NMOD
15	drug	drug	B-NP	NN	O	17	NMOD
16	induced	induced	I-NP	JJ	O	17	NMOD
17	hypothermia	hypothermia	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	5	P

1	Tricuspid	Tricuspid	B-NP	JJ	O	3	NMOD
2	valve	valve	I-NP	NN	O	3	NMOD
3	regurgitation	regurgitation	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	lithium	lithium	B-NP	NN	O	7	NMOD
6	carbonate	carbonate	I-NP	NN	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	newborn	newborn	I-NP	JJ	O	11	NMOD
11	infant	infant	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	2	NMOD
2	newborn	newborn	I-NP	NN	O	21	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	massive	massive	B-NP	JJ	O	6	NMOD
5	tricuspid	tricuspid	I-NP	JJ	O	6	NMOD
6	regurgitation	regurgitation	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	21	P
8	atrial	atrial	B-NP	JJ	O	9	NMOD
9	flutter	flutter	I-NP	NN	O	21	SUB
10	,	,	O	,	O	21	P
11	congestive	congestive	B-NP	JJ	O	13	NMOD
12	heart	heart	I-NP	NN	O	13	NMOD
13	failure	failure	I-NP	NN	O	21	SUB
14	,	,	O	,	O	21	P
15	and	and	O	CC	O	21	VMOD
16	a	a	B-NP	DT	O	20	NMOD
17	high	high	I-NP	JJ	O	20	NMOD
18	serum	serum	I-NP	NN	O	20	NMOD
19	lithium	lithium	I-NP	NN	O	20	NMOD
20	level	level	I-NP	NN	O	21	SUB
21	is	be	B-VP	VBZ	O	0	ROOT
22	described	describe	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	This	This	B-NP	DT	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	first	first	I-NP	JJ	O	5	NMOD
5	patient	patient	I-NP	NN	O	2	PRD
6	to	to	B-VP	TO	O	8	VMOD
7	initially	initially	I-VP	RB	O	8	VMOD
8	manifest	manifest	I-VP	VB	O	5	NMOD
9	tricuspid	tricuspid	B-NP	JJ	O	10	NMOD
10	regurgitation	regurgitation	I-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	atrial	atrial	B-NP	JJ	O	13	NMOD
13	flutter	flutter	I-NP	NN	O	8	OBJ
14	,	,	O	,	O	2	VMOD
15	and	and	O	CC	O	19	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	11th	11th	I-NP	JJ	O	19	NMOD
18	described	describe	I-NP	VBN	O	19	NMOD
19	patient	patient	I-NP	NN	O	14	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	cardiac	cardiac	B-NP	JJ	O	22	NMOD
22	disease	disease	I-NP	NN	O	20	PMOD
23	among	among	B-PP	IN	O	19	NMOD
24	infants	infant	B-NP	NNS	O	23	PMOD
25	exposed	expose	B-VP	VBN	O	24	NMOD
26	to	to	B-PP	TO	O	25	VMOD
27	lithium	lithium	B-NP	NN	O	28	NMOD
28	compounds	compound	I-NP	NNS	O	26	PMOD
29	in	in	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	first	first	I-NP	JJ	O	32	NMOD
32	trimester	trimester	I-NP	NN	O	29	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	pregnancy	pregnancy	B-NP	NN	O	33	PMOD
35	.	.	O	.	O	2	P

1	Lithium	Lithium	B-NP	NN	O	2	NMOD
2	carbonate	carbonate	I-NP	NN	O	3	SUB
3	may	may	B-VP	MD	O	0	ROOT
4	be	be	I-VP	VB	O	3	VC
5	a	a	B-NP	DT	O	6	NMOD
6	factor	factor	I-NP	NN	O	4	PRD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	increasing	increase	I-NP	VBG	O	10	NMOD
10	incidence	incidence	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	congenital	congenital	B-NP	JJ	O	14	NMOD
13	heart	heart	I-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	PMOD
15	when	when	B-ADVP	WRB	O	3	VMOD
16	taken	take	B-VP	VBN	O	15	SBAR
17	during	during	B-PP	IN	O	16	VMOD
18	early	early	B-NP	JJ	O	19	NMOD
19	pregnancy	pregnancy	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	3	P

1	Phenobarbital	Phenobarbital	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	dyskinesia	dyskinesia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	neurologically-impaired	neurologically-impaired	I-NP	JJ	O	7	NMOD
7	child	child	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	2-year-old	2-year-old	I-NP	JJ	O	3	NMOD
3	child	child	I-NP	NN	O	8	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	known	known	B-NP	JJ	O	7	NMOD
6	neurologic	neurologic	I-NP	JJ	O	7	NMOD
7	impairment	impairment	I-NP	NN	O	4	PMOD
8	developed	develop	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	10	NMOD
10	dyskinesia	dyskinesia	I-NP	NN	O	8	OBJ
11	soon	soon	B-ADVP	RB	O	8	VMOD
12	after	after	B-PP	IN	O	11	PMOD
13	starting	start	B-VP	VBG	O	12	PMOD
14	phenobarbital	phenobarbital	B-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	13	OBJ
16	for	for	B-PP	IN	O	15	NMOD
17	seizures	seizure	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	8	P

1	On	On	B-PP	IN	O	9	VMOD
2	repeat	repeat	B-NP	NN	O	3	NMOD
3	challenge	challenge	I-NP	NN	O	1	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	phenobarbital	phenobarbital	B-NP	NN	O	4	PMOD
6	,	,	O	,	O	9	P
7	the	the	B-NP	DT	O	8	NMOD
8	dyskinesia	dyskinesia	I-NP	NN	O	9	SUB
9	recurred	recur	B-VP	VBD	O	0	ROOT
10	.	.	O	.	O	9	P

1	Valproic	Valproic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	6	SUB
3	(	(	O	(	O	5	DEP
4	VPA	VPA	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	given	give	I-VP	VBN	O	6	VC
8	to	to	B-PP	TO	O	7	VMOD
9	24	24	B-NP	CD	O	11	NMOD
10	epileptic	epileptic	I-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	8	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	were	be	B-VP	VBD	O	12	SBAR
14	already	already	I-VP	RB	O	13	VMOD
15	being	be	I-VP	VBG	O	13	VC
16	treated	treat	I-VP	VBN	O	15	VC
17	with	with	B-PP	IN	O	16	VMOD
18	other	other	B-NP	JJ	O	20	NMOD
19	antiepileptic	antiepileptic	I-NP	JJ	O	20	NMOD
20	drugs	drug	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	6	P

1	Ammonia	Ammonia	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	NH3	NH3	B-NP	NN	B-protein	4	DEP
4	)	)	O	)	O	1	NMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	higher	high	B-ADJP	JJR	O	5	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	,	,	O	,	O	9	P
11	during	during	B-PP	IN	O	8	NMOD
12	continuous	continuous	B-NP	JJ	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	5	P
15	complained	complain	B-VP	VBD	O	5	VMOD
16	of	of	B-PP	IN	O	15	VMOD
17	drowsiness	drowsiness	B-NP	NN	O	16	PMOD
18	(	(	O	(	O	21	DEP
19	7	7	B-NP	CD	O	20	NMOD
20	patients	patient	I-NP	NNS	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	than	than	B-PP	IN	O	15	VMOD
23	in	in	B-PP	IN	O	22	PMOD
24	those	those	B-NP	DT	O	23	PMOD
25	who	who	B-NP	WP	O	24	NMOD
26	were	be	B-VP	VBD	O	25	SBAR
27	symptom-free	symptom-free	B-ADJP	JJ	O	26	PRD
28	(	(	O	(	O	31	DEP
29	17	17	B-NP	CD	O	30	NMOD
30	patients	patient	I-NP	NNS	O	31	DEP
31	)	)	O	)	O	27	AMOD
32	,	,	O	,	O	15	P
33	although	although	B-SBAR	IN	O	15	VMOD
34	VPA	VPA	B-NP	NN	B-protein	36	NMOD
35	plasma	plasma	I-NP	NN	O	36	NMOD
36	levels	level	I-NP	NNS	O	37	SUB
37	were	be	B-VP	VBD	O	33	SBAR
38	similar	similar	B-ADJP	JJ	O	37	PRD
39	in	in	B-PP	IN	O	38	AMOD
40	both	both	B-NP	DT	O	41	NMOD
41	groups	group	I-NP	NNS	O	39	PMOD
42	.	.	O	.	O	5	P

1	Calcitonin	Calcitonin	B-NP	NN	O	2	NMOD
2	injection	injection	I-NP	NN	O	3	SUB
3	resulted	result	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	potentiation	potentiation	I-NP	NN	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	haloperidol	haloperidol	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	4	SBAR
10	catalepsy	catalepsy	B-NP	NN	O	14	NMOD
11	and	and	O	CC	O	14	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	partial	partial	I-NP	JJ	O	14	NMOD
14	prevention	prevention	I-NP	NN	O	9	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	apomorphine	apomorphine	B-NP	NN	O	18	NMOD
17	induced	induced	I-NP	JJ	O	18	NMOD
18	hyperactivity	hyperactivity	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	3	P

1	Development	Development	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	isoproterenol	isoproterenol	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	cardiac	cardiac	B-NP	JJ	O	6	NMOD
6	hypertrophy	hypertrophy	I-NP	NN	O	4	OBJ
7	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	development	development	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cardiac	cardiac	B-NP	JJ	O	5	NMOD
5	hypertrophy	hypertrophy	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	studied	study	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	adult	adult	B-NP	JJ	O	12	NMOD
10	female	female	I-NP	JJ	O	12	NMOD
11	Wistar	Wistar	I-NP	NNP	O	12	NMOD
12	rats	rat	I-NP	NNS	O	8	PMOD
13	following	follow	B-PP	VBG	O	7	VMOD
14	daily	daily	B-NP	JJ	O	16	NMOD
15	subcutaneous	subcutaneous	I-NP	JJ	O	16	NMOD
16	injections	injection	I-NP	NNS	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	isoproterenol	isoproterenol	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	21	DEP
20	ISO	ISO	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	(	(	O	(	O	27	DEP
23	0.3	0.3	B-NP	CD	O	26	NMOD
24	mg/kg	mg/kg	I-NP	NN	O	26	NMOD
25	body	body	I-NP	NN	O	26	NMOD
26	weight	weight	I-NP	NN	O	27	DEP
27	)	)	O	)	O	18	NMOD
28	.	.	O	.	O	6	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	adaptive	adaptive	I-NP	JJ	O	7	NMOD
7	response	response	I-NP	NN	O	10	SUB
8	to	to	B-PP	TO	O	7	NMOD
9	ISO	ISO	B-NP	NN	B-protein	8	PMOD
10	shows	show	B-VP	VBZ	O	4	SBAR
11	an	an	B-NP	DT	O	14	NMOD
12	early	early	I-NP	JJ	O	14	NMOD
13	hypertrophic	hypertrophic	I-NP	JJ	O	14	NMOD
14	phase	phase	I-NP	NN	O	10	OBJ
15	(	(	O	(	O	18	DEP
16	1-4	1-4	B-NP	CD	O	17	NMOD
17	days	day	I-NP	NNS	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	characterized	characterize	B-VP	VBN	O	14	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	substantial	substantial	I-NP	JJ	O	23	NMOD
23	increase	increase	I-NP	NN	O	20	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	RNA	RNA	B-NP	NN	O	26	NMOD
26	content	content	I-NP	NN	O	29	NMOD
27	and	and	O	CC	O	29	NMOD
28	cardiac	cardiac	B-NP	JJ	O	29	NMOD
29	mass	mass	I-NP	NN	O	24	PMOD
30	in	in	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	32	NMOD
32	absence	absence	I-NP	NN	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	changes	change	B-NP	NNS	O	33	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	DNA	DNA	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	3	P

1	Co-carcinogenic	Co-carcinogenic	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	retinyl	retinyl	B-NP	NN	O	5	NMOD
5	acetate	acetate	I-NP	NN	O	3	PMOD
6	on	on	B-PP	IN	O	2	NMOD
7	forestomach	forestomach	B-NP	NN	O	8	NMOD
8	carcinogenesis	carcinogenesis	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	male	male	B-NP	JJ	O	12	NMOD
11	F344	F344	I-NP	NN	O	12	NMOD
12	rats	rat	I-NP	NNS	O	9	PMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	butylated	butylate	B-NP	VBN	O	16	NMOD
16	hydroxyanisole	hydroxyanisole	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	potential	potential	I-NP	JJ	O	4	NMOD
3	modifying	modifying	I-NP	NN	O	4	NMOD
4	effect	effect	I-NP	NN	O	17	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	retinyl	retinyl	B-NP	NN	O	7	NMOD
7	acetate	acetate	I-NP	NN	O	5	PMOD
8	(	(	O	(	O	10	DEP
9	RA	RA	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	on	on	B-PP	IN	O	4	NMOD
12	butylated	butylate	B-NP	VBN	O	13	NMOD
13	hydroxyanisole	hydroxyanisole	I-NP	NN	O	11	PMOD
14	(	(	O	(	O	16	DEP
15	BHA	BHA	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	induced	induce	B-VP	VBD	O	21	VMOD
18	rat	rat	B-NP	NN	O	20	NMOD
19	forestomach	forestomach	I-NP	NN	O	20	NMOD
20	tumorigenesis	tumorigenesis	I-NP	NN	O	21	SUB
21	was	be	B-VP	VBD	O	0	ROOT
22	examined	examine	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	In	In	B-PP	IN	O	34	VMOD
2	groups	group	B-NP	NNS	O	1	PMOD
3	given	give	B-VP	VBN	O	2	NMOD
4	2	2	B-NP	CD	O	6	NMOD
5	%	%	I-NP	NN	O	6	NMOD
6	BHA	BHA	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	34	P
8	although	although	B-SBAR	IN	O	34	VMOD
9	marked	marked	B-NP	JJ	O	10	AMOD
10	hyperplastic	hyperplastic	I-NP	JJ	O	11	NMOD
11	changes	change	I-NP	NNS	O	16	SUB
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	forestomach	forestomach	I-NP	NN	O	15	NMOD
15	epithelium	epithelium	I-NP	NN	O	12	PMOD
16	were	be	B-VP	VBD	O	8	SBAR
17	observed	observe	I-VP	VBN	O	16	VC
18	in	in	B-PP	IN	O	17	VMOD
19	all	all	B-NP	DT	O	20	NMOD
20	animals	animal	I-NP	NNS	O	18	PMOD
21	,	,	O	,	O	34	P
22	co-administration	co-administration	B-NP	NN	O	34	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	0.25	0.25	B-NP	CD	O	26	NMOD
25	%	%	I-NP	NN	O	26	NMOD
26	RA	RA	I-NP	NN	O	23	PMOD
27	significantly	significantly	B-ADVP	RB	O	34	VMOD
28	(	(	O	(	O	33	DEP
29	P	P	B-NP	NN	O	31	SUB
30	less	less	B-ADJP	JJR	O	31	AMOD
31	than	than	B-PP	IN	O	33	DEP
32	0.05	0.05	B-NP	CD	O	31	AMOD
33	)	)	O	)	O	27	AMOD
34	increased	increase	B-VP	VBD	O	0	ROOT
35	the	the	B-NP	DT	O	36	NMOD
36	incidence	incidence	I-NP	NN	O	34	OBJ
37	of	of	B-PP	IN	O	36	NMOD
38	forestomach	forestomach	B-NP	NN	O	39	NMOD
39	tumors	tumor	I-NP	NNS	O	37	PMOD
40	(	(	O	(	O	46	DEP
41	squamous	squamous	B-NP	JJ	O	43	NMOD
42	cell	cell	I-NP	NN	O	43	NMOD
43	papilloma	papilloma	I-NP	NN	O	45	NMOD
44	and	and	O	CC	O	45	NMOD
45	carcinoma	carcinoma	B-NP	NN	O	46	DEP
46	)	)	O	)	O	39	NMOD
47	to	to	B-PP	TO	O	36	NMOD
48	60	60	B-NP	CD	O	49	NMOD
49	%	%	I-NP	NN	O	47	PMOD
50	(	(	O	(	O	57	DEP
51	9/15	9/15	B-NP	CD	O	54	NMOD
52	,	,	O	,	O	54	P
53	2	2	B-NP	CD	O	54	NMOD
54	rats	rat	I-NP	NNS	O	57	DEP
55	with	with	B-PP	IN	O	54	NMOD
56	carcinoma	carcinoma	B-NP	NN	O	55	PMOD
57	)	)	O	)	O	36	NMOD
58	from	from	B-PP	IN	O	34	VMOD
59	15	15	B-NP	CD	O	60	NMOD
60	%	%	I-NP	NN	O	58	PMOD
61	(	(	O	(	O	68	DEP
62	3/20	3/20	B-NP	CD	O	65	NMOD
63	,	,	O	,	O	65	P
64	one	one	B-NP	CD	O	65	NMOD
65	rat	rat	I-NP	NN	O	68	DEP
66	with	with	B-PP	IN	O	65	NMOD
67	carcinoma	carcinoma	B-NP	NN	O	66	PMOD
68	)	)	O	)	O	60	NMOD
69	in	in	B-PP	IN	O	34	VMOD
70	the	the	B-NP	DT	O	71	NMOD
71	group	group	I-NP	NN	O	69	PMOD
72	given	give	B-PP	VBN	O	71	NMOD
73	RA-free	RA-free	B-NP	JJ	O	74	NMOD
74	water	water	I-NP	NN	O	72	PMOD
75	.	.	O	.	O	34	P

1	In	In	B-PP	IN	O	22	VMOD
2	rats	rat	B-NP	NNS	O	1	PMOD
3	given	give	B-VP	VBN	O	2	NMOD
4	1	1	B-NP	CD	O	6	NMOD
5	%	%	I-NP	NN	O	6	NMOD
6	BHA	BHA	I-NP	NN	O	8	NMOD
7	,	,	O	,	O	8	P
8	RA	RA	B-NP	NN	O	3	PMOD
9	co-administered	co-administere	B-VP	VBN	O	8	NMOD
10	at	at	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	12	NMOD
12	dose	dose	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	0.05	0.05	B-NP	CD	O	21	NMOD
15	,	,	I-NP	,	O	21	P
16	0.1	0.1	I-NP	CD	O	21	NMOD
17	,	,	I-NP	,	O	21	P
18	0.2	0.2	I-NP	CD	O	21	NMOD
19	or	or	I-NP	CC	O	21	NMOD
20	0.25	0.25	I-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	13	PMOD
22	showed	show	B-VP	VBD	O	0	ROOT
23	a	a	B-NP	DT	O	26	NMOD
24	dose-dependent	dose-dependent	I-NP	JJ	O	26	NMOD
25	enhancing	enhancing	I-NP	NN	O	26	NMOD
26	effect	effect	I-NP	NN	O	33	SUB
27	on	on	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	29	NMOD
29	development	development	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	32	NMOD
32	BHA	BHA	I-NP	NN	B-protein	30	PMOD
33	induced	induce	B-VP	VBD	O	22	VMOD
34	epithelial	epithelial	B-NP	JJ	O	35	NMOD
35	hyperplasia	hyperplasia	I-NP	NN	O	33	OBJ
36	.	.	O	.	O	22	P

1	Tumors	Tumor	B-NP	NNS	O	4	NMOD
2	,	,	O	,	O	4	P
3	all	all	B-NP	DT	O	4	NMOD
4	papillomas	papilloma	I-NP	NNS	O	6	SUB
5	,	,	O	,	O	4	P
6	were	be	B-VP	VBD	O	0	ROOT
7	induced	induce	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	3	3	B-NP	CD	O	10	NMOD
10	rats	rat	I-NP	NNS	O	8	PMOD
11	(	(	O	(	O	14	DEP
12	17	17	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	with	with	B-PP	IN	O	7	VMOD
16	0.25	0.25	B-NP	CD	O	17	AMOD
17	%	%	I-NP	NN	O	18	NMOD
18	RA	RA	I-NP	NN	O	15	PMOD
19	and	and	O	CC	O	15	PMOD
20	in	in	B-PP	IN	O	15	PMOD
21	one	one	B-NP	CD	O	22	NMOD
22	rat	rat	I-NP	NN	O	20	PMOD
23	(	(	O	(	O	26	DEP
24	10	10	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	26	DEP
26	)	)	O	)	O	22	NMOD
27	with	with	B-PP	IN	O	22	NMOD
28	0.05	0.05	B-NP	CD	O	29	AMOD
29	%	%	I-NP	NN	O	31	NMOD
30	RA	RA	I-NP	NN	O	31	NMOD
31	co-administration	co-administration	I-NP	NN	O	27	PMOD
32	.	.	O	.	O	6	P

1	Ketanserin	Ketanserin	B-NP	NN	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	3	SUB
3	reverses	reverse	B-VP	VBZ	O	0	ROOT
4	alfentanil	alfentanil	B-NP	NN	O	7	NMOD
5	induced	induce	I-NP	VBN	O	7	NMOD
6	muscle	muscle	I-NP	NN	O	7	NMOD
7	rigidity	rigidity	I-NP	NN	O	3	OBJ
8	.	.	O	.	O	3	P

1	Systemic	Systemic	B-NP	JJ	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	15	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	ketanserin	ketanserin	B-NP	NN	O	12	NMOD
5	,	,	O	,	O	12	P
6	a	a	B-NP	DT	O	12	NMOD
7	relatively	relatively	I-NP	RB	O	8	AMOD
8	specific	specific	I-NP	JJ	O	12	NMOD
9	type-2	type-2	I-NP	NN	O	12	NMOD
10	serotonin	serotonin	I-NP	NN	O	12	NMOD
11	receptor	receptor	I-NP	NN	O	12	NMOD
12	antagonist	antagonist	I-NP	NN	O	3	PMOD
13	,	,	O	,	O	2	P
14	significantly	significantly	B-VP	RB	O	15	VMOD
15	attenuated	attenuate	I-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	18	NMOD
17	muscle	muscle	I-NP	NN	O	18	NMOD
18	rigidity	rigidity	I-NP	NN	O	15	OBJ
19	produced	produce	B-VP	VBN	O	18	NMOD
20	in	in	B-PP	IN	O	19	VMOD
21	rats	rat	B-NP	NNS	O	20	PMOD
22	by	by	B-PP	IN	O	19	VMOD
23	the	the	B-NP	DT	O	28	NMOD
24	potent	potent	I-NP	JJ	O	28	NMOD
25	short-acting	short-acting	I-NP	JJ	O	28	NMOD
26	opiate	opiate	I-NP	NN	O	28	NMOD
27	agonist	agonist	I-NP	NN	O	28	NMOD
28	alfentanil	alfentanil	I-NP	NN	O	22	PMOD
29	.	.	O	.	O	15	P

1	Chlordiazepoxide	Chlordiazepoxide	B-NP	NN	O	8	SUB
2	at	at	B-PP	IN	O	1	NMOD
3	doses	dose	B-NP	NNS	O	7	NMOD
4	up	up	B-NP	RB	O	7	NMOD
5	to	to	I-NP	TO	O	4	AMOD
6	10	10	I-NP	CD	O	4	AMOD
7	mg/kg	mg/kg	I-NP	NN	O	2	PMOD
8	failed	fail	B-VP	VBD	O	0	ROOT
9	to	to	I-VP	TO	O	11	VMOD
10	significantly	significantly	I-VP	RB	O	11	VMOD
11	influence	influence	I-VP	VB	O	8	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	rigidity	rigidity	I-NP	NN	O	11	OBJ
14	produced	produce	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	alfentanil	alfentanil	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	8	P

1	Despite	Despite	B-PP	IN	O	21	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	absence	absence	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	rigidity	rigidity	B-NP	NN	O	7	NMOD
6	,	,	O	,	O	7	P
7	animals	animal	B-NP	NNS	O	4	PMOD
8	that	that	B-NP	WDT	O	3	NMOD
9	received	receive	B-VP	VBD	O	8	SBAR
10	ketanserin	ketanserin	B-NP	NN	O	9	OBJ
11	(	(	O	(	O	17	DEP
12	greater	great	B-NP	JJR	O	17	DEP
13	than	than	I-NP	IN	O	12	AMOD
14	0.31	0.31	I-NP	CD	O	15	NMOD
15	mg/kg	mg/kg	I-NP	NN	O	13	PMOD
16	i.p.	i.p.	B-ADVP	RB	O	12	NMOD
17	)	)	O	)	O	1	NMOD
18	followed	follow	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	alfentanil	alfentanil	B-NP	NN	O	19	PMOD
21	were	be	B-VP	VBD	O	0	ROOT
22	motionless	motionless	B-ADJP	JJ	O	21	PRD
23	,	,	O	,	O	21	P
24	flaccid	flaccid	B-NP	NN	O	28	AMOD
25	,	,	O	,	O	28	P
26	and	and	O	CC	O	28	AMOD
27	less	less	B-ADJP	RBR	O	28	AMOD
28	responsive	responsive	I-ADJP	JJ	O	21	PRD
29	to	to	B-PP	TO	O	28	AMOD
30	external	external	B-NP	JJ	O	31	NMOD
31	stimuli	stimulus	I-NP	NNS	O	29	PMOD
32	than	than	B-SBAR	IN	O	28	AMOD
33	were	be	B-VP	VBD	O	32	SBAR
34	animals	animal	B-NP	NNS	O	33	PRD
35	receiving	receive	B-VP	VBG	O	34	NMOD
36	alfentanil	alfentanil	B-NP	NN	O	35	OBJ
37	alone	alone	B-ADVP	RB	O	36	NMOD
38	.	.	O	.	O	21	P

1	Pretreatment	Pretreatment	B-NP	NN	O	6	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	type-2	type-2	B-NP	NN	O	5	NMOD
4	serotonin	serotonin	I-NP	NN	O	5	NMOD
5	antagonists	antagonist	I-NP	NNS	O	2	PMOD
6	may	may	B-VP	MD	O	0	ROOT
7	be	be	I-VP	VB	O	6	VC
8	clinically	clinically	B-ADJP	RB	O	9	AMOD
9	useful	useful	I-ADJP	JJ	O	7	PRD
10	in	in	B-PP	IN	O	9	AMOD
11	attenuating	attenuate	B-VP	VBG	O	10	PMOD
12	opiate	opiate	B-NP	NN	O	11	OBJ
13	induced	induce	B-VP	VBD	O	6	VMOD
14	rigidity	rigidity	B-NP	NN	O	13	OBJ
15	,	,	O	,	O	6	P
16	although	although	B-SBAR	IN	O	6	VMOD
17	further	further	B-NP	JJ	O	18	NMOD
18	studies	study	I-NP	NNS	O	19	SUB
19	will	will	B-VP	MD	O	16	SBAR
20	be	be	I-VP	VB	O	19	VC
21	necessary	necessary	B-ADJP	JJ	O	20	PRD
22	to	to	B-VP	TO	O	23	VMOD
23	assess	assess	I-VP	VB	O	21	AMOD
24	the	the	B-NP	DT	O	25	NMOD
25	interaction	interaction	I-NP	NN	O	23	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	possibly	possibly	B-NP	RB	O	28	AMOD
28	enhanced	enhance	I-NP	VBN	O	29	NMOD
29	CNS	CNS	I-NP	NN	B-protein	35	NMOD
30	,	,	O	,	O	35	P
31	cardiovascular	cardiovascular	B-ADJP	JJ	O	35	NMOD
32	,	,	O	,	O	35	P
33	and	and	O	CC	O	35	NMOD
34	respiratory	respiratory	B-NP	JJ	O	35	NMOD
35	depression	depression	I-NP	NN	O	26	PMOD
36	.	.	O	.	O	6	P

1	Use	Use	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	glycopyrronium	glycopyrronium	B-NP	NN	B-protein	6	NMOD
4	5	5	I-NP	CD	I-protein	6	NMOD
5	micrograms	microgram	I-NP	NNS	I-protein	6	NMOD
6	kg-1	kg-1	I-NP	NN	I-protein	2	PMOD
7	provided	provide	B-VP	VBD	O	27	VMOD
8	greater	great	B-NP	JJR	O	10	NMOD
9	cardiovascular	cardiovascular	I-NP	JJ	O	10	NMOD
10	stability	stability	I-NP	NN	O	15	NMOD
11	and	and	O	CC	O	15	NMOD
12	,	,	O	,	O	15	P
13	given	give	B-PP	VBN	O	15	NMOD
14	1	1	B-NP	CD	O	15	NMOD
15	min	min	I-NP	NN	O	7	OBJ
16	before	before	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	edrophonium	edrophonium	I-NP	NN	O	16	PMOD
19	,	,	O	,	O	7	P
20	was	be	B-VP	VBD	O	7	VMOD
21	sufficient	sufficient	B-ADJP	JJ	O	20	PRD
22	to	to	B-VP	TO	O	23	VMOD
23	minimize	minimize	I-VP	VB	O	21	AMOD
24	early	early	B-ADVP	RB	O	23	VMOD
25	,	,	O	,	O	7	P
26	edrophonium	edrophonium	B-NP	NN	O	27	SUB
27	induced	induce	B-VP	VBD	O	0	ROOT
28	bradycardias	bradycardia	B-NP	NNS	O	27	OBJ
29	.	.	O	.	O	27	P

1	Involvement	Involvement	B-NP	NN	O	7	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	locus	locus	B-NP	NN	O	4	NMOD
4	coeruleus	coeruleus	I-NP	NN	O	2	PMOD
5	and	and	O	CC	O	7	NMOD
6	noradrenergic	noradrenergic	B-NP	JJ	O	7	NMOD
7	neurotransmission	neurotransmission	I-NP	NN	O	10	SUB
8	in	in	B-PP	IN	O	7	NMOD
9	fentanyl	fentanyl	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	muscular	muscular	B-NP	JJ	O	12	NMOD
12	rigidity	rigidity	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	10	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	rat	rat	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	10	P

1	Whereas	Whereas	B-PP	IN	O	0	ROOT
2	muscular	muscular	B-NP	JJ	O	3	NMOD
3	rigidity	rigidity	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	SBAR
5	a	a	B-NP	DT	O	8	NMOD
6	well-known	well-known	I-NP	JJ	O	8	NMOD
7	side	side	I-NP	NN	O	8	NMOD
8	effect	effect	I-NP	NN	O	4	PRD
9	that	that	B-NP	WDT	O	8	NMOD
10	is	be	B-VP	VBZ	O	9	SBAR
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	high-dose	high-dose	B-NP	JJ	O	15	NMOD
14	fentanyl	fentanyl	I-NP	NN	O	15	NMOD
15	anesthesia	anesthesia	I-NP	NN	O	18	NMOD
16	,	,	O	,	O	18	P
17	a	a	B-NP	DT	O	18	NMOD
18	paucity	paucity	I-NP	NN	O	12	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	information	information	B-NP	NN	O	19	PMOD
21	exists	exist	B-VP	VBZ	O	1	VMOD
22	with	with	B-PP	IN	O	21	VMOD
23	regard	regard	B-NP	NN	O	22	PMOD
24	to	to	B-PP	TO	O	23	NMOD
25	its	its	B-NP	PRP$	O	29	NMOD
26	underlying	underlie	I-NP	VBG	O	29	NMOD
27	mechanism	mechanism	I-NP	NN	O	29	NMOD
28	(	(	I-NP	(	O	29	NMOD
29	s	s	I-NP	NNS	O	24	PMOD
30	)	)	O	)	O	29	NMOD
31	.	.	O	.	O	1	P

1	Such	Such	B-NP	PDT	O	5	NMOD
2	an	an	I-NP	DT	O	5	NMOD
3	induced	induce	I-NP	VBN	O	5	NMOD
4	muscular	muscular	I-NP	JJ	O	5	NMOD
5	rigidity	rigidity	I-NP	NN	O	10	SUB
6	by	by	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	narcotic	narcotic	I-NP	JJ	O	9	NMOD
9	agent	agent	I-NP	NN	O	6	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	significantly	significantly	I-VP	RB	O	10	VMOD
12	antagonized	antagonize	I-VP	VBN	O	10	VC
13	or	or	O	CC	O	12	VMOD
14	even	even	B-VP	RB	O	15	VMOD
15	reduced	reduce	I-VP	VBN	O	12	VMOD
16	by	by	B-PP	IN	O	15	VMOD
17	prior	prior	B-NP	JJ	O	19	NMOD
18	electrolytic	electrolytic	I-NP	JJ	O	19	NMOD
19	lesions	lesion	I-NP	NNS	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	locus	locus	I-NP	NN	O	23	NMOD
23	coeruleus	coeruleus	I-NP	NN	O	25	NMOD
24	or	or	I-NP	CC	O	25	NMOD
25	pretreatment	pretreatment	I-NP	NN	O	20	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	alpha-adrenoceptor	alpha-adrenoceptor	I-NP	NN	O	29	NMOD
29	blocker	blocker	I-NP	NN	O	31	NMOD
30	,	,	O	,	O	31	P
31	prazosin	prazosin	B-NP	NN	O	26	PMOD
32	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	42-year-old	42-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	superior	superior	B-NP	JJ	O	14	NMOD
9	sagittal	sagittal	I-NP	JJ	O	11	AMOD
10	and	and	I-NP	CC	O	11	AMOD
11	left	left	I-NP	JJ	O	14	NMOD
12	transverse	transverse	I-NP	JJ	O	14	NMOD
13	sinus	sinus	I-NP	NN	O	14	NMOD
14	thrombosis	thrombosis	I-NP	NN	O	7	OBJ
15	associated	associate	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	prolonged	prolonged	B-NP	JJ	O	20	NMOD
18	epsilon-aminocaproic	epsilon-aminocaproic	I-NP	JJ	O	20	NMOD
19	acid	acid	I-NP	NN	O	20	NMOD
20	therapy	therapy	I-NP	NN	O	16	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	menorrhagia	menorrhagia	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	19	SUB
2	increased	increase	B-NP	VBN	O	3	NMOD
3	risk	risk	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	thromboembolic	thromboembolic	B-NP	JJ	O	6	NMOD
6	disease	disease	I-NP	NN	O	4	PMOD
7	has	have	B-VP	VBZ	O	1	SBAR
8	been	be	I-VP	VBN	O	7	VC
9	reported	report	I-VP	VBN	O	8	VC
10	during	during	B-PP	IN	O	9	VMOD
11	treatment	treatment	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	epsilon-aminocaproic	epsilon-aminocaproic	B-NP	JJ	O	14	NMOD
14	acid	acid	I-NP	NN	O	18	NMOD
15	,	,	O	,	O	18	P
16	cerebral	cerebral	B-NP	JJ	O	18	NMOD
17	sinus	sinus	I-NP	NN	O	18	NMOD
18	thrombosis	thrombosis	I-NP	NN	O	12	PMOD
19	has	have	B-VP	VBZ	O	0	ROOT
20	not	not	I-VP	RB	O	19	VMOD
21	been	be	I-VP	VBN	O	19	VC
22	previously	previously	I-VP	RB	O	21	VMOD
23	described	describe	I-VP	VBN	O	21	VC
24	.	.	O	.	O	19	P

1	Hemorrhagic	Hemorrhagic	B-NP	JJ	O	2	NMOD
2	cystitis	cystitis	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	7	NMOD
5	potentially	potentially	I-NP	RB	O	6	AMOD
6	serious	serious	I-NP	JJ	O	7	NMOD
7	complication	complication	I-NP	NN	O	3	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	high-dose	high-dose	B-NP	JJ	O	11	NMOD
10	cyclophosphamide	cyclophosphamide	I-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	8	PMOD
12	administered	administer	B-VP	VBN	O	11	NMOD
13	before	before	B-PP	IN	O	12	VMOD
14	bone	bone	B-NP	NN	O	16	NMOD
15	marrow	marrow	I-NP	NN	O	16	NMOD
16	transplantation	transplantation	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	13	VMOD
2	an	an	B-NP	DT	O	3	NMOD
3	attempt	attempt	I-NP	NN	O	1	PMOD
4	to	to	B-VP	TO	O	5	VMOD
5	obviate	obviate	I-VP	VB	O	3	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	inconvenience	inconvenience	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	bladder	bladder	B-NP	NN	O	10	NMOD
10	irrigation	irrigation	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	13	P
12	we	we	B-NP	PRP	O	13	SUB
13	conducted	conduct	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	16	NMOD
15	feasibility	feasibility	I-NP	NN	O	16	NMOD
16	trial	trial	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	uroprophylaxis	uroprophylaxis	B-NP	NN	O	17	PMOD
19	with	with	B-PP	IN	O	13	VMOD
20	mesna	mesna	B-NP	NN	O	19	PMOD
21	,	,	O	,	O	20	P
22	which	which	B-NP	WDT	O	20	NMOD
23	neutralizes	neutralize	B-VP	VBZ	O	22	SBAR
24	the	the	B-NP	DT	O	26	NMOD
25	hepatic	hepatic	I-NP	JJ	O	26	NMOD
26	metabolite	metabolite	I-NP	NN	O	23	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	cyclophosphamide	cyclophosphamide	B-NP	NN	O	27	PMOD
29	that	that	B-NP	WDT	O	28	NMOD
30	causes	cause	B-VP	VBZ	O	29	SBAR
31	hemorrhagic	hemorrhagic	B-NP	JJ	O	32	NMOD
32	cystitis	cystitis	I-NP	NN	O	30	OBJ
33	.	.	O	.	O	13	P

1	In	In	B-PP	IN	O	0	ROOT
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	1	VMOD
4	two	two	B-NP	CD	O	5	AMOD
5	of	of	I-NP	IN	O	8	NMOD
6	four	four	I-NP	CD	O	5	AMOD
7	consecutive	consecutive	I-NP	JJ	O	8	NMOD
8	patients	patient	I-NP	NNS	O	3	ROOT
9	who	who	B-NP	WP	O	8	NMOD
10	received	receive	B-VP	VBD	O	9	SBAR
11	mesna	mesna	B-NP	NN	O	12	NMOD
12	uroprophylaxis	uroprophylaxis	I-NP	NN	O	10	OBJ
13	before	before	B-PP	IN	O	10	VMOD
14	allogeneic	allogeneic	B-NP	JJ	O	17	NMOD
15	bone	bone	I-NP	NN	O	17	NMOD
16	marrow	marrow	I-NP	NN	O	17	NMOD
17	transplantation	transplantation	I-NP	NN	O	18	SUB
18	had	have	B-VP	VBD	O	13	SBAR
19	severe	severe	B-NP	JJ	O	21	NMOD
20	hemorrhagic	hemorrhagic	I-NP	JJ	O	21	NMOD
21	cystitis	cystitis	I-NP	NN	O	18	OBJ
22	for	for	B-PP	IN	O	18	VMOD
23	at	at	B-NP	IN	O	26	NMOD
24	least	least	I-NP	JJS	O	23	AMOD
25	2	2	I-NP	CD	O	23	AMOD
26	weeks	week	I-NP	NNS	O	22	PMOD
27	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	5	NMOD
2	most	most	I-NP	RBS	O	3	AMOD
3	common	common	I-NP	JJ	O	5	NMOD
4	adverse	adverse	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	nausea	nausea	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	vomiting	vomiting	I-NP	NN	O	6	PRD
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	flumazenil	flumazenil	I-NP	NN	O	13	NMOD
13	group	group	I-NP	NN	O	18	NMOD
14	and	and	O	CC	O	18	NMOD
15	nausea	nausea	B-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	injection-site	injection-site	B-NP	JJ	O	18	NMOD
18	pain	pain	I-NP	NN	O	10	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	placebo	placebo	I-NP	NN	O	22	NMOD
22	group	group	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	6	P

1	Hepatic	Hepatic	B-NP	JJ	O	2	NMOD
2	adenomas	adenoma	I-NP	NNS	O	18	NMOD
3	and	and	O	CC	O	6	NMOD
4	focal	focal	B-NP	JJ	O	6	NMOD
5	nodular	nodular	I-NP	JJ	O	6	NMOD
6	hyperplasia	hyperplasia	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	liver	liver	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	young	young	B-NP	JJ	O	12	NMOD
12	women	woman	I-NP	NNS	O	10	PMOD
13	on	on	B-PP	IN	O	12	NMOD
14	oral	oral	B-NP	JJ	O	15	NMOD
15	contraceptives	contraceptive	I-NP	NNS	O	13	PMOD
16	:	:	O	:	O	2	P
17	case	case	B-NP	NN	O	18	NMOD
18	reports	report	I-NP	NNS	O	0	ROOT
19	.	.	O	.	O	18	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	7	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	hepatic	hepatic	B-NP	JJ	O	5	NMOD
5	adenoma	adenoma	I-NP	NN	O	3	PMOD
6	and	and	O	CC	O	7	NMOD
7	one	one	B-NP	CD	O	21	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	focal	focal	B-NP	JJ	O	11	NMOD
10	nodular	nodular	I-NP	JJ	O	11	NMOD
11	hyperplasia	hyperplasia	I-NP	NN	O	8	PMOD
12	presumably	presumably	B-VP	RB	O	13	VMOD
13	associated	associate	I-VP	VBN	O	11	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	use	use	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	oral	oral	B-NP	JJ	O	19	NMOD
19	contraceptives	contraceptive	I-NP	NNS	O	17	PMOD
20	,	,	O	,	O	7	P
21	are	be	B-VP	VBP	O	0	ROOT
22	reported	report	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	Arterial	Arterial	B-NP	JJ	O	2	NMOD
2	thromboembolism	thromboembolism	I-NP	NN	O	11	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	receiving	receive	B-VP	VBG	O	4	NMOD
6	systemic	systemic	B-NP	JJ	O	8	NMOD
7	heparin	heparin	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	OBJ
9	:	:	O	:	O	2	P
10	a	a	B-NP	DT	O	11	NMOD
11	complication	complication	I-NP	NN	O	0	ROOT
12	associated	associate	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	heparin	heparin	B-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	thrombocytopenia	thrombocytopenia	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	11	P

1	Arterial	Arterial	B-NP	JJ	O	2	NMOD
2	thromboembolism	thromboembolism	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	recognized	recognize	I-NP	VBN	O	6	NMOD
6	complication	complication	I-NP	NN	O	3	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	systemic	systemic	B-NP	JJ	O	10	NMOD
9	heparin	heparin	I-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	3	P

1	Characteristic	Characteristic	B-NP	JJ	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	entity	entity	I-NP	NN	O	2	PMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	arterial	arterial	B-NP	JJ	O	7	NMOD
7	occlusion	occlusion	I-NP	NN	O	5	PRD
8	by	by	B-PP	IN	O	7	NMOD
9	platelet-fibrin	platelet-fibrin	B-NP	NN	B-protein	10	NMOD
10	thrombi	thrombi	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	distal	distal	B-NP	JJ	O	13	NMOD
13	ischemia	ischemia	I-NP	NN	O	11	PMOD
14	occurring	occur	B-VP	VBG	O	13	NMOD
15	four	four	B-NP	CD	O	17	AMOD
16	to	to	I-NP	TO	O	17	AMOD
17	twenty	twenty	I-NP	CD	O	18	NMOD
18	days	day	I-NP	NNS	O	14	OBJ
19	after	after	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	initiation	initiation	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	heparin	heparin	B-NP	NN	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	5	P
26	preceded	precede	B-VP	VBN	O	5	VC
27	by	by	B-PP	IN	O	26	VMOD
28	profound	profound	B-NP	JJ	O	29	NMOD
29	thrombocytopenia	thrombocytopenia	I-NP	NN	O	27	PMOD
30	with	with	B-PP	IN	O	29	NMOD
31	platelet	platelet	B-NP	NN	O	32	NMOD
32	counts	count	I-NP	NNS	O	30	PMOD
33	in	in	B-PP	IN	O	32	NMOD
34	the	the	B-NP	DT	O	35	NMOD
35	range	range	I-NP	NN	O	33	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	30	30	B-NP	CD	O	43	NMOD
38	,	,	I-NP	,	O	43	P
39	000	000	I-NP	CD	O	41	AMOD
40	to	to	I-NP	TO	O	41	AMOD
41	40	40	I-NP	CD	O	43	NMOD
42	,	,	I-NP	,	O	43	P
43	000	000	I-NP	CD	O	36	PMOD
44	per	per	B-PP	IN	O	29	NMOD
45	cubic	cubic	B-NP	JJ	O	46	NMOD
46	millimeter	millimeter	I-NP	NN	O	44	PMOD
47	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	3	NMOD
2	common	common	I-NP	JJ	O	3	NMOD
3	factor	factor	I-NP	NN	O	8	SUB
4	relating	relate	B-VP	VBG	O	3	NMOD
5	thromboembolism	thromboembolism	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	thrombocytopenia	thrombocytopenia	I-NP	NN	O	4	OBJ
8	is	be	B-VP	VBZ	O	0	ROOT
9	heparin	heparin	B-NP	NN	O	12	NMOD
10	induced	induced	I-NP	JJ	O	12	NMOD
11	platelet	platelet	I-NP	NN	O	12	NMOD
12	aggregation	aggregation	I-NP	NN	O	8	PRD
13	.	.	O	.	O	8	P

1	Long-term	Long-term	B-NP	JJ	O	2	NMOD
2	prognosis	prognosis	I-NP	NN	O	8	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	transplant-free	transplant-free	B-NP	JJ	O	5	NMOD
5	survivors	survivor	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	paracetamol	paracetamol	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	acute	acute	B-NP	JJ	O	11	NMOD
10	liver	liver	I-NP	NN	O	11	NMOD
11	failure	failure	I-NP	NN	O	8	OBJ
12	.	.	O	.	O	8	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	14	SUB
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	prognosis	prognosis	I-NP	NN	O	10	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	transplant-free	transplant-free	B-NP	JJ	O	7	NMOD
7	survivors	survivor	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	paracetamol	paracetamol	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	14	VMOD
11	acute	acute	B-NP	JJ	O	13	NMOD
12	liver	liver	I-NP	NN	O	13	NMOD
13	failure	failure	I-NP	NN	O	10	OBJ
14	remains	remain	B-VP	VBZ	O	0	ROOT
15	unknown	unknown	B-ADJP	JJ	O	14	PRD
16	.	.	O	.	O	14	P

1	AIM	AIM	B-NP	NN	O	11	SUB
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	examine	examine	I-VP	VB	O	1	NMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	paracetamol	paracetamol	B-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	5	SBAR
8	acute	acute	B-NP	JJ	O	10	NMOD
9	liver	liver	I-NP	NN	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	OBJ
11	increases	increase	B-VP	VBZ	O	0	ROOT
12	long-term	long-term	B-NP	JJ	O	13	NMOD
13	mortality	mortality	I-NP	NN	O	11	OBJ
14	.	.	O	.	O	11	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	followed	follow	B-VP	VBD	O	1	NMOD
5	up	up	B-PRT	RP	O	4	VMOD
6	all	all	B-NP	DT	O	8	NMOD
7	transplant-free	transplant-free	I-NP	JJ	O	8	NMOD
8	survivors	survivor	I-NP	NNS	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	paracetamol	paracetamol	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	4	VMOD
12	acute	acute	B-NP	JJ	O	14	NMOD
13	liver	liver	I-NP	NN	O	14	NMOD
14	injury	injury	I-NP	NN	O	11	OBJ
15	,	,	O	,	O	4	P
16	hospitalized	hospitalize	B-VP	VBN	O	4	VMOD
17	in	in	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	22	NMOD
19	Danish	Danish	I-NP	JJ	O	22	NMOD
20	national	national	I-NP	JJ	O	22	NMOD
21	referral	referral	I-NP	JJ	O	22	NMOD
22	centre	centre	I-NP	NN	O	17	PMOD
23	during	during	B-PP	IN	O	16	VMOD
24	1984-2004	1984-2004	B-NP	CD	O	23	PMOD
25	.	.	O	.	O	1	P

1	On	On	B-PP	IN	O	7	VMOD
2	average	average	B-NP	JJ	O	4	AMOD
3	,	,	I-NP	,	O	4	P
4	age-specific	age-specific	I-NP	JJ	O	6	NMOD
5	mortality	mortality	I-NP	NN	O	6	NMOD
6	rates	rate	I-NP	NNS	O	7	SUB
7	were	be	B-VP	VBD	O	42	VMOD
8	slightly	slightly	B-ADJP	RB	O	9	AMOD
9	higher	high	I-ADJP	JJR	O	7	PRD
10	for	for	B-PP	IN	O	9	AMOD
11	the	the	B-NP	DT	O	13	NMOD
12	101	101	I-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	18	NMOD
14	whose	whose	B-NP	WP$	O	15	NMOD
15	paracetamol	paracetamol	I-NP	NN	O	18	NMOD
16	induced	induce	B-VP	VBD	O	18	NMOD
17	liver	liver	B-NP	NN	O	18	NMOD
18	injury	injury	I-NP	NN	O	10	PMOD
19	had	have	B-VP	VBD	O	7	VMOD
20	caused	cause	I-VP	VBN	O	24	NMOD
21	an	an	B-NP	DT	O	24	NMOD
22	acute	acute	I-NP	JJ	O	24	NMOD
23	liver	liver	I-NP	NN	O	24	NMOD
24	failure	failure	I-NP	NN	O	19	OBJ
25	(	(	O	(	O	37	DEP
26	adjusted	adjust	B-NP	VBN	O	29	NMOD
27	mortality	mortality	I-NP	NN	O	29	NMOD
28	rate	rate	I-NP	NN	O	29	NMOD
29	ratio	ratio	I-NP	NN	O	35	NMOD
30	=	=	B-VP	SYM	O	29	NMOD
31	1.70	1.70	B-NP	CD	O	30	AMOD
32	,	,	O	,	O	35	P
33	95	95	B-NP	CD	O	35	NMOD
34	%	%	I-NP	NN	O	35	NMOD
35	CI	CI	I-NP	NN	O	37	DEP
36	1.02-2.85	1.02-2.85	I-NP	CD	O	35	NMOD
37	)	)	O	)	O	24	NMOD
38	,	,	O	,	O	42	P
39	but	but	O	CC	O	42	VMOD
40	the	the	B-NP	DT	O	41	NMOD
41	association	association	I-NP	NN	O	42	SUB
42	was	be	B-VP	VBD	O	0	ROOT
43	age-dependent	age-dependent	B-ADJP	JJ	O	42	PRD
44	,	,	O	,	O	47	P
45	and	and	O	CC	O	47	NMOD
46	no	no	B-NP	DT	O	47	NMOD
47	survivors	survivor	I-NP	NNS	O	42	VMOD
48	of	of	B-PP	IN	O	47	NMOD
49	acute	acute	B-NP	JJ	O	51	NMOD
50	liver	liver	I-NP	NN	O	51	NMOD
51	failure	failure	I-NP	NN	O	48	PMOD
52	died	die	B-VP	VBD	O	47	NMOD
53	of	of	B-PP	IN	O	52	VMOD
54	liver	liver	B-NP	NN	O	55	NMOD
55	disease	disease	I-NP	NN	O	53	PMOD
56	,	,	O	,	O	42	P
57	whereas	whereas	O	IN	O	42	VMOD
58	suicides	suicide	B-NP	NNS	O	59	SUB
59	were	be	B-VP	VBD	O	57	SBAR
60	frequent	frequent	B-ADJP	JJ	O	59	PRD
61	in	in	B-PP	IN	O	60	AMOD
62	both	both	B-NP	DT	O	63	NMOD
63	groups	group	I-NP	NNS	O	61	PMOD
64	.	.	O	.	O	42	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Paracetamol	Paracetamol	B-NP	NN	O	7	NMOD
4	induced	induce	B-VP	VBD	O	7	NMOD
5	acute	acute	B-NP	JJ	O	7	NMOD
6	liver	liver	I-NP	NN	O	7	NMOD
7	failure	failure	I-NP	NN	O	8	SUB
8	did	do	B-VP	VBD	O	1	NMOD
9	not	not	I-VP	RB	O	8	VMOD
10	affect	affect	I-VP	VB	O	8	VC
11	long-term	long-term	B-NP	JJ	O	12	NMOD
12	mortality	mortality	I-NP	NN	O	10	OBJ
13	.	.	O	.	O	1	P

1	Serotonin	Serotonin	B-NP	NN	B-DNA	4	NMOD
2	6	6	I-NP	CD	I-DNA	4	NMOD
3	receptor	receptor	I-NP	NN	I-DNA	4	NMOD
4	gene	gene	I-NP	NN	I-DNA	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	associated	associate	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	methamphetamine	methamphetamine	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	8	NMOD
10	psychosis	psychosis	B-NP	NN	O	9	OBJ
11	in	in	B-PP	IN	O	9	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	Japanese	Japanese	I-NP	JJ	B-cell_line	14	NMOD
14	population	population	I-NP	NN	I-cell_line	11	PMOD
15	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	7	NMOD
2	serotonin	serotonin	I-NP	NN	B-protein	7	NMOD
3	6	6	I-NP	CD	I-protein	7	NMOD
4	(	(	O	(	I-protein	7	NMOD
5	5-HT6	5-HT6	B-NP	NN	I-protein	7	NMOD
6	)	)	O	)	I-protein	7	NMOD
7	receptor	receptor	B-NP	NN	I-protein	8	SUB
8	is	be	B-VP	VBZ	O	29	VMOD
9	therapeutically	therapeutically	I-VP	RB	O	8	VMOD
10	targeted	target	I-VP	VBN	O	8	VC
11	by	by	B-PP	IN	O	10	VMOD
12	several	several	B-NP	JJ	O	15	NMOD
13	second	second	I-NP	JJ	O	15	NMOD
14	generation	generation	I-NP	NN	O	15	NMOD
15	antipsychotics	antipsychotic	I-NP	NNS	O	11	PMOD
16	,	,	O	,	O	15	P
17	such	such	B-PP	JJ	O	18	PMOD
18	as	as	I-PP	IN	O	15	NMOD
19	clozapine	clozapine	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	olanzapine	olanzapine	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	29	P
23	and	and	O	CC	O	29	VMOD
24	d-amphetamine	d-amphetamine	B-NP	NN	O	29	SUB
25	induced	induce	B-VP	VBD	O	24	NMOD
26	hyperactivity	hyperactivity	B-NP	NN	O	25	OBJ
27	in	in	B-PP	IN	O	25	VMOD
28	rats	rat	B-NP	NNS	O	27	PMOD
29	is	be	B-VP	VBZ	O	0	ROOT
30	corrected	correct	I-VP	VBN	O	29	VC
31	with	with	B-PP	IN	O	30	VMOD
32	the	the	B-NP	DT	O	33	NMOD
33	use	use	I-NP	NN	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	a	a	B-NP	DT	O	39	NMOD
36	selective	selective	I-NP	JJ	O	39	NMOD
37	5-HT6	5-HT6	I-NP	NN	O	39	NMOD
38	receptor	receptor	I-NP	NN	O	39	NMOD
39	antagonist	antagonist	I-NP	NN	O	34	PMOD
40	.	.	O	.	O	29	P

1	These	These	B-NP	DT	O	3	NMOD
2	animal	animal	I-NP	JJ	O	3	NMOD
3	models	model	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	18	VMOD
5	considered	consider	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	reflect	reflect	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	positive	positive	I-NP	JJ	O	10	NMOD
10	symptoms	symptom	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	schizophrenia	schizophrenia	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	18	P
14	and	and	O	CC	O	18	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	above	above	I-NP	JJ	O	17	NMOD
17	evidence	evidence	I-NP	NN	O	18	SUB
18	suggests	suggest	B-VP	VBZ	O	0	ROOT
19	that	that	B-SBAR	IN	O	18	VMOD
20	altered	alter	B-NP	VBN	B-protein	22	NMOD
21	5-HT6	5-HT6	I-NP	NN	I-protein	22	NMOD
22	receptors	receptor	I-NP	NNS	I-protein	23	SUB
23	are	be	B-VP	VBP	O	19	SBAR
24	involved	involve	I-VP	VBN	O	23	VC
25	in	in	B-PP	IN	O	24	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	pathophysiology	pathophysiology	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	psychotic	psychotic	B-NP	JJ	O	30	NMOD
30	disorders	disorder	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	18	P

1	The	The	B-NP	DT	O	2	NMOD
2	symptoms	symptom	I-NP	NNS	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	methamphetamine	methamphetamine	B-NP	NN	O	9	NMOD
5	(	(	O	(	O	7	DEP
6	METH	METH	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	induced	induce	B-NP	VBN	O	9	NMOD
9	psychosis	psychosis	I-NP	NN	O	3	PMOD
10	are	be	B-VP	VBP	O	0	ROOT
11	similar	similar	B-ADJP	JJ	O	10	PRD
12	to	to	B-PP	TO	O	11	AMOD
13	those	those	B-NP	DT	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	paranoid	paranoid	B-NP	JJ	O	17	NMOD
16	type	type	I-NP	NN	O	17	NMOD
17	schizophrenia	schizophrenia	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	10	P

1	Therefore	Therefore	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	conducted	conduct	B-VP	VBD	O	0	ROOT
5	an	an	B-NP	DT	O	6	NMOD
6	analysis	analysis	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	association	association	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	5-HT6	5-HT6	I-NP	NN	B-DNA	13	NMOD
13	gene	gene	I-NP	NN	I-DNA	10	PMOD
14	(	(	O	(	O	16	DEP
15	HTR6	HTR6	B-NP	NN	B-protein	16	DEP
16	)	)	O	)	O	13	NMOD
17	with	with	B-PP	IN	O	9	NMOD
18	METH	METH	B-NP	NN	O	20	NMOD
19	induced	induced	I-NP	JJ	O	20	NMOD
20	psychosis	psychosis	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	4	P

1	METHOD	METHOD	B-NP	NN	O	20	SUB
2	:	:	O	:	O	1	P
3	Using	Use	B-VP	VBG	O	1	NMOD
4	five	five	B-NP	CD	O	6	NMOD
5	tagging	tag	I-NP	VBG	O	6	NMOD
6	SNPs	SNP	I-NP	NNS	O	3	OBJ
7	(	(	O	(	O	17	DEP
8	rs6693503	rs6693503	B-NP	NN	O	16	NMOD
9	,	,	O	,	O	16	P
10	rs1805054	rs1805054	B-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	rs4912138	rs4912138	B-NP	NN	O	16	NMOD
13	,	,	O	,	O	16	P
14	rs3790757	rs3790757	B-NP	NN	O	16	NMOD
15	and	and	O	CC	O	16	NMOD
16	rs9659997	rs9659997	B-NP	NN	O	17	DEP
17	)	)	O	)	O	6	NMOD
18	,	,	O	,	O	20	P
19	we	we	B-NP	PRP	O	20	SUB
20	conducted	conduct	B-VP	VBD	O	0	ROOT
21	a	a	B-NP	DT	O	24	NMOD
22	genetic	genetic	I-NP	JJ	O	24	NMOD
23	association	association	I-NP	NN	O	24	NMOD
24	analysis	analysis	I-NP	NN	O	20	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	case-control	case-control	B-NP	JJ	O	27	NMOD
27	samples	sample	I-NP	NNS	O	25	PMOD
28	(	(	O	(	O	37	DEP
29	197	197	B-NP	CD	O	30	NMOD
30	METH	METH	I-NP	NN	O	33	NMOD
31	induced	induce	B-VP	VBD	O	33	NMOD
32	psychosis	psychosis	B-NP	NN	O	33	NMOD
33	patients	patient	I-NP	NNS	O	36	NMOD
34	and	and	O	CC	O	36	NMOD
35	337	337	B-NP	CD	O	36	NMOD
36	controls	control	I-NP	NNS	O	37	DEP
37	)	)	O	)	O	27	NMOD
38	in	in	B-PP	IN	O	27	NMOD
39	the	the	B-NP	DT	O	41	NMOD
40	Japanese	Japanese	I-NP	JJ	B-cell_line	41	NMOD
41	population	population	I-NP	NN	I-cell_line	38	PMOD
42	.	.	O	.	O	20	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	rs6693503	rs6693503	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	METH	METH	B-NP	NN	B-protein	10	NMOD
8	induced	induce	B-VP	VBD	O	10	NMOD
9	psychosis	psychosis	B-NP	NN	O	10	NMOD
10	patients	patient	I-NP	NNS	O	6	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	allele/genotype-wise	allele/genotype-wise	I-NP	JJ	O	14	NMOD
14	analysis	analysis	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	haplotype-wise	haplotype-wise	I-NP	JJ	O	4	NMOD
4	analysis	analysis	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	we	we	B-NP	PRP	O	7	SUB
7	detected	detect	B-VP	VBD	O	0	ROOT
8	an	an	B-NP	DT	O	9	NMOD
9	association	association	I-NP	NN	O	7	OBJ
10	between	between	B-PP	IN	O	9	NMOD
11	two	two	B-NP	CD	O	12	NMOD
12	markers	marker	I-NP	NNS	O	20	NMOD
13	(	(	O	(	O	17	DEP
14	rs6693503	rs6693503	B-NP	NN	O	16	NMOD
15	and	and	O	CC	O	16	NMOD
16	rs1805054	rs1805054	B-NP	NN	O	17	DEP
17	)	)	O	)	O	12	NMOD
18	and	and	O	CC	O	20	NMOD
19	three	three	B-NP	CD	O	20	NMOD
20	markers	marker	I-NP	NNS	O	10	PMOD
21	(	(	O	(	O	27	DEP
22	rs6693503	rs6693503	B-NP	NN	O	26	NMOD
23	,	,	O	,	O	26	P
24	rs1805054	rs1805054	B-NP	NN	O	26	NMOD
25	and	and	O	CC	O	26	NMOD
26	rs4912138	rs4912138	B-NP	NN	O	27	DEP
27	)	)	O	)	O	20	NMOD
28	in	in	B-PP	IN	O	9	NMOD
29	HTR6	HTR6	B-NP	NN	B-protein	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	METH	METH	I-NP	NN	O	28	PMOD
32	induced	induce	B-VP	VBD	O	34	NMOD
33	psychosis	psychosis	B-NP	NN	O	34	NMOD
34	patients	patient	I-NP	NNS	O	28	PMOD
35	,	,	O	,	O	9	P
36	respectively	respectively	B-ADVP	RB	O	9	NMOD
37	.	.	O	.	O	7	P

1	Effect	Effect	B-NP	NN	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	increasing	increase	B-VP	VBG	O	2	PMOD
4	intraperitoneal	intraperitoneal	B-NP	JJ	O	6	NMOD
5	infusion	infusion	I-NP	NN	O	6	NMOD
6	rates	rate	I-NP	NNS	O	3	OBJ
7	on	on	B-PP	IN	O	3	VMOD
8	bupropion	bupropion	B-NP	NN	O	9	NMOD
9	hydrochloride	hydrochloride	I-NP	NN	O	7	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	seizures	seizure	B-NP	NNS	O	10	OBJ
12	in	in	B-PP	IN	O	10	VMOD
13	mice	mouse	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	10	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	It	It	B-NP	PRP	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	not	not	I-VP	RB	O	4	VMOD
6	known	know	I-VP	VBN	O	4	VC
7	if	if	B-SBAR	IN	O	6	VMOD
8	there	there	B-NP	EX	O	9	SUB
9	is	be	B-VP	VBZ	O	7	SBAR
10	a	a	B-NP	DT	O	11	NMOD
11	relationship	relationship	I-NP	NN	O	9	PRD
12	between	between	B-PP	IN	O	11	NMOD
13	input	input	B-NP	NN	O	14	NMOD
14	rate	rate	I-NP	NN	O	16	NMOD
15	and	and	O	CC	O	16	NMOD
16	incidence	incidence	B-NP	NN	O	12	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	bupropion	bupropion	B-NP	NN	O	20	NMOD
19	induced	induce	I-NP	VBN	O	20	NMOD
20	seizures	seizure	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	investigated	investigate	B-VP	VBD	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	varying	vary	B-VP	VBG	O	7	PMOD
9	the	the	B-NP	DT	O	12	NMOD
10	intraperitoneal	intraperitoneal	I-NP	JJ	O	12	NMOD
11	infusion	infusion	I-NP	NN	O	12	NMOD
12	rates	rate	I-NP	NNS	O	8	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	bupropion	bupropion	B-NP	NN	O	17	NMOD
15	HCl	HCl	I-NP	NN	O	17	NMOD
16	120	120	I-NP	CD	O	17	NMOD
17	mg/kg	mg/kg	I-NP	NN	O	13	PMOD
18	,	,	O	,	O	22	P
19	a	a	B-NP	DT	O	22	NMOD
20	known	known	I-NP	JJ	O	22	NMOD
21	convulsive	convulsive	I-NP	JJ	O	22	NMOD
22	dose	dose	I-NP	NN	O	17	NMOD
23	50	50	I-NP	CD	O	22	NMOD
24	(	(	O	(	O	26	DEP
25	CD50	CD50	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	22	NMOD
27	,	,	O	,	O	22	P
28	on	on	B-PP	IN	O	22	NMOD
29	the	the	B-NP	DT	O	32	NMOD
30	incidence	incidence	I-NP	NN	O	32	NMOD
31	and	and	I-NP	CC	O	32	NMOD
32	severity	severity	I-NP	NN	O	28	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	bupropion	bupropion	B-NP	NN	O	36	NMOD
35	induced	induce	I-NP	VBN	O	36	NMOD
36	convulsions	convulsion	I-NP	NNS	O	33	PMOD
37	in	in	B-PP	IN	O	22	NMOD
38	the	the	B-NP	DT	O	41	NMOD
39	Swiss	Swiss	I-NP	JJ	O	41	NMOD
40	albino	albino	I-NP	NN	O	41	NMOD
41	mice	mouse	I-NP	NNS	O	37	PMOD
42	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	showed	show	B-VP	VBD	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	IP	IP	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	17	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	bupropion	bupropion	B-NP	NN	O	13	NMOD
11	HCl	HCl	I-NP	NN	O	13	NMOD
12	120	120	I-NP	CD	O	13	NMOD
13	mg/kg	mg/kg	I-NP	NN	O	9	PMOD
14	by	by	B-PP	IN	O	8	NMOD
15	bolus	bolus	B-NP	NN	O	16	NMOD
16	injection	injection	I-NP	NN	O	14	PMOD
17	induced	induce	B-VP	VBD	O	6	SBAR
18	convulsions	convulsion	B-NP	NNS	O	17	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	6	6	B-NP	CD	O	22	AMOD
21	out	out	I-NP	IN	O	22	AMOD
22	of	of	I-NP	IN	O	24	NMOD
23	10	10	I-NP	CD	O	22	AMOD
24	mice	mouse	I-NP	NNS	O	19	PMOD
25	(	(	O	(	O	31	DEP
26	60	60	B-NP	CD	O	27	NMOD
27	%	%	I-NP	NN	O	31	DEP
28	of	of	B-PP	IN	O	27	NMOD
29	convulsing	convulse	B-VP	VBG	O	30	NMOD
30	mice	mouse	B-NP	NNS	O	28	PMOD
31	)	)	O	)	O	24	NMOD
32	in	in	B-PP	IN	O	17	VMOD
33	group	group	B-NP	NN	O	32	PMOD
34	1	1	I-NP	CD	O	33	NMOD
35	.	.	O	.	O	1	P

1	Logistic	Logistic	B-NP	JJ	O	3	NMOD
2	regression	regression	I-NP	NN	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	4	SUB
4	revealed	reveal	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	infusion	infusion	B-NP	NN	O	7	NMOD
7	time	time	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	5	SBAR
9	significant	significant	B-ADJP	JJ	O	8	PRD
10	(	(	O	(	O	19	DEP
11	p	p	B-NP	NN	O	19	DEP
12	=	=	B-VP	SYM	O	11	NMOD
13	0.0004	0.0004	B-NP	CD	O	12	AMOD
14	;	;	O	:	O	19	P
15	odds	odd	B-NP	NNS	O	19	DEP
16	ratio	ratio	I-NP	NN	O	18	SUB
17	=	=	B-VP	SYM	O	18	VMOD
18	0.974	0.974	B-NP	CD	O	15	NMOD
19	)	)	O	)	O	8	VMOD
20	and	and	O	CC	O	8	VMOD
21	increasing	increase	B-VP	VBG	O	31	SUB
22	the	the	B-NP	DT	O	25	NMOD
23	IP	IP	I-NP	NN	O	25	NMOD
24	infusion	infusion	I-NP	NN	O	25	NMOD
25	time	time	I-NP	NN	O	21	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	bupropion	bupropion	B-NP	NN	O	30	NMOD
28	HCl	HCl	I-NP	NN	O	30	NMOD
29	120	120	I-NP	CD	O	30	NMOD
30	mg/kg	mg/kg	I-NP	NN	O	26	PMOD
31	was	be	B-VP	VBD	O	8	VMOD
32	associated	associate	I-VP	VBN	O	31	VC
33	with	with	B-PP	IN	O	32	VMOD
34	a	a	B-NP	DT	O	36	NMOD
35	91	91	I-NP	CD	O	36	NMOD
36	%	%	I-NP	NN	O	33	PMOD
37	reduced	reduce	B-VP	VBD	O	31	VMOD
38	odds	odd	B-NP	NNS	O	37	OBJ
39	of	of	B-PP	IN	O	38	NMOD
40	convulsions	convulsion	B-NP	NNS	O	39	PMOD
41	at	at	B-PP	IN	O	37	VMOD
42	infusion	infusion	B-NP	NN	O	43	NMOD
43	times	time	I-NP	NNS	O	41	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	15	15	B-NP	CD	O	47	AMOD
46	to	to	I-NP	TO	O	47	AMOD
47	90	90	I-NP	CD	O	48	NMOD
48	min	min	I-NP	NN	O	44	PMOD
49	compared	compare	B-VP	VBN	O	37	VMOD
50	to	to	B-PP	TO	O	49	PMOD
51	bolus	bolus	B-NP	NN	O	52	NMOD
52	injection	injection	I-NP	NN	O	50	PMOD
53	.	.	O	.	O	4	P

1	Detailed	Detailed	B-NP	JJ	O	4	NMOD
2	spectral	spectral	I-NP	JJ	O	4	NMOD
3	profile	profile	I-NP	NN	O	4	NMOD
4	analysis	analysis	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	penicillin	penicillin	B-NP	NN	B-protein	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	epileptiform	epileptiform	B-NP	NN	O	9	NMOD
9	activity	activity	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	anesthetized	anesthetize	B-NP	VBN	O	12	NMOD
12	rats	rat	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	7	P

1	Penicillin	Penicillin	B-NP	NN	O	2	NMOD
2	model	model	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	8	NMOD
5	widely	widely	I-NP	RB	O	6	AMOD
6	used	use	I-NP	VBN	O	8	NMOD
7	experimental	experimental	I-NP	JJ	O	8	NMOD
8	model	model	I-NP	NN	O	3	PRD
9	for	for	B-PP	IN	O	8	NMOD
10	epilepsy	epilepsy	B-NP	NN	O	11	NMOD
11	research	research	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	6	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	we	we	B-NP	PRP	O	6	SUB
6	aimed	aim	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	portray	portray	I-VP	VB	O	6	VMOD
9	a	a	B-NP	DT	O	12	NMOD
10	detailed	detailed	I-NP	JJ	O	12	NMOD
11	spectral	spectral	I-NP	JJ	O	12	NMOD
12	analysis	analysis	I-NP	NN	O	15	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	penicillin	penicillin	B-NP	NN	B-protein	13	PMOD
15	induced	induce	B-VP	VBD	O	8	VMOD
16	epileptiform	epileptiform	B-NP	NN	O	17	NMOD
17	activity	activity	I-NP	NN	O	15	OBJ
18	in	in	B-PP	IN	O	15	VMOD
19	comparison	comparison	B-NP	NN	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	basal	basal	B-NP	JJ	O	23	NMOD
22	brain	brain	I-NP	NN	O	23	NMOD
23	activity	activity	I-NP	NN	O	20	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	anesthetized	anesthetize	B-NP	VBN	O	27	NMOD
26	Wistar	Wistar	I-NP	NNP	O	27	NMOD
27	rats	rat	I-NP	NNS	O	24	PMOD
28	.	.	O	.	O	6	P

1	After	After	B-PP	IN	O	12	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	short	short	I-NP	JJ	O	4	NMOD
4	period	period	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	basal	basal	B-NP	JJ	O	8	NMOD
7	activity	activity	I-NP	NN	O	8	NMOD
8	recording	recording	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	12	P
10	epileptic	epileptic	B-NP	JJ	O	11	NMOD
11	focus	focus	I-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	0	ROOT
13	induced	induce	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	injecting	inject	B-VP	VBG	O	14	PMOD
16	400IU/2	400IU/2	B-NP	CD	O	19	NMOD
17	microl	microl	I-NP	NN	O	19	NMOD
18	penicillin-G	penicillin-G	I-NP	NN	O	19	NMOD
19	potassium	potassium	I-NP	NN	O	15	OBJ
20	into	into	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	24	NMOD
22	left	left	I-NP	JJ	O	24	NMOD
23	lateral	lateral	I-NP	JJ	O	24	NMOD
24	ventricle	ventricle	I-NP	NN	O	20	PMOD
25	while	while	B-SBAR	IN	O	12	VMOD
26	the	the	B-NP	DT	O	28	NMOD
27	cortical	cortical	I-NP	JJ	O	28	NMOD
28	activity	activity	I-NP	NN	O	29	SUB
29	was	be	B-VP	VBD	O	25	SBAR
30	continuously	continuously	I-VP	RB	O	29	VMOD
31	recorded	record	I-VP	VBN	O	29	VC
32	.	.	O	.	O	12	P

1	Basal	Basal	B-NP	JJ	O	2	NMOD
2	activity	activity	I-NP	NN	O	8	NMOD
3	,	,	O	,	O	8	P
4	latent	latent	B-NP	JJ	O	5	NMOD
5	period	period	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	penicillin	penicillin	I-NP	NN	B-protein	9	SUB
9	induced	induce	B-VP	VBD	O	13	VMOD
10	epileptiform	epileptiform	B-NP	NN	O	12	NMOD
11	activity	activity	I-NP	NN	O	12	NMOD
12	periods	period	I-NP	NNS	O	13	SUB
13	were	be	B-VP	VBD	O	0	ROOT
14	then	then	I-VP	RB	O	13	VMOD
15	analyzed	analyze	I-VP	VBN	O	13	VC
16	using	use	B-VP	VBG	O	15	VMOD
17	both	both	O	CC	O	22	NMOD
18	conventional	conventional	B-NP	JJ	O	19	NMOD
19	methods	method	I-NP	NNS	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	spectral	spectral	B-NP	JJ	O	22	NMOD
22	analysis	analysis	I-NP	NN	O	16	OBJ
23	.	.	O	.	O	13	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	dexmedetomidine	dexmedetomidine	B-NP	NN	O	3	NMOD
3	sedation	sedation	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	SBAR
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	10	NMOD
8	16	16	I-NP	CD	O	9	AMOD
9	%	%	I-NP	NN	O	10	NMOD
10	incidence	incidence	I-NP	NN	O	6	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	bradycardia	bradycardia	B-NP	NN	O	19	NMOD
13	,	,	O	,	O	19	P
14	all	all	B-NP	DT	O	19	NMOD
15	concomitant	concomitant	I-NP	JJ	O	19	NMOD
16	mean	mean	I-NP	JJ	O	19	NMOD
17	arterial	arterial	I-NP	JJ	O	19	NMOD
18	blood	blood	I-NP	NN	O	19	NMOD
19	pressures	pressure	I-NP	NNS	O	11	PMOD
20	were	be	B-VP	VBD	O	1	DEP
21	within	within	B-PP	IN	O	20	PRD
22	20	20	B-NP	CD	O	23	NMOD
23	%	%	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	age-adjusted	age-adjusted	B-NP	JJ	O	27	NMOD
26	normal	normal	I-NP	JJ	O	27	NMOD
27	range	range	I-NP	NN	O	30	NMOD
28	and	and	I-NP	CC	O	30	NMOD
29	oxygen	oxygen	I-NP	NN	O	30	NMOD
30	saturations	saturation	I-NP	NNS	O	24	PMOD
31	were	be	B-VP	VBD	O	20	VMOD
32	95	95	B-NP	CD	O	33	NMOD
33	%	%	I-NP	NN	O	35	AMOD
34	or	or	O	CC	O	35	AMOD
35	higher	high	B-ADVP	JJR	O	31	PRD
36	.	.	O	.	O	1	P

1	Methamphetamine	Methamphetamine	B-NP	NN	O	2	SUB
2	causes	cause	B-VP	VBZ	O	0	ROOT
3	alterations	alteration	B-NP	NNS	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	MAP	MAP	I-NP	NN	O	8	NMOD
7	kinase-related	kinase-related	I-NP	JJ	O	8	NMOD
8	pathways	pathway	I-NP	NNS	O	4	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	brains	brain	I-NP	NNS	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	mice	mouse	B-NP	NNS	O	12	PMOD
14	that	that	B-NP	WDT	O	13	NMOD
15	display	display	B-VP	VBP	O	14	SBAR
16	increased	increase	B-NP	VBN	O	17	NMOD
17	aggressiveness	aggressiveness	I-NP	NN	O	15	OBJ
18	.	.	O	.	O	2	P

1	Aggressive	Aggressive	B-NP	JJ	O	2	NMOD
2	behaviors	behavior	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	reported	report	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	who	who	B-NP	WP	O	7	NMOD
9	suffer	suffer	B-VP	VBP	O	8	SBAR
10	from	from	B-PP	IN	O	9	VMOD
11	some	some	B-NP	DT	O	13	NMOD
12	psychiatric	psychiatric	I-NP	JJ	O	13	NMOD
13	disorders	disorder	I-NP	NNS	O	10	PMOD
14	,	,	O	,	O	3	P
15	and	and	O	CC	O	3	VMOD
16	are	be	B-VP	VBP	O	3	VMOD
17	common	common	B-ADJP	JJ	O	16	PRD
18	in	in	B-PP	IN	O	17	AMOD
19	methamphetamine	methamphetamine	B-NP	NN	O	23	NMOD
20	(	(	O	(	O	22	DEP
21	METH	METH	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	abusers	abuser	B-NP	NNS	O	18	PMOD
24	.	.	O	.	O	3	P

1	Herein	Herein	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	report	report	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	multiple	multiple	B-NP	JJ	O	16	SUB
7	(	(	O	(	O	11	DEP
8	but	but	O	CC	O	11	DEP
9	not	not	O	RB	O	10	AMOD
10	single	single	B-ADJP	JJ	O	11	DEP
11	)	)	O	)	O	6	NMOD
12	injections	injection	B-NP	NNS	O	6	NMOD
13	of	of	B-PP	IN	O	6	NMOD
14	METH	METH	B-NP	NN	O	13	PMOD
15	significantly	significantly	B-ADVP	RB	O	16	VMOD
16	increased	increase	B-VP	VBD	O	5	SBAR
17	aggressiveness	aggressiveness	B-NP	NN	O	16	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	male	male	B-NP	JJ	O	21	NMOD
20	CD-1	CD-1	I-NP	NN	O	21	NMOD
21	mice	mouse	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	2	NMOD
2	increase	increase	I-NP	NN	O	5	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	aggressiveness	aggressiveness	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	not	not	O	RB	O	5	VMOD
7	secondary	secondary	B-ADJP	JJ	O	5	PRD
8	to	to	B-PP	TO	O	7	AMOD
9	METH	METH	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	hyperactivity	hyperactivity	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	5	P

1	Lamotrigine	Lamotrigine	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	exacerbation	exacerbation	B-NP	NN	O	8	NMOD
5	or	or	B-NP	CC	O	8	NMOD
6	de	de	I-NP	FW	O	7	AMOD
7	novo	novo	I-NP	FW	O	8	NMOD
8	myoclonus	myoclonus	I-NP	NN	O	3	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	idiopathic	idiopathic	B-NP	JJ	O	12	NMOD
11	generalized	generalize	I-NP	VBN	O	12	NMOD
12	epilepsies	epilepsy	I-NP	NNS	O	9	PMOD
13	.	.	O	.	O	1	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	idiopathic	idiopathic	B-NP	JJ	O	6	NMOD
5	generalized	generalize	I-NP	VBN	O	6	NMOD
6	epilepsies	epilepsy	I-NP	NNS	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	IGE	IGE	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	treated	treat	B-VP	VBN	O	6	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	lamotrigine	lamotrigine	B-NP	NN	O	17	NMOD
13	(	(	I-NP	(	O	17	NMOD
14	LTG	LTG	I-NP	NN	O	17	NMOD
15	)	)	I-NP	)	O	17	NMOD
16	experienced	experienced	I-NP	JJ	O	17	NMOD
17	exacerbation	exacerbation	I-NP	NN	O	21	NMOD
18	or	or	I-NP	CC	O	21	NMOD
19	de	de	I-NP	FW	O	20	AMOD
20	novo	novo	I-NP	FW	O	21	NMOD
21	appearance	appearance	I-NP	NN	O	11	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	myoclonic	myoclonic	B-NP	JJ	O	24	NMOD
24	jerks	jerk	I-NP	NNS	O	22	PMOD
25	(	(	O	(	O	27	DEP
26	MJ	MJ	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	6	VMOD
2	three	three	B-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	LTG	LTG	B-NP	NN	B-protein	6	SUB
6	exacerbated	exacerbate	B-VP	VBD	O	0	ROOT
7	MJ	MJ	B-NP	NN	O	6	OBJ
8	in	in	B-PP	IN	O	6	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	dose-dependent	dose-dependent	I-NP	JJ	O	11	NMOD
11	manner	manner	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	6	VMOD
13	early	early	B-NP	JJ	O	14	NMOD
14	aggravation	aggravation	I-NP	NN	O	12	PMOD
15	during	during	B-PP	IN	O	6	VMOD
16	titration	titration	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	6	P

1	MJ	MJ	B-NP	NN	O	2	SUB
2	disappeared	disappear	B-VP	VBD	O	0	ROOT
3	when	when	B-ADVP	WRB	O	2	VMOD
4	LTG	LTG	B-NP	NN	O	5	NMOD
5	dose	dose	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	3	SBAR
7	decreased	decrease	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	25	25	B-NP	CD	O	11	AMOD
10	to	to	I-NP	TO	O	11	AMOD
11	50	50	I-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	8	PMOD
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	5	NMOD
2	neural	neural	I-NP	JJ	O	3	NMOD
3	mechanisms	mechanism	I-NP	NNS	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	circuitry	circuitry	I-NP	NN	O	11	SUB
6	involved	involve	B-VP	VBN	O	5	NMOD
7	in	in	B-PP	IN	O	6	VMOD
8	levodopa	levodopa	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	dyskinesia	dyskinesia	I-NP	NN	O	7	PMOD
11	are	be	B-VP	VBP	O	0	ROOT
12	unclear	unclear	B-ADJP	JJ	O	11	PRD
13	.	.	O	.	O	11	P

1	Assessment	Assessment	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	onset	onset	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	persistence	persistence	I-NP	NN	O	2	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	amnesia	amnesia	B-NP	NN	O	7	PMOD
9	during	during	B-PP	IN	O	1	NMOD
10	procedural	procedural	B-NP	JJ	O	11	NMOD
11	sedation	sedation	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	propofol	propofol	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	1	P

1	Assessment	Assessment	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	done	do	I-VP	VBN	O	2	VC
4	on	on	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	following	following	I-NP	NN	O	4	PMOD
7	:	:	O	:	O	2	P
8	prenatal	prenatal	B-NP	JJ	O	9	NMOD
9	screening	screening	I-NP	NN	O	28	NMOD
10	for	for	B-PP	IN	O	9	NMOD
11	hepatitis	hepatitis	B-NP	NN	O	12	NMOD
12	B	B	I-NP	NN	O	14	NMOD
13	and	and	O	CC	O	14	NMOD
14	rubella	rubella	B-NP	NN	O	10	PMOD
15	,	,	O	,	O	28	P
16	administration	administration	B-NP	NN	O	28	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	23	NMOD
19	hepatitis	hepatitis	I-NP	NN	O	23	NMOD
20	B	B	I-NP	NN	O	23	NMOD
21	vaccine	vaccine	I-NP	NN	O	23	NMOD
22	birth	birth	I-NP	NN	O	23	NMOD
23	dose	dose	I-NP	NN	O	17	PMOD
24	to	to	B-PP	TO	O	16	NMOD
25	all	all	B-NP	DT	O	26	NMOD
26	infants	infant	I-NP	NNS	O	24	PMOD
27	,	,	O	,	O	28	P
28	administration	administration	B-NP	NN	O	50	NMOD
29	of	of	B-PP	IN	O	28	NMOD
30	hepatitis	hepatitis	B-NP	NN	B-protein	33	NMOD
31	B	B	I-NP	NN	I-protein	33	NMOD
32	immune	immune	I-NP	JJ	I-protein	33	NMOD
33	globulin	globulin	I-NP	NN	I-protein	29	PMOD
34	to	to	B-PP	TO	O	28	NMOD
35	infants	infant	B-NP	NNS	O	34	PMOD
36	who	who	B-NP	WP	O	28	NMOD
37	were	be	B-VP	VBD	O	36	SBAR
38	born	bear	I-VP	VBN	O	37	VC
39	to	to	B-PP	TO	O	38	VMOD
40	hepatitis	hepatitis	B-NP	NN	O	44	NMOD
41	B	B	I-NP	NN	O	44	NMOD
42	surface	surface	I-NP	NN	O	44	NMOD
43	antigen-positive	antigen-positive	I-NP	JJ	O	44	NMOD
44	mothers	mother	I-NP	NNS	O	39	PMOD
45	,	,	O	,	O	50	P
46	rubella	rubella	B-NP	NN	O	47	NMOD
47	immunity	immunity	I-NP	NN	O	50	NMOD
48	,	,	O	,	O	50	P
49	and	and	O	CC	O	50	NMOD
50	administration	administration	B-NP	NN	O	2	VMOD
51	of	of	B-PP	IN	O	50	NMOD
52	in-hospital	in-hospital	B-NP	JJ	O	55	NMOD
53	postpartum	postpartum	I-NP	NN	O	55	NMOD
54	rubella	rubella	I-NP	NN	O	55	NMOD
55	vaccine	vaccine	I-NP	NN	O	51	PMOD
56	to	to	B-VP	TO	O	57	VMOD
57	rubella	rubella	I-VP	VB	O	50	NMOD
58	nonimmune	nonimmune	B-NP	JJ	O	59	NMOD
59	women	woman	I-NP	NNS	O	57	OBJ
60	.	.	O	.	O	2	P

1	All	All	B-NP	DT	O	2	NMOD
2	infants	infant	I-NP	NNS	O	0	ROOT
3	who	who	B-NP	WP	O	2	NMOD
4	were	be	B-VP	VBD	O	3	SBAR
5	born	bear	I-VP	VBN	O	4	VC
6	to	to	B-PP	TO	O	5	VMOD
7	hepatitis	hepatitis	B-NP	NN	B-protein	11	NMOD
8	B	B	I-NP	NN	I-protein	11	NMOD
9	surface	surface	I-NP	NN	I-protein	11	NMOD
10	antigen-positive	antigen-positive	I-NP	JJ	I-protein	11	NMOD
11	mothers	mother	I-NP	NNS	I-protein	6	PMOD
12	also	also	B-ADVP	RB	I-protein	13	VMOD
13	received	receive	B-VP	VBD	I-protein	11	NMOD
14	hepatitis	hepatitis	B-NP	NN	I-protein	17	NMOD
15	B	B	I-NP	NN	I-protein	17	NMOD
16	immune	immune	I-NP	JJ	I-protein	17	NMOD
17	globulin	globulin	I-NP	NN	I-protein	13	OBJ
18	.	.	O	.	O	2	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	anti-tumor	anti-tumor	I-NP	JJ	O	5	NMOD
5	agent	agent	I-NP	NN	O	2	PRD
6	that	that	B-NP	WDT	O	5	NMOD
7	represses	repress	B-VP	VBZ	O	6	SBAR
8	cardiac-specific	cardiac-specific	B-NP	JJ	B-DNA	10	NMOD
9	gene	gene	I-NP	NN	I-DNA	10	NMOD
10	expression	expression	I-NP	NN	O	7	OBJ
11	and	and	O	CC	O	7	VMOD
12	induces	induce	B-VP	VBZ	O	7	VMOD
13	myocardial	myocardial	B-NP	JJ	B-cell_type	15	NMOD
14	cell	cell	I-NP	NN	I-cell_type	15	NMOD
15	apoptosis	apoptosis	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	2	P

1	Mitochondrial	Mitochondrial	B-NP	JJ	B-DNA	2	NMOD
2	DNA	DNA	I-NP	NN	I-DNA	7	NMOD
3	and	and	O	CC	O	7	NMOD
4	its	its	B-NP	PRP$	O	7	NMOD
5	respiratory	respiratory	I-NP	JJ	O	7	NMOD
6	chain	chain	I-NP	NN	O	7	NMOD
7	products	product	I-NP	NNS	O	8	SUB
8	are	be	B-VP	VBP	O	0	ROOT
9	defective	defective	B-ADJP	JJ	O	8	PRD
10	in	in	B-PP	IN	O	9	AMOD
11	doxorubicin	doxorubicin	B-NP	NN	O	12	NMOD
12	nephrosis	nephrosis	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	8	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Doxorubicin	Doxorubicin	B-NP	NN	O	4	SUB
4	induces	induce	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	self-perpetuating	self-perpetuating	I-NP	JJ	O	7	NMOD
7	nephropathy	nephropathy	I-NP	NN	O	4	OBJ
8	characterized	characterize	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	early	early	B-NP	JJ	O	15	NMOD
11	glomerular	glomerular	I-NP	JJ	O	10	NMOD
12	and	and	I-NP	CC	O	10	NMOD
13	late-onset	late-onset	I-NP	JJ	O	15	NMOD
14	tubular	tubular	I-NP	JJ	O	15	NMOD
15	lesions	lesion	I-NP	NNS	O	9	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	6	NMOD
4	'long-term	'long-term	I-NP	NN	O	6	NMOD
5	'	'	B-NP	POS	O	6	NMOD
6	group	group	I-NP	NN	O	7	SUB
7	had	have	B-VP	VBD	O	1	NMOD
8	significant	significant	B-NP	JJ	O	12	NMOD
9	glomerular	glomerular	I-NP	JJ	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	tubular	tubular	I-NP	JJ	O	12	NMOD
12	lesions	lesion	I-NP	NNS	O	7	OBJ
13	,	,	O	,	O	15	P
14	depressed	depressed	B-NP	JJ	O	15	NMOD
15	activities	activity	I-NP	NNS	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	mtDNA-encoded	mtDNA-encoded	B-NP	JJ	B-protein	19	NMOD
18	NADH	NADH	I-NP	NN	I-protein	19	NMOD
19	dehydrogenase	dehydrogenase	I-NP	NN	I-protein	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	cytochrome-c	cytochrome-c	B-NP	NN	B-protein	22	NMOD
22	oxidase	oxidase	I-NP	NN	I-protein	30	NMOD
23	(	(	O	(	O	25	DEP
24	COX	COX	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	and	and	O	CC	O	30	NMOD
27	increased	increase	B-NP	VBN	O	30	NMOD
28	citrate	citrate	I-NP	NN	B-protein	30	NMOD
29	synthase	synthase	I-NP	NN	I-protein	30	NMOD
30	activity	activity	I-NP	NN	O	16	PMOD
31	.	.	O	.	O	1	P

1	Amphotericin	Amphotericin	B-NP	NN	B-protein	2	NMOD
2	B	B	I-NP	NN	I-protein	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	seizures	seizure	B-NP	NNS	O	3	OBJ
5	in	in	B-PP	IN	O	3	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	AIDS	AIDS	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	multiple	multiple	B-NP	JJ	O	9	NMOD
9	episodes	episode	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	seizure	seizure	B-NP	NN	O	12	NMOD
12	activity	activity	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	6	NMOD
14	an	an	B-NP	DT	O	16	NMOD
15	AIDS	AIDS	I-NP	NNP	O	16	NMOD
16	patent	patent	I-NP	NN	O	13	PMOD
17	following	follow	B-PP	VBG	O	16	NMOD
18	amphotericin	amphotericin	B-NP	NN	O	20	NMOD
19	B	B	I-NP	NN	O	20	NMOD
20	infusion	infusion	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	7	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	7	NMOD
5	46-year-old	46-year-old	I-NP	JJ	O	7	NMOD
6	African-American	African-American	I-NP	JJ	O	7	NMOD
7	man	man	I-NP	NN	O	8	SUB
8	experienced	experience	B-VP	VBD	O	0	ROOT
9	recurrent	recurrent	B-NP	JJ	O	12	NMOD
10	grand	grand	I-NP	JJ	O	12	NMOD
11	mal	mal	I-NP	JJ	O	12	NMOD
12	seizures	seizure	I-NP	NNS	O	8	OBJ
13	during	during	B-PP	IN	O	8	VMOD
14	intravenous	intravenous	B-NP	JJ	O	15	NMOD
15	infusion	infusion	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	amphotericin	amphotericin	B-NP	NN	O	18	NMOD
18	B	B	I-NP	NN	O	16	PMOD
19	,	,	O	,	O	8	P
20	then	then	B-ADVP	RB	O	8	VMOD
21	petit	petit	B-VP	VBP	O	8	VMOD
22	mal	mal	B-NP	JJ	O	23	NMOD
23	seizures	seizure	I-NP	NNS	O	21	OBJ
24	as	as	B-PP	IN	O	21	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	infusion	infusion	I-NP	NN	O	24	PMOD
27	was	be	B-VP	VBD	O	33	VMOD
28	stopped	stop	I-VP	VBN	O	27	VC
29	and	and	O	CC	O	33	VMOD
30	the	the	B-NP	DT	O	32	NMOD
31	drug	drug	I-NP	NN	O	32	NMOD
32	concentrations	concentration	I-NP	NNS	O	33	SUB
33	decreased	decrease	B-VP	VBD	O	21	VMOD
34	with	with	B-PP	IN	O	33	VMOD
35	time	time	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	8	P

1	Despite	Despite	B-PP	IN	O	10	VMOD
2	administration	administration	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	phenytoin	phenytoin	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	lorazepam	lorazepam	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	10	P
8	the	the	B-NP	DT	O	9	NMOD
9	seizures	seizure	I-NP	NNS	O	10	SUB
10	persisted	persist	B-VP	VBD	O	0	ROOT
11	and	and	O	CC	O	10	VMOD
12	occurred	occur	B-VP	VBD	O	10	VMOD
13	only	only	B-ADVP	RB	O	14	PMOD
14	during	during	B-PP	IN	O	12	VMOD
15	amphotercin	amphotercin	B-NP	NN	O	17	NMOD
16	B	B	I-NP	NN	O	17	NMOD
17	administration	administration	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	had	have	B-VP	VBD	O	16	VMOD
4	a	a	B-NP	DT	O	5	NMOD
5	history	history	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	alcohol	alcohol	B-NP	NN	O	8	NMOD
8	abuse	abuse	I-NP	NN	O	6	PMOD
9	;	;	O	:	O	16	P
10	alcohol	alcohol	B-NP	NN	O	11	NMOD
11	intake	intake	I-NP	NN	O	15	NMOD
12	as	as	B-CONJP	RB	O	15	NMOD
13	well	well	I-CONJP	RB	O	12	DEP
14	as	as	I-CONJP	IN	O	12	DEP
15	withdrawal	withdrawal	B-NP	NN	O	16	SUB
16	can	can	B-VP	MD	O	0	ROOT
17	also	also	I-VP	RB	O	16	VMOD
18	cause	cause	I-VP	VB	O	16	VC
19	seizures	seizure	B-NP	NNS	O	18	OBJ
20	.	.	O	.	O	16	P

1	Didanosine	Didanosine	B-NP	NN	O	3	SUB
2	also	also	B-ADVP	RB	O	3	VMOD
3	has	have	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	5	NMOD
5	potential	potential	I-NP	NN	O	3	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	inducing	induce	B-VP	VBG	O	8	NMOD
8	seizures	seizure	B-NP	NNS	O	6	PMOD
9	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	time	time	I-NP	NN	O	3	NMOD
3	course	course	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	events	event	B-NP	NNS	O	4	PMOD
6	suggested	suggest	B-VP	VBD	O	0	ROOT
7	that	that	B-SBAR	IN	O	6	VMOD
8	amphotericin	amphotericin	B-NP	NN	O	9	NMOD
9	B	B	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	7	SBAR
11	the	the	B-NP	DT	O	12	NMOD
12	cause	cause	I-NP	NN	O	10	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	seizures	seizure	I-NP	NNS	O	13	PMOD
16	in	in	B-PP	IN	O	10	VMOD
17	this	this	B-NP	DT	O	19	NMOD
18	AIDS	AIDS	I-NP	NNP	O	19	NMOD
19	patient	patient	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	6	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Amphotericin	Amphotericin	B-NP	NN	O	4	NMOD
4	B	B	I-NP	NN	O	5	SUB
5	seems	seem	B-VP	VBZ	O	1	NMOD
6	to	to	I-VP	TO	O	7	VMOD
7	be	be	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	probable	probable	I-NP	JJ	O	10	NMOD
10	cause	cause	I-NP	NN	O	7	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	seizures	seizure	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	dosage	dosage	B-NP	NN	O	9	NMOD
9	regimen	regimen	I-NP	NN	O	7	PMOD
10	(	(	O	(	O	14	DEP
11	once-daily	once-daily	B-ADJP	JJ	O	13	AMOD
12	vs.	vs.	B-PP	IN	O	13	AMOD
13	twice-daily	twice-daily	B-ADJP	JJ	O	14	DEP
14	)	)	O	)	O	4	VMOD
15	of	of	B-PP	IN	O	4	VMOD
16	tobramicyn	tobramicyn	B-NP	NN	O	15	PMOD
17	on	on	B-PP	IN	O	4	VMOD
18	steady-state	steady-state	B-NP	JJ	O	20	NMOD
19	serum	serum	I-NP	NN	O	20	NMOD
20	concentrations	concentration	I-NP	NNS	O	22	NMOD
21	and	and	O	CC	O	22	NMOD
22	toxicity	toxicity	B-NP	NN	O	17	PMOD
23	.	.	O	.	O	1	P

1	Increased	Increase	B-NP	VBN	O	3	NMOD
2	serum	serum	I-NP	NN	O	3	NMOD
3	creatinine	creatinine	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	observed	observe	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	73	73	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	patients	patient	B-NP	NNS	O	15	NMOD
11	in	in	B-PP	IN	O	10	NMOD
12	OD	OD	B-NP	NN	O	11	PMOD
13	versus	versus	B-PP	IN	O	15	NMOD
14	57	57	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	9	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	TD	TD	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	5	P
21	without	without	B-PP	IN	O	5	VMOD
22	evidence	evidence	B-NP	NN	O	21	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	nephrotoxicity	nephrotoxicity	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	4	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	8	NMOD
5	novel	novel	I-NP	JJ	O	8	NMOD
6	synthetic	synthetic	I-NP	JJ	O	8	NMOD
7	anthracycline	anthracycline	I-NP	NN	O	8	NMOD
8	derivative	derivative	I-NP	NN	O	3	PMOD
9	(	(	O	(	O	11	DEP
10	SM-5887	SM-5887	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	on	on	B-PP	IN	O	2	NMOD
13	normal	normal	B-NP	JJ	O	14	NMOD
14	heart	heart	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	doxorubicin	doxorubicin	I-NP	NN	O	12	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	cardiomyopathy	cardiomyopathy	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	beagle	beagle	B-NP	NN	O	21	NMOD
21	dogs	dog	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	17	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	investigate	investigate	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	10	NMOD
8	chronic	chronic	I-NP	JJ	O	10	NMOD
9	cardiotoxic	cardiotoxic	I-NP	JJ	O	10	NMOD
10	potential	potential	I-NP	NN	O	17	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	SM-5887	SM-5887	B-NP	NN	B-protein	11	PMOD
13	and	and	O	CC	O	17	NMOD
14	a	a	B-NP	DT	O	17	NMOD
15	possible	possible	I-NP	JJ	O	17	NMOD
16	deteriorating	deteriorate	I-NP	VBG	O	17	NMOD
17	effect	effect	I-NP	NN	O	6	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	SM-5887	SM-5887	B-NP	NN	O	18	PMOD
20	on	on	B-PP	IN	O	17	NMOD
21	low-grade	low-grade	B-NP	JJ	O	23	NMOD
22	cardiotoxicity	cardiotoxicity	I-NP	NN	O	23	NMOD
23	pre	pre	I-NP	NN	O	20	PMOD
24	induced	induce	B-VP	VBN	O	23	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	doxorubicin	doxorubicin	B-NP	NN	O	25	PMOD
27	in	in	B-PP	IN	O	24	VMOD
28	beagle	beagle	B-NP	NN	O	29	NMOD
29	dogs	dog	I-NP	NNS	O	27	PMOD
30	.	.	O	.	O	3	P

1	Animals	Animal	B-NP	NNS	O	9	SUB
2	which	which	B-NP	WDT	O	1	NMOD
3	received	receive	B-VP	VBD	O	2	SBAR
4	over	over	B-NP	IN	O	6	NMOD
5	six	six	I-NP	CD	O	4	AMOD
6	courses	course	I-NP	NNS	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	doxorubicin	doxorubicin	B-NP	NN	O	7	PMOD
9	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	11	NMOD
11	electrocardiogram	electrocardiogram	I-NP	NN	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	ECG	ECG	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	changes	change	B-NP	NNS	O	24	NMOD
16	,	,	O	,	O	24	P
17	decrease	decrease	B-NP	NN	O	24	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	blood	blood	B-NP	NN	O	20	NMOD
20	pressure	pressure	I-NP	NN	O	18	PMOD
21	and	and	O	CC	O	24	NMOD
22	high-grade	high-grade	B-NP	JJ	O	24	NMOD
23	histopathological	histopathological	I-NP	JJ	O	24	NMOD
24	cardiomyopathy	cardiomyopathy	I-NP	NN	O	9	OBJ
25	,	,	O	,	O	9	P
26	while	while	B-SBAR	IN	O	9	VMOD
27	animals	animal	B-NP	NNS	O	36	SUB
28	which	which	B-NP	WDT	O	27	NMOD
29	were	be	B-VP	VBD	O	28	SBAR
30	terminally	terminally	I-VP	RB	O	29	VMOD
31	sacrificed	sacrifice	I-VP	VBN	O	29	VC
32	after	after	B-PP	IN	O	31	VMOD
33	the	the	B-NP	DT	O	35	NMOD
34	SM-5887	SM-5887	I-NP	NN	O	35	NMOD
35	administration	administration	I-NP	NN	O	32	PMOD
36	did	do	B-VP	VBD	O	26	SBAR
37	not	not	I-VP	RB	O	36	VMOD
38	show	show	I-VP	VB	O	36	VC
39	any	any	B-NP	DT	O	40	NMOD
40	changes	change	I-NP	NNS	O	48	NMOD
41	in	in	B-PP	IN	O	40	NMOD
42	ECG	ECG	B-NP	NN	O	41	PMOD
43	,	,	O	,	O	48	P
44	blood	blood	B-NP	NN	O	45	NMOD
45	pressure	pressure	I-NP	NN	O	48	NMOD
46	and	and	O	CC	O	48	NMOD
47	histopathological	histopathological	B-NP	JJ	O	48	NMOD
48	examinations	examination	I-NP	NNS	O	38	OBJ
49	.	.	O	.	O	9	P

1	To	To	B-VP	TO	O	2	VMOD
2	examine	examine	I-VP	VB	O	13	VMOD
3	a	a	B-NP	DT	O	7	NMOD
4	possibly	possibly	I-NP	RB	O	5	AMOD
5	deteriorating	deteriorate	I-NP	VBG	O	7	NMOD
6	cardiotoxic	cardiotoxic	I-NP	JJ	O	7	NMOD
7	effect	effect	I-NP	NN	O	2	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	SM-5887	SM-5887	B-NP	NN	B-protein	8	PMOD
10	,	,	O	,	O	13	P
11	low-grade	low-grade	B-NP	JJ	O	12	NMOD
12	cardiomyopathy	cardiomyopathy	I-NP	NN	O	13	SUB
13	was	be	B-VP	VBD	O	0	ROOT
14	induced	induce	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	dogs	dog	B-NP	NNS	O	15	PMOD
17	by	by	B-PP	IN	O	14	VMOD
18	four	four	B-NP	CD	O	19	NMOD
19	courses	course	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	doxorubicin	doxorubicin	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	25	DEP
23	1.5	1.5	B-NP	CD	O	24	NMOD
24	mg/kg	mg/kg	I-NP	NN	O	25	DEP
25	)	)	O	)	O	21	NMOD
26	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	4	NMOD
2	low-grade	low-grade	I-NP	JJ	O	4	NMOD
3	cardiotoxic	cardiotoxic	I-NP	JJ	O	4	NMOD
4	changes	change	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	enhanced	enhance	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	11	NMOD
9	additional	additional	I-NP	JJ	O	11	NMOD
10	doxorubicin	doxorubicin	I-NP	NN	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	5	P

1	On	On	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	contrary	contrary	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	8	P
5	the	the	B-NP	DT	O	7	NMOD
6	SM-5887	SM-5887	I-NP	NN	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	8	SUB
8	did	do	B-VP	VBD	O	0	ROOT
9	not	not	I-VP	RB	O	8	VMOD
10	progress	progress	I-VP	VB	O	8	VC
11	the	the	B-NP	DT	O	12	NMOD
12	grade	grade	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	cardiomyopathy	cardiomyopathy	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	8	P

1	Neuropeptide-Y	Neuropeptide-Y	B-NP	JJ	O	2	NMOD
2	immunoreactivity	immunoreactivity	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	pilocarpine	pilocarpine	I-NP	NN	O	6	NMOD
6	model	model	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	temporal	temporal	B-NP	JJ	O	10	NMOD
9	lobe	lobe	I-NP	NN	O	10	NMOD
10	epilepsy	epilepsy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	pilocarpine	pilocarpine	I-NP	NN	O	9	SUB
3	(	(	O	(	O	5	DEP
4	PILO	PILO	B-NP	NN	B-protein	5	DEP
5	)	)	O	)	O	2	NMOD
6	model	model	B-NP	NN	O	2	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	epilepsy	epilepsy	B-NP	NN	O	7	PMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	characterized	characterize	I-VP	VBN	O	9	VC
11	by	by	B-PP	IN	O	10	VMOD
12	an	an	B-NP	DT	O	14	NMOD
13	acute	acute	I-NP	JJ	O	14	NMOD
14	period	period	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	status	status	B-NP	NN	O	17	NMOD
17	epilepticus	epilepticus	I-NP	NN	O	15	PMOD
18	followed	follow	B-VP	VBN	O	14	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	spontaneous	spontaneous	B-NP	JJ	O	22	NMOD
21	recurrent	recurrent	I-NP	JJ	O	22	NMOD
22	seizures	seizure	I-NP	NNS	O	26	NMOD
23	and	and	O	CC	O	26	NMOD
24	related	relate	B-NP	VBN	O	26	NMOD
25	brain	brain	I-NP	NN	O	26	NMOD
26	damage	damage	I-NP	NN	O	19	PMOD
27	.	.	O	.	O	9	P

1	During	During	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	follow-up	follow-up	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	11	P
5	3	3	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	11	SUB
7	(	(	O	(	O	10	DEP
8	12	12	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	developed	develop	B-VP	VBD	O	0	ROOT
12	steroid	steroid	B-NP	NN	O	16	NMOD
13	induced	induced	I-NP	JJ	O	16	NMOD
14	elevated	elevated	I-NP	JJ	O	16	NMOD
15	intraocular	intraocular	I-NP	JJ	O	16	NMOD
16	pressure	pressure	I-NP	NN	O	11	OBJ
17	(	(	O	(	O	19	DEP
18	IOP	IOP	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	that	that	B-NP	WDT	O	16	NMOD
21	resolved	resolve	B-VP	VBD	O	20	SBAR
22	after	after	B-PP	IN	O	21	VMOD
23	corticosteroid	corticosteroid	B-NP	NN	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	25	SUB
25	was	be	B-VP	VBD	O	22	SBAR
26	discontinued	discontinue	I-VP	VBN	O	25	VC
27	.	.	O	.	O	11	P

1	Liposomal	Liposomal	B-NP	JJ	O	2	NMOD
2	daunorubicin	daunorubicin	I-NP	NN	O	12	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	advanced	advance	B-VP	VBN	O	7	NMOD
5	Kaposi	Kaposi	B-NP	NNP	O	7	NMOD
6	's	's	B-NP	POS	O	7	NMOD
7	sarcoma	sarcoma	I-NP	NN	O	3	PMOD
8	:	:	O	:	O	2	P
9	a	a	B-NP	DT	O	12	NMOD
10	phase	phase	I-NP	NN	O	12	NMOD
11	II	II	I-NP	CD	O	12	NMOD
12	study	study	I-NP	NN	O	0	ROOT
13	.	.	O	.	O	12	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	8	NMOD
4	non-randomized	non-randomized	I-NP	JJ	O	8	NMOD
5	Phase	Phase	I-NP	NN	O	8	NMOD
6	II	II	I-NP	CD	O	8	NMOD
7	clinical	clinical	I-NP	JJ	O	8	NMOD
8	trial	trial	I-NP	NN	O	26	SUB
9	to	to	B-VP	TO	O	10	VMOD
10	assess	assess	I-VP	VB	O	8	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	efficacy	efficacy	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	safety	safety	I-NP	NN	O	10	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	liposomal	liposomal	B-NP	JJ	O	17	NMOD
17	daunorubicin	daunorubicin	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	DaunoXome	DaunoXome	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	in	in	B-PP	IN	O	10	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	treatment	treatment	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	AIDS	AIDS	B-NP	NNP	O	24	PMOD
26	related	relate	B-VP	VBD	O	2	VMOD
27	Kaposi	Kaposi	B-NP	NNP	O	29	NMOD
28	's	's	B-NP	POS	O	29	NMOD
29	sarcoma	sarcoma	I-NP	NN	O	26	OBJ
30	.	.	O	.	O	2	P

1	Failure	Failure	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ancrod	ancrod	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	heparin	heparin	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	arterial	arterial	B-NP	JJ	O	11	NMOD
11	thrombosis	thrombosis	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	4	NMOD
2	morbidity	morbidity	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	mortality	mortality	I-NP	NN	O	10	SUB
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	heparin	heparin	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	thrombosis	thrombosis	I-NP	NN	O	6	PMOD
10	remain	remain	B-VP	VBP	O	0	ROOT
11	high	high	B-ADJP	JJ	O	10	PRD
12	despite	despite	B-PP	IN	O	11	AMOD
13	numerous	numerous	B-NP	JJ	O	15	NMOD
14	empirical	empirical	I-NP	JJ	O	15	NMOD
15	therapies	therapy	I-NP	NNS	O	12	PMOD
16	.	.	O	.	O	10	P

1	Ancrod	Ancrod	B-NP	NNP	O	2	SUB
2	has	have	B-VP	VBZ	O	28	NMOD
3	been	be	I-VP	VBN	O	2	VC
4	used	use	I-VP	VBN	O	3	VC
5	successfully	successfully	B-ADVP	RB	O	4	VMOD
6	for	for	B-PP	IN	O	4	VMOD
7	prophylaxis	prophylaxis	B-NP	NN	O	6	PMOD
8	against	against	B-PP	IN	O	7	NMOD
9	development	development	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	thrombosis	thrombosis	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	9	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	heparin	heparin	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	2	VMOD
17	platelet	platelet	B-NP	NN	B-cell_type	18	NMOD
18	aggregation	aggregation	I-NP	NN	O	16	OBJ
19	who	who	B-NP	WP	O	18	NMOD
20	require	require	B-VP	VBP	O	19	SBAR
21	brief	brief	B-NP	JJ	O	22	NMOD
22	reexposure	reexposure	I-NP	NN	O	20	OBJ
23	to	to	B-PP	TO	O	20	VMOD
24	heparin	heparin	B-NP	NN	O	23	PMOD
25	,	,	O	,	O	28	P
26	but	but	O	CC	O	28	NMOD
27	its	its	B-NP	PRP$	O	28	NMOD
28	success	success	I-NP	NN	O	37	SUB
29	in	in	B-PP	IN	O	28	NMOD
30	patients	patient	B-NP	NNS	O	29	PMOD
31	who	who	B-NP	WP	O	30	NMOD
32	have	have	B-VP	VBP	O	31	SBAR
33	developed	develop	I-VP	VBN	O	32	VC
34	the	the	B-NP	DT	O	36	NMOD
35	thrombosis	thrombosis	I-NP	NN	O	36	NMOD
36	syndrome	syndrome	I-NP	NN	O	33	OBJ
37	is	be	B-VP	VBZ	O	0	ROOT
38	not	not	I-VP	RB	O	37	VMOD
39	well	well	I-VP	RB	O	37	VMOD
40	defined	define	I-VP	VBN	O	37	VC
41	.	.	O	.	O	37	P

1	Seizure	Seizure	B-NP	NN	O	0	ROOT
2	after	after	B-PP	IN	O	1	NMOD
3	flumazenil	flumazenil	B-NP	NN	O	4	NMOD
4	administration	administration	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	pediatric	pediatric	I-NP	JJ	O	8	NMOD
8	patient	patient	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	1	P

1	Flumazenil	Flumazenil	B-NP	NNP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	benzodiazepine	benzodiazepine	I-NP	NN	O	6	NMOD
5	receptor	receptor	I-NP	NN	O	6	NMOD
6	antagonist	antagonist	I-NP	NN	O	2	PRD
7	used	use	B-VP	VBN	O	6	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	reverse	reverse	I-VP	VB	O	7	VMOD
10	sedation	sedation	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	respiratory	respiratory	B-NP	JJ	O	13	NMOD
13	depression	depression	I-NP	NN	O	9	OBJ
14	induced	induce	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	benzodiazepines	benzodiazepine	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	2	P

1	Remodelling	Remodelling	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	nerve	nerve	B-NP	NN	O	4	NMOD
4	structure	structure	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	experimental	experimental	B-NP	JJ	O	8	NMOD
7	isoniazid	isoniazid	I-NP	NN	O	8	NMOD
8	neuropathy	neuropathy	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	rat	rat	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	1	P

1	Frequencies	Frequency	B-NP	NNS	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ventricular	ventricular	B-NP	JJ	O	4	NMOD
4	fibrillation	fibrillation	I-NP	NN	O	2	PMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	significantly	significantly	B-ADJP	RB	O	7	AMOD
7	lower	low	I-ADJP	JJR	O	5	PRD
8	(	(	O	(	O	13	DEP
9	p	p	B-NP	NN	O	11	SUB
10	less	less	B-ADJP	JJR	O	11	AMOD
11	than	than	B-PP	IN	O	13	DEP
12	0.05	0.05	B-NP	CD	O	11	AMOD
13	)	)	O	)	O	5	VMOD
14	after	after	B-PP	IN	O	5	VMOD
15	iopentol	iopentol	B-NP	NN	O	21	NMOD
16	(	(	O	(	O	19	DEP
17	0	0	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	15	NMOD
20	and	and	O	CC	O	21	NMOD
21	iohexol	iohexol	B-NP	NN	O	14	PMOD
22	(	(	O	(	O	25	DEP
23	3	3	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	25	DEP
25	)	)	O	)	O	21	NMOD
26	than	than	B-PP	IN	O	5	VMOD
27	after	after	B-PP	IN	O	26	PMOD
28	metrizoate	metrizoate	B-NP	NN	O	27	PMOD
29	(	(	O	(	O	32	DEP
30	22	22	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	32	DEP
32	)	)	O	)	O	28	NMOD
33	.	.	O	.	O	5	P

1	Relation	Relation	B-NP	NN	O	17	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	perfusion	perfusion	B-NP	NN	O	4	NMOD
4	defects	defect	I-NP	NNS	O	2	PMOD
5	observed	observe	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	myocardial	myocardial	B-NP	JJ	O	9	NMOD
8	contrast	contrast	I-NP	NN	O	9	NMOD
9	echocardiography	echocardiography	I-NP	NN	O	6	PMOD
10	to	to	B-PP	TO	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	severity	severity	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	coronary	coronary	B-NP	JJ	O	15	NMOD
15	stenosis	stenosis	I-NP	NN	O	13	PMOD
16	:	:	O	:	O	1	P
17	correlation	correlation	B-NP	NN	O	0	ROOT
18	with	with	B-PP	IN	O	17	NMOD
19	thallium-201	thallium-201	B-NP	CD	O	22	NMOD
20	single-photon	single-photon	I-NP	JJ	O	22	NMOD
21	emission	emission	I-NP	NN	O	22	NMOD
22	tomography	tomography	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	17	P

1	During	During	B-PP	IN	O	16	VMOD
2	dipyridamole	dipyridamole	B-NP	NN	O	1	PMOD
3	induced	induce	B-VP	VBD	O	2	NMOD
4	hyperemia	hyperemia	B-NP	NN	O	6	NMOD
5	,	,	O	,	O	6	P
6	12	12	B-NP	CD	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	16	16	I-NP	CD	O	10	NMOD
10	dogs	dog	I-NP	NNS	O	7	PMOD
11	with	with	B-PP	IN	O	3	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	partial	partial	I-NP	JJ	O	14	AMOD
14	coronary	coronary	I-NP	JJ	O	15	NMOD
15	stenosis	stenosis	I-NP	NN	O	11	PMOD
16	had	have	B-VP	VBD	O	0	ROOT
17	a	a	B-NP	DT	O	19	NMOD
18	visible	visible	I-NP	JJ	O	19	NMOD
19	area	area	I-NP	NN	O	16	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	hypoperfusion	hypoperfusion	B-NP	NN	O	20	PMOD
22	by	by	B-PP	IN	O	16	VMOD
23	contrast	contrast	B-NP	NN	O	24	NMOD
24	echocardiography	echocardiography	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	3	NMOD
2	four	four	I-NP	CD	O	3	NMOD
3	dogs	dog	I-NP	NNS	O	8	SUB
4	without	without	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	perfusion	perfusion	I-NP	NN	O	7	NMOD
7	defect	defect	I-NP	NN	O	4	PMOD
8	had	have	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	10	NMOD
10	stenosis	stenosis	I-NP	NN	O	8	OBJ
11	that	that	B-NP	WDT	O	10	NMOD
12	resulted	result	B-VP	VBD	O	11	SBAR
13	in	in	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	23	NMOD
15	mild	mild	I-NP	JJ	O	23	NMOD
16	(	(	O	(	O	22	DEP
17	0	0	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	22	DEP
19	to	to	B-PP	TO	O	18	NMOD
20	50	50	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	19	PMOD
22	)	)	O	)	O	15	AMOD
23	reduction	reduction	B-NP	NN	O	13	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	dipyridamole	dipyridamole	B-NP	NN	O	27	NMOD
26	induced	induced	I-NP	JJ	O	27	NMOD
27	hyperemia	hyperemia	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	8	P

1	Thallium-201	Thallium-201	B-NP	NN	O	2	NMOD
2	SPECT	SPECT	I-NP	NN	O	3	SUB
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	perfusion	perfusion	I-NP	NN	O	6	NMOD
6	defect	defect	I-NP	NN	O	14	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	all	all	B-NP	DT	O	10	NMOD
9	14	14	I-NP	CD	O	10	NMOD
10	dogs	dog	I-NP	NNS	O	7	PMOD
11	analyzed	analyze	B-VP	VBN	O	10	NMOD
12	during	during	B-PP	IN	O	11	VMOD
13	dipyridamole	dipyridamole	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	3	VMOD
15	hyperemia	hyperemia	B-NP	NN	O	14	OBJ
16	;	;	O	:	O	23	P
17	the	the	B-NP	DT	O	18	NMOD
18	size	size	I-NP	NN	O	23	SUB
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	perfusion	perfusion	I-NP	NN	O	22	NMOD
22	defect	defect	I-NP	NN	O	19	PMOD
23	correlated	correlate	B-VP	VBD	O	14	VMOD
24	with	with	B-PP	IN	O	23	VMOD
25	the	the	B-NP	DT	O	27	NMOD
26	anatomic	anatomic	I-NP	JJ	O	27	NMOD
27	area	area	I-NP	NN	O	24	PMOD
28	at	at	B-PP	IN	O	27	NMOD
29	risk	risk	B-NP	NN	O	28	PMOD
30	(	(	O	(	O	39	DEP
31	r	r	B-NP	NN	O	39	DEP
32	=	=	B-VP	SYM	O	31	NMOD
33	0.58	0.58	B-NP	CD	O	32	AMOD
34	;	;	O	:	O	39	P
35	p	p	B-NP	NN	O	37	SUB
36	less	less	B-ADJP	JJR	O	37	AMOD
37	than	than	B-PP	IN	O	39	DEP
38	0.03	0.03	B-NP	CD	O	37	AMOD
39	)	)	O	)	O	27	NMOD
40	and	and	O	CC	O	24	PMOD
41	with	with	B-PP	IN	O	24	PMOD
42	the	the	B-NP	DT	O	44	NMOD
43	perfusion	perfusion	I-NP	NN	O	44	NMOD
44	defect	defect	I-NP	NN	O	41	PMOD
45	by	by	B-PP	IN	O	44	NMOD
46	contrast	contrast	B-NP	NN	O	47	NMOD
47	echocardiography	echocardiography	I-NP	NN	O	45	PMOD
48	(	(	O	(	O	57	DEP
49	r	r	B-NP	NN	O	57	DEP
50	=	=	B-VP	SYM	O	49	NMOD
51	0.58	0.58	B-NP	CD	O	50	AMOD
52	;	;	O	:	O	57	P
53	p	p	B-NP	NN	O	57	DEP
54	less	less	B-ADJP	JJR	O	53	NMOD
55	than	than	B-PP	IN	O	54	AMOD
56	0.03	0.03	B-NP	CD	O	55	PMOD
57	)	)	O	)	O	44	NMOD
58	.	.	O	.	O	3	P

1	Potential	Potential	B-NP	JJ	O	3	NMOD
2	deleterious	deleterious	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	furosemide	furosemide	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	radiocontrast	radiocontrast	B-NP	NN	O	8	NMOD
8	nephropathy	nephropathy	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	efficacy	efficacy	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	furosemide	furosemide	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	addition	addition	B-NP	NN	O	13	PMOD
15	to	to	B-PP	TO	O	14	NMOD
16	intravenous	intravenous	B-NP	JJ	O	17	NMOD
17	fluids	fluid	I-NP	NNS	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	prevention	prevention	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	radiocontrast	radiocontrast	B-NP	NN	O	25	NMOD
23	nephropathy.	nephropathy.	I-NP	NN	O	25	NMOD
24	18	18	B-NP	CD	O	25	NMOD
25	patients	patient	I-NP	NNS	O	21	PMOD
26	,	,	O	,	O	6	P
27	referred	refer	B-VP	VBD	O	6	VMOD
28	to	to	B-PP	TO	O	27	VMOD
29	a	a	B-NP	DT	O	31	NMOD
30	radiocontrast	radiocontrast	I-NP	NN	O	31	NMOD
31	study	study	I-NP	NN	O	28	PMOD
32	,	,	O	,	O	27	P
33	considered	consider	B-VP	VBN	O	27	VMOD
34	at	at	B-PP	IN	O	33	VMOD
35	risk	risk	B-NP	NN	O	34	PMOD
36	because	because	B-PP	IN	O	33	VMOD
37	of	of	I-PP	IN	O	36	PMOD
38	preexisting	preexist	B-VP	VBG	O	37	PMOD
39	renal	renal	B-NP	JJ	O	40	NMOD
40	insufficiency	insufficiency	I-NP	NN	O	38	OBJ
41	,	,	O	,	O	6	P
42	were	be	B-VP	VBD	O	6	VMOD
43	enrolled	enrol	I-VP	VBN	O	42	VC
44	in	in	B-PP	IN	O	43	VMOD
45	a	a	B-NP	DT	O	51	NMOD
46	prospective	prospective	I-NP	JJ	O	51	NMOD
47	,	,	I-NP	,	O	51	P
48	randomized	randomize	I-NP	VBN	O	51	NMOD
49	,	,	I-NP	,	O	51	P
50	controlled	control	I-NP	VBN	O	51	NMOD
51	trial	trial	I-NP	NN	O	44	PMOD
52	,	,	O	,	O	42	P
53	performed	perform	B-VP	VBN	O	42	VC
54	at	at	B-PP	IN	O	53	VMOD
55	the	the	B-NP	DT	O	58	NMOD
56	secondary	secondary	I-NP	JJ	O	58	NMOD
57	care	care	I-NP	NN	O	58	NMOD
58	center	center	I-NP	NN	O	66	NMOD
59	of	of	B-PP	IN	O	58	NMOD
60	a	a	B-NP	DT	O	59	PMOD
61	1	1	I-NP	CD	O	60	NMOD
62	,	,	O	,	O	66	P
63	100-bed	100-bed	B-NP	JJ	O	66	NMOD
64	private	private	I-NP	JJ	O	66	NMOD
65	university	university	I-NP	NN	O	66	NMOD
66	hospital	hospital	I-NP	NN	O	54	PMOD
67	.	.	O	.	O	6	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	function	function	I-NP	NN	O	0	ROOT
3	significantly	significantly	B-VP	RB	O	4	VMOD
4	deteriorated	deteriorate	I-VP	VBN	O	2	NMOD
5	in	in	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	group	group	I-NP	NN	O	5	PMOD
8	pretreated	pretreate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	furosemide	furosemide	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	17	DEP
12	p	p	B-NP	NN	O	14	NMOD
13	<	<	B-NP	JJR	O	14	NMOD
14	0.005	0.005	I-NP	CD	O	17	DEP
15	by	by	B-PP	IN	O	14	NMOD
16	ANOVA	ANOVA	B-NP	NN	B-protein	15	PMOD
17	)	)	O	)	O	2	NMOD
18	,	,	O	,	O	2	P
19	with	with	B-PP	IN	O	2	NMOD
20	a	a	B-NP	DT	O	21	NMOD
21	rise	rise	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	serum	serum	B-NP	NN	O	24	NMOD
24	creatinine	creatinine	I-NP	NN	O	22	PMOD
25	from	from	B-PP	IN	O	21	NMOD
26	145	145	B-NP	CD	O	28	AMOD
27	+/-	+/-	I-NP	SYM	O	28	AMOD
28	13	13	I-NP	CD	O	25	PMOD
29	to	to	B-PP	TO	O	25	PMOD
30	182	182	B-NP	CD	O	32	AMOD
31	+/-	+/-	I-NP	SYM	O	32	AMOD
32	16	16	I-NP	CD	O	33	NMOD
33	mumol/l	mumol/l	I-NP	NN	O	29	PMOD
34	at	at	B-PP	IN	O	2	NMOD
35	24	24	B-NP	CD	O	36	NMOD
36	h	h	I-NP	NN	O	34	PMOD
37	,	,	O	,	O	2	P
38	while	while	B-SBAR	IN	O	2	VMOD
39	no	no	B-NP	DT	O	40	NMOD
40	change	change	I-NP	NN	O	41	SUB
41	occurred	occur	B-VP	VBD	O	38	SBAR
42	in	in	B-PP	IN	O	41	VMOD
43	the	the	B-NP	DT	O	45	NMOD
44	control	control	I-NP	NN	O	45	NMOD
45	group	group	I-NP	NN	O	42	PMOD
46	(	(	O	(	O	56	DEP
47	from	from	B-PP	IN	O	55	NMOD
48	141	141	B-NP	CD	O	50	AMOD
49	+/-	+/-	I-NP	SYM	O	50	AMOD
50	6	6	I-NP	CD	O	47	PMOD
51	to	to	I-NP	TO	O	47	PMOD
52	142	142	I-NP	CD	O	54	AMOD
53	+/-	+/-	I-NP	SYM	O	54	AMOD
54	7	7	I-NP	CD	O	51	PMOD
55	mumol/l	mumol/l	I-NP	NN	O	56	DEP
56	)	)	O	)	O	45	NMOD
57	.	.	O	.	O	2	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	failure	failure	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	weight	weight	B-NP	NN	O	7	NMOD
7	loss	loss	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	furosemide-treated	furosemide-treated	I-NP	JJ	O	11	NMOD
11	group	group	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	pathology	pathology	I-NP	NN	O	9	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	lithium	lithium	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	diabetes	diabetes	B-NP	NN	O	11	NMOD
11	insipidus	insipidus	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	lithium	lithium	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	8	VMOD
6	diabetes	diabetes	B-NP	NN	O	7	NMOD
7	insipidus	insipidus	I-NP	NN	O	8	SUB
8	is	be	B-VP	VBZ	O	0	ROOT
9	reported	report	I-VP	VBN	O	8	VC
10	.	.	O	.	O	8	P

1	Etiologic	Etiologic	B-NP	JJ	B-protein	2	NMOD
2	factors	factor	I-NP	NNS	I-protein	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	pathogenesis	pathogenesis	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	liver	liver	B-NP	NN	O	8	NMOD
8	tumors	tumor	I-NP	NNS	O	6	PMOD
9	associated	associate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	oral	oral	B-NP	JJ	O	12	NMOD
12	contraceptives	contraceptive	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	2	P

1	Within	Within	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	last	last	I-NP	JJ	O	5	NMOD
4	several	several	I-NP	JJ	O	5	NMOD
5	years	year	I-NP	NNS	O	1	PMOD
6	,	,	O	,	O	11	P
7	previously	previously	B-NP	RB	O	8	AMOD
8	rare	rare	I-NP	JJ	O	10	NMOD
9	liver	liver	I-NP	NN	O	10	NMOD
10	tumors	tumor	I-NP	NNS	O	11	SUB
11	have	have	B-VP	VBP	O	0	ROOT
12	been	be	I-VP	VBN	O	11	VC
13	seen	see	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	young	young	B-NP	JJ	O	16	NMOD
16	women	woman	I-NP	NNS	O	14	PMOD
17	using	use	B-VP	VBG	O	11	VMOD
18	oral	oral	B-NP	JJ	O	20	NMOD
19	contraceptive	contraceptive	I-NP	JJ	O	20	NMOD
20	steroids	steroid	I-NP	NNS	O	17	OBJ
21	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	2	NMOD
2	Registry	Registry	I-NP	NN	O	18	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	Liver	Liver	B-NP	NN	O	5	NMOD
5	Tumors	Tumor	I-NP	NNS	O	3	PMOD
6	Associated	Associate	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	Oral	Oral	B-NP	JJ	O	9	NMOD
9	Contraceptives	Contraceptive	I-NP	NNS	O	7	PMOD
10	at	at	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	University	University	I-NP	NNP	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	California	California	B-NP	NNP	O	16	NMOD
15	,	,	O	,	O	16	P
16	Irvine	Irvine	B-NP	NNP	O	13	PMOD
17	,	,	O	,	O	2	P
18	has	have	B-VP	VBZ	O	0	ROOT
19	clearly	clearly	I-VP	RB	O	18	VMOD
20	identified	identify	I-VP	VBN	O	18	VC
21	27	27	B-NP	CD	O	22	NMOD
22	cases	case	I-NP	NNS	O	20	OBJ
23	.	.	O	.	O	18	P

1	Graft-versus-host	Graft-versus-host	B-NP	JJ	O	3	NMOD
2	disease	disease	I-NP	NN	O	3	NMOD
3	prophylaxis	prophylaxis	I-NP	NN	O	8	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	everolimus	everolimus	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	tacrolimus	tacrolimus	I-NP	NN	O	4	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	associated	associate	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	high	high	I-NP	JJ	O	13	NMOD
13	incidence	incidence	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	sinusoidal	sinusoidal	B-NP	JJ	O	17	NMOD
16	obstruction	obstruction	I-NP	NN	O	17	NMOD
17	syndrome	syndrome	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	microangiopathy	microangiopathy	I-NP	NN	O	14	PMOD
20	:	:	O	:	O	8	P
21	results	result	B-NP	NNS	O	8	PRD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	EVTAC	EVTAC	I-NP	NN	O	25	NMOD
25	trial	trial	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	3	NMOD
2	calcineurin	calcineurin	I-NP	NN	B-protein	3	NMOD
3	inhibitor	inhibitor	I-NP	NN	O	7	SUB
4	combined	combine	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	methotrexate	methotrexate	B-NP	NN	O	5	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	the	the	B-NP	DT	O	10	NMOD
9	standard	standard	I-NP	JJ	O	10	NMOD
10	prophylaxis	prophylaxis	I-NP	NN	O	7	PRD
11	for	for	B-PP	IN	O	10	NMOD
12	graft-versus-host	graft-versus-host	B-NP	JJ	O	13	NMOD
13	disease	disease	I-NP	NN	O	11	PMOD
14	(	(	O	(	O	16	DEP
15	GVHD	GVHD	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	after	after	B-PP	IN	O	13	NMOD
18	allogeneic	allogeneic	B-NP	JJ	O	22	NMOD
19	hematopoietic	hematopoietic	I-NP	JJ	O	22	NMOD
20	stem	stem	I-NP	NN	O	22	NMOD
21	cell	cell	I-NP	NN	O	22	NMOD
22	transplantation	transplantation	I-NP	NN	O	17	PMOD
23	(	(	O	(	O	25	DEP
24	HSCT	HSCT	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	on	on	B-PP	IN	O	2	VMOD
4	a	a	B-NP	DT	O	5	NMOD
5	combination	combination	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	everolimus	everolimus	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	tacrolimus	tacrolimus	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	24	24	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	(	(	O	(	O	19	DEP
14	median	median	B-NP	JJ	O	15	NMOD
15	age	age	I-NP	NN	O	18	NMOD
16	,	,	O	,	O	18	P
17	62	62	B-NP	CD	O	18	NMOD
18	years	year	I-NP	NNS	O	19	DEP
19	)	)	O	)	O	12	NMOD
20	with	with	B-PP	IN	O	12	NMOD
21	either	either	B-NP	CC	O	23	NMOD
22	myelodysplastic	myelodysplastic	I-NP	JJ	O	23	NMOD
23	syndrome	syndrome	I-NP	NN	O	20	PMOD
24	(	(	O	(	O	30	DEP
25	MDS	MDS	B-NP	NN	O	27	NMOD
26	;	;	O	:	O	27	P
27	n	n	B-NP	NN	O	29	SUB
28	=	=	B-VP	SYM	O	29	VMOD
29	17	17	B-NP	CD	O	30	DEP
30	)	)	O	)	O	23	NMOD
31	or	or	O	CC	O	34	NMOD
32	acute	acute	B-NP	JJ	O	34	NMOD
33	myeloid	myeloid	I-NP	JJ	O	34	NMOD
34	leukemia	leukemia	I-NP	NN	O	12	NMOD
35	(	(	O	(	O	41	DEP
36	AML	AML	B-NP	NN	O	38	NMOD
37	;	;	O	:	O	38	P
38	n	n	B-NP	NN	O	40	SUB
39	=	=	B-VP	SYM	O	40	VMOD
40	7	7	B-NP	CD	O	41	DEP
41	)	)	O	)	O	34	NMOD
42	undergoing	undergo	B-VP	VBG	O	34	NMOD
43	intensive	intensive	B-NP	JJ	O	44	NMOD
44	conditioning	conditioning	I-NP	NN	O	42	OBJ
45	followed	follow	B-VP	VBN	O	44	NMOD
46	by	by	B-PP	IN	O	45	VMOD
47	HSCT	HSCT	B-NP	NN	B-protein	46	PMOD
48	from	from	B-PP	IN	O	47	NMOD
49	related	related	B-NP	JJ	O	62	NMOD
50	(	(	O	(	O	54	DEP
51	n	n	B-NP	NN	O	53	SUB
52	=	=	B-VP	SYM	O	53	VMOD
53	4	4	B-NP	CD	O	54	DEP
54	)	)	O	)	O	49	NMOD
55	or	or	O	CC	O	61	NMOD
56	unrelated	unrelated	B-NP	JJ	O	61	NMOD
57	(	(	O	(	O	61	DEP
58	n	n	B-NP	NN	O	61	DEP
59	=	=	B-VP	SYM	O	58	NMOD
60	20	20	B-NP	CD	O	59	AMOD
61	)	)	O	)	O	49	AMOD
62	donors	donor	B-NP	NNS	O	48	PMOD
63	.	.	O	.	O	2	P

1	Loreclezole	Loreclezole	B-NP	NN	O	6	SUB
2	(	(	O	(	O	5	DEP
3	5	5	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	exerted	exert	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	10	NMOD
8	significant	significant	I-NP	JJ	O	10	NMOD
9	protective	protective	I-NP	JJ	O	10	NMOD
10	action	action	I-NP	NN	O	6	OBJ
11	in	in	B-PP	IN	O	6	VMOD
12	amygdala-kindled	amygdala-kindled	B-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	11	PMOD
14	,	,	O	,	O	6	P
15	reducing	reduce	B-VP	VBG	O	6	VMOD
16	both	both	O	CC	O	20	NMOD
17	seizure	seizure	B-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	afterdischarge	afterdischarge	B-NP	JJ	O	20	NMOD
20	durations	duration	I-NP	NNS	O	15	OBJ
21	.	.	O	.	O	6	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	liver	liver	I-NP	NN	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	with	with	B-PP	IN	O	3	NMOD
5	concurrent	concurrent	B-NP	JJ	O	6	NMOD
6	bupropion	bupropion	I-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	carbimazole	carbimazole	I-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	4	PMOD
10	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	fatal	fatal	B-NP	JJ	O	10	NMOD
9	liver	liver	I-NP	NN	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	PMOD
11	possibly	possibly	B-VP	RB	O	12	VMOD
12	associated	associate	I-VP	VBN	O	10	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	concurrent	concurrent	B-NP	JJ	O	15	NMOD
15	use	use	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	bupropion	bupropion	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	carbimazole	carbimazole	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	7	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	7	NMOD
5	41-year-old	41-year-old	I-NP	JJ	O	7	NMOD
6	Chinese	Chinese	I-NP	JJ	O	7	NMOD
7	man	man	I-NP	NN	O	13	SUB
8	with	with	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	history	history	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	hyperthyroidism	hyperthyroidism	B-NP	NN	O	11	PMOD
13	had	have	B-VP	VBD	O	0	ROOT
14	been	be	I-VP	VBN	O	13	VC
15	treated	treat	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	carbimazole	carbimazole	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	propranolol	propranolol	I-NP	NN	O	16	PMOD
20	for	for	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	24	NMOD
22	past	past	I-NP	JJ	O	24	NMOD
23	5	5	I-NP	CD	O	24	NMOD
24	years	year	I-NP	NNS	O	20	PMOD
25	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	2	NMOD
2	likelihood	likelihood	I-NP	NN	O	10	SUB
3	that	that	B-SBAR	IN	O	2	NMOD
4	bupropion	bupropion	B-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	3	SBAR
6	hepatotoxicity	hepatotoxicity	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	our	our	B-NP	PRP$	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	possible	possible	B-ADJP	JJ	O	10	PRD
12	,	,	O	,	O	10	P
13	based	base	B-PP	VBN	O	10	VMOD
14	on	on	B-PP	IN	O	13	PMOD
15	the	the	B-NP	DT	O	18	NMOD
16	Naranjo	Naranjo	I-NP	NNP	O	18	NMOD
17	probability	probability	I-NP	NN	O	18	NMOD
18	scale	scale	I-NP	NN	O	14	PMOD
19	.	.	O	.	O	10	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	15	SUB
2	:	:	O	:	O	1	P
3	Although	Although	B-SBAR	IN	O	1	AMOD
4	there	there	B-NP	EX	O	5	SUB
5	is	be	B-VP	VBZ	O	3	SBAR
6	increasing	increase	I-VP	VBG	O	7	NMOD
7	evidence	evidence	B-NP	NN	O	5	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	hepatotoxicity	hepatotoxicity	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	bupropion	bupropion	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	15	P
14	this	this	B-NP	DT	O	15	SUB
15	is	be	B-VP	VBZ	O	0	ROOT
16	the	the	B-NP	DT	O	18	NMOD
17	first	first	I-NP	JJ	O	18	NMOD
18	case	case	I-NP	NN	O	15	PRD
19	of	of	B-PP	IN	O	18	NMOD
20	fatality	fatality	B-NP	NN	O	19	PMOD
21	that	that	B-NP	WDT	O	20	NMOD
22	could	could	B-VP	MD	O	21	SBAR
23	have	have	I-VP	VB	O	22	VC
24	resulted	result	I-VP	VBN	O	23	VC
25	from	from	B-PP	IN	O	24	VMOD
26	acute	acute	B-NP	JJ	O	28	NMOD
27	liver	liver	I-NP	NN	O	28	NMOD
28	failure	failure	I-NP	NN	O	25	PMOD
29	in	in	B-PP	IN	O	28	NMOD
30	a	a	B-NP	DT	O	31	NMOD
31	patient	patient	I-NP	NN	O	29	PMOD
32	receiving	receive	B-VP	VBG	O	31	NMOD
33	bupropion	bupropion	B-NP	NN	O	32	OBJ
34	while	while	B-SBAR	IN	O	32	VMOD
35	on	on	B-PP	IN	O	34	PMOD
36	concomitant	concomitant	B-NP	JJ	O	37	NMOD
37	treatment	treatment	I-NP	NN	O	35	PMOD
38	with	with	B-PP	IN	O	37	NMOD
39	carbimazole	carbimazole	B-NP	NN	O	38	PMOD
40	.	.	O	.	O	15	P

1	Long-term	Long-term	B-NP	JJ	O	3	NMOD
2	oestrogen-only	oestrogen-only	I-NP	JJ	O	3	NMOD
3	HT	HT	I-NP	NN	O	5	SUB
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	increased	increase	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	7	NMOD
7	risk	risk	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	venous	venous	B-NP	JJ	O	10	NMOD
10	thrombo-embolism	thrombo-embolism	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	5	VMOD
12	stroke	stroke	B-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	gallbladder	gallbladder	B-NP	NN	O	15	NMOD
15	disease	disease	I-NP	NN	O	11	OBJ
16	(	(	O	(	O	31	DEP
17	after	after	B-PP	IN	O	31	DEP
18	one	one	B-NP	CD	O	29	NMOD
19	to	to	B-PP	TO	O	18	NMOD
20	two	two	B-NP	CD	O	21	NMOD
21	years	year	I-NP	NNS	O	19	PMOD
22	,	,	O	,	O	29	P
23	three	three	B-NP	CD	O	24	NMOD
24	years	year	I-NP	NNS	O	29	NMOD
25	and	and	O	CC	O	29	NMOD
26	seven	seven	B-NP	CD	O	28	NMOD
27	years	year	I-NP	NNS	O	28	NMOD
28	'	'	B-NP	POS	O	29	NMOD
29	use	use	I-NP	NN	O	17	PMOD
30	respectively	respectively	B-ADVP	RB	O	29	NMOD
31	)	)	O	)	O	15	NMOD
32	,	,	O	,	O	15	P
33	but	but	O	CC	O	15	NMOD
34	did	do	B-VP	VBD	O	33	DEP
35	not	not	I-VP	RB	O	34	VMOD
36	significantly	significantly	I-VP	RB	O	34	VMOD
37	increase	increase	I-VP	VB	O	34	VC
38	the	the	B-NP	DT	O	39	NMOD
39	risk	risk	I-NP	NN	O	37	OBJ
40	of	of	B-PP	IN	O	39	NMOD
41	breast	breast	B-NP	NN	O	42	NMOD
42	cancer	cancer	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	5	P

1	Passage	Passage	B-NP	NN	O	12	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	mannitol	mannitol	B-NP	NN	O	2	PMOD
4	into	into	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	brain	brain	I-NP	NN	O	4	PMOD
7	around	around	B-PP	IN	O	1	NMOD
8	gliomas	glioma	B-NP	NNS	O	7	PMOD
9	:	:	O	:	O	1	P
10	a	a	B-NP	DT	O	12	NMOD
11	potential	potential	I-NP	JJ	O	12	NMOD
12	cause	cause	I-NP	NN	O	0	ROOT
13	of	of	B-PP	IN	O	12	NMOD
14	rebound	rebound	B-NP	NN	O	15	NMOD
15	phenomenon	phenomenon	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	12	P

1	AIM	AIM	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Widespread	Widespread	B-NP	JJ	O	4	NMOD
4	use	use	I-NP	NN	O	14	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	mannitol	mannitol	B-NP	NN	O	5	PMOD
7	to	to	B-VP	TO	O	8	VMOD
8	reduce	reduce	I-VP	VB	O	4	NMOD
9	brain	brain	B-NP	NN	O	10	NMOD
10	edema	edema	I-NP	NN	O	8	OBJ
11	and	and	O	CC	O	14	NMOD
12	lower	low	B-NP	JJR	O	14	NMOD
13	elevated	elevated	I-NP	JJ	O	14	NMOD
14	ICP	ICP	I-NP	NN	O	19	SUB
15	in	in	B-PP	IN	O	14	NMOD
16	brain	brain	B-NP	NN	O	18	NMOD
17	tumor	tumor	I-NP	NN	O	18	NMOD
18	patients	patient	I-NP	NNS	O	15	PMOD
19	continues	continue	B-VP	VBZ	O	0	ROOT
20	to	to	I-VP	TO	O	21	VMOD
21	be	be	I-VP	VB	O	19	VMOD
22	afflicted	afflict	I-VP	VBN	O	21	VC
23	by	by	B-PP	IN	O	22	VMOD
24	the	the	B-NP	DT	O	27	NMOD
25	so-called	so-called	I-NP	JJ	O	27	NMOD
26	rebound	rebound	I-NP	NN	O	27	NMOD
27	phenomenon	phenomenon	I-NP	NN	O	23	PMOD
28	.	.	O	.	O	19	P

1	As	As	B-PP	IN	O	8	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	contribution	contribution	I-NP	NN	O	1	PMOD
4	to	to	B-PP	TO	O	3	NMOD
5	this	this	B-NP	DT	O	6	NMOD
6	issue	issue	I-NP	NN	O	4	PMOD
7	we	we	B-NP	PRP	O	8	SUB
8	decided	decide	B-VP	VBD	O	0	ROOT
9	to	to	I-VP	TO	O	10	VMOD
10	research	research	I-VP	VB	O	8	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	possible	possible	I-NP	JJ	O	13	NMOD
13	passage	passage	I-NP	NN	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	mannitol	mannitol	B-NP	NN	O	14	PMOD
16	into	into	B-PP	IN	O	13	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	brain	brain	I-NP	NN	O	16	PMOD
19	after	after	B-PP	IN	O	10	VMOD
20	administration	administration	B-NP	NN	O	19	PMOD
21	to	to	B-PP	TO	O	20	NMOD
22	21	21	B-NP	CD	O	23	AMOD
23	brain	brain	I-NP	NN	O	25	NMOD
24	tumor	tumor	B-NP	NN	O	25	NMOD
25	patients	patient	I-NP	NNS	O	21	PMOD
26	.	.	O	.	O	8	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Mannitol	Mannitol	B-NP	NN	O	12	SUB
4	(	(	O	(	O	11	DEP
5	18	18	B-NP	CD	O	7	NMOD
6	%	%	I-NP	NN	O	7	NMOD
7	solution	solution	I-NP	NN	O	10	NMOD
8	;	;	O	:	O	10	P
9	1	1	B-NP	CD	O	10	NMOD
10	g/kg	g/kg	I-NP	NN	O	11	DEP
11	)	)	O	)	O	3	NMOD
12	was	be	B-VP	VBD	O	1	NMOD
13	administered	administer	I-VP	VBN	O	12	VC
14	as	as	B-PP	IN	O	13	VMOD
15	a	a	B-NP	DT	O	16	NMOD
16	bolus	bolus	I-NP	NN	O	14	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	(	(	O	(	O	31	DEP
20	ten	ten	B-NP	CD	O	21	SUB
21	had	have	B-VP	VBD	O	31	DEP
22	malignant	malignant	B-NP	JJ	O	23	NMOD
23	glioma	glioma	I-NP	NN	O	21	OBJ
24	,	,	O	,	O	21	P
25	seven	seven	B-NP	CD	O	27	NMOD
26	brain	brain	I-NP	NN	O	27	NMOD
27	metastases	metastasis	I-NP	NNS	O	30	NMOD
28	and	and	O	CC	O	30	NMOD
29	four	four	B-NP	CD	O	30	NMOD
30	meningioma	meningioma	I-NP	NN	O	21	OBJ
31	)	)	O	)	O	18	NMOD
32	about	about	B-NP	IN	O	34	NMOD
33	30	30	I-NP	CD	O	32	AMOD
34	minutes	minute	I-NP	NNS	O	13	VMOD
35	before	before	B-PP	IN	O	34	NMOD
36	craniotomy	craniotomy	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	13	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	13	VMOD
4	most	most	B-NP	JJS	O	6	NMOD
5	glioma	glioma	I-NP	NN	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	,	,	O	,	O	13	P
8	mannitol	mannitol	B-NP	NN	O	9	NMOD
9	concentrations	concentration	I-NP	NNS	O	13	SUB
10	in	in	B-PP	IN	O	9	NMOD
11	white	white	B-NP	JJ	O	12	NMOD
12	matter	matter	I-NP	NN	O	10	PMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	2	2	B-NP	CD	O	16	AMOD
15	to	to	B-PP	TO	O	16	AMOD
16	6	6	B-ADJP	CD	O	17	AMOD
17	times	time	I-ADJP	NNS	O	18	AMOD
18	higher	high	I-ADJP	JJR	O	13	PRD
19	than	than	B-PP	IN	O	18	AMOD
20	in	in	B-PP	IN	O	19	PMOD
21	plasma	plasma	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	26	DEP
23	mean	mean	B-NP	NN	O	25	SUB
24	3.5	3.5	B-NP	CD	O	25	NMOD
25	times	time	I-NP	NNS	O	26	DEP
26	)	)	O	)	O	18	AMOD
27	.	.	O	.	O	13	P

1	In	In	B-PP	IN	O	10	VMOD
2	meningioma	meningioma	B-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	metastases	metastasis	B-NP	NNS	O	5	NMOD
5	patients	patient	I-NP	NNS	O	1	PMOD
6	plasma	plasma	I-NP	NN	O	7	NMOD
7	concentrations	concentration	I-NP	NNS	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	mannitol	mannitol	B-NP	NN	O	8	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	higher	high	B-ADJP	JJR	O	10	PRD
12	than	than	B-PP	IN	O	11	AMOD
13	white	white	B-NP	JJ	O	15	NMOD
14	matter	matter	I-NP	NN	O	15	NMOD
15	concentrations	concentration	I-NP	NNS	O	12	PMOD
16	except	except	B-PP	IN	O	15	NMOD
17	in	in	B-PP	IN	O	16	PMOD
18	three	three	B-NP	CD	O	19	NMOD
19	cases	case	I-NP	NNS	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	infiltration	infiltration	B-NP	NN	O	20	PMOD
22	by	by	B-PP	IN	O	11	AMOD
23	neoplastic	neoplastic	B-NP	JJ	B-cell_type	24	NMOD
24	cells	cell	I-NP	NNS	I-cell_type	22	PMOD
25	.	.	O	.	O	10	P

1	Can	Can	O	MD	O	0	ROOT
2	lidocaine	lidocaine	B-NP	NN	O	1	OBJ
3	reduce	reduce	B-VP	VB	O	2	NMOD
4	succinylcholine	succinylcholine	B-NP	NN	O	7	NMOD
5	induced	induced	I-NP	JJ	O	7	NMOD
6	postoperative	postoperative	I-NP	JJ	O	7	NMOD
7	myalgia	myalgia	I-NP	NN	O	3	OBJ
8	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	undertaken	undertake	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	determine	determine	I-VP	VB	O	3	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	effect	effect	I-NP	NN	O	16	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	lidocaine	lidocaine	B-NP	NN	O	11	NMOD
11	pretreatment	pretreatment	I-NP	NN	O	9	PMOD
12	on	on	B-PP	IN	O	8	NMOD
13	reduction	reduction	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	succinylcholine	succinylcholine	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	6	VMOD
17	myalgia	myalgia	B-NP	NN	O	16	OBJ
18	in	in	B-PP	IN	O	16	VMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	undergoing	undergo	B-VP	VBG	O	19	NMOD
21	general	general	B-NP	JJ	O	22	NMOD
22	anesthesia	anesthesia	I-NP	NN	O	20	OBJ
23	for	for	B-PP	IN	O	20	VMOD
24	gynecological	gynecological	B-NP	JJ	O	25	NMOD
25	surgery	surgery	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	3	P

1	Open-label	Open-label	B-NP	JJ	O	2	NMOD
2	assessment	assessment	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	levofloxacin	levofloxacin	B-NP	NN	O	3	PMOD
5	for	for	B-PP	IN	O	2	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	acute	acute	B-NP	JJ	O	11	NMOD
10	bacterial	bacterial	I-NP	JJ	O	11	NMOD
11	sinusitis	sinusitis	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	7	NMOD
13	adults	adult	B-NP	NNS	O	12	PMOD
14	.	.	O	.	O	2	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	efficacy	efficacy	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	safety	safety	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	levofloxacin	levofloxacin	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	22	DEP
12	500	500	B-NP	CD	O	13	NMOD
13	mg	mg	I-NP	NN	O	22	DEP
14	orally	orally	B-ADJP	RB	O	13	NMOD
15	once	once	I-ADJP	RB	O	14	AMOD
16	daily	daily	I-ADJP	JJ	O	14	AMOD
17	for	for	B-PP	IN	O	14	DEP
18	10	10	B-NP	CD	O	20	AMOD
19	to	to	I-NP	TO	O	20	AMOD
20	14	14	I-NP	CD	O	21	NMOD
21	days	day	I-NP	NNS	O	17	PMOD
22	)	)	O	)	O	10	NMOD
23	in	in	B-PP	IN	O	4	VMOD
24	treating	treat	B-VP	VBG	O	23	PMOD
25	adult	adult	B-NP	JJ	O	26	NMOD
26	outpatients	outpatient	I-NP	NNS	O	24	OBJ
27	with	with	B-PP	IN	O	24	VMOD
28	acute	acute	B-NP	JJ	O	30	NMOD
29	bacterial	bacterial	I-NP	JJ	O	30	NMOD
30	sinusitis	sinusitis	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	4	P

1	At	At	B-PP	IN	O	21	VMOD
2	various	various	B-NP	JJ	O	4	NMOD
3	time	time	I-NP	NN	O	4	NMOD
4	intervals	interval	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	21	P
6	physical	physical	B-NP	JJ	O	7	NMOD
7	examination	examination	I-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	blood	blood	I-NP	NN	O	10	NMOD
10	collection	collection	I-NP	NN	O	17	NMOD
11	for	for	B-PP	IN	O	10	NMOD
12	ex	ex	B-NP	FW	O	13	AMOD
13	vivo	vivo	I-NP	FW	O	15	NMOD
14	platelet	platelet	I-NP	NN	O	15	NMOD
15	aggregation	aggregation	I-NP	NN	O	11	PMOD
16	and	and	I-NP	CC	O	17	NMOD
17	determination	determination	I-NP	NN	O	21	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	intraplatelet	intraplatelet	B-NP	JJ	O	20	NMOD
20	cAMP	cAMP	I-NP	NN	O	18	PMOD
21	were	be	B-VP	VBD	O	0	ROOT
22	performed	perform	I-VP	VBN	O	21	VC
23	.	.	O	.	O	21	P

1	Seven	Seven	B-NP	CD	O	3	AMOD
2	out	out	I-NP	IN	O	3	AMOD
3	of	of	I-NP	IN	O	5	NMOD
4	12	12	I-NP	CD	O	3	AMOD
5	subjects	subject	I-NP	NNS	O	6	SUB
6	experienced	experience	B-VP	VBD	O	0	ROOT
7	headache	headache	B-NP	NN	O	6	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	short	short	I-NP	JJ	O	11	NMOD
11	duration	duration	I-NP	NN	O	8	PMOD
12	accompanying	accompany	B-VP	VBG	O	11	NMOD
13	facial	facial	B-NP	JJ	O	14	NMOD
14	flush	flush	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	one	one	B-NP	CD	O	18	NMOD
17	and	and	O	CC	O	18	NMOD
18	nausea	nausea	B-NP	NN	O	15	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	one	one	B-NP	CD	O	19	PMOD
21	,	,	O	,	O	6	P
22	especially	especially	B-ADVP	RB	O	23	PMOD
23	after	after	B-PP	IN	O	6	VMOD
24	ingestion	ingestion	B-NP	NN	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	CLZ	CLZ	B-NP	NN	B-protein	25	PMOD
27	.	.	O	.	O	6	P

1	Gastrointestinal	Gastrointestinal	B-NP	JJ	O	2	NMOD
2	tolerability	tolerability	I-NP	NN	O	10	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	etoricoxib	etoricoxib	B-NP	NN	B-protein	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	rheumatoid	rheumatoid	B-NP	JJ	O	8	NMOD
7	arthritis	arthritis	I-NP	NN	O	8	NMOD
8	patients	patient	I-NP	NNS	O	5	PMOD
9	:	:	O	:	O	2	P
10	results	result	B-NP	NNS	O	0	ROOT
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	etoricoxib	etoricoxib	I-NP	NN	O	11	PMOD
14	vs	vs	B-PP	IN	O	13	NMOD
15	diclofenac	diclofenac	B-NP	NN	O	18	NMOD
16	sodium	sodium	I-NP	NN	O	18	NMOD
17	gastrointestinal	gastrointestinal	I-NP	JJ	O	18	NMOD
18	tolerability	tolerability	I-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	effectiveness	effectiveness	I-NP	NN	O	21	NMOD
21	trial	trial	I-NP	NN	O	14	PMOD
22	(	(	O	(	O	24	DEP
23	EDGE-II	EDGE-II	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	.	.	O	.	O	10	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	19	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	7	NMOD
4	randomised	randomise	I-NP	VBN	O	6	AMOD
5	,	,	I-NP	,	O	6	P
6	double-blind	double-blind	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	19	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	compare	compare	I-VP	VB	O	7	NMOD
10	the	the	B-NP	DT	O	15	NMOD
11	gastrointestinal	gastrointestinal	I-NP	JJ	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	GI	GI	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	AMOD
15	tolerability	tolerability	B-NP	NN	O	9	OBJ
16	,	,	O	,	O	19	P
17	safety	safety	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	efficacy	efficacy	I-NP	NN	O	0	ROOT
20	of	of	B-PP	IN	O	19	NMOD
21	etoricoxib	etoricoxib	B-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	diclofenac	diclofenac	I-NP	NN	O	20	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	patients	patient	B-NP	NNS	O	24	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	rheumatoid	rheumatoid	B-NP	JJ	O	28	NMOD
28	arthritis	arthritis	I-NP	NN	O	26	PMOD
29	(	(	O	(	O	31	DEP
30	RA	RA	B-NP	NN	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	.	.	O	.	O	19	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	A	A	B-NP	DT	O	6	NMOD
6	total	total	I-NP	NN	O	19	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	4086	4086	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	(	(	O	(	O	15	DEP
11	mean	mean	B-NP	JJ	O	14	NMOD
12	age	age	I-NP	NN	O	14	NMOD
13	60.8	60.8	B-NP	CD	O	14	NMOD
14	years	year	I-NP	NNS	O	15	DEP
15	)	)	O	)	O	6	NMOD
16	diagnosed	diagnose	B-VP	VBN	O	6	NMOD
17	with	with	B-PP	IN	O	16	VMOD
18	RA	RA	B-NP	NN	O	17	PMOD
19	were	be	B-VP	VBD	O	3	NMOD
20	enrolled	enrol	I-VP	VBN	O	19	VC
21	and	and	O	CC	O	20	VMOD
22	received	receive	B-VP	VBN	O	20	VMOD
23	etoricoxib	etoricoxib	B-NP	NN	O	33	NMOD
24	90	90	I-NP	CD	O	23	NMOD
25	mg	mg	I-NP	NN	O	24	NMOD
26	daily	daily	I-NP	JJ	O	25	AMOD
27	(	(	O	(	O	31	DEP
28	n	n	B-NP	NN	O	31	DEP
29	=	=	B-VP	SYM	O	28	NMOD
30	2032	2032	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	25	NMOD
32	or	or	O	CC	O	33	NMOD
33	diclofenac	diclofenac	B-NP	NN	O	35	NMOD
34	75	75	B-NP	CD	O	35	NMOD
35	mg	mg	I-NP	NN	O	20	VMOD
36	twice	twice	B-ADVP	RB	O	35	NMOD
37	daily	daily	O	RB	O	36	AMOD
38	(	(	O	(	O	42	DEP
39	n	n	B-NP	NN	O	41	SUB
40	=	=	B-VP	SYM	O	41	VMOD
41	2054	2054	B-NP	CD	O	42	DEP
42	)	)	O	)	O	36	AMOD
43	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	4	NMOD
2	cumulative	cumulative	I-NP	JJ	O	4	NMOD
3	discontinuation	discontinuation	I-NP	NN	O	4	NMOD
4	rate	rate	I-NP	NN	O	9	SUB
5	due	due	B-PP	IN	O	4	NMOD
6	to	to	I-PP	TO	O	5	PMOD
7	GI	GI	B-NP	NN	B-protein	8	NMOD
8	AEs	AE	I-NP	NNS	I-protein	5	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	significantly	significantly	B-ADJP	RB	O	11	AMOD
11	lower	low	I-ADJP	JJR	O	9	PRD
12	with	with	B-PP	IN	O	11	AMOD
13	etoricoxib	etoricoxib	B-NP	NN	O	12	PMOD
14	than	than	B-PP	IN	O	11	AMOD
15	diclofenac	diclofenac	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	9	VMOD
17	5.2	5.2	B-NP	CD	O	20	NMOD
18	vs	vs	I-NP	IN	O	20	NMOD
19	8.5	8.5	I-NP	CD	O	20	NMOD
20	events	event	I-NP	NNS	O	28	NMOD
21	per	per	B-PP	IN	O	20	NMOD
22	100	100	B-NP	CD	O	23	NMOD
23	patient-years	patient-year	I-NP	NNS	O	21	PMOD
24	,	,	O	,	O	20	P
25	respectively	respectively	B-ADVP	RB	O	20	NMOD
26	;	;	O	:	O	28	P
27	hazard	hazard	B-NP	NN	O	28	NMOD
28	ratio	ratio	I-NP	NN	O	16	PMOD
29	0.62	0.62	I-NP	CD	O	28	NMOD
30	(	(	O	(	O	43	DEP
31	95	95	B-NP	CD	O	33	NMOD
32	%	%	I-NP	NN	O	33	NMOD
33	CI	CI	I-NP	NN	O	37	NMOD
34	:	:	O	:	O	37	P
35	0.47	0.47	B-NP	CD	O	37	NMOD
36	,	,	I-NP	,	O	37	P
37	0.81	0.81	I-NP	CD	O	43	DEP
38	;	;	O	:	O	43	P
39	p	p	B-NP	NN	O	43	DEP
40	<	<	B-NP	JJR	O	39	NMOD
41	or=0.001	or=0.001	I-NP	CD	O	40	AMOD
42	)	)	O	)	O	39	NMOD
43	)	)	O	)	O	28	NMOD
44	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	discontinuations	discontinuation	B-NP	NNS	O	3	PMOD
5	for	for	B-PP	IN	O	4	NMOD
6	hypertension-related	hypertension-related	B-NP	JJ	O	8	AMOD
7	and	and	I-NP	CC	O	8	AMOD
8	oedema-related	oedema-related	I-NP	JJ	O	9	NMOD
9	AEs	AE	I-NP	NNS	O	5	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	significantly	significantly	B-ADJP	RB	O	12	AMOD
12	higher	high	I-ADJP	JJR	O	10	PRD
13	with	with	B-PP	IN	O	12	AMOD
14	etoricoxib	etoricoxib	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	22	DEP
16	2.5	2.5	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	1.1	1.1	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	22	DEP
21	respectively	respectively	B-ADVP	RB	O	20	VMOD
22	)	)	O	)	O	14	NMOD
23	compared	compare	B-PP	VBN	O	12	AMOD
24	with	with	B-PP	IN	O	23	PMOD
25	diclofenac	diclofenac	B-NP	NN	O	24	PMOD
26	(	(	O	(	O	45	DEP
27	1.5	1.5	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	31	NMOD
29	and	and	O	CC	O	31	NMOD
30	0.4	0.4	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	36	NMOD
32	respectively	respectively	B-ADVP	RB	O	31	NMOD
33	;	;	O	:	O	36	P
34	p	p	B-NP	NN	O	36	SUB
35	<	<	B-VP	SYM	O	36	VMOD
36	0.001	0.001	B-NP	CD	O	45	DEP
37	for	for	B-PP	IN	O	36	NMOD
38	hypertension	hypertension	B-NP	NN	O	40	NMOD
39	and	and	I-NP	CC	O	40	NMOD
40	p	p	I-NP	NN	O	37	PMOD
41	<	<	B-NP	SYM	O	40	NMOD
42	0.01	0.01	B-NP	CD	O	41	AMOD
43	for	for	B-PP	IN	O	40	NMOD
44	oedema	oedema	B-NP	NN	O	43	PMOD
45	)	)	O	)	O	25	NMOD
46	.	.	O	.	O	10	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Etoricoxib	Etoricoxib	B-NP	NN	O	5	NMOD
4	90	90	B-NP	CD	O	5	NMOD
5	mg	mg	I-NP	NN	O	6	SUB
6	demonstrated	demonstrate	B-VP	VBD	O	1	NMOD
7	a	a	B-NP	DT	O	10	NMOD
8	significantly	significantly	I-NP	RB	O	9	AMOD
9	lower	low	I-NP	JJR	O	10	NMOD
10	risk	risk	I-NP	NN	O	6	OBJ
11	for	for	B-PP	IN	O	10	NMOD
12	discontinuing	discontinue	B-VP	VBG	O	11	PMOD
13	treatment	treatment	B-NP	NN	O	12	OBJ
14	due	due	B-PP	IN	O	12	VMOD
15	to	to	B-PP	TO	O	14	PMOD
16	GI	GI	B-NP	NN	B-protein	17	NMOD
17	AEs	AE	I-NP	NNS	I-protein	14	PMOD
18	compared	compare	B-PP	VBN	O	17	NMOD
19	with	with	B-PP	IN	O	18	PMOD
20	diclofenac	diclofenac	B-NP	NN	O	22	NMOD
21	150	150	I-NP	CD	O	22	NMOD
22	mg	mg	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	1	P

1	Placebo-level	Placebo-level	B-NP	JJ	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	extrapyramidal	extrapyramidal	B-NP	JJ	O	5	NMOD
5	symptoms	symptom	I-NP	NNS	O	3	PMOD
6	(	(	O	(	O	8	DEP
7	EPS	EPS	B-NP	NNS	B-protein	8	DEP
8	)	)	O	)	O	5	NMOD
9	with	with	B-PP	IN	O	2	NMOD
10	quetiapine	quetiapine	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	controlled	controlled	B-NP	JJ	O	13	NMOD
13	studies	study	I-NP	NNS	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	bipolar	bipolar	B-NP	JJ	O	18	NMOD
18	mania	mania	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	2	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	extrapyramidal	extrapyramidal	B-NP	JJ	O	6	NMOD
6	symptoms	symptom	I-NP	NNS	O	4	OBJ
7	(	(	O	(	O	9	DEP
8	EPS	EPS	B-NP	NNS	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	,	,	O	,	O	4	P
11	including	include	B-PP	VBG	O	4	VMOD
12	akathisia	akathisia	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	4	P
14	with	with	B-PP	IN	O	4	VMOD
15	quetiapine	quetiapine	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	bipolar	bipolar	B-NP	JJ	O	20	NMOD
20	mania	mania	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	incidence	incidence	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	EPS-related	EPS-related	B-NP	JJ	O	8	NMOD
7	adverse	adverse	I-NP	JJ	O	8	NMOD
8	events	event	I-NP	NNS	O	5	PMOD
9	,	,	O	,	O	8	P
10	including	include	B-PP	VBG	O	8	NMOD
11	akathisia	akathisia	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	4	P
13	was	be	B-VP	VBD	O	1	NMOD
14	no	no	B-NP	DT	O	15	NMOD
15	different	different	I-NP	JJ	O	13	PRD
16	with	with	B-PP	IN	O	13	VMOD
17	quetiapine	quetiapine	B-NP	NN	O	18	NMOD
18	monotherapy	monotherapy	I-NP	NN	O	16	PMOD
19	(	(	O	(	O	22	DEP
20	12.9	12.9	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	22	DEP
22	)	)	O	)	O	18	NMOD
23	than	than	B-PP	IN	O	13	VMOD
24	with	with	B-PP	IN	O	23	PMOD
25	placebo	placebo	B-NP	NN	O	24	PMOD
26	(	(	O	(	O	29	DEP
27	13.1	13.1	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	29	DEP
29	)	)	O	)	O	25	NMOD
30	.	.	O	.	O	1	P

1	Similarly	Similarly	B-ADVP	RB	O	14	VMOD
2	,	,	O	,	O	14	P
3	EPS-related	EPS-related	B-NP	JJ	O	5	NMOD
4	adverse	adverse	I-NP	JJ	O	5	NMOD
5	events	event	I-NP	NNS	O	14	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	QTP	QTP	B-NP	NN	B-protein	9	NMOD
8	+	+	I-NP	SYM	O	9	NMOD
9	Li/DVP	Li/DVP	I-NP	NN	B-protein	6	PMOD
10	(	(	O	(	O	13	DEP
11	21.4	21.4	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	no	no	B-ADJP	RB	O	16	AMOD
16	different	different	I-ADJP	JJ	O	14	PRD
17	than	than	B-PP	IN	O	16	AMOD
18	with	with	B-PP	IN	O	17	PMOD
19	PBO	PBO	B-NP	NN	B-protein	21	NMOD
20	+	+	O	SYM	O	21	NMOD
21	Li/DVP	Li/DVP	B-NP	NN	B-protein	18	PMOD
22	(	(	O	(	O	25	DEP
23	19.2	19.2	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	25	DEP
25	)	)	O	)	O	21	NMOD
26	.	.	O	.	O	14	P

1	Adverse	Adverse	B-NP	JJ	O	2	NMOD
2	events	event	I-NP	NNS	O	6	SUB
3	related	relate	B-VP	VBN	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	EPS	EPS	B-NP	NNP	B-protein	4	PMOD
6	occurred	occur	B-VP	VBD	O	0	ROOT
7	in	in	B-PP	IN	O	6	VMOD
8	59.6	59.6	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	haloperidol	haloperidol	B-NP	NN	O	20	NMOD
15	(	(	O	(	O	19	DEP
16	n	n	B-NP	NN	O	19	DEP
17	=	=	B-VP	SYM	O	16	NMOD
18	99	99	B-NP	CD	O	17	AMOD
19	)	)	O	)	O	14	NMOD
20	monotherapy	monotherapy	B-NP	NN	O	13	PMOD
21	,	,	O	,	O	6	P
22	whereas	whereas	O	IN	O	6	VMOD
23	26.5	26.5	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	36	SUB
25	of	of	B-PP	IN	O	24	NMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	treated	treat	B-VP	VBN	O	26	NMOD
28	with	with	B-PP	IN	O	27	VMOD
29	lithium	lithium	B-NP	NN	O	35	NMOD
30	(	(	O	(	O	34	DEP
31	n	n	B-NP	NN	O	34	DEP
32	=	=	B-VP	SYM	O	31	NMOD
33	98	98	B-NP	CD	O	32	AMOD
34	)	)	O	)	O	29	NMOD
35	monotherapy	monotherapy	B-NP	NN	O	28	PMOD
36	experienced	experience	B-VP	VBD	O	22	SBAR
37	adverse	adverse	B-NP	JJ	O	38	NMOD
38	events	event	I-NP	NNS	O	36	OBJ
39	related	relate	B-VP	VBN	O	38	NMOD
40	to	to	B-PP	TO	O	39	AMOD
41	EPS	EPS	B-NP	NNP	B-protein	40	PMOD
42	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	akathisia	akathisia	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	low	low	B-ADJP	JJ	O	8	AMOD
7	and	and	I-ADJP	CC	O	8	AMOD
8	similar	similar	I-ADJP	JJ	O	5	PRD
9	with	with	B-PP	IN	O	8	AMOD
10	quetiapine	quetiapine	B-NP	NN	O	11	NMOD
11	monotherapy	monotherapy	I-NP	NN	O	17	NMOD
12	(	(	O	(	O	15	DEP
13	3.3	3.3	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	15	DEP
15	)	)	O	)	O	11	NMOD
16	and	and	O	CC	O	17	NMOD
17	placebo	placebo	B-NP	NN	O	9	PMOD
18	(	(	O	(	O	21	DEP
19	6.1	6.1	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	,	,	O	,	O	5	VMOD
23	and	and	O	CC	O	22	VMOD
24	with	with	B-PP	IN	O	23	PRD
25	QTP	QTP	B-NP	NN	B-protein	27	NMOD
26	+	+	O	SYM	O	27	NMOD
27	Li/DVP	Li/DVP	B-NP	NN	B-protein	35	NMOD
28	(	(	O	(	O	31	DEP
29	3.6	3.6	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	31	DEP
31	)	)	O	)	O	27	NMOD
32	and	and	O	CC	O	35	NMOD
33	PBO	PBO	B-NP	NN	B-protein	35	NMOD
34	+	+	O	SYM	O	35	NMOD
35	Li/DVP	Li/DVP	B-NP	NN	B-protein	24	PMOD
36	(	(	O	(	O	39	DEP
37	4.9	4.9	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	39	DEP
39	)	)	O	)	O	35	NMOD
40	.	.	O	.	O	5	P

1	Lithium	Lithium	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	39	VMOD
3	associated	associate	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	significantly	significantly	I-NP	RB	O	7	AMOD
7	higher	high	I-NP	JJR	O	8	NMOD
8	incidence	incidence	I-NP	NN	O	4	PMOD
9	(	(	O	(	O	13	DEP
10	p	p	B-NP	NN	O	13	DEP
11	<	<	O	SYM	O	10	NMOD
12	0.05	0.05	B-NP	CD	O	11	AMOD
13	)	)	O	)	O	8	NMOD
14	of	of	B-PP	IN	O	8	NMOD
15	tremor	tremor	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	19	DEP
17	18.4	18.4	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	19	DEP
19	)	)	O	)	O	15	NMOD
20	than	than	B-PP	IN	O	3	VMOD
21	quetiapine	quetiapine	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	25	DEP
23	5.6	5.6	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	25	DEP
25	)	)	O	)	O	21	NMOD
26	;	;	O	:	O	39	P
27	cerebellar	cerebellar	B-NP	JJ	O	28	NMOD
28	tremor	tremor	I-NP	NN	O	39	SUB
29	,	,	O	,	O	28	P
30	which	which	B-NP	WDT	O	28	NMOD
31	is	be	B-VP	VBZ	O	30	SBAR
32	a	a	B-NP	DT	O	35	NMOD
33	known	known	I-NP	JJ	O	35	NMOD
34	adverse	adverse	I-NP	JJ	O	35	NMOD
35	effect	effect	I-NP	NN	O	31	PRD
36	of	of	B-PP	IN	O	35	NMOD
37	lithium	lithium	B-NP	NN	O	36	PMOD
38	,	,	O	,	O	28	P
39	may	may	B-VP	MD	O	0	ROOT
40	have	have	I-VP	VB	O	39	VC
41	contributed	contribute	I-VP	VBN	O	40	VC
42	to	to	B-PP	TO	O	41	VMOD
43	the	the	B-NP	DT	O	45	NMOD
44	elevated	elevate	I-NP	VBN	O	45	NMOD
45	rate	rate	I-NP	NN	O	42	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	tremor	tremor	B-NP	NN	O	46	PMOD
48	in	in	B-PP	IN	O	45	NMOD
49	patients	patient	B-NP	NNS	O	48	PMOD
50	receiving	receive	B-VP	VBG	O	49	NMOD
51	lithium	lithium	B-NP	NN	O	52	NMOD
52	therapy	therapy	I-NP	NN	O	50	OBJ
53	.	.	O	.	O	39	P

1	Haloperidol	Haloperidol	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	significantly	significantly	I-NP	RB	O	5	AMOD
5	higher	high	I-NP	JJR	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	2	OBJ
7	(	(	O	(	O	11	DEP
8	p	p	B-NP	NN	O	11	DEP
9	<	<	O	SYM	O	8	NMOD
10	0.001	0.001	B-NP	CD	O	9	AMOD
11	)	)	O	)	O	6	NMOD
12	of	of	B-PP	IN	O	6	NMOD
13	akathisia	akathisia	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	13	NMOD
15	33.3	33.3	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	14	ROOT
17	versus	versus	B-PP	IN	O	16	NMOD
18	5.9	5.9	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	33	NMOD
20	)	)	O	)	O	19	NMOD
21	,	,	O	,	O	33	P
22	tremor	tremor	B-NP	NN	O	33	NMOD
23	(	(	O	(	O	29	DEP
24	30.3	30.3	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	28	NMOD
26	versus	versus	B-PP	IN	O	28	NMOD
27	7.8	7.8	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	29	DEP
29	)	)	O	)	O	22	NMOD
30	,	,	O	,	O	33	P
31	and	and	O	CC	O	33	NMOD
32	extrapyramidal	extrapyramidal	B-NP	JJ	O	33	NMOD
33	syndrome	syndrome	I-NP	NN	O	17	PMOD
34	(	(	O	(	O	40	DEP
35	35.4	35.4	B-NP	CD	O	36	NMOD
36	%	%	I-NP	NN	O	39	NMOD
37	versus	versus	B-PP	IN	O	39	NMOD
38	5.9	5.9	B-NP	CD	O	39	NMOD
39	%	%	I-NP	NN	O	40	DEP
40	)	)	O	)	O	33	NMOD
41	than	than	B-PP	IN	O	33	NMOD
42	quetiapine	quetiapine	B-NP	NN	O	41	PMOD
43	.	.	O	.	O	16	P

1	Contribution	Contribution	B-NP	NN	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	sympathetic	sympathetic	I-NP	JJ	O	6	NMOD
5	nervous	nervous	I-NP	JJ	O	6	NMOD
6	system	system	I-NP	NN	O	2	PMOD
7	to	to	B-PP	TO	O	6	NMOD
8	salt-sensitivity	salt-sensitivity	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	lifetime	lifetime	B-NP	NN	O	9	PMOD
11	captopril-treated	captopril-treate	B-VP	VBD	O	0	ROOT
12	spontaneously	spontaneously	B-NP	RB	O	13	AMOD
13	hypertensive	hypertensive	I-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	11	OBJ
15	.	.	O	.	O	11	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	23	SUB
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	test	test	I-VP	VB	O	23	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	hypothesis	hypothesis	I-NP	NN	O	4	OBJ
7	that	that	B-NP	IN	O	6	NMOD
8	,	,	O	,	O	7	P
9	in	in	B-PP	IN	O	11	VMOD
10	lifetime	lifetime	B-NP	NN	O	9	PMOD
11	captopril-treated	captopril-treate	B-VP	VBD	O	7	SBAR
12	spontaneously	spontaneously	B-NP	RB	O	13	AMOD
13	hypertensive	hypertensive	I-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	11	OBJ
15	(	(	O	(	O	17	DEP
16	SHR	SHR	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	,	,	O	,	O	23	P
19	the	the	B-NP	DT	O	22	NMOD
20	sympathetic	sympathetic	I-NP	JJ	O	22	NMOD
21	nervous	nervous	I-NP	JJ	O	22	NMOD
22	system	system	I-NP	NN	O	23	SUB
23	contributes	contribute	B-VP	VBZ	O	0	ROOT
24	importantly	importantly	B-ADVP	RB	O	23	VMOD
25	to	to	B-PP	TO	O	23	VMOD
26	the	the	B-NP	DT	O	28	NMOD
27	hypertensive	hypertensive	I-NP	JJ	O	28	NMOD
28	effect	effect	I-NP	NN	O	25	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	dietary	dietary	B-NP	JJ	O	33	NMOD
31	sodium	sodium	I-NP	NN	O	33	NMOD
32	chloride	chloride	I-NP	NN	O	33	NMOD
33	supplementation	supplementation	I-NP	NN	O	29	PMOD
34	.	.	O	.	O	23	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	infusion	infusion	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	7	NMOD
5	ganglionic	ganglionic	I-NP	JJ	O	7	NMOD
6	blocker	blocker	I-NP	NN	O	7	NMOD
7	hexamethonium	hexamethonium	I-NP	NN	O	3	PMOD
8	resulted	result	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	12	NMOD
11	rapid	rapid	I-NP	JJ	O	12	NMOD
12	decline	decline	I-NP	NN	O	21	SUB
13	in	in	B-PP	IN	O	12	NMOD
14	MAP	MAP	B-NP	NN	O	13	PMOD
15	that	that	B-NP	WDT	O	12	NMOD
16	eliminated	eliminate	B-VP	VBD	O	15	SBAR
17	the	the	B-NP	DT	O	20	NMOD
18	dietary	dietary	I-NP	JJ	O	20	NMOD
19	sodium	sodium	I-NP	NN	O	20	NMOD
20	chloride	chloride	I-NP	NN	O	16	OBJ
21	induced	induce	B-VP	VBD	O	9	SBAR
22	increase	increase	B-NP	NN	O	21	OBJ
23	in	in	B-PP	IN	O	22	NMOD
24	MAP	MAP	B-NP	NN	O	23	PMOD
25	in	in	B-PP	IN	O	21	VMOD
26	both	both	B-NP	DT	O	27	NMOD
27	groups	group	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	8	P

1	Dose-related	Dose-related	B-NP	JJ	O	5	NMOD
2	beneficial	beneficial	I-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	adverse	adverse	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	11	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	dietary	dietary	B-NP	JJ	O	8	NMOD
8	corticosterone	corticosterone	I-NP	NN	O	6	PMOD
9	on	on	B-PP	IN	O	5	NMOD
10	organophosphorus	organophosphorus	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	delayed	delay	B-NP	VBN	O	13	NMOD
13	neuropathy	neuropathy	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	11	VMOD
15	chickens	chicken	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	11	P

1	Although	Although	B-SBAR	IN	O	30	VMOD
2	low	low	B-NP	JJ	O	3	NMOD
3	concentrations	concentration	I-NP	NNS	O	15	SUB
4	(	(	O	(	O	12	DEP
5	less	less	B-NP	JJR	O	6	AMOD
6	than	than	B-PP	IN	O	12	DEP
7	or	or	O	CC	O	6	AMOD
8	equal	equal	B-ADJP	JJ	O	6	DEP
9	to	to	B-PP	TO	O	8	AMOD
10	50	50	B-NP	CD	O	11	NMOD
11	ppm	ppm	I-NP	NN	O	9	PMOD
12	)	)	O	)	O	3	NMOD
13	of	of	B-PP	IN	O	3	NMOD
14	corticosterone	corticosterone	B-NP	NN	O	13	PMOD
15	had	have	B-VP	VBD	O	1	SBAR
16	beneficial	beneficial	B-NP	JJ	O	17	NMOD
17	effects	effect	I-NP	NNS	O	15	OBJ
18	on	on	B-PP	IN	O	15	VMOD
19	TOTP	TOTP	B-NP	NN	B-protein	21	NMOD
20	induced	induce	B-VP	VBD	O	21	NMOD
21	neuropathy	neuropathy	B-NP	NN	O	18	PMOD
22	,	,	O	,	O	26	P
23	greater	great	B-ADJP	JJR	O	26	AMOD
24	than	than	B-PP	IN	O	23	AMOD
25	or	or	O	CC	O	26	AMOD
26	equal	equal	B-ADJP	JJ	O	29	NMOD
27	to	to	B-PP	TO	O	26	AMOD
28	200	200	B-NP	CD	O	26	AMOD
29	ppm	ppm	I-NP	NN	O	30	SUB
30	exacerbated	exacerbate	B-VP	VBD	O	0	ROOT
31	clinical	clinical	B-NP	JJ	O	32	NMOD
32	signs	sign	I-NP	NNS	O	30	OBJ
33	in	in	B-PP	IN	O	32	NMOD
34	chickens	chicken	B-NP	NNS	O	33	PMOD
35	given	give	B-VP	VBN	O	34	NMOD
36	either	either	O	CC	O	39	NMOD
37	TOTP	TOTP	B-NP	NN	B-protein	39	NMOD
38	or	or	I-NP	CC	O	39	NMOD
39	DFP	DFP	I-NP	NN	O	35	OBJ
40	.	.	O	.	O	30	P

1	Neurotoxic	Neurotoxic	B-NP	JJ	O	3	NMOD
2	esterase	esterase	I-NP	NN	O	3	NMOD
3	activities	activity	I-NP	NNS	O	5	NMOD
4	24	24	B-NP	CD	O	5	NMOD
5	hr	hr	I-NP	NN	O	10	SUB
6	after	after	B-PP	IN	O	5	NMOD
7	TOTP	TOTP	B-NP	NN	B-protein	9	NMOD
8	or	or	I-NP	CC	O	9	NMOD
9	DFP	DFP	I-NP	NN	O	6	PMOD
10	were	be	B-VP	VBD	O	0	ROOT
11	less	less	B-NP	JJR	O	12	AMOD
12	than	than	I-NP	IN	O	14	NMOD
13	20	20	I-NP	CD	O	12	AMOD
14	%	%	I-NP	NN	O	10	PRD
15	of	of	B-PP	IN	O	14	NMOD
16	values	value	B-NP	NNS	O	15	PMOD
17	measured	measure	B-VP	VBN	O	16	NMOD
18	in	in	B-PP	IN	O	17	VMOD
19	chickens	chicken	B-NP	NNS	O	23	NMOD
20	not	not	B-VP	RB	O	21	AMOD
21	given	give	I-VP	VBN	O	23	NMOD
22	organophosphorous	organophosphorous	B-NP	JJ	O	23	NMOD
23	compounds	compound	I-NP	NNS	O	18	PMOD
24	.	.	O	.	O	10	P

1	In	In	B-NP	FW	O	2	AMOD
2	vivo	vivo	I-NP	FW	O	3	NMOD
3	characterization	characterization	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	10	NMOD
6	dual	dual	I-NP	JJ	O	10	NMOD
7	adenosine	adenosine	I-NP	NN	O	10	NMOD
8	A2A/A1	A2A/A1	I-NP	NN	O	10	NMOD
9	receptor	receptor	I-NP	NN	O	10	NMOD
10	antagonist	antagonist	I-NP	NN	O	4	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	animal	animal	B-NP	NN	O	13	NMOD
13	models	model	I-NP	NNS	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	Parkinson	Parkinson	B-NP	NNP	O	17	NMOD
16	's	's	B-NP	POS	O	17	NMOD
17	disease	disease	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	4	NMOD
2	in	in	I-NP	FW	O	3	AMOD
3	vivo	vivo	I-NP	FW	O	4	NMOD
4	characterization	characterization	I-NP	NN	O	27	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	dual	dual	I-NP	JJ	O	9	NMOD
8	adenosine	adenosine	I-NP	NN	O	9	NMOD
9	A	A	I-NP	NN	O	17	NMOD
10	(	(	O	(	O	12	DEP
11	2A	2A	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	/A	/A	B-NP	NN	B-protein	17	NMOD
14	(	(	O	(	I-protein	17	NMOD
15	1	1	B-NP	CD	I-protein	17	NMOD
16	)	)	O	)	I-protein	17	NMOD
17	receptor	receptor	B-NP	NN	I-protein	18	NMOD
18	antagonist	antagonist	I-NP	NN	O	5	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	several	several	B-NP	JJ	O	22	NMOD
21	animal	animal	I-NP	NN	O	22	NMOD
22	models	model	I-NP	NNS	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	Parkinson	Parkinson	B-NP	NNP	O	25	NMOD
25	's	's	B-NP	POS	O	26	NMOD
26	disease	disease	I-NP	NN	O	23	PMOD
27	is	be	B-VP	VBZ	O	0	ROOT
28	described	describe	I-VP	VBN	O	27	VC
29	.	.	O	.	O	27	P

1	An	An	B-NP	DT	O	4	NMOD
2	extremely	extremely	I-NP	RB	O	3	AMOD
3	rare	rare	I-NP	JJ	O	4	NMOD
4	case	case	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	delusional	delusional	B-NP	JJ	O	7	NMOD
7	parasitosis	parasitosis	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	a	a	B-NP	DT	O	13	NMOD
10	chronic	chronic	I-NP	JJ	O	13	NMOD
11	hepatitis	hepatitis	I-NP	NN	O	13	NMOD
12	C	C	I-NP	NN	O	13	NMOD
13	patient	patient	I-NP	NN	O	20	NMOD
14	during	during	B-PP	IN	O	13	NMOD
15	pegylated	pegylate	B-NP	VBN	O	17	NMOD
16	interferon	interferon	I-NP	NN	B-protein	17	NMOD
17	alpha-2b	alpha-2b	I-NP	NN	I-protein	14	PMOD
18	and	and	O	CC	O	20	NMOD
19	ribavirin	ribavirin	B-NP	NN	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	8	PMOD
21	.	.	O	.	O	4	P

1	During	During	B-PP	IN	O	18	VMOD
2	treatment	treatment	B-NP	NN	O	1	PMOD
3	of	of	B-PP	IN	O	2	NMOD
4	chronic	chronic	B-NP	JJ	O	7	NMOD
5	hepatitis	hepatitis	I-NP	NN	O	7	NMOD
6	C	C	I-NP	NN	O	7	NMOD
7	patients	patient	I-NP	NNS	O	3	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	interferon	interferon	B-NP	NN	B-protein	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	ribavirin	ribavirin	I-NP	NN	B-protein	8	PMOD
12	,	,	O	,	O	18	P
13	a	a	B-NP	DT	O	14	NMOD
14	lot	lot	I-NP	NN	O	18	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	side	side	B-NP	JJ	O	17	NMOD
17	effects	effect	I-NP	NNS	O	15	PMOD
18	are	be	B-VP	VBP	O	0	ROOT
19	described	describe	I-VP	VBN	O	18	VC
20	.	.	O	.	O	18	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	49-year-old	49-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	a	a	B-NP	DT	O	10	NMOD
9	delusional	delusional	I-NP	JJ	O	10	NMOD
10	parasitosis	parasitosis	I-NP	NN	O	7	OBJ
11	during	during	B-PP	IN	O	7	VMOD
12	treatment	treatment	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	pegylated	pegylate	B-NP	VBN	O	16	NMOD
15	interferon	interferon	I-NP	NN	B-protein	16	NMOD
16	alpha-2b	alpha-2b	I-NP	NN	I-protein	13	PMOD
17	weekly	weekly	B-ADVP	RB	O	19	NMOD
18	and	and	O	CC	O	17	DEP
19	ribavirin	ribavirin	B-NP	NN	O	7	OBJ
20	.	.	O	.	O	2	P

1	Possible	Possible	B-NP	JJ	O	4	NMOD
2	neuroleptic	neuroleptic	I-NP	JJ	O	4	NMOD
3	malignant	malignant	I-NP	JJ	O	4	NMOD
4	syndrome	syndrome	I-NP	NN	O	0	ROOT
5	related	relate	B-VP	VBN	O	4	NMOD
6	to	to	B-PP	TO	O	5	AMOD
7	concomitant	concomitant	B-NP	JJ	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	paroxetine	paroxetine	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	alprazolam	alprazolam	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	On	On	B-PP	IN	O	13	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	10th	10th	I-NP	JJ	O	4	NMOD
4	day	day	I-NP	NN	O	1	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	paroxetine	paroxetine	B-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	alprazolam	alprazolam	I-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	5	PMOD
10	,	,	O	,	O	13	P
11	the	the	B-NP	DT	O	12	NMOD
12	patient	patient	I-NP	NN	O	13	SUB
13	exhibited	exhibit	B-VP	VBD	O	0	ROOT
14	marked	marked	B-NP	JJ	O	16	NMOD
15	psychomotor	psychomotor	I-NP	NN	O	16	NMOD
16	retardation	retardation	I-NP	NN	O	23	NMOD
17	,	,	O	,	O	23	P
18	disorientation	disorientation	B-NP	NN	O	23	NMOD
19	,	,	O	,	O	23	P
20	and	and	O	CC	O	23	NMOD
21	severe	severe	B-NP	JJ	O	23	NMOD
22	muscle	muscle	I-NP	NN	O	23	NMOD
23	rigidity	rigidity	I-NP	NN	O	13	OBJ
24	with	with	B-PP	IN	O	23	NMOD
25	tremors	tremor	B-NP	NNS	O	24	PMOD
26	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	received	receive	B-VP	VBD	O	25	VMOD
4	bromocriptine	bromocriptine	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	diazepam	diazepam	I-NP	NN	O	3	OBJ
7	to	to	B-VP	TO	O	8	VMOD
8	treat	treat	I-VP	VB	O	3	VMOD
9	his	his	B-NP	PRP$	O	10	NMOD
10	symptoms.	symptoms.	I-NP	NN	O	12	NMOD
11	7	7	B-NP	CD	O	10	NMOD
12	days	day	I-NP	NNS	O	8	OBJ
13	later	later	B-ADVP	RB	O	8	VMOD
14	,	,	O	,	O	3	P
15	the	the	B-NP	DT	O	16	NMOD
16	fever	fever	I-NP	NN	O	17	SUB
17	disappeared	disappear	B-VP	VBD	O	25	VMOD
18	and	and	O	CC	O	25	VMOD
19	the	the	B-NP	DT	O	24	NMOD
20	patient	patient	I-NP	NN	O	24	NMOD
21	's	's	B-NP	POS	O	24	NMOD
22	serum	serum	I-NP	NN	O	24	NMOD
23	CPK	CPK	I-NP	NN	B-protein	24	NMOD
24	levels	level	I-NP	NNS	O	25	SUB
25	were	be	B-VP	VBD	O	0	ROOT
26	normalized	normalize	I-VP	VBN	O	25	VC
27	(	(	O	(	O	30	DEP
28	175	175	B-NP	CD	O	29	NMOD
29	IU/L	IU/L	I-NP	NN	O	30	DEP
30	)	)	O	)	O	26	VMOD
31	.	.	O	.	O	25	P

1	This	This	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	presented	present	B-VP	VBD	O	0	ROOT
4	with	with	B-PP	IN	O	3	VMOD
5	symptoms	symptom	B-NP	NNS	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	neuroleptic	neuroleptic	B-NP	JJ	O	9	NMOD
8	malignant	malignant	I-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	6	PMOD
10	(	(	O	(	O	12	DEP
11	NMS	NMS	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	,	,	O	,	O	3	P
14	thus	thus	B-ADVP	RB	O	15	VMOD
15	demonstrating	demonstrate	B-VP	VBG	O	3	VMOD
16	that	that	B-SBAR	IN	O	15	VMOD
17	NMS-like	NMS-like	B-NP	JJ	O	18	NMOD
18	symptoms	symptom	I-NP	NNS	O	19	SUB
19	can	can	B-VP	MD	O	16	SBAR
20	occur	occur	I-VP	VB	O	19	VC
21	after	after	B-PP	IN	O	20	VMOD
22	combined	combine	B-NP	VBN	O	26	NMOD
23	paroxetine	paroxetine	I-NP	NN	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	alprazolam	alprazolam	I-NP	NN	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	3	P

1	Pilocarpine	Pilocarpine	B-NP	NN	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	cause	cause	B-VP	VBP	O	0	ROOT
4	age-dependent	age-dependent	B-NP	JJ	O	5	NMOD
5	impairment	impairment	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	auditory	auditory	B-NP	JJ	O	9	NMOD
8	location	location	I-NP	NN	O	9	NMOD
9	discrimination	discrimination	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	3	P

1	Pilocarpine	Pilocarpine	B-NP	NN	O	5	SUB
2	on	on	B-PP	IN	O	1	NMOD
3	either	either	B-NP	CC	O	4	NMOD
4	day	day	I-NP	NN	O	2	PMOD
5	induced	induce	B-VP	VBD	O	13	VMOD
6	status	status	B-NP	NN	O	7	NMOD
7	epilepticus	epilepticus	I-NP	NN	O	5	OBJ
8	;	;	O	:	O	13	P
9	status	status	B-NP	NN	O	10	NMOD
10	epilepticus	epilepticus	I-NP	NN	O	13	SUB
11	at	at	B-PP	IN	O	10	NMOD
12	P45	P45	B-NP	NN	B-protein	11	PMOD
13	resulted	result	B-VP	VBD	O	0	ROOT
14	in	in	B-PP	IN	O	13	VMOD
15	CA3	CA3	B-NP	NN	O	17	NMOD
16	cell	cell	I-NP	NN	O	17	NMOD
17	loss	loss	I-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	spontaneous	spontaneous	B-NP	JJ	O	20	NMOD
20	seizures	seizure	I-NP	NNS	O	14	PMOD
21	,	,	O	,	O	13	P
22	whereas	whereas	O	IN	O	13	VMOD
23	P20	P20	B-NP	NN	B-protein	24	NMOD
24	rats	rat	I-NP	NNS	O	25	SUB
25	had	have	B-VP	VBD	O	22	SBAR
26	no	no	B-NP	DT	O	31	NMOD
27	cell	cell	I-NP	NN	O	28	NMOD
28	loss	loss	I-NP	NN	O	31	NMOD
29	or	or	O	CC	O	31	NMOD
30	spontaneous	spontaneous	B-NP	JJ	O	31	NMOD
31	seizures	seizure	I-NP	NNS	O	25	OBJ
32	.	.	O	.	O	13	P

1	Randomised	Randomise	B-VP	VBN	O	6	NMOD
2	clinical	clinical	B-NP	JJ	O	3	NMOD
3	trials	trial	I-NP	NNS	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	observational	observational	B-NP	JJ	O	6	NMOD
6	studies	study	I-NP	NNS	O	7	SUB
7	have	have	B-VP	VBP	O	0	ROOT
8	shown	show	I-VP	VBN	O	7	VC
9	an	an	B-NP	DT	O	11	NMOD
10	increased	increase	I-NP	VBN	O	11	NMOD
11	risk	risk	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	infarction	infarction	I-NP	NN	O	21	NMOD
15	,	,	O	,	O	21	P
16	stroke	stroke	B-NP	NN	O	21	NMOD
17	,	,	O	,	O	21	P
18	hypertension	hypertension	B-NP	NN	O	21	NMOD
19	and	and	I-NP	CC	O	21	NMOD
20	heart	heart	I-NP	NN	O	21	NMOD
21	failure	failure	I-NP	NN	O	12	PMOD
22	during	during	B-PP	IN	O	8	VMOD
23	treatment	treatment	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	cyclooxygenase	cyclooxygenase	B-NP	NN	B-protein	26	NMOD
26	inhibitors	inhibitor	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	7	P

1	Predictors	Predictor	B-NP	NNS	O	17	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	decreased	decrease	B-NP	VBN	O	5	NMOD
4	renal	renal	I-NP	JJ	O	5	NMOD
5	function	function	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	heart	heart	B-NP	NN	O	10	NMOD
10	failure	failure	I-NP	NN	O	8	PMOD
11	during	during	B-PP	IN	O	1	NMOD
12	angiotensin-converting	angiotensin-converting	B-NP	JJ	O	15	NMOD
13	enzyme	enzyme	I-NP	NN	O	15	NMOD
14	inhibitor	inhibitor	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	11	PMOD
16	:	:	O	:	O	1	P
17	results	result	B-NP	NNS	O	49	SUB
18	from	from	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	studies	study	I-NP	NNS	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	left	left	B-NP	JJ	O	24	NMOD
23	ventricular	ventricular	I-NP	JJ	O	24	NMOD
24	dysfunction	dysfunction	I-NP	NN	O	28	NMOD
25	(	(	O	(	O	27	DEP
26	SOLVD	SOLVD	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	BACKGROUND	BACKGROUND	B-NP	NN	O	21	PMOD
29	:	:	O	:	O	17	P
30	Although	Although	B-SBAR	IN	O	17	VMOD
31	angiotensin-converting	angiotensin-converting	B-NP	JJ	B-protein	34	NMOD
32	enzyme	enzyme	I-NP	NN	I-protein	34	NMOD
33	inhibitor	inhibitor	I-NP	NN	O	34	NMOD
34	therapy	therapy	I-NP	NN	O	35	SUB
35	reduces	reduce	B-VP	VBZ	O	30	SBAR
36	mortality	mortality	B-NP	NN	O	37	NMOD
37	rates	rate	I-NP	NNS	O	35	OBJ
38	in	in	B-PP	IN	O	35	VMOD
39	patients	patient	B-NP	NNS	O	38	PMOD
40	with	with	B-PP	IN	O	39	NMOD
41	congestive	congestive	B-NP	JJ	O	43	NMOD
42	heart	heart	I-NP	NN	O	43	NMOD
43	failure	failure	I-NP	NN	O	40	PMOD
44	(	(	O	(	O	46	DEP
45	CHF	CHF	B-NP	NN	B-protein	46	DEP
46	)	)	O	)	O	43	NMOD
47	,	,	O	,	O	17	P
48	it	it	B-NP	PRP	O	49	SUB
49	may	may	B-VP	MD	O	0	ROOT
50	also	also	I-VP	RB	O	49	VMOD
51	cause	cause	I-VP	VB	O	49	VC
52	decreased	decrease	I-VP	VBN	O	54	NMOD
53	renal	renal	B-NP	JJ	O	54	NMOD
54	function	function	I-NP	NN	O	51	OBJ
55	.	.	O	.	O	49	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	quantify	quantify	I-VP	VB	O	1	NMOD
5	specific	specific	B-NP	JJ	O	7	NMOD
6	clinical	clinical	I-NP	JJ	O	7	NMOD
7	predictors	predictor	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	reduction	reduction	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	4	VMOD
11	renal	renal	B-NP	JJ	O	12	NMOD
12	function	function	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	CHF	CHF	B-NP	NN	B-protein	15	PMOD
17	who	who	B-NP	WP	O	14	NMOD
18	are	be	B-VP	VBP	O	17	SBAR
19	prescribed	prescribe	I-VP	VBN	O	18	VC
20	angiotensin-converting	angiotensin-converting	B-NP	JJ	O	23	NMOD
21	enzyme	enzyme	I-NP	NN	O	23	NMOD
22	inhibitor	inhibitor	I-NP	NN	O	23	NMOD
23	therapy	therapy	I-NP	NN	O	19	OBJ
24	.	.	O	.	O	4	P

1	METHOD	METHOD	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	analyzed	analyze	B-VP	VBD	O	1	NMOD
5	data	datum	B-NP	NNS	O	4	OBJ
6	from	from	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	Studies	Study	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	Left	Left	B-NP	NNP	O	12	NMOD
11	Ventricular	Ventricular	I-NP	JJ	O	12	NMOD
12	Dysfunction	Dysfunction	I-NP	NN	O	23	NMOD
13	(	(	O	(	O	15	DEP
14	SOLVD	SOLVD	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	,	,	O	,	O	23	P
17	a	a	B-NP	DT	O	23	NMOD
18	randomized	randomize	I-NP	VBN	O	22	AMOD
19	,	,	I-NP	,	O	22	P
20	double-blind	double-blind	I-NP	JJ	O	22	AMOD
21	,	,	I-NP	,	O	22	P
22	placebo-controlled	placebo-controlled	I-NP	JJ	O	23	NMOD
23	trial	trial	I-NP	NN	O	9	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	enalapril	enalapril	B-NP	NN	O	24	PMOD
26	for	for	B-PP	IN	O	23	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	treatment	treatment	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	CHF	CHF	B-NP	NN	B-protein	29	PMOD
31	.	.	O	.	O	1	P

1	Decreased	Decrease	B-NP	VBN	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	function	function	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	defined	define	I-VP	VBN	O	4	VC
6	as	as	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	rise	rise	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	serum	serum	B-NP	NN	O	14	NMOD
11	creatinine	creatinine	I-NP	NN	O	14	NMOD
12	>	>	O	SYM	O	14	NMOD
13	/=0.5	/=0.5	B-NP	CD	O	14	NMOD
14	mg/dL	mg/dL	I-NP	NN	O	9	PMOD
15	(	(	O	(	O	18	DEP
16	44	44	B-NP	CD	O	17	NMOD
17	micromol/L	micromol/L	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	from	from	B-PP	IN	O	14	NMOD
20	baseline	baseline	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	time-to-event	time-to-event	B-NP	JJ	O	4	NMOD
4	analysis	analysis	I-NP	NN	O	2	OBJ
5	to	to	B-VP	TO	O	6	VMOD
6	identify	identify	I-VP	VB	O	4	NMOD
7	potential	potential	B-NP	JJ	O	8	NMOD
8	predictors	predictor	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	decrease	decrease	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	renal	renal	B-NP	JJ	O	13	NMOD
13	function	function	I-NP	NN	O	11	PMOD
14	including	include	B-PP	VBG	O	13	NMOD
15	age	age	B-NP	NN	O	27	NMOD
16	,	,	O	,	O	27	P
17	baseline	baseline	B-NP	NN	O	19	NMOD
18	ejection	ejection	I-NP	NN	O	19	NMOD
19	fraction	fraction	I-NP	NN	O	27	NMOD
20	,	,	O	,	O	27	P
21	baseline	baseline	B-NP	NN	O	22	NMOD
22	creatinine	creatinine	I-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	low	low	B-NP	JJ	O	27	NMOD
25	systolic	systolic	I-NP	JJ	O	27	NMOD
26	blood	blood	I-NP	NN	O	27	NMOD
27	pressure	pressure	I-NP	NN	O	35	NMOD
28	(	(	O	(	O	33	DEP
29	<	<	B-NP	SYM	O	31	AMOD
30	100	100	I-NP	CD	O	31	AMOD
31	mm	mm	I-NP	NN	O	32	NMOD
32	Hg	Hg	I-NP	NN	O	33	DEP
33	)	)	O	)	O	27	NMOD
34	,	,	O	,	O	35	P
35	history	history	B-NP	NN	O	14	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	hypertension	hypertension	B-NP	NN	O	42	NMOD
38	,	,	O	,	O	42	P
39	diabetes	diabetes	B-NP	NN	O	42	NMOD
40	,	,	O	,	O	42	P
41	and	and	O	CC	O	42	NMOD
42	use	use	B-NP	NN	O	36	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	antiplatelet	antiplatelet	B-NP	JJ	O	50	NMOD
45	,	,	I-NP	,	O	50	P
46	diuretic	diuretic	I-NP	JJ	O	50	NMOD
47	,	,	O	,	O	50	P
48	and	and	O	CC	O	50	NMOD
49	beta-blocker	beta-blocker	B-NP	NN	O	50	NMOD
50	therapy	therapy	I-NP	NN	O	43	PMOD
51	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Patients	Patient	B-NP	NNS	O	8	SUB
4	randomly	randomly	B-VP	RB	O	5	VMOD
5	assigned	assign	I-VP	VBN	O	3	NMOD
6	to	to	I-VP	TO	O	7	VMOD
7	enalapril	enalapril	I-VP	VB	O	5	VMOD
8	had	have	B-VP	VBD	O	1	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	33	33	I-NP	CD	O	11	NMOD
11	%	%	I-NP	NN	O	12	AMOD
12	greater	great	B-NP	JJR	O	13	NMOD
13	likelihood	likelihood	I-NP	NN	O	8	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	decreased	decrease	B-NP	VBN	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	function	function	I-NP	NN	O	14	PMOD
18	than	than	B-PP	IN	O	13	NMOD
19	controls	control	B-NP	NNS	O	18	PMOD
20	(	(	O	(	O	23	DEP
21	P	P	B-NP	NN	O	23	DEP
22	=.003	=.003	I-NP	CD	O	21	NMOD
23	)	)	O	)	O	19	NMOD
24	.	.	O	.	O	8	P

1	By	By	B-PP	IN	O	20	VMOD
2	multivariate	multivariate	B-NP	JJ	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	20	P
5	in	in	B-PP	IN	O	20	VMOD
6	both	both	B-NP	CC	O	11	NMOD
7	the	the	I-NP	DT	O	11	NMOD
8	placebo	placebo	I-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	enalapril	enalapril	I-NP	NN	O	11	NMOD
11	groups	group	I-NP	NNS	O	13	NMOD
12	older	old	B-NP	JJR	O	13	NMOD
13	age	age	I-NP	NN	O	5	PMOD
14	,	,	O	,	O	20	P
15	diuretic	diuretic	B-NP	JJ	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	20	SUB
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	VMOD
19	diabetes	diabete	B-NP	NNS	O	20	SUB
20	were	be	B-VP	VBD	O	27	VMOD
21	associated	associate	I-VP	VBN	O	20	VC
22	with	with	B-PP	IN	O	21	VMOD
23	decreased	decrease	B-NP	VBN	O	25	NMOD
24	renal	renal	I-NP	JJ	O	25	NMOD
25	function	function	I-NP	NN	O	22	PMOD
26	,	,	O	,	O	27	P
27	whereas	whereas	O	IN	O	0	ROOT
28	beta-blocker	beta-blocker	B-NP	NN	O	29	NMOD
29	therapy	therapy	I-NP	NN	O	33	NMOD
30	and	and	O	CC	O	33	NMOD
31	higher	high	B-NP	JJR	O	33	NMOD
32	ejection	ejection	I-NP	NN	O	33	NMOD
33	fraction	fraction	I-NP	NN	O	34	SUB
34	were	be	B-VP	VBD	O	27	VMOD
35	renoprotective	renoprotective	B-ADJP	JJ	O	34	PRD
36	.	.	O	.	O	27	P

1	Older	Old	B-NP	JJR	O	2	NMOD
2	age	age	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	8	NMOD
7	greater	great	I-NP	JJR	O	8	NMOD
8	risk	risk	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	developing	develop	B-VP	VBG	O	9	PMOD
11	decreased	decrease	B-NP	VBN	O	13	NMOD
12	renal	renal	I-NP	JJ	O	13	NMOD
13	function	function	I-NP	NN	O	10	OBJ
14	in	in	B-PP	IN	O	10	VMOD
15	both	both	B-NP	DT	O	16	NMOD
16	groups	group	I-NP	NNS	O	14	PMOD
17	,	,	O	,	O	4	P
18	but	but	O	CC	O	4	VMOD
19	significantly	significantly	B-ADVP	RB	O	4	VMOD
20	more	more	I-ADVP	RBR	O	19	AMOD
21	so	so	I-ADVP	RB	O	19	AMOD
22	in	in	B-PP	IN	O	19	AMOD
23	the	the	B-NP	DT	O	25	NMOD
24	enalapril	enalapril	I-NP	NN	O	25	NMOD
25	group	group	I-NP	NN	O	22	PMOD
26	(	(	O	(	O	59	DEP
27	enalapril	enalapril	B-NP	NN	O	30	NMOD
28	:	:	O	:	O	27	P
29	risk	risk	B-NP	NN	O	30	NMOD
30	ratio	ratio	I-NP	NN	O	42	NMOD
31	[	[	O	(	O	33	DEP
32	RR	RR	B-NP	NN	O	33	DEP
33	]	]	O	)	O	30	NMOD
34	1.42	1.42	B-NP	CD	O	42	NMOD
35	per	per	B-PP	IN	O	34	NMOD
36	10	10	B-NP	CD	O	37	NMOD
37	years	year	I-NP	NNS	O	35	PMOD
38	,	,	O	,	O	42	P
39	95	95	B-NP	CD	O	42	NMOD
40	%	%	I-NP	NN	O	42	NMOD
41	confidence	confidence	I-NP	NN	O	42	NMOD
42	interval	interval	I-NP	NN	O	46	NMOD
43	[	[	O	(	O	45	DEP
44	CI	CI	B-NP	NN	O	45	DEP
45	]	]	O	)	O	42	NMOD
46	1.32-1.52	1.32-1.52	B-NP	CD	O	50	NMOD
47	with	with	B-PP	IN	O	46	NMOD
48	enalapril	enalapril	B-NP	NN	O	47	PMOD
49	;	;	O	:	O	46	P
50	placebo	placebo	B-NP	NN	O	57	NMOD
51	:	:	O	:	O	57	P
52	RR	RR	B-NP	NN	O	57	NMOD
53	1.18	1.18	I-NP	CD	O	52	NMOD
54	,	,	O	,	O	57	P
55	95	95	B-NP	CD	O	57	NMOD
56	%	%	I-NP	NN	O	57	NMOD
57	CI	CI	I-NP	NN	O	59	DEP
58	1.12-1.25	1.12-1.25	I-NP	CD	O	57	NMOD
59	)	)	O	)	O	25	NMOD
60	.	.	O	.	O	3	P

1	Diuretic	Diuretic	B-NP	JJ	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	likewise	likewise	I-VP	RB	O	3	VMOD
5	associated	associate	I-VP	VBN	O	3	VC
6	with	with	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	greater	great	I-NP	JJR	O	9	NMOD
9	risk	risk	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	decreased	decrease	B-NP	VBN	O	13	NMOD
12	renal	renal	I-NP	JJ	O	13	NMOD
13	function	function	I-NP	NN	O	10	PMOD
14	in	in	B-PP	IN	O	5	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	enalapril	enalapril	I-NP	NN	O	17	NMOD
17	group	group	I-NP	NN	O	14	PMOD
18	(	(	O	(	O	26	DEP
19	RR	RR	B-NP	NN	O	24	NMOD
20	1.89	1.89	I-NP	CD	O	19	NMOD
21	,	,	O	,	O	24	P
22	95	95	B-NP	CD	O	24	NMOD
23	%	%	I-NP	NN	O	24	NMOD
24	CI	CI	I-NP	NN	O	26	DEP
25	1.70-2.08	1.70-2.08	I-NP	CD	O	24	NMOD
26	)	)	O	)	O	17	NMOD
27	than	than	B-PP	IN	O	5	VMOD
28	in	in	B-PP	IN	O	27	PMOD
29	the	the	B-NP	DT	O	31	NMOD
30	placebo	placebo	I-NP	NN	O	31	NMOD
31	group	group	I-NP	NN	O	28	PMOD
32	(	(	O	(	O	40	DEP
33	RR	RR	B-NP	NN	O	38	NMOD
34	1.35	1.35	I-NP	CD	O	33	NMOD
35	,	,	O	,	O	38	P
36	95	95	B-NP	CD	O	38	NMOD
37	%	%	I-NP	NN	O	38	NMOD
38	CI	CI	I-NP	NN	O	40	DEP
39	1.09-1.66	1.09-1.66	I-NP	CD	O	38	NMOD
40	)	)	O	)	O	5	VMOD
41	.	.	O	.	O	3	P

1	Conversely	Conversely	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	enalapril	enalapril	B-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	8	NMOD
6	relative	relative	I-NP	JJ	O	8	NMOD
7	renoprotective	renoprotective	I-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	4	OBJ
9	(	(	O	(	O	17	DEP
10	RR	RR	B-NP	NN	O	15	NMOD
11	1.33	1.33	I-NP	CD	O	10	NMOD
12	,	,	O	,	O	15	P
13	95	95	B-NP	CD	O	15	NMOD
14	%	%	I-NP	NN	O	15	NMOD
15	CI	CI	I-NP	NN	O	17	DEP
16	1.13-1.53	1.13-1.53	I-NP	CD	O	15	NMOD
17	)	)	O	)	O	8	NMOD
18	compared	compare	B-PP	VBN	O	4	VMOD
19	with	with	B-PP	IN	O	18	PMOD
20	placebo	placebo	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	29	DEP
22	RR	RR	B-NP	NN	O	27	NMOD
23	1.96	1.96	I-NP	CD	O	22	NMOD
24	,	,	O	,	O	27	P
25	95	95	B-NP	CD	O	27	NMOD
26	%	%	I-NP	NN	O	27	NMOD
27	CI	CI	I-NP	NN	O	29	DEP
28	1.57-2.44	1.57-2.44	I-NP	CD	O	27	NMOD
29	)	)	O	)	O	20	NMOD
30	in	in	B-PP	IN	O	20	NMOD
31	patients	patient	B-NP	NNS	O	30	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	diabetes	diabetes	B-NP	NN	O	32	PMOD
34	.	.	O	.	O	4	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Enalapril	Enalapril	B-NP	NNP	O	4	NMOD
4	use	use	I-NP	NN	O	5	SUB
5	caused	cause	B-VP	VBD	O	1	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	33	33	I-NP	CD	O	8	AMOD
8	%	%	I-NP	NN	O	9	NMOD
9	increase	increase	I-NP	NN	O	5	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	risk	risk	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	decreased	decrease	B-NP	VBN	O	16	NMOD
15	renal	renal	I-NP	JJ	O	16	NMOD
16	function	function	I-NP	NN	O	13	PMOD
17	in	in	B-PP	IN	O	12	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	CHF	CHF	B-NP	NN	B-protein	19	PMOD
21	.	.	O	.	O	1	P

1	Pemoline	Pemoline	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	acute	acute	B-NP	JJ	O	4	NMOD
4	choreoathetosis	choreoathetosis	I-NP	NN	O	2	OBJ
5	:	:	O	:	O	2	P
6	case	case	B-NP	NN	O	7	NMOD
7	report	report	I-NP	NN	O	9	NMOD
8	and	and	O	CC	O	9	NMOD
9	review	review	B-NP	NN	O	2	VMOD
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	literature	literature	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Pemoline	Pemoline	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	an	an	B-NP	DT	O	7	NMOD
6	oxazolidine	oxazolidine	I-NP	NN	O	7	NMOD
7	derivative	derivative	I-NP	NN	O	4	PRD
8	that	that	B-NP	WDT	O	7	NMOD
9	is	be	B-VP	VBZ	O	8	SBAR
10	structurally	structurally	B-ADJP	RB	O	11	AMOD
11	different	different	I-ADJP	JJ	O	9	PRD
12	from	from	B-PP	IN	O	11	AMOD
13	amphetamines	amphetamine	B-NP	NNS	O	12	PMOD
14	and	and	O	CC	O	15	VMOD
15	used	use	B-VP	VBN	O	8	SBAR
16	in	in	B-PP	IN	O	15	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	attention	attention	B-NP	NN	O	22	NMOD
21	deficit	deficit	I-NP	NN	O	22	NMOD
22	disorder	disorder	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	1	P

1	Pemoline	Pemoline	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	been	be	I-VP	VBN	O	2	VC
5	commonly	commonly	I-VP	RB	O	4	VMOD
6	associated	associate	I-VP	VBN	O	4	VC
7	in	in	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	literature	literature	I-NP	NN	O	7	PMOD
10	as	as	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	cause	cause	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	acute	acute	B-NP	JJ	O	16	NMOD
15	movement	movement	I-NP	NN	O	16	NMOD
16	disorders	disorder	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	following	follow	I-NP	VBG	O	3	NMOD
3	case	case	I-NP	NN	O	4	SUB
4	describes	describe	B-VP	VBZ	O	0	ROOT
5	two	two	B-NP	CD	O	6	NMOD
6	children	child	I-NP	NNS	O	4	OBJ
7	acutely	acutely	B-VP	RB	O	8	VMOD
8	poisoned	poison	I-VP	VBN	O	6	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	pemoline	pemoline	B-NP	NN	O	9	PMOD
11	who	who	B-NP	WP	O	8	VMOD
12	experienced	experience	B-VP	VBD	O	11	SBAR
13	profound	profound	B-NP	JJ	O	14	NMOD
14	choreoathetosis	choreoathetosis	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	children	child	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	medical	medical	I-NP	JJ	O	6	NMOD
6	history	history	I-NP	NN	O	3	OBJ
7	significant	significant	B-ADJP	JJ	O	6	NMOD
8	for	for	B-PP	IN	O	7	AMOD
9	attention	attention	B-NP	NN	O	11	NMOD
10	deficit	deficit	I-NP	NN	O	11	NMOD
11	disorder	disorder	I-NP	NN	O	8	PMOD
12	previously	previously	B-VP	RB	O	13	VMOD
13	treated	treat	I-VP	VBN	O	11	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	methylphenidate	methylphenidate	B-NP	NN	O	14	PMOD
16	without	without	B-PP	IN	O	13	VMOD
17	success	success	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	children	child	I-NP	NNS	O	3	SUB
3	received	receive	B-VP	VBD	O	0	ROOT
4	gastrointestinal	gastrointestinal	B-NP	JJ	O	5	NMOD
5	decontamination	decontamination	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	high	high	B-NP	JJ	O	8	NMOD
8	doses	dose	I-NP	NNS	O	3	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	intravenous	intravenous	B-NP	JJ	O	11	NMOD
11	benzodiazepines	benzodiazepine	I-NP	NNS	O	9	PMOD
12	in	in	B-PP	IN	O	8	NMOD
13	an	an	B-NP	DT	O	14	NMOD
14	attempt	attempt	I-NP	NN	O	12	PMOD
15	to	to	B-VP	TO	O	16	VMOD
16	control	control	I-VP	VB	O	14	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	choreoathetoid	choreoathetoid	I-NP	JJ	O	19	NMOD
19	movements	movement	I-NP	NNS	O	16	OBJ
20	.	.	O	.	O	3	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Pemoline	Pemoline	B-NP	NN	O	6	NMOD
4	associated	associate	I-NP	VBN	O	6	NMOD
5	movement	movement	I-NP	NN	O	6	NMOD
6	disorder	disorder	I-NP	NN	O	7	SUB
7	has	have	B-VP	VBZ	O	1	NMOD
8	been	be	I-VP	VBN	O	7	VC
9	rarely	rarely	I-VP	RB	O	8	VMOD
10	reported	report	I-VP	VBN	O	8	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	acute	acute	I-NP	JJ	O	15	NMOD
14	toxicology	toxicology	I-NP	NN	O	15	NMOD
15	literature	literature	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	7	P

1	Continuous	Continuous	B-NP	JJ	O	3	NMOD
2	subcutaneous	subcutaneous	I-NP	JJ	O	3	NMOD
3	administration	administration	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	mesna	mesna	B-NP	NN	O	4	PMOD
6	to	to	B-VP	TO	O	7	VMOD
7	prevent	prevent	I-VP	VB	O	3	NMOD
8	ifosfamide	ifosfamide	B-NP	NN	O	11	NMOD
9	induced	induced	I-NP	JJ	O	11	NMOD
10	hemorrhagic	hemorrhagic	I-NP	JJ	O	11	NMOD
11	cystitis	cystitis	I-NP	NN	O	7	OBJ
12	.	.	O	.	O	3	P

1	Hemorrhagic	Hemorrhagic	B-NP	JJ	O	2	NMOD
2	cystitis	cystitis	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	7	NMOD
5	major	major	I-NP	JJ	O	7	NMOD
6	potential	potential	I-NP	JJ	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	3	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	ifosfamide	ifosfamide	B-NP	NN	O	8	PMOD
10	that	that	B-NP	WDT	O	9	NMOD
11	can	can	B-VP	MD	O	10	SBAR
12	be	be	I-VP	VB	O	11	VC
13	prevented	prevent	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	administering	administer	B-VP	VBG	O	14	PMOD
16	mesna	mesna	B-NP	NN	O	15	OBJ
17	along	along	B-PP	IN	O	15	VMOD
18	with	with	B-PP	IN	O	17	PMOD
19	the	the	B-NP	DT	O	21	NMOD
20	cytotoxic	cytotoxic	I-NP	JJ	O	21	NMOD
21	agent	agent	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	10	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	10	P
4	subcutaneous	subcutaneous	B-NP	JJ	O	5	NMOD
5	delivery	delivery	I-NP	NN	O	10	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	neutralizing	neutralize	I-NP	VBG	O	9	NMOD
9	agent	agent	I-NP	NN	O	6	PMOD
10	will	will	B-VP	MD	O	0	ROOT
11	not	not	I-VP	RB	O	10	VMOD
12	be	be	I-VP	VB	O	10	VC
13	associated	associate	I-VP	VBN	O	12	VC
14	with	with	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	risk	risk	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	inadequate	inadequate	B-NP	JJ	O	21	NMOD
19	urinary	urinary	I-NP	JJ	O	21	NMOD
20	mesna	mesna	I-NP	NN	O	21	NMOD
21	concentrations	concentration	I-NP	NNS	O	17	PMOD
22	,	,	O	,	O	21	P
23	such	such	B-PP	JJ	O	24	PMOD
24	as	as	I-PP	IN	O	21	NMOD
25	in	in	B-PP	IN	O	24	PMOD
26	a	a	B-NP	DT	O	27	NMOD
27	patient	patient	I-NP	NN	O	25	PMOD
28	taking	take	B-VP	VBG	O	27	NMOD
29	oral	oral	B-NP	JJ	O	30	NMOD
30	mesna	mesna	I-NP	NN	O	28	OBJ
31	who	who	B-NP	WP	O	30	NMOD
32	experiences	experience	B-VP	VBZ	O	31	SBAR
33	severe	severe	B-NP	JJ	O	34	NMOD
34	ifosfamide	ifosfamide	I-NP	NN	O	32	OBJ
35	induced	induce	B-VP	VBD	O	10	VMOD
36	emesis	emesis	B-NP	NN	O	35	OBJ
37	and	and	O	CC	O	10	VMOD
38	is	be	B-VP	VBZ	O	10	VMOD
39	unable	unable	B-ADJP	JJ	O	38	PRD
40	to	to	B-VP	TO	O	41	VMOD
41	absorb	absorb	I-VP	VB	O	39	AMOD
42	the	the	B-NP	DT	O	43	NMOD
43	drug	drug	I-NP	NN	O	41	OBJ
44	.	.	O	.	O	10	P

1	Pretreatment	Pretreatment	B-NP	NN	O	14	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	ammonium	ammonium	B-NP	NN	O	4	NMOD
4	acetate	acetate	I-NP	NN	O	2	PMOD
5	(	(	O	(	O	7	DEP
6	NH4Ac	NH4Ac	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	(	(	O	(	O	12	DEP
9	6	6	B-NP	CD	O	11	NMOD
10	mmol/kg	mmol/kg	I-NP	NN	O	11	NMOD
11	s.c.	s.c.	I-NP	NN	O	12	DEP
12	)	)	O	)	O	4	NMOD
13	approximately	approximately	B-ADVP	RB	O	14	VMOD
14	doubled	double	B-VP	VBD	O	36	VMOD
15	the	the	B-NP	DT	O	18	NMOD
16	time	time	I-NP	NN	O	18	NMOD
17	morphine-treated	morphine-treated	B-NP	JJ	O	18	NMOD
18	mice	mouse	I-NP	NNS	O	19	SUB
19	remained	remain	B-VP	VBD	O	36	VMOD
20	on	on	B-PP	IN	O	19	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	hot	hot	I-NP	JJ	O	23	NMOD
23	surface	surface	I-NP	NN	O	20	PMOD
24	and	and	O	CC	O	19	VMOD
25	similarly	similarly	B-NP	RB	O	26	AMOD
26	increased	increase	I-NP	VBN	O	28	NMOD
27	muscular	muscular	I-NP	JJ	O	28	NMOD
28	incoordination	incoordination	I-NP	NN	O	36	VMOD
29	by	by	B-PP	IN	O	28	NMOD
30	diazepam	diazepam	B-NP	NN	O	29	PMOD
31	,	,	O	,	O	36	P
32	but	but	O	CC	O	36	VMOD
33	NH4Ac	NH4Ac	B-NP	NN	O	34	NMOD
34	treatment	treatment	I-NP	NN	O	36	SUB
35	alone	alone	B-ADVP	RB	O	34	NMOD
36	had	have	B-VP	VBD	O	0	ROOT
37	no	no	B-NP	DT	O	38	NMOD
38	effect	effect	I-NP	NN	O	36	OBJ
39	.	.	O	.	O	36	P

1	Addition	Addition	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	excess	excess	B-NP	JJ	O	4	NMOD
4	calcium	calcium	I-NP	NN	O	2	PMOD
5	reversed	reverse	B-VP	VBD	O	18	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	depression	depression	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	both	both	B-NP	DT	O	10	NMOD
10	tissues	tissue	I-NP	NNS	O	8	PMOD
11	,	,	O	,	O	18	P
12	but	but	O	CC	O	18	VMOD
13	calcium-independent	calcium-independent	B-NP	JJ	O	15	NMOD
14	catecholamine	catecholamine	I-NP	NN	O	15	NMOD
15	release	release	I-NP	NN	O	18	SUB
16	by	by	B-PP	IN	O	15	NMOD
17	acetaldehyde	acetaldehyde	B-NP	NN	O	16	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	not	not	I-VP	RB	O	18	VMOD
20	blocked	block	I-VP	VBN	O	18	VC
21	by	by	B-PP	IN	O	20	VMOD
22	NH4Ac	NH4Ac	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	18	P

1	Both	Both	O	CC	O	10	NMOD
2	verapamil	verapamil	B-NP	NN	O	10	NMOD
3	(	(	O	(	O	7	DEP
4	10	10	B-NP	CD	O	5	NMOD
5	mg/kg	mg/kg	I-NP	NN	O	7	DEP
6	i.p.	i.p.	B-ADVP	RB	O	5	NMOD
7	)	)	O	)	O	2	NMOD
8	and	and	O	CC	O	10	NMOD
9	NH4Ac	NH4Ac	B-NP	NN	O	10	NMOD
10	pretreatment	pretreatment	I-NP	NN	O	11	SUB
11	enhanced	enhance	B-VP	VBD	O	31	VMOD
12	morphine	morphine	B-NP	NN	O	13	NMOD
13	analgesia-	analgesia-	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	diazepam	diazepam	I-NP	NN	O	18	NMOD
16	induced	induce	B-VP	VBD	O	18	NMOD
17	muscular	muscular	B-NP	JJ	O	18	NMOD
18	incoordination	incoordination	I-NP	NN	O	22	SUB
19	and	and	O	CC	O	22	VMOD
20	antagonized	antagonize	B-NP	VBN	O	21	NMOD
21	amphetamine	amphetamine	I-NP	NN	O	22	SUB
22	induced	induce	B-VP	VBD	O	31	VMOD
23	motor	motor	B-NP	NN	O	24	NMOD
24	activity	activity	I-NP	NN	O	22	OBJ
25	,	,	O	,	O	31	P
26	and	and	O	CC	O	30	NMOD
27	neither	neither	O	CC	O	30	NMOD
28	verapamil	verapamil	B-NP	NN	O	30	NMOD
29	nor	nor	I-NP	CC	O	30	NMOD
30	NH4Ac	NH4Ac	I-NP	NN	O	31	SUB
31	affected	affect	B-VP	VBD	O	0	ROOT
32	the	the	B-NP	DT	O	34	NMOD
33	convulsant	convulsant	I-NP	JJ	O	34	NMOD
34	action	action	I-NP	NN	O	31	OBJ
35	of	of	B-PP	IN	O	34	NMOD
36	metrazol	metrazol	B-NP	NN	O	35	PMOD
37	.	.	O	.	O	31	P

1	Risk	Risk	B-NP	NN	O	18	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	nephropathy	nephropathy	B-NP	NN	O	2	PMOD
4	after	after	B-PP	IN	O	1	NMOD
5	consumption	consumption	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	nonionic	nonionic	B-NP	JJ	O	9	NMOD
8	contrast	contrast	I-NP	NN	O	9	NMOD
9	media	medium	I-NP	NNS	O	6	PMOD
10	by	by	B-PP	IN	O	5	NMOD
11	children	child	B-NP	NNS	O	10	PMOD
12	undergoing	undergo	B-VP	VBG	O	11	NMOD
13	cardiac	cardiac	B-NP	JJ	O	14	NMOD
14	angiography	angiography	I-NP	NN	O	12	OBJ
15	:	:	O	:	O	1	P
16	a	a	B-NP	DT	O	18	NMOD
17	prospective	prospective	I-NP	JJ	O	18	NMOD
18	study	study	I-NP	NN	O	0	ROOT
19	.	.	O	.	O	18	P

1	Despite	Despite	B-PP	IN	O	8	VMOD
2	increasing	increase	B-VP	VBG	O	3	NMOD
3	reports	report	B-NP	NNS	O	1	PMOD
4	on	on	B-PP	IN	O	3	NMOD
5	nonionic	nonionic	B-NP	JJ	O	7	NMOD
6	contrast	contrast	I-NP	NN	O	7	NMOD
7	media	medium	I-NP	NNS	O	4	PMOD
8	induced	induce	B-VP	VBD	O	25	VMOD
9	nephropathy	nephropathy	B-NP	NN	O	8	OBJ
10	(	(	O	(	O	12	DEP
11	CIN	CIN	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	in	in	B-PP	IN	O	8	VMOD
14	hospitalized	hospitalize	B-NP	VBN	O	16	NMOD
15	adult	adult	I-NP	JJ	O	16	NMOD
16	patients	patient	I-NP	NNS	O	13	PMOD
17	during	during	B-PP	IN	O	16	NMOD
18	cardiac	cardiac	B-NP	JJ	O	19	NMOD
19	procedures	procedure	I-NP	NNS	O	17	PMOD
20	,	,	O	,	O	8	P
21	the	the	B-NP	DT	O	22	NMOD
22	studies	study	I-NP	NNS	O	25	SUB
23	in	in	B-PP	IN	O	22	NMOD
24	pediatrics	pediatric	B-NP	NNS	O	23	PMOD
25	are	be	B-VP	VBP	O	0	ROOT
26	limited	limit	I-VP	VBN	O	25	VC
27	,	,	O	,	O	26	P
28	with	with	B-PP	IN	O	26	VMOD
29	even	even	B-NP	RB	O	31	NMOD
30	less	less	I-NP	JJR	O	29	AMOD
31	focus	focus	I-NP	NN	O	28	PMOD
32	on	on	B-PP	IN	O	31	NMOD
33	possible	possible	B-NP	JJ	O	35	NMOD
34	predisposing	predispose	I-NP	VBG	O	35	NMOD
35	factors	factor	I-NP	NNS	O	38	NMOD
36	and	and	O	CC	O	38	NMOD
37	preventive	preventive	B-NP	JJ	O	38	NMOD
38	measures	measure	I-NP	NNS	O	32	PMOD
39	for	for	B-PP	IN	O	38	NMOD
40	patients	patient	B-NP	NNS	O	39	PMOD
41	undergoing	undergo	B-VP	VBG	O	40	NMOD
42	cardiac	cardiac	B-NP	JJ	O	43	NMOD
43	angiography	angiography	I-NP	NN	O	41	OBJ
44	.	.	O	.	O	25	P

1	This	This	B-NP	DT	O	3	NMOD
2	prospective	prospective	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	determined	determine	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	CIN	CIN	B-NP	NN	B-protein	7	PMOD
9	for	for	B-PP	IN	O	6	NMOD
10	two	two	B-NP	CD	O	13	NMOD
11	nonionic	nonionic	I-NP	JJ	O	13	NMOD
12	contrast	contrast	I-NP	NN	O	13	NMOD
13	media	medium	I-NP	NNS	O	20	NMOD
14	(	(	O	(	O	16	DEP
15	CM	CM	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	,	,	O	,	O	20	P
18	iopromide	iopromide	B-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	iohexol	iohexol	I-NP	NN	O	9	PMOD
21	,	,	O	,	O	20	P
22	among	among	B-PP	IN	O	20	NMOD
23	80	80	B-NP	CD	O	24	NMOD
24	patients	patient	I-NP	NNS	O	22	PMOD
25	younger	young	B-ADJP	JJR	O	24	NMOD
26	than	than	B-PP	IN	O	25	AMOD
27	18	18	B-NP	CD	O	28	NMOD
28	years	year	I-NP	NNS	O	26	PMOD
29	and	and	O	CC	O	4	VMOD
30	compared	compare	B-VP	VBD	O	4	VMOD
31	the	the	B-NP	DT	O	32	NMOD
32	rates	rate	I-NP	NNS	O	30	OBJ
33	for	for	B-PP	IN	O	32	NMOD
34	this	this	B-NP	DT	O	35	NMOD
35	complication	complication	I-NP	NN	O	33	PMOD
36	in	in	B-PP	IN	O	30	VMOD
37	relation	relation	B-NP	NN	O	36	PMOD
38	to	to	B-PP	TO	O	37	NMOD
39	the	the	B-NP	DT	O	42	NMOD
40	type	type	I-NP	NN	O	42	NMOD
41	and	and	I-NP	CC	O	42	NMOD
42	dosage	dosage	I-NP	NN	O	47	NMOD
43	of	of	B-PP	IN	O	42	NMOD
44	CM	CM	B-NP	NN	O	43	PMOD
45	and	and	O	CC	O	47	NMOD
46	the	the	B-NP	DT	O	47	NMOD
47	presence	presence	I-NP	NN	O	38	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	cyanosis	cyanosis	B-NP	NN	O	48	PMOD
50	.	.	O	.	O	4	P

1	Whereas	Whereas	B-SBAR	IN	O	22	VMOD
2	33.3	33.3	B-NP	CD	O	3	NMOD
3	%	%	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	CIN	CIN	B-NP	NN	B-protein	7	PMOD
9	were	be	B-VP	VBD	O	1	SBAR
10	among	among	B-PP	IN	O	9	PRD
11	those	those	B-NP	DT	O	10	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	received	receive	B-VP	VBD	O	12	SBAR
14	the	the	B-NP	DT	O	16	NMOD
15	proper	proper	I-NP	JJ	O	16	NMOD
16	dosage	dosage	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	CM	CM	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	22	P
20	the	the	B-NP	DT	O	21	NMOD
21	percentage	percentage	I-NP	NN	O	22	SUB
22	increased	increase	B-VP	VBD	O	0	ROOT
23	to	to	B-PP	TO	O	22	VMOD
24	66.6	66.6	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	23	PMOD
26	among	among	B-PP	IN	O	22	VMOD
27	those	those	B-NP	DT	O	26	PMOD
28	who	who	B-NP	WP	O	27	NMOD
29	received	receive	B-VP	VBD	O	28	SBAR
30	larger	large	B-NP	JJR	O	31	NMOD
31	doses	dose	I-NP	NNS	O	29	OBJ
32	,	,	O	,	O	22	P
33	with	with	B-PP	IN	O	22	VMOD
34	a	a	B-NP	DT	O	36	NMOD
35	significant	significant	I-NP	JJ	O	36	NMOD
36	difference	difference	I-NP	NN	O	33	PMOD
37	in	in	B-PP	IN	O	36	NMOD
38	the	the	B-NP	DT	O	39	NMOD
39	incidence	incidence	I-NP	NN	O	37	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	CIN	CIN	B-NP	NN	B-protein	40	PMOD
42	related	relate	B-VP	VBN	O	41	NMOD
43	to	to	B-PP	TO	O	42	AMOD
44	the	the	B-NP	DT	O	46	NMOD
45	different	different	I-NP	JJ	O	46	NMOD
46	dosages	dosage	I-NP	NNS	O	43	PMOD
47	of	of	B-PP	IN	O	46	NMOD
48	CM	CM	B-NP	NN	O	47	PMOD
49	(	(	O	(	O	53	DEP
50	p	p	B-NP	NN	O	53	DEP
51	=	=	B-VP	SYM	O	50	NMOD
52	0.014	0.014	B-NP	CD	O	51	AMOD
53	)	)	O	)	O	46	NMOD
54	.	.	O	.	O	22	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	ventricular	ventricular	B-NP	JJ	O	5	NMOD
5	tachycardia	tachycardia	I-NP	NN	O	3	PMOD
6	related	relate	B-VP	VBN	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	caffeine	caffeine	B-NP	NN	O	9	NMOD
9	pretreatment	pretreatment	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	caffeine	caffeine	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	commonly	commonly	I-VP	RB	O	3	VMOD
5	used	use	I-VP	VBN	O	3	VC
6	to	to	B-VP	TO	O	7	VMOD
7	improve	improve	I-VP	VB	O	5	VMOD
8	seizure	seizure	B-NP	NN	O	9	NMOD
9	duration	duration	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	quality	quality	I-NP	NN	O	7	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	such	such	B-NP	JJ	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	and	and	O	CC	O	3	VMOD
16	is	be	B-VP	VBZ	O	3	VMOD
17	generally	generally	I-VP	RB	O	19	VMOD
18	well	well	I-VP	RB	O	17	AMOD
19	tolerated	tolerate	I-VP	VBN	O	16	VC
20	aside	aside	B-ADVP	RB	O	19	VMOD
21	from	from	B-PP	IN	O	19	VMOD
22	occasional	occasional	B-NP	JJ	O	23	NMOD
23	reports	report	I-NP	NNS	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	relatively	relatively	B-NP	RB	O	26	AMOD
26	benign	benign	I-NP	JJ	O	28	NMOD
27	ventricular	ventricular	I-NP	JJ	O	28	NMOD
28	ectopy	ectopy	I-NP	NN	O	24	PMOD
29	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	13	NMOD
5	with	with	B-PP	IN	O	4	NMOD
6	no	no	B-NP	DT	O	8	NMOD
7	previous	previous	I-NP	JJ	O	8	NMOD
8	history	history	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cardiac	cardiac	B-NP	JJ	O	11	NMOD
11	disease	disease	I-NP	NN	O	9	PMOD
12	or	or	O	CC	O	13	NMOD
13	arrhythmia	arrhythmia	B-NP	NN	O	2	OBJ
14	who	who	B-NP	WP	O	13	NMOD
15	developed	develop	B-VP	VBD	O	14	SBAR
16	sustained	sustained	B-NP	JJ	O	17	NMOD
17	bigeminy	bigeminy	I-NP	JJ	O	21	NMOD
18	and	and	I-NP	CC	O	21	NMOD
19	2	2	I-NP	CD	O	21	NMOD
20	brief	brief	I-NP	JJ	O	21	NMOD
21	runs	run	I-NP	NNS	O	15	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	ventricular	ventricular	B-NP	JJ	O	24	NMOD
24	tachycardia	tachycardia	I-NP	NN	O	22	PMOD
25	after	after	B-PP	IN	O	15	VMOD
26	caffeine	caffeine	B-NP	NN	O	27	NMOD
27	administration	administration	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	2	P

1	Optical	Optical	B-NP	JJ	O	3	NMOD
2	coherence	coherence	I-NP	NN	O	3	NMOD
3	tomography	tomography	I-NP	NN	O	4	SUB
4	can	can	B-VP	MD	O	0	ROOT
5	measure	measure	I-VP	VB	O	4	VC
6	axonal	axonal	B-NP	JJ	O	7	NMOD
7	loss	loss	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	ethambutol	ethambutol	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	5	VMOD
13	optic	optic	B-NP	JJ	O	14	NMOD
14	neuropathy	neuropathy	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	4	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	map	map	I-VP	VB	O	1	NMOD
5	and	and	I-VP	CC	O	4	VMOD
6	identify	identify	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	pattern	pattern	I-NP	NN	O	4	OBJ
9	,	,	O	,	O	4	P
10	in	in	B-ADVP	FW	O	4	VMOD
11	vivo	vivo	I-ADVP	FW	O	10	AMOD
12	,	,	O	,	O	4	P
13	of	of	B-PP	IN	O	4	VMOD
14	axonal	axonal	B-NP	JJ	O	15	NMOD
15	degeneration	degeneration	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	4	VMOD
17	ethambutol	ethambutol	B-NP	NN	O	20	NMOD
18	induced	induce	B-VP	VBD	O	17	AMOD
19	optic	optic	B-NP	JJ	O	20	NMOD
20	neuropathy	neuropathy	I-NP	NN	O	16	PMOD
21	using	use	B-VP	VBG	O	4	VMOD
22	optical	optical	B-NP	JJ	O	24	NMOD
23	coherence	coherence	I-NP	NN	O	24	NMOD
24	tomography	tomography	I-NP	NN	O	21	OBJ
25	(	(	O	(	O	27	DEP
26	OCT	OCT	B-NP	NN	B-DNA	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	4	P

1	Ethambutol	Ethambutol	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	5	NMOD
4	antimycobacterial	antimycobacterial	I-NP	JJ	O	5	NMOD
5	agent	agent	I-NP	NN	O	2	PRD
6	often	often	B-VP	RB	O	7	VMOD
7	used	use	I-VP	VBN	O	5	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	treat	treat	I-VP	VB	O	7	VMOD
10	tuberculosis	tuberculosis	B-NP	NN	O	9	OBJ
11	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	serious	serious	I-NP	JJ	O	3	NMOD
3	complication	complication	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	ethambutol	ethambutol	B-NP	NN	O	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	an	an	B-NP	DT	O	9	NMOD
8	optic	optic	I-NP	JJ	O	9	NMOD
9	neuropathy	neuropathy	I-NP	NN	O	6	PRD
10	that	that	B-NP	WDT	O	9	NMOD
11	impairs	impair	B-VP	VBZ	O	10	SBAR
12	visual	visual	B-NP	JJ	O	13	NMOD
13	acuity	acuity	I-NP	NN	O	20	NMOD
14	,	,	O	,	O	20	P
15	contrast	contrast	B-NP	NN	O	16	NMOD
16	sensitivity	sensitivity	I-NP	NN	O	20	NMOD
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	NMOD
19	color	color	B-NP	NN	O	20	NMOD
20	vision	vision	I-NP	NN	O	11	OBJ
21	.	.	O	.	O	6	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Three	Three	B-NP	CD	O	4	NMOD
4	subjects	subject	I-NP	NNS	O	13	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	history	history	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	ethambutol	ethambutol	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	12	DEP
11	EMB	EMB	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	induced	induce	B-VP	VBD	O	1	NMOD
14	optic	optic	B-NP	JJ	O	15	NMOD
15	neuropathy	neuropathy	I-NP	NN	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	short-	short-	B-NP	NN	O	25	SUB
18	,	,	O	,	O	25	P
19	intermediate-	intermediate-	B-NP	NN	O	25	SUB
20	,	,	O	,	O	25	P
21	and	and	O	CC	O	25	VMOD
22	long-term	long-term	B-NP	JJ	O	24	NMOD
23	visual	visual	I-NP	JJ	O	24	NMOD
24	deficits	deficit	I-NP	NNS	O	25	SUB
25	were	be	B-VP	VBD	O	16	SBAR
26	administered	administer	I-VP	VBN	O	25	VC
27	a	a	B-NP	DT	O	30	NMOD
28	full	full	I-NP	JJ	O	29	AMOD
29	neuro-ophthalmologic	neuro-ophthalmologic	I-NP	JJ	O	30	NMOD
30	examination	examination	I-NP	NN	O	26	OBJ
31	including	include	B-PP	VBG	O	30	NMOD
32	visual	visual	B-NP	JJ	O	33	NMOD
33	acuity	acuity	I-NP	NN	O	43	NMOD
34	,	,	O	,	O	43	P
35	color	color	B-NP	NN	O	36	NMOD
36	vision	vision	I-NP	NN	O	43	NMOD
37	,	,	O	,	O	43	P
38	contrast	contrast	B-NP	NN	O	39	NMOD
39	sensitivity	sensitivity	I-NP	NN	O	43	NMOD
40	,	,	O	,	O	43	P
41	and	and	O	CC	O	43	NMOD
42	fundus	fundus	B-NP	NN	O	43	NMOD
43	examination	examination	I-NP	NN	O	31	PMOD
44	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	13	VMOD
2	all	all	B-NP	DT	O	3	NMOD
3	subjects	subject	I-NP	NNS	O	8	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	history	history	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	EMB	EMB	B-NP	NN	B-protein	6	PMOD
8	induced	induce	B-VP	VBD	O	1	SBAR
9	optic	optic	B-NP	JJ	O	10	NMOD
10	neuropathy	neuropathy	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	13	P
12	there	there	B-NP	EX	O	13	SUB
13	was	be	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	16	NMOD
15	mean	mean	I-NP	JJ	O	16	NMOD
16	loss	loss	I-NP	NN	O	13	PRD
17	of	of	B-PP	IN	O	16	NMOD
18	72	72	B-NP	CD	O	19	AMOD
19	%	%	I-NP	NN	O	23	NMOD
20	nerve	nerve	I-NP	NN	O	23	NMOD
21	fiber	fiber	I-NP	NN	O	23	NMOD
22	layer	layer	I-NP	NN	O	23	NMOD
23	thickness	thickness	I-NP	NN	O	17	PMOD
24	in	in	B-PP	IN	O	13	VMOD
25	the	the	B-NP	DT	O	27	NMOD
26	temporal	temporal	I-NP	JJ	O	27	NMOD
27	quadrant	quadrant	I-NP	NN	O	24	PMOD
28	(	(	O	(	O	68	DEP
29	patient	patient	B-NP	NN	O	30	NMOD
30	A	A	I-NP	NN	O	43	NMOD
31	,	,	O	,	O	30	P
32	with	with	B-PP	IN	O	30	NMOD
33	eventual	eventual	B-NP	JJ	O	34	NMOD
34	recovery	recovery	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	visual	visual	B-NP	JJ	O	37	NMOD
37	acuity	acuity	I-NP	NN	O	39	NMOD
38	and	and	I-NP	CC	O	39	NMOD
39	fields	field	I-NP	NNS	O	35	PMOD
40	,	,	O	,	O	43	P
41	58	58	B-NP	CD	O	42	AMOD
42	%	%	I-NP	NN	O	43	NMOD
43	loss	loss	I-NP	NN	O	46	NMOD
44	;	;	O	:	O	46	P
45	patient	patient	B-NP	NN	O	46	NMOD
46	B	B	I-NP	NN	O	55	NMOD
47	,	,	O	,	O	46	P
48	with	with	B-PP	IN	O	46	NMOD
49	intermediate	intermediate	B-NP	JJ	O	51	NMOD
50	visual	visual	I-NP	JJ	O	51	NMOD
51	deficits	deficit	I-NP	NNS	O	48	PMOD
52	,	,	O	,	O	55	P
53	68	68	B-NP	CD	O	54	AMOD
54	%	%	I-NP	NN	O	55	NMOD
55	loss	loss	I-NP	NN	O	58	NMOD
56	;	;	O	:	O	58	P
57	patient	patient	B-NP	NN	O	58	NMOD
58	C	C	I-NP	NN	O	68	DEP
59	,	,	O	,	O	58	P
60	with	with	B-PP	IN	O	58	NMOD
61	chronic	chronic	B-NP	JJ	O	63	NMOD
62	visual	visual	I-NP	JJ	O	63	NMOD
63	deficits	deficit	I-NP	NNS	O	67	NMOD
64	,	,	O	,	O	67	P
65	90	90	B-NP	CD	O	66	AMOD
66	%	%	I-NP	NN	O	67	NMOD
67	loss	loss	I-NP	NN	O	60	PMOD
68	)	)	O	)	O	27	NMOD
69	,	,	O	,	O	13	P
70	with	with	B-PP	IN	O	13	VMOD
71	an	an	B-NP	DT	O	76	NMOD
72	average	average	I-NP	JJ	O	76	NMOD
73	mean	mean	I-NP	JJ	O	76	NMOD
74	optic	optic	I-NP	JJ	O	76	NMOD
75	nerve	nerve	I-NP	NN	O	76	NMOD
76	thickness	thickness	I-NP	NN	O	70	PMOD
77	of	of	B-PP	IN	O	76	NMOD
78	26+/-16	26+/-16	B-NP	CD	O	79	NMOD
79	microm	microm	I-NP	NN	O	77	PMOD
80	.	.	O	.	O	13	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	OCT	OCT	I-NP	NN	B-DNA	5	SUB
5	results	result	B-VP	VBZ	O	1	NMOD
6	in	in	B-PP	IN	O	5	VMOD
7	these	these	B-NP	DT	O	8	NMOD
8	patients	patient	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	EMB	EMB	B-NP	NN	B-protein	9	PMOD
11	induced	induce	B-VP	VBD	O	5	VMOD
12	optic	optic	B-NP	JJ	O	13	NMOD
13	neuropathy	neuropathy	I-NP	NN	O	11	OBJ
14	show	show	B-VP	VBP	O	5	VMOD
15	considerable	considerable	B-NP	JJ	O	16	NMOD
16	loss	loss	I-NP	NN	O	14	OBJ
17	especially	especially	B-ADVP	RB	O	16	NMOD
18	of	of	B-PP	IN	O	17	AMOD
19	the	the	B-NP	DT	O	21	NMOD
20	temporal	temporal	I-NP	JJ	O	21	NMOD
21	fibers	fiber	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	1	P

1	Effects	Effect	B-NP	NNS	O	13	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	7	NMOD
4	cyclooxygenase-2	cyclooxygenase-2	I-NP	NN	B-protein	7	NMOD
5	specific	specific	I-NP	JJ	O	7	NMOD
6	inhibitor	inhibitor	I-NP	NN	O	7	NMOD
7	valdecoxib	valdecoxib	I-NP	NN	O	2	PMOD
8	versus	versus	B-PP	IN	O	7	NMOD
9	nonsteroidal	nonsteroidal	B-NP	JJ	O	11	NMOD
10	antiinflammatory	antiinflammatory	I-NP	JJ	O	11	NMOD
11	agents	agent	I-NP	NNS	O	8	PMOD
12	and	and	O	CC	O	13	NMOD
13	placebo	placebo	B-NP	NN	O	0	ROOT
14	on	on	B-PP	IN	O	13	NMOD
15	cardiovascular	cardiovascular	B-NP	JJ	O	17	NMOD
16	thrombotic	thrombotic	I-NP	JJ	O	17	NMOD
17	events	event	I-NP	NNS	O	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	arthritis	arthritis	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	13	P

1	We	We	B-NP	PRP	O	2	SUB
2	evaluated	evaluate	B-VP	VBD	O	0	ROOT
3	cardiovascular	cardiovascular	B-NP	JJ	O	5	NMOD
4	event	event	I-NP	NN	O	5	NMOD
5	data	datum	I-NP	NNS	O	2	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	valdecoxib	valdecoxib	B-NP	NN	O	12	NMOD
8	,	,	O	,	O	12	P
9	a	a	B-NP	DT	O	12	NMOD
10	new	new	I-NP	JJ	O	12	NMOD
11	COX-2-specific	COX-2-specific	I-NP	JJ	O	12	NMOD
12	inhibitor	inhibitor	I-NP	NN	O	6	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	approximately	approximately	B-NP	RB	O	16	NMOD
15	8000	8000	I-NP	CD	O	14	AMOD
16	patients	patient	I-NP	NNS	O	13	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	osteoarthritis	osteoarthritis	B-NP	NN	O	21	NMOD
19	and	and	O	CC	O	21	NMOD
20	rheumatoid	rheumatoid	B-NP	JJ	O	21	NMOD
21	arthritis	arthritis	I-NP	NN	O	17	PMOD
22	treated	treat	B-VP	VBN	O	21	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	this	this	B-NP	DT	O	25	NMOD
25	agent	agent	I-NP	NN	O	23	PMOD
26	in	in	B-PP	IN	O	22	VMOD
27	randomized	randomize	B-NP	VBN	O	29	NMOD
28	clinical	clinical	I-NP	JJ	O	29	NMOD
29	trials	trial	I-NP	NNS	O	26	PMOD
30	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	19	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cardiovascular	cardiovascular	B-NP	JJ	O	6	NMOD
5	thrombotic	thrombotic	I-NP	JJ	O	6	NMOD
6	events	event	I-NP	NNS	O	3	PMOD
7	(	(	O	(	O	18	DEP
8	cardiac	cardiac	B-NP	JJ	O	12	AMOD
9	,	,	I-NP	,	O	12	P
10	cerebrovascular	cerebrovascular	I-NP	JJ	O	12	AMOD
11	and	and	I-NP	CC	O	12	AMOD
12	peripheral	peripheral	I-NP	JJ	O	13	NMOD
13	vascular	vascular	I-NP	JJ	O	17	NMOD
14	,	,	O	,	O	17	P
15	or	or	O	CC	O	17	NMOD
16	arterial	arterial	B-NP	JJ	O	17	NMOD
17	thrombotic	thrombotic	I-NP	NN	O	18	DEP
18	)	)	O	)	O	6	NMOD
19	was	be	B-VP	VBD	O	0	ROOT
20	determined	determine	I-VP	VBN	O	19	VC
21	by	by	B-PP	IN	O	20	VMOD
22	analyzing	analyze	B-VP	VBG	O	21	PMOD
23	pooled	pool	B-NP	VBN	O	24	NMOD
24	valdecoxib	valdecoxib	I-NP	NN	O	22	OBJ
25	(	(	O	(	O	29	DEP
26	10-80	10-80	B-NP	CD	O	27	NMOD
27	mg	mg	I-NP	NN	O	28	NMOD
28	daily	daily	I-NP	JJ	O	29	DEP
29	)	)	O	)	O	24	NMOD
30	,	,	O	,	O	19	P
31	nonselective	nonselective	B-NP	JJ	O	32	NMOD
32	NSAID	NSAID	I-NP	NN	O	52	NMOD
33	(	(	O	(	O	49	DEP
34	diclofenac	diclofenac	B-NP	NN	O	36	NMOD
35	75	75	I-NP	CD	O	36	NMOD
36	mg	mg	I-NP	NN	O	48	NMOD
37	bid	bid	B-ADVP	RB	O	36	NMOD
38	,	,	O	,	O	48	P
39	ibuprofen	ibuprofen	B-NP	NN	O	42	NMOD
40	800	800	I-NP	CD	O	42	NMOD
41	mg	mg	I-NP	NN	O	42	NMOD
42	tid	tid	I-NP	NN	O	48	NMOD
43	,	,	O	,	O	48	P
44	or	or	O	CC	O	48	NMOD
45	naproxen	naproxen	B-NP	NN	O	47	AMOD
46	500	500	I-NP	CD	O	47	AMOD
47	mg	mg	I-NP	NN	O	48	NMOD
48	bid	bid	I-NP	NN	O	49	DEP
49	)	)	O	)	O	32	NMOD
50	and	and	O	CC	O	52	NMOD
51	placebo	placebo	B-NP	NN	O	52	NMOD
52	data	datum	I-NP	NNS	O	19	VMOD
53	from	from	B-PP	IN	O	52	NMOD
54	10	10	B-NP	CD	O	60	NMOD
55	randomized	randomize	I-NP	VBN	O	60	NMOD
56	osteoarthritis	osteoarthritis	I-NP	NN	O	60	NMOD
57	and	and	I-NP	CC	O	60	NMOD
58	rheumatoid	rheumatoid	I-NP	JJ	O	60	NMOD
59	arthritis	arthritis	I-NP	NN	O	60	NMOD
60	trials	trial	I-NP	NNS	O	53	PMOD
61	that	that	B-NP	WDT	O	60	NMOD
62	were	be	B-VP	VBD	O	61	SBAR
63	6-52	6-52	B-NP	CD	O	64	NMOD
64	weeks	week	I-NP	NNS	O	62	PRD
65	in	in	B-PP	IN	O	62	VMOD
66	duration	duration	B-NP	NN	O	65	PMOD
67	.	.	O	.	O	19	P

1	Crude	Crude	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	exposure-adjusted	exposure-adjusted	I-NP	JJ	O	4	NMOD
4	incidences	incidence	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	thrombotic	thrombotic	B-NP	JJ	O	7	NMOD
7	events	event	I-NP	NNS	O	5	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	similar	similar	B-ADJP	JJ	O	8	PRD
10	for	for	B-PP	IN	O	9	AMOD
11	valdecoxib	valdecoxib	B-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	NSAIDs	NSAID	B-NP	NNS	O	16	NMOD
14	,	,	O	,	O	16	P
15	and	and	O	CC	O	16	NMOD
16	placebo	placebo	B-NP	NN	O	10	PMOD
17	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	risk	risk	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	serious	serious	B-NP	JJ	O	5	AMOD
5	thrombotic	thrombotic	I-NP	JJ	O	6	NMOD
6	events	event	I-NP	NNS	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	also	also	B-ADVP	RB	O	7	VMOD
9	similar	similar	B-ADJP	JJ	O	7	PRD
10	for	for	B-PP	IN	O	9	AMOD
11	each	each	B-NP	DT	O	13	NMOD
12	valdecoxib	valdecoxib	I-NP	NN	O	13	NMOD
13	dose	dose	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	7	P

1	Thrombotic	Thrombotic	B-NP	JJ	B-protein	2	NMOD
2	risk	risk	I-NP	NN	I-protein	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	consistently	consistently	B-ADJP	RB	O	5	AMOD
5	higher	high	I-ADJP	JJR	O	3	PRD
6	for	for	B-PP	IN	O	3	VMOD
7	users	user	B-NP	NNS	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	aspirin	aspirin	B-NP	NN	O	10	NMOD
10	users	user	I-NP	NNS	O	8	PMOD
11	than	than	B-PP	IN	O	3	VMOD
12	nonusers	nonuser	B-NP	NNS	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	aspirin	aspirin	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	39	DEP
16	placebo	placebo	B-NP	NN	O	19	NMOD
17	,	,	O	,	O	19	P
18	1.4	1.4	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	22	NMOD
20	vs.	vs.	B-PP	IN	O	22	NMOD
21	0	0	B-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	38	NMOD
23	;	;	O	:	O	38	P
24	valdecoxib	valdecoxib	B-NP	NN	O	27	NMOD
25	,	,	O	,	O	27	P
26	1.7	1.7	B-NP	CD	O	27	NMOD
27	%	%	I-NP	NN	O	38	NMOD
28	vs.	vs.	B-PP	IN	O	27	NMOD
29	0.2	0.2	B-NP	CD	O	30	NMOD
30	%	%	I-NP	NN	O	28	PMOD
31	;	;	O	:	O	38	P
32	NSAIDs	NSAID	B-NP	NNS	O	35	NMOD
33	,	,	O	,	O	35	P
34	1.9	1.9	B-NP	CD	O	35	NMOD
35	%	%	I-NP	NN	O	38	NMOD
36	vs.	vs.	B-PP	IN	O	38	NMOD
37	0.5	0.5	B-NP	CD	O	38	NMOD
38	%	%	I-NP	NN	O	39	DEP
39	)	)	O	)	O	14	NMOD
40	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	7	NMOD
2	randomized	randomize	I-NP	VBN	O	6	AMOD
3	,	,	I-NP	,	O	6	P
4	placebo-controlled	placebo-controlled	I-NP	JJ	O	6	AMOD
5	,	,	I-NP	,	O	6	P
6	crossover	crossover	I-NP	JJ	O	7	NMOD
7	study	study	I-NP	NN	O	12	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	ephedrine	ephedrine	B-NP	NN	O	8	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	SSRI	SSRI	B-NP	NN	B-protein	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	female	female	B-NP	JJ	O	15	NMOD
14	sexual	sexual	I-NP	JJ	O	15	NMOD
15	dysfunction	dysfunction	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	objective	objective	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	PRD
9	whether	whether	B-SBAR	IN	O	8	VMOD
10	ephedrine	ephedrine	B-NP	NN	O	16	NMOD
11	,	,	O	,	O	16	P
12	an	an	B-NP	DT	O	16	NMOD
13	alpha-	alpha-	I-NP	NN	O	16	NMOD
14	and	and	I-NP	CC	O	16	NMOD
15	beta-adrenergic	beta-adrenergic	I-NP	JJ	O	16	NMOD
16	agonist	agonist	I-NP	NN	O	27	SUB
17	previously	previously	B-VP	RB	O	18	VMOD
18	shown	show	I-VP	VBN	O	16	NMOD
19	to	to	I-VP	TO	O	20	VMOD
20	enhance	enhance	I-VP	VB	O	18	VMOD
21	genital	genital	B-NP	JJ	O	23	NMOD
22	blood	blood	I-NP	NN	O	23	NMOD
23	flow	flow	I-NP	NN	O	20	OBJ
24	in	in	B-PP	IN	O	23	NMOD
25	women	woman	B-NP	NNS	O	24	PMOD
26	,	,	O	,	O	16	P
27	has	have	B-VP	VBZ	O	9	SBAR
28	beneficial	beneficial	B-NP	JJ	O	29	NMOD
29	effects	effect	I-NP	NNS	O	27	OBJ
30	in	in	B-PP	IN	O	27	VMOD
31	reversing	reverse	B-VP	VBG	O	30	PMOD
32	antidepressant	antidepressant	B-NP	NN	O	31	OBJ
33	induced	induce	B-VP	VBD	O	27	VMOD
34	sexual	sexual	B-NP	JJ	O	35	NMOD
35	dysfunction	dysfunction	I-NP	NN	O	33	OBJ
36	.	.	O	.	O	6	P

1	Nineteen	Nineteen	B-NP	CD	O	4	NMOD
2	sexually	sexually	I-NP	RB	O	3	AMOD
3	dysfunctional	dysfunctional	I-NP	JJ	O	4	NMOD
4	women	woman	I-NP	NNS	O	13	SUB
5	receiving	receive	B-VP	VBG	O	4	NMOD
6	either	either	O	CC	O	12	NMOD
7	fluoxetine	fluoxetine	B-NP	NN	O	12	NMOD
8	,	,	O	,	O	12	P
9	sertraline	sertraline	B-NP	NN	O	12	NMOD
10	,	,	O	,	O	12	P
11	or	or	O	CC	O	12	NMOD
12	paroxetine	paroxetine	B-NP	NN	O	5	OBJ
13	participated	participate	B-VP	VBD	O	0	ROOT
14	in	in	B-PP	IN	O	13	VMOD
15	an	an	B-NP	DT	O	23	NMOD
16	eight-week	eight-week	I-NP	JJ	O	22	AMOD
17	,	,	I-NP	,	O	22	P
18	double-blind	double-blind	I-NP	JJ	O	22	AMOD
19	,	,	I-NP	,	O	22	P
20	placebo-controlled	placebo-controlled	I-NP	JJ	O	22	AMOD
21	,	,	I-NP	,	O	22	P
22	cross-over	cross-over	I-NP	JJ	O	23	NMOD
23	study	study	I-NP	NN	O	14	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	effects	effect	I-NP	NNS	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	ephedrine	ephedrine	B-NP	NN	O	27	PMOD
29	(	(	O	(	O	32	DEP
30	50	50	B-NP	CD	O	31	NMOD
31	mg	mg	I-NP	NN	O	32	DEP
32	)	)	O	)	O	28	NMOD
33	on	on	B-PP	IN	O	26	NMOD
34	self-report	self-report	B-NP	JJ	O	35	NMOD
35	measures	measure	I-NP	NNS	O	33	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	sexual	sexual	B-NP	JJ	O	38	NMOD
38	desire	desire	I-NP	NN	O	46	NMOD
39	,	,	O	,	O	46	P
40	arousal	arousal	B-NP	NN	O	46	NMOD
41	,	,	O	,	O	46	P
42	orgasm	orgasm	B-NP	NN	O	46	NMOD
43	,	,	O	,	O	46	P
44	and	and	O	CC	O	46	NMOD
45	sexual	sexual	B-NP	JJ	O	46	NMOD
46	satisfaction	satisfaction	I-NP	NN	O	36	PMOD
47	.	.	O	.	O	13	P

1	Potential	Potential	B-NP	JJ	O	2	AMOD
2	therapeutic	therapeutic	I-NP	JJ	O	3	NMOD
3	use	use	I-NP	NN	O	16	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	10	NMOD
6	selective	selective	I-NP	JJ	O	10	NMOD
7	dopamine	dopamine	I-NP	NN	O	10	NMOD
8	D1	D1	I-NP	NN	O	10	NMOD
9	receptor	receptor	I-NP	NN	O	10	NMOD
10	agonist	agonist	I-NP	NN	O	12	NMOD
11	,	,	O	,	O	12	P
12	A-86929	A-86929	B-NP	NN	O	4	PMOD
13	:	:	O	:	O	3	P
14	an	an	B-NP	DT	O	16	NMOD
15	acute	acute	I-NP	JJ	O	16	NMOD
16	study	study	I-NP	NN	O	0	ROOT
17	in	in	B-PP	IN	O	16	NMOD
18	parkinsonian	parkinsonian	B-NP	JJ	O	20	NMOD
19	levodopa-primed	levodopa-primed	I-NP	JJ	O	20	NMOD
20	monkeys	monkey	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	3	NMOD
2	clinical	clinical	I-NP	JJ	O	3	NMOD
3	utility	utility	I-NP	NN	O	22	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	dopamine	dopamine	B-NP	NN	O	11	NMOD
6	(	(	O	(	O	8	DEP
7	DA	DA	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	D1	D1	B-NP	NN	O	11	NMOD
10	receptor	receptor	I-NP	NN	O	11	NMOD
11	agonists	agonist	I-NP	NNS	O	4	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	Parkinson	Parkinson	B-NP	NNP	O	17	NMOD
17	's	's	B-NP	POS	O	18	NMOD
18	disease	disease	I-NP	NN	O	15	PMOD
19	(	(	O	(	O	21	DEP
20	PD	PD	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	is	be	B-VP	VBZ	O	0	ROOT
23	still	still	B-ADVP	RB	O	22	VMOD
24	unclear	unclear	B-ADJP	JJ	O	22	PRD
25	.	.	O	.	O	22	P

1	We	We	B-NP	PRP	O	3	SUB
2	therefore	therefore	B-ADVP	RB	O	3	VMOD
3	conducted	conduct	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	8	NMOD
5	present	present	I-NP	JJ	O	8	NMOD
6	acute	acute	I-NP	JJ	O	8	NMOD
7	dose-response	dose-response	I-NP	JJ	O	8	NMOD
8	study	study	I-NP	NN	O	3	OBJ
9	in	in	B-PP	IN	O	3	VMOD
10	four	four	B-NP	CD	O	23	NMOD
11	1-methyl-4-phenyl-1	1-methyl-4-phenyl-1	I-NP	CD	O	10	NMOD
12	,	,	I-NP	,	O	23	P
13	2	2	I-NP	CD	O	23	NMOD
14	,	,	I-NP	,	O	23	P
15	3	3	I-NP	CD	O	23	NMOD
16	,	,	O	,	O	23	P
17	6-tetrahydropyridine	6-tetrahydropyridine	B-NP	NN	O	23	NMOD
18	(	(	O	(	O	20	DEP
19	MPTP	MPTP	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	-exposed	-exposed	B-NP	JJ	O	23	NMOD
22	cynomolgus	cynomolgus	I-NP	NN	O	23	NMOD
23	monkeys	monkey	I-NP	NNS	O	9	PMOD
24	primed	prim	B-VP	VBN	O	23	NMOD
25	to	to	B-VP	TO	O	26	VMOD
26	exhibit	exhibit	I-VP	VB	O	24	VMOD
27	levodopa	levodopa	B-NP	NN	O	29	NMOD
28	induced	induced	I-NP	JJ	O	29	NMOD
29	dyskinesias	dyskinesia	I-NP	NNS	O	26	OBJ
30	to	to	B-VP	TO	O	31	VMOD
31	evaluate	evaluate	I-VP	VB	O	29	NMOD
32	the	the	B-NP	DT	O	36	NMOD
33	locomotor	locomotor	I-NP	NN	O	36	NMOD
34	and	and	O	CC	O	36	NMOD
35	dyskinetic	dyskinetic	B-NP	JJ	O	36	NMOD
36	effects	effect	I-NP	NNS	O	31	OBJ
37	on	on	B-PP	IN	O	36	NMOD
38	challenge	challenge	B-NP	NN	O	37	PMOD
39	with	with	B-PP	IN	O	31	VMOD
40	four	four	B-NP	CD	O	41	NMOD
41	doses	dose	I-NP	NNS	O	59	NMOD
42	(	(	O	(	O	48	DEP
43	from	from	B-PP	IN	O	48	DEP
44	0.03	0.03	B-NP	CD	O	43	AMOD
45	to	to	I-NP	TO	O	43	AMOD
46	1.0	1.0	I-NP	CD	O	43	AMOD
47	mg/kg	mg/kg	I-NP	NN	O	43	PMOD
48	)	)	O	)	O	41	NMOD
49	of	of	B-PP	IN	O	41	NMOD
50	A-86929	A-86929	B-NP	NN	O	49	PMOD
51	(	(	O	(	O	54	DEP
52	[	[	O	(	O	53	DEP
53	-	-	O	HYPH	O	54	DEP
54	]	]	O	)	O	41	NMOD
55	-	-	B-NP	HYPH	O	59	P
56	[	[	I-NP	(	O	59	NMOD
57	5aR	5aR	I-NP	NN	O	59	NMOD
58	,	,	I-NP	,	O	59	P
59	11bS	11bS	I-NP	NN	O	87	NMOD
60	]	]	I-NP	)	O	59	NMOD
61	-4	-4	I-NP	CD	O	59	NMOD
62	,	,	I-NP	,	O	59	P
63	5	5	I-NP	CD	O	59	NMOD
64	,	,	I-NP	,	O	87	P
65	5a	5a	I-NP	CD	O	87	NMOD
66	,	,	I-NP	,	O	87	P
67	6	6	I-NP	CD	O	87	NMOD
68	,	,	I-NP	,	O	87	P
69	7	7	I-NP	CD	O	87	NMOD
70	,	,	I-NP	,	O	87	P
71	11b-hexahydro-2-propyl-3-thia-5-+	11b-hexahydro-2-propyl-3-thia-5-+	I-NP	JJ	O	87	NMOD
72	++azacyclopent-1-	++azacyclopent-1-	I-NP	CC	O	87	NMOD
73	ena	ena	I-NP	NN	O	87	NMOD
74	[	[	I-NP	(	O	78	DEP
75	c	c	I-NP	NN	O	77	NMOD
76	]	]	I-NP	)	O	77	NMOD
77	phenathrene-9-10-diol	phenathrene-9-10-diol	I-NP	NN	O	78	DEP
78	)	)	O	)	O	73	NMOD
79	,	,	O	,	O	87	P
80	a	a	B-NP	DT	O	87	NMOD
81	selective	selective	I-NP	JJ	O	87	NMOD
82	and	and	I-NP	CC	O	87	NMOD
83	full	full	I-NP	JJ	O	84	AMOD
84	DA	DA	I-NP	NN	O	87	NMOD
85	D1-like	D1-like	I-NP	JJ	O	84	AMOD
86	receptor	receptor	I-NP	NN	O	87	NMOD
87	agonist	agonist	I-NP	NN	O	39	PMOD
88	with	with	B-PP	IN	O	87	NMOD
89	an	an	B-NP	DT	O	91	NMOD
90	intermediate	intermediate	I-NP	JJ	O	91	NMOD
91	duration	duration	I-NP	NN	O	88	PMOD
92	of	of	B-PP	IN	O	91	NMOD
93	action	action	B-NP	NN	O	92	PMOD
94	.	.	O	.	O	3	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	A-86929	A-86929	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	as	as	B-ADJP	RB	O	7	AMOD
7	efficacious	efficacious	I-ADJP	JJ	O	5	PRD
8	in	in	B-PP	IN	O	7	AMOD
9	alleviating	alleviate	B-VP	VBG	O	8	PMOD
10	MPTP	MPTP	B-NP	NN	B-protein	9	OBJ
11	induced	induce	B-VP	VBD	O	5	VMOD
12	parkinsonism	parkinsonism	B-NP	NN	O	11	OBJ
13	as	as	B-PP	IN	O	11	VMOD
14	levodopa	levodopa	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	LY-171555	LY-171555	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	5	P
18	but	but	O	CC	O	5	VMOD
19	was	be	B-VP	VBD	O	5	VMOD
20	less	less	B-ADJP	RBR	O	21	AMOD
21	likely	likely	I-ADJP	JJ	O	19	PRD
22	to	to	B-VP	TO	O	23	VMOD
23	reproduce	reproduce	I-VP	VB	O	21	AMOD
24	the	the	B-NP	DT	O	25	NMOD
25	levodopa	levodopa	I-NP	NN	O	26	SUB
26	induced	induce	B-VP	VBD	O	23	VMOD
27	dyskinesias	dyskinesia	B-NP	NNS	O	26	OBJ
28	in	in	B-PP	IN	O	27	NMOD
29	these	these	B-NP	DT	O	30	NMOD
30	animals	animal	I-NP	NNS	O	28	PMOD
31	than	than	B-PP	IN	O	27	NMOD
32	with	with	B-PP	IN	O	31	PMOD
33	either	either	O	CC	O	37	NMOD
34	LY-171555	LY-171555	B-NP	NN	O	37	NMOD
35	or	or	O	CC	O	37	NMOD
36	subsequent	subsequent	B-NP	JJ	O	37	NMOD
37	challenge	challenge	I-NP	NN	O	32	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	levodopa	levodopa	B-NP	NN	O	38	PMOD
40	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	3	NMOD
2	CD50	CD50	I-NP	NN	B-protein	3	NMOD
3	dose	dose	I-NP	NN	O	16	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	local	local	B-NP	JJ	O	9	NMOD
6	anesthetic	anesthetic	I-NP	JJ	O	9	NMOD
7	(	(	O	(	O	9	NMOD
8	causing	cause	B-VP	VBG	O	9	NMOD
9	convulsions	convulsion	B-NP	NNS	O	4	PMOD
10	in	in	B-PP	IN	O	3	NMOD
11	50	50	B-NP	CD	O	12	NMOD
12	%	%	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	mice	mouse	B-NP	NNS	O	13	PMOD
15	)	)	O	)	O	12	NMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	fatal	fatal	B-ADJP	JJ	O	16	PRD
18	in	in	B-PP	IN	O	17	AMOD
19	90	90	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	bupivacaine	bupivacaine	B-NP	NN	O	24	NMOD
23	induced	induce	I-NP	VBN	O	24	NMOD
24	seizures	seizure	I-NP	NNS	O	21	PMOD
25	,	,	O	,	O	16	P
26	in	in	B-PP	IN	O	16	VMOD
27	57	57	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	32	NMOD
31	chloroprocaine	chloroprocaine	I-NP	NN	O	32	NMOD
32	group	group	I-NP	NN	O	29	PMOD
33	,	,	O	,	O	16	VMOD
34	and	and	O	CC	O	33	VMOD
35	in	in	B-PP	IN	O	34	PRD
36	6	6	B-NP	CD	O	37	NMOD
37	%	%	I-NP	NN	O	35	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	the	the	B-NP	DT	O	41	NMOD
40	lidocaine	lidocaine	I-NP	NN	O	41	NMOD
41	group	group	I-NP	NN	O	38	PMOD
42	.	.	O	.	O	16	P

1	Myoclonic	Myoclonic	B-NP	JJ	O	7	NMOD
2	,	,	I-NP	,	O	7	P
3	atonic	atonic	I-NP	JJ	O	7	NMOD
4	,	,	O	,	O	7	P
5	and	and	O	CC	O	7	NMOD
6	absence	absence	B-NP	NN	O	7	NMOD
7	seizures	seizure	I-NP	NNS	O	0	ROOT
8	following	follow	B-PP	VBG	O	7	NMOD
9	institution	institution	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	carbamazepine	carbamazepine	B-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	children	child	B-NP	NNS	O	13	PMOD
15	.	.	O	.	O	7	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	children	child	I-NP	NNS	O	16	SUB
3	,	,	O	,	O	2	P
4	aged	age	B-VP	VBN	O	2	NMOD
5	3	3	B-NP	CD	O	7	AMOD
6	to	to	I-NP	TO	O	7	AMOD
7	11	11	I-NP	CD	O	8	NMOD
8	years	year	I-NP	NNS	O	4	AMOD
9	,	,	O	,	O	2	P
10	treated	treat	B-VP	VBN	O	2	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	carbamazepine	carbamazepine	B-NP	NN	O	11	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	epilepsy	epilepsy	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	2	P
16	had	have	B-VP	VBD	O	0	ROOT
17	an	an	B-NP	DT	O	20	NMOD
18	acute	acute	I-NP	JJ	O	19	AMOD
19	aberrant	aberrant	I-NP	JJ	O	20	NMOD
20	reaction	reaction	I-NP	NN	O	16	OBJ
21	characterized	characterize	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	onset	onset	I-NP	NN	O	36	NMOD
25	of	of	B-PP	IN	O	24	NMOD
26	myoclonic	myoclonic	B-NP	JJ	O	28	AMOD
27	,	,	I-NP	,	O	28	P
28	atypical	atypical	I-NP	JJ	O	29	NMOD
29	absence	absence	I-NP	NN	O	25	PMOD
30	and/or	and/or	O	CC	O	36	NMOD
31	atonic	atonic	O	JJ	O	36	NMOD
32	(	(	O	(	O	35	DEP
33	minor	minor	B-NP	JJ	O	34	NMOD
34	motor	motor	I-NP	NN	O	35	DEP
35	)	)	O	)	O	31	AMOD
36	seizures	seizure	B-NP	NNS	O	22	PMOD
37	within	within	B-PP	IN	O	36	NMOD
38	a	a	B-NP	DT	O	40	NMOD
39	few	few	I-NP	JJ	O	40	NMOD
40	days	day	I-NP	NNS	O	37	PMOD
41	.	.	O	.	O	16	P

1	Naloxone	Naloxone	B-NP	NN	O	2	NMOD
2	reversal	reversal	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	hypotension	hypotension	B-NP	NN	O	3	PMOD
5	due	due	B-ADJP	JJ	O	2	NMOD
6	to	to	B-VP	TO	O	7	VMOD
7	captopril	captopril	I-VP	VB	O	5	AMOD
8	overdose	overdose	B-ADVP	RB	O	7	VMOD
9	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	opioid	opioid	I-NP	JJ	O	4	NMOD
3	antagonist	antagonist	I-NP	NN	O	4	NMOD
4	naloxone	naloxone	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	shown	show	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	block	block	I-VP	VB	O	7	VMOD
10	or	or	I-VP	CC	O	9	VMOD
11	reverse	reverse	I-VP	VB	O	9	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	hypotensive	hypotensive	I-NP	JJ	O	14	NMOD
14	actions	action	I-NP	NNS	O	11	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	captopril	captopril	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	an	an	B-NP	DT	O	9	NMOD
7	intentional	intentional	I-NP	JJ	O	9	NMOD
8	captopril	captopril	I-NP	NN	O	9	NMOD
9	overdose	overdose	I-NP	NN	O	5	PMOD
10	,	,	O	,	O	4	P
11	manifested	manifest	B-VP	VBN	O	4	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	marked	marked	B-NP	JJ	O	14	NMOD
14	hypotension	hypotension	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	4	P
16	that	that	B-NP	WDT	O	4	NMOD
17	resolved	resolve	B-VP	VBD	O	16	SBAR
18	promptly	promptly	B-ADVP	RB	O	17	VMOD
19	with	with	B-PP	IN	O	17	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	administration	administration	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	naloxone	naloxone	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	2	P

1	To	To	B-PP	TO	O	6	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	this	this	B-NP	DT	O	6	SUB
6	is	be	B-VP	VBZ	O	13	VMOD
7	the	the	B-NP	DT	O	10	NMOD
8	first	first	I-NP	JJ	O	10	NMOD
9	reported	report	I-NP	VBN	O	10	NMOD
10	case	case	I-NP	NN	O	13	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	captopril	captopril	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	hypotension	hypotension	B-NP	NN	O	13	OBJ
15	treated	treat	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	naloxone	naloxone	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	13	P

1	Carbamazepine	Carbamazepine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cardiac	cardiac	B-NP	JJ	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	14	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	sinus	sinus	B-NP	NN	O	5	NMOD
5	bradycardia	bradycardia	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	atrioventricular	atrioventricular	B-NP	JJ	O	8	NMOD
8	block	block	I-NP	NN	O	3	PMOD
9	,	,	O	,	O	2	P
10	induced	induce	B-VP	VBN	O	2	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	carbamazepine	carbamazepine	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	2	P
14	prompted	prompt	B-VP	VBD	O	0	ROOT
15	an	an	B-NP	DT	O	18	NMOD
16	extensive	extensive	I-NP	JJ	O	18	NMOD
17	literature	literature	I-NP	NN	O	18	NMOD
18	review	review	I-NP	NN	O	14	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	all	all	B-NP	DT	O	23	NMOD
21	previously	previously	I-NP	RB	O	22	AMOD
22	reported	report	I-NP	VBN	O	23	NMOD
23	cases	case	I-NP	NNS	O	19	PMOD
24	.	.	O	.	O	14	P

1	From	From	B-PP	IN	O	15	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	analysis	analysis	I-NP	NN	O	15	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	these	these	B-NP	DT	O	6	NMOD
6	cases	case	I-NP	NNS	O	10	NMOD
7	,	,	O	,	O	10	P
8	two	two	B-NP	CD	O	10	NMOD
9	distinct	distinct	I-NP	JJ	O	10	NMOD
10	forms	form	I-NP	NNS	O	4	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	carbamazepine-associated	carbamazepine-associated	B-NP	JJ	O	14	NMOD
13	cardiac	cardiac	I-NP	JJ	O	14	NMOD
14	dysfunction	dysfunction	I-NP	NN	O	11	PMOD
15	emerged	emerge	B-VP	VBD	O	0	ROOT
16	.	.	O	.	O	15	P

1	One	One	B-NP	CD	O	3	NMOD
2	patient	patient	I-NP	NN	O	3	NMOD
3	group	group	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	sinus	sinus	B-NP	NN	O	6	NMOD
6	tachycardias	tachycardia	I-NP	NNS	O	4	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	setting	setting	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	14	NMOD
12	massive	massive	I-NP	JJ	O	14	NMOD
13	carbamazepine	carbamazepine	I-NP	NN	O	14	NMOD
14	overdose	overdose	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	second	second	I-NP	JJ	O	3	NMOD
3	group	group	I-NP	NN	O	4	SUB
4	consisted	consist	B-VP	VBD	O	0	ROOT
5	almost	almost	B-ADVP	RB	O	4	VMOD
6	exclusively	exclusively	I-ADVP	RB	O	5	AMOD
7	of	of	B-PP	IN	O	5	AMOD
8	elderly	elderly	B-NP	JJ	O	9	NMOD
9	women	woman	I-NP	NNS	O	7	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	developed	develop	B-VP	VBD	O	10	SBAR
12	potentially	potentially	B-NP	RB	O	13	AMOD
13	life-threatening	life-threatening	I-NP	JJ	O	14	NMOD
14	bradyarrhythmias	bradyarrhythmia	I-NP	NNS	O	18	NMOD
15	or	or	O	CC	O	18	NMOD
16	atrioventricular	atrioventricular	B-NP	JJ	O	18	NMOD
17	conduction	conduction	I-NP	NN	O	18	NMOD
18	delay	delay	I-NP	NN	O	11	OBJ
19	,	,	O	,	O	4	P
20	associated	associate	B-VP	VBN	O	4	VMOD
21	with	with	B-PP	IN	O	20	VMOD
22	either	either	O	CC	O	29	NMOD
23	therapeutic	therapeutic	B-ADJP	JJ	O	29	NMOD
24	or	or	O	CC	O	29	NMOD
25	modestly	modestly	B-NP	RB	O	26	AMOD
26	elevated	elevated	I-NP	JJ	O	29	NMOD
27	carbamazepine	carbamazepine	I-NP	NN	O	29	NMOD
28	serum	serum	I-NP	NN	O	29	NMOD
29	levels	level	I-NP	NNS	O	21	PMOD
30	.	.	O	.	O	4	P

1	Glutamatergic	Glutamatergic	B-NP	JJ	O	2	NMOD
2	neurotransmission	neurotransmission	I-NP	NN	O	11	SUB
3	mediated	mediate	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	NMDA	NMDA	B-NP	NN	B-protein	6	NMOD
6	receptors	receptor	I-NP	NNS	I-protein	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	inferior	inferior	I-NP	JJ	O	10	NMOD
10	colliculus	colliculus	I-NP	NN	O	7	PMOD
11	can	can	B-VP	MD	O	0	ROOT
12	modulate	modulate	I-VP	VB	O	11	VC
13	haloperidol	haloperidol	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	catalepsy	catalepsy	I-NP	NN	O	12	OBJ
16	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	examined	examine	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	influence	influence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	excitatory	excitatory	B-NP	JJ	O	11	NMOD
9	amino	amino	I-NP	JJ	O	11	NMOD
10	acid-mediated	acid-mediated	I-NP	JJ	O	11	NMOD
11	mechanisms	mechanism	I-NP	NNS	O	7	PMOD
12	in	in	B-PP	IN	O	6	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	IC	IC	I-NP	NN	O	12	PMOD
15	on	on	B-PP	IN	O	6	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	catalepsy	catalepsy	I-NP	NN	O	15	PMOD
18	induced	induce	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	the	the	B-NP	DT	O	24	NMOD
21	dopamine	dopamine	I-NP	NN	O	24	NMOD
22	receptor	receptor	I-NP	NN	O	24	NMOD
23	blocker	blocker	I-NP	NN	O	24	NMOD
24	haloperidol	haloperidol	I-NP	NN	O	19	PMOD
25	administered	administer	B-VP	VBN	O	24	NMOD
26	systemically	systemically	B-ADVP	RB	O	25	VMOD
27	(	(	O	(	O	32	DEP
28	1	1	B-NP	CD	O	30	AMOD
29	or	or	I-NP	CC	O	30	AMOD
30	0.5	0.5	I-NP	CD	O	31	NMOD
31	mg/kg	mg/kg	I-NP	NN	O	32	DEP
32	)	)	O	)	O	26	AMOD
33	in	in	B-PP	IN	O	25	VMOD
34	rats	rat	B-NP	NNS	O	33	PMOD
35	.	.	O	.	O	4	P

1	Haloperidol	Haloperidol	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	catalepsy	catalepsy	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	challenged	challenge	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	prior	prior	B-NP	JJ	O	9	NMOD
8	intracollicular	intracollicular	I-NP	JJ	O	9	NMOD
9	microinjections	microinjection	I-NP	NNS	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	glutamate	glutamate	B-NP	NN	O	14	NMOD
12	NMDA	NMDA	I-NP	NN	O	14	NMOD
13	receptor	receptor	I-NP	NN	O	14	NMOD
14	antagonists	antagonist	I-NP	NNS	O	25	NMOD
15	,	,	O	,	O	25	P
16	MK-801	MK-801	B-NP	NN	B-protein	25	NMOD
17	(	(	O	(	O	23	DEP
18	15	15	B-NP	CD	O	20	AMOD
19	or	or	I-NP	CC	O	20	AMOD
20	30	30	I-NP	CD	O	22	NMOD
21	mmol/0.5	mmol/0.5	I-NP	NN	O	22	NMOD
22	microl	microl	I-NP	NN	O	23	DEP
23	)	)	O	)	O	16	NMOD
24	and	and	O	CC	O	25	NMOD
25	AP7	AP7	B-NP	NN	B-protein	10	PMOD
26	(	(	O	(	O	32	DEP
27	10	10	B-NP	CD	O	29	AMOD
28	or	or	I-NP	CC	O	29	AMOD
29	20	20	I-NP	CD	O	31	NMOD
30	nmol/0.5	nmol/0.5	I-NP	NN	O	31	NMOD
31	microl	microl	I-NP	NN	O	32	DEP
32	)	)	O	)	O	25	NMOD
33	,	,	O	,	O	6	P
34	or	or	O	CC	O	6	PMOD
35	of	of	B-PP	IN	O	6	PMOD
36	the	the	B-NP	DT	O	40	NMOD
37	NMDA	NMDA	I-NP	NN	B-protein	40	NMOD
38	receptor	receptor	I-NP	NN	I-protein	40	NMOD
39	agonist	agonist	I-NP	NN	O	40	NMOD
40	N-methyl-d-aspartate	N-methyl-d-aspartate	I-NP	NN	O	35	PMOD
41	(	(	O	(	O	49	DEP
42	NMDA	NMDA	B-NP	NN	B-protein	48	NMOD
43	,	,	O	,	O	48	P
44	20	20	B-NP	CD	O	46	AMOD
45	or	or	I-NP	CC	O	46	AMOD
46	30	30	I-NP	CD	O	48	NMOD
47	nmol/0.5	nmol/0.5	I-NP	NN	O	48	NMOD
48	microl	microl	I-NP	NN	O	49	DEP
49	)	)	O	)	O	40	NMOD
50	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	showed	show	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	intracollicular	intracollicular	B-NP	JJ	O	6	NMOD
6	microinjection	microinjection	I-NP	NN	O	18	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	MK-801	MK-801	B-NP	NN	B-protein	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	AP7	AP7	I-NP	NN	B-protein	7	PMOD
11	previous	previous	B-ADJP	JJ	O	10	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	systemic	systemic	B-NP	JJ	O	14	NMOD
14	injections	injection	I-NP	NNS	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	haloperidol	haloperidol	B-NP	NN	O	15	PMOD
17	significantly	significantly	B-ADVP	RB	O	18	VMOD
18	attenuated	attenuate	B-VP	VBD	O	4	SBAR
19	the	the	B-NP	DT	O	20	NMOD
20	catalepsy	catalepsy	I-NP	NN	O	18	OBJ
21	,	,	O	,	O	18	P
22	as	as	B-SBAR	IN	O	18	VMOD
23	indicated	indicate	B-VP	VBN	O	22	SBAR
24	by	by	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	27	NMOD
26	reduced	reduce	I-NP	VBN	O	27	NMOD
27	latency	latency	I-NP	NN	O	24	PMOD
28	to	to	B-VP	TO	O	29	VMOD
29	step	step	I-VP	VB	O	23	VMOD
30	down	down	B-PRT	RP	O	29	VMOD
31	from	from	B-PP	IN	O	29	VMOD
32	a	a	B-NP	DT	O	34	NMOD
33	horizontal	horizontal	I-NP	JJ	O	34	NMOD
34	bar	bar	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	3	P

1	Metabotropic	Metabotropic	B-NP	JJ	O	5	NMOD
2	glutamate	glutamate	I-NP	NN	O	5	NMOD
3	7	7	I-NP	CD	O	5	NMOD
4	receptor	receptor	I-NP	NN	O	5	NMOD
5	subtype	subtype	I-NP	NN	O	6	SUB
6	modulates	modulate	B-VP	VBZ	O	0	ROOT
7	motor	motor	B-NP	NN	O	8	NMOD
8	symptoms	symptom	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	rodent	rodent	B-NP	NN	O	11	NMOD
11	models	model	I-NP	NNS	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	Parkinson	Parkinson	B-NP	NNP	O	15	NMOD
14	's	's	B-NP	POS	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	6	P

1	Metabotropic	Metabotropic	B-NP	JJ	B-protein	6	NMOD
2	glutamate	glutamate	I-NP	NN	I-protein	6	NMOD
3	(	(	O	(	I-protein	6	NMOD
4	mGlu	mGlu	B-NP	NN	I-protein	6	NMOD
5	)	)	O	)	I-protein	6	NMOD
6	receptors	receptor	B-NP	NNS	I-protein	7	SUB
7	modulate	modulate	B-VP	VBP	O	0	ROOT
8	synaptic	synaptic	B-NP	JJ	O	9	NMOD
9	transmission	transmission	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	the	the	B-NP	DT	O	14	NMOD
12	central	central	I-NP	JJ	O	14	NMOD
13	nervous	nervous	I-NP	JJ	O	14	NMOD
14	system	system	I-NP	NN	O	10	PMOD
15	and	and	O	CC	O	7	VMOD
16	represent	represent	B-VP	VBP	O	7	VMOD
17	promising	promising	B-NP	JJ	O	18	AMOD
18	therapeutic	therapeutic	I-NP	JJ	O	19	NMOD
19	targets	target	I-NP	NNS	O	16	OBJ
20	for	for	B-PP	IN	O	19	NMOD
21	symptomatic	symptomatic	B-NP	JJ	O	22	NMOD
22	treatment	treatment	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	Parkinson	Parkinson	B-NP	NNP	O	25	NMOD
25	's	's	B-NP	POS	O	26	NMOD
26	disease	disease	I-NP	NN	O	23	PMOD
27	(	(	O	(	O	29	DEP
28	PD	PD	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	23	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	N	N	B-NP	NN	O	18	NMOD
5	,	,	O	,	O	18	P
6	N'-dibenzhydrylethane-1	N'-dibenzhydrylethane-1	B-NP	NN	O	18	NMOD
7	,	,	O	,	O	18	P
8	2-diamine	2-diamine	B-NP	NN	O	9	NMOD
9	dihydrochloride	dihydrochloride	I-NP	NN	O	18	NMOD
10	(	(	O	(	O	12	DEP
11	AMN082	AMN082	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	,	,	O	,	O	18	P
14	the	the	B-NP	DT	O	18	NMOD
15	first	first	I-NP	JJ	O	18	NMOD
16	selective	selective	I-NP	JJ	O	18	NMOD
17	allosteric	allosteric	I-NP	JJ	O	18	NMOD
18	activator	activator	I-NP	NN	O	3	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	mGlu7	mGlu7	B-NP	NN	B-protein	21	NMOD
21	receptors	receptor	I-NP	NNS	I-protein	19	PMOD
22	,	,	O	,	O	2	P
23	were	be	B-VP	VBD	O	0	ROOT
24	thus	thus	I-VP	RB	O	23	VMOD
25	tested	test	I-VP	VBN	O	23	VC
26	in	in	B-PP	IN	O	25	VMOD
27	different	different	B-NP	JJ	O	29	NMOD
28	rodent	rodent	I-NP	NN	O	29	NMOD
29	models	model	I-NP	NNS	O	26	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	PD	PD	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	23	P

1	Here	Here	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	show	show	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	oral	oral	B-NP	JJ	O	13	NMOD
7	(	(	O	(	O	10	DEP
8	5	5	B-NP	CD	O	9	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	or	or	O	CC	O	13	NMOD
12	intrastriatal	intrastriatal	B-NP	JJ	O	13	NMOD
13	administration	administration	I-NP	NN	O	22	SUB
14	(	(	O	(	O	19	DEP
15	0.1	0.1	B-NP	CD	O	17	AMOD
16	and	and	I-NP	CC	O	17	AMOD
17	0.5	0.5	I-NP	CD	O	18	NMOD
18	nmol	nmol	I-NP	NN	O	19	DEP
19	)	)	O	)	O	13	NMOD
20	of	of	B-PP	IN	O	13	NMOD
21	AMN082	AMN082	B-NP	NN	B-protein	20	PMOD
22	reverses	reverse	B-VP	VBZ	O	5	SBAR
23	haloperidol	haloperidol	B-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	catalepsy	catalepsy	I-NP	NN	O	22	OBJ
26	in	in	B-PP	IN	O	25	NMOD
27	rats	rat	B-NP	NNS	O	26	PMOD
28	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	20	VMOD
2	a	a	B-NP	DT	O	5	NMOD
3	more	more	I-NP	RBR	O	4	AMOD
4	complex	complex	I-NP	JJ	O	5	NMOD
5	task	task	I-NP	NN	O	1	PMOD
6	commonly	commonly	B-VP	RB	O	7	VMOD
7	used	use	I-VP	VBN	O	5	NMOD
8	to	to	B-VP	TO	O	9	VMOD
9	evaluate	evaluate	I-VP	VB	O	7	VMOD
10	major	major	B-NP	JJ	O	12	NMOD
11	akinetic	akinetic	I-NP	JJ	O	12	NMOD
12	symptoms	symptom	I-NP	NNS	O	9	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	PD	PD	B-NP	NN	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	20	P
17	5	5	B-NP	CD	O	19	NMOD
18	mg/kg	mg/kg	I-NP	NN	O	19	NMOD
19	AMN082	AMN082	I-NP	NN	O	20	SUB
20	reverses	reverse	B-VP	VBZ	O	0	ROOT
21	the	the	B-NP	DT	O	24	NMOD
22	increased	increase	I-NP	VBN	O	24	NMOD
23	reaction	reaction	I-NP	NN	O	24	NMOD
24	time	time	I-NP	NN	O	20	OBJ
25	to	to	B-VP	TO	O	26	VMOD
26	respond	respond	I-VP	VB	O	24	NMOD
27	to	to	B-PP	TO	O	26	VMOD
28	a	a	B-NP	DT	O	29	NMOD
29	cue	cue	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	bilateral	bilateral	B-NP	JJ	O	33	NMOD
32	6-OHDA-lesioned	6-OHDA-lesioned	I-NP	JJ	O	33	NMOD
33	rats	rat	I-NP	NNS	O	30	PMOD
34	.	.	O	.	O	20	P

1	In	In	B-PP	IN	O	5	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	AMN082	AMN082	B-NP	NN	B-protein	5	SUB
5	reduces	reduce	B-VP	VBZ	O	0	ROOT
6	the	the	B-NP	DT	O	7	NMOD
7	duration	duration	I-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	haloperidol	haloperidol	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	5	VMOD
11	catalepsy	catalepsy	B-NP	NN	O	10	OBJ
12	in	in	B-PP	IN	O	10	VMOD
13	a	a	B-NP	DT	O	16	NMOD
14	mGlu7	mGlu7	I-NP	NN	O	16	NMOD
15	receptor-dependent	receptor-dependent	I-NP	JJ	O	16	NMOD
16	manner	manner	I-NP	NN	O	12	PMOD
17	in	in	B-PP	IN	O	10	VMOD
18	wild-type	wild-type	B-ADJP	JJ	O	24	NMOD
19	but	but	I-ADJP	CC	O	24	NMOD
20	not	not	I-ADJP	RB	O	19	DEP
21	mGlu7	mGlu7	B-NP	NN	O	24	NMOD
22	receptor	receptor	I-NP	NN	O	24	NMOD
23	knockout	knockout	I-NP	NN	O	24	NMOD
24	mice	mouse	I-NP	NNS	O	17	PMOD
25	.	.	O	.	O	5	P

1	Higher	High	B-NP	JJR	O	2	NMOD
2	doses	dose	I-NP	NNS	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	AMN082	AMN082	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	11	DEP
6	10	10	B-NP	CD	O	8	AMOD
7	and	and	I-NP	CC	O	8	AMOD
8	20	20	I-NP	CD	O	10	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	10	NMOD
10	p.o.	p.o.	I-NP	NN	O	11	DEP
11	)	)	O	)	O	2	NMOD
12	have	have	B-VP	VBP	O	0	ROOT
13	no	no	B-NP	DT	O	14	NMOD
14	effect	effect	I-NP	NN	O	12	OBJ
15	on	on	B-PP	IN	O	12	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	same	same	I-NP	JJ	O	18	NMOD
18	models	model	I-NP	NNS	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	PD	PD	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	12	P

1	Nimodipine	Nimodipine	B-NP	NN	O	2	SUB
2	prevents	prevent	B-VP	VBZ	O	0	ROOT
3	memory	memory	B-NP	NN	O	4	NMOD
4	impairment	impairment	I-NP	NN	O	8	SUB
5	caused	cause	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	nitroglycerin	nitroglycerin	B-NP	NN	B-protein	6	PMOD
8	induced	induce	B-VP	VBD	O	2	VMOD
9	hypotension	hypotension	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	adult	adult	B-NP	JJ	O	12	NMOD
12	mice	mouse	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	tested	test	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	hypothesis	hypothesis	I-NP	NN	O	2	OBJ
5	that	that	B-NP	IN	O	4	NMOD
6	nimodipine	nimodipine	B-NP	NN	O	21	SUB
7	(	(	O	(	O	9	DEP
8	NIMO	NIMO	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	administered	administer	B-VP	VBN	O	6	NMOD
11	at	at	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	onset	onset	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	nitroglycerin	nitroglycerin	B-NP	NN	O	20	NMOD
16	(	(	O	(	O	18	DEP
17	NTG	NTG	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	induced	induce	B-NP	VBN	O	20	NMOD
20	hypotension	hypotension	I-NP	NN	O	14	PMOD
21	would	would	B-VP	MD	O	5	SBAR
22	preserve	preserve	I-VP	VB	O	21	VC
23	long-term	long-term	B-NP	JJ	O	25	NMOD
24	associative	associative	I-NP	JJ	O	25	NMOD
25	memory	memory	I-NP	NN	O	22	OBJ
26	.	.	O	.	O	2	P

1	Mice	Mouse	B-NP	NNS	O	6	SUB
2	subjected	subject	B-VP	VBN	O	1	NMOD
3	to	to	B-PP	TO	O	2	VMOD
4	hypotensive	hypotensive	B-NP	JJ	O	5	NMOD
5	episodes	episode	I-NP	NNS	O	3	PMOD
6	showed	show	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	significant	significant	I-NP	JJ	O	9	NMOD
9	decrease	decrease	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	latency	latency	B-NP	NN	O	12	NMOD
12	time	time	I-NP	NN	O	10	PMOD
13	(	(	O	(	O	18	DEP
14	178	178	B-NP	CD	O	16	AMOD
15	+/-	+/-	I-NP	SYM	O	16	AMOD
16	156	156	I-NP	CD	O	17	NMOD
17	s	s	I-NP	NN	O	18	DEP
18	)	)	O	)	O	9	NMOD
19	compared	compare	B-PP	VBN	O	6	VMOD
20	with	with	B-PP	IN	O	19	PMOD
21	those	those	B-NP	DT	O	32	NMOD
22	injected	inject	B-VP	VBN	O	21	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	saline	saline	B-NP	NN	O	23	PMOD
25	,	,	O	,	O	32	P
26	NTG	NTG	B-NP	NN	B-protein	28	NMOD
27	+	+	I-NP	SYM	O	28	NMOD
28	NIMO	NIMO	I-NP	NN	B-protein	32	NMOD
29	,	,	O	,	O	32	P
30	or	or	O	CC	O	32	NMOD
31	delayed	delay	B-NP	VBN	O	32	NMOD
32	NTG	NTG	I-NP	NN	O	20	PMOD
33	(	(	O	(	O	51	DEP
34	580	580	B-NP	CD	O	36	AMOD
35	+/-	+/-	I-NP	SYM	O	36	AMOD
36	81	81	I-NP	CD	O	37	NMOD
37	s	s	I-NP	NN	O	48	NMOD
38	,	,	O	,	O	48	P
39	557	557	B-NP	CD	O	41	AMOD
40	+/-	+/-	I-NP	SYM	O	41	AMOD
41	67	67	I-NP	CD	O	42	NMOD
42	s	s	I-NP	NN	O	48	NMOD
43	,	,	O	,	O	48	P
44	and	and	O	CC	O	48	NMOD
45	493	493	B-NP	CD	O	47	AMOD
46	+/-	+/-	I-NP	SYM	O	47	AMOD
47	146	146	I-NP	CD	O	48	NMOD
48	s	s	I-NP	NN	O	51	DEP
49	,	,	O	,	O	48	P
50	respectively	respectively	B-ADVP	RB	O	48	NMOD
51	)	)	O	)	O	32	NMOD
52	.	.	O	.	O	6	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	27	VMOD
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	27	VMOD
4	a	a	B-NP	DT	O	7	NMOD
5	PA	PA	I-NP	NN	O	7	NMOD
6	retention	retention	I-NP	NN	O	7	NMOD
7	paradigm	paradigm	I-NP	NN	O	3	PMOD
8	,	,	O	,	O	27	P
9	the	the	B-NP	DT	O	10	NMOD
10	injection	injection	I-NP	NN	O	27	VMOD
11	of	of	B-PP	IN	O	10	NMOD
12	NTG	NTG	B-NP	NN	B-protein	11	PMOD
13	immediately	immediately	B-ADVP	RB	O	14	PMOD
14	after	after	B-SBAR	IN	O	10	NMOD
15	learning	learning	B-NP	NN	O	16	SUB
16	produced	produce	B-VP	VBD	O	14	SBAR
17	a	a	B-NP	DT	O	19	NMOD
18	significant	significant	I-NP	JJ	O	19	NMOD
19	impairment	impairment	I-NP	NN	O	16	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	long-term	long-term	B-NP	JJ	O	23	NMOD
22	associative	associative	I-NP	JJ	O	23	NMOD
23	memory	memory	I-NP	NN	O	20	PMOD
24	in	in	B-PP	IN	O	16	VMOD
25	mice	mouse	B-NP	NNS	O	24	PMOD
26	,	,	O	,	O	27	P
27	whereas	whereas	O	IN	O	0	ROOT
28	delayed	delay	B-NP	VBN	O	30	NMOD
29	induced	induce	I-NP	VBN	O	30	NMOD
30	hypotension	hypotension	I-NP	NN	O	31	SUB
31	had	have	B-VP	VBD	O	27	VMOD
32	no	no	B-NP	DT	O	33	NMOD
33	effect	effect	I-NP	NN	O	31	OBJ
34	.	.	O	.	O	27	P

1	NIMO	NIMO	B-NP	NN	B-protein	2	SUB
2	attenuated	attenuate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	disruption	disruption	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	consolidation	consolidation	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	long-term	long-term	B-NP	JJ	O	9	NMOD
9	memory	memory	I-NP	NN	O	7	PMOD
10	caused	cause	B-VP	VBN	O	6	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	NTG	NTG	B-NP	NN	B-protein	11	PMOD
13	but	but	O	CC	O	2	VMOD
14	did	do	B-VP	VBD	O	2	VMOD
15	not	not	I-VP	RB	O	14	VMOD
16	improve	improve	I-VP	VB	O	14	VC
17	latency	latency	B-NP	NN	O	16	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	absence	absence	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	hypotension	hypotension	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	2	P

1	Fatal	Fatal	B-NP	JJ	O	2	NMOD
2	haemopericardium	haemopericardium	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	gastrointestinal	gastrointestinal	B-NP	JJ	O	5	NMOD
5	haemorrhage	haemorrhage	I-NP	NN	O	0	ROOT
6	due	due	B-PP	JJ	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	possible	possible	B-NP	JJ	O	9	NMOD
9	interaction	interaction	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	cranberry	cranberry	B-NP	NN	O	12	NMOD
12	juice	juice	I-NP	NN	O	10	PMOD
13	with	with	B-PP	IN	O	9	NMOD
14	warfarin	warfarin	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	fatal	fatal	B-NP	JJ	O	8	NMOD
7	internal	internal	I-NP	JJ	O	8	NMOD
8	haemorrhage	haemorrhage	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	an	an	B-NP	DT	O	12	NMOD
11	elderly	elderly	I-NP	JJ	O	12	NMOD
12	man	man	I-NP	NN	O	9	PMOD
13	who	who	B-NP	WP	O	4	NMOD
14	consumed	consume	B-VP	VBD	O	13	SBAR
15	only	only	B-NP	RB	O	17	NMOD
16	cranberry	cranberry	I-NP	NN	O	17	NMOD
17	juice	juice	I-NP	NN	O	14	OBJ
18	for	for	B-PP	IN	O	14	VMOD
19	two	two	B-NP	CD	O	20	NMOD
20	weeks	week	I-NP	NNS	O	18	PMOD
21	while	while	B-SBAR	IN	O	14	VMOD
22	maintaining	maintain	B-VP	VBG	O	21	SBAR
23	his	his	B-NP	PRP$	O	25	NMOD
24	usual	usual	I-NP	JJ	O	25	NMOD
25	dosage	dosage	I-NP	NN	O	22	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	warfarin	warfarin	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	2	P

1	Isoproterenol	Isoproterenol	B-NP	NN	O	2	SUB
2	induces	induce	B-VP	VBZ	O	0	ROOT
3	primary	primary	B-NP	JJ	O	4	NMOD
4	loss	loss	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	dystrophin	dystrophin	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	rat	rat	B-NP	NN	O	9	NMOD
9	hearts	heart	I-NP	NNS	O	7	PMOD
10	:	:	O	:	O	2	VMOD
11	correlation	correlation	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	injury	injury	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanism	mechanism	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	isoproterenol	isoproterenol	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	25	VMOD
6	myocardial	myocardial	B-NP	JJ	O	7	NMOD
7	damage	damage	I-NP	NN	O	5	OBJ
8	is	be	B-VP	VBZ	O	5	VMOD
9	unknown	unknown	B-ADJP	JJ	O	8	PRD
10	,	,	O	,	O	25	P
11	but	but	O	CC	O	25	VMOD
12	a	a	B-NP	DT	O	13	NMOD
13	mismatch	mismatch	I-NP	NN	O	25	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	oxygen	oxygen	B-NP	NN	O	16	NMOD
16	supply	supply	I-NP	NN	O	14	PMOD
17	vs.	vs.	B-PP	IN	O	13	NMOD
18	demand	demand	B-NP	NN	O	17	PMOD
19	following	follow	B-PP	VBG	O	18	NMOD
20	coronary	coronary	B-NP	JJ	O	21	NMOD
21	hypotension	hypotension	I-NP	NN	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	myocardial	myocardial	B-NP	JJ	O	24	NMOD
24	hyperactivity	hyperactivity	I-NP	NN	O	19	PMOD
25	is	be	B-VP	VBZ	O	0	ROOT
26	the	the	B-NP	DT	O	27	NMOD
27	best	good	I-NP	JJS	O	25	PRD
28	explanation	explanation	I-NP	NN	O	27	NMOD
29	for	for	B-PP	IN	O	27	NMOD
30	the	the	B-NP	DT	O	33	NMOD
31	complex	complex	I-NP	JJ	O	33	NMOD
32	morphological	morphological	I-NP	JJ	O	33	NMOD
33	alterations	alteration	I-NP	NNS	O	29	PMOD
34	observed	observe	B-VP	VBN	O	33	NMOD
35	.	.	O	.	O	25	P

1	High	High	B-NP	JJ	O	5	NMOD
2	fat	fat	I-NP	JJ	O	5	NMOD
3	diet-fed	diet-fed	I-NP	JJ	O	5	NMOD
4	obese	obese	I-NP	JJ	O	5	NMOD
5	rats	rat	I-NP	NNS	O	6	SUB
6	are	be	B-VP	VBP	O	0	ROOT
7	highly	highly	B-ADJP	RB	O	8	AMOD
8	sensitive	sensitive	I-ADJP	JJ	O	6	PRD
9	to	to	B-PP	TO	O	8	AMOD
10	doxorubicin	doxorubicin	B-NP	NN	O	12	NMOD
11	induced	induced	I-NP	JJ	O	12	NMOD
12	cardiotoxicity	cardiotoxicity	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	6	P

1	Often	Often	B-ADVP	RB	O	9	VMOD
2	,	,	O	,	O	9	P
3	chemotherapy	chemotherapy	B-NP	NN	O	9	SUB
4	by	by	B-PP	IN	O	3	NMOD
5	doxorubicin	doxorubicin	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	8	DEP
7	Adriamycin	Adriamycin	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	limited	limit	I-VP	VBN	O	9	VC
11	due	due	B-PP	IN	O	12	PMOD
12	to	to	B-PP	TO	O	10	VMOD
13	life	life	B-NP	NN	O	15	NMOD
14	threatening	threatening	I-NP	JJ	O	15	NMOD
15	cardiotoxicity	cardiotoxicity	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	during	during	B-PP	IN	O	17	NMOD
19	and	and	O	CC	O	18	PMOD
20	posttherapy	posttherapy	B-NP	NN	O	18	PMOD
21	.	.	O	.	O	9	P

1	Recently	Recently	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	shown	show	I-VP	VBN	O	4	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	moderate	moderate	B-NP	JJ	O	9	NMOD
8	diet	diet	I-NP	NN	O	9	NMOD
9	restriction	restriction	I-NP	NN	O	11	SUB
10	remarkably	remarkably	B-ADVP	RB	O	11	VMOD
11	protects	protect	B-VP	VBZ	O	6	SBAR
12	against	against	B-PP	IN	O	11	VMOD
13	doxorubicin	doxorubicin	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	cardiotoxicity	cardiotoxicity	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	current	current	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	we	we	B-NP	PRP	O	7	SUB
7	investigated	investigate	B-VP	VBD	O	0	ROOT
8	whether	whether	B-SBAR	IN	O	7	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	physiological	physiological	I-NP	JJ	O	11	NMOD
11	intervention	intervention	I-NP	NN	O	35	SUB
12	by	by	B-PP	IN	O	11	NMOD
13	feeding	feed	B-VP	VBG	O	12	PMOD
14	40	40	B-NP	CD	O	15	AMOD
15	%	%	I-NP	NN	O	18	NMOD
16	high	high	I-NP	JJ	O	18	NMOD
17	fat	fat	I-NP	NN	O	18	NMOD
18	diet	diet	I-NP	NN	O	13	OBJ
19	(	(	O	(	O	21	DEP
20	HFD	HFD	B-NP	NN	B-protein	21	DEP
21	)	)	O	)	O	18	NMOD
22	,	,	O	,	O	11	P
23	which	which	B-NP	WDT	O	11	NMOD
24	induces	induce	B-VP	VBZ	O	23	SBAR
25	obesity	obesity	B-NP	NN	O	24	OBJ
26	in	in	B-PP	IN	O	24	VMOD
27	male	male	B-NP	JJ	O	29	NMOD
28	Sprague-Dawley	Sprague-Dawley	I-NP	JJ	O	29	NMOD
29	rats	rat	I-NP	NNS	O	26	PMOD
30	(	(	O	(	O	33	DEP
31	250-275	250-275	B-NP	CD	O	32	NMOD
32	g	g	I-NP	NN	O	33	DEP
33	)	)	O	)	O	29	NMOD
34	,	,	O	,	O	11	P
35	sensitizes	sensitize	B-VP	VBZ	O	8	SBAR
36	to	to	B-PP	TO	O	35	VMOD
37	doxorubicin	doxorubicin	B-NP	NN	O	39	NMOD
38	induced	induced	I-NP	JJ	O	39	NMOD
39	cardiotoxicity	cardiotoxicity	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	2	NMOD
2	LD	LD	I-NP	NN	O	23	SUB
3	(	(	O	(	O	5	DEP
4	10	10	B-NP	CD	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	dose	dose	B-NP	NN	O	2	NMOD
7	(	(	O	(	O	13	DEP
8	8	8	B-NP	CD	O	10	NMOD
9	mg	mg	I-NP	NN	O	10	NMOD
10	doxorubicin/kg	doxorubicin/kg	I-NP	NN	O	13	DEP
11	,	,	O	,	O	10	P
12	ip	ip	B-ADVP	RB	O	10	NMOD
13	)	)	O	)	O	6	NMOD
14	administered	administer	B-VP	VBN	O	6	NMOD
15	on	on	B-PP	IN	O	14	VMOD
16	day	day	B-NP	NN	O	15	PMOD
17	43	43	I-NP	CD	O	16	NMOD
18	of	of	B-PP	IN	O	16	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	HFD	HFD	I-NP	NN	O	22	NMOD
21	feeding	feeding	I-NP	NN	O	22	NMOD
22	regimen	regiman	I-NP	NNS	O	18	PMOD
23	led	lead	B-VP	VBD	O	0	ROOT
24	to	to	B-PP	TO	O	23	VMOD
25	higher	high	B-NP	JJR	O	26	NMOD
26	cardiotoxicity	cardiotoxicity	I-NP	NN	O	37	NMOD
27	,	,	O	,	O	37	P
28	cardiac	cardiac	B-NP	JJ	O	29	NMOD
29	dysfunction	dysfunction	I-NP	NN	O	37	NMOD
30	,	,	O	,	O	37	P
31	lipid	lipid	B-NP	NN	O	32	NMOD
32	peroxidation	peroxidation	I-NP	NN	O	37	NMOD
33	,	,	O	,	O	37	P
34	and	and	O	CC	O	37	NMOD
35	80	80	B-NP	CD	O	36	AMOD
36	%	%	I-NP	NN	O	37	NMOD
37	mortality	mortality	I-NP	NN	O	24	PMOD
38	in	in	B-PP	IN	O	37	NMOD
39	the	the	B-NP	DT	O	44	NMOD
40	obese	obese	I-NP	JJ	O	44	NMOD
41	(	(	O	(	O	43	DEP
42	OB	OB	B-NP	NN	O	43	DEP
43	)	)	O	)	O	40	AMOD
44	rats	rat	B-NP	NNS	O	38	PMOD
45	in	in	B-PP	IN	O	37	NMOD
46	the	the	B-NP	DT	O	47	NMOD
47	absence	absence	I-NP	NN	O	45	PMOD
48	of	of	B-PP	IN	O	47	NMOD
49	any	any	B-NP	DT	O	54	NMOD
50	significant	significant	I-NP	JJ	O	54	NMOD
51	renal	renal	I-NP	JJ	O	54	NMOD
52	or	or	I-NP	CC	O	54	NMOD
53	hepatic	hepatic	I-NP	JJ	O	54	NMOD
54	toxicity	toxicity	I-NP	NN	O	48	PMOD
55	.	.	O	.	O	23	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	3	NMOD
2	toxicokinetics	toxicokinetic	I-NP	NNS	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	revealed	reveal	B-VP	VBD	O	0	ROOT
5	no	no	B-NP	DT	O	6	NMOD
6	change	change	I-NP	NN	O	4	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	accumulation	accumulation	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	doxorubicin	doxorubicin	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	doxorubicinol	doxorubicinol	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	16	DEP
14	toxic	toxic	B-NP	JJ	O	15	NMOD
15	metabolite	metabolite	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	NMOD
17	in	in	B-PP	IN	O	8	NMOD
18	the	the	B-NP	DT	O	26	NMOD
19	normal	normal	I-NP	JJ	O	20	AMOD
20	diet-fed	diet-fed	I-NP	JJ	O	26	NMOD
21	(	(	O	(	O	23	DEP
22	ND	ND	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	AMOD
24	and	and	O	CC	O	26	NMOD
25	OB	OB	B-NP	NN	O	26	NMOD
26	hearts	heart	I-NP	NNS	O	17	PMOD
27	.	.	O	.	O	4	P

1	Mechanistic	Mechanistic	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	OB	OB	B-NP	NN	O	6	NMOD
6	rats	rat	I-NP	NNS	O	7	SUB
7	are	be	B-VP	VBP	O	4	SBAR
8	sensitized	sensitize	I-VP	VBN	O	7	VC
9	due	due	B-ADJP	JJ	O	10	PMOD
10	to	to	B-PP	TO	O	8	VMOD
11	:	:	O	:	O	42	P
12	(	(	B-LST	(	O	13	DEP
13	1	1	I-LST	LS	O	42	VMOD
14	)	)	O	)	O	13	DEP
15	higher	high	B-NP	JJR	O	17	NMOD
16	oxyradical	oxyradical	I-NP	JJ	O	17	NMOD
17	stress	stress	I-NP	NN	O	42	SUB
18	leading	lead	B-VP	VBG	O	17	NMOD
19	to	to	B-PP	TO	O	18	VMOD
20	upregulation	upregulation	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	uncoupling	uncouple	B-VP	VBG	O	36	VMOD
23	proteins	protein	B-NP	NNS	O	22	OBJ
24	2	2	I-NP	CD	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	3	3	I-NP	CD	O	23	NMOD
27	,	,	O	,	O	36	P
28	(	(	B-LST	(	O	29	DEP
29	2	2	I-LST	LS	O	31	NMOD
30	)	)	O	)	O	29	DEP
31	downregulation	downregulation	B-NP	NN	O	36	SUB
32	of	of	B-PP	IN	O	31	NMOD
33	cardiac	cardiac	B-NP	JJ	B-protein	35	NMOD
34	peroxisome	peroxisome	I-NP	NN	I-protein	35	NMOD
35	proliferators	proliferator	I-NP	NNS	I-protein	32	PMOD
36	activated	activate	B-VP	VBD	I-protein	37	NMOD
37	receptor-alpha	receptor-alpha	B-NP	NN	I-protein	40	NMOD
38	,	,	O	,	O	40	P
39	(	(	O	(	O	40	DEP
40	3	3	B-NP	CD	O	21	PMOD
41	)	)	O	)	O	40	NMOD
42	decreased	decrease	B-VP	VBD	O	48	VMOD
43	plasma	plasma	B-NP	NN	B-protein	45	NMOD
44	adiponectin	adiponectin	I-NP	NN	I-protein	45	NMOD
45	levels	level	I-NP	NNS	O	42	OBJ
46	,	,	O	,	O	48	P
47	(	(	O	(	O	48	NMOD
48	4	4	B-NP	CD	O	50	SUB
49	)	)	O	)	O	48	NMOD
50	decreased	decrease	B-VP	VBD	O	4	SBAR
51	cardiac	cardiac	B-NP	JJ	O	53	NMOD
52	fatty-acid	fatty-acid	I-NP	JJ	O	53	NMOD
53	oxidation	oxidation	I-NP	NN	O	50	OBJ
54	(	(	O	(	O	70	DEP
55	666.9+/-14.0	666.9+/-14.0	B-NP	CD	O	57	NMOD
56	nmol/min/g	nmol/min/g	I-NP	NN	O	57	NMOD
57	heart	heart	I-NP	NN	O	69	NMOD
58	in	in	B-PP	IN	O	57	NMOD
59	ND	ND	B-NP	NN	O	63	NMOD
60	versus	versus	B-PP	IN	O	63	NMOD
61	400.2+/-11.8	400.2+/-11.8	B-NP	CD	O	63	NMOD
62	nmol/min/g	nmol/min/g	I-NP	NN	O	63	NMOD
63	heart	heart	I-NP	NN	O	58	PMOD
64	in	in	B-PP	IN	O	63	NMOD
65	OB	OB	B-NP	NN	B-protein	64	PMOD
66	)	)	O	)	O	63	NMOD
67	,	,	O	,	O	69	P
68	(	(	O	(	O	69	NMOD
69	5	5	B-NP	CD	O	70	DEP
70	)	)	O	)	O	53	NMOD
71	decreased	decrease	B-VP	VBD	O	50	VMOD
72	mitochondrial	mitochondrial	B-NP	JJ	B-protein	75	NMOD
73	AMP-alpha2	AMP-alpha2	I-NP	NN	I-protein	75	NMOD
74	protein	protein	I-NP	NN	I-protein	75	NMOD
75	kinase	kinase	I-NP	NN	I-protein	71	OBJ
76	,	,	O	,	O	50	P
77	and	and	O	CC	O	83	NMOD
78	(	(	O	(	O	83	NMOD
79	6	6	B-NP	CD	O	83	NMOD
80	)	)	O	)	O	83	NMOD
81	86	86	B-NP	CD	O	83	NMOD
82	%	%	I-NP	NN	O	83	NMOD
83	drop	drop	I-NP	NN	O	50	OBJ
84	in	in	B-PP	IN	O	83	NMOD
85	cardiac	cardiac	B-NP	JJ	O	87	NMOD
86	ATP	ATP	I-NP	NN	O	87	NMOD
87	levels	level	I-NP	NNS	O	84	PMOD
88	accompanied	accompany	B-VP	VBN	O	87	NMOD
89	by	by	B-PP	IN	O	88	VMOD
90	decreased	decrease	B-NP	VBN	O	92	NMOD
91	ATP/ADP	ATP/ADP	I-NP	NN	O	92	NMOD
92	ratio	ratio	I-NP	NN	O	89	PMOD
93	after	after	B-PP	IN	O	92	NMOD
94	doxorubicin	doxorubicin	B-NP	NN	O	95	NMOD
95	administration	administration	I-NP	NN	O	93	PMOD
96	.	.	O	.	O	3	P

1	Complete	Complete	B-NP	JJ	O	3	NMOD
2	atrioventricular	atrioventricular	I-NP	JJ	O	3	NMOD
3	block	block	I-NP	NN	O	0	ROOT
4	secondary	secondary	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	lithium	lithium	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	3	P

1	Sinus	Sinus	B-NP	NN	O	3	NMOD
2	node	node	I-NP	NN	O	3	NMOD
3	dysfunction	dysfunction	I-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	reported	report	I-VP	VBN	O	5	VC
7	most	most	B-ADVP	RBS	O	8	AMOD
8	frequently	frequently	I-ADVP	RB	O	6	VMOD
9	among	among	B-PP	IN	O	6	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	adverse	adverse	I-NP	JJ	O	13	NMOD
12	cardiovascular	cardiovascular	I-NP	JJ	O	13	NMOD
13	effects	effect	I-NP	NNS	O	9	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	lithium	lithium	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	case	case	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	11	P
6	complete	complete	B-NP	JJ	O	7	NMOD
7	atrioventricular	atrioventricular	I-NP	JJ	O	11	SUB
8	(	(	O	(	O	10	DEP
9	AV	AV	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	block	block	B-VP	VBP	O	0	ROOT
12	with	with	B-PP	IN	O	11	VMOD
13	syncopal	syncopal	B-NP	JJ	O	14	NMOD
14	attacks	attack	I-NP	NNS	O	12	PMOD
15	developed	develop	B-VP	VBD	O	11	VMOD
16	secondary	secondary	B-ADJP	JJ	O	15	VMOD
17	to	to	B-PP	TO	O	16	AMOD
18	lithium	lithium	B-NP	NN	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	11	P
21	necessitating	necessitate	B-VP	VBG	O	11	VMOD
22	permanent	permanent	B-NP	JJ	O	24	NMOD
23	pacemaker	pacemaker	I-NP	NN	O	24	NMOD
24	implantation	implantation	I-NP	NN	O	21	OBJ
25	.	.	O	.	O	11	P

1	Serum	Serum	B-NP	NN	O	3	NMOD
2	lithium	lithium	I-NP	NN	O	3	NMOD
3	levels	level	I-NP	NNS	O	4	SUB
4	remained	remain	B-VP	VBD	O	0	ROOT
5	under	under	B-PP	IN	O	4	VMOD
6	or	or	I-PP	CC	O	5	PMOD
7	within	within	I-PP	IN	O	5	PMOD
8	the	the	B-NP	DT	O	10	NMOD
9	therapeutic	therapeutic	I-NP	JJ	O	10	NMOD
10	range	range	I-NP	NN	O	5	PMOD
11	during	during	B-PP	IN	O	4	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	syncopal	syncopal	I-NP	JJ	O	14	NMOD
14	attacks	attack	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	4	P

1	Neuroleptic	Neuroleptic	B-NP	JJ	O	3	NMOD
2	malignant	malignant	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	0	ROOT
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	ziprasidone	ziprasidone	B-NP	NN	O	5	PMOD
7	on	on	B-PP	IN	O	4	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	second	second	I-NP	JJ	O	10	NMOD
10	day	day	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	treatment	treatment	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	neuroleptic	neuroleptic	B-NP	JJ	O	8	NMOD
7	malignant	malignant	I-NP	JJ	O	8	NMOD
8	syndrome	syndrome	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	11	DEP
10	NMS	NMS	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	associated	associate	B-VP	VBN	O	8	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	use	use	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	ziprasidone	ziprasidone	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	16	VMOD
2	conventional	conventional	B-NP	JJ	O	3	NMOD
3	neuroleptics	neuroleptic	I-NP	NNS	O	4	SUB
4	are	be	B-VP	VBP	O	1	SBAR
5	more	more	I-VP	RBR	O	6	AMOD
6	frequently	frequently	I-VP	RB	O	7	VMOD
7	associated	associate	I-VP	VBN	O	4	VC
8	with	with	B-PP	IN	O	7	VMOD
9	NMS	NMS	B-NP	NN	B-protein	13	NMOD
10	,	,	O	,	O	13	P
11	atypical	atypical	B-NP	JJ	O	13	NMOD
12	antipsychotic	antipsychotic	I-NP	JJ	O	13	NMOD
13	drugs	drug	I-NP	NNS	O	8	PMOD
14	like	like	B-PP	IN	O	13	NMOD
15	ziprasidone	ziprasidone	B-NP	NN	O	14	PMOD
16	may	may	B-VP	MD	O	0	ROOT
17	also	also	I-VP	RB	O	16	VMOD
18	be	be	I-VP	VB	O	16	VC
19	a	a	B-NP	DT	O	20	NMOD
20	cause	cause	I-NP	NN	O	18	PRD
21	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	24-year-old	24-year-old	I-NP	JJ	O	6	NMOD
6	male	male	I-NP	NN	O	3	PRD
7	with	with	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	history	history	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	schizophrenia	schizophrenia	B-NP	NN	O	10	PMOD
12	who	who	B-NP	WP	O	6	NMOD
13	developed	develop	B-VP	VBD	O	12	SBAR
14	signs	sign	B-NP	NNS	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	symptoms	symptom	I-NP	NNS	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	NMS	NMS	B-NP	NN	O	17	PMOD
19	after	after	B-PP	IN	O	13	VMOD
20	2	2	B-NP	CD	O	21	NMOD
21	days	day	I-NP	NNS	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	treatment	treatment	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	an	an	B-NP	DT	O	27	NMOD
26	80-mg/day	80-mg/day	I-NP	JJ	O	27	NMOD
27	dose	dose	I-NP	NN	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	orally	orally	B-NP	RB	O	30	AMOD
30	administrated	administrate	I-NP	VBN	O	31	NMOD
31	ziprasidone	ziprasidone	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	3	P

1	Role	Role	B-NP	NN	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	mangiferin	mangiferin	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	biochemical	biochemical	B-NP	JJ	O	6	NMOD
6	alterations	alteration	I-NP	NNS	O	9	NMOD
7	and	and	O	CC	O	9	NMOD
8	antioxidant	antioxidant	B-NP	JJ	O	9	NMOD
9	status	status	I-NP	NN	O	4	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	isoproterenol	isoproterenol	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	infarction	infarction	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	14	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	12	P

1	(	(	O	(	O	3	DEP
2	Anacardiaceae	Anacardiaceae	B-NP	NNP	O	3	DEP
3	)	)	O	)	O	0	ROOT
4	,	,	O	,	O	3	P
5	on	on	B-PP	IN	O	3	VMOD
6	isoproterenol	isoproterenol	B-NP	NN	O	10	SUB
7	(	(	O	(	O	9	DEP
8	ISPH	ISPH	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	induced	induce	B-VP	VBD	O	5	SBAR
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	infarction	infarction	I-NP	NN	O	10	OBJ
13	(	(	O	(	O	15	DEP
14	MI	MI	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	in	in	B-PP	IN	O	10	VMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	through	through	B-PP	IN	O	10	VMOD
19	its	its	B-NP	PRP$	O	21	NMOD
20	antioxidative	antioxidative	I-NP	JJ	O	21	NMOD
21	mechanism	mechanism	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	3	P

1	Subcutaneous	Subcutaneous	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	21	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ISPH	ISPH	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	14	DEP
6	200	200	B-NP	CD	O	7	AMOD
7	mg/kg	mg/kg	I-NP	NN	O	9	NMOD
8	body	body	I-NP	NN	O	9	NMOD
9	weight	weight	I-NP	NN	O	14	DEP
10	in	in	B-PP	IN	O	9	NMOD
11	1	1	B-NP	CD	O	13	NMOD
12	ml	ml	I-NP	NN	O	13	NMOD
13	saline	saline	I-NP	NN	O	10	PMOD
14	)	)	O	)	O	4	NMOD
15	to	to	B-PP	TO	O	2	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	for	for	B-PP	IN	O	2	NMOD
18	2	2	B-NP	CD	O	20	NMOD
19	consecutive	consecutive	I-NP	JJ	O	20	NMOD
20	days	day	I-NP	NNS	O	17	PMOD
21	caused	cause	B-VP	VBD	O	0	ROOT
22	myocardial	myocardial	B-NP	JJ	O	23	NMOD
23	damage	damage	I-NP	NN	O	21	OBJ
24	in	in	B-PP	IN	O	23	NMOD
25	rat	rat	B-NP	NN	O	26	NMOD
26	heart	heart	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	23	P
28	which	which	B-NP	WDT	O	23	NMOD
29	was	be	B-VP	VBD	O	28	SBAR
30	determined	determine	I-VP	VBN	O	29	VC
31	by	by	B-PP	IN	O	30	VMOD
32	the	the	B-NP	DT	O	34	NMOD
33	increased	increase	I-NP	VBN	O	34	NMOD
34	activity	activity	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	serum	serum	B-NP	NN	B-protein	38	NMOD
37	lactate	lactate	I-NP	NN	I-protein	38	NMOD
38	dehydrogenase	dehydrogenase	I-NP	NN	I-protein	45	NMOD
39	(	(	O	(	O	41	DEP
40	LDH	LDH	B-NP	NN	B-protein	41	DEP
41	)	)	O	)	O	38	NMOD
42	and	and	O	CC	O	45	NMOD
43	creatine	creatine	B-NP	NN	B-protein	45	NMOD
44	phosphokinase	phosphokinase	I-NP	NN	I-protein	45	NMOD
45	isoenzymes	isoenzyme	I-NP	NNS	I-protein	59	NMOD
46	(	(	O	(	O	48	DEP
47	CK-MB	CK-MB	B-NP	NN	B-protein	48	DEP
48	)	)	O	)	O	45	NMOD
49	,	,	O	,	O	59	P
50	increased	increase	B-NP	VBN	O	53	NMOD
51	uric	uric	I-NP	JJ	O	53	NMOD
52	acid	acid	I-NP	NN	O	53	NMOD
53	level	level	I-NP	NN	O	59	NMOD
54	and	and	O	CC	O	59	NMOD
55	reduced	reduce	B-NP	VBN	O	59	NMOD
56	plasma	plasma	I-NP	NN	O	59	NMOD
57	iron	iron	I-NP	NN	O	59	NMOD
58	binding	binding	I-NP	NN	O	59	NMOD
59	capacity	capacity	I-NP	NN	O	35	PMOD
60	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	3	NMOD
2	protective	protective	I-NP	JJ	O	3	NMOD
3	role	role	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	mangiferin	mangiferin	B-NP	NN	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	analyzed	analyze	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	triphenyl	triphenyl	B-NP	NN	O	11	NMOD
10	tetrazolium	tetrazolium	I-NP	NN	O	11	NMOD
11	chloride	chloride	I-NP	NN	O	15	NMOD
12	(	(	O	(	O	14	DEP
13	TTC	TTC	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	test	test	B-NP	NN	O	8	PMOD
16	used	use	B-VP	VBN	O	15	NMOD
17	for	for	B-PP	IN	O	16	VMOD
18	macroscopic	macroscopic	B-NP	JJ	O	21	NMOD
19	enzyme	enzyme	I-NP	NN	O	21	NMOD
20	mapping	mapping	I-NP	NN	O	21	NMOD
21	assay	assay	I-NP	NN	O	17	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	ischemic	ischemic	I-NP	JJ	O	25	NMOD
25	myocardium	myocardium	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	5	NMOD
2	heart	heart	I-NP	NN	B-protein	5	NMOD
3	tissue	tissue	I-NP	NN	I-protein	5	NMOD
4	antioxidant	antioxidant	I-NP	JJ	I-protein	5	NMOD
5	enzymes	enzyme	I-NP	NNS	I-protein	37	SUB
6	such	such	B-PP	JJ	O	7	PMOD
7	as	as	I-PP	IN	O	5	NMOD
8	superoxide	superoxide	B-NP	NN	B-protein	9	NMOD
9	dismutase	dismutase	I-NP	NN	I-protein	20	NMOD
10	,	,	O	,	O	20	P
11	catalase	catalase	B-NP	NN	B-protein	20	NMOD
12	,	,	O	,	O	20	P
13	glutathione	glutathione	B-NP	NN	B-protein	14	NMOD
14	peroxidase	peroxidase	I-NP	NN	I-protein	20	NMOD
15	,	,	O	,	O	20	P
16	glutathione	glutathione	B-NP	NN	B-protein	17	NMOD
17	transferase	transferase	I-NP	NN	I-protein	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	glutathione	glutathione	B-NP	NN	B-protein	20	NMOD
20	reductase	reductase	I-NP	NN	I-protein	21	NMOD
21	activities	activity	I-NP	NNS	O	24	NMOD
22	,	,	O	,	O	24	P
23	non-enzymic	non-enzymic	B-NP	JJ	O	24	NMOD
24	antioxidants	antioxidant	I-NP	NNS	O	7	PMOD
25	such	such	B-PP	JJ	O	26	PMOD
26	as	as	I-PP	IN	O	24	NMOD
27	cerruloplasmin	cerruloplasmin	B-NP	NN	O	36	NMOD
28	,	,	O	,	O	36	P
29	Vitamin	Vitamin	B-NP	NNP	O	30	NMOD
30	C	C	I-NP	NNP	O	36	NMOD
31	,	,	O	,	O	36	P
32	Vitamin	Vitamin	B-NP	NN	O	33	NMOD
33	E	E	I-NP	NN	O	36	NMOD
34	and	and	I-NP	CC	O	36	NMOD
35	glutathione	glutathione	I-NP	NN	O	36	NMOD
36	levels	level	I-NP	NNS	O	26	PMOD
37	were	be	B-VP	VBD	O	0	ROOT
38	altered	alter	I-VP	VBN	O	37	VC
39	in	in	B-PP	IN	O	38	VMOD
40	MI	MI	B-NP	NN	O	41	NMOD
41	rats	rat	I-NP	NNS	O	39	PMOD
42	.	.	O	.	O	37	P

1	Upon	Upon	B-PP	IN	O	0	ROOT
2	pretreatment	pretreatment	B-NP	NN	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	mangiferin	mangiferin	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	4	NMOD
6	100	100	B-NP	CD	O	9	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	9	NMOD
8	body	body	I-NP	NN	O	9	NMOD
9	weight	weight	I-NP	NN	O	26	SUB
10	suspended	suspend	B-VP	VBN	O	9	NMOD
11	in	in	B-PP	IN	O	10	VMOD
12	2	2	B-NP	CD	O	13	NMOD
13	ml	ml	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	dimethyl	dimethyl	B-NP	NN	O	16	NMOD
16	sulphoxide	sulphoxide	I-NP	NN	O	14	PMOD
17	)	)	O	)	O	16	NMOD
18	given	give	B-VP	VBN	O	13	NMOD
19	intraperitoneally	intraperitoneally	B-ADVP	RB	O	18	VMOD
20	for	for	B-PP	IN	O	18	VMOD
21	28	28	B-NP	CD	O	22	NMOD
22	days	day	I-NP	NNS	O	20	PMOD
23	to	to	B-PP	TO	O	22	NMOD
24	MI	MI	B-NP	NN	O	25	NMOD
25	rats	rat	I-NP	NNS	O	23	PMOD
26	protected	protect	B-VP	VBD	O	5	SBAR
27	the	the	B-NP	DT	O	29	NMOD
28	above-mentioned	above-mentioned	I-NP	JJ	O	29	NMOD
29	parameters	parameter	I-NP	NNS	O	26	OBJ
30	to	to	B-VP	TO	O	31	VMOD
31	fall	fall	I-VP	VB	O	26	VMOD
32	from	from	B-PP	IN	O	31	VMOD
33	the	the	B-NP	DT	O	35	NMOD
34	normal	normal	I-NP	JJ	O	35	NMOD
35	levels	level	I-NP	NNS	O	32	PMOD
36	.	.	O	.	O	1	P

1	Activities	Activity	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	heart	heart	B-NP	NN	O	6	NMOD
4	tissue	tissue	I-NP	NN	O	6	NMOD
5	enzymic	enzymic	I-NP	JJ	O	6	NMOD
6	antioxidants	antioxidant	I-NP	NNS	O	2	PMOD
7	and	and	O	CC	O	11	NMOD
8	serum	serum	B-NP	NN	O	11	NMOD
9	non-enzymic	non-enzymic	I-NP	JJ	O	11	NMOD
10	antioxidants	antioxidant	I-NP	NNS	O	11	NMOD
11	levels	level	I-NP	NNS	O	12	SUB
12	rose	rise	B-VP	VBD	O	1	NMOD
13	significantly	significantly	B-ADVP	RB	O	12	VMOD
14	upon	upon	B-PP	IN	O	12	VMOD
15	mangiferin	mangiferin	B-NP	NN	O	16	NMOD
16	administration	administration	I-NP	NN	O	14	PMOD
17	as	as	B-SBAR	IN	O	12	VMOD
18	compared	compare	B-PP	VBN	O	17	SBAR
19	to	to	B-PP	TO	O	18	VMOD
20	ISPH	ISPH	B-NP	NN	B-protein	23	NMOD
21	induced	induced	I-NP	JJ	O	23	NMOD
22	MI	MI	I-NP	NN	O	23	NMOD
23	rats	rat	I-NP	NNS	O	19	PMOD
24	.	.	O	.	O	1	P

1	Remifentanil	Remifentanil	B-NP	NN	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	3	SUB
3	reduces	reduce	B-VP	VBZ	O	0	ROOT
4	myoclonus	myoclonus	B-NP	NN	O	3	OBJ
5	after	after	B-PP	IN	O	3	VMOD
6	etomidate	etomidate	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	3	P

1	STUDY	STUDY	B-NP	NN	O	2	NMOD
2	OBJECTIVE	OBJECTIVE	I-NP	NN	O	0	ROOT
3	:	:	O	:	O	2	P
4	The	The	B-NP	DT	O	5	NMOD
5	aim	aim	I-NP	NN	O	9	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	study	study	I-NP	NN	O	6	PMOD
9	was	be	B-VP	VBD	O	2	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	compare	compare	I-VP	VB	O	9	PRD
12	the	the	B-NP	DT	O	13	NMOD
13	effect	effect	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	pretreatment	pretreatment	B-NP	NN	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	remifentanil	remifentanil	B-NP	NN	O	19	NMOD
18	1	1	I-NP	CD	O	19	NMOD
19	microg/kg	microg/kg	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	effect	effect	I-NP	NN	O	16	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	gender	gender	B-NP	NN	O	23	PMOD
25	on	on	B-PP	IN	O	22	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	incidence	incidence	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	myoclonus	myoclonus	B-NP	NN	O	28	PMOD
30	after	after	B-PP	IN	O	27	NMOD
31	anesthesia	anesthesia	B-NP	NN	O	32	NMOD
32	induction	induction	I-NP	NN	O	30	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	etomidate	etomidate	B-NP	NN	O	33	PMOD
35	.	.	O	.	O	9	P

1	MAIN	MAIN	B-NP	NN	O	2	NMOD
2	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT
3	:	:	O	:	O	2	P
4	The	The	B-NP	DT	O	5	NMOD
5	incidence	incidence	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	myoclonus	myoclonus	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	2	NMOD
9	significantly	significantly	B-ADJP	RB	O	10	AMOD
10	lower	low	I-ADJP	JJR	O	8	PRD
11	in	in	B-PP	IN	O	10	AMOD
12	the	the	B-NP	DT	O	14	NMOD
13	remifentanil	remifentanil	I-NP	NN	O	14	NMOD
14	group	group	I-NP	NN	O	11	PMOD
15	(	(	O	(	O	18	DEP
16	6.7	6.7	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	18	DEP
18	)	)	O	)	O	8	VMOD
19	than	than	B-PP	IN	O	8	VMOD
20	in	in	B-PP	IN	O	19	PMOD
21	the	the	B-NP	DT	O	23	NMOD
22	placebo	placebo	I-NP	NN	O	23	NMOD
23	group	group	I-NP	NN	O	20	PMOD
24	(	(	O	(	O	27	DEP
25	70	70	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	27	DEP
27	)	)	O	)	O	23	NMOD
28	(	(	O	(	O	32	DEP
29	P	P	B-NP	NN	O	31	SUB
30	<	<	O	SYM	O	31	VMOD
31	0.001	0.001	B-NP	CD	O	32	DEP
32	)	)	O	)	O	8	VMOD
33	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	placebo	placebo	I-NP	NN	O	4	NMOD
4	group	group	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	8	P
6	male	male	B-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	8	SUB
8	were	be	B-VP	VBD	O	0	ROOT
9	associated	associate	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	significantly	significantly	B-NP	RB	O	12	AMOD
12	increased	increase	I-NP	VBN	O	13	NMOD
13	incidence	incidence	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	myoclonus	myoclonus	B-NP	NN	O	14	PMOD
16	after	after	B-PP	IN	O	13	NMOD
17	etomidate	etomidate	B-NP	NN	O	18	NMOD
18	administration	administration	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	8	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	3	P
3	Pretreatment	Pretreatment	B-NP	NN	O	8	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	remifentanil	remifentanil	B-NP	NN	O	7	NMOD
6	1	1	I-NP	CD	O	7	NMOD
7	microg/kg	microg/kg	I-NP	NN	O	4	PMOD
8	reduced	reduce	B-VP	VBD	O	0	ROOT
9	myoclonus	myoclonus	B-NP	NN	O	8	OBJ
10	after	after	B-PP	IN	O	8	VMOD
11	etomidate	etomidate	B-NP	NN	O	12	NMOD
12	induction	induction	I-NP	NN	O	10	PMOD
13	without	without	B-PP	IN	O	12	NMOD
14	side	side	B-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	13	PMOD
16	such	such	B-PP	JJ	O	17	PMOD
17	as	as	I-PP	IN	O	15	NMOD
18	sedation	sedation	B-NP	NN	O	25	NMOD
19	,	,	O	,	O	25	P
20	apnea	apnea	B-NP	NN	O	25	NMOD
21	,	,	O	,	O	25	P
22	nausea	nausea	B-NP	NN	O	25	NMOD
23	,	,	O	,	O	25	P
24	or	or	O	CC	O	25	NMOD
25	pruritus	pruritus	B-NP	NN	O	17	PMOD
26	.	.	O	.	O	8	P

1	Daidzein	Daidzein	B-NP	NN	O	2	SUB
2	activates	activate	B-VP	VBZ	O	0	ROOT
3	choline	choline	B-NP	NN	B-protein	4	NMOD
4	acetyltransferase	acetyltransferase	I-NP	NN	I-protein	2	OBJ
5	from	from	B-PP	IN	O	4	NMOD
6	MC-IXC	MC-IXC	B-NP	NN	B-cell_line	7	NMOD
7	cells	cell	I-NP	NNS	I-cell_line	5	PMOD
8	and	and	O	CC	O	2	VMOD
9	improves	improve	B-VP	VBZ	O	2	VMOD
10	drug	drug	B-NP	NN	O	12	NMOD
11	induced	induced	I-NP	JJ	O	12	NMOD
12	amnesia	amnesia	I-NP	NN	O	9	OBJ
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	7	NMOD
2	choline	choline	I-NP	NN	B-protein	7	NMOD
3	acetyltransferase	acetyltransferase	I-NP	NN	I-protein	7	NMOD
4	(	(	O	(	I-protein	7	NMOD
5	ChAT	ChAT	B-NP	NN	I-protein	7	NMOD
6	)	)	O	)	I-protein	7	NMOD
7	activator	activator	B-NP	NN	I-protein	26	SUB
8	,	,	O	,	O	7	P
9	which	which	B-NP	WDT	O	7	NMOD
10	enhances	enhance	B-VP	VBZ	O	9	SBAR
11	cholinergic	cholinergic	B-NP	JJ	O	12	NMOD
12	transmission	transmission	I-NP	NN	O	10	OBJ
13	via	via	B-PP	IN	O	10	VMOD
14	an	an	B-NP	DT	O	15	NMOD
15	augmentation	augmentation	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	enzymatic	enzymatic	I-NP	JJ	O	19	NMOD
19	production	production	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	acetylcholine	acetylcholine	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	24	DEP
23	ACh	ACh	B-NP	NN	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	,	,	O	,	O	7	P
26	is	be	B-VP	VBZ	O	0	ROOT
27	an	an	B-NP	DT	O	29	NMOD
28	important	important	I-NP	JJ	O	29	NMOD
29	factor	factor	I-NP	NN	O	26	PRD
30	in	in	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	32	NMOD
32	treatment	treatment	I-NP	NN	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	Alzheimer	Alzheimer	B-NP	NNP	O	36	NMOD
35	's	's	B-NP	POS	O	36	NMOD
36	disease	disease	I-NP	NN	O	33	PMOD
37	(	(	O	(	O	39	DEP
38	AD	AD	B-NP	NN	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	.	.	O	.	O	26	P

1	In	In	B-SBAR	IN	O	22	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	investigate	investigate	I-VP	VB	O	1	SBAR
5	the	the	B-NP	DT	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	daidzein	daidzein	B-NP	NN	O	7	PMOD
9	from	from	B-PP	IN	O	6	NMOD
10	Pueraria	Pueraria	B-NP	NNP	O	11	NMOD
11	thunbergiana	thunbergiana	I-NP	NN	O	9	PMOD
12	on	on	B-PP	IN	O	6	NMOD
13	scopolamine	scopolamine	B-NP	NN	O	15	NMOD
14	induced	induce	B-VP	VBN	O	15	NMOD
15	impairments	impairment	B-NP	NNS	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	learning	learning	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	memory	memory	I-NP	NN	O	16	PMOD
20	,	,	O	,	O	22	P
21	we	we	B-NP	PRP	O	22	SUB
22	conducted	conduct	B-VP	VBD	O	0	ROOT
23	a	a	B-NP	DT	O	24	NMOD
24	series	series	I-NP	NN	O	22	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	in	in	B-NP	FW	O	27	AMOD
27	vivo	vivo	I-NP	FW	O	28	NMOD
28	tests	test	I-NP	NNS	O	25	PMOD
29	.	.	O	.	O	22	P

1	Administration	Administration	B-NP	NN	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	daidzein	daidzein	B-NP	NN	O	2	PMOD
4	(	(	O	(	O	9	DEP
5	4.5	4.5	B-NP	CD	O	8	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	8	NMOD
7	body	body	I-NP	NN	O	8	NMOD
8	weight	weight	I-NP	NN	O	9	DEP
9	)	)	O	)	O	3	NMOD
10	to	to	B-PP	TO	O	1	NMOD
11	mice	mouse	B-NP	NNS	O	10	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	shown	show	I-VP	VBN	O	12	VC
14	significantly	significantly	B-ADVP	RB	O	13	VMOD
15	to	to	B-VP	TO	O	16	VMOD
16	reverse	reverse	I-VP	VB	O	13	VMOD
17	scopolamine	scopolamine	B-NP	NN	O	19	NMOD
18	induced	induced	I-NP	JJ	O	19	NMOD
19	amnesia	amnesia	I-NP	NN	O	16	OBJ
20	,	,	O	,	O	16	P
21	according	accord	B-PP	VBG	O	16	VMOD
22	to	to	B-PP	TO	O	21	PMOD
23	the	the	B-NP	DT	O	24	NMOD
24	results	result	I-NP	NNS	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	a	a	B-NP	DT	O	28	NMOD
27	Y-maze	Y-maze	I-NP	JJ	O	28	NMOD
28	test	test	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	12	P

1	Possible	Possible	B-NP	JJ	O	3	NMOD
2	azithromycin-associated	azithromycin-associated	I-NP	JJ	O	3	NMOD
3	hiccups	hiccup	I-NP	NNS	O	0	ROOT
4	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	persistent	persistent	B-NP	JJ	O	9	NMOD
9	hiccups	hiccup	I-NP	NNS	O	7	PMOD
10	associated	associate	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	azithromycin	azithromycin	B-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	6	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	6	NMOD
5	76-year-old	76-year-old	I-NP	JJ	O	6	NMOD
6	man	man	I-NP	NN	O	0	ROOT
7	presented	present	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	persistent	persistent	B-NP	JJ	O	10	NMOD
10	hiccups	hiccup	I-NP	NNS	O	8	PMOD
11	after	after	B-PP	IN	O	6	NMOD
12	beginning	begin	B-VP	VBG	O	11	PMOD
13	azithromycin	azithromycin	B-NP	NN	O	12	OBJ
14	for	for	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	pharyngitis	pharyngitis	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	6	P

1	Discontinuation	Discontinuation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	azithromycin	azithromycin	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	2	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	baclofen	baclofen	B-NP	NN	O	10	NMOD
8	finally	finally	B-NP	RB	O	10	NMOD
9	resolved	resolve	I-NP	VBN	O	10	NMOD
10	hiccups	hiccup	I-NP	NNS	O	6	PMOD
11	.	.	O	.	O	1	P

1	Corticosteroids	Corticosteroid	B-NP	NNS	O	14	NMOD
2	(	(	O	(	O	6	DEP
3	dexamethasone	dexamethasone	B-NP	NN	O	5	NMOD
4	and	and	O	CC	O	5	NMOD
5	methylprednisolone	methylprednisolone	B-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	,	,	O	,	O	14	P
8	benzodiazepines	benzodiazepine	B-NP	NNS	O	14	NMOD
9	(	(	O	(	O	11	DEP
10	midazolam	midazolam	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	and	and	O	CC	O	14	NMOD
13	general	general	B-NP	JJ	O	14	NMOD
14	anaesthesia	anaesthesia	I-NP	NN	O	15	SUB
15	have	have	B-VP	VBP	O	0	ROOT
16	been	be	I-VP	VBN	O	15	VC
17	the	the	B-NP	DT	O	19	NMOD
18	specific	specific	I-NP	JJ	O	19	NMOD
19	agents	agent	I-NP	NNS	O	20	SUB
20	mentioned	mention	B-VP	VBD	O	16	VC
21	most	most	B-ADVP	RBS	O	22	AMOD
22	frequently	frequently	I-ADVP	RB	O	20	VMOD
23	in	in	B-PP	IN	O	22	AMOD
24	the	the	B-NP	DT	O	25	NMOD
25	literature	literature	I-NP	NN	O	23	PMOD
26	as	as	B-PP	IN	O	20	VMOD
27	being	be	B-VP	VBG	O	26	PMOD
28	associated	associate	I-VP	VBN	O	27	VC
29	with	with	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	development	development	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	hiccups	hiccup	B-NP	NNS	O	32	PMOD
34	.	.	O	.	O	15	P

1	Few	Few	B-NP	JJ	O	2	NMOD
2	cases	case	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	drug	drug	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	hiccups	hiccup	I-NP	NNS	O	3	PMOD
7	have	have	B-VP	VBP	O	0	ROOT
8	been	be	I-VP	VBN	O	7	VC
9	reported	report	I-VP	VBN	O	8	VC
10	related	relate	B-ADJP	VBN	O	9	VMOD
11	to	to	B-PP	TO	O	10	AMOD
12	macrolide	macrolide	B-NP	NN	O	13	NMOD
13	antimicrobials	antimicrobial	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	7	P

1	Using	Use	B-VP	VBG	O	11	SUB
2	the	the	B-NP	DT	O	8	NMOD
3	Naranjo	Naranjo	I-NP	NNP	O	8	NMOD
4	adverse	adverse	I-NP	JJ	O	8	NMOD
5	effect	effect	I-NP	NN	O	8	NMOD
6	reaction	reaction	I-NP	NN	O	8	NMOD
7	probability	probability	I-NP	NN	O	8	NMOD
8	scale	scale	I-NP	NN	O	1	OBJ
9	this	this	B-NP	DT	O	10	NMOD
10	event	event	I-NP	NN	O	1	OBJ
11	could	could	B-VP	MD	O	0	ROOT
12	be	be	I-VP	VB	O	11	VC
13	classified	classify	I-VP	VBN	O	12	VC
14	as	as	B-PP	IN	O	13	VMOD
15	possible	possible	B-ADJP	JJ	O	14	PMOD
16	(	(	O	(	O	20	DEP
17	score	score	B-NP	NN	O	19	NMOD
18	5	5	B-NP	CD	O	19	NMOD
19	points	point	I-NP	NNS	O	20	DEP
20	)	)	O	)	O	15	NMOD
21	,	,	O	,	O	13	P
22	mostly	mostly	B-ADVP	RB	O	23	PMOD
23	because	because	B-PP	IN	O	13	VMOD
24	of	of	I-PP	IN	O	23	PMOD
25	the	the	B-NP	DT	O	28	NMOD
26	close	close	I-NP	JJ	B-DNA	28	NMOD
27	temporal	temporal	I-NP	JJ	I-DNA	28	NMOD
28	sequence	sequence	I-NP	NN	I-DNA	31	NMOD
29	,	,	O	,	O	31	P
30	previous	previous	B-NP	JJ	O	31	NMOD
31	reports	report	I-NP	NNS	O	23	PMOD
32	on	on	B-PP	IN	O	31	NMOD
33	this	this	B-NP	DT	O	34	NMOD
34	reaction	reaction	I-NP	NN	O	32	PMOD
35	with	with	B-PP	IN	O	34	NMOD
36	other	other	B-NP	JJ	O	37	NMOD
37	macrolides	macrolide	I-NP	NNS	O	40	NMOD
38	and	and	O	CC	O	40	NMOD
39	the	the	B-NP	DT	O	40	NMOD
40	absence	absence	I-NP	NN	O	35	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	any	any	B-NP	DT	O	44	NMOD
43	alternative	alternative	I-NP	JJ	O	44	NMOD
44	explanation	explanation	I-NP	NN	O	41	PMOD
45	for	for	B-PP	IN	O	44	NMOD
46	hiccups	hiccup	B-NP	NNS	O	45	PMOD
47	.	.	O	.	O	11	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	hypothesis	hypothesis	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	PRD
5	a	a	B-NP	DT	O	7	NMOD
6	vagal	vagal	I-NP	JJ	O	7	NMOD
7	mechanism	mechanism	I-NP	NN	O	11	SUB
8	mediated	mediate	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	azithromycin	azithromycin	B-NP	NN	O	9	PMOD
11	could	could	B-VP	MD	O	4	SBAR
12	be	be	I-VP	VB	O	11	VC
13	the	the	B-NP	DT	O	14	NMOD
14	pathogenesis	pathogenesis	I-NP	NN	O	12	PRD
15	of	of	B-PP	IN	O	14	NMOD
16	hiccups	hiccup	B-NP	NNS	O	15	PMOD
17	in	in	B-PP	IN	O	12	VMOD
18	our	our	B-NP	PRP$	O	19	NMOD
19	patient	patient	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	3	P

1	Time	Time	B-NP	NN	O	2	NMOD
2	trends	trend	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	warfarin-associated	warfarin-associated	B-NP	JJ	O	5	NMOD
5	hemorrhage	hemorrhage	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	annual	annual	I-NP	JJ	O	3	NMOD
3	incidence	incidence	I-NP	NN	O	13	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	warfarin-related	warfarin-related	B-NP	JJ	O	6	NMOD
6	bleeding	bleeding	I-NP	NN	O	4	PMOD
7	at	at	B-PP	IN	O	3	NMOD
8	Brigham	Brigham	B-NP	NNP	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	Women	Women	B-NP	NNP	O	11	NMOD
11	's	's	B-NP	POS	O	12	NMOD
12	Hospital	Hospital	I-NP	NN	O	7	PMOD
13	increased	increase	B-VP	VBD	O	0	ROOT
14	from	from	B-PP	IN	O	13	VMOD
15	0.97/1	0.97/1	B-NP	CD	O	19	NMOD
16	,	,	O	,	O	19	P
17	000	000	B-NP	CD	O	19	NMOD
18	patient	patient	I-NP	NN	O	19	NMOD
19	admissions	admission	I-NP	NNS	O	14	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	24	NMOD
22	first	first	I-NP	JJ	O	24	NMOD
23	time	time	I-NP	NN	O	24	NMOD
24	period	period	I-NP	NN	O	20	PMOD
25	(	(	O	(	O	31	DEP
26	January	January	B-NP	NNP	O	29	NMOD
27	1995	1995	I-NP	CD	O	29	NMOD
28	to	to	B-PP	TO	O	29	NMOD
29	October	October	B-NP	NNP	O	31	DEP
30	1998	1998	I-NP	CD	O	29	NMOD
31	)	)	O	)	O	19	NMOD
32	to	to	B-PP	TO	O	14	PMOD
33	1.19/1	1.19/1	B-NP	CD	O	32	PMOD
34	,	,	O	,	O	13	P
35	000	000	B-NP	CD	O	37	NMOD
36	patient	patient	I-NP	NN	O	37	NMOD
37	admissions	admission	I-NP	NNS	O	13	OBJ
38	in	in	B-PP	IN	O	37	NMOD
39	the	the	B-NP	DT	O	42	NMOD
40	second	second	I-NP	JJ	O	42	NMOD
41	time	time	I-NP	NN	O	42	NMOD
42	period	period	I-NP	NN	O	38	PMOD
43	(	(	O	(	O	49	DEP
44	November	November	B-NP	NNP	O	47	NMOD
45	1998	1998	I-NP	CD	O	47	NMOD
46	to	to	B-PP	TO	O	47	NMOD
47	August	August	B-NP	NNP	O	49	DEP
48	2002	2002	I-NP	CD	O	47	NMOD
49	)	)	O	)	O	37	NMOD
50	of	of	B-PP	IN	O	37	NMOD
51	this	this	B-NP	DT	O	52	NMOD
52	study	study	I-NP	NN	O	50	PMOD
53	.	.	O	.	O	13	P

1	Fatal	Fatal	B-NP	JJ	O	3	NMOD
2	haemorrhagic	haemorrhagic	I-NP	JJ	O	3	NMOD
3	myocarditis	myocarditis	I-NP	NN	O	0	ROOT
4	secondary	secondary	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	cyclophosphamide	cyclophosphamide	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	3	P

1	Glyceryl	Glyceryl	B-NP	NN	O	2	NMOD
2	trinitrate	trinitrate	I-NP	NN	O	3	SUB
3	induces	induce	B-VP	VBZ	O	0	ROOT
4	attacks	attack	B-NP	NNS	O	3	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	migraine	migraine	B-NP	NN	O	5	PMOD
7	without	without	B-PP	IN	O	3	VMOD
8	aura	aura	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	3	VMOD
10	sufferers	sufferer	B-NP	NNS	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	migraine	migraine	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	aura	aura	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	7	VMOD
2	recent	recent	B-NP	JJ	O	3	NMOD
3	years	year	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	7	P
5	increasing	increase	B-VP	VBG	O	6	NMOD
6	evidence	evidence	B-NP	NN	O	7	SUB
7	has	have	B-VP	VBZ	O	0	ROOT
8	suggested	suggest	I-VP	VBN	O	7	VC
9	that	that	B-SBAR	IN	O	8	VMOD
10	the	the	B-NP	DT	O	14	NMOD
11	messenger	messenger	I-NP	NN	O	14	NMOD
12	molecule	molecule	I-NP	NN	O	14	NMOD
13	nitric	nitric	I-NP	JJ	O	14	NMOD
14	oxide	oxide	I-NP	NN	O	18	SUB
15	(	(	O	(	O	17	DEP
16	NO	NO	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	is	be	B-VP	VBZ	O	9	SBAR
19	involved	involve	I-VP	VBN	O	18	VC
20	in	in	B-PP	IN	O	19	VMOD
21	pain	pain	B-NP	NN	O	22	NMOD
22	mechanisms	mechanism	I-NP	NNS	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	migraine	migraine	B-NP	NN	O	23	PMOD
25	without	without	B-PP	IN	O	22	NMOD
26	aura	aura	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	7	P

1	In	In	B-SBAR	IN	O	20	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	clarify	clarify	I-VP	VB	O	20	VMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	same	same	I-NP	JJ	O	8	SUB
8	is	be	B-VP	VBZ	O	5	SBAR
9	true	true	B-ADJP	JJ	O	8	PRD
10	for	for	B-PP	IN	O	9	AMOD
11	migraine	migraine	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	aura	aura	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	4	P
15	in	in	B-PP	IN	O	4	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	present	present	I-NP	JJ	O	18	NMOD
18	study	study	I-NP	NN	O	15	PMOD
19	we	we	B-NP	PRP	O	20	SUB
20	examined	examine	B-VP	VBD	O	0	ROOT
21	the	the	B-NP	DT	O	23	NMOD
22	headache	headache	I-NP	NN	O	23	NMOD
23	response	response	I-NP	NN	O	20	OBJ
24	to	to	B-PP	TO	O	23	NMOD
25	intravenous	intravenous	B-NP	JJ	O	26	NMOD
26	infusion	infusion	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	glyceryl	glyceryl	B-NP	NN	O	29	NMOD
29	trinitrate	trinitrate	I-NP	NN	O	27	PMOD
30	(	(	O	(	O	32	DEP
31	GTN	GTN	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	29	NMOD
33	(	(	O	(	O	39	DEP
34	0.5	0.5	B-NP	CD	O	35	NMOD
35	microg/kg/min	microg/kg/min	I-NP	NN	O	39	DEP
36	for	for	B-PP	IN	O	35	NMOD
37	20	20	B-NP	CD	O	38	NMOD
38	min	min	I-NP	NN	O	36	PMOD
39	)	)	O	)	O	29	NMOD
40	in	in	B-PP	IN	O	20	VMOD
41	12	12	B-NP	CD	O	42	NMOD
42	sufferers	sufferer	I-NP	NNS	O	40	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	migraine	migraine	B-NP	NN	O	43	PMOD
45	with	with	B-PP	IN	O	44	NMOD
46	aura	aura	B-NP	NN	O	45	PMOD
47	.	.	O	.	O	20	P

1	Headache	Headache	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	more	more	B-ADJP	RBR	O	4	AMOD
4	severe	severe	I-ADJP	JJ	O	2	PRD
5	in	in	B-PP	IN	O	4	AMOD
6	migraineurs	migraineur	B-NP	NNS	O	5	PMOD
7	than	than	B-PP	IN	O	4	AMOD
8	in	in	B-PP	IN	O	7	PMOD
9	the	the	B-NP	DT	O	10	NMOD
10	controls	control	I-NP	NNS	O	8	PMOD
11	during	during	B-PP	IN	O	10	NMOD
12	and	and	O	CC	O	11	PMOD
13	immediately	immediately	B-ADVP	RB	O	11	PMOD
14	after	after	B-PP	IN	O	8	PMOD
15	GTN	GTN	B-NP	NN	O	16	NMOD
16	infusion	infusion	I-NP	NN	O	8	PMOD
17	(	(	O	(	O	19	DEP
18	p=0.037	p=0.037	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	as	as	B-CONJP	RB	O	16	NMOD
21	well	well	I-CONJP	RB	O	20	DEP
22	as	as	I-CONJP	IN	O	20	DEP
23	during	during	B-PP	IN	O	20	AMOD
24	the	the	B-NP	DT	O	27	NMOD
25	following	follow	I-NP	VBG	O	27	NMOD
26	11	11	I-NP	CD	O	27	NMOD
27	h	h	I-NP	NN	O	23	PMOD
28	(	(	O	(	O	32	DEP
29	p	p	B-NP	NN	O	32	DEP
30	=	=	B-VP	SYM	O	29	NMOD
31	0.008	0.008	B-NP	CD	O	30	AMOD
32	)	)	O	)	O	20	AMOD
33	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	controls	control	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	7	P
5	the	the	B-NP	DT	O	6	NMOD
6	GTN	GTN	I-NP	NN	B-protein	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	headache	headache	B-NP	PRP	O	7	OBJ
9	gradually	gradually	B-ADVP	RB	O	7	VMOD
10	disappeared	disappear	B-VP	VBD	O	7	VMOD
11	,	,	O	,	O	7	P
12	whereas	whereas	O	IN	O	7	VMOD
13	in	in	B-PP	IN	O	15	VMOD
14	migraineurs	migraineur	B-NP	NNS	O	13	PMOD
15	peak	peak	B-VP	VBP	O	18	VMOD
16	headache	headache	B-NP	NN	O	17	NMOD
17	intensity	intensity	I-NP	NN	O	18	SUB
18	occurred	occur	B-VP	VBD	O	12	SBAR
19	at	at	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	mean	mean	I-NP	JJ	O	22	NMOD
22	time	time	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	240	240	B-NP	CD	O	26	NMOD
25	min	min	I-NP	NN	O	26	NMOD
26	post-infusion	post-infusion	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	4	SUB
3	therefore	therefore	B-ADVP	RB	O	4	VMOD
4	suggest	suggest	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	NO	NO	B-NP	NN	B-protein	7	SUB
7	is	be	B-VP	VBZ	O	5	SBAR
8	involved	involve	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	pain	pain	I-NP	NN	O	12	NMOD
12	mechanisms	mechanism	I-NP	NNS	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	migraine	migraine	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	aura	aura	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	4	P

1	Stroke	Stroke	B-NP	NN	O	6	NMOD
2	and	and	I-NP	CC	O	6	NMOD
3	cocaine	cocaine	I-NP	NN	O	6	NMOD
4	or	or	I-NP	CC	O	6	NMOD
5	amphetamine	amphetamine	I-NP	NN	O	6	NMOD
6	use	use	I-NP	NN	O	0	ROOT
7	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cocaine	cocaine	B-NP	NN	O	7	NMOD
5	and	and	I-NP	CC	O	7	NMOD
6	amphetamine	amphetamine	I-NP	NN	O	7	NMOD
7	use	use	I-NP	NN	O	3	PMOD
8	with	with	B-PP	IN	O	2	NMOD
9	hemorrhagic	hemorrhagic	B-NP	JJ	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	ischemic	ischemic	I-NP	JJ	O	12	NMOD
12	stroke	stroke	I-NP	NN	O	8	PMOD
13	is	be	B-VP	VBZ	O	0	ROOT
14	based	base	I-VP	VBN	O	13	VC
15	almost	almost	B-ADVP	RB	O	14	VMOD
16	solely	solely	I-ADVP	RB	O	15	AMOD
17	on	on	B-PP	IN	O	15	AMOD
18	data	datum	B-NP	NNS	O	17	PMOD
19	from	from	B-PP	IN	O	18	NMOD
20	case	case	B-NP	NN	O	21	NMOD
21	series	series	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	3	NMOD
2	limited	limited	I-NP	JJ	O	3	NMOD
3	number	number	I-NP	NN	O	15	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	epidemiologic	epidemiologic	B-NP	JJ	O	6	NMOD
6	studies	study	I-NP	NNS	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	stroke	stroke	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	use	use	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	cocaine	cocaine	B-NP	NN	O	14	NMOD
13	and/or	and/or	I-NP	CC	O	14	NMOD
14	amphetamine	amphetamine	I-NP	NN	O	11	PMOD
15	have	have	B-VP	VBP	O	0	ROOT
16	been	be	I-VP	VBN	O	15	VC
17	done	do	I-VP	VBN	O	16	VC
18	in	in	B-PP	IN	O	17	VMOD
19	settings	setting	B-NP	NNS	O	18	PMOD
20	that	that	B-NP	WDT	O	19	NMOD
21	serve	serve	B-VP	VBP	O	20	SBAR
22	mostly	mostly	B-ADVP	RB	O	21	VMOD
23	the	the	B-NP	DT	O	26	NMOD
24	poor	poor	I-NP	JJ	O	26	NMOD
25	and/or	and/or	O	CC	O	26	NMOD
26	minorities	minority	B-NP	NNS	O	21	VMOD
27	.	.	O	.	O	15	P

1	The	The	B-NP	DT	O	3	NMOD
2	univariate	univariate	I-NP	JJ	O	3	NMOD
3	matched	matched	I-NP	NN	O	4	SUB
4	odds	odd	B-VP	VBZ	O	0	ROOT
5	ratio	ratio	B-NP	NN	O	4	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	stroke	stroke	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	4	VMOD
9	women	woman	B-NP	NNS	O	17	SUB
10	who	who	B-NP	WP	O	9	NMOD
11	admitted	admit	B-VP	VBD	O	10	SBAR
12	to	to	B-PP	TO	O	11	VMOD
13	using	use	B-VP	VBG	O	12	PMOD
14	cocaine	cocaine	B-NP	NN	O	16	NMOD
15	and/or	and/or	I-NP	CC	O	16	NMOD
16	amphetamine	amphetamine	I-NP	NN	O	13	OBJ
17	was	be	B-VP	VBD	O	8	SBAR
18	8.5	8.5	B-NP	CD	O	17	PRD
19	(	(	O	(	O	26	DEP
20	95	95	B-NP	CD	O	23	NMOD
21	%	%	I-NP	NN	O	23	NMOD
22	confidence	confidence	I-NP	NN	O	23	NMOD
23	interval	interval	I-NP	NN	O	26	DEP
24	=	=	B-VP	SYM	O	23	NMOD
25	3.6-20.0	3.6-20.0	B-NP	CD	O	24	AMOD
26	)	)	O	)	O	18	NMOD
27	.	.	O	.	O	4	P

1	Prevention	Prevention	B-NP	NN	O	9	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	breast	breast	B-NP	NN	O	4	NMOD
4	cancer	cancer	I-NP	NN	O	2	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	tamoxifen	tamoxifen	B-NP	NN	O	5	PMOD
7	:	:	O	:	O	1	P
8	preliminary	preliminary	B-NP	JJ	O	9	NMOD
9	findings	finding	I-NP	NNS	O	0	ROOT
10	from	from	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	Italian	Italian	I-NP	JJ	O	14	NMOD
13	randomised	randomise	I-NP	VBN	O	14	NMOD
14	trial	trial	I-NP	NN	O	10	PMOD
15	among	among	B-PP	IN	O	14	NMOD
16	hysterectomised	hysterectomised	B-NP	JJ	O	17	NMOD
17	women	woman	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	9	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Tamoxifen	Tamoxifen	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	a	a	B-NP	DT	O	8	NMOD
6	candidate	candidate	I-NP	NN	O	8	NMOD
7	chemopreventive	chemopreventive	I-NP	JJ	O	8	NMOD
8	agent	agent	I-NP	NN	O	4	PRD
9	in	in	B-PP	IN	O	8	NMOD
10	breast	breast	B-NP	NN	O	11	NMOD
11	cancer	cancer	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	4	P
13	although	although	B-SBAR	IN	O	4	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	drug	drug	I-NP	NN	O	16	SUB
16	may	may	B-VP	MD	O	13	SBAR
17	be	be	I-VP	VB	O	16	VC
18	associated	associate	I-VP	VBN	O	17	VC
19	with	with	B-PP	IN	O	18	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	development	development	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	endometrial	endometrial	B-NP	JJ	O	24	NMOD
24	cancer	cancer	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	4	P

1	METHODS	METHODS	B-NP	NNS	O	9	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	9	VMOD
4	October	October	B-NP	NNP	O	6	NMOD
5	,	,	O	,	O	6	P
6	1992	1992	B-NP	CD	O	3	PMOD
7	,	,	O	,	O	9	P
8	we	we	B-NP	PRP	O	9	SUB
9	started	start	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	15	NMOD
11	double-blind	double-blind	I-NP	JJ	O	12	AMOD
12	placebo-controlled	placebo-controlled	I-NP	JJ	O	15	NMOD
13	,	,	I-NP	,	O	12	P
14	randomised	randomise	I-NP	VBN	O	15	NMOD
15	trial	trial	I-NP	NN	O	9	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	tamoxifen	tamoxifen	B-NP	NN	O	16	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	women	woman	B-NP	NNS	O	18	PMOD
20	(	(	O	(	O	15	NMOD
21	mainly	mainly	B-ADVP	RB	O	22	PMOD
22	in	in	B-PP	IN	O	20	PMOD
23	Italy	Italy	B-NP	NNP	O	22	PMOD
24	)	)	O	)	O	23	NMOD
25	who	who	B-NP	WP	O	23	NMOD
26	did	do	B-VP	VBD	O	25	SBAR
27	not	not	I-VP	RB	O	26	VMOD
28	have	have	I-VP	VB	O	26	VC
29	breast	breast	B-NP	NN	O	30	NMOD
30	cancer	cancer	I-NP	NN	O	28	OBJ
31	and	and	O	CC	O	22	PMOD
32	who	who	B-NP	WP	O	22	PMOD
33	had	have	B-VP	VBD	O	32	SBAR
34	had	have	I-VP	VBN	O	33	VC
35	a	a	B-NP	DT	O	36	NMOD
36	hysterectomy	hysterectomy	I-NP	NN	O	34	OBJ
37	.	.	O	.	O	9	P

1	There	There	B-NP	EX	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	difference	difference	I-NP	NN	O	2	PRD
5	in	in	B-PP	IN	O	4	NMOD
6	breast-cancer	breast-cancer	B-NP	NN	O	7	NMOD
7	frequency	frequency	I-NP	NN	O	5	PMOD
8	between	between	B-PP	IN	O	4	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	placebo	placebo	I-NP	NN	O	16	NMOD
11	(	(	O	(	O	14	DEP
12	22	22	B-NP	CD	O	13	NMOD
13	cases	case	I-NP	NNS	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	and	and	O	CC	O	16	NMOD
16	tamoxifen	tamoxifen	B-NP	NN	O	8	PMOD
17	(	(	O	(	O	19	DEP
18	19	19	B-NP	CD	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	arms	arm	B-NP	NNS	O	16	NMOD
21	.	.	O	.	O	2	P

1	There	There	B-NP	EX	O	2	SUB
2	is	be	B-VP	VBZ	O	35	VMOD
3	a	a	B-NP	DT	O	6	NMOD
4	statistically	statistically	I-NP	RB	O	5	AMOD
5	significant	significant	I-NP	JJ	O	6	NMOD
6	reduction	reduction	I-NP	NN	O	2	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	breast	breast	B-NP	NN	O	9	NMOD
9	cancer	cancer	I-NP	NN	O	7	PMOD
10	among	among	B-PP	IN	O	6	NMOD
11	women	woman	B-NP	NNS	O	10	PMOD
12	receiving	receive	B-VP	VBG	O	11	NMOD
13	tamoxifen	tamoxifen	B-NP	NN	O	12	OBJ
14	who	who	B-NP	WP	O	6	NMOD
15	also	also	B-ADVP	RB	O	16	VMOD
16	used	use	B-VP	VBD	O	14	SBAR
17	hormone-replacement	hormone-replacement	B-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	16	OBJ
19	during	during	B-PP	IN	O	16	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	trial	trial	I-NP	NN	O	19	PMOD
22	:	:	O	:	O	35	P
23	among	among	B-PP	IN	O	35	VMOD
24	390	390	B-NP	CD	O	25	NMOD
25	women	woman	I-NP	NNS	O	23	PMOD
26	on	on	B-PP	IN	O	25	NMOD
27	such	such	B-NP	JJ	O	28	NMOD
28	therapy	therapy	I-NP	NN	O	26	PMOD
29	and	and	O	CC	O	23	PMOD
30	allocated	allocate	B-VP	VBN	O	23	PMOD
31	to	to	B-PP	TO	O	30	VMOD
32	placebo	placebo	B-NP	NN	O	31	PMOD
33	,	,	O	,	O	35	P
34	we	we	B-NP	PRP	O	35	SUB
35	found	find	B-VP	VBD	O	0	ROOT
36	eight	eight	B-NP	CD	O	37	NMOD
37	cases	case	I-NP	NNS	O	35	OBJ
38	of	of	B-PP	IN	O	37	NMOD
39	breast	breast	B-NP	NN	O	40	NMOD
40	cancer	cancer	I-NP	NN	O	38	PMOD
41	compared	compare	B-VP	VBN	O	35	VMOD
42	with	with	B-PP	IN	O	41	VMOD
43	one	one	B-NP	CD	O	44	NMOD
44	case	case	I-NP	NN	O	42	PMOD
45	among	among	B-PP	IN	O	41	VMOD
46	362	362	B-NP	CD	O	47	NMOD
47	women	woman	I-NP	NNS	O	45	PMOD
48	allocated	allocate	B-VP	VBN	O	47	NMOD
49	to	to	B-PP	TO	O	48	VMOD
50	tamoxifen	tamoxifen	B-NP	NN	O	49	PMOD
51	.	.	O	.	O	35	P

1	Compared	Compare	B-PP	VBN	O	8	VMOD
2	with	with	B-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	5	NMOD
4	placebo	placebo	I-NP	NN	O	5	NMOD
5	group	group	I-NP	NN	O	2	PMOD
6	,	,	O	,	O	8	P
7	there	there	B-NP	EX	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	a	a	B-NP	DT	O	12	NMOD
10	significantly	significantly	I-NP	RB	O	11	AMOD
11	increased	increase	I-NP	VBN	O	12	NMOD
12	risk	risk	I-NP	NN	O	17	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	vascular	vascular	B-NP	JJ	O	15	NMOD
15	events	event	I-NP	NNS	O	13	PMOD
16	and	and	O	CC	O	17	NMOD
17	hypertriglyceridaemia	hypertriglyceridaemia	B-NP	NN	O	8	PRD
18	among	among	B-PP	IN	O	17	NMOD
19	women	woman	B-NP	NNS	O	18	PMOD
20	on	on	B-PP	IN	O	19	NMOD
21	tamoxifen	tamoxifen	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	8	P

1	INTERPRETATION	INTERPRETATION	B-NP	NN	O	26	NMOD
2	:	:	O	:	O	1	P
3	Although	Although	B-SBAR	IN	O	1	NMOD
4	this	this	B-NP	DT	O	6	NMOD
5	preliminary	preliminary	I-NP	JJ	O	6	NMOD
6	analysis	analysis	I-NP	NN	O	7	SUB
7	has	have	B-VP	VBZ	O	3	SBAR
8	low	low	B-NP	JJ	O	9	NMOD
9	power	power	I-NP	NN	O	7	OBJ
10	,	,	O	,	O	1	P
11	in	in	B-PP	IN	O	1	NMOD
12	this	this	B-NP	DT	O	13	NMOD
13	cohort	cohort	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	women	woman	B-NP	NNS	O	14	PMOD
16	at	at	B-PP	IN	O	15	NMOD
17	low-to-normal	low-to-normal	B-NP	JJ	O	18	NMOD
18	risk	risk	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	breast	breast	B-NP	NN	O	21	NMOD
21	cancer	cancer	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	26	P
23	the	the	B-NP	DT	O	26	NMOD
24	postulated	postulate	I-NP	VBN	O	26	NMOD
25	protective	protective	I-NP	JJ	O	26	NMOD
26	effects	effect	I-NP	NNS	O	29	SUB
27	of	of	B-PP	IN	O	26	NMOD
28	tamoxifen	tamoxifen	B-NP	NN	O	27	PMOD
29	are	be	B-VP	VBP	O	0	ROOT
30	not	not	O	RB	O	29	VMOD
31	yet	yet	B-ADJP	RB	O	29	VMOD
32	apparent	apparent	I-ADJP	JJ	O	29	PRD
33	.	.	O	.	O	29	P

1	A	A	B-NP	DT	O	2	NMOD
2	measure	measure	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	pupillary	pupillary	B-NP	JJ	O	5	NMOD
5	oscillation	oscillation	I-NP	NN	O	3	PMOD
6	as	as	B-PP	IN	O	2	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	marker	marker	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cocaine	cocaine	B-NP	NN	O	12	NMOD
11	induced	induced	I-NP	JJ	O	12	NMOD
12	paranoia	paranoia	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	2	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	paranoia	paranoia	B-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	CIP	CIP	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	remains	remain	B-VP	VBZ	O	2	VMOD
8	an	an	B-NP	DT	O	10	NMOD
9	important	important	I-NP	JJ	O	10	NMOD
10	drug	drug	I-NP	NN	O	12	NMOD
11	induced	induce	B-VP	VBD	O	12	NMOD
12	model	model	B-NP	NN	O	7	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	idiopathic	idiopathic	B-NP	JJ	O	15	NMOD
15	paranoia	paranoia	I-NP	NN	O	13	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	which	which	B-NP	WDT	O	16	PMOD
18	no	no	B-NP	DT	O	20	NMOD
19	psychophysiologic	psychophysiologic	I-NP	JJ	B-protein	20	NMOD
20	marker	marker	I-NP	NN	I-protein	16	PMOD
21	has	have	B-VP	VBZ	O	2	VMOD
22	yet	yet	I-VP	RB	O	21	VMOD
23	emerged	emerge	I-VP	VBN	O	21	VC
24	.	.	O	.	O	2	P

1	Seizures	Seizure	B-NP	NNS	O	0	ROOT
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	combined	combine	B-NP	VBN	O	6	NMOD
5	levomepromazine-fluvoxamine	levomepromazine-fluvoxamine	I-NP	NN	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	combined	combine	B-NP	VBN	O	10	NMOD
7	levomepromazine-fluvoxamine	levomepromazine-fluvoxamine	I-NP	NN	O	10	NMOD
8	treatment	treatment	I-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	seizures	seizure	I-NP	NNS	O	5	PMOD
11	.	.	O	.	O	2	P

1	Why	Why	B-ADVP	WRB	O	0	ROOT
2	may	may	O	MD	O	1	SBAR
3	epsilon-aminocaproic	epsilon-aminocaproic	B-NP	JJ	O	4	NMOD
4	acid	acid	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	EACA	EACA	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	induce	induce	B-VP	VBP	O	2	SBAR
9	myopathy	myopathy	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	man	man	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	1	P

1	Sixty	Sixty	B-NP	CD	O	2	NMOD
2	percent	percent	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	males	male	I-NP	NNS	O	3	PMOD
6	developed	develop	B-VP	VBD	O	0	ROOT
7	breast	breast	B-NP	NN	O	8	NMOD
8	changes	change	I-NP	NNS	O	10	NMOD
9	or	or	O	CC	O	10	NMOD
10	impotence	impotence	B-NP	NN	O	6	OBJ
11	while	while	B-SBAR	IN	O	6	VMOD
12	taking	take	B-VP	VBG	O	11	SBAR
13	cimetidine	cimetidine	B-NP	NN	O	12	OBJ
14	and	and	B-PP	CC	O	11	DEP
15	in	in	B-PP	IN	O	14	DEP
16	all	all	B-NP	DT	O	17	NMOD
17	cases	case	I-NP	NNS	O	15	PMOD
18	these	these	B-NP	DT	O	19	NMOD
19	changes	change	I-NP	NNS	O	15	PMOD
20	disappeared	disappear	B-VP	VBD	O	19	NMOD
21	when	when	B-ADVP	WRB	O	20	VMOD
22	cimetidine	cimetidine	B-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	21	SBAR
24	replaced	replace	I-VP	VBN	O	23	VC
25	by	by	B-PP	IN	O	24	VMOD
26	ranitidine	ranitidine	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	6	P

1	Treatment	Treatment	B-NP	NN	O	26	NMOD
2	with	with	B-PP	IN	O	1	NMOD
3	high	high	B-NP	JJ	O	4	NMOD
4	doses	dose	I-NP	NNS	O	19	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	cimetidine	cimetidine	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	17	DEP
8	one	one	B-NP	CD	O	10	AMOD
9	to	to	I-NP	TO	O	10	AMOD
10	60	60	I-NP	CD	O	11	NMOD
11	months	month	I-NP	NNS	O	17	DEP
12	;	;	O	:	O	17	P
13	median	median	B-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	11	11	B-NP	CD	O	16	NMOD
16	months	month	I-NP	NNS	O	17	DEP
17	)	)	O	)	O	4	NMOD
18	or	or	O	CC	O	19	NMOD
19	ranitidine	ranitidine	B-NP	NN	O	24	NMOD
20	(	(	O	(	O	24	NMOD
21	two	two	B-NP	CD	O	23	AMOD
22	to	to	I-NP	TO	O	23	AMOD
23	31	31	I-NP	CD	O	24	NMOD
24	months	month	I-NP	NNS	O	2	PMOD
25	;	;	O	:	O	1	P
26	median	median	B-NP	NN	O	29	NMOD
27	,	,	O	,	O	29	P
28	14	14	B-NP	CD	O	29	NMOD
29	months	month	I-NP	NNS	O	31	SUB
30	)	)	O	)	O	29	NMOD
31	was	be	B-VP	VBD	O	49	VMOD
32	not	not	I-VP	RB	O	31	VMOD
33	associated	associate	I-VP	VBN	O	31	VC
34	with	with	B-PP	IN	O	33	VMOD
35	hepatic	hepatic	B-NP	JJ	O	40	NMOD
36	or	or	I-NP	CC	O	40	NMOD
37	hematologic	hematologic	I-NP	JJ	O	38	NMOD
38	toxicity	toxicity	I-NP	NN	O	40	NMOD
39	or	or	I-NP	CC	O	40	NMOD
40	alterations	alteration	I-NP	NNS	O	34	PMOD
41	of	of	B-PP	IN	O	40	NMOD
42	serum	serum	B-NP	NN	O	44	NMOD
43	gastrin	gastrin	I-NP	NN	O	44	NMOD
44	concentrations	concentration	I-NP	NNS	O	41	PMOD
45	,	,	O	,	O	49	P
46	but	but	O	CC	O	49	VMOD
47	ranitidine	ranitidine	B-NP	NN	O	48	NMOD
48	therapy	therapy	I-NP	NN	O	49	SUB
49	was	be	B-VP	VBD	O	0	ROOT
50	associated	associate	I-VP	VBN	O	49	VC
51	with	with	B-PP	IN	O	50	VMOD
52	a	a	B-NP	DT	O	57	NMOD
53	significantly	significantly	I-NP	RB	O	54	AMOD
54	lower	low	I-NP	JJR	O	57	NMOD
55	serum	serum	I-NP	NN	O	57	NMOD
56	creatinine	creatinine	I-NP	NN	O	57	NMOD
57	level	level	I-NP	NN	O	51	PMOD
58	than	than	B-SBAR	IN	O	50	VMOD
59	seen	see	B-VP	VBN	O	58	SBAR
60	with	with	B-PP	IN	O	59	VMOD
61	cimetidine	cimetidine	B-NP	NN	O	62	NMOD
62	therapy	therapy	I-NP	NN	O	60	PMOD
63	.	.	O	.	O	49	P

1	Beta-2-adrenoceptor-mediated	Beta-2-adrenoceptor-mediated	B-NP	JJ	O	2	NMOD
2	hypokalemia	hypokalemia	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	its	its	B-NP	PRP$	O	5	NMOD
5	abolishment	abolishment	I-NP	NN	O	0	ROOT
6	by	by	B-PP	IN	O	5	NMOD
7	oxprenolol	oxprenolol	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	6	NMOD
2	time	time	I-NP	NN	O	3	NMOD
3	course	course	I-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	concentration-effect	concentration-effect	B-NP	NN	O	6	NMOD
6	relationship	relationship	I-NP	NN	O	11	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	terbutaline	terbutaline	B-NP	NN	O	10	NMOD
9	induced	induce	I-NP	VBN	O	10	NMOD
10	hypokalemia	hypokalemia	I-NP	NN	O	7	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	studied	study	I-VP	VBN	O	11	VC
13	,	,	O	,	O	12	P
14	using	use	B-VP	VBG	O	12	VMOD
15	computer-aided	computer-aided	B-NP	JJ	O	17	NMOD
16	pharmacokinetic-dynamic	pharmacokinetic-dynamic	I-NP	JJ	O	17	NMOD
17	modeling	modeling	I-NP	NN	O	14	OBJ
18	.	.	O	.	O	11	P

1	Subsequently	Subsequently	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	investigated	investigate	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	efficacy	efficacy	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	oxprenolol	oxprenolol	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	antagonizing	antagonize	B-VP	VBG	O	8	PMOD
10	such	such	B-NP	JJ	O	11	NMOD
11	hypokalemia	hypokalemia	I-NP	NN	O	9	OBJ
12	,	,	O	,	O	5	P
13	together	together	B-ADVP	RB	O	14	PMOD
14	with	with	B-PP	IN	O	5	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	pharmacokinetic	pharmacokinetic	I-NP	JJ	O	17	NMOD
17	interaction	interaction	I-NP	NN	O	14	PMOD
18	between	between	B-PP	IN	O	17	NMOD
19	both	both	B-NP	DT	O	20	NMOD
20	drugs	drug	I-NP	NNS	O	18	PMOD
21	.	.	O	.	O	3	P

1	Midline	Midline	B-NP	NN	O	3	NMOD
2	B3	B3	I-NP	NN	O	3	NMOD
3	serotonin	serotonin	I-NP	NN	O	4	SUB
4	nerves	nerve	B-VP	VBZ	O	0	ROOT
5	in	in	B-PP	IN	O	4	VMOD
6	rat	rat	B-NP	NN	O	7	NMOD
7	medulla	medulla	I-NP	NN	O	5	PMOD
8	are	be	B-VP	VBP	O	4	VMOD
9	involved	involve	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	hypotensive	hypotensive	B-NP	JJ	O	12	NMOD
12	effect	effect	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	methyldopa	methyldopa	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	4	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	experiments	experiment	I-NP	NNS	O	6	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	laboratory	laboratory	I-NP	NN	O	3	PMOD
6	have	have	B-VP	VBP	O	0	ROOT
7	shown	show	I-VP	VBN	O	6	VC
8	that	that	B-SBAR	IN	O	7	VMOD
9	microinjection	microinjection	B-NP	NN	O	24	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	methyldopa	methyldopa	B-NP	NN	O	10	PMOD
12	onto	onto	B-PP	IN	O	9	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	ventrolateral	ventrolateral	I-NP	JJ	B-cell_type	15	NMOD
15	cells	cell	I-NP	NNS	I-cell_type	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	B3	B3	I-NP	NN	B-DNA	20	NMOD
19	serotonin	serotonin	I-NP	NN	I-DNA	20	NMOD
20	neurons	neuron	I-NP	NNS	I-DNA	16	PMOD
21	in	in	B-PP	IN	O	9	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	medulla	medulla	I-NP	NN	O	21	PMOD
24	elicits	elicit	B-VP	VBZ	O	8	SBAR
25	a	a	B-NP	DT	O	27	NMOD
26	hypotensive	hypotensive	I-NP	JJ	O	27	NMOD
27	response	response	I-NP	NN	O	24	OBJ
28	mediated	mediate	B-VP	VBN	O	27	NMOD
29	by	by	B-PP	IN	O	28	VMOD
30	a	a	B-NP	DT	O	31	NMOD
31	projection	projection	I-NP	NN	O	29	PMOD
32	descending	descend	B-VP	VBG	O	31	NMOD
33	into	into	B-PP	IN	O	32	VMOD
34	the	the	B-NP	DT	O	36	NMOD
35	spinal	spinal	I-NP	JJ	O	36	NMOD
36	cord	cord	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	25	VMOD
2	spontaneously	spontaneously	B-NP	RB	O	3	AMOD
3	hypertensive	hypertensive	I-NP	JJ	O	6	NMOD
4	,	,	I-NP	,	O	6	P
5	stroke-prone	stroke-prone	I-NP	JJ	O	6	NMOD
6	rats	rat	I-NP	NNS	O	1	PMOD
7	,	,	O	,	O	25	P
8	microinjection	microinjection	B-NP	NN	O	25	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	methyldopa	methyldopa	B-NP	NN	O	9	PMOD
11	into	into	B-PP	IN	O	8	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	area	area	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	20	NMOD
16	midline	midline	I-NP	NN	O	20	NMOD
17	B3	B3	I-NP	NN	O	20	NMOD
18	serotonin	serotonin	I-NP	NN	O	20	NMOD
19	cell	cell	I-NP	NN	O	20	NMOD
20	group	group	I-NP	NN	O	14	PMOD
21	in	in	B-PP	IN	O	8	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	ventral	ventral	I-NP	JJ	O	24	NMOD
24	medulla	medulla	I-NP	NN	O	21	PMOD
25	caused	cause	B-VP	VBD	O	0	ROOT
26	a	a	B-NP	DT	O	28	NMOD
27	potent	potent	I-NP	JJ	O	28	NMOD
28	hypotension	hypotension	I-NP	NN	O	25	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	30-40	30-40	B-NP	CD	O	32	NMOD
31	mm	mm	I-NP	NN	O	32	NMOD
32	Hg	Hg	I-NP	NN	O	29	PMOD
33	,	,	O	,	O	28	P
34	which	which	B-NP	WDT	O	28	NMOD
35	was	be	B-VP	VBD	O	34	SBAR
36	maximal	maximal	B-ADJP	JJ	O	38	NMOD
37	2-3	2-3	B-NP	CD	O	38	NMOD
38	h	h	I-NP	NN	O	39	PMOD
39	after	after	B-PP	IN	O	35	VMOD
40	administration	administration	B-NP	NN	O	39	PMOD
41	and	and	O	CC	O	35	VMOD
42	was	be	B-VP	VBD	O	35	VMOD
43	abolished	abolish	I-VP	VBN	O	42	VC
44	by	by	B-PP	IN	O	43	VMOD
45	the	the	B-NP	DT	O	47	NMOD
46	serotonin	serotonin	I-NP	NN	O	47	NMOD
47	neurotoxin	neurotoxin	I-NP	NN	O	44	PMOD
48	5	5	I-NP	CD	O	47	NMOD
49	,	,	O	,	O	50	P
50	7-dihydroxytryptamine	7-dihydroxytryptamine	B-NP	NN	O	47	NMOD
51	(	(	O	(	O	55	DEP
52	5	5	B-NP	CD	O	54	NMOD
53	,	,	O	,	O	54	P
54	7-DHT	7-DHT	B-NP	NN	O	55	DEP
55	)	)	O	)	O	50	NMOD
56	injected	inject	B-VP	VBN	O	50	NMOD
57	intracerebroventricularly	intracerebroventricularly	B-ADVP	RB	O	56	VMOD
58	.	.	O	.	O	25	P

1	However	However	B-ADVP	RB	O	24	VMOD
2	,	,	O	,	O	24	P
3	intraspinal	intraspinal	B-NP	JJ	O	4	NMOD
4	injection	injection	I-NP	NN	O	24	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	5	5	B-NP	CD	O	10	VMOD
7	,	,	O	,	O	10	P
8	7-DHT	7-DHT	B-NP	NN	O	10	SUB
9	to	to	B-VP	TO	O	10	VMOD
10	produce	produce	I-VP	VB	O	5	PMOD
11	a	a	B-NP	DT	O	14	NMOD
12	more	more	I-NP	RBR	O	13	AMOD
13	selective	selective	I-NP	JJ	O	14	NMOD
14	lesion	lesion	I-NP	NN	O	10	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	only	only	B-VP	RB	O	17	VMOD
17	descending	descend	I-VP	VBG	O	15	PMOD
18	serotonin	serotonin	B-NP	NN	O	19	NMOD
19	projections	projection	I-NP	NNS	O	17	OBJ
20	in	in	B-PP	IN	O	17	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	spinal	spinal	I-NP	JJ	O	23	NMOD
23	cord	cord	I-NP	NN	O	20	PMOD
24	did	do	B-VP	VBD	O	0	ROOT
25	not	not	I-VP	RB	O	24	VMOD
26	affect	affect	I-VP	VB	O	24	VC
27	this	this	B-NP	DT	O	28	NMOD
28	hypotension	hypotension	I-NP	NN	O	26	OBJ
29	.	.	O	.	O	24	P

1	Yohimbine	Yohimbine	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	sexual	sexual	B-NP	JJ	O	6	NMOD
5	side	side	I-NP	NN	O	6	NMOD
6	effects	effect	I-NP	NNS	O	3	PMOD
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	serotonin	serotonin	B-NP	NN	O	11	NMOD
10	reuptake	reuptake	I-NP	NN	O	11	NMOD
11	blockers	blocker	I-NP	NNS	O	8	PMOD
12	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Preclinical	Preclinical	B-NP	JJ	O	5	AMOD
4	and	and	I-NP	CC	O	5	AMOD
5	clinical	clinical	I-NP	JJ	O	6	NMOD
6	studies	study	I-NP	NNS	O	7	SUB
7	suggest	suggest	B-VP	VBP	O	1	NMOD
8	that	that	B-SBAR	IN	O	7	VMOD
9	yohimbine	yohimbine	B-NP	PRP	O	10	SUB
10	facilitates	facilitate	B-VP	VBZ	O	8	SBAR
11	sexual	sexual	B-NP	JJ	O	12	NMOD
12	behavior	behavior	I-NP	NN	O	10	OBJ
13	and	and	O	CC	O	10	VMOD
14	may	may	B-VP	MD	O	10	VMOD
15	be	be	I-VP	VB	O	14	VC
16	helpful	helpful	B-ADJP	JJ	O	15	PRD
17	in	in	B-PP	IN	O	16	AMOD
18	the	the	B-NP	DT	O	19	NMOD
19	treatment	treatment	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	male	male	B-NP	JJ	O	22	NMOD
22	impotence	impotence	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	4	NMOD
2	single	single	I-NP	JJ	O	4	NMOD
3	case	case	I-NP	NN	O	4	NMOD
4	report	report	I-NP	NN	O	5	SUB
5	suggests	suggest	B-VP	VBZ	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	yohimbine	yohimbine	B-NP	PRP	O	8	SUB
8	may	may	B-VP	MD	O	6	SBAR
9	be	be	I-VP	VB	O	8	VC
10	used	use	I-VP	VBN	O	9	VC
11	to	to	B-VP	TO	O	12	VMOD
12	treat	treat	I-VP	VB	O	10	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	sexual	sexual	I-NP	JJ	O	16	NMOD
15	side	side	I-NP	NN	O	16	NMOD
16	effects	effect	I-NP	NNS	O	12	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	clomipramine	clomipramine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	5	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	evaluated	evaluate	B-VP	VBD	O	0	ROOT
4	yohimbine	yohimbine	B-NP	PRP	O	3	OBJ
5	as	as	B-PP	IN	O	3	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	for	for	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	12	NMOD
10	sexual	sexual	I-NP	JJ	O	12	NMOD
11	side	side	I-NP	NN	O	12	NMOD
12	effects	effect	I-NP	NNS	O	8	PMOD
13	caused	cause	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	serotonin	serotonin	B-NP	NN	O	17	NMOD
16	reuptake	reuptake	I-NP	NN	O	17	NMOD
17	blockers	blocker	I-NP	NNS	O	14	PMOD
18	.	.	O	.	O	3	P

1	METHOD	METHOD	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Six	Six	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	29	SUB
5	with	with	B-PP	IN	O	4	NMOD
6	either	either	B-NP	CC	O	17	NMOD
7	obsessive	obsessive	I-NP	JJ	O	9	NMOD
8	compulsive	compulsive	I-NP	JJ	O	9	NMOD
9	disorder	disorder	I-NP	NN	O	17	NMOD
10	,	,	O	,	O	17	P
11	trichotillomania	trichotillomania	B-NP	NN	O	17	NMOD
12	,	,	O	,	O	17	P
13	anxiety	anxiety	B-NP	NN	O	17	NMOD
14	,	,	O	,	O	17	P
15	or	or	O	CC	O	17	NMOD
16	affective	affective	B-NP	JJ	O	17	NMOD
17	disorders	disorder	I-NP	NNS	O	5	PMOD
18	who	who	B-NP	WP	O	17	NMOD
19	suffered	suffer	B-VP	VBD	O	18	SBAR
20	sexual	sexual	B-NP	JJ	O	22	NMOD
21	side	side	I-NP	NN	O	22	NMOD
22	effects	effect	I-NP	NNS	O	19	OBJ
23	after	after	B-PP	IN	O	19	VMOD
24	treatment	treatment	B-NP	NN	O	23	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	serotonin	serotonin	B-NP	NN	O	28	NMOD
27	reuptake	reuptake	I-NP	NN	O	28	NMOD
28	blockers	blocker	I-NP	NNS	O	25	PMOD
29	were	be	B-VP	VBD	O	0	ROOT
30	given	give	I-VP	VBN	O	29	VC
31	yohimbine	yohimbine	B-NP	NN	O	30	OBJ
32	on	on	B-PP	IN	O	31	NMOD
33	a	a	B-NP	DT	O	35	NMOD
34	p.r.n.	p.r.n.	I-NP	JJ	O	35	NMOD
35	basis	basis	I-NP	NN	O	32	PMOD
36	in	in	B-PP	IN	O	30	VMOD
37	an	an	B-NP	DT	O	40	NMOD
38	open	open	I-NP	JJ	O	40	NMOD
39	clinical	clinical	I-NP	JJ	O	40	NMOD
40	trial	trial	I-NP	NN	O	36	PMOD
41	.	.	O	.	O	29	P

1	Side	Side	B-NP	NN	O	2	NMOD
2	effects	effect	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	yohimbine	yohimbine	B-NP	NN	O	3	PMOD
5	included	include	B-VP	VBD	O	0	ROOT
6	excessive	excessive	B-NP	JJ	O	7	NMOD
7	sweating	sweating	I-NP	NN	O	15	NMOD
8	,	,	O	,	O	15	P
9	increased	increase	B-NP	VBN	O	10	NMOD
10	anxiety	anxiety	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	and	and	O	CC	O	15	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	wound-up	wound-up	I-NP	JJ	O	15	NMOD
15	feeling	feeling	I-NP	NN	O	5	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	some	some	B-NP	DT	O	18	NMOD
18	patients	patient	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	5	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	indicate	indicate	B-VP	VBP	O	1	NMOD
9	that	that	B-SBAR	IN	O	8	VMOD
10	yohimbine	yohimbine	B-NP	PRP	O	11	SUB
11	may	may	B-VP	MD	O	9	SBAR
12	be	be	I-VP	VB	O	11	VC
13	an	an	B-NP	DT	O	15	NMOD
14	effective	effective	I-NP	JJ	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	12	PRD
16	for	for	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	20	NMOD
18	sexual	sexual	I-NP	JJ	O	20	NMOD
19	side	side	I-NP	NN	O	20	NMOD
20	effects	effect	I-NP	NNS	O	16	PMOD
21	caused	cause	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	serotonin	serotonin	B-NP	NN	O	25	NMOD
24	reuptake	reuptake	I-NP	NN	O	25	NMOD
25	blockers	blocker	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	1	P

1	Hypersensitivity	Hypersensitivity	B-NP	NN	O	3	NMOD
2	immune	immune	I-NP	JJ	O	3	NMOD
3	reaction	reaction	I-NP	NN	O	0	ROOT
4	as	as	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	mechanism	mechanism	I-NP	NN	O	4	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	dilevalol-associated	dilevalol-associated	B-NP	JJ	O	9	NMOD
9	hepatitis	hepatitis	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	27	NMOD
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	assess	assess	I-VP	VB	O	1	NMOD
5	lymphocyte	lymphocyte	B-NP	NN	O	6	NMOD
6	reactivity	reactivity	I-NP	NN	O	4	OBJ
7	to	to	B-PP	TO	O	6	NMOD
8	dilevalol	dilevalol	B-NP	NN	O	7	PMOD
9	and	and	B-PP	CC	O	7	PMOD
10	to	to	B-PP	TO	O	7	PMOD
11	serum	serum	B-NP	NN	O	10	PMOD
12	containing	contain	B-VP	VBG	O	11	NMOD
13	putative	putative	B-NP	JJ	O	19	NMOD
14	ex	ex	I-NP	FW	O	15	AMOD
15	vivo	vivo	I-NP	FW	O	13	NMOD
16	dilevalol	dilevalol	I-NP	NN	B-protein	13	NMOD
17	antigens	antigen	I-NP	NNS	I-protein	13	NMOD
18	or	or	I-NP	CC	O	13	NMOD
19	metabolites	metabolite	I-NP	NNS	O	12	OBJ
20	in	in	B-PP	IN	O	11	NMOD
21	a	a	B-NP	DT	O	22	NMOD
22	case	case	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	dilevalol	dilevalol	B-NP	NN	O	23	PMOD
25	induced	induce	B-VP	VBD	O	27	NMOD
26	liver	liver	B-NP	NN	O	27	NMOD
27	injury	injury	I-NP	NN	O	0	ROOT
28	.	.	O	.	O	27	P

1	PATIENT	PATIENT	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	58-year-old	58-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	12	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	clinical	clinical	I-NP	JJ	O	9	NMOD
9	diagnosis	diagnosis	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	dilevalol	dilevalol	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	liver	liver	B-NP	NN	O	14	NMOD
14	injury	injury	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	12	P

1	Reversible	Reversible	B-NP	JJ	O	3	NMOD
2	myocardial	myocardial	I-NP	JJ	O	3	NMOD
3	hypertrophy	hypertrophy	I-NP	NN	O	15	NMOD
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	tacrolimus	tacrolimus	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	VMOD
8	a	a	B-NP	DT	O	12	NMOD
9	pediatric	pediatric	I-NP	JJ	O	12	NMOD
10	heart	heart	I-NP	NN	O	12	NMOD
11	transplant	transplant	I-NP	NN	O	12	NMOD
12	recipient	recipient	I-NP	NN	O	7	PMOD
13	:	:	O	:	O	3	P
14	case	case	B-NP	NN	O	15	NMOD
15	report	report	I-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	Herein	Herein	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	describe	describe	B-VP	VBP	O	0	ROOT
4	transient	transient	B-NP	JJ	O	5	AMOD
5	myocardial	myocardial	I-NP	JJ	O	6	NMOD
6	hypertrophy	hypertrophy	I-NP	NN	O	3	OBJ
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	tacrolimus	tacrolimus	B-NP	NN	O	8	PMOD
10	after	after	B-PP	IN	O	7	VMOD
11	heart	heart	B-NP	NN	O	12	NMOD
12	transplantation	transplantation	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	3	P

1	Myocardial	Myocardial	B-NP	JJ	O	2	NMOD
2	hypertrophy	hypertrophy	I-NP	NN	O	0	ROOT
3	completely	completely	B-VP	RB	O	4	VMOD
4	resolved	resolve	I-VP	VBN	O	2	NMOD
5	upon	upon	B-PP	IN	O	4	VMOD
6	reducing	reduce	B-VP	VBG	O	5	PMOD
7	the	the	B-NP	DT	O	9	NMOD
8	target	target	I-NP	NN	O	9	NMOD
9	concentration	concentration	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	tacrolimus	tacrolimus	B-NP	NN	O	10	PMOD
12	and	and	O	CC	O	2	VMOD
13	did	do	B-VP	VBD	O	12	DEP
14	not	not	I-VP	RB	O	13	VMOD
15	recur	recur	I-VP	VB	O	13	VC
16	,	,	O	,	O	13	P
17	as	as	B-SBAR	IN	O	13	VMOD
18	confirmed	confirm	B-VP	VBN	O	17	SBAR
19	at	at	B-PP	IN	O	18	VMOD
20	echocardiography	echocardiography	B-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	myocardial	myocardial	B-NP	JJ	O	23	NMOD
23	biopsy	biopsy	I-NP	NN	O	19	PMOD
24	.	.	O	.	O	2	P

1	Thus	Thus	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	conclude	conclude	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	tacrolimus	tacrolimus	B-NP	NN	O	7	SUB
7	induces	induce	B-VP	VBZ	O	5	SBAR
8	reversible	reversible	B-NP	JJ	O	10	NMOD
9	myocardial	myocardial	I-NP	JJ	O	10	NMOD
10	hypertrophy	hypertrophy	I-NP	NN	O	7	OBJ
11	.	.	O	.	O	4	P

1	Ten	Ten	B-NP	CD	O	3	NMOD
2	consecutive	consecutive	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	0	ROOT
4	(	(	O	(	O	18	DEP
5	mean	mean	B-NP	JJ	O	6	NMOD
6	age	age	I-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	58.4	58.4	B-NP	CD	O	10	AMOD
9	+/-	+/-	I-NP	CC	O	10	AMOD
10	6.8	6.8	I-NP	CD	O	11	NMOD
11	years	year	I-NP	NNS	O	18	DEP
12	;	;	O	:	O	18	P
13	7	7	B-NP	CD	O	14	NMOD
14	men	man	I-NP	NNS	O	17	NMOD
15	,	,	O	,	O	17	P
16	3	3	B-NP	CD	O	17	NMOD
17	women	woman	I-NP	NNS	O	18	DEP
18	)	)	O	)	O	3	NMOD
19	with	with	B-PP	IN	O	3	NMOD
20	similar	similar	B-NP	JJ	O	21	NMOD
21	characteristics	characteristic	I-NP	NNS	O	19	PMOD
22	at	at	B-PP	IN	O	3	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	duration	duration	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	disease	disease	B-NP	NN	O	25	PMOD
27	(	(	O	(	O	36	DEP
28	mean	mean	B-NP	JJ	O	30	NMOD
29	disease	disease	I-NP	NN	O	30	NMOD
30	time	time	I-NP	NN	O	35	NMOD
31	,	,	O	,	O	35	P
32	8.4	8.4	B-NP	CD	O	34	AMOD
33	+/-	+/-	I-NP	CC	O	34	AMOD
34	3.5	3.5	I-NP	CD	O	35	NMOD
35	years	year	I-NP	NNS	O	36	DEP
36	)	)	O	)	O	24	NMOD
37	,	,	O	,	O	3	P
38	disabling	disable	B-VP	VBG	O	3	NMOD
39	motor	motor	B-NP	NN	O	40	NMOD
40	fluctuations	fluctuation	I-NP	NNS	O	38	OBJ
41	(	(	O	(	O	50	DEP
42	Hoehn	Hoehn	B-NP	NNP	O	45	NMOD
43	_	_	I-NP	NNP	O	45	NMOD
44	Yahr	Yahr	I-NP	NNP	O	45	NMOD
45	stage	stage	I-NP	NN	O	50	DEP
46	3-5	3-5	I-NP	CD	O	45	NMOD
47	in	in	B-PP	IN	O	45	NMOD
48	off-drug	off-drug	B-NP	JJ	O	49	NMOD
49	phases	phase	I-NP	NNS	O	47	PMOD
50	)	)	O	)	O	3	NMOD
51	and	and	O	CC	O	54	NMOD
52	levodopa	levodopa	B-NP	NN	O	54	NMOD
53	induced	induce	I-NP	VBN	O	54	NMOD
54	dyskinesias	dyskinesia	I-NP	NNS	O	55	SUB
55	were	be	B-VP	VBD	O	3	NMOD
56	selected	select	I-VP	VBN	O	55	VC
57	.	.	O	.	O	3	P

1	Complications	Complication	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	9	VMOD
3	observed	observe	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	two	two	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	:	:	O	:	O	2	P
8	one	one	B-NP	CD	O	9	SUB
9	had	have	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	13	NMOD
11	left	left	I-NP	JJ	O	13	NMOD
12	homonymous	homonymous	I-NP	JJ	O	13	NMOD
13	hemianopsia	hemianopsia	I-NP	NN	O	9	OBJ
14	after	after	B-PP	IN	O	9	VMOD
15	pallidotomy	pallidotomy	B-NP	NN	O	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	another	another	B-NP	DT	O	18	NMOD
18	one	one	I-NP	CD	O	20	SUB
19	developed	develop	B-VP	VBN	O	18	NMOD
20	left	leave	B-VP	VBD	O	14	SBAR
21	hemiballistic	hemiballistic	B-NP	JJ	O	22	NMOD
22	movements	movement	I-NP	NNS	O	24	NMOD
23	3	3	B-NP	CD	O	24	NMOD
24	days	day	I-NP	NNS	O	20	OBJ
25	after	after	B-PP	IN	O	24	NMOD
26	subthalamotomy	subthalamotomy	B-NP	NN	O	25	PMOD
27	which	which	B-NP	WDT	O	24	NMOD
28	partly	partly	B-ADVP	RB	O	29	VMOD
29	improved	improve	B-VP	VBD	O	27	SBAR
30	within	within	B-PP	IN	O	29	VMOD
31	1	1	B-NP	CD	O	32	NMOD
32	month	month	I-NP	NN	O	30	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	Valproate	Valproate	B-NP	NN	O	36	NMOD
35	1000	1000	I-NP	CD	O	36	NMOD
36	mg/day	mg/day	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	9	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	antithrombin	antithrombin	B-NP	NN	B-protein	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	puromycin	puromycin	B-NP	NN	O	8	NMOD
7	aminonucleoside	aminonucleoside	I-NP	NN	O	8	NMOD
8	nephrosis	nephrosis	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	20	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	antithrombin	antithrombin	B-NP	NN	B-protein	10	NMOD
7	,	,	O	,	O	10	P
8	a	a	B-NP	DT	O	10	NMOD
9	plasma	plasma	I-NP	NN	O	10	NMOD
10	inhibitor	inhibitor	I-NP	NN	O	5	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	coagulation	coagulation	B-NP	NN	B-protein	13	NMOD
13	factors	factor	I-NP	NNS	I-protein	11	PMOD
14	,	,	O	,	O	4	P
15	in	in	B-PP	IN	O	4	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	4	NMOD
18	puromycin	puromycin	B-NP	NN	O	19	NMOD
19	aminonucleoside	aminonucleoside	I-NP	NN	O	17	PMOD
20	induced	induce	B-VP	VBD	O	2	VMOD
21	nephrosis	nephrosis	B-NP	NN	O	20	OBJ
22	,	,	O	,	O	21	P
23	which	which	B-NP	WDT	O	21	NMOD
24	is	be	B-VP	VBZ	O	23	SBAR
25	an	an	B-NP	DT	O	27	NMOD
26	experimental	experimental	I-NP	JJ	O	27	NMOD
27	model	model	I-NP	NN	O	24	PRD
28	of	of	B-PP	IN	O	27	NMOD
29	human	human	B-NP	JJ	O	31	NMOD
30	nephrotic	nephrotic	I-NP	JJ	O	31	NMOD
31	syndrome	syndrome	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	2	P

1	Treatment	Treatment	B-NP	NN	O	4	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	antithrombin	antithrombin	B-NP	NN	B-protein	2	PMOD
4	attenuated	attenuate	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	puromycin	puromycin	I-NP	NN	O	7	NMOD
7	aminonucleoside	aminonucleoside	I-NP	NN	O	10	NMOD
8	induced	induce	B-VP	VBD	O	10	NMOD
9	hematological	hematological	B-NP	JJ	O	10	NMOD
10	abnormalities	abnormality	I-NP	NNS	O	4	OBJ
11	.	.	O	.	O	4	P

1	Puromycin	Puromycin	B-NP	NN	O	2	NMOD
2	aminonucleoside	aminonucleoside	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	renal	renal	B-NP	JJ	O	5	NMOD
5	dysfunction	dysfunction	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	hyperlipidemia	hyperlipidemia	I-NP	NN	O	3	OBJ
8	were	be	B-VP	VBD	O	3	VMOD
9	also	also	I-VP	RB	O	8	VMOD
10	suppressed	suppress	I-VP	VBN	O	8	VC
11	.	.	O	.	O	3	P

1	These	These	B-NP	DT	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	thrombin	thrombin	B-NP	NN	B-protein	6	SUB
6	plays	play	B-VP	VBZ	O	4	SBAR
7	an	an	B-NP	DT	O	9	NMOD
8	important	important	I-NP	JJ	O	9	NMOD
9	role	role	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	pathogenesis	pathogenesis	I-NP	NN	O	16	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	puromycin	puromycin	B-NP	NN	O	15	NMOD
15	aminonucleoside	aminonucleoside	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBD	O	10	SBAR
17	nephrotic	nephrotic	B-NP	JJ	O	18	NMOD
18	syndrome	syndrome	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	3	P

1	Reverse	Reverse	B-ADJP	JJ	O	3	AMOD
2	or	or	O	CC	O	3	AMOD
3	inverted	invert	B-VP	VBN	O	0	ROOT
4	left	leave	B-VP	VBD	O	3	VMOD
5	ventricular	ventricular	B-NP	JJ	O	8	NMOD
6	apical	apical	I-NP	JJ	O	8	NMOD
7	ballooning	ballooning	I-NP	NN	O	8	NMOD
8	syndrome	syndrome	I-NP	NN	O	4	OBJ
9	(	(	O	(	O	13	DEP
10	reverse	reverse	B-NP	JJ	O	12	NMOD
11	Takotsubo	Takotsubo	I-NP	NNP	O	12	NMOD
12	cardiomyopathy	cardiomyopathy	I-NP	NN	O	13	DEP
13	)	)	O	)	O	8	NMOD
14	in	in	B-PP	IN	O	4	VMOD
15	a	a	B-NP	DT	O	17	NMOD
16	young	young	I-NP	JJ	O	17	NMOD
17	woman	woman	I-NP	NN	O	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	setting	setting	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	amphetamine	amphetamine	B-NP	NN	O	23	NMOD
23	use	use	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	3	P

1	Amphetamine	Amphetamine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	locomotor	locomotor	B-NP	NN	O	4	NMOD
4	hyperactivity	hyperactivity	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	2	VMOD
6	similar	similar	B-ADJP	JJ	O	5	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	all	all	B-NP	DT	O	9	NMOD
9	groups	group	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	2	P

1	Peripheral	Peripheral	B-NP	JJ	O	3	NMOD
2	iron	iron	I-NP	NN	O	3	NMOD
3	dextran	dextran	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	degeneration	degeneration	B-NP	NN	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	dopaminergic	dopaminergic	B-NP	JJ	B-cell_type	8	NMOD
8	neurons	neuron	I-NP	NNS	I-cell_type	6	PMOD
9	in	in	B-PP	IN	O	5	NMOD
10	rat	rat	B-NP	NN	O	12	NMOD
11	substantia	substantia	I-NP	NN	O	12	NMOD
12	nigra	nigra	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	Iron	Iron	B-NP	NN	O	2	NMOD
2	accumulation	accumulation	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	considered	consider	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	be	be	I-VP	VB	O	4	VMOD
7	involved	involve	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	pathogenesis	pathogenesis	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	Parkinson	Parkinson	B-NP	NNP	O	14	NMOD
13	's	's	B-NP	POS	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	3	P

1	To	To	B-VP	TO	O	2	VMOD
2	demonstrate	demonstrate	I-VP	VB	O	26	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	relationship	relationship	I-NP	NN	O	2	OBJ
5	between	between	B-PP	IN	O	4	NMOD
6	peripheral	peripheral	B-NP	JJ	O	8	NMOD
7	iron	iron	I-NP	NN	O	8	NMOD
8	overload	overload	I-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	dopaminergic	dopaminergic	B-NP	JJ	O	12	NMOD
11	neuron	neuron	I-NP	NN	O	12	NMOD
12	loss	loss	I-NP	NN	O	5	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	rat	rat	B-NP	NN	O	16	NMOD
15	substantia	substantia	I-NP	NN	O	16	NMOD
16	nigra	nigra	I-NP	NN	O	13	PMOD
17	(	(	O	(	O	19	DEP
18	SN	SN	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	,	,	O	,	O	26	P
21	in	in	B-PP	IN	O	26	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	present	present	I-NP	JJ	O	24	NMOD
24	study	study	I-NP	NN	O	21	PMOD
25	we	we	B-NP	PRP	O	26	SUB
26	used	use	B-VP	VBD	O	0	ROOT
27	fast	fast	B-NP	JJ	O	29	NMOD
28	cyclic	cyclic	I-NP	JJ	O	29	NMOD
29	voltammetry	voltammetry	I-NP	NN	O	36	NMOD
30	,	,	O	,	O	36	P
31	tyrosine	tyrosine	B-NP	NN	B-protein	32	NMOD
32	hydroxylase	hydroxylase	I-NP	NN	I-protein	36	NMOD
33	(	(	O	(	O	35	DEP
34	TH	TH	B-NP	NN	O	35	DEP
35	)	)	O	)	O	32	NMOD
36	immunohistochemistry	immunohistochemistry	B-NP	NN	O	26	OBJ
37	,	,	O	,	O	26	P
38	Perls	Perls	B-NP	NNP	O	39	NMOD
39	'	'	B-NP	POS	O	41	NMOD
40	iron	iron	I-NP	NN	O	41	NMOD
41	staining	staining	I-NP	NN	O	26	OBJ
42	,	,	O	,	O	26	P
43	and	and	O	CC	O	26	VMOD
44	high	high	B-NP	JJ	O	48	NMOD
45	performance	performance	I-NP	NN	O	48	NMOD
46	liquid	liquid	I-NP	JJ	O	48	NMOD
47	chromatography-electrochemical	chromatography-electrochemical	I-NP	JJ	O	48	NMOD
48	detection	detection	I-NP	NN	O	26	OBJ
49	to	to	B-VP	TO	O	50	VMOD
50	study	study	I-VP	VB	O	26	VMOD
51	the	the	B-NP	DT	O	52	NMOD
52	degeneration	degeneration	I-NP	NN	O	59	NMOD
53	of	of	B-PP	IN	O	52	NMOD
54	dopaminergic	dopaminergic	B-NP	JJ	O	55	NMOD
55	neurons	neuron	I-NP	NNS	O	53	PMOD
56	and	and	O	CC	O	59	NMOD
57	increased	increase	B-NP	VBN	O	59	NMOD
58	iron	iron	I-NP	NN	O	59	NMOD
59	content	content	I-NP	NN	O	66	SUB
60	in	in	B-PP	IN	O	59	NMOD
61	the	the	B-NP	DT	O	62	NMOD
62	SN	SN	I-NP	NN	O	60	PMOD
63	of	of	B-PP	IN	O	62	NMOD
64	iron	iron	B-NP	NN	O	65	NMOD
65	dextran	dextran	I-NP	NN	O	63	PMOD
66	overloaded	overload	B-VP	VBD	O	50	SBAR
67	animals	animal	B-NP	NNS	O	66	OBJ
68	.	.	O	.	O	26	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	peripheral	peripheral	B-NP	JJ	O	7	NMOD
6	iron	iron	I-NP	NN	O	7	NMOD
7	dextran	dextran	I-NP	NN	O	8	SUB
8	can	can	B-VP	MD	O	4	SBAR
9	increase	increase	I-VP	VB	O	8	VC
10	the	the	B-NP	DT	O	12	NMOD
11	iron	iron	I-NP	NN	O	12	NMOD
12	level	level	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	SN	SN	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	15	P
17	where	where	B-ADVP	WRB	O	15	NMOD
18	excessive	excessive	B-NP	JJ	O	19	NMOD
19	iron	iron	I-NP	NN	O	20	SUB
20	causes	cause	B-VP	VBZ	O	17	SBAR
21	the	the	B-NP	DT	O	22	NMOD
22	degeneration	degeneration	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	dopaminergic	dopaminergic	B-NP	JJ	O	25	NMOD
25	neurons	neuron	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	3	P

1	Warfarin	Warfarin	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	leukocytoclastic	leukocytoclastic	B-NP	JJ	O	4	NMOD
4	vasculitis	vasculitis	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	4	4	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	with	with	B-PP	IN	O	4	NMOD
6	late-onset	late-onset	B-NP	JJ	O	7	NMOD
7	LV	LV	I-NP	NN	O	5	PMOD
8	probably	probably	B-ADVP	RB	O	9	PMOD
9	due	due	B-PP	IN	O	4	NMOD
10	to	to	B-PP	TO	O	9	PMOD
11	warfarin	warfarin	B-NP	NN	O	9	PMOD
12	.	.	O	.	O	2	P

1	All	All	B-NP	DT	O	3	NMOD
2	4	4	I-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	4	SUB
4	presented	present	B-VP	VBD	O	0	ROOT
5	with	with	B-PP	IN	O	4	VMOD
6	skin	skin	B-NP	NN	O	7	NMOD
7	eruptions	eruption	I-NP	NNS	O	5	PMOD
8	that	that	B-NP	WDT	O	7	NMOD
9	developed	develop	B-VP	VBD	O	8	SBAR
10	after	after	B-PP	IN	O	9	VMOD
11	receiving	receive	B-VP	VBG	O	10	PMOD
12	warfarin	warfarin	B-NP	NN	O	11	OBJ
13	for	for	B-PP	IN	O	12	NMOD
14	several	several	B-NP	JJ	O	15	NMOD
15	years	year	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	skin	skin	B-NP	NN	O	6	NMOD
5	lesion	lesion	I-NP	NN	O	6	NMOD
6	biopsies	biopsy	I-NP	NNS	O	3	PMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	available	available	B-ADJP	JJ	O	7	PRD
9	in	in	B-PP	IN	O	7	VMOD
10	3	3	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	,	,	O	,	O	7	P
13	confirming	confirm	B-VP	VBG	O	7	VMOD
14	LV	LV	B-NP	NN	O	16	NMOD
15	Cutaneous	Cutaneous	I-NP	JJ	O	16	NMOD
16	lesions	lesion	I-NP	NNS	O	13	OBJ
17	resolved	resolve	B-VP	VBN	O	16	NMOD
18	in	in	B-PP	IN	O	17	VMOD
19	all	all	B-NP	DT	O	20	NMOD
20	patients	patient	I-NP	NNS	O	18	PMOD
21	after	after	B-SBAR	IN	O	20	NMOD
22	warfarin	warfarin	B-NP	NN	O	21	PMOD
23	was	be	B-VP	VBD	O	7	VMOD
24	discontinued	discontinue	I-VP	VBN	O	23	VC
25	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	activation	activation	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	spinal	spinal	B-NP	JJ	B-protein	6	NMOD
5	N-methyl-D-aspartate	N-methyl-D-aspartate	I-NP	NN	I-protein	6	NMOD
6	receptors	receptor	I-NP	NNS	I-protein	3	PMOD
7	may	may	B-VP	MD	O	0	ROOT
8	contribute	contribute	I-VP	VB	O	7	VC
9	to	to	B-PP	TO	O	8	VMOD
10	degeneration	degeneration	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	spinal	spinal	B-NP	JJ	B-protein	14	NMOD
13	motor	motor	I-NP	NN	I-protein	14	NMOD
14	neurons	neuron	I-NP	NNS	I-protein	11	PMOD
15	induced	induce	B-VP	VBN	O	10	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	neuraxial	neuraxial	B-NP	JJ	O	18	NMOD
18	morphine	morphine	I-NP	NN	O	16	PMOD
19	after	after	B-PP	IN	O	15	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	noninjurious	noninjurious	I-NP	JJ	O	22	NMOD
22	interval	interval	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	spinal	spinal	B-NP	JJ	O	26	NMOD
25	cord	cord	I-NP	NN	O	26	NMOD
26	ischemia	ischemia	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	relationship	relationship	I-NP	NN	O	2	OBJ
5	between	between	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	degeneration	degeneration	I-NP	NN	O	13	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	spinal	spinal	B-NP	JJ	B-cell_type	11	NMOD
10	motor	motor	I-NP	NN	I-cell_type	11	NMOD
11	neurons	neuron	I-NP	NNS	I-cell_type	8	PMOD
12	and	and	O	CC	O	13	NMOD
13	activation	activation	B-NP	NN	O	5	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	N-methyl-d-aspartate	N-methyl-d-aspartate	B-NP	NN	B-protein	19	NMOD
16	(	(	O	(	I-protein	19	NMOD
17	NMDA	NMDA	B-NP	NN	I-protein	19	NMOD
18	)	)	O	)	I-protein	19	NMOD
19	receptors	receptor	B-NP	NNS	I-protein	14	PMOD
20	after	after	B-PP	IN	O	4	NMOD
21	neuraxial	neuraxial	B-NP	JJ	O	22	NMOD
22	morphine	morphine	I-NP	NN	O	20	PMOD
23	following	follow	B-PP	VBG	O	2	VMOD
24	a	a	B-NP	DT	O	26	NMOD
25	noninjurious	noninjurious	I-NP	JJ	O	26	NMOD
26	interval	interval	I-NP	NN	O	23	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	aortic	aortic	B-NP	JJ	O	29	NMOD
29	occlusion	occlusion	I-NP	NN	O	27	PMOD
30	in	in	B-PP	IN	O	26	NMOD
31	rats	rat	B-NP	NNS	O	30	PMOD
32	.	.	O	.	O	2	P

1	Second	Second	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	investigated	investigate	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	IT	IT	B-NP	NN	O	9	NMOD
9	MK-801	MK-801	I-NP	NN	O	7	PMOD
10	(	(	O	(	O	13	DEP
11	30	30	B-NP	CD	O	12	NMOD
12	mug	mug	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	on	on	B-PP	IN	O	6	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	histopathologic	histopathologic	I-NP	JJ	O	17	NMOD
17	changes	change	I-NP	NNS	O	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	spinal	spinal	I-NP	JJ	O	21	NMOD
21	cord	cord	I-NP	NN	O	18	PMOD
22	after	after	B-SBAR	IN	O	4	VMOD
23	morphine	morphine	B-NP	NN	O	24	SUB
24	induced	induce	B-VP	VBD	O	22	SBAR
25	spastic	spastic	B-NP	JJ	O	26	NMOD
26	paraparesis	paraparesis	I-NP	NN	O	24	OBJ
27	.	.	O	.	O	4	P

1	IT	IT	B-NP	NN	O	2	NMOD
2	MK-801	MK-801	I-NP	NN	O	4	SUB
3	significantly	significantly	B-VP	RB	O	4	VMOD
4	reduced	reduce	I-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	number	number	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	dark-stained	dark-stained	B-NP	JJ	B-protein	9	NMOD
9	alpha-motoneurons	alpha-motoneuron	I-NP	NNS	I-protein	7	PMOD
10	after	after	B-SBAR	IN	O	4	VMOD
11	morphine	morphine	B-NP	NN	O	12	SUB
12	induced	induce	B-VP	VBD	O	10	SBAR
13	spastic	spastic	B-NP	JJ	O	14	NMOD
14	paraparesis	paraparesis	I-NP	NN	O	12	OBJ
15	compared	compare	B-PP	VBN	O	12	VMOD
16	with	with	B-PP	IN	O	15	PMOD
17	the	the	B-NP	DT	O	19	NMOD
18	saline	saline	I-NP	NN	O	19	NMOD
19	group	group	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	4	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	IT	IT	B-NP	NN	O	6	NMOD
6	morphine	morphine	I-NP	NN	O	7	SUB
7	induces	induce	B-VP	VBZ	O	4	SBAR
8	spastic	spastic	B-NP	JJ	O	9	NMOD
9	paraparesis	paraparesis	I-NP	NN	O	7	OBJ
10	with	with	B-PP	IN	O	7	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	concomitant	concomitant	I-NP	JJ	O	13	NMOD
13	increase	increase	I-NP	NN	O	10	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	CSF	CSF	B-NP	NN	B-protein	16	NMOD
16	glutamate	glutamate	I-NP	NN	O	14	PMOD
17	,	,	O	,	O	13	P
18	which	which	B-NP	WDT	O	13	NMOD
19	is	be	B-VP	VBZ	O	18	SBAR
20	involved	involve	I-VP	VBN	O	19	VC
21	in	in	B-PP	IN	O	20	VMOD
22	NMDA	NMDA	B-NP	NN	B-protein	24	NMOD
23	receptor	receptor	I-NP	NN	I-protein	24	NMOD
24	activation	activation	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	3	P

1	Reduced	Reduce	B-NP	VBN	O	4	NMOD
2	sodium	sodium	I-NP	NN	O	4	NMOD
3	channel	channel	I-NP	NN	O	4	NMOD
4	density	density	I-NP	NN	O	6	SUB
5	,	,	O	,	O	4	P
6	altered	alter	B-VP	VBD	O	0	ROOT
7	voltage	voltage	B-NP	NN	O	8	NMOD
8	dependence	dependence	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	inactivation	inactivation	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	6	P
12	and	and	O	CC	O	6	VMOD
13	increased	increase	B-VP	VBD	O	6	VMOD
14	susceptibility	susceptibility	B-NP	NN	O	13	OBJ
15	to	to	B-PP	TO	O	14	NMOD
16	seizures	seizure	B-NP	NNS	O	15	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	mice	mouse	B-NP	NNS	O	17	PMOD
19	lacking	lack	B-VP	VBG	O	18	NMOD
20	sodium	sodium	B-NP	NN	B-protein	23	NMOD
21	channel	channel	I-NP	NN	I-protein	23	NMOD
22	beta	beta	I-NP	NN	I-protein	23	NMOD
23	2-subunits	2-subunit	I-NP	NNS	I-protein	19	OBJ
24	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	35	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	35	P
4	the	the	B-NP	DT	O	6	NMOD
5	conduction	conduction	I-NP	NN	O	6	NMOD
6	velocity	velocity	I-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	the	the	B-NP	DT	O	11	NMOD
9	number	number	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	size	size	I-NP	NN	O	22	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	axons	axon	B-NP	NNS	O	12	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	optic	optic	I-NP	JJ	O	17	NMOD
17	nerve	nerve	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	22	P
19	and	and	O	CC	O	22	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	specific	specific	I-NP	JJ	O	22	NMOD
22	localization	localization	I-NP	NN	O	35	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	Na	Na	B-NP	NN	B-protein	26	NMOD
25	(	(	O	(	I-protein	26	NMOD
26	v	v	B-NP	NN	I-protein	23	PMOD
27	)	)	O	)	I-protein	26	NMOD
28	1.6	1.6	B-NP	CD	I-protein	26	NMOD
29	channels	channel	I-NP	NNS	I-protein	26	NMOD
30	in	in	B-PP	IN	O	22	NMOD
31	the	the	B-NP	DT	O	32	NMOD
32	nodes	node	I-NP	NNS	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	Ranvier	Ranvier	B-NP	NN	B-protein	33	PMOD
35	were	be	B-VP	VBD	I-protein	0	ROOT
36	unchanged.	unchanged.	B-NP	JJ	I-protein	37	NMOD
37	beta2	beta2	I-NP	NN	I-protein	41	NMOD
38	(	(	O	(	O	40	DEP
39	-/-	-/-	O	JJ	O	40	DEP
40	)	)	O	)	O	37	NMOD
41	mice	mouse	B-NP	NNS	O	35	SUB
42	displayed	display	B-VP	VBD	O	35	VMOD
43	increased	increase	B-NP	VBN	O	44	NMOD
44	susceptibility	susceptibility	I-NP	NN	O	42	OBJ
45	to	to	B-PP	TO	O	44	NMOD
46	seizures	seizure	B-NP	NNS	O	45	PMOD
47	,	,	O	,	O	35	P
48	as	as	B-SBAR	IN	O	35	VMOD
49	indicated	indicate	B-VP	VBN	O	48	SBAR
50	by	by	B-PP	IN	O	49	VMOD
51	reduced	reduce	B-NP	VBN	O	52	NMOD
52	latency	latency	I-NP	NN	O	54	NMOD
53	and	and	I-NP	CC	O	54	NMOD
54	threshold	threshold	I-NP	NN	O	50	PMOD
55	for	for	B-PP	IN	O	54	NMOD
56	pilocarpine	pilocarpine	B-NP	NN	O	58	NMOD
57	induced	induce	I-NP	VBN	O	58	NMOD
58	seizures	seizure	I-NP	NNS	O	55	PMOD
59	,	,	O	,	O	35	P
60	but	but	O	CC	O	35	VMOD
61	seemed	seem	B-VP	VBD	O	35	VMOD
62	normal	normal	B-ADJP	JJ	O	61	PRD
63	in	in	B-PP	IN	O	62	AMOD
64	other	other	B-NP	JJ	O	66	NMOD
65	neurological	neurological	I-NP	JJ	O	66	NMOD
66	tests	test	I-NP	NNS	O	63	PMOD
67	.	.	O	.	O	35	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	objective	objective	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	determine	determine	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	12	NMOD
12	prevalence	prevalence	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	positive	positive	B-NP	JJ	O	17	NMOD
15	plasma	plasma	I-NP	NN	O	17	NMOD
16	drug	drug	I-NP	NN	O	17	NMOD
17	screening	screening	I-NP	NN	O	13	PMOD
18	for	for	B-PP	IN	O	17	NMOD
19	cocaine	cocaine	B-NP	NN	O	21	NMOD
20	or	or	I-NP	CC	O	21	NMOD
21	amphetamine	amphetamine	I-NP	NN	O	18	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	adult	adult	B-NP	JJ	O	27	NMOD
24	emergency	emergency	I-NP	NN	O	27	NMOD
25	department	department	I-NP	NN	O	27	NMOD
26	seizure	seizure	I-NP	NN	O	27	NMOD
27	patients	patient	I-NP	NNS	O	22	PMOD
28	.	.	O	.	O	8	P

1	Patient	Patient	B-NP	NN	O	2	NMOD
2	demographics	demographic	I-NP	NNS	O	4	NMOD
3	,	,	O	,	O	4	P
4	history	history	B-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	underlying	underlie	B-VP	VBG	O	5	PMOD
7	drug	drug	B-NP	NN	O	11	NMOD
8	or	or	O	CC	O	11	NMOD
9	alcohol-related	alcohol-related	B-NP	JJ	O	11	NMOD
10	seizure	seizure	I-NP	NN	O	11	NMOD
11	disorder	disorder	I-NP	NN	O	6	OBJ
12	,	,	O	,	O	4	P
13	estimated	estimate	B-VP	VBN	O	4	NMOD
14	time	time	B-NP	NN	O	43	VMOD
15	from	from	B-PP	IN	O	14	NMOD
16	seizure	seizure	B-NP	NN	O	15	PMOD
17	to	to	B-PP	TO	O	14	NMOD
18	sample	sample	B-NP	NN	O	19	NMOD
19	collection	collection	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	43	P
21	history	history	B-NP	NN	O	23	NMOD
22	or	or	I-NP	CC	O	23	NMOD
23	suspicion	suspicion	I-NP	NN	O	43	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	cocaine	cocaine	B-NP	NN	O	28	NMOD
26	or	or	I-NP	CC	O	28	NMOD
27	amphetamine	amphetamine	I-NP	NN	O	28	NMOD
28	abuse	abuse	I-NP	NN	O	24	PMOD
29	,	,	O	,	O	43	P
30	results	result	B-NP	NNS	O	43	VMOD
31	of	of	B-PP	IN	O	30	NMOD
32	clinical	clinical	B-NP	JJ	O	34	NMOD
33	urine	urine	I-NP	NN	O	34	NMOD
34	testing	testing	I-NP	NN	O	31	PMOD
35	for	for	B-PP	IN	O	34	NMOD
36	drugs	drug	B-NP	NNS	O	35	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	abuse	abuse	B-NP	NN	O	37	PMOD
39	,	,	O	,	O	43	P
40	and	and	O	CC	O	43	VMOD
41	assay	assay	B-NP	NN	O	42	NMOD
42	results	result	I-NP	NNS	O	43	SUB
43	were	be	B-VP	VBD	O	13	VMOD
44	recorded	record	I-VP	VBN	O	43	VC
45	without	without	B-PP	IN	O	44	VMOD
46	patient	patient	B-NP	NN	O	47	NMOD
47	identifiers	identifier	I-NP	NNS	O	45	PMOD
48	.	.	O	.	O	4	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	19	SUB
2	:	:	O	:	O	1	P
3	During	During	B-PP	IN	O	19	VMOD
4	this	this	B-NP	DT	O	6	NMOD
5	study	study	I-NP	NN	O	6	NMOD
6	period	period	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	19	P
8	routine	routine	B-NP	JJ	O	10	NMOD
9	plasma	plasma	I-NP	NN	O	10	NMOD
10	screening	screening	I-NP	NN	O	19	SUB
11	for	for	B-PP	IN	O	10	NMOD
12	cocaine	cocaine	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	amphetamines	amphetamine	I-NP	NNS	O	11	PMOD
15	in	in	B-PP	IN	O	10	NMOD
16	adult	adult	B-NP	JJ	O	18	NMOD
17	seizure	seizure	I-NP	NN	O	18	NMOD
18	patients	patient	I-NP	NNS	O	15	PMOD
19	had	have	B-VP	VBD	O	0	ROOT
20	a	a	B-NP	DT	O	22	NMOD
21	low	low	I-NP	JJ	O	22	NMOD
22	yield	yield	I-NP	NN	O	19	OBJ
23	.	.	O	.	O	19	P

1	The	The	B-NP	DT	O	2	NMOD
2	objective	objective	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	explore	explore	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	11	NMOD
10	functional	functional	I-NP	JJ	O	11	NMOD
11	anatomy	anatomy	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	16	NMOD
14	globus	globus	I-NP	NN	O	16	NMOD
15	pallidus	pallidus	I-NP	NN	O	16	NMOD
16	internus	internus	I-NP	NN	O	12	PMOD
17	(	(	O	(	O	19	DEP
18	GPi	GPi	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	by	by	B-PP	IN	O	8	VMOD
21	studying	study	B-VP	VBG	O	20	PMOD
22	the	the	B-NP	DT	O	23	NMOD
23	effects	effect	I-NP	NNS	O	21	OBJ
24	of	of	B-PP	IN	O	23	NMOD
25	unilateral	unilateral	B-NP	JJ	O	26	NMOD
26	pallidotomy	pallidotomy	I-NP	NN	O	24	PMOD
27	on	on	B-PP	IN	O	23	NMOD
28	parkinsonian	parkinsonian	B-NP	NN	O	31	NMOD
29	'off	'off	B-NP	POS	O	31	NMOD
30	'	'	B-NP	POS	O	31	NMOD
31	signs	sign	I-NP	NNS	O	35	NMOD
32	and	and	O	CC	O	35	NMOD
33	levodopa	levodopa	B-NP	NN	O	35	NMOD
34	induced	induce	I-NP	VBN	O	35	NMOD
35	dyskinesias	dyskinesia	I-NP	NNS	O	27	PMOD
36	(	(	O	(	O	38	DEP
37	LID	LID	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	found	find	B-VP	VBD	O	0	ROOT
3	significant	significant	B-NP	JJ	O	4	AMOD
4	positive	positive	I-NP	JJ	O	5	NMOD
5	correlations	correlation	I-NP	NNS	O	2	OBJ
6	between	between	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	preoperative	preoperative	I-NP	JJ	O	10	NMOD
9	levodopa	levodopa	I-NP	NN	O	10	NMOD
10	responsiveness	responsiveness	I-NP	NN	O	6	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	motor	motor	B-NP	NN	O	13	NMOD
13	signs	sign	I-NP	NNS	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	levodopa	levodopa	I-NP	NN	O	17	NMOD
17	responsiveness	responsiveness	I-NP	NN	O	11	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	scores	score	B-NP	NNS	O	18	PMOD
20	in	in	B-PP	IN	O	10	NMOD
21	timed	time	B-NP	VBN	O	22	NMOD
22	tests	test	I-NP	NNS	O	20	PMOD
23	(	(	O	(	O	30	DEP
24	Core	Core	B-NP	NNP	O	26	NMOD
25	Assessment	Assessment	I-NP	NNP	O	26	NMOD
26	Program	Program	I-NP	NNP	O	30	DEP
27	for	for	B-PP	IN	O	26	NMOD
28	Intracerebral	Intracerebral	B-NP	NNP	O	29	NMOD
29	Transplantations	Transplantations	I-NP	NNP	O	27	PMOD
30	)	)	O	)	O	5	NMOD
31	in	in	B-PP	IN	O	5	NMOD
32	the	the	B-NP	DT	O	34	NMOD
33	contralateral	contralateral	I-NP	JJ	O	34	NMOD
34	limbs	limb	I-NP	NNS	O	37	NMOD
35	and	and	O	CC	O	37	NMOD
36	the	the	B-NP	DT	O	37	NMOD
37	improvement	improvement	I-NP	NN	O	31	PMOD
38	in	in	B-PP	IN	O	37	NMOD
39	these	these	B-NP	DT	O	40	NMOD
40	scores	score	I-NP	NNS	O	38	PMOD
41	after	after	B-PP	IN	O	40	NMOD
42	surgery	surgery	B-NP	NN	O	41	PMOD
43	,	,	O	,	O	2	P
44	whereas	whereas	O	IN	O	2	VMOD
45	there	there	B-NP	EX	O	46	SUB
46	was	be	B-VP	VBD	O	44	SBAR
47	no	no	B-NP	DT	O	48	NMOD
48	correlation	correlation	I-NP	NN	O	46	PRD
49	with	with	B-PP	IN	O	48	NMOD
50	the	the	B-NP	DT	O	51	NMOD
51	improvement	improvement	I-NP	NN	O	49	PMOD
52	in	in	B-PP	IN	O	51	NMOD
53	LID	LID	B-NP	NN	O	52	PMOD
54	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	differential	differential	I-NP	JJ	O	4	NMOD
3	predictive	predictive	I-NP	JJ	O	4	NMOD
4	value	value	I-NP	NN	O	33	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	levodopa	levodopa	B-NP	NN	O	7	NMOD
7	responsiveness	responsiveness	I-NP	NN	O	5	PMOD
8	for	for	B-PP	IN	O	4	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	outcome	outcome	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	parkinsonian	parkinsonian	B-NP	NN	O	15	NMOD
13	'off	'off	B-NP	POS	O	15	NMOD
14	'	'	B-NP	POS	O	15	NMOD
15	signs	sign	I-NP	NNS	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	LID	LID	I-NP	NN	O	11	PMOD
18	and	and	O	CC	O	21	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	different	different	I-NP	JJ	O	21	NMOD
21	correlations	correlation	I-NP	NNS	O	8	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	ventral	ventral	B-NP	JJ	O	25	NMOD
24	lesion	lesion	I-NP	NN	O	25	NMOD
25	volume	volume	I-NP	NN	O	22	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	dyskinesias	dyskinesia	B-NP	NNS	O	32	NMOD
28	and	and	O	CC	O	32	NMOD
29	parkinsonian	parkinsonian	B-NP	JJ	O	32	NMOD
30	'off	'off	I-NP	NN	O	32	NMOD
31	'	'	B-NP	POS	O	32	NMOD
32	signs	sign	I-NP	NNS	O	26	PMOD
33	indicate	indicate	B-VP	VBP	O	0	ROOT
34	that	that	B-SBAR	IN	O	33	VMOD
35	different	different	B-NP	JJ	O	39	NMOD
36	anatomical	anatomical	I-NP	JJ	O	39	NMOD
37	or	or	I-NP	CC	O	39	NMOD
38	pathophysiological	pathophysiological	I-NP	JJ	O	39	NMOD
39	substrates	substrate	I-NP	NNS	O	40	SUB
40	may	may	B-VP	MD	O	34	SBAR
41	be	be	I-VP	VB	O	40	VC
42	responsible	responsible	B-ADJP	JJ	O	41	PRD
43	for	for	B-PP	IN	O	42	AMOD
44	the	the	B-NP	DT	O	45	NMOD
45	generation	generation	I-NP	NN	O	43	PMOD
46	of	of	B-PP	IN	O	45	NMOD
47	parkinsonian	parkinsonian	B-NP	NN	O	52	NMOD
48	'off	'off	B-NP	POS	O	52	NMOD
49	'	'	B-NP	POS	O	52	NMOD
50	signs	sign	I-NP	NNS	O	52	NMOD
51	and	and	I-NP	CC	O	52	NMOD
52	dyskinesias	dyskinesia	I-NP	NNS	O	46	PMOD
53	.	.	O	.	O	33	P

1	Pain	Pain	B-NP	NN	O	2	NMOD
2	responses	response	I-NP	NNS	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	methadone-maintained	methadone-maintained	B-NP	JJ	O	6	NMOD
5	opioid	opioid	I-NP	JJ	O	6	NMOD
6	abusers	abuser	I-NP	NNS	O	3	PMOD
7	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	describe	describe	I-VP	VB	O	4	VMOD
7	pain	pain	B-NP	NN	O	8	NMOD
8	tolerance	tolerance	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	analgesic	analgesic	B-NP	JJ	O	11	NMOD
11	response	response	I-NP	NN	O	6	OBJ
12	in	in	B-PP	IN	O	6	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	sample	sample	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	opioid	opioid	B-NP	JJ	O	17	NMOD
17	addicts	addict	I-NP	NNS	O	15	PMOD
18	stabilized	stabilize	B-VP	VBN	O	17	NMOD
19	in	in	B-PP	IN	O	18	VMOD
20	methadone-maintenance	methadone-maintenance	B-NP	NN	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	MM	MM	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	treatment	treatment	B-NP	NN	O	19	PMOD
25	(	(	O	(	O	29	DEP
26	n	n	B-NP	NN	O	29	DEP
27	=	=	B-VP	SYM	O	26	NMOD
28	60	60	B-NP	CD	O	27	AMOD
29	)	)	O	)	O	24	NMOD
30	in	in	B-PP	IN	O	24	NMOD
31	comparison	comparison	B-NP	NN	O	30	PMOD
32	to	to	B-PP	TO	O	31	NMOD
33	matched	match	B-NP	VBN	O	36	NMOD
34	nondependent	nondependent	I-NP	JJ	O	36	NMOD
35	control	control	I-NP	JJ	O	36	NMOD
36	subjects	subject	I-NP	NNS	O	32	PMOD
37	(	(	O	(	O	41	DEP
38	n	n	B-NP	NN	O	41	DEP
39	=	=	B-VP	SYM	O	38	NMOD
40	60	60	B-NP	CD	O	39	AMOD
41	)	)	O	)	O	36	NMOD
42	.	.	O	.	O	3	P

1	By	By	B-PP	IN	O	17	VMOD
2	using	use	B-VP	VBG	O	1	PMOD
3	a	a	B-NP	DT	O	8	NMOD
4	placebo-controlled	placebo-controlled	I-NP	JJ	O	8	NMOD
5	,	,	I-NP	,	O	8	P
6	two-way	two-way	I-NP	JJ	O	8	NMOD
7	factorial	factorial	I-NP	JJ	O	8	NMOD
8	design	design	I-NP	NN	O	2	OBJ
9	,	,	O	,	O	17	P
10	tolerance	tolerance	B-NP	NN	O	17	SUB
11	to	to	B-PP	TO	O	10	NMOD
12	cold-pressor	cold-pressor	B-NP	NN	B-protein	16	NMOD
13	(	(	O	(	O	15	DEP
14	CP	CP	B-NP	NN	B-DNA	15	DEP
15	)	)	O	)	O	12	NMOD
16	pain	pain	B-NP	NN	O	11	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	examined	examine	I-VP	VBN	O	17	VC
19	,	,	O	,	O	18	P
20	both	both	O	CC	O	18	VMOD
21	before	before	B-PP	IN	O	20	PMOD
22	and	and	I-PP	CC	O	20	PMOD
23	after	after	I-PP	IN	O	20	PMOD
24	oral	oral	B-NP	JJ	O	25	NMOD
25	administration	administration	I-NP	NN	O	39	NMOD
26	of	of	B-PP	IN	O	25	NMOD
27	therapeutic	therapeutic	B-NP	JJ	O	28	NMOD
28	doses	dose	I-NP	NNS	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	common	common	B-NP	JJ	O	31	NMOD
31	opioid	opioid	I-NP	NN	O	29	PMOD
32	(	(	O	(	O	36	DEP
33	hydromorphone	hydromorphone	B-NP	NN	O	35	NMOD
34	2	2	I-NP	CD	O	35	NMOD
35	mg	mg	I-NP	NN	O	36	DEP
36	)	)	O	)	O	28	NMOD
37	and	and	O	CC	O	39	NMOD
38	nonsteroidal	nonsteroidal	B-NP	JJ	O	39	NMOD
39	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	46	NMOD
40	(	(	O	(	O	44	DEP
41	ketorolac	ketorolac	B-NP	NN	O	43	AMOD
42	10	10	I-NP	CD	O	43	AMOD
43	mg	mg	I-NP	NN	O	44	DEP
44	)	)	I-NP	)	O	39	AMOD
45	analgesic	analgesic	I-NP	JJ	O	46	NMOD
46	agents	agent	I-NP	NNS	O	23	PMOD
47	.	.	O	.	O	17	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Puromycin	Puromycin	B-NP	NN	O	4	NMOD
4	aminonucleoside	aminonucleoside	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	PAN	PAN	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	administered	administer	I-VP	VBN	O	8	VC
10	to	to	B-PP	TO	O	9	VMOD
11	Sprague	Sprague	B-NP	NNP	O	13	NMOD
12	Dawley	Dawley	I-NP	NNP	O	13	NMOD
13	rats	rat	I-NP	NNS	O	10	PMOD
14	to	to	B-VP	TO	O	15	VMOD
15	induce	induce	I-VP	VB	O	9	VMOD
16	proteinuria	proteinuria	B-NP	NN	O	15	OBJ
17	.	.	O	.	O	1	P

1	Over	Over	B-PP	IN	O	20	VMOD
2	expression	expression	B-NP	NN	O	10	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	vascular	vascular	B-NP	JJ	B-protein	7	NMOD
5	endothelial	endothelial	I-NP	JJ	I-protein	7	NMOD
6	growth	growth	I-NP	NN	I-protein	7	NMOD
7	factor	factor	I-NP	NN	I-protein	3	PMOD
8	and	and	O	CC	O	10	NMOD
9	its	its	B-NP	PRP$	O	10	NMOD
10	receptor	receptor	I-NP	NN	O	1	PMOD
11	during	during	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	development	development	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	estrogen	estrogen	B-NP	NN	O	19	NMOD
16	induced	induced	I-NP	JJ	O	19	NMOD
17	rat	rat	I-NP	NN	O	19	NMOD
18	pituitary	pituitary	I-NP	JJ	O	19	NMOD
19	tumors	tumor	I-NP	NNS	O	14	PMOD
20	may	may	B-VP	MD	O	0	ROOT
21	mediate	mediate	I-VP	VB	O	20	VC
22	estrogen-initiated	estrogen-initiated	B-NP	JJ	O	24	NMOD
23	tumor	tumor	I-NP	NN	O	24	NMOD
24	angiogenesis	angiogenesis	I-NP	NN	O	21	OBJ
25	.	.	O	.	O	20	P

1	Estrogens	Estrogen	B-NP	NNS	O	16	SUB
2	,	,	O	,	O	1	P
3	which	which	B-NP	WDT	O	1	NMOD
4	have	have	B-VP	VBP	O	3	SBAR
5	been	be	I-VP	VBN	O	4	VC
6	associated	associate	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	several	several	B-NP	JJ	O	9	NMOD
9	types	type	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	human	human	B-NP	JJ	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	animal	animal	I-NP	JJ	O	14	NMOD
14	cancers	cancer	I-NP	NNS	O	10	PMOD
15	,	,	O	,	O	1	P
16	can	can	B-VP	MD	O	0	ROOT
17	induce	induce	I-VP	VB	O	16	VC
18	tumor	tumor	B-NP	NN	O	19	NMOD
19	angiogenesis	angiogenesis	I-NP	NN	O	17	OBJ
20	in	in	B-PP	IN	O	17	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	pituitary	pituitary	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	Fischer	Fischer	B-NP	NNP	O	26	NMOD
25	344	344	I-NP	CD	O	26	NMOD
26	rats	rat	I-NP	NNS	O	23	PMOD
27	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	3	NMOD
2	mechanistic	mechanistic	I-NP	JJ	O	3	NMOD
3	details	detail	I-NP	NNS	O	13	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	tumor	tumor	B-NP	NN	O	7	NMOD
6	angiogenesis	angiogenesis	I-NP	NN	O	7	NMOD
7	induction	induction	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	3	P
9	during	during	B-PP	IN	O	3	NMOD
10	estrogen	estrogen	B-NP	NN	O	11	NMOD
11	carcinogenesis	carcinogenesis	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	3	P
13	are	be	B-VP	VBP	O	0	ROOT
14	still	still	B-ADVP	RB	O	13	VMOD
15	unknown	unknown	B-ADJP	JJ	O	13	PRD
16	.	.	O	.	O	13	P

1	To	To	B-VP	TO	O	2	VMOD
2	elucidate	elucidate	I-VP	VB	O	25	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	role	role	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	estrogen	estrogen	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	regulation	regulation	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	tumor	tumor	B-NP	NN	O	12	NMOD
12	angiogenesis	angiogenesis	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	9	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	pituitary	pituitary	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	female	female	B-NP	JJ	O	18	NMOD
18	rats	rat	I-NP	NNS	O	16	PMOD
19	,	,	O	,	O	25	P
20	the	the	B-NP	DT	O	21	NMOD
21	density	density	I-NP	NN	O	25	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	blood	blood	B-NP	NN	O	24	NMOD
24	vessels	vessel	I-NP	NNS	O	22	PMOD
25	was	be	B-VP	VBD	O	0	ROOT
26	analysed	analyse	I-VP	VBN	O	25	VC
27	using	use	B-VP	VBG	O	26	VMOD
28	factor	factor	B-NP	NN	O	31	NMOD
29	VIII	VIII	I-NP	CD	O	31	NMOD
30	related	related	I-NP	JJ	O	31	NMOD
31	antigen	antigen	I-NP	NN	O	35	NMOD
32	(	(	O	(	O	34	DEP
33	FVIIIRAg	FVIIIRAg	B-NP	NN	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	immunohistochemistry	immunohistochemistry	B-NP	NN	O	38	NMOD
36	and	and	O	CC	O	38	NMOD
37	the	the	B-NP	DT	O	38	NMOD
38	expression	expression	I-NP	NN	O	27	OBJ
39	of	of	B-PP	IN	O	38	NMOD
40	vascular	vascular	B-NP	JJ	B-protein	45	NMOD
41	endothelial	endothelial	I-NP	JJ	I-protein	45	NMOD
42	growth	growth	I-NP	NN	I-protein	45	NMOD
43	factor/vascular	factor/vascular	I-NP	JJ	I-protein	45	NMOD
44	permeability	permeability	I-NP	NN	I-protein	45	NMOD
45	factor	factor	I-NP	NN	I-protein	39	PMOD
46	(	(	O	(	O	48	DEP
47	VEGF/VPF	VEGF/VPF	B-NP	NN	B-protein	48	DEP
48	)	)	O	)	O	45	NMOD
49	was	be	B-VP	VBD	O	25	VMOD
50	examined	examine	I-VP	VBN	O	49	VC
51	by	by	B-PP	IN	O	50	VMOD
52	Western	Western	B-NP	JJ	O	53	NMOD
53	blot	blot	I-NP	NN	O	56	NMOD
54	and	and	O	CC	O	56	NMOD
55	immunohistochemical	immunohistochemical	B-NP	JJ	O	56	NMOD
56	analysis	analysis	I-NP	NN	O	51	PMOD
57	.	.	O	.	O	25	P

1	The	The	B-NP	DT	O	5	NMOD
2	high	high	I-NP	JJ	O	5	NMOD
3	tumor	tumor	I-NP	NN	O	5	NMOD
4	angiogenic	angiogenic	I-NP	JJ	O	5	NMOD
5	potential	potential	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	associated	associate	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	an	an	B-NP	DT	O	13	NMOD
10	elevated	elevated	I-NP	JJ	O	13	NMOD
11	VEGF/VPF	VEGF/VPF	I-NP	NN	O	13	NMOD
12	protein	protein	I-NP	NN	O	13	NMOD
13	expression	expression	I-NP	NN	O	8	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	E2	E2	I-NP	NN	B-DNA	18	NMOD
17	exposed	expose	B-VP	VBN	O	18	NMOD
18	pituitary	pituitary	B-NP	NN	O	14	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	ovariectomized	ovariectomize	O	VBN	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	OVEX	OVEX	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	AMOD
24	rats	rat	B-NP	NNS	O	19	PMOD
25	.	.	O	.	O	6	P

1	Pravastatin-associated	Pravastatin-associated	B-NP	JJ	O	2	NMOD
2	myopathy	myopathy	I-NP	NN	O	0	ROOT
3	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	24	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	acute	acute	B-NP	JJ	O	5	AMOD
5	inflammatory	inflammatory	I-NP	JJ	O	6	NMOD
6	myopathy	myopathy	I-NP	NN	O	3	PMOD
7	associated	associate	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	pravastatin	pravastatin	B-NP	NN	B-protein	22	NMOD
13	,	,	O	,	O	22	P
14	a	a	B-NP	DT	O	22	NMOD
15	new	new	I-NP	JJ	O	22	NMOD
16	hydrophilic	hydrophilic	I-NP	JJ	O	22	NMOD
17	3-hydroxy-3	3-hydroxy-3	I-NP	NN	O	22	NMOD
18	methylglutaril	methylglutaril	I-NP	NN	O	22	NMOD
19	coenzyme	coenzyme	I-NP	NN	O	22	NMOD
20	A	A	I-NP	NN	O	22	NMOD
21	reductase	reductase	I-NP	NN	O	22	NMOD
22	inhibitor	inhibitor	I-NP	NN	O	11	PMOD
23	,	,	O	,	O	2	P
24	is	be	B-VP	VBZ	O	0	ROOT
25	reported	report	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	He	He	B-NP	PRP	O	2	SUB
2	assumed	assume	B-VP	VBD	O	0	ROOT
3	pravastatin	pravastatin	B-NP	NN	O	2	OBJ
4	(	(	O	(	O	7	DEP
5	20	20	B-NP	CD	O	6	NMOD
6	mg/day	mg/day	I-NP	NN	O	7	DEP
7	)	)	O	)	O	3	NMOD
8	because	because	B-PP	IN	O	2	VMOD
9	of	of	I-PP	IN	O	8	PMOD
10	hypercholesterolemia	hypercholesterolemia	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	He	He	B-NP	PRP	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	admitted	admit	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	acute	acute	B-NP	JJ	O	6	NMOD
6	myopathy	myopathy	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	lower	low	I-NP	JJR	O	10	NMOD
10	limbs	limb	I-NP	NNS	O	7	PMOD
11	which	which	B-NP	WDT	O	10	NMOD
12	resolved	resolve	B-VP	VBD	O	11	SBAR
13	in	in	B-PP	IN	O	12	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	few	few	I-NP	JJ	O	16	NMOD
16	days	day	I-NP	NNS	O	13	PMOD
17	after	after	B-PP	IN	O	16	NMOD
18	pravastatin	pravastatin	B-NP	NN	O	19	NMOD
19	discontinuation	discontinuation	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	2	P

1	Dose-effect	Dose-effect	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	structure-function	structure-function	I-NP	JJ	O	4	NMOD
4	relationships	relationship	I-NP	NNS	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	doxorubicin	doxorubicin	B-NP	NN	O	7	NMOD
7	cardiomyopathy	cardiomyopathy	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	cardiomyopathy	cardiomyopathy	I-NP	NN	O	18	SUB
3	(	(	O	(	O	5	DEP
4	CM	CM	B-NP	NN	O	5	DEP
5	)	)	O	)	O	2	NMOD
6	produced	produce	B-VP	VBN	O	2	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	11	NMOD
9	anticancer	anticancer	I-NP	JJ	O	11	NMOD
10	drug	drug	I-NP	NN	O	11	NMOD
11	doxorubicin	doxorubicin	I-NP	NN	O	7	PMOD
12	(	(	O	(	O	14	DEP
13	DXR	DXR	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	(	(	O	(	O	17	DEP
16	Adriamycin	Adriamycin	B-NP	NN	O	17	DEP
17	)	)	O	)	O	11	NMOD
18	provides	provide	B-VP	VBZ	O	0	ROOT
19	a	a	B-NP	DT	O	21	NMOD
20	unique	unique	I-NP	JJ	O	21	NMOD
21	opportunity	opportunity	I-NP	NN	O	18	OBJ
22	to	to	B-VP	TO	O	23	VMOD
23	analyze	analyze	I-VP	VB	O	21	NMOD
24	dose-effect	dose-effect	B-NP	NN	O	27	NMOD
25	and	and	O	CC	O	27	NMOD
26	structure-function	structure-function	B-NP	JJ	O	27	NMOD
27	relationships	relationship	I-NP	NNS	O	23	OBJ
28	during	during	B-PP	IN	O	27	NMOD
29	development	development	B-NP	NN	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	myocardial	myocardial	B-NP	JJ	O	32	NMOD
32	disease	disease	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	18	P

1	Fatal	Fatal	B-NP	JJ	O	3	NMOD
2	aplastic	aplastic	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	0	ROOT
4	following	follow	B-PP	VBG	O	3	NMOD
5	topical	topical	B-NP	JJ	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	ophthalmic	ophthalmic	B-NP	JJ	O	9	NMOD
9	chloramphenicol	chloramphenicol	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	73-year-old	73-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	4	SUB
4	died	die	B-VP	VBD	O	0	ROOT
5	of	of	B-PP	IN	O	4	VMOD
6	aplastic	aplastic	B-NP	JJ	O	7	NMOD
7	anemia	anemia	I-NP	NN	O	5	PMOD
8	less	less	B-NP	JJR	O	9	AMOD
9	than	than	I-NP	IN	O	4	VMOD
10	two	two	I-NP	CD	O	9	AMOD
11	months	month	I-NP	NNS	O	9	PMOD
12	after	after	B-SBAR	IN	O	4	VMOD
13	undergoing	undergo	B-VP	VBG	O	12	DEP
14	cataract	cataract	B-NP	NN	O	15	NMOD
15	extraction	extraction	I-NP	NN	O	13	OBJ
16	and	and	O	CC	O	13	VMOD
17	beginning	begin	B-VP	VBG	O	13	VMOD
18	topical	topical	B-NP	JJ	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	17	OBJ
20	with	with	B-PP	IN	O	19	NMOD
21	chloramphenicol	chloramphenicol	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	pattern	pattern	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	aplastic	aplastic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	an	an	B-NP	DT	O	12	NMOD
11	idiosyncratic	idiosyncratic	I-NP	JJ	O	12	NMOD
12	response	response	I-NP	NN	O	9	PMOD
13	to	to	B-PP	TO	O	12	NMOD
14	chloramphenicol	chloramphenicol	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	7	P

1	This	This	B-NP	DT	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	second	second	I-NP	JJ	O	5	NMOD
5	report	report	I-NP	NN	O	2	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	fatal	fatal	B-NP	JJ	O	9	NMOD
8	aplastic	aplastic	I-NP	JJ	O	9	NMOD
9	anemia	anemia	I-NP	NN	O	6	PMOD
10	after	after	B-PP	IN	O	9	NMOD
11	topical	topical	B-NP	JJ	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	10	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	chloramphenicol	chloramphenicol	B-NP	NN	O	13	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	ocular	ocular	B-NP	JJ	O	17	NMOD
17	conditions	condition	I-NP	NNS	O	15	PMOD
18	,	,	O	,	O	2	P
19	although	although	B-SBAR	IN	O	2	VMOD
20	two	two	B-NP	CD	O	21	NMOD
21	cases	case	I-NP	NNS	O	27	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	reversible	reversible	B-NP	JJ	O	26	NMOD
24	bone	bone	I-NP	NN	O	26	NMOD
25	marrow	marrow	I-NP	NN	O	26	NMOD
26	hypoplasia	hypoplasia	I-NP	NN	O	22	PMOD
27	have	have	B-VP	VBP	O	19	SBAR
28	also	also	I-VP	RB	O	27	VMOD
29	been	be	I-VP	VBN	O	27	VC
30	reported	report	I-VP	VBN	O	29	VC
31	.	.	O	.	O	2	P

1	Bradycardia	Bradycardia	B-NP	NNP	O	0	ROOT
2	due	due	B-PP	IN	O	1	NMOD
3	to	to	B-PP	TO	O	2	PMOD
4	trihexyphenidyl	trihexyphenidyl	B-NP	NN	O	5	NMOD
5	hydrochloride	hydrochloride	I-NP	NN	O	2	PMOD
6	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	4	NMOD
2	chronic	chronic	I-NP	JJ	O	4	NMOD
3	schizophrenic	schizophrenic	I-NP	JJ	O	4	NMOD
4	patient	patient	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	treated	treat	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	an	an	B-NP	DT	O	10	NMOD
9	anticholinergic	anticholinergic	I-NP	JJ	O	10	NMOD
10	drug	drug	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	6	P
12	trihexyphenidyl	trihexyphenidyl	B-NP	NN	O	13	NMOD
13	hydrochloride	hydrochloride	I-NP	NN	O	6	VMOD
14	.	.	O	.	O	5	P

1	Experimental	Experimental	B-NP	JJ	O	3	NMOD
2	cyclosporine	cyclosporine	I-NP	NN	O	3	NMOD
3	nephrotoxicity	nephrotoxicity	I-NP	NN	O	5	NMOD
4	:	:	O	:	O	3	P
5	risk	risk	B-NP	NN	O	0	ROOT
6	of	of	B-PP	IN	O	5	NMOD
7	concomitant	concomitant	B-NP	JJ	O	8	NMOD
8	chemotherapy	chemotherapy	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	21	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cyclosporine	cyclosporine	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	7	DEP
6	CSA	CSA	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	alone	alone	B-ADVP	RB	O	4	NMOD
9	or	or	O	CC	O	8	DEP
10	in	in	B-PP	IN	O	8	DEP
11	combination	combination	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	various	various	B-NP	JJ	O	14	NMOD
14	chemotherapeutics	chemotherapeutic	I-NP	NNS	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	development	development	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	renal	renal	B-NP	JJ	O	20	NMOD
20	toxicity	toxicity	I-NP	NN	O	18	PMOD
21	was	be	B-VP	VBD	O	0	ROOT
22	evaluated	evaluate	I-VP	VBN	O	21	VC
23	in	in	B-PP	IN	O	22	VMOD
24	rats	rat	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	3	NMOD
2	combined	combined	I-NP	JJ	O	3	NMOD
3	administration	administration	I-NP	NN	O	27	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	CSA	CSA	B-NP	NN	O	9	NMOD
6	and	and	O	CC	O	9	NMOD
7	various	various	B-NP	JJ	O	9	NMOD
8	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	9	NMOD
9	drugs	drug	I-NP	NNS	O	4	PMOD
10	with	with	B-PP	IN	O	3	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	nephrotoxic	nephrotoxic	I-NP	JJ	O	13	NMOD
13	potential	potential	I-NP	NN	O	10	PMOD
14	,	,	O	,	O	3	P
15	such	such	B-PP	JJ	O	16	PMOD
16	as	as	I-PP	IN	O	3	NMOD
17	gentamicin	gentamicin	B-NP	NN	O	16	PMOD
18	(	(	O	(	O	16	PMOD
19	at	at	B-PP	IN	O	16	PMOD
20	therapeutic	therapeutic	B-NP	JJ	O	21	NMOD
21	doses	dose	I-NP	NNS	O	19	PMOD
22	)	)	O	)	O	3	NMOD
23	,	,	O	,	O	27	P
24	amphothericin	amphothericin	B-NP	NN	O	25	NMOD
25	B	B	I-NP	NN	O	27	NMOD
26	and	and	O	CC	O	27	NMOD
27	ketoconazole	ketoconazole	B-NP	NN	O	37	SUB
28	,	,	O	,	O	27	P
29	which	which	B-NP	WDT	O	27	NMOD
30	are	be	B-VP	VBP	O	29	SBAR
31	frequently	frequently	I-VP	RB	O	30	VMOD
32	used	use	I-VP	VBN	O	30	VC
33	in	in	B-PP	IN	O	32	VMOD
34	immunosuppressed	immunosuppressed	B-NP	JJ	O	35	NMOD
35	patients	patient	I-NP	NNS	O	33	PMOD
36	,	,	O	,	O	27	P
37	did	do	B-VP	VBD	O	0	ROOT
38	not	not	I-VP	RB	O	37	VMOD
39	aggravate	aggravate	I-VP	VB	O	37	VC
40	the	the	B-NP	DT	O	41	NMOD
41	CSA	CSA	I-NP	NN	O	43	NMOD
42	induced	induce	B-VP	VBD	O	41	AMOD
43	toxicity	toxicity	B-NP	NN	O	39	OBJ
44	in	in	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	47	NMOD
46	rat	rat	I-NP	NN	O	47	NMOD
47	model	model	I-NP	NN	O	44	PMOD
48	.	.	O	.	O	37	P

1	Gentamicin	Gentamicin	B-NP	NN	O	10	NMOD
2	at	at	B-PP	IN	O	1	NMOD
3	toxic	toxic	B-NP	JJ	O	4	NMOD
4	doses	dose	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	1	P
6	however	however	B-ADVP	RB	O	10	VMOD
7	,	,	O	,	O	10	P
8	increased	increase	B-NP	VBN	O	10	NMOD
9	CSA	CSA	I-NP	NN	O	10	NMOD
10	nephrotoxicity	nephrotoxicity	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	Receptor	Receptor	B-NP	NN	O	2	NMOD
2	mechanisms	mechanism	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	nicotine	nicotine	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	locomotor	locomotor	B-NP	NN	O	7	NMOD
7	hyperactivity	hyperactivity	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	5	VMOD
9	chronic	chronic	B-NP	JJ	O	11	NMOD
10	nicotine-treated	nicotine-treated	I-NP	JJ	O	11	NMOD
11	rats	rat	I-NP	NNS	O	8	PMOD
12	.	.	O	.	O	5	P

1	Hydrocortisone	Hydrocortisone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hypertension	hypertension	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	3	NMOD
5	humans	human	B-NP	NNS	O	4	PMOD
6	:	:	O	:	O	2	P
7	pressor	pressor	B-NP	NN	O	8	NMOD
8	responsiveness	responsiveness	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	sympathetic	sympathetic	B-NP	JJ	O	11	NMOD
11	function	function	I-NP	NN	O	2	VMOD
12	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	23	VMOD
2	suprofen	suprofen	B-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	1	SBAR
4	been	be	I-VP	VBN	O	3	VC
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	development	development	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	acute	acute	B-NP	JJ	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	failure	failure	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	8	NMOD
14	greater	great	B-NP	JJR	O	15	AMOD
15	than	than	I-NP	IN	O	17	NMOD
16	100	100	I-NP	CD	O	15	AMOD
17	subjects	subject	I-NP	NNS	O	13	PMOD
18	,	,	O	,	O	23	P
19	the	the	B-NP	DT	O	20	NMOD
20	mechanism	mechanism	I-NP	NN	O	23	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	damage	damage	B-NP	NN	O	21	PMOD
23	remains	remain	B-VP	VBZ	O	0	ROOT
24	unclear	unclear	B-ADJP	JJ	O	23	PRD
25	.	.	O	.	O	23	P

1	The	The	B-NP	DT	O	4	NMOD
2	direct	direct	I-NP	JJ	O	3	AMOD
3	nephrotoxic	nephrotoxic	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	14	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	single	single	I-NP	JJ	O	8	NMOD
8	dose	dose	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	15	15	B-NP	CD	O	11	NMOD
11	mg	mg	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	suprofen	suprofen	B-NP	NN	O	12	PMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	compared	compare	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	the	the	B-NP	DT	O	21	NMOD
18	recirculating	recirculate	I-NP	VBG	O	21	NMOD
19	isolated	isolate	I-NP	VBN	O	21	NMOD
20	rat	rat	I-NP	NN	O	21	NMOD
21	kidney	kidney	I-NP	NN	O	16	PMOD
22	perfused	perfuse	B-VP	VBN	O	21	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	cell-free	cell-free	B-NP	JJ	O	25	NMOD
25	buffer	buffer	I-NP	NN	O	23	PMOD
26	with	with	B-PP	IN	O	21	NMOD
27	or	or	B-PP	CC	O	26	PMOD
28	without	without	B-PP	IN	O	26	PMOD
29	the	the	B-NP	DT	O	30	NMOD
30	addition	addition	I-NP	NN	O	26	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	5	5	B-NP	CD	O	33	NMOD
33	mg/dL	mg/dL	I-NP	NN	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	uric	uric	B-NP	JJ	O	36	NMOD
36	acid	acid	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	14	P

1	Cocaine	Cocaine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	brainstem	brainstem	B-NP	NN	O	4	NMOD
4	seizures	seizure	I-NP	NNS	O	6	NMOD
5	and	and	O	CC	O	6	NMOD
6	behavior	behavior	B-NP	NN	O	2	OBJ
7	.	.	O	.	O	2	P

1	Increased	Increase	B-NP	VBN	O	2	NMOD
2	sulfation	sulfation	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	decreased	decrease	B-VP	VBD	O	5	NMOD
5	7alpha-hydroxylation	7alpha-hydroxylation	B-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	deoxycholic	deoxycholic	B-NP	JJ	O	8	NMOD
8	acid	acid	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	5	NMOD
10	ethinyl	ethinyl	B-NP	NN	O	11	NMOD
11	estradiol	estradiol	I-NP	NN	O	9	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	cholestasis	cholestasis	B-NP	NN	O	12	OBJ
14	in	in	B-PP	IN	O	12	VMOD
15	rats	rat	B-NP	NNS	O	14	PMOD
16	.	.	O	.	O	12	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	ouabain	ouabain	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	myocardial	myocardial	B-NP	JJ	O	7	NMOD
6	oxygen	oxygen	I-NP	NN	O	7	NMOD
7	supply	supply	I-NP	NN	O	9	NMOD
8	and	and	O	CC	O	9	NMOD
9	demand	demand	B-NP	NN	O	4	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	chronic	chronic	B-NP	JJ	O	16	NMOD
14	coronary	coronary	I-NP	JJ	O	16	NMOD
15	artery	artery	I-NP	NN	O	16	NMOD
16	disease	disease	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	digitalis	digitalis	B-NP	NN	O	5	NMOD
5	glycosides	glycoside	I-NP	NNS	O	3	PMOD
6	on	on	B-PP	IN	O	2	NMOD
7	myocardial	myocardial	B-NP	JJ	O	9	NMOD
8	oxygen	oxygen	I-NP	NN	O	9	NMOD
9	supply	supply	I-NP	NN	O	11	NMOD
10	and	and	O	CC	O	11	NMOD
11	demand	demand	B-NP	NN	O	6	PMOD
12	are	be	B-VP	VBP	O	0	ROOT
13	of	of	B-PP	IN	O	12	PRD
14	particular	particular	B-NP	JJ	O	15	NMOD
15	interest	interest	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	12	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	presence	presence	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	obstructive	obstructive	B-NP	JJ	O	23	NMOD
21	coronary	coronary	I-NP	JJ	O	23	NMOD
22	artery	artery	I-NP	NN	O	23	NMOD
23	disease	disease	I-NP	NN	O	19	PMOD
24	,	,	O	,	O	12	P
25	but	but	O	CC	O	12	VMOD
26	have	have	B-VP	VBP	O	12	VMOD
27	not	not	I-VP	RB	O	26	VMOD
28	been	be	I-VP	VBN	O	26	VC
29	measured	measure	I-VP	VBN	O	28	VC
30	previously	previously	B-ADVP	RB	O	29	VMOD
31	in	in	B-PP	IN	O	29	VMOD
32	man	man	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	12	P

1	We	We	B-NP	PRP	O	2	SUB
2	assessed	assess	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	ouabain	ouabain	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	12	DEP
8	0.015	0.015	B-NP	CD	O	11	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	11	NMOD
10	body	body	I-NP	NN	O	11	NMOD
11	weight	weight	I-NP	NN	O	12	DEP
12	)	)	O	)	O	6	NMOD
13	on	on	B-PP	IN	O	4	NMOD
14	hemodynamic	hemodynamic	B-NP	JJ	O	20	NMOD
15	,	,	I-NP	,	O	20	P
16	volumetric	volumetric	I-NP	JJ	O	20	NMOD
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	NMOD
19	metabolic	metabolic	B-NP	JJ	O	20	NMOD
20	parameters	parameter	I-NP	NNS	O	13	PMOD
21	in	in	B-PP	IN	O	4	NMOD
22	11	11	B-NP	CD	O	23	NMOD
23	patients	patient	I-NP	NNS	O	21	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	severe	severe	B-NP	JJ	O	29	NMOD
26	chronic	chronic	I-NP	JJ	O	29	NMOD
27	coronary	coronary	I-NP	JJ	O	29	NMOD
28	artery	artery	I-NP	NN	O	29	NMOD
29	disease	disease	I-NP	NN	O	24	PMOD
30	without	without	B-PP	IN	O	4	NMOD
31	clinical	clinical	B-NP	JJ	O	34	NMOD
32	congestive	congestive	I-NP	JJ	O	34	NMOD
33	heart	heart	I-NP	NN	O	34	NMOD
34	failure	failure	I-NP	NN	O	30	PMOD
35	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	conclude	conclude	B-VP	VBP	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	in	in	B-PP	IN	O	19	VMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	chronic	chronic	B-NP	JJ	O	10	NMOD
8	coronary	coronary	I-NP	JJ	O	10	NMOD
9	artery	artery	I-NP	NN	O	10	NMOD
10	disease	disease	I-NP	NN	O	6	PMOD
11	who	who	B-NP	WP	O	5	NMOD
12	are	be	B-VP	VBP	O	11	SBAR
13	not	not	O	RB	O	12	VMOD
14	in	in	B-PP	IN	O	12	VMOD
15	clinical	clinical	B-NP	JJ	O	18	NMOD
16	congestive	congestive	I-NP	JJ	O	18	NMOD
17	heart	heart	I-NP	NN	O	18	NMOD
18	failure	failure	I-NP	NN	O	14	PMOD
19	left	leave	B-VP	VBD	O	3	SBAR
20	ventricular	ventricular	B-NP	JJ	O	22	NMOD
21	end-diastolic	end-diastolic	I-NP	JJ	O	22	NMOD
22	volume	volume	I-NP	NN	O	19	OBJ
23	falls	fall	B-VP	VBZ	O	19	VMOD
24	after	after	B-PP	IN	O	23	VMOD
25	ouabain	ouabain	B-NP	NN	O	26	NMOD
26	administration	administration	I-NP	NN	O	24	PMOD
27	even	even	B-ADVP	RB	O	28	AMOD
28	when	when	B-ADVP	WRB	O	23	VMOD
29	it	it	B-NP	PRP	O	30	SUB
30	is	be	B-VP	VBZ	O	28	SBAR
31	initially	initially	B-ADJP	RB	O	30	VMOD
32	normal	normal	I-ADJP	JJ	O	30	PRD
33	.	.	O	.	O	2	P

1	Prolongation	Prolongation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	QT	QT	I-NP	NN	O	5	NMOD
5	interval	interval	I-NP	NN	O	2	PMOD
6	related	relate	B-VP	VBN	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	cisapride-diltiazem	cisapride-diltiazem	B-NP	JJ	O	9	NMOD
9	interaction	interaction	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	1	P

1	Cisapride	Cisapride	B-NP	NN	O	10	NMOD
2	,	,	O	,	O	10	P
3	a	a	B-NP	DT	O	6	NMOD
4	cytochrome	cytochrome	I-NP	NN	B-protein	6	NMOD
5	P450	P450	I-NP	NN	I-protein	6	NMOD
6	3A4	3A4	I-NP	NN	I-protein	10	NMOD
7	(	(	O	(	O	9	DEP
8	CYP3A4	CYP3A4	B-NP	NN	B-protein	9	DEP
9	)	)	O	)	O	6	NMOD
10	substrate	substrate	B-NP	NN	O	12	SUB
11	,	,	O	,	O	10	P
12	is	be	B-VP	VBZ	O	0	ROOT
13	widely	widely	I-VP	RB	O	12	VMOD
14	prescribed	prescribe	I-VP	VBN	O	12	VC
15	for	for	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	gastrointestinal	gastrointestinal	B-NP	JJ	O	21	NMOD
20	motility	motility	I-NP	NN	O	21	NMOD
21	disorders	disorder	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	12	P

1	Prolongation	Prolongation	B-NP	NN	O	13	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	QT	QT	B-NP	NN	O	4	NMOD
4	interval	interval	I-NP	NN	O	2	PMOD
5	,	,	O	,	O	13	P
6	torsades	torsades	B-NP	FW	O	8	NMOD
7	de	de	I-NP	FW	O	8	NMOD
8	pointes	pointes	I-NP	FW	O	13	NMOD
9	,	,	O	,	O	13	P
10	and	and	O	CC	O	13	NMOD
11	sudden	sudden	B-NP	JJ	O	13	NMOD
12	cardiac	cardiac	I-NP	JJ	O	13	NMOD
13	death	death	I-NP	NN	O	14	SUB
14	have	have	B-VP	VBP	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	reported	report	I-VP	VBN	O	15	VC
17	after	after	B-PP	IN	O	16	VMOD
18	concomitant	concomitant	B-NP	JJ	O	19	NMOD
19	administration	administration	I-NP	NN	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	erythromycin	erythromycin	B-NP	NN	O	25	NMOD
22	or	or	I-NP	CC	O	25	NMOD
23	azole	azole	I-NP	NN	O	25	NMOD
24	antifungal	antifungal	I-NP	JJ	O	25	NMOD
25	agents	agent	I-NP	NNS	O	20	PMOD
26	,	,	B-PP	,	O	17	P
27	but	but	I-PP	CC	O	17	PMOD
28	not	not	B-PP	RB	O	29	PMOD
29	with	with	I-PP	IN	O	17	PMOD
30	other	other	B-NP	JJ	O	32	NMOD
31	CYP3A4	CYP3A4	I-NP	NN	B-protein	32	NMOD
32	inhibitors	inhibitor	I-NP	NNS	O	29	PMOD
33	.	.	O	.	O	14	P

1	A	A	B-NP	DT	O	4	NMOD
2	possible	possible	I-NP	JJ	O	4	NMOD
3	drug	drug	I-NP	NN	O	4	NMOD
4	interaction	interaction	I-NP	NN	O	5	SUB
5	occurred	occur	B-VP	VBD	O	0	ROOT
6	in	in	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	45-year-old	45-year-old	I-NP	JJ	O	9	NMOD
9	woman	woman	I-NP	NN	O	6	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	was	be	B-VP	VBD	O	10	SBAR
12	taking	take	I-VP	VBG	O	11	VC
13	cisapride	cisapride	B-NP	NN	O	12	OBJ
14	for	for	B-PP	IN	O	13	NMOD
15	gastroesophageal	gastroesophageal	B-NP	JJ	O	17	NMOD
16	reflux	reflux	I-NP	NN	O	17	NMOD
17	disorder	disorder	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	diltiazem	diltiazem	I-NP	NN	O	22	NMOD
20	,	,	O	,	O	22	P
21	an	an	B-NP	DT	O	22	NMOD
22	agent	agent	I-NP	NN	O	14	PMOD
23	that	that	B-NP	WDT	O	22	NMOD
24	has	have	B-VP	VBZ	O	23	SBAR
25	inhibitory	inhibitory	B-NP	JJ	O	26	NMOD
26	effect	effect	I-NP	NN	O	24	OBJ
27	on	on	B-PP	IN	O	26	NMOD
28	CYP3A4	CYP3A4	B-NP	NN	B-protein	27	PMOD
29	,	,	O	,	O	9	P
30	for	for	B-PP	IN	O	9	NMOD
31	hypertension	hypertension	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	5	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	0	ROOT
2	combined	combine	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	carboplatin	carboplatin	B-NP	NN	B-protein	3	PMOD
5	in	in	B-PP	IN	O	2	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	first-line	first-line	I-NP	JJ	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	advanced	advance	B-NP	VBN	O	12	NMOD
11	ovarian	ovarian	I-NP	JJ	O	12	NMOD
12	cancer	cancer	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	0	ROOT
2	a	a	B-NP	DT	O	5	NMOD
3	phase	phase	I-NP	NN	O	5	NMOD
4	I	I	I-NP	CD	O	5	NMOD
5	study	study	I-NP	NN	O	75	NMOD
6	to	to	B-VP	TO	O	7	VMOD
7	determine	determine	I-VP	VB	O	5	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	maximum	maximum	I-NP	NN	O	11	NMOD
10	tolerated	tolerate	I-NP	VBN	O	11	NMOD
11	dose	dose	I-NP	NN	O	7	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	paclitaxel	paclitaxel	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	75	NMOD
15	Taxol	Taxol	B-NP	NN	O	47	VMOD
16	;	;	O	:	O	47	P
17	Bristol-Myers	Bristol-Myers	B-NP	NNP	O	19	NMOD
18	Squibb	Squibb	I-NP	NNP	O	19	NMOD
19	Company	Company	I-NP	NNP	O	21	NMOD
20	,	,	O	,	O	21	P
21	Princeton	Princeton	B-NP	NNP	O	23	NMOD
22	,	,	O	,	O	23	P
23	NJ	NJ	B-NP	NNP	O	47	SUB
24	)	)	O	)	O	23	DEP
25	given	give	B-VP	VBN	O	23	NMOD
26	as	as	B-PP	IN	O	25	VMOD
27	a	a	B-NP	DT	O	29	NMOD
28	3-hour	3-hour	I-NP	JJ	O	29	NMOD
29	infusion	infusion	I-NP	NN	O	26	PMOD
30	in	in	B-PP	IN	O	29	NMOD
31	combination	combination	B-NP	NN	O	30	PMOD
32	with	with	B-PP	IN	O	31	NMOD
33	carboplatin	carboplatin	B-NP	NN	B-protein	34	SUB
34	administered	administer	B-VP	VBN	O	32	PMOD
35	every	every	B-NP	DT	O	37	NMOD
36	21	21	I-NP	CD	O	37	NMOD
37	days	day	I-NP	NNS	O	34	OBJ
38	to	to	B-PP	TO	O	37	NMOD
39	women	woman	B-NP	NNS	O	46	NMOD
40	with	with	B-PP	IN	O	39	NMOD
41	advanced	advance	B-NP	VBN	O	43	NMOD
42	ovarian	ovarian	I-NP	JJ	O	43	NMOD
43	cancer	cancer	I-NP	NN	O	40	PMOD
44	,	,	O	,	O	46	P
45	paclitaxel	paclitaxel	B-NP	NN	O	46	NMOD
46	doses	dose	I-NP	NNS	O	38	PMOD
47	were	be	B-VP	VBD	O	75	NMOD
48	escalated	escalate	I-VP	VBN	O	47	VC
49	as	as	B-SBAR	IN	O	47	VMOD
50	follows	follow	B-VP	VBZ	O	49	SBAR
51	:	:	O	:	O	75	P
52	level	level	B-NP	NN	O	56	NMOD
53	1	1	I-NP	CD	O	52	NMOD
54	,	,	I-NP	,	O	56	P
55	135	135	I-NP	CD	O	56	NMOD
56	mg/m2	mg/m2	I-NP	NN	O	75	NMOD
57	;	;	O	:	O	75	P
58	level	level	B-NP	NN	O	62	NMOD
59	2	2	I-NP	CD	O	58	NMOD
60	,	,	O	,	O	62	P
61	160	160	B-NP	CD	O	62	NMOD
62	mg/m2	mg/m2	I-NP	NN	O	75	NMOD
63	;	;	O	:	O	75	P
64	level	level	B-NP	NN	O	68	NMOD
65	3	3	I-NP	CD	O	68	NMOD
66	,	,	I-NP	,	O	68	P
67	185	185	I-NP	CD	O	68	NMOD
68	mg/m2	mg/m2	I-NP	NN	O	75	NMOD
69	;	;	O	:	O	75	P
70	and	and	O	CC	O	75	NMOD
71	level	level	B-NP	NN	O	75	NMOD
72	4	4	I-NP	CD	O	71	NMOD
73	,	,	I-NP	,	O	75	P
74	210	210	I-NP	CD	O	75	NMOD
75	mg/m2	mg/m2	I-NP	NN	O	1	PMOD
76	.	.	O	.	O	1	P

1	Relative	Relative	B-NP	JJ	O	2	NMOD
2	efficacy	efficacy	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	netilmicin	netilmicin	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	tobramycin	tobramycin	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	oncology	oncology	B-NP	NN	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	3	SUB
2	prospectively	prospectively	B-ADVP	RB	O	3	VMOD
3	compared	compare	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	7	NMOD
5	efficacy	efficacy	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	safety	safety	I-NP	NN	O	3	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	netilmicin	netilmicin	B-NP	NN	O	10	NMOD
10	sulfate	sulfate	I-NP	NN	O	13	NMOD
11	or	or	O	CC	O	13	NMOD
12	tobramycin	tobramycin	B-NP	NN	O	13	NMOD
13	sulfate	sulfate	I-NP	NN	O	8	PMOD
14	in	in	B-PP	IN	O	3	VMOD
15	conjunction	conjunction	B-NP	NN	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	piperacillin	piperacillin	B-NP	NN	O	18	NMOD
18	sodium	sodium	I-NP	NN	O	16	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	118	118	B-NP	CD	O	22	NMOD
21	immunocompromised	immunocompromised	I-NP	JJ	O	22	NMOD
22	patients	patient	I-NP	NNS	O	19	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	presumed	presume	B-NP	VBN	O	26	NMOD
25	severe	severe	I-NP	JJ	O	26	NMOD
26	infections	infection	I-NP	NNS	O	23	PMOD
27	.	.	O	.	O	3	P

1	Nephrotoxicity	Nephrotoxicity	B-NP	NN	O	2	SUB
2	occurred	occur	B-VP	VBD	O	0	ROOT
3	in	in	B-PP	IN	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	similar	similar	I-NP	JJ	O	6	NMOD
6	proportion	proportion	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	treated	treat	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	netilmicin	netilmicin	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	tobramycin	tobramycin	I-NP	NN	O	10	PMOD
14	(	(	O	(	O	20	DEP
15	17	17	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	19	NMOD
17	vs	vs	B-PP	IN	O	19	NMOD
18	11	11	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	20	DEP
20	)	)	O	)	O	13	NMOD
21	.	.	O	.	O	2	P

1	Ototoxicity	Ototoxicity	B-NP	NN	O	2	SUB
2	occurred	occur	B-VP	VBD	O	0	ROOT
3	in	in	B-PP	IN	O	2	VMOD
4	four	four	B-NP	CD	O	3	PMOD
5	(	(	O	(	O	8	DEP
6	9.5	9.5	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	of	of	B-PP	IN	O	4	NMOD
10	42	42	B-NP	CD	O	11	NMOD
11	netilmicin	netilmicin	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	piperacillin	piperacillin	I-NP	NN	O	9	PMOD
14	and	and	O	CC	O	3	PMOD
15	in	in	B-PP	IN	O	3	PMOD
16	12	12	B-NP	CD	O	15	PMOD
17	(	(	O	(	O	20	DEP
18	22	22	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	20	DEP
20	)	)	O	)	O	16	NMOD
21	of	of	B-PP	IN	O	16	NMOD
22	54	54	B-NP	CD	O	23	NMOD
23	tobramycin	tobramycin	I-NP	NN	O	21	PMOD
24	and	and	O	CC	O	26	NMOD
25	piperacillin-treated	piperacillin-treated	B-NP	JJ	O	26	NMOD
26	patients	patient	I-NP	NNS	O	2	VMOD
27	.	.	O	.	O	2	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	prostaglandin	prostaglandin	B-NP	NN	B-protein	5	NMOD
4	synthetase	synthetase	I-NP	NN	I-protein	5	NMOD
5	inhibitors	inhibitor	I-NP	NNS	O	2	PMOD
6	on	on	B-PP	IN	O	1	NMOD
7	experimentally	experimentally	B-NP	RB	O	8	AMOD
8	induced	induce	I-NP	VBN	O	9	NMOD
9	convulsions	convulsion	I-NP	NNS	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	rats	rat	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	1	P

1	To	To	B-VP	TO	O	2	VMOD
2	investigate	investigate	I-VP	VB	O	37	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	relationship	relationship	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	prostaglandins	prostaglandin	B-NP	NNS	O	5	PMOD
7	(	(	O	(	O	9	DEP
8	PGs	PG	B-NP	NNS	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	seizure	seizure	I-VP	VB	O	4	NMOD
12	induction	induction	B-NP	NN	O	11	OBJ
13	,	,	O	,	O	37	P
14	the	the	B-NP	DT	O	15	NMOD
15	effects	effect	I-NP	NNS	O	37	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	six	six	B-NP	CD	O	20	NMOD
18	PG	PG	I-NP	NN	O	20	NMOD
19	synthetase	synthetase	I-NP	NN	O	20	NMOD
20	inhibitors	inhibitor	I-NP	NNS	O	16	PMOD
21	on	on	B-PP	IN	O	15	NMOD
22	convulsions	convulsion	B-NP	NNS	O	21	PMOD
23	induced	induce	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	flurothyl	flurothyl	B-NP	NN	O	36	NMOD
26	,	,	O	,	O	36	P
27	picrotoxin	picrotoxin	B-NP	NN	O	36	NMOD
28	,	,	O	,	O	36	P
29	pentetrazol	pentetrazol	B-NP	NN	O	36	NMOD
30	(	(	O	(	O	32	DEP
31	PTZ	PTZ	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	29	NMOD
33	,	,	O	,	O	36	P
34	electroshock	electroshock	B-NP	NN	O	36	NMOD
35	or	or	I-NP	CC	O	36	NMOD
36	bicuculline	bicuculline	I-NP	NN	O	24	PMOD
37	were	be	B-VP	VBD	O	0	ROOT
38	evaluated	evaluate	I-VP	VBN	O	37	VC
39	.	.	O	.	O	37	P

1	This	This	B-NP	DT	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	case	case	I-NP	NN	O	5	NMOD
5	report	report	I-NP	NN	O	2	PRD
6	on	on	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	11	NMOD
8	45-year	45-year	I-NP	JJ	O	11	NMOD
9	old	old	I-NP	JJ	O	11	NMOD
10	African-American	African-American	I-NP	JJ	O	11	NMOD
11	female	female	I-NP	NN	O	6	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	newly	newly	B-NP	RB	O	14	AMOD
14	diagnosed	diagnose	I-NP	VBN	O	15	NMOD
15	hypertension	hypertension	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	11	P
17	who	who	B-NP	WP	O	11	NMOD
18	was	be	B-VP	VBD	O	17	SBAR
19	started	start	I-VP	VBN	O	18	VC
20	on	on	B-PP	IN	O	19	VMOD
21	a	a	B-NP	DT	O	23	NMOD
22	combination	combination	I-NP	NN	O	23	NMOD
23	pill	pill	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	amlodipine/benazapril	amlodipine/benazapril	B-NP	NN	O	27	NMOD
26	10/5	10/5	I-NP	CD	O	27	NMOD
27	mg	mg	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	2	P

1	Valproic	Valproic	B-NP	JJ	O	2	NMOD
2	acid	acid	I-NP	NN	O	6	NMOD
3	I	I	I-NP	CD	O	2	NMOD
4	:	:	O	:	O	6	P
5	time	time	B-NP	NN	O	6	NMOD
6	course	course	I-NP	NN	O	19	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	lipid	lipid	B-NP	NN	O	10	NMOD
9	peroxidation	peroxidation	I-NP	NN	O	10	NMOD
10	biomarkers	biomarker	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	19	P
12	liver	liver	B-NP	NN	O	13	NMOD
13	toxicity	toxicity	I-NP	NN	O	19	NMOD
14	,	,	O	,	O	19	P
15	and	and	O	CC	O	19	NMOD
16	valproic	valproic	B-NP	JJ	O	19	NMOD
17	acid	acid	I-NP	NN	O	19	NMOD
18	metabolite	metabolite	I-NP	NN	O	19	NMOD
19	levels	level	I-NP	NNS	O	0	ROOT
20	in	in	B-PP	IN	O	19	NMOD
21	rats	rat	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	19	P

1	To	To	B-VP	TO	O	2	VMOD
2	determine	determine	I-VP	VB	O	20	VMOD
3	whether	whether	B-SBAR	IN	O	2	VMOD
4	there	there	B-NP	EX	O	5	SUB
5	was	be	B-VP	VBD	O	3	SBAR
6	a	a	B-NP	DT	O	8	NMOD
7	temporal	temporal	I-NP	JJ	O	8	NMOD
8	relationship	relationship	I-NP	NN	O	5	PRD
9	between	between	B-PP	IN	O	5	VMOD
10	VPA-associated	VPA-associated	B-NP	JJ	O	12	NMOD
11	oxidative	oxidative	I-NP	JJ	O	12	NMOD
12	stress	stress	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	hepatotoxicity	hepatotoxicity	I-NP	NN	O	19	NMOD
15	,	,	O	,	O	19	P
16	adult	adult	B-NP	JJ	O	19	NMOD
17	male	male	I-NP	JJ	O	19	NMOD
18	Sprague-Dawley	Sprague-Dawley	I-NP	JJ	O	19	NMOD
19	rats	rat	I-NP	NNS	O	9	PMOD
20	were	be	B-VP	VBD	O	0	ROOT
21	treated	treat	I-VP	VBN	O	20	VC
22	ip	ip	B-ADVP	RB	O	21	VMOD
23	with	with	B-PP	IN	O	21	VMOD
24	VPA	VPA	B-NP	NN	B-protein	32	NMOD
25	(	(	O	(	O	28	DEP
26	500	500	B-NP	CD	O	27	NMOD
27	mg/kg	mg/kg	I-NP	NN	O	28	DEP
28	)	)	O	)	O	24	NMOD
29	or	or	O	CC	O	32	NMOD
30	0.9	0.9	B-NP	CD	O	32	NMOD
31	%	%	I-NP	NN	O	32	NMOD
32	saline	saline	I-NP	NN	O	23	PMOD
33	(	(	O	(	O	35	DEP
34	vehicle	vehicle	B-NP	NN	O	35	DEP
35	)	)	O	)	O	32	NMOD
36	once	once	B-ADVP	RB	O	21	VMOD
37	daily	daily	I-ADVP	RB	O	36	AMOD
38	for	for	B-PP	IN	O	36	PMOD
39	2	2	B-NP	CD	O	49	NMOD
40	,	,	I-NP	,	O	49	P
41	4	4	I-NP	CD	O	49	NMOD
42	,	,	I-NP	,	O	49	P
43	7	7	I-NP	CD	O	49	NMOD
44	,	,	I-NP	,	O	49	P
45	10	10	I-NP	CD	O	49	NMOD
46	,	,	O	,	O	49	P
47	or	or	O	CC	O	49	NMOD
48	14	14	B-NP	CD	O	49	NMOD
49	days	day	I-NP	NNS	O	38	PMOD
50	.	.	O	.	O	20	P

1	Liver	Liver	B-NP	NN	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	evaluated	evaluate	I-VP	VBN	O	3	VC
5	based	base	B-PP	VBN	O	4	VMOD
6	on	on	B-PP	IN	O	5	PMOD
7	serum	serum	B-NP	NN	O	8	NMOD
8	levels	level	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	alpha-glutathione	alpha-glutathione	B-NP	NN	B-protein	11	NMOD
11	S-transferase	S-transferase	I-NP	NN	I-protein	9	PMOD
12	(	(	O	(	O	14	DEP
13	alpha-GST	alpha-GST	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	and	and	O	CC	O	5	PMOD
16	by	by	B-PP	IN	O	15	PRD
17	histology	histology	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	3	P

1	Pheochromocytoma	Pheochromocytoma	B-NP	NN	O	0	ROOT
2	unmasked	unmasked	B-ADJP	JJ	O	1	NMOD
3	by	by	B-PP	IN	O	2	AMOD
4	amisulpride	amisulpride	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	tiapride	tiapride	I-NP	NN	O	3	PMOD
7	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	describe	describe	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	unmasking	unmasking	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	pheochromocytoma	pheochromocytoma	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	a	a	B-NP	DT	O	11	NMOD
11	patient	patient	I-NP	NN	O	9	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	amisulpride	amisulpride	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	tiapride	tiapride	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	7	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	7	NMOD
5	42-year-old	42-year-old	I-NP	JJ	O	7	NMOD
6	white	white	I-NP	JJ	O	7	NMOD
7	man	man	I-NP	NN	O	8	SUB
8	developed	develop	B-VP	VBD	O	0	ROOT
9	acute	acute	B-NP	JJ	O	10	NMOD
10	hypertension	hypertension	I-NP	NN	O	8	OBJ
11	with	with	B-PP	IN	O	10	NMOD
12	severe	severe	B-NP	JJ	O	13	NMOD
13	headache	headache	I-NP	NN	O	11	PMOD
14	and	and	O	CC	O	8	VMOD
15	vomiting	vomit	B-VP	VBG	O	8	VMOD
16	2	2	B-NP	CD	O	17	NMOD
17	hours	hour	I-NP	NNS	O	15	OBJ
18	after	after	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	first	first	I-NP	JJ	O	21	NMOD
21	doses	dose	I-NP	NNS	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	amisulpride	amisulpride	B-NP	NN	O	25	AMOD
24	100	100	I-NP	CD	O	25	AMOD
25	mg	mg	I-NP	NN	O	29	NMOD
26	and	and	I-NP	CC	O	29	NMOD
27	tiapride	tiapride	I-NP	NN	O	29	NMOD
28	100	100	I-NP	CD	O	29	NMOD
29	mg	mg	I-NP	NN	O	22	PMOD
30	.	.	O	.	O	8	P

1	DISCUSSION	DISCUSSION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Drug	Drug	B-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	23	VMOD
5	symptoms	symptom	B-NP	NNS	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	pheochromocytoma	pheochromocytoma	B-NP	NN	O	6	PMOD
8	are	be	B-VP	VBP	O	4	VMOD
9	often	often	I-VP	RB	O	8	VMOD
10	associated	associate	I-VP	VBN	O	8	VC
11	with	with	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	use	use	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	substituted	substitute	B-NP	VBN	O	17	NMOD
16	benzamide	benzamide	I-NP	NN	O	17	NMOD
17	drugs	drug	I-NP	NNS	O	14	PMOD
18	,	,	O	,	O	23	P
19	but	but	O	CC	O	23	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	underlying	underlying	I-NP	JJ	O	22	NMOD
22	mechanism	mechanism	I-NP	NN	O	23	SUB
23	is	be	B-VP	VBZ	O	0	ROOT
24	unknown	unknown	B-ADJP	JJ	O	23	PRD
25	.	.	O	.	O	23	P

1	In	In	B-PP	IN	O	11	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	case	case	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	11	P
5	use	use	B-NP	NN	O	11	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	Naranjo	Naranjo	I-NP	NNP	O	10	NMOD
9	probability	probability	I-NP	NN	O	10	NMOD
10	scale	scale	I-NP	NN	O	6	PMOD
11	indicated	indicate	B-VP	VBD	O	0	ROOT
12	a	a	B-NP	DT	O	14	NMOD
13	possible	possible	I-NP	JJ	O	14	NMOD
14	relationship	relationship	I-NP	NN	O	11	OBJ
15	between	between	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	hypertensive	hypertensive	I-NP	JJ	O	18	NMOD
18	crisis	crisis	I-NP	NN	O	20	NMOD
19	and	and	I-NP	CC	O	20	NMOD
20	amisulpride	amisulpride	I-NP	NN	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	tiapride	tiapride	I-NP	NN	O	23	NMOD
23	therapy	therapy	I-NP	NN	O	15	PMOD
24	.	.	O	.	O	11	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	As	As	B-PP	IN	O	1	NMOD
4	of	of	B-PP	IN	O	3	PMOD
5	March	March	B-NP	NNP	O	8	NMOD
6	24	24	I-NP	CD	O	5	NMOD
7	,	,	I-NP	,	O	8	P
8	2005	2005	I-NP	CD	O	4	PMOD
9	,	,	O	,	O	11	P
10	this	this	B-NP	DT	O	11	SUB
11	is	be	B-VP	VBZ	O	1	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	first	first	I-NP	JJ	O	15	NMOD
14	reported	report	I-NP	VBN	O	15	NMOD
15	case	case	I-NP	NN	O	20	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	amisulpride-	amisulpride-	B-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	tiapride	tiapride	I-NP	NN	O	16	PMOD
20	induced	induce	B-VP	VBD	O	11	VMOD
21	hypertensive	hypertensive	B-NP	JJ	O	22	NMOD
22	crisis	crisis	I-NP	NN	O	20	OBJ
23	in	in	B-PP	IN	O	20	VMOD
24	a	a	B-NP	DT	O	25	NMOD
25	patient	patient	I-NP	NN	O	23	PMOD
26	with	with	B-PP	IN	O	25	NMOD
27	pheochromocytoma	pheochromocytoma	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	1	P

1	Quantitative	Quantitative	B-NP	JJ	O	3	NMOD
2	drug	drug	I-NP	NN	O	3	NMOD
3	levels	level	I-NP	NNS	O	8	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	stimulant	stimulant	B-NP	JJ	O	6	NMOD
6	psychosis	psychosis	I-NP	NN	O	4	PMOD
7	:	:	O	:	O	3	P
8	relationship	relationship	B-NP	NN	O	15	NMOD
9	to	to	B-PP	TO	O	8	NMOD
10	symptom	symptom	B-NP	NN	O	11	NMOD
11	severity	severity	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	15	P
13	catecholamines	catecholamine	B-NP	NNS	O	15	NMOD
14	and	and	O	CC	O	15	NMOD
15	hyperkinesia	hyperkinesia	B-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	To	To	B-VP	TO	O	2	VMOD
2	examine	examine	I-VP	VB	O	40	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	relationship	relationship	I-NP	NN	O	2	OBJ
5	between	between	B-PP	IN	O	4	NMOD
6	quantitative	quantitative	B-NP	JJ	O	9	NMOD
7	stimulant	stimulant	I-NP	JJ	O	9	NMOD
8	drug	drug	I-NP	NN	O	9	NMOD
9	levels	level	I-NP	NNS	O	33	SUB
10	,	,	O	,	O	33	P
11	catecholamines	catecholamine	B-NP	NNS	O	33	VMOD
12	,	,	O	,	O	33	P
13	and	and	O	CC	O	33	VMOD
14	psychotic	psychotic	B-NP	JJ	O	15	NMOD
15	symptoms	symptom	I-NP	NNS	O	33	SUB
16	,	,	O	,	O	33	P
17	nineteen	nineteen	B-NP	CD	O	18	NMOD
18	patients	patient	I-NP	NNS	O	33	SUB
19	in	in	B-PP	IN	O	18	NMOD
20	a	a	B-NP	DT	O	23	NMOD
21	psychiatric	psychiatric	I-NP	JJ	O	23	NMOD
22	emergency	emergency	I-NP	NN	O	23	NMOD
23	service	service	I-NP	NN	O	19	PMOD
24	with	with	B-PP	IN	O	18	NMOD
25	a	a	B-NP	DT	O	26	NMOD
26	diagnosis	diagnosis	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	amphetamine-	amphetamine-	B-NP	NN	O	32	NMOD
29	or	or	I-NP	CC	O	32	NMOD
30	cocaine	cocaine	I-NP	NN	O	31	AMOD
31	induced	induce	I-NP	VBN	O	32	NMOD
32	psychosis	psychosis	I-NP	NN	O	27	PMOD
33	were	be	B-VP	VBD	O	5	SBAR
34	interviewed	interview	I-VP	VBN	O	33	VC
35	,	,	O	,	O	40	P
36	and	and	O	CC	O	39	NMOD
37	plasma	plasma	B-NP	NN	O	39	NMOD
38	and	and	I-NP	CC	O	39	NMOD
39	urine	urine	I-NP	NN	O	40	SUB
40	were	be	B-VP	VBD	O	0	ROOT
41	collected	collect	I-VP	VBN	O	40	VC
42	for	for	B-PP	IN	O	41	VMOD
43	quantitative	quantitative	B-NP	JJ	O	44	NMOD
44	assays	assay	I-NP	NNS	O	42	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	stimulant	stimulant	B-NP	NN	O	47	NMOD
47	drug	drug	I-NP	NN	O	51	NMOD
48	and	and	O	CC	O	51	NMOD
49	catecholamine	catecholamine	B-NP	NN	O	51	NMOD
50	metabolite	metabolite	I-NP	NN	O	51	NMOD
51	levels	level	I-NP	NNS	O	45	PMOD
52	.	.	O	.	O	40	P

1	Methamphetamine	Methamphetamine	B-NP	NN	O	4	NMOD
2	or	or	I-NP	CC	O	4	NMOD
3	amphetamine	amphetamine	I-NP	NN	O	4	NMOD
4	levels	level	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	related	relate	I-VP	VBN	O	5	VC
7	to	to	B-PP	TO	O	6	VMOD
8	several	several	B-NP	JJ	O	10	NMOD
9	psychopathology	psychopathology	I-NP	NN	B-DNA	10	NMOD
10	scores	score	I-NP	NNS	I-DNA	15	NMOD
11	and	and	O	CC	O	15	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	global	global	I-NP	JJ	O	15	NMOD
14	hyperkinesia	hyperkinesia	I-NP	NN	O	15	NMOD
15	rating	rating	I-NP	NN	O	7	PMOD
16	.	.	O	.	O	5	P

1	Delayed	Delay	B-NP	VBN	O	4	NMOD
2	asystolic	asystolic	I-NP	JJ	O	4	NMOD
3	cardiac	cardiac	I-NP	JJ	O	4	NMOD
4	arrest	arrest	I-NP	NN	O	0	ROOT
5	after	after	B-PP	IN	O	4	NMOD
6	diltiazem	diltiazem	B-NP	NN	O	7	NMOD
7	overdose	overdose	I-NP	NN	O	5	PMOD
8	;	;	O	:	O	4	P
9	resuscitation	resuscitation	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	high	high	B-NP	JJ	O	14	NMOD
12	dose	dose	I-NP	NN	O	14	NMOD
13	intravenous	intravenous	I-NP	JJ	O	14	NMOD
14	calcium	calcium	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	5	NMOD
2	51	51	I-NP	CD	O	3	AMOD
3	year	year	I-NP	NN	O	5	NMOD
4	old	old	I-NP	JJ	O	5	NMOD
5	man	man	I-NP	NN	O	6	SUB
6	took	take	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	mixed	mix	I-NP	VBN	O	9	NMOD
9	overdose	overdose	I-NP	NN	O	6	OBJ
10	including	include	B-PP	VBG	O	9	NMOD
11	1.8-3.6	1.8-3.6	B-NP	CD	O	12	NMOD
12	g	g	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	diltiazem	diltiazem	B-NP	NN	O	24	NMOD
15	,	,	O	,	O	24	P
16	paracetamol	paracetamol	B-NP	NN	O	24	NMOD
17	,	,	O	,	O	24	P
18	aspirin	aspirin	B-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	isosorbide	isosorbide	B-NP	NN	O	21	NMOD
21	nitrate	nitrate	I-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	alcohol	alcohol	B-NP	NN	O	13	PMOD
25	.	.	O	.	O	6	P

1	This	This	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	3	SUB
3	suggests	suggest	B-VP	VBZ	O	0	ROOT
4	there	there	B-NP	EX	O	5	SUB
5	is	be	B-VP	VBZ	O	3	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	role	role	I-NP	NN	O	5	PRD
8	for	for	B-PP	IN	O	7	NMOD
9	aggressive	aggressive	B-NP	JJ	O	14	NMOD
10	high	high	I-NP	JJ	O	14	NMOD
11	dose	dose	I-NP	NN	O	14	NMOD
12	intravenous	intravenous	I-NP	JJ	O	14	NMOD
13	calcium	calcium	I-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	8	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	severe	severe	B-NP	JJ	O	18	NMOD
17	diltiazem	diltiazem	I-NP	NN	O	18	NMOD
18	overdose	overdose	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	15	P
20	particularly	particularly	B-ADVP	RB	O	15	PMOD
21	with	with	B-PP	IN	O	15	PMOD
22	the	the	B-NP	DT	O	23	NMOD
23	onset	onset	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	asystole	asystole	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	3	P

1	It	It	B-NP	PRP	O	2	SUB
2	should	should	B-VP	MD	O	0	ROOT
3	be	be	I-VP	VB	O	2	VC
4	considered	consider	I-VP	VBN	O	3	VC
5	early	early	B-ADVP	RB	O	4	VMOD
6	in	in	B-PP	IN	O	4	VMOD
7	cases	case	B-NP	NNS	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	cardiac	cardiac	B-NP	JJ	O	10	NMOD
10	arrest	arrest	I-NP	NN	O	8	PMOD
11	after	after	B-PP	IN	O	4	VMOD
12	diltiazem	diltiazem	B-NP	NN	O	13	NMOD
13	overdose	overdose	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	Renal	Renal	B-NP	JJ	O	3	NMOD
2	papillary	papillary	I-NP	JJ	O	3	NMOD
3	necrosis	necrosis	I-NP	NN	O	0	ROOT
4	due	due	B-PP	IN	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	naproxen	naproxen	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	31-year-old	31-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	24	NMOD
4	with	with	B-PP	IN	O	3	NMOD
5	rheumatoid	rheumatoid	B-NP	JJ	O	6	NMOD
6	arthritis	arthritis	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	3	P
8	who	who	B-NP	WP	O	3	NMOD
9	had	have	B-VP	VBD	O	8	SBAR
10	previously	previously	I-VP	RB	O	9	VMOD
11	been	be	I-VP	VBN	O	9	VC
12	treated	treat	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	sulindac	sulindac	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	24	P
16	fenoprofen	fenoprofen	B-NP	NN	O	17	NMOD
17	calcium	calcium	I-NP	NN	O	24	NMOD
18	,	,	O	,	O	24	P
19	high	high	B-NP	JJ	O	21	NMOD
20	dose	dose	I-NP	NN	O	21	NMOD
21	salicylates	salicylate	I-NP	NNS	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	gold	gold	B-NP	NN	O	24	NMOD
24	salts	salt	I-NP	NNS	O	26	SUB
25	,	,	O	,	O	24	P
26	developed	develop	B-VP	VBD	O	0	ROOT
27	renal	renal	B-NP	JJ	O	29	NMOD
28	papillary	papillary	I-NP	JJ	O	29	NMOD
29	necrosis	necrosis	I-NP	NN	O	34	NMOD
30	(	(	O	(	O	32	DEP
31	RPN	RPN	B-NP	NN	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	4	4	B-NP	CD	O	29	NMOD
34	months	month	I-NP	NNS	O	35	PMOD
35	after	after	B-PP	IN	O	26	VMOD
36	institution	institution	B-NP	NN	O	35	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	naproxen	naproxen	B-NP	NN	O	39	NMOD
39	therapy	therapy	I-NP	NN	O	37	PMOD
40	.	.	O	.	O	26	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	7	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	ischaemic	ischaemic	B-NP	JJ	O	6	NMOD
5	heart	heart	I-NP	NN	O	6	NMOD
6	disease	disease	I-NP	NN	O	3	PMOD
7	developed	develop	B-VP	VBD	O	0	ROOT
8	profound	profound	B-NP	JJ	O	10	NMOD
9	cardiac	cardiac	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	14	NMOD
11	,	,	O	,	O	14	P
12	hypotension	hypotension	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	bradycardia	bradycardia	I-NP	NN	O	7	OBJ
15	during	during	B-PP	IN	O	14	NMOD
16	combined	combine	B-NP	VBN	O	17	NMOD
17	therapy	therapy	I-NP	NN	O	15	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	verapamil	verapamil	B-NP	NN	O	23	NMOD
20	and	and	O	CC	O	23	NMOD
21	beta-adrenergic	beta-adrenergic	B-NP	JJ	O	23	NMOD
22	blocking	blocking	I-NP	NN	O	23	NMOD
23	drugs	drug	I-NP	NNS	O	18	PMOD
24	.	.	O	.	O	7	P

1	Adverse	Adverse	B-NP	JJ	O	2	NMOD
2	reactions	reaction	I-NP	NNS	O	0	ROOT
3	to	to	B-PP	TO	O	2	NMOD
4	bendrofluazide	bendrofluazide	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	propranolol	propranolol	I-NP	NN	O	3	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	mild	mild	B-NP	JJ	O	12	NMOD
12	hypertension	hypertension	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	2	P

1	Participants	Participant	B-NP	NNS	O	12	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	8	NMOD
4	Medical	Medical	I-NP	NNP	O	8	NMOD
5	Research	Research	I-NP	NNP	O	8	NMOD
6	Council	Council	I-NP	NNP	O	8	NMOD
7	treatment	treatment	I-NP	NN	O	8	NMOD
8	trial	trial	I-NP	NN	O	2	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	mild	mild	B-NP	JJ	O	11	NMOD
11	hypertension	hypertension	I-NP	NN	O	9	PMOD
12	are	be	B-VP	VBP	O	0	ROOT
13	randomly	randomly	I-VP	RB	O	12	VMOD
14	allocated	allocate	I-VP	VBN	O	12	VC
15	to	to	B-PP	TO	O	14	VMOD
16	one	one	B-NP	CD	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	four	four	B-NP	CD	O	20	NMOD
19	treatment	treatment	I-NP	NN	O	20	NMOD
20	groups	group	I-NP	NNS	O	17	PMOD
21	:	:	O	:	O	12	P
22	bendrofluazide	bendrofluazide	B-NP	NN	O	28	NMOD
23	,	,	O	,	O	28	P
24	propranolol	propranolol	B-NP	NN	O	28	NMOD
25	,	,	O	,	O	28	P
26	or	or	O	CC	O	28	NMOD
27	a	a	B-NP	DT	O	28	NMOD
28	placebo	placebo	I-NP	NN	O	12	PRD
29	for	for	B-PP	IN	O	28	NMOD
30	either	either	B-NP	DT	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	these	these	B-NP	DT	O	33	NMOD
33	drugs	drug	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	show	show	B-VP	VBP	O	15	VMOD
4	an	an	B-NP	DT	O	5	NMOD
5	association	association	I-NP	NN	O	3	OBJ
6	between	between	B-PP	IN	O	5	NMOD
7	bendrofluazide	bendrofluazide	B-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	impotence	impotence	I-NP	NN	O	6	PMOD
11	,	,	O	,	O	15	P
12	and	and	O	CC	O	13	NMOD
13	impotence	impotence	B-NP	NN	O	15	SUB
14	also	also	B-ADVP	RB	O	15	VMOD
15	occurred	occur	B-VP	VBD	O	0	ROOT
16	more	more	B-ADVP	RBR	O	17	AMOD
17	frequently	frequently	I-ADVP	RB	O	15	VMOD
18	in	in	B-PP	IN	O	17	AMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	taking	take	B-VP	VBG	O	19	NMOD
21	propranolol	propranolol	B-NP	NN	O	20	OBJ
22	than	than	B-PP	IN	O	20	VMOD
23	in	in	B-PP	IN	O	22	PMOD
24	those	those	B-NP	DT	O	26	NMOD
25	taking	take	I-NP	VBG	O	26	NMOD
26	placebos	placebo	I-NP	NNS	O	23	PMOD
27	.	.	O	.	O	15	P

1	Other	Other	B-NP	JJ	O	3	NMOD
2	adverse	adverse	I-NP	JJ	O	3	NMOD
3	reactions	reaction	I-NP	NNS	O	9	SUB
4	significantly	significantly	B-VP	RB	O	5	VMOD
5	linked	link	I-VP	VBN	O	3	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	active	active	B-NP	JJ	O	8	NMOD
8	drugs	drug	I-NP	NNS	O	6	PMOD
9	include	include	B-VP	VBP	O	0	ROOT
10	impaired	impaired	B-NP	JJ	O	12	NMOD
11	glucose	glucose	I-NP	NN	O	12	NMOD
12	tolerance	tolerance	I-NP	NN	O	18	NMOD
13	in	in	B-PP	IN	O	12	NMOD
14	men	man	B-NP	NNS	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	women	woman	I-NP	NNS	O	13	PMOD
17	and	and	O	CC	O	18	NMOD
18	gout	gout	B-NP	NN	O	32	NMOD
19	in	in	B-PP	IN	O	18	NMOD
20	men	man	B-NP	NNS	O	19	PMOD
21	,	,	O	,	O	18	P
22	associated	associate	B-VP	VBN	O	18	NMOD
23	with	with	B-PP	IN	O	22	VMOD
24	bendrofluazide	bendrofluazide	B-NP	NN	O	25	NMOD
25	treatment	treatment	I-NP	NN	O	23	PMOD
26	,	,	O	,	O	32	P
27	and	and	O	CC	O	32	NMOD
28	Raynaud	Raynaud	B-NP	NNP	O	29	NMOD
29	's	's	B-NP	POS	O	30	NMOD
30	phenomenon	phenomenon	I-NP	NN	O	32	NMOD
31	and	and	I-NP	CC	O	32	NMOD
32	dyspnoea	dyspnoea	I-NP	NN	O	9	OBJ
33	in	in	B-PP	IN	O	32	NMOD
34	men	man	B-NP	NNS	O	36	NMOD
35	and	and	I-NP	CC	O	36	NMOD
36	women	woman	I-NP	NNS	O	33	PMOD
37	taking	take	B-VP	VBG	O	36	NMOD
38	propranolol	propranolol	B-NP	NN	O	37	OBJ
39	.	.	O	.	O	9	P

1	No	No	B-NP	DT	O	3	NMOD
2	corneal	corneal	I-NP	JJ	O	3	NMOD
3	disease	disease	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	known	know	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	have	have	I-VP	VB	O	5	VMOD
8	occurred	occur	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	propranolol	propranolol	I-NP	NN	O	12	NMOD
12	group	group	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	Dexmedetomidine	Dexmedetomidine	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	associated	associate	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	trend	trend	I-NP	NN	O	4	PMOD
7	towards	towards	B-PP	IN	O	6	NMOD
8	improved	improve	B-NP	VBN	O	10	NMOD
9	cardiac	cardiac	I-NP	JJ	O	10	NMOD
10	outcomes	outcome	I-NP	NNS	O	7	PMOD
11	;	;	O	:	O	2	VMOD
12	all-cause	all-cause	B-NP	JJ	O	13	NMOD
13	mortality	mortality	I-NP	NN	O	47	NMOD
14	(	(	O	(	O	26	DEP
15	OR	OR	B-NP	NN	O	23	NMOD
16	0.27	0.27	I-NP	CD	O	15	NMOD
17	,	,	O	,	O	23	P
18	95	95	B-NP	CD	O	20	NMOD
19	%	%	I-NP	NN	O	20	NMOD
20	CI	CI	I-NP	NN	O	23	NMOD
21	0.01-7.13	0.01-7.13	I-NP	CD	O	20	NMOD
22	,	,	O	,	O	23	P
23	p	p	B-NP	NN	O	26	DEP
24	=	=	B-VP	SYM	O	23	NMOD
25	0.44	0.44	B-NP	CD	O	24	AMOD
26	)	)	O	)	O	13	NMOD
27	,	,	O	,	O	47	P
28	non-fatal	non-fatal	B-NP	JJ	O	30	NMOD
29	myocardial	myocardial	I-NP	JJ	O	30	NMOD
30	infarction	infarction	I-NP	NN	O	47	NMOD
31	(	(	O	(	O	43	DEP
32	OR	OR	B-NP	NN	O	40	NMOD
33	0.26	0.26	I-NP	CD	O	32	NMOD
34	,	,	O	,	O	40	P
35	95	95	B-NP	CD	O	37	NMOD
36	%	%	I-NP	NN	O	37	NMOD
37	CI	CI	I-NP	NN	O	40	NMOD
38	0.04-1.60	0.04-1.60	I-NP	CD	O	37	NMOD
39	,	,	O	,	O	40	P
40	p	p	B-NP	NN	O	42	SUB
41	=	=	B-VP	SYM	O	42	VMOD
42	0.14	0.14	B-NP	CD	O	43	DEP
43	)	)	O	)	O	30	NMOD
44	,	,	O	,	O	47	P
45	and	and	O	CC	O	47	NMOD
46	myocardial	myocardial	B-NP	JJ	O	47	NMOD
47	ischaemia	ischaemia	I-NP	NN	O	11	OBJ
48	(	(	O	(	O	60	DEP
49	OR	OR	B-NP	NN	O	57	NMOD
50	0.65	0.65	I-NP	CD	O	49	NMOD
51	,	,	O	,	O	57	P
52	95	95	B-NP	CD	O	54	NMOD
53	%	%	I-NP	NN	O	54	NMOD
54	CI	CI	I-NP	NN	O	57	NMOD
55	0.26-1.63	0.26-1.63	I-NP	CD	O	54	NMOD
56	,	,	O	,	O	57	P
57	p	p	B-NP	NN	O	60	DEP
58	=	=	B-VP	SYM	O	57	NMOD
59	0.36	0.36	B-NP	CD	O	58	AMOD
60	)	)	O	)	O	47	NMOD
61	.	.	O	.	O	2	P

1	Differential	Differential	B-NP	JJ	O	2	NMOD
2	diagnosis	diagnosis	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	high	high	B-NP	JJ	O	8	NMOD
5	serum	serum	I-NP	NN	B-protein	8	NMOD
6	creatine	creatine	I-NP	NN	I-protein	8	NMOD
7	kinase	kinase	I-NP	NN	I-protein	8	NMOD
8	levels	level	I-NP	NNS	O	3	PMOD
9	in	in	B-PP	IN	O	2	NMOD
10	systemic	systemic	B-NP	JJ	O	12	NMOD
11	lupus	lupus	I-NP	NN	O	12	NMOD
12	erythematosus	erythematosus	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	7	NMOD
4	clinical	clinical	I-NP	JJ	O	6	AMOD
5	and	and	I-NP	CC	O	6	AMOD
6	bioptic	bioptic	I-NP	JJ	O	7	NMOD
7	findings	finding	I-NP	NNS	O	15	SUB
8	for	for	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	57-year-old	57-year-old	I-NP	JJ	O	11	NMOD
11	woman	woman	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	severe	severe	B-NP	JJ	O	14	NMOD
14	chloroquine	chloroquine	I-NP	NN	O	12	PMOD
15	induced	induce	B-VP	VBD	O	2	VMOD
16	myopathy	myopathy	B-NP	NN	O	15	OBJ
17	.	.	O	.	O	2	P

1	Since	Since	B-PP	IN	O	5	VMOD
2	1989	1989	B-NP	CD	O	1	PMOD
3	,	,	O	,	O	5	P
4	she	she	B-NP	PRP	O	5	SUB
5	had	have	B-VP	VBD	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	suffering	suffer	I-VP	VBG	O	6	VC
8	from	from	B-PP	IN	O	7	VMOD
9	systemic	systemic	B-NP	JJ	O	11	NMOD
10	lupus	lupus	I-NP	NN	O	11	NMOD
11	erythematosus	erythematosus	I-NP	NN	O	8	PMOD
12	(	(	O	(	O	14	DEP
13	SLE	SLE	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	with	with	B-PP	IN	O	11	NMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	involvement	involvement	I-NP	NN	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	undergone	undergone	I-NP	NN	O	20	NMOD
20	periods	period	I-NP	NNS	O	15	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	treatment	treatment	B-NP	NN	O	21	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	azathioprine	azathioprine	B-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	cyclophosphamide	cyclophosphamide	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	5	P

1	Additional	Additional	B-NP	JJ	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	8	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	chloroquine	chloroquine	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	7	DEP
6	CQ	CQ	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	started	start	I-VP	VBN	O	8	VC
10	because	because	B-PP	IN	O	9	VMOD
11	of	of	I-PP	IN	O	10	PMOD
12	arthralgia	arthralgia	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	8	P

1	Myositis	Myositis	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	8	VMOD
3	suspected	suspect	I-VP	VBN	O	2	VC
4	,	,	O	,	O	8	P
5	and	and	O	CC	O	8	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	0	ROOT
9	treated	treat	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	steroids	steroid	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	8	P

1	As	As	B-SBAR	IN	O	9	VMOD
2	it	it	B-NP	PRP	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	1	SBAR
4	chloroquine	chloroquine	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	myopathy	myopathy	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	9	P
8	medication	medication	B-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	0	ROOT
10	stopped	stop	I-VP	VBN	O	9	VC
11	.	.	O	.	O	9	P

1	Intravenous	Intravenous	B-NP	JJ	O	3	NMOD
2	ribavirin	ribavirin	I-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	0	ROOT
4	for	for	B-PP	IN	O	3	NMOD
5	severe	severe	B-NP	JJ	O	7	NMOD
6	adenovirus	adenovirus	I-NP	NN	O	7	NMOD
7	disease	disease	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	3	NMOD
9	immunocompromised	immunocompromised	B-NP	JJ	O	10	NMOD
10	children	child	I-NP	NNS	O	8	PMOD
11	.	.	O	.	O	3	P

1	Ribavirin	Ribavirin	B-NP	NN	B-protein	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	licensed	license	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	aerosol	aerosol	B-NP	NN	O	6	NMOD
6	form	form	I-NP	NN	O	4	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	respiratory	respiratory	B-NP	JJ	O	14	NMOD
12	syncytial	syncytial	I-NP	JJ	O	14	NMOD
13	virus	virus	I-NP	NN	O	14	NMOD
14	infection	infection	I-NP	NN	O	10	PMOD
15	,	,	O	,	O	2	VMOD
16	and	and	O	CC	O	15	VMOD
17	orally	orally	B-ADVP	RB	O	16	DEP
18	in	in	B-PP	IN	O	17	AMOD
19	combination	combination	B-NP	NN	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	interferon	interferon	B-NP	NN	B-protein	20	PMOD
22	to	to	B-VP	TO	O	23	VMOD
23	treat	treat	I-VP	VB	O	19	NMOD
24	hepatitis	hepatitis	B-NP	NN	O	25	NMOD
25	C	C	I-NP	NN	O	23	OBJ
26	.	.	O	.	O	2	P

1	Intravenous	Intravenous	B-NP	JJ	B-protein	2	NMOD
2	ribavirin	ribavirin	I-NP	NN	I-protein	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	choice	choice	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	5	NMOD
9	infection	infection	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	hemorrhagic	hemorrhagic	B-NP	JJ	O	13	NMOD
12	fever	fever	I-NP	NN	O	13	NMOD
13	viruses	virus	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	5	NMOD
2	most	most	I-NP	RBS	O	3	AMOD
3	common	common	I-NP	JJ	O	5	NMOD
4	adverse	adverse	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	9	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	intravenous	intravenous	B-NP	JJ	O	8	NMOD
8	ribavirin	ribavirin	I-NP	NN	O	6	PMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	reversible	reversible	B-NP	JJ	O	12	NMOD
11	mild	mild	I-NP	JJ	O	12	NMOD
12	anemia	anemia	I-NP	NN	O	9	PRD
13	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	use	use	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	cidofovir	cidofovir	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	severe	severe	B-NP	JJ	O	8	NMOD
7	adenovirus	adenovirus	I-NP	NN	O	8	NMOD
8	infection	infection	I-NP	NN	O	5	PMOD
9	has	have	B-VP	VBZ	O	0	ROOT
10	been	be	I-VP	VBN	O	9	VC
11	limited	limit	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	adverse	adverse	B-NP	JJ	O	14	NMOD
14	effects	effect	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	19	P
16	the	the	B-NP	DT	O	19	NMOD
17	most	most	I-NP	RBS	O	18	AMOD
18	significant	significant	I-NP	JJ	O	19	NMOD
19	of	of	B-PP	IN	O	14	NMOD
20	which	which	B-NP	WDT	O	19	PMOD
21	is	be	B-VP	VBZ	O	19	SBAR
22	nephrotoxicity	nephrotoxicity	B-NP	NN	O	21	PRD
23	.	.	O	.	O	9	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	report	report	B-VP	VBP	O	1	NMOD
5	our	our	B-NP	PRP$	O	6	NMOD
6	experience	experience	I-NP	NN	O	4	OBJ
7	with	with	B-PP	IN	O	6	NMOD
8	intravenous	intravenous	B-NP	JJ	O	10	NMOD
9	ribavirin	ribavirin	I-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	7	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	severe	severe	B-NP	JJ	O	14	NMOD
13	adenovirus	adenovirus	I-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	10	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	series	series	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	immunocompromised	immunocompromised	B-NP	JJ	O	20	NMOD
20	children	child	I-NP	NNS	O	18	PMOD
21	and	and	O	CC	O	4	VMOD
22	review	review	B-VP	VB	O	4	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	literature	literature	I-NP	NN	O	22	OBJ
25	.	.	O	.	O	1	P

1	DESIGN/METHODS	DESIGN/METHODS	B-NP	NN	O	5	SUB
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	5	SUB
4	retrospectively	retrospectively	B-ADVP	RB	O	5	VMOD
5	reviewed	review	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	8	NMOD
7	medical	medical	I-NP	JJ	O	8	NMOD
8	records	record	I-NP	NNS	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	5	5	B-NP	CD	O	11	NMOD
11	children	child	I-NP	NNS	O	9	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	intravenous	intravenous	B-NP	JJ	O	15	NMOD
15	ribavirin	ribavirin	I-NP	NN	O	13	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	documented	document	B-NP	VBN	O	20	NMOD
18	severe	severe	I-NP	JJ	O	20	NMOD
19	adenovirus	adenovirus	I-NP	NN	O	20	NMOD
20	disease	disease	I-NP	NN	O	16	PMOD
21	.	.	O	.	O	5	P

1	Use	Use	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	cidofovir	cidofovir	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	1	1	B-NP	CD	O	6	NMOD
6	child	child	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	progressive	progressive	B-NP	JJ	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	failure	failure	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	neutropenia	neutropenia	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	7	P

1	Although	Although	B-SBAR	IN	O	23	VMOD
2	intravenous	intravenous	B-NP	JJ	O	3	NMOD
3	ribavirin	ribavirin	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	SBAR
5	not	not	O	RB	O	4	VMOD
6	effective	effective	B-ADJP	JJ	O	4	PRD
7	for	for	B-PP	IN	O	6	AMOD
8	all	all	B-NP	DT	O	9	NMOD
9	children	child	I-NP	NNS	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	severe	severe	B-NP	JJ	O	13	NMOD
12	adenovirus	adenovirus	I-NP	NN	O	13	NMOD
13	disease	disease	I-NP	NN	O	10	PMOD
14	in	in	B-PP	IN	O	9	NMOD
15	this	this	B-NP	DT	O	16	NMOD
16	series	series	I-NP	NN	O	14	PMOD
17	or	or	B-PP	CC	O	14	PMOD
18	in	in	B-PP	IN	O	14	PMOD
19	the	the	B-NP	DT	O	20	NMOD
20	literature	literature	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	23	P
22	therapy	therapy	B-NP	NN	O	23	SUB
23	is	be	B-VP	VBZ	O	0	ROOT
24	unlikely	unlikely	B-ADJP	JJ	O	23	PRD
25	to	to	B-VP	TO	O	26	VMOD
26	be	be	I-VP	VB	O	24	AMOD
27	of	of	B-PP	IN	O	26	PRD
28	benefit	benefit	B-NP	NN	O	27	PMOD
29	if	if	B-SBAR	IN	O	26	VMOD
30	begun	begin	B-VP	VBN	O	29	SBAR
31	late	late	B-ADVP	RB	O	30	VMOD
32	in	in	B-PP	IN	O	30	VMOD
33	the	the	B-NP	DT	O	34	NMOD
34	course	course	I-NP	NN	O	32	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	the	the	B-NP	DT	O	37	NMOD
37	infection	infection	I-NP	NN	O	35	PMOD
38	.	.	O	.	O	23	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Two	Two	B-NP	CD	O	4	AMOD
4	of	of	B-PP	IN	O	1	NMOD
5	5	5	B-NP	CD	O	6	NMOD
6	children	child	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	severe	severe	B-NP	JJ	O	10	NMOD
9	adenovirus	adenovirus	I-NP	NN	O	10	NMOD
10	disease	disease	I-NP	NN	O	7	PMOD
11	treated	treat	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	intravenous	intravenous	B-NP	JJ	O	14	NMOD
14	ribavirin	ribavirin	I-NP	NN	O	12	PMOD
15	recovered	recover	B-VP	VBD	O	4	SBAR
16	.	.	O	.	O	1	P

1	Hepatotoxicity	Hepatotoxicity	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	amiodarone	amiodarone	B-NP	NN	O	2	PMOD
4	.	.	O	.	O	1	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	proved	prove	I-VP	VBN	O	2	VC
4	very	very	B-ADJP	RB	O	5	AMOD
5	effective	effective	I-ADJP	JJ	O	3	PRD
6	in	in	B-PP	IN	O	5	AMOD
7	the	the	B-NP	DT	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	otherwise	otherwise	B-NP	RB	O	11	AMOD
11	resistant	resistant	I-NP	JJ	O	13	NMOD
12	cardiac	cardiac	I-NP	JJ	O	13	NMOD
13	tachyarrhythmias	tachyarrhythmia	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	10	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	cholestatic	cholestatic	B-NP	JJ	O	5	NMOD
5	hepatitis	hepatitis	I-NP	NN	O	3	PMOD
6	due	due	B-ADJP	JJ	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	amiodarone	amiodarone	B-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	7	PMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	presented	present	I-VP	VBN	O	10	VC
12	below	below	B-PP	IN	O	11	VMOD
13	and	and	O	CC	O	12	PMOD
14	a	a	B-NP	DT	O	15	NMOD
15	review	review	I-NP	NN	O	21	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	hepatotoxicity	hepatotoxicity	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	amiodarone	amiodarone	B-NP	NN	O	19	PMOD
21	is	be	B-VP	VBZ	O	12	SBAR
22	given	give	I-VP	VBN	O	21	VC
23	.	.	O	.	O	10	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	concluded	conclude	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	solid	solid	B-NP	JJ	O	6	NMOD
6	evidence	evidence	I-NP	NN	O	7	SUB
7	exists	exist	B-VP	VBZ	O	4	SBAR
8	of	of	B-PP	IN	O	7	VMOD
9	hepatic	hepatic	B-NP	JJ	O	10	NMOD
10	injury	injury	I-NP	NN	O	8	PMOD
11	due	due	B-ADJP	JJ	O	7	VMOD
12	to	to	B-PP	TO	O	11	AMOD
13	amiodarone	amiodarone	B-NP	NN	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	14	P
16	including	include	B-PP	VBG	O	14	NMOD
17	steatosis	steatosis	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	19	P
19	alterations	alteration	B-NP	NNS	O	17	OBJ
20	resembling	resemble	B-VP	VBG	O	19	NMOD
21	alcoholic	alcoholic	B-NP	JJ	O	22	NMOD
22	hepatitis	hepatitis	I-NP	NN	O	28	NMOD
23	,	,	O	,	O	28	P
24	cholestatic	cholestatic	B-NP	JJ	O	25	NMOD
25	hepatitis	hepatitis	I-NP	NN	O	28	NMOD
26	and	and	O	CC	O	28	NMOD
27	micronodular	micronodular	B-NP	JJ	O	28	NMOD
28	cirrhosis	cirrhosis	I-NP	NN	O	20	OBJ
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	liver	liver	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	2	P

1	Catalepsy	Catalepsy	B-NP	NN	O	16	NMOD
2	induced	induce	B-VP	VBN	O	1	NMOD
3	by	by	B-PP	IN	O	2	VMOD
4	combinations	combination	B-NP	NNS	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	ketamine	ketamine	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	morphine	morphine	I-NP	NN	O	5	PMOD
9	:	:	O	:	O	1	P
10	potentiation	potentiation	B-NP	NN	O	16	NMOD
11	,	,	I-NP	,	O	16	P
12	antagonism	antagonism	I-NP	NN	O	16	NMOD
13	,	,	I-NP	,	O	16	P
14	tolerance	tolerance	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	cross-tolerance	cross-tolerance	I-NP	NN	O	0	ROOT
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	rat	rat	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	16	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	both	both	O	CC	O	8	NMOD
6	ketamine	ketamine	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	morphine	morphine	I-NP	NN	O	9	SUB
9	induced	induce	B-VP	VBD	O	4	SBAR
10	analgesia	analgesia	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	catalepsy	catalepsy	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	rat	rat	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	3	P

1	Pre-treatment	Pre-treatment	B-NP	NN	O	4	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	ketamine	ketamine	B-NP	NN	O	2	PMOD
4	produced	produce	B-VP	VBD	O	28	VMOD
5	cross-tolerance	cross-tolerance	B-NP	NN	O	4	OBJ
6	to	to	B-PP	TO	O	5	NMOD
7	morphine	morphine	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	9	P
9	whereas	whereas	O	IN	O	4	VMOD
10	pretreatment	pretreatment	B-NP	NN	O	13	SUB
11	with	with	B-PP	IN	O	10	NMOD
12	morphine	morphine	B-NP	NN	O	11	PMOD
13	did	do	B-VP	VBD	O	9	SBAR
14	not	not	I-VP	RB	O	13	VMOD
15	induce	induce	I-VP	VB	O	13	VC
16	cross-tolerance	cross-tolerance	B-NP	NN	O	15	OBJ
17	to	to	B-PP	TO	O	16	NMOD
18	ketamine	ketamine	B-NP	NN	O	17	PMOD
19	but	but	O	CC	O	13	VMOD
20	rather	rather	B-VP	RB	O	13	VMOD
21	augmented	augment	I-VP	VBD	O	13	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	cataleptic	cataleptic	I-NP	JJ	O	24	NMOD
24	response	response	I-NP	NN	O	21	OBJ
25	;	;	O	:	O	28	P
26	this	this	B-NP	DT	O	27	NMOD
27	augmentation	augmentation	I-NP	NN	O	28	SUB
28	was	be	B-VP	VBD	O	0	ROOT
29	attributed	attribute	I-VP	VBN	O	28	VC
30	to	to	B-PP	TO	O	29	VMOD
31	residual	residual	B-NP	JJ	O	32	NMOD
32	morphine	morphine	I-NP	NN	O	30	PMOD
33	in	in	B-PP	IN	O	32	NMOD
34	the	the	B-NP	DT	O	35	NMOD
35	brain	brain	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	28	P

1	Latency	Latency	B-NP	NN	O	15	SUB
2	to	to	B-PP	TO	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	loss	loss	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	righting	right	B-VP	VBG	O	5	PMOD
7	reflex	reflex	B-NP	NN	O	11	NMOD
8	,	,	I-NP	,	O	11	P
9	rigidity	rigidity	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	behavior	behavior	I-NP	NN	O	6	OBJ
12	on	on	B-PP	IN	O	6	VMOD
13	recovery	recovery	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	1	P
15	reflected	reflect	B-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	18	NMOD
17	relative	relative	I-NP	JJ	O	18	NMOD
18	predominance	predominance	I-NP	NN	O	15	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	ketamine	ketamine	B-NP	NN	O	22	NMOD
21	or	or	I-NP	CC	O	22	NMOD
22	morphine	morphine	I-NP	NN	O	19	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	each	each	B-NP	DT	O	25	NMOD
25	combination	combination	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	15	P

1	Naloxone	Naloxone	B-NP	NN	O	2	SUB
2	inhibited	inhibit	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	induced	induce	I-NP	VBN	O	6	NMOD
5	cataleptic	cataleptic	I-NP	JJ	O	6	NMOD
6	effects	effect	I-NP	NNS	O	2	OBJ
7	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	AIDS	AIDS	B-NP	NN	O	6	PMOD
8	on	on	B-PP	IN	O	5	NMOD
9	tenofovir	tenofovir	B-NP	NN	O	8	PMOD
10	while	while	B-SBAR	IN	O	3	NMOD
11	receiving	receive	B-VP	VBG	O	10	SBAR
12	prolonged	prolong	B-NP	VBN	O	14	NMOD
13	vancomycin	vancomycin	I-NP	NN	O	14	NMOD
14	course	course	I-NP	NN	O	11	OBJ
15	for	for	B-PP	IN	O	11	VMOD
16	osteomyelitis	osteomyelitis	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	3	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	failure	failure	I-NP	NN	O	3	SUB
3	developed	develop	B-VP	VBD	O	0	ROOT
4	after	after	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	prolonged	prolonged	I-NP	JJ	O	7	NMOD
7	course	course	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	vancomycin	vancomycin	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	3	VMOD
12	2	2	B-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	11	PMOD
14	who	who	B-NP	WP	O	13	NMOD
15	were	be	B-VP	VBD	O	14	SBAR
16	receiving	receive	I-VP	VBG	O	15	VC
17	tenofovir	tenofovir	B-NP	NN	O	19	NMOD
18	disoproxil	disoproxil	I-NP	NN	O	19	NMOD
19	fumarate	fumarate	I-NP	NN	O	16	OBJ
20	as	as	B-PP	IN	O	16	VMOD
21	part	part	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	an	an	B-NP	DT	O	25	NMOD
24	antiretroviral	antiretroviral	I-NP	JJ	O	25	NMOD
25	regimen	regimen	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	3	P

1	Tenofovir	Tenofovir	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	implicated	implicate	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	development	development	I-NP	NN	O	13	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	Fanconi	Fanconi	B-NP	NNP	O	10	NMOD
10	syndrome	syndrome	I-NP	NN	O	8	PMOD
11	and	and	O	CC	O	13	NMOD
12	renal	renal	B-NP	JJ	O	13	NMOD
13	insufficiency	insufficiency	I-NP	NN	O	5	PMOD
14	because	because	B-PP	IN	O	4	VMOD
15	of	of	I-PP	IN	O	14	PMOD
16	its	its	B-NP	PRP$	O	17	NMOD
17	effects	effect	I-NP	NNS	O	14	PMOD
18	on	on	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	proximal	proximal	I-NP	JJ	O	22	NMOD
21	renal	renal	I-NP	JJ	O	22	NMOD
22	tubule	tubule	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	2	P

1	Vancomycin	Vancomycin	B-NP	NN	O	2	NMOD
2	nephrotoxicity	nephrotoxicity	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	infrequent	infrequent	B-ADJP	JJ	O	3	PRD
5	but	but	O	CC	O	3	VMOD
6	may	may	B-VP	MD	O	3	VMOD
7	result	result	I-VP	VB	O	6	VC
8	from	from	B-PP	IN	O	7	VMOD
9	coadministration	coadministration	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	nephrotoxic	nephrotoxic	I-NP	JJ	O	13	NMOD
13	agent	agent	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	transient	transient	I-NP	JJ	O	5	NMOD
5	leukoencephalopathy	leukoencephalopathy	I-NP	NN	O	9	SUB
6	mimicking	mimic	B-VP	VBG	O	5	NMOD
7	cerebrovascular	cerebrovascular	B-NP	JJ	O	8	NMOD
8	accident	accident	I-NP	NN	O	6	OBJ
9	has	have	B-VP	VBZ	O	1	NMOD
10	been	be	I-VP	VBN	O	9	VC
11	described	describe	I-VP	VBN	O	10	VC
12	as	as	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	complication	complication	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	chemotherapy	chemotherapy	B-NP	NN	O	15	PMOD
17	,	,	O	,	O	9	P
18	most	most	B-ADVP	RBS	O	19	AMOD
19	commonly	commonly	I-ADVP	RB	O	9	VMOD
20	in	in	B-PP	IN	O	19	AMOD
21	recipients	recipient	B-NP	NNS	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	intrathecal	intrathecal	B-NP	JJ	O	24	NMOD
24	methotrexate	methotrexate	I-NP	NN	O	22	PMOD
25	for	for	B-PP	IN	O	24	NMOD
26	childhood	childhood	B-NP	NN	O	27	NMOD
27	leukaemia	leukaemia	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	9	P

1	RESULTS	RESULTS	B-NP	NNS	O	4	VMOD
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	identified	identify	B-VP	VBD	O	0	ROOT
5	27	27	B-NP	CD	O	6	NMOD
6	reports	report	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	toxic	toxic	B-NP	JJ	O	9	NMOD
9	leukoencephalopathy	leukoencephalopathy	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	28	NMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	methotrexate	methotrexate	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	19	DEP
16	intrathecal	intrathecal	B-ADJP	JJ	O	18	AMOD
17	,	,	O	,	O	18	P
18	systemic	systemic	B-ADVP	JJ	O	19	DEP
19	)	)	O	)	O	14	NMOD
20	,	,	O	,	O	28	P
21	5-fluorouracil	5-fluorouracil	B-NP	NN	O	25	NMOD
22	and	and	O	CC	O	25	NMOD
23	its	its	B-NP	PRP$	O	25	NMOD
24	derivative	derivative	I-NP	JJ	O	25	NMOD
25	carmofur	carmofur	I-NP	NN	O	28	NMOD
26	,	,	O	,	O	28	P
27	and	and	O	CC	O	28	NMOD
28	capecitabine	capecitabine	B-NP	NN	O	10	PMOD
29	.	.	O	.	O	4	P

1	Down-regulation	Down-regulation	B-NP	NN	O	20	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	norepinephrine	norepinephrine	B-NP	NN	O	5	NMOD
4	transporter	transporter	I-NP	NN	O	5	NMOD
5	function	function	I-NP	NN	O	2	PMOD
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	chronic	chronic	B-NP	JJ	O	9	NMOD
9	administration	administration	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	desipramine	desipramine	B-NP	NN	O	10	PMOD
12	linking	link	B-VP	VBG	O	11	NMOD
13	to	to	B-PP	TO	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	alteration	alteration	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	sensitivity	sensitivity	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	local-anesthetics	local-anesthetic	B-NP	NNS	O	18	PMOD
20	induced	induce	B-VP	VBD	O	0	ROOT
21	convulsions	convulsion	B-NP	NNS	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	counteraction	counteraction	I-NP	NN	O	20	OBJ
25	by	by	B-PP	IN	O	20	VMOD
26	co-administration	co-administration	B-NP	NN	O	25	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	local	local	B-NP	JJ	O	29	NMOD
29	anesthetics	anesthetic	I-NP	NNS	O	27	PMOD
30	.	.	O	.	O	20	P

1	Alterations	Alteration	B-NP	NNS	O	20	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	norepinephrine	norepinephrine	B-NP	NN	O	4	NMOD
4	transporter	transporter	I-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	NET	NET	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	function	function	B-NP	NN	O	2	PMOD
9	by	by	B-PP	IN	O	8	NMOD
10	chronic	chronic	B-NP	JJ	O	11	NMOD
11	inhibition	inhibition	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	NET	NET	B-NP	NN	B-protein	12	PMOD
14	in	in	B-PP	IN	O	1	NMOD
15	relation	relation	B-NP	NN	O	14	PMOD
16	to	to	B-PP	TO	O	15	NMOD
17	sensitization	sensitization	B-NP	NN	O	16	PMOD
18	to	to	B-PP	TO	O	17	NMOD
19	seizures	seizure	B-NP	NNS	O	18	PMOD
20	induce	induce	B-VP	VBP	O	0	ROOT
21	by	by	B-PP	IN	O	20	VMOD
22	cocaine	cocaine	B-NP	NN	O	25	NMOD
23	and	and	O	CC	O	25	NMOD
24	local	local	B-NP	JJ	O	25	NMOD
25	anesthetics	anesthetic	I-NP	NNS	O	21	PMOD
26	were	be	B-VP	VBD	O	20	VMOD
27	studied	study	I-VP	VBN	O	26	VC
28	in	in	B-PP	IN	O	27	VMOD
29	mice	mouse	B-NP	NNS	O	28	PMOD
30	.	.	O	.	O	20	P

1	Daily	Daily	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	desipramine	desipramine	B-NP	NN	O	3	PMOD
5	increased	increase	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	7	NMOD
7	incidence	incidence	I-NP	NN	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	appearance	appearance	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	lidocaine	lidocaine	B-NP	NN	O	13	NMOD
12	induced	induce	I-NP	VBN	O	13	NMOD
13	convulsions	convulsion	I-NP	NNS	O	10	PMOD
14	and	and	O	CC	O	5	VMOD
15	decreased	decrease	B-VP	VBD	O	5	VMOD
16	that	that	B-NP	DT	O	15	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	cocaine	cocaine	B-NP	NN	O	20	NMOD
19	induced	induce	I-NP	VBN	O	20	NMOD
20	convulsions	convulsion	I-NP	NNS	O	17	PMOD
21	.	.	O	.	O	5	P

1	Co-administration	Co-administration	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	lidocaine	lidocaine	B-NP	NN	O	2	PMOD
4	with	with	B-PP	IN	O	1	NMOD
5	desipramine	desipramine	B-NP	NN	O	4	PMOD
6	reversed	reverse	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	changes	change	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	convulsive	convulsive	B-NP	JJ	O	11	NMOD
11	activity	activity	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	lidocaine	lidocaine	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	cocaine	cocaine	I-NP	NN	O	12	PMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	repeated	repeat	B-NP	VBN	O	19	NMOD
19	administration	administration	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	desipramine	desipramine	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	6	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	down-regulation	down-regulation	B-NP	NN	O	15	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	hippocampal	hippocampal	B-NP	JJ	O	8	NMOD
8	NET	NET	I-NP	NN	O	6	PMOD
9	induced	induce	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	chronic	chronic	B-NP	JJ	O	12	NMOD
12	administration	administration	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	desipramine	desipramine	B-NP	NN	O	13	PMOD
15	may	may	B-VP	MD	O	4	SBAR
16	be	be	I-VP	VB	O	15	VC
17	relevant	relevant	B-ADJP	JJ	O	16	PRD
18	to	to	B-PP	TO	O	17	AMOD
19	desipramine	desipramine	B-NP	NN	O	18	PMOD
20	induced	induce	B-VP	VBD	O	15	VMOD
21	sensitization	sensitization	B-NP	NN	O	20	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	lidocaine	lidocaine	B-NP	NN	O	24	NMOD
24	convulsions	convulsion	I-NP	NNS	O	22	PMOD
25	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	4	NMOD
2	current	current	I-NP	JJ	O	3	AMOD
3	best	good	I-NP	JJS	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	8	SUB
5	for	for	B-PP	IN	O	4	NMOD
6	HCV	HCV	B-NP	NN	O	7	NMOD
7	infection	infection	I-NP	NN	O	5	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	combination	combination	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PRD
11	with	with	B-PP	IN	O	10	NMOD
12	pegylated	pegylate	B-NP	VBN	B-protein	13	NMOD
13	interferon	interferon	I-NP	NN	I-protein	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	ribavirin	ribavirin	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	8	P

1	Hemoglobin	Hemoglobin	B-NP	NN	B-protein	2	NMOD
2	concentrations	concentration	I-NP	NNS	O	3	SUB
3	decrease	decrease	B-VP	VBP	O	0	ROOT
4	mainly	mainly	B-ADVP	RB	O	3	VMOD
5	as	as	B-PP	IN	O	3	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	result	result	I-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	ribavirin	ribavirin	B-NP	NN	B-protein	8	PMOD
10	induced	induce	B-VP	VBD	O	5	SBAR
11	hemolysis	hemolysis	B-NP	NN	O	10	OBJ
12	,	,	O	,	O	16	P
13	and	and	O	CC	O	16	VMOD
14	this	this	B-NP	DT	O	15	NMOD
15	anemia	anemia	I-NP	NN	O	16	SUB
16	can	can	B-VP	MD	O	3	VMOD
17	be	be	I-VP	VB	O	16	VC
18	problematic	problematic	B-ADJP	JJ	O	17	PRD
19	in	in	B-PP	IN	O	18	AMOD
20	patients	patient	B-NP	NNS	O	19	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	HCV	HCV	B-NP	NN	O	23	NMOD
23	infection	infection	I-NP	NN	O	21	PMOD
24	,	,	O	,	O	17	P
25	especially	especially	B-ADVP	RB	O	26	NMOD
26	those	those	B-NP	DT	O	17	PRD
27	who	who	B-NP	WP	O	26	NMOD
28	have	have	B-VP	VBP	O	27	SBAR
29	comorbid	comorbid	I-VP	VBN	O	28	VC
30	renal	renal	B-NP	JJ	O	33	NMOD
31	or	or	I-NP	CC	O	33	NMOD
32	cardiovascular	cardiovascular	I-NP	JJ	O	33	NMOD
33	disorders	disorder	I-NP	NNS	O	29	OBJ
34	.	.	O	.	O	3	P

1	Although	Although	B-SBAR	IN	O	15	VMOD
2	ribavirin-associated	ribavirin-associated	B-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	4	SUB
4	can	can	B-VP	MD	O	1	SBAR
5	be	be	I-VP	VB	O	4	VC
6	reversed	reverse	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	dose	dose	B-NP	NN	O	9	NMOD
9	reduction	reduction	I-NP	NN	O	11	NMOD
10	or	or	I-NP	CC	O	11	NMOD
11	discontinuation	discontinuation	I-NP	NN	O	7	PMOD
12	,	,	O	,	O	15	P
13	this	this	B-NP	DT	O	14	NMOD
14	approach	approach	I-NP	NN	O	15	SUB
15	compromises	compromise	B-VP	VBZ	O	0	ROOT
16	outcomes	outcome	B-NP	NNS	O	15	OBJ
17	by	by	B-PP	IN	O	15	VMOD
18	significantly	significantly	B-VP	RB	O	19	VMOD
19	decreasing	decrease	I-VP	VBG	O	17	PMOD
20	SVR	SVR	B-NP	NN	O	21	NMOD
21	rates	rate	I-NP	NNS	O	19	OBJ
22	.	.	O	.	O	15	P

1	Recombinant	Recombinant	B-NP	JJ	B-protein	3	NMOD
2	human	human	I-NP	JJ	I-protein	3	NMOD
3	erythropoietin	erythropoietin	I-NP	NN	I-protein	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	used	use	I-VP	VBN	O	5	VC
7	to	to	I-VP	TO	O	8	VMOD
8	manage	manage	I-VP	VB	O	6	VMOD
9	ribavirin-associated	ribavirin-associated	B-NP	JJ	O	10	NMOD
10	anemia	anemia	I-NP	NN	O	8	OBJ
11	but	but	O	CC	O	4	VMOD
12	has	have	B-VP	VBZ	O	4	VMOD
13	other	other	B-NP	JJ	O	15	NMOD
14	potential	potential	I-NP	JJ	O	15	NMOD
15	disadvantages	disadvantage	I-NP	NNS	O	12	OBJ
16	.	.	O	.	O	4	P

1	Calcium	Calcium	B-NP	NN	O	3	NMOD
2	carbonate	carbonate	I-NP	NN	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	8	NMOD
4	:	:	O	:	O	3	P
5	the	the	B-NP	DT	O	8	NMOD
6	updated	update	I-NP	VBN	O	8	NMOD
7	milk-alkali	milk-alkali	I-NP	JJ	O	8	NMOD
8	syndrome	syndrome	I-NP	NN	O	15	NMOD
9	;	;	O	:	O	15	P
10	report	report	B-NP	NN	O	15	NMOD
11	of	of	B-PP	IN	O	10	NMOD
12	3	3	B-NP	CD	O	13	NMOD
13	cases	case	I-NP	NNS	O	11	PMOD
14	and	and	I-NP	CC	O	15	NMOD
15	review	review	I-NP	NN	O	0	ROOT
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	literature	literature	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	15	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	describe	describe	I-VP	VB	O	1	NMOD
5	3	3	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	OBJ
7	with	with	B-PP	IN	O	6	NMOD
8	calcium	calcium	B-NP	NN	O	9	NMOD
9	carbonate	carbonate	I-NP	NN	O	7	PMOD
10	induced	induce	B-VP	VBD	O	4	VMOD
11	hypercalcemia	hypercalcemia	B-NP	NN	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	gain	gain	I-NP	NN	O	14	NMOD
14	insights	insight	I-NP	NNS	O	10	OBJ
15	into	into	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	cause	cause	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	management	management	I-NP	NN	O	15	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	milk-alkali	milk-alkali	I-NP	JJ	O	23	NMOD
23	syndrome	syndrome	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	1	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	report	report	B-VP	VBP	O	1	NMOD
5	the	the	B-NP	DT	O	9	NMOD
6	clinical	clinical	I-NP	JJ	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	laboratory	laboratory	I-NP	JJ	O	9	NMOD
9	data	datum	I-NP	NNS	O	4	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	3	3	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	who	who	B-NP	WP	O	12	NMOD
14	presented	present	B-VP	VBD	O	13	SBAR
15	with	with	B-PP	IN	O	14	VMOD
16	severe	severe	B-NP	JJ	O	17	NMOD
17	hypercalcemia	hypercalcemia	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	17	NMOD
19	corrected	correct	B-NP	VBN	O	21	NMOD
20	serum	serum	I-NP	NN	O	21	NMOD
21	calcium	calcium	I-NP	NN	O	29	SUB
22	>	>	B-VP	SYM	O	21	NMOD
23	or	or	O	CC	O	27	DEP
24	=	=	B-VP	SYM	O	27	DEP
25	14	14	B-NP	CD	O	26	NMOD
26	mg/dL	mg/dL	I-NP	NN	O	24	AMOD
27	)	)	O	)	O	22	AMOD
28	and	and	O	CC	O	29	VMOD
29	review	review	B-VP	VBP	O	18	SBAR
30	the	the	B-NP	DT	O	32	NMOD
31	pertinent	pertinent	I-NP	JJ	O	32	NMOD
32	literature	literature	I-NP	NN	O	29	OBJ
33	on	on	B-PP	IN	O	32	NMOD
34	milk-alkali	milk-alkali	B-NP	JJ	O	35	NMOD
35	syndrome	syndrome	I-NP	NN	O	33	PMOD
36	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	3	3	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	6	SUB
6	had	have	B-VP	VBD	O	1	NMOD
7	acute	acute	B-NP	JJ	O	9	NMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	insufficiency	insufficiency	I-NP	NN	O	18	NMOD
10	,	,	O	,	O	18	P
11	relative	relative	B-NP	JJ	O	13	NMOD
12	metabolic	metabolic	I-NP	JJ	O	13	NMOD
13	alkalosis	alkalosis	I-NP	NN	O	18	NMOD
14	,	,	O	,	O	18	P
15	and	and	O	CC	O	18	NMOD
16	low	low	B-NP	JJ	O	18	NMOD
17	parathyroid	parathyroid	I-NP	NN	O	18	NMOD
18	hormone	hormone	I-NP	NN	O	31	NMOD
19	(	(	O	(	O	21	DEP
20	PTH	PTH	B-NP	NN	B-protein	21	DEP
21	)	)	O	)	O	18	NMOD
22	,	,	O	,	O	31	P
23	PTH-related	PTH-related	B-NP	JJ	O	24	NMOD
24	peptide	peptide	I-NP	NN	O	31	NMOD
25	,	,	O	,	O	31	P
26	and	and	O	CC	O	27	NMOD
27	1	1	B-NP	CD	O	31	NMOD
28	,	,	O	,	O	31	P
29	25-dihydroxyvitamin	25-dihydroxyvitamin	B-NP	NN	O	31	NMOD
30	D	D	I-NP	NN	O	31	NMOD
31	concentrations	concentration	I-NP	NNS	O	6	OBJ
32	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	2	2	I-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	10	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	9	NMOD
6	higher	high	I-NP	JJR	O	9	NMOD
7	serum	serum	I-NP	NN	O	9	NMOD
8	calcium	calcium	I-NP	NN	O	9	NMOD
9	concentrations	concentration	I-NP	NNS	O	4	PMOD
10	received	receive	B-VP	VBD	O	0	ROOT
11	pamidronate	pamidronate	B-NP	NN	O	10	OBJ
12	intravenously	intravenously	B-ADVP	RB	O	10	VMOD
13	(	(	O	(	O	20	DEP
14	60	60	B-NP	CD	O	16	AMOD
15	and	and	I-NP	CC	O	16	AMOD
16	30	30	I-NP	CD	O	17	NMOD
17	mg	mg	I-NP	NN	O	20	DEP
18	,	,	O	,	O	17	P
19	respectively	respectively	B-ADVP	RB	O	17	NMOD
20	)	)	O	)	O	12	AMOD
21	,	,	O	,	O	10	P
22	which	which	B-NP	WDT	O	10	VMOD
23	caused	cause	B-VP	VBD	O	22	SBAR
24	severe	severe	B-NP	JJ	O	25	NMOD
25	hypocalcemia	hypocalcemia	I-NP	NN	O	23	OBJ
26	.	.	O	.	O	10	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	14	SUB
2	:	:	O	:	O	1	P
3	Milk-alkali	Milk-alkali	B-NP	JJ	O	4	NMOD
4	syndrome	syndrome	I-NP	NN	O	5	SUB
5	may	may	B-VP	MD	O	14	VMOD
6	be	be	I-VP	VB	O	5	VC
7	a	a	B-NP	DT	O	9	NMOD
8	common	common	I-NP	JJ	O	9	NMOD
9	cause	cause	I-NP	NN	O	6	PRD
10	of	of	B-PP	IN	O	9	NMOD
11	unexplained	unexplained	B-NP	JJ	O	12	NMOD
12	hypercalcemia	hypercalcemia	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	5	VMOD
14	can	can	B-VP	MD	O	0	ROOT
15	be	be	I-VP	VB	O	14	VC
16	precipitated	precipitate	I-VP	VBN	O	15	VC
17	by	by	B-PP	IN	O	16	VMOD
18	small	small	B-NP	JJ	O	19	NMOD
19	amounts	amount	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	orally	orally	B-NP	RB	O	22	AMOD
22	ingested	ingest	I-NP	VBN	O	24	NMOD
23	calcium	calcium	I-NP	NN	O	24	NMOD
24	carbonate	carbonate	I-NP	NN	O	20	PMOD
25	in	in	B-PP	IN	O	19	NMOD
26	susceptible	susceptible	B-NP	JJ	O	27	NMOD
27	persons	person	I-NP	NNS	O	25	PMOD
28	.	.	O	.	O	14	P

1	Management	Management	B-NP	NN	O	2	NMOD
2	strategies	strategy	I-NP	NNS	O	5	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	ribavirin	ribavirin	B-NP	NN	B-protein	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	hemolytic	hemolytic	B-NP	JJ	O	7	NMOD
7	anemia	anemia	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	5	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	hepatitis	hepatitis	B-NP	NN	O	13	NMOD
13	C	C	I-NP	NN	O	11	PMOD
14	:	:	O	:	O	5	P
15	clinical	clinical	B-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	economic	economic	I-NP	JJ	O	18	NMOD
18	implications	implication	I-NP	NNS	O	5	VMOD
19	.	.	O	.	O	5	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	5	NMOD
2	:	:	O	:	O	1	P
3	Recently	Recently	B-NP	RB	O	4	AMOD
4	published	publish	I-NP	VBN	O	5	NMOD
5	studies	study	I-NP	NNS	O	6	SUB
6	have	have	B-VP	VBP	O	0	ROOT
7	demonstrated	demonstrate	I-VP	VBN	O	6	VC
8	increased	increase	B-NP	VBN	O	11	NMOD
9	efficacy	efficacy	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	cost-effectiveness	cost-effectiveness	I-NP	NN	O	7	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	combination	combination	B-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	interferon	interferon	B-NP	NN	B-protein	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	alpha-2b/ribavirin	alpha-2b/ribavirin	I-NP	NN	B-protein	15	PMOD
19	compared	compare	B-PP	VBN	O	7	VMOD
20	with	with	B-PP	IN	O	19	PMOD
21	interferon-alpha	interferon-alpha	B-NP	NN	B-protein	22	NMOD
22	monotherapy	monotherapy	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	treatment	treatment	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	chronic	chronic	B-NP	JJ	O	29	NMOD
28	hepatitis	hepatitis	I-NP	NN	O	29	NMOD
29	C	C	I-NP	NN	O	26	PMOD
30	(	(	O	(	O	32	DEP
31	CHC	CHC	B-NP	NN	B-protein	32	DEP
32	)	)	O	)	O	29	NMOD
33	.	.	O	.	O	6	P

1	Combination	Combination	B-NP	NN	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	a	a	B-NP	DT	O	10	NMOD
7	clinically	clinically	I-NP	RB	O	8	AMOD
8	important	important	I-NP	JJ	O	10	NMOD
9	adverse	adverse	I-NP	JJ	O	10	NMOD
10	effect	effect	I-NP	NN	O	5	PMOD
11	:	:	O	:	O	3	P
12	ribavirin	ribavirin	B-NP	NN	B-protein	3	PRD
13	induced	induce	B-VP	VBD	O	12	NMOD
14	hemolytic	hemolytic	B-NP	JJ	O	15	NMOD
15	anemia	anemia	I-NP	NN	O	13	OBJ
16	(	(	O	(	O	18	DEP
17	RIHA	RIHA	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	standard	standard	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	care	care	B-NP	NN	O	3	PMOD
5	for	for	B-PP	IN	O	2	NMOD
6	management	management	B-NP	NN	O	5	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	RIHA	RIHA	B-NP	NN	B-protein	7	PMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	reduction	reduction	B-NP	NN	O	12	NMOD
11	or	or	I-NP	CC	O	12	NMOD
12	discontinuation	discontinuation	I-NP	NN	O	9	PRD
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	16	NMOD
15	ribavirin	ribavirin	I-NP	NN	O	16	NMOD
16	dosage	dosage	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	9	P

1	Questions	Question	B-NP	NNS	O	2	SUB
2	remain	remain	B-VP	VBP	O	0	ROOT
3	about	about	B-PP	IN	O	2	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	optimal	optimal	I-NP	JJ	O	6	NMOD
6	dose	dose	I-NP	NN	O	11	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	ribavirin	ribavirin	B-NP	NN	O	7	PMOD
9	and	and	O	CC	O	11	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	incidence	incidence	I-NP	NN	O	3	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	RIHA	RIHA	B-NP	NN	B-protein	12	PMOD
14	in	in	B-PP	IN	O	11	NMOD
15	a	a	B-NP	DT	O	17	NMOD
16	real-world	real-world	I-NP	JJ	B-cell_line	17	NMOD
17	population	population	I-NP	NN	I-cell_line	14	PMOD
18	.	.	O	.	O	2	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	amine	amine	B-NP	NN	O	4	NMOD
4	pretreatment	pretreatment	I-NP	NN	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	ketamine	ketamine	B-NP	NN	O	7	NMOD
7	catatonia	catatonia	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	pinealectomized	pinealectomize	B-NP	VBN	O	12	NMOD
10	or	or	I-NP	CC	O	12	NMOD
11	hypophysectomized	hypophysectomize	I-NP	VBN	O	12	NMOD
12	animals	animal	I-NP	NNS	O	8	PMOD
13	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	designed	design	I-VP	VBN	O	4	VC
6	to	to	B-VP	TO	O	7	VMOD
7	clarify	clarify	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	role	role	I-NP	NN	O	17	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	catecholamines	catecholamine	B-NP	NNS	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	pineal	pineal	B-NP	JJ	O	14	NMOD
14	idolamines	idolamine	I-NP	NNS	O	10	PMOD
15	on	on	B-PP	IN	O	9	NMOD
16	ketamine	ketamine	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	7	VMOD
18	catatonia	catatonia	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	the	the	B-NP	DT	O	28	NMOD
21	intact	intact	I-NP	JJ	O	25	AMOD
22	,	,	I-NP	,	O	25	P
23	pinealectomized	pinealectomize	I-NP	VBN	O	25	AMOD
24	or	or	I-NP	CC	O	25	AMOD
25	hypophysectomized	hypophysectomize	I-NP	VBN	O	28	NMOD
26	chick	chick	I-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	rat	rat	I-NP	NN	O	19	PMOD
29	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	9	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	pinealectomized	pinealectomize	I-NP	VBN	O	4	NMOD
4	chick	chick	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	9	P
6	pretreatment	pretreatment	B-NP	NN	O	9	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	dopamine	dopamine	B-NP	NN	O	7	PMOD
9	increased	increase	B-VP	VBD	O	24	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	duration	duration	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	catatonia	catatonia	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	16	DEP
15	DOC	DOC	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	after	after	B-PP	IN	O	9	VMOD
18	ketamine	ketamine	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	24	P
20	but	but	O	CC	O	24	VMOD
21	pretreatment	pretreatment	B-NP	NN	O	24	SUB
22	with	with	B-PP	IN	O	21	NMOD
23	norepinephrine	norepinephrine	B-NP	NN	O	22	PMOD
24	did	do	B-VP	VBD	O	0	ROOT
25	not	not	O	RB	O	24	VMOD
26	.	.	O	.	O	24	P

1	Multicenter	Multicenter	B-NP	JJ	O	7	AMOD
2	,	,	I-NP	,	O	7	P
3	double-blind	double-blind	I-NP	JJ	O	7	AMOD
4	,	,	I-NP	,	O	7	P
5	multiple-dose	multiple-dose	I-NP	JJ	O	7	AMOD
6	,	,	I-NP	,	O	7	P
7	parallel-groups	parallel-groups	I-NP	JJ	O	11	NMOD
8	efficacy	efficacy	I-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	safety	safety	I-NP	NN	O	11	NMOD
11	trial	trial	I-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	azelastine	azelastine	B-NP	NN	O	18	NMOD
14	,	,	O	,	O	18	P
15	chlorpheniramine	chlorpheniramine	B-NP	NN	O	18	NMOD
16	,	,	O	,	O	18	P
17	and	and	O	CC	O	18	NMOD
18	placebo	placebo	B-NP	NN	O	12	PMOD
19	in	in	B-PP	IN	O	11	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	spring	spring	B-NP	NN	O	25	NMOD
24	allergic	allergic	I-NP	JJ	O	25	NMOD
25	rhinitis	rhinitis	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	11	P

1	Azelastine	Azelastine	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	a	a	B-NP	DT	O	6	NMOD
4	novel	novel	I-NP	JJ	O	6	NMOD
5	antiallergic	antiallergic	I-NP	JJ	O	6	NMOD
6	medication	medication	I-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	was	be	B-VP	VBD	O	0	ROOT
9	compared	compare	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	chlorpheniramine	chlorpheniramine	B-NP	NN	O	12	NMOD
12	maleate	maleate	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	placebo	placebo	I-NP	NN	O	10	PMOD
15	for	for	B-PP	IN	O	14	NMOD
16	efficacy	efficacy	B-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	safety	safety	I-NP	NN	O	15	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	spring	spring	B-NP	NN	O	25	NMOD
24	allergic	allergic	I-NP	JJ	O	25	NMOD
25	rhinitis	rhinitis	I-NP	NN	O	22	PMOD
26	in	in	B-PP	IN	O	21	NMOD
27	a	a	B-NP	DT	O	35	NMOD
28	multicenter	multicenter	I-NP	JJ	O	34	AMOD
29	,	,	I-NP	,	O	34	P
30	double-blind	double-blind	I-NP	JJ	O	34	AMOD
31	,	,	I-NP	,	O	34	P
32	multiple-dose	multiple-dose	I-NP	JJ	O	34	AMOD
33	,	,	I-NP	,	O	34	P
34	parallel-groups	parallel-groups	I-NP	JJ	O	35	NMOD
35	study	study	I-NP	NN	O	26	PMOD
36	.	.	O	.	O	8	P

1	Drowsiness	Drowsiness	B-NP	NN	O	5	NMOD
2	and	and	I-NP	CC	O	5	NMOD
3	altered	altered	I-NP	JJ	O	5	NMOD
4	taste	taste	I-NP	NN	O	5	NMOD
5	perception	perception	I-NP	NN	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	increased	increase	I-VP	VBN	O	6	VC
8	significantly	significantly	B-ADVP	RB	O	7	VMOD
9	over	over	B-PP	IN	O	7	VMOD
10	placebo	placebo	B-NP	NN	O	9	PMOD
11	only	only	B-ADVP	RB	O	12	PMOD
12	in	in	B-PP	IN	O	7	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	high-dose	high-dose	I-NP	JJ	O	16	NMOD
15	azelastine	azelastine	I-NP	NN	O	16	NMOD
16	group	group	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	6	P

1	Prolonged	Prolonged	B-NP	JJ	O	2	NMOD
2	paralysis	paralysis	I-NP	NN	O	0	ROOT
3	due	due	B-ADJP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	nondepolarizing	nondepolarize	B-VP	VBG	O	4	PMOD
6	neuromuscular	neuromuscular	B-NP	JJ	O	8	NMOD
7	blocking	block	I-NP	VBG	O	8	NMOD
8	agents	agent	I-NP	NNS	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	corticosteroids	corticosteroid	I-NP	NNS	O	5	OBJ
11	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	long-term	long-term	I-NP	JJ	O	3	NMOD
3	use	use	I-NP	NN	O	12	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	nondepolarizing	nondepolarize	B-VP	VBG	O	4	PMOD
6	neuromuscular	neuromuscular	B-NP	JJ	O	8	NMOD
7	blocking	block	I-NP	VBG	O	8	NMOD
8	agents	agent	I-NP	NNS	O	5	OBJ
9	(	(	O	(	O	11	DEP
10	ND-NMBA	ND-NMBA	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	has	have	B-VP	VBZ	O	0	ROOT
13	recently	recently	I-VP	RB	O	12	VMOD
14	been	be	I-VP	VBN	O	12	VC
15	implicated	implicate	I-VP	VBN	O	14	VC
16	as	as	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	18	NMOD
18	cause	cause	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	prolonged	prolong	B-NP	VBN	O	22	NMOD
21	muscle	muscle	I-NP	NN	O	22	NMOD
22	weakness	weakness	I-NP	NN	O	19	PMOD
23	,	,	O	,	O	12	P
24	although	although	B-SBAR	IN	O	12	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	site	site	I-NP	NN	O	33	NMOD
27	of	of	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	29	NMOD
29	lesion	lesion	I-NP	NN	O	27	PMOD
30	and	and	O	CC	O	33	NMOD
31	the	the	B-NP	DT	O	33	NMOD
32	predisposing	predispose	I-NP	VBG	B-protein	33	NMOD
33	factors	factor	I-NP	NNS	I-protein	34	SUB
34	have	have	B-VP	VBP	O	24	SBAR
35	been	be	I-VP	VBN	O	34	VC
36	unclear	unclear	B-ADJP	JJ	O	35	PRD
37	.	.	O	.	O	12	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	3	3	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	(	(	O	(	O	9	DEP
6	age	age	B-NP	NN	O	8	SUB
7	37-52	37-52	B-NP	CD	O	8	NMOD
8	years	year	I-NP	NNS	O	9	DEP
9	)	)	O	)	O	4	NMOD
10	with	with	B-PP	IN	O	4	NMOD
11	acute	acute	B-NP	JJ	O	13	NMOD
12	respiratory	respiratory	I-NP	JJ	O	13	NMOD
13	insufficiency	insufficiency	I-NP	NN	O	10	PMOD
14	who	who	B-NP	WP	O	4	NMOD
15	developed	develop	B-VP	VBD	O	14	SBAR
16	prolonged	prolong	I-VP	VBN	O	17	NMOD
17	weakness	weakness	B-NP	NN	O	15	OBJ
18	following	follow	B-PP	VBG	O	15	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	discontinuation	discontinuation	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	ND-NMBAs	ND-NMBA	B-NP	NNS	O	21	PMOD
23	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	weakness	weakness	I-NP	NN	O	6	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	these	these	B-NP	DT	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	due	due	B-PP	IN	O	8	PMOD
8	to	to	B-PP	TO	O	6	PRD
9	pathology	pathology	B-NP	NN	O	8	PMOD
10	at	at	B-PP	IN	O	9	NMOD
11	both	both	O	CC	O	14	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	neuromuscular	neuromuscular	I-NP	JJ	O	14	NMOD
14	junction	junction	I-NP	NN	O	23	NMOD
15	(	(	O	(	O	21	DEP
16	most	most	B-ADVP	RBS	O	17	AMOD
17	likely	likely	I-ADVP	RB	O	21	DEP
18	due	due	B-PP	IN	O	21	DEP
19	to	to	B-PP	TO	O	18	PMOD
20	ND-NMBA	ND-NMBA	B-NP	NN	B-protein	18	PMOD
21	)	)	O	)	O	14	NMOD
22	and	and	O	CC	O	23	NMOD
23	muscle	muscle	B-NP	NN	O	10	PMOD
24	(	(	O	(	O	30	DEP
25	most	most	B-ADVP	RBS	O	26	AMOD
26	likely	likely	I-ADVP	RB	O	30	DEP
27	due	due	B-PP	IN	O	28	PMOD
28	to	to	B-PP	TO	O	26	AMOD
29	corticosteroids	corticosteroid	B-NP	NNS	O	28	PMOD
30	)	)	O	)	O	23	NMOD
31	.	.	O	.	O	6	P

1	Prostaglandin	Prostaglandin	B-NP	NN	O	2	NMOD
2	E2	E2	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	bladder	bladder	B-NP	NN	O	5	NMOD
5	hyperactivity	hyperactivity	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	normal	normal	B-NP	JJ	O	10	NMOD
8	,	,	I-NP	,	O	10	P
9	conscious	conscious	I-NP	JJ	O	10	NMOD
10	rats	rat	I-NP	NNS	O	6	PMOD
11	:	:	O	:	O	3	P
12	involvement	involvement	B-NP	NN	O	3	VMOD
13	of	of	B-PP	IN	O	12	NMOD
14	tachykinins	tachykinin	B-NP	NNS	B-protein	13	PMOD
15	.	.	O	.	O	3	P

1	Thiazide	Thiazide	B-NP	NN	O	2	NMOD
2	diuretics	diuretic	I-NP	NNS	O	7	NMOD
3	,	,	O	,	O	7	P
4	hypokalemia	hypokalemia	B-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	cardiac	cardiac	B-NP	JJ	O	7	NMOD
7	arrhythmias	arrhythmia	I-NP	NNS	O	0	ROOT
8	.	.	O	.	O	7	P

1	Hypokalemia	Hypokalemia	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	7	NMOD
4	commonly	commonly	I-NP	RB	O	5	AMOD
5	encountered	encounter	I-NP	VBN	O	7	NMOD
6	metabolic	metabolic	I-NP	JJ	O	7	NMOD
7	consequence	consequence	I-NP	NN	O	2	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	chronic	chronic	B-NP	JJ	O	11	NMOD
10	thiazide	thiazide	I-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	treated	treat	B-VP	VBD	O	0	ROOT
3	38	38	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	(	(	O	(	O	13	DEP
6	22	22	B-NP	CD	O	8	NMOD
7	low	low	I-NP	JJ	O	8	NMOD
8	renin	renin	I-NP	NN	B-protein	12	NMOD
9	,	,	O	,	O	12	P
10	16	16	B-NP	CD	O	12	NMOD
11	normal	normal	I-NP	JJ	O	12	NMOD
12	renin	renin	I-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	4	NMOD
14	with	with	B-PP	IN	O	4	NMOD
15	moderate	moderate	B-NP	JJ	O	17	NMOD
16	diastolic	diastolic	I-NP	JJ	O	17	NMOD
17	hypertension	hypertension	I-NP	NN	O	14	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	hydrochlorothiazide	hydrochlorothiazide	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	22	DEP
21	HCTC	HCTC	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	administered	administer	B-VP	VBN	O	19	NMOD
24	on	on	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	28	NMOD
26	twice	twice	I-NP	RB	O	27	AMOD
27	daily	daily	I-NP	JJ	O	28	NMOD
28	schedule	schedule	I-NP	NN	O	24	PMOD
29	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	4	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	we	we	B-NP	PRP	O	4	SUB
4	found	find	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	thiazide	thiazide	B-NP	NN	O	7	NMOD
7	diuretics	diuretic	I-NP	NNS	O	8	SUB
8	cause	cause	B-VP	VBP	O	5	SBAR
9	hypokalemia	hypokalemia	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	depletion	depletion	I-NP	NN	O	8	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	body	body	B-NP	NN	O	14	NMOD
14	potassium	potassium	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	4	P

1	Diuretics	Diuretic	B-NP	NNS	O	5	NMOD
2	,	,	O	,	O	5	P
3	potassium	potassium	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	arrhythmias	arrhythmia	I-NP	NNS	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	hypertensive	hypertensive	B-NP	JJ	O	9	NMOD
8	coronary	coronary	I-NP	JJ	O	9	NMOD
9	disease	disease	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	5	P

1	It	It	B-NP	PRP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	proposed	propose	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	modest	modest	B-NP	JJ	O	7	NMOD
7	changes	change	I-NP	NNS	O	11	SUB
8	in	in	B-PP	IN	O	7	NMOD
9	plasma	plasma	B-NP	NN	O	10	NMOD
10	potassium	potassium	I-NP	NN	O	8	PMOD
11	can	can	B-VP	MD	O	5	SBAR
12	alter	alter	I-VP	VB	O	11	VC
13	the	the	B-NP	DT	O	14	NMOD
14	tendency	tendency	I-NP	NN	O	12	OBJ
15	towards	towards	B-PP	IN	O	14	NMOD
16	cardiac	cardiac	B-NP	JJ	O	17	NMOD
17	arrhythmias	arrhythmia	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	2	P

1	Thus	Thus	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	myocardial	myocardial	B-NP	JJ	O	5	NMOD
4	electrical	electrical	I-NP	JJ	O	5	NMOD
5	excitability	excitability	I-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	measured	measure	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	mild	mild	B-NP	JJ	O	13	NMOD
12	essential	essential	I-NP	JJ	O	13	NMOD
13	hypertension	hypertension	I-NP	NN	O	18	NMOD
14	and	and	O	CC	O	18	NMOD
15	known	know	B-NP	VBN	O	18	NMOD
16	coronary	coronary	I-NP	JJ	O	18	NMOD
17	artery	artery	I-NP	NN	O	18	NMOD
18	disease	disease	I-NP	NN	O	10	PMOD
19	after	after	B-PP	IN	O	9	NMOD
20	8	8	B-NP	CD	O	21	NMOD
21	weeks	week	I-NP	NNS	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	treatment	treatment	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	a	a	B-NP	DT	O	34	NMOD
26	potassium-conserving	potassium-conserving	I-NP	JJ	O	27	AMOD
27	diuretic	diuretic	I-NP	JJ	O	34	NMOD
28	(	(	O	(	O	30	DEP
29	amiloride	amiloride	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	AMOD
31	and	and	O	CC	O	34	NMOD
32	a	a	B-NP	DT	O	34	NMOD
33	similar	similar	I-NP	JJ	O	34	NMOD
34	period	period	I-NP	NN	O	24	PMOD
35	on	on	B-PP	IN	O	9	NMOD
36	a	a	B-NP	DT	O	35	PMOD
37	potassium-losing	potassium-losing	I-NP	JJ	O	38	AMOD
38	diuretic	diuretic	I-NP	JJ	O	36	NMOD
39	(	(	O	(	O	41	DEP
40	chlorthalidone	chlorthalidone	B-NP	NN	O	41	DEP
41	)	)	O	)	O	38	AMOD
42	in	in	B-PP	IN	O	38	NMOD
43	a	a	B-NP	DT	O	45	NMOD
44	randomised	randomise	I-NP	VBN	O	45	NMOD
45	study	study	I-NP	NN	O	42	PMOD
46	.	.	O	.	O	6	P

1	Compared	Compare	B-PP	VBN	O	9	VMOD
2	to	to	B-PP	TO	O	1	PMOD
3	amiloride	amiloride	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	,	,	O	,	O	9	P
6	the	the	B-NP	DT	O	8	NMOD
7	chlorthalidone	chlorthalidone	I-NP	NN	O	8	NMOD
8	phase	phase	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	49	VMOD
10	associated	associate	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	an	an	B-NP	DT	O	14	NMOD
13	increased	increase	I-NP	VBN	O	14	NMOD
14	frequency	frequency	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	ventricular	ventricular	B-NP	JJ	O	18	NMOD
17	ectopic	ectopic	I-NP	JJ	O	18	NMOD
18	beats	beat	I-NP	NNS	O	33	NMOD
19	(	(	O	(	O	23	DEP
20	24-hour	24-hour	B-NP	JJ	O	22	NMOD
21	Holter	Holter	I-NP	NNP	O	22	NMOD
22	monitoring	monitoring	I-NP	NN	O	23	DEP
23	)	)	O	)	O	18	NMOD
24	and	and	O	CC	O	28	NMOD
25	a	a	B-NP	DT	O	28	NMOD
26	higher	high	I-NP	JJR	O	28	NMOD
27	Lown	Lown	I-NP	JJ	O	28	NMOD
28	grading	grading	I-NP	NN	O	33	NMOD
29	,	,	O	,	O	33	P
30	increased	increase	B-NP	VBN	O	33	NMOD
31	upslope	upslope	I-NP	NN	O	33	NMOD
32	and	and	I-NP	CC	O	33	NMOD
33	duration	duration	I-NP	NN	O	15	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	38	NMOD
36	monophasic	monophasic	I-NP	JJ	O	38	NMOD
37	action	action	I-NP	NN	O	38	NMOD
38	potential	potential	I-NP	NN	O	34	PMOD
39	,	,	O	,	O	9	P
40	prolonged	prolong	B-VP	VBD	O	9	VMOD
41	ventricular	ventricular	B-NP	JJ	O	43	AMOD
42	effective	effective	I-NP	JJ	O	43	AMOD
43	refractory	refractory	I-NP	JJ	O	44	NMOD
44	period	period	I-NP	NN	O	40	OBJ
45	,	,	O	,	O	49	P
46	and	and	O	CC	O	49	NMOD
47	increased	increase	B-NP	VBN	O	49	NMOD
48	electrical	electrical	I-NP	JJ	O	49	NMOD
49	instability	instability	I-NP	NN	O	0	ROOT
50	during	during	B-PP	IN	O	49	NMOD
51	programmed	program	B-NP	VBN	O	53	NMOD
52	ventricular	ventricular	I-NP	JJ	O	53	NMOD
53	stimulation	stimulation	I-NP	NN	O	50	PMOD
54	.	.	O	.	O	49	P

1	GABA	GABA	B-NP	NN	O	2	NMOD
2	involvement	involvement	I-NP	NN	O	5	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	naloxone	naloxone	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	reversal	reversal	B-NP	NN	O	5	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	respiratory	respiratory	B-NP	JJ	O	9	NMOD
9	paralysis	paralysis	I-NP	NN	O	7	PMOD
10	produced	produce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	thiopental	thiopental	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	18	VMOD
2	this	this	B-NP	DT	O	4	NMOD
3	study	study	I-NP	NN	O	4	NMOD
4	naloxone	naloxone	I-NP	NN	O	5	SUB
5	reversed	reverse	B-VP	VBD	O	1	SBAR
6	respiratory	respiratory	B-NP	JJ	O	7	NMOD
7	paralysis	paralysis	I-NP	NN	O	5	OBJ
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	thiopental	thiopental	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	VMOD
12	rats.	rats.	B-NP	NN	O	14	NMOD
13	25	25	I-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	18	P
16	i.v.	i.v.	B-NP	JJ	O	17	NMOD
17	thiopental	thiopental	I-NP	NN	O	18	SUB
18	produced	produce	B-VP	VBD	O	0	ROOT
19	anesthesia	anesthesia	B-NP	NN	O	18	OBJ
20	without	without	B-PP	IN	O	18	VMOD
21	altering	alter	B-VP	VBG	O	20	PMOD
22	respiratory	respiratory	B-NP	JJ	O	23	NMOD
23	rate	rate	I-NP	NN	O	21	OBJ
24	,	,	O	,	O	18	P
25	increased	increase	B-NP	VBN	O	26	NMOD
26	GABA	GABA	I-NP	NN	B-protein	29	NMOD
27	,	,	O	,	O	29	P
28	decreased	decrease	B-NP	VBN	O	29	NMOD
29	glutamate	glutamate	I-NP	NN	O	18	OBJ
30	,	,	O	,	O	18	P
31	and	and	O	CC	O	18	VMOD
32	had	have	B-VP	VBD	O	18	VMOD
33	no	no	B-NP	DT	O	34	NMOD
34	effect	effect	I-NP	NN	O	32	OBJ
35	on	on	B-PP	IN	O	32	VMOD
36	aspartate	aspartate	B-NP	NN	O	39	NMOD
37	or	or	I-NP	CC	O	39	NMOD
38	glycine	glycine	I-NP	NN	O	39	NMOD
39	levels	level	I-NP	NNS	O	35	PMOD
40	compared	compare	B-VP	VBN	O	39	NMOD
41	to	to	B-PP	TO	O	40	VMOD
42	controls	control	B-NP	NNS	O	41	PMOD
43	in	in	B-PP	IN	O	42	NMOD
44	rat	rat	B-NP	NN	O	45	NMOD
45	cortex	cortex	I-NP	NN	O	48	NMOD
46	and	and	I-NP	CC	O	48	NMOD
47	brain	brain	I-NP	NN	O	48	NMOD
48	stem	stem	I-NP	NN	O	43	PMOD
49	.	.	O	.	O	18	P

1	Pretreatment	Pretreatment	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	rats	rat	B-NP	NNS	O	2	PMOD
4	with	with	B-PP	IN	O	1	NMOD
5	thiosemicarbazide	thiosemicarbazide	B-NP	NN	O	4	PMOD
6	for	for	B-PP	IN	O	1	NMOD
7	30	30	B-NP	CD	O	8	NMOD
8	minutes	minute	I-NP	NNS	O	6	PMOD
9	abolished	abolish	B-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	12	NMOD
11	anesthetic	anesthetic	I-NP	JJ	O	12	NMOD
12	action	action	I-NP	NN	O	19	NMOD
13	as	as	B-CONJP	RB	O	19	NMOD
14	well	well	I-CONJP	RB	O	13	DEP
15	as	as	I-CONJP	IN	O	13	DEP
16	the	the	B-NP	DT	O	19	NMOD
17	respiratory	respiratory	I-NP	JJ	O	19	NMOD
18	depressant	depressant	I-NP	NN	O	19	NMOD
19	action	action	I-NP	NN	O	9	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	thiopental.	thiopental.	B-NP	NN	O	23	NMOD
22	50	50	I-NP	CD	O	23	NMOD
23	mg/kg	mg/kg	I-NP	NN	O	20	PMOD
24	,	,	O	,	O	9	P
25	i.v.	i.v.	B-NP	JJ	O	26	NMOD
26	thiopental	thiopental	I-NP	NN	O	29	NMOD
27	produced	produce	B-VP	VBD	O	29	NMOD
28	respiratory	respiratory	B-NP	JJ	O	29	NMOD
29	arrest	arrest	I-NP	NN	O	9	OBJ
30	with	with	B-PP	IN	O	29	NMOD
31	further	further	B-NP	JJ	O	32	NMOD
32	increase	increase	I-NP	NN	O	36	NMOD
33	in	in	B-PP	IN	O	32	NMOD
34	GABA	GABA	B-NP	NN	B-protein	33	PMOD
35	and	and	I-NP	CC	O	36	NMOD
36	decrease	decrease	I-NP	NN	O	30	PMOD
37	in	in	B-PP	IN	O	36	NMOD
38	glutamate	glutamate	B-NP	NN	O	37	PMOD
39	again	again	B-ADVP	RB	O	40	PMOD
40	in	in	B-PP	IN	O	29	NMOD
41	cortex	cortex	B-NP	NN	O	44	NMOD
42	and	and	I-NP	CC	O	44	NMOD
43	brain	brain	I-NP	NN	O	44	NMOD
44	stem	stem	I-NP	NN	O	40	PMOD
45	without	without	B-PP	IN	O	29	NMOD
46	affecting	affect	B-VP	VBG	O	45	PMOD
47	any	any	B-NP	DT	O	46	OBJ
48	of	of	B-PP	IN	O	47	NMOD
49	the	the	B-NP	DT	O	51	NMOD
50	amino	amino	I-NP	JJ	O	51	NMOD
51	acids	acid	I-NP	NNS	O	48	PMOD
52	studied	study	B-VP	VBN	O	51	NMOD
53	in	in	B-PP	IN	O	52	VMOD
54	four	four	B-NP	CD	O	55	NMOD
55	regions	region	I-NP	NNS	O	53	PMOD
56	of	of	B-PP	IN	O	55	NMOD
57	rat	rat	B-NP	NN	O	58	NMOD
58	brain	brain	I-NP	NN	O	56	PMOD
59	.	.	O	.	O	9	P

1	Naloxone	Naloxone	B-NP	NN	O	8	SUB
2	(	(	O	(	O	7	DEP
3	2.5	2.5	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	7	DEP
5	,	,	O	,	O	4	P
6	i.v.	i.v.	B-ADJP	JJ	O	4	NMOD
7	)	)	O	)	O	1	NMOD
8	reversed	reverse	B-VP	VBD	O	0	ROOT
9	respiratory	respiratory	B-NP	JJ	O	10	NMOD
10	paralysis	paralysis	I-NP	NN	O	15	NMOD
11	,	,	O	,	O	15	P
12	glutamate	glutamate	B-NP	NN	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	GABA	GABA	I-NP	NN	B-protein	15	NMOD
15	levels	level	I-NP	NNS	O	8	OBJ
16	to	to	B-VP	TO	O	17	VMOD
17	control	control	I-VP	VB	O	8	VMOD
18	values	value	B-NP	NNS	O	17	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	brain	brain	B-NP	NN	O	21	NMOD
21	stem	stem	I-NP	NN	O	23	NMOD
22	and	and	O	CC	O	23	NMOD
23	cortex	cortex	B-NP	NN	O	19	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	no	no	B-NP	DT	O	26	NMOD
26	changes	change	I-NP	NNS	O	24	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	caudate	caudate	B-NP	NN	O	30	NMOD
29	or	or	I-NP	CC	O	30	NMOD
30	cerebellum	cerebellum	I-NP	NN	O	27	PMOD
31	.	.	O	.	O	8	P

1	These	These	B-NP	DT	O	2	NMOD
2	infants	infant	I-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	0	ROOT
4	treated	treat	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	two	two	B-NP	CD	O	7	NMOD
7	injections	injection	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	hepatitis	hepatitis	B-NP	NN	B-protein	12	NMOD
10	B	B	I-NP	NN	I-protein	12	NMOD
11	immune	immune	I-NP	JJ	I-protein	12	NMOD
12	globulin	globulin	I-NP	NN	I-protein	8	PMOD
13	(	(	O	(	O	15	DEP
14	HBIG	HBIG	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	3	VMOD
17	at	at	B-NP	IN	O	20	NMOD
18	least	least	I-NP	JJS	O	17	AMOD
19	three	three	I-NP	CD	O	17	AMOD
20	injections	injection	I-NP	NNS	O	16	PRD
21	of	of	B-PP	IN	O	20	NMOD
22	plasma	plasma	B-NP	NN	O	26	NMOD
23	derived	derive	I-NP	VBN	O	22	AMOD
24	hepatitis	hepatitis	I-NP	NN	O	26	NMOD
25	B	B	I-NP	NN	O	26	NMOD
26	vaccine	vaccine	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	intrathecal	intrathecal	B-NP	JJ	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	prostaglandins	prostaglandin	B-NP	NNS	O	6	PMOD
8	on	on	B-PP	IN	O	2	NMOD
9	pain	pain	B-NP	NN	O	10	NMOD
10	responses	response	I-NP	NNS	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	conscious	conscious	B-NP	JJ	O	13	NMOD
13	mice	mouse	I-NP	NNS	O	11	PMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	evaluated	evaluate	I-VP	VBN	O	14	VC
16	by	by	B-PP	IN	O	15	VMOD
17	using	use	B-VP	VBG	O	16	PMOD
18	hot	hot	B-NP	JJ	O	19	NMOD
19	plate	plate	I-NP	NN	O	24	NMOD
20	and	and	O	CC	O	24	NMOD
21	acetic	acetic	B-NP	JJ	O	24	NMOD
22	acid	acid	I-NP	NN	O	24	NMOD
23	writhing	writhing	I-NP	NN	O	24	NMOD
24	tests	test	I-NP	NNS	O	17	OBJ
25	.	.	O	.	O	14	P

1	Prostaglandin	Prostaglandin	B-NP	NN	O	2	NMOD
2	D2	D2	I-NP	NN	O	7	SUB
3	(	(	O	(	O	6	DEP
4	0.5-3	0.5-3	B-NP	CD	O	5	NMOD
5	ng/mouse	ng/mouse	I-NP	NN	O	6	DEP
6	)	)	O	)	O	2	NMOD
7	had	have	B-VP	VBD	O	0	ROOT
8	a	a	B-NP	DT	O	10	NMOD
9	hyperalgesic	hyperalgesic	I-NP	JJ	O	10	NMOD
10	action	action	I-NP	NN	O	7	OBJ
11	on	on	B-PP	IN	O	7	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	response	response	I-NP	NN	O	11	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	a	a	B-NP	DT	O	17	NMOD
16	hot	hot	I-NP	JJ	O	17	NMOD
17	plate	plate	I-NP	NN	O	14	PMOD
18	during	during	B-PP	IN	O	7	VMOD
19	a	a	B-NP	DT	O	22	NMOD
20	3-60	3-60	I-NP	CD	O	21	AMOD
21	min	min	I-NP	NN	O	22	NMOD
22	period	period	I-NP	NN	O	18	PMOD
23	after	after	B-PP	IN	O	22	NMOD
24	injection	injection	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	7	P

1	Prostaglandin	Prostaglandin	B-NP	NN	O	2	NMOD
2	E2	E2	I-NP	NN	O	3	SUB
3	showed	show	B-VP	VBD	O	19	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	hyperalgesic	hyperalgesic	I-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	3	OBJ
7	at	at	B-PP	IN	O	3	VMOD
8	doses	dose	B-NP	NNS	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	1	1	B-NP	CD	O	11	NMOD
11	pg	pg	I-NP	NN	O	9	PMOD
12	to	to	B-PP	TO	O	8	NMOD
13	10	10	B-NP	CD	O	14	NMOD
14	ng/mouse	ng/mouse	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	19	P
16	but	but	O	CC	O	19	VMOD
17	the	the	B-NP	DT	O	18	NMOD
18	effect	effect	I-NP	NN	O	19	SUB
19	lasted	last	B-VP	VBD	O	0	ROOT
20	shorter	short	B-ADJP	JJR	O	19	PRD
21	(	(	O	(	O	24	DEP
22	3-30	3-30	B-NP	CD	O	23	NMOD
23	min	min	I-NP	NN	O	24	DEP
24	)	)	O	)	O	20	AMOD
25	than	than	B-PP	IN	O	20	AMOD
26	that	that	B-NP	DT	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	prostaglandin	prostaglandin	B-NP	NN	B-protein	29	NMOD
29	D2	D2	I-NP	NN	I-protein	27	PMOD
30	.	.	O	.	O	19	P

1	The	The	B-NP	DT	O	3	NMOD
2	hyperalgesic	hyperalgesic	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	prostaglandin	prostaglandin	B-NP	NN	B-protein	6	NMOD
6	D2	D2	I-NP	NN	I-protein	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	blocked	block	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	simultaneous	simultaneous	B-NP	JJ	O	11	NMOD
11	injection	injection	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	16	NMOD
14	substance	substance	I-NP	NN	O	16	NMOD
15	P	P	I-NP	NN	O	16	NMOD
16	antagonist	antagonist	I-NP	NN	O	12	PMOD
17	(	(	O	(	O	25	DEP
18	greater	great	B-ADJP	JJR	O	21	AMOD
19	than	than	B-PP	IN	O	18	AMOD
20	or	or	O	CC	O	21	AMOD
21	equal	equal	B-ADJP	JJ	O	25	DEP
22	to	to	B-PP	TO	O	21	AMOD
23	100	100	B-NP	CD	O	24	NMOD
24	ng	ng	I-NP	NN	O	22	PMOD
25	)	)	O	)	O	16	NMOD
26	but	but	B-PP	CC	O	9	PMOD
27	not	not	B-NP	RB	O	28	PMOD
28	by	by	B-PP	IN	O	9	PMOD
29	AH6809	AH6809	B-NP	NN	O	34	NMOD
30	,	,	O	,	O	34	P
31	a	a	B-NP	DT	O	34	NMOD
32	prostanoid	prostanoid	I-NP	NN	O	34	NMOD
33	EP1-receptor	EP1-receptor	I-NP	NN	O	34	NMOD
34	antagonist	antagonist	I-NP	NN	O	28	PMOD
35	.	.	O	.	O	7	P

1	Conversely	Conversely	B-ADVP	RB	O	7	VMOD
2	,	,	O	,	O	7	P
3	prostaglandin	prostaglandin	B-NP	NN	B-protein	4	NMOD
4	E2	E2	I-NP	NN	I-protein	6	NMOD
5	induced	induce	B-NP	VBN	O	6	NMOD
6	hyperalgesia	hyperalgesia	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	blocked	block	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	AH6809	AH6809	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	19	DEP
12	greater	great	B-ADJP	JJR	O	15	AMOD
13	than	than	B-PP	IN	O	12	AMOD
14	or	or	O	CC	O	15	AMOD
15	equal	equal	B-ADJP	JJ	O	19	DEP
16	to	to	B-PP	TO	O	15	AMOD
17	500	500	B-NP	CD	O	18	NMOD
18	ng	ng	I-NP	NN	O	16	PMOD
19	)	)	O	)	O	10	NMOD
20	but	but	B-PP	CC	O	9	PMOD
21	not	not	B-PP	RB	O	22	PMOD
22	by	by	I-PP	IN	O	9	PMOD
23	the	the	B-NP	DT	O	26	NMOD
24	substance	substance	I-NP	NN	O	26	NMOD
25	P	P	I-NP	NN	O	26	NMOD
26	antagonist	antagonist	I-NP	NN	O	22	PMOD
27	.	.	O	.	O	7	P

1	Prostaglandin	Prostaglandin	B-NP	NN	B-protein	3	NMOD
2	F2	F2	I-NP	NN	I-protein	3	NMOD
3	alpha	alpha	I-NP	NN	I-protein	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	little	little	B-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	OBJ
7	on	on	B-PP	IN	O	4	VMOD
8	pain	pain	B-NP	NN	O	9	NMOD
9	responses	response	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	4	P

1	Swallowing	Swallow	B-VP	VBG	O	0	ROOT
2	induced	induce	B-NP	VBN	O	4	NMOD
3	atrial	atrial	I-NP	JJ	O	4	NMOD
4	tachyarrhythmia	tachyarrhythmia	I-NP	NN	O	1	OBJ
5	triggered	trigger	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	salbutamol	salbutamol	B-NP	NN	O	6	PMOD
8	:	:	O	:	O	1	P
9	case	case	B-NP	NN	O	10	NMOD
10	report	report	I-NP	NN	O	12	NMOD
11	and	and	O	CC	O	12	NMOD
12	review	review	B-NP	NN	O	1	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	literature	literature	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	arrhythmia	arrhythmia	I-NP	NN	O	10	SUB
3	resolved	resolve	B-VP	VBN	O	2	NMOD
4	after	after	B-PP	IN	O	3	VMOD
5	therapy	therapy	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	atenolol	atenolol	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	2	P
9	but	but	O	CC	O	2	VMOD
10	recurred	recur	B-VP	VBD	O	0	ROOT
11	a	a	B-NP	DT	O	12	NMOD
12	year	year	I-NP	NN	O	10	OBJ
13	later	later	B-ADVP	RB	O	10	VMOD
14	.	.	O	.	O	10	P

1	After	After	B-PP	IN	O	16	VMOD
2	stopping	stop	B-VP	VBG	O	1	PMOD
3	the	the	B-NP	DT	O	4	NMOD
4	beta-agonist	beta-agonist	I-NP	NN	O	2	OBJ
5	,	,	O	,	O	16	P
6	and	and	O	CC	O	16	VMOD
7	after	after	B-PP	IN	O	16	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	week	week	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	atenolol	atenolol	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	16	P
14	the	the	B-NP	DT	O	15	NMOD
15	arrhythmia	arrhythmia	I-NP	NN	O	16	SUB
16	disappeared	disappear	B-VP	VBD	O	0	ROOT
17	.	.	O	.	O	16	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Salbutamol	Salbutamol	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	presented	present	I-VP	VBN	O	4	VC
6	here	here	B-ADVP	RB	O	5	VMOD
7	as	as	B-PP	IN	O	5	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	possible	possible	I-NP	JJ	O	10	NMOD
10	trigger	trigger	I-NP	NN	O	7	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	SIAT	SIAT	B-NP	NN	B-protein	11	PMOD
13	.	.	O	.	O	1	P

1	Coenzyme	Coenzyme	B-NP	NN	O	3	NMOD
2	Q10	Q10	I-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	4	SUB
4	ameliorates	ameliorate	B-VP	VBZ	O	0	ROOT
5	acute	acute	B-NP	JJ	O	7	NMOD
6	cisplatin	cisplatin	I-NP	NN	O	7	NMOD
7	nephrotoxicity	nephrotoxicity	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	mice	mouse	B-NP	NNS	O	8	PMOD
10	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	nephroprotective	nephroprotective	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	coenzyme	coenzyme	B-NP	NN	O	6	NMOD
6	Q10	Q10	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	investigated	investigate	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	mice	mouse	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	acute	acute	B-NP	JJ	O	14	NMOD
13	renal	renal	I-NP	JJ	O	14	NMOD
14	injury	injury	I-NP	NN	O	11	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	single	single	I-NP	JJ	O	20	NMOD
19	i.p.	i.p.	I-NP	JJ	O	20	NMOD
20	injection	injection	I-NP	NN	O	16	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	cisplatin	cisplatin	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	26	DEP
24	5	5	B-NP	CD	O	25	NMOD
25	mg/kg	mg/kg	I-NP	NN	O	26	DEP
26	)	)	O	)	O	22	NMOD
27	.	.	O	.	O	7	P

1	Coenzyme	Coenzyme	B-NP	NN	O	2	NMOD
2	Q10	Q10	I-NP	NN	O	4	SUB
3	significantly	significantly	B-ADVP	RB	O	4	VMOD
4	compensated	compensate	B-VP	VBD	O	0	ROOT
5	deficits	deficit	B-NP	NNS	O	4	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	antioxidant	antioxidant	I-NP	JJ	O	10	NMOD
9	defense	defense	I-NP	NN	O	10	NMOD
10	mechanisms	mechanism	I-NP	NNS	O	6	PMOD
11	(	(	O	(	O	19	DEP
12	reduced	reduce	B-NP	VBN	O	14	NMOD
13	glutathione	glutathione	I-NP	NN	O	14	NMOD
14	level	level	I-NP	NN	O	18	NMOD
15	and	and	I-NP	CC	O	18	NMOD
16	superoxide	superoxide	I-NP	NN	B-protein	18	NMOD
17	dismutase	dismutase	I-NP	NN	I-protein	18	NMOD
18	activity	activity	I-NP	NN	O	19	DEP
19	)	)	O	)	O	10	NMOD
20	,	,	O	,	O	4	P
21	suppressed	suppress	B-VP	VBD	O	4	VMOD
22	lipid	lipid	B-NP	NN	O	23	NMOD
23	peroxidation	peroxidation	I-NP	NN	O	21	OBJ
24	,	,	O	,	O	4	P
25	decreased	decrease	B-VP	VBD	O	4	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	elevations	elevation	I-NP	NNS	O	25	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	tumor	tumor	B-NP	NN	B-protein	31	NMOD
30	necrosis	necrosis	I-NP	NN	I-protein	31	NMOD
31	factor-alpha	factor-alpha	I-NP	NN	I-protein	38	NMOD
32	,	,	O	,	O	38	P
33	nitric	nitric	B-NP	JJ	O	34	NMOD
34	oxide	oxide	I-NP	NN	O	38	NMOD
35	and	and	I-NP	CC	O	38	NMOD
36	platinum	platinum	I-NP	NN	O	38	NMOD
37	ion	ion	I-NP	NN	O	38	NMOD
38	concentration	concentration	I-NP	NN	O	28	PMOD
39	,	,	O	,	O	4	P
40	and	and	O	CC	O	4	VMOD
41	attenuated	attenuate	B-VP	VBD	O	4	VMOD
42	the	the	B-NP	DT	O	43	NMOD
43	reductions	reduction	I-NP	NNS	O	41	OBJ
44	of	of	B-PP	IN	O	43	NMOD
45	selenium	selenium	B-NP	NN	O	48	NMOD
46	and	and	I-NP	CC	O	48	NMOD
47	zinc	zinc	I-NP	NN	O	48	NMOD
48	ions	ion	I-NP	NNS	O	44	PMOD
49	in	in	B-PP	IN	O	43	NMOD
50	renal	renal	B-NP	JJ	O	51	NMOD
51	tissue	tissue	I-NP	NN	O	49	PMOD
52	resulted	result	B-VP	VBD	O	41	VMOD
53	from	from	B-PP	IN	O	52	VMOD
54	cisplatin	cisplatin	B-NP	NN	O	55	NMOD
55	administration	administration	I-NP	NN	O	53	PMOD
56	.	.	O	.	O	4	P

1	Also	Also	B-ADVP	RB	O	10	VMOD
2	,	,	O	,	O	10	P
3	histopathological	histopathological	B-NP	JJ	O	6	NMOD
4	renal	renal	I-NP	JJ	O	6	NMOD
5	tissue	tissue	I-NP	NN	O	6	NMOD
6	damage	damage	I-NP	NN	O	10	SUB
7	mediated	mediate	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	cisplatin	cisplatin	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	ameliorated	ameliorate	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	coenzyme	coenzyme	B-NP	NN	O	15	NMOD
14	Q10	Q10	I-NP	NN	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	10	P

1	Metformin	Metformin	B-NP	NN	O	2	SUB
2	prevents	prevent	B-VP	VBZ	O	0	ROOT
3	experimental	experimental	B-NP	JJ	O	4	NMOD
4	gentamicin	gentamicin	I-NP	NN	O	2	OBJ
5	induced	induce	B-VP	VBD	O	4	NMOD
6	nephropathy	nephropathy	B-NP	NN	O	5	OBJ
7	by	by	B-PP	IN	O	5	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	mitochondria-dependent	mitochondria-dependent	I-NP	JJ	O	10	NMOD
10	pathway	pathway	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	4	NMOD
2	antidiabetic	antidiabetic	I-NP	JJ	B-protein	4	NMOD
3	drug	drug	I-NP	NN	I-protein	4	NMOD
4	metformin	metformin	I-NP	NN	I-protein	5	SUB
5	can	can	B-VP	MD	O	0	ROOT
6	diminish	diminish	I-VP	VB	O	5	VC
7	apoptosis	apoptosis	B-NP	NN	O	6	OBJ
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	oxidative	oxidative	B-NP	JJ	O	11	NMOD
11	stress	stress	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	endothelial	endothelial	B-NP	JJ	B-cell_type	14	NMOD
14	cells	cell	I-NP	NNS	I-cell_type	12	PMOD
15	and	and	O	CC	O	6	VMOD
16	prevent	prevent	B-VP	VB	O	6	VMOD
17	vascular	vascular	B-NP	JJ	O	18	NMOD
18	dysfunction	dysfunction	I-NP	NN	O	16	OBJ
19	even	even	B-ADVP	RB	O	20	PMOD
20	in	in	B-PP	IN	O	16	VMOD
21	nondiabetic	nondiabetic	B-NP	JJ	O	22	NMOD
22	patients	patient	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	5	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	tested	test	B-VP	VBD	O	0	ROOT
4	whether	whether	B-SBAR	IN	O	3	VMOD
5	it	it	B-NP	PRP	O	6	SUB
6	has	have	B-VP	VBZ	O	4	SBAR
7	a	a	B-NP	DT	O	9	NMOD
8	beneficial	beneficial	I-NP	JJ	O	9	NMOD
9	effect	effect	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	rat	rat	I-NP	NN	O	13	NMOD
13	model	model	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	gentamicin	gentamicin	B-NP	NN	O	16	NMOD
16	toxicity	toxicity	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	3	P

1	Metformin	Metformin	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	4	SUB
3	fully	fully	B-ADVP	RB	O	4	VMOD
4	blocked	block	B-VP	VBD	O	0	ROOT
5	gentamicin-mediated	gentamicin-mediated	B-NP	JJ	O	8	NMOD
6	acute	acute	I-NP	JJ	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	failure	failure	I-NP	NN	O	4	OBJ
9	.	.	O	.	O	4	P

1	These	These	B-NP	DT	O	4	NMOD
2	in	in	I-NP	FW	O	3	AMOD
3	vivo	vivo	I-NP	FW	O	4	NMOD
4	markers	marker	I-NP	NNS	O	10	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	kidney	kidney	B-NP	NN	O	7	NMOD
7	dysfunction	dysfunction	I-NP	NN	O	5	PMOD
8	and	and	O	CC	O	10	NMOD
9	their	their	B-NP	PRP$	O	10	NMOD
10	correction	correction	I-NP	NN	O	13	SUB
11	by	by	B-PP	IN	O	10	NMOD
12	metformin	metformin	B-NP	NN	O	11	PMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	complemented	complement	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	in	in	B-NP	FW	O	17	AMOD
17	vitro	vitro	I-NP	FW	O	18	NMOD
18	studies	study	I-NP	NNS	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	mitochondrial	mitochondrial	B-NP	JJ	O	21	NMOD
21	function	function	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	13	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	We	We	B-NP	PRP	O	6	SUB
6	performed	perform	B-VP	VBD	O	3	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	double-blind	double-blind	I-NP	JJ	O	6	VMOD
9	,	,	O	,	O	6	P
10	randomized	randomize	B-VP	VBN	O	6	VMOD
11	controlled	control	B-NP	VBN	O	12	NMOD
12	trial	trial	I-NP	NN	O	10	OBJ
13	at	at	B-PP	IN	O	12	NMOD
14	an	an	B-NP	DT	O	17	NMOD
15	academic	academic	I-NP	JJ	O	17	NMOD
16	medical	medical	I-NP	JJ	O	17	NMOD
17	center	center	I-NP	NN	O	13	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	elderly	elderly	B-NP	JJ	O	20	NMOD
20	patients	patient	I-NP	NNS	O	18	PMOD
21	(	(	O	(	O	25	DEP
22	>	>	B-NP	SYM	O	24	NMOD
23	or=65	or=65	B-NP	CD	O	24	NMOD
24	years	year	I-NP	NNS	O	25	DEP
25	)	)	O	)	O	20	NMOD
26	without	without	B-PP	IN	O	10	VMOD
27	preoperative	preoperative	B-NP	JJ	O	28	NMOD
28	delirium	delirium	I-NP	NN	O	31	NMOD
29	or	or	O	CC	O	31	NMOD
30	severe	severe	B-NP	JJ	O	31	NMOD
31	dementia	dementia	I-NP	NN	O	26	PMOD
32	who	who	B-NP	WP	O	31	NMOD
33	underwent	undergo	B-VP	VBD	O	32	SBAR
34	hip	hip	B-NP	NN	O	36	NMOD
35	fracture	fracture	I-NP	NN	O	36	NMOD
36	repair	repair	I-NP	NN	O	33	OBJ
37	under	under	B-PP	IN	O	33	VMOD
38	spinal	spinal	B-NP	JJ	O	39	NMOD
39	anesthesia	anesthesia	I-NP	NN	O	37	PMOD
40	with	with	B-PP	IN	O	39	NMOD
41	propofol	propofol	B-NP	NN	O	42	NMOD
42	sedation	sedation	I-NP	NN	O	40	PMOD
43	.	.	O	.	O	3	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	use	use	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	light	light	B-NP	JJ	O	8	NMOD
7	propofol	propofol	I-NP	NN	O	8	NMOD
8	sedation	sedation	I-NP	NN	O	5	PMOD
9	decreased	decrease	B-VP	VBD	O	1	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	prevalence	prevalence	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	postoperative	postoperative	B-NP	JJ	O	14	NMOD
14	delirium	delirium	I-NP	NN	O	12	PMOD
15	by	by	B-PP	IN	O	9	VMOD
16	50	50	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	15	PMOD
18	compared	compare	B-PP	VBN	O	9	VMOD
19	with	with	B-PP	IN	O	18	PMOD
20	deep	deep	B-NP	JJ	O	21	NMOD
21	sedation	sedation	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	1	P

1	Sorafenib	Sorafenib	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	acute	acute	B-NP	JJ	O	5	NMOD
4	myocardial	myocardial	I-NP	JJ	O	5	NMOD
5	infarction	infarction	I-NP	NN	O	2	OBJ
6	due	due	B-PP	JJ	O	5	NMOD
7	to	to	B-PP	TO	O	6	AMOD
8	coronary	coronary	B-NP	JJ	O	10	NMOD
9	artery	artery	I-NP	NN	O	10	NMOD
10	spasm	spasm	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	Addition	Addition	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	oral	oral	B-NP	JJ	O	4	NMOD
4	nicorandil	nicorandil	I-NP	NN	O	2	PMOD
5	reduced	reduce	B-VP	VBD	O	0	ROOT
6	his	his	B-NP	PRP$	O	7	NMOD
7	symptoms	symptom	I-NP	NNS	O	5	OBJ
8	and	and	O	CC	O	5	VMOD
9	maintained	maintain	B-VP	VBN	O	5	VMOD
10	stable	stable	B-NP	JJ	O	12	NMOD
11	angina	angina	I-NP	NN	O	12	NMOD
12	status	status	I-NP	NN	O	9	OBJ
13	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	first	first	I-NP	JJ	O	5	NMOD
5	case	case	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	sorafenib	sorafenib	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	2	VMOD
9	coronary	coronary	B-NP	JJ	O	11	NMOD
10	artery	artery	I-NP	NN	O	11	NMOD
11	spasm	spasm	I-NP	NN	O	8	OBJ
12	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	indicate	indicate	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	ciprofloxacin-	ciprofloxacin-	B-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	norfloxacin-treated	norfloxacin-treated	B-NP	JJ	O	10	NMOD
10	rats	rat	I-NP	NNS	O	11	SUB
11	showed	show	B-VP	VBD	O	6	SBAR
12	anxious	anxious	B-NP	JJ	O	13	NMOD
13	behaviour	behaviour	I-NP	NN	O	11	OBJ
14	in	in	B-PP	IN	O	11	VMOD
15	comparison	comparison	B-NP	NN	O	14	PMOD
16	to	to	B-PP	TO	O	15	NMOD
17	control	control	B-NP	NN	O	18	NMOD
18	rats	rat	I-NP	NNS	O	16	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	all	all	B-NP	PDT	O	22	NMOD
21	the	the	I-NP	DT	O	22	NMOD
22	parameters	parameter	I-NP	NNS	O	19	PMOD
23	studied	study	B-VP	VBN	O	22	NMOD
24	.	.	O	.	O	1	P

1	Myocardial	Myocardial	B-NP	JJ	O	4	NMOD
2	Fas	Fas	I-NP	NN	B-protein	4	NMOD
3	ligand	ligand	I-NP	NN	I-protein	4	NMOD
4	expression	expression	I-NP	NN	O	5	SUB
5	increases	increase	B-VP	VBZ	O	0	ROOT
6	susceptibility	susceptibility	B-NP	NN	O	5	OBJ
7	to	to	B-PP	TO	O	6	NMOD
8	AZT	AZT	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	cardiomyopathy	cardiomyopathy	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	5	P

1	METHODS	METHODS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	In	In	B-SBAR	IN	O	3	VMOD
6	order	order	O	NN	O	5	DEP
7	to	to	B-VP	TO	O	8	VMOD
8	investigate	investigate	I-VP	VB	O	5	SBAR
9	whether	whether	B-SBAR	IN	O	8	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	HAART	HAART	I-NP	NN	O	13	NMOD
12	component	component	I-NP	NN	O	13	NMOD
13	zidovudine	zidovudine	I-NP	NN	O	22	SUB
14	(	(	O	(	O	21	DEP
15	3'-azido-2	3'-azido-2	B-NP	CD	O	18	NMOD
16	'	'	O	SYM	O	15	NMOD
17	,	,	O	,	O	18	P
18	3'-deoxythymidine	3'-deoxythymidine	B-NP	NN	O	20	NMOD
19	;	;	O	:	O	20	P
20	AZT	AZT	B-NP	NN	O	21	DEP
21	)	)	O	)	O	13	NMOD
22	triggers	trigger	B-VP	VBZ	O	9	SBAR
23	the	the	B-NP	DT	O	26	NMOD
24	Fas-dependent	Fas-dependent	I-NP	JJ	O	26	NMOD
25	cell-death	cell-death	I-NP	NN	O	26	NMOD
26	pathway	pathway	I-NP	NN	O	22	OBJ
27	and	and	O	CC	O	5	DEP
28	cause	cause	B-VP	VBP	O	5	DEP
29	cytoskeletal	cytoskeletal	B-NP	JJ	O	30	NMOD
30	disruption	disruption	I-NP	NN	O	28	OBJ
31	in	in	B-PP	IN	O	28	VMOD
32	a	a	B-NP	DT	O	34	NMOD
33	murine	murine	I-NP	JJ	O	34	NMOD
34	model	model	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	DCM	DCM	B-NP	NN	O	52	NMOD
37	,	,	O	,	O	52	P
38	8-week-old	8-week-old	B-NP	JJ	O	39	NMOD
39	transgenic	transgenic	I-NP	JJ	O	52	NMOD
40	(	(	O	(	O	50	DEP
41	expressing	express	B-VP	VBG	O	50	DEP
42	Fas	Fas	B-NP	NN	B-protein	43	NMOD
43	ligand	ligand	I-NP	NN	I-protein	41	OBJ
44	in	in	B-PP	IN	O	41	VMOD
45	the	the	B-NP	DT	O	46	NMOD
46	myocardium	myocardium	I-NP	NN	O	44	PMOD
47	:	:	O	:	O	41	P
48	FasL	FasL	B-NP	NN	B-protein	49	NMOD
49	Tg	Tg	I-NP	NN	O	41	DEP
50	)	)	O	)	O	39	NMOD
51	and	and	O	CC	O	52	NMOD
52	non-transgenic	non-transgenic	B-NP	JJ	O	35	PMOD
53	(	(	O	(	O	55	DEP
54	NTg	NTg	B-NP	NN	O	55	DEP
55	)	)	O	)	O	52	AMOD
56	mice	mouse	B-NP	NNS	O	52	NMOD
57	received	receive	B-VP	VBD	O	28	VMOD
58	water	water	B-NP	NN	O	60	NMOD
59	ad	ad	I-NP	NN	O	60	NMOD
60	libitum	libitum	I-NP	NN	O	57	OBJ
61	containing	contain	B-VP	VBG	O	60	NMOD
62	different	different	B-NP	JJ	O	63	NMOD
63	concentrations	concentration	I-NP	NNS	O	61	OBJ
64	of	of	B-PP	IN	O	63	NMOD
65	AZT	AZT	B-NP	NN	O	64	PMOD
66	(	(	O	(	O	76	DEP
67	0	0	B-NP	CD	O	75	NMOD
68	,	,	I-NP	,	O	75	P
69	0.07	0.07	I-NP	CD	O	75	NMOD
70	,	,	I-NP	,	O	75	P
71	0.2	0.2	I-NP	CD	O	75	NMOD
72	,	,	O	,	O	75	P
73	and	and	O	CC	O	75	NMOD
74	0.7	0.7	B-NP	CD	O	75	NMOD
75	mg/ml	mg/ml	I-NP	NN	O	76	DEP
76	)	)	O	)	O	63	NMOD
77	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	8	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	8	P
4	AZT-treated	AZT-treated	B-NP	JJ	O	7	NMOD
5	FasL	FasL	I-NP	NN	B-protein	7	NMOD
6	Tg	Tg	I-NP	NN	O	7	NMOD
7	mice	mouse	I-NP	NNS	O	8	SUB
8	developed	develop	B-VP	VBD	O	0	ROOT
9	cardiac	cardiac	B-NP	JJ	O	10	NMOD
10	dilation	dilation	I-NP	NN	O	8	OBJ
11	and	and	O	CC	O	8	VMOD
12	depressed	depress	B-VP	VBD	O	8	VMOD
13	cardiac	cardiac	B-NP	JJ	O	14	NMOD
14	function	function	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	a	a	B-NP	DT	O	18	NMOD
17	dose-dependent	dose-dependent	I-NP	JJ	O	18	NMOD
18	manner	manner	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	12	P
20	with	with	B-PP	IN	O	12	VMOD
21	concomitant	concomitant	B-NP	JJ	O	22	AMOD
22	inflammatory	inflammatory	I-NP	JJ	O	23	NMOD
23	infiltration	infiltration	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	both	both	B-NP	DT	O	26	NMOD
26	ventricles	ventricle	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	8	P

1	Valproate	Valproate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	chorea	chorea	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	encephalopathy	encephalopathy	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	atypical	atypical	B-NP	JJ	O	9	NMOD
8	nonketotic	nonketotic	I-NP	JJ	O	9	NMOD
9	hyperglycinemia	hyperglycinemia	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	2	P

1	Nonketotic	Nonketotic	B-NP	JJ	O	2	NMOD
2	hyperglycinemia	hyperglycinemia	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	5	NMOD
5	disorder	disorder	I-NP	NN	O	3	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	amino	amino	B-NP	JJ	O	9	NMOD
8	acid	acid	I-NP	NN	O	9	NMOD
9	metabolism	metabolism	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	5	NMOD
11	which	which	B-NP	WDT	O	10	PMOD
12	a	a	B-NP	DT	O	13	NMOD
13	defect	defect	I-NP	NN	O	19	SUB
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	18	NMOD
16	glycine	glycine	I-NP	NN	O	18	NMOD
17	cleavage	cleavage	I-NP	NN	O	18	NMOD
18	system	system	I-NP	NN	O	14	PMOD
19	leads	lead	B-VP	VBZ	O	10	SBAR
20	to	to	B-PP	TO	O	19	VMOD
21	an	an	B-NP	DT	O	22	NMOD
22	accumulation	accumulation	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	glycine	glycine	B-NP	NN	O	23	PMOD
25	in	in	B-PP	IN	O	22	NMOD
26	the	the	B-NP	DT	O	31	NMOD
27	brain	brain	I-NP	NN	O	31	NMOD
28	and	and	O	CC	O	31	NMOD
29	other	other	B-NP	JJ	O	31	NMOD
30	body	body	I-NP	NN	O	31	NMOD
31	compartments	compartment	I-NP	NNS	O	25	PMOD
32	.	.	O	.	O	3	P

1	Microinjection	Microinjection	B-NP	NN	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ritanserin	ritanserin	B-NP	NN	O	2	PMOD
4	into	into	B-PP	IN	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	CA1	CA1	I-NP	NN	B-DNA	7	NMOD
7	region	region	I-NP	NN	I-DNA	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	hippocampus	hippocampus	B-NP	NN	O	8	PMOD
10	improves	improve	B-VP	VBZ	O	0	ROOT
11	scopolamine	scopolamine	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	amnesia	amnesia	I-NP	NN	O	10	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	adult	adult	B-NP	JJ	O	17	NMOD
16	male	male	I-NP	JJ	O	17	NMOD
17	rats	rat	I-NP	NNS	O	14	PMOD
18	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ritanserin	ritanserin	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	8	DEP
6	5-HT2	5-HT2	B-NP	NN	O	7	NMOD
7	antagonist	antagonist	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	on	on	B-PP	IN	O	2	NMOD
10	scopolamine	scopolamine	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	15	DEP
12	muscarinic	muscarinic	B-NP	JJ	O	14	NMOD
13	cholinergic	cholinergic	I-NP	JJ	O	14	NMOD
14	antagonist	antagonist	I-NP	NN	O	15	DEP
15	)	)	O	)	O	10	NMOD
16	induced	induce	B-VP	VBD	O	0	ROOT
17	amnesia	amnesia	B-NP	NN	O	16	OBJ
18	in	in	B-PP	IN	O	16	VMOD
19	Morris	Morris	B-NP	NNP	O	21	NMOD
20	water	water	I-NP	NN	O	21	NMOD
21	maze	maze	I-NP	NN	O	18	PMOD
22	(	(	O	(	O	24	DEP
23	MWM	MWM	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	was	be	B-VP	VBD	O	16	VMOD
26	investigated	investigate	I-VP	VBN	O	25	VC
27	.	.	O	.	O	16	P

1	With	With	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	model	model	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	able	able	B-ADJP	JJ	O	6	PRD
8	to	to	B-VP	TO	O	9	VMOD
9	identify	identify	I-VP	VB	O	7	AMOD
10	diffuse	diffuse	B-NP	JJ	O	11	AMOD
11	cortical	cortical	I-NP	JJ	O	12	NMOD
12	hypoxia	hypoxia	I-NP	NN	O	9	OBJ
13	in	in	B-PP	IN	O	9	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	puromycin	puromycin	I-NP	NN	O	16	NMOD
16	aminonucleoside	aminonucleoside	I-NP	NN	O	19	NMOD
17	induced	induce	B-VP	VBD	O	16	AMOD
18	nephrotic	nephrotic	B-NP	JJ	O	19	NMOD
19	syndrome	syndrome	I-NP	NN	O	13	PMOD
20	and	and	O	CC	O	9	VMOD
21	focal	focal	B-NP	JJ	O	23	AMOD
22	and	and	I-NP	CC	O	23	AMOD
23	segmental	segmental	I-NP	JJ	O	24	NMOD
24	hypoxia	hypoxia	I-NP	NN	O	9	OBJ
25	in	in	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	29	NMOD
27	remnant	remnant	I-NP	NN	O	29	NMOD
28	kidney	kidney	I-NP	NN	O	29	NMOD
29	model	model	I-NP	NN	O	25	PMOD
30	.	.	O	.	O	6	P

1	Expression	Expression	B-NP	NN	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	hypoxia-responsive	hypoxia-responsive	I-NP	JJ	B-DNA	5	NMOD
5	transgene	transgene	I-NP	NN	I-DNA	2	PMOD
6	increased	increase	B-VP	VBD	O	0	ROOT
7	throughout	throughout	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	observation	observation	I-NP	NN	O	10	NMOD
10	period	period	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	6	P
12	reaching	reach	B-VP	VBG	O	6	VMOD
13	2.2-fold	2.2-fold	B-ADVP	RB	O	12	VMOD
14	at	at	B-PP	IN	O	12	VMOD
15	2	2	B-NP	CD	O	16	NMOD
16	weeks	week	I-NP	NNS	O	14	PMOD
17	in	in	B-PP	IN	O	12	VMOD
18	the	the	B-NP	DT	O	21	NMOD
19	puromycin	puromycin	I-NP	NN	O	21	NMOD
20	aminonucleoside	aminonucleoside	I-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	17	PMOD
22	and	and	O	CC	O	12	VMOD
23	2.6-fold	2.6-fold	B-ADVP	RB	O	24	PMOD
24	at	at	B-PP	IN	O	12	VMOD
25	4	4	B-NP	CD	O	26	NMOD
26	weeks	week	I-NP	NNS	O	24	PMOD
27	in	in	B-PP	IN	O	12	VMOD
28	the	the	B-NP	DT	O	31	NMOD
29	remnant	remnant	I-NP	NN	O	31	NMOD
30	kidney	kidney	I-NP	NN	O	31	NMOD
31	model	model	I-NP	NN	O	27	PMOD
32	,	,	O	,	O	6	P
33	whereas	whereas	O	IN	O	6	VMOD
34	that	that	B-NP	DT	O	40	SUB
35	of	of	B-PP	IN	O	34	NMOD
36	vascular	vascular	B-NP	JJ	B-protein	39	NMOD
37	endothelial	endothelial	I-NP	JJ	I-protein	39	NMOD
38	growth	growth	I-NP	NN	I-protein	39	NMOD
39	factor	factor	I-NP	NN	I-protein	35	PMOD
40	showed	show	B-VP	VBD	O	33	SBAR
41	a	a	B-NP	DT	O	43	NMOD
42	mild	mild	I-NP	JJ	O	43	NMOD
43	decrease	decrease	I-NP	NN	O	40	OBJ
44	,	,	O	,	O	40	P
45	reflecting	reflect	B-VP	VBG	O	40	VMOD
46	distinct	distinct	B-NP	JJ	O	47	NMOD
47	behaviors	behavior	I-NP	NNS	O	45	OBJ
48	of	of	B-PP	IN	O	47	NMOD
49	the	the	B-NP	DT	O	51	NMOD
50	two	two	I-NP	CD	O	51	NMOD
51	genes	gene	I-NP	NNS	O	48	PMOD
52	.	.	O	.	O	6	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	caution	caution	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	required	require	I-VP	VBN	O	4	VC
6	when	when	B-ADVP	WRB	O	13	DEP
7	cyclophosphamide	cyclophosphamide	B-NP	NN	O	9	NMOD
8	or	or	O	CC	O	9	NMOD
9	anthracyclines	anthracycline	B-NP	NNS	O	13	SUB
10	such	such	B-PP	JJ	O	11	PMOD
11	as	as	I-PP	IN	O	9	NMOD
12	mitoxantrone	mitoxantrone	B-NP	NN	O	11	PMOD
13	are	be	B-VP	VBP	O	5	VMOD
14	used	use	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	22	NMOD
19	possible	possible	I-NP	JJ	O	22	NMOD
20	underlying	underlie	I-NP	VBG	O	22	NMOD
21	heart	heart	I-NP	NN	O	22	NMOD
22	damage	damage	I-NP	NN	O	17	PMOD
23	,	,	O	,	O	13	P
24	for	for	B-PP	IN	O	13	VMOD
25	example	example	B-NP	NN	O	24	PMOD
26	,	,	O	,	O	13	P
27	systemic	systemic	B-NP	JJ	O	29	NMOD
28	sclerosis	sclerosis	I-NP	NN	O	29	NMOD
29	patients	patient	I-NP	NNS	O	13	PRD
30	.	.	O	.	O	4	P

1	Immunohistochemical	Immunohistochemical	B-NP	JJ	O	2	NMOD
2	study	study	I-NP	NN	O	0	ROOT
3	on	on	B-PP	IN	O	2	NMOD
4	inducible	inducible	B-NP	JJ	O	5	NMOD
5	type	type	I-NP	NN	O	23	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	nitric	nitric	B-NP	JJ	O	8	NMOD
8	oxide	oxide	I-NP	NN	O	6	PMOD
9	(	(	O	(	O	11	DEP
10	iNOS	iNOS	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	,	,	O	,	O	23	P
13	basic	basic	B-NP	JJ	B-protein	16	NMOD
14	fibroblast	fibroblast	I-NP	NN	I-protein	16	NMOD
15	growth	growth	I-NP	NN	I-protein	16	NMOD
16	factor	factor	I-NP	NN	I-protein	23	NMOD
17	(	(	O	(	O	19	DEP
18	bFGF	bFGF	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	and	and	O	CC	O	23	NMOD
21	tumor	tumor	B-NP	NN	B-protein	23	NMOD
22	growth	growth	I-NP	NN	I-protein	23	NMOD
23	factor-beta1	factor-beta1	I-NP	NN	I-protein	37	NMOD
24	(	(	O	(	O	26	DEP
25	TGF-beta1	TGF-beta1	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	in	in	B-PP	IN	O	23	NMOD
28	arteritis	arteritis	B-NP	NN	O	27	PMOD
29	induced	induce	B-VP	VBN	O	28	NMOD
30	in	in	B-PP	IN	O	29	VMOD
31	rats	rat	B-NP	NNS	O	30	PMOD
32	by	by	B-PP	IN	O	29	VMOD
33	fenoldopam	fenoldopam	B-NP	NN	O	35	NMOD
34	and	and	I-NP	CC	O	35	NMOD
35	theophylline	theophylline	I-NP	NN	O	32	PMOD
36	,	,	O	,	O	37	P
37	vasodilators	vasodilator	B-NP	NNS	O	3	PMOD
38	.	.	O	.	O	2	P

1	Arteritis	Arteritis	B-NP	NN	O	10	NMOD
2	induced	induce	B-VP	VBN	O	1	NMOD
3	in	in	B-PP	IN	O	2	VMOD
4	rats	rat	B-NP	NNS	O	3	PMOD
5	by	by	B-PP	IN	O	2	VMOD
6	vasodilators	vasodilator	B-NP	NNS	O	5	PMOD
7	,	,	O	,	O	10	P
8	fenoldopam	fenoldopam	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	theophylline	theophylline	I-NP	NN	O	12	SUB
11	,	,	O	,	O	10	P
12	was	be	B-VP	VBD	O	0	ROOT
13	examined	examine	I-VP	VBN	O	12	VC
14	immunohistochemically	immunohistochemically	B-ADVP	RB	O	13	VMOD
15	for	for	B-PP	IN	O	13	VMOD
16	expressions	expression	B-NP	NNS	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	inducible	inducible	B-NP	JJ	O	19	NMOD
19	type	type	I-NP	NN	O	31	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	nitric	nitric	B-NP	JJ	B-protein	23	NMOD
22	oxide	oxide	I-NP	NN	I-protein	23	NMOD
23	synthase	synthase	I-NP	NN	I-protein	20	PMOD
24	(	(	O	(	O	26	DEP
25	iNOS	iNOS	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	,	,	O	,	O	31	P
28	basic	basic	B-NP	JJ	B-protein	31	NMOD
29	fibroblast	fibroblast	I-NP	NN	I-protein	31	NMOD
30	growth	growth	I-NP	NN	I-protein	31	NMOD
31	factor	factor	I-NP	NN	I-protein	38	NMOD
32	(	(	O	(	O	34	DEP
33	bFGF	bFGF	B-NP	NN	B-protein	34	DEP
34	)	)	O	)	O	31	NMOD
35	and	and	O	CC	O	38	NMOD
36	tumor	tumor	B-NP	NN	B-protein	38	NMOD
37	growth	growth	I-NP	NN	I-protein	38	NMOD
38	factor-beta1	factor-beta1	I-NP	NN	I-protein	17	PMOD
39	(	(	O	(	O	41	DEP
40	TGF-beta1	TGF-beta1	B-NP	NN	B-protein	41	DEP
41	)	)	O	)	O	38	NMOD
42	.	.	O	.	O	12	P

1	Topiramate	Topiramate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	nephrolithiasis	nephrolithiasis	B-NP	NN	O	2	OBJ
4	.	.	O	.	O	2	P

1	Topiramate	Topiramate	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	7	NMOD
4	recently	recently	I-NP	RB	O	5	AMOD
5	developed	develop	I-NP	VBN	O	7	NMOD
6	antiepileptic	antiepileptic	I-NP	JJ	O	7	NMOD
7	medication	medication	I-NP	NN	O	2	PRD
8	that	that	B-NP	WDT	O	7	NMOD
9	is	be	B-VP	VBZ	O	8	SBAR
10	becoming	become	I-VP	VBG	O	9	VC
11	more	more	B-VP	RBR	O	12	AMOD
12	widely	widely	I-VP	RB	O	13	VMOD
13	prescribed	prescribe	I-VP	VBN	O	10	VC
14	because	because	B-PP	IN	O	13	VMOD
15	of	of	I-PP	IN	O	14	PMOD
16	its	its	B-NP	PRP$	O	17	NMOD
17	efficacy	efficacy	I-NP	NN	O	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	treating	treat	B-VP	VBG	O	18	PMOD
20	refractory	refractory	B-NP	JJ	O	21	NMOD
21	seizures	seizure	I-NP	NNS	O	19	OBJ
22	.	.	O	.	O	2	P

1	These	These	B-NP	DT	O	2	NMOD
2	factors	factor	I-NP	NNS	O	3	SUB
3	can	can	B-VP	MD	O	0	ROOT
4	lead	lead	I-VP	VB	O	3	VC
5	to	to	B-PP	TO	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	development	development	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	calcium	calcium	B-NP	NN	O	11	NMOD
10	phosphate	phosphate	I-NP	NN	O	11	NMOD
11	nephrolithiasis	nephrolithiasis	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	3	P

1	Spironolactone	Spironolactone	B-NP	NN	O	3	SUB
2	:	:	O	:	O	1	P
3	is	be	B-VP	VBZ	O	0	ROOT
4	it	it	B-NP	PRP	O	7	SUB
5	a	a	B-NP	DT	O	7	NMOD
6	novel	novel	I-NP	JJ	O	7	NMOD
7	drug	drug	I-NP	NN	O	3	PRD
8	for	for	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	prevention	prevention	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	amphotericin	amphotericin	B-NP	NN	O	14	NMOD
13	B-related	B-related	I-NP	JJ	O	14	NMOD
14	hypokalemia	hypokalemia	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	cancer	cancer	B-NP	NN	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Nephrotoxicity	Nephrotoxicity	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	major	major	I-NP	JJ	O	8	NMOD
7	adverse	adverse	I-NP	JJ	O	8	NMOD
8	effect	effect	I-NP	NN	O	4	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	amphotericin	amphotericin	B-NP	NN	O	11	NMOD
11	B	B	I-NP	NN	O	9	PMOD
12	(	(	O	(	O	14	DEP
13	AmB	AmB	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	,	,	O	,	O	4	P
16	often	often	B-ADVP	RB	O	17	VMOD
17	limiting	limit	B-VP	VBG	O	4	VMOD
18	administration	administration	B-NP	NN	O	17	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	full	full	B-NP	JJ	O	21	NMOD
21	dosage	dosage	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	4	P

1	Selective	Selective	B-NP	JJ	O	5	NMOD
2	distal	distal	I-NP	JJ	O	5	NMOD
3	tubular	tubular	I-NP	JJ	O	5	NMOD
4	epithelial	epithelial	I-NP	JJ	O	5	NMOD
5	toxicity	toxicity	I-NP	NN	O	6	SUB
6	seems	seem	B-VP	VBZ	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	be	be	I-VP	VB	O	6	VMOD
9	responsible	responsible	B-ADJP	JJ	O	8	PRD
10	for	for	B-PP	IN	O	9	AMOD
11	the	the	B-NP	DT	O	14	NMOD
12	profound	profound	I-NP	JJ	O	14	NMOD
13	potassium	potassium	I-NP	NN	O	14	NMOD
14	wasting	wasting	I-NP	NN	O	10	PMOD
15	that	that	B-NP	WDT	O	14	NMOD
16	is	be	B-VP	VBZ	O	15	SBAR
17	a	a	B-NP	DT	O	21	NMOD
18	major	major	I-NP	JJ	O	21	NMOD
19	clinical	clinical	I-NP	JJ	O	21	NMOD
20	side	side	I-NP	NN	O	21	NMOD
21	effect	effect	I-NP	NN	O	16	PRD
22	of	of	B-PP	IN	O	21	NMOD
23	treatment	treatment	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	AmB	AmB	B-NP	NN	B-protein	24	PMOD
26	.	.	O	.	O	6	P

1	Potassium	Potassium	B-NP	NN	O	2	NMOD
2	depletion	depletion	I-NP	NN	O	4	SUB
3	also	also	B-ADVP	RB	O	4	VMOD
4	potentiates	potentiate	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	tubular	tubular	I-NP	JJ	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	AmB	AmB	B-NP	NN	B-protein	8	PMOD
10	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	assess	assess	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	ability	ability	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	spironolactone	spironolactone	B-NP	NN	O	9	PMOD
11	to	to	B-VP	TO	O	12	VMOD
12	reduce	reduce	I-VP	VB	O	8	NMOD
13	potassium	potassium	B-NP	NN	O	14	NMOD
14	requirements	requirement	I-NP	NNS	O	12	OBJ
15	and	and	O	CC	O	12	VMOD
16	to	to	B-VP	TO	O	17	VMOD
17	prevent	prevent	I-VP	VB	O	12	VMOD
18	hypokalemia	hypokalemia	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	neutropenic	neutropenic	B-NP	JJ	O	21	NMOD
21	patients	patient	I-NP	NNS	O	19	PMOD
22	on	on	B-PP	IN	O	21	NMOD
23	AmB	AmB	B-NP	NN	B-protein	24	NMOD
24	treatment	treatment	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	1	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	7	NMOD
6	26	26	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	3	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	various	various	B-NP	JJ	O	11	NMOD
10	hematological	hematological	I-NP	JJ	O	11	NMOD
11	disorders	disorder	I-NP	NNS	O	8	PMOD
12	were	be	B-VP	VBD	O	3	SBAR
13	randomized	randomize	I-VP	VBN	O	12	VC
14	to	to	B-VP	TO	O	15	VMOD
15	receive	receive	I-VP	VB	O	13	VMOD
16	either	either	B-NP	CC	O	18	NMOD
17	intravenous	intravenous	I-NP	JJ	O	18	NMOD
18	AmB	AmB	I-NP	NN	O	21	NMOD
19	alone	alone	B-ADVP	RB	O	18	NMOD
20	or	or	O	CC	O	21	NMOD
21	AmB	AmB	B-NP	NN	B-protein	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	oral	oral	B-NP	JJ	O	24	NMOD
24	spironolactone	spironolactone	I-NP	NN	O	26	NMOD
25	100	100	B-NP	CD	O	26	NMOD
26	mg	mg	I-NP	NN	O	15	OBJ
27	twice	twice	B-ADVP	RB	O	29	DEP
28	daily	daily	I-ADVP	RB	O	27	AMOD
29	when	when	B-ADVP	WRB	O	15	VMOD
30	developing	develop	B-VP	VBG	O	29	SBAR
31	a	a	B-NP	DT	O	36	NMOD
32	proven	prove	I-NP	VBN	O	36	NMOD
33	or	or	I-NP	CC	O	36	NMOD
34	suspected	suspect	I-NP	VBN	O	36	NMOD
35	fungal	fungal	I-NP	JJ	O	36	NMOD
36	infection	infection	I-NP	NN	O	30	OBJ
37	.	.	O	.	O	1	P

1	Dopamine	Dopamine	B-NP	NN	O	11	SUB
2	(	(	O	(	O	4	DEP
3	DA	DA	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	,	,	O	,	O	1	P
6	through	through	B-PP	IN	O	1	NMOD
7	D1/D2	D1/D2	B-NP	NN	O	9	NMOD
8	receptor-mediated	receptor-mediated	I-NP	JJ	O	9	NMOD
9	signaling	signaling	I-NP	NN	O	6	PMOD
10	,	,	O	,	O	1	P
11	plays	play	B-VP	VBZ	O	0	ROOT
12	a	a	B-NP	DT	O	14	NMOD
13	major	major	I-NP	JJ	O	14	NMOD
14	role	role	I-NP	NN	O	11	OBJ
15	in	in	B-PP	IN	O	11	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	control	control	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	epileptic	epileptic	B-NP	JJ	O	20	NMOD
20	seizures	seizure	I-NP	NNS	O	18	PMOD
21	arising	arise	B-VP	VBG	O	20	NMOD
22	in	in	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	limbic	limbic	I-NP	JJ	O	25	NMOD
25	system	system	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	respect	respect	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	little	little	B-NP	JJ	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	known	know	I-VP	VBN	O	6	VC
8	about	about	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	10	NMOD
10	role	role	I-NP	NN	O	19	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	DA	DA	B-NP	NN	B-protein	13	NMOD
13	receptors	receptor	I-NP	NNS	I-protein	11	PMOD
14	in	in	B-PP	IN	O	10	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	occurrence	occurrence	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	epilepsy	epilepsy	B-NP	NN	O	17	PMOD
19	induced	induce	B-VP	VBD	O	8	SBAR
20	neuronal	neuronal	B-NP	JJ	B-cell_type	22	NMOD
21	cell	cell	I-NP	NN	I-cell_type	22	NMOD
22	death	death	I-NP	NN	O	19	OBJ
23	.	.	O	.	O	6	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	analyze	analyze	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	occurrence	occurrence	I-NP	NN	O	9	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	seizures	seizure	B-NP	NNS	O	6	PMOD
8	and	and	O	CC	O	9	NMOD
9	neurotoxicity	neurotoxicity	B-NP	NN	O	3	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	D2R	D2R	B-NP	NN	B-protein	13	NMOD
12	-/-	-/-	I-NP	JJ	O	13	NMOD
13	mice	mouse	I-NP	NNS	O	10	PMOD
14	treated	treat	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	19	NMOD
17	cholinergic	cholinergic	I-NP	JJ	O	19	NMOD
18	agonist	agonist	I-NP	NN	O	19	NMOD
19	pilocarpine	pilocarpine	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	3	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	pilocarpine	pilocarpine	B-NP	NN	O	5	NMOD
4	induced	induced	I-NP	JJ	O	5	NMOD
5	seizures	seizure	I-NP	NNS	O	6	SUB
6	result	result	B-VP	VBP	O	0	ROOT
7	in	in	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	12	NMOD
9	more	more	I-NP	RBR	O	10	AMOD
10	widespread	widespread	I-NP	JJ	O	12	NMOD
11	neuronal	neuronal	I-NP	JJ	O	12	NMOD
12	death	death	I-NP	NN	O	7	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	both	both	O	CC	O	19	NMOD
15	WT	WT	B-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	D2R	D2R	B-NP	NN	B-protein	19	NMOD
18	-/-	-/-	I-NP	JJ	O	19	NMOD
19	brains	brain	I-NP	NNS	O	13	PMOD
20	in	in	B-PP	IN	O	6	VMOD
21	comparison	comparison	B-NP	NN	O	20	PMOD
22	to	to	B-PP	TO	O	21	NMOD
23	KA	KA	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	6	P

1	Thus	Thus	B-ADVP	RB	O	7	VMOD
2	,	,	O	,	O	7	P
3	the	the	B-NP	DT	O	4	NMOD
4	absence	absence	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	D2R	D2R	B-NP	NN	B-protein	5	PMOD
7	lowers	lower	B-VP	VBZ	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	threshold	threshold	I-NP	NN	O	7	OBJ
10	for	for	B-PP	IN	O	7	VMOD
11	seizures	seizure	B-NP	NNS	O	10	PMOD
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	both	both	O	CC	O	17	NMOD
15	glutamate	glutamate	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	acetylcholine	acetylcholine	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	7	P

1	Treatment	Treatment	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	risperidone	risperidone	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	4	OBJ
6	with	with	B-PP	IN	O	4	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	dopamine	dopamine	I-NP	NN	O	9	NMOD
9	agonist	agonist	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	children	child	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Risperidone	Risperidone	B-NP	NN	O	7	NMOD
4	,	,	O	,	O	7	P
5	a	a	B-NP	DT	O	7	NMOD
6	potent	potent	I-NP	JJ	O	7	NMOD
7	antagonist	antagonist	I-NP	NN	O	18	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	both	both	O	CC	O	17	NMOD
10	serotonergic	serotonergic	O	JJ	O	17	NMOD
11	(	(	O	(	O	13	DEP
12	5HT2A	5HT2A	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	and	and	O	CC	O	17	NMOD
15	dopaminergic	dopaminergic	B-NP	JJ	B-protein	17	NMOD
16	D2	D2	I-NP	NN	I-protein	17	NMOD
17	receptors	receptor	I-NP	NNS	I-protein	8	PMOD
18	is	be	B-VP	VBZ	O	1	NMOD
19	associated	associate	I-VP	VBN	O	18	VC
20	with	with	B-PP	IN	O	19	VMOD
21	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	20	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	adults	adult	B-NP	NNS	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	children	child	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	18	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	successful	successful	I-NP	JJ	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	risperidone	risperidone	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	2	VMOD
9	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	8	OBJ
10	with	with	B-PP	IN	O	9	NMOD
11	cabergoline	cabergoline	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	youth	youth	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	undertook	undertake	B-VP	VBD	O	14	VMOD
5	a	a	B-NP	DT	O	8	NMOD
6	retrospective	retrospective	I-NP	JJ	O	8	NMOD
7	case	case	I-NP	NN	O	8	NMOD
8	review	review	I-NP	NN	O	14	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	four	four	B-NP	CD	O	11	NMOD
11	children	child	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	risperidone	risperidone	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	1	NMOD
15	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	14	OBJ
16	treated	treat	B-VP	VBN	O	15	NMOD
17	with	with	B-PP	IN	O	16	VMOD
18	cabergoline	cabergoline	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Four	Four	B-NP	CD	O	4	NMOD
4	males	male	I-NP	NNS	O	44	SUB
5	(	(	O	(	O	9	DEP
6	age	age	B-NP	NN	O	8	NMOD
7	6-11	6-11	B-NP	CD	O	8	NMOD
8	years	year	I-NP	NNS	O	9	DEP
9	)	)	O	)	O	4	NMOD
10	with	with	B-PP	IN	O	4	NMOD
11	Diagnostic	Diagnostic	B-NP	NNP	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	Statistical	Statistical	I-NP	NNP	O	14	NMOD
14	Manual	Manual	I-NP	NNP	O	10	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	Mental	Mental	B-NP	NNP	O	17	NMOD
17	Disorders	Disorders	I-NP	NNP	O	15	PMOD
18	(	(	O	(	O	21	DEP
19	fourth	fourth	B-NP	JJ	O	20	NMOD
20	edition	edition	I-NP	NN	O	21	DEP
21	)	)	I-NP	)	O	17	NMOD
22	bipolar	bipolar	I-NP	JJ	O	23	NMOD
23	disorder	disorder	I-NP	NN	O	17	NMOD
24	or	or	I-NP	CC	O	17	NMOD
25	psychoses	psychos	I-NP	NNS	O	17	NMOD
26	,	,	O	,	O	4	P
27	with	with	B-PP	IN	O	4	NMOD
28	risperidone	risperidone	B-NP	NN	O	30	NMOD
29	induced	induce	I-NP	VBN	O	30	NMOD
30	elevations	elevation	I-NP	NNS	O	27	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	serum	serum	B-NP	NN	O	34	NMOD
33	prolactin	prolactin	I-NP	NN	O	34	NMOD
34	levels	level	I-NP	NNS	O	31	PMOD
35	(	(	O	(	O	42	DEP
36	57.5-129	57.5-129	B-NP	CD	O	37	NMOD
37	ng/mL	ng/mL	I-NP	NN	O	41	NMOD
38	,	,	O	,	O	37	P
39	normal	normal	B-ADVP	JJ	O	41	NMOD
40	5-15	5-15	B-NP	CD	O	41	NMOD
41	ng/mL	ng/mL	I-NP	NN	O	42	DEP
42	)	)	O	)	O	34	NMOD
43	,	,	O	,	O	4	P
44	were	be	B-VP	VBD	O	1	NMOD
45	treated	treat	I-VP	VBN	O	44	VC
46	with	with	B-PP	IN	O	45	VMOD
47	cabergoline	cabergoline	B-NP	NN	O	46	PMOD
48	(	(	O	(	O	55	DEP
49	mean	mean	B-NP	JJ	O	50	NMOD
50	dose	dose	I-NP	NN	O	54	NMOD
51	2.13	2.13	I-NP	CD	O	53	AMOD
52	+/-	+/-	I-NP	SYM	O	53	AMOD
53	0.09	0.09	I-NP	CD	O	54	NMOD
54	mg/week	mg/week	I-NP	NN	O	55	DEP
55	)	)	O	)	O	45	VMOD
56	.	.	O	.	O	1	P

1	Cholestatic	Cholestatic	B-NP	JJ	O	2	NMOD
2	jaundice	jaundice	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	use	use	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	metformin	metformin	B-NP	NN	O	7	PMOD
9	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	who	who	B-NP	WP	O	4	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	cholestatic	cholestatic	B-NP	JJ	O	8	NMOD
8	jaundice	jaundice	I-NP	NN	O	6	OBJ
9	shortly	shortly	B-ADVP	RB	O	10	PMOD
10	after	after	B-PP	IN	O	6	VMOD
11	initiation	initiation	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	treatment	treatment	B-NP	NN	O	12	PMOD
14	with	with	B-PP	IN	O	11	NMOD
15	metformin	metformin	B-NP	NN	O	16	NMOD
16	hydrochloride	hydrochloride	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	Metformin	Metformin	B-NP	NN	O	2	NMOD
2	hydrochloride	hydrochloride	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	11	VMOD
4	discontinued	discontinue	I-VP	VBN	O	3	VC
5	,	,	O	,	O	11	P
6	and	and	O	CC	O	10	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	patient	patient	I-NP	NN	O	10	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	jaundice	jaundice	I-NP	NN	O	11	SUB
11	resolved	resolve	B-VP	VBD	O	0	ROOT
12	slowly	slowly	B-ADVP	RB	O	11	VMOD
13	over	over	B-PP	IN	O	11	VMOD
14	a	a	B-NP	DT	O	15	NMOD
15	period	period	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	several	several	B-NP	JJ	O	18	NMOD
18	months	month	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	11	P

1	Electro-oculography	Electro-oculography	B-NP	NN	O	11	NMOD
2	,	,	O	,	O	11	P
3	electroretinography	electroretinography	B-NP	NN	O	11	NMOD
4	,	,	O	,	O	11	P
5	visual	visual	B-NP	JJ	O	7	NMOD
6	evoked	evoked	I-NP	JJ	O	7	NMOD
7	potentials	potential	I-NP	NNS	O	11	NMOD
8	,	,	O	,	O	11	P
9	and	and	O	CC	O	11	NMOD
10	multifocal	multifocal	B-NP	JJ	O	11	NMOD
11	electroretinography	electroretinography	I-NP	NN	O	0	ROOT
12	in	in	B-PP	IN	O	11	NMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	vigabatrin-attributed	vigabatrin-attributed	B-NP	JJ	O	18	NMOD
16	visual	visual	I-NP	JJ	O	18	NMOD
17	field	field	I-NP	NN	O	18	NMOD
18	constriction	constriction	I-NP	NN	O	14	PMOD
19	.	.	O	.	O	11	P

1	PURPOSE	PURPOSE	B-NP	NN	O	6	NMOD
2	:	:	O	:	O	1	P
3	Symptomatic	Symptomatic	B-NP	JJ	O	6	NMOD
4	visual	visual	I-NP	JJ	O	6	NMOD
5	field	field	I-NP	NN	O	6	NMOD
6	constriction	constriction	I-NP	NN	O	13	SUB
7	thought	think	B-VP	VBN	O	6	NMOD
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	7	VMOD
10	associated	associate	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	vigabatrin	vigabatrin	B-NP	NN	O	11	PMOD
13	has	have	B-VP	VBZ	O	0	ROOT
14	been	be	I-VP	VBN	O	13	VC
15	reported	report	I-VP	VBN	O	14	VC
16	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	3	NMOD
2	current	current	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	investigated	investigate	B-VP	VBD	O	24	VMOD
5	the	the	B-NP	DT	O	10	NMOD
6	visual	visual	I-NP	JJ	O	7	NMOD
7	fields	field	I-NP	NNS	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	visual	visual	B-NP	JJ	O	10	NMOD
10	electrophysiology	electrophysiology	I-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	eight	eight	B-NP	CD	O	13	NMOD
13	patients	patient	I-NP	NNS	O	11	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	known	known	B-NP	JJ	O	19	NMOD
16	vigabatrin-attributed	vigabatrin-attributed	I-NP	JJ	O	19	NMOD
17	visual	visual	I-NP	JJ	O	19	NMOD
18	field	field	I-NP	NN	O	19	NMOD
19	loss	loss	I-NP	NN	O	14	PMOD
20	,	,	O	,	O	4	P
21	three	three	B-NP	CD	O	24	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	whom	whom	B-NP	WP	O	22	PMOD
24	were	be	B-VP	VBD	O	0	ROOT
25	reported	report	I-VP	VBN	O	24	VC
26	previously	previously	B-ADVP	RB	O	25	VMOD
27	.	.	O	.	O	24	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Marked	Mark	B-NP	VBN	O	6	NMOD
4	visual	visual	I-NP	JJ	O	6	NMOD
5	field	field	I-NP	NN	O	6	NMOD
6	constriction	constriction	I-NP	NN	O	7	SUB
7	appears	appear	B-VP	VBZ	O	1	NMOD
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	7	VMOD
10	associated	associate	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	vigabatrin	vigabatrin	B-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	aim	aim	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	is	be	B-VP	VBZ	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	evaluate	evaluate	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	12	NMOD
12	effects	effect	I-NP	NNS	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	RAPA	RAPA	B-NP	NN	O	15	NMOD
15	conversion	conversion	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	12	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	undergoing	undergo	B-VP	VBG	O	17	NMOD
19	cyclosporine	cyclosporine	B-NP	NN	O	24	NMOD
20	(	(	O	(	O	22	DEP
21	CsA	CsA	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	or	or	O	CC	O	24	NMOD
24	tacrolimus	tacrolimus	B-NP	NN	O	28	NMOD
25	(	(	O	(	O	27	DEP
26	Tac	Tac	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	toxicity	toxicity	B-NP	NN	O	18	OBJ
29	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	indications	indication	I-NP	NNS	O	5	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	switch	switch	B-NP	NN	O	3	PMOD
5	were	be	B-VP	VBD	O	44	VMOD
6	chronic	chronic	B-NP	JJ	O	10	NMOD
7	CsA	CsA	I-NP	NN	O	10	NMOD
8	or	or	O	CC	O	10	NMOD
9	Tac	Tac	B-NP	NN	O	10	NMOD
10	nephrotoxicity	nephrotoxicity	I-NP	NN	O	19	NMOD
11	(	(	O	(	O	13	DEP
12	12	12	B-NP	CD	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	,	,	O	,	O	19	P
15	acute	acute	B-NP	JJ	O	16	NMOD
16	CsA	CsA	I-NP	NN	O	19	NMOD
17	or	or	O	CC	O	19	NMOD
18	Tac	Tac	B-NP	NN	O	19	NMOD
19	toxicity	toxicity	I-NP	NN	O	26	NMOD
20	(	(	O	(	O	22	DEP
21	3	3	B-NP	CD	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	,	,	O	,	O	26	P
24	severe	severe	B-NP	JJ	O	26	NMOD
25	facial	facial	I-NP	JJ	O	26	NMOD
26	dysmorphism	dysmorphism	I-NP	NN	O	33	NMOD
27	(	(	O	(	O	29	DEP
28	2	2	B-NP	CD	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	,	,	O	,	O	33	P
31	posttransplant	posttransplant	B-NP	JJ	O	33	NMOD
32	lymphoproliferative	lymphoproliferative	I-NP	JJ	O	33	NMOD
33	disorder	disorder	I-NP	NN	O	5	PRD
34	(	(	O	(	O	36	DEP
35	PTLD	PTLD	B-NP	NN	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	in	in	B-PP	IN	O	33	NMOD
38	remission	remission	B-NP	NN	O	37	PMOD
39	(	(	O	(	O	41	DEP
40	2	2	B-NP	CD	O	41	DEP
41	)	)	O	)	O	37	PMOD
42	,	,	O	,	O	44	P
43	and	and	O	CC	O	44	NMOD
44	hepatotoxicity	hepatotoxicity	B-NP	NN	O	0	ROOT
45	in	in	B-PP	IN	O	44	NMOD
46	1	1	B-NP	CD	O	45	PMOD
47	.	.	O	.	O	44	P

1	RESULTS	RESULTS	B-NP	NNS	O	13	SUB
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	13	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	12	12	I-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	3	PMOD
7	switched	switch	B-VP	VBD	O	13	VMOD
8	because	because	B-PP	IN	O	13	VMOD
9	of	of	I-PP	IN	O	8	PMOD
10	chronic	chronic	B-NP	JJ	O	11	NMOD
11	nephrotoxicity	nephrotoxicity	I-NP	NN	O	13	SUB
12	there	there	B-NP	EX	O	13	SUB
13	was	be	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	16	NMOD
15	significant	significant	I-NP	JJ	O	16	NMOD
16	decrease	decrease	I-NP	NN	O	24	NMOD
17	in	in	B-PP	IN	O	16	NMOD
18	serum	serum	B-NP	NN	O	19	NMOD
19	creatinine	creatinine	I-NP	NN	O	17	PMOD
20	[	[	O	(	O	24	NMOD
21	233+/-34	233+/-34	B-NP	CD	O	23	AMOD
22	to	to	O	TO	O	23	AMOD
23	210+/-56	210+/-56	B-NP	CD	O	24	NMOD
24	micromol/liter	micromol/liter	I-NP	NN	O	13	PRD
25	(	(	O	(	O	29	DEP
26	P	P	B-NP	NN	O	29	DEP
27	<	<	B-NP	SYM	O	26	NMOD
28	0.05	0.05	I-NP	CD	O	27	AMOD
29	)	)	O	)	O	24	NMOD
30	at	at	B-PP	IN	O	13	VMOD
31	6	6	B-NP	CD	O	32	NMOD
32	months	month	I-NP	NNS	O	30	PMOD
33	]	]	O	)	O	13	VMOD
34	.	.	O	.	O	13	P

1	RAPA	RAPA	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	discontinued	discontinue	I-VP	VBN	O	2	VC
4	in	in	B-PP	IN	O	3	VMOD
5	four	four	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	,	,	O	,	O	3	P
8	because	because	B-PP	IN	O	3	VMOD
9	of	of	I-PP	IN	O	8	PMOD
10	pneumonia	pneumonia	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	3	VMOD
12	two	two	B-NP	CD	O	11	PMOD
13	,	,	O	,	O	21	P
14	PTLD	PTLD	B-NP	NN	O	21	NMOD
15	in	in	B-PP	IN	O	14	NMOD
16	one	one	B-NP	CD	O	15	PMOD
17	,	,	O	,	O	21	P
18	and	and	O	CC	O	21	NMOD
19	oral	oral	B-NP	JJ	O	21	NMOD
20	aphtous	aphtous	I-NP	JJ	O	21	NMOD
21	ulcers	ulcer	I-NP	NNS	O	2	VMOD
22	in	in	B-PP	IN	O	21	NMOD
23	one	one	B-NP	CD	O	22	PMOD
24	.	.	O	.	O	2	P

1	Worsening	Worsening	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	levodopa	levodopa	B-NP	NN	O	5	NMOD
4	induced	induce	I-NP	VBN	O	5	NMOD
5	dyskinesias	dyskinesia	I-NP	NNS	O	2	PMOD
6	by	by	B-PP	IN	O	1	NMOD
7	motor	motor	B-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	mental	mental	B-NP	JJ	O	10	NMOD
10	tasks	task	I-NP	NNS	O	6	PMOD
11	.	.	O	.	O	1	P

1	Ten	Ten	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	11	SUB
3	who	who	B-NP	WP	O	2	NMOD
4	had	have	B-VP	VBD	O	3	SBAR
5	Parkinson	Parkinson	B-NP	NNP	O	7	NMOD
6	's	's	B-NP	POS	O	7	NMOD
7	disease	disease	I-NP	NN	O	4	OBJ
8	with	with	B-PP	IN	O	4	VMOD
9	disabling	disable	B-NP	VBG	O	10	NMOD
10	dyskinesia	dyskinesia	I-NP	NN	O	8	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	included	include	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	this	this	B-NP	DT	O	15	NMOD
15	study	study	I-NP	NN	O	13	PMOD
16	to	to	B-VP	TO	O	17	VMOD
17	evaluate	evaluate	I-VP	VB	O	12	VMOD
18	the	the	B-NP	DT	O	19	NMOD
19	role	role	I-NP	NN	O	17	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	mental	mental	O	JJ	O	27	NMOD
22	(	(	O	(	O	25	DEP
23	mental	mental	B-NP	JJ	O	24	NMOD
24	calculation	calculation	I-NP	NN	O	25	DEP
25	)	)	O	)	O	21	NMOD
26	and	and	O	CC	O	27	NMOD
27	motor	motor	B-NP	NN	O	47	NMOD
28	(	(	O	(	O	46	DEP
29	flexion/extension	flexion/extension	B-NP	NN	O	34	NMOD
30	of	of	B-PP	IN	O	29	NMOD
31	right	right	B-NP	JJ	O	32	NMOD
32	fingers	finger	I-NP	NNS	O	30	PMOD
33	,	,	O	,	O	34	P
34	flexion/extension	flexion/extension	B-NP	NN	O	39	NMOD
35	of	of	B-PP	IN	O	34	NMOD
36	left	left	B-NP	JJ	B-protein	37	NMOD
37	fingers	finger	I-NP	NNS	I-protein	35	PMOD
38	,	,	O	,	O	39	P
39	flexion/extension	flexion/extension	B-NP	NN	O	46	DEP
40	of	of	B-PP	IN	O	39	NMOD
41	the	the	B-NP	DT	O	42	NMOD
42	neck	neck	I-NP	NN	O	40	PMOD
43	,	,	O	,	O	39	P
44	speaking	speak	B-VP	VBG	O	39	NMOD
45	aloud	aloud	B-ADVP	RB	O	44	VMOD
46	)	)	O	)	O	27	NMOD
47	tasks	task	B-NP	NNS	O	20	PMOD
48	on	on	B-PP	IN	O	19	NMOD
49	the	the	B-NP	DT	O	50	NMOD
50	worsening	worsening	I-NP	NN	O	48	PMOD
51	of	of	B-PP	IN	O	50	NMOD
52	peak-dose	peak-dose	B-NP	JJ	O	53	NMOD
53	dyskinesia	dyskinesia	I-NP	NN	O	51	PMOD
54	following	follow	B-PP	VBG	O	17	VMOD
55	administration	administration	B-NP	NN	O	54	PMOD
56	of	of	B-PP	IN	O	55	NMOD
57	an	an	B-NP	DT	O	60	NMOD
58	effective	effective	I-NP	JJ	O	59	AMOD
59	single	single	I-NP	JJ	O	60	NMOD
60	dose	dose	I-NP	NN	O	56	PMOD
61	of	of	B-PP	IN	O	60	NMOD
62	apomorphine	apomorphine	B-NP	NN	O	61	PMOD
63	.	.	O	.	O	11	P

1	Structural	Structural	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	functional	functional	I-NP	JJ	O	4	NMOD
4	impairment	impairment	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	mitochondria	mitochondrion	B-NP	NNS	O	5	PMOD
7	in	in	B-PP	IN	O	4	NMOD
8	adriamycin	adriamycin	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	cardiomyopathy	cardiomyopathy	B-NP	NN	O	9	OBJ
11	in	in	B-PP	IN	O	9	VMOD
12	mice	mouse	B-NP	NNS	O	11	PMOD
13	:	:	O	:	O	9	P
14	suppression	suppression	B-NP	NN	O	9	VMOD
15	of	of	B-PP	IN	O	14	NMOD
16	cytochrome	cytochrome	B-NP	NN	B-DNA	20	NMOD
17	c	c	I-NP	NN	I-DNA	20	NMOD
18	oxidase	oxidase	I-NP	NN	I-DNA	20	NMOD
19	II	II	I-NP	CD	I-DNA	20	NMOD
20	gene	gene	I-NP	NN	I-DNA	21	NMOD
21	expression	expression	I-NP	NN	O	15	PMOD
22	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	use	use	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	adriamycin	adriamycin	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	7	DEP
6	ADR	ADR	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	in	in	B-PP	IN	O	2	NMOD
9	cancer	cancer	B-NP	NN	O	10	NMOD
10	chemotherapy	chemotherapy	I-NP	NN	O	8	PMOD
11	has	have	B-VP	VBZ	O	0	ROOT
12	been	be	I-VP	VBN	O	11	VC
13	limited	limit	I-VP	VBN	O	12	VC
14	due	due	B-ADJP	JJ	O	15	PMOD
15	to	to	B-PP	TO	O	13	VMOD
16	its	its	B-NP	PRP$	O	19	NMOD
17	cumulative	cumulative	I-NP	JJ	O	19	NMOD
18	cardiovascular	cardiovascular	I-NP	JJ	O	19	NMOD
19	toxicity	toxicity	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	11	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicated	indicate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	1	1	B-LST	LS	O	7	NMOD
6	)	)	O	)	O	5	DEP
7	treatment	treatment	B-NP	NN	O	12	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	mice	mouse	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	7	NMOD
11	ADR	ADR	B-NP	NN	B-protein	10	PMOD
12	caused	cause	B-VP	VBD	O	4	SBAR
13	cardiovascular	cardiovascular	B-NP	JJ	O	14	NMOD
14	arrhythmias	arrhythmia	I-NP	NNS	O	12	OBJ
15	characterized	characterize	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	bradycardia	bradycardia	B-NP	NN	O	19	NMOD
18	,	,	O	,	O	19	P
19	extension	extension	B-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	ventricular	ventricular	B-NP	JJ	O	23	NMOD
22	depolarization	depolarization	I-NP	NN	O	23	NMOD
23	time	time	I-NP	NN	O	20	PMOD
24	(	(	O	(	O	26	DEP
25	tQRS	tQRS	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	,	,	O	,	O	29	P
28	and	and	O	CC	O	29	NMOD
29	failure	failure	B-NP	NN	O	49	SUB
30	of	of	B-PP	IN	O	29	NMOD
31	QRS	QRS	B-NP	NN	B-protein	30	PMOD
32	at	at	B-PP	IN	O	29	NMOD
33	high	high	B-NP	JJ	O	34	NMOD
34	concentrations	concentration	I-NP	NNS	O	32	PMOD
35	(	(	O	(	O	42	DEP
36	10-14	10-14	B-NP	CD	O	41	NMOD
37	mg/kg	mg/kg	I-NP	NN	O	41	NMOD
38	body	body	I-NP	NN	O	41	NMOD
39	weight	weight	I-NP	NN	O	41	NMOD
40	cumulative	cumulative	I-NP	JJ	O	41	NMOD
41	dose	dose	I-NP	NN	O	42	DEP
42	)	)	O	)	O	34	NMOD
43	;	;	O	:	O	49	P
44	2	2	B-LST	LS	O	49	VMOD
45	)	)	O	)	O	44	DEP
46	the	the	B-NP	DT	O	48	NMOD
47	heart	heart	I-NP	NN	O	48	NMOD
48	mitochondria	mitochondrion	I-NP	NNS	O	49	SUB
49	underwent	undergo	B-VP	VBD	O	12	VMOD
50	swelling	swelling	B-NP	NN	O	57	NMOD
51	,	,	O	,	O	57	P
52	fusion	fusion	B-NP	NN	O	57	NMOD
53	,	,	O	,	O	57	P
54	dissolution	dissolution	B-NP	NN	O	57	NMOD
55	,	,	O	,	O	57	P
56	and/or	and/or	O	CC	O	57	NMOD
57	disruption	disruption	B-NP	NN	O	49	OBJ
58	of	of	B-PP	IN	O	57	NMOD
59	mitochondrial	mitochondrial	B-NP	JJ	O	60	NMOD
60	cristae	crista	I-NP	NNS	O	58	PMOD
61	after	after	B-PP	IN	O	49	VMOD
62	several	several	B-NP	JJ	O	63	NMOD
63	weeks	week	I-NP	NNS	O	61	PMOD
64	of	of	B-PP	IN	O	63	NMOD
65	treatment	treatment	B-NP	NN	O	64	PMOD
66	.	.	O	.	O	3	P

1	Enhanced	Enhance	B-NP	VBN	O	2	NMOD
2	bradycardia	bradycardia	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	beta-adrenoceptor	beta-adrenoceptor	B-NP	NN	O	6	NMOD
6	antagonists	antagonist	I-NP	NNS	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	pretreated	pretreate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	isoniazid	isoniazid	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	2	P

1	High	High	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	isoniazid	isoniazid	B-NP	NN	O	6	NMOD
5	increase	increase	I-NP	NN	O	6	NMOD
6	hypotension	hypotension	I-NP	NN	O	3	PMOD
7	induced	induce	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	vasodilators	vasodilator	B-NP	NNS	O	8	PMOD
10	and	and	O	CC	O	2	VMOD
11	change	change	B-VP	VB	O	2	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	accompanying	accompany	I-NP	VBG	O	15	NMOD
14	reflex	reflex	I-NP	NN	O	15	NMOD
15	tachycardia	tachycardia	I-NP	NN	O	11	OBJ
16	to	to	B-PP	TO	O	11	VMOD
17	bradycardia	bradycardia	B-NP	NN	O	20	NMOD
18	,	,	O	,	O	20	P
19	an	an	B-NP	DT	O	20	NMOD
20	interaction	interaction	I-NP	NN	O	16	PMOD
21	attributed	attribute	B-VP	VBN	O	20	NMOD
22	to	to	B-PP	TO	O	21	VMOD
23	decreased	decrease	B-NP	VBN	O	24	NMOD
24	synthesis	synthesis	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	brain	brain	B-NP	NN	O	28	NMOD
27	gamma-aminobutyric	gamma-aminobutyric	I-NP	JJ	O	28	NMOD
28	acid	acid	I-NP	NN	O	25	PMOD
29	(	(	O	(	O	31	DEP
30	GABA	GABA	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	17	P
6	the	the	B-NP	DT	O	8	NMOD
7	possible	possible	I-NP	JJ	O	8	NMOD
8	enhancement	enhancement	I-NP	NN	O	17	SUB
9	by	by	B-PP	IN	O	8	NMOD
10	isoniazid	isoniazid	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	bradycardia	bradycardia	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	beta-adrenoceptor	beta-adrenoceptor	B-NP	NN	O	16	NMOD
16	antagonists	antagonist	I-NP	NNS	O	14	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	determined	determine	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	anaesthetised	anaesthetise	B-VP	VBN	O	20	NMOD
22	with	with	B-PP	IN	O	21	VMOD
23	chloralose-urethane	chloralose-urethane	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	17	P

1	Isoniazid	Isoniazid	B-NP	NN	O	3	SUB
2	significantly	significantly	B-ADVP	RB	O	3	VMOD
3	increased	increase	B-VP	VBD	O	0	ROOT
4	bradycardia	bradycardia	B-NP	NN	O	3	OBJ
5	after	after	B-PP	IN	O	3	VMOD
6	propranolol	propranolol	B-NP	NN	O	12	NMOD
7	,	,	O	,	O	12	P
8	pindolol	pindolol	B-NP	NN	O	12	NMOD
9	,	,	O	,	O	12	P
10	labetalol	labetalol	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	atenolol	atenolol	I-NP	NN	O	5	PMOD
13	,	,	O	,	O	3	P
14	as	as	B-CONJP	RB	O	3	VMOD
15	well	well	I-CONJP	RB	O	14	DEP
16	as	as	I-CONJP	IN	O	14	DEP
17	after	after	B-PP	IN	O	14	PMOD
18	clonidine	clonidine	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	3	P
20	but	but	O	CC	O	3	VMOD
21	not	not	B-PP	RB	O	3	VMOD
22	after	after	I-PP	IN	O	3	VMOD
23	hexamethonium	hexamethonium	B-NP	NN	O	25	NMOD
24	or	or	I-NP	CC	O	25	NMOD
25	carbachol	carbachol	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	3	P

1	Epileptogenic	Epileptogenic	B-NP	JJ	O	2	NMOD
2	activity	activity	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	folic	folic	B-NP	JJ	O	5	NMOD
5	acid	acid	I-NP	NN	O	3	PMOD
6	after	after	B-SBAR	IN	O	2	NMOD
7	drug	drug	B-NP	NN	O	8	SUB
8	induces	induce	B-VP	VBZ	O	6	SBAR
9	SLE	SLE	B-NP	NN	O	16	NMOD
10	(	(	O	(	O	15	DEP
11	folic	folic	B-NP	JJ	O	12	NMOD
12	acid	acid	I-NP	NN	O	14	NMOD
13	and	and	O	CC	O	14	NMOD
14	epilepsy	epilepsy	B-NP	NN	O	15	DEP
15	)	)	O	)	O	9	NMOD
16	OBJECTIVE	OBJECTIVE	B-NP	NN	O	8	OBJ
17	:	:	O	:	O	2	P
18	To	To	B-VP	TO	O	19	VMOD
19	study	study	I-VP	VB	O	2	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	effect	effect	I-NP	NN	O	19	OBJ
22	of	of	B-PP	IN	O	21	NMOD
23	folic	folic	B-NP	JJ	O	26	NMOD
24	acid-containing	acid-containing	I-NP	JJ	O	26	NMOD
25	multivitamin	multivitamin	I-NP	NN	O	26	NMOD
26	supplementation	supplementation	I-NP	NN	O	22	PMOD
27	in	in	B-PP	IN	O	21	NMOD
28	epileptic	epileptic	B-NP	JJ	O	29	NMOD
29	women	woman	I-NP	NNS	O	27	PMOD
30	before	before	B-PP	IN	O	19	VMOD
31	and	and	I-PP	CC	O	30	PMOD
32	during	during	I-PP	IN	O	30	PMOD
33	pregnancy	pregnancy	B-NP	NN	O	30	PMOD
34	in	in	B-SBAR	IN	O	19	VMOD
35	order	order	O	NN	O	34	DEP
36	to	to	B-VP	TO	O	37	VMOD
37	determine	determine	I-VP	VB	O	34	SBAR
38	the	the	B-NP	DT	O	39	NMOD
39	rate	rate	I-NP	NN	O	37	OBJ
40	of	of	B-PP	IN	O	39	NMOD
41	structural	structural	B-NP	JJ	O	43	NMOD
42	birth	birth	I-NP	NN	O	43	NMOD
43	defects	defect	I-NP	NNS	O	47	NMOD
44	and	and	O	CC	O	47	NMOD
45	epilepsy-related	epilepsy-related	B-NP	JJ	O	47	NMOD
46	side	side	I-NP	NN	O	47	NMOD
47	effects	effect	I-NP	NNS	O	40	PMOD
48	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Of	Of	B-PP	IN	O	21	VMOD
4	60	60	B-NP	CD	O	6	NMOD
5	epileptic	epileptic	I-NP	JJ	O	6	NMOD
6	women	woman	I-NP	NNS	O	3	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	periconceptional	periconceptional	B-NP	JJ	O	10	NMOD
9	folic	folic	I-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	17	NMOD
11	(	(	O	(	O	14	DEP
12	0.8	0.8	B-NP	CD	O	13	NMOD
13	mg	mg	I-NP	NN	O	14	DEP
14	)	)	O	)	O	10	NMOD
15	-containing	-containing	B-NP	JJ	O	17	NMOD
16	multivitamin	multivitamin	I-NP	NN	O	17	NMOD
17	supplementation	supplementation	I-NP	NN	O	7	PMOD
18	,	,	O	,	O	21	P
19	no	no	B-NP	DT	O	20	NMOD
20	one	one	I-NP	NN	O	21	SUB
21	developed	develop	B-VP	VBD	O	1	NMOD
22	epilepsy-related	epilepsy-related	B-NP	JJ	O	24	NMOD
23	side	side	I-NP	NN	O	24	NMOD
24	effects	effect	I-NP	NNS	O	21	OBJ
25	during	during	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	periconception	periconception	I-NP	NN	O	28	NMOD
28	period	period	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	4	NMOD
2	22-year-old	22-year-old	I-NP	JJ	O	4	NMOD
3	epileptic	epileptic	I-NP	JJ	O	4	NMOD
4	woman	woman	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	treated	treat	I-VP	VBN	O	5	VC
7	continuously	continuously	B-ADVP	RB	O	6	VMOD
8	by	by	B-PP	IN	O	6	VMOD
9	carbamazepine	carbamazepine	B-NP	NN	O	13	NMOD
10	and	and	O	CC	O	13	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	folic	folic	I-NP	JJ	O	13	NMOD
13	acid	acid	I-NP	NN	O	19	NMOD
14	(	(	O	(	O	17	DEP
15	1	1	B-NP	CD	O	16	NMOD
16	mg	mg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	-containing	-containing	B-NP	JJ	O	19	NMOD
19	multivitamin	multivitamin	I-NP	NN	O	8	PMOD
20	from	from	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	20th	20th	I-NP	JJ	O	23	NMOD
23	week	week	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	gestation	gestation	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	5	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	9	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	9	NMOD
4	epileptic	epileptic	I-NP	JJ	O	9	NMOD
5	pregnant	pregnant	I-NP	JJ	O	9	NMOD
6	patient	patient	I-NP	NN	O	9	NMOD
7	's	's	B-NP	POS	O	9	NMOD
8	autoimmune	autoimmune	I-NP	JJ	O	9	NMOD
9	disease	disease	I-NP	NN	O	16	SUB
10	(	(	O	(	O	15	DEP
11	probably	probably	B-ADVP	RB	O	15	DEP
12	drug	drug	B-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	lupus	lupus	I-NP	NN	O	15	DEP
15	)	)	O	)	O	9	NMOD
16	could	could	B-VP	MD	O	35	VMOD
17	damage	damage	I-VP	VB	O	35	VMOD
18	the	the	B-NP	DT	O	20	NMOD
19	blood-brain	blood-brain	I-NP	NN	O	20	NMOD
20	barrier	barrier	I-NP	NN	O	17	OBJ
21	,	,	O	,	O	17	P
22	therefore	therefore	B-ADVP	RB	O	17	VMOD
23	the	the	B-NP	DT	O	25	NMOD
24	therapeutic	therapeutic	I-NP	JJ	O	25	NMOD
25	dose	dose	I-NP	NN	O	35	SUB
26	(	(	O	(	O	31	DEP
27	>	>	B-NP	SYM	O	30	NMOD
28	or	or	O	CC	O	30	NMOD
29	=1	=1	B-NP	CD	O	30	NMOD
30	mg	mg	I-NP	NN	O	31	DEP
31	)	)	O	)	O	25	NMOD
32	of	of	B-PP	IN	O	25	NMOD
33	folic	folic	B-NP	JJ	O	34	NMOD
34	acid	acid	I-NP	NN	O	32	PMOD
35	triggered	trigger	B-VP	VBD	O	0	ROOT
36	a	a	B-NP	DT	O	37	NMOD
37	cluster	cluster	I-NP	NN	O	35	OBJ
38	of	of	B-PP	IN	O	37	NMOD
39	seizures	seizure	B-NP	NNS	O	38	PMOD
40	.	.	O	.	O	35	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	cisapride	cisapride	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	symptoms	symptom	B-NP	NNS	O	10	NMOD
6	and	and	O	CC	O	10	NMOD
7	postcibal	postcibal	B-NP	JJ	O	10	NMOD
8	small-bowel	small-bowel	I-NP	JJ	O	10	NMOD
9	motor	motor	I-NP	NN	O	10	NMOD
10	function	function	I-NP	NN	O	4	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	irritable	irritable	B-NP	JJ	O	16	NMOD
15	bowel	bowel	I-NP	NN	O	16	NMOD
16	syndrome	syndrome	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	1	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	aim	aim	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	to	to	B-VP	TO	O	5	VMOD
5	assess	assess	I-VP	VB	O	3	PRD
6	the	the	B-NP	DT	O	7	NMOD
7	effects	effect	I-NP	NNS	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	long-term	long-term	B-NP	JJ	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	with	with	B-PP	IN	O	5	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	prokinetic	prokinetic	I-NP	JJ	O	14	NMOD
14	agent	agent	I-NP	NN	O	16	NMOD
15	,	,	O	,	O	16	P
16	cisapride	cisapride	B-NP	NN	O	11	PMOD
17	,	,	O	,	O	5	P
18	on	on	B-PP	IN	O	5	VMOD
19	postprandial	postprandial	B-NP	JJ	O	21	NMOD
20	jejunal	jejunal	I-NP	JJ	O	21	NMOD
21	motility	motility	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	symptoms	symptom	I-NP	NNS	O	18	PMOD
24	in	in	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	28	NMOD
26	irritable	irritable	I-NP	JJ	O	28	NMOD
27	bowel	bowel	I-NP	NN	O	28	NMOD
28	syndrome	syndrome	I-NP	NN	O	24	PMOD
29	(	(	O	(	O	31	DEP
30	IBS	IBS	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Thirty-eight	Thirty-eight	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	NMOD
5	with	with	B-PP	IN	O	4	NMOD
6	IBS	IBS	B-NP	NN	B-protein	5	PMOD
7	(	(	O	(	O	6	NMOD
8	constipation-predominant	constipation-predominant	B-ADJP	JJ	O	20	VMOD
9	,	,	O	,	O	20	P
10	n	n	B-NP	NN	O	20	SUB
11	=	=	B-VP	SYM	O	10	NMOD
12	17	17	B-NP	CD	O	11	AMOD
13	;	;	O	:	O	20	P
14	diarrhoea-predominant	diarrhoea-predominant	B-NP	JJ	O	20	SUB
15	,	,	I-NP	,	O	20	P
16	n	n	I-NP	NN	O	20	SUB
17	=	=	B-VP	SYM	O	16	NMOD
18	21	21	B-NP	CD	O	17	AMOD
19	)	)	O	)	O	16	NMOD
20	underwent	undergo	B-VP	VBD	O	7	SBAR
21	24-h	24-h	B-NP	JJ	O	24	NMOD
22	ambulatory	ambulatory	I-NP	JJ	O	24	NMOD
23	jejunal	jejunal	I-NP	JJ	O	24	NMOD
24	manometry	manometry	I-NP	NN	O	20	OBJ
25	before	before	B-PP	IN	O	20	VMOD
26	and	and	I-PP	CC	O	25	PMOD
27	after	after	I-PP	IN	O	25	PMOD
28	12	12	B-NP	CD	O	31	NMOD
29	week	week	I-NP	NN	O	30	NMOD
30	's	's	B-NP	POS	O	31	NMOD
31	treatment	treatment	I-NP	NN	O	46	NMOD
32	[	[	O	(	O	46	NMOD
33	cisapride	cisapride	B-NP	NN	O	36	NMOD
34	,	,	O	,	O	36	P
35	5	5	B-NP	CD	O	36	AMOD
36	mg	mg	I-NP	NN	O	46	NMOD
37	three	three	B-NP	CD	O	36	NMOD
38	times	time	I-NP	NNS	O	37	NMOD
39	daily	daily	I-NP	JJ	O	38	NMOD
40	(	(	O	(	O	44	DEP
41	n	n	B-NP	NN	O	44	DEP
42	=	=	B-VP	SYM	O	41	NMOD
43	19	19	B-NP	CD	O	42	AMOD
44	)	)	O	)	O	39	NMOD
45	or	or	O	CC	O	46	NMOD
46	placebo	placebo	B-NP	NN	O	25	PMOD
47	(	(	O	(	O	51	DEP
48	n	n	B-NP	NN	O	51	DEP
49	=	=	B-VP	SYM	O	48	NMOD
50	19	19	B-NP	CD	O	49	AMOD
51	)	)	O	)	O	46	NMOD
52	]	]	O	)	O	46	NMOD
53	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	11	VMOD
4	diarrhoea-predominant	diarrhoea-predominant	B-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	significant	significant	B-NP	JJ	O	7	NMOD
7	differences	difference	I-NP	NNS	O	3	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	contraction	contraction	B-NP	NN	O	10	NMOD
10	characteristics	characteristic	I-NP	NNS	O	8	PMOD
11	were	be	B-VP	VBD	O	1	NMOD
12	observed	observe	I-VP	VBN	O	11	VC
13	between	between	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	18	NMOD
15	cisapride	cisapride	I-NP	NN	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	placebo	placebo	I-NP	NN	O	18	NMOD
18	groups	group	I-NP	NNS	O	13	PMOD
19	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	9	VMOD
2	cisapride-treated	cisapride-treated	B-NP	JJ	O	4	NMOD
3	diarrhoea-predominant	diarrhoea-predominant	I-NP	JJ	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	PMOD
5	the	the	B-NP	DT	O	8	NMOD
6	mean	mean	I-NP	JJ	O	8	NMOD
7	contraction	contraction	I-NP	NN	O	8	NMOD
8	amplitude	amplitude	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	0	ROOT
10	higher	high	B-ADJP	JJR	O	24	NMOD
11	(	(	O	(	O	24	NMOD
12	29.3	29.3	B-NP	CD	O	14	NMOD
13	+/-	+/-	I-NP	SYM	O	14	NMOD
14	3.2	3.2	I-NP	CD	O	20	NMOD
15	versus	versus	B-PP	IN	O	20	NMOD
16	24.9	24.9	B-NP	CD	O	18	AMOD
17	+/-	+/-	I-NP	SYM	O	18	AMOD
18	2.6	2.6	I-NP	CD	O	20	NMOD
19	mm	mm	I-NP	NN	O	20	NMOD
20	Hg	Hg	I-NP	NN	O	24	NMOD
21	,	,	O	,	O	24	P
22	cisapride	cisapride	B-NP	NN	O	24	NMOD
23	versus	versus	O	CC	O	24	NMOD
24	placebo	placebo	B-NP	NN	O	37	NMOD
25	(	(	O	(	O	29	DEP
26	P	P	B-NP	NN	O	28	SUB
27	<	<	O	SYM	O	28	VMOD
28	0.001	0.001	B-NP	CD	O	29	DEP
29	)	)	O	)	O	24	NMOD
30	;	;	O	:	O	37	P
31	pretreatment	pretreatment	B-NP	NN	O	37	NMOD
32	,	,	O	,	O	37	P
33	25.7	25.7	B-NP	CD	O	35	AMOD
34	+/-	+/-	I-NP	SYM	O	35	AMOD
35	6.0	6.0	I-NP	CD	O	37	NMOD
36	mm	mm	I-NP	NN	O	37	NMOD
37	Hg	Hg	I-NP	NN	O	38	DEP
38	)	)	O	)	O	9	VMOD
39	,	,	O	,	O	9	P
40	the	the	B-NP	DT	O	43	NMOD
41	mean	mean	I-NP	JJ	O	43	NMOD
42	contraction	contraction	I-NP	NN	O	43	NMOD
43	duration	duration	I-NP	NN	O	57	NMOD
44	longer	longer	B-ADVP	RB	O	57	NMOD
45	(	(	O	(	O	57	NMOD
46	3.4	3.4	B-NP	CD	O	48	AMOD
47	+/-	+/-	I-NP	SYM	O	48	AMOD
48	0.2	0.2	I-NP	CD	O	53	NMOD
49	versus	versus	B-PP	IN	O	53	NMOD
50	3.0	3.0	B-NP	CD	O	52	AMOD
51	+/-	+/-	I-NP	SYM	O	52	AMOD
52	0.2	0.2	I-NP	CD	O	53	NMOD
53	sec	sec	I-NP	NN	O	57	NMOD
54	,	,	O	,	O	57	P
55	cisapride	cisapride	B-NP	NN	O	57	NMOD
56	versus	versus	O	CC	O	57	NMOD
57	placebo	placebo	B-NP	NN	O	9	PRD
58	(	(	O	(	O	62	DEP
59	P	P	B-NP	NN	O	61	SUB
60	<	<	O	SYM	O	61	VMOD
61	0.001	0.001	B-NP	CD	O	62	DEP
62	)	)	O	)	O	57	NMOD
63	;	;	O	:	O	9	P
64	pretreatment	pretreatment	B-NP	NN	O	69	NMOD
65	,	,	O	,	O	69	P
66	3.1	3.1	B-NP	CD	O	68	AMOD
67	+/-	+/-	I-NP	SYM	O	68	AMOD
68	0.5	0.5	I-NP	CD	O	69	NMOD
69	sec	sec	I-NP	NN	O	90	NMOD
70	)	)	O	)	O	69	NMOD
71	,	,	O	,	O	90	P
72	and	and	O	CC	O	90	NMOD
73	the	the	B-NP	DT	O	76	NMOD
74	mean	mean	I-NP	JJ	O	76	NMOD
75	contraction	contraction	I-NP	NN	O	76	NMOD
76	frequency	frequency	I-NP	NN	O	90	NMOD
77	lower	low	B-ADVP	JJR	O	90	NMOD
78	(	(	O	(	O	90	NMOD
79	2.0	2.0	B-NP	CD	O	81	AMOD
80	+/-	+/-	I-NP	SYM	O	81	AMOD
81	0.2	0.2	I-NP	CD	O	86	NMOD
82	versus	versus	B-PP	IN	O	86	NMOD
83	2.5	2.5	B-NP	CD	O	85	AMOD
84	+/-	+/-	I-NP	SYM	O	85	AMOD
85	0.4	0.4	I-NP	CD	O	86	NMOD
86	cont./min	cont./min	I-NP	NN	O	90	NMOD
87	,	,	O	,	O	90	P
88	cisapride	cisapride	B-NP	NN	O	90	NMOD
89	versus	versus	O	CC	O	90	NMOD
90	placebo	placebo	B-NP	NN	O	102	NMOD
91	(	(	O	(	O	95	DEP
92	P	P	B-NP	NN	O	94	SUB
93	<	<	O	SYM	O	94	VMOD
94	0.001	0.001	B-NP	CD	O	95	DEP
95	)	)	O	)	O	90	NMOD
96	;	;	O	:	O	102	P
97	pretreatment	pretreatment	B-NP	NN	O	102	NMOD
98	,	,	O	,	O	102	P
99	2.5	2.5	B-NP	CD	O	101	AMOD
100	+/-	+/-	I-NP	SYM	O	101	AMOD
101	1.1	1.1	I-NP	CD	O	102	NMOD
102	cont./min	cont./min	I-NP	NN	O	9	VMOD
103	]	]	O	)	O	102	NMOD
104	than	than	B-PP	IN	O	102	AMOD
105	patients	patient	B-NP	NNS	O	104	PMOD
106	treated	treat	B-VP	VBN	O	105	NMOD
107	with	with	B-PP	IN	O	106	VMOD
108	placebo	placebo	B-NP	NN	O	107	PMOD
109	.	.	O	.	O	9	P

1	Symptom	Symptom	B-NP	NN	O	2	NMOD
2	scores	score	I-NP	NNS	O	9	SUB
3	relating	relate	B-VP	VBG	O	2	NMOD
4	to	to	B-PP	TO	O	3	VMOD
5	the	the	B-NP	DT	O	6	NMOD
6	severity	severity	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	constipation	constipation	B-NP	NN	O	7	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	lower	low	B-ADJP	JJR	O	9	PRD
11	in	in	B-PP	IN	O	9	VMOD
12	cisapride-treated	cisapride-treated	B-NP	JJ	O	15	NMOD
13	constipation-predominant	constipation-predominant	I-NP	JJ	O	15	NMOD
14	IBS	IBS	I-NP	NN	O	15	NMOD
15	patients	patient	I-NP	NNS	O	30	NMOD
16	[	[	O	(	O	30	NMOD
17	score	score	B-NP	NN	O	21	NMOD
18	,	,	O	,	O	17	P
19	54	54	B-NP	CD	O	21	NMOD
20	+/-	+/-	I-NP	SYM	O	21	NMOD
21	5	5	I-NP	CD	O	26	NMOD
22	versus	versus	B-PP	IN	O	26	NMOD
23	67	67	B-NP	CD	O	25	AMOD
24	+/-	+/-	I-NP	SYM	O	25	AMOD
25	14	14	I-NP	CD	O	26	NMOD
26	mm	mm	I-NP	NN	O	30	NMOD
27	,	,	O	,	O	30	P
28	cisapride	cisapride	B-NP	NN	O	30	NMOD
29	versus	versus	O	CC	O	30	NMOD
30	placebo	placebo	B-NP	NN	O	11	PMOD
31	(	(	O	(	O	35	DEP
32	P	P	B-NP	NN	O	35	DEP
33	<	<	O	SYM	O	32	NMOD
34	0.05	0.05	B-NP	CD	O	33	AMOD
35	)	)	O	)	O	30	NMOD
36	;	;	O	:	O	9	P
37	pretreatment	pretreatment	B-NP	NN	O	42	NMOD
38	,	,	O	,	O	42	P
39	62	62	B-NP	CD	O	41	AMOD
40	+/-	+/-	I-NP	SYM	O	41	AMOD
41	19	19	I-NP	CD	O	42	NMOD
42	mm	mm	I-NP	NN	O	43	DEP
43	]	]	O	)	O	9	VMOD
44	.	.	O	.	O	9	P

1	Diarrhoea-predominant	Diarrhoea-predominant	B-NP	JJ	O	3	NMOD
2	IBS	IBS	I-NP	NN	O	3	NMOD
3	patients	patient	I-NP	NNS	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	8	NMOD
6	higher	high	I-NP	JJR	O	8	NMOD
7	pain	pain	I-NP	NN	O	8	NMOD
8	score	score	I-NP	NN	O	4	OBJ
9	after	after	B-PP	IN	O	4	VMOD
10	cisapride	cisapride	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	9	PMOD
12	[	[	O	(	O	26	NMOD
13	score	score	B-NP	NN	O	22	NMOD
14	,	,	O	,	O	13	P
15	55	55	B-NP	CD	O	17	AMOD
16	+/-	+/-	I-NP	SYM	O	17	AMOD
17	15	15	I-NP	CD	O	22	NMOD
18	versus	versus	I-NP	IN	O	22	NMOD
19	34	34	I-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	12	12	I-NP	CD	O	22	NMOD
22	mm	mm	I-NP	NN	O	26	NMOD
23	,	,	O	,	O	26	P
24	cisapride	cisapride	B-NP	NN	O	26	NMOD
25	versus	versus	O	CC	O	26	NMOD
26	placebo	placebo	B-NP	NN	O	4	OBJ
27	(	(	O	(	O	31	DEP
28	P	P	B-NP	NN	O	31	DEP
29	<	<	O	SYM	O	28	NMOD
30	0.05	0.05	B-NP	CD	O	29	AMOD
31	)	)	O	)	O	26	NMOD
32	;	;	O	:	O	4	P
33	pretreatment	pretreatment	B-NP	NN	O	38	NMOD
34	,	,	O	,	O	38	P
35	67	67	B-NP	CD	O	37	AMOD
36	+/-	+/-	I-NP	SYM	O	37	AMOD
37	19	19	I-NP	CD	O	38	NMOD
38	mm	mm	I-NP	NN	O	39	DEP
39	]	]	O	)	O	4	VMOD
40	.	.	O	.	O	4	P

1	Clarithromycin	Clarithromycin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	ventricular	ventricular	B-NP	JJ	O	4	NMOD
4	tachycardia	tachycardia	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	29	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	side-effect	side-effect	I-NP	JJ	O	4	NMOD
4	profile	profile	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	erythromycin	erythromycin	B-NP	NN	O	5	PMOD
7	is	be	B-VP	VBZ	O	1	SBAR
8	established	establish	I-VP	VBN	O	7	VC
9	,	,	O	,	O	29	P
10	including	include	B-PP	VBG	O	29	VMOD
11	gastroenteritis	gastroenteritis	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	interactions	interaction	I-NP	NNS	O	29	SUB
14	with	with	B-PP	IN	O	13	NMOD
15	other	other	B-NP	JJ	O	16	NMOD
16	drugs	drug	I-NP	NNS	O	14	PMOD
17	subject	subject	B-ADJP	JJ	O	16	NMOD
18	to	to	B-PP	TO	O	17	AMOD
19	hepatic	hepatic	B-NP	JJ	B-protein	22	NMOD
20	mixed-function	mixed-function	I-NP	JJ	I-protein	22	NMOD
21	oxidase	oxidase	I-NP	NN	I-protein	22	NMOD
22	metabolism	metabolism	I-NP	NN	O	18	PMOD
23	,	,	O	,	O	29	P
24	experience	experience	B-NP	NN	O	29	SUB
25	with	with	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	newer	new	I-NP	JJR	O	28	NMOD
28	macrolides	macrolide	I-NP	NNS	O	25	PMOD
29	is	be	B-VP	VBZ	O	0	ROOT
30	still	still	I-VP	RB	O	29	VMOD
31	being	be	I-VP	VBG	O	29	VC
32	recorded	record	I-VP	VBN	O	31	VC
33	.	.	O	.	O	29	P

1	Cardiotoxicity	Cardiotoxicity	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	demonstrated	demonstrate	I-VP	VBN	O	3	VC
5	after	after	B-PP	IN	O	4	VMOD
6	both	both	B-NP	CC	O	9	AMOD
7	intravenous	intravenous	I-NP	JJ	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	oral	oral	I-NP	JJ	O	10	NMOD
10	administration	administration	I-NP	NN	O	5	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	erythromycin	erythromycin	B-NP	NN	O	11	PMOD
13	but	but	O	CC	O	2	VMOD
14	has	have	B-VP	VBZ	O	2	VMOD
15	never	never	I-VP	RB	O	14	VMOD
16	been	be	I-VP	VBN	O	14	VC
17	reported	report	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	21	NMOD
20	newer	new	I-NP	JJR	O	21	NMOD
21	macrolides	macrolide	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	ventricular	ventricular	B-NP	JJ	O	7	NMOD
7	dysrhythmias	dysrhythmia	I-NP	NNS	O	5	PMOD
8	that	that	B-NP	WDT	O	7	NMOD
9	occurred	occur	B-VP	VBD	O	8	SBAR
10	after	after	B-SBAR	IN	O	9	VMOD
11	six	six	B-NP	CD	O	13	NMOD
12	therapeutic	therapeutic	I-NP	JJ	O	13	NMOD
13	doses	dose	I-NP	NNS	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	clarithromycin	clarithromycin	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	2	P

1	Persistent	Persistent	B-NP	JJ	O	4	NMOD
2	nephrogenic	nephrogenic	I-NP	JJ	O	4	NMOD
3	diabetes	diabetes	I-NP	NN	O	4	NMOD
4	insipidus	insipidus	I-NP	NN	O	0	ROOT
5	following	follow	B-PP	VBG	O	4	NMOD
6	lithium	lithium	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	4	P

1	Ten	Ten	B-NP	CD	O	2	NMOD
2	years	year	I-NP	NNS	O	5	SUB
3	previously	previously	B-ADVP	RB	O	5	VMOD
4	he	he	B-NP	PRP	O	5	SUB
5	had	have	B-VP	VBD	O	19	VMOD
6	been	be	I-VP	VBN	O	5	VC
7	diagnosed	diagnose	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	have	have	I-VP	VB	O	7	VMOD
10	lithium	lithium	B-NP	NN	O	14	NMOD
11	induced	induced	I-NP	JJ	O	14	NMOD
12	nephrogenic	nephrogenic	I-NP	JJ	O	14	NMOD
13	diabetes	diabetes	I-NP	NN	O	14	NMOD
14	insipidus	insipidus	I-NP	NN	O	9	OBJ
15	,	,	O	,	O	19	P
16	and	and	O	CC	O	19	VMOD
17	lithium	lithium	B-NP	NN	O	18	NMOD
18	therapy	therapy	I-NP	NN	O	19	SUB
19	had	have	B-VP	VBD	O	0	ROOT
20	been	be	I-VP	VBN	O	19	VC
21	discontinued	discontinue	I-VP	VBN	O	20	VC
22	.	.	O	.	O	19	P

1	He	He	B-NP	PRP	O	2	SUB
2	remained	remain	B-VP	VBD	O	0	ROOT
3	thirsty	thirsty	B-ADJP	JJ	O	5	AMOD
4	and	and	I-ADJP	CC	O	5	AMOD
5	polyuric	polyuric	I-ADJP	JJ	O	2	PRD
6	despite	despite	B-PP	IN	O	2	VMOD
7	cessation	cessation	B-NP	NN	O	11	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	lithium	lithium	B-NP	NN	O	8	PMOD
10	and	and	I-NP	CC	O	11	NMOD
11	investigations	investigation	I-NP	NNS	O	6	PMOD
12	on	on	B-PP	IN	O	11	NMOD
13	admission	admission	B-NP	NN	O	12	PMOD
14	showed	show	B-VP	VBD	O	2	VMOD
15	him	him	B-NP	PRP	O	17	SUB
16	to	to	B-VP	TO	O	17	VMOD
17	have	have	I-VP	VB	O	14	VMOD
18	normal	normal	B-NP	JJ	O	19	AMOD
19	osmoregulated	osmoregulated	I-NP	JJ	O	23	NMOD
20	thirst	thirst	I-NP	NN	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	vasopressin	vasopressin	I-NP	NN	O	23	NMOD
23	secretion	secretion	I-NP	NN	O	17	OBJ
24	,	,	O	,	O	17	P
25	with	with	B-PP	IN	O	17	VMOD
26	clear	clear	B-NP	JJ	O	27	NMOD
27	evidence	evidence	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	nephrogenic	nephrogenic	B-NP	JJ	O	31	NMOD
30	diabetes	diabetes	I-NP	NN	O	31	NMOD
31	insipidus	insipidus	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	2	P

1	Lithium	Lithium	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	6	VMOD
3	nephrogenic	nephrogenic	B-NP	JJ	O	5	NMOD
4	diabetes	diabetes	I-NP	NN	O	5	NMOD
5	insipidus	insipidus	I-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	0	ROOT
7	considered	consider	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	be	be	I-VP	VB	O	7	VMOD
10	reversible	reversible	B-ADJP	JJ	O	9	PRD
11	on	on	B-PP	IN	O	10	AMOD
12	cessation	cessation	B-NP	NN	O	16	NMOD
13	of	of	B-PP	IN	O	12	NMOD
14	therapy	therapy	B-NP	NN	O	13	PMOD
15	but	but	O	CC	O	16	NMOD
16	polyuria	polyuria	B-NP	NN	O	11	PMOD
17	persisted	persist	B-VP	VBD	O	6	VMOD
18	in	in	B-PP	IN	O	17	VMOD
19	this	this	B-NP	DT	O	20	NMOD
20	patient	patient	I-NP	NN	O	18	PMOD
21	for	for	B-PP	IN	O	20	NMOD
22	ten	ten	B-NP	CD	O	23	NMOD
23	years	year	I-NP	NNS	O	21	PMOD
24	after	after	B-SBAR	IN	O	20	NMOD
25	lithium	lithium	B-NP	NN	O	24	PMOD
26	was	be	B-VP	VBD	O	17	VMOD
27	stopped	stop	I-VP	VBN	O	26	VC
28	.	.	O	.	O	6	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	function	function	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	assessed	assess	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	long-term	long-term	B-NP	JJ	O	7	NMOD
7	survivors	survivor	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	malignant	malignant	B-NP	JJ	B-cell_type	11	NMOD
10	bone	bone	I-NP	NN	I-cell_type	11	NMOD
11	tumors	tumor	I-NP	NNS	I-cell_type	26	NMOD
12	who	who	B-NP	WP	O	11	NMOD
13	were	be	B-VP	VBD	O	12	SBAR
14	treated	treat	I-VP	VBN	O	13	VC
15	according	accord	B-PP	VBG	O	14	VMOD
16	to	to	B-PP	TO	O	15	PMOD
17	Rosen	Rosen	B-NP	NNP	O	18	NMOD
18	's	's	B-NP	POS	O	22	NMOD
19	T5	T5	I-NP	NN	O	22	NMOD
20	or	or	I-NP	CC	O	22	NMOD
21	T10	T10	I-NP	NN	O	22	NMOD
22	protocol	protocol	I-NP	NN	O	16	PMOD
23	,	,	O	,	O	26	P
24	both	both	B-NP	DT	O	26	NMOD
25	including	include	I-NP	VBG	O	26	NMOD
26	doxorubicin	doxorubicin	I-NP	NN	O	8	PMOD
27	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	doxorubicin	doxorubicin	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	cardiotoxicity	cardiotoxicity	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	high	high	B-ADJP	JJ	O	7	PRD
9	and	and	O	CC	O	7	VMOD
10	increases	increase	B-VP	VBZ	O	7	VMOD
11	with	with	B-PP	IN	O	10	VMOD
12	follow-up	follow-up	B-NP	JJ	O	11	PMOD
13	,	,	I-NP	,	O	12	P
14	irrespective	irrespective	I-NP	JJ	O	12	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	cumulative	cumulative	B-NP	JJ	O	17	NMOD
17	dose	dose	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	7	P

1	Venous	Venous	B-NP	JJ	O	2	NMOD
2	complications	complication	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	midazolam	midazolam	B-NP	NN	O	6	NMOD
5	versus	versus	B-PP	IN	O	6	NMOD
6	diazepam	diazepam	B-NP	NN	O	3	PMOD
7	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	22	VMOD
2	some	some	B-NP	DT	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	1	SBAR
5	suggested	suggest	I-VP	VBN	O	4	VC
6	fewer	few	B-NP	JJR	O	8	NMOD
7	venous	venous	I-NP	JJ	O	8	NMOD
8	complications	complication	I-NP	NNS	O	9	SUB
9	are	be	B-VP	VBP	O	5	VMOD
10	associated	associate	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	midazolam	midazolam	B-NP	NN	O	11	PMOD
13	than	than	B-PP	IN	O	10	VMOD
14	with	with	B-PP	IN	O	13	PMOD
15	diazepam	diazepam	B-NP	NN	O	14	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	endoscopic	endoscopic	B-NP	JJ	O	18	NMOD
18	procedures	procedure	I-NP	NNS	O	16	PMOD
19	,	,	O	,	O	22	P
20	this	this	B-NP	DT	O	21	NMOD
21	variable	variable	I-NP	NN	O	22	SUB
22	has	have	B-VP	VBZ	O	0	ROOT
23	not	not	I-VP	RB	O	22	VMOD
24	been	be	I-VP	VBN	O	22	VC
25	well	well	B-ADJP	RB	O	24	VMOD
26	documented	document	I-ADJP	VBN	O	24	VC
27	.	.	O	.	O	22	P

1	We	We	B-NP	PRP	O	3	SUB
2	prospectively	prospectively	B-ADVP	RB	O	3	VMOD
3	evaluated	evaluate	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	incidence	incidence	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	venous	venous	B-NP	JJ	O	8	NMOD
8	complications	complication	I-NP	NNS	O	6	PMOD
9	after	after	B-PP	IN	O	5	NMOD
10	intravenous	intravenous	B-NP	JJ	O	11	NMOD
11	injection	injection	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	diazepam	diazepam	B-NP	NN	O	15	NMOD
14	or	or	I-NP	CC	O	15	NMOD
15	midazolam	midazolam	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	11	NMOD
17	122	122	B-NP	CD	O	19	NMOD
18	consecutive	consecutive	I-NP	JJ	O	19	NMOD
19	patients	patient	I-NP	NNS	O	16	PMOD
20	undergoing	undergo	B-VP	VBG	O	19	NMOD
21	colonoscopy	colonoscopy	B-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	esophagogastroduodenoscopy	esophagogastroduodenoscopy	I-NP	NN	O	20	OBJ
24	.	.	O	.	O	3	P

1	Overall	Overall	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	venous	venous	B-NP	JJ	O	4	NMOD
4	complications	complication	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	more	more	B-ADJP	RBR	O	7	AMOD
7	frequent	frequent	I-ADJP	JJ	O	5	PRD
8	with	with	B-PP	IN	O	7	AMOD
9	diazepam	diazepam	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	15	DEP
11	22	22	B-NP	CD	O	15	DEP
12	of	of	B-PP	IN	O	11	NMOD
13	62	62	B-NP	CD	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	)	)	O	)	O	7	AMOD
16	than	than	B-PP	IN	O	7	AMOD
17	with	with	B-PP	IN	O	16	PMOD
18	midazolam	midazolam	B-NP	NN	O	17	PMOD
19	(	(	O	(	O	24	DEP
20	4	4	B-NP	CD	O	24	DEP
21	of	of	B-PP	IN	O	20	NMOD
22	60	60	B-NP	CD	O	23	NMOD
23	patients	patient	I-NP	NNS	O	21	PMOD
24	)	)	O	)	O	18	NMOD
25	(	(	O	(	O	29	DEP
26	p	p	B-NP	NN	O	28	SUB
27	<	<	O	SYM	O	28	VMOD
28	0.001	0.001	B-NP	CD	O	29	DEP
29	)	)	O	)	O	5	VMOD
30	.	.	O	.	O	5	P

1	Pain	Pain	B-NP	NN	O	6	SUB
2	at	at	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	injection	injection	I-NP	NN	B-DNA	5	NMOD
5	site	site	I-NP	NN	I-DNA	2	PMOD
6	occurred	occur	B-VP	VBD	O	0	ROOT
7	in	in	B-PP	IN	O	6	VMOD
8	35	35	B-NP	CD	O	9	NMOD
9	%	%	I-NP	NN	O	7	PMOD
10	(	(	O	(	O	14	DEP
11	22	22	B-NP	CD	O	12	AMOD
12	of	of	B-PP	IN	O	14	DEP
13	62	62	B-NP	CD	O	12	AMOD
14	)	)	O	)	O	9	NMOD
15	of	of	B-PP	IN	O	9	NMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	diazepam	diazepam	I-NP	NN	O	20	NMOD
20	group	group	I-NP	NN	O	17	PMOD
21	compared	compare	B-PP	VBN	O	6	VMOD
22	with	with	B-PP	IN	O	21	PMOD
23	7	7	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	22	PMOD
25	(	(	O	(	O	30	DEP
26	4	4	B-NP	CD	O	30	DEP
27	of	of	B-PP	IN	O	26	NMOD
28	60	60	B-NP	CD	O	29	NMOD
29	patients	patient	I-NP	NNS	O	27	PMOD
30	)	)	O	)	O	24	NMOD
31	in	in	B-PP	IN	O	24	NMOD
32	the	the	B-NP	DT	O	34	NMOD
33	midazolam	midazolam	I-NP	NN	O	34	NMOD
34	group	group	I-NP	NN	O	31	PMOD
35	(	(	O	(	O	39	DEP
36	p	p	B-NP	NN	O	38	SUB
37	<	<	O	SYM	O	38	VMOD
38	0.001	0.001	B-NP	CD	O	39	DEP
39	)	)	O	)	O	6	VMOD
40	.	.	O	.	O	6	P

1	Tetany	Tetany	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	rhabdomyolysis	rhabdomyolysis	I-NP	NN	O	9	NMOD
4	due	due	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	surreptitious	surreptitious	B-NP	JJ	O	7	NMOD
7	furosemide	furosemide	I-NP	NN	O	5	PMOD
8	--	--	O	:	O	3	P
9	importance	importance	B-NP	NN	O	0	ROOT
10	of	of	B-PP	IN	O	9	NMOD
11	magnesium	magnesium	B-NP	NN	O	12	NMOD
12	supplementation	supplementation	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	9	P

1	While	While	B-SBAR	IN	O	11	VMOD
2	severe	severe	B-NP	JJ	O	3	NMOD
3	hypokalemia	hypokalemia	I-NP	NN	O	4	SUB
4	may	may	B-VP	MD	O	1	SBAR
5	cause	cause	I-VP	VB	O	4	VC
6	muscle	muscle	B-NP	NN	O	7	NMOD
7	weakness	weakness	I-NP	NN	O	5	OBJ
8	,	,	O	,	O	11	P
9	severe	severe	B-NP	JJ	O	10	NMOD
10	hypomagnesemia	hypomagnesemia	I-NP	NN	O	11	SUB
11	is	be	B-VP	VBZ	O	0	ROOT
12	associated	associate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	muscle	muscle	B-NP	NN	O	15	NMOD
15	spasms	spasm	I-NP	NNS	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	tetany	tetany	B-NP	NN	O	13	PMOD
18	which	which	B-NP	WDT	O	17	NMOD
19	can	can	B-VP	MD	O	18	SBAR
20	not	not	I-VP	RB	O	19	VMOD
21	be	be	I-VP	VB	O	19	VC
22	corrected	correct	I-VP	VBN	O	21	VC
23	by	by	B-PP	IN	O	22	VMOD
24	potassium	potassium	B-NP	NN	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	calcium	calcium	I-NP	NN	O	27	NMOD
27	supplementation	supplementation	I-NP	NN	O	23	PMOD
28	alone	alone	B-ADVP	RB	O	27	NMOD
29	(	(	O	(	O	33	DEP
30	1	1	B-NP	CD	O	32	NMOD
31	,	,	I-NP	,	O	32	P
32	2	2	I-NP	CD	O	33	DEP
33	)	)	O	)	O	27	NMOD
34	.	.	O	.	O	11	P

1	Loss	Loss	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	glutamate	glutamate	B-NP	NN	B-protein	6	NMOD
4	decarboxylase	decarboxylase	I-NP	NN	I-protein	6	NMOD
5	mRNA-containing	mRNA-containing	I-NP	JJ	O	6	NMOD
6	neurons	neuron	I-NP	NNS	O	2	PMOD
7	in	in	B-PP	IN	O	1	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	rat	rat	I-NP	NN	O	11	NMOD
10	dentate	dentate	I-NP	NN	O	11	NMOD
11	gyrus	gyrus	I-NP	NN	O	7	PMOD
12	following	follow	B-PP	VBG	O	1	NMOD
13	pilocarpine	pilocarpine	B-NP	NN	O	15	NMOD
14	induced	induced	I-NP	JJ	O	15	NMOD
15	seizures	seizure	I-NP	NNS	O	12	PMOD
16	.	.	O	.	O	1	P

1	In	In	B-NP	FW	O	2	AMOD
2	situ	situ	I-NP	FW	O	4	NMOD
3	hybridization	hybridization	I-NP	NN	O	4	NMOD
4	methods	method	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	0	ROOT
6	used	use	I-VP	VBN	O	5	VC
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	VMOD
9	if	if	B-SBAR	IN	O	8	VMOD
10	glutamic	glutamic	B-NP	JJ	B-protein	12	NMOD
11	acid	acid	I-NP	NN	I-protein	12	NMOD
12	decarboxylase	decarboxylase	I-NP	NN	I-protein	17	NMOD
13	(	(	O	(	O	15	DEP
14	GAD	GAD	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	mRNA-containing	mRNA-containing	B-NP	JJ	O	17	NMOD
17	neurons	neuron	I-NP	NNS	O	25	SUB
18	within	within	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	hilus	hilus	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	dentate	dentate	I-NP	NN	O	24	NMOD
24	gyrus	gyrus	I-NP	NN	O	21	PMOD
25	are	be	B-VP	VBP	O	9	SBAR
26	vulnerable	vulnerable	B-ADJP	JJ	O	25	PRD
27	to	to	B-PP	TO	O	26	AMOD
28	seizure	seizure	B-NP	NN	O	27	PMOD
29	induced	induce	B-VP	VBD	O	5	VMOD
30	damage	damage	B-NP	NN	O	29	OBJ
31	in	in	B-PP	IN	O	29	VMOD
32	a	a	B-NP	DT	O	33	NMOD
33	model	model	I-NP	NN	O	31	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	chronic	chronic	B-NP	JJ	O	36	NMOD
36	seizures	seizure	I-NP	NNS	O	34	PMOD
37	.	.	O	.	O	5	P

1	Sprague-Dawley	Sprague-Dawley	B-NP	JJ	O	2	NMOD
2	rats	rat	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	13	VMOD
4	injected	inject	I-VP	VBN	O	3	VC
5	intraperitoneally	intraperitoneally	B-ADVP	RB	O	4	VMOD
6	with	with	B-PP	IN	O	4	VMOD
7	pilocarpine	pilocarpine	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	13	P
9	and	and	O	CC	O	12	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	hippocampal	hippocampal	I-NP	JJ	O	12	NMOD
12	formation	formation	I-NP	NN	O	13	SUB
13	was	be	B-VP	VBD	O	0	ROOT
14	studied	study	I-VP	VBN	O	13	VC
15	histologically	histologically	B-ADVP	RB	O	14	VMOD
16	at	at	B-PP	IN	O	14	VMOD
17	1	1	B-NP	CD	O	26	NMOD
18	,	,	I-NP	,	O	26	P
19	2	2	I-NP	CD	O	26	NMOD
20	,	,	I-NP	,	O	26	P
21	4	4	I-NP	CD	O	26	NMOD
22	,	,	O	,	O	26	P
23	and	and	O	CC	O	26	NMOD
24	8	8	B-NP	CD	O	26	NMOD
25	week	week	I-NP	NN	O	26	NMOD
26	intervals	interval	I-NP	NNS	O	16	PMOD
27	after	after	B-PP	IN	O	26	NMOD
28	pilocarpine	pilocarpine	B-NP	NN	O	30	NMOD
29	induced	induce	I-NP	VBN	O	30	NMOD
30	seizures	seizure	I-NP	NNS	O	27	PMOD
31	.	.	O	.	O	13	P

1	Additional	Additional	B-NP	JJ	O	3	NMOD
2	neuronanatomical	neuronanatomical	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	23	SUB
4	,	,	O	,	O	3	P
5	including	include	B-PP	VBG	O	3	NMOD
6	cresyl	cresyl	B-NP	NN	O	8	NMOD
7	violet	violet	I-NP	NN	O	8	NMOD
8	staining	staining	I-NP	NN	O	16	NMOD
9	,	,	O	,	O	16	P
10	neuronal	neuronal	B-NP	JJ	O	12	NMOD
11	degeneration	degeneration	I-NP	NN	O	12	NMOD
12	methods	method	I-NP	NNS	O	16	NMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	NMOD
15	histochemical	histochemical	B-NP	JJ	O	16	NMOD
16	localization	localization	I-NP	NN	O	5	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	glial	glial	B-NP	JJ	B-protein	21	NMOD
19	fibrillary	fibrillary	I-NP	JJ	I-protein	21	NMOD
20	acidic	acidic	I-NP	JJ	I-protein	21	NMOD
21	protein	protein	I-NP	NN	I-protein	17	PMOD
22	,	,	O	,	O	3	P
23	suggested	suggest	B-VP	VBD	O	0	ROOT
24	that	that	B-SBAR	IN	O	23	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	decrease	decrease	I-NP	NN	O	34	SUB
27	in	in	B-PP	IN	O	26	NMOD
28	the	the	B-NP	DT	O	29	NMOD
29	number	number	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	GAD	GAD	B-NP	NN	B-protein	33	NMOD
32	mRNA-containing	mRNA-containing	I-NP	JJ	I-protein	33	NMOD
33	neurons	neuron	I-NP	NNS	I-protein	30	PMOD
34	was	be	B-VP	VBD	O	24	SBAR
35	related	related	B-ADJP	JJ	O	34	PRD
36	to	to	B-PP	TO	O	35	AMOD
37	neuronal	neuronal	B-NP	JJ	O	38	NMOD
38	loss	loss	I-NP	NN	O	36	PMOD
39	rather	rather	B-CONJP	RB	O	38	NMOD
40	than	than	I-CONJP	IN	O	39	DEP
41	to	to	B-PP	TO	O	39	AMOD
42	a	a	B-NP	DT	O	43	NMOD
43	decrease	decrease	I-NP	NN	O	41	PMOD
44	in	in	B-PP	IN	O	43	NMOD
45	GAD	GAD	B-NP	NN	B-RNA	47	NMOD
46	mRNA	mRNA	I-NP	NN	I-RNA	47	NMOD
47	levels	level	I-NP	NNS	O	44	PMOD
48	.	.	O	.	O	23	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	misoprostol	misoprostol	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	indomethacin	indomethacin	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	renal	renal	B-NP	JJ	O	9	NMOD
9	dysfunction	dysfunction	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	7	VMOD
11	elderly	elderly	B-NP	JJ	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	7	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Hospitalized	Hospitalize	B-VP	VBN	O	5	NMOD
4	elderly	elderly	B-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	6	SUB
6	are	be	B-VP	VBP	O	1	NMOD
7	at	at	B-PP	IN	O	6	PRD
8	risk	risk	B-NP	NN	O	7	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	developing	develop	B-VP	VBG	O	9	PMOD
11	indomethacin	indomethacin	B-NP	NN	O	14	NMOD
12	related	related	I-NP	JJ	O	14	NMOD
13	renal	renal	I-NP	JJ	O	14	NMOD
14	dysfunction	dysfunction	I-NP	NN	O	10	OBJ
15	.	.	O	.	O	1	P

1	Nephrotoxic	Nephrotoxic	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	aminoglycoside	aminoglycoside	B-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	on	on	B-PP	IN	O	2	NMOD
7	renal	renal	B-NP	JJ	O	9	NMOD
8	protein	protein	I-NP	NN	O	9	NMOD
9	reabsorption	reabsorption	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	accumulation	accumulation	I-NP	NN	O	6	PMOD
12	.	.	O	.	O	2	P

1	Its	Its	B-NP	PRP$	O	3	NMOD
2	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	3	NMOD
3	effectiveness	effectiveness	I-NP	NN	O	4	SUB
4	surpasses	surpass	B-VP	VBZ	O	0	ROOT
5	that	that	B-NP	DT	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	propranolol	propranolol	B-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	pindolol	pindolol	I-NP	NN	O	6	PMOD
10	inhibiting	inhibit	B-VP	VBG	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	ouabain	ouabain	I-NP	NN	O	13	NMOD
13	arrhythmia	arrhythmia	I-NP	NN	O	10	OBJ
14	in	in	B-PP	IN	O	10	VMOD
15	dogs	dog	B-NP	NNS	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	cats	cat	I-NP	NNS	O	14	PMOD
18	.	.	O	.	O	4	P

1	Chorea	Chorea	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	oral	oral	B-NP	JJ	O	5	NMOD
5	contraception	contraception	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	1	P

1	Three	Three	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	developed	develop	B-VP	VBD	O	0	ROOT
4	chorea	chorea	B-NP	NN	O	3	OBJ
5	while	while	B-SBAR	IN	O	3	VMOD
6	receiving	receive	B-VP	VBG	O	5	SBAR
7	oral	oral	B-NP	JJ	O	8	NMOD
8	contraceptives	contraceptive	I-NP	NNS	O	6	OBJ
9	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	third	third	I-NP	JJ	O	3	NMOD
3	patient	patient	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	acute	acute	B-NP	JJ	O	6	NMOD
6	amphetamine	amphetamine	I-NP	NN	O	8	NMOD
7	induced	induce	B-VP	VBD	O	8	NMOD
8	chorea	chorea	B-NP	NN	O	4	OBJ
9	after	after	B-PP	IN	O	4	VMOD
10	prolonged	prolonged	B-NP	JJ	O	12	NMOD
11	oral	oral	I-NP	JJ	O	12	NMOD
12	contraception	contraception	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	Reversal	Reversal	B-NP	NN	O	12	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	ammonia	ammonia	B-NP	NN	O	4	NMOD
4	coma	coma	I-NP	NN	O	2	PMOD
5	in	in	B-PP	IN	O	1	NMOD
6	rats	rat	B-NP	NNS	O	5	PMOD
7	by	by	B-PP	IN	O	1	NMOD
8	L-dopa	L-dopa	B-NP	NN	O	7	PMOD
9	:	:	O	:	O	1	P
10	a	a	B-NP	DT	O	12	NMOD
11	peripheral	peripheral	I-NP	JJ	O	12	NMOD
12	effect	effect	I-NP	NN	O	0	ROOT
13	.	.	O	.	O	12	P

1	Ammonia	Ammonia	B-NP	NNP	O	2	NMOD
2	coma	coma	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	produced	produce	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	rats	rat	B-NP	NNS	O	5	PMOD
7	within	within	B-PP	IN	O	4	VMOD
8	10	10	B-NP	CD	O	10	AMOD
9	to	to	I-NP	TO	O	10	AMOD
10	15	15	I-NP	CD	O	11	NMOD
11	minutes	minute	I-NP	NNS	O	7	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	an	an	B-NP	DT	O	14	NMOD
14	intraperitonealinjection	intraperitonealinjection	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	1.7	1.7	B-NP	CD	O	18	NMOD
17	mmol	mmol	I-NP	NN	O	18	NMOD
18	NH4CL	NH4CL	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	coma	coma	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	prevented	prevent	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	1.68	1.68	B-NP	CD	O	8	NMOD
7	mmol	mmol	I-NP	NN	O	8	NMOD
8	L-dopa	L-dopa	I-NP	NN	O	5	PMOD
9	given	give	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	gastric	gastric	B-NP	JJ	O	12	NMOD
12	intubation	intubation	I-NP	NN	O	14	NMOD
13	15	15	B-NP	CD	O	14	NMOD
14	minutes	minute	I-NP	NNS	O	10	PMOD
15	before	before	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	19	NMOD
17	ammonium	ammonium	I-NP	NN	O	19	NMOD
18	salt	salt	I-NP	NN	O	19	NMOD
19	injection	injection	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	3	P

1	Intraventricular	Intraventricular	B-NP	JJ	O	2	NMOD
2	infusion	infusion	I-NP	NN	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	dopamine	dopamine	B-NP	NN	O	3	PMOD
5	sufficient	sufficient	B-ADJP	JJ	O	4	NMOD
6	to	to	B-VP	TO	O	7	VMOD
7	raise	raise	I-VP	VB	O	5	AMOD
8	the	the	B-NP	DT	O	10	NMOD
9	brain	brain	I-NP	NN	O	10	NMOD
10	dopamine	dopamine	I-NP	NN	O	7	OBJ
11	to	to	B-PP	TO	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	same	same	I-NP	JJ	O	14	NMOD
14	extent	extent	I-NP	NN	O	11	PMOD
15	did	do	B-VP	VBD	O	0	ROOT
16	not	not	I-VP	RB	O	15	VMOD
17	prevent	prevent	I-VP	VB	O	15	VC
18	the	the	B-NP	DT	O	20	NMOD
19	ammonia	ammonia	I-NP	NN	O	20	NMOD
20	coma	coma	I-NP	NN	O	17	OBJ
21	nor	nor	O	CC	O	17	VMOD
22	affect	affect	B-VP	VB	O	17	VMOD
23	the	the	B-NP	DT	O	28	NMOD
24	blood	blood	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	brain	brain	I-NP	NN	O	28	NMOD
27	ammonia	ammonia	I-NP	NN	O	28	NMOD
28	concentrations	concentration	I-NP	NNS	O	22	OBJ
29	.	.	O	.	O	15	P

1	Bilateral	Bilateral	B-NP	JJ	O	2	NMOD
2	nephrectomy	nephrectomy	I-NP	NN	O	3	SUB
3	eliminated	eliminate	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	beneficial	beneficial	I-NP	JJ	O	6	NMOD
6	effect	effect	I-NP	NN	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	L-dopa	L-dopa	B-NP	NN	O	7	PMOD
9	on	on	B-PP	IN	O	3	VMOD
10	blood	blood	B-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	brain	brain	I-NP	NN	O	13	NMOD
13	ammonia	ammonia	I-NP	NN	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	ammonia	ammonia	I-NP	NN	O	17	NMOD
17	coma	coma	I-NP	NN	O	18	SUB
18	was	be	B-VP	VBD	O	9	SBAR
19	not	not	I-VP	RB	O	18	VMOD
20	prevented	prevent	I-VP	VBN	O	18	VC
21	.	.	O	.	O	3	P

1	Thus	Thus	B-ADVP	RB	O	19	VMOD
2	,	,	O	,	O	19	P
3	the	the	B-NP	DT	O	4	NMOD
4	reduction	reduction	I-NP	NN	O	12	NMOD
5	in	in	B-PP	IN	O	4	NMOD
6	blood	blood	B-NP	NN	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	brain	brain	I-NP	NN	O	9	NMOD
9	ammonia	ammonia	I-NP	NN	O	5	PMOD
10	and	and	O	CC	O	12	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	prevention	prevention	I-NP	NN	O	19	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	ammonia	ammonia	B-NP	NN	O	15	NMOD
15	coma	coma	I-NP	NN	O	13	PMOD
16	after	after	B-PP	IN	O	15	NMOD
17	L-dopa	L-dopa	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	12	P
19	can	can	B-VP	MD	O	0	ROOT
20	be	be	I-VP	VB	O	19	VC
21	accounted	account	I-VP	VBN	O	20	VC
22	for	for	B-PP	IN	O	21	VMOD
23	by	by	B-PP	IN	O	22	PMOD
24	the	the	B-NP	DT	O	26	NMOD
25	peripheral	peripheral	I-NP	JJ	O	26	NMOD
26	effect	effect	I-NP	NN	O	36	NMOD
27	of	of	B-PP	IN	O	26	NMOD
28	dopamine	dopamine	B-NP	NN	O	27	PMOD
29	on	on	B-PP	IN	O	26	NMOD
30	renal	renal	B-NP	JJ	O	31	NMOD
31	function	function	I-NP	NN	O	29	PMOD
32	rather	rather	B-CONJP	RB	O	36	NMOD
33	than	than	I-CONJP	IN	O	32	DEP
34	its	its	B-NP	PRP$	O	36	NMOD
35	central	central	I-NP	JJ	O	36	NMOD
36	action	action	I-NP	NN	O	23	PMOD
37	.	.	O	.	O	19	P

1	Heparin	Heparin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	thrombocytopenia	thrombocytopenia	B-NP	NN	O	2	OBJ
4	after	after	B-PP	IN	O	2	VMOD
5	liver	liver	B-NP	NN	O	6	NMOD
6	transplantation	transplantation	I-NP	NN	O	4	PMOD
7	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Unfractionated	Unfractionated	B-NP	JJ	O	5	NMOD
4	heparin	heparin	I-NP	NN	O	5	NMOD
5	sodium	sodium	I-NP	NN	O	12	NMOD
6	(	(	O	(	O	8	DEP
7	UFH	UFH	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	or	or	O	CC	O	12	NMOD
10	low-molecular	low-molecular	B-NP	JJ	B-protein	12	NMOD
11	weight	weight	I-NP	NN	I-protein	12	NMOD
12	heparin	heparin	I-NP	NN	I-protein	16	SUB
13	(	(	O	(	O	15	DEP
14	LMWH	LMWH	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	is	be	B-VP	VBZ	O	1	NMOD
17	used	use	I-VP	VBN	O	16	VC
18	in	in	B-PP	IN	O	17	VMOD
19	anticoagulant	anticoagulant	B-NP	JJ	O	20	NMOD
20	protocols	protocol	I-NP	NNS	O	18	PMOD
21	at	at	B-PP	IN	O	20	NMOD
22	several	several	B-NP	JJ	O	23	NMOD
23	institutions	institution	I-NP	NNS	O	21	PMOD
24	to	to	B-VP	TO	O	25	VMOD
25	prevent	prevent	I-VP	VB	O	16	VMOD
26	thrombosis	thrombosis	B-NP	NN	O	25	OBJ
27	after	after	B-PP	IN	O	25	VMOD
28	liver	liver	B-NP	NN	O	29	NMOD
29	transplantation	transplantation	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	16	P

1	Heparin	Heparin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	thrombocytopenia	thrombocytopenia	B-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	HIT	HIT	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	2	VMOD
8	an	an	B-NP	DT	O	11	NMOD
9	adverse	adverse	I-NP	JJ	O	11	NMOD
10	immune-mediated	immune-mediated	I-NP	JJ	O	11	NMOD
11	reaction	reaction	I-NP	NN	O	7	PRD
12	to	to	B-PP	TO	O	11	NMOD
13	heparin	heparin	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	7	P
15	resulting	result	B-VP	VBG	O	7	VMOD
16	in	in	B-PP	IN	O	15	VMOD
17	platelet	platelet	B-NP	NN	O	18	NMOD
18	count	count	I-NP	NN	O	19	SUB
19	decreases	decrease	B-VP	VBZ	O	16	SBAR
20	of	of	B-PP	IN	O	19	VMOD
21	more	more	B-NP	JJR	O	22	AMOD
22	than	than	I-NP	IN	O	24	NMOD
23	50	50	I-NP	CD	O	22	AMOD
24	%	%	I-NP	NN	O	20	PMOD
25	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	frequencies	frequency	I-NP	NNS	O	25	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	HIT	HIT	B-NP	NN	B-protein	3	PMOD
5	after	after	B-PP	IN	O	2	NMOD
6	liver	liver	B-NP	NN	O	7	NMOD
7	transplantation	transplantation	I-NP	NN	O	12	NMOD
8	and	and	O	CC	O	12	NMOD
9	platelet	platelet	B-NP	NN	B-protein	12	NMOD
10	factor	factor	I-NP	NN	I-protein	12	NMOD
11	4/heparin-reactive	4/heparin-reactive	I-NP	JJ	I-protein	12	NMOD
12	antibody	antibody	I-NP	NN	I-protein	17	NMOD
13	(	(	O	(	O	16	DEP
14	HIT	HIT	B-NP	NN	B-protein	15	NMOD
15	antibody	antibody	I-NP	NN	I-protein	16	DEP
16	)	)	O	)	O	12	NMOD
17	positivity	positivity	B-NP	NN	O	5	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	liver	liver	B-NP	NN	O	21	NMOD
20	transplantation	transplantation	I-NP	NN	O	21	NMOD
21	patients	patient	I-NP	NNS	O	18	PMOD
22	,	,	O	,	O	25	P
23	however	however	B-ADVP	RB	O	25	VMOD
24	,	,	O	,	O	25	P
25	are	be	B-VP	VBP	O	0	ROOT
26	unknown	unknown	B-ADJP	JJ	O	25	PRD
27	.	.	O	.	O	25	P

1	The	The	B-NP	DT	O	2	NMOD
2	heparin	heparin	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	platelet	platelet	B-NP	NN	B-cell_type	6	NMOD
5	aggregation	aggregation	I-NP	NN	O	6	NMOD
6	test	test	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	3	VMOD
8	negative	negative	B-ADJP	JJ	O	7	PRD
9	in	in	B-PP	IN	O	7	VMOD
10	these	these	B-NP	DT	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	3	P

1	None	None	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	subjects/patients	subjects/patient	I-NP	NNS	O	2	PMOD
5	developed	develop	B-VP	VBD	O	0	ROOT
6	UFH-related	UFH-related	B-NP	JJ	O	7	NMOD
7	HIT	HIT	I-NP	NN	O	5	OBJ
8	.	.	O	.	O	5	P

1	PTU-associated	PTU-associated	B-NP	JJ	O	2	NMOD
2	vasculitis	vasculitis	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	girl	girl	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	Turner	Turner	B-NP	NN	O	8	NMOD
8	Syndrome	Syndrome	I-NP	NN	O	12	NMOD
9	and	and	I-NP	CC	O	12	NMOD
10	Graves	Graves	I-NP	NN	O	12	NMOD
11	'	'	B-NP	POS	O	12	NMOD
12	disease	disease	I-NP	NN	O	6	PMOD
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	diagnosis	diagnosis	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	propylthiouracil	propylthiouracil	B-NP	NN	O	9	NMOD
5	(	(	O	(	O	7	DEP
6	PTU	PTU	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	-associated	-associated	B-NP	JJ	O	9	NMOD
9	vasculitis	vasculitis	I-NP	NN	O	3	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	made	make	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	observation	observation	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	consistent	consistent	B-NP	JJ	O	16	AMOD
16	clinical	clinical	I-NP	JJ	O	17	NMOD
17	features	feature	I-NP	NNS	O	14	PMOD
18	,	,	O	,	O	10	P
19	the	the	B-NP	DT	O	20	NMOD
20	detection	detection	I-NP	NN	O	34	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	elevated	elevated	B-NP	JJ	O	23	NMOD
23	ANA	ANA	I-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	ANCA	ANCA	I-NP	NN	B-protein	21	PMOD
26	in	in	B-PP	IN	O	20	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	blood	blood	I-NP	NN	O	26	PMOD
29	,	,	O	,	O	34	P
30	and	and	O	CC	O	34	NMOD
31	the	the	B-NP	DT	O	34	NMOD
32	observed	observe	I-NP	VBN	O	34	NMOD
33	clinical	clinical	I-NP	JJ	O	34	NMOD
34	resolution	resolution	I-NP	NN	O	10	VMOD
35	of	of	B-PP	IN	O	34	NMOD
36	symptoms	symptom	B-NP	NNS	O	35	PMOD
37	following	follow	B-PP	VBG	O	34	NMOD
38	withdrawal	withdrawal	B-NP	NN	O	37	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	PTU	PTU	B-NP	NN	B-protein	39	PMOD
41	.	.	O	.	O	10	P

1	Succinylcholine	Succinylcholine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	masseter	masseter	B-NP	NN	O	5	NMOD
4	muscle	muscle	I-NP	NN	O	5	NMOD
5	rigidity	rigidity	I-NP	NN	O	2	OBJ
6	during	during	B-PP	IN	O	2	VMOD
7	bronchoscopic	bronchoscopic	B-NP	JJ	O	8	NMOD
8	removal	removal	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	13	NMOD
11	tracheal	tracheal	I-NP	JJ	O	13	NMOD
12	foreign	foreign	I-NP	JJ	O	13	NMOD
13	body	body	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	2	P

1	Here	Here	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	describe	describe	B-VP	VBP	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	severe	severe	B-NP	JJ	O	11	NMOD
9	masseter	masseter	I-NP	NN	O	11	NMOD
10	muscle	muscle	I-NP	NN	O	11	NMOD
11	rigidity	rigidity	I-NP	NN	O	7	PMOD
12	(	(	O	(	O	16	DEP
13	jaw	jaw	B-NP	NN	O	16	DEP
14	of	of	B-PP	IN	O	13	NMOD
15	steel	steel	B-NP	NN	O	14	PMOD
16	)	)	O	)	O	11	NMOD
17	after	after	B-PP	IN	O	6	NMOD
18	succinylcholine	succinylcholine	B-NP	NN	O	22	NMOD
19	(	(	O	(	O	21	DEP
20	Sch	Sch	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	administration	administration	B-NP	NN	O	17	PMOD
23	during	during	B-PP	IN	O	22	NMOD
24	general	general	B-NP	JJ	O	26	NMOD
25	anesthetic	anesthetic	I-NP	JJ	O	26	NMOD
26	management	management	I-NP	NN	O	23	PMOD
27	for	for	B-PP	IN	O	26	NMOD
28	rigid	rigid	B-NP	JJ	O	30	NMOD
29	bronchoscopic	bronchoscopic	I-NP	JJ	O	30	NMOD
30	removal	removal	I-NP	NN	O	27	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	a	a	B-NP	DT	O	35	NMOD
33	tracheal	tracheal	I-NP	JJ	O	35	NMOD
34	foreign	foreign	I-NP	JJ	O	35	NMOD
35	body	body	I-NP	NN	O	31	PMOD
36	.	.	O	.	O	4	P

1	Minor	Minor	B-NP	JJ	O	3	NMOD
2	neurological	neurological	I-NP	JJ	O	3	NMOD
3	dysfunction	dysfunction	I-NP	NN	O	10	NMOD
4	,	,	O	,	O	10	P
5	cognitive	cognitive	B-NP	JJ	O	6	NMOD
6	development	development	I-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	and	and	O	CC	O	10	NMOD
9	somatic	somatic	B-NP	JJ	O	10	NMOD
10	development	development	I-NP	NN	O	0	ROOT
11	at	at	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	age	age	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	3	3	B-NP	CD	O	17	AMOD
16	to	to	I-NP	TO	O	17	AMOD
17	7	7	I-NP	CD	O	18	NMOD
18	years	year	I-NP	NNS	O	14	PMOD
19	after	after	B-PP	IN	O	10	NMOD
20	dexamethasone	dexamethasone	B-NP	NN	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	very-low	very-low	B-NP	JJ	O	25	NMOD
24	birth-weight	birth-weight	I-NP	JJ	O	25	NMOD
25	infants	infant	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	objective	objective	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	assess	assess	I-VP	VB	O	6	PRD
9	minor	minor	B-NP	JJ	O	11	NMOD
10	neurological	neurological	I-NP	JJ	O	11	NMOD
11	dysfunction	dysfunction	I-NP	NN	O	8	OBJ
12	,	,	O	,	O	8	VMOD
13	cognitive	cognitive	B-NP	JJ	O	14	NMOD
14	development	development	I-NP	NN	O	18	NMOD
15	,	,	O	,	O	18	P
16	and	and	O	CC	O	18	NMOD
17	somatic	somatic	B-NP	JJ	O	18	NMOD
18	development	development	I-NP	NN	O	12	PMOD
19	after	after	B-PP	IN	O	18	NMOD
20	dexamethasone	dexamethasone	B-NP	NN	O	21	NMOD
21	therapy	therapy	I-NP	NN	O	19	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	very-low-birthweight	very-low-birthweight	B-NP	JJ	O	24	NMOD
24	infants	infant	I-NP	NNS	O	22	PMOD
25	.	.	O	.	O	6	P

1	After	After	B-PP	IN	O	6	VMOD
2	dexamethasone	dexamethasone	B-NP	NN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	children	child	B-NP	NNS	O	6	SUB
6	showed	show	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	higher	high	I-NP	JJR	O	9	NMOD
9	rate	rate	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	minor	minor	B-NP	JJ	O	13	NMOD
12	neurological	neurological	I-NP	JJ	O	13	NMOD
13	dysfunctions	dysfunction	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	6	P

1	Force	Force	B-NP	NN	O	2	NMOD
2	overflow	overflow	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	levodopa	levodopa	B-NP	NN	O	6	NMOD
5	induced	induce	I-NP	VBN	O	6	NMOD
6	dyskinesias	dyskinesia	I-NP	NNS	O	0	ROOT
7	in	in	B-PP	IN	O	6	NMOD
8	Parkinson	Parkinson	B-NP	NNP	O	10	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	disease	disease	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	assessed	assess	B-VP	VBD	O	0	ROOT
3	force	force	B-NP	NN	O	4	NMOD
4	coordination	coordination	I-NP	NN	O	14	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	hand	hand	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	Parkinson	Parkinson	B-NP	NNP	O	10	NMOD
10	's	's	B-NP	POS	O	11	NMOD
11	disease	disease	I-NP	NN	O	8	PMOD
12	and	and	O	CC	O	14	NMOD
13	its	its	B-NP	PRP$	O	14	NMOD
14	relationship	relationship	I-NP	NN	O	2	OBJ
15	to	to	B-PP	TO	O	14	NMOD
16	motor	motor	B-NP	NN	O	17	NMOD
17	complications	complication	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	levodopa	levodopa	B-NP	NN	O	20	NMOD
20	therapy	therapy	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	14	P
22	particularly	particularly	B-ADVP	RB	O	23	PMOD
23	to	to	B-PP	TO	O	14	NMOD
24	levodopa	levodopa	B-NP	NN	O	26	NMOD
25	induced	induced	I-NP	JJ	O	26	NMOD
26	dyskinesias	dyskinesia	I-NP	NNS	O	23	PMOD
27	(	(	O	(	O	29	DEP
28	LID	LID	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	two	two	B-NP	CD	O	4	NMOD
4	groups	group	I-NP	NNS	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	Parkinson	Parkinson	B-NP	NNP	O	7	NMOD
7	's	's	B-NP	POS	O	9	NMOD
8	disease	disease	I-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	5	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	(	(	O	(	O	21	DEP
12	Parkinson	Parkinson	B-NP	NNP	O	16	NMOD
13	's	's	B-NP	POS	O	16	NMOD
14	disease	disease	I-NP	NN	O	16	NMOD
15	+	+	O	SYM	O	16	NMOD
16	LID	LID	B-NP	NN	O	20	NMOD
17	,	,	O	,	O	20	P
18	n	n	B-NP	NN	O	20	SUB
19	=	=	B-VP	SYM	O	20	VMOD
20	23	23	B-NP	CD	O	21	DEP
21	)	)	O	)	O	9	NMOD
22	and	and	O	CC	O	4	DEP
23	without	without	B-PP	IN	O	4	NMOD
24	levodopa	levodopa	B-NP	NN	O	26	NMOD
25	induced	induce	I-NP	VBN	O	26	NMOD
26	dyskinesias	dyskinesia	I-NP	NNS	O	23	PMOD
27	(	(	O	(	O	37	DEP
28	Parkinson	Parkinson	B-NP	NNP	O	30	NMOD
29	's	's	B-NP	POS	O	30	NMOD
30	disease	disease	I-NP	NN	O	36	NMOD
31	-	-	O	HYPH	O	36	P
32	LID	LID	B-NP	NN	O	36	NMOD
33	,	,	O	,	O	36	P
34	n	n	B-NP	NN	O	36	SUB
35	=	=	B-VP	SYM	O	36	VMOD
36	10	10	B-NP	CD	O	37	DEP
37	)	)	O	)	O	2	VMOD
38	,	,	O	,	O	42	P
39	and	and	O	CC	O	42	NMOD
40	age-matched	age-matched	B-NP	JJ	O	42	NMOD
41	healthy	healthy	I-NP	JJ	O	42	NMOD
42	controls	control	I-NP	NNS	O	2	VMOD
43	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	motor	motor	I-NP	NN	O	3	NMOD
3	score	score	I-NP	NN	O	22	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	11	NMOD
6	Unified	Unified	I-NP	NNP	O	11	NMOD
7	Parkinson	Parkinson	I-NP	NNP	O	11	NMOD
8	's	's	B-NP	POS	O	11	NMOD
9	Disease	Disease	I-NP	NNP	O	11	NMOD
10	Rating	Rating	I-NP	NNP	O	11	NMOD
11	Scale	Scale	I-NP	NNP	O	17	NMOD
12	,	,	O	,	O	17	P
13	a	a	B-NP	DT	O	17	NMOD
14	dyskinesia	dyskinesia	I-NP	NN	O	15	NMOD
15	score	score	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	force	force	I-NP	NN	O	4	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	a	a	B-NP	DT	O	21	NMOD
20	grip-lift	grip-lift	I-NP	JJ	O	21	NMOD
21	paradigm	paradigm	I-NP	NN	O	18	PMOD
22	were	be	B-VP	VBD	O	0	ROOT
23	assessed	assess	I-VP	VBN	O	22	VC
24	ON	ON	B-NP	NN	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	OFF	OFF	I-NP	NN	O	27	NMOD
27	levodopa	levodopa	I-NP	NN	O	23	OBJ
28	.	.	O	.	O	22	P

1	In	In	B-PP	IN	O	18	VMOD
2	Parkinson	Parkinson	B-NP	NNP	O	6	NMOD
3	's	's	B-NP	POS	O	6	NMOD
4	disease	disease	I-NP	NN	O	6	NMOD
5	+	+	O	SYM	O	6	NMOD
6	LID	LID	B-NP	NN	O	1	PMOD
7	,	,	O	,	O	18	P
8	the	the	B-NP	DT	O	9	NMOD
9	force	force	I-NP	NN	O	15	NMOD
10	involved	involve	B-VP	VBN	O	9	NMOD
11	in	in	B-PP	IN	O	10	VMOD
12	pressing	press	B-VP	VBG	O	11	PMOD
13	down	down	B-PRT	RP	O	12	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	object	object	I-NP	NN	O	18	SUB
16	before	before	B-PP	IN	O	15	NMOD
17	lifting	lifting	B-NP	NN	O	16	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	significantly	significantly	I-VP	RB	O	18	VMOD
20	increased	increase	I-VP	VBN	O	18	VC
21	by	by	B-PP	IN	O	20	VMOD
22	levodopa	levodopa	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	31	DEP
24	by	by	B-PP	IN	O	31	DEP
25	61	61	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	31	P
28	P	P	B-NP	NN	O	31	DEP
29	<	<	B-NP	SYM	O	28	NMOD
30	0.05	0.05	I-NP	CD	O	29	AMOD
31	)	)	O	)	O	22	NMOD
32	.	.	O	.	O	18	P

1	Postinfarction	Postinfarction	B-NP	NN	O	4	NMOD
2	ventricular	ventricular	I-NP	JJ	O	4	NMOD
3	septal	septal	I-NP	JJ	O	4	NMOD
4	defect	defect	I-NP	NN	O	0	ROOT
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	long-term	long-term	B-NP	JJ	O	9	NMOD
8	steroid	steroid	I-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	4	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	postinfarction	postinfarction	B-NP	NN	O	7	NMOD
5	ventricular	ventricular	I-NP	JJ	O	7	NMOD
6	septal	septal	I-NP	JJ	O	7	NMOD
7	rupture	rupture	I-NP	NN	O	3	PMOD
8	in	in	B-PP	IN	O	2	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	long-term	long-term	B-NP	JJ	O	13	NMOD
12	steroid	steroid	I-NP	NN	O	13	NMOD
13	therapy	therapy	I-NP	NN	O	10	PMOD
14	are	be	B-VP	VBP	O	0	ROOT
15	presented	present	I-VP	VBN	O	14	VC
16	and	and	O	CC	O	14	VMOD
17	the	the	B-NP	DT	O	19	NMOD
18	favourable	favourable	I-NP	JJ	O	19	NMOD
19	outcome	outcome	I-NP	NN	O	16	PRD
20	in	in	B-PP	IN	O	19	NMOD
21	both	both	B-NP	DT	O	22	NMOD
22	cases	case	I-NP	NNS	O	20	PMOD
23	described	describe	B-VP	VBN	O	22	NMOD
24	.	.	O	.	O	14	P

1	Angioedema	Angioedema	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	droperidol	droperidol	B-NP	NN	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	1	P

1	Clarithromycin-associated	Clarithromycin-associated	B-NP	JJ	O	3	NMOD
2	visual	visual	I-NP	JJ	O	3	NMOD
3	hallucinations	hallucination	I-NP	NNS	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	chronic	chronic	B-NP	JJ	O	10	NMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	PMOD
11	on	on	B-PP	IN	O	6	NMOD
12	continuous	continuous	B-NP	JJ	O	15	NMOD
13	ambulatory	ambulatory	I-NP	JJ	O	15	NMOD
14	peritoneal	peritoneal	I-NP	JJ	O	15	NMOD
15	dialysis	dialysis	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	3	P

1	Unreported	Unreporte	B-VP	VBN	O	5	VMOD
2	in	in	B-PP	IN	O	1	VMOD
3	the	the	B-NP	DT	O	4	NMOD
4	literature	literature	I-NP	NN	O	2	PMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	visual	visual	B-NP	JJ	O	7	NMOD
7	hallucinations	hallucination	I-NP	NNS	O	5	PRD
8	occurring	occur	B-VP	VBG	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	association	association	B-NP	NN	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	new	new	I-NP	JJ	O	15	NMOD
14	macrolide	macrolide	I-NP	NN	O	15	NMOD
15	antibiotic	antibiotic	I-NP	NN	O	17	NMOD
16	,	,	O	,	O	17	P
17	clarithromycin	clarithromycin	B-NP	NN	O	11	PMOD
18	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	combination	combination	I-NP	NN	O	27	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	7	NMOD
5	relatively	relatively	I-NP	RB	O	6	AMOD
6	high	high	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	clarithromycin	clarithromycin	B-NP	NN	O	8	PMOD
10	in	in	B-PP	IN	O	2	NMOD
11	face	face	B-NP	NN	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	chronic	chronic	B-NP	JJ	O	15	NMOD
14	renal	renal	I-NP	JJ	O	15	NMOD
15	failure	failure	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	11	NMOD
17	a	a	B-NP	DT	O	20	NMOD
18	functionally	functionally	I-NP	RB	O	19	AMOD
19	anephric	anephric	I-NP	JJ	O	20	NMOD
20	patient	patient	I-NP	NN	O	16	PMOD
21	,	,	O	,	O	2	P
22	with	with	B-PP	IN	O	2	NMOD
23	underlying	underlie	B-VP	VBG	O	22	PMOD
24	aluminum	aluminum	B-NP	NN	O	25	NMOD
25	intoxication	intoxication	I-NP	NN	O	23	OBJ
26	,	,	O	,	O	2	P
27	may	may	B-VP	MD	O	0	ROOT
28	have	have	I-VP	VB	O	27	VC
29	facilitated	facilitate	I-VP	VBN	O	28	VC
30	the	the	B-NP	DT	O	31	NMOD
31	appearance	appearance	I-NP	NN	O	29	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	this	this	B-NP	DT	O	36	NMOD
34	neurotoxic	neurotoxic	I-NP	JJ	O	36	NMOD
35	side	side	I-NP	NN	O	36	NMOD
36	effect	effect	I-NP	NN	O	32	PMOD
37	.	.	O	.	O	27	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	doxorubicin	doxorubicin	B-NP	NN	O	11	NMOD
6	(	(	O	(	O	8	DEP
7	adriamycin	adriamycin	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	-loaded	-loaded	B-NP	JJ	O	11	NMOD
10	cyanoacrylate	cyanoacrylate	I-NP	NN	O	11	NMOD
11	nanoparticles	nanoparticle	I-NP	NNS	O	4	PMOD
12	.	.	O	.	O	3	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	doxorubicin-loaded	doxorubicin-loaded	I-NP	JJ	O	3	NMOD
3	nanoparticle	nanoparticle	I-NP	NN	O	8	NMOD
4	(	(	O	(	O	6	DEP
5	DXNP	DXNP	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	renal	renal	B-NP	JJ	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	0	ROOT
10	explored	explore	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	both	both	B-NP	DT	O	16	NMOD
13	normal	normal	I-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	rats	rat	I-NP	NNS	O	11	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	experimental	experimental	B-NP	JJ	O	19	NMOD
19	glomerulonephritis	glomerulonephritis	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	3	NMOD
2	3	3	I-NP	CD	O	3	AMOD
3	times	time	I-NP	NNS	O	5	NMOD
4	higher	high	I-NP	JJR	O	5	NMOD
5	proteinuria	proteinuria	I-NP	NN	O	6	SUB
6	appeared	appear	B-VP	VBD	O	0	ROOT
7	in	in	B-PP	IN	O	6	VMOD
8	animals	animal	B-NP	NNS	O	7	PMOD
9	treated	treat	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	DXNP	DXNP	B-NP	NN	B-protein	10	PMOD
12	than	than	B-PP	IN	O	6	VMOD
13	in	in	B-PP	IN	O	12	PMOD
14	those	those	B-NP	DT	O	13	PMOD
15	treated	treat	B-VP	VBN	O	14	NMOD
16	with	with	B-PP	IN	O	15	VMOD
17	DX	DX	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	12	VMOD
2	rats	rat	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	immune	immune	B-NP	JJ	O	6	NMOD
5	experimental	experimental	I-NP	JJ	O	6	NMOD
6	glomerulonephritis	glomerulonephritis	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	12	P
8	5/6	5/6	B-NP	CD	O	9	NMOD
9	rats	rat	I-NP	NNS	O	11	NMOD
10	given	give	B-NP	VBN	O	11	NMOD
11	DX	DX	I-NP	NN	O	12	SUB
12	died	die	B-VP	VBD	O	0	ROOT
13	within	within	B-PP	IN	O	12	VMOD
14	7	7	B-NP	CD	O	15	NMOD
15	days	day	I-NP	NNS	O	13	PMOD
16	,	,	O	,	O	12	P
17	in	in	B-PP	IN	O	12	VMOD
18	contrast	contrast	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	animals	animal	B-NP	NNS	O	19	PMOD
21	treated	treat	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	DXNP	DXNP	B-NP	NN	B-protein	28	AMOD
24	,	,	O	,	O	28	P
25	NP	NP	B-NP	NN	B-protein	28	AMOD
26	,	,	O	,	O	28	P
27	or	or	O	CC	O	28	AMOD
28	untreated	untreated	B-ADJP	JJ	O	22	PMOD
29	,	,	O	,	O	28	P
30	which	which	B-NP	WDT	O	28	NMOD
31	all	all	O	DT	O	32	VMOD
32	survived	survive	B-VP	VBD	O	30	SBAR
33	.	.	O	.	O	12	P

1	Proteinuria	Proteinuria	B-NP	NNP	O	2	SUB
2	appeared	appear	B-VP	VBD	O	0	ROOT
3	in	in	B-PP	IN	O	2	VMOD
4	all	all	B-NP	DT	O	5	NMOD
5	series	series	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	2	P
7	but	but	O	CC	O	2	VMOD
8	was	be	B-VP	VBD	O	2	VMOD
9	2-5	2-5	B-NP	CD	O	10	NMOD
10	times	time	I-NP	NNS	O	8	PRD
11	more	more	B-ADJP	RBR	O	12	AMOD
12	intense	intense	I-ADJP	JJ	O	10	NMOD
13	(	(	O	(	O	17	DEP
14	p	p	B-NP	NN	O	16	SUB
15	>	>	O	SYM	O	16	VMOD
16	0.001	0.001	B-NP	CD	O	17	DEP
17	)	)	O	)	O	12	AMOD
18	and	and	O	CC	O	8	VMOD
19	prolonged	prolong	B-VP	VBD	O	8	VMOD
20	after	after	B-PP	IN	O	19	VMOD
21	doxorubicin	doxorubicin	B-NP	NN	O	22	NMOD
22	treatment	treatment	I-NP	NN	O	20	PMOD
23	(	(	O	(	O	26	DEP
24	400-700	400-700	B-NP	CD	O	25	NMOD
25	mg/day	mg/day	I-NP	NN	O	26	DEP
26	)	)	O	)	O	19	VMOD
27	,	,	O	,	O	19	P
28	without	without	B-PP	IN	O	19	VMOD
29	significant	significant	B-NP	JJ	O	30	NMOD
30	difference	difference	I-NP	NN	O	28	PMOD
31	between	between	B-PP	IN	O	30	NMOD
32	DXNP	DXNP	B-NP	NN	B-protein	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	DX	DX	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	2	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	,	,	O	,	O	4	P
6	in	in	B-PP	IN	O	12	VMOD
7	these	these	B-NP	DT	O	9	NMOD
8	experimental	experimental	I-NP	JJ	O	9	NMOD
9	conditions	condition	I-NP	NNS	O	6	PMOD
10	,	,	O	,	O	12	P
11	DXNP	DXNP	B-NP	NN	B-protein	12	SUB
12	killed	kill	B-VP	VBD	O	4	SBAR
13	less	less	B-NP	JJR	O	14	NMOD
14	animals	animal	I-NP	NNS	O	12	OBJ
15	than	than	B-PP	IN	O	14	NMOD
16	free	free	B-NP	JJ	O	17	NMOD
17	DX	DX	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	12	P
19	despite	despite	B-PP	IN	O	12	VMOD
20	of	of	B-PP	IN	O	19	PMOD
21	an	an	B-NP	DT	O	24	NMOD
22	enhanced	enhance	I-NP	VBN	O	24	NMOD
23	renal	renal	I-NP	JJ	O	24	NMOD
24	toxicity	toxicity	I-NP	NN	O	20	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	former	former	I-NP	JJ	O	25	PMOD
28	.	.	O	.	O	3	P

1	Etoposide-related	Etoposide-related	B-NP	JJ	O	3	NMOD
2	myocardial	myocardial	I-NP	JJ	O	3	NMOD
3	infarction	infarction	I-NP	NN	O	0	ROOT
4	.	.	O	.	O	3	P

1	Subjective	Subjective	B-NP	JJ	O	2	NMOD
2	assessment	assessment	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	sexual	sexual	B-NP	JJ	O	5	NMOD
5	dysfunction	dysfunction	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	on	on	B-PP	IN	O	2	NMOD
9	long-term	long-term	B-NP	JJ	O	10	NMOD
10	administration	administration	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	digoxin	digoxin	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	8	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	and	and	I-NP	CC	O	8	NMOD
7	control	control	I-NP	NN	O	8	NMOD
8	group	group	I-NP	NN	O	13	SUB
9	(	(	O	(	O	12	DEP
10	without	without	B-PP	IN	O	12	DEP
11	digoxin	digoxin	B-NP	NN	O	10	PMOD
12	)	)	O	)	O	8	NMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	of	of	B-PP	IN	O	13	PRD
15	similar	similar	B-NP	JJ	O	17	AMOD
16	cardiac	cardiac	I-NP	JJ	O	17	AMOD
17	functional	functional	I-NP	JJ	O	14	PMOD
18	capacity	capacity	I-NP	NN	O	17	NMOD
19	and	and	O	CC	O	13	VMOD
20	age	age	B-NP	NN	O	19	PMOD
21	(	(	O	(	O	24	DEP
22	25-40	25-40	B-NP	CD	O	23	NMOD
23	years	year	I-NP	NNS	O	24	DEP
24	)	)	O	)	O	20	NMOD
25	and	and	O	CC	O	20	NMOD
26	were	be	B-VP	VBD	O	25	SBAR
27	randomly	randomly	I-VP	RB	O	26	VMOD
28	selected	select	I-VP	VBN	O	26	VC
29	from	from	B-PP	IN	O	28	VMOD
30	the	the	B-NP	DT	O	34	NMOD
31	rheumatic	rheumatic	I-NP	JJ	O	34	NMOD
32	heart	heart	I-NP	NN	O	34	NMOD
33	disease	disease	I-NP	NN	O	34	NMOD
34	patients	patient	B-NP	NNS	O	29	PMOD
35	.	.	O	.	O	13	P

1	Fatal	Fatal	B-NP	JJ	O	3	NMOD
2	aplastic	aplastic	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	0	ROOT
4	due	due	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	indomethacin	indomethacin	B-NP	NN	O	10	NMOD
7	--	--	O	:	O	10	P
8	lymphocyte	lymphocyte	B-NP	NN	O	10	NMOD
9	transformation	transformation	I-NP	NN	O	10	NMOD
10	tests	test	I-NP	NNS	O	5	PMOD
11	in	in	B-ADVP	FW	O	3	NMOD
12	vitro	vitro	I-ADVP	FW	O	11	AMOD
13	.	.	O	.	O	3	P

1	Although	Although	B-SBAR	IN	O	24	VMOD
2	indomethacin	indomethacin	B-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	1	SBAR
4	been	be	I-VP	VBN	O	3	VC
5	implicated	implicate	I-VP	VBN	O	4	VC
6	as	as	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	possible	possible	I-NP	JJ	O	9	NMOD
9	cause	cause	I-NP	NN	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	aplastic	aplastic	B-NP	JJ	O	12	NMOD
12	anemia	anemia	I-NP	NN	O	10	PMOD
13	on	on	B-PP	IN	O	5	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	basis	basis	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	a	a	B-NP	DT	O	20	NMOD
18	few	few	I-NP	JJ	O	20	NMOD
19	clinical	clinical	I-NP	JJ	O	20	NMOD
20	observations	observation	I-NP	NNS	O	16	PMOD
21	,	,	O	,	O	24	P
22	its	its	B-NP	PRP$	O	23	NMOD
23	role	role	I-NP	NN	O	24	SUB
24	has	have	B-VP	VBZ	O	0	ROOT
25	not	not	I-VP	RB	O	24	VMOD
26	been	be	I-VP	VBN	O	24	VC
27	definitely	definitely	I-VP	RB	O	26	VMOD
28	established	establish	I-VP	VBN	O	26	VC
29	.	.	O	.	O	24	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	fatal	fatal	B-NP	JJ	O	6	NMOD
5	aplastic	aplastic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	described	describe	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	which	which	B-NP	WDT	O	9	PMOD
11	no	no	B-NP	DT	O	12	NMOD
12	drugs	drug	I-NP	NNS	O	18	SUB
13	other	other	B-ADJP	JJ	O	12	NMOD
14	than	than	B-PP	IN	O	13	AMOD
15	allopurinol	allopurinol	B-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	indomethacin	indomethacin	I-NP	NN	O	14	PMOD
18	were	be	B-VP	VBD	O	9	SBAR
19	given	give	I-VP	VBN	O	18	VC
20	.	.	O	.	O	7	P

1	Plasma	Plasma	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	urinary	urinary	I-NP	JJ	O	4	NMOD
4	lipids	lipid	I-NP	NNS	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	lipoproteins	lipoprotein	I-NP	NNS	B-protein	0	ROOT
7	during	during	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	development	development	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	nephrotic	nephrotic	B-NP	JJ	O	12	NMOD
12	syndrome	syndrome	I-NP	NN	O	10	PMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	in	in	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	rat	rat	I-NP	NN	O	14	PMOD
17	by	by	B-PP	IN	O	13	VMOD
18	puromycin	puromycin	B-NP	NN	O	19	NMOD
19	aminonucleoside	aminonucleoside	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	6	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	undertaken	undertake	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	ascertain	ascertain	I-VP	VB	O	4	VMOD
7	whether	whether	B-SBAR	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	alterations	alteration	I-NP	NNS	O	21	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	plasma	plasma	B-NP	NN	B-protein	12	NMOD
12	lipoproteins	lipoprotein	I-NP	NNS	I-protein	10	PMOD
13	found	find	B-VP	VBN	O	9	NMOD
14	in	in	B-PP	IN	O	13	VMOD
15	nephrotic	nephrotic	B-NP	JJ	O	16	NMOD
16	syndrome	syndrome	I-NP	NN	O	14	PMOD
17	induced	induce	B-VP	VBN	O	16	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	puromycin	puromycin	B-NP	NN	O	20	NMOD
20	aminonucleoside	aminonucleoside	I-NP	NN	O	18	PMOD
21	were	be	B-VP	VBD	O	7	SBAR
22	due	due	B-ADJP	JJ	O	21	PRD
23	to	to	B-PP	TO	O	22	AMOD
24	nephrotic	nephrotic	B-NP	JJ	O	25	NMOD
25	syndrome	syndrome	I-NP	NN	O	23	PMOD
26	per	per	B-ADVP	FW	O	25	NMOD
27	se	se	I-ADVP	FW	O	26	AMOD
28	,	,	O	,	O	25	P
29	or	or	O	CC	O	23	PMOD
30	,	,	O	,	O	21	P
31	at	at	B-ADVP	IN	O	33	PMOD
32	least	least	I-ADVP	JJS	O	31	AMOD
33	in	in	B-PP	IN	O	21	VMOD
34	part	part	B-NP	NN	O	33	PMOD
35	,	,	O	,	O	6	P
36	to	to	B-PP	TO	O	6	VMOD
37	the	the	B-NP	DT	O	38	NMOD
38	aminonucleoside	aminonucleoside	I-NP	NN	O	36	PMOD
39	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	investigate	investigate	I-VP	VB	O	7	PRD
10	the	the	B-NP	DT	O	11	NMOD
11	changes	change	I-NP	NNS	O	9	OBJ
12	in	in	B-PP	IN	O	11	NMOD
13	plasma	plasma	B-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	urinary	urinary	B-NP	JJ	B-protein	16	NMOD
16	lipoproteins	lipoprotein	I-NP	NNS	I-protein	12	PMOD
17	during	during	B-PP	IN	O	11	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	administration	administration	I-NP	NN	O	33	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	puromycin	puromycin	B-NP	NN	O	22	NMOD
22	aminonucleoside	aminonucleoside	I-NP	NN	O	20	PMOD
23	(	(	O	(	O	29	DEP
24	20	20	B-NP	CD	O	25	NMOD
25	mg/kg	mg/kg	I-NP	NN	O	29	DEP
26	for	for	B-PP	IN	O	25	NMOD
27	7	7	B-NP	CD	O	28	NMOD
28	days	day	I-NP	NNS	O	26	PMOD
29	)	)	O	)	O	19	NMOD
30	and	and	O	CC	O	33	NMOD
31	the	the	B-NP	DT	O	33	NMOD
32	subsequent	subsequent	I-NP	JJ	O	33	NMOD
33	development	development	I-NP	NN	O	17	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	nephrotic	nephrotic	B-NP	JJ	O	36	NMOD
36	syndrome	syndrome	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	14	VMOD
2	pre-nephrotic	pre-nephrotic	B-NP	JJ	O	3	NMOD
3	stage	stage	I-NP	NN	O	1	PMOD
4	the	the	B-NP	DT	O	6	NMOD
5	plasma	plasma	I-NP	NN	O	6	NMOD
6	level	level	I-NP	NN	O	1	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	fatty	fatty	B-NP	JJ	O	9	NMOD
9	acids	acid	I-NP	NNS	O	7	PMOD
10	,	,	O	,	O	14	P
11	triacylglycerol	triacylglycerol	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	VLDL	VLDL	I-NP	NN	B-protein	14	SUB
14	decreased	decrease	B-VP	VBD	O	0	ROOT
15	while	while	B-SBAR	IN	O	14	VMOD
16	that	that	B-NP	DT	O	23	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	phospholipid	phospholipid	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	23	P
20	cholesteryl	cholesteryl	B-NP	NN	O	21	NMOD
21	esters	ester	I-NP	NNS	O	23	NMOD
22	and	and	O	CC	O	23	NMOD
23	HDL	HDL	B-NP	NN	O	24	SUB
24	remained	remain	B-VP	VBD	O	15	SBAR
25	constant	constant	B-ADJP	JJ	O	24	PRD
26	.	.	O	.	O	14	P

1	Acid	Acid	B-NP	NN	B-protein	2	NMOD
2	protease	protease	I-NP	NN	I-protein	7	NMOD
3	(	(	O	(	O	7	NMOD
4	cathepsin	cathepsin	B-NP	NN	B-protein	7	NMOD
5	D	D	I-NP	NN	I-protein	7	NMOD
6	)	)	O	)	O	7	NMOD
7	activity	activity	B-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	30	VMOD
9	increased	increase	I-VP	VBN	O	8	VC
10	about	about	B-ADJP	RB	O	9	VMOD
11	tenfold	tenfold	I-ADJP	RB	O	12	PMOD
12	in	in	B-PP	IN	O	9	VMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	who	who	B-NP	WP	O	13	NMOD
15	died	die	B-VP	VBD	O	14	SBAR
16	and	and	O	CC	O	15	VMOD
17	nearly	nearly	B-ADVP	RB	O	15	VMOD
18	fourfold	fourfold	I-ADVP	RB	O	17	AMOD
19	in	in	B-PP	IN	O	17	AMOD
20	those	those	B-NP	DT	O	19	PMOD
21	who	who	B-NP	WP	O	20	NMOD
22	survived	survive	B-VP	VBD	O	21	SBAR
23	fulminant	fulminant	B-NP	JJ	O	25	NMOD
24	hepatic	hepatic	I-NP	JJ	O	25	NMOD
25	failure	failure	I-NP	NN	O	22	OBJ
26	after	after	B-PP	IN	O	22	VMOD
27	paracetamol	paracetamol	B-NP	NN	O	28	NMOD
28	overdose	overdose	I-NP	NN	O	26	PMOD
29	,	,	O	,	O	30	P
30	whereas	whereas	O	IN	O	0	ROOT
31	activities	activity	B-NP	NNS	O	32	SUB
32	were	be	B-VP	VBD	O	30	VMOD
33	increased	increase	I-VP	VBN	O	32	VC
34	equally	equally	B-ADVP	RB	O	33	VMOD
35	in	in	B-PP	IN	O	33	VMOD
36	patients	patient	B-NP	NNS	O	35	PMOD
37	with	with	B-PP	IN	O	36	NMOD
38	fulminant	fulminant	B-NP	JJ	O	40	NMOD
39	hepatic	hepatic	I-NP	JJ	O	40	NMOD
40	failure	failure	I-NP	NN	O	37	PMOD
41	due	due	B-PP	JJ	O	42	PMOD
42	to	to	B-PP	TO	O	33	VMOD
43	viral	viral	B-NP	JJ	O	44	NMOD
44	hepatitis	hepatitis	I-NP	NN	O	42	PMOD
45	whether	whether	B-SBAR	IN	O	33	VMOD
46	or	or	O	CC	O	45	DEP
47	not	not	O	RB	O	45	DEP
48	they	they	B-NP	PRP	O	49	SUB
49	survived	survive	B-VP	VBD	O	45	SBAR
50	.	.	O	.	O	30	P

1	Transketolase	Transketolase	B-NP	NN	O	2	NMOD
2	abnormality	abnormality	I-NP	NN	O	5	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	tolazamide	tolazamide	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	Wernicke	Wernicke	B-NP	NNP	O	8	NMOD
7	's	's	B-NP	POS	O	8	NMOD
8	encephalopathy	encephalopathy	I-NP	NN	O	5	OBJ
9	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	thiamine-dependent	thiamine-dependent	I-NP	JJ	B-protein	5	NMOD
5	enzyme	enzyme	I-NP	NN	I-protein	7	NMOD
6	,	,	O	,	O	7	P
7	transketolase	transketolase	B-NP	NN	B-protein	2	OBJ
8	,	,	O	,	O	7	P
9	from	from	B-PP	IN	O	7	NMOD
10	fibroblasts	fibroblast	B-NP	NNS	B-cell_type	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	diabetic	diabetic	I-NP	JJ	O	14	NMOD
14	patient	patient	I-NP	NN	O	11	PMOD
15	who	who	B-NP	WP	O	14	NMOD
16	developed	develop	B-VP	VBD	O	15	SBAR
17	Wernicke	Wernicke	B-NP	NNP	O	18	NMOD
18	's	's	B-NP	POS	O	19	NMOD
19	encephalopathy	encephalopathy	I-NP	NN	O	16	OBJ
20	when	when	B-ADVP	WRB	O	16	VMOD
21	treated	treat	B-VP	VBN	O	20	SBAR
22	with	with	B-PP	IN	O	21	VMOD
23	tolazamide	tolazamide	B-NP	NN	O	22	PMOD
24	,	,	O	,	O	2	P
25	in	in	B-SBAR	IN	O	2	VMOD
26	order	order	O	NN	O	25	DEP
27	to	to	B-VP	TO	O	28	VMOD
28	delineate	delineate	I-VP	VB	O	25	SBAR
29	if	if	B-SBAR	IN	O	28	VMOD
30	this	this	B-NP	DT	O	31	NMOD
31	patient	patient	I-NP	NN	O	33	SUB
32	also	also	B-ADVP	RB	O	33	VMOD
33	had	have	B-VP	VBD	O	29	SBAR
34	transketolase	transketolase	B-NP	NN	O	35	NMOD
35	abnormality	abnormality	I-NP	NN	O	33	OBJ
36	[	[	O	(	O	45	DEP
37	high	high	B-NP	JJ	O	38	NMOD
38	Km	Km	I-NP	NN	O	45	DEP
39	for	for	B-PP	IN	O	38	NMOD
40	thiamine	thiamine	B-NP	NN	O	41	NMOD
41	pyrophosphate	pyrophosphate	I-NP	NN	O	39	PMOD
42	(	(	O	(	O	44	DEP
43	TPP	TPP	B-NP	NN	B-protein	44	DEP
44	)	)	O	)	O	41	NMOD
45	]	]	O	)	O	28	VMOD
46	,	,	O	,	O	28	P
47	as	as	O	RB	O	28	VMOD
48	previously	previously	B-ADVP	RB	O	49	VMOD
49	reported	report	B-VP	VBN	O	28	VMOD
50	in	in	B-PP	IN	O	49	VMOD
51	postalcoholic	postalcoholic	B-NP	JJ	O	53	NMOD
52	Wernicke-Korsakoff	Wernicke-Korsakoff	I-NP	JJ	O	53	NMOD
53	syndrome	syndrome	I-NP	NN	O	50	PMOD
54	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	found	find	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	above-mentioned	above-mentioned	I-NP	JJ	O	6	NMOD
6	patient	patient	I-NP	NN	O	8	NMOD
7	and	and	O	CC	O	8	NMOD
8	one	one	B-NP	CD	O	20	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	diabetic	diabetic	I-NP	JJ	O	12	NMOD
12	kindreds	kindred	I-NP	NNS	O	9	PMOD
13	with	with	B-PP	IN	O	8	NMOD
14	no	no	B-NP	DT	O	15	NMOD
15	history	history	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	Wernicke	Wernicke	B-NP	NNP	O	18	NMOD
18	's	's	B-NP	POS	O	19	NMOD
19	encephalopathy	encephalopathy	I-NP	NN	O	16	PMOD
20	had	have	B-VP	VBD	O	3	SBAR
21	abnormal	abnormal	B-NP	JJ	O	22	NMOD
22	transketolase	transketolase	I-NP	NN	O	20	OBJ
23	as	as	B-SBAR	IN	O	20	VMOD
24	determined	determine	B-VP	VBN	O	23	SBAR
25	by	by	B-PP	IN	O	24	VMOD
26	its	its	B-NP	PRP$	O	27	NMOD
27	Km	Km	I-NP	NN	O	25	PMOD
28	for	for	B-PP	IN	O	27	NMOD
29	TPP	TPP	B-NP	NN	B-protein	28	PMOD
30	.	.	O	.	O	2	P

1	Mechanisms	Mechanism	B-NP	NNS	O	9	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	myocardial	myocardial	B-NP	JJ	O	4	NMOD
4	ischemia	ischemia	I-NP	NN	O	2	PMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	epinephrine	epinephrine	B-NP	NN	O	6	PMOD
8	:	:	O	:	O	1	P
9	comparison	comparison	B-NP	NN	O	0	ROOT
10	with	with	B-PP	IN	O	9	NMOD
11	exercise	exercise	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	ischemia	ischemia	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	epinephrine	epinephrine	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	eliciting	elicit	B-VP	VBG	O	5	PMOD
7	myocardial	myocardial	B-NP	JJ	O	8	NMOD
8	ischemia	ischemia	I-NP	NN	O	6	OBJ
9	was	be	B-VP	VBD	O	0	ROOT
10	examined	examine	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	coronary	coronary	B-NP	JJ	O	16	NMOD
15	artery	artery	I-NP	NN	O	16	NMOD
16	disease	disease	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	9	P

1	Objective	Objective	B-NP	JJ	O	2	NMOD
2	signs	sign	I-NP	NNS	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ischemia	ischemia	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	factors	factor	I-NP	NNS	O	3	PMOD
7	increasing	increase	B-VP	VBG	O	6	NMOD
8	myocardial	myocardial	B-NP	JJ	O	10	NMOD
9	oxygen	oxygen	I-NP	NN	O	10	NMOD
10	consumption	consumption	I-NP	NN	O	7	OBJ
11	were	be	B-VP	VBD	O	0	ROOT
12	compared	compare	I-VP	VBN	O	11	VC
13	during	during	B-PP	IN	O	12	VMOD
14	epinephrine	epinephrine	B-NP	NN	O	15	NMOD
15	infusion	infusion	I-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	supine	supine	B-NP	NN	O	19	NMOD
18	bicycle	bicycle	I-NP	NN	O	19	NMOD
19	exercise	exercise	I-NP	NN	O	13	PMOD
20	.	.	O	.	O	11	P

1	Both	Both	O	CC	O	4	NMOD
2	epinephrine	epinephrine	B-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	exercise	exercise	I-NP	NN	O	5	SUB
5	produced	produce	B-VP	VBD	O	0	ROOT
6	myocardial	myocardial	B-NP	JJ	O	7	NMOD
7	ischemia	ischemia	I-NP	NN	O	5	OBJ
8	as	as	B-SBAR	IN	O	5	VMOD
9	evidenced	evidence	B-VP	VBN	O	8	SBAR
10	by	by	B-PP	IN	O	9	VMOD
11	ST	ST	B-NP	JJ	O	13	NMOD
12	segment	segment	I-NP	NN	O	13	NMOD
13	depression	depression	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	angina	angina	I-NP	NN	O	10	PMOD
16	.	.	O	.	O	5	P

1	However	However	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	the	the	B-NP	DT	O	4	NMOD
4	mechanisms	mechanism	I-NP	NNS	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	myocardial	myocardial	B-NP	JJ	O	7	NMOD
7	ischemia	ischemia	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	by	by	B-PP	IN	O	8	VMOD
10	epinephrine	epinephrine	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	significantly	significantly	B-ADJP	RB	O	13	AMOD
13	different	different	I-ADJP	JJ	O	11	PRD
14	from	from	B-PP	IN	O	13	AMOD
15	those	those	B-NP	DT	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	exercise	exercise	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	11	P

1	Exercise	Exercise	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	myocardial	myocardial	B-NP	JJ	O	4	NMOD
4	ischemia	ischemia	I-NP	NN	O	2	OBJ
5	was	be	B-VP	VBD	O	2	VMOD
6	marked	mark	I-VP	VBN	O	5	VC
7	predominantly	predominantly	B-ADVP	RB	O	6	VMOD
8	by	by	B-PP	IN	O	6	VMOD
9	increased	increase	B-NP	VBN	O	11	NMOD
10	heart	heart	I-NP	NN	O	11	NMOD
11	rate	rate	I-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	rate-pressure	rate-pressure	B-NP	JJ	B-protein	14	NMOD
14	product	product	I-NP	NN	I-protein	8	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	18	NMOD
17	minor	minor	I-NP	JJ	O	18	NMOD
18	contribution	contribution	I-NP	NN	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	end-diastolic	end-diastolic	B-NP	JJ	O	21	NMOD
21	volume	volume	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	2	P
23	while	while	B-SBAR	IN	O	2	VMOD
24	epinephrine	epinephrine	B-NP	NN	O	26	NMOD
25	induced	induce	I-NP	VBN	O	24	AMOD
26	ischemia	ischemia	I-NP	NN	O	27	SUB
27	was	be	B-VP	VBD	O	23	SBAR
28	characterized	characterize	I-VP	VBN	O	27	VC
29	by	by	B-PP	IN	O	28	VMOD
30	a	a	B-NP	DT	O	32	NMOD
31	marked	marked	I-NP	JJ	O	32	NMOD
32	increase	increase	I-NP	NN	O	39	NMOD
33	in	in	B-PP	IN	O	32	NMOD
34	contractility	contractility	B-NP	NN	O	33	PMOD
35	and	and	O	CC	O	39	NMOD
36	a	a	B-NP	DT	O	39	NMOD
37	less	less	I-NP	RBR	O	38	AMOD
38	pronounced	pronounced	I-NP	JJ	O	39	NMOD
39	increase	increase	I-NP	NN	O	29	PMOD
40	in	in	B-PP	IN	O	39	NMOD
41	heart	heart	B-NP	NN	O	42	NMOD
42	rate	rate	I-NP	NN	O	45	NMOD
43	and	and	O	CC	O	45	NMOD
44	rate-pressure	rate-pressure	B-NP	JJ	B-protein	45	NMOD
45	product	product	I-NP	NN	I-protein	40	PMOD
46	.	.	O	.	O	2	P

1	Transient	Transient	B-NP	JJ	O	3	NMOD
2	contralateral	contralateral	I-NP	JJ	O	3	NMOD
3	rotation	rotation	I-NP	NN	O	9	SUB
4	following	follow	B-PP	VBG	O	3	NMOD
5	unilateral	unilateral	B-NP	JJ	O	8	NMOD
6	substantia	substantia	I-NP	NN	O	8	NMOD
7	nigra	nigra	I-NP	NN	O	8	NMOD
8	lesion	lesion	I-NP	NN	O	4	PMOD
9	reflects	reflect	B-VP	VBZ	O	0	ROOT
10	susceptibility	susceptibility	B-NP	NN	O	9	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	nigrostriatal	nigrostriatal	I-NP	JJ	O	14	NMOD
14	system	system	I-NP	NN	O	11	PMOD
15	to	to	B-PP	TO	O	10	NMOD
16	exhaustion	exhaustion	B-NP	NN	O	15	PMOD
17	by	by	B-PP	IN	O	16	NMOD
18	amphetamine	amphetamine	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	9	P

1	Following	Follow	B-PP	VBG	O	14	SUB
2	unilateral	unilateral	B-NP	JJ	O	3	NMOD
3	6-OHDA	6-OHDA	I-NP	NN	O	1	PMOD
4	induced	induce	B-VP	VBD	O	3	NMOD
5	SN	SN	B-NP	NN	O	6	NMOD
6	lesion	lesion	I-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	a	a	B-NP	DT	O	10	NMOD
9	transient	transient	I-NP	JJ	O	10	NMOD
10	period	period	I-NP	NN	O	4	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	contralateral	contralateral	B-NP	JJ	O	13	NMOD
13	rotation	rotation	I-NP	NN	O	11	PMOD
14	has	have	B-VP	VBZ	O	0	ROOT
15	been	be	I-VP	VBN	O	14	VC
16	reported	report	I-VP	VBN	O	15	VC
17	to	to	I-VP	TO	O	18	VMOD
18	precede	precede	I-VP	VB	O	16	VMOD
19	the	the	B-NP	DT	O	22	NMOD
20	predominant	predominant	I-NP	JJ	O	22	NMOD
21	ipsilateral	ipsilateral	I-NP	JJ	O	22	NMOD
22	circling	circling	I-NP	NN	O	18	OBJ
23	.	.	O	.	O	14	P

1	In	In	B-SBAR	IN	O	13	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	clarify	clarify	I-VP	VB	O	1	SBAR
5	the	the	B-NP	DT	O	6	NMOD
6	nature	nature	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	this	this	B-NP	DT	O	11	NMOD
9	initial	initial	I-NP	JJ	O	11	NMOD
10	contralateral	contralateral	I-NP	JJ	O	11	NMOD
11	rotation	rotation	I-NP	NN	O	7	PMOD
12	we	we	B-NP	PRP	O	13	SUB
13	examined	examine	B-VP	VBD	O	0	ROOT
14	the	the	B-NP	DT	O	15	NMOD
15	effect	effect	I-NP	NN	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	duration	duration	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	recovery	recovery	B-NP	NN	O	21	NMOD
21	period	period	I-NP	NN	O	19	PMOD
22	after	after	B-PP	IN	O	13	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	lesion	lesion	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	13	P
26	on	on	B-PP	IN	O	13	VMOD
27	amphetamine	amphetamine	B-NP	NN	O	30	NMOD
28	induced	induce	B-VP	VBD	O	27	AMOD
29	rotational	rotational	B-NP	JJ	O	30	NMOD
30	behavior	behavior	I-NP	NN	O	26	PMOD
31	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	3	NMOD
2	substantial	substantial	I-NP	JJ	O	3	NMOD
3	degree	degree	I-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	contralateral	contralateral	B-NP	JJ	O	6	NMOD
6	preference	preference	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	still	still	B-ADVP	RB	O	7	VMOD
9	evident	evident	B-ADJP	JJ	O	7	PRD
10	when	when	B-ADVP	WRB	O	7	VMOD
11	amphetamine	amphetamine	B-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	10	SBAR
13	administered	administer	I-VP	VBN	O	12	VC
14	for	for	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	19	NMOD
16	first	first	I-NP	JJ	O	19	NMOD
17	time	time	I-NP	NN	O	19	NMOD
18	24	24	B-NP	CD	O	19	NMOD
19	days	day	I-NP	NNS	O	14	PMOD
20	after	after	B-PP	IN	O	13	VMOD
21	lesioning	lesione	B-VP	VBG	O	20	PMOD
22	,	,	O	,	O	21	P
23	indicating	indicate	B-VP	VBG	O	21	VMOD
24	involvement	involvement	B-NP	NN	O	23	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	spared	spar	B-NP	VBN	B-cell_type	27	NMOD
27	cells	cell	I-NP	NNS	I-cell_type	25	PMOD
28	in	in	B-PP	IN	O	24	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	contralateral	contralateral	I-NP	JJ	O	31	NMOD
31	rotation	rotation	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	7	P

1	However	However	B-ADVP	RB	O	29	VMOD
2	,	,	O	,	O	29	P
3	regardless	regardless	B-ADVP	RB	O	29	VMOD
4	of	of	B-PP	IN	O	3	AMOD
5	the	the	B-NP	DT	O	6	NMOD
6	duration	duration	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	recovery	recovery	B-NP	NN	O	28	NMOD
9	(	(	O	(	O	27	VMOD
10	and	and	O	CC	O	27	VMOD
11	irrespective	irrespective	B-ADJP	JJ	O	27	VMOD
12	of	of	B-PP	IN	O	11	AMOD
13	either	either	O	CC	O	23	NMOD
14	lesion	lesion	B-NP	NN	O	15	NMOD
15	volume	volume	I-NP	NN	O	23	NMOD
16	,	,	O	,	O	23	P
17	amphetamine	amphetamine	B-NP	NN	O	18	NMOD
18	dose	dose	I-NP	NN	O	23	NMOD
19	,	,	O	,	O	23	P
20	or	or	O	CC	O	23	NMOD
21	post-lesion	post-lesion	B-NP	JJ	O	23	NMOD
22	motor	motor	I-NP	NN	O	23	NMOD
23	exercise	exercise	I-NP	NN	O	12	PMOD
24	)	)	O	)	O	23	NMOD
25	,	,	O	,	O	27	P
26	amphetamine	amphetamine	B-NP	NN	O	27	SUB
27	induced	induce	B-VP	VBD	O	28	NMOD
28	rotation	rotation	B-NP	NN	O	7	PMOD
29	tended	tend	B-VP	VBD	O	44	VMOD
30	to	to	I-VP	TO	O	31	VMOD
31	become	become	I-VP	VB	O	29	VMOD
32	gradually	gradually	B-ADJP	RB	O	34	AMOD
33	more	more	I-ADJP	RBR	O	34	AMOD
34	ipsilateral	ipsilateral	I-ADJP	JJ	O	31	PRD
35	as	as	B-PP	IN	O	34	AMOD
36	the	the	B-NP	DT	O	38	NMOD
37	observation	observation	I-NP	NN	O	38	NMOD
38	session	session	I-NP	NN	O	35	PMOD
39	progressed	progress	B-VP	VBD	O	29	VMOD
40	,	,	O	,	O	44	P
41	and	and	O	CC	O	44	VMOD
42	all	all	B-NP	DT	O	43	NMOD
43	rats	rat	I-NP	NNS	O	44	SUB
44	circled	circle	B-VP	VBD	O	0	ROOT
45	ipsilaterally	ipsilaterally	B-ADVP	RB	O	44	VMOD
46	to	to	B-PP	TO	O	44	VMOD
47	the	the	B-NP	DT	O	48	NMOD
48	lesion	lesion	I-NP	NN	O	46	PMOD
49	in	in	B-PP	IN	O	48	NMOD
50	response	response	B-NP	NN	O	49	PMOD
51	to	to	B-PP	TO	O	50	NMOD
52	further	further	B-NP	JJ	O	54	NMOD
53	amphetamine	amphetamine	I-NP	NN	O	54	NMOD
54	injections	injection	I-NP	NNS	O	51	PMOD
55	.	.	O	.	O	44	P

1	It	It	B-NP	PRP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	suggested	suggest	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	adenylate	adenylate	B-NP	NN	B-protein	8	NMOD
7	cyclase	cyclase	I-NP	NN	I-protein	8	NMOD
8	inhibition	inhibition	I-NP	NN	O	9	SUB
9	may	may	B-VP	MD	O	5	SBAR
10	be	be	I-VP	VB	O	9	VC
11	important	important	B-ADJP	JJ	O	10	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	14	NMOD
14	development	development	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	both	both	B-NP	CC	O	18	NMOD
17	nephrogenic	nephrogenic	I-NP	JJ	O	18	NMOD
18	diabetes	diabete	I-NP	NNS	O	21	NMOD
19	insipidus	insipidus	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	hypothyroidism	hypothyroidism	I-NP	NN	O	15	PMOD
22	during	during	B-PP	IN	O	10	VMOD
23	lithium	lithium	B-NP	NN	O	24	NMOD
24	treatment	treatment	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	2	P

1	Hypothyroidism	Hypothyroidism	B-NP	NN	O	2	SUB
2	developed	develop	B-VP	VBD	O	0	ROOT
3	in	in	B-PP	IN	O	2	VMOD
4	eight	eight	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	while	while	B-SBAR	IN	O	2	VMOD
7	they	they	B-NP	PRP	O	8	SUB
8	were	be	B-VP	VBD	O	6	SBAR
9	taking	take	I-VP	VBG	O	8	VC
10	lithium	lithium	B-NP	NN	O	9	OBJ
11	.	.	O	.	O	2	P

1	Sensitivity	Sensitivity	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	erythroid	erythroid	B-NP	JJ	B-cell_line	5	NMOD
4	progenitor	progenitor	I-NP	NN	I-cell_line	5	NMOD
5	colonies	colony	I-NP	NNS	I-cell_line	2	PMOD
6	to	to	B-PP	TO	O	1	NMOD
7	erythropoietin	erythropoietin	B-NP	NN	B-protein	6	PMOD
8	in	in	B-PP	IN	O	1	NMOD
9	azidothymidine	azidothymidine	B-NP	NN	O	12	NMOD
10	treated	treat	B-VP	VBN	O	12	NMOD
11	immunodeficient	immunodeficient	B-NP	JJ	O	12	NMOD
12	mice	mouse	I-NP	NNS	O	8	PMOD
13	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	anaemia	anaemia	I-NP	NN	O	9	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	3'-azido-3'dideoxythymidine	3'-azido-3'dideoxythymidine	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	8	DEP
7	AZT	AZT	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	is	be	B-VP	VBZ	O	0	ROOT
10	poorly	poorly	I-VP	RB	O	9	VMOD
11	understood	understand	I-VP	VBN	O	9	VC
12	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	used	use	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	6	NMOD
5	murine	murine	I-NP	JJ	O	6	NMOD
6	model	model	I-NP	NN	O	25	VMOD
7	of	of	B-PP	IN	O	6	NMOD
8	AIDS	AIDS	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	25	P
10	infection	infection	B-NP	NN	O	25	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	female	female	B-NP	JJ	O	14	NMOD
13	C57BL/6	C57BL/6	I-NP	NN	O	14	NMOD
14	mice	mouse	I-NP	NNS	O	11	PMOD
15	with	with	B-PP	IN	O	10	NMOD
16	LP-BM5	LP-BM5	B-NP	NN	O	18	NMOD
17	murine	murine	I-NP	JJ	O	18	NMOD
18	leukaemia	leukaemia	I-NP	NN	O	22	NMOD
19	(	(	O	(	O	21	DEP
20	MuLV	MuLV	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	virus	virus	B-NP	NN	O	15	PMOD
23	,	,	O	,	O	10	P
24	to	to	B-VP	TO	O	25	VMOD
25	determine	determine	I-VP	VB	O	3	VMOD
26	if	if	B-SBAR	IN	O	25	VMOD
27	AZT	AZT	B-NP	NNP	O	29	NMOD
28	induced	induce	I-NP	VBN	O	29	NMOD
29	anaemia	anaemia	I-NP	NN	O	30	SUB
30	is	be	B-VP	VBZ	O	26	SBAR
31	due	due	B-ADJP	JJ	O	30	PRD
32	,	,	O	,	O	31	P
33	in	in	B-PP	IN	O	31	AMOD
34	part	part	B-NP	NN	O	33	PMOD
35	,	,	O	,	O	31	P
36	to	to	B-PP	TO	O	31	AMOD
37	decreased	decrease	B-NP	VBN	O	38	NMOD
38	responsiveness	responsiveness	I-NP	NN	O	36	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	erythropoietic	erythropoietic	B-NP	JJ	B-cell_type	41	NMOD
41	precursors	precursor	I-NP	NNS	I-cell_type	39	PMOD
42	(	(	O	(	O	44	DEP
43	BFU-e	BFU-e	B-NP	NN	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	to	to	B-PP	TO	O	38	NMOD
46	erythropoietin	erythropoietin	B-NP	NN	B-protein	45	PMOD
47	(	(	O	(	O	49	DEP
48	EPO	EPO	B-NP	NN	B-protein	49	DEP
49	)	)	O	)	O	46	NMOD
50	.	.	O	.	O	2	P

1	AZT	AZT	B-NP	NN	O	2	SUB
2	produced	produce	B-VP	VBD	O	0	ROOT
3	anaemia	anaemia	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	both	both	B-NP	DT	O	6	NMOD
6	groups	group	I-NP	NNS	O	4	PMOD
7	,	,	O	,	O	2	P
8	in	in	B-PP	IN	O	2	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	dose-dependent	dose-dependent	I-NP	JJ	O	11	NMOD
11	fashion	fashion	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	Despite	Despite	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	anaemia	anaemia	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	17	P
5	the	the	B-NP	DT	O	6	NMOD
6	number	number	I-NP	NN	O	17	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	splenic	splenic	B-NP	JJ	O	12	NMOD
9	and	and	I-NP	CC	O	12	NMOD
10	bone	bone	I-NP	NN	O	12	NMOD
11	marrow	marrow	I-NP	NN	O	12	NMOD
12	BFU-e	BFU-e	I-NP	NN	O	7	PMOD
13	in	in	B-PP	IN	O	6	NMOD
14	AZT	AZT	B-NP	NNP	O	16	NMOD
15	treated	treat	I-NP	VBN	O	16	NMOD
16	mice	mouse	I-NP	NNS	O	13	PMOD
17	increased	increase	B-VP	VBD	O	0	ROOT
18	up	up	B-ADVP	RB	O	17	VMOD
19	to	to	B-PP	TO	O	17	VMOD
20	five-fold	five-fold	B-ADJP	JJ	O	19	PMOD
21	over	over	B-PP	IN	O	17	VMOD
22	levels	level	B-NP	NNS	O	21	PMOD
23	observed	observe	B-VP	VBN	O	22	NMOD
24	in	in	B-PP	IN	O	23	VMOD
25	infected	infected	B-NP	JJ	O	27	NMOD
26	untreated	untreated	I-NP	JJ	O	27	NMOD
27	animals	animal	I-NP	NNS	O	24	PMOD
28	after	after	B-PP	IN	O	17	VMOD
29	15	15	B-NP	CD	O	30	NMOD
30	d	d	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	treatment	treatment	B-NP	NN	O	31	PMOD
33	.	.	O	.	O	17	P

1	The	The	B-NP	DT	O	4	NMOD
2	mean	mean	I-NP	JJ	O	4	NMOD
3	plasma	plasma	I-NP	NN	O	4	NMOD
4	levels	level	I-NP	NNS	O	12	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	EPO	EPO	B-NP	NN	B-protein	5	PMOD
7	observed	observe	B-VP	VBN	O	4	NMOD
8	in	in	B-PP	IN	O	7	VMOD
9	AZT	AZT	B-NP	NNP	O	11	NMOD
10	treated	treat	I-NP	VBN	O	11	NMOD
11	mice	mouse	I-NP	NNS	O	8	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	appropriate	appropriate	B-ADJP	JJ	O	12	PRD
14	for	for	B-PP	IN	O	13	AMOD
15	the	the	B-NP	DT	O	16	NMOD
16	degree	degree	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	anaemia	anaemia	B-NP	NN	O	17	PMOD
19	observed	observe	B-VP	VBN	O	16	NMOD
20	when	when	B-ADVP	WRB	O	19	VMOD
21	compared	compare	B-PP	VBN	O	20	SBAR
22	with	with	B-PP	IN	O	21	VMOD
23	phenylhydrazine	phenylhydrazine	B-NP	NN	O	28	NMOD
24	(	(	O	(	O	26	DEP
25	PHZ	PHZ	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	treated	treat	B-NP	VBN	O	28	NMOD
28	mice	mouse	I-NP	NNS	O	22	PMOD
29	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	numbers	number	I-NP	NNS	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	BFU-e	BFU-e	B-NP	NN	B-protein	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	percentage	percentage	I-NP	NN	O	3	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	bone	bone	B-NP	NN	B-cell_type	11	NMOD
10	marrow	marrow	I-NP	NN	I-cell_type	11	NMOD
11	erythroblasts	erythroblast	I-NP	NNS	I-cell_type	8	PMOD
12	observed	observe	B-VP	VBN	O	11	NMOD
13	were	be	B-VP	VBD	O	0	ROOT
14	comparable	comparable	B-ADJP	JJ	O	13	PRD
15	in	in	B-PP	IN	O	14	AMOD
16	AZT	AZT	B-NP	NN	O	18	NMOD
17	and	and	O	CC	O	18	NMOD
18	PHZ	PHZ	B-NP	NN	B-protein	20	NMOD
19	treated	treat	B-VP	VBN	O	20	NMOD
20	mice	mouse	B-NP	NNS	O	15	PMOD
21	with	with	B-PP	IN	O	20	NMOD
22	similar	similar	B-NP	JJ	O	23	NMOD
23	degrees	degree	I-NP	NNS	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	anaemia	anaemia	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	13	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	reticulocytosis	reticulocytosis	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	inappropriate	inappropriate	B-ADJP	JJ	O	4	PRD
6	for	for	B-PP	IN	O	5	AMOD
7	the	the	B-NP	DT	O	8	NMOD
8	degree	degree	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	anaemia	anaemia	B-NP	NN	O	9	PMOD
11	observed	observe	B-VP	VBN	O	8	NMOD
12	in	in	B-PP	IN	O	11	VMOD
13	AZT	AZT	B-NP	NNP	O	16	NMOD
14	treated	treat	B-VP	VBN	O	16	NMOD
15	infected	infected	B-NP	JJ	O	16	NMOD
16	mice	mouse	I-NP	NNS	O	12	PMOD
17	.	.	O	.	O	4	P

1	Detection	Detection	B-NP	NN	O	10	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	abnormal	abnormal	B-NP	JJ	O	7	NMOD
4	cardiac	cardiac	I-NP	JJ	O	7	NMOD
5	adrenergic	adrenergic	I-NP	JJ	O	7	NMOD
6	neuron	neuron	I-NP	NN	O	7	NMOD
7	activity	activity	I-NP	NN	O	2	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	adriamycin	adriamycin	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBD	O	0	ROOT
11	cardiomyopathy	cardiomyopathy	B-NP	NN	O	10	OBJ
12	with	with	B-PP	IN	O	11	NMOD
13	iodine-125-metaiodobenzylguanidine	iodine-125-metaiodobenzylguanidine	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	10	P

1	Using	Use	B-VP	VBG	O	7	SUB
2	a	a	B-NP	DT	O	4	NMOD
3	rat	rat	I-NP	NN	O	4	NMOD
4	model	model	I-NP	NN	O	1	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	adriamycin	adriamycin	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	cardiomyopathy	cardiomyopathy	B-NP	NN	O	7	OBJ
9	,	,	O	,	O	7	P
10	we	we	B-NP	PRP	O	11	SUB
11	tested	test	B-VP	VBD	O	7	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	hypothesis	hypothesis	I-NP	NN	O	11	OBJ
14	that	that	B-SBAR	IN	O	13	NMOD
15	abnormal	abnormal	B-NP	JJ	O	19	NMOD
16	cardiac	cardiac	I-NP	JJ	O	19	NMOD
17	adrenergic	adrenergic	I-NP	JJ	O	19	NMOD
18	neuron	neuron	I-NP	NN	O	19	NMOD
19	activity	activity	I-NP	NN	O	20	SUB
20	may	may	B-VP	MD	O	14	SBAR
21	appear	appear	I-VP	VB	O	20	VC
22	and	and	O	CC	O	21	VMOD
23	be	be	B-VP	VB	O	21	VMOD
24	exacerbated	exacerbate	I-VP	VBN	O	23	VC
25	dose-dependently	dose-dependently	B-ADVP	RB	O	24	VMOD
26	in	in	B-PP	IN	O	24	VMOD
27	adriamycin	adriamycin	B-NP	NN	O	28	NMOD
28	cardiomyopathy	cardiomyopathy	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	degree	degree	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	vacuolar	vacuolar	B-NP	JJ	O	5	NMOD
5	degeneration	degeneration	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	myocardial	myocardial	B-NP	JJ	B-cell_type	8	NMOD
8	cells	cell	I-NP	NNS	I-cell_type	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	analyzed	analyze	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	relation	relation	B-NP	NN	O	11	PMOD
13	to	to	B-PP	TO	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	duration	duration	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	adriamycin	adriamycin	B-NP	NN	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	(	(	O	(	O	26	DEP
20	2	2	B-NP	CD	O	21	NMOD
21	mg/kg	mg/kg	I-NP	NN	O	25	NMOD
22	,	,	O	,	O	21	P
23	once	once	B-ADVP	RB	O	25	NMOD
24	a	a	B-NP	DT	O	25	NMOD
25	week	week	I-NP	NN	O	26	DEP
26	)	)	O	)	O	15	NMOD
27	.	.	O	.	O	9	P

1	Amnestic	Amnestic	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	10	NMOD
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	propranolol	propranolol	B-NP	NN	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	4	PMOD
7	:	:	O	:	O	2	P
8	a	a	B-NP	DT	O	10	NMOD
9	case	case	I-NP	NN	O	10	NMOD
10	report	report	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	An	An	B-NP	DT	O	3	NMOD
2	elderly	elderly	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	an	an	B-NP	DT	O	8	NMOD
6	Alzheimer-like	Alzheimer-like	I-NP	JJ	O	8	NMOD
7	subacute	subacute	I-NP	JJ	O	8	NMOD
8	dementia	dementia	I-NP	NN	O	4	OBJ
9	as	as	B-PP	IN	O	4	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	result	result	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	propranolol	propranolol	B-NP	NN	O	14	NMOD
14	toxicity	toxicity	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	4	P

1	Injections	Injection	B-NP	NNS	O	15	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ketamine	ketamine	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	doses	dose	B-NP	NNS	O	4	PMOD
6	from	from	B-PP	IN	O	5	NMOD
7	100	100	B-NP	CD	O	8	NMOD
8	microgram	microgram	I-NP	NN	O	6	PMOD
9	to	to	B-PP	TO	O	4	PMOD
10	3	3	B-NP	CD	O	11	NMOD
11	mg	mg	I-NP	NN	O	4	PMOD
12	into	into	B-PP	IN	O	1	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	artery	artery	I-NP	NN	O	12	PMOD
15	produced	produce	B-VP	VBD	O	0	ROOT
16	a	a	B-NP	DT	O	17	NMOD
17	depression	depression	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	SA	SA	I-NP	NN	O	22	NMOD
21	nodal	nodal	I-NP	JJ	O	22	NMOD
22	activity	activity	I-NP	NN	O	18	PMOD
23	by	by	B-PP	IN	O	15	VMOD
24	a	a	B-NP	DT	O	26	NMOD
25	direct	direct	I-NP	JJ	O	26	NMOD
26	action	action	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	15	P

1	Bilateral	Bilateral	B-NP	JJ	O	2	NMOD
2	vagotomy	vagotomy	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	sympathectomy	sympathectomy	I-NP	NN	O	7	NMOD
5	or	or	O	CC	O	7	NMOD
6	prior	prior	B-NP	JJ	O	7	NMOD
7	administration	administration	I-NP	NN	O	12	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	ganglion	ganglion	I-NP	NN	O	11	NMOD
11	blocker	blocker	I-NP	NN	O	8	PMOD
12	failed	fail	B-VP	VBD	O	0	ROOT
13	to	to	I-VP	TO	O	14	VMOD
14	inhibit	inhibit	I-VP	VB	O	12	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	occurrence	occurrence	I-NP	NN	O	20	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	ketamine	ketamine	I-NP	NN	O	17	PMOD
20	induced	induce	B-VP	VBD	O	14	VMOD
21	tachycardia	tachycardia	B-NP	NN	O	20	OBJ
22	,	,	O	,	O	12	P
23	while	while	B-SBAR	IN	O	12	VMOD
24	it	it	B-NP	PRP	O	25	SUB
25	was	be	B-VP	VBD	O	23	SBAR
26	completely	completely	I-VP	RB	O	25	VMOD
27	abolished	abolish	I-VP	VBN	O	25	VC
28	in	in	B-PP	IN	O	27	VMOD
29	the	the	B-NP	DT	O	31	NMOD
30	reserpinized	reserpinize	I-NP	VBN	O	31	NMOD
31	dogs	dog	I-NP	NNS	O	28	PMOD
32	or	or	B-PP	CC	O	28	PMOD
33	by	by	B-PP	IN	O	28	PMOD
34	a	a	B-NP	DT	O	36	NMOD
35	prior	prior	I-NP	JJ	O	36	NMOD
36	injection	injection	I-NP	NN	O	33	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	a	a	B-NP	DT	O	40	NMOD
39	beta-blocking	beta-blocking	I-NP	JJ	O	40	NMOD
40	agent	agent	I-NP	NN	O	37	PMOD
41	into	into	B-PP	IN	O	27	VMOD
42	the	the	B-NP	DT	O	45	NMOD
43	SA	SA	I-NP	NN	O	45	NMOD
44	node	node	I-NP	NN	O	45	NMOD
45	artery	artery	I-NP	NN	O	41	PMOD
46	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	use	use	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	serum	serum	B-NP	NN	B-protein	5	NMOD
5	cholinesterase	cholinesterase	I-NP	NN	I-protein	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	succinylcholine	succinylcholine	B-NP	NN	O	8	NMOD
8	apnoea	apnoea	I-NP	NN	O	6	PMOD
9	.	.	O	.	O	2	P

1	Fifteen	Fifteen	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	12	SUB
3	demonstrating	demonstrate	B-VP	VBG	O	2	NMOD
4	unexpected	unexpected	B-NP	JJ	O	6	NMOD
5	prolonged	prolong	I-NP	VBN	O	6	NMOD
6	apnoea	apnoea	I-NP	NN	O	3	OBJ
7	lasting	last	B-VP	VBG	O	6	NMOD
8	several	several	B-NP	JJ	O	9	NMOD
9	hours	hour	I-NP	NNS	O	10	PMOD
10	after	after	B-PP	IN	O	7	VMOD
11	succinylcholine	succinylcholine	B-NP	NN	O	10	PMOD
12	have	have	B-VP	VBP	O	0	ROOT
13	been	be	I-VP	VBN	O	12	VC
14	treated	treat	I-VP	VBN	O	13	VC
15	by	by	B-PP	IN	O	14	VMOD
16	a	a	B-NP	DT	O	18	NMOD
17	new	new	I-NP	JJ	O	18	NMOD
18	preparation	preparation	I-NP	NN	O	15	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	human	human	B-NP	JJ	B-protein	22	NMOD
21	serum	serum	I-NP	NN	I-protein	22	NMOD
22	cholinesterase	cholinesterase	I-NP	NN	I-protein	19	PMOD
23	.	.	O	.	O	12	P

1	Orthostatic	Orthostatic	B-NP	JJ	O	2	NMOD
2	hypotension	hypotension	I-NP	NN	O	3	SUB
3	occurs	occur	B-VP	VBZ	O	0	ROOT
4	following	follow	B-PP	VBG	O	3	VMOD
5	alpha	alpha	B-NP	SYM	O	7	NMOD
6	2-adrenoceptor	2-adrenoceptor	I-NP	NN	O	7	NMOD
7	blockade	blockade	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	chronic	chronic	B-NP	JJ	O	14	NMOD
10	prazosin-pretreated	prazosin-pretreated	I-NP	JJ	O	14	NMOD
11	conscious	conscious	I-NP	JJ	O	13	AMOD
12	spontaneously	spontaneously	I-NP	RB	O	13	AMOD
13	hypertensive	hypertensive	I-NP	JJ	O	14	NMOD
14	rats.	rats.	I-NP	NNS	O	8	PMOD
15	1	1	I-NP	CD	O	14	NMOD
16	.	.	O	.	O	3	P

1	Studies	Study	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	performed	perform	I-VP	VBN	O	2	VC
4	to	to	I-VP	TO	O	5	VMOD
5	evaluate	evaluate	I-VP	VB	O	3	VMOD
6	whether	whether	B-SBAR	IN	O	5	VMOD
7	chronic	chronic	B-NP	JJ	O	9	NMOD
8	prazosin	prazosin	I-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	10	SUB
10	alters	alter	B-VP	VBZ	O	6	SBAR
11	the	the	B-NP	DT	O	14	NMOD
12	alpha	alpha	I-NP	NN	O	14	NMOD
13	2-adrenoceptor	2-adrenoceptor	I-NP	NN	O	14	NMOD
14	function	function	I-NP	NN	O	10	OBJ
15	for	for	B-PP	IN	O	14	NMOD
16	orthostatic	orthostatic	B-NP	JJ	O	17	NMOD
17	control	control	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	arterial	arterial	B-NP	JJ	O	21	NMOD
20	blood	blood	I-NP	NN	O	21	NMOD
21	pressure	pressure	I-NP	NN	O	18	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	conscious	conscious	B-NP	JJ	O	25	AMOD
24	spontaneously	spontaneously	I-NP	RB	O	25	AMOD
25	hypertensive	hypertensive	I-NP	JJ	O	26	NMOD
26	rats	rat	I-NP	NNS	O	22	PMOD
27	(	(	O	(	O	29	DEP
28	SHR	SHR	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	2	P
31	2	2	B-NP	CD	O	2	VMOD
32	.	.	O	.	O	2	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	the	the	B-NP	DT	O	5	NMOD
4	head-up	head-up	I-NP	JJ	B-protein	5	NMOD
5	tilt	tilt	I-NP	NN	I-protein	6	SUB
6	induced	induce	B-VP	VBD	O	0	ROOT
7	orthostatic	orthostatic	B-NP	JJ	O	8	NMOD
8	hypotension	hypotension	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	6	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	SHR	SHR	I-NP	NN	B-protein	9	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	prazosin	prazosin	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	23	DEP
16	-16	-16	B-NP	CD	O	18	NMOD
17	%	%	I-NP	NN	O	18	NMOD
18	MAP	MAP	I-NP	NN	O	22	NMOD
19	,	,	O	,	O	22	P
20	n	n	B-NP	NN	O	22	SUB
21	=	=	B-VP	JJ	O	22	VMOD
22	6	6	B-NP	CD	O	23	DEP
23	)	)	O	)	O	14	NMOD
24	,	,	O	,	O	9	P
25	but	but	B-PP	CC	O	9	PMOD
26	not	not	B-PP	RB	O	27	PMOD
27	in	in	I-PP	IN	O	9	PMOD
28	the	the	B-NP	DT	O	29	NMOD
29	SHR	SHR	I-NP	NN	B-protein	27	PMOD
30	treated	treat	B-VP	VBN	O	29	NMOD
31	with	with	B-PP	IN	O	30	VMOD
32	rauwolscine	rauwolscine	B-NP	NN	O	31	PMOD
33	(	(	O	(	O	43	DEP
34	less	less	B-NP	JJR	O	43	DEP
35	than	than	I-NP	IN	O	34	AMOD
36	+2	+2	I-NP	CD	O	37	AMOD
37	%	%	I-NP	NN	O	38	NMOD
38	MAP	MAP	I-NP	NN	O	42	NMOD
39	,	,	O	,	O	42	P
40	n	n	B-NP	NN	O	42	SUB
41	=	=	B-VP	JJ	O	42	VMOD
42	6	6	B-NP	CD	O	35	PMOD
43	)	)	O	)	O	6	VMOD
44	.	.	O	.	O	6	P
45	3	3	B-NP	CD	O	6	VMOD
46	.	.	O	.	O	6	P

1	Head-up	Head-up	B-NP	JJ	O	2	NMOD
2	tilts	tilt	I-NP	NNS	O	6	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	these	these	B-NP	DT	O	5	NMOD
5	rats	rat	I-NP	NNS	O	3	PMOD
6	did	do	B-VP	VBD	O	0	ROOT
7	not	not	I-VP	RB	O	6	VMOD
8	produce	produce	I-VP	VB	O	6	VC
9	orthostatic	orthostatic	B-NP	JJ	O	10	NMOD
10	hypotension	hypotension	I-NP	NN	O	8	OBJ
11	when	when	B-ADVP	WRB	O	8	VMOD
12	performed	perform	B-VP	VBN	O	11	SBAR
13	either	either	O	CC	O	19	NMOD
14	prior	prior	B-ADJP	JJ	O	15	PMOD
15	to	to	B-PP	TO	O	13	PMOD
16	or	or	B-PP	CC	O	13	PMOD
17	after	after	I-PP	IN	O	13	PMOD
18	acute	acute	B-NP	JJ	O	19	NMOD
19	dosing	dosing	I-NP	NN	O	12	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	prazosin	prazosin	B-NP	NN	O	20	PMOD
22	(	(	O	(	O	27	DEP
23	0.1	0.1	B-NP	CD	O	25	NMOD
24	mg	mg	I-NP	NN	O	25	NMOD
25	kg-1	kg-1	I-NP	NN	O	27	DEP
26	i.p.	i.p.	B-ADVP	RB	O	25	NMOD
27	)	)	O	)	O	21	NMOD
28	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	5	NMOD
2	pressor	pressor	I-NP	NN	O	3	NMOD
3	responses	response	I-NP	NNS	O	5	NMOD
4	and	and	O	CC	O	5	NMOD
5	bradycardia	bradycardia	B-NP	NN	O	34	NMOD
6	to	to	B-PP	TO	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	alpha	alpha	I-NP	NN	O	10	NMOD
9	1-agonist	1-agonist	I-NP	NN	O	10	NMOD
10	cirazoline	cirazoline	I-NP	NN	O	6	PMOD
11	(	(	O	(	O	18	DEP
12	0.6	0.6	B-NP	CD	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	2	2	I-NP	CD	O	15	NMOD
15	micrograms	microgram	I-NP	NNS	O	18	DEP
16	kg-1	kg-1	I-NP	NN	O	15	NMOD
17	i.v.	i.v.	B-ADJP	JJ	O	16	NMOD
18	)	)	O	)	O	10	NMOD
19	,	,	O	,	O	34	P
20	the	the	B-NP	DT	O	23	NMOD
21	alpha	alpha	I-NP	NN	O	23	NMOD
22	2-agonist	2-agonist	I-NP	NN	O	23	NMOD
23	Abbott-53693	Abbott-53693	I-NP	NN	O	34	NMOD
24	(	(	O	(	O	31	DEP
25	1	1	B-NP	CD	O	30	NMOD
26	and	and	I-NP	CC	O	30	NMOD
27	3	3	I-NP	CD	O	30	NMOD
28	micrograms	microgram	I-NP	NNS	O	30	NMOD
29	kg-1	kg-1	I-NP	NN	O	30	NMOD
30	i.v.	i.v.	B-ADJP	JJ	O	31	DEP
31	)	)	O	)	O	23	NMOD
32	,	,	O	,	O	34	P
33	and	and	O	CC	O	34	NMOD
34	noradrenaline	noradrenaline	B-NP	NN	O	43	SUB
35	(	(	O	(	O	42	DEP
36	0.1	0.1	B-NP	CD	O	39	NMOD
37	and	and	I-NP	CC	O	39	NMOD
38	1.0	1.0	I-NP	CD	O	39	NMOD
39	micrograms	microgram	I-NP	NNS	O	42	DEP
40	kg-1	kg-1	I-NP	NN	O	39	NMOD
41	i.v.	i.v.	B-ADJP	JJ	O	40	NMOD
42	)	)	O	)	O	34	NMOD
43	were	be	B-VP	VBD	O	0	ROOT
44	determined	determine	I-VP	VBN	O	43	VC
45	in	in	B-PP	IN	O	44	VMOD
46	conscious	conscious	B-NP	JJ	O	47	NMOD
47	SHR	SHR	I-NP	NN	O	45	PMOD
48	with	with	B-PP	IN	O	47	NMOD
49	and	and	O	CC	O	48	PMOD
50	without	without	B-PP	IN	O	48	PMOD
51	chronic	chronic	B-NP	JJ	O	53	NMOD
52	prazosin	prazosin	I-NP	NN	O	53	NMOD
53	pretreatment	pretreatment	I-NP	NN	O	48	PMOD
54	.	.	O	.	O	43	P

1	Both	Both	O	CC	O	6	NMOD
2	the	the	B-NP	DT	O	6	NMOD
3	pressor	pressor	I-NP	NN	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	bradycardia	bradycardia	I-NP	NN	O	6	NMOD
6	effects	effect	I-NP	NNS	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	cirazoline	cirazoline	B-NP	NN	O	7	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	abolished	abolish	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	chronic	chronic	B-NP	JJ	O	13	NMOD
13	prazosin	prazosin	I-NP	NN	O	11	PMOD
14	treated	treat	B-VP	VBN	O	13	NMOD
15	SHR	SHR	B-NP	NN	B-protein	14	OBJ
16	(	(	O	(	O	20	DEP
17	n	n	B-NP	NN	O	19	SUB
18	=	=	B-VP	SYM	O	19	VMOD
19	4	4	B-NP	CD	O	20	DEP
20	)	)	O	)	O	15	NMOD
21	as	as	B-SBAR	IN	O	10	VMOD
22	compared	compare	B-VP	VBN	O	21	SBAR
23	to	to	B-PP	TO	O	22	VMOD
24	the	the	B-NP	DT	O	26	NMOD
25	untreated	untreated	I-NP	JJ	O	26	NMOD
26	SHR	SHR	I-NP	NN	O	23	PMOD
27	(	(	O	(	O	31	DEP
28	n	n	B-NP	NN	O	30	SUB
29	=	=	B-VP	SYM	O	30	VMOD
30	4	4	B-NP	CD	O	31	DEP
31	)	)	O	)	O	26	NMOD
32	.	.	O	.	O	9	P

1	On	On	B-PP	IN	O	11	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	11	P
6	the	the	B-NP	DT	O	8	NMOD
7	pressor	pressor	I-NP	NN	O	8	NMOD
8	effects	effect	I-NP	NNS	O	11	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	Abbott-53693	Abbott-53693	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	23	VMOD
12	similar	similar	B-ADJP	JJ	O	11	PRD
13	in	in	B-PP	IN	O	12	AMOD
14	both	both	B-NP	DT	O	15	NMOD
15	groups	group	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	SHR	SHR	B-NP	NN	B-protein	16	PMOD
18	,	,	O	,	O	23	P
19	but	but	O	CC	O	23	VMOD
20	the	the	B-NP	DT	O	22	NMOD
21	accompanying	accompany	I-NP	VBG	O	22	NMOD
22	bradycardia	bradycardia	I-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	0	ROOT
24	greater	great	B-ADJP	JJR	O	23	PRD
25	in	in	B-PP	IN	O	24	AMOD
26	SHR	SHR	B-NP	NN	B-protein	25	PMOD
27	with	with	B-PP	IN	O	24	AMOD
28	chronic	chronic	B-NP	JJ	O	30	NMOD
29	prazosin	prazosin	I-NP	NN	O	30	NMOD
30	treatment	treatment	I-NP	NN	O	27	PMOD
31	than	than	B-PP	IN	O	24	AMOD
32	without	without	B-PP	IN	O	31	PMOD
33	such	such	B-NP	JJ	O	34	NMOD
34	treatment	treatment	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	23	P

1	A	A	B-NP	DT	O	5	NMOD
2	forty-six	forty-six	I-NP	JJ	O	5	NMOD
3	year-old	year-old	I-NP	JJ	O	5	NMOD
4	premenopausal	premenopausal	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	6	SUB
6	developed	develop	B-VP	VBD	O	0	ROOT
7	headache	headache	B-NP	NN	O	11	NMOD
8	,	,	I-NP	,	O	11	P
9	nausea	nausea	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	vomiting	vomiting	I-NP	NN	O	6	OBJ
12	,	,	O	,	O	6	P
13	left	leave	B-VP	VBD	O	6	VMOD
14	hemiparesis	hemiparesis	B-NP	NN	O	18	NMOD
15	and	and	I-NP	CC	O	18	NMOD
16	seizure	seizure	I-NP	NN	O	18	NMOD
17	two	two	B-NP	CD	O	18	NMOD
18	days	day	I-NP	NNS	O	13	OBJ
19	after	after	B-PP	IN	O	13	VMOD
20	parenteral	parenteral	B-NP	JJ	O	21	NMOD
21	use	use	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	progesterone	progesterone	B-NP	NN	O	25	NMOD
24	and	and	I-NP	CC	O	25	NMOD
25	estradiol	estradiol	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	6	P

1	Chloroquine	Chloroquine	B-NP	NN	O	5	NMOD
2	related	related	I-NP	JJ	O	1	AMOD
3	complete	complete	I-NP	JJ	O	5	NMOD
4	heart	heart	I-NP	NN	O	5	NMOD
5	block	block	I-NP	NN	O	10	NMOD
6	with	with	B-PP	IN	O	5	NMOD
7	blindness	blindness	B-NP	NN	O	6	PMOD
8	:	:	O	:	O	5	P
9	case	case	B-NP	NN	O	10	NMOD
10	report	report	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	5	NMOD
2	27-year	27-year	I-NP	JJ	O	5	NMOD
3	old	old	I-NP	JJ	O	5	NMOD
4	African	African	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	12	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	history	history	B-NP	NN	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	regular	regular	B-NP	JJ	O	11	NMOD
10	chloroquine	chloroquine	I-NP	NN	O	11	NMOD
11	ingestion	ingestion	I-NP	NN	O	8	PMOD
12	presented	present	B-VP	VBD	O	0	ROOT
13	with	with	B-PP	IN	O	12	VMOD
14	progressive	progressive	B-NP	JJ	O	15	NMOD
15	deterioration	deterioration	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	vision	vision	B-NP	NN	O	16	PMOD
18	,	,	O	,	O	24	P
19	easy	easy	B-NP	JJ	O	20	NMOD
20	fatiguability	fatiguability	I-NP	NN	O	24	NMOD
21	,	,	O	,	O	24	P
22	dyspnoea	dyspnoea	B-NP	NN	O	24	NMOD
23	,	,	O	,	O	24	P
24	dizziness	dizziness	B-NP	NN	O	12	OBJ
25	progressing	progress	B-VP	VBG	O	24	NMOD
26	to	to	B-PP	TO	O	25	VMOD
27	syncopal	syncopal	B-NP	JJ	O	28	NMOD
28	attacks	attack	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	12	P

1	Ophthalmological	Ophthalmological	B-NP	JJ	O	2	NMOD
2	assessment	assessment	I-NP	NN	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	11	VMOD
4	features	feature	B-NP	NNS	O	10	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	chloroquine	chloroquine	B-NP	NN	O	7	NMOD
7	retinopathy	retinopathy	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	10	P
9	cardiac	cardiac	B-NP	JJ	O	10	NMOD
10	assessment	assessment	I-NP	NN	O	11	SUB
11	revealed	reveal	B-VP	VBD	O	0	ROOT
12	features	feature	B-NP	NNS	O	11	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	heart	heart	B-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	13	PMOD
16	and	and	O	CC	O	11	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	complete	complete	I-NP	JJ	O	20	NMOD
19	heart	heart	I-NP	NN	O	20	NMOD
20	block	block	I-NP	NN	O	16	PRD
21	with	with	B-PP	IN	O	20	NMOD
22	right	right	B-NP	JJ	O	26	NMOD
23	bundle	bundle	I-NP	NN	O	26	NMOD
24	branch	branch	I-NP	NN	O	26	NMOD
25	block	block	I-NP	NN	O	26	NMOD
26	pattern	pattern	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	heart	heart	I-NP	NN	O	3	NMOD
3	block	block	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	13	VMOD
5	treated	treat	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	pacemaker	pacemaker	B-NP	NN	O	8	NMOD
8	insertion	insertion	I-NP	NN	O	6	PMOD
9	and	and	O	CC	O	13	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	heart	heart	I-NP	NN	O	12	NMOD
12	failure	failure	I-NP	NN	O	13	SUB
13	resolved	resolve	B-VP	VBD	O	0	ROOT
14	spontaneously	spontaneously	I-VP	RB	O	15	AMOD
15	following	follow	I-VP	VBG	O	13	VMOD
16	chloroquine	chloroquine	B-NP	NN	O	17	NMOD
17	discontinuation	discontinuation	I-NP	NN	O	15	OBJ
18	.	.	O	.	O	13	P

1	Systemic	Systemic	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	resuscitation	resuscitation	I-NP	NN	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	bupivacaine-	bupivacaine-	B-NP	NN	O	12	NMOD
7	,	,	O	,	O	12	P
8	levobupivacaine-	levobupivacaine-	B-NP	NN	O	12	NMOD
9	,	,	O	,	O	12	P
10	or	or	O	CC	O	12	NMOD
11	ropivacaine-infused	ropivacaine-infused	B-NP	JJ	O	12	NMOD
12	rats	rat	I-NP	NNS	O	5	PMOD
13	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	compared	compare	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	systemic	systemic	I-NP	JJ	O	5	NMOD
5	toxicity	toxicity	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	bupivacaine	bupivacaine	B-NP	NN	O	12	NMOD
8	,	,	O	,	O	12	P
9	levobupivacaine	levobupivacaine	B-NP	NN	O	12	NMOD
10	,	,	O	,	O	12	P
11	and	and	O	CC	O	12	NMOD
12	ropivacaine	ropivacaine	B-NP	NN	O	6	PMOD
13	in	in	B-PP	IN	O	2	VMOD
14	anesthetized	anesthetize	B-NP	VBN	O	15	NMOD
15	rats	rat	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	cumulative	cumulative	I-NP	JJ	O	3	NMOD
3	doses	dose	I-NP	NNS	O	11	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	levobupivacaine	levobupivacaine	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	ropivacaine	ropivacaine	I-NP	NN	O	4	PMOD
8	that	that	B-NP	WDT	O	3	NMOD
9	produced	produce	B-VP	VBD	O	8	SBAR
10	seizures	seizure	B-NP	NNS	O	9	OBJ
11	were	be	B-VP	VBD	O	0	ROOT
12	similar	similar	B-ADJP	JJ	O	11	PRD
13	and	and	O	CC	O	11	VMOD
14	were	be	B-VP	VBD	O	11	VMOD
15	larger	large	B-ADJP	JJR	O	14	PRD
16	than	than	B-PP	IN	O	15	AMOD
17	those	those	B-NP	DT	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	bupivacaine	bupivacaine	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	cumulative	cumulative	I-NP	JJ	O	3	NMOD
3	doses	dose	I-NP	NNS	O	11	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	levobupivacaine	levobupivacaine	B-NP	NN	O	4	PMOD
6	that	that	B-NP	WDT	O	3	NMOD
7	produced	produce	B-VP	VBD	O	6	SBAR
8	dysrhythmias	dysrhythmia	B-NP	NNS	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	asystole	asystole	I-NP	NN	O	7	OBJ
11	were	be	B-VP	VBD	O	22	VMOD
12	smaller	small	B-ADJP	JJR	O	11	PRD
13	than	than	B-PP	IN	O	12	AMOD
14	the	the	B-NP	DT	O	16	NMOD
15	corresponding	correspond	I-NP	VBG	O	16	NMOD
16	doses	dose	I-NP	NNS	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	ropivacaine	ropivacaine	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	22	P
20	but	but	O	CC	O	22	VMOD
21	they	they	B-NP	PRP	O	22	SUB
22	were	be	B-VP	VBD	O	0	ROOT
23	larger	large	B-ADJP	JJR	O	22	PRD
24	than	than	B-PP	IN	O	23	AMOD
25	those	those	B-NP	DT	O	24	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	bupivacaine	bupivacaine	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	22	P

1	22-oxacalcitriol	22-oxacalcitriol	B-NP	NN	O	2	SUB
2	suppresses	suppress	B-VP	VBZ	O	0	ROOT
3	secondary	secondary	B-NP	JJ	O	4	NMOD
4	hyperparathyroidism	hyperparathyroidism	I-NP	NN	O	2	OBJ
5	without	without	B-PP	IN	O	2	VMOD
6	inducing	induce	B-VP	VBG	O	5	PMOD
7	low	low	B-NP	JJ	O	9	NMOD
8	bone	bone	I-NP	NN	O	9	NMOD
9	turnover	turnover	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	6	VMOD
11	dogs	dog	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	renal	renal	B-NP	JJ	O	14	NMOD
14	failure	failure	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Calcitriol	Calcitriol	B-NP	NN	O	4	NMOD
4	therapy	therapy	I-NP	NN	O	5	SUB
5	suppresses	suppress	B-VP	VBZ	O	1	NMOD
6	serum	serum	B-NP	NN	O	7	NMOD
7	levels	level	I-NP	NNS	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	parathyroid	parathyroid	B-NP	NN	O	10	NMOD
10	hormone	hormone	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	PTH	PTH	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	in	in	B-PP	IN	O	5	VMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	renal	renal	B-NP	JJ	O	18	NMOD
18	failure	failure	I-NP	NN	O	16	PMOD
19	but	but	O	CC	O	5	VMOD
20	has	have	B-VP	VBZ	O	5	VMOD
21	several	several	B-NP	JJ	O	22	NMOD
22	drawbacks	drawback	I-NP	NNS	O	20	OBJ
23	,	,	O	,	O	22	P
24	including	include	B-PP	VBG	O	22	NMOD
25	hypercalcemia	hypercalcemia	B-NP	NN	O	28	NMOD
26	and/or	and/or	O	CC	O	28	NMOD
27	marked	marked	B-NP	JJ	O	28	NMOD
28	suppression	suppression	I-NP	NN	O	24	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	bone	bone	B-NP	NN	O	31	NMOD
31	turnover	turnover	I-NP	NN	O	29	PMOD
32	,	,	O	,	O	28	P
33	which	which	B-NP	WDT	O	28	NMOD
34	may	may	B-VP	MD	O	33	SBAR
35	lead	lead	I-VP	VB	O	34	VC
36	to	to	B-PP	TO	O	35	VMOD
37	adynamic	adynamic	B-NP	JJ	O	39	NMOD
38	bone	bone	I-NP	NN	O	39	NMOD
39	disease	disease	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	undertaken	undertake	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	determine	determine	I-VP	VB	O	3	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	effects	effect	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	OCT	OCT	B-NP	NN	B-DNA	9	PMOD
11	on	on	B-PP	IN	O	8	NMOD
12	serum	serum	B-NP	NN	O	14	NMOD
13	PTH	PTH	I-NP	NN	O	14	NMOD
14	levels	level	I-NP	NNS	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	bone	bone	B-NP	NN	O	17	NMOD
17	turnover	turnover	I-NP	NN	O	11	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	states	state	B-NP	NNS	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	normal	normal	B-NP	JJ	O	25	NMOD
22	or	or	I-NP	CC	O	24	AMOD
23	impaired	impaired	I-NP	JJ	O	24	AMOD
24	renal	renal	I-NP	JJ	O	25	NMOD
25	function	function	I-NP	NN	O	20	PMOD
26	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	9	VMOD
4	Nx	Nx	B-NP	NN	O	5	NMOD
5	dogs	dog	I-NP	NNS	O	3	PMOD
6	,	,	O	,	O	9	P
7	OCT	OCT	B-NP	NN	B-DNA	9	SUB
8	significantly	significantly	B-ADVP	RB	O	9	VMOD
9	decreased	decrease	B-VP	VBD	O	1	NMOD
10	serum	serum	B-NP	NN	O	12	NMOD
11	PTH	PTH	I-NP	NN	O	12	NMOD
12	levels	level	I-NP	NNS	O	9	OBJ
13	soon	soon	B-ADVP	RB	O	9	VMOD
14	after	after	B-PP	IN	O	13	PMOD
15	the	the	B-NP	DT	O	16	NMOD
16	induction	induction	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	renal	renal	B-NP	JJ	O	19	NMOD
19	insufficiency	insufficiency	I-NP	NN	O	17	PMOD
20	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	11	VMOD
2	long-standing	long-standing	B-NP	JJ	O	4	NMOD
3	secondary	secondary	I-NP	JJ	O	4	NMOD
4	hyperparathyroidism	hyperparathyroidism	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	11	P
6	OCT	OCT	B-NP	NN	B-DNA	11	SUB
7	(	(	O	(	O	10	DEP
8	0.03	0.03	B-NP	CD	O	9	NMOD
9	microg/kg	microg/kg	I-NP	NN	O	10	DEP
10	)	)	O	)	O	6	NMOD
11	stabilized	stabilize	B-VP	VBD	O	0	ROOT
12	serum	serum	B-NP	NN	O	14	NMOD
13	PTH	PTH	I-NP	NN	O	14	NMOD
14	levels	level	I-NP	NNS	O	11	OBJ
15	during	during	B-PP	IN	O	11	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	first	first	I-NP	JJ	O	18	NMOD
18	months	month	I-NP	NNS	O	15	PMOD
19	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	6	VMOD
2	Nx	Nx	B-NP	NN	O	3	NMOD
3	dogs	dog	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	OCT	OCT	B-NP	NN	B-DNA	6	SUB
6	reversed	reverse	B-VP	VBD	O	0	ROOT
7	abnormal	abnormal	B-NP	JJ	O	9	NMOD
8	bone	bone	I-NP	NN	O	9	NMOD
9	formation	formation	I-NP	NN	O	6	OBJ
10	,	,	O	,	O	9	P
11	such	such	B-PP	JJ	O	12	PMOD
12	as	as	I-PP	IN	O	9	NMOD
13	woven	woven	B-NP	JJ	O	14	AMOD
14	osteoid	osteoid	I-NP	JJ	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	fibrosis	fibrosis	I-NP	NN	O	12	PMOD
17	,	,	O	,	O	6	P
18	but	but	O	CC	O	6	VMOD
19	did	do	B-VP	VBD	O	6	VMOD
20	not	not	I-VP	RB	O	19	VMOD
21	significantly	significantly	I-VP	RB	O	19	VMOD
22	alter	alter	I-VP	VB	O	19	VC
23	the	the	B-NP	DT	O	24	NMOD
24	level	level	I-NP	NN	O	22	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	bone	bone	B-NP	NN	O	27	NMOD
27	turnover	turnover	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	6	P

1	Chemotherapy	Chemotherapy	B-NP	NN	O	15	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	advanced	advance	B-NP	VBN	O	8	NMOD
4	inoperable	inoperable	I-NP	JJ	O	8	NMOD
5	non-small	non-small	I-NP	JJ	O	8	NMOD
6	cell	cell	I-NP	NN	O	8	NMOD
7	lung	lung	I-NP	NN	O	8	NMOD
8	cancer	cancer	I-NP	NN	O	2	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	paclitaxel	paclitaxel	B-NP	NN	O	9	PMOD
11	:	:	O	:	O	1	P
12	a	a	B-NP	DT	O	15	NMOD
13	phase	phase	I-NP	NN	O	15	NMOD
14	II	II	I-NP	CD	O	15	NMOD
15	trial	trial	I-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	13	SUB
2	(	(	O	(	O	13	VMOD
3	Taxol	Taxol	B-NP	NN	O	13	SUB
4	;	;	O	:	O	13	P
5	Bristol-Myers	Bristol-Myers	B-NP	NNP	O	7	NMOD
6	Squibb	Squibb	I-NP	NNP	O	7	NMOD
7	Company	Company	I-NP	NNP	O	9	NMOD
8	,	,	O	,	O	9	P
9	Princeton	Princeton	B-NP	NNP	O	11	NMOD
10	,	,	O	,	O	11	P
11	NJ	NJ	B-NP	NNP	O	13	SUB
12	)	)	O	)	O	11	DEP
13	has	have	B-VP	VBZ	O	0	ROOT
14	demonstrated	demonstrate	I-VP	VBN	O	13	VC
15	significant	significant	B-NP	JJ	O	17	NMOD
16	antineoplastic	antineoplastic	I-NP	JJ	O	17	NMOD
17	activity	activity	I-NP	NN	O	14	OBJ
18	against	against	B-PP	IN	O	17	NMOD
19	different	different	B-NP	JJ	O	21	NMOD
20	tumor	tumor	I-NP	NN	O	21	NMOD
21	types	type	I-NP	NNS	O	27	NMOD
22	,	,	O	,	O	27	P
23	notably	notably	B-NP	RB	O	27	NMOD
24	ovarian	ovarian	I-NP	JJ	O	27	NMOD
25	and	and	I-NP	CC	O	27	NMOD
26	breast	breast	I-NP	NN	O	27	NMOD
27	carcinoma	carcinoma	I-NP	NN	O	18	PMOD
28	.	.	O	.	O	13	P

1	Two	Two	B-NP	CD	O	4	NMOD
2	phase	phase	I-NP	NN	O	4	NMOD
3	II	II	B-NP	CD	O	4	NMOD
4	trials	trial	I-NP	NNS	O	24	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	24-hour	24-hour	B-NP	JJ	O	8	NMOD
7	paclitaxel	paclitaxel	I-NP	NN	O	8	NMOD
8	infusions	infusion	I-NP	NNS	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	chemotherapy-naive	chemotherapy-naive	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	stage	stage	B-NP	NN	O	20	NMOD
14	IIIB	IIIB	I-NP	CD	O	13	NMOD
15	or	or	I-NP	CC	O	13	NMOD
16	IV	IV	I-NP	CD	O	13	NMOD
17	non-small	non-small	I-NP	JJ	O	20	NMOD
18	cell	cell	I-NP	NN	O	20	NMOD
19	lung	lung	I-NP	NN	O	20	NMOD
20	cancer	cancer	I-NP	NN	O	12	PMOD
21	(	(	O	(	O	23	DEP
22	NSCLC	NSCLC	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	reported	report	B-VP	VBD	O	0	ROOT
25	response	response	B-NP	NN	O	26	NMOD
26	rates	rate	I-NP	NNS	O	24	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	21	21	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	32	NMOD
30	and	and	O	CC	O	32	NMOD
31	24	24	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	27	PMOD
33	.	.	O	.	O	24	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	efficacy	efficacy	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	2	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	11	NMOD
9	3-hour	3-hour	I-NP	JJ	O	11	NMOD
10	paclitaxel	paclitaxel	I-NP	NN	O	11	NMOD
11	infusion	infusion	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	6	NMOD
13	a	a	B-NP	DT	O	16	NMOD
14	phase	phase	I-NP	NN	O	16	NMOD
15	II	II	I-NP	CD	O	16	NMOD
16	trial	trial	I-NP	NN	O	12	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	inoperable	inoperable	B-NP	JJ	O	22	NMOD
21	stage	stage	I-NP	NN	O	22	NMOD
22	IIIB	IIIB	I-NP	NN	O	25	NMOD
23	or	or	O	CC	O	25	NMOD
24	IV	IV	B-NP	CD	O	25	NMOD
25	NSCLC	NSCLC	I-NP	NN	O	19	PMOD
26	.	.	O	.	O	2	P

1	Paclitaxel	Paclitaxel	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	thus	thus	B-ADVP	RB	O	2	VMOD
4	an	an	B-NP	DT	O	7	NMOD
5	active	active	I-NP	JJ	O	7	NMOD
6	single	single	I-NP	JJ	O	7	NMOD
7	agent	agent	I-NP	NN	O	2	PRD
8	in	in	B-PP	IN	O	7	NMOD
9	this	this	B-NP	DT	O	11	NMOD
10	patient	patient	I-NP	NN	O	11	NMOD
11	population	population	I-NP	NN	O	8	PMOD
12	,	,	O	,	O	2	P
13	with	with	B-PP	IN	O	2	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	3-hour	3-hour	I-NP	JJ	O	16	NMOD
16	infusion	infusion	I-NP	NN	O	17	SUB
17	proving	prove	B-VP	VBG	O	13	PMOD
18	comparably	comparably	B-ADJP	RB	O	19	AMOD
19	effective	effective	I-ADJP	JJ	O	25	NMOD
20	to	to	B-PP	TO	O	19	AMOD
21	a	a	B-NP	DT	O	23	NMOD
22	24-hour	24-hour	I-NP	JJ	O	23	NMOD
23	infusion	infusion	I-NP	NN	O	20	PMOD
24	and	and	I-NP	CC	O	25	NMOD
25	superior	superior	I-NP	NN	O	17	OBJ
26	in	in	B-PP	IN	O	17	VMOD
27	terms	term	B-NP	NNS	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	incidence	incidence	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	hematologic	hematologic	B-NP	JJ	O	35	NMOD
33	and	and	I-NP	CC	O	35	NMOD
34	nonhematologic	nonhematologic	I-NP	JJ	O	35	NMOD
35	toxicity	toxicity	I-NP	NN	O	31	PMOD
36	.	.	O	.	O	2	P

1	Cerebral	Cerebral	B-NP	JJ	O	2	NMOD
2	hemorrhage	hemorrhage	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	phenylpropanolamine	phenylpropanolamine	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	combination	combination	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	caffeine	caffeine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	2	P

1	Phenylpropanolamine	Phenylpropanolamine	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	PPA	PPA	B-NP	NN	B-protein	4	DEP
4	)	)	O	)	O	1	NMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	a	a	B-NP	DT	O	7	NMOD
7	drug	drug	I-NP	NN	O	5	PRD
8	that	that	B-NP	WDT	O	7	NMOD
9	has	have	B-VP	VBZ	O	8	SBAR
10	been	be	I-VP	VBN	O	9	VC
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	serious	serious	B-NP	JJ	O	15	NMOD
14	side	side	I-NP	NN	O	15	NMOD
15	effects	effect	I-NP	NNS	O	12	PMOD
16	including	include	B-PP	VBG	O	15	NMOD
17	stroke	stroke	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	5	P

1	In	In	B-SBAR	IN	O	18	VMOD
2	order	order	O	NN	O	1	DEP
3	to	to	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	SBAR
5	if	if	B-SBAR	IN	O	4	VMOD
6	PPA/caffeine	PPA/caffeine	B-NP	NN	O	7	SUB
7	can	can	B-VP	MD	O	5	SBAR
8	lead	lead	I-VP	VB	O	7	VC
9	to	to	I-VP	TO	O	10	VMOD
10	stroke	stroke	I-VP	VB	O	8	VMOD
11	in	in	B-PP	IN	O	10	VMOD
12	normotensive	normotensive	B-NP	JJ	O	15	NMOD
13	and/or	and/or	I-NP	CC	O	15	NMOD
14	hypertensive	hypertensive	I-NP	JJ	O	15	NMOD
15	rats	rat	I-NP	NNS	O	11	PMOD
16	,	,	O	,	O	18	P
17	we	we	B-NP	PRP	O	18	SUB
18	administered	administer	B-VP	VBD	O	0	ROOT
19	the	the	B-NP	DT	O	20	NMOD
20	combination	combination	I-NP	NN	O	18	OBJ
21	in	in	B-PP	IN	O	18	VMOD
22	six	six	B-NP	CD	O	23	AMOD
23	times	time	I-NP	NNS	O	21	PMOD
24	the	the	I-NP	DT	O	27	NMOD
25	allowed	allow	I-NP	VBN	O	27	NMOD
26	human	human	I-NP	JJ	O	27	NMOD
27	dose	dose	I-NP	NN	O	18	VMOD
28	calculated	calculate	B-VP	VBN	O	27	NMOD
29	on	on	B-PP	IN	O	28	VMOD
30	a	a	B-NP	DT	O	38	NMOD
31	per	per	B-PP	IN	O	30	NMOD
32	weight	weight	B-NP	NN	O	31	PMOD
33	basis	basis	I-NP	NN	O	31	PMOD
34	for	for	B-PP	IN	O	38	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	rats	rat	I-NP	NNS	O	34	PMOD
37	two	two	B-NP	CD	O	38	NMOD
38	times	time	I-NP	NNS	O	29	PMOD
39	per	per	B-PP	IN	O	38	NMOD
40	day	day	B-NP	NN	O	39	PMOD
41	for	for	B-PP	IN	O	38	NMOD
42	five	five	B-NP	CD	O	43	NMOD
43	days	day	I-NP	NNS	O	41	PMOD
44	.	.	O	.	O	18	P

1	A	A	B-NP	DT	O	4	NMOD
2	single	single	I-NP	JJ	O	4	NMOD
3	PPA/caffeine	PPA/caffeine	I-NP	NN	O	4	NMOD
4	administration	administration	I-NP	NN	O	9	SUB
5	(	(	O	(	O	8	DEP
6	same	same	B-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	lead	lead	B-VP	VBP	O	0	ROOT
10	to	to	B-PP	TO	O	9	VMOD
11	acute	acute	B-NP	JJ	O	12	NMOD
12	hypertension	hypertension	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	both	both	B-NP	CC	O	19	NMOD
15	the	the	I-NP	DT	O	19	NMOD
16	normotensive	normotensive	I-NP	JJ	O	19	NMOD
17	and	and	I-NP	CC	O	19	NMOD
18	hypertensive	hypertensive	I-NP	JJ	O	19	NMOD
19	animals	animal	I-NP	NNS	O	13	PMOD
20	.	.	O	.	O	9	P

1	Long-term	Long-term	B-NP	JJ	O	2	NMOD
2	efficacy	efficacy	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	toxicity	toxicity	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	high-dose	high-dose	B-NP	JJ	O	8	NMOD
7	amiodarone	amiodarone	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	ventricular	ventricular	B-NP	JJ	O	11	NMOD
11	tachycardia	tachycardia	I-NP	NN	O	14	NMOD
12	or	or	O	CC	O	14	NMOD
13	ventricular	ventricular	B-NP	JJ	O	14	NMOD
14	fibrillation	fibrillation	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	4	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	administered	administer	I-VP	VBN	O	2	VC
4	to	to	B-PP	TO	O	3	VMOD
5	154	154	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	who	who	B-NP	WP	O	6	NMOD
8	had	have	B-VP	VBD	O	7	SBAR
9	sustained	sustain	I-VP	VBN	O	8	VC
10	,	,	O	,	O	2	P
11	symptomatic	symptomatic	B-NP	JJ	O	13	NMOD
12	ventricular	ventricular	I-NP	JJ	O	13	NMOD
13	tachycardia	tachycardia	I-NP	NN	O	25	NMOD
14	(	(	O	(	O	16	DEP
15	VT	VT	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	(	(	O	(	O	21	DEP
18	n	n	B-NP	NN	O	20	SUB
19	=	=	B-VP	SYM	O	20	VMOD
20	118	118	B-NP	CD	O	21	DEP
21	)	)	O	)	O	13	NMOD
22	or	or	O	CC	O	25	NMOD
23	a	a	B-NP	DT	O	25	NMOD
24	cardiac	cardiac	I-NP	JJ	O	25	NMOD
25	arrest	arrest	I-NP	NN	O	2	VMOD
26	(	(	O	(	O	30	DEP
27	n	n	B-NP	NN	O	29	SUB
28	=	=	B-VP	SYM	O	29	VMOD
29	36	36	B-NP	CD	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	and	and	O	CC	O	25	NMOD
32	who	who	B-NP	WP	O	31	AMOD
33	were	be	B-VP	VBD	O	32	SBAR
34	refractory	refractory	B-ADJP	JJ	O	33	PRD
35	to	to	B-PP	TO	O	34	AMOD
36	conventional	conventional	B-NP	JJ	O	38	NMOD
37	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	38	NMOD
38	drugs	drug	I-NP	NNS	O	35	PMOD
39	.	.	O	.	O	2	P

1	Sixty-nine	Sixty-nine	B-NP	CD	O	2	NMOD
2	percent	percent	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	continued	continue	B-VP	VBD	O	0	ROOT
6	treatment	treatment	B-NP	NN	O	5	OBJ
7	with	with	B-PP	IN	O	6	NMOD
8	amiodarone	amiodarone	B-NP	NN	O	7	PMOD
9	and	and	O	CC	O	5	VMOD
10	had	have	B-VP	VBD	O	5	VMOD
11	no	no	B-NP	DT	O	12	NMOD
12	recurrence	recurrence	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	symptomatic	symptomatic	B-NP	JJ	O	15	NMOD
15	VT	VT	I-NP	NN	O	13	PMOD
16	or	or	O	CC	O	18	NMOD
17	ventricular	ventricular	B-NP	JJ	O	18	NMOD
18	fibrillation	fibrillation	I-NP	NN	O	15	NMOD
19	(	(	O	(	O	21	DEP
20	VF	VF	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	over	over	B-PP	IN	O	10	VMOD
23	a	a	B-NP	DT	O	24	NMOD
24	follow-up	follow-up	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	6	6	B-NP	CD	O	28	AMOD
27	to	to	I-NP	TO	O	28	AMOD
28	52	52	I-NP	CD	O	29	NMOD
29	months	month	I-NP	NNS	O	25	PMOD
30	(	(	O	(	O	38	DEP
31	mean	mean	B-NP	NN	O	34	NMOD
32	+/-	+/-	O	CC	O	34	NMOD
33	standard	standard	B-NP	JJ	O	34	NMOD
34	deviation	deviation	I-NP	NN	O	38	DEP
35	14.2	14.2	B-NP	CD	O	37	AMOD
36	+/-	+/-	I-NP	CC	O	37	AMOD
37	8.2	8.2	I-NP	CD	O	34	NMOD
38	)	)	O	)	O	5	VMOD
39	.	.	O	.	O	5	P

1	Six	Six	B-NP	CD	O	2	NMOD
2	percent	percent	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	had	have	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	nonfatal	nonfatal	I-NP	JJ	O	9	NMOD
9	recurrence	recurrence	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	VT	VT	B-NP	NN	O	10	PMOD
12	and	and	O	CC	O	6	VMOD
13	were	be	B-VP	VBD	O	6	VMOD
14	successfully	successfully	I-VP	RB	O	13	VMOD
15	managed	manage	I-VP	VBN	O	13	VC
16	by	by	B-PP	IN	O	15	VMOD
17	continuing	continue	B-NP	VBG	O	18	NMOD
18	amiodarone	amiodarone	I-NP	NN	O	16	PMOD
19	at	at	B-PP	IN	O	18	NMOD
20	a	a	B-NP	DT	O	22	NMOD
21	higher	high	I-NP	JJR	O	22	NMOD
22	dose	dose	I-NP	NN	O	19	PMOD
23	or	or	B-PP	CC	O	16	PMOD
24	by	by	B-PP	IN	O	16	PMOD
25	the	the	B-NP	DT	O	26	NMOD
26	addition	addition	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	a	a	B-NP	DT	O	31	NMOD
29	conventional	conventional	I-NP	JJ	O	31	NMOD
30	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	31	NMOD
31	drug	drug	I-NP	NN	O	27	PMOD
32	.	.	O	.	O	6	P

1	Although	Although	B-SBAR	IN	O	22	VMOD
2	large-dose	large-dose	B-NP	JJ	O	3	NMOD
3	amiodarone	amiodarone	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	1	SBAR
5	highly	highly	B-ADJP	RB	O	6	AMOD
6	effective	effective	I-ADJP	JJ	O	4	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	the	the	B-NP	DT	O	10	NMOD
9	long-term	long-term	I-NP	JJ	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	VT	VT	B-NP	NN	O	14	NMOD
13	or	or	I-NP	CC	O	14	NMOD
14	VF	VF	I-NP	NN	O	11	PMOD
15	refractory	refractory	B-ADJP	JJ	O	14	NMOD
16	to	to	B-PP	TO	O	15	AMOD
17	conventional	conventional	B-NP	JJ	O	19	NMOD
18	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	19	NMOD
19	drugs	drug	I-NP	NNS	O	16	PMOD
20	,	,	O	,	O	22	P
21	it	it	B-NP	PRP	O	22	SUB
22	causes	cause	B-VP	VBZ	O	0	ROOT
23	significant	significant	B-NP	JJ	O	24	NMOD
24	toxicity	toxicity	I-NP	NN	O	22	OBJ
25	in	in	B-PP	IN	O	22	VMOD
26	approximately	approximately	B-NP	RB	O	28	NMOD
27	50	50	I-NP	CD	O	26	AMOD
28	%	%	I-NP	NN	O	25	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	patients	patient	B-NP	NNS	O	29	PMOD
31	.	.	O	.	O	22	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	calcium	calcium	B-NP	NN	O	4	NMOD
4	chloride	chloride	I-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	4-aminopyridine	4-aminopyridine	B-NP	NN	O	7	NMOD
7	therapy	therapy	I-NP	NN	O	2	PMOD
8	on	on	B-PP	IN	O	1	NMOD
9	desipramine	desipramine	B-NP	NN	O	10	NMOD
10	toxicity	toxicity	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	rats	rat	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	addressed	address	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	potential	potential	I-NP	JJ	O	6	NMOD
6	role	role	I-NP	NN	O	15	NMOD
7	of	of	B-PP	IN	O	6	NMOD
8	calcium	calcium	B-NP	NN	O	10	NMOD
9	channel	channel	I-NP	NN	O	10	NMOD
10	blockade	blockade	I-NP	NN	O	7	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	tricyclic	tricyclic	B-NP	JJ	O	13	NMOD
13	antidepressant	antidepressant	I-NP	NN	O	11	PMOD
14	induced	induce	B-VP	VBD	O	15	NMOD
15	hypotension	hypotension	B-NP	NN	O	3	OBJ
16	.	.	O	.	O	3	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Two	Two	B-NP	CD	O	4	NMOD
4	interventions	intervention	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	1	NMOD
6	studied	study	I-VP	VBN	O	5	VC
7	that	that	B-NP	WDT	O	6	VMOD
8	have	have	B-VP	VBP	O	7	SBAR
9	been	be	I-VP	VBN	O	8	VC
10	shown	show	I-VP	VBN	O	9	VC
11	previously	previously	B-ADVP	RB	O	10	VMOD
12	to	to	B-VP	TO	O	13	VMOD
13	improve	improve	I-VP	VB	O	10	VMOD
14	blood	blood	B-NP	NN	O	15	NMOD
15	pressure	pressure	I-NP	NN	O	13	OBJ
16	with	with	B-PP	IN	O	15	NMOD
17	calcium	calcium	B-NP	NN	O	20	NMOD
18	channel	channel	I-NP	NN	O	20	NMOD
19	blocker	blocker	I-NP	NN	O	20	NMOD
20	overdose	overdose	I-NP	NN	O	16	PMOD
21	.	.	O	.	O	1	P

1	Anesthetized	Anesthetize	B-NP	VBN	O	2	NMOD
2	rats	rat	I-NP	NNS	O	3	SUB
3	received	receive	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	8	NMOD
5	tricyclic	tricyclic	I-NP	JJ	O	8	NMOD
6	antidepressant	antidepressant	I-NP	NN	O	8	NMOD
7	desipramine	desipramine	I-NP	NN	O	8	NMOD
8	IP	IP	I-NP	NN	O	3	OBJ
9	to	to	B-VP	TO	O	10	VMOD
10	produce	produce	I-VP	VB	O	8	NMOD
11	hypotension	hypotension	B-NP	NN	O	17	NMOD
12	,	,	O	,	O	17	P
13	QRS	QRS	B-NP	NN	B-protein	14	NMOD
14	prolongation	prolongation	I-NP	NN	O	17	NMOD
15	,	,	O	,	O	17	P
16	and	and	O	CC	O	17	NMOD
17	bradycardia	bradycardia	B-NP	NN	O	10	OBJ
18	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	NaHCO3	NaHCO3	B-NP	NN	O	4	NMOD
4	briefly	briefly	I-NP	NN	O	9	SUB
5	(	(	O	(	O	8	DEP
6	5	5	B-NP	CD	O	7	NMOD
7	min	min	I-NP	NN	O	8	DEP
8	)	)	O	)	O	4	NMOD
9	reversed	reverse	B-VP	VBD	O	1	NMOD
10	hypotension	hypotension	B-NP	NN	O	13	NMOD
11	and	and	I-NP	CC	O	13	NMOD
12	QRS	QRS	I-NP	NN	B-protein	13	NMOD
13	prolongation	prolongation	I-NP	NN	O	9	OBJ
14	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	12	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	ventricular	ventricular	B-NP	JJ	O	5	NMOD
5	arrhythmias	arrhythmia	I-NP	NNS	O	3	PMOD
6	(	(	O	(	O	10	DEP
7	p	p	B-NP	NN	O	9	SUB
8	=	=	B-VP	SYM	O	9	VMOD
9	0.004	0.004	B-NP	CD	O	10	DEP
10	)	)	O	)	O	2	NMOD
11	and	and	O	CC	O	12	NMOD
12	seizures	seizure	B-NP	NNS	O	22	SUB
13	(	(	O	(	O	17	DEP
14	p	p	B-NP	NN	O	17	DEP
15	=	=	B-VP	SYM	O	14	NMOD
16	0.03	0.03	B-NP	CD	O	15	AMOD
17	)	)	O	)	O	12	NMOD
18	in	in	B-PP	IN	O	12	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	CaCl2	CaCl2	I-NP	NN	O	21	NMOD
21	group	group	I-NP	NN	O	18	PMOD
22	was	be	B-VP	VBD	O	0	ROOT
23	higher	high	B-ADJP	JJR	O	22	PRD
24	than	than	B-PP	IN	O	23	AMOD
25	the	the	B-NP	DT	O	27	NMOD
26	other	other	I-NP	JJ	O	27	NMOD
27	groups	group	I-NP	NNS	O	24	PMOD
28	.	.	O	.	O	22	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	administration	administration	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	CaCl2	CaCl2	B-NP	NN	O	8	NMOD
7	or	or	I-NP	CC	O	8	NMOD
8	4-aminopyridine	4-aminopyridine	I-NP	NN	O	5	PMOD
9	did	do	B-VP	VBD	O	1	NMOD
10	not	not	I-VP	RB	O	9	VMOD
11	reverse	reverse	I-VP	VB	O	9	VC
12	tricyclic	tricyclic	B-NP	JJ	O	13	NMOD
13	antidepressant	antidepressant	I-NP	NN	O	15	NMOD
14	induced	induce	B-VP	VBD	O	15	NMOD
15	hypotension	hypotension	B-NP	NN	O	11	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	1	P

1	CaCl2	CaCl2	B-NP	NN	O	2	NMOD
2	therapy	therapy	I-NP	NN	O	3	SUB
3	may	may	B-VP	MD	O	0	ROOT
4	possibly	possibly	I-VP	RB	O	3	VMOD
5	worsen	worsen	I-VP	VB	O	3	VC
6	both	both	O	CC	O	12	NMOD
7	cardiovascular	cardiovascular	B-NP	JJ	O	9	AMOD
8	and	and	I-NP	CC	O	9	AMOD
9	central	central	I-NP	JJ	O	12	NMOD
10	nervous	nervous	I-NP	JJ	O	12	NMOD
11	system	system	I-NP	NN	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	5	OBJ
13	.	.	O	.	O	3	P

1	Phase	Phase	B-NP	NN	O	3	NMOD
2	I	I	I-NP	CD	O	3	NMOD
3	trial	trial	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	13-cis-retinoic	13-cis-retinoic	B-NP	JJ	O	6	NMOD
6	acid	acid	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	children	child	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	neuroblastoma	neuroblastoma	B-NP	NN	B-cell_type	9	PMOD
11	following	follow	B-PP	VBG	O	8	NMOD
12	bone	bone	B-NP	NN	O	14	NMOD
13	marrow	marrow	I-NP	NN	O	14	NMOD
14	transplantation	transplantation	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	3	P

1	PURPOSE	PURPOSE	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Treatment	Treatment	B-NP	NN	O	14	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	neuroblastoma	neuroblastoma	B-NP	NN	B-cell_line	7	NMOD
6	cell	cell	I-NP	NN	I-cell_line	7	NMOD
7	lines	line	I-NP	NNS	I-cell_line	4	PMOD
8	with	with	B-PP	IN	O	3	NMOD
9	13-cis-retinoic	13-cis-retinoic	B-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	cis-RA	cis-RA	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	can	can	B-VP	MD	O	0	ROOT
15	cause	cause	I-VP	VB	O	14	VC
16	sustained	sustained	B-NP	JJ	O	17	NMOD
17	inhibition	inhibition	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	proliferation	proliferation	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	14	P

1	Since	Since	B-SBAR	IN	O	12	VMOD
2	cis-RA	cis-RA	B-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	1	SBAR
4	demonstrated	demonstrate	I-VP	VBN	O	3	VC
5	clinical	clinical	B-NP	JJ	O	6	NMOD
6	responses	response	I-NP	NNS	O	4	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	neuroblastoma	neuroblastoma	B-NP	NN	B-cell_type	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	,	,	O	,	O	12	P
11	it	it	B-NP	PRP	O	12	SUB
12	may	may	B-VP	MD	O	0	ROOT
13	be	be	I-VP	VB	O	12	VC
14	effective	effective	B-ADJP	JJ	O	13	PRD
15	in	in	B-PP	IN	O	13	VMOD
16	preventing	prevent	B-VP	VBG	O	15	PMOD
17	relapse	relapse	B-NP	NN	O	16	OBJ
18	after	after	B-PP	IN	O	16	VMOD
19	cytotoxic	cytotoxic	B-NP	JJ	O	20	NMOD
20	therapy	therapy	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	12	P

1	This	This	B-NP	DT	O	4	NMOD
2	phase	phase	I-NP	NN	O	4	NMOD
3	I	I	I-NP	CD	O	4	NMOD
4	trial	trial	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	designed	design	I-VP	VBN	O	5	VC
7	to	to	B-VP	TO	O	8	VMOD
8	determine	determine	I-VP	VB	O	6	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	maximal-tolerated	maximal-tolerated	I-NP	JJ	O	11	NMOD
11	dosage	dosage	I-NP	NN	O	16	NMOD
12	(	(	O	(	O	14	DEP
13	MTD	MTD	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	,	,	O	,	O	16	P
16	toxicities	toxicity	B-NP	NNS	O	8	VMOD
17	,	,	O	,	O	19	P
18	and	and	O	CC	O	19	NMOD
19	pharmacokinetics	pharmacokinetic	B-NP	NNS	O	16	NMOD
20	of	of	B-PP	IN	O	19	NMOD
21	cis-RA	cis-RA	B-NP	NN	O	20	PMOD
22	administered	administer	B-VP	VBN	O	21	NMOD
23	on	on	B-PP	IN	O	22	VMOD
24	an	an	B-NP	DT	O	26	NMOD
25	intermittent	intermittent	I-NP	JJ	O	26	NMOD
26	schedule	schedule	I-NP	NN	O	23	PMOD
27	in	in	B-PP	IN	O	26	NMOD
28	children	child	B-NP	NNS	O	27	PMOD
29	with	with	B-PP	IN	O	28	NMOD
30	neuroblastoma	neuroblastoma	B-NP	NN	B-cell_type	29	PMOD
31	following	follow	B-PP	VBG	O	28	NMOD
32	bone	bone	B-NP	NN	O	34	NMOD
33	marrow	marrow	I-NP	NN	O	34	NMOD
34	transplantation	transplantation	I-NP	NN	O	31	PMOD
35	(	(	O	(	O	37	DEP
36	BMT	BMT	B-NP	NN	O	37	DEP
37	)	)	O	)	O	34	NMOD
38	.	.	O	.	O	5	P

1	All	All	B-NP	DT	O	2	NMOD
2	toxicities	toxicity	I-NP	NNS	O	6	SUB
3	resolved	resolve	B-VP	VBN	O	2	NMOD
4	after	after	B-PP	IN	O	3	VMOD
5	cis-RA	cis-RA	B-NP	NN	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	discontinued	discontinue	I-VP	VBN	O	6	VC
8	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	DLT	DLT	I-NP	NN	O	3	SUB
3	included	include	B-VP	VBD	O	0	ROOT
4	hypercalcemia	hypercalcemia	B-NP	NN	O	3	OBJ
5	,	,	O	,	O	3	P
6	and	and	O	CC	O	3	VMOD
7	may	may	B-VP	MD	O	3	VMOD
8	be	be	I-VP	VB	O	7	VC
9	predicted	predict	I-VP	VBN	O	8	VC
10	by	by	B-PP	IN	O	9	VMOD
11	serum	serum	B-NP	NN	O	13	NMOD
12	cis-RA	cis-RA	I-NP	NN	O	13	NMOD
13	levels	level	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	55	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	calcium	calcium	B-NP	NN	O	5	NMOD
5	chloride	chloride	I-NP	NN	O	3	PMOD
6	injected	inject	B-VP	VBN	O	5	NMOD
7	into	into	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	cerebral	cerebral	I-NP	JJ	O	10	NMOD
10	ventricles	ventricle	I-NP	NNS	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	group-housed	group-housed	B-NP	JJ	O	14	NMOD
13	unanaesthetized	unanaesthetized	I-NP	JJ	O	14	NMOD
14	cats	cat	I-NP	NNS	O	11	PMOD
15	upon	upon	B-PP	IN	O	2	NMOD
16	vocalization	vocalization	B-NP	NN	O	47	NMOD
17	(	(	O	(	O	23	DEP
18	rage	rage	B-NP	NN	O	22	NMOD
19	,	,	O	,	O	22	P
20	hissing	hissing	B-NP	NN	O	22	NMOD
21	and	and	O	CC	O	22	NMOD
22	snarling	snarling	B-NP	NN	O	23	DEP
23	)	)	O	)	O	16	NMOD
24	,	,	O	,	O	47	P
25	fighting	fighting	B-NP	NN	O	47	NMOD
26	(	(	O	(	O	40	DEP
27	attack	attack	B-NP	NN	O	39	SUB
28	with	with	B-PP	IN	O	27	NMOD
29	paws	paw	B-NP	NNS	O	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	claws	claw	I-NP	NNS	O	28	PMOD
32	,	,	O	,	O	39	P
33	defense	defense	B-NP	NN	O	39	SUB
34	with	with	B-PP	IN	O	33	NMOD
35	paws	paw	B-NP	NNS	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	claws	claw	I-NP	NNS	O	34	PMOD
38	and	and	O	CC	O	39	NMOD
39	biting	bite	B-VP	VBG	O	40	DEP
40	)	)	O	)	O	25	NMOD
41	,	,	O	,	O	47	P
42	mydriasis	mydriasis	B-NP	NN	O	47	NMOD
43	,	,	O	,	O	47	P
44	tremor	tremor	B-NP	NN	O	47	NMOD
45	and	and	O	CC	O	47	NMOD
46	clonic-tonic	clonic-tonic	B-NP	JJ	O	47	NMOD
47	convulsions	convulsion	I-NP	NNS	O	15	PMOD
48	produced	produce	B-VP	VBN	O	47	NMOD
49	by	by	B-PP	IN	O	48	VMOD
50	carbachol	carbachol	B-NP	NN	O	52	NMOD
51	and	and	I-NP	CC	O	52	NMOD
52	eserine	eserine	I-NP	NN	O	49	PMOD
53	injected	inject	B-VP	VBN	O	52	NMOD
54	similarly	similarly	B-ADVP	RB	O	53	VMOD
55	was	be	B-VP	VBD	O	0	ROOT
56	investigated	investigate	I-VP	VBN	O	55	VC
57	.	.	O	.	O	55	P

1	On	On	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	17	P
6	mydriasis	mydriasis	B-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	tremor	tremor	B-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	clonic-tonic	clonic-tonic	B-NP	JJ	O	11	NMOD
11	convulsions	convulsion	I-NP	NNS	O	17	SUB
12	evoked	evoke	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	carbachol	carbachol	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	eserine	eserine	I-NP	NN	O	13	PMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	not	not	I-VP	RB	O	17	VMOD
19	significantly	significantly	I-VP	RB	O	17	VMOD
20	changed	change	I-VP	VBN	O	17	VC
21	by	by	B-PP	IN	O	20	VMOD
22	calcium	calcium	B-NP	NN	O	23	NMOD
23	chloride	chloride	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	17	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	apparent	apparent	B-ADJP	JJ	O	2	PRD
4	that	that	B-SBAR	IN	O	2	VMOD
5	calcium	calcium	B-NP	NN	O	6	NMOD
6	chloride	chloride	I-NP	NN	O	7	SUB
7	can	can	B-VP	MD	O	4	SBAR
8	"	"	O	"	O	7	VMOD
9	dissociate	dissociate	B-VP	VB	O	7	VC
10	"	"	O	"	O	9	VMOD
11	vocalization	vocalization	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	fighting	fighting	I-NP	NN	O	10	OBJ
14	from	from	B-PP	IN	O	13	NMOD
15	autonomic	autonomic	B-NP	JJ	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	motor	motor	I-NP	NN	O	18	NMOD
18	phenomena	phenomenon	I-NP	NNS	O	14	PMOD
19	such	such	B-PP	JJ	O	20	PMOD
20	as	as	I-PP	IN	O	18	NMOD
21	mydriasis	mydriasis	B-NP	NN	O	26	NMOD
22	,	,	O	,	O	26	P
23	tremor	tremor	B-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	clonic-tonic	clonic-tonic	B-NP	JJ	O	26	NMOD
26	convulsions	convulsion	I-NP	NNS	O	20	PMOD
27	caused	cause	B-VP	VBN	O	26	NMOD
28	by	by	B-PP	IN	O	27	VMOD
29	carbachol	carbachol	B-NP	NN	O	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	eserine	eserine	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	2	P

1	Multiple	Multiple	B-NP	JJ	O	3	NMOD
2	side	side	I-NP	NN	O	3	NMOD
3	effects	effect	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	penicillamine	penicillamine	B-NP	NN	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	4	PMOD
7	in	in	B-PP	IN	O	3	NMOD
8	one	one	B-NP	CD	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	rheumatoid	rheumatoid	B-NP	JJ	O	12	NMOD
12	arthritis	arthritis	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	3	P

1	Skin	Skin	B-NP	NN	O	2	NMOD
2	rashes	rash	I-NP	NNS	O	13	NMOD
3	,	,	O	,	O	13	P
4	proteinuria	proteinuria	B-NP	NN	O	13	NMOD
5	,	,	O	,	O	13	P
6	systemic	systemic	B-NP	JJ	O	8	NMOD
7	lupus	lupus	I-NP	NN	O	8	NMOD
8	erythematosus	erythematosus	I-NP	NN	O	13	NMOD
9	,	,	O	,	O	13	P
10	polymyositis	polymyositis	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	myasthenia	myasthenia	B-NP	NN	O	13	NMOD
13	gravis	gravis	I-NP	NN	O	14	SUB
14	have	have	B-VP	VBP	O	0	ROOT
15	all	all	O	DT	O	14	VMOD
16	been	be	B-VP	VBN	O	14	VC
17	recorded	record	I-VP	VBN	O	16	VC
18	as	as	B-PP	IN	O	17	VMOD
19	complications	complication	B-NP	NNS	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	penicillamine	penicillamine	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	patients	patient	B-NP	NNS	O	23	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	rheumatoid	rheumatoid	B-NP	JJ	O	27	NMOD
27	arthritis	arthritis	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	14	P

1	Although	Although	B-SBAR	IN	O	13	VMOD
2	most	most	B-NP	JJS	O	3	NMOD
3	patients	patient	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	1	SBAR
5	receiving	receive	I-VP	VBG	O	4	VC
6	several	several	B-NP	JJ	O	7	NMOD
7	drugs	drug	I-NP	NNS	O	9	NMOD
8	,	,	O	,	O	9	P
9	Mellaril	Mellaril	B-NP	NNP	O	5	OBJ
10	(	(	O	(	O	12	DEP
11	thioridazine	thioridazine	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	appeared	appear	B-VP	VBD	O	0	ROOT
14	to	to	I-VP	TO	O	15	VMOD
15	be	be	I-VP	VB	O	13	VMOD
16	responsible	responsible	B-ADJP	JJ	O	15	PRD
17	for	for	B-PP	IN	O	16	AMOD
18	five	five	B-NP	CD	O	19	NMOD
19	cases	case	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	ventricular	ventricular	B-NP	JJ	O	22	NMOD
22	tachycardia	tachycardia	I-NP	NN	O	20	PMOD
23	,	,	O	,	O	16	P
24	one	one	B-NP	CD	O	25	NMOD
25	of	of	B-PP	IN	O	16	AMOD
26	which	which	B-NP	WDT	O	25	PMOD
27	was	be	B-VP	VBD	O	25	SBAR
28	fatal	fatal	B-ADJP	JJ	O	27	PRD
29	in	in	B-PP	IN	O	28	AMOD
30	a	a	B-NP	DT	O	34	NMOD
31	35	35	I-NP	CD	O	34	NMOD
32	year	year	I-NP	NN	O	34	NMOD
33	old	old	I-NP	JJ	O	34	NMOD
34	woman	woman	I-NP	NN	O	29	PMOD
35	.	.	O	.	O	13	P

1	Supraventricular	Supraventricular	B-NP	JJ	O	2	NMOD
2	tachycardia	tachycardia	I-NP	NN	O	0	ROOT
3	developed	develop	B-VP	VBN	O	2	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	one	one	B-NP	CD	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	receiving	receive	B-VP	VBG	O	6	NMOD
8	Thorazine	Thorazine	B-NP	NN	O	7	OBJ
9	(	(	O	(	O	11	DEP
10	chlorpromazine	chlorpromazine	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	.	.	O	.	O	2	P

1	Aventyl	Aventyl	B-NP	NN	O	6	NMOD
2	(	(	O	(	O	4	DEP
3	nortriptyline	nortriptyline	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	and	and	O	CC	O	6	NMOD
6	Elavil	Elavil	B-NP	NN	O	10	NMOD
7	(	(	O	(	O	9	DEP
8	amitriptyline	amitriptyline	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	each	each	B-NP	DT	O	11	SUB
11	produced	produce	B-VP	VBD	O	0	ROOT
12	left	left	B-NP	JJ	O	15	NMOD
13	bundle	bundle	I-NP	NN	O	15	NMOD
14	branch	branch	I-NP	NN	O	15	NMOD
15	block	block	I-NP	NN	O	11	OBJ
16	in	in	B-PP	IN	O	11	VMOD
17	a	a	B-NP	DT	O	21	NMOD
18	73	73	I-NP	CD	O	21	NMOD
19	year	year	I-NP	NN	O	21	NMOD
20	old	old	I-NP	JJ	O	21	NMOD
21	woman	woman	I-NP	NN	O	16	PMOD
22	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	ventricular	ventricular	I-NP	JJ	O	3	NMOD
3	arrhythmias	arrhythmia	I-NP	NNS	O	4	SUB
4	responded	respond	B-VP	VBD	O	19	VMOD
5	to	to	B-PP	TO	O	4	VMOD
6	intravenous	intravenous	B-NP	JJ	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	lidocaine	lidocaine	B-NP	NN	O	8	PMOD
10	and	and	O	CC	O	4	VMOD
11	to	to	B-VP	TO	O	12	VMOD
12	direct	direct	I-VP	VB	O	4	VMOD
13	current	current	B-NP	JJ	O	14	AMOD
14	electric	electric	I-NP	JJ	O	15	NMOD
15	shock	shock	I-NP	NN	O	12	OBJ
16	;	;	O	:	O	19	P
17	ventricular	ventricular	B-NP	JJ	O	18	NMOD
18	pacing	pacing	I-NP	NN	O	19	SUB
19	was	be	B-VP	VBD	O	0	ROOT
20	required	require	I-VP	VBN	O	19	VC
21	in	in	B-PP	IN	O	20	VMOD
22	some	some	B-NP	DT	O	26	NMOD
23	instances	instance	I-NP	NNS	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	intravenous	intravenous	B-NP	JJ	O	26	NMOD
26	administration	administration	I-NP	NN	O	21	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	propranolol	propranolol	B-NP	NN	O	27	PMOD
29	combined	combine	B-VP	VBN	O	28	NMOD
30	with	with	B-PP	IN	O	29	VMOD
31	ventricular	ventricular	B-NP	JJ	O	32	NMOD
32	pacing	pacing	I-NP	NN	O	30	PMOD
33	in	in	B-PP	IN	O	32	NMOD
34	one	one	B-NP	CD	O	33	PMOD
35	.	.	O	.	O	19	P

1	Serotonergic	Serotonergic	B-NP	JJ	O	2	NMOD
2	drugs	drug	I-NP	NNS	O	6	NMOD
3	,	,	O	,	O	6	P
4	benzodiazepines	benzodiazepine	B-NP	NNS	O	6	NMOD
5	and	and	O	CC	O	6	NMOD
6	baclofen	baclofen	B-NP	NN	O	7	SUB
7	block	block	B-VP	VBP	O	0	ROOT
8	muscimol	muscimol	B-NP	NN	O	7	OBJ
9	induced	induce	B-VP	VBD	O	8	NMOD
10	myoclonic	myoclonic	B-NP	JJ	B-protein	11	NMOD
11	jerks	jerk	I-NP	NNS	I-protein	9	OBJ
12	in	in	B-PP	IN	O	9	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	strain	strain	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	mice	mouse	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	7	VMOD
2	male	male	B-NP	JJ	O	4	NMOD
3	Swiss	Swiss	I-NP	JJ	O	4	NMOD
4	mice	mouse	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	7	P
6	muscimol	muscimol	B-NP	NN	O	7	SUB
7	produced	produce	B-VP	VBD	O	0	ROOT
8	myoclonic	myoclonic	B-NP	JJ	O	9	NMOD
9	jerks	jerk	I-NP	NNS	O	7	OBJ
10	.	.	O	.	O	7	P

1	Of	Of	B-PP	IN	O	10	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	benzodiazepines	benzodiazepine	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	10	P
5	clonazepam	clonazepam	B-NP	NN	O	10	SUB
6	(	(	O	(	O	9	DEP
7	0.1-0.3	0.1-0.3	B-NP	CD	O	8	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	9	DEP
9	)	)	O	)	O	5	NMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	found	find	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	11	VMOD
14	several	several	B-ADJP	JJ	O	15	AMOD
15	fold	fold	B-ADJP	RB	O	13	PRD
16	more	more	I-ADJP	RBR	O	17	AMOD
17	potent	potent	I-ADJP	JJ	O	15	AMOD
18	than	than	B-PP	IN	O	15	AMOD
19	diazepam	diazepam	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	23	DEP
21	0.3-3	0.3-3	B-NP	CD	O	22	NMOD
22	mg/kg	mg/kg	I-NP	NN	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	in	in	B-PP	IN	O	19	NMOD
25	blocking	block	B-VP	VBG	O	24	PMOD
26	the	the	B-NP	DT	O	28	NMOD
27	myoclonic	myoclonic	I-NP	JJ	B-protein	28	NMOD
28	jerks	jerk	I-NP	NNS	I-protein	25	OBJ
29	.	.	O	.	O	10	P

1	Considering	Consider	B-VP	VBG	O	26	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	fact	fact	I-NP	NN	O	1	OBJ
4	that	that	B-SBAR	IN	O	3	NMOD
5	5-HTP	5-HTP	B-NP	NN	B-protein	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	benzodiazepines	benzodiazepine	I-NP	NNS	O	9	SUB
9	have	have	B-VP	VBP	O	4	SBAR
10	been	be	I-VP	VBN	O	9	VC
11	found	find	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	11	VMOD
14	beneficial	beneficial	B-ADJP	JJ	O	13	PRD
15	in	in	B-PP	IN	O	13	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	management	management	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	clinical	clinical	B-NP	JJ	O	20	NMOD
20	myoclonus	myoclonus	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	26	P
22	the	the	B-NP	DT	O	25	NMOD
23	muscimol	muscimol	I-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	myoclonus	myoclonus	I-NP	NN	O	26	SUB
26	seems	seem	B-VP	VBZ	O	0	ROOT
27	to	to	I-VP	TO	O	28	VMOD
28	be	be	I-VP	VB	O	26	VMOD
29	a	a	B-NP	DT	O	32	NMOD
30	satisfactory	satisfactory	I-NP	JJ	O	32	NMOD
31	animal	animal	I-NP	NN	O	32	NMOD
32	model	model	I-NP	NN	O	28	PRD
33	that	that	B-NP	WDT	O	32	NMOD
34	may	may	B-VP	MD	O	33	SBAR
35	prove	prove	I-VP	VB	O	34	VC
36	useful	useful	B-ADJP	JJ	O	35	PRD
37	for	for	B-PP	IN	O	36	AMOD
38	the	the	B-NP	DT	O	39	NMOD
39	development	development	I-NP	NN	O	37	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	new	new	B-NP	JJ	O	43	NMOD
42	drug	drug	I-NP	NN	O	43	NMOD
43	treatments	treatment	I-NP	NNS	O	40	PMOD
44	for	for	B-PP	IN	O	43	NMOD
45	this	this	B-NP	DT	O	46	NMOD
46	condition	condition	I-NP	NN	O	44	PMOD
47	.	.	O	.	O	26	P

1	Following	Follow	B-PP	VBG	O	10	VMOD
2	short	short	B-NP	JJ	O	3	NMOD
3	exposure	exposure	I-NP	NN	O	1	PMOD
4	to	to	B-PP	TO	O	3	NMOD
5	oral	oral	B-NP	JJ	O	6	NMOD
6	prednisone	prednisone	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	10	P
8	both	both	B-NP	DT	O	9	NMOD
9	boys	boy	I-NP	NNS	O	10	SUB
10	developed	develop	B-VP	VBD	O	0	ROOT
11	lethargy	lethargy	B-NP	NN	O	10	OBJ
12	,	,	O	,	O	11	P
13	increasing	increase	B-VP	VBG	O	11	NMOD
14	somnolence	somnolence	B-NP	NN	O	21	NMOD
15	,	,	O	,	O	21	P
16	polydipsia	polydipsia	B-NP	NN	O	21	NMOD
17	,	,	O	,	O	21	P
18	polyphagia	polyphagia	B-NP	NN	O	21	NMOD
19	,	,	O	,	O	21	P
20	and	and	O	CC	O	21	NMOD
21	polyuria	polyuria	B-NP	NN	O	13	OBJ
22	.	.	O	.	O	10	P

1	Nonketotic	Nonketotic	B-NP	JJ	O	3	NMOD
2	lactic	lactic	I-NP	JJ	O	3	NMOD
3	acidosis	acidosis	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	present	present	B-ADJP	JJ	O	4	PRD
6	in	in	B-PP	IN	O	5	AMOD
7	one	one	B-NP	CD	O	9	NMOD
8	and	and	O	CC	O	9	NMOD
9	ketosis	ketosis	B-NP	NN	O	6	PMOD
10	without	without	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	15	NMOD
12	known	know	I-NP	VBN	O	15	NMOD
13	serum	serum	I-NP	NN	O	15	NMOD
14	lactate	lactate	I-NP	NN	O	15	NMOD
15	level	level	I-NP	NN	O	10	PMOD
16	was	be	B-VP	VBD	O	4	VMOD
17	present	present	B-ADJP	JJ	O	16	PRD
18	in	in	B-PP	IN	O	17	AMOD
19	the	the	B-NP	DT	O	20	NMOD
20	other	other	I-NP	JJ	O	18	PMOD
21	.	.	O	.	O	4	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	active	active	B-NP	JJ	O	4	NMOD
4	constituents	constituent	I-NP	NNS	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	Crocus	Crocus	B-NP	NNP	O	8	NMOD
7	sativus	sativus	I-NP	NNP	O	8	NMOD
8	L.	L.	I-NP	NNP	O	13	VMOD
9	,	,	O	,	O	13	P
10	crocin	crocin	B-NP	NN	O	13	SUB
11	on	on	B-PP	IN	O	10	NMOD
12	streptozocin	streptozocin	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	5	SBAR
14	model	model	B-NP	NN	O	13	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	sporadic	sporadic	B-NP	JJ	O	19	NMOD
17	Alzheimer	Alzheimer	I-NP	NNP	O	19	NMOD
18	's	's	B-NP	POS	O	19	NMOD
19	disease	disease	I-NP	NN	O	15	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	male	male	B-NP	JJ	O	22	NMOD
22	rats	rat	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	28	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	28	P
6	the	the	B-NP	DT	O	7	NMOD
7	effect	effect	I-NP	NN	O	28	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	crocins	crocin	B-NP	NNS	O	8	PMOD
10	on	on	B-PP	IN	O	7	NMOD
11	sporadic	sporadic	B-NP	JJ	O	14	NMOD
12	Alzheimer	Alzheimer	I-NP	NNP	O	14	NMOD
13	's	's	B-NP	POS	O	14	NMOD
14	disease	disease	I-NP	NN	O	10	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	intracerebroventricular	intracerebroventricular	B-NP	JJ	O	21	NMOD
18	(	(	O	(	O	20	DEP
19	icv	icv	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	AMOD
21	streptozocin	streptozocin	B-NP	NN	O	16	PMOD
22	(	(	O	(	O	24	DEP
23	STZ	STZ	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	in	in	B-PP	IN	O	21	NMOD
26	male	male	B-NP	JJ	O	27	NMOD
27	rats	rat	I-NP	NNS	O	25	PMOD
28	was	be	B-VP	VBD	O	0	ROOT
29	investigated	investigate	I-VP	VBN	O	28	VC
30	.	.	O	.	O	28	P

1	In	In	B-PP	IN	O	8	VMOD
2	Alzheimer	Alzheimer	B-NP	NNP	O	3	NMOD
3	's	's	B-NP	POS	O	5	NMOD
4	disease	disease	I-NP	NN	O	5	NMOD
5	groups	group	I-NP	NNS	O	1	PMOD
6	,	,	O	,	O	8	P
7	rats	rat	B-NP	NNS	O	8	SUB
8	were	be	B-VP	VBD	O	29	VMOD
9	injected	inject	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	STZ-icv	STZ-icv	B-NP	NN	O	10	PMOD
12	bilaterally	bilaterally	B-ADVP	RB	O	9	VMOD
13	(	(	O	(	O	16	DEP
14	3	3	B-NP	CD	O	15	NMOD
15	mg/kg	mg/kg	I-NP	NN	O	16	DEP
16	)	)	O	)	O	12	AMOD
17	in	in	B-PP	IN	O	9	VMOD
18	first	first	B-NP	JJ	O	19	NMOD
19	day	day	I-NP	NN	O	17	PMOD
20	and	and	O	CC	O	29	VMOD
21	3	3	B-NP	CD	O	22	NMOD
22	days	day	I-NP	NNS	O	29	SUB
23	later	later	B-ADVP	RB	O	29	VMOD
24	,	,	O	,	O	29	P
25	a	a	B-NP	DT	O	28	NMOD
26	similar	similar	I-NP	JJ	O	28	NMOD
27	STZ-icv	STZ-icv	I-NP	NN	O	28	NMOD
28	application	application	I-NP	NN	O	29	SUB
29	was	be	B-VP	VBD	O	0	ROOT
30	repeated	repeat	I-VP	VBN	O	29	VC
31	.	.	O	.	O	29	P

1	In	In	B-PP	IN	O	9	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	9	P
4	crocin	crocin	B-NP	NN	O	9	SUB
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	mentioned	mention	I-NP	VBN	O	8	NMOD
8	dose	dose	I-NP	NN	O	5	PMOD
9	could	could	B-VP	MD	O	0	ROOT
10	significantly	significantly	I-VP	RB	O	9	VMOD
11	attenuated	attenuate	I-VP	VBD	O	9	VC
12	learning	learning	B-NP	NN	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	memory	memory	I-NP	NN	O	15	NMOD
15	impairment	impairment	I-NP	NN	O	11	OBJ
16	in	in	B-PP	IN	O	11	VMOD
17	treated	treat	B-NP	VBN	O	19	NMOD
18	STZ-injected	STZ-injected	I-NP	JJ	O	19	NMOD
19	group	group	I-NP	NN	O	16	PMOD
20	in	in	B-PP	IN	O	19	NMOD
21	passive	passive	B-NP	JJ	O	23	NMOD
22	avoidance	avoidance	I-NP	NN	O	23	NMOD
23	test	test	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	9	P

1	Rosaceiform	Rosaceiform	B-NP	NN	O	2	NMOD
2	dermatitis	dermatitis	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	topical	topical	B-NP	JJ	O	7	NMOD
6	tacrolimus	tacrolimus	I-NP	NN	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	herein	herein	B-NP	RB	O	5	NMOD
4	3	3	I-NP	CD	O	3	AMOD
5	patients	patient	I-NP	NNS	O	2	OBJ
6	who	who	B-NP	WP	O	5	NMOD
7	developed	develop	B-VP	VBD	O	6	SBAR
8	rosacea-like	rosacea-like	B-NP	JJ	O	10	NMOD
9	dermatitis	dermatitis	I-NP	NN	O	10	NMOD
10	eruptions	eruption	I-NP	NNS	O	7	OBJ
11	while	while	B-SBAR	IN	O	7	VMOD
12	using	use	B-VP	VBG	O	11	SBAR
13	0.03	0.03	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	19	NMOD
15	or	or	I-NP	CC	O	19	NMOD
16	0.1	0.1	I-NP	CD	O	17	AMOD
17	%	%	I-NP	NN	O	19	NMOD
18	tacrolimus	tacrolimus	I-NP	NN	O	19	NMOD
19	ointment	ointment	I-NP	NN	O	12	OBJ
20	for	for	B-PP	IN	O	19	NMOD
21	facial	facial	B-NP	JJ	O	22	NMOD
22	dermatitis	dermatitis	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	2	P

1	Tacrine	Tacrine	B-NP	NN	O	9	SUB
2	,	,	O	,	O	1	P
3	administered	administer	B-VP	VBN	O	1	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	LiCl	LiCl	B-NP	NN	O	7	NMOD
6	pre-treated	pre-treated	I-NP	JJ	O	7	NMOD
7	rats	rat	I-NP	NNS	O	4	PMOD
8	,	,	O	,	O	1	P
9	induces	induce	B-VP	VBZ	O	0	ROOT
10	electrocorticographic	electrocorticographic	B-NP	JJ	O	11	NMOD
11	seizures	seizure	I-NP	NNS	O	15	NMOD
12	and	and	O	CC	O	15	NMOD
13	delayed	delay	B-VP	VBN	O	15	NMOD
14	hippocampal	hippocampal	B-NP	JJ	O	15	NMOD
15	damage	damage	I-NP	NN	O	9	OBJ
16	.	.	O	.	O	9	P

1	All	All	B-NP	PDT	O	3	NMOD
2	the	the	I-NP	DT	O	3	NMOD
3	animals	animal	I-NP	NNS	O	8	SUB
4	treated	treat	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	tacrine-loaded	tacrine-loaded	B-NP	JJ	O	7	NMOD
7	nanoparticles	nanoparticle	I-NP	NNS	O	5	PMOD
8	showed	show	B-VP	VBD	O	0	ROOT
9	an	an	B-NP	DT	O	11	NMOD
10	earlier	early	I-NP	JJR	O	11	NMOD
11	outcome	outcome	I-NP	NN	O	19	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	CNS	CNS	B-NP	NN	B-protein	15	NMOD
14	adverse	adverse	I-NP	JJ	O	15	NMOD
15	symptoms	symptom	I-NP	NNS	O	12	PMOD
16	,	,	O	,	O	19	P
17	i.e.	i.e.	B-NP	FW	O	19	NMOD
18	epileptic	epileptic	I-NP	JJ	O	19	NMOD
19	onset	onset	I-NP	NN	O	8	OBJ
20	,	,	O	,	O	8	P
21	with	with	B-PP	IN	O	8	VMOD
22	respect	respect	B-NP	NN	O	21	PMOD
23	to	to	B-PP	TO	O	21	PMOD
24	those	those	B-NP	DT	O	25	NMOD
25	animals	animal	I-NP	NNS	O	23	PMOD
26	treated	treat	B-VP	VBN	O	25	NMOD
27	with	with	B-PP	IN	O	26	VMOD
28	the	the	B-NP	DT	O	30	NMOD
29	free	free	I-NP	JJ	O	30	NMOD
30	compound	compound	I-NP	NN	O	27	PMOD
31	(	(	O	(	O	38	DEP
32	10	10	B-NP	CD	O	33	NMOD
33	min	min	I-NP	NN	O	38	DEP
34	vs.	vs.	B-PP	IN	O	33	NMOD
35	22	22	B-NP	CD	O	36	NMOD
36	min	min	I-NP	NN	O	34	PMOD
37	respectively	respectively	B-ADVP	RB	O	33	NMOD
38	)	)	O	)	O	25	NMOD
39	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	7	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	7	P
4	tacrine-loaded	tacrine-loaded	B-NP	JJ	O	6	NMOD
5	nanoparticles	nanoparticle	I-NP	NNS	O	6	NMOD
6	administration	administration	I-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	damage	damage	B-NP	NN	O	7	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	neuronal	neuronal	B-NP	JJ	B-cell_type	11	NMOD
11	cells	cell	I-NP	NNS	I-cell_type	9	PMOD
12	in	in	B-PP	IN	O	7	VMOD
13	CA1	CA1	B-NP	NN	O	14	NMOD
14	field	field	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	hippocampus	hippocampus	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	7	VMOD
19	all	all	B-NP	DT	O	21	NMOD
20	treated	treat	I-NP	VBN	O	21	NMOD
21	animals	animal	I-NP	NNS	O	18	PMOD
22	,	,	O	,	O	7	P
23	while	while	B-SBAR	IN	O	7	VMOD
24	the	the	B-NP	DT	O	26	NMOD
25	saline	saline	I-NP	NN	O	26	NMOD
26	solution	solution	I-NP	NN	O	23	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	tacrine	tacrine	B-NP	NN	O	27	PMOD
29	only	only	B-PP	RB	O	30	PMOD
30	in	in	I-PP	IN	O	26	NMOD
31	60	60	B-NP	CD	O	32	NMOD
32	%	%	I-NP	NN	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	animals	animal	B-NP	NNS	O	33	PMOD
35	.	.	O	.	O	7	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	evaluate	evaluate	I-VP	VB	O	3	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	effects	effect	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	pilocarpine	pilocarpine	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	6	VMOD
12	explore	explore	B-VP	VB	O	6	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	underlying	underlie	I-NP	VBG	O	16	NMOD
15	ionic	ionic	I-NP	JJ	O	16	NMOD
16	mechanism	mechanism	I-NP	NN	O	12	OBJ
17	,	,	O	,	O	6	P
18	using	use	B-VP	VBG	O	6	VMOD
19	both	both	O	CC	O	21	VMOD
20	aconitine	aconitine	B-NP	NN	O	21	SUB
21	induced	induce	B-VP	VBD	O	18	SBAR
22	rat	rat	B-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	ouabain	ouabain	I-NP	NN	O	29	NMOD
25	induced	induce	B-VP	VBD	O	29	NMOD
26	guinea	guinea	B-NP	NN	O	29	NMOD
27	pig	pig	I-NP	NN	O	29	NMOD
28	arrhythmia	arrhythmia	I-NP	NN	O	29	NMOD
29	models	model	I-NP	NNS	O	21	OBJ
30	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	current	current	I-NP	JJ	O	3	NMOD
3	data	datum	I-NP	NNS	O	4	SUB
4	showed	show	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	pilocarpine	pilocarpine	B-NP	NN	O	8	SUB
7	significantly	significantly	B-ADVP	RB	O	8	VMOD
8	delayed	delay	B-VP	VBD	O	5	SBAR
9	onset	onset	B-NP	NN	O	8	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	arrhythmias	arrhythmia	B-NP	NNS	O	10	PMOD
12	,	,	O	,	O	4	P
13	decreased	decrease	B-VP	VBD	O	4	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	time	time	I-NP	NN	O	16	NMOD
16	course	course	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	ventricular	ventricular	B-NP	JJ	O	19	NMOD
19	tachycardia	tachycardia	I-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	fibrillation	fibrillation	I-NP	NN	O	17	PMOD
22	,	,	O	,	O	4	P
23	reduced	reduce	B-VP	VBD	O	4	VMOD
24	arrhythmia	arrhythmia	B-NP	NN	O	25	NMOD
25	score	score	I-NP	NN	O	23	OBJ
26	,	,	O	,	O	4	P
27	and	and	O	CC	O	4	VMOD
28	increased	increase	B-VP	VBD	O	4	VMOD
29	the	the	B-NP	DT	O	31	NMOD
30	survival	survival	I-NP	NN	O	31	NMOD
31	time	time	I-NP	NN	O	37	NMOD
32	of	of	B-PP	IN	O	31	NMOD
33	arrhythmic	arrhythmic	B-NP	JJ	O	34	NMOD
34	rats	rat	I-NP	NNS	O	32	PMOD
35	and	and	O	CC	O	37	NMOD
36	guinea	guinea	B-NP	NN	O	37	NMOD
37	pigs.	pigs.	I-NP	NN	O	47	NMOD
38	[	[	O	(	O	43	DEP
39	Ca	Ca	B-NP	NN	O	43	DEP
40	(	(	O	(	O	42	DEP
41	2+	2+	B-ADJP	JJ	O	42	DEP
42	)	)	O	)	O	39	NMOD
43	]	]	O	)	O	37	NMOD
44	(	(	B-LST	(	O	45	DEP
45	i	i	I-LST	LS	O	47	NMOD
46	)	)	O	)	O	45	DEP
47	overload	overload	B-NP	NN	O	28	OBJ
48	induced	induce	B-VP	VBN	O	47	NMOD
49	by	by	B-PP	IN	O	48	VMOD
50	aconitine	aconitine	B-NP	NN	O	52	NMOD
51	or	or	I-NP	CC	O	52	NMOD
52	ouabain	ouabain	I-NP	NN	O	49	PMOD
53	was	be	B-VP	VBD	O	28	VMOD
54	reduced	reduce	I-VP	VBN	O	53	VC
55	in	in	B-PP	IN	O	54	VMOD
56	isolated	isolate	B-NP	VBN	O	57	NMOD
57	myocytes	myocyte	I-NP	NNS	O	55	PMOD
58	pretreated	pretreate	B-VP	VBN	O	57	NMOD
59	with	with	B-PP	IN	O	58	VMOD
60	pilocarpine	pilocarpine	B-NP	NN	O	59	PMOD
61	.	.	O	.	O	4	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	pilocarpine	pilocarpine	B-NP	NN	O	6	SUB
6	produced	produce	B-VP	VBD	O	4	SBAR
7	antiarrhythmic	antiarrhythmic	B-NP	JJ	O	8	NMOD
8	actions	action	I-NP	NNS	O	6	OBJ
9	on	on	B-PP	IN	O	8	NMOD
10	arrhythmic	arrhythmic	B-NP	JJ	O	11	NMOD
11	rat	rat	I-NP	NN	O	15	NMOD
12	and	and	I-NP	CC	O	15	NMOD
13	guinea	guinea	I-NP	NN	O	15	NMOD
14	pig	pig	I-NP	NN	O	15	NMOD
15	models	model	I-NP	NNS	O	9	PMOD
16	induced	induce	B-VP	VBN	O	8	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	aconitine	aconitine	B-NP	NN	O	20	NMOD
19	or	or	I-NP	CC	O	20	NMOD
20	ouabain	ouabain	I-NP	NN	O	17	PMOD
21	via	via	B-PP	IN	O	16	VMOD
22	stimulating	stimulate	B-VP	VBG	O	21	PMOD
23	the	the	B-NP	DT	O	29	NMOD
24	cardiac	cardiac	I-NP	JJ	B-protein	25	NMOD
25	M	M	I-NP	NN	I-protein	29	NMOD
26	(	(	O	(	I-protein	29	NMOD
27	3	3	B-NP	CD	I-protein	29	NMOD
28	)	)	O	)	I-protein	29	NMOD
29	-mAChR	-mAChR	B-NP	NN	I-protein	22	OBJ
30	.	.	O	.	O	3	P

1	Disulfiram	Disulfiram	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	transient	transient	B-NP	JJ	O	6	AMOD
4	optic	optic	I-NP	JJ	O	6	AMOD
5	and	and	I-NP	CC	O	6	AMOD
6	peripheral	peripheral	I-NP	JJ	O	7	NMOD
7	neuropathy	neuropathy	I-NP	NN	O	2	OBJ
8	:	:	O	:	O	2	P
9	a	a	B-NP	DT	O	11	NMOD
10	case	case	I-NP	NN	O	11	NMOD
11	report	report	I-NP	NN	O	2	VMOD
12	.	.	O	.	O	2	P

1	AIM	AIM	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	optic	optic	B-NP	JJ	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	peripheral	peripheral	I-NP	JJ	O	11	NMOD
11	neuropathy	neuropathy	I-NP	NN	O	7	PMOD
12	after	after	B-PP	IN	O	11	NMOD
13	chronic	chronic	B-NP	JJ	O	14	NMOD
14	use	use	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	disulfiram	disulfiram	B-NP	NN	O	15	PMOD
17	for	for	B-PP	IN	O	14	NMOD
18	alcohol	alcohol	B-NP	NN	O	20	NMOD
19	dependence	dependence	I-NP	NN	O	20	NMOD
20	management	management	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	1	P

1	He	He	B-NP	PRP	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	taking	take	I-VP	VBG	O	3	VC
5	disulfiram	disulfiram	B-NP	NN	O	4	OBJ
6	for	for	B-PP	IN	O	5	NMOD
7	alcohol	alcohol	B-NP	NN	O	8	NMOD
8	dependence	dependence	I-NP	NN	O	6	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	13	NMOD
11	preceding	precede	I-NP	VBG	O	13	NMOD
12	3	3	I-NP	CD	O	13	NMOD
13	years	year	I-NP	NNS	O	9	PMOD
14	.	.	O	.	O	2	P

1	Sustained	Sustain	B-NP	VBN	O	3	NMOD
2	clinical	clinical	I-NP	JJ	O	3	NMOD
3	improvement	improvement	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	decompensated	decompensate	B-NP	VBN	O	12	NMOD
9	hepatitis	hepatitis	I-NP	NN	O	12	NMOD
10	B	B	I-NP	NN	O	12	NMOD
11	virus-related	virus-related	I-NP	JJ	O	12	NMOD
12	cirrhosis	cirrhosis	I-NP	NN	O	7	PMOD
13	after	after	B-PP	IN	O	3	NMOD
14	treatment	treatment	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	lamivudine	lamivudine	B-NP	NN	O	17	NMOD
17	monotherapy	monotherapy	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	3	P

1	Dual	Dual	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	melatonin	melatonin	B-NP	NN	O	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	barbiturate	barbiturate	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	narcosis	narcosis	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	7	P

1	Melatonin	Melatonin	B-NP	NN	O	2	SUB
2	affects	affect	B-VP	VBZ	O	10	VMOD
3	the	the	B-NP	DT	O	6	NMOD
4	circadian	circadian	I-NP	JJ	O	6	NMOD
5	sleep/wake	sleep/wake	I-NP	NN	O	6	NMOD
6	cycle	cycle	I-NP	NN	O	2	OBJ
7	,	,	O	,	O	10	P
8	but	but	O	CC	O	10	VMOD
9	it	it	B-NP	PRP	O	10	SUB
10	is	be	B-VP	VBZ	O	0	ROOT
11	not	not	O	RB	O	10	VMOD
12	clear	clear	B-ADJP	JJ	O	10	PRD
13	whether	whether	B-SBAR	IN	O	10	VMOD
14	it	it	B-NP	PRP	O	15	SUB
15	may	may	B-VP	MD	O	13	SBAR
16	influence	influence	I-VP	VB	O	15	VC
17	drug	drug	B-NP	NN	O	19	NMOD
18	induced	induced	I-NP	JJ	O	19	NMOD
19	narcosis	narcosis	I-NP	NN	O	16	OBJ
20	.	.	O	.	O	10	P

1	Melatonin	Melatonin	B-NP	NN	O	2	NMOD
2	pre-treatment	pre-treatment	I-NP	NN	O	16	SUB
3	affected	affect	B-VP	VBN	O	2	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	9	NMOD
6	dual	dual	I-NP	JJ	O	9	NMOD
7	manner	manner	I-NP	NN	O	9	NMOD
8	barbiturate	barbiturate	I-NP	NN	O	9	NMOD
9	narcosis	narcosis	I-NP	NN	O	4	PMOD
10	,	,	O	,	O	2	P
11	however	however	B-ADVP	RB	O	16	VMOD
12	,	,	O	,	O	16	P
13	no	no	B-NP	DT	O	15	NMOD
14	dose-effect	dose-effect	I-NP	NN	O	15	NMOD
15	correlation	correlation	I-NP	NN	O	16	SUB
16	was	be	B-VP	VBD	O	0	ROOT
17	found	find	I-VP	VBN	O	16	VC
18	.	.	O	.	O	16	P

1	In	In	B-PP	IN	O	6	VMOD
2	particular	particular	B-NP	JJ	O	1	PMOD
3	,	,	I-NP	,	O	6	P
4	low	low	I-NP	JJ	O	5	NMOD
5	doses	dose	I-NP	NNS	O	6	SUB
6	reduced	reduce	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	latency	latency	I-NP	NN	O	6	OBJ
9	to	to	B-PP	TO	O	6	VMOD
10	and	and	O	CC	O	9	PMOD
11	prolonged	prolong	B-VP	VBD	O	9	SBAR
12	the	the	B-NP	DT	O	13	NMOD
13	duration	duration	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	barbiturate	barbiturate	B-NP	NN	O	16	NMOD
16	narcosis	narcosis	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	13	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	13	P
4	the	the	B-NP	DT	O	6	NMOD
5	highest	high	I-NP	JJS	O	6	NMOD
6	dose	dose	I-NP	NN	O	13	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	melatonin	melatonin	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	12	DEP
10	50	50	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	caused	cause	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	16	NMOD
15	paradoxical	paradoxical	I-NP	JJ	O	16	NMOD
16	increase	increase	I-NP	NN	O	13	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	latency	latency	I-NP	NN	O	17	PMOD
20	and	and	O	CC	O	13	VMOD
21	produced	produce	B-VP	VBD	O	13	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	sustained	sustained	I-NP	JJ	O	24	NMOD
24	reduction	reduction	I-NP	NN	O	21	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	27	NMOD
27	duration	duration	I-NP	NN	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	narcosis	narcosis	B-NP	NN	O	28	PMOD
30	,	,	O	,	O	13	VMOD
31	and	and	O	CC	O	33	NMOD
32	a	a	B-NP	DT	O	33	NMOD
33	reduction	reduction	I-NP	NN	O	30	SUB
34	in	in	B-PP	IN	O	33	NMOD
35	mortality	mortality	B-NP	NN	O	36	NMOD
36	rate	rate	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	13	P

1	Melatonin	Melatonin	B-NP	NN	O	5	NMOD
2	0.5	0.5	I-NP	CD	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	5	5	I-NP	CD	O	5	NMOD
5	mg/kg	mg/kg	I-NP	NN	O	6	SUB
6	influenced	influence	B-VP	VBD	O	17	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	duration	duration	I-NP	NN	O	12	NMOD
9	but	but	B-NP	CC	O	12	NMOD
10	not	not	I-NP	RB	O	9	DEP
11	the	the	B-NP	DT	O	12	NMOD
12	latency	latency	I-NP	NN	O	17	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	ketamine-	ketamine-	B-NP	NN	O	16	NMOD
15	or	or	I-NP	CC	O	16	NMOD
16	diazepam	diazepam	I-NP	NN	O	13	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	narcosis	narcosis	B-NP	NN	O	17	OBJ
19	.	.	O	.	O	17	P

1	Effects	Effect	B-NP	NNS	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	NIK-247	NIK-247	B-NP	NN	B-protein	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	cholinesterase	cholinesterase	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	scopolamine	scopolamine	I-NP	NN	O	4	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	amnesia	amnesia	B-NP	NN	O	8	OBJ
10	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	NIK-247	NIK-247	B-NP	NN	B-protein	3	PMOD
5	on	on	B-PP	IN	O	2	NMOD
6	cholinesterase	cholinesterase	B-NP	NN	B-protein	5	PMOD
7	,	,	O	,	O	9	P
8	scopolamine	scopolamine	B-NP	NN	O	9	SUB
9	induced	induce	B-VP	VBD	O	0	ROOT
10	amnesia	amnesia	B-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	spontaneous	spontaneous	B-NP	JJ	O	13	NMOD
13	movement	movement	I-NP	NN	O	9	OBJ
14	were	be	B-VP	VBD	O	9	VMOD
15	examined	examine	I-VP	VBN	O	14	VC
16	and	and	O	CC	O	15	VMOD
17	compared	compare	B-PP	VBN	O	15	VMOD
18	with	with	B-PP	IN	O	17	PMOD
19	those	those	B-NP	DT	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	24	NMOD
22	well-known	well-known	I-NP	JJ	O	24	NMOD
23	cholinesterase	cholinesterase	I-NP	NN	O	24	NMOD
24	inhibitors	inhibitor	I-NP	NNS	O	27	NMOD
25	tacrine	tacrine	I-NP	NN	O	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	E-2020	E-2020	I-NP	NN	O	20	PMOD
28	.	.	O	.	O	9	P

1	All	All	B-NP	DT	O	2	NMOD
2	compounds	compound	I-NP	NNS	O	8	SUB
3	at	at	B-PP	IN	O	2	NMOD
4	0.1-1	0.1-1	B-NP	CD	O	6	NMOD
5	mg/kg	mg/kg	I-NP	NN	O	6	NMOD
6	p.o.	p.o.	I-NP	NN	O	3	PMOD
7	significantly	significantly	B-ADVP	RB	O	8	VMOD
8	improved	improve	B-VP	VBD	O	0	ROOT
9	the	the	B-NP	DT	O	10	NMOD
10	amnesia	amnesia	I-NP	NN	O	8	OBJ
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	scopolamine	scopolamine	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	18	DEP
15	0.5	0.5	B-NP	CD	O	17	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	NMOD
17	s.c.	s.c.	I-NP	NN	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	in	in	B-PP	IN	O	13	NMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	performing	perform	B-VP	VBG	O	20	NMOD
22	a	a	B-NP	DT	O	25	NMOD
23	passive	passive	I-NP	JJ	O	25	NMOD
24	avoidance	avoidance	I-NP	NN	O	25	NMOD
25	task	task	I-NP	NN	O	21	OBJ
26	.	.	O	.	O	8	P

1	These	These	B-NP	DT	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	NIK-247	NIK-247	B-NP	NN	B-protein	15	SUB
6	at	at	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	low	low	I-NP	JJ	O	9	NMOD
9	dose	dose	I-NP	NN	O	6	PMOD
10	(	(	O	(	O	14	DEP
11	0.1-1	0.1-1	B-NP	CD	O	13	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	13	NMOD
13	p.o.	p.o.	I-NP	NN	O	14	DEP
14	)	)	O	)	O	9	NMOD
15	improves	improve	B-VP	VBZ	O	4	SBAR
16	scopolamine	scopolamine	B-NP	NN	O	18	NMOD
17	induced	induced	I-NP	JJ	O	18	NMOD
18	amnesia	amnesia	I-NP	NN	O	15	OBJ
19	but	but	O	CC	O	15	VMOD
20	does	do	B-VP	VBZ	O	15	VMOD
21	not	not	I-VP	RB	O	20	VMOD
22	affect	affect	I-VP	VB	O	20	VC
23	spontaneous	spontaneous	B-NP	JJ	O	24	NMOD
24	movement	movement	I-NP	NN	O	22	OBJ
25	.	.	O	.	O	3	P

1	Nightmares	Nightmare	B-NP	NNS	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	hallucinations	hallucination	I-NP	NNS	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	long-term	long-term	B-NP	JJ	O	6	NMOD
6	intake	intake	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	tramadol	tramadol	B-NP	NN	O	7	PMOD
9	combined	combine	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	antidepressants	antidepressant	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	3	P

1	Tramadol	Tramadol	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	weak	weak	I-NP	JJ	O	5	NMOD
5	opioid	opioid	I-NP	NN	O	2	PRD
6	with	with	B-PP	IN	O	5	NMOD
7	effects	effect	B-NP	NNS	O	6	PMOD
8	on	on	B-PP	IN	O	7	NMOD
9	adrenergic	adrenergic	B-NP	JJ	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	serotonergic	serotonergic	I-NP	JJ	O	12	NMOD
12	neurotransmission	neurotransmission	I-NP	NN	O	8	PMOD
13	that	that	B-NP	WDT	O	12	NMOD
14	is	be	B-VP	VBZ	O	13	SBAR
15	used	use	I-VP	VBN	O	14	VC
16	to	to	B-VP	TO	O	17	VMOD
17	treat	treat	I-VP	VB	O	14	VMOD
18	cancer	cancer	B-NP	NN	O	19	NMOD
19	pain	pain	I-NP	NN	O	24	NMOD
20	and	and	O	CC	O	24	NMOD
21	chronic	chronic	B-NP	JJ	O	24	NMOD
22	non	non	I-NP	JJ	O	24	NMOD
23	malignant	malignant	I-NP	JJ	O	24	NMOD
24	pain	pain	I-NP	NN	O	17	OBJ
25	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	drug	drug	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	initiated	initiate	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	association	association	B-NP	NN	O	5	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	paroxetine	paroxetine	B-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	dosulepine	dosulepine	I-NP	NN	O	11	NMOD
11	hydrochloride	hydrochloride	I-NP	NN	O	7	PMOD
12	in	in	B-PP	IN	O	6	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	tetraparetic	tetraparetic	I-NP	JJ	O	15	NMOD
15	patient	patient	I-NP	NN	O	12	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	chronic	chronic	B-NP	JJ	O	18	NMOD
18	pain	pain	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	3	P

1	Fifty-six	Fifty-six	B-NP	CD	O	2	NMOD
2	days	day	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	0	ROOT
4	initiation	initiation	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	5	PMOD
8	the	the	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	10	SUB
10	presented	present	B-VP	VBD	O	3	VMOD
11	hallucinations	hallucination	B-NP	NNS	O	10	OBJ
12	that	that	B-NP	WDT	O	11	NMOD
13	only	only	B-ADVP	RB	O	14	VMOD
14	stopped	stop	B-VP	VBD	O	12	SBAR
15	after	after	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	withdrawal	withdrawal	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	psycho-active	psycho-active	B-NP	JJ	O	20	NMOD
20	drugs	drug	I-NP	NNS	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	tramadol	tramadol	I-NP	NN	O	18	PMOD
23	.	.	O	.	O	3	P

1	BMT	BMT	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	used	use	I-VP	VBN	O	2	VC
4	to	to	B-VP	TO	O	5	VMOD
5	treat	treat	I-VP	VB	O	3	VMOD
6	severe	severe	B-NP	JJ	O	7	AMOD
7	aplastic	aplastic	I-NP	JJ	O	8	NMOD
8	anemia	anemia	I-NP	NN	O	5	OBJ
9	which	which	B-NP	WDT	O	8	NMOD
10	was	be	B-VP	VBD	O	9	SBAR
11	caused	cause	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	gold	gold	B-NP	NN	O	12	PMOD
14	in	in	B-PP	IN	O	11	VMOD
15	one	one	B-NP	CD	O	16	NMOD
16	case	case	I-NP	NN	O	14	PMOD
17	and	and	O	CC	O	10	VMOD
18	D-penicillamine	D-penicillamine	B-NP	NN	O	17	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	other	other	I-NP	JJ	O	19	PMOD
22	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	experimental	experimental	I-NP	JJ	O	3	NMOD
3	models	model	I-NP	NNS	O	20	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	renal	renal	B-NP	JJ	O	6	NMOD
6	damage	damage	I-NP	NN	O	4	PMOD
7	to	to	B-PP	TO	O	3	NMOD
8	the	the	B-NP	DT	O	16	NMOD
9	proximal	proximal	I-NP	JJ	O	16	NMOD
10	tubular	tubular	I-NP	JJ	O	16	NMOD
11	,	,	I-NP	,	O	16	P
12	glomerular	glomerular	I-NP	JJ	O	16	NMOD
13	,	,	O	,	O	16	P
14	and	and	O	CC	O	16	NMOD
15	papillary	papillary	B-NP	JJ	O	16	NMOD
16	regions	region	I-NP	NNS	O	7	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	rat	rat	I-NP	NN	O	17	PMOD
20	were	be	B-VP	VBD	O	0	ROOT
21	produced	produce	I-VP	VBN	O	20	VC
22	by	by	B-PP	IN	O	21	VMOD
23	administration	administration	B-NP	NN	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	hexachloro-1	hexachloro-1	B-NP	NN	B-protein	24	PMOD
26	:	:	O	:	O	20	P
27	3-butadiene	3-butadiene	B-NP	NN	O	39	NMOD
28	(	(	O	(	O	30	DEP
29	HCBD	HCBD	B-NP	NN	B-protein	30	DEP
30	)	)	O	)	O	27	NMOD
31	,	,	O	,	O	39	P
32	puromycin	puromycin	B-NP	NN	O	33	NMOD
33	aminonucleoside	aminonucleoside	I-NP	NN	O	39	NMOD
34	(	(	O	(	O	36	DEP
35	PAN	PAN	B-NP	NN	B-protein	36	DEP
36	)	)	O	)	O	33	NMOD
37	,	,	O	,	O	39	P
38	and	and	O	CC	O	39	NMOD
39	2-bromoethylamine	2-bromoethylamine	B-NP	NN	O	20	VMOD
40	(	(	O	(	O	42	DEP
41	BEA	BEA	B-NP	NN	B-protein	42	DEP
42	)	)	O	)	O	39	NMOD
43	,	,	O	,	O	39	P
44	respectively	respectively	B-ADVP	RB	O	39	NMOD
45	.	.	O	.	O	20	P

1	Tubular	Tubular	B-NP	JJ	O	2	NMOD
2	damage	damage	I-NP	NN	O	8	SUB
3	produced	produce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	HCBD	HCBD	B-NP	NN	B-protein	7	NMOD
6	or	or	I-NP	CC	O	7	NMOD
7	BEA	BEA	I-NP	NN	O	4	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	discriminated	discriminate	I-VP	VBN	O	8	VC
10	both	both	O	CC	O	11	AMOD
11	quantitatively	quantitatively	B-ADVP	RB	O	9	VMOD
12	and	and	I-ADVP	CC	O	11	AMOD
13	qualitatively	qualitatively	I-ADVP	RB	O	11	AMOD
14	from	from	B-PP	IN	O	9	VMOD
15	glomerular	glomerular	B-NP	JJ	O	16	NMOD
16	damage	damage	I-NP	NN	O	14	PMOD
17	produced	produce	B-VP	VBN	O	16	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	PAN	PAN	B-NP	NN	B-protein	18	PMOD
20	.	.	O	.	O	8	P

1	Neuromuscular	Neuromuscular	B-NP	JJ	O	2	NMOD
2	blockade	blockade	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	magnesium	magnesium	B-NP	NN	O	5	NMOD
5	sulfate	sulfate	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	nifedipine	nifedipine	I-NP	NN	O	3	PMOD
8	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	8	SUB
3	who	who	B-NP	WP	O	2	NMOD
4	received	receive	B-VP	VBD	O	3	SBAR
5	tocolysis	tocolysis	B-NP	NN	O	4	OBJ
6	with	with	B-PP	IN	O	4	VMOD
7	nifedipine	nifedipine	B-NP	NN	O	6	PMOD
8	developed	develop	B-VP	VBD	O	0	ROOT
9	neuromuscular	neuromuscular	B-NP	JJ	O	10	NMOD
10	blockade	blockade	I-NP	NN	O	8	OBJ
11	after	after	B-PP	IN	O	8	VMOD
12	500	500	B-NP	CD	O	13	NMOD
13	mg	mg	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	magnesium	magnesium	B-NP	NN	O	16	NMOD
16	sulfate	sulfate	I-NP	NN	O	14	PMOD
17	was	be	B-VP	VBD	O	8	VMOD
18	administered	administer	I-VP	VBN	O	17	VC
19	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	4	NMOD
2	frequency	frequency	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	predictability	predictability	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	hematuria	hematuria	B-NP	NN	O	5	PMOD
7	are	be	B-VP	VBP	O	19	VMOD
8	not	not	O	RB	O	7	VMOD
9	precise	precise	B-ADJP	JJ	O	7	PRD
10	,	,	O	,	O	19	P
11	and	and	O	CC	O	15	NMOD
12	at	at	B-NP	IN	O	15	NMOD
13	least	least	I-NP	JJS	O	12	AMOD
14	daily	daily	I-NP	JJ	O	15	NMOD
15	monitoring	monitoring	I-NP	NN	O	19	SUB
16	by	by	B-PP	IN	O	15	NMOD
17	urine	urine	B-NP	NN	O	18	NMOD
18	Hematest	Hematest	I-NP	NN	O	16	PMOD
19	is	be	B-VP	VBZ	O	0	ROOT
20	essential	essential	B-ADJP	JJ	O	19	PRD
21	,	,	O	,	O	19	P
22	adding	add	B-VP	VBG	O	19	VMOD
23	Mesna	Mesna	B-NP	NNP	O	22	OBJ
24	to	to	B-PP	TO	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	infusate	infusate	I-NP	NN	O	24	PMOD
27	in	in	B-PP	IN	O	22	VMOD
28	patients	patient	B-NP	NNS	O	27	PMOD
29	with	with	B-PP	IN	O	28	NMOD
30	persistent	persistent	B-NP	JJ	O	31	NMOD
31	hematuria	hematuria	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	19	P

1	Myocardial	Myocardial	B-NP	JJ	O	2	NMOD
2	infarction	infarction	I-NP	NN	O	15	NMOD
3	in	in	B-PP	IN	O	2	NMOD
4	pregnancy	pregnancy	B-NP	NN	O	3	PMOD
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	clomiphene	clomiphene	B-NP	NN	O	8	NMOD
8	citrate	citrate	I-NP	NN	O	6	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	ovulation	ovulation	B-NP	NN	O	11	NMOD
11	induction	induction	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	2	P
13	a	a	B-NP	DT	O	15	NMOD
14	case	case	I-NP	NN	O	15	NMOD
15	report	report	I-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	Thromboembolism	Thromboembolism	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	7	NMOD
4	rare	rare	I-NP	JJ	O	6	AMOD
5	but	but	I-NP	CC	O	6	AMOD
6	life-threatening	life-threatening	I-NP	JJ	O	7	NMOD
7	complication	complication	I-NP	NN	O	2	PRD
8	that	that	B-NP	WDT	O	7	NMOD
9	has	have	B-VP	VBZ	O	8	SBAR
10	been	be	I-VP	VBN	O	9	VC
11	reported	report	I-VP	VBN	O	10	VC
12	after	after	B-PP	IN	O	11	VMOD
13	ovulation	ovulation	B-NP	NN	O	14	NMOD
14	induction	induction	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	CC	CC	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	2	P

1	CASE	CASE	B-NP	NN	B-protein	5	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	5	NMOD
4	33-year-old	33-year-old	I-NP	JJ	O	5	NMOD
5	woman	woman	I-NP	NN	O	10	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	5-week	5-week	I-NP	JJ	O	9	NMOD
9	gestation	gestation	I-NP	NN	O	6	PMOD
10	had	have	B-VP	VBD	O	0	ROOT
11	recently	recently	I-VP	RB	O	10	VMOD
12	received	receive	I-VP	VBN	O	10	VMOD
13	CC	CC	B-NP	NN	O	12	OBJ
14	for	for	B-PP	IN	O	13	NMOD
15	ovulation	ovulation	B-NP	NN	O	16	NMOD
16	induction	induction	I-NP	NN	O	14	PMOD
17	and	and	O	CC	O	10	VMOD
18	presented	present	B-VP	VBD	O	10	VMOD
19	with	with	B-PP	IN	O	18	VMOD
20	chest	chest	B-NP	NN	O	21	NMOD
21	pain	pain	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	10	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	SUB
4	appears	appear	B-VP	VBZ	O	1	NMOD
5	to	to	I-VP	TO	O	6	VMOD
6	be	be	I-VP	VB	O	4	VMOD
7	the	the	B-NP	DT	O	10	NMOD
8	first	first	I-NP	JJ	O	10	NMOD
9	reported	report	I-NP	VBN	O	10	NMOD
10	case	case	I-NP	NN	O	6	PRD
11	documenting	document	B-VP	VBG	O	6	VMOD
12	a	a	B-NP	DT	O	14	NMOD
13	possible	possible	I-NP	JJ	O	14	NMOD
14	association	association	I-NP	NN	O	11	OBJ
15	between	between	B-PP	IN	O	14	NMOD
16	CC	CC	B-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	myocardial	myocardial	B-NP	JJ	O	19	NMOD
19	infarction	infarction	I-NP	NN	O	15	PMOD
20	.	.	O	.	O	1	P

1	Hepatonecrosis	Hepatonecrosis	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	cholangitis	cholangitis	I-NP	NN	O	12	NMOD
4	related	relate	B-VP	VBN	O	3	NMOD
5	to	to	B-PP	TO	O	4	VMOD
6	long-term	long-term	B-NP	JJ	O	8	NMOD
7	phenobarbital	phenobarbital	I-NP	NN	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	:	:	O	:	O	3	P
10	an	an	B-NP	DT	O	12	NMOD
11	autopsy	autopsy	I-NP	NN	O	12	NMOD
12	report	report	I-NP	NN	O	0	ROOT
13	of	of	B-PP	IN	O	12	NMOD
14	two	two	B-NP	CD	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	12	P

1	Phenobarbital	Phenobarbital	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	PB	PB	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	has	have	B-VP	VBZ	O	13	VMOD
6	a	a	B-NP	DT	O	7	NMOD
7	reputation	reputation	I-NP	NN	O	5	OBJ
8	for	for	B-PP	IN	O	7	NMOD
9	safety	safety	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	13	P
11	and	and	O	CC	O	13	VMOD
12	it	it	B-NP	PRP	O	13	SUB
13	is	be	B-VP	VBZ	O	0	ROOT
14	commonly	commonly	I-VP	RB	O	13	VMOD
15	believed	believe	I-VP	VBN	O	13	VC
16	that	that	B-SBAR	IN	O	15	VMOD
17	PB-related	PB-related	B-NP	JJ	O	18	NMOD
18	increases	increase	I-NP	NNS	O	23	SUB
19	in	in	B-PP	IN	O	18	NMOD
20	serum	serum	B-NP	NN	B-protein	22	NMOD
21	aminotransferase	aminotransferase	I-NP	NN	I-protein	22	NMOD
22	levels	level	I-NP	NNS	O	19	PMOD
23	do	do	B-VP	VBP	O	16	SBAR
24	not	not	I-VP	RB	O	23	VMOD
25	indicate	indicate	I-VP	VB	O	23	VC
26	or	or	I-VP	CC	O	25	VMOD
27	predict	predict	I-VP	VB	O	25	VMOD
28	the	the	B-NP	DT	O	29	NMOD
29	development	development	I-NP	NN	O	27	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	significant	significant	B-NP	JJ	O	34	NMOD
32	chronic	chronic	I-NP	JJ	O	34	NMOD
33	liver	liver	I-NP	NN	O	34	NMOD
34	disease	disease	I-NP	NN	O	30	PMOD
35	.	.	O	.	O	13	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	report	report	B-VP	VBP	O	0	ROOT
4	of	of	B-PP	IN	O	3	VMOD
5	two	two	B-NP	CD	O	7	NMOD
6	adult	adult	I-NP	JJ	O	7	NMOD
7	patients	patient	I-NP	NNS	O	4	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	long	long	I-NP	JJ	O	11	NMOD
11	history	history	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	epilepsy	epilepsy	B-NP	NN	O	12	PMOD
14	treated	treat	B-VP	VBN	O	13	NMOD
15	with	with	B-PP	IN	O	14	VMOD
16	PB	PB	B-NP	NN	O	15	PMOD
17	who	who	B-NP	WP	O	7	NMOD
18	died	die	B-VP	VBD	O	17	SBAR
19	suddenly	suddenly	B-ADVP	RB	O	18	VMOD
20	:	:	O	:	O	3	P
21	one	one	B-NP	CD	O	29	NMOD
22	as	as	B-PP	IN	O	21	NMOD
23	consequence	consequence	B-NP	NN	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	cardiac	cardiac	B-NP	JJ	O	26	NMOD
26	arrest	arrest	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	29	P
28	the	the	B-NP	DT	O	29	NMOD
29	other	other	I-NP	NN	O	3	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	acute	acute	B-NP	JJ	O	32	NMOD
32	bronchopneumonia	bronchopneumonia	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	3	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	illustrate	illustrate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	PB	PB	B-NP	NN	O	6	SUB
6	may	may	B-VP	MD	O	4	SBAR
7	be	be	I-VP	VB	O	6	VC
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	chronic	chronic	B-NP	JJ	O	12	NMOD
11	liver	liver	I-NP	NN	O	12	NMOD
12	damage	damage	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	6	P
14	which	which	B-NP	WDT	O	6	VMOD
15	may	may	B-VP	MD	O	14	SBAR
16	lead	lead	I-VP	VB	O	15	VC
17	to	to	B-PP	TO	O	16	VMOD
18	more	more	B-NP	RBR	O	22	NMOD
19	serious	serious	I-NP	JJ	O	22	NMOD
20	and	and	I-NP	CC	O	22	NMOD
21	deleterious	deleterious	I-NP	JJ	O	22	NMOD
22	consequences	consequence	I-NP	NNS	O	17	PMOD
23	.	.	O	.	O	3	P

1	Ethambutol-associated	Ethambutol-associated	B-NP	JJ	O	3	NMOD
2	optic	optic	I-NP	JJ	O	3	NMOD
3	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
4	.	.	O	.	O	3	P

1	INTRODUCTION	INTRODUCTION	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Ethambutol	Ethambutol	B-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	used	use	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	tuberculosis	tuberculosis	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	8	P
12	which	which	B-NP	WDT	O	8	NMOD
13	is	be	B-VP	VBZ	O	12	SBAR
14	still	still	B-ADVP	RB	O	13	VMOD
15	prevalent	prevalent	B-ADJP	JJ	O	13	PRD
16	in	in	B-PP	IN	O	15	AMOD
17	Southeast	Southeast	B-NP	NNP	O	18	NMOD
18	Asia	Asia	I-NP	NNP	O	16	PMOD
19	,	,	O	,	O	4	P
20	and	and	O	CC	O	4	VMOD
21	can	can	B-VP	MD	O	4	VMOD
22	be	be	I-VP	VB	O	21	VC
23	associated	associate	I-VP	VBN	O	22	VC
24	with	with	B-PP	IN	O	23	VMOD
25	permanent	permanent	B-NP	JJ	O	27	NMOD
26	visual	visual	I-NP	JJ	O	27	NMOD
27	loss	loss	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	4	P

1	CLINICAL	CLINICAL	B-NP	JJ	O	2	NMOD
2	PICTURE	PICTURE	I-NP	NN	O	5	SUB
3	:	:	O	:	O	2	P
4	Three	Three	B-NP	CD	O	2	NMOD
5	patients	patient	I-NP	NNS	O	11	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	ethambutol-associated	ethambutol-associated	B-NP	JJ	O	10	NMOD
8	toxic	toxic	I-NP	JJ	O	10	NMOD
9	optic	optic	I-NP	JJ	O	10	NMOD
10	neuropathy	neuropathy	I-NP	NN	O	6	PMOD
11	are	be	B-VP	VBP	O	0	ROOT
12	described	describe	I-VP	VBN	O	11	VC
13	.	.	O	.	O	11	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Ethambutol	Ethambutol	B-NP	NN	O	4	NMOD
4	usage	usage	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	associated	associate	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	permanent	permanent	B-NP	JJ	O	10	NMOD
9	visual	visual	I-NP	JJ	O	10	NMOD
10	loss	loss	I-NP	NN	O	7	PMOD
11	and	and	O	CC	O	5	VMOD
12	should	should	B-VP	MD	O	5	VMOD
13	be	be	I-VP	VB	O	12	VC
14	avoided	avoid	I-VP	VBN	O	13	VC
15	if	if	B-SBAR	IN	O	14	VMOD
16	possible	possible	B-ADJP	JJ	O	18	AMOD
17	or	or	O	CC	O	18	AMOD
18	used	use	B-VP	VBN	O	15	SBAR
19	with	with	B-PP	IN	O	18	VMOD
20	caution	caution	B-NP	NN	O	24	NMOD
21	and	and	O	CC	O	24	NMOD
22	proper	proper	B-NP	JJ	O	24	NMOD
23	ophthalmological	ophthalmological	I-NP	JJ	O	24	NMOD
24	follow-up	follow-up	I-NP	NN	O	19	PMOD
25	.	.	O	.	O	1	P

1	Tolerability	Tolerability	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	nimesulide	nimesulide	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	paracetamol	paracetamol	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	NSAID	NSAID	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	urticaria/angioedema	urticaria/angioedema	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	5	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	we	we	B-NP	PRP	O	5	SUB
5	investigated	investigate	B-VP	VBD	O	0	ROOT
6	tolerability	tolerability	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	reliability	reliability	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	nimesulide	nimesulide	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	paracetamol	paracetamol	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	8	NMOD
14	a	a	B-NP	DT	O	17	NMOD
15	very	very	I-NP	RB	O	16	AMOD
16	large	large	I-NP	JJ	O	17	NMOD
17	number	number	I-NP	NN	O	13	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	an	an	B-NP	DT	O	24	NMOD
22	exclusive	exclusive	I-NP	JJ	O	24	NMOD
23	well-documented	well-documented	I-NP	JJ	O	24	NMOD
24	history	history	I-NP	NN	O	20	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	NSAID	NSAID	B-NP	NN	O	28	NMOD
27	induced	induced	I-NP	JJ	O	28	NMOD
28	urticaria/angioedema	urticaria/angioedema	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	5	P

1	A	A	B-NP	DT	O	5	NMOD
2	single-placebo-controlled	single-placebo-controlled	I-NP	JJ	O	5	NMOD
3	oral	oral	I-NP	JJ	O	5	NMOD
4	challenge	challenge	I-NP	NN	O	5	NMOD
5	procedure	procedure	I-NP	NN	O	10	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	nimesulide	nimesulide	B-NP	NN	O	9	NMOD
8	or	or	I-NP	CC	O	9	NMOD
9	paracetamol	paracetamol	I-NP	NN	O	6	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	applied	apply	I-VP	VBN	O	10	VC
12	to	to	B-PP	TO	O	11	VMOD
13	829	829	B-NP	CD	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	17	NMOD
17	history	history	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	NSAID	NSAID	B-NP	NN	O	21	NMOD
20	induced	induced	I-NP	JJ	O	21	NMOD
21	urticaria/angioedema	urticaria/angioedema	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	10	P

1	Furthermore	Furthermore	B-ADVP	RB	O	23	VMOD
2	,	,	O	,	O	23	P
3	18.28	18.28	B-NP	CD	O	4	NMOD
4	%	%	I-NP	NN	O	23	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	patients	patient	B-NP	NNS	O	15	NMOD
7	with	with	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	history	history	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	chronic	chronic	B-NP	JJ	O	12	NMOD
12	urticaria	urticaria	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	15	NMOD
14	11.8	11.8	B-NP	CD	O	15	NMOD
15	%	%	I-NP	NN	O	5	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	subjects	subject	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	4	NMOD
19	an	an	B-NP	DT	O	20	NMOD
20	history	history	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	NSAID	NSAID	B-NP	NN	B-protein	21	PMOD
23	induced	induce	B-VP	VBD	O	0	ROOT
24	urticaria/angioedema	urticaria/angioedema	B-NP	NN	O	26	NMOD
25	or	or	I-NP	CC	O	26	NMOD
26	angioedema	angioedema	I-NP	NN	O	23	OBJ
27	alone	alone	B-ADVP	RB	O	23	VMOD
28	(	(	O	(	O	34	DEP
29	with	with	B-PP	IN	O	34	DEP
30	or	or	B-PP	CC	O	29	PMOD
31	without	without	B-PP	IN	O	29	PMOD
32	chronic	chronic	B-NP	JJ	O	33	NMOD
33	urticaria	urticaria	I-NP	NN	O	29	PMOD
34	)	)	O	)	O	27	AMOD
35	resulted	result	B-VP	VBD	O	23	VMOD
36	to	to	I-VP	TO	O	37	VMOD
37	be	be	I-VP	VB	O	35	VMOD
38	intolerant	intolerant	B-ADJP	JJ	O	37	PRD
39	to	to	B-PP	TO	O	38	AMOD
40	alternative	alternative	B-NP	JJ	O	41	NMOD
41	drugs	drug	I-NP	NNS	O	39	PMOD
42	.	.	O	.	O	23	P

1	Taken	Take	B-VP	VBN	O	6	VMOD
2	together	together	B-ADVP	RB	O	1	VMOD
3	,	,	O	,	O	6	P
4	our	our	B-NP	PRP$	O	5	NMOD
5	results	result	I-NP	NNS	O	6	SUB
6	confirm	confirm	B-VP	VBP	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	good	good	I-NP	JJ	O	9	NMOD
9	tolerability	tolerability	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	nimesulide	nimesulide	B-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	paracetamol	paracetamol	I-NP	NN	O	10	PMOD
14	in	in	B-PP	IN	O	13	NMOD
15	patients	patient	B-NP	NNS	O	18	NMOD
16	who	who	B-NP	WP	O	18	NMOD
17	experienced	experience	B-VP	VBD	O	18	NMOD
18	urticaria/angioedema	urticaria/angioedema	B-NP	NN	O	14	PMOD
19	caused	cause	B-VP	VBN	O	18	NMOD
20	by	by	B-PP	IN	O	19	VMOD
21	NSAIDs	NSAID	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	6	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	verapamil	verapamil	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	atrial	atrial	B-NP	JJ	O	6	NMOD
6	fibrillation	fibrillation	I-NP	NN	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	its	its	B-NP	PRP$	O	10	NMOD
9	electrophysiological	electrophysiological	I-NP	JJ	O	10	NMOD
10	determinants	determinant	I-NP	NNS	O	4	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	dogs	dog	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Atrial	Atrial	B-NP	JJ	O	4	NMOD
4	tachycardia	tachycardia	I-NP	NN	O	6	NMOD
5	induced	induce	B-NP	VBN	O	6	NMOD
6	remodeling	remodeling	I-NP	NN	O	7	SUB
7	promotes	promote	B-VP	VBZ	O	1	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	occurrence	occurrence	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	maintenance	maintenance	I-NP	NN	O	7	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	atrial	atrial	B-NP	JJ	O	14	NMOD
14	fibrillation	fibrillation	I-NP	NN	O	12	PMOD
15	(	(	O	(	O	17	DEP
16	AF	AF	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	and	and	O	CC	O	7	VMOD
19	decreases	decrease	B-VP	VBZ	O	7	VMOD
20	L-type	L-type	B-NP	JJ	O	21	NMOD
21	Ca	Ca	I-NP	NN	O	19	OBJ
22	(	(	O	(	O	24	DEP
23	2+	2+	O	JJ	O	24	DEP
24	)	)	O	)	O	19	VMOD
25	current	current	B-NP	NN	O	19	VMOD
26	.	.	O	.	O	1	P

1	There	There	B-NP	EX	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	also	also	B-ADVP	RB	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	clinical	clinical	I-NP	JJ	O	6	NMOD
6	suggestion	suggestion	I-NP	NN	O	2	PRD
7	that	that	B-NP	IN	O	6	NMOD
8	acute	acute	B-NP	JJ	O	10	NMOD
9	L-type	L-type	I-NP	JJ	O	10	NMOD
10	Ca	Ca	I-NP	NN	O	15	NMOD
11	(	(	O	(	O	13	DEP
12	2	2	B-NP	CD	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	channel	channel	B-NP	NN	O	15	NMOD
15	blockade	blockade	I-NP	NN	O	16	SUB
16	can	can	B-VP	MD	O	7	SBAR
17	promote	promote	I-VP	VB	O	16	VC
18	AF	AF	B-NP	NN	O	17	OBJ
19	,	,	O	,	O	6	P
20	consistent	consistent	B-ADJP	JJ	O	6	NMOD
21	with	with	B-PP	IN	O	20	AMOD
22	an	an	B-NP	DT	O	23	NMOD
23	AF	AF	I-NP	NN	O	21	PMOD
24	promoting	promote	B-VP	VBG	O	23	NMOD
25	effect	effect	B-NP	NN	O	24	OBJ
26	of	of	B-PP	IN	O	25	NMOD
27	Ca	Ca	B-NP	NN	O	32	NMOD
28	(	(	O	(	O	30	DEP
29	2+	2+	O	JJ	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	channel	channel	B-NP	NN	O	32	NMOD
32	inhibition	inhibition	I-NP	NN	O	26	PMOD
33	.	.	O	.	O	2	P

1	METHODS	METHODS	B-NP	NNS	O	20	SUB
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	20	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	potential	potential	I-NP	JJ	O	7	NMOD
7	mechanisms	mechanism	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	AF	AF	B-NP	NN	O	10	NMOD
10	promotion	promotion	I-NP	NN	O	8	PMOD
11	by	by	B-PP	IN	O	4	VMOD
12	Ca	Ca	B-NP	NN	O	17	NMOD
13	(	(	O	(	O	15	DEP
14	2+	2+	O	JJ	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	channel	channel	B-NP	NN	O	17	NMOD
17	blockers	blocker	I-NP	NNS	O	11	PMOD
18	,	,	O	,	O	20	P
19	we	we	B-NP	PRP	O	20	SUB
20	administered	administer	B-VP	VBD	O	0	ROOT
21	verapamil	verapamil	B-NP	NN	O	20	OBJ
22	to	to	B-PP	TO	O	20	VMOD
23	morphine-chloralose	morphine-chloralose	B-NP	JJ	O	25	NMOD
24	anesthetized	anesthetize	I-NP	VBN	O	25	NMOD
25	dogs	dog	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	20	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Verapamil	Verapamil	B-NP	NN	O	4	SUB
4	caused	cause	B-VP	VBD	O	1	NMOD
5	AF	AF	B-NP	NN	O	6	NMOD
6	promotion	promotion	I-NP	NN	O	4	OBJ
7	in	in	B-PP	IN	O	4	VMOD
8	six	six	B-NP	CD	O	9	NMOD
9	dogs	dog	I-NP	NNS	O	7	PMOD
10	,	,	O	,	O	4	P
11	increasing	increase	B-VP	VBG	O	4	VMOD
12	mean	mean	B-NP	JJ	O	13	NMOD
13	duration	duration	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	AF	AF	B-NP	NN	B-protein	14	PMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	burst	burst	B-NP	NN	O	19	NMOD
19	pacing	pacing	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	4	P
21	from	from	B-PP	IN	O	4	VMOD
22	8+/-4	8+/-4	B-NP	CD	O	23	NMOD
23	s	s	I-NP	NN	O	25	NMOD
24	(	(	O	(	O	25	NMOD
25	mean+/-S	mean+/-S	B-NP	NN	O	21	PMOD
26	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	6	VMOD
2	these	these	B-NP	DT	O	3	NMOD
3	experiments	experiment	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	6	P
5	verapamil	verapamil	B-NP	NN	O	6	SUB
6	shortened	shorten	B-VP	VBD	O	0	ROOT
7	mean	mean	B-NP	JJ	O	9	AMOD
8	effective	effective	I-NP	JJ	O	9	AMOD
9	refractory	refractory	I-NP	JJ	O	6	OBJ
10	period	period	I-NP	NN	O	9	NMOD
11	(	(	O	(	O	13	DEP
12	ERP	ERP	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	from	from	B-PP	IN	O	6	VMOD
15	122+/-5	122+/-5	B-NP	CD	O	14	PMOD
16	to	to	I-NP	TO	O	18	NMOD
17	114+/-4	114+/-4	I-NP	CD	O	16	PMOD
18	ms	ms	I-NP	NN	O	32	SUB
19	(	(	O	(	O	23	DEP
20	P	P	B-NP	NN	O	23	DEP
21	<	<	B-NP	JJR	O	20	NMOD
22	0.02	0.02	I-NP	CD	O	21	AMOD
23	)	)	O	)	O	18	NMOD
24	at	at	B-PP	IN	O	18	NMOD
25	a	a	B-NP	DT	O	27	NMOD
26	cycle	cycle	I-NP	NN	O	27	NMOD
27	length	length	I-NP	NN	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	300	300	B-NP	CD	O	30	NMOD
30	ms	ms	I-NP	NN	O	28	PMOD
31	,	,	O	,	O	18	P
32	decreased	decrease	B-VP	VBD	O	14	SBAR
33	ERP	ERP	B-NP	NN	B-protein	34	NMOD
34	heterogeneity	heterogeneity	I-NP	NN	O	32	OBJ
35	(	(	O	(	O	32	VMOD
36	from	from	B-PP	IN	O	48	VMOD
37	15+/-1	15+/-1	B-NP	CD	O	39	AMOD
38	to	to	B-PP	TO	O	39	AMOD
39	10+/-1	10+/-1	B-NP	CD	O	40	NMOD
40	%	%	I-NP	NN	O	36	PMOD
41	,	,	O	,	O	48	P
42	P	P	B-NP	NN	O	48	SUB
43	<	<	B-NP	SYM	O	42	NMOD
44	0.05	0.05	I-NP	CD	O	43	AMOD
45	)	)	O	)	O	42	NMOD
46	,	,	O	,	O	42	P
47	heterogeneously	heterogeneously	B-ADVP	RB	O	48	VMOD
48	accelerated	accelerate	B-VP	VBD	O	35	SBAR
49	atrial	atrial	B-NP	JJ	O	50	NMOD
50	conduction	conduction	I-NP	NN	O	48	OBJ
51	and	and	O	CC	O	48	VMOD
52	decreased	decrease	B-VP	VBD	O	48	VMOD
53	the	the	B-NP	DT	O	55	NMOD
54	cycle	cycle	I-NP	NN	O	55	NMOD
55	length	length	I-NP	NN	O	52	OBJ
56	of	of	B-PP	IN	O	55	NMOD
57	AF	AF	B-NP	NN	O	56	PMOD
58	(	(	O	(	O	67	DEP
59	94+/-4	94+/-4	B-NP	CD	O	61	AMOD
60	to	to	I-NP	TO	O	61	AMOD
61	84+/-3	84+/-3	I-NP	CD	O	62	NMOD
62	ms	m	I-NP	NNS	O	67	DEP
63	,	,	O	,	O	67	P
64	P	P	B-NP	NN	O	67	DEP
65	<	<	B-NP	SYM	O	64	NMOD
66	0.005	0.005	I-NP	CD	O	65	AMOD
67	)	)	O	)	O	57	NMOD
68	.	.	O	.	O	6	P

1	Diltiazem	Diltiazem	B-NP	NNP	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	affect	affect	I-VP	VB	O	2	VC
5	ERP	ERP	B-NP	NN	B-protein	12	NMOD
6	,	,	O	,	O	12	P
7	AF	AF	B-NP	NN	O	9	NMOD
8	cycle	cycle	I-NP	NN	O	9	NMOD
9	length	length	I-NP	NN	O	12	NMOD
10	or	or	O	CC	O	12	NMOD
11	AF	AF	B-NP	NN	O	12	NMOD
12	duration	duration	I-NP	NN	O	4	OBJ
13	,	,	O	,	O	2	P
14	but	but	O	CC	O	2	VMOD
15	produced	produce	B-VP	VBD	O	2	VMOD
16	conduction	conduction	B-NP	NN	O	17	NMOD
17	acceleration	acceleration	I-NP	NN	O	15	OBJ
18	similar	similar	B-ADJP	JJ	O	17	NMOD
19	to	to	B-PP	TO	O	18	AMOD
20	that	that	B-NP	DT	O	19	PMOD
21	caused	cause	B-VP	VBN	O	20	NMOD
22	by	by	B-PP	IN	O	21	VMOD
23	verapamil	verapamil	B-NP	NN	O	22	PMOD
24	(	(	O	(	O	26	DEP
25	n=5	n=5	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	9	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	presence	presence	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	autonomic	autonomic	B-NP	JJ	O	6	NMOD
6	blockade	blockade	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	9	P
8	verapamil	verapamil	B-NP	NN	O	9	SUB
9	failed	fail	B-VP	VBD	O	0	ROOT
10	to	to	I-VP	TO	O	11	VMOD
11	promote	promote	I-VP	VB	O	9	VMOD
12	AF	AF	B-NP	NN	O	11	OBJ
13	and	and	O	CC	O	9	VMOD
14	increased	increase	B-VP	VBD	O	9	VMOD
15	,	,	O	,	O	14	P
16	rather	rather	B-PP	RB	O	14	VMOD
17	than	than	I-PP	IN	O	16	PMOD
18	decreasing	decrease	B-VP	VBG	O	20	NMOD
19	,	,	O	,	O	20	P
20	refractoriness	refractoriness	B-NP	NN	O	17	PMOD
21	.	.	O	.	O	9	P

1	Epicardial	Epicardial	B-NP	JJ	O	2	NMOD
2	mapping	mapping	I-NP	NN	O	3	SUB
3	suggested	suggest	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	verapamil	verapamil	B-NP	NN	B-protein	6	SUB
6	promoted	promote	B-VP	VBD	I-protein	4	SBAR
7	AF	AF	B-NP	NN	I-protein	6	OBJ
8	by	by	B-PP	IN	O	6	VMOD
9	increasing	increase	B-VP	VBG	O	8	PMOD
10	the	the	B-NP	DT	O	11	NMOD
11	number	number	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	simultaneous	simultaneous	B-NP	JJ	O	14	NMOD
14	wavefronts	wavefront	I-NP	NNS	O	12	PMOD
15	reflected	reflect	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	separate	separate	B-NP	JJ	O	18	NMOD
18	zones	zone	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	reactivation	reactivation	B-NP	NN	O	19	PMOD
21	in	in	B-PP	IN	O	15	VMOD
22	each	each	B-NP	DT	O	23	NMOD
23	cycle	cycle	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	3	P

1	Hypotension	Hypotension	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	bradycardia	bradycardia	B-NP	NN	O	6	NMOD
4	,	,	O	,	O	6	P
5	and	and	O	CC	O	6	NMOD
6	asystole	asystole	B-NP	NN	O	0	ROOT
7	after	after	B-PP	IN	O	6	NMOD
8	high-dose	high-dose	B-NP	JJ	O	10	NMOD
9	intravenous	intravenous	I-NP	JJ	O	10	NMOD
10	methylprednisolone	methylprednisolone	I-NP	NN	O	7	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	monitored	monitor	I-NP	VBN	O	14	NMOD
14	patient	patient	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	hypotension	hypotension	B-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	bradycardia	bradycardia	B-NP	NN	O	11	NMOD
9	,	,	O	,	O	11	P
10	and	and	O	CC	O	11	NMOD
11	asystole	asystole	B-NP	NN	O	5	PMOD
12	after	after	B-SBAR	IN	O	4	NMOD
13	intravenous	intravenous	B-NP	JJ	O	14	NMOD
14	administration	administration	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	high-dose	high-dose	B-NP	JJ	O	17	NMOD
17	methylprednisolone	methylprednisolone	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	14	NMOD
19	a	a	B-NP	DT	O	21	NMOD
20	73-year-old	73-year-old	I-NP	JJ	O	21	NMOD
21	patient	patient	I-NP	NN	O	18	PMOD
22	who	who	B-NP	WP	O	21	NMOD
23	underwent	undergo	B-VP	VBD	O	22	SBAR
24	electrocardiographic	electrocardiographic	B-ADJP	JJ	O	28	NMOD
25	(	(	O	(	O	27	DEP
26	ECG	ECG	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	AMOD
28	monitoring	monitoring	B-NP	NN	O	23	OBJ
29	throughout	throughout	B-PP	IN	O	23	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	episode	episode	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	reviews	review	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	7	NMOD
5	current	current	I-NP	JJ	O	7	NMOD
6	proposed	propose	I-NP	VBN	O	7	NMOD
7	mechanisms	mechanism	I-NP	NNS	O	3	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	sudden	sudden	B-NP	JJ	O	10	NMOD
10	death	death	I-NP	NN	O	8	PMOD
11	after	after	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	high	high	I-NP	JJ	O	14	NMOD
14	dose	dose	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	intravenous	intravenous	B-NP	JJ	O	17	NMOD
17	methylprednisolone	methylprednisolone	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	IVMP	IVMP	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	.	.	O	.	O	3	P

1	Lifetime	Lifetime	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	mice	mouse	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	2	NMOD
6	azidothymidine	azidothymidine	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	9	DEP
8	AZT	AZT	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	produces	produce	B-VP	VBZ	O	0	ROOT
11	myelodysplasia	myelodysplasia	B-NP	NN	O	10	OBJ
12	.	.	O	.	O	10	P

1	AZT	AZT	B-NP	NNP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	a	a	B-NP	DT	O	6	NMOD
5	macrocytic	macrocytic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	3	OBJ
7	in	in	B-PP	IN	O	3	VMOD
8	AIDS	AIDS	B-NP	NN	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	long	long	B-NP	JJ	O	14	NMOD
12	term	term	I-NP	NN	O	14	NMOD
13	AZT	AZT	I-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	2	P

1	Influence	Influence	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	diet	diet	B-NP	NN	O	2	PMOD
4	free	free	B-ADJP	JJ	O	3	NMOD
5	of	of	B-PP	IN	O	4	AMOD
6	NAD-precursors	NAD-precursor	B-NP	NNS	B-cell_type	5	PMOD
7	on	on	B-PP	IN	O	1	NMOD
8	acetaminophen	acetaminophen	B-NP	NN	O	9	NMOD
9	hepatotoxicity	hepatotoxicity	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	mice	mouse	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	1	P

1	Recently	Recently	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	7	NMOD
6	hepatoprotective	hepatoprotective	I-NP	JJ	O	7	NMOD
7	effects	effect	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	nicotinic	nicotinic	B-NP	JJ	O	11	NMOD
10	acid	acid	I-NP	NN	O	11	NMOD
11	amide	amide	I-NP	NN	O	15	NMOD
12	,	,	O	,	O	15	P
13	a	a	B-NP	DT	O	15	NMOD
14	selective	selective	I-NP	JJ	O	15	NMOD
15	inhibitor	inhibitor	I-NP	NN	O	8	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	poly	poly	B-NP	NN	B-protein	21	NMOD
18	(	(	O	(	I-protein	21	NMOD
19	ADP-ribose	ADP-ribose	B-NP	NN	I-protein	21	NMOD
20	)	)	O	)	I-protein	21	NMOD
21	polymerase	polymerase	B-NP	NN	I-protein	16	PMOD
22	(	(	O	(	O	27	DEP
23	PARP	PARP	B-NP	NN	B-protein	26	NMOD
24	;	;	O	:	O	26	P
25	EC	EC	B-NP	NNP	B-cell_type	26	NMOD
26	2.4.2.30	2.4.2.30	I-NP	CD	O	27	DEP
27	)	)	O	)	O	21	NMOD
28	on	on	B-PP	IN	O	4	VMOD
29	mice	mouse	B-NP	NNS	O	28	PMOD
30	suffering	suffer	B-VP	VBG	O	29	NMOD
31	from	from	B-PP	IN	O	30	VMOD
32	acetaminophen	acetaminophen	B-NP	NN	O	36	NMOD
33	(	(	O	(	O	35	DEP
34	AAP	AAP	B-NP	NN	O	35	DEP
35	)	)	O	)	O	32	NMOD
36	-hepatitis	-hepatitis	B-NP	NN	O	31	PMOD
37	,	,	O	,	O	4	P
38	suggesting	suggest	B-VP	VBG	O	4	VMOD
39	that	that	B-SBAR	IN	O	38	VMOD
40	the	the	B-NP	DT	O	41	NMOD
41	AAP	AAP	I-NP	NN	B-protein	42	SUB
42	induced	induce	B-VP	VBD	O	39	SBAR
43	liver	liver	B-NP	NN	O	44	NMOD
44	injury	injury	I-NP	NN	O	42	OBJ
45	involves	involve	B-VP	VBZ	O	38	VMOD
46	a	a	B-NP	DT	O	47	NMOD
47	step	step	I-NP	NN	O	45	OBJ
48	which	which	B-NP	WDT	O	47	NMOD
49	depends	depend	B-VP	VBZ	O	48	SBAR
50	on	on	B-PP	IN	O	49	VMOD
51	adenoribosylation	adenoribosylation	B-NP	NN	O	50	PMOD
52	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	investigates	investigate	B-VP	VBZ	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	effects	effect	I-NP	NNS	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	diet	diet	I-NP	NN	O	7	PMOD
10	free	free	B-ADJP	JJ	O	9	NMOD
11	of	of	B-PP	IN	O	10	AMOD
12	precursors	precursor	B-NP	NNS	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	NAD	NAD	B-NP	NN	B-protein	13	PMOD
15	,	,	O	,	O	4	P
16	the	the	B-NP	DT	O	17	NMOD
17	substrate	substrate	I-NP	NN	O	4	OBJ
18	on	on	B-PP	IN	O	17	NMOD
19	which	which	B-NP	WDT	O	18	PMOD
20	PARP	PARP	B-NP	NN	B-protein	21	SUB
21	acts	act	B-VP	VBZ	O	18	SBAR
22	,	,	O	,	O	21	P
23	in	in	B-PP	IN	O	21	VMOD
24	female	female	B-NP	JJ	O	26	NMOD
25	NMRI	NMRI	I-NP	NN	O	26	NMOD
26	mice	mouse	I-NP	NNS	O	23	PMOD
27	with	with	B-PP	IN	O	23	PMOD
28	AAP	AAP	B-NP	NN	O	29	NMOD
29	hepatitis	hepatitis	I-NP	NN	O	27	PMOD
30	and	and	O	CC	O	21	VMOD
31	evaluates	evaluate	B-VP	VBZ	O	21	VMOD
32	the	the	B-NP	DT	O	33	NMOD
33	influence	influence	I-NP	NN	O	31	OBJ
34	of	of	B-PP	IN	O	33	NMOD
35	simultaneous	simultaneous	B-NP	JJ	O	37	NMOD
36	ethanol	ethanol	I-NP	NN	O	37	NMOD
37	consumption	consumption	I-NP	NN	O	34	PMOD
38	in	in	B-PP	IN	O	33	NMOD
39	these	these	B-NP	DT	O	40	NMOD
40	animals	animal	I-NP	NNS	O	38	PMOD
41	.	.	O	.	O	4	P

1	Liver	Liver	B-NP	NN	O	2	NMOD
2	injuries	injury	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	quantified	quantify	I-VP	VBN	O	3	VC
5	as	as	B-PP	IN	O	4	VMOD
6	serum	serum	B-NP	NN	O	7	NMOD
7	activities	activity	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	glutamate-oxaloacetate	glutamate-oxaloacetate	B-NP	NN	B-protein	10	NMOD
10	transaminase	transaminase	I-NP	NN	I-protein	16	NMOD
11	(	(	O	(	O	13	DEP
12	GOT	GOT	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	and	and	O	CC	O	16	NMOD
15	glutamate-pyruvate	glutamate-pyruvate	B-NP	JJ	B-protein	16	NMOD
16	transaminase	transaminase	I-NP	NN	I-protein	8	PMOD
17	(	(	O	(	O	19	DEP
18	GPT	GPT	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	12	VMOD
2	these	these	B-NP	DT	O	3	NMOD
3	animals	animal	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	12	P
5	only	only	B-NP	RB	O	6	AMOD
6	minor	minor	I-NP	JJ	O	7	NMOD
7	increases	increase	I-NP	NNS	O	12	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	serum	serum	B-NP	NN	B-protein	11	NMOD
10	transaminase	transaminase	I-NP	NN	I-protein	11	NMOD
11	activities	activity	I-NP	NNS	O	8	PMOD
12	were	be	B-VP	VBD	O	37	VMOD
13	measured	measure	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	presence	presence	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	AAP	AAP	B-NP	NN	B-protein	17	PMOD
19	,	,	O	,	O	37	P
20	and	and	O	CC	O	37	VMOD
21	unlike	unlike	B-PP	IN	O	37	VMOD
22	the	the	B-NP	DT	O	23	NMOD
23	exacerbation	exacerbation	I-NP	NN	O	21	PMOD
24	caused	cause	B-VP	VBN	O	23	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	ethanol	ethanol	B-NP	NN	O	25	PMOD
27	in	in	B-PP	IN	O	24	VMOD
28	mice	mouse	B-NP	NNS	O	27	PMOD
29	on	on	B-PP	IN	O	28	NMOD
30	a	a	B-NP	DT	O	32	NMOD
31	standard	standard	I-NP	JJ	O	32	NMOD
32	diet	diet	I-NP	NN	O	29	PMOD
33	,	,	O	,	O	37	P
34	the	the	B-NP	DT	O	36	NMOD
35	liver	liver	I-NP	NN	O	36	NMOD
36	damage	damage	I-NP	NN	O	37	SUB
37	was	be	B-VP	VBD	O	0	ROOT
38	inhibited	inhibit	I-VP	VBN	O	37	VC
39	by	by	B-PP	IN	O	38	VMOD
40	50	50	B-NP	CD	O	41	NMOD
41	%	%	I-NP	NN	O	39	PMOD
42	by	by	B-PP	IN	O	38	VMOD
43	ethanol	ethanol	B-NP	NN	O	42	PMOD
44	.	.	O	.	O	37	P

1	A	A	B-NP	DT	O	5	NMOD
2	further	further	I-NP	JJ	O	5	NMOD
3	64	64	I-NP	CD	O	5	NMOD
4	%	%	I-NP	NN	O	3	AMOD
5	reduction	reduction	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	hepatitis	hepatitis	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	observed	observe	I-VP	VBN	O	8	VC
10	,	,	O	,	O	8	P
11	when	when	B-ADVP	WRB	O	8	VMOD
12	NAA	NAA	B-NP	NN	B-protein	13	SUB
13	was	be	B-VP	VBD	O	11	SBAR
14	given	give	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	ethanol/AAP-mice	ethanol/AAP-mice	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	8	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	provide	provide	B-VP	VBP	O	0	ROOT
4	evidence	evidence	B-NP	NN	O	3	OBJ
5	that	that	B-SBAR	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	AAP	AAP	I-NP	NN	B-protein	8	SUB
8	induced	induce	B-VP	VBD	O	5	SBAR
9	hepatitis	hepatitis	B-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	its	its	B-NP	PRP$	O	12	NMOD
12	exacerbation	exacerbation	I-NP	NN	O	8	OBJ
13	by	by	B-PP	IN	O	8	VMOD
14	ethanol	ethanol	B-NP	NN	O	13	PMOD
15	can	can	B-VP	MD	O	8	VMOD
16	either	either	O	CC	O	15	VMOD
17	be	be	B-VP	VB	O	15	VC
18	reduced	reduce	I-VP	VBN	O	17	VC
19	by	by	B-PP	IN	O	18	VMOD
20	end-product	end-product	B-NP	NN	O	21	NMOD
21	inhibition	inhibition	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	PARP	PARP	B-NP	NN	B-protein	22	PMOD
24	by	by	B-PP	IN	O	21	NMOD
25	NAA	NAA	B-NP	NN	B-protein	24	PMOD
26	or	or	B-PP	CC	O	24	PMOD
27	by	by	B-PP	IN	O	24	PMOD
28	dietary	dietary	B-NP	JJ	O	29	NMOD
29	depletion	depletion	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	the	the	B-NP	DT	O	33	NMOD
32	enzyme	enzyme	I-NP	NN	O	33	NMOD
33	's	's	B-NP	POS	O	35	NMOD
34	substrate	substrate	I-NP	NN	O	35	NMOD
35	NAD	NAD	I-NP	NN	O	30	PMOD
36	.	.	O	.	O	3	P

1	Antiarrhythmic	Antiarrhythmic	B-NP	JJ	O	3	NMOD
2	plasma	plasma	I-NP	NN	O	3	NMOD
3	concentrations	concentration	I-NP	NNS	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	cibenzoline	cibenzoline	B-NP	NN	O	4	PMOD
6	on	on	B-PP	IN	O	3	NMOD
7	canine	canine	B-NP	JJ	O	9	NMOD
8	ventricular	ventricular	I-NP	JJ	O	9	NMOD
9	arrhythmias	arrhythmia	I-NP	NNS	O	6	PMOD
10	.	.	O	.	O	3	P

1	Using	Use	B-VP	VBG	O	19	VMOD
2	two-stage	two-stage	B-NP	JJ	O	4	NMOD
3	coronary	coronary	I-NP	JJ	O	4	NMOD
4	ligation-	ligation-	I-NP	NN	O	1	OBJ
5	,	,	O	,	O	10	P
6	digitalis-	digitalis-	B-NP	NN	O	10	SUB
7	,	,	O	,	O	10	P
8	and	and	O	CC	O	10	VMOD
9	adrenaline	adrenaline	B-NP	NN	O	10	SUB
10	induced	induce	B-VP	VBD	O	4	NMOD
11	canine	canine	B-NP	JJ	O	13	NMOD
12	ventricular	ventricular	I-NP	JJ	O	13	NMOD
13	arrhythmias	arrhythmia	I-NP	NNS	O	10	OBJ
14	,	,	O	,	O	19	P
15	antiarrhythmic	antiarrhythmic	B-NP	JJ	O	16	NMOD
16	effects	effect	I-NP	NNS	O	19	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	cibenzoline	cibenzoline	B-NP	NN	O	17	PMOD
19	were	be	B-VP	VBD	O	31	VMOD
20	examined	examine	I-VP	VBN	O	19	VC
21	and	and	O	CC	O	31	VMOD
22	the	the	B-NP	DT	O	26	NMOD
23	minimum	minimum	I-NP	JJ	O	26	NMOD
24	effective	effective	I-NP	JJ	O	26	NMOD
25	plasma	plasma	I-NP	NN	O	26	NMOD
26	concentration	concentration	I-NP	NN	O	31	SUB
27	for	for	B-PP	IN	O	26	NMOD
28	each	each	B-NP	DT	O	30	NMOD
29	arrhythmia	arrhythmia	I-NP	NN	O	30	NMOD
30	model	model	I-NP	NN	O	27	PMOD
31	was	be	B-VP	VBD	O	0	ROOT
32	determined	determine	I-VP	VBN	O	31	VC
33	.	.	O	.	O	31	P

1	Cibenzoline	Cibenzoline	B-NP	NN	O	2	SUB
2	suppressed	suppress	B-VP	VBD	O	29	VMOD
3	all	all	B-NP	PDT	O	5	NMOD
4	the	the	I-NP	DT	O	5	NMOD
5	arrhythmias	arrhythmia	I-NP	NNS	O	2	OBJ
6	,	,	O	,	O	12	P
7	and	and	O	CC	O	12	NMOD
8	the	the	B-NP	DT	O	12	NMOD
9	minimum	minimum	I-NP	JJ	O	10	AMOD
10	effective	effective	I-NP	JJ	O	12	NMOD
11	plasma	plasma	I-NP	NN	O	12	NMOD
12	concentrations	concentration	I-NP	NNS	O	29	SUB
13	for	for	B-PP	IN	O	12	NMOD
14	arrhythmias	arrhythmia	B-NP	NNS	O	13	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	24-h	24-h	B-NP	JJ	O	19	NMOD
18	coronary	coronary	I-NP	JJ	O	19	NMOD
19	ligation	ligation	I-NP	NN	O	16	PMOD
20	,	,	O	,	O	29	P
21	48-h	48-h	B-NP	JJ	O	23	NMOD
22	coronary	coronary	I-NP	JJ	O	23	NMOD
23	ligation	ligation	I-NP	NN	O	29	SUB
24	,	,	O	,	O	29	P
25	digitalis	digitalis	B-NP	NN	O	29	SUB
26	,	,	O	,	O	29	P
27	and	and	O	CC	O	29	VMOD
28	adrenaline	adrenaline	B-NP	NN	O	29	SUB
29	were	be	B-VP	VBD	O	0	ROOT
30	1.9	1.9	B-NP	CD	O	32	AMOD
31	+/-	+/-	I-NP	SYM	O	32	AMOD
32	0.9	0.9	I-NP	CD	O	42	NMOD
33	(	(	O	(	O	38	DEP
34	by	by	B-PP	IN	O	38	DEP
35	8	8	B-NP	CD	O	37	NMOD
36	mg/kg	mg/kg	I-NP	NN	O	37	NMOD
37	i.v.	i.v.	I-NP	NN	O	34	PMOD
38	)	)	O	)	O	32	NMOD
39	,	,	O	,	O	42	P
40	1.6	1.6	B-NP	CD	O	42	NMOD
41	+/-	+/-	I-NP	CC	O	42	NMOD
42	0.5	0.5	I-NP	CD	O	52	NMOD
43	(	(	O	(	O	48	DEP
44	by	by	B-PP	IN	O	48	DEP
45	8	8	B-NP	CD	O	47	NMOD
46	mg/kg	mg/kg	I-NP	NN	O	47	NMOD
47	i.v.	i.v.	I-NP	NN	O	44	PMOD
48	)	)	O	)	O	42	NMOD
49	,	,	O	,	O	52	P
50	0.6	0.6	B-NP	CD	O	52	NMOD
51	+/-	+/-	I-NP	CC	O	52	NMOD
52	0.2	0.2	I-NP	CD	O	63	NMOD
53	(	(	O	(	O	58	DEP
54	by	by	B-PP	IN	O	58	DEP
55	2	2	B-NP	CD	O	57	NMOD
56	mg/kg	mg/kg	I-NP	NN	O	57	NMOD
57	i.v.	i.v.	I-NP	NN	O	54	PMOD
58	)	)	O	)	O	52	NMOD
59	,	,	O	,	O	52	P
60	and	and	O	CC	O	63	NMOD
61	3.5	3.5	B-NP	CD	O	63	NMOD
62	+/-	+/-	I-NP	CC	O	63	NMOD
63	1.3	1.3	I-NP	CD	O	29	PRD
64	(	(	O	(	O	63	NMOD
65	by	by	B-PP	IN	O	64	DEP
66	5	5	B-NP	CD	O	67	AMOD
67	mg/kg	mg/kg	I-NP	NN	O	70	NMOD
68	i.v.	i.v.	I-NP	NN	O	70	NMOD
69	)	)	O	)	O	70	NMOD
70	micrograms/ml	micrograms/ml	B-NP	NN	O	65	PMOD
71	,	,	O	,	O	65	P
72	respectively	respectively	B-ADVP	RB	O	65	PRD
73	(	(	O	(	O	81	DEP
74	mean	mean	B-NP	NN	O	76	NMOD
75	+/-	+/-	O	SYM	O	76	NMOD
76	SDM	SDM	B-NP	NN	O	80	VMOD
77	,	,	O	,	O	80	P
78	n	n	B-NP	NN	O	80	SUB
79	=	=	B-VP	SYM	O	80	VMOD
80	6-7	6-7	B-NP	CD	O	81	DEP
81	)	)	O	)	O	72	AMOD
82	.	.	O	.	O	29	P

1	The	The	B-NP	DT	O	2	NMOD
2	concentration	concentration	I-NP	NN	O	7	SUB
3	for	for	B-PP	IN	O	2	NMOD
4	adrenaline	adrenaline	B-NP	NN	O	6	NMOD
5	induced	induce	I-NP	VBN	O	6	NMOD
6	arrhythmia	arrhythmia	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	significantly	significantly	B-ADJP	RB	O	9	AMOD
9	higher	high	I-ADJP	JJR	O	7	PRD
10	than	than	B-PP	IN	O	9	AMOD
11	those	those	B-NP	DT	O	10	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	other	other	I-NP	JJ	O	15	NMOD
15	types	type	I-NP	NNS	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	arrhythmias	arrhythmia	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	7	P

1	Immunopathology	Immunopathology	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	penicillamine	penicillamine	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	glomerular	glomerular	B-NP	JJ	O	6	NMOD
6	disease	disease	I-NP	NN	O	4	OBJ
7	.	.	O	.	O	4	P

1	Four	Four	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	6	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	rheumatoid	rheumatoid	B-NP	JJ	O	5	NMOD
5	arthritis	arthritis	I-NP	NN	O	3	PMOD
6	developed	develop	B-VP	VBD	O	0	ROOT
7	heavy	heavy	B-NP	JJ	O	8	NMOD
8	proteinuria	proteinuria	I-NP	NN	O	6	OBJ
9	after	after	B-PP	IN	O	6	VMOD
10	five	five	B-NP	CD	O	12	AMOD
11	to	to	I-NP	TO	O	12	AMOD
12	12	12	I-NP	CD	O	13	NMOD
13	months	month	I-NP	NNS	O	9	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	treatment	treatment	B-NP	NN	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	D-penicillamine	D-penicillamine	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	6	P

1	Ventricular	Ventricular	B-NP	JJ	O	2	NMOD
2	fibrillation	fibrillation	I-NP	NN	O	0	ROOT
3	from	from	B-PP	IN	O	2	NMOD
4	diatrizoate	diatrizoate	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	2	NMOD
6	and	and	B-PP	CC	O	5	PMOD
7	without	without	B-PP	IN	O	5	PMOD
8	chelating	chelate	B-NP	VBG	O	9	NMOD
9	agents	agent	I-NP	NNS	O	5	PMOD
10	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	Renografin	Renografin	B-NP	NN	O	6	NMOD
5	76	76	B-NP	CD	O	6	NMOD
6	%	%	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	compared	compare	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	that	that	B-NP	DT	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	Hypaque	Hypaque	B-NP	NN	O	14	NMOD
13	76	76	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	11	PMOD
15	by	by	B-PP	IN	O	8	VMOD
16	selective	selective	B-NP	JJ	O	17	NMOD
17	injection	injection	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	each	each	B-NP	DT	O	18	PMOD
20	into	into	B-PP	IN	O	17	NMOD
21	the	the	B-NP	DT	O	24	NMOD
22	right	right	I-NP	JJ	O	24	NMOD
23	coronary	coronary	I-NP	JJ	O	24	NMOD
24	artery	artery	I-NP	NN	O	20	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	dogs	dog	B-NP	NNS	O	25	PMOD
27	.	.	O	.	O	7	P

1	Rapid	Rapid	B-NP	JJ	O	2	NMOD
2	reversal	reversal	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	anticoagulation	anticoagulation	B-NP	NN	O	3	PMOD
5	reduces	reduce	B-VP	VBZ	O	0	ROOT
6	hemorrhage	hemorrhage	B-NP	NN	O	7	NMOD
7	volume	volume	I-NP	NN	O	5	OBJ
8	in	in	B-PP	IN	O	5	VMOD
9	a	a	B-NP	DT	O	11	NMOD
10	mouse	mouse	I-NP	NN	O	11	NMOD
11	model	model	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	warfarin-associated	warfarin-associated	B-NP	JJ	O	15	NMOD
14	intracerebral	intracerebral	I-NP	JJ	O	15	NMOD
15	hemorrhage	hemorrhage	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	5	P

1	Warfarin-associated	Warfarin-associated	B-NP	JJ	O	3	NMOD
2	intracerebral	intracerebral	I-NP	JJ	O	3	NMOD
3	hemorrhage	hemorrhage	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	W-ICH	W-ICH	B-NP	NN	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	10	NMOD
9	severe	severe	I-NP	JJ	O	10	NMOD
10	type	type	I-NP	NN	O	7	PRD
11	of	of	B-PP	IN	O	10	NMOD
12	stroke	stroke	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	provide	provide	B-VP	VBP	O	0	ROOT
3	experimental	experimental	B-NP	JJ	O	4	NMOD
4	data	datum	I-NP	NNS	O	2	OBJ
5	suggesting	suggest	B-VP	VBG	O	4	NMOD
6	PCC	PCC	B-NP	NN	O	8	SUB
7	to	to	B-VP	TO	O	8	VMOD
8	be	be	I-VP	VB	O	5	VMOD
9	an	an	B-NP	DT	O	12	NMOD
10	effective	effective	I-NP	JJ	O	11	AMOD
11	acute	acute	I-NP	JJ	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	8	PRD
13	for	for	B-PP	IN	O	12	NMOD
14	W-ICH	W-ICH	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	8	VMOD
16	terms	term	B-NP	NNS	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	reducing	reduce	B-VP	VBG	O	17	PMOD
19	hemorrhagic	hemorrhagic	B-NP	JJ	O	21	NMOD
20	blood	blood	I-NP	NN	O	21	NMOD
21	volume	volume	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	examined	examine	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	utility	utility	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	biometry	biometry	B-NP	NN	O	6	PMOD
8	for	for	B-PP	IN	O	5	NMOD
9	detecting	detect	B-VP	VBG	O	8	PMOD
10	alcohol-related	alcohol-related	B-NP	JJ	O	13	NMOD
11	fetal	fetal	I-NP	JJ	O	13	NMOD
12	growth	growth	I-NP	NN	O	13	NMOD
13	impairment	impairment	I-NP	NN	O	9	OBJ
14	.	.	O	.	O	3	P

1	Any	Any	B-NP	DT	O	5	NMOD
2	alcohol	alcohol	I-NP	NN	O	5	NMOD
3	consumption	consumption	I-NP	NN	O	5	NMOD
4	postpregnancy	postpregnancy	I-NP	NN	O	5	NMOD
5	recognition	recognition	I-NP	NN	O	10	SUB
6	among	among	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	heavy	heavy	I-NP	JJ	O	9	NMOD
9	drinkers	drinker	I-NP	NNS	O	6	PMOD
10	resulted	result	B-VP	VBD	O	0	ROOT
11	in	in	B-PP	IN	O	10	VMOD
12	reduced	reduce	B-NP	VBN	O	14	NMOD
13	cerebellar	cerebellar	I-NP	JJ	O	14	NMOD
14	growth	growth	I-NP	NN	O	19	NMOD
15	as	as	B-CONJP	RB	O	19	NMOD
16	well	well	I-CONJP	RB	O	15	DEP
17	as	as	I-CONJP	IN	O	15	DEP
18	decreased	decrease	B-NP	VBN	O	19	NMOD
19	cranial	cranial	I-NP	NN	O	11	PMOD
20	to	to	B-PP	TO	O	19	NMOD
21	body	body	B-NP	NN	O	22	NMOD
22	growth	growth	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	10	VMOD
24	comparison	comparison	B-NP	NN	O	23	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	women	woman	B-NP	NNS	O	25	PMOD
27	who	who	B-NP	WP	O	26	NMOD
28	either	either	O	CC	O	27	SBAR
29	quit	quit	B-NP	NN	O	30	NMOD
30	drinking	drinking	I-NP	NN	O	28	PMOD
31	or	or	O	CC	O	30	NMOD
32	who	who	B-NP	WP	O	31	DEP
33	were	be	B-VP	VBD	O	32	SBAR
34	nondrinkers	nondrinker	B-NP	NNS	O	33	PRD
35	.	.	O	.	O	10	P

1	Urinary	Urinary	B-NP	JJ	O	2	NMOD
2	symptoms	symptom	I-NP	NNS	O	4	NMOD
3	and	and	O	CC	O	4	NMOD
4	quality	quality	B-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	life	life	B-NP	NN	O	7	NMOD
7	changes	change	I-NP	NNS	O	5	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	Thai	Thai	B-NP	JJ	O	10	NMOD
10	women	woman	I-NP	NNS	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	overactive	overactive	B-NP	JJ	O	13	NMOD
13	bladder	bladder	I-NP	NN	O	11	PMOD
14	after	after	B-PP	IN	O	10	NMOD
15	tolterodine	tolterodine	B-NP	NN	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	4	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	study	study	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	urinary	urinary	I-NP	JJ	O	7	NMOD
7	symptoms	symptom	I-NP	NNS	O	9	NMOD
8	and	and	O	CC	O	9	NMOD
9	quality	quality	B-NP	NN	O	4	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	life	life	B-NP	NN	O	12	NMOD
12	changes	change	I-NP	NNS	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	Thai	Thai	B-NP	JJ	O	15	NMOD
15	women	woman	I-NP	NNS	O	13	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	overactive	overactive	B-NP	JJ	O	18	NMOD
18	bladder	bladder	I-NP	NN	O	16	PMOD
19	(	(	O	(	O	21	DEP
20	OAB	OAB	B-NP	NN	B-protein	21	DEP
21	)	)	O	)	O	18	NMOD
22	after	after	B-PP	IN	O	18	NMOD
23	tolterodine	tolterodine	B-NP	NN	O	24	NMOD
24	treatment	treatment	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	1	P

1	Absence	Absence	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	acute	acute	B-NP	JJ	O	5	NMOD
4	cerebral	cerebral	I-NP	JJ	O	5	NMOD
5	vasoconstriction	vasoconstriction	I-NP	NN	O	2	PMOD
6	after	after	B-PP	IN	O	1	NMOD
7	cocaine-associated	cocaine-associated	B-NP	JJ	O	9	NMOD
8	subarachnoid	subarachnoid	I-NP	JJ	O	9	NMOD
9	hemorrhage	hemorrhage	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	1	P

1	INTRODUCTION	INTRODUCTION	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Cocaine	Cocaine	B-NP	NN	O	4	NMOD
4	use	use	I-NP	NN	O	5	SUB
5	has	have	B-VP	VBZ	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	associated	associate	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	neurovascular	neurovascular	B-NP	JJ	O	10	NMOD
10	complications	complication	I-NP	NNS	O	8	PMOD
11	,	,	O	,	O	10	P
12	including	include	B-PP	VBG	O	10	NMOD
13	arterial	arterial	B-NP	JJ	O	14	NMOD
14	vasoconstriction	vasoconstriction	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	vasculitis	vasculitis	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	5	P

1	Information	Information	B-NP	NN	O	5	SUB
2	on	on	B-PP	IN	O	1	NMOD
3	these	these	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	2	PMOD
5	could	could	B-VP	MD	O	0	ROOT
6	be	be	I-VP	VB	O	5	VC
7	obtained	obtain	I-VP	VBN	O	6	VC
8	from	from	B-PP	IN	O	7	VMOD
9	angiograms	angiogram	B-NP	NNS	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	cocaine-associated	cocaine-associated	B-NP	JJ	O	15	NMOD
14	subarachnoid	subarachnoid	I-NP	JJ	O	15	NMOD
15	hemorrhage	hemorrhage	I-NP	NN	O	12	PMOD
16	(	(	O	(	O	18	DEP
17	SAH	SAH	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	who	who	B-NP	WP	O	11	NMOD
20	underwent	undergo	B-VP	VBD	O	19	SBAR
21	angiography	angiography	B-NP	NN	O	20	OBJ
22	shortly	shortly	B-ADVP	RB	O	20	VMOD
23	after	after	B-PP	IN	O	20	VMOD
24	cocaine	cocaine	B-NP	NN	O	25	NMOD
25	use	use	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	5	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	screened	screen	B-VP	VBD	O	1	NMOD
5	patients	patient	B-NP	NNS	O	4	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	SAH	SAH	B-NP	NN	O	6	PMOD
8	retrospectively	retrospectively	B-ADVP	RB	O	4	VMOD
9	and	and	O	CC	O	4	VMOD
10	identified	identify	B-VP	VBD	O	4	VMOD
11	those	those	B-NP	DT	O	10	OBJ
12	with	with	B-PP	IN	O	11	NMOD
13	positive	positive	B-NP	JJ	O	15	NMOD
14	urine	urine	I-NP	NN	O	15	NMOD
15	toxicology	toxicology	I-NP	NN	O	12	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	cocaine	cocaine	B-NP	NN	O	20	NMOD
18	or	or	O	CC	O	20	NMOD
19	its	its	B-NP	PRP$	O	20	NMOD
20	metabolites	metabolite	I-NP	NNS	O	16	PMOD
21	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	authors	author	I-NP	NNS	O	3	SUB
3	describe	describe	B-VP	VBP	O	0	ROOT
4	the	the	B-NP	DT	O	6	NMOD
5	unusual	unusual	I-NP	JJ	O	6	NMOD
6	association	association	I-NP	NN	O	3	OBJ
7	between	between	B-PP	IN	O	6	NMOD
8	diffuse	diffuse	B-NP	JJ	O	11	NMOD
9	B-cell	B-cell	I-NP	NN	O	11	NMOD
10	gastric	gastric	I-NP	JJ	O	11	NMOD
11	lymphoma	lymphoma	I-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	myotonic	myotonic	B-NP	JJ	O	14	NMOD
14	dystrophy	dystrophy	I-NP	NN	O	7	PMOD
15	,	,	O	,	O	3	P
16	the	the	B-NP	DT	O	19	NMOD
17	most	most	I-NP	RBS	O	18	AMOD
18	common	common	I-NP	JJ	O	19	NMOD
19	form	form	I-NP	NN	O	3	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	adult	adult	B-NP	JJ	O	23	NMOD
22	muscular	muscular	I-NP	JJ	O	23	NMOD
23	dystrophy	dystrophy	I-NP	NN	O	20	PMOD
24	,	,	O	,	O	28	P
25	and	and	O	CC	O	28	NMOD
26	sudden	sudden	B-NP	JJ	O	28	NMOD
27	atrial	atrial	I-NP	JJ	O	28	NMOD
28	fibrillation	fibrillation	I-NP	NN	O	3	VMOD
29	following	follow	B-PP	VBG	O	3	VMOD
30	one	one	B-NP	CD	O	31	NMOD
31	cycle	cycle	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	doxorubicin-based	doxorubicin-based	B-NP	JJ	O	34	NMOD
34	chemotherapy	chemotherapy	I-NP	NN	O	32	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	same	same	I-NP	JJ	O	38	NMOD
38	patient	patient	I-NP	NN	O	35	PMOD
39	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	4	NMOD
2	phase	phase	I-NP	NN	O	4	NMOD
3	II	II	I-NP	CD	O	4	NMOD
4	study	study	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	thalidomide	thalidomide	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	advanced	advance	B-NP	VBN	O	12	NMOD
9	metastatic	metastatic	I-NP	JJ	O	12	NMOD
10	renal	renal	I-NP	JJ	O	12	NMOD
11	cell	cell	I-NP	NN	O	12	NMOD
12	carcinoma	carcinoma	I-NP	NN	O	7	PMOD
13	.	.	O	.	O	4	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	toxicity	toxicity	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	activity	activity	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	thalidomide	thalidomide	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	advanced	advance	B-NP	VBN	O	18	NMOD
15	metastatic	metastatic	I-NP	JJ	O	18	NMOD
16	renal	renal	I-NP	JJ	O	18	NMOD
17	cell	cell	I-NP	NN	O	18	NMOD
18	cancer	cancer	I-NP	NN	O	13	PMOD
19	and	and	O	CC	O	4	VMOD
20	to	to	B-VP	TO	O	21	VMOD
21	measure	measure	I-VP	VB	O	4	VMOD
22	changes	change	B-NP	NNS	O	21	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	one	one	B-NP	CD	O	31	NMOD
25	angiogenic	angiogenic	I-NP	JJ	B-protein	26	NMOD
26	factor	factor	I-NP	NN	I-protein	24	NMOD
27	,	,	O	,	O	31	P
28	vascular	vascular	B-NP	JJ	B-protein	31	NMOD
29	endothelial	endothelial	I-NP	JJ	I-protein	31	NMOD
30	growth	growth	I-NP	NN	I-protein	31	NMOD
31	factor	factor	I-NP	NN	I-protein	23	PMOD
32	(	(	O	(	O	34	DEP
33	VEGF	VEGF	B-NP	NN	B-protein	34	DEP
34	)	)	O	)	O	31	NMOD
35	165	165	B-NP	CD	O	31	NMOD
36	,	,	O	,	O	31	P
37	with	with	B-PP	IN	O	31	NMOD
38	therapy	therapy	B-NP	NN	O	37	PMOD
39	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	These	These	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	are	be	B-VP	VBP	O	1	NMOD
6	consistent	consistent	B-ADJP	JJ	O	5	PRD
7	with	with	B-PP	IN	O	6	AMOD
8	a	a	B-NP	DT	O	10	NMOD
9	low	low	I-NP	JJ	O	10	NMOD
10	level	level	I-NP	NN	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	activity	activity	B-NP	NN	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	thalidomide	thalidomide	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	10	NMOD
16	renal	renal	B-NP	JJ	O	18	NMOD
17	cell	cell	I-NP	NN	O	18	NMOD
18	carcinoma	carcinoma	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	1	P

1	Haloperidol	Haloperidol	B-NP	NN	O	7	SUB
2	(	(	O	(	O	6	DEP
3	1	1	B-NP	CD	O	5	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	NMOD
5	ip	ip	I-NP	NN	O	6	DEP
6	)	)	O	)	O	1	NMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	parkinsonian-like	parkinsonian-like	B-NP	JJ	O	10	NMOD
9	muscle	muscle	I-NP	NN	O	10	NMOD
10	rigidity	rigidity	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	10	P
12	measured	measure	B-VP	VBN	O	10	NMOD
13	as	as	B-PP	IN	O	12	VMOD
14	an	an	B-NP	DT	O	16	NMOD
15	increased	increase	I-NP	VBN	O	16	NMOD
16	resistance	resistance	I-NP	NN	O	27	NMOD
17	of	of	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	22	NMOD
19	rat	rat	I-NP	NN	O	20	NMOD
20	's	's	B-NP	POS	O	22	NMOD
21	hind	hind	I-NP	NN	O	22	NMOD
22	foot	foot	I-NP	NN	O	17	PMOD
23	to	to	B-PP	TO	O	16	NMOD
24	passive	passive	B-NP	JJ	O	25	NMOD
25	flexion	flexion	I-NP	NN	O	23	PMOD
26	and	and	I-NP	CC	O	27	NMOD
27	extension	extension	I-NP	NN	O	13	PMOD
28	at	at	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	ankle	ankle	I-NP	NN	O	31	NMOD
31	joint	joint	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	7	P

1	AIDA	AIDA	B-NP	NN	O	8	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	doses	dose	B-NP	NNS	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	7.5-15	7.5-15	B-NP	CD	O	7	NMOD
6	microg/0.5	microg/0.5	I-NP	NN	O	7	NMOD
7	microl	microl	I-NP	NN	O	4	PMOD
8	diminished	diminish	B-VP	VBD	O	0	ROOT
9	the	the	B-NP	DT	O	13	NMOD
10	haloperidol	haloperidol	I-NP	NN	O	11	AMOD
11	induced	induce	I-NP	VBN	O	13	NMOD
12	muscle	muscle	I-NP	NN	O	13	NMOD
13	rigidity	rigidity	I-NP	NN	O	8	OBJ
14	.	.	O	.	O	8	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	cholestatic	cholestatic	I-NP	JJ	O	3	NMOD
3	hepatitis	hepatitis	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	exposure	exposure	B-NP	NN	O	4	PMOD
6	to	to	B-PP	TO	O	5	NMOD
7	isoflurane	isoflurane	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	acute	acute	B-NP	JJ	O	10	NMOD
9	cholestatic	cholestatic	I-NP	JJ	O	10	NMOD
10	hepatitis	hepatitis	I-NP	NN	O	7	PMOD
11	following	follow	B-PP	VBG	O	4	VMOD
12	exposure	exposure	B-NP	NN	O	11	PMOD
13	to	to	B-PP	TO	O	12	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	inhalational	inhalational	I-NP	JJ	O	17	NMOD
16	anesthetic	anesthetic	I-NP	JJ	O	17	NMOD
17	isoflurane	isoflurane	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	1	P

1	No	No	B-NP	DT	O	3	NMOD
2	other	other	I-NP	JJ	O	3	NMOD
3	medications	medication	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	involved	involve	I-VP	VBN	O	4	VC
6	except	except	B-PP	IN	O	5	VMOD
7	for	for	B-PP	IN	O	6	PMOD
8	dipyrone	dipyrone	B-NP	NN	O	7	PMOD
9	for	for	B-PP	IN	O	8	NMOD
10	analgesia	analgesia	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	4	P

1	Calcitonin	Calcitonin	B-NP	NN	O	4	NMOD
2	gene-related	gene-related	I-NP	JJ	O	4	NMOD
3	peptide	peptide	I-NP	NN	O	4	NMOD
4	levels	level	I-NP	NNS	O	8	SUB
5	during	during	B-PP	IN	O	4	NMOD
6	nitric	nitric	B-NP	JJ	O	7	NMOD
7	oxide	oxide	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	headache	headache	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	patients	patient	B-NP	NNS	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	chronic	chronic	B-NP	JJ	O	15	NMOD
14	tension-type	tension-type	I-NP	JJ	O	15	NMOD
15	headache	headache	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	8	P

1	It	It	B-NP	PRP	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	proposed	propose	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	nitric	nitric	B-NP	JJ	O	7	NMOD
7	oxide	oxide	I-NP	NN	O	11	SUB
8	(	(	O	(	O	10	DEP
9	NO	NO	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	induced	induce	B-VP	VBD	O	5	SBAR
12	headache	headache	B-NP	NN	O	11	OBJ
13	in	in	B-PP	IN	O	11	VMOD
14	primary	primary	B-NP	JJ	O	15	NMOD
15	headaches	headache	I-NP	NNS	O	13	PMOD
16	may	may	B-VP	MD	O	11	VMOD
17	be	be	I-VP	VB	O	16	VC
18	associated	associate	I-VP	VBN	O	17	VC
19	with	with	B-PP	IN	O	18	VMOD
20	release	release	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	calcitonin	calcitonin	B-NP	NN	O	24	NMOD
23	gene-related	gene-related	I-NP	JJ	O	24	NMOD
24	peptide	peptide	I-NP	NN	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	CGRP	CGRP	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	6	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	we	we	B-NP	PRP	O	6	SUB
6	aimed	aim	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	investigate	investigate	I-VP	VB	O	6	VMOD
9	plasma	plasma	B-NP	NN	O	10	NMOD
10	levels	level	I-NP	NNS	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	CGRP	CGRP	B-NP	NN	B-protein	11	PMOD
13	during	during	B-PP	IN	O	10	NMOD
14	headache	headache	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	the	the	B-NP	DT	O	21	NMOD
18	NO	NO	I-NP	NN	O	21	NMOD
19	donor	donor	I-NP	NN	O	21	NMOD
20	glyceryl	glyceryl	I-NP	NN	O	21	NMOD
21	trinitrate	trinitrate	I-NP	NN	O	16	PMOD
22	(	(	O	(	O	24	DEP
23	GTN	GTN	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	in	in	B-PP	IN	O	15	VMOD
26	16	16	B-NP	CD	O	27	NMOD
27	patients	patient	I-NP	NNS	O	35	NMOD
28	with	with	B-PP	IN	O	27	NMOD
29	chronic	chronic	B-NP	JJ	O	31	NMOD
30	tension-type	tension-type	I-NP	JJ	O	31	NMOD
31	headache	headache	I-NP	NN	O	28	PMOD
32	and	and	O	CC	O	35	NMOD
33	16	16	B-NP	CD	O	35	NMOD
34	healthy	healthy	I-NP	JJ	O	35	NMOD
35	controls	control	I-NP	NNS	O	25	PMOD
36	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	2	NMOD
2	subjects	subject	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	randomly	randomly	I-VP	RB	O	3	VMOD
5	allocated	allocate	I-VP	VBN	O	3	VC
6	to	to	I-VP	TO	O	7	VMOD
7	receive	receive	I-VP	VB	O	5	VMOD
8	0.5	0.5	B-NP	CD	O	10	NMOD
9	microg/kg/min	microg/kg/min	I-NP	NN	O	10	NMOD
10	GTN	GTN	I-NP	NN	O	12	NMOD
11	or	or	I-NP	CC	O	12	NMOD
12	placebo	placebo	I-NP	NN	O	7	OBJ
13	over	over	B-PP	IN	O	7	VMOD
14	20	20	B-NP	CD	O	15	NMOD
15	min	min	I-NP	NN	O	13	PMOD
16	on	on	B-PP	IN	O	7	VMOD
17	two	two	B-NP	CD	O	19	NMOD
18	headache-free	headache-free	I-NP	JJ	O	19	NMOD
19	days	day	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	3	P

1	Both	Both	B-NP	DT	O	4	NMOD
2	patients	patient	I-NP	NNS	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	controls	control	I-NP	NNS	O	5	SUB
5	developed	develop	B-VP	VBD	O	22	VMOD
6	significantly	significantly	B-NP	RB	O	7	AMOD
7	stronger	strong	I-NP	JJR	O	9	NMOD
8	immediate	immediate	I-NP	JJ	O	9	NMOD
9	headache	headache	I-NP	NN	O	22	VMOD
10	on	on	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	GTN	GTN	I-NP	NN	O	13	NMOD
13	day	day	I-NP	NN	O	10	PMOD
14	than	than	B-PP	IN	O	9	NMOD
15	on	on	B-PP	IN	O	14	PMOD
16	the	the	B-NP	DT	O	18	NMOD
17	placebo	placebo	I-NP	NN	O	18	NMOD
18	day	day	I-NP	NN	O	15	PMOD
19	and	and	O	CC	O	21	NMOD
20	the	the	B-NP	DT	O	21	NMOD
21	headache	headache	I-NP	NN	O	22	SUB
22	was	be	B-VP	VBD	O	0	ROOT
23	significantly	significantly	B-ADJP	RB	O	22	PRD
24	more	more	I-ADJP	RBR	O	23	AMOD
25	pronounced	pronounced	I-ADJP	JJ	O	23	AMOD
26	in	in	B-PP	IN	O	22	VMOD
27	patients	patient	B-NP	NNS	O	26	PMOD
28	than	than	B-PP	IN	O	27	NMOD
29	in	in	B-PP	IN	O	28	PMOD
30	controls	control	B-NP	NNS	O	29	PMOD
31	.	.	O	.	O	22	P

1	Myocardial	Myocardial	B-NP	JJ	O	2	NMOD
2	ischemia	ischemia	I-NP	NN	O	0	ROOT
3	due	due	B-PP	JJ	O	2	NMOD
4	to	to	B-PP	TO	O	3	AMOD
5	coronary	coronary	B-NP	JJ	O	7	NMOD
6	artery	artery	I-NP	NN	O	7	NMOD
7	spasm	spasm	I-NP	NN	O	4	PMOD
8	during	during	B-PP	IN	O	7	NMOD
9	dobutamine	dobutamine	B-NP	NN	O	11	NMOD
10	stress	stress	I-NP	NN	O	11	NMOD
11	echocardiography	echocardiography	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	Dobutamine	Dobutamine	B-NP	NN	O	3	NMOD
2	stress	stress	I-NP	NN	O	3	NMOD
3	echocardiography	echocardiography	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	DSE	DSE	B-NP	NN	B-DNA	6	DEP
6	)	)	O	)	O	3	NMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	13	NMOD
9	useful	useful	I-NP	JJ	O	13	NMOD
10	and	and	I-NP	CC	O	13	NMOD
11	safe	safe	I-NP	JJ	O	13	NMOD
12	provocation	provocation	I-NP	NN	O	13	NMOD
13	test	test	I-NP	NN	O	7	PRD
14	for	for	B-PP	IN	O	13	NMOD
15	myocardial	myocardial	B-NP	JJ	O	16	NMOD
16	ischemia	ischemia	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	present	present	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	to	to	B-VP	TO	O	9	VMOD
9	examine	examine	I-VP	VB	O	7	PRD
10	whether	whether	B-SBAR	IN	O	9	VMOD
11	myocardial	myocardial	B-NP	JJ	O	12	NMOD
12	ischemia	ischemia	I-NP	NN	O	17	SUB
13	due	due	B-PP	JJ	O	12	NMOD
14	to	to	B-PP	TO	O	13	PMOD
15	coronary	coronary	B-NP	JJ	O	16	NMOD
16	spasm	spasm	I-NP	NN	O	14	PMOD
17	is	be	B-VP	VBZ	O	10	SBAR
18	induced	induce	I-VP	VBN	O	17	VC
19	by	by	B-PP	IN	O	18	VMOD
20	dobutamine	dobutamine	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	7	P

1	Coronary	Coronary	B-NP	JJ	O	2	NMOD
2	spasm	spasm	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	17	VMOD
4	induced	induce	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	intracoronary	intracoronary	B-NP	JJ	O	7	NMOD
7	injection	injection	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	acetylcholine	acetylcholine	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	17	P
11	and	and	O	CC	O	17	VMOD
12	no	no	B-NP	DT	O	16	NMOD
13	fixed	fix	I-NP	VBN	O	16	NMOD
14	coronary	coronary	I-NP	JJ	O	16	NMOD
15	artery	artery	I-NP	NN	O	16	NMOD
16	stenosis	stenosis	I-NP	NN	O	17	SUB
17	was	be	B-VP	VBD	O	0	ROOT
18	documented	document	I-VP	VBN	O	17	VC
19	on	on	B-PP	IN	O	18	VMOD
20	angiograms	angiogram	B-NP	NNS	O	19	PMOD
21	in	in	B-PP	IN	O	20	NMOD
22	all	all	B-NP	DT	O	23	NMOD
23	patients	patient	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	17	P

1	These	These	B-NP	DT	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	dobutamine	dobutamine	B-NP	NN	O	6	SUB
6	can	can	B-VP	MD	O	4	SBAR
7	provoke	provoke	I-VP	VB	O	6	VC
8	coronary	coronary	B-NP	JJ	O	9	NMOD
9	spasm	spasm	I-NP	NN	O	7	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	some	some	B-NP	DT	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	coronary	coronary	B-NP	JJ	O	16	NMOD
15	spastic	spastic	I-NP	JJ	O	16	NMOD
16	angina	angina	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	Nitric	Nitric	B-NP	JJ	B-protein	3	NMOD
2	oxide	oxide	I-NP	NN	I-protein	3	NMOD
3	synthase	synthase	I-NP	NN	I-protein	4	NMOD
4	expression	expression	I-NP	NN	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	course	course	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	lead	lead	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	hypertension	hypertension	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	3	SUB
2	recently	recently	B-ADVP	RB	O	3	VMOD
3	showed	show	B-VP	VBD	O	0	ROOT
4	elevated	elevated	B-NP	JJ	O	5	AMOD
5	reactive	reactive	I-NP	JJ	O	7	NMOD
6	oxygen	oxygen	I-NP	NN	O	7	NMOD
7	species	specie	I-NP	NNS	O	12	SUB
8	(	(	O	(	O	10	DEP
9	ROS	ROS	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	,	,	O	,	O	12	P
12	reduced	reduce	B-VP	VBD	O	3	VMOD
13	urinary	urinary	B-NP	JJ	O	14	NMOD
14	excretion	excretion	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	NO	NO	B-NP	NN	O	17	NMOD
17	metabolites	metabolite	I-NP	NNS	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	NOx	NOx	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	,	,	O	,	O	3	P
22	and	and	O	CC	O	3	VMOD
23	increased	increase	B-VP	VBD	O	3	VMOD
24	NO	NO	B-NP	NN	O	25	NMOD
25	sequestration	sequestration	I-NP	NN	O	23	OBJ
26	as	as	B-PP	IN	O	23	VMOD
27	nitrotyrosine	nitrotyrosine	B-NP	NN	O	26	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	various	various	B-NP	JJ	O	30	NMOD
30	tissues	tissue	I-NP	NNS	O	28	PMOD
31	in	in	B-PP	IN	O	30	NMOD
32	rats	rat	B-NP	NNS	O	31	PMOD
33	with	with	B-PP	IN	O	32	NMOD
34	lead	lead	B-NP	NN	O	36	NMOD
35	induced	induced	I-NP	JJ	O	36	NMOD
36	hypertension	hypertension	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	3	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	designed	design	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	discern	discern	I-VP	VB	O	4	VMOD
7	whether	whether	B-SBAR	IN	O	6	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	reduction	reduction	I-NP	NN	O	17	SUB
10	in	in	B-PP	IN	O	9	NMOD
11	urinary	urinary	B-NP	JJ	O	12	NMOD
12	NOx	NOx	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	lead	lead	B-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	hypertension	hypertension	I-NP	NN	O	13	PMOD
17	is	be	B-VP	VBZ	O	7	SBAR
18	,	,	O	,	O	17	P
19	in	in	B-PP	IN	O	17	VMOD
20	part	part	B-NP	NN	O	19	PMOD
21	,	,	O	,	O	17	P
22	due	due	B-PP	JJ	O	17	PRD
23	to	to	B-PP	TO	O	22	AMOD
24	depressed	depressed	B-NP	JJ	O	26	NMOD
25	NO	NO	I-NP	NN	O	26	NMOD
26	synthase	synthase	I-NP	NN	O	30	NMOD
27	(	(	O	(	O	29	DEP
28	NOS	NOS	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	expression	expression	B-NP	NN	O	23	PMOD
31	.	.	O	.	O	3	P

1	Vitamin	Vitamin	B-NP	NN	O	3	NMOD
2	E	E	I-NP	NN	O	3	NMOD
3	supplementation	supplementation	I-NP	NN	O	4	SUB
4	ameliorated	ameliorate	B-VP	VBD	O	0	ROOT
5	hypertension	hypertension	B-NP	NN	O	4	OBJ
6	,	,	O	,	O	4	P
7	lowered	lower	B-VP	VBD	O	4	VMOD
8	plasma	plasma	B-NP	NN	O	10	NMOD
9	MDA	MDA	I-NP	NN	O	10	NMOD
10	concentration	concentration	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	4	P
12	and	and	O	CC	O	4	VMOD
13	raised	raise	B-VP	VBD	O	4	VMOD
14	urinary	urinary	B-NP	JJ	O	16	NMOD
15	NOx	NOx	I-NP	NN	O	16	NMOD
16	excretion	excretion	I-NP	NN	O	13	OBJ
17	while	while	B-SBAR	IN	O	13	VMOD
18	significantly	significantly	B-VP	RB	O	19	VMOD
19	lowering	lower	I-VP	VBG	O	17	SBAR
20	vascular	vascular	B-ADJP	JJ	O	19	PRD
21	,	,	O	,	O	19	P
22	but	but	O	CC	O	24	AMOD
23	not	not	B-ADJP	RB	O	24	AMOD
24	renal	renal	I-ADJP	JJ	O	19	VMOD
25	,	,	O	,	O	19	P
26	tissue	tissue	B-NP	NN	O	27	NMOD
27	eNOS	eNOS	I-NP	NN	O	30	NMOD
28	and	and	O	CC	O	30	NMOD
29	iNOS	iNOS	B-NP	NN	B-protein	30	NMOD
30	expression	expression	I-NP	NN	O	19	OBJ
31	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	5	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	lead	lead	B-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	0	ROOT
6	hypertension	hypertension	B-NP	NN	O	10	SUB
7	in	in	B-PP	IN	O	6	NMOD
8	this	this	B-NP	DT	O	9	NMOD
9	model	model	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	5	VMOD
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	compensatory	compensatory	I-NP	JJ	O	15	NMOD
15	upregulation	upregulation	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	renal	renal	B-NP	JJ	O	23	NMOD
18	and	and	I-NP	CC	O	23	NMOD
19	vascular	vascular	I-NP	JJ	O	20	NMOD
20	eNOS	eNOS	I-NP	NN	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	iNOS	iNOS	I-NP	NN	B-protein	23	NMOD
23	expression	expression	I-NP	NN	O	16	PMOD
24	.	.	O	.	O	5	P

1	Risk	Risk	B-NP	NN	O	0	ROOT
2	for	for	B-PP	IN	O	1	NMOD
3	valvular	valvular	B-NP	JJ	O	5	NMOD
4	heart	heart	I-NP	NN	O	5	NMOD
5	disease	disease	I-NP	NN	O	2	PMOD
6	among	among	B-PP	IN	O	1	NMOD
7	users	user	B-NP	NNS	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	fenfluramine	fenfluramine	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	dexfenfluramine	dexfenfluramine	I-NP	NN	O	8	PMOD
12	who	who	B-NP	WP	O	11	NMOD
13	underwent	undergo	B-VP	VBD	O	12	SBAR
14	echocardiography	echocardiography	B-NP	NN	O	13	OBJ
15	before	before	B-PP	IN	O	13	VMOD
16	use	use	B-NP	NN	O	15	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	medication	medication	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	7	SUB
2	:	:	O	:	O	1	P
3	Because	Because	B-SBAR	IN	O	1	NMOD
4	uncontrolled	uncontrolled	B-NP	JJ	O	5	AMOD
5	echocardiographic	echocardiographic	I-NP	JJ	O	6	NMOD
6	surveys	survey	I-NP	NNS	O	3	PMOD
7	suggested	suggest	B-VP	VBD	O	28	VMOD
8	that	that	B-SBAR	IN	O	7	VMOD
9	up	up	B-NP	RB	O	15	NMOD
10	to	to	I-NP	TO	O	9	AMOD
11	30	30	I-NP	CD	O	9	AMOD
12	%	%	I-NP	NN	O	9	NMOD
13	to	to	I-NP	TO	O	9	AMOD
14	38	38	I-NP	CD	O	9	AMOD
15	%	%	I-NP	NN	O	22	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	users	user	B-NP	NNS	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	fenfluramine	fenfluramine	B-NP	NN	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	dexfenfluramine	dexfenfluramine	I-NP	NN	O	18	PMOD
22	had	have	B-VP	VBD	O	8	SBAR
23	valvular	valvular	B-NP	JJ	O	24	NMOD
24	disease	disease	I-NP	NN	O	22	OBJ
25	,	,	O	,	O	7	P
26	these	these	B-NP	DT	O	27	NMOD
27	drugs	drug	I-NP	NNS	O	28	SUB
28	were	be	B-VP	VBD	O	0	ROOT
29	withdrawn	withdraw	I-VP	VBN	O	28	VC
30	from	from	B-PP	IN	O	29	VMOD
31	the	the	B-NP	DT	O	32	NMOD
32	market	market	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	28	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	risk	risk	I-NP	NN	O	4	OBJ
7	for	for	B-PP	IN	O	6	NMOD
8	new	new	B-ADJP	JJ	O	12	NMOD
9	or	or	O	CC	O	12	NMOD
10	worsening	worsen	B-VP	VBG	O	12	NMOD
11	valvular	valvular	B-NP	JJ	O	12	NMOD
12	abnormalities	abnormality	I-NP	NNS	O	7	PMOD
13	among	among	B-PP	IN	O	12	NMOD
14	users	user	B-NP	NNS	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	fenfluramine	fenfluramine	B-NP	NN	O	18	NMOD
17	or	or	I-NP	CC	O	18	NMOD
18	dexfenfluramine	dexfenfluramine	I-NP	NN	O	15	PMOD
19	who	who	B-NP	WP	O	18	NMOD
20	underwent	undergo	B-VP	VBD	O	19	SBAR
21	echocardiography	echocardiography	B-NP	NN	O	20	OBJ
22	before	before	B-SBAR	IN	O	20	VMOD
23	they	they	B-NP	PRP	O	24	SUB
24	began	begin	B-VP	VBD	O	22	SBAR
25	to	to	I-VP	TO	O	26	VMOD
26	take	take	I-VP	VB	O	24	VMOD
27	these	these	B-NP	DT	O	28	NMOD
28	medications	medication	I-NP	NNS	O	26	OBJ
29	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Two	Two	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	1	NMOD
5	(	(	O	(	O	4	NMOD
6	4.3	4.3	B-NP	CD	O	7	NMOD
7	%	%	I-NP	NN	O	5	PMOD
8	[	[	O	(	O	7	NMOD
9	95	95	B-NP	CD	O	11	NMOD
10	%	%	I-NP	NN	O	11	NMOD
11	CI	CI	I-NP	NN	O	22	SUB
12	,	,	O	,	O	22	P
13	0.6	0.6	B-NP	CD	O	14	NMOD
14	%	%	I-NP	NN	O	22	SUB
15	to	to	B-PP	TO	O	14	NMOD
16	14.8	14.8	B-NP	CD	O	17	NMOD
17	%	%	I-NP	NN	O	15	PMOD
18	]	]	O	)	O	14	NMOD
19	)	)	O	)	O	14	NMOD
20	receiving	receive	B-VP	VBG	O	14	NMOD
21	fenfluramine-phentermine	fenfluramine-phentermine	B-NP	NN	O	20	OBJ
22	developed	develop	B-VP	VBD	O	8	SBAR
23	valvular	valvular	B-NP	JJ	O	25	NMOD
24	heart	heart	I-NP	NN	O	25	NMOD
25	disease	disease	I-NP	NN	O	22	OBJ
26	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	18	SUB
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	most	most	I-NP	RBS	O	5	AMOD
5	striking	striking	I-NP	JJ	O	1	NMOD
6	of	of	B-PP	IN	O	5	AMOD
7	carboplatin	carboplatin	B-NP	NN	O	9	NMOD
8	's	's	B-NP	POS	O	9	NMOD
9	advantages	advantage	I-NP	NNS	O	6	PMOD
10	(	(	O	(	O	12	DEP
11	CBDCA	CBDCA	B-NP	NN	B-protein	12	DEP
12	)	)	O	)	O	9	NMOD
13	over	over	B-PP	IN	O	5	NMOD
14	cisplatin	cisplatin	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	17	DEP
16	CDDP	CDDP	B-NP	NN	B-protein	17	DEP
17	)	)	O	)	O	14	NMOD
18	is	be	B-VP	VBZ	O	0	ROOT
19	its	its	B-NP	PRP$	O	22	NMOD
20	markedly	markedly	I-NP	RB	O	21	AMOD
21	reduced	reduce	I-NP	VBN	O	22	NMOD
22	rate	rate	I-NP	NN	O	18	PRD
23	of	of	B-PP	IN	O	22	NMOD
24	neurotoxic	neurotoxic	B-NP	JJ	O	25	NMOD
25	effects	effect	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	18	P

1	However	However	B-ADVP	RB	O	18	VMOD
2	,	,	O	,	O	18	P
3	the	the	B-NP	DT	O	4	NMOD
4	use	use	I-NP	NN	O	11	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	CBDCA	CBDCA	B-NP	NN	B-protein	8	NMOD
7	higher-intensity	higher-intensity	I-NP	NN	O	8	NMOD
8	schedules	schedule	I-NP	NNS	O	5	PMOD
9	and	and	O	CC	O	11	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	association	association	I-NP	NN	O	18	SUB
12	with	with	B-PP	IN	O	11	NMOD
13	other	other	B-NP	JJ	O	15	NMOD
14	neurotoxic	neurotoxic	I-NP	JJ	O	15	NMOD
15	drugs	drug	I-NP	NNS	O	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	polychemotherapy	polychemotherapy	B-NP	NN	O	16	PMOD
18	may	may	B-VP	MD	O	0	ROOT
19	cause	cause	I-VP	VB	O	18	VC
20	some	some	B-NP	DT	O	21	NMOD
21	concern	concern	I-NP	NN	O	19	OBJ
22	about	about	B-PP	IN	O	19	VMOD
23	its	its	B-NP	PRP$	O	24	NMOD
24	safety	safety	I-NP	NN	O	22	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	respect	respect	B-NP	NN	O	25	PMOD
27	to	to	B-PP	TO	O	26	NMOD
28	peripheral	peripheral	B-NP	JJ	O	31	NMOD
29	nervous	nervous	I-NP	JJ	O	31	NMOD
30	system	system	I-NP	NN	O	31	NMOD
31	damage	damage	I-NP	NN	O	27	PMOD
32	.	.	O	.	O	18	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	CBDCA	CBDCA	B-NP	NN	O	4	NMOD
4	administration	administration	I-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	1	NMOD
6	dose-dependent	dose-dependent	B-NP	JJ	O	8	NMOD
7	peripheral	peripheral	I-NP	JJ	O	8	NMOD
8	neurotoxicity	neurotoxicity	I-NP	NN	O	5	OBJ
9	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	CBDCA	CBDCA	B-NP	NN	B-protein	4	SUB
4	is	be	B-VP	VBZ	O	17	VMOD
5	neurotoxic	neurotoxic	B-ADJP	JJ	O	4	PRD
6	in	in	B-PP	IN	O	5	AMOD
7	our	our	B-NP	PRP$	O	8	NMOD
8	model	model	I-NP	NN	O	6	PMOD
9	,	,	O	,	O	17	P
10	and	and	O	CC	O	12	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	type	type	I-NP	NN	O	17	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	pathological	pathological	B-NP	JJ	O	15	NMOD
15	changes	change	I-NP	NNS	O	13	PMOD
16	it	it	B-NP	PRP	O	17	SUB
17	induces	induce	B-VP	VBZ	O	1	NMOD
18	are	be	B-VP	VBP	O	1	NMOD
19	so	so	B-ADJP	RB	O	18	VMOD
20	closely	closely	I-ADJP	RB	O	21	AMOD
21	similar	similar	I-ADJP	JJ	O	18	PRD
22	to	to	B-PP	TO	O	21	AMOD
23	those	those	B-NP	DT	O	22	PMOD
24	caused	cause	B-VP	VBN	O	23	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	CDDP	CDDP	B-NP	NN	B-protein	25	PMOD
27	that	that	B-SBAR	IN	O	24	VMOD
28	it	it	B-NP	PRP	O	29	SUB
29	is	be	B-VP	VBZ	O	27	SBAR
30	probable	probable	B-ADJP	JJ	O	29	PRD
31	that	that	B-SBAR	IN	O	29	VMOD
32	neurotoxicity	neurotoxicity	B-NP	NN	O	33	SUB
33	is	be	B-VP	VBZ	O	31	SBAR
34	induced	induce	I-VP	VBN	O	33	VC
35	in	in	B-PP	IN	O	34	VMOD
36	the	the	B-NP	DT	O	38	NMOD
37	two	two	I-NP	CD	O	38	NMOD
38	drugs	drug	I-NP	NNS	O	35	PMOD
39	by	by	B-PP	IN	O	34	VMOD
40	the	the	B-NP	DT	O	42	NMOD
41	same	same	I-NP	JJ	O	42	NMOD
42	mechanism	mechanism	I-NP	NN	O	39	PMOD
43	.	.	O	.	O	1	P

1	Since	Since	B-SBAR	IN	O	25	VMOD
2	tamoxifen	tamoxifen	B-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	1	SBAR
4	widely	widely	I-VP	RB	O	3	VMOD
5	used	use	I-VP	VBN	O	3	VC
6	in	in	B-PP	IN	O	5	VMOD
7	breast	breast	B-NP	NN	O	9	NMOD
8	cancer	cancer	I-NP	NN	O	9	NMOD
9	treatment	treatment	I-NP	NN	O	6	PMOD
10	and	and	O	CC	O	3	VMOD
11	has	have	B-VP	VBZ	O	3	VMOD
12	been	be	I-VP	VBN	O	11	VC
13	proposed	propose	I-VP	VBN	O	12	VC
14	for	for	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	prevention	prevention	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	breast	breast	B-NP	NN	O	19	NMOD
19	cancer	cancer	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	25	P
21	its	its	B-NP	PRP$	O	24	NMOD
22	endometrial	endometrial	I-NP	JJ	O	23	AMOD
23	iatrogenic	iatrogenic	I-NP	JJ	O	24	NMOD
24	effects	effect	I-NP	NNS	O	25	SUB
25	must	must	B-VP	MD	O	0	ROOT
26	be	be	I-VP	VB	O	25	VC
27	carefully	carefully	I-VP	RB	O	26	VMOD
28	examined	examine	I-VP	VBN	O	26	VC
29	.	.	O	.	O	25	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	investigated	investigate	I-VP	VBN	O	2	VC
4	the	the	B-NP	DT	O	5	NMOD
5	association	association	I-NP	NN	O	3	OBJ
6	between	between	B-PP	IN	O	5	NMOD
7	endometrial	endometrial	B-NP	JJ	O	8	NMOD
8	cancer	cancer	I-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	tamoxifen	tamoxifen	I-NP	NN	O	11	NMOD
11	use	use	I-NP	NN	O	14	NMOD
12	or	or	O	CC	O	14	NMOD
13	other	other	B-NP	JJ	O	14	NMOD
14	treatments	treatment	I-NP	NNS	O	6	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	women	woman	B-NP	NNS	O	15	PMOD
17	treated	treat	B-VP	VBN	O	16	NMOD
18	for	for	B-PP	IN	O	17	VMOD
19	breast	breast	B-NP	NN	O	20	NMOD
20	cancer	cancer	I-NP	NN	O	18	PMOD
21	in	in	B-PP	IN	O	17	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	case-control	case-control	I-NP	JJ	O	24	NMOD
24	study	study	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	2	P

1	Women	Woman	B-NP	NNS	O	6	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	had	have	B-VP	VBD	O	2	SBAR
4	received	receive	I-VP	VBN	O	3	VC
5	tamoxifen	tamoxifen	B-NP	NN	O	4	OBJ
6	were	be	B-VP	VBD	O	0	ROOT
7	significantly	significantly	B-ADJP	RB	O	6	PRD
8	more	more	I-ADJP	RBR	O	7	AMOD
9	likely	likely	I-ADJP	JJ	O	7	AMOD
10	to	to	B-VP	TO	O	11	VMOD
11	have	have	I-VP	VB	O	6	VMOD
12	endometrial	endometrial	B-NP	JJ	O	13	NMOD
13	cancer	cancer	I-NP	NN	O	11	OBJ
14	diagnosed	diagnose	B-VP	VBN	O	13	NMOD
15	than	than	B-PP	IN	O	14	VMOD
16	those	those	B-NP	DT	O	15	PMOD
17	who	who	B-NP	WP	O	30	DEP
18	had	have	B-VP	VBD	O	17	SBAR
19	not	not	O	RB	O	18	VMOD
20	(	(	O	(	O	30	DEP
21	crude	crude	B-NP	JJ	O	23	NMOD
22	relative	relative	I-NP	JJ	O	23	NMOD
23	risk	risk	I-NP	NN	O	27	NMOD
24	=	=	B-VP	SYM	O	23	NMOD
25	4.9	4.9	B-NP	CD	O	24	AMOD
26	,	,	O	,	O	27	P
27	p	p	B-NP	NN	O	29	SUB
28	=	=	B-VP	SYM	O	29	VMOD
29	0.0001	0.0001	B-NP	CD	O	30	DEP
30	)	)	O	)	O	16	NMOD
31	.	.	O	.	O	6	P

1	Women	Woman	B-NP	NNS	O	7	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	had	have	B-VP	VBD	O	2	SBAR
4	endometrial	endometrial	B-NP	JJ	O	5	NMOD
5	cancer	cancer	I-NP	NN	O	3	OBJ
6	and	and	O	CC	O	7	VMOD
7	had	have	B-VP	VBD	O	0	ROOT
8	received	receive	I-VP	VBN	O	7	VC
9	tamoxifen	tamoxifen	B-NP	NN	O	8	OBJ
10	had	have	B-VP	VBD	O	7	VMOD
11	more	more	B-NP	RBR	O	12	AMOD
12	advanced	advanced	I-NP	JJ	O	13	NMOD
13	disease	disease	I-NP	NN	O	10	OBJ
14	and	and	O	CC	O	10	VMOD
15	poorer	poor	B-NP	JJR	O	16	NMOD
16	prognosis	prognosis	I-NP	NN	O	14	OBJ
17	than	than	B-PP	IN	O	16	NMOD
18	those	those	B-NP	DT	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	endometrial	endometrial	B-NP	JJ	O	21	NMOD
21	cancer	cancer	I-NP	NN	O	19	PMOD
22	who	who	B-NP	WP	O	21	NMOD
23	had	have	B-VP	VBD	O	22	SBAR
24	not	not	I-VP	RB	O	23	VMOD
25	received	receive	I-VP	VBN	O	23	VC
26	this	this	B-NP	DT	O	27	NMOD
27	treatment	treatment	I-NP	NN	O	25	OBJ
28	.	.	O	.	O	7	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	causal	causal	I-NP	JJ	O	6	NMOD
6	role	role	I-NP	NN	O	3	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	tamoxifen	tamoxifen	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	endometrial	endometrial	B-NP	JJ	O	11	NMOD
11	cancer	cancer	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	3	P
13	particularly	particularly	B-ADVP	RB	O	14	AMOD
14	when	when	B-ADVP	WRB	O	3	VMOD
15	used	use	B-VP	VBN	O	14	SBAR
16	as	as	B-PP	IN	O	15	VMOD
17	currently	currently	B-ADVP	RB	O	18	VMOD
18	proposed	propose	B-VP	VBN	O	16	SBAR
19	for	for	B-PP	IN	O	18	VMOD
20	breast	breast	B-NP	NN	O	22	NMOD
21	cancer	cancer	I-NP	NN	O	22	NMOD
22	prevention	prevention	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	3	P

1	Endometrial	Endometrial	B-NP	JJ	O	2	NMOD
2	cancers	cancer	I-NP	NNS	O	9	SUB
3	diagnosed	diagnose	B-VP	VBN	O	2	NMOD
4	in	in	B-PP	IN	O	3	VMOD
5	women	woman	B-NP	NNS	O	4	PMOD
6	treated	treat	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	tamoxifen	tamoxifen	B-NP	NN	O	7	PMOD
9	have	have	B-VP	VBP	O	0	ROOT
10	poorer	poor	B-NP	JJR	O	11	NMOD
11	prognosis	prognosis	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	Women	Woman	B-NP	NNS	O	8	SUB
2	who	who	B-NP	WP	O	1	NMOD
3	receive	receive	B-VP	VBP	O	2	SBAR
4	tamoxifen	tamoxifen	B-NP	NN	O	3	OBJ
5	for	for	B-PP	IN	O	4	NMOD
6	breast	breast	B-NP	NN	O	7	NMOD
7	cancer	cancer	I-NP	NN	O	5	PMOD
8	should	should	B-VP	MD	O	0	ROOT
9	be	be	I-VP	VB	O	8	VC
10	offered	offer	I-VP	VBN	O	12	NMOD
11	gynaecological	gynaecological	B-NP	JJ	O	12	NMOD
12	surveillance	surveillance	I-NP	NN	O	9	PRD
13	during	during	B-PP	IN	O	9	VMOD
14	and	and	I-PP	CC	O	13	PMOD
15	after	after	I-PP	IN	O	13	PMOD
16	treatment	treatment	B-NP	NN	O	13	PMOD
17	.	.	O	.	O	8	P

1	Granulosa	Granulosa	B-NP	NN	O	3	NMOD
2	cell	cell	I-NP	NN	O	3	NMOD
3	tumor	tumor	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	ovary	ovary	I-NP	NN	O	4	PMOD
7	associated	associate	B-VP	VBN	O	3	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	antecedent	antecedent	B-NP	JJ	O	11	NMOD
10	tamoxifen	tamoxifen	I-NP	NN	O	11	NMOD
11	use	use	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	3	P

1	Review	Review	B-NP	NN	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	literature	literature	I-NP	NN	O	2	PMOD
5	reveals	reveal	B-VP	VBZ	O	0	ROOT
6	an	an	B-NP	DT	O	7	NMOD
7	association	association	I-NP	NN	O	5	OBJ
8	between	between	B-PP	IN	O	7	NMOD
9	tamoxifen	tamoxifen	B-NP	NN	O	10	NMOD
10	use	use	I-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	gynecologic	gynecologic	B-NP	JJ	O	13	NMOD
13	tumors	tumor	I-NP	NNS	O	8	PMOD
14	.	.	O	.	O	5	P

1	CASE	CASE	B-NP	NN	B-protein	6	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	6	NMOD
4	52-year-old	52-year-old	I-NP	JJ	O	6	NMOD
5	postmenopausal	postmenopausal	I-NP	JJ	O	6	NMOD
6	woman	woman	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	treated	treat	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	tamoxifen	tamoxifen	B-NP	NN	O	9	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	stage	stage	B-NP	NN	O	17	NMOD
13	II	II	I-NP	CD	O	17	NMOD
14	estrogen	estrogen	I-NP	NN	O	17	NMOD
15	receptor-positive	receptor-positive	I-NP	JJ	O	17	NMOD
16	breast	breast	I-NP	NN	O	17	NMOD
17	carcinoma	carcinoma	I-NP	NN	O	11	PMOD
18	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	3	NMOD
2	murine	murine	I-NP	JJ	O	3	NMOD
3	model	model	I-NP	NN	O	8	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	adenomyosis	adenomyosis	B-NP	NN	O	4	PMOD
6	:	:	O	:	O	3	P
7	the	the	B-NP	DT	O	8	NMOD
8	effects	effect	I-NP	NNS	O	0	ROOT
9	of	of	B-PP	IN	O	8	NMOD
10	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	fluoxetine	fluoxetine	B-NP	NN	O	14	NMOD
14	hydrochloride	hydrochloride	I-NP	NN	O	20	NMOD
15	,	,	O	,	O	20	P
16	a	a	B-NP	DT	O	20	NMOD
17	selective	selective	I-NP	JJ	O	20	NMOD
18	serotonin	serotonin	I-NP	NN	O	20	NMOD
19	reuptake	reuptake	I-NP	NN	O	20	NMOD
20	inhibitor	inhibitor	I-NP	NN	O	12	PMOD
21	,	,	O	,	O	8	P
22	on	on	B-PP	IN	O	8	NMOD
23	adenomyosis	adenomyosis	B-NP	NN	O	24	NMOD
24	induction	induction	I-NP	NN	O	22	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	Wistar	Wistar	B-NP	NNP	O	28	NMOD
27	albino	albino	I-NP	NNP	O	28	NMOD
28	rats	rat	I-NP	NNS	O	25	PMOD
29	.	.	O	.	O	8	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	aim	aim	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	investigate	investigate	I-VP	VB	O	8	PRD
11	whether	whether	B-SBAR	IN	O	10	VMOD
12	fluoxetine	fluoxetine	B-NP	NN	O	19	SUB
13	given	give	B-VP	VBN	O	12	NMOD
14	to	to	B-PP	TO	O	13	VMOD
15	castrated	castrate	B-NP	VBN	O	18	NMOD
16	and	and	I-NP	CC	O	18	NMOD
17	noncastrated	noncastrated	I-NP	JJ	O	18	NMOD
18	rats	rat	I-NP	NNS	O	14	PMOD
19	caused	cause	B-VP	VBD	O	11	SBAR
20	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	its	its	B-NP	PRP$	O	23	NMOD
23	effects	effect	I-NP	NNS	O	19	OBJ
24	with	with	B-PP	IN	O	19	VMOD
25	respect	respect	B-NP	NN	O	24	PMOD
26	to	to	B-PP	TO	O	25	NMOD
27	adenomyosis	adenomyosis	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	8	P

1	DESIGN	DESIGN	B-NP	NN	O	8	NMOD
2	:	:	O	:	O	1	P
3	Fluoxetine	Fluoxetine	B-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	a	a	B-NP	DT	O	8	NMOD
6	serotonin	serotonin	I-NP	NN	O	8	NMOD
7	reuptake	reuptake	I-NP	NN	O	8	NMOD
8	inhibitor	inhibitor	I-NP	NN	O	10	SUB
9	,	,	O	,	O	8	P
10	was	be	B-VP	VBD	O	0	ROOT
11	given	give	I-VP	VBN	O	10	VC
12	to	to	B-PP	TO	O	11	VMOD
13	Wistar	Wistar	B-NP	NNP	O	15	NMOD
14	Albino	Albino	I-NP	NNP	O	15	NMOD
15	rats	rat	I-NP	NNS	O	12	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	98	98	B-NP	CD	O	18	NMOD
18	days	day	I-NP	NNS	O	16	PMOD
19	to	to	B-VP	TO	O	20	VMOD
20	produce	produce	I-VP	VB	O	11	VMOD
21	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	20	OBJ
22	.	.	O	.	O	10	P

1	Histological	Histological	B-NP	JJ	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	revealed	reveal	B-VP	VBD	O	0	ROOT
4	11	11	B-NP	CD	O	5	NMOD
5	cases	case	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	adenomyosis	adenomyosis	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	3	P
9	all	all	B-NP	DT	O	3	VMOD
10	within	within	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	noncastrated	noncastrated	I-NP	JJ	O	13	NMOD
13	group	group	I-NP	NN	O	10	PMOD
14	receiving	receive	B-VP	VBG	O	13	NMOD
15	fluoxetine	fluoxetine	B-NP	NN	O	14	OBJ
16	.	.	O	.	O	3	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	deliberate	deliberate	B-NP	JJ	O	4	NMOD
4	hypotension	hypotension	I-NP	NN	O	2	PMOD
5	induced	induce	B-VP	VBN	O	4	NMOD
6	by	by	B-PP	IN	O	5	VMOD
7	labetalol	labetalol	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	5	VMOD
9	isoflurane	isoflurane	B-NP	NN	O	8	PMOD
10	on	on	B-PP	IN	O	5	VMOD
11	neuropsychological	neuropsychological	B-NP	JJ	O	12	NMOD
12	function	function	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	1	P

1	Twenty-four	Twenty-four	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	anaesthetized	anaesthetize	I-VP	VBN	O	3	VC
5	for	for	B-PP	IN	O	4	VMOD
6	middle-ear	middle-ear	B-NP	JJ	O	7	NMOD
7	surgery	surgery	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	deliberate	deliberate	B-NP	JJ	O	10	NMOD
10	hypotension	hypotension	I-NP	NN	O	8	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	labetalol	labetalol	B-NP	NN	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	isoflurane	isoflurane	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	19	DEP
17	hypotensive	hypotensive	B-NP	JJ	O	18	NMOD
18	group	group	I-NP	NN	O	19	DEP
19	)	)	O	)	O	15	NMOD
20	.	.	O	.	O	3	P

1	Somewhat	Somewhat	B-NP	RB	O	6	NMOD
2	fewer	few	I-NP	JJR	O	6	NMOD
3	cardiovascular	cardiovascular	I-NP	JJ	O	6	NMOD
4	and	and	I-NP	CC	O	6	NMOD
5	local	local	I-NP	JJ	O	6	NMOD
6	sequelae	sequela	I-NP	NNS	O	7	SUB
7	were	be	B-VP	VBD	O	0	ROOT
8	found	find	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	midazolam	midazolam	I-NP	NN	O	12	NMOD
12	group	group	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	16	P
14	but	but	O	CC	O	16	DEP
15	,	,	O	,	O	16	P
16	although	although	B-SBAR	IN	O	7	VMOD
17	apnoea	apnoea	B-NP	NN	O	18	SUB
18	occurred	occur	B-VP	VBD	O	16	SBAR
19	less	less	B-ADVP	RBR	O	20	AMOD
20	often	often	I-ADVP	RB	O	18	OBJ
21	in	in	B-PP	IN	O	20	AMOD
22	the	the	B-NP	DT	O	24	NMOD
23	midazolam	midazolam	I-NP	NN	O	24	NMOD
24	group	group	I-NP	NN	O	21	PMOD
25	it	it	B-NP	PRP	O	26	SUB
26	lasted	last	B-VP	VBD	O	16	DEP
27	longer	longer	B-ADVP	RBR	O	26	VMOD
28	.	.	O	.	O	16	P

1	Cardiotoxic	Cardiotoxic	B-NP	JJ	O	4	AMOD
2	and	and	I-NP	CC	O	4	AMOD
3	possible	possible	I-NP	JJ	O	4	AMOD
4	leukemogenic	leukemogenic	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	16	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	adriamycin	adriamycin	B-NP	NN	O	6	PMOD
8	in	in	B-PP	IN	O	5	NMOD
9	nonhuman	nonhuman	B-NP	JJ	O	10	NMOD
10	primates.	primates.	I-NP	NN	O	12	NMOD
11	10	10	B-NP	CD	O	10	NMOD
12	monkeys	monkey	I-NP	NNS	O	8	PMOD
13	(	(	O	(	O	15	DEP
14	macaques	macaque	B-NP	NNS	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	received	receive	B-VP	VBD	O	0	ROOT
17	adriamycin	adriamycin	B-NP	NN	O	16	OBJ
18	by	by	B-PP	IN	O	16	VMOD
19	monthly	monthly	B-NP	JJ	O	21	NMOD
20	intravenous	intravenous	I-NP	JJ	O	21	NMOD
21	injections	injection	I-NP	NNS	O	18	PMOD
22	at	at	B-PP	IN	O	16	VMOD
23	12	12	B-NP	CD	O	24	NMOD
24	mg/m2	mg/m2	I-NP	NN	O	22	PMOD
25	(	(	O	(	O	28	DEP
26	1	1	B-NP	CD	O	27	NMOD
27	mg/kg	mg/kg	I-NP	NN	O	28	DEP
28	)	)	O	)	O	24	NMOD
29	.	.	O	.	O	22	P
30	8	8	B-NP	CD	O	35	SUB
31	of	of	B-PP	IN	O	30	NMOD
32	the	the	B-NP	DT	O	34	NMOD
33	10	10	I-NP	CD	O	34	NMOD
34	monkeys	monkey	I-NP	NNS	O	31	PMOD
35	developed	develop	B-VP	VBD	O	22	SBAR
36	congestive	congestive	B-NP	JJ	O	38	NMOD
37	heart	heart	I-NP	NN	O	38	NMOD
38	failure	failure	I-NP	NN	O	35	OBJ
39	at	at	B-PP	IN	O	35	VMOD
40	an	an	B-NP	DT	O	44	NMOD
41	average	average	I-NP	JJ	O	44	NMOD
42	cumulative	cumulative	I-NP	JJ	O	44	NMOD
43	adriamycin	adriamycin	I-NP	NN	O	44	NMOD
44	dose	dose	I-NP	NN	O	39	PMOD
45	(	(	O	(	O	48	DEP
46	310	310	B-NP	CD	O	47	NMOD
47	mg/m2	mg/m2	I-NP	NN	O	48	DEP
48	)	)	O	)	O	44	NMOD
49	well	well	B-PP	RB	O	39	PMOD
50	below	below	I-PP	IN	O	39	PMOD
51	that	that	B-NP	DT	O	56	NMOD
52	considered	consider	B-VP	VBN	O	56	NMOD
53	the	the	B-NP	DT	O	56	NMOD
54	safe	safe	I-NP	JJ	O	56	NMOD
55	upper	upper	I-NP	JJ	O	56	NMOD
56	limit	limit	I-NP	NN	O	50	PMOD
57	(	(	O	(	O	60	DEP
58	550	550	B-NP	CD	O	59	NMOD
59	mg/m2	mg/m2	I-NP	NN	O	60	DEP
60	)	)	O	)	O	56	NMOD
61	in	in	B-PP	IN	O	35	VMOD
62	man	man	B-NP	NN	O	61	PMOD
63	.	.	O	.	O	16	P

1	Histologically	Histologically	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	the	the	B-NP	DT	O	5	NMOD
4	myocardial	myocardial	I-NP	JJ	O	5	NMOD
5	lesions	lesion	I-NP	NNS	O	6	SUB
6	resembled	resemble	B-VP	VBD	O	33	VMOD
7	those	those	B-NP	DT	O	6	OBJ
8	found	find	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	human	human	B-NP	JJ	O	11	NMOD
11	anthracycline	anthracycline	I-NP	NN	O	9	PMOD
12	induced	induce	B-VP	VBD	O	6	VMOD
13	cardiomyopathy.	cardiomyopathy.	B-NP	NN	B-protein	12	OBJ
14	1	1	I-NP	CD	I-protein	13	NMOD
15	of	of	B-PP	IN	O	13	NMOD
16	the	the	B-NP	DT	O	18	NMOD
17	10	10	I-NP	CD	O	18	NMOD
18	monkeys	monkey	I-NP	NNS	O	15	PMOD
19	developed	develop	B-VP	VBD	O	6	VMOD
20	acute	acute	B-NP	JJ	O	22	NMOD
21	myeloblastic	myeloblastic	I-NP	JJ	O	22	NMOD
22	leukemia	leukemia	I-NP	NN	O	19	OBJ
23	after	after	B-PP	IN	O	19	VMOD
24	receiving	receive	B-VP	VBG	O	23	PMOD
25	324	324	B-NP	CD	O	26	NMOD
26	mg/m2	mg/m2	I-NP	NN	O	24	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	adriamycin	adriamycin	B-NP	NN	O	27	PMOD
29	;	;	O	:	O	33	P
30	the	the	B-NP	DT	O	32	NMOD
31	10th	10th	I-NP	JJ	O	32	NMOD
32	monkey	monkey	I-NP	NN	O	33	SUB
33	is	be	B-VP	VBZ	O	0	ROOT
34	alive	alive	B-ADJP	JJ	O	38	NMOD
35	and	and	O	CC	O	38	NMOD
36	well	well	B-NP	RB	O	38	NMOD
37	26	26	I-NP	CD	O	38	NMOD
38	months	month	I-NP	NNS	O	33	PRD
39	after	after	B-PP	IN	O	38	NMOD
40	the	the	B-NP	DT	O	42	NMOD
41	last	last	I-NP	JJ	O	42	NMOD
42	dose	dose	I-NP	NN	O	39	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	drug	drug	B-NP	NN	O	43	PMOD
45	.	.	O	.	O	33	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	NMOD
2	cardiomyopathy	cardiomyopathy	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	children	child	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	left-sided	left-sided	B-NP	JJ	O	8	NMOD
7	Wilms	Wilms	I-NP	NNP	O	8	NMOD
8	tumor	tumor	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	children	child	I-NP	NNS	O	10	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	Wilms	Wilms	B-NP	NNP	O	5	NMOD
5	tumor	tumor	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	left	left	I-NP	JJ	O	9	NMOD
9	kidney	kidney	I-NP	NN	O	6	PMOD
10	experienced	experience	B-VP	VBD	O	0	ROOT
11	severe	severe	B-NP	JJ	O	13	NMOD
12	anthracycline	anthracycline	I-NP	NN	O	13	NMOD
13	cardiomyopathy	cardiomyopathy	I-NP	NN	O	10	OBJ
14	after	after	B-PP	IN	O	10	VMOD
15	irradiation	irradiation	B-NP	NN	O	14	PMOD
16	to	to	B-PP	TO	O	10	VMOD
17	the	the	B-NP	DT	O	22	NMOD
18	tumor	tumor	I-NP	NN	O	19	NMOD
19	bed	bed	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	conventional	conventional	B-NP	JJ	O	22	NMOD
22	dosage	dosage	I-NP	NN	O	16	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	doxorubicin	doxorubicin	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	cardiomyopathy	cardiomyopathy	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	attributed	attribute	I-VP	VBN	O	5	NMOD
5	1	1	B-NP	CD	O	3	PRD
6	)	)	O	)	O	3	VMOD
7	to	to	B-PP	TO	O	3	VMOD
8	the	the	B-NP	DT	O	9	NMOD
9	fact	fact	I-NP	NN	O	7	PMOD
10	that	that	B-SBAR	IN	O	9	NMOD
11	radiation	radiation	B-NP	NN	O	12	NMOD
12	fields	field	I-NP	NNS	O	17	SUB
13	for	for	B-PP	IN	O	12	NMOD
14	left	left	B-NP	JJ	O	16	NMOD
15	Wilms	Wilms	I-NP	NNP	O	16	NMOD
16	tumor	tumor	I-NP	NN	O	13	PMOD
17	include	include	B-VP	VBP	O	10	SBAR
18	the	the	B-NP	DT	O	20	NMOD
19	lower	low	I-NP	JJR	O	20	NMOD
20	portion	portion	I-NP	NN	O	17	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	23	NMOD
23	heart	heart	I-NP	NN	O	21	PMOD
24	and	and	O	CC	O	20	NMOD
25	2	2	B-LST	LS	O	24	DEP
26	)	)	O	)	O	25	DEP
27	to	to	B-PP	TO	O	25	VMOD
28	the	the	B-NP	DT	O	29	NMOD
29	interaction	interaction	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	doxorubicin	doxorubicin	B-NP	NN	O	33	NMOD
32	and	and	I-NP	CC	O	33	NMOD
33	irradiation	irradiation	I-NP	NN	O	30	PMOD
34	on	on	B-PP	IN	O	29	NMOD
35	cardiac	cardiac	B-NP	JJ	O	36	NMOD
36	muscle	muscle	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	3	P

1	Promotional	Promotional	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	testosterone	testosterone	B-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	dietary	dietary	B-NP	JJ	O	7	NMOD
7	fat	fat	I-NP	NN	O	3	PMOD
8	on	on	B-PP	IN	O	2	NMOD
9	prostate	prostate	B-NP	NN	O	10	NMOD
10	carcinogenesis	carcinogenesis	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	genetically	genetically	B-NP	RB	O	13	AMOD
13	susceptible	susceptible	I-NP	JJ	O	14	NMOD
14	rats	rat	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	2	P

1	Conventional	Conventional	B-NP	JJ	O	3	NMOD
2	LW	LW	I-NP	NN	O	3	NMOD
3	rats	rat	I-NP	NNS	O	13	SUB
4	,	,	O	,	O	3	P
5	implanted	implant	B-VP	VBN	O	3	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	testosterone	testosterone	B-NP	NN	O	6	PMOD
8	at	at	B-PP	IN	O	5	VMOD
9	age	age	B-NP	NN	O	11	NMOD
10	4	4	I-NP	CD	O	11	NMOD
11	months	month	I-NP	NNS	O	8	PMOD
12	,	,	O	,	O	3	P
13	developed	develop	B-VP	VBD	O	30	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	higher	high	I-NP	JJR	O	16	NMOD
16	incidence	incidence	I-NP	NN	O	13	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	prostate	prostate	B-NP	NN	O	19	NMOD
19	cancer	cancer	I-NP	NN	O	17	PMOD
20	after	after	B-PP	IN	O	16	NMOD
21	an	an	B-NP	DT	O	23	NMOD
22	average	average	I-NP	JJ	O	23	NMOD
23	interval	interval	I-NP	NN	O	20	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	14	14	B-NP	CD	O	26	NMOD
26	months	month	I-NP	NNS	O	24	PMOD
27	:	:	O	:	O	13	P
28	24	24	B-NP	CD	O	29	NMOD
29	%	%	I-NP	NN	O	30	SUB
30	had	have	B-VP	VBD	O	0	ROOT
31	developed	develop	I-VP	VBN	O	30	VC
32	gross	gross	B-NP	JJ	O	33	NMOD
33	tumors	tumor	I-NP	NNS	O	37	NMOD
34	,	,	O	,	O	37	P
35	and	and	O	CC	O	37	NMOD
36	40	40	B-NP	CD	O	37	NMOD
37	%	%	I-NP	NN	O	31	OBJ
38	when	when	B-ADVP	WRB	O	30	VMOD
39	it	it	B-NP	PRP	O	40	SUB
40	included	include	B-VP	VBD	O	38	SBAR
41	microscopic	microscopic	B-NP	JJ	O	42	NMOD
42	tumors	tumor	I-NP	NNS	O	40	OBJ
43	.	.	O	.	O	30	P

1	Preliminary	Preliminary	B-NP	JJ	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	indicate	indicate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	testosterone-treated	testosterone-treated	B-NP	JJ	O	7	NMOD
6	LW	LW	I-NP	NN	O	7	NMOD
7	rats	rat	I-NP	NNS	O	27	SUB
8	that	that	B-NP	WDT	O	7	NMOD
9	were	be	B-VP	VBD	O	8	SBAR
10	fed	feed	I-VP	VBN	O	9	VC
11	the	the	B-NP	DT	O	13	NMOD
12	same	same	I-NP	JJ	O	13	NMOD
13	diet	diet	I-NP	NN	O	10	OBJ
14	,	,	O	,	O	13	P
15	which	which	B-NP	WDT	O	13	NMOD
16	was	be	B-VP	VBD	O	15	SBAR
17	supplemented	supplement	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	corn	corn	B-NP	NN	O	20	NMOD
20	oil	oil	I-NP	NN	O	25	NMOD
21	up	up	B-NP	IN	O	25	NMOD
22	to	to	I-NP	TO	O	21	AMOD
23	20	20	I-NP	CD	O	21	AMOD
24	%	%	I-NP	NN	O	25	NMOD
25	fat	fat	I-NP	NN	O	18	PMOD
26	,	,	O	,	O	10	P
27	developed	develop	B-VP	VBD	O	4	SBAR
28	prostate	prostate	B-NP	NN	O	29	NMOD
29	cancer	cancer	I-NP	NN	O	27	OBJ
30	after	after	B-PP	IN	O	29	NMOD
31	intervals	interval	B-NP	NNS	O	30	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	6-12	6-12	B-NP	CD	O	34	NMOD
34	months	month	I-NP	NNS	O	32	PMOD
35	.	.	O	.	O	3	P

1	Conventional	Conventional	B-NP	JJ	O	3	NMOD
2	SD	SD	I-NP	NN	O	3	NMOD
3	rats	rat	I-NP	NNS	O	11	SUB
4	fed	feed	B-VP	VBN	O	6	NMOD
5	diet	diet	B-NP	NN	O	6	NMOD
6	L-485	L-485	I-NP	NN	O	3	NMOD
7	and	and	O	CC	O	6	NMOD
8	treated	treat	B-VP	VBN	O	7	SBAR
9	with	with	B-PP	IN	O	8	VMOD
10	testosterone	testosterone	B-NP	NN	O	9	PMOD
11	developed	develop	B-VP	VBD	O	0	ROOT
12	only	only	B-NP	RB	O	13	NMOD
13	prostatitis	prostatitis	I-NP	NN	O	11	OBJ
14	.	.	O	.	O	11	P

1	Mitomycin	Mitomycin	B-NP	NN	O	2	NMOD
2	C	C	I-NP	NN	O	6	NMOD
3	associated	associate	B-VP	VBN	O	6	NMOD
4	hemolytic	hemolytic	B-NP	JJ	O	6	NMOD
5	uremic	uremic	I-NP	JJ	O	6	NMOD
6	syndrome	syndrome	I-NP	NN	O	0	ROOT
7	.	.	O	.	O	6	P

1	Mitomycin	Mitomycin	B-NP	NN	O	2	NMOD
2	C	C	I-NP	NN	O	10	SUB
3	associated	associate	B-VP	VBN	O	2	NMOD
4	Hemolytic	Hemolytic	B-NP	JJ	O	6	NMOD
5	Uremic	Uremic	I-NP	JJ	O	6	NMOD
6	Syndrome	Syndrome	I-NP	NN	O	3	VMOD
7	(	(	O	(	O	9	DEP
8	HUS	HUS	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	a	a	B-NP	DT	O	16	NMOD
12	potentially	potentially	I-NP	RB	O	13	AMOD
13	fatal	fatal	I-NP	JJ	O	15	AMOD
14	but	but	I-NP	CC	O	15	AMOD
15	uncommon	uncommon	I-NP	JJ	O	16	NMOD
16	condition	condition	I-NP	NN	O	10	PRD
17	that	that	B-NP	WDT	O	16	NMOD
18	is	be	B-VP	VBZ	O	17	SBAR
19	not	not	I-VP	RB	O	18	VMOD
20	yet	yet	I-VP	RB	O	18	VMOD
21	widely	widely	I-VP	RB	O	22	VMOD
22	recognised	recognise	I-VP	VBN	O	18	VC
23	.	.	O	.	O	10	P

1	It	It	B-NP	PRP	O	2	SUB
2	consists	consist	B-VP	VBZ	O	0	ROOT
3	of	of	B-PP	IN	O	2	VMOD
4	microangiopathic	microangiopathic	B-NP	JJ	O	6	NMOD
5	hemolytic	hemolytic	I-NP	JJ	O	6	NMOD
6	anemia	anemia	I-NP	NN	O	12	NMOD
7	,	,	O	,	O	12	P
8	thrombocytopenia	thrombocytopenia	B-NP	NN	O	12	NMOD
9	and	and	O	CC	O	12	NMOD
10	progressive	progressive	B-NP	JJ	O	12	NMOD
11	renal	renal	I-NP	JJ	O	12	NMOD
12	failure	failure	I-NP	NN	O	3	PMOD
13	associated	associate	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	mitomycin	mitomycin	B-NP	NN	O	17	NMOD
16	C	C	I-NP	NN	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	14	PMOD
18	and	and	O	CC	O	2	VMOD
19	affects	affect	B-VP	VBZ	O	2	VMOD
20	about	about	B-NP	RB	O	22	NMOD
21	10	10	I-NP	CD	O	20	AMOD
22	%	%	I-NP	NN	O	19	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	patients	patient	B-NP	NNS	O	23	PMOD
25	treated	treat	B-VP	VBN	O	24	NMOD
26	with	with	B-PP	IN	O	25	VMOD
27	this	this	B-NP	DT	O	28	NMOD
28	agent	agent	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	5	SUB
4	usually	usually	B-ADVP	RB	O	5	VMOD
5	develops	develop	B-VP	VBZ	O	18	VMOD
6	about	about	B-NP	IN	O	8	NMOD
7	8-10	8-10	I-NP	CD	O	6	AMOD
8	mth	mth	I-NP	NN	O	5	OBJ
9	after	after	B-PP	IN	O	5	VMOD
10	start	start	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	mitomycin	mitomycin	B-NP	NN	O	14	NMOD
13	C	C	I-NP	NN	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	11	PMOD
15	and	and	O	CC	O	18	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	mortality	mortality	I-NP	NN	O	18	SUB
18	is	be	B-VP	VBZ	O	0	ROOT
19	approximately	approximately	B-NP	RB	O	21	NMOD
20	60	60	I-NP	CD	O	19	AMOD
21	%	%	I-NP	NN	O	18	PRD
22	from	from	B-PP	IN	O	21	NMOD
23	renal	renal	B-NP	JJ	O	24	NMOD
24	failure	failure	I-NP	NN	O	27	NMOD
25	or	or	O	CC	O	27	NMOD
26	pulmonary	pulmonary	B-NP	JJ	O	27	NMOD
27	edema	edema	I-NP	NN	O	22	PMOD
28	.	.	O	.	O	18	P

1	Although	Although	B-SBAR	IN	O	20	VMOD
2	there	there	B-NP	EX	O	3	SUB
3	have	have	B-VP	VBP	O	1	SBAR
4	been	be	I-VP	VBN	O	3	VC
5	anecdotal	anecdotal	B-NP	JJ	O	6	NMOD
6	reports	report	I-NP	NNS	O	4	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	cardiac	cardiac	B-NP	JJ	O	9	NMOD
9	toxicity	toxicity	I-NP	NN	O	7	PMOD
10	associated	associate	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	fluorouracil	fluorouracil	B-NP	NN	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	5-FU	5-FU	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	therapy	therapy	B-NP	NN	O	11	PMOD
17	,	,	O	,	O	20	P
18	this	this	B-NP	DT	O	19	NMOD
19	phenomenon	phenomenon	I-NP	NN	O	20	SUB
20	has	have	B-VP	VBZ	O	0	ROOT
21	not	not	I-VP	RB	O	20	VMOD
22	been	be	I-VP	VBN	O	20	VC
23	studied	study	I-VP	VBN	O	22	VC
24	in	in	B-PP	IN	O	23	VMOD
25	a	a	B-NP	DT	O	27	NMOD
26	systematic	systematic	I-NP	JJ	O	27	NMOD
27	fashion	fashion	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	20	P

1	We	We	B-NP	PRP	O	3	SUB
2	prospectively	prospectively	B-ADVP	RB	O	3	VMOD
3	performed	perform	B-VP	VBD	O	0	ROOT
4	continuous	continuous	B-NP	JJ	O	6	NMOD
5	ambulatory	ambulatory	I-NP	JJ	O	6	NMOD
6	ECG	ECG	I-NP	NN	O	3	OBJ
7	monitoring	monitor	B-VP	VBG	O	6	NMOD
8	on	on	B-PP	IN	O	7	VMOD
9	25	25	B-NP	CD	O	10	NMOD
10	patients	patient	I-NP	NNS	O	8	PMOD
11	undergoing	undergo	B-VP	VBG	O	10	NMOD
12	5-FU	5-FU	B-NP	NN	O	13	NMOD
13	infusion	infusion	I-NP	NN	O	11	OBJ
14	for	for	B-PP	IN	O	11	VMOD
15	treatment	treatment	B-NP	NN	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	solid	solid	B-NP	JJ	O	18	NMOD
18	tumors	tumor	I-NP	NNS	O	16	PMOD
19	in	in	B-SBAR	IN	O	15	NMOD
20	order	order	O	NN	O	19	DEP
21	to	to	B-VP	TO	O	22	VMOD
22	assess	assess	I-VP	VB	O	19	SBAR
23	the	the	B-NP	DT	O	24	NMOD
24	incidence	incidence	I-NP	NN	O	22	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	ischemic	ischemic	B-NP	JJ	O	28	NMOD
27	ST	ST	I-NP	NN	O	28	NMOD
28	changes	change	I-NP	NNS	O	25	PMOD
29	.	.	O	.	O	3	P

1	Anginal	Anginal	B-NP	JJ	O	2	NMOD
2	episodes	episode	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	rare	rare	B-ADJP	JJ	O	3	PRD
5	:	:	O	:	O	9	P
6	only	only	B-NP	RB	O	8	NMOD
7	one	one	I-NP	CD	O	6	AMOD
8	patient	patient	I-NP	NN	O	9	SUB
9	had	have	B-VP	VBD	O	3	VMOD
10	angina	angina	B-NP	NN	O	9	OBJ
11	(	(	O	(	O	15	DEP
12	during	during	B-PP	IN	O	15	DEP
13	5-FU	5-FU	B-NP	NN	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	12	PMOD
15	)	)	O	)	O	10	NMOD
16	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ischemic	ischemic	B-NP	JJ	O	5	NMOD
5	episodes	episode	I-NP	NNS	O	3	PMOD
6	per	per	B-PP	IN	O	2	NMOD
7	patient	patient	B-NP	NN	O	6	PMOD
8	per	per	B-PP	IN	O	2	NMOD
9	hour	hour	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	37	VMOD
11	0.05	0.05	B-NP	CD	O	13	AMOD
12	+/-	+/-	I-NP	SYM	O	13	AMOD
13	0.02	0.02	I-NP	CD	O	10	PRD
14	prior	prior	I-NP	JJ	O	15	PMOD
15	to	to	B-PP	TO	O	13	NMOD
16	5-FU	5-FU	B-NP	NN	O	17	NMOD
17	infusion	infusion	I-NP	NN	O	15	PMOD
18	v	v	B-PP	IN	O	13	NMOD
19	0.13	0.13	B-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	0.03	0.03	I-NP	CD	O	18	PMOD
22	during	during	B-PP	IN	O	10	VMOD
23	5-FU	5-FU	B-NP	NN	O	24	NMOD
24	infusion	infusion	I-NP	NN	O	22	PMOD
25	(	(	O	(	O	30	DEP
26	P	P	B-NP	NN	O	28	SUB
27	less	less	B-ADJP	JJR	O	28	AMOD
28	than	than	B-PP	IN	O	30	DEP
29	.001	.001	B-NP	CD	O	28	AMOD
30	)	)	O	)	O	24	NMOD
31	;	;	O	:	O	10	P
32	the	the	B-NP	DT	O	33	NMOD
33	duration	duration	I-NP	NN	O	37	SUB
34	of	of	B-PP	IN	O	33	NMOD
35	ECG	ECG	B-NP	NN	O	36	NMOD
36	changes	change	I-NP	NNS	O	34	PMOD
37	was	be	B-VP	VBD	O	0	ROOT
38	0.6	0.6	B-NP	CD	O	40	AMOD
39	+/-	+/-	I-NP	SYM	O	40	AMOD
40	0.3	0.3	I-NP	CD	O	41	NMOD
41	minutes	minute	I-NP	NNS	O	37	PRD
42	per	per	B-PP	IN	O	41	NMOD
43	patient	patient	B-NP	NN	O	42	PMOD
44	per	per	B-PP	IN	O	41	VMOD
45	hour	hour	B-NP	NN	O	44	PMOD
46	before	before	B-PP	IN	O	41	NMOD
47	5-FU	5-FU	B-NP	NN	O	48	NMOD
48	v	v	I-NP	NN	O	52	NMOD
49	1.9	1.9	B-NP	CD	O	51	AMOD
50	+/-	+/-	I-NP	CC	O	51	AMOD
51	0.5	0.5	I-NP	CD	O	48	NMOD
52	minutes	minute	I-NP	NNS	O	46	PMOD
53	per	per	B-PP	IN	O	52	NMOD
54	patient	patient	B-NP	NN	O	53	PMOD
55	per	per	B-PP	IN	O	41	NMOD
56	hour	hour	B-NP	NN	O	55	PMOD
57	during	during	B-PP	IN	O	41	NMOD
58	5-FU	5-FU	B-NP	NN	O	57	PMOD
59	(	(	O	(	O	64	DEP
60	P	P	B-NP	NN	O	64	DEP
61	less	less	B-ADJP	JJR	O	60	NMOD
62	than	than	B-PP	IN	O	61	AMOD
63	.01	.01	B-NP	CD	O	62	PMOD
64	)	)	O	)	O	58	NMOD
65	.	.	O	.	O	37	P

1	Lethal	Lethal	B-NP	JJ	O	2	NMOD
2	anuria	anuria	I-NP	NN	O	0	ROOT
3	complicating	complicate	B-VP	VBG	O	2	NMOD
4	high	high	B-NP	JJ	O	7	NMOD
5	dose	dose	I-NP	NN	O	7	NMOD
6	ifosfamide	ifosfamide	I-NP	NN	O	7	NMOD
7	chemotherapy	chemotherapy	I-NP	NN	O	3	OBJ
8	in	in	B-PP	IN	O	3	VMOD
9	a	a	B-NP	DT	O	12	NMOD
10	breast	breast	I-NP	NN	O	12	NMOD
11	cancer	cancer	I-NP	NN	O	12	NMOD
12	patient	patient	I-NP	NN	O	8	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	an	an	B-NP	DT	O	17	NMOD
15	impaired	impaired	I-NP	JJ	O	17	NMOD
16	renal	renal	I-NP	JJ	O	17	NMOD
17	function	function	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	sixty-year-old	sixty-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	14	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	advanced	advance	B-NP	VBN	O	7	NMOD
6	breast	breast	I-NP	NN	O	7	NMOD
7	cancer	cancer	I-NP	NN	O	4	PMOD
8	,	,	O	,	O	3	P
9	previously	previously	B-VP	RB	O	10	VMOD
10	treated	treat	I-VP	VBN	O	3	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	cisplatin	cisplatin	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	3	P
14	developed	develop	B-VP	VBD	O	0	ROOT
15	an	an	B-NP	DT	O	19	NMOD
16	irreversible	irreversible	I-NP	JJ	O	19	NMOD
17	lethal	lethal	I-NP	JJ	O	19	NMOD
18	renal	renal	I-NP	JJ	O	19	NMOD
19	failure	failure	I-NP	NN	O	24	NMOD
20	with	with	B-PP	IN	O	19	NMOD
21	anuria	anuria	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	24	P
23	the	the	B-NP	DT	O	24	NMOD
24	day	day	I-NP	NN	O	14	OBJ
25	after	after	B-PP	IN	O	24	NMOD
26	5	5	B-NP	CD	O	27	AMOD
27	g/m2	g/m2	I-NP	NN	O	29	NMOD
28	bolus	bolus	I-NP	NN	O	29	NMOD
29	ifosfamide	ifosfamide	I-NP	NN	O	25	PMOD
30	.	.	O	.	O	14	P

1	Ifosfamide	Ifosfamide	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	known	known	I-NP	JJ	O	6	NMOD
5	nephrotoxic	nephrotoxic	I-NP	JJ	O	6	NMOD
6	drug	drug	I-NP	NN	O	2	PRD
7	with	with	B-PP	IN	O	6	NMOD
8	demonstrated	demonstrate	B-NP	VBN	O	9	NMOD
9	tubulopathies	tubulopathy	I-NP	NNS	O	7	PMOD
10	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	3	SUB
2	strongly	strongly	B-ADVP	RB	O	3	VMOD
3	suspect	suspect	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	this	this	B-NP	DT	O	7	NMOD
6	lethal	lethal	I-NP	JJ	O	7	NMOD
7	anuria	anuria	I-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	4	SBAR
9	mainly	mainly	B-ADJP	RB	O	10	AMOD
10	due	due	I-ADJP	JJ	O	8	PRD
11	to	to	B-PP	TO	O	10	AMOD
12	ifosfamide	ifosfamide	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	10	P
14	occurring	occur	B-VP	VBG	O	10	AMOD
15	in	in	B-PP	IN	O	14	VMOD
16	a	a	B-NP	DT	O	17	NMOD
17	patient	patient	I-NP	NN	O	15	PMOD
18	having	have	B-VP	VBG	O	17	NMOD
19	received	receive	I-VP	VBN	O	18	VC
20	previous	previous	B-NP	JJ	O	22	NMOD
21	cisplatin	cisplatin	I-NP	NN	O	22	NMOD
22	chemotherapy	chemotherapy	I-NP	NN	O	19	OBJ
23	and	and	B-PP	CC	O	19	VMOD
24	with	with	B-PP	IN	O	19	VMOD
25	poor	poor	B-NP	JJ	O	27	NMOD
26	kidney	kidney	I-NP	NN	O	27	NMOD
27	perfusion	perfusion	I-NP	NN	O	24	PMOD
28	due	due	B-ADJP	JJ	O	27	NMOD
29	to	to	B-PP	TO	O	28	AMOD
30	transient	transient	B-NP	JJ	O	31	NMOD
31	hypotension	hypotension	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	3	P

1	Central	Central	B-NP	JJ	O	3	NMOD
2	vein	vein	I-NP	NN	O	3	NMOD
3	thrombosis	thrombosis	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	topical	topical	B-NP	JJ	O	7	NMOD
6	dipivalyl	dipivalyl	I-NP	NN	O	7	NMOD
7	epinephrine	epinephrine	I-NP	NN	O	0	ROOT
8	.	.	O	.	O	7	P

1	Amelioration	Amelioration	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	bendrofluazide	bendrofluazide	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	hypokalemia	hypokalemia	B-NP	NN	O	4	OBJ
6	by	by	B-PP	IN	O	4	VMOD
7	timolol	timolol	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	5	NMOD
2	beta	beta	I-NP	NN	O	5	NMOD
3	adrenergic	adrenergic	I-NP	JJ	O	5	NMOD
4	blocking	block	I-NP	VBG	O	5	NMOD
5	drug	drug	I-NP	NN	O	7	NMOD
6	,	,	O	,	O	7	P
7	timolol	timolol	B-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	tended	tend	B-VP	VBD	O	0	ROOT
10	to	to	I-VP	TO	O	11	VMOD
11	correct	correct	I-VP	VB	O	9	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	hypokalemia	hypokalemia	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	short-term	short-term	B-NP	JJ	O	17	NMOD
16	bendrofluazide	bendrofluazide	I-NP	NN	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	14	PMOD
18	in	in	B-PP	IN	O	11	VMOD
19	6	6	B-NP	CD	O	22	NMOD
20	healthy	healthy	I-NP	JJ	O	22	NMOD
21	male	male	I-NP	JJ	O	22	NMOD
22	subjects	subject	I-NP	NNS	O	18	PMOD
23	and	and	O	CC	O	9	VMOD
24	although	although	B-SBAR	IN	O	9	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	effect	effect	I-NP	NN	O	27	SUB
27	was	be	B-VP	VBD	O	24	SBAR
28	small	small	B-ADJP	JJ	O	27	PRD
29	it	it	B-NP	PRP	O	30	SUB
30	was	be	B-VP	VBD	O	24	SBAR
31	significant	significant	B-ADJP	JJ	O	30	PRD
32	.	.	O	.	O	9	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	aim	aim	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	present	present	I-NP	JJ	O	8	NMOD
8	study	study	I-NP	NN	O	5	PMOD
9	was	be	B-VP	VBD	O	1	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	investigate	investigate	I-VP	VB	O	9	PRD
12	the	the	B-NP	DT	O	13	NMOD
13	effect	effect	I-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	risperidone	risperidone	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBD	O	11	VMOD
17	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	16	OBJ
18	on	on	B-PP	IN	O	16	VMOD
19	trabecular	trabecular	B-NP	JJ	O	22	NMOD
20	bone	bone	I-NP	NN	O	22	NMOD
21	mineral	mineral	I-NP	NN	O	22	NMOD
22	density	density	I-NP	NN	O	18	PMOD
23	(	(	O	(	O	25	DEP
24	BMD	BMD	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	in	in	B-PP	IN	O	22	NMOD
27	children	child	B-NP	NNS	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	adolescents	adolescent	I-NP	NNS	O	26	PMOD
30	.	.	O	.	O	9	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Hyperprolactinemia	Hyperprolactinemia	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	1	NMOD
5	present	present	B-ADJP	JJ	O	4	PRD
6	in	in	B-PP	IN	O	5	AMOD
7	49	49	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	83	83	B-NP	CD	O	11	NMOD
11	boys	boy	I-NP	NNS	O	9	PMOD
12	(	(	O	(	O	16	DEP
13	n	n	B-NP	NN	O	16	DEP
14	=	=	B-VP	SYM	O	13	NMOD
15	41	41	B-NP	CD	O	14	AMOD
16	)	)	O	)	O	11	NMOD
17	treated	treat	B-VP	VBN	O	11	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	risperidone	risperidone	B-NP	NN	O	18	PMOD
20	for	for	B-PP	IN	O	17	VMOD
21	a	a	B-NP	DT	O	22	NMOD
22	mean	mean	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	2.9	2.9	B-NP	CD	O	25	NMOD
25	years	year	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	1	P

1	Serum	Serum	B-NP	NN	O	3	NMOD
2	testosterone	testosterone	I-NP	NN	O	3	NMOD
3	concentration	concentration	I-NP	NN	O	4	SUB
4	increased	increase	B-VP	VBD	O	0	ROOT
5	with	with	B-PP	IN	O	4	VMOD
6	pubertal	pubertal	B-NP	JJ	O	7	NMOD
7	status	status	I-NP	NN	O	5	PMOD
8	but	but	O	CC	O	4	VMOD
9	was	be	B-VP	VBD	O	4	VMOD
10	not	not	I-VP	RB	O	9	VMOD
11	affected	affect	I-VP	VBN	O	9	VC
12	by	by	B-PP	IN	O	11	VMOD
13	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	4	P

1	Of	Of	B-PP	IN	O	7	VMOD
2	13	13	B-NP	CD	O	4	NMOD
3	documented	document	I-NP	VBN	O	4	NMOD
4	fractures	fracture	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	7	P
6	3	3	B-NP	CD	O	7	SUB
7	occurred	occur	B-VP	VBD	O	17	VMOD
8	after	after	B-PP	IN	O	7	VMOD
9	risperidone	risperidone	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	SSRIs	SSRI	I-NP	NNS	B-protein	12	SUB
12	were	be	B-VP	VBD	O	8	SBAR
13	started	start	I-VP	VBN	O	12	VC
14	,	,	O	,	O	17	P
15	and	and	O	CC	O	16	NMOD
16	none	none	B-NP	NN	O	17	SUB
17	occurred	occur	B-VP	VBD	O	0	ROOT
18	in	in	B-PP	IN	O	17	VMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	17	P

1	Seizures	Seizure	B-NP	NNS	O	10	NMOD
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	levofloxacin	levofloxacin	B-NP	NN	O	3	PMOD
5	:	:	O	:	O	1	P
6	case	case	B-NP	NN	O	7	NMOD
7	presentation	presentation	I-NP	NN	O	10	NMOD
8	and	and	O	CC	O	10	NMOD
9	literature	literature	B-NP	NN	O	10	NMOD
10	review	review	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	PURPOSE	PURPOSE	B-NP	NN	O	4	SUB
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	present	present	B-VP	VBP	O	0	ROOT
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	a	a	B-NP	DT	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	developed	develop	B-VP	VBD	O	10	SBAR
12	seizures	seizure	B-NP	NNS	O	11	OBJ
13	shortly	shortly	B-ADVP	RB	O	11	VMOD
14	after	after	B-PP	IN	O	11	VMOD
15	initiating	initiate	B-VP	VBG	O	14	PMOD
16	treatment	treatment	B-NP	NN	O	15	OBJ
17	with	with	B-PP	IN	O	15	VMOD
18	levofloxacin	levofloxacin	B-NP	NN	O	17	PMOD
19	and	and	O	CC	O	4	VMOD
20	to	to	B-VP	TO	O	21	VMOD
21	discuss	discuss	I-VP	VB	O	4	VMOD
22	the	the	B-NP	DT	O	25	NMOD
23	potential	potential	I-NP	JJ	O	25	NMOD
24	drug-drug	drug-drug	I-NP	JJ	O	25	NMOD
25	interactions	interaction	I-NP	NNS	O	21	OBJ
26	related	relate	B-VP	VBN	O	25	NMOD
27	to	to	B-PP	TO	O	26	AMOD
28	the	the	B-NP	DT	O	29	NMOD
29	inhibition	inhibition	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	cytochrome	cytochrome	B-NP	NN	B-protein	36	NMOD
32	P450	P450	I-NP	NN	I-protein	36	NMOD
33	(	(	O	(	I-protein	36	NMOD
34	CYP	CYP	B-NP	NN	I-protein	36	NMOD
35	)	)	O	)	I-protein	36	NMOD
36	1A2	1A2	B-NP	NN	I-protein	30	PMOD
37	in	in	B-PP	IN	O	29	NMOD
38	this	this	B-NP	DT	O	39	NMOD
39	case	case	I-NP	NN	O	37	PMOD
40	,	,	O	,	O	48	P
41	as	as	B-CONJP	RB	O	48	NMOD
42	well	well	I-CONJP	RB	O	41	DEP
43	as	as	I-CONJP	IN	O	41	DEP
44	in	in	B-PP	IN	O	41	DEP
45	other	other	B-NP	JJ	O	46	NMOD
46	cases	case	I-NP	NNS	O	44	PMOD
47	,	,	O	,	O	48	P
48	of	of	B-PP	IN	O	29	NMOD
49	levofloxacin	levofloxacin	B-NP	NN	O	51	NMOD
50	induced	induce	I-NP	VBN	O	51	NMOD
51	seizures	seizure	I-NP	NNS	O	48	PMOD
52	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Six	Six	B-NP	CD	O	4	NMOD
4	cases	case	I-NP	NNS	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	levofloxacin	levofloxacin	B-NP	NN	O	8	NMOD
7	induced	induced	I-NP	JJ	O	8	NMOD
8	seizures	seizure	I-NP	NNS	O	5	PMOD
9	have	have	B-VP	VBP	O	1	NMOD
10	been	be	I-VP	VBN	O	9	VC
11	reported	report	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	literature	literature	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	Mice	Mouse	B-NP	NNS	O	4	SUB
2	lacking	lack	B-VP	VBG	O	1	NMOD
3	mPGES-1	mPGES-1	B-NP	NN	B-protein	2	OBJ
4	are	be	B-VP	VBP	O	0	ROOT
5	resistant	resistant	B-ADJP	JJ	O	4	PRD
6	to	to	B-PP	TO	O	5	AMOD
7	lithium	lithium	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	polyuria	polyuria	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	4	P

1	Cyclooxygenase-2	Cyclooxygenase-2	B-NP	NN	B-protein	2	NMOD
2	activity	activity	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	required	require	I-VP	VBN	O	3	VC
5	for	for	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	development	development	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	lithium	lithium	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	polyuria	polyuria	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	undertaken	undertake	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	assess	assess	I-VP	VB	O	5	VMOD
8	lithium	lithium	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	polyuria	polyuria	I-NP	NN	O	7	OBJ
11	in	in	B-PP	IN	O	7	VMOD
12	mice	mouse	B-NP	NNS	O	11	PMOD
13	deficient	deficient	B-ADJP	JJ	O	12	NMOD
14	in	in	B-PP	IN	O	13	AMOD
15	microsomal	microsomal	B-NP	JJ	O	18	NMOD
16	prostaglandin	prostaglandin	I-NP	NN	O	18	NMOD
17	E	E	I-NP	NN	O	18	NMOD
18	synthase-1	synthase-1	I-NP	NN	O	14	PMOD
19	(	(	O	(	O	21	DEP
20	mPGES-1	mPGES-1	B-NP	NN	B-protein	21	DEP
21	)	)	O	)	O	18	NMOD
22	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	2-wk	2-wk	I-NP	JJ	O	3	NMOD
3	administration	administration	I-NP	NN	O	22	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	LiCl	LiCl	B-NP	NN	O	12	NMOD
6	(	(	O	(	O	12	NMOD
7	4	4	B-NP	CD	O	8	NMOD
8	mmol.kg	mmol.kg	I-NP	NN	O	12	NMOD
9	(	(	O	(	O	11	DEP
10	-1	-1	B-NP	CD	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	.day	.day	B-NP	NN	O	4	PMOD
13	(	(	O	(	O	15	DEP
14	-1	-1	B-NP	CD	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	ip	ip	B-NP	NN	O	12	NMOD
17	)	)	O	)	O	12	NMOD
18	in	in	B-PP	IN	O	3	NMOD
19	mPGES-1	mPGES-1	B-NP	NN	O	21	NMOD
20	+/+	+/+	B-NP	SYM	O	21	NMOD
21	mice	mouse	I-NP	NNS	O	18	PMOD
22	led	lead	B-VP	VBD	O	0	ROOT
23	to	to	B-PP	TO	O	22	VMOD
24	a	a	B-NP	DT	O	26	NMOD
25	marked	marked	I-NP	JJ	O	26	NMOD
26	polyuria	polyuria	I-NP	NN	O	23	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	hyposmotic	hyposmotic	B-NP	JJ	O	29	NMOD
29	urine	urine	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	22	P

1	In	In	B-PP	IN	O	7	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	7	P
4	mPGES-1	mPGES-1	B-NP	NN	O	6	NMOD
5	-/-	-/-	I-NP	JJ	O	6	NMOD
6	mice	mouse	I-NP	NNS	O	7	SUB
7	were	be	B-VP	VBD	O	0	ROOT
8	largely	largely	B-ADJP	RB	O	9	AMOD
9	resistant	resistant	I-ADJP	JJ	O	7	PRD
10	to	to	B-PP	TO	O	9	AMOD
11	lithium	lithium	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	7	VMOD
13	polyuria	polyuria	B-NP	NN	O	12	OBJ
14	and	and	O	CC	O	12	VMOD
15	a	a	B-NP	DT	O	16	NMOD
16	urine	urine	I-NP	NN	O	18	NMOD
17	concentrating	concentrate	I-NP	VBG	O	18	NMOD
18	defect	defect	I-NP	NN	O	14	PMOD
19	,	,	O	,	O	18	P
20	accompanied	accompany	B-VP	VBN	O	18	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	nearly	nearly	B-NP	RB	O	23	AMOD
23	complete	complete	I-NP	JJ	O	24	NMOD
24	blockade	blockade	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	high	high	B-NP	JJ	O	28	NMOD
27	urine	urine	I-NP	NN	O	28	NMOD
28	PGE	PGE	I-NP	NN	O	34	NMOD
29	(	(	O	(	O	31	DEP
30	2	2	B-NP	CD	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	and	and	O	CC	O	34	NMOD
33	cAMP	cAMP	B-NP	NN	O	34	NMOD
34	output	output	I-NP	NN	O	25	PMOD
35	.	.	O	.	O	7	P

1	Recently	Recently	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	a	a	B-NP	DT	O	4	NMOD
4	number	number	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	commercial	commercial	B-NP	JJ	O	7	NMOD
7	lots	lot	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	heparin	heparin	B-NP	NN	B-protein	10	NMOD
10	products	product	I-NP	NNS	I-protein	8	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	found	find	I-VP	VBN	O	11	VC
13	to	to	I-VP	TO	O	14	VMOD
14	be	be	I-VP	VB	O	12	VMOD
15	contaminated	contaminate	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	an	an	B-NP	DT	O	20	NMOD
18	oversulfated	oversulfated	I-NP	JJ	O	20	NMOD
19	chondroitin	chondroitin	I-NP	NN	O	20	NMOD
20	sulfate	sulfate	I-NP	NN	O	16	PMOD
21	(	(	O	(	O	23	DEP
22	OSCS	OSCS	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	derivative	derivative	B-NP	NN	O	20	NMOD
25	that	that	B-NP	WDT	O	20	NMOD
26	could	could	B-VP	MD	O	25	SBAR
27	elicit	elicit	I-VP	VB	O	26	VC
28	a	a	B-NP	DT	O	30	NMOD
29	hypotensive	hypotensive	I-NP	JJ	O	30	NMOD
30	response	response	I-NP	NN	O	27	OBJ
31	in	in	B-PP	IN	O	27	VMOD
32	pigs	pig	B-NP	NNS	O	31	PMOD
33	following	follow	B-PP	VBG	O	27	VMOD
34	a	a	B-NP	DT	O	37	NMOD
35	single	single	I-NP	JJ	O	37	NMOD
36	high-dose	high-dose	I-NP	JJ	O	37	NMOD
37	infusion	infusion	I-NP	NN	O	33	PMOD
38	.	.	O	.	O	11	P

1	Using	Use	B-VP	VBG	O	13	VMOD
2	both	both	O	CC	O	10	NMOD
3	contaminated	contaminate	B-NP	VBN	O	5	NMOD
4	heparin	heparin	I-NP	NN	B-protein	5	NMOD
5	products	product	I-NP	NNS	I-protein	10	NMOD
6	and	and	O	CC	O	10	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	synthetically	synthetically	I-NP	RB	O	9	AMOD
9	produced	produce	I-NP	VBN	O	10	NMOD
10	derivative	derivative	I-NP	NN	O	1	OBJ
11	,	,	O	,	O	13	P
12	we	we	B-NP	PRP	O	13	SUB
13	showed	show	B-VP	VBD	O	0	ROOT
14	that	that	B-SBAR	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	OSCS	OSCS	I-NP	NN	B-protein	17	SUB
17	produces	produce	B-VP	VBZ	O	14	SBAR
18	dose-dependent	dose-dependent	B-NP	JJ	O	19	NMOD
19	hypotension	hypotension	I-NP	NN	O	17	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	pigs	pig	B-NP	NNS	O	20	PMOD
22	.	.	O	.	O	13	P

1	Doxorubicin	Doxorubicin	B-NP	NN	O	2	NMOD
2	cardiomyopathy	cardiomyopathy	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	inflammation	inflammation	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	apoptosis	apoptosis	I-NP	NN	O	7	SUB
7	are	be	B-VP	VBP	O	3	VMOD
8	attenuated	attenuate	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	gene	gene	B-NP	NN	O	11	NMOD
11	deletion	deletion	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	16	NMOD
14	kinin	kinin	I-NP	NN	B-protein	16	NMOD
15	B1	B1	I-NP	NN	I-protein	16	NMOD
16	receptor	receptor	I-NP	NN	I-protein	12	PMOD
17	.	.	O	.	O	3	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	use	use	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	anthracycline	anthracycline	I-NP	NN	O	6	NMOD
6	doxorubicin	doxorubicin	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	DOX	DOX	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	limited	limit	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	its	its	B-NP	PRP$	O	15	NMOD
14	cardiotoxic	cardiotoxic	I-NP	JJ	O	15	NMOD
15	effects	effect	I-NP	NNS	O	12	PMOD
16	,	,	O	,	O	15	P
17	which	which	B-NP	WDT	O	15	NMOD
18	are	be	B-VP	VBP	O	17	SBAR
19	attributed	attribute	I-VP	VBN	O	18	VC
20	to	to	B-PP	TO	O	19	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	induction	induction	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	apoptosis	apoptosis	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	10	P

1	To	To	B-VP	TO	O	2	VMOD
2	elucidate	elucidate	I-VP	VB	O	22	VMOD
3	the	the	B-NP	DT	O	5	NMOD
4	possible	possible	I-NP	JJ	O	5	NMOD
5	role	role	I-NP	NN	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	kinin	kinin	I-NP	NN	B-protein	10	NMOD
9	B1	B1	I-NP	NN	I-protein	10	NMOD
10	receptor	receptor	I-NP	NN	I-protein	6	PMOD
11	(	(	O	(	O	13	DEP
12	B1R	B1R	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	during	during	B-PP	IN	O	5	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	development	development	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	DOX	DOX	B-NP	NN	O	19	NMOD
19	cardiomyopathy	cardiomyopathy	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	22	P
21	we	we	B-NP	PRP	O	22	SUB
22	studied	study	B-VP	VBD	O	0	ROOT
23	B1R	B1R	B-NP	NN	B-protein	25	NMOD
24	knockout	knockout	I-NP	NN	O	25	NMOD
25	mice	mouse	I-NP	NNS	O	22	OBJ
26	(	(	O	(	O	31	DEP
27	B1R	B1R	B-NP	NN	B-protein	31	DEP
28	(	(	O	(	O	30	DEP
29	-/-	-/-	B-ADJP	JJ	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	)	)	O	)	O	25	NMOD
32	by	by	B-PP	IN	O	22	VMOD
33	investigating	investigate	B-VP	VBG	O	32	PMOD
34	cardiac	cardiac	B-NP	JJ	O	35	NMOD
35	inflammation	inflammation	I-NP	NN	O	37	NMOD
36	and	and	I-NP	CC	O	37	NMOD
37	apoptosis	apoptosis	I-NP	NN	O	33	OBJ
38	after	after	B-PP	IN	O	33	VMOD
39	induction	induction	B-NP	NN	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	DOX	DOX	B-NP	NN	O	43	NMOD
42	induced	induced	I-NP	JJ	O	43	NMOD
43	cardiomyopathy	cardiomyopathy	I-NP	NN	O	40	PMOD
44	.	.	O	.	O	22	P

1	DOX	DOX	B-NP	NN	O	3	NMOD
2	control	control	I-NP	NN	O	3	NMOD
3	mice	mouse	I-NP	NNS	O	4	SUB
4	showed	show	B-VP	VBD	O	0	ROOT
5	cardiac	cardiac	B-NP	JJ	O	6	NMOD
6	dysfunction	dysfunction	I-NP	NN	O	10	SUB
7	measured	measure	B-VP	VBN	O	6	NMOD
8	by	by	B-PP	IN	O	7	VMOD
9	pressure-volume	pressure-volume	B-NP	NN	O	8	PMOD
10	loops	loop	B-VP	VBZ	O	4	VMOD
11	in	in	B-ADVP	FW	O	10	VMOD
12	vivo	vivo	I-ADVP	FW	O	11	AMOD
13	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	11	VMOD
2	DOX	DOX	B-NP	NN	O	3	NMOD
3	B1R	B1R	I-NP	NN	O	7	NMOD
4	(	(	O	(	O	6	DEP
5	-/-	-/-	O	JJ	O	6	DEP
6	)	)	O	)	O	3	NMOD
7	mice	mouse	B-NP	NNS	O	1	PMOD
8	,	,	O	,	O	11	P
9	cardiac	cardiac	B-NP	JJ	O	10	NMOD
10	dysfunction	dysfunction	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	improved	improve	I-VP	VBN	O	11	VC
13	compared	compare	B-PP	VBN	O	12	VMOD
14	to	to	B-PP	TO	O	13	PMOD
15	DOX	DOX	B-NP	NN	O	17	NMOD
16	control	control	I-NP	NN	O	17	NMOD
17	mice	mouse	I-NP	NNS	O	14	PMOD
18	,	,	O	,	O	17	P
19	which	which	B-NP	WDT	O	17	NMOD
20	was	be	B-VP	VBD	O	19	SBAR
21	associated	associate	I-VP	VBN	O	20	VC
22	with	with	B-PP	IN	O	21	VMOD
23	normalization	normalization	B-NP	NN	O	22	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	bax/bcl-2	bax/bcl-2	I-NP	NN	O	27	NMOD
27	ratio	ratio	I-NP	NN	O	29	NMOD
28	and	and	O	CC	O	29	NMOD
29	interleukin	interleukin	B-NP	NN	B-protein	37	NMOD
30	6	6	I-NP	CD	I-protein	29	NMOD
31	,	,	O	,	O	37	P
32	as	as	B-CONJP	RB	O	37	NMOD
33	well	well	I-CONJP	RB	O	32	DEP
34	as	as	I-CONJP	IN	O	32	DEP
35	AKT	AKT	B-NP	NN	O	37	NMOD
36	activation	activation	I-NP	NN	O	37	NMOD
37	state	state	I-NP	NN	O	24	PMOD
38	.	.	O	.	O	11	P

1	These	These	B-NP	DT	O	2	NMOD
2	findings	finding	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	B1R	B1R	B-NP	NN	B-protein	6	SUB
6	is	be	B-VP	VBZ	O	4	SBAR
7	detrimental	detrimental	B-ADJP	JJ	O	6	PRD
8	in	in	B-PP	IN	O	7	AMOD
9	DOX	DOX	B-NP	NN	O	10	NMOD
10	cardiomyopathy	cardiomyopathy	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	AMOD
12	that	that	B-NP	IN	O	11	PMOD
13	it	it	B-NP	PRP	O	14	SUB
14	mediates	mediate	B-VP	VBZ	O	12	SBAR
15	the	the	B-NP	DT	O	19	NMOD
16	inflammatory	inflammatory	I-NP	JJ	O	17	NMOD
17	response	response	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	apoptosis	apoptosis	I-NP	NN	O	14	OBJ
20	.	.	O	.	O	3	P

1	Hepatotoxicity	Hepatotoxicity	B-NP	NN	O	11	NMOD
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	sulfasalazine	sulfasalazine	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	4	NMOD
6	inflammatory	inflammatory	B-NP	JJ	O	7	NMOD
7	arthritis	arthritis	I-NP	NN	O	5	PMOD
8	:	:	O	:	O	1	P
9	A	A	B-NP	DT	O	11	NMOD
10	case	case	I-NP	NN	O	11	NMOD
11	series	series	I-NP	NN	O	0	ROOT
12	from	from	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	local	local	I-NP	JJ	O	15	NMOD
15	surveillance	surveillance	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	serious	serious	B-NP	JJ	O	19	NMOD
18	adverse	adverse	I-NP	JJ	O	19	NMOD
19	events	event	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	11	P

1	Patients	Patient	B-NP	NNS	O	2	NMOD
2	'	'	B-NP	POS	O	10	SUB
3	,	,	O	,	O	2	P
4	who	who	B-NP	WP	O	2	NMOD
5	had	have	B-VP	VBD	O	4	SBAR
6	hepatotoxicity	hepatotoxicity	B-NP	NN	O	5	OBJ
7	on	on	B-PP	IN	O	5	VMOD
8	sulfasalazine	sulfasalazine	B-NP	NN	O	7	PMOD
9	and	and	O	CC	O	2	VMOD
10	met	meet	B-VP	VBD	O	0	ROOT
11	a	a	B-NP	DT	O	12	NMOD
12	definition	definition	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	a	a	B-NP	DT	O	16	NMOD
15	serious	serious	I-NP	JJ	O	16	NMOD
16	ADR	ADR	I-NP	NN	O	13	PMOD
17	,	,	O	,	O	10	P
18	were	be	B-VP	VBD	O	10	VMOD
19	identified	identify	I-VP	VBN	O	18	VC
20	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	3	NMOD
2	likely	likely	I-NP	JJ	O	3	NMOD
3	frequency	frequency	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	hepatotoxicity	hepatotoxicity	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	sulfasalazine	sulfasalazine	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	estimated	estimate	I-VP	VBN	O	8	VC
10	by	by	B-PP	IN	O	9	VMOD
11	making	make	B-VP	VBG	O	10	PMOD
12	a	a	B-NP	DT	O	13	NMOD
13	series	series	I-NP	NN	O	11	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	conservative	conservative	B-NP	JJ	O	16	NMOD
16	assumptions	assumption	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	3	NMOD
2	likely	likely	I-NP	JJ	O	3	NMOD
3	frequency	frequency	I-NP	NN	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	serious	serious	B-NP	JJ	O	6	NMOD
6	hepatotoxicity	hepatotoxicity	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	sulfasalazine	sulfasalazine	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	estimated	estimate	I-VP	VBN	O	9	VC
11	at	at	B-PP	IN	O	10	VMOD
12	0.4	0.4	B-NP	CD	O	13	NMOD
13	%	%	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	treated	treat	B-NP	VBN	O	16	NMOD
16	patients	patient	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	9	P

1	An	An	B-NP	DT	O	2	NMOD
2	evaluation	evaluation	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	amikacin	amikacin	B-NP	NN	O	5	NMOD
5	nephrotoxicity	nephrotoxicity	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	hematology/oncology	hematology/oncology	I-NP	NN	B-cell_type	9	NMOD
9	population	population	I-NP	NN	I-cell_type	6	PMOD
10	.	.	O	.	O	2	P

1	Amikacin	Amikacin	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	4	NMOD
4	aminoglycoside	aminoglycoside	I-NP	NN	O	2	PRD
5	commonly	commonly	B-VP	RB	O	6	VMOD
6	used	use	I-VP	VBN	O	4	NMOD
7	to	to	B-VP	TO	O	8	VMOD
8	provide	provide	I-VP	VB	O	6	VMOD
9	empirical	empirical	B-NP	JJ	O	12	NMOD
10	double	double	I-NP	JJ	O	12	NMOD
11	gram-negative	gram-negative	I-NP	JJ	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	8	OBJ
13	for	for	B-PP	IN	O	12	NMOD
14	febrile	febrile	B-NP	JJ	O	15	NMOD
15	neutropenia	neutropenia	I-NP	NN	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	other	other	B-NP	JJ	O	19	NMOD
18	suspected	suspect	I-NP	VBN	O	19	NMOD
19	infections	infection	I-NP	NNS	O	13	PMOD
20	.	.	O	.	O	2	P

1	To	To	B-VP	TO	O	2	VMOD
2	evaluate	evaluate	I-VP	VB	O	18	VMOD
3	amikacin-associated	amikacin-associated	B-NP	JJ	O	4	NMOD
4	nephrotoxicity	nephrotoxicity	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	an	an	B-NP	DT	O	9	NMOD
7	adult	adult	I-NP	JJ	O	9	NMOD
8	hematology/oncology	hematology/oncology	I-NP	NN	O	9	NMOD
9	population	population	I-NP	NN	O	17	NMOD
10	,	,	O	,	O	17	P
11	a	a	B-NP	DT	O	17	NMOD
12	prospective	prospective	I-NP	JJ	O	16	AMOD
13	,	,	I-NP	,	O	16	P
14	randomized	randomize	I-NP	VBN	O	16	AMOD
15	,	,	I-NP	,	O	16	P
16	open-label	open-label	I-NP	JJ	O	17	NMOD
17	trial	trial	I-NP	NN	O	5	PMOD
18	was	be	B-VP	VBD	O	0	ROOT
19	conducted	conduct	I-VP	VBN	O	18	VC
20	at	at	B-PP	IN	O	19	VMOD
21	a	a	B-NP	DT	O	24	NMOD
22	university-affiliated	university-affiliated	I-NP	JJ	O	24	NMOD
23	medical	medical	I-NP	JJ	O	24	NMOD
24	center	center	I-NP	NN	O	20	PMOD
25	.	.	O	.	O	18	P

1	Although	Although	B-SBAR	IN	O	28	VMOD
2	3	3	B-NP	CD	O	10	SUB
3	,	,	O	,	O	10	P
4	4-methylenedioxymethamphetamine	4-methylenedioxymethamphetamine	B-NP	NN	O	10	SUB
5	(	(	O	(	O	9	DEP
6	MDMA	MDMA	B-NP	NN	O	8	NMOD
7	or	or	O	CC	O	8	NMOD
8	ecstasy	ecstasy	B-NP	NN	O	9	DEP
9	)	)	O	)	O	4	NMOD
10	has	have	B-VP	VBZ	O	1	SBAR
11	been	be	I-VP	VBN	O	10	VC
12	shown	show	I-VP	VBN	O	11	VC
13	to	to	I-VP	TO	O	14	VMOD
14	damage	damage	I-VP	VB	O	12	VMOD
15	brain	brain	B-NP	NN	O	16	NMOD
16	serotonin	serotonin	I-NP	NN	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	5-HT	5-HT	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	neurons	neuron	B-NP	NNS	O	14	OBJ
21	in	in	B-PP	IN	O	20	NMOD
22	animals	animal	B-NP	NNS	O	25	NMOD
23	and	and	O	CC	O	25	NMOD
24	possibly	possibly	B-NP	RB	O	25	NMOD
25	humans	human	I-NP	NNS	O	21	PMOD
26	,	,	O	,	O	28	P
27	little	little	B-NP	JJ	O	28	SUB
28	is	be	B-VP	VBZ	O	0	ROOT
29	known	know	I-VP	VBN	O	28	VC
30	about	about	B-PP	IN	O	29	VMOD
31	the	the	B-NP	DT	O	33	NMOD
32	long-term	long-term	I-NP	JJ	O	33	NMOD
33	consequences	consequence	I-NP	NNS	O	30	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	MDMA	MDMA	B-NP	NN	B-protein	34	PMOD
36	induced	induce	B-VP	VBD	O	28	VMOD
37	5-HT	5-HT	B-NP	NN	O	39	NMOD
38	neurotoxic	neurotoxic	I-NP	JJ	O	39	NMOD
39	lesions	lesion	I-NP	NNS	O	36	OBJ
40	on	on	B-PP	IN	O	36	VMOD
41	functions	function	B-NP	NNS	O	40	PMOD
42	in	in	B-PP	IN	O	41	NMOD
43	which	which	B-NP	WDT	O	42	PMOD
44	5-HT	5-HT	B-NP	NN	O	45	SUB
45	is	be	B-VP	VBZ	O	42	SBAR
46	involved	involve	I-VP	VBN	O	45	VC
47	,	,	O	,	O	46	P
48	such	such	B-PP	JJ	O	49	PMOD
49	as	as	I-PP	IN	O	46	VMOD
50	cognitive	cognitive	B-NP	JJ	O	51	NMOD
51	function	function	I-NP	NN	O	49	PMOD
52	.	.	O	.	O	28	P

1	In	In	B-PP	IN	O	9	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	9	P
4	no	no	B-NP	DT	O	5	NMOD
5	evidence	evidence	I-NP	NN	O	9	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	memory	memory	B-NP	NN	O	8	NMOD
8	impairment	impairment	I-NP	NN	O	6	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	observed	observe	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	moderate	moderate	B-NP	JJ	O	14	NMOD
13	MDMA	MDMA	I-NP	NN	O	14	NMOD
14	users	user	I-NP	NNS	O	11	PMOD
15	.	.	O	.	O	9	P

1	While	While	B-SBAR	IN	O	28	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	use	use	I-NP	NN	O	15	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	MDMA	MDMA	B-NP	NN	B-protein	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	quantities	quantity	B-NP	NNS	O	6	PMOD
8	that	that	B-NP	WDT	O	3	NMOD
9	may	may	B-VP	MD	O	8	SBAR
10	be	be	I-VP	VB	O	9	VC
11	considered	consider	I-VP	VBN	O	13	AMOD
12	"	"	B-ADJP	"	O	13	AMOD
13	moderate	moderate	I-ADJP	JJ	O	10	PRD
14	"	"	O	"	O	13	AMOD
15	is	be	B-VP	VBZ	O	1	SBAR
16	not	not	I-VP	RB	O	15	VMOD
17	associated	associate	I-VP	VBN	O	15	VC
18	with	with	B-PP	IN	O	17	VMOD
19	impaired	impaired	B-NP	JJ	O	20	NMOD
20	memory	memory	I-NP	NN	O	24	NMOD
21	functioning	function	B-VP	VBG	O	20	NMOD
22	,	,	O	,	O	24	P
23	heavy	heavy	B-NP	JJ	O	24	NMOD
24	use	use	I-NP	NN	O	18	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	MDMA	MDMA	B-NP	NN	O	27	NMOD
27	use	use	I-NP	NN	O	25	PMOD
28	may	may	B-VP	MD	O	0	ROOT
29	lead	lead	I-VP	VB	O	28	VC
30	to	to	B-PP	TO	O	29	VMOD
31	long	long	B-NP	JJ	O	32	AMOD
32	lasting	lasting	I-NP	JJ	O	34	NMOD
33	memory	memory	I-NP	NN	O	34	NMOD
34	impairments	impairment	I-NP	NNS	O	30	PMOD
35	.	.	O	.	O	28	P

1	Aging	Age	B-VP	VBG	O	0	ROOT
2	process	process	B-NP	NN	O	1	OBJ
3	of	of	B-PP	IN	O	2	NMOD
4	epithelial	epithelial	B-NP	JJ	B-cell_type	5	NMOD
5	cells	cell	I-NP	NNS	I-cell_type	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	11	NMOD
8	rat	rat	I-NP	NN	O	11	NMOD
9	prostate	prostate	I-NP	NN	O	11	NMOD
10	lateral	lateral	I-NP	JJ	O	11	NMOD
11	lobe	lobe	I-NP	NN	O	6	PMOD
12	in	in	B-PP	IN	O	1	VMOD
13	experimental	experimental	B-NP	JJ	O	14	NMOD
14	hyperprolactinemia	hyperprolactinemia	I-NP	NN	O	12	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	haloperidol	haloperidol	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	examine	examine	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	influence	influence	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	hyperprolactinemia	hyperprolactinemia	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	8	P
14	induced	induce	B-VP	VBN	O	8	VMOD
15	by	by	B-PP	IN	O	14	VMOD
16	haloperidol	haloperidol	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	19	DEP
18	HAL	HAL	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	on	on	B-PP	IN	O	14	VMOD
21	age	age	B-NP	NN	O	26	NMOD
22	related	relate	I-NP	VBN	O	26	NMOD
23	morphology	morphology	I-NP	NN	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	function	function	I-NP	NN	O	26	NMOD
26	changes	change	I-NP	NNS	O	20	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	epithelial	epithelial	B-NP	JJ	B-cell_type	29	NMOD
29	cells	cell	I-NP	NNS	I-cell_type	27	PMOD
30	in	in	B-PP	IN	O	26	NMOD
31	rat	rat	B-NP	NN	O	34	NMOD
32	prostate	prostate	I-NP	NN	O	34	NMOD
33	lateral	lateral	I-NP	JJ	O	34	NMOD
34	lobe	lobe	I-NP	NN	O	30	PMOD
35	.	.	O	.	O	6	P

1	Does	Do	O	VBZ	O	0	ROOT
2	supplemental	supplemental	B-NP	JJ	O	4	NMOD
3	vitamin	vitamin	I-NP	NN	O	4	NMOD
4	C	C	I-NP	NN	O	5	SUB
5	increase	increase	B-VP	VBP	O	1	VMOD
6	cardiovascular	cardiovascular	B-NP	JJ	O	8	NMOD
7	disease	disease	I-NP	NN	O	8	NMOD
8	risk	risk	I-NP	NN	O	5	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	women	woman	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	diabetes	diabetes	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	1	P

1	These	These	B-NP	DT	O	2	NMOD
2	observations	observation	I-NP	NNS	O	3	SUB
3	led	lead	B-VP	VBD	O	0	ROOT
4	us	us	B-NP	PRP	O	6	SUB
5	to	to	B-VP	TO	O	6	VMOD
6	hypothesize	hypothesize	I-VP	VB	O	3	VMOD
7	that	that	B-SBAR	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	high	high	I-NP	JJ	O	10	NMOD
10	intake	intake	I-NP	NN	O	17	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	vitamin	vitamin	B-NP	NN	O	13	NMOD
13	C	C	I-NP	NN	O	11	PMOD
14	in	in	B-PP	IN	O	10	NMOD
15	diabetic	diabetic	B-NP	JJ	O	16	NMOD
16	persons	person	I-NP	NNS	O	14	PMOD
17	might	might	B-VP	MD	O	7	SBAR
18	promote	promote	I-VP	VB	O	17	VC
19	atherosclerosis	atherosclerosis	B-NP	NN	O	18	OBJ
20	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	objective	objective	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	1	NMOD
6	to	to	B-VP	TO	O	7	VMOD
7	examine	examine	I-VP	VB	O	5	PRD
8	the	the	B-NP	DT	O	9	NMOD
9	relation	relation	I-NP	NN	O	7	OBJ
10	between	between	B-PP	IN	O	9	NMOD
11	vitamin	vitamin	B-NP	NN	O	13	NMOD
12	C	C	I-NP	NN	O	13	NMOD
13	intake	intake	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	mortality	mortality	I-NP	NN	O	10	PMOD
16	from	from	B-PP	IN	O	15	NMOD
17	cardiovascular	cardiovascular	B-NP	JJ	O	18	NMOD
18	disease	disease	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	5	P

1	DESIGN	DESIGN	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	studied	study	B-VP	VBD	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	relation	relation	I-NP	NN	O	4	OBJ
7	between	between	B-PP	IN	O	6	NMOD
8	vitamin	vitamin	B-NP	NN	O	10	NMOD
9	C	C	I-NP	NN	O	10	NMOD
10	intake	intake	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	mortality	mortality	I-NP	NN	O	25	NMOD
13	from	from	B-PP	IN	O	12	NMOD
14	total	total	B-NP	JJ	O	16	NMOD
15	cardiovascular	cardiovascular	I-NP	JJ	O	16	NMOD
16	disease	disease	I-NP	NN	O	13	PMOD
17	(	(	O	(	O	21	DEP
18	n	n	B-NP	NN	O	20	SUB
19	=	=	B-VP	SYM	O	20	VMOD
20	281	281	B-NP	CD	O	21	DEP
21	)	)	O	)	O	12	NMOD
22	,	,	O	,	O	25	P
23	coronary	coronary	B-NP	JJ	O	25	NMOD
24	artery	artery	I-NP	NN	O	25	NMOD
25	disease	disease	I-NP	NN	O	7	PMOD
26	(	(	O	(	O	30	DEP
27	n	n	B-NP	NN	O	29	SUB
28	=	=	B-VP	SYM	O	29	VMOD
29	175	175	B-NP	CD	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	,	,	O	,	O	33	P
32	and	and	O	CC	O	33	NMOD
33	stroke	stroke	B-NP	NN	O	4	VMOD
34	(	(	O	(	O	38	DEP
35	n	n	B-NP	NN	O	38	DEP
36	=	=	B-VP	SYM	O	35	NMOD
37	57	57	B-NP	CD	O	36	AMOD
38	)	)	O	)	O	33	NMOD
39	in	in	B-PP	IN	O	33	NMOD
40	1923	1923	B-NP	CD	O	42	NMOD
41	postmenopausal	postmenopausal	I-NP	JJ	O	42	NMOD
42	women	woman	I-NP	NNS	O	39	PMOD
43	who	who	B-NP	WP	O	42	NMOD
44	reported	report	B-VP	VBD	O	43	SBAR
45	being	be	I-VP	VBG	O	44	VC
46	diabetic	diabetic	B-ADJP	JJ	O	45	PRD
47	at	at	B-PP	IN	O	46	AMOD
48	baseline	baseline	B-NP	NN	O	47	PMOD
49	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	41	SUB
2	:	:	O	:	O	1	P
3	After	After	B-PP	IN	O	41	VMOD
4	adjustment	adjustment	B-NP	NN	O	3	PMOD
5	for	for	B-PP	IN	O	4	NMOD
6	cardiovascular	cardiovascular	B-NP	JJ	B-protein	9	NMOD
7	disease	disease	I-NP	NN	I-protein	9	NMOD
8	risk	risk	I-NP	NN	I-protein	9	NMOD
9	factors	factor	I-NP	NNS	I-protein	11	NMOD
10	,	,	O	,	O	11	P
11	type	type	B-NP	NN	O	5	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	diabetes	diabetes	B-NP	NN	O	14	NMOD
14	medication	medication	I-NP	NN	O	12	PMOD
15	used	use	B-VP	VBN	O	14	NMOD
16	,	,	O	,	O	41	P
17	duration	duration	B-NP	NN	O	35	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	diabetes	diabetes	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	35	P
21	and	and	O	CC	O	22	NMOD
22	intakes	intake	B-NP	NNS	O	35	NMOD
23	of	of	B-PP	IN	O	22	NMOD
24	folate	folate	B-NP	NN	O	30	NMOD
25	,	,	O	,	O	30	P
26	vitamin	vitamin	B-NP	NN	O	27	NMOD
27	E	E	I-NP	NN	O	30	NMOD
28	,	,	O	,	O	30	P
29	and	and	O	CC	O	30	NMOD
30	beta-carotene	beta-carotene	B-NP	NN	B-DNA	23	PMOD
31	,	,	O	,	O	35	P
32	the	the	B-NP	DT	O	35	NMOD
33	adjusted	adjust	I-NP	VBN	O	35	NMOD
34	relative	relative	I-NP	JJ	O	35	NMOD
35	risks	risk	I-NP	NNS	O	41	SUB
36	of	of	B-PP	IN	O	35	NMOD
37	total	total	B-NP	JJ	O	40	NMOD
38	cardiovascular	cardiovascular	I-NP	JJ	O	40	NMOD
39	disease	disease	I-NP	NN	O	40	NMOD
40	mortality	mortality	I-NP	NN	O	36	PMOD
41	were	be	B-VP	VBD	O	0	ROOT
42	1.0	1.0	B-NP	CD	O	51	NMOD
43	,	,	I-NP	,	O	51	P
44	0.97	0.97	I-NP	CD	O	51	NMOD
45	,	,	I-NP	,	O	51	P
46	1.11	1.11	I-NP	CD	O	51	NMOD
47	,	,	I-NP	,	O	51	P
48	1.47	1.47	I-NP	CD	O	51	NMOD
49	,	,	O	,	O	51	P
50	and	and	O	CC	O	51	NMOD
51	1.84	1.84	B-NP	CD	O	41	PRD
52	(	(	O	(	O	58	DEP
53	P	P	B-NP	NN	O	58	DEP
54	for	for	B-PP	IN	O	53	NMOD
55	trend	trend	B-NP	NN	O	54	PMOD
56	<	<	B-NP	SYM	O	55	NMOD
57	0.01	0.01	I-NP	CD	O	56	AMOD
58	)	)	O	)	O	51	NMOD
59	across	across	B-PP	IN	O	51	NMOD
60	quintiles	quintile	B-NP	NNS	O	59	PMOD
61	of	of	B-PP	IN	O	60	NMOD
62	total	total	B-NP	JJ	O	65	NMOD
63	vitamin	vitamin	I-NP	NN	O	65	NMOD
64	C	C	I-NP	NN	O	65	NMOD
65	intake	intake	I-NP	NN	O	61	PMOD
66	from	from	B-PP	IN	O	65	NMOD
67	food	food	B-NP	NN	O	69	NMOD
68	and	and	I-NP	CC	O	69	NMOD
69	supplements	supplement	I-NP	NNS	O	66	PMOD
70	.	.	O	.	O	41	P

1	Vitamin	Vitamin	B-NP	NN	O	3	NMOD
2	C	C	I-NP	NN	O	3	NMOD
3	intake	intake	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	unrelated	unrelated	B-ADJP	JJ	O	4	PRD
6	to	to	B-PP	TO	O	5	AMOD
7	mortality	mortality	B-NP	NN	O	6	PMOD
8	from	from	B-PP	IN	O	7	NMOD
9	cardiovascular	cardiovascular	B-NP	JJ	O	10	NMOD
10	disease	disease	I-NP	NN	O	8	PMOD
11	in	in	B-PP	IN	O	7	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	nondiabetic	nondiabetic	I-NP	JJ	O	14	NMOD
14	subjects	subject	I-NP	NNS	O	11	PMOD
15	at	at	B-PP	IN	O	7	NMOD
16	baseline	baseline	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	4	P

1	Absolute	Absolute	B-NP	JJ	O	3	AMOD
2	and	and	I-NP	CC	O	3	AMOD
3	attributable	attributable	I-NP	JJ	O	4	NMOD
4	risk	risk	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	venous	venous	B-NP	JJ	O	7	NMOD
7	thromboembolism	thromboembolism	I-NP	NN	O	5	PMOD
8	in	in	B-PP	IN	O	4	NMOD
9	women	woman	B-NP	NNS	O	8	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	combined	combine	B-NP	VBN	O	15	NMOD
12	cyproterone	cyproterone	I-NP	NN	O	13	NMOD
13	acetate	acetate	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	ethinylestradiol	ethinylestradiol	I-NP	NN	O	10	PMOD
16	.	.	O	.	O	4	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	achieve	achieve	I-VP	VB	O	1	NMOD
5	absolute	absolute	B-NP	JJ	O	7	NMOD
6	risk	risk	I-NP	NN	O	7	NMOD
7	estimates	estimate	I-NP	NNS	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	venous	venous	B-NP	JJ	O	10	NMOD
10	thromboembolism	thromboembolism	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	VTE	VTE	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	among	among	B-PP	IN	O	7	NMOD
15	women	woman	B-NP	NNS	O	14	PMOD
16	on	on	B-PP	IN	O	15	NMOD
17	cyproterone	cyproterone	B-NP	NN	O	18	NMOD
18	acetate	acetate	I-NP	NN	O	20	NMOD
19	plus	plus	O	CC	O	20	NMOD
20	ethinylestradiol	ethinylestradiol	B-NP	NN	O	16	PMOD
21	(	(	O	(	O	23	DEP
22	CPA/EE	CPA/EE	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	,	,	O	,	O	35	P
25	and	and	O	CC	O	35	NMOD
26	among	among	B-PP	IN	O	25	PRD
27	women	woman	B-NP	NNS	O	26	PMOD
28	on	on	B-PP	IN	O	27	NMOD
29	combined	combined	B-NP	JJ	O	31	NMOD
30	oral	oral	I-NP	JJ	O	31	NMOD
31	contraceptives	contraceptive	I-NP	NNS	O	28	PMOD
32	(	(	O	(	O	34	DEP
33	COCs	COC	B-NP	NNS	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	.	.	O	.	O	4	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	During	During	B-PP	IN	O	13	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	time	time	I-NP	NN	O	6	NMOD
6	frame	frame	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	study	study	I-NP	NN	O	7	PMOD
10	,	,	O	,	O	13	P
11	330	330	B-NP	CD	O	12	NMOD
12	women	woman	I-NP	NNS	O	13	SUB
13	were	be	B-VP	VBD	O	1	NMOD
14	found	find	I-VP	VBN	O	13	VC
15	to	to	I-VP	TO	O	16	VMOD
16	have	have	I-VP	VB	O	14	VMOD
17	had	have	I-VP	VBN	O	16	VC
18	VTE	VTE	B-NP	NNP	O	17	OBJ
19	while	while	B-SBAR	IN	O	17	VMOD
20	on	on	B-PP	IN	O	19	PMOD
21	COCs	COC	B-NP	NNS	B-cell_type	20	PMOD
22	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	4	NMOD
2	corresponding	correspond	I-NP	VBG	O	4	NMOD
3	absolute	absolute	I-NP	JJ	O	4	NMOD
4	risk	risk	I-NP	NN	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	VTE	VTE	B-NP	NN	B-protein	5	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	3.4	3.4	B-NP	CD	O	7	PRD
9	(	(	O	(	O	13	DEP
10	range	range	B-NP	NN	O	12	NMOD
11	,	,	O	,	O	12	P
12	3.1-3.8	3.1-3.8	B-NP	CD	O	13	DEP
13	)	)	O	)	O	8	NMOD
14	per	per	B-PP	IN	O	8	NMOD
15	10	10	B-NP	CD	O	18	NMOD
16	000	000	I-NP	CD	O	17	AMOD
17	women	woman	I-NP	NNS	O	18	NMOD
18	years	year	I-NP	NNS	O	14	PMOD
19	among	among	B-PP	IN	O	7	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	women	woman	I-NP	NNS	O	19	PMOD
22	on	on	B-PP	IN	O	21	NMOD
23	COCs	COC	B-NP	NNS	B-cell_type	22	PMOD
24	,	,	O	,	O	25	P
25	4.2	4.2	B-NP	CD	O	21	NMOD
26	(	(	O	(	O	30	DEP
27	range	range	B-NP	NN	O	29	NMOD
28	,	,	O	,	O	29	P
29	3.2-5.2	3.2-5.2	B-NP	CD	O	30	DEP
30	)	)	O	)	O	25	NMOD
31	per	per	B-PP	IN	O	25	NMOD
32	10	10	B-NP	CD	O	35	NMOD
33	000	000	I-NP	CD	O	35	NMOD
34	women	woman	I-NP	NNS	O	35	NMOD
35	years	year	I-NP	NNS	O	31	PMOD
36	among	among	B-PP	IN	O	25	NMOD
37	women	woman	B-NP	NNS	O	36	PMOD
38	on	on	B-PP	IN	O	37	NMOD
39	levonorgestrel-containing	levonorgestrel-containing	B-NP	JJ	B-cell_type	40	NMOD
40	COCs	COC	I-NP	NNS	I-cell_type	38	PMOD
41	,	,	O	,	O	59	P
42	and	and	O	CC	O	59	NMOD
43	3.1	3.1	B-NP	CD	O	42	PRD
44	(	(	O	(	O	48	DEP
45	range	range	B-NP	NN	O	47	NMOD
46	,	,	O	,	O	47	P
47	1.3-4.9	1.3-4.9	B-NP	CD	O	48	DEP
48	)	)	O	)	O	43	NMOD
49	per	per	B-PP	IN	O	43	NMOD
50	10	10	B-NP	CD	O	53	NMOD
51	000	000	I-NP	CD	O	52	AMOD
52	women	woman	I-NP	NNS	O	53	NMOD
53	years	year	I-NP	NNS	O	49	PMOD
54	among	among	B-PP	IN	O	43	NMOD
55	the	the	B-NP	DT	O	56	NMOD
56	women	woman	I-NP	NNS	O	54	PMOD
57	on	on	B-PP	IN	O	56	NMOD
58	CPA/EE	CPA/EE	B-NP	NN	B-protein	57	PMOD
59	.	.	O	.	O	25	P

1	Effect	Effect	B-NP	NN	O	11	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	lindane	lindane	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	hepatic	hepatic	B-NP	JJ	O	9	NMOD
6	and	and	I-NP	CC	O	9	NMOD
7	brain	brain	I-NP	NN	O	9	NMOD
8	cytochrome	cytochrome	I-NP	NN	O	9	NMOD
9	P450s	P450	I-NP	NNS	O	4	PMOD
10	and	and	I-NP	CC	O	11	NMOD
11	influence	influence	I-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	P450	P450	B-NP	NN	B-protein	14	NMOD
14	modulation	modulation	I-NP	NN	O	12	PMOD
15	in	in	B-PP	IN	O	11	NMOD
16	lindane	lindane	B-NP	NN	O	18	NMOD
17	induced	induced	I-NP	JJ	O	18	NMOD
18	neurotoxicity	neurotoxicity	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	11	P

1	Induction	Induction	B-NP	NN	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	further	further	I-VP	RBR	O	3	VMOD
5	shown	show	I-VP	VBN	O	3	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	while	while	B-SBAR	IN	O	58	VMOD
8	pretreatment	pretreatment	B-NP	NN	O	54	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	3-methylcholanthrene	3-methylcholanthrene	B-NP	NN	O	20	SUB
11	(	(	O	(	O	13	DEP
12	MC	MC	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	,	,	O	,	O	20	P
15	an	an	B-NP	DT	O	16	NMOD
16	inducer	inducer	I-NP	NN	O	20	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	P4501A1/1A2	P4501A1/1A2	B-NP	NN	B-protein	17	PMOD
19	,	,	O	,	O	16	P
20	did	do	B-VP	VBD	O	9	SBAR
21	not	not	I-VP	RB	O	20	VMOD
22	produce	produce	I-VP	VB	O	20	VC
23	any	any	B-NP	DT	O	25	NMOD
24	significant	significant	I-NP	JJ	O	25	NMOD
25	effect	effect	I-NP	NN	O	22	OBJ
26	in	in	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	incidence	incidence	I-NP	NN	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	lindane	lindane	B-NP	NN	O	32	NMOD
31	induced	induce	I-NP	VBN	O	32	NMOD
32	convulsions	convulsion	I-NP	NNS	O	29	PMOD
33	,	,	O	,	O	54	P
34	pretreatment	pretreatment	B-NP	NN	O	54	SUB
35	with	with	B-PP	IN	O	34	NMOD
36	phenobarbital	phenobarbital	B-NP	NN	O	42	NMOD
37	(	(	O	(	O	39	DEP
38	PB	PB	B-NP	NN	O	39	DEP
39	)	)	O	)	O	36	NMOD
40	,	,	O	,	O	42	P
41	an	an	B-NP	DT	O	42	NMOD
42	inducer	inducer	I-NP	NN	O	35	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	P450	P450	B-NP	NN	B-protein	45	NMOD
45	2B1/2B2	2B1/2B2	I-NP	NN	I-protein	47	NMOD
46	or	or	I-NP	CC	O	47	NMOD
47	ethanol	ethanol	I-NP	NN	O	50	NMOD
48	,	,	O	,	O	50	P
49	an	an	B-NP	DT	O	50	NMOD
50	inducer	inducer	I-NP	NN	O	43	PMOD
51	of	of	B-PP	IN	O	50	NMOD
52	P450	P450	B-NP	NN	B-protein	53	NMOD
53	2E1	2E1	I-NP	NN	O	51	PMOD
54	catalysed	catalyse	B-VP	VBD	O	7	SBAR
55	reactions	reaction	B-NP	NNS	O	54	OBJ
56	,	,	O	,	O	58	P
57	significantly	significantly	B-VP	RB	O	58	VMOD
58	increased	increase	I-VP	VBD	O	6	SBAR
59	the	the	B-NP	DT	O	60	NMOD
60	incidence	incidence	I-NP	NN	O	58	OBJ
61	of	of	B-PP	IN	O	60	NMOD
62	lindane	lindane	B-NP	NN	O	64	NMOD
63	induced	induce	I-NP	VBN	O	64	NMOD
64	convulsions	convulsion	I-NP	NNS	O	61	PMOD
65	.	.	O	.	O	3	P

1	Seizure	Seizure	B-NP	NN	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	sleep	sleep	B-NP	NN	O	5	NMOD
5	deprivation	deprivation	I-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	sustained-release	sustained-release	B-NP	JJ	O	8	NMOD
8	bupropion	bupropion	I-NP	NN	O	3	PMOD
9	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	3	NMOD
2	case	case	I-NP	NN	O	3	NMOD
3	report	report	I-NP	NN	O	4	SUB
4	describes	describe	B-VP	VBZ	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	generalized	generalize	I-NP	VBN	O	7	NMOD
7	seizure	seizure	I-NP	NN	O	4	OBJ
8	associated	associate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	sustained-release	sustained-release	B-NP	JJ	O	12	NMOD
11	bupropion	bupropion	I-NP	NN	O	12	NMOD
12	use	use	I-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	sleep	sleep	B-NP	NN	O	15	NMOD
15	deprivation	deprivation	I-NP	NN	O	9	PMOD
16	.	.	O	.	O	4	P

1	After	After	B-PP	IN	O	10	VMOD
2	5	5	B-NP	CD	O	3	NMOD
3	weeks	week	I-NP	NNS	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	bupropion	bupropion	B-NP	NN	O	6	NMOD
6	use	use	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	10	P
8	the	the	B-NP	DT	O	9	NMOD
9	subject	subject	I-NP	NN	O	10	SUB
10	experienced	experience	B-VP	VBD	O	0	ROOT
11	a	a	B-NP	DT	O	15	NMOD
12	generalized	generalize	I-NP	VBN	O	15	NMOD
13	tonic	tonic	I-NP	JJ	O	15	NMOD
14	clonic	clonic	I-NP	JJ	O	15	NMOD
15	seizure	seizure	I-NP	NN	O	10	OBJ
16	after	after	B-PP	IN	O	10	VMOD
17	staying	stay	B-VP	VBG	O	16	PMOD
18	up	up	B-PRT	RP	O	17	VMOD
19	nearly	nearly	B-NP	RB	O	20	AMOD
20	all	all	I-NP	DT	O	22	NMOD
21	night	night	I-NP	NN	O	22	NMOD
22	packing	packing	I-NP	NN	O	17	OBJ
23	and	and	O	CC	O	10	VMOD
24	moving	move	B-VP	VBG	O	10	VMOD
25	to	to	B-PP	TO	O	24	VMOD
26	a	a	B-NP	DT	O	28	NMOD
27	new	new	I-NP	JJ	O	28	NMOD
28	residence	residence	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	10	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	We	We	B-NP	PRP	O	4	SUB
4	conducted	conduct	B-VP	VBD	O	1	NMOD
5	a	a	B-NP	DT	O	13	NMOD
6	randomized	randomize	I-NP	VBN	O	12	AMOD
7	,	,	I-NP	,	O	12	P
8	double-blind	double-blind	I-NP	JJ	O	12	AMOD
9	,	,	I-NP	,	O	12	P
10	prospective	prospective	I-NP	JJ	O	12	AMOD
11	,	,	I-NP	,	O	12	P
12	multicenter	multicenter	I-NP	JJ	O	13	NMOD
13	study	study	I-NP	NN	O	4	OBJ
14	comparing	compare	B-VP	VBG	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	nephrotoxic	nephrotoxic	I-NP	JJ	O	17	NMOD
17	effects	effect	I-NP	NNS	O	14	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	an	an	B-NP	DT	O	28	NMOD
20	iso-osmolar	iso-osmolar	I-NP	JJ	O	28	NMOD
21	,	,	I-NP	,	O	28	P
22	dimeric	dimeric	I-NP	JJ	O	28	NMOD
23	,	,	I-NP	,	O	28	P
24	nonionic	nonionic	I-NP	JJ	O	26	NMOD
25	contrast	contrast	I-NP	NN	O	26	NMOD
26	medium	medium	I-NP	NN	O	28	NMOD
27	,	,	O	,	O	28	P
28	iodixanol	iodixanol	B-NP	NN	O	18	PMOD
29	,	,	O	,	O	4	P
30	with	with	B-PP	IN	O	4	VMOD
31	those	those	B-NP	DT	O	30	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	a	a	B-NP	DT	O	40	NMOD
34	low-osmolar	low-osmolar	I-NP	JJ	O	40	NMOD
35	,	,	I-NP	,	O	40	P
36	nonionic	nonionic	I-NP	JJ	O	40	NMOD
37	,	,	I-NP	,	O	40	P
38	monomeric	monomeric	I-NP	JJ	O	40	NMOD
39	contrast	contrast	I-NP	NN	O	40	NMOD
40	medium	medium	I-NP	NN	O	42	NMOD
41	,	,	O	,	O	42	P
42	iohexol	iohexol	B-NP	NN	O	32	PMOD
43	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	involved	involve	B-VP	VBD	O	0	ROOT
4	129	129	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	OBJ
6	with	with	B-PP	IN	O	5	NMOD
7	diabetes	diabetes	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	serum	serum	B-NP	NN	O	11	NMOD
10	creatinine	creatinine	I-NP	NN	O	11	NMOD
11	concentrations	concentration	I-NP	NNS	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	1.5	1.5	B-NP	CD	O	15	AMOD
14	to	to	I-NP	TO	O	15	AMOD
15	3.5	3.5	I-NP	CD	O	16	NMOD
16	mg	mg	I-NP	NN	O	12	PMOD
17	per	per	B-PP	IN	O	5	NMOD
18	deciliter	deciliter	B-NP	NN	O	17	PMOD
19	who	who	B-NP	WP	O	5	NMOD
20	underwent	undergo	B-VP	VBD	O	19	SBAR
21	coronary	coronary	B-NP	JJ	O	24	NMOD
22	or	or	I-NP	CC	O	24	NMOD
23	aortofemoral	aortofemoral	I-NP	JJ	O	24	NMOD
24	angiography	angiography	I-NP	NN	O	20	OBJ
25	.	.	O	.	O	3	P

1	Experimental	Experimental	B-NP	JJ	O	3	NMOD
2	cranial	cranial	I-NP	JJ	O	3	NMOD
3	pain	pain	I-NP	NN	O	10	NMOD
4	elicited	elicit	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	capsaicin	capsaicin	B-NP	NN	O	5	PMOD
7	:	:	O	:	O	3	P
8	a	a	B-NP	DT	O	10	NMOD
9	PET	PET	I-NP	NN	O	10	NMOD
10	study	study	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	3	NMOD
2	small	small	I-NP	JJ	O	3	NMOD
3	amount	amount	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	capsaicin	capsaicin	B-NP	NN	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	administered	administer	I-VP	VBN	O	6	VC
8	subcutaneously	subcutaneously	B-ADVP	RB	O	7	VMOD
9	in	in	B-PP	IN	O	7	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	right	right	I-NP	JJ	O	12	NMOD
12	forehead	forehead	I-NP	NN	O	9	PMOD
13	to	to	B-VP	TO	O	14	VMOD
14	evoke	evoke	I-VP	VB	O	6	VMOD
15	a	a	B-NP	DT	O	18	NMOD
16	burning	burn	I-NP	VBG	O	18	NMOD
17	painful	painful	I-NP	JJ	O	18	NMOD
18	sensation	sensation	I-NP	NN	O	14	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	first	first	I-NP	JJ	O	22	NMOD
22	division	division	I-NP	NN	O	19	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	trigeminal	trigeminal	I-NP	JJ	O	26	NMOD
26	nerve	nerve	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	6	P

1	Neuroleptic	Neuroleptic	B-NP	JJ	O	3	NMOD
2	malignant	malignant	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	0	ROOT
4	with	with	B-PP	IN	O	3	NMOD
5	risperidone	risperidone	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	3	P

1	Neuroleptic	Neuroleptic	B-NP	JJ	O	3	NMOD
2	malignant	malignant	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	thought	think	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	be	be	I-VP	VB	O	5	VMOD
8	a	a	B-NP	DT	O	9	NMOD
9	result	result	I-NP	NN	O	7	PRD
10	of	of	B-PP	IN	O	9	NMOD
11	dopamine	dopamine	B-NP	NN	O	14	NMOD
12	D2	D2	I-NP	NN	O	14	NMOD
13	receptor	receptor	I-NP	NN	O	14	NMOD
14	blockade	blockade	I-NP	NN	O	10	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	striatum	striatum	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	basal	basal	I-NP	JJ	B-cell_type	21	NMOD
21	ganglia	ganglia	I-NP	NNS	I-cell_type	18	PMOD
22	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	high	high	I-NP	JJ	O	3	NMOD
3	ratio	ratio	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	believed	believe	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	impart	impart	I-VP	VB	O	5	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	low	low	I-NP	JJ	O	10	NMOD
10	frequency	frequency	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	extrapyramidal	extrapyramidal	B-NP	JJ	O	13	NMOD
13	symptoms	symptom	I-NP	NNS	O	11	PMOD
14	with	with	B-PP	IN	O	7	VMOD
15	risperidone	risperidone	B-NP	NN	O	14	PMOD
16	at	at	B-PP	IN	O	15	NMOD
17	low	low	B-NP	JJ	O	18	NMOD
18	dosages	dosage	I-NP	NNS	O	16	PMOD
19	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	73-year-old	73-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	4	SUB
4	developed	develop	B-VP	VBD	O	0	ROOT
5	neuroleptic	neuroleptic	B-NP	JJ	O	7	NMOD
6	malignant	malignant	I-NP	JJ	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	4	OBJ
8	after	after	B-PP	IN	O	7	NMOD
9	monotherapy	monotherapy	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	risperidone	risperidone	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	4	P

1	Plasma	Plasma	B-NP	NN	O	2	NMOD
2	concentration	concentration	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	urine	urine	B-NP	NN	O	5	NMOD
5	excretion	excretion	I-NP	NN	O	11	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	renin-angiotensin	renin-angiotensin	I-NP	NN	B-protein	10	NMOD
9	system	system	I-NP	NN	I-protein	10	NMOD
10	proteins	protein	I-NP	NNS	I-protein	6	PMOD
11	are	be	B-VP	VBP	O	0	ROOT
12	altered	alter	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	rats	rat	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	nephrotic	nephrotic	B-NP	JJ	O	17	NMOD
17	syndrome	syndrome	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	20	DEP
19	NS	NS	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	.	.	O	.	O	11	P

1	NS	NS	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	single	single	I-NP	JJ	O	7	NMOD
7	injection	injection	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	puromycin	puromycin	B-NP	NN	O	10	NMOD
10	amino-nucleoside	amino-nucleoside	I-NP	NN	O	8	PMOD
11	(	(	O	(	O	13	DEP
12	PAN	PAN	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	31	VMOD
2	a	a	B-NP	DT	O	5	NMOD
3	great	great	I-NP	JJ	O	5	NMOD
4	urinary	urinary	I-NP	JJ	O	5	NMOD
5	excretion	excretion	I-NP	NN	O	9	NMOD
6	and	and	O	CC	O	9	NMOD
7	half-normal	half-normal	B-NP	JJ	O	9	NMOD
8	plasma	plasma	I-NP	NN	O	9	NMOD
9	levels	level	I-NP	NNS	O	12	SUB
10	of	of	B-PP	IN	O	9	NMOD
11	Ao	Ao	B-NP	NNP	O	10	PMOD
12	were	be	B-VP	VBD	O	1	SBAR
13	observed	observe	I-VP	VBN	O	12	VC
14	on	on	B-PP	IN	O	13	VMOD
15	day	day	B-NP	NN	O	14	PMOD
16	6	6	I-NP	CD	O	15	NMOD
17	after	after	B-PP	IN	O	13	VMOD
18	PAN	PAN	B-NP	NN	O	19	NMOD
19	injection	injection	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	31	P
21	when	when	B-ADVP	WRB	O	31	VMOD
22	NS	NS	B-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	21	SBAR
24	clearly	clearly	I-VP	RB	O	23	VMOD
25	established	establish	I-VP	VBN	O	23	VC
26	,	,	O	,	O	31	P
27	hepatic	hepatic	B-NP	JJ	B-RNA	29	NMOD
28	Ao	Ao	I-NP	NN	I-RNA	29	NMOD
29	mRNA	mRNA	I-NP	NN	I-RNA	30	NMOD
30	levels	level	I-NP	NNS	O	31	SUB
31	did	do	B-VP	VBD	O	0	ROOT
32	not	not	I-VP	RB	O	31	VMOD
33	change	change	I-VP	VB	O	31	VC
34	.	.	O	.	O	31	P

1	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	4	NMOD
2	associated	associate	I-NP	VBN	O	4	NMOD
3	bladder	bladder	I-NP	NN	O	4	NMOD
4	cancer	cancer	I-NP	NN	O	9	NMOD
5	--	--	O	:	O	4	P
6	a	a	B-NP	DT	O	9	NMOD
7	highly	highly	I-NP	RB	O	8	AMOD
8	aggressive	aggressive	I-NP	JJ	O	9	NMOD
9	disease	disease	I-NP	NN	O	11	NMOD
10	:	:	O	:	O	11	P
11	analysis	analysis	B-NP	NN	O	0	ROOT
12	of	of	B-PP	IN	O	11	NMOD
13	12	12	B-NP	CD	O	14	NMOD
14	cases	case	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	11	P

1	PURPOSE	PURPOSE	B-NP	NN	O	4	SUB
2	:	:	O	:	O	4	P
3	We	We	B-NP	PRP	O	4	SUB
4	gained	gain	B-VP	VBD	O	0	ROOT
5	knowledge	knowledge	B-NP	NN	O	4	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	etiology	etiology	I-NP	NN	O	12	NMOD
9	,	,	I-NP	,	O	12	P
10	treatment	treatment	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	prevention	prevention	I-NP	NN	O	6	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	cyclophosphamide	cyclophosphamide	B-NP	NN	O	17	NMOD
15	associated	associated	I-NP	JJ	O	17	NMOD
16	urothelial	urothelial	I-NP	JJ	O	17	NMOD
17	cancer	cancer	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	4	P

1	MATERIALS	MATERIALS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	The	The	B-NP	DT	O	7	NMOD
6	medical	medical	I-NP	JJ	O	7	NMOD
7	records	record	I-NP	NNS	O	25	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	6	6	B-NP	CD	O	10	NMOD
10	men	man	I-NP	NNS	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	6	6	B-NP	CD	O	13	NMOD
13	women	woman	I-NP	NNS	O	8	PMOD
14	(	(	O	(	O	19	DEP
15	mean	mean	B-NP	JJ	O	18	NMOD
16	age	age	I-NP	NN	O	18	NMOD
17	55	55	B-NP	CD	O	18	NMOD
18	years	year	I-NP	NNS	O	19	DEP
19	)	)	O	)	O	13	NMOD
20	with	with	B-PP	IN	O	7	NMOD
21	cyclophosphamide	cyclophosphamide	B-NP	NN	O	24	NMOD
22	associated	associate	I-NP	VBN	O	24	NMOD
23	bladder	bladder	I-NP	NN	O	24	NMOD
24	cancer	cancer	I-NP	NN	O	20	PMOD
25	were	be	B-VP	VBD	O	3	NMOD
26	reviewed	review	I-VP	VBN	O	25	VC
27	.	.	O	.	O	3	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	6	NMOD
4	associated	associate	I-NP	VBN	O	6	NMOD
5	bladder	bladder	I-NP	NN	O	6	NMOD
6	tumor	tumor	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	1	NMOD
8	an	an	B-NP	DT	O	10	NMOD
9	aggressive	aggressive	I-NP	JJ	O	10	NMOD
10	disease	disease	I-NP	NN	O	7	PRD
11	.	.	O	.	O	1	P

1	Leg	Leg	B-NP	NNP	O	4	NMOD
2	and	and	O	CC	O	4	NMOD
3	back	back	B-NP	JJ	O	4	NMOD
4	pain	pain	I-NP	NN	O	0	ROOT
5	after	after	B-PP	IN	O	4	NMOD
6	spinal	spinal	B-NP	JJ	O	7	NMOD
7	anaesthesia	anaesthesia	I-NP	NN	O	5	PMOD
8	involving	involve	B-VP	VBG	O	7	NMOD
9	hyperbaric	hyperbaric	B-NP	JJ	O	11	AMOD
10	5	5	I-NP	CD	O	11	AMOD
11	%	%	I-NP	NN	O	12	NMOD
12	lignocaine	lignocaine	I-NP	NN	O	8	OBJ
13	.	.	O	.	O	4	P

1	Five	Five	B-NP	CD	O	13	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	13	13	I-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	2	PMOD
6	(	(	O	(	O	9	DEP
7	38	38	B-NP	CD	O	8	NMOD
8	%	%	I-NP	NN	O	9	DEP
9	)	)	O	)	O	1	NMOD
10	with	with	B-PP	IN	O	1	NMOD
11	pain	pain	B-NP	NN	O	10	PMOD
12	and	and	O	CC	O	13	NMOD
13	seven	seven	B-NP	CD	O	0	ROOT
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	41	41	I-NP	CD	O	17	NMOD
17	patients	patient	I-NP	NNS	O	14	PMOD
18	(	(	O	(	O	21	DEP
19	17	17	B-NP	CD	O	20	NMOD
20	%	%	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	without	without	B-PP	IN	O	13	VMOD
23	pain	pain	B-NP	NN	O	22	PMOD
24	admitted	admit	B-VP	VBN	O	23	NMOD
25	to	to	B-PP	TO	O	24	VMOD
26	a	a	B-NP	DT	O	29	NMOD
27	high	high	I-NP	JJ	O	29	NMOD
28	alcohol	alcohol	I-NP	NN	O	29	NMOD
29	intake	intake	I-NP	NN	O	25	PMOD
30	,	,	O	,	O	29	P
31	which	which	B-NP	WDT	O	29	NMOD
32	might	might	B-VP	MD	O	31	SBAR
33	be	be	I-VP	VB	O	32	VC
34	a	a	B-NP	DT	O	36	NMOD
35	contributing	contribute	I-NP	VBG	O	36	NMOD
36	factor	factor	I-NP	NN	O	33	PRD
37	.	.	O	.	O	13	P

1	Acute	Acute	B-NP	JJ	O	4	NMOD
2	blood	blood	I-NP	NN	O	4	NMOD
3	pressure	pressure	I-NP	NN	O	4	NMOD
4	elevations	elevation	I-NP	NNS	O	0	ROOT
5	with	with	B-PP	IN	O	4	NMOD
6	caffeine	caffeine	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	men	man	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	borderline	borderline	B-NP	JJ	O	12	NMOD
11	systemic	systemic	I-NP	JJ	O	12	NMOD
12	hypertension	hypertension	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	Whether	Whether	B-PP	IN	O	12	SUB
2	the	the	B-NP	DT	O	4	NMOD
3	vasoconstrictive	vasoconstrictive	I-NP	JJ	O	4	NMOD
4	actions	action	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	caffeine	caffeine	B-NP	NN	O	5	PMOD
7	are	be	B-VP	VBP	O	1	SBAR
8	enhanced	enhance	I-VP	VBN	O	7	VC
9	in	in	B-PP	IN	O	8	VMOD
10	hypertensive	hypertensive	B-NP	JJ	O	11	NMOD
11	persons	person	I-NP	NNS	O	9	PMOD
12	has	have	B-VP	VBZ	O	0	ROOT
13	not	not	I-VP	RB	O	12	VMOD
14	been	be	I-VP	VBN	O	12	VC
15	demonstrated	demonstrate	I-VP	VBN	O	14	VC
16	.	.	O	.	O	12	P

1	Consequently	Consequently	B-ADVP	RB	O	3	VMOD
2	,	,	O	,	O	3	P
3	whereas	whereas	O	IN	O	20	VMOD
4	all	all	B-NP	DT	O	5	NMOD
5	participants	participant	I-NP	NNS	O	6	SUB
6	exhibited	exhibit	B-VP	VBD	O	3	SBAR
7	normotensive	normotensive	B-NP	JJ	O	8	NMOD
8	levels	level	I-NP	NNS	O	6	OBJ
9	during	during	B-PP	IN	O	6	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	resting	rest	I-NP	VBG	O	13	NMOD
12	predrug	predrug	I-NP	NN	O	13	NMOD
13	baseline	baseline	I-NP	NN	O	9	PMOD
14	,	,	O	,	O	20	P
15	33	33	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	20	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	borderline	borderline	B-NP	JJ	O	19	NMOD
19	subjects	subject	I-NP	NNS	O	17	PMOD
20	achieved	achieve	B-VP	VBD	O	0	ROOT
21	hypertensive	hypertensive	B-NP	JJ	O	23	NMOD
22	BP	BP	I-NP	NN	O	23	NMOD
23	levels	level	I-NP	NNS	O	20	OBJ
24	after	after	B-PP	IN	O	20	VMOD
25	caffeine	caffeine	B-NP	NN	O	26	NMOD
26	ingestion	ingestion	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	20	P

1	Thus	Thus	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	in	in	B-PP	IN	O	8	VMOD
4	borderline	borderline	B-NP	JJ	O	6	NMOD
5	hypertensive	hypertensive	I-NP	JJ	O	6	NMOD
6	men	man	I-NP	NNS	O	3	PMOD
7	,	,	O	,	O	8	P
8	exaggerated	exaggerate	B-VP	VBD	O	30	VMOD
9	responses	response	B-NP	NNS	O	8	OBJ
10	to	to	B-PP	TO	O	9	NMOD
11	caffeine	caffeine	B-NP	NN	O	10	PMOD
12	were	be	B-VP	VBD	O	8	VMOD
13	:	:	O	:	O	8	P
14	selective	selective	B-ADJP	JJ	O	8	VMOD
15	for	for	B-PP	IN	O	14	AMOD
16	diastolic	diastolic	B-NP	JJ	O	17	NMOD
17	BP	BP	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	8	P
19	consistent	consistent	B-ADJP	JJ	O	8	VMOD
20	with	with	B-PP	IN	O	19	AMOD
21	greater	great	B-NP	JJR	O	22	NMOD
22	vasoconstriction	vasoconstriction	I-NP	NN	O	20	PMOD
23	,	,	O	,	O	8	P
24	replicated	replicate	B-VP	VBN	O	8	VC
25	in	in	B-PP	IN	O	24	VMOD
26	2	2	B-NP	CD	O	27	NMOD
27	protocols	protocol	I-NP	NNS	O	25	PMOD
28	,	,	O	,	O	30	P
29	and	and	O	CC	O	30	NMOD
30	representative	representative	B-NP	NN	O	0	ROOT
31	of	of	B-PP	IN	O	30	NMOD
32	nearly	nearly	B-NP	RB	O	34	AMOD
33	all	all	I-NP	DT	O	34	AMOD
34	borderline	borderline	I-NP	JJ	O	35	NMOD
35	hypertensives	hypertensive	I-NP	NNS	O	31	PMOD
36	.	.	O	.	O	30	P

1	Hallucinations	Hallucination	B-NP	NNS	O	4	SUB
2	and	and	I-NP	CC	O	3	NMOD
3	ifosfamide	ifosfamide	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	neurotoxicity	neurotoxicity	B-NP	NN	O	4	OBJ
6	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Hallucinations	Hallucination	B-NP	NNS	O	10	SUB
4	as	as	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	symptom	symptom	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	central	central	B-NP	JJ	O	9	NMOD
9	neurotoxicity	neurotoxicity	I-NP	NN	O	7	PMOD
10	are	be	B-VP	VBP	O	1	NMOD
11	a	a	B-NP	DT	O	12	NMOD
12	known	known	I-NP	JJ	O	17	NMOD
13	but	but	O	CC	O	15	AMOD
14	poorly	poorly	B-NP	RB	O	15	AMOD
15	described	describe	I-NP	VBN	O	17	NMOD
16	side	side	I-NP	NN	O	17	NMOD
17	effect	effect	I-NP	NN	O	10	PRD
18	of	of	B-PP	IN	O	17	NMOD
19	ifosfamide	ifosfamide	B-NP	NN	O	18	PMOD
20	.	.	O	.	O	10	P

1	Most	Most	B-NP	JJS	O	2	NMOD
2	cases	case	I-NP	NNS	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	ifosfamide	ifosfamide	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	hallucinations	hallucination	I-NP	NNS	O	3	PMOD
7	have	have	B-VP	VBP	O	0	ROOT
8	been	be	I-VP	VBN	O	7	VC
9	reported	report	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	other	other	B-NP	JJ	O	14	NMOD
12	mental	mental	I-NP	JJ	O	14	NMOD
13	status	status	I-NP	NN	O	14	NMOD
14	changes	change	I-NP	NNS	O	10	PMOD
15	.	.	O	.	O	7	P

1	METHODS	METHODS	B-NP	NNS	O	5	VMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	authors	author	I-NP	NNS	O	5	SUB
5	interviewed	interview	B-VP	VBD	O	0	ROOT
6	six	six	B-NP	CD	O	7	NMOD
7	persons	person	I-NP	NNS	O	5	OBJ
8	with	with	B-PP	IN	O	7	NMOD
9	ifosfamide	ifosfamide	B-NP	NN	O	11	NMOD
10	induced	induce	I-NP	VBN	O	11	NMOD
11	hallucinations	hallucination	I-NP	NNS	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	presence	presence	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	18	NMOD
17	clear	clear	I-NP	JJ	O	18	NMOD
18	sensorium	sensorium	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	clinician	clinician	I-NP	NN	O	3	SUB
3	should	should	B-VP	MD	O	0	ROOT
4	be	be	I-VP	VB	O	3	VC
5	alerted	alert	I-VP	VBN	O	4	VC
6	for	for	B-PP	IN	O	5	VMOD
7	possible	possible	B-NP	JJ	O	10	NMOD
8	ifosfamide	ifosfamide	I-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	hallucinations	hallucination	I-NP	NNS	O	6	PMOD
11	,	,	O	,	O	3	P
12	which	which	B-NP	WDT	O	3	NMOD
13	may	may	B-VP	MD	O	12	SBAR
14	occur	occur	I-VP	VB	O	13	VC
15	without	without	B-PP	IN	O	14	VMOD
16	other	other	B-NP	JJ	O	17	NMOD
17	signs	sign	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	neurotoxicity.	neurotoxicity.	B-NP	NN	O	24	NMOD
20	"	"	I-NP	"	O	24	NMOD
21	Eyes-closed	Eyes-closed	I-NP	JJ	O	24	NMOD
22	"	"	I-NP	"	O	24	NMOD
23	hallucinatory	hallucinatory	I-NP	JJ	O	24	NMOD
24	experiences	experience	I-NP	NNS	O	18	PMOD
25	appear	appear	B-VP	VBP	O	3	VMOD
26	to	to	I-VP	TO	O	27	VMOD
27	be	be	I-VP	VB	O	25	VMOD
28	an	an	B-NP	DT	O	30	NMOD
29	unusual	unusual	I-NP	JJ	O	30	NMOD
30	feature	feature	I-NP	NN	O	27	PRD
31	of	of	B-PP	IN	O	30	NMOD
32	this	this	B-NP	DT	O	33	NMOD
33	presentation	presentation	I-NP	NN	O	31	PMOD
34	.	.	O	.	O	3	P

1	Chlorpropamide	Chlorpropamide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	optic	optic	B-NP	JJ	O	4	NMOD
4	neuropathy	neuropathy	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	65-year-old	65-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	13	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	adult-onset	adult-onset	B-NP	JJ	O	6	NMOD
6	diabetes	diabete	I-NP	NNS	O	4	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	chlorpropamide	chlorpropamide	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	12	DEP
11	Diabenese	Diabenese	B-NP	NN	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	had	have	B-VP	VBD	O	0	ROOT
14	a	a	B-NP	DT	O	17	NMOD
15	toxic	toxic	I-NP	JJ	O	16	AMOD
16	optic	optic	I-NP	JJ	O	17	NMOD
17	neuropathy	neuropathy	I-NP	NN	O	13	OBJ
18	that	that	B-NP	WDT	O	17	NMOD
19	resolved	resolve	B-VP	VBD	O	18	SBAR
20	with	with	B-PP	IN	O	19	VMOD
21	discontinuation	discontinuation	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	chlorpropamide	chlorpropamide	B-NP	NN	O	24	NMOD
24	therapy	therapy	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	13	P

1	Levodopa	Levodopa	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	dyskinesia	dyskinesia	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	thalamotomy	thalamotomy	I-NP	NN	O	2	OBJ
6	.	.	O	.	O	2	P

1	Levodopa	Levodopa	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	dyskinesia	dyskinesia	B-NP	NN	O	2	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	limbs	limb	I-NP	NNS	O	4	PMOD
7	in	in	B-PP	IN	O	2	VMOD
8	thirteen	thirteen	B-NP	CD	O	9	NMOD
9	cases	case	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	Parkinsonism	Parkinsonism	B-NP	NNP	O	10	PMOD
12	,	,	O	,	O	11	P
13	which	which	B-NP	WDT	O	11	NMOD
14	was	be	B-VP	VBD	O	13	SBAR
15	choreic	choreic	B-ADJP	JJ	O	19	AMOD
16	,	,	O	,	O	19	P
17	ballistic	ballistic	B-ADJP	JJ	O	19	AMOD
18	or	or	I-ADJP	CC	O	19	AMOD
19	dystonic	dystonic	I-ADJP	JJ	O	14	PRD
20	in	in	B-PP	IN	O	19	AMOD
21	type	type	B-NP	NN	O	20	PMOD
22	,	,	O	,	O	2	P
23	was	be	B-VP	VBD	O	2	VMOD
24	alleviated	alleviate	I-VP	VBN	O	23	VC
25	almost	almost	B-ADVP	RB	O	24	VMOD
26	completely	completely	I-ADVP	RB	O	25	AMOD
27	by	by	B-PP	IN	O	24	VMOD
28	stereotaxic	stereotaxic	B-NP	JJ	O	29	NMOD
29	surgery	surgery	I-NP	NN	O	27	PMOD
30	using	use	B-VP	VBG	O	23	VMOD
31	a	a	B-NP	DT	O	33	NMOD
32	microelectrode	microelectrode	I-NP	NN	O	33	NMOD
33	technique	technique	I-NP	NN	O	30	OBJ
34	for	for	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	36	NMOD
36	ventralis	ventralis	I-NP	NN	O	34	PMOD
37	oralis	orali	B-VP	VBZ	O	23	VMOD
38	anterior	anterior	B-NP	JJ	O	41	NMOD
39	and	and	I-NP	CC	O	41	NMOD
40	posterior	posterior	I-NP	JJ	O	41	NMOD
41	nuclei	nucleus	I-NP	NNS	O	37	OBJ
42	of	of	B-PP	IN	O	41	NMOD
43	the	the	B-NP	DT	O	44	NMOD
44	thalamus	thalamus	I-NP	NN	O	42	PMOD
45	,	,	O	,	O	37	P
46	but	but	O	CC	O	48	AMOD
47	much	much	B-ADJP	RB	O	48	AMOD
48	less	less	I-ADJP	JJR	O	37	VMOD
49	by	by	B-PP	IN	O	48	AMOD
50	the	the	B-NP	DT	O	53	NMOD
51	ventralis	ventralis	I-NP	NN	O	53	NMOD
52	intermedius	intermedius	I-NP	NN	O	53	NMOD
53	nucleus	nucleus	I-NP	NN	O	49	PMOD
54	.	.	O	.	O	2	P

1	Factors	Factor	B-NP	NNS	O	0	ROOT
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	nephrotoxicity	nephrotoxicity	B-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	clinical	clinical	B-NP	JJ	O	7	NMOD
7	outcome	outcome	I-NP	NN	O	3	PMOD
8	in	in	B-PP	IN	O	7	NMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	receiving	receive	B-VP	VBG	O	9	NMOD
11	amikacin	amikacin	B-NP	NN	O	10	OBJ
12	.	.	O	.	O	1	P

1	Data	Datum	B-NP	NNS	O	8	SUB
2	from	from	B-PP	IN	O	1	NMOD
3	60	60	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	PMOD
5	treated	treat	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	amikacin	amikacin	B-NP	NN	O	6	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	analyzed	analyze	I-VP	VBN	O	8	VC
10	for	for	B-PP	IN	O	9	VMOD
11	factors	factor	B-NP	NNS	O	10	PMOD
12	associated	associate	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	nephrotoxicity	nephrotoxicity	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	8	P

1	Group	Group	B-NP	NN	B-protein	4	SUB
2	II	II	I-NP	CD	I-protein	1	NMOD
3	also	also	B-ADVP	RB	O	4	VMOD
4	showed	show	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	significant	significant	I-NP	JJ	O	7	NMOD
7	decrease	decrease	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	chronic	chronic	B-NP	JJ	O	10	NMOD
10	nephrotoxicity	nephrotoxicity	I-NP	NN	O	8	PMOD
11	secondary	secondary	B-ADJP	JJ	O	10	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	long-term	long-term	B-NP	JJ	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	cyclosporine	cyclosporine	B-NP	NN	O	15	PMOD
17	.	.	O	.	O	4	P

1	Reversible	Reversible	B-NP	JJ	O	2	NMOD
2	cholestasis	cholestasis	I-NP	NN	O	0	ROOT
3	with	with	B-PP	IN	O	2	NMOD
4	bile	bile	B-NP	NN	O	6	NMOD
5	duct	duct	I-NP	NN	O	6	NMOD
6	injury	injury	I-NP	NN	O	3	PMOD
7	following	follow	B-PP	VBG	O	6	NMOD
8	azathioprine	azathioprine	B-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	67-year-old	67-year-old	I-NP	JJ	O	3	NMOD
3	patient	patient	I-NP	NN	O	16	SUB
4	,	,	O	,	O	3	P
5	with	with	B-PP	IN	O	3	NMOD
6	primary	primary	B-NP	JJ	O	7	NMOD
7	polymyositis	polymyositis	I-NP	NN	O	5	PMOD
8	and	and	O	CC	O	16	VMOD
9	without	without	B-PP	IN	O	16	VMOD
10	previous	previous	B-NP	JJ	O	11	NMOD
11	evidence	evidence	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	liver	liver	B-NP	NN	O	14	NMOD
14	disease	disease	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	16	P
16	developed	develop	B-VP	VBD	O	0	ROOT
17	clinical	clinical	B-NP	JJ	O	19	AMOD
18	and	and	I-NP	CC	O	19	AMOD
19	biochemical	biochemical	I-NP	JJ	O	20	NMOD
20	features	feature	I-NP	NNS	O	16	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	severe	severe	B-NP	JJ	O	23	NMOD
23	cholestasis	cholestasis	I-NP	NN	O	25	NMOD
24	3	3	B-NP	CD	O	23	NMOD
25	months	month	I-NP	NNS	O	21	PMOD
26	after	after	B-PP	IN	O	16	VMOD
27	initiation	initiation	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	azathioprine	azathioprine	B-NP	NN	O	30	NMOD
30	therapy	therapy	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	16	P

1	Renal	Renal	B-NP	JJ	O	2	NMOD
2	function	function	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	hemodynamics	hemodynamic	I-NP	NNS	O	8	SUB
5	during	during	B-PP	IN	O	4	NMOD
6	prolonged	prolonged	B-NP	JJ	O	7	NMOD
7	isoflurane	isoflurane	I-NP	NN	O	5	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	hypotension	hypotension	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	humans	human	B-NP	NNS	O	10	PMOD
12	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	isoflurane	isoflurane	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	14	VMOD
6	hypotension	hypotension	B-NP	NN	O	5	OBJ
7	on	on	B-PP	IN	O	5	VMOD
8	glomerular	glomerular	B-NP	JJ	O	9	NMOD
9	function	function	I-NP	NN	O	7	PMOD
10	and	and	O	CC	O	14	VMOD
11	renal	renal	B-NP	JJ	O	13	NMOD
12	blood	blood	I-NP	NN	O	13	NMOD
13	flow	flow	I-NP	NN	O	14	SUB
14	was	be	B-VP	VBD	O	0	ROOT
15	investigated	investigate	I-VP	VBN	O	14	VC
16	in	in	B-PP	IN	O	15	VMOD
17	20	20	B-NP	CD	O	19	NMOD
18	human	human	I-NP	JJ	O	19	NMOD
19	subjects	subject	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	14	P

1	Hypotension	Hypotension	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	for	for	B-PP	IN	O	3	VMOD
5	236.9	236.9	B-NP	CD	O	7	AMOD
6	+/-	+/-	I-NP	SYM	O	7	AMOD
7	15.1	15.1	I-NP	CD	O	8	NMOD
8	min	min	I-NP	NN	O	4	PMOD
9	by	by	B-PP	IN	O	3	VMOD
10	increasing	increase	B-VP	VBG	O	9	PMOD
11	the	the	B-NP	DT	O	12	NMOD
12	isoflurane	isoflurane	I-NP	NN	O	10	OBJ
13	inspired	inspire	B-VP	VBD	O	2	VMOD
14	concentration	concentration	B-NP	NN	O	16	SUB
15	to	to	B-VP	TO	O	16	VMOD
16	maintain	maintain	I-VP	VB	O	13	VMOD
17	a	a	B-NP	DT	O	20	NMOD
18	mean	mean	I-NP	JJ	O	20	NMOD
19	arterial	arterial	I-NP	JJ	O	20	NMOD
20	pressure	pressure	I-NP	NN	O	16	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	59.8	59.8	B-NP	CD	O	24	AMOD
23	+/-	+/-	I-NP	SYM	O	24	AMOD
24	0.4	0.4	I-NP	CD	O	25	NMOD
25	mmHg	mmHg	I-NP	NN	O	21	PMOD
26	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	drug	drug	I-NP	NN	O	3	NMOD
3	effect	effect	I-NP	NN	O	5	SUB
4	studied	study	B-VP	VBN	O	3	NMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	7	NMOD
7	antagonism	antagonism	I-NP	NN	O	5	PRD
8	by	by	B-PP	IN	O	7	NMOD
9	metoprolol	metoprolol	B-NP	NN	O	8	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	terbutaline	terbutaline	B-NP	NN	O	13	NMOD
12	induced	induced	I-NP	JJ	O	13	NMOD
13	hypokalemia	hypokalemia	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	5	P

1	Cefotetan	Cefotetan	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	immune	immune	B-NP	JJ	O	5	NMOD
4	hemolytic	hemolytic	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	2	OBJ
6	.	.	O	.	O	2	P

1	Immune	Immune	B-NP	JJ	O	3	NMOD
2	hemolytic	hemolytic	I-NP	JJ	O	3	NMOD
3	anemia	anemia	I-NP	NN	O	9	SUB
4	due	due	B-PP	JJ	O	5	PMOD
5	to	to	B-PP	TO	O	3	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	drug-adsorption	drug-adsorption	I-NP	NN	O	8	NMOD
8	mechanism	mechanism	I-NP	NN	O	5	PMOD
9	has	have	B-VP	VBZ	O	0	ROOT
10	been	be	I-VP	VBN	O	9	VC
11	described	describe	I-VP	VBN	O	10	VC
12	primarily	primarily	B-ADVP	RB	O	13	PMOD
13	in	in	B-PP	IN	O	11	VMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	receiving	receive	B-VP	VBG	O	14	NMOD
16	penicillins	penicillin	B-NP	NNS	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	first-generation	first-generation	B-NP	JJ	O	19	NMOD
19	cephalosporins	cephalosporin	I-NP	NNS	O	15	OBJ
20	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	who	who	B-NP	WP	O	4	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	anemia	anemia	B-NP	NN	O	6	OBJ
8	while	while	B-SBAR	IN	O	6	VMOD
9	receiving	receive	B-VP	VBG	O	8	SBAR
10	intravenous	intravenous	B-NP	JJ	O	11	NMOD
11	cefotetan	cefotetan	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	subsequent	subsequent	B-ADJP	JJ	O	3	NMOD
5	to	to	B-PP	TO	O	4	AMOD
6	the	the	B-NP	DT	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	rifampicin	rifampicin	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	had	have	B-VP	VBD	O	0	ROOT
4	developed	develop	I-VP	VBN	O	3	VC
5	transient	transient	B-NP	JJ	O	6	AMOD
6	renal	renal	I-NP	JJ	O	7	NMOD
7	failure	failure	I-NP	NN	O	4	OBJ
8	after	after	B-PP	IN	O	4	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	intermittent	intermittent	I-NP	JJ	O	11	NMOD
11	administration	administration	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	rifampicin	rifampicin	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	3	P

1	Hepatitis	Hepatitis	B-NP	NN	B-protein	4	NMOD
2	B	B	I-NP	NN	I-protein	4	NMOD
3	immune	immune	I-NP	JJ	I-protein	4	NMOD
4	globulin	globulin	I-NP	NN	I-protein	11	NMOD
5	(	(	O	(	O	7	DEP
6	HBIG	HBIG	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	and	and	O	CC	O	11	NMOD
9	immune	immune	B-NP	JJ	B-protein	11	NMOD
10	serum	serum	I-NP	NN	I-protein	11	NMOD
11	globulin	globulin	I-NP	NN	I-protein	15	SUB
12	(	(	O	(	O	14	DEP
13	ISG	ISG	B-NP	NN	B-DNA	14	DEP
14	)	)	O	)	O	11	NMOD
15	were	be	B-VP	VBD	O	0	ROOT
16	examined	examine	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	22	NMOD
19	randomized	randomize	I-NP	VBN	O	21	AMOD
20	,	,	I-NP	,	O	21	P
21	double-blind	double-blind	I-NP	JJ	O	22	NMOD
22	trial	trial	I-NP	NN	O	17	PMOD
23	to	to	B-VP	TO	O	24	VMOD
24	assess	assess	I-VP	VB	O	15	VMOD
25	their	their	B-NP	PRP$	O	27	NMOD
26	relative	relative	I-NP	JJ	O	27	NMOD
27	efficacies	efficacy	I-NP	NNS	O	24	OBJ
28	in	in	B-PP	IN	O	24	VMOD
29	preventing	prevent	B-VP	VBG	O	28	PMOD
30	type	type	B-NP	NN	O	32	NMOD
31	B	B	I-NP	NN	O	32	NMOD
32	hepatitis	hepatitis	I-NP	NN	O	29	OBJ
33	after	after	B-PP	IN	O	29	VMOD
34	needle-stick	needle-stick	B-NP	JJ	O	35	NMOD
35	exposure	exposure	I-NP	NN	O	33	PMOD
36	to	to	B-PP	TO	O	35	NMOD
37	hepatitis	hepatitis	B-NP	NN	B-protein	40	NMOD
38	B	B	I-NP	NN	I-protein	40	NMOD
39	surface	surface	I-NP	NN	I-protein	40	NMOD
40	antigen	antigen	I-NP	NN	I-protein	45	NMOD
41	(	(	O	(	O	45	NMOD
42	HBsAG	HBsAG	B-NP	NN	B-protein	45	NMOD
43	)	)	O	)	O	45	NMOD
44	-positive	-positive	B-NP	JJ	O	45	NMOD
45	donors	donor	I-NP	NNS	O	36	PMOD
46	.	.	O	.	O	15	P

1	Serotonin	Serotonin	B-NP	NN	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	from	from	B-PP	IN	O	2	NMOD
4	venlafaxine-tranylcypromine	venlafaxine-tranylcypromine	B-NP	JJ	O	5	NMOD
5	interaction	interaction	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	Excessive	Excessive	B-NP	JJ	O	2	NMOD
2	stimulation	stimulation	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	serotonin	serotonin	B-NP	NN	B-protein	6	NMOD
5	5HT1A	5HT1A	I-NP	NN	I-protein	6	NMOD
6	receptors	receptor	I-NP	NNS	I-protein	3	PMOD
7	causes	cause	B-VP	VBZ	O	0	ROOT
8	a	a	B-NP	DT	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	serotonin	serotonin	B-NP	NN	O	12	NMOD
12	excess	excess	I-NP	NN	O	10	PMOD
13	that	that	B-NP	WDT	O	12	NMOD
14	consists	consist	B-VP	VBZ	O	13	SBAR
15	of	of	B-PP	IN	O	14	VMOD
16	shivering	shivering	B-NP	NN	O	27	NMOD
17	,	,	O	,	O	27	P
18	muscle	muscle	B-NP	NN	O	19	NMOD
19	rigidity	rigidity	I-NP	NN	O	27	NMOD
20	,	,	O	,	O	27	P
21	salivation	salivation	B-NP	NN	O	27	NMOD
22	,	,	O	,	O	27	P
23	confusion	confusion	B-NP	NN	O	27	NMOD
24	,	,	O	,	O	27	P
25	agitation	agitation	B-NP	NN	O	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	hyperthermia	hyperthermia	I-NP	NN	O	15	PMOD
28	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	venlafaxine-MAOI	venlafaxine-MAOI	I-NP	NN	O	5	NMOD
5	interaction	interaction	I-NP	NN	O	2	OBJ
6	that	that	B-NP	WDT	O	5	NMOD
7	resulted	result	B-VP	VBD	O	6	SBAR
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	serotonin	serotonin	I-NP	NN	O	11	NMOD
11	syndrome	syndrome	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	15	NMOD
14	23-y-old	23-y-old	I-NP	JJ	O	15	NMOD
15	male	male	I-NP	NN	O	12	PMOD
16	who	who	B-NP	WP	O	15	NMOD
17	was	be	B-VP	VBD	O	16	SBAR
18	taking	take	I-VP	VBG	O	17	VC
19	tranylcypromine	tranylcypromine	B-NP	NN	O	18	OBJ
20	for	for	B-PP	IN	O	19	NMOD
21	depression	depression	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	8	VMOD
2	180	180	B-NP	CD	O	3	NMOD
3	mg	mg	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	diazepam	diazepam	B-NP	NN	O	4	PMOD
6	i.v.	i.v.	B-ADVP	RB	O	8	VMOD
7	he	he	B-NP	PRP	O	8	SUB
8	remained	remain	B-VP	VBD	O	0	ROOT
9	tremulous	tremulous	B-ADJP	JJ	O	8	PRD
10	with	with	B-PP	IN	O	9	AMOD
11	muscle	muscle	B-NP	NN	O	12	NMOD
12	rigidity	rigidity	I-NP	NN	O	15	NMOD
13	and	and	O	CC	O	15	NMOD
14	clenched	clenched	B-NP	JJ	O	15	NMOD
15	jaws	jaw	I-NP	NNS	O	10	PMOD
16	.	.	O	.	O	8	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	nondopaminergic	nondopaminergic	B-NP	JJ	O	4	NMOD
4	drugs	drug	I-NP	NNS	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	L-dopa	L-dopa	B-NP	NN	B-protein	8	NMOD
7	induced	induce	I-NP	VBN	O	8	NMOD
8	dyskinesias	dyskinesia	I-NP	NNS	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	MPTP-treated	MPTP-treated	B-NP	JJ	O	11	NMOD
11	monkeys	monkey	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	1	P

1	A	A	B-NP	DT	O	2	NMOD
2	group	group	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	four	four	B-NP	CD	O	5	NMOD
5	monkeys	monkey	I-NP	NNS	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	rendered	render	I-VP	VBN	O	6	VC
8	parkinsonian	parkinsonian	B-ADJP	JJ	O	7	VMOD
9	with	with	B-PP	IN	O	8	AMOD
10	the	the	B-NP	DT	O	12	NMOD
11	toxin	toxin	I-NP	NN	O	12	NMOD
12	MPTP	MPTP	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	2	NMOD
2	series	series	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	agents	agent	B-NP	NNS	O	3	PMOD
5	acting	act	B-VP	VBG	O	4	NMOD
6	primarily	primarily	B-ADVP	RB	O	7	PMOD
7	on	on	B-PP	IN	O	5	VMOD
8	neurotransmitters	neurotransmitter	B-NP	NNS	O	7	PMOD
9	other	other	B-ADJP	JJ	O	8	NMOD
10	than	than	B-PP	IN	O	9	AMOD
11	dopamine	dopamine	B-NP	NN	O	10	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	then	then	I-VP	RB	O	12	VMOD
14	tested	test	I-VP	VBN	O	12	VC
15	in	in	B-PP	IN	O	14	VMOD
16	combination	combination	B-NP	NN	O	15	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	L-DOPA	L-DOPA	B-NP	NN	B-protein	17	PMOD
19	to	to	B-VP	TO	O	20	VMOD
20	see	see	I-VP	VB	O	16	NMOD
21	if	if	B-SBAR	IN	O	20	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	dyskinetic	dyskinetic	I-NP	JJ	O	24	NMOD
24	movements	movement	I-NP	NNS	O	25	SUB
25	would	would	B-VP	MD	O	21	SBAR
26	be	be	I-VP	VB	O	25	VC
27	modified	modify	I-VP	VBN	O	26	VC
28	.	.	O	.	O	12	P

1	Several	Several	B-NP	JJ	O	2	NMOD
2	drugs	drug	I-NP	NNS	O	19	SUB
3	,	,	O	,	O	2	P
4	including	include	B-PP	VBG	O	2	NMOD
5	clonidine	clonidine	B-NP	NN	O	16	NMOD
6	,	,	O	,	O	16	P
7	physostigmine	physostigmine	B-NP	NN	O	16	NMOD
8	,	,	O	,	O	16	P
9	methysergide	methysergide	B-NP	NN	O	16	NMOD
10	,	,	O	,	O	16	P
11	5-MDOT	5-MDOT	B-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	propranolol	propranolol	B-NP	NN	O	16	NMOD
14	,	,	O	,	O	16	P
15	and	and	O	CC	O	16	NMOD
16	MK-801	MK-801	B-NP	NN	B-protein	4	PMOD
17	,	,	O	,	O	2	P
18	markedly	markedly	B-ADVP	RB	O	19	VMOD
19	reduced	reduce	B-VP	VBD	O	0	ROOT
20	the	the	B-NP	DT	O	22	NMOD
21	dyskinetic	dyskinetic	I-NP	JJ	O	22	NMOD
22	movements	movement	I-NP	NNS	O	19	OBJ
23	but	but	B-PP	CC	O	19	VMOD
24	at	at	B-PP	IN	O	19	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	cost	cost	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	a	a	B-NP	DT	O	29	NMOD
29	return	return	I-NP	NN	O	27	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	parkinsonian	parkinsonian	B-NP	JJ	O	32	NMOD
32	symptomatology	symptomatology	I-NP	NN	O	30	PMOD
33	.	.	O	.	O	19	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	yohimbine	yohimbine	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	meperidine	meperidine	I-NP	NN	O	6	SUB
6	reduced	reduce	B-VP	VBD	O	0	ROOT
7	predominantly	predominantly	B-ADVP	RB	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	dyskinetic	dyskinetic	I-NP	JJ	O	10	NMOD
10	movements	movement	I-NP	NNS	O	6	OBJ
11	.	.	O	.	O	6	P

1	Baclofen	Baclofen	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	also	also	B-ADVP	RB	O	2	VMOD
4	useful	useful	B-ADJP	JJ	O	2	PRD
5	in	in	B-PP	IN	O	4	AMOD
6	one	one	B-NP	CD	O	7	NMOD
7	monkey	monkey	I-NP	NN	O	5	PMOD
8	against	against	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	12	NMOD
10	more	more	I-NP	RBR	O	11	AMOD
11	dystonic	dystonic	I-NP	JJ	O	12	NMOD
12	form	form	I-NP	NN	O	8	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	dyskinesia	dyskinesia	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	2	P

1	CCNU	CCNU	B-NP	NN	B-protein	5	NMOD
2	(	(	O	(	O	4	DEP
3	lomustine	lomustine	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	toxicity	toxicity	B-NP	NN	O	11	NMOD
6	in	in	B-PP	IN	O	5	NMOD
7	dogs	dog	B-NP	NNS	O	6	PMOD
8	:	:	O	:	O	5	P
9	a	a	B-NP	DT	O	11	NMOD
10	retrospective	retrospective	I-NP	JJ	O	11	NMOD
11	study	study	I-NP	NN	O	0	ROOT
12	(	(	O	(	O	14	DEP
13	2002-07	2002-07	B-NP	CD	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	.	.	O	.	O	11	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	describe	describe	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	haematological	haematological	B-NP	JJ	O	15	NMOD
9	,	,	I-NP	,	O	15	P
10	renal	renal	I-NP	JJ	O	15	NMOD
11	,	,	I-NP	,	O	15	P
12	hepatic	hepatic	I-NP	JJ	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	gastrointestinal	gastrointestinal	I-NP	JJ	O	15	NMOD
15	toxicities	toxicity	I-NP	NNS	O	7	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	tumour-bearing	tumour-bearing	B-NP	JJ	O	18	NMOD
18	dogs	dog	I-NP	NNS	O	16	PMOD
19	receiving	receive	B-VP	VBG	O	18	NMOD
20	1-	1-	B-NP	NN	O	24	NMOD
21	(	(	O	(	O	23	DEP
22	2-chloroethyl	2-chloroethyl	B-NP	NN	O	23	DEP
23	)	)	O	)	O	20	NMOD
24	-3-cyclohexyl-1-nitrosourea	-3-cyclohexyl-1-nitrosourea	B-NP	NN	O	19	OBJ
25	(	(	O	(	O	27	DEP
26	CCNU	CCNU	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Of	Of	B-PP	IN	O	12	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	206	206	I-NP	CD	O	6	NMOD
6	dogs	dog	I-NP	NNS	O	3	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	CCNU	CCNU	B-NP	NN	O	8	PMOD
10	,	,	O	,	O	12	P
11	185	185	B-NP	CD	O	12	SUB
12	met	meet	B-VP	VBD	O	1	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	inclusion	inclusion	I-NP	NN	O	15	NMOD
15	criteria	criterion	I-NP	NNS	O	12	OBJ
16	for	for	B-PP	IN	O	15	NMOD
17	at	at	B-NP	IN	O	20	NMOD
18	least	least	I-NP	JJS	O	17	AMOD
19	one	one	I-NP	CD	O	17	AMOD
20	class	class	I-NP	NN	O	16	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	toxicity	toxicity	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	1	P

1	CCNU	CCNU	B-NP	NN	B-protein	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	used	use	I-VP	VBN	O	2	VC
4	most	most	B-ADVP	RBS	O	5	AMOD
5	commonly	commonly	I-ADVP	RB	O	3	VMOD
6	in	in	B-PP	IN	O	3	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	lymphoma	lymphoma	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	23	P
12	mast	mast	B-NP	NN	O	14	NMOD
13	cell	cell	I-NP	NN	O	14	NMOD
14	tumour	tumour	I-NP	NN	O	23	NMOD
15	,	,	O	,	O	23	P
16	brain	brain	B-NP	NN	O	17	NMOD
17	tumour	tumour	I-NP	NN	O	23	NMOD
18	,	,	O	,	O	23	P
19	histiocytic	histiocytic	B-NP	JJ	O	20	NMOD
20	tumours	tumour	I-NP	NNS	O	23	NMOD
21	and	and	O	CC	O	23	NMOD
22	epitheliotropic	epitheliotropic	B-NP	JJ	O	23	NMOD
23	lymphoma	lymphoma	I-NP	NN	O	2	VMOD
24	.	.	O	.	O	2	P

1	Potential	Potential	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	elevated	elevated	B-NP	JJ	O	7	NMOD
6	alanine	alanine	I-NP	NN	O	7	NMOD
7	transaminase	transaminase	I-NP	NN	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	ALT	ALT	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	concentration	concentration	B-NP	NN	O	12	SUB
12	were	be	B-VP	VBD	O	0	ROOT
13	reported	report	I-VP	VBN	O	12	VC
14	in	in	B-PP	IN	O	13	VMOD
15	12.2	12.2	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	19	NMOD
17	and	and	O	CC	O	19	NMOD
18	48.8	48.8	B-NP	CD	O	19	NMOD
19	%	%	I-NP	NN	O	14	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	dogs	dog	B-NP	NNS	O	20	PMOD
22	,	,	O	,	O	13	P
23	respectively	respectively	B-ADVP	RB	O	13	VMOD
24	.	.	O	.	O	12	P

1	Neuroactive	Neuroactive	B-NP	JJ	O	2	NMOD
2	steroids	steroid	I-NP	NNS	O	3	SUB
3	protect	protect	B-VP	VBP	O	0	ROOT
4	against	against	B-PP	IN	O	3	VMOD
5	pilocarpine-	pilocarpine-	B-NP	NN	O	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	kainic	kainic	B-NP	JJ	O	8	NMOD
8	acid	acid	I-NP	NN	O	9	SUB
9	induced	induce	B-VP	VBD	O	4	SBAR
10	limbic	limbic	B-NP	JJ	O	11	NMOD
11	seizures	seizure	I-NP	NNS	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	status	status	B-NP	NN	O	14	NMOD
14	epilepticus	epilepticus	I-NP	NN	O	9	OBJ
15	in	in	B-PP	IN	O	9	VMOD
16	mice	mouse	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	3	P

1	Several	Several	B-NP	JJ	O	3	AMOD
2	structurally	structurally	I-NP	RB	O	3	AMOD
3	related	relate	I-NP	VBN	O	4	NMOD
4	metabolites	metabolite	I-NP	NNS	O	22	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	progesterone	progesterone	B-NP	NN	O	13	NMOD
7	(	(	O	(	O	11	DEP
8	3	3	B-NP	CD	O	10	NMOD
9	alpha-hydroxy	alpha-hydroxy	I-NP	NN	O	10	NMOD
10	pregnane-20-ones	pregnane-20-one	I-NP	NNS	O	11	DEP
11	)	)	O	)	O	6	NMOD
12	and	and	O	CC	O	13	NMOD
13	deoxycorticosterone	deoxycorticosterone	B-NP	NN	O	5	PMOD
14	(	(	O	(	O	18	DEP
15	3	3	B-NP	CD	O	17	NMOD
16	alpha-hydroxy	alpha-hydroxy	I-NP	NN	O	17	NMOD
17	pregnane-21-diol-20-ones	pregnane-21-diol-20-one	I-NP	NNS	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	and	and	O	CC	O	22	NMOD
20	their	their	B-NP	PRP$	O	22	NMOD
21	3	3	I-NP	CD	O	22	NMOD
22	beta-epimers	beta-epimer	I-NP	NNS	O	23	SUB
23	were	be	B-VP	VBD	O	0	ROOT
24	evaluated	evaluate	I-VP	VBN	O	23	VC
25	for	for	B-PP	IN	O	24	VMOD
26	protective	protective	B-NP	JJ	O	27	NMOD
27	activity	activity	I-NP	NN	O	25	PMOD
28	against	against	B-PP	IN	O	27	NMOD
29	pilocarpine-	pilocarpine-	B-NP	NN	O	34	NMOD
30	,	,	O	,	O	34	P
31	kainic	kainic	B-NP	JJ	O	32	NMOD
32	acid-	acid-	I-NP	NN	O	34	NMOD
33	and	and	O	CC	O	34	NMOD
34	N-methyl-D-aspartate	N-methyl-D-aspartate	B-NP	NN	O	39	NMOD
35	(	(	O	(	O	37	DEP
36	NMDA	NMDA	B-NP	NN	B-protein	37	DEP
37	)	)	O	)	O	34	NMOD
38	induced	induce	B-NP	VBN	O	39	NMOD
39	seizures	seizure	I-NP	NNS	O	28	PMOD
40	in	in	B-PP	IN	O	27	NMOD
41	mice	mouse	B-NP	NNS	O	40	PMOD
42	.	.	O	.	O	23	P

1	Steroids	Steroid	B-NP	NNS	O	16	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	3-hydroxy	3-hydroxy	I-NP	NN	O	5	NMOD
5	group	group	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	10	NMOD
8	alpha-position	alpha-position	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	5-H	5-H	I-NP	NN	O	6	PMOD
11	in	in	B-PP	IN	O	5	NMOD
12	the	the	B-NP	DT	O	15	NMOD
13	alpha-	alpha-	I-NP	NN	O	15	NMOD
14	or	or	I-NP	CC	O	15	NMOD
15	beta-configurations	beta-configuration	I-NP	NNS	O	11	PMOD
16	were	be	B-VP	VBD	O	0	ROOT
17	highly	highly	B-ADJP	RB	O	18	AMOD
18	effective	effective	I-ADJP	JJ	O	16	PRD
19	in	in	B-PP	IN	O	16	VMOD
20	protecting	protect	B-VP	VBG	O	29	SUB
21	against	against	B-PP	IN	O	20	VMOD
22	pilocarpine	pilocarpine	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	28	DEP
24	416	416	B-NP	CD	O	25	NMOD
25	mg/kg	mg/kg	I-NP	NN	O	28	DEP
26	,	,	O	,	O	25	P
27	s.c.	s.c.	B-ADJP	JJ	O	25	NMOD
28	)	)	O	)	O	22	NMOD
29	induced	induce	B-VP	VBD	O	19	SBAR
30	limbic	limbic	B-NP	JJ	O	32	NMOD
31	motor	motor	I-NP	NN	O	32	NMOD
32	seizures	seizure	I-NP	NNS	O	29	OBJ
33	and	and	O	CC	O	35	NMOD
34	status	status	B-NP	NN	O	35	NMOD
35	epilepticus	epilepticus	I-NP	NN	O	32	NMOD
36	(	(	O	(	O	44	DEP
37	ED50	ED50	B-NP	NN	O	38	NMOD
38	values	value	I-NP	NNS	O	41	NMOD
39	,	,	O	,	O	41	P
40	7.0-18.7	7.0-18.7	B-NP	CD	O	41	NMOD
41	mg/kg	mg/kg	I-NP	NN	O	44	DEP
42	,	,	O	,	O	41	P
43	i.p.	i.p.	B-ADVP	RB	O	41	NMOD
44	)	)	O	)	O	35	NMOD
45	.	.	O	.	O	16	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	the	the	B-NP	DT	O	4	NMOD
3	neuroactive	neuroactive	I-NP	JJ	O	4	NMOD
4	steroids	steroid	I-NP	NNS	O	5	SUB
5	were	be	B-VP	VBD	O	1	SBAR
6	considerably	considerably	B-ADJP	RB	O	5	PRD
7	less	less	I-ADJP	RBR	O	6	AMOD
8	potent	potent	I-ADJP	JJ	O	6	AMOD
9	than	than	B-PP	IN	O	6	AMOD
10	the	the	B-NP	DT	O	12	NMOD
11	benzodiazepine	benzodiazepine	I-NP	NN	O	12	NMOD
12	clonazepam	clonazepam	I-NP	NN	O	9	PMOD
13	in	in	B-PP	IN	O	6	AMOD
14	protecting	protect	B-VP	VBG	O	13	PMOD
15	against	against	B-PP	IN	O	14	NMOD
16	pilocarpine	pilocarpine	B-NP	NN	O	17	NMOD
17	seizures	seizure	I-NP	NNS	O	15	PMOD
18	,	,	O	,	O	1	P
19	steroids	steroid	B-NP	NNS	O	18	ROOT
20	with	with	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	27	SUB
22	5	5	I-NP	CD	O	27	VMOD
23	alpha	alpha	I-NP	SYM	O	27	VMOD
24	,	,	O	,	O	27	P
25	3	3	B-NP	CD	O	26	AMOD
26	alpha-configuration	alpha-configuration	I-NP	NN	O	27	SUB
27	had	have	B-VP	VBD	O	20	SBAR
28	comparable	comparable	B-NP	JJ	O	33	NMOD
29	or	or	I-NP	CC	O	33	NMOD
30	higher	high	I-NP	JJR	O	31	AMOD
31	protective	protective	I-NP	JJ	O	33	NMOD
32	index	index	I-NP	NN	O	33	NMOD
33	values	value	I-NP	NNS	O	27	OBJ
34	(	(	O	(	O	45	DEP
35	TD50	TD50	B-NP	NN	B-protein	45	DEP
36	for	for	B-PP	IN	O	35	NMOD
37	motor	motor	B-NP	NN	O	38	NMOD
38	impairment	impairment	I-NP	NN	O	36	PMOD
39	divided	divide	B-VP	VBN	O	38	NMOD
40	by	by	B-PP	IN	O	39	VMOD
41	ED50	ED50	B-NP	NN	B-protein	40	PMOD
42	for	for	B-PP	IN	O	39	VMOD
43	seizure	seizure	B-NP	NN	O	44	NMOD
44	protection	protection	I-NP	NN	O	42	PMOD
45	)	)	O	)	O	33	NMOD
46	than	than	B-PP	IN	O	27	VMOD
47	clonazepam	clonazepam	B-NP	NN	O	46	PMOD
48	,	,	O	,	O	19	P
49	indicating	indicate	B-VP	VBG	O	19	NMOD
50	that	that	B-SBAR	IN	O	49	VMOD
51	some	some	B-NP	DT	O	53	NMOD
52	neuroactive	neuroactive	I-NP	JJ	O	53	NMOD
53	steroids	steroid	I-NP	NNS	O	54	SUB
54	may	may	B-VP	MD	O	50	SBAR
55	have	have	I-VP	VB	O	54	VC
56	lower	low	B-NP	JJR	O	58	NMOD
57	relative	relative	I-NP	JJ	O	58	NMOD
58	toxicity	toxicity	I-NP	NN	O	55	OBJ
59	.	.	O	.	O	19	P

1	Steroids	Steroid	B-NP	NNS	O	16	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	14	NMOD
4	5	5	I-NP	CD	O	14	NMOD
5	alpha	alpha	I-NP	SYM	O	14	NMOD
6	,	,	O	,	O	14	P
7	3	3	B-NP	CD	O	8	NMOD
8	alpha-	alpha-	I-NP	NN	O	14	NMOD
9	or	or	O	CC	O	11	NMOD
10	5	5	B-NP	CD	O	11	NMOD
11	beta	beta	B-NP	SYM	O	14	NMOD
12	,	,	O	,	O	14	P
13	3	3	B-NP	CD	O	14	NMOD
14	alpha-configurations	alpha-configuration	I-NP	NNS	O	2	PMOD
15	also	also	B-ADVP	RB	O	16	VMOD
16	produced	produce	B-VP	VBD	O	0	ROOT
17	a	a	B-NP	DT	O	19	NMOD
18	dose-dependent	dose-dependent	I-NP	JJ	O	19	NMOD
19	delay	delay	I-NP	NN	O	16	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	onset	onset	I-NP	NN	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	limbic	limbic	B-NP	JJ	O	25	NMOD
25	seizures	seizure	I-NP	NNS	O	23	PMOD
26	induced	induce	B-VP	VBN	O	25	NMOD
27	by	by	B-PP	IN	O	26	VMOD
28	kainic	kainic	B-NP	JJ	O	29	NMOD
29	acid	acid	I-NP	NN	O	27	PMOD
30	(	(	O	(	O	35	DEP
31	32	32	B-NP	CD	O	32	NMOD
32	mg/kg	mg/kg	I-NP	NN	O	35	DEP
33	,	,	O	,	O	32	P
34	s.c.	s.c.	B-ADVP	JJ	O	32	NMOD
35	)	)	O	)	O	29	NMOD
36	,	,	O	,	O	16	P
37	but	but	O	CC	O	16	VMOD
38	did	do	B-VP	VBD	O	16	VMOD
39	not	not	I-VP	RB	O	38	VMOD
40	completely	completely	I-VP	RB	O	38	VMOD
41	protect	protect	I-VP	VB	O	38	VC
42	against	against	B-PP	IN	O	41	VMOD
43	the	the	B-NP	DT	O	44	NMOD
44	seizures	seizure	I-NP	NNS	O	42	PMOD
45	.	.	O	.	O	16	P

1	However	However	B-ADVP	RB	O	0	ROOT
2	,	,	O	,	O	33	P
3	when	when	B-ADVP	WRB	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	second	second	I-NP	JJ	O	6	NMOD
6	dose	dose	I-NP	NN	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	steroid	steroid	I-NP	NN	O	7	PMOD
10	was	be	B-VP	VBD	O	3	SBAR
11	administered	administer	I-VP	VBN	O	10	VC
12	1	1	B-NP	CD	O	13	NMOD
13	hr	hr	I-NP	NN	O	20	NMOD
14	after	after	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	first	first	I-NP	JJ	O	17	NMOD
17	dose	dose	I-NP	NN	O	14	PMOD
18	,	,	O	,	O	20	P
19	complete	complete	B-NP	JJ	O	20	NMOD
20	protection	protection	I-NP	NN	O	25	SUB
21	from	from	B-PP	IN	O	20	NMOD
22	the	the	B-NP	DT	O	24	NMOD
23	kainic	kainic	I-NP	JJ	O	24	NMOD
24	acid	acid	I-NP	NN	O	21	PMOD
25	induced	induce	B-VP	VBD	O	11	VMOD
26	limbic	limbic	B-NP	JJ	O	27	NMOD
27	seizures	seizure	I-NP	NNS	O	25	OBJ
28	and	and	O	CC	O	30	NMOD
29	status	status	B-NP	NN	O	30	NMOD
30	epilepticus	epilepticus	I-NP	NN	O	31	SUB
31	was	be	B-VP	VBD	O	27	NMOD
32	obtained	obtain	I-VP	VBN	O	31	VC
33	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	steroids	steroid	I-NP	NNS	O	4	SUB
3	also	also	B-ADVP	RB	O	4	VMOD
4	caused	cause	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	dose-dependent	dose-dependent	I-NP	JJ	O	7	NMOD
7	delay	delay	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	NMDA	NMDA	B-NP	NN	B-protein	17	NMOD
10	(	(	O	(	O	15	DEP
11	257	257	B-NP	CD	O	12	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	15	DEP
13	,	,	O	,	O	12	P
14	s.c.	s.c.	B-ADJP	JJ	O	12	NMOD
15	)	)	O	)	O	9	NMOD
16	induced	induce	B-NP	VBN	O	17	NMOD
17	lethality	lethality	I-NP	NN	O	8	PMOD
18	,	,	O	,	O	4	P
19	but	but	O	CC	O	4	VMOD
20	did	do	B-VP	VBD	O	4	VMOD
21	not	not	I-VP	RB	O	20	VMOD
22	completely	completely	I-VP	RB	O	20	VMOD
23	protect	protect	I-VP	VB	O	20	VC
24	against	against	B-PP	IN	O	23	VMOD
25	NMDA	NMDA	B-NP	NN	O	26	NMOD
26	seizures	seizure	I-NP	NNS	O	28	NMOD
27	or	or	O	CC	O	28	NMOD
28	lethality	lethality	B-NP	NN	O	24	PMOD
29	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	4	NMOD
2	safety	safety	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	efficacy	efficacy	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	combination	combination	B-NP	NN	O	7	NMOD
7	N-butyl-deoxynojirimycin	N-butyl-deoxynojirimycin	I-NP	NN	O	12	NMOD
8	(	(	O	(	O	10	DEP
9	SC-48334	SC-48334	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	and	and	O	CC	O	12	NMOD
12	zidovudine	zidovudine	B-NP	NN	O	5	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	21	NMOD
15	with	with	B-PP	IN	O	14	NMOD
16	HIV-1	HIV-1	B-NP	NN	O	17	NMOD
17	infection	infection	I-NP	NN	O	15	PMOD
18	and	and	O	CC	O	21	NMOD
19	200-500	200-500	B-NP	CD	O	21	NMOD
20	CD4	CD4	I-NP	NN	O	21	NMOD
21	cells/mm3	cells/mm3	I-NP	NN	O	13	PMOD
22	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	6	NMOD
2	mean	mean	I-NP	JJ	O	6	NMOD
3	SC-48334	SC-48334	I-NP	NN	O	6	NMOD
4	steady-state	steady-state	I-NP	JJ	O	6	NMOD
5	trough	trough	I-NP	NN	O	6	NMOD
6	level	level	I-NP	NN	O	13	SUB
7	(	(	O	(	O	12	DEP
8	4.04	4.04	B-NP	CD	O	10	AMOD
9	+/-	+/-	I-NP	CC	O	10	AMOD
10	0.99	0.99	I-NP	CD	O	11	NMOD
11	micrograms/ml	micrograms/ml	I-NP	NNS	O	12	DEP
12	)	)	O	)	O	6	NMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	below	below	B-PP	IN	O	13	PRD
15	the	the	B-NP	DT	O	19	NMOD
16	in	in	I-NP	FW	O	17	AMOD
17	vitro	vitro	I-NP	FW	O	19	NMOD
18	inhibitory	inhibitory	I-NP	JJ	O	19	NMOD
19	concentration	concentration	I-NP	NN	O	14	PMOD
20	for	for	B-PP	IN	O	19	NMOD
21	human	human	B-NP	JJ	O	23	NMOD
22	immunodeficiency	immunodeficiency	I-NP	NN	O	23	NMOD
23	virus	virus	I-NP	NN	O	20	PMOD
24	(	(	O	(	O	26	DEP
25	HIV	HIV	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	.	.	O	.	O	13	P

1	CB	CB	B-NP	NN	O	7	NMOD
2	3717	3717	I-NP	CD	O	1	NMOD
3	,	,	O	,	O	7	P
4	N10-propargyl-5	N10-propargyl-5	B-NP	NN	B-protein	7	NMOD
5	,	,	O	,	O	7	P
6	8-dideazafolic	8-dideazafolic	B-NP	JJ	O	7	NMOD
7	acid	acid	I-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	is	be	B-VP	VBZ	O	21	VMOD
10	a	a	B-NP	DT	O	12	NMOD
11	tight-binding	tight-binding	I-NP	JJ	O	12	NMOD
12	inhibitor	inhibitor	I-NP	NN	O	21	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	thymidylate	thymidylate	B-NP	NN	B-protein	15	NMOD
15	synthase	synthase	I-NP	NN	I-protein	20	NMOD
16	(	(	O	(	O	18	DEP
17	TS	TS	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	whose	whose	B-NP	WP$	O	20	NMOD
20	cytotoxicity	cytotoxicity	I-NP	NN	O	13	PMOD
21	is	be	B-VP	VBZ	O	0	ROOT
22	mediated	mediate	I-VP	VBN	O	21	VC
23	solely	solely	B-ADVP	RB	O	24	PMOD
24	through	through	B-PP	IN	O	22	VMOD
25	the	the	B-NP	DT	O	26	NMOD
26	inhibition	inhibition	I-NP	NN	O	24	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	this	this	B-NP	DT	O	29	NMOD
29	enzyme	enzyme	I-NP	NN	B-protein	27	PMOD
30	.	.	O	.	O	21	P

1	As	As	B-SBAR	IN	O	0	ROOT
2	inhibitors	inhibitor	B-NP	NNS	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	isolated	isolate	B-NP	VBN	O	6	NMOD
5	L1210	L1210	I-NP	NN	O	6	NMOD
6	TS	TS	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	17	P
8	CB	CB	B-NP	NN	O	10	NMOD
9	3717	3717	I-NP	CD	O	10	NMOD
10	di-	di-	I-NP	NN	O	17	SUB
11	,	,	O	,	O	17	P
12	tri-	tri-	B-NP	NN	O	17	SUB
13	,	,	O	,	O	17	P
14	tetra-	tetra-	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	pentaglutamate	pentaglutamate	I-NP	NN	O	17	SUB
17	are	be	B-VP	VBP	O	1	SBAR
18	26-	26-	B-NP	CD	O	36	VMOD
19	,	,	I-NP	,	O	36	P
20	87-	87-	I-NP	CD	O	36	VMOD
21	,	,	I-NP	,	O	36	P
22	119-	119-	I-NP	CD	O	36	SUB
23	and	and	O	CC	O	36	VMOD
24	114-fold	114-fold	B-ADJP	RB	O	36	VMOD
25	more	more	I-ADJP	RBR	O	24	AMOD
26	potent	potent	I-ADJP	JJ	O	24	AMOD
27	than	than	B-PP	IN	O	24	AMOD
28	CB	CB	B-NP	NN	O	27	PMOD
29	3717	3717	I-NP	CD	O	28	NMOD
30	,	,	O	,	O	36	P
31	respectively	respectively	B-ADVP	RB	O	36	VMOD
32	,	,	O	,	O	36	P
33	and	and	O	CC	O	36	VMOD
34	their	their	B-NP	PRP$	O	35	NMOD
35	formation	formation	I-NP	NN	O	36	SUB
36	may	may	B-VP	MD	O	17	VMOD
37	,	,	O	,	O	17	P
38	therefore	therefore	B-ADVP	RB	O	17	VMOD
39	,	,	O	,	O	17	P
40	be	be	B-VP	VB	O	17	VMOD
41	an	an	B-NP	DT	O	43	NMOD
42	important	important	I-NP	JJ	O	43	NMOD
43	determinant	determinant	I-NP	NN	O	40	PRD
44	of	of	B-PP	IN	O	43	NMOD
45	CB	CB	B-NP	NN	O	47	NMOD
46	3717	3717	I-NP	CD	O	47	NMOD
47	cytotoxicity	cytotoxicity	I-NP	NN	O	44	PMOD
48	.	.	O	.	O	1	P

1	In	In	B-PP	IN	O	10	VMOD
2	early	early	B-NP	JJ	O	4	NMOD
3	clinical	clinical	I-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	1	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	CB	CB	B-NP	NN	O	5	PMOD
7	3717	3717	I-NP	CD	O	6	NMOD
8	,	,	O	,	O	10	P
9	activity	activity	B-NP	NN	O	10	SUB
10	has	have	B-VP	VBZ	O	0	ROOT
11	been	be	I-VP	VBN	O	10	VC
12	seen	see	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	breast	breast	B-NP	NN	O	15	NMOD
15	cancer	cancer	I-NP	NN	O	13	PMOD
16	,	,	O	,	O	10	P
17	ovarian	ovarian	B-NP	JJ	O	18	NMOD
18	cancer	cancer	I-NP	NN	O	23	NMOD
19	,	,	O	,	O	23	P
20	hepatoma	hepatoma	B-NP	NN	O	23	NMOD
21	,	,	O	,	O	23	P
22	and	and	O	CC	O	23	NMOD
23	mesothelioma	mesothelioma	B-NP	NN	O	10	VMOD
24	.	.	O	.	O	10	P

1	Ethopropazine	Ethopropazine	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	benztropine	benztropine	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	neuroleptic	neuroleptic	B-NP	JJ	O	7	NMOD
6	induced	induce	I-NP	VBN	O	7	NMOD
7	parkinsonism	parkinsonism	I-NP	NN	O	4	PMOD
8	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	7	VMOD
2	a	a	B-NP	DT	O	6	NMOD
3	12-week	12-week	I-NP	JJ	O	6	NMOD
4	controlled	control	I-NP	VBN	O	6	NMOD
5	study	study	I-NP	NN	O	6	NMOD
6	ethopropazine	ethopropazine	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	compared	compare	I-VP	VBN	O	7	VC
9	to	to	B-PP	TO	O	8	VMOD
10	benztropine	benztropine	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	parkinsonism	parkinsonism	B-NP	NN	O	14	PMOD
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	fluphenazine	fluphenazine	B-NP	NN	O	19	NMOD
19	enanthate	enanthate	I-NP	NN	O	17	PMOD
20	in	in	B-PP	IN	O	16	VMOD
21	60	60	B-NP	CD	O	23	NMOD
22	schizophrenic	schizophrenic	I-NP	JJ	O	23	NMOD
23	outpatients	outpatient	I-NP	NNS	O	20	PMOD
24	.	.	O	.	O	7	P

1	Ethopropazine	Ethopropazine	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	benztropine	benztropine	I-NP	NN	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	found	find	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	be	be	I-VP	VB	O	5	VMOD
8	equally	equally	B-ADJP	RB	O	9	AMOD
9	effective	effective	I-ADJP	JJ	O	7	PRD
10	in	in	B-PP	IN	O	7	VMOD
11	controlling	control	B-VP	VBG	O	10	PMOD
12	parkinsonian	parkinsonian	B-NP	JJ	O	13	NMOD
13	symptoms	symptom	I-NP	NNS	O	11	OBJ
14	and	and	O	CC	O	4	VMOD
15	were	be	B-VP	VBD	O	24	NMOD
16	as	as	B-ADJP	RB	O	17	AMOD
17	efficacious	efficacious	I-ADJP	JJ	O	15	PRD
18	as	as	B-PP	IN	O	17	AMOD
19	procyclidine	procyclidine	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	24	P
21	their	their	B-NP	PRP$	O	24	NMOD
22	previous	previous	I-NP	JJ	O	24	NMOD
23	antiparkinsonian	antiparkinsonian	I-NP	JJ	O	24	NMOD
24	drug	drug	I-NP	NN	O	4	VMOD
25	.	.	O	.	O	4	P

1	However	However	B-ADVP	RB	O	6	VMOD
2	,	,	O	,	O	6	P
3	benztropine	benztropine	B-NP	NN	O	5	NMOD
4	treated	treat	B-VP	VBN	O	5	NMOD
5	patients	patient	B-NP	NNS	O	6	SUB
6	had	have	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	9	NMOD
8	significant	significant	I-NP	JJ	O	9	NMOD
9	increase	increase	I-NP	NN	O	6	OBJ
10	in	in	B-PP	IN	O	9	NMOD
11	tardive	tardive	B-NP	JJ	O	12	NMOD
12	dyskinesia	dyskinesia	I-NP	NN	O	10	PMOD
13	compared	compare	B-VP	VBN	O	6	VMOD
14	to	to	B-PP	TO	O	13	VMOD
15	their	their	B-NP	PRP$	O	16	NMOD
16	condition	condition	I-NP	NN	O	14	PMOD
17	during	during	B-PP	IN	O	16	NMOD
18	procyclindine	procyclindine	B-NP	NN	O	19	NMOD
19	treatment	treatment	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	13	P
21	and	and	O	CC	O	13	VMOD
22	significantly	significantly	B-NP	RB	O	23	AMOD
23	more	more	I-NP	JJR	O	26	NMOD
24	anxiety	anxiety	I-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	depression	depression	I-NP	NN	O	13	OBJ
27	than	than	B-PP	IN	O	26	NMOD
28	ethopropazine	ethopropazine	B-NP	NN	O	30	NMOD
29	treated	treat	B-VP	VBN	O	30	NMOD
30	patients	patient	B-NP	NNS	O	27	PMOD
31	.	.	O	.	O	6	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	alpha-tocopherol	alpha-tocopherol	B-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	deferoxamine	deferoxamine	I-NP	NN	O	2	PMOD
6	on	on	B-PP	IN	O	1	NMOD
7	methamphetamine	methamphetamine	B-NP	NN	O	9	NMOD
8	induced	induced	I-NP	JJ	O	9	NMOD
9	neurotoxicity	neurotoxicity	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	1	P

1	Methamphetamine	Methamphetamine	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	MA	MA	B-NP	NN	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	induced	induce	B-VP	VBD	O	8	VMOD
6	dopaminergic	dopaminergic	B-NP	JJ	O	7	NMOD
7	neurotoxicity	neurotoxicity	I-NP	NN	O	8	SUB
8	is	be	B-VP	VBZ	O	0	ROOT
9	believed	believe	I-VP	VBN	O	8	VC
10	to	to	I-VP	TO	O	11	VMOD
11	be	be	I-VP	VB	O	9	VMOD
12	associated	associate	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	increased	increase	I-NP	VBN	O	16	NMOD
16	formation	formation	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	free	free	B-NP	JJ	O	19	NMOD
19	radicals	radical	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	8	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	examined	examine	B-VP	VBD	O	27	VMOD
4	the	the	B-NP	DT	O	5	NMOD
5	effect	effect	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	alpha-tocopherol	alpha-tocopherol	B-NP	NN	O	13	NMOD
8	(	(	O	(	O	10	DEP
9	alpha-TC	alpha-TC	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	,	,	O	,	O	13	P
12	a	a	B-NP	DT	O	13	NMOD
13	scavenger	scavenger	I-NP	NN	O	6	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	reactive	reactive	B-NP	JJ	O	17	NMOD
16	oxygen	oxygen	I-NP	NN	O	17	NMOD
17	species	specie	I-NP	NNS	O	14	PMOD
18	,	,	O	,	O	27	P
19	and	and	O	CC	O	20	NMOD
20	deferoxamine	deferoxamine	B-NP	NN	O	27	NMOD
21	(	(	O	(	O	23	DEP
22	DFO	DFO	B-NP	NN	B-protein	23	DEP
23	)	)	O	)	O	20	NMOD
24	,	,	O	,	O	27	P
25	an	an	B-NP	DT	O	27	NMOD
26	iron	iron	I-NP	NN	O	27	NMOD
27	chelator	chelator	I-NP	NN	O	0	ROOT
28	,	,	O	,	O	27	P
29	on	on	B-PP	IN	O	27	NMOD
30	the	the	B-NP	DT	O	33	NMOD
31	MA	MA	I-NP	NN	O	33	NMOD
32	induced	induced	I-NP	JJ	O	33	NMOD
33	neurotoxicity	neurotoxicity	I-NP	NN	O	29	PMOD
34	.	.	O	.	O	27	P

1	The	The	B-NP	DT	O	2	NMOD
2	concentrations	concentration	I-NP	NNS	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	dopamine	dopamine	B-NP	NN	O	12	NMOD
5	(	(	O	(	O	7	DEP
6	DA	DA	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	,	,	O	,	O	12	P
9	serotonin	serotonin	B-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	their	their	B-NP	PRP$	O	12	NMOD
12	metabolites	metabolite	I-NP	NNS	O	3	PMOD
13	decreased	decrease	B-VP	VBD	O	0	ROOT
14	significantly	significantly	B-ADVP	RB	O	13	VMOD
15	after	after	B-SBAR	IN	O	13	VMOD
16	MA	MA	B-NP	JJ	O	17	NMOD
17	administration	administration	I-NP	NN	O	31	SUB
18	,	,	O	,	O	17	P
19	which	which	B-NP	WDT	O	17	NMOD
20	was	be	B-VP	VBD	O	19	SBAR
21	inhibited	inhibit	I-VP	VBN	O	20	VC
22	by	by	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	28	NMOD
24	alpha-TC	alpha-TC	I-NP	NN	O	28	NMOD
25	and	and	I-NP	CC	O	28	NMOD
26	DFO	DFO	I-NP	NN	O	28	NMOD
27	pretreatment.	pretreatment.	I-NP	NN	O	28	NMOD
28	alpha-TC	alpha-TC	I-NP	NN	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	DFO	DFO	I-NP	NN	O	22	PMOD
31	attenuated	attenuate	B-VP	VBD	O	15	SBAR
32	the	the	B-NP	DT	O	33	NMOD
33	MA	MA	I-NP	NN	B-protein	35	NMOD
34	induced	induce	B-VP	VBD	O	35	NMOD
35	hyperthermia	hyperthermia	B-NP	NN	O	40	NMOD
36	as	as	B-CONJP	RB	O	40	NMOD
37	well	well	I-CONJP	RB	O	36	DEP
38	as	as	I-CONJP	IN	O	36	DEP
39	the	the	B-NP	DT	O	40	NMOD
40	alterations	alteration	I-NP	NNS	O	31	OBJ
41	in	in	B-PP	IN	O	40	NMOD
42	the	the	B-NP	DT	O	44	NMOD
43	locomotor	locomotor	I-NP	NN	O	44	NMOD
44	activity	activity	I-NP	NN	O	41	PMOD
45	.	.	O	.	O	13	P

1	Use	Use	B-NP	NN	O	11	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	dexamethasone	dexamethasone	B-NP	NN	O	2	PMOD
4	with	with	B-PP	IN	O	1	NMOD
5	mesna	mesna	B-NP	NN	O	4	PMOD
6	for	for	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	prevention	prevention	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	ifosfamide	ifosfamide	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	0	ROOT
12	hemorrhagic	hemorrhagic	B-NP	JJ	O	13	NMOD
13	cystitis	cystitis	I-NP	NN	O	11	OBJ
14	.	.	O	.	O	11	P

1	AIM	AIM	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Hemorrhagic	Hemorrhagic	B-NP	JJ	O	4	NMOD
4	cystitis	cystitis	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	HC	HC	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	a	a	B-NP	DT	O	11	NMOD
10	limiting	limit	I-NP	VBG	O	11	NMOD
11	side-effect	side-effect	I-NP	NN	O	8	PRD
12	of	of	B-PP	IN	O	11	NMOD
13	chemotherapy	chemotherapy	B-NP	NN	O	12	PMOD
14	with	with	B-PP	IN	O	11	NMOD
15	ifosfamide	ifosfamide	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	18	DEP
17	IFS	IFS	B-NP	NN	B-protein	18	DEP
18	)	)	O	)	O	15	NMOD
19	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	presented	present	B-VP	VBN	O	3	NMOD
5	here	here	B-ADVP	RB	O	4	VMOD
6	,	,	O	,	O	8	P
7	we	we	B-NP	PRP	O	8	SUB
8	investigated	investigate	B-VP	VBD	O	0	ROOT
9	the	the	B-NP	DT	O	10	NMOD
10	use	use	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	dexamethasone	dexamethasone	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	combination	combination	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	mesna	mesna	B-NP	NN	O	15	PMOD
17	for	for	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	prevention	prevention	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	IFS	IFS	B-NP	NN	B-protein	23	NMOD
22	induced	induced	I-NP	JJ	O	23	NMOD
23	HC	HC	I-NP	NN	O	20	PMOD
24	.	.	O	.	O	8	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Dexamethasone	Dexamethasone	B-NP	NN	O	8	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	combination	combination	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	mesna	mesna	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	efficient	efficient	B-ADJP	JJ	O	8	PRD
10	in	in	B-PP	IN	O	9	AMOD
11	blocking	block	B-VP	VBG	O	10	PMOD
12	IFS	IFS	B-NP	NN	B-protein	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	HC	HC	I-NP	NN	O	11	OBJ
15	.	.	O	.	O	8	P

1	Reserpine	Reserpine	B-NP	NN	O	11	NMOD
2	(	(	O	(	O	5	DEP
3	1	1	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	,	,	O	,	O	1	P
7	administered	administer	B-VP	VBN	O	11	NMOD
8	once	once	B-ADVP	RB	O	7	VMOD
9	every	every	B-NP	DT	O	11	NMOD
10	other	other	I-NP	JJ	O	11	NMOD
11	day	day	I-NP	NN	O	16	SUB
12	for	for	B-PP	IN	O	11	NMOD
13	4	4	B-NP	CD	O	14	NMOD
14	days	day	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	11	P
16	produced	produce	B-VP	VBD	O	0	ROOT
17	increases	increase	B-NP	NNS	O	26	NMOD
18	in	in	B-PP	IN	O	17	NMOD
19	orofacial	orofacial	B-NP	JJ	O	20	NMOD
20	dyskinesia	dyskinesia	I-NP	NN	O	18	PMOD
21	,	,	O	,	O	26	P
22	tongue	tongue	B-NP	NN	O	23	NMOD
23	protrusion	protrusion	I-NP	NN	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	vacuous	vacuous	B-NP	JJ	O	26	NMOD
26	chewing	chewing	I-NP	NN	O	16	OBJ
27	in	in	B-PP	IN	O	26	NMOD
28	mice	mouse	B-NP	NNS	O	27	PMOD
29	,	,	O	,	O	28	P
30	which	which	B-NP	WDT	O	28	NMOD
31	are	be	B-VP	VBP	O	30	SBAR
32	signs	sign	B-NP	NNS	O	31	PRD
33	indicative	indicative	B-ADJP	JJ	O	32	NMOD
34	of	of	B-PP	IN	O	33	AMOD
35	tardive	tardive	B-NP	JJ	O	36	NMOD
36	dyskinesia	dyskinesia	I-NP	NN	O	34	PMOD
37	.	.	O	.	O	16	P

1	Reserpine	Reserpine	B-NP	NN	O	3	SUB
2	also	also	B-ADVP	RB	O	3	VMOD
3	produced	produce	B-VP	VBD	O	0	ROOT
4	tremor	tremor	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	catalepsy	catalepsy	I-NP	NN	O	3	OBJ
7	,	,	O	,	O	6	P
8	which	which	B-NP	WDT	O	6	NMOD
9	are	be	B-VP	VBP	O	8	SBAR
10	signs	sign	B-NP	NNS	O	9	PRD
11	suggestive	suggestive	B-ADJP	JJ	O	10	NMOD
12	of	of	B-PP	IN	O	11	AMOD
13	Parkinson	Parkinson	B-NP	NNP	O	15	NMOD
14	's	's	B-NP	POS	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	3	P

1	MK-801	MK-801	B-NP	NN	O	9	NMOD
2	(	(	O	(	O	5	DEP
3	0.1	0.1	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	,	,	O	,	O	1	P
7	administered	administer	B-VP	VBN	O	9	NMOD
8	30	30	B-NP	CD	O	9	NMOD
9	min	min	I-NP	NN	O	15	SUB
10	before	before	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	observation	observation	I-NP	NN	O	13	NMOD
13	test	test	I-NP	NN	O	10	PMOD
14	,	,	O	,	O	9	P
15	prevented	prevent	B-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	19	NMOD
17	vacuous	vacuous	I-NP	JJ	O	19	NMOD
18	chewing	chewing	I-NP	NN	O	19	NMOD
19	movements	movement	I-NP	NNS	O	24	NMOD
20	,	,	O	,	O	24	P
21	tongue	tongue	B-NP	NN	O	22	NMOD
22	protrusions	protrusion	I-NP	NNS	O	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	catalepsy	catalepsy	B-NP	NN	O	15	OBJ
25	induced	induce	B-VP	VBN	O	24	NMOD
26	by	by	B-PP	IN	O	25	VMOD
27	reserpine	reserpine	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	15	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	MK-801	MK-801	B-NP	NN	O	4	NMOD
4	injection	injection	I-NP	NN	O	5	SUB
5	produced	produce	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	8	NMOD
7	significant	significant	I-NP	JJ	O	8	NMOD
8	increase	increase	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	tremor	tremor	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	reserpine-treated	reserpine-treated	B-NP	JJ	O	13	NMOD
13	mice	mouse	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	5	P

1	Reserpine	Reserpine	B-NP	NN	O	7	SUB
2	(	(	O	(	O	5	DEP
3	1	1	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	,	,	O	,	O	1	P
7	administered	administer	B-VP	VBN	O	9	NMOD
8	90	90	B-NP	CD	O	9	NMOD
9	min	min	I-NP	NN	O	28	SUB
10	before	before	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	test	test	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	9	VMOD
14	followed	follow	B-VP	VBN	O	9	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	apomophine	apomophine	B-NP	NN	O	17	NMOD
17	injection	injection	I-NP	NN	O	23	NMOD
18	(	(	O	(	O	21	DEP
19	0.1	0.1	B-NP	CD	O	20	NMOD
20	mg/kg	mg/kg	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	5	5	B-NP	CD	O	23	NMOD
23	min	min	I-NP	NN	O	15	PMOD
24	before	before	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	test	test	I-NP	NN	O	24	PMOD
27	,	,	O	,	O	9	P
28	did	do	B-VP	VBD	O	0	ROOT
29	not	not	I-VP	RB	O	28	VMOD
30	produce	produce	I-VP	VB	O	28	VC
31	oral	oral	B-NP	JJ	O	32	NMOD
32	dyskinesia	dyskinesia	I-NP	NN	O	30	OBJ
33	in	in	B-PP	IN	O	32	NMOD
34	mice	mouse	B-NP	NNS	O	33	PMOD
35	.	.	O	.	O	28	P

1	On	On	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	hand	hand	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	reserpine	reserpine	B-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	increases	increase	B-NP	NNS	O	7	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	tremor	tremor	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	catalepsy	catalepsy	I-NP	NN	O	9	PMOD
13	compared	compare	B-VP	VBN	O	8	NMOD
14	to	to	B-PP	TO	O	13	PMOD
15	control	control	B-NP	NN	O	16	NMOD
16	mice	mouse	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	7	P

1	MK-801	MK-801	B-NP	NN	O	6	NMOD
2	(	(	O	(	O	5	DEP
3	0.1	0.1	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	5	DEP
5	)	)	O	)	O	1	NMOD
6	administration	administration	B-NP	NN	O	7	SUB
7	attenuated	attenuate	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	11	NMOD
9	catalepsy	catalepsy	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	tremor	tremor	I-NP	NN	O	7	OBJ
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	reserpine	reserpine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	7	P

1	Pretreatment	Pretreatment	B-NP	NN	O	14	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	reserpine	reserpine	B-NP	NN	O	9	NMOD
4	(	(	O	(	O	7	DEP
5	1	1	B-NP	CD	O	6	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	7	DEP
7	)	)	O	)	O	3	NMOD
8	24	24	B-NP	CD	O	9	NMOD
9	h	h	I-NP	NN	O	2	PMOD
10	before	before	B-PP	IN	O	1	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	observation	observation	I-NP	NN	O	13	NMOD
13	test	test	I-NP	NN	O	10	PMOD
14	produced	produce	B-VP	VBD	O	33	VMOD
15	increases	increase	B-NP	NNS	O	22	NMOD
16	in	in	B-PP	IN	O	15	NMOD
17	vacuous	vacuous	B-NP	JJ	O	19	NMOD
18	chewing	chewing	I-NP	NN	O	19	NMOD
19	movements	movement	I-NP	NNS	O	16	PMOD
20	and	and	O	CC	O	22	NMOD
21	tongue	tongue	B-NP	NN	O	22	NMOD
22	protrusion	protrusion	I-NP	NN	O	27	NMOD
23	,	,	O	,	O	27	P
24	as	as	B-CONJP	RB	O	27	NMOD
25	well	well	I-CONJP	RB	O	24	DEP
26	as	as	I-CONJP	IN	O	24	DEP
27	increases	increase	B-NP	NNS	O	14	OBJ
28	in	in	B-PP	IN	O	27	NMOD
29	tremor	tremor	B-NP	NN	O	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	catalepsy	catalepsy	I-NP	NN	O	28	PMOD
32	,	,	O	,	O	33	P
33	whereas	whereas	O	IN	O	0	ROOT
34	MK-801	MK-801	B-NP	NN	B-protein	39	NMOD
35	(	(	O	(	O	38	DEP
36	0.1	0.1	B-NP	CD	O	37	NMOD
37	mg/kg	mg/kg	I-NP	NN	O	38	DEP
38	)	)	O	)	O	34	NMOD
39	injection	injection	B-NP	NN	O	41	NMOD
40	90	90	I-NP	CD	O	41	NMOD
41	min	min	I-NP	NN	O	45	SUB
42	before	before	B-PP	IN	O	41	NMOD
43	the	the	B-NP	DT	O	44	NMOD
44	test	test	I-NP	NN	O	42	PMOD
45	reversed	reverse	B-VP	VBD	O	33	VMOD
46	the	the	B-NP	DT	O	47	NMOD
47	effects	effect	I-NP	NNS	O	45	OBJ
48	of	of	B-PP	IN	O	47	NMOD
49	reserpine	reserpine	B-NP	NN	O	48	PMOD
50	.	.	O	.	O	33	P

1	These	These	B-NP	DT	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	show	show	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	reserpine	reserpine	B-NP	NN	O	6	SUB
6	produces	produce	B-VP	VBZ	O	4	SBAR
7	different	different	B-NP	JJ	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	abnormal	abnormal	I-NP	JJ	O	10	NMOD
10	movements	movement	I-NP	NNS	O	6	OBJ
11	,	,	O	,	O	10	P
12	which	which	B-NP	WDT	O	10	NMOD
13	are	be	B-VP	VBP	O	12	SBAR
14	related	relate	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	dose	dose	B-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	schedule	schedule	I-NP	NN	O	15	PMOD
19	employed	employ	B-VP	VBN	O	18	NMOD
20	and	and	O	CC	O	13	VMOD
21	can	can	B-VP	MD	O	13	VMOD
22	be	be	I-VP	VB	O	21	VC
23	considered	consider	I-VP	VBN	O	22	VC
24	as	as	B-PP	IN	O	23	VMOD
25	parkinsonian-like	parkinsonian-like	B-NP	JJ	O	27	AMOD
26	and	and	I-NP	CC	O	27	AMOD
27	tardive	tardive	I-NP	JJ	O	29	NMOD
28	dsykinesia	dsykinesia	I-NP	NN	O	29	NMOD
29	signs	sign	I-NP	NNS	O	24	PMOD
30	.	.	O	.	O	3	P

1	Effect	Effect	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	glyceryl	glyceryl	B-NP	NN	O	4	NMOD
4	trinitrate	trinitrate	I-NP	NN	O	2	PMOD
5	on	on	B-PP	IN	O	1	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	sphincter	sphincter	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	Oddi	Oddi	B-NP	NNP	O	10	NMOD
10	spasm	spasm	I-NP	NN	O	8	PMOD
11	evoked	evoke	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	prostigmine-morphine	prostigmine-morphine	B-NP	NN	O	14	NMOD
14	administration	administration	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	In	In	B-PP	IN	O	1	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	the	the	B-NP	DT	O	7	NMOD
7	effect	effect	I-NP	NN	O	14	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	glyceryl	glyceryl	B-NP	NN	O	10	NMOD
10	trinitrate	trinitrate	I-NP	NN	O	8	PMOD
11	on	on	B-PP	IN	O	7	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	prostigmine-morphine	prostigmine-morphine	I-NP	NN	O	11	PMOD
14	induced	induce	B-VP	VBD	O	3	SBAR
15	sphincter	sphincter	B-NP	NN	O	14	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	Oddi	Oddi	B-NP	NNP	O	18	NMOD
18	spasm	spasm	I-NP	NN	O	16	PMOD
19	was	be	B-VP	VBD	O	14	VMOD
20	evaluated	evaluate	I-VP	VBN	O	19	VC
21	in	in	B-PP	IN	O	20	VMOD
22	nine	nine	B-NP	CD	O	24	NMOD
23	female	female	I-NP	JJ	O	24	NMOD
24	patients	patient	I-NP	NNS	O	21	PMOD
25	with	with	B-PP	IN	O	24	NMOD
26	sphincter	sphincter	B-NP	NN	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	Oddi	Oddi	B-NP	NNP	O	29	NMOD
29	dyskinesia	dyskinesia	I-NP	NN	O	27	PMOD
30	.	.	O	.	O	1	P

1	METHOD	METHOD	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	1	P
3	Sphincter	Sphincter	B-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	Oddi	Oddi	B-NP	NNP	O	6	NMOD
6	spasm	spasm	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	induced	induce	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	prostigmine-morphine	prostigmine-morphine	B-NP	NN	O	11	NMOD
11	administration	administration	I-NP	NN	O	9	PMOD
12	(	(	O	(	O	11	NMOD
13	0.5	0.5	B-NP	CD	O	14	AMOD
14	mg	mg	I-NP	NN	O	15	NMOD
15	prostigmine	prostigmine	I-NP	NN	O	12	PMOD
16	intramuscularly	intramuscularly	B-ADVP	RB	O	24	VMOD
17	and	and	O	CC	O	16	AMOD
18	10	10	B-NP	CD	O	16	AMOD
19	mg	mg	I-NP	NN	O	20	NMOD
20	morphine	morphine	I-NP	NN	O	22	DEP
21	subcutaneously	subcutaneously	B-ADVP	RB	O	20	NMOD
22	)	)	O	)	O	16	AMOD
23	and	and	O	CC	O	16	DEP
24	visualized	visualize	B-VP	VBN	O	15	NMOD
25	by	by	B-PP	IN	O	24	VMOD
26	quantitative	quantitative	B-NP	JJ	O	28	NMOD
27	hepatobiliary	hepatobiliary	I-NP	JJ	O	28	NMOD
28	scintigraphy	scintigraphy	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	7	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Prostigmine-morphine	Prostigmine-morphine	B-NP	NN	O	4	NMOD
4	provocation	provocation	I-NP	NN	O	5	SUB
5	caused	cause	B-VP	VBD	O	1	NMOD
6	significant	significant	B-NP	JJ	O	7	NMOD
7	increases	increase	I-NP	NNS	O	36	NMOD
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	time	time	I-NP	NN	O	8	PMOD
11	to	to	B-PP	TO	O	10	NMOD
12	peak	peak	B-NP	JJ	O	13	NMOD
13	activity	activity	I-NP	NN	O	11	PMOD
14	(	(	O	(	O	16	DEP
15	Tmax	Tmax	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	over	over	B-PP	IN	O	7	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	hepatic	hepatic	I-NP	JJ	O	20	NMOD
20	hilum	hilum	I-NP	NN	O	17	PMOD
21	(	(	O	(	O	31	DEP
22	HH	HH	B-NP	NN	O	30	NMOD
23	:	:	O	:	O	30	P
24	34.33	34.33	B-NP	CD	O	26	AMOD
25	+/-	+/-	I-NP	CC	O	26	AMOD
26	5.05	5.05	I-NP	CD	O	30	NMOD
27	vs.	vs.	B-PP	CC	O	30	NMOD
28	22.77	22.77	B-NP	CD	O	30	NMOD
29	+/-	+/-	I-NP	CC	O	30	NMOD
30	3.26	3.26	I-NP	CD	O	31	DEP
31	)	)	O	)	O	20	NMOD
32	and	and	O	CC	O	36	NMOD
33	the	the	B-NP	DT	O	36	NMOD
34	common	common	I-NP	JJ	O	36	NMOD
35	bile	bile	I-NP	NN	O	36	NMOD
36	duct	duct	I-NP	NN	O	5	OBJ
37	(	(	O	(	O	47	DEP
38	CBD	CBD	B-NP	NN	O	46	SUB
39	:	:	O	:	O	46	P
40	60.44	60.44	B-NP	CD	O	42	AMOD
41	+/-	+/-	I-NP	CC	O	42	AMOD
42	5.99	5.99	I-NP	CD	O	46	NMOD
43	vs.	vs.	B-PP	CC	O	46	NMOD
44	40.0	40.0	B-NP	CD	O	46	NMOD
45	+/-	+/-	I-NP	CC	O	46	NMOD
46	2.88	2.88	I-NP	CD	O	47	DEP
47	)	)	O	)	O	36	NMOD
48	and	and	O	CC	O	36	NMOD
49	in	in	B-PP	IN	O	48	DEP
50	the	the	B-NP	DT	O	51	NMOD
51	half-time	half-time	I-NP	NN	O	49	PMOD
52	of	of	B-PP	IN	O	51	NMOD
53	excretion	excretion	B-NP	NN	O	52	PMOD
54	(	(	O	(	O	56	DEP
55	T1/2	T1/2	B-NP	NN	O	56	DEP
56	)	)	O	)	O	53	NMOD
57	over	over	B-PP	IN	O	49	PMOD
58	the	the	B-NP	DT	O	60	NMOD
59	liver	liver	I-NP	NN	O	60	NMOD
60	parenchyma	parenchyma	I-NP	NN	O	84	NMOD
61	(	(	O	(	O	71	DEP
62	LP	LP	B-NP	NN	O	70	NMOD
63	:	:	O	:	O	70	P
64	120.04	120.04	B-NP	CD	O	66	AMOD
65	+/-	+/-	I-NP	CC	O	66	AMOD
66	16.01	16.01	I-NP	CD	O	70	NMOD
67	vs.	vs.	B-PP	CC	O	70	NMOD
68	27.37	27.37	B-NP	CD	O	70	AMOD
69	+/-	+/-	I-NP	CC	O	70	AMOD
70	2.19	2.19	I-NP	CD	O	71	DEP
71	)	)	O	)	O	60	NMOD
72	,	,	O	,	O	84	P
73	HH	HH	B-NP	NN	O	84	NMOD
74	(	(	O	(	O	82	DEP
75	117.61	117.61	B-NP	CD	O	77	AMOD
76	+/-	+/-	I-NP	SYM	O	77	AMOD
77	14.71	14.71	I-NP	CD	O	81	NMOD
78	vs.	vs.	B-PP	IN	O	81	NMOD
79	31.85	31.85	B-NP	CD	O	81	AMOD
80	+/-	+/-	I-NP	SYM	O	81	AMOD
81	3.99	3.99	I-NP	CD	O	82	DEP
82	)	)	O	)	O	73	NMOD
83	and	and	O	CC	O	84	NMOD
84	CBD	CBD	B-NP	NN	B-protein	57	PMOD
85	(	(	O	(	O	93	DEP
86	158.11	158.11	B-NP	CD	O	88	AMOD
87	+/-	+/-	I-NP	SYM	O	88	AMOD
88	9.18	9.18	I-NP	CD	O	93	DEP
89	vs.	vs.	B-PP	IN	O	88	NMOD
90	40.1	40.1	B-NP	CD	O	92	AMOD
91	+/-	+/-	I-NP	SYM	O	92	AMOD
92	6.24	6.24	I-NP	CD	O	89	PMOD
93	)	)	O	)	O	84	NMOD
94	,	,	O	,	O	95	P
95	indicating	indicate	B-VP	VBG	O	49	PMOD
96	a	a	B-NP	DT	O	98	NMOD
97	complete	complete	I-NP	JJ	O	98	NMOD
98	spasm	spasm	I-NP	NN	O	95	OBJ
99	at	at	B-PP	IN	O	98	NMOD
100	the	the	B-NP	DT	O	101	NMOD
101	level	level	I-NP	NN	O	99	PMOD
102	of	of	B-PP	IN	O	101	NMOD
103	the	the	B-NP	DT	O	104	NMOD
104	sphincter	sphincter	I-NP	NN	O	102	PMOD
105	of	of	B-PP	IN	O	104	NMOD
106	Oddi	Oddi	B-NP	NNP	O	105	PMOD
107	.	.	O	.	O	1	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	These	These	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	provide	provide	B-VP	VBP	O	1	NMOD
6	the	the	B-NP	DT	O	8	NMOD
7	first	first	I-NP	JJ	O	8	NMOD
8	evidence	evidence	I-NP	NN	O	5	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	effectiveness	effectiveness	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	glyceryl	glyceryl	B-NP	NN	O	14	NMOD
14	trinitrate	trinitrate	I-NP	NN	O	12	PMOD
15	on	on	B-PP	IN	O	11	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	morphine	morphine	I-NP	NN	O	15	PMOD
18	induced	induce	B-VP	VBD	O	5	VMOD
19	sphincter	sphincter	B-NP	NN	O	18	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	Oddi	Oddi	B-NP	NNP	O	22	NMOD
22	spasm	spasm	I-NP	NN	O	20	PMOD
23	in	in	B-PP	IN	O	19	NMOD
24	humans	human	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	1	P

1	Occasional	Occasional	B-NP	JJ	O	3	NMOD
2	case	case	I-NP	NN	O	3	NMOD
3	reports	report	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	shown	show	I-VP	VBN	O	4	VC
6	that	that	B-SBAR	IN	O	5	VMOD
7	acute	acute	B-NP	JJ	O	8	NMOD
8	myopathy	myopathy	I-NP	NN	O	9	SUB
9	may	may	B-VP	MD	O	6	SBAR
10	occur	occur	I-VP	VB	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	treated	treat	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	massive	massive	B-NP	JJ	O	16	NMOD
16	doses	dose	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	corticosteroids	corticosteroid	B-NP	NNS	O	17	PMOD
19	.	.	O	.	O	4	P

1	Nutritional	Nutritional	B-NP	JJ	O	2	NMOD
2	intake	intake	I-NP	NN	O	10	SUB
3	,	,	O	,	O	2	P
4	measured	measure	B-VP	VBN	O	2	NMOD
5	daily	daily	B-ADVP	RB	O	4	VMOD
6	in	in	B-PP	IN	O	4	VMOD
7	15	15	B-NP	CD	O	8	NMOD
8	animals	animal	I-NP	NNS	O	6	PMOD
9	,	,	O	,	O	2	P
10	showed	show	B-VP	VBD	O	0	ROOT
11	a	a	B-NP	DT	O	13	NMOD
12	significant	significant	I-NP	JJ	O	13	NMOD
13	reduction	reduction	I-NP	NN	O	10	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	food	food	B-NP	NN	O	16	NMOD
16	intake	intake	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	13	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	steroid-treated	steroid-treated	I-NP	JJ	O	20	NMOD
20	groups	group	I-NP	NNS	O	17	PMOD
21	(	(	O	(	O	32	DEP
22	-50	-50	B-NP	CD	O	24	AMOD
23	and	and	I-NP	CC	O	24	AMOD
24	-79	-79	I-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	32	DEP
26	in	in	B-PP	IN	O	25	NMOD
27	M	M	B-NP	NN	O	29	NMOD
28	and	and	O	CC	O	29	NMOD
29	T	T	B-NP	NN	O	26	PMOD
30	,	,	O	,	O	25	P
31	respectively	respectively	B-ADVP	RB	O	25	NMOD
32	)	)	O	)	O	13	NMOD
33	.	.	O	.	O	10	P

1	Half-relaxation	Half-relaxation	B-NP	NN	O	2	NMOD
2	time	time	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	15	VMOD
4	prolonged	prolong	I-VP	VBN	O	3	VC
5	in	in	B-PP	IN	O	4	VMOD
6	both	both	O	CC	O	8	NMOD
7	steroid	steroid	B-NP	NN	O	8	NMOD
8	groups	group	I-NP	NNS	O	5	PMOD
9	,	,	O	,	O	15	P
10	and	and	O	CC	O	15	VMOD
11	time	time	B-NP	NN	O	15	SUB
12	to	to	B-PP	TO	O	11	NMOD
13	peak	peak	B-NP	JJ	O	14	NMOD
14	tension	tension	I-NP	NN	O	12	PMOD
15	was	be	B-VP	VBD	O	0	ROOT
16	longer	longer	B-ADVP	RBR	O	15	PRD
17	with	with	B-PP	IN	O	16	AMOD
18	M	M	B-NP	NN	O	17	PMOD
19	,	,	O	,	O	15	P
20	whereas	whereas	O	IN	O	15	VMOD
21	tetanic	tetanic	B-NP	JJ	O	22	NMOD
22	tensions	tension	I-NP	NNS	O	23	SUB
23	were	be	B-VP	VBD	O	20	SBAR
24	similar	similar	B-ADJP	JJ	O	23	PRD
25	.	.	O	.	O	15	P

1	ATPase	ATPase	B-NP	NN	O	2	NMOD
2	staining	staining	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	diaphragm	diaphragm	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	12	P
7	scalenus	scalenus	B-NP	NN	O	8	NMOD
8	medius	medius	I-NP	NN	O	12	SUB
9	,	,	O	,	O	12	P
10	and	and	O	CC	O	12	VMOD
11	gastrocnemius	gastrocnemius	B-NP	NN	O	12	SUB
12	showed	show	B-VP	VBD	O	0	ROOT
13	type	type	B-NP	NN	O	16	NMOD
14	IIb	IIb	I-NP	NN	O	16	NMOD
15	fiber	fiber	I-NP	NN	O	16	NMOD
16	atrophy	atrophy	I-NP	NN	O	12	OBJ
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	steroid	steroid	I-NP	NN	O	20	NMOD
20	groups	group	I-NP	NNS	O	17	PMOD
21	and	and	O	CC	O	17	PMOD
22	also	also	B-ADVP	RB	O	17	PMOD
23	diaphragmatic	diaphragmatic	B-NP	JJ	O	26	NMOD
24	type	type	I-NP	NN	O	26	NMOD
25	IIa	IIa	I-NP	NN	O	26	NMOD
26	atrophy	atrophy	I-NP	NN	O	22	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	T	T	B-NP	NN	O	27	PMOD
29	,	,	O	,	O	12	P
30	whereas	whereas	O	IN	O	12	VMOD
31	histologic	histologic	B-NP	JJ	O	32	NMOD
32	examinations	examination	I-NP	NNS	O	33	SUB
33	revealed	reveal	B-VP	VBD	O	30	SBAR
34	a	a	B-NP	DT	O	37	NMOD
35	normal	normal	I-NP	JJ	O	37	NMOD
36	muscular	muscular	I-NP	JJ	O	37	NMOD
37	pattern	pattern	I-NP	NN	O	33	OBJ
38	with	with	B-PP	IN	O	37	NMOD
39	absence	absence	B-NP	NN	O	38	PMOD
40	of	of	B-PP	IN	O	39	NMOD
41	necrosis	necrosis	B-NP	NN	O	40	PMOD
42	.	.	O	.	O	12	P

1	Finally	Finally	B-ADVP	RB	O	23	VMOD
2	,	,	O	,	O	23	P
3	a	a	B-NP	DT	O	4	NMOD
4	pair-fed	pair-fed	I-NP	JJ	O	23	VMOD
5	(	(	O	(	O	7	DEP
6	PF	PF	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	study	study	B-NP	NN	O	4	NMOD
9	,	,	O	,	O	4	P
10	performed	perform	B-VP	VBN	O	4	NMOD
11	in	in	B-PP	IN	O	10	VMOD
12	18	18	B-NP	CD	O	13	NMOD
13	rats	rat	I-NP	NNS	O	11	PMOD
14	(	(	O	(	O	21	DEP
15	C	C	B-NP	NN	O	20	NMOD
16	,	,	O	,	O	20	P
17	T	T	B-NP	NN	O	20	NMOD
18	,	,	O	,	O	20	P
19	and	and	O	CC	O	20	NMOD
20	PF	PF	B-NP	NN	B-protein	21	DEP
21	)	)	O	)	O	13	NMOD
22	,	,	O	,	O	23	P
23	showed	show	B-VP	VBD	O	0	ROOT
24	that	that	B-SBAR	IN	O	23	VMOD
25	muscle	muscle	B-NP	NN	O	26	NMOD
26	atrophy	atrophy	I-NP	NN	O	27	SUB
27	was	be	B-VP	VBD	O	24	SBAR
28	considerably	considerably	B-ADJP	RB	O	27	PRD
29	less	less	I-ADJP	RBR	O	28	AMOD
30	pronounced	pronounced	I-ADJP	JJ	O	28	AMOD
31	in	in	B-PP	IN	O	28	AMOD
32	PF	PF	B-NP	NN	O	33	NMOD
33	animals	animal	I-NP	NNS	O	31	PMOD
34	than	than	B-PP	IN	O	28	AMOD
35	in	in	B-PP	IN	O	34	PMOD
36	T-treated	T-treated	B-NP	JJ	O	37	NMOD
37	animals	animal	I-NP	NNS	O	35	PMOD
38	.	.	O	.	O	23	P

1	(	(	B-LST	(	O	2	DEP
2	2	2	I-LST	LS	O	8	VMOD
3	)	)	O	)	O	2	DEP
4	both	both	B-NP	DT	O	5	NMOD
5	types	type	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	steroids	steroid	B-NP	NNS	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	predominantly	predominantly	B-NP	RB	O	8	VMOD
10	type	type	I-NP	NN	O	12	NMOD
11	IIb	IIb	I-NP	NN	O	12	NMOD
12	atrophy	atrophy	I-NP	NN	O	8	OBJ
13	,	,	O	,	O	8	P
14	resulting	result	B-VP	VBG	O	8	VMOD
15	in	in	B-PP	IN	O	14	VMOD
16	the	the	B-NP	DT	O	18	NMOD
17	expected	expected	I-NP	JJ	O	18	NMOD
18	alterations	alteration	I-NP	NNS	O	15	PMOD
19	in	in	B-PP	IN	O	18	NMOD
20	diaphragm	diaphragm	B-NP	NN	O	22	NMOD
21	contractile	contractile	I-NP	JJ	O	22	NMOD
22	properties	property	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	8	P

1	(	(	B-LST	(	O	2	DEP
2	3	3	I-LST	LS	O	6	VMOD
3	)	)	O	)	O	2	DEP
4	neither	neither	B-NP	DT	O	5	NMOD
5	steroid	steroid	I-NP	NN	O	6	SUB
6	caused	cause	B-VP	VBD	O	0	ROOT
7	muscle	muscle	B-NP	NN	O	8	NMOD
8	necrosis	necrosis	I-NP	NN	O	6	OBJ
9	.	.	O	.	O	6	P

1	Refractory	Refractory	B-NP	JJ	O	3	NMOD
2	cardiogenic	cardiogenic	I-NP	JJ	O	3	NMOD
3	shock	shock	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	complete	complete	B-NP	JJ	O	7	NMOD
6	heart	heart	I-NP	NN	O	7	NMOD
7	block	block	I-NP	NN	O	0	ROOT
8	after	after	B-PP	IN	O	7	NMOD
9	verapamil	verapamil	B-NP	NN	B-protein	10	NMOD
10	SR	SR	I-NP	NN	I-protein	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	metoprolol	metoprolol	B-NP	NN	O	13	NMOD
13	treatment	treatment	I-NP	NN	O	8	PMOD
14	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	3	NMOD
2	seventy-eight-year-old	seventy-eight-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	4	SUB
4	presented	present	B-VP	VBD	O	0	ROOT
5	with	with	B-PP	IN	O	4	VMOD
6	complete	complete	B-NP	JJ	O	8	NMOD
7	heart	heart	I-NP	NN	O	8	NMOD
8	block	block	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	refractory	refractory	B-NP	JJ	O	11	NMOD
11	hypotension	hypotension	I-NP	NN	O	13	NMOD
12	two	two	B-NP	CD	O	13	NMOD
13	days	day	I-NP	NNS	O	5	PMOD
14	after	after	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	17	NMOD
16	therapeutic	therapeutic	I-NP	JJ	O	17	NMOD
17	dose	dose	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	sustained-release	sustained-release	B-NP	JJ	O	20	NMOD
20	verapamil	verapamil	I-NP	NN	O	18	PMOD
21	with	with	B-PP	IN	O	17	NMOD
22	concomitant	concomitant	B-NP	JJ	O	23	NMOD
23	use	use	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	metoprolol	metoprolol	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	3	SUB
3	continued	continue	B-VP	VBD	O	0	ROOT
4	to	to	I-VP	TO	O	5	VMOD
5	remain	remain	I-VP	VB	O	3	VMOD
6	hypotensive	hypotensive	B-ADJP	JJ	O	5	PRD
7	with	with	B-PP	IN	O	6	AMOD
8	complete	complete	B-NP	JJ	O	10	NMOD
9	heart	heart	I-NP	NN	O	10	NMOD
10	block	block	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	3	P
12	even	even	B-ADVP	RB	O	13	PMOD
13	with	with	B-PP	IN	O	3	VMOD
14	multiple	multiple	B-NP	JJ	O	15	NMOD
15	uses	use	I-NP	NNS	O	23	NMOD
16	of	of	B-PP	IN	O	15	NMOD
17	intravenous	intravenous	B-NP	JJ	O	18	NMOD
18	atropine	atropine	I-NP	NN	O	16	PMOD
19	as	as	B-CONJP	RB	O	23	NMOD
20	well	well	I-CONJP	RB	O	19	DEP
21	as	as	I-CONJP	IN	O	19	DEP
22	high	high	B-NP	JJ	O	23	NMOD
23	doses	dose	I-NP	NNS	O	13	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	pressor	pressor	B-NP	NN	O	26	NMOD
26	agents	agent	I-NP	NNS	O	24	PMOD
27	such	such	B-PP	JJ	O	28	PMOD
28	as	as	I-PP	IN	O	26	NMOD
29	dopamine	dopamine	B-NP	NN	O	31	NMOD
30	and	and	I-NP	CC	O	31	NMOD
31	dobutamine	dobutamine	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	3	P

1	Extensive	Extensive	B-NP	JJ	O	6	NMOD
2	experimental	experimental	I-NP	JJ	O	5	AMOD
3	and	and	I-NP	CC	O	5	AMOD
4	limited	limited	I-NP	JJ	O	5	AMOD
5	clinical	clinical	I-NP	JJ	O	6	NMOD
6	data	datum	I-NP	NNS	O	7	SUB
7	have	have	B-VP	VBP	O	0	ROOT
8	shown	show	I-VP	VBN	O	7	VC
9	that	that	B-SBAR	IN	O	8	VMOD
10	lometrexol	lometrexol	B-NP	NN	O	11	SUB
11	has	have	B-VP	VBZ	O	9	SBAR
12	activity	activity	B-NP	NN	O	11	OBJ
13	against	against	B-PP	IN	O	11	VMOD
14	tumours	tumour	B-NP	NNS	O	13	PMOD
15	which	which	B-NP	WDT	O	14	NMOD
16	are	be	B-VP	VBP	O	15	SBAR
17	refractory	refractory	B-ADJP	JJ	O	16	PRD
18	to	to	B-PP	TO	O	17	AMOD
19	other	other	B-NP	JJ	O	20	NMOD
20	drugs	drug	I-NP	NNS	O	18	PMOD
21	,	,	O	,	O	23	P
22	notably	notably	B-NP	RB	O	23	NMOD
23	methotrexate	methotrexate	I-NP	NN	O	11	VMOD
24	.	.	O	.	O	7	P

1	However	However	B-ADVP	RB	O	9	VMOD
2	,	,	O	,	O	9	P
3	the	the	B-NP	DT	O	6	NMOD
4	initial	initial	I-NP	JJ	O	6	NMOD
5	clinical	clinical	I-NP	JJ	O	6	NMOD
6	development	development	I-NP	NN	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	lometrexol	lometrexol	B-NP	NN	O	7	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	curtailed	curtail	I-VP	VBN	O	9	VC
11	because	because	B-PP	IN	O	10	VMOD
12	of	of	I-PP	IN	O	11	PMOD
13	severe	severe	B-NP	JJ	O	15	AMOD
14	and	and	I-NP	CC	O	15	AMOD
15	cumulative	cumulative	I-NP	JJ	O	17	NMOD
16	antiproliferative	antiproliferative	I-NP	JJ	O	17	NMOD
17	toxicities	toxicity	I-NP	NNS	O	12	PMOD
18	.	.	O	.	O	9	P

1	Preclinical	Preclinical	B-NP	JJ	O	3	NMOD
2	murine	murine	I-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	4	SUB
4	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	lometrexol	lometrexol	B-NP	NN	O	8	PMOD
10	can	can	B-VP	MD	O	5	SBAR
11	be	be	I-VP	VB	O	10	VC
12	prevented	prevent	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	low	low	B-NP	JJ	O	18	NMOD
15	dose	dose	I-NP	NN	O	18	NMOD
16	folic	folic	I-NP	JJ	O	18	NMOD
17	acid	acid	I-NP	NN	O	18	NMOD
18	administration	administration	I-NP	NN	O	13	PMOD
19	,	,	O	,	O	13	P
20	i.e.	i.e.	B-PP	FW	O	13	PMOD
21	for	for	B-PP	IN	O	12	VMOD
22	7	7	B-NP	CD	O	23	NMOD
23	days	day	I-NP	NNS	O	28	NMOD
24	prior	prior	B-ADJP	JJ	O	23	NMOD
25	to	to	B-PP	TO	O	24	AMOD
26	and	and	O	CC	O	28	NMOD
27	7	7	B-NP	CD	O	28	NMOD
28	days	day	I-NP	NNS	O	21	PMOD
29	following	follow	B-PP	VBG	O	12	VMOD
30	a	a	B-NP	DT	O	33	NMOD
31	single	single	I-NP	JJ	O	33	NMOD
32	bolus	bolus	I-NP	NN	O	33	NMOD
33	dose	dose	I-NP	NN	O	29	PMOD
34	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	2	NMOD
2	observation	observation	I-NP	NN	O	3	SUB
3	prompted	prompt	B-VP	VBD	O	0	ROOT
4	a	a	B-NP	DT	O	8	NMOD
5	Phase	Phase	I-NP	NN	O	8	NMOD
6	I	I	I-NP	CD	O	8	NMOD
7	clinical	clinical	I-NP	JJ	O	8	NMOD
8	study	study	I-NP	NN	O	3	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	lometrexol	lometrexol	B-NP	NN	O	9	PMOD
11	given	give	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	folic	folic	B-NP	JJ	O	15	NMOD
14	acid	acid	I-NP	NN	O	15	NMOD
15	supplementation	supplementation	I-NP	NN	O	12	PMOD
16	which	which	B-NP	WDT	O	15	NMOD
17	has	have	B-VP	VBZ	O	16	SBAR
18	confirmed	confirm	I-VP	VBN	O	17	VC
19	that	that	B-SBAR	IN	O	18	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	toxicity	toxicity	I-NP	NN	O	24	SUB
22	of	of	B-PP	IN	O	21	NMOD
23	lometrexol	lometrexol	B-NP	NN	O	22	PMOD
24	can	can	B-VP	MD	O	19	SBAR
25	be	be	I-VP	VB	O	24	VC
26	markedly	markedly	I-VP	RB	O	25	VMOD
27	reduced	reduce	I-VP	VBN	O	25	VC
28	by	by	B-PP	IN	O	27	VMOD
29	folic	folic	B-NP	JJ	O	31	NMOD
30	acid	acid	I-NP	NN	O	31	NMOD
31	supplementation	supplementation	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	3	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	5	NMOD
4	clear	clear	I-NP	JJ	O	5	NMOD
5	relationship	relationship	I-NP	NN	O	2	PRD
6	between	between	B-PP	IN	O	2	VMOD
7	clinical	clinical	B-NP	JJ	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	extent	extent	I-NP	NN	O	6	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	plasma	plasma	B-NP	NN	O	15	NMOD
14	folate	folate	I-NP	NN	O	15	NMOD
15	elevation	elevation	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	Associated	Associate	B-NP	VBN	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	lometrexol	lometrexol	B-NP	NN	O	7	NMOD
6	plasma	plasma	I-NP	NN	O	7	NMOD
7	pharmacokinetics	pharmacokinetic	I-NP	NNS	O	8	SUB
8	were	be	B-VP	VBD	O	4	SBAR
9	not	not	I-VP	RB	O	8	VMOD
10	altered	alter	I-VP	VBN	O	8	VC
11	by	by	B-PP	IN	O	10	VMOD
12	folic	folic	B-NP	JJ	O	14	NMOD
13	acid	acid	I-NP	NN	O	14	NMOD
14	administration	administration	I-NP	NN	O	11	PMOD
15	indicating	indicate	B-VP	VBG	O	10	VMOD
16	that	that	B-SBAR	IN	O	15	VMOD
17	supplementation	supplementation	B-NP	NN	O	18	SUB
18	is	be	B-VP	VBZ	O	16	SBAR
19	unlikely	unlikely	B-ADJP	JJ	O	18	PRD
20	to	to	B-VP	TO	O	21	VMOD
21	reduce	reduce	I-VP	VB	O	19	AMOD
22	toxicity	toxicity	B-NP	NN	O	21	OBJ
23	by	by	B-PP	IN	O	21	VMOD
24	enhancing	enhance	B-VP	VBG	O	23	PMOD
25	lometrexol	lometrexol	B-NP	NN	O	27	NMOD
26	plasma	plasma	I-NP	NN	O	27	NMOD
27	clearance	clearance	I-NP	NN	O	24	OBJ
28	.	.	O	.	O	3	P

1	Intradermal	Intradermal	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	11	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	mu	mu	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	11	P
6	but	but	B-NP	CC	O	11	NMOD
7	not	not	I-NP	RB	O	6	DEP
8	delta	delta	B-NP	NN	B-protein	11	NMOD
9	or	or	O	CC	O	11	NMOD
10	kappa	kappa	B-NP	NN	O	11	NMOD
11	opioid-agonists	opioid-agonist	I-NP	NNS	O	15	SUB
12	,	,	O	,	O	15	P
13	however	however	B-ADVP	RB	O	15	VMOD
14	,	,	O	,	O	15	P
15	produced	produce	B-VP	VBD	O	21	VMOD
16	dose-dependent	dose-dependent	B-NP	JJ	O	17	NMOD
17	inhibition	inhibition	I-NP	NN	O	21	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	prostaglandin	prostaglandin	B-NP	NN	B-protein	20	NMOD
20	E2	E2	I-NP	NN	I-protein	18	PMOD
21	induced	induce	B-VP	VBD	O	0	ROOT
22	hyperalgesia	hyperalgesia	B-NP	NN	O	21	OBJ
23	.	.	O	.	O	21	P

1	Morphine	Morphine	B-NP	NN	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	not	not	O	RB	O	2	VMOD
4	,	,	O	,	O	2	P
5	however	however	B-ADVP	RB	O	2	VMOD
6	,	,	O	,	O	2	P
7	alter	alter	B-VP	VB	O	2	VC
8	the	the	B-NP	DT	O	9	NMOD
9	hyperalgesia	hyperalgesia	I-NP	NN	O	7	OBJ
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	8-bromo	8-bromo	B-NP	JJ	O	15	NMOD
13	cyclic	cyclic	I-NP	JJ	O	15	NMOD
14	adenosine	adenosine	I-NP	NN	O	15	NMOD
15	monophosphate	monophosphate	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	2	P

1	Adequate	Adequate	B-NP	JJ	O	2	NMOD
2	timing	timing	I-NP	NN	O	16	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	ribavirin	ribavirin	B-NP	NN	O	5	NMOD
5	reduction	reduction	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	hemolysis	hemolysis	B-NP	NN	O	8	PMOD
10	during	during	B-PP	IN	O	2	NMOD
11	combination	combination	B-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	interferon	interferon	B-NP	NN	B-protein	13	PMOD
15	and	and	I-NP	CC	O	16	NMOD
16	ribavirin	ribavirin	I-NP	NN	O	0	ROOT
17	for	for	B-PP	IN	O	16	NMOD
18	chronic	chronic	B-NP	JJ	O	20	NMOD
19	hepatitis	hepatitis	I-NP	NN	O	20	NMOD
20	C	C	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	16	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Hemolytic	Hemolytic	B-NP	JJ	O	4	NMOD
4	anemia	anemia	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	1	NMOD
6	one	one	B-NP	CD	O	5	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	11	NMOD
9	major	major	I-NP	JJ	O	11	NMOD
10	adverse	adverse	I-NP	JJ	O	11	NMOD
11	events	event	I-NP	NNS	O	7	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	combination	combination	I-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	interferon	interferon	B-NP	NN	B-protein	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	ribavirin	ribavirin	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	1	P

1	Because	Because	B-PP	IN	O	9	VMOD
2	of	of	I-PP	IN	O	1	PMOD
3	ribavirin-related	ribavirin-related	B-NP	JJ	O	5	NMOD
4	hemolytic	hemolytic	I-NP	JJ	O	5	NMOD
5	anemia	anemia	I-NP	NN	O	1	PMOD
6	,	,	O	,	O	9	P
7	dose	dose	B-NP	NN	O	8	NMOD
8	reduction	reduction	I-NP	NN	O	9	SUB
9	is	be	B-VP	VBZ	O	0	ROOT
10	a	a	B-NP	DT	O	12	NMOD
11	common	common	I-NP	JJ	O	12	NMOD
12	event	event	I-NP	NN	O	9	PRD
13	in	in	B-PP	IN	O	12	NMOD
14	this	this	B-NP	DT	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	9	P

1	In	In	B-PP	IN	O	8	VMOD
2	this	this	B-NP	DT	O	6	NMOD
3	clinical	clinical	I-NP	JJ	O	6	NMOD
4	retrospective	retrospective	I-NP	JJ	O	6	NMOD
5	cohort	cohort	I-NP	JJ	O	6	NMOD
6	study	study	I-NP	NN	O	1	PMOD
7	we	we	B-NP	PRP	O	8	SUB
8	have	have	B-VP	VBP	O	0	ROOT
9	examined	examine	I-VP	VBN	O	8	VC
10	the	the	B-NP	DT	O	12	NMOD
11	suitable	suitable	I-NP	JJ	O	12	NMOD
12	timing	timing	I-NP	NN	O	9	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	ribavirin	ribavirin	B-NP	NN	O	15	NMOD
15	reduction	reduction	I-NP	NN	O	13	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	hemolysis	hemolysis	B-NP	NN	O	18	PMOD
20	during	during	B-PP	IN	O	9	VMOD
21	combination	combination	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	8	P

1	However	However	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	10	10	B-NP	CD	O	4	AMOD
4	of	of	B-PP	IN	O	6	NMOD
5	37	37	B-NP	CD	O	4	AMOD
6	patients	patient	I-NP	NNS	O	11	SUB
7	with	with	B-PP	IN	O	6	NMOD
8	reduction	reduction	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	ribavirin	ribavirin	B-NP	NN	O	9	PMOD
11	could	could	B-VP	MD	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	continue	continue	I-VP	VB	O	11	VC
14	combination	combination	B-NP	NN	O	15	NMOD
15	therapy	therapy	I-NP	NN	O	13	OBJ
16	because	because	B-SBAR	IN	O	13	VMOD
17	their	their	B-NP	PRP$	O	22	NMOD
18	<	<	I-NP	SYM	O	22	NMOD
19	8.5	8.5	I-NP	CD	O	22	NMOD
20	g/dl	g/dl	I-NP	NN	O	22	NMOD
21	hemoglobin	hemoglobin	I-NP	NN	O	22	NMOD
22	values	value	I-NP	NNS	O	23	SUB
23	decreased	decrease	B-VP	VBD	O	16	SBAR
24	to	to	B-PP	TO	O	23	VMOD
25	or	or	O	CC	O	24	PMOD
26	anemia-related	anemia-related	B-NP	JJ	O	27	AMOD
27	severe	severe	I-NP	JJ	O	29	NMOD
28	side	side	I-NP	NN	O	29	NMOD
29	effects	effect	I-NP	NNS	O	30	SUB
30	occurred	occur	B-VP	VBD	O	24	SBAR
31	(	(	O	(	O	34	DEP
32	group	group	B-NP	NN	B-protein	33	NMOD
33	B	B	I-NP	NN	I-protein	34	DEP
34	)	)	O	)	O	30	VMOD
35	.	.	O	.	O	11	P

1	Increased	Increase	B-NP	VBN	O	2	NMOD
2	expression	expression	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	apical	apical	B-NP	JJ	O	5	NMOD
5	targeting	targeting	I-NP	NN	O	13	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	renal	renal	B-NP	JJ	B-protein	9	NMOD
8	ENaC	ENaC	I-NP	NN	I-protein	9	NMOD
9	subunits	subunit	I-NP	NNS	I-protein	6	PMOD
10	in	in	B-PP	IN	O	5	NMOD
11	puromycin	puromycin	B-NP	NN	O	12	NMOD
12	aminonucleoside	aminonucleoside	I-NP	NN	O	10	PMOD
13	induced	induce	B-VP	VBD	O	0	ROOT
14	nephrotic	nephrotic	B-NP	JJ	O	15	NMOD
15	syndrome	syndrome	I-NP	NN	O	13	OBJ
16	in	in	B-PP	IN	O	13	VMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	13	P

1	Nephrotic	Nephrotic	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	often	often	I-VP	RB	O	3	VMOD
5	accompanied	accompany	I-VP	VBN	O	3	VC
6	by	by	B-PP	IN	O	5	VMOD
7	sodium	sodium	B-NP	NN	O	8	NMOD
8	retention	retention	I-NP	NN	O	11	NMOD
9	and	and	O	CC	O	11	NMOD
10	generalized	generalize	B-NP	VBN	O	11	NMOD
11	edema	edema	I-NP	NN	O	6	PMOD
12	.	.	O	.	O	3	P

1	After	After	B-PP	IN	O	7	VMOD
2	7	7	B-NP	CD	O	3	NMOD
3	days	day	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	7	P
5	PAN	PAN	B-NP	NN	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	7	SUB
7	induced	induce	B-VP	VBD	O	0	ROOT
8	significant	significant	B-NP	JJ	O	9	NMOD
9	proteinuria	proteinuria	I-NP	NN	O	11	NMOD
10	,	,	O	,	O	11	P
11	hypoalbuminemia	hypoalbuminemia	B-NP	NN	O	7	OBJ
12	,	,	O	,	O	7	P
13	decreased	decrease	B-VP	VBD	O	7	VMOD
14	urinary	urinary	B-NP	JJ	O	16	NMOD
15	sodium	sodium	I-NP	NN	O	16	NMOD
16	excretion	excretion	I-NP	NN	O	13	OBJ
17	,	,	O	,	O	20	P
18	and	and	O	CC	O	20	NMOD
19	extensive	extensive	B-NP	JJ	O	20	NMOD
20	ascites	ascite	I-NP	NNS	O	7	VMOD
21	.	.	O	.	O	7	P

1	In	In	B-PP	IN	O	27	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	27	P
4	the	the	B-NP	DT	O	8	NMOD
5	increased	increase	I-NP	VBN	O	7	AMOD
6	or	or	I-NP	CC	O	7	AMOD
7	sustained	sustain	I-NP	VBN	O	8	NMOD
8	expression	expression	I-NP	NN	O	26	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	ENaC	ENaC	B-NP	NN	B-protein	11	NMOD
11	subunits	subunit	I-NP	NNS	I-protein	9	PMOD
12	combined	combine	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	increased	increase	B-NP	VBN	O	16	NMOD
15	apical	apical	I-NP	JJ	O	16	NMOD
16	targeting	targeting	I-NP	NN	O	13	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	19	NMOD
19	DCT2	DCT2	I-NP	NN	B-DNA	17	PMOD
20	,	,	O	,	O	8	P
21	connecting	connect	B-VP	VBG	O	8	NMOD
22	tubule	tubule	B-NP	NN	O	21	OBJ
23	,	,	O	,	O	26	P
24	and	and	O	CC	O	26	NMOD
25	collecting	collect	B-VP	VBG	O	26	NMOD
26	duct	duct	B-NP	NN	O	27	SUB
27	are	be	B-VP	VBP	O	0	ROOT
28	likely	likely	B-ADJP	JJ	O	27	PRD
29	to	to	B-VP	TO	O	30	VMOD
30	play	play	I-VP	VB	O	28	AMOD
31	a	a	B-NP	DT	O	32	NMOD
32	role	role	I-NP	NN	O	30	OBJ
33	in	in	B-PP	IN	O	30	VMOD
34	the	the	B-NP	DT	O	36	NMOD
35	sodium	sodium	I-NP	NN	O	36	NMOD
36	retention	retention	I-NP	NN	O	40	SUB
37	associated	associate	B-VP	VBN	O	36	NMOD
38	with	with	B-PP	IN	O	37	VMOD
39	PAN	PAN	B-NP	NN	B-protein	38	PMOD
40	induced	induce	B-VP	VBD	O	33	SBAR
41	nephrotic	nephrotic	B-NP	JJ	O	42	NMOD
42	syndrome	syndrome	I-NP	NN	O	40	OBJ
43	.	.	O	.	O	27	P

1	Patients	Patient	B-NP	NNS	O	22	NMOD
2	participating	participate	B-VP	VBG	O	1	NMOD
3	in	in	B-PP	IN	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	randomised	randomise	I-NP	VBN	O	6	NMOD
6	trial	trial	I-NP	NN	O	3	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	anastrozole	anastrozole	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	13	P
10	tamoxifen	tamoxifen	B-NP	NN	O	13	AMOD
11	alone	alone	B-ADVP	RB	O	10	NMOD
12	or	or	O	CC	O	13	AMOD
13	combined	combine	B-VP	VBN	O	1	NMOD
14	(	(	O	(	O	16	DEP
15	ATAC	ATAC	B-NP	NN	O	16	DEP
16	)	)	O	)	O	1	NMOD
17	(	(	O	(	O	19	DEP
18	n=94	n=94	B-NP	NN	O	19	DEP
19	)	)	O	)	O	1	NMOD
20	and	and	O	CC	O	22	NMOD
21	a	a	B-NP	DT	O	22	NMOD
22	group	group	I-NP	NN	O	31	SUB
23	of	of	B-PP	IN	O	22	NMOD
24	women	woman	B-NP	NNS	O	23	PMOD
25	without	without	B-PP	IN	O	24	NMOD
26	breast	breast	B-NP	NN	O	27	NMOD
27	cancer	cancer	I-NP	NN	O	25	PMOD
28	(	(	O	(	O	30	DEP
29	n=35	n=35	B-NP	NN	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	completed	complete	B-VP	VBD	O	0	ROOT
32	a	a	B-NP	DT	O	33	NMOD
33	battery	battery	I-NP	NN	O	31	OBJ
34	of	of	B-PP	IN	O	33	NMOD
35	neuropsychological	neuropsychological	B-NP	JJ	O	36	NMOD
36	measures	measure	I-NP	NNS	O	34	PMOD
37	.	.	O	.	O	31	P

1	Association	Association	B-NP	NN	O	7	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	nitric	nitric	B-NP	JJ	O	5	NMOD
4	oxide	oxide	I-NP	NN	O	5	NMOD
5	production	production	I-NP	NN	O	2	PMOD
6	and	and	I-NP	CC	O	7	NMOD
7	apoptosis	apoptosis	I-NP	NN	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	model	model	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	experimental	experimental	B-NP	JJ	O	13	NMOD
13	nephropathy	nephropathy	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	7	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	studied	study	I-VP	VBN	O	2	VC
4	the	the	B-NP	DT	O	5	NMOD
5	role	role	I-NP	NN	O	10	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	NO	NO	B-NP	NN	O	6	PMOD
8	and	and	O	CC	O	10	NMOD
9	its	its	B-NP	PRP$	O	10	NMOD
10	association	association	I-NP	NN	O	3	OBJ
11	with	with	B-PP	IN	O	10	NMOD
12	apoptosis	apoptosis	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	an	an	B-NP	DT	O	16	NMOD
15	experimental	experimental	I-NP	JJ	O	16	NMOD
16	model	model	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	nephrotic	nephrotic	B-NP	JJ	O	19	NMOD
19	syndrome	syndrome	I-NP	NN	O	17	PMOD
20	induced	induce	B-VP	VBN	O	19	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	single	single	I-NP	JJ	O	24	NMOD
24	injection	injection	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	adriamycin	adriamycin	B-NP	NN	O	25	PMOD
27	(	(	O	(	O	29	DEP
28	ADR	ADR	B-NP	NN	B-protein	29	DEP
29	)	)	O	)	O	26	NMOD
30	.	.	O	.	O	2	P

1	Rats	Rat	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	stratified	stratify	I-VP	VBN	O	2	VC
4	into	into	B-PP	IN	O	3	VMOD
5	control	control	B-NP	NN	O	6	NMOD
6	groups	group	I-NP	NNS	O	8	NMOD
7	and	and	O	CC	O	8	NMOD
8	ADR	ADR	B-NP	NN	B-protein	11	NMOD
9	induced	induce	B-VP	VBD	O	8	AMOD
10	nephropathy	nephropathy	B-NP	NN	O	11	NMOD
11	groups	group	I-NP	NNS	O	4	PMOD
12	.	.	O	.	O	2	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Histopathological	Histopathological	B-NP	JJ	O	4	NMOD
4	examination	examination	I-NP	NN	O	13	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	kidneys	kidney	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	rats	rat	B-NP	NNS	O	8	PMOD
10	treated	treat	B-VP	VBN	O	9	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	ADR	ADR	B-NP	NN	B-protein	11	PMOD
13	revealed	reveal	B-VP	VBD	O	1	NMOD
14	focal	focal	B-NP	JJ	O	15	NMOD
15	areas	area	I-NP	NNS	O	13	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	mesangial	mesangial	B-NP	JJ	O	18	NMOD
18	proliferation	proliferation	I-NP	NN	O	22	NMOD
19	and	and	O	CC	O	22	NMOD
20	mild	mild	B-NP	JJ	O	22	NMOD
21	tubulointerstitial	tubulointerstitial	I-NP	JJ	O	22	NMOD
22	inflammation	inflammation	I-NP	NN	O	16	PMOD
23	.	.	O	.	O	1	P

1	Urine	Urine	B-NP	NN	O	3	NMOD
2	nitrite	nitrite	I-NP	NN	O	3	NMOD
3	levels	level	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	significantly	significantly	I-VP	RB	O	4	VMOD
6	increased	increase	I-VP	VBN	O	4	VC
7	in	in	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	ADR-nephropathy	ADR-nephropathy	I-NP	JJ	O	10	NMOD
10	group	group	I-NP	NN	O	7	PMOD
11	(	(	O	(	O	15	DEP
12	P	P	B-NP	NN	O	15	DEP
13	<	<	O	SYM	O	12	NMOD
14	0.05	0.05	B-NP	CD	O	13	AMOD
15	)	)	O	)	O	6	VMOD
16	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	9	VMOD
2	the	the	B-NP	DT	O	8	NMOD
3	IPRK	IPRK	I-NP	NN	O	4	NMOD
4	phenylephrine	phenylephrine	I-NP	NN	O	8	NMOD
5	and	and	I-NP	CC	O	8	NMOD
6	acetylcholine	acetylcholine	I-NP	NN	O	8	NMOD
7	related	relate	I-NP	VBN	O	8	NMOD
8	responses	response	I-NP	NNS	O	9	SUB
9	were	be	B-VP	VBD	O	0	ROOT
10	significantly	significantly	B-ADJP	RB	O	11	AMOD
11	impaired	impaired	I-ADJP	JJ	O	9	VC
12	in	in	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	ADR-nephropathy	ADR-nephropathy	I-NP	JJ	O	15	NMOD
15	group	group	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	9	P

1	However	However	B-ADVP	RB	O	11	VMOD
2	,	,	O	,	O	11	P
3	in	in	B-PP	IN	O	11	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	ADR-nephropathy	ADR-nephropathy	I-NP	JJ	O	6	NMOD
6	group	group	I-NP	NN	O	3	PMOD
7	,	,	O	,	O	11	P
8	numerous	numerous	B-NP	JJ	O	11	SUB
9	apoptotic	apoptotic	I-NP	JJ	B-cell_type	10	NMOD
10	cells	cell	I-NP	NNS	I-cell_type	8	NMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	identified	identify	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	tubulointerstitial	tubulointerstitial	I-NP	JJ	O	16	NMOD
16	areas	area	I-NP	NNS	O	13	PMOD
17	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	attenuating	attenuate	I-NP	VBG	O	3	NMOD
3	effect	effect	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	carteolol	carteolol	B-NP	NN	O	6	NMOD
6	hydrochloride	hydrochloride	I-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	a	a	B-NP	DT	O	10	NMOD
9	beta-adrenoceptor	beta-adrenoceptor	I-NP	NN	O	10	NMOD
10	antagonist	antagonist	I-NP	NN	O	4	PMOD
11	,	,	O	,	O	3	P
12	on	on	B-PP	IN	O	3	NMOD
13	neuroleptic	neuroleptic	B-NP	JJ	O	15	NMOD
14	induced	induce	I-NP	VBN	O	15	NMOD
15	catalepsy	catalepsy	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	3	P

1	Therefore	Therefore	B-ADVP	RB	O	14	VMOD
2	,	,	O	,	O	14	P
3	the	the	B-NP	DT	O	4	NMOD
4	effects	effect	I-NP	NNS	O	14	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	carteolol	carteolol	B-NP	NN	O	10	NMOD
7	,	,	O	,	O	10	P
8	a	a	B-NP	DT	O	10	NMOD
9	beta-adrenoceptor	beta-adrenoceptor	I-NP	NN	O	10	NMOD
10	antagonist	antagonist	I-NP	NN	O	5	PMOD
11	,	,	O	,	O	4	P
12	on	on	B-PP	IN	O	4	NMOD
13	haloperidol	haloperidol	B-NP	NN	O	12	PMOD
14	induced	induce	B-VP	VBD	O	0	ROOT
15	catalepsy	catalepsy	B-NP	NN	O	14	OBJ
16	in	in	B-PP	IN	O	14	VMOD
17	rats	rat	B-NP	NNS	O	16	PMOD
18	were	be	B-VP	VBD	O	14	VMOD
19	behaviorally	behaviorally	I-VP	RB	O	18	VMOD
20	studied	study	I-VP	VBN	O	18	VC
21	and	and	O	CC	O	20	VMOD
22	compared	compare	B-PP	VBN	O	20	VMOD
23	with	with	B-PP	IN	O	22	PMOD
24	those	those	B-NP	DT	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	propranolol	propranolol	B-NP	NN	O	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	biperiden	biperiden	I-NP	NN	O	33	NMOD
29	,	,	O	,	O	33	P
30	a	a	B-NP	DT	O	33	NMOD
31	muscarinic	muscarinic	I-NP	JJ	O	33	NMOD
32	receptor	receptor	I-NP	NN	O	33	NMOD
33	antagonist	antagonist	I-NP	NN	O	25	PMOD
34	.	.	O	.	O	14	P

1	Carteolol	Carteolol	B-NP	NN	O	8	NMOD
2	,	,	O	,	O	8	P
3	as	as	B-CONJP	RB	O	8	NMOD
4	well	well	I-CONJP	RB	O	3	DEP
5	as	as	I-CONJP	IN	O	3	DEP
6	propranolol	propranolol	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	biperiden	biperiden	I-NP	NN	O	10	SUB
9	,	,	O	,	O	8	P
10	inhibited	inhibit	B-VP	VBD	O	0	ROOT
11	the	the	B-NP	DT	O	14	NMOD
12	haloperidol	haloperidol	I-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	catalepsy	catalepsy	I-NP	NN	O	10	OBJ
15	.	.	O	.	O	10	P

1	Carteolol	Carteolol	B-NP	NN	O	2	SUB
2	did	do	B-VP	VBD	O	0	ROOT
3	not	not	I-VP	RB	O	2	VMOD
4	evoke	evoke	I-VP	VB	O	2	VC
5	postsynaptic	postsynaptic	B-NP	JJ	O	9	NMOD
6	dopamine	dopamine	I-NP	NN	O	9	NMOD
7	receptor-stimulating	receptor-stimulating	I-NP	JJ	O	9	NMOD
8	behavioral	behavioral	I-NP	JJ	O	9	NMOD
9	signs	sign	I-NP	NNS	O	4	OBJ
10	such	such	B-PP	JJ	O	11	PMOD
11	as	as	I-PP	IN	O	9	NMOD
12	stereotypy	stereotypy	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	hyperlocomotion	hyperlocomotion	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	.	.	O	.	O	2	P

1	Penicillamine	Penicillamine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	rapidly	rapidly	B-NP	RB	O	4	AMOD
4	progressive	progressive	I-NP	JJ	O	5	NMOD
5	glomerulonephritis	glomerulonephritis	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	a	a	B-NP	DT	O	8	NMOD
8	patient	patient	I-NP	NN	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	rheumatoid	rheumatoid	B-NP	JJ	O	11	NMOD
11	arthritis	arthritis	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	67-year-old	67-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	7	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	rheumatoid	rheumatoid	B-NP	JJ	O	6	NMOD
6	arthritis	arthritis	I-NP	NN	O	4	PMOD
7	presented	present	B-VP	VBD	O	0	ROOT
8	rapidly	rapidly	B-NP	RB	O	9	AMOD
9	progressive	progressive	I-NP	JJ	O	7	OBJ
10	glomerulonephritis	glomerulonephritis	I-NP	NN	O	9	NMOD
11	(	(	O	(	O	13	DEP
12	RPGN	RPGN	B-NP	NN	B-protein	13	DEP
13	)	)	O	)	O	10	NMOD
14	after	after	B-PP	IN	O	7	VMOD
15	5	5	B-NP	CD	O	16	NMOD
16	months	month	I-NP	NNS	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	D-penicillamine	D-penicillamine	B-NP	NN	O	23	NMOD
19	(	(	O	(	O	22	DEP
20	250	250	B-NP	CD	O	21	NMOD
21	mg/day	mg/day	I-NP	NN	O	22	DEP
22	)	)	O	)	O	18	NMOD
23	treatment	treatment	B-NP	NN	O	17	PMOD
24	.	.	O	.	O	7	P

1	This	This	B-NP	DT	O	3	NMOD
2	new	new	I-NP	JJ	O	3	NMOD
3	case	case	I-NP	NN	O	12	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	RPGN	RPGN	B-NP	NN	B-protein	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	course	course	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	D-penicillamine	D-penicillamine	B-NP	NN	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	emphasizes	emphasize	B-VP	VBZ	O	0	ROOT
13	the	the	B-NP	DT	O	14	NMOD
14	need	need	I-NP	NN	O	12	OBJ
15	for	for	B-PP	IN	O	14	NMOD
16	frequent	frequent	B-NP	JJ	O	17	NMOD
17	monitoring	monitoring	I-NP	NN	O	22	NMOD
18	of	of	B-PP	IN	O	17	NMOD
19	renal	renal	B-NP	JJ	O	20	NMOD
20	function	function	I-NP	NN	O	18	PMOD
21	and	and	I-NP	CC	O	22	NMOD
22	evaluation	evaluation	I-NP	NN	O	15	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	urinary	urinary	B-NP	JJ	O	25	NMOD
25	sediment	sediment	I-NP	NN	O	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	proteinuria	proteinuria	I-NP	NN	O	23	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	these	these	B-NP	DT	O	30	NMOD
30	patients	patient	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	12	P

1	Bilateral	Bilateral	B-NP	JJ	O	3	NMOD
2	optic	optic	I-NP	JJ	O	3	NMOD
3	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
4	due	due	B-PP	JJ	O	5	PMOD
5	to	to	B-PP	TO	O	3	NMOD
6	combined	combine	B-NP	VBN	O	10	NMOD
7	ethambutol	ethambutol	I-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	isoniazid	isoniazid	I-NP	NN	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	5	PMOD
11	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	hazards	hazard	I-NP	NNS	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	optic	optic	B-NP	JJ	O	6	NMOD
5	nerve	nerve	I-NP	NN	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	3	PMOD
7	due	due	B-PP	IN	O	2	NMOD
8	to	to	I-PP	TO	O	7	PMOD
9	ethambutol	ethambutol	B-NP	NN	O	8	PMOD
10	are	be	B-VP	VBP	O	0	ROOT
11	known	know	I-VP	VBN	O	10	VC
12	.	.	O	.	O	10	P

1	Thromboembolic	Thromboembolic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	other	other	I-NP	JJ	O	4	NMOD
4	complications	complication	I-NP	NNS	O	20	NMOD
5	of	of	B-PP	IN	O	4	NMOD
6	oral	oral	B-NP	JJ	O	8	NMOD
7	contraceptive	contraceptive	I-NP	JJ	O	8	NMOD
8	therapy	therapy	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	relationship	relationship	B-NP	NN	O	9	PMOD
11	to	to	B-PP	TO	O	10	NMOD
12	pretreatment	pretreatment	B-NP	NN	O	13	NMOD
13	levels	level	I-NP	NNS	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	blood	blood	B-NP	NN	B-protein	17	NMOD
16	coagulation	coagulation	I-NP	NN	I-protein	17	NMOD
17	factors	factor	I-NP	NNS	I-protein	14	PMOD
18	:	:	O	:	O	4	P
19	summary	summary	B-NP	JJ	O	20	NMOD
20	report	report	I-NP	NN	O	0	ROOT
21	of	of	B-PP	IN	O	20	NMOD
22	a	a	B-NP	DT	O	24	NMOD
23	ten-year	ten-year	I-NP	JJ	O	24	NMOD
24	study	study	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	20	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	arrest	arrest	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	child	child	I-NP	NN	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	cerebral	cerebral	B-NP	JJ	O	11	NMOD
8	palsy	palsy	I-NP	JJ	O	11	NMOD
9	undergoing	undergo	I-NP	VBG	O	11	NMOD
10	sevoflurane	sevoflurane	I-NP	NN	O	11	NMOD
11	induction	induction	I-NP	NN	O	6	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	anesthesia	anesthesia	B-NP	NN	O	12	PMOD
14	after	after	B-PP	IN	O	11	NMOD
15	preoperative	preoperative	B-NP	JJ	O	16	NMOD
16	clonidine	clonidine	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	5-year-old	5-year-old	I-NP	JJ	O	8	NMOD
8	child	child	I-NP	NN	O	5	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	cerebral	cerebral	B-NP	JJ	O	11	NMOD
11	palsy	palsy	I-NP	NN	O	14	NMOD
12	and	and	I-NP	CC	O	14	NMOD
13	seizure	seizure	I-NP	NN	O	14	NMOD
14	disorder	disorder	I-NP	NN	O	9	PMOD
15	,	,	O	,	O	2	P
16	receiving	receive	B-VP	VBG	O	2	VMOD
17	clonidine	clonidine	B-NP	NN	O	16	OBJ
18	for	for	B-PP	IN	O	17	NMOD
19	restlessness	restlessness	B-NP	NN	O	18	PMOD
20	,	,	O	,	O	16	P
21	who	who	B-NP	WP	O	16	VMOD
22	presented	present	B-VP	VBD	O	21	SBAR
23	for	for	B-PP	IN	O	22	VMOD
24	placement	placement	B-NP	NN	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	a	a	B-NP	DT	O	28	NMOD
27	baclofen	baclofen	I-NP	NN	O	28	NMOD
28	pump	pump	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	2	P

1	Without	Without	B-PP	IN	O	0	ROOT
2	the	the	B-NP	DT	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	medical	medical	I-NP	JJ	O	7	NMOD
7	personnel	personnel	I-NP	NNS	O	4	PMOD
8	,	,	O	,	O	1	VMOD
9	the	the	B-NP	DT	O	12	NMOD
10	patient	patient	I-NP	NN	O	12	NMOD
11	's	's	B-NP	POS	O	12	NMOD
12	mother	mother	I-NP	NN	O	8	SUB
13	administered	administer	B-VP	VBN	O	12	NMOD
14	three	three	B-NP	CD	O	15	NMOD
15	doses	dose	I-NP	NNS	O	13	VMOD
16	of	of	B-PP	IN	O	15	NMOD
17	clonidine	clonidine	B-NP	NN	O	16	PMOD
18	during	during	B-PP	IN	O	12	NMOD
19	the	the	B-NP	DT	O	20	NMOD
20	evening	evening	I-NP	NN	O	18	PMOD
21	before	before	B-PP	IN	O	12	NMOD
22	and	and	O	CC	O	21	PMOD
23	morning	morning	B-NP	NN	O	27	SUB
24	of	of	B-PP	IN	O	23	NMOD
25	surgery	surgery	B-NP	NN	O	24	PMOD
26	to	to	B-VP	TO	O	27	VMOD
27	reduce	reduce	I-VP	VB	O	21	SBAR
28	anxiety	anxiety	B-NP	NN	O	27	OBJ
29	.	.	O	.	O	1	P

1	Earlier	Early	B-NP	JJR	O	2	NMOD
2	studies	study	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	demonstrated	demonstrate	I-VP	VBN	O	3	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	antagonism	antagonism	B-NP	NN	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	sigma1	sigma1	B-NP	NN	B-protein	9	NMOD
9	receptors	receptor	I-NP	NNS	I-protein	7	PMOD
10	attenuates	attenuate	B-VP	VBZ	O	5	SBAR
11	the	the	B-NP	DT	O	20	NMOD
12	convulsive	convulsive	I-NP	JJ	O	20	NMOD
13	,	,	I-NP	,	O	20	P
14	lethal	lethal	I-NP	JJ	O	20	NMOD
15	,	,	I-NP	,	O	20	P
16	locomotor	locomotor	I-NP	JJ	O	20	NMOD
17	stimulatory	stimulatory	I-NP	JJ	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	rewarding	rewarding	I-NP	JJ	O	20	NMOD
20	actions	action	I-NP	NNS	O	10	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	cocaine	cocaine	B-NP	NN	O	21	PMOD
23	in	in	B-PP	IN	O	10	VMOD
24	mice	mouse	B-NP	NNS	O	23	PMOD
25	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	19	VMOD
2	behavioral	behavioral	B-NP	JJ	O	3	NMOD
3	studies	study	I-NP	NNS	O	1	PMOD
4	,	,	O	,	O	19	P
5	pretreatment	pretreatment	B-NP	NN	O	16	NMOD
6	of	of	B-PP	IN	O	5	NMOD
7	Swiss	Swiss	B-NP	JJ	O	9	NMOD
8	Webster	Webster	I-NP	NNP	O	9	NMOD
9	mice	mouse	I-NP	NNS	O	6	PMOD
10	with	with	B-PP	IN	O	5	NMOD
11	UMB24	UMB24	B-NP	NN	B-DNA	10	PMOD
12	or	or	O	CC	O	16	NMOD
13	(	(	O	(	O	15	DEP
14	+/-	+/-	O	CC	O	15	DEP
15	)	)	O	)	O	16	NMOD
16	-SM	-SM	B-NP	NN	O	19	SUB
17	21	21	I-NP	CD	O	16	NMOD
18	significantly	significantly	B-ADVP	RB	O	19	VMOD
19	attenuated	attenuate	B-VP	VBD	O	0	ROOT
20	cocaine	cocaine	B-NP	NN	O	22	NMOD
21	induced	induced	I-NP	JJ	O	22	NMOD
22	convulsions	convulsion	I-NP	NNS	O	25	NMOD
23	and	and	O	CC	O	25	NMOD
24	locomotor	locomotor	B-NP	NN	O	25	NMOD
25	activity	activity	I-NP	NN	O	19	OBJ
26	,	,	O	,	O	29	P
27	but	but	O	CC	O	29	NMOD
28	not	not	O	RB	O	27	DEP
29	lethality	lethality	B-NP	NN	O	19	VMOD
30	.	.	O	.	O	19	P

1	Methimazole	Methimazole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cholestatic	cholestatic	B-NP	JJ	O	4	NMOD
4	jaundice	jaundice	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	3	NMOD
2	43-year-old	43-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	4	SUB
4	had	have	B-VP	VBD	O	0	ROOT
5	severe	severe	B-NP	JJ	O	6	NMOD
6	jaundice	jaundice	I-NP	NN	O	4	OBJ
7	and	and	O	CC	O	4	VMOD
8	itching	itch	B-VP	VBG	O	4	VMOD
9	1	1	B-NP	CD	O	10	NMOD
10	month	month	I-NP	NN	O	8	OBJ
11	after	after	B-PP	IN	O	8	VMOD
12	receiving	receive	B-VP	VBG	O	11	PMOD
13	methimazole	methimazole	B-NP	NN	O	20	NMOD
14	(	(	O	(	O	18	DEP
15	10	10	B-NP	CD	O	16	AMOD
16	mg	mg	I-NP	NN	O	17	NMOD
17	tid	tid	I-NP	NN	O	18	DEP
18	)	)	O	)	O	13	NMOD
19	and	and	O	CC	O	20	NMOD
20	propranolol	propranolol	B-NP	NN	O	12	OBJ
21	(	(	O	(	O	25	DEP
22	20	20	B-NP	CD	O	23	AMOD
23	mg	mg	I-NP	NN	O	24	NMOD
24	tid	tid	I-NP	NN	O	25	DEP
25	)	)	O	)	O	20	NMOD
26	for	for	B-PP	IN	O	12	VMOD
27	treatment	treatment	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	hyperthyroidism	hyperthyroidism	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	4	P

1	Methimazole	Methimazole	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	cholestasis	cholestasis	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	10	VMOD
5	diagnosed	diagnose	I-VP	VBN	O	4	VC
6	,	,	O	,	O	10	P
7	and	and	O	CC	O	10	VMOD
8	propranolol	propranolol	B-NP	NN	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	resumed	resume	I-VP	VBN	O	10	VC
12	.	.	O	.	O	10	P

1	Ciprofloxacin	Ciprofloxacin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	acute	acute	B-NP	JJ	O	5	NMOD
4	interstitial	interstitial	I-NP	JJ	O	5	NMOD
5	nephritis	nephritis	I-NP	NN	O	9	NMOD
6	and	and	O	CC	O	9	NMOD
7	autoimmune	autoimmune	B-NP	JJ	O	9	NMOD
8	hemolytic	hemolytic	I-NP	JJ	O	9	NMOD
9	anemia	anemia	I-NP	NN	O	2	OBJ
10	.	.	O	.	O	2	P

1	Ciprofloxacin	Ciprofloxacin	B-NP	NN	O	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	associated	associate	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	several	several	B-NP	JJ	O	8	NMOD
7	side	side	I-NP	NN	O	8	NMOD
8	effects	effect	I-NP	NNS	O	5	PMOD
9	including	include	B-PP	VBG	O	8	NMOD
10	interstitial	interstitial	B-NP	JJ	O	11	NMOD
11	nephritis	nephritis	I-NP	NN	O	14	NMOD
12	and	and	O	CC	O	14	NMOD
13	hemolytic	hemolytic	B-NP	JJ	O	14	NMOD
14	anemia	anemia	I-NP	NN	O	9	PMOD
15	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	6	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	report	report	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	we	we	B-NP	PRP	O	6	SUB
6	describe	describe	B-VP	VBP	O	0	ROOT
7	a	a	B-NP	DT	O	8	NMOD
8	case	case	I-NP	NN	O	11	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	ciprofloxacin	ciprofloxacin	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	6	VMOD
12	interstitial	interstitial	B-NP	JJ	O	13	NMOD
13	nephritis	nephritis	I-NP	NN	O	17	NMOD
14	and	and	O	CC	O	17	NMOD
15	autoimmune	autoimmune	B-NP	JJ	O	17	NMOD
16	hemolytic	hemolytic	I-NP	JJ	O	17	NMOD
17	anemia	anemia	I-NP	NN	O	11	OBJ
18	.	.	O	.	O	6	P

1	Hemolytic	Hemolytic	B-NP	JJ	O	2	NMOD
2	anemia	anemia	I-NP	NN	O	3	SUB
3	improved	improve	B-VP	VBD	O	0	ROOT
4	after	after	B-PP	IN	O	3	VMOD
5	stopping	stop	B-VP	VBG	O	4	PMOD
6	the	the	B-NP	DT	O	7	NMOD
7	drug	drug	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	initiation	initiation	I-NP	NN	O	5	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	steroid	steroid	B-NP	NN	O	12	NMOD
12	therapy	therapy	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	3	P

1	Contribution	Contribution	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	sodium	sodium	B-NP	NN	O	4	NMOD
4	valproate	valproate	I-NP	NN	O	2	PMOD
5	to	to	B-PP	TO	O	1	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	inappropriate	inappropriate	B-NP	JJ	O	10	NMOD
10	secretion	secretion	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	antidiuretic	antidiuretic	B-NP	JJ	O	13	NMOD
13	hormone	hormone	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	8	NMOD
7	62-year-old	62-year-old	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	who	who	B-NP	WP	O	8	NMOD
10	was	be	B-VP	VBD	O	9	SBAR
11	administered	administer	I-VP	VBN	O	10	VC
12	sodium	sodium	B-NP	NN	O	13	NMOD
13	valproate	valproate	I-NP	NN	O	20	SUB
14	(	(	O	(	O	16	DEP
15	VPA	VPA	B-NP	NN	B-protein	16	DEP
16	)	)	O	)	O	13	NMOD
17	and	and	O	CC	O	20	VMOD
18	who	who	B-NP	WP	O	20	VMOD
19	subsequently	subsequently	B-ADVP	RB	O	20	VMOD
20	developed	develop	B-VP	VBD	O	11	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	syndrome	syndrome	I-NP	NN	O	20	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	inappropriate	inappropriate	B-NP	JJ	O	25	NMOD
25	secretion	secretion	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	antidiuretic	antidiuretic	B-NP	JJ	O	28	NMOD
28	hormone	hormone	I-NP	NN	O	26	PMOD
29	(	(	O	(	O	31	DEP
30	SIADH	SIADH	B-NP	NN	B-protein	31	DEP
31	)	)	O	)	O	28	NMOD
32	.	.	O	.	O	2	P

1	He	He	B-NP	PRP	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	taking	take	I-VP	VBG	O	3	VC
5	VPA	VPA	B-NP	NN	B-protein	4	OBJ
6	for	for	B-PP	IN	O	4	VMOD
7	treatment	treatment	B-NP	NN	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	idiopathic	idiopathic	B-NP	JJ	O	12	NMOD
10	generalized	generalize	I-NP	VBN	O	12	NMOD
11	tonic-clonic	tonic-clonic	I-NP	JJ	O	12	NMOD
12	convulsions	convulsion	I-NP	NNS	O	8	PMOD
13	since	since	B-SBAR	IN	O	4	VMOD
14	he	he	B-NP	PRP	O	15	SUB
15	was	be	B-VP	VBD	O	13	SBAR
16	56	56	B-NP	CD	O	17	NMOD
17	years	year	I-NP	NNS	O	18	SUB
18	old	old	B-ADJP	JJ	O	15	PRD
19	.	.	O	.	O	2	P

1	Vasopressin	Vasopressin	B-NP	NN	O	7	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	milrinone	milrinone	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	hypotension	hypotension	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	severe	severe	B-NP	JJ	O	12	NMOD
11	heart	heart	I-NP	NN	O	12	NMOD
12	failure	failure	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	2	NMOD
2	use	use	I-NP	NN	O	16	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	phosphodiesterase	phosphodiesterase	B-NP	NN	O	5	NMOD
5	inhibitors	inhibitor	I-NP	NNS	O	3	PMOD
6	such	such	B-PP	JJ	O	7	PMOD
7	as	as	I-PP	IN	O	5	NMOD
8	milrinone	milrinone	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	2	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	treatment	treatment	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	severe	severe	B-NP	JJ	O	15	NMOD
14	heart	heart	I-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	12	PMOD
16	is	be	B-VP	VBZ	O	0	ROOT
17	frequently	frequently	B-ADJP	RB	O	18	AMOD
18	restricted	restricted	I-ADJP	JJ	O	16	PRD
19	because	because	B-SBAR	IN	O	16	VMOD
20	they	they	B-NP	PRP	O	21	SUB
21	cause	cause	B-VP	VBP	O	19	SBAR
22	vasodilation	vasodilation	B-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	hypotension	hypotension	I-NP	NN	O	21	OBJ
25	.	.	O	.	O	16	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	halogenated	halogenate	I-NP	VBN	O	3	NMOD
3	anesthetics	anesthetic	I-NP	NNS	O	7	NMOD
4	,	,	I-NP	,	O	7	P
5	enflurane	enflurane	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	isoflurane	isoflurane	I-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	have	have	B-VP	VBP	O	0	ROOT
10	been	be	I-VP	VBN	O	9	VC
11	associated	associate	I-VP	VBN	O	10	VC
12	with	with	B-PP	IN	O	11	VMOD
13	an	an	B-NP	DT	O	16	NMOD
14	allergic-type	allergic-type	I-NP	JJ	O	16	NMOD
15	hepatic	hepatic	I-NP	JJ	O	16	NMOD
16	injury	injury	I-NP	NN	O	12	PMOD
17	both	both	O	CC	O	18	AMOD
18	alone	alone	B-ADVP	RB	O	11	VMOD
19	and	and	O	CC	O	18	AMOD
20	following	follow	B-PP	VBG	O	11	VMOD
21	previous	previous	B-NP	JJ	O	22	NMOD
22	exposure	exposure	I-NP	NN	O	20	PMOD
23	to	to	B-PP	TO	O	22	NMOD
24	halothane	halothane	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	9	P

1	Halothane	Halothane	B-NP	NN	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	3	SUB
3	appears	appear	B-VP	VBZ	O	0	ROOT
4	to	to	I-VP	TO	O	5	VMOD
5	involve	involve	I-VP	VB	O	3	VMOD
6	an	an	B-NP	DT	O	9	NMOD
7	aberrant	aberrant	I-NP	JJ	O	9	NMOD
8	immune	immune	I-NP	JJ	O	9	NMOD
9	response	response	I-NP	NN	O	5	OBJ
10	.	.	O	.	O	3	P

1	An	An	B-NP	DT	O	3	NMOD
2	antibody	antibody	I-NP	NN	O	3	NMOD
3	response	response	I-NP	NN	O	13	SUB
4	to	to	B-PP	TO	O	3	NMOD
5	a	a	B-NP	DT	O	8	NMOD
6	protein-bound	protein-bound	I-NP	JJ	B-protein	8	NMOD
7	biotransformation	biotransformation	I-NP	NN	I-protein	8	NMOD
8	product	product	I-NP	NN	I-protein	4	PMOD
9	(	(	O	(	O	12	DEP
10	trifluoroacetyl	trifluoroacetyl	B-NP	NN	O	11	NMOD
11	adduct	adduct	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	has	have	B-VP	VBZ	O	0	ROOT
14	been	be	I-VP	VBN	O	13	VC
15	detected	detect	I-VP	VBN	O	14	VC
16	on	on	B-PP	IN	O	15	VMOD
17	halothane	halothane	B-NP	NN	O	19	NMOD
18	hepatitis	hepatitis	I-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	16	PMOD
20	.	.	O	.	O	13	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	performed	perform	I-VP	VBN	O	3	VC
5	to	to	B-VP	TO	O	6	VMOD
6	determine	determine	I-VP	VB	O	3	VMOD
7	cross-reactivity	cross-reactivity	B-NP	NN	O	6	OBJ
8	between	between	B-PP	IN	O	7	NMOD
9	enflurane	enflurane	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	isoflurane	isoflurane	I-NP	NN	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	hypersensitivity	hypersensitivity	I-NP	NN	O	12	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	halothane	halothane	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	3	P

1	Induction	Induction	B-NP	NN	O	0	ROOT
2	by	by	B-PP	IN	O	1	NMOD
3	paracetamol	paracetamol	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	bladder	bladder	B-NP	NN	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	liver	liver	I-NP	NN	O	8	NMOD
8	tumours	tumour	I-NP	NNS	O	4	PMOD
9	in	in	B-PP	IN	O	3	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	rat	rat	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	1	P

1	Papillomas	Papilloma	B-NP	NNS	O	18	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	transitional	transitional	I-NP	JJ	O	5	NMOD
5	epithelium	epithelium	I-NP	NN	O	2	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	bladder	bladder	I-NP	NN	O	6	PMOD
9	developed	develop	B-VP	VBN	O	8	NMOD
10	in	in	B-PP	IN	O	9	VMOD
11	all	all	B-NP	DT	O	13	NMOD
12	paracetamol-treated	paracetamol-treated	I-NP	JJ	O	13	NMOD
13	groups	group	I-NP	NNS	O	10	PMOD
14	,	,	O	,	O	18	P
15	and	and	O	CC	O	18	VMOD
16	three	three	B-NP	CD	O	17	NMOD
17	rats	rat	I-NP	NNS	O	18	SUB
18	bore	bear	B-VP	VBD	O	0	ROOT
19	bladder	bladder	B-NP	NN	O	20	NMOD
20	carcinomas	carcinoma	I-NP	NNS	O	18	OBJ
21	.	.	O	.	O	18	P

1	Additionally	Additionally	B-ADVP	RB	O	10	VMOD
2	,	,	O	,	O	10	P
3	20	20	B-NP	CD	O	5	AMOD
4	to	to	I-NP	TO	O	5	AMOD
5	25	25	I-NP	CD	O	6	NMOD
6	%	%	I-NP	NN	O	10	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	paracetamol-treated	paracetamol-treated	B-NP	JJ	O	9	NMOD
9	rats	rat	I-NP	NNS	O	7	PMOD
10	developed	develop	B-VP	VBD	O	0	ROOT
11	hyperplasia	hyperplasia	B-NP	NN	O	10	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	bladder	bladder	I-NP	NN	O	15	NMOD
15	epithelium	epithelium	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	11	P
17	which	which	B-NP	WDT	O	11	NMOD
18	was	be	B-VP	VBD	O	17	SBAR
19	not	not	O	RB	O	18	VMOD
20	coincident	coincident	B-ADJP	JJ	O	18	PRD
21	with	with	B-PP	IN	O	20	AMOD
22	the	the	B-NP	DT	O	23	NMOD
23	presence	presence	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	bladder	bladder	B-NP	NN	O	26	NMOD
26	calculi	calculus	I-NP	NNS	O	24	PMOD
27	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	3	NMOD
2	low	low	I-NP	JJ	O	3	NMOD
3	yield	yield	I-NP	NN	O	11	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	tumours	tumour	B-NP	NNS	O	4	PMOD
6	at	at	B-PP	IN	O	3	NMOD
7	various	various	B-NP	JJ	O	9	NMOD
8	other	other	I-NP	JJ	O	9	NMOD
9	sites	site	I-NP	NNS	O	6	PMOD
10	also	also	B-ADVP	RB	O	11	VMOD
11	arose	arise	B-VP	VBP	O	0	ROOT
12	following	follow	B-PP	VBG	O	11	VMOD
13	paracetamol	paracetamol	B-NP	NN	O	14	NMOD
14	feeding	feeding	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	9	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	to	to	B-PP	TO	O	2	NMOD
4	muscle	muscle	B-NP	NN	O	5	NMOD
5	damage	damage	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	9	P
7	severe	severe	B-NP	JJ	O	8	NMOD
8	damage	damage	I-NP	NN	O	9	SUB
9	was	be	B-VP	VBD	O	0	ROOT
10	also	also	I-VP	RB	O	9	VMOD
11	seen	see	I-VP	VBN	O	9	VC
12	in	in	B-PP	IN	O	11	VMOD
13	harderian	harderian	B-NP	JJ	O	14	NMOD
14	glands	gland	I-NP	NNS	O	12	PMOD
15	,	,	O	,	O	11	P
16	especially	especially	B-ADVP	RB	O	11	VMOD
17	after	after	B-SBAR	IN	O	11	VMOD
18	exposure	exposure	B-NP	NN	O	17	PMOD
19	to	to	B-PP	TO	O	18	NMOD
20	mepivacaine	mepivacaine	B-NP	NN	O	24	NMOD
21	and	and	I-NP	CC	O	24	NMOD
22	lidocaine	lidocaine	I-NP	NN	O	24	NMOD
23	plus	plus	I-NP	CC	O	24	NMOD
24	epinephrine	epinephrine	I-NP	NN	O	19	PMOD
25	.	.	O	.	O	9	P

1	Reversal	Reversal	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	neuroleptic	neuroleptic	B-NP	JJ	O	5	NMOD
4	induced	induce	I-NP	VBN	O	5	NMOD
5	catalepsy	catalepsy	I-NP	NN	O	2	PMOD
6	by	by	B-PP	IN	O	1	NMOD
7	novel	novel	B-NP	JJ	O	10	NMOD
8	aryl-piperazine	aryl-piperazine	I-NP	NN	O	10	NMOD
9	anxiolytic	anxiolytic	I-NP	JJ	O	10	NMOD
10	drugs	drug	I-NP	NNS	O	6	PMOD
11	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	4	NMOD
2	novel	novel	I-NP	JJ	O	4	NMOD
3	anxiolytic	anxiolytic	I-NP	JJ	O	4	NMOD
4	drug	drug	I-NP	NN	O	6	NMOD
5	,	,	O	,	O	6	P
6	buspirone	buspirone	B-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	reverses	reverse	B-VP	VBZ	O	0	ROOT
9	catalepsy	catalepsy	B-NP	NN	O	8	OBJ
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	haloperidol	haloperidol	B-NP	NN	O	11	PMOD
13	.	.	O	.	O	8	P

1	A	A	B-NP	DT	O	2	NMOD
2	series	series	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	aryl-piperazine	aryl-piperazine	B-NP	NN	O	5	NMOD
5	analogues	analogue	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	buspirone	buspirone	B-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	other	other	B-NP	JJ	O	11	NMOD
10	5-hydroxytryptaminergic	5-hydroxytryptaminergic	I-NP	JJ	O	11	NMOD
11	agonists	agonist	I-NP	NNS	O	6	PMOD
12	were	be	B-VP	VBD	O	0	ROOT
13	tested	test	I-VP	VBN	O	12	VC
14	for	for	B-PP	IN	O	13	VMOD
15	their	their	B-NP	PRP$	O	16	NMOD
16	ability	ability	I-NP	NN	O	14	PMOD
17	to	to	B-VP	TO	O	18	VMOD
18	reverse	reverse	I-VP	VB	O	16	NMOD
19	haloperidol	haloperidol	B-NP	NN	O	21	NMOD
20	induced	induced	I-NP	JJ	O	21	NMOD
21	catalepsy	catalepsy	I-NP	NN	O	18	OBJ
22	.	.	O	.	O	12	P

1	Those	Those	B-NP	DT	O	2	NMOD
2	drugs	drug	I-NP	NNS	O	9	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	strong	strong	B-NP	JJ	O	5	NMOD
5	affinity	affinity	I-NP	NN	O	3	PMOD
6	for	for	B-PP	IN	O	5	NMOD
7	5-hydroxytryptamine1a	5-hydroxytryptamine1a	B-NP	NN	B-protein	8	NMOD
8	receptors	receptor	I-NP	NNS	I-protein	6	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	able	able	B-ADJP	JJ	O	9	PRD
11	to	to	B-VP	TO	O	12	VMOD
12	reverse	reverse	I-VP	VB	O	10	AMOD
13	catalepsy	catalepsy	B-NP	NN	O	12	OBJ
14	.	.	O	.	O	9	P

1	Diazepam	Diazepam	B-NP	NN	O	2	SUB
2	facilitates	facilitate	B-VP	VBZ	O	0	ROOT
3	reflex	reflex	B-NP	NN	O	4	NMOD
4	bradycardia	bradycardia	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	conscious	conscious	B-NP	JJ	O	7	NMOD
7	rats	rat	I-NP	NNS	O	5	PMOD
8	.	.	O	.	O	2	P

1	Also	Also	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	reflex	reflex	B-NP	NN	O	4	NMOD
4	bradycardia	bradycardia	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	produced	produce	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	rats	rat	B-NP	NNS	O	7	PMOD
9	by	by	B-PP	IN	O	6	VMOD
10	intravenous	intravenous	B-NP	JJ	O	11	NMOD
11	infusion	infusion	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	adrenaline	adrenaline	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	18	DEP
15	1.25-2.5	1.25-2.5	B-NP	CD	O	17	NMOD
16	micrograms	microgram	I-NP	NNS	O	17	NMOD
17	kg-1	kg-1	I-NP	NN	B-cell_line	18	DEP
18	)	)	O	)	O	13	NMOD
19	.	.	O	.	O	5	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	pretreatment	pretreatment	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	rats	rat	I-NP	NNS	O	3	PMOD
6	with	with	B-PP	IN	O	2	NMOD
7	diazepam	diazepam	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	2	P
9	although	although	B-SBAR	IN	O	2	VMOD
10	causing	cause	B-VP	VBG	O	9	SBAR
11	no	no	B-NP	DT	O	12	NMOD
12	change	change	I-NP	NN	O	10	OBJ
13	in	in	B-PP	IN	O	10	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	adrenaline	adrenaline	I-NP	NN	O	13	PMOD
16	induced	induce	B-VP	VBD	O	9	DEP
17	pressor	pressor	B-NP	NN	O	18	NMOD
18	effect	effect	I-NP	NN	O	16	OBJ
19	,	,	O	,	O	16	P
20	did	do	B-VP	VBD	O	16	VMOD
21	enhance	enhance	I-VP	VB	O	20	VC
22	the	the	B-NP	DT	O	23	NMOD
23	adrenaline	adrenaline	I-NP	NN	O	26	NMOD
24	induced	induce	B-VP	VBD	O	23	AMOD
25	reflex	reflex	B-NP	NN	O	26	NMOD
26	bradycardia	bradycardia	I-NP	NN	O	21	OBJ
27	.	.	O	.	O	2	P

1	However	However	B-ADVP	RB	O	8	VMOD
2	,	,	O	,	O	8	P
3	the	the	B-NP	DT	O	5	NMOD
4	diazepam	diazepam	I-NP	NN	O	5	NMOD
5	enhancement	enhancement	I-NP	NN	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	adrenaline	adrenaline	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	reflex	reflex	B-NP	NN	O	10	NMOD
10	bradycardia	bradycardia	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	8	VMOD
12	antagonized	antagonize	I-VP	VBN	O	11	VC
13	by	by	B-PP	IN	O	12	VMOD
14	pretreatment	pretreatment	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	with	with	B-PP	IN	O	14	NMOD
18	an	an	B-NP	DT	O	20	NMOD
19	intravenous	intravenous	I-NP	JJ	O	20	NMOD
20	dose	dose	I-NP	NN	O	17	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	picrotoxin	picrotoxin	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	40	DEP
24	an	an	B-NP	DT	O	25	NMOD
25	agent	agent	I-NP	NN	O	26	SUB
26	blocks	block	B-VP	VBZ	O	40	DEP
27	chloride	chloride	B-NP	NN	B-protein	28	NMOD
28	channels	channel	I-NP	NNS	I-protein	26	OBJ
29	by	by	B-PP	IN	O	26	VMOD
30	binding	bind	B-VP	VBG	O	29	PMOD
31	to	to	B-PP	TO	O	30	VMOD
32	sites	site	B-NP	NNS	O	31	PMOD
33	associated	associate	B-VP	VBN	O	32	NMOD
34	with	with	B-PP	IN	O	33	VMOD
35	the	the	B-NP	DT	O	39	NMOD
36	benzodiazepine-GABA-chloride	benzodiazepine-GABA-chloride	I-NP	NN	B-protein	39	NMOD
37	channel	channel	I-NP	NN	I-protein	39	NMOD
38	macromolecular	macromolecular	I-NP	JJ	I-protein	39	NMOD
39	complex	complex	I-NP	NN	I-protein	34	PMOD
40	)	)	O	)	O	22	NMOD
41	.	.	O	.	O	8	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	carbamazepine	carbamazepine	I-NP	NN	O	3	SUB
3	inhibits	inhibit	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	development	development	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	local	local	B-NP	JJ	O	9	NMOD
8	anesthetic	anesthetic	I-NP	JJ	O	9	NMOD
9	seizures	seizure	I-NP	NNS	O	6	PMOD
10	kindled	kindle	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	cocaine	cocaine	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	lidocaine	lidocaine	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	carbamazepine	carbamazepine	B-NP	NN	O	8	NMOD
5	(	(	O	(	O	7	DEP
6	CBZ	CBZ	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	treatment	treatment	B-NP	NN	O	3	PMOD
9	on	on	B-PP	IN	O	2	NMOD
10	local	local	B-NP	JJ	O	12	NMOD
11	anesthetic-kindled	anesthetic-kindled	I-NP	JJ	O	12	NMOD
12	seizures	seizure	I-NP	NNS	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	lethality	lethality	I-NP	NN	O	9	PMOD
15	were	be	B-VP	VBD	O	0	ROOT
16	evaluated	evaluate	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	different	different	B-NP	JJ	O	19	NMOD
19	stages	stage	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	the	the	B-NP	DT	O	23	NMOD
22	kindling	kindling	I-NP	NN	O	23	NMOD
23	process	process	I-NP	NN	O	20	PMOD
24	and	and	B-PP	CC	O	17	PMOD
25	under	under	B-PP	IN	O	17	PMOD
26	different	different	B-NP	JJ	O	27	NMOD
27	methods	method	I-NP	NNS	O	25	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	CBZ	CBZ	B-NP	NN	B-protein	30	NMOD
30	administration	administration	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	15	P

1	Chronic	Chronic	B-NP	JJ	O	3	NMOD
2	oral	oral	I-NP	JJ	O	3	NMOD
3	CBZ	CBZ	I-NP	NN	O	4	SUB
4	inhibited	inhibit	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	development	development	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	both	both	O	CC	O	13	NMOD
9	lidocaine-	lidocaine-	B-NP	NN	O	13	NMOD
10	and	and	I-NP	CC	O	13	NMOD
11	cocaine	cocaine	I-NP	NN	O	13	NMOD
12	induced	induce	I-NP	VBN	O	13	NMOD
13	seizures	seizure	I-NP	NNS	O	7	PMOD
14	,	,	O	,	O	4	P
15	but	but	O	CC	O	4	VMOD
16	had	have	B-VP	VBD	O	4	VMOD
17	little	little	B-NP	JJ	O	18	NMOD
18	effect	effect	I-NP	NN	O	16	OBJ
19	on	on	B-PP	IN	O	16	VMOD
20	the	the	B-NP	DT	O	25	NMOD
21	fully	fully	I-NP	RB	O	22	AMOD
22	developed	develop	I-NP	VBN	O	25	NMOD
23	local	local	I-NP	JJ	O	25	NMOD
24	anesthetic	anesthetic	I-NP	JJ	O	25	NMOD
25	seizures	seizure	I-NP	NNS	O	19	PMOD
26	.	.	O	.	O	4	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	CBZ	CBZ	I-NP	NN	O	4	SUB
3	also	also	B-ADVP	RB	O	4	VMOD
4	decreased	decrease	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	incidence	incidence	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	seizure-related	seizure-related	B-NP	JJ	O	9	NMOD
9	mortality	mortality	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	13	NMOD
12	cocaine-injected	cocaine-injected	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	4	P

1	Acute	Acute	B-NP	JJ	B-protein	2	NMOD
2	CBZ	CBZ	I-NP	NN	I-protein	12	SUB
3	over	over	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	range	range	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	doses	dose	B-NP	NNS	O	6	PMOD
8	(	(	O	(	O	11	DEP
9	15-50	15-50	B-NP	CD	O	10	NMOD
10	mg/kg	mg/kg	I-NP	NN	O	11	DEP
11	)	)	O	)	O	2	NMOD
12	had	have	B-VP	VBD	O	0	ROOT
13	no	no	B-NP	DT	O	14	NMOD
14	effect	effect	I-NP	NN	O	12	OBJ
15	on	on	B-PP	IN	O	12	VMOD
16	completed	complete	B-NP	VBN	O	20	NMOD
17	lidocaine-kindled	lidocaine-kindled	I-NP	JJ	O	20	NMOD
18	or	or	I-NP	CC	O	20	NMOD
19	acute	acute	I-NP	JJ	O	20	NMOD
20	cocaine	cocaine	I-NP	NN	O	21	SUB
21	induced	induce	B-VP	VBD	O	22	NMOD
22	seizures	seizure	B-NP	NNS	O	15	PMOD
23	.	.	O	.	O	12	P

1	Repeated	Repeat	B-NP	VBN	O	3	NMOD
2	i.p.	i.p.	I-NP	JJ	O	3	NMOD
3	injection	injection	I-NP	NN	O	11	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	CBZ	CBZ	B-NP	NN	B-protein	4	PMOD
6	(	(	O	(	O	9	DEP
7	15	15	B-NP	CD	O	8	NMOD
8	mg/kg	mg/kg	I-NP	NN	O	9	DEP
9	)	)	O	)	O	5	NMOD
10	also	also	B-ADVP	RB	O	11	VMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	without	without	B-PP	IN	O	11	PRD
13	effect	effect	B-NP	NN	O	12	PMOD
14	on	on	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	development	development	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	lidocaine-	lidocaine-	B-NP	NN	O	21	NMOD
19	or	or	O	CC	O	21	NMOD
20	cocaine-kindled	cocaine-kindled	B-NP	JJ	O	21	NMOD
21	seizures	seizure	I-NP	NNS	O	17	PMOD
22	.	.	O	.	O	11	P

1	The	The	B-NP	DT	O	3	NMOD
2	differential	differential	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	12	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	CBZ	CBZ	B-NP	NN	B-protein	4	PMOD
6	depending	depend	B-VP	VBG	O	3	NMOD
7	upon	upon	B-PP	IN	O	6	VMOD
8	stage	stage	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	seizure	seizure	B-NP	NN	O	11	NMOD
11	development	development	I-NP	NN	O	9	PMOD
12	suggest	suggest	B-VP	VBP	O	0	ROOT
13	that	that	B-SBAR	IN	O	12	VMOD
14	distinct	distinct	B-NP	JJ	O	15	NMOD
15	mechanisms	mechanism	I-NP	NNS	O	16	SUB
16	underlie	underlie	B-VP	VBP	O	13	SBAR
17	the	the	B-NP	DT	O	18	NMOD
18	development	development	I-NP	NN	O	16	OBJ
19	versus	versus	B-PP	IN	O	18	NMOD
20	maintenance	maintenance	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	local	local	B-NP	JJ	O	24	NMOD
23	anesthetic-kindled	anesthetic-kindled	I-NP	JJ	O	24	NMOD
24	seizures	seizure	I-NP	NNS	O	21	PMOD
25	.	.	O	.	O	12	P

1	D-penicillamine	D-penicillamine	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	localized	localize	B-NP	VBN	O	7	NMOD
7	scleroderma	scleroderma	I-NP	NN	O	5	PMOD
8	.	.	O	.	O	1	P

1	Case	Case	B-NP	NN	O	2	NMOD
2	reports	report	I-NP	NNS	O	17	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	11	11	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	severe	severe	B-NP	JJ	O	9	AMOD
8	,	,	I-NP	,	O	9	P
9	extensive	extensive	I-NP	JJ	O	11	NMOD
10	localized	localized	I-NP	JJ	O	11	NMOD
11	scleroderma	scleroderma	I-NP	NN	O	6	PMOD
12	who	who	B-NP	WP	O	5	NMOD
13	were	be	B-VP	VBD	O	12	SBAR
14	treated	treat	I-VP	VBN	O	13	VC
15	with	with	B-PP	IN	O	14	VMOD
16	D-penicillamine	D-penicillamine	B-NP	NN	O	15	PMOD
17	are	be	B-VP	VBP	O	0	ROOT
18	summarized	summarize	I-VP	VBN	O	17	VC
19	in	in	B-PP	IN	O	18	VMOD
20	this	this	B-NP	DT	O	21	NMOD
21	article	article	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	17	P

1	D-Penicillamine	D-Penicillamine	B-NP	NN	O	2	SUB
2	caused	cause	B-VP	VBD	O	0	ROOT
3	nephrotic	nephrotic	B-NP	JJ	O	4	NMOD
4	syndrome	syndrome	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	1	1	B-NP	CD	O	7	NMOD
7	patient	patient	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	milder	mild	B-NP	JJR	O	11	NMOD
10	reversible	reversible	I-NP	JJ	O	11	NMOD
11	proteinuria	proteinuria	I-NP	NN	O	5	PMOD
12	in	in	B-PP	IN	O	2	VMOD
13	3	3	B-NP	CD	O	15	NMOD
14	other	other	I-NP	JJ	O	15	NMOD
15	patients	patient	I-NP	NNS	O	12	PMOD
16	;	;	O	:	O	2	P
17	none	none	B-NP	NN	O	20	NMOD
18	developed	develop	B-VP	VBD	O	20	NMOD
19	renal	renal	B-NP	JJ	O	20	NMOD
20	insufficiency	insufficiency	I-NP	NN	O	2	VMOD
21	.	.	O	.	O	2	P

1	Preservation	Preservation	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	renal	renal	B-NP	JJ	O	5	NMOD
4	blood	blood	I-NP	NN	O	5	NMOD
5	flow	flow	I-NP	NN	O	2	PMOD
6	during	during	B-PP	IN	O	1	NMOD
7	hypotension	hypotension	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	fenoldopam	fenoldopam	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	dogs	dog	B-NP	NNS	O	11	PMOD
13	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	hypothesis	hypothesis	I-NP	NN	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	NMOD
4	fenoldopam	fenoldopam	B-NP	NN	O	5	SUB
5	could	could	B-VP	MD	O	3	SBAR
6	be	be	I-VP	VB	O	5	VC
7	used	use	I-VP	VBN	O	6	VC
8	to	to	B-VP	TO	O	9	VMOD
9	induce	induce	I-VP	VB	O	5	VMOD
10	hypotension	hypotension	B-NP	NN	O	9	OBJ
11	and	and	O	CC	O	9	VMOD
12	preserve	preserve	B-VP	VB	O	9	VMOD
13	blood	blood	B-NP	NN	O	14	NMOD
14	flow	flow	I-NP	NN	O	12	OBJ
15	to	to	B-PP	TO	O	12	VMOD
16	the	the	B-NP	DT	O	17	NMOD
17	kidney	kidney	I-NP	NN	O	15	PMOD
18	was	be	B-VP	VBD	O	9	VMOD
19	tested	test	I-VP	VBN	O	18	VC
20	.	.	O	.	O	2	P

1	Renal	Renal	B-NP	JJ	O	3	NMOD
2	blood	blood	I-NP	NN	O	3	NMOD
3	flow	flow	I-NP	NN	O	7	SUB
4	(	(	O	(	O	6	DEP
5	RBF	RBF	B-NP	NN	B-protein	6	DEP
6	)	)	O	)	O	3	NMOD
7	increased	increase	B-VP	VBD	O	0	ROOT
8	during	during	B-PP	IN	O	7	VMOD
9	fenoldopam	fenoldopam	B-NP	NN	O	11	NMOD
10	induced	induce	B-VP	VBD	O	11	NMOD
11	hypotension	hypotension	B-NP	NN	O	8	PMOD
12	11	11	I-NP	CD	O	14	NMOD
13	+/-	+/-	I-NP	SYM	O	14	NMOD
14	7	7	I-NP	CD	O	11	NMOD
15	per	per	B-PP	IN	O	11	NMOD
16	cent	cent	B-NP	NN	O	15	PMOD
17	and	and	O	CC	O	7	VMOD
18	decreased	decrease	B-VP	VBD	O	7	VMOD
19	21	21	B-NP	CD	O	21	AMOD
20	+/-	+/-	I-NP	SYM	O	21	AMOD
21	8	8	I-NP	CD	O	18	OBJ
22	per	per	B-PP	IN	O	21	NMOD
23	cent	cent	B-NP	NN	O	22	PMOD
24	during	during	B-PP	IN	O	18	VMOD
25	sodium	sodium	B-NP	NN	O	26	NMOD
26	nitroprusside	nitroprusside	I-NP	NN	O	28	NMOD
27	induced	induce	B-VP	VBD	O	26	AMOD
28	hypotension	hypotension	B-NP	NN	O	24	PMOD
29	(	(	O	(	O	34	DEP
30	P	P	B-NP	NN	O	34	DEP
31	less	less	B-ADJP	JJR	O	30	NMOD
32	than	than	B-PP	IN	O	31	AMOD
33	0.01	0.01	B-NP	CD	O	32	PMOD
34	)	)	O	)	O	28	NMOD
35	.	.	O	.	O	7	P

1	Sodium	Sodium	B-NP	NN	O	2	NMOD
2	nitroprusside	nitroprusside	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	9	NMOD
5	non-selective	non-selective	I-NP	JJ	O	9	NMOD
6	arteriolar	arteriolar	I-NP	JJ	O	9	NMOD
7	and	and	I-NP	CC	O	9	NMOD
8	venous	venous	I-NP	JJ	O	9	NMOD
9	vasodilator	vasodilator	I-NP	NN	O	3	PRD
10	that	that	B-NP	WDT	O	9	NMOD
11	can	can	B-VP	MD	O	10	SBAR
12	produce	produce	I-VP	VB	O	11	VC
13	redistribution	redistribution	B-NP	NN	O	12	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	blood	blood	B-NP	NN	O	16	NMOD
16	flow	flow	I-NP	NN	O	14	PMOD
17	away	away	B-ADVP	RB	O	12	VMOD
18	from	from	B-PP	IN	O	17	AMOD
19	the	the	B-NP	DT	O	20	NMOD
20	kidney	kidney	I-NP	NN	O	18	PMOD
21	during	during	B-PP	IN	O	20	NMOD
22	induced	induce	B-NP	VBN	O	23	NMOD
23	hypotension	hypotension	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	3	P

1	Antiarrhythmic	Antiarrhythmic	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	optical	optical	B-NP	JJ	O	5	NMOD
5	isomers	isomer	I-NP	NNS	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	cibenzoline	cibenzoline	B-NP	NN	O	6	PMOD
8	on	on	B-PP	IN	O	2	NMOD
9	canine	canine	B-NP	JJ	O	11	NMOD
10	ventricular	ventricular	I-NP	JJ	O	11	NMOD
11	arrhythmias	arrhythmia	I-NP	NNS	O	8	PMOD
12	.	.	O	.	O	2	P

1	Antiarrhythmic	Antiarrhythmic	B-NP	JJ	O	2	NMOD
2	effects	effect	I-NP	NNS	O	12	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	(	(	O	(	O	6	DEP
5	+	+	O	SYM	O	6	DEP
6	)	)	O	)	O	7	NMOD
7	-cibenzoline	-cibenzoline	B-NP	NN	O	3	PMOD
8	and	and	O	CC	O	10	NMOD
9	(	(	O	(	O	10	DEP
10	-	-	O	SYM	O	11	DEP
11	)	)	O	)	O	2	NMOD
12	-cibenzoline	-cibenzoline	B-NP	NN	O	13	SUB
13	were	be	B-VP	VBD	O	0	ROOT
14	examined	examine	I-VP	VBN	O	13	VC
15	using	use	B-VP	VBG	O	14	VMOD
16	two	two	B-NP	CD	O	20	NMOD
17	canine	canine	I-NP	JJ	O	20	NMOD
18	ventricular	ventricular	I-NP	JJ	O	20	NMOD
19	arrhythmia	arrhythmia	I-NP	NN	O	20	NMOD
20	models	model	I-NP	NNS	O	15	OBJ
21	.	.	O	.	O	13	P

1	Digitalis	Digitalis	B-NP	NNP	O	2	NMOD
2	arrhythmia	arrhythmia	I-NP	NN	O	12	SUB
3	,	,	O	,	O	2	P
4	which	which	B-NP	WDT	O	2	NMOD
5	is	be	B-VP	VBZ	O	4	SBAR
6	suppressed	suppress	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	Na	Na	B-NP	NN	O	10	NMOD
9	channel	channel	I-NP	NN	O	10	NMOD
10	blockers	blocker	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	2	P
12	was	be	B-VP	VBD	O	0	ROOT
13	induced	induce	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	intermittent	intermittent	B-NP	JJ	O	20	NMOD
16	intravenous	intravenous	I-NP	JJ	O	20	NMOD
17	(	(	O	(	O	19	DEP
18	i.v.	i.v.	B-ADJP	JJ	O	19	DEP
19	)	)	O	)	O	16	AMOD
20	injection	injection	B-NP	NN	O	14	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	ouabain	ouabain	B-NP	NN	O	21	PMOD
23	in	in	B-PP	IN	O	20	NMOD
24	pentobarbital-anesthetized	pentobarbital-anesthetized	B-NP	JJ	O	25	NMOD
25	dogs	dog	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	12	P

1	Adrenaline	Adrenaline	B-NP	NN	O	2	NMOD
2	arrhythmia	arrhythmia	I-NP	NN	O	12	SUB
3	,	,	O	,	O	2	P
4	which	which	B-NP	WDT	O	2	NMOD
5	is	be	B-VP	VBZ	O	4	SBAR
6	suppressed	suppress	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	Ca	Ca	B-NP	NN	O	10	NMOD
9	channel	channel	I-NP	NN	O	10	NMOD
10	blockers	blocker	I-NP	NNS	O	7	PMOD
11	,	,	O	,	O	2	P
12	was	be	B-VP	VBD	O	0	ROOT
13	induced	induce	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	adrenaline	adrenaline	B-NP	NN	O	16	NMOD
16	infusion	infusion	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	halothane-anesthetized	halothane-anesthetized	B-NP	JJ	O	19	NMOD
19	dogs	dog	I-NP	NNS	O	17	PMOD
20	.	.	O	.	O	12	P

1	(	(	O	(	O	3	DEP
2	+	+	B-NP	SYM	O	3	DEP
3	)	)	O	)	O	4	NMOD
4	-cibenzoline	-cibenzoline	B-NP	NN	O	5	SUB
5	suppressed	suppress	B-VP	VBD	O	0	ROOT
6	digitalis-	digitalis-	B-NP	NN	O	10	NMOD
7	and	and	I-NP	CC	O	10	NMOD
8	adrenaline	adrenaline	I-NP	NN	O	10	NMOD
9	induced	induce	I-NP	VBN	O	10	NMOD
10	arrhythmias	arrhythmia	I-NP	NNS	O	5	OBJ
11	,	,	O	,	O	10	P
12	respectively	respectively	B-ADVP	RB	O	10	NMOD
13	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	5	NMOD
2	minimum	minimum	I-NP	JJ	O	3	AMOD
3	effective	effective	I-NP	JJ	O	5	NMOD
4	plasma	plasma	I-NP	NN	O	5	NMOD
5	concentrations	concentration	I-NP	NNS	O	17	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	(	(	O	(	O	9	DEP
8	+	+	O	SYM	O	9	DEP
9	)	)	O	)	O	10	NMOD
10	-cibenzoline	-cibenzoline	B-NP	NN	O	6	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	digitalis-	digitalis-	B-NP	NN	O	16	NMOD
13	and	and	I-NP	CC	O	16	NMOD
14	adrenaline	adrenaline	I-NP	NN	O	16	NMOD
15	induced	induce	I-NP	VBN	O	16	NMOD
16	arrhythmias	arrhythmia	I-NP	NNS	O	11	PMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	1.4	1.4	B-NP	CD	O	20	AMOD
19	+/-	+/-	I-NP	SYM	O	20	AMOD
20	0.4	0.4	I-NP	CD	O	25	NMOD
21	and	and	I-NP	CC	O	25	NMOD
22	2.0	2.0	I-NP	CD	O	24	AMOD
23	+/-	+/-	I-NP	CC	O	24	AMOD
24	0.6	0.6	I-NP	CD	O	25	NMOD
25	micrograms/ml	micrograms/ml	I-NP	NNS	O	17	PRD
26	,	,	O	,	O	25	P
27	respectively	respectively	B-ADVP	RB	O	25	NMOD
28	(	(	O	(	O	36	DEP
29	mean	mean	B-NP	NN	O	31	NMOD
30	+/-	+/-	O	SYM	O	31	NMOD
31	SD	SD	B-NP	NN	O	35	VMOD
32	,	,	O	,	O	35	P
33	n	n	B-NP	NN	O	35	SUB
34	=	=	B-VP	JJ	O	35	VMOD
35	6	6	B-NP	CD	O	36	DEP
36	)	)	O	)	O	25	NMOD
37	.	.	O	.	O	17	P

1	A	A	B-NP	DT	O	3	NMOD
2	lower	low	I-NP	JJR	O	3	NMOD
3	dose	dose	I-NP	NN	O	13	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	1	1	B-NP	CD	O	7	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	7	NMOD
7	i.v.	i.v.	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	(	(	O	(	O	11	DEP
10	-	-	O	SYM	O	11	DEP
11	)	)	O	)	O	12	NMOD
12	-cibenzoline	-cibenzoline	B-NP	NN	O	8	PMOD
13	suppressed	suppress	B-VP	VBD	O	0	ROOT
14	the	the	B-NP	DT	O	15	NMOD
15	digitalis	digitalis	I-NP	NN	O	13	OBJ
16	induced	induce	B-VP	VBD	O	15	NMOD
17	arrhythmia	arrhythmia	B-NP	NN	O	16	OBJ
18	,	,	O	,	O	13	P
19	whereas	whereas	O	IN	O	13	VMOD
20	5	5	B-NP	CD	O	21	AMOD
21	mg/kg	mg/kg	I-NP	NN	O	22	NMOD
22	i.v.	i.v.	I-NP	NN	O	23	SUB
23	was	be	B-VP	VBD	O	19	SBAR
24	needed	need	I-VP	VBN	O	23	VC
25	to	to	B-VP	TO	O	26	VMOD
26	suppress	suppress	I-VP	VB	O	24	VMOD
27	adrenaline	adrenaline	B-NP	NN	O	29	NMOD
28	induced	induced	I-NP	JJ	O	29	NMOD
29	arrhythmias	arrhythmia	I-NP	NNS	O	26	OBJ
30	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	5	NMOD
2	minimum	minimum	I-NP	JJ	O	3	AMOD
3	effective	effective	I-NP	JJ	O	5	NMOD
4	plasma	plasma	I-NP	NN	O	5	NMOD
5	concentrations	concentration	I-NP	NNS	O	17	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	(	(	O	(	O	9	DEP
8	-	-	O	SYM	O	9	DEP
9	)	)	O	)	O	10	NMOD
10	-cibenzoline	-cibenzoline	B-NP	NN	O	6	PMOD
11	for	for	B-PP	IN	O	10	NMOD
12	digitalis-	digitalis-	B-NP	NN	O	16	NMOD
13	and	and	I-NP	CC	O	16	NMOD
14	adrenaline	adrenaline	I-NP	NN	O	16	NMOD
15	induced	induce	I-NP	VBN	O	16	NMOD
16	arrhythmia	arrhythmia	I-NP	NN	O	11	PMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	0.06	0.06	B-NP	CD	O	20	AMOD
19	+/-	+/-	I-NP	SYM	O	20	AMOD
20	0.04	0.04	I-NP	CD	O	25	NMOD
21	and	and	I-NP	CC	O	25	NMOD
22	0.7	0.7	I-NP	CD	O	24	AMOD
23	+/-	+/-	I-NP	CC	O	24	AMOD
24	0.1	0.1	I-NP	CD	O	25	NMOD
25	micrograms/ml	micrograms/ml	I-NP	NNS	O	17	PRD
26	,	,	O	,	O	25	P
27	respectively	respectively	B-ADVP	RB	O	25	NMOD
28	(	(	O	(	O	36	DEP
29	mean	mean	B-NP	NN	O	31	NMOD
30	+/-	+/-	O	SYM	O	31	NMOD
31	SD	SD	B-NP	NN	O	35	VMOD
32	,	,	O	,	O	35	P
33	n	n	B-NP	NN	O	35	SUB
34	=	=	B-VP	JJ	O	35	VMOD
35	6	6	B-NP	CD	O	36	DEP
36	)	)	O	)	O	25	NMOD
37	.	.	O	.	O	17	P

1	Effect	Effect	B-NP	NN	O	13	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	methanolic	methanolic	B-NP	JJ	O	4	NMOD
4	extract	extract	I-NP	NN	O	2	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	Hibiscus	Hibiscus	B-NP	NNP	O	8	NMOD
7	rosa	rosa	I-NP	NN	O	8	NMOD
8	sinensis	sinensis	I-NP	NN	O	5	PMOD
9	(	(	O	(	O	12	DEP
10	100-300	100-300	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	12	DEP
12	)	)	O	)	O	8	NMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	studied	study	I-VP	VBN	O	13	VC
15	on	on	B-PP	IN	O	14	VMOD
16	reserpine	reserpine	B-NP	NN	O	15	PMOD
17	induced	induce	B-VP	VBD	O	16	NMOD
18	orofacial	orofacial	B-NP	JJ	O	19	NMOD
19	dyskinesia	dyskinesia	I-NP	NN	O	22	NMOD
20	and	and	O	CC	O	22	NMOD
21	neurochemical	neurochemical	B-NP	JJ	O	22	NMOD
22	alterations	alteration	I-NP	NNS	O	17	OBJ
23	.	.	O	.	O	13	P

1	Comparison	Comparison	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	aqueous	aqueous	B-NP	JJ	O	7	NMOD
4	and	and	I-NP	CC	O	7	NMOD
5	gellan	gellan	I-NP	JJ	O	7	NMOD
6	ophthalmic	ophthalmic	I-NP	JJ	O	7	NMOD
7	timolol	timolol	I-NP	NN	O	2	PMOD
8	with	with	B-PP	IN	O	1	NMOD
9	placebo	placebo	B-NP	NN	O	8	PMOD
10	on	on	B-PP	IN	O	1	NMOD
11	the	the	B-NP	DT	O	15	NMOD
12	24-hour	24-hour	I-NP	JJ	O	15	NMOD
13	heart	heart	I-NP	NN	O	15	NMOD
14	rate	rate	I-NP	NN	O	15	NMOD
15	response	response	I-NP	NN	O	10	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	on	on	B-PP	IN	O	17	NMOD
19	treatment	treatment	B-NP	NN	O	18	PMOD
20	for	for	B-PP	IN	O	19	NMOD
21	glaucoma	glaucoma	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	1	P

1	DESIGN	DESIGN	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	This	This	B-NP	DT	O	4	NMOD
4	trial	trial	I-NP	NN	O	5	SUB
5	evaluated	evaluate	B-VP	VBD	O	0	ROOT
6	the	the	B-NP	DT	O	7	NMOD
7	effect	effect	I-NP	NN	O	24	NMOD
8	of	of	B-PP	IN	O	7	NMOD
9	placebo	placebo	B-NP	NN	O	12	AMOD
10	,	,	O	,	O	12	P
11	0.5	0.5	B-NP	CD	O	12	AMOD
12	%	%	I-NP	NN	O	14	NMOD
13	aqueous	aqueous	I-NP	JJ	O	14	NMOD
14	timolol	timolol	I-NP	NN	O	8	PMOD
15	(	(	O	(	O	18	DEP
16	timolol	timolol	B-NP	NN	O	17	NMOD
17	solution	solution	I-NP	NN	O	18	DEP
18	)	)	O	)	O	14	NMOD
19	and	and	O	CC	O	24	NMOD
20	a	a	B-NP	DT	O	24	NMOD
21	0.5	0.5	I-NP	CD	O	22	AMOD
22	%	%	I-NP	NN	O	24	NMOD
23	timolol	timolol	I-NP	NN	O	24	NMOD
24	suspension	suspension	I-NP	NN	O	5	OBJ
25	that	that	B-NP	WDT	O	24	NMOD
26	forms	form	B-VP	VBZ	O	25	SBAR
27	a	a	B-NP	DT	O	28	NMOD
28	gel	gel	I-NP	NN	O	26	OBJ
29	on	on	B-PP	IN	O	26	VMOD
30	application	application	B-NP	NN	O	29	PMOD
31	to	to	B-PP	TO	O	26	VMOD
32	the	the	B-NP	DT	O	33	NMOD
33	conjunctiva	conjunctiva	I-NP	NN	O	31	PMOD
34	(	(	O	(	O	37	DEP
35	timolol	timolol	B-NP	NN	O	36	NMOD
36	gellan	gellan	I-NP	NN	O	37	DEP
37	)	)	O	)	O	33	NMOD
38	on	on	B-PP	IN	O	33	NMOD
39	the	the	B-NP	DT	O	42	NMOD
40	24-hour	24-hour	I-NP	JJ	O	42	NMOD
41	heart	heart	I-NP	NN	O	42	NMOD
42	rate	rate	I-NP	NN	O	38	PMOD
43	in	in	B-PP	IN	O	42	NMOD
44	patients	patient	B-NP	NNS	O	43	PMOD
45	currently	currently	B-VP	RB	O	46	VMOD
46	being	be	I-VP	VBG	O	44	NMOD
47	treated	treat	I-VP	VBN	O	46	VC
48	for	for	B-PP	IN	O	47	VMOD
49	glaucoma	glaucoma	B-NP	NN	O	48	PMOD
50	to	to	B-VP	TO	O	51	VMOD
51	quantify	quantify	I-VP	VB	O	47	VMOD
52	the	the	B-NP	DT	O	53	NMOD
53	reduction	reduction	I-NP	NN	O	51	OBJ
54	in	in	B-PP	IN	O	53	NMOD
55	mean	mean	B-NP	JJ	O	57	NMOD
56	heart	heart	I-NP	NN	O	57	NMOD
57	rate	rate	I-NP	NN	O	54	PMOD
58	.	.	O	.	O	5	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Forty-three	Forty-three	B-NP	CD	O	5	NMOD
4	Caucasian	Caucasian	I-NP	JJ	O	5	NMOD
5	patients	patient	I-NP	NNS	O	26	SUB
6	with	with	B-PP	IN	O	5	NMOD
7	primary	primary	B-NP	JJ	O	9	NMOD
8	open-angle	open-angle	I-NP	JJ	O	9	NMOD
9	glaucoma	glaucoma	I-NP	NN	O	12	NMOD
10	or	or	O	CC	O	12	NMOD
11	ocular	ocular	B-NP	JJ	O	12	NMOD
12	hypertension	hypertension	I-NP	NN	O	6	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	a	a	O	DT	O	19	NMOD
15	mean	mean	O	JJ	O	19	NMOD
16	(	(	O	(	O	18	DEP
17	+/-SD	+/-SD	B-ADJP	JJ	O	18	DEP
18	)	)	O	)	O	15	AMOD
19	age	age	B-NP	NN	O	13	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	63	63	B-NP	CD	O	25	NMOD
22	(	(	O	(	O	24	DEP
23	+/-8	+/-8	B-NP	CD	O	24	DEP
24	)	)	O	)	O	21	NMOD
25	years	year	B-NP	NNS	O	20	PMOD
26	were	be	B-VP	VBD	O	1	NMOD
27	randomized	randomize	I-VP	VBN	O	26	VC
28	and	and	O	CC	O	27	VMOD
29	crossed	cross	B-VP	VBN	O	27	VMOD
30	over	over	B-PRT	RP	O	29	VMOD
31	in	in	B-PP	IN	O	29	VMOD
32	a	a	B-NP	DT	O	34	NMOD
33	double-masked	double-masked	I-NP	JJ	O	34	NMOD
34	manner	manner	I-NP	NN	O	31	PMOD
35	to	to	B-PP	TO	O	29	VMOD
36	14	14	B-NP	CD	O	37	NMOD
37	days	day	I-NP	NNS	O	35	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	treatment	treatment	B-NP	NN	O	38	PMOD
40	with	with	B-PP	IN	O	39	NMOD
41	placebo	placebo	B-NP	NN	O	45	NMOD
42	(	(	O	(	O	45	NMOD
43	morning	morning	B-NP	NN	O	45	NMOD
44	and	and	O	CC	O	45	NMOD
45	evening	evening	B-NP	NN	O	40	PMOD
46	in	in	B-PP	IN	O	39	NMOD
47	both	both	B-NP	DT	O	48	NMOD
48	eyes	eye	I-NP	NNS	O	46	PMOD
49	)	)	O	)	O	39	NMOD
50	,	,	O	,	O	27	P
51	timolol	timolol	B-NP	NN	O	52	NMOD
52	solution	solution	I-NP	NN	O	56	NMOD
53	(	(	O	(	O	56	NMOD
54	morning	morning	B-NP	NN	O	56	NMOD
55	and	and	O	CC	O	56	NMOD
56	evening	evening	B-NP	NN	O	64	NMOD
57	in	in	B-PP	IN	O	56	NMOD
58	both	both	B-NP	DT	O	59	NMOD
59	eyes	eye	I-NP	NNS	O	57	PMOD
60	)	)	O	)	O	56	NMOD
61	,	,	O	,	O	64	P
62	or	or	O	CC	O	64	NMOD
63	timolol	timolol	B-NP	NN	O	64	NMOD
64	gellan	gellan	I-NP	NN	O	27	VMOD
65	(	(	O	(	O	75	DEP
66	morning	morning	B-NP	NN	O	75	DEP
67	in	in	B-PP	IN	O	66	NMOD
68	both	both	B-NP	DT	O	69	NMOD
69	eyes	eye	I-NP	NNS	O	67	PMOD
70	with	with	B-PP	IN	O	66	NMOD
71	placebo	placebo	B-NP	NN	O	70	PMOD
72	in	in	B-PP	IN	O	66	NMOD
73	the	the	B-NP	DT	O	74	NMOD
74	evening	evening	I-NP	NN	O	72	PMOD
75	)	)	O	)	O	64	NMOD
76	.	.	O	.	O	1	P

1	5	5	B-NP	CD	O	2	NMOD
2	flourouracil	flourouracil	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	apical	apical	B-NP	JJ	O	6	NMOD
5	ballooning	ballooning	I-NP	NN	O	6	NMOD
6	syndrome	syndrome	I-NP	NN	O	3	OBJ
7	:	:	O	:	O	3	P
8	a	a	B-NP	DT	O	10	NMOD
9	case	case	I-NP	NN	O	10	NMOD
10	report	report	I-NP	NN	O	3	VMOD
11	.	.	O	.	O	3	P

1	She	She	B-NP	PRP	O	2	SUB
2	underwent	undergo	B-VP	VBD	O	0	ROOT
3	recent	recent	B-NP	JJ	O	4	NMOD
4	chemotherapy	chemotherapy	I-NP	NN	O	2	OBJ
5	with	with	B-PP	IN	O	2	VMOD
6	fluorouracil	fluorouracil	B-NP	NN	O	5	PMOD
7	for	for	B-PP	IN	O	6	NMOD
8	metastatic	metastatic	B-NP	JJ	O	10	NMOD
9	colorectal	colorectal	I-NP	JJ	O	10	NMOD
10	cancer	cancer	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	Reduction	Reduction	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	pain	pain	B-NP	NN	O	2	PMOD
4	during	during	B-PP	IN	O	1	NMOD
5	induction	induction	B-NP	NN	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	target-controlled	target-controlled	B-NP	JJ	O	8	NMOD
8	propofol	propofol	I-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	remifentanil	remifentanil	I-NP	NN	O	6	PMOD
11	.	.	O	.	O	1	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	3	NMOD
2	:	:	O	:	O	3	P
3	Pain	Pain	B-NP	NN	B-protein	8	SUB
4	on	on	B-PP	IN	O	3	NMOD
5	injection	injection	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	propofol	propofol	B-NP	NN	O	6	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	unpleasant	unpleasant	B-ADJP	JJ	O	8	PRD
10	.	.	O	.	O	8	P

1	We	We	B-NP	PRP	O	2	SUB
2	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	propofol	propofol	B-NP	NN	B-protein	6	NMOD
5	infusion	infusion	I-NP	NN	I-protein	6	NMOD
6	pain	pain	I-NP	NN	I-protein	7	SUB
7	might	might	B-VP	MD	O	3	SBAR
8	be	be	I-VP	VB	O	7	VC
9	prevented	prevent	I-VP	VBN	O	8	VC
10	by	by	B-PP	IN	O	9	VMOD
11	infusing	infuse	B-VP	VBG	O	10	PMOD
12	remifentanil	remifentanil	B-NP	NN	O	11	OBJ
13	before	before	B-PP	IN	O	11	VMOD
14	starting	start	B-VP	VBG	O	13	PMOD
15	the	the	B-NP	DT	O	17	NMOD
16	propofol	propofol	I-NP	NN	O	17	NMOD
17	infusion	infusion	I-NP	NN	O	14	OBJ
18	in	in	B-PP	IN	O	17	NMOD
19	a	a	B-NP	DT	O	18	PMOD
20	clinical	clinical	I-NP	JJ	O	19	PRD
21	setting	set	I-NP	VBG	O	20	AMOD
22	where	where	B-ADVP	WRB	O	21	VMOD
23	target-controlled	target-controlled	B-NP	JJ	O	24	NMOD
24	infusions	infusion	I-NP	NNS	O	31	SUB
25	(	(	O	(	O	27	DEP
26	TCI	TCI	B-NP	NN	B-protein	27	DEP
27	)	)	O	)	O	24	NMOD
28	of	of	B-PP	IN	O	24	NMOD
29	both	both	B-NP	DT	O	30	NMOD
30	drugs	drug	I-NP	NNS	O	28	PMOD
31	were	be	B-VP	VBD	O	22	SBAR
32	used	use	I-VP	VBN	O	31	VC
33	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	9	NMOD
2	prospective	prospective	I-NP	JJ	O	8	AMOD
3	,	,	I-NP	,	O	8	P
4	randomized	randomize	I-NP	VBN	O	8	AMOD
5	,	,	I-NP	,	O	8	P
6	double-blind	double-blind	I-NP	JJ	O	8	AMOD
7	,	,	I-NP	,	O	8	P
8	placebo-controlled	placebo-controlled	I-NP	JJ	O	9	NMOD
9	trial	trial	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	performed	perform	I-VP	VBN	O	10	VC
12	to	to	B-VP	TO	O	13	VMOD
13	determine	determine	I-VP	VB	O	11	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	effect-site	effect-site	I-NP	NN	O	16	NMOD
16	concentration	concentration	I-NP	NN	O	13	OBJ
17	(	(	O	(	O	19	DEP
18	Ce	Ce	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	of	of	B-PP	IN	O	16	NMOD
21	remifentanil	remifentanil	B-NP	NN	O	20	PMOD
22	to	to	B-VP	TO	O	23	VMOD
23	prevent	prevent	I-VP	VB	O	16	NMOD
24	the	the	B-NP	DT	O	25	NMOD
25	pain	pain	I-NP	NN	O	23	OBJ
26	without	without	B-PP	IN	O	23	VMOD
27	producing	produce	B-VP	VBG	O	28	NMOD
28	complications	complication	B-NP	NNS	O	26	PMOD
29	.	.	O	.	O	10	P

1	Remifentanil-related	Remifentanil-related	B-NP	JJ	O	2	NMOD
2	complications	complication	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	15	VMOD
4	assessed	assess	I-VP	VBN	O	3	VC
5	during	during	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	remifentanil	remifentanil	I-NP	NN	O	8	NMOD
8	infusion	infusion	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	11	P
10	and	and	O	CC	O	11	NMOD
11	pain	pain	B-NP	NN	O	15	SUB
12	caused	cause	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	propofol	propofol	B-NP	NN	O	13	PMOD
15	was	be	B-VP	VBD	O	0	ROOT
16	evaluated	evaluate	I-VP	VBN	O	15	VC
17	using	use	B-VP	VBG	O	15	VMOD
18	a	a	B-NP	DT	O	20	NMOD
19	four-point	four-point	I-NP	JJ	O	20	NMOD
20	scale	scale	I-NP	NN	O	17	OBJ
21	during	during	B-PP	IN	O	17	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	propofol	propofol	I-NP	NN	O	24	NMOD
24	infusion	infusion	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	15	P

1	Prenatal	Prenatal	B-NP	JJ	O	2	NMOD
2	exposure	exposure	I-NP	NN	O	5	SUB
3	to	to	B-PP	TO	O	2	NMOD
4	fluoxetine	fluoxetine	B-NP	NN	O	3	PMOD
5	induces	induce	B-VP	VBZ	O	0	ROOT
6	fetal	fetal	B-NP	JJ	O	8	NMOD
7	pulmonary	pulmonary	I-NP	JJ	O	8	NMOD
8	hypertension	hypertension	I-NP	NN	O	5	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	rat	rat	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	5	P

1	Epidemiological	Epidemiological	B-NP	JJ	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	fluoxetine	fluoxetine	B-NP	NN	O	6	NMOD
6	exposure	exposure	I-NP	NN	O	8	SUB
7	prenatally	prenatally	B-ADVP	RB	O	8	VMOD
8	increases	increase	B-VP	VBZ	O	4	SBAR
9	the	the	B-NP	DT	O	10	NMOD
10	prevalence	prevalence	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	persistent	persistent	B-NP	JJ	O	15	NMOD
13	pulmonary	pulmonary	I-NP	JJ	O	15	NMOD
14	hypertension	hypertension	I-NP	NN	O	15	NMOD
15	syndrome	syndrome	I-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	newborn	newborn	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanism	mechanism	I-NP	NN	O	7	SUB
3	responsible	responsible	B-ADJP	JJ	O	2	NMOD
4	for	for	B-PP	IN	O	3	AMOD
5	this	this	B-NP	DT	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	unclear	unclear	B-ADJP	JJ	O	10	AMOD
9	and	and	I-ADJP	CC	O	10	AMOD
10	paradoxical	paradoxical	I-ADJP	JJ	O	7	PRD
11	,	,	O	,	O	7	P
12	considering	consider	B-VP	VBG	O	7	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	current	current	I-NP	JJ	O	15	NMOD
15	evidence	evidence	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	a	a	B-NP	DT	O	22	NMOD
18	pulmonary	pulmonary	I-NP	JJ	O	22	NMOD
19	hypertension	hypertension	I-NP	NN	O	22	NMOD
20	protective	protective	I-NP	JJ	O	22	NMOD
21	fluoxetine	fluoxetine	I-NP	NN	O	22	NMOD
22	effect	effect	I-NP	NN	O	16	PMOD
23	in	in	B-PP	IN	O	22	NMOD
24	adult	adult	B-NP	JJ	O	25	NMOD
25	rodents	rodent	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	7	P

1	As	As	B-SBAR	IN	O	8	VMOD
2	compared	compare	B-PP	VBN	O	1	SBAR
3	with	with	B-PP	IN	O	2	PMOD
4	controls	control	B-NP	NNS	O	3	PMOD
5	,	,	O	,	O	8	P
6	fluoxetine	fluoxetine	B-NP	NN	O	7	NMOD
7	exposure	exposure	I-NP	NN	O	8	SUB
8	resulted	result	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	fetal	fetal	B-NP	JJ	O	12	NMOD
11	pulmonary	pulmonary	I-NP	JJ	O	12	NMOD
12	hypertension	hypertension	I-NP	NN	O	9	PMOD
13	as	as	B-SBAR	IN	O	8	VMOD
14	evidenced	evidence	B-VP	VBN	O	13	SBAR
15	by	by	B-PP	IN	O	14	VMOD
16	an	an	B-NP	DT	O	17	NMOD
17	increase	increase	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	weight	weight	I-NP	NN	O	21	NMOD
21	ratio	ratio	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	right	right	I-NP	JJ	O	25	NMOD
25	ventricle	ventricle	I-NP	NN	O	22	PMOD
26	to	to	B-PP	TO	O	21	NMOD
27	the	the	B-NP	DT	O	29	NMOD
28	left	left	I-NP	JJ	O	29	NMOD
29	ventricle	ventricle	I-NP	NN	O	31	NMOD
30	plus	plus	O	CC	O	31	NMOD
31	septum	septum	B-NP	NN	O	26	PMOD
32	(	(	O	(	O	36	DEP
33	P	P	B-NP	NN	O	36	DEP
34	=	=	B-VP	SYM	O	33	NMOD
35	0.02	0.02	B-NP	CD	O	34	AMOD
36	)	)	O	)	O	17	NMOD
37	and	and	O	CC	O	15	PMOD
38	by	by	B-PP	IN	O	15	PMOD
39	an	an	B-NP	DT	O	40	NMOD
40	increase	increase	I-NP	NN	O	38	PMOD
41	in	in	B-PP	IN	O	40	NMOD
42	pulmonary	pulmonary	B-NP	JJ	O	45	NMOD
43	arterial	arterial	I-NP	JJ	O	45	NMOD
44	medial	medial	I-NP	JJ	O	45	NMOD
45	thickness	thickness	I-NP	NN	O	41	PMOD
46	(	(	O	(	O	50	DEP
47	P	P	B-NP	NN	O	50	DEP
48	<	<	O	SYM	O	47	NMOD
49	0.01	0.01	B-NP	CD	O	48	AMOD
50	)	)	O	)	O	8	VMOD
51	.	.	O	.	O	8	P

1	Syncope	Syncope	B-NP	NN	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	QT	QT	I-NP	NN	O	4	NMOD
4	prolongation	prolongation	I-NP	NN	O	0	ROOT
5	among	among	B-PP	IN	O	4	NMOD
6	patients	patient	B-NP	NNS	O	5	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	methadone	methadone	B-NP	NN	O	8	PMOD
10	for	for	B-PP	IN	O	7	VMOD
11	heroin	heroin	B-NP	NN	O	12	NMOD
12	dependence	dependence	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	city	city	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	Copenhagen	Copenhagen	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	4	P

1	Prolongation	Prolongation	B-NP	NN	O	18	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	QT	QT	I-NP	NN	O	5	NMOD
5	interval	interval	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	1	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	ECG	ECG	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	torsade	torsade	B-NP	FW	O	14	NMOD
13	de	de	I-NP	FW	O	14	NMOD
14	pointes	pointes	I-NP	FW	O	11	PMOD
15	(	(	O	(	O	17	DEP
16	TdP	TdP	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	AMOD
18	has	have	B-VP	VBZ	O	0	ROOT
19	been	be	I-VP	VBN	O	18	VC
20	reported	report	I-VP	VBN	O	19	VC
21	in	in	B-PP	IN	O	20	VMOD
22	methadone	methadone	B-NP	NN	O	23	NMOD
23	users	user	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	18	P

1	As	As	B-SBAR	IN	O	5	VMOD
2	heroin	heroin	B-NP	NN	O	3	NMOD
3	addicts	addict	I-NP	NNS	O	5	SUB
4	sometimes	sometimes	B-ADVP	RB	O	5	VMOD
5	faint	faint	B-VP	VBP	O	42	VMOD
6	while	while	B-SBAR	IN	O	5	VMOD
7	using	use	B-VP	VBG	O	6	SBAR
8	illicit	illicit	B-NP	JJ	O	9	NMOD
9	drugs	drug	I-NP	NNS	O	7	OBJ
10	,	,	O	,	O	5	P
11	doctors	doctor	B-NP	NNS	O	12	SUB
12	might	might	B-VP	MD	O	5	VMOD
13	attribute	attribute	I-VP	VB	O	12	VC
14	too	too	B-NP	RB	O	15	AMOD
15	many	many	I-NP	JJ	O	16	NMOD
16	episodes	episode	I-NP	NNS	O	25	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	syncope	syncope	B-NP	NN	O	17	PMOD
19	to	to	B-VP	TO	O	20	VMOD
20	illicit	illicit	I-VP	VB	O	16	NMOD
21	drug	drug	B-NP	NN	O	22	NMOD
22	use	use	I-NP	NN	O	20	OBJ
23	and	and	O	CC	O	20	VMOD
24	thereby	thereby	B-VP	RB	O	25	VMOD
25	underestimate	underestimate	I-VP	VBP	O	13	VMOD
26	the	the	B-NP	DT	O	27	NMOD
27	incidence	incidence	I-NP	NN	O	25	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	TdP	TdP	B-NP	NN	B-protein	28	PMOD
30	in	in	B-PP	IN	O	25	VMOD
31	this	this	B-NP	DT	O	33	NMOD
32	special	special	I-NP	JJ	O	33	NMOD
33	population	population	I-NP	NN	O	30	PMOD
34	,	,	O	,	O	42	P
35	and	and	O	CC	O	38	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	high	high	I-NP	JJ	O	38	NMOD
38	mortality	mortality	I-NP	NN	O	42	SUB
39	in	in	B-PP	IN	O	38	NMOD
40	this	this	B-NP	DT	O	41	NMOD
41	population	population	I-NP	NN	O	39	PMOD
42	may	may	B-VP	MD	O	0	ROOT
43	,	,	O	,	O	42	P
44	in	in	B-PP	IN	O	42	VMOD
45	part	part	B-NP	NN	O	44	PMOD
46	,	,	O	,	O	42	P
47	be	be	B-VP	VB	O	42	VC
48	caused	cause	I-VP	VBN	O	47	VC
49	by	by	B-PP	IN	O	48	VMOD
50	the	the	B-NP	DT	O	52	NMOD
51	proarrhythmic	proarrhythmic	I-NP	JJ	O	52	NMOD
52	effect	effect	I-NP	NN	O	49	PMOD
53	of	of	B-PP	IN	O	52	NMOD
54	methadone	methadone	B-NP	NN	O	53	PMOD
55	.	.	O	.	O	42	P

1	The	The	B-NP	DT	O	2	NMOD
2	association	association	I-NP	NN	O	13	NMOD
3	between	between	B-PP	IN	O	2	NMOD
4	opioid	opioid	B-NP	JJ	O	5	NMOD
5	dose	dose	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	QT	QT	I-NP	NN	O	3	PMOD
8	,	,	O	,	O	13	P
9	and	and	O	CC	O	13	NMOD
10	methadone	methadone	B-NP	NN	O	11	NMOD
11	dose	dose	I-NP	NN	O	13	NMOD
12	and	and	O	CC	O	13	NMOD
13	reporting	reporting	B-NP	NN	O	16	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	syncope	syncope	B-NP	NN	O	14	PMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	assessed	assess	I-VP	VBN	O	16	VC
18	using	use	B-VP	VBG	O	17	VMOD
19	multivariate	multivariate	B-NP	JJ	O	21	NMOD
20	linear	linear	I-NP	JJ	O	21	NMOD
21	regression	regression	I-NP	NN	O	24	NMOD
22	and	and	O	CC	O	24	NMOD
23	logistic	logistic	B-NP	JJ	O	24	NMOD
24	regression	regression	I-NP	NN	O	18	OBJ
25	,	,	O	,	O	24	P
26	respectively	respectively	B-ADVP	RB	O	24	NMOD
27	.	.	O	.	O	16	P

1	Among	Among	B-PP	IN	O	15	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	subjects	subject	I-NP	NNS	O	1	PMOD
4	treated	treat	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	methadone	methadone	B-NP	NN	O	5	PMOD
7	,	,	O	,	O	15	P
8	28	28	B-NP	CD	O	10	NMOD
9	%	%	I-NP	NN	O	10	NMOD
10	men	man	I-NP	NNS	O	14	NMOD
11	and	and	O	CC	O	14	NMOD
12	32	32	B-NP	CD	O	14	NMOD
13	%	%	I-NP	NN	O	14	NMOD
14	women	woman	I-NP	NNS	O	15	SUB
15	had	have	B-VP	VBD	O	0	ROOT
16	prolonged	prolong	I-VP	VBN	O	15	VC
17	QTc	QTc	B-NP	NN	O	18	NMOD
18	interval	interval	I-NP	NN	O	16	OBJ
19	.	.	O	.	O	15	P

1	A	A	B-NP	DT	O	3	NMOD
2	50	50	I-NP	CD	O	3	AMOD
3	mg	mg	I-NP	NN	O	6	NMOD
4	higher	high	B-NP	JJR	O	6	NMOD
5	methadone	methadone	I-NP	NN	O	6	NMOD
6	dose	dose	I-NP	NN	O	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	11	NMOD
11	1.2	1.2	I-NP	CD	O	22	NMOD
12	(	(	O	(	O	19	DEP
13	95	95	B-NP	CD	O	15	NMOD
14	%	%	I-NP	NN	O	15	NMOD
15	CI	CI	I-NP	NN	O	19	DEP
16	1.1	1.1	B-NP	CD	O	18	NMOD
17	to	to	I-NP	TO	O	18	NMOD
18	1.4	1.4	I-NP	CD	O	15	NMOD
19	)	)	O	)	O	11	NMOD
20	times	time	B-NP	NNS	O	11	NMOD
21	higher	high	B-NP	JJR	O	22	NMOD
22	odds	odd	I-NP	NNS	O	9	PMOD
23	for	for	B-PP	IN	O	22	NMOD
24	syncope	syncope	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	7	P

1	Peripheral	Peripheral	B-NP	JJ	O	2	NMOD
2	neuropathy	neuropathy	I-NP	NN	O	0	ROOT
3	caused	cause	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	high-dose	high-dose	B-NP	JJ	O	8	NMOD
6	cytosine	cytosine	I-NP	NN	O	8	NMOD
7	arabinoside	arabinoside	I-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	4	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	11	NMOD
11	patient	patient	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	acute	acute	B-NP	JJ	O	15	NMOD
14	myeloid	myeloid	I-NP	JJ	O	15	NMOD
15	leukemia	leukemia	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	5	NMOD
2	central	central	I-NP	JJ	O	5	NMOD
3	nervous	nervous	I-NP	JJ	O	5	NMOD
4	system	system	I-NP	NN	O	5	NMOD
5	toxicity	toxicity	I-NP	NN	O	10	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	high-dose	high-dose	B-NP	JJ	O	9	NMOD
8	cytosine	cytosine	I-NP	NN	O	9	NMOD
9	arabinoside	arabinoside	I-NP	NN	O	6	PMOD
10	is	be	B-VP	VBZ	O	25	VMOD
11	well	well	I-VP	RB	O	10	VMOD
12	recognized	recognize	I-VP	VBN	O	10	VC
13	,	,	O	,	O	25	P
14	but	but	O	CC	O	25	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	toxicity	toxicity	I-NP	NN	O	25	SUB
17	of	of	B-PP	IN	O	16	NMOD
18	cytosine	cytosine	B-NP	NN	O	19	NMOD
19	arabinoside	arabinoside	I-NP	NN	O	17	PMOD
20	in	in	B-PP	IN	O	16	NMOD
21	the	the	B-NP	DT	O	24	NMOD
22	peripheral	peripheral	I-NP	JJ	O	24	NMOD
23	nervous	nervous	I-NP	JJ	O	24	NMOD
24	system	system	I-NP	NN	O	20	PMOD
25	has	have	B-VP	VBZ	O	0	ROOT
26	been	be	I-VP	VBN	O	25	VC
27	infrequently	infrequently	I-VP	RB	O	26	VMOD
28	reported	report	I-VP	VBN	O	26	VC
29	.	.	O	.	O	25	P

1	The	The	B-NP	DT	O	3	NMOD
2	first	first	I-NP	JJ	O	3	NMOD
3	course	course	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	high-dose	high-dose	B-NP	JJ	O	7	NMOD
6	cytosine	cytosine	I-NP	NN	O	7	NMOD
7	arabinoside	arabinoside	I-NP	NN	O	4	PMOD
8	resulted	result	B-VP	VBD	O	0	ROOT
9	in	in	B-PP	IN	O	8	VMOD
10	no	no	B-NP	DT	O	12	NMOD
11	unusual	unusual	I-NP	JJ	O	12	NMOD
12	symptoms	symptom	I-NP	NNS	O	9	PMOD
13	,	,	B-PP	,	O	9	P
14	but	but	I-PP	CC	O	9	PMOD
15	on	on	B-PP	IN	O	9	PMOD
16	day	day	B-NP	NN	O	15	PMOD
17	21	21	I-NP	CD	O	16	NMOD
18	of	of	B-PP	IN	O	16	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	second	second	I-NP	JJ	O	21	NMOD
21	course	course	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	treatment	treatment	B-NP	NN	O	22	PMOD
24	,	,	O	,	O	8	P
25	the	the	B-NP	DT	O	26	NMOD
26	patient	patient	I-NP	NN	O	8	VMOD
27	complained	complain	B-VP	VBD	O	26	NMOD
28	of	of	B-PP	IN	O	27	VMOD
29	numbness	numbness	B-NP	NN	O	28	PMOD
30	in	in	B-PP	IN	O	27	VMOD
31	his	his	B-NP	PRP$	O	33	NMOD
32	right	right	I-NP	JJ	O	33	NMOD
33	foot	foot	I-NP	NN	O	30	PMOD
34	.	.	O	.	O	8	P

1	This	This	B-NP	DT	O	2	NMOD
2	neuropathy	neuropathy	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	12	VMOD
4	gradually	gradually	I-VP	RB	O	5	VMOD
5	resolving	resolve	I-VP	VBG	O	3	VMOD
6	;	;	O	:	O	12	P
7	however	however	B-ADVP	RB	O	12	VMOD
8	,	,	O	,	O	12	P
9	after	after	B-PP	IN	O	12	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	patient	patient	I-NP	NN	O	9	PMOD
12	received	receive	B-VP	VBD	O	20	VMOD
13	allogeneic	allogeneic	B-NP	JJ	O	16	NMOD
14	bone	bone	I-NP	NN	O	16	NMOD
15	marrow	marrow	I-NP	NN	O	16	NMOD
16	transplantation	transplantation	I-NP	NN	O	12	OBJ
17	,	,	O	,	O	20	P
18	the	the	B-NP	DT	O	19	NMOD
19	symptoms	symptom	I-NP	NNS	O	20	SUB
20	worsened	worsen	B-VP	VBD	O	0	ROOT
21	,	,	O	,	O	20	P
22	with	with	B-PP	IN	O	20	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	development	development	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	graft-versus-host	graft-versus-host	B-NP	JJ	O	27	NMOD
27	disease	disease	I-NP	NN	O	25	PMOD
28	,	,	O	,	O	31	P
29	and	and	O	CC	O	31	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	symptoms	symptom	I-NP	NNS	O	20	OBJ
32	subsequently	subsequently	B-ADVP	RB	O	20	VMOD
33	responded	respond	B-VP	VBD	O	20	VMOD
34	to	to	B-PP	TO	O	33	VMOD
35	methylprednisolone	methylprednisolone	B-NP	NN	O	34	PMOD
36	.	.	O	.	O	20	P

1	Atorvastatin	Atorvastatin	B-NP	NN	O	2	SUB
2	prevented	prevent	B-VP	VBD	O	0	ROOT
3	and	and	O	CC	O	2	VMOD
4	reversed	reverse	B-VP	VBD	O	2	VMOD
5	dexamethasone	dexamethasone	B-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	hypertension	hypertension	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	rat	rat	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	2	P

1	To	To	B-VP	TO	O	2	VMOD
2	assess	assess	I-VP	VB	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	antioxidant	antioxidant	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	2	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	atorvastatin	atorvastatin	B-NP	NN	O	6	PMOD
8	(	(	O	(	O	10	DEP
9	atorva	atorva	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	on	on	B-PP	IN	O	5	NMOD
12	dexamethasone	dexamethasone	B-NP	NN	O	17	NMOD
13	(	(	O	(	O	15	DEP
14	dex	dex	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	induced	induce	B-NP	VBN	O	17	NMOD
17	hypertension	hypertension	I-NP	NN	O	22	NMOD
18	,	,	O	,	O	22	P
19	60	60	B-NP	CD	O	22	NMOD
20	male	male	I-NP	JJ	O	22	NMOD
21	Sprague-Dawley	Sprague-Dawley	I-NP	JJ	O	22	NMOD
22	rats	rat	I-NP	NNS	O	11	PMOD
23	were	be	B-VP	VBD	O	2	VMOD
24	treated	treat	I-VP	VBN	O	23	VC
25	with	with	B-PP	IN	O	24	VMOD
26	atorva	atorva	B-NP	NN	O	31	NMOD
27	30	30	I-NP	CD	O	31	NMOD
28	mg/kg/day	mg/kg/day	I-NP	NN	O	31	NMOD
29	or	or	I-NP	CC	O	31	NMOD
30	tap	tap	I-NP	NN	O	31	NMOD
31	water	water	I-NP	NN	O	25	PMOD
32	for	for	B-PP	IN	O	31	NMOD
33	15	15	B-NP	CD	O	34	NMOD
34	days	day	I-NP	NNS	O	32	PMOD
35	.	.	O	.	O	2	P

1	Atorva	Atorva	B-NP	NNP	O	2	SUB
2	reversed	reverse	B-VP	VBD	O	0	ROOT
3	dex	dex	B-NP	NN	O	5	NMOD
4	induced	induced	I-NP	JJ	O	5	NMOD
5	hypertension	hypertension	I-NP	NN	O	10	NMOD
6	(	(	O	(	O	10	NMOD
7	129	129	B-NP	CD	O	9	AMOD
8	+/-	+/-	I-NP	SYM	O	9	AMOD
9	0.6	0.6	I-NP	CD	O	10	NMOD
10	mmHg	mmHg	I-NP	NN	O	2	OBJ
11	,	,	O	,	O	2	P
12	vs.	vs.	B-PP	IN	O	2	VMOD
13	135	135	B-NP	CD	O	15	AMOD
14	+/-	+/-	I-NP	SYM	O	15	AMOD
15	0.6	0.6	I-NP	CD	O	17	NMOD
16	mmHg	mmHg	I-NP	NN	O	17	NMOD
17	P	P	I-NP	NN	O	25	NMOD
18	'	'	O	"	O	17	NMOD
19	<	<	B-NP	SYM	O	17	NMOD
20	0.05	0.05	I-NP	CD	O	19	AMOD
21	)	)	O	)	O	17	NMOD
22	and	and	O	CC	O	25	NMOD
23	decreased	decrease	B-NP	VBN	O	25	NMOD
24	plasma	plasma	I-NP	NN	O	25	NMOD
25	superoxide	superoxide	I-NP	NN	O	12	PMOD
26	(	(	O	(	O	42	DEP
27	7931	7931	B-NP	CD	O	29	AMOD
28	+/-	+/-	I-NP	SYM	O	29	AMOD
29	392.8	392.8	I-NP	CD	O	30	NMOD
30	dex	dex	I-NP	NN	O	37	NMOD
31	,	,	O	,	O	37	P
32	1187	1187	B-NP	CD	O	34	AMOD
33	+/-	+/-	I-NP	SYM	O	34	AMOD
34	441.2	441.2	I-NP	CD	O	37	NMOD
35	atorva	atorva	I-NP	NN	O	37	NMOD
36	+	+	O	SYM	O	37	NMOD
37	dex	dex	B-NP	NN	O	39	NMOD
38	,	,	O	,	O	39	P
39	P	P	B-NP	NN	O	42	DEP
40	<	<	B-NP	SYM	O	39	NMOD
41	0.0001	0.0001	I-NP	CD	O	40	AMOD
42	)	)	O	)	O	25	NMOD
43	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	prodrugs	prodrug	I-NP	NNS	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	potent	potent	B-NP	JJ	O	6	AMOD
5	and	and	I-NP	CC	O	6	AMOD
6	selective	selective	I-NP	JJ	O	11	NMOD
7	GluR5	GluR5	I-NP	NN	O	11	NMOD
8	kainate	kainate	I-NP	NN	O	11	NMOD
9	receptor	receptor	I-NP	NN	O	11	NMOD
10	antagonists	antagonist	I-NP	NNS	O	11	NMOD
11	actives	active	I-NP	NNS	O	3	PMOD
12	in	in	B-PP	IN	O	2	NMOD
13	three	three	B-NP	CD	O	15	NMOD
14	animal	animal	I-NP	NN	O	15	NMOD
15	models	model	I-NP	NNS	O	12	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	pain	pain	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	2	P

1	Erythropoietin	Erythropoietin	B-NP	NN	B-protein	2	SUB
2	restores	restore	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	anemia	anemia	I-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	2	VMOD
6	reduction	reduction	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	cyclophosphamide	cyclophosphamide	B-NP	NN	O	9	NMOD
9	cytotoxicity	cytotoxicity	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	6	NMOD
11	rat	rat	B-NP	NN	O	12	NMOD
12	tumors	tumor	I-NP	NNS	O	10	PMOD
13	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	examine	examine	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	impact	impact	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	anemia	anemia	B-NP	NN	O	13	NMOD
13	prevention	prevention	I-NP	NN	O	11	PMOD
14	by	by	B-PP	IN	O	10	NMOD
15	recombinant	recombinant	B-NP	JJ	B-protein	17	NMOD
16	human	human	I-NP	JJ	I-protein	17	NMOD
17	erythropoietin	erythropoietin	I-NP	NN	I-protein	21	NMOD
18	(	(	O	(	O	20	DEP
19	rHuEPO	rHuEPO	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	treatment	treatment	B-NP	NN	O	14	PMOD
22	on	on	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	cytotoxicity	cytotoxicity	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	cyclophosphamide	cyclophosphamide	B-NP	NN	O	25	PMOD
27	in	in	B-PP	IN	O	24	NMOD
28	solid	solid	B-NP	JJ	O	30	NMOD
29	experimental	experimental	I-NP	JJ	O	30	NMOD
30	tumors	tumor	I-NP	NNS	O	27	PMOD
31	.	.	O	.	O	6	P

1	Anemia	Anemia	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	induced	induce	I-VP	VBN	O	2	VC
4	using	use	I-VP	VBG	O	2	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	single	single	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	4	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	carboplatin	carboplatin	B-NP	NN	O	8	PMOD
10	(	(	O	(	O	14	DEP
11	50	50	B-NP	CD	O	13	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	13	NMOD
13	i.v.	i.v.	I-NP	NN	O	14	DEP
14	)	)	O	)	O	9	NMOD
15	resulting	result	B-VP	VBG	O	4	VMOD
16	in	in	B-PP	IN	O	15	VMOD
17	a	a	B-NP	DT	O	19	NMOD
18	long-lasting	long-lasting	I-NP	JJ	O	19	NMOD
19	reduction	reduction	I-NP	NN	O	16	PMOD
20	(	(	O	(	O	23	DEP
21	30	30	B-NP	CD	O	22	NMOD
22	%	%	I-NP	NN	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	of	of	B-PP	IN	O	19	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	hemoglobin	hemoglobin	I-NP	NN	B-protein	27	NMOD
27	concentration	concentration	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	10	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	second	second	I-NP	JJ	O	4	NMOD
4	group	group	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	10	P
6	the	the	B-NP	DT	O	7	NMOD
7	development	development	I-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	anemia	anemia	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	0	ROOT
11	prevented	prevent	I-VP	VBN	O	10	VC
12	by	by	B-PP	IN	O	11	VMOD
13	rHuEPO	rHuEPO	B-NP	NN	B-protein	21	NMOD
14	(	(	O	(	O	17	DEP
15	1000	1000	B-NP	CD	O	16	NMOD
16	IU/kg	IU/kg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	administered	administer	B-VP	VBN	O	21	NMOD
19	s.c.	s.c.	B-NP	NN	O	21	NMOD
20	three	three	I-NP	CD	O	21	NMOD
21	times/week	times/week	I-NP	NN	O	12	PMOD
22	starting	start	B-VP	VBG	O	21	NMOD
23	7	7	B-NP	CD	O	24	NMOD
24	days	day	I-NP	NNS	O	22	OBJ
25	before	before	B-PP	IN	O	22	VMOD
26	carboplatin	carboplatin	B-NP	NN	O	27	NMOD
27	application	application	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	10	P

1	Four	Four	B-NP	CD	O	2	NMOD
2	days	day	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	14	VMOD
4	carboplatin	carboplatin	B-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	14	P
7	tumors	tumor	B-NP	NNS	O	14	SUB
8	(	(	O	(	O	13	DEP
9	DS-sarcoma	DS-sarcoma	B-NP	NN	O	13	DEP
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	rat	rat	I-NP	NN	O	10	PMOD
13	)	)	O	)	O	7	NMOD
14	were	be	B-VP	VBD	O	0	ROOT
15	implanted	implant	I-VP	VBN	O	14	VC
16	s.c.	s.c.	B-ADJP	JJ	O	15	VMOD
17	onto	onto	B-PP	IN	O	16	AMOD
18	the	the	B-NP	DT	O	21	NMOD
19	hind	hind	I-NP	NN	O	21	NMOD
20	food	food	I-NP	NN	O	21	NMOD
21	dorsum	dorsum	I-NP	NN	O	17	PMOD
22	.	.	O	.	O	14	P

1	Neither	Neither	O	CC	O	5	NMOD
2	carboplatin	carboplatin	B-NP	NN	B-protein	5	NMOD
3	nor	nor	O	CC	O	5	NMOD
4	rHuEPO	rHuEPO	B-NP	NN	B-protein	5	NMOD
5	treatment	treatment	I-NP	NN	O	6	SUB
6	influenced	influence	B-VP	VBD	O	0	ROOT
7	tumor	tumor	B-NP	NN	O	9	NMOD
8	growth	growth	I-NP	NN	O	9	NMOD
9	rate	rate	I-NP	NN	O	6	OBJ
10	per	per	B-ADVP	FW	O	6	VMOD
11	se	se	I-ADVP	FW	O	10	AMOD
12	.	.	O	.	O	6	P

1	When	When	B-ADVP	WRB	O	0	ROOT
2	tumors	tumor	B-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	1	SBAR
4	treated	treat	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	31	VMOD
6	a	a	B-NP	DT	O	8	NMOD
7	single	single	I-NP	JJ	O	8	NMOD
8	dose	dose	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cyclophosphamide	cyclophosphamide	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	15	DEP
12	60	60	B-NP	CD	O	13	NMOD
13	mg/kg	mg/kg	I-NP	NN	O	15	DEP
14	i.p.	i.p.	B-ADVP	RB	O	13	NMOD
15	)	)	O	)	O	8	NMOD
16	5	5	B-NP	CD	O	17	NMOD
17	days	day	I-NP	NNS	O	31	SUB
18	after	after	B-PP	IN	O	17	NMOD
19	implantation	implantation	B-NP	NN	O	23	NMOD
20	,	,	O	,	O	23	P
21	a	a	B-NP	DT	O	23	NMOD
22	growth	growth	I-NP	NN	O	23	NMOD
23	delay	delay	I-NP	NN	O	18	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	a	a	B-NP	DT	O	27	NMOD
26	subsequent	subsequent	I-NP	JJ	O	27	NMOD
27	regrowth	regrowth	I-NP	NN	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	30	NMOD
30	tumors	tumor	I-NP	NNS	O	28	PMOD
31	was	be	B-VP	VBD	O	4	VMOD
32	observed	observe	I-VP	VBN	O	31	VC
33	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	role	role	I-NP	NN	O	8	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	nitrergic	nitrergic	B-NP	JJ	O	5	NMOD
5	system	system	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	lidocaine	lidocaine	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	convulsion	convulsion	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	mouse	mouse	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	11	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	N-nitro-L-arginine-methyl	N-nitro-L-arginine-methyl	B-NP	NN	O	5	NMOD
5	ester	ester	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	8	DEP
7	L-NAME	L-NAME	B-NP	NN	B-protein	8	DEP
8	)	)	O	)	O	5	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	nitric	nitric	I-NP	JJ	O	11	NMOD
11	oxide	oxide	I-NP	NN	O	18	NMOD
12	(	(	O	(	O	14	DEP
13	NO	NO	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	synthase	synthase	B-NP	NN	O	16	NMOD
16	inhibitor	inhibitor	I-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	L-arginine	L-arginine	I-NP	NN	O	22	NMOD
19	,	,	O	,	O	22	P
20	a	a	B-NP	DT	O	22	NMOD
21	NO	NO	I-NP	NN	B-protein	22	NMOD
22	precursor	precursor	I-NP	NN	I-protein	24	SUB
23	,	,	O	,	O	22	P
24	were	be	B-VP	VBD	O	0	ROOT
25	investigated	investigate	I-VP	VBN	O	24	VC
26	on	on	B-PP	IN	O	25	VMOD
27	lidocaine	lidocaine	B-NP	NN	O	29	NMOD
28	induced	induce	I-NP	VBN	O	29	NMOD
29	convulsions	convulsion	I-NP	NNS	O	26	PMOD
30	.	.	O	.	O	24	P

1	L-NAME	L-NAME	B-NP	NN	B-protein	9	NMOD
2	(	(	O	(	O	7	DEP
3	100	100	B-NP	CD	O	4	NMOD
4	mg/kg	mg/kg	I-NP	NN	O	7	DEP
5	,	,	O	,	O	4	P
6	i.p.	i.p.	B-ADVP	RB	O	4	NMOD
7	)	)	O	)	O	1	NMOD
8	and	and	O	CC	O	9	NMOD
9	diazepam	diazepam	B-NP	NN	O	15	SUB
10	(	(	O	(	O	13	DEP
11	2	2	B-NP	CD	O	12	NMOD
12	mg/kg	mg/kg	I-NP	NN	O	13	DEP
13	)	)	O	)	O	9	NMOD
14	significantly	significantly	B-ADVP	RB	O	15	VMOD
15	decreased	decrease	B-VP	VBD	O	0	ROOT
16	the	the	B-NP	DT	O	17	NMOD
17	incidence	incidence	I-NP	NN	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	lidocaine	lidocaine	B-NP	NN	O	25	NMOD
20	(	(	O	(	O	23	DEP
21	50	50	B-NP	CD	O	22	NMOD
22	mg/kg	mg/kg	I-NP	NN	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	induced	induce	B-NP	VBN	O	25	NMOD
25	convulsions	convulsion	I-NP	NNS	O	18	PMOD
26	.	.	O	.	O	15	P

1	In	In	B-PP	IN	O	7	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	7	P
4	the	the	B-NP	DT	O	6	NMOD
5	L-arginine	L-arginine	I-NP	NN	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	7	SUB
7	increased	increase	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	9	NMOD
9	incidence	incidence	I-NP	NN	O	7	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	lidocaine	lidocaine	B-NP	NN	O	19	NMOD
12	(	(	O	(	O	17	DEP
13	80	80	B-NP	CD	O	14	NMOD
14	mg/kg	mg/kg	I-NP	NN	O	17	DEP
15	,	,	O	,	O	14	P
16	i.p.	i.p.	B-ADVP	RB	O	14	NMOD
17	)	)	O	)	O	11	NMOD
18	induced	induce	B-NP	VBN	O	19	NMOD
19	convulsions	convulsion	I-NP	NNS	O	10	PMOD
20	significantly	significantly	B-ADVP	RB	O	19	NMOD
21	.	.	O	.	O	7	P

1	Effect	Effect	B-NP	NN	O	12	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	intravenous	intravenous	B-NP	JJ	O	4	NMOD
4	metoprolol	metoprolol	I-NP	NN	O	9	NMOD
5	or	or	O	CC	O	9	NMOD
6	intravenous	intravenous	B-NP	JJ	O	7	NMOD
7	metoprolol	metoprolol	I-NP	NN	O	9	NMOD
8	plus	plus	O	CC	O	9	NMOD
9	glucagon	glucagon	B-NP	NN	O	2	PMOD
10	on	on	B-PP	IN	O	9	NMOD
11	dobutamine	dobutamine	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	ischemia	ischemia	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	12	P

1	Prednisolone	Prednisolone	B-NP	NN	O	4	NMOD
2	induced	induce	B-VP	VBD	O	4	NMOD
3	muscle	muscle	B-NP	NN	O	4	NMOD
4	dysfunction	dysfunction	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	caused	cause	I-VP	VBN	O	5	VC
7	more	more	B-NP	JJR	O	6	VMOD
8	by	by	B-PP	IN	O	7	AMOD
9	atrophy	atrophy	B-NP	NN	O	8	PMOD
10	than	than	B-PP	IN	O	7	AMOD
11	by	by	B-PP	IN	O	10	PMOD
12	altered	altered	B-NP	JJ	B-protein	15	NMOD
13	acetylcholine	acetylcholine	I-NP	NN	I-protein	15	NMOD
14	receptor	receptor	I-NP	NN	I-protein	15	NMOD
15	expression	expression	I-NP	NN	O	11	PMOD
16	.	.	O	.	O	5	P

1	On	On	B-PP	IN	O	28	VMOD
2	Day	Day	B-NP	NN	O	1	PMOD
3	8	8	I-NP	CD	O	2	NMOD
4	,	,	O	,	O	28	P
5	the	the	B-NP	DT	O	9	NMOD
6	nerve-evoked	nerve-evoked	I-NP	JJ	O	9	NMOD
7	peak	peak	I-NP	JJ	O	9	NMOD
8	twitch	twitch	I-NP	NN	O	9	NMOD
9	tensions	tension	I-NP	NNS	O	20	NMOD
10	,	,	O	,	O	20	P
11	tetanic	tetanic	B-NP	JJ	O	12	NMOD
12	tensions	tension	I-NP	NNS	O	20	NMOD
13	,	,	O	,	O	20	P
14	and	and	O	CC	O	15	NMOD
15	fatigability	fatigability	B-NP	NN	O	20	NMOD
16	,	,	O	,	O	20	P
17	and	and	O	CC	O	20	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	dose-response	dose-response	I-NP	JJ	O	20	NMOD
20	curves	curve	I-NP	NNS	O	28	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	d-tubocurarine	d-tubocurarine	B-NP	NN	O	21	PMOD
23	in	in	B-PP	IN	O	20	NMOD
24	the	the	B-NP	DT	O	27	NMOD
25	tibialis	tibialis	I-NP	NN	O	27	NMOD
26	cranialis	cranialis	I-NP	NN	O	27	NMOD
27	muscle	muscle	I-NP	NN	O	23	PMOD
28	were	be	B-VP	VBD	O	0	ROOT
29	measured	measure	I-VP	VBN	O	28	VC
30	in	in	B-ADVP	FW	O	29	VMOD
31	vivo	vivo	I-ADVP	FW	O	30	AMOD
32	and	and	O	CC	O	29	VMOD
33	related	relate	B-VP	VBN	O	29	VMOD
34	to	to	B-PP	TO	O	33	AMOD
35	muscle	muscle	B-NP	NN	O	36	NMOD
36	mass	mass	I-NP	NN	O	38	NMOD
37	or	or	O	CC	O	38	NMOD
38	expression	expression	B-NP	NN	O	34	PMOD
39	of	of	B-PP	IN	O	38	NMOD
40	AChRs	AChR	B-NP	NNS	B-protein	39	PMOD
41	.	.	O	.	O	28	P

1	Our	Our	B-NP	PRP$	O	2	NMOD
2	results	result	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	neuromuscular	neuromuscular	I-NP	JJ	O	7	NMOD
7	dysfunction	dysfunction	I-NP	NN	O	10	SUB
8	after	after	B-SBAR	IN	O	7	NMOD
9	prednisolone	prednisolone	B-NP	NN	O	8	PMOD
10	is	be	B-VP	VBZ	O	4	SBAR
11	dose-dependent	dose-dependent	B-ADJP	JJ	O	10	PRD
12	,	,	O	,	O	3	P
13	and	and	O	CC	O	3	VMOD
14	derives	derive	B-VP	VBZ	O	3	VMOD
15	primarily	primarily	B-ADVP	RB	O	16	PMOD
16	from	from	B-PP	IN	O	14	VMOD
17	muscle	muscle	B-NP	NN	O	18	NMOD
18	atrophy	atrophy	I-NP	NN	O	16	PMOD
19	and	and	O	CC	O	14	VMOD
20	derives	derive	B-VP	VBZ	O	14	VMOD
21	less	less	B-ADVP	RBR	O	22	AMOD
22	so	so	I-ADVP	RB	O	20	VMOD
23	from	from	B-PP	IN	O	22	AMOD
24	changes	change	B-NP	NNS	O	23	PMOD
25	in	in	B-PP	IN	O	24	NMOD
26	AChR	AChR	B-NP	NN	B-protein	27	NMOD
27	expression	expression	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	3	P

1	Rapid	Rapid	B-NP	JJ	O	2	NMOD
2	reversal	reversal	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	life-threatening	life-threatening	B-NP	JJ	O	5	NMOD
5	diltiazem	diltiazem	I-NP	NN	O	3	PMOD
6	induced	induce	B-VP	VBD	O	0	ROOT
7	tetany	tetany	B-NP	NN	O	6	OBJ
8	with	with	B-PP	IN	O	6	VMOD
9	calcium	calcium	B-NP	NN	O	10	NMOD
10	chloride	chloride	I-NP	NN	O	8	PMOD
11	.	.	O	.	O	6	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	who	who	B-NP	WP	O	4	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	tetany	tetany	B-NP	NN	O	6	OBJ
8	with	with	B-PP	IN	O	6	VMOD
9	sudden	sudden	B-NP	JJ	O	11	NMOD
10	respiratory	respiratory	I-NP	JJ	O	11	NMOD
11	arrest	arrest	I-NP	NN	O	8	PMOD
12	after	after	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	14	NMOD
14	infusion	infusion	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	intravenous	intravenous	B-NP	JJ	O	17	NMOD
17	diltiazem	diltiazem	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	administration	administration	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	calcium	calcium	B-NP	NN	O	5	NMOD
5	chloride	chloride	I-NP	NN	O	3	PMOD
6	rapidly	rapidly	B-ADVP	RB	O	7	VMOD
7	resolved	resolve	B-VP	VBD	O	0	ROOT
8	the	the	B-NP	DT	O	11	NMOD
9	patient	patient	I-NP	NN	O	11	NMOD
10	's	's	B-NP	POS	O	11	NMOD
11	tetany	tetany	I-NP	NN	O	7	OBJ
12	with	with	B-PP	IN	O	11	NMOD
13	prompt	prompt	B-NP	JJ	O	14	NMOD
14	recovery	recovery	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	respiratory	respiratory	B-NP	JJ	O	17	NMOD
17	function	function	I-NP	NN	O	15	PMOD
18	,	,	O	,	O	7	P
19	averting	avert	B-VP	VBG	O	7	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	need	need	I-NP	NN	O	19	OBJ
22	for	for	B-PP	IN	O	21	NMOD
23	more	more	B-NP	RBR	O	24	AMOD
24	aggressive	aggressive	I-NP	JJ	O	29	NMOD
25	airway	airway	I-NP	NN	O	26	NMOD
26	management	management	I-NP	NN	O	24	NMOD
27	and	and	O	CC	O	29	NMOD
28	ventilatory	ventilatory	B-NP	JJ	O	29	NMOD
29	support	support	I-NP	NN	O	22	PMOD
30	.	.	O	.	O	7	P

1	Patients	Patient	B-NP	NNS	O	9	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	aneurysmal	aneurysmal	B-NP	JJ	O	5	NMOD
4	subarachnoid	subarachnoid	I-NP	JJ	O	5	NMOD
5	hemorrhage	hemorrhage	I-NP	NN	O	2	PMOD
6	(	(	O	(	O	8	DEP
7	SAH	SAH	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	randomized	randomize	I-VP	VBN	O	9	VC
11	to	to	B-VP	TO	O	12	VMOD
12	receive	receive	I-VP	VB	O	10	VMOD
13	either	either	O	CC	O	20	NMOD
14	ketoprofen	ketoprofen	B-NP	NN	O	20	NMOD
15	,	,	O	,	O	20	P
16	100	100	B-NP	CD	O	17	NMOD
17	mg	mg	I-NP	NN	O	20	SUB
18	,	,	O	,	O	20	P
19	three	three	B-NP	CD	O	20	AMOD
20	times	time	I-NP	NNS	O	12	OBJ
21	a	a	B-NP	DT	O	22	NMOD
22	day	day	I-NP	NN	O	12	VMOD
23	(	(	O	(	O	52	DEP
24	ketoprofen	ketoprofen	B-NP	NN	O	25	NMOD
25	group	group	I-NP	NN	O	42	SUB
26	,	,	O	,	O	42	P
27	n	n	B-NP	NN	O	34	NMOD
28	=	=	B-VP	SYM	O	27	NMOD
29	9	9	B-NP	CD	O	28	AMOD
30	)	)	O	)	O	27	NMOD
31	or	or	O	CC	O	34	NMOD
32	a	a	B-NP	DT	O	34	NMOD
33	weak	weak	I-NP	JJ	O	34	NMOD
34	NSAID	NSAID	I-NP	NN	O	42	SUB
35	,	,	O	,	O	42	P
36	acetaminophen	acetaminophen	B-NP	NN	O	42	SUB
37	,	,	O	,	O	42	P
38	1	1	B-NP	CD	O	39	NMOD
39	g	g	I-NP	NN	O	42	SUB
40	,	,	O	,	O	42	P
41	three	three	B-NP	CD	O	42	AMOD
42	times	time	I-NP	NNS	O	44	NMOD
43	a	a	B-NP	DT	O	44	NMOD
44	day	day	I-NP	NN	O	52	DEP
45	(	(	O	(	O	52	DEP
46	acetaminophen	acetaminophen	B-NP	NN	O	47	NMOD
47	group	group	I-NP	NN	O	52	DEP
48	,	,	O	,	O	52	P
49	n	n	B-NP	NN	O	52	DEP
50	=	=	B-VP	SYM	O	49	NMOD
51	9	9	B-NP	CD	O	50	AMOD
52	)	)	O	)	O	22	NMOD
53	starting	start	B-VP	VBG	O	22	NMOD
54	immediately	immediately	B-ADVP	RB	O	53	VMOD
55	after	after	B-PP	IN	O	53	VMOD
56	the	the	B-NP	DT	O	57	NMOD
57	diagnosis	diagnosis	I-NP	NN	O	55	PMOD
58	of	of	B-PP	IN	O	57	NMOD
59	aneurysmal	aneurysmal	B-NP	JJ	O	60	NMOD
60	SAH	SAH	I-NP	NN	O	58	PMOD
61	.	.	O	.	O	9	P

1	Maximal	Maximal	B-NP	JJ	O	3	NMOD
2	platelet	platelet	I-NP	NN	O	3	NMOD
3	aggregation	aggregation	I-NP	NN	O	11	SUB
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	6	6	B-NP	CD	O	7	NMOD
7	microM	microM	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	adenosine	adenosine	B-NP	NN	O	10	NMOD
10	diphosphate	diphosphate	I-NP	NN	O	8	PMOD
11	decreased	decrease	B-VP	VBD	O	0	ROOT
12	after	after	B-PP	IN	O	11	VMOD
13	administration	administration	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	ketoprofen	ketoprofen	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	7	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	7	P
4	maximal	maximal	B-NP	JJ	O	6	NMOD
5	platelet	platelet	I-NP	NN	O	6	NMOD
6	aggregation	aggregation	I-NP	NN	O	7	SUB
7	increased	increase	B-VP	VBD	O	0	ROOT
8	in	in	B-PP	IN	O	7	VMOD
9	the	the	B-NP	DT	O	11	NMOD
10	acetaminophen	acetaminophen	I-NP	NN	O	11	NMOD
11	group	group	I-NP	NN	O	8	PMOD
12	on	on	B-PP	IN	O	7	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	third	third	I-NP	JJ	O	16	NMOD
15	postoperative	postoperative	I-NP	JJ	O	16	NMOD
16	day	day	I-NP	NN	O	12	PMOD
17	as	as	B-PP	IN	O	7	VMOD
18	compared	compare	B-PP	VBN	O	17	PMOD
19	with	with	B-PP	IN	O	18	VMOD
20	the	the	B-NP	DT	O	24	NMOD
21	pretreatment	pretreatment	I-NP	NN	O	24	NMOD
22	platelet	platelet	I-NP	NN	O	24	NMOD
23	aggregation	aggregation	I-NP	NN	O	24	NMOD
24	results	result	I-NP	NNS	O	19	PMOD
25	(	(	O	(	O	29	DEP
26	P	P	B-NP	NN	O	29	DEP
27	<	<	B-NP	JJR	O	26	NMOD
28	.05	.05	I-NP	CD	O	27	AMOD
29	)	)	O	)	O	24	NMOD
30	.	.	O	.	O	7	P

1	One	One	B-NP	CD	O	2	NMOD
2	patient	patient	I-NP	NN	O	7	SUB
3	in	in	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	6	NMOD
5	ketoprofen	ketoprofen	I-NP	NN	O	6	NMOD
6	group	group	I-NP	NN	O	3	PMOD
7	developed	develop	B-VP	VBD	O	0	ROOT
8	a	a	B-NP	DT	O	11	NMOD
9	postoperative	postoperative	I-NP	JJ	O	11	NMOD
10	intracranial	intracranial	I-NP	JJ	O	11	NMOD
11	hematoma	hematoma	I-NP	NN	O	7	OBJ
12	.	.	O	.	O	7	P

1	Ketoprofen	Ketoprofen	B-NP	NN	O	0	ROOT
2	but	but	O	CC	O	4	VMOD
3	not	not	O	RB	O	2	DEP
4	acetaminophen	acetaminophen	B-VP	VB	O	1	NMOD
5	impaired	impaired	B-NP	JJ	O	7	NMOD
6	platelet	platelet	I-NP	NN	O	7	NMOD
7	function	function	I-NP	NN	O	4	OBJ
8	in	in	B-PP	IN	O	4	VMOD
9	patients	patient	B-NP	NNS	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	SAH	SAH	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	1	P

1	Value	Value	B-NP	NN	O	24	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	methylprednisolone	methylprednisolone	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	prevention	prevention	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	arthralgia-myalgia	arthralgia-myalgia	I-NP	JJ	O	9	NMOD
9	syndrome	syndrome	I-NP	NN	O	6	PMOD
10	associated	associate	B-VP	VBN	O	5	NMOD
11	with	with	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	total	total	I-NP	JJ	O	15	NMOD
14	dose	dose	I-NP	NN	O	15	NMOD
15	infusion	infusion	I-NP	NN	O	11	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	iron	iron	B-NP	NN	O	18	NMOD
18	dextran	dextran	I-NP	NN	O	16	PMOD
19	:	:	O	:	O	1	P
20	a	a	B-NP	DT	O	24	NMOD
21	double	double	I-NP	JJ	O	24	NMOD
22	blind	blind	I-NP	JJ	O	24	NMOD
23	randomized	randomize	I-NP	VBN	O	24	NMOD
24	trial	trial	I-NP	NN	O	0	ROOT
25	.	.	O	.	O	24	P

1	These	These	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	administration	administration	B-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	MP	MP	B-NP	NN	O	6	PMOD
8	before	before	B-PP	IN	O	5	NMOD
9	and	and	I-PP	CC	O	8	PMOD
10	after	after	I-PP	IN	O	8	PMOD
11	TDI	TDI	B-NP	NN	B-protein	8	PMOD
12	reduces	reduce	B-VP	VBZ	O	4	SBAR
13	the	the	B-NP	DT	O	16	NMOD
14	frequency	frequency	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	severity	severity	I-NP	NN	O	12	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	arthralgia-myalgia	arthralgia-myalgia	I-NP	JJ	O	20	NMOD
20	syndrome	syndrome	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	3	P

1	Forty	Forty	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	23	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	Non-Hodgkin	Non-Hodgkin	B-NP	JJ	O	6	NMOD
5	's	's	B-NP	POS	O	6	NMOD
6	Lymphoma	Lymphoma	I-NP	NN	O	3	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	vincristine	vincristine	B-NP	NN	O	8	PMOD
10	between	between	B-PP	IN	O	7	VMOD
11	1984	1984	B-NP	CD	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	1990	1990	I-NP	CD	O	10	PMOD
14	(	(	O	(	O	22	DEP
15	cumulative	cumulative	B-NP	JJ	O	18	NMOD
16	dose	dose	I-NP	NN	O	18	NMOD
17	12	12	I-NP	CD	O	18	NMOD
18	mg	mg	I-NP	NN	O	22	DEP
19	in	in	B-PP	IN	O	18	NMOD
20	18-24	18-24	B-NP	CD	O	21	NMOD
21	weeks	week	I-NP	NNS	O	19	PMOD
22	)	)	O	)	O	13	NMOD
23	were	be	B-VP	VBD	O	0	ROOT
24	investigated	investigate	I-VP	VBN	O	23	VC
25	in	in	B-SBAR	IN	O	24	VMOD
26	order	order	O	NN	O	25	DEP
27	to	to	B-VP	TO	O	28	VMOD
28	evaluate	evaluate	I-VP	VB	O	25	SBAR
29	the	the	B-NP	DT	O	32	NMOD
30	long	long	I-NP	JJ	O	32	NMOD
31	term	term	I-NP	NN	O	32	NMOD
32	effects	effect	I-NP	NNS	O	28	OBJ
33	of	of	B-PP	IN	O	32	NMOD
34	vincristine	vincristine	B-NP	NN	O	33	PMOD
35	on	on	B-PP	IN	O	32	NMOD
36	the	the	B-NP	DT	O	39	NMOD
37	peripheral	peripheral	I-NP	JJ	O	39	NMOD
38	nervous	nervous	I-NP	JJ	O	39	NMOD
39	system	system	I-NP	NN	O	35	PMOD
40	.	.	O	.	O	23	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	polymyositis	polymyositis	B-NP	NN	O	3	PMOD
5	in	in	B-PP	IN	O	2	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	primary	primary	B-NP	JJ	O	11	NMOD
10	biliary	biliary	I-NP	JJ	O	11	NMOD
11	cirrhosis	cirrhosis	I-NP	NN	O	8	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	D-penicillamine	D-penicillamine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	2	P

1	Although	Although	B-SBAR	IN	O	12	VMOD
2	D-penicillamine	D-penicillamine	B-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	1	SBAR
4	been	be	I-VP	VBN	O	3	VC
5	used	use	I-VP	VBN	O	4	VC
6	for	for	B-PP	IN	O	5	VMOD
7	many	many	B-NP	JJ	O	9	NMOD
8	rheumatologic	rheumatologic	I-NP	JJ	O	9	NMOD
9	diseases	disease	I-NP	NNS	O	6	PMOD
10	,	,	O	,	O	12	P
11	toxicity	toxicity	B-NP	NN	O	12	SUB
12	limits	limit	B-VP	VBZ	O	0	ROOT
13	its	its	B-NP	PRP$	O	14	NMOD
14	usefulness	usefulness	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	many	many	B-NP	JJ	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	12	P

1	Polymyositis/dermatomyositis	Polymyositis/dermatomyositis	B-NP	NN	O	2	SUB
2	can	can	B-VP	MD	O	18	VMOD
3	develop	develop	I-VP	VB	O	2	VC
4	as	as	B-PP	IN	O	3	VMOD
5	one	one	B-NP	CD	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	9	NMOD
8	autoimmune	autoimmune	I-NP	JJ	O	9	NMOD
9	complications	complication	I-NP	NNS	O	6	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	D-penicillamine	D-penicillamine	B-NP	NN	O	12	NMOD
12	treatment	treatment	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	18	P
14	but	but	O	CC	O	18	VMOD
15	its	its	B-NP	PRP$	O	17	NMOD
16	exact	exact	I-NP	JJ	O	17	NMOD
17	pathogenesis	pathogenesis	I-NP	NN	O	18	SUB
18	remains	remain	B-VP	VBZ	O	0	ROOT
19	unclear	unclear	B-ADJP	JJ	O	18	PRD
20	.	.	O	.	O	18	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	with	with	B-PP	IN	O	4	NMOD
6	primary	primary	B-NP	JJ	O	8	NMOD
7	biliary	biliary	I-NP	JJ	O	8	NMOD
8	cirrhosis	cirrhosis	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	4	P
10	who	who	B-NP	WP	O	4	NMOD
11	developed	develop	B-VP	VBD	O	10	SBAR
12	polymyositis	polymyositis	B-NP	NN	O	11	OBJ
13	while	while	B-SBAR	IN	O	11	VMOD
14	receiving	receive	B-VP	VBG	O	13	SBAR
15	D-penicillamine	D-penicillamine	B-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	14	OBJ
17	.	.	O	.	O	2	P

1	Photodistributed	Photodistribute	B-NP	VBN	O	2	NMOD
2	nifedipine	nifedipine	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	facial	facial	B-NP	JJ	O	5	NMOD
5	telangiectasia	telangiectasia	I-NP	NN	O	3	OBJ
6	.	.	O	.	O	3	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	months	month	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	0	ROOT
4	starting	start	B-VP	VBG	O	3	NMOD
5	nifedipine	nifedipine	B-NP	NN	O	11	NMOD
6	(	(	O	(	O	8	DEP
7	Adalat	Adalat	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	,	,	O	,	O	11	P
10	two	two	B-NP	CD	O	11	NMOD
11	patients	patient	I-NP	NNS	O	4	OBJ
12	developed	develop	B-VP	VBD	O	3	VMOD
13	photodistributed	photodistribute	I-VP	VBN	O	15	NMOD
14	facial	facial	B-NP	JJ	O	15	NMOD
15	telangiectasia	telangiectasia	I-NP	NN	O	12	OBJ
16	,	,	O	,	O	15	P
17	which	which	B-NP	WDT	O	15	NMOD
18	became	become	B-VP	VBD	O	17	SBAR
19	more	more	B-ADJP	RBR	O	20	AMOD
20	noticeable	noticeable	I-ADJP	JJ	O	18	PRD
21	with	with	B-PP	IN	O	20	AMOD
22	time	time	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	3	P

1	One	One	B-NP	CD	O	2	SUB
2	commenced	commence	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	9	NMOD
4	closely	closely	I-NP	RB	O	5	AMOD
5	related	related	I-NP	JJ	O	9	NMOD
6	drug	drug	I-NP	NN	O	9	NMOD
7	amlodipine	amlodipine	I-NP	NN	O	9	NMOD
8	3	3	B-NP	CD	O	9	NMOD
9	years	year	I-NP	NNS	O	2	OBJ
10	later	later	B-ADVP	RB	O	2	VMOD
11	,	,	O	,	O	2	P
12	with	with	B-PP	IN	O	2	VMOD
13	recurrence	recurrence	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	telangiectasia	telangiectasia	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	2	P

1	Nephrotoxicity	Nephrotoxicity	B-NP	NN	O	8	NMOD
2	of	of	B-PP	IN	O	1	NMOD
3	cyclosporin	cyclosporin	B-NP	NN	O	4	NMOD
4	A	A	I-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	FK506	FK506	I-NP	NN	O	2	PMOD
7	:	:	O	:	O	1	P
8	inhibition	inhibition	B-NP	NN	O	0	ROOT
9	of	of	B-PP	IN	O	8	NMOD
10	calcineurin	calcineurin	B-NP	NN	B-protein	11	NMOD
11	phosphatase	phosphatase	I-NP	NN	I-protein	9	PMOD
12	.	.	O	.	O	8	P

1	Cyclosporin	Cyclosporin	B-NP	NN	O	2	NMOD
2	A	A	I-NP	NN	O	10	NMOD
3	(	(	O	(	O	8	DEP
4	CsA	CsA	B-NP	NN	O	7	NMOD
5	;	;	O	:	O	7	P
6	50	50	B-NP	CD	O	7	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	8	DEP
8	)	)	O	)	O	2	NMOD
9	and	and	O	CC	O	10	NMOD
10	Fujimycine	Fujimycine	B-NP	NN	O	24	NMOD
11	(	(	O	(	O	16	DEP
12	FK506	FK506	B-NP	NN	O	15	NMOD
13	;	;	O	:	O	15	P
14	5	5	B-NP	CD	O	15	NMOD
15	mg/kg	mg/kg	I-NP	NN	O	16	DEP
16	)	)	O	)	O	10	NMOD
17	,	,	O	,	O	24	P
18	but	but	B-CONJP	CC	O	24	NMOD
19	not	not	I-CONJP	RB	O	18	DEP
20	the	the	B-NP	DT	O	24	NMOD
21	related	relate	I-NP	VBN	O	24	NMOD
22	macrolide	macrolide	I-NP	NN	O	24	NMOD
23	immunosuppressant	immunosuppressant	I-NP	NN	O	24	NMOD
24	rapamycin	rapamycin	I-NP	NN	O	30	SUB
25	(	(	O	(	O	28	DEP
26	5	5	B-NP	CD	O	27	NMOD
27	mg/kg	mg/kg	I-NP	NN	O	28	DEP
28	)	)	O	)	O	24	NMOD
29	,	,	O	,	O	24	P
30	caused	cause	B-VP	VBD	O	0	ROOT
31	a	a	B-NP	DT	O	32	NMOD
32	reduction	reduction	I-NP	NN	O	46	NMOD
33	of	of	B-PP	IN	O	32	NMOD
34	glomerular	glomerular	B-NP	JJ	O	36	NMOD
35	filtration	filtration	I-NP	NN	O	36	NMOD
36	rate	rate	I-NP	NN	O	33	PMOD
37	,	,	O	,	O	46	P
38	degenerative	degenerative	B-NP	JJ	O	39	NMOD
39	changes	change	I-NP	NNS	O	46	NMOD
40	of	of	B-PP	IN	O	39	NMOD
41	proximal	proximal	B-NP	JJ	O	43	NMOD
42	tubular	tubular	I-NP	JJ	O	43	NMOD
43	epithelium	epithelium	I-NP	NN	O	40	PMOD
44	,	,	O	,	O	46	P
45	and	and	O	CC	O	46	NMOD
46	hypertrophy	hypertrophy	B-NP	NN	O	30	OBJ
47	of	of	B-PP	IN	O	46	NMOD
48	the	the	B-NP	DT	O	50	NMOD
49	juxtaglomerular	juxtaglomerular	I-NP	JJ	O	50	NMOD
50	apparatus	apparatus	I-NP	NN	O	47	PMOD
51	in	in	B-PP	IN	O	50	NMOD
52	male	male	B-NP	JJ	O	54	NMOD
53	Wistar	Wistar	I-NP	NNP	O	54	NMOD
54	rats	rat	I-NP	NNS	O	51	PMOD
55	when	when	B-ADVP	WRB	O	30	VMOD
56	given	give	B-VP	VBN	O	55	SBAR
57	for	for	B-PP	IN	O	56	VMOD
58	10	10	B-NP	CD	O	59	NMOD
59	days	day	I-NP	NNS	O	57	PMOD
60	.	.	O	.	O	30	P

1	The	The	B-NP	DT	O	3	NMOD
2	molecular	molecular	I-NP	JJ	O	3	NMOD
3	mechanisms	mechanism	I-NP	NNS	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	CsA	CsA	B-NP	NN	O	8	NMOD
6	and	and	I-NP	CC	O	8	NMOD
7	FK506	FK506	I-NP	NN	O	8	NMOD
8	toxicity	toxicity	I-NP	NN	O	4	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	investigated	investigate	I-VP	VBN	O	9	VC
11	.	.	O	.	O	9	P

1	Massive	Massive	B-NP	JJ	O	3	NMOD
2	cerebral	cerebral	I-NP	JJ	O	3	NMOD
3	edema	edema	I-NP	NN	O	14	NMOD
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	fulminant	fulminant	B-NP	JJ	O	8	NMOD
7	hepatic	hepatic	I-NP	JJ	O	8	NMOD
8	failure	failure	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	acetaminophen	acetaminophen	B-NP	NN	O	11	NMOD
11	overdose	overdose	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	3	P
13	possible	possible	B-NP	JJ	O	14	NMOD
14	role	role	I-NP	NN	O	0	ROOT
15	of	of	B-PP	IN	O	14	NMOD
16	cranial	cranial	B-NP	JJ	O	17	NMOD
17	decompression	decompression	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	14	P

1	Gentamicin	Gentamicin	B-NP	NN	O	2	NMOD
2	nephropathy	nephropathy	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	5	NMOD
5	neonate	neonate	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	5	NMOD
2	clinical	clinical	I-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	autopsy	autopsy	I-NP	NN	O	5	NMOD
5	findings	finding	I-NP	NNS	O	26	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	9	NMOD
8	premature	premature	I-NP	JJ	O	9	NMOD
9	baby	baby	I-NP	NN	O	6	PMOD
10	who	who	B-NP	WP	O	9	NMOD
11	died	die	B-VP	VBD	O	10	SBAR
12	of	of	B-PP	IN	O	11	VMOD
13	acute	acute	B-NP	JJ	O	15	NMOD
14	renal	renal	I-NP	JJ	O	15	NMOD
15	failure	failure	I-NP	NN	O	12	PMOD
16	after	after	B-PP	IN	O	11	VMOD
17	therapy	therapy	B-NP	NN	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	gentamicin	gentamicin	B-NP	NN	O	25	NMOD
20	(	(	O	(	O	23	DEP
21	5	5	B-NP	CD	O	22	NMOD
22	mg/kg/day	mg/kg/day	I-NP	NN	O	23	DEP
23	)	)	O	)	O	19	NMOD
24	and	and	O	CC	O	25	NMOD
25	penicillin	penicillin	B-NP	NN	B-protein	18	PMOD
26	are	be	B-VP	VBP	O	0	ROOT
27	presented	present	I-VP	VBN	O	26	VC
28	.	.	O	.	O	26	P

1	The	The	B-NP	DT	O	4	NMOD
2	serum	serum	I-NP	NN	O	4	NMOD
3	gentamicin	gentamicin	I-NP	NN	O	4	NMOD
4	concentration	concentration	I-NP	NN	O	5	SUB
5	had	have	B-VP	VBD	O	0	ROOT
6	reached	reach	I-VP	VBN	O	5	VC
7	toxic	toxic	B-NP	JJ	O	8	NMOD
8	levels	level	I-NP	NNS	O	6	OBJ
9	when	when	B-ADVP	WRB	O	6	VMOD
10	anuria	anuria	B-NP	NN	O	11	SUB
11	developed	develop	B-VP	VBD	O	9	SBAR
12	.	.	O	.	O	5	P

1	Anti-carcinogenic	Anti-carcinogenic	B-NP	JJ	O	2	NMOD
2	action	action	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	phenobarbital	phenobarbital	B-NP	NN	O	3	PMOD
5	given	give	B-VP	VBN	O	2	NMOD
6	simultaneously	simultaneously	B-ADVP	RB	O	5	VMOD
7	with	with	B-PP	IN	O	5	VMOD
8	diethylnitrosamine	diethylnitrosamine	B-NP	NN	O	7	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	rat	rat	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	present	present	I-NP	JJ	O	3	NMOD
3	work	work	I-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	planned	plan	I-VP	VBN	O	5	VC
7	in	in	B-SBAR	IN	O	6	VMOD
8	order	order	O	NN	O	7	DEP
9	to	to	B-VP	TO	O	10	VMOD
10	elucidate	elucidate	I-VP	VB	O	7	SBAR
11	the	the	B-NP	DT	O	12	NMOD
12	effect	effect	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	phenobarbital	phenobarbital	B-NP	NN	O	19	NMOD
15	(	(	O	(	O	19	NMOD
16	PB	PB	B-NP	NN	O	19	NMOD
17	:	:	O	:	O	19	P
18	15	15	B-NP	CD	O	19	NMOD
19	mg	mg	I-NP	NN	O	13	PMOD
20	per	per	B-PP	IN	O	10	VMOD
21	rat	rat	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	ingested	ingest	B-NP	VBN	O	24	NMOD
24	dose	dose	I-NP	NN	O	22	PMOD
25	)	)	O	)	O	10	VMOD
26	on	on	B-PP	IN	O	10	VMOD
27	carcinogenesis	carcinogenesis	B-NP	NN	O	26	PMOD
28	when	when	B-ADVP	WRB	O	10	VMOD
29	it	it	B-NP	PRP	O	30	SUB
30	is	be	B-VP	VBZ	O	28	SBAR
31	administered	administer	I-VP	VBN	O	30	VC
32	simultaneously	simultaneously	B-ADVP	RB	O	31	VMOD
33	with	with	B-PP	IN	O	31	VMOD
34	diethylnitrosamine	diethylnitrosamine	B-NP	NN	O	33	PMOD
35	(	(	O	(	O	40	DEP
36	DEN	DEN	B-NP	NN	O	39	NMOD
37	:	:	O	:	O	39	P
38	10	10	B-NP	CD	O	39	NMOD
39	mg/kg/day	mg/kg/day	I-NP	NN	O	40	DEP
40	)	)	O	)	O	34	NMOD
41	.	.	O	.	O	4	P

1	Wistar	Wistar	B-NP	NNP	O	2	NMOD
2	rats	rat	I-NP	NNS	O	7	SUB
3	(	(	O	(	O	6	DEP
4	180	180	B-NP	CD	O	5	NMOD
5	g	g	I-NP	NN	O	6	DEP
6	)	)	O	)	O	2	NMOD
7	were	be	B-VP	VBD	O	0	ROOT
8	treated	treat	I-VP	VBN	O	7	VC
9	by	by	B-PP	IN	O	8	VMOD
10	DEN	DEN	B-NP	NN	O	9	PMOD
11	alone	alone	B-ADVP	RB	O	10	NMOD
12	or	or	O	CC	O	9	PMOD
13	by	by	B-PP	IN	O	9	PMOD
14	DEN	DEN	B-NP	NN	B-protein	16	NMOD
15	+	+	B-NP	SYM	I-protein	16	NMOD
16	PB	PB	I-NP	NN	I-protein	13	PMOD
17	during	during	B-PP	IN	O	8	VMOD
18	2	2	B-NP	CD	O	23	NMOD
19	,	,	I-NP	,	O	23	P
20	4	4	I-NP	CD	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	6	6	I-NP	CD	O	23	NMOD
23	weeks	week	I-NP	NNS	O	17	PMOD
24	according	accord	B-PP	VBG	O	8	VMOD
25	to	to	B-PP	TO	O	24	PMOD
26	our	our	B-NP	PRP$	O	27	NMOD
27	schedule	schedule	I-NP	NN	O	25	PMOD
28	for	for	B-PP	IN	O	27	NMOD
29	hepatocarcinogenesis	hepatocarcinogenesis	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	7	P

1	After	After	B-PP	IN	O	19	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	end	end	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	6	NMOD
6	treatment	treatment	I-NP	NN	O	4	PMOD
7	,	,	O	,	O	19	P
8	the	the	B-NP	DT	O	9	NMOD
9	number	number	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	the	the	B-NP	DT	O	12	NMOD
12	size	size	I-NP	NN	O	19	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	induced	induce	B-NP	VBN	O	18	NMOD
15	PAS	PAS	I-NP	NN	B-DNA	18	NMOD
16	positive	positive	I-NP	JJ	I-DNA	18	NMOD
17	preneoplastic	preneoplastic	I-NP	JJ	I-DNA	18	NMOD
18	foci	focus	I-NP	NNS	I-DNA	13	PMOD
19	was	be	B-VP	VBD	O	0	ROOT
20	significantly	significantly	I-VP	RB	O	19	VMOD
21	reduced	reduce	I-VP	VBN	O	19	VC
22	when	when	B-ADVP	WRB	O	21	VMOD
23	PB	PB	B-NP	NN	O	24	SUB
24	was	be	B-VP	VBD	O	22	SBAR
25	given	give	I-VP	VBN	O	24	VC
26	simultaneously	simultaneously	B-ADVP	RB	O	25	VMOD
27	with	with	B-PP	IN	O	25	VMOD
28	DEN	DEN	B-NP	NN	O	27	PMOD
29	for	for	B-PP	IN	O	28	NMOD
30	4	4	B-NP	CD	O	32	AMOD
31	and	and	I-NP	CC	O	32	AMOD
32	6	6	I-NP	CD	O	33	NMOD
33	weeks	week	I-NP	NNS	O	29	PMOD
34	.	.	O	.	O	19	P

1	In	In	B-PP	IN	O	10	VMOD
2	DEN	DEN	B-NP	NN	O	4	NMOD
3	+	+	B-NP	SYM	O	4	NMOD
4	PB	PB	I-NP	NN	O	6	NMOD
5	treated	treat	I-NP	VBN	O	6	NMOD
6	rats	rat	I-NP	NNS	O	1	PMOD
7	,	,	O	,	O	10	P
8	the	the	B-NP	DT	O	9	NMOD
9	survival	survival	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	16	VMOD
11	prolonged	prolonged	B-ADJP	JJ	O	10	PRD
12	and	and	O	CC	O	16	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	tumor	tumor	I-NP	NN	O	15	NMOD
15	incidence	incidence	I-NP	NN	O	16	SUB
16	decreased	decrease	B-VP	VBD	O	0	ROOT
17	as	as	B-ADVP	RB	O	16	VMOD
18	compared	compare	B-PP	VBN	O	16	VMOD
19	with	with	B-PP	IN	O	18	PMOD
20	the	the	B-NP	DT	O	21	NMOD
21	results	result	I-NP	NNS	O	19	PMOD
22	obtained	obtain	B-VP	VBN	O	21	NMOD
23	by	by	B-PP	IN	O	22	VMOD
24	DEN	DEN	B-NP	NN	B-protein	23	PMOD
25	alone	alone	B-ADVP	RB	O	24	NMOD
26	.	.	O	.	O	16	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	concluded	conclude	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	PB	PB	B-NP	NN	O	17	SUB
6	,	,	O	,	O	5	P
7	which	which	B-NP	WDT	O	5	NMOD
8	promotes	promote	B-VP	VBZ	O	7	SBAR
9	carcinogenesis	carcinogenesis	B-NP	NN	O	8	OBJ
10	when	when	B-ADVP	WRB	O	8	VMOD
11	administered	administer	B-VP	VBN	O	10	SBAR
12	after	after	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	DEN	DEN	I-NP	NN	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	12	PMOD
16	,	,	O	,	O	5	P
17	reduces	reduce	B-VP	VBZ	O	4	SBAR
18	the	the	B-NP	DT	O	20	NMOD
19	carcinogen	carcinogen	I-NP	NN	O	20	NMOD
20	effect	effect	I-NP	NN	O	17	OBJ
21	when	when	B-ADVP	WRB	O	17	VMOD
22	given	give	B-VP	VBN	O	21	SBAR
23	simultaneously	simultaneously	B-ADVP	RB	O	22	VMOD
24	with	with	B-PP	IN	O	22	VMOD
25	DEN	DEN	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	2	P

1	Post-operative	Post-operative	B-NP	JJ	O	2	NMOD
2	rigidity	rigidity	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	fentanyl	fentanyl	B-NP	NN	O	5	NMOD
5	administration	administration	I-NP	NN	O	3	PMOD
6	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	case	case	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	thoraco-abdominal	thoraco-abdominal	B-NP	JJ	O	5	NMOD
5	rigidity	rigidity	I-NP	NN	O	3	PMOD
6	leading	lead	B-VP	VBG	O	5	NMOD
7	to	to	B-PP	TO	O	6	VMOD
8	respiratory	respiratory	B-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	7	PMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	described	describe	I-VP	VBN	O	10	VC
12	in	in	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	15	NMOD
14	post-operative	post-operative	I-NP	JJ	O	15	NMOD
15	period	period	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	11	VMOD
17	an	an	B-NP	DT	O	19	NMOD
18	elderly	elderly	I-NP	JJ	O	19	NMOD
19	patient	patient	I-NP	NN	O	16	PMOD
20	who	who	B-NP	WP	O	19	NMOD
21	received	receive	B-VP	VBD	O	20	SBAR
22	a	a	B-NP	DT	O	24	NMOD
23	moderate	moderate	I-NP	JJ	O	24	NMOD
24	dose	dose	I-NP	NN	O	21	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	fentanyl	fentanyl	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	10	P

1	Postpartum	Postpartum	B-NP	NNP	O	2	NMOD
2	psychosis	psychosis	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	bromocriptine	bromocriptine	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	multigravida	multigravida	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	9	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	no	no	B-NP	DT	O	8	NMOD
6	prior	prior	I-NP	JJ	O	8	NMOD
7	psychiatric	psychiatric	I-NP	JJ	O	8	NMOD
8	history	history	I-NP	NN	O	4	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	seen	see	I-VP	VBN	O	9	VC
11	with	with	B-PP	IN	O	10	VMOD
12	postpartum	postpartum	B-NP	NN	O	13	NMOD
13	psychosis	psychosis	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	10	P
15	having	have	B-VP	VBG	O	10	VMOD
16	received	receive	I-VP	VBN	O	17	NMOD
17	bromocriptine	bromocriptine	B-NP	NN	O	15	OBJ
18	for	for	B-PP	IN	O	17	NMOD
19	inhibition	inhibition	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	lactation	lactation	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	9	P

1	Bromocriptine	Bromocriptine	B-NP	NN	O	6	SUB
2	given	give	B-PP	VBN	O	1	NMOD
3	in	in	B-PP	IN	O	2	VMOD
4	high	high	B-NP	JJ	O	5	NMOD
5	doses	dose	I-NP	NNS	O	3	PMOD
6	has	have	B-VP	VBZ	O	0	ROOT
7	been	be	I-VP	VBN	O	6	VC
8	associated	associate	I-VP	VBN	O	7	VC
9	with	with	B-PP	IN	O	8	VMOD
10	psychosis	psychosis	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	10	NMOD
12	patients	patient	B-NP	NNS	O	11	PMOD
13	receiving	receive	B-VP	VBG	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	drug	drug	I-NP	NN	O	13	OBJ
16	for	for	B-PP	IN	O	13	VMOD
17	Parkinson	Parkinson	B-NP	NNP	O	19	NMOD
18	's	's	B-NP	POS	O	19	NMOD
19	disease	disease	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	3	NMOD
2	prospective	prospective	I-NP	JJ	O	3	NMOD
3	study	study	I-NP	NN	O	0	ROOT
4	on	on	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	dose	dose	I-NP	NN	O	7	NMOD
7	dependency	dependency	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	cardiotoxicity	cardiotoxicity	B-NP	NN	O	8	PMOD
10	induced	induce	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	mitomycin	mitomycin	B-NP	NN	O	13	NMOD
13	C	C	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	3	P

1	Since	Since	B-SBAR	IN	O	0	ROOT
2	1975	1975	B-NP	CD	O	4	NMOD
3	mitomycin	mitomycin	I-NP	NN	O	4	NMOD
4	C	C	I-NP	NN	O	8	SUB
5	(	(	O	(	O	7	DEP
6	MMC	MMC	B-NP	NN	B-protein	7	DEP
7	)	)	O	)	O	4	NMOD
8	has	have	B-VP	VBZ	O	1	VMOD
9	been	be	I-VP	VBN	O	8	VC
10	suggested	suggest	I-VP	VBN	O	9	VC
11	to	to	I-VP	TO	O	12	VMOD
12	be	be	I-VP	VB	O	10	VMOD
13	cardiotoxic	cardiotoxic	B-ADJP	JJ	O	12	PRD
14	,	,	O	,	O	8	P
15	especially	especially	B-ADVP	RB	O	16	AMOD
16	when	when	B-ADVP	WRB	O	8	VMOD
17	combined	combine	B-VP	VBN	O	16	SBAR
18	with	with	B-PP	IN	O	17	VMOD
19	or	or	O	CC	O	18	PMOD
20	given	give	B-PP	VBN	O	18	PMOD
21	following	follow	B-PP	VBG	O	20	VMOD
22	doxorubicin	doxorubicin	B-NP	NN	O	21	PMOD
23	.	.	O	.	O	1	P

1	One	One	B-NP	CD	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	PMOD
5	developed	develop	B-VP	VBD	O	0	ROOT
6	cardiac	cardiac	B-NP	JJ	O	7	NMOD
7	failure	failure	I-NP	NN	O	5	OBJ
8	after	after	B-PP	IN	O	5	VMOD
9	30	30	B-NP	CD	O	10	AMOD
10	mg	mg	I-NP	NN	O	12	NMOD
11	m-2	m-2	I-NP	NN	O	12	NMOD
12	MMC	MMC	I-NP	NN	O	8	PMOD
13	and	and	O	CC	O	18	NMOD
14	only	only	B-NP	RB	O	18	NMOD
15	150	150	I-NP	CD	O	14	AMOD
16	mg	mg	I-NP	NN	O	18	NMOD
17	m-2	m-2	I-NP	NN	O	18	NMOD
18	doxorubicin	doxorubicin	I-NP	NN	O	5	OBJ
19	.	.	O	.	O	5	P

1	Phlorizin	Phlorizin	B-NP	NN	B-protein	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	glycosuria	glycosuria	B-NP	NN	O	4	SUB
4	does	do	B-VP	VBZ	O	2	VMOD
5	not	not	I-VP	RB	O	4	VMOD
6	prevent	prevent	I-VP	VB	O	4	VC
7	gentamicin	gentamicin	B-NP	NN	O	8	NMOD
8	nephrotoxicity	nephrotoxicity	I-NP	NN	O	6	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	rats	rat	B-NP	NNS	O	9	PMOD
11	.	.	O	.	O	2	P

1	Because	Because	B-SBAR	IN	O	26	VMOD
2	rats	rat	B-NP	NNS	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	streptozotocin	streptozotocin	B-NP	NN	B-protein	3	PMOD
5	induced	induce	B-VP	VBD	O	1	SBAR
6	diabetes	diabetes	B-NP	NN	O	7	NMOD
7	mellitus	mellitus	I-NP	NN	O	5	OBJ
8	(	(	O	(	O	10	DEP
9	DM	DM	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	have	have	B-VP	VBP	O	5	VMOD
12	a	a	B-NP	DT	O	15	NMOD
13	high	high	I-NP	JJ	O	15	NMOD
14	solute	solute	I-NP	JJ	O	15	NMOD
15	diuresis	diuresis	I-NP	NN	O	11	OBJ
16	(	(	O	(	O	23	DEP
17	glycosuria	glycosuria	B-NP	NN	O	23	DEP
18	of	of	B-PP	IN	O	17	NMOD
19	10	10	B-NP	CD	O	21	AMOD
20	to	to	I-NP	TO	O	21	AMOD
21	12	12	I-NP	CD	O	22	NMOD
22	g/day	g/day	I-NP	NN	O	18	PMOD
23	)	)	O	)	O	15	NMOD
24	,	,	O	,	O	26	P
25	we	we	B-NP	PRP	O	26	SUB
26	have	have	B-VP	VBP	O	0	ROOT
27	suggested	suggest	I-VP	VBN	O	26	VC
28	that	that	B-SBAR	IN	O	27	VMOD
29	this	this	B-NP	DT	O	30	NMOD
30	may	may	I-NP	NN	O	33	SUB
31	in	in	B-PP	IN	O	30	NMOD
32	part	part	B-NP	NN	O	31	PMOD
33	be	be	B-VP	VB	O	28	SBAR
34	responsible	responsible	B-ADJP	JJ	O	33	PRD
35	for	for	B-PP	IN	O	34	AMOD
36	their	their	B-NP	PRP$	O	37	NMOD
37	resistance	resistance	I-NP	NN	O	35	PMOD
38	to	to	B-PP	TO	O	37	NMOD
39	gentamicin	gentamicin	B-NP	NN	O	38	PMOD
40	induced	induce	B-VP	VBD	O	26	VMOD
41	acute	acute	B-NP	JJ	O	43	NMOD
42	renal	renal	I-NP	JJ	O	43	NMOD
43	failure	failure	I-NP	NN	O	40	OBJ
44	(	(	O	(	O	46	DEP
45	ARF	ARF	B-NP	NN	B-protein	46	DEP
46	)	)	O	)	O	43	NMOD
47	.	.	O	.	O	26	P

1	The	The	B-NP	DT	O	2	NMOD
2	protection	protection	I-NP	NN	O	6	SUB
3	from	from	B-PP	IN	O	2	NMOD
4	gentamicin	gentamicin	B-NP	NN	O	5	NMOD
5	nephrotoxicity	nephrotoxicity	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	studied	study	I-VP	VBN	O	6	VC
8	in	in	B-PP	IN	O	7	VMOD
9	non-diabetic	non-diabetic	B-NP	JJ	O	10	NMOD
10	rats	rat	I-NP	NNS	O	8	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	chronic	chronic	B-NP	JJ	O	14	NMOD
13	solute	solute	I-NP	JJ	O	14	NMOD
14	diuresis	diuresis	I-NP	NN	O	11	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	blockage	blockage	B-NP	NN	O	16	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	tubular	tubular	B-NP	JJ	O	21	NMOD
20	glucose	glucose	I-NP	NN	O	21	NMOD
21	reabsorption	reabsorption	I-NP	NN	O	18	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	phlorizin	phlorizin	B-NP	NN	O	22	PMOD
24	(	(	O	(	O	26	DEP
25	P	P	B-NP	NN	O	26	DEP
26	)	)	O	)	O	23	NMOD
27	.	.	O	.	O	6	P

1	DM	DM	B-NP	NN	O	2	NMOD
2	rats	rat	I-NP	NNS	O	18	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	mild	mild	B-NP	JJ	O	5	NMOD
5	glycosuria	glycosuria	I-NP	NN	O	3	PMOD
6	(	(	O	(	O	17	DEP
7	similar	similar	B-ADJP	JJ	O	17	DEP
8	in	in	B-PP	IN	O	7	AMOD
9	degree	degree	B-NP	NN	O	8	PMOD
10	to	to	B-PP	TO	O	7	NMOD
11	that	that	B-NP	DT	O	10	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	the	the	B-NP	DT	O	16	NMOD
14	P	P	I-NP	NN	O	16	NMOD
15	treated	treat	I-NP	VBN	O	16	NMOD
16	animals	animal	I-NP	NNS	O	12	PMOD
17	)	)	O	)	O	5	NMOD
18	were	be	B-VP	VBD	O	0	ROOT
19	also	also	I-VP	RB	O	18	VMOD
20	studied	study	I-VP	VBN	O	18	VC
21	.	.	O	.	O	18	P

1	Group	Group	B-NP	NN	O	7	SUB
2	1	1	I-NP	CD	O	1	NMOD
3	(	(	O	(	O	6	DEP
4	P	P	B-NP	NN	O	6	DEP
5	alone	alone	B-ADVP	RB	O	4	NMOD
6	)	)	O	)	O	1	NMOD
7	received	receive	B-VP	VBD	O	0	ROOT
8	P	P	B-NP	NN	O	11	NMOD
9	,	,	O	,	O	11	P
10	360	360	B-NP	CD	O	11	NMOD
11	mg/day	mg/day	I-NP	NN	O	7	OBJ
12	,	,	O	,	O	11	P
13	for	for	B-PP	IN	O	11	NMOD
14	15	15	B-NP	CD	O	15	NMOD
15	days	day	I-NP	NNS	O	13	PMOD
16	;	;	O	:	O	7	P
17	Group	Group	B-NP	NN	B-protein	7	OBJ
18	II	II	I-NP	CD	I-protein	17	NMOD
19	(	(	O	(	O	23	DEP
20	P	P	B-NP	NN	O	22	NMOD
21	+	+	O	SYM	O	22	NMOD
22	gentamicin	gentamicin	B-NP	NN	O	23	DEP
23	)	)	O	)	O	17	NMOD
24	;	;	O	:	O	7	P
25	Group	Group	B-NP	NN	O	32	NMOD
26	III	III	I-NP	CD	O	25	NMOD
27	(	(	O	(	O	30	DEP
28	gentamicin	gentamicin	B-NP	NN	O	30	DEP
29	alone	alone	B-ADVP	RB	O	28	NMOD
30	)	)	O	)	O	25	NMOD
31	and	and	O	CC	O	32	NMOD
32	Group	Group	B-NP	NN	B-protein	7	OBJ
33	IV	IV	I-NP	CD	I-protein	32	NMOD
34	(	(	O	(	O	39	DEP
35	mild	mild	B-NP	JJ	O	38	NMOD
36	DM	DM	I-NP	NN	O	38	NMOD
37	+	+	B-NP	SYM	O	38	NMOD
38	gentamicin	gentamicin	I-NP	NN	O	39	DEP
39	)	)	O	)	O	32	NMOD
40	.	.	O	.	O	7	P

1	Nephrotoxic	Nephrotoxic	B-NP	JJ	O	2	NMOD
2	doses	dose	I-NP	NNS	O	11	SUB
3	(	(	O	(	O	8	DEP
4	40	40	B-NP	CD	O	7	NMOD
5	mg/kg	mg/kg	I-NP	NN	O	7	NMOD
6	body	body	I-NP	NN	O	7	NMOD
7	wt/day	wt/day	I-NP	NN	O	8	DEP
8	)	)	O	)	O	2	NMOD
9	of	of	B-PP	IN	O	2	NMOD
10	gentamicin	gentamicin	B-NP	NN	O	9	PMOD
11	were	be	B-VP	VBD	O	0	ROOT
12	injected	inject	I-VP	VBN	O	11	VC
13	during	during	B-PP	IN	O	12	VMOD
14	the	the	B-NP	DT	O	17	NMOD
15	last	last	I-NP	JJ	O	17	NMOD
16	nine	nine	I-NP	CD	O	17	NMOD
17	days	day	I-NP	NNS	O	13	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	study	study	B-NP	NN	O	18	PMOD
20	to	to	B-PP	TO	O	17	NMOD
21	the	the	B-NP	DT	O	22	NMOD
22	animals	animal	I-NP	NNS	O	20	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	groups	group	B-NP	NNS	B-protein	23	PMOD
25	II	II	B-NP	CD	I-protein	24	NMOD
26	to	to	B-PP	TO	O	22	NMOD
27	IV	IV	B-NP	CD	O	26	PMOD
28	.	.	O	.	O	11	P

1	In	In	B-PP	IN	O	6	VMOD
2	Group	Group	B-NP	NN	B-cell_line	3	NMOD
3	I	I	I-NP	NN	I-cell_line	1	PMOD
4	,	,	O	,	O	6	P
5	P	P	B-NP	NN	O	6	SUB
6	induced	induce	B-VP	VBD	O	26	VMOD
7	a	a	B-NP	DT	O	11	NMOD
8	moderate	moderate	I-NP	JJ	O	10	AMOD
9	and	and	I-NP	CC	O	10	AMOD
10	stable	stable	I-NP	JJ	O	11	NMOD
11	glycosuria	glycosuria	I-NP	NN	O	6	OBJ
12	(	(	O	(	O	19	DEP
13	3.9	3.9	B-NP	CD	O	15	AMOD
14	+/-	+/-	I-NP	SYM	O	15	AMOD
15	0.1	0.1	I-NP	CD	O	16	NMOD
16	g/day	g/day	I-NP	NN	O	18	NMOD
17	,	,	O	,	O	18	P
18	SE	SE	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	11	NMOD
20	,	,	O	,	O	26	P
21	and	and	O	CC	O	26	NMOD
22	no	no	B-NP	DT	O	26	NMOD
23	functional	functional	I-NP	JJ	O	25	AMOD
24	or	or	I-NP	CC	O	25	AMOD
25	morphologic	morphologic	I-NP	JJ	O	26	NMOD
26	evidence	evidence	I-NP	NN	O	0	ROOT
27	of	of	B-PP	IN	O	26	NMOD
28	renal	renal	B-NP	JJ	O	29	NMOD
29	dysfunction	dysfunction	I-NP	NN	O	42	NMOD
30	(	(	O	(	O	40	DEP
31	baseline	baseline	B-NP	NN	O	32	NMOD
32	CCr	CCr	I-NP	NN	O	36	NMOD
33	2.1	2.1	B-NP	CD	O	35	AMOD
34	+/-	+/-	I-NP	SYM	O	35	AMOD
35	0.1	0.1	I-NP	CD	O	36	NMOD
36	ml/min	ml/min	I-NP	NN	O	39	NMOD
37	,	,	O	,	O	39	P
38	undetectable	undetectable	B-NP	JJ	O	39	NMOD
39	lysozymuria	lysozymuria	I-NP	NN	O	40	DEP
40	)	)	O	)	O	29	NMOD
41	or	or	O	CC	O	42	NMOD
42	damage	damage	B-NP	NN	O	27	PMOD
43	(	(	O	(	O	53	DEP
44	tubular	tubular	B-NP	JJ	O	46	NMOD
45	necrosis	necrosis	I-NP	NN	O	46	NMOD
46	score	score	I-NP	NN	O	52	NMOD
47	[	[	O	(	O	50	DEP
48	maximum	maximum	B-NP	NN	O	50	DEP
49	4	4	I-NP	CD	O	48	NMOD
50	]	]	O	)	O	46	NMOD
51	,	,	O	,	O	52	P
52	zero	zero	B-NP	CD	O	53	DEP
53	)	)	O	)	O	42	NMOD
54	.	.	O	.	O	26	P

1	In	In	B-PP	IN	O	6	VMOD
2	Group	Group	B-NP	NN	B-cell_line	1	PMOD
3	II	II	I-NP	CD	I-cell_line	2	NMOD
4	,	,	O	,	O	6	P
5	P	P	B-NP	NN	O	6	SUB
6	did	do	B-VP	VBD	O	0	ROOT
7	not	not	I-VP	RB	O	6	VMOD
8	prevent	prevent	I-VP	VB	O	6	VC
9	gentamicin-ARF	gentamicin-ARF	O	JJ	O	8	PRD
10	(	(	O	(	O	41	DEP
11	maximal	maximal	B-NP	JJ	O	12	NMOD
12	decrease	decrease	I-NP	NN	O	20	NMOD
13	in	in	B-PP	IN	O	12	NMOD
14	CCr	CCr	B-NP	NN	B-protein	13	PMOD
15	at	at	B-PP	IN	O	12	NMOD
16	day	day	B-NP	NN	O	18	NMOD
17	9.89	9.89	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	20	P
20	P	P	B-NP	NN	O	41	DEP
21	less	less	B-ADJP	JJR	O	20	NMOD
22	than	than	B-PP	IN	O	21	AMOD
23	0.001	0.001	B-NP	CD	O	22	PMOD
24	;	;	O	:	O	40	P
25	peak	peak	B-NP	JJ	O	26	NMOD
26	lysozymuria	lysozymuria	I-NP	NN	O	31	NMOD
27	,	,	O	,	O	31	P
28	1863	1863	B-NP	CD	O	30	AMOD
29	+/-	+/-	I-NP	SYM	O	30	AMOD
30	321	321	I-NP	CD	O	31	NMOD
31	micrograms/day	micrograms/day	I-NP	NN	O	40	SUB
32	;	;	O	:	O	40	P
33	and	and	O	CC	O	40	NMOD
34	tubular	tubular	B-NP	JJ	O	36	NMOD
35	necrosis	necrosis	I-NP	NN	O	36	NMOD
36	score	score	I-NP	NN	O	40	NMOD
37	,	,	O	,	O	40	P
38	3.9	3.9	B-NP	CD	O	40	AMOD
39	+/-	+/-	I-NP	CC	O	40	AMOD
40	0.1	0.1	I-NP	CD	O	20	NMOD
41	)	)	O	)	O	9	AMOD
42	.	.	O	.	O	6	P

1	Tiapride	Tiapride	B-NP	NN	O	4	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	levodopa	levodopa	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	involuntary	involuntary	B-NP	JJ	O	6	NMOD
6	movements	movement	I-NP	NNS	O	4	OBJ
7	.	.	O	.	O	4	P

1	Tiapride	Tiapride	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	a	a	B-NP	DT	O	6	NMOD
4	substituted	substitute	I-NP	VBN	O	6	NMOD
5	benzamide	benzamide	I-NP	NN	O	6	NMOD
6	derivative	derivative	I-NP	NN	O	12	SUB
7	closely	closely	B-ADJP	RB	O	8	AMOD
8	related	related	I-ADJP	JJ	O	6	NMOD
9	to	to	B-PP	TO	O	8	AMOD
10	metoclopramide	metoclopramide	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	6	P
12	reduced	reduce	B-VP	VBD	O	0	ROOT
13	levodopa	levodopa	B-NP	NN	O	18	NMOD
14	induced	induced	I-NP	JJ	O	18	NMOD
15	peak	peak	I-NP	JJ	O	18	NMOD
16	dose	dose	I-NP	NN	O	18	NMOD
17	involuntary	involuntary	I-NP	JJ	O	18	NMOD
18	movements	movement	I-NP	NNS	O	12	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	16	16	B-NP	CD	O	21	NMOD
21	patients	patient	I-NP	NNS	O	19	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	idiopathic	idiopathic	B-NP	JJ	O	26	NMOD
24	Parkinson	Parkinson	I-NP	NNP	O	26	NMOD
25	's	's	B-NP	POS	O	26	NMOD
26	disease	disease	I-NP	NN	O	22	PMOD
27	.	.	O	.	O	12	P

1	Tiapride	Tiapride	B-NP	NN	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	4	NMOD
4	effect	effect	I-NP	NN	O	2	OBJ
5	on	on	B-PP	IN	O	2	VMOD
6	levodopa	levodopa	B-NP	NN	O	9	NMOD
7	induced	induce	B-VP	VBD	O	6	AMOD
8	early	early	B-NP	JJ	O	9	NMOD
9	morning	morning	I-NP	NN	O	5	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	"	"	B-NP	"	O	15	NMOD
12	off-period	off-period	I-NP	JJ	O	15	NMOD
13	"	"	I-NP	"	O	15	NMOD
14	segmental	segmental	I-NP	JJ	O	15	NMOD
15	dystonia	dystonia	I-NP	NN	O	10	PMOD
16	.	.	O	.	O	2	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	7	NMOD
4	hippocampal	hippocampal	I-NP	JJ	O	7	NMOD
5	deep	deep	I-NP	JJ	O	7	NMOD
6	brain	brain	I-NP	NN	O	7	NMOD
7	stimulation	stimulation	I-NP	NN	O	2	PMOD
8	on	on	B-PP	IN	O	1	NMOD
9	cortical	cortical	B-NP	JJ	O	11	NMOD
10	epileptic	epileptic	I-NP	JJ	O	11	NMOD
11	discharges	discharge	I-NP	NNS	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	penicillin	penicillin	B-NP	NN	B-protein	17	NMOD
14	-	-	B-NP	HYPH	O	17	P
15	induced	induce	I-NP	VBN	O	17	NMOD
16	epilepsy	epilepsy	I-NP	NN	O	17	NMOD
17	model	model	I-NP	NN	O	12	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	to	to	B-VP	TO	O	5	VMOD
5	evaluate	evaluate	I-VP	VB	O	3	PRD
6	the	the	B-NP	DT	O	7	NMOD
7	effects	effect	I-NP	NNS	O	5	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	high	high	B-NP	JJ	O	12	NMOD
10	frequency	frequency	I-NP	NN	O	12	NMOD
11	hippocampal	hippocampal	I-NP	JJ	O	12	NMOD
12	stimulation	stimulation	I-NP	NN	O	8	PMOD
13	on	on	B-PP	IN	O	7	NMOD
14	cortical	cortical	B-NP	JJ	O	16	NMOD
15	epileptic	epileptic	I-NP	JJ	O	16	NMOD
16	activity	activity	I-NP	NN	O	13	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	penicillin	penicillin	B-NP	NN	B-protein	17	PMOD
19	induced	induce	B-VP	VBD	O	5	VMOD
20	epilepsy	epilepsy	B-NP	NN	O	21	NMOD
21	model	model	I-NP	NN	O	19	OBJ
22	.	.	O	.	O	3	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	High	High	B-NP	JJ	O	6	NMOD
4	frequency	frequency	I-NP	NN	O	6	NMOD
5	hippocampal	hippocampal	I-NP	JJ	O	6	NMOD
6	DBS	DBS	I-NP	NNP	O	7	SUB
7	suppressed	suppress	B-VP	VBD	O	1	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	acute	acute	I-NP	JJ	B-protein	10	NMOD
10	penicillin	penicillin	I-NP	NN	I-protein	14	NMOD
11	induced	induce	B-VP	VBD	O	14	NMOD
12	cortical	cortical	B-NP	JJ	O	14	NMOD
13	epileptic	epileptic	I-NP	JJ	O	14	NMOD
14	activity	activity	I-NP	NN	O	7	OBJ
15	independent	independent	B-ADJP	JJ	O	14	NMOD
16	from	from	B-PP	IN	O	15	AMOD
17	stimulus	stimulus	B-NP	NN	O	18	NMOD
18	intensity	intensity	I-NP	NN	O	16	PMOD
19	.	.	O	.	O	1	P

1	Neural	Neural	B-NP	JJ	O	2	NMOD
2	correlates	correlate	I-NP	NNS	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	S-ketamine	S-ketamine	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	psychosis	psychosis	B-NP	NN	O	5	OBJ
7	during	during	B-PP	IN	O	5	VMOD
8	overt	overt	B-NP	JJ	O	11	NMOD
9	continuous	continuous	I-NP	JJ	O	11	NMOD
10	verbal	verbal	I-NP	JJ	O	11	NMOD
11	fluency	fluency	I-NP	NN	O	7	PMOD
12	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	7	NMOD
2	glutamatergic	glutamatergic	I-NP	JJ	B-protein	7	NMOD
3	N-methyl-D-aspartate	N-methyl-D-aspartate	I-NP	NN	I-protein	7	NMOD
4	(	(	O	(	I-protein	7	NMOD
5	NMDA	NMDA	B-NP	NN	I-protein	7	NMOD
6	)	)	O	)	I-protein	7	NMOD
7	receptor	receptor	B-NP	NN	I-protein	8	SUB
8	has	have	B-VP	VBZ	O	0	ROOT
9	been	be	I-VP	VBN	O	8	VC
10	implicated	implicate	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	pathophysiology	pathophysiology	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	schizophrenia	schizophrenia	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	8	P

1	Administered	Administer	B-VP	VBN	O	8	NMOD
2	to	to	B-PP	TO	O	1	VMOD
3	healthy	healthy	B-NP	JJ	O	4	NMOD
4	volunteers	volunteer	I-NP	NNS	O	2	PMOD
5	,	,	O	,	O	8	P
6	a	a	B-NP	DT	O	8	NMOD
7	subanesthetic	subanesthetic	I-NP	JJ	O	8	NMOD
8	dose	dose	I-NP	NN	O	16	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	15	NMOD
11	non-competitive	non-competitive	I-NP	JJ	O	15	NMOD
12	NMDA	NMDA	I-NP	NN	O	15	NMOD
13	receptor	receptor	I-NP	NN	O	15	NMOD
14	antagonist	antagonist	I-NP	NN	O	15	NMOD
15	ketamine	ketamine	I-NP	NN	O	9	PMOD
16	leads	lead	B-VP	VBZ	O	0	ROOT
17	to	to	B-PP	TO	O	16	VMOD
18	psychopathological	psychopathological	B-NP	JJ	O	19	NMOD
19	symptoms	symptom	I-NP	NNS	O	17	PMOD
20	similar	similar	B-ADJP	JJ	O	19	NMOD
21	to	to	B-PP	TO	O	20	AMOD
22	those	those	B-NP	DT	O	21	PMOD
23	observed	observe	B-VP	VBN	O	22	NMOD
24	in	in	B-PP	IN	O	23	VMOD
25	schizophrenia	schizophrenia	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	16	P

1	In	In	B-PP	IN	O	7	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	schizophrenia	schizophrenia	B-NP	NN	O	3	PMOD
5	,	,	O	,	O	7	P
6	ketamine	ketamine	B-NP	NN	O	7	SUB
7	exacerbates	exacerbate	B-VP	VBZ	O	0	ROOT
8	the	the	B-NP	DT	O	10	NMOD
9	core	core	I-NP	NN	O	10	NMOD
10	symptoms	symptom	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	illness	illness	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	7	P
14	supporting	support	B-VP	VBG	O	7	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	hypothesis	hypothesis	I-NP	NN	O	14	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	glutamatergic	glutamatergic	I-NP	JJ	O	20	NMOD
20	dysfunction	dysfunction	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	7	P

1	Ketamine	Ketamine	B-NP	NN	O	2	SUB
2	elicited	elicit	B-VP	VBD	O	0	ROOT
3	psychosis	psychosis	B-NP	NN	O	2	OBJ
4	like	like	B-PP	IN	O	3	NMOD
5	psychopathology	psychopathology	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	Ketamine	Ketamine	B-NP	NN	O	2	SUB
2	induces	induce	B-VP	VBZ	O	0	ROOT
3	activation	activation	B-NP	NN	O	4	NMOD
4	changes	change	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	healthy	healthy	B-NP	JJ	O	7	NMOD
7	subjects	subject	I-NP	NNS	O	5	PMOD
8	similar	similar	B-ADJP	JJ	O	4	NMOD
9	to	to	B-PP	TO	O	8	AMOD
10	those	those	B-NP	DT	O	9	PMOD
11	observed	observe	B-VP	VBN	O	10	NMOD
12	in	in	B-PP	IN	O	11	VMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	schizophrenia	schizophrenia	B-NP	NN	O	14	PMOD
16	,	,	O	,	O	4	P
17	particularly	particularly	B-ADVP	RB	O	18	PMOD
18	in	in	B-PP	IN	O	4	NMOD
19	frontal	frontal	B-NP	JJ	O	21	AMOD
20	and	and	I-NP	CC	O	21	AMOD
21	temporal	temporal	I-NP	JJ	O	23	NMOD
22	brain	brain	I-NP	NN	O	23	NMOD
23	regions	region	I-NP	NNS	O	18	PMOD
24	.	.	O	.	O	2	P

1	Dopamine	Dopamine	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	not	not	O	RB	O	2	VMOD
4	essential	essential	B-ADJP	JJ	O	2	PRD
5	for	for	B-PP	IN	O	4	AMOD
6	the	the	B-NP	DT	O	7	NMOD
7	development	development	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	methamphetamine	methamphetamine	B-NP	NN	O	11	NMOD
10	induced	induced	I-NP	JJ	O	11	NMOD
11	neurotoxicity	neurotoxicity	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	2	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	widely	widely	I-VP	RB	O	2	VMOD
4	believed	believe	I-VP	VBN	O	2	VC
5	that	that	B-SBAR	IN	O	4	VMOD
6	dopamine	dopamine	B-NP	NN	O	10	SUB
7	(	(	O	(	O	9	DEP
8	DA	DA	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	mediates	mediate	B-VP	VBZ	O	5	SBAR
11	methamphetamine	methamphetamine	B-NP	NN	O	15	SUB
12	(	(	O	(	O	14	DEP
13	METH	METH	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	induced	induce	B-VP	VBD	O	10	VMOD
16	toxicity	toxicity	B-NP	NN	O	15	OBJ
17	to	to	B-VP	TO	O	18	VMOD
18	brain	brain	I-VP	VB	O	16	NMOD
19	dopaminergic	dopaminergic	B-NP	JJ	O	20	NMOD
20	neurons	neuron	I-NP	NNS	O	18	OBJ
21	,	,	O	,	O	15	P
22	because	because	B-SBAR	IN	O	15	VMOD
23	drugs	drug	B-NP	NNS	O	22	PMOD
24	that	that	B-NP	WDT	O	23	NMOD
25	interfere	interfere	B-VP	VBP	O	24	SBAR
26	with	with	B-PP	IN	O	25	VMOD
27	DA	DA	B-NP	NN	O	30	NMOD
28	neurotransmission	neurotransmission	I-NP	NN	O	30	NMOD
29	decrease	decrease	I-NP	NN	O	30	NMOD
30	toxicity	toxicity	I-NP	NN	O	26	PMOD
31	,	,	O	,	O	10	P
32	whereas	whereas	O	IN	O	10	VMOD
33	drugs	drug	B-NP	NNS	O	38	SUB
34	that	that	B-NP	WDT	O	33	NMOD
35	increase	increase	B-VP	VBP	O	34	SBAR
36	DA	DA	B-NP	NN	O	37	NMOD
37	neurotransmission	neurotransmission	I-NP	NN	O	35	OBJ
38	enhance	enhance	B-VP	VBP	O	32	SBAR
39	toxicity	toxicity	B-NP	NN	O	38	OBJ
40	.	.	O	.	O	2	P

1	Here	Here	B-ADVP	RB	O	3	VMOD
2	we	we	B-NP	PRP	O	3	SUB
3	show	show	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	recently	recently	I-NP	RB	O	7	AMOD
7	reported	report	I-NP	VBN	O	8	NMOD
8	ability	ability	I-NP	NN	O	20	SUB
9	of	of	B-PP	IN	O	8	NMOD
10	L-dihydroxyphenylalanine	L-dihydroxyphenylalanine	B-NP	NN	O	9	PMOD
11	to	to	B-VP	TO	O	12	VMOD
12	reverse	reverse	I-VP	VB	O	8	NMOD
13	the	the	B-NP	DT	O	15	NMOD
14	protective	protective	I-NP	JJ	O	15	NMOD
15	effect	effect	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	alpha-methyl-para-tyrosine	alpha-methyl-para-tyrosine	B-NP	NN	O	16	PMOD
18	on	on	B-PP	IN	O	15	NMOD
19	METH	METH	B-NP	NN	B-protein	18	PMOD
20	induced	induce	B-VP	VBD	O	4	SBAR
21	DA	DA	B-NP	NN	O	22	NMOD
22	neurotoxicity	neurotoxicity	I-NP	NN	O	20	OBJ
23	is	be	B-VP	VBZ	O	3	VMOD
24	also	also	I-VP	RB	O	23	VMOD
25	confounded	confound	I-VP	VBN	O	23	VC
26	by	by	B-PP	IN	O	25	VMOD
27	drug	drug	B-NP	NN	O	28	NMOD
28	effects	effect	I-NP	NNS	O	26	PMOD
29	on	on	B-PP	IN	O	28	NMOD
30	body	body	B-NP	NN	O	31	NMOD
31	temperature	temperature	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	3	P

1	Further	Further	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	show	show	B-VP	VBP	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	mice	mouse	B-NP	NNS	O	15	SUB
7	genetically	genetically	B-VP	RB	O	8	VMOD
8	engineered	engineer	I-VP	VBN	O	6	NMOD
9	to	to	I-VP	TO	O	10	VMOD
10	be	be	I-VP	VB	O	8	VMOD
11	deficient	deficient	B-ADJP	JJ	O	10	PRD
12	in	in	B-PP	IN	O	10	VMOD
13	brain	brain	B-NP	NN	O	14	NMOD
14	DA	DA	I-NP	NN	O	12	PMOD
15	develop	develop	B-VP	VBP	O	5	SBAR
16	METH	METH	B-NP	NN	O	17	NMOD
17	neurotoxicity	neurotoxicity	I-NP	NN	O	15	OBJ
18	,	,	O	,	O	15	P
19	as	as	B-ADVP	RB	O	15	VMOD
20	long	long	I-ADVP	RB	O	19	AMOD
21	as	as	B-SBAR	IN	O	19	AMOD
22	the	the	B-NP	DT	O	24	NMOD
23	thermic	thermic	I-NP	JJ	O	24	NMOD
24	effects	effect	I-NP	NNS	O	27	SUB
25	of	of	B-PP	IN	O	24	NMOD
26	METH	METH	B-NP	NN	O	25	PMOD
27	are	be	B-VP	VBP	O	21	SBAR
28	preserved	preserve	I-VP	VBN	O	27	VC
29	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	5	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	we	we	B-NP	PRP	O	5	SUB
5	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	mice	mouse	B-NP	NNS	O	15	SUB
8	genetically	genetically	B-VP	RB	O	9	VMOD
9	engineered	engineer	I-VP	VBN	O	7	NMOD
10	to	to	I-VP	TO	O	11	VMOD
11	have	have	I-VP	VB	O	9	VMOD
12	unilateral	unilateral	B-NP	JJ	O	14	NMOD
13	brain	brain	I-NP	NN	O	14	NMOD
14	DA	DA	I-NP	NN	O	11	OBJ
15	deficits	deficit	B-VP	VBZ	O	6	SBAR
16	develop	develop	B-NP	NN	O	17	NMOD
17	METH	METH	I-NP	NN	O	20	NMOD
18	induced	induce	B-VP	VBD	O	20	NMOD
19	dopaminergic	dopaminergic	B-NP	JJ	O	20	NMOD
20	deficits	deficit	I-NP	NNS	O	15	OBJ
21	that	that	B-NP	WDT	O	20	NMOD
22	are	be	B-VP	VBP	O	21	SBAR
23	of	of	B-PP	IN	O	22	PRD
24	comparable	comparable	B-NP	JJ	O	25	NMOD
25	magnitude	magnitude	I-NP	NN	O	23	PMOD
26	on	on	B-PP	IN	O	22	VMOD
27	both	both	B-NP	DT	O	28	NMOD
28	sides	side	I-NP	NNS	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	brain	brain	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	5	P

1	Brainstem	Brainstem	B-NP	NN	O	2	NMOD
2	dysgenesis	dysgenesis	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	an	an	B-NP	DT	O	5	NMOD
5	infant	infant	I-NP	NN	O	3	PMOD
6	prenatally	prenatally	B-VP	RB	O	7	VMOD
7	exposed	expose	I-VP	VBN	O	5	NMOD
8	to	to	B-PP	TO	O	7	VMOD
9	cocaine	cocaine	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	protective	protective	I-NP	JJ	O	3	NMOD
3	role	role	I-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	Nrf2	Nrf2	B-NP	NN	B-protein	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	streptozotocin	streptozotocin	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	diabetic	diabetic	B-NP	JJ	O	10	NMOD
10	nephropathy	nephropathy	I-NP	NN	O	8	OBJ
11	.	.	O	.	O	8	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	4	NMOD
2	:	:	O	:	O	1	P
3	Diabetic	Diabetic	B-NP	JJ	O	4	NMOD
4	nephropathy	nephropathy	I-NP	NN	O	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	one	one	B-NP	CD	O	5	PRD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	major	major	I-NP	JJ	O	10	NMOD
10	causes	cause	I-NP	NNS	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	renal	renal	B-NP	JJ	O	13	NMOD
13	failure	failure	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	6	P
15	which	which	B-NP	WDT	O	6	NMOD
16	is	be	B-VP	VBZ	O	15	SBAR
17	accompanied	accompany	I-VP	VBN	O	16	VC
18	by	by	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	production	production	I-NP	NN	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	reactive	reactive	B-NP	JJ	O	24	NMOD
23	oxygen	oxygen	I-NP	NN	O	24	NMOD
24	species	specie	I-NP	NNS	O	21	PMOD
25	(	(	O	(	O	27	DEP
26	ROS	ROS	B-NP	NNS	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	.	.	O	.	O	5	P

1	RESEARCH	RESEARCH	B-NP	NN	O	4	NMOD
2	DESIGN	DESIGN	I-NP	NN	O	4	NMOD
3	AND	AND	I-NP	CC	O	4	NMOD
4	METHODS	METHODS	I-NP	NNS	O	0	ROOT
5	:	:	O	:	O	4	P
6	We	We	B-NP	PRP	O	7	SUB
7	explore	explore	B-VP	VBP	O	4	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	protective	protective	I-NP	JJ	O	10	NMOD
10	role	role	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	Nrf2	Nrf2	B-NP	NN	B-protein	11	PMOD
13	against	against	B-PP	IN	O	10	NMOD
14	diabetic	diabetic	B-NP	JJ	O	15	NMOD
15	nephropathy	nephropathy	I-NP	NN	O	13	PMOD
16	using	use	B-VP	VBG	O	10	NMOD
17	human	human	B-NP	JJ	O	20	NMOD
18	kidney	kidney	I-NP	NN	O	20	NMOD
19	biopsy	biopsy	I-NP	NN	O	20	NMOD
20	tissues	tissue	I-NP	NNS	O	16	OBJ
21	from	from	B-PP	IN	O	20	NMOD
22	diabetic	diabetic	B-NP	JJ	O	24	NMOD
23	nephropathy	nephropathy	I-NP	NN	O	24	NMOD
24	patients	patient	I-NP	NNS	O	21	PMOD
25	,	,	O	,	O	7	P
26	a	a	B-NP	DT	O	27	NMOD
27	streptozotocin	streptozotocin	I-NP	NN	O	31	NMOD
28	induced	induce	B-VP	VBD	O	27	AMOD
29	diabetic	diabetic	B-NP	JJ	O	31	NMOD
30	nephropathy	nephropathy	I-NP	NN	O	31	NMOD
31	model	model	I-NP	NN	O	43	NMOD
32	in	in	B-PP	IN	O	31	NMOD
33	Nrf2	Nrf2	B-NP	NN	B-protein	37	NMOD
34	(	(	O	(	O	36	DEP
35	-/-	-/-	O	JJ	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	mice	mouse	B-NP	NNS	O	32	PMOD
38	,	,	O	,	O	31	P
39	and	and	O	CC	O	43	NMOD
40	cultured	culture	B-VP	VBN	B-cell_line	43	NMOD
41	human	human	B-NP	JJ	I-cell_line	43	NMOD
42	mesangial	mesangial	I-NP	JJ	I-cell_line	43	NMOD
43	cells	cell	I-NP	NNS	I-cell_line	7	VMOD
44	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	7	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	animal	animal	I-NP	NN	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	7	P
6	Nrf2	Nrf2	B-NP	NN	B-protein	7	SUB
7	was	be	B-VP	VBD	O	0	ROOT
8	demonstrated	demonstrate	I-VP	VBN	O	7	VC
9	to	to	I-VP	TO	O	10	VMOD
10	be	be	I-VP	VB	O	8	VMOD
11	crucial	crucial	B-ADJP	JJ	O	10	PRD
12	in	in	B-PP	IN	O	11	AMOD
13	ameliorating	ameliorate	B-VP	VBG	O	12	PMOD
14	streptozotocin	streptozotocin	B-NP	NN	B-protein	13	OBJ
15	induced	induce	B-VP	VBD	O	7	VMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	damage	damage	I-NP	NN	O	15	OBJ
18	.	.	O	.	O	7	P

1	High-dose	High-dose	B-NP	JJ	O	3	NMOD
2	tranexamic	tranexamic	I-NP	JJ	O	3	NMOD
3	Acid	Acid	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	nonischemic	nonischemic	B-NP	JJ	O	9	NMOD
8	clinical	clinical	I-NP	JJ	O	9	NMOD
9	seizures	seizure	I-NP	NNS	O	6	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	cardiac	cardiac	B-NP	JJ	O	13	NMOD
12	surgical	surgical	I-NP	JJ	O	13	NMOD
13	patients	patient	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	review	review	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	perform	perform	I-VP	VB	O	6	PRD
9	a	a	B-NP	DT	O	11	NMOD
10	retrospective	retrospective	I-NP	JJ	O	11	NMOD
11	analysis	analysis	I-NP	NN	O	8	OBJ
12	to	to	B-VP	TO	O	13	VMOD
13	examine	examine	I-VP	VB	O	8	VMOD
14	whether	whether	B-SBAR	IN	O	13	VMOD
15	there	there	B-NP	EX	O	16	SUB
16	was	be	B-VP	VBD	O	14	SBAR
17	a	a	B-NP	DT	O	18	NMOD
18	relation	relation	I-NP	NN	O	16	PRD
19	between	between	B-PP	IN	O	18	NMOD
20	TXA	TXA	B-NP	NN	O	21	NMOD
21	usage	usage	I-NP	NN	O	23	NMOD
22	and	and	O	CC	O	23	NMOD
23	seizures	seizure	B-NP	NNS	O	19	PMOD
24	after	after	B-PP	IN	O	23	NMOD
25	cardiac	cardiac	B-NP	JJ	O	26	NMOD
26	surgery	surgery	I-NP	NN	O	24	PMOD
27	.	.	O	.	O	6	P

1	All	All	B-NP	DT	O	3	NMOD
2	24	24	I-NP	CD	O	3	NMOD
3	patients	patient	I-NP	NNS	O	6	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	seizures	seizure	B-NP	NNS	O	4	PMOD
6	received	receive	B-VP	VBD	O	29	VMOD
7	high	high	B-NP	JJ	O	8	NMOD
8	doses	dose	I-NP	NNS	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	TXA	TXA	B-NP	NN	B-protein	9	PMOD
11	intraoperatively	intraoperatively	B-VP	RB	O	12	VMOD
12	ranging	range	I-VP	VBG	O	8	NMOD
13	from	from	B-PP	IN	O	12	VMOD
14	61	61	B-NP	CD	O	13	AMOD
15	to	to	I-NP	TO	O	13	PMOD
16	259	259	I-NP	CD	O	15	PMOD
17	mg/kg	mg/kg	I-NP	NN	O	13	PMOD
18	,	,	O	,	O	6	P
19	had	have	B-VP	VBD	O	6	VMOD
20	a	a	B-NP	DT	O	22	NMOD
21	mean	mean	I-NP	JJ	O	22	NMOD
22	age	age	I-NP	NN	O	19	OBJ
23	of	of	B-PP	IN	O	22	NMOD
24	69.9	69.9	B-NP	CD	O	25	NMOD
25	years	year	I-NP	NNS	O	23	PMOD
26	,	,	O	,	O	29	P
27	and	and	O	CC	O	29	NMOD
28	21	21	B-NP	CD	O	29	AMOD
29	of	of	B-PP	IN	O	0	ROOT
30	24	24	B-NP	CD	O	29	AMOD
31	had	have	B-VP	VBD	O	29	VMOD
32	undergone	undergo	I-VP	VBN	O	31	VC
33	open	open	B-NP	JJ	O	34	NMOD
34	chamber	chamber	I-NP	NN	O	32	OBJ
35	rather	rather	B-PP	RB	O	39	NMOD
36	than	than	I-PP	IN	O	35	DEP
37	coronary	coronary	B-NP	JJ	O	39	NMOD
38	bypass	bypass	I-NP	NN	O	39	NMOD
39	procedures	procedure	I-NP	NNS	O	32	VMOD
40	.	.	O	.	O	29	P

1	Recurrent	Recurrent	B-NP	JJ	O	2	NMOD
2	dysosmia	dysosmia	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	pyrazinamide	pyrazinamide	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	Pyrazinamide	Pyrazinamide	B-NP	NN	O	2	SUB
2	can	can	B-VP	MD	O	0	ROOT
3	have	have	I-VP	VB	O	2	VC
4	adverse	adverse	B-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	3	OBJ
6	such	such	B-PP	JJ	O	7	PMOD
7	as	as	I-PP	IN	O	5	NMOD
8	hepatic	hepatic	B-NP	JJ	O	9	NMOD
9	toxicity	toxicity	I-NP	NN	O	14	NMOD
10	,	,	O	,	O	14	P
11	hyperuricemia	hyperuricemia	B-NP	NN	O	14	NMOD
12	or	or	O	CC	O	14	NMOD
13	digestive	digestive	B-NP	JJ	O	14	NMOD
14	disorders	disorder	I-NP	NNS	O	7	PMOD
15	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	reversible	reversible	B-NP	JJ	O	8	NMOD
7	olfactory	olfactory	I-NP	JJ	O	8	NMOD
8	disorder	disorder	I-NP	NN	O	5	PMOD
9	related	relate	B-VP	VBN	O	8	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	pyrazinamide	pyrazinamide	B-NP	NN	O	10	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	a	a	B-NP	DT	O	14	NMOD
14	woman	woman	I-NP	NN	O	12	PMOD
15	,	,	O	,	O	2	P
16	with	with	B-PP	IN	O	2	VMOD
17	a	a	B-NP	DT	O	19	NMOD
18	positive	positive	I-NP	JJ	O	19	NMOD
19	rechallenge	rechallenge	I-NP	NN	O	16	PMOD
20	.	.	O	.	O	2	P

1	Longitudinal	Longitudinal	B-NP	JJ	O	2	NMOD
2	assessment	assessment	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	air	air	B-NP	NN	O	6	NMOD
5	conduction	conduction	I-NP	NN	O	6	NMOD
6	audiograms	audiogram	I-NP	NNS	O	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	a	a	B-NP	DT	O	12	NMOD
9	phase	phase	I-NP	NN	O	12	NMOD
10	III	III	I-NP	CD	O	12	NMOD
11	clinical	clinical	I-NP	JJ	O	12	NMOD
12	trial	trial	I-NP	NN	O	7	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	difluoromethylornithine	difluoromethylornithine	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	sulindac	sulindac	I-NP	NN	O	13	PMOD
17	for	for	B-PP	IN	O	12	NMOD
18	prevention	prevention	B-NP	NN	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	sporadic	sporadic	B-NP	JJ	O	22	NMOD
21	colorectal	colorectal	I-NP	JJ	O	22	NMOD
22	adenomas	adenoma	I-NP	NNS	O	19	PMOD
23	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	5	NMOD
2	phase	phase	I-NP	NN	O	5	NMOD
3	III	III	I-NP	CD	O	5	NMOD
4	clinical	clinical	I-NP	JJ	O	5	NMOD
5	trial	trial	I-NP	NN	O	6	SUB
6	assessed	assess	B-VP	VBD	O	0	ROOT
7	the	the	B-NP	DT	O	8	NMOD
8	recurrence	recurrence	I-NP	NN	O	6	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	adenomatous	adenomatous	B-NP	JJ	O	11	NMOD
11	polyps	polyp	I-NP	NNS	O	9	PMOD
12	after	after	B-PP	IN	O	6	VMOD
13	treatment	treatment	B-NP	NN	O	12	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	36	36	B-NP	CD	O	16	NMOD
16	months	month	I-NP	NNS	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	difluoromethylornithine	difluoromethylornithine	B-NP	NN	O	23	NMOD
19	(	(	O	(	O	21	DEP
20	DFMO	DFMO	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	plus	plus	O	CC	O	23	NMOD
23	sulindac	sulindac	B-NP	NN	O	26	NMOD
24	or	or	O	CC	O	26	NMOD
25	matched	match	B-NP	VBN	O	26	NMOD
26	placebos	placebo	I-NP	NNS	O	17	PMOD
27	.	.	O	.	O	6	P

1	Temporary	Temporary	B-NP	JJ	O	3	NMOD
2	hearing	hearing	I-NP	NN	O	3	NMOD
3	loss	loss	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	17	VMOD
5	a	a	B-NP	DT	O	7	NMOD
6	known	known	I-NP	JJ	O	7	NMOD
7	toxicity	toxicity	I-NP	NN	O	4	PRD
8	of	of	B-PP	IN	O	7	NMOD
9	treatment	treatment	B-NP	NN	O	8	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	DFMO	DFMO	B-NP	NN	O	10	PMOD
12	,	,	O	,	O	17	P
13	thus	thus	B-ADVP	RB	O	17	VMOD
14	a	a	B-NP	DT	O	16	NMOD
15	comprehensive	comprehensive	I-NP	JJ	O	16	NMOD
16	approach	approach	I-NP	NN	O	17	SUB
17	was	be	B-VP	VBD	O	0	ROOT
18	developed	develop	I-VP	VBN	O	17	VC
19	to	to	I-VP	TO	O	20	VMOD
20	analyze	analyze	I-VP	VB	O	18	VMOD
21	serial	serial	B-NP	JJ	O	24	NMOD
22	air	air	I-NP	NN	O	24	NMOD
23	conduction	conduction	I-NP	NN	O	24	NMOD
24	audiograms	audiogram	I-NP	NNS	O	20	OBJ
25	.	.	O	.	O	17	P

1	There	There	B-NP	EX	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	5	NMOD
4	significant	significant	I-NP	JJ	O	5	NMOD
5	difference	difference	I-NP	NN	O	2	PRD
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	proportion	proportion	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	subjects	subject	B-NP	NNS	O	9	PMOD
11	in	in	B-PP	IN	O	2	VMOD
12	the	the	B-NP	DT	O	16	NMOD
13	DFMO	DFMO	I-NP	NN	B-DNA	16	NMOD
14	plus	plus	I-NP	CC	O	16	NMOD
15	sulindac	sulindac	I-NP	NN	O	16	NMOD
16	group	group	I-NP	NN	O	11	PMOD
17	who	who	B-NP	WP	O	16	NMOD
18	experienced	experience	B-VP	VBD	O	17	SBAR
19	clinically	clinically	B-NP	RB	O	20	AMOD
20	significant	significant	I-NP	JJ	O	22	NMOD
21	hearing	hearing	I-NP	NN	O	22	NMOD
22	loss	loss	I-NP	NN	O	18	OBJ
23	compared	compare	B-VP	VBN	O	2	VMOD
24	with	with	B-PP	IN	O	23	VMOD
25	the	the	B-NP	DT	O	27	NMOD
26	placebo	placebo	I-NP	NN	O	27	NMOD
27	group	group	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	2	P

1	Increased	Increase	B-NP	VBN	O	3	NMOD
2	mental	mental	I-NP	JJ	O	3	NMOD
3	slowing	slowing	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	9	NMOD
7	APOE	APOE	I-NP	NN	B-DNA	9	NMOD
8	epsilon4	epsilon4	I-NP	NN	I-DNA	9	NMOD
9	allele	allele	I-NP	NN	I-DNA	5	PMOD
10	after	after	B-PP	IN	O	9	NMOD
11	trihexyphenidyl	trihexyphenidyl	B-NP	NN	O	14	NMOD
12	oral	oral	I-NP	JJ	O	14	NMOD
13	anticholinergic	anticholinergic	I-NP	JJ	O	14	NMOD
14	challenge	challenge	I-NP	NN	O	10	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	healthy	healthy	B-NP	JJ	O	17	NMOD
17	elderly	elderly	I-NP	JJ	O	15	PMOD
18	.	.	O	.	O	3	P

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	8	VMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	objectives	objective	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	were	be	B-VP	VBD	O	0	ROOT
9	to	to	I-VP	TO	O	10	VMOD
10	examine	examine	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	12	NMOD
12	relationship	relationship	I-NP	NN	O	10	OBJ
13	between	between	B-PP	IN	O	12	NMOD
14	APOE	APOE	B-NP	NN	B-protein	15	NMOD
15	epsilon4	epsilon4	I-NP	NN	I-protein	18	NMOD
16	and	and	O	CC	O	18	NMOD
17	subjective	subjective	B-NP	JJ	O	18	NMOD
18	effects	effect	I-NP	NNS	O	13	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	trihexyphenidyl	trihexyphenidyl	B-NP	NN	O	19	PMOD
21	on	on	B-PP	IN	O	18	NMOD
22	measures	measure	B-NP	NNS	O	21	PMOD
23	reflecting	reflect	B-VP	VBG	O	22	NMOD
24	sedation	sedation	B-NP	NN	O	26	NMOD
25	and	and	I-NP	CC	O	26	NMOD
26	confusion	confusion	I-NP	NN	O	23	OBJ
27	and	and	O	CC	O	10	VMOD
28	to	to	B-VP	TO	O	29	VMOD
29	investigate	investigate	I-VP	VB	O	10	VMOD
30	the	the	B-NP	DT	O	31	NMOD
31	relationship	relationship	I-NP	NN	O	34	SUB
32	between	between	B-PP	IN	O	31	NMOD
33	trihexyphenidyl	trihexyphenidyl	B-NP	NN	O	32	PMOD
34	induced	induce	B-VP	VBD	O	29	VMOD
35	subjective	subjective	B-NP	JJ	O	36	NMOD
36	effects	effect	I-NP	NNS	O	40	NMOD
37	and	and	O	CC	O	40	NMOD
38	objective	objective	B-NP	JJ	O	40	NMOD
39	memory	memory	I-NP	NN	O	40	NMOD
40	performance	performance	I-NP	NN	O	34	OBJ
41	.	.	O	.	O	8	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	6	NMOD
4	2.0-mg	2.0-mg	I-NP	JJ	O	6	NMOD
5	oral	oral	I-NP	JJ	O	6	NMOD
6	dose	dose	I-NP	NN	O	9	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	trihexyphenidyl	trihexyphenidyl	B-NP	NN	O	7	PMOD
9	resulted	result	B-VP	VBD	O	1	NMOD
10	in	in	B-PP	IN	O	9	VMOD
11	increased	increase	B-NP	VBN	O	13	NMOD
12	subjective	subjective	I-NP	JJ	O	13	NMOD
13	ratings	rating	I-NP	NNS	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	mental	mental	B-NP	JJ	O	16	NMOD
16	slowness	slowness	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	13	NMOD
18	carriers	carrier	B-NP	NNS	O	17	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	23	NMOD
21	APOE	APOE	I-NP	NN	B-DNA	23	NMOD
22	epsilon4	epsilon4	I-NP	NN	I-DNA	23	NMOD
23	allele	allele	I-NP	NN	I-DNA	19	PMOD
24	only	only	B-ADVP	RB	O	13	NMOD
25	.	.	O	.	O	1	P

1	Drug	Drug	B-NP	NN	O	2	NMOD
2	effects	effect	I-NP	NNS	O	0	ROOT
3	as	as	B-SBAR	IN	O	2	NMOD
4	determined	determine	B-VP	VBN	O	3	SBAR
5	by	by	B-PP	IN	O	4	VMOD
6	difference	difference	B-NP	NN	O	7	NMOD
7	scores	score	I-NP	NNS	O	5	PMOD
8	between	between	B-PP	IN	O	7	NMOD
9	2.0	2.0	B-NP	CD	O	10	AMOD
10	mg	mg	I-NP	NN	O	11	NMOD
11	trihexyphenidyl	trihexyphenidyl	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	placebo	placebo	I-NP	NN	O	8	PMOD
14	on	on	B-PP	IN	O	4	VMOD
15	ratings	rating	B-NP	NNS	O	14	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	mental	mental	B-NP	JJ	O	18	NMOD
18	slowness	slowness	I-NP	NN	O	16	PMOD
19	significantly	significantly	B-VP	RB	O	20	VMOD
20	correlated	correlate	I-VP	VBD	O	15	NMOD
21	with	with	B-PP	IN	O	20	VMOD
22	total	total	B-NP	JJ	O	25	NMOD
23	and	and	I-NP	CC	O	25	NMOD
24	delayed	delay	I-NP	VBN	O	25	NMOD
25	recall	recall	I-NP	NN	O	21	PMOD
26	on	on	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	31	NMOD
28	Buschke	Buschke	I-NP	NNP	O	31	NMOD
29	Selective	Selective	I-NP	NNP	O	31	NMOD
30	Reminding	Reminding	I-NP	NNP	O	31	NMOD
31	Test	Test	I-NP	NNP	O	26	PMOD
32	in	in	B-PP	IN	O	31	NMOD
33	carriers	carrier	B-NP	NNS	O	32	PMOD
34	of	of	B-PP	IN	O	33	NMOD
35	the	the	B-NP	DT	O	38	NMOD
36	APOE	APOE	I-NP	NN	B-DNA	38	NMOD
37	epsilon4	epsilon4	I-NP	NN	I-DNA	38	NMOD
38	allele	allele	I-NP	NN	I-DNA	34	PMOD
39	only	only	B-ADVP	RB	O	25	NMOD
40	.	.	O	.	O	2	P

1	Chronic	Chronic	B-NP	JJ	O	2	NMOD
2	exposure	exposure	I-NP	NN	O	7	SUB
3	to	to	B-PP	TO	O	2	NMOD
4	PCPA	PCPA	B-NP	NN	B-protein	3	PMOD
5	alone	alone	B-ADVP	RB	O	2	NMOD
6	significantly	significantly	B-VP	RB	O	5	AMOD
7	decreased	decrease	I-VP	VBD	O	0	ROOT
8	locomotor	locomotor	B-NP	NN	O	9	NMOD
9	activity	activity	I-NP	NN	O	7	OBJ
10	and	and	O	CC	O	7	VMOD
11	increased	increase	B-VP	VBD	O	7	VMOD
12	irritability	irritability	B-NP	NN	O	11	OBJ
13	but	but	O	CC	O	7	VMOD
14	had	have	B-VP	VBD	O	7	VMOD
15	no	no	B-NP	DT	O	16	NMOD
16	effect	effect	I-NP	NN	O	14	OBJ
17	on	on	B-PP	IN	O	14	VMOD
18	sexual	sexual	B-NP	JJ	O	19	NMOD
19	behavior	behavior	I-NP	NN	O	17	PMOD
20	,	,	O	,	O	7	P
21	partner	partner	B-NP	NN	O	22	NMOD
22	preference	preference	I-NP	NN	O	25	NMOD
23	,	,	O	,	O	25	P
24	or	or	O	CC	O	25	NMOD
25	aggression	aggression	B-NP	NN	O	7	VMOD
26	.	.	O	.	O	7	P

1	T	T	B-NP	NN	O	3	SUB
2	alone	alone	B-ADVP	RB	O	1	NMOD
3	had	have	B-VP	VBD	O	0	ROOT
4	no	no	B-NP	DT	O	5	NMOD
5	effect	effect	I-NP	NN	O	3	OBJ
6	on	on	B-PP	IN	O	3	VMOD
7	locomotion	locomotion	B-NP	NN	O	13	NMOD
8	,	,	O	,	O	13	P
9	irritability	irritability	B-NP	NN	O	13	NMOD
10	,	,	O	,	O	13	P
11	or	or	O	CC	O	13	NMOD
12	sexual	sexual	B-NP	JJ	O	13	NMOD
13	behavior	behavior	I-NP	NN	O	6	PMOD
14	but	but	O	CC	O	3	VMOD
15	increased	increase	B-VP	VBD	O	3	VMOD
16	partner	partner	B-NP	NN	O	17	NMOD
17	preference	preference	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	aggression	aggression	I-NP	NN	O	15	OBJ
20	.	.	O	.	O	3	P

1	Intracavitary	Intracavitary	B-NP	JJ	O	2	NMOD
2	chemotherapy	chemotherapy	I-NP	NN	O	15	NMOD
3	(	(	O	(	O	9	DEP
4	paclitaxel/carboplatin	paclitaxel/carboplatin	B-NP	NN	O	8	NMOD
5	liquid	liquid	I-NP	NN	O	8	NMOD
6	crystalline	crystalline	I-NP	NN	O	8	NMOD
7	cubic	cubic	I-NP	JJ	O	8	NMOD
8	phases	phase	I-NP	NNS	O	9	DEP
9	)	)	O	)	O	2	NMOD
10	for	for	B-PP	IN	O	2	NMOD
11	recurrent	recurrent	B-NP	JJ	O	12	NMOD
12	glioblastoma	glioblastoma	I-NP	NN	O	10	PMOD
13	--	--	O	:	O	2	P
14	clinical	clinical	B-NP	JJ	O	15	NMOD
15	observations	observation	I-NP	NNS	O	0	ROOT
16	.	.	O	.	O	15	P

1	For	For	B-PP	IN	O	29	VMOD
2	human	human	B-NP	JJ	O	4	NMOD
3	glioblastoma	glioblastoma	I-NP	NN	O	4	NMOD
4	recurrences	recurrence	I-NP	NNS	O	1	PMOD
5	,	,	O	,	O	29	P
6	the	the	B-NP	DT	O	7	NMOD
7	feasibility	feasibility	I-NP	NN	O	13	NMOD
8	,	,	O	,	O	13	P
9	safety	safety	B-NP	NN	O	13	NMOD
10	,	,	O	,	O	13	P
11	and	and	O	CC	O	13	NMOD
12	short-term	short-term	B-NP	JJ	O	13	NMOD
13	effects	effect	I-NP	NNS	O	29	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	a	a	B-NP	DT	O	18	NMOD
16	surgical	surgical	I-NP	JJ	O	18	NMOD
17	intracavitary	intracavitary	I-NP	JJ	O	18	NMOD
18	application	application	I-NP	NN	O	14	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	paclitaxel	paclitaxel	B-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	carboplatin	carboplatin	I-NP	NN	O	19	PMOD
23	encapsulated	encapsulate	B-VP	VBN	O	22	NMOD
24	by	by	B-PP	IN	O	23	VMOD
25	liquid	liquid	B-NP	JJ	O	28	NMOD
26	crystalline	crystalline	I-NP	NN	O	28	NMOD
27	cubic	cubic	I-NP	JJ	O	28	NMOD
28	phases	phase	I-NP	NNS	O	24	PMOD
29	are	be	B-VP	VBP	O	0	ROOT
30	examined	examine	I-VP	VBN	O	29	VC
31	in	in	B-PP	IN	O	30	VMOD
32	a	a	B-NP	DT	O	34	NMOD
33	pilot	pilot	I-NP	NN	O	34	NMOD
34	study	study	I-NP	NN	O	31	PMOD
35	.	.	O	.	O	29	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	13	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	12	12	B-NP	CD	O	5	NMOD
5	patients	patient	I-NP	NNS	O	3	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	recurrence	recurrence	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	a	a	B-NP	DT	O	12	NMOD
11	glioblastoma	glioblastoma	I-NP	NN	B-protein	12	NMOD
12	multiforme	multiforme	I-NP	NN	I-protein	9	PMOD
13	underwent	undergo	B-VP	VBD	O	0	ROOT
14	re-resection	re-resection	B-NP	NN	O	13	OBJ
15	and	and	O	CC	O	13	VMOD
16	received	receive	B-VP	VBD	O	13	VMOD
17	an	an	B-NP	DT	O	19	NMOD
18	intracavitary	intracavitary	I-NP	JJ	O	19	NMOD
19	application	application	I-NP	NN	O	16	OBJ
20	of	of	B-PP	IN	O	19	NMOD
21	paclitaxel	paclitaxel	B-NP	NN	O	25	NMOD
22	and	and	O	CC	O	25	NMOD
23	carboplatin	carboplatin	B-NP	NN	O	25	NMOD
24	cubic	cubic	I-NP	JJ	O	25	NMOD
25	phases	phase	I-NP	NNS	O	20	PMOD
26	in	in	B-PP	IN	O	16	VMOD
27	different	different	B-NP	JJ	O	28	NMOD
28	dosages	dosage	I-NP	NNS	O	26	PMOD
29	.	.	O	.	O	13	P

1	Six	Six	B-NP	CD	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	PMOD
5	received	receive	B-VP	VBD	O	0	ROOT
6	more	more	B-NP	JJR	O	7	AMOD
7	than	than	I-NP	IN	O	5	VMOD
8	15	15	I-NP	CD	O	7	AMOD
9	mg	mg	I-NP	NN	O	10	NMOD
10	paclitaxel	paclitaxel	I-NP	NN	O	7	PMOD
11	and	and	O	CC	O	5	VMOD
12	suffered	suffer	B-VP	VBD	O	5	VMOD
13	from	from	B-PP	IN	O	12	VMOD
14	moderate	moderate	B-ADJP	JJ	O	13	PMOD
15	to	to	B-PP	TO	O	13	PMOD
16	severe	severe	B-NP	JJ	O	15	PMOD
17	brain	brain	I-NP	NN	O	15	PMOD
18	edema	edema	I-NP	NN	O	13	PMOD
19	,	,	O	,	O	5	P
20	while	while	B-SBAR	IN	O	5	VMOD
21	the	the	B-NP	DT	O	23	NMOD
22	remaining	remain	I-NP	VBG	O	23	NMOD
23	patients	patient	I-NP	NNS	O	24	SUB
24	received	receive	B-VP	VBD	O	20	SBAR
25	only	only	B-NP	RB	O	27	NMOD
26	a	a	I-NP	DT	O	27	NMOD
27	total	total	I-NP	NN	O	24	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	15	15	B-NP	CD	O	30	AMOD
30	mg	mg	I-NP	NN	O	31	NMOD
31	paclitaxel	paclitaxel	I-NP	NN	O	28	PMOD
32	.	.	O	.	O	5	P

1	Methylphenidate	Methylphenidate	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	obsessive-compulsive	obsessive-compulsive	B-NP	JJ	O	4	NMOD
4	symptoms	symptom	I-NP	NNS	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	an	an	B-NP	DT	O	8	NMOD
7	elderly	elderly	I-NP	JJ	O	8	NMOD
8	man	man	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	An	An	B-NP	DT	O	3	NMOD
2	82-year-old	82-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	11	NMOD
4	with	with	B-PP	IN	O	3	NMOD
5	treatment-resistant	treatment-resistant	B-NP	JJ	O	6	NMOD
6	depression	depression	I-NP	NN	O	4	PMOD
7	and	and	O	CC	O	11	NMOD
8	early	early	B-NP	JJ	O	11	NMOD
9	Alzheimer	Alzheimer	I-NP	NNP	O	11	NMOD
10	's	's	B-NP	POS	O	11	NMOD
11	disease	disease	I-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	0	ROOT
13	started	start	I-VP	VBN	O	12	VC
14	on	on	B-PP	IN	O	13	VMOD
15	methylphenidate	methylphenidate	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	12	P

1	Significant	Significant	B-NP	JJ	O	3	NMOD
2	obsessive-compulsive	obsessive-compulsive	I-NP	JJ	O	3	NMOD
3	behavior	behavior	I-NP	NN	O	4	SUB
4	ensued	ensue	B-VP	VBD	O	0	ROOT
5	but	but	I-VP	CC	O	4	VMOD
6	diminished	diminish	I-VP	VBD	O	4	VMOD
7	over	over	B-PP	IN	O	6	VMOD
8	several	several	B-NP	JJ	O	9	NMOD
9	weeks	week	I-NP	NNS	O	7	PMOD
10	when	when	B-ADVP	WRB	O	6	VMOD
11	methylphenidate	methylphenidate	B-NP	NN	O	12	SUB
12	was	be	B-VP	VBD	O	10	SBAR
13	replaced	replace	I-VP	VBN	O	12	VC
14	by	by	B-PP	IN	O	13	VMOD
15	fluvoxamine	fluvoxamine	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	4	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	arrest	arrest	I-NP	NN	O	0	ROOT
3	after	after	B-PP	IN	O	2	NMOD
4	intravenous	intravenous	B-NP	JJ	O	5	NMOD
5	metoclopramide	metoclopramide	I-NP	NN	O	8	NMOD
6	-	-	O	HYPH	O	8	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	case	case	I-NP	NN	O	3	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	five	five	B-NP	CD	O	12	NMOD
11	repeated	repeat	I-NP	VBN	O	12	NMOD
12	injections	injection	I-NP	NNS	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	metoclopramide	metoclopramide	B-NP	NN	O	13	PMOD
15	causing	cause	B-VP	VBG	O	14	NMOD
16	five	five	B-NP	CD	O	17	NMOD
17	episodes	episode	I-NP	NNS	O	15	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	cardiac	cardiac	B-NP	JJ	O	20	NMOD
20	arrest	arrest	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	patient	patient	I-NP	NN	O	2	OBJ
5	where	where	B-ADVP	WRB	O	4	NMOD
6	intravenous	intravenous	B-NP	JJ	O	7	NMOD
7	injection	injection	I-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	metoclopramide	metoclopramide	B-NP	NN	O	8	PMOD
10	was	be	B-VP	VBD	O	5	SBAR
11	immediately	immediately	I-VP	RB	O	10	VMOD
12	followed	follow	I-VP	VBN	O	10	VC
13	by	by	B-PP	IN	O	12	VMOD
14	asystole	asystole	B-NP	NN	O	13	PMOD
15	repeatedly	repeatedly	B-ADVP	RB	O	14	NMOD
16	.	.	O	.	O	2	P

1	After	After	B-PP	IN	O	13	VMOD
2	interviewing	interview	B-VP	VBG	O	1	PMOD
3	the	the	B-NP	DT	O	5	NMOD
4	attending	attend	I-NP	VBG	O	5	NMOD
5	nurses	nurse	I-NP	NNS	O	2	OBJ
6	and	and	O	CC	O	2	VMOD
7	reviewing	review	B-VP	VBG	O	2	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	written	write	I-NP	VBN	O	10	NMOD
10	documentation	documentation	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	13	P
12	it	it	B-NP	PRP	O	13	SUB
13	is	be	B-VP	VBZ	O	0	ROOT
14	clear	clear	B-ADJP	JJ	O	13	PRD
15	that	that	B-SBAR	IN	O	13	VMOD
16	every	every	B-NP	DT	O	17	NMOD
17	administration	administration	I-NP	NN	O	20	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	metoclopramide	metoclopramide	B-NP	NN	O	18	PMOD
20	was	be	B-VP	VBD	O	15	SBAR
21	immediately	immediately	B-ADVP	RB	O	20	VMOD
22	(	(	O	(	O	25	DEP
23	within	within	B-PP	IN	O	25	DEP
24	s	s	B-NP	NNS	O	23	PMOD
25	)	)	O	)	O	21	AMOD
26	followed	follow	B-VP	VBN	O	20	VMOD
27	by	by	B-PP	IN	O	26	VMOD
28	asystole	asystole	B-NP	NN	O	27	PMOD
29	.	.	O	.	O	13	P

1	We	We	B-NP	PRP	O	2	SUB
2	interpret	interpret	B-VP	VBP	O	0	ROOT
3	this	this	B-NP	DT	O	2	OBJ
4	as	as	B-PP	IN	O	3	NMOD
5	episodes	episode	B-NP	NNS	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	cardiac	cardiac	B-NP	JJ	O	8	NMOD
8	arrest	arrest	I-NP	NN	O	6	PMOD
9	caused	cause	B-VP	VBN	O	8	NMOD
10	by	by	B-PP	IN	O	9	VMOD
11	metoclopramide	metoclopramide	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	2	P

1	Severe	Severe	B-NP	JJ	O	3	AMOD
2	immune	immune	I-NP	JJ	O	3	AMOD
3	hemolytic	hemolytic	I-NP	JJ	O	4	NMOD
4	anemia	anemia	I-NP	NN	O	0	ROOT
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	prophylactic	prophylactic	B-NP	JJ	O	8	NMOD
8	use	use	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cefotetan	cefotetan	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	obstetric	obstetric	B-NP	JJ	O	15	NMOD
13	and	and	I-NP	CC	O	15	NMOD
14	gynecologic	gynecologic	I-NP	JJ	O	15	NMOD
15	procedures	procedure	I-NP	NNS	O	11	PMOD
16	.	.	O	.	O	4	P

1	Second-	Second-	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	third-generation	third-generation	I-NP	JJ	O	4	NMOD
4	cephalosporins	cephalosporin	I-NP	NNS	O	7	NMOD
5	,	,	O	,	O	7	P
6	especially	especially	B-NP	RB	O	7	NMOD
7	cefotetan	cefotetan	I-NP	NN	O	9	SUB
8	,	,	O	,	O	7	P
9	are	be	B-VP	VBP	O	0	ROOT
10	increasingly	increasingly	I-VP	RB	O	9	VMOD
11	associated	associate	I-VP	VBN	O	9	VC
12	with	with	B-PP	IN	O	11	VMOD
13	severe	severe	B-NP	JJ	O	16	AMOD
14	,	,	I-NP	,	O	16	P
15	sometimes	sometimes	I-NP	RB	O	16	AMOD
16	fatal	fatal	I-NP	JJ	O	19	NMOD
17	immune	immune	I-NP	JJ	O	19	NMOD
18	hemolytic	hemolytic	I-NP	JJ	O	19	NMOD
19	anemia	anemia	I-NP	NN	O	12	PMOD
20	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	noticed	notice	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	10	10	B-NP	CD	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	our	our	B-NP	PRP$	O	8	NMOD
7	35	35	I-NP	CD	O	8	NMOD
8	cases	case	I-NP	NNS	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cefotetan	cefotetan	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBD	O	3	SBAR
12	hemolytic	hemolytic	B-NP	JJ	O	13	NMOD
13	anemias	anemia	I-NP	NNS	O	11	OBJ
14	were	be	B-VP	VBD	O	11	VMOD
15	in	in	B-PP	IN	O	14	PRD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	who	who	B-NP	WP	O	16	NMOD
18	had	have	B-VP	VBD	O	17	SBAR
19	received	receive	I-VP	VBN	O	18	VC
20	cefotetan	cefotetan	B-NP	NN	O	19	OBJ
21	prophylactically	prophylactically	B-ADVP	RB	O	19	VMOD
22	for	for	B-PP	IN	O	19	VMOD
23	obstetric	obstetric	B-NP	JJ	O	26	NMOD
24	and	and	I-NP	CC	O	26	NMOD
25	gynecologic	gynecologic	I-NP	JJ	O	26	NMOD
26	procedures	procedure	I-NP	NNS	O	22	PMOD
27	.	.	O	.	O	2	P

1	Cauda	Cauda	B-NP	NNP	O	3	NMOD
2	equina	equina	I-NP	NNP	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	14	NMOD
4	after	after	B-PP	IN	O	3	NMOD
5	spinal	spinal	B-NP	JJ	O	6	NMOD
6	anaesthesia	anaesthesia	I-NP	NN	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	hyperbaric	hyperbaric	B-NP	JJ	O	11	NMOD
9	5	5	I-NP	CD	O	10	AMOD
10	%	%	I-NP	NN	O	11	NMOD
11	lignocaine	lignocaine	I-NP	NN	O	7	PMOD
12	:	:	O	:	O	3	P
13	a	a	B-NP	DT	O	14	NMOD
14	review	review	I-NP	NN	O	0	ROOT
15	of	of	B-PP	IN	O	14	NMOD
16	six	six	B-NP	CD	O	17	NMOD
17	cases	case	I-NP	NNS	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	cauda	cauda	B-NP	NN	O	21	NMOD
20	equina	equina	I-NP	NN	O	21	NMOD
21	syndrome	syndrome	I-NP	NN	O	18	PMOD
22	reported	report	B-VP	VBN	O	17	NMOD
23	to	to	B-PP	TO	O	22	VMOD
24	the	the	B-NP	DT	O	27	NMOD
25	Swedish	Swedish	I-NP	NNP	O	27	NMOD
26	Pharmaceutical	Pharmaceutical	I-NP	NNP	O	27	NMOD
27	Insurance	Insurance	I-NP	NNP	O	23	PMOD
28	1993-1997	1993-1997	I-NP	CD	O	27	NMOD
29	.	.	O	.	O	14	P

1	Three	Three	B-NP	CD	O	5	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	4	NMOD
4	cases	case	I-NP	NNS	O	2	PMOD
5	were	be	B-VP	VBD	O	0	ROOT
6	most	most	I-VP	RBS	O	7	AMOD
7	likely	likely	I-VP	RB	O	8	VMOD
8	caused	cause	I-VP	VBN	O	5	VC
9	by	by	B-PP	IN	O	8	VMOD
10	direct	direct	B-NP	JJ	O	11	NMOD
11	neurotoxicity	neurotoxicity	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	hyperbaric	hyperbaric	B-NP	JJ	O	15	AMOD
14	5	5	I-NP	CD	O	15	AMOD
15	%	%	I-NP	NN	O	16	NMOD
16	lignocaine	lignocaine	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	5	P

1	Cortical	Cortical	B-NP	JJ	O	3	NMOD
2	motor	motor	I-NP	NN	O	3	NMOD
3	overactivation	overactivation	I-NP	NN	O	9	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	parkinsonian	parkinsonian	B-NP	JJ	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	L-dopa	L-dopa	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	0	ROOT
10	peak-dose	peak-dose	B-NP	JJ	O	11	NMOD
11	dyskinesia	dyskinesia	I-NP	NN	O	9	OBJ
12	.	.	O	.	O	9	P

1	We	We	B-NP	PRP	O	2	SUB
2	have	have	B-VP	VBP	O	0	ROOT
3	studied	study	I-VP	VBN	O	2	VC
4	the	the	B-NP	DT	O	8	NMOD
5	regional	regional	I-NP	JJ	O	8	NMOD
6	cerebral	cerebral	I-NP	JJ	O	8	NMOD
7	blood	blood	I-NP	NN	O	8	NMOD
8	flow	flow	I-NP	NN	O	12	NMOD
9	(	(	O	(	O	11	DEP
10	rCBF	rCBF	B-NP	NN	O	11	DEP
11	)	)	O	)	O	8	NMOD
12	changes	change	B-NP	NNS	O	42	NMOD
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	execution	execution	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	a	a	B-NP	DT	O	22	NMOD
19	finger-to-thumb	finger-to-thumb	I-NP	JJ	O	22	NMOD
20	opposition	opposition	I-NP	NN	O	22	NMOD
21	motor	motor	I-NP	NN	O	22	NMOD
22	task	task	I-NP	NN	O	17	PMOD
23	in	in	B-PP	IN	O	13	VMOD
24	the	the	B-NP	DT	O	29	NMOD
25	supplementary	supplementary	I-NP	JJ	O	27	AMOD
26	and	and	I-NP	CC	O	27	AMOD
27	primary	primary	I-NP	JJ	O	29	NMOD
28	motor	motor	I-NP	NN	O	29	NMOD
29	cortex	cortex	I-NP	NN	O	23	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	two	two	B-NP	CD	O	32	NMOD
32	groups	group	I-NP	NNS	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	parkinsonian	parkinsonian	B-NP	JJ	O	35	NMOD
35	patients	patient	I-NP	NNS	O	33	PMOD
36	on	on	B-PP	IN	O	13	VMOD
37	L-dopa	L-dopa	B-NP	NN	O	38	NMOD
38	medication	medication	I-NP	NN	O	36	PMOD
39	,	,	O	,	O	42	P
40	the	the	B-NP	DT	O	42	NMOD
41	first	first	I-NP	JJ	O	42	NMOD
42	one	one	I-NP	NN	O	3	OBJ
43	without	without	B-PP	IN	O	42	NMOD
44	L-dopa	L-dopa	B-NP	NN	B-protein	46	NMOD
45	induced	induce	I-NP	VBN	O	46	NMOD
46	dyskinesia	dyskinesia	I-NP	NN	O	54	NMOD
47	(	(	O	(	O	51	DEP
48	n	n	B-NP	NN	O	50	SUB
49	=	=	B-VP	SYM	O	50	VMOD
50	23	23	B-NP	CD	O	51	DEP
51	)	)	O	)	O	46	NMOD
52	and	and	O	CC	O	54	NMOD
53	the	the	B-NP	DT	O	54	NMOD
54	other	other	I-NP	JJ	O	43	PMOD
55	with	with	B-PP	IN	O	54	NMOD
56	moderate	moderate	B-NP	JJ	O	58	NMOD
57	peak-dose	peak-dose	I-NP	JJ	O	58	NMOD
58	dyskinesia	dyskinesia	I-NP	NN	O	55	PMOD
59	(	(	O	(	O	63	DEP
60	n	n	B-NP	NN	O	63	DEP
61	=	=	B-VP	SYM	O	60	NMOD
62	15	15	B-NP	CD	O	61	AMOD
63	)	)	O	)	O	54	NMOD
64	,	,	O	,	O	42	P
65	and	and	O	CC	O	42	NMOD
66	of	of	B-PP	IN	O	65	DEP
67	a	a	B-NP	DT	O	68	NMOD
68	group	group	I-NP	NN	O	66	PMOD
69	of	of	B-PP	IN	O	68	NMOD
70	14	14	B-NP	CD	O	72	NMOD
71	normal	normal	I-NP	JJ	O	72	NMOD
72	subjects	subject	I-NP	NNS	O	69	PMOD
73	.	.	O	.	O	2	P

1	Dexamethasone	Dexamethasone	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	ocular	ocular	B-NP	JJ	O	4	NMOD
4	hypertension	hypertension	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	4	NMOD
6	perfusion-cultured	perfusion-cultured	B-NP	JJ	O	8	NMOD
7	human	human	I-NP	JJ	O	8	NMOD
8	eyes	eye	I-NP	NNS	O	5	PMOD
9	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	8	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	8	P
4	the	the	B-NP	DT	O	7	NMOD
5	dexamethasone-treated	dexamethasone-treated	I-NP	JJ	O	7	NMOD
6	hypertensive	hypertensive	I-NP	JJ	O	7	NMOD
7	eyes	eye	I-NP	NNS	O	8	SUB
8	had	have	B-VP	VBD	O	0	ROOT
9	thickened	thicken	I-VP	VBN	O	11	NMOD
10	trabecular	trabecular	B-NP	JJ	O	11	NMOD
11	beams	beam	I-NP	NNS	O	8	OBJ
12	,	,	O	,	O	8	P
13	decreased	decrease	B-VP	VBD	O	8	VMOD
14	intertrabecular	intertrabecular	B-NP	JJ	O	15	NMOD
15	spaces	space	I-NP	NNS	O	13	OBJ
16	,	,	O	,	O	8	P
17	thickened	thicken	B-VP	VBD	O	8	VMOD
18	juxtacanalicular	juxtacanalicular	B-NP	JJ	O	19	NMOD
19	tissue	tissue	I-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	activated	activate	B-NP	VBN	B-cell_type	24	NMOD
22	trabecular	trabecular	I-NP	JJ	I-cell_type	24	NMOD
23	meshwork	meshwork	I-NP	NN	I-cell_type	24	NMOD
24	cells	cell	I-NP	NNS	I-cell_type	17	OBJ
25	,	,	O	,	O	28	P
26	and	and	O	CC	O	28	NMOD
27	increased	increase	B-NP	VBN	O	28	NMOD
28	amounts	amount	I-NP	NNS	O	8	VMOD
29	of	of	B-PP	IN	O	28	NMOD
30	amorphogranular	amorphogranular	B-NP	JJ	O	32	NMOD
31	extracellular	extracellular	I-NP	JJ	O	32	NMOD
32	material	material	I-NP	NN	O	29	PMOD
33	,	,	O	,	O	28	P
34	especially	especially	B-ADVP	RB	O	35	PMOD
35	in	in	B-PP	IN	O	28	NMOD
36	the	the	B-NP	DT	O	38	NMOD
37	juxtacanalicular	juxtacanalicular	I-NP	JJ	O	38	NMOD
38	tissue	tissue	I-NP	NN	O	35	PMOD
39	and	and	B-PP	CC	O	35	PMOD
40	beneath	beneath	B-PP	IN	O	28	NMOD
41	the	the	B-NP	DT	O	43	NMOD
42	endothelial	endothelial	I-NP	JJ	O	43	NMOD
43	lining	lining	I-NP	NN	O	40	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	46	NMOD
46	canal	canal	I-NP	NN	O	44	PMOD
47	of	of	B-PP	IN	O	46	NMOD
48	Schlemm	Schlemm	B-NP	NNP	O	47	PMOD
49	.	.	O	.	O	8	P

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Dexamethasone	Dexamethasone	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	11	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	isolated	isolate	B-NP	VBN	O	8	AMOD
7	,	,	I-NP	,	O	8	P
8	perfusion-cultured	perfusion-cultured	I-NP	JJ	O	10	NMOD
9	human	human	I-NP	JJ	O	10	NMOD
10	eyes	eye	I-NP	NNS	O	5	PMOD
11	led	lead	B-VP	VBD	O	1	NMOD
12	to	to	B-PP	TO	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	generation	generation	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	ocular	ocular	B-NP	JJ	O	17	NMOD
17	hypertension	hypertension	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	approximately	approximately	B-NP	RB	O	21	NMOD
20	30	30	I-NP	CD	O	19	AMOD
21	%	%	I-NP	NN	O	18	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	25	NMOD
24	dexamethasone-treated	dexamethasone-treated	I-NP	JJ	O	25	NMOD
25	eyes	eye	I-NP	NNS	O	22	PMOD
26	.	.	O	.	O	1	P

1	Steroid	Steroid	B-NP	NN	O	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	resulted	result	B-VP	VBD	O	0	ROOT
4	in	in	B-PP	IN	O	3	VMOD
5	morphologic	morphologic	B-NP	JJ	O	6	NMOD
6	changes	change	I-NP	NNS	O	4	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	10	NMOD
9	trabecular	trabecular	I-NP	JJ	O	10	NMOD
10	meshwork	meshwork	I-NP	NN	O	7	PMOD
11	similar	similar	B-ADJP	JJ	O	10	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	those	those	B-NP	DT	O	12	PMOD
14	reported	report	B-VP	VBN	O	13	NMOD
15	for	for	B-PP	IN	O	14	VMOD
16	corticosteroid	corticosteroid	B-NP	NN	O	17	NMOD
17	glaucoma	glaucoma	I-NP	NN	O	21	NMOD
18	and	and	O	CC	O	21	NMOD
19	open	open	B-NP	JJ	O	21	NMOD
20	angle	angle	I-NP	NN	O	21	NMOD
21	glaucoma	glaucoma	I-NP	NN	O	15	PMOD
22	.	.	O	.	O	3	P

1	Cognitive	Cognitive	B-NP	JJ	O	2	NMOD
2	deterioration	deterioration	I-NP	NN	O	11	NMOD
3	from	from	B-PP	IN	O	2	NMOD
4	long-term	long-term	B-NP	JJ	O	5	NMOD
5	abuse	abuse	I-NP	NN	O	3	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	dextromethorphan	dextromethorphan	B-NP	NN	O	6	PMOD
8	:	:	O	:	O	2	P
9	a	a	B-NP	DT	O	11	NMOD
10	case	case	I-NP	NN	O	11	NMOD
11	report	report	I-NP	NN	O	0	ROOT
12	.	.	O	.	O	11	P

1	Complete	Complete	B-NP	JJ	O	3	NMOD
2	heart	heart	I-NP	NN	O	3	NMOD
3	block	block	I-NP	NN	O	0	ROOT
4	following	follow	B-PP	VBG	O	3	NMOD
5	a	a	B-NP	DT	O	7	NMOD
6	single	single	I-NP	JJ	O	7	NMOD
7	dose	dose	I-NP	NN	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	trazodone	trazodone	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	Forty	Forty	B-NP	CD	O	2	NMOD
2	minutes	minute	I-NP	NNS	O	3	PMOD
3	after	after	B-PP	IN	O	14	VMOD
4	receiving	receive	B-VP	VBG	O	3	PMOD
5	a	a	B-NP	DT	O	8	NMOD
6	single	single	I-NP	JJ	O	8	NMOD
7	starting	start	I-NP	VBG	O	8	NMOD
8	dose	dose	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	trazodone	trazodone	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	14	P
12	a	a	B-NP	DT	O	13	NMOD
13	patient	patient	I-NP	NN	O	14	SUB
14	developed	develop	B-VP	VBD	O	0	ROOT
15	complete	complete	B-NP	JJ	O	17	NMOD
16	heart	heart	I-NP	NN	O	17	NMOD
17	block	block	I-NP	NN	O	14	OBJ
18	.	.	O	.	O	14	P

1	Quinidine	Quinidine	B-NP	NN	O	2	NMOD
2	phenylethylbarbiturate	phenylethylbarbiturate	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	fulminant	fulminant	B-NP	JJ	O	5	NMOD
5	hepatitis	hepatitis	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	pregnant	pregnant	I-NP	JJ	O	9	NMOD
9	woman	woman	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	9	NMOD
7	19-year-old	19-year-old	I-NP	JJ	O	9	NMOD
8	Laotian	Laotian	I-NP	JJ	O	9	NMOD
9	patient	patient	I-NP	NN	O	5	PMOD
10	affected	affect	B-VP	VBN	O	9	NMOD
11	by	by	B-PP	IN	O	10	VMOD
12	fulminant	fulminant	B-NP	JJ	O	13	NMOD
13	hepatitis	hepatitis	I-NP	NN	O	11	PMOD
14	during	during	B-PP	IN	O	10	VMOD
15	the	the	B-NP	DT	O	17	NMOD
16	third	third	I-NP	JJ	O	17	NMOD
17	trimester	trimester	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	her	her	B-NP	PRP$	O	20	NMOD
20	pregnancy	pregnancy	I-NP	NN	O	18	PMOD
21	after	after	B-PP	IN	O	17	NMOD
22	a	a	B-NP	DT	O	24	NMOD
23	1-month	1-month	I-NP	JJ	O	24	NMOD
24	administration	administration	I-NP	NN	O	21	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	quinidine	quinidine	B-NP	NN	O	27	NMOD
27	phenylethylbarbiturate	phenylethylbarbiturate	I-NP	NN	O	25	PMOD
28	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	epidemiology	epidemiology	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	8	NMOD
5	acute	acute	I-NP	JJ	O	8	NMOD
6	flank	flank	I-NP	NN	O	8	NMOD
7	pain	pain	I-NP	NN	O	8	NMOD
8	syndrome	syndrome	I-NP	NN	O	3	PMOD
9	from	from	B-PP	IN	O	8	NMOD
10	suprofen	suprofen	B-NP	NN	O	9	PMOD
11	.	.	O	.	O	2	P

1	Case	Case	B-NP	NN	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	more	more	B-ADJP	RBR	O	5	AMOD
5	likely	likely	I-ADJP	JJ	O	3	PRD
6	to	to	B-VP	TO	O	7	VMOD
7	be	be	I-VP	VB	O	5	AMOD
8	men	man	B-NP	NNS	O	7	PRD
9	(	(	O	(	O	21	DEP
10	odds	odd	B-NP	NNS	O	11	NMOD
11	ratio	ratio	I-NP	NN	O	20	NMOD
12	,	,	O	,	O	20	P
13	3.8	3.8	B-NP	CD	O	20	NMOD
14	;	;	O	:	O	20	P
15	95	95	B-NP	CD	O	18	NMOD
16	%	%	I-NP	NN	O	18	NMOD
17	confidence	confidence	I-NP	NN	O	18	NMOD
18	interval	interval	I-NP	NN	O	20	SUB
19	,	,	O	,	O	20	P
20	1.2-12.1	1.2-12.1	B-NP	CD	O	21	DEP
21	)	)	O	)	O	7	VMOD
22	,	,	O	,	O	7	P
23	suffer	suffer	B-VP	VBP	O	7	VMOD
24	from	from	B-PP	IN	O	23	VMOD
25	hay	hay	B-NP	NN	O	26	NMOD
26	fever	fever	I-NP	NN	O	28	NMOD
27	and	and	O	CC	O	28	NMOD
28	asthma	asthma	B-NP	NN	O	24	PMOD
29	(	(	O	(	O	28	NMOD
30	odds	odd	B-NP	NNS	O	31	NMOD
31	ratio	ratio	I-NP	NN	O	29	PMOD
32	,	,	O	,	O	40	P
33	3.4	3.4	B-NP	CD	O	40	NMOD
34	;	;	O	:	O	40	P
35	95	95	B-NP	CD	O	38	NMOD
36	%	%	I-NP	NN	O	38	NMOD
37	confidence	confidence	I-NP	NN	O	38	NMOD
38	interval	interval	I-NP	NN	O	40	NMOD
39	,	,	O	,	O	40	P
40	1.0-11.9	1.0-11.9	B-NP	CD	O	31	NMOD
41	)	)	O	)	O	40	NMOD
42	;	;	O	:	O	44	P
43	to	to	B-VP	TO	O	44	VMOD
44	participate	participate	I-VP	VB	O	40	VMOD
45	in	in	B-PP	IN	O	44	VMOD
46	regular	regular	B-NP	JJ	O	47	NMOD
47	exercise	exercise	I-NP	NN	O	45	PMOD
48	(	(	O	(	O	60	DEP
49	odds	odd	B-NP	NNS	O	50	NMOD
50	ratio	ratio	I-NP	NN	O	59	NMOD
51	,	,	O	,	O	59	P
52	5.9	5.9	B-NP	CD	O	59	NMOD
53	;	;	O	:	O	59	P
54	95	95	B-NP	CD	O	57	NMOD
55	%	%	I-NP	NN	O	57	NMOD
56	confidence	confidence	I-NP	NN	O	57	NMOD
57	interval	interval	I-NP	NN	O	59	SUB
58	,	,	O	,	O	59	P
59	1.1-30.7	1.1-30.7	B-NP	CD	O	60	DEP
60	)	)	O	)	O	47	NMOD
61	,	,	O	,	O	44	P
62	especially	especially	B-ADVP	RB	O	63	PMOD
63	in	in	B-PP	IN	O	44	VMOD
64	the	the	B-NP	DT	O	65	NMOD
65	use	use	I-NP	NN	O	63	PMOD
66	of	of	B-PP	IN	O	65	NMOD
67	Nautilus	Nautilus	B-NP	NN	O	68	NMOD
68	equipment	equipment	I-NP	NN	O	66	PMOD
69	(	(	O	(	O	73	DEP
70	p	p	B-NP	NN	O	73	DEP
71	=	=	B-VP	SYM	O	70	NMOD
72	0.02	0.02	B-NP	CD	O	71	AMOD
73	)	)	O	)	O	44	VMOD
74	;	;	O	:	O	77	P
75	and	and	O	CC	O	77	VMOD
76	to	to	B-VP	TO	O	77	VMOD
77	use	use	I-VP	VB	O	44	VMOD
78	alcohol	alcohol	B-NP	NN	O	77	OBJ
79	(	(	O	(	O	91	DEP
80	odds	odd	B-NP	NNS	O	81	NMOD
81	ratio	ratio	I-NP	NN	O	90	NMOD
82	,	,	O	,	O	90	P
83	4.4	4.4	B-NP	CD	O	90	NMOD
84	;	;	O	:	O	90	P
85	95	95	B-NP	CD	O	88	NMOD
86	%	%	I-NP	NN	O	88	NMOD
87	confidence	confidence	I-NP	NN	O	88	NMOD
88	interval	interval	I-NP	NN	O	90	SUB
89	,	,	O	,	O	90	P
90	1.1-17.5	1.1-17.5	B-NP	CD	O	91	DEP
91	)	)	O	)	O	78	NMOD
92	.	.	O	.	O	3	P

1	Possible	Possible	B-NP	JJ	O	3	NMOD
2	risk	risk	I-NP	NN	O	3	NMOD
3	factors	factor	I-NP	NNS	O	4	SUB
4	included	include	B-VP	VBD	O	48	VMOD
5	young	young	B-NP	JJ	O	6	NMOD
6	age	age	I-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	concurrent	concurrent	B-NP	JJ	O	9	NMOD
9	use	use	I-NP	NN	O	4	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	other	other	B-NP	JJ	O	13	NMOD
12	analgesic	analgesic	I-NP	JJ	O	13	NMOD
13	agents	agent	I-NP	NNS	O	10	PMOD
14	(	(	O	(	O	17	DEP
15	especially	especially	B-NP	RB	O	16	NMOD
16	ibuprofen	ibuprofen	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	,	,	O	,	O	4	P
19	preexisting	preexist	B-VP	VBG	O	4	VMOD
20	renal	renal	B-NP	JJ	O	21	NMOD
21	disease	disease	I-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	a	a	B-NP	DT	O	24	NMOD
24	history	history	I-NP	NN	O	30	NMOD
25	of	of	B-PP	IN	O	24	NMOD
26	kidney	kidney	B-NP	NN	O	27	NMOD
27	stones	stone	I-NP	NNS	O	25	PMOD
28	,	,	O	,	O	30	P
29	a	a	B-NP	DT	O	30	NMOD
30	history	history	I-NP	NN	O	19	OBJ
31	of	of	B-PP	IN	O	30	NMOD
32	gout	gout	B-NP	NN	O	36	NMOD
33	,	,	O	,	O	36	P
34	a	a	B-NP	DT	O	36	NMOD
35	recent	recent	I-NP	JJ	O	36	NMOD
36	increase	increase	I-NP	NN	O	31	PMOD
37	in	in	B-PP	IN	O	36	NMOD
38	activity	activity	B-NP	NN	O	42	NMOD
39	,	,	O	,	O	42	P
40	a	a	B-NP	DT	O	42	NMOD
41	recent	recent	I-NP	JJ	O	42	NMOD
42	increase	increase	I-NP	NN	O	37	PMOD
43	in	in	B-PP	IN	O	42	NMOD
44	sun	sun	B-NP	NN	O	45	NMOD
45	exposure	exposure	I-NP	NN	O	43	PMOD
46	,	,	O	,	O	48	P
47	and	and	O	CC	O	48	NMOD
48	residence	residence	B-NP	NN	O	0	ROOT
49	in	in	B-PP	IN	O	48	NMOD
50	the	the	B-NP	DT	O	51	NMOD
51	Sunbelt	Sunbelt	I-NP	NNP	O	49	PMOD
52	.	.	O	.	O	48	P

1	Hemolytic-uremic	Hemolytic-uremic	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	ingestion	ingestion	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	quinine	quinine	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	2	P

1	Hemolytic-uremic	Hemolytic-uremic	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	6	SUB
3	following	follow	B-PP	VBG	O	2	NMOD
4	quinine	quinine	B-NP	NN	O	5	NMOD
5	ingestion	ingestion	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	a	a	B-NP	DT	O	10	NMOD
8	newly	newly	I-NP	RB	O	9	AMOD
9	described	describe	I-NP	VBN	O	10	NMOD
10	phenomenon	phenomenon	I-NP	NN	O	6	PRD
11	,	,	O	,	O	10	P
12	with	with	B-PP	IN	O	10	NMOD
13	just	just	B-NP	RB	O	16	NMOD
14	two	two	I-NP	CD	O	13	AMOD
15	previous	previous	I-NP	JJ	O	16	NMOD
16	descriptions	description	I-NP	NNS	O	12	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	4	4	B-NP	CD	O	19	NMOD
19	cases	case	I-NP	NNS	O	17	PMOD
20	in	in	B-PP	IN	O	6	VMOD
21	the	the	B-NP	DT	O	22	NMOD
22	literature	literature	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	6	P

1	Quinine-associated	Quinine-associated	B-NP	JJ	O	3	NMOD
2	hemolytic-uremic	hemolytic-uremic	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	5	SUB
4	probably	probably	B-ADVP	RB	O	5	VMOD
5	occurs	occur	B-VP	VBZ	O	0	ROOT
6	more	more	B-ADVP	RBR	O	7	AMOD
7	often	often	I-ADVP	RB	O	5	VMOD
8	than	than	B-SBAR	IN	O	7	AMOD
9	is	be	B-VP	VBZ	O	8	SBAR
10	recognized	recognize	I-VP	VBN	O	9	VC
11	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	2	NMOD
2	disease	disease	I-NP	NN	O	3	SUB
3	occurred	occur	B-VP	VBD	O	0	ROOT
4	subsequent	subsequent	B-ADJP	JJ	O	3	VMOD
5	to	to	B-PP	TO	O	4	AMOD
6	the	the	B-NP	DT	O	7	NMOD
7	initiation	initiation	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	heparin	heparin	B-NP	NN	O	10	NMOD
10	therapy	therapy	I-NP	NN	O	8	PMOD
11	for	for	B-PP	IN	O	7	NMOD
12	suspected	suspect	B-NP	VBN	O	14	NMOD
13	pelvic	pelvic	I-NP	JJ	O	14	NMOD
14	thrombophlebitis	thrombophlebitis	I-NP	NN	O	11	PMOD
15	and	and	O	CC	O	3	VMOD
16	cleared	clear	B-VP	VBD	O	3	VMOD
17	rapidly	rapidly	B-ADJP	RB	O	18	AMOD
18	subsequent	subsequent	I-ADJP	JJ	O	16	PRD
19	to	to	B-PP	TO	O	18	AMOD
20	its	its	B-NP	PRP$	O	21	NMOD
21	discontinuation	discontinuation	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	3	P

1	Changes	Change	B-NP	NNS	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	peroxisomes	peroxisome	B-NP	NNS	O	2	PMOD
4	in	in	B-PP	IN	O	3	NMOD
5	preneoplastic	preneoplastic	B-NP	JJ	O	6	NMOD
6	liver	liver	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	hepatoma	hepatoma	I-NP	NN	O	4	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	mice	mouse	B-NP	NNS	O	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	alpha-benzene	alpha-benzene	B-NP	NN	O	14	NMOD
14	hexachloride	hexachloride	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	1	P

1	Peroxisomes	Peroxisome	B-NP	NNS	O	17	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	hepatomas	hepatoma	B-NP	NNS	O	8	NMOD
4	and	and	O	CC	O	8	NMOD
5	hyperplastic	hyperplastic	B-NP	JJ	O	8	NMOD
6	preneoplastic	preneoplastic	I-NP	JJ	O	8	NMOD
7	liver	liver	I-NP	NN	O	8	NMOD
8	lesions	lesion	I-NP	NNS	O	2	PMOD
9	induced	induce	B-VP	VBN	O	8	NMOD
10	in	in	B-PP	IN	O	9	VMOD
11	mice	mouse	B-NP	NNS	O	10	PMOD
12	by	by	B-PP	IN	O	9	VMOD
13	500	500	B-NP	CD	O	16	NMOD
14	ppm	ppm	I-NP	NN	O	16	NMOD
15	alpha-benzene	alpha-benzene	I-NP	NN	O	16	NMOD
16	hexachloride	hexachloride	I-NP	NN	O	12	PMOD
17	were	be	B-VP	VBD	O	0	ROOT
18	examined	examine	I-VP	VBN	O	17	VC
19	histochemically	histochemically	B-ADVP	RB	O	18	VMOD
20	and	and	O	CC	O	21	NMOD
21	electron	electron	B-NP	NN	O	19	PMOD
22	microscopically	microscopically	B-ADVP	RB	O	21	NMOD
23	.	.	O	.	O	17	P

1	Although	Although	B-SBAR	IN	O	0	ROOT
2	most	most	B-NP	JJS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	5	NMOD
5	hepatomas	hepatoma	I-NP	NNS	O	3	PMOD
6	were	be	B-VP	VBD	O	1	SBAR
7	well-differentiated	well-differentiated	B-NP	JJ	O	8	NMOD
8	tumors	tumor	I-NP	NNS	O	6	PRD
9	and	and	O	CC	O	6	VMOD
10	contained	contain	B-VP	VBD	O	6	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	considerable	considerable	I-NP	JJ	O	13	NMOD
13	number	number	I-NP	NN	O	19	NMOD
14	of	of	B-PP	IN	O	13	NMOD
15	peroxisomes	peroxisome	B-NP	NNS	O	14	PMOD
16	,	,	O	,	O	19	P
17	the	the	B-NP	DT	O	19	NMOD
18	tumor	tumor	I-NP	NN	B-cell_type	19	NMOD
19	cells	cell	I-NP	NNS	I-cell_type	20	SUB
20	did	do	B-VP	VBD	O	10	VMOD
21	not	not	I-VP	RB	O	20	VMOD
22	respond	respond	I-VP	VB	O	20	VC
23	to	to	I-VP	TO	O	24	VMOD
24	ethyl-alpha-p-chlorophenoxyisobutyrate	ethyl-alpha-p-chlorophenoxyisobutyrate	I-VP	VB	O	22	VMOD
25	with	with	B-PP	IN	O	24	VMOD
26	proliferation	proliferation	B-NP	NN	O	25	PMOD
27	of	of	B-PP	IN	O	26	NMOD
28	peroxisomes	peroxisome	B-NP	NNS	O	27	PMOD
29	.	.	O	.	O	1	P

1	Quinidine	Quinidine	B-NP	NN	O	2	NMOD
2	hepatitis	hepatitis	I-NP	NN	O	0	ROOT
3	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	concluded	conclude	B-VP	VBD	O	0	ROOT
3	that	that	B-SBAR	IN	O	2	VMOD
4	this	this	B-NP	DT	O	5	NMOD
5	patient	patient	I-NP	NN	O	6	SUB
6	had	have	B-VP	VBD	O	3	SBAR
7	quinidine	quinidine	B-NP	NN	O	8	NMOD
8	hepatotoxicity	hepatotoxicity	I-NP	NN	O	6	OBJ
9	and	and	O	CC	O	6	VMOD
10	believe	believe	B-VP	VBP	O	6	VMOD
11	that	that	B-SBAR	IN	O	10	VMOD
12	this	this	B-NP	DT	O	13	SUB
13	is	be	B-VP	VBZ	O	11	SBAR
14	the	the	B-NP	DT	O	16	NMOD
15	first	first	I-NP	JJ	O	16	NMOD
16	case	case	I-NP	NN	O	13	PRD
17	reported	report	B-VP	VBN	O	16	NMOD
18	with	with	B-PP	IN	O	17	VMOD
19	liver	liver	B-NP	NN	O	21	NMOD
20	biopsy	biopsy	I-NP	NN	O	21	NMOD
21	documentation	documentation	I-NP	NN	O	18	PMOD
22	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	21	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	to	to	B-PP	TO	O	2	NMOD
4	its	its	B-NP	PRP$	O	5	NMOD
5	use	use	I-NP	NN	O	3	PMOD
6	as	as	B-PP	IN	O	5	NMOD
7	a	a	B-NP	DT	O	8	NMOD
8	stabilizer/rigidifier	stabilizer/rigidifier	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	membranes	membrane	B-NP	NNS	O	9	PMOD
11	,	,	O	,	O	21	P
12	cholesteryl	cholesteryl	B-NP	NN	O	13	NMOD
13	hemisuccinate	hemisuccinate	I-NP	NN	O	21	SUB
14	,	,	O	,	O	21	P
15	tris	tris	B-NP	NN	O	16	NMOD
16	salt	salt	I-NP	NN	O	21	SUB
17	(	(	O	(	O	19	DEP
18	CS	CS	B-NP	NN	O	19	DEP
19	)	)	O	)	O	16	NMOD
20	administration	administration	B-NP	NN	O	21	SUB
21	has	have	B-VP	VBZ	O	0	ROOT
22	also	also	I-VP	RB	O	21	VMOD
23	been	be	I-VP	VBN	O	21	VC
24	shown	show	I-VP	VBN	O	23	VC
25	to	to	I-VP	TO	O	26	VMOD
26	protect	protect	I-VP	VB	O	24	VMOD
27	rats	rat	B-NP	NNS	O	26	OBJ
28	from	from	B-PP	IN	O	26	VMOD
29	the	the	B-NP	DT	O	31	NMOD
30	hepatotoxic	hepatotoxic	I-NP	JJ	O	31	NMOD
31	effects	effect	I-NP	NNS	O	28	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	carbon	carbon	B-NP	NN	O	34	NMOD
34	tetrachloride	tetrachloride	I-NP	NN	O	32	PMOD
35	(	(	O	(	O	37	DEP
36	CCl4	CCl4	B-NP	NN	O	37	DEP
37	)	)	O	)	O	34	NMOD
38	.	.	O	.	O	21	P

1	To	To	B-VP	TO	O	2	VMOD
2	further	further	I-VP	VB	O	13	VMOD
3	our	our	B-NP	PRP$	O	4	NMOD
4	understanding	understanding	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	mechanism	mechanism	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	CS	CS	B-NP	NN	O	10	NMOD
10	cytoprotection	cytoprotection	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	13	P
12	we	we	B-NP	PRP	O	13	SUB
13	examined	examine	B-VP	VBD	O	0	ROOT
14	in	in	B-PP	IN	O	13	VMOD
15	rats	rat	B-NP	NNS	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	mice	mouse	I-NP	NNS	O	14	PMOD
18	the	the	B-NP	DT	O	20	NMOD
19	protective	protective	I-NP	JJ	O	20	NMOD
20	abilities	ability	I-NP	NNS	O	13	VMOD
21	of	of	B-PP	IN	O	20	NMOD
22	CS	CS	B-NP	NN	B-protein	27	NMOD
23	and	and	O	CC	O	27	NMOD
24	the	the	B-NP	DT	O	27	NMOD
25	non-hydrolyzable	non-hydrolyzable	I-NP	JJ	O	27	NMOD
26	ether	ether	I-NP	NN	O	27	NMOD
27	form	form	I-NP	NN	O	35	NMOD
28	of	of	B-PP	IN	O	27	NMOD
29	CS	CS	B-NP	NN	B-protein	28	PMOD
30	,	,	O	,	O	35	P
31	gamma-cholesteryloxybutyric	gamma-cholesteryloxybutyric	B-NP	JJ	O	32	NMOD
32	acid	acid	I-NP	NN	O	35	NMOD
33	,	,	O	,	O	35	P
34	tris	tris	B-NP	NN	O	35	NMOD
35	salt	salt	I-NP	NN	O	21	PMOD
36	(	(	O	(	O	38	DEP
37	CSE	CSE	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	against	against	B-PP	IN	O	35	NMOD
40	acetaminophen-	acetaminophen-	B-NP	NN	O	49	NMOD
41	,	,	O	,	O	49	P
42	adriamycin-	adriamycin-	B-NP	NN	O	49	NMOD
43	,	,	O	,	O	49	P
44	carbon	carbon	B-NP	NN	O	45	NMOD
45	tetrachloride-	tetrachloride-	I-NP	NN	O	49	NMOD
46	,	,	O	,	O	49	P
47	chloroform-	chloroform-	B-NP	NN	O	49	NMOD
48	and	and	I-NP	CC	O	49	NMOD
49	galactosamine	galactosamine	I-NP	NN	O	50	SUB
50	induced	induce	B-VP	VBD	O	39	SBAR
51	toxicity	toxicity	B-NP	NN	O	50	OBJ
52	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	3	NMOD
2	24-h	24-h	I-NP	JJ	O	3	NMOD
3	pretreatment	pretreatment	I-NP	NN	O	21	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	both	both	B-NP	DT	O	8	NMOD
6	rats	rat	I-NP	NNS	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	mice	mouse	I-NP	NNS	O	4	PMOD
9	with	with	B-PP	IN	O	3	NMOD
10	a	a	B-NP	DT	O	12	NMOD
11	single	single	I-NP	JJ	O	12	NMOD
12	dose	dose	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	CS	CS	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	19	DEP
16	100mg/kg	100mg/kg	B-NP	CD	O	19	DEP
17	,	,	O	,	O	19	P
18	i.p.	i.p.	B-ADVP	RB	O	19	DEP
19	)	)	O	)	O	12	NMOD
20	,	,	O	,	O	3	P
21	resulted	result	B-VP	VBD	O	0	ROOT
22	in	in	B-PP	IN	O	21	VMOD
23	significant	significant	B-NP	JJ	O	24	NMOD
24	protection	protection	I-NP	NN	O	22	PMOD
25	against	against	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	hepatotoxic	hepatotoxic	I-NP	JJ	O	28	NMOD
28	effects	effect	I-NP	NNS	O	25	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	CCl4	CCl4	B-NP	NN	O	36	NMOD
31	,	,	I-NP	,	O	36	P
32	CHCl3	CHCl3	I-NP	NN	B-protein	36	NMOD
33	,	,	I-NP	,	O	36	P
34	acetaminophen	acetaminophen	I-NP	NN	O	36	NMOD
35	and	and	I-NP	CC	O	36	NMOD
36	galactosamine	galactosamine	I-NP	NN	O	29	PMOD
37	and	and	O	CC	O	22	PMOD
38	against	against	B-PP	IN	O	22	PMOD
39	the	the	B-NP	DT	O	40	NMOD
40	lethal	lethal	I-NP	JJ	O	38	PMOD
41	(	(	O	(	O	45	DEP
42	and	and	O	CC	O	45	DEP
43	presumably	presumably	B-ADJP	RB	O	44	AMOD
44	cardiotoxic	cardiotoxic	I-ADJP	JJ	O	45	DEP
45	)	)	O	)	O	40	NMOD
46	effect	effect	B-NP	NN	O	40	NMOD
47	of	of	B-PP	IN	O	40	NMOD
48	adriamycin	adriamycin	B-NP	NN	O	49	NMOD
49	administration	administration	I-NP	NN	O	47	PMOD
50	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	2	NMOD
2	mechanism	mechanism	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	CS	CS	B-NP	NN	O	5	NMOD
5	protection	protection	I-NP	NN	O	3	PMOD
6	does	do	B-VP	VBZ	O	0	ROOT
7	not	not	I-VP	RB	O	6	VMOD
8	appear	appear	I-VP	VB	O	6	VC
9	to	to	I-VP	TO	O	10	VMOD
10	be	be	I-VP	VB	O	8	VMOD
11	dependent	dependent	B-ADJP	JJ	O	10	PRD
12	on	on	B-PP	IN	O	11	AMOD
13	the	the	B-NP	DT	O	14	NMOD
14	inhibition	inhibition	I-NP	NN	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	chemical	chemical	B-NP	JJ	O	17	NMOD
17	bioactivation	bioactivation	I-NP	NN	O	15	PMOD
18	to	to	B-PP	TO	O	17	NMOD
19	a	a	B-NP	DT	O	22	NMOD
20	toxic	toxic	I-NP	JJ	O	22	NMOD
21	reactive	reactive	I-NP	JJ	O	22	NMOD
22	intermediate	intermediate	I-NP	NN	O	18	PMOD
23	(	(	O	(	O	33	DEP
24	in	in	B-PP	IN	O	33	DEP
25	light	light	B-NP	NN	O	24	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	the	the	B-NP	DT	O	28	NMOD
28	protection	protection	I-NP	NN	O	26	PMOD
29	observed	observe	B-VP	VBN	O	28	NMOD
30	against	against	B-PP	IN	O	29	VMOD
31	galactosamine	galactosamine	B-NP	NN	O	32	NMOD
32	hepatotoxicity	hepatotoxicity	I-NP	NN	O	30	PMOD
33	)	)	O	)	O	22	NMOD
34	.	.	O	.	O	6	P

1	DSMM	DSMM	B-NP	NN	O	3	NMOD
2	XI	XI	I-NP	NN	O	3	NMOD
3	study	study	I-NP	NN	O	0	ROOT
4	:	:	O	:	O	3	P
5	dose	dose	B-NP	NN	O	6	NMOD
6	definition	definition	I-NP	NN	O	3	NMOD
7	for	for	B-PP	IN	O	6	NMOD
8	intravenous	intravenous	B-NP	JJ	O	9	NMOD
9	cyclophosphamide	cyclophosphamide	I-NP	NN	O	7	PMOD
10	in	in	B-PP	IN	O	9	NMOD
11	combination	combination	B-NP	NN	O	10	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	bortezomib/dexamethasone	bortezomib/dexamethasone	B-NP	NN	O	12	PMOD
14	for	for	B-PP	IN	O	13	NMOD
15	remission	remission	B-NP	NN	O	16	NMOD
16	induction	induction	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	newly	newly	B-NP	RB	O	21	AMOD
21	diagnosed	diagnose	I-NP	VBN	O	22	NMOD
22	myeloma	myeloma	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	clinical	clinical	I-NP	JJ	O	3	NMOD
3	trial	trial	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	initiated	initiate	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	evaluate	evaluate	I-VP	VB	O	4	VMOD
8	the	the	B-NP	DT	O	10	NMOD
9	recommended	recommend	I-NP	VBN	O	10	NMOD
10	dose	dose	I-NP	NN	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	cyclophosphamide	cyclophosphamide	B-NP	NN	O	11	PMOD
13	in	in	B-PP	IN	O	10	NMOD
14	combination	combination	B-NP	NN	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	bortezomib	bortezomib	B-NP	NN	O	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	dexamethasone	dexamethasone	I-NP	NN	O	15	PMOD
19	as	as	B-PP	IN	O	7	VMOD
20	induction	induction	B-NP	NN	O	21	NMOD
21	treatment	treatment	I-NP	NN	O	19	PMOD
22	before	before	B-PP	IN	O	21	NMOD
23	stem	stem	B-NP	NN	O	25	NMOD
24	cell	cell	I-NP	NN	O	25	NMOD
25	transplantation	transplantation	I-NP	NN	O	22	PMOD
26	for	for	B-PP	IN	O	25	NMOD
27	younger	young	B-NP	JJR	O	28	NMOD
28	patients	patient	I-NP	NNS	O	26	PMOD
29	with	with	B-PP	IN	O	28	NMOD
30	newly	newly	B-NP	RB	O	31	AMOD
31	diagnosed	diagnose	I-NP	VBN	O	33	NMOD
32	multiple	multiple	I-NP	JJ	O	33	NMOD
33	myeloma	myeloma	I-NP	NN	O	29	PMOD
34	(	(	O	(	O	36	DEP
35	MM	MM	B-NP	NN	O	36	DEP
36	)	)	O	)	O	33	NMOD
37	.	.	O	.	O	4	P

1	Results	Result	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	18	NMOD
4	comparative	comparative	I-NP	JJ	O	17	AMOD
5	,	,	I-NP	,	O	17	P
6	phase	phase	I-NP	NN	B-DNA	17	AMOD
7	III	III	I-NP	CD	I-DNA	6	NMOD
8	,	,	O	,	O	17	P
9	12-week	12-week	B-NP	JJ	O	17	AMOD
10	,	,	I-NP	,	O	17	P
11	multicenter	multicenter	I-NP	JJ	O	17	AMOD
12	,	,	I-NP	,	O	17	P
13	prospective	prospective	I-NP	JJ	O	17	AMOD
14	,	,	I-NP	,	O	17	P
15	randomized	randomize	I-NP	VBN	O	17	AMOD
16	,	,	I-NP	,	O	17	P
17	double-blind	double-blind	I-NP	JJ	O	18	NMOD
18	assessment	assessment	I-NP	NN	O	2	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	the	the	B-NP	DT	O	23	NMOD
21	efficacy	efficacy	I-NP	NN	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	tolerability	tolerability	I-NP	NN	O	19	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	a	a	B-NP	DT	O	27	NMOD
26	fixed-dose	fixed-dose	I-NP	JJ	O	27	NMOD
27	combination	combination	I-NP	NN	O	24	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	telmisartan	telmisartan	B-NP	NN	O	34	NMOD
30	and	and	I-NP	CC	O	34	NMOD
31	amlodipine	amlodipine	I-NP	NN	O	34	NMOD
32	versus	versus	I-NP	CC	O	34	NMOD
33	amlodipine	amlodipine	I-NP	NN	O	34	NMOD
34	monotherapy	monotherapy	I-NP	NN	O	28	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	Indian	Indian	B-NP	JJ	O	37	NMOD
37	adults	adult	I-NP	NNS	O	35	PMOD
38	with	with	B-PP	IN	O	37	NMOD
39	stage	stage	B-NP	NN	O	41	NMOD
40	II	II	I-NP	CD	O	41	NMOD
41	hypertension	hypertension	I-NP	NN	O	38	PMOD
42	.	.	O	.	O	1	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	aim	aim	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	this	this	B-NP	DT	O	7	NMOD
7	study	study	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	1	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	evaluate	evaluate	I-VP	VB	O	8	PRD
11	the	the	B-NP	DT	O	14	NMOD
12	efficacy	efficacy	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	tolerability	tolerability	I-NP	NN	O	10	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	19	NMOD
17	new	new	I-NP	JJ	O	19	NMOD
18	fixed-dose	fixed-dose	I-NP	JJ	O	19	NMOD
19	combination	combination	I-NP	NN	O	15	PMOD
20	(	(	O	(	O	22	DEP
21	FDC	FDC	B-NP	NN	B-cell_type	22	DEP
22	)	)	O	)	O	19	NMOD
23	of	of	B-PP	IN	O	19	NMOD
24	telmisartan	telmisartan	B-NP	NN	O	23	PMOD
25	40	40	I-NP	CD	O	24	NMOD
26	mg	mg	I-NP	NN	O	25	NMOD
27	+	+	B-VP	SYM	O	26	NMOD
28	amlodipine	amlodipine	B-NP	NN	O	30	NMOD
29	5	5	I-NP	CD	O	30	NMOD
30	mg	mg	I-NP	NN	O	27	AMOD
31	(	(	O	(	O	33	DEP
32	T+A	T+A	B-NP	NN	O	33	DEP
33	)	)	O	)	O	30	NMOD
34	compared	compare	B-PP	VBN	O	10	VMOD
35	with	with	B-PP	IN	O	34	PMOD
36	amlodipine	amlodipine	B-NP	NN	O	38	NMOD
37	5-mg	5-mg	I-NP	NN	O	38	NMOD
38	monotherapy	monotherapy	I-NP	NN	O	35	PMOD
39	(	(	O	(	O	41	DEP
40	A	A	B-NP	NN	O	41	DEP
41	)	)	O	)	O	38	NMOD
42	in	in	B-PP	IN	O	38	NMOD
43	adult	adult	B-NP	JJ	O	45	NMOD
44	Indian	Indian	I-NP	JJ	O	45	NMOD
45	patients	patient	I-NP	NNS	O	42	PMOD
46	with	with	B-PP	IN	O	45	NMOD
47	stage	stage	B-NP	NN	O	49	NMOD
48	II	II	I-NP	CD	O	49	NMOD
49	hypertension	hypertension	I-NP	NN	O	46	PMOD
50	.	.	O	.	O	8	P

1	Cutaneous	Cutaneous	B-NP	JJ	O	3	NMOD
2	leucocytoclastic	leucocytoclastic	I-NP	JJ	O	3	NMOD
3	vasculitis	vasculitis	I-NP	NN	O	0	ROOT
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	oxacillin	oxacillin	B-NP	NN	B-protein	5	PMOD
7	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	67-year-old	67-year-old	I-NP	JJ	O	3	NMOD
3	man	man	I-NP	NN	O	0	ROOT
4	who	who	B-NP	WP	O	3	NMOD
5	was	be	B-VP	VBD	O	4	SBAR
6	treated	treat	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	oxacillin	oxacillin	B-NP	NN	O	7	PMOD
9	for	for	B-PP	IN	O	6	VMOD
10	one	one	B-NP	CD	O	11	NMOD
11	week	week	I-NP	NN	O	9	PMOD
12	because	because	B-PP	IN	O	6	VMOD
13	of	of	I-PP	IN	O	12	PMOD
14	Staphylococcus	Staphylococcus	B-NP	FW	O	16	NMOD
15	aureus	aureus	I-NP	FW	O	16	NMOD
16	bacteremia	bacteremia	I-NP	NN	O	18	SUB
17	,	,	O	,	O	16	P
18	developed	develop	B-VP	VBD	O	12	SBAR
19	renal	renal	B-NP	JJ	O	20	NMOD
20	failure	failure	I-NP	NN	O	28	NMOD
21	and	and	O	CC	O	28	NMOD
22	diffuse	diffuse	B-NP	JJ	O	26	AMOD
23	,	,	I-NP	,	O	26	P
24	symmetric	symmetric	I-NP	JJ	O	26	AMOD
25	,	,	I-NP	,	O	26	P
26	palpable	palpable	I-NP	JJ	O	28	NMOD
27	purpuric	purpuric	I-NP	JJ	O	28	NMOD
28	lesions	lesion	I-NP	NNS	O	18	OBJ
29	on	on	B-PP	IN	O	28	NMOD
30	his	his	B-NP	PRP$	O	31	NMOD
31	feet	foot	I-NP	NNS	O	29	PMOD
32	.	.	O	.	O	3	P

1	Pretreatment	Pretreatment	B-NP	NN	O	5	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	naloxazone	naloxazone	B-NP	NN	O	2	PMOD
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	blocked	block	B-VP	VBD	O	0	ROOT
6	morphine	morphine	B-NP	NN	O	7	NMOD
7	analgesia	analgesia	I-NP	NN	O	11	NMOD
8	,	,	O	,	O	11	P
9	catalepsy	catalepsy	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	hypothermia	hypothermia	I-NP	NN	O	5	OBJ
12	at	at	B-PP	IN	O	5	VMOD
13	a	a	B-NP	DT	O	14	NMOD
14	dose	dose	I-NP	NN	O	12	PMOD
15	which	which	B-NP	WDT	O	14	NMOD
16	completely	completely	B-ADVP	RB	O	17	VMOD
17	eliminated	eliminate	B-VP	VBD	O	15	SBAR
18	high-affinity	high-affinity	B-NP	JJ	O	19	NMOD
19	binding	binding	I-NP	NN	O	17	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	brain	brain	B-NP	NN	O	22	NMOD
22	membranes	membrane	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	5	P

1	Moreover	Moreover	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	naloxazone	naloxazone	B-NP	NN	O	5	SUB
4	significantly	significantly	B-ADVP	RB	O	5	VMOD
5	attenuated	attenuate	B-VP	VBD	O	14	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	morphine	morphine	I-NP	NN	O	8	SUB
8	induced	induce	B-VP	VBD	O	5	VMOD
9	hypotension	hypotension	B-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	respiratory	respiratory	B-NP	JJ	O	12	NMOD
12	depression	depression	I-NP	NN	O	8	OBJ
13	,	,	O	,	O	14	P
14	whereas	whereas	O	IN	O	0	ROOT
15	morphine	morphine	B-NP	NN	O	17	NMOD
16	induced	induce	I-NP	VBN	O	15	AMOD
17	bradycardia	bradycardia	I-NP	NN	O	18	SUB
18	was	be	B-VP	VBD	O	14	VMOD
19	less	less	I-VP	RBR	O	18	VMOD
20	affected	affect	I-VP	VBN	O	18	VC
21	.	.	O	.	O	14	P

1	Dexrazoxane	Dexrazoxane	B-NP	NN	O	2	SUB
2	protects	protect	B-VP	VBZ	O	0	ROOT
3	against	against	B-PP	IN	O	2	VMOD
4	myelosuppression	myelosuppression	B-NP	NN	O	3	PMOD
5	from	from	B-PP	IN	O	2	VMOD
6	the	the	B-NP	DT	O	9	NMOD
7	DNA	DNA	I-NP	NN	O	9	NMOD
8	cleavage-enhancing	cleavage-enhancing	I-NP	NN	O	9	NMOD
9	drugs	drug	I-NP	NNS	O	15	NMOD
10	etoposide	etoposide	I-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	daunorubicin	daunorubicin	I-NP	NN	O	15	NMOD
13	but	but	B-NP	CC	O	15	NMOD
14	not	not	I-NP	RB	O	13	DEP
15	doxorubicin	doxorubicin	B-NP	NN	O	5	PMOD
16	.	.	O	.	O	2	P

1	PURPOSE	PURPOSE	B-NP	NN	O	7	NMOD
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	anthracyclines	anthracycline	I-NP	NNS	O	7	NMOD
5	daunorubicin	daunorubicin	I-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	doxorubicin	doxorubicin	I-NP	NN	O	11	NMOD
8	and	and	O	CC	O	11	NMOD
9	the	the	B-NP	DT	O	11	NMOD
10	epipodophyllotoxin	epipodophyllotoxin	I-NP	NN	O	11	NMOD
11	etoposide	etoposide	I-NP	NN	O	12	SUB
12	are	be	B-VP	VBP	O	31	VMOD
13	potent	potent	B-NP	JJ	O	16	NMOD
14	DNA	DNA	I-NP	NN	O	16	NMOD
15	cleavage-enhancing	cleavage-enhancing	I-NP	NN	O	16	NMOD
16	drugs	drug	I-NP	NNS	O	12	PRD
17	that	that	B-NP	WDT	O	16	NMOD
18	are	be	B-VP	VBP	O	17	SBAR
19	widely	widely	I-VP	RB	O	18	VMOD
20	used	use	I-VP	VBN	O	18	VC
21	in	in	B-PP	IN	O	20	VMOD
22	clinical	clinical	B-NP	JJ	O	23	NMOD
23	oncology	oncology	I-NP	NN	O	21	PMOD
24	;	;	O	:	O	31	P
25	however	however	B-ADVP	RB	O	31	VMOD
26	,	,	O	,	O	31	P
27	myelosuppression	myelosuppression	B-NP	NN	O	30	NMOD
28	and	and	O	CC	O	30	NMOD
29	cardiac	cardiac	B-NP	JJ	O	30	NMOD
30	toxicity	toxicity	I-NP	NN	O	31	SUB
31	limit	limit	B-VP	VBP	O	0	ROOT
32	their	their	B-NP	PRP$	O	33	NMOD
33	use	use	I-NP	NN	O	31	OBJ
34	.	.	O	.	O	31	P

1	Dexrazoxane	Dexrazoxane	B-NP	NN	O	5	SUB
2	(	(	O	(	O	4	DEP
3	ICRF-187	ICRF-187	B-NP	NN	B-protein	4	DEP
4	)	)	O	)	O	1	NMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	recommended	recommend	I-VP	VBN	O	5	VC
7	for	for	B-PP	IN	O	6	VMOD
8	protection	protection	B-NP	NN	O	7	PMOD
9	against	against	B-PP	IN	O	8	NMOD
10	anthracycline	anthracycline	B-NP	NN	O	12	NMOD
11	induced	induced	I-NP	JJ	O	12	NMOD
12	cardiotoxicity	cardiotoxicity	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	5	P

1	EXPERIMENTAL	EXPERIMENTAL	B-NP	JJ	O	2	NMOD
2	DESIGN	DESIGN	I-NP	NN	O	12	NMOD
3	:	:	O	:	O	2	P
4	Because	Because	B-PP	IN	O	12	NMOD
5	of	of	I-PP	IN	O	4	PMOD
6	their	their	B-NP	PRP$	O	8	NMOD
7	widespread	widespread	I-NP	JJ	O	8	NMOD
8	use	use	I-NP	NN	O	5	PMOD
9	,	,	O	,	O	12	P
10	the	the	B-NP	DT	O	12	NMOD
11	hematologic	hematologic	I-NP	JJ	O	12	NMOD
12	toxicity	toxicity	I-NP	NN	O	25	SUB
13	following	follow	B-PP	VBG	O	12	NMOD
14	coadministration	coadministration	B-NP	NN	O	24	NMOD
15	of	of	B-PP	IN	O	14	NMOD
16	dexrazoxane	dexrazoxane	B-NP	NN	O	15	PMOD
17	and	and	O	CC	O	24	NMOD
18	these	these	B-NP	DT	O	24	NMOD
19	three	three	I-NP	CD	O	24	NMOD
20	structurally	structurally	I-NP	RB	O	21	AMOD
21	different	different	I-NP	JJ	O	24	NMOD
22	DNA	DNA	I-NP	NN	B-DNA	24	NMOD
23	cleavage	cleavage	I-NP	NN	I-DNA	24	NMOD
24	enhancers	enhancer	I-NP	NNS	I-DNA	13	PMOD
25	was	be	B-VP	VBD	O	0	ROOT
26	investigated	investigate	I-VP	VBN	O	25	VC
27	:	:	O	:	O	25	P
28	Sensitivity	Sensitivity	B-NP	NN	O	25	VMOD
29	of	of	B-PP	IN	O	28	NMOD
30	human	human	B-NP	JJ	B-cell_type	35	NMOD
31	and	and	I-NP	CC	I-cell_type	35	NMOD
32	murine	murine	I-NP	JJ	I-cell_type	35	NMOD
33	blood	blood	I-NP	NN	I-cell_type	35	NMOD
34	progenitor	progenitor	I-NP	NN	I-cell_type	35	NMOD
35	cells	cell	I-NP	NNS	I-cell_type	29	PMOD
36	to	to	B-PP	TO	O	28	NMOD
37	etoposide	etoposide	B-NP	NN	O	45	SUB
38	,	,	O	,	O	45	P
39	daunorubicin	daunorubicin	B-NP	NN	O	45	SUB
40	,	,	O	,	O	45	P
41	and	and	O	CC	O	45	VMOD
42	doxorubicin	doxorubicin	B-NP	NN	O	44	NMOD
43	+/-	+/-	I-NP	SYM	O	44	NMOD
44	dexrazoxane	dexrazoxane	I-NP	NN	O	45	SUB
45	was	be	B-VP	VBD	O	36	SBAR
46	determined	determine	I-VP	VBN	O	45	VC
47	in	in	B-PP	IN	O	46	VMOD
48	granulocyte-macrophage	granulocyte-macrophage	B-NP	JJ	O	49	NMOD
49	colony	colony	I-NP	NN	O	51	NMOD
50	forming	form	B-VP	VBG	O	51	NMOD
51	assays	assay	B-NP	NNS	O	47	PMOD
52	.	.	O	.	O	25	P

1	RESULTS	RESULTS	B-NP	NNS	O	32	SUB
2	:	:	O	:	O	1	P
3	Nontoxic	Nontoxic	B-NP	JJ	O	4	NMOD
4	doses	dose	I-NP	NNS	O	7	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	dexrazoxane	dexrazoxane	B-NP	NN	O	5	PMOD
7	reduced	reduce	B-VP	VBD	O	32	VMOD
8	myelosuppression	myelosuppression	B-NP	NN	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	weight	weight	I-NP	NN	O	11	NMOD
11	loss	loss	I-NP	NN	O	7	OBJ
12	from	from	B-PP	IN	O	11	NMOD
13	daunorubicin	daunorubicin	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	etoposide	etoposide	I-NP	NN	O	12	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	mice	mouse	B-NP	NNS	O	16	PMOD
18	and	and	O	CC	O	7	VMOD
19	antagonized	antagonize	B-VP	VBD	O	7	VMOD
20	their	their	B-NP	PRP$	O	22	NMOD
21	antiproliferative	antiproliferative	I-NP	JJ	O	22	NMOD
22	effects	effect	I-NP	NNS	O	19	OBJ
23	in	in	B-PP	IN	O	19	VMOD
24	the	the	B-NP	DT	O	26	NMOD
25	colony	colony	I-NP	NN	O	26	NMOD
26	assay	assay	I-NP	NN	O	23	PMOD
27	;	;	O	:	O	32	P
28	however	however	B-ADVP	RB	O	32	VMOD
29	,	,	O	,	O	32	P
30	dexrazoxane	dexrazoxane	B-NP	NN	O	32	SUB
31	neither	neither	O	CC	O	32	VMOD
32	reduced	reduce	B-VP	VBD	O	0	ROOT
33	myelosuppression	myelosuppression	B-NP	NN	O	42	NMOD
34	,	,	O	,	O	42	P
35	weight	weight	B-NP	NN	O	36	NMOD
36	loss	loss	I-NP	NN	O	42	NMOD
37	,	,	O	,	O	42	P
38	nor	nor	O	CC	O	42	NMOD
39	the	the	B-NP	DT	O	42	NMOD
40	in	in	I-NP	FW	O	41	AMOD
41	vitro	vitro	I-NP	FW	O	42	NMOD
42	cytotoxicity	cytotoxicity	I-NP	NN	O	32	OBJ
43	from	from	B-PP	IN	O	42	NMOD
44	doxorubicin	doxorubicin	B-NP	NN	O	43	PMOD
45	.	.	O	.	O	32	P

1	Effects	Effect	B-NP	NNS	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	novel	novel	I-NP	JJ	O	6	NMOD
5	compound	compound	I-NP	NN	O	6	NMOD
6	aniracetam	aniracetam	I-NP	NN	O	2	PMOD
7	(	(	O	(	O	10	DEP
8	Ro	Ro	B-NP	NN	O	10	DEP
9	13-5057	13-5057	I-NP	CD	O	8	NMOD
10	)	)	O	)	O	6	NMOD
11	upon	upon	B-PP	IN	O	1	NMOD
12	impaired	impaired	B-NP	JJ	O	13	NMOD
13	learning	learning	I-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	memory	memory	I-NP	NN	O	11	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	rodents	rodent	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	effect	effect	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	aniracetam	aniracetam	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	10	DEP
6	Ro	Ro	B-NP	NN	O	9	NMOD
7	13-5057	13-5057	I-NP	CD	O	6	NMOD
8	,	,	I-NP	,	O	9	P
9	1-anisoyl-2-pyrrolidinone	1-anisoyl-2-pyrrolidinone	I-NP	NN	O	10	DEP
10	)	)	O	)	O	4	NMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	studied	study	I-VP	VBN	O	11	VC
13	on	on	B-PP	IN	O	12	VMOD
14	various	various	B-NP	JJ	O	15	NMOD
15	forms	form	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	experimentally	experimentally	B-NP	RB	O	18	AMOD
18	impaired	impaired	I-NP	JJ	O	20	NMOD
19	cognitive	cognitive	I-NP	JJ	O	20	NMOD
20	functions	function	I-NP	NNS	O	16	PMOD
21	(	(	O	(	O	25	DEP
22	learning	learning	B-NP	NN	O	24	NMOD
23	and	and	O	CC	O	24	NMOD
24	memory	memory	B-NP	NN	O	25	DEP
25	)	)	O	)	O	20	NMOD
26	in	in	B-PP	IN	O	15	NMOD
27	rodents	rodent	B-NP	NNS	O	26	PMOD
28	and	and	O	CC	O	11	VMOD
29	produced	produce	B-VP	VBD	O	11	VMOD
30	the	the	B-NP	DT	O	32	NMOD
31	following	following	I-NP	JJ	O	32	NMOD
32	effects	effect	I-NP	NNS	O	29	OBJ
33	:	:	O	:	O	11	P
34	(	(	B-LST	(	O	35	DEP
35	1	1	I-LST	LS	O	11	VMOD
36	)	)	O	)	O	35	DEP
37	almost	almost	B-NP	RB	O	38	AMOD
38	complete	complete	I-NP	JJ	O	39	NMOD
39	prevention	prevention	I-NP	NN	O	35	DEP
40	of	of	B-PP	IN	O	39	NMOD
41	the	the	B-NP	DT	O	42	NMOD
42	incapacity	incapacity	I-NP	NN	O	40	PMOD
43	to	to	B-VP	TO	O	44	VMOD
44	learn	learn	I-VP	VB	O	39	NMOD
45	a	a	B-NP	DT	O	48	NMOD
46	discrete	discrete	I-NP	JJ	O	48	NMOD
47	escape	escape	I-NP	NN	O	48	NMOD
48	response	response	I-NP	NN	O	44	OBJ
49	in	in	B-PP	IN	O	44	VMOD
50	rats	rat	B-NP	NNS	O	49	PMOD
51	exposed	expose	B-VP	VBN	O	50	NMOD
52	to	to	B-PP	TO	O	51	VMOD
53	sublethal	sublethal	B-NP	JJ	O	54	NMOD
54	hypercapnia	hypercapnia	I-NP	NN	O	52	PMOD
55	immediately	immediately	B-ADVP	RB	O	44	VMOD
56	before	before	B-PP	IN	O	44	VMOD
57	the	the	B-NP	DT	O	59	NMOD
58	acquisition	acquisition	I-NP	NN	O	59	NMOD
59	session	session	I-NP	NN	O	56	PMOD
60	.	.	O	.	O	11	P

1	(	(	B-LST	(	O	2	DEP
2	2	2	I-LST	LS	O	17	VMOD
3	)	)	O	)	O	2	DEP
4	partial	partial	O	JJ	O	13	NMOD
5	(	(	O	(	O	7	DEP
6	rats	rat	B-NP	NNS	O	7	DEP
7	)	)	O	)	O	4	AMOD
8	or	or	O	CC	O	13	NMOD
9	complete	complete	B-ADJP	JJ	O	13	NMOD
10	(	(	O	(	O	12	DEP
11	mice	mouse	B-NP	NNS	O	12	DEP
12	)	)	O	)	O	9	AMOD
13	prevention	prevention	B-NP	NN	O	17	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	scopolamine	scopolamine	I-NP	NN	O	14	PMOD
17	induced	induce	B-VP	VBD	O	0	ROOT
18	short-term	short-term	B-NP	JJ	O	19	NMOD
19	amnesia	amnesia	I-NP	NN	O	17	OBJ
20	for	for	B-PP	IN	O	17	VMOD
21	a	a	B-NP	DT	O	24	NMOD
22	passive	passive	I-NP	JJ	B-protein	24	NMOD
23	avoidance	avoidance	I-NP	NN	I-protein	24	NMOD
24	task	task	I-NP	NN	I-protein	20	PMOD
25	.	.	O	.	O	17	P

1	These	These	B-NP	DT	O	4	NMOD
2	improvements	improvement	I-NP	NNS	O	4	NMOD
3	or	or	I-NP	CC	O	4	NMOD
4	normalizations	normalization	I-NP	NNS	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	impaired	impaired	B-NP	JJ	O	8	NMOD
7	cognitive	cognitive	I-NP	JJ	O	8	NMOD
8	functions	function	I-NP	NNS	O	5	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	seen	see	I-VP	VBN	O	9	VC
11	at	at	B-PP	IN	O	10	VMOD
12	oral	oral	B-NP	JJ	O	14	NMOD
13	aniracetam	aniracetam	I-NP	NN	O	14	NMOD
14	doses	dose	I-NP	NNS	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	10-100	10-100	B-NP	CD	O	17	NMOD
17	mg/kg	mg/kg	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	9	P

1	Nicotine	Nicotine	B-NP	NN	O	2	NMOD
2	potentiation	potentiation	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	morphine	morphine	B-NP	NN	O	3	PMOD
5	induced	induce	B-VP	VBD	O	0	ROOT
6	catalepsy	catalepsy	B-NP	NN	O	5	OBJ
7	in	in	B-PP	IN	O	5	VMOD
8	mice	mouse	B-NP	NNS	O	7	PMOD
9	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	16	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	16	P
6	effects	effect	B-NP	NNS	O	16	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	nicotine	nicotine	B-NP	NN	O	7	PMOD
9	on	on	B-PP	IN	O	6	NMOD
10	catalepsy	catalepsy	B-NP	NN	O	9	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	morphine	morphine	B-NP	NN	O	12	PMOD
14	in	in	B-PP	IN	O	11	VMOD
15	mice	mouse	B-NP	NNS	O	14	PMOD
16	have	have	B-VP	VBP	O	0	ROOT
17	been	be	I-VP	VBN	O	16	VC
18	investigated	investigate	I-VP	VBN	O	17	VC
19	.	.	O	.	O	16	P

1	Morphine	Morphine	B-NP	NN	O	4	NMOD
2	but	but	B-NP	CC	O	4	NMOD
3	not	not	I-NP	RB	O	2	DEP
4	nicotine	nicotine	B-NP	NN	O	5	SUB
5	induced	induce	B-VP	VBD	O	0	ROOT
6	a	a	B-NP	DT	O	8	NMOD
7	dose-dependent	dose-dependent	I-NP	JJ	O	8	NMOD
8	catalepsy	catalepsy	I-NP	NN	O	5	OBJ
9	.	.	O	.	O	5	P

1	Intraperitoneal	Intraperitoneal	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	atropine	atropine	B-NP	NN	O	11	NMOD
5	,	,	O	,	O	11	P
6	naloxone	naloxone	B-NP	NN	O	11	NMOD
7	,	,	O	,	O	11	P
8	mecamylamine	mecamylamine	B-NP	NN	O	11	NMOD
9	,	,	O	,	O	11	P
10	and	and	O	CC	O	11	NMOD
11	hexamethonium	hexamethonium	B-NP	NN	O	3	PMOD
12	to	to	B-PP	TO	O	2	NMOD
13	mice	mouse	B-NP	NNS	O	12	PMOD
14	reduced	reduce	B-VP	VBD	O	0	ROOT
15	catalepsy	catalepsy	B-NP	NN	O	14	OBJ
16	induced	induce	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	a	a	B-NP	DT	O	19	NMOD
19	combination	combination	I-NP	NN	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	morphine	morphine	B-NP	NN	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	nicotine	nicotine	B-NP	NN	O	22	PMOD
24	.	.	O	.	O	14	P

1	Intracerebroventricular	Intracerebroventricular	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	atropine	atropine	B-NP	NN	O	9	NMOD
5	,	,	O	,	O	9	P
6	hexamethonium	hexamethonium	B-NP	NN	O	9	NMOD
7	,	,	O	,	O	9	P
8	and	and	O	CC	O	9	NMOD
9	naloxone	naloxone	B-NP	NN	O	3	PMOD
10	also	also	B-ADVP	RB	O	11	VMOD
11	decreased	decrease	B-VP	VBD	O	0	ROOT
12	catalepsy	catalepsy	B-NP	NN	O	11	OBJ
13	induced	induce	B-VP	VBN	O	12	NMOD
14	by	by	B-PP	IN	O	13	VMOD
15	morphine	morphine	B-NP	NN	O	17	NMOD
16	plus	plus	I-NP	CC	O	17	NMOD
17	nicotine	nicotine	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	11	P

1	Reduced	Reduce	B-NP	VBN	O	2	NMOD
2	cardiotoxicity	cardiotoxicity	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	preserved	preserve	B-VP	VBN	O	6	NMOD
5	antitumor	antitumor	B-NP	JJ	O	6	NMOD
6	efficacy	efficacy	I-NP	NN	O	0	ROOT
7	of	of	B-PP	IN	O	6	NMOD
8	liposome-encapsulated	liposome-encapsulated	B-NP	JJ	O	9	NMOD
9	doxorubicin	doxorubicin	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	cyclophosphamide	cyclophosphamide	I-NP	NN	O	7	PMOD
12	compared	compare	B-PP	VBN	O	6	NMOD
13	with	with	B-PP	IN	O	12	PMOD
14	conventional	conventional	B-NP	JJ	O	15	NMOD
15	doxorubicin	doxorubicin	I-NP	NN	O	17	NMOD
16	and	and	I-NP	CC	O	17	NMOD
17	cyclophosphamide	cyclophosphamide	I-NP	NN	O	13	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	a	a	B-NP	DT	O	23	NMOD
20	randomized	randomize	I-NP	VBN	O	22	AMOD
21	,	,	I-NP	,	O	22	P
22	multicenter	multicenter	I-NP	JJ	O	23	NMOD
23	trial	trial	I-NP	NN	O	18	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	metastatic	metastatic	B-NP	JJ	O	27	NMOD
26	breast	breast	I-NP	NN	O	27	NMOD
27	cancer	cancer	I-NP	NN	O	24	PMOD
28	.	.	O	.	O	6	P

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	determine	determine	I-VP	VB	O	1	NMOD
5	whether	whether	B-SBAR	IN	O	4	VMOD
6	Myocet	Myocet	B-NP	NN	O	27	SUB
7	(	(	O	(	O	27	VMOD
8	liposome-encapsulated	liposome-encapsulated	B-NP	JJ	O	9	NMOD
9	doxorubicin	doxorubicin	I-NP	NN	O	27	SUB
10	;	;	O	:	O	27	P
11	The	The	B-NP	DT	O	13	NMOD
12	Liposome	Liposome	I-NP	NNP	O	13	NMOD
13	Company	Company	I-NP	NNP	O	18	NMOD
14	,	,	O	,	O	18	P
15	Elan	Elan	B-NP	NNP	O	16	NMOD
16	Corporation	Corporation	I-NP	NNP	O	18	NMOD
17	,	,	O	,	O	18	P
18	Princeton	Princeton	B-NP	NNP	O	20	NMOD
19	,	,	O	,	O	20	P
20	NJ	NJ	B-NP	NNP	O	27	SUB
21	)	)	O	)	O	20	DEP
22	in	in	B-PP	IN	O	20	NMOD
23	combination	combination	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	cyclophosphamide	cyclophosphamide	B-NP	NN	O	24	PMOD
26	significantly	significantly	B-ADVP	RB	O	27	VMOD
27	reduces	reduce	B-VP	VBZ	O	5	SBAR
28	doxorubicin	doxorubicin	B-NP	NN	O	29	NMOD
29	cardiotoxicity	cardiotoxicity	I-NP	NN	O	27	OBJ
30	while	while	B-SBAR	IN	O	27	VMOD
31	providing	provide	B-VP	VBG	O	30	SBAR
32	comparable	comparable	B-NP	JJ	O	33	AMOD
33	antitumor	antitumor	I-NP	JJ	O	34	NMOD
34	efficacy	efficacy	I-NP	NN	O	31	OBJ
35	in	in	B-PP	IN	O	31	VMOD
36	first-line	first-line	B-NP	JJ	O	37	NMOD
37	treatment	treatment	I-NP	NN	O	35	PMOD
38	of	of	B-PP	IN	O	37	NMOD
39	metastatic	metastatic	B-NP	JJ	O	41	NMOD
40	breast	breast	I-NP	NN	O	41	NMOD
41	cancer	cancer	I-NP	NN	O	38	PMOD
42	(	(	O	(	O	44	DEP
43	MBC	MBC	B-NP	NN	O	44	DEP
44	)	)	O	)	O	41	NMOD
45	.	.	O	.	O	4	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD
2	AND	AND	I-NP	CC	O	3	NMOD
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT
4	:	:	O	:	O	3	P
5	Two	Two	B-NP	CD	O	7	AMOD
6	hundred	hundred	I-NP	CD	O	7	AMOD
7	ninety-seven	ninety-seven	I-NP	CD	O	8	NMOD
8	patients	patient	I-NP	NNS	O	14	NMOD
9	with	with	B-PP	IN	O	8	NMOD
10	MBC	MBC	B-NP	NN	O	9	PMOD
11	and	and	O	CC	O	14	NMOD
12	no	no	B-NP	DT	O	14	NMOD
13	prior	prior	I-NP	JJ	O	14	NMOD
14	chemotherapy	chemotherapy	I-NP	NN	O	18	SUB
15	for	for	B-PP	IN	O	14	NMOD
16	metastatic	metastatic	B-NP	JJ	O	17	NMOD
17	disease	disease	I-NP	NN	O	15	PMOD
18	were	be	B-VP	VBD	O	3	NMOD
19	randomized	randomize	I-VP	VBN	O	18	VC
20	to	to	B-VP	TO	O	21	VMOD
21	receive	receive	I-VP	VB	O	19	VMOD
22	either	either	O	CC	O	21	VMOD
23	60	60	B-NP	CD	O	24	NMOD
24	mg/m	mg/m	I-NP	NN	O	22	PMOD
25	(	(	O	(	O	24	NMOD
26	2	2	B-NP	CD	O	24	NMOD
27	)	)	O	)	O	24	NMOD
28	of	of	B-PP	IN	O	24	NMOD
29	Myocet	Myocet	B-NP	NN	O	35	NMOD
30	(	(	O	(	O	32	DEP
31	M	M	B-NP	NN	O	32	DEP
32	)	)	O	)	O	29	NMOD
33	or	or	O	CC	O	35	NMOD
34	conventional	conventional	B-NP	JJ	O	35	NMOD
35	doxorubicin	doxorubicin	I-NP	NN	O	28	PMOD
36	(	(	O	(	O	38	DEP
37	A	A	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	,	,	O	,	O	24	P
40	in	in	B-PP	IN	O	24	NMOD
41	combination	combination	B-NP	NN	O	40	PMOD
42	with	with	B-PP	IN	O	41	NMOD
43	600	600	B-NP	CD	O	44	NMOD
44	mg/m	mg/m	I-NP	NN	O	42	PMOD
45	(	(	O	(	O	47	DEP
46	2	2	B-NP	CD	O	47	DEP
47	)	)	O	)	O	44	NMOD
48	of	of	B-PP	IN	O	44	NMOD
49	cyclophosphamide	cyclophosphamide	B-NP	NN	O	56	NMOD
50	(	(	O	(	O	52	DEP
51	C	C	B-NP	NN	O	52	DEP
52	)	)	O	)	O	49	NMOD
53	,	,	O	,	O	56	P
54	every	every	B-NP	DT	O	56	NMOD
55	3	3	I-NP	CD	O	56	NMOD
56	weeks	week	I-NP	NNS	O	48	PMOD
57	until	until	B-PP	IN	O	44	NMOD
58	disease	disease	B-NP	NN	O	59	NMOD
59	progression	progression	I-NP	NN	O	62	NMOD
60	or	or	O	CC	O	62	NMOD
61	unacceptable	unacceptable	B-NP	JJ	O	62	NMOD
62	toxicity	toxicity	I-NP	NN	O	57	PMOD
63	.	.	O	.	O	3	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	8	NMOD
5	specific	specific	I-NP	JJ	O	8	NMOD
6	platelet-activating	platelet-activating	I-NP	JJ	B-protein	8	NMOD
7	factor	factor	I-NP	NN	I-protein	8	NMOD
8	antagonist	antagonist	I-NP	NN	O	15	VMOD
9	,	,	O	,	O	15	P
10	BN	BN	B-NP	NN	O	15	SUB
11	52021	52021	I-NP	CD	O	10	NMOD
12	,	,	O	,	O	10	P
13	on	on	B-PP	IN	O	10	NMOD
14	bupivacaine	bupivacaine	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	3	SBAR
16	cardiovascular	cardiovascular	B-NP	JJ	O	17	NMOD
17	impairments	impairment	I-NP	NNS	O	15	OBJ
18	in	in	B-PP	IN	O	15	VMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	2	P

1	Administration	Administration	B-NP	NN	O	17	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	6	NMOD
4	local	local	I-NP	JJ	O	6	NMOD
5	anaesthetic	anaesthetic	I-NP	JJ	O	6	NMOD
6	bupivacaine	bupivacaine	I-NP	NN	O	2	PMOD
7	(	(	O	(	O	14	DEP
8	1.5	1.5	B-NP	CD	O	10	AMOD
9	or	or	I-NP	CC	O	10	AMOD
10	2	2	I-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	14	DEP
12	,	,	O	,	O	11	P
13	i.v.	i.v.	B-ADJP	JJ	O	14	DEP
14	)	)	O	)	O	6	NMOD
15	to	to	B-PP	TO	O	1	NMOD
16	rats	rat	B-NP	NNS	O	15	PMOD
17	elicited	elicit	B-VP	VBD	O	0	ROOT
18	a	a	B-NP	DT	O	20	NMOD
19	marked	marked	I-NP	JJ	O	20	NMOD
20	decrease	decrease	I-NP	NN	O	17	OBJ
21	of	of	B-PP	IN	O	20	NMOD
22	mean	mean	B-NP	JJ	O	25	NMOD
23	arterial	arterial	I-NP	JJ	O	25	NMOD
24	blood	blood	I-NP	NN	O	25	NMOD
25	pressure	pressure	I-NP	NN	O	31	NMOD
26	(	(	O	(	O	28	DEP
27	MBP	MBP	B-NP	NN	B-protein	28	DEP
28	)	)	O	)	O	25	NMOD
29	and	and	O	CC	O	31	NMOD
30	heart	heart	B-NP	NN	O	31	NMOD
31	rate	rate	I-NP	NN	O	21	PMOD
32	(	(	O	(	O	34	DEP
33	HR	HR	B-NP	NN	O	34	DEP
34	)	)	O	)	O	31	NMOD
35	leading	lead	B-VP	VBG	O	17	VMOD
36	to	to	B-PP	TO	O	35	VMOD
37	death	death	B-NP	NN	O	36	PMOD
38	(	(	O	(	O	48	DEP
39	in	in	B-PP	IN	O	48	DEP
40	67	67	B-NP	CD	O	41	NMOD
41	%	%	I-NP	NN	O	44	NMOD
42	or	or	O	CC	O	44	NMOD
43	90	90	B-NP	CD	O	44	NMOD
44	%	%	I-NP	NN	O	39	PMOD
45	of	of	B-PP	IN	O	44	NMOD
46	animals	animal	B-NP	NNS	O	45	PMOD
47	respectively	respectively	B-ADVP	RB	O	39	VMOD
48	)	)	O	)	O	37	NMOD
49	.	.	O	.	O	17	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	injection	injection	I-NP	NN	O	29	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	the	the	B-NP	DT	O	12	NMOD
5	specific	specific	I-NP	JJ	O	12	NMOD
6	platelet-activating	platelet-activating	I-NP	JJ	B-protein	7	NMOD
7	factor	factor	I-NP	NN	I-protein	12	NMOD
8	(	(	O	(	O	10	DEP
9	PAF	PAF	B-NP	NN	B-protein	10	DEP
10	)	)	O	)	O	7	NMOD
11	antagonist	antagonist	B-NP	NN	O	12	NMOD
12	BN	BN	I-NP	NN	O	20	NMOD
13	52021	52021	I-NP	CD	O	12	NMOD
14	(	(	O	(	O	17	DEP
15	10	10	B-NP	CD	O	16	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	12	NMOD
18	,	,	O	,	O	20	P
19	30	30	B-NP	CD	O	20	NMOD
20	min	min	I-NP	NN	O	3	PMOD
21	before	before	B-PP	IN	O	20	NMOD
22	bupivacaine	bupivacaine	B-NP	NN	O	23	NMOD
23	administration	administration	I-NP	NN	O	21	PMOD
24	(	(	O	(	O	28	DEP
25	2	2	B-NP	CD	O	27	NMOD
26	mg/kg	mg/kg	I-NP	NN	O	27	NMOD
27	i.v.	i.v.	I-NP	NN	O	28	DEP
28	)	)	O	)	O	23	NMOD
29	suppressed	suppress	B-VP	VBD	O	0	ROOT
30	both	both	O	CC	O	29	VMOD
31	the	the	B-NP	DT	O	32	NMOD
32	decrease	decrease	I-NP	NN	O	30	PMOD
33	of	of	B-PP	IN	O	32	NMOD
34	MBP	MBP	B-NP	NN	B-protein	36	NMOD
35	and	and	I-NP	CC	O	36	NMOD
36	HR	HR	I-NP	NN	O	33	PMOD
37	.	.	O	.	O	29	P

1	When	When	B-ADVP	WRB	O	32	VMOD
2	BN	BN	B-NP	NN	O	9	SUB
3	52021	52021	I-NP	CD	O	2	NMOD
4	(	(	O	(	O	8	DEP
5	20	20	B-NP	CD	O	7	NMOD
6	mg/kg	mg/kg	I-NP	NN	O	7	NMOD
7	i.v.	i.v.	I-NP	NN	O	8	DEP
8	)	)	O	)	O	2	NMOD
9	was	be	B-VP	VBD	O	1	SBAR
10	injected	inject	I-VP	VBN	O	9	VC
11	immediately	immediately	B-ADVP	RB	O	10	VMOD
12	after	after	B-PP	IN	O	10	VMOD
13	bupivacaine	bupivacaine	B-NP	NN	O	21	NMOD
14	(	(	O	(	O	17	DEP
15	2	2	B-NP	CD	O	16	NMOD
16	mg/kg	mg/kg	I-NP	NN	O	17	DEP
17	)	)	O	)	O	13	NMOD
18	,	,	O	,	O	21	P
19	a	a	B-NP	DT	O	21	NMOD
20	partial	partial	I-NP	JJ	O	21	NMOD
21	reversion	reversion	I-NP	NN	O	12	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	decrease	decrease	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	MBP	MBP	B-NP	NN	B-protein	28	NMOD
27	and	and	I-NP	CC	O	28	NMOD
28	HR	HR	I-NP	NN	O	25	PMOD
29	was	be	B-VP	VBD	O	1	SBAR
30	observed	observe	I-VP	VBN	O	29	VC
31	,	,	O	,	O	32	P
32	whereas	whereas	O	IN	O	0	ROOT
33	the	the	B-NP	DT	O	34	NMOD
34	dose	dose	I-NP	NN	O	38	SUB
35	of	of	B-PP	IN	O	34	NMOD
36	10	10	B-NP	CD	O	37	NMOD
37	mg/kg	mg/kg	I-NP	NN	O	35	PMOD
38	was	be	B-VP	VBD	O	32	VMOD
39	ineffective	ineffective	B-ADJP	JJ	O	38	PRD
40	.	.	O	.	O	32	P

1	Since	Since	B-SBAR	IN	O	13	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	administration	administration	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	BN	BN	B-NP	NN	O	4	PMOD
6	52021	52021	I-NP	CD	O	5	NMOD
7	,	,	O	,	O	13	P
8	at	at	B-PP	IN	O	13	VMOD
9	all	all	B-NP	DT	O	10	NMOD
10	doses	dose	I-NP	NNS	O	8	PMOD
11	studied	study	B-VP	VBN	O	10	NMOD
12	,	,	O	,	O	13	P
13	did	do	B-VP	VBD	O	0	ROOT
14	not	not	I-VP	RB	O	13	VMOD
15	alter	alter	I-VP	VB	O	13	VC
16	MBP	MBP	B-NP	NN	B-protein	18	NMOD
17	and	and	I-NP	CC	O	18	NMOD
18	HR	HR	I-NP	NN	O	15	OBJ
19	at	at	B-PP	IN	O	15	VMOD
20	the	the	B-NP	DT	O	21	NMOD
21	doses	dose	I-NP	NNS	O	19	PMOD
22	used	use	B-VP	VBN	O	21	NMOD
23	,	,	O	,	O	13	P
24	the	the	B-NP	DT	O	25	NMOD
25	bulk	bulk	I-NP	NN	O	30	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	these	these	B-NP	DT	O	28	NMOD
28	results	result	I-NP	NNS	O	26	PMOD
29	clearly	clearly	B-ADVP	RB	O	30	VMOD
30	demonstrate	demonstrate	B-VP	VBP	O	13	VMOD
31	a	a	B-NP	DT	O	33	NMOD
32	protective	protective	I-NP	JJ	O	33	NMOD
33	action	action	I-NP	NN	O	40	NMOD
34	of	of	B-PP	IN	O	33	NMOD
35	BN	BN	B-NP	NN	O	34	PMOD
36	52021	52021	I-NP	CD	O	35	NMOD
37	,	,	O	,	O	40	P
38	a	a	B-NP	DT	O	40	NMOD
39	specific	specific	I-NP	JJ	O	40	NMOD
40	antagonist	antagonist	I-NP	NN	O	46	SUB
41	of	of	B-PP	IN	O	40	NMOD
42	PAF	PAF	B-NP	NN	B-protein	41	PMOD
43	,	,	O	,	O	40	P
44	against	against	B-PP	IN	O	40	NMOD
45	bupivacaine	bupivacaine	B-NP	NN	O	44	PMOD
46	induced	induce	B-VP	VBD	O	30	VMOD
47	cardiovascular	cardiovascular	B-NP	JJ	O	48	NMOD
48	toxicity	toxicity	I-NP	NN	O	46	OBJ
49	.	.	O	.	O	13	P

1	Benzylacyclouridine	Benzylacyclouridine	B-NP	NN	O	2	SUB
2	reverses	reverse	B-VP	VBZ	O	0	ROOT
3	azidothymidine	azidothymidine	B-NP	NN	O	6	NMOD
4	induced	induced	I-NP	JJ	O	6	NMOD
5	marrow	marrow	I-NP	NN	O	6	NMOD
6	suppression	suppression	I-NP	NN	O	2	OBJ
7	without	without	B-PP	IN	O	2	VMOD
8	impairment	impairment	B-NP	NN	O	7	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	anti-human	anti-human	B-NP	JJ	O	13	NMOD
11	immunodeficiency	immunodeficiency	I-NP	NN	O	13	NMOD
12	virus	virus	I-NP	NN	O	13	NMOD
13	activity	activity	I-NP	NN	O	9	PMOD
14	.	.	O	.	O	2	P

1	Increased	Increase	B-NP	VBN	O	3	NMOD
2	extracellular	extracellular	I-NP	JJ	O	3	NMOD
3	concentrations	concentration	I-NP	NNS	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	uridine	uridine	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	8	DEP
7	Urd	Urd	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	have	have	B-VP	VBP	O	0	ROOT
10	been	be	I-VP	VBN	O	9	VC
11	reported	report	I-VP	VBN	O	10	VC
12	to	to	I-VP	TO	O	13	VMOD
13	reduce	reduce	I-VP	VB	O	11	VMOD
14	,	,	O	,	O	13	P
15	in	in	B-ADVP	FW	O	13	VMOD
16	vitro	vitro	I-ADVP	FW	O	15	AMOD
17	,	,	O	,	O	9	P
18	azidothymidine	azidothymidine	B-NP	NN	O	23	NMOD
19	(	(	O	(	O	21	DEP
20	AZT	AZT	B-NP	NN	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	induced	induce	B-VP	VBD	O	23	NMOD
23	inhibition	inhibition	B-NP	NN	O	9	VMOD
24	of	of	B-PP	IN	O	23	NMOD
25	human	human	B-NP	JJ	B-cell_type	28	NMOD
26	granulocyte-macrophage	granulocyte-macrophage	I-NP	JJ	I-cell_type	28	NMOD
27	progenitor	progenitor	I-NP	NN	I-cell_type	28	NMOD
28	cells	cell	I-NP	NNS	I-cell_type	24	PMOD
29	without	without	B-PP	IN	O	23	NMOD
30	impairment	impairment	B-NP	NN	O	29	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	its	its	B-NP	PRP$	O	35	NMOD
33	antihuman	antihuman	I-NP	JJ	O	35	NMOD
34	immunodeficiency	immunodeficiency	I-NP	NN	O	35	NMOD
35	virus	virus	I-NP	NN	O	39	NMOD
36	(	(	O	(	O	38	DEP
37	HIV	HIV	B-NP	NN	O	38	DEP
38	)	)	O	)	O	35	NMOD
39	activity	activity	B-NP	NN	O	31	PMOD
40	.	.	O	.	O	9	P

1	Because	Because	B-PP	IN	O	26	VMOD
2	of	of	I-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	5	NMOD
4	clinical	clinical	I-NP	JJ	O	5	NMOD
5	toxicities	toxicity	I-NP	NNS	O	1	PMOD
6	associated	associate	B-VP	VBN	O	5	NMOD
7	with	with	B-PP	IN	O	6	VMOD
8	chronic	chronic	B-NP	JJ	O	10	NMOD
9	Urd	Urd	I-NP	NNP	O	10	NMOD
10	administration	administration	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	26	P
12	the	the	B-NP	DT	O	13	NMOD
13	ability	ability	I-NP	NN	O	26	SUB
14	of	of	B-PP	IN	O	13	NMOD
15	benzylacyclouridine	benzylacyclouridine	B-NP	NN	O	14	PMOD
16	(	(	O	(	O	18	DEP
17	BAU	BAU	B-NP	NN	O	18	DEP
18	)	)	O	)	O	15	NMOD
19	to	to	B-PP	TO	O	13	NMOD
20	effect	effect	B-NP	NN	O	19	PMOD
21	,	,	O	,	O	26	P
22	in	in	B-ADVP	FW	O	26	VMOD
23	vivo	vivo	I-ADVP	FW	O	22	AMOD
24	,	,	O	,	O	26	P
25	AZT	AZT	B-NP	NNP	O	26	SUB
26	induced	induce	B-VP	VBD	O	30	VMOD
27	anemia	anemia	B-NP	NN	O	29	NMOD
28	and	and	I-NP	CC	O	29	NMOD
29	leukopenia	leukopenia	I-NP	NN	O	30	SUB
30	was	be	B-VP	VBD	O	0	ROOT
31	assessed	assess	I-VP	VBN	O	30	VC
32	.	.	O	.	O	30	P

1	This	This	B-NP	DT	O	2	NMOD
2	agent	agent	I-NP	NN	O	3	SUB
3	inhibits	inhibit	B-VP	VBZ	O	0	ROOT
4	Urd	Urd	B-NP	NNP	O	5	NMOD
5	catabolism	catabolism	I-NP	NN	O	3	OBJ
6	and	and	O	CC	O	3	VMOD
7	,	,	O	,	O	3	P
8	in	in	B-ADVP	FW	O	3	VMOD
9	vivo	vivo	I-ADVP	FW	O	8	AMOD
10	,	,	O	,	O	3	P
11	increases	increase	B-VP	VBZ	O	3	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	plasma	plasma	I-NP	NN	O	14	NMOD
14	concentration	concentration	I-NP	NN	O	11	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	Urd	Urd	B-NP	NNP	O	15	PMOD
17	in	in	B-PP	IN	O	14	NMOD
18	a	a	B-NP	DT	O	20	NMOD
19	dose-dependent	dose-dependent	I-NP	JJ	O	20	NMOD
20	manner	manner	I-NP	NN	O	17	PMOD
21	,	,	O	,	O	11	P
22	without	without	B-PP	IN	O	11	VMOD
23	Urd-related	Urd-related	B-NP	JJ	O	24	NMOD
24	toxicity	toxicity	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	38	VMOD
2	mice	mouse	B-NP	NNS	O	3	SUB
3	rendered	render	B-VP	VBD	O	1	SBAR
4	anemic	anemic	B-NP	JJ	O	6	AMOD
5	and	and	I-NP	CC	O	6	AMOD
6	leukopenic	leukopenic	I-NP	JJ	O	3	VMOD
7	by	by	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	9	NMOD
9	administration	administration	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	AZT	AZT	B-NP	NNP	O	10	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	28	28	B-NP	CD	O	14	NMOD
14	days	day	I-NP	NNS	O	12	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	drinking	drinking	B-NP	NN	O	17	NMOD
17	water	water	I-NP	NN	O	15	PMOD
18	(	(	O	(	O	21	DEP
19	1.5	1.5	B-NP	CD	O	20	NMOD
20	mg/mL	mg/mL	I-NP	NN	O	21	DEP
21	)	)	O	)	O	17	NMOD
22	,	,	O	,	O	38	P
23	the	the	B-NP	DT	O	25	NMOD
24	continued	continued	I-NP	JJ	O	25	NMOD
25	administration	administration	I-NP	NN	O	38	SUB
26	of	of	B-PP	IN	O	25	NMOD
27	AZT	AZT	B-NP	NNP	O	30	NMOD
28	plus	plus	O	CC	O	30	NMOD
29	daily	daily	B-NP	JJ	O	30	NMOD
30	BAU	BAU	I-NP	NN	O	26	PMOD
31	(	(	O	(	O	36	DEP
32	300	300	B-NP	CD	O	33	NMOD
33	mg/kg	mg/kg	I-NP	NN	O	36	DEP
34	,	,	O	,	O	33	P
35	orally	orally	B-ADVP	RB	O	33	NMOD
36	)	)	O	)	O	30	NMOD
37	partially	partially	B-ADVP	RB	O	38	VMOD
38	reversed	reverse	B-VP	VBD	O	0	ROOT
39	AZT	AZT	B-NP	NN	O	41	NMOD
40	induced	induced	I-NP	JJ	O	41	NMOD
41	anemia	anemia	I-NP	NN	O	43	NMOD
42	and	and	O	CC	O	43	NMOD
43	leukopenia	leukopenia	B-NP	NN	O	53	NMOD
44	(	(	O	(	O	49	DEP
45	P	P	B-NP	NN	O	49	DEP
46	less	less	B-ADJP	JJR	O	45	NMOD
47	than	than	B-PP	IN	O	46	AMOD
48	.05	.05	B-NP	CD	O	47	PMOD
49	)	)	O	)	O	43	NMOD
50	,	,	O	,	O	43	P
51	increased	increase	B-NP	VBN	O	53	NMOD
52	peripheral	peripheral	I-NP	JJ	B-cell_type	53	NMOD
53	reticulocytes	reticulocyte	I-NP	NNS	I-cell_type	66	NMOD
54	(	(	O	(	O	63	DEP
55	to	to	B-PP	TO	O	59	NMOD
56	4.9	4.9	B-NP	CD	O	57	NMOD
57	%	%	I-NP	NN	O	55	PMOD
58	,	,	O	,	O	59	P
59	P	P	B-NP	NN	O	61	SUB
60	less	less	B-ADJP	JJR	O	61	AMOD
61	than	than	B-PP	IN	O	63	DEP
62	.01	.01	B-NP	CD	O	61	AMOD
63	)	)	O	)	O	53	NMOD
64	,	,	O	,	O	53	P
65	increased	increase	B-NP	VBN	O	66	NMOD
66	cellularity	cellularity	I-NP	NN	O	38	OBJ
67	in	in	B-PP	IN	O	66	NMOD
68	the	the	B-NP	DT	O	69	NMOD
69	marrow	marrow	I-NP	NN	O	67	PMOD
70	,	,	O	,	O	73	P
71	and	and	O	CC	O	73	NMOD
72	improved	improve	B-NP	VBN	O	73	NMOD
73	megaloblastosis	megaloblastosis	I-NP	NN	O	38	VMOD
74	.	.	O	.	O	38	P

1	When	When	B-ADVP	WRB	O	13	VMOD
2	coadministered	coadministere	B-VP	VBN	O	1	SBAR
3	with	with	B-PP	IN	O	2	VMOD
4	AZT	AZT	B-NP	NN	O	3	PMOD
5	from	from	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	onset	onset	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	drug	drug	B-NP	NN	O	10	NMOD
10	administration	administration	I-NP	NN	O	8	PMOD
11	,	,	O	,	O	13	P
12	BAU	BAU	B-NP	NN	B-protein	13	SUB
13	reduced	reduce	B-VP	VBD	O	0	ROOT
14	AZT	AZT	B-NP	NN	O	17	NMOD
15	induced	induced	I-NP	JJ	O	17	NMOD
16	marrow	marrow	I-NP	NN	O	17	NMOD
17	toxicity	toxicity	I-NP	NN	O	13	OBJ
18	.	.	O	.	O	13	P

1	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	cystitis	cystitis	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	freely-moving	freely-moving	B-NP	JJ	O	7	NMOD
6	conscious	conscious	I-NP	JJ	O	7	NMOD
7	rats	rat	I-NP	NNS	O	4	PMOD
8	:	:	O	:	O	2	VMOD
9	behavioral	behavioral	B-NP	JJ	O	10	NMOD
10	approach	approach	I-NP	NN	O	8	OBJ
11	to	to	B-PP	TO	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	new	new	I-NP	JJ	O	14	NMOD
14	model	model	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	visceral	visceral	B-NP	JJ	B-protein	17	NMOD
17	pain	pain	I-NP	NN	I-protein	15	PMOD
18	.	.	O	.	O	2	P

1	Cyclophosphamide	Cyclophosphamide	B-NP	NN	O	8	NMOD
2	(	(	O	(	O	4	DEP
3	CP	CP	B-NP	NN	B-DNA	4	DEP
4	)	)	O	)	O	1	NMOD
5	,	,	O	,	O	8	P
6	an	an	B-NP	DT	O	8	NMOD
7	antitumoral	antitumoral	I-NP	JJ	O	8	NMOD
8	agent	agent	I-NP	NN	O	25	SUB
9	known	know	B-VP	VBN	O	8	NMOD
10	to	to	B-VP	TO	O	11	VMOD
11	produce	produce	I-VP	VB	O	9	VMOD
12	toxic	toxic	B-NP	JJ	O	13	NMOD
13	effects	effect	I-NP	NNS	O	11	OBJ
14	on	on	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	17	NMOD
16	bladder	bladder	I-NP	NN	O	17	NMOD
17	wall	wall	I-NP	NN	O	14	PMOD
18	through	through	B-PP	IN	O	11	VMOD
19	its	its	B-NP	PRP$	O	23	NMOD
20	main	main	I-NP	JJ	O	23	NMOD
21	toxic	toxic	I-NP	JJ	O	23	NMOD
22	metabolite	metabolite	I-NP	NN	O	23	NMOD
23	acrolein	acrolein	I-NP	NN	O	18	PMOD
24	,	,	O	,	O	8	P
25	was	be	B-VP	VBD	O	0	ROOT
26	used	use	I-VP	VBN	O	25	VC
27	to	to	B-VP	TO	O	28	VMOD
28	induce	induce	I-VP	VB	O	26	VMOD
29	cystitis	cystitis	B-NP	NN	O	28	OBJ
30	.	.	O	.	O	25	P

1	Morphine	Morphine	B-NP	NN	O	3	SUB
2	dose-dependently	dose-dependently	B-ADVP	RB	O	3	VMOD
3	reversed	reverse	B-VP	VBD	O	0	ROOT
4	these	these	B-NP	DT	O	6	NMOD
5	behavioral	behavioral	I-NP	JJ	O	6	NMOD
6	disorders	disorder	I-NP	NNS	O	3	OBJ
7	.	.	O	.	O	3	P

1	At	At	B-PP	IN	O	24	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	time	time	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	administration	administration	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	morphine	morphine	B-NP	NN	O	6	PMOD
8	,	,	O	,	O	24	P
9	histological	histological	B-NP	JJ	O	10	NMOD
10	modifications	modification	I-NP	NNS	O	24	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	14	NMOD
13	bladder	bladder	I-NP	NN	O	14	NMOD
14	wall	wall	I-NP	NN	O	11	PMOD
15	,	,	O	,	O	10	P
16	such	such	B-PP	JJ	O	17	PMOD
17	as	as	I-PP	IN	O	10	NMOD
18	chorionic	chorionic	B-NP	JJ	O	22	NMOD
19	and	and	I-NP	CC	O	22	NMOD
20	muscle	muscle	I-NP	NN	O	22	NMOD
21	layer	layer	I-NP	NN	O	22	NMOD
22	edema	edema	I-NP	NN	O	17	PMOD
23	,	,	O	,	O	10	P
24	were	be	B-VP	VBD	O	0	ROOT
25	observed	observe	I-VP	VBN	O	24	VC
26	.	.	O	.	O	24	P

1	Hyperalgesia	Hyperalgesia	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	myoclonus	myoclonus	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	terminal	terminal	B-NP	JJ	O	7	NMOD
6	cancer	cancer	I-NP	NN	O	7	NMOD
7	patients	patient	I-NP	NNS	O	4	PMOD
8	treated	treat	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	continuous	continuous	B-NP	JJ	O	12	NMOD
11	intravenous	intravenous	I-NP	JJ	O	12	NMOD
12	morphine	morphine	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	3	P

1	Eight	Eight	B-NP	CD	O	3	NMOD
2	cancer	cancer	I-NP	NN	O	3	NMOD
3	patients	patient	I-NP	NNS	O	18	SUB
4	in	in	B-PP	IN	O	3	NMOD
5	the	the	B-NP	DT	O	7	NMOD
6	terminal	terminal	I-NP	JJ	O	7	NMOD
7	stages	stage	I-NP	NNS	O	4	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	disease	disease	I-NP	NN	O	8	PMOD
11	treated	treat	B-VP	VBN	O	10	NMOD
12	with	with	B-PP	IN	O	11	VMOD
13	high	high	B-NP	JJ	O	14	NMOD
14	doses	dose	I-NP	NNS	O	12	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	intravenous	intravenous	B-NP	JJ	O	17	NMOD
17	morphine	morphine	I-NP	NN	O	15	PMOD
18	developed	develop	B-VP	VBD	O	0	ROOT
19	hyperalgesia	hyperalgesia	B-NP	NN	O	18	OBJ
20	.	.	O	.	O	18	P

1	Vancomycin	Vancomycin	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	curative	curative	B-ADJP	JJ	O	2	PRD
4	in	in	B-PP	IN	O	3	AMOD
5	95	95	B-NP	CD	O	6	NMOD
6	%	%	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	43	43	B-NP	CD	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	proven	proven	B-NP	JJ	O	12	NMOD
12	infection	infection	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	2	P

1	Thrombophlebitis	Thrombophlebitis	B-NP	NN	O	2	SUB
2	occurred	occur	B-VP	VBD	O	13	VMOD
3	only	only	B-ADVP	RB	O	4	PMOD
4	with	with	B-PP	IN	O	2	VMOD
5	infusion	infusion	B-NP	NN	O	4	PMOD
6	through	through	B-PP	IN	O	2	VMOD
7	peripheral	peripheral	B-NP	JJ	O	8	NMOD
8	cannulae	cannulae	I-NP	NNS	O	6	PMOD
9	;	;	O	:	O	2	P
10	nephrotoxicity	nephrotoxicity	B-NP	NN	O	12	NMOD
11	and	and	I-NP	CC	O	12	NMOD
12	ototoxicity	ototoxicity	I-NP	NN	O	13	SUB
13	were	be	B-VP	VBD	O	0	ROOT
14	confined	confine	I-VP	VBN	O	13	VC
15	to	to	B-PP	TO	O	14	VMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	receiving	receive	B-VP	VBG	O	16	NMOD
18	an	an	B-NP	DT	O	21	NMOD
19	aminoglycoside	aminoglycoside	I-NP	NN	O	21	NMOD
20	plus	plus	I-NP	CC	O	21	NMOD
21	vancomycin	vancomycin	I-NP	NN	O	17	OBJ
22	.	.	O	.	O	13	P

1	Blockade	Blockade	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	both	both	O	CC	O	8	NMOD
4	D-1	D-1	B-NP	NN	B-protein	8	NMOD
5	and	and	O	CC	O	8	NMOD
6	D-2	D-2	B-NP	NN	B-protein	8	NMOD
7	dopamine	dopamine	I-NP	NN	I-protein	8	NMOD
8	receptors	receptor	I-NP	NNS	I-protein	2	PMOD
9	may	may	B-VP	MD	O	0	ROOT
10	induce	induce	I-VP	VB	O	9	VC
11	catalepsy	catalepsy	B-NP	NN	O	10	OBJ
12	in	in	B-PP	IN	O	10	VMOD
13	mice.	mice.	B-NP	NN	O	12	PMOD
14	1	1	I-NP	CD	O	13	NMOD
15	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	2	NMOD
2	catalepsy	catalepsy	I-NP	NN	O	7	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	dopamine	dopamine	B-NP	NN	O	6	NMOD
6	antagonists	antagonist	I-NP	NNS	O	4	PMOD
7	has	have	B-VP	VBZ	O	0	ROOT
8	been	be	I-VP	VBN	O	7	VC
9	tested	test	I-VP	VBN	O	8	VC
10	and	and	O	CC	O	7	VMOD
11	the	the	B-NP	DT	O	14	NMOD
12	possible	possible	I-NP	JJ	O	14	NMOD
13	dopamine	dopamine	I-NP	NN	O	14	NMOD
14	subtypes	subtype	I-NP	NNS	O	10	PRD
15	involved	involve	B-VP	VBN	O	14	NMOD
16	in	in	B-PP	IN	O	15	VMOD
17	catalepsy	catalepsy	B-NP	NN	B-protein	19	NMOD
18	was	be	B-VP	VBD	I-protein	19	NMOD
19	determined.	determined.	B-NP	NN	I-protein	16	PMOD
20	2	2	I-NP	CD	I-protein	19	NMOD
21	.	.	O	.	O	7	P

1	Dopamine	Dopamine	B-NP	NN	O	3	NMOD
2	antagonist	antagonist	I-NP	NN	O	3	NMOD
3	fluphenazine	fluphenazine	I-NP	NN	O	14	NMOD
4	,	,	O	,	O	14	P
5	D-1	D-1	B-NP	NN	O	7	NMOD
6	antagonist	antagonist	I-NP	NN	O	7	NMOD
7	SCH	SCH	I-NP	NN	O	14	NMOD
8	23390	23390	B-NP	CD	O	7	NMOD
9	or	or	I-NP	CC	O	12	NMOD
10	D-2	D-2	I-NP	NN	O	12	NMOD
11	antagonist	antagonist	I-NP	NN	O	12	NMOD
12	sulpiride	sulpiride	I-NP	NN	O	14	NMOD
13	induced	induce	B-VP	VBD	O	14	NMOD
14	catalepsy	catalepsy	B-NP	NN	O	0	ROOT
15	.	.	O	.	O	14	P

1	Combination	Combination	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	SCH	SCH	B-NP	NN	O	2	PMOD
4	23390	23390	I-NP	CD	O	3	NMOD
5	with	with	B-PP	IN	O	1	NMOD
6	sulpiride	sulpiride	B-NP	NN	O	5	PMOD
7	did	do	B-VP	VBD	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	induce	induce	I-VP	VB	O	7	VC
10	catalepsy	catalepsy	B-NP	NN	B-protein	11	NMOD
11	potentiation.	potentiation.	I-NP	NN	I-protein	9	OBJ
12	3	3	I-NP	CD	I-protein	11	NMOD
13	.	.	O	.	O	7	P

1	D-1	D-1	B-NP	NN	O	3	NMOD
2	agonist	agonist	I-NP	NN	O	3	NMOD
3	SKF	SKF	I-NP	NN	O	8	NMOD
4	38393	38393	B-NP	CD	O	3	NMOD
5	or	or	I-NP	CC	O	3	NMOD
6	D-2	D-2	I-NP	NN	O	8	NMOD
7	agonist	agonist	I-NP	NN	O	8	NMOD
8	quinpirole	quinpirole	I-NP	NN	O	9	SUB
9	decreased	decrease	B-VP	VBD	O	0	ROOT
10	the	the	B-NP	DT	O	11	NMOD
11	catalepsy	catalepsy	I-NP	NN	O	19	NMOD
12	induced	induce	B-VP	VBN	O	11	NMOD
13	by	by	B-PP	IN	O	12	VMOD
14	fluphenazine	fluphenazine	B-NP	NN	O	13	PMOD
15	,	,	O	,	O	19	P
16	SCH	SCH	B-NP	NN	O	19	NMOD
17	23390	23390	I-NP	CD	O	16	NMOD
18	or	or	O	CC	O	19	NMOD
19	sulpiride.	sulpiride.	B-NP	NN	O	9	OBJ
20	4	4	I-NP	CD	O	19	NMOD
21	.	.	O	.	O	9	P

1	Combination	Combination	B-NP	NN	O	7	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	SKF	SKF	B-NP	NN	O	2	PMOD
4	38393	38393	I-NP	CD	O	3	NMOD
5	with	with	B-PP	IN	O	1	NMOD
6	quinpirole	quinpirole	B-NP	NN	O	5	PMOD
7	did	do	B-VP	VBD	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	cause	cause	I-VP	VB	O	7	VC
10	potentiated	potentiated	B-NP	JJ	O	12	NMOD
11	inhibitory	inhibitory	I-NP	JJ	O	12	NMOD
12	effect	effect	I-NP	NN	O	9	OBJ
13	on	on	B-PP	IN	O	9	VMOD
14	catalepsy	catalepsy	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBN	O	14	NMOD
16	by	by	B-PP	IN	O	15	VMOD
17	dopamine	dopamine	B-NP	NN	B-protein	18	NMOD
18	antagonists.	antagonists.	I-NP	NN	I-protein	16	PMOD
19	5	5	I-NP	CD	I-protein	18	NMOD
20	.	.	O	.	O	7	P

1	Acute	Acute	B-NP	JJ	O	5	NMOD
2	analgesic	analgesic	I-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	antiinflammatory	antiinflammatory	I-NP	JJ	O	5	NMOD
5	activities	activity	I-NP	NNS	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	ascertained	ascertain	I-VP	VBN	O	6	VC
8	using	use	B-VP	VBG	O	6	VMOD
9	acetic	acetic	B-NP	JJ	O	10	NMOD
10	acid	acid	I-NP	NN	O	8	OBJ
11	induced	induce	B-VP	VBD	O	8	VMOD
12	writhing	writhe	I-VP	VBG	O	11	VMOD
13	model	model	B-NP	NN	O	18	NMOD
14	(	(	O	(	O	16	DEP
15	mice	mouse	B-NP	NNS	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	and	and	O	CC	O	18	NMOD
18	carrageenan	carrageenan	B-NP	NN	O	23	NMOD
19	induced	induce	B-VP	VBD	O	18	AMOD
20	rat	rat	B-NP	NN	O	23	NMOD
21	paw	paw	I-NP	NN	O	23	NMOD
22	edema	edema	I-NP	NN	O	23	NMOD
23	model	model	I-NP	NN	O	12	OBJ
24	,	,	O	,	O	11	P
25	respectively	respectively	B-ADVP	RB	O	11	VMOD
26	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	4	NMOD
2	47-year-old	47-year-old	I-NP	JJ	O	4	NMOD
3	female	female	I-NP	JJ	O	4	NMOD
4	patient	patient	I-NP	NN	O	12	SUB
5	,	,	O	,	O	4	P
6	known	know	B-VP	VBN	O	4	NMOD
7	to	to	I-VP	TO	O	8	VMOD
8	have	have	I-VP	VB	O	6	VMOD
9	hypertrophic	hypertrophic	B-NP	JJ	O	10	NMOD
10	cardiomyopathy	cardiomyopathy	I-NP	NN	O	8	OBJ
11	,	,	O	,	O	4	P
12	was	be	B-VP	VBD	O	0	ROOT
13	admitted	admit	I-VP	VBN	O	12	VC
14	with	with	B-PP	IN	O	13	VMOD
15	biventricular	biventricular	B-NP	JJ	O	16	NMOD
16	failure	failure	I-NP	NN	O	14	PMOD
17	and	and	O	CC	O	12	VMOD
18	managed	manage	B-VP	VBD	O	12	VMOD
19	aggressively	aggressively	B-ADVP	RB	O	18	VMOD
20	with	with	B-PP	IN	O	18	VMOD
21	dobutamine	dobutamine	B-NP	NN	O	22	NMOD
22	infusion	infusion	I-NP	NN	O	20	PMOD
23	and	and	O	CC	O	25	NMOD
24	other	other	B-NP	JJ	O	25	NMOD
25	drugs	drug	I-NP	NNS	O	22	NMOD
26	while	while	B-SBAR	IN	O	12	VMOD
27	being	be	B-VP	VBG	O	26	SBAR
28	assessed	assess	I-VP	VBN	O	27	VC
29	for	for	B-PP	IN	O	28	VMOD
30	heart	heart	B-NP	NN	O	31	NMOD
31	transplantation	transplantation	I-NP	NN	O	29	PMOD
32	.	.	O	.	O	12	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	likely	likely	B-ADJP	JJ	O	2	PRD
4	that	that	B-SBAR	IN	O	3	AMOD
5	the	the	B-NP	DT	O	6	NMOD
6	hypersensitivity	hypersensitivity	I-NP	NN	O	10	NMOD
7	(	(	O	(	O	9	DEP
8	eosinophilic	eosinophilic	O	JJ	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	myocarditis	myocarditis	B-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	4	SBAR
12	related	related	B-ADJP	JJ	O	11	PRD
13	to	to	B-PP	TO	O	12	AMOD
14	dobutamine	dobutamine	B-NP	NN	O	16	NMOD
15	infusion	infusion	I-NP	NN	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	2	P

1	All-	All-	B-NP	DT	O	3	NMOD
2	trans-retinoic	trans-retinoic	I-NP	JJ	O	3	NMOD
3	acid	acid	I-NP	NN	O	4	SUB
4	induced	induce	B-VP	VBD	O	0	ROOT
5	erythema	erythema	B-NP	NN	O	6	NMOD
6	nodosum	nodosum	I-NP	NN	O	4	OBJ
7	in	in	B-PP	IN	O	4	VMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	acute	acute	B-NP	JJ	O	12	NMOD
11	promyelocytic	promyelocytic	I-NP	JJ	O	12	NMOD
12	leukemia	leukemia	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	4	P

1	Erythema	Erythema	B-NP	NN	O	2	NMOD
2	nodosum	nodosum	I-NP	NN	O	18	SUB
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	all-	all-	B-NP	JJ	O	7	NMOD
6	trans-retinoic	trans-retinoic	I-NP	JJ	O	7	NMOD
7	acid	acid	I-NP	NN	O	4	PMOD
8	(	(	O	(	O	10	DEP
9	ATRA	ATRA	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	for	for	B-PP	IN	O	7	NMOD
12	acute	acute	B-NP	JJ	O	14	NMOD
13	promyelocytic	promyelocytic	I-NP	JJ	O	14	NMOD
14	leukemia	leukemia	I-NP	NN	O	11	PMOD
15	(	(	O	(	O	17	DEP
16	APL	APL	B-NP	NN	O	17	DEP
17	)	)	O	)	O	14	NMOD
18	is	be	B-VP	VBZ	O	0	ROOT
19	very	very	B-ADJP	RB	O	20	AMOD
20	rare	rare	I-ADJP	JJ	O	18	PRD
21	.	.	O	.	O	18	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	four	four	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	2	OBJ
5	with	with	B-PP	IN	O	4	NMOD
6	classic	classic	B-NP	JJ	O	7	NMOD
7	APL	APL	I-NP	NN	O	5	PMOD
8	who	who	B-NP	WP	O	4	NMOD
9	developed	develop	B-VP	VBD	O	8	SBAR
10	erythema	erythema	B-NP	NN	O	11	NMOD
11	nodosum	nodosum	I-NP	NN	O	9	OBJ
12	during	during	B-PP	IN	O	9	VMOD
13	ATRA	ATRA	B-NP	NN	O	14	NMOD
14	therapy	therapy	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	2	P

1	Fever	Fever	B-ADVP	RB	O	0	ROOT
2	and	and	O	CC	O	1	AMOD
3	subsequent	subsequent	B-NP	JJ	O	1	AMOD
4	multiple	multiple	I-NP	JJ	O	6	AMOD
5	painful	painful	I-NP	JJ	O	6	AMOD
6	erythematous	erythematous	I-NP	JJ	O	7	NMOD
7	nodules	nodule	I-NP	NNS	O	1	AMOD
8	over	over	B-PP	IN	O	7	NMOD
9	extremities	extremity	B-NP	NNS	O	8	PMOD
10	developed	develop	B-VP	VBN	O	9	NMOD
11	on	on	B-PP	IN	O	10	VMOD
12	D11	D11	B-NP	NN	B-protein	19	NMOD
13	,	,	O	,	O	19	P
14	D16	D16	B-NP	NN	B-protein	19	NMOD
15	,	,	O	,	O	19	P
16	D17	D17	B-NP	NN	B-protein	19	NMOD
17	,	,	O	,	O	19	P
18	and	and	O	CC	O	19	NMOD
19	D19	D19	B-NP	NN	B-protein	11	PMOD
20	,	,	O	,	O	7	P
21	respectively	respectively	B-ADVP	RB	O	7	NMOD
22	,	,	O	,	O	21	P
23	after	after	B-PP	IN	O	21	PMOD
24	ATRA	ATRA	B-NP	NN	O	25	NMOD
25	therapy	therapy	I-NP	NN	O	23	PMOD
26	.	.	O	.	O	1	P

1	ATRA	ATRA	B-NP	NN	O	2	SUB
2	seemed	seem	B-VP	VBD	O	0	ROOT
3	to	to	I-VP	TO	O	4	VMOD
4	be	be	I-VP	VB	O	2	VMOD
5	the	the	B-NP	DT	O	8	NMOD
6	most	most	I-NP	RBS	O	7	AMOD
7	possible	possible	I-NP	JJ	O	8	NMOD
8	etiology	etiology	I-NP	NN	O	4	PRD
9	of	of	B-PP	IN	O	8	NMOD
10	erythema	erythema	B-NP	NN	O	11	NMOD
11	nodosum	nodosum	I-NP	NN	O	9	PMOD
12	in	in	B-PP	IN	O	4	VMOD
13	our	our	B-NP	PRP$	O	14	NMOD
14	patients	patient	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	2	P

1	Delayed-onset	Delayed-onset	B-NP	JJ	O	2	NMOD
2	heparin	heparin	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	0	ROOT
4	thrombocytopenia	thrombocytopenia	B-NP	NN	O	3	OBJ
5	.	.	O	.	O	3	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Heparin	Heparin	B-NP	NN	O	1	NMOD
4	induced	induce	B-VP	VBD	O	3	SBAR
5	thrombocytopenia	thrombocytopenia	B-NP	NN	B-protein	6	NMOD
6	presents	present	I-NP	NNS	I-protein	4	OBJ
7	5	5	B-NP	CD	I-protein	6	NMOD
8	to	to	I-NP	TO	O	6	NMOD
9	12	12	I-NP	CD	O	10	NMOD
10	days	day	I-NP	NNS	O	8	PMOD
11	after	after	B-PP	IN	O	4	VMOD
12	heparin	heparin	B-NP	NN	O	13	NMOD
13	exposure	exposure	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	4	P
15	with	with	B-PP	IN	O	4	VMOD
16	or	or	B-PP	CC	O	15	PMOD
17	without	without	B-PP	IN	O	15	PMOD
18	arterial	arterial	B-NP	JJ	O	21	NMOD
19	or	or	I-NP	CC	O	21	NMOD
20	venous	venous	I-NP	JJ	O	21	NMOD
21	thromboemboli	thromboemboli	I-NP	NNS	O	15	PMOD
22	.	.	O	.	O	1	P

1	Delayed	Delay	B-NP	VBN	O	4	NMOD
2	recognition	recognition	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	heparin	heparin	B-NP	NN	O	8	NMOD
7	induced	induced	I-NP	JJ	O	8	NMOD
8	thrombocytopenia	thrombocytopenia	I-NP	NN	O	5	PMOD
9	contribute	contribute	B-VP	VBP	O	0	ROOT
10	to	to	B-PP	TO	O	9	VMOD
11	poor	poor	B-NP	JJ	O	13	NMOD
12	patient	patient	I-NP	NN	O	13	NMOD
13	outcomes	outcome	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	9	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	describe	describe	I-VP	VB	O	1	NMOD
5	and	and	I-VP	CC	O	4	VMOD
6	increase	increase	I-VP	VB	O	4	VMOD
7	awareness	awareness	B-NP	NN	O	6	OBJ
8	of	of	B-PP	IN	O	7	NMOD
9	a	a	B-NP	DT	O	11	NMOD
10	clinical	clinical	I-NP	JJ	O	11	NMOD
11	scenario	scenario	I-NP	NN	O	8	PMOD
12	in	in	B-PP	IN	O	11	NMOD
13	which	which	B-NP	WDT	O	12	PMOD
14	the	the	B-NP	DT	O	17	NMOD
15	onset	onset	I-NP	NN	O	17	NMOD
16	or	or	I-NP	CC	O	17	NMOD
17	manifestations	manifestation	I-NP	NNS	O	22	SUB
18	of	of	B-PP	IN	O	17	NMOD
19	heparin	heparin	B-NP	NN	O	21	NMOD
20	induced	induced	I-NP	JJ	O	21	NMOD
21	thrombocytopenia	thrombocytopenia	I-NP	NN	O	18	PMOD
22	are	be	B-VP	VBP	O	12	SBAR
23	delayed	delay	I-VP	VBN	O	22	VC
24	.	.	O	.	O	1	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	4	NMOD
2	:	:	O	:	O	1	P
3	14	14	B-NP	CD	O	4	NMOD
4	patients	patient	I-NP	NNS	O	0	ROOT
5	seen	see	B-VP	VBN	O	4	NMOD
6	over	over	B-PP	IN	O	5	VMOD
7	a	a	B-NP	DT	O	9	NMOD
8	3-year	3-year	I-NP	JJ	O	9	NMOD
9	period	period	I-NP	NN	O	6	PMOD
10	in	in	B-PP	IN	O	5	VMOD
11	whom	whom	B-NP	WP	O	10	PMOD
12	heparin	heparin	B-NP	NN	O	14	NMOD
13	induced	induce	I-NP	VBN	O	14	NMOD
14	thrombocytopenia	thrombocytopenia	I-NP	NN	O	15	SUB
15	became	become	B-VP	VBD	O	11	SBAR
16	apparent	apparent	B-ADJP	JJ	O	15	PRD
17	on	on	B-PP	IN	O	16	AMOD
18	delayed	delay	B-NP	VBN	O	19	NMOD
19	presentation	presentation	I-NP	NN	O	17	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	thromboembolic	thromboembolic	B-NP	JJ	O	22	NMOD
22	complications	complication	I-NP	NNS	O	20	PMOD
23	.	.	O	.	O	4	P

1	MEASUREMENTS	MEASUREMENTS	B-NP	NNS	O	23	NMOD
2	:	:	O	:	O	1	P
3	Platelet	Platelet	B-NP	NN	O	4	NMOD
4	counts	count	I-NP	NNS	O	15	SUB
5	,	,	O	,	O	15	P
6	onset	onset	B-NP	NN	O	15	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	objectively	objectively	B-NP	RB	O	9	AMOD
9	determined	determine	I-NP	VBN	O	10	NMOD
10	thromboembolism	thromboembolism	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	15	P
12	results	result	B-NP	NNS	O	15	SUB
13	of	of	B-PP	IN	O	12	NMOD
14	heparin	heparin	B-NP	NN	O	13	PMOD
15	induced	induce	B-VP	VBD	O	23	NMOD
16	platelet	platelet	B-NP	NN	B-protein	20	NMOD
17	factor	factor	I-NP	NN	I-protein	20	NMOD
18	4	4	I-NP	CD	I-protein	20	NMOD
19	antibody	antibody	I-NP	NN	I-protein	20	NMOD
20	tests	test	I-NP	NNS	O	15	OBJ
21	,	,	O	,	O	23	P
22	and	and	O	CC	O	23	NMOD
23	outcomes	outcome	B-NP	NNS	O	0	ROOT
24	.	.	O	.	O	23	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Patients	Patient	B-NP	NNS	O	4	SUB
4	went	go	B-VP	VBD	O	21	VMOD
5	home	home	B-ADVP	RB	O	4	VMOD
6	after	after	B-PP	IN	O	4	VMOD
7	hospitalizations	hospitalization	B-NP	NNS	O	6	PMOD
8	that	that	B-NP	WDT	O	7	NMOD
9	had	have	B-VP	VBD	O	8	SBAR
10	included	include	I-VP	VBN	O	12	NMOD
11	heparin	heparin	B-NP	NN	O	12	NMOD
12	exposure	exposure	I-NP	NN	O	9	OBJ
13	--	--	O	:	O	21	P
14	in	in	B-PP	IN	O	21	VMOD
15	most	most	B-NP	JJS	O	16	NMOD
16	cases	case	I-NP	NNS	O	14	PMOD
17	,	,	O	,	O	21	P
18	with	with	B-PP	IN	O	21	VMOD
19	no	no	B-NP	DT	O	20	NMOD
20	thrombocytopenia	thrombocytopenia	I-NP	NN	O	18	PMOD
21	recognized	recognize	B-VP	VBD	O	1	NMOD
22	--	--	O	:	O	21	P
23	only	only	B-ADVP	RB	O	25	VMOD
24	to	to	B-VP	TO	O	25	VMOD
25	return	return	I-VP	VB	O	21	VMOD
26	to	to	B-PP	TO	O	25	VMOD
27	the	the	B-NP	DT	O	28	NMOD
28	hospital	hospital	I-NP	NN	O	26	PMOD
29	(	(	O	(	O	34	DEP
30	median	median	B-NP	NN	O	32	NMOD
31	,	,	O	,	O	32	P
32	day	day	B-NP	NN	O	34	DEP
33	14	14	I-NP	CD	O	32	NMOD
34	)	)	O	)	O	28	NMOD
35	with	with	B-PP	IN	O	28	NMOD
36	thromboembolic	thromboembolic	B-NP	JJ	O	37	NMOD
37	complications	complication	I-NP	NNS	O	35	PMOD
38	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Delayed-onset	Delayed-onset	B-NP	JJ	O	6	NMOD
4	heparin	heparin	I-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	thrombocytopenia	thrombocytopenia	I-NP	NN	O	7	SUB
7	is	be	B-VP	VBZ	O	1	NMOD
8	increasingly	increasingly	I-VP	RB	O	9	VMOD
9	being	be	I-VP	VBG	O	7	VC
10	recognized	recognize	I-VP	VBN	O	9	VC
11	.	.	O	.	O	1	P

1	Valsartan	Valsartan	B-NP	NNP	O	7	NMOD
2	,	,	O	,	O	7	P
3	a	a	B-NP	DT	O	7	NMOD
4	new	new	I-NP	JJ	O	7	NMOD
5	angiotensin	angiotensin	I-NP	NN	O	7	NMOD
6	II	II	I-NP	CD	O	7	NMOD
7	antagonist	antagonist	I-NP	NN	O	17	NMOD
8	for	for	B-PP	IN	O	7	NMOD
9	the	the	B-NP	DT	O	10	NMOD
10	treatment	treatment	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	essential	essential	B-NP	JJ	O	13	NMOD
13	hypertension	hypertension	I-NP	NN	O	11	PMOD
14	:	:	O	:	O	7	P
15	a	a	B-NP	DT	O	17	NMOD
16	comparative	comparative	I-NP	JJ	O	17	NMOD
17	study	study	I-NP	NN	O	0	ROOT
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	22	NMOD
20	efficacy	efficacy	I-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	safety	safety	I-NP	NN	O	18	PMOD
23	against	against	B-PP	IN	O	22	NMOD
24	amlodipine	amlodipine	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	17	P

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	One	One	B-NP	CD	O	7	NMOD
4	hundred	hundred	I-NP	CD	O	7	NMOD
5	sixty-eight	sixty-eight	I-NP	JJ	O	6	AMOD
6	adult	adult	I-NP	JJ	O	7	NMOD
7	outpatients	outpatient	I-NP	NNS	O	13	SUB
8	with	with	B-PP	IN	O	7	NMOD
9	mild	mild	B-ADJP	JJ	O	8	PMOD
10	to	to	B-PP	TO	O	9	AMOD
11	moderate	moderate	B-NP	JJ	O	12	NMOD
12	hypertension	hypertension	I-NP	NN	O	10	PMOD
13	were	be	B-VP	VBD	O	1	NMOD
14	randomly	randomly	I-VP	RB	O	13	VMOD
15	allocated	allocate	I-VP	VBN	O	13	VC
16	in	in	B-PP	IN	O	15	VMOD
17	double-blind	double-blind	B-NP	JJ	O	18	NMOD
18	fashion	fashion	I-NP	NN	O	16	PMOD
19	and	and	O	CC	O	13	VMOD
20	equal	equal	B-NP	JJ	O	21	NMOD
21	number	number	I-NP	NN	O	19	OBJ
22	to	to	B-VP	TO	O	23	VMOD
23	receive	receive	I-VP	VB	O	21	NMOD
24	80	80	B-NP	CD	O	26	NMOD
25	mg	mg	I-NP	NN	O	26	NMOD
26	valsartan	valsartan	I-NP	NN	O	30	NMOD
27	or	or	O	CC	O	30	NMOD
28	5	5	B-NP	CD	O	29	AMOD
29	mg	mg	I-NP	NN	O	30	NMOD
30	amlodipine	amlodipine	I-NP	NN	O	23	OBJ
31	for	for	B-PP	IN	O	30	NMOD
32	12	12	B-NP	CD	O	33	NMOD
33	weeks	week	I-NP	NNS	O	31	PMOD
34	.	.	O	.	O	1	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	drug-related	drug-related	B-NP	JJ	O	5	AMOD
5	dependent	dependent	I-NP	JJ	O	6	NMOD
6	edema	edema	I-NP	NN	O	3	PMOD
7	was	be	B-VP	VBD	O	0	ROOT
8	somewhat	somewhat	B-ADJP	RB	O	9	AMOD
9	higher	high	I-ADJP	JJR	O	7	PRD
10	in	in	B-PP	IN	O	9	AMOD
11	the	the	B-NP	DT	O	13	NMOD
12	amlodipine	amlodipine	I-NP	NN	O	13	NMOD
13	group	group	I-NP	NN	O	10	PMOD
14	,	,	O	,	O	9	P
15	particularly	particularly	B-ADVP	RB	O	16	PMOD
16	at	at	B-PP	IN	O	9	AMOD
17	a	a	B-NP	DT	O	18	NMOD
18	dose	dose	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	10	10	B-NP	CD	O	21	NMOD
21	mg	mg	I-NP	NN	O	19	PMOD
22	per	per	B-PP	IN	O	18	NMOD
23	day	day	B-NP	NN	O	22	PMOD
24	(	(	O	(	O	54	DEP
25	2.4	2.4	B-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	40	NMOD
27	for	for	B-PP	IN	O	26	NMOD
28	80	80	B-NP	CD	O	29	AMOD
29	mg	mg	I-NP	NN	O	30	NMOD
30	valsartan	valsartan	I-NP	NN	O	27	PMOD
31	;	;	O	:	O	40	P
32	3.6	3.6	B-NP	CD	O	33	NMOD
33	%	%	I-NP	NN	O	40	NMOD
34	for	for	B-PP	IN	O	33	NMOD
35	5	5	B-NP	CD	O	36	AMOD
36	mg	mg	I-NP	NN	O	37	NMOD
37	amlodipine	amlodipine	I-NP	NN	O	34	PMOD
38	;	;	O	:	O	40	P
39	0	0	B-NP	CD	O	40	NMOD
40	%	%	I-NP	NN	O	54	DEP
41	for	for	B-PP	IN	O	40	NMOD
42	valsartan	valsartan	B-NP	NN	O	46	NMOD
43	plus	plus	O	CC	O	46	NMOD
44	5	5	B-NP	CD	O	45	AMOD
45	mg	mg	I-NP	NN	O	46	NMOD
46	amlodipine	amlodipine	I-NP	NN	O	41	PMOD
47	;	;	O	:	O	54	P
48	14.3	14.3	B-NP	CD	O	49	NMOD
49	%	%	I-NP	NN	O	54	DEP
50	for	for	B-PP	IN	O	49	NMOD
51	10	10	B-NP	CD	O	52	AMOD
52	mg	mg	I-NP	NN	O	53	NMOD
53	amlodipine	amlodipine	I-NP	NN	O	50	PMOD
54	)	)	O	)	O	18	NMOD
55	.	.	O	.	O	7	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	4	NMOD
4	data	datum	I-NP	NNS	O	5	SUB
5	show	show	B-VP	VBP	O	1	NMOD
6	that	that	B-SBAR	IN	O	5	VMOD
7	valsartan	valsartan	B-NP	NN	O	8	SUB
8	is	be	B-VP	VBZ	O	6	SBAR
9	at	at	B-ADVP	IN	O	13	PMOD
10	least	least	I-ADVP	JJS	O	9	AMOD
11	as	as	B-ADJP	RB	O	12	AMOD
12	effective	effective	I-ADJP	JJ	O	9	AMOD
13	as	as	B-PP	IN	O	8	PRD
14	amlodipine	amlodipine	B-NP	NN	O	13	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	treatment	treatment	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	mild	mild	B-NP	JJ	O	18	PMOD
20	to	to	B-PP	TO	O	17	NMOD
21	moderate	moderate	B-NP	JJ	O	22	NMOD
22	hypertension	hypertension	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	1	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	14	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	KF17837	KF17837	B-NP	NN	O	3	PMOD
5	(	(	O	(	O	12	DEP
6	2.5	2.5	B-NP	CD	O	11	NMOD
7	,	,	I-NP	,	O	11	P
8	10.0	10.0	I-NP	CD	O	11	NMOD
9	and	and	I-NP	CC	O	11	NMOD
10	30.0	30.0	I-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	12	DEP
12	)	)	O	)	O	4	NMOD
13	significantly	significantly	B-VP	RB	O	14	VMOD
14	ameliorated	ameliorate	I-VP	VBD	O	0	ROOT
15	the	the	B-NP	DT	O	17	NMOD
16	cataleptic	cataleptic	I-NP	JJ	O	17	NMOD
17	responses	response	I-NP	NNS	O	14	OBJ
18	induced	induce	B-VP	VBN	O	17	NMOD
19	by	by	B-PP	IN	O	18	VMOD
20	intracerebroventricular	intracerebroventricular	B-NP	JJ	O	21	NMOD
21	administration	administration	I-NP	NN	O	19	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	an	an	B-NP	DT	O	27	NMOD
24	adenosine	adenosine	I-NP	NN	B-protein	27	NMOD
25	A2A	A2A	I-NP	NN	I-protein	27	NMOD
26	receptor	receptor	I-NP	NN	I-protein	27	NMOD
27	agonist	agonist	I-NP	NN	O	22	PMOD
28	,	,	O	,	O	14	P
29	CGS	CGS	B-NP	NN	O	14	VMOD
30	21680	21680	I-NP	CD	O	29	NMOD
31	(	(	O	(	O	34	DEP
32	10	10	B-NP	CD	O	33	NMOD
33	micrograms	microgram	I-NP	NNS	O	34	DEP
34	)	)	O	)	O	29	NMOD
35	,	,	O	,	O	29	P
36	in	in	B-PP	IN	O	29	NMOD
37	a	a	B-NP	DT	O	39	NMOD
38	dose-dependent	dose-dependent	I-NP	JJ	O	39	NMOD
39	manner	manner	I-NP	NN	O	36	PMOD
40	.	.	O	.	O	14	P

1	KF17837	KF17837	B-NP	NN	O	3	SUB
2	also	also	B-ADVP	RB	O	3	VMOD
3	reduced	reduce	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	catalepsy	catalepsy	I-NP	NN	O	3	OBJ
6	induced	induce	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	haloperidol	haloperidol	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	13	DEP
10	1	1	B-NP	CD	O	11	NMOD
11	mg/kg	mg/kg	I-NP	NN	O	13	DEP
12	i.p.	i.p.	B-ADVP	RB	O	11	NMOD
13	)	)	O	)	O	8	NMOD
14	and	and	O	CC	O	3	VMOD
15	by	by	B-PP	IN	O	3	VMOD
16	reserpine	reserpine	B-NP	NN	O	15	PMOD
17	(	(	O	(	O	21	DEP
18	5	5	B-NP	CD	O	19	NMOD
19	mg/kg	mg/kg	I-NP	NN	O	21	DEP
20	i.p.	i.p.	B-ADVP	RB	O	19	NMOD
21	)	)	O	)	O	16	NMOD
22	.	.	O	.	O	3	P

1	A	A	B-NP	DT	O	3	NMOD
2	repeated	repeat	I-NP	VBN	O	3	NMOD
3	treatment	treatment	I-NP	NN	O	13	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	fluvoxamine	fluvoxamine	B-NP	NN	O	4	PMOD
6	(	(	O	(	O	12	DEP
7	twice	twice	B-ADVP	RB	O	12	DEP
8	daily	daily	I-ADVP	RB	O	7	AMOD
9	for	for	B-PP	IN	O	7	DEP
10	14	14	B-NP	CD	O	11	NMOD
11	days	day	I-NP	NNS	O	9	PMOD
12	)	)	O	)	O	5	NMOD
13	potentiated	potentiate	B-VP	VBD	O	0	ROOT
14	in	in	B-PP	IN	O	13	VMOD
15	mice	mouse	B-NP	NNS	O	14	PMOD
16	and	and	B-PP	CC	O	14	PMOD
17	in	in	B-PP	IN	O	14	PMOD
18	rats	rat	B-NP	NNS	O	17	PMOD
19	(	(	O	(	O	21	DEP
20	weaker	weak	B-ADJP	JJR	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	the	the	B-NP	DT	O	25	NMOD
23	amphetamine	amphetamine	I-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	hyperactivity	hyperactivity	I-NP	NN	O	13	OBJ
26	.	.	O	.	O	13	P

1	The	The	B-NP	DT	O	2	NMOD
2	hyperactivity	hyperactivity	I-NP	NN	O	8	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	nomifensine	nomifensine	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	VMOD
7	mice	mouse	B-NP	NNS	O	6	PMOD
8	remained	remain	B-VP	VBD	O	0	ROOT
9	unaffected	unaffected	B-ADJP	JJ	O	8	VC
10	by	by	B-PP	IN	O	9	VMOD
11	fluvoxamine	fluvoxamine	B-NP	NN	O	10	PMOD
12	.	.	O	.	O	8	P

1	Severe	Severe	B-NP	JJ	O	5	NMOD
2	congestive	congestive	I-NP	JJ	O	5	NMOD
3	heart	heart	I-NP	NN	O	5	NMOD
4	failure	failure	I-NP	NN	O	5	NMOD
5	patient	patient	I-NP	NN	O	15	NMOD
6	on	on	B-PP	IN	O	5	NMOD
7	amiodarone	amiodarone	B-NP	NN	O	6	PMOD
8	presenting	present	B-VP	VBG	O	5	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	myxedemic	myxedemic	B-NP	JJ	O	11	NMOD
11	coma	coma	I-NP	NN	O	9	PMOD
12	:	:	O	:	O	5	P
13	a	a	B-NP	DT	O	15	NMOD
14	case	case	I-NP	NN	O	15	NMOD
15	report	report	I-NP	NN	O	0	ROOT
16	.	.	O	.	O	15	P

1	This	This	B-NP	DT	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	case	case	I-NP	NN	O	5	NMOD
5	report	report	I-NP	NN	O	12	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	myxedema	myxedema	B-NP	NN	O	8	NMOD
8	coma	coma	I-NP	NN	O	6	PMOD
9	secondary	secondary	B-ADJP	JJ	O	8	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	amiodarone	amiodarone	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	2	VMOD
13	hypothyroidism	hypothyroidism	B-NP	NN	O	12	OBJ
14	in	in	B-PP	IN	O	12	VMOD
15	a	a	B-NP	DT	O	16	NMOD
16	patient	patient	I-NP	NN	O	14	PMOD
17	with	with	B-PP	IN	O	16	NMOD
18	severe	severe	B-NP	JJ	O	21	NMOD
19	congestive	congestive	I-NP	JJ	O	21	NMOD
20	heart	heart	I-NP	NN	O	21	NMOD
21	failure	failure	I-NP	NN	O	17	PMOD
22	(	(	O	(	O	24	DEP
23	CHF	CHF	B-NP	NN	B-protein	24	DEP
24	)	)	O	)	O	21	NMOD
25	.	.	O	.	O	2	P

1	To	To	B-PP	TO	O	10	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	knowledge	knowledge	I-NP	NN	O	1	PMOD
4	and	and	B-PP	CC	O	1	PMOD
5	after	after	B-PP	IN	O	1	PMOD
6	reviewing	review	B-VP	VBG	O	5	PMOD
7	the	the	B-NP	DT	O	8	NMOD
8	literature	literature	I-NP	NN	O	6	OBJ
9	there	there	B-NP	EX	O	1	VMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	one	one	B-NP	CD	O	13	NMOD
12	case	case	I-NP	NN	O	13	NMOD
13	report	report	I-NP	NN	O	10	PRD
14	of	of	B-PP	IN	O	13	NMOD
15	myxedema	myxedema	B-NP	NN	O	16	NMOD
16	coma	coma	I-NP	NN	O	14	PMOD
17	during	during	B-PP	IN	O	10	VMOD
18	long	long	B-NP	JJ	O	21	NMOD
19	term	term	I-NP	NN	O	21	NMOD
20	amiodarone	amiodarone	I-NP	NN	O	21	NMOD
21	therapy	therapy	I-NP	NN	O	17	PMOD
22	.	.	O	.	O	10	P

1	Patients	Patient	B-NP	NNS	O	6	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	CHF	CHF	B-NP	NN	B-protein	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	amiodarone	amiodarone	B-NP	NN	O	4	PMOD
6	may	may	B-VP	MD	O	0	ROOT
7	suffer	suffer	I-VP	VB	O	6	VC
8	serious	serious	B-NP	JJ	O	9	NMOD
9	morbidity	morbidity	I-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	mortality	mortality	I-NP	NN	O	7	OBJ
12	from	from	B-PP	IN	O	11	NMOD
13	hypothyroidism	hypothyroidism	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	6	P
15	and	and	O	CC	O	6	VMOD
16	thus	thus	B-VP	RB	O	6	VMOD
17	may	may	I-VP	MD	O	6	VMOD
18	deserve	deserve	I-VP	VB	O	17	VC
19	closer	closer	B-VP	RBR	O	20	VMOD
20	follow	follow	I-VP	VB	O	18	VMOD
21	up	up	B-PRT	RP	O	20	VMOD
22	for	for	B-PP	IN	O	20	VMOD
23	thyroid	thyroid	B-NP	NN	O	22	PMOD
24	stimulating	stimulate	B-VP	VBG	O	23	NMOD
25	hormone	hormone	B-NP	NN	O	29	NMOD
26	(	(	O	(	O	28	DEP
27	TSH	TSH	B-NP	NN	O	28	DEP
28	)	)	O	)	O	25	NMOD
29	levels	level	B-NP	NNS	O	24	OBJ
30	.	.	O	.	O	6	P

1	This	This	B-NP	DT	O	3	NMOD
2	case	case	I-NP	NN	O	3	NMOD
3	report	report	I-NP	NN	O	4	SUB
4	carries	carry	B-VP	VBZ	O	0	ROOT
5	an	an	B-NP	DT	O	8	NMOD
6	important	important	I-NP	JJ	O	7	AMOD
7	clinical	clinical	I-NP	JJ	O	8	NMOD
8	application	application	I-NP	NN	O	4	OBJ
9	given	give	B-PP	VBN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	frequent	frequent	I-NP	JJ	O	12	NMOD
12	usage	usage	I-NP	NN	O	9	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	amiodarone	amiodarone	B-NP	NN	O	13	PMOD
15	among	among	B-PP	IN	O	12	NMOD
16	CHF	CHF	B-NP	NN	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	4	P

1	Proteinase	Proteinase	B-NP	NN	B-protein	4	NMOD
2	3-antineutrophil	3-antineutrophil	I-NP	NN	I-protein	4	NMOD
3	cytoplasmic	cytoplasmic	I-NP	JJ	I-protein	4	NMOD
4	antibody-	antibody-	I-NP	NN	I-protein	10	NMOD
5	(	(	O	(	O	7	DEP
6	PR3-ANCA	PR3-ANCA	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	positive	positive	B-NP	JJ	O	10	NMOD
9	necrotizing	necrotize	I-NP	VBG	O	10	NMOD
10	glomerulonephritis	glomerulonephritis	I-NP	NN	O	0	ROOT
11	after	after	B-PP	IN	O	10	NMOD
12	restarting	restart	B-VP	VBG	O	11	PMOD
13	sulphasalazine	sulphasalazine	B-NP	NN	O	14	NMOD
14	treatment	treatment	I-NP	NN	O	12	OBJ
15	.	.	O	.	O	10	P

1	A	A	B-NP	DT	O	3	NMOD
2	59-year-old	59-year-old	I-NP	JJ	O	3	NMOD
3	woman	woman	I-NP	NN	O	7	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	ulcerative	ulcerative	B-NP	JJ	O	6	NMOD
6	colitis	colitis	I-NP	NN	O	4	PMOD
7	developed	develop	B-VP	VBD	O	0	ROOT
8	red	red	B-NP	JJ	O	9	NMOD
9	eyes	eye	I-NP	NNS	O	17	NMOD
10	,	,	O	,	O	17	P
11	pleural	pleural	B-NP	JJ	O	12	NMOD
12	effusion	effusion	I-NP	NN	O	17	NMOD
13	,	,	O	,	O	17	P
14	eosinophilia	eosinophilia	B-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	urinary	urinary	B-NP	JJ	O	17	NMOD
17	abnormalities	abnormality	I-NP	NNS	O	7	OBJ
18	after	after	B-PP	IN	O	17	NMOD
19	restarting	restart	B-VP	VBG	O	18	PMOD
20	of	of	B-PP	IN	O	19	VMOD
21	sulphasalazine	sulphasalazine	B-NP	NN	O	22	NMOD
22	treatment	treatment	I-NP	NN	O	20	PMOD
23	.	.	O	.	O	7	P

1	Although	Although	B-SBAR	IN	O	30	VMOD
2	cessation	cessation	B-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	sulphasalazine	sulphasalazine	B-NP	NN	O	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	resulted	result	B-VP	VBD	O	1	SBAR
7	in	in	B-PP	IN	O	6	VMOD
8	improvements	improvement	B-NP	NNS	O	23	NMOD
9	in	in	B-PP	IN	O	8	NMOD
10	fever	fever	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	23	P
12	red	red	B-NP	JJ	O	13	NMOD
13	eyes	eye	I-NP	NNS	O	23	NMOD
14	,	,	O	,	O	23	P
15	chest	chest	B-NP	NN	O	16	NMOD
16	pain	pain	I-NP	NN	O	23	NMOD
17	,	,	O	,	O	23	P
18	titer	titer	B-NP	NN	O	23	NMOD
19	of	of	B-PP	IN	O	18	NMOD
20	C-reactive	C-reactive	B-NP	JJ	B-protein	21	NMOD
21	protein	protein	I-NP	NN	I-protein	19	PMOD
22	and	and	I-NP	CC	O	23	NMOD
23	volume	volume	I-NP	NN	O	7	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	the	the	B-NP	DT	O	27	NMOD
26	pleural	pleural	I-NP	JJ	O	27	NMOD
27	effusions	effusion	I-NP	NNS	O	24	PMOD
28	,	,	O	,	O	30	P
29	we	we	B-NP	PRP	O	30	SUB
30	initiated	initiate	B-VP	VBD	O	0	ROOT
31	steroid	steroid	B-NP	NN	O	32	NMOD
32	therapy	therapy	I-NP	NN	O	30	OBJ
33	,	,	O	,	O	30	P
34	because	because	B-SBAR	IN	O	30	VMOD
35	PR3-ANCA	PR3-ANCA	B-NP	NN	O	36	NMOD
36	titer	titer	I-NP	NN	O	37	SUB
37	rose	rise	B-VP	VBD	O	44	VMOD
38	to	to	B-PP	TO	O	37	VMOD
39	320	320	B-NP	CD	O	40	NMOD
40	EU	EU	I-NP	NN	O	38	PMOD
41	,	,	O	,	O	44	P
42	eosinophil	eosinophil	B-NP	NN	O	43	NMOD
43	count	count	I-NP	NN	O	44	SUB
44	increased	increase	B-VP	VBD	O	34	SBAR
45	to	to	B-PP	TO	O	44	VMOD
46	1	1	B-NP	CD	O	54	NMOD
47	,	,	O	,	O	54	P
48	100	100	B-NP	CD	O	49	NMOD
49	cells/microl	cells/microl	I-NP	NN	O	54	NMOD
50	,	,	O	,	O	54	P
51	and	and	O	CC	O	54	NMOD
52	the	the	B-NP	DT	O	54	NMOD
53	pleural	pleural	I-NP	JJ	O	54	NMOD
54	effusion	effusion	I-NP	NN	O	45	PMOD
55	remained	remain	B-VP	VBD	O	44	VMOD
56	.	.	O	.	O	30	P

1	One	One	B-NP	CD	O	2	NMOD
2	month	month	I-NP	NN	O	10	SUB
3	after	after	B-PP	IN	O	2	NMOD
4	steroid	steroid	B-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	10	P
7	the	the	B-NP	DT	O	9	NMOD
8	pleural	pleural	I-NP	JJ	O	9	NMOD
9	effusion	effusion	I-NP	NN	O	10	SUB
10	disappeared	disappear	B-VP	VBD	O	15	VMOD
11	,	,	O	,	O	15	P
12	and	and	O	CC	O	15	VMOD
13	PR3-ANCA	PR3-ANCA	B-NP	NN	O	14	NMOD
14	titer	titer	I-NP	NN	O	15	SUB
15	normalized	normalize	B-VP	VBD	O	0	ROOT
16	3	3	B-NP	CD	O	17	NMOD
17	months	month	I-NP	NNS	O	15	OBJ
18	later	later	B-ADVP	RB	O	15	VMOD
19	.	.	O	.	O	15	P

1	Is	Be	O	VBZ	O	0	ROOT
2	phenytoin	phenytoin	B-NP	NN	O	3	NMOD
3	administration	administration	I-NP	NN	O	1	OBJ
4	safe	safe	B-ADJP	JJ	O	3	NMOD
5	in	in	B-PP	IN	O	4	AMOD
6	a	a	B-NP	DT	O	8	NMOD
7	hypothermic	hypothermic	I-NP	JJ	O	8	NMOD
8	child	child	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	1	P

1	Intravenous	Intravenous	B-NP	JJ	O	2	NMOD
2	phenytoin	phenytoin	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	administered	administer	I-VP	VBN	O	3	VC
5	during	during	B-PP	IN	O	4	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	later	later	I-NP	JJ	O	8	NMOD
8	part	part	I-NP	NN	O	5	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	surgery	surgery	I-NP	NN	O	9	PMOD
12	for	for	B-PP	IN	O	11	NMOD
13	seizure	seizure	B-NP	NN	O	14	NMOD
14	prophylaxis	prophylaxis	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	3	P

1	Following	Follow	B-PP	VBG	O	7	VMOD
2	phenytoin	phenytoin	B-NP	NN	O	3	NMOD
3	administration	administration	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	7	P
5	the	the	B-NP	DT	O	6	NMOD
6	patient	patient	I-NP	NN	O	7	SUB
7	developed	develop	B-VP	VBD	O	0	ROOT
8	acute	acute	B-NP	JJ	O	10	NMOD
9	severe	severe	I-NP	JJ	O	10	NMOD
10	bradycardia	bradycardia	I-NP	NN	O	7	OBJ
11	,	,	O	,	O	10	P
12	refractory	refractory	B-ADJP	JJ	O	10	NMOD
13	to	to	B-PP	TO	O	12	AMOD
14	atropine	atropine	B-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	adrenaline	adrenaline	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	7	P

1	The	The	B-NP	DT	O	4	NMOD
2	cardiac	cardiac	I-NP	JJ	O	4	NMOD
3	depressant	depressant	I-NP	JJ	O	4	NMOD
4	actions	action	I-NP	NNS	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	phenytoin	phenytoin	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	hypothermia	hypothermia	I-NP	NN	O	5	PMOD
9	can	can	B-VP	MD	O	0	ROOT
10	be	be	I-VP	VB	O	9	VC
11	additive	additive	B-ADJP	JJ	O	10	PRD
12	.	.	O	.	O	9	P

1	Administration	Administration	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	phenytoin	phenytoin	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	the	the	I-PP	DT	O	6	NMOD
6	presence	presence	I-PP	NN	O	4	PMOD
7	of	of	I-PP	IN	O	6	NMOD
8	hypothermia	hypothermia	B-NP	NN	O	7	PMOD
9	may	may	B-VP	MD	O	0	ROOT
10	lead	lead	I-VP	VB	O	9	VC
11	to	to	B-PP	TO	O	10	VMOD
12	an	an	B-NP	DT	O	15	NMOD
13	adverse	adverse	I-NP	JJ	O	15	NMOD
14	cardiac	cardiac	I-NP	JJ	O	15	NMOD
15	event	event	I-NP	NN	O	11	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	children	child	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	9	P

1	Amisulpride	Amisulpride	B-NP	NN	O	4	NMOD
2	related	related	I-NP	JJ	O	4	NMOD
3	tic-like	tic-like	I-NP	JJ	O	4	NMOD
4	symptoms	symptom	I-NP	NNS	O	0	ROOT
5	in	in	B-PP	IN	O	4	NMOD
6	an	an	B-NP	DT	O	8	NMOD
7	adolescent	adolescent	I-NP	JJ	O	8	NMOD
8	schizophrenic	schizophrenic	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	4	P

1	Tic	Tic	B-NP	JJ	O	2	NMOD
2	disorders	disorder	I-NP	NNS	O	3	SUB
3	can	can	B-VP	MD	O	0	ROOT
4	be	be	I-VP	VB	O	3	VC
5	effectively	effectively	I-VP	RB	O	4	VMOD
6	treated	treat	I-VP	VBN	O	4	VC
7	by	by	B-PP	IN	O	6	VMOD
8	atypical	atypical	B-NP	JJ	O	9	NMOD
9	antipsychotics	antipsychotic	I-NP	NNS	O	7	PMOD
10	such	such	B-PP	JJ	O	11	PMOD
11	as	as	I-PP	IN	O	9	NMOD
12	risperidone	risperidone	B-NP	NN	O	16	NMOD
13	,	,	I-NP	,	O	16	P
14	olanzapine	olanzapine	I-NP	NN	O	16	NMOD
15	and	and	I-NP	CC	O	16	NMOD
16	ziprasidone	ziprasidone	I-NP	NN	O	11	PMOD
17	.	.	O	.	O	3	P

1	However	However	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	there	there	B-NP	EX	O	4	SUB
4	are	be	B-VP	VBP	O	0	ROOT
5	two	two	B-NP	CD	O	7	NMOD
6	case	case	I-NP	NN	O	7	NMOD
7	reports	report	I-NP	NNS	O	4	PRD
8	that	that	B-NP	WDT	O	7	NMOD
9	show	show	B-VP	VBP	O	8	SBAR
10	tic-like	tic-like	B-NP	JJ	O	11	NMOD
11	symptoms	symptom	I-NP	NNS	O	9	OBJ
12	,	,	O	,	O	11	P
13	including	include	B-PP	VBG	O	11	NMOD
14	motor	motor	B-NP	NN	O	17	NMOD
15	and	and	O	CC	O	17	NMOD
16	phonic	phonic	B-NP	JJ	B-protein	17	NMOD
17	variants	variant	I-NP	NNS	I-protein	13	PMOD
18	,	,	O	,	O	17	P
19	occurring	occur	B-VP	VBG	O	17	NMOD
20	during	during	B-PP	IN	O	19	VMOD
21	treatment	treatment	B-NP	NN	O	20	PMOD
22	with	with	B-PP	IN	O	21	NMOD
23	quetiapine	quetiapine	B-NP	NN	O	25	NMOD
24	or	or	I-NP	CC	O	25	NMOD
25	clozapine	clozapine	I-NP	NN	O	22	PMOD
26	.	.	O	.	O	4	P

1	We	We	B-NP	PRP	O	2	SUB
2	present	present	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	15-year-old	15-year-old	I-NP	JJ	O	6	NMOD
5	girl	girl	I-NP	NN	O	6	NMOD
6	schizophrenic	schizophrenic	I-NP	NN	O	2	OBJ
7	who	who	B-NP	WP	O	6	NMOD
8	developed	develop	B-VP	VBD	O	7	SBAR
9	frequent	frequent	B-NP	JJ	O	12	NMOD
10	involuntary	involuntary	I-NP	JJ	O	12	NMOD
11	eye-blinking	eye-blinking	I-NP	JJ	O	12	NMOD
12	movements	movement	I-NP	NNS	O	8	OBJ
13	after	after	B-PP	IN	O	12	NMOD
14	5	5	B-NP	CD	O	15	NMOD
15	months	month	I-NP	NNS	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	amisulpride	amisulpride	B-NP	NN	O	18	NMOD
18	treatment	treatment	I-NP	NN	O	16	PMOD
19	(	(	O	(	O	24	DEP
20	1000	1000	B-NP	CD	O	21	NMOD
21	mg	mg	I-NP	NN	O	24	DEP
22	per	per	B-PP	IN	O	21	NMOD
23	day	day	B-NP	NN	O	22	PMOD
24	)	)	O	)	O	15	NMOD
25	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	tic-like	tic-like	I-NP	JJ	O	3	NMOD
3	symptoms	symptom	I-NP	NNS	O	0	ROOT
4	resolved	resolve	B-VP	VBN	O	3	NMOD
5	completely	completely	B-ADVP	RB	O	4	VMOD
6	after	after	B-SBAR	IN	O	4	VMOD
7	we	we	B-NP	PRP	O	8	SUB
8	reduced	reduce	B-VP	VBD	O	6	SBAR
9	the	the	B-NP	DT	O	10	NMOD
10	dose	dose	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	amisulpride	amisulpride	B-NP	NN	O	11	PMOD
13	down	down	B-ADVP	RB	O	16	NMOD
14	to	to	B-PP	TO	O	13	AMOD
15	800	800	B-NP	CD	O	13	AMOD
16	mg	mg	I-NP	NN	O	8	OBJ
17	per	per	B-PP	IN	O	16	NMOD
18	day	day	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	3	P

1	Aspirin	Aspirin	B-NP	NN	O	16	NMOD
2	(	(	O	(	O	8	DEP
3	acetylsalicylic	acetylsalicylic	B-NP	JJ	O	4	NMOD
4	acid	acid	I-NP	NN	O	8	DEP
5	[	[	O	(	O	7	DEP
6	ASA	ASA	B-NP	NN	O	7	DEP
7	]	]	O	)	O	4	NMOD
8	)	)	O	)	O	1	NMOD
9	,	,	O	,	O	16	P
10	an	an	B-NP	DT	O	12	NMOD
11	irreversible	irreversible	I-NP	JJ	O	12	NMOD
12	cyclooxygenase	cyclooxygenase	I-NP	NN	O	16	NMOD
13	1	1	I-NP	CD	O	12	NMOD
14	and	and	I-NP	CC	O	12	NMOD
15	2	2	I-NP	CD	O	16	NMOD
16	inhibitor	inhibitor	I-NP	NN	O	18	SUB
17	,	,	O	,	O	16	P
18	induces	induce	B-VP	VBZ	O	0	ROOT
19	developmental	developmental	B-NP	JJ	O	20	NMOD
20	anomalies	anomaly	I-NP	NNS	O	18	OBJ
21	when	when	B-ADVP	WRB	O	18	VMOD
22	administered	administer	B-VP	VBN	O	21	SBAR
23	to	to	B-PP	TO	O	22	VMOD
24	Wistar	Wistar	B-NP	NNP	O	25	NMOD
25	rats	rat	I-NP	NNS	O	23	PMOD
26	on	on	B-PP	IN	O	22	VMOD
27	gestational	gestational	B-NP	JJ	O	28	NMOD
28	day	day	I-NP	NN	O	26	PMOD
29	(	(	O	(	O	31	DEP
30	GD	GD	B-NP	NN	O	31	DEP
31	)	)	O	)	O	28	NMOD
32	9	9	B-NP	CD	O	28	NMOD
33	,	,	I-NP	,	O	28	P
34	10	10	I-NP	CD	O	28	NMOD
35	,	,	O	,	O	37	P
36	or	or	O	CC	O	37	NMOD
37	11	11	B-NP	CD	O	18	VMOD
38	.	.	O	.	O	18	P

1	Objectives	Objective	B-NP	NNS	O	6	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	5	NMOD
4	current	current	I-NP	JJ	O	5	NMOD
5	study	study	I-NP	NN	O	2	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	to	to	I-VP	TO	O	8	VMOD
8	compare	compare	I-VP	VB	O	6	VMOD
9	results	result	B-NP	NNS	O	8	OBJ
10	between	between	B-PP	IN	O	9	NMOD
11	Sprague-Dawley	Sprague-Dawley	B-NP	NNP	O	17	NMOD
12	(	(	O	(	O	14	DEP
13	SD	SD	B-NP	NNP	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	and	and	O	CC	O	17	NMOD
16	Wistar	Wistar	B-NP	NNP	O	17	NMOD
17	strains	strain	I-NP	NNS	O	10	PMOD
18	when	when	B-ADVP	WRB	O	8	VMOD
19	ASA	ASA	B-NP	NN	O	20	SUB
20	is	be	B-VP	VBZ	O	18	SBAR
21	administered	administer	I-VP	VBN	O	20	VC
22	on	on	B-PP	IN	O	21	VMOD
23	GD	GD	B-NP	NN	B-protein	22	PMOD
24	9	9	I-NP	CD	I-protein	23	NMOD
25	,	,	I-NP	,	O	23	P
26	10	10	I-NP	CD	O	23	NMOD
27	,	,	O	,	O	29	P
28	or	or	O	CC	O	29	NMOD
29	11	11	B-NP	CD	O	8	OBJ
30	;	;	O	:	O	8	P
31	to	to	B-VP	TO	O	32	VMOD
32	compare	compare	I-VP	VB	O	8	VMOD
33	the	the	B-NP	DT	O	35	NMOD
34	malformation	malformation	I-NP	NN	O	35	NMOD
35	patterns	pattern	I-NP	NNS	O	32	OBJ
36	following	follow	B-PP	VBG	O	35	NMOD
37	single	single	B-NP	JJ	O	40	NMOD
38	and	and	I-NP	CC	O	40	NMOD
39	multiple	multiple	I-NP	JJ	O	40	NMOD
40	dosings	dosing	I-NP	NNS	O	36	PMOD
41	during	during	B-PP	IN	O	40	NMOD
42	organogenesis	organogenesis	B-NP	NN	O	41	PMOD
43	in	in	B-PP	IN	O	42	NMOD
44	SD	SD	B-NP	NNP	O	45	NMOD
45	rats	rat	I-NP	NNS	O	43	PMOD
46	;	;	O	:	O	49	P
47	and	and	O	CC	O	49	VMOD
48	to	to	B-VP	TO	O	49	VMOD
49	test	test	I-VP	VB	O	6	VMOD
50	the	the	B-NP	DT	O	51	NMOD
51	hypothesis	hypothesis	I-NP	NN	O	49	OBJ
52	that	that	B-SBAR	IN	O	51	NMOD
53	maternal	maternal	B-NP	JJ	O	55	NMOD
54	gastrointestinal	gastrointestinal	I-NP	JJ	O	55	NMOD
55	toxicity	toxicity	I-NP	NN	O	56	SUB
56	confounds	confound	B-VP	VBZ	O	52	SBAR
57	the	the	B-NP	DT	O	58	NMOD
58	detection	detection	I-NP	NN	O	56	OBJ
59	of	of	B-PP	IN	O	58	NMOD
60	low	low	B-NP	JJ	O	62	NMOD
61	incidence	incidence	I-NP	NN	O	62	NMOD
62	malformations	malformation	I-NP	NNS	O	59	PMOD
63	with	with	B-PP	IN	O	62	NMOD
64	ASA	ASA	B-NP	NN	O	63	PMOD
65	when	when	B-ADVP	WRB	O	56	VMOD
66	a	a	B-NP	DT	O	69	NMOD
67	multiple	multiple	I-NP	JJ	O	69	NMOD
68	dosing	dosing	I-NP	NN	O	69	NMOD
69	paradigm	paradigm	I-NP	NN	O	70	SUB
70	is	be	B-VP	VBZ	O	65	SBAR
71	used	use	I-VP	VBN	O	70	VC
72	.	.	O	.	O	6	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	The	The	B-NP	DT	O	5	NMOD
4	literature	literature	I-NP	NN	O	5	NMOD
5	evaluation	evaluation	I-NP	NN	O	6	SUB
6	suggested	suggest	B-VP	VBD	O	1	NMOD
7	that	that	B-SBAR	IN	O	6	VMOD
8	NSAIDs	NSAID	B-NP	NNS	O	9	SUB
9	induce	induce	B-VP	VBP	O	7	SBAR
10	ventricular	ventricular	B-NP	JJ	O	12	NMOD
11	septal	septal	I-NP	JJ	O	12	NMOD
12	defects	defect	I-NP	NNS	O	18	NMOD
13	(	(	O	(	O	15	DEP
14	VSDs	VSD	B-NP	NNS	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	18	NMOD
17	midline	midline	B-NP	NN	O	18	NMOD
18	defects	defect	I-NP	NNS	O	9	OBJ
19	(	(	O	(	O	21	DEP
20	MDs	MD	B-NP	NNS	O	21	DEP
21	)	)	O	)	O	18	NMOD
22	in	in	B-PP	IN	O	18	NMOD
23	rats	rat	B-NP	NNS	O	34	NMOD
24	and	and	O	CC	O	26	NMOD
25	diaphragmatic	diaphragmatic	B-NP	JJ	O	26	NMOD
26	hernia	hernia	I-NP	NN	O	34	NMOD
27	(	(	O	(	O	29	DEP
28	DH	DH	B-NP	NN	O	29	DEP
29	)	)	O	)	O	26	NMOD
30	,	,	O	,	O	34	P
31	MDs	MD	B-NP	NNS	O	34	NMOD
32	,	,	O	,	O	34	P
33	and	and	O	CC	O	34	NMOD
34	VSDs	VSD	B-NP	NNS	B-protein	22	PMOD
35	in	in	B-PP	IN	O	34	NMOD
36	rabbits	rabbit	B-NP	NNS	O	35	PMOD
37	(	(	O	(	O	44	DEP
38	Cook	Cook	B-NP	NNP	O	43	NMOD
39	JC	JC	I-NP	NNP	O	43	NMOD
40	et	et	I-NP	FW	O	39	NMOD
41	al.	al.	I-NP	FW	O	39	NMOD
42	,	,	O	,	O	43	P
43	2003	2003	B-NP	CD	O	44	DEP
44	)	)	O	)	O	1	NMOD
45	;	;	O	:	O	1	P
46	hence	hence	B-ADVP	RB	O	51	VMOD
47	,	,	O	,	O	51	P
48	the	the	B-NP	DT	O	50	NMOD
49	present	present	I-NP	JJ	O	50	NMOD
50	study	study	I-NP	NN	O	51	SUB
51	focused	focus	B-VP	VBD	O	1	NMOD
52	on	on	B-PP	IN	O	51	VMOD
53	these	these	B-NP	DT	O	54	NMOD
54	malformations	malformation	I-NP	NNS	O	52	PMOD
55	,	,	O	,	O	51	P
56	even	even	B-SBAR	RB	O	57	DEP
57	though	though	I-SBAR	IN	O	51	VMOD
58	ASA	ASA	B-NP	NN	O	59	SUB
59	induces	induce	B-VP	VBZ	O	57	SBAR
60	several	several	B-NP	JJ	O	63	NMOD
61	other	other	I-NP	JJ	O	63	NMOD
62	low-incidence	low-incidence	I-NP	NN	O	63	NMOD
63	malformations	malformation	I-NP	NNS	O	59	OBJ
64	.	.	O	.	O	1	P

1	Variations	Variation	B-NP	NNS	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	malformations	malformation	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	0	ROOT
5	similar	similar	B-ADJP	JJ	O	4	PRD
6	when	when	B-ADVP	WRB	O	4	VMOD
7	ASA	ASA	B-NP	NN	O	8	SUB
8	was	be	B-VP	VBD	O	6	SBAR
9	administered	administer	I-VP	VBN	O	8	VC
10	as	as	B-PP	IN	O	9	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	single	single	I-NP	JJ	O	13	NMOD
13	dose	dose	I-NP	NN	O	10	PMOD
14	or	or	B-PP	CC	O	10	PMOD
15	during	during	B-PP	IN	O	10	PMOD
16	the	the	B-NP	DT	O	17	NMOD
17	period	period	I-NP	NN	O	15	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	organogenesis	organogenesis	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	25	DEP
21	GDs	GD	B-NP	NNS	O	25	DEP
22	6	6	B-NP	CD	O	24	AMOD
23	to	to	B-PP	TO	O	24	AMOD
24	17	17	B-NP	CD	O	21	NMOD
25	)	)	O	)	O	15	PMOD
26	.	.	O	.	O	4	P

1	Torsade	Torsade	B-NP	FW	O	3	NMOD
2	de	de	I-NP	FW	O	3	NMOD
3	pointes	pointes	I-NP	FW	O	0	ROOT
4	induced	induce	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	metoclopramide	metoclopramide	B-NP	NN	O	5	PMOD
7	in	in	B-PP	IN	O	4	VMOD
8	an	an	B-NP	DT	O	10	NMOD
9	elderly	elderly	I-NP	JJ	O	10	NMOD
10	woman	woman	I-NP	NN	O	7	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	preexisting	preexist	B-VP	VBG	O	11	PMOD
13	complete	complete	B-NP	JJ	O	17	NMOD
14	left	left	I-NP	JJ	O	17	NMOD
15	bundle	bundle	I-NP	NN	O	17	NMOD
16	branch	branch	I-NP	NN	O	17	NMOD
17	block	block	I-NP	NN	O	12	OBJ
18	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	on	on	B-PP	IN	O	2	VMOD
4	a	a	B-NP	DT	O	6	NMOD
5	92-year-old	92-year-old	I-NP	JJ	O	6	NMOD
6	woman	woman	I-NP	NN	O	3	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	preexisting	preexist	B-VP	VBG	O	7	PMOD
9	complete	complete	B-NP	JJ	O	13	NMOD
10	left	left	I-NP	JJ	O	13	NMOD
11	bundle	bundle	I-NP	NN	O	13	NMOD
12	branch	branch	I-NP	NN	O	13	NMOD
13	block	block	I-NP	NN	O	8	OBJ
14	who	who	B-NP	WP	O	13	NMOD
15	developed	develop	B-VP	VBD	O	18	VMOD
16	torsade	torsade	B-NP	FW	O	18	NMOD
17	de	de	I-NP	FW	O	18	NMOD
18	pointes	pointes	I-NP	FW	O	14	SBAR
19	after	after	B-PP	IN	O	18	VMOD
20	intravenous	intravenous	B-NP	JJ	O	22	AMOD
21	and	and	I-NP	CC	O	22	AMOD
22	oral	oral	I-NP	JJ	O	23	NMOD
23	administration	administration	I-NP	NN	O	19	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	metoclopramide	metoclopramide	B-NP	NN	O	24	PMOD
26	.	.	O	.	O	2	P

1	This	This	B-NP	DT	O	2	NMOD
2	patient	patient	I-NP	NN	O	4	SUB
3	also	also	B-ADVP	RB	O	4	VMOD
4	developed	develop	B-VP	VBD	O	0	ROOT
5	torsade	torsade	B-NP	FW	O	7	NMOD
6	de	de	I-NP	FW	O	7	NMOD
7	pointes	pointes	I-NP	FW	O	4	VMOD
8	when	when	B-ADVP	WRB	O	7	AMOD
9	cisapride	cisapride	B-NP	NN	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	erythromycin	erythromycin	I-NP	NN	O	12	SUB
12	were	be	B-VP	VBD	O	8	SBAR
13	given	give	I-VP	VBN	O	12	VC
14	simultaneously	simultaneously	B-ADVP	RB	O	13	VMOD
15	.	.	O	.	O	4	P

1	This	This	B-NP	DT	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	the	the	B-NP	DT	O	5	NMOD
4	first	first	I-NP	JJ	O	5	NMOD
5	documentation	documentation	I-NP	NN	O	2	PRD
6	that	that	B-NP	IN	O	5	NMOD
7	metoclopramide	metoclopramide	B-NP	NN	O	8	NMOD
8	provokes	provoke	I-NP	NNS	O	6	SBAR
9	torsade	torsade	B-NP	FW	O	11	NMOD
10	de	de	I-NP	FW	O	11	NMOD
11	pointes	pointes	I-NP	FW	O	12	NMOD
12	clinically	clinically	B-ADVP	RB	O	8	OBJ
13	.	.	O	.	O	2	P

1	Apomorphine	Apomorphine	B-NP	NN	O	5	NMOD
2	:	:	O	:	O	1	P
3	an	an	B-NP	DT	O	5	NMOD
4	underutilized	underutilized	I-NP	JJ	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	0	ROOT
6	for	for	B-PP	IN	O	5	NMOD
7	Parkinson	Parkinson	B-NP	NNP	O	9	NMOD
8	's	's	B-NP	POS	O	9	NMOD
9	disease	disease	I-NP	NN	O	6	PMOD
10	.	.	O	.	O	5	P

1	Apomorphine	Apomorphine	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	6	NMOD
4	first	first	I-NP	JJ	O	6	NMOD
5	dopaminergic	dopaminergic	I-NP	JJ	O	6	NMOD
6	drug	drug	I-NP	NN	O	2	PRD
7	ever	ever	B-VP	RB	O	8	VMOD
8	used	use	I-VP	VBN	O	6	NMOD
9	to	to	B-VP	TO	O	10	VMOD
10	treat	treat	I-VP	VB	O	8	VMOD
11	symptoms	symptom	B-NP	NNS	O	10	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	Parkinson	Parkinson	B-NP	NNP	O	15	NMOD
14	's	's	B-NP	POS	O	15	NMOD
15	disease	disease	I-NP	NN	O	12	PMOD
16	.	.	O	.	O	2	P

1	While	While	B-SBAR	IN	O	26	VMOD
2	powerful	powerful	B-NP	JJ	O	4	NMOD
3	antiparkinsonian	antiparkinsonian	I-NP	JJ	O	4	NMOD
4	effects	effect	I-NP	NNS	O	5	SUB
5	had	have	B-VP	VBD	O	1	SBAR
6	been	be	I-VP	VBN	O	5	VC
7	observed	observe	I-VP	VBN	O	6	VC
8	as	as	B-ADVP	RB	O	7	VMOD
9	early	early	I-ADVP	RB	O	8	AMOD
10	as	as	B-PP	IN	O	8	AMOD
11	1951	1951	B-NP	CD	O	10	PMOD
12	,	,	O	,	O	26	P
13	the	the	B-NP	DT	O	14	NMOD
14	potential	potential	I-NP	NN	O	26	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	treating	treat	B-VP	VBG	O	15	PMOD
17	fluctuating	fluctuate	I-VP	VBG	O	16	VC
18	Parkinson	Parkinson	B-NP	NNP	O	19	NMOD
19	's	's	B-NP	POS	O	20	NMOD
20	disease	disease	I-NP	NN	O	17	OBJ
21	by	by	B-PP	IN	O	20	NMOD
22	subcutaneous	subcutaneous	B-NP	JJ	O	23	NMOD
23	administration	administration	I-NP	NN	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	apomorphine	apomorphine	B-NP	NN	O	24	PMOD
26	has	have	B-VP	VBZ	O	0	ROOT
27	only	only	I-VP	RB	O	26	VMOD
28	recently	recently	I-VP	RB	O	27	AMOD
29	become	become	I-VP	VB	O	26	VC
30	the	the	B-NP	DT	O	31	NMOD
31	subject	subject	I-NP	NN	O	29	OBJ
32	of	of	B-PP	IN	O	31	NMOD
33	systematic	systematic	B-NP	JJ	O	34	NMOD
34	study	study	I-NP	NN	O	32	PMOD
35	.	.	O	.	O	26	P

1	In	In	B-PP	IN	O	5	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	there	there	B-NP	EX	O	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	convincing	convince	I-VP	VBG	O	8	NMOD
7	clinical	clinical	B-NP	JJ	O	8	NMOD
8	evidence	evidence	I-NP	NN	O	5	PRD
9	that	that	B-SBAR	IN	O	8	NMOD
10	monotherapy	monotherapy	B-NP	NN	O	16	SUB
11	with	with	B-PP	IN	O	10	NMOD
12	continuous	continuous	B-NP	JJ	O	15	NMOD
13	subcutaneous	subcutaneous	I-NP	JJ	O	15	NMOD
14	apomorphine	apomorphine	I-NP	NN	O	15	NMOD
15	infusions	infusion	I-NP	NNS	O	11	PMOD
16	is	be	B-VP	VBZ	O	9	SBAR
17	associated	associate	I-VP	VBN	O	16	VC
18	with	with	B-PP	IN	O	17	VMOD
19	marked	marked	B-NP	JJ	O	20	NMOD
20	reductions	reduction	I-NP	NNS	O	18	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	preexisting	preexist	B-VP	VBG	O	21	PMOD
23	levodopa	levodopa	B-NP	NN	O	25	NMOD
24	induced	induced	I-NP	JJ	O	25	NMOD
25	dyskinesias	dyskinesia	I-NP	NNS	O	22	OBJ
26	.	.	O	.	O	5	P

1	The	The	B-NP	DT	O	4	NMOD
2	main	main	I-NP	JJ	O	4	NMOD
3	side	side	I-NP	NN	O	4	NMOD
4	effects	effect	I-NP	NNS	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	subcutaneous	subcutaneous	B-NP	JJ	O	8	NMOD
7	apomorphine	apomorphine	I-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	5	PMOD
9	are	be	B-VP	VBP	O	16	VMOD
10	related	relate	I-VP	VBN	O	9	PRD
11	to	to	B-PP	TO	O	10	AMOD
12	cutaneous	cutaneous	B-NP	JJ	O	14	NMOD
13	tolerability	tolerability	I-NP	NN	O	14	NMOD
14	problems	problem	I-NP	NNS	O	11	PMOD
15	,	,	O	,	O	16	P
16	whereas	whereas	O	IN	O	0	ROOT
17	sedation	sedation	B-NP	NN	O	20	NMOD
18	and	and	O	CC	O	20	NMOD
19	psychiatric	psychiatric	B-NP	JJ	O	20	NMOD
20	complications	complication	I-NP	NNS	O	21	SUB
21	play	play	B-VP	VBP	O	16	VMOD
22	a	a	B-NP	DT	O	24	NMOD
23	lesser	less	I-NP	JJR	O	24	NMOD
24	role	role	I-NP	NN	O	21	OBJ
25	.	.	O	.	O	16	P

1	Fatal	Fatal	B-NP	JJ	O	3	NMOD
2	excited	excited	I-NP	JJ	O	3	NMOD
3	delirium	delirium	I-NP	NN	O	9	NMOD
4	following	follow	B-PP	VBG	O	3	NMOD
5	cocaine	cocaine	B-NP	NN	O	6	NMOD
6	use	use	I-NP	NN	O	4	PMOD
7	:	:	O	:	O	3	P
8	epidemiologic	epidemiologic	B-NP	JJ	O	9	NMOD
9	findings	finding	I-NP	NNS	O	10	SUB
10	provide	provide	B-VP	VBP	O	0	ROOT
11	new	new	B-NP	JJ	O	12	NMOD
12	evidence	evidence	I-NP	NN	O	10	OBJ
13	for	for	B-PP	IN	O	12	NMOD
14	mechanisms	mechanism	B-NP	NNS	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	cocaine	cocaine	B-NP	NN	O	17	NMOD
17	toxicity	toxicity	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	10	P

1	We	We	B-NP	PRP	O	2	SUB
2	describe	describe	B-VP	VBP	O	0	ROOT
3	an	an	B-NP	DT	O	4	NMOD
4	outbreak	outbreak	I-NP	NN	O	9	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	deaths	death	B-NP	NNS	O	5	PMOD
7	from	from	B-PP	IN	O	6	NMOD
8	cocaine	cocaine	B-NP	NN	O	7	PMOD
9	induced	induce	B-VP	VBD	O	2	VMOD
10	excited	excited	B-NP	JJ	O	11	NMOD
11	delirium	delirium	I-NP	NN	O	9	OBJ
12	(	(	O	(	O	14	DEP
13	EDDs	EDD	B-NP	NNS	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	in	in	B-PP	IN	O	9	VMOD
16	Dade	Dade	B-NP	NNP	O	17	NMOD
17	County	County	I-NP	NNP	O	15	PMOD
18	,	,	O	,	O	2	P
19	Florida	Florida	B-NP	NNP	O	2	VMOD
20	between	between	B-PP	IN	O	19	NMOD
21	1979	1979	B-NP	CD	O	23	NMOD
22	and	and	I-NP	CC	O	23	NMOD
23	1990	1990	I-NP	CD	O	20	PMOD
24	.	.	O	.	O	2	P

1	From	From	B-PP	IN	O	19	VMOD
2	a	a	B-NP	DT	O	3	NMOD
3	registry	registry	I-NP	NN	O	1	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	all	all	B-NP	DT	O	7	NMOD
6	cocaine-related	cocaine-related	I-NP	JJ	O	7	NMOD
7	deaths	death	I-NP	NNS	O	4	PMOD
8	in	in	B-PP	IN	O	3	NMOD
9	Dade	Dade	B-NP	NNP	O	10	NMOD
10	County	County	I-NP	NNP	O	8	PMOD
11	,	,	O	,	O	19	P
12	Florida	Florida	B-NP	NNP	O	19	VMOD
13	,	,	O	,	O	19	P
14	from	from	B-PP	IN	O	19	VMOD
15	1969-1990	1969-1990	B-NP	CD	O	14	PMOD
16	,	,	O	,	O	19	P
17	58	58	B-NP	CD	O	18	NMOD
18	EDDs	EDD	I-NP	NNS	O	19	SUB
19	were	be	B-VP	VBD	O	0	ROOT
20	compared	compare	I-VP	VBN	O	19	VC
21	with	with	B-PP	IN	O	20	VMOD
22	125	125	B-NP	CD	O	23	NMOD
23	victims	victim	I-NP	NNS	O	21	PMOD
24	of	of	B-PP	IN	O	23	NMOD
25	accidental	accidental	B-NP	JJ	O	27	NMOD
26	cocaine	cocaine	I-NP	NN	O	27	NMOD
27	overdose	overdose	I-NP	NN	O	24	PMOD
28	without	without	B-PP	IN	O	20	VMOD
29	excited	excited	B-NP	JJ	O	30	NMOD
30	delirium	delirium	I-NP	NN	O	28	PMOD
31	.	.	O	.	O	19	P

1	EDDs	EDD	B-NP	NNS	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	concentrations	concentration	B-NP	NNS	O	2	OBJ
4	of	of	B-PP	IN	O	3	NMOD
5	cocaine	cocaine	B-NP	NN	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	benzoylecgonine	benzoylecgonine	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	2	VMOD
9	autopsy	autopsy	B-NP	NN	O	10	NMOD
10	blood	blood	I-NP	NN	O	8	PMOD
11	that	that	B-NP	WDT	O	10	NMOD
12	were	be	B-VP	VBD	O	11	SBAR
13	similar	similar	B-ADJP	JJ	O	12	PRD
14	to	to	B-PP	TO	O	13	AMOD
15	those	those	B-NP	DT	O	14	PMOD
16	for	for	B-PP	IN	O	15	NMOD
17	controls	control	B-NP	NNS	O	16	PMOD
18	.	.	O	.	O	2	P

1	Heparin	Heparin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	thrombocytopenia	thrombocytopenia	B-NP	NN	O	8	NMOD
4	,	,	O	,	O	8	P
5	thrombosis	thrombosis	B-NP	NN	O	8	NMOD
6	,	,	O	,	O	8	P
7	and	and	O	CC	O	8	NMOD
8	hemorrhage	hemorrhage	B-NP	NN	O	2	OBJ
9	.	.	O	.	O	2	P

1	Sixty-two	Sixty-two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	8	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	a	a	B-NP	DT	O	7	NMOD
5	heparin	heparin	I-NP	NN	O	7	NMOD
6	induced	induced	I-NP	JJ	O	7	NMOD
7	thrombocytopenia	thrombocytopenia	I-NP	NN	O	3	PMOD
8	are	be	B-VP	VBP	O	0	ROOT
9	reported	report	I-VP	VBN	O	8	VC
10	.	.	O	.	O	8	P

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD
2	manifestations	manifestation	I-NP	NNS	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	disorder	disorder	I-NP	NN	O	3	PMOD
6	include	include	B-VP	VBP	O	0	ROOT
7	hemorrhage	hemorrhage	B-NP	NN	O	6	OBJ
8	or	or	O	CC	O	7	NMOD
9	,	,	O	,	O	11	P
10	more	more	B-ADVP	RBR	O	11	AMOD
11	frequently	frequently	I-ADVP	RB	O	8	AMOD
12	,	,	O	,	O	14	P
13	thromboembolic	thromboembolic	B-NP	JJ	O	14	NMOD
14	events	event	I-NP	NNS	O	11	AMOD
15	in	in	B-PP	IN	O	14	NMOD
16	patients	patient	B-NP	NNS	O	15	PMOD
17	receiving	receive	B-VP	VBG	O	16	NMOD
18	heparin	heparin	B-NP	NN	O	17	OBJ
19	.	.	O	.	O	6	P

1	Laboratory	Laboratory	B-NP	NN	O	2	NMOD
2	testing	testing	I-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	0	ROOT
4	revealed	reveal	I-VP	VBN	O	3	VC
5	a	a	B-NP	DT	O	8	NMOD
6	falling	fall	I-NP	VBG	O	8	NMOD
7	platelet	platelet	I-NP	NN	O	8	NMOD
8	count	count	I-NP	NN	O	16	NMOD
9	,	,	O	,	O	16	P
10	increased	increase	B-VP	VBD	O	11	NMOD
11	resistance	resistance	B-NP	NN	O	16	NMOD
12	to	to	B-PP	TO	O	11	NMOD
13	heparin	heparin	B-NP	NN	O	12	PMOD
14	,	,	O	,	O	16	P
15	and	and	O	CC	O	16	NMOD
16	aggregation	aggregation	B-NP	NN	O	4	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	platelets	platelet	B-NP	NNS	B-cell_type	17	PMOD
19	by	by	B-PP	IN	O	16	NMOD
20	the	the	B-NP	DT	O	22	NMOD
21	patient	patient	I-NP	NN	O	22	NMOD
22	's	's	B-NP	POS	O	23	NMOD
23	plasma	plasma	I-NP	NN	O	19	PMOD
24	when	when	B-ADVP	WRB	O	4	VMOD
25	heparin	heparin	B-NP	NN	O	26	SUB
26	is	be	B-VP	VBZ	O	24	SBAR
27	added	add	I-VP	VBN	O	26	VC
28	.	.	O	.	O	3	P

1	If	If	B-SBAR	IN	O	30	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	platelet	platelet	I-NP	NN	O	4	NMOD
4	count	count	I-NP	NN	O	5	SUB
5	falls	fall	B-VP	VBZ	O	1	SBAR
6	to	to	B-PP	TO	O	5	VMOD
7	less	less	B-NP	JJR	O	8	AMOD
8	than	than	I-NP	IN	O	6	PMOD
9	100	100	I-NP	CD	O	8	AMOD
10	,	,	I-NP	,	O	8	P
11	000/mm3	000/mm3	I-NP	CD	O	8	AMOD
12	,	,	O	,	O	30	P
13	while	while	B-SBAR	IN	O	30	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	patient	patient	I-NP	NN	O	16	SUB
16	is	be	B-VP	VBZ	O	13	SBAR
17	receiving	receive	I-VP	VBG	O	16	VC
18	heparin	heparin	B-NP	NN	O	22	NMOD
19	,	,	O	,	O	22	P
20	platelet	platelet	B-NP	NN	O	22	NMOD
21	aggregation	aggregation	I-NP	NN	O	22	NMOD
22	testing	testing	I-NP	NN	O	17	OBJ
23	,	,	O	,	O	30	P
24	using	use	B-VP	VBG	O	30	VMOD
25	the	the	B-NP	DT	O	28	NMOD
26	patient	patient	I-NP	NN	O	28	NMOD
27	's	's	B-NP	POS	O	28	NMOD
28	plasma	plasma	I-NP	NN	O	24	OBJ
29	,	,	O	,	O	30	P
30	is	be	B-VP	VBZ	O	0	ROOT
31	indicated	indicate	I-VP	VBN	O	30	VC
32	.	.	O	.	O	30	P

1	Cardiac	Cardiac	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	5-fluorouracil	5-fluorouracil	B-NP	NN	O	3	PMOD
5	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	4	NMOD
4	case	case	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	a	a	B-NP	DT	O	7	NMOD
7	patient	patient	I-NP	NN	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	colon	colon	B-NP	NN	O	10	NMOD
10	carcinoma	carcinoma	I-NP	NN	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	liver	liver	B-NP	NN	O	13	NMOD
13	metastasis	metastasis	I-NP	NN	O	8	PMOD
14	who	who	B-NP	WP	O	7	NMOD
15	presented	present	B-VP	VBD	O	14	SBAR
16	chest	chest	B-NP	NN	O	17	NMOD
17	pain	pain	I-NP	NN	O	15	OBJ
18	after	after	B-PP	IN	O	15	VMOD
19	5-fluorouracil	5-fluorouracil	B-NP	NN	O	23	NMOD
20	(	(	O	(	O	22	DEP
21	5-FU	5-FU	B-NP	NN	O	22	DEP
22	)	)	O	)	O	19	NMOD
23	administration	administration	B-NP	NN	O	18	PMOD
24	.	.	O	.	O	2	P

1	Clinical	Clinical	B-NP	JJ	O	3	NMOD
2	electrocardiographic	electrocardiographic	I-NP	JJ	O	3	NMOD
3	evolution	evolution	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	similar	similar	B-ADJP	JJ	O	4	PRD
6	to	to	B-PP	TO	O	5	AMOD
7	that	that	B-NP	DT	O	6	PMOD
8	observed	observe	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	Prinzmetal	Prinzmetal	B-NP	NNP	O	12	NMOD
11	's	's	B-NP	POS	O	12	NMOD
12	angina	angina	I-NP	NN	O	9	PMOD
13	,	,	O	,	O	4	VMOD
14	and	and	O	CC	O	13	VMOD
15	chest	ch	B-NP	JJS	O	16	NMOD
16	pain	pain	I-NP	NN	O	14	PRD
17	promptly	promptly	B-VP	RB	O	18	VMOD
18	resolved	resolve	I-VP	VBN	O	16	NMOD
19	with	with	B-PP	IN	O	18	VMOD
20	nifedipine	nifedipine	B-NP	NN	O	19	PMOD
21	.	.	O	.	O	4	P

1	A	A	B-NP	DT	O	3	NMOD
2	strong	strong	I-NP	JJ	O	3	NMOD
3	association	association	I-NP	NN	O	4	SUB
4	has	have	B-VP	VBZ	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	found	find	I-VP	VBN	O	5	VC
7	between	between	B-PP	IN	O	6	VMOD
8	nephritis	nephritis	B-NP	NN	O	10	NMOD
9	and	and	I-NP	CC	O	10	NMOD
10	dermatitis	dermatitis	I-NP	NN	O	7	PMOD
11	due	due	B-ADJP	JJ	O	10	NMOD
12	to	to	B-PP	TO	O	11	AMOD
13	Tiopronin	Tiopronin	B-NP	NN	B-protein	24	NMOD
14	(	(	O	(	O	19	DEP
15	a	a	B-NP	DT	O	16	NMOD
16	D-Penicillamine	D-Penicillamine	I-NP	NN	O	19	DEP
17	like	like	B-PP	IN	O	16	NMOD
18	compound	compound	B-NP	NN	O	17	PMOD
19	)	)	O	)	O	13	NMOD
20	and	and	O	CC	O	24	NMOD
21	class	class	B-NP	NN	B-protein	24	NMOD
22	I	I	I-NP	CD	I-protein	24	NMOD
23	antigens	antigen	I-NP	NNS	I-protein	24	NMOD
24	B35-Cw4	B35-Cw4	I-NP	NN	I-protein	12	PMOD
25	,	,	O	,	O	7	P
26	and	and	O	CC	O	7	PMOD
27	between	between	B-PP	IN	O	7	PMOD
28	dermatitis	dermatitis	B-NP	NN	O	27	PMOD
29	due	due	B-ADJP	JJ	O	28	NMOD
30	to	to	B-PP	TO	O	29	AMOD
31	gold	gold	B-NP	NN	O	32	NMOD
32	thiosulphate	thiosulphate	I-NP	NN	O	34	NMOD
33	and	and	I-NP	CC	O	34	NMOD
34	B35	B35	I-NP	NN	B-protein	30	PMOD
35	.	.	O	.	O	4	P

1	Transient	Transient	B-NP	JJ	O	2	NMOD
2	hemiparesis	hemiparesis	I-NP	NN	O	6	NMOD
3	:	:	O	:	O	2	P
4	a	a	B-NP	DT	O	6	NMOD
5	rare	rare	I-NP	JJ	O	6	NMOD
6	manifestation	manifestation	I-NP	NN	O	0	ROOT
7	of	of	B-PP	IN	O	6	NMOD
8	diphenylhydantoin	diphenylhydantoin	B-NP	NN	O	9	NMOD
9	toxicity	toxicity	I-NP	NN	O	7	PMOD
10	.	.	O	.	O	6	P

1	Among	Among	B-PP	IN	O	19	VMOD
2	the	the	B-NP	DT	O	5	NMOD
3	common	common	I-NP	JJ	O	5	NMOD
4	side	side	I-NP	NN	O	5	NMOD
5	effects	effect	I-NP	NNS	O	19	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	diphenylhydantoin	diphenylhydantoin	B-NP	NN	O	11	NMOD
8	(	(	O	(	O	10	DEP
9	DPH	DPH	B-NP	NN	O	10	DEP
10	)	)	O	)	O	7	NMOD
11	overdose	overdose	B-NP	NN	O	18	NMOD
12	,	,	O	,	O	18	P
13	the	the	B-NP	DT	O	18	NMOD
14	most	most	I-NP	RBS	O	15	AMOD
15	frequently	frequently	I-NP	RB	O	17	AMOD
16	encountered	encounter	I-NP	VBN	O	17	AMOD
17	neurological	neurological	I-NP	JJ	O	18	NMOD
18	signs	sign	I-NP	NNS	O	6	PMOD
19	are	be	B-VP	VBP	O	0	ROOT
20	those	those	B-NP	DT	O	19	PRD
21	of	of	B-PP	IN	O	20	NMOD
22	cerebellar	cerebellar	B-NP	JJ	O	23	NMOD
23	dysfunction	dysfunction	I-NP	NN	O	21	PMOD
24	.	.	O	.	O	19	P

1	Two	Two	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	are	be	B-VP	VBP	O	0	ROOT
4	presented	present	I-VP	VBN	O	8	NMOD
5	who	who	B-NP	WP	O	8	NMOD
6	suffered	suffer	B-VP	VBD	O	8	NMOD
7	progressive	progressive	B-NP	JJ	O	8	NMOD
8	hemiparesis	hemiparesis	I-NP	NN	O	3	PRD
9	due	due	B-ADJP	JJ	O	8	NMOD
10	to	to	B-PP	TO	O	9	AMOD
11	DPH	DPH	B-NP	NN	O	12	NMOD
12	overdose	overdose	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	3	P

1	Nerve	Nerve	B-NP	NN	B-protein	3	NMOD
2	growth	growth	I-NP	NN	I-protein	3	NMOD
3	factor	factor	I-NP	NN	I-protein	5	NMOD
4	and	and	O	CC	O	5	NMOD
5	prostaglandins	prostaglandin	B-NP	NNS	O	0	ROOT
6	in	in	B-PP	IN	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	urine	urine	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	female	female	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	overactive	overactive	B-NP	JJ	O	14	NMOD
14	bladder	bladder	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	5	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	changes	change	B-NP	NNS	O	8	NMOD
4	in	in	B-PP	IN	O	3	NMOD
5	urinary	urinary	B-NP	JJ	O	6	NMOD
6	NGF	NGF	I-NP	NN	B-protein	4	PMOD
7	and	and	I-NP	CC	O	8	NMOD
8	PGs	PG	I-NP	NNS	O	2	OBJ
9	in	in	B-PP	IN	O	8	NMOD
10	women	woman	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	OAB	OAB	B-NP	NN	B-protein	11	PMOD
13	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	18	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	18	P
4	correlations	correlation	B-NP	NNS	O	13	NMOD
5	between	between	B-PP	IN	O	4	NMOD
6	urinary	urinary	B-NP	JJ	O	9	NMOD
7	NGF	NGF	I-NP	NN	B-protein	6	NMOD
8	and	and	I-NP	CC	O	6	NMOD
9	PG	PG	I-NP	NN	O	5	PMOD
10	,	,	O	,	O	13	P
11	and	and	O	CC	O	13	NMOD
12	urodynamic	urodynamic	B-NP	JJ	O	13	NMOD
13	parameters	parameter	I-NP	NNS	O	18	SUB
14	in	in	B-PP	IN	O	13	NMOD
15	patients	patient	B-NP	NNS	O	14	PMOD
16	with	with	B-PP	IN	O	15	NMOD
17	OAB	OAB	B-NP	NN	B-protein	16	PMOD
18	were	be	B-VP	VBD	O	0	ROOT
19	examined	examine	I-VP	VBN	O	18	VC
20	.	.	O	.	O	18	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Urinary	Urinary	B-NP	JJ	O	4	NMOD
4	NGF	NGF	I-NP	NN	B-protein	8	NMOD
5	,	,	O	,	O	8	P
6	PGE2	PGE2	B-NP	NN	B-protein	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	PGF2alpha	PGF2alpha	I-NP	NN	O	9	SUB
9	were	be	B-VP	VBD	O	1	NMOD
10	significantly	significantly	I-VP	RB	O	9	VMOD
11	increased	increase	I-VP	VBN	O	9	VC
12	in	in	B-PP	IN	O	11	VMOD
13	patients	patient	B-NP	NNS	O	12	PMOD
14	with	with	B-PP	IN	O	13	NMOD
15	OAB	OAB	B-NP	NN	B-protein	14	PMOD
16	compared	compare	B-PP	VBN	O	11	VMOD
17	with	with	B-PP	IN	O	16	PMOD
18	controls	control	B-NP	NNS	O	17	PMOD
19	(	(	O	(	O	23	DEP
20	p	p	B-NP	NN	O	23	DEP
21	<	<	O	SYM	O	20	NMOD
22	0.05	0.05	B-NP	CD	O	21	AMOD
23	)	)	O	)	O	18	NMOD
24	.	.	O	.	O	1	P

1	However	However	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	urinary	urinary	B-NP	JJ	O	4	NMOD
4	PGI2	PGI2	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	not	not	O	RB	O	5	VMOD
7	different	different	B-ADJP	JJ	O	5	PRD
8	between	between	B-PP	IN	O	5	VMOD
9	controls	control	B-NP	NNS	O	11	NMOD
10	and	and	O	CC	O	11	NMOD
11	patients	patient	B-NP	NNS	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	OAB	OAB	B-NP	NN	B-protein	12	PMOD
14	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	8	VMOD
2	patients	patient	B-NP	NNS	O	1	PMOD
3	with	with	B-PP	IN	O	2	NMOD
4	OAB	OAB	B-NP	NN	B-protein	6	NMOD
5	urinary	urinary	I-NP	JJ	O	6	NMOD
6	PGE2	PGE2	I-NP	NN	O	3	PMOD
7	positively	positively	B-ADVP	RB	O	8	VMOD
8	correlated	correlate	B-VP	VBD	O	0	ROOT
9	with	with	B-PP	IN	O	8	VMOD
10	volume	volume	B-NP	NN	O	9	PMOD
11	at	at	B-PP	IN	O	10	NMOD
12	first	first	B-NP	JJ	O	13	NMOD
13	desire	desire	I-NP	NN	O	11	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	void	void	B-NP	NN	O	19	NMOD
16	and	and	O	CC	O	19	NMOD
17	maximum	maximum	B-NP	JJ	O	19	NMOD
18	cystometric	cystometric	I-NP	JJ	O	19	NMOD
19	capacity	capacity	I-NP	NN	O	14	PMOD
20	(	(	O	(	O	24	DEP
21	p	p	B-NP	NN	O	24	DEP
22	<	<	O	SYM	O	21	NMOD
23	0.05	0.05	B-NP	CD	O	22	AMOD
24	)	)	O	)	O	8	VMOD
25	.	.	O	.	O	8	P

1	Urinary	Urinary	B-NP	JJ	O	7	SUB
2	NGF	NGF	I-NP	NN	B-protein	6	NMOD
3	,	,	I-NP	,	O	6	P
4	PGF2alpha	PGF2alpha	I-NP	NN	B-protein	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	PGI2	PGI2	I-NP	NN	B-protein	1	NMOD
7	did	do	B-VP	VBD	O	0	ROOT
8	not	not	I-VP	RB	O	7	VMOD
9	correlate	correlate	I-VP	VB	O	7	VC
10	with	with	B-PP	IN	O	9	VMOD
11	urodynamic	urodynamic	B-NP	JJ	O	12	NMOD
12	parameters	parameter	I-NP	NNS	O	10	PMOD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	OAB	OAB	B-NP	NN	B-protein	15	PMOD
17	.	.	O	.	O	7	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	NGF	NGF	B-NP	NN	B-protein	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	PGs	PG	I-NP	NNS	O	6	SUB
6	have	have	B-VP	VBP	O	1	NMOD
7	important	important	B-NP	JJ	O	8	NMOD
8	roles	role	I-NP	NNS	O	6	OBJ
9	in	in	B-PP	IN	O	6	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	development	development	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	OAB	OAB	B-NP	NN	O	14	NMOD
14	symptoms	symptom	I-NP	NNS	O	12	PMOD
15	in	in	B-PP	IN	O	11	NMOD
16	female	female	B-NP	JJ	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	1	P

1	Acute	Acute	B-NP	JJ	O	4	NMOD
2	low	low	I-NP	JJ	O	4	NMOD
3	back	back	I-NP	JJ	O	4	NMOD
4	pain	pain	I-NP	NN	O	12	NMOD
5	during	during	B-PP	IN	O	4	NMOD
6	intravenous	intravenous	B-NP	JJ	O	7	NMOD
7	administration	administration	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	amiodarone	amiodarone	B-NP	NN	O	8	PMOD
10	:	:	O	:	O	4	P
11	a	a	B-NP	DT	O	12	NMOD
12	report	report	I-NP	NN	O	0	ROOT
13	of	of	B-PP	IN	O	12	NMOD
14	two	two	B-NP	CD	O	15	NMOD
15	cases	case	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	12	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	represents	represent	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	6	NMOD
4	effective	effective	I-NP	JJ	O	5	AMOD
5	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	6	NMOD
6	drug	drug	I-NP	NN	O	2	OBJ
7	for	for	B-PP	IN	O	6	NMOD
8	cardioversion	cardioversion	B-NP	NN	O	17	NMOD
9	of	of	B-PP	IN	O	8	NMOD
10	recent-onset	recent-onset	B-NP	JJ	O	12	NMOD
11	atrial	atrial	I-NP	JJ	O	12	NMOD
12	fibrillation	fibrillation	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	AF	AF	B-NP	NN	O	15	DEP
15	)	)	O	)	O	12	NMOD
16	and	and	O	CC	O	17	NMOD
17	maintenance	maintenance	B-NP	NN	O	7	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	sinus	sinus	B-NP	NN	O	20	NMOD
20	rhythm	rhythm	I-NP	NN	O	18	PMOD
21	.	.	O	.	O	2	P

1	Postoperative	Postoperative	B-NP	JJ	O	2	NMOD
2	myalgia	myalgia	I-NP	NN	O	7	NMOD
3	after	after	B-PP	IN	O	2	NMOD
4	succinylcholine	succinylcholine	B-NP	NN	O	3	PMOD
5	:	:	O	:	O	2	P
6	no	no	B-NP	DT	O	7	NMOD
7	evidence	evidence	I-NP	NN	O	0	ROOT
8	for	for	B-PP	IN	O	7	NMOD
9	an	an	B-NP	DT	O	11	NMOD
10	inflammatory	inflammatory	I-NP	JJ	O	11	NMOD
11	origin	origin	I-NP	NN	O	8	PMOD
12	.	.	O	.	O	7	P

1	A	A	B-NP	DT	O	4	NMOD
2	common	common	I-NP	JJ	O	4	NMOD
3	side	side	I-NP	NN	O	4	NMOD
4	effect	effect	I-NP	NN	O	8	SUB
5	associated	associate	B-VP	VBN	O	4	NMOD
6	with	with	B-PP	IN	O	5	VMOD
7	succinylcholine	succinylcholine	B-NP	NN	O	6	PMOD
8	is	be	B-VP	VBZ	O	0	ROOT
9	postoperative	postoperative	B-NP	JJ	O	10	NMOD
10	myalgia	myalgia	I-NP	NN	O	8	PRD
11	.	.	O	.	O	8	P

1	The	The	B-NP	DT	O	4	NMOD
2	incidence	incidence	I-NP	NN	O	4	NMOD
3	and	and	I-NP	CC	O	4	NMOD
4	severity	severity	I-NP	NN	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	succinylcholine-associated	succinylcholine-associated	B-NP	JJ	O	7	NMOD
7	myalgia	myalgia	I-NP	NN	O	5	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	determined	determine	I-VP	VBN	O	8	VC
10	in	in	B-PP	IN	O	9	VMOD
11	64	64	B-NP	CD	O	12	NMOD
12	patients	patient	I-NP	NNS	O	10	PMOD
13	pretreated	pretreate	B-VP	VBN	O	12	NMOD
14	with	with	B-PP	IN	O	13	VMOD
15	saline	saline	B-NP	NN	O	17	NMOD
16	or	or	I-NP	CC	O	17	NMOD
17	dexamethasone	dexamethasone	I-NP	NN	O	14	PMOD
18	before	before	B-PP	IN	O	12	NMOD
19	succinylcholine	succinylcholine	B-NP	NN	O	18	PMOD
20	(	(	O	(	O	26	DEP
21	n	n	B-NP	NN	O	26	DEP
22	=	=	B-VP	JJ	O	21	NMOD
23	32	32	B-NP	CD	O	22	AMOD
24	for	for	B-PP	IN	O	21	NMOD
25	each	each	B-NP	DT	O	24	PMOD
26	)	)	O	)	O	19	NMOD
27	.	.	O	.	O	8	P

1	Incidence	Incidence	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	severity	severity	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	myalgia	myalgia	B-NP	NN	O	4	PMOD
6	did	do	B-VP	VBD	O	36	VMOD
7	not	not	I-VP	RB	O	6	VMOD
8	differ	differ	I-VP	VB	O	6	VC
9	significantly	significantly	B-ADVP	RB	O	8	VMOD
10	between	between	B-PP	IN	O	8	VMOD
11	the	the	B-NP	DT	O	13	NMOD
12	two	two	I-NP	CD	O	13	NMOD
13	groups	group	I-NP	NNS	O	10	PMOD
14	:	:	O	:	O	6	P
15	15	15	B-NP	CD	O	16	NMOD
16	patients	patient	I-NP	NNS	O	21	SUB
17	in	in	B-PP	IN	O	16	NMOD
18	the	the	B-NP	DT	O	20	NMOD
19	dexamethasone	dexamethasone	I-NP	NN	O	20	NMOD
20	group	group	I-NP	NN	O	17	PMOD
21	complained	complain	B-VP	VBD	O	6	VMOD
22	of	of	B-PP	IN	O	21	VMOD
23	myalgia	myalgia	B-NP	NN	O	22	PMOD
24	compared	compare	B-PP	VBN	O	21	VMOD
25	with	with	B-PP	IN	O	24	PMOD
26	18	18	B-NP	CD	O	27	NMOD
27	patients	patient	I-NP	NNS	O	25	PMOD
28	in	in	B-PP	IN	O	27	NMOD
29	the	the	B-NP	DT	O	31	NMOD
30	saline	saline	I-NP	NN	O	31	NMOD
31	group	group	I-NP	NN	O	28	PMOD
32	,	,	O	,	O	36	P
33	and	and	O	CC	O	36	VMOD
34	severe	severe	B-NP	JJ	O	35	NMOD
35	myalgia	myalgia	I-NP	NN	O	36	SUB
36	was	be	B-VP	VBD	O	0	ROOT
37	reported	report	I-VP	VBN	O	36	VC
38	by	by	B-PP	IN	O	37	VMOD
39	five	five	B-NP	CD	O	40	NMOD
40	patients	patient	I-NP	NNS	O	43	NMOD
41	and	and	O	CC	O	43	NMOD
42	three	three	B-NP	CD	O	43	NMOD
43	patients	patient	I-NP	NNS	O	38	PMOD
44	,	,	O	,	O	37	P
45	respectively	respectively	B-ADVP	RB	O	37	VMOD
46	(	(	O	(	O	49	DEP
47	not	not	O	RB	O	48	AMOD
48	significant	significant	B-ADJP	JJ	O	49	DEP
49	)	)	O	)	O	45	AMOD
50	.	.	O	.	O	36	P

1	In	In	B-PP	IN	O	5	VMOD
2	conclusion	conclusion	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	there	there	B-NP	EX	O	5	SUB
5	is	be	B-VP	VBZ	O	0	ROOT
6	no	no	B-NP	DT	O	7	NMOD
7	evidence	evidence	I-NP	NN	O	5	PRD
8	for	for	B-PP	IN	O	7	NMOD
9	an	an	B-NP	DT	O	11	NMOD
10	inflammatory	inflammatory	I-NP	JJ	O	11	NMOD
11	origin	origin	I-NP	NN	O	8	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	succinylcholine-associated	succinylcholine-associated	B-NP	JJ	O	14	NMOD
14	myalgia	myalgia	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	5	P

1	IMPLICATIONS	IMPLICATIONS	B-NP	NNS	O	3	NMOD
2	:	:	O	:	O	1	P
3	Administration	Administration	B-NP	NN	O	8	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	dexamethasone	dexamethasone	B-NP	NN	O	4	PMOD
6	before	before	B-PP	IN	O	3	NMOD
7	succinylcholine	succinylcholine	B-NP	NN	O	6	PMOD
8	was	be	B-VP	VBD	O	0	ROOT
9	not	not	O	RB	O	8	VMOD
10	effective	effective	B-ADJP	JJ	O	8	PRD
11	in	in	B-PP	IN	O	10	AMOD
12	decreasing	decrease	B-VP	VBG	O	11	PMOD
13	the	the	B-NP	DT	O	14	NMOD
14	incidence	incidence	I-NP	NN	O	17	NMOD
15	or	or	O	CC	O	17	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	severity	severity	I-NP	NN	O	12	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	succinylcholine	succinylcholine	B-NP	NN	O	18	PMOD
20	induced	induce	B-VP	VBD	O	8	VMOD
21	postoperative	postoperative	B-NP	JJ	O	22	NMOD
22	myalgia	myalgia	I-NP	NN	O	20	OBJ
23	.	.	O	.	O	8	P

1	Levodopa	Levodopa	B-NP	NNP	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	oromandibular	oromandibular	B-NP	JJ	O	4	NMOD
4	dystonia	dystonia	I-NP	NN	O	2	OBJ
5	in	in	B-PP	IN	O	2	VMOD
6	progressive	progressive	B-NP	JJ	O	8	NMOD
7	supranuclear	supranuclear	I-NP	JJ	O	8	NMOD
8	palsy	palsy	I-NP	NN	O	5	PMOD
9	.	.	O	.	O	2	P

1	Levodopa	Levodopa	B-NP	NN	O	3	NMOD
2	induced	induced	I-NP	JJ	O	3	NMOD
3	dyskinesias	dyskinesia	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	reported	report	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	Parkinson	Parkinson	B-NP	NNP	O	9	NMOD
9	's	's	B-NP	POS	O	10	NMOD
10	disease	disease	I-NP	NN	O	14	NMOD
11	and	and	O	CC	O	14	NMOD
12	multiple	multiple	B-NP	JJ	O	14	NMOD
13	system	system	I-NP	NN	O	14	NMOD
14	atrophy	atrophy	I-NP	NN	O	7	PMOD
15	.	.	O	.	O	4	P

1	Protective	Protective	B-NP	JJ	O	2	NMOD
2	effect	effect	I-NP	NN	O	7	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	edaravone	edaravone	B-NP	NN	O	3	PMOD
5	against	against	B-PP	IN	O	2	NMOD
6	streptomycin	streptomycin	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	0	ROOT
8	vestibulotoxicity	vestibulotoxicity	B-NP	NN	O	7	OBJ
9	in	in	B-PP	IN	O	7	VMOD
10	the	the	B-NP	DT	O	12	NMOD
11	guinea	guinea	I-NP	NN	O	12	NMOD
12	pig	pig	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	7	P

1	This	This	B-NP	DT	O	2	NMOD
2	study	study	I-NP	NN	O	3	SUB
3	investigated	investigate	B-VP	VBD	O	0	ROOT
4	alleviation	alleviation	B-NP	NN	O	3	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	streptomycin	streptomycin	B-NP	NN	O	5	PMOD
7	induced	induce	B-VP	VBD	O	4	NMOD
8	vestibulotoxicity	vestibulotoxicity	B-NP	NN	O	7	OBJ
9	by	by	B-PP	IN	O	7	VMOD
10	edaravone	edaravone	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	7	VMOD
12	guinea	guinea	B-NP	NN	O	13	NMOD
13	pigs	pig	I-NP	NNS	O	11	PMOD
14	.	.	O	.	O	3	P

1	Edaravone	Edaravone	B-NP	NN	O	6	NMOD
2	,	,	O	,	O	6	P
3	a	a	B-NP	DT	O	6	NMOD
4	free	free	I-NP	JJ	O	6	NMOD
5	radical	radical	I-NP	NN	O	6	NMOD
6	scavenger	scavenger	I-NP	NN	O	8	SUB
7	,	,	O	,	O	6	P
8	has	have	B-VP	VBZ	O	0	ROOT
9	potent	potent	B-NP	JJ	O	11	NMOD
10	free	free	I-NP	JJ	O	11	NMOD
11	radical	radical	I-NP	NN	O	8	OBJ
12	quenching	quench	B-VP	VBG	O	11	NMOD
13	action	action	B-NP	NN	O	12	OBJ
14	and	and	O	CC	O	8	VMOD
15	is	be	B-VP	VBZ	O	8	VMOD
16	used	use	I-VP	VBN	O	15	VC
17	in	in	B-PP	IN	O	16	VMOD
18	clinical	clinical	B-NP	JJ	O	19	NMOD
19	practice	practice	I-NP	NN	O	17	PMOD
20	to	to	B-VP	TO	O	21	VMOD
21	treat	treat	I-VP	VB	O	16	VMOD
22	cerebral	cerebral	B-NP	JJ	O	23	NMOD
23	infarction	infarction	I-NP	NN	O	21	OBJ
24	.	.	O	.	O	8	P

1	Diazepam	Diazepam	B-NP	NN	O	0	ROOT
2	,	,	O	,	O	1	P
3	unless	unless	B-SBAR	IN	O	1	NMOD
4	contraindicated	contraindicate	B-NP	VBN	O	6	AMOD
5	or	or	I-NP	CC	O	6	AMOD
6	risky	risky	I-NP	JJ	O	8	SUB
7	,	,	O	,	O	6	P
8	remains	remain	B-VP	VBZ	O	3	SBAR
9	the	the	B-NP	DT	O	13	NMOD
10	only	only	I-NP	RB	O	11	AMOD
11	necessary	necessary	I-NP	JJ	O	13	NMOD
12	complementary	complementary	I-NP	JJ	O	13	NMOD
13	drug	drug	I-NP	NN	O	8	PRD
14	to	to	B-PP	TO	O	13	NMOD
15	ketamine	ketamine	B-NP	NN	O	14	PMOD
16	as	as	B-SBAR	IN	O	8	VMOD
17	it	it	B-NP	PRP	O	18	SUB
18	buffers	buffer	B-VP	VBZ	O	16	SBAR
19	its	its	B-NP	PRP$	O	21	NMOD
20	cardiovascular	cardiovascular	I-NP	JJ	O	21	NMOD
21	response	response	I-NP	NN	O	18	OBJ
22	and	and	O	CC	O	18	VMOD
23	decreases	decrease	B-VP	VBZ	O	18	VMOD
24	the	the	B-NP	DT	O	27	NMOD
25	duration	duration	I-NP	NN	O	27	NMOD
26	and	and	I-NP	CC	O	27	NMOD
27	intensity	intensity	I-NP	NN	O	23	OBJ
28	of	of	B-PP	IN	O	27	NMOD
29	operative	operative	B-NP	JJ	O	31	AMOD
30	and	and	I-NP	CC	O	31	AMOD
31	postoperative	postoperative	I-NP	JJ	O	32	NMOD
32	hallucinations	hallucination	I-NP	NNS	O	28	PMOD
33	.	.	O	.	O	1	P

1	Steroid	Steroid	B-NP	NN	O	2	NMOD
2	structure	structure	I-NP	NN	O	5	NMOD
3	and	and	O	CC	O	5	NMOD
4	pharmacological	pharmacological	B-NP	JJ	O	5	NMOD
5	properties	property	I-NP	NNS	O	6	SUB
6	determine	determine	B-VP	VBP	O	0	ROOT
7	the	the	B-NP	DT	O	9	NMOD
8	anti-amnesic	anti-amnesic	I-NP	JJ	O	9	NMOD
9	effects	effect	I-NP	NNS	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	pregnenolone	pregnenolone	B-NP	NN	O	12	NMOD
12	sulphate	sulphate	I-NP	NN	O	10	PMOD
13	in	in	B-PP	IN	O	9	NMOD
14	the	the	B-NP	DT	O	17	NMOD
15	passive	passive	I-NP	JJ	O	17	NMOD
16	avoidance	avoidance	I-NP	NN	O	17	NMOD
17	task	task	I-NP	NN	O	13	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	rats	rat	B-NP	NNS	O	18	PMOD
20	.	.	O	.	O	6	P

1	Moreover	Moreover	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	PREGS	PREGS	B-NP	NN	B-protein	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	able	able	B-ADJP	JJ	O	4	PRD
6	to	to	B-VP	TO	O	7	VMOD
7	reverse	reverse	I-VP	VB	O	5	AMOD
8	the	the	B-NP	DT	O	10	NMOD
9	amnesic-like	amnesic-like	I-NP	JJ	O	10	NMOD
10	effects	effect	I-NP	NNS	O	7	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	NMDAR	NMDAR	B-NP	NN	B-protein	19	NMOD
13	and	and	I-NP	CC	O	19	NMOD
14	GABA	GABA	I-NP	NN	B-protein	19	NMOD
15	(	(	I-NP	(	O	19	NMOD
16	A	A	I-NP	NN	O	19	NMOD
17	)	)	I-NP	)	O	19	NMOD
18	R	R	I-NP	NN	O	19	NMOD
19	ligands	ligand	I-NP	NNS	O	11	PMOD
20	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	memory-enhancing	memory-enhancing	I-NP	JJ	O	3	NMOD
3	effects	effect	I-NP	NNS	O	9	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	PREGS	PREGS	B-NP	NN	B-protein	8	NMOD
6	and	and	O	CC	O	8	NMOD
7	its	its	B-NP	PRP$	O	8	NMOD
8	analogs	analog	I-NP	NNS	O	4	PMOD
9	were	be	B-VP	VBD	O	0	ROOT
10	tested	test	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	15	NMOD
13	passive	passive	I-NP	JJ	O	15	NMOD
14	avoidance	avoidance	I-NP	NN	O	15	NMOD
15	task	task	I-NP	NN	O	11	PMOD
16	using	use	B-VP	VBG	O	15	NMOD
17	the	the	B-NP	DT	O	18	NMOD
18	model	model	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	scopolamine	scopolamine	B-NP	NN	O	22	NMOD
21	induced	induced	I-NP	JJ	O	22	NMOD
22	amnesia	amnesia	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	9	P

1	Moreover	Moreover	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	enantioselectivity	enantioselectivity	B-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	demonstrated	demonstrate	I-VP	VBN	O	4	VC
6	by	by	B-PP	IN	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	ability	ability	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	natural	natural	B-NP	JJ	O	11	NMOD
11	PREGS	PREGS	I-NP	NN	O	9	PMOD
12	to	to	B-VP	TO	O	13	VMOD
13	be	be	I-VP	VB	O	8	NMOD
14	an	an	B-NP	DT	O	15	NMOD
15	order	order	I-NP	NN	O	19	AMOD
16	of	of	B-PP	IN	O	15	NMOD
17	magnitude	magnitude	B-NP	NN	O	16	PMOD
18	more	more	B-ADJP	RBR	O	19	AMOD
19	effective	effective	I-ADJP	JJ	O	23	NMOD
20	than	than	B-PP	IN	O	23	NMOD
21	its	its	B-NP	PRP$	O	23	NMOD
22	synthetic	synthetic	I-NP	JJ	O	23	NMOD
23	enantiomer	enantiomer	I-NP	NN	O	13	PRD
24	in	in	B-PP	IN	O	23	NMOD
25	reversing	reverse	B-VP	VBG	O	24	PMOD
26	scopolamine	scopolamine	B-NP	NN	O	28	NMOD
27	induced	induced	I-NP	JJ	O	28	NMOD
28	amnesia	amnesia	I-NP	NN	O	25	OBJ
29	.	.	O	.	O	4	P

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	Preclinical	Preclinical	B-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	8	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	intrathecal	intrathecal	B-NP	JJ	O	7	NMOD
7	adenosine	adenosine	I-NP	NN	O	5	PMOD
8	suggest	suggest	B-VP	VBP	O	37	VMOD
9	it	it	B-NP	PRP	O	8	SUB
10	may	may	B-VP	MD	O	8	VMOD
11	be	be	I-VP	VB	O	10	VC
12	effective	effective	B-ADJP	JJ	O	11	PRD
13	in	in	B-PP	IN	O	11	VMOD
14	the	the	B-NP	DT	O	15	NMOD
15	treatment	treatment	I-NP	NN	O	13	PMOD
16	of	of	B-PP	IN	O	15	NMOD
17	acute	acute	B-NP	JJ	O	20	NMOD
18	and	and	I-NP	CC	O	20	NMOD
19	chronic	chronic	I-NP	JJ	O	20	NMOD
20	pain	pain	I-NP	NN	O	16	PMOD
21	in	in	B-PP	IN	O	15	NMOD
22	humans	human	B-NP	NNS	O	21	PMOD
23	,	,	O	,	O	37	P
24	and	and	O	CC	O	26	NMOD
25	preliminary	preliminary	B-NP	JJ	O	26	NMOD
26	studies	study	I-NP	NNS	O	37	SUB
27	in	in	B-PP	IN	O	26	NMOD
28	volunteers	volunteer	B-NP	NNS	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	patients	patient	I-NP	NNS	O	27	PMOD
31	with	with	B-PP	IN	O	30	NMOD
32	a	a	B-NP	DT	O	34	NMOD
33	Swedish	Swedish	I-NP	JJ	O	34	NMOD
34	formulation	formulation	I-NP	NN	O	31	PMOD
35	of	of	B-PP	IN	O	34	NMOD
36	adenosine	adenosine	B-NP	NN	O	35	PMOD
37	suggests	suggest	B-VP	VBZ	O	1	NMOD
38	it	it	B-NP	PRP	O	37	OBJ
39	may	may	B-VP	MD	O	37	VMOD
40	be	be	I-VP	VB	O	39	VC
41	effective	effective	B-ADJP	JJ	O	40	PRD
42	in	in	B-PP	IN	O	40	VMOD
43	hypersensitivity	hypersensitivity	B-NP	NN	O	44	NMOD
44	states	state	I-NP	NNS	O	42	PMOD
45	but	but	B-PP	CC	O	42	PMOD
46	not	not	B-PP	RB	O	47	PMOD
47	with	with	I-PP	IN	O	42	PMOD
48	acute	acute	B-NP	JJ	O	50	NMOD
49	noxious	noxious	I-NP	JJ	O	50	NMOD
50	stimulation	stimulation	I-NP	NN	O	47	PMOD
51	.	.	O	.	O	37	P

1	The	The	B-NP	DT	O	2	NMOD
2	purpose	purpose	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	study	study	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	screen	screen	I-VP	VB	O	6	PRD
9	for	for	B-PP	IN	O	8	VMOD
10	efficacy	efficacy	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	a	a	B-NP	DT	O	14	NMOD
13	different	different	I-NP	JJ	O	14	NMOD
14	formulation	formulation	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	adenosine	adenosine	B-NP	NN	O	15	PMOD
17	marketed	market	B-VP	VBN	O	16	NMOD
18	in	in	B-PP	IN	O	17	VMOD
19	the	the	B-NP	DT	O	20	NMOD
20	US	US	I-NP	NNP	O	18	PMOD
21	,	,	O	,	O	8	P
22	using	use	B-VP	VBG	O	8	VMOD
23	both	both	O	CC	O	30	NMOD
24	acute	acute	B-NP	JJ	O	26	NMOD
25	noxious	noxious	I-NP	JJ	O	26	NMOD
26	stimulation	stimulation	I-NP	NN	O	30	NMOD
27	and	and	O	CC	O	30	NMOD
28	capsaicin-evoked	capsaicin-evoked	B-NP	JJ	O	30	NMOD
29	mechanical	mechanical	I-NP	JJ	O	30	NMOD
30	hypersensitivity	hypersensitivity	I-NP	NN	O	22	OBJ
31	.	.	O	.	O	6	P

1	Cerebrospinal	Cerebrospinal	B-NP	JJ	O	2	NMOD
2	fluid	fluid	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	29	VMOD
4	obtained	obtain	I-VP	VBN	O	3	VC
5	for	for	B-PP	IN	O	4	VMOD
6	pharmacokinetic	pharmacokinetic	B-NP	JJ	O	7	NMOD
7	analysis	analysis	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	11	P
9	and	and	O	CC	O	11	NMOD
10	pain	pain	B-NP	NN	O	11	NMOD
11	ratings	rating	I-NP	NNS	O	3	PRD
12	in	in	B-PP	IN	O	3	VMOD
13	response	response	B-NP	NN	O	12	PMOD
14	to	to	B-PP	TO	O	13	NMOD
15	acute	acute	B-NP	JJ	O	17	NMOD
16	heat	heat	I-NP	NN	O	17	NMOD
17	stimuli	stimulus	I-NP	NNS	O	14	PMOD
18	and	and	I-NP	CC	O	29	VMOD
19	areas	area	I-NP	NNS	O	29	SUB
20	of	of	B-PP	IN	O	19	NMOD
21	mechanical	mechanical	B-NP	JJ	O	22	NMOD
22	hyperalgesia	hyperalgesia	I-NP	NN	O	24	NMOD
23	and	and	I-NP	CC	O	24	NMOD
24	allodynia	allodynia	I-NP	NN	O	20	PMOD
25	after	after	B-PP	IN	O	19	NMOD
26	intradermal	intradermal	B-NP	JJ	O	28	NMOD
27	capsaicin	capsaicin	I-NP	NN	O	28	NMOD
28	injection	injection	I-NP	NN	O	25	PMOD
29	were	be	B-VP	VBD	O	0	ROOT
30	determined	determine	I-VP	VBN	O	29	VC
31	.	.	O	.	O	29	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Adenosine	Adenosine	B-NP	NN	O	4	SUB
4	produced	produce	B-VP	VBD	O	1	NMOD
5	no	no	B-NP	DT	O	6	NMOD
6	effect	effect	I-NP	NN	O	4	OBJ
7	on	on	B-PP	IN	O	6	NMOD
8	pain	pain	B-NP	NN	O	9	NMOD
9	report	report	I-NP	NN	O	7	PMOD
10	to	to	B-PP	TO	O	9	NMOD
11	acute	acute	B-NP	JJ	O	13	NMOD
12	noxious	noxious	I-NP	JJ	O	13	NMOD
13	thermal	thermal	I-NP	JJ	O	10	PMOD
14	or	or	I-NP	CC	O	16	NMOD
15	chemical	chemical	I-NP	JJ	O	16	NMOD
16	stimulation	stimulation	I-NP	NN	O	13	NMOD
17	but	but	O	CC	O	4	VMOD
18	reduced	reduce	B-VP	VBD	O	4	VMOD
19	mechanical	mechanical	B-NP	JJ	O	20	NMOD
20	hyperalgesia	hyperalgesia	I-NP	NN	O	22	NMOD
21	and	and	I-NP	CC	O	22	NMOD
22	allodynia	allodynia	I-NP	NN	O	18	OBJ
23	from	from	B-PP	IN	O	18	VMOD
24	intradermal	intradermal	B-NP	JJ	O	26	NMOD
25	capsaicin	capsaicin	I-NP	NN	O	26	NMOD
26	injection	injection	I-NP	NN	O	23	PMOD
27	for	for	B-PP	IN	O	18	VMOD
28	at	at	B-NP	IN	O	31	NMOD
29	least	least	I-NP	JJS	O	28	AMOD
30	24	24	I-NP	CD	O	28	AMOD
31	h	h	I-NP	NN	O	27	PMOD
32	.	.	O	.	O	1	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	These	These	B-NP	DT	O	4	NMOD
4	results	result	I-NP	NNS	O	5	SUB
5	show	show	B-VP	VBP	O	1	NMOD
6	selective	selective	B-NP	JJ	O	7	NMOD
7	inhibition	inhibition	I-NP	NN	O	5	OBJ
8	by	by	B-PP	IN	O	7	NMOD
9	intrathecal	intrathecal	B-NP	JJ	O	10	NMOD
10	adenosine	adenosine	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	hypersensitivity	hypersensitivity	B-NP	NN	O	11	PMOD
13	,	,	O	,	O	7	P
14	presumed	presume	B-VP	VBN	O	7	NMOD
15	to	to	I-VP	TO	O	16	VMOD
16	reflect	reflect	I-VP	VB	O	14	VMOD
17	central	central	B-NP	JJ	O	18	NMOD
18	sensitization	sensitization	I-NP	NN	O	16	OBJ
19	in	in	B-PP	IN	O	18	NMOD
20	humans	human	B-NP	NNS	O	19	PMOD
21	after	after	B-PP	IN	O	20	NMOD
22	peripheral	peripheral	B-NP	JJ	O	24	NMOD
23	capsaicin	capsaicin	I-NP	NN	O	24	NMOD
24	injection	injection	I-NP	NN	O	21	PMOD
25	.	.	O	.	O	1	P

1	These	These	B-NP	DT	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	evaluated	evaluate	I-VP	VBN	O	2	VC
4	with	with	B-PP	IN	O	3	VMOD
5	respect	respect	B-NP	NN	O	4	PMOD
6	to	to	B-PP	TO	O	5	NMOD
7	the	the	B-NP	DT	O	8	NMOD
8	duration	duration	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	lithium	lithium	B-NP	NN	O	11	NMOD
11	therapy	therapy	I-NP	NN	O	19	NMOD
12	,	,	O	,	O	19	P
13	age	age	B-NP	NN	O	19	NMOD
14	,	,	O	,	O	19	P
15	sex	sex	B-NP	NN	O	19	NMOD
16	,	,	O	,	O	19	P
17	and	and	O	CC	O	19	NMOD
18	family	family	B-NP	NN	O	19	NMOD
19	history	history	I-NP	NN	O	9	PMOD
20	(	(	O	(	O	33	DEP
21	whether	whether	B-SBAR	IN	O	26	VMOD
22	or	or	O	CC	O	21	DEP
23	not	not	O	RB	O	21	DEP
24	the	the	B-NP	DT	O	25	NMOD
25	patient	patient	I-NP	NN	O	26	SUB
26	had	have	B-VP	VBD	O	33	DEP
27	a	a	B-NP	DT	O	29	NMOD
28	first-degree	first-degree	I-NP	JJ	O	29	NMOD
29	relative	relative	I-NP	NN	O	26	OBJ
30	with	with	B-PP	IN	O	26	VMOD
31	thyroid	thyroid	B-NP	NN	O	32	NMOD
32	disease	disease	I-NP	NN	O	30	PMOD
33	)	)	O	)	O	3	VMOD
34	.	.	O	.	O	2	P

1	PATIENTS	PATIENTS	B-NP	NNS	O	7	NMOD
2	:	:	O	:	O	1	P
3	One	One	B-NP	CD	O	7	NMOD
4	hundred	hundred	I-NP	CD	O	3	NMOD
5	and	and	O	CC	O	7	NMOD
6	one	one	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	0	ROOT
8	(	(	O	(	O	14	DEP
9	28	28	B-NP	CD	O	10	NMOD
10	men	man	I-NP	NNS	O	13	NMOD
11	and	and	O	CC	O	13	NMOD
12	73	73	B-NP	CD	O	13	NMOD
13	women	woman	I-NP	NNS	O	14	DEP
14	)	)	O	)	O	7	NMOD
15	with	with	B-PP	IN	O	7	NMOD
16	bipolar	bipolar	B-NP	JJ	O	17	NMOD
17	disorder	disorder	I-NP	NN	O	15	PMOD
18	receiving	receive	B-VP	VBG	O	17	NMOD
19	lithium	lithium	B-NP	NN	O	21	NMOD
20	maintenance	maintenance	I-NP	NN	O	21	NMOD
21	therapy	therapy	I-NP	NN	O	18	OBJ
22	ranging	range	B-VP	VBG	O	21	NMOD
23	from	from	B-PP	IN	O	22	VMOD
24	1	1	B-NP	CD	O	26	NMOD
25	year	year	I-NP	NN	O	26	NMOD
26	's	's	B-NP	POS	O	23	PMOD
27	to	to	B-PP	TO	O	22	VMOD
28	32	32	B-NP	CD	O	31	NMOD
29	years	year	I-NP	NNS	O	30	NMOD
30	'	'	B-NP	POS	O	31	NMOD
31	duration	duration	I-NP	NN	O	27	PMOD
32	.	.	O	.	O	7	P

1	All	All	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	10	SUB
3	having	have	B-VP	VBG	O	2	NMOD
4	first-degree	first-degree	B-NP	JJ	O	5	NMOD
5	relatives	relative	I-NP	NNS	O	3	OBJ
6	affected	affect	B-VP	VBN	O	5	NMOD
7	by	by	B-PP	IN	O	6	VMOD
8	thyroid	thyroid	B-NP	JJ	O	9	NMOD
9	illness	illness	I-NP	NN	O	7	PMOD
10	had	have	B-VP	VBD	O	0	ROOT
11	accelerated	accelerate	I-VP	VBN	O	10	VC
12	onset	onset	B-NP	NN	O	11	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	hypothyroidism	hypothyroidism	B-NP	NN	O	13	PMOD
15	(	(	O	(	O	23	DEP
16	3.7	3.7	B-NP	CD	O	17	NMOD
17	years	year	I-NP	NNS	O	18	PMOD
18	after	after	B-PP	IN	O	23	DEP
19	onset	onset	B-NP	NN	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	lithium	lithium	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	)	)	O	)	O	14	NMOD
24	compared	compare	B-PP	VBN	O	11	VMOD
25	with	with	B-PP	IN	O	24	PMOD
26	patients	patient	B-NP	NNS	O	25	PMOD
27	without	without	B-PP	IN	O	26	NMOD
28	a	a	B-NP	DT	O	30	NMOD
29	family	family	I-NP	NN	O	30	NMOD
30	history	history	I-NP	NN	O	27	PMOD
31	(	(	O	(	O	39	DEP
32	8.6	8.6	B-NP	CD	O	33	NMOD
33	years	year	I-NP	NNS	O	39	DEP
34	after	after	B-PP	IN	O	33	NMOD
35	onset	onset	B-NP	NN	O	34	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	lithium	lithium	B-NP	NN	O	38	NMOD
38	therapy	therapy	I-NP	NN	O	36	PMOD
39	)	)	O	)	O	26	NMOD
40	.	.	O	.	O	10	P

1	Systemic	Systemic	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	14	NMOD
3	following	follow	B-PP	VBG	O	2	NMOD
4	administration	administration	B-NP	NN	O	3	PMOD
5	of	of	B-PP	IN	O	4	NMOD
6	sirolimus	sirolimus	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	10	DEP
8	formerly	formerly	B-ADVP	RB	O	10	DEP
9	rapamycin	rapamycin	B-NP	NN	O	8	DEP
10	)	)	O	)	O	2	NMOD
11	for	for	B-PP	IN	O	2	NMOD
12	psoriasis	psoriasis	B-NP	NN	O	11	PMOD
13	:	:	O	:	O	2	P
14	association	association	B-NP	NN	O	0	ROOT
15	of	of	B-PP	IN	O	14	NMOD
16	capillary	capillary	B-NP	JJ	O	18	NMOD
17	leak	leak	I-NP	NN	O	18	NMOD
18	syndrome	syndrome	I-NP	NN	O	15	PMOD
19	with	with	B-PP	IN	O	14	NMOD
20	apoptosis	apoptosis	B-NP	NN	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	lesional	lesional	B-NP	JJ	B-cell_type	23	NMOD
23	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	21	PMOD
24	.	.	O	.	O	14	P

1	After	After	B-PP	IN	O	6	VMOD
2	2	2	B-NP	CD	O	3	NMOD
3	individuals	individual	I-NP	NNS	O	1	PMOD
4	with	with	B-PP	IN	O	3	NMOD
5	psoriasis	psoriasis	B-NP	NN	O	4	PMOD
6	developed	develop	B-VP	VBD	O	0	ROOT
7	a	a	B-NP	DT	O	10	NMOD
8	capillary	capillary	I-NP	JJ	O	10	NMOD
9	leak	leak	I-NP	NN	O	10	NMOD
10	syndrome	syndrome	I-NP	NN	O	6	OBJ
11	following	follow	B-PP	VBG	O	10	NMOD
12	treatment	treatment	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	oral	oral	B-NP	JJ	B-cell_type	18	NMOD
15	sirolimus	sirolimus	I-NP	NN	I-cell_type	18	NMOD
16	lesional	lesional	I-NP	JJ	I-cell_type	18	NMOD
17	skin	skin	I-NP	NN	I-cell_type	18	NMOD
18	cells	cell	I-NP	NNS	I-cell_type	23	NMOD
19	and	and	O	CC	O	23	NMOD
20	activated	activate	B-NP	VBN	B-cell_type	23	NMOD
21	peripheral	peripheral	I-NP	JJ	I-cell_type	23	NMOD
22	blood	blood	I-NP	NN	I-cell_type	23	NMOD
23	cells	cell	I-NP	NNS	I-cell_type	13	PMOD
24	were	be	B-VP	VBD	O	6	VMOD
25	analyzed	analyze	I-VP	VBN	O	24	VC
26	for	for	B-PP	IN	O	25	VMOD
27	induction	induction	B-NP	NN	O	26	PMOD
28	of	of	B-PP	IN	O	27	NMOD
29	apoptosis	apoptosis	B-NP	NN	O	28	PMOD
30	.	.	O	.	O	6	P

1	OBSERVATIONS	OBSERVATIONS	B-NP	NNS	O	6	NMOD
2	:	:	O	:	O	1	P
3	A	A	B-NP	DT	O	6	NMOD
4	keratome	keratome	I-NP	NN	O	6	NMOD
5	skin	skin	I-NP	NN	O	6	NMOD
6	specimen	specimen	I-NP	NN	O	12	SUB
7	from	from	B-PP	IN	O	6	NMOD
8	1	1	B-NP	CD	O	9	NMOD
9	patient	patient	I-NP	NN	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	sirolimus	sirolimus	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	16	VMOD
13	capillary	capillary	B-NP	JJ	O	15	NMOD
14	leak	leak	I-NP	NN	O	15	NMOD
15	syndrome	syndrome	I-NP	NN	O	16	SUB
16	had	have	B-VP	VBD	O	0	ROOT
17	a	a	B-NP	DT	O	19	NMOD
18	2.3-fold	2.3-fold	I-NP	JJ	O	19	NMOD
19	increase	increase	I-NP	NN	O	16	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	percentage	percentage	B-NP	NN	O	20	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	apoptotic	apoptotic	B-NP	JJ	B-cell_type	24	NMOD
24	cells	cell	I-NP	NNS	I-cell_type	22	PMOD
25	(	(	O	(	O	29	DEP
26	to	to	B-PP	TO	O	29	DEP
27	48	48	B-NP	CD	O	28	NMOD
28	%	%	I-NP	NN	O	26	PMOD
29	)	)	O	)	O	24	NMOD
30	compared	compare	B-PP	VBN	O	16	VMOD
31	with	with	B-PP	IN	O	30	PMOD
32	an	an	B-NP	DT	O	35	NMOD
33	unaffected	unaffected	I-NP	JJ	O	35	NMOD
34	sirolimus-treated	sirolimus-treated	I-NP	JJ	O	35	NMOD
35	patient	patient	I-NP	NN	O	31	PMOD
36	with	with	B-PP	IN	O	35	NMOD
37	psoriasis	psoriasis	B-NP	NN	O	36	PMOD
38	(	(	O	(	O	41	DEP
39	21	21	B-NP	CD	O	40	NMOD
40	%	%	I-NP	NN	O	41	DEP
41	)	)	O	)	O	37	NMOD
42	.	.	O	.	O	16	P

1	Activated	Activate	B-NP	VBN	O	5	NMOD
2	peripheral	peripheral	I-NP	JJ	B-cell_type	5	NMOD
3	blood	blood	I-NP	NN	I-cell_type	5	NMOD
4	T	T	I-NP	NN	I-cell_type	5	NMOD
5	cells	cell	I-NP	NNS	I-cell_type	10	SUB
6	from	from	B-PP	IN	O	5	NMOD
7	patients	patient	B-NP	NNS	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	psoriasis	psoriasis	B-NP	NN	O	8	PMOD
10	tended	tend	B-VP	VBD	O	0	ROOT
11	to	to	I-VP	TO	O	12	VMOD
12	exhibit	exhibit	I-VP	VB	O	10	VMOD
13	greater	great	B-NP	JJR	O	16	NMOD
14	spontaneous	spontaneous	I-NP	JJ	O	16	NMOD
15	or	or	I-NP	CC	O	16	NMOD
16	dexamethasone	dexamethasone	I-NP	NN	O	18	NMOD
17	induced	induce	B-VP	VBD	O	16	AMOD
18	apoptosis	apoptosis	B-NP	NN	O	12	OBJ
19	than	than	B-SBAR	IN	O	18	NMOD
20	did	do	O	VBD	O	19	SBAR
21	normal	normal	B-NP	JJ	O	23	NMOD
22	T	T	I-NP	NN	B-cell_type	23	NMOD
23	cells	cell	I-NP	NNS	I-cell_type	20	SUB
24	,	,	O	,	O	20	P
25	particularly	particularly	B-ADVP	RB	O	20	VMOD
26	in	in	B-PP	IN	O	25	AMOD
27	the	the	I-PP	DT	O	28	NMOD
28	presence	presence	I-PP	NN	O	26	PMOD
29	of	of	I-PP	IN	O	28	NMOD
30	sirolimus	sirolimus	B-NP	NN	O	29	PMOD
31	.	.	O	.	O	10	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Severe	Severe	B-NP	JJ	O	5	NMOD
4	adverse	adverse	I-NP	JJ	O	5	NMOD
5	effects	effect	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	sirolimus	sirolimus	B-NP	NN	O	6	PMOD
8	include	include	B-VP	VBP	O	1	NMOD
9	fever	fever	B-NP	NN	O	16	NMOD
10	,	,	O	,	O	16	P
11	anemia	anemia	B-NP	NN	O	16	NMOD
12	,	,	O	,	O	16	P
13	and	and	O	CC	O	16	NMOD
14	capillary	capillary	B-NP	JJ	O	16	NMOD
15	leak	leak	I-NP	NN	O	16	NMOD
16	syndrome	syndrome	I-NP	NN	O	8	OBJ
17	.	.	O	.	O	1	P

1	Muscle	Muscle	B-NP	NN	O	2	NMOD
2	rigidity	rigidity	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	0	ROOT
4	induced	induce	I-VP	VBN	O	3	VC
5	by	by	B-PP	IN	O	4	VMOD
6	haloperidol	haloperidol	B-NP	NN	O	5	PMOD
7	(	(	O	(	O	11	DEP
8	2.5	2.5	B-NP	CD	O	9	NMOD
9	mg/kg	mg/kg	I-NP	NN	O	11	DEP
10	i.p.	i.p.	B-ADVP	RB	O	9	NMOD
11	)	)	O	)	O	6	NMOD
12	.	.	O	.	O	3	P
13	5	5	B-NP	CD	O	27	NMOD
14	,	,	O	,	O	27	P
15	7-dichlorokynurenic	7-dichlorokynurenic	B-NP	JJ	O	16	NMOD
16	acid	acid	I-NP	NN	O	27	NMOD
17	(	(	O	(	O	21	DEP
18	5	5	B-NP	CD	O	20	NMOD
19	,	,	O	,	O	20	P
20	7-DCKA	7-DCKA	B-NP	NN	O	21	DEP
21	)	)	O	)	O	16	NMOD
22	,	,	O	,	O	27	P
23	a	a	B-NP	DT	O	27	NMOD
24	selective	selective	I-NP	JJ	O	27	NMOD
25	glycine	glycine	I-NP	NN	O	27	NMOD
26	site	site	I-NP	NN	O	27	NMOD
27	antagonist	antagonist	I-NP	NN	O	48	SUB
28	,	,	O	,	O	27	P
29	injected	inject	B-VP	VBN	O	27	NMOD
30	in	in	B-PP	IN	O	29	VMOD
31	doses	dose	B-NP	NNS	O	30	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	2.5	2.5	B-NP	CD	O	35	AMOD
34	and	and	I-NP	CC	O	35	AMOD
35	4.5	4.5	I-NP	CD	O	37	NMOD
36	microg/0.5	microg/0.5	I-NP	NN	O	37	NMOD
37	microl	microl	I-NP	NN	O	32	PMOD
38	bilaterally	bilaterally	B-ADVP	RB	O	29	VMOD
39	,	,	O	,	O	27	P
40	into	into	B-PP	IN	O	27	NMOD
41	the	the	B-NP	DT	O	43	NMOD
42	rostral	rostral	I-NP	JJ	B-DNA	43	NMOD
43	region	region	I-NP	NN	I-DNA	40	PMOD
44	of	of	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	46	NMOD
46	striatum	striatum	I-NP	NN	O	44	PMOD
47	,	,	O	,	O	27	P
48	decreased	decrease	B-VP	VBD	O	3	VMOD
49	both	both	O	CC	O	69	NMOD
50	the	the	B-NP	DT	O	51	NMOD
51	haloperidol	haloperidol	I-NP	NN	O	69	NMOD
52	induced	induce	B-VP	VBN	O	51	NMOD
53	muscle	muscle	B-NP	NN	O	54	NMOD
54	rigidity	rigidity	I-NP	NN	O	62	NMOD
55	(	(	O	(	O	57	DEP
56	MMG	MMG	B-NP	NN	B-protein	57	DEP
57	)	)	O	)	O	54	NMOD
58	and	and	O	CC	O	62	NMOD
59	the	the	B-NP	DT	O	62	NMOD
60	enhanced	enhance	I-NP	VBN	O	62	NMOD
61	electromyographic	electromyographic	I-NP	JJ	O	62	NMOD
62	activity	activity	I-NP	NN	O	52	VMOD
63	(	(	O	(	O	65	DEP
64	EMG	EMG	B-NP	NN	B-protein	65	DEP
65	)	)	O	)	O	62	NMOD
66	.	.	O	.	O	51	P
67	5	5	B-NP	CD	O	51	NMOD
68	,	,	O	,	O	69	P
69	7-DCKA	7-DCKA	B-NP	NN	O	48	OBJ
70	injected	inject	B-VP	VBN	O	69	NMOD
71	bilaterally	bilaterally	B-ADVP	RB	O	70	VMOD
72	in	in	B-PP	IN	O	70	VMOD
73	a	a	B-NP	DT	O	74	NMOD
74	dose	dose	I-NP	NN	O	72	PMOD
75	of	of	B-PP	IN	O	74	NMOD
76	4.5	4.5	B-NP	CD	O	77	AMOD
77	microg/0.5	microg/0.5	I-NP	NN	O	78	NMOD
78	microl	microl	I-NP	NN	O	75	PMOD
79	into	into	B-PP	IN	O	74	NMOD
80	the	the	B-NP	DT	O	82	NMOD
81	intermediate-caudal	intermediate-caudal	I-NP	JJ	B-DNA	82	NMOD
82	region	region	I-NP	NN	I-DNA	79	PMOD
83	of	of	B-PP	IN	O	82	NMOD
84	the	the	B-NP	DT	O	85	NMOD
85	striatum	striatum	I-NP	NN	O	83	PMOD
86	of	of	B-PP	IN	O	85	NMOD
87	rats	rat	B-NP	NNS	O	86	PMOD
88	not	not	B-VP	RB	O	89	VMOD
89	pretreated	pretreate	I-VP	VBN	O	87	NMOD
90	with	with	B-PP	IN	O	89	VMOD
91	haloperidol	haloperidol	B-NP	NN	O	90	PMOD
92	had	have	B-VP	VBD	O	48	VMOD
93	no	no	B-NP	DT	O	94	NMOD
94	effect	effect	I-NP	NN	O	92	OBJ
95	on	on	B-PP	IN	O	92	VMOD
96	the	the	B-NP	DT	O	98	NMOD
97	muscle	muscle	I-NP	NN	O	98	NMOD
98	tone	tone	I-NP	NN	O	95	PMOD
99	.	.	O	.	O	3	P

1	Efficacy	Efficacy	B-NP	NN	O	3	NMOD
2	and	and	I-NP	CC	O	3	NMOD
3	tolerability	tolerability	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	lovastatin	lovastatin	B-NP	NN	O	4	PMOD
6	in	in	B-PP	IN	O	3	NMOD
7	3390	3390	B-NP	CD	O	8	NMOD
8	women	woman	I-NP	NNS	O	6	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	moderate	moderate	B-NP	JJ	O	11	NMOD
11	hypercholesterolemia	hypercholesterolemia	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	3	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	evaluate	evaluate	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	efficacy	efficacy	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	safety	safety	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	lovastatin	lovastatin	B-NP	NN	O	9	PMOD
11	in	in	B-PP	IN	O	8	NMOD
12	women	woman	B-NP	NNS	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	moderate	moderate	B-NP	JJ	O	15	NMOD
15	hypercholesterolemia	hypercholesterolemia	I-NP	NN	O	13	PMOD
16	.	.	O	.	O	1	P

1	Myopathy	Myopathy	B-NP	NN	O	21	SUB
2	,	,	O	,	O	1	P
3	defined	define	B-VP	VBN	O	1	NMOD
4	as	as	B-PP	IN	O	3	VMOD
5	muscle	muscle	B-NP	NN	O	6	NMOD
6	symptoms	symptom	I-NP	NNS	O	4	PMOD
7	with	with	B-PP	IN	O	6	NMOD
8	creatine	creatine	B-NP	NN	O	10	NMOD
9	kinase	kinase	I-NP	NN	O	10	NMOD
10	elevations	elevation	I-NP	NNS	O	17	NMOD
11	greater	great	B-NP	JJR	O	14	AMOD
12	than	than	I-NP	IN	O	14	AMOD
13	10	10	I-NP	CD	O	12	AMOD
14	times	time	I-NP	NNS	O	17	NMOD
15	the	the	I-NP	DT	O	17	NMOD
16	upper	upper	I-NP	JJ	O	17	NMOD
17	limit	limit	I-NP	NN	O	7	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	normal	normal	B-NP	JJ	O	18	PMOD
20	,	,	O	,	O	1	P
21	was	be	B-VP	VBD	O	0	ROOT
22	rare	rare	B-ADJP	JJ	O	21	PRD
23	and	and	O	CC	O	22	DEP
24	associated	associate	B-VP	VBN	O	22	DEP
25	with	with	B-PP	IN	O	24	VMOD
26	the	the	B-NP	DT	O	30	NMOD
27	highest	high	I-NP	JJS	O	30	NMOD
28	recommended	recommend	I-NP	VBN	O	30	NMOD
29	daily	daily	I-NP	JJ	O	30	NMOD
30	dose	dose	I-NP	NN	O	25	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	lovastatin	lovastatin	B-NP	NN	O	31	PMOD
33	(	(	O	(	O	36	DEP
34	80	80	B-NP	CD	O	35	NMOD
35	mg	mg	I-NP	NN	O	36	DEP
36	)	)	O	)	O	30	NMOD
37	.	.	O	.	O	21	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	REM	REM	B-NP	NN	O	6	NMOD
5	sleep	sleep	I-NP	NN	O	6	NMOD
6	deprivation	deprivation	I-NP	NN	O	3	PMOD
7	(	(	O	(	O	9	DEP
8	REMD	REMD	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	on	on	B-PP	IN	O	2	NMOD
11	apomorphine	apomorphine	B-NP	NN	O	10	PMOD
12	induced	induce	B-VP	VBD	O	0	ROOT
13	aggressiveness	aggressiveness	B-NP	NN	O	15	NMOD
14	and	and	I-NP	CC	O	15	NMOD
15	quipazine	quipazine	I-NP	NN	O	12	OBJ
16	induced	induce	B-VP	VBD	O	15	NMOD
17	head	head	B-NP	NN	O	18	NMOD
18	twitches	twitch	I-NP	NNS	O	16	OBJ
19	in	in	B-PP	IN	O	16	VMOD
20	rats	rat	B-NP	NNS	O	19	PMOD
21	were	be	B-VP	VBD	O	12	VMOD
22	determined	determine	I-VP	VBN	O	21	VC
23	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	incidence	incidence	I-NP	NN	O	5	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	parkinsonism	parkinsonism	B-NP	NN	O	3	PMOD
5	was	be	B-VP	VBD	O	0	ROOT
6	higher	high	B-ADJP	JJR	O	5	PRD
7	at	at	B-PP	IN	O	6	AMOD
8	higher	high	B-NP	JJR	O	9	NMOD
9	doses	dose	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	haloperidol	haloperidol	B-NP	NN	O	10	PMOD
12	and	and	O	CC	O	6	AMOD
13	in	in	B-PP	IN	O	12	PMOD
14	younger	young	B-NP	JJR	O	15	NMOD
15	patients	patient	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	5	P

1	Akathisia	Akathisia	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	controlled	control	I-VP	VBN	O	2	VC
4	by	by	B-PP	IN	O	3	VMOD
5	the	the	B-NP	DT	O	7	NMOD
6	benzodiazepine	benzodiazepine	I-NP	NN	O	7	NMOD
7	lorazepam	lorazepam	I-NP	NN	O	4	PMOD
8	in	in	B-PP	IN	O	3	VMOD
9	14	14	B-NP	CD	O	11	AMOD
10	out	out	I-NP	IN	O	11	AMOD
11	of	of	I-NP	IN	O	13	NMOD
12	16	16	I-NP	CD	O	11	AMOD
13	patients	patient	I-NP	NNS	O	8	PMOD
14	,	,	O	,	O	3	P
15	while	while	B-SBAR	IN	O	3	VMOD
16	prophylactic	prophylactic	B-NP	JJ	O	17	NMOD
17	antiparkinsonians	antiparkinsonian	I-NP	NNS	O	18	SUB
18	were	be	B-VP	VBD	O	15	SBAR
19	ineffective	ineffective	B-ADJP	JJ	O	18	PRD
20	.	.	O	.	O	2	P

1	Hepatic	Hepatic	B-NP	JJ	O	3	NMOD
2	veno-occlusive	veno-occlusive	I-NP	JJ	O	3	NMOD
3	disease	disease	I-NP	NN	O	0	ROOT
4	caused	cause	B-VP	VBN	O	3	NMOD
5	by	by	B-PP	IN	O	4	VMOD
6	6-thioguanine	6-thioguanine	B-NP	NN	O	5	PMOD
7	.	.	O	.	O	3	P

1	Clinically	Clinically	B-NP	RB	O	3	AMOD
2	reversible	reversible	I-NP	JJ	O	3	AMOD
3	veno-occlusive	veno-occlusive	I-NP	JJ	O	4	NMOD
4	disease	disease	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	the	the	B-NP	DT	O	7	NMOD
7	liver	liver	I-NP	NN	O	5	PMOD
8	developed	develop	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	a	a	B-NP	DT	O	12	NMOD
11	23-year-old	23-year-old	I-NP	JJ	O	12	NMOD
12	man	man	I-NP	NN	O	9	PMOD
13	with	with	B-PP	IN	O	9	PMOD
14	acute	acute	B-NP	JJ	O	16	NMOD
15	lymphocytic	lymphocytic	I-NP	JJ	O	16	NMOD
16	leukemia	leukemia	I-NP	NN	O	13	PMOD
17	after	after	B-PP	IN	O	4	NMOD
18	10	10	B-NP	CD	O	19	NMOD
19	months	month	I-NP	NNS	O	17	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	maintenance	maintenance	B-NP	NN	O	22	NMOD
22	therapy	therapy	I-NP	NN	O	20	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	6-thioguanine	6-thioguanine	B-NP	NN	O	23	PMOD
25	.	.	O	.	O	4	P

1	Treatment	Treatment	B-NP	NN	O	4	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	ifosfamide	ifosfamide	B-NP	NN	O	2	PMOD
4	induced	induce	B-VP	VBD	O	0	ROOT
5	urothelial	urothelial	B-NP	JJ	O	6	NMOD
6	toxicity	toxicity	I-NP	NN	O	4	OBJ
7	by	by	B-PP	IN	O	4	VMOD
8	oral	oral	B-NP	JJ	O	9	NMOD
9	administration	administration	I-NP	NN	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	sodium	sodium	B-NP	NN	O	13	NMOD
12	2-mercaptoethane	2-mercaptoethane	I-NP	NN	O	13	NMOD
13	sulphonate	sulphonate	I-NP	NN	O	10	PMOD
14	(	(	O	(	O	16	DEP
15	MESNA	MESNA	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	to	to	B-PP	TO	O	9	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	inoperable	inoperable	B-NP	JJ	O	22	NMOD
21	lung	lung	I-NP	NN	O	22	NMOD
22	cancer	cancer	I-NP	NN	O	19	PMOD
23	.	.	O	.	O	4	P

1	The	The	B-NP	DT	O	3	NMOD
2	protective	protective	I-NP	JJ	O	3	NMOD
3	effect	effect	I-NP	NN	O	26	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	oral	oral	B-NP	JJ	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	the	the	B-NP	DT	O	13	NMOD
9	thiol	thiol	I-NP	NN	O	13	NMOD
10	compound	compound	I-NP	NN	O	13	NMOD
11	sodium	sodium	I-NP	NN	O	13	NMOD
12	2-mercaptoethane	2-mercaptoethane	I-NP	NN	O	13	NMOD
13	sulphonate	sulphonate	I-NP	NN	O	7	PMOD
14	(	(	O	(	O	16	DEP
15	MESNA	MESNA	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	against	against	B-PP	IN	O	6	NMOD
18	urothelial	urothelial	B-NP	JJ	O	19	NMOD
19	toxicity	toxicity	I-NP	NN	O	17	PMOD
20	induced	induce	B-VP	VBN	O	19	NMOD
21	by	by	B-PP	IN	O	20	VMOD
22	ifosfamide	ifosfamide	B-NP	NN	O	21	PMOD
23	(	(	O	(	O	25	DEP
24	IF	IF	B-NP	NN	B-protein	25	DEP
25	)	)	O	)	O	22	NMOD
26	was	be	B-VP	VBD	O	0	ROOT
27	tested	test	I-VP	VBN	O	26	VC
28	in	in	B-PP	IN	O	27	VMOD
29	a	a	B-NP	DT	O	30	NMOD
30	group	group	I-NP	NN	O	28	PMOD
31	of	of	B-PP	IN	O	30	NMOD
32	45	45	B-NP	CD	O	33	NMOD
33	patients	patient	I-NP	NNS	O	31	PMOD
34	with	with	B-PP	IN	O	33	NMOD
35	inoperable	inoperable	B-NP	JJ	O	37	NMOD
36	lung	lung	I-NP	NN	O	37	NMOD
37	cancer	cancer	I-NP	NN	O	34	PMOD
38	under	under	B-PP	IN	O	27	VMOD
39	treatment	treatment	B-NP	NN	O	38	PMOD
40	with	with	B-PP	IN	O	39	NMOD
41	IF	IF	B-NP	NN	B-protein	40	PMOD
42	(	(	O	(	O	48	DEP
43	2250	2250	B-NP	CD	O	44	NMOD
44	mg/m2	mg/m2	I-NP	NN	O	48	DEP
45	on	on	B-PP	IN	O	44	NMOD
46	days	day	B-NP	NNS	O	45	PMOD
47	2-5	2-5	B-NP	CD	O	46	NMOD
48	)	)	O	)	O	41	NMOD
49	as	as	B-PP	IN	O	39	NMOD
50	part	part	B-NP	NN	O	49	PMOD
51	of	of	B-PP	IN	O	50	NMOD
52	a	a	B-NP	DT	O	54	NMOD
53	polychemotherapy	polychemotherapy	I-NP	NN	O	54	NMOD
54	regimen	regimen	I-NP	NN	O	51	PMOD
55	repeated	repeat	B-VP	VBN	O	54	NMOD
56	in	in	B-PP	IN	O	55	VMOD
57	a	a	B-NP	DT	O	59	NMOD
58	4-week	4-week	I-NP	JJ	O	59	NMOD
59	cycle	cycle	I-NP	NN	O	56	PMOD
60	.	.	O	.	O	26	P

1	There	There	B-NP	EX	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	no	no	B-NP	DT	O	5	NMOD
4	appreciable	appreciable	I-NP	JJ	O	5	NMOD
5	differences	difference	I-NP	NNS	O	2	PRD
6	between	between	B-PP	IN	O	2	VMOD
7	the	the	B-NP	DT	O	9	NMOD
8	MESNA	MESNA	I-NP	NN	O	9	NMOD
9	series	series	I-NP	NN	O	14	NMOD
10	and	and	O	CC	O	14	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	conventional	conventional	I-NP	JJ	O	14	NMOD
13	prophylaxis	prophylaxis	I-NP	NN	O	14	NMOD
14	series	series	I-NP	NN	O	6	PMOD
15	with	with	B-PP	IN	O	2	VMOD
16	respect	respect	B-NP	NN	O	15	PMOD
17	to	to	B-PP	TO	O	16	NMOD
18	either	either	O	CC	O	22	NMOD
19	haematological	haematological	B-NP	JJ	O	22	NMOD
20	or	or	I-NP	CC	O	22	NMOD
21	systemic	systemic	I-NP	JJ	O	22	NMOD
22	toxicity	toxicity	I-NP	NN	O	17	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	the	the	B-NP	DT	O	26	NMOD
25	cytostatic	cytostatic	I-NP	JJ	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	23	PMOD
27	.	.	O	.	O	2	P

1	Production	Production	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	autochthonous	autochthonous	B-NP	JJ	O	5	NMOD
4	prostate	prostate	I-NP	NN	O	5	NMOD
5	cancer	cancer	I-NP	NN	O	2	PMOD
6	in	in	B-PP	IN	O	1	NMOD
7	Lobund-Wistar	Lobund-Wistar	B-NP	JJ	O	8	NMOD
8	rats	rat	I-NP	NNS	O	6	PMOD
9	by	by	B-PP	IN	O	1	NMOD
10	treatments	treatment	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	N-nitroso-N-methylurea	N-nitroso-N-methylurea	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	testosterone	testosterone	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	1	P

1	More	More	B-NP	JJR	O	2	AMOD
2	than	than	I-NP	IN	O	4	NMOD
3	50	50	I-NP	CD	O	2	AMOD
4	%	%	I-NP	NN	O	12	SUB
5	of	of	B-PP	IN	O	4	NMOD
6	Lobund-Wistar	Lobund-Wistar	B-NP	JJ	O	11	NMOD
7	(	(	O	(	O	9	DEP
8	L-W	L-W	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	AMOD
10	strain	strain	B-NP	NN	O	11	NMOD
11	rats	rat	I-NP	NNS	O	5	PMOD
12	developed	develop	B-VP	VBD	O	48	VMOD
13	large	large	B-NP	JJ	O	15	AMOD
14	,	,	I-NP	,	O	15	P
15	palpable	palpable	I-NP	JJ	O	17	NMOD
16	prostate	prostate	I-NP	NN	O	17	NMOD
17	adenocarcinomas	adenocarcinoma	I-NP	NNS	O	12	OBJ
18	(	(	O	(	O	20	DEP
19	PAs	PA	B-NP	NNS	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	following	follow	B-PP	VBG	O	17	NMOD
22	treatments	treatment	B-NP	NNS	O	21	PMOD
23	with	with	B-PP	IN	O	22	NMOD
24	N-nitroso-N-methylurea	N-nitroso-N-methylurea	B-NP	NN	O	32	NMOD
25	(	(	O	(	O	29	DEP
26	CAS	CAS	B-NP	NN	O	28	NMOD
27	:	:	O	:	O	28	P
28	684-93-5	684-93-5	B-NP	CD	O	29	DEP
29	)	)	O	)	O	24	NMOD
30	and	and	O	CC	O	32	NMOD
31	testosterone	testosterone	B-NP	NN	O	32	NMOD
32	propionate	propionate	I-NP	NN	O	39	NMOD
33	[	[	O	(	O	36	DEP
34	(	(	O	(	O	36	DEP
35	TP	TP	B-NP	NN	O	36	DEP
36	)	)	O	)	O	32	NMOD
37	CAS	CAS	B-NP	NN	O	39	NMOD
38	:	:	O	:	O	39	P
39	57-85-2	57-85-2	B-NP	CD	O	23	PMOD
40	]	]	O	)	O	39	NMOD
41	,	,	O	,	O	43	P
42	and	and	O	CC	O	43	NMOD
43	most	most	B-NP	JJS	O	48	SUB
44	of	of	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	47	NMOD
46	tumor-bearing	tumor-bearing	I-NP	JJ	O	47	NMOD
47	rats	rat	I-NP	NNS	O	44	PMOD
48	manifested	manifest	B-VP	VBD	O	0	ROOT
49	metastatic	metastatic	B-NP	JJ	O	50	NMOD
50	lesions	lesion	I-NP	NNS	O	48	OBJ
51	.	.	O	.	O	48	P

1	Within	Within	B-PP	IN	O	9	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	same	same	I-NP	JJ	O	4	NMOD
4	timeframe	timeframe	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	9	P
6	no	no	B-NP	DT	O	8	NMOD
7	L-W	L-W	I-NP	NN	O	8	NMOD
8	rat	rat	I-NP	NN	O	9	SUB
9	developed	develop	B-VP	VBD	O	0	ROOT
10	a	a	B-NP	DT	O	13	NMOD
11	similar	similar	I-NP	JJ	O	13	NMOD
12	palpable	palpable	I-NP	JJ	O	13	NMOD
13	PA	PA	I-NP	NN	O	9	OBJ
14	when	when	B-ADVP	WRB	O	9	VMOD
15	treated	treat	B-VP	VBN	O	14	SBAR
16	only	only	B-ADVP	RB	O	17	PMOD
17	with	with	B-PP	IN	O	15	VMOD
18	TP	TP	B-NP	NN	B-protein	17	PMOD
19	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	3	NMOD
2	dystonia-like	dystonia-like	I-NP	JJ	O	3	NMOD
3	syndrome	syndrome	I-NP	NN	O	0	ROOT
4	after	after	B-PP	IN	O	3	NMOD
5	neuropeptide	neuropeptide	B-NP	NN	O	9	NMOD
6	(	(	O	(	O	8	DEP
7	MSH/ACTH	MSH/ACTH	B-NP	NN	O	8	DEP
8	)	)	O	)	O	5	NMOD
9	stimulation	stimulation	B-NP	NN	O	4	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	the	the	B-NP	DT	O	14	NMOD
12	rat	rat	I-NP	NN	O	14	NMOD
13	locus	locus	I-NP	NN	O	14	NMOD
14	ceruleus	ceruleus	I-NP	NN	O	10	PMOD
15	.	.	O	.	O	3	P

1	Dexmedetomidine	Dexmedetomidine	B-NP	NN	O	9	SUB
2	,	,	O	,	O	1	P
3	acting	act	B-VP	VBG	O	1	NMOD
4	through	through	B-PP	IN	O	3	VMOD
5	central	central	B-NP	JJ	B-protein	7	NMOD
6	alpha-2	alpha-2	I-NP	NN	I-protein	7	NMOD
7	adrenoceptors	adrenoceptor	I-NP	NNS	I-protein	4	PMOD
8	,	,	O	,	O	1	P
9	prevents	prevent	B-VP	VBZ	O	0	ROOT
10	opiate	opiate	B-NP	NN	O	13	NMOD
11	induced	induce	I-NP	VBN	O	13	NMOD
12	muscle	muscle	I-NP	NN	O	13	NMOD
13	rigidity	rigidity	I-NP	NN	O	9	OBJ
14	in	in	B-PP	IN	O	13	NMOD
15	the	the	B-NP	DT	O	16	NMOD
16	rat	rat	I-NP	NN	O	14	PMOD
17	.	.	O	.	O	9	P

1	The	The	B-NP	DT	O	6	NMOD
2	highly-selective	highly-selective	I-NP	JJ	O	6	NMOD
3	alpha-2	alpha-2	I-NP	NN	O	6	NMOD
4	adrenergic	adrenergic	I-NP	JJ	O	6	NMOD
5	agonist	agonist	I-NP	NN	O	6	NMOD
6	dexmedetomidine	dexmedetomidine	I-NP	NN	O	10	SUB
7	(	(	O	(	O	9	DEP
8	D-MED	D-MED	B-NP	NN	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	is	be	B-VP	VBZ	O	0	ROOT
11	capable	capable	B-ADJP	JJ	O	10	PRD
12	of	of	B-PP	IN	O	11	AMOD
13	inducing	induce	B-VP	VBG	O	12	PMOD
14	muscle	muscle	B-NP	NN	O	15	NMOD
15	flaccidity	flaccidity	I-NP	NN	O	17	NMOD
16	and	and	O	CC	O	17	NMOD
17	anesthesia	anesthesia	B-NP	NN	O	13	OBJ
18	in	in	B-PP	IN	O	13	VMOD
19	rats	rat	B-NP	NNS	O	21	NMOD
20	and	and	I-NP	CC	O	21	NMOD
21	dogs	dog	I-NP	NNS	O	18	PMOD
22	.	.	O	.	O	10	P

1	In	In	B-PP	IN	O	8	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	8	P
6	the	the	B-NP	DT	O	7	NMOD
7	authors	author	I-NP	NNS	O	8	SUB
8	determined	determine	B-VP	VBD	O	0	ROOT
9	if	if	B-SBAR	IN	O	8	VMOD
10	treatment	treatment	B-NP	NN	O	13	SUB
11	with	with	B-PP	IN	O	10	NMOD
12	D-MED	D-MED	B-NP	NN	O	11	PMOD
13	prevents	prevent	B-VP	VBZ	O	9	SBAR
14	the	the	B-NP	DT	O	16	NMOD
15	muscle	muscle	I-NP	NN	O	16	NMOD
16	rigidity	rigidity	I-NP	NN	O	13	OBJ
17	caused	cause	B-VP	VBN	O	16	NMOD
18	by	by	B-PP	IN	O	17	VMOD
19	high-dose	high-dose	B-NP	JJ	O	21	NMOD
20	alfentanil	alfentanil	I-NP	NN	O	21	NMOD
21	anesthesia	anesthesia	I-NP	NN	O	18	PMOD
22	in	in	B-PP	IN	O	21	NMOD
23	the	the	B-NP	DT	O	24	NMOD
24	rat	rat	I-NP	NN	O	22	PMOD
25	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	5	VMOD
2	contrast	contrast	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	D-MED	D-MED	B-NP	NN	O	5	SUB
5	prevented	prevent	B-VP	VBD	O	0	ROOT
6	alfentanil	alfentanil	B-NP	NN	O	9	NMOD
7	induced	induced	I-NP	JJ	O	9	NMOD
8	muscle	muscle	I-NP	NN	O	9	NMOD
9	rigidity	rigidity	I-NP	NN	O	5	OBJ
10	in	in	B-PP	IN	O	5	VMOD
11	a	a	B-NP	DT	O	13	NMOD
12	dose-dependent	dose-dependent	I-NP	JJ	O	13	NMOD
13	fashion	fashion	I-NP	NN	O	10	PMOD
14	.	.	O	.	O	5	P

1	Seizure	Seizure	B-NP	NN	O	2	NMOD
2	activity	activity	I-NP	NN	O	10	NMOD
3	with	with	B-PP	IN	O	2	NMOD
4	imipenem	imipenem	B-NP	NN	O	5	NMOD
5	therapy	therapy	I-NP	NN	O	3	PMOD
6	:	:	O	:	O	2	P
7	incidence	incidence	B-NP	NN	O	10	NMOD
8	and	and	I-NP	CC	O	10	NMOD
9	risk	risk	I-NP	NN	O	10	NMOD
10	factors	factor	I-NP	NNS	O	0	ROOT
11	.	.	O	.	O	10	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	elderly	elderly	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	20	NMOD
4	with	with	B-PP	IN	O	3	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	history	history	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	either	either	B-NP	CC	O	17	NMOD
9	cerebral	cerebral	I-NP	JJ	O	11	NMOD
10	vascular	vascular	I-NP	JJ	O	11	NMOD
11	accident	accident	I-NP	NN	O	17	NMOD
12	(	(	O	(	O	14	DEP
13	CVA	CVA	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	11	NMOD
15	or	or	O	CC	O	17	NMOD
16	head	head	B-NP	NN	O	17	NMOD
17	trauma	trauma	I-NP	NN	O	7	PMOD
18	and	and	O	CC	O	20	NMOD
19	no	no	B-NP	DT	O	20	NMOD
20	evidence	evidence	I-NP	NN	O	24	SUB
21	of	of	B-PP	IN	O	20	NMOD
22	renal	renal	B-NP	JJ	O	23	NMOD
23	disease	disease	I-NP	NN	O	21	PMOD
24	developed	develop	B-VP	VBD	O	0	ROOT
25	seizures	seizure	B-NP	NNS	O	24	OBJ
26	while	while	B-SBAR	IN	O	24	VMOD
27	receiving	receive	B-VP	VBG	O	26	SBAR
28	maximum	maximum	B-NP	JJ	O	29	NMOD
29	doses	dose	I-NP	NNS	O	27	OBJ
30	of	of	B-PP	IN	O	29	NMOD
31	imipenem/cilastatin	imipenem/cilastatin	B-NP	NN	O	30	PMOD
32	.	.	O	.	O	24	P

1	All	All	B-NP	DT	O	2	NMOD
2	seizures	seizure	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	0	ROOT
4	controlled	control	I-VP	VBN	O	3	VC
5	with	with	B-PP	IN	O	4	VMOD
6	therapeutic	therapeutic	B-NP	JJ	O	7	NMOD
7	doses	dose	I-NP	NNS	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	phenytoin	phenytoin	B-NP	NN	O	8	PMOD
10	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	ability	ability	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	insulin	insulin	B-NP	NN	B-protein	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	to	to	B-VP	TO	O	7	VMOD
7	reverse	reverse	I-VP	VB	O	2	NMOD
8	or	or	I-VP	CC	O	7	VMOD
9	prevent	prevent	I-VP	VB	O	7	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	changes	change	I-NP	NNS	O	7	VMOD
12	in	in	B-PP	IN	O	11	NMOD
13	urinary	urinary	B-NP	JJ	O	15	NMOD
14	bladder	bladder	I-NP	NN	O	15	NMOD
15	function	function	I-NP	NN	O	12	PMOD
16	caused	cause	B-VP	VBN	O	15	NMOD
17	by	by	B-PP	IN	O	16	VMOD
18	streptozotocin	streptozotocin	B-NP	NN	B-protein	17	PMOD
19	induced	induce	B-VP	VBD	O	11	NMOD
20	diabetes	diabetes	B-NP	NN	O	21	NMOD
21	mellitus.	mellitus.	I-NP	NN	O	19	OBJ
22	1	1	I-NP	CD	O	21	NMOD
23	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	effects	effect	I-NP	NNS	O	18	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	insulin	insulin	B-NP	NN	B-protein	5	NMOD
5	treatment	treatment	I-NP	NN	O	3	PMOD
6	on	on	B-PP	IN	O	2	NMOD
7	in	in	B-ADVP	FW	O	8	AMOD
8	vivo	vivo	I-ADVP	FW	O	14	NMOD
9	and	and	O	CC	O	14	NMOD
10	in	in	B-NP	FW	O	11	AMOD
11	vitro	vitro	I-NP	FW	O	14	NMOD
12	urinary	urinary	I-NP	JJ	O	14	NMOD
13	bladder	bladder	I-NP	NN	O	14	NMOD
14	function	function	I-NP	NN	O	6	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	streptozotocin-diabetic	streptozotocin-diabetic	B-NP	JJ	O	17	NMOD
17	rats	rat	I-NP	NNS	O	15	PMOD
18	were	be	B-VP	VBD	O	0	ROOT
19	investigated.	investigated.	B-NP	NN	O	18	PRD
20	2	2	I-NP	CD	O	19	NMOD
21	.	.	O	.	O	18	P

1	Insulin	Insulin	B-NP	NN	B-protein	2	NMOD
2	treatment	treatment	I-NP	NN	O	4	SUB
3	also	also	B-ADVP	RB	O	4	VMOD
4	prevented	prevent	B-VP	VBD	O	0	ROOT
5	the	the	B-NP	DT	O	6	NMOD
6	increases	increase	I-NP	NNS	O	4	OBJ
7	in	in	B-PP	IN	O	6	NMOD
8	contractile	contractile	B-NP	JJ	O	9	NMOD
9	responses	response	I-NP	NNS	O	7	PMOD
10	of	of	B-PP	IN	O	9	NMOD
11	bladder	bladder	B-NP	NN	B-protein	13	NMOD
12	body	body	I-NP	NN	I-protein	13	NMOD
13	strips	strip	I-NP	NNS	I-protein	10	PMOD
14	from	from	B-PP	IN	O	13	NMOD
15	diabetic	diabetic	B-NP	JJ	O	16	NMOD
16	rats	rat	I-NP	NNS	O	14	PMOD
17	to	to	B-PP	TO	O	9	NMOD
18	nerve	nerve	B-NP	NN	O	19	NMOD
19	stimulation	stimulation	I-NP	NN	O	24	NMOD
20	,	,	O	,	O	24	P
21	ATP	ATP	B-NP	NN	O	24	NMOD
22	,	,	O	,	O	24	P
23	and	and	O	CC	O	24	NMOD
24	bethanechol.	bethanechol.	B-NP	NN	B-protein	17	PMOD
25	4	4	I-NP	CD	I-protein	24	NMOD
26	.	.	O	.	O	4	P

1	Insulin	Insulin	B-NP	NN	B-protein	2	NMOD
2	treatment	treatment	I-NP	NN	O	3	SUB
3	reversed	reverse	B-VP	VBD	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	increases	increase	I-NP	NNS	O	3	OBJ
6	in	in	B-PP	IN	O	5	NMOD
7	contractile	contractile	B-NP	JJ	O	8	NMOD
8	responses	response	I-NP	NNS	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	bladder	bladder	B-NP	NN	B-protein	12	NMOD
11	body	body	I-NP	NN	I-protein	12	NMOD
12	strips	strip	I-NP	NNS	I-protein	9	PMOD
13	from	from	B-PP	IN	O	12	NMOD
14	diabetic	diabetic	B-NP	JJ	O	15	NMOD
15	rats	rat	I-NP	NNS	O	13	PMOD
16	to	to	B-PP	TO	O	8	NMOD
17	nerve	nerve	B-NP	NN	O	18	NMOD
18	stimulation	stimulation	I-NP	NN	O	24	NMOD
19	,	,	O	,	O	24	P
20	ATP	ATP	B-NP	NN	O	24	NMOD
21	,	,	O	,	O	24	P
22	and	and	O	CC	O	24	NMOD
23	bethanechol.	bethanechol.	B-NP	RB	O	24	NMOD
24	6	6	I-NP	CD	O	16	PMOD
25	.	.	O	.	O	3	P

1	Under	Under	B-PP	IN	O	12	VMOD
2	isoflurane	isoflurane	B-NP	NN	O	3	NMOD
3	anesthesia	anesthesia	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	12	P
5	the	the	B-NP	DT	O	6	NMOD
6	MCA	MCA	I-NP	NNP	O	12	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	14	14	B-NP	CD	O	11	NMOD
9	spontaneously	spontaneously	I-NP	RB	O	10	AMOD
10	hypertensive	hypertensive	I-NP	JJ	O	11	NMOD
11	rats	rat	I-NP	NNS	O	7	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	occluded	occlude	I-VP	VBN	O	12	VC
14	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	extent	extent	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	neuronal	neuronal	B-NP	JJ	O	5	NMOD
5	injury	injury	I-NP	NN	O	3	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	determined	determine	I-VP	VBN	O	6	VC
8	by	by	B-PP	IN	O	7	VMOD
9	2	2	B-NP	CD	O	14	NMOD
10	,	,	I-NP	,	O	14	P
11	3	3	I-NP	CD	O	14	NMOD
12	,	,	O	,	O	14	P
13	5-triphenyltetrazolium	5-triphenyltetrazolium	B-NP	JJ	O	14	NMOD
14	staining	staining	I-NP	NN	O	8	PMOD
15	.	.	O	.	O	6	P

1	Amiodarone	Amiodarone	B-NP	NN	O	3	NMOD
2	pulmonary	pulmonary	I-NP	JJ	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	0	ROOT
4	.	.	O	.	O	3	P

1	Amiodarone	Amiodarone	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	an	an	B-NP	DT	O	6	NMOD
4	effective	effective	I-NP	JJ	O	5	AMOD
5	antiarrhythmic	antiarrhythmic	I-NP	JJ	O	6	NMOD
6	agent	agent	I-NP	NN	O	19	NMOD
7	whose	whose	B-NP	WP$	O	8	NMOD
8	utility	utility	I-NP	NN	O	9	SUB
9	is	be	B-VP	VBZ	O	6	NMOD
10	limited	limit	I-VP	VBN	O	9	VC
11	by	by	B-PP	IN	O	10	VMOD
12	many	many	B-NP	JJ	O	13	NMOD
13	side-effects	side-effect	I-NP	NNS	O	11	PMOD
14	,	,	O	,	O	19	P
15	the	the	B-NP	DT	O	19	NMOD
16	most	most	I-NP	RBS	O	17	AMOD
17	problematic	problematic	I-NP	JJ	O	19	NMOD
18	being	be	I-NP	VBG	O	19	NMOD
19	pneumonitis	pneumonitis	I-NP	NN	O	2	PRD
20	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	3	NMOD
2	pulmonary	pulmonary	I-NP	JJ	O	3	NMOD
3	toxicity	toxicity	I-NP	NN	O	6	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	amiodarone	amiodarone	B-NP	NN	O	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	thought	think	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	result	result	I-VP	VB	O	7	VMOD
10	from	from	B-PP	IN	O	9	VMOD
11	direct	direct	B-NP	JJ	O	12	NMOD
12	injury	injury	I-NP	NN	O	10	PMOD
13	related	relate	B-VP	VBN	O	12	NMOD
14	to	to	B-PP	TO	O	13	AMOD
15	the	the	B-NP	DT	O	17	NMOD
16	intracellular	intracellular	I-NP	JJ	O	17	NMOD
17	accumulation	accumulation	I-NP	NN	O	14	PMOD
18	of	of	B-PP	IN	O	17	NMOD
19	phospholipid	phospholipid	B-NP	NN	O	24	NMOD
20	and	and	I-NP	CC	O	24	NMOD
21	T	T	I-NP	NN	O	24	NMOD
22	cell-mediated	cell-mediated	I-NP	JJ	O	21	AMOD
23	hypersensitivity	hypersensitivity	I-NP	NN	O	24	NMOD
24	pneumonitis	pneumonitis	I-NP	NN	O	18	PMOD
25	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	5	NMOD
2	clinical	clinical	I-NP	JJ	O	5	NMOD
3	and	and	I-NP	CC	O	5	NMOD
4	radiographic	radiographic	I-NP	JJ	O	5	NMOD
5	features	feature	I-NP	NNS	O	8	SUB
6	of	of	B-PP	IN	O	5	NMOD
7	amiodarone	amiodarone	B-NP	NN	O	6	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	pulmonary	pulmonary	B-NP	JJ	O	10	NMOD
10	toxicity	toxicity	I-NP	NN	O	8	OBJ
11	are	be	B-VP	VBP	O	8	VMOD
12	characteristic	characteristic	B-ADJP	JJ	O	14	AMOD
13	but	but	I-ADJP	CC	O	14	AMOD
14	nonspecific	nonspecific	I-ADJP	JJ	O	11	PRD
15	.	.	O	.	O	8	P

1	Light	Light	B-NP	NN	O	3	NMOD
2	chain	chain	I-NP	NN	O	3	NMOD
3	proteinuria	proteinuria	I-NP	NN	O	7	NMOD
4	and	and	O	CC	O	7	NMOD
5	cellular	cellular	B-NP	JJ	O	7	NMOD
6	mediated	mediate	I-NP	VBN	O	7	NMOD
7	immunity	immunity	I-NP	NN	O	0	ROOT
8	in	in	B-PP	IN	O	7	NMOD
9	rifampin	rifampin	B-NP	NN	O	11	NMOD
10	treated	treat	B-VP	VBN	O	11	NMOD
11	patients	patient	B-NP	NNS	O	8	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	tuberculosis	tuberculosis	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	7	P

1	Light	Light	B-NP	NN	O	3	NMOD
2	chain	chain	I-NP	NN	O	3	NMOD
3	proteinuria	proteinuria	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	found	find	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	9	9	B-NP	CD	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	17	17	B-NP	CD	O	11	NMOD
10	tuberculosis	tuberculosis	I-NP	NN	O	11	NMOD
11	patients	patient	I-NP	NNS	O	8	PMOD
12	treated	treat	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	rifampin	rifampin	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	4	P

1	Initial	Initial	B-NP	JJ	O	3	NMOD
2	potassium	potassium	I-NP	NN	O	3	NMOD
3	loss	loss	I-NP	NN	O	5	NMOD
4	and	and	I-NP	CC	O	5	NMOD
5	hypokalaemia	hypokalaemia	I-NP	NN	O	16	NMOD
6	during	during	B-PP	IN	O	5	NMOD
7	chlorthalidone	chlorthalidone	B-NP	NN	O	8	NMOD
8	administration	administration	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	essential	essential	B-NP	JJ	O	13	NMOD
13	hypertension	hypertension	I-NP	NN	O	11	PMOD
14	:	:	O	:	O	5	P
15	the	the	B-NP	DT	O	16	NMOD
16	influence	influence	I-NP	NN	O	0	ROOT
17	of	of	B-PP	IN	O	16	NMOD
18	dietary	dietary	B-NP	JJ	O	20	NMOD
19	sodium	sodium	I-NP	NN	O	20	NMOD
20	restriction	restriction	I-NP	NN	O	17	PMOD
21	.	.	O	.	O	16	P

1	To	To	B-VP	TO	O	2	VMOD
2	investigate	investigate	I-VP	VB	O	22	VMOD
3	the	the	B-NP	DT	O	8	NMOD
4	initial	initial	I-NP	JJ	O	6	NMOD
5	potassium	potassium	I-NP	NN	O	6	NMOD
6	loss	loss	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	development	development	I-NP	NN	O	2	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	hypokalaemia	hypokalaemia	B-NP	NN	O	9	PMOD
11	during	during	B-PP	IN	O	8	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	administration	administration	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	an	an	B-NP	DT	O	21	NMOD
16	oral	oral	I-NP	JJ	O	19	AMOD
17	diuretic	diuretic	I-NP	JJ	O	19	AMOD
18	,	,	I-NP	,	O	19	P
19	metabolic	metabolic	I-NP	JJ	O	21	NMOD
20	balance	balance	I-NP	NN	O	21	NMOD
21	studies	study	I-NP	NNS	O	14	PMOD
22	were	be	B-VP	VBD	O	0	ROOT
23	performed	perform	I-VP	VBN	O	22	VC
24	in	in	B-PP	IN	O	23	VMOD
25	ten	ten	B-NP	CD	O	26	NMOD
26	patients	patient	I-NP	NNS	O	24	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	essential	essential	B-NP	JJ	O	29	NMOD
29	hypertension	hypertension	I-NP	NN	O	27	PMOD
30	who	who	B-NP	WP	O	29	NMOD
31	had	have	B-VP	VBD	O	30	SBAR
32	shown	show	I-VP	VBN	O	31	VC
33	hypokalaemia	hypokalaemia	B-NP	NN	O	32	OBJ
34	under	under	B-PP	IN	O	32	VMOD
35	prior	prior	B-NP	JJ	O	38	NMOD
36	oral	oral	I-NP	JJ	O	38	NMOD
37	diuretic	diuretic	I-NP	JJ	O	38	NMOD
38	treatment	treatment	I-NP	NN	O	34	PMOD
39	.	.	O	.	O	22	P

1	In	In	B-PP	IN	O	5	VMOD
2	this	this	B-NP	DT	O	3	NMOD
3	study	study	I-NP	NN	O	1	PMOD
4	we	we	B-NP	PRP	O	5	SUB
5	postulated	postulate	B-VP	VBD	O	0	ROOT
6	that	that	B-SBAR	IN	O	5	VMOD
7	during	during	B-PP	IN	O	22	VMOD
8	acute	acute	B-NP	JJ	O	9	AMOD
9	renal	renal	I-NP	JJ	O	10	NMOD
10	failure	failure	I-NP	NN	O	7	PMOD
11	induced	induce	B-VP	VBN	O	10	NMOD
12	by	by	B-PP	IN	O	11	VMOD
13	gentamicin	gentamicin	B-NP	NN	O	12	PMOD
14	the	the	B-NP	DT	O	18	NMOD
15	transient	transient	I-NP	JJ	O	18	NMOD
16	or	or	I-NP	CC	O	18	NMOD
17	dynamic	dynamic	I-NP	JJ	O	18	NMOD
18	response	response	I-NP	NN	O	11	VMOD
19	of	of	B-PP	IN	O	18	NMOD
20	blood	blood	B-NP	NN	O	21	NMOD
21	vessels	vessel	I-NP	NNS	O	19	PMOD
22	could	could	B-VP	MD	O	6	SBAR
23	be	be	I-VP	VB	O	22	VC
24	affected	affect	I-VP	VBN	O	23	VC
25	,	,	O	,	O	27	P
26	and	and	O	CC	O	27	DEP
27	that	that	B-SBAR	IN	O	24	VMOD
28	antioxidants	antioxidant	B-NP	NNS	O	29	SUB
29	can	can	B-VP	MD	O	27	SBAR
30	prevent	prevent	I-VP	VB	O	29	VC
31	the	the	B-NP	DT	O	32	NMOD
32	changes	change	I-NP	NNS	O	30	OBJ
33	in	in	B-PP	IN	O	32	NMOD
34	dynamic	dynamic	B-NP	JJ	O	35	NMOD
35	responses	response	I-NP	NNS	O	33	PMOD
36	of	of	B-PP	IN	O	35	NMOD
37	blood	blood	B-NP	NN	O	38	NMOD
38	vessels	vessel	I-NP	NNS	O	36	PMOD
39	.	.	O	.	O	5	P

1	Oxytocin	Oxytocin	B-NP	NN	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	commonly	commonly	I-NP	RB	O	5	AMOD
5	used	use	I-NP	VBN	O	6	NMOD
6	uterotonic	uterotonic	I-NP	JJ	O	2	PRD
7	that	that	B-NP	WDT	O	6	NMOD
8	can	can	B-VP	MD	O	7	SBAR
9	cause	cause	I-VP	VB	O	8	VC
10	significant	significant	B-NP	JJ	O	13	AMOD
11	and	and	I-NP	CC	O	13	AMOD
12	even	even	I-NP	RB	O	13	AMOD
13	fatal	fatal	I-NP	JJ	O	14	NMOD
14	hypotension	hypotension	I-NP	NN	O	9	OBJ
15	,	,	O	,	O	9	P
16	particularly	particularly	B-ADVP	RB	O	17	AMOD
17	when	when	B-ADVP	WRB	O	9	VMOD
18	given	give	B-VP	VBN	O	17	SBAR
19	as	as	B-PP	IN	O	18	VMOD
20	a	a	B-NP	DT	O	21	NMOD
21	bolus	bolus	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	2	P

1	Oxytocin	Oxytocin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	hypotension	hypotension	B-NP	NN	O	2	OBJ
4	at	at	B-PP	IN	O	2	VMOD
5	cesarean	cesarean	B-NP	JJ	O	6	NMOD
6	delivery	delivery	I-NP	NN	O	4	PMOD
7	may	may	B-VP	MD	O	2	VMOD
8	be	be	I-VP	VB	O	7	VC
9	incorrectly	incorrectly	I-VP	RB	O	8	VMOD
10	attributed	attribute	I-VP	VBN	O	8	VC
11	to	to	B-PP	TO	O	10	VMOD
12	blood	blood	B-NP	NN	O	13	NMOD
13	loss	loss	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	Hypotension	Hypotension	B-NP	NN	O	6	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	response	response	B-NP	NN	O	2	PMOD
4	to	to	B-PP	TO	O	3	NMOD
5	oxytocin	oxytocin	B-NP	NN	O	4	PMOD
6	was	be	B-VP	VBD	O	0	ROOT
7	associated	associate	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	a	a	B-NP	DT	O	10	NMOD
10	decrease	decrease	I-NP	NN	O	18	NMOD
11	in	in	B-PP	IN	O	10	NMOD
12	systemic	systemic	B-NP	JJ	O	14	NMOD
13	vascular	vascular	I-NP	JJ	O	14	NMOD
14	resistance	resistance	I-NP	NN	O	11	PMOD
15	and	and	O	CC	O	18	NMOD
16	a	a	B-NP	DT	O	18	NMOD
17	compensatory	compensatory	I-NP	JJ	O	18	NMOD
18	increase	increase	I-NP	NN	O	27	NMOD
19	in	in	B-PP	IN	O	18	NMOD
20	stroke	stroke	B-NP	NN	O	21	NMOD
21	volume	volume	I-NP	NN	O	19	PMOD
22	,	,	O	,	O	27	P
23	heart	heart	B-NP	NN	O	24	NMOD
24	rate	rate	I-NP	NN	O	27	NMOD
25	and	and	O	CC	O	27	NMOD
26	cardiac	cardiac	B-NP	JJ	O	27	NMOD
27	output	output	I-NP	NN	O	8	PMOD
28	.	.	O	.	O	6	P

1	Exaggerated	Exaggerate	B-NP	VBN	O	2	NMOD
2	expression	expression	I-NP	NN	O	0	ROOT
3	of	of	B-PP	IN	O	2	NMOD
4	inflammatory	inflammatory	B-NP	JJ	B-protein	5	NMOD
5	mediators	mediator	I-NP	NNS	I-protein	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	vasoactive	vasoactive	B-NP	JJ	O	10	NMOD
8	intestinal	intestinal	I-NP	JJ	O	10	NMOD
9	polypeptide	polypeptide	I-NP	NN	O	10	NMOD
10	knockout	knockout	I-NP	NN	O	14	NMOD
11	(	(	O	(	O	13	DEP
12	VIP-/-	VIP-/-	O	JJ	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	mice	mouse	B-NP	NNS	O	6	PMOD
15	with	with	B-PP	IN	O	2	NMOD
16	cyclophosphamide	cyclophosphamide	B-NP	NN	O	21	NMOD
17	(	(	O	(	O	19	DEP
18	CYP	CYP	B-NP	NN	B-protein	19	DEP
19	)	)	O	)	O	16	NMOD
20	induced	induce	B-NP	VBN	O	21	NMOD
21	cystitis	cystitis	I-NP	NN	O	15	PMOD
22	.	.	O	.	O	2	P

1	VIP	VIP	B-NP	NN	B-protein	5	NMOD
2	(	(	O	(	O	4	DEP
3	-/-	-/-	O	JJ	O	4	DEP
4	)	)	O	)	O	1	NMOD
5	mice	mouse	B-NP	NNS	O	6	SUB
6	exhibit	exhibit	B-VP	VBP	O	0	ROOT
7	altered	alter	I-VP	VBN	O	9	NMOD
8	bladder	bladder	B-NP	NN	O	9	NMOD
9	function	function	I-NP	NN	O	12	NMOD
10	and	and	O	CC	O	12	NMOD
11	neurochemical	neurochemical	B-NP	JJ	O	12	NMOD
12	properties	property	I-NP	NNS	O	6	OBJ
13	in	in	B-PP	IN	O	12	NMOD
14	micturition	micturition	B-NP	NN	O	15	NMOD
15	pathways	pathway	I-NP	NNS	O	13	PMOD
16	after	after	B-PP	IN	O	15	NMOD
17	cyclophosphamide	cyclophosphamide	B-NP	NN	O	22	NMOD
18	(	(	O	(	O	20	DEP
19	CYP	CYP	B-NP	NN	B-protein	20	DEP
20	)	)	O	)	O	17	NMOD
21	induced	induce	B-NP	VBN	O	22	NMOD
22	cystitis	cystitis	I-NP	NN	O	16	PMOD
23	.	.	O	.	O	6	P

1	A	A	B-NP	DT	O	9	NMOD
2	mouse	mouse	I-NP	NN	B-protein	4	NMOD
3	inflammatory	inflammatory	I-NP	JJ	I-protein	4	NMOD
4	cytokine	cytokine	I-NP	NN	I-protein	9	NMOD
5	and	and	I-NP	CC	O	9	NMOD
6	receptor	receptor	I-NP	NN	O	9	NMOD
7	RT2	RT2	I-NP	NN	O	9	NMOD
8	profiler	profiler	I-NP	NN	O	9	NMOD
9	array	array	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	used	use	I-VP	VBN	O	10	VC
12	to	to	B-VP	TO	O	13	VMOD
13	determine	determine	I-VP	VB	O	11	VMOD
14	regulated	regulated	B-NP	JJ	B-RNA	15	NMOD
15	transcripts	transcript	I-NP	NNS	I-RNA	13	OBJ
16	in	in	B-PP	IN	O	15	NMOD
17	the	the	B-NP	DT	O	19	NMOD
18	urinary	urinary	I-NP	JJ	O	19	NMOD
19	bladder	bladder	I-NP	NN	O	16	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	wild	wild	B-NP	JJ	O	22	NMOD
22	type	type	I-NP	NN	O	27	NMOD
23	(	(	O	(	O	25	DEP
24	WT	WT	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	and	and	O	CC	O	27	NMOD
27	VIP	VIP	B-NP	NN	B-protein	31	NMOD
28	(	(	O	(	O	30	DEP
29	-/-	-/-	O	JJ	O	30	DEP
30	)	)	O	)	O	27	NMOD
31	mice	mouse	B-NP	NNS	O	20	PMOD
32	with	with	B-PP	IN	O	19	NMOD
33	or	or	B-PP	CC	O	32	PMOD
34	without	without	B-PP	IN	O	32	PMOD
35	CYP	CYP	B-NP	NN	B-protein	36	AMOD
36	induced	induce	I-NP	VBN	O	37	NMOD
37	cystitis	cystitis	I-NP	NN	O	32	PMOD
38	(	(	O	(	O	46	DEP
39	150	150	B-NP	CD	O	40	NMOD
40	mg/kg	mg/kg	I-NP	NN	O	45	NMOD
41	;	;	O	:	O	40	P
42	i.p.	i.p.	B-ADVP	RB	O	40	NMOD
43	;	;	O	:	O	45	P
44	48	48	B-NP	CD	O	45	NMOD
45	h	h	I-NP	NN	O	46	DEP
46	)	)	O	)	O	37	NMOD
47	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	data	datum	I-NP	NNS	O	3	SUB
3	suggest	suggest	B-VP	VBP	O	0	ROOT
4	that	that	B-SBAR	IN	O	3	VMOD
5	in	in	B-PP	IN	O	17	VMOD
6	VIP	VIP	B-NP	NN	B-protein	10	NMOD
7	(	(	O	(	O	9	DEP
8	-/-	-/-	O	JJ	O	9	DEP
9	)	)	O	)	O	6	NMOD
10	mice	mouse	B-NP	NNS	O	5	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	bladder	bladder	B-NP	NN	O	13	NMOD
13	inflammation	inflammation	I-NP	NN	O	11	PMOD
14	,	,	O	,	O	17	P
15	inflammatory	inflammatory	B-NP	JJ	B-protein	16	NMOD
16	mediators	mediator	I-NP	NNS	I-protein	17	SUB
17	are	be	B-VP	VBP	O	4	SBAR
18	increased	increase	I-VP	VBN	O	17	VC
19	above	above	B-PP	IN	O	18	VMOD
20	that	that	B-NP	DT	O	19	PMOD
21	observed	observe	B-VP	VBN	O	20	NMOD
22	in	in	B-PP	IN	O	21	VMOD
23	WT	WT	B-NP	NN	O	22	PMOD
24	with	with	B-PP	IN	O	23	NMOD
25	CYP	CYP	B-NP	NN	B-protein	24	PMOD
26	.	.	O	.	O	3	P

1	Intraocular	Intraocular	B-NP	JJ	O	2	NMOD
2	pressure	pressure	I-NP	NN	O	0	ROOT
3	in	in	B-PP	IN	O	2	NMOD
4	patients	patient	B-NP	NNS	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	uveitis	uveitis	B-NP	NN	O	5	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	fluocinolone	fluocinolone	B-NP	NN	O	11	NMOD
10	acetonide	acetonide	I-NP	NN	O	11	NMOD
11	implants	implant	I-NP	NNS	O	8	PMOD
12	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	report	report	I-VP	VB	O	1	NMOD
5	the	the	B-NP	DT	O	8	NMOD
6	incidence	incidence	I-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	management	management	I-NP	NN	O	4	OBJ
9	of	of	B-PP	IN	O	8	NMOD
10	elevated	elevated	B-NP	JJ	O	12	NMOD
11	intraocular	intraocular	I-NP	JJ	O	12	NMOD
12	pressure	pressure	I-NP	NN	O	9	PMOD
13	(	(	O	(	O	15	DEP
14	IOP	IOP	B-NP	NN	B-protein	15	DEP
15	)	)	O	)	O	12	NMOD
16	in	in	B-PP	IN	O	12	NMOD
17	patients	patient	B-NP	NNS	O	16	PMOD
18	with	with	B-PP	IN	O	17	NMOD
19	uveitis	uveitis	B-NP	NN	O	18	PMOD
20	treated	treat	B-VP	VBN	O	19	NMOD
21	with	with	B-PP	IN	O	20	VMOD
22	the	the	B-NP	DT	O	24	NMOD
23	fluocinolone	fluocinolone	I-NP	NN	O	24	NMOD
24	acetonide	acetonide	I-NP	NN	O	29	NMOD
25	(	(	O	(	O	27	DEP
26	FA	FA	B-NP	NN	O	27	DEP
27	)	)	O	)	O	24	NMOD
28	intravitreal	intravitreal	B-NP	JJ	O	29	NMOD
29	implant	implant	I-NP	NN	O	21	PMOD
30	.	.	O	.	O	1	P

1	Pallidal	Pallidal	B-NP	JJ	O	2	NMOD
2	stimulation	stimulation	I-NP	NN	O	3	SUB
3	improves	improve	B-VP	VBZ	O	16	VMOD
4	bradykinesia	bradykinesia	B-NP	NN	O	6	NMOD
5	and	and	I-NP	CC	O	6	NMOD
6	rigidity	rigidity	I-NP	NN	O	3	OBJ
7	to	to	B-PP	TO	O	6	NMOD
8	a	a	B-NP	DT	O	10	NMOD
9	minor	minor	I-NP	JJ	O	10	NMOD
10	extent	extent	I-NP	NN	O	7	PMOD
11	;	;	O	:	O	16	P
12	however	however	B-ADVP	RB	O	16	VMOD
13	,	,	O	,	O	16	P
14	its	its	B-NP	PRP$	O	15	NMOD
15	strength	strength	I-NP	NN	O	16	SUB
16	seems	seem	B-VP	VBZ	O	0	ROOT
17	to	to	I-VP	TO	O	18	VMOD
18	be	be	I-VP	VB	O	16	VMOD
19	in	in	B-PP	IN	O	18	VMOD
20	improving	improve	B-VP	VBG	O	19	PMOD
21	levodopa	levodopa	B-NP	NN	O	23	NMOD
22	induced	induced	I-NP	JJ	O	23	NMOD
23	dyskinesias	dyskinesia	I-NP	NNS	O	20	OBJ
24	.	.	O	.	O	16	P

1	Case	Case	B-NP	NN	O	2	NMOD
2	report	report	I-NP	NN	O	0	ROOT
3	:	:	O	:	O	2	P
4	Dexatrim	Dexatrim	B-NP	NN	O	2	NMOD
5	(	(	O	(	O	7	DEP
6	Phenylpropanolamine	Phenylpropanolamine	B-NP	NN	O	7	DEP
7	)	)	O	)	O	4	NMOD
8	as	as	B-PP	IN	O	2	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	cause	cause	I-NP	NN	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	myocardial	myocardial	B-NP	JJ	O	13	NMOD
13	infarction	infarction	I-NP	NN	O	11	PMOD
14	.	.	O	.	O	2	P

1	Several	Several	B-NP	JJ	O	2	NMOD
2	reports	report	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	linked	link	I-VP	VBN	O	3	VC
5	the	the	B-NP	DT	O	6	NMOD
6	abuse	abuse	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	PPA	PPA	B-NP	NN	B-protein	7	PMOD
9	with	with	B-PP	IN	O	6	NMOD
10	myocardial	myocardial	B-NP	JJ	O	11	NMOD
11	injury	injury	I-NP	NN	O	9	PMOD
12	,	,	O	,	O	4	P
13	especially	especially	B-ADVP	RB	O	14	AMOD
14	when	when	B-ADVP	WRB	O	4	VMOD
15	overdose	overdose	B-NP	NN	O	16	SUB
16	is	be	B-VP	VBZ	O	14	SBAR
17	involved	involve	I-VP	VBN	O	16	VC
18	.	.	O	.	O	3	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	here	here	B-ADVP	RB	O	2	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	first	first	I-NP	JJ	O	6	NMOD
6	case	case	I-NP	NN	O	12	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	Dexatrim	Dexatrim	B-NP	NN	O	7	PMOD
9	(	(	O	(	O	11	DEP
10	PPA	PPA	B-NP	NN	B-protein	11	DEP
11	)	)	O	)	O	8	NMOD
12	induced	induce	B-VP	VBD	O	2	VMOD
13	myocardial	myocardial	B-NP	JJ	O	14	NMOD
14	injury	injury	I-NP	NN	O	12	OBJ
15	in	in	B-PP	IN	O	12	VMOD
16	a	a	B-NP	DT	O	18	NMOD
17	young	young	I-NP	JJ	O	18	NMOD
18	woman	woman	I-NP	NN	O	15	PMOD
19	who	who	B-NP	WP	O	18	NMOD
20	was	be	B-VP	VBD	O	19	SBAR
21	using	use	I-VP	VBG	O	20	VMOD
22	it	it	B-NP	PRP	O	21	OBJ
23	at	at	B-PP	IN	O	21	VMOD
24	recommended	recommend	B-NP	VBN	O	25	NMOD
25	doses	dose	I-NP	NNS	O	23	PMOD
26	for	for	B-PP	IN	O	21	VMOD
27	weight	weight	B-NP	NN	O	28	NMOD
28	control	control	I-NP	NN	O	26	PMOD
29	.	.	O	.	O	2	P

1	In	In	B-PP	IN	O	5	VMOD
2	addition	addition	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	5	P
4	we	we	B-NP	PRP	O	5	SUB
5	review	review	B-VP	VBP	O	0	ROOT
6	the	the	B-NP	DT	O	9	NMOD
7	7	7	I-NP	CD	O	9	NMOD
8	other	other	I-NP	JJ	O	9	NMOD
9	cases	case	I-NP	NNS	O	5	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	PPA	PPA	B-NP	NN	O	14	NMOD
12	related	related	I-NP	JJ	O	14	NMOD
13	myocardial	myocardial	I-NP	JJ	O	14	NMOD
14	injury	injury	I-NP	NN	O	10	PMOD
15	that	that	B-NP	WDT	O	9	NMOD
16	have	have	B-VP	VBP	O	15	SBAR
17	been	be	I-VP	VBN	O	16	VC
18	reported	report	I-VP	VBN	O	17	VC
19	so	so	B-ADVP	RB	O	18	VMOD
20	far	far	I-ADVP	RB	O	19	AMOD
21	.	.	O	.	O	5	P

1	Risperidone-associated	Risperidone-associated	B-NP	JJ	O	5	AMOD
2	,	,	I-NP	,	O	5	P
3	benign	benign	I-NP	JJ	O	5	AMOD
4	transient	transient	I-NP	JJ	O	5	AMOD
5	visual	visual	I-NP	JJ	O	6	NMOD
6	disturbances	disturbance	I-NP	NNS	O	0	ROOT
7	in	in	B-PP	IN	O	6	NMOD
8	schizophrenic	schizophrenic	B-NP	JJ	O	9	NMOD
9	patients	patient	I-NP	NNS	O	7	PMOD
10	with	with	B-PP	IN	O	9	NMOD
11	a	a	B-NP	DT	O	13	NMOD
12	past	past	I-NP	JJ	O	13	NMOD
13	history	history	I-NP	NN	O	10	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	LSD	LSD	B-NP	NN	B-protein	16	NMOD
16	abuse	abuse	I-NP	NN	I-protein	14	PMOD
17	.	.	O	.	O	6	P

1	Two	Two	B-NP	CD	O	3	NMOD
2	schizophrenic	schizophrenic	I-NP	JJ	O	3	NMOD
3	patients	patient	I-NP	NNS	O	23	SUB
4	,	,	O	,	O	3	P
5	who	who	B-NP	WP	O	3	NMOD
6	had	have	B-VP	VBD	O	5	SBAR
7	a	a	B-NP	DT	O	9	NMOD
8	prior	prior	I-NP	JJ	O	9	NMOD
9	history	history	I-NP	NN	O	6	OBJ
10	of	of	B-PP	IN	O	9	NMOD
11	LSD	LSD	B-NP	NN	O	12	NMOD
12	abuse	abuse	I-NP	NN	O	10	PMOD
13	and	and	O	CC	O	23	VMOD
14	who	who	B-NP	WP	O	23	VMOD
15	had	have	B-VP	VBD	O	14	SBAR
16	previously	previously	I-VP	RB	O	15	VMOD
17	developed	develop	I-VP	VBN	O	15	VC
18	EPS	EPS	B-NP	NN	B-protein	17	OBJ
19	with	with	B-PP	IN	O	17	VMOD
20	classic	classic	B-NP	JJ	O	21	NMOD
21	antipsychotics	antipsychotic	I-NP	NNS	O	19	PMOD
22	,	,	O	,	O	23	P
23	were	be	B-VP	VBD	O	0	ROOT
24	successfully	successfully	I-VP	RB	O	23	VMOD
25	treated	treat	I-VP	VBN	O	23	VC
26	with	with	B-PP	IN	O	25	VMOD
27	risperidone	risperidone	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	23	P

1	They	They	B-NP	PRP	O	0	ROOT
2	both	both	O	DT	O	1	NMOD
3	reported	report	B-VP	VBD	O	2	SBAR
4	short	short	B-NP	JJ	O	5	NMOD
5	episodes	episode	I-NP	NNS	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	transient	transient	B-NP	JJ	O	9	NMOD
8	visual	visual	I-NP	JJ	O	9	NMOD
9	disturbances	disturbance	I-NP	NNS	O	6	PMOD
10	,	,	O	,	O	5	P
11	which	which	B-NP	WDT	O	5	NMOD
12	appeared	appear	B-VP	VBD	O	11	SBAR
13	immediately	immediately	B-ADVP	RB	O	12	VMOD
14	after	after	B-PP	IN	O	12	VMOD
15	starting	start	B-VP	VBG	O	14	PMOD
16	treatment	treatment	B-NP	NN	O	15	OBJ
17	with	with	B-PP	IN	O	16	NMOD
18	risperidone	risperidone	B-NP	NN	O	17	PMOD
19	.	.	O	.	O	1	P

1	This	This	B-NP	DT	O	2	NMOD
2	imagery	imagery	I-NP	NN	O	3	SUB
3	resembled	resemble	B-VP	VBD	O	0	ROOT
4	visual	visual	B-NP	JJ	O	5	NMOD
5	disturbances	disturbance	I-NP	NNS	O	3	OBJ
6	previously	previously	B-ADVP	RB	O	3	VMOD
7	experienced	experience	B-VP	VBD	O	3	VMOD
8	as	as	B-PP	IN	O	7	VMOD
9	"	"	O	"	O	10	NMOD
10	flashbacks	flashback	B-NP	NNS	O	8	PMOD
11	"	"	O	"	O	10	NMOD
12	related	relate	B-VP	VBN	O	10	NMOD
13	to	to	B-PP	TO	O	12	AMOD
14	prior	prior	B-NP	JJ	O	16	NMOD
15	LSD	LSD	I-NP	NN	O	16	NMOD
16	consumption	consumption	I-NP	NN	O	13	PMOD
17	.	.	O	.	O	3	P

1	Risperidone	Risperidone	B-NP	NN	O	2	NMOD
2	administration	administration	I-NP	NN	O	3	SUB
3	was	be	B-VP	VBD	O	10	VMOD
4	continued	continue	I-VP	VBN	O	3	VC
5	and	and	O	CC	O	10	VMOD
6	the	the	B-NP	DT	O	8	NMOD
7	visual	visual	I-NP	JJ	O	8	NMOD
8	disturbances	disturbance	I-NP	NNS	O	10	SUB
9	gradually	gradually	B-ADVP	RB	O	10	VMOD
10	wore	wear	B-VP	VBD	O	0	ROOT
11	off	off	B-PRT	RP	O	10	VMOD
12	.	.	O	.	O	10	P

1	Activation	Activation	B-NP	NN	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	poly	poly	B-NP	NN	B-protein	7	NMOD
4	(	(	O	(	I-protein	7	NMOD
5	ADP-ribose	ADP-ribose	B-NP	NN	I-protein	7	NMOD
6	)	)	O	)	I-protein	7	NMOD
7	polymerase	polymerase	B-NP	NN	I-protein	2	PMOD
8	contributes	contribute	B-VP	VBZ	O	0	ROOT
9	to	to	B-PP	TO	O	8	VMOD
10	development	development	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	doxorubicin	doxorubicin	B-NP	NN	O	11	PMOD
13	induced	induce	B-VP	VBD	O	8	VMOD
14	heart	heart	B-NP	NN	O	15	NMOD
15	failure	failure	I-NP	NN	O	13	OBJ
16	.	.	O	.	O	8	P

1	Increased	Increase	B-NP	VBN	O	3	NMOD
2	oxidative	oxidative	I-NP	JJ	O	3	NMOD
3	stress	stress	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	a	a	B-NP	DT	O	7	NMOD
6	major	major	I-NP	JJ	O	7	NMOD
7	factor	factor	I-NP	NN	O	4	PRD
8	implicated	implicate	B-VP	VBN	O	7	NMOD
9	in	in	B-PP	IN	O	8	VMOD
10	the	the	B-NP	DT	O	11	NMOD
11	cardiotoxicity	cardiotoxicity	I-NP	NN	O	23	NMOD
12	of	of	B-PP	IN	O	11	NMOD
13	doxorubicin	doxorubicin	B-NP	NN	O	12	PMOD
14	(	(	O	(	O	16	DEP
15	DOX	DOX	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	,	,	O	,	O	23	P
18	a	a	B-NP	DT	O	23	NMOD
19	widely	widely	I-NP	RB	O	20	AMOD
20	used	use	I-NP	VBN	O	23	NMOD
21	antitumor	antitumor	I-NP	JJ	O	23	NMOD
22	anthracycline	anthracycline	I-NP	NN	O	23	NMOD
23	antibiotic	antibiotic	I-NP	NN	O	9	PMOD
24	.	.	O	.	O	4	P

1	Thus	Thus	B-ADVP	RB	O	4	VMOD
2	,	,	O	,	O	4	P
3	we	we	B-NP	PRP	O	4	SUB
4	hypothesized	hypothesize	B-VP	VBD	O	0	ROOT
5	that	that	B-SBAR	IN	O	4	VMOD
6	the	the	B-NP	DT	O	7	NMOD
7	activation	activation	I-NP	NN	O	10	SUB
8	of	of	B-PP	IN	O	7	NMOD
9	PARP	PARP	B-NP	NN	B-protein	8	PMOD
10	may	may	B-VP	MD	O	5	SBAR
11	contribute	contribute	I-VP	VB	O	10	VC
12	to	to	B-PP	TO	O	11	VMOD
13	the	the	B-NP	DT	O	16	NMOD
14	DOX	DOX	I-NP	NN	O	16	NMOD
15	induced	induced	I-NP	JJ	O	16	NMOD
16	cardiotoxicity	cardiotoxicity	I-NP	NN	O	12	PMOD
17	.	.	O	.	O	4	P

1	Using	Use	B-VP	VBG	O	24	VMOD
2	a	a	B-NP	DT	O	4	NMOD
3	dual	dual	I-NP	JJ	O	4	NMOD
4	approach	approach	I-NP	NN	O	1	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	PARP-1	PARP-1	B-NP	NN	B-protein	7	NMOD
7	suppression	suppression	I-NP	NN	O	5	PMOD
8	,	,	O	,	O	24	P
9	by	by	B-PP	IN	O	24	VMOD
10	genetic	genetic	B-NP	JJ	O	11	NMOD
11	deletion	deletion	I-NP	NN	O	14	NMOD
12	or	or	O	CC	O	14	NMOD
13	pharmacological	pharmacological	B-NP	JJ	O	14	NMOD
14	inhibition	inhibition	I-NP	NN	O	9	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	20	NMOD
17	phenanthridinone	phenanthridinone	I-NP	NN	O	20	NMOD
18	PARP	PARP	I-NP	NN	O	20	NMOD
19	inhibitor	inhibitor	I-NP	NN	O	20	NMOD
20	PJ34	PJ34	I-NP	NN	O	15	PMOD
21	,	,	O	,	O	24	P
22	we	we	B-NP	PRP	O	24	SUB
23	now	now	B-ADVP	RB	O	24	VMOD
24	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT
25	the	the	B-NP	DT	O	26	NMOD
26	role	role	I-NP	NN	O	24	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	PARP	PARP	B-NP	NN	B-protein	27	PMOD
29	in	in	B-PP	IN	O	26	NMOD
30	the	the	B-NP	DT	O	31	NMOD
31	development	development	I-NP	NN	O	29	PMOD
32	of	of	B-PP	IN	O	31	NMOD
33	cardiac	cardiac	B-NP	JJ	O	34	NMOD
34	dysfunction	dysfunction	I-NP	NN	O	32	PMOD
35	induced	induce	B-VP	VBN	O	34	NMOD
36	by	by	B-PP	IN	O	35	VMOD
37	DOX	DOX	B-NP	NN	O	36	PMOD
38	.	.	O	.	O	24	P

1	Treatment	Treatment	B-NP	NN	O	6	SUB
2	with	with	B-PP	IN	O	1	NMOD
3	a	a	B-NP	DT	O	4	NMOD
4	PJ34	PJ34	I-NP	NN	B-protein	2	PMOD
5	significantly	significantly	B-ADVP	RB	O	6	VMOD
6	improved	improve	B-VP	VBD	O	0	ROOT
7	cardiac	cardiac	B-NP	JJ	O	8	NMOD
8	dysfunction	dysfunction	I-NP	NN	O	6	OBJ
9	and	and	O	CC	O	6	VMOD
10	increased	increase	B-VP	VBD	O	6	VMOD
11	the	the	B-NP	DT	O	12	NMOD
12	survival	survival	I-NP	NN	O	10	OBJ
13	of	of	B-PP	IN	O	12	NMOD
14	the	the	B-NP	DT	O	15	NMOD
15	animals	animal	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	6	P

1	Thus	Thus	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	PARP	PARP	B-NP	NN	B-protein	4	NMOD
4	activation	activation	I-NP	NN	O	5	SUB
5	contributes	contribute	B-VP	VBZ	O	0	ROOT
6	to	to	B-PP	TO	O	5	VMOD
7	the	the	B-NP	DT	O	8	NMOD
8	cardiotoxicity	cardiotoxicity	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	DOX	DOX	B-NP	NN	B-protein	9	PMOD
11	.	.	O	.	O	5	P

1	Fluconazole	Fluconazole	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	torsade	torsade	B-NP	FW	O	2	VMOD
4	de	de	I-NP	FW	O	5	NMOD
5	pointes	pointes	I-NP	FW	O	3	AMOD
6	.	.	O	.	O	2	P

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	0	ROOT
2	:	:	O	:	O	1	P
3	To	To	B-VP	TO	O	4	VMOD
4	present	present	I-VP	VB	O	1	NMOD
5	a	a	B-NP	DT	O	6	NMOD
6	case	case	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	fluconazole-associated	fluconazole-associated	B-NP	JJ	O	11	NMOD
9	torsade	torsade	I-NP	FW	O	11	NMOD
10	de	de	I-NP	FW	O	11	NMOD
11	pointes	pointes	I-NP	FW	O	14	NMOD
12	(	(	O	(	O	14	DEP
13	TDP	TDP	B-NP	NN	B-protein	14	DEP
14	)	)	O	)	O	7	PMOD
15	and	and	O	CC	O	4	VMOD
16	discuss	discuss	B-VP	VBP	O	4	VMOD
17	fluconazole	fluconazole	B-NP	NN	O	19	NMOD
18	's	's	B-NP	POS	O	19	NMOD
19	role	role	I-NP	NN	O	16	OBJ
20	in	in	B-PP	IN	O	19	NMOD
21	causing	cause	B-VP	VBG	O	20	PMOD
22	TDP	TDP	B-NP	NN	B-protein	21	OBJ
23	.	.	O	.	O	1	P

1	CASE	CASE	B-NP	NN	O	2	NMOD
2	SUMMARY	SUMMARY	I-NP	NN	O	7	NMOD
3	:	:	O	:	O	2	P
4	A	A	B-NP	DT	O	7	NMOD
5	68-year-old	68-year-old	I-NP	JJ	O	7	NMOD
6	white	white	I-NP	JJ	O	7	NMOD
7	woman	woman	I-NP	NN	O	16	SUB
8	with	with	B-PP	IN	O	7	NMOD
9	Candida	Candida	B-NP	NNP	O	10	NMOD
10	glabrata	glabrata	I-NP	NNS	O	8	PMOD
11	isolated	isolate	B-VP	VBN	O	10	NMOD
12	from	from	B-PP	IN	O	11	VMOD
13	a	a	B-NP	DT	O	15	NMOD
14	presacral	presacral	I-NP	JJ	O	15	NMOD
15	abscess	abscess	I-NP	NN	O	12	PMOD
16	developed	develop	B-VP	VBD	O	49	VMOD
17	TDP	TDP	B-NP	NN	O	19	NMOD
18	eight	eight	B-NP	CD	O	19	NMOD
19	days	day	I-NP	NNS	O	20	PMOD
20	after	after	B-PP	IN	O	16	VMOD
21	commencing	commence	B-VP	VBG	O	20	PMOD
22	oral	oral	B-NP	JJ	O	23	NMOD
23	fluconazole	fluconazole	I-NP	NN	O	21	OBJ
24	The	The	B-NP	DT	O	25	NMOD
25	patient	patient	I-NP	NN	O	20	PMOD
26	had	have	B-VP	VBD	O	49	VMOD
27	no	no	B-NP	DT	O	30	NMOD
28	other	other	I-NP	JJ	O	30	NMOD
29	risk	risk	I-NP	NN	O	30	NMOD
30	factors	factor	I-NP	NNS	O	26	OBJ
31	for	for	B-PP	IN	O	26	VMOD
32	TDP	TDP	B-NP	NN	B-protein	31	PMOD
33	,	,	O	,	O	32	P
34	including	include	B-PP	VBG	O	32	NMOD
35	coronary	coronary	B-NP	JJ	O	37	NMOD
36	artery	artery	I-NP	NN	O	37	NMOD
37	disease	disease	I-NP	NN	O	47	NMOD
38	,	,	O	,	O	47	P
39	cardiomyopathy	cardiomyopathy	B-NP	NN	O	47	NMOD
40	,	,	O	,	O	47	P
41	congestive	congestive	B-NP	JJ	O	43	NMOD
42	heart	heart	I-NP	NN	O	43	NMOD
43	failure	failure	I-NP	NN	O	47	NMOD
44	,	,	O	,	O	47	P
45	and	and	O	CC	O	47	NMOD
46	electrolyte	electrolyte	B-NP	NN	O	47	NMOD
47	abnormalities	abnormality	I-NP	NNS	O	34	PMOD
48	There	There	B-NP	EX	O	49	SUB
49	was	be	B-VP	VBD	O	0	ROOT
50	a	a	B-NP	DT	O	52	NMOD
51	temporal	temporal	I-NP	JJ	O	52	NMOD
52	association	association	I-NP	NN	O	49	PRD
53	between	between	B-PP	IN	O	52	NMOD
54	the	the	B-NP	DT	O	55	NMOD
55	initiation	initiation	I-NP	NN	O	53	PMOD
56	of	of	B-PP	IN	O	55	NMOD
57	fluconazole	fluconazole	B-NP	NN	O	59	NMOD
58	and	and	I-NP	CC	O	59	NMOD
59	TDP	TDP	I-NP	NN	B-protein	56	PMOD
60	.	.	O	.	O	49	P

1	The	The	B-NP	DT	O	2	NMOD
2	TDP	TDP	I-NP	NN	B-protein	13	SUB
3	resolved	resolve	B-VP	VBN	O	2	NMOD
4	when	when	B-ADVP	WRB	O	3	VMOD
5	fluconazole	fluconazole	B-NP	NN	O	6	SUB
6	was	be	B-VP	VBD	O	4	SBAR
7	discontinued	discontinue	I-VP	VBN	O	6	VC
8	;	;	O	:	O	13	P
9	however	however	B-ADVP	RB	O	13	VMOD
10	,	,	O	,	O	13	P
11	the	the	B-NP	DT	O	12	NMOD
12	patient	patient	I-NP	NN	O	13	SUB
13	continued	continue	B-VP	VBD	O	40	VMOD
14	to	to	I-VP	TO	O	15	VMOD
15	have	have	I-VP	VB	O	13	VMOD
16	premature	premature	B-NP	JJ	O	18	NMOD
17	ventricular	ventricular	I-NP	JJ	O	18	NMOD
18	contractions	contraction	I-NP	NNS	O	15	OBJ
19	and	and	O	CC	O	22	NMOD
20	nonsustained	nonsustained	B-NP	JJ	O	22	NMOD
21	ventricular	ventricular	I-NP	JJ	O	22	NMOD
22	tachycardia	tachycardia	I-NP	NN	O	18	OBJ
23	(	(	O	(	O	25	DEP
24	NSVT	NSVT	B-NP	NN	O	25	DEP
25	)	)	O	)	O	22	NMOD
26	until	until	B-PP	IN	O	22	NMOD
27	six	six	B-NP	CD	O	28	NMOD
28	days	day	I-NP	NNS	O	26	PMOD
29	after	after	B-PP	IN	O	28	NMOD
30	drug	drug	B-NP	NN	O	32	NMOD
31	cessation	cessation	I-NP	NN	O	32	NMOD
32	DISCUSSION	DISCUSSION	I-NP	NN	O	29	PMOD
33	:	:	O	:	O	13	P
34	Use	Use	B-NP	NN	O	40	SUB
35	of	of	B-PP	IN	O	34	NMOD
36	the	the	B-NP	DT	O	39	NMOD
37	Naranjo	Naranjo	I-NP	NNP	O	39	NMOD
38	probability	probability	I-NP	NN	O	39	NMOD
39	scale	scale	I-NP	NN	O	35	PMOD
40	indicates	indicate	B-VP	VBZ	O	0	ROOT
41	a	a	B-NP	DT	O	43	NMOD
42	probable	probable	I-NP	JJ	O	43	NMOD
43	relationship	relationship	I-NP	NN	O	40	OBJ
44	between	between	B-PP	IN	O	43	NMOD
45	the	the	B-NP	DT	O	46	NMOD
46	use	use	I-NP	NN	O	51	NMOD
47	of	of	B-PP	IN	O	46	NMOD
48	fluconazole	fluconazole	B-NP	NN	O	47	PMOD
49	and	and	O	CC	O	51	NMOD
50	the	the	B-NP	DT	O	51	NMOD
51	development	development	I-NP	NN	O	44	PMOD
52	of	of	B-PP	IN	O	51	NMOD
53	TDP	TDP	B-NP	NN	B-protein	52	PMOD
54	.	.	O	.	O	40	P

1	The	The	B-NP	DT	O	3	NMOD
2	possible	possible	I-NP	JJ	O	3	NMOD
3	mechanism	mechanism	I-NP	NN	O	4	SUB
4	is	be	B-VP	VBZ	O	0	ROOT
5	depression	depression	B-NP	NN	O	4	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	rapidly	rapidly	B-VP	RB	O	8	VMOD
8	activating	activate	I-VP	VBG	O	6	PMOD
9	delayed	delay	I-VP	VBN	O	12	NMOD
10	rectifier	rectifi	B-NP	JJR	O	12	NMOD
11	potassium	potassium	I-NP	NN	O	12	NMOD
12	currents	current	I-NP	NNS	O	8	OBJ
13	.	.	O	.	O	4	P

1	In	In	B-PP	IN	O	6	VMOD
2	our	our	B-NP	PRP$	O	3	NMOD
3	patient	patient	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	6	P
5	there	there	B-NP	EX	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	no	no	B-NP	DT	O	9	NMOD
8	other	other	I-NP	JJ	O	9	NMOD
9	etiology	etiology	I-NP	NN	O	10	SUB
10	identified	identify	B-VP	VBD	O	6	PRD
11	that	that	B-NP	WDT	O	10	VMOD
12	could	could	B-VP	MD	O	11	SBAR
13	explain	explain	I-VP	VB	O	12	VC
14	QT	QT	B-NP	NN	O	15	NMOD
15	prolongation	prolongation	I-NP	NN	O	17	NMOD
16	or	or	O	CC	O	17	NMOD
17	TDP	TDP	B-NP	NN	O	20	NMOD
18	The	The	B-NP	DT	O	20	NMOD
19	complete	complete	I-NP	JJ	O	20	NMOD
20	disappearance	disappearance	I-NP	NN	O	26	NMOD
21	of	of	B-PP	IN	O	20	NMOD
22	NSVT	NSVT	B-NP	NN	B-protein	21	PMOD
23	and	and	O	CC	O	26	NMOD
24	premature	premature	B-NP	JJ	O	26	NMOD
25	ventricular	ventricular	I-NP	JJ	O	26	NMOD
26	contractions	contraction	I-NP	NNS	O	13	OBJ
27	followed	follow	B-VP	VBN	O	26	NMOD
28	by	by	B-PP	IN	O	27	VMOD
29	normalization	normalization	B-NP	NN	O	28	PMOD
30	of	of	B-PP	IN	O	29	NMOD
31	QT	QT	B-NP	NN	O	32	NMOD
32	interval	interval	I-NP	NN	O	30	PMOD
33	after	after	B-PP	IN	O	29	NMOD
34	the	the	B-NP	DT	O	35	NMOD
35	drug	drug	I-NP	NN	O	33	PMOD
36	was	be	B-VP	VBD	O	11	SBAR
37	stopped	stop	I-VP	VBN	O	36	VC
38	strongly	strongly	B-ADVP	RB	O	39	VMOD
39	suggests	suggest	B-VP	VBZ	O	37	VMOD
40	fluconazole	fluconazole	B-NP	NN	O	39	OBJ
41	as	as	B-SBAR	IN	O	40	NMOD
42	the	the	B-NP	DT	O	43	NMOD
43	etiology	etiology	I-NP	NN	O	41	PMOD
44	.	.	O	.	O	6	P

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Clinicians	Clinician	B-NP	NNS	O	4	SUB
4	should	should	B-VP	MD	O	1	NMOD
5	be	be	I-VP	VB	O	4	VC
6	aware	aware	B-ADJP	JJ	O	5	PRD
7	that	that	B-SBAR	IN	O	5	VMOD
8	fluconazole	fluconazole	B-NP	NN	O	15	SUB
9	,	,	O	,	O	8	P
10	even	even	B-ADVP	RB	O	11	PMOD
11	at	at	B-PP	IN	O	8	NMOD
12	low	low	B-NP	JJ	O	13	NMOD
13	doses	dose	I-NP	NNS	O	11	PMOD
14	,	,	O	,	O	8	P
15	may	may	B-VP	MD	O	7	SBAR
16	cause	cause	I-VP	VB	O	15	VC
17	prolongation	prolongation	B-NP	NN	O	16	OBJ
18	of	of	B-PP	IN	O	17	NMOD
19	the	the	B-NP	DT	O	21	NMOD
20	QT	QT	I-NP	NN	O	21	NMOD
21	interval	interval	I-NP	NN	O	18	PMOD
22	,	,	O	,	O	15	P
23	leading	lead	B-VP	VBG	O	15	VMOD
24	to	to	B-PP	TO	O	23	VMOD
25	TDP	TDP	B-NP	NN	B-protein	24	PMOD
26	.	.	O	.	O	1	P

1	High-dose	High-dose	B-NP	JJ	O	2	NMOD
2	methylprednisolone	methylprednisolone	I-NP	NN	O	3	SUB
3	may	may	B-VP	MD	O	0	ROOT
4	do	do	I-VP	VB	O	3	VC
5	more	more	B-NP	JJR	O	6	NMOD
6	harm	harm	I-NP	NN	O	4	OBJ
7	for	for	B-PP	IN	O	6	NMOD
8	spinal	spinal	B-NP	JJ	O	10	NMOD
9	cord	cord	I-NP	NN	O	10	NMOD
10	injury	injury	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	3	P

1	Because	Because	B-PP	IN	O	16	VMOD
2	of	of	I-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	9	NMOD
4	National	National	I-NP	NNP	O	9	NMOD
5	Acute	Acute	I-NP	NNP	O	9	NMOD
6	Spinal	Spinal	I-NP	NNP	O	9	NMOD
7	Cord	Cord	I-NP	NNP	O	9	NMOD
8	Injury	Injury	I-NP	NNP	O	9	NMOD
9	Studies	Studies	I-NP	NNP	O	16	VMOD
10	(	(	O	(	O	12	DEP
11	NASCIS	NASCIS	B-NP	NNP	O	12	DEP
12	)	)	O	)	O	9	NMOD
13	,	,	O	,	O	16	P
14	high-dose	high-dose	B-NP	JJ	O	15	NMOD
15	methylprednisolone	methylprednisolone	I-NP	NN	O	16	SUB
16	became	become	B-VP	VBD	O	0	ROOT
17	the	the	B-NP	DT	O	18	NMOD
18	standard	standard	I-NP	NN	O	16	OBJ
19	of	of	B-PP	IN	O	18	NMOD
20	care	care	B-NP	NN	O	19	PMOD
21	for	for	B-PP	IN	O	18	NMOD
22	the	the	B-NP	DT	O	26	NMOD
23	acute	acute	I-NP	JJ	O	26	NMOD
24	spinal	spinal	I-NP	JJ	O	26	NMOD
25	cord	cord	I-NP	NN	O	26	NMOD
26	injury	injury	I-NP	NN	O	21	PMOD
27	.	.	O	.	O	16	P

1	In	In	B-PP	IN	O	6	VMOD
2	the	the	B-NP	DT	O	3	NMOD
3	NASCIS	NASCIS	I-NP	NNP	O	1	PMOD
4	,	,	O	,	O	6	P
5	there	there	B-NP	EX	O	6	SUB
6	was	be	B-VP	VBD	O	0	ROOT
7	no	no	B-NP	DT	O	8	NMOD
8	mention	mention	I-NP	NN	O	6	PRD
9	regarding	regard	B-VP	VBG	O	8	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	possibility	possibility	I-NP	NN	O	9	OBJ
12	of	of	B-PP	IN	O	11	NMOD
13	acute	acute	B-NP	JJ	O	15	NMOD
14	corticosteroid	corticosteroid	I-NP	NN	O	15	NMOD
15	myopathy	myopathy	I-NP	NN	O	12	PMOD
16	that	that	B-NP	IN	O	15	NMOD
17	high-dose	high-dose	B-NP	JJ	O	18	NMOD
18	methylprednisolone	methylprednisolone	I-NP	NN	O	19	SUB
19	may	may	B-VP	MD	O	16	SBAR
20	cause	cause	I-VP	VB	O	19	VC
21	.	.	O	.	O	6	P

1	Further	Further	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	steroid	steroid	B-NP	NN	O	4	NMOD
4	myopathy	myopathy	I-NP	NN	O	5	SUB
5	recovers	recover	B-VP	VBZ	O	0	ROOT
6	naturally	naturally	B-ADVP	RB	O	10	NMOD
7	and	and	O	CC	O	6	AMOD
8	the	the	B-NP	DT	O	10	NMOD
9	neurological	neurological	I-NP	JJ	O	10	NMOD
10	improvement	improvement	I-NP	NN	O	15	SUB
11	shown	show	B-VP	VBN	O	10	NMOD
12	in	in	B-PP	IN	O	11	VMOD
13	the	the	B-NP	DT	O	14	NMOD
14	NASCIS	NASCIS	I-NP	NNP	O	12	PMOD
15	may	may	B-VP	MD	O	5	VMOD
16	be	be	I-VP	VB	O	15	VC
17	just	just	B-NP	RB	O	19	NMOD
18	a	a	I-NP	DT	O	19	NMOD
19	recording	recording	I-NP	NN	O	16	PRD
20	of	of	B-PP	IN	O	19	NMOD
21	this	this	B-NP	DT	O	24	NMOD
22	natural	natural	I-NP	JJ	O	24	NMOD
23	motor	motor	I-NP	NN	O	24	NMOD
24	recovery	recovery	I-NP	NN	O	20	PMOD
25	from	from	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	28	NMOD
27	steroid	steroid	I-NP	NN	O	28	NMOD
28	myopathy	myopathy	I-NP	NN	O	25	PMOD
29	,	,	O	,	O	16	P
30	instead	instead	B-PP	RB	O	31	PMOD
31	of	of	I-PP	IN	O	16	VMOD
32	any	any	B-NP	DT	O	33	NMOD
33	protection	protection	I-NP	NN	O	31	PMOD
34	that	that	B-SBAR	IN	O	15	VMOD
35	methylprednisolone	methylprednisolone	B-NP	NN	O	36	SUB
36	offers	offer	B-VP	VBZ	O	34	SBAR
37	to	to	B-PP	TO	O	36	VMOD
38	the	the	B-NP	DT	O	41	NMOD
39	spinal	spinal	I-NP	JJ	O	41	NMOD
40	cord	cord	I-NP	NN	O	41	NMOD
41	injury	injury	I-NP	NN	O	37	PMOD
42	.	.	O	.	O	5	P

1	OUTCOME	OUTCOME	B-NP	NN	O	2	NMOD
2	MEASURES	MEASURES	I-NP	NNS	O	5	NMOD
3	:	:	O	:	O	2	P
4	Pupil	Pupil	B-NP	NN	O	5	NMOD
5	size	size	I-NP	NN	O	17	SUB
6	at	at	B-PP	IN	O	5	NMOD
7	time	time	B-NP	NN	O	8	NMOD
8	points	point	I-NP	NNS	O	6	PMOD
9	after	after	B-PP	IN	O	8	NMOD
10	administration	administration	B-NP	NN	O	9	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	tropicamide	tropicamide	B-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	pilocarpine	pilocarpine	I-NP	NN	O	11	PMOD
15	;	;	O	:	O	17	P
16	scopolamine	scopolamine	B-NP	NN	O	17	SUB
17	induced	induce	B-VP	VBD	O	0	ROOT
18	impairment	impairment	B-NP	NN	O	17	OBJ
19	in	in	B-PP	IN	O	17	VMOD
20	word	word	B-NP	NN	O	21	NMOD
21	recall	recall	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	17	P

1	Compared	Compare	B-PP	VBN	O	10	VMOD
2	with	with	B-PP	IN	O	1	PMOD
3	the	the	B-NP	DT	O	5	NMOD
4	young	young	I-NP	JJ	O	5	NMOD
5	group	group	I-NP	NN	O	2	PMOD
6	,	,	O	,	O	10	P
7	the	the	B-NP	DT	O	9	NMOD
8	elderly	elderly	I-NP	JJ	O	9	NMOD
9	group	group	I-NP	NN	O	10	SUB
10	had	have	B-VP	VBD	O	0	ROOT
11	greater	great	B-NP	JJR	O	12	NMOD
12	scopolamine	scopolamine	I-NP	NN	O	14	NMOD
13	induced	induce	B-VP	VBD	O	14	NMOD
14	impairment	impairment	B-NP	NN	O	10	OBJ
15	in	in	B-PP	IN	O	10	VMOD
16	word	word	B-NP	NN	O	17	NMOD
17	recall	recall	I-NP	NN	O	23	NMOD
18	60	60	I-NP	CD	O	17	NMOD
19	,	,	I-NP	,	O	23	P
20	90	90	I-NP	CD	O	23	NMOD
21	and	and	I-NP	CC	O	23	NMOD
22	120	120	I-NP	CD	O	23	NMOD
23	minutes	minute	I-NP	NNS	O	15	PMOD
24	after	after	B-PP	IN	O	23	NMOD
25	administration	administration	B-NP	NN	O	24	PMOD
26	(	(	O	(	O	30	DEP
27	p	p	B-NP	NN	O	30	DEP
28	<	<	O	SYM	O	27	NMOD
29	0.05	0.05	B-NP	CD	O	28	AMOD
30	)	)	O	)	O	23	NMOD
31	.	.	O	.	O	10	P

1	Acetazolamide	Acetazolamide	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	Gerstmann	Gerstmann	B-NP	NNP	O	4	NMOD
4	syndrome	syndrome	I-NP	NN	O	2	OBJ
5	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	2	NMOD
2	confusion	confusion	I-NP	NN	O	6	SUB
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	acetazolamide	acetazolamide	B-NP	NN	O	4	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	a	a	B-NP	DT	O	12	NMOD
8	well	well	I-NP	RB	O	9	AMOD
9	known	know	I-NP	VBN	O	12	NMOD
10	adverse	adverse	I-NP	JJ	O	12	NMOD
11	drug	drug	I-NP	NN	O	12	NMOD
12	reaction	reaction	I-NP	NN	O	6	PRD
13	in	in	B-PP	IN	O	12	NMOD
14	patients	patient	B-NP	NNS	O	13	PMOD
15	with	with	B-PP	IN	O	14	NMOD
16	renal	renal	B-NP	JJ	O	17	NMOD
17	impairment	impairment	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	6	P

1	Hypomania-like	Hypomania-like	B-NP	JJ	O	2	NMOD
2	syndrome	syndrome	I-NP	NN	O	0	ROOT
3	induced	induce	B-VP	VBN	O	2	NMOD
4	by	by	B-PP	IN	O	3	VMOD
5	olanzapine	olanzapine	B-NP	NN	O	4	PMOD
6	.	.	O	.	O	2	P

1	Neutrophil	Neutrophil	B-NP	NN	O	2	NMOD
2	superoxide	superoxide	I-NP	NN	O	6	NMOD
3	and	and	O	CC	O	6	NMOD
4	hydrogen	hydrogen	B-NP	NN	O	6	NMOD
5	peroxide	peroxide	I-NP	NN	O	6	NMOD
6	production	production	I-NP	NN	O	0	ROOT
7	in	in	B-PP	IN	O	6	NMOD
8	patients	patient	B-NP	NNS	O	7	PMOD
9	with	with	B-PP	IN	O	8	NMOD
10	acute	acute	B-NP	JJ	O	12	NMOD
11	liver	liver	I-NP	NN	O	12	NMOD
12	failure	failure	I-NP	NN	O	9	PMOD
13	.	.	O	.	O	6	P

1	Defects	Defect	B-NP	NNS	O	8	SUB
2	in	in	B-PP	IN	O	1	NMOD
3	superoxide	superoxide	B-NP	NN	O	7	NMOD
4	and	and	I-NP	CC	O	7	NMOD
5	hydrogen	hydrogen	I-NP	NN	O	7	NMOD
6	peroxide	peroxide	I-NP	NN	O	7	NMOD
7	production	production	I-NP	NN	O	2	PMOD
8	may	may	B-VP	MD	O	0	ROOT
9	be	be	I-VP	VB	O	8	VC
10	implicated	implicate	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	the	the	B-NP	DT	O	14	NMOD
13	high	high	I-NP	JJ	O	14	NMOD
14	incidence	incidence	I-NP	NN	O	11	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	bacterial	bacterial	B-NP	JJ	O	17	NMOD
17	infections	infection	I-NP	NNS	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	patients	patient	B-NP	NNS	O	18	PMOD
20	with	with	B-PP	IN	O	19	NMOD
21	acute	acute	B-NP	JJ	O	23	NMOD
22	liver	liver	I-NP	NN	O	23	NMOD
23	failure	failure	I-NP	NN	O	20	PMOD
24	(	(	O	(	O	26	DEP
25	ALF	ALF	B-NP	NN	B-protein	26	DEP
26	)	)	O	)	O	23	NMOD
27	.	.	O	.	O	8	P

1	In	In	B-PP	IN	O	17	VMOD
2	the	the	B-NP	DT	O	4	NMOD
3	present	present	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	17	P
6	oxygen	oxygen	B-NP	NN	O	8	NMOD
7	radical	radical	I-NP	NN	O	8	NMOD
8	production	production	I-NP	NN	O	17	SUB
9	in	in	B-PP	IN	O	8	NMOD
10	patients	patient	B-NP	NNS	O	9	PMOD
11	with	with	B-PP	IN	O	10	NMOD
12	ALF	ALF	B-NP	NN	O	11	PMOD
13	due	due	B-ADJP	JJ	O	12	NMOD
14	to	to	B-PP	TO	O	13	AMOD
15	paracetamol	paracetamol	B-NP	NN	O	16	NMOD
16	overdose	overdose	I-NP	NN	O	14	PMOD
17	was	be	B-VP	VBD	O	0	ROOT
18	compared	compare	I-VP	VBN	O	17	VC
19	with	with	B-PP	IN	O	18	VMOD
20	that	that	B-NP	DT	O	19	PMOD
21	of	of	B-PP	IN	O	20	NMOD
22	healthy	healthy	B-NP	JJ	O	23	NMOD
23	volunteers	volunteer	I-NP	NNS	O	21	PMOD
24	.	.	O	.	O	17	P

1	Superoxide	Superoxide	B-NP	NN	O	5	NMOD
2	and	and	I-NP	CC	O	5	NMOD
3	hydrogen	hydrogen	I-NP	NN	O	5	NMOD
4	peroxide	peroxide	I-NP	NN	O	5	NMOD
5	production	production	I-NP	NN	O	16	SUB
6	by	by	B-PP	IN	O	5	NMOD
7	ALF	ALF	B-NP	NN	B-cell_type	8	NMOD
8	neutrophils	neutrophil	I-NP	NNS	I-cell_type	6	PMOD
9	stimulated	stimulate	B-VP	VBN	O	8	NMOD
10	with	with	B-PP	IN	O	9	VMOD
11	zymosan	zymosan	B-NP	NN	O	10	PMOD
12	opsonized	opsonize	B-VP	VBN	O	11	NMOD
13	with	with	B-PP	IN	O	12	VMOD
14	ALF	ALF	B-NP	NN	O	15	NMOD
15	serum	serum	I-NP	NN	O	13	PMOD
16	was	be	B-VP	VBD	O	0	ROOT
17	significantly	significantly	I-VP	RB	O	16	VMOD
18	reduced	reduce	I-VP	VBN	O	16	VC
19	compared	compare	B-PP	VBN	O	18	VMOD
20	with	with	B-PP	IN	O	19	PMOD
21	the	the	B-NP	DT	O	23	NMOD
22	control	control	I-NP	NN	O	23	NMOD
23	subjects	subject	I-NP	NNS	O	20	PMOD
24	(	(	O	(	O	28	DEP
25	P	P	B-NP	NN	O	28	DEP
26	<	<	O	SYM	O	25	NMOD
27	0.01	0.01	B-NP	CD	O	26	AMOD
28	)	)	O	)	O	23	NMOD
29	.	.	O	.	O	16	P

1	Superoxide	Superoxide	B-NP	NN	O	5	NMOD
2	and	and	I-NP	CC	O	5	NMOD
3	hydrogen	hydrogen	I-NP	NN	O	5	NMOD
4	peroxide	peroxide	I-NP	NN	O	5	NMOD
5	production	production	I-NP	NN	O	20	SUB
6	in	in	B-PP	IN	O	5	NMOD
7	neutrophils	neutrophil	B-NP	NNS	B-cell_type	6	PMOD
8	stimulated	stimulate	B-VP	VBN	O	7	NMOD
9	with	with	B-PP	IN	O	8	VMOD
10	formyl-methionyl-leucyl-phenylalanine	formyl-methionyl-leucyl-phenylalanine	B-NP	NN	O	9	PMOD
11	(	(	O	(	O	13	DEP
12	fMLP	fMLP	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	from	from	B-PP	IN	O	10	NMOD
15	a	a	B-NP	DT	O	19	NMOD
16	further	further	I-NP	JJ	O	19	NMOD
17	18	18	I-NP	CD	O	19	NMOD
18	ALF	ALF	I-NP	NN	O	19	NMOD
19	patients	patient	I-NP	NNS	O	14	PMOD
20	was	be	B-VP	VBD	O	0	ROOT
21	unaffected	unaffected	B-ADJP	JJ	O	20	VC
22	compared	compare	B-PP	VBN	O	21	VMOD
23	with	with	B-PP	IN	O	22	PMOD
24	control	control	B-NP	NN	O	25	NMOD
25	neutrophils	neutrophil	I-NP	NNS	O	23	PMOD
26	.	.	O	.	O	20	P

1	Absence	Absence	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	effect	effect	B-NP	NN	O	2	PMOD
4	of	of	B-PP	IN	O	3	NMOD
5	sertraline	sertraline	B-NP	NN	O	4	PMOD
6	on	on	B-PP	IN	O	3	NMOD
7	time-based	time-based	B-NP	JJ	O	8	NMOD
8	sensitization	sensitization	I-NP	NN	O	6	PMOD
9	of	of	B-PP	IN	O	8	NMOD
10	cognitive	cognitive	B-NP	JJ	O	11	NMOD
11	impairment	impairment	I-NP	NN	O	9	PMOD
12	with	with	B-PP	IN	O	11	NMOD
13	haloperidol	haloperidol	B-NP	NN	O	12	PMOD
14	.	.	O	.	O	1	P

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT
2	:	:	O	:	O	1	P
3	Impairment	Impairment	B-NP	NN	O	7	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	cognitive	cognitive	B-NP	JJ	O	6	NMOD
6	function	function	I-NP	NN	O	4	PMOD
7	was	be	B-VP	VBD	O	1	NMOD
8	observed	observe	I-VP	VBN	O	7	VC
9	6	6	B-NP	CD	O	11	AMOD
10	to	to	I-NP	TO	O	11	AMOD
11	8	8	I-NP	CD	O	12	NMOD
12	hours	hour	I-NP	NNS	O	13	PMOD
13	after	after	B-PP	IN	O	8	VMOD
14	administration	administration	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	haloperidol	haloperidol	B-NP	NN	O	15	PMOD
17	on	on	B-PP	IN	O	14	NMOD
18	Day	Day	B-NP	NN	O	17	PMOD
19	2	2	I-NP	CD	O	18	NMOD
20	but	but	O	CC	O	7	VMOD
21	was	be	B-VP	VBD	O	7	VMOD
22	not	not	O	RB	O	21	VMOD
23	evident	evident	B-ADJP	JJ	O	25	NMOD
24	23	23	B-NP	CD	O	25	NMOD
25	hours	hour	I-NP	NNS	O	26	PMOD
26	after	after	B-PP	IN	O	21	VMOD
27	dosing	dosing	B-NP	NN	O	26	PMOD
28	.	.	O	.	O	1	P

1	Ciprofloxacin	Ciprofloxacin	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	0	ROOT
3	nephrotoxicity	nephrotoxicity	B-NP	NN	O	2	OBJ
4	in	in	B-PP	IN	O	2	VMOD
5	patients	patient	B-NP	NNS	O	4	PMOD
6	with	with	B-PP	IN	O	5	NMOD
7	cancer	cancer	B-NP	NN	O	6	PMOD
8	.	.	O	.	O	2	P

1	Nephrotoxicity	Nephrotoxicity	B-NP	NN	O	5	SUB
2	associated	associate	B-VP	VBN	O	1	NMOD
3	with	with	B-PP	IN	O	2	VMOD
4	ciprofloxacin	ciprofloxacin	B-NP	NN	O	3	PMOD
5	is	be	B-VP	VBZ	O	0	ROOT
6	uncommon	uncommon	B-ADJP	JJ	O	5	PRD
7	.	.	O	.	O	5	P

1	Five	Five	B-NP	CD	O	2	NMOD
2	patients	patient	I-NP	NNS	O	15	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	cancer	cancer	B-NP	NN	O	3	PMOD
5	who	who	B-NP	WP	O	2	NMOD
6	developed	develop	B-VP	VBD	O	5	SBAR
7	acute	acute	B-NP	JJ	O	8	AMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	6	OBJ
10	that	that	B-NP	WDT	O	9	NMOD
11	followed	follow	B-VP	VBD	O	10	SBAR
12	treatment	treatment	B-NP	NN	O	11	OBJ
13	with	with	B-PP	IN	O	12	NMOD
14	ciprofloxacin	ciprofloxacin	B-NP	NN	O	13	PMOD
15	are	be	B-VP	VBP	O	26	VMOD
16	described	describe	I-VP	VBN	O	15	VC
17	and	and	O	CC	O	26	VMOD
18	an	an	B-NP	DT	O	21	NMOD
19	additional	additional	I-NP	JJ	O	21	NMOD
20	15	15	I-NP	CD	O	21	NMOD
21	cases	case	I-NP	NNS	O	26	SUB
22	reported	report	B-VP	VBN	O	21	NMOD
23	in	in	B-PP	IN	O	22	VMOD
24	the	the	B-NP	DT	O	25	NMOD
25	literature	literature	I-NP	NN	O	23	PMOD
26	are	be	B-VP	VBP	O	0	ROOT
27	reviewed	review	I-VP	VBN	O	26	VC
28	.	.	O	.	O	26	P

1	Case	Case	B-NP	NN	O	2	NMOD
2	report	report	I-NP	NN	O	8	NMOD
3	:	:	O	:	O	2	P
4	pentamidine	pentamidine	B-NP	NN	O	8	NMOD
5	and	and	O	CC	O	8	NMOD
6	polymorphic	polymorphic	B-NP	JJ	O	8	NMOD
7	ventricular	ventricular	I-NP	JJ	O	8	NMOD
8	tachycardia	tachycardia	I-NP	NN	O	0	ROOT
9	revisited	revisit	B-VP	VBN	O	8	NMOD
10	.	.	O	.	O	8	P

1	Pentamidine	Pentamidine	B-NP	NN	O	2	NMOD
2	isethionate	isethionate	I-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	associated	associate	I-VP	VBN	O	4	VC
6	with	with	B-PP	IN	O	5	VMOD
7	ventricular	ventricular	B-NP	JJ	O	8	NMOD
8	tachyarrhythmias	tachyarrhythmia	I-NP	NNS	O	6	PMOD
9	,	,	O	,	O	8	P
10	including	include	B-PP	VBG	O	8	NMOD
11	torsade	torsade	B-NP	FW	O	13	NMOD
12	de	de	I-NP	FW	O	13	NMOD
13	pointes	pointes	I-NP	FW	O	10	PMOD
14	.	.	O	.	O	3	P

1	Pentamidine	Pentamidine	B-NP	NN	O	2	SUB
2	induced	induce	B-VP	VBD	O	5	NMOD
3	torsade	torsade	B-NP	FW	O	5	NMOD
4	de	de	I-NP	FW	O	5	NMOD
5	pointes	pointe	I-NP	NNS	O	6	SUB
6	may	may	B-VP	MD	O	0	ROOT
7	be	be	I-VP	VB	O	6	VC
8	related	relate	I-VP	VBN	O	7	PRD
9	to	to	B-PP	TO	O	8	AMOD
10	serum	serum	B-NP	NN	O	12	NMOD
11	magnesium	magnesium	I-NP	NN	O	12	NMOD
12	levels	level	I-NP	NNS	O	14	NMOD
13	and	and	O	CC	O	14	NMOD
14	hypomagnesemia	hypomagnesemia	B-NP	NN	O	9	PMOD
15	may	may	B-VP	MD	O	6	VMOD
16	synergistically	synergistically	I-VP	RB	O	15	VMOD
17	induce	induce	I-VP	VB	O	15	VC
18	torsade	torsade	B-NP	NN	O	17	OBJ
19	.	.	O	.	O	6	P

1	Torsade	Torsade	B-NP	FW	O	3	NMOD
2	de	de	I-NP	FW	O	3	NMOD
3	pointes	pointes	I-NP	FW	O	4	SUB
4	occurred	occur	B-VP	VBD	O	0	ROOT
5	after	after	B-PP	IN	O	4	VMOD
6	an	an	B-NP	DT	O	7	NMOD
7	average	average	I-NP	NN	O	5	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	10	10	B-NP	CD	O	10	NMOD
10	days	day	I-NP	NNS	O	8	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	treatment	treatment	B-NP	NN	O	11	PMOD
13	with	with	B-PP	IN	O	12	NMOD
14	pentamidine	pentamidine	B-NP	NN	O	13	PMOD
15	.	.	O	.	O	4	P

1	Torsade	Torsade	B-NP	NNP	O	4	SUB
2	de	de	I-NP	FW	O	1	NMOD
3	pointes	pointes	I-NP	FW	O	1	NMOD
4	can	can	B-VP	MD	O	0	ROOT
5	be	be	I-VP	VB	O	4	VC
6	treated	treat	I-VP	VBN	O	5	VC
7	when	when	B-ADVP	WRB	O	6	VMOD
8	recognized	recognize	B-VP	VBN	O	7	SBAR
9	early	early	B-ADVP	RB	O	8	VMOD
10	,	,	O	,	O	6	P
11	possibly	possibly	B-ADVP	RB	O	6	VMOD
12	without	without	B-PP	IN	O	6	VMOD
13	discontinuation	discontinuation	B-NP	NN	O	12	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	pentamidine	pentamidine	B-NP	NN	O	14	PMOD
16	.	.	O	.	O	4	P

1	Time	Time	B-NP	NN	O	2	NMOD
2	dependence	dependence	I-NP	NN	O	10	NMOD
3	of	of	B-PP	IN	O	2	NMOD
4	plasma	plasma	B-NP	NN	O	5	NMOD
5	malondialdehyde	malondialdehyde	I-NP	NN	O	3	PMOD
6	,	,	O	,	O	10	P
7	oxypurines	oxypurine	B-NP	NNS	O	10	NMOD
8	,	,	O	,	O	10	P
9	and	and	O	CC	O	10	NMOD
10	nucleosides	nucleoside	B-NP	NNS	O	0	ROOT
11	during	during	B-PP	IN	O	10	NMOD
12	incomplete	incomplete	B-NP	JJ	O	14	NMOD
13	cerebral	cerebral	I-NP	JJ	O	14	NMOD
14	ischemia	ischemia	I-NP	NN	O	11	PMOD
15	in	in	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	rat	rat	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	10	P

1	During	During	B-PP	IN	O	12	VMOD
2	ischemia	ischemia	B-NP	NN	O	1	PMOD
3	,	,	O	,	O	12	P
4	a	a	B-NP	DT	O	6	NMOD
5	time-dependent	time-dependent	I-NP	JJ	O	6	NMOD
6	increase	increase	I-NP	NN	O	12	SUB
7	of	of	B-PP	IN	O	6	NMOD
8	plasma	plasma	B-NP	NN	O	9	NMOD
9	oxypurines	oxypurine	I-NP	NNS	O	11	NMOD
10	and	and	I-NP	CC	O	11	NMOD
11	nucleosides	nucleoside	I-NP	NNS	O	7	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	observed	observe	I-VP	VBN	O	12	VC
14	.	.	O	.	O	12	P

1	Plasma	Plasma	B-NP	NN	O	2	NMOD
2	malondialdehyde	malondialdehyde	I-NP	NN	O	22	SUB
3	,	,	O	,	O	2	P
4	which	which	B-NP	WDT	O	2	NMOD
5	was	be	B-VP	VBD	O	4	SBAR
6	present	present	B-ADJP	JJ	O	5	PRD
7	in	in	B-PP	IN	O	6	AMOD
8	minimal	minimal	B-NP	JJ	O	9	NMOD
9	amount	amount	I-NP	NN	O	7	PMOD
10	at	at	B-PP	IN	O	9	NMOD
11	zero	zero	B-NP	CD	O	12	NMOD
12	time	time	I-NP	NN	O	10	PMOD
13	(	(	O	(	O	20	DEP
14	0.058	0.058	B-NP	CD	O	16	NMOD
15	mumol/liter	mumol/liter	I-NP	NN	O	16	NMOD
16	plasma	plasma	I-NP	NN	O	20	DEP
17	;	;	O	:	O	18	P
18	SD	SD	B-NP	NN	O	16	NMOD
19	0.015	0.015	I-NP	CD	O	18	NMOD
20	)	)	O	)	O	12	NMOD
21	,	,	O	,	O	2	P
22	increased	increase	B-VP	VBD	O	0	ROOT
23	after	after	B-PP	IN	O	22	VMOD
24	5	5	B-NP	CD	O	25	NMOD
25	min	min	I-NP	NN	O	23	PMOD
26	of	of	B-PP	IN	O	25	NMOD
27	ischemia	ischemia	B-NP	NN	O	26	PMOD
28	,	,	O	,	O	22	P
29	resulting	result	B-VP	VBG	O	22	VMOD
30	in	in	B-PP	IN	O	29	VMOD
31	a	a	B-NP	DT	O	33	NMOD
32	fivefold	fivefold	I-NP	JJ	O	33	NMOD
33	increase	increase	I-NP	NN	O	30	PMOD
34	after	after	B-PP	IN	O	33	NMOD
35	30	30	B-NP	CD	O	36	NMOD
36	min	min	I-NP	NN	O	34	PMOD
37	of	of	B-PP	IN	O	36	NMOD
38	carotid	carotid	B-NP	NN	O	39	NMOD
39	occlusion	occlusion	I-NP	NN	O	37	PMOD
40	(	(	O	(	O	47	DEP
41	0.298	0.298	B-NP	CD	O	43	NMOD
42	mumol/liter	mumol/liter	I-NP	NN	O	43	NMOD
43	plasma	plasma	I-NP	NN	O	45	NMOD
44	;	;	O	:	O	45	P
45	SD	SD	B-NP	NN	O	47	DEP
46	0.078	0.078	I-NP	CD	O	45	NMOD
47	)	)	O	)	O	39	NMOD
48	.	.	O	.	O	22	P

1	Increased	Increase	B-NP	VBN	O	3	NMOD
2	plasma	plasma	I-NP	NN	O	3	NMOD
3	malondialdehyde	malondialdehyde	I-NP	NN	O	4	SUB
4	was	be	B-VP	VBD	O	0	ROOT
5	also	also	I-VP	RB	O	4	VMOD
6	recorded	record	I-VP	VBN	O	4	VC
7	in	in	B-PP	IN	O	6	VMOD
8	two	two	B-NP	CD	O	10	NMOD
9	other	other	I-NP	JJ	O	10	NMOD
10	groups	group	I-NP	NNS	O	7	PMOD
11	of	of	B-PP	IN	O	10	NMOD
12	animals	animal	B-NP	NNS	O	11	PMOD
13	subjected	subject	B-VP	VBN	O	12	NMOD
14	to	to	B-PP	TO	O	13	VMOD
15	the	the	B-NP	DT	O	18	NMOD
16	same	same	I-NP	JJ	O	18	NMOD
17	experimental	experimental	I-NP	JJ	O	18	NMOD
18	model	model	I-NP	NN	O	14	PMOD
19	,	,	O	,	O	4	P
20	one	one	B-NP	CD	O	36	NMOD
21	receiving	receive	B-VP	VBG	O	20	NMOD
22	20	20	B-NP	CD	O	24	NMOD
23	mg/kg	mg/kg	I-NP	NN	O	24	NMOD
24	b.w.	b.w.	I-NP	NN	O	21	OBJ
25	of	of	B-PP	IN	O	24	NMOD
26	the	the	B-NP	DT	O	29	NMOD
27	cyclooxygenase	cyclooxygenase	I-NP	NN	B-protein	29	NMOD
28	inhibitor	inhibitor	I-NP	NN	O	29	NMOD
29	acetylsalicylate	acetylsalicylate	I-NP	NN	O	25	PMOD
30	intravenously	intravenously	B-ADVP	RB	O	20	NMOD
31	immediately	immediately	I-ADVP	RB	O	30	AMOD
32	before	before	B-PP	IN	O	20	NMOD
33	ischemia	ischemia	B-NP	NN	O	32	PMOD
34	,	,	O	,	O	36	P
35	the	the	B-NP	DT	O	36	NMOD
36	other	other	I-NP	JJ	O	4	VMOD
37	receiving	receive	B-VP	VBG	O	36	NMOD
38	650	650	B-NP	CD	O	40	NMOD
39	micrograms/kg	micrograms/kg	I-NP	NN	O	40	NMOD
40	b.w.	b.w.	I-NP	NN	O	37	OBJ
41	of	of	B-PP	IN	O	40	NMOD
42	the	the	B-NP	DT	O	45	NMOD
43	hypotensive	hypotensive	I-NP	JJ	O	45	NMOD
44	drug	drug	I-NP	NN	O	45	NMOD
45	nitroprusside	nitroprusside	I-NP	NN	O	41	PMOD
46	at	at	B-PP	IN	O	37	VMOD
47	a	a	B-NP	DT	O	49	NMOD
48	flow	flow	I-NP	NN	O	49	NMOD
49	rate	rate	I-NP	NN	O	46	PMOD
50	of	of	B-PP	IN	O	49	NMOD
51	103	103	B-NP	CD	O	52	NMOD
52	microliters/min	microliters/min	I-NP	NN	O	50	PMOD
53	intravenously	intravenously	B-ADVP	RB	O	54	PMOD
54	during	during	B-PP	IN	O	37	VMOD
55	ischemia	ischemia	B-NP	NN	O	54	PMOD
56	,	,	O	,	O	36	P
57	although	although	B-SBAR	IN	O	36	NMOD
58	in	in	B-PP	IN	O	63	VMOD
59	this	this	B-NP	DT	O	62	NMOD
60	latter	latter	I-NP	JJ	O	62	NMOD
61	group	group	I-NP	NN	O	62	NMOD
62	malondialdehyde	malondialdehyde	I-NP	NN	O	63	SUB
63	was	be	B-VP	VBD	O	57	SBAR
64	significantly	significantly	B-ADJP	RB	O	65	AMOD
65	higher	high	I-ADJP	JJR	O	63	PRD
66	.	.	O	.	O	4	P

1	Cholinergic	Cholinergic	B-NP	JJ	O	2	NMOD
2	toxicity	toxicity	I-NP	NN	O	0	ROOT
3	resulting	result	B-VP	VBG	O	2	NMOD
4	from	from	B-PP	IN	O	3	VMOD
5	ocular	ocular	B-NP	JJ	O	6	NMOD
6	instillation	instillation	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	echothiophate	echothiophate	B-NP	NN	O	11	NMOD
9	iodide	iodide	I-NP	NN	O	11	NMOD
10	eye	eye	I-NP	NN	O	11	NMOD
11	drops	drop	I-NP	NNS	O	7	PMOD
12	.	.	O	.	O	2	P

1	Acute	Acute	B-NP	JJ	O	3	NMOD
2	renal	renal	I-NP	JJ	O	3	NMOD
3	failure	failure	I-NP	NN	O	0	ROOT
4	in	in	B-PP	IN	O	3	NMOD
5	high	high	B-NP	JJ	O	8	NMOD
6	dose	dose	I-NP	NN	O	8	NMOD
7	carboplatin	carboplatin	I-NP	NN	O	8	NMOD
8	chemotherapy	chemotherapy	I-NP	NN	O	4	PMOD
9	.	.	O	.	O	3	P

1	Carboplatin	Carboplatin	B-NP	NN	B-protein	2	SUB
2	has	have	B-VP	VBZ	O	0	ROOT
3	been	be	I-VP	VBN	O	2	VC
4	reported	report	I-VP	VBN	O	3	VC
5	to	to	I-VP	TO	O	6	VMOD
6	cause	cause	I-VP	VB	O	4	VMOD
7	acute	acute	B-NP	JJ	O	9	NMOD
8	renal	renal	I-NP	JJ	O	9	NMOD
9	failure	failure	I-NP	NN	O	6	OBJ
10	when	when	B-ADVP	WRB	O	4	VMOD
11	administered	administer	B-VP	VBN	O	10	SBAR
12	in	in	B-PP	IN	O	11	VMOD
13	high	high	B-NP	JJ	O	14	NMOD
14	doses	dose	I-NP	NNS	O	12	PMOD
15	to	to	B-PP	TO	O	11	VMOD
16	adult	adult	B-NP	JJ	O	17	NMOD
17	patients	patient	I-NP	NNS	O	15	PMOD
18	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	report	report	B-VP	VBP	O	0	ROOT
3	a	a	B-NP	DT	O	6	NMOD
4	4	4	I-NP	CD	O	6	NMOD
5	1/2-year-old	1/2-year-old	I-NP	JJ	O	6	NMOD
6	girl	girl	I-NP	NN	O	2	OBJ
7	who	who	B-NP	WP	O	6	NMOD
8	was	be	B-VP	VBD	O	7	SBAR
9	treated	treat	I-VP	VBN	O	8	VC
10	with	with	B-PP	IN	O	9	VMOD
11	high-dose	high-dose	B-NP	JJ	O	12	NMOD
12	carboplatin	carboplatin	I-NP	NN	O	10	PMOD
13	for	for	B-PP	IN	O	12	NMOD
14	metastatic	metastatic	B-NP	JJ	O	17	NMOD
15	parameningeal	parameningeal	I-NP	JJ	O	17	NMOD
16	embryonal	embryonal	I-NP	JJ	O	17	NMOD
17	rhabdomyosarcoma	rhabdomyosarcoma	I-NP	NN	O	13	PMOD
18	.	.	O	.	O	2	P

1	She	She	B-NP	PRP	O	2	SUB
2	had	have	B-VP	VBD	O	0	ROOT
3	ovarian	ovarian	B-NP	JJ	O	4	NMOD
4	failure	failure	I-NP	NN	O	2	OBJ
5	after	after	B-PP	IN	O	2	VMOD
6	abdominal	abdominal	B-NP	JJ	O	7	NMOD
7	irradiation	irradiation	I-NP	NN	O	9	NMOD
8	and	and	I-NP	CC	O	9	NMOD
9	chemotherapy	chemotherapy	I-NP	NN	O	5	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	Hodgkin	Hodgkin	B-NP	NN	O	12	NMOD
12	disease	disease	I-NP	NN	O	10	PMOD
13	,	,	O	,	O	2	P
14	and	and	O	CC	O	2	VMOD
15	received	receive	B-VP	VBD	O	2	VMOD
16	exogenous	exogenous	B-NP	JJ	O	17	NMOD
17	estrogens	estrogen	I-NP	NNS	O	15	OBJ
18	,	,	O	,	O	2	P
19	a	a	B-NP	DT	O	20	NMOD
20	treatment	treatment	I-NP	NN	O	2	OBJ
21	implicated	implicate	B-VP	VBN	O	20	NMOD
22	in	in	B-PP	IN	O	21	VMOD
23	the	the	B-NP	DT	O	24	NMOD
24	development	development	I-NP	NN	O	22	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	endometrial	endometrial	B-NP	JJ	O	27	NMOD
27	cancer	cancer	I-NP	NN	O	25	PMOD
28	in	in	B-PP	IN	O	24	NMOD
29	menopausal	menopausal	B-NP	JJ	O	30	NMOD
30	women	woman	I-NP	NNS	O	28	PMOD
31	.	.	O	.	O	2	P

1	Induction	Induction	B-NP	NN	O	0	ROOT
2	of	of	B-PP	IN	O	1	NMOD
3	the	the	B-NP	DT	O	7	NMOD
4	obstructive	obstructive	I-NP	JJ	O	7	NMOD
5	sleep	sleep	I-NP	NN	O	7	NMOD
6	apnea	apnea	I-NP	NN	O	7	NMOD
7	syndrome	syndrome	I-NP	NN	O	2	PMOD
8	in	in	B-PP	IN	O	1	NMOD
9	a	a	B-NP	DT	O	10	NMOD
10	woman	woman	I-NP	NN	O	8	PMOD
11	by	by	B-PP	IN	O	1	NMOD
12	exogenous	exogenous	B-NP	JJ	O	14	NMOD
13	androgen	androgen	I-NP	NN	O	14	NMOD
14	administration	administration	I-NP	NN	O	11	PMOD
15	.	.	O	.	O	1	P

1	We	We	B-NP	PRP	O	2	SUB
2	documented	document	B-VP	VBD	O	0	ROOT
3	airway	airway	B-NP	NN	O	4	NMOD
4	occlusion	occlusion	I-NP	NN	O	12	NMOD
5	during	during	B-PP	IN	O	4	NMOD
6	sleep	sleep	B-NP	NN	O	5	PMOD
7	and	and	O	CC	O	12	NMOD
8	an	an	B-NP	DT	O	12	NMOD
9	abnormally	abnormally	I-NP	RB	O	10	AMOD
10	high	high	I-NP	JJ	O	12	NMOD
11	supraglottic	supraglottic	I-NP	JJ	O	12	NMOD
12	resistance	resistance	I-NP	NN	O	2	OBJ
13	while	while	B-SBAR	IN	O	12	NMOD
14	awake	awake	B-NP	NN	O	13	SBAR
15	in	in	B-PP	IN	O	14	NMOD
16	a	a	B-NP	DT	O	18	NMOD
17	54-yr-old	54-yr-old	I-NP	JJ	O	18	NMOD
18	woman	woman	I-NP	NN	O	15	PMOD
19	who	who	B-NP	WP	O	18	NMOD
20	had	have	B-VP	VBD	O	19	SBAR
21	developed	develop	I-VP	VBN	O	20	VC
22	physical	physical	B-NP	JJ	O	23	NMOD
23	changes	change	I-NP	NNS	O	26	NMOD
24	and	and	O	CC	O	26	NMOD
25	the	the	B-NP	DT	O	26	NMOD
26	syndrome	syndrome	I-NP	NN	O	21	OBJ
27	of	of	B-PP	IN	O	26	NMOD
28	obstructive	obstructive	B-NP	JJ	O	30	NMOD
29	sleep	sleep	I-NP	NN	O	30	NMOD
30	apnea	apnea	I-NP	NN	O	27	PMOD
31	while	while	B-SBAR	IN	O	14	VMOD
32	being	be	B-VP	VBG	O	31	SBAR
33	administered	administer	I-VP	VBN	O	35	NMOD
34	exogenous	exogenous	B-NP	JJ	O	35	NMOD
35	androgens	androgen	I-NP	NNS	O	32	PRD
36	.	.	O	.	O	2	P

1	A	A	B-NP	DT	O	2	NMOD
2	rechallenge	rechallenge	I-NP	NN	O	5	SUB
3	with	with	B-PP	IN	O	2	NMOD
4	androgen	androgen	B-NP	NN	O	3	PMOD
5	produced	produce	B-VP	VBD	O	0	ROOT
6	symptoms	symptom	B-NP	NNS	O	5	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	obstructive	obstructive	B-NP	JJ	O	10	NMOD
9	sleep	sleep	I-NP	JJ	O	10	NMOD
10	apnea	apnea	I-NP	NN	O	7	PMOD
11	that	that	B-NP	WDT	O	6	NMOD
12	abated	abate	B-VP	VBD	O	11	SBAR
13	upon	upon	B-PP	IN	O	12	VMOD
14	withdrawal	withdrawal	B-NP	NN	O	13	PMOD
15	of	of	B-PP	IN	O	14	NMOD
16	the	the	B-NP	DT	O	17	NMOD
17	hormone	hormone	I-NP	NN	O	15	PMOD
18	.	.	O	.	O	5	P

1	Previous	Previous	B-NP	JJ	O	2	NMOD
2	reports	report	I-NP	NNS	O	3	SUB
3	have	have	B-VP	VBP	O	0	ROOT
4	favored	favor	I-VP	VBN	O	3	VC
5	a	a	B-NP	DT	O	6	NMOD
6	role	role	I-NP	NN	O	4	OBJ
7	of	of	B-PP	IN	O	6	NMOD
8	androgens	androgen	B-NP	NNS	O	7	PMOD
9	in	in	B-PP	IN	O	6	NMOD
10	the	the	B-NP	DT	O	11	NMOD
11	pathogenesis	pathogenesis	I-NP	NN	O	9	PMOD
12	of	of	B-PP	IN	O	11	NMOD
13	sleep	sleep	B-NP	NN	O	14	NMOD
14	apnea	apnea	I-NP	NN	O	12	PMOD
15	.	.	O	.	O	3	P

1	Effect	Effect	B-NP	NN	O	8	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	captopril	captopril	B-NP	NN	O	2	PMOD
4	on	on	B-PP	IN	O	1	NMOD
5	pre-existing	pre-existing	B-NP	JJ	O	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	aminonucleoside	aminonucleoside	I-NP	NN	O	4	PMOD
8	induced	induce	B-VP	VBD	O	0	ROOT
9	proteinuria	proteinuria	B-NP	NN	O	8	OBJ
10	in	in	B-PP	IN	O	8	VMOD
11	spontaneously	spontaneously	B-NP	RB	O	12	AMOD
12	hypertensive	hypertensive	I-NP	JJ	O	13	NMOD
13	rats	rat	I-NP	NNS	O	10	PMOD
14	.	.	O	.	O	8	P

1	Proteinuria	Proteinuria	B-NP	NNP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	a	a	B-NP	DT	O	5	NMOD
4	side	side	I-NP	JJ	O	5	NMOD
5	effect	effect	I-NP	NN	O	2	PRD
6	of	of	B-PP	IN	O	5	NMOD
7	captopril	captopril	B-NP	NN	O	8	NMOD
8	treatment	treatment	I-NP	NN	O	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	hypertensive	hypertensive	B-NP	JJ	O	11	NMOD
11	patients	patient	I-NP	NNS	O	9	PMOD
12	.	.	O	.	O	2	P

1	The	The	B-NP	DT	O	2	NMOD
2	possibility	possibility	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	reproducing	reproduce	B-VP	VBG	O	3	PMOD
5	the	the	B-NP	DT	O	8	NMOD
6	same	same	I-NP	JJ	O	8	NMOD
7	renal	renal	I-NP	JJ	O	8	NMOD
8	abnormality	abnormality	I-NP	NN	O	4	OBJ
9	with	with	B-PP	IN	O	4	VMOD
10	captopril	captopril	B-NP	NN	O	9	PMOD
11	was	be	B-VP	VBD	O	0	ROOT
12	examined	examine	I-VP	VBN	O	11	VC
13	in	in	B-PP	IN	O	12	VMOD
14	SHR	SHR	B-NP	NN	B-protein	13	PMOD
15	.	.	O	.	O	11	P

1	Oral	Oral	B-NP	JJ	O	2	NMOD
2	administration	administration	I-NP	NN	O	11	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	captopril	captopril	B-NP	NN	O	3	PMOD
5	at	at	B-PP	IN	O	2	NMOD
6	100	100	B-NP	CD	O	7	NMOD
7	mg/kg	mg/kg	I-NP	NN	O	5	PMOD
8	for	for	B-PP	IN	O	2	NMOD
9	14	14	B-NP	CD	O	10	NMOD
10	days	day	I-NP	NNS	O	8	PMOD
11	failed	fail	B-VP	VBD	O	0	ROOT
12	to	to	I-VP	TO	O	13	VMOD
13	aggravate	aggravate	I-VP	VB	O	11	VMOD
14	proteinuria	proteinuria	B-NP	NN	O	13	OBJ
15	pre-existing	pre-existing	B-ADJP	JJ	O	14	NMOD
16	in	in	B-PP	IN	O	15	AMOD
17	SHR	SHR	B-NP	NN	B-protein	16	PMOD
18	.	.	O	.	O	11	P

1	Also	Also	B-ADVP	RB	O	5	VMOD
2	,	,	O	,	O	5	P
3	captopril	captopril	B-NP	NN	O	4	NMOD
4	treatment	treatment	I-NP	NN	O	5	SUB
5	failed	fail	B-VP	VBD	O	0	ROOT
6	to	to	I-VP	TO	O	7	VMOD
7	potentiate	potentiate	I-VP	VB	O	5	VMOD
8	or	or	I-VP	CC	O	7	VMOD
9	facilitate	facilitate	I-VP	VB	O	7	VMOD
10	development	development	B-NP	NN	O	9	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	massive	massive	B-NP	JJ	O	13	NMOD
13	proteinuria	proteinuria	I-NP	NN	O	11	PMOD
14	invoked	invoke	B-VP	VBN	O	13	NMOD
15	by	by	B-PP	IN	O	14	VMOD
16	puromycin	puromycin	B-NP	NN	O	17	NMOD
17	aminonucleoside	aminonucleoside	I-NP	NN	O	15	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	SHR	SHR	B-NP	NN	B-protein	18	PMOD
20	.	.	O	.	O	5	P

1	In	In	B-PP	IN	O	11	VMOD
2	one	one	B-NP	CD	O	3	NMOD
3	patient	patient	I-NP	NN	O	1	PMOD
4	,	,	O	,	O	11	P
5	enflurane	enflurane	B-NP	NN	O	11	SUB
6	administered	administer	B-VP	VBN	O	5	NMOD
7	during	during	B-PP	IN	O	6	VMOD
8	a	a	B-NP	DT	O	10	NMOD
9	donor	donor	I-NP	NN	O	10	NMOD
10	nephrectomy	nephrectomy	I-NP	NN	O	7	PMOD
11	resulted	result	B-VP	VBD	O	0	ROOT
12	in	in	B-PP	IN	O	11	VMOD
13	unexpected	unexpected	B-NP	JJ	O	16	NMOD
14	partial	partial	I-NP	JJ	O	16	NMOD
15	motor	motor	I-NP	NN	O	16	NMOD
16	seizures	seizure	I-NP	NNS	O	12	PMOD
17	.	.	O	.	O	11	P

1	Epileptic	Epileptic	B-NP	JJ	O	2	NMOD
2	foci	focus	I-NP	NNS	O	8	SUB
3	delineated	delineate	B-VP	VBN	O	2	NMOD
4	and	and	I-VP	CC	O	3	VMOD
5	activated	activate	I-VP	VBN	O	3	VMOD
6	by	by	B-PP	IN	O	5	VMOD
7	enflurane	enflurane	B-NP	NN	O	6	PMOD
8	were	be	B-VP	VBD	O	14	VMOD
9	surgically	surgically	I-VP	RB	O	8	VMOD
10	ablated	ablate	I-VP	VBN	O	8	VC
11	and	and	O	CC	O	14	VMOD
12	the	the	B-NP	DT	O	13	NMOD
13	patients	patient	I-NP	NNS	O	14	SUB
14	are	be	B-VP	VBP	O	0	ROOT
15	now	now	B-ADVP	RB	O	14	VMOD
16	seizure-free	seizure-free	B-ADJP	JJ	O	14	PRD
17	.	.	O	.	O	14	P

1	Reversible	Reversible	B-NP	JJ	O	3	NMOD
2	cerebral	cerebral	I-NP	JJ	O	3	NMOD
3	lesions	lesion	I-NP	NNS	O	10	NMOD
4	associated	associate	B-VP	VBN	O	3	NMOD
5	with	with	B-PP	IN	O	4	VMOD
6	tiazofurin	tiazofurin	B-NP	NN	O	7	NMOD
7	usage	usage	I-NP	NN	O	5	PMOD
8	:	:	O	:	O	3	P
9	MR	MR	B-NP	NN	B-protein	10	NMOD
10	demonstration	demonstration	I-NP	NN	O	0	ROOT
11	.	.	O	.	O	10	P

1	Enhanced	Enhance	B-NP	VBN	O	2	NMOD
2	stimulus	stimulus	I-NP	NN	O	3	SUB
3	induced	induce	B-VP	VBD	O	11	VMOD
4	neurotransmitter	neurotransmitter	B-NP	NN	O	5	NMOD
5	overflow	overflow	I-NP	NN	O	3	OBJ
6	in	in	B-PP	IN	O	3	VMOD
7	epinephrine	epinephrine	B-NP	NN	O	10	NMOD
8	induced	induce	B-VP	VBD	O	10	NMOD
9	hypertensive	hypertensive	B-NP	JJ	O	10	NMOD
10	rats	rat	I-NP	NNS	O	6	PMOD
11	is	be	B-VP	VBZ	O	0	ROOT
12	not	not	I-VP	RB	O	11	VMOD
13	mediated	mediate	I-VP	VBN	O	11	VC
14	by	by	B-PP	IN	O	13	VMOD
15	prejunctional	prejunctional	B-NP	JJ	O	17	NMOD
16	beta-adrenoceptor	beta-adrenoceptor	I-NP	NN	O	17	NMOD
17	activation	activation	I-NP	NN	O	14	PMOD
18	.	.	O	.	O	11	P

1	Even	Even	B-ADVP	RB	O	15	VMOD
2	after	after	B-PP	IN	O	15	VMOD
3	early	early	B-NP	JJ	O	4	NMOD
4	detection	detection	I-NP	NN	O	7	NMOD
5	and	and	O	CC	O	7	NMOD
6	prompt	prompt	B-NP	JJ	O	7	NMOD
7	treatment	treatment	I-NP	NN	O	2	PMOD
8	,	,	O	,	O	15	P
9	41	41	B-NP	CD	O	10	NMOD
10	%	%	I-NP	NN	O	15	SUB
11	of	of	B-PP	IN	O	10	NMOD
12	cases	case	B-NP	NNS	O	11	PMOD
13	of	of	B-PP	IN	O	12	NMOD
14	uveitis	uveitis	B-NP	NN	O	13	PMOD
15	did	do	B-VP	VBD	O	0	ROOT
16	not	not	I-VP	RB	O	15	VMOD
17	respond	respond	I-VP	VB	O	15	VC
18	to	to	B-PP	TO	O	17	VMOD
19	more	more	B-NP	JJR	O	20	AMOD
20	than	than	I-NP	IN	O	22	NMOD
21	six	six	I-NP	CD	O	20	AMOD
22	months	month	I-NP	NNS	O	18	PMOD
23	of	of	B-PP	IN	O	22	NMOD
24	intensive	intensive	B-NP	JJ	O	26	NMOD
25	topical	topical	I-NP	JJ	O	26	NMOD
26	treatment	treatment	I-NP	NN	O	23	PMOD
27	with	with	B-PP	IN	O	26	NMOD
28	corticosteroids	corticosteroid	B-NP	NNS	O	30	NMOD
29	and	and	I-NP	CC	O	30	NMOD
30	mydriatics	mydriatic	I-NP	NNS	O	27	PMOD
31	.	.	O	.	O	15	P

1	We	We	B-NP	PRP	O	2	SUB
2	used	use	B-VP	VBD	O	0	ROOT
3	chloroquine	chloroquine	B-NP	NN	O	5	NMOD
4	or	or	I-NP	CC	O	5	NMOD
5	hydroxychloroquine	hydroxychloroquine	I-NP	NN	O	2	OBJ
6	in	in	B-PP	IN	O	2	VMOD
7	173	173	B-NP	CD	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	210	210	B-NP	CD	O	10	NMOD
10	cases	case	I-NP	NNS	O	8	PMOD
11	and	and	O	CC	O	2	VMOD
12	found	find	B-VP	VBN	O	2	VMOD
13	only	only	B-NP	RB	O	15	NMOD
14	one	one	I-NP	CD	O	13	AMOD
15	case	case	I-NP	NN	O	12	OBJ
16	of	of	B-PP	IN	O	15	NMOD
17	chorioretinopathy	chorioretinopathy	B-NP	NN	O	16	PMOD
18	attributable	attributable	B-ADJP	JJ	O	17	NMOD
19	to	to	B-PP	TO	O	18	AMOD
20	these	these	B-NP	DT	O	21	NMOD
21	drugs	drug	I-NP	NNS	O	19	PMOD
22	.	.	O	.	O	2	P

1	Systemically	Systemically	B-NP	RB	O	2	AMOD
2	administered	administer	I-NP	VBN	O	3	NMOD
3	corticosteroids	corticosteroid	I-NP	NNS	O	4	SUB
4	were	be	B-VP	VBD	O	19	VMOD
5	used	use	I-VP	VBN	O	4	VC
6	in	in	B-PP	IN	O	5	VMOD
7	75	75	B-NP	CD	O	6	PMOD
8	of	of	B-PP	IN	O	7	NMOD
9	210	210	B-NP	CD	O	10	NMOD
10	cases	case	I-NP	NNS	O	8	PMOD
11	;	;	O	:	O	4	P
12	a	a	B-NP	DT	O	14	NMOD
13	significant	significant	I-NP	JJ	O	14	NMOD
14	number	number	I-NP	NN	O	19	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	posterior	posterior	B-NP	JJ	O	18	NMOD
17	subcapsular	subcapsular	I-NP	JJ	O	18	NMOD
18	cataracts	cataract	I-NP	NNS	O	15	PMOD
19	was	be	B-VP	VBD	O	0	ROOT
20	found	find	I-VP	VBN	O	19	VC
21	.	.	O	.	O	19	P

1	Water	Water	B-NP	JJ	O	2	NMOD
2	intoxication	intoxication	I-NP	NN	O	0	ROOT
3	associated	associate	B-VP	VBN	O	2	NMOD
4	with	with	B-PP	IN	O	3	VMOD
5	oxytocin	oxytocin	B-NP	NN	O	6	NMOD
6	administration	administration	I-NP	NN	O	4	PMOD
7	during	during	B-PP	IN	O	6	NMOD
8	saline	saline	B-NP	NN	O	10	NMOD
9	induced	induced	I-NP	JJ	O	10	NMOD
10	abortion	abortion	I-NP	NN	O	7	PMOD
11	.	.	O	.	O	2	P

1	Four	Four	B-NP	CD	O	2	NMOD
2	cases	case	I-NP	NNS	O	15	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	water	water	B-NP	NN	O	5	NMOD
5	intoxication	intoxication	I-NP	NN	O	3	PMOD
6	in	in	B-PP	IN	O	2	NMOD
7	connection	connection	B-NP	NN	O	6	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	oxytocin	oxytocin	B-NP	NN	O	10	NMOD
10	administration	administration	I-NP	NN	O	8	PMOD
11	during	during	B-PP	IN	O	2	NMOD
12	saline	saline	B-NP	NN	O	14	NMOD
13	induced	induced	I-NP	JJ	O	14	NMOD
14	abortions	abortion	I-NP	NNS	O	11	PMOD
15	are	be	B-VP	VBP	O	0	ROOT
16	described	describe	I-VP	VBN	O	15	VC
17	.	.	O	.	O	15	P

1	Oxytocin	Oxytocin	B-NP	NN	O	2	NMOD
2	administration	administration	I-NP	NN	O	7	SUB
3	during	during	B-PP	IN	O	2	NMOD
4	midtrimester	midtrimester	B-NP	NN	O	6	NMOD
5	induced	induced	I-NP	JJ	O	6	NMOD
6	abortions	abortion	I-NP	NNS	O	3	PMOD
7	is	be	B-VP	VBZ	O	0	ROOT
8	advocated	advocate	I-VP	VBN	O	7	VC
9	only	only	B-SBAR	RB	O	10	DEP
10	if	if	I-SBAR	IN	O	8	VMOD
11	it	it	B-NP	PRP	O	12	SUB
12	can	can	B-VP	MD	O	10	SBAR
13	be	be	I-VP	VB	O	12	VC
14	carried	carry	I-VP	VBN	O	13	VC
15	out	out	B-PRT	RP	O	14	VMOD
16	under	under	B-PP	IN	O	14	VMOD
17	careful	careful	B-NP	JJ	O	18	NMOD
18	observations	observation	I-NP	NNS	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	an	an	B-NP	DT	O	23	NMOD
21	alert	alert	I-NP	JJ	O	23	NMOD
22	nursing	nursing	I-NP	NN	O	23	NMOD
23	staff	staff	I-NP	NN	O	19	PMOD
24	,	,	O	,	O	10	P
25	aware	aware	B-ADJP	JJ	O	10	DEP
26	of	of	B-PP	IN	O	25	AMOD
27	the	the	B-NP	DT	O	28	NMOD
28	symptoms	symptom	I-NP	NNS	O	26	PMOD
29	of	of	B-PP	IN	O	28	NMOD
30	water	water	B-NP	NN	O	31	NMOD
31	intoxication	intoxication	I-NP	NN	O	29	PMOD
32	and	and	O	CC	O	33	AMOD
33	instructed	instruct	B-VP	VBN	O	25	DEP
34	to	to	B-VP	TO	O	35	VMOD
35	watch	watch	I-VP	VB	O	33	VMOD
36	the	the	B-NP	DT	O	39	NMOD
37	diuresis	diuresis	I-NP	NN	O	39	NMOD
38	and	and	I-NP	CC	O	39	NMOD
39	report	report	I-NP	NN	O	42	NMOD
40	such	such	B-NP	JJ	O	39	AMOD
41	early	early	I-NP	JJ	O	42	NMOD
42	signs	sign	I-NP	NNS	O	35	OBJ
43	of	of	B-PP	IN	O	42	NMOD
44	the	the	B-NP	DT	O	45	NMOD
45	syndrome	syndrome	I-NP	NN	O	43	PMOD
46	as	as	B-PP	IN	O	35	VMOD
47	asthenia	asthenia	B-NP	NN	O	46	PMOD
48	,	,	O	,	O	53	P
49	muscular	muscular	B-NP	JJ	O	50	NMOD
50	irritability	irritability	I-NP	NN	O	53	NMOD
51	,	,	O	,	O	53	P
52	or	or	O	CC	O	53	NMOD
53	headaches	headache	B-NP	NNS	O	8	VMOD
54	.	.	O	.	O	7	P

